﻿FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Yadav, M
   Schiavone, N
   Guzman-Aranguez, A
   Giansanti, F
   Papucci, L
   de Lara, MJP
   Singh, M
   Kaur, IP
AF Yadav, Monika
   Schiavone, Nicola
   Guzman-Aranguez, Ana
   Giansanti, Fabrizio
   Papucci, Laura
   de Lara, Maria J. Perez
   Singh, Mandeep
   Kaur, Indu Pal
TI Atorvastatin-loaded solid lipid nanoparticles as eye drops: proposed
   treatment option for age-related macular degeneration (AMD)
SO DRUG DELIVERY AND TRANSLATIONAL RESEARCH
LA English
DT Article
DE Ocular delivery; In vivo safety; Uptake studies; Ocular
   pharmacokinetics; Posterior eye delivery; Statins; Nanostructured
   carriers
ID IN-VITRO EVALUATION; CHOROIDAL NEOVASCULARIZATION; TISSUE DISTRIBUTION;
   OCULAR TOLERANCE; PARTICLE-SIZE; DRY EYE; DRUG; STATINS; DELIVERY;
   FORMULATION
AB Statins, widely prescribed for cardiovascular diseases, are also being eyed for management of age-related macular degeneration (AMD). Poor bioavailability and blood-aqueous barrier may however limit significant ocular concentration of statins following oral administration. We for the first time propose and investigate local application of atorvastatin (ATS; representative statin) loaded into solid lipid nanoparticles (SLNs), as self-administrable eye drops. Insolubility, instability, and high molecular weight > 500 of ATS, and ensuring that SLNs reach posterior eye were the challenges to be met. ATS-SLNs, developed (2339/DEL/2014) using suitable components, quality-by-design (QBD) approach, and scalable hot high-pressure homogenization, were characterized and evaluated comprehensively for ocular suitability. ATS-SLNs were 8 and 12 times more bioavailable (AUC) in aqueous and vitreous humor, respectively, than free ATS. Three-tier (in vitro, ex vivo, and in vivo) ocular safety, higher corneal flux (2.5-fold), and improved stability (13.62 times) including photostability of ATS on incorporation in ATS-SLNs were established. Autoclavability and aqueous nature are the other highlights of ATS-SLNs. Presence of intact fluorescein-labeled SLNs (F-SLNs) in internal eye tissues post-in vivo application as eye drops provides direct evidence of successful delivery. Perinuclear fluorescence in ARPE-19 cells confirms the effective uptake of F-SLNs. Prolonged residence, up to 7 h, was attributed to the mucus-penetrating nature of ATS-SLNs.
C1 [Yadav, Monika; Singh, Mandeep; Kaur, Indu Pal] Panjab Univ, Univ Inst Pharmaceut Sci, Dept Pharmaceut, Chandigarh 160014, India.
   [Schiavone, Nicola; Giansanti, Fabrizio; Papucci, Laura] Dept Expt & Clin Biomed Sci, Sect Expt Pathol & Oncol, Viale Morgagni 50, Florence 50134, Italy.
   [Guzman-Aranguez, Ana; de Lara, Maria J. Perez] Univ Complutense Madrid, Fac Opt & Optometria, Dept Bioquim & Biol Mol 4, C Arcos de Jalon 118, Madrid 28037, Spain.
C3 Panjab University; Complutense University of Madrid
RP Kaur, IP (通讯作者)，Panjab Univ, Univ Inst Pharmaceut Sci, Dept Pharmaceut, Chandigarh 160014, India.
EM dripkuips@gmail.com
OI Schiavone, Nicola/0000-0002-1592-4244
CR Abul Kalam M, 2013, J BIOMED MATER RES A, V101, P1828, DOI 10.1002/jbm.a.34467
   Aggarwal D, 2004, J PHARM PHARMACOL, V56, P1509, DOI 10.1211/0022357044896
   Agrahari V., 2016, EXPERT OPIN DRUG DEL, P1
   Alqawlaq S, 2014, NANOMED-NANOTECHNOL, V10, P1637, DOI 10.1016/j.nano.2014.05.010
   Amrite AC, 2008, MOL VIS, V14, P150
   Anjana D, 2012, AM J INFECT DIS, V8, P41, DOI 10.3844/ajidsp.2012.41.49
   Anwar M, 2011, EUR J PHARM SCI, V44, P241, DOI 10.1016/j.ejps.2011.08.001
   Aragona P, 2002, BRIT J OPHTHALMOL, V86, P879, DOI 10.1136/bjo.86.8.879
   Arunkumar N, 2010, ASIAN J PHARM, V4, P28, DOI 10.4103/0973-8398.63982
   Attama AA, 2007, EUR J PHARM BIOPHARM, V67, P48, DOI 10.1016/j.ejpb.2006.12.004
   Attama AA, 2008, INT J PHARM, V355, P307, DOI 10.1016/j.ijpharm.2007.12.007
   Baranowski P, 2014, SCI WORLD J, DOI 10.1155/2014/861904
   Basaran E, 2010, J MICROENCAPSUL, V27, P37, DOI 10.3109/02652040902846883
   Bhandari R, 2013, INT J PHARMACEUT, V441, P202, DOI 10.1016/j.ijpharm.2012.11.042
   Bhatia A, 2013, INT J PHARMACEUT, V444, P47, DOI 10.1016/j.ijpharm.2013.01.029
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Calvo P, 1996, J PHARM PHARMACOL, V48, P1147, DOI 10.1111/j.2042-7158.1996.tb03911.x
   Cannon CP, 2004, NEW ENGL J MED, V350, P1495, DOI 10.1056/NEJMoa040583
   Carvalho A, 2015, J APPL SOLUTION CHEM, P4
   Choudhary A, 2012, ACTA PHARM SIN B, V2, P421, DOI 10.1016/j.apsb.2012.05.002
   Costa P, 2001, EUR J PHARM SCI, V13, P123, DOI 10.1016/S0928-0987(01)00095-1
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Davidson MH, 2006, EXPERT OPIN PHARMACO, V7, P1701, DOI 10.1517/14656566.7.13.1701
   Djebli N, 2017, EUR J DRUG METAB PH, V42, P59, DOI 10.1007/s13318-016-0319-4
   El-Azab MF, 2011, EXPERT REV OPHTHALMO, V6, P269, DOI 10.1586/eop.11.36
   Ensign LM, 2012, ADV MATER, V24, P3887, DOI 10.1002/adma.201201800
   Fangueiro JF, 2016, INT J PHARMACEUT, V502, P161, DOI 10.1016/j.ijpharm.2016.02.039
   Felton T, 2014, CLIN MICROBIOL REV, V27, P68, DOI 10.1128/CMR.00046-13
   Fong CW, 2014, EUR J MED CHEM, V85, P661, DOI 10.1016/j.ejmech.2014.08.037
   Gehlbach P, 2008, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD006927, DOI 10.1002/14651858.CD006927]
   Gehlbach P, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006927.pub4
   Gipson IK, 2003, INVEST OPHTH VIS SCI, V44, P2496, DOI 10.1167/iovs.02-0851
   Goke K, 2016, MOL PHARMACEUT, V13, P3187, DOI 10.1021/acs.molpharmaceut.6b00395
   Gokce EH, 2009, CURR EYE RES, V34, P996, DOI 10.3109/02713680903261405
   Guymer RH, 2005, SURV OPHTHALMOL, V50, P194, DOI 10.1016/j.survophthal.2004.12.002
   Hackley VA, 2011, METHODS MOL BIOL, V697, P35, DOI 10.1007/978-1-60327-198-1_4
   Hall NF, 2001, BRIT MED J, V323, P375, DOI 10.1136/bmj.323.7309.375
   Han S, 2010, ACTA PHARMACOL SIN, V31, P990, DOI 10.1038/aps.2010.98
   Hindler K, 2006, ONCOLOGIST, V11, P306, DOI 10.1634/theoncologist.11-3-306
   Hirani A, 2016, PHARM DEV TECHNOL, V21, P61, DOI 10.3109/10837450.2014.965326
   Iester M, 2000, EYE, V14, P892, DOI 10.1038/eye.2000.244
   IP, 2007, 2211 STER, V1, P52
   James CB, 2013, CLIN UPDATE STATINS, P1
   Jiao J, 2008, ADV DRUG DELIVER REV, V60, P1663, DOI 10.1016/j.addr.2008.09.002
   Joshi L, 1993, US Patent publication, Patent No. [2009/0247603A1, 20090247603]
   Juarez-Moreno K, 2015, APPL BIOCHEM BIOTECH, V177, P1364, DOI 10.1007/s12010-015-1820-y
   Judde A, 2003, J AM OIL CHEM SOC, V80, P1209, DOI 10.1007/s11746-003-0844-4
   Jung HJ, 2013, J OCUL PHARMACOL TH, V29, P229, DOI 10.1089/jop.2012.0114
   Kakkar S, 2015, INT J PHARMACEUT, V495, P276, DOI 10.1016/j.ijpharm.2015.08.088
   Kakkar S, 2011, INT J PHARMACEUT, V413, P202, DOI 10.1016/j.ijpharm.2011.04.027
   Kakkar V, 2018, DRUG DEV IND PHARM, V44, P1701, DOI 10.1080/03639045.2018.1492607
   Kaur IP, 2014, J CONTROL RELEASE, V193, P100, DOI 10.1016/j.jconrel.2014.05.031
   Kaur IP, 2002, DRUG DEV IND PHARM, V28, P353, DOI 10.1081/DDC-120002997
   Kaur IP, 2014, OCULAR FORMULATION S
   Khush KK, 2004, CLEV CLIN J MED, V71, P609, DOI 10.3949/ccjm.71.8.609
   Kumar PP., 2012, IOSR J PHARM, V2, P23, DOI DOI 10.9790/3013-25102332
   Lam MW, 2005, AQUAT SCI, V67, P177, DOI 10.1007/s00027-004-0768-8
   Lemarchand C, 2003, PHARMACEUT RES, V20, P1284, DOI 10.1023/A:1025017502379
   Li HP, 2016, RSC ADV, V6, P84164, DOI 10.1039/c6ra18724b
   Li X, 2008, INT J PHARMACEUT, V363, P177, DOI 10.1016/j.ijpharm.2008.07.017
   Liu CH, 2010, COLLOID SURFACE A, V353, P149, DOI 10.1016/j.colsurfa.2009.11.006
   Liu M, 2015, ASIAN J PHARM SCI, V10, P275, DOI 10.1016/j.ajps.2014.12.007
   Liu SY, 2016, MOL PHARMACEUT, V13, P2897, DOI 10.1021/acs.molpharmaceut.6b00445
   Loma P, 2015, EXP EYE RES, V134, P141, DOI 10.1016/j.exer.2015.02.014
   Ma L, 2015, SCI REP-UK, V5, DOI 10.1038/srep18280
   Mach F, 2002, TRANSPL IMMUNOL, V9, P197, DOI 10.1016/S0966-3274(02)00030-8
   Maguire MG, 2009, OPHTHALMOLOGY, V116, P2381, DOI 10.1016/j.ophtha.2009.06.055
   Mahmoodzadeh E, 2012, RES PHARM SCI, P7
   Mahmoud Y, 2013, J CHROMATOGR B, V917, P1
   Maisel K, 2016, NANOMEDICINE-UK, V11, P1337, DOI 10.2217/nnm-2016-0047
   Margheri F, 2006, ARTHRITIS RHEUM-US, V54, P3926, DOI 10.1002/art.22263
   Maria DS, 2013, PLASMA OCULAR PREDNI, P1
   McCann P, 2016, INVEST OPHTH VIS SCI, V57, P2729, DOI 10.1167/iovs.15-18595
   McDermott AM, 2018, CURR EYE RES, V43, P1097, DOI 10.1080/02713683.2018.1480043
   McGwin G, 2005, OPHTHALMOLOGY, V112, P488, DOI 10.1016/j.ophtha.2004.10.027
   Monem AS, 2000, INT J PHARM, V198, P29, DOI 10.1016/S0378-5173(99)00348-8
   Muller RH, 2006, INT J PHARMACEUT, V317, P82, DOI 10.1016/j.ijpharm.2006.02.045
   Nissen SE, 2005, AM J CARDIOL, V96, p61F, DOI 10.1016/j.amjcard.2005.07.013
   Nissen SE, 2006, JAMA-J AM MED ASSOC, V295, P1556, DOI 10.1001/jama.295.13.jpc60002
   OECD, 2015, OECD GUID TEST CHEM, P1
   OECD, 2017, OB UPD 2017, DOI DOI 10.1787/2415170X
   Paliwal R, 2014, AAPS PHARMSCITECH, V15, P1527, DOI 10.1208/s12249-014-0177-9
   Panghal Dharmila, 2014, Sci Pharm, V82, P177, DOI 10.3797/scipharm.1301-23
   Papucci L, 2003, J BIOL CHEM, V278, P28220, DOI 10.1074/jbc.M302297200
   Pastor-Clerigues A, 2016, CURR EYE RES, V41, P890, DOI 10.3109/02713683.2015.1082187
   Polar O, 2017, TURK OFTALMOL DERG, V47, P205, DOI 10.4274/tjo.28003
   Qaddoumi MG, 2004, PHARM RES-DORDR, V21, P641, DOI 10.1023/B:PHAM.0000022411.47059.76
   Reich S, 2003, MOL VIS, V9, P210
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sabe AA, 2015, J CARDIAC SURG, V30, P218, DOI 10.1111/jocs.12488
   Sakurai E, 2001, OPHTHALMIC RES, V33, P31, DOI 10.1159/000055638
   SALMASO S, 2013, J DRUG DELIV, V2013, DOI DOI 10.1155/2013/374252
   Sanna V, 2004, AAPS PHARMSCITECH, V5, DOI 10.1208/pt050227
   Sarath CI, 2014, INT J BIOPHARM, V5, P214
   SCHILLER LR, 1988, GASTROENTEROLOGY, V94, P933, DOI 10.1016/0016-5085(88)90550-1
   Schmidt-Erfurth UM, 2007, ACTA OPHTHALMOL SCAN, V85, P486, DOI 10.1111/j.1600-0420.2007.00979.x
   Schopf LR, 2015, TRANSL VIS SCI TECHN, V4, DOI 10.1167/tvst.4.3.11
   Seigel GM, 2014, MOL VIS, V20, P301
   Seyfoddin A, 2010, DRUG DELIV, V17, P467, DOI 10.3109/10717544.2010.483257
   Sharma N, 2016, ASIAN J PHARM SCI, V11, P404, DOI 10.1016/j.ajps.2015.09.004
   Shen Y, 2007, AAPS J, V9, DOI 10.1208/aapsj0903044
   Singh B, 2006, AAPS PHARMSCITECH, V7, DOI 10.1208/pt070103
   Sivaprasad S, 2005, CLIN EXP OPHTHALMOL, V33, P518, DOI 10.1111/j.1442-9071.2005.01074.x
   Souto EB, 2006, J MICROENCAPSUL, V23, P417, DOI 10.1080/02652040600612439
   Sripriyalakshmi S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086317
   Suzuki M, 2007, MOL VIS, V13, P772
   Tanaka K, 2004, CLIN EXP PHARMACOL P, V31, P360, DOI 10.1111/j.1440-1681.2004.04010.x
   Tempestini A, 2003, EUR J OPHTHALMOL, V13, pS11
   Tham YC, 2014, OPHTHALMOLOGY, V121, P2081, DOI 10.1016/j.ophtha.2014.05.013
   Tian QQ, 2016, RSC ADV, V6, P35901, DOI 10.1039/c6ra02371a
   Tomlinson A, 2006, INVEST OPHTH VIS SCI, V47, P4309, DOI 10.1167/iovs.05-1504
   Vavvas DG, 2016, EBIOMEDICINE, V5, P198, DOI 10.1016/j.ebiom.2016.01.033
   Wang JY, 2016, CELL PHYSIOL BIOCHEM, V38, P207, DOI 10.1159/000438622
   Wilson HL, 2004, AM J OPHTHALMOL, V137, P615, DOI 10.1016/j.ajo.2003.10.025
   Wilson SL, 2015, TOXICOLOGY, V327, P32, DOI 10.1016/j.tox.2014.11.003
   Xie Y, 2009, AAPS PHARMSCITECH, V10, P631, DOI 10.1208/s12249-009-9246-x
   Yadav M, 2010, CARBOHYD POLYM, V81, P871, DOI 10.1016/j.carbpol.2010.03.065
   Yamada K, 2007, INVEST OPHTH VIS SCI, V48, P1839, DOI 10.1167/iovs.06-1085
   Yip JLY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132565
   Yu LMY, 2004, COLLOID SURFACE B, V36, P167, DOI 10.1016/j.colsurfb.2004.06.005
   Zhang L, 2017, ASIAN J PHARM SCI, V12, P1, DOI 10.1016/j.ajps.2016.07.006
NR 121
TC 40
Z9 40
U1 8
U2 22
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 2190-393X
EI 2190-3948
J9 DRUG DELIV TRANSL RE
JI Drug Deliv. Transl. Res.
PD AUG
PY 2020
VL 10
IS 4
SI SI
BP 919
EP 944
DI 10.1007/s13346-020-00733-4
EA APR 2020
PG 26
WC Instruments & Instrumentation; Medicine, Research & Experimental;
   Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Instruments & Instrumentation; Research & Experimental Medicine;
   Pharmacology & Pharmacy
GA MC7MQ
UT WOS:000529736300001
PM 32270439
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Gopinath, B
   Flood, VM
   Kifley, A
   Liew, G
   Mitchell, P
AF Gopinath, Bamini
   Flood, Victoria M.
   Kifley, Annette
   Liew, Gerald
   Mitchell, Paul
TI Smoking, Antioxidant Supplementation and Dietary Intakes among Older
   Adults with Age-Related Macular Degeneration over 10 Years
SO PLOS ONE
LA English
DT Article
ID 10-YEAR INCIDENCE; GLYCEMIC INDEX; EYE DISEASE; RISK; MACULOPATHY;
   ADHERENCE; QUESTIONNAIRE; PROGRESSION; PREVALENCE; AUSTRALIA
AB We aimed to compare the micronutrient usage and other lifestyle behaviors over 10 years among those with and without age-related macular degeneration (AMD). 1612 participants aged 49+ years at baseline were re-examined over 10 years, west of Sydney, Australia. AMD was assessed from retinal photographs. Dietary data were collected using a semi-quantitative food frequency questionnaire. Smoking status was self-reported. 56 participants had any AMD at baseline, of these 25% quit smoking at 5 years and were still not smoking at 10-year follow-up. Among participants who had below the recommended intake of vitamins A, C or E supplements at baseline, those who did compared to those who did not develop late AMD over 10 years were more likely to report vitamins A (total), C or E supplement intake above the recommended intake at 10-year follow-up: multivariable-adjusted OR 4.21 (95% CI 1.65-10.73); OR 6.52 (95% CI 2.76-15.41); and OR 5.71 (95% CI 2.42-13.51), respectively. Participants with compared to without AMD did not appreciably increase fish, fruit and vegetable consumption and overall diet quality. Adherence to smoking and dietary recommendations was poor among older adults with AMD. However, uptake of antioxidant supplements increased significantly among those with late AMD.
C1 [Gopinath, Bamini; Kifley, Annette; Liew, Gerald; Mitchell, Paul] Univ Sydney, Ctr Vis Res, Dept Ophthalmol, Sydney, NSW 2006, Australia.
   [Gopinath, Bamini; Kifley, Annette; Liew, Gerald; Mitchell, Paul] Univ Sydney, Westmead Millennium Inst, Sydney, NSW 2006, Australia.
   [Flood, Victoria M.] Univ Sydney, Fac Hlth Sci, Sydney, NSW 2006, Australia.
   [Flood, Victoria M.] St Vincents Hosp, Sydney, NSW 2010, Australia.
C3 University of Sydney; University of Sydney; Westmead Institute for
   Medical Research; University of Sydney; St Vincents Hospital Sydney
RP Gopinath, B (通讯作者)，Univ Sydney, Ctr Vis Res, Dept Ophthalmol, Sydney, NSW 2006, Australia.
EM bamini.gopinath@sydney.edu.au
RI Flood, Victoria M/A-8732-2016; Gopinath, Bamini/K-4286-2019; Mitchell,
   Paul/P-1498-2014; Liew, Gerald/AAB-6870-2022
OI Flood, Victoria M/0000-0001-5310-7221; Gopinath,
   Bamini/0000-0003-3573-359X; 
FU Australian National Health and Medical Research Council [974159, 991407,
   211069, 262120]; Westmead Millennium Institute; Macular Degeneration
   Foundation; Blackmores Dr Paul Beaumont Fellowship
FX The Blue Mountains Eye Study was funded by the Australian National
   Health and Medical Research Council (Grant Nos. 974159, 991407, 211069,
   262120), and Westmead Millennium Institute. Bamini Gopinath is supported
   by a Macular Degeneration Foundation and Blackmores Dr Paul Beaumont
   Fellowship. The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Age-related Eye Disease Study, 2011, AB AREDS2
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   [Anonymous], 2005, NIH Consens State Sci Statements, V22, P1
   [Anonymous], 2005, ARCH OPHTHALMOL-CHIC, V123, P1570, DOI DOI 10.1001/ARCHOPHT.123.11.1570
   Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   Australian Institute of Health and Welfare, 2007, AUSTR DIET QUAL IND
   Barclay AW, 2008, PUBLIC HEALTH NUTR, V11, P573, DOI 10.1017/S1368980007001103
   Bourla DH, 2006, J AM GERIATR SOC, V54, P1130, DOI 10.1111/j.1532-5415.2006.00771.x
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Charkoudian LD, 2008, OPHTHALMOLOGY, V115, P1032, DOI 10.1016/j.ophtha.2007.08.003
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P142, DOI 10.1001/jamaophthalmol.2013.7376
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Christen WG, 2009, ARCH INTERN MED, V169, P335, DOI 10.1001/archinternmed.2008.574
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Department of Community Services and Health, 1995, NUTTAB95 NUTR DAT TA
   Department of Community Services and Health, 1990, NUTTAB90 NUTR DATA T
   Health National and Medical Research Council, 2003, DIET GUID AUSTR AD
   Ho L, 2011, ARCH OPHTHALMOL-CHIC, V129, P758, DOI 10.1001/archophthalmol.2011.141
   Hochstetler BS, 2010, RETINA-J RET VIT DIS, V30, P1166, DOI 10.1097/IAE.0b013e3181cea5c6
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kaushik S, 2008, AM J CLIN NUTR, V88, P1104, DOI 10.1093/ajcn/88.4.1104
   Kennedy RD, 2012, CLIN EXP OPTOM, V95, P590, DOI 10.1111/j.1444-0938.2012.00789.x
   KLEIN BEK, 1989, INVEST OPHTH VIS SCI, V30, P304
   McLennan W, 1995, 48070 AUSTR BUR STAT
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Ng WT, 2006, CLIN EXP OPHTHALMOL, V34, P9, DOI 10.1111/j.1442-9071.2006.01141.x
   Russell J, 2013, BRIT J NUTR, V109, P547, DOI 10.1017/S0007114512001377
   Shah SU, 2013, CAN J OPHTHALMOL, V48, P204, DOI 10.1016/j.jcjo.2013.01.013
   Sin HPY, 2013, ACTA OPHTHALMOL, V91, P6, DOI 10.1111/j.1755-3768.2011.02357.x
   Smith A, 1998, AUSTR GUIDE HLTH EAT, P1
   Smith W, 1998, AUST NZ J PUBL HEAL, V22, P456, DOI 10.1111/j.1467-842X.1998.tb01414.x
   Tan JSL, 2009, ARCH OPHTHALMOL-CHIC, V127, P656, DOI 10.1001/archophthalmol.2009.76
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Wang JJ, 2009, AM J EPIDEMIOL, V169, P633, DOI 10.1093/aje/kwn358
   WILLETT WC, 1988, AM J EPIDEMIOL, V127, P188, DOI 10.1093/oxfordjournals.aje.a114780
   Yu X. Q., 1999, Australian Journal of Nutrition and Dietetics, V56, P69
NR 38
TC 12
Z9 12
U1 0
U2 12
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 30
PY 2015
VL 10
IS 3
AR e0122548
DI 10.1371/journal.pone.0122548
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA CE9AD
UT WOS:000352134700185
PM 25822372
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Chang, TS
   Kokame, G
   Casey, R
   Prenner, J
   Feiner, L
   Anderson, N
AF Chang, Tom S.
   Kokame, Gregg
   Casey, Raynor
   Prenner, Jonathan
   Feiner, Leonard
   Anderson, Nick
TI SHORT-TERM EFFECTIVENESS OF INTRAVITREAL BEVACIZUMAB VERSUS RANIBIZUMAB
   INJECTIONS FOR PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR
   DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE ranibizumab; bevacizumab; Lucentis; Avastin; age-related macular
   degeneration (AMD); intravitreal injection; OCT
ID ENDOTHELIAL GROWTH-FACTOR; OPTICAL COHERENCE TOMOGRAPHY; PRIMARY BREAST
   LYMPHOMA; CHOROIDAL NEOVASCULARIZATION; VISUAL-ACUITY; AVASTIN
   TREATMENT; MEMBRANES; SECONDARY; PHARMACOKINETICS; MASTECTOMY
AB Purpose: To compare the effectiveness of three consecutive intravitreal injections of bevacizumab (Avastin) and ranibizumab (Lucentis) in patients with treatment-naive neovascular age-related macular degeneration.
   Methods: This is a retrospective comparative study of qualifying consecutively treated patients (n = 176) with new-onset subfoveal choroidal neovascularization presenting at 6 retina referral centers. Patients were treated with 3 consecutive monthly injections of ranibizumab (0.5 mg) or 3 injections of bevacizumab every 6 weeks (1.25 mg) as determined by physician and patient preference. Ophthalmologic evaluations included monthly visual acuity measurements, ocular examinations, and optical coherence tomography imaging at each visit.
   Results: A 29.2% reduction in the mean central foveal thickness measurement through optical coherence tomography was found in the ranibizumab-treated patients versus a 20.9% reduction in the bevacizumab-treated patients (P <= 0.02). Fifty-three percent of ranibizumab-treated patients had returned to a central foveal thickness of <200 mu m by the completion of 3 injections compared with 35% of patients treated with bevacizumab (P <= 0.07). No ocular or systemic adverse events were reported in either group.
   Conclusion: Short-term effectiveness of ranibizumab treatment, as measured by incremental improvement in optical coherence tomography parameters, was significantly greater than bevacizumab treatment, suggesting that there is a difference in the biologic activities of ranibizumab and bevacizumab. RETINA 29:1235-1241, 2009
C1 [Chang, Tom S.] Retina Inst Calif, Pasadena, CA 91105 USA.
   [Kokame, Gregg] Kapiolani Med Ctr, Retina Ctr Pali Momi, Aiea, HI USA.
   [Casey, Raynor] Retina Associates PC, Raleigh, NC USA.
   [Prenner, Jonathan] Retina Vitreous Ctr, New Brunswick, NJ USA.
   [Feiner, Leonard] Retina Associates New Jersey PA, Teaneck, NJ USA.
   [Anderson, Nick] SE Retina Associates, Oak Ridge, TN USA.
RP Chang, TS (通讯作者)，Retina Inst Calif, 800 S Fairmt Ave,Suite 312, Pasadena, CA 91105 USA.
EM tchang@retina2020.com
CR AVERY RL, 2006, OPHTHALMOLOGY, V113
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P2179, DOI 10.1016/j.ophtha.2007.09.012
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P855, DOI 10.1016/j.ophtha.2007.01.017
   Bashshur ZF, 2008, AM J OPHTHALMOL, V145, P249, DOI 10.1016/j.ajo.2007.09.031
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Browning DJ, 2009, RETINA-J RET VIT DIS, V29, P300, DOI 10.1097/IAE.0b013e318194995d
   Chan A, 2005, ARCH OPHTHALMOL-CHIC, V123, P939, DOI 10.1001/archopht.123.7.939
   Chen CY, 2007, AM J OPHTHALMOL, V143, P510, DOI 10.1016/j.ajo.2006.10.004
   Emerson MV, 2007, RETINA-J RET VIT DIS, V27, P439, DOI 10.1097/IAE.0b013e31804b3e15
   Falkenstein IA, 2007, RETINA-J RET VIT DIS, V27, P701, DOI 10.1097/IAE.0b013e3180654240
   Frank RN, 1996, AM J OPHTHALMOL, V122, P393, DOI 10.1016/S0002-9394(14)72066-5
   GOLDBERGER MJ, RANIBIZUMBAB APPROVA
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   HEIER JS, 2006, OPHTHALMOLOGY, V113
   Jeanneret-Sozzi W, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-86
   Jennings WC, 2007, ANN SURG, V245, P784, DOI 10.1097/01.sla.0000254418.90192.59
   Keane PA, 2008, OPHTHALMOLOGY, V115, P2206, DOI 10.1016/j.ophtha.2008.08.016
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Lazic R, 2007, GRAEF ARCH CLIN EXP, V245, P68, DOI 10.1007/s00417-006-0466-4
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Otani A, 2002, MICROVASC RES, V64, P162, DOI 10.1006/mvre.2002.2407
   Piroth MD, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-114
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHALMOLOGY, V112, P1048, DOI 10.1016/j.ophtha.2005.01.043
   Ruckman J, 1998, J BIOL CHEM, V273, P20556, DOI 10.1074/jbc.273.32.20556
   Scott IU, 2009, OPHTHALMOLOGY, V116, P504, DOI 10.1016/j.ophtha.2008.10.017
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
NR 30
TC 21
Z9 21
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD OCT
PY 2009
VL 29
IS 9
BP 1235
EP 1241
DI 10.1097/IAE.0b013e3181b20eed
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 506EF
UT WOS:000270755800004
PM 19934818
DA 2022-11-30
ER

PT J
AU Giancipoli, E
   Pinna, A
   Boscia, F
   Zasa, G
   Sotgiu, G
   Dore, S
   Ricci, GD
AF Giancipoli, Ermete
   Pinna, Antonio
   Boscia, Francesco
   Zasa, Gianluigi
   Sotgiu, Giovanni
   Dore, Simone
   Ricci, Giuseppe D'Amico
TI Intravitreal Dexamethasone in Patients with Wet Age-Related Macular
   Degeneration Resistant to Anti-VEGF: A Prospective Pilot Study
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID TRIAMCINOLONE ACETONIDE; PHOTODYNAMIC THERAPY; RANIBIZUMAB; IMPLANT;
   MANAGEMENT; FLUID
AB Purpose. To evaluate the efficacy and safety of a single intravitreal dexamethasone implant (DXI) combined with intravitreal antivascular endothelial growth factor (anti-VEGF) therapy, in patients with neovascular age-related macular degeneration (wet-AMD) resistant to conventional treatment. Methods. In this randomized, controlled pilot study, 16 eyes of 15 patients, unresponsive to anti-VEGF therapy, were enrolled and randomly assigned to two groups: DXI + anti-VEGF (treatment group: 11 eyes) and monthly anti-VEGF alone (control group: 5 eyes). Patients were treated at baseline and followed for 6 months. Best corrected visual acuity (BCVA), optical coherence tomography (OCT) parameters, and fluorescein angiography (FA) were evaluated. Results. Eight eyes (72.7%) in the treatment group and 2 eyes in the control group (40%) showed complete retinal fluid resorption (p = 0.049). BCVA showed no significant change from baseline in both the treatment group and the control group (p = 0.40 and p = 0.29, respectively). Both median central foveal thickness (CFT) and median macular volume showed a greater reduction from baseline in the treatment group. Conclusion. In patients showing an incomplete response to anti-VEGF therapy, DXI combined with intravitreal anti-VEGF seems to improve retinal fluid resorption without functional advantage.
C1 [Giancipoli, Ermete; Ricci, Giuseppe D'Amico] Univ Sassari, Dept Biomed Sci, Sassari, Italy.
   [Pinna, Antonio; Boscia, Francesco; Zasa, Gianluigi] Univ Sassari, Dept Med Surg & Expt Sci, Ophthalmol Unit, Sassari, Italy.
   [Pinna, Antonio; Boscia, Francesco; Sotgiu, Giovanni] Azienda Osped Univ AOU Sassari, Sassari, Italy.
   [Sotgiu, Giovanni; Dore, Simone] Univ Sassari, Dept Biomed Sci, Clin Epidemiol & Med Stat Unit, Sassari, Italy.
C3 University of Sassari; University of Sassari; University of Sassari
RP Ricci, GD (通讯作者)，Univ Sassari, Dept Biomed Sci, Sassari, Italy.
EM giuseppedamicoricci@icloud.com
RI Sotgiu, Giovanni/N-1032-2017; Ricci, Giuseppe D'Amico/O-6051-2019;
   Boscia, Francesco/AAC-7729-2022; Pinna, Antonio/H-5067-2018; Dore,
   Sylvain/AAG-1470-2020
OI Sotgiu, Giovanni/0000-0002-1600-4474; Ricci, Giuseppe
   D'Amico/0000-0002-9022-4790; Pinna, Antonio/0000-0003-3052-2662; Dore,
   Simone/0000-0003-4770-0445; Dore, Sylvain/0000-0003-3771-5109
CR Amoaku WM, 2015, EYE, V29, P721, DOI 10.1038/eye.2015.48
   Barikian A, 2017, RETINA-J RET VIT DIS, V37, P1337, DOI 10.1097/IAE.0000000000001366
   Boyer DS, 2014, OPHTHALMOLOGY, V121, P1904, DOI 10.1016/j.ophtha.2014.04.024
   Brown DM, 2013, RETINA-J RET VIT DIS, V33, P23, DOI 10.1097/IAE.0b013e318263cedf
   Calvo P, 2015, BRIT J OPHTHALMOL, V99, P723, DOI 10.1136/bjophthalmol-2014-305684
   Chan A, 2009, OPHTHAL SURG LAS IM, V40, P561, DOI 10.3928/15428877-20091030-05
   Chaudhary V, 2016, CAN J OPHTHALMOL, V51, P302, DOI 10.1016/j.jcjo.2016.04.020
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Edelman JL, 2005, EXP EYE RES, V80, P249, DOI 10.1016/j.exer.2004.09.013
   Felinski EA, 2008, EXP EYE RES, V86, P867, DOI 10.1016/j.exer.2008.01.002
   Fung AT, 2012, EYE, V26, P1181, DOI 10.1038/eye.2012.174
   Gianniou C, 2015, RETINA-J RET VIT DIS, V35, P1195, DOI 10.1097/IAE.0000000000000465
   Haller JA, 2011, OPHTHALMOLOGY, V118, P2453, DOI 10.1016/j.ophtha.2011.05.014
   Hatta Y, 2010, RETINA-J RET VIT DIS, V30, P495, DOI 10.1097/IAE.0b013e3181bcedbe
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Jaffe GJ, 2013, OPHTHALMOLOGY, V120, P1860, DOI 10.1016/j.ophtha.2013.01.073
   Joshi L, 2013, BRIT J OPHTHALMOL, V97, P1040, DOI 10.1136/bjophthalmol-2013-303207
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Kuppermann BD, 2015, OPHTHALMOLOGICA, V234, P40, DOI 10.1159/000381865
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Nussenblatt RB, 2014, AM J OPHTHALMOL, V158, P5, DOI 10.1016/j.ajo.2014.03.014
   Oh H, 1999, INVEST OPHTH VIS SCI, V40, P1891
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Piri Niloofar, 2014, J Ophthalmic Vis Res, V9, P469, DOI 10.4103/2008-322X.150826
   Rezar-Dreindl S, 2017, RETINA-J RET VIT DIS, V37, P962, DOI 10.1097/IAE.0000000000001264
   Ricci G. D'Amico, 2017, ACTA OPHTHALMOLOGICA, V95
   Schaal S, 2008, OPHTHALMOLOGY, V115, P2199, DOI 10.1016/j.ophtha.2008.07.007
   Schmidt-Erfurth U, 2016, PROG RETIN EYE RES, V50, P1, DOI 10.1016/j.preteyeres.2015.07.007
NR 28
TC 13
Z9 13
U1 0
U2 2
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PY 2018
VL 2018
AR 5612342
DI 10.1155/2018/5612342
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GQ3HX
UT WOS:000441554200001
PM 30151278
OA Green Submitted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Park, JY
   Kang, MJ
   Kim, BG
   Chung, KH
   Sim, H
   Lee, SW
   Kim, JS
   Lee, HS
   Hwang, JH
AF Park, Jae Yong
   Kang, Min-Ji
   Kim, Bum Gi
   Chung, Kyu Ho
   Sim, Ha Eun
   Lee, Seong Woo
   Kim, Jae Suk
   Lee, Hyeon Seok
   Hwang, Je Hyung
TI TOPOGRAPHIC CHANGES IN CHOROIDAL THICKNESS IN AGE-RELATED MACULAR
   DEGENERATION DURING THE DEVELOPMENT OF ACTIVE CHOROIDAL
   NEOVASCULARIZATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; choroidal neovascularization;
   choroidal thickness
ID BLINDNESS; EYES
AB Purpose: To evaluate topographic changes in choroidal thickness during development of choroidal neovascularization (CNV) in treatment-naive age-related macular degeneration (AMD) and to test the value of such changes as a predictive tool of CNV development. Methods: This retrospective cohort included 86 eyes that developed CNV from intermediate AMD, 43 eyes with intermediate AMD, and 36 eyes without AMD. Patients with intermediate AMD underwent spectral domain optical coherence tomography using enhanced depth imaging mode every 6 months until CNV was detected. Choroidal neovascularization was localized to one of the subfields of Early Treatment of Diabetic Retinopathy Study grid on fluorescein angiography. Average choroidal thickness of each subfield was calculated. Results: Choroidal thickness of the subfield where CNV developed at first clinical detection significantly increased compared with that 6 months before (P = 0.000 for central, P = 0.001 for superior parafoveal, P = 0.002 for temporal parafoveal, P = 0.002 for inferior parafoveal, and P = 0.001 for nasal parafoveal subfield). In eight patients who visited unexpectedly 3 months before CNV development in central subfield, choroidal thickness of central subfield increased significantly compared with that 6 months before CNV development (P = 0.001). Conclusion: Choroidal neovascularization development accompanied choroidal thickening of the corresponding subfield. Regular measurement of choroidal thickness may assist in prediction of CNV.
C1 [Park, Jae Yong; Kang, Min-Ji; Kim, Bum Gi; Chung, Kyu Ho; Sim, Ha Eun; Lee, Seong Woo; Kim, Jae Suk; Hwang, Je Hyung] Inje Univ, Sanggye Paik Hosp, Dept Ophthalmol, Coll Med, Seoul, South Korea.
   [Lee, Hyeon Seok] Nun Seeone Eye Clin, Busan, South Korea.
C3 Inje University
RP Hwang, JH (通讯作者)，Inje Univ, Sanggye Paik Hosp, Dept Ophthalmol, 1342 Dongil Ro, Seoul 139707, South Korea.
EM violentviolet15@daum.net
OI Hwang, Jehyung/0000-0001-8081-7771
CR Age-Related Eye Disease Study 2 Research Group, 2013, JAMA, V309, P2005, DOI 10.1001/jama.2013.4997
   Agrawal R, 2016, SCI REP-UK, V6, DOI 10.1038/srep21090
   Baffi J, 2000, INVEST OPHTH VIS SCI, V41, P3582
   Beaumont PE, 2006, ARCH OPHTHALMOL-CHIC, V124, P807, DOI 10.1001/archopht.124.6.807
   Bhisitkul RB, 2006, BRIT J OPHTHALMOL, V90, P1542, DOI 10.1136/bjo.2006.098426
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Branchini L, 2013, JAMA OPHTHALMOL, V131, P693, DOI 10.1001/jamaophthalmol.2013.692
   Bressler NM, 2011, ARCH OPHTHALMOL-CHIC, V129, P709, DOI 10.1001/archophthalmol.2011.140
   Carnevali A, 2018, OPHTHALMOL RETINA, V2, P922, DOI 10.1016/j.oret.2018.02.002
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Fein JG, 2014, OPHTHAL SURG LAS IM, V45, P32, DOI 10.3928/23258160-20131220-04
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Hussain MA, 2018, COMPUT MED IMAG GRAP, V63, P41, DOI 10.1016/j.compmedimag.2018.01.001
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Ikuno Y, 2010, INVEST OPHTH VIS SCI, V51, P2173, DOI 10.1167/iovs.09-4383
   Invernizzi A, 2018, INVEST OPHTH VIS SCI, V59, P3836, DOI 10.1167/iovs.18-23960
   Jirarattanasopa P, 2014, CLIN OPHTHALMOL, V8, P2209, DOI 10.2147/OPTH.S71343
   Koh LHL, 2017, ACTA OPHTHALMOL, V95, pE597, DOI 10.1111/aos.13399
   Lee S, 2013, INVEST OPHTH VIS SCI, V54, P2864, DOI 10.1167/iovs.12-11521
   Maloca P, 2018, TRANSL VIS SCI TECHN, V7, DOI 10.1167/tvst.7.4.8
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   Mazzaferri J, 2017, SCI REP-UK, V7, DOI 10.1038/srep42112
   Park JY, 2017, INVEST OPHTH VIS SCI, V58, P5819, DOI 10.1167/iovs.17-22581
   Querques G, 2013, INVEST OPHTH VIS SCI, V54, P6886, DOI 10.1167/iovs.13-11665
   Schultz DW, 2003, HUM MOL GENET, V12, P3315, DOI 10.1093/hmg/ddg348
   Shin Joong Won, 2012, Korean J Ophthalmol, V26, P255, DOI 10.3341/kjo.2012.26.4.255
   Wang SM, 2015, BMC OPHTHALMOL, V15, DOI 10.1186/s12886-015-0059-2
   Wei X, 2017, RETINA-J RET VIT DIS, V37, P1120, DOI 10.1097/IAE.0000000000001312
   Yiu G, 2015, AM J OPHTHALMOL, V159, P617, DOI 10.1016/j.ajo.2014.12.010
   Zhao Shi-hong, 2004, Zhonghua Yan Ke Za Zhi, V40, P522
NR 32
TC 4
Z9 4
U1 1
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD FEB
PY 2021
VL 41
IS 2
BP 409
EP 422
DI 10.1097/IAE.0000000000002845
PG 14
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA SL0VU
UT WOS:000656635200036
PM 32453064
DA 2022-11-30
ER

PT J
AU Nagai, N
   Minami, S
   Suzuki, M
   Shinoda, H
   Kurihara, T
   Sonobe, H
   Watanabe, K
   Uchida, A
   Ban, N
   Tsubota, K
   Ozawa, Y
AF Nagai, Norihiro
   Minami, Sakiko
   Suzuki, Misa
   Shinoda, Hajime
   Kurihara, Toshihide
   Sonobe, Hideki
   Watanabe, Kazuhiro
   Uchida, Atsuro
   Ban, Norimitsu
   Tsubota, Kazuo
   Ozawa, Yoko
TI Macular Pigment Optical Density and Photoreceptor Outer Segment Length
   as Predisease Biomarkers for Age-Related Macular Degeneration
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Article
DE macular pigment; photoreceptor; age-related macular degeneration;
   retina; medical checkup; biomarker
ID HUMAN RETINA; EYE DISEASE; LUTEIN
AB To explore predisease biomarkers, which may help screen for the risk of age-related macular degeneration (AMD) at very early stages, macular pigment optical density (MPOD) and photoreceptor outer segment (PROS) length were analyzed. Thirty late AMD fellow eyes, which are at high risk and represent the predisease condition of AMD, were evaluated and compared with 30 age-matched control eyes without retinal diseases; there was no early AMD involvement in the AMD fellow eyes. MPOD was measured using MPS2 (R) (M.E. Technica Co. Ltd., Tokyo, Japan), and PROS length was measured based on optical coherence tomography images. MPOD levels and PROS length in the AMD fellow eyes were significantly lower and shorter, respectively, than in control eyes. MPOD and PROS length were positively correlated in control eyes (R = 0.386; p = 0.035) but not in AMD fellow eyes. Twenty (67%) AMD fellow eyes met the criteria of MPOD < 0.65 and/or PROS length < 35 mu m, while only five (17%) control eyes did. After adjusting for age and sex, AMD fellow eyes more frequently satisfied the definition (p < 0.001; 95% confidence interval, 3.50-60.4; odds ratio, 14.6). The combination of MPOD and PROS length may be a useful biomarker for screening predisease AMD patients, although further studies are required in this regard.
C1 [Nagai, Norihiro; Suzuki, Misa; Ozawa, Yoko] Keio Univ, Lab Retinal Cell Biol, Sch Med, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.
   [Nagai, Norihiro; Minami, Sakiko; Suzuki, Misa; Shinoda, Hajime; Kurihara, Toshihide; Sonobe, Hideki; Watanabe, Kazuhiro; Uchida, Atsuro; Ban, Norimitsu; Tsubota, Kazuo; Ozawa, Yoko] Keio Univ, Dept Ophthalmol, Sch Med, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.
   [Ozawa, Yoko] St Lukes Int Hosp, Dept Ophthalmol, Chuo Ku, 9-1 Akashi Cho, Tokyo 1048560, Japan.
   [Ozawa, Yoko] St Lukes Int Univ, Chuo Ku, 9-1 Akashi Cho, Tokyo 1048560, Japan.
C3 Keio University; Keio University; St. Luke's International Hospital; St.
   Luke's International Hospital
RP Ozawa, Y (通讯作者)，Keio Univ, Lab Retinal Cell Biol, Sch Med, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.; Ozawa, Y (通讯作者)，Keio Univ, Dept Ophthalmol, Sch Med, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.; Ozawa, Y (通讯作者)，St Lukes Int Hosp, Dept Ophthalmol, Chuo Ku, 9-1 Akashi Cho, Tokyo 1048560, Japan.; Ozawa, Y (通讯作者)，St Lukes Int Univ, Chuo Ku, 9-1 Akashi Cho, Tokyo 1048560, Japan.
EM nagai@a5.keio.jp; saki.love5@icloud.com; misayutakatomo@icloud.com;
   shinoha@mac.com; kurihara@z8.keio.jp; betty_vol2@ybb.ne.jp;
   gaku047nikoniko3mickey@yahoo.co.jp; uchidats@gmail.com; nban@keio.jp;
   tsubota@z3.keio.jp; ozawa@a5.keio.jp
RI Kurihara, Toshihide/ABA-7058-2020; Uchida, Atsuro/GVT-8593-2022;
   Tsubota, Kazuo/M-1915-2013
OI Kurihara, Toshihide/0000-0002-5457-2720; Ozawa,
   Yoko/0000-0003-4797-5705; Tsubota, Kazuo/0000-0002-8874-7111
CR Amissah-Arthur KN, 2012, EYE, V26, P394, DOI 10.1038/eye.2011.335
   Arunkumar R., 2020, BIOCH BIOPHYS ACTA B
   Barker FM, 2011, INVEST OPHTH VIS SCI, V52, P3934, DOI 10.1167/iovs.10-5898
   Brandl C, 2019, INVEST OPHTH VIS SCI, V60, P1581, DOI 10.1167/iovs.18-25332
   Calvo MM, 2005, CRIT REV FOOD SCI, V45, P671, DOI 10.1080/10408690590957034
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chew EY, 2012, OPHTHALMOLOGY, V119, P2282, DOI 10.1016/j.ophtha.2012.05.027
   Fasler K, 2020, BRIT J OPHTHALMOL, V104, P684, DOI 10.1136/bjophthalmol-2019-314446
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Hasegawa T, 2015, GRAEF ARCH CLIN EXP, V253, P343, DOI 10.1007/s00417-014-2695-2
   Izumi-Nagai K, 2007, ARTERIOSCL THROM VAS, V27, P2555, DOI 10.1161/ATVBAHA.107.151431
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kamoshita M, 2016, SCI REP-UK, V6, DOI 10.1038/srep30226
   Kamoshita M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103013
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kogo J, 2017, ADV THER, V34, P2139, DOI 10.1007/s12325-017-0598-4
   Lains I, 2018, RETINA-J RET VIT DIS, V38, P1145, DOI 10.1097/IAE.0000000000001659
   Lains I, 2017, OPHTHALMOLOGY, V124, P1340, DOI 10.1016/j.ophtha.2017.03.061
   Lamin A, 2019, EYE, V33, P428, DOI 10.1038/s41433-018-0234-9
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Morizane Y, 2019, JPN J OPHTHALMOL, V63, P26, DOI 10.1007/s10384-018-0623-4
   Nag TC, 2012, MICRON, V43, P759, DOI 10.1016/j.micron.2012.01.011
   Nagai N, 2015, RETINA-J RET VIT DIS, V35, P820, DOI 10.1097/IAE.0000000000000382
   Obana A, 2008, OPHTHALMOLOGY, V115, P147, DOI 10.1016/j.ophtha.2007.02.028
   Obana A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139257
   Okamoto T, 2019, TRANSL VIS SCI TECHN, V8, DOI 10.1167/tvst.8.6.20
   Osada H, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178627
   Ozawa Y, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0557-5
   Ozawa Y, 2012, CURR PHARM DESIGN, V18, P51, DOI 10.2174/138161212798919101
   Ozawa Y, 2008, J BIOL CHEM, V283, P24561, DOI 10.1074/jbc.M802238200
   POKORNY J, 1987, APPL OPTICS, V26, P1437, DOI 10.1364/AO.26.001437
   Rozing MP, 2020, PROG RETIN EYE RES, V76, DOI 10.1016/j.preteyeres.2019.100825
   Sasaki M, 2010, DIABETOLOGIA, V53, P971, DOI 10.1007/s00125-009-1655-6
   Sasaki M, 2012, J NUTR BIOCHEM, V23, P423, DOI 10.1016/j.jnutbio.2011.01.006
   Sasaki M, 2009, INVEST OPHTH VIS SCI, V50, P1433, DOI 10.1167/iovs.08-2493
   Sene A, 2015, TRENDS MOL MED, V21, P43, DOI 10.1016/j.molmed.2014.10.005
   Sharpe LT, 1998, VISION RES, V38, P3233, DOI 10.1016/S0042-6989(97)00457-4
   Shiono A, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0199552
   Shiono A, 2013, OPHTHALMOLOGY, V120, P788, DOI 10.1016/j.ophtha.2012.09.044
   SNODDERLY DM, 1984, INVEST OPHTH VIS SCI, V25, P674
   Tomita Y, 2016, OPTOMETRY VISION SCI, V93, P70, DOI 10.1097/OPX.0000000000000755
   Toprak I, 2017, INT OPHTHALMOL, V37, P801, DOI 10.1007/s10792-016-0331-3
   Trieschmann M, 2008, EYE, V22, P132, DOI 10.1038/sj.eye.6702780
   van der Veen RLP, 2009, OPHTHAL PHYSL OPT, V29, P127, DOI 10.1111/j.1475-1313.2008.00618.x
   Xu J, 1997, J OPT SOC AM A, V14, P953, DOI 10.1364/JOSAA.14.000953
NR 45
TC 7
Z9 7
U1 0
U2 2
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD MAY
PY 2020
VL 9
IS 5
AR 1347
DI 10.3390/jcm9051347
PG 10
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA LY0OO
UT WOS:000540223800104
PM 32380638
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Wada, I
   Oshima, Y
   Shiose, S
   Kano, K
   Nakao, S
   Kaizu, Y
   Yoshida, S
   Ishibashi, T
   Sonoda, K
AF Wada, Iori
   Oshima, Yuji
   Shiose, Satomi
   Kano, Kumiko
   Nakao, Shintaro
   Kaizu, Yoshihiro
   Yoshida, Shigeo
   Ishibashi, Tatsuro
   Sonoda, Koh-hei
TI Five-year treatment outcomes following intravitreal ranibizumab
   injections for neovascular age-related macular degeneration in Japanese
   patients
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Ranibizumab; Long-term treatment; Pro
   re nata treatment; Macular atrophy
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; GEOGRAPHIC ATROPHY; PHOTODYNAMIC
   THERAPY; VERTEPORFIN; GROWTH; HORIZON; ANCHOR; MARINA
AB PurposeTo assess the real-world 5-year treatment outcomes of ranibizumab therapy in Japanese patients with neovascular age-related macular degeneration (AMD).MethodsThis was a retrospective, observational, and open-label effectiveness study that included 295 eyes. The participants were patients with treatment-naive neovascular AMD who received intravitreal ranibizumab (IVR) monthly injection at least three times as the loading phase, followed by further injections as needed (pro re nata (PRN)) and follow-up assessments for 5years. Outcomes were determined at least 5years after the first ranibizumab injection.ResultsMean logMAR best-corrected visual acuity (BCVA) at baseline was 0.52. The mean BCVA significantly improved after three loading injections; however, it declined gradually. The BCVA at 1year was significantly better than the baseline BCVA, whereas the 3-year, 4-year, and 5-year BCVA values were significantly lower than the baseline values. The average central foveal thickness improved significantly from 366125m to 268 +/- 134m (p<0.0001). Macular atrophy was significantly more likely to occur in cases with classic choroidal neovascularization (CNV) than in cases with other AMD (p=0.01).Conclusions IVR is well tolerated in eyes with AMD. However, a PRN regimen for AMD may have limited real-world effectiveness for long-term maintenance of improved visual acuity. Macular atrophy may occur more frequently in classic CNV. To maintain good vision, IVR treatment should be started earlier and performed continuously.
C1 [Wada, Iori; Oshima, Yuji; Shiose, Satomi; Kano, Kumiko; Nakao, Shintaro; Kaizu, Yoshihiro; Yoshida, Shigeo; Ishibashi, Tatsuro; Sonoda, Koh-hei] Kyushu Univ, Grad Sch Med Sci, Dept Ophthalmol, Higashi Ku, 3-1-1 Maidashi, Fukuoka, Fukuoka 8128582, Japan.
   [Oshima, Yuji] Fukuoka Univ, Chikushi Hosp, Dept Ophthalmol, Fukuoka, Fukuoka, Japan.
C3 Kyushu University; Fukuoka University
RP Oshima, Y (通讯作者)，Kyushu Univ, Grad Sch Med Sci, Dept Ophthalmol, Higashi Ku, 3-1-1 Maidashi, Fukuoka, Fukuoka 8128582, Japan.; Oshima, Y (通讯作者)，Fukuoka Univ, Chikushi Hosp, Dept Ophthalmol, Fukuoka, Fukuoka, Japan.
EM yuji@eye.med.kyushu-u.ac.jp
FU JSPS KAKENHI [Kiban C 17K11454]
FX This study was funded by the JSPS KAKENHI Grant Number (Kiban C 17K11454
   (to Y.O.)).
CR Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Bhisitkul RB, 2015, AM J OPHTHALMOL, V159, P915, DOI 10.1016/j.ajo.2015.01.032
   Boulanger-Scemama E, 2016, J FR OPHTALMOL, V39, P668, DOI 10.1016/j.jfo.2016.06.001
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2011, OPHTHALMOLOGY, V118, P1089, DOI 10.1016/j.ophtha.2011.02.039
   Francis PJ, 2011, CLIN OPHTHALMOL, V5, P1127, DOI 10.2147/OPTH.S11627
   Gheorghe Andreea, 2015, Rom J Ophthalmol, V59, P74
   Grunwald JE, 2017, OPHTHALMOLOGY, V124, P97, DOI 10.1016/j.ophtha.2016.09.012
   Grunwald JE, 2015, OPHTHALMOLOGY, V122, P809, DOI 10.1016/j.ophtha.2014.11.007
   Heimes B, 2011, GRAEF ARCH CLIN EXP, V249, P639, DOI 10.1007/s00417-010-1524-5
   HOLZ FG, 1994, OPHTHALMOLOGY, V101, P1522
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   MAGUIRE P, 1986, AM J OPHTHALMOL, V102, P621, DOI 10.1016/0002-9394(86)90535-0
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Munk MR, 2016, ACTA OPHTHALMOL, V94, pE757, DOI 10.1111/aos.13157
   Ogasawara M, 2018, JPN J OPHTHALMOL, V62, P584, DOI 10.1007/s10384-018-0605-6
   Oshima Y, 2017, OPHTHALMOLOGICA, V238, P163, DOI 10.1159/000477448
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1220
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   Takahashi A, 2016, AM J OPHTHALMOL, V168, P260, DOI 10.1016/j.ajo.2016.06.006
   Takahashi Y, 2018, JPN J OPHTHALMOL, V62, P576, DOI 10.1007/s10384-018-0615-4
   Wecker T, 2017, BRIT J OPHTHALMOL, V101, P353, DOI 10.1136/bjophthalmol-2016-308668
NR 28
TC 10
Z9 10
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD JUL
PY 2019
VL 257
IS 7
BP 1411
EP 1418
DI 10.1007/s00417-019-04361-8
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA IC7WI
UT WOS:000471187800008
PM 31119425
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Ho, AC
   Albini, TA
   Brown, DM
   Boyer, DS
   Regillo, CD
   Heier, JS
AF Ho, Allen C.
   Albini, Thomas A.
   Brown, David M.
   Boyer, David S.
   Regillo, Carl D.
   Heier, Jeffrey S.
TI The Potential Importance of Detection of Neovascular Age-Related Macular
   Degeneration When Visual Acuity Is Relatively Good
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID BASE-LINE-CHARACTERISTICS; TREATMENTS TRIALS CATT; CHOROIDAL
   NEOVASCULARIZATION; CLINICAL CHARACTERISTICS; SUBGROUP ANALYSIS; LESION
   SIZE; RANIBIZUMAB; OUTCOMES; VERTEPORFIN; BEVACIZUMAB
AB The advent of anti-vascular endothelial growth factor treatment has changed the prognosis for patients with neovascular age-related macular degeneration (nvAMD). The ability to stabilize or improve vision with these treatments is a major step in enabling patients to continue to function at the highest possible level. Many studies have demonstrated that the better the visual acuity (VA) is at the time of treatment initiation, the higher the likelihood that VA will be better during at least the following 2 years; as such, detection of nvAMD when VA is relatively good is important. Data on the VA of patients with intermediate AMD and VA at the time of nvAMD diagnosis suggest that patients are typically losing an average of 3 to 5 lines of vision and possibly more between the time that intermediate AMD progresses to nvAMD and the diagnosis of nvAMD is made. The average patient may have nvAMD for 6 to 12 months before diagnosis and treatment initiation. Current efforts in management of nvAMD are primarily aimed at optimizing anti-vascular endothelial growth factor treatments that have the potential to improve VA outcomes by amagnitude of letters. Additional tools or other efforts to identify patients with nvAMD before substantial vision loss has occurred may reduce the amount of visual loss sustained with anti-vascular endothelial growth factor therapy, and have the potential to improve VA outcomes substantially.
C1 [Ho, Allen C.; Regillo, Carl D.] Wills Eye Hosp & Res Inst, Mid Atlantic Retina, 840 Walnut St,10th Floor, Philadelphia, PA 19107 USA.
   [Albini, Thomas A.] Bascom Palmer Eye Inst, Palm Beach Gardens, FL USA.
   [Brown, David M.] Retina Consultants Houston, Houston, TX USA.
   [Boyer, David S.] Retina, Vitreous Associates Med Grp, Beverly Hills, CA USA.
   [Heier, Jeffrey S.] Ophthalm Consultants Boston, Boston, MA USA.
C3 Jefferson University; Bascom Palmer Eye Institute; Retina Vitreous
   Associates Medical Group; Ophthalmic Consultants of Boston
RP Ho, AC (通讯作者)，Wills Eye Hosp & Res Inst, Mid Atlantic Retina, 840 Walnut St,10th Floor, Philadelphia, PA 19107 USA.
EM acho@midatlanticretina.com
OI Albini, Thomas/0000-0003-2199-9047; Ho, Allen/0000-0003-3921-608X
CR Acharya N, 2009, BRIT J OPHTHALMOL, V93, P627, DOI 10.1136/bjo.2008.147231
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chew EY, 2012, OPHTHALMOLOGY, V119, P2282, DOI 10.1016/j.ophtha.2012.05.027
   Cohen SY, 2009, AM J OPHTHALMOL, V148, P409, DOI 10.1016/j.ajo.2009.04.001
   Finger RP, 2014, SURV OPHTHALMOL, V59, P1, DOI 10.1016/j.survophthal.2013.03.009
   Fong DS, 2010, OPHTHALMOLOGY, V117, P298, DOI 10.1016/j.ophtha.2009.07.023
   Gillies MC, 2015, OPHTHALMOLOGY, V122, P1837, DOI 10.1016/j.ophtha.2015.05.010
   Hagstrom SA, 2013, OPHTHALMOLOGY, V120, P593, DOI 10.1016/j.ophtha.2012.11.037
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hirami Y, 2009, JPN J OPHTHALMOL, V53, P396, DOI 10.1007/s10384-009-0669-4
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Keenan TDL, 2013, BRIT J OPHTHALMOL, V97, P1168, DOI 10.1136/bjophthalmol-2013-303233
   Larsen M, 2012, OPHTHALMOLOGY, V119, P992, DOI 10.1016/j.ophtha.2012.02.002
   Lee AY, 2015, BRIT J OPHTHALMOL, V99, P1045, DOI 10.1136/bjophthalmol-2014-306229
   Liu TYA, 2013, JAMA OPHTHALMOL, V131, P335, DOI 10.1001/jamaophthalmol.2013.818
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Olsen TW, 2004, OPHTHALMOLOGY, V111, P250, DOI 10.1016/j.ophtha.2003.05.030
   Rayess N, 2015, AM J OPHTHALMOL, V159, P3, DOI 10.1016/j.ajo.2014.09.011
   Regillo CD, 2015, AM J OPHTHALMOL, V160, P1014, DOI 10.1016/j.ajo.2015.07.034
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   VANDER JF, 1989, OPHTHALMOLOGY, V96, P1422
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Wong TY, 2008, OPHTHALMOLOGY, V115, P1524
   Ying GS, 2015, OPHTHALMOLOGY, V122, P2523, DOI 10.1016/j.ophtha.2015.08.015
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
   Zawinka C, 2005, RETINA-J RET VIT DIS, V25, P324, DOI 10.1097/00006982-200504000-00012
NR 31
TC 32
Z9 32
U1 0
U2 3
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD MAR 1
PY 2017
VL 135
IS 3
BP 268
EP 273
DI 10.1001/jamaophthalmol.2016.5314
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EP6MO
UT WOS:000397493800022
PM 28114653
DA 2022-11-30
ER

PT J
AU Motohashi, R
   Noma, H
   Yasuda, K
   Kotake, O
   Goto, H
   Shimura, M
AF Motohashi, Ryosuke
   Noma, Hidetaka
   Yasuda, Kanako
   Kotake, Osamu
   Goto, Hiroshi
   Shimura, Masahiko
TI Dynamics of Inflammatory Factors in Aqueous Humor during Ranibizumab or
   Aflibercept Treatment for Age-Related Macular Degeneration
SO OPHTHALMIC RESEARCH
LA English
DT Article
DE Vascular endothelial growth factor; Monocyte chemoattractant protein-1;
   Platelet-derived growth factor-AA; Interleukin; Ranibizuma; Aflibercept;
   Age-related macular degeneration
ID ENDOTHELIAL GROWTH-FACTOR; MONOCYTE CHEMOATTRACTANT PROTEIN-1; RETINAL
   VEIN OCCLUSION; NF-KAPPA B; INTRAVITREAL AFLIBERCEPT; VEGF-TRAP;
   EXPRESSION; ACTIVATION; EDEMA; EYE
AB Purpose: To evaluate the dynamic changes of the aqueous humor levels of inflammatory factors between patients receiving intravitreal ranibizumab injection (IRI) and aflibercept injection (IAI) in patients with exudative age-related macular degeneration (AMD). Methods: The study was performed on 30 eyes with AMD that were scheduled to receive 3 doses of IRI (15 eyes) or IAI (15 eyes) at monthly intervals. Aqueous humor samples were collected when injection was done. The concentrations of VEGF, monocyte chemoattractant protein 1 (MCP-1), platelet-derived growth factor (PDGF)-AA, interleukin (IL)-6, and IL-8 were measured in aqueous humor samples from the 30 AMD patients and 10 cataract patients (as controls) by the suspension array method. Results: Aqueous levels of the inflammatory factors (MCP-1, PDGF-AA, IL-6, and IL-8) were significantly correlated with each other. In both the IRI-treated eyes and the IAI-treated eyes, visual acuity and central macular thickness improved significantly, and the aqueous level of VEGF showed a significant decrease. In IAI-treated eyes, the aqueous levels of MCP-1 and PDGF-AA were significantly decreased at 2 months. Conclusions: These findings suggest that the inflammatory factors are involved in the pathogenesis of AMD and also the possibility that the interaction between these inflammatory factors and IRI or IAI is different. (C) 2017 S. Karger AG, Basel
C1 [Motohashi, Ryosuke; Noma, Hidetaka; Yasuda, Kanako; Kotake, Osamu; Shimura, Masahiko] Tokyo Med Univ, Hachioji Med Ctr, Dept Ophthalmol, 1163 Tatemachi, Hachioji, Tokyo 1930998, Japan.
   [Goto, Hiroshi] Tokyo Med Univ, Dept Ophthalmol, Tokyo, Japan.
C3 Tokyo Medical University; Tokyo Medical University
RP Noma, H (通讯作者)，Tokyo Med Univ, Hachioji Med Ctr, Dept Ophthalmol, 1163 Tatemachi, Hachioji, Tokyo 1930998, Japan.
EM noma-hide@umin.ac.jp
FU Ministry of Education, Culture, Sports, Science and Technology of Japan
   [KAKENHI 25462737]
FX This work was supported in part by a grant-in-aid for Scientific
   Research from the Ministry of Education, Culture, Sports, Science and
   Technology of Japan (KAKENHI 25462737).
CR Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649
   Carmeliet P, 2001, NAT MED, V7, P575, DOI 10.1038/87904
   Chang AA, 2014, OPHTHALMOLOGY, V121, P188, DOI 10.1016/j.ophtha.2013.08.035
   Clauss M, 1996, J BIOL CHEM, V271, P17629, DOI 10.1074/jbc.271.30.17629
   Dorrell M, 2007, SURV OPHTHALMOL, V52, pS3, DOI 10.1016/j.survophthal.2006.10.017
   Fauser S, 2014, AM J OPHTHALMOL, V158, P532, DOI 10.1016/j.ajo.2014.05.025
   Funatsu H, 2005, GRAEF ARCH CLIN EXP, V243, P3, DOI 10.1007/s00417-004-0950-7
   Funk M, 2009, OPHTHALMOLOGY, V116, P2393, DOI 10.1016/j.ophtha.2009.05.039
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Heier JS, 2006, OPHTHALMOLOGY, V113, P633, DOI 10.1016/j.ophtha.2005.10.052
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Jonas JB, 2012, ACTA OPHTHALMOL, V90, pe381, DOI 10.1111/j.1755-3768.2012.02414.x
   Jonas JB, 2010, ARCH OPHTHALMOL-CHIC, V128, P1281, DOI 10.1001/archophthalmol.2010.227
   Kanda A, 2015, SCI REP-UK, V5, DOI 10.1038/srep17946
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Kraiss LW, 1996, CIRC RES, V79, P45, DOI 10.1161/01.RES.79.1.45
   Marumo T, 1997, CIRCULATION, V96, P2361
   Noma H, 2015, INVEST OPHTH VIS SCI, V56, P1122, DOI 10.1167/iovs.14-15789
   Noma H, 2014, INVEST OPHTH VIS SCI, V55, P3878, DOI 10.1167/iovs.14-13961
   Otani A, 2002, MICROVASC RES, V64, P162, DOI 10.1006/mvre.2002.2407
   Rezar-Dreindl S, 2016, INVEST OPHTH VIS SCI, V57, P4144, DOI 10.1167/iovs.16-19772
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Saito M, 2014, RETINA-J RET VIT DIS, V34, P2192, DOI 10.1097/IAE.0000000000000236
   Schober A, 2007, THROMB HAEMOSTASIS, V97, P730, DOI 10.1160/TH07-02-0085
   Stewart MW, 2008, BRIT J OPHTHALMOL, V92, P667, DOI 10.1136/bjo.2007.134874
   Stewart MW, 2012, RETINA-J RET VIT DIS, V32, P434, DOI 10.1097/IAE.0B013E31822C290F
   Taub DD, 1996, J CLIN INVEST, V97, P1931, DOI 10.1172/JCI118625
   Thylefors B, 2002, OPHTHALMIC EPIDEMIOL, V9, P83, DOI 10.1076/opep.9.2.83.1523
   Wang XY, 2014, GRAEF ARCH CLIN EXP, V252, P1033, DOI 10.1007/s00417-013-2505-2
NR 29
TC 12
Z9 14
U1 0
U2 0
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3747
EI 1423-0259
J9 OPHTHALMIC RES
JI Ophthalmic Res.
PY 2017
VL 58
IS 4
BP 209
EP 216
DI 10.1159/000478705
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FL1FD
UT WOS:000413959100004
PM 28796997
DA 2022-11-30
ER

PT J
AU Cavar, I
   Lovric, S
   Vukojevic, M
   Sesar, I
   Petric-Vickovic, I
   Sesar, A
AF Cavar, Ivan
   Lovric, Sanjin
   Vukojevic, Mladenka
   Sesar, Irena
   Petric-Vickovic, Ivanka
   Sesar, Antonio
TI METABOLIC RISK FACTORS, COPING WITH STRESS, AND PSYCHOLOGICAL WELL-BEING
   IN PATIENTS WITH AGE-RELATED MACULAR DEGENERATION
SO ACTA CLINICA CROATICA
LA English
DT Article
DE Macular degeneration; Aging; Risk factors; Adaptation, psychological;
   Quality of life
ID QUALITY-OF-LIFE; CARDIOVASCULAR RISK; EYE DISEASE; ALCOHOL-CONSUMPTION;
   METAANALYSIS; ASSOCIATION; PREVALENCE; SUBTYPES; STROKE
AB The aim of this study was to determine the relationship between the risk factors (age, obesity, hypertension, hyperlipidemia, smoking, consumption of alchohol and drugs, positive family history, and exposure to sunlight), coping with stress, psychological well-being and age-related macular degeneration (ARMD). Forty patients with ARMD (case group) and 63 presbyopes (control group) participated in the study. Patient data were collected through general information questionnaire including patient habits, the COPE questionnaire that showed the way the patients handling stress, and the GHQ that analyzed the psychological aspects of their quality of life. These questionnaires were administered to the patients during ophthalmologic examination. The study involved 46 (44.66%) men and 57 (55.33%) women. Statistical analysis showed that the major risks for the development of ARMD were elevated cholesterol, triglycerides and LDL cholesterol in plasma. A significantly higher number of ARMD patients had a positive family history when compared with presbyopes. This study showed presbyopes to cope with emotional problems significantly better and to have a lower level of social dysfunction when compared with ARMD patients. However, it is necessary to conduct further studies in a large number of patients to determine more accurately the pathophysiological mechanisms of metabolic factors as well as the impact of the disease on the quality of life in patients with ARMD.
C1 [Cavar, Ivan; Sesar, Irena; Sesar, Antonio] Mostar Univ Hosp, Dept Clin Ophthalmol, Mostar, Bosnia & Herceg.
   [Lovric, Sanjin] Mostar Univ Hosp, Clin Dept Psychiat, Mostar, Bosnia & Herceg.
   [Vukojevic, Mladenka] Mostar Univ Hosp, Clin Dept Pediat, Mostar, Bosnia & Herceg.
   [Petric-Vickovic, Ivanka] Sestre Milosrdnice Univ Hosp Ctr, Clin Dept Ophthalmol, Zagreb, Croatia.
C3 University of Mostar; University of Mostar; University of Mostar;
   University of Zagreb
RP Cavar, I (通讯作者)，Mostar Univ Hosp, Dept Ophthalmol, Bijeli Brijeg Bb 88000, Mostar, Bosnia & Herceg.
EM ivancavarsb@yahoo.com
RI Cavar, Ivan/HCI-4973-2022
OI Cavar, Ivan/0000-0002-0685-3982
CR Akpek EK, 2013, AM J MANAG CARE, V19, pS67
   Augustin A, 2007, INVEST OPHTH VIS SCI, V48, P1498, DOI 10.1167/iovs.06-0761
   Bone RA, 2012, ACTA BIOCHIM POL, V59, P91
   Brody BL, 2011, ANN CLIN PSYCHIATRY, V23, P277
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chen YH, 2011, ARCH OPHTHALMOL-CHIC, V129, P344, DOI 10.1001/archophthalmol.2011.10
   Chiang CE, 2010, J FORMOS MED ASSOC, V109, P740, DOI 10.1016/S0929-6646(10)60120-9
   Cho EY, 2000, ARCH OPHTHALMOL-CHIC, V118, P681, DOI 10.1001/archopht.118.5.681
   Chong EWT, 2007, BMJ-BRIT MED J, V335, P755, DOI 10.1136/bmj.39350.500428.47
   Cong RH, 2008, ANN EPIDEMIOL, V18, P647, DOI 10.1016/j.annepidem.2008.04.002
   Cosway R, 2000, J APPL BIOBEHAV RES, V5, P121, DOI 10.1111/j.1751-9861.2000.tb00069.x
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Demarin V, 2010, ACTA CLIN CROAT, V49, P429
   Evans K, 2009, CLIN OPHTHALMOL, V3, P433
   Feehan M, 2011, BMC MED GENET, V12, DOI 10.1186/1471-2350-12-83
   Fraser-Bell S, 2008, AM J OPHTHALMOL, V145, P308, DOI 10.1016/j.ajo.2007.10.007
   Herreros-Villanueva M, 2013, WORLD J GASTROENTERO, V19, P638, DOI 10.3748/wjg.v19.i5.638
   Jones AA, 2007, AUST FAM PHYSICIAN, V36, P1026
   Kiernan DF, 2010, RETINA-J RET VIT DIS, V30, P1573, DOI 10.1097/IAE.0b013e3181e2266d
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   Kovacevic D, 2008, COLLEGIUM ANTROPOL, V32, P5
   Liu Mimi, 2004, Curr Opin Ophthalmol, V15, P221, DOI 10.1097/01.icu.0000122122.24016.f1
   MANDIC Z, 2002, ACTA CLIN CROAT, V43, P321
   Mathew RS, 2011, OPHTHAL PHYSL OPT, V31, P375, DOI 10.1111/j.1475-1313.2011.00848.x
   Meyer-Ruesenberg B, 2010, KLIN MONATSBL AUGENH, V227, P646, DOI 10.1055/s-0029-1245118
   Meyers KJ, 2013, INVEST OPHTH VIS SCI, V54, P2333, DOI [10.1167/iovs.12-10867, 10.1167/iovs.13-13216]
   Mielke A, 2013, OPHTHALMOLOGE, V110, P433, DOI 10.1007/s00347-012-2715-8
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Miniszewska Joanna, 2012, Przegl Lek, V69, P253
   Moeini HA, 2005, BRIT J OPHTHALMOL, V89, P964, DOI 10.1136/bjo.2005.066241
   Nagyova I, 2005, PATIENT EDUC COUNS, V58, P55, DOI 10.1016/j.pec.2004.06.011
   Olea JL, 2012, EUR J OPHTHALMOL, V22, P404, DOI 10.5301/ejo.5000023
   Pokharel S, 2009, J NEPAL MED ASSOC, V48, P217
   Renzi LM, 2012, LIPIDS HEALTH DIS, V11, DOI 10.1186/1476-511X-11-33
   Ryu E, 2010, MOL VIS, V16, P2811
   Sarangarajan R, 2005, MOL VIS, V11, P482
   Sayin O, 2012, ACTA CLIN CROAT, V51, P227
   SCHMUCKER C, 2012, PLOS ONE, P7
   Siaudvytyte L, 2012, MEDICINA-LITHUANIA, V48, P109, DOI 10.3390/medicina48020015
   Stein JD, 2003, BRIT J OPHTHALMOL, V87, P8, DOI 10.1136/bjo.87.1.8
   Tanaka K, 2011, MOL VIS, V17, P2751
   Tuo JS, 2012, OCUL IMMUNOL INFLAMM, V20, P27, DOI 10.3109/09273948.2011.628432
   van de Ven JPH, 2012, MOL VIS, V18, P2271
   Wahl HW, 2008, OPHTHALMOLOGE, V105, P735, DOI 10.1007/s00347-008-1724-0
   Wieberdink RG, 2011, STROKE, V42, P2138, DOI 10.1161/STROKEAHA.111.616359
   Wiliams RA, 1998, ARCH OPHTHALMOL-CHIC, V116, P514
   You QS, 2012, OPHTHALMOLOGY, V119, P2519, DOI 10.1016/j.ophtha.2012.06.043
NR 47
TC 4
Z9 6
U1 0
U2 7
PU SESTRE MILOSRDNICE UNIV HOSPITAL
PI ZAGREB
PA VINOGRADSKA C 29, ZAGREB, HR-10000, CROATIA
SN 0353-9466
EI 1333-9451
J9 ACTA CLIN CROAT
JI Acta Clin. Croat.
PD MAR
PY 2014
VL 53
IS 1
BP 79
EP 87
PG 9
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA AI8ZZ
UT WOS:000337216800010
PM 24974669
DA 2022-11-30
ER

PT J
AU Simmons, KT
   Mazzilli, JL
   Mueller-Ortiz, SL
   Domozhirov, AY
   Garcia, CA
   Zsigmond, EM
   Wetsel, RA
AF Simmons, Ken T.
   Mazzilli, John L.
   Mueller-Ortiz, Stacey L.
   Domozhirov, Aleksey Y.
   Garcia, Charles A.
   Zsigmond, Eva M.
   Wetsel, Rick A.
TI Complement Receptor 1 (CR1/CD35)-expressing retinal pigment epithelial
   cells as a potential therapy for age-related macular degeneration
SO MOLECULAR IMMUNOLOGY
LA English
DT Article
DE Age-related macular degeneration; CR1; Retinal pigment epithelium;
   Complement; Cell therapy
ID REGULATORY PROTEIN CD46; MEMBRANE-ATTACK-COMPLEX; OXIDATIVE STRESS; VEGF
   SECRETION; STEM-CELLS; ACTIVATION; EXPRESSION; SYSTEM; DERIVATION;
   IMMUNOLOGY
AB The purpose of this study was to identify a membrane-bound complement inhibitor that could be overexpressed on retinal pigment epithelial cells (RPE) providing a potential therapy for age-related macular degeneration (AMD). This type of therapy may allow replacement of damaged RPE with cells that are able to limit complement activation in the retina. Complement Receptor 1 (CR1) is a membrane-bound complement inhibitor commonly found on erythrocytes and immune cells. In this study, QPCR and flow cytometry data demonstrated that CR1 is not well-expressed by RPE, indicating that its overexpression may provide extra protection from complement activation. To screen CR1 for this ability, a stable CR1-expressing ARPE19 line was created using a combination of antibiotic selection and FACS. Cell-based assays were used to demonstrate that addition of CR1 inhibited deposition of complement proteins C3b and C6 on the transfected line. In the end, this study identifies CR1 as a complement inhibitor that may be overexpressed on stem cell-derived RPE to create a potential "enhanced" cell therapy for AMD. A combination cell/complement therapy may create transplantable RPE better suited to avoid complement-mediated lysis and limit chronic inflammation in the retina.
C1 [Simmons, Ken T.; Mazzilli, John L.; Mueller-Ortiz, Stacey L.; Domozhirov, Aleksey Y.; Zsigmond, Eva M.; Wetsel, Rick A.] Univ Texas Hlth Sci Ctr Houston, McGovern Med Sch, Res Ctr Immunol & Autoimmune Dis, Brown Fdn Inst Mol Med, Houston, TX 77030 USA.
   [Garcia, Charles A.] Univ Texas Hlth Sci Ctr Houston, McGovern Med Sch, Dept Ophthalmol & Visual Sci, Houston, TX 77030 USA.
C3 University of Texas System; University of Texas Health Science Center
   Houston; University of Texas System; University of Texas Health Science
   Center Houston
RP Wetsel, RA (通讯作者)，Univ Texas Hlth Sci Ctr Houston, Ctr Immunol & Autoimmune Dis, Inst Mol Med, 1825 Pressler St,SRB 430A, Houston, TX 77030 USA.
EM rick.a.wetsel@uth.tmc.edu
FU Clive and Nancy Runnells Embryonic Stem Cell Research Fund; Pierce
   Runnells Memorial Endowment for Embryonic Stem Cell Research
FX This work was supported by the Clive and Nancy Runnells Embryonic Stem
   Cell Research Fund and the Pierce Runnells Memorial Endowment for
   Embryonic Stem Cell Research. This manuscript is dedicated to the memory
   of Clive and Nancy Runnels. Without their generosity these studies would
   have not been possible.
CR Ajona D, 2019, SEMIN CELL DEV BIOL, V85, P153, DOI 10.1016/j.semcdb.2017.11.023
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Benhar I, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00296
   BOK D, 1993, J CELL SCI, P189
   Brandstetter C, 2015, J BIOL CHEM, V290, P31189, DOI 10.1074/jbc.M115.671180
   Campagne MV, 2016, IMMUNOBIOLOGY, V221, P733, DOI 10.1016/j.imbio.2015.11.007
   Cashman SM, 2011, INVEST OPHTH VIS SCI, V52, P3436, DOI 10.1167/iovs.10-6002
   Clark SJ, 2018, SEMIN IMMUNOPATHOL, V40, P65, DOI 10.1007/s00281-017-0649-6
   Coffey PJ, 2007, P NATL ACAD SCI USA, V104, P16651, DOI 10.1073/pnas.0705079104
   Cortright DN, 2009, CURR EYE RES, V34, P57, DOI 10.1080/02713680802546658
   da Cruz L, 2018, NAT BIOTECHNOL, V36, P1, DOI 10.1038/nbt.4114
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Ebrahimi KB, 2013, J PATHOL, V229, P729, DOI 10.1002/path.4128
   Fernandez-Godino R, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28143-0
   Fett AL, 2012, HISTOL HISTOPATHOL, V27, P357, DOI 10.14670/HH-27.357
   Fong H, 2011, METHODS MOL BIOL, V767, P333, DOI 10.1007/978-1-61779-201-4_24
   Georgiannakis A, 2015, J IMMUNOL, V195, P3382, DOI 10.4049/jimmunol.1500937
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hill A, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.28
   Horii T, 2016, ENDOCR J, V63, P213, DOI 10.1507/endocrj.EJ15-0734
   Irschick EU, 2004, OPHTHALMIC RES, V36, P200, DOI 10.1159/000078778
   Java A, 2015, MOL IMMUNOL, V67, P584, DOI 10.1016/j.molimm.2015.07.016
   Jha P, 2007, MOL IMMUNOL, V44, P3901, DOI 10.1016/j.molimm.2007.06.145
   Kijlstra A, 2015, OPHTHALMIC RES, V54, P64, DOI 10.1159/000432401
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klimanskaya I, 2004, CLONING STEM CELLS, V6, P217, DOI 10.1089/1536230042323420
   Kremlitzka M, 2018, HUM MOL GENET, V27, P2678, DOI 10.1093/hmg/ddy178
   Kunchithapautham K, 2011, J BIOL CHEM, V286, P23717, DOI 10.1074/jbc.M110.214593
   Langford-Smith A, 2014, J INNATE IMMUN, V6, P407, DOI 10.1159/000356513
   Liu D, 2009, IMMUNOPHARM IMMUNOT, V31, P524, DOI 10.3109/08923970902845768
   Long Q, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/6958752
   Lueck K, 2011, EYE, V25, P1074, DOI 10.1038/eye.2011.109
   Lyzogubov VV, 2016, AM J PATHOL, V186, P2088, DOI 10.1016/j.ajpath.2016.03.021
   MAKRIDES SC, 1992, J BIOL CHEM, V267, P24754
   Mazzilli JL, 2017, STEM CELL RES, V18, P37, DOI 10.1016/j.scr.2016.12.005
   McLaughlin BJ, 2003, INVEST OPHTH VIS SCI, V44, P3669, DOI 10.1167/iovs.02-0813
   Moore JC, 2010, STEM CELL RES THER, V1, DOI 10.1186/scrt23
   Mullins RF, 2014, AM J PATHOL, V184, P3142, DOI 10.1016/j.ajpath.2014.07.017
   Regal JF, 2017, CURR HYPERTENS REP, V19, DOI 10.1007/s11906-017-0784-4
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Rohrer B, 2018, ADV EXP MED BIOL, V1074, P45, DOI 10.1007/978-3-319-75402-4_6
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Sergejeva O, 2016, MEDICINA-LITHUANIA, V52, P79, DOI 10.1016/j.medici.2016.02.004
   Sohn JH, 2003, NAT MED, V9, P206, DOI 10.1038/nm814
   Song WK, 2015, STEM CELL REP, V4, P860, DOI 10.1016/j.stemcr.2015.04.005
   Sreekumar PG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033420
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Sugita S, 2018, INVEST OPHTH VIS SCI, V59, P4198, DOI 10.1167/iovs.18-24769
   Tan PL, 2017, INVEST OPHTH VIS SCI, V58, P1570, DOI 10.1167/iovs.16-20867
   Tan PL, 2016, HUM GENOMICS, V10, DOI 10.1186/s40246-016-0079-x
   Thurman JM, 2009, J BIOL CHEM, V284, P16939, DOI 10.1074/jbc.M808166200
   Tseng WA, 2013, INVEST OPHTH VIS SCI, V54, P110, DOI 10.1167/iovs.12-10655
   Vogt SD, 2006, EXP EYE RES, V83, P834, DOI 10.1016/j.exer.2006.04.002
   Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406
   Walport MJ, 2001, NEW ENGL J MED, V344, P1140, DOI 10.1056/NEJM200104123441506
   Wu ZH, 2007, J BIOL CHEM, V282, P22414, DOI 10.1074/jbc.M702321200
   Xu HP, 2016, EUR J PHARMACOL, V787, P94, DOI 10.1016/j.ejphar.2016.03.001
   Yang P, 2014, INVEST OPHTH VIS SCI, V55, P3012, DOI 10.1167/iovs.13-13554
   Yang P, 2009, INVEST OPHTH VIS SCI, V50, P3473, DOI 10.1167/iovs.08-3202
   Yves L, 2017, MOL IMMUNOL, V84, P51, DOI 10.1016/j.molimm.2016.11.013
   Zhan XW, 2013, NAT GENET, V45, P1375, DOI 10.1038/ng.2758
   Zhou JL, 2006, P NATL ACAD SCI USA, V103, P16182, DOI 10.1073/pnas.0604255103
NR 64
TC 4
Z9 5
U1 0
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0161-5890
J9 MOL IMMUNOL
JI Mol. Immunol.
PD FEB
PY 2020
VL 118
BP 91
EP 98
DI 10.1016/j.molimm.2019.11.007
PG 8
WC Biochemistry & Molecular Biology; Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Immunology
GA KH9DE
UT WOS:000510948500010
PM 31862673
DA 2022-11-30
ER

PT J
AU Akiyama, M
   Takahashi, A
   Momozawa, Y
   Arakawa, S
   Miya, F
   Tsunoda, T
   Ashikawa, K
   Oshima, Y
   Yasuda, M
   Yoshida, S
   Enaida, H
   Tan, X
   Yanagi, Y
   Yasukawa, T
   Ogura, Y
   Nagai, Y
   Takahashi, K
   Fujisawa, K
   Inoue, M
   Arakawa, A
   Tanaka, K
   Yuzawa, M
   Kadonosono, K
   Sonoda, KH
   Ishibashi, T
   Kubo, M
AF Akiyama, Masato
   Takahashi, Atsushi
   Momozawa, Yukihide
   Arakawa, Satoshi
   Miya, Fuyuki
   Tsunoda, Tatsuhiko
   Ashikawa, Kyota
   Oshima, Yuji
   Yasuda, Miho
   Yoshida, Shigeo
   Enaida, Hiroshi
   Tan, Xue
   Yanagi, Yasuo
   Yasukawa, Tsutomu
   Ogura, Yuichiro
   Nagai, Yoshimi
   Takahashi, Kanji
   Fujisawa, Kimihiko
   Inoue, Maiko
   Arakawa, Akira
   Tanaka, Koji
   Yuzawa, Mitsuko
   Kadonosono, Kazuaki
   Sonoda, Koh-Hei
   Ishibashi, Tatsuro
   Kubo, Michiaki
TI Genome-wide association study suggests four variants influencing
   outcomes with ranibizumab therapy in exudative age-related macular
   degeneration
SO JOURNAL OF HUMAN GENETICS
LA English
DT Article
ID COMPLEMENT FACTOR-H; SUBGROUP ANALYSIS; BEVACIZUMAB; PHARMACOGENETICS;
   VISUALIZATION; GENOTYPES; GENE; CATT
AB To identify factors associated with ranibizumab responses in patients with exudative age-related macular degeneration (AMD), we performed a genome-wide association study (GWAS) and a replication study using a total of 919 exudative AMD patients treated with intravitreal ranibizumab in a Japanese population. In the combined analysis of GWAS and the replication study, no loci reached genome-wide significant level; however, we found four variants showed suggestive level of associations with visual loss at month three (rs17822656, rs76150532, rs17296444, and rs75165563: P-combined < 1.0 x 10(-5)). Of the candidate genes within these loci, three were relevant to VEGF-related pathway (KCNMA1, SOCS2, and OTX2). The proportions of patients who worsened visual acuity were 13.7%, 38.8%, 58.0%, and 80.0% in patients with 0, 1, 2, and 3 or more identified risk variants, respectively. Changes in visual acuity decreased linearly as the number of risk variants increased (P = 1.67 x 10(-12)). The area under the curve using age, baseline visual acuity, and history of previous treatment was 0.607, and improved significantly to 0.713 in combination with identified variants (P < 0.0001). Although further study is needed to confirm their associations, our results offer candidate variants influencing response to ranibizumab therapy.
C1 [Akiyama, Masato; Momozawa, Yukihide; Ashikawa, Kyota; Kubo, Michiaki] RIKEN Ctr Integrat Med Sci, Lab Genotyping Dev, Tsurumi Ku, 1-7-22 Suehiro Cho, Yokohama, Kanagawa 2300045, Japan.
   [Akiyama, Masato; Arakawa, Satoshi; Oshima, Yuji; Yasuda, Miho; Yoshida, Shigeo; Enaida, Hiroshi; Sonoda, Koh-Hei; Ishibashi, Tatsuro] Kyushu Univ, Grad Sch Med Sci, Dept Ophthalmol, Higashi Ku, 3-1-1 Maedashi, Fukuoka, Fukuoka 8128582, Japan.
   [Akiyama, Masato; Takahashi, Atsushi] RIKEN Ctr Integrat Med Sci, Lab Stat Anal, Tsurumi Ku, 1-7-22 Suehiro Cho, Yokohama, Kanagawa 2300045, Japan.
   [Takahashi, Atsushi] Natl Cerebral & Cardiovasc Ctr, Res Inst, Dept Genom Med, Osaka 5658565, Japan.
   [Arakawa, Satoshi; Fujisawa, Kimihiko] Kyushu Hosp, Japan Community Hlth care Org, Yahatanishi Ku, 1-8-1 Kishinoura, Kitakyushu, Fukuoka 8060034, Japan.
   [Arakawa, Satoshi] Steel Mem Yawata Hosp, Yahatahigashi kU, 1-1-1 Harunomachi, Kitakyushu, Fukuoka 8058508, Japan.
   [Miya, Fuyuki; Tsunoda, Tatsuhiko] RIKEN Ctr Integrat Med Sci, Lab Med Sci Math, Tsurumi Ku, 1-7-22 Suehiro Cho, Yokohama, Kanagawa 2300045, Japan.
   [Miya, Fuyuki; Tsunoda, Tatsuhiko] Tokyo Med & Dent Univ, Med Res Inst, Dept Med Sci Math, Tokyo 1138510, Japan.
   [Oshima, Yuji] Fukuoka Univ, Chikushi Hosp, Dept Ophthalmol, Fukuoka, Fukuoka 8188502, Japan.
   [Enaida, Hiroshi] Saga Univ, Dept Ophthalmol, Fac Med, 5-1-1 Nabeshima, Saga, Saga 8498501, Japan.
   [Tan, Xue; Yanagi, Yasuo] Univ Tokyo, Sch Med, Dept Ophthalmol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.
   [Yanagi, Yasuo] Singapore Eye Res Inst, Singapore 168751, Singapore.
   [Yanagi, Yasuo] Singapore Natl Eye Ctr, Med Retina Dept, Singapore 168751, Singapore.
   [Yasukawa, Tsutomu; Ogura, Yuichiro] Nagoya City Univ, Grad Sch Med Sci, Dept Ophthalmol & Visual Sci, Mizuho Ku, 1 Kawasumi,Mizuho Cho, Nagoya, Aichi 4678601, Japan.
   [Nagai, Yoshimi; Takahashi, Kanji] Kansai Med Univ, Dept Ophthalmol, 2-5-1 Shin Machi, Hirakata, Osaka 5731010, Japan.
   [Inoue, Maiko; Arakawa, Akira] Yokohama City Univ, Med Ctr, Dept Ophthalmol, Minami Ku, 4-57 Urafune Cho, Yokohama, Kanagawa 2320024, Japan.
   [Arakawa, Akira] St Marianna Univ, Sch Med, Yokohama City Seibu Hosp, Dept Ophthalmol, Yokohama, Kanagawa 2410811, Japan.
   [Tanaka, Koji; Yuzawa, Mitsuko] Nihon Univ, Sch Med, Dept Visual Sci, Div Ophthalmol,Chiyoda Ku, 1-8-13 Kandasurugadai, Tokyo 1018309, Japan.
   [Kadonosono, Kazuaki] Yokohama City Univ, Grad Sch Med, Dept Ophthalmol & Microtechnol, Yokohama, Kanagawa 2320024, Japan.
C3 RIKEN; Kyushu University; RIKEN; National Cerebral & Cardiovascular
   Center - Japan; RIKEN; Tokyo Medical & Dental University (TMDU); Fukuoka
   University; Saga University; University of Tokyo; National University of
   Singapore; Singapore National Eye Center; Singapore National Eye Center;
   Nagoya City University; Kansai Medical University; Yokohama City
   University; Saint Marianna University; Nihon University; Yokohama City
   University
RP Akiyama, M (通讯作者)，RIKEN Ctr Integrat Med Sci, Lab Genotyping Dev, Tsurumi Ku, 1-7-22 Suehiro Cho, Yokohama, Kanagawa 2300045, Japan.; Akiyama, M (通讯作者)，Kyushu Univ, Grad Sch Med Sci, Dept Ophthalmol, Higashi Ku, 3-1-1 Maedashi, Fukuoka, Fukuoka 8128582, Japan.; Akiyama, M (通讯作者)，RIKEN Ctr Integrat Med Sci, Lab Stat Anal, Tsurumi Ku, 1-7-22 Suehiro Cho, Yokohama, Kanagawa 2300045, Japan.
EM masato.akiyama@riken.jp
RI Tanaka, Koji/H-3119-2019; Yanagi, Yasuo/AAA-5441-2022; Yanagi,
   Yasuo/AAF-2670-2020; Akiyama, Masato/AHC-2589-2022; Tsunoda,
   Tatsuhiko/K-2061-2014
OI Tanaka, Koji/0000-0003-3323-4148; Tsunoda,
   Tatsuhiko/0000-0002-5439-7918; Miya, Fuyuki/0000-0001-6758-2015; Yanagi,
   Yasuo/0000-0002-0362-7285
FU BioBank Japan project - Ministry of Education, Sports, Science and
   Technology; Japan Society for the Promotion of Science (Kakenhi)
   [24249083]
FX The study was funded in part by the BioBank Japan project supported by
   Ministry of Education, Sports, Science and Technology and Grants-in-Aid
   for Scientific Research from Japan Society for the Promotion of Science
   (Kakenhi 24249083).
CR Abedi F, 2013, OPHTHALMOLOGY, V120, P115, DOI 10.1016/j.ophtha.2012.10.006
   Ahmad M, 1997, CANCER RES, V57, P615
   Altshuler D, 2010, NATURE, V467, P1061, DOI 10.1038/nature09534
   Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   Bloch SB, 2012, AM J OPHTHALMOL, V153, P209, DOI 10.1016/j.ajo.2011.10.016
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Danias J, 2011, INVEST OPHTH VIS SCI, V52, P8636, DOI 10.1167/iovs.11-7563
   Farkas MH, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-486
   Francis Peter James, 2011, Trans Am Ophthalmol Soc, V109, P115
   Hagstrom SA, 2013, OPHTHALMOLOGY, V120, P593, DOI 10.1016/j.ophtha.2012.11.037
   Juel HB, 2011, EXP EYE RES, V92, P180, DOI 10.1016/j.exer.2011.01.003
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Lee AY, 2009, BRIT J OPHTHALMOL, V93, P610, DOI 10.1136/bjo.2008.150995
   Li Y, 2010, GENET EPIDEMIOL, V34, P816, DOI 10.1002/gepi.20533
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Ohnishi Y, 2001, J HUM GENET, V46, P471, DOI 10.1007/s100380170047
   Park UC, 2014, MOL VIS, V20, P1680
   Price AL, 2006, NAT GENET, V38, P904, DOI 10.1038/ng1847
   Pruim RJ, 2010, BIOINFORMATICS, V26, P2336, DOI 10.1093/bioinformatics/btq419
   Robin X, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-77
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   Stein Joshua D, 2013, Trans Am Ophthalmol Soc, V111, P56
   Wang LW, 2011, NEW ENGL J MED, V364, P1144, DOI 10.1056/NEJMra1010600
   Yamashiro K, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09632-0
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
NR 30
TC 7
Z9 7
U1 0
U2 3
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1434-5161
EI 1435-232X
J9 J HUM GENET
JI J. Hum. Genet.
PD OCT
PY 2018
VL 63
IS 10
BP 1083
EP 1091
DI 10.1038/s10038-018-0493-0
PG 9
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA GU7UV
UT WOS:000445533500009
PM 30054556
DA 2022-11-30
ER

PT J
AU Langford-Smith, A
   Keenan, TDL
   Clark, SJ
   Bishop, PN
   Day, AJ
AF Langford-Smith, Alex
   Keenan, Tiarnan D. L.
   Clark, Simon J.
   Bishop, Paul N.
   Day, Anthony J.
TI The Role of Complement in age-Related Macular Degeneration : Heparan
   Sulphate, a ZIP Code for Complement Factor H?
SO JOURNAL OF INNATE IMMUNITY
LA English
DT Review
DE Complement factor H; Age-related macular degeneration; Heparan sulphate;
   Tissue-specific immune recognition
ID HEMOLYTIC-UREMIC SYNDROME; DISEASE-ASSOCIATED FORM; C-REACTIVE PROTEIN;
   ADULT HUMAN RETINA; DIFFERENTIAL DISTRIBUTION; REGULATORY PROTEINS;
   BRUCHS MEMBRANE; NECROTIC CELLS; STEM-CELL; HIGH-RISK
AB Age-related macular degeneration (AMD) is the leading cause of blindness in developed nations and has been associated with complement dysregulation in the central retina. The Y402H polymorphism in the complement regulatory protein factor H (CFH) can confer a >5-fold increased risk of developing AMD and is present in approximately 30% of people of European descent. CFH, in conjunction with other factors, regulates complement activation in host tissues, and the Y402H polymorphism has been found to alter the protein's specificity for heparan sulphate (HS)-a complex polysaccharide found ubiquitously in mammals. HS, which is present on the cell surface and also in the extracellular matrix, exhibits huge structural diversity due to variations in the level/pattern of sulphation, where particular structures may act as 'ZIP codes' for different tissue/cellular locations. Recent work has demonstrated that CFH contains two HS-binding domains that each recognize specific HS ZIP codes, allowing differential recognition of Bruch's membrane (in the eye) or the glomerular basement membrane (in the kidney). Importantly, the Y402H polymorphism impairs the binding of CFH to the HS in Bruch's membrane, which could result in increased complement activation and chronic local inflammation (in 402H individuals) and thereby contribute to AMD pathology. (c) 2013 S. Karger AG, Basel
C1 [Langford-Smith, Alex; Keenan, Tiarnan D. L.; Day, Anthony J.] Univ Manchester, Fac Life Sci, Wellcome Trust Ctr Cell Mat Res, Manchester M13 9PT, Lancs, England.
   [Keenan, Tiarnan D. L.; Clark, Simon J.; Bishop, Paul N.] Univ Manchester, Ctr Hearing & Vis Res, Inst Human Dev, Manchester M13 9PT, Lancs, England.
   [Keenan, Tiarnan D. L.; Clark, Simon J.; Bishop, Paul N.] Cent Manchester Univ Hosp NHS Fdn Trust, Manchester Acad Hlth Sci Ctr, Ctr Adv Discovery & Expt Therapeut, Manchester, Lancs, England.
   [Keenan, Tiarnan D. L.; Clark, Simon J.; Bishop, Paul N.] Cent Manchester Univ Hosp NHS Fdn Trust, Manchester Acad Hlth Sci Ctr, Manchester Royal Eye Hosp, Manchester, Lancs, England.
C3 University of Manchester; University of Manchester; University of
   Manchester; Manchester Royal Eye Hospital; University of Manchester
RP Day, AJ (通讯作者)，Univ Manchester, Fac Life Sci, Wellcome Trust Ctr Cell Mat Res, Michael Smith Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.
EM anthony.day@manchester.ac.uk
RI Langford-Smith, Alex/K-7624-2017; Day, Anthony/O-1658-2015;
   Langford-Smith, Alex/H-5249-2011
OI Langford-Smith, Alex/0000-0001-7006-0592; Day,
   Anthony/0000-0002-1415-3134; Langford-Smith, Alex/0000-0001-7006-0592;
   Clark, Simon/0000-0001-8394-8355; Bishop, Paul/0000-0001-7937-7932
FU Macular Disease Society [1866]; Medical Research Council [G0900592,
   K004441]; MRC [MR/K004441/1, MR/K024418/1, G0900538] Funding Source:
   UKRI; Medical Research Council [MR/K024418/1, G0900538, MR/K004441/1]
   Funding Source: researchfish; Fight for Sight [1865/66] Funding Source:
   researchfish
FX We would like to thank Fight for Sight (grant 1866), the Macular Disease
   Society, and the Medical Research Council (grants G0900592 and K004441)
   for their past and present funding. We would also like to acknowledge
   the important contributions of our many colleagues and collaborators to
   the research described in this review.
CR Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Avery RL, 2010, OPHTHALMOLOGY, V117, P2442, DOI 10.1016/j.ophtha.2010.08.052
   Bishop JR, 2007, NATURE, V446, P1030, DOI 10.1038/nature05817
   Booij JC, 2010, PROG RETIN EYE RES, V29, P1, DOI 10.1016/j.preteyeres.2009.08.003
   Cipriani V, 2012, HUM MOL GENET, V21, P4138, DOI 10.1093/hmg/dds225
   Clark SJ, 2006, J BIOL CHEM, V281, P24713, DOI 10.1074/jbc.M605083200
   Clark SJ, 2013, J IMMUNOL, V190, P2049, DOI 10.4049/jimmunol.1201751
   Clark SJ, 2011, INVEST OPHTH VIS SCI, V52, P6511, DOI 10.1167/iovs.11-7909
   Clark SJ, 2010, BIOCHEM SOC T, V38, P1342, DOI 10.1042/BST0381342
   Clark SJ, 2010, J BIOL CHEM, V285, P30192, DOI 10.1074/jbc.M110.103986
   Coffey PJ, 2007, P NATL ACAD SCI USA, V104, P16651, DOI 10.1073/pnas.0705079104
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   DAY AJ, 1988, IMMUNOGENETICS, V27, P211, DOI 10.1007/BF00346588
   Day AJ, 2011, EXPERT REV OPHTHALMO, V6, P123, DOI 10.1586/EOP.11.10
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Feyzi E, 1998, J BIOL CHEM, V273, P13395, DOI 10.1074/jbc.273.22.13395
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Fritsche LG, 2010, HUM MOL GENET, V19, P4694, DOI 10.1093/hmg/ddq399
   Galor A, 2011, CURR OPIN OPHTHALMOL, V22, P477, DOI 10.1097/ICU.0b013e32834bbe7a
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hecker LA, 2010, HUM MOL GENET, V19, P209, DOI 10.1093/hmg/ddp472
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Issa PC, 2011, GRAEF ARCH CLIN EXP, V249, P163, DOI 10.1007/s00417-010-1568-6
   Johnson PT, 2006, P NATL ACAD SCI USA, V103, P17456, DOI 10.1073/pnas.0606234103
   Keenan TDL, 2012, INVEST OPHTH VIS SCI, V53, P7528, DOI 10.1167/iovs.12-10797
   Khandhadia S, 2012, IMMUNOBIOLOGY, V217, P127, DOI 10.1016/j.imbio.2011.07.019
   Kim DD, 2006, CLIN IMMUNOL, V118, P127, DOI 10.1016/j.clim.2005.10.014
   Krohne TU, 2010, EXP EYE RES, V90, P465, DOI 10.1016/j.exer.2009.12.011
   Langford-Smith A, 2012, MOL THER, V20, P1610, DOI 10.1038/mt.2012.82
   Lauer N, 2011, J IMMUNOL, V187, P4374, DOI 10.4049/jimmunol.1002488
   Makou E, 2013, BIOCHEMISTRY-US, V52, P3949, DOI 10.1021/bi4003452
   Manuelian T, 2003, J CLIN INVEST, V111, P1181, DOI 10.1172/JCI200316651
   Meade KA, 2013, J BIOL CHEM, V288, P5530, DOI 10.1074/jbc.M112.423012
   Mihlan M, 2011, FASEB J, V25, P4198, DOI 10.1096/fj.11-186460
   Mullins RF, 2011, EXP EYE RES, V93, P565, DOI 10.1016/j.exer.2011.06.015
   Parekh N, 2009, ARCH OPHTHALMOL-CHIC, V127, P1483, DOI 10.1001/archophthalmol.2009.130
   Pennesi ME, 2012, MOL ASPECTS MED, V33, P487, DOI 10.1016/j.mam.2012.06.003
   Prosser BE, 2007, J EXP MED, V204, P2277, DOI 10.1084/jem.20071069
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   RIPOCHE J, 1988, BIOCHEM J, V249, P593, DOI 10.1042/bj2490593
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   Sanchez-Corral P, 2002, AM J HUM GENET, V71, P1285, DOI 10.1086/344515
   Seddon JM, 2013, FARADAY DISCUSS, V161, P9, DOI 10.1039/c2fd90045a
   Seok J, 2013, P NATL ACAD SCI USA, V110, P3507, DOI 10.1073/pnas.1222878110
   Sjoberg AP, 2007, J BIOL CHEM, V282, P10894, DOI 10.1074/jbc.M610256200
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P339, DOI 10.1016/j.ophtha.2011.07.056
   Sofat R, 2012, INT J EPIDEMIOL, V41, P250, DOI 10.1093/ije/dyr204
   Thakkinstian A, 2012, AM J EPIDEMIOL, V176, P361, DOI 10.1093/aje/kws031
   Thakkinstian A, 2011, AM J EPIDEMIOL, V173, P1365, DOI 10.1093/aje/kwr025
   Toida T, 1997, BIOCHEM J, V322, P499, DOI 10.1042/bj3220499
   Turnbull JE, 2010, BIOCHEM SOC T, V38, P1356, DOI 10.1042/BST0381356
   Ufret-Vincenty RL, 2010, INVEST OPHTH VIS SCI, V51, P5878, DOI 10.1167/iovs.09-4457
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   Zaferani A, 2012, J BIOL CHEM, V287, P31471, DOI 10.1074/jbc.M112.380386
NR 54
TC 45
Z9 46
U1 0
U2 4
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 1662-811X
EI 1662-8128
J9 J INNATE IMMUN
JI J. Innate Immun.
PY 2014
VL 6
IS 4
BP 407
EP 416
DI 10.1159/000356513
PG 10
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA AJ4OO
UT WOS:000337655900002
PM 24335201
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Sato, T
   Takeuchi, M
   Karasawa, Y
   Takayama, K
   Enoki, T
AF Sato, Tomohito
   Takeuchi, Masaru
   Karasawa, Yoko
   Takayama, Kei
   Enoki, Toshio
TI Comprehensive expression patterns of inflammatory cytokines in aqueous
   humor of patients with neovascular age-related macular degeneration
SO SCIENTIFIC REPORTS
LA English
DT Article
ID MONOCYTE CHEMOATTRACTANT PROTEIN-1; INTERFERON-GAMMA; INDUCIBLE
   PROTEIN-10; VITREOUS LEVELS; ANGIOGENESIS; INHIBITION; GROWTH;
   ACTIVATION; GENERATION; PROFILE
AB Neovascular age-related macular degeneration (nAMD) is a complex and multi-factorial disease, and low-grade inflammation is associated with pathogenesis of nAMD. Aqueous humor could reflect intraocular immune environments in various eye diseases. The research so far used aqueous humor samples and revealed that inflammation is involved in pathophysiology of nAMD, although immunological roles of cytokines were evaluated inadequately with aspect to individual effects. Here we used 27 kinds of cytokines covering general immunologic reactions, examined specific expression patterns of cytokines, and assessed relationships between inflammation and pathophysiology of nAMD by multivariate analyses. In nAMD eyes, principal component analysis showed that IL-7, MCP-1, MIP-1 beta and VEGF had high principal component loadings of over 0.6 in the first principal component constituting 32.6% of all variability of the data. In exploratory factor analysis, IL-6, MCP-1 and MIP-1 beta had high factor loadings (FL) of over 0.5 in Factor 1 constituting 32.6% of all variability, while VEGF had FL of over 1.0 in Factor 3 constituting 10.7% of all variability. In hierarchical cluster analysis, MCP-1 and VEGF were located in the cluster of first proximate mutual distance to central retinal thickness. These data could suggest that low-grade inflammation is a principal contributor in nAMD.
C1 [Sato, Tomohito; Takeuchi, Masaru; Karasawa, Yoko; Takayama, Kei] Natl Def Med Coll, Dept Ophthalmol, Tokorozawa, Saitama, Japan.
   [Enoki, Toshio] Enoki Eye Clin, Sayama, Saitama, Japan.
C3 National Defense Medical College - Japan
RP Takeuchi, M (通讯作者)，Natl Def Med Coll, Dept Ophthalmol, Tokorozawa, Saitama, Japan.
EM masatake@ndmc.ac.jp
FU Japan Society for the Promotion of Science [16K11337]; Novartis Research
   Grant; Alcon Research Grant; Daiwa Securities Health Foundation;
   National Defense Medical Collage, Japan
FX lThis study was supported by Grant-in-Aid for Scientific Research C from
   the Japan Society for the Promotion of Science (16K11337), Novartis
   Research Grant, Alcon Research Grant, Research Grant from Daiwa
   Securities Health Foundation, and Grant-in-Aid from National Defense
   Medical Collage, Japan for Advanced Medical Development. The funders of
   the study had no role in study design, data collection, data analysis,
   data interpretation, or writing of the report. The funding source had no
   involvement in study design; in the collection, analysis, and
   interpretation of data; in the writing of the report; and in the
   decision to submit the paper for publication. The corresponding author
   had full access to all the data in the study and had final
   responsibility for the decision to submit for publication.
CR Agawa T, 2014, RETINA-J RET VIT DIS, V34, P1811, DOI 10.1097/IAE.0000000000000157
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   ANGIOLILLO AL, 1995, J EXP MED, V182, P155, DOI 10.1084/jem.182.1.155
   [Anonymous], 1987, Int Ophthalmol Clin, V27, P265
   Benson JM, 2011, NAT BIOTECHNOL, V29, P615, DOI 10.1038/nbt.1903
   Bodnar RJ, 2006, CIRC RES, V98, P617, DOI 10.1161/01.RES.0000209968.66606.10
   Chen M, 2016, CURR MOL MED, V16, P412, DOI 10.2174/1566524016666160324130031
   Chen M, 2015, J LEUKOCYTE BIOL, V98, P713, DOI 10.1189/jlb.3RI0615-239R
   Chiu WK, 2006, J IMMUNOL, V177, P7802, DOI 10.4049/jimmunol.177.11.7802
   COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155
   Cohen MC, 1996, AM J CLIN PATHOL, V105, P589
   Deshmane SL, 2009, J INTERF CYTOK RES, V29, P313, DOI 10.1089/jir.2008.0027
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Duda DG, 2000, CANCER RES, V60, P1111
   Eberly Lynn E., 2007, V404, P165, DOI 10.1007/978-1-59745-530-5_9
   Fry TJ, 2005, J IMMUNOL, V174, P6571, DOI 10.4049/jimmunol.174.11.6571
   Fujimura S, 2012, INVEST OPHTH VIS SCI, V53, P1999, DOI 10.1167/iovs.11-8232
   Funatsu H, 2005, GRAEF ARCH CLIN EXP, V243, P3, DOI 10.1007/s00417-004-0950-7
   Funk M, 2009, OPHTHALMOLOGY, V116, P2393, DOI 10.1016/j.ophtha.2009.05.039
   Gillies MC, 2003, ARCH OPHTHALMOL-CHIC, V121, P667, DOI 10.1001/archopht.121.5.667
   Grunin M, 2016, SCI REP-UK, V6, DOI 10.1038/srep29046
   Grunin M, 2012, INVEST OPHTH VIS SCI, V53, P5292, DOI 10.1167/iovs.11-9165
   Heller EA, 2006, CIRCULATION, V113, P2301, DOI 10.1161/CIRCULATIONAHA.105.605121
   HOLZINGER C, 1993, IMMUNOL LETT, V35, P109, DOI 10.1016/0165-2478(93)90078-G
   Hong KH, 2005, BLOOD, V105, P1405, DOI 10.1182/blood-2004-08-3178
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   Jolliffe I., 2011, INT ENCY STAT SCI, P1094, DOI [10.1007/978-3-642-04898-2_455, DOI 10.1007/978-3-642-04898-2_455]
   Jonas JB, 2012, ACTA OPHTHALMOL, V90, pe381, DOI 10.1111/j.1755-3768.2012.02414.x
   Jonas JB, 2010, ARCH OPHTHALMOL-CHIC, V128, P1281, DOI 10.1001/archophthalmol.2010.227
   Kumar S, 2004, MUSCLE STRENGTH, P1, DOI 10.1201/9780203503591.ch1
   Kurup S. K., 2010, ACTA OPHTHALMOL COPE, V88
   Lechner J, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0820-y
   Liu JH, 2000, J BIOL CHEM, V275, P29354, DOI 10.1074/jbc.M910191199
   Liutkeviciene R, 2010, MEDICINA-LITHUANIA, V46, P89, DOI 10.3390/medicina46020013
   Markomichelakis NN, 2005, AM J OPHTHALMOL, V139, P537, DOI 10.1016/j.ajo.2004.09.058
   MCKNIGHT AJ, 1994, J IMMUNOL, V152, P2172
   Mizutani T, 2013, INVEST OPHTH VIS SCI, V54, P1564, DOI 10.1167/iovs.11-9095
   Mo FM, 2010, INVEST OPHTH VIS SCI, V51, P4226, DOI 10.1167/iovs.09-3910
   Neumann B, 1998, IMMUNOLOGY, V95, P512
   Noma H, 2008, EYE, V22, P42, DOI 10.1038/sj.eye.6702498
   Norris M, 2010, J AUTISM DEV DISORD, V40, P8, DOI 10.1007/s10803-009-0816-2
   Perez VL, 2015, TRENDS IMMUNOL, V36, P354, DOI 10.1016/j.it.2015.04.003
   Pokharel A, 2016, CLIN OPHTHALMOL, V10, P511, DOI 10.2147/OPTH.S95956
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Rezar-Dreindl S, 2016, INVEST OPHTH VIS SCI, V57, P4144, DOI 10.1167/iovs.16-19772
   Ristau T, 2014, INVEST OPHTH VIS SCI, V55, P210, DOI 10.1167/iovs.13-13248
   Roh MI, 2009, RETINA-J RET VIT DIS, V29, P523, DOI 10.1097/IAE.0b013e318195cb15
   Sadda S. R., 2018, OPHTHALMOLOGY, V125
   Sato T, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-19594-6
   Seidler S, 2010, BMC IMMUNOL, V11, DOI 10.1186/1471-2172-11-30
   Sene A, 2015, TRENDS MOL MED, V21, P43, DOI 10.1016/j.molmed.2014.10.005
   Subhi Y, 2019, ACTA OPHTHALMOL, V97, P99, DOI 10.1111/aos.13886
   Tager AM, 2004, AM J RESP CELL MOL, V31, P395, DOI 10.1165/rcmb.2004-0175OC
   Takeda A, 2009, NATURE, V460, P225, DOI 10.1038/nature08151
   Theodossiadis PG, 2009, AM J OPHTHALMOL, V147, P825, DOI 10.1016/j.ajo.2008.12.004
   Tilg H, 1997, IMMUNOL TODAY, V18, P428, DOI 10.1016/S0167-5699(97)01103-1
   TRINCHIERI G, 1995, ANNU REV IMMUNOL, V13, P251, DOI 10.1146/annurev.immunol.13.1.251
   VOEST EE, 1995, J NATL CANCER I, V87, P581, DOI 10.1093/jnci/87.8.581
   Wilks D.S., 2011, INT GEOPHYS, V100, P603, DOI [10.1016/B978-0-12-385022-5.00015-4, DOI 10.1016/B978-0-12-385022-5.00015-4]
   Winkler BS, 1999, MOL VIS, V5
   Yeon SM, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-11492-7
   Zhang JM, 2007, INT ANESTHESIOL CLIN, V45, P27, DOI 10.1097/AIA.0b013e318034194e
NR 64
TC 18
Z9 18
U1 1
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD DEC 19
PY 2019
VL 9
AR 19447
DI 10.1038/s41598-019-55191-x
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA KE8ZA
UT WOS:000508836900041
PM 31857597
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Lyzogubov, VV
   Bora, PS
   Wu, XB
   Horn, LE
   de Roque, R
   Rudolf, XV
   Atkinson, JP
   Bora, NS
AF Lyzogubov, Valeriy V.
   Bora, Puran S.
   Wu, Xiaobo
   Horn, Leah E.
   de Roque, Ryan
   Rudolf, Xeniya V.
   Atkinson, John P.
   Bora, Nalini S.
TI The Complement Regulatory Protein CD46 Deficient Mouse Spontaneously
   Develops Dry-Type Age-Related Macular Degeneration-Like Phenotype
SO AMERICAN JOURNAL OF PATHOLOGY
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; INDUCED CHOROIDAL NEOVASCULARIZATION;
   MEMBRANE ATTACK COMPLEX; FACTOR-H; BRUCHS MEMBRANE; TRANSGENIC MICE;
   ANIMAL-MODELS; LIPOFUSCIN ACCUMULATION; DEPENDENT PATHOGENESIS;
   ALTERNATIVE PATHWAY
AB In the mouse, membrane cofactor protein (CD46), a key regulator of the alternative pathway of the complement system, is only expressed in the eye and on the inner acrosomal membrane of spermatozoa. We noted that although Cd46(-/-) mice have normal systemic alternative pathway activating ability, lack of CD46 leads to dysregulated complement activation in the eye, as evidenced by increased deposition of C5b-9 in the retinal pigment epithelium (RPE) and choroid. A knockout of CD46 induced the following cardinal features of human dry age-related macular degeneration (AMD) in 12-month-old male and female mice: accumulation of autofluorescent material in and hypertrophy of the RPE, dense deposits in and thickening of Bruch's membrane, loss of photoreceptors, cells in subretinal space, and a reduction of choroidal vessels. Collectively, our results demonstrate spontaneous age-related degenerative changes in the retina, RPE, and choroid of Cd46(-/-) mice that are consistent with human dry AMD. These findings provide the exciting possibility of using Cd46(-/-) mice as a convenient and reliable animal model for dry AMD. Having such a relatively straight-forward model for dry AMD should provide valuable insights into pathogenesis and a test model system for novel drug targets. More important, tissue-specific expression of CD46 gives the Cd46(-/-) mouse model of dry AMD a unique advantage over other mouse models using knockout strains.
C1 [Lyzogubov, Valeriy V.; Bora, Puran S.; Horn, Leah E.; de Roque, Ryan; Rudolf, Xeniya V.; Bora, Nalini S.] Univ Arkansas Med Sci, Pat & Willard Walker Eye Res Ctr, Jones Eye Inst, Dept Ophthalmol, Little Rock, AR USA.
   [Wu, Xiaobo; Atkinson, John P.] Washington Univ, Sch Med, Dept Med, Div Rheumatol, St Louis, MO USA.
   [Horn, Leah E.; Bora, Nalini S.] Univ Arkansas Med Sci, Dept Microbiol & Immunol, Little Rock, AR USA.
   [de Roque, Ryan] Univ Arkansas Med Sci, Coll Med, Little Rock, AR USA.
C3 University of Arkansas System; University of Arkansas Medical Sciences;
   Washington University (WUSTL); University of Arkansas System; University
   of Arkansas Medical Sciences; University of Arkansas System; University
   of Arkansas Medical Sciences
RP Bora, NS (通讯作者)，Univ Arkansas Med Sci, Jones Eye Inst, Dept Ophthalmol, 4301 W Markham,523-7, Little Rock, AR 72205 USA.
EM nbora@uams.edu
OI Bora, Puran/0000-0003-4781-1217
FU Edward N. and Della L. Thome Memorial Foundation grant; Lions of
   Arkansas Foundation, Inc., grant; Pat and Willard Walker Eye Research
   Center grant; Jones Eye Institute (Little Rock, AR) grant; Protein
   Production and Purification Core Facility of the Rheumatic Diseases Core
   Center under Award [P30AR048335]; National Institute of Arthritis and
   Musculoskeletal and Skin Diseases; National Institute of General Medical
   Sciences [R01 GM099111]; National Institute of Allergy and Infectious
   Diseases under Award [R01 AI041592]; NATIONAL INSTITUTE OF ALLERGY AND
   INFECTIOUS DISEASES [R01AI041592] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES
   [P30AR048335] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF
   GENERAL MEDICAL SCIENCES [R01GM099111] Funding Source: NIH RePORTER
FX Supported by The Edward N. and Della L. Thome Memorial Foundation grant,
   Lions of Arkansas Foundation, Inc., grant, the Pat and Willard Walker
   Eye Research Center grant, and Jones Eye Institute (Little Rock, AR)
   grant, the Protein Production and Purification Core Facility of the
   Rheumatic Diseases Core Center under Award P30AR048335, National
   Institute of Arthritis and Musculoskeletal and Skin Diseases (J.P.A.),
   National Institute of General Medical Sciences under Award R01 GM099111
   (J.P.A.), and National Institute of Allergy and Infectious Diseases
   under Award R01 AI041592 (J.P.A. and X.W.).
CR Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Bertram Paula, 2015, Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, V34, P1, DOI 10.1089/mab.2014.0066
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Bora NS, 2008, SEMIN IMMUNOPATHOL, V30, P85, DOI 10.1007/s00281-008-0110-y
   Bora NS, 2007, J IMMUNOL, V178, P1783, DOI 10.4049/jimmunol.178.3.1783
   Bora NS, 2006, J IMMUNOL, V177, P1872, DOI 10.4049/jimmunol.177.3.1872
   Bora NS, 2015, MOL IMMUNOL, V63, P176, DOI 10.1016/j.molimm.2014.07.012
   Bora Nalini S., 2011, Current Immunology Reviews, V7, P360
   Bora NS, 2010, J BIOL CHEM, V285, P33826, DOI 10.1074/jbc.M110.153130
   Bora PS, 2005, J IMMUNOL, V174, P491, DOI 10.4049/jimmunol.174.1.491
   Chader GJ, 2002, VISION RES, V42, P393, DOI 10.1016/S0042-6989(01)00212-7
   Chang B, 2005, VISUAL NEUROSCI, V22, P587, DOI 10.1017/S0952523805225075
   Chang B, 2013, INVEST OPHTH VIS SCI, V54, P4974, DOI 10.1167/iovs.13-12289
   Cho KS, 2012, INVEST OPHTH VIS SCI, V53, P5344, DOI 10.1167/iovs.12-9827
   Choi AMK, 2013, NEW ENGL J MED, V368, P651, DOI [10.1056/NEJMra1205406, 10.1056/NEJMc1303158]
   Christoforidis JB, 2011, CURR DRUG TARGETS, V12, P221
   Circolo A, 1999, IMMUNOPHARMACOLOGY, V42, P135, DOI 10.1016/S0162-3109(99)00021-1
   Coffey PJ, 2007, P NATL ACAD SCI USA, V104, P16651, DOI 10.1073/pnas.0705079104
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Edwards Albert O., 2007, Angiogenesis, V10, P119, DOI 10.1007/s10456-007-9064-2
   Espinosa-Heidmann DG, 2004, INVEST OPHTH VIS SCI, V45, P260, DOI 10.1167/iovs.03-0910
   Ethen CM, 2005, INVEST OPHTH VIS SCI, V46, P769, DOI 10.1167/iovs.04-0810
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fu L, 2007, HUM MOL GENET, V16, P2411, DOI 10.1093/hmg/ddm198
   Fujihara M, 2009, EXP EYE RES, V88, P1115, DOI 10.1016/j.exer.2009.01.017
   Fujihara M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003119
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Hadziahmetovic M, 2008, INVEST OPHTH VIS SCI, V49, P2728, DOI 10.1167/iovs.07-1472
   Hafezi F, 2000, BRIT J OPHTHALMOL, V84, P922, DOI 10.1136/bjo.84.8.922
   Hageman G.S., 1995, ORIANIZATION RETINA
   Hashizume K, 2008, AM J PATHOL, V172, P1325, DOI 10.2353/ajpath.2008.070730
   Helgason H, 2013, NAT GENET, V45, P1371, DOI 10.1038/ng.2740
   Horie-Inoue K, 2014, BIOCHEM BIOPH RES CO, V452, P263, DOI 10.1016/j.bbrc.2014.08.013
   Husain Deeba, 2002, Ophthalmol Clin North Am, V15, P87, DOI 10.1016/S0896-1549(01)00009-8
   Imamura Y, 2006, P NATL ACAD SCI USA, V103, P11282, DOI 10.1073/pnas.0602131103
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Justilien V, 2007, INVEST OPHTH VIS SCI, V48, P4407, DOI 10.1167/iovs.07-0432
   Kaarniranta K, 2012, FUTURE MED CHEM, V4, P2153, DOI [10.4155/FMC.12.169, 10.4155/fmc.12.169]
   Kaliappan S, 2008, FEBS LETT, V582, P3451, DOI 10.1016/j.febslet.2008.09.009
   Karan G, 2005, P NATL ACAD SCI USA, V102, P4164, DOI 10.1073/pnas.0407698102
   Kavanagh D, 2015, HUM MOL GENET, V24, P3861, DOI 10.1093/hmg/ddv091
   Khandhadia S, 2012, ADV EXP MED BIOL, V724, P15, DOI 10.1007/978-1-4614-0653-2_2
   Liszewski M.K., 1998, HUMAN COMPLEMENT SYS, P149
   Liszewski MK, 2005, SPRINGER SEMIN IMMUN, V27, P345, DOI 10.1007/s00281-005-0002-3
   Liszewski MK, 2000, J BIOL CHEM, V275, P37692, DOI 10.1074/jbc.M004650200
   Liu J, 2011, J BIOL CHEM, V286, P20991, DOI 10.1074/jbc.M111.226266
   Luhmann UFO, 2013, EXP EYE RES, V107, P80, DOI 10.1016/j.exer.2012.11.015
   Luhmann UFO, 2009, INVEST OPHTH VIS SCI, V50, P5934, DOI 10.1167/iovs.09-3462
   Lyzogubov V, 2014, AM J PATHOL, V184, P2537, DOI 10.1016/j.ajpath.2014.06.001
   Lyzogubov VV, 2014, EXP EYE RES, V127, P143, DOI 10.1016/j.exer.2014.07.021
   Lyzogubov VV, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.204701
   Lyzogubov VV, 2010, AM J PATHOL, V177, P1870, DOI 10.2353/ajpath.2010.091168
   Majji AB, 2000, INVEST OPHTH VIS SCI, V41, P3936
   Malek G, 2005, P NATL ACAD SCI USA, V102, P11900, DOI 10.1073/pnas.0503015102
   Mata NL, 2001, INVEST OPHTH VIS SCI, V42, P1685
   Matsumoto M, 1997, P NATL ACAD SCI USA, V94, P8720, DOI 10.1073/pnas.94.16.8720
   Mehalow AK, 2003, HUM MOL GENET, V12, P2179, DOI 10.1093/hmg/ddg232
   Morgan B. P., 1999, COMPLEMENT REGULATOR
   Neuhardt T, 1999, EXP EYE RES, V68, P75, DOI 10.1006/exer.1998.0589
   Pickering MC, 2002, NAT GENET, V31, P424, DOI 10.1038/ng912
   Querques G, 2014, OPHTHALMIC RES, V52, P107, DOI 10.1159/000363187
   Radu RA, 2014, J BIOL CHEM, V289, P9113, DOI 10.1074/jbc.M114.548669
   Rakoczy PE, 2006, EXP EYE RES, V82, P741, DOI 10.1016/j.exer.2005.10.012
   Ramkumar HL, 2010, PROG RETIN EYE RES, V29, P169, DOI 10.1016/j.preteyeres.2010.02.002
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Ross RJ, 2008, EXP EYE RES, V86, P675, DOI 10.1016/j.exer.2008.01.014
   Saint-Geniez M, 2006, INVEST OPHTH VIS SCI, V47, P3135, DOI 10.1167/iovs.05-1229
   Sallo FB, 2009, EXP EYE RES, V89, P178, DOI 10.1016/j.exer.2009.03.006
   Schmidt-Erfurth U, 2008, INVEST OPHTH VIS SCI, V49, P390, DOI 10.1167/iovs.07-0227
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Sparrow JR, 2012, PROG RETIN EYE RES, V31, P121, DOI 10.1016/j.preteyeres.2011.12.001
   Spraul CW, 1999, SURV OPHTHALMOL, V44, pS10, DOI 10.1016/S0039-6257(99)00086-7
   Stover CM, 2008, J IMMUNOL, V180, P3313, DOI 10.4049/jimmunol.180.5.3313
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Triebwasser MP, 2015, INVEST OPHTH VIS SCI, V56, P6873, DOI 10.1167/iovs.15-17432
   Tuo JS, 2007, INVEST OPHTH VIS SCI, V48, P3827, DOI 10.1167/iovs.07-0051
   Ufret-Vincenty RL, 2010, INVEST OPHTH VIS SCI, V51, P5878, DOI 10.1167/iovs.09-4457
   Viiri J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069563
   Wang AL, 2010, VISION RES, V50, P638, DOI 10.1016/j.visres.2009.08.029
   Wang AL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004160
   Yates JRW, 2000, J MED GENET, V37, P83, DOI 10.1136/jmg.37.2.83
   Yu Y, 2014, HUM MOL GENET, V23, P5283, DOI 10.1093/hmg/ddu226
   Zarbin MA, 2010, RETINA-J RET VIT DIS, V30, P1350, DOI 10.1097/IAE.0b013e3181f57e30
   Zeiss CJ, 2010, VET PATHOL, V47, P396, DOI 10.1177/0300985809359598
   Zhao ZY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019456
NR 90
TC 26
Z9 26
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9440
EI 1525-2191
J9 AM J PATHOL
JI Am. J. Pathol.
PD AUG
PY 2016
VL 186
IS 8
BP 2088
EP 2104
DI 10.1016/j.ajpath.2016.03.021
PG 17
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA DS2ON
UT WOS:000380623500010
PM 27295359
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Fletcher, AE
AF Fletcher, A. E.
TI Free Radicals, Antioxidants and Eye Diseases: Evidence from
   Epidemiological Studies on Cataract and Age-Related Macular Degeneration
SO OPHTHALMIC RESEARCH
LA English
DT Article
DE Free radicals; Age-related cataract; Age-related macular degeneration
ID VITAMIN-C; SUN EXPOSURE; VISUAL IMPAIRMENT; OXIDATIVE DAMAGE; LENS
   OPACITIES; RISK-FACTORS; PREVALENCE; SMOKING; MACULOPATHY; CAROTENOIDS
AB Cataract and age-related macular degeneration (AMD) are the major causes of vision impairment and blindness worldwide. Both conditions are strongly age related with earlier signs (usually asymptomatic) occurring in middle age and becoming severer and more prevalent with increasing age. The aetiology of these conditions is thought to fit with the 'free radical theory' of ageing which postulates that ageing and age-related diseases result from the accumulation of cellular damage from reactive oxygen species (ROS). Mitochondrial energy production is a major source of endogenous ROS. External sources of ROS include environmental sources especially solar radiation, biomass fuels and tobacco smoking. There is strong evidence from epidemiological studies that smoking is a risk factor for both cataract and AMD. There is moderate evidence for an association with sunlight and cataract but weak evidence for sunlight and AMD. The few studies that have investigated this suggest an adverse effect of biomass fuels on cataract risk. The antioxidant defence system of the lens and retina include antioxidant vitamins C and E and the carotenoids lutein and zinc, and there is mixed evidence on their associations with cataract and AMD from epidemiological studies. Most epidemiological studies have been conducted in well-nourished western populations but evidence is now emerging from other populations with different dietary patterns and antioxidant levels. Copyright (C) 2010 S. Karger AG, Basel
C1 Univ London London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, London WC1E 7HT, England.
C3 University of London; London School of Hygiene & Tropical Medicine
RP Fletcher, AE (通讯作者)，Univ London London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, Keppel St, London WC1E 7HT, England.
EM astrid.fletcher@lshtm.ac.uk
FU Wellcome Trust UK
FX A.E.F. receives funding from the Wellcome Trust UK for the INDEYE study
   (a study of risk factors for age-related cataract and AMD in India).
CR Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Balaban RS, 2005, CELL, V120, P483, DOI 10.1016/j.cell.2005.02.001
   Beal MF, 2004, J BIOENERG BIOMEMBR, V36, P381, DOI 10.1023/B:JOBB.0000041772.74810.92
   Beatty S, 1999, BRIT J OPHTHALMOL, V83, P867, DOI 10.1136/bjo.83.7.867
   Berthoud VM, 2009, ANTIOXID REDOX SIGN, V11, P339, DOI 10.1089/ars.2008.2119
   Bjelakovic G, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007176
   Brennan LA, 2009, EXP EYE RES, V88, P195, DOI 10.1016/j.exer.2008.05.018
   Bruce N, 2000, B WORLD HEALTH ORGAN, V78, P1078
   Canter JA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002091
   Chiu CJ, 2007, EXP EYE RES, V84, P229, DOI 10.1016/j.exer.2006.05.015
   Cho EY, 2004, ARCH OPHTHALMOL-CHIC, V122, P883, DOI 10.1001/archopht.122.6.883
   Cong RH, 2008, ANN EPIDEMIOL, V18, P647, DOI 10.1016/j.annepidem.2008.04.002
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P487
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   CRUICKSHANKS KJ, 1993, ARCH OPHTHALMOL-CHIC, V111, P514, DOI 10.1001/archopht.1993.01090040106042
   Cruickshanks KJ, 2001, ARCH OPHTHALMOL-CHIC, V119, P246
   Darzins P, 1997, OPHTHALMOLOGY, V104, P770, DOI 10.1016/S0161-6420(97)30235-8
   Delcourt C, 2001, ARCH OPHTHALMOL-CHIC, V119, P1463
   Dherani M, 2008, INVEST OPHTH VIS SCI, V49, P3328, DOI 10.1167/iovs.07-1202
   Dietrich M, 2003, AM J CLIN NUTR, V77, P160, DOI 10.1093/ajcn/77.1.160
   Fletcher AE, 2008, ARCH OPHTHALMOL-CHIC, V126, P1396, DOI 10.1001/archopht.126.10.1396
   Fletcher AE, 2009, AM J OPHTHALMOL, V147, P384, DOI 10.1016/j.ajo.2008.04.024
   Gritz DC, 2006, BRIT J OPHTHALMOL, V90, P847, DOI 10.1136/bjo.2005.088104
   HARMAN D, 1972, J AM GERIATR SOC, V20, P145, DOI 10.1111/j.1532-5415.1972.tb00787.x
   HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298
   Jarrett SG, 2008, PROG RETIN EYE RES, V27, P596, DOI 10.1016/j.preteyeres.2008.09.001
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1439, DOI 10.1001/archopht.119.10.1439
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kelly SP, 2005, J CATARACT REFR SURG, V31, P2395, DOI 10.1016/j.jcrs.2005.06.039
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P29, DOI 10.1136/bjo.2005.073825
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2007, AM J OPHTHALMOL, V143, P473, DOI 10.1016/j.ajo.2006.11.058
   Krishnaiah S, 2005, INVEST OPHTH VIS SCI, V46, P58, DOI 10.1167/iovs.04-0089
   Kujoth GC, 2007, PLOS GENET, V3, P161, DOI 10.1371/journal.pgen.0030024
   Lawlor DA, 2004, LANCET, V363, P1724, DOI 10.1016/S0140-6736(04)16260-0
   Loktionov A, 2003, J NUTR BIOCHEM, V14, P426, DOI 10.1016/S0955-2863(03)00032-9
   Maraini G, 2008, OPHTHALMOLOGY, V115, P599, DOI 10.1016/j.ophtha.2008.01.005
   McCarty CA, 2002, DEV OPHTHALMOL, V35, P21
   McNeil JJ, 2004, OPHTHALMOLOGY, V111, P75, DOI 10.1016/j.ophtha.2003.04.009
   Moeller SM, 2004, J NUTR, V134, P1812, DOI 10.1093/jn/134.7.1812
   MOHAN M, 1989, ARCH OPHTHALMOL-CHIC, V107, P670, DOI 10.1001/archopht.1989.01070010688028
   Muller FL, 2007, FREE RADICAL BIO MED, V43, P477, DOI 10.1016/j.freeradbiomed.2007.03.034
   Murthy GVS, 2007, INVEST OPHTH VIS SCI, V48, P88, DOI 10.1167/iovs.06-0284
   Neale RE, 2003, EPIDEMIOLOGY, V14, P707, DOI 10.1097/01.ede.0000086881.84657.98
   Nirmalan PK, 2004, BRIT J OPHTHALMOL, V88, P989, DOI 10.1136/bjo.2003.038380
   Oliva Matthew S., 2005, International Ophthalmology Clinics, V45, P1
   Pastor-Valero Maria, 2007, BMC Ophthalmol, V7, P18, DOI 10.1186/1471-2415-7-18
   Pokhrel AK, 2005, INT J EPIDEMIOL, V34, P702, DOI 10.1093/ije/dyi015
   Raju P, 2006, BRIT J OPHTHALMOL, V90, P1374, DOI 10.1136/bjo.2006.097295
   RAMAKRISHNAN S, 1995, BRIT J OPHTHALMOL, V79, P202, DOI 10.1136/bjo.79.3.202
   RAO CM, 1995, CURR EYE RES, V14, P295, DOI 10.3109/02713689509033529
   Redman LM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004377
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   SanGiovanni JP, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005508
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   SHALINI VK, 1994, INDIAN J BIOCHEM BIO, V31, P261
   Shang F, 2003, FREE RADICAL BIO MED, V34, P521, DOI 10.1016/S0891-5849(02)01304-7
   Skibola CF, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002816
   Sreenivas V, 1999, J Epidemiol, V9, P327
   Stitt AW, 2001, BRIT J OPHTHALMOL, V85, P746, DOI 10.1136/bjo.85.6.746
   Taylor A, 2001, NUTRITION, V17, P845, DOI 10.1016/S0899-9007(01)00655-4
   TAYLOR HR, 1992, ARCH OPHTHALMOL-CHIC, V110, P99, DOI 10.1001/archopht.1992.01080130101035
   Udar N, 2009, INVEST OPHTH VIS SCI, V50, P2966, DOI 10.1167/iovs.08-2646
   Ughade Suresh N., 1998, Indian Journal of Ophthalmology, V46, P221
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   VARMA SD, 1987, ANN NY ACAD SCI, V498, P280, DOI 10.1111/j.1749-6632.1987.tb23768.x
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Weintraub JM, 2002, INT J OBESITY, V26, P1588, DOI 10.1038/sj.ijo.0802158
   Winkler BS, 1999, MOL VIS, V5
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   Zerbib J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007341
NR 71
TC 78
Z9 80
U1 2
U2 30
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3747
EI 1423-0259
J9 OPHTHALMIC RES
JI Ophthalmic Res.
PY 2010
VL 44
IS 3
BP 191
EP 198
DI 10.1159/000316476
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 652AN
UT WOS:000281972300007
PM 20829643
DA 2022-11-30
ER

PT J
AU Wei, X
   Ting, DSW
   Ng, WY
   Khandelwal, N
   Agrawal, R
   Cheung, CMG
AF Wei, Xin
   Ting, Daniel Shu Wei
   Ng, Wei Yan
   Khandelwal, Neha
   Agrawal, Rupesh
   Cheung, Chui Ming Gemmy
TI CHOROIDAL VASCULARITY INDEX A Novel Optical Coherence Tomography Based
   Parameter in Patients With Exudative Age-Related Macular Degeneration
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE choroidal vascularity index; age-related macular degeneration; choroidal
   neovascular membrane; polypoidal choroidal vasculopathy; choroidal
   thickness
ID HEALTHY EYES; MORPHOMETRIC-ANALYSIS; BRUCHS MEMBRANE; BLOOD-FLOW;
   THICKNESS; DRUSEN; VASCULOPATHY; CHORIOCAPILLARIS; PATHOGENESIS;
   INFLAMMATION
AB Purpose: To evaluate choroidal structural changes in exudative age-related macular degeneration (AMD) using choroidal vascularity index computed from image binarization on spectral domain optical coherence tomography with enhanced depth imaging.
   Methods: This prospective case series included 42 consecutive patients with unilateral exudative AMD. Choroidal images were segmented into luminal area and stromal area. Choroidal vascularity index was defined as the ratio of luminal area to total choroid area. Mean choroidal vascularity index and mean choroidal thickness between study and fellow eyes of the same patient with dry AMD were compared using Student's t-test.
   Results: There was a significantly lower choroidal vascularity index in eyes with exudative AMD (60.14 +/- 4.55 vs. 62.75 +/- 4.82, P < 0.01). Luminal area (P < 0.01) was decreased in eyes with exudative AMD but there was no significant difference in total choroid area (P = 0.05) and choroidal thickness (P = 0.93) between study and fellow eyes.
   Conclusion: Eyes with exudative AMD demonstrated reduced choroidal vascularity index but insignificant differences in choroidal thickness compared with their fellow eyes. Choroidal vascularity index may be a potential noninvasive tool for studying structural changes in choroid and monitoring choroidal disease in exudative AMD.
C1 [Wei, Xin; Khandelwal, Neha; Agrawal, Rupesh] Tan Tock Seng Hosp, Natl Healthcare Grp Eye Inst, Singapore, Singapore.
   [Ting, Daniel Shu Wei; Ng, Wei Yan; Agrawal, Rupesh; Cheung, Chui Ming Gemmy] Singapore Eye Res Inst, Singapore, Singapore.
   [Ting, Daniel Shu Wei; Ng, Wei Yan; Cheung, Chui Ming Gemmy] Singapore Natl Eye Ctr, 11 Third Hosp Ave, Singapore 168751, Singapore.
C3 Tan Tock Seng Hospital; National University of Singapore; Singapore
   National Eye Center; Singapore National Eye Center
RP Cheung, CMG (通讯作者)，Singapore Natl Eye Ctr, 11 Third Hosp Ave, Singapore 168751, Singapore.
EM Gemmy.cheung.c.m@snec.com.sg
OI Wei, Xin/0000-0001-8865-1956; Bidwai, Pooja Vishal/0000-0002-3077-4395;
   Cheung, Chui Ming Gemmy/0000-0003-3358-3516
CR Agrawal R, 2016, SCI REP-UK, V6, DOI 10.1038/srep21090
   Agrawal R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146344
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   [Anonymous], 1991, Arch Ophthalmol, V109, P1220
   Balaratnasingam C, 2016, RETINA-J RET VIT DIS, V36, P1, DOI 10.1097/IAE.0000000000000774
   Berenberg TL, 2012, RETINA-J RET VIT DIS, V32, P25, DOI 10.1097/IAE.0b013e3182150483
   Bourne RRA, 2013, LANCET GLOB HEALTH, V1, pE339, DOI 10.1016/S2214-109X(13)70113-X
   Branchini LA, 2013, OPHTHALMOLOGY, V120, P1901, DOI 10.1016/j.ophtha.2013.01.066
   Bressler SB, 2009, OPHTHALMOLOGY, V116, pS1, DOI 10.1016/j.ophtha.2009.06.045
   Chen SJ, 2001, BRIT J OPHTHALMOL, V85, P1411, DOI 10.1136/bjo.85.12.1411
   Cheung CMG, 2012, CLIN EXP OPHTHALMOL, V40, P727, DOI 10.1111/j.1442-9071.2012.02765.x
   Cheung CMG, 2015, RETINA-J RET VIT DIS, V35, P1375, DOI 10.1097/IAE.0000000000000482
   Coleman DJ, 2013, BRIT J OPHTHALMOL, V97, P1020, DOI 10.1136/bjophthalmol-2013-303143
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Gallego-Pinazo Roberto, 2014, Med Hypothesis Discov Innov Ophthalmol, V3, P111
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Jonas JB, 2014, RETINA-J RET VIT DIS, V34, P1149, DOI 10.1097/IAE.0000000000000035
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kim SW, 2011, RETINA-J RET VIT DIS, V31, P1904, DOI 10.1097/IAE.0b013e31821801c5
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Manjunath V, 2011, AM J OPHTHALMOL, V152, P663, DOI 10.1016/j.ajo.2011.03.008
   McLeod DS, 2002, INVEST OPHTH VIS SCI, V43, P1986
   Metelitsina TI, 2008, INVEST OPHTH VIS SCI, V49, P358, DOI 10.1167/iovs.07-0526
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Pang CE, 2015, RETINA-J RET VIT DIS, V35, P1, DOI 10.1097/IAE.0000000000000331
   Pauleikhoff D, 1999, ARCH OPHTHALMOL-CHIC, V117, P1353, DOI 10.1001/archopht.117.10.1353
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]
   Sonoda S, 2014, INVEST OPHTH VIS SCI, V55, P3893, DOI 10.1167/iovs.14-14447
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Spraul CW, 1996, INVEST OPHTH VIS SCI, V37, P2724
   Ting DSW, 2015, CLIN EXP OPHTHALMOL, V43, P815, DOI 10.1111/ceo.12580
   Ting DSW, 2016, AM J OPHTHALMOL, V164, P128, DOI 10.1016/j.ajo.2015.12.024
   Wood A, 2011, AM J OPHTHALMOL, V152, P1030, DOI 10.1016/j.ajo.2011.05.021
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 36
TC 77
Z9 80
U1 1
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUN
PY 2017
VL 37
IS 6
BP 1120
EP 1125
DI 10.1097/IAE.0000000000001312
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EW0KL
UT WOS:000402179100030
PM 27632714
DA 2022-11-30
ER

PT J
AU Gold, B
   Merriam, JE
   Zernant, J
   Hancox, LS
   Taiber, AJ
   Gehrs, K
   Cramer, K
   Neel, J
   Bergeron, J
   Barile, GR
   Smith, RT
   Dean, M
   Allikmets, R
AF Gold, B
   Merriam, JE
   Zernant, J
   Hancox, LS
   Taiber, AJ
   Gehrs, K
   Cramer, K
   Neel, J
   Bergeron, J
   Barile, GR
   Smith, RT
   Dean, M
   Allikmets, R
CA AMD Genetics Clin Study Grp
TI Variation in factor B (BF) and complement component 2 (C2) genes is
   associated with age-related macular degeneration
SO NATURE GENETICS
LA English
DT Article
ID FACTOR-H POLYMORPHISM; DISEASE; DRUSEN; MACULOPATHY; DEFICIENCY;
   SUSCEPTIBILITY; EPIDEMIOLOGY; HAPLOTYPE; ETIOLOGY; VARIANT
AB Age-related macular degeneration (AMD) is the most common form of irreversible blindness in developed countries(1,2). Variants in the factor H gene (CFH, also known as HF1), which encodes a major inhibitor of the alternative complement pathway, are associated with the risk for developing AMD(3-8). Here we test the hypothesis that variation in genes encoding other regulatory proteins of the same pathway is associated with AMD. We screened factor B (BF) and complement component 2 (C2) genes, located in the major histocompatibility complex class III region, for genetic variation in two independent cohorts comprising similar to 900 individuals with AMD and similar to 400 matched controls. Haplotype analyses identify a statistically significant common risk haplotype (H1) and two protective haplotypes. The L9H variant of BF and the E318D variant of C2 (H10), as well as a variant in intron 10 of C2 and the R32Q variant of BF (H7), confer a significantly reduced risk of AMD (odds ratio=0.45 and 0.36, respectively). Combined analysis of the C2 and BF haplotypes and CFH variants shows that variation in the two loci can predict the clinical outcome in 74% of the affected individuals and 56% of the controls. These data expand and refine our understanding of the genetic risk for AMD.
C1 Columbia Univ, Dept Ophthalmol, New York, NY 10032 USA.
   NCI, Lab Genom Divers, Frederick, MD 21702 USA.
   Univ Iowa, Ctr Macular Degenerat, Dept Ophthalmol & Visual Sci, Iowa City, IA 52240 USA.
   Sapio Sci LLC, York, PA 17402 USA.
   SAIC Frederick, Frederick, MD 21702 USA.
   Columbia Univ, Dept Pathol & Cell Biol, New York, NY 10032 USA.
C3 Columbia University; National Institutes of Health (NIH) - USA; NIH
   National Cancer Institute (NCI); University of Iowa; Science
   Applications International Corporation (SAIC); SAIC-Frederick; Columbia
   University
RP Allikmets, R (通讯作者)，Columbia Univ, Dept Ophthalmol, New York, NY 10032 USA.
EM dean@ncifcrf.gov; rla22@columbia.edu
RI Dean, Michael/R-7501-2019; Mohammed, Imran/J-8271-2012; Allikmets,
   Rando/ABD-4533-2021; Dean, Michael C/G-8172-2012
OI Mohammed, Imran/0000-0002-8412-0768; Dean, Michael
   C/0000-0003-2234-0631; smith, theodore/0000-0002-1693-943X; Hancox,
   Lisa/0000-0003-1940-2619; Gehrs, Karen/0000-0003-4510-9678
FU NATIONAL CANCER INSTITUTE [Z01BC005652] Funding Source: NIH RePORTER;
   NATIONAL EYE INSTITUTE [R01EY011515, R01EY013435, R01EY015520] Funding
   Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline; NCI
   NIH HHS [N01-CO-124000] Funding Source: Medline; NEI NIH HHS [EY11515,
   R01 EY015520-01A2, R01 EY015520-03, R01 EY015520-04, R01 EY015520-05,
   R01 EY013435, R01 EY015520, R01 EY011515, EY13435, R01 EY015520-02]
   Funding Source: Medline
CR Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   Alper CA, 2003, J CLIN IMMUNOL, V23, P297, DOI 10.1023/A:1024540917593
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bok D, 2005, P NATL ACAD SCI USA, V102, P7053, DOI 10.1073/pnas.0502819102
   Conley YP, 2005, HUM MOL GENET, V14, P1991, DOI 10.1093/hmg/ddi204
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   DAVIS CA, 1980, J LAB CLIN MED, V96, P633
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Goverdhan SV, 2005, INVEST OPHTH VIS SCI, V46, P1726, DOI 10.1167/iovs.04-0928
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hayashi M, 2004, Ophthalmic Genet, V25, P111
   Holers VM, 2004, MOL IMMUNOL, V41, P147, DOI 10.1016/j.molimm.2004.03.012
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   KINOSHITA T, 1991, IMMUNOL TODAY, V12, P291, DOI 10.1016/0167-5699(91)90001-A
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Larsen CE, 2004, CURR OPIN IMMUNOL, V16, P660, DOI 10.1016/j.coi.2004.07.014
   LOKKI ML, 1991, IMMUNOGENETICS, V34, P242, DOI 10.1007/BF00215259
   MORGAN BP, 1991, IMMUNOL TODAY, V12, P301, DOI 10.1016/0167-5699(91)90003-C
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Myers S, 2005, SCIENCE, V310, P321, DOI 10.1126/science.1117196
   RAUM D, 1979, AM J HUM GENET, V31, P35
   Stewart CA, 2004, GENOME RES, V14, P1176, DOI 10.1101/gr.2188104
   van Leeuwen R, 2003, EUR J EPIDEMIOL, V18, P845, DOI 10.1023/A:1025643303914
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
NR 30
TC 860
Z9 935
U1 0
U2 34
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1061-4036
EI 1546-1718
J9 NAT GENET
JI Nature Genet.
PD APR
PY 2006
VL 38
IS 4
BP 458
EP 462
DI 10.1038/ng1750
PG 5
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 026LN
UT WOS:000236340500019
PM 16518403
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Takayama, K
   Kaneko, H
   Ueno, S
   Maruko, R
   Piao, CH
   Yasuda, S
   Kawano, K
   Ito, Y
   Terasaki, H
AF Takayama, Kei
   Kaneko, Hiroki
   Ueno, Shinji
   Maruko, Ruka
   Piao, Chang-Hua
   Yasuda, Shunsuke
   Kawano, Kenichi
   Ito, Yasuki
   Terasaki, Hiroko
TI EVALUATION OF SHORT-TERM OUTCOMES OF INTRAVITREAL AFLIBERCEPT INJECTIONS
   FOR AGE-RELATED MACULAR DEGENERATION USING FOCAL MACULAR
   ELECTRORETINOGRAPHY
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE aflibercept; AMD; focal macular electroretinogram
ID CHOROIDAL VASCULAR HYPERPERMEABILITY; PHOTODYNAMIC THERAPY; EPIRETINAL
   MEMBRANE; RANIBIZUMAB; EYES; BEVACIZUMAB; THICKNESS; EFFICACY; SURGERY;
   REMOVAL
AB Purpose: To evaluate the relationship between morphological changes and functional improvements assessed using focal macular electroretinograms after intravitreal aflibercept (IVA) injections in eyes with wet age-related macular degeneration.
   Methods: The clinical records of 42 eyes of 42 consecutive patients with naive, wet agerelated macular degeneration received 3 monthly IVA were reviewed. The best-corrected visual acuity, central foveal thickness, outer retinal thickness, inner retinal thickness at baseline and 1 month after each IVA, and focal macular electroretinograms at baseline and 1 month after the first and third IVA were compared.
   Results: Best-corrected visual acuity was improved after the third IVA (P = 0.0091). Central foveal thickness and outer retinal thickness showed decreases after every IVA (P < 0.001, respectively). Inner retinal thickness showed a decrease after the second IVA (P = 0.002), after and third IVA (P = 0.001). On focal macular electroretinograms, a-and b-wave amplitudes showed increases after the third IVA (P = 0.0028, P = 0.0012, respectively). Significant correlations were observed between best-corrected visual acuity and central foveal thickness, a-wave amplitude and outer retinal thickness, and b-wave amplitude and inner retinal thickness changes after the third IVA.
   Conclusion: All parameters significantly recovered after three monthly IVA, with a correlation between functional improvements and morphological changes.
C1 [Takayama, Kei; Kaneko, Hiroki; Ueno, Shinji; Maruko, Ruka; Piao, Chang-Hua; Yasuda, Shunsuke; Kawano, Kenichi; Ito, Yasuki; Terasaki, Hiroko] Nagoya Univ, Grad Sch Med, Dept Ophthalmol, Nagoya, Aichi, Japan.
C3 Nagoya University
RP Terasaki, H (通讯作者)，Nagoya Univ, Grad Sch Med, Dept Ophthalmol, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.
EM terasaki@med.nagoya-u.ac.jp
RI Kaneko, Hiroki/O-7695-2015; Ito, Yasuki/M-4876-2014; Kaneko,
   Hiroki/AHA-2461-2022; Maruko, Ruka/M-4929-2014
OI Kaneko, Hiroki/0000-0003-0731-6465; Ito, Yasuki/0000-0001-9219-9261;
   Kaneko, Hiroki/0000-0003-0731-6465; Maruko, Ruka/0000-0003-0208-1011;
   Takayama, Kei/0000-0002-1477-9014; Kawano, Kenichi/0000-0002-6463-9650
CR Beazley-Long N, 2013, AM J PATHOL, V183, P918, DOI 10.1016/j.ajpath.2013.05.031
   Foxton RH, 2013, AM J PATHOL, V182, P1379, DOI 10.1016/j.ajpath.2012.12.032
   Gregori NZ, 2010, RETINA-J RET VIT DIS, V30, P1046, DOI 10.1097/IAE.0b013e3181d87e04
   Hata M, 2014, INVEST OPHTH VIS SCI, V55, P7874, DOI 10.1167/iovs.14-14610
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hibi N, 2013, INVEST OPHTH VIS SCI, V54, P7207, DOI 10.1167/iovs.13-12884
   Ishikawa K, 2007, INVEST OPHTH VIS SCI, V48, P2254, DOI 10.1167/iovs.06-1277
   Iwata E, 2012, INVEST OPHTH VIS SCI, V53, P4185, DOI 10.1167/iovs.11-9335
   Julien S, 2014, BRIT J OPHTHALMOL, V98, P813, DOI 10.1136/bjophthalmol-2013-304019
   Mackay AM, 2007, DOC OPHTHALMOL, V115, P69, DOI 10.1007/s10633-007-9056-y
   Mitchell J, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-97
   MIYAKE Y, 1989, INVEST OPHTH VIS SCI, V30, P1743
   MIYAKE Y, 1988, INVEST OPHTH VIS SCI, V29, P1631
   Nishihara H, 2008, INVEST OPHTH VIS SCI, V49, P3121, DOI 10.1167/iovs.08-1835
   Nishimura T, 2015, GRAEF ARCH CLIN EXP, V253, P1201, DOI 10.1007/s00417-014-2779-z
   Niwa T, 2003, INVEST OPHTH VIS SCI, V44, P1652, DOI 10.1167/iovs.02-0404
   Nomura Y, 2015, JPN J OPHTHALMOL, V59, P261, DOI 10.1007/s10384-015-0387-z
   Ogino K, 2013, INVEST OPHTH VIS SCI, V54, P3771, DOI 10.1167/iovs.12-11494
   Pirozzi E, 2006, ACTA OPHTHALMOL SCAN, V84, P27, DOI 10.1111/j.1600-0420.2005.00529.x
   Schmid MK, 2015, BRIT J OPHTHALMOL, V99, P141, DOI 10.1136/bjophthalmol-2014-305149
   SEIPLE WH, 1986, INVEST OPHTH VIS SCI, V27, P1123
   Shin HJ, 2011, RETINA-J RET VIT DIS, V31, P1627, DOI 10.1097/IAE.0b013e31820d3d01
   Sophie Raafay, 2012, Biol Ther, V2, P3, DOI 10.1007/s13554-012-0003-4
   Terasaki H, 2001, Nagoya J Med Sci, V64, P1
   Terasaki H, 2003, INVEST OPHTH VIS SCI, V44, P4465, DOI 10.1167/iovs.02-1313
   Terasaki H, 2001, INVEST OPHTH VIS SCI, V42, P229
NR 26
TC 4
Z9 4
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAR
PY 2017
VL 37
IS 3
BP 553
EP 560
DI 10.1097/IAE.0000000000001225
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EQ3QM
UT WOS:000397987600029
PM 27465570
DA 2022-11-30
ER

PT J
AU Wang, ZY
   Sadda, SR
   Lee, A
   Hu, ZJ
AF Wang, Ziyuan
   Sadda, Srinivas Reddy
   Lee, Aaron
   Hu, Zhihong Jewel
TI Automated segmentation and feature discovery of age-related macular
   degeneration and Stargardt disease via self-attended neural networks
SO SCIENTIFIC REPORTS
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; GEOGRAPHIC ATROPHY; RETINAL LAYER;
   PROGRESSION
AB Age-related macular degeneration (AMD) and Stargardt disease are the leading causes of blindness for the elderly and young adults respectively. Geographic atrophy (GA) of AMD and Stargardt atrophy are their end-stage outcomes. Efficient methods for segmentation and quantification of these atrophic lesions are critical for clinical research. In this study, we developed a deep convolutional neural network (CNN) with a trainable self-attended mechanism for accurate GA and Stargardt atrophy segmentation. Compared with traditional post-hoc attention mechanisms which can only visualize CNN features, our self-attended mechanism is embedded in a fully convolutional network and directly involved in training the CNN to actively attend key features for enhanced algorithm performance. We applied the self-attended CNN on the segmentation of AMD and Stargardt atrophic lesions on fundus autofluorescence (FAF) images. Compared with a preexisting regular fully convolutional network (the U-Net), our self-attended CNN achieved 10.6% higher Dice coefficient and 17% higher IoU (intersection over union) for AMD GA segmentation, and a 22% higher Dice coefficient and a 32% higher IoU for Stargardt atrophy segmentation. With longitudinal image data having over a longer time, the developed self-attended mechanism can also be applied on the visual discovery of early AMD and Stargardt features.
C1 [Wang, Ziyuan; Sadda, Srinivas Reddy; Hu, Zhihong Jewel] Doheny Eye Inst, 150 N Orange Grove Blvd, Pasadena, CA 91103 USA.
   [Wang, Ziyuan; Sadda, Srinivas Reddy] Univ Calif Los Angeles, Los Angeles, CA 90095 USA.
   [Lee, Aaron] Univ Washington, Seattle, WA 98195 USA.
C3 Doheny Eye Institute; University of California System; University of
   California Los Angeles; University of Washington; University of
   Washington Seattle
RP Hu, ZJ (通讯作者)，Doheny Eye Inst, 150 N Orange Grove Blvd, Pasadena, CA 91103 USA.
EM jhu@doheny.org
FU National Eye Institute of the National Institutes of Health
   [R21EY030619, R21EY029839]
FX Research reported in this publication was partially supported by the
   National Eye Institute of the National Institutes of Health under Award
   Number R21EY030619 and R21EY029839.
CR Charng J, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-73339-y
   Chen Q, 2013, BIOMED OPT EXPRESS, V4, P2729, DOI 10.1364/BOE.4.002729
   Chu ZD, 2022, BIOMED OPT EXPRESS, V13, P1328, DOI 10.1364/BOE.449314
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Devisetti K, 2011, IEEE ENG MED BIO, P3958, DOI 10.1109/IEMBS.2011.6090983
   Fang LY, 2017, BIOMED OPT EXPRESS, V8, P2732, DOI 10.1364/BOE.8.002732
   Fergus R., 2013, ARXIV
   Gulshan V, 2016, JAMA-J AM MED ASSOC, V316, P2402, DOI 10.1001/jama.2016.17216
   Hernandez M, 2015, IEEE WINT CONF APPL, P907, DOI 10.1109/WACV.2015.125
   Hu K, 2019, NEUROCOMPUTING, V365, P302, DOI 10.1016/j.neucom.2019.07.079
   Hu ZH, 2018, PROC SPIE, V10575, DOI 10.1117/12.2287001
   Hu ZH, 2015, J MED IMAGING, V2, DOI 10.1117/1.JMI.2.1.014501
   Hu ZH, 2013, INVEST OPHTH VIS SCI, V54, P8375, DOI 10.1167/iovs.13-12552
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Jetley S., 2018, PROC
   Ji ZX, 2018, TRANSL VIS SCI TECHN, V7, DOI 10.1167/tvst.7.1.1
   Klein R, 2006, AM J OPHTHALMOL, V142, P539, DOI 10.1016/j.ajo.2006.06.015
   Kugelman J, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-49816-4
   Lecun Y, 1995, HDB BRAIN THEORY NEU
   Liefers B, 2020, OPHTHALMOLOGY, V127, P1086, DOI 10.1016/j.ophtha.2020.02.009
   Ma X, 2020, IEEE J BIOMED HEALTH, V24, P3443, DOI 10.1109/JBHI.2020.2999588
   Mukherjee N, 2014, DIAGNOSIS MANAGEMENT
   Oktay O, 2018, ARXIV
   Ramsey DJ, 2014, RETINA-J RET VIT DIS, V34, P1296, DOI 10.1097/IAE.0000000000000069
   Ronneberger O., 2015, ARXIV
   Roy AG, 2017, BIOMED OPT EXPRESS, V8, P3627, DOI 10.1364/BOE.8.003627
   Saha S, 2020, APPL LETT, V1, pe16, DOI DOI 10.1002/AIL2.16
   Saha S, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-47390-3
   Schmidt-Erfurth U, 2020, AM J OPHTHALMOL, V216, P257, DOI 10.1016/j.ajo.2020.03.042
   Schmitz-Valckenberg S, 2008, RETINA-J RET VIT DIS, V28, P385, DOI 10.1097/IAE.0b013e318164a907
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P7640, DOI 10.1167/iovs.11-7457
   Selvaraju RR, 2017, IEEE I CONF COMP VIS, P618, DOI 10.1109/ICCV.2017.74
   Stahl A, 2020, DTSCH ARZTEBL INT, V117, P513, DOI 10.3238/arztebl.2020.0513
   Strauss RW, 2016, OPHTHALMOLOGY, V123, P817, DOI 10.1016/j.ophtha.2015.12.009
   Venhuizen FG, 2017, BIOMED OPT EXPRESS, V8, P3292, DOI 10.1364/BOE.8.003292
   Wang ZY, 2019, PROC SPIE, V10950, DOI 10.1117/12.2511538
NR 36
TC 0
Z9 0
U1 2
U2 2
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD AUG 26
PY 2022
VL 12
IS 1
AR 14565
DI 10.1038/s41598-022-18785-6
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 4C6PC
UT WOS:000846571700049
PM 36028647
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Baek, SK
   Kim, JH
   Kim, JW
   Kim, CG
AF Baek, Seung Kook
   Kim, Jae Hui
   Kim, Jong Woo
   Kim, Chul Gu
TI Increase in the Population of Patients with Neovascular Age-Related
   Macular Degeneration Who Underwent Long-Term Active Treatment
SO SCIENTIFIC REPORTS
LA English
DT Article
ID DOSING REGIMEN; DISEASE BURDEN; RANIBIZUMAB; EXTEND; PREVALENCE;
   AFLIBERCEPT; DISCONTINUATION; EXPERIENCE
AB To investigate changes in the size of the population of patients who are receiving long-term, active treatment for neovascular age-related macular degeneration (AMD). This retrospective, observational study included 18,165 patients who received anti-vascular endothelial growth factor injections (3,974 eyes). The injections performed were divided into the following three groups: group 1, injections performed right after the initial diagnosis; group 2, injections performed <24 months; and group 3, injection performed >= 24 months. Time-dependent changes in the proportion of injections in each group were analyzed. The total number of injections markedly increased from 431 in the 1st quarter of 2014 to 1,323 in the 4th quarter of 2018. There were significant changes in the proportion of injections in each group over time (P < 0.001). The proportions of group 1, group 2, and group 3 in the 1st quarter of 2014 were 17.4%, 65.4%, and 17.2%, respectively. The proportions changed to 10.6%, 50.2%, and 39.5% in the 4th quarter of 2018, respectively. The marked increase in the proportions of group 3 may suggest an increase in the patient population that underwent long-term active treatment. The socioeconomic influence of this trend should be considered when establishing future strategies for neovascular AMD.
C1 [Baek, Seung Kook] Konyang Univ, Dept Ophthalmol, Coll Med, Daejeon, South Korea.
   [Kim, Jae Hui; Kim, Jong Woo; Kim, Chul Gu] Konyang Univ, Kims Eye Hosp, Dept Ophthalmol, Coll Med, Seoul, South Korea.
C3 Konyang University; Konyang University Hospital; Konyang University;
   Konyang University Hospital
RP Kim, JH (通讯作者)，Konyang Univ, Kims Eye Hosp, Dept Ophthalmol, Coll Med, Seoul, South Korea.
EM kimoph@gmail.com
OI Kim, Jae Hui/0000-0001-8121-6353; Baek, Seungkook/0000-0003-3601-9582
FU Kim's Eye Hospital Research Center
FX This study was supported by Kim's Eye Hospital Research Center.
CR Cohen SY, 2013, GRAEF ARCH CLIN EXP, V251, P2499, DOI 10.1007/s00417-013-2338-z
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Dawson SR, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-78
   Day S, 2011, AM J OPHTHALMOL, V152, P1014, DOI 10.1016/j.ajo.2011.05.008
   Dugel PU, 2017, OPHTHALMOLOGY, V124, P1296, DOI 10.1016/j.ophtha.2017.03.057
   Falk MK, 2013, AM J OPHTHALMOL, V155, P89, DOI 10.1016/j.ajo.2012.06.031
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Freund KB, 2015, RETINA-J RET VIT DIS, V35, P1489, DOI 10.1097/IAE.0000000000000627
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gohil R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129361
   Hatz K, 2017, ACTA OPHTHALMOL, V95, pE67, DOI 10.1111/aos.13031
   Hatz K, 2016, BRIT J OPHTHALMOL, V100, P1341, DOI 10.1136/bjophthalmol-2015-307299
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holz FG, 2016, BRIT J OPHTHALMOL, V100, P1623, DOI 10.1136/bjophthalmol-2015-308166
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Korobelnik JF, 2006, INVEST OPHTH VIS SCI, V47, P4270, DOI 10.1167/iovs.05-1467
   Kvannli L, 2017, ACTA OPHTHALMOL, V95, P678, DOI 10.1111/aos.13356
   Lance KD, 2016, DRUG DELIV TRANSL RE, V6, P771, DOI 10.1007/s13346-016-0298-7
   Lyman GH, 2018, NEW ENGL J MED, V378, P2036, DOI [10.1056/NEJMc1808348, 10.1056/NEJMhle1800125]
   McCloud C, 2015, EYE, V29, P1561, DOI 10.1038/eye.2015.167
   Park SJ, 2015, OPHTHALMOLOGY, V122, P2063, DOI 10.1016/j.ophtha.2015.06.018
   Prenner JL, 2015, AM J OPHTHALMOL, V160, P725, DOI 10.1016/j.ajo.2015.06.023
   Rim T. H., 2018, BRIT J OPHTHALMOLOGY
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rufai SR, 2017, EYE, V31, P1337, DOI 10.1038/eye.2017.67
   Saxena N, 2016, OPHTHAL EPIDEMIOL, V23, P232, DOI 10.1080/09286586.2016.1193617
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Sharma A, 2018, CLIN OPHTHALMOL, V12, P2137, DOI 10.2147/OPTH.S180393
   Sloan FA, 2014, JAMA OPHTHALMOL, V132, P456, DOI 10.1001/jamaophthalmol.2013.7647
   Spaide R, 2007, AM J OPHTHALMOL, V143, P679, DOI 10.1016/j.ajo.2007.02.024
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   Vaze A, 2014, RETINA-J RET VIT DIS, V34, P1774, DOI 10.1097/IAE.0000000000000173
   Vukicevic M, 2016, EYE, V30, P413, DOI 10.1038/eye.2015.235
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wykoff CC, 2015, OPHTHALMOLOGY, V122, P2514, DOI 10.1016/j.ophtha.2015.08.009
   Zhang LL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135608
NR 37
TC 12
Z9 12
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD SEP 13
PY 2019
VL 9
AR 13264
DI 10.1038/s41598-019-49749-y
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA IX4UK
UT WOS:000485680900061
PM 31519960
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Kearns, V
   Mistry, A
   Mason, S
   Krishna, Y
   Sheridan, C
   Short, R
   Williams, RL
AF Kearns, Victoria
   Mistry, Anita
   Mason, Sharon
   Krishna, Yamini
   Sheridan, Carl
   Short, Robert
   Williams, Rachel L.
TI Plasma polymer coatings to aid retinal pigment epithelial growth for
   transplantation in the treatment of age related macular degeneration
SO JOURNAL OF MATERIALS SCIENCE-MATERIALS IN MEDICINE
LA English
DT Article
ID RAY PHOTOELECTRON-SPECTROSCOPY; SELF-ASSEMBLED MONOLAYERS; ACRYLIC-ACID;
   HUMAN KERATINOCYTES; IMMUNOGLOBULIN-G; ALLYL ALCOHOL; CELL-ADHESION;
   SURFACES; ATTACHMENT; VITRONECTIN
AB Subretinal transplantation of functioning retinal pigment epithelial (RPE) cells grown on a synthetic substrate is a potential treatment for age-related macular degeneration (AMD), a common cause of irreversible vision loss in developed countries. Plasma polymers give the opportunity to tailor the surface chemistry of the artificial substrate whilst maintaining the bulk properties. In this study, plasma polymers with different functionalities were investigated in terms of their effect on RPE attachment and growth. Plasma polymers of acrylic acid (AC), allyl amine (AM) and allyl alcohol (AL) were fabricated and characterised using X-ray photoelectron spectroscopy (XPS) and water contact angle measurements. Octadiene (OD) hydrocarbon films and tissue culture polystyrene were used as controls. Wettability varied from hydrophobic OD to relatively hydrophilic AC. XPS demonstrated four very different surfaces with the expected functionalities. Attachment, proliferation and morphological examination of an RPE cell line and primary RPE cells were investigated. Both cell types grew on all surfaces, with the exception of OD, although the proliferation rate of primary cells was low. Good epithelial morphology was also demonstrated. Plasma polymerised films show potential as cell carrier surfaces for RPE cells in the treatment of AMD.
C1 [Kearns, Victoria; Mason, Sharon; Krishna, Yamini; Sheridan, Carl; Williams, Rachel L.] Univ Liverpool, Dept Eye & Vis Sci, Liverpool L69 3BX, Merseyside, England.
   [Mistry, Anita] Univ Sheffield, Sch Mat Engn, Sheffield S10 2TN, S Yorkshire, England.
   [Short, Robert] Univ So Australia, Mawson Inst, Adelaide, SA 5095, Australia.
C3 University of Liverpool; University of Sheffield; University of South
   Australia
RP Williams, RL (通讯作者)，Univ Liverpool, Dept Eye & Vis Sci, Liverpool L69 3BX, Merseyside, England.
EM rlw@liverpool.ac.uk
RI Kearns, Victoria/I-3271-2012; Sheridan, Carl/AAH-3607-2021; Short,
   Robert D/D-4580-2009
OI Kearns, Victoria/0000-0003-1426-6048; Sheridan,
   Carl/0000-0003-0100-9587; Short, Robert/0000-0001-9173-1180; Williams,
   Rachel/0000-0002-1954-0256; , Yamini/0000-0001-5067-3682
CR Alexander MR, 1998, J MATER CHEM, V8, P937
   Barton D, 1999, J PHYS CHEM B, V103, P4423, DOI 10.1021/jp9844821
   Beck AJ, 1996, POLYMER, V37, P5537, DOI 10.1016/S0032-3861(96)00479-X
   Briggs G., 1992, J CHEM EDUC, V70, pA25, DOI [DOI 10.1021/ED070PA25.5, 10.1021/ed070pa25.5]
   Bullett NA, 2003, J MATER CHEM, V13, P1546, DOI 10.1039/b302176a
   CAMPOCHIARO PA, 1991, INVEST OPHTH VIS SCI, V32, P65
   Candan S, 1998, J VAC SCI TECHNOL A, V16, P1702, DOI 10.1116/1.581288
   CURTIS ASG, 1984, J CELL SCI, V71, P17
   Daw R, 1998, J MATER CHEM, V8, P2583, DOI 10.1039/a806612d
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   France RM, 1998, CHEM MATER, V10, P1176, DOI 10.1021/cm970761+
   France RM, 1998, J MATER CHEM, V8, P37, DOI 10.1039/a705098d
   France RM, 1998, LANGMUIR, V14, P4827, DOI 10.1021/la9713053
   GENGENBACH TR, 1994, J POLYM SCI POL CHEM, V32, P1399, DOI 10.1002/pola.1994.080320801
   Haddow DB, 1999, J BIOMED MATER RES, V47, P379, DOI 10.1002/(SICI)1097-4636(19991205)47:3<379::AID-JBM13>3.0.CO;2-#
   Harsch A, 2000, J NEUROSCI METH, V98, P135, DOI 10.1016/S0165-0270(00)00196-5
   Krishna Y, 2011, BRIT J OPHTHALMOL, V95, P569, DOI 10.1136/bjo.2009.169953
   Krishna Y, 2007, J BIOMED MATER RES A, V80A, P669, DOI 10.1002/jbm.a.30953
   Sheridan C, 2007, EXPERT REV OPHTHALMO, V2, P497, DOI 10.1586/17469899.2.3.497
   STEELE JG, 1995, BIOMATERIALS, V16, P1057, DOI 10.1016/0142-9612(95)98901-P
   UNDERWOOD PA, 1989, J CELL SCI, V93, P641
   Wells N, 2009, BIOMATERIALS, V30, P1066, DOI 10.1016/j.biomaterials.2008.10.027
   Whittle JD, 2002, J MATER CHEM, V12, P2726, DOI 10.1039/b201471h
   Whittle JD, 2000, CHEM MATER, V12, P2664, DOI 10.1021/cm0002158
   Williams RL, 2005, J MATER SCI-MATER M, V16, P1087, DOI 10.1007/s10856-005-4710-y
   Wilson DJ, 2001, SURF INTERFACE ANAL, V31, P385, DOI 10.1002/sia.1065
   Wilson DJ, 2001, SURF INTERFACE ANAL, V31, P397, DOI 10.1002/sia.1066
   Yasuda H., 1985, PLASMA POLYM
   Yasunari T, 1999, OPHTHALMIC RES, V31, P24, DOI 10.1159/000055509
NR 29
TC 26
Z9 26
U1 0
U2 18
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0957-4530
J9 J MATER SCI-MATER M
JI J. Mater. Sci.-Mater. Med.
PD AUG
PY 2012
VL 23
IS 8
BP 2013
EP 2021
DI 10.1007/s10856-012-4675-6
PG 9
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering; Materials Science
GA 976LT
UT WOS:000306586900018
PM 22618272
DA 2022-11-30
ER

PT J
AU Hodge, WG
   Barnes, D
   Schachter, HM
   Pan, YI
   Lowcock, EC
   Zhang, L
   Sampson, M
   Morrison, A
   Tran, K
   Miguelez, M
   Lewin, G
AF Hodge, William G.
   Barnes, David
   Schachter, Howard M.
   Pan, Yi Irene
   Lowcock, Elizabeth C.
   Zhang, Li
   Sampson, Margaret
   Morrison, Andra
   Tran, Khai
   Miguelez, Maia
   Lewin, Gabriela
TI Evidence for the effect of Omega-3 fatty acids on progression of
   age-related macular degeneration - A systematic review
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; omega-3 fatty acids; progression;
   systematic review
ID DOCOSAHEXAENOIC ACID; DIETARY-FAT; DEFICIENCY; RHODOPSIN
AB Background: As part of a larger systematic review on the effect of omega-3 fatty acids on eye health, the aim of this report was to appraise and synthesize the evidence for the effects of omega-3 fatty acids in slowing down the progression of age-related macular degeneration (AMD) and/or decreasing the rate of progression to advanced forms of AMD.
   Methods: A comprehensive search was undertaken in six databases (MEDLINE, PreMEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, CAB Health, and Dissertation Abstracts).
   Results: Two unique studies, one randomized clinical trial (RCT) and one prospective cohort study, satisfied the eligibility criteria and were included in the review. The RCT reported evidence on the effect of omega-3 fatty acids in slowing down the progression of AMD. The prospective cohort Study addressed the question: what is the evidence that omega-3 fatty acids decrease the rate of progression to advanced forms of AMD?
   Conclusions: Clinical research on this topic is scarce. Only two studies were eligible to be included in this review. Although one study result indicated efficacy of preventing AMD progression to its advanced form, this result needs to be duplicated and supported by future research.
C1 Univ Ottawa, Ottawa Hosp Eye Inst, Dept Ophthalmol, Ottawa, ON K1H 8L6, Canada.
   CHEO Res Inst, Chalmers Res Grp, Ottawa, ON, Canada.
C3 University of Ottawa; Ottawa Hospital Research Institute; University of
   Ottawa; Children's Hospital of Eastern Ontario
RP Hodge, WG (通讯作者)，Univ Ottawa, Ottawa Hosp Eye Inst, Dept Ophthalmol, 501 Smyth Rd,Tower 3, Ottawa, ON K1H 8L6, Canada.
EM whodge@ottawahospital.on.ca
RI Sampson, Margaret/A-9128-2011
OI Sampson, Margaret/0000-0003-2550-9893; Zhang, Li/0000-0001-9056-7868
FU PHS HHS [290-02-0021] Funding Source: Medline
CR BROWN MF, 1994, CHEM PHYS LIPIDS, V73, P159, DOI 10.1016/0009-3084(94)90180-5
   Deeks J J, 2003, Health Technol Assess, V7, piii
   DETURCO EBR, 1991, J NEUROSCI, V11, P3667
   Downs SH, 1998, J EPIDEMIOL COMMUN H, V52, P377, DOI 10.1136/jech.52.6.377
   Evans JR, 2004, OPHTHALMOLOGY, V111, P513, DOI 10.1016/j.ophtha.2003.07.012
   GIBSON NJ, 1993, BIOCHEMISTRY-US, V32, P2438, DOI 10.1021/bi00060a040
   Innis SM, 2003, J PEDIATR-US, V143, pS1, DOI 10.1067/S0022-3476(03)00396-2
   Jadad AR, 1998, RANDOMISED CONTROLLE
   Litman BJ, 2001, J MOL NEUROSCI, V16, P237, DOI 10.1385/JMN:16:2-3:237
   McAuley L, 2000, LANCET, V356, P1228, DOI 10.1016/S0140-6736(00)02786-0
   Moher D, 2003, Health Technol Assess, V7, P1
   NEURINGER M, 1986, P NATL ACAD SCI USA, V83, P4021, DOI 10.1073/pnas.83.11.4021
   NEURINGER M, 1984, J CLIN INVEST, V73, P272, DOI 10.1172/JCI111202
   Ouchi M, 2002, OPHTHALMOLOGICA, V216, P363, DOI 10.1159/000066178
   SARMA U, 1994, EUR J CLIN NUTR, V48, P1
   Scorolli L, 2002, CAN J OPHTHALMOL, V37, P399, DOI 10.1016/S0008-4182(02)80042-4
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   TINOCO J, 1977, BIOCHIM BIOPHYS ACTA, V486, P575, DOI 10.1016/0005-2760(77)90111-4
   2000, 3 S SYST REV BAS JUL
NR 21
TC 24
Z9 26
U1 2
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD FEB
PY 2007
VL 27
IS 2
BP 216
EP 221
DI 10.1097/01.iae.0000233322.83713.2d
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 175BD
UT WOS:000246986100013
PM 17290205
DA 2022-11-30
ER

PT J
AU Tolman, J
   Hill, RD
   Kleinschmidt, JJ
   Gregg, CH
AF Tolman, J
   Hill, RD
   Kleinschmidt, JJ
   Gregg, CH
TI Psychosocial adaptation to visual impairment and its relationship to
   depressive affect in older adults with age-related macular degeneration
SO GERONTOLOGIST
LA English
DT Article
DE vision loss; depression; eye disease; legally blind
ID RAMAN MEASUREMENT; VISION LOSS
AB Purpose: In this study we examined psychosocial adaptation to vision loss and its relationship to depressive symptomatology in legally blind older adults with age-related macular degeneration (ARMD). Design and Methods: The 144 study participants were outpatients of a large regional vision clinic that specializes in the diagnosis and treatment of ARMD in older adults. They were administered a battery of cognitive and psychological screening instruments including the Adaptation to Vision Loss Scale, the Short Portable Mental Status Questionnaire, and the short form of the Geriatric Depression Scale. Results: A principal components analysis of the Adaptation to Vision Loss Scale identified three distinct adaptation factors, namely, acceptance of vision loss, negative impact on relationships, and attitudes toward compensation. Of these, acceptance of vision loss and attitudes toward compensation were positively associated with depressive affect. In addition, self-reported use of outpatient rehabilitative services was less frequent in those reporting greater depressive symptomatology. Implications: These findings support the contention that depressive symptomatology as measured by self-report in older adults with ARMD is mediated by one's perceived sense of individual control as it relates to intrapersonal factors underlying adaptation to profound vision loss in old age caused. by ARMD.
C1 Univ Utah, Dept Educ Psychol, Salt Lake City, UT 84112 USA.
   Univ Utah, Dept Ophthalmol, Salt Lake City, UT 84112 USA.
C3 Utah System of Higher Education; University of Utah; Utah System of
   Higher Education; University of Utah
RP Tolman, J (通讯作者)，Univ Utah, Dept Educ Psychol, 1705 Campus Ctr Dr,Room 327, Salt Lake City, UT 84112 USA.
EM jennifer.tolman@hsc.utah.edu
CR *AM AC OPTH, 1994, OPHTH MED ASS IND ST
   [Anonymous], 1997, DIAGNOSIS TREATMENT
   Bernstein PS, 2002, OPHTHALMOLOGY, V109, P1780, DOI 10.1016/S0161-6420(02)01173-9
   Burmedi D., 2002, VISUAL IMPAIRMENT RE, V4, P47
   CHERRY KE, 1991, J GERONTOL SOC WORK, V17, P99, DOI 10.1300/J083v17n03_09
   Conrod BE, 1998, J VISUAL IMPAIR BLIN, V92, P464, DOI 10.1177/0145482X9809200707
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Gellermann W, 2002, J OPT SOC AM A, V19, P1172, DOI 10.1364/JOSAA.19.001172
   Haddad WM, 2002, BRIT J OPHTHALMOL, V86, P663, DOI 10.1136/bjo.86.6.663
   Horowitz A, 1998, J VISUAL IMPAIR BLIN, V92, P30, DOI 10.1177/0145482X9809200106
   Horowitz A, 2000, J VISUAL IMPAIR BLIN, V94, P328, DOI 10.1177/0145482X0009400509
   HOROWITZ A, 1995, AGING VISION NEWS, V7, P1
   Jose R. T, 1983, UNDERSTANDING LOW VI
   Kirtley D. D., 1975, PSYCHOL BLINDNESS
   KLEINSCHMIDT JJ, 1995, J HLTH ED, V26, P26, DOI DOI 10.1080/10556699.1995.10603073
   KLEINSCHMIDT JJ, 1995, IMPACT VISION LOSS E
   la Cour M, 2002, DRUG AGING, V19, P101, DOI 10.2165/00002512-200219020-00003
   LEINHAAS MAM, 1994, GERIATRICS, V49, P53
   Mares-Perlman JA, 2002, J NUTR, V132, p518S, DOI 10.1093/jn/132.3.518S
   MORELLO RF, 1989, AGING EYE, V8, P83
   *NAT EYE ADV COUNC, 1998, UNPUB RAW DAT
   Orr A. L., 1998, ISSUES AGING VISION
   PFEIFFER E, 1975, J AM GERIATR SOC, V23, P433, DOI 10.1111/j.1532-5415.1975.tb00927.x
   *PREV BLINDN AM, 1994, VIS PROBL US
   Robbins J, 1988, Dysphagia, V3, P11, DOI 10.1007/BF02406275
   Rovner BW, 2002, AM J GERIAT PSYCHIAT, V10, P305
   Rovner BW, 2001, J AM GERIATR SOC, V49, P1097, DOI 10.1046/j.1532-5415.2001.49215.x
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Seddon Johanna M., 2004, International Ophthalmology Clinics, V44, P17, DOI 10.1097/00004397-200404440-00004
   Sheikh JL, 1986, CLIN GERONTOLOGY GUI, P163
   Sickenberg M, 2001, OPHTHALMOLOGICA, V215, P247, DOI 10.1159/000050869
   TANI PM, 1980, AM J OPHTHALMOL, V90, P525, DOI 10.1016/S0002-9394(14)75023-8
   Wahl HW, 2004, PSYCHOL AGING, V19, P235, DOI 10.1037/0882-7974.19.1.235
   Woodburn KW, 2002, RETINA-J RET VIT DIS, V22, P391, DOI 10.1097/00006982-200208000-00001
NR 34
TC 67
Z9 68
U1 1
U2 12
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0016-9013
EI 1758-5341
J9 GERONTOLOGIST
JI Gerontologist
PD DEC
PY 2005
VL 45
IS 6
BP 747
EP 753
DI 10.1093/geront/45.6.747
PG 7
WC Gerontology
WE Social Science Citation Index (SSCI)
SC Geriatrics & Gerontology
GA 989UN
UT WOS:000233699500004
PM 16326656
OA Bronze
DA 2022-11-30
ER

PT J
AU Mones, J
   Rubin, GS
AF Mones, J
   Rubin, GS
TI Contrast sensitivity as an outcome measure in patients with subfoveal
   choroidal neovascularisation due to age-related macular degeneration
SO EYE
LA English
DT Review
DE age-related macular degeneration; choroidal neovascularisation; contrast
   sensitivity; laser photocoagulation; subfoveal; verteporfin
ID RANDOMIZED CLINICAL-TRIAL; BLUE MOUNTAINS EYE; BEAVER DAM EYE; VISUAL
   FUNCTION; PHOTODYNAMIC THERAPY; LASER PHOTOCOAGULATION; SUBMACULAR
   SURGERY; OLDER-ADULTS; VERTEPORFIN THERAPY; MOBILITY PERFORMANCE
AB Purpose Although visual acuity is the most frequently used primary outcome measure in clinical trials of treatments for choroidal neovascularisation (CNV) due to age-related macular degeneration (AMD), contrast sensitivity may provide valuable additional information. This paper reviews the evidence for using contrast sensitivity as a measure of visual function and as an outcome measure in clinical trials in patients with subfoveal CNV due to AMD.
   Methods Medline database searches were performed to retrieve relevant articles on contrast sensitivity. In addition, articles were included from the authors' knowledge of the literature and from the reference lists of retrieved articles.
   Results The published literature demonstrates that contrast sensitivity is an important measure of visual function in patients with subfoveal CNV due to AMD. Most clinical trials of treatments for CNV due to AMD have reported visual acuity as the primary outcome. However, there is evidence that treatment (such as verteporfin therapy) may also provide additional benefits in terms of contrast sensitivity. These benefits may not be completely characterised by measurement of visual acuity alone.
   Conclusions The inclusion of contrast sensitivity as an outcome measure in studies of patients with CNV due to AMD may provide a more complete understanding of the effects of treatment on visual function and the likely benefits for patients.
C1 Inst Microcirugia Ocular Barcelona, Barcelona 08022, Spain.
   UCL, Inst Ophthalmol, London, England.
C3 University of London; University College London
RP Mones, J (通讯作者)，Inst Microcirugia Ocular Barcelona, Calle Munner 10, Barcelona 08022, Spain.
EM jordi_mones@comb.es
RI mones, jordi/CAJ-2963-2022
OI mones, jordi/0000-0003-3685-2160
CR ALEXANDER MF, 1988, ARCH OPHTHALMOL-CHIC, V106, P1543, DOI 10.1001/archopht.1988.01060140711040
   *AM AC OPHTH, 2001, PREF PRACT PATT AG R
   ARDEN GB, 1978, BRIT J OPHTHALMOL, V62, P198, DOI 10.1136/bjo.62.4.198
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Bellmann C, 2003, GRAEF ARCH CLIN EXP, V241, P968, DOI 10.1007/s00417-003-0689-6
   Bergink GJ, 1998, GRAEF ARCH CLIN EXP, V236, P321, DOI 10.1007/s004170050085
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Bressler NM, 2001, OPHTHALMOLOGY, V108, P435, DOI 10.1016/S0161-6420(00)00666-7
   Bressler NM, 1997, ARCH OPHTHALMOL-CHIC, V115, P1071, DOI 10.1001/archopht.1997.01100160241017
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown G C, 1999, Trans Am Ophthalmol Soc, V97, P473
   Brown GC, 2000, ARCH OPHTHALMOL-CHIC, V118, P47
   Brown GC, 2000, CAN J OPHTHALMOL, V35, P127, DOI 10.1016/S0008-4182(00)80005-8
   Carta A, 1998, CURR EYE RES, V17, P506, DOI 10.1076/ceyr.17.5.506.5191
   CHAKRAVARTHY U, 1993, BRIT J OPHTHALMOL, V77, P265, DOI 10.1136/bjo.77.5.265
   CUMMINGS SR, 1995, NEW ENGL J MED, V332, P767, DOI 10.1056/NEJM199503233321202
   DargentMolina P, 1996, LANCET, V348, P145, DOI 10.1016/S0140-6736(96)01440-7
   Doris N, 2001, BRIT J OPHTHALMOL, V85, P184, DOI 10.1136/bjo.85.2.184
   ELLIOTT DB, 1991, CLIN VISION SCI, V6, P471
   ELLIOTT DB, 1990, EYE, V4, P712, DOI 10.1038/eye.1990.100
   Foran S, 2003, OPHTHALMIC EPIDEMIOL, V10, P215, DOI 10.1076/opep.10.4.215.15906
   GREEVES AL, 1988, OPHTHAL PHYSL OPT, V8, P371, DOI 10.1111/j.1475-1313.1988.tb01171.x
   Haegerstrom-Portnoy G, 2000, OPTOMETRY VISION SCI, V77, P653, DOI 10.1097/00006324-200012000-00012
   Hart PM, 1998, EYE, V12, P124, DOI 10.1038/eye.1998.20
   Hart PM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1029
   Hassan SE, 2002, OPTOMETRY VISION SCI, V79, P697, DOI 10.1097/00006324-200211000-00007
   HAWKINS BS, 1991, ARCH OPHTHALMOL-CHIC, V109, P1109
   Hooper CY, 2003, CLIN EXP OPHTHALMOL, V31, P376, DOI 10.1046/j.1442-9071.2003.00683.x
   Hyman L, 1992, AGE RELATED MACULAR, P1
   HYVARINEN L, 1983, ACTA OPHTHALMOL, V61, P161
   Ivers RQ, 2000, CLIN EXP OPHTHALMOL, V28, P41, DOI 10.1046/j.1442-9071.2000.00236.x
   Ivers RQ, 1998, J AM GERIATR SOC, V46, P58
   Jaakkola A, 1999, ACTA OPHTHALMOL SCAN, V77, P57, DOI 10.1034/j.1600-0420.1999.770113.x
   Jin C J, 1992, Yan Ke Xue Bao, V8, P45
   Klein BEK, 2003, OPHTHALMOLOGY, V110, P644, DOI 10.1016/S0161-6420(02)01935-8
   Klein BEK, 1998, OPHTHALMOLOGY, V105, P160, DOI 10.1016/S0161-6420(98)91911-X
   Kuyk T, 1999, J REHABIL RES DEV, V36, P303
   LEAT SJ, 1993, OPHTHAL PHYSL OPT, V13, P9, DOI 10.1111/j.1475-1313.1993.tb00420.x
   LEGGE GE, 1992, INVEST OPHTH VIS SCI, V33, P677
   Lewis H, 1998, AM J OPHTHALMOL, V126, P127
   Lott LA, 2001, OPTOMETRY VISION SCI, V78, P316, DOI 10.1097/00006324-200105000-00015
   Marcus DM, 2004, BRIT J OPHTHALMOL, V88, P114, DOI 10.1136/bjo.88.1.114
   Marcus DM, 2001, ARCH OPHTHALMOL-CHIC, V119, P171
   MARRON JA, 1982, AM J OPTOM PHYS OPT, V59, P413
   McGwin G, 2000, ACCIDENT ANAL PREV, V32, P735, DOI 10.1016/S0001-4575(99)00123-2
   OLSEN TW, 1997, SEM OPHTHALMOL, V12, P34
   OWSLEY C, 1987, BRIT J OPHTHALMOL, V71, P791, DOI 10.1136/bjo.71.10.791
   Owsley C, 2001, OPTOMETRY VISION SCI, V78, P350, DOI 10.1097/00006324-200105000-00019
   OWSLEY C, 1981, INVEST OPHTH VIS SCI, V21, P362
   PELLI DG, 1988, CLIN VISION SCI, V2, P187
   Roth DB, 1997, OPHTHALMIC SURG LAS, V28, P920
   RUBIN GS, 1988, CLIN VISION SCI, V2, P169
   Rubin GS, 2002, RETINA-J RET VIT DIS, V22, P536, DOI 10.1097/00006982-200210000-00002
   Rubin GS, 2001, INVEST OPHTH VIS SCI, V42, P64
   Rubin GS, 1997, INVEST OPHTH VIS SCI, V38, P557
   RUBIN GS, 1994, OPTOMETRY VISION SCI, V71, P750, DOI 10.1097/00006324-199412000-00005
   SCHACHAT AP, 1994, ARCH OPHTHALMOL-CHIC, V112, P500
   Scott IU, 2002, AM J OPHTHALMOL, V133, P350, DOI 10.1016/S0002-9394(01)01406-4
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1232
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1220
   Tejeria L, 2002, BRIT J OPHTHALMOL, V86, P1019, DOI 10.1136/bjo.86.9.1019
   *VERT ROUNDT 2000, 2002, RETINA, V22, P6
   Wood JM, 2002, HUM FACTORS, V44, P482, DOI 10.1518/0018720024497664
NR 66
TC 51
Z9 52
U1 0
U2 10
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
J9 EYE
JI Eye
PD NOV
PY 2005
VL 19
IS 11
BP 1142
EP 1150
DI 10.1038/sj.eye.6701717
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 982EZ
UT WOS:000233142000002
PM 15467700
OA Bronze
DA 2022-11-30
ER

PT J
AU Peavey, J
   Parmar, VM
   Malek, G
AF Peavey, Jeremy
   Parmar, Vipul M.
   Malek, Goldis
TI Nuclear Receptor Atlases of Choroidal Tissues Reveal Candidate Receptors
   Associated with Age-Related Macular Degeneration
SO CELLS
LA English
DT Article
DE choroidal endothelial cells; nuclear receptor atlas; choroidal injury;
   age-related macular degeneration
ID RETINAL-PIGMENT EPITHELIUM; MINERALOCORTICOID RECEPTOR;
   ESTROGEN-RECEPTORS; ALPHA AGONIST; NEOVASCULARIZATION; GAMMA;
   PREVALENCE; METABOLISM; EXPRESSION; REGULATOR
AB The choroid is a vulnerable tissue site in the eye, impacted in several blinding diseases including age related macular degeneration (AMD), which is the leading cause of central vision loss in the aging population. Choroidal thinning and choriocapillary dropout are features of the early form of AMD, and endothelial dysfunction and vascular changes are primary characteristics of the neovascular clinical sub-type of AMD. Given the importance, the choroidal endothelium and outer vasculature play in supporting visual function, a better understanding of baseline choroidal signaling pathways engaged in tissue and cellular homeostasis is needed. Nuclear receptors are a large family of transcription factors responsible for maintaining various cellular processes during development, aging and disease. Herein we developed a comprehensive nuclear receptor atlas of human choroidal endothelial cells and freshly isolated choroidal tissue by examining the expression levels of all members of this transcription family using quantitative real time PCR. Given the close relationship between the choroid and retinal pigment epithelium (RPE), this data was cross-referenced with the expression profile of nuclear receptors in human RPE cells, to discover potential overlap versus cell-specific nuclear receptor expression. Finally, to identify candidate receptors that may participate in the pathobiology of AMD, we cataloged nuclear receptor expression in a murine model of wet AMD, from which we discovered a subset of nuclear receptors differentially regulated following neovascularization. Overall, these databases serve as useful resources establishing the influence of nuclear receptor signaling pathways on the outer vascular tissue of the eye, while providing a list of receptors, for more focused investigations in the future, to determine their suitability as potential therapeutic targets for diseases, in which the choroid is affected.
C1 [Peavey, Jeremy; Parmar, Vipul M.; Malek, Goldis] Duke Univ, Sch Med, Duke Eye Ctr, Dept Ophthalmol, Durham, NC 27710 USA.
   [Malek, Goldis] Duke Univ, Sch Med, Dept Pathol, Durham, NC 27710 USA.
C3 Duke University; Duke University
RP Malek, G (通讯作者)，Duke Univ, Sch Med, Duke Eye Ctr, Dept Ophthalmol, Durham, NC 27710 USA.; Malek, G (通讯作者)，Duke Univ, Sch Med, Dept Pathol, Durham, NC 27710 USA.
EM jeremypeavey@gmail.com; vipulkumar.parmar@duke.edu; gmalek@duke.edu
OI Malek, Goldis/0000-0003-0026-2388
FU National Eye Institute [P30 EY005722, R01 EY027802, R01 EY028160, R01
   EY032751]; Unrestricted Research to Prevent Blindness, Inc. (RPB),
   Chicago, IL, USA, Core grant
FX National Eye Institute grant R01 EY027802; National Eye Institute grant
   R01 EY028160; National Eye Institute grant R01 EY032751; National Eye
   Institute grant P30 EY005722; Unrestricted Research to Prevent
   Blindness, Inc. (RPB), Chicago, IL, USA, Core grant.
CR Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Aranda A, 2001, PHYSIOL REV, V81, P1269, DOI 10.1152/physrev.2001.81.3.1269
   Arimura S, 2016, EXP EYE RES, V149, P1, DOI 10.1016/j.exer.2016.06.004
   Audet-Walsh E, 2015, ACTA PHARMACOL SIN, V36, P51, DOI 10.1038/aps.2014.121
   Biesemeier A, 2014, NEUROBIOL AGING, V35, P2562, DOI 10.1016/j.neurobiolaging.2014.05.003
   Bolego C, 2010, FASEB J, V24, P2262, DOI 10.1096/fj.09-139220
   Campbell M, 2013, ADV EXP MED BIOL, V763, P70
   Cat AND, 2010, FASEB J, V24, P2454, DOI 10.1096/fj.09-147926
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Cheloni R, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-022188
   Chirco KR, 2017, EYE, V31, P10, DOI 10.1038/eye.2016.216
   Choudhary M, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21186777
   Choudhary M, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.131928
   Choudhary M, 2018, BBA-MOL BASIS DIS, V1864, P1583, DOI 10.1016/j.bbadis.2018.02.015
   Choudhary M, 2016, AGING-US, V8, P1952, DOI 10.18632/aging.101031
   Choudhary M, 2015, J PATHOL, V235, P101, DOI 10.1002/path.4433
   Cousins SW, 2003, INVEST OPHTH VIS SCI, V44, P1221, DOI 10.1167/iovs.02-0285
   Cruz NM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087942
   Das UN, 2016, ARCH MED SCI, V12, P1142, DOI 10.5114/aoms.2016.61918
   Dawson MI, 2012, BBA-MOL CELL BIOL L, V1821, P21, DOI 10.1016/j.bbalip.2011.09.014
   DuSell CD, 2010, ENDOCRINOLOGY, V151, P3675, DOI 10.1210/en.2010-0080
   Dwyer MA, 2011, MOL ENDOCRINOL, V25, P360, DOI 10.1210/me.2010-0392
   Espinosa-Heidmann DG, 2002, INVEST OPHTH VIS SCI, V43, P1567
   Farazdaghi MK, 2019, J OPHTHAL VIS RES, V14, P78, DOI 10.4103/jovr.jovr_125_18
   Festuccia N, 2021, DEVELOPMENT, V148, DOI 10.1242/dev.199604
   Fisher CR, 2018, INVEST OPHTH VIS SCI, V59, pAMD41, DOI 10.1167/iovs.18-24289
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Furrer R, 2017, SCI REP-UK, V7, DOI 10.1038/srep40789
   Gao HW, 2020, J BIOL CHEM, V295, P10726, DOI 10.1074/jbc.RA119.012404
   Layana AG, 2017, NUTRIENTS, V9, DOI 10.3390/nu9101120
   Gillespie M, 2022, NUCLEIC ACIDS RES, V50, pD687, DOI 10.1093/nar/gkab1028
   HARAN EF, 1994, CANCER RES, V54, P5511
   HARDING HP, 1993, MOL CELL BIOL, V13, P3113, DOI 10.1128/MCB.13.5.3113
   Harris HA, 2002, ENDOCRINOLOGY, V143, P4172, DOI 10.1210/en.2002-220403
   Herzlich Alexandra A, 2009, Open Biol J, V2, P141
   Hogan MJ., 1971, HISTOLOGY HUMAN EYE
   Hu P, 2013, P NATL ACAD SCI USA, V110, pE4069, DOI 10.1073/pnas.1307574110
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Huppunen J, 2004, BIOCHEM BIOPH RES CO, V314, P964, DOI 10.1016/j.bbrc.2003.12.194
   Ikeda R, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-46656-0
   Jamali N, 2018, AM J PHYSIOL-HEART C, V314, pH753, DOI 10.1152/ajpheart.00319.2017
   Jamali N, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0190131
   Johns A, 1996, ENDOCRINOLOGY, V137, P4511, DOI 10.1210/en.137.10.4511
   Jun SJ, 2019, EXP EYE RES, V181, P346, DOI 10.1016/j.exer.2018.09.023
   Khanal T, 2019, FASEB J, V33, P8335, DOI 10.1096/fj.201801881RR
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Lambert V, 2003, FASEB J, V17, P2290, DOI 10.1096/fj.03-0113fje
   Landreth G, 2007, CURR ALZHEIMER RES, V4, P159, DOI 10.2174/156720507780362092
   le Maire A, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8111392
   Li C, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/9702820
   Li SJ, 2021, GENE THER, V28, P223, DOI 10.1038/s41434-020-0134-z
   Li TY, 2017, BMC MOL BIOL, V18, DOI 10.1186/s12867-017-0086-z
   Lutty GA, 2020, EXP EYE RES, V192, DOI 10.1016/j.exer.2020.107939
   Malek G, 2003, AM J PATHOL, V162, P413, DOI 10.1016/S0002-9440(10)63836-9
   Marcantoni E, 2012, PROSTAG OTH LIPID M, V98, P122, DOI 10.1016/j.prostaglandins.2012.01.006
   Marin-Castano ME, 2006, INVEST OPHTH VIS SCI, V47, P4098, DOI 10.1167/iovs.05-1230
   Marin-Castano ME, 2003, INVEST OPHTH VIS SCI, V44, P50, DOI 10.1167/iovs.01-1276
   McCurley A, 2012, MOL CELL ENDOCRINOL, V350, P256, DOI 10.1016/j.mce.2011.06.014
   McDonnell DP, 1997, OSTEOPOROSIS INT, V7, P29, DOI 10.1007/BF01674810
   MINNEMAN KP, 1977, MOL PHARMACOL, V13, P735
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Mollema NJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017494
   Nickla DL, 2010, PROG RETIN EYE RES, V29, P144, DOI 10.1016/j.preteyeres.2009.12.002
   Nita M, 2014, MED SCI MONITOR, V20, P1003, DOI 10.12659/MSM.889887
   Overington JP, 2006, NAT REV DRUG DISCOV, V5, P993, DOI 10.1038/nrd2199
   Pare G, 2002, CIRC RES, V90, P1087, DOI 10.1161/01.RES.0000021114.92282.FA
   Park YY, 2012, EMBO MOL MED, V4, P52, DOI 10.1002/emmm.201100187
   Percharde M, 2012, GENE DEV, V26, P2286, DOI 10.1101/gad.195545.112
   Serena AP, 2022, INT J RETINA VITR, V8, DOI 10.1186/s40942-022-00368-2
   Peters JM, 2012, NAT REV CANCER, V12, P181, DOI 10.1038/nrc3214
   PUISTOLA U, 1995, FERTIL STERIL, V64, P81, DOI 10.1016/S0015-0282(16)57659-6
   Qiu FF, 2017, INVEST OPHTH VIS SCI, V58, P5065, DOI 10.1167/iovs.17-22091
   Razzaque MA, 2004, GENE, V340, P275, DOI 10.1016/j.gene.2004.07.010
   Safi SZ, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/801269
   Sanchez AM, 2011, MOL HUM REPROD, V17, P219, DOI 10.1093/molehr/gaq097
   Santos R, 2017, NAT REV DRUG DISCOV, V16, P19, DOI 10.1038/nrd.2016.230
   Seddon JM, 2016, JAMA OPHTHALMOL, V134, P1272, DOI 10.1001/jamaophthalmol.2016.3519
   Sherman BT, 2022, NUCLEIC ACIDS RES, V50, pW216, DOI 10.1093/nar/gkac194
   Son YO, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01868-8
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Streilein JW, 2002, VISION RES, V42, P487, DOI 10.1016/S0042-6989(01)00185-7
   Sulaiman RS, 2018, STEROIDS, V133, P60, DOI 10.1016/j.steroids.2017.11.002
   Tan W, 2020, INT J BIOL SCI, V16, P2989, DOI 10.7150/ijbs.49890
   Voigt AP, 2019, P NATL ACAD SCI USA, V116, P24100, DOI 10.1073/pnas.1914143116
   Wang B, 2018, NAT REV ENDOCRINOL, V14, P452, DOI 10.1038/s41574-018-0037-x
   Wang H, 2019, BMC OPHTHALMOL, V19, DOI 10.1186/s12886-019-1189-8
   Wang XL, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10124-4
   Whitmore SS, 2015, PROG RETIN EYE RES, V45, P1, DOI 10.1016/j.preteyeres.2014.11.005
   WILSON TE, 1992, SCIENCE, V256, P107, DOI 10.1126/science.1314418
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xu J, 2012, ANGIOGENESIS, V15, P213, DOI 10.1007/s10456-012-9254-4
   Yao PL, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21082889
   Zechel C, 2005, MOL REPROD DEV, V72, P550, DOI 10.1002/mrd.20377
   Zhao J, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-22745-4
   Zhao LJ, 2019, ENDOCR REV, V40, P1207, DOI 10.1210/er.2018-00222
   Zhao M, 2012, J CLIN INVEST, V122, P2672, DOI 10.1172/JCI61427
   Zhu ZL, 2020, J INVEST DERMATOL, V140, P1233, DOI 10.1016/j.jid.2019.11.022
NR 97
TC 1
Z9 1
U1 4
U2 4
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2073-4409
J9 CELLS-BASEL
JI Cells
PD AUG
PY 2022
VL 11
IS 15
AR 2386
DI 10.3390/cells11152386
PG 24
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 3T4ON
UT WOS:000840255700001
PM 35954227
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Tan, R
   Guymer, RH
   Luu, CD
AF Tan, Rose
   Guymer, Robyn H.
   Luu, Chi D.
TI Subretinal Drusenoid Deposits and the Loss of Rod Function in
   Intermediate Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE reticular pseudodrusen; age-related macular degeneration; rod function
ID MEDIATED DARK-ADAPTATION; RETICULAR PSEUDODRUSEN; CHOROIDAL THICKNESS;
   ATROPHY; PREVALENCE; PROGRESSION; AUTOPHAGY; EYES
AB PURPOSE. To compare static rod function obtained with and without photobleach in control and intermediate age-related macular degeneration (iAMD) participants with and without subretinal drusenoid deposits (SDD).
   METHODS. In this cross-sectional study, retinal sensitivities within the central 248 retina were obtained twice using a dark-adapted chromatic perimeter, both with 505- and 625-nm stimuli. Tests were performed after 30 minutes of dark-adaptation either with or without a preceding photobleach. Multimodal imaging was performed to grade AMD and SDD status, and other retinal changes considered being risk factors for progression to late AMD. The sensitivity difference between both stimuli was used to assess rod function. The average point wise sensitivity difference (PWSD) was compared among the study groups.
   RESULTS. Twenty-nine control subjects and 20 iAMD without SDD and 17 iAMD with SDD cases were recruited. The average PWSD of the SDD group was significantly reduced (more with photobleach) compared with that of the control (P < 0.001) and no-SDD groups (P < 0.001), but only within the central 88. The average PWSD of the non-SDD group was also reduced compared with the control group but only for measurements with photobleach (P = 0.020). There was no difference in average PWSD between the presence and absence of hyperreflective foci and/or nascent geographic atrophy in iAMD eyes without SDD (P = 0.60) or with SDD (P = 0.12).
   CONCLUSIONS. iAMD eyes with SDD are associated with worse static rod function compared with eyes without SDD. The greatest abnormality in rods is observed within the central 88 and when tested with a preceding photobleach.
C1 [Tan, Rose; Guymer, Robyn H.; Luu, Chi D.] Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, East Melbourne, Vic, Australia.
   [Tan, Rose; Guymer, Robyn H.; Luu, Chi D.] Univ Melbourne, Dept Surg Ophthalmol, East Melbourne, Vic, Australia.
   [Tan, Rose] Trisakti Univ, Dept Ophthalmol, Jakarta, Indonesia.
C3 Centre for Eye Research Australia; Royal Victorian Eye & Ear Hospital;
   University of Melbourne; Universitas Trisakti
RP Luu, CD (通讯作者)，Ctr Eye Res Australia, Level 8,Smorgon Family Wing,32 Gisborne St, East Melbourne, Vic 3002, Australia.
EM cluu@unimelb.edu.au
OI Rose, Rose/0000-0002-7351-2774
FU Ryan Initiative for Macular Research; Macular Disease Foundation
   Australia; Australia Awards Scholarship; National Health and Medical
   Research Council (NHMRC) Fellowship [1103013]
FX Supported by grants from Ryan Initiative for Macular Research, Macular
   Disease Foundation Australia, Australia Awards Scholarship (RT;
   Canberra, Australian Capital Territory, Australia), National Health and
   Medical Research Council (NHMRC) Fellowship (#1103013, RHG; Canberra,
   Australian Capital Territory, Australia). The Centre for Eye Research
   Australia (CERA; East Melbourne, Victoria, Australia) receives
   Operational Infrastructure Support from the Victorian Government.
CR Ahlers C, 2010, INVEST OPHTH VIS SCI, V51, P2149, DOI 10.1167/iovs.09-3817
   Christenbury JG, 2013, OPHTHALMOLOGY, V120, P1038, DOI 10.1016/j.ophtha.2012.10.018
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   Dimitrov PN, 2008, INVEST OPHTH VIS SCI, V49, P55, DOI 10.1167/iovs.06-1048
   Dimitrov PN, 2011, INVEST OPHTH VIS SCI, V52, P9457, DOI 10.1167/iovs.10-7043
   Ferguson TA, 2014, AUTOPHAGY, V10, P165, DOI 10.4161/auto.26735
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Finger RP, 2014, OPHTHALMOLOGY, V121, P1252, DOI 10.1016/j.ophtha.2013.12.034
   Flamendorf J, 2015, OPHTHALMOLOGY, V122, P2053, DOI 10.1016/j.ophtha.2015.06.023
   Flynn OJ, 2018, INVEST OPHTH VIS SCI, V59, P2411, DOI 10.1167/iovs.17-22874
   Folgar FA, 2012, INVEST OPHTH VIS SCI, V53, P4626, DOI 10.1167/iovs.12-9813
   Fraser RG, 2016, INVEST OPHTH VIS SCI, V57, P5436, DOI 10.1167/iovs.16-19295
   Garg A, 2013, INVEST OPHTH VIS SCI, V54, P7075, DOI 10.1167/iovs.13-12474
   Goerdt L, 2017, INVEST OPHTH VIS SCI, V58
   Haas P, 2014, INVEST OPHTH VIS SCI, V55, P2674, DOI 10.1167/iovs.13-13338
   Ho CYD, 2018, CLIN EXP OPHTHALMOL, V46, P485, DOI 10.1111/ceo.13131
   Jackson GR, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.13-13745
   Kim JY, 2013, CELL, V154, P365, DOI 10.1016/j.cell.2013.06.012
   Lains I, 2017, OPHTHALMOLOGY, V124, P1340, DOI 10.1016/j.ophtha.2017.03.061
   Marsiglia M, 2013, INVEST OPHTH VIS SCI, V54, P7362, DOI 10.1167/iovs.12-11073
   Owsley C, 2001, OPHTHALMOLOGY, V108, P1196, DOI 10.1016/S0161-6420(01)00580-2
   Owsley C, 2007, OPHTHALMOLOGY, V114, P1728, DOI 10.1016/j.ophtha.2006.12.023
   Querques G, 2011, RETINA-J RET VIT DIS, V31, P518, DOI 10.1097/IAE.0b013e3181f04974
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P1258, DOI 10.1167/iovs.11-8907
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Steinberg JS, 2017, TRANSL VIS SCI TECHN, V6, DOI 10.1167/tvst.6.4.7
   Steinberg JS, 2015, JAMA OPHTHALMOL, V133, P690, DOI 10.1001/jamaophthalmol.2015.0477
   Tan RS, 2018, TRANSL VIS SCI TECHN, V7, DOI 10.1167/tvst.7.3.3
   Thylefors B, 2002, OPHTHALMIC EPIDEMIOL, V9, P83, DOI 10.1076/opep.9.2.83.1523
   Wu ZC, 2016, INVEST OPHTH VIS SCI, V57, P1310, DOI 10.1167/iovs.15-18682
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P2415, DOI 10.1016/j.ophtha.2014.06.034
   Zhang YH, 2014, AM J OPHTHALMOL, V158, P584, DOI 10.1016/j.ajo.2014.05.038
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 34
TC 18
Z9 18
U1 0
U2 2
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD AUG
PY 2018
VL 59
IS 10
BP 4154
EP 4161
DI 10.1167/iovs.18-23970
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GR7EB
UT WOS:000442849800004
PM 30105370
DA 2022-11-30
ER

PT J
AU Geitzenauer, W
   Michels, S
   Prager, F
   Rosenfeld, PJ
   Kornek, G
   Vormittag, L
   Schmidt-Erfurth, U
AF Geitzenauer, Wolfgang
   Michels, Stephan
   Prager, Franz
   Rosenfeld, Philip J.
   Kornek, Gabriela
   Vormittag, Laurenz
   Schmidt-Erfurth, Ursula
TI COMPARISON OF 2.5 mg/kg AND 5 mg/kg SYSTEMIC BEVACIZUMAB IN NEOVASCULAR
   AGE-RELATED MACULAR DEGENERATION Twenty-Four Week Results of an
   Uncontrolled, Prospective Cohort Study
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; anti-VEGF therapy; bevacizumab
ID COHERENCE TOMOGRAPHY FINDINGS; INTRAVITREAL BEVACIZUMAB; CHOROIDAL
   NEOVASCULARIZATION; AVASTIN; INJECTION; RANIBIZUMAB; ANTIBODY; THERAPY
AB Background: To compare safety, visual acuity (VA), and anatomic outcomes of 2.5 mg/kg and 5 mg/kg intravenous bevacizumab in patients with neovascular age-related macular degeneration.
   Methods: In an institutional cohort study, 16 patients (2 cohorts, 27 eyes) with neovascular age-related macular degeneration were treated with 5 mg/kg intravenous bevacizumab and 2.5 mg/kg, respectively. All patients received 3 initial intravenous infusions at 2-week intervals. The main outcome measures were VA, optical coherence tomography, and fluorescein angiography.
   Results: No serious systemic or ocular adverse events were identified. By Day 7, mean VA increased from 56 letters (20/80(+1)) at baseline to 60 letters (20/63) in the 5 mg/kg group and mean central retinal thickness decreased by 83 mu m. In the 2.5 mg/kg group, mean VA increased from 55 letters (20/80) to 66 letters (20/50(+1)) and mean central retinal thickness decreased by 93 mu m. By Month 3, VA improved by 10 letters compared to baseline in the 5 mg/kg group and by 9 letters in the 2.5 mg/kg group. Central retinal thickness was reduced by 128 mu m in the 5 mg/kg group and by 127 mu m in the 2.5 mg/kg group. These benefits were sustained through 6 months. No statistically significant difference was found between both treatment groups regarding safety, VA, and anatomic outcomes.
   Conclusion: Similar VA, optical coherence tomography, and angiographic improvements were observed in both treatment groups up to 6 months. Further follow-up is required to evaluate the long-term durability and safety of both treatment regimens.
C1 [Michels, Stephan] Univ Zurich Hosp, Dept Ophthalmol, CH-8091 Zurich, Switzerland.
   [Geitzenauer, Wolfgang; Prager, Franz; Schmidt-Erfurth, Ursula] Med Univ Vienna, Dept Ophthalmol, Vienna, Austria.
   [Rosenfeld, Philip J.] Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, Dept Ophthalmol, Miami, FL 33136 USA.
   [Kornek, Gabriela; Vormittag, Laurenz] Med Univ Vienna, Dept Internal Med, Vienna, Austria.
C3 University of Zurich; University Zurich Hospital; Medical University of
   Vienna; Bascom Palmer Eye Institute; University of Miami; Medical
   University of Vienna
RP Michels, S (通讯作者)，Univ Zurich Hosp, Dept Ophthalmol, Frauenklin Str 24, CH-8091 Zurich, Switzerland.
EM stephan.michels@usz.ch
FU Medizinisch-Wissenschfatlicher Fonds des Burgermeisters der
   Bundeshaupstadt Wien; Jubilaumsfonds der Osterreichischen Nationalbank;
   German Research Council (DFG)
FX Supported by Medizinisch-Wissenschfatlicher Fonds des Burgermeisters der
   Bundeshaupstadt Wien, Jubilaumsfonds der Osterreichischen Nationalbank
   and German Research Council (DFG).
CR Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bashshur ZF, 2006, AM J OPHTHALMOL, V142, P1, DOI 10.1016/j.ajo.2006.02.037
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chen Y, 1999, J MOL BIOL, V293, P865, DOI 10.1006/jmbi.1999.3192
   Costa RA, 2006, INVEST OPHTH VIS SCI, V47, P4569, DOI 10.1167/iovs.06-0433
   Ferrara N, 2005, BIOCHEM BIOPH RES CO, V333, P328, DOI 10.1016/j.bbrc.2005.05.132
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Hurwitz Herbert, 2004, Clin Colorectal Cancer, V4 Suppl 2, pS62, DOI 10.3816/CCC.2004.s.010
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Moshfeghi AA, 2006, OPHTHALMOLOGY, V113, p[e1, 12]
   Ng YS, 2006, EXP CELL RES, V312, P527, DOI 10.1016/j.yexcr.2005.11.008
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P336, DOI 10.3928/1542-8877-20050701-15
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Shahar J, 2006, RETINA-J RET VIT DIS, V26, P262, DOI 10.1097/00006982-200603000-00002
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
NR 16
TC 10
Z9 10
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD NOV-DEC
PY 2008
VL 28
IS 10
BP 1375
EP 1386
DI 10.1097/IAE.0b013e3181863f96
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 373LH
UT WOS:000260972600001
PM 18784625
DA 2022-11-30
ER

PT J
AU Merry, GF
   Munk, MR
   Dotson, RS
   Walker, MG
   Devenyi, RG
AF Merry, Graham F.
   Munk, Marion R.
   Dotson, Robert S.
   Walker, Michael G.
   Devenyi, Robert G.
TI Photobiomodulation reduces drusen volume and improves visual acuity and
   contrast sensitivity in dry age-related macular degeneration
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration; contrast; drusen; photobiomodulation;
   sensitivity; visual acuity
ID OPTICAL COHERENCE TOMOGRAPHY; CYTOCHROME-C-OXIDASE; GEOGRAPHIC ATROPHY;
   THERAPEUTIC PHOTOBIOMODULATION; DIABETIC-RETINOPATHY; INCREASES ATP;
   IN-VITRO; MITOCHONDRIAL; LIGHT; PROGRESSION
AB PurposeTo evaluate the efficacy of photobiomodulation (PBM) treatment for patients with dry age-related macular degeneration (AMD).
   MethodsAssessments on 42 eyes with dry AMD (age related eye disease study (AREDS) 2-4) were conducted. Multiwavelength light emitting diode (LED) light comprising of yellow (590nm), red (670nm) and near-infrared (790nm) bandwidths was applied to subjects' eyes for a treatment course of 3weeks. Outcome measures were changes in best-corrected visual acuity (BCVA), contrast sensitivity (CS), drusen volume and central drusen thickness.
   ResultsSignificant improvement in mean BCVA of 5.90 letters (p<0.001) was seen on completion of the 3-week treatment and 5.14 letters (p<0.001) after 3months. Contrast sensitivity improved significantly (log unit improvement of 0.11 (p=0.02) at 3weeks and 3months (log unit improvement of 0.16 (p=0.02) at three cycles per degree. Drusen volume decreased by 0.024mm(3) (p<0.001) and central drusen thickness was significantly reduced by a mean of 3.78m (p<0.001), while overall central retinal thickness and retinal volume remained stable.
   ConclusionThis is the first study demonstrating improvements in functional and anatomical outcomes in dry AMD subjects with PBM therapy. These findings corroborate an earlier pilot study that looked at functional outcomemeasures. The addition of anatomical evidence contributes to thebasis for further development of a non-invasive PBM treatment for dry AMD.
C1 [Merry, Graham F.; Dotson, Robert S.] Photospectra Hlth Sci, 271 Mutual St, Toronto, ON M4Y 1X6, Canada.
   [Munk, Marion R.] Univ Hosp, Dept Ophthalmol, Inselspital, Bern, Switzerland.
   [Walker, Michael G.] Walker Stat Consulting, Carlsbad, CA USA.
   [Devenyi, Robert G.] Univ Hlth Network, Donald K Johnson Eye Ctr, Retinal Serv, Toronto, ON, Canada.
   [Devenyi, Robert G.] Univ Toronto, Ophthalmol, Toronto, ON, Canada.
   [Devenyi, Robert G.] Kensington Eye Inst, Toronto, ON, Canada.
C3 University of Bern; University Hospital of Bern; University of Toronto;
   University Toronto Affiliates; University Health Network Toronto;
   University of Toronto
RP Merry, GF (通讯作者)，Photospectra Hlth Sci, 271 Mutual St, Toronto, ON M4Y 1X6, Canada.
EM gmerry@lumithera.com
CR Albarracin R, 2011, INVEST OPHTH VIS SCI, V52, P3582, DOI 10.1167/iovs.10-6664
   Alten F, 2015, BRIT J OPHTHALMOL, V99, P717, DOI 10.1136/bjophthalmol-2014-305339
   Beck RW, 2003, AM J OPHTHALMOL, V135, P194, DOI 10.1016/S0002-9394(02)01825-1
   Chowers I, 2015, PROG RETIN EYE RES, V47, P64, DOI 10.1016/j.preteyeres.2015.02.001
   Ctori I, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129005
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Eells JT, 2003, P NATL ACAD SCI USA, V100, P3439, DOI 10.1073/pnas.0534746100
   ELLIOTT DB, 1988, OPHTHAL PHYSL OPT, V8, P397, DOI 10.1111/j.1475-1313.1988.tb01176.x
   Evans J, 1996, BRIT J OPHTHALMOL, V80, P9, DOI 10.1136/bjo.80.1.9
   Fuma S, 2015, MOL VIS, V21, P883
   Geneva II, 2016, INT J OPHTHALMOL-CHI, V9, P145, DOI 10.18240/ijo.2016.01.24
   Gkotsi D, 2014, EXP EYE RES, V122, P50, DOI 10.1016/j.exer.2014.02.023
   Gordois A, 2012, GLOB PUBLIC HEALTH, V7, P465, DOI 10.1080/17441692.2011.634815
   Gregori G, 2014, INVEST OPHTH VIS SCI, V55, P7662, DOI 10.1167/iovs.14-15273
   Ivandic BT, 2008, PHOTOMED LASER SURG, V26, P241, DOI 10.1089/pho.2007.2132
   KARU T, 1995, J PHOTOCH PHOTOBIO B, V27, P219, DOI 10.1016/1011-1344(94)07078-3
   Karu TI, 2005, PHOTOMED LASER SURG, V23, P355, DOI 10.1089/pho.2005.23.355
   Marsiglia M, 2013, INVEST OPHTH VIS SCI, V54, P7362, DOI 10.1167/iovs.12-11073
   Passarella S, 2014, J PHOTOCH PHOTOBIO B, V140, P344, DOI 10.1016/j.jphotobiol.2014.07.021
   Poyton RO, 2011, DISCOV MED, V11, P154
   Qin S, 2008, J INFLAMM RES, V1, P49
   Rojas JC, 2011, LOW LEVEL LIGHT THER, V2011, P49
   Rojas JC, 2008, J NEUROSCI, V28, P13511, DOI 10.1523/JNEUROSCI.3457-08.2008
   Rykov S, 2015, CLIN CASE REPORTS
   Sarraf D, 1999, RETINA-J RET VIT DIS, V19, P513, DOI 10.1097/00006982-199911000-00006
   Sayegh RG, 2011, OPHTHALMOLOGY, V118, P1844, DOI 10.1016/j.ophtha.2011.01.043
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1441, DOI 10.1097/IAE.0b013e3181ee5ce8
   Suzuki M, 2015, RETINA-J RET VIT DIS, V35, P859, DOI 10.1097/IAE.0000000000000503
   Tang J, 2014, BRIT J OPHTHALMOL, V98, P1013, DOI 10.1136/bjophthalmol-2013-304477
   Tang J, 2013, INVEST OPHTH VIS SCI, V54, P3681, DOI 10.1167/iovs.12-11018
   Tata DB, 2011, LASER PHOTONICS REV, V5, P1, DOI 10.1002/lpor.200900032
   Wong-Riley MTT, 2005, J BIOL CHEM, V280, P4761, DOI 10.1074/jbc.M409650200
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P679, DOI 10.1016/j.ophtha.2010.08.018
NR 33
TC 37
Z9 39
U1 1
U2 21
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD JUN
PY 2017
VL 95
IS 4
BP E270
EP E277
DI 10.1111/aos.13354
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EX6OJ
UT WOS:000403361300003
PM 27989012
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Nagai, N
   Suzuki, M
   Uchida, A
   Kurihara, T
   Kamoshita, M
   Minami, S
   Shinoda, H
   Tsubota, K
   Ozawa, Y
AF Nagai, Norihiro
   Suzuki, Misa
   Uchida, Atsuro
   Kurihara, Toshihide
   Kamoshita, Mamoru
   Minami, Sakiko
   Shinoda, Hajime
   Tsubota, Kazuo
   Ozawa, Yoko
TI Non-responsiveness to intravitreal aflibercept treatment in neovascular
   age-related macular degeneration: implications of serous pigment
   epithelial detachment
SO SCIENTIFIC REPORTS
LA English
DT Article
ID RANIBIZUMAB TREATMENT; CHOROIDAL THICKNESS; VEGF-TRAP; THERAPY;
   TACHYPHYLAXIS; GUIDELINES; INJECTION; SAFETY; EYE
AB The prognosis of neovascular age-related macular degeneration (AMD) has been improved by anti-vascular endothelial growth factor treatments, including intravitreal aflibercept (IVA) treatment. However, many patients remain incurable. In this study, we retrospectively evaluated non-responsiveness to IVA monotherapy at 12 months in 133 eyes of 133 AMD patients. Sixty-two patients were initially treatment-naive, and 71 had received other treatments before IVA (the treatment-switched group). Mean best-corrected visual acuity (BCVA) was improved in the treatment-naive group but not in the treatment-switched group, although mean central retinal thickness (CRT) decreased in both groups. The respective percentages of non-responders as determined by worsened BCVA in the treatment-naive and treatment-switched groups were 8.1% and 15.5%, and via fundus findings, they were 12.9% and 8.5%. Multivariate analyses adjusted for age, gender, CRT, and greatest linear dimension showed that serous pigment epithelial detachment (PED) at baseline was associated with non-responsiveness in both groups as determined by BCVA and by fundus findings, and fibrovascular PED measurements indicated no response as determined by fundus findings in the treatment-switched group. The results reported herein may assist the formulation of appropriate treatment protocols for AMD patients.
C1 [Nagai, Norihiro; Suzuki, Misa; Uchida, Atsuro; Kamoshita, Mamoru; Ozawa, Yoko] Keio Univ, Lab Retinal Cell Biol, Sch Med, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.
   [Nagai, Norihiro; Suzuki, Misa; Kurihara, Toshihide; Kamoshita, Mamoru; Minami, Sakiko; Shinoda, Hajime; Tsubota, Kazuo; Ozawa, Yoko] Keio Univ, Dept Ophthalmol, Sch Med, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.
C3 Keio University; Keio University
RP Ozawa, Y (通讯作者)，Keio Univ, Lab Retinal Cell Biol, Sch Med, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.; Ozawa, Y (通讯作者)，Keio Univ, Dept Ophthalmol, Sch Med, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.
EM ozawa@a5.keio.jp
RI Ozawa, Yoko/AAH-9888-2020; Uchida, Atsuro/GVT-8593-2022; Kurihara,
   Toshihide/ABA-7058-2020
OI Kurihara, Toshihide/0000-0002-5457-2720; Uchida,
   Atsuro/0000-0002-1378-7151
CR [Anonymous], 1999, Arch Ophthalmol, V117, P1329
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chakravarthy U, 2013, EYE, V27, P1429, DOI 10.1038/eye.2013.233
   Chang TS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1460, DOI 10.1001/archopht.125.11.1460
   Cheng CY, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7063
   Clemons Traci E, 2005, Ophthalmology, V112, P533
   Dirani A, 2015, AM J OPHTHALMOL, V160, P732, DOI 10.1016/j.ajo.2015.06.025
   Gasperini JL, 2012, BRIT J OPHTHALMOL, V96, P14, DOI 10.1136/bjo.2011.204685
   Hassan M, 2016, EXPERT OPIN BIOL TH, V16, P699, DOI 10.1517/14712598.2016.1167182
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Kanda A, 2015, SCI REP-UK, V5, DOI 10.1038/srep17946
   Kanesa-Thasan A, 2015, OSLI RETINA, V46, P638, DOI 10.3928/23258160-20150610-07
   Koizumi H, 2016, OPHTHALMOLOGY, V123, P617, DOI 10.1016/j.ophtha.2015.10.039
   Koizumi H, 2015, AM J OPHTHALMOL, V159, P627, DOI 10.1016/j.ajo.2014.12.025
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Matamoros E, 2015, OPHTHALMOLOGICA, V234, P151, DOI 10.1159/000433448
   Moroi SE, 2008, OPHTHALMOLOGY, V115, P925, DOI 10.1016/j.ophtha.2008.04.020
   Ogura Y, 2015, BRIT J OPHTHALMOL, V99, P92, DOI 10.1136/bjophthalmol-2014-305076
   Peters S, 2007, AM J OPHTHALMOL, V143, P995, DOI 10.1016/j.ajo.2007.03.007
   Pinheiro-Costa J, 2015, OPHTHALMOLOGICA, V233, P155, DOI 10.1159/000381221
   Schaal S, 2008, OPHTHALMOLOGY, V115, P2199, DOI 10.1016/j.ophtha.2008.07.007
   Semeraro F, 2013, DRUG DES DEV THER, V7, P711, DOI 10.2147/DDDT.S40215
   Singerman LJ, 2008, BRIT J OPHTHALMOL, V92, P1606, DOI 10.1136/bjo.2007.132597
   Suzuki M., 2016, AM J OPHTHALMOL, DOI [10.1016/j.ajo.2016.03.024, DOI 10.1016/J.AJ0.2016.03.024]
   Suzuki M, 2014, BRIT J OPHTHALMOL, V98, P1186, DOI 10.1136/bjophthalmol-2013-304670
   Takahashi Kanji, 2012, Nippon Ganka Gakkai Zasshi, V116, P1150
   Takahashi Kanji, 2008, Nippon Ganka Gakkai Zasshi, V112, P1076
   Varano M, 2016, CLIN OPHTHALMOL, V10, P257, DOI 10.2147/OPTH.S92616
   Wako Rina, 2014, Nippon Ganka Gakkai Zasshi, V118, P495
   Yamashiro K, 2012, AM J OPHTHALMOL, V154, P125, DOI 10.1016/j.ajo.2012.01.010
   Yasuda M, 2009, OPHTHALMOLOGY, V116, P2135, DOI 10.1016/j.ophtha.2009.04.017
   Zinkernagel MS, 2016, OPHTHALMOLOGICA, V235, P42, DOI 10.1159/000441428
NR 33
TC 32
Z9 33
U1 0
U2 6
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD JUL 11
PY 2016
VL 6
AR 29619
DI 10.1038/srep29619
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA DR0VX
UT WOS:000379626100001
PM 27403807
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Toto, L
   Borrelli, E
   Di Antonio, L
   Carpineto, P
   Mastropasqua, R
AF Toto, Lisa
   Borrelli, Enrico
   Di Antonio, Luca
   Carpineto, Paolo
   Mastropasqua, Rodolfo
TI RETINAL VASCULAR PLEXUSES' CHANGES IN DRY AGE-RELATED MACULAR
   DEGENERATION, EVALUATED BY MEANS OF OPTICAL COHERENCE TOMOGRAPHY
   ANGIOGRAPHY
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; AMD; choroid; choroidal thickness;
   optical coherence tomography angiography; retinal vessel; vessel density
ID SOURCE OCT ANGIOGRAPHY; CHOROIDAL THICKNESS; BLOOD-FLOW; MACULOPATHY;
   EYES; PROGRESSION; AMD
AB Purpose: To investigate alteration in superficial and deep retinal vascular densities and choroidal thickness, in patients affected by early and intermediate age-related macular degeneration (AMD).
   Methods: All patients had undergone optical coherence tomography angiography (OCTA). All eyes were grouped into two stages: "early AMD" and "intermediate AMD." Outcome measures were superficial vessel density, deep vessel density, and choroidal thickness. A control group of healthy subjects was selected for the statistical comparisons.
   Results: A total of 37 eyes of 37 dry AMD patients were enrolled for the study. Fourteen of 37 eyes were classified as having early AMD, the remaining 23 of 37 eyes were classified as being affected by intermediate AMD. Superficial and deep vessel densities were 39.21% +/- 10.67% and 43.84% +/- 11.57%, respectively, in the control group and 28.30% +/- 10.73% and 36.41% +/- 12.30%, respectively, in AMD patients (P = 0.001 and P = 0.017, respectively). Choroidal thickness was significantly reduced in AMD patients.
   Conclusion: In the last years, several studies have reported vascular factors playing an important role in AMD pathogenesis. We demonstrated that both superficial and deep retinal plexuses are altered among patients affected by AMD. Interestingly, this alteration starts immediately at the intermediate AMD stage and also the choroidal thickness reduction.
C1 [Toto, Lisa; Borrelli, Enrico; Di Antonio, Luca; Carpineto, Paolo] Univ G dAnnunzio, Dept Med & Sci Ageing, Ophthalmol Clin, Chieti, Italy.
   [Mastropasqua, Rodolfo] Univ Verona, Dept Neurol Neuropsychol Morphol & Movement Sci, Ophthalmol Unit, Verona, Italy.
C3 G d'Annunzio University of Chieti-Pescara; University of Verona
RP Borrelli, E (通讯作者)，Univ G dAnnunzio, Dept Med & Sci Ageing, Ophthalmol Clin, Chieti, Italy.
EM borrelli.enrico@yahoo.com
RI Mastropasqua, Rodolfo/AAC-6453-2022; Toto, Lisa/K-3473-2018; Borrelli,
   Enrico/AAR-3693-2020; Carpineto, Paolo/AAN-9688-2020
OI Toto, Lisa/0000-0001-5311-5184; Borrelli, Enrico/0000-0003-2815-5031; 
CR Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Bird AC, 2014, JAMA OPHTHALMOL, V132, P338, DOI 10.1001/jamaophthalmol.2013.5799
   Boltz A, 2010, INVEST OPHTH VIS SCI, V51, P4220, DOI 10.1167/iovs.09-4968
   Choi W, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081499
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Esmaeelpour M, 2014, INVEST OPHTH VIS SCI, V55, P5074, DOI 10.1167/iovs.14-14646
   Feigl B, 2009, PROG RETIN EYE RES, V28, P63, DOI 10.1016/j.preteyeres.2008.11.004
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Harb E, 2015, AM J OPHTHALMOL, V160, P62, DOI 10.1016/j.ajo.2015.04.018
   Huang YP, 2014, OSLI RETINA, V45, P382, DOI 10.3928/23258160-20140909-08
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Jia YL, 2012, BIOMED OPT EXPRESS, V3, DOI 10.1364/BOE.3.003127
   Lee JY, 2013, INVEST OPHTH VIS SCI, V54, P7812, DOI 10.1167/iovs.13-12284
   Leveziel N, 2011, OPHTHALMOLOGICA, V226, DOI 10.1159/000328981
   Lumbroso B, 2015, CLIN GUIDE ANGIO OCT
   Lumbroso B., 2015, CLIN OCT ANGIOGRAPHY
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P743, DOI 10.1001/archopht.1995.01100060069034
   Moult E, 2014, OSLI RETINA, V45, P496, DOI 10.3928/23258160-20141118-03
   Remsch H, 2000, GRAEF ARCH CLIN EXP, V238, P960, DOI 10.1007/s004170000202
   Rogala J, 2015, INVEST OPHTH VIS SCI, V56, P1689, DOI 10.1167/iovs.14-16221
   Savastano MC, 2015, RETINA-J RET VIT DIS, V35, P2196, DOI 10.1097/IAE.0000000000000635
   Spaide RF, 2015, JAMA OPHTHALMOL, V133, P45, DOI 10.1001/jamaophthalmol.2014.3616
   Spraul CW, 1999, SURV OPHTHALMOL, V44, pS10, DOI 10.1016/S0039-6257(99)00086-7
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   Wang JJ, 2004, BRIT J OPHTHALMOL, V88, P104, DOI 10.1136/bjo.88.1.104
   Wei E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081343
   Zarbin MA, 2010, RETINA-J RET VIT DIS, V30, P1350, DOI 10.1097/IAE.0b013e3181f57e30
   Zerbib J, 2014, GRAEF ARCH CLIN EXP, V252, P899, DOI 10.1007/s00417-013-2537-7
NR 29
TC 68
Z9 70
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD AUG
PY 2016
VL 36
IS 8
BP 1566
EP 1572
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DS7MI
UT WOS:000380967200036
PM 26807629
DA 2022-11-30
ER

PT J
AU Hatz, K
   Zimmermann, F
   Kardamakis, D
   Lazaridis, E
   Turksever, C
   Binder, J
   Papachristofilou, A
   Prunte, C
AF Hatz, Katja
   Zimmermann, Frank
   Kardamakis, Dimitrios
   Lazaridis, Emmanouil
   Turksever, Cengiz
   Binder, Jorg
   Papachristofilou, Alexandros
   Prunte, Christian
TI Low-Energy Stereotactic Radiotherapy for Treatment of Exudative
   Age-Related Macular Degeneration in a Treat-and-Extend Regimen
SO OPHTHALMIC SURGERY LASERS & IMAGING RETINA
LA English
DT Article
ID X-RAY-IRRADIATION; SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; NEEDED
   RANIBIZUMAB THERAPY; EPIMACULAR BRACHYTHERAPY; VISUAL IMPAIRMENT;
   RADIATION-THERAPY; OUTCOMES; SAFETY; TRIAL
AB BACKGROUND AND OBJECTIVE: To evaluate the effectiveness and safety of low-energy stereotactic radiotherapy (SRT) combined with anti-vascular endothelial growth factor (VEGF) treatment following a treat-and-extend regimen (TER) in wet age-related macular degeneration (AMD).
   PATIENTS AND METHODS: Before/after SRT, the authors compared retrospective consecutive case series of 50 patients requiring frequent anti-VEGF treatment (every 4 or 6 weeks) in wet AMD, treated with a single session of SRT and TER (same manner pre/post-SRT). Outcomes were visual acuity (VA), recurrence-free interval, and central retinal thickness (CRT).
   RESULTS: After SRT, CRT was reduced from baseline (407.3 mu m +/- 153.2 mu m) to 12 months (320.2 mu m +/- 112.1 mu m; P <.001), with statistical significance from month 2 onward. VA was stable for 12 months (64.0 letters +/- 15.1 letters vs. 63.6 letters +/- 16.2 letters). The mean recurrence-free interval increased from 4.24 weeks +/- 0.66 weeks to 7.52 weeks +/- 3.05 weeks at 12 months (P <.001). No severe side effects were observed.
   CONCLUSION: Low-energy SRT, combined with antiVEGF TER, was associated with reduced injection frequency and preserved VA during 12 months of follow-up.
C1 [Hatz, Katja; Turksever, Cengiz] Vista Klin Binningen, Hauptstr 55, CH-4102 Binningen, Switzerland.
   [Prunte, Christian] Kantonsspital Liestal, Dept Ophthalmol, Liestal, Switzerland.
   [Hatz, Katja; Prunte, Christian] Univ Basel, Basel, Switzerland.
   [Zimmermann, Frank; Papachristofilou, Alexandros] Univ Clin Basel, Dept Radiat Oncol, Basel, Switzerland.
   [Kardamakis, Dimitrios] Med Sch, Dept Radiat Oncol, Patras, Greece.
   [Lazaridis, Emmanouil; Binder, Jorg] EyeRAD SWISS Med Ctr, Binningen, Switzerland.
C3 Kantonsspital Baselland; University of Basel; University of Basel
RP Hatz, K (通讯作者)，Vista Klin Binningen, Hauptstr 55, CH-4102 Binningen, Switzerland.
EM khatz@vistaklinik.ch
RI Türksever, Cengiz/AAB-3134-2019
OI Papachristofilou, Alexandros/0000-0001-5619-747X
FU Oraya Therapeutics, Newark, CA
FX Editorial support was provided by Touch Medical Media, Reading, UK, and
   funded by Oraya Therapeutics, Newark, CA. Neither Touch Medical Media
   nor Oraya Therapeutics had influence in the study design; in the
   collection, analysis, and interpretation of the data; in the writing of
   the report; or in the decision to submit the paper for publication.
CR Avila MP, 2009, BRIT J OPHTHALMOL, V93, P305, DOI 10.1136/bjo.2008.145912
   Campbell JP, 2012, ARCH OPHTHALMOL-CHIC, V130, P794, DOI 10.1001/archophthalmol.2011.2480
   CHAKRAVARTHY U, 1993, BRIT J OPHTHALMOL, V77, P265, DOI 10.1136/bjo.77.5.265
   Chen L, 2014, BRIT J OPHTHALMOL, V98, P1212, DOI 10.1136/bjophthalmol-2013-304761
   Day S, 2011, AM J OPHTHALMOL, V152, P1014, DOI 10.1016/j.ajo.2011.05.008
   Dugel PU, 2013, OPHTHALMOLOGY, V120, P317, DOI 10.1016/j.ophtha.2012.07.068
   Evans JR, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004004.pub3
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holz FG, 1999, OPHTHALMOLOGY, V106, P2239
   Jackson TL, 2016, OPHTHALMOLOGY, V123, P1287, DOI 10.1016/j.ophtha.2016.02.028
   Jackson TL, 2015, RETINA-J RET VIT DIS, V35, P194, DOI 10.1097/IAE.0000000000000283
   Jackson TL, 2015, OPHTHALMOLOGY, V122, P138, DOI 10.1016/j.ophtha.2014.07.043
   Jackson TL, 2013, OPHTHALMOLOGY, V120, P1893, DOI 10.1016/j.ophtha.2013.02.016
   Kishan AU, 2013, INT J RADIAT ONCOL, V85, P583, DOI 10.1016/j.ijrobp.2012.07.2352
   Canton VM, 2012, OPHTHAL SURG LAS IM, V43, P20, DOI 10.3928/15428877-20111129-01
   Morales-Canton V, 2013, AM J OPHTHALMOL, V155, P1000, DOI 10.1016/j.ajo.2013.01.015
   Moshfeghi AA, 2012, BRIT J OPHTHALMOL, V96, P1320, DOI 10.1136/bjophthalmol-2011-301222
   Moshfeghi AA, 2011, OPHTHAL SURG LAS IM, V42, P460, DOI 10.3928/15428877-20110804-03
   Moshfeghi DM, 2011, BRIT J OPHTHALMOL, V95, P185, DOI 10.1136/bjo.2009.163907
   Neffendorf JE, 2016, TRIALS, V17, DOI 10.1186/s13063-016-1676-7
   Neffendorf JE, 2015, CLIN OPHTHALMOL, V9, P1829, DOI 10.2147/OPTH.S75638
   Neubauer AS, 2016, KLIN MONATSBL AUGENH, V233, P951, DOI 10.1055/s-0042-100473
   Pascolini D, 2004, OPHTHAL EPIDEMIOL, V11, P67, DOI 10.1076/opep.11.2.67.28158
   Ranjbar M, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000005729
   Razavi S, 2015, AM J OPHTHALMOL, V160, P1006, DOI 10.1016/j.ajo.2015.08.009
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Shin JY, 2015, ACTA OPHTHALMOL, V93, P524, DOI 10.1111/aos.12653
   Stevenson MR, 2005, BRIT J OPHTHALMOL, V89, P1045, DOI 10.1136/bjo.2003.030445
   Valmaggia C, 2002, AM J OPHTHALMOL, V133, P521, DOI 10.1016/S0002-9394(02)01336-3
   Zarranz-Ventura J, 2014, OPHTHALMOLOGY, V121, P1966, DOI 10.1016/j.ophtha.2014.04.026
NR 31
TC 4
Z9 4
U1 0
U2 1
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 2325-8160
EI 2325-8179
J9 OSLI RETINA
JI Ophthalmic Surg. Lasers Imag. Retin.
PD FEB
PY 2018
VL 49
IS 2
BP 86
EP 93
DI 10.3928/23258160-20180129-02
PG 8
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA FX1XM
UT WOS:000425848800002
PM 29443357
DA 2022-11-30
ER

PT J
AU Mantel, I
   Niderprim, SA
   Gianniou, C
   Deli, A
   Ambresin, A
AF Mantel, Irmela
   Niderprim, Sophie-Alexia
   Gianniou, Christina
   Deli, Angeliki
   Ambresin, Aude
TI Reducing the clinical burden of ranibizumab treatment for neovascular
   age-related macular degeneration using an individually planned regimen
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID INTRAVITREAL RANIBIZUMAB; DOSING REGIMEN; THERAPY; VERTEPORFIN;
   EFFICACY; SAFETY
AB Aims The purpose of this study was to clinically validate an individually planned treatment regimen for neovascular age-related macular degeneration (nAMD), termed, observe and plan. This regimen was based on the predictability of an individual's need for retreatment and aimed to reduce the clinical burden, while obtaining good functional results.
   Methods This was a prospective case series that included 104 patients (115 eyes) with treatment-naive nAMD. Following three loading doses of ranibizumab, monthly observation visits allowed the disease recurrence interval to be determined. The recurrence interval was reduced by 2 weeks to give the retreatment interval for the next three injections. Periodical control visits (at least every 6 months) allowed the effectiveness of the treatment to be assessed and individual intervals adjusted.
   Results Mean visual acuity (VA) improved by 8.7 and 9.8 letters in months 3 and 12, respectively. The mean number of injections during the 12-month study was 7.8, while the mean number of ophthalmic examinations between months 3 and 12 was 3.97. The mean treatment interval after the loading doses was 1.97 months.
   Conclusions The observe-and-plan regimen significantly improved VA. This was obtained with fewer clinic visits compared with other regimens, which could ease the burden of nAMD treatment.
C1 [Mantel, Irmela; Niderprim, Sophie-Alexia; Gianniou, Christina; Deli, Angeliki; Ambresin, Aude] Univ Lausanne, Jules Gonin Eye Hosp, Dept Ophthalmol, Lausanne, Switzerland.
C3 University of Lausanne
RP Mantel, I (通讯作者)，Univ Eye Hosp Jules Gonin, Dept Ophthalmol, 15 Av France,Case Postale 133, CH-1000 Lausanne 7, Switzerland.
EM irmela.mantel@fa2.ch
FU Novartis
FX Medical writing support was provided by Gillian Groeger, Fishawack
   Communications Ltd, UK, and was funded by Novartis.
CR Abraham P, 2010, AM J OPHTHALMOL, V150, P315, DOI 10.1016/j.ajo.2010.04.011
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Cohen SY, 2009, AM J OPHTHALMOL, V148, P409, DOI 10.1016/j.ajo.2009.04.001
   Dadgostar H, 2009, OPHTHALMOLOGY, V116, P1740, DOI 10.1016/j.ophtha.2009.05.033
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Han DP, 2013, JAMA OPHTHALMOL, V131, P1124, DOI 10.1001/jamaophthalmol.2013.432
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Mantel I, 2008, OPHTHALMOLOGICA, V222, P321, DOI 10.1159/000144075
   Mantel I, 2013, GRAEF ARCH CLIN EXP, V251, P697, DOI 10.1007/s00417-012-2090-9
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Oubraham H, 2011, RETINA-J RET VIT DIS, V31, P26, DOI 10.1097/IAE.0b013e3181de5609
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
NR 23
TC 49
Z9 53
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD SEP
PY 2014
VL 98
IS 9
BP 1192
EP 1196
DI 10.1136/bjophthalmol-2013-304556
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AN3QW
UT WOS:000340504400008
PM 24729031
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Bin, Y
   Liu, YY
   Jiang, SQ
   Peng, H
AF Bin, Yue
   Liu, Yanyao
   Jiang, Shaoqiu
   Peng, Hui
TI Elevated YKL-40 serum levels may contribute to wet age-related macular
   degeneration via the ERK1/2 pathway
SO FEBS OPEN BIO
LA English
DT Article
DE age-related macular degeneration; choroidal neovascularization; YKL-40;
   vascular endothelial growth factor
ID DISEASE; ANGIOGENESIS; EXPRESSION; PROTEIN; KINASE; CHI3L1; CELLS
AB Choroidal neovascularization (CNV) is a key characteristic of wet age-related macular degeneration (AMD) that can lead to severe vision loss in the elderly. Anti-VEGF therapy is currently the premier strategy for wet AMD, but it has limited efficacy. Previous studies have shown that chitinase-3-like-1 (YKL-40) can promote microangiogenesis and inflammation, but its effect on CNV formation has not yet been studied. Here, we investigated the potential role of YKL-40 in wet AMD and the underlying mechanism(s). We report that the serum expression of YKL-40 in wet AMD patients was significantly higher than that in control patients and was positively correlated with VEGF expression, indicating that YKL-40 may participate in the development of wet AMD. In addition, YKL-40 and VEGF expression levels were observed to be increased and the ERK1/2 pathway activated in the neuroretinal (NR) and RPE/choroid tissues of mice with laser-induced CNV. The YKL-40 and phosphorylated protein levels of the ERK1/2 pathway were decreased after intravitreal injection with an anti-YKL-40 antibody, suggesting that anti-YKL-40 could inhibit the activation of the ERK1/2 pathway. These results indicate that YKL-40 may serve as a novel target for the diagnosis and treatment of wet AMD.
C1 [Bin, Yue; Liu, Yanyao; Peng, Hui] Chongqing Med Univ, Chongqing Key Lab Ophthalmol, Dept Ophthalmol, Affiliated Hosp 1, Chongqing, Peoples R China.
   [Bin, Yue; Liu, Yanyao; Peng, Hui] Chongqing Med Univ, Chongqing Eye Inst, Affiliated Hosp 1, Chongqing, Peoples R China.
   [Jiang, Shaoqiu] Chongqing Med Univ, Dept Ophthalmol, Affiliated Hosp 2, Chongqing, Peoples R China.
C3 Chongqing Medical University; Chongqing Medical University; Chongqing
   Medical University
RP Peng, H (通讯作者)，Chongqing Med Univ, Affiliated Hosp 1, Dept Ophthalmol, 1 Youyi Rd, Chongqing 400016, Peoples R China.
EM pengh9@sina.com
FU National Natural Science Foundation of China [81670881]; Chongqing
   Science and Technology Commission [2014pt-sy10002]
FX This study is supported by the National Natural Science Foundation of
   China Grants (81670881) and the Chongqing Science and Technology
   Commission (2014pt-sy10002). We acknowledge Dr. Hui Peng for her support
   and guidance. In addition, we gratefully thank Dr. Danning Liu and Dr.
   Yong Du for helping to establish the laser-induced CNV mouse model used
   in this research.
CR Adhya Z, 2019, LUPUS, V28, P713, DOI 10.1177/0961203319845487
   Ambreen F, 2015, MOL VIS, V21, P985
   Andreoli CM, 2007, CURR OPIN OPHTHALMOL, V18, P502, DOI 10.1097/ICU.0b013e3282f0ca54
   Burotto M, 2014, CANCER-AM CANCER SOC, V120, P3446, DOI 10.1002/cncr.28864
   Chen CQ, 2020, INT IMMUNOPHARMACOL, V88, DOI 10.1016/j.intimp.2020.106878
   Coffman F, 2008, CRIT REV CL LAB SCI, V45, P531, DOI [10.1080/10408360802334743, 10.1080/10408360802334743 ]
   Craig-Schapiro R, 2010, BIOL PSYCHIAT, V68, P903, DOI 10.1016/j.biopsych.2010.08.025
   Di Rosa M, 2016, PATHOBIOLOGY, V83, P228, DOI 10.1159/000444855
   Di Rosa M, 2016, IMMUNOBIOLOGY, V221, P399, DOI 10.1016/j.imbio.2015.11.014
   Faibish M, 2011, MOL CANCER THER, V10, P742, DOI 10.1158/1535-7163.MCT-10-0868
   Francescone RA, 2011, J BIOL CHEM, V286, P15332, DOI 10.1074/jbc.M110.212514
   Jafari-Nakhjavani MR, 2019, CASP J INTERN MED, V10, P92, DOI 10.22088/cjim.10.1.92
   JOHANSEN JS, 1992, J BONE MINER RES, V7, P501
   Kawada M, 2012, ONCOGENE, V31, P3111, DOI 10.1038/onc.2011.498
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Kim Steve H, 2007, World J Surg Oncol, V5, P17, DOI 10.1186/1477-7819-5-17
   Krzeslak A, 2010, POSTEP HIG MED DOSW, V64, P490
   Lee CG, 2012, AM J RESP CRIT CARE, V185, P692, DOI 10.1164/rccm.201202-0203ED
   Qiu YG, 2014, INVEST OPHTH VIS SCI, V55, P3809, DOI 10.1167/iovs.14-13883
   Querol-Vilaseca M, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0893-7
   Rakic JM, 2003, INVEST OPHTH VIS SCI, V44, P1740, DOI 10.1167/iovs.02-0775
   Recklies AD, 2002, BIOCHEM J, V365, P119, DOI 10.1042/BJ20020075
   Rusak A, 2018, ANTICANCER RES, V38, P3357, DOI 10.21873/anticanres.12602
   Sacewicz I, 2009, POSTEP HIG MED DOSW, V63, P159
   Salah NY, 2020, CYTOKINE, V133, DOI 10.1016/j.cyto.2020.155120
   Schroder J, 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.119.014634
   Shao R, 2009, ONCOGENE, V28, P4456, DOI 10.1038/onc.2009.292
   Shao R, 2015, ONCOTARGET, V6, P40507, DOI 10.18632/oncotarget.5943
   Shao R, 2013, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00122
   Shao R, 2014, CARCINOGENESIS, V35, P373, DOI 10.1093/carcin/bgt380
   Vaananen T, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/215140
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yang K, 2011, OPHTHALMOLOGY, V118, P1395, DOI 10.1016/j.ophtha.2010.12.030
   Zampros I, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/319728
NR 34
TC 0
Z9 0
U1 4
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2211-5463
J9 FEBS OPEN BIO
JI FEBS Open Bio
PD NOV
PY 2021
VL 11
IS 11
BP 2933
EP 2942
DI 10.1002/2211-5463.13223
EA SEP 2021
PG 10
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA WQ7FO
UT WOS:000702134800001
PM 34110111
OA Green Published
DA 2022-11-30
ER

PT J
AU Lee, JY
   Bae, K
AF Lee, Ju-Yeun
   Bae, Kunho
TI RISK OF EXUDATIVE AGE-RELATED MACULAR DEGENERATION IN PATIENTS WITH
   CENTRAL SEROUS CHORIORETINOPATHY A Nationwide Cohort Study
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; central serous chorioretinopathy;
   pachychoroid disease; polypoidal choroidal vasculopathy;
   population-based cohort study
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; PREVALENCE; NEOVASCULARIZATION
AB Purpose: To estimate the risk of incident age-related macular degeneration (AMD) in patients with central serous chorioretinopathy (CSC). Methods: This population-based cohort study was finally conducted from January 2015 to December 2019. All patients with CSC from the entire population aged between 30 and 80 years were included. The incidence of CSC was estimated. Log-rank analysis and Cox proportional hazards regression analysis was used to evaluate the risk of exudative AMD in the CSC group compared with the non-CSC group. Results: During a recent 5-year study period, 36,053 patients were identified as having incident CSC. The annual incidence in the latest year was 19.61 (95% confidence interval, 19.58 to 19.63) per 100,000 people. A total of 11,492 patients were included in the study group and 22,984 in the non-CSC group. The CSC and non-CSC groups included 166 (1.44%) and 73 (0.32%) cases of exudative AMD, respectively. The risk of exudative AMD was significantly higher in the CSC group than in the non-CSC group (adjusted hazard ratio: 4.86; 95% confidence interval: 2.98 to 5.88; P < 0.001). Conclusion: This study showed that subjects with CSC are at an increased risk of exudative AMD. This evidence supports a possible link between CSC and exudative AMD, particularly in Asian populations.
C1 [Lee, Ju-Yeun] Hanyang Univ, Coll Med, Dept Ophthalmol, Myongji Hosp, Goyang, South Korea.
   [Lee, Ju-Yeun] Seoul Natl Univ, Dept Prevent Med, Coll Med, Seoul, South Korea.
   [Lee, Ju-Yeun] Seoul Natl Univ, Integrated Major Innovat Med Sci, Coll Med, Seoul, South Korea.
   [Bae, Kunho] Seoul Natl Univ Hosp, Dept Ophthalmol, Seoul, South Korea.
C3 Hanyang University; Myongji Hospital; Seoul National University (SNU);
   Seoul National University (SNU); Seoul National University (SNU); Seoul
   National University Hospital
RP Bae, K (通讯作者)，Seoul Natl Univ Hosp, Dept Ophthalmol, Seoul, South Korea.
EM leejy5293@gmail.com; luben81@gmail.com
FU National Research Foundation of Korea (NRF) - Korea government (MSIT)
   [2020R1F1A1072264]
FX Supported by the National Research Foundation of Korea (NRF) grant
   funded by the Korea government (MSIT) (2020R1F1A1072264). The funder had
   no role in the design or conduct of the study; collection, management,
   analysis, and interpretation of the data; preparation, review, or
   approval of the manuscript or the decision to submit the manuscript for
   publication.
CR Ahuja RM, 2001, OPHTHALMOLOGY, V108, P1009, DOI 10.1016/S0161-6420(00)00614-X
   Bae K, 2019, GRAEF ARCH CLIN EXP, V257, P279, DOI 10.1007/s00417-018-4201-8
   Balaratnasingam C, 2016, RETINA-J RET VIT DIS, V36, P1, DOI 10.1097/IAE.0000000000000774
   Borrelli E, 2021, RETINA-J RET VIT DIS, V41, P296, DOI 10.1097/IAE.0000000000002846
   Cheung CMG, 2019, EYE, V33, P14, DOI 10.1038/s41433-018-0158-4
   Chiu CJ, 2014, AM J OPHTHALMOL, V158, P118, DOI 10.1016/j.ajo.2014.04.016
   Daruich A, 2015, PROG RETIN EYE RES, V48, P82, DOI 10.1016/j.preteyeres.2015.05.003
   Erke MG, 2012, OPHTHALMOLOGY, V119, P1737, DOI 10.1016/j.ophtha.2012.03.016
   Han J, 2021, J NEUROL, V268, P1276, DOI 10.1007/s00415-020-10270-2
   Hikichi T, 2009, RETINA-J RET VIT DIS, V29, P395, DOI 10.1097/IAE.0b013e318192f53a
   Kitzmann AS, 2008, OPHTHALMOLOGY, V115, P169, DOI [10.1016/j.ophtha.2007.02.032, 10.1016/j.ophtha.2008.01.009]
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Korb CA, 2014, GRAEF ARCH CLIN EXP, V252, P1403, DOI 10.1007/s00417-014-2591-9
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lee GI, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-40406-y
   Lee JY, 2020, OPHTHALMOLOGY, V127, P417, DOI 10.1016/j.ophtha.2019.09.032
   Lehmann M, 2015, RETINA-J RET VIT DIS, V35, P10, DOI 10.1097/IAE.0000000000000287
   Loo RH, 2002, RETINA-J RET VIT DIS, V22, P19, DOI 10.1097/00006982-200202000-00004
   Manayath GJ, 2018, RETINA-J RET VIT DIS, V38, P1195, DOI 10.1097/IAE.0000000000001665
   Pang CE, 2015, RETINA-J RET VIT DIS, V35, P1, DOI 10.1097/IAE.0000000000000331
   Park SJ, 2014, AM J OPHTHALMOL, V158, P1155, DOI 10.1016/j.ajo.2014.08.010
   Park SJ, 2014, OPHTHALMOLOGY, V121, P1756, DOI 10.1016/j.ophtha.2014.03.022
   Peiretti E, 2015, RETINA-J RET VIT DIS, V35, P1360, DOI 10.1097/IAE.0000000000000529
   Rim TH, 2018, JAMA OPHTHALMOL, V136, P1164, DOI 10.1001/jamaophthalmol.2018.3293
   Savastano MC, 2021, RETINA-J RET VIT DIS, V41, P302, DOI 10.1097/IAE.0000000000002810
   Shiragami C, 2018, AM J OPHTHALMOL, V193, P80, DOI 10.1016/j.ajo.2018.06.009
   Spaide RF, 1996, OPHTHALMOLOGY, V103, P2070, DOI 10.1016/S0161-6420(96)30386-2
   Toyama T, 2014, EYE, V28, P992, DOI 10.1038/eye.2014.132
   Tsai DC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066858
   Tsujikawa A, 2010, RETINA-J RET VIT DIS, V30, P801, DOI 10.1097/IAE.0b013e3181c72068
   van Rijssen TJ, 2019, PROG RETIN EYE RES, V73, DOI 10.1016/j.preteyeres.2019.07.003
   Wang M, 2008, ACTA OPHTHALMOL, V86, P126, DOI 10.1111/j.1600-0420.2007.00889.x
   Yang LH, 2015, ACTA OPHTHALMOL, V93, pE512, DOI 10.1111/aos.12606
NR 33
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAY
PY 2022
VL 42
IS 5
BP 852
EP 858
DI 10.1097/IAE.0000000000003412
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 0U0LT
UT WOS:000787351800006
PM 35067609
DA 2022-11-30
ER

PT J
AU Querques, G
   Kamami-Levy, C
   Georges, A
   Pedinielli, A
   Capuano, V
   Blanco-Garavito, R
   Poulon, F
   Souied, EH
AF Querques, Giuseppe
   Kamami-Levy, Cynthia
   Georges, Anouk
   Pedinielli, Alexandre
   Capuano, Vittorio
   Blanco-Garavito, Rocio
   Poulon, Fanny
   Souied, Eric H.
TI ADAPTIVE OPTICS IMAGING OF FOVEAL SPARING IN GEOGRAPHIC ATROPHY
   SECONDARY TO AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE adaptive optics; age-related macular degeneration; autofluorescence;
   Bruch membrane; drusen; geographic atrophy; infrared; retinal pigment
   epithelium; spectral domain optical coherence tomography
ID NEAR-INFRARED AUTOFLUORESCENCE; SCANNING LASER OPHTHALMOSCOPE; FUNDUS
   AUTOFLUORESCENCE; VISUAL-LOSS; MICROPERIMETRY; QUALITY; EYES
AB Background:To describe adaptive optics (AO) imaging of foveal sparing in geographic atrophy (GA) secondary to age-related macular degeneration.Methods:Flood-illumination AO infrared (IR) fundus images were obtained in four consecutive patients with GA using an AO retinal camera (rtx1; Imagine Eyes). Adaptive optics IR images were overlaid with confocal scanning laser ophthalmoscope near-IR autofluorescence images to allow direct correlation of en face AO features with areas of foveal sparing. Adaptive optics appearance of GA and foveal sparing, preservation of functional photoreceptors, and cone densities in areas of foveal sparing were investigated.Results:In 5 eyes of 4 patients (all female; mean age 74.2 11.9 years), a total of 5 images, sized 4 degrees x 4 degrees, of foveal sparing visualized on confocal scanning laser ophthalmoscope near-IR autofluorescence were investigated by AO imaging. En face AO images revealed GA as regions of inhomogeneous hyperreflectivity with irregularly dispersed hyporeflective clumps. By direct comparison with adjacent regions of GA, foveal sparing appeared as well-demarcated areas of reduced reflectivity with less hyporeflective clumps (mean 14.2 vs. 3.2; P = 0.03). Of note, in these areas, en face AO IR images revealed cone photoreceptors as hyperreflective dots over the background reflectivity (mean cone density 3,271 +/- 1,109 cones per square millimeter). Microperimetry demonstrated residual function in areas of foveal sparing detected by confocal scanning laser ophthalmoscope near-IR autofluorescence.Conclusion:Adaptive optics allows the appreciation of differences in reflectivity between regions of GA and foveal sparing. Preservation of functional cone photoreceptors was demonstrated on en face AO IR images in areas of foveal sparing detected by confocal scanning laser ophthalmoscope near-IR autofluorescence.
C1 [Querques, Giuseppe; Kamami-Levy, Cynthia; Georges, Anouk; Pedinielli, Alexandre; Capuano, Vittorio; Blanco-Garavito, Rocio; Souied, Eric H.] Univ Paris Est Creteil, Dept Ophthalmol, Ctr Hosp Intercommunal Creteil, Creteil, France.
   [Poulon, Fanny] Inst Opt, Grad Sch, Palaiseau, France.
C3 Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil;
   UDICE-French Research Universities; Universite Paris Saclay
RP Querques, G (通讯作者)，Ctr Hosp Intercommunal Creteil, Dept Ophthalmol, 40 Ave Verdun, F-94000 Creteil, France.
EM giuseppe.querques@hotmail.it
OI Kamami-Levy, Cynthia/0000-0002-5770-5269; Querques,
   Giuseppe/0000-0002-3292-9581
CR Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   BENNETT AG, 1994, GRAEF ARCH CLIN EXP, V232, P361, DOI 10.1007/BF00175988
   Bird AC, 2014, JAMA OPHTHALMOL, V132, P338, DOI 10.1001/jamaophthalmol.2013.5799
   Boretsky A, 2012, LASER SURG MED, V44, P603, DOI 10.1002/lsm.22070
   Brader HS, 2011, INVEST OPHTH VIS SCI, V52, P9218, DOI 10.1167/iovs.11-7493
   Curcio CA, 1998, INVEST OPHTH VIS SCI, V39, P1085
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   Duncker T, 2013, INVEST OPHTH VIS SCI, V54, P585, DOI 10.1167/iovs.12-11176
   Forte R, 2013, RETINA-J RET VIT DIS, V33, P482, DOI 10.1097/IAE.0b013e318276e11e
   Fujii GY, 2003, AM J OPHTHALMOL, V136, P1067, DOI 10.1016/S0002-9394(03)00663-9
   Gocho K, 2013, INVEST OPHTH VIS SCI, V54, P3673, DOI 10.1167/iovs.12-10672
   Gobel AP, 2011, OPHTHALMOLOGICA, V226, P182, DOI 10.1159/000330420
   Hofer H, 2001, OPT EXPRESS, V8, P631, DOI 10.1364/OE.8.000631
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Keilhauer CN, 2006, INVEST OPHTH VIS SCI, V47, P3556, DOI 10.1167/iovs.06-0122
   Kellner U, 2010, RETINA-J RET VIT DIS, V30, P6, DOI 10.1097/IAE.0b013e3181b8348b
   Kim SW, 2012, BRIT J OPHTHALMOL, V96, P350, DOI 10.1136/bjo.2011.204503
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Kulcsar C, 2013, IMAGING APPL OPTICS
   Landa G, 2010, OPHTHALMIC RES, V43, P92, DOI 10.1159/000247593
   Li KY, 2010, INVEST OPHTH VIS SCI, V51, P6858, DOI 10.1167/iovs.10-5499
   Liang JZ, 1997, J OPT SOC AM A, V14, P2884, DOI 10.1364/JOSAA.14.002884
   Pilotto E, 2013, BRIT J OPHTHALMOL, V97, P622, DOI 10.1136/bjophthalmol-2012-302633
   Pilotto E, 2011, BRIT J OPHTHALMOL, V95, P1140, DOI 10.1136/bjo.2010.187344
   Querques G, 2014, OPTOMETRY VISION SCI, V91, pE9, DOI 10.1097/OPX.0000000000000110
   Querques L, 2012, AM J OPHTHALMOL, V153, P1110, DOI 10.1016/j.ajo.2011.11.002
   Schmitz-Valckenberg S, 2008, AM J OPHTHALMOL, V146, P183, DOI 10.1016/j.ajo.2008.04.006
   Skondra D, 2012, SEMIN OPHTHALMOL, V27, P202, DOI 10.3109/08820538.2012.708806
   Spaide RF, 2011, RETINA-J RET VIT DIS, V31, P1609, DOI 10.1097/IAE.0b013e3182247535
   SUNNESS JS, 1995, AM J OPHTHALMOL, V119, P143, DOI 10.1016/S0002-9394(14)73866-8
   Toju R, 2012, AM J OPHTHALMOL, V153, P314, DOI 10.1016/j.ajo.2011.06.026
   Zhang K, 2011, P NATL ACAD SCI USA, V108, P6241, DOI 10.1073/pnas.1018987108
NR 32
TC 17
Z9 17
U1 0
U2 10
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD FEB
PY 2016
VL 36
IS 2
BP 247
EP 254
DI 10.1097/IAE.0000000000000692
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DC9AU
UT WOS:000369513500002
PM 26200512
DA 2022-11-30
ER

PT J
AU Jonas, JB
   Tao, Y
   Rensch, F
AF Jonas, Jost B.
   Tao, Yong
   Rensch, Florian
TI Bilateral Intravitreal Bevacizumab Injection for Exudative Age-Related
   Macular Degeneration: Effect of Baseline Visual Acuity
SO JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
LA English
DT Article
ID OCCULT CHOROIDAL NEOVASCULARIZATION; AVASTIN(R); TRIAMCINOLONE;
   TACHYPHYLAXIS; RANIBIZUMAB
AB Purposec To assess side differences in patients undergoing bilateral intravitreal bevacizumab injections as treatment of exudative age-related macular degeneration (AMD).
   Methods: The clinical interventional case series study included 48 patients (96 eyes) who consecutively and bilaterally received 3 intravitreal bevacizumab injections. The mean age was 76.5 +/- 7.5 years (range: 59-88 years). Follow-up was 6 months. Main outcome parameters were best-corrected visual acuity (BCVA) and measurements by optic coherence tomography. The eyes of the same patient were assigned to a study group 1 for the eye with the higher visual acuity at baseline, and study group 2 for the contralateral eye with the lower visual acuity at baseline.
   Results: The increase in BCVA was significantly (P = 0.02) greater in group 2 (0.07 +/- 0.25 logarithm of the minimum angle of resolution, LogMAR) than in group 1 (0.05 +/- 0.29 LogMAR). The height of a detached retinal pigment epithelium, the height of subretinal fluid, and the tissue thickness of the macula decreased significantly (P < 0.05) in group 2 during follow-up, whereas these parameters did not markedly change in the eyes of group 1 (P = 0.96, P = 0.38, and P = 0.07, respectively). The reduction in the height of a detached retinal pigment epithelium and in the height of subretinal fluid was significantly more pronounced in group 2 than in group 1 (P = 0.03, P = 0.04, respectively).
   Conclusions: After an initial set of 3 bilateral bevacizumab injections, patients with bilateral exudative AMD have a higher likelihood for an improvement in vision in the worse-seeing eye at baseline than in the better-seeing eye.
C1 [Jonas, Jost B.] Univ Heidelberg, Dept Ophthalmol, Med Fac Mannheim, Univ Augenklin, D-68167 Mannheim, Germany.
   [Tao, Yong] Peking Univ, Peoples Hosp, Dept Ophthalmol, Beijing 100871, Peoples R China.
C3 Ruprecht Karls University Heidelberg; University of Hamburg; University
   Medical Center Hamburg-Eppendorf; Peking University
RP Jonas, JB (通讯作者)，Univ Heidelberg, Dept Ophthalmol, Med Fac Mannheim, Univ Augenklin, Theodor Kutzer Ufer 1-3, D-68167 Mannheim, Germany.
EM jost.jonas@augen.ma.uni-heidelberg.de
FU German Academic Exchange Service (DAAD)
FX The work of Yong Tao was supported by K.C. Wong Fellowship from the
   German Academic Exchange Service (DAAD).
CR Algvere PV, 2008, ACTA OPHTHALMOL, V86, P482, DOI 10.1111/j.1600-0420.2007.01113.x
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bashshur ZF, 2006, AM J OPHTHALMOL, V142, P1, DOI 10.1016/j.ajo.2006.02.037
   Emerson MV, 2007, RETINA-J RET VIT DIS, V27, P439, DOI 10.1097/IAE.0b013e31804b3e15
   Forooghian F, 2009, RETINA-J RET VIT DIS, V29, P723, DOI 10.1097/IAE.0b013e3181a2c1c3
   Forte R, 2010, ACTA OPHTHALMOL, V88, pe305, DOI 10.1111/j.1755-3768.2010.02021.x
   Furino C, 2009, ACTA OPHTHALMOL, V87, P404, DOI 10.1111/j.1755-3768.2008.01262.x
   Goff MJ, 2007, RETINA-J RET VIT DIS, V27, P432, DOI 10.1097/IAE.0b013e318042b53f
   Jonas JB, 2004, BRIT J OPHTHALMOL, V88, P1557, DOI 10.1136/bjo.2003.039552
   Jonas JB, 2007, ACTA OPHTHALMOL SCAN, V85, P563, DOI 10.1111/j.1600-0420.2007.00891.x
   Krebs I, 2009, ACTA OPHTHALMOL, V87, P611, DOI 10.1111/j.1755-3768.2008.01312.x
   Leydolt C, 2010, ACTA OPHTHALMOL, V88, P594, DOI 10.1111/j.1755-3768.2008.01485.x
   MEKJAVIC PJ, 2009, ACTA OPHTHALMOL 1023
   Pedersen KB, 2009, ACTA OPHTHALMOL, V87, P714, DOI 10.1111/j.1755-3768.2008.01346.x
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Sadda SR, 2010, RETINA-J RET VIT DIS, V30, P1390, DOI 10.1097/IAE.0b013e3181e44599
   Schaal S, 2008, OPHTHALMOLOGY, V115, P2199, DOI 10.1016/j.ophtha.2008.07.007
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Yoon YH, 2009, ACTA OPHTHALMOL, V87, P685, DOI 10.1111/j.1755-3768.2008.01281.x
NR 22
TC 4
Z9 4
U1 0
U2 1
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1080-7683
J9 J OCUL PHARMACOL TH
JI J. Ocular Pharmacol. Ther.
PD AUG
PY 2011
VL 27
IS 4
BP 401
EP 405
DI 10.1089/jop.2011.0080
PG 5
WC Ophthalmology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Pharmacology & Pharmacy
GA 800TC
UT WOS:000293388900015
PM 21810019
DA 2022-11-30
ER

PT J
AU Figueroa, M
   Schocket, LS
   DuPont, J
   Metelitsina, TI
   Grunwald, JE
AF Figueroa, Mauricio
   Schocket, Lisa S.
   DuPont, Joan
   Metelitsina, Tatyana I.
   Grunwald, Juan E.
TI Long-term effect of laser treatment for dry age-related macular
   degeneration on choroidal hemodynamics
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID BLOOD-FLOW; GRID PHOTOCOAGULATION; DRUSEN REDUCTION; PROGNOSIS;
   ABNORMALITIES; MACULOPATHY; RISK
AB PURPOSE: To determine whether laser treatment applied according to the complications of age-related macular degeneration prevention trial (CAPT) has an effect on the choroidal circulation.
   DESIGN: Randomized controlled trial.
   METHODS: This study included 30 CAPT patients with bilateral drusen. Laser Doppler flowmetry was used to measure relative choroidal blood flow (Ch(flow)) in the fovea. Measurements were obtained through dilated pupils in both eyes of each patient before photocoagulation was applied in one eye. Measurements were repeated at three months (30 patients) and 28 months (23 patients).
   RESULTS: Average Ch(flow) at baseline, three months, and 28 months was 7.2 +/- 2.1 (+/- 1 SD), 7.3 +/- 2.5, and 6.8 +/- 2.7 arbitrary units (AU) in the control eyes and 6.6 +/- 1.6, 7.0 +/- 2.3, and 7.8 +/- 3.0 AU in the treated eyes. In comparison to control eyes, there was no significant change in Ch(flow) in the treated eyes at three months after treatment. At 28 months, however, there was a 5.6% drop in Ch(flow) in control eyes and an 18.2% increase in Ch(flow) in treated eyes from baseline. The average difference of 23.8% between the percentage changes in Ch(flow) observed in the control and treated eyes was statistically significant (paired two,tailed Student t test; P = .05).
   CONCLUSIONS: Our results suggest an increase in choroidal blood flow 28 months after laser treatment according to the CAPT protocol. This increase may play a role in the mechanism leading to the disappearance of drusen after photocoagulation. Whether removal of drusen after photocoagulation is beneficial to the patients is not known at this time.
C1 Univ Penn, Dept Ophthalmol, Scheie Eye Inst, Sch Med, Philadelphia, PA 19104 USA.
   Eye Consultants Maryland, Baltimore, MD USA.
C3 University of Pennsylvania
RP Grunwald, JE (通讯作者)，Univ Penn, Dept Ophthalmol, Scheie Eye Inst, Sch Med, 51 N 39th St, Philadelphia, PA 19104 USA.
EM juangrun@mail.rned.upenn.edu
FU NEI NIH HHS [EY 12769, 5P30 EY 01583] Funding Source: Medline; NATIONAL
   EYE INSTITUTE [R01EY012769, P30EY001583] Funding Source: NIH RePORTER
CR BRESSLER NM, 1994, RETINA-J RET VIT DIS, V14, P130, DOI 10.1097/00006982-199414020-00006
   BRESSLER SB, 1990, ARCH OPHTHALMOL-CHIC, V108, P1442, DOI 10.1001/archopht.1990.01070120090035
   Ciulla TA, 1999, AM J OPHTHALMOL, V128, P75, DOI 10.1016/S0002-9394(99)00061-6
   Ciulla TA, 2002, BRIT J OPHTHALMOL, V86, P209, DOI 10.1136/bjo.86.2.209
   Figueroa M, 2004, BRIT J OPHTHALMOL, V88, P792, DOI 10.1136/bjo.2003.033837
   FIGUEROA MS, 1994, RETINA-J RET VIT DIS, V14, P391, DOI 10.1097/00006982-199414050-00001
   Frennesson C, 1998, BRIT J OPHTHALMOL, V82, P1169, DOI 10.1136/bjo.82.10.1169
   FRIEDMAN E, 1989, OPHTHALMOLOGY, V96, P104
   FRIEDMAN E, 1995, OPHTHALMOLOGY, V102, P640, DOI 10.1016/S0161-6420(95)30974-8
   Grunwald JE, 1998, ARCH OPHTHALMOL-CHIC, V116, P150
   Grunwald JE, 1998, INVEST OPHTH VIS SCI, V39, P385
   Ho AC, 1999, OPHTHALMOLOGY, V106, P1367, DOI 10.1016/S0161-6420(99)00735-6
   HOLZ FG, 1994, OPHTHALMOLOGY, V101, P1522
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Little HL, 1997, OPHTHALMOLOGY, V104, P623, DOI 10.1016/S0161-6420(97)30261-9
   Olk RJ, 1999, OPHTHALMOLOGY, V106, P2082, DOI 10.1016/S0161-6420(99)90487-6
   Pauleikhoff D, 1999, ARCH OPHTHALMOL-CHIC, V117, P1353, DOI 10.1001/archopht.117.10.1353
   PAULEIKHOFF D, 1990, AM J OPHTHALMOL, V109, P211, DOI 10.1016/S0002-9394(14)75989-6
   RIVA CE, 1994, INVEST OPHTH VIS SCI, V35, P4273
   Rodanant N, 2002, AM J OPHTHALMOL, V134, P577, DOI 10.1016/S0002-9394(02)01691-4
   SMIDDY WE, 1984, OPHTHALMOLOGY, V91, P271
   Sternberg P, 2003, OPHTHALMOLOGY, V110, P971, DOI 10.1016/S0161-6420(03)00098-8
   Wang JJ, 2003, ARCH OPHTHALMOL-CHIC, V121, P658, DOI 10.1001/archopht.121.5.658
NR 23
TC 8
Z9 9
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD MAY
PY 2006
VL 141
IS 5
BP 863
EP 867
DI 10.1016/j.ajo.2005.11.049
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 043JW
UT WOS:000237598300009
PM 16527229
DA 2022-11-30
ER

PT J
AU Muether, PS
   Hermann, MM
   Viebahn, U
   Kirchhof, B
   Fauser, S
AF Muether, Philipp S.
   Hermann, Manuel M.
   Viebahn, Ulrike
   Kirchhof, Bernd
   Fauser, Sascha
TI Vascular Endothelial Growth Factor in Patients with Exudative
   Age-related Macular Degeneration Treated with Ranibizumab
SO OPHTHALMOLOGY
LA English
DT Article
ID AQUEOUS-HUMOR LEVELS; VITREOUS LEVELS; PHARMACOKINETICS; CYTOKINES
AB Objectives: To analyze the temporal correlations of vascular endothelial growth factor (VEGF) suppression, morphologic recurrence of choroidal neovascularization (CNV), and visual acuity loss in eyes with exudative age-related macular degeneration (AMD) treated with ranibizumab.
   Design: Nonrandomized, prospective, clinical study.
   Participants: Forty-seven eyes of 47 patients with exudative AMD undergoing intravitreal ranibizumab injections.
   Methods: Aqueous humor specimens were taken before each intravitreal ranibizumab injection. Visual acuity testing, spectral domain optical coherence tomography (SD-OCT), and fundoscopy were performed before each injection. Vascular endothelial growth factor A was measured by Luminex multiplex bead analysis (Luminex Inc., Austin, TX).
   Main Outcome Measures: Intraocular VEGF concentration, recurrence of CNV activity shown by SD-OCT, and vision loss.
   Results: Ranibizumab resulted in complete VEGF suppression within a mean period of 37.8 days (standard deviation [SD] +/- 4.8 days; range, 26-49 days). Recurrences of CNV activity as determined by SD-OCT occurred 93.7 days (SD +/- 69.9 days; range, 57-368 days) after the last ranibizumab treatment. The VEGF levels were never suppressed when a recurrence occurred. Functional recurrence (visual acuity) occurred 114.3 days (SD +/- 81.4 days; range, 57-398 days) after previous treatment. The VEGF levels did not differ significantly between baseline and recurrence (69.3 pg/ml vs. 74.14 pg/ml; 95% confidence interval, -18.87 to 9.12).
   Conclusions: A monthly intravitreal injection of 0.5 mg ranibizumab yields a durable VEGF inhibition. The recurrences of CNV as determined by SD-OCT are always preceded by a loss of intraocular VEGF suppression and usually followed by loss of visual acuity in the further course.
C1 [Muether, Philipp S.; Hermann, Manuel M.; Viebahn, Ulrike; Kirchhof, Bernd; Fauser, Sascha] Univ Cologne, Dept Vitreoretinal Surg, Ctr Ophthalmol, D-50924 Cologne, Germany.
C3 University of Cologne
RP Fauser, S (通讯作者)，Univ Cologne, Dept Vitreoretinal Surg, Ctr Ophthalmol, Kerpener Str 62, D-50924 Cologne, Germany.
EM sfauser@gmx.net
FU Koln Fortune Program (Faculty of Medicine, University of Cologne); Gilen
   Foundation; Nolting Foundation; Imhoff Foundation
FX Supported by the Koln Fortune Program (Faculty of Medicine, University
   of Cologne). Additional support provided by the Gilen, Nolting, and
   Imhoff Foundations.
CR Bakri SJ, 2007, OPHTHALMOLOGY, V114, P2179, DOI 10.1016/j.ophtha.2007.09.012
   Funatsu H, 2005, GRAEF ARCH CLIN EXP, V243, P3, DOI 10.1007/s00417-004-0950-7
   Funk M, 2009, OPHTHALMOLOGY, V116, P2393, DOI 10.1016/j.ophtha.2009.05.039
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   Gaudreault J, 2007, RETINA-J RET VIT DIS, V27, P1260, DOI 10.1097/IAE.0b013e318134eecd
   Hoerster R, 2011, BRIT J OPHTHALMOL, V95, P1424, DOI 10.1136/bjo.2010.201129
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Noma H, 2008, EYE, V22, P42, DOI 10.1038/sj.eye.6702498
   Ohr M, 2012, EXPERT OPIN PHARMACO, V13, P585, DOI 10.1517/14656566.2012.658368
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
NR 10
TC 53
Z9 54
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
J9 OPHTHALMOLOGY
JI Ophthalmology
PD OCT
PY 2012
VL 119
IS 10
BP 2082
EP 2086
DI 10.1016/j.ophtha.2012.07.041
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 030PF
UT WOS:000310581900022
PM 22920670
DA 2022-11-30
ER

PT J
AU Gliem, M
   Muller, PL
   Finger, RP
   McGuinness, MB
   Holz, FG
   Issa, PC
AF Gliem, Martin
   Mueller, Philipp L.
   Finger, Robert P.
   McGuinness, Myra B.
   Holz, Frank G.
   Issa, Peter Charbel
TI Quantitative Fundus Autofluorescence in Early and Intermediate
   Age-Related Macular Degeneration
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; GEOGRAPHIC ATROPHY; LIPOFUSCIN; RPE; DRUSEN;
   FLUORESCENCE; TOPOGRAPHY; DISEASE; LIGHT; MAPS
AB IMPORTANCE Increased lipofuscin accumulation is assumed to be an important factor in the pathogenesis of age-related macular degeneration (AMD), although direct evidence for this hypothesis is missing.
   OBJECTIVE To quantitatively investigate lipofuscin-associated fundus autofluorescence (AF) in patients with early and intermediate AMD.
   DESIGN, SETTING, AND PARTICIPANTS A prospective, single-center, case-control studywas conducted from August 1, 2014, to October 31, 2015, at a university referral center. Participants included 40 patients aged 65 years or younger and 108 individuals without eye disease serving as controls. All participants underwent quantitative fundus AF (qAF) imaging with a modified scanning laser ophthalmoscope equipped with an internal fluorescent reference. Mean qAF values of an 8-segment circular ring centered on the fovea (qAF(8)) were measured and compared between patients and controls. For subgroup analysis, drusen were categorized as soft drusen, cuticular drusen, and/or reticular pseudodrusen (RPD).
   MAIN OUTCOMES AND MEASURES The qAF(8) levels.
   RESULTS In the 40 patients with AMD, mean (SD) age was 54.8 (5.6) years, and 32 (80%) were women. None of the investigated patients had qAF(8) values above the 95% prediction interval (PI) of the 108 controls. In the soft drusen (28 [70%]) and cuticular drusen (8 [20%]) groups, qAF(8) levels within the 95% PI were noted in 22 patients (79%; 95% CI, 60% to 90%) and 7 patients (88%; 95% CI, 51% to 99%) respectively. The qAF(8) values in the RPD group (4 [10%]) were below the 95% PI in 3 patients (75%; 95% CI, 29% to 97%). Compared with the controls, statistical analysis revealed lower qAF(8) values in the overall AMD cohort after adjusting for age (difference, -19.9%[95% CI, -25.6% to -12.7%], P <.001) as well as in all subgroups (soft drusen, -17.1% [95% CI, -24.1% to -9.5%], P <.001; cuticular drusen, -19.6% [95% CI, -30.3% to -7.2%], P = .003; and RPD, -34.5%[95% CI, -47.1% to -21.3%]; P <.001).
   CONCLUSIONS AND RELEVANCE The qAF(8) measurements in this sample showed no increased lipofuscin-related fundus AF in patients with early and intermediate AMD. Lower qAF levels in certain subgroups may point to subnormal lipofuscin levels in the retinal pigment epithelium or, alternatively, limitations to detection of true retinal pigment epithelial lipofuscin content. The results of this study might expand the understanding of the pathogenesis of AMD and may have an effect on upcoming treatment trials that aim to modify lipofuscin accumulation.
C1 [Gliem, Martin; Mueller, Philipp L.; Finger, Robert P.; Holz, Frank G.; Issa, Peter Charbel] Univ Hosp Bonn, Dept Ophthalmol, Ernst Abbe Str 2, D-53127 Bonn, Germany.
   [Finger, Robert P.; McGuinness, Myra B.] Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Melbourne, Vic, Australia.
C3 University of Bonn; Centre for Eye Research Australia; Royal Victorian
   Eye & Ear Hospital; University of Melbourne
RP Issa, PC (通讯作者)，Univ Hosp Bonn, Dept Ophthalmol, Ernst Abbe Str 2, D-53127 Bonn, Germany.
EM peter.issa@ukb.uni-bonn.de
RI Müller, Philipp L./P-3350-2019; Issa, Peter Charbel/E-8935-2018; Issa,
   Peter Charbel/O-2580-2019; McGuinness, Myra/G-4900-2017
OI Issa, Peter Charbel/0000-0002-0351-6673; Issa, Peter
   Charbel/0000-0002-0351-6673; McGuinness, Myra/0000-0002-5422-040X;
   Finger, Robert P/0000-0003-4253-7597
FU ProRetina Deutschland; BONFOR research program of the University of
   Bonn; National Health and Medical Research Council Centre for Clinical
   Research Excellence [529923]
FX This work was supported by the ProRetina Deutschland, the BONFOR
   research program of the University of Bonn, and grant 529923 from the
   National Health and Medical Research Council Centre for Clinical
   Research Excellence. The Department of Ophthalmology, University of
   Bonn, receives imaging devices from Heidelberg Engineering; Centre for
   Eye Research Australia receives Operational Infrastructure Support from
   the Victorian government.
CR Ach T, 2015, INVEST OPHTH VIS SCI, V56
   Ach T, 2015, INVEST OPHTH VIS SCI, V56, P3242, DOI 10.1167/iovs.14-16274
   Ach T, 2014, INVEST OPHTH VIS SCI, V55, P4832, DOI 10.1167/iovs.14-14802
   BIRNBACH CD, 1994, OPHTHALMOLOGY, V101, P1211
   Boon CJF, 2013, PROG RETIN EYE RES, V37, P90, DOI 10.1016/j.preteyeres.2013.08.003
   Burke TR, 2014, INVEST OPHTH VIS SCI, V55, P2841, DOI 10.1167/iovs.13-13624
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P2327
   Delori FC, 2000, INVEST OPHTH VIS SCI, V41, P496
   Delori FC, 1998, DOC OPHTH P, V62, P37
   Delori FC, 2001, INVEST OPHTH VIS SCI, V42, P1855
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   Delori F, 2011, INVEST OPHTH VIS SCI, V52, P9379, DOI 10.1167/iovs.11-8319
   EAGLE RC, 1980, OPHTHALMOLOGY, V87, P1189
   FEENEY L, 1978, INVEST OPHTH VIS SCI, V17, P583
   FEENEYBURNS L, 1984, INVEST OPHTH VIS SCI, V25, P195
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   General Assembly of the World Medical Association, 2014, J Am Coll Dent, V81, P14
   Gliem M, 2015, JAMA OPHTHALMOL, V133, P581, DOI 10.1001/jamaophthalmol.2015.117
   Greenberg JP, 2013, INVEST OPHTH VIS SCI, V54, P5684, DOI 10.1167/iovs.13-12445
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   Holz FG, 1999, GRAEF ARCH CLIN EXP, V237, P145, DOI 10.1007/s004170050209
   Holz FG, 2014, J CLIN INVEST, V124, P1430, DOI 10.1172/JCI71029
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lois N, 2002, AM J OPHTHALMOL, V133, P341, DOI 10.1016/S0002-9394(01)01404-0
   Meyerle CB, 2007, RETINA-J RET VIT DIS, V27, P1101, DOI 10.1097/IAE.0b013e3181451617
   Muller PL, 2015, INVEST OPHTH VIS SCI, V56, P8179, DOI 10.1167/iovs.15-17629
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P1258, DOI 10.1167/iovs.11-8907
   Smith RT, 2009, AM J OPHTHALMOL, V148, P733, DOI 10.1016/j.ajo.2009.06.028
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1441, DOI 10.1097/IAE.0b013e3181ee5ce8
   Sparrow JR, 2014, J CLIN MED, V3, P1302, DOI 10.3390/jcm3041302
   Sparrow JR, 2012, PROG RETIN EYE RES, V31, P121, DOI 10.1016/j.preteyeres.2011.12.001
   Sparrow JR, 2000, INVEST OPHTH VIS SCI, V41, P1981
   vonRuckmann A, 1997, INVEST OPHTH VIS SCI, V38, P478
   WING GL, 1978, INVEST OPHTH VIS SCI, V17, P601
   Zhou J, 2009, INVEST OPHTH VIS SCI, V50, P1392, DOI 10.1167/iovs.08-2868
NR 36
TC 78
Z9 78
U1 0
U2 2
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD JUL
PY 2016
VL 134
IS 7
BP 817
EP 824
DI 10.1001/jamaophthalmol.2016.1475
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DR0KA
UT WOS:000379595200021
PM 27253610
OA Bronze
DA 2022-11-30
ER

PT J
AU Martin, DF
   Maguire, MG
   Fine, SL
   Ying, GS
   Jaffe, GJ
   Grunwald, JE
   Toth, C
   Redford, M
   Ferris, FL
AF Martin, Daniel F.
   Maguire, Maureen G.
   Fine, Stuart L.
   Ying, Gui-shuang
   Jaffe, Glenn J.
   Grunwald, Juan E.
   Toth, Cynthia
   Redford, Maryann
   Ferris, Frederick L., III
CA Comparison Age-related Macular
TI Ranibizumab and Bevacizumab for Treatment of Neovascular Age-Related
   Macular Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
AB Objective: To describe effects of ranibizumab and bevacizumab when administered monthly or as needed for 2 years and to describe the impact of switching to as-needed treatment after 1 year of monthly treatment.
   Design: Multicenter, randomized clinical trial.
   Participants: Patients (n = 1107) who were followed up during year 2 among 1185 patients with neovascular age-related macular degeneration who were enrolled in the clinical trial.
   Interventions: At enrollment, patients were assigned to 4 treatment groups defined by drug (ranibizumab or bevacizumab) and dosing regimen (monthly or as needed). At 1 year, patients initially assigned to monthly treatment were reassigned randomly to monthly or as-needed treatment, without changing the drug assignment.
   Main Outcome Measures: Mean change in visual acuity.
   Results: Among patients following the same regimen for 2 years, mean gain in visual acuity was similar for both drugs (bevacizumab-ranibizumab difference, -1.4 letters; 95% confidence interval [CI], -3.7 to 0.8; P = 0.21). Mean gain was greater for monthly than for as-needed treatment (difference, -2.4 letters; 95% CI, -4.8 to -0.1; P = 0.046). The proportion without fluid ranged from 13.9% in the bevacizumab-as-needed group to 45.5% in the ranibizumab monthly group (drug, P = 0.0003; regimen, P < 0.0001). Switching from monthly to as-needed treatment resulted in greater mean decrease in vision during year 2 (-2.2 letters; P = 0.03) and a lower proportion without fluid (-19%; P < 0.0001). Rates of death and arteriothrombotic events were similar for both drugs (P > 0.60). The proportion of patients with 1 or more systemic serious adverse events was higher with bevacizumab than ranibizumab (39.9% vs. 31.7%; adjusted risk ratio, 1.30; 95% CI, 1.07-1.57; P = 0.009). Most of the excess events have not been associated previously with systemic therapy targeting vascular endothelial growth factor (VEGF).
   Conclusions: Ranibizumab and bevacizumab had similar effects on visual acuity over a 2-year period. Treatment as needed resulted in less gain in visual acuity, whether instituted at enrollment or after 1 year of monthly treatment. There were no differences between drugs in rates of death or arteriothrombotic events. The interpretation of the persistence of higher rates of serious adverse events with bevacizumab is uncertain because of the lack of specificity to conditions associated with inhibition of VEGF.
   Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references. Ophthalmology 2012;xx:xxx (C) 2012 by the American Academy of Ophthalmology.
C1 [Maguire, Maureen G.; Ying, Gui-shuang; Grunwald, Juan E.] Univ Penn, Dept Ophthalmol, Philadelphia, PA 19104 USA.
   [Martin, Daniel F.] Cleveland Clin, Cole Eye Inst, Cleveland, OH 44106 USA.
   [Fine, Stuart L.] Univ Colorado, Dept Ophthalmol, Denver, CO 80202 USA.
   [Jaffe, Glenn J.; Toth, Cynthia] Duke Univ, Dept Ophthalmol, Durham, NC USA.
   [Redford, Maryann; Ferris, Frederick L., III] NEI, NIH, Bethesda, MD 20892 USA.
C3 University of Pennsylvania; Cleveland Clinic Foundation; University of
   Colorado System; University of Colorado Denver; Duke University;
   National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI)
RP Maguire, MG (通讯作者)，Univ Penn, Dept Ophthalmol, 3535 Market St,Suite 700, Philadelphia, PA 19104 USA.
EM maguirem@mail.med.upenn.edu
RI Toth, Cynthia/L-5534-2019; Ciulla, Thomas/AAA-1299-2020
OI Toth, Cynthia/0000-0002-2324-0854; Ciulla, Thomas/0000-0001-5557-6777;
   Ferris, Frederick/0000-0002-4933-0639; Vavvas,
   Demetrios/0000-0002-8622-6478; Pistilli, Maxwell/0000-0002-4266-4150;
   Losordo, Douglas/0000-0002-6857-7506; Folk, James/0000-0002-6271-2906
FU Regeneron; Genentech; Bioptigen; Physical Sciences Incorporated;
   National Eye Institute, National Institutes of Health, Department of
   Health and Human Services [U10 EY017823, U10 EY017825, U10 EY017826, U10
   EY017828]; NATIONAL EYE INSTITUTE [U10EY017823, U10EY017825,
   U10EY017826, ZIAEY000485, U10EY017828] Funding Source: NIH RePORTER
FX Glenn J. Jaffe - Consultant - Heidelberg Engineering; Financial support
   - Regeneron; Cynthia Toth - Consultant - Physical Sciences Incorporated;
   Financial support - Genentech, Bioptigen, and Physical Sciences
   Incorporated; Patents pending - OCT analysis technology related to
   analysis for age-related macular degeneration; Royalties - Alcon
   Laboratories for ophthalmic surgical technologies; Supported by
   cooperative agreements U10 EY017823, U10 EY017825, U10 EY017826, and U10
   EY017828 from the National Eye Institute, National Institutes of Health,
   Department of Health and Human Services. The funding organization
   participated in the design and conduct of the study, data analysis and
   interpretation, and review of the manuscript.
CR ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Brechner RJ, 2011, AM J OPHTHALMOL, V151, P887, DOI 10.1016/j.ajo.2010.11.017
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chen HX, 2009, NAT REV CLIN ONCOL, V6, P465, DOI 10.1038/nrclinonc.2009.94
   COX DR, 1972, J R STAT SOC B, V34, P187
   Fish G, 2003, OPHTHALMOLOGY, V110, P979, DOI 10.1016/S0161-6420(03)00085-X
   HAWKINS BS, 1993, ARCH OPHTHALMOL-CHIC, V111, P1200
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Nalluri SR, 2008, JAMA-J AM MED ASSOC, V300, P2277, DOI 10.1001/jama.2008.656
   Office of the Inspector General Department of Health and Human Services, 2011, REV MED B
   ROSENBAUM PR, 1983, BIOMETRIKA, V70, P41, DOI 10.1093/biomet/70.1.41
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Uday J, 1987, RESISTANCES REVOLUTI, P15
   ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248
NR 16
TC 1288
Z9 1321
U1 6
U2 106
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JUL
PY 2012
VL 119
IS 7
DI 10.1016/j.ophtha.2012.03.053
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 968UQ
UT WOS:000306011000021
PM 22555112
OA Green Accepted
HC Y
HP N
DA 2022-11-30
ER

PT J
AU Fletcher, EL
AF Fletcher, Erica L.
TI Contribution of microglia and monocytes to the development and
   progression of age related macular degeneration
SO OPHTHALMIC AND PHYSIOLOGICAL OPTICS
LA English
DT Review
DE age; age related macular degeneration; microglia; photoreceptor; retinal
   degeneration
ID P2X7 RECEPTOR; RETINAL MICROGLIA; PHOTORECEPTOR DEGENERATION; SUBRETINAL
   INFLAMMATION; CIRCULATING MONOCYTES; INNATE PHAGOCYTOSIS; SCAVENGER
   RECEPTOR; P2X(7) RECEPTORS; APOPTOTIC CELLS; MOUSE MODEL
AB Purpose Age related macular degeneration (AMD) is the leading cause of irreversible vision loss in industrialised nations. Based on genetics, as well as proteome analysis of drusen, the role the innate immune system in the development and/or progression of the disease is well established. Mononuclear phagocytes, such as microglia and monocytes, play critical roles in innate immunity. Here, the role of retinal microglia in mediating normal retinal function, and how these cells change with age is discussed, so as to understand their role in the development and progression of AMD.
   Recent findings It is now known that microglia dynamically survey the neural environment, responding rapidly to even the most subtle neural injury. The dynamic and phagocytic roles of microglia can change with age contributing to alteration in the response of these cells to damage with age. Accumulation of innate immune cells in the subretinal space is a hallmark feature of the development of AMD, reflecting either an increase in migration of monocytes into the retina, or a failure of immune cell elimination from the retina. Furthermore, changes in phagocytic ability of immune cells could contribute to the accumulation of drusen deposits in the posterior eye.
   An overview of how retinal microglia maintain retinal homeostasis under normal conditions is provided, and then how they contribute to each stage of AMD. In addition, circulating monocytes are altered in those with AMD, contributing to the overall inflammatory state. Understanding the role of cells of the innate immune system in AMD may uncover novel therapeutic targets with which to reduce either the development or progression of disease.
C1 [Fletcher, Erica L.] Univ Melbourne, Dept Anat & Neurosci, Parkville, Vic, Australia.
C3 University of Melbourne
RP Fletcher, EL (通讯作者)，Univ Melbourne, Dept Anat & Neurosci, Parkville, Vic, Australia.
EM elf@unimelb.edu.au
RI Fletcher, Erica/E-6364-2012
OI Fletcher, Erica/0000-0001-9412-9523
FU National Health and Medical Research Council of Australia; Macular
   Disease Foundation of Australia
FX National Health and Medical Research Council of Australia, Macular
   Disease Foundation of Australia.
CR Bjerregaard T, 2019, BMJ OPEN OPHTHALMOL, V4, DOI 10.1136/bmjophth-2019-000307
   Calippe B, 2017, IMMUNITY, V46, P261, DOI 10.1016/j.immuni.2017.01.006
   Cardona AE, 2006, NAT NEUROSCI, V9, P917, DOI 10.1038/nn1715
   Chen M, 2016, CURR MOL MED, V16, P412, DOI 10.2174/1566524016666160324130031
   Chinnery HR, 2012, NEUROBIOL AGING, V33, P1769, DOI 10.1016/j.neurobiolaging.2011.03.010
   Christenbury JG, 2013, OPHTHALMOLOGY, V120, P1038, DOI 10.1016/j.ophtha.2012.10.018
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Copland DA, 2018, INVEST OPHTH VIS SCI, V59, pAMD83, DOI 10.1167/iovs.18-23893
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Damani MR, 2011, AGING CELL, V10, P263, DOI 10.1111/j.1474-9726.2010.00660.x
   Davalos D, 2005, NAT NEUROSCI, V8, P752, DOI 10.1038/nn1472
   Downie LE, 2008, GLIA, V56, P1076, DOI 10.1002/glia.20680
   Downie LE, 2007, J COMP NEUROL, V504, P404, DOI 10.1002/cne.21449
   Downie LE, 2010, J COMP NEUROL, V518, P41, DOI 10.1002/cne.22205
   Eandi CM, 2016, ELIFE, V5, DOI 10.7554/eLife.16490
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fiala M, 2005, J ALZHEIMERS DIS, V7, P221, DOI 10.3233/jad-2005-7304
   Fletcher EL, 2019, DRUG DISCOV TODAY, V24, P1598, DOI 10.1016/j.drudis.2019.03.029
   Fontainhas AM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015973
   Grunin M, 2016, SCI REP-UK, V6, DOI 10.1038/srep29046
   Gu BJ, 2016, ACTA NEUROPATHOL, V132, P377, DOI 10.1007/s00401-016-1596-3
   Gu BJ, 2013, FASEB J, V27, P1479, DOI 10.1096/fj.12-215368
   Gu BJ, 2011, J IMMUNOL, V187, P2365, DOI 10.4049/jimmunol.1101178
   Gu BJ, 2010, BLOOD, V115, P1621, DOI 10.1182/blood-2009-11-251744
   Guillonneau X, 2017, PROG RETIN EYE RES, V61, P98, DOI 10.1016/j.preteyeres.2017.06.002
   Gulbransen BD, 2012, NAT MED, V18, P600, DOI 10.1038/nm.2679
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hanisch UK, 2007, NAT NEUROSCI, V10, P1387, DOI 10.1038/nn1997
   Harrison JK, 1998, P NATL ACAD SCI USA, V95, P10896, DOI 10.1073/pnas.95.18.10896
   Ho T, 2016, J OCUL PHARMACOL TH, V32, P509, DOI 10.1089/jop.2015.0158
   Jobling AI, 2015, FASEB J, V29, P696, DOI 10.1096/fj.14-262444
   JOBLING AI, 2018, INVEST OPHTH VIS SCI, V59
   Jobling AI, 2018, J NEUROSCI, V38, P4708, DOI 10.1523/JNEUROSCI.2368-17.2018
   Kaczmarek-Hajek K, 2018, ELIFE, V7, DOI 10.7554/eLife.36217
   Lechner J, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0820-y
   Lee JE, 2008, INVEST OPHTH VIS SCI, V49, P4169, DOI 10.1167/iovs.08-2076
   Lehrman EK, 2018, NEURON, V100, P120, DOI 10.1016/j.neuron.2018.09.017
   Levy O, 2015, J NEUROSCI, V35, P13568, DOI 10.1523/JNEUROSCI.2468-15.2015
   Levy O, 2015, EMBO MOL MED, V7, P211, DOI 10.15252/emmm.201404524
   Liang KJ, 2009, INVEST OPHTH VIS SCI, V50, P4444, DOI 10.1167/iovs.08-3357
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Litwinska Z, 2019, FRONT AGING NEUROSCI, V11, DOI 10.3389/fnagi.2019.00286
   Ma WX, 2013, NEUROBIOL AGING, V34, P2310, DOI 10.1016/j.neurobiolaging.2013.03.022
   Mathis T, 2017, AGING CELL, V16, P173, DOI 10.1111/acel.12540
   Miller EB, 2019, P NATL ACAD SCI USA, V116, P16603, DOI 10.1073/pnas.1903336116
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Nassisi M, 2018, INVEST OPHTH VIS SCI, V59, P3431, DOI 10.1167/iovs.18-24143
   Natoli R, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01666
   Nielsen MK, 2019, CLIN EXP OPHTHALMOL, V47, P69, DOI 10.1111/ceo.13362
   Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647
   O'Koren EG, 2019, IMMUNITY, V50, P723, DOI 10.1016/j.immuni.2019.02.007
   Opie NL, 2012, INVEST OPHTH VIS SCI, V53, P7802, DOI 10.1167/iovs.12-10600
   Phipps JA, 2018, INVEST OPHTH VIS SCI, V59, P487, DOI 10.1167/iovs.17-22416
   Puthussery T, 2004, J COMP NEUROL, V472, P13, DOI 10.1002/cne.20045
   Puthussery T, 2006, EUR J NEUROSCI, V24, P7, DOI 10.1111/j.1460-9568.2006.04895.x
   Ronning KE, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-41141-0
   Rutar M, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-221
   Schafer DP, 2012, NEURON, V74, P691, DOI 10.1016/j.neuron.2012.03.026
   Sennlaub F, 2013, EMBO MOL MED, V5, P1775, DOI 10.1002/emmm.201302692
   Silverman SM, 2019, J EXP MED, V216, P1925, DOI 10.1084/jem.20190009
   Singaravelu J, 2017, BRAIN STRUCT FUNCT, V222, P2759, DOI 10.1007/s00429-017-1370-x
   Singh A, 2013, OPHTHALMOLOGY, V120, P1029, DOI 10.1016/j.ophtha.2012.11.002
   Stein-Streilein J, 2013, INT REV IMMUNOL, V32, P42, DOI 10.3109/08830185.2012.740535
   Stevens B, 2007, CELL, V131, P1164, DOI 10.1016/j.cell.2007.10.036
   Stevens B, 2018, DEV NEUROBIOL, V78, P559, DOI 10.1002/dneu.22594
   Subhi Y, 2019, IMMUN AGEING, V16, DOI 10.1186/s12979-019-0160-0
   Subhi Y, 2018, CLIN EXP OPHTHALMOL, V46, P661, DOI 10.1111/ceo.13152
   Subhi Y, 2017, ACTA OPHTHALMOL, V95, P472, DOI 10.1111/aos.13330
   Toomey CB, 2015, P NATL ACAD SCI USA, V112, pE3040, DOI 10.1073/pnas.1424391112
   Tremblay ME, 2019, MOL NEURODEGENER, V14, DOI 10.1186/s13024-019-0314-8
   Tremblay ME, 2011, J NEUROSCI, V31, P16064, DOI 10.1523/JNEUROSCI.4158-11.2011
   Vessey KA, 2011, J COMP NEUROL, V519, P506, DOI 10.1002/cne.22530
   Vessey KA, 2017, AM J PATHOL, V187, P1670, DOI 10.1016/j.ajpath.2017.04.016
   Vessey KA, 2015, INVEST OPHTH VIS SCI, V56, P1238, DOI 10.1167/iovs.14-15334
   Vessey KA, 2012, INVEST OPHTH VIS SCI, V53, P7833, DOI 10.1167/iovs.12-10650
   Vessey KA, 2012, ADV EXP MED BIOL, V723, P813, DOI 10.1007/978-1-4614-0631-0_104
   Wang X, 2016, J NEUROSCI, V36, P2827, DOI 10.1523/JNEUROSCI.3575-15.2016
   Wiley JS, 2011, TISSUE ANTIGENS, V78, P321, DOI 10.1111/j.1399-0039.2011.01780.x
   Wiley JS, 2012, PURINERG SIGNAL, V8, P579, DOI 10.1007/s11302-012-9308-5
   Wong KL, 2011, BLOOD, V118, pE15, DOI 10.1182/blood-2010-12-326355
   Yang LP, 2007, MOL VIS, V13, P1073
   Zabel MK, 2016, GLIA, V64, P1479, DOI 10.1002/glia.23016
   Zhao L, 2015, EMBO MOL MED, V7, P1179, DOI 10.15252/emmm.201505298
NR 84
TC 15
Z9 15
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0275-5408
EI 1475-1313
J9 OPHTHAL PHYSL OPT
JI Ophthalmic Physiol. Opt.
PD MAR
PY 2020
VL 40
IS 2
SI SI
BP 128
EP 139
DI 10.1111/opo.12671
EA FEB 2020
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA KW1KZ
UT WOS:000510699100001
PM 32017190
OA Green Published
DA 2022-11-30
ER

PT J
AU Taylor, DJ
   Edwards, LA
   Binns, AM
   Crabb, DP
AF Taylor, Deanna J.
   Edwards, Laura A.
   Binns, Alison M.
   Crabb, David P.
TI Seeing it differently: self-reported description of vision loss in dry
   age-related macular degeneration
SO OPHTHALMIC AND PHYSIOLOGICAL OPTICS
LA English
DT Article
DE geographic atrophy; low vision; macular degeneration; scotoma
ID AWARENESS; HEALTH; AMD; EYE; CLASSIFICATION; KNOWLEDGE; GLAUCOMA;
   DISEASE; ACUITY; STATE
AB PurposeA realistic description of visual symptoms associated with dry age-related macular degeneration (AMD) is important for raising awareness of the condition and educating patients. This study aimed to develop a set of descriptors for dry AMD and examine the realism of images currently and frequently used to show visual symptoms of the condition.
   MethodsVolunteers with dry AMD with a range of disease severity were given an eye examination and were asked to describe visual symptoms of their condition in a conversational interview. Participants were also asked to comment on a photograph typically used to portray the visual symptoms of AMD. Interviews were audio recorded, transcribed and subjected to content analysis.
   ResultsTwenty-nine participants were interviewed. Median (interquartile range [IQR]) age was 75 (70, 79) years. Median (IQR) binocular visual acuity (VA) and Pelli-Robson contrast sensitivity (CS) was 0.2 (0.18, 0.36) logMAR and 1.65 (1.50, 1.95) log CS respectively. Three, 17 and nine patients had early, intermediate and late (geographic atrophy, GA) AMD, respectively. The most frequently reported descriptor group was blur (n=13) followed by missing (n=10) and distortion (n=7). We chose the most popular image used to portray the visual symptoms of dry AMD based on an internet search and showed this to 21 participants. Sixteen participants (76% [95% confidence interval 53-92%]), including three out of the seven people with geographic atrophy, unequivocally rejected the realism of the image.
   ConclusionsPeople with dry AMD use a wide range of descriptors for their visual experience. Visual symptoms of dry AMD as portrayed by commonly shown images were not the experience of most people in this study.
C1 [Taylor, Deanna J.; Edwards, Laura A.; Binns, Alison M.; Crabb, David P.] City Univ London, Sch Hlth Sci, Div Optometry & Visual Sci, London, England.
C3 City University London
RP Crabb, DP (通讯作者)，City Univ London, Sch Hlth Sci, Div Optometry & Visual Sci, London, England.
EM David.Crabb.1@city.ac.uk
RI Edwards, Laura/AAO-7792-2020
OI Taylor, Deanna/0000-0001-8261-5225; Crabb, David/0000-0001-8754-3902;
   Binns, Alison/0000-0001-8621-498X
FU Roche Products Ltd UK
FX This study was funded as part of an unrestricted investigator initiated
   research grant from Roche Products Ltd UK. The authors thank the Macular
   Society for their invaluable help with participant recruitment.
CR Allen L, 2000, HOLE MY VISION ARTIS
   Anstis S, 1998, PERCEPTION, V27, P817, DOI 10.1068/p270817
   Brown Melissa M., 2001, International Ophthalmology, V24, P123, DOI 10.1023/A:1021171000838
   Butt T, 2015, BRIT J OPHTHALMOL, V99, P540, DOI 10.1136/bjophthalmol-2014-305802
   Chen YL, 2009, OPT EXPRESS, V17, P4046, DOI 10.1364/OE.17.004046
   CHYLACK LT, 1993, ARCH OPHTHALMOL-CHIC, V111, P831, DOI 10.1001/archopht.1993.01090060119035
   Cimarolli VR, 2012, EDUC GERONTOL, V38, P530, DOI 10.1080/03601277.2011.595286
   Crabb DP, 2013, OPHTHALMOLOGY, V120, P1120, DOI 10.1016/j.ophtha.2012.11.043
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fletcher Donald C, 2012, Optom Vis Sci, V89, P1395, DOI 10.1097/OPX.0b013e318264cc77
   FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6
   Gibson DM, 2012, AM J PREV MED, V43, P48, DOI 10.1016/j.amepre.2012.02.028
   Heraghty J, 2012, AM J PUBLIC HEALTH, V102, P1655, DOI 10.2105/AJPH.2012.300657
   Hirneiss C, 2014, CLIN OPHTHALMOL, V8, P1703, DOI 10.2147/OPTH.S64200
   Hu CX, 2014, AM J MED SCI, V348, P403, DOI 10.1097/MAJ.0000000000000319
   Huang OS, 2013, OPHTHAL EPIDEMIOL, V20, P52, DOI 10.3109/09286586.2012.751429
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Marmor DJ, 2010, ARCH OPHTHALMOL-CHIC, V128, P117, DOI 10.1001/archophthalmol.2009.366
   Marsiglia M, 2013, INVEST OPHTH VIS SCI, V54, P7362, DOI 10.1167/iovs.12-11073
   McKeague C, 2014, OPTOMETRY VISION SCI, V91, P916, DOI 10.1097/OPX.0000000000000318
   National Eye Institute, EYE DIS SIM
   Rabin R, 2001, ANN MED, V33, P337, DOI 10.3109/07853890109002087
   Rubin GS, 2000, INVEST OPHTH VIS SCI, V41, P3327
   Sanjay S, 2014, OPHTHAL EPIDEMIOL, V21, P230, DOI 10.3109/09286586.2014.929708
   Schuchard RA, 1999, J REHABIL RES DEV, V36, P294
   Scott AW, 2016, JAMA OPHTHALMOL, V134, P1111, DOI 10.1001/jamaophthalmol.2016.2627
   SPERDUTO RD, 1983, JAMA-J AM MED ASSOC, V250, P2506, DOI 10.1001/jama.250.18.2506
   Taylor DJ, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-011504
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 29
TC 15
Z9 15
U1 1
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0275-5408
EI 1475-1313
J9 OPHTHAL PHYSL OPT
JI Ophthalmic Physiol. Opt.
PD JAN
PY 2018
VL 38
IS 1
BP 98
EP 105
DI 10.1111/opo.12419
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA FQ7PM
UT WOS:000418554600010
PM 29168192
OA hybrid, Green Accepted
DA 2022-11-30
ER

PT J
AU Uehara, H
   Mamalis, C
   McFadden, M
   Taggart, M
   Stagg, B
   Passi, S
   Earle, P
   Chakravarthy, U
   Hogg, RE
   Ambati, BK
AF Uehara, Hironori
   Mamalis, Christina
   McFadden, Molly
   Taggart, Michael
   Stagg, Brian
   Passi, Samuel
   Earle, Phillip
   Chakravarthy, Usha
   Hogg, Ruth E.
   Ambati, Balamurali K.
TI The Reduction of Serum Soluble Flt-1 in Patients With Neovascular
   Age-Related Macular Degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; C-REACTIVE PROTEIN; ERYTHROCYTE
   SEDIMENTATION-RATE; FACTOR-H POLYMORPHISM; CHOROIDAL NEOVASCULARIZATION;
   CARDIOVASCULAR-DISEASE; GRADING SYSTEM; UNITED-STATES; RISK-FACTORS;
   RANIBIZUMAB
AB center dot PURPOSE: To evaluate serum soluble Flt-1 (sFlt-1) in age-related macular degeneration (AMD) patients.
   center dot DESIGN: Case-control study.
   center dot METHODS: Study involved 56 non-AMD participants, 53 early AMD patients, and 97 neovascular AMD patients from Belfast in Northern Ireland. Serum samples were collected from each patient. Serum sFlt-1 was measured by human sVEGFR1/sFlt-1 ELISA kit. The results were analyzed by Excel and SPSS.
   center dot RESULTS: Serum sFlt-1 concentration of non-AMD, early AMD, and neovascular AMD were 90.8 +/- 2.9 pg/mL (+/- standard error of the mean), 88.2 +/- 2.6 pg/mL, and 79.9 +/- 2.2 pg/mL. sFlt-1 from neovascular AMD patients was significantly decreased compared to non-AMD and early AMD patients (ANOVA, P < .01). For each 10-point increase in sFlt-1, the odds for having neovascular AMD compared with non-AMD and neovascular AMD decrease by 27.8%, odds ratio (OR) = 0.722 (95% confidence interval [CI]: 0.588-0.888, P = .002) and 27.0%, OR = 0.730 (95% CI: 0.594-0.898, P = .003), respectively. In patients over 73 years of age, serum sFlt-1 <80 pg/mL was associated with a > 6-fold higher risk of neovascular AMD.
   center dot CONCLUSIONS: Reduced serum sFlt-1 differentiates those patients with neovascular AMD from both early AMD and non-AMD participants. In those aged over 73, serum sFlt-1 <80 pg/mL seems to indicate a particularly high risk of neovascular AMD. Our results indicate serum sFlt-1 could be a biomarker for development of neovascular AMD. (C) 2015 by Elsevier Inc. All rights reserved.
C1 [Uehara, Hironori; Mamalis, Christina; Taggart, Michael; Stagg, Brian; Passi, Samuel; Ambati, Balamurali K.] Univ Utah, John A Moran Eye Ctr, Salt Lake City, UT 84132 USA.
   [McFadden, Molly] Univ Utah, Div Epidemiol, Salt Lake City, UT 84132 USA.
   [Earle, Phillip; Chakravarthy, Usha; Hogg, Ruth E.] Queens Univ Belfast, Ctr Med Expt, Belfast, Antrim, North Ireland.
C3 Utah System of Higher Education; University of Utah; Utah System of
   Higher Education; University of Utah; Queens University Belfast
RP Ambati, BK (通讯作者)，Univ Utah, 65 Mario Capecchi Dr, Salt Lake City, UT 84132 USA.
EM Bala.ambati@utah.edu
RI Hogg, Ruth E./ABC-9602-2020
OI Hogg, Ruth E./0000-0001-9413-2669; Stagg, Brian/0000-0003-4023-1885;
   Chakravarthy, Usha/0000-0002-2606-3734
FU Queen's University Belfast, Belfast, Ireland; Bausch and Lomb,
   Rochester, New York; Fight for Sight Grant, New York, New York;
   Novartis; Bayer, Leverkusen, Germany; NEI/NIH, Bethesda, Maryland; Dept
   of Veterans Affairs, Washington, DC; NIH Bethesda, Maryland
   [R01EY0179500]; Fight for Sight, CVS, New York, New York [R2800];
   Research to Prevent Blindness, Inc, New York, New York; University of
   Utah Study Deign and Biostatistics Center; National Center for Research
   Resources and the National Center for Advancing Translational Sciences,
   National Institutes Of Health, Bethesda Maryland [8UL1TR000105];
   NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000105,
   UL1TR001067] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH
   RESOURCES [UL1RR025764] Funding Source: NIH RePORTER; NATIONAL EYE
   INSTITUTE [R01EY017950, R01EY017182] Funding Source: NIH RePORTER;
   NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T35HL007744] Funding Source:
   NIH RePORTER; Fight for Sight [1376] Funding Source: researchfish
FX Usha Chakravarthy has a grant from the Queen's University Belfast,
   Belfast, Ireland, and has received funding from Bausch and Lomb,
   Rochester, New York (speaker fees for presentations at various meetings
   and travel support to meetings for the study of other purposes); Ruth E.
   Hogg has a Fight for Sight Grant, New York, New York; serves on an
   advisory board for Novartis, Basel Switzerland; and has funding from
   Novartis and from Bayer, Leverkusen, Germany, for the grading of retinal
   images; Balamurali K. Ambati has grants or grants pending from the
   NEI/NIH, Bethesda, Maryland and the Dept of Veterans Affairs,
   Washington, DC; is employed at the University of Utah, Salt Lake City,
   Utah in other departments; is an expert witness for CCLB Law, Atlanta,
   Georgia; and has patents filed with iVeena, LLC, Salt Lake City, Utah.
   This study was supported by NIH R01EY0179500, Bethesda, Maryland; Fight
   for Sight grant number R2800 CVS, New York, New York; and in part by an
   unrestricted grant from Research to Prevent Blindness, Inc, New York,
   New York, to the Department of Ophthalmology and Visual Sciences,
   University of Utah. This investigation was supported by the University
   of Utah Study Deign and Biostatistics Center, with funding in part from
   the National Center for Research Resources and the National Center for
   Advancing Translational Sciences, National Institutes Of Health,
   Bethesda Maryland, through Grant 8UL1TR000105 (formerly UL1RR025764).
CR Ambati BK, 2006, NATURE, V443, P993, DOI 10.1038/nature05249
   Anand A, 2013, OXID MED CELL LONGEV, V2013, DOI DOI 10.1155/2013/365046
   Belgore FM, 2000, BRIT J BIOMED SCI, V57, P207
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Carneiro AM, 2012, ACTA OPHTHALMOL, V90, pE25, DOI 10.1111/j.1755-3768.2011.02240.x
   Chew EY, 2014, OPHTHALMOLOGY, V121, P535, DOI 10.1016/j.ophtha.2013.10.027
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ersoy L, 2014, INVEST OPHTH VIS SCI, V55, P1842, DOI 10.1167/iovs.13-13420
   Fang AM, 2009, MOL VIS, V15, P2710
   Francis Peter James, 2011, Trans Am Ophthalmol Soc, V109, P115
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Ghosh S, 2013, NEPAL J OPHTHALMOL, V5, P195, DOI 10.3126/nepjoph.v5i2.8728
   Gu XY, 2014, CURR EYE RES, V39, P518, DOI 10.3109/02713683.2013.848899
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hermann MM, 2014, OPHTHALMOLOGY, V121, P905, DOI 10.1016/j.ophtha.2013.10.047
   Hogg RE, 2008, OPHTHALMOLOGY, V115, P1046, DOI 10.1016/j.ophtha.2007.07.031
   Hong T, 2011, SURV OPHTHALMOL, V56, P184, DOI 10.1016/j.survophthal.2010.08.007
   Huang C, 2013, MOL VIS, V19, P1211
   Kermani TA, 2012, SEMIN ARTHRITIS RHEU, V41, P866, DOI 10.1016/j.semarthrit.2011.10.005
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Luo L, 2013, ELIFE, V2, DOI 10.7554/eLife.00324
   Neelam K, 2008, OPHTHAL EPIDEMIOL, V15, P389, DOI 10.1080/09286580802154275
   Reynolds R, 2010, OPHTHALMOLOGY, V117, P1989, DOI 10.1016/j.ophtha.2010.07.009
   Ridker PM, 2000, NEW ENGL J MED, V342, P836, DOI 10.1056/NEJM200003233421202
   Schmidt-Lucke C, 2005, INT J CARDIOL, V100, P207, DOI 10.1016/j.ijcard.2004.05.046
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Sharma NK, 2013, DNA CELL BIOL, V32, P549, DOI 10.1089/dna.2013.2072
   Sharma NK, 2012, CURR NEUROVASC RES, V9, P256
   Sharma NK, 2012, DNA CELL BIOL, V31, P1618, DOI 10.1089/dna.2012.1786
   Shen XL, 2012, J NUTR HEALTH AGING, V16, P201, DOI 10.1007/s12603-011-0350-8
   Shibuya M, 2006, J BIOCHEM MOL BIOL, V39, P469
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Wolfe F, 1997, J RHEUMATOL, V24, P1477
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yu HH, 2013, DNA CELL BIOL, V32, P717, DOI 10.1089/dna.2013.2127
NR 40
TC 15
Z9 16
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JAN
PY 2015
VL 159
IS 1
BP 92
EP 100
DI 10.1016/j.ajo.2014.09.036
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AY7NU
UT WOS:000347747500013
PM 25284761
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Caljkusic-Mance, T
   Kovacevic, D
   Sepic, T
   Strenja-Linic, I
   Alpeza-Dunato, Z
   Vojnikovic, B
AF Caljkusic-Mance, Tea
   Kovacevic, Damir
   Sepic, Tanja
   Strenja-Linic, Ines
   Alpeza-Dunato, Zvjezdana
   Vojnikovic, Bozo
TI The Circulatory Influence on Development of Age-Related Macular
   Degeneration and Hearing and Equilibrium Impairments
SO COLLEGIUM ANTROPOLOGICUM
LA English
DT Article
DE age-related macular degeneration; microcirculatory disorders; hearing
   impairments; equilibrium impairments
ID RADIATION
AB This study attempts to answer the question if any level of head and neck circulation takes a part in development of Age-Related Macular Degeneration (ARMD) and hearing and equilibrium impairments. Condition of large blood vessels was examined by Color-Doppler ultrasound, and carotid and ophthalmic arteries were included. The microcirculatory changes were examined directly by fundus photography and fluorescein angiography and indirectly testing hearing and equilibrium. The study group included 40 patients (21 females, 19 males) aging from 53 to 84 years with different stages of ARMD. The control group included 40 patients (18 females, 22 males) aging from 51 to 82 years without ARMD. Patients were inhabitants of Primorsko-Goranska County. There was no relationship between ARMD and condition of large blood vessels because significant stenosis of carotid arteries was found in 2 patients (5%) in study group and 3 patients (7.5%) in the control group (p>0.05). On the contrary, we found correlation between ARMD and hearing (p=0.0127) and equilibriium impairments (p=0.0242). Fluorescein angiograms shows raised number of ischemic retinal capillaries in patients with ARMD (p=0.0053). Results lead to conclusion that circulatory disorders on microcirculatory level take a great part in development of ARMD and hearing and equilibrium impairments in the elderly. The key is damage of sensory cells of the retina and inner ear caused by microcirculatory disorders. Interesting data was noticed that 9 patients with more serious ARMD on one side of head had greater hearing loss on the same side. If we find a new treatment for microcirculatory disorders, maybe we can treat both sensory impairments in earlier stage.
C1 [Caljkusic-Mance, Tea; Kovacevic, Damir; Alpeza-Dunato, Zvjezdana] Rijeka Univ Hosp, Dept Ophtalmol, Rijeka 51000, Croatia.
   [Sepic, Tanja] Rijeka Univ Hosp, Dept Otorhinolaryngol Audiol, Rijeka 51000, Croatia.
   [Strenja-Linic, Ines] Rijeka Univ Hosp, Dept Neurol, Rijeka 51000, Croatia.
   [Vojnikovic, Bozo] Daily Eye Clin Dr Bozo Vojnikovic, Rijeka, Croatia.
C3 University of Rijeka; University of Rijeka; University of Rijeka
RP Caljkusic-Mance, T (通讯作者)，Rijeka Univ Hosp, Dept Ophtalmol, Kresimirova 42, Rijeka 51000, Croatia.
EM tea.caljkusic-mance1@ri.t-com
OI Strenja, Ines/0000-0002-2910-2217
CR Chia EM, 2006, ARCH OPHTHALMOL-CHIC, V124, P1465, DOI 10.1001/archopht.124.10.1465
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   Klingel R, 2002, THER APHER, V6, P271, DOI 10.1046/j.1526-0968.2002.00418.x
   Kovacevic D, 2008, COLLEGIUM ANTROPOL, V32, P5
   Liew G, 2007, EAR HEARING, V28, P394, DOI 10.1097/AUD.0b013e3180479388
   Njiric S, 2007, COLLEGIUM ANTROPOL, V31, P107
   Plestina-Borjan I, 2007, COLLEGIUM ANTROPOL, V31, P33
   Vojnikovic B, 2007, COLLEGIUM ANTROPOL, V31, P43
   Vojnikovic B, 2008, COLLEGIUM ANTROPOL, V32, P3
NR 9
TC 2
Z9 2
U1 0
U2 0
PU COLLEGIUM ANTROPOLOGICUM
PI ZAGREB
PA INST ANTHROPOLOGICAL RES, P O BOX 290, ULICA GRADA VUKOVARA 72/IV, 10000
   ZAGREB, CROATIA
SN 0350-6134
J9 COLLEGIUM ANTROPOL
JI Coll. Anthropol.
PD APR
PY 2010
VL 34
SU 2
BP 65
EP 67
PG 3
WC Anthropology
WE Social Science Citation Index (SSCI)
SC Anthropology
GA 677AI
UT WOS:000283961100014
PM 21302704
DA 2022-11-30
ER

PT J
AU Despriet, DDG
   Bergen, AAB
   Merriam, JE
   Zernant, J
   Barile, GR
   Smith, T
   Barbazetto, IA
   van Soest, S
   Bakker, A
   de Jong, PTVM
   Allikmets, R
   Klaver, CCW
AF Despriet, Dominiek D. G.
   Bergen, Arthur A. B.
   Merriam, Joanna E.
   Zernant, Jana
   Barile, Gaetano R.
   Smith, Theodore
   Barbazetto, Irene A.
   van Soest, Simone
   Bakker, Arne
   de Jong, Paulus T. V. M.
   Allikmets, Rando
   Klaver, Caroline C. W.
TI Comprehensive analysis of the candidate genes CCL2, CCR2, and TLR4 in
   age-related macular degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID FACTOR-H POLYMORPHISM; TOLL-LIKE RECEPTORS; DISEASE PROGRESSION; BRUCHS
   MEMBRANE; VARIANT; RISK; TOLL-LIKE-RECEPTOR-4; SUSCEPTIBILITY;
   PATHOGENESIS; MACULOPATHY
AB PURPOSE. To determine whether variants in the candidate genes TLR4, CCL2, and CCR2 are associated with age-related macular degeneration (AMD).
   METHODS. This study was performed in two independent Caucasian populations that included 357 cases and 173 controls from the Netherlands and 368 cases and 368 controls from the United States. Exon 4 of the TLR4 gene and the promoter, all exons, and flanking intronic regions of the CCL2 and CCR2 genes were analyzed in the Dutch study and common variants were validated in the U. S. study. Quantitative (q) PCR reactions were performed to evaluate expression of these genes in laser-dissected retinal pigment epithelium from 13 donor AMD and 13 control eyes.
   RESULTS. Analysis of single nucleotide polymorphisms (SNPs) in the TLR4 gene did not show a significant association between D299G or T399I and AMD, nor did haplotypes containing these variants. Univariate analyses of the SNPs in CCL2 and CCR2 did not demonstrate an association with AMD. For CCR2, haplotype frequencies were not significantly different between cases and controls. For CCL2, one haplotype containing the minor allele of C35C was significantly associated with AMD (P = 0.03), but this did not sustain after adjustment for multiple testing (q = 0.30). Expression analysis did not demonstrate altered RNA expression of CCL2 and CCR2 in the retinal pigment epithelium from AMD eyes (for CCL2 P = 0.62; for CCR2 P = 0.97).
   CONCLUSIONS. No evidence was found of an association between TLR4, CCR2, and CCL2 and AMD, which implies that the common genetic variation in these genes does not play a significant role in the etiology of AMD.
C1 [Despriet, Dominiek D. G.; Klaver, Caroline C. W.] Erasmus Univ, Med Ctr, Dept Ophthalmol, NL-3000 CA Rotterdam, Netherlands.
   [Despriet, Dominiek D. G.; de Jong, Paulus T. V. M.; Klaver, Caroline C. W.] Erasmus Univ, Med Ctr, Dept Epidemiol & Biostat, NL-3000 CA Rotterdam, Netherlands.
   [Despriet, Dominiek D. G.; Bergen, Arthur A. B.; van Soest, Simone; Bakker, Arne; de Jong, Paulus T. V. M.; Klaver, Caroline C. W.] Royal Netherlands Acad Arts & Sci KNAW, Netherlands Inst Neurosci, Dept Clin & Mol Ophthalmolgenet, Amsterdam, Netherlands.
   [Bergen, Arthur A. B.] Univ Amsterdam, Acad Med Ctr, Dept Clin Genet, NL-1105 AZ Amsterdam, Netherlands.
   [de Jong, Paulus T. V. M.] Univ Amsterdam, Acad Med Ctr, Dept Ophthalmol, NL-1105 AZ Amsterdam, Netherlands.
   [Merriam, Joanna E.; Zernant, Jana; Barile, Gaetano R.; Smith, Theodore; Barbazetto, Irene A.; Allikmets, Rando] Columbia Univ, Dept Ophthalmol, New York, NY 10027 USA.
   [Allikmets, Rando] Columbia Univ, Dept Pathol & Cell Biol, New York, NY USA.
C3 Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam;
   Erasmus MC; Royal Netherlands Academy of Arts & Sciences; Netherlands
   Institute for Neuroscience (NIN-KNAW); University of Amsterdam; Academic
   Medical Center Amsterdam; Vrije Universiteit Amsterdam; University of
   Amsterdam; Academic Medical Center Amsterdam; Columbia University;
   Columbia University
RP Klaver, CCW (通讯作者)，Erasmus Univ, Med Ctr, Dept Ophthalmol, POB 2040, NL-3000 CA Rotterdam, Netherlands.
EM carolineklaver@yahoo.com
RI Bergen, Arthur/J-3637-2013; Allikmets, Rando/ABD-4533-2021; Klaver,
   Caroline C.W./A-2013-2016
OI smith, theodore/0000-0002-1693-943X; Bergen, Arthur/0000-0002-6333-9576;
   Klaver, Caroline/0000-0002-2355-5258
FU NATIONAL EYE INSTITUTE [R01EY013435, R01EY015520, R24EY017404] Funding
   Source: NIH RePORTER; NEI NIH HHS [R01 EY013435, R01 EY015520, R01
   EY015520-01A2, R24 EY017404, EY 13435, R01 EY015520-02, EY 017404, R01
   EY015520-03] Funding Source: Medline
CR Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Arbour NC, 2000, NAT GENET, V25, P187, DOI 10.1038/76048
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Charo IF, 2004, CIRC RES, V95, P858, DOI 10.1161/01.RES.0000146672.10582.17
   Cook DN, 2004, NAT IMMUNOL, V5, P975, DOI 10.1038/ni1116
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Freimer NB, 2005, HUM MOL GENET, V14, P2481, DOI 10.1093/hmg/ddi251
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gonzalez E, 2002, P NATL ACAD SCI USA, V99, P13795, DOI 10.1073/pnas.202357499
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Ioannidis JPA, 2001, ANN INTERN MED, V135, P782, DOI 10.7326/0003-4819-135-9-200111060-00008
   Kaur I, 2006, INVEST OPHTH VIS SCI, V47, P3729, DOI 10.1167/iovs.05-1430
   Kindzelskii AL, 2004, J GEN PHYSIOL, V124, P139, DOI 10.1085/jgp.200409062
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Michelsen KS, 2004, P NATL ACAD SCI USA, V101, P10679, DOI 10.1073/pnas.0403249101
   Parker LC, 2004, J IMMUNOL, V172, P4977, DOI 10.4049/jimmunol.172.8.4977
   Pasare C, 2004, MICROBES INFECT, V6, P1382, DOI 10.1016/j.micinf.2004.08.018
   Philpott S, 2004, CLIN INFECT DIS, V39, P861, DOI 10.1086/423386
   Storey JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI 10.1073/pnas.1530509100
   Szalai C, 2001, ATHEROSCLEROSIS, V158, P233, DOI 10.1016/S0021-9150(01)00423-3
   Valdes AM, 2002, ARTERIOSCL THROM VAS, V22, P1924, DOI 10.1161/01.ATV.0000038486.48400.E7
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   van Soest SS, 2007, MOL VIS, V13, P1608
   Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034
   Zareparsi S, 2005, HUM MOL GENET, V14, P1449, DOI 10.1093/hmg/ddi154
NR 29
TC 45
Z9 45
U1 0
U2 3
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JAN
PY 2008
VL 49
IS 1
BP 364
EP 371
DI 10.1167/iovs.07-0656
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 256RJ
UT WOS:000252747000048
PM 18172114
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Indaram, M
   Ma, WX
   Zhao, L
   Fariss, RN
   Rodriguez, IR
   Wong, WT
AF Indaram, Maanasa
   Ma, Wenxin
   Zhao, Lian
   Fariss, Robert N.
   Rodriguez, Ignacio R.
   Wong, Wai T.
TI 7-Ketocholesterol Increases Retinal Microglial Migration, Activation,
   and Angiogenicity: A Potential Pathogenic Mechanism Underlying
   Age-related Macular Degeneration
SO SCIENTIFIC REPORTS
LA English
DT Article
ID NF-KAPPA-B; CHOROIDAL NEOVASCULARIZATION; NLRP3 INFLAMMASOME;
   ENDOTHELIAL-CELLS; BRUCHS MEMBRANE; PHOTORECEPTOR DEGENERATION;
   SUBRETINAL MICROGLIA; DENSITY-LIPOPROTEIN; VISUAL IMPAIRMENT;
   EPITHELIAL-CELLS
AB Age-related macular degeneration (AMD) has been associated with both accumulation of lipid and lipid oxidative products, as well as increased neuroinflammatory changes and microglial activation in the outer retina. However, the relationships between these factors are incompletely understood. 7-Ketocholesterol (7KCh) is a cholesterol oxidation product localized to the outer retina with prominent pro-inflammatory effects. To explore the potential relationship between 7KCh and microglial activation, we localized 7KCh and microglia to the outer retina of aged mice and investigated 7KCh effects on retinal microglia in both in vitro and in vivo systems. We found that retinal microglia demonstrated a prominent chemotropism to 7KCh and readily internalized 7KCh. Sublethal concentrations of 7KCh resulted in microglial activation and polarization to a pro-inflammatory M1 state via NLRP3 inflammasome activation. Microglia exposed to 7KCh reduced expression of neurotrophic growth factors but increased expression of angiogenic factors, transitioning to a more neurotoxic and pro-angiogenic phenotype. Finally, subretinal transplantation of 7KCh-exposed microglia promoted choroidal neovascularization (CNV) relative to control microglia in a Matrigel-CNV model. The interaction of retinal microglia with 7KCh in the aged retina may thus underlie how outer retinal lipid accumulation in intermediate AMD results in neuroinflammation that ultimately drives progression towards advanced AMD.
C1 [Indaram, Maanasa; Ma, Wenxin; Zhao, Lian; Wong, Wai T.] NEI, Retinal Cell & Mol Biol Lab, Unit Neuron Glia Interact Retinal Dis, NIH, Bethesda, MD 20892 USA.
   [Fariss, Robert N.] NEI, Retinal Cell & Mol Biol Lab, Biol Imaging Core, NIH, Bethesda, MD 20892 USA.
   [Rodriguez, Ignacio R.] NEI, Retinal Cell & Mol Biol Lab, Mech Retinal Dis Sect, Bethesda, MD 20892 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); National Institutes of Health (NIH) - USA; NIH National Eye
   Institute (NEI); National Institutes of Health (NIH) - USA; NIH National
   Eye Institute (NEI)
RP Wong, WT (通讯作者)，NEI, Retinal Cell & Mol Biol Lab, Unit Neuron Glia Interact Retinal Dis, NIH, Bethesda, MD 20892 USA.
EM wongw@nei.nih.gov
RI Fariss, Robert/ABI-1771-2020; Wong, Wai/B-6118-2017
OI Wong, Wai/0000-0003-0681-4016; Fariss, Robert/0000-0003-3227-7170
FU NATIONAL EYE INSTITUTE [ZIAEY000541, ZICEY000459, ZICEY000461,
   ZIAEY000505] Funding Source: NIH RePORTER
CR Amaral J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056099
   Anderson M, 2006, VET OPHTHALMOL, V9, P201, DOI 10.1111/j.1463-5224.2006.00463.x
   Baba T, 2010, AM J PATHOL, V176, P3085, DOI 10.2353/ajpath.2010.090989
   Berthier A, 2005, FEBS J, V272, P3093, DOI 10.1111/j.1742-4658.2005.04723.x
   Cao JT, 2010, INVEST OPHTH VIS SCI, V51, P6009, DOI 10.1167/iovs.09-4956
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Chinnery HR, 2012, NEUROBIOL AGING, V33, P1769, DOI 10.1016/j.neurobiolaging.2011.03.010
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Congdon NG, 2003, JAMA-J AM MED ASSOC, V290, P2057, DOI 10.1001/jama.290.15.2057
   Curcio CA, 2005, EXP EYE RES, V81, P731, DOI 10.1016/j.exer.2005.04.012
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   Curcio CA, 2010, J LIPID RES, V51, P451, DOI 10.1194/jlr.R002238
   Damani MR, 2011, AGING CELL, V10, P263, DOI 10.1111/j.1474-9726.2010.00660.x
   Dulakk J, 2001, ATHEROSCLEROSIS, V159, P325, DOI 10.1016/S0021-9150(01)00520-2
   Eibinger G, 2013, EXP CELL RES, V319, P1828, DOI 10.1016/j.yexcr.2013.03.025
   Favret S, 2013, AGING-US, V5, P427, DOI 10.18632/aging.100563
   Ferrari D, 1997, J IMMUNOL, V159, P1451
   Fogerty J, 2014, ADV EXP MED BIOL, V801, P355, DOI 10.1007/978-1-4614-3209-8_45
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   Gupta N, 2003, EXP EYE RES, V76, P463, DOI 10.1016/S0014-4835(02)00332-9
   Hahn P, 2006, NEUROREPORT, V17, P1803, DOI 10.1097/WNR.0b013e3280107776
   Haimovici R, 2001, INVEST OPHTH VIS SCI, V42, P1592
   Hayden JM, 2002, J LIPID RES, V43, P26
   Huang H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071808
   Huang JD, 2007, EXP EYE RES, V85, P202, DOI 10.1016/j.exer.2007.03.011
   Huang JD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100985
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Johnson LV, 2011, P NATL ACAD SCI USA, V108, P18277, DOI 10.1073/pnas.1109703108
   Jung S, 2000, MOL CELL BIOL, V20, P4106, DOI 10.1128/MCB.20.11.4106-4114.2000
   Kahlenberg JM, 2005, J IMMUNOL, V175, P7611, DOI 10.4049/jimmunol.175.11.7611
   Krause TA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094313
   Kumar A, 2014, INVEST OPHTH VIS SCI, V55, P1787, DOI 10.1167/iovs.13-13522
   Lampugnani MG, 1999, METH MOL B, V96, P177
   Larrayoz IM, 2010, INVEST OPHTH VIS SCI, V51, P4942, DOI 10.1167/iovs.09-4854
   Lee HS, 2005, BIOCHEM BIOPH RES CO, V333, P1093, DOI 10.1016/j.bbrc.2005.05.196
   Lemaire S, 1998, FEBS LETT, V440, P434, DOI 10.1016/S0014-5793(98)01496-3
   Li YW, 2008, NAT PROTOC, V3, P1703, DOI 10.1038/nprot.2008.172
   Liang CC, 2007, NAT PROTOC, V2, P329, DOI 10.1038/nprot.2007.30
   Lordan S, 2009, J NUTR BIOCHEM, V20, P321, DOI 10.1016/j.jnutbio.2009.01.001
   Luthra S, 2008, MICROVASC RES, V75, P343, DOI 10.1016/j.mvr.2007.10.003
   Ma WX, 2013, NEUROBIOL AGING, V34, P943, DOI 10.1016/j.neurobiolaging.2012.06.010
   Ma WX, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007945
   Malek G, 2003, AM J PATHOL, V162, P413, DOI 10.1016/S0002-9440(10)63836-9
   Marneros AG, 2013, CELL REP, V4, P945, DOI 10.1016/j.celrep.2013.08.002
   Mattapallil MJ, 2012, INVEST OPHTH VIS SCI, V53, P2921, DOI 10.1167/iovs.12-9662
   Moreira EF, 2009, INVEST OPHTH VIS SCI, V50, P523, DOI 10.1167/iovs.08-2373
   Nakajima Kazuyuki, 2004, Curr Drug Targets Cardiovasc Haematol Disord, V4, P65, DOI 10.2174/1568006043481284
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Oak ASW, 2014, RETINA-J RET VIT DIS, V34, P825, DOI 10.1097/IAE.0000000000000121
   Omri S, 2011, AM J PATHOL, V179, P942, DOI 10.1016/j.ajpath.2011.04.018
   Palozza P, 2007, FREE RADICAL BIO MED, V42, P1579, DOI 10.1016/j.freeradbiomed.2007.02.023
   Parkhurst CN, 2013, CELL, V155, P1596, DOI 10.1016/j.cell.2013.11.030
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   Pedruzzi E, 2004, MOL CELL BIOL, V24, P10703, DOI 10.1128/MCB.24.24.10703-10717.2004
   Poli G, 2013, REDOX BIOL, V1, P125, DOI 10.1016/j.redox.2012.12.001
   Raccosta L, 2013, J EXP MED, V210, P1711, DOI 10.1084/jem.20130440
   Rodriguez IR, 2010, J LIPID RES, V51, P2847, DOI 10.1194/jlr.R004820
   Rodriguez IR, 2009, PHOTOCHEM PHOTOBIOL, V85, P1116, DOI 10.1111/j.1751-1097.2009.00568.x
   Rodriguez IR, 2004, INVEST OPHTH VIS SCI, V45, P2830, DOI 10.1167/iovs.04-0075
   Rodriguez IR, 2014, EXP EYE RES
   Ruberti JW, 2003, INVEST OPHTH VIS SCI, V44, P1753, DOI 10.1167/iovs.02-0496
   Sennlaub F, 2013, EMBO MOL MED, V5, P1775, DOI 10.1002/emmm.201302692
   Shimozawa M, 2004, REDOX REP, V9, P370, DOI 10.1179/135100004225006902
   Spaide RF, 1999, RETINA-J RET VIT DIS, V19, P141, DOI 10.1097/00006982-199902000-00010
   Subramanian N, 2013, CELL, V153, P348, DOI 10.1016/j.cell.2013.02.054
   Tamai K, 2002, EXP EYE RES, V74, P301, DOI 10.1006/exer.2001.1121
   Tan E, 2004, INVEST OPHTH VIS SCI, V45, P764, DOI 10.1167/iovs.03-1114
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Tseng WA, 2013, INVEST OPHTH VIS SCI, V54, P110, DOI 10.1167/iovs.12-10655
   Tuo JS, 2007, INVEST OPHTH VIS SCI, V48, P3827, DOI 10.1167/iovs.07-0051
   Ueno M, 2013, NAT NEUROSCI, V16, P543, DOI 10.1038/nn.3358
   Vejux A, 2009, MOL ASPECTS MED, V30, P153, DOI 10.1016/j.mam.2009.02.006
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   Xu HP, 2008, AGING CELL, V7, P58, DOI 10.1111/j.1474-9726.2007.00351.x
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   Zhao L, 2011, AM J PATHOL, V179, P1265, DOI 10.1016/j.ajpath.2011.05.042
NR 79
TC 61
Z9 64
U1 2
U2 15
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD MAR 16
PY 2015
VL 5
AR 9144
DI 10.1038/srep09144
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA CD6DZ
UT WOS:000351181000008
PM 25775051
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Kim, NR
   Kang, JH
   Kwon, OW
   Lee, SJ
   Oh, JH
   Chin, HS
AF Kim, Na Rae
   Kang, Ju Hee
   Kwon, Oh Woong
   Lee, Seok Joon
   Oh, Jung Hyub
   Chin, Hee Seung
TI Association between complement factor H gene polymorphisms and
   neovascular age-related macular degeneration in Koreans
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID CHOROIDAL NEOVASCULARIZATION; JAPANESE POPULATION; Y402H; RISK;
   SUSCEPTIBILITY; VARIANT; MACULOPATHY; DISEASE; EYE; LOC387715
AB PURPOSE. This study was undertaken to investigate the association between the complement factor H (CFH) gene and exudative age-related macular degeneration (AMD) in Korean patients.
   METHODS. Genomic DNA was isolated from the peripheral leukocytes of patients with exudative AMD (n = 114) and control subjects (n = 187). The sole criterion for exudative AMD was the presence of choroidal neovascularization. Four single-nucleotide polymorphisms (SNPs: -275C>T, I62V, Y402H, and IVS15) located in promoter, exon 2, exon 9, and intron 15 of the CFH gene were genotyped by PCR-based direct sequencing.
   RESULTS. The frequency of the C allele of Y402H (AMD, 10.5%; control, 6.5%) was found to be lower in Koreans than in Caucasians. In the present study, the difference between the frequencies of Y402H in cases and control subjects did not reach statistical significance (P = 0.071). However, the frequencies of the major alleles of three SNPs (-275C>T, I62V, and IVS15) were significantly different in patients and control subjects, and these SNPs were found to be separately associated with an elevated risk of exudative AMD. Seven haplotypes were identified in Koreans. Haplotype analysis showed that two haplotypes (TGTG, CGTG) conferred significantly higher risks of exudative AMD (P = 0.013, 0.035), and one haplotype (CATA) was significantly protective (P < 0.001).
   CONCLUSIONS. In Korean subjects, CFH polymorphism appears to be a considerable hereditary contributor to exudative AMD. Y402H polymorphism which has been suggested to be a major risk factor of AMD in Caucasians was found to be only marginally associated with exudative AMD with low frequency, whereas three adjacent SNPs in the CFH gene were significantly associated with AMD in Koreans.
C1 [Kim, Na Rae; Oh, Jung Hyub; Chin, Hee Seung] Inha Univ, Dept Ophthalmol, Inchon, South Korea.
   [Kang, Ju Hee; Oh, Jung Hyub] Inha Univ, Ctr Adv Med Educ, BK 21 Project, Inchon, South Korea.
   [Kang, Ju Hee] Inha Univ, Inha Res Inst Med Sci, Med Toxicol Res Ctr, Dept Pharmacol, Inchon, South Korea.
   [Kwon, Oh Woong] Yonsei Univ, Coll Med, Dept Ophthalmol, Seoul, South Korea.
   [Lee, Seok Joon] Yonsei Univ, Wonju Coll Med, Wonju Christian Hosp, Dept Ophthalmol, Wonju, Kangwon Do, South Korea.
C3 Inha University; Inha University; Inha University; Yonsei University;
   Yonsei University Health System; Yonsei University
RP Chin, HS (通讯作者)，Inha Univ Hosp, Dept Ophthalmol, 7-206 Shinheung Dong, Inchon, South Korea.
EM hschin@inha.ac.kr
CR BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Chen LJ, 2006, MOL VIS, V12, P1536
   Conley YP, 2005, HUM MOL GENET, V14, P1991, DOI 10.1093/hmg/ddi204
   de Cordoba SR, 2004, MOL IMMUNOL, V41, P355, DOI 10.1016/j.molimm.2004.02.005
   Dewan A, 2007, CURR OPIN GENET DEV, V17, P228, DOI 10.1016/j.gde.2007.04.004
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ennis S, 2007, BRIT J OPHTHALMOL, V91, P966, DOI 10.1136/bjo.2007.114090
   Gotoh N, 2006, HUM GENET, V120, P139, DOI 10.1007/s00439-006-0187-0
   Grassi MA, 2006, HUM MUTAT, V27, P921, DOI 10.1002/humu.20359
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Lau LI, 2006, INVEST OPHTH VIS SCI, V47, P3242, DOI 10.1167/iovs.05-1532
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Munoz B, 2000, ARCH OPHTHALMOL-CHIC, V118, P819, DOI 10.1001/archopht.118.6.819
   Okamoto H, 2006, MOL VIS, V12, P156
   Oshima Y, 2001, BRIT J OPHTHALMOL, V85, P1153, DOI 10.1136/bjo.85.10.1153
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Sepp T, 2006, INVEST OPHTH VIS SCI, V47, P536, DOI 10.1167/iovs.05-1143
   Spaide RF, 2003, RETINA-J RET VIT DIS, V23, P595, DOI 10.1097/00006982-200310000-00001
   Tano Y, 2003, AM J OPHTHALMOL, V136, P1049, DOI 10.1016/S0002-9394(03)00576-2
   Uyama M, 2000, BRIT J OPHTHALMOL, V84, P1018, DOI 10.1136/bjo.84.9.1018
   Wang ZF, 2004, CELL, V119, P831, DOI 10.1016/j.cell.2004.11.010
   Ward HM, 1997, IMMUNOL CELL BIOL, V75, P508, DOI 10.1038/icb.1997.79
   Warwicker P, 1997, IMMUNOGENETICS, V46, P437, DOI 10.1007/s002510050300
   Yates JRW, 2000, J MED GENET, V37, P83, DOI 10.1136/jmg.37.2.83
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
   Zipfel PF, 2002, BIOCHEM SOC T, V30, P971, DOI 10.1042/bst0300971
NR 31
TC 64
Z9 69
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAY
PY 2008
VL 49
IS 5
BP 2071
EP 2076
DI 10.1167/iovs.07-1195
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 292UH
UT WOS:000255291100044
PM 18223247
DA 2022-11-30
ER

PT J
AU Morris, MS
   Jacques, PF
   Chylack, LT
   Hankinson, SE
   Willett, WC
   Hubbard, LD
   Taylor, A
AF Morris, Martha Savaria
   Jacques, Paul F.
   Chylack, Leo T.
   Hankinson, Susan E.
   Willett, Walter C.
   Hubbard, Larry D.
   Taylor, Allen
TI Intake of zinc and antioxidant micronutrients and early age-related
   maculopathy lesions
SO OPHTHALMIC EPIDEMIOLOGY
LA English
DT Article
DE aging; antioxidant carotenoid; eye; macular
ID MACULAR DEGENERATION; NATIONAL-HEALTH; DIETARY CAROTENOIDS; VISUAL
   IMPAIRMENT; LUTEIN; ZEAXANTHIN; RISK; PIGMENT; SERUM; POPULATION
AB Background: Macular degeneration, the end stage of age-related maculopathy (ARM), is the leading cause of legal blindness worldwide, and few modifiable risk factors are known. The high concentration of carotenoids in the macula, plus evidence linking oxidative stress to ARM and carotenoids to antioxidation, generated the hypothesis that higher antioxidant intakes can prevent ARM. Results of observational and intervention studies have been inconsistent. Objective: To evaluate associations between intakes of zinc and antioxidant micronutrients and early ARM. Methods: Between 1993 and 1995, ARM was assessed in 398 Boston-area women aged 53-74 y using the Wisconsin Age-related Maculopathy System of grading retinal fundus photographs. The women were a subset of the Nurses' Health Study cohort. Micronutrient intake was assessed by semi-quantitative food frequency questionnaires administered four times between 1980 and the baseline eye examinations. Results: After multivariate adjustment for potential confounders, 1980 energy-adjusted intakes of alpha-carotene, beta-carotene, lycopene, total retinol, total vitamin A, and total vitamin E were significantly inversely related to the prevalence of pigmentary abnormalities (PA). Furthermore, increasing frequency of consuming foods high in alpha- or beta-carotene was associated with lower odds of PA; compared to women consuming these foods <5 times/wk, odds ratios (95% Cl) were 0.7 (0.3-1.6) for 5-6 times/wk, 0.6 (0.2-1.3) for 7-9.5 times/wk, and 0.3 (0.1-0.7)for >= 10 times/wk. Lutein/zeaxanthin intakes and more recent intakes of most carotenoids were unrelated to PA, and intakes of zinc and antioxidant micronutrients were unrelated to having large or intermediate drusen alone.
C1 Tufts Univ, Res Ctr Aging, Jean Mayer USDA Human Nutr, Boston, MA 02111 USA.
   Harvard Univ, Sch Med, Boston, MA USA.
   Brigham & Womens Hosp, Ctr Ophthalmic Res, Boston, MA 02115 USA.
   Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA USA.
   Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
   Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA.
   Univ Wisconsin, Fundus Photog Reading Ctr, Madison, WI USA.
C3 Tufts University; United States Department of Agriculture (USDA);
   Harvard University; Harvard Medical School; Harvard University; Brigham
   & Women's Hospital; Harvard University; Brigham & Women's Hospital;
   Harvard University; Harvard T.H. Chan School of Public Health; Harvard
   University; Harvard T.H. Chan School of Public Health; University of
   Wisconsin System; University of Wisconsin Madison
RP Morris, MS (通讯作者)，Tufts Univ, Res Ctr Aging, Jean Mayer USDA Human Nutr, 711 Washington St,Rm 901D, Boston, MA 02111 USA.
EM martha.morris@tufts.edu
FU NEI NIH HHS [EY13250, EY09611, EY014183-01A2] Funding Source: Medline;
   NATIONAL EYE INSTITUTE [R01EY013250, R03EY014183, R01EY009611] Funding
   Source: NIH RePORTER
CR Abdelsalam A, 1999, SURV OPHTHALMOL, V44, P1, DOI 10.1016/S0039-6257(99)00072-7
   Alves-Rodrigues A, 2004, TOXICOL LETT, V150, P57, DOI 10.1016/j.toxlet.2003.10.031
   Beatty S, 2001, INVEST OPHTH VIS SCI, V42, P439
   Berendschot TTJM, 2000, INVEST OPHTH VIS SCI, V41, P3322
   Bernstein PS, 2002, OPHTHALMOLOGY, V109, P1780, DOI 10.1016/S0161-6420(02)01173-9
   Bone RA, 2001, INVEST OPHTH VIS SCI, V42, P235
   Bone RA, 2000, EXP EYE RES, V71, P239, DOI 10.1006/exer.2000.0870
   Cho EY, 2004, ARCH OPHTHALMOL-CHIC, V122, P883, DOI 10.1001/archopht.122.6.883
   Cho EY, 2001, ANN EPIDEMIOL, V11, P328, DOI 10.1016/S1047-2797(01)00217-4
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Delamere N A, 1996, Subcell Biochem, V25, P313
   Delcourt C, 1999, ARCH OPHTHALMOL-CHIC, V117, P1384, DOI 10.1001/archopht.117.10.1384
   Flood V, 2002, OPHTHALMOLOGY, V109, P2272, DOI 10.1016/S0161-6420(02)01263-0
   Gale CR, 2003, INVEST OPHTH VIS SCI, V44, P2461, DOI 10.1167/iovs.02-0929
   GOLDBERG J, 1988, AM J EPIDEMIOL, V128, P700, DOI 10.1093/oxfordjournals.aje.a115023
   Grahn BH, 2001, J AM COLL NUTR, V20, P106, DOI 10.1080/07315724.2001.10719022
   Jacques PF, 2001, ARCH OPHTHALMOL-CHIC, V119, P1009, DOI 10.1001/archopht.119.7.1009
   Johnson EJ, 2000, AM J CLIN NUTR, V71, P1555
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 1999, OPHTHALMOLOGY, V106, P1056, DOI 10.1016/S0161-6420(99)90255-5
   Krinsky NI, 2002, J NUTR, V132, p540S, DOI 10.1093/jn/132.3.540S
   Landrum JT, 2001, ARCH BIOCHEM BIOPHYS, V385, P28, DOI 10.1006/abbi.2000.2171
   Mares-Perlman J.A., 1999, CRC MOD NUT, P181
   Mares-Perlman JA, 2001, AM J EPIDEMIOL, V153, P424, DOI 10.1093/aje/153.5.424
   MaresPerlman JA, 1996, ARCH OPHTHALMOL-CHIC, V114, P991, DOI 10.1001/archopht.1996.01100140199014
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P1518, DOI 10.1001/archopht.1995.01100120048007
   Munoz B, 2002, BRIT J OPHTHALMOL, V86, P498, DOI 10.1136/bjo.86.5.498
   NEWSOME DA, 1988, ARCH OPHTHALMOL-CHIC, V106, P192
   Osganian SK, 2003, AM J CLIN NUTR, V77, P1390, DOI 10.1093/ajcn/77.6.1390
   Quillen DA, 1999, AM FAM PHYSICIAN, V60, P99
   SCHLACH W, 1999, NUTR ENV INFLUENCES, P215
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Smith W, 1999, OPHTHALMOLOGY, V106, P761, DOI 10.1016/S0161-6420(99)90164-1
   VandenLangenberg GM, 1998, AM J EPIDEMIOL, V148, P204, DOI 10.1093/oxfordjournals.aje.a009625
   WALD G, 1945, SCIENCE, V101, P653, DOI 10.1126/science.101.2635.653
   Willett W., 2013, NUTR EPIDEMIOLOGY, V3rd
NR 41
TC 10
Z9 11
U1 0
U2 9
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0928-6586
EI 1744-5086
J9 OPHTHAL EPIDEMIOL
JI Ophthalmic Epidemiol.
PD SEP-OCT
PY 2007
VL 14
IS 5
BP 288
EP 298
DI 10.1080/09286580601186759
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 228OM
UT WOS:000250739300004
PM 17994438
DA 2022-11-30
ER

PT J
AU Trouw, LA
   Bohringer, S
   Daha, NA
   Stahl, EA
   Raychaudhuri, S
   Kurreeman, FA
   Stoeken-Rijsbergen, G
   Houwing-Duistermaat, JJ
   Huizinga, TW
   Toes, RE
AF Trouw, L. A.
   Bohringer, S.
   Daha, N. A.
   Stahl, E. A.
   Raychaudhuri, S.
   Kurreeman, F. A.
   Stoeken-Rijsbergen, G.
   Houwing-Duistermaat, J. J.
   Huizinga, T. W.
   Toes, R. E.
TI The major risk alleles of age-related macular degeneration (AMD) in CFH
   do not play a major role in rheumatoid arthritis (RA)
SO CLINICAL AND EXPERIMENTAL IMMUNOLOGY
LA English
DT Article
DE autoimmunity; complement; factor h; genetics; rheumatoid arthritis
ID COMPLEMENT ACTIVATION; VARIANT; ASSOCIATION; BINDING; PATHWAY; DISEASE;
   GENES; Y402H
AB Because activation of the alternative pathway (AP) of the complement system is an important aspect of both age-related macular degeneration (AMD) and rheumatoid arthritis (RA), we wished to address the question whether genetic risk factors of the AP inhibitor complement factor H (CFH) for AMD would also be risk factors for RA. For this purpose we genotyped single nucleotide polymorphisms (SNPs) in a Dutch set of RA patients and controls. Similarly, a meta-analysis using a Spanish cohort of RA as well as six large genome-wide association studies (GWAS) studies was performed. For these SNPs we analysed more than 6000 patients and 20 000 controls. The CFH variants, I62V, Y402H, IVS1 and IVS10, known to associate strongly with AMD, did not show a significant association with the risk of developing RA despite a strong statistical power to detect such differences. In conclusion, the major risk alleles of AMD in CFH do not have a similar effect on developing RA.
C1 [Trouw, L. A.; Daha, N. A.; Kurreeman, F. A.; Stoeken-Rijsbergen, G.; Huizinga, T. W.; Toes, R. E.] Leiden Univ, Med Ctr, Dept Rheumatol, NL-2300 RC Leiden, Netherlands.
   [Bohringer, S.; Houwing-Duistermaat, J. J.] Leiden Univ, Med Ctr, Dept Biostat & Bioinformat, NL-2300 RC Leiden, Netherlands.
   [Stahl, E. A.; Raychaudhuri, S.; Kurreeman, F. A.] Brigham & Womens Hosp, Div Rheumatol Immunol & Allergy, Boston, MA 02115 USA.
C3 Leiden University; Leiden University Medical Center (LUMC); Leiden
   University - Excl LUMC; Leiden University; Leiden University Medical
   Center (LUMC); Leiden University - Excl LUMC; Harvard University;
   Brigham & Women's Hospital
RP Trouw, LA (通讯作者)，Leiden Univ, Med Ctr, Dept Rheumatol, C 05 61,Postbus 9600, NL-2300 RC Leiden, Netherlands.
EM l.a.trouw@lumc.nl
RI Boehringer, Stefan/Y-2442-2018; Houwing-Duistermaat, Jeanne/V-9048-2018;
   Trouw, Leendert/AGK-5202-2022
OI Boehringer, Stefan/0000-0001-9108-9212; Trouw,
   Leendert/0000-0001-5186-2290; Houwing-Duistermaat,
   Jeanine/0000-0002-4505-7137; Raychaudhuri, Soumya/0000-0002-1901-8265;
   Toes, Rene/0000-0002-9618-6414
FU LUMC; LGTC unit; European Union; Netherlands Genomics Initiative (NGI)
   as part of the Netherlands Proteomics Center (NPC); Center for Medical
   Systems Biology (CMSB); VENI; NWO-ZON-MW; EMBO; Unesco-L'Oreal for Women
   in Science Fellowship
FX We thank the support of Dennis Kremer from the LUMC, LGTC unit for
   support regarding the Sequenom analysis. The authors wish to acknowledge
   the support of the European Union (Sixth Framework Programme integrated
   project Autocure and Seventh Framework Programme integrated project
   Masterswitch). This study was also supported by national funding from
   the Netherlands Genomics Initiative (NGI) as part of the Netherlands
   Proteomics Center (NPC) and the Center for Medical Systems Biology
   (CMSB). L.T. was supported financially by a VENI-grant from NWO-ZON-MW.
   R.T. was supported financially by a VICI-grant from NWO-ZON-MW. F.K was
   supported by the EMBO long-term fellowship and the Unesco-L'Oreal for
   Women in Science Fellowship.
CR Aggarwal A, 2000, RHEUMATOLOGY, V39, P189, DOI 10.1093/rheumatology/39.2.189
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Banda NK, 2007, J IMMUNOL, V179, P4101, DOI 10.4049/jimmunol.179.6.4101
   Banda NK, 2006, J IMMUNOL, V177, P1904, DOI 10.4049/jimmunol.177.3.1904
   Clark SJ, 2010, J BIOL CHEM, V285, P30192, DOI 10.1074/jbc.M110.103986
   Daha NA, 2011, MOL IMMUNOL, V48, P1656, DOI 10.1016/j.molimm.2011.04.024
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Dieguez-Gonzalez R, 2009, J RHEUMATOL, V36, P1590, DOI 10.3899/jrheum.090022
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Ji H, 2002, IMMUNITY, V16, P157, DOI 10.1016/S1074-7613(02)00275-3
   Kurreeman FAS, 2007, PLOS MED, V4, P1515, DOI 10.1371/journal.pmed.0040278
   Laine M, 2007, J IMMUNOL, V178, P3831, DOI 10.4049/jimmunol.178.6.3831
   Okroj M, 2007, ANN MED, V39, P517, DOI 10.1080/07853890701477546
   Pritchard JK, 2001, AM J HUM GENET, V69, P1, DOI 10.1086/321275
   Raychaudhuri S, 2008, NAT GENET, V40, P1216, DOI 10.1038/ng.233
   Sjoberg AP, 2009, TRENDS IMMUNOL, V30, P83, DOI 10.1016/j.it.2008.11.003
   Sjoberg AP, 2007, J BIOL CHEM, V282, P10894, DOI 10.1074/jbc.M610256200
   Skerka C, 2007, MOL IMMUNOL, V44, P3398, DOI 10.1016/j.molimm.2007.02.012
   Stahl EA, 2010, NAT GENET, V42, P508, DOI 10.1038/ng.582
   Trouw LA, 2009, ARTHRITIS RHEUM-US, V60, P1923, DOI 10.1002/art.24622
   van Gaalen F, 2005, J IMMUNOL, V175, P5575, DOI 10.4049/jimmunol.175.9.5575
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
NR 24
TC 10
Z9 10
U1 0
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0009-9104
EI 1365-2249
J9 CLIN EXP IMMUNOL
JI Clin. Exp. Immunol.
PD DEC
PY 2011
VL 166
IS 3
BP 333
EP 337
DI 10.1111/j.1365-2249.2011.04482.x
PG 5
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA 846OF
UT WOS:000296912400004
PM 22059990
OA Green Published
DA 2022-11-30
ER

PT J
AU Frampton, JE
AF Frampton, James E.
TI Ranibizumab: A Review of Its Use in the Treatment of Neovascular
   Age-Related Macular Degeneration
SO DRUGS & AGING
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; VERTEPORFIN PHOTODYNAMIC THERAPY;
   VISION-RELATED FUNCTION; OPEN-LABEL EXTENSION; COST-EFFECTIVENESS;
   CHOROIDAL NEOVASCULARIZATION; INTRAVITREAL INJECTION;
   INTRAOCULAR-PRESSURE; DOSING REGIMEN; IN-VITRO
AB Ranibizumab (Lucentis((R))), an inhibitor of all vascular endothelial growth factor (VEGF) A isoforms, is approved for the intravitreal treatment of neovascular age-related macular degeneration (AMD). In pivotal trials, monthly injections of ranibizumab were superior to verteporfin photodynamic therapy in the treatment of predominantly classic choroidal neovascularization (CNV) due to neovascular AMD (ANCHOR) and sham in the treatment of minimally classic or occult CNV due to neovascular AMD (MARINA). Monthly or less frequent injections of ranibizumab are generally well tolerated and associated with low rates of ocular and systemic serious adverse events (SAEs). Less frequent dosing has been evaluated with the aim of reducing the burden, risk and cost of monthly injections. In the landmark CATT trial, monthly monitoring and retreatment as-needed with ranibizumab was equivalent to monthly treatment in terms of the vision gain at 1 year, but reduced the number of injections (and the related cost) by approximately one-half. In head-to-head comparisons, aflibercept administered bimonthly was noninferior to ranibizumab administered monthly (VIEW 1 and 2), bevacizumab administered monthly was equivalent to ranibizumab administered monthly (CATT), and bevacizumab administered as-needed was equivalent to ranibizumab administered as-needed (CATT). Bevacizumab is widely used (off-label) for economic reasons; while it was less costly than ranibizumab, it was associated with more systemic SAEs. Notwithstanding the availability of other similarly effective anti-VEGF therapies that are approved (aflibercept) or unapproved (bevacizumab), ranibizumab continues to set the standard as regards the totality of evidence from randomized clinical trials demonstrating its efficacy and tolerability (particularly that of the monthly regimen) in the treatment of neovascular AMD.
C1 Adis, Auckland 0754, New Zealand.
C3 Adis International
RP Frampton, JE (通讯作者)，Adis, 41 Centorian Dr,Private Bag 65901, Auckland 0754, New Zealand.
EM demail@springer.com
CR Abraham P, 2010, AM J OPHTHALMOL, V150, P315, DOI 10.1016/j.ajo.2010.04.011
   Academic Medical Center (AMC) Department of Ophtalmology, COMPARISON OF BEVACI
   Adamski J, 2010, BMC HEALTH SERV RES, V10, P10
   AMD Alliance International, AMD ALLIANCE INTERNA
   American Academy of Ophthalmology, AGE RELATED MACULAR
   [Anonymous], EYLEA AFLIBERCEPT IN
   [Anonymous], UCENTIS 10 MG ML SOL
   Antoszyk AN, 2008, AM J OPHTHALMOL, V145, P862, DOI 10.1016/j.ajo.2007.12.029
   Athanasakis K, 2012, CLIN THER, V34, P446, DOI 10.1016/j.clinthera.2012.01.005
   Bandukwala T, 2010, CAN J OPHTHALMOL, V45, P590, DOI 10.3129/i10-082
   Barbazetto I, 2010, RETINA-J RET VIT DIS, V30, P1376, DOI 10.1097/IAE.0b013e3181dcfb0b
   Bhisitkul RB, 2006, BRIT J OPHTHALMOL, V90, P1542, DOI 10.1136/bjo.2006.098426
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Blick SKA, 2007, DRUGS, V67, P1199, DOI 10.2165/00003495-200767080-00007
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Brechner RJ, 2011, AM J OPHTHALMOL, V151, P887, DOI 10.1016/j.ajo.2010.11.017
   Bressler NM, 2013, OPHTHALMOLOGY, V120, P160, DOI 10.1016/j.ophtha.2012.07.027
   Bressler NM, 2012, RETINA-J RET VIT DIS, V32, P1821, DOI 10.1097/IAE.0b013e31825db6ba
   Bressler NM, 2011, ARCH OPHTHALMOL-CHIC, V129, P709, DOI 10.1001/archophthalmol.2011.140
   Bressler NM, 2009, ARCH OPHTHALMOL-CHIC, V127, P13, DOI 10.1001/archophthalmol.2008.562
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Brown MM, 2008, OPHTHALMOLOGY, V115, P1039, DOI 10.1016/j.ophtha.2007.08.033
   Canadian Agency for Drugs and Technologies in Health, 2008, COMMON DRUG REVIEW R
   Carneiro A, 2009, EXP EYE RES, V88, P522, DOI 10.1016/j.exer.2008.11.011
   Carneiro AM, 2012, ACTA OPHTHALMOL, V90, pE25, DOI 10.1111/j.1755-3768.2011.02240.x
   Casten R, 2008, J VISUAL IMPAIR BLIN, V102, P591, DOI 10.1177/0145482X0810201003
   Center for Drug Evaluation and Research, BLA APPLICATION NUMB
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chang TS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1460, DOI 10.1001/archopht.125.11.1460
   Chappelow AV, 2008, DRUGS, V68, P1029, DOI 10.2165/00003495-200868080-00002
   Cohen SY, 2008, GRAEF ARCH CLIN EXP, V246, P1527, DOI 10.1007/s00417-008-0890-8
   Colquitt JL, 2008, HEALTH TECHNOL ASSES, V12, P1
   Cook HL, 2008, BRIT MED BULL, V85, P127, DOI 10.1093/bmb/ldn012
   Costa R, 2009, J CELL BIOCHEM, V108, P1410, DOI 10.1002/jcb.22378
   Cunningham ET, 2011, OPHTHALMOLOGY, V118, P2447, DOI 10.1016/j.ophtha.2011.05.026
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Dhoot DS, 2012, EXPERT OPIN BIOL TH, V12, P371, DOI 10.1517/14712598.2012.660523
   European Medicines Agency, ASSESSMENT REPORT
   Falk MK, 2013, AM J OPHTHALMOL, V155, P89, DOI 10.1016/j.ajo.2012.06.031
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Fintak DR, 2008, RETINA-J RET VIT DIS, V28, P1395, DOI 10.1097/IAE.0b013e3181884fd2
   Folk JC, 2010, NEW ENGL J MED, V363, P1648, DOI 10.1056/NEJMct1000495
   Frampton JE, 2012, DRUG AGING, V29, P839, DOI 10.1007/s40266-012-0015-2
   Frampton JE, 2012, DRUGS, V72, P509, DOI 10.2165/11208410-000000000-00000
   Frenkel MPC, 2010, ARCH OPHTHALMOL-CHIC, V128, P1523, DOI 10.1001/archophthalmol.2010.297
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Heier JS, 2006, ARCH OPHTHALMOL-CHIC, V124, P1532, DOI 10.1001/archopht.124.11.1532
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Heimes B, 2011, GRAEF ARCH CLIN EXP, V249, P639, DOI 10.1007/s00417-010-1524-5
   Hjelmqvist L, 2011, J OPHTHALMOL, V2011, DOI 10.1155/2011/405724
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Hurley Susan F, 2008, Cost Eff Resour Alloc, V6, P12, DOI 10.1186/1478-7547-6-12
   Hernandez-Pastor LJ, 2010, GRAEF ARCH CLIN EXP, V248, P467, DOI 10.1007/s00417-009-1156-9
   Hernandez-Pastor LJ, 2008, CLIN THER, V30, P2436, DOI 10.1016/j.clinthera.2008.12.025
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Kaiser PK, 2007, OPHTHALMOLOGY, V114, P1868, DOI 10.1016/j.ophtha.2007.04.030
   Kaiser PK, 2006, GRAEF ARCH CLIN EXP, V244, P1132, DOI 10.1007/s00417-005-0199-9
   Kaiser PK, 2012, GRAEF ARCH CLIN EXP, V250, P1563, DOI 10.1007/s00417-012-2123-4
   Kaiser PK, 2012, OPHTHALMOLOGY, V119, P1001, DOI 10.1016/j.ophtha.2012.02.003
   Katz G, 2012, RETINA-J RET VIT DIS, V32, P293, DOI 10.1097/IAE.0b013e31821e20b0
   Khandhadia S, 2012, ADV EXP MED BIOL, V724, P15, DOI 10.1007/978-1-4614-0653-2_2
   Klettner A, 2008, INVEST OPHTH VIS SCI, V49, P4523, DOI 10.1167/iovs.08-2055
   Klinikum Bremen-Mitte GmbH, NCT00559715
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Kovach JL, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/786870
   Krohne TU, 2012, AM J OPHTHALMOL, V154, P682, DOI 10.1016/j.ajo.2012.03.047
   Kumar A, 2011, BRIT J OPHTHALMOL, V95, P530, DOI 10.1136/bjo.2009.171868
   Ladas ID, 2009, RETINA-J RET VIT DIS, V29, P313, DOI 10.1097/IAE.0b013e31819a5f98
   Lally DR, 2012, CURR OPIN OPHTHALMOL, V23, P182, DOI 10.1097/ICU.0b013e328352411c
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Larsen M, 2012, OPHTHALMOLOGY, V119, P992, DOI 10.1016/j.ophtha.2012.02.002
   Lotery A, 2012, RETINAL PHYSICIAN, V9, P25
   Lowe J, 2007, EXP EYE RES, V85, P425, DOI 10.1016/j.exer.2007.05.008
   Lucentis&REG;(ranibizumab injection), US PRESCRIBING INFOR
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Mitchell P, 2011, PHARMACOECONOMICS, V29, P107, DOI 10.2165/11585520-000000000-00000
   Mojica G, 2008, BRIT J OPHTHALMOL, V92, P584, DOI 10.1136/bjo.2007.126193
   Muether PS, 2012, OPHTHALMOLOGY, V119, P2082, DOI 10.1016/j.ophtha.2012.07.041
   Neubauer AS, 2010, CLIN THER, V32, P1343, DOI 10.1016/j.clinthera.2010.07.010
   Novartis, NCT00433017
   Nwanze CC, 2012, CLIN MED INSIGHTS-TH, V4, P29, DOI 10.4137/CMT.S7439
   Oubraham H, 2011, RETINA-J RET VIT DIS, V31, P26, DOI 10.1097/IAE.0b013e3181de5609
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Patel JJ, 2012, J EVAL CLIN PRACT, V18, P247, DOI 10.1111/j.1365-2753.2010.01546.x
   Pitlick JM, 2012, ANN PHARMACOTHER, V46, P290, DOI 10.1345/aph.1Q471
   Pushpoth S, 2012, BRIT J OPHTHALMOL, V96, P1469, DOI 10.1136/bjophthalmol-2012-302167
   Querques G, 2010, BRIT J OPHTHALMOL, V94, P292, DOI 10.1136/bjo.2009.170670
   Raftery J, 2007, BRIT J OPHTHALMOL, V91, P1244, DOI 10.1136/bjo.2007.116616
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rothenbuehler SP, 2009, AM J OPHTHALMOL, V147, P831, DOI 10.1016/j.ajo.2008.12.005
   Sadda SR, 2010, RETINA-J RET VIT DIS, V30, P1390, DOI 10.1097/IAE.0b013e3181e44599
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Schmidt-Erfurth U, 2010, EXPERT OPIN DRUG SAF, V9, P149, DOI 10.1517/14740330903418422
   Semeraro F, 2011, CURR VASC PHARMACOL, V9, P629, DOI 10.2174/157016111796642670
   Shah CP, 2011, OPHTHALMOLOGY, V118, P2028, DOI 10.1016/j.ophtha.2011.02.034
   Sharei V, 2010, EUR J OPHTHALMOL, V20, P174, DOI 10.1177/112067211002000124
   Sharma S, 2012, CAN J OPHTHALMOL, V47, P275, DOI 10.1016/j.jcjo.2012.03.026
   Silva R, 2013, OPHTHALMOLOGY, V120, P130, DOI 10.1016/j.ophtha.2012.07.026
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Spaide R, 2007, AM J OPHTHALMOL, V143, P679, DOI 10.1016/j.ajo.2007.02.024
   Spitzer MS, 2007, GRAEF ARCH CLIN EXP, V245, P1837, DOI 10.1007/s00417-007-0568-7
   Stewart MW, 2012, MAYO CLIN PROC, V87, P77, DOI 10.1016/j.mayocp.2011.10.001
   Suner IJ, 2011, ASSOCIATION FOR RESE
   Takahashi H, 2005, CLIN SCI, V109, P227, DOI 10.1042/CS20040370
   The Royal College of Ophthalmologists, AGE RELATED MACULAR
   Toalster N, 2011, CLIN EXP OPHTHALMOL, V39, P70
   Vedula SS, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub2
   Vinores SA, 2006, INT J NANOMED, V1, P263
   Waisbourd M, 2007, DRUG AGING, V24, P643, DOI 10.2165/00002512-200724080-00003
   Wykoff CC, CONTROVERSIES IN THE
   Yu LL, 2011, BIOCHEM BIOPH RES CO, V408, P276, DOI 10.1016/j.bbrc.2011.04.014
   Ziemssen F, 2011, DRUG AGING, V28, P853, DOI 10.2165/11594720-000000000-00000
   Ziemssen F, 2009, DRUG AGING, V26, P295, DOI 10.2165/00002512-200926040-00002
NR 121
TC 35
Z9 37
U1 0
U2 33
PU ADIS INT LTD
PI NORTHCOTE
PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
SN 1170-229X
EI 1179-1969
J9 DRUG AGING
JI Drugs Aging
PD MAY
PY 2013
VL 30
IS 5
BP 331
EP 358
DI 10.1007/s40266-013-0077-9
PG 28
WC Geriatrics & Gerontology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology; Pharmacology & Pharmacy
GA 139ID
UT WOS:000318574800006
PM 23539234
DA 2022-11-30
ER

PT J
AU Golan, S
   Shalev, V
   Treister, G
   Chodick, G
   Loewenstein, A
AF Golan, S.
   Shalev, V.
   Treister, G.
   Chodick, G.
   Loewenstein, A.
TI Continuing Medical Education: Reconsidering the connection between
   vitamin D levels and age-related macular degeneration
SO EYE
LA English
DT Article
DE age-related macular degeneration; serum 25-OH vitamin D; Maccabi
   Healthcare Services; Health Maintenance Organization
ID COMPLEMENT FACTOR-H; C-REACTIVE PROTEIN; DIETARY-FAT; BRUCHS MEMBRANE;
   DOWN-REGULATION; ASSOCIATION; RISK; DRUSEN; PATHOGENESIS; MACULOPATHY
AB Purpose Recent evidence has suggested a correlation between reduced vitamin D levels and delayed angiogenesis and reduced inflammatory response, which are known to have a major role in the development and progression of age-related macular degeneration (AMD).
   Design Cross-sectional study.
   Participants Members of the Maccabi Healthcare Services (MHS, one of the four largest Israeli Health Maintenance Organization) aged >= 60 years, whose vitamin D levels were taken as part of routine examinations between 2000 and 2008.
   Methods All data for this study were obtained from MHS databases that include medical information on 1.8 million subscribers.
   Main outcome measures Serum 25-OH vitamin D levels.
   Results The total study population comprised of 1045 members diagnosed as having AMD, and 8124 as non-AMD, for whom there was information on vitamin D levels. The mean +/- SD level of 25-OH vitamin D was 24.1 +/- 9.41 ng/ml (range 0.8-120) for the AMD patients and 24.13 +/- 9.50 ng/ml (range 0.0-120) for the controls (P = ns). One-third (33.6%) of the AMD patients and 32.86% of the controls had a 25-OH vitamin D level < 16 ng/ml, and the proportions of tests in which the 25-OH vitamin D level was > 74 ng/ml were 0.19 and 0.14%, respectively (P = ns)
   Conclusions No association was detected between vitamin D levels and the presence of AMD in this cross-sectional study. These results raise some doubt about an association between reduced vitamin D levels and the prevalence of AMD. Eye (2011) 25, 1122-1129; doi: 10.1038/eye.2011.174; published online 5 August 2011
C1 [Golan, S.; Loewenstein, A.] Tel Aviv Med Ctr & Sch Med, Dept Ophthalmol, IL-64239 Tel Aviv, Israel.
   [Shalev, V.; Treister, G.; Chodick, G.] Maccabi Hlth Care Serv, Tel Aviv, Israel.
   [Golan, S.; Shalev, V.; Treister, G.; Loewenstein, A.] Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel.
C3 Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University;
   Sackler Faculty of Medicine
RP Golan, S (通讯作者)，Tel Aviv Med Ctr & Sch Med, Dept Ophthalmol, 6 Weizman St, IL-64239 Tel Aviv, Israel.
EM shanigol2@walla.com
OI /0000-0002-5189-8995
CR Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Augustin AJ, 2009, EXPERT OPIN THER TAR, V13, P641, DOI 10.1517/14728220902942322
   Bernardi RJ, 2002, ENDOCRINOLOGY, V143, P2508, DOI 10.1210/en.143.7.2508
   D'Ambrosio D, 1998, J CLIN INVEST, V101, P252, DOI 10.1172/JCI1050
   d'Hellencourt CL, 2003, J NEUROSCI RES, V71, P575, DOI 10.1002/jnr.10491
   DASTGHEIB K, 1994, ARCH OPHTHALMOL-CHIC, V112, P813, DOI 10.1001/archopht.1994.01090180111045
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   *DIASORIN INC, 2004, 25 HYDR D 1251 RIA K
   Gorin MB, 2007, ARCH OPHTHALMOL-CHIC, V125, P21, DOI 10.1001/archopht.125.1.21
   Gunter E.W., 1996, LAB PROCEDURES USED
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hayes CE, 2003, CELL MOL BIOL, V49, P277
   Holick MF, 2004, AM J CLIN NUTR, V79, P362
   HUTCHINSON AK, 1993, ARCH OPHTHALMOL-CHIC, V111, P734, DOI 10.1001/archopht.1993.01090060020010
   Iseki K, 1999, INT J CANCER, V81, P730, DOI 10.1002/(SICI)1097-0215(19990531)81:5&lt;730::AID-IJC11&gt;3.0.CO;2-Q
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KLEIN ML, 1994, ARCH OPHTHALMOL-CHIC, V112, P932, DOI 10.1001/archopht.1994.01090190080025
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein R, 2003, ARCH OPHTHALMOL-CHIC, V121, P674, DOI 10.1001/archopht.121.5.674
   Klein R, 2003, OPHTHALMOLOGY, V110, P25, DOI 10.1016/S0161-6420(02)01565-8
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   MANOLAGAS SC, 1986, J CLIN ENDOCR METAB, V63, P394, DOI 10.1210/jcem-63-2-394
   MARES J, 2003, CAROTENOIDS HLTH DIS, P19
   Mares-Perlman JA, 2002, J NUTR, V132, p518S, DOI 10.1093/jn/132.3.518S
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P743, DOI 10.1001/archopht.1995.01100060069034
   Melamed ML, 2008, ARCH INTERN MED, V168, P1629, DOI 10.1001/archinte.168.15.1629
   Merlino LA, 2004, ARTHRITIS RHEUM-US, V50, P72, DOI 10.1002/art.11434
   Mitchell P, 2002, ARCH OPHTHALMOL-CHIC, V120, P1357, DOI 10.1001/archopht.120.10.1357
   MULLER K, 1991, INT J IMMUNOPHARMACO, V13, P525, DOI 10.1016/0192-0561(91)90072-F
   *NIH OFF DIET SUPP, 2011, DIET SUPPL FACT SHEE
   Parekh N, 2007, ARCH OPHTHALMOL-CHIC, V125, P661, DOI 10.1001/archopht.125.5.661
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Sepp T, 2006, INVEST OPHTH VIS SCI, V47, P536, DOI 10.1167/iovs.05-1143
   SEREGARD S, 1994, GRAEF ARCH CLIN EXP, V232, P325, DOI 10.1007/BF00175983
   SHOKRAVI MT, 1995, INVEST OPHTH VIS SCI, V36, P83
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   Takahashi K, 2002, IMMUNOPHARM IMMUNOT, V24, P1, DOI 10.1081/IPH-120003399
   Tandeter H, 2009, ISR MED ASSOC J, V11, P339
   TAYLOR HR, 1992, ARCH OPHTHALMOL-CHIC, V110, P99, DOI 10.1001/archopht.1992.01080130101035
   THOMASSET M, 1994, PATHOL BIOL, V42, P163
   Timms PM, 2002, QJM-INT J MED, V95, P787, DOI 10.1093/qjmed/95.12.787
   Topilski I, 2004, EUR J IMMUNOL, V34, P1068, DOI 10.1002/eji.200324532
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
NR 53
TC 33
Z9 33
U1 0
U2 8
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD SEP
PY 2011
VL 25
IS 9
BP 1122
EP 1129
DI 10.1038/eye.2011.174
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 818NW
UT WOS:000294760300004
PM 21818133
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Moriarty-Craige, SE
   Adkison, J
   Lynn, M
   Gensler, G
   Bressler, S
   Jones, DP
   Sternberg, P
AF Moriarty-Craige, SE
   Adkison, J
   Lynn, M
   Gensler, G
   Bressler, S
   Jones, DP
   Sternberg, P
TI Antioxidant supplements prevent oxidation of cysteine/cystine redox in
   patients with age-related macular degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID PIGMENT EPITHELIAL-CELLS; HUMAN PLASMA; GLUTATHIONE; STATE;
   PATHOGENESIS; ASSOCIATION; PROTECTION; APOPTOSIS; DECLINE; DRUSEN
AB PURPOSE: Determine whether antioxidant supplements alter the plasma glutathione and/or cysteine redox potential in age-related macular degeneration (AMD) patients.
   DESIGN: This was an ancillary study to the Age-Related Eye Disease Study (AREDS), where subset of AREDS subjects at two sites were studied at two time points, an average of 1.7 and 6.7 years after enrollment.
   METHODS: Plasma glutathione (GSH), glutathione disulfide (GSSG), cysteine (Cys), and cystine (CySS) were measured by high-performance liquid chromatography, and redox potentials of GSH/GSSG (E-h GSH) and Cys/CySS (E-h Cys) were calculated. The means of the metabolites and redox potentials were compared by repeated-measures analysis of variance for subjects receiving antioxidants and those not receiving antioxidants.
   RESULTS: At the first blood draw, the means for the antioxidant group (n = 153) and no antioxidant group (n = 159) were not significantly different for any of the metabolites or redox potentials. At the second draw, the GSH parameters were not significantly different between the antioxidant (n = 37) and no antioxidant (n = 45) groups; however, mean Cys was significantly higher in the antioxidant group (9.5 vs 7.2 mu mol/l, P =.008). Also, mean Eh Cys was significantly more reduced in the antioxidant group (-74 vs -67.3 mV, P =.03).
   CONCLUSIONS: The AREDS antioxidant supplements reduced oxidation of E-h, Cys but had no effect on GSH. Because Cys is important for cell growth, apoptosis, and immune function, the beneficial effect of antioxidant supplementation on progression to advanced AMD may be partially explained by its effect on E-h, Cys and/or its effect on Cys availability.
C1 Emory Univ, Dept Ophthalmol Biochem & Med, Atlanta, GA 30322 USA.
   Emory Univ, Rollins Sch Publ Hlth, Dept Biostat, Atlanta, GA 30322 USA.
   EMMES Corp, Rockville, MD USA.
   Johns Hopkins Univ Hosp, Wilmer Eye Inst, Baltimore, MD 21287 USA.
   Vanderbilt Univ, Dept Ophthalmol & Visual Sci, Nashville, TN USA.
   Childrens Hosp Boston, Div Emergency Med, Boston, MA USA.
   Harvard Sch Med, Cambridge, MA USA.
C3 Emory University; Emory University; Rollins School Public Health; Emmes
   Corporation; Johns Hopkins University; Johns Hopkins Medicine;
   Vanderbilt University; Harvard University; Boston Children's Hospital;
   Harvard University; Harvard Medical School
RP Sternberg, P (通讯作者)，Vanderbilt Univ, Med Ctr, Vanderbilt Eye Inst, 8030 Med Ctr E, Nashville, TN 37232 USA.
EM paul.sternberg@vanderbilt.edu
FU NEI NIH HHS [EY 06360, EY 07892, T32 EY 07092-19, EY 08126] Funding
   Source: Medline; NATIONAL EYE INSTITUTE [R01EY007892, R29EY007892,
   P30EY008126, T32EY007092] Funding Source: NIH RePORTER
CR Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   BUETTNER GR, 1993, ARCH BIOCHEM BIOPHYS, V300, P535, DOI 10.1006/abbi.1993.1074
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Cudkowicz ME, 1999, NEUROLOGY, V52, P1492, DOI 10.1212/WNL.52.7.1492
   DAVIDSON PC, 1994, INVEST OPHTH VIS SCI, V35, P2843
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   Go YM, 2003, FREE RADICAL BIO MED, V35, pS53
   Hildebrandt W, 2002, MECH AGEING DEV, V123, P1269, DOI 10.1016/S0047-6374(02)00013-1
   ISHIBASHI T, 1986, INVEST OPHTH VIS SCI, V27, P184
   Jiang SN, 2005, INVEST OPHTH VIS SCI, V46, P1054, DOI 10.1167/iovs.04-0949
   Jones DP, 2000, FREE RADICAL BIO MED, V28, P625, DOI 10.1016/S0891-5849(99)00275-0
   Jones DP, 1998, CLIN CHIM ACTA, V275, P175, DOI 10.1016/S0009-8981(98)00089-8
   Jones DP, 2004, FASEB J, V18, P1246, DOI 10.1096/fj.03-0971fje
   Jones DP, 2002, FREE RADICAL BIO MED, V33, P1290, DOI 10.1016/S0891-5849(02)01040-7
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Moriarty SE, 2003, FREE RADICAL BIO MED, V35, P1582, DOI 10.1016/j.freeradbiomed.2003.09.006
   NETER J, 1996, APPL LINEAR STAT MOD, P1164
   Samiec PS, 1998, FREE RADICAL BIO MED, V24, P699, DOI 10.1016/S0891-5849(97)00286-4
   *SAS I INC, 1999, SAS STAT US GUID VER, P2083
   Schlingemann RO, 2004, GRAEF ARCH CLIN EXP, V242, P91, DOI 10.1007/s00417-003-0828-0
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   STERNBERG P, 1993, INVEST OPHTH VIS SCI, V34, P3661
NR 24
TC 63
Z9 64
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD DEC
PY 2005
VL 140
IS 6
BP 1020
EP 1026
DI 10.1016/j.ajo.2005.06.043
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 000QA
UT WOS:000234475900008
PM 16376645
DA 2022-11-30
ER

PT J
AU Aspinall, A
   Hill, AR
   Dhillon, B
   Armbrecht, AM
   Nelson, P
   Lumsden, C
   Farini-Hudson, E
   Brice, R
   Vickers, A
   Buchholz, P
AF Aspinall, A.
   Hill, A. R.
   Dhillon, B.
   Armbrecht, A. M.
   Nelson, P.
   Lumsden, C.
   Farini-Hudson, E.
   Brice, R.
   Vickers, A.
   Buchholz, P.
TI Quality of life and relative importance: a comparison of time trade-off
   and conjoint analysis methods in patients with age-related macular
   degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID FUNCTIONAL IMPAIRMENT; DIABETIC-RETINOPATHY; UTILITY-ASSESSMENT;
   VISUAL-ACUITY; CLINICIAN; VALUES; INDEX; STATE; PREFERENCES; CATARACT
AB Aim: To investigate the relative priorities in quality of life (QoL) in patients with age-related macular degeneration (AMD).
   Methods: Measures of visual function, QoL and utility associated with visual loss were obtained from 122 patients with AMD classified according to macular morphology. The two methods of utility assessment were time trade-off (TTO) and conjoint analysis ( CA), which have been recommended by the UK's National Institute of Clinical Excellence as techniques for the assessment of healthcare priorities.
   Results: Results show that the two methods for assessing utility are poorly related: TTO relates moderately to visual function and disease severity but CA does not. CA identified two different subgroups of patients: one with outdoor mobility and the other with reading as their main priority.
   Conclusion: Further work is needed and caution required in interpreting data obtained using these methodologies for determining their relative importance in vision-related QoL studies.
C1 Heriot Watt Univ, Visual Impairment Res Grp, Sch Built Environm, Edinburgh EH14 3AZ, Midlothian, Scotland.
   Adelpi Res Grp, Bollington, Cheshire, England.
   Allergan Europe, Pforzheimersts, Ettlingen, Germany.
C3 Heriot Watt University; AbbVie; Allergan
RP Aspinall, A (通讯作者)，Heriot Watt Univ, Visual Impairment Res Grp, Sch Built Environm, Edinburgh EH14 3AZ, Midlothian, Scotland.
EM aspinall@sbe.hw.ac.uk
CR Bass EB, 1997, MED DECIS MAKING, V17, P324, DOI 10.1177/0272989X9701700309
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Brown GC, 2000, ARCH OPHTHALMOL-CHIC, V118, P47
   BROWN GC, 2001, T AM OPHTHAL SOC, V91, P199
   Brown Melissa M., 2001, International Ophthalmology, V24, P123, DOI 10.1023/A:1021171000838
   Brown MM, 1999, AM J OPHTHALMOL, V128, P324, DOI 10.1016/S0002-9394(99)00146-4
   Brown MM, 2002, ARCH OPHTHALMOL-CHIC, V120, P481
   CASSARD SD, 1995, ARCH OPHTHALMOL-CHIC, V113, P1508, DOI 10.1001/archopht.1995.01100120038005
   FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6
   Gold MR., 1996, COST EFFECTIVENESS H
   Hart PM, 1999, BRIT J OPHTHALMOL, V83, P1115, DOI 10.1136/bjo.83.10.1115
   HILL AR, 1986, PROGR RETINAL RES, V6, P207
   Hollands H, 2001, CAN J OPHTHALMOL, V36, P202, DOI 10.1016/S0008-4182(01)80041-7
   JOHNSON R, 2001, CONJOINT ANAL SOFTWA
   MANGIONE CM, 1992, MED CARE, V30, P1111, DOI 10.1097/00005650-199212000-00004
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   Massof RW, 1998, OPTOMETRY VISION SCI, V75, P349, DOI 10.1097/00006324-199805000-00025
   MIGUEL FS, 1997, 0697 U AB HLTH EC RE
   Nelson P, 1999, BRIT J OPHTHALMOL, V83, P546, DOI 10.1136/bjo.83.5.546
   *NICE, 2004, GUID METH TECHN APPR, P24
   Orme B., 1998, SAMPLE SIZE ISSUES C
   REDELMEIER DA, 1995, PRIMARY CARE, V22, P271
   Rubin GS, 2000, INVEST OPHTH VIS SCI, V41, P3327
   Ryan M, 1999, SOC SCI MED, V48, P535, DOI 10.1016/S0277-9536(98)00374-8
   RYAN M, 1994, 0794 U AB HLTH EC RE
   Sharma S, 2002, BRIT J OPHTHALMOL, V86, P493, DOI 10.1136/bjo.86.5.493
   Singh J, 1998, MED CARE, V36, pAS31, DOI 10.1097/00005650-199808001-00005
   Stein JD, 2003, BRIT J OPHTHALMOL, V87, P8, DOI 10.1136/bjo.87.1.8
   STEINBERG EP, 1994, ARCH OPHTHALMOL-CHIC, V112, P630, DOI 10.1001/archopht.1994.01090170074026
   Szeinbach SL, 1999, DRUG INF J, V33, P849, DOI 10.1177/009286159903300326
   TORRANCE GW, 1986, J HEALTH ECON, V5, P1, DOI 10.1016/0167-6296(86)90020-2
   van der Pol M, 1998, J Health Serv Res Policy, V3, P70
   Wade DT., 1992, MEASUREMENT NEUROLOG
   [No title captured], DOI DOI 10.1017/CBO9780511809477
NR 34
TC 11
Z9 11
U1 0
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD JUN
PY 2007
VL 91
IS 6
BP 766
EP 772
DI 10.1136/bjo.2006.104679
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 169BA
UT WOS:000246566500018
PM 17229802
OA Green Published
DA 2022-11-30
ER

PT J
AU Musel, B
   Hera, R
   Chokron, S
   Alleysson, D
   Chiquet, C
   Romanet, JP
   Guyader, N
   Peyrin, C
AF Musel, Benoit
   Hera, Ruxandra
   Chokron, Sylvie
   Alleysson, David
   Chiquet, Christophe
   Romanet, Jean-Paul
   Guyader, Nathalie
   Peyrin, Carole
TI Residual abilities in age-related macular degeneration to process
   spatial frequencies during natural scene categorization
SO VISUAL NEUROSCIENCE
LA English
DT Article
DE Low vision; Indoor/Outdoor; Low spatial frequency; High spatial
   frequency; Visual categorization
ID PRIMARY VISUAL-CORTEX; QUALITY-OF-LIFE; LOW-VISION;
   HEMISPHERIC-SPECIALIZATION; OBJECT RECOGNITION; FACE RECOGNITION;
   REORGANIZATION; MACULOPATHY; IMPAIRMENT; LESIONS
AB Age-related macular degeneration (AMD) is characterized by a central vision loss. We explored the relationship between the retinal lesions in AMD patients and the processing of spatial frequencies in natural scene categorization. Since the lesion on the retina is central, we expected preservation of low spatial frequency (LSF) processing and the impairment of high spatial frequency (HSF) processing. We conducted two experiments that differed in the set of scene stimuli used and their exposure duration. Twelve AMD patients and 12 healthy age-matched participants in Experiment 1 and 10 different AMD patients and 10 healthy age-matched participants in Experiment 2 performed categorization tasks of natural scenes (Indoors vs. Outdoors) filtered in LSF and HSF. Experiment 1 revealed that AMD patients made more no-responses to categorize HSF than LSF scenes, irrespective of the scene category. In addition, AMD patients had longer reaction times to categorize HSF than LSF scenes only for indoors. Healthy participants' performance was not differentially affected by spatial frequency content of the scenes. In Experiment 2, AMD patients demonstrated the same pattern of errors as in Experiment 1. Furthermore, AMD patients had longer reaction times to categorize HSF than LSF scenes, irrespective of the scene category. Again, spatial frequency processing was equivalent for healthy participants. The present findings point to a specific deficit in the processing of HSF information contained in photographs of natural scenes in AMD patients. The processing of LSF information is relatively preserved. Moreover, the fact that the deficit is more important when categorizing HSF indoors, may lead to new perspectives for rehabilitation procedures in AMD.
C1 [Musel, Benoit; Chokron, Sylvie; Alleysson, David; Peyrin, Carole] Univ Pierre Mendes France, Lab Psychol & NeuroCognit, CNRS, UMR 5105, F-38040 Grenoble, France.
   [Hera, Ruxandra; Chiquet, Christophe; Romanet, Jean-Paul] CHU Albert Michalon, Serv Ophtalmol, Grenoble, France.
   [Chokron, Sylvie] Fdn Ophtalmol Rothschild, Unite Fonct Vis & Cognit, Paris, France.
   [Guyader, Nathalie] CNRS, UMR 5216, Grenoble Image Parole Signal Automat GIPSA Lab, Grenoble, France.
C3 Centre National de la Recherche Scientifique (CNRS); CNRS - National
   Institute for Biology (INSB); UDICE-French Research Universities;
   Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA);
   Universite de Savoie; CHU Grenoble Alpes; UDICE-French Research
   Universities; Communaute Universite Grenoble Alpes; Institut National
   Polytechnique de Grenoble; Universite Grenoble Alpes (UGA); Centre
   National de la Recherche Scientifique (CNRS)
RP Musel, B (通讯作者)，Univ Pierre Mendes France, Lab Psychol & NeuroCognit, CNRS, UMR 5105, BP 47, F-38040 Grenoble, France.
EM benoit.musel@upmf-grenoble.fr
RI Chiquet, Christophe/M-7426-2014
OI Chiquet, Christophe/0000-0002-7601-4885; Peyrin,
   Carole/0000-0001-7792-092X
FU Region Rhone-Alpes
FX This work was supported by Region Rhone-Alpes.
CR Baker CI, 2008, VISION RES, V48, P1910, DOI 10.1016/j.visres.2008.05.020
   Baker CI, 2005, J NEUROSCI, V25, P614, DOI 10.1523/JNEUROSCI.3476-04.2005
   Boucard CC, 2009, BRAIN, V132, P1898, DOI 10.1093/brain/awp119
   Boucart M., 2008, VISUAL NEUROSCI, V25, P1
   Boucart M, 2008, VISUAL NEUROSCI, V25, P685, DOI 10.1017/S0952523808080826
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   Brown MM, 2002, ARCH OPHTHALMOL-CHIC, V120, P481
   BULLIMORE MA, 1991, INVEST OPHTH VIS SCI, V32, P2020
   Calford MB, 2003, J NEUROSCI, V23, P6434
   Callaway EM, 2005, PROG BRAIN RES, V149, P59, DOI 10.1016/S0079-6123(05)49005-6
   CAMPBELL FW, 1965, J PHYSIOL-LONDON, V181, P576, DOI 10.1113/jphysiol.1965.sp007784
   Cavezian C, 2010, CORTEX, V46, P1123, DOI 10.1016/j.cortex.2009.08.013
   Cheung SH, 2005, VISUAL NEUROSCI, V22, P187, DOI 10.1017/S0952523805222071
   CHINO YM, 1995, J NEUROSCI, V15, P2417, DOI 10.1523/JNEUROSCI.15-03-02417.1995
   CURCIO CA, 1990, J COMP NEUROL, V292, P497, DOI 10.1002/cne.902920402
   Dacey DM, 2003, CURR OPIN NEUROBIOL, V13, P421, DOI 10.1016/S0959-4388(03)00103-X
   DEVALOIS RL, 1982, VISION RES, V22, P545, DOI 10.1016/0042-6989(82)90113-4
   Faubert J, 2000, J AM GERIATR SOC, V48, P375, DOI 10.1111/j.1532-5415.2000.tb04693.x
   FINE EM, 1995, J OPT SOC AM A, V12, P2286, DOI 10.1364/JOSAA.12.002286
   Fletcher DC, 1999, J REHABIL RES DEV, V36, P356
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   GILBERT CD, 1992, NATURE, V356, P150, DOI 10.1038/356150a0
   Ginsburg A.P., 1986, HDB PERCEPTION HUMAN, V2
   Guyader N, 2004, CR BIOL, V327, P313, DOI 10.1016/j.crvi.2004.02.006
   Hassan SE, 2002, OPTOMETRY VISION SCI, V79, P697, DOI 10.1097/00006324-200211000-00007
   HEINEN SJ, 1991, EXP BRAIN RES, V83, P670
   Hera R, 2005, AM J OPHTHALMOL, V139, P589, DOI 10.1016/j.ajo.2004.11.064
   Horton JC, 1998, J NEUROSCI, V18, P5433, DOI 10.1523/JNEUROSCI.18-14-05433.1998
   Hughes HC, 1996, J COGNITIVE NEUROSCI, V8, P197, DOI 10.1162/jocn.1996.8.3.197
   KAAS JH, 1990, SCIENCE, V248, P229, DOI 10.1126/science.2326637
   Keck T, 2008, NAT NEUROSCI, V11, P1162, DOI 10.1038/nn.2181
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   KLEINER RC, 1988, ARCH OPHTHALMOL-CHIC, V106, P55
   Kulkarni AD, 2005, ADV DRUG DELIVER REV, V57, P1994, DOI 10.1016/j.addr.2005.09.003
   Lee SCS, 2005, EUR J NEUROSCI, V22, P437, DOI 10.1111/j.1460-9568.2005.04231.x
   LEGGE GE, 1985, VISION RES, V25, P253, DOI 10.1016/0042-6989(85)90118-X
   LEGGE GE, 1992, INVEST OPHTH VIS SCI, V33, P677
   Mangione CM, 1999, AM J OPHTHALMOL, V128, P45, DOI 10.1016/S0002-9394(99)00169-5
   Midena E, 1997, INVEST OPHTH VIS SCI, V38, P469
   Mitchell J, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-97
   Murakami I, 1997, VISUAL NEUROSCI, V14, P89, DOI 10.1017/S0952523800008798
   Osterberg G, 1935, Acta Ophthalmol., V13, P11
   Peli E., 1994, J OPT SOC AM A, V11, P1029
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Peyrin C, 2006, BRAIN RES, V1073, P1, DOI 10.1016/j.brainres.2005.12.051
   Peyrin C, 2004, NEUROIMAGE, V23, P698, DOI 10.1016/j.neuroimage.2004.06.020
   Peyrin C, 2003, BRAIN COGNITION, V53, P278, DOI 10.1016/S0278-2626(03)00126-X
   Peyrin C, 2006, BRAIN COGNITION, V62, P214, DOI 10.1016/j.bandc.2006.05.005
   Peyrin C, 2010, J COGNITIVE NEUROSCI, V22, P2768, DOI 10.1162/jocn.2010.21424
   Rosenholtz R, 2007, J VISION, V7, DOI 10.1167/7.2.17
   Rovner BW, 2002, AM J GERIAT PSYCHIAT, V10, P305
   SALIVE ME, 1994, J AM GERIATR SOC, V42, P287, DOI 10.1111/j.1532-5415.1994.tb01753.x
   Schyns PG, 1999, COGNITION, V69, P243, DOI 10.1016/S0010-0277(98)00069-9
   Seiple W, 2005, INVEST OPHTH VIS SCI, V46, P2886, DOI 10.1167/iovs.04-1296
   Shams L, 2002, VISION RES, V42, P2547, DOI 10.1016/S0042-6989(02)00202-X
   Smirnakis SM, 2005, NATURE, V435, P300, DOI 10.1038/nature03495
   Sunness JS, 2004, OPHTHALMOLOGY, V111, P1595, DOI 10.1016/j.ophtha.2003.12.050
   Tejeria L, 2002, BRIT J OPHTHALMOL, V86, P1019, DOI 10.1136/bjo.86.9.1019
   Torralba A, 2003, NETWORK-COMP NEURAL, V14, P391, DOI 10.1088/0954-898X/14/3/302
   Tran THC, 2010, INVEST OPHTHALMOL, V12, P6868
   Van Essen David C., 1995, P383
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Wang YZ, 2002, INVEST OPHTH VIS SCI, V43, P2055
   West SK, 1997, INVEST OPHTH VIS SCI, V38, P72
   Wiliams RA, 1998, ARCH OPHTHALMOL-CHIC, V116, P514
   Wright V., 1995, LEARNING USE YOUR VI
   YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1016/0039-6257(87)90115-9
NR 68
TC 10
Z9 10
U1 0
U2 11
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 0952-5238
EI 1469-8714
J9 VISUAL NEUROSCI
JI Visual Neurosci.
PD NOV
PY 2011
VL 28
IS 6
BP 529
EP 541
DI 10.1017/S0952523811000435
PG 13
WC Neurosciences; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology; Ophthalmology
GA 873AN
UT WOS:000298853000006
PM 22192508
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Phipps, JA
   Guymer, RH
   Vingrys, AJ
AF Phipps, JA
   Guymer, RH
   Vingrys, AJ
TI Loss of cone function in age-related maculopathy
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID DARK-ADAPTATION; CONTRAST SENSITIVITY; FLICKER SENSITIVITY; FUNDUS
   APPEARANCE; GLARE RECOVERY; FELLOW EYE; ABNORMALITIES; DEGENERATION;
   REGENERATION; PATHOGENESIS
AB PURPOSE. To evaluate cone visual function of subjects with age-related maculopathy (ARM).
   METHODS. Cone thresholds in 16 patients with ARM and 14 age-matched control subjects were compared. All subjects had visual acuity of 6/12 or better in the studied eye. A range of contrast thresholds were measured to evaluate diverse aspects of cone visual function under steady state conditions (spatio-temporal, color and luminance, and photopic sensitivity) or after bleaching (adaptation dynamics).
   RESULTS. ARM produced a diffuse loss across all cone steady state visual functions in 31% to 44% of subjects. The adaptation time constant of cone recovery was significantly prolonged in most (69%) ARM eyes. A cross-correlational analysis found adaptational kinetics to be independent of other steady state losses, with cone photopigment regeneration being the most affected visual function in ARM (chi(2) = 4.03, P < 0.05).
   CONCLUSIONS. The results show that cone-adaptational kinetics are affected in ARM more so than are steady state thresholds. Given that cone recovery is easy to examine in a clinical setting, this test may provide a useful index of photopic function in patients with ARM.
C1 Univ Melbourne, Dept Optometry & Vis Sci, Melbourne, Vic 3010, Australia.
   Univ Melbourne, Ctr Eye Res, Melbourne, Vic 3010, Australia.
C3 University of Melbourne; University of Melbourne
RP Vingrys, AJ (通讯作者)，Univ Melbourne, Dept Optometry & Vis Sci, Melbourne, Vic 3010, Australia.
EM algis@unimelb.edu.au
OI Guymer, Robyn/0000-0002-9441-4356; Vingrys, Algis/0000-0001-5920-4604
CR APPLEGATE RA, 1987, APPL OPTICS, V26, P1458, DOI 10.1364/AO.26.001458
   BIRD AC, 1991, EYE, V5, P1
   BIRD AC, 1986, T OPHTHAL SOC UK, V105, P674
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BRESSLER NM, 1994, RETINA-J RET VIT DIS, V14, P130, DOI 10.1097/00006982-199414020-00006
   BROWN B, 1986, OPHTHAL PHYSL OPT, V6, P81, DOI 10.1111/j.1475-1313.1986.tb00704.x
   BROWN B, 1983, AM J OPTOM PHYS OPT, V60, P645
   Brown B, 1987, CLIN EXP OPTOM, V70, P112
   Bui BV, 1998, DOC OPHTHALMOL, V95, P15
   BURGESS DB, 1993, ARCH OPHTHALMOL-CHIC, V111, P1189
   CHENG AS, 1993, OPTOMETRY VISION SCI, V70, P89, DOI 10.1097/00006324-199302000-00001
   CHUANG EL, 1988, AM J OPHTHALMOL, V105, P285, DOI 10.1016/0002-9394(88)90011-6
   COILE DC, 1992, VISUAL NEUROSCI, V8, P27, DOI 10.1017/S0952523800006465
   COLLINS M, 1989, CLIN VISION SCI, V4, P145
   COLLINS M, 1989, CLIN VISION SCI, V4, P155
   Collins MJ, 1986, CLIN EXP OPTOM, V69, P223, DOI DOI 10.1111/J.1444-0938.1986.TB04596.X
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   DEMIREL S, 1995, PERIMETRY UPDATE 1994/1995, P83
   EISNER A, 1991, INVEST OPHTH VIS SCI, V32, P8
   EISNER A, 1992, INVEST OPHTH VIS SCI, V33, P3091
   EISNER A, 1987, INVEST OPHTH VIS SCI, V28, P1832
   FOSTER DH, 1987, BIOL CYBERN, V57, P341, DOI 10.1007/BF00338826
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   HAEGERSTROMPORTNOY G, 1989, CLIN VISION SCI, V4, P165
   Keppel G., 1991, DESIGN ANAL RES HDB
   KLEIN R, 1984, ARCH OPHTHALMOL-CHIC, V102, P527, DOI 10.1001/archopht.1984.01040030405011
   KLEINER RC, 1988, ARCH OPHTHALMOL-CHIC, V106, P55
   Leibrock CS, 1998, EYE, V12, P511, DOI 10.1038/eye.1998.139
   MACLEOD DIA, 1979, J OPT SOC AM, V69, P1183, DOI 10.1364/JOSA.69.001183
   MALONEY LT, 1990, PERCEPT PSYCHOPHYS, V47, P127, DOI 10.3758/BF03205977
   MAYER MJ, 1992, INVEST OPHTH VIS SCI, V33, P3136
   MAYER MJ, 1994, INVEST OPHTH VIS SCI, V35, P1138
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   MITCHELL RA, 1993, OPTOMETRY VISION SCI, V70, P102, DOI 10.1097/00006324-199302000-00003
   Owsley C, 2000, INVEST OPHTH VIS SCI, V41, P267
   Owsley C, 2001, OPHTHALMOLOGY, V108, P1196, DOI 10.1016/S0161-6420(01)00580-2
   PENTLAND A, 1980, PERCEPT PSYCHOPHYS, V28, P377, DOI 10.3758/BF03204398
   Phipps Joanna A, 2001, Clin Exp Optom, V84, P264
   Pianta MJ, 2000, J PHYSIOL-LONDON, V528, P591, DOI 10.1111/j.1469-7793.2000.00591.x
   Sandberg MA, 1999, INVEST OPHTH VIS SCI, V40, P2457
   SANDBERG MA, 1995, RETINA-J RET VIT DIS, V15, P407, DOI 10.1097/00006982-199515050-00006
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SARKS JP, 1994, EYE, V8, P269, DOI 10.1038/eye.1994.57
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Sliney D. H., 1980, SAFETY LASERS OTHER
   STEINMETZ RL, 1993, BRIT J OPHTHALMOL, V77, P549, DOI 10.1136/bjo.77.9.549
   SUNNESS JS, 1989, OPHTHALMOLOGY, V96, P375, DOI 10.1016/S0161-6420(89)32883-1
   YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1016/0039-6257(87)90115-9
NR 48
TC 69
Z9 70
U1 0
U2 13
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAY
PY 2003
VL 44
IS 5
BP 2277
EP 2283
DI 10.1167/iovs.02-0769
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 672CQ
UT WOS:000182503700066
PM 12714671
DA 2022-11-30
ER

PT J
AU Arias, L
   Armada, F
   Donate, J
   Garcia-Arumi, J
   Giralt, J
   Pazos, B
   Pinero, A
   Martinez, F
   Mondejar, JJ
   Ortega, I
   Zlateva, G
   Buggage, R
AF Arias, L.
   Armada, F.
   Donate, J.
   Garcia-Arumi, J.
   Giralt, J.
   Pazos, B.
   Pinero, A.
   Martinez, F.
   Mondejar, J. J.
   Ortega, I.
   Zlateva, G.
   Buggage, R.
TI Delay in treating age-related macular degeneration in Spain is
   associated with progressive vision loss
SO EYE
LA English
DT Article
DE NV-AMD; visual acuity; treatment delay; Spain
ID QUALITY-OF-LIFE; PEGAPTANIB SODIUM; MACULOPATHY; COHORT; IMPACT; TIME
AB Purpose To assess the impact on visual acuity of delays between diagnosis and treatment in patients with subfoveal neovascular age-related macular degeneration (NV-AMD) and to evaluate NV-AMD patients' emotional status before therapy initiation.
   Methods This retrospective, multicenter, epidemiological study included newly diagnosed NV-AMD patients registered in the Spanish national health system and referred to regional health centers for evaluation/treatment by a retinal specialist from 09/2005 to 03/2006. Records were reviewed and data abstracted at referring physicians' offices (diagnosis visit) and regional health centers (treatment visit). Treatment was at physicians' discretion. The Hospital Anxiety and Depression Scale was administered at the treatment visit (before therapy).
   Results Median time from the diagnosis to treatment visit was 2.3 months (95% confidence interval: 0.2-10.8 months). Vision loss had progressed at the treatment visit with a doubling in the percentage of patients with a visual acuity of 20/400 or worse (from 12.4 to 24.7%). The decrease in visual acuity from the diagnosis to the treatment visit was highly statistically significant (P<0.0001) as was the correlation between months to treatment and visual acuity change (r = 0.5234, P<0.0001). Time from the diagnosis to the treatment visit remained a significant predictor of progressive vision loss when visual acuity at diagnosis and change in lesion size between diagnosis and treatment were controlled (P<0.0001). Patients with more severe vision loss prior to treatment tended to report more depression.
   Conclusions Delayed treatment of patients newly diagnosed with NV-AMD is associated with substantial visual acuity loss.
C1 [Arias, L.] Bellvitge Univ Hosp, Dept Ophthalmol, Barcelona 08907, Spain.
   [Armada, F.; Ortega, I.] La Paz Univ Hosp, Dept Ophthalmol, Madrid, Spain.
   [Donate, J.] Clin San Carlos Hosp, Dept Ophthalmol, Madrid, Spain.
   [Garcia-Arumi, J.; Giralt, J.] Univ Autonoma Barcelona, Dept Ophthalmol, Vall dHebron Univ Hosp, E-08193 Barcelona, Spain.
   [Pazos, B.] INGO, Santiago De Compostela, Spain.
   [Pinero, A.] Nuestra Senora de Valme Univ Hosp, Dept Ophthalmol, Seville, Spain.
   [Martinez, F.] Marques de Valdecilla Univ Hosp, Dept Ophthalmol, Santander, Spain.
   [Mondejar, J. J.] La Fe Univ Hosp, Dept Ophthalmol, Valencia, Spain.
   [Zlateva, G.; Buggage, R.] Pfizer Inc, New York, NY USA.
C3 Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Bellvitge
   University Hospital; University of Barcelona; Hospital Universitario La
   Paz; Hospital Clinico San Carlos; Autonomous University of Barcelona;
   Hospital Universitari Vall d'Hebron; Hospital Universitario Marques de
   Valdecilla (HUMV); Pfizer
RP Arias, L (通讯作者)，Bellvitge Univ Hosp, Dept Ophthalmol, C Feixa Llarga S-N, Barcelona 08907, Spain.
EM luisarias@telefonica.net
RI Donate-Lopez, Juan/AAB-5144-2019
OI Donate-Lopez, Juan/0000-0002-9944-6736; ARIAS, LUIS/0000-0001-7041-5576;
   Garcia-Arumi, Jose/0000-0001-8827-1160
CR *AM AC OPHTH, 2006, PREF PRACT PATT AG R, P4
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   [Anonymous], 1991, Arch Ophthalmol, V109, P1220
   Bonastre J, 2003, PHARMACOECONOMICS, V21, P181, DOI 10.2165/00019053-200321030-00003
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1901
   Chakravarthy U, 2006, OPHTHALMOLOGY, V113, P1508, DOI 10.1016/j.ophtha.2006.02.064
   Chia EM, 2004, INVEST OPHTH VIS SCI, V45, P71, DOI 10.1167/iovs.03-0661
   D'Amico DJ, 2006, OPHTHALMOLOGY, V113, P992, DOI 10.1016/j.ophtha.2006.02.027
   Dandona L, 1998, ARCH OPHTHALMOL-CHIC, V116, P545, DOI 10.1001/archopht.116.4.514
   DeCarlo DK, 2003, OPTOMETRY VISION SCI, V80, P207, DOI 10.1097/00006324-200303000-00010
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   FERRIS FL, 1983, AM J EPIDEMIOL, V118, P132, DOI 10.1093/oxfordjournals.aje.a113624
   Gonzales CR, 2005, RETINA-J RET VIT DIS, V25, P815
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Hopley C, 2004, BRIT J OPHTHALMOL, V88, P450, DOI 10.1136/bjo.2003.035279
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   Mangione CM, 1999, AM J OPHTHALMOL, V128, P45, DOI 10.1016/S0002-9394(99)00169-5
   Oliver-Fernandez M, 2005, CAN J OPHTHALMOL, V40, P313, DOI 10.1016/S0008-4182(05)80074-2
   Rovner BW, 2002, ARCH OPHTHALMOL-CHIC, V120, P1041
   Scott IU, 2002, AM J OPHTHALMOL, V133, P350, DOI 10.1016/S0002-9394(01)01406-4
   SHAH SM, 2006, INVEST OPHTHALMOL VI, V47
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
NR 23
TC 46
Z9 47
U1 2
U2 6
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD FEB
PY 2009
VL 23
IS 2
BP 326
EP 333
DI 10.1038/sj.eye.6703053
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 406US
UT WOS:000263321000015
PM 18202712
OA Bronze
DA 2022-11-30
ER

PT J
AU Kaiserman, I
   Kaiserman, N
   Elhayany, A
   Vinker, S
AF Kaiserman, Igor
   Kaiserman, Nadia
   Elhayany, Asher
   Vinker, Shlomo
TI Risk factors for photodynamic therapy of predominantly classic choroidal
   neovascularization in age-related macular degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID BODY-MASS INDEX; CARDIOVASCULAR-DISEASE; 5-YEAR INCIDENCE; POOLED
   FINDINGS; MACULOPATHY; PREVALENCE; ASSOCIATION
AB center dot PURPOSE: To investigate the influence of various risk factors for age related macular degeneration (AMD) on the rate of undergoing photodynamic therapy (PDT).
   center dot DESIGN: An observational population based cohort study.
   center dot METHODS: SETTINGS: A district of the largest health maintenance organization (HMO) in Israel. STUDY POPULATION: All HMO members in the district, older than 50 years on January 1, 2001, who did not terminate their membership until May 31, 2005 (139,894 members); of those, 283 underwent PDT for AMD during the study period (775 procedures). OBSERVATION PROCEDURES: We extracted information from the chronic disease registry of the HMO as well as demographic information including age, gender, country of birth, place of residency, and social security economic status. MAIN OUTCOME MEASURES: Effect of various risk factors for AMD on the rate of PDT.
   center dot RESULTS: The age,adjusted proportion of patients requiring PDT was significantly higher in hypertensives (P = .03, chi(2) test), in hyperlipidemics (P = .002), in ischemic heart disease patients (P = .002) and among males (P = .03) and Ashkenazi Jews (P = .02). No significant difference in PDT rates was noted in diabetics, congestive heart failure (CHF), and chronic renal failure (CRF) patients. PDT rates were lower in the lower socioeconomic class (P = .002). Logistic regression found a significant effect of age, hyperlipidemia, hypertension, socioeconomic status, and gender on the rate of PDT, while ischemic heart disease (IHD), diabetes, CHF, CRF, place of birth, and place of residence did not contribute significantly to the model.
   center dot CONCLUSIONS: Advanced age, hypertension, hyperlipidemia, male gender, and socioeconomic status are risk factors for undergoing PDT for predominantly classic neovascular AMD.
C1 Barzilai Govt Hosp, Dept Ophthalmol, IL-78306 Ashqelon, Israel.
   Hadassah Med Ctr, Dept Ophthalmol, IL-91120 Jerusalem, Israel.
   Clalit Hlth Serv, Dept Family Med, Rehovot, Israel.
   Tel Aviv Univ, Sackler Fac Med, Dept Family Med, IL-69978 Tel Aviv, Israel.
C3 Ben Gurion University; Barzilai Medical Center; Hebrew University of
   Jerusalem; Hadassah University Medical Center; Clalit Health Services;
   Tel Aviv University; Sackler Faculty of Medicine
RP Kaiserman, I (通讯作者)，Barzilai Govt Hosp, Dept Ophthalmol, IL-78306 Ashqelon, Israel.
EM Igor@Dr-Kaiserman.com
OI Kaiserman, Igor/0000-0003-0130-8819
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Belda Sanchis J I, 2001, Arch Soc Esp Oftalmol, V76, P13
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Bressler NM, 2000, BRIT MED J, V321, P1425, DOI 10.1136/bmj.321.7274.1425
   Buch H, 2005, ACTA OPHTHALMOL SCAN, V83, P409, DOI 10.1111/J.1600-0420.2005.00492.x
   Chaine G, 1998, BRIT J OPHTHALMOL, V82, P996, DOI 10.1136/bjo.82.9.996
   Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2
   Clemons Traci E, 2005, Ophthalmology, V112, P533
   Conroy RM, 2003, EUR HEART J, V24, P987, DOI 10.1016/S0195-668X(03)00114-3
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   Evans JR, 2005, BRIT J OPHTHALMOL, V89, P550, DOI 10.1136/bjo.2004.049726
   Grizzard WS, 2003, OPHTHAL EPIDEMIOL, V10, P315, DOI 10.1076/opep.10.5.315.17317
   Haddad WM, 2002, BRIT J OPHTHALMOL, V86, P663, DOI 10.1136/bjo.86.6.663
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   Javitt JC, 2003, OPHTHALMOLOGY, V110, P1534, DOI 10.1016/S0161-6420(03)00495-0
   KAUNISTO RMV, 2000, DIABETES CARE, V23, P1672
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klein B E, 2001, Ophthalmic Epidemiol, V8, P251, DOI 10.1076/opep.8.4.251.1612
   KLEIN BE, 1982, ARCH OPHTHALMOL-CHIC, V100, P571
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2001, AM J OPHTHALMOL, V132, P128, DOI 10.1016/S0002-9394(00)00931-4
   LEIBOWITZ H, 1973, SURV OPHTHALMOL, V24, P335
   McCarty CA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1455
   Mitchell P, 1999, AUST NZ J OPHTHALMOL, V27, P197, DOI 10.1046/j.1440-1606.1999.00211.x
   Miyazaki M, 2005, INVEST OPHTH VIS SCI, V46, P1907, DOI 10.1167/iovs.04-0923
   Moeini HA, 2005, BRIT J OPHTHALMOL, V89, P964, DOI 10.1136/bjo.2005.066241
   Rennert G, 2001, ISR MED ASSOC J, V3, P404
   Santos Laura Patrícia Ferreira, 2005, Arq. Bras. Oftalmol., V68, P229, DOI 10.1590/S0004-27492005000200014
   Schaumberg DA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1259
   Schultz Dennis W, 2005, Ophthalmic Genet, V26, P101, DOI 10.1080/13816810590968023
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Smith W, 1998, AUST NZ J OPHTHALMOL, V26, P203, DOI 10.1111/j.1442-9071.1998.tb01311.x
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   van Leeuwen R, 2004, AM J OPHTHALMOL, V137, P750, DOI 10.1016/S0002-9394(03)01089-4
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
   Wachter A, 2004, OPHTHALMOLOGE, V101, P50, DOI 10.1007/s00347-003-0868-1
   Walter-Ginzburg A, 2001, J AM GERIATR SOC, V49, P1176, DOI 10.1046/j.1532-5415.2001.49234.x
   Yoshida A, 2000, JPN J OPHTHALMOL, V44, P290, DOI 10.1016/S0021-5155(99)00227-0
   1997, ARCH INTERN MED, V157, P2413
NR 43
TC 4
Z9 5
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD SEP
PY 2006
VL 142
IS 3
BP 441
EP 447
DI 10.1016/j.ajo.2006.04.031
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 082MJ
UT WOS:000240390600011
PM 16935589
DA 2022-11-30
ER

PT J
AU Venza, I
   Visalli, M
   Cucinotta, M
   Teti, D
   Venza, M
AF Venza, Isabella
   Visalli, Maria
   Cucinotta, Maria
   Teti, Diana
   Venza, Mario
TI Association between oxidative stress and macromolecular damage in
   elderly patients with age-related macular degeneration
SO AGING CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Article
DE Aging; age-related macular degeneration; antioxidant/pro-oxidant
   balance; gender; macromolecular damage; menopause
ID GLUTATHIONE-PEROXIDASE; SUPEROXIDE-DISMUTASE; LIPID-PEROXIDATION;
   DNA-DAMAGE
AB Background and aims: The aim of the present study was to determine whether age and gender affect the imbalance between oxidant production and antioxidant levels in age-related macular degeneration (ARMD) patients. Methods: Total superoxide dismutase (T-SOD), total glutathi one peroxidase (T-GSHPx), and catalase (CAT) activities, as well as malondialdehyde (MDA), protein carbonyl (PC), 8-Hydroxy-29-deoxyguanosine (8-OHdG) and total oxidation status (TOS) levels, were measured in the following groups subdivided by age and gender: 156 early-ARMD patients; 80 wet-late ARMD patients; 72 dry-late ARMD patients; and 207 healthy controls. Results: Among all study participants, women aged 50-54 had higher T-SOD and T-GSHPx activities and lower MDA, PC, TOS and 8-OHdG levels than age-matched men (p<0.05), whereas older women were not significantly different from age-matched older men. Significantly increased oxidative damage was associated with ARMD patients >60 years of age in both sexes compared with controls (p<0.01 for 60-64 and 65-69-year-old ARMD subgroups; p<0.001 for 70-74 and 75-80-year-old ARMD subgroups). Multiple regression analysis demonstrates that age significantly affects antioxidant status and oxidative damage in ARMD patients compared with controls (controls, p<0.05; ARMD patients, p<0.001). A direct correlation with antioxidant enzyme activities and an inverse correlation with oxidative DNA, protein and lipid damage were also observed in premenopausal women (controls, p<0.05; ARMD patients, p<0.001). Conclusions: Aging and postmenopausal status may be aggravating factors contributing to redox imbalance and oxidative damage in ARMD patients. (Aging Clin Exp Res 2012; 24: 21-27) (C)2012, Editrice Kurtis
C1 [Venza, Isabella] Azienda Ospedaliera Univ G Martino, Dept Surg Special, Messina, Italy.
   [Visalli, Maria; Cucinotta, Maria; Teti, Diana] Azienda Ospedaliera Univ G Martino, Dept Expt Pathol & Microbiol, Messina, Italy.
   [Venza, Mario] Azienda Ospedaliera Univ G Martino, Dept Odontostomatol, Messina, Italy.
C3 AOU Policlinico Gaetano Martino; AOU Policlinico Gaetano Martino; AOU
   Policlinico Gaetano Martino
RP Teti, D (通讯作者)，Azienda Ospedaliera Univ, Dept Expt Pathol & Microbiol, Expt Pathol Sect, Via Consolare Valeria 1 Gazzi, I-98125 Messina, Italy.
EM dteti@unime.it
CR AEBI H, 1984, METHOD ENZYMOL, V105, P121
   Baeza I, 2010, BIOGERONTOLOGY, V11, P687, DOI 10.1007/s10522-010-9282-7
   Bailey TA, 2004, INVEST OPHTH VIS SCI, V45, P675, DOI 10.1167/iovs.03-0351
   Baynes JW, 2002, ANN NY ACAD SCI, V959, P360, DOI 10.1111/j.1749-6632.2002.tb02107.x
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   CURRIE MS, 1990, BLOOD, V75, P1699
   Erel O, 2005, CLIN BIOCHEM, V38, P1103, DOI 10.1016/j.clinbiochem.2005.08.008
   Evereklioglu C, 2003, DOC OPHTHALMOL, V106, P129, DOI 10.1023/A:1022512402811
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gautam N, 2010, OXID MED CELL LONGEV, V3, P275, DOI 10.4161/oxim.3.4.12860
   GUEMOURI L, 1991, CLIN CHEM, V37, P1932
   Javitt JC, 2003, OPHTHALMOLOGY, V110, P1534, DOI 10.1016/S0161-6420(03)00495-0
   LEVINE RL, 1990, METHOD ENZYMOL, V186, P464
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   Mendoza-Nunez VM, 2010, J WOMENS HEALTH, V19, P919, DOI 10.1089/jwh.2009.1684
   MaresPerlman JA, 1996, ARCH OPHTHALMOL-CHIC, V114, P991, DOI 10.1001/archopht.1996.01100140199014
   MARKLUND SL, 1984, J CLIN INVEST, V74, P1398, DOI 10.1172/JCI111550
   MARKLUND SL, 1982, CLIN CHIM ACTA, V126, P41, DOI 10.1016/0009-8981(82)90360-6
   MICELI MV, 1994, EXP CELL RES, V214, P242, DOI 10.1006/excr.1994.1254
   Miquel J, 2006, ARCH GERONTOL GERIAT, V42, P289, DOI 10.1016/j.archger.2005.08.005
   Nowak M, 2003, EUR J OPHTHALMOL, V13, P281, DOI 10.1177/112067210301300307
   PAGLIA DE, 1967, J LAB CLIN MED, V70, P158
   Smith W, 1997, AUST NZ J OPHTHALMOL, V25, pS13
   SUN Y, 1988, CLIN CHEM, V34, P497
   Szaflik JP, 2009, MUTAT RES-FUND MOL M, V669, P169, DOI 10.1016/j.mrfmmm.2009.06.008
   TAKAHASHI K, 1986, BLOOD, V68, P640
   Totan Y, 2009, CURR EYE RES, V34, P1089, DOI 10.3109/02713680903353772
   VALENZUELA A, 1991, LIFE SCI, V48, P301, DOI 10.1016/0024-3205(91)90550-U
   Wang AL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005304
   Winkler B S, 1999, Mol Vis, V5, P32
NR 33
TC 25
Z9 26
U1 0
U2 10
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1594-0667
EI 1720-8319
J9 AGING CLIN EXP RES
JI Aging Clin. Exp. Res.
PD FEB
PY 2012
VL 24
IS 1
BP 21
EP 27
DI 10.3275/7659
PG 7
WC Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology
GA 970RJ
UT WOS:000306149700004
PM 21499024
DA 2022-11-30
ER

PT J
AU Lee, KS
   Lin, SX
   Copland, DA
   Dick, AD
   Liu, J
AF Lee, Keng Siang
   Lin, Shuxiao
   Copland, David A.
   Dick, Andrew D.
   Liu, Jian
TI Cellular senescence in the aging retina and developments of
   senotherapies for age-related macular degeneration
SO JOURNAL OF NEUROINFLAMMATION
LA English
DT Review
DE Macular degeneration; Cellular senescence; SASP; Immune aging; Retinal
   pigment epithelium; Microglia; Neuron
AB Age-related macular degeneration (AMD), a degenerative disease in the central macula area of the neuroretina and the supporting retinal pigment epithelium, is the most common cause of vision loss in the elderly. Although advances have been made, treatment to prevent the progressive degeneration is lacking. Besides the association of innate immune pathway genes with AMD susceptibility, environmental stress- and cellular senescence-induced alterations in pathways such as metabolic functions and inflammatory responses are also implicated in the pathophysiology of AMD. Cellular senescence is an adaptive cell process in response to noxious stimuli in both mitotic and postmitotic cells, activated by tumor suppressor proteins and prosecuted via an inflammatory secretome. In addition to physiological roles in embryogenesis and tissue regeneration, cellular senescence is augmented with age and contributes to a variety of age-related chronic conditions. Accumulation of senescent cells accompanied by an impairment in the immune-mediated elimination mechanisms results in increased frequency of senescent cells, termed "chronic" senescence. Age-associated senescent cells exhibit abnormal metabolism, increased generation of reactive oxygen species, and a heightened senescence-associated secretory phenotype that nurture a proinflammatory milieu detrimental to neighboring cells. Senescent changes in various retinal and choroidal tissue cells including the retinal pigment epithelium, microglia, neurons, and endothelial cells, contemporaneous with systemic immune aging in both innate and adaptive cells, have emerged as important contributors to the onset and development of AMD. The repertoire of senotherapeutic strategies such as senolytics, senomorphics, cell cycle regulation, and restoring cell homeostasis targeted both at tissue and systemic levels is expanding with the potential to treat a spectrum of age-related diseases, including AMD.
C1 [Lee, Keng Siang; Copland, David A.; Dick, Andrew D.; Liu, Jian] Univ Bristol, Bristol Med Sch, Translat Hlth Sci, Bristol BS8 1TD, Avon, England.
   [Lin, Shuxiao] Univ Bristol, Sch Cellular & Mol Med, Bristol BS8 1TD, Avon, England.
   [Dick, Andrew D.] UCL, Inst Ophthalmol, London EC1V 9EL, England.
   [Dick, Andrew D.] Moorfields Eye Hosp, Natl Inst Hlth Res, Biomed Res Ctr, London EC1V 2QH, England.
C3 University of Bristol; University of Bristol; University of London;
   University College London; University of London; University College
   London; Moorfields Eye Hospital NHS Foundation Trust
RP Dick, AD; Liu, J (通讯作者)，Univ Bristol, Bristol Med Sch, Translat Hlth Sci, Bristol BS8 1TD, Avon, England.
EM a.dick@bristol.ac.uk; jian.liu@bristol.ac.uk
OI Dick, Andrew/0000-0002-0742-3159
FU Rosetrees Trust; Stoneygate Trust [M418-F1]
FX This work was supported by a joint grant from the Rosetrees Trust and
   Stoneygate Trust (grant no. M418-F1).
CR Ach T, 2015, INVEST OPHTH VIS SCI, V56, P3242, DOI 10.1167/iovs.14-16274
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Askou AL, 2021, GENE THER, V28, P209, DOI 10.1038/s41434-020-0168-2
   Baar MP, 2017, CELL, V169, P132, DOI 10.1016/j.cell.2017.02.031
   Baruch K, 2016, NAT MED, V22, P135, DOI 10.1038/nm.4022
   Bellon M, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9100289
   Binet F, 2020, SCIENCE, V369, P934, DOI 10.1126/science.aay5356
   Blasiak J, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/5293258
   BORGHESAN M, 2020, TRENDS CELL BIOL
   Bratic I, 2010, BBA-BIOENERGETICS, V1797, P961, DOI 10.1016/j.bbabio.2010.01.004
   Cabrera AP, 2016, INVEST OPHTH VIS SCI, V57, P5910, DOI 10.1167/iovs.16-19727
   Campello L, 2013, MOL NEUROBIOL, V47, P790, DOI 10.1007/s12035-012-8391-5
   Cao LN, 2013, INVEST OPHTH VIS SCI, V54, P3738, DOI 10.1167/iovs.13-11612
   Carneiro A, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/6469138
   Chaum E, 2015, MAMM GENOME, V26, P210, DOI 10.1007/s00335-015-9568-9
   Chen F, 2016, J IMMUNOL METHODS, V434, P1, DOI 10.1016/j.jim.2016.03.005
   Chen M, 2015, J LEUKOCYTE BIOL, V98, P713, DOI 10.1189/jlb.3RI0615-239R
   Chen Y, 2010, INVEST OPHTH VIS SCI, V51, P5314, DOI 10.1167/iovs.10-5280
   Cherepanoff S, 2006, CLIN EXP OPHTHALMOL, V34, P590, DOI 10.1111/j.1442-9071.2006.01281.x
   Chew EY, 2012, OPHTHALMOLOGY, V119, P2282, DOI 10.1016/j.ophtha.2012.05.027
   Childs BG, 2016, SCIENCE, V354, P472, DOI 10.1126/science.aaf6659
   Childs BG, 2015, NAT MED, V21, P1424, DOI 10.1038/nm.4000
   Chinta SJ, 2018, CELL REP, V22, P930, DOI 10.1016/j.celrep.2017.12.092
   Chirco KR, 2017, EYE, V31, P10, DOI 10.1038/eye.2016.216
   Chou JP, 2013, CURR PHARM DESIGN, V19, P1680
   Chougnet CA, 2011, J IMMUNOL, V186, P156, DOI 10.4049/jimmunol.1001505
   ClinicalTrials.gov, 2019, 1 HUM STUD EV SAF EF
   ClinicalTrials.gov, 2017, TREATM ADV DRY AG RE
   ClinicalTrials.gov, 2020, SAF TOL STUD UBX1325
   Cohen J, 2019, AGING CELL, V18, DOI 10.1111/acel.12937
   Collado M, 2007, CELL, V130, P223, DOI 10.1016/j.cell.2007.07.003
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Connoy AC, 2006, EXP GERONTOL, V41, P225, DOI 10.1016/j.exger.2005.11.003
   Copland DA, 2018, INVEST OPHTH VIS SCI, V59, pAMD83, DOI 10.1167/iovs.18-23893
   Coppe JP, 2010, ANNU REV PATHOL-MECH, V5, P99, DOI 10.1146/annurev-pathol-121808-102144
   Costantini E, 2018, MEDIAT INFLAMM, V2018, DOI 10.1155/2018/6039171
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Damani MR, 2011, AGING CELL, V10, P263, DOI 10.1111/j.1474-9726.2010.00660.x
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   Do KV, 2019, P NATL ACAD SCI USA, V116, P24317, DOI 10.1073/pnas.1912959116
   Ebeling MC, 2020, REDOX BIOL, V34, DOI 10.1016/j.redox.2020.101552
   Ezzat MK, 2008, BRIT J OPHTHALMOL, V92, P976, DOI 10.1136/bjo.2007.129742
   Faber C, 2013, OPHTHALMOLOGY, V120, P2310, DOI 10.1016/j.ophtha.2013.04.014
   Farr JN, 2017, NAT MED, V23, P1072, DOI 10.1038/nm.4385
   Felszeghy S, 2019, REDOX BIOL, V20, P1, DOI 10.1016/j.redox.2018.09.011
   Fernandez-Robredo P, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/510285
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fulop T, 2018, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01960
   Gong ZW, 2014, FRONT ENDOCRINOL, V5, DOI 10.3389/fendo.2014.00210
   Grupp SA, 2013, NEW ENGL J MED, V368, P1509, DOI 10.1056/NEJMoa1215134
   Gruver AL, 2007, J PATHOL, V211, P144, DOI 10.1002/path.2104
   Guillonneau X, 2017, PROG RETIN EYE RES, V61, P98, DOI 10.1016/j.preteyeres.2017.06.002
   Guimaraes TAC, 2020, BRIT J OPHTHALMOL
   Handa JT, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11262-1
   HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6
   Hector SM, 2017, CLIN OPHTHALMOL, V11, P179, DOI 10.2147/OPTH.S121332
   Heesterbeek TJ, 2020, OPHTHAL PHYSL OPT, V40, P140, DOI 10.1111/opo.12675
   Heier JS, 2017, LANCET, V390, P50, DOI 10.1016/S0140-6736(17)30979-0
   Herranz N, 2018, J CLIN INVEST, V128, P1238, DOI 10.1172/JCI95148
   Herranz N, 2015, NAT CELL BIOL, V17, P1205, DOI 10.1038/ncb3225
   Hickson LJ, 2019, EBIOMEDICINE, V47, P446, DOI 10.1016/j.ebiom.2019.08.069
   Hoare M, 2016, NAT CELL BIOL, V18, P979, DOI 10.1038/ncb3397
   Huang JC, 2019, THERANOSTICS, V9, P1170, DOI 10.7150/thno.26281
   Hulsmans M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030414
   Hyttinen JMT, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20225800
   Ibrahim AS, 2020, J CLIN MED, V9, DOI 10.3390/jcm9072293
   Jolly JK, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01076
   Jones A, 2011, P NATL ACAD SCI USA, V108, P14578, DOI 10.1073/pnas.1102853108
   Judge SJ, 2020, FRONT CELL INFECT MI, V10, DOI 10.3389/fcimb.2020.00049
   Jun B, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05433-7
   Jurk D, 2012, AGING CELL, V11, P996, DOI 10.1111/j.1474-9726.2012.00870.x
   Justice JN, 2019, EBIOMEDICINE, V40, P554, DOI 10.1016/j.ebiom.2018.12.052
   Kaarniranta K, 2017, CELL BIOL TOXICOL, V33, P113, DOI 10.1007/s10565-016-9371-8
   Kaarniranta K, 2013, AUTOPHAGY, V9, P973, DOI 10.4161/auto.24546
   Kang C, 2015, SCIENCE, V349, DOI 10.1126/science.aaa5612
   Kanow MA, 2017, ELIFE, V6, DOI 10.7554/eLife.28899
   Kastenhuber ER, 2017, CELL, V170, P1062, DOI 10.1016/j.cell.2017.08.028
   Kim BC, 2014, ONCOL REP, V31, P2229, DOI 10.3892/or.2014.3069
   Kirkland JL, 2017, EBIOMEDICINE, V21, P21, DOI 10.1016/j.ebiom.2017.04.013
   Kirkwood TBL, 2005, CELL, V120, P437, DOI 10.1016/j.cell.2005.01.027
   Knickelbein Jared E, 2015, Int Ophthalmol Clin, V55, P63, DOI 10.1097/IIO.0000000000000073
   Konig J, 2017, REDOX BIOL, V11, P673, DOI 10.1016/j.redox.2017.01.017
   Kozhevnikova OS, 2013, CELL CYCLE, V12, P1745, DOI 10.4161/cc.24825
   Kozlowski MR, 2012, MED HYPOTHESES, V78, P505, DOI 10.1016/j.mehy.2012.01.018
   Krizhanovsky V, 2008, CELL, V134, P657, DOI 10.1016/j.cell.2008.06.049
   Kurihara T, 2016, ELIFE, V5, DOI 10.7554/eLife.14319
   Laberge RM, 2015, NAT CELL BIOL, V17, P1049, DOI 10.1038/ncb3195
   Lazzarini R, 2018, AGING-US, V10, P3173, DOI 10.18632/aging.101624
   Leveillard T, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20030762
   Li J, 2017, MOL VIS, V23, P149
   Lin HJ, 2011, INVEST OPHTH VIS SCI, V52, P3521, DOI 10.1167/iovs.10-6163
   Lin JB, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.120157
   Lin MK, 2018, AGING CELL, V17, DOI 10.1111/acel.12710
   Linton PJ, 2014, IMMUNOL LETT, V162, P290, DOI 10.1016/j.imlet.2014.06.017
   Liu BY, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-111
   Liu J, 2016, SCI REP-UK, V6, DOI 10.1038/srep20639
   Liu J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072935
   Lopez-Luppo M, 2017, INVEST OPHTH VIS SCI, V58, P2832, DOI 10.1167/iovs.16-20312
   Lopez-Otin C, 2013, CELL, V153, P1194, DOI 10.1016/j.cell.2013.05.039
   Ma WX, 2013, NEUROBIOL AGING, V34, P2310, DOI 10.1016/j.neurobiolaging.2013.03.022
   Ma WX, 2013, NEUROBIOL AGING, V34, P943, DOI 10.1016/j.neurobiolaging.2012.06.010
   Machado-Oliveira G, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9102146
   Marazita MC, 2016, REDOX BIOL, V7, P78, DOI 10.1016/j.redox.2015.11.011
   Masaldan S, 2019, PHARMACEUTICALS-BASE, V12, DOI 10.3390/ph12020093
   Masland RH, 2012, NEURON, V76, P266, DOI 10.1016/j.neuron.2012.10.002
   McHugh D, 2018, J CELL BIOL, V217, P65, DOI 10.1083/jcb.201708092
   Marques JCMT, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-16224-5
   Mihaylova MM, 2011, NAT CELL BIOL, V13, P1016, DOI 10.1038/ncb2329
   Mishima K, 1999, INVEST OPHTH VIS SCI, V40, P1590
   Moreno-Blas D, 2019, AGING-US, V11, P6175, DOI 10.18632/aging.102181
   Moreno-Garcia A, 2018, FRONT NEUROSCI-SWITZ, V12, DOI 10.3389/fnins.2018.00464
   Mosteiro L, 2016, SCIENCE, V354, DOI 10.1126/science.aaf4445
   Mowla SN, 2014, AGING CELL, V13, P773, DOI 10.1111/acel.12242
   Nassar K, 2015, GRAEF ARCH CLIN EXP, V253, P699, DOI 10.1007/s00417-014-2738-8
   Nussenblatt RB, 2014, AM J OPHTHALMOL, V158, P5, DOI 10.1016/j.ajo.2014.03.014
   Ong SM, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0327-1
   Oubaha M, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf9440
   Ovadya Y, 2018, J CLIN INVEST, V128, P1247, DOI 10.1172/JCI95149
   Pangrazzi L, 2020, EXP GERONTOL, V134, DOI 10.1016/j.exger.2020.110887
   Park JT, 2018, AGEING RES REV, V47, P176, DOI 10.1016/j.arr.2018.08.003
   Patel N, 2005, IMMUNOLOGY, V115, P422, DOI 10.1111/j.1365-2567.2005.02173.x
   Penn JS, 2008, PROG RETIN EYE RES, V27, P331, DOI 10.1016/j.preteyeres.2008.05.001
   Pereira BI, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10335-5
   Picca A, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18050933
   Plotegher N, 2017, FRONT CELL DEV BIOL, V5, DOI 10.3389/fcell.2017.00110
   Porter LF, 2019, CLIN EPIGENETICS, V11, DOI 10.1186/s13148-019-0608-2
   Ramirez AI, 2017, FRONT AGING NEUROSCI, V9, DOI 10.3389/fnagi.2017.00214
   Remmerie A, 2018, CELL IMMUNOL, V330, P27, DOI 10.1016/j.cellimm.2018.01.020
   Robertson JD, 2000, BRIT J HAEMATOL, V109, P272, DOI 10.1046/j.1365-2141.2000.01970.x
   Rocha LR, 2020, AGING CELL, V19, DOI 10.1111/acel.13089
   Rohrer B, 2016, ADV EXP MED BIOL, V854, P793, DOI 10.1007/978-3-319-17121-0_106
   Sagiv A, 2016, AGING-US, V8, P328, DOI 10.18632/aging.100897
   Salminen A, 2012, CELL SIGNAL, V24, P835, DOI 10.1016/j.cellsig.2011.12.006
   Samiy Nasrollah, 2014, J Ophthalmic Vis Res, V9, P506, DOI 10.4103/2008-322X.150831
   Schmeisser K, 2019, FRONT CELL DEV BIOL, V7, DOI 10.3389/fcell.2019.00192
   Schmitt V, 2013, EXP GERONTOL, V48, P1379, DOI 10.1016/j.exger.2013.09.003
   Schwab N, 2019, ACTA NEUROPATHOL COM, V7, DOI 10.1186/s40478-019-0822-3
   Scott AW, 2016, JAMA OPHTHALMOL, V134, P1111, DOI 10.1001/jamaophthalmol.2016.2627
   Sene A, 2013, CELL METAB, V17, P549, DOI 10.1016/j.cmet.2013.03.009
   Sikora E, 2011, AGEING RES REV, V10, P146, DOI 10.1016/j.arr.2010.10.002
   Sinha D, 2016, EXP EYE RES, V144, P46, DOI 10.1016/j.exer.2015.08.018
   Song P, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9030671
   Sreekumar PG, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/2583601
   Sreekumar PG, 2016, INVEST OPHTH VIS SCI, V57, P1238, DOI 10.1167/iovs.15-17053
   Storer M, 2013, CELL, V155, P1119, DOI 10.1016/j.cell.2013.10.041
   Sun Q, 2018, CURR MOL MED, V18, P575, DOI 10.2174/1566524019666190107154250
   Sun Y, 2017, J EXP MED, V214, P1753, DOI 10.1084/jem.20161645
   Supanji, 2013, EXP EYE RES, V112, P79, DOI 10.1016/j.exer.2013.04.013
   Szaflik JP, 2009, MUTAT RES-FUND MOL M, V669, P169, DOI 10.1016/j.mrfmmm.2009.06.008
   Tai HR, 2017, AUTOPHAGY, V13, P99, DOI 10.1080/15548627.2016.1247143
   Taskintuna I, 2016, MIDDLE EAST AFR J OP, V23, P13, DOI 10.4103/0974-9233.173134
   Terman A, 2010, ANTIOXID REDOX SIGN, V12, P503, DOI 10.1089/ars.2009.2598
   Theodoropoulou S, 2017, J PATHOL, V241, P45, DOI 10.1002/path.4816
   Tonade D, 2017, DIABETOLOGIA, V60, P2111, DOI 10.1007/s00125-017-4381-5
   Tseng WA, 2013, INVEST OPHTH VIS SCI, V54, P110, DOI 10.1167/iovs.12-10655
   Vallejo AN, 2005, IMMUNOL REV, V205, P158, DOI 10.1111/j.0105-2896.2005.00256.x
   van Deursen JM, 2014, NATURE, V509, P439, DOI 10.1038/nature13193
   van Rhee F, 2014, LANCET ONCOL, V15, P966, DOI 10.1016/S1470-2045(14)70319-5
   von Kobbe C, 2018, CELL MOL LIFE SCI, V75, P3553, DOI 10.1007/s00018-018-2879-8
   Wakita M, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15719-6
   Wang SB, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.588050
   Wang SB, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/3632169
   Watanabe S, 2017, CANCER SCI, V108, P563, DOI 10.1111/cas.13184
   Weng XL, 2015, EXP GERONTOL, V69, P36, DOI 10.1016/j.exger.2015.06.004
   Wengerodt D, 2019, CELLS-BASEL, V8
   Wu JH, 2020, MOL THER, V28, P820, DOI 10.1016/j.ymthe.2019.12.012
   Wu JL, 2019, DRUG DES DEV THER, V13, P2413, DOI 10.2147/DDDT.S206355
   Xu J, 2011, FASEB J, V25, P2221, DOI 10.1096/fj.10-178350
   Xu YH, 2015, GRAEF ARCH CLIN EXP, V253, P1085, DOI 10.1007/s00417-015-2961-y
   Xue W, 2007, NATURE, V445, P656, DOI 10.1038/nature05529
   Yamane M, 2020, FASEB J, V34, P10778, DOI 10.1096/fj.201900218R
   Yi HS, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1494-4
   Yosef R, 2017, EMBO J, V36, P2280, DOI 10.15252/embj.201695553
   Yosef R, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11190
   Yu AL, 2009, INVEST OPHTH VIS SCI, V50, P926, DOI 10.1167/iovs.07-1003
   Yu B, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16312-7
   Zhang M, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-59244-4
   Zhang MY, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/7524308
   Zhao C, 2011, J CLIN INVEST, V121, P369, DOI 10.1172/JCI44303
   Zhou M, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00501
   Zhu DH, 2009, J BIOL CHEM, V284, P9529, DOI 10.1074/jbc.M809393200
   Zhu Y, 2017, AGING-US, V9, P955, DOI 10.18632/aging.101202
   Zhu Y, 2015, AGING CELL, V14, P644, DOI 10.1111/acel.12344
   Ziegler DV, 2015, AGING CELL, V14, P1, DOI 10.1111/acel.12287
NR 184
TC 28
Z9 29
U1 14
U2 31
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1742-2094
J9 J NEUROINFLAMM
JI J. Neuroinflamm.
PD JAN 22
PY 2021
VL 18
IS 1
AR 32
DI 10.1186/s12974-021-02088-0
PG 17
WC Immunology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology; Neurosciences & Neurology
GA QA3LX
UT WOS:000613349900002
PM 33482879
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Dinu, M
   Pagliai, G
   Casini, A
   Sofi, F
AF Dinu, Monica
   Pagliai, Giuditta
   Casini, Alessandro
   Sofi, Francesco
TI Food groups and risk of age-related macular degeneration: a systematic
   review with meta-analysis
SO EUROPEAN JOURNAL OF NUTRITION
LA English
DT Review
DE Food; Macular degeneration; Nutrition; Diet
ID GLYCATION END-PRODUCTS; DIETARY FATTY-ACIDS; ALCOHOL-CONSUMPTION;
   GENETIC SUSCEPTIBILITY; MEDITERRANEAN DIET; OXIDATIVE STRESS; 5-YEAR
   INCIDENCE; NATIONAL-HEALTH; BETA-CAROTENE; ASSOCIATION
AB Objective To systematically review all the available evidence from prospective cohort studies that investigated the association between consumption of food groups and the occurrence of age-related macular degeneration (AMD).
   Methods We conducted an electronic literature search through MedLine, Embase, Google Scholar, Web of Science, and bibliographies of retrieved articles up to January, 2018. Studies were included if they analysed prospectively the association between consumption of food groups and AMD.
   Results At the end of the selection process, 26 articles were included in the meta-analysis, for a total of 211,676 subjects and 7154 cases of AMD. By comparing the highest vs. the lowest consumption, pooled analyses showed no significant association with AMD for vegetables, fruit, nuts, grains, dairy products, as well as dietary fats such as oils, butter and margarine. Fish determined a significant (p<0.05) reduction of risk for total AMD (RR 0.82 95% CI 0.75-0.90), as well as for both early (RR 0.84 95% CI 0.73-0.97), and late (RR 0.79 95% CI 0.70-0.90) AMD. On the other hand, high meat consumption was associated with a significant increased risk of early (RR 1.17 95% CI 1.02-1.34), but not late AMD. Finally, a significant increased risk of AMD for the highest consumption of alcohol (RR 1.20 95% CI 1.04-1.39) was reported.
   Conclusions The results of the present meta-analysis show a significant 18% reduced risk for fish and a 20% increased risk for alcohol consumption. In addition, an increased risk was observed for meat, but only in the subgroup of early AMD.
C1 [Dinu, Monica; Pagliai, Giuditta; Casini, Alessandro; Sofi, Francesco] Univ Florence, Dept Expt & Clin Med, Largo Brambilla 3, I-50134 Florence, Italy.
   [Dinu, Monica; Pagliai, Giuditta; Casini, Alessandro; Sofi, Francesco] Careggi Univ Hosp, Clin Nutr Unit, Florence, Italy.
   [Sofi, Francesco] Onlus IRCCS, Don Carlo Gnocchi Fdn Italy, Florence, Italy.
C3 University of Florence; University of Florence; Azienda Ospedaliero
   Universitaria Careggi; IRCCS Fondazione Don Carlo Gnocchi Onlus
RP Dinu, M (通讯作者)，Univ Florence, Dept Expt & Clin Med, Largo Brambilla 3, I-50134 Florence, Italy.; Dinu, M (通讯作者)，Careggi Univ Hosp, Clin Nutr Unit, Florence, Italy.
EM mdinu@unifi.it
RI Sofi, Francesco/W-4610-2019; Dinu, Monica/I-4864-2017; Pagliai,
   Giuditta/K-9592-2016
OI Sofi, Francesco/0000-0001-7113-7424; Dinu, Monica/0000-0003-1687-2527;
   Pagliai, Giuditta/0000-0002-2177-2857
CR Adams MKM, 2012, AM J EPIDEMIOL, V176, P289, DOI 10.1093/aje/kws004
   Ajani UA, 1999, ANN EPIDEMIOL, V9, P172, DOI 10.1016/S1047-2797(98)00053-2
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Arnarsson A, 2006, AM J OPHTHALMOL, V142, P419, DOI 10.1016/j.ajo.2006.04.015
   Boekhoorn SS, 2008, ARCH OPHTHALMOL-CHIC, V126, P834, DOI 10.1001/archopht.126.6.834
   Bora PS, 2006, FEBS J, V273, P1403, DOI 10.1111/j.1742-4658.2006.05163.x
   Buch H, 2005, ACTA OPHTHALMOL SCAN, V83, P409, DOI 10.1111/J.1600-0420.2005.00492.x
   Carneiro A, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/6469138
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chiu CJ, 2017, INVEST OPHTH VIS SCI, V58, P1404, DOI 10.1167/iovs.16-20454
   Chiu CJ, 2014, AM J OPHTHALMOL, V158, P118, DOI 10.1016/j.ajo.2014.04.016
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Cho EY, 2004, ARCH OPHTHALMOL-CHIC, V122, P883, DOI 10.1001/archopht.122.6.883
   Cho EY, 2000, ARCH OPHTHALMOL-CHIC, V118, P681, DOI 10.1001/archopht.118.5.681
   Chong EWT, 2008, AM J OPHTHALMOL, V145, P707, DOI 10.1016/j.ajo.2007.12.005
   Chong EWT, 2009, ARCH OPHTHALMOL-CHIC, V127, P674, DOI 10.1001/archophthalmol.2009.60
   Chong EWT, 2009, AM J EPIDEMIOL, V169, P867, DOI 10.1093/aje/kwn393
   Christen WG, 1996, ANN EPIDEMIOL, V6, P60, DOI 10.1016/1047-2797(95)00094-1
   Christen WG, 2011, ARCH OPHTHALMOL-CHIC, V129, P921, DOI 10.1001/archophthalmol.2011.34
   Chua B, 2006, ARCH OPHTHALMOL-CHIC, V124, P981, DOI 10.1001/archopht.124.7.981
   Coleman AL, 2010, AM J OPHTHALMOL, V149, P160, DOI 10.1016/j.ajo.2009.07.025
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Cross AJ, 2003, CANCER RES, V63, P2358
   Ebrahem Q, 2006, P NATL ACAD SCI USA, V103, P13480, DOI 10.1073/pnas.0601552103
   Ersoy L, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/413150
   Evans JR, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000254.pub4
   GOLDBERG J, 1988, AM J EPIDEMIOL, V128, P700, DOI 10.1093/oxfordjournals.aje.a115023
   Gopinath B, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-04697-3
   Gopinath B, 2014, BRIT J NUTR, V111, P1673, DOI 10.1017/S000711451300408X
   Hogg RE, 2017, OPHTHALMOLOGY, V124, P82, DOI 10.1016/j.ophtha.2016.09.019
   Ishibashi T, 1998, ARCH OPHTHALMOL-CHIC, V116, P1629, DOI 10.1001/archopht.116.12.1629
   Islam FMA, 2014, OPHTHALMOLOGY, V121, P1428, DOI 10.1016/j.ophtha.2014.01.002
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Joachim N, 2015, OPHTHALMOLOGY, V122, P2482, DOI 10.1016/j.ophtha.2015.08.002
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kaushik S, 2008, AM J CLIN NUTR, V88, P1104, DOI 10.1093/ajcn/88.4.1104
   Kim EK, 2018, EUR J CLIN NUTR, V72, P161, DOI 10.1038/ejcn.2017.152
   Knudtson MD, 2007, AM J OPHTHALMOL, V143, P1026, DOI 10.1016/j.ajo.2007.01.036
   Lawrenson JG, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010015.pub3
   Lu M, 1998, J CLIN INVEST, V101, P1219, DOI 10.1172/JCI1277
   Ma L, 2016, NUTRIENTS, V8, DOI 10.3390/nu8070426
   Macdonald Geraldine, 2012, Cochrane Database Syst Rev, pCD001930, DOI 10.1002/14651858.CD001930.pub3
   Mares JA, 2011, ARCH OPHTHALMOL-CHIC, V129, P470, DOI 10.1001/archophthalmol.2010.314
   Merle BMJ, 2015, AM J CLIN NUTR, V102, P1196, DOI 10.3945/ajcn.115.111047
   Miyazaki M, 2005, INVEST OPHTH VIS SCI, V46, P1907, DOI 10.1167/iovs.04-0923
   Moher David, 2009, BMJ, V339, pb2535, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535]
   Montgomery MP, 2010, OPHTHAL EPIDEMIOL, V17, P58, DOI 10.3109/09286580903450353
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Rehm J, 2009, LANCET, V373, P2223, DOI 10.1016/S0140-6736(09)60746-7
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Shim SH, 2016, OPHTHAL EPIDEMIOL, V23, P80, DOI 10.3109/09286586.2015.1129425
   Tan JSL, 2009, ARCH OPHTHALMOL-CHIC, V127, P656, DOI 10.1001/archophthalmol.2009.76
   Wang JJ, 2014, OPHTHALMOLOGY, V121, P667, DOI 10.1016/j.ophtha.2013.10.017
   Wells G, 2000, NEWCASTLE OTTAWA SCA
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu DF, 2003, ALCOHOL RES HEALTH, V27, P277
   Wu J, 2017, OPHTHALMOLOGY, V124, P634, DOI 10.1016/j.ophtha.2016.12.033
   Zhu W, 2016, NUTRIENTS, V8, DOI 10.3390/nu8110743
NR 59
TC 12
Z9 14
U1 0
U2 9
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 1436-6207
EI 1436-6215
J9 EUR J NUTR
JI Eur. J. Nutr.
PD AUG
PY 2019
VL 58
IS 5
BP 2123
EP 2143
DI 10.1007/s00394-018-1771-5
PG 21
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA IK3MJ
UT WOS:000476492800033
PM 29978377
DA 2022-11-30
ER

PT J
AU Kent, D
AF Kent, D.
TI The stereotypical molecular cascade in neovascular age-related macular
   degeneration: the role of dynamic reciprocity
SO EYE
LA English
DT Review
ID PIGMENT EPITHELIAL-CELLS; COMPLEMENT FACTOR-H; GROWTH-FACTOR-BETA;
   HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; OCULAR HISTOPLASMOSIS SYNDROME;
   RANDOMIZED CLINICAL-TRIAL; C-REACTIVE PROTEIN; CHOROIDAL
   NEOVASCULARIZATION; EXTRACELLULAR-MATRIX; GENE-EXPRESSION
AB This review summarises our current understanding of the molecular basis of subretinal neovascularisation (SRNV) in age-related macular degeneration (AMD). The term neovascular AMD (NVAMD) is derived from the dominant early clinical features of haemorrhage, fluid, and lipid in the subretinal space (SRS) and the historical role of fluorescein angiography in detecting the presence of NV tissue. However, at the cellular level, SRNV resembles an aberrant but stereotypical tissue repair response that incorporates both an early inflammatory phase and a late fibrotic phase in addition to the neovascular (NV) component that dominates the early clinical presentation. This review will seek not only to highlight the important molecules involved in each of these components but to demonstrate that the development of SRNV has its origins in the earliest events in non-NV AMD pathogenesis. Current evidence suggests that this early-stage pathogenesis is characterised by complement-mediated immune dysregulation, leading to a state of chronic inflammation in the retinal pigment epithelium/Bruch's membrane/choriocapillaris complex. These initial events can be seamlessly and inextricably linked to late-stage development of SRNV in AMD by the process of dynamic reciprocity (DyR), the ongoing bidirectional communication between cells, and their surrounding matrix. Moreover, this correlation between disease onset and eventual outcome is reflected in the temporal and spatial correlation between chronic inflammation, NV, and fibrosis within the reparative microenvironment of the SRS. In summary, the downstream consequences of the earliest dysfunctional molecular events in AMD can result in the late-stage entity we recognize clinically as SRNV and is characterized by a spectrum of predictable, related, and stereotypical processes referred to as DyR.
C1 [Kent, D.] Vis Clin, Kilkenny, Ireland.
   [Kent, D.] Univ Liverpool, Inst Ageing & Chron Dis, Fac Hlth & Life Sci, Liverpool L69 3BX, Merseyside, England.
C3 University of Liverpool
RP Kent, D (通讯作者)，Vis Clin, Circular Rd, Kilkenny, Ireland.
EM dkent@liverpool.ac.uk
CR Abe R, 2001, J IMMUNOL, V166, P7556, DOI 10.4049/jimmunol.166.12.7556
   Akasaka Y, 2001, WOUND REPAIR REGEN, V9, P501, DOI 10.1046/j.1524-475x.2001.00501.x
   Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   AMIN R, 1994, INVEST OPHTH VIS SCI, V35, P3178
   Apte RS, 2006, PLOS MED, V3, P1371, DOI 10.1371/journal.pmed.0030310
   Armour A, 2007, WOUND REPAIR REGEN, V15, pS6, DOI 10.1111/j.1524-475X.2007.00219.x
   Berrier AL, 2007, J CELL PHYSIOL, V213, P565, DOI 10.1002/jcp.21237
   Bian ZM, 1999, CURR EYE RES, V18, P349, DOI 10.1076/ceyr.18.5.349.5353
   BISSELL MJ, 1982, J THEOR BIOL, V99, P31, DOI 10.1016/0022-5193(82)90388-5
   Bock O, 2005, ACTA DERM-VENEREOL, V85, P216, DOI 10.1080/00015550410025453
   BORDER WA, 1992, NATURE, V360, P361, DOI 10.1038/360361a0
   BORNSTEIN P, 1995, J CELL BIOL, V130, P503, DOI 10.1083/jcb.130.3.503
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Bride J, 2004, ARCH DERMATOL RES, V295, P312, DOI 10.1007/s00403-003-0438-z
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Busik JV, 2009, J EXP MED, V206, P2897, DOI 10.1084/jem.20090889
   Campochiaro PA, 2013, J MOL MED, V91, P311, DOI 10.1007/s00109-013-0993-5
   Cao XG, 2011, PATHOL INT, V61, P528, DOI 10.1111/j.1440-1827.2011.02695.x
   CHAMBERLIN JA, 1989, OPHTHALMOLOGY, V96, P1526
   Chandel NS, 2000, J BIOL CHEM, V275, P25130, DOI 10.1074/jbc.M001914200
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   CLARK RAF, 1993, J DERMATOL SURG ONC, V19, P693, DOI 10.1111/j.1524-4725.1993.tb00413.x
   Clark SJ, 2010, J BIOL CHEM, V285, P30192, DOI 10.1074/jbc.M110.103986
   Cousins SW, 2004, ARCH OPHTHALMOL-CHIC, V122, P1013, DOI 10.1001/archopht.122.7.1013
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Cruz-Guilloty F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088201
   Cuneo AA, 2009, CURR VASC PHARMACOL, V7, P267, DOI 10.2174/157016109788340721
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   Dong A, 2009, J CELL PHYSIOL, V219, P544, DOI 10.1002/jcp.21698
   Doucet C, 1998, J CLIN INVEST, V101, P2129, DOI 10.1172/JCI741
   Du SS, 2013, EXP EYE RES, V116, P151, DOI 10.1016/j.exer.2013.08.019
   Eckes B, 2010, FIBROGENESIS TISSUE, V3, DOI 10.1186/1755-1536-3-4
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   ELNER SG, 1991, LAB INVEST, V64, P819
   ELNER VM, 1990, AM J PATHOL, V136, P745
   Erwig LP, 1998, J IMMUNOL, V161, P1983
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P3586, DOI 10.1167/iovs.03-0038
   Faber C, 2013, OPHTHALMOLOGY, V120, P2310, DOI 10.1016/j.ophtha.2013.04.014
   Fagiani E, 2013, CANCER LETT, V328, P18, DOI 10.1016/j.canlet.2012.08.018
   Fernando MR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094188
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   FINE SL, 1982, ARCH OPHTHALMOL-CHIC, V100, P912
   Forrester JV, 2013, EYE, V27, P340, DOI 10.1038/eye.2012.265
   Frank RN, 1996, AM J OPHTHALMOL, V122, P393, DOI 10.1016/S0002-9394(14)72066-5
   Freund KB, 2008, RETINA-J RET VIT DIS, V28, P201, DOI 10.1097/IAE.0b013e3181669504
   GAILIT J, 1994, CURR OPIN CELL BIOL, V6, P717, DOI 10.1016/0955-0674(94)90099-X
   Gordon S, 2005, NAT REV IMMUNOL, V5, P953, DOI 10.1038/nri1733
   Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Greenwood JA, 1998, MICROSC RES TECHNIQ, V43, P420, DOI 10.1002/(SICI)1097-0029(19981201)43:5<420::AID-JEMT8>3.0.CO;2-B
   GROSSNIKLAUS HE, 1992, AM J OPHTHALMOL, V114, P464, DOI 10.1016/S0002-9394(14)71859-8
   GROSSNIKLAUS HE, 1994, OPHTHALMOLOGY, V101, P1099
   Grossniklaus HE, 1998, ARCH OPHTHALMOL-CHIC, V116, P745, DOI 10.1001/archopht.116.6.745
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   Hagedorn M, 1993, Ger J Ophthalmol, V2, P28
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   HERMAN IM, 1987, TISSUE CELL, V19, P1, DOI 10.1016/0040-8166(87)90052-8
   Huang YH, 2012, P NATL ACAD SCI USA, V109, P17561, DOI 10.1073/pnas.1215397109
   Hynes RO, 2009, SCIENCE, V326, P1216, DOI 10.1126/science.1176009
   Inatani M, 1999, INVEST OPHTH VIS SCI, V40, P1783
   Jo N, 2006, AM J PATHOL, V168, P2036, DOI 10.2353/ajpath.2006.050588
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Johnson PT, 2006, P NATL ACAD SCI USA, V103, P17456, DOI 10.1073/pnas.0606234103
   Juel HB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064619
   Juel HB, 2011, EXP EYE RES, V92, P180, DOI 10.1016/j.exer.2011.01.003
   Kaneko H, 2011, NATURE, V471, P325, DOI 10.1038/nature09830
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kent D, 2003, MOL VIS, V9, P747
   Kent DL, 2014, MOL VIS, V20, P46
   Kirwan RP, 2009, MOL VIS, V15, P76
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kobayashi T, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-141
   Laine M, 2007, J IMMUNOL, V178, P3831, DOI 10.4049/jimmunol.178.6.3831
   Lee S, 2010, J PHYS-CONDENS MAT, V22, DOI 10.1088/0953-8984/22/19/194115
   Lee TY, 1999, ANN PLAS SURG, V43, P179
   LOPEZ PF, 1991, AM J OPHTHALMOL, V112, P647, DOI 10.1016/S0002-9394(14)77270-8
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Mantovani A, 2005, IMMUNITY, V23, P344, DOI 10.1016/j.immuni.2005.10.001
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Massova I, 1998, FASEB J, V12, P1075, DOI 10.1096/fasebj.12.12.1075
   MAZURE A, 1992, INVEST OPHTH VIS SCI, V33, P3407
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Miyajima-Uchida H, 2000, INVEST OPHTH VIS SCI, V41, P561
   Mohan RR, 2011, CURR MOL MED, V11, P110
   Mohan RR, 2011, INVEST OPHTH VIS SCI, V52, P4833, DOI 10.1167/iovs.11-7357
   Mori L, 2005, EXP CELL RES, V304, P81, DOI 10.1016/j.yexcr.2004.11.011
   Moulin V, 2004, J CELL PHYSIOL, V198, P350, DOI 10.1002/jcp.10415
   Mousa SA, 1999, J CELL BIOCHEM, V74, P135, DOI 10.1002/(SICI)1097-4644(19990701)74:1<135::AID-JCB15>3.0.CO;2-#
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Nagase H, 2006, CARDIOVASC RES, V69, P562, DOI 10.1016/j.cardiores.2005.12.002
   Nambu H, 2005, J CELL PHYSIOL, V204, P227, DOI 10.1002/jcp.20292
   Nambu H, 2004, GENE THER, V11, P865, DOI 10.1038/sj.gt.3302230
   Nasir MA, 1997, BRIT J OPHTHALMOL, V81, P481, DOI 10.1136/bjo.81.6.481
   Nassar K, 2011, GRAEF ARCH CLIN EXP, V249, P1649, DOI 10.1007/s00417-011-1730-9
   Nedelec B, 2001, SURGERY, V130, P798, DOI 10.1067/msy.2001.116453
   Nicolo M, 2000, GRAEF ARCH CLIN EXP, V238, P107, DOI 10.1007/s004170050018
   Oh H, 1999, INVEST OPHTH VIS SCI, V40, P1891
   Olson N, 2011, NITRIC OXIDE-BIOL CH, V25, P125, DOI 10.1016/j.niox.2010.12.010
   Osawa T, 2013, CANCER RES, V73, P3019, DOI 10.1158/0008-5472.CAN-12-3231
   Otani A, 1999, INVEST OPHTH VIS SCI, V40, P1912
   Quan TE, 2004, INT J BIOCHEM CELL B, V36, P598, DOI 10.1016/j.biocel.2003.10.005
   RAGHOW R, 1994, FASEB J, V8, P823, DOI 10.1096/fasebj.8.11.8070631
   REDDY VM, 1995, AM J OPHTHALMOL, V120, P291, DOI 10.1016/S0002-9394(14)72158-0
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sandler NG, 2003, J IMMUNOL, V171, P3655, DOI 10.4049/jimmunol.171.7.3655
   Sarks JP, 1997, EYE, V11, P515, DOI 10.1038/eye.1997.137
   SAXE SJ, 1993, ARCH OPHTHALMOL-CHIC, V111, P88, DOI 10.1001/archopht.1993.01090010092033
   Sayani K, 2000, HISTOPATHOLOGY, V36, P262
   Schlingemann RO, 2004, GRAEF ARCH CLIN EXP, V242, P91, DOI 10.1007/s00417-003-0828-0
   Schultz GS, 2011, WOUND REPAIR REGEN, V19, P134, DOI 10.1111/j.1524-475X.2011.00673.x
   Semenza GL, 2000, J APPL PHYSIOL, V88, P1474, DOI 10.1152/jappl.2000.88.4.1474
   Sengupta N, 2003, INVEST OPHTH VIS SCI, V44, P4908, DOI 10.1167/iovs.03-0342
   Sheridan CM, 2009, GRAEF ARCH CLIN EXP, V247, P1361, DOI 10.1007/s00417-009-1133-3
   Sheridan CM, 2006, INVEST OPHTH VIS SCI, V47, P1642, DOI 10.1167/iovs.05-0779
   Sidgwick GP, 2012, J EUR ACAD DERMATOL, V26, P141, DOI 10.1111/j.1468-3083.2011.04200.x
   Silva RLE, 2007, FASEB J, V21, P3219, DOI 10.1096/fj.06-7359com
   Singer AJ, 1999, NEW ENGL J MED, V341, P738, DOI 10.1056/NEJM199909023411006
   Sjoberg AP, 2007, J BIOL CHEM, V282, P10894, DOI 10.1074/jbc.M610256200
   Soo C, 2000, AM J PATHOL, V157, P423, DOI 10.1016/S0002-9440(10)64555-5
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   Tomasek JJ, 2002, NAT REV MOL CELL BIO, V3, P349, DOI 10.1038/nrm809
   Tuo JS, 2012, OCUL IMMUNOL INFLAMM, V20, P27, DOI 10.3109/09273948.2011.628432
   WANG GL, 1993, P NATL ACAD SCI USA, V90, P4304, DOI 10.1073/pnas.90.9.4304
   WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510
   Werner S, 2003, PHYSIOL REV, V83, P835, DOI 10.1152/physrev.2003.83.3.835
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu YJ, 2007, WOUND REPAIR REGEN, V15, pS18, DOI 10.1111/j.1524-475X.2007.00221.x
   Wynn TA, 2004, NAT REV IMMUNOL, V4, P583, DOI 10.1038/nri1412
   Xu HP, 2009, PROG RETIN EYE RES, V28, P348, DOI 10.1016/j.preteyeres.2009.06.001
   YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0
   Yang LJ, 2005, WOUND REPAIR REGEN, V13, P398, DOI 10.1111/j.1067-1927.2005.130407.x
   Yehoshua Z, 2014, OPHTHALMOLOGY, V121, P693, DOI 10.1016/j.ophtha.2013.09.044
   YOUNG WC, 1985, J CELL SCI, V73, P19
NR 137
TC 1
Z9 1
U1 0
U2 3
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD NOV
PY 2015
VL 29
IS 11
BP 1416
EP 1426
DI 10.1038/eye.2015.140
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CW5HZ
UT WOS:000365027600002
PM 26228288
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Kim, JM
   Lee, MW
   Lim, HB
   Won, YK
   Shin, YI
   Lee, WH
   Kim, JY
AF Kim, Ju Mi
   Lee, Min-Woo
   Lim, Hyung Bin
   Won, Yeo Kyoung
   Shin, Yong-il
   Lee, Woo-Hyuck
   Kim, Jung-Yeul
TI Longitudinal changes in the ganglion cell-inner plexiform layer
   thickness of age-related macular degeneration
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE GC&#8208; IPL; non&#8208; exudative AMD; spectral domain optical
   coherence tomography
AB Purpose To determine longitudinal changes of the ganglion cell-inner plexiform layer (GC-IPL) thickness in patients with non-exudative age-related macular degeneration (AMD) without other ophthalmic disease.
   Methods Thirty-three eyes of 33 patients with early and intermediate non-exudative AMD (non-exudative AMD group) and 33 normal control eyes were followed for 2 years, and GC-IPL thickness was measured by spectral domain optical coherence tomography at 1-year intervals. The mean rate of GC-IPL reduction was estimated using a linear mixed model and compared between two groups.
   Results The mean age of patients in the non-exudative AMD group and control groups were 68.82 +/- 6.81 years and 67.73 +/- 5.87 years, respectively (p = 0.488). The mean GC-IPL thickness at the first visit was 76.61 +/- 16.33 mu m in the non-exudative AMD and 81.76 +/- 3.69 mu m in control group (p = 0.387), and these values significantly decreased over time, with an average reduction rate of average GC-IPL -0.86 mu m/year in the non-exudative AMD group and -0.32 mu m/year in the control group. The difference between two groups was statistically significant (p < 0.001), and there was also a significant interaction between group and duration in linear mixed models in mean GC-IPL thickness (p = 0.001).
   Conclusions The reduction rate of the GC-IPL thickness was greater in non-exudative AMD eyes, even at relatively early stages of the disease. Physicians should maintain awareness of the presence of non-exudative AMD in various cases of ophthalmic diseases where GC-IPL thickness evaluation is necessary.
C1 [Kim, Ju Mi; Lim, Hyung Bin; Won, Yeo Kyoung; Shin, Yong-il; Lee, Woo-Hyuck; Kim, Jung-Yeul] Chungnam Natl Univ, Coll Med, Dept Ophthalmol, Daejeon, South Korea.
   [Lee, Min-Woo] Konyang Univ, Dept Ophthalmol, Coll Med, Daejeon, South Korea.
C3 Chungnam National University; Konyang University; Konyang University
   Hospital
RP Kim, JY (通讯作者)，Chungnam Natl Univ Hosp, Dept Ophthalmol, 640 Daesa Dong, Daejeon 301721, South Korea.
EM kimjy@cnu.ac.kr
OI Kim, Jung yeul/0000-0003-3679-1310
CR Arya M, 2018, EYE VISION, V5, DOI 10.1186/s40662-018-0118-x
   Biarnes M, 2015, AM J OPHTHALMOL, V160, P345, DOI 10.1016/j.ajo.2015.05.009
   BLANKS JC, 1974, J COMP NEUROL, V156, P95, DOI 10.1002/cne.901560108
   Buschini E, 2015, CLIN OPHTHALMOL, V9, P563, DOI 10.2147/OPTH.S59724
   CLARKE S, 1994, EUR J NEUROSCI, V6, P725, DOI 10.1111/j.1460-9568.1994.tb00984.x
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Hu CC, 2017, EYE, V31, P872, DOI 10.1038/eye.2016.325
   Humayun MS, 1996, ARCH OPHTHALMOL-CHIC, V114, P40, DOI 10.1001/archopht.1996.01100130038006
   Ishikawa H, 2005, INVEST OPHTH VIS SCI, V46, P2012, DOI 10.1167/iovs.04-0335
   Kim NR, 2011, BRIT J OPHTHALMOL, V95, P1115, DOI 10.1136/bjo.2010.182493
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Law SK, 2004, AM J OPHTHALMOL, V138, P38, DOI 10.1016/j.ajo.2004.02.021
   Lee EK, 2015, INVEST OPHTH VIS SCI, V56, P3976, DOI 10.1167/iovs.15-17013
   Leung CKS, 2013, OPHTHALMOLOGY, V120, P2485, DOI 10.1016/j.ophtha.2013.07.021
   Medeiros NE, 2001, INVEST OPHTH VIS SCI, V42, P795
   Mehta S, 2015, PRIMARY CARE, V42, P377, DOI 10.1016/j.pop.2015.05.009
   Moussa K, 2013, RETINA-J RET VIT DIS, V33, P1590, DOI 10.1097/IAE.0b013e31828d6052
   Muftuoglu IK, 2018, RETINA-J RET VIT DIS, V38, P1478, DOI 10.1097/IAE.0000000000001759
   Mwanza JC, 2011, INVEST OPHTH VIS SCI, V52, P7872, DOI 10.1167/iovs.11-7896
   Nieves-Moreno M, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0194169
   Pappuru RR, 2011, INVEST OPHTH VIS SCI, V52, P6743, DOI 10.1167/iovs.10-6723
   Ramirez JM, 2001, EXP EYE RES, V73, P601, DOI 10.1006/exer.2001.1061
   Ramkumar HL, 2018, RETINA-J RET VIT DIS, V38, P2159, DOI 10.1097/IAE.0000000000001867
   Rimayanti U, 2014, GRAEF ARCH CLIN EXP, V252, P563, DOI 10.1007/s00417-013-2496-z
   Sato S, 2013, INVEST OPHTH VIS SCI, V54, P3046, DOI 10.1167/iovs.12-11173
   Savastano MC, 2014, INVEST OPHTH VIS SCI, V55, P560, DOI 10.1167/iovs.13-12172
   Schmidt-Erfurth U, 2017, EYE, V31, P26, DOI 10.1038/eye.2016.227
   Schuman SG, 2009, OPHTHALMOLOGY, V116, P488, DOI 10.1016/j.ophtha.2008.10.006
   Strettoi E, 2002, J NEUROSCI, V22, P5492
   Toto L, 2016, RETINA-J RET VIT DIS, V36, P1566, DOI 10.1097/IAE.0000000000000962
   Villegas-Perez MP, 1998, J COMP NEUROL, V392, P58, DOI 10.1002/(SICI)1096-9861(19980302)392:1<58::AID-CNE5>3.0.CO;2-O
   Wood A, 2011, AM J OPHTHALMOL, V152, P1030, DOI 10.1016/j.ajo.2011.05.021
   Xu Q, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-0842-y
   Zajac-Pytrus HM, 2015, ADV CLIN EXP MED, V24, P1099, DOI 10.17219/acem/27093
   Zhang X, 2016, TRANSL VIS SCI TECHN, V5, DOI 10.1167/tvst.5.2.1
NR 37
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD NOV
PY 2021
VL 99
IS 7
BP E1056
EP E1062
DI 10.1111/aos.14784
EA FEB 2021
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA WD6YR
UT WOS:000615925200001
PM 33555661
DA 2022-11-30
ER

PT J
AU Brandl, C
   Brucklmayer, C
   Gunther, F
   Zimmermann, ME
   Kuchenhoff, H
   Helbig, H
   Weber, BHF
   Heid, IM
   Stark, KJ
AF Brandl, Caroline
   Bruecklmayer, Christiane
   Guenther, Felix
   Zimmermann, Martina E.
   Kuechenhoff, Helmut
   Helbig, Horst
   Weber, Bernhard H. F.
   Heid, Iris M.
   Stark, Klaus J.
TI Retinal Layer Thicknesses in Early Age-Related Macular Degeneration:
   Results From the German AugUR Study
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE age-related macular degeneration (AMD); optical coherence tomography
   (OCT); population-based study of the elderly; retinal layer
   segmentation; retinal layer thicknesses; imaging biomarker
ID OPTICAL COHERENCE TOMOGRAPHY; PHOTORECEPTOR LAYER; HEALTHY EYES; FIBER
   LAYER; SD-OCT; PROGRESSION; ADULTS; CLASSIFICATION; ASSOCIATIONS; DRUSEN
AB PURPOSE. To systematically analyze thicknesses of retinal layers in an older population and their link to early age-related macular degeneration (AMD).
   METHODS. In the AugUR baseline survey from a population aged >= 70 years, we conducted multimodal retinal imaging, including spectral-domain optical coherence tomography. Autosegmentation of eight distinct retinal layers was followed by manual correction of segmentation errors. AMD status was graded on color fundus images according to the Three Continent AMD Consortium Severity Scale. We tested the association of early AMD on retinal layer thicknesses by using linear mixed models and replicated significant results in independent data also from the AugUR platform.
   RESULTS. When comparing layer thicknesses between early AMD and no AMD (822 eyes, 449 participants), the retinal pigment epithelium/Bruch's membrane complex demonstrated a statistically significant thickening (e.g., P = 6.41 x 10(-92) for severe early versus no AMD) and photoreceptor layers showed a significant thinning. Autosegmented retinal layer thicknesses revealed similar associations as manually corrected values but underestimated some effects. Independent replication analysis in 1026 eyes (546 participants) confirmed associations (e.g., P = 9.38 x 10(-36) for retinal pigment epithelium/Bruch's membrane complex, severe early versus no AMD).
   CONCLUSIONS. This first population-based study on spectral-domain optical coherence tomography-derived retinal layer thicknesses in a total of similar to 1000 individuals provides insights into the reliability of autosegmentation and layer-specific reference values for an older population. Our findings show a difference in thicknesses between early AMD and no AMD for some retinal layers, suggesting these as potential imaging biomarkers. The thinning of photoreceptor layers substantiates a photoreceptor cell loss/damage already occurring in early AMD.
C1 [Brandl, Caroline; Bruecklmayer, Christiane; Guenther, Felix; Zimmermann, Martina E.; Heid, Iris M.; Stark, Klaus J.] Univ Regensburg, Dept Genet Epidemiol, Regensburg, Germany.
   [Brandl, Caroline; Helbig, Horst] Univ Hosp Regensburg, Dept Ophthalmol, Regensburg, Germany.
   [Brandl, Caroline; Weber, Bernhard H. F.] Univ Regensburg, Inst Human Genet, Regensburg, Germany.
   [Guenther, Felix; Kuechenhoff, Helmut] Ludwig Maximilians Univ Munchen, Dept Stat, Stat Consulting Unit StaBLab, Munich, Germany.
C3 University of Regensburg; University of Regensburg; University of
   Regensburg; University of Munich
RP Brandl, C (通讯作者)，Univ Regensburg, Dept Genet Epidemiol, Dept Ophthalmol, Franz Josef Strauss Allee 11, D-93053 Regensburg, Germany.
EM Caroline.Brandl@ukr.de
RI Zimmermann, Martina/AAL-2990-2021
OI Zimmermann, Martina/0000-0002-6916-4404; Kuchenhoff,
   Helmut/0000-0002-6372-2487; Brandl, Caroline/0000-0001-8223-6137
FU German Federal Ministry of Education and Research [BMBF 01ER1206, BMBF
   01ER1507]; National Institutes of Health [NIH R01 EY RES 511967];
   Institute of Human Genetics, Department of Genetic Epidemiology,
   University of Regensburg
FX Supported by the German Federal Ministry of Education and Research (BMBF
   01ER1206, BMBF 01ER1507), by the National Institutes of Health (NIH R01
   EY RES 511967), and institutional budget (Institute of Human Genetics,
   Department of Genetic Epidemiology, University of Regensburg).
CR Abdelfattah NS, 2016, INVEST OPHTH VIS SCI, V57, P1839, DOI 10.1167/iovs.15-18572
   Abdolrahimzadeh S, 2016, RETINA-J RET VIT DIS, V36, P2329, DOI 10.1097/IAE.0000000000001097
   Acton JH, 2012, INVEST OPHTH VIS SCI, V53, P7618, DOI 10.1167/iovs.12-10361
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Bates D, 2015, J STAT SOFTW, V67, P1, DOI 10.18637/jss.v067.i01
   Brandao LM, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/8307639
   Brandl C, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-26629-5
   Carroll RJ, 2006, MEASUREMENT ERROR NO
   Chan A, 2006, ARCH OPHTHALMOL-CHIC, V124, P193, DOI 10.1001/archopht.124.2.193
   Chan A, 2006, RETINA-J RET VIT DIS, V26, P655, DOI 10.1097/00006982-200607000-00011
   Chiu SJ, 2012, INVEST OPHTH VIS SCI, V53, P53, DOI 10.1167/iovs.11-7640
   Christenbury JG, 2013, OPHTHALMOLOGY, V120, P1038, DOI 10.1016/j.ophtha.2012.10.018
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Curcio CA, 2011, INVEST OPHTH VIS SCI, V52, P3943, DOI 10.1167/iovs.10-6377
   Farsiu S, 2014, OPHTHALMOLOGY, V121, P162, DOI 10.1016/j.ophtha.2013.07.013
   Ferrara D, 2017, INVEST OPHTH VIS SCI, V58, P3519, DOI 10.1167/iovs.17-21696
   Forte R, 2012, ACTA OPHTHALMOL, V90, pE281, DOI 10.1111/j.1755-3768.2011.02331.x
   Garrity ST, 2018, INVEST OPHTH VIS SCI, V59, pAMD48, DOI 10.1167/iovs.18-24158
   Grace YY, 2016, STAT ANAL MEASUREMEN
   Grover S, 2009, AM J OPHTHALMOL, V148, P266, DOI 10.1016/j.ajo.2009.03.006
   Halekoh U, 2014, J STAT SOFTW, V59, P1
   Huisingh C, 2016, INVEST OPHTH VIS SCI, V57, P739, DOI 10.1167/iovs.15-18316
   Jonas JB, 2016, INVEST OPHTH VIS SCI, V57, P1791, DOI 10.1167/iovs.15-18529
   Kashani AH, 2010, AM J OPHTHALMOL, V149, P496, DOI 10.1016/j.ajo.2009.09.025
   Keane PA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0164095
   Klein R, 2014, OPHTHAL EPIDEMIOL, V21, P14, DOI 10.3109/09286586.2013.867512
   Ko F, 2017, OPHTHALMOLOGY, V124, P105, DOI 10.1016/j.ophtha.2016.07.033
   Kolb H., 1995, WEBVISION ORG RETINA
   Lee DJ, 2018, INVEST OPHTH VIS SCI, V59, P5336, DOI 10.1167/iovs.18-24145
   Lee Jong Yeon, 2012, Korean J Ophthalmol, V26, P163, DOI 10.3341/kjo.2012.26.3.163
   Lei JQ, 2017, GRAEF ARCH CLIN EXP, V255, P1551, DOI 10.1007/s00417-017-3693-y
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lujan BJ, 2011, INVEST OPHTH VIS SCI, V52, P1486, DOI 10.1167/iovs.10-5946
   Muftuoglu IK, 2018, RETINA-J RET VIT DIS, V38, P1478, DOI 10.1097/IAE.0000000000001759
   Myers CE, 2015, AM J OPHTHALMOL, V159, P445, DOI 10.1016/j.ajo.2014.11.025
   Owsley C, 2016, OPHTHALMOLOGY, V123, P344, DOI 10.1016/j.ophtha.2015.09.041
   Pan CW, 2013, OPHTHALMOLOGY, V120, P2058, DOI 10.1016/j.ophtha.2013.03.028
   Patel PJ, 2016, OPHTHALMOLOGY, V123, P829, DOI 10.1016/j.ophtha.2015.11.009
   Ross DH, 2015, INVEST OPHTH VIS SCI, V56, P4166, DOI 10.1167/iovs.14-15256
   Rougier MB, 2015, ACTA OPHTHALMOL, V93, P539, DOI 10.1111/aos.12658
   Sadigh S, 2013, INVEST OPHTH VIS SCI, V54, P1603, DOI 10.1167/iovs.12-11286
   Salmon AE, 2018, INVEST OPHTH VIS SCI, V59, P3037, DOI 10.1167/iovs.17-23549
   Schuman SG, 2009, OPHTHALMOLOGY, V116, P488, DOI 10.1016/j.ophtha.2008.10.006
   Sevilla MB, 2016, AM J OPHTHALMOL, V165, P65, DOI 10.1016/j.ajo.2016.02.021
   Spaide RF, 2018, SURV OPHTHALMOL, V63, P782, DOI 10.1016/j.survophthal.2018.05.005
   Spaide RF, 2018, RETINA-J RET VIT DIS, V38, P891, DOI 10.1097/IAE.0000000000001732
   Spaide RF, 2011, RETINA-J RET VIT DIS, V31, P1609, DOI 10.1097/IAE.0b013e3182247535
   Stark K, 2015, BMC GERIATR, V15, DOI 10.1186/s12877-015-0122-0
   Staurenghi G, 2014, OPHTHALMOLOGY, V121, P1572, DOI 10.1016/j.ophtha.2014.02.023
   Szigeti A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142383
   Tan CS, 2015, OSLI RETINA, V46, P172, DOI 10.3928/23258160-20150213-23
   Team RC, 2013, R LANG ENV STAT COMP
   Terry L, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162001
   von Hanno T, 2017, ACTA OPHTHALMOL, V95, P262, DOI 10.1111/aos.13337
   Wang G, 2015, INT J OPHTHALMOL-CHI, V8, P1196, DOI 10.3980/j.issn.2222-3959.2015.06.21
   Won JY, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000005441
NR 56
TC 23
Z9 23
U1 0
U2 2
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD APR
PY 2019
VL 60
IS 5
BP 1581
EP 1594
DI 10.1167/iovs.18-25332
PG 14
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HW5VL
UT WOS:000466757300034
PM 30995315
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Lin, HJ
   Xu, HF
   Liang, FQ
   Liang, H
   Gupta, P
   Havey, AN
   Boulton, ME
   Godley, BF
AF Lin, Haijiang
   Xu, Haifeng
   Liang, Fong-Qi
   Liang, Hao
   Gupta, Praveena
   Havey, Anna N.
   Boulton, Michael E.
   Godley, Bernard F.
TI Mitochondrial DNA Damage and Repair in RPE Associated with Aging and
   Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; BASE EXCISION-REPAIR; OXIDATIVE STRESS;
   PROGRESSIVE STAGES; CELLS; NUCLEAR; GENE; GLYCOSYLASE; EXPRESSION;
   PROTEOMICS
AB PURPOSE. Mitochondrial DNA (mtDNA) damage may be associated with age-related diseases, such as age-related macular degeneration (AMD). The present study was designed to test whether the frequency of mtDNA damage, heteroplasmic mtDNA mutations, and repair capacity correlate with progression of AMD.
   METHODS. Macular and peripheral RPE cells were isolated and cultured from human donor eyes with and without AMD. The stages of AMD were graded according to the Minnesota Grading System. Confluent primary RPE cells were used to test the frequency of endogenous mtDNA damage by quantitative PCR. Mutation detection kits were used to detect heteroplasmic mtDNA mutation. To test the mtDNA repair capacity, cultured RPE cells were allowed to recover for 3 and 6 hours after exposure to H(2)O(2), and repair was assessed by quantitative PCR. The levels of human OGG1 protein, which is associated with mtDNA repair, were analyzed by Western blot.
   RESULTS. This study showed that mtDNA damage increased with aging and that more lesions occurred in RPE cells from the macular region than the periphery. Furthermore, mtDNA repair capacity decreased with aging, with less mtDNA repair capacity in the macular region compared with the periphery in samples from aged subjects. Most interestingly, the mtDNA damage was positively correlated with the grading level of AMD, whereas repair capacity was negatively correlated. In addition, more mitochondrial heteroplasmic mutations were detected in eyes with AMD.
   CONCLUSIONS. These data show macula-specific increases in mtDNA damage, heteroplasmic mutations, and diminished repair that are associated with aging and AMD severity. (Invest Ophthalmol Vis Sci. 2010;51:3521-3529) DOI: 10.1167/iovs.10-6163
C1 [Lin, Haijiang; Xu, Haifeng; Liang, Hao; Gupta, Praveena; Havey, Anna N.; Godley, Bernard F.] Univ Texas Med Branch, Dept Ophthalmol & Visual Sci, Galveston, TX 77555 USA.
   [Liang, Fong-Qi; Godley, Bernard F.] Retina Fdn SW, Dallas, TX USA.
   [Boulton, Michael E.] Univ Florida, Gainesville, FL USA.
C3 University of Texas System; University of Texas Medical Branch
   Galveston; Retina Foundation of the Southwest; State University System
   of Florida; University of Florida
RP Godley, BF (通讯作者)，Univ Texas Med Branch, Dept Ophthalmol & Visual Sci, Galveston, TX 77555 USA.
EM bgodley@utmb.edu
OI Lin, Haijiang/0000-0003-2931-468X
FU National Institutes of Health [EY12850, R01EY019688]; Research to
   Prevent Blindness, Inc.; NATIONAL EYE INSTITUTE [R01EY012850,
   R01EY019688, P30EY021721] Funding Source: NIH RePORTER
FX Supported by National Institutes of Health Grants EY12850 and
   R01EY019688 and by Research to Prevent Blindness, Inc.
CR Akbari M, 2008, DNA REPAIR, V7, P605, DOI 10.1016/j.dnarep.2008.01.002
   Ballinger SW, 1999, EXP EYE RES, V68, P765, DOI 10.1006/exer.1998.0661
   Ballinger SW, 1996, CANCER RES, V56, P5692
   Bannwarth S, 2006, NAT PROTOC, V1, P2037, DOI 10.1038/nprot.2006.318
   Barreau E, 1996, INVEST OPHTH VIS SCI, V37, P384
   Brennan LA, 2009, EXP EYE RES, V88, P195, DOI 10.1016/j.exer.2008.05.018
   Cai J, 2006, J BIOL CHEM, V281, P3604, DOI 10.1074/jbc.M507401200
   Chen DX, 2002, J NEUROCHEM, V81, P1273, DOI 10.1046/j.1471-4159.2002.00916.x
   Cortina MS, 2005, EXP EYE RES, V81, P742, DOI 10.1016/j.exer.2005.04.017
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   de Souza-Pinto NC, 2001, CANCER RES, V61, P5378
   Decanini A, 2007, AM J OPHTHALMOL, V143, P607, DOI 10.1016/j.ajo.2006.12.006
   Dianov GL, 2001, PROG NUCLEIC ACID RE, V68, P285
   Druzhyna NM, 2008, MECH AGEING DEV, V129, P383, DOI 10.1016/j.mad.2008.03.002
   Druzhyna NM, 2003, GLIA, V42, P370, DOI 10.1002/glia.10230
   Feher J, 2006, NEUROBIOL AGING, V27, P983, DOI 10.1016/j.neurobiolaging.2005.05.012
   Frank RN, 1999, AM J OPHTHALMOL, V127, P694, DOI 10.1016/S0002-9394(99)00032-X
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Godley BF, 2005, J BIOL CHEM, V280, P21061, DOI 10.1074/jbc.M502194200
   GRAMAJO AL, INVEST OPHTHALMOL VI, V51, P1164
   Howes KA, 2004, INVEST OPHTH VIS SCI, V45, P3713, DOI 10.1167/iovs.04-0404
   Imam SZ, 2006, NEUROBIOL AGING, V27, P1129, DOI 10.1016/j.neurobiolaging.2005.06.002
   Jarrett SG, 2010, OPHTHALMIC RES, V44, P179, DOI 10.1159/000316480
   Jarrett SG, 2008, PROG RETIN EYE RES, V27, P596, DOI 10.1016/j.preteyeres.2008.09.001
   Justilien V, 2007, INVEST OPHTH VIS SCI, V48, P4407, DOI 10.1167/iovs.07-0432
   Karunadharma PP, 2010, INVEST OPHTH VIS SCI, V51, P5470, DOI 10.1167/iovs.10-5429
   Kenney MC, 2010, INVEST OPHTH VIS SCI, V51, P4289, DOI 10.1167/iovs.09-4778
   LeDoux SP, 2007, NEUROSCIENCE, V145, P1249, DOI 10.1016/j.neuroscience.2006.10.002
   Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X
   Miceli MV, 2005, INVEST OPHTH VIS SCI, V46, P1765, DOI 10.1167/iovs.04-1327
   Nordgaard CL, 2006, INVEST OPHTH VIS SCI, V47, P815, DOI 10.1167/iovs.05-0976
   Nordgaard CL, 2008, INVEST OPHTH VIS SCI, V49, P2848, DOI 10.1167/iovs.07-1352
   Olsen TW, 2004, INVEST OPHTH VIS SCI, V45, P4484, DOI 10.1167/iovs.04-0342
   Santos JH, 2003, J BIOL CHEM, V278, P1728, DOI 10.1074/jbc.M208752200
   Shen GP, 2003, DNA REPAIR, V2, P673, DOI 10.1016/S1568-7864(03)00006-5
   Singh KK, 2001, NUCLEIC ACIDS RES, V29, P1381, DOI 10.1093/nar/29.6.1381
   Udar N, 2009, INVEST OPHTH VIS SCI, V50, P2966, DOI 10.1167/iovs.08-2646
   Wang AL, 2008, MOL VIS, V14, P644
   Wang AL, 2010, NEUROBIOL AGING, V31, P2002, DOI 10.1016/j.neurobiolaging.2008.10.019
   WANG W, DISCOV MED, V9, P13
   Yakes FM, 1997, P NATL ACAD SCI USA, V94, P514, DOI 10.1073/pnas.94.2.514
NR 41
TC 101
Z9 105
U1 0
U2 10
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAY
PY 2011
VL 52
IS 6
BP 3521
EP 3529
DI 10.1167/iovs.10-6163
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 800CF
UT WOS:000293335400011
PM 21273542
OA Green Published
DA 2022-11-30
ER

PT J
AU Pei, XT
   Li, XX
   Bao, YZ
   Yu, WZ
   Yan, Z
   Qi, HJ
   Qian, T
   Xiao, HX
AF Pei, Xue-Ting
   Li, Xiao-Xin
   Bao, Yong-Zhen
   Yu, Wen-Zhen
   Yan, Zheng
   Qi, Hui-Jun
   Qian, Tong
   Xiao, Hong-Xiang
TI Association of C3 Gene Polymorphisms with Neovascular Age-Related
   Macular Degeneration in a Chinese Population
SO CURRENT EYE RESEARCH
LA English
DT Article
DE age-related macular degeneration; Chinese; complement factor 3;
   polymorphism
ID FACTOR-H POLYMORPHISM; FACTOR-B; RISK; VARIANT; Y402H; MACULOPATHY;
   INCREASES; DISEASE; EYE
AB Purpose: The purpose of this study was to determine whether the genetic polymorphisms of complement factor 3 (C3) are associated with neovascular age-related macular degeneration (AMD) in the Chinese population. Methods: A total of 123 unrelated Chinese Han patients with neovascular AMD and 130 control subjects were recruited. Their six single-nucleotide polymorphisms (SNPs) in the C3 gene, one in the complement factor H (CFH) gene and two in the complement factor B (CFB) gene were characterized. Their genotypes, allele frequencies, and odds ratios were analyzed. Results: The G allele of the C3 IVS2 rs2250656, but not other tested C3 SNPs of rs2230205, rs10411506, rs2230199, rs339392, and rs163913, was significantly associated with a reduced risk for AMD in the Chinese population (OR 0.605, 95% CI 0.39-0.93, p = 0.023), even after adjusting for age, gender, smoking status, CFH rs1061170, CFB rs4151667, and CFB rs641153 allele status (OR 0.58, 95% CI 0.35-0.96, p = 0.033). However, the C3 haplotype of A-A-C-A-T-T was identified as a statistically significant risk factor for neovascular AMD (OR 1.41, 95% CI 1.02-1.94). Furthermore, the C allele of the CFH rs1061170, but not the CFB rs4151667 and rs641153, was significnatly associated with increased risk for AMD (OR 3.09, 95% CI 1.55-6.15, p < 0.001). Conclusion: The G allele of C3 IVS2 rs2250656 may be a significantly protective factor for neovascular AMD in the Chinese population. This, together with low MAF of C3 R102G, may be partially responsible for the low prevalence of AMD in the Chinese population.
C1 [Pei, Xue-Ting; Li, Xiao-Xin; Bao, Yong-Zhen; Yu, Wen-Zhen; Yan, Zheng; Qi, Hui-Jun; Qian, Tong; Xiao, Hong-Xiang] Peking Univ, People Eye Ctr, Peoples Hosp, Beijing 100044, Peoples R China.
C3 Peking University
RP Li, XX (通讯作者)，Peking Univ, People Eye Ctr, Peoples Hosp, Beijing 100044, Peoples R China.
EM drlixiaoxin@yahoo.cn
CR Baird PN, 2006, INVEST OPHTH VIS SCI, V47, P4194, DOI 10.1167/iovs.05-1285
   Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BOTTO M, 1990, J EXP MED, V172, P1011, DOI 10.1084/jem.172.4.1011
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   FRANCIS PJ, 2008, J MED GENET     1117
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hughes AE, 2007, NAT GENET, V39, P567, DOI 10.1038/ng0407-567c
   Jaremko M, 2005, HUM MUTAT, V25, P232, DOI 10.1002/humu.20141
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P943
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Lau LI, 2006, INVEST OPHTH VIS SCI, V47, P3242, DOI 10.1167/iovs.05-1532
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Rodriguez-Trelles F, 2006, ANNU REV GENET, V40, P47, DOI 10.1146/annurev.genet.40.110405.090625
   Sepp T, 2006, INVEST OPHTH VIS SCI, V47, P536, DOI 10.1167/iovs.05-1143
   Shi YY, 2005, CELL RES, V15, P97, DOI 10.1038/sj.cr.7290272
   Spencer KL, 2008, HUM MOL GENET, V17, P1821, DOI 10.1093/hmg/ddn075
   Spencer KL, 2007, HUM MOL GENET, V16, P1986, DOI 10.1093/hmg/ddm146
   Tost J, 2005, CLIN BIOCHEM, V38, P335, DOI 10.1016/j.clinbiochem.2004.12.005
   WU LZ, 1987, JPN J OPHTHALMOL, V31, P349
   Xu L, 2006, OPHTHALMOLOGY, V113, P1134, DOI 10.1016/j.ophtha.2006.01.035
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
NR 27
TC 38
Z9 40
U1 0
U2 4
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0271-3683
EI 1460-2202
J9 CURR EYE RES
JI Curr. Eye Res.
PY 2009
VL 34
IS 8
BP 615
EP 622
DI 10.1080/02713680903003484
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 482JL
UT WOS:000268882000001
PM 19899988
DA 2022-11-30
ER

PT J
AU Tuo, J
   Ross, RJ
   Reed, GF
   Yan, Q
   Wang, JJ
   Bojanowski, CM
   Chew, EY
   Feng, X
   Olsen, TW
   Ferris, FL
   Mitchell, P
   Chan, CC
AF Tuo, Jingsheng
   Ross, Robert J.
   Reed, George F.
   Yan, Qing
   Wang, Jie Jin
   Bojanowski, Christine M.
   Chew, Emily Y.
   Feng, Xiao
   Olsen, Timothy W.
   Ferris, Frederick L., III
   Mitchell, Paul
   Chan, Chi-Chao
TI The HtrA1 Promoter Polymorphism, Smoking, and Age-related Macular
   Degeneration in Multiple Case-control Samples
SO OPHTHALMOLOGY
LA English
DT Article
ID COMPLEMENT-FACTOR-H; GENOMEWIDE-SCAN; JAPANESE POPULATION; GENE
   POLYMORPHISM; SERINE-PROTEASE; COMMON VARIANTS; GRADING SYSTEM;
   RISK-FACTORS; SUSCEPTIBILITY; MACULOPATHY
AB Objective: To assess the association and combined effect on the risk of age-related macular degeneration (AMD) by the HtrA1 and complement factor H (CFH) polymorphisms, smoking, and serum cholesterol.
   Design: Clinic-based and population-based case control study.
   Participants: A total of 805 AMD cases and 921 controls from The Eye Clinic of National Eye Institute, Age-Related Eye Diseases Study, Blue Mountain Eye Study Cohort, and Minnesota Lions Eye Bank.
   Methods: DNA samples were genotyped for polymorphisms of rs11200638 in HtrA1 promoter and rs380390 in CFH. HtrA1 protein in ocular tissue was measured. Interactions of the HtrA1 risk allele with the CFH risk variant, smoking status, and cholesterol were assessed.
   Main Outcome Measures: AMD was evaluated by retinal specialists, and AMD subtypes (geographic atrophy and neovascularization) were determined.
   Results: Strong associations of the HtrA1 risk allele (A) with AMD were present in all sample sets. A similar magnitude of association was observed for central geographic atrophy and neovascular AMD. The combination of the HtrA1 and CFH risk alleles increased AMD susceptibility, as did the combination of the HtrA1 risk allele with smoking. No combined effect of HtrA1 risk allele and cholesterol level was found. Enhanced expression of HtrA1 protein was detected in retina with AMD.
   Conclusions: Findings from multiple samples support an AMD genetic variant harbored within HtrA1. The risk of advanced AMD increased when the presence of risk alleles from HtrA 1 was combined with either CFH risk alleles or history of smoking.
   Financial Disclosure(s): The authors have no proprietary or commercial interest in any materials discussed in this article. Ophthalmology 2008; 115:1891-1898 (C) 2008 by the American Academy of Ophthalmology.
C1 [Tuo, Jingsheng; Ross, Robert J.; Bojanowski, Christine M.; Chan, Chi-Chao] NEI, Immunol Lab, NIH, Bethesda, MD 20892 USA.
   [Reed, George F.; Yan, Qing; Chew, Emily Y.; Ferris, Frederick L., III] NEI, Div Epidemiol & Clin Res, NIH, Bethesda, MD 20892 USA.
   [Wang, Jie Jin; Mitchell, Paul] Univ Sydney, Ctr Vis Sci, Dept Ophthalmol, Westmead, NSW 2145, Australia.
   [Wang, Jie Jin; Mitchell, Paul] Univ Sydney, Westmead Millennium Inst, Westmead, NSW 2145, Australia.
   [Feng, Xiao; Olsen, Timothy W.] Univ Minnesota, Dept Ophthalmol, Minneapolis, MN 55455 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); National Institutes of Health (NIH) - USA; NIH National Eye
   Institute (NEI); University of Sydney; University of Sydney; Westmead
   Institute for Medical Research; University of Minnesota System;
   University of Minnesota Twin Cities
RP Chan, CC (通讯作者)，NEI, Immunol Lab, NIH, Bldg 10,Room 10N103,10 Ctr Dr, Bethesda, MD 20892 USA.
EM chanc@nei.nih.gov
RI Wang, Jie Jin/P-1499-2014; Mitchell, Paul/P-1498-2014; wang,
   jie/GRS-0942-2022
OI Wang, Jie Jin/0000-0001-9491-4898; Tuo, Jingsheng/0000-0002-1372-7810;
   Ferris, Frederick/0000-0002-4933-0639
FU NATIONAL EYE INSTITUTE [ZIEEY000487, ZICEY000461, ZIAEY000222,
   ZIAEY000418] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING
   [R01AG025392] Funding Source: NIH RePORTER; Intramural NIH HHS [ZIA
   EY000489-01, Z01 EY000418-04, Z99 EY999999] Funding Source: Medline; NIA
   NIH HHS [AG025392, R01 AG025392] Funding Source: Medline
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bojanowski CM, 2006, ENVIRON MOL MUTAGEN, V47, P594, DOI 10.1002/em.20233
   Cameron DJ, 2007, CELL CYCLE, V6, P1122, DOI 10.4161/cc.6.9.4157
   Chan CC, 2005, HISTOL HISTOPATHOL, V20, P857, DOI 10.14670/HH-20.857
   Chan Chi-Chao, 2007, Trans Am Ophthalmol Soc, V105, P92
   Chen CS, 2006, BIOL BLOOD MARROW TR, V12, P42, DOI 10.1016/j.bbmt.2005.11.132
   Chien J, 2004, ONCOGENE, V23, P1636, DOI 10.1038/sj.onc.1207271
   Conley YP, 2006, HUM MOL GENET, V15, P3206, DOI 10.1093/hmg/ddl396
   De Luca A, 2004, J HISTOCHEM CYTOCHEM, V52, P1609, DOI 10.1369/jhc.4A6330.2004
   DeAngelis MM, 2008, OPHTHALMOLOGY, V115, P1209, DOI 10.1016/j.ophtha.2007.10.032
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Foran S, 2003, OPHTHALMIC EPIDEMIOL, V10, P215, DOI 10.1076/opep.10.4.215.15906
   Fuse N, 2006, AM J OPHTHALMOL, V142, P1074, DOI 10.1016/j.ajo.2006.07.030
   Gensler G, 2002, J NUTR, V132, P697
   Gilicze A, 2007, MOL IMMUNOL, V44, P2961, DOI 10.1016/j.molimm.2007.01.004
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Ioannidis JPA, 2001, NAT GENET, V29, P306, DOI 10.1038/ng749
   Iyengar SK, 2004, AM J HUM GENET, V74, P20, DOI 10.1086/380912
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kenealy SJ, 2004, MOL VIS, V10, P57
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Leveziel N, 2008, INVEST OPHTH VIS SCI, V49, P3090, DOI 10.1167/iovs.07-1540
   Lohmueller KE, 2003, NAT GENET, V33, P177, DOI 10.1038/ng1071
   Majewski J, 2003, AM J HUM GENET, V73, P540, DOI 10.1086/377701
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Mori K, 2007, J HUM GENET, V52, P636, DOI 10.1007/s10038-007-0162-1
   Mullins Robert F., 2007, International Ophthalmology Clinics, V47, P1, DOI 10.1097/IIO.0b013e31802bd3e6
   Oka C, 2004, DEVELOPMENT, V131, P1041, DOI 10.1242/dev.00999
   Okamoto H, 2006, MOL VIS, V12, P156
   Olsen TW, 2004, INVEST OPHTH VIS SCI, V45, P4484, DOI 10.1167/iovs.04-0342
   Postel EA, 2006, OPHTHALMOLOGY, V113, P1504, DOI 10.1016/j.ophtha.2006.02.049
   Ross RJ, 2007, EXPERT REV OPHTHALMO, V2, P443, DOI 10.1586/17469899.2.3.443
   Ross RJ, 2007, INVEST OPHTH VIS SCI, V48, P1128, DOI 10.1167/iovs.06-0999
   Seddon JM, 2003, AM J HUM GENET, V73, P780, DOI 10.1086/378505
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Seddon JM, 2006, HUM HERED, V61, P157, DOI 10.1159/000094141
   Shastry BS, 2007, J HUM GENET, V52, P384, DOI 10.1007/s10038-007-0120-y
   Shastry BS, 2006, OPHTHALMOLOGICA, V220, P291, DOI 10.1159/000094617
   Smith W, 1996, ARCH OPHTHALMOL-CHIC, V114, P1518, DOI 10.1001/archopht.1996.01100140716016
   Spencer KL, 2008, HUM MOL GENET, V17, P971, DOI 10.1093/hmg/ddm369
   Tam POS, 2008, INVEST OPHTH VIS SCI, V49, P2357, DOI 10.1167/iovs.07-1520
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   Tou JS, 2004, FASEB J, V18, P1297, DOI 10.1096/fj.04-1862fje
   Tuo JS, 2006, P NATL ACAD SCI USA, V103, P9256, DOI 10.1073/pnas.0603485103
   Tuo JS, 2004, PROG RETIN EYE RES, V23, P229, DOI 10.1016/j.preteyeres.2004.02.001
   Uka J, 2006, RETINA-J RET VIT DIS, V26, P985, DOI 10.1097/01.iae.0000244068.18520.3e
   WALTER SD, 1975, BIOMETRIKA, V62, P371, DOI 10.1093/biomet/62.2.371
   Weeks DE, 2004, AM J HUM GENET, V75, P174, DOI 10.1086/422476
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yoshida T, 2007, MOL VIS, V13, P545
   Zareparsi S, 2005, HUM MOL GENET, V14, P1449, DOI 10.1093/hmg/ddi154
NR 65
TC 40
Z9 43
U1 0
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD NOV
PY 2008
VL 115
IS 11
BP 1891
EP 1898
DI 10.1016/j.ophtha.2008.05.021
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 365ZO
UT WOS:000260448900006
PM 18718667
OA Green Accepted
DA 2022-11-30
ER

PT J
AU O'Connor, SR
   Treanor, C
   Ward, E
   Wickens, RA
   O'Connell, A
   Culliford, LA
   Rogers, CA
   Gidman, EA
   Peto, T
   Knox, PC
   Burton, BJL
   Lotery, AJ
   Sivaprasad, S
   Reeves, BC
   Hogg, RE
   Donnelly, M
AF O'Connor, Sean R.
   Treanor, Charlene
   Ward, Elizabeth
   Wickens, Robin A.
   O'Connell, Abby
   Culliford, Lucy A.
   Rogers, Chris A.
   Gidman, Eleanor A.
   Peto, Tunde
   Knox, Paul C.
   Burton, Benjamin J. L.
   Lotery, Andrew J.
   Sivaprasad, Sobha
   Reeves, Barnaby C.
   Hogg, Ruth E.
   Donnelly, Michael
CA MONARCH Study Grp
TI Patient Acceptability of Home Monitoring for Neovascular Age-Related
   Macular Degeneration Reactivation: A Qualitative Study
SO INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH
LA English
DT Article
DE patient perspective; technology acceptance; ophthalmic care; qualitative
   methods
ID HEALTH-CARE; TECHNOLOGY; ACCEPTANCE; CHINESE; ACUITY; MODEL
AB Neovascular age-related macular degeneration (nAMD) is a chronic, progressive condition and the commonest cause of visual disability in older adults. This study formed part of a diagnostic test accuracy study to quantify the ability of three index home monitoring (HM) tests (one paper-based and two digital tests) to identify reactivation in nAMD. The aim of this qualitative research was to investigate patients' or participants' views about acceptability and explore adherence to weekly HM. Semi-structured interviews were held with 78/297 participants (26%), with close family members (n = 11) and with healthcare professionals involved in training participants in HM procedures (n = 9) (n = 98 in total). A directed thematic analytical approach was applied to the data using a deductive and inductive coding framework informed by theories of technology acceptance. Five themes emerged related to: 1. The role of HM; 2. Suitability of procedures and instruments; 3. Experience of HM; 4. Feasibility of HM in usual practice; and 5. Impediments to patient acceptability of HM. Various factors influenced acceptability including a patient's understanding about the purpose of monitoring. While initial training and ongoing support were regarded as essential for overcoming unfamiliarity with use of digital technology, patients viewed HM as relatively straightforward and non-burdensome. There is a need for further research about how use of performance feedback, level of support and nature of tailoring might facilitate further the implementation of routinely conducted HM. Home monitoring was acceptable to patients and they recognised its potential to reduce clinic visits during non-active treatment phases. Findings have implications for implementation of digital HM in the care of older people with nAMD and other long-term conditions.
C1 [O'Connor, Sean R.] Queens Univ Belfast, Sch Psychol, Belfast BT7 1NN, Antrim, North Ireland.
   [Treanor, Charlene; Peto, Tunde; Hogg, Ruth E.; Donnelly, Michael] Queens Univ Belfast, Ctr Publ Hlth, Belfast, Belfast BT12 6BA, Antrim, North Ireland.
   [Ward, Elizabeth; Wickens, Robin A.; Culliford, Lucy A.; Rogers, Chris A.; Gidman, Eleanor A.; Reeves, Barnaby C.] Univ Bristol, Bristol Royal Infirm, Bristol Trials Ctr CTEU, Bristol BS2 8HW, Avon, England.
   [Wickens, Robin A.] Univ Southampton, Southampton Clin Trials Unit, Univ Rd, Southampton SO17 1BJ, Hants, England.
   [O'Connell, Abby] Univ Exeter, Exeter Clin Trials Unit EXECTU, St Lukes Campus, Exeter EX1 2LT, Devon, England.
   [Knox, Paul C.] Univ Liverpool, Dept Eye & Vis Sci, Liverpool L7 8TX, Merseyside, England.
   [Burton, Benjamin J. L.] James Paget Univ Hosp NHS Fdn Trust, Great Yarmouth NR31 6LA, Norfolk, England.
   [Lotery, Andrew J.] Univ Southampton, Fac Med, Dept Clin & Expt Sci, Southampton SO16 6YD, Hants, England.
   [Sivaprasad, Sobha] Moorfields Eye Hosp NHS Fdn Trust, NIHR Moorfields Biomed Res Ctr, London EC1V 2PD, England.
C3 Queens University Belfast; Queens University Belfast; Bristol Royal
   Infirmary; University of Bristol; University of Southampton; University
   of Exeter; University of Liverpool; University of Southampton;
   University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust
RP O'Connor, SR (通讯作者)，Queens Univ Belfast, Sch Psychol, Belfast BT7 1NN, Antrim, North Ireland.; Treanor, C (通讯作者)，Queens Univ Belfast, Ctr Publ Hlth, Belfast, Belfast BT12 6BA, Antrim, North Ireland.
EM s.oconnor@qub.ac.uk; c.treanor@qub.ac.uk
RI ; Peto, Tunde/M-2081-2013
OI Lotery, Andrew/0000-0001-5541-4305; Sivaprasad,
   Sobha/0000-0001-8952-0659; O'Connor, Sean R/0000-0001-6805-8899; Reeves,
   Barnaby/0000-0002-5101-9487; Gidman, Eleanor/0000-0002-5261-5213; Peto,
   Tunde/0000-0001-6265-0381; Hogg, Ruth/0000-0001-9413-2669
FU National Institute for Health Research, Health Technology Assessment
   (HTA) Programme [15/97/02]
FX This project was funded by the National Institute for Health Research,
   Health Technology Assessment (HTA) Programme (ref 15/97/02). The views
   and opinions are the authors' and do not necessarily reflect the HTA
   programme, NIHR, NHS or the Department of Health and Social Care.
CR Al Aufa B, 2020, ENFERM CLIN, V30, P110, DOI 10.1016/j.enfcli.2020.06.025
   Assarroudi A, 2018, J RES NURS, V23, P42, DOI 10.1177/1744987117741667
   Bittner Ava K, 2014, J Clin Exp Ophthalmol, V5, P320
   Boyle J, 2018, PSYCHOL HEALTH MED, V23, P127, DOI 10.1080/13548506.2016.1274040
   Byambasuren O, 2018, NPJ DIGIT MED, V1, DOI 10.1038/s41746-018-0021-9
   Chao CM, 2019, FRONT PSYCHOL, V10, DOI 10.3389/fpsyg.2019.01652
   Chen DA, 2022, TELEMED E-HEALTH, V28, P798, DOI 10.1089/tmj.2021.0392
   Chen K, 2014, ERGONOMICS, V57, P635, DOI 10.1080/00140139.2014.895855
   Ciulla TA, 2020, OPHTHALMOL RETINA, V4, P19, DOI 10.1016/j.oret.2019.05.017
   Faes L, 2021, EYE, V35, P3035, DOI 10.1038/s41433-020-01356-2
   Freund K.B., 2019, J VITR DIS, V3, P167, DOI [10.1177/2474126419834702, DOI 10.1177/2474126419834702]
   Ha J, 2020, CLIN INTERV AGING, V15, P1873, DOI 10.2147/CIA.S268606
   Ho AC, 2017, JAMA OPHTHALMOL, V135, P268, DOI 10.1001/jamaophthalmol.2016.5314
   Ho CYD, 2018, TRANSL VIS SCI TECHN, V7, DOI 10.1167/tvst.7.2.2
   Hogarty DT, 2020, SURV OPHTHALMOL, V65, P250, DOI 10.1016/j.survophthal.2019.09.001
   Holden RJ, 2010, J BIOMED INFORM, V43, P159, DOI 10.1016/j.jbi.2009.07.002
   Jeng MY, 2022, BEHAV SCI-BASEL, V12, DOI 10.3390/bs12040114
   Kavandi H, 2020, HEALTH SOC CARE COMM, V28, P1827, DOI 10.1111/hsc.13011
   Khurana RN, 2021, AM J OPHTHALMOL, V227, P222, DOI [10.1016/i.aio.2021.03.033, 10.1016/j.ajo.2021.03.033]
   Korevaar Daniel A, 2019, Diagn Progn Res, V3, P22, DOI 10.1186/s41512-019-0069-2
   Lee JA, 2018, BMC MED INFORM DECIS, V18, DOI 10.1186/s12911-018-0591-0
   Li JQ, 2020, BRIT J OPHTHALMOL, V104, P1077, DOI 10.1136/bjophthalmol-2019-314422
   Lin XL, 2021, EUR J OPHTHALMOL, V31, P1161, DOI 10.1177/1120672120927256
   Lindeke-Myers A, 2021, JAMA OPHTHALMOL, V139, P508, DOI 10.1001/jamaophthalmol.2021.0114
   Maloca P, 2018, TRANSL VIS SCI TECHN, V7, DOI 10.1167/tvst.7.4.8
   Nadal C, 2020, J MED INTERNET RES, V22, DOI 10.2196/17256
   O'Connor S, 2022, INT J ENV RES PUB HE, V19, DOI 10.3390/ijerph19159488
   Prea SM, 2022, AM J OPHTHALMOL, V235, P280, DOI 10.1016/j.ajo.2021.09.003
   Prea SM, 2021, AM J OPHTHALMOL, V223, P286, DOI 10.1016/j.ajo.2020.10.023
   Ricci F, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21218242
   Riley WT, 2011, TRANSL BEHAV MED, V1, P53, DOI 10.1007/s13142-011-0021-7
   Saldana J., 2018, OXFORD HDB QUALITATI, V2nd ed.
   Schmid MK, 2019, EYE, V33, P1584, DOI 10.1038/s41433-019-0455-6
   Sekhon M., 2016, EUR HLTH PSYCHOL, V18, P565
   Sekhon M, 2018, BRIT J HEALTH PSYCH, V23, P519, DOI 10.1111/bjhp.12295
   Sekhon M, 2017, BMC HEALTH SERV RES, V17, DOI 10.1186/s12913-017-2031-8
   Setiawan I Made Agus, 2019, JMIR Form Res, V3, pe12982, DOI 10.2196/12982
   Song Y, 2022, SENSORS-BASEL, V22, DOI 10.3390/s22041614
   Taylor DJ, 2020, EYE, V34, P461, DOI 10.1038/s41433-019-0445-8
   Taylor KI, 2020, NPJ DIGIT MED, V3, DOI 10.1038/s41746-020-0305-8
   Tong A, 2007, INT J QUAL HEALTH C, V19, P349, DOI 10.1093/intqhc/mzm042
   Townsend D, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2014-007400
   Tsai TH, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0227270
   Vazquez NP, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0207342
   Venkatesh V, 2003, MIS QUART, V27, P425, DOI 10.2307/30036540
   Vindrola-Padros C, 2021, ECLINICALMEDICINE, V34, DOI 10.1016/j.eclinm.2021.100799
   Wang SA, 2021, J MED SYST, V45, DOI 10.1007/s10916-021-01773-0
   Wang YZ, 2015, INVEST OPHTH VIS SCI, V56
   Ward E, 2021, EYE, V35, P592, DOI 10.1038/s41433-020-0910-4
   Winther C, 2015, ACTA OPHTHALMOL, V93, P481, DOI 10.1111/aos.12659
   Winther C, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/285463
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yardley L, 2016, AM J PREV MED, V51, P833, DOI 10.1016/j.amepre.2016.06.015
   Zhou M, 2019, INT J MED INFORM, V126, P118, DOI 10.1016/j.ijmedinf.2019.04.001
NR 54
TC 0
Z9 0
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1660-4601
J9 INT J ENV RES PUB HE
JI Int. J. Environ. Res. Public Health
PD OCT
PY 2022
VL 19
IS 20
AR 13714
DI 10.3390/ijerph192013714
PG 14
WC Environmental Sciences; Public, Environmental & Occupational Health
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
   Health
GA 5P5IH
UT WOS:000873183800001
PM 36294292
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Gopinath, B
   Kifley, A
   Cummins, R
   Heraghty, J
   Mitchell, P
AF Gopinath, Bamini
   Kifley, Annette
   Cummins, Rob
   Heraghty, Julie
   Mitchell, Paul
TI Predictors of psychological distress in caregivers of older persons with
   wet age-related macular degeneration
SO AGING & MENTAL HEALTH
LA English
DT Article
DE caregiver; Macular Diseases Foundation Australia; care recipient;
   age-related macular degeneration; psychological distress
ID PROBLEM-SOLVING ABILITIES; DEPRESSIVE SYMPTOMS; ADJUSTMENT; BURDEN;
   IMPACT; INDIVIDUALS; STRESSORS
AB Objectives: Several studies have investigated the biopsychosocial impacts of age-related macular degeneration (AMD) in regards to the older patient, little is known about the impacts associated with caring for individuals with AMD. We aimed to determine the predictors of subjective caregiver distress and other negative outcomes associated with caring for someone with advanced AMD.
   Methods: Cross-sectional, self-complete survey involving 500 caregivers of persons with advanced AMD. Respondents were identified from the Macular Disease Foundation of Australia client database. Logistic regression tested the independent effects of care recipient and caregiver characteristics on study outcomes, including: caregiver psychological well-being, participation in recreational/social activities and retirement plans.
   Results: Around one third of caregivers self-reported a high level of care recipient dependence. Over one in two caregivers reported a negative state of mind. Comorbid chronic illnesses in the care recipient were associated with the caregiver reporting psychological distress, multivariable-adjusted odds ratio, OR, 1.45 (95% confidence intervals, CI, 1.14-1.86). If the care recipient was highly dependent on the caregiver, there was 99% greater likelihood of caregiver distress, OR 1.99 (95% CI 1.01-3.93). Comorbid chronic conditions in the care recipient was associated with 49% and 31% higher odds of the caregiver reporting disruption to other areas of their life and retirement plans related to the caregiving experience, respectively.
   Conclusions: A high prevalence of caregiver distress related to caring for persons with advanced AMD was observed. Level of dependence on the caregiver and presence of comorbid chronic illnesses were independent predictors of the caregiver experiencing psychological distress.
C1 [Gopinath, Bamini; Kifley, Annette; Mitchell, Paul] Univ Sydney, Ctr Vis Res, Dept Ophthalmol, Sydney, NSW 2006, Australia.
   [Gopinath, Bamini; Kifley, Annette; Mitchell, Paul] Univ Sydney, Westmead Millennium Inst, Sydney, NSW 2006, Australia.
   [Cummins, Rob; Heraghty, Julie] Macular Dis Fdn Australia, Sydney, NSW, Australia.
C3 University of Sydney; University of Sydney; Westmead Institute for
   Medical Research
RP Gopinath, B (通讯作者)，Univ Sydney, Ctr Vis Res, Dept Ophthalmol, Sydney, NSW 2006, Australia.
EM bamini.gopinath@sydney.edu.au
RI Gopinath, Bamini/K-4286-2019; Mitchell, Paul/P-1498-2014
OI Gopinath, Bamini/0000-0003-3573-359X; 
FU Bayer Australia
FX This survey was funded by Bayer Australia.
CR Bambara JK, 2009, INVEST OPHTH VIS SCI, V50, P1585, DOI 10.1167/iovs.08-2744
   Bialon LN, 2012, AM J HOSP PALLIAT ME, V29, P210, DOI 10.1177/1049909111416494
   Braich PS, 2012, OPHTHALMOLOGY, V119, P221, DOI 10.1016/j.ophtha.2011.07.038
   Carlson LE, 2000, J PSYCHOSOC ONCOL, V18, P39, DOI 10.1300/J077v18n02_03
   Elliott TR, 2001, J COUNS PSYCHOL, V48, P223, DOI 10.1037//0022-0167.48.2.223
   Hassell JB, 2006, BRIT J OPHTHALMOL, V90, P593, DOI 10.1136/bjo.2005.086595
   Kim H, 2012, J ADV NURS, V68, P846, DOI 10.1111/j.1365-2648.2011.05787.x
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Malhotra C, 2012, INT PSYCHOGERIATR, V24, P1335, DOI 10.1017/S1041610212000324
   Miller B, 2001, J GERONTOL B-PSYCHOL, V56, pS249, DOI 10.1093/geronb/56.4.S249
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Pinquart M, 2003, J GERONTOL B-PSYCHOL, V58, pP112, DOI 10.1093/geronb/58.2.P112
   Robison J, 2009, J GERONTOL B-PSYCHOL, V64, P788, DOI 10.1093/geronb/gbp015
   Savla J, 2008, J GERONTOL B-PSYCHOL, V63, pS154, DOI 10.1093/geronb/63.3.S154
   Schmier JK, 2006, RETINA-J RET VIT DIS, V26, P1056, DOI 10.1097/01.iae.0000254890.48272.5a
   SCHUMACHER KL, 1993, RES NURS HEALTH, V16, P395, DOI 10.1002/nur.4770160603
   Wiliams RA, 1998, ARCH OPHTHALMOL-CHIC, V116, P514
NR 17
TC 10
Z9 10
U1 0
U2 18
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 1360-7863
EI 1364-6915
J9 AGING MENT HEALTH
JI Aging Ment. Health
PD MAR 4
PY 2015
VL 19
IS 3
BP 239
EP 246
DI 10.1080/13607863.2014.924477
PG 8
WC Geriatrics & Gerontology; Gerontology; Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Geriatrics & Gerontology; Psychiatry
GA AX8JF
UT WOS:000347155200007
PM 24943714
DA 2022-11-30
ER

PT J
AU Wightman, AJ
   Abbott, CJ
   McGuinness, MB
   Caruso, E
   Guymer, RH
   Luu, CD
AF Wightman, Antony J.
   Abbott, Carla J.
   McGuinness, Myra B.
   Caruso, Emily
   Guymer, Robyn H.
   Luu, Chi D.
TI Presymptomatic Retinal Sensitivity Changes in Intermediate Age-Related
   Macular Degeneration Associated With New Retinal Fluid
SO TRANSLATIONAL VISION SCIENCE & TECHNOLOGY
LA English
DT Article
DE age-related macular degeneration; microperimetry; retinal sensitivity;
   SD-OCT; retinal fluid
ID LUMINANCE VISUAL-ACUITY; MONITORING-SYSTEM; NATURAL-HISTORY; NEOVASCULAR
   AMD; GROWTH-FACTOR; MICROPERIMETRY; RANIBIZUMAB; BEVACIZUMAB; THERAPY;
   AUTOFLUORESCENCE
AB Purpose: To determine whether change in retinal sensitivity in areas with subretinal or intraretinal fluid secondary to age-related macular degeneration (AMD) precedes visual symptoms. If confirmed, retinal sensitivity testing could be used for home monitoring in AMD.
   Methods: Individuals with intermediate AMD enrolled in a longitudinal study were seen every 6 months and underwent best-corrected visual acuity testing (BCVA), spectral domain-optical coherence tomography (SD-OCT), and microperimetry. Asymptomatic individuals who developed incidental, reading center-determined retinal fluid detected on SD-OCT were identified. The point-wise sensitivity (PWS) at the time of fluid detection was compared with 6 and 12 months prior.
   Results: Fourteen of 161 individuals developed fluid without symptoms. PWS over fluid areas at detection was reduced compared with 6 (difference 02.04 dB, P < 0.001) and 12 months (-2.27 dB, P < 0.001) prior. PWS over fluid areas was reduced compared with perifluid areas (difference -1.02 dB, P = 0.03), peripheral areas (-1.51 dB, P < 0.001), nonprogressed fellow eyes (-1.49 dB, P = 0.006), and nonprogressed age-matched intermediate AMD eyes (-2.29 dB, P = 0.001). No difference in BCVA was observed in eyes developing fluid compared to eyes that do not develop fluid (P = 0.76).
   Conclusions: Retinal areas with fluid on SD-OCT had a corresponding reduction in retinal sensitivity at the time of fluid detection compared with 6 and 12 months prior, in asymptomatic intermediate AMD without change in BCVA.
   Translational Relevance: Development of self-monitoring tools to detect changes in retinal sensitivity may be helpful for early detection of retinal fluid suggestive of progression to neovascular AMD before acuity is affected.
C1 [Wightman, Antony J.; Abbott, Carla J.; McGuinness, Myra B.; Caruso, Emily; Guymer, Robyn H.; Luu, Chi D.] Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Melbourne, Vic, Australia.
   [Abbott, Carla J.; Guymer, Robyn H.; Luu, Chi D.] Univ Melbourne, Dept Surg, Ophthalmol, Melbourne, Vic, Australia.
C3 Centre for Eye Research Australia; Royal Victorian Eye & Ear Hospital;
   University of Melbourne
RP Guymer, RH (通讯作者)，Ctr Eye Res Australia, Macular Res Unit, Level 8 Smorgon Family Wing,32 Gisborne St, East Melbourne, Vic 3002, Australia.
EM rhg@unimelb.edu.au
RI McGuinness, Myra/G-4900-2017; Abbott, Carla J/H-9510-2019
OI McGuinness, Myra/0000-0002-5422-040X; Abbott, Carla
   J/0000-0002-1432-8977
FU National Health and Medical Research Council (NHMRC) Fellowship
   [1103013]; NHMRC [1084081]
FX Supported by National Health and Medical Research Council (NHMRC)
   Fellowship (#1103013, RHG) and NHMRC Project Grant (1084081). The Centre
   for Eye Research Australia (CERA) receives operational infrastructure
   support from the Victorian State Government.
CR Acton JH, 2012, INVEST OPHTH VIS SCI, V53, P7618, DOI 10.1167/iovs.12-10361
   AMSLER M, 1953, BRIT J OPHTHALMOL, V37, P521, DOI 10.1136/bjo.37.9.521
   Asahara T, 1999, EMBO J, V18, P3964, DOI 10.1093/emboj/18.14.3964
   Barthelmes D, 2014, OPHTHALMOLOGY, V121, P2073, DOI 10.1016/j.ophtha.2014.05.007
   Bloch SB, 2012, AM J OPHTHALMOL, V153, P209, DOI 10.1016/j.ajo.2011.10.016
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Cassels NK, 2018, SURV OPHTHALMOL, V63, P40, DOI 10.1016/j.survophthal.2017.05.007
   Chew EY, 2014, OPHTHALMOLOGY, V121, P535, DOI 10.1016/j.ophtha.2013.10.027
   Dias JRD, 2018, OPHTHALMOLOGY, V125, P255, DOI 10.1016/j.ophtha.2017.08.030
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   FINE AM, 1986, ARCH OPHTHALMOL-CHIC, V104, P513
   Finger RP, 2014, SURV OPHTHALMOL, V59, P1, DOI 10.1016/j.survophthal.2013.03.009
   Fong DS, 2010, OPHTHALMOLOGY, V117, P298, DOI 10.1016/j.ophtha.2009.07.023
   Ho CYD, 2018, TRANSL VIS SCI TECHN, V7, DOI 10.1167/tvst.7.2.2
   Jung JJ, 2014, AM J OPHTHALMOL, V158, P769, DOI 10.1016/j.ajo.2014.07.006
   Kaiser PK, 2013, RETINA-J RET VIT DIS, V33, P1863, DOI 10.1097/IAE.0b013e3182899258
   Kelly BD, 2003, CIRC RES, V93, P1074, DOI 10.1161/01.RES.0000102937.50486.1B
   Landa G, 2011, RETINA-J RET VIT DIS, V31, P364, DOI 10.1097/IAE.0b013e3181e91132
   Lee AY, 2015, BRIT J OPHTHALMOL, V99, P1045, DOI 10.1136/bjophthalmol-2014-306229
   Lim JH, 2012, AM J OPHTHALMOL, V153, P678, DOI 10.1016/j.ajo.2011.09.013
   Luu CD, 2012, ARCH OPHTHALMOL-CHIC, V130, P690, DOI 10.1001/archophthalmol.2012.277
   Marmor MF, 2000, SURV OPHTHALMOL, V44, P343, DOI 10.1016/S0039-6257(99)00113-7
   Midena E, 2007, BRIT J OPHTHALMOL, V91, P1499, DOI 10.1136/bjo.2007.119685
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Mitchell P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101072
   Molina-Martin A, 2016, CURR EYE RES, V41, P400, DOI 10.3109/02713683.2015.1020170
   Munk MR, 2013, AM J OPHTHALMOL, V156, P633, DOI 10.1016/j.ajo.2013.05.037
   Olsen TW, 2004, OPHTHALMOLOGY, V111, P250, DOI 10.1016/j.ophtha.2003.05.030
   Ouyang YL, 2013, OPHTHALMOLOGY, V120, P2656, DOI 10.1016/j.ophtha.2013.05.029
   Ozaki H, 1999, INVEST OPHTH VIS SCI, V40, P182
   Parravano M, 2010, RETINA-J RET VIT DIS, V30, P1017, DOI 10.1097/IAE.0b013e3181cfd3c6
   Prager F, 2008, RETINA-J RET VIT DIS, V28, P682, DOI 10.1097/IAE.0b013e318161dc70
   Querques G, 2013, INVEST OPHTH VIS SCI, V54, P6886, DOI 10.1167/iovs.13-11665
   Querques L, 2012, AM J OPHTHALMOL, V153, P1110, DOI 10.1016/j.ajo.2011.11.002
   Razavi H, 2018, CLIN EXP OPHTHALMOL, V46, P480, DOI 10.1111/ceo.13097
   Redmond T, 2010, INVEST OPHTH VIS SCI, V51, P6540, DOI 10.1167/iovs.10-5718
   Rosenfeld PJ, 2016, INVEST OPHTH VIS SCI, V57, pOCT14, DOI 10.1167/iovs.16-19969
   Sardell RJ, 2016, INVEST OPHTH VIS SCI, V57, P6107, DOI 10.1167/iovs.16-19519
   Schmitz-Valckenberg S, 2016, OPHTHALMOLOGY, V123, P361, DOI 10.1016/j.ophtha.2015.09.036
   SCHUCHARD RA, 1993, ARCH OPHTHALMOL-CHIC, V111, P776, DOI 10.1001/archopht.1993.01090060064024
   Squirrell DM, 2010, RETINA-J RET VIT DIS, V30, P436, DOI 10.1097/IAE.0b013e3181bd2f29
   Stefansson E, 2011, PROG RETIN EYE RES, V30, P72, DOI 10.1016/j.preteyeres.2010.09.003
   Sulzbacher F, 2012, INVEST OPHTH VIS SCI, V53, P6448, DOI 10.1167/iovs.11-9162
   Thylefors B, 2002, OPHTHALMIC EPIDEMIOL, V9, P83, DOI 10.1076/opep.9.2.83.1523
   Ting TD, 2002, ARCH OPHTHALMOL-CHIC, V120, P731
   Trevino Richard, 2008, Optometry, V79, P397, DOI 10.1016/j.optm.2007.09.017
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   von der Emde L, 2019, TRANSL VIS SCI TECHN, V8, DOI 10.1167/tvst.8.1.7
   Wang WQ, 2016, SIGNAL TRANSDUCT TAR, V1, DOI 10.1038/sigtrans.2016.16
   Wu ZC, 2015, TRANSL VIS SCI TECHN, V4, DOI 10.1167/tvst.4.3.13
   Wu ZC, 2015, JAMA OPHTHALMOL, V133, P442, DOI 10.1001/jamaophthalmol.2014.5963
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P2415, DOI 10.1016/j.ophtha.2014.06.034
   Wu ZC, 2014, INVEST OPHTH VIS SCI, V55, P6431, DOI 10.1167/iovs.14-14407
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P1612, DOI 10.1016/j.ophtha.2014.02.005
   Wu ZC, 2013, INVEST OPHTH VIS SCI, V54, P7378, DOI 10.1167/iovs.13-12617
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
   Zaidi FH, 2004, EYE, V18, P503, DOI 10.1038/sj.eye.6700708
NR 57
TC 6
Z9 6
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 2164-2591
J9 TRANSL VIS SCI TECHN
JI Transl. Vis. Sci. Technol.
PD NOV
PY 2019
VL 8
IS 6
AR 3
DI 10.1167/tvst.8.6.3
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA JM1RN
UT WOS:000495999700001
PM 31737427
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Bloch, SB
   Larsen, M
   Munch, IC
AF Bloch, Sara Brandi
   Larsen, Michael
   Munch, Inger Christine
TI Incidence of Legal Blindness From Age-Related Macular Degeneration in
   Denmark: Year 2000 to 2010
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID MACULOPATHY; RANIBIZUMAB; PREVALENCE
AB PURPOSE: To report incidence rates of legal blindness from age-related macular degeneration (AMD) and other causes in Denmark from years 2000 to 2010 in the age group at risk of AMD aged 50 years and older.
   DESIGN: Population-based observational registry study.
   METHODS: SETTINGS: Membership register of the Danish Association of the Blind, the primary admission criterion of which is best-corrected visual acuity 0.1 (20/200) or lower in a person's better-seeing eye. STUDY POPULATION: A total of 11 848 incident cases of legal blindness from a population of citizens aged >= 50 years numbering 1.71 million in 2000 and 1.87 million in 2010 with free access to a single-payer public health care system. MAIN OUTCOME MEASURES: Incidence rates of legal blindness from AMD from 2000 to 2010.
   RESULTS: The incidence rate of legal blindness attributable to AMD in citizens aged >= 50 years decreased from 52.2 cases per year per 100 000 in 2000 to 25.7 cases per year per 100 000 in 2010, corresponding to a reduction of 50% (95% confidence interval [CI95]: 45%-56%, P < .0001, adjusted for age), the bulk of the reduction occurring after 2006. The incidence of legal blindness from causes other than AMD decreased by 33% (CI95: 21%-44%, P < .0001), most of the reduction occurring between 2000 and 2006.
   CONCLUSION: From 2000 to 2010 the incidence of legal blindness from AMD fell to half the baseline incidence. The bulk of the reduction occurred after the introduction of intravitreally injected inhibitors of vascular endothelial growth factor in 2006. (Am J Ophthalmol 2012;153:209-213. (C) 2012 by Elsevier Inc. All rights reserved.)
C1 [Bloch, Sara Brandi; Larsen, Michael; Munch, Inger Christine] Glostrup Cty Hosp, Dept Ophthalmol, DK-2600 Glostrup, Denmark.
   [Larsen, Michael] Kennedy Ctr, Natl Eye Clin, Glostrup, Denmark.
   [Bloch, Sara Brandi; Larsen, Michael; Munch, Inger Christine] Univ Copenhagen, Fac Hlth Sci, Copenhagen, Denmark.
C3 University of Copenhagen; University of Copenhagen
RP Bloch, SB (通讯作者)，Glostrup Cty Hosp, Dept Ophthalmol, Nordre Ringvej 57, DK-2600 Glostrup, Denmark.
EM sabrbl01@regionh.dk
RI Larsen, Michael/E-9620-2010; Munch, Inger Christine/E-9652-2010
OI Larsen, Michael/0000-0002-5172-5891; 
FU Bagenkop Nielsen Myopia Foundation, Frederiksberg, Denmark; Center for
   Biomedical Optics and New Laser Systems (BIOP), Technical University of
   Denmark, Roskilde, Denmark; Novartis; Pfizer; Novo Nordisk;
   Glaxo-Smith-Kline
FX THE AUTHORS HAVE COMPLETED AND SUBMITTED THE ICMJE FORM FOR DISCLOSURE
   OF POTENTIAL CONFLICTS OF Interest. Publication of this article was
   supported by the Bagenkop Nielsen Myopia Foundation, Frederiksberg,
   Denmark, and the Center for Biomedical Optics and New Laser Systems
   (BIOP), Technical University of Denmark, Roskilde, Denmark. The funding
   organizations had no role in the design or the conduct of this study.
   The authors' employer, The Glostrup Hospital, has received compensation
   from Novartis, Alcon, Eli Lilly, Pfizer, Glaxo-Smith-Kline, and
   competing entities for consultancies and contract research. On behalf of
   the Glostrup Hospital, Sara Brandi Bloch has participated in an ESASO
   meeting on AMD sponsored by Novartis, Inger Christine Munch has received
   payment from Novartis for presenting a lecture and has served as primary
   investigator on trials for Pfizer and Glaxo-Smith-Kline, and Michael
   Larsen has served as advisory board member for Novartis, Pfizer, and
   Thrombogenics; has participated as investigator in multicenter
   interventional trials for Novartis, Pfizer, Alcon, Glaxo-Smith-Kline,
   Bayer, and Allergan; and has received payment for lectures from
   Novartis, Pfizer, Novo Nordisk, and Glaxo-Smith-Kline. Involved in
   conception and design of the study (S.B.B., M.L., I.C.M.); conduct of
   the study (S.B.B., M.L., I.C.M.); data collection (S.B.B.); management
   (S.B.B.); analysis (S.B.B., I.C.M.); interpretation of the data (S.B.B.,
   M.L., I.C.M.); preparation and critical review (S.B.B., M.L., I.C.M.);
   and final approval of the manuscript (S.B.B., M.L., I.C.M.). The study
   was approved by the national data protection agency (Datatilsynet). The
   medical ethics committee (Institutional Review Board; IRB) waived the
   need for IRB approval of this research because the study was
   retrospective, did not involve biological material, and was based on
   anonymous registries. The authors are grateful for the assistance of the
   Danish Association of the Blind and the departments of ophthalmology of
   the Aalborg, Aarhus, Holstebro, Vejle, Sonderborg, Odense, and Roskilde
   Hospitals.
CR Bloch SB, ACTA OPHTHA IN PRESS
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Bressler NM, 2011, ARCH OPHTHALMOL-CHIC, V129, P709, DOI 10.1001/archophthalmol.2011.140
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Buch H, 2005, OPHTHALMOLOGY, V112, P787, DOI 10.1016/j.ophtha.2004.11.040
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Huang GH, 2003, AM J EPIDEMIOL, V157, P721, DOI 10.1093/aje/kwg011
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2008, OPHTHALMOLOGY, V115, P1460, DOI 10.1016/j.ophtha.2008.01.026
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Rosenberg T, 1996, ACTA OPHTHALMOL SCAN, V74, P399
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Smith W, 1996, ARCH OPHTHALMOL-CHIC, V114, P1518, DOI 10.1001/archopht.1996.01100140716016
   Statistics Denmark, POP EL
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
NR 18
TC 212
Z9 220
U1 0
U2 15
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD FEB
PY 2012
VL 153
IS 2
BP 209
EP 213
DI 10.1016/j.ajo.2011.10.016
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 884OQ
UT WOS:000299717800004
PM 22264944
DA 2022-11-30
ER

PT J
AU SanGiovanni, JP
   SanGiovanni, PM
   Sapieha, P
   De Guire, V
AF SanGiovanni, John Paul
   SanGiovanni, Peter M.
   Sapieha, Przemyslaw
   De Guire, Vincent
TI miRNAs, single nucleotide polymorphisms (SNPs) and age-related macular
   degeneration (AMD)
SO CLINICAL CHEMISTRY AND LABORATORY MEDICINE
LA English
DT Article
DE age related macular degeneration; hsa-miR-146a; micro RNA; retina;
   single nucleotide polymorphism (SNP)
ID GENOME-WIDE ASSOCIATION; SEVERITY SCALE; DISEASE; COMMON;
   SUSCEPTIBILITY; COMPLEMENT; STRATEGIES; BIOMARKERS; MICRORNAS; VARIANTS
AB Advanced age-related macular degeneration (AAMD) is a complex sight-threating disease of public health significance. Micro RNAs (miRNAs) have been proposed as biomarkers for AAMD. The presence of certain single nucleotide polymorphisms (SNPs) may influence the explanatory value of these biomarkers. Here we present findings from an integrated approach used to determine whether AAMD-associated SNPs have the capacity to influence miRNA-mRNA pairing and, if so, to what extent such pairing may be manifested in a discrete AAMD transcriptome. Using a panel of 8854 SNPs associated with AAMD at p-values <= 5.0E-7 from a cohort of > 30,000 elderly people, we identified SNPs in miRNA target-encoding constituents of: (1) regulator of complement activation (RCA) genes (rs390679, CFHR1, p <= 2.14E-214 | rs12140421, CFHR3, p <= 4.63E-29); (2) genes of major histocompatibility complex (MHC) loci (rs4151672, CFB, p <= 8.91E-41 | rs115404146, HLA-C, p <= 6.32E-12 | rs1055821, HLA-B, p <= 1.93E-9 | rs1063355, HLA-DQB1, p <= 6.82E-14); and (3) genes of the 10q26 AAMD locus (rs1045216, PLEKHA1, p <= 4.17E-142 | rs2672603, ARMS2, p <= 7.14E-46). We used these findings with existing data on AAMD-related retinal miRNA and transcript profiles for the purpose of making inferences on SNP-mRNA-miRNA-AAMD relationships. Four of 12 miRNAs significantly elevated in AAMD retina (hsa-miR-155-5p, hsa-let-7a-5p, hsa-let-7b-5p hsa-let7-d-5p) also showed strong pairing capacity (TarBase 7.1 context++ score < -0.2, miRanda 3.3 pairing score > 150) with miRNA target transcripts encoded by AAMD-associated SNPs resident in HLA-DQB1 (rs1063355, hsamiR- 155-5p) and TGFBR1 (rs868, hsa-let-7). Three of the 12 miRNAs overexpressed in AAMD retina are inducible by NFkB and have high affinity targets in the complement factor H (CFH) mRNA 3' UTR. We used ENSEMBL to identify polymorphic regions in the CFH mRNA 3' UTR with the capacity to disrupt miRNA-mRNA pairing. Two variants (rs766666504 and rs459598) existed in DNA sequence encoding the seed region of hsa-miR-146a-5p in the CFH mRNA 3' UTR -as this miRNA is also elevated in both vitreous and serum of people with AAMD, it shows great value as a biomarker. Our findings suggest that knowledge on the nature of DNA sequence variation may increase the explanatory power of miRNA biomarkers in genetically diverse populations, while yielding information with which to develop: (1) mechanistic tests on processes implicated in AMD pathogenesis; and, (2) site-specific small molecules (synthetic mimetics or anti-miRNAs) with preventive or therapeutic efficacy for AAMD.
C1 [SanGiovanni, John Paul] NIAAA, Lab Membrane Biochem & Biophys, Sect Nutr Neurosci, NIH, Bethesda, MD USA.
   [SanGiovanni, John Paul] Georgetown Sch Med, Dept Biochem & Cellular & Mol Biol, Washington, DC USA.
   [De Guire, Vincent] Univ Montreal, Maisonneuve Rosemont Hosp, Div Clin Biochem, Dept Biochem & Mol Med, Montreal, PQ, Canada.
   [SanGiovanni, Peter M.] Black Duck Software, Burlington, MA USA.
   [Sapieha, Przemyslaw] Univ Montreal, Maisonneuve Rosemont Hosp, Res Ctr, Dept Biochem, Montreal, PQ, Canada.
   [Sapieha, Przemyslaw] Univ Montreal, Maisonneuve Rosemont Hosp, Res Ctr, Dept Ophthalmol, Montreal, PQ, Canada.
   [Sapieha, Przemyslaw] McGill Univ, Dept Neurosci, Montreal, PQ, Canada.
C3 National Institutes of Health (NIH) - USA; NIH National Institute on
   Alcohol Abuse & Alcoholism (NIAAA); Universite de Montreal; Universite
   de Montreal; Universite de Montreal; McGill University
RP SanGiovanni, JP (通讯作者)，NIAAA, Lab Membrane Biochem & Biophys, Sect Nutr Neurosci, NIH, Bethesda, MD USA.; SanGiovanni, JP (通讯作者)，Georgetown Sch Med, Dept Biochem & Cellular & Mol Biol, Washington, DC USA.; De Guire, V (通讯作者)，Univ Montreal, Maisonneuve Rosemont Hosp, Div Clin Biochem, Dept Biochem & Mol Med, Montreal, PQ, Canada.
EM jpsangio@post.harvard.edu; vdeguire.hmr@ssss.gouv.qc.ca
RI SanGiovanni, John Paul/AAU-3895-2020
FU JPSG; PMSG; PS (Foundation Fighting Blindness); VDG
FX JPSG (None). PMSG (None). PS (Foundation Fighting Blindness). VDG
   (None).
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Anderson NL, 2002, MOL CELL PROTEOMICS, V1, P845, DOI 10.1074/mcp.R200007-MCP200
   Bhattacharjee S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150211
   Bird AC, 2010, J CLIN INVEST, V120, P3033, DOI 10.1172/JCI42437
   Bradley DT, 2011, EYE, V25, P683, DOI 10.1038/eye.2011.37
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   De Guire V, 2013, CLIN BIOCHEM, V46, P846, DOI 10.1016/j.clinbiochem.2013.03.015
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Friedman RC, 2009, GENOME RES, V19, P92, DOI 10.1101/gr.082701.108
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Gehrs KM, 2010, ARCH OPHTHALMOL-CHIC, V128, P349, DOI 10.1001/archophthalmol.2010.18
   Gorin MB, 2012, MOL ASPECTS MED, V33, P467, DOI 10.1016/j.mam.2012.04.004
   Goverdhan SV, 2008, INVEST OPHTH VIS SCI, V49, P5077, DOI 10.1167/iovs.08-1837
   Goverdhan SV, 2005, INVEST OPHTH VIS SCI, V46, P1726, DOI 10.1167/iovs.04-0928
   Hageman GS, 2009, AGE RELATED MACULAR
   Hill JM, 2014, FRONT MOL NEUROSCI, V7, DOI 10.3389/fnmol.2014.00010
   Jorgenson E, 2016, EUR J HUM GENET, V24, P1049, DOI 10.1038/ejhg.2015.247
   Karali M, 2016, NUCLEIC ACIDS RES, V44, P1525, DOI 10.1093/nar/gkw039
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Kutty RK, 2013, MOL VIS, V19, P737
   Lukiw WJ, 2008, J BIOL CHEM, V283, P31315, DOI 10.1074/jbc.M805371200
   Lukiw Walter J, 2012, Int J Biochem Mol Biol, V3, P105
   Menard C, 2016, ONCOTARGET, V7, P19171, DOI 10.18632/oncotarget.8280
   Miller JW, 2013, AM J OPHTHALMOL, V155, P1, DOI 10.1016/j.ajo.2012.10.018
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Newman AM, 2012, GENOME MED, V4, DOI [10.1186/PREACCEPT-1418491035586234, 10.1186/gm315]
   Penfold PL, 1997, INVEST OPHTH VIS SCI, V38, P2125
   Pruim RJ, 2010, BIOINFORMATICS, V26, P2336, DOI 10.1093/bioinformatics/btq419
   SanGiovanni JP, 2014, COLD SPRING HARB PER, V4, P1
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   Taganov KD, 2006, P NATL ACAD SCI USA, V103, P12481, DOI 10.1073/pnas.0605298103
   Tetreault N, 2013, CLIN BIOCHEM, V46, P842, DOI 10.1016/j.clinbiochem.2013.02.009
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 35
TC 26
Z9 27
U1 0
U2 14
PU WALTER DE GRUYTER GMBH
PI BERLIN
PA GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY
SN 1434-6621
EI 1437-4331
J9 CLIN CHEM LAB MED
JI Clin. Chem. Lab. Med.
PD MAY
PY 2017
VL 55
IS 5
BP 763
EP 775
DI 10.1515/cclm-2016-0898
PG 13
WC Medical Laboratory Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Medical Laboratory Technology
GA ES1VF
UT WOS:000399314400015
PM 28343170
DA 2022-11-30
ER

PT J
AU Mathew, R
   Pefkianaki, M
   Kopsachilis, N
   Brar, M
   Richardson, M
   Sivaprasad, S
AF Mathew, Raeba
   Pefkianaki, Maria
   Kopsachilis, Nickolaos
   Brar, Manpreet
   Richardson, Matthew
   Sivaprasad, Sobha
TI Correlation of Fundus Fluorescein Angiography and Spectral-Domain
   Optical Coherence Tomography in Identification of Membrane Subtypes in
   Neovascular Age-Related Macular Degeneration
SO OPHTHALMOLOGICA
LA English
DT Article
DE Neovascular age-related macular degeneration; Spectral-domain optical
   coherence tomography; Fundus fluorescein angiography; Indocyanine green
   angiography
ID CHOROIDAL NEOVASCULARIZATION
AB Aims: To assess the sensitivity and specificity of spectral-domain optical coherence tomography (SDOCT) for the determination of choroidal neovascularization (CNV) subtypes in neovascular age-related macular degeneration (AMD) compared to fundus fluorescein angiography (FFA) and also the agreement between the two procedures. Design: This was a retrospective, observational study. Methods: We evaluated and compared the CNV subtypes on FFA and OCT in 100 eyes initiated on ranibizumab for neovascular AMD. Results: SDOCT showed high sensitivity (85.7-98.3%) and specificity (84.2-100%) compared to FFA in the diagnosis of the CNV subtype. The area under the receiver-operating characteristic curve ranged from 0.9 to 0.93 (p value < 0.0001) for the different CNV subtypes. Weighted kappa statistics showed a near-perfect agreement of 0.85 between the procedures. Conclusion: SDOCT is a reliable tool for the diagnosis of CNV subtypes in neovascular AMD obviating the need for an invasive procedure such as FFA. (C) 2013 S. Karger AG, Basel
C1 [Mathew, Raeba; Richardson, Matthew; Sivaprasad, Sobha] Kings Coll Hosp London, Dept Ophthalmol, Laser & Retinal Res Unit, London SE5 9RS, England.
   [Mathew, Raeba; Pefkianaki, Maria; Kopsachilis, Nickolaos; Brar, Manpreet; Sivaprasad, Sobha] Moorfields Eye Hosp, NIHR, Biomed Ctr Ophthalmol, London, England.
C3 King's College Hospital NHS Foundation Trust; King's College Hospital;
   University of London; King's College London; University College London;
   Moorfields Eye Hospital NHS Foundation Trust
RP Sivaprasad, S (通讯作者)，Kings Coll Hosp London, Dept Ophthalmol, Laser & Retinal Res Unit, Denmark Hill, London SE5 9RS, England.
EM r_mathew@hotmail.com
RI Sivaprasad, S./D-6876-2015
OI Sivaprasad, S./0000-0001-8952-0659; Richardson,
   Matthew/0000-0002-7390-9480
FU Allergan; Novartis; Bayer; Pfizer
FX Conflict of interest: none. Raeba Mathew has received speaker fees from
   Allergan and travel grants from Allergan and Novartis. Sobha Sivaprasad
   has received research grants, speaker fees and travel grants from
   Novartis, Bayer, Allergan and Pfizer.
CR Do DV, 2012, OPHTHALMOLOGY, V119, P771, DOI 10.1016/j.ophtha.2011.10.019
   Flahault A, 2005, J CLIN EPIDEMIOL, V58, P859, DOI 10.1016/j.jclinepi.2004.12.009
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   GASS JDM, 1994, AM J OPHTHALMOL, V118, P285, DOI 10.1016/S0002-9394(14)72951-4
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310
   Regatieri Caio V, 2011, Ophthalmic Surg Lasers Imaging, V42 Suppl, pS56, DOI 10.3928/15428877-20110627-05
   Sandhu SS, 2005, BRIT J OPHTHALMOL, V89, P967, DOI 10.1136/bjo.2004.060863
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P644, DOI 10.1016/j.ajo.2008.10.005
   YANNUZZI LA, 1986, OPHTHALMOLOGY, V93, P611
NR 11
TC 7
Z9 7
U1 0
U2 2
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2014
VL 231
IS 3
BP 153
EP 159
DI 10.1159/000355091
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AD3ES
UT WOS:000333121700005
PM 24217293
DA 2022-11-30
ER

PT J
AU Enriquez, AB
   Baumal, CR
   Crane, AM
   Witkin, AJ
   Lally, DR
   Liang, MC
   Enriquez, JR
   Eichenbaum, DA
AF Enriquez, Ana Bety
   Baumal, Caroline R.
   Crane, Ashley M.
   Witkin, Andre J.
   Lally, David R.
   Liang, Michelle C.
   Enriquez, Jose Ramon
   Eichenbaum, David A.
TI Early Experience With Brolucizumab Treatment of Neovascular Age-Related
   Macular Degeneration
SO JAMA OPHTHALMOLOGY
LA English
DT Article
AB IMPORTANCE Outcome data are limited regarding early experience with brolucizumab, the most recently approved anti-vascular endothelial growth factor (VEGF) agent for the treatment of neovascular age-related macular degeneration (nAMD).
   OBJECTIVE To report dinical outcomes after intravitreous injection (IVI) of brolucizumab, 6 mg, for nAMD.
   DESIGN, SETTING, AND PARTICIPANTS This retrospective case series conducted at 15 private or academic ophthalmological centers in the United States included all consecutive patients with eyes treated with brolucizumab by 6 retina specialists between October 17, 2019, and April 1, 2020.
   EXPOSURES Treatment with brolucizumab IVI, 6 mg.
   MAIN OUTCOMES AND MEASURES Change in mean visual acuity (VA) and optical coherence tomography parameters, including mean central subfield thickness and presence or absence of subretinal and/or intraretinal fluid. Secondary outcomes included ocular and systemic safety.
   RESULTS A total of 172 eyes from 152 patients (87 women [57.2%]; mean [SD] age, 80.0 [8.0] years) were included. Most eyes (166 [96.5%]) were not treatment naive, and 65.7% of these eyes (109 of 166) were switched from the prior anti-VEGF agent because of persistent fluid detected on optical coherence tomography scans. Study eyes received a mean (SD) of 1.46 (0.62) brolucizumab IVIs. The mean (SD) VA prior to starting brolucizumab was a 64.1 (15.9) Early Treatment Diabetic Retinopathy Study (ETDRS) letter score (Snellen equivalent, 20/50) and was a 63.3 (17.2) ETDRS letter score (Snellen equivalent, 20/63) at the last study evaluation (mean difference, 0.8; 95% CI, -2.7 to 4.3; P = .65). When analyzed by number of brolucizumab IVIs. the presence or absence of fluid prior to starting brolucizumab, or the presence or absence of intraocular inflammation after receiving brolucizumab, there was no difference in mean VA prior to starting brolucizumab compared with after brolucizumab IVIs or at the final study evaluation. The mean (SD) central subfield thickness in all eyes prior to starting brolucizumab was 296.7 (88.0) mu m and was 269.8 (66.5) mu m at the last study examination (mean difference, 26.9 mu m; 95% CI, 9.0-44.7 mu m; P = .003). Intraocular inflammation was reported in 14 eyes (8.1%) and was self-limited and resolved without treatment in almost half those eyes (n = 6). One previously reported eye (0.6%) had occlusive retinal vasculitis and severe loss of vision.
   CONCLUSIONS AND RELEVANCE In this analysis of brolucizumab IVI for nAMD, VA remained stable, with a reduction in central subfield thickness. intraocular inflammation events ranged from mild with spontaneous resolution to severe occlusive retinal vasculitis in 1 eye.
C1 [Enriquez, Ana Bety; Baumal, Caroline R.; Witkin, Andre J.; Liang, Michelle C.] Tufts Univ, Sch Med, Dept Ophthalmol, New England Eye Ctr, 800Washington St,Box 450, Boston, MA 02116 USA.
   [Crane, Ashley M.; Eichenbaum, David A.] Retina Vitreous Associates Florida, Tampa, FL USA.
   [Lally, David R.] New England Retina Consultants, Springfield, MA USA.
   [Lally, David R.] Univ Massachusetts, Med Sch Baystate, Dept Surg, Springfield, MA USA.
   [Enriquez, Jose Ramon] Harvard Univ, Cambridge, MA 02138 USA.
C3 Tufts University; University of Massachusetts System; Harvard University
RP Baumal, CR (通讯作者)，Tufts Univ, Sch Med, Dept Ophthalmol, New England Eye Ctr, 800Washington St,Box 450, Boston, MA 02116 USA.
EM cbaumal@tuftsmedicalcenter.org
CR AGRAWAL S, 2013, MEDIAT INFLAMM, V2013, DOI [10.1155/2013/943409, DOI 10.1155/2013/943409]
   American Society of Retina Specialists, 2020, NOV APP SAF REV COMM
   American Society of Retina Specialists Research and Safety in Therapeutics (ReST) Committee, ADV EV REP
   American Society of Retina Specialists Research and Safety in Therapeutics (ReST) Committee, 2020, BEOV UPD
   Avery RL, 2017, RETINA-J RET VIT DIS, V37, P1847, DOI 10.1097/IAE.0000000000001493
   BAILEY IL, 1976, AM J OPTOM PHYS OPT, V53, P740
   Baumal CR, 2020, OPHTHALMOLOGY, V127, P1345, DOI 10.1016/j.ophtha.2020.04.017
   Beck RW, 2003, AM J OPHTHALMOL, V135, P194, DOI 10.1016/S0002-9394(02)01825-1
   Beovu, 2019, PRESCR INF NOV PHARM
   Center for Drug Evaluation and Research, 2019, CLIN REV BLA 761125
   Committee for Medicinal Products for Human Use (CHMP) European Medicines Agency, 2019, ASS REP BEOV
   Dugel PU, 2021, OPHTHALMOLOGY, V128, P89, DOI [10.1016/j.opatha.2020.06.028, 10.1016/j.ophtha.2020.06.028]
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Dugel PU, 2017, OPHTHALMOLOGY, V124, P1296, DOI 10.1016/j.ophtha.2017.03.057
   FERRIS FL, 1993, AM J OPHTHALMOL, V116, P735
   Gaudreault J., 2012, INVEST OPHTHALMOL VI, V53, P3025
   Goldberg RA, 2014, AM J OPHTHALMOL, V158, P733, DOI 10.1016/j.ajo.2014.06.019
   Greenberg JP, 2019, OPHTHALMOL RETINA, V3, P753, DOI 10.1016/j.oret.2019.04.006
   Gregori NZ, 2010, RETINA-J RET VIT DIS, V30, P1046, DOI 10.1097/IAE.0b013e3181d87e04
   Hahn P, 2015, JAMA OPHTHALMOL, V133, P421, DOI 10.1001/jamaophthalmol.2014.5650
   Hahn P, 2013, OPHTHALMOLOGY, V120, P1100, DOI 10.1016/j.ophtha.2012.11.018
   Haug Sara J, 2020, Am J Ophthalmol Case Rep, V18, P100680, DOI 10.1016/j.ajoc.2020.100680
   Holladay JT, 1997, J REFRACT SURG, V13, P388
   Holladay JT, 2004, J CATARACT REFR SURG, V30, P287, DOI 10.1016/j.jcrs.2004.01.014
   Holz FG, 2016, OPHTHALMOLOGY, V123, P1080, DOI 10.1016/j.ophtha.2015.12.030
   International Council of Ophthalmology AC, 2002, VISUAL STANDARDS ASP
   Jabs DA, 2005, AM J OPHTHALMOL, V140, P509, DOI 10.1016/j.ajo.2005.03.057
   Jain Atul, 2020, Am J Ophthalmol Case Rep, V18, P100687, DOI 10.1016/j.ajoc.2020.100687
   Johnson D, 2013, CURR OPIN OPHTHALMOL, V24, P205, DOI 10.1097/ICU.0b013e32835f8ec0
   Kaiser P., 2020, 43 ANN MAC SOC M FEB
   Markham A, 2019, DRUGS, V79, P1997, DOI 10.1007/s40265-019-01231-9
   Murray, 2020, OCCLUSIVE RETINAL VA
   Novartis Pharmaceuticals Corporation, 2020, NOV PROV UPD  US SAF
   NUSSENBLATT RB, 1985, OPHTHALMOLOGY, V92, P467
   Patel PJ, 2008, INVEST OPHTH VIS SCI, V49, P4347, DOI 10.1167/iovs.08-1935
   Nguyen QD, 2020, OPHTHALMOLOGY, V127, P963, DOI 10.1016/j.ophtha.2019.12.031
   Schulze-Bonsel K, 2006, INVEST OPHTH VIS SCI, V47, P1236, DOI 10.1167/iovs.05-0981
   Sharma A, 2021, EYE, V35, P1045, DOI 10.1038/s41433-020-1111-x
   Sharma A, 2020, EYE, V34, P1726, DOI 10.1038/s41433-020-0853-9
   Sharma A, 2020, EYE, V34, P611, DOI 10.1038/s41433-019-0583-z
   Tietz J, 2015, INVEST OPHTH VIS SCI, V56
   Tiew S, 2020, EYE, V34, P2148, DOI 10.1038/s41433-020-0783-6
   Witkin Andre J, 2020, J Vitreoretin Dis, V4, P269, DOI 10.1177/2474126420930863
   World Med Assoc, 2013, JAMA-J AM MED ASSOC, V310, P2191, DOI 10.1001/jama.2013.281053
   Yannuzzi NA, 2019, CLIN OPHTHALMOL, V13, P1323, DOI 10.2147/OPTH.S184706
NR 45
TC 23
Z9 23
U1 2
U2 2
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD APR
PY 2021
VL 139
IS 4
BP 441
EP 448
DI 10.1001/jamaophthalmol.2020.7085
EA FEB 2021
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA RQ8AR
UT WOS:000621914000004
PM 33630045
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Kalouda, P
   Anastasakis, A
   Tsika, C
   Tsilimbaris, KM
AF Kalouda, Pelagia
   Anastasakis, Anastasios
   Tsika, Chrysanthi
   Tsilimbaris, K. Miltiadis
TI The Effect of Intravitreal Anti-VEGF on the Pigment Epithelial
   Detachment in Eyes with the Exudative Type of Age-Related Macular
   Degeneration
SO SEMINARS IN OPHTHALMOLOGY
LA English
DT Article
DE Choroidal neovascularization; optical coherence tomography; ranibizumab;
   VEGF
ID OCCULT CHOROIDAL NEOVASCULARIZATION; OPTICAL COHERENCE TOMOGRAPHY;
   VISUAL-ACUITY; BEVACIZUMAB; RANIBIZUMAB; THERAPY
AB Purpose: To evaluate the effect of anti-VEGF treatment on pigment epithelial detachment (PED) secondary to the exudative type of age-related macular degeneration (AMD). Methods: Retrospective analysis of 30 eyes (28 patients) with exudative AMD accompanied by PED (receiving anti-VEGF injections). Alterations of the PED morphology were qualitatively assessed with optical coherence tomography (OCT). Changes in best-corrected visual acuity (BCVA) and number of injections were compared to 30 control eyes (30 patients) exhibiting exudative AMD without PED. Results: Mean follow-up was 19.8 months. Changes of the extent of PED were as follows: unchanged: 11 eyes (36.7%); reduced: 12 (40%); significantly reduced: 7 (23.3%). Mean paired difference in BCVA was -0.08 logMAR (p = 0.46) and in the number of injections was 2.1 injections (p = 0.04). Conclusions: A substantial number of the studied patients showed reduction of the extent of the PED after anti-VEGF treatment. The PED group required a higher number of injections.
C1 [Kalouda, Pelagia; Anastasakis, Anastasios; Tsika, Chrysanthi; Tsilimbaris, K. Miltiadis] Univ Crete, Sch Med, Dept Ophthalmol, Iraklion, Greece.
C3 University of Crete
RP Tsilimbaris, KM (通讯作者)，Univ Crete, Sch Med, Iraklion, Greece.
EM tsilimb@med.uoc.gr
OI Tsilimbaris, Miltiadis/0000-0002-0130-1150
CR Ach T, 2010, RETINA-J RET VIT DIS, V30, P1420, DOI 10.1097/IAE.0b013e3181d87e97
   Aggio FB, 2006, ACTA OPHTHALMOL SCAN, V84, P713, DOI 10.1111/j.1600-0420.2006.00759.x
   Arias L, 2010, CLIN OPHTHALMOL, V4, P369
   Arora S, 2011, EYE, V25, P1034, DOI 10.1038/eye.2011.115
   Baba T, 2012, OPHTHALMOLOGICA, V228, P102, DOI 10.1159/000337251
   Chan CK, 2010, RETINA-J RET VIT DIS, V30, P203, DOI 10.1097/IAE.0b013e3181babda5
   Chen E, 2007, RETINA-J RET VIT DIS, V27, P445, DOI 10.1097/01.iae.0000249574.89437.40
   Chiang A, 2008, RETINA-J RET VIT DIS, V28, P1265, DOI 10.1097/IAE.0b013e31817d5d03
   Hee MR, 1996, OPHTHALMOLOGY, V103, P1260, DOI 10.1016/S0161-6420(96)30512-5
   Heier JS, 2006, OPHTHALMOLOGY, V113, p642e1
   Introini U, 2012, GRAEF ARCH CLIN EXP, V250, P1283, DOI 10.1007/s00417-012-1955-2
   Joeres S, 2008, OPHTHALMOLOGY, V115, P347, DOI 10.1016/j.ophtha.2007.03.082
   Khetpal V, 2009, ACTA OPHTHALMOL, V87, P115, DOI 10.1111/j.1755-3768.2008.01176.x
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Ladas ID, 2007, OPHTHALMOLOGICA, V221, P313, DOI 10.1159/000104761
   Lommatzsch A, 2009, EYE, V23, P2163, DOI 10.1038/eye.2008.425
   Loukianou E, 2010, OPHTHALMOLOGY, V1, P110
   Matri L, 2010, GRAEFES ARCH CLIN EX, V248, P779
   Parodi MB, 2013, AM J OPHTHALMOL, V155, P103, DOI 10.1016/j.ajo.2012.07.001
   Pepple K, 2011, SEMIN OPHTHALMOL, V26, P198, DOI 10.3109/08820538.2011.570850
   Plainis S, 2007, OPTOMETRY VISION SCI, V84, P647, DOI 10.1097/OPX.0b013e3180dc9a60
   Ritter M, 2010, EYE, V24, P962, DOI 10.1038/eye.2009.265
   Rosenfeld Philip J, 2006, Ophthalmol Clin North Am, V19, P361
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Zayit-Soudry S, 2007, SURV OPHTHALMOL, V52, P227, DOI 10.1016/j.survophthal.2007.02.008
NR 25
TC 6
Z9 6
U1 0
U2 8
PU INFORMA HEALTHCARE
PI NEW YORK
PA 52 VANDERBILT AVE, NEW YORK, NY 10017 USA
SN 0882-0538
EI 1744-5205
J9 SEMIN OPHTHALMOL
JI Semin. Ophthalmol.
PD JAN
PY 2015
VL 30
IS 1
BP 6
EP 10
DI 10.3109/08820538.2013.807852
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AW7YT
UT WOS:000346478400002
PM 23952911
DA 2022-11-30
ER

PT J
AU Tranos, P
   Singh, M
   Peter, NM
   Dhir, L
   Kon, C
   Rassam, S
AF Tranos, P
   Singh, M
   Peter, NM
   Dhir, L
   Kon, C
   Rassam, S
TI Transpupillary thermotherapy for the treatment of subfoveal choroidal
   neovascularization associated with age-related macular degeneration
SO ACTA OPHTHALMOLOGICA SCANDINAVICA
LA English
DT Article
DE subfoveal choroidal neovascularization; transpupillary thermotherapy;
   age-related macular degeneration
ID RANDOMIZED CLINICAL-TRIAL; LASER PHOTOCOAGULATION; SUBRETINAL
   NEOVASCULARIZATION; LESIONS; MACULOPATHY; PREVALENCE; SECONDARY;
   BLINDNESS; OUTCOMES; THERAPY
AB Objective: To evaluate the efficacy of transpupillary thermotherapy (TTT) for the treatment of choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD).
   Design: Prospective, non-randomized, non-masked, case-selected series.
   Methods: All patients with subfoveal CNV due to AMD and initial visual acuity (VA) between 6/9 and 6/60 were offered the opportunity to undergo TTT. Recruited subjects were treated using a diode laser (810 nm) with a beam size of 1.2-3.0 mm and power settings of 460-1200 mW. Treatment was applied for 60 seconds in a subthreshold manner.
   Main outocome measures: Differences in VA and changes in the angiographic appearance of CNV.
   Results: Thirty-one occult/predominantly occult and five classic/predominantly classic membranes were treated with TTT and were followed-up for a mean of 6.0 +/- 1.2 months. Following an average of 1.5 +/- 0.7 (range 1-4) laser sessions, VA remained stable ( - 1 to + 1 Snellen line) in 24 (66.7%) eyes, improved by > 1 line in two (5.6%) eyes and decreased significantly (greater than or equal to 2 Snellen lines) in 10 (27.8%) eyes. Angiographically confirmed closure of CNV was detected in 22 (61.1%) patients. Membranes persisted in 11 (30.6%) eyes and recurred in three (8.3%) eyes. There was no association between reduction, elimination or persistence of angiographic leakage of CNV and change in VA after treatment (p = 0.347).
   Conclusions: Transpupillary thermotherapy may be effective at preserving vision and reducing CNV leakage in a number of patients with exudative AMD. Further studies are required to compare TTT with the natural course of subfoveal CNV and alternative treatment options.
C1 Worthing Gen Hosp, Dept Ophthalmol, Worthing BN11 2DH, England.
RP Tranos, P (通讯作者)，Worthing Gen Hosp, Dept Ophthalmol, Lyndhurst Rd, Worthing BN11 2DH, England.
EM ptranos@doctors.org.uk
CR Algvere PV, 2003, ACTA OPHTHALMOL SCAN, V81, P110, DOI 10.1034/j.1600-0420.2003.00041.x
   Benner JD, 2002, AM J OPHTHALMOL, V134, P765, DOI 10.1016/S0002-9394(02)01694-X
   Bressler NM, 2000, AM J OPHTHALMOL, V130, P387
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1443
   BRESSLER NM, 1988, ARCH OPHTHALMOL-CHIC, V106, P1537, DOI 10.1001/archopht.1988.01060140705039
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Guyer DR, 1997, ARCH OPHTHALMOL-CHIC, V115, P865
   Holz FG, 1999, OPHTHALMOLOGY, V106, P2239
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Lanzetta P, 2002, OPHTHALMOLOGY, V109, P1098, DOI 10.1016/S0161-6420(02)01034-5
   MILLER H, 1990, INVEST OPHTH VIS SCI, V31, P899
   MILLER H, 1986, INVEST OPHTH VIS SCI, V27, P1644
   Newsom RSB, 2001, BRIT J OPHTHALMOL, V85, P173, DOI 10.1136/bjo.85.2.173
   Reichel E, 1999, OPHTHALMOLOGY, V106, P1908, DOI 10.1016/S0161-6420(99)90400-1
   SOMMER A, 1991, NEW ENGL J MED, V325, P1412, DOI 10.1056/NEJM199111143252004
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1232
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1220
   Thach AB, 2003, ARCH OPHTHALMOL-CHIC, V121, P817, DOI 10.1001/archopht.121.6.817
   Thompson JT, 2001, AM J OPHTHALMOL, V131, P662, DOI 10.1016/S0002-9394(00)00879-5
NR 20
TC 4
Z9 5
U1 0
U2 0
PU BLACKWELL MUNKSGAARD
PI COPENHAGEN
PA 35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK
SN 1395-3907
J9 ACTA OPHTHALMOL SCAN
JI Acta Ophthalmol. Scand.
PD OCT
PY 2004
VL 82
IS 5
BP 585
EP 590
DI 10.1111/j.1600-0420.2004.00327.x
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 858DE
UT WOS:000224169700016
PM 15453858
DA 2022-11-30
ER

PT J
AU Little, K
   Ma, JH
   Yang, N
   Chen, M
   Xu, HP
AF Little, Karis
   Ma, Jacey H.
   Yang, Nan
   Chen, Mei
   Xu, Heping
TI Myofibroblasts in macular fibrosis secondary to neovascular age-related
   macular degeneration - the potential sources and molecular cues for
   their recruitment and activation
SO EBIOMEDICINE
LA English
DT Review
DE Age-related macular degeneration; Macular fibrosis; Myofibroblast; Risk
   factors; Inflammation
ID EPITHELIAL-MESENCHYMAL TRANSITION; OCCULT CHOROIDAL NEOVASCULARIZATION;
   RETINAL ANGIOMATOUS PROLIFERATION; ENDOTHELIAL GROWTH-FACTOR; SUBRETINAL
   FIBROSIS; GLOBAL PREVALENCE; COMPLEMENT-SYSTEM; EGFR ACTIVATION;
   TISSUE-REPAIR; CELLS
AB Age-related macular degeneration (AMD) is the leading cause of blindness in the elderly in developed countries. Neovascular AMD (nAMD) accounts for 90% of AMD-related vision loss. Although intravitreal injection of VEGF inhibitors can improve vision in nAMD, approximately 1/3 of patients do not benefit from the therapy due to macular fibrosis. The molecular mechanism underlying the transition of the neovascular lesion to a fibrovascular phenotype remains unknown. Here we discussed the clinical features and risk factors of macular fibrosis secondary to nAMD. Myofibroblasts are key cells in fibrosis development. However, fibroblasts do not exist in the macula. Potential sources of myofibroblast precursors, the molecular cues in the macular microenvironment that recruit them and the pathways that control their differentiation and activation in macular fibrosis were also discussed. Furthermore, we highlighted the challenges in macular fibrosis research and the urgent need for better animal models for mechanistic and therapeutic studies. (c) 2018 The Authors. Published by Elsevier B.V.
C1 [Little, Karis; Yang, Nan; Chen, Mei; Xu, Heping] Queens Univ Belfast, Sch Med Dent & Biomed Sci, Welcomme Wolfson Inst Expt Med, Belfast, Antrim, North Ireland.
   [Ma, Jacey H.; Xu, Heping] Cent S Univ, Aier Eye Inst, Aier Sch Ophthalmol, Changsha, Hunan, Peoples R China.
   [Ma, Jacey H.] Guangzhou Aier Eye Hosp, Guangzhou, Guangdong, Peoples R China.
C3 Queens University Belfast; Central South University
RP Xu, HP (通讯作者)，Queens Univ Belfast, Wellcome Wolfson Inst Expt Med, 97 Lisburn Rd, Belfast BT9 7BL, Antrim, North Ireland.
EM heping.xu@qub.ac.uk
RI Xu, Heping/A-4430-2008
OI Xu, Heping/0000-0003-4000-931X
FU Fight for Sight [5057/5058]; Department for the Economy (DfE) of
   Northern Ireland; National Natural Science Funds for Distinguished Young
   Scholar [NSFC 81500749]
FX This work is supported by Fight for Sight (5057/5058), the Department
   for the Economy (DfE) of Northern Ireland, and National Natural Science
   Funds for Distinguished Young Scholar (NSFC 81500749).
CR Algvere PV, 2003, ACTA OPHTHALMOL SCAN, V81, P110, DOI 10.1034/j.1600-0420.2003.00041.x
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Aono Y, 2014, AM J RESP CELL MOL, V51, P793, DOI 10.1165/rcmb.2013-0455OC
   Aziz KA, 2003, BLOOD, V102, P1051, DOI 10.1182/blood-2002-12-3737
   Black JRM, 2016, GENET MED, V18, P283, DOI 10.1038/gim.2015.70
   Bloch SB, 2013, AM J OPHTHALMOL, V156, P116, DOI 10.1016/j.ajo.2013.02.012
   Bringmann A, 2009, PROG RETIN EYE RES, V28, P423, DOI 10.1016/j.preteyeres.2009.07.001
   Caballero S, 2009, EXP EYE RES, V88, P367, DOI 10.1016/j.exer.2008.07.012
   Cabello-Verrugio C, 2012, J BIOL CHEM, V287, P6773, DOI 10.1074/jbc.M111.312488
   Campisi J, 2016, ANN AM THORAC SOC, V13, pS402, DOI 10.1513/AnnalsATS.201609-703AW
   Cao JT, 2010, INVEST OPHTH VIS SCI, V51, P6009, DOI 10.1167/iovs.09-4956
   Chaudhary NI, 2007, EUR RESPIR J, V29, P976, DOI 10.1183/09031936.00152106
   Chen HC, 2012, LAB INVEST, V92, P676, DOI 10.1038/labinvest.2011.201
   Chen M, 2015, J LEUKOCYTE BIOL, V98, P713, DOI 10.1189/jlb.3RI0615-239R
   Chen M, 2012, AM J PATHOL, V180, P235, DOI 10.1016/j.ajpath.2011.09.020
   Chen Zhuang-Gui, 2018, J Asthma, V55, P975, DOI 10.1080/02770903.2017.1386213
   Choi SS, 2009, HEPATOLOGY, V50, P2007, DOI 10.1002/hep.23196
   Dailey L, 2005, CYTOKINE GROWTH F R, V16, P233, DOI 10.1016/j.cytogfr.2005.01.007
   Daniel E, 2014, OPHTHALMOLOGY, V121, P656, DOI 10.1016/j.ophtha.2013.10.019
   DeAngelis MM, 2017, HUM MOL GENET, V26, pR45, DOI 10.1093/hmg/ddx228
   DEJUAN E, 1988, AM J OPHTHALMOL, V105, P25, DOI 10.1016/0002-9394(88)90116-X
   Dikmetas O, 2013, MOL VIS, V19, P2571
   Espinosa-Heidmann DG, 2005, EXP EYE RES, V80, P369, DOI 10.1016/j.exer.2004.10.005
   Gass J.D., 1967, AM J OPHTHALMOL, V63, P1
   Gianniou C, 2015, RETINA-J RET VIT DIS, V35, P1195, DOI 10.1097/IAE.0000000000000465
   Grossniklaus HE, 1998, ARCH OPHTHALMOL-CHIC, V116, P745, DOI 10.1001/archopht.116.6.745
   Hall-Glenn F, 2011, CELL MOL LIFE SCI, V68, P3209, DOI 10.1007/s00018-011-0782-7
   He S, 2003, ARCH OPHTHALMOL-CHIC, V121, P1283, DOI 10.1001/archopht.121.9.1283
   Herbst RS, 2004, INT J RADIAT ONCOL, V59, P21, DOI 10.1016/j.ijrobp.2003.11.041
   Hillebrandt S, 2005, NAT GENET, V37, P835, DOI 10.1038/ng1599
   Hinz B, 2016, EXP EYE RES, V142, P56, DOI 10.1016/j.exer.2015.07.009
   Hwang JC, 2011, OPHTHAL SURG LAS IM, V42, DOI 10.3928/15428877-20100924-01
   Ishikawa K, 2016, AM J PATHOL, V186, P859, DOI 10.1016/j.ajpath.2015.11.014
   Ishikawa K, 2016, EXP EYE RES, V142, P19, DOI 10.1016/j.exer.2015.03.009
   Jaffe GJ, 2017, OPHTHALMOLOGY, V124, P224, DOI 10.1016/j.ophtha.2016.10.010
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jiang J, 2018, EUR J PHARM SCI, V121, P251, DOI 10.1016/j.ejps.2018.04.043
   Jo YJ, 2011, INVEST OPHTH VIS SCI, V52, P6089, DOI 10.1167/iovs.10-5189
   Jonas JB, 2014, LANCET GLOB HEALTH, V2, pE65, DOI 10.1016/S2214-109X(13)70163-3
   Jonas JB, 2012, RETINA-J RET VIT DIS, V32, P2150, DOI 10.1097/IAE.0b013e3182576d07
   Kehlet SN, 2017, BMC PULM MED, V17, P1, DOI 10.1186/s12890-017-0455-x
   Kim JH, 2018, RETINA-J RET VIT DIS, V38, P2168, DOI 10.1097/IAE.0000000000001845
   Kimura K, 2015, J MOL MED, V93, P749, DOI 10.1007/s00109-015-1289-8
   Klinkhammer BM, 2018, MOL ASPECTS MED, V62, P44, DOI 10.1016/j.mam.2017.11.008
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Kuiper EJ, 2006, ARCH OPHTHALMOL-CHIC, V124, P1457, DOI 10.1001/archopht.124.10.1457
   Lechner J, 2016, IMMUN AGEING, V13, DOI 10.1186/s12979-016-0060-5
   Li JH, 2007, STEM CELLS, V25, P697, DOI 10.1634/stemcells.2006-0133
   Liu Y, 2017, CIRCULATING FIBROCYT
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Luo XT, 2018, DIS MODEL MECH, V11, DOI 10.1242/dmm.032060
   MacKinnon AC, 2012, AM J RESP CRIT CARE, V185, P537, DOI 10.1164/rccm.201106-0965OC
   Miere A, 2015, RETINA-J RET VIT DIS, V35, P2275, DOI 10.1097/IAE.0000000000000819
   Moore BB, 2006, AM J RESP CELL MOL, V35, P175, DOI 10.1165/rcmb.2005-0239OC
   Morry J, 2017, REDOX BIOL, V11, P240, DOI 10.1016/j.redox.2016.12.011
   Numano F, 2015, INT J CARDIOL, V201, P429, DOI 10.1016/j.ijcard.2015.07.063
   Park GB, 2018, MOL MED REP, V17, P3563, DOI 10.3892/mmr.2017.8355
   Pokroy R, 2018, RETINA-J RET VIT DIS, V38, P1485, DOI 10.1097/IAE.0000000000001748
   Pyne NJ, 2013, BBA-MOL CELL BIOL L, V1831, P228, DOI 10.1016/j.bbalip.2012.07.003
   Reddy VS, 2015, CURR MOL MED, V15, P47, DOI 10.2174/1566524015666150114112853
   Reilkoff RA, 2011, NAT REV IMMUNOL, V11, P427, DOI 10.1038/nri2990
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rogers AH, 2002, AM J OPHTHALMOL, V134, P566, DOI 10.1016/S0002-9394(02)01566-0
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   Samarakoon R, 2013, CELL SIGNAL, V25, P2198, DOI 10.1016/j.cellsig.2013.07.007
   Sendler M, 2016, 2 MOUSE MODELS CHRON, P2
   Shi-Wen X, 2008, CYTOKINE GROWTH F R, V19, P133, DOI 10.1016/j.cytogfr.2008.01.002
   Siedlecki J, 2018, GRAEF ARCH CLIN EXP, V256, P1141, DOI 10.1007/s00417-018-3987-8
   Singh A., 2013, PLOS ONE, V8
   Sobrin L, 2014, PROG RETIN EYE RES, V40, P1, DOI 10.1016/j.preteyeres.2013.12.004
   Stevens TS, 1997, ARCH OPHTHALMOL-CHIC, V115, P345, DOI 10.1001/archopht.1997.01100150347006
   Sun JX, 2018, ANGIOGENESIS, V21, P635, DOI 10.1007/s10456-018-9614-9
   Tamiya S, 2010, INVEST OPHTH VIS SCI, V51, P2755, DOI 10.1167/iovs.09-4725
   Tang ZY, 2009, J AM SOC NEPHROL, V20, P593, DOI 10.1681/ASN.2008040434
   Taniguchi T, 2012, J RHEUMATOL, V39, P539, DOI 10.3899/jrheum.110755
   Viola F, 2009, RETINA-J RET VIT DIS, V29, P732, DOI 10.1097/IAE.0b013e3181a395cb
   Wang CH, 2015, J ALLERGY CLIN IMMUN, V135, P1154, DOI 10.1016/j.jaci.2014.09.011
   Wang S, 2016, ONCOTARGET, V7, P8809, DOI 10.18632/oncotarget.6604
   Wei ZB, 2017, AM J PATHOL, V187, P2399, DOI 10.1016/j.ajpath.2017.07.018
   Willenborg S, 2012, BLOOD, V120, P613, DOI 10.1182/blood-2012-01-403386
   Willis BC, 2007, AM J PHYSIOL-LUNG C, V293, pL525, DOI 10.1152/ajplung.00163.2007
   Willoughby AS, 2015, OPHTHALMOLOGY, V122, P1846, DOI 10.1016/j.ophtha.2015.05.042
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu D, 2019, FASEB J, V33, P2498, DOI 10.1096/fj.201801227R
   Wynn TA, 2016, IMMUNITY, V44, P450, DOI 10.1016/j.immuni.2016.02.015
   Xu HP, 2016, EUR J PHARMACOL, V787, P94, DOI 10.1016/j.ejphar.2016.03.001
   Yannuzzi LA, 2008, RETINA-J RET VIT DIS, V28, P375, DOI 10.1097/IAE.0b013e3181619c55
   Zeisberg EM, 2007, NAT MED, V13, P952, DOI 10.1038/nm1613
   Zeisberg M, 2004, J MOL MED, V82, P175, DOI 10.1007/s00109-003-0517-9
   Zhang RS, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146808
NR 91
TC 29
Z9 29
U1 1
U2 12
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2352-3964
J9 EBIOMEDICINE
JI EBioMedicine
PD DEC
PY 2018
VL 38
BP 283
EP 291
DI 10.1016/j.ebiom.2018.11.029
PG 9
WC Medicine, General & Internal; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine; Research & Experimental Medicine
GA HF2FN
UT WOS:000454052500037
PM 30473378
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Sadigh, S
   Luo, XD
   Cideciyan, AV
   Sumaroka, A
   Boxley, SL
   Hall, LM
   Sheplock, R
   Feuer, WJ
   Stambolian, DS
   Jacobson, SG
AF Sadigh, Sam
   Luo, Xunda
   Cideciyan, Artur V.
   Sumaroka, Alexander
   Boxley, Stacy L.
   Hall, Laura M.
   Sheplock, Rebecca
   Feuer, William J.
   Stambolian, Dwight S.
   Jacobson, Samuel G.
TI Drusen and Photoreceptor Abnormalities in African-Americans with
   Intermediate Non-neovascular Age-related Macular Degeneration
SO CURRENT EYE RESEARCH
LA English
DT Article
DE African-American age-related macular degeneration; drusen; optical
   coherence tomography; photoreceptor outer nuclear layer
ID CILIARY NEUROTROPHIC FACTOR; RACIAL-DIFFERENCES; PREVALENCE; EYE;
   AUTOFLUORESCENCE; MORPHOLOGY; EVOLUTION; DEPOSITS; THERAPY; RETINA
AB Purpose/Aim: To investigate the relationship of drusen and photoreceptor abnormalities in African-American (AA) patients with intermediate non-neovascular age-related macular degeneration (AMD).
   Materials and methods: AA patients with intermediate AMD (n = 11; age 52-77 years) were studied with spectral-domain optical coherence tomography. Macular location and characteristics of large drusen (>= 125 mu m) were determined. Thickness of photoreceptor laminae was quantified overlying drusen and in other macular regions. A patient with advanced AMD (age 87) was included to illustrate the disease spectrum.
   Results: In this AA patient cohort, the spectrum of changes known to occur in AMD, including large drusen, sub-retinal drusenoid deposits and geographic atrophy, were identified. In intermediate AMD eyes (n = 17), there were 183 large drusen, the majority of which were pericentral in location. Overlying the drusen there was significant thinning of the photoreceptor outer nuclear layer (termed ONL+) as well as the inner and outer segments (IS+OS). The reductions in IS+OS thickness were directly related to ONL+ thickness. In a fraction (similar to 8%) of paradrusen locations with normal lamination sampled within similar to 280 mu m of peak drusen height, ONL+ was significantly thickened compared to age and retinal-location-matched normal values. Topographical maps of the macula confirmed ONL thickening in regions neighboring and distant to large drusen.
   Conclusions: We confirm there is a pericentral distribution of drusen across AA-AMD maculae rather than the central localization in Caucasian AMD. Reductions in the photoreceptor laminae overlying drusen are evident. ONL+ thickening in some macular areas of AA-AMD eyes may be an early phenotypic marker for photoreceptor stress.
C1 [Sadigh, Sam; Luo, Xunda; Cideciyan, Artur V.; Sumaroka, Alexander; Boxley, Stacy L.; Hall, Laura M.; Sheplock, Rebecca; Jacobson, Samuel G.] Univ Penn, Scheie Eye Inst, Perelman Sch Med, Dept Ophthalmol, Philadelphia, PA 19104 USA.
   [Feuer, William J.] Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, Miami, FL 33136 USA.
   [Stambolian, Dwight S.] Univ Penn, Perelman Sch Med, Dept Ophthalmol & Genet, Philadelphia, PA 19104 USA.
C3 University of Pennsylvania; Pennsylvania Medicine; Bascom Palmer Eye
   Institute; University of Miami; University of Pennsylvania; Pennsylvania
   Medicine
RP Cideciyan, AV (通讯作者)，Univ Penn, Scheie Eye Inst, 51 N 39th St, Philadelphia, PA 19104 USA.
EM cideciya@mail.med.upenn.edu; jacobsos@mail.med.upenn.edu
RI Cideciyan, Artur V/A-1075-2007
OI Cideciyan, Artur V/0000-0002-2018-0905; Jacobson,
   Samuel/0000-0003-2122-169X
FU Pennsylvania Department of Health [NEI/NIH R01 EY017549]; Foundation
   Fighting Blindness; NATIONAL EYE INSTITUTE [P30EY001583, R01EY017549]
   Funding Source: NIH RePORTER
FX The authors report no conflicts of interest. This work was supported by
   a grant from the Pennsylvania Department of Health to the University of
   Pennsylvania, Macula Vision Research Foundation, NEI/NIH R01 EY017549,
   and the Foundation Fighting Blindness. AVC is a RPB Senior Scientific
   Investigator.
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Beltran WA, 2007, EXP EYE RES, V84, P753, DOI 10.1016/j.exer.2006.12.019
   Beltran WA, 2009, INVEST OPHTH VIS SCI, V50, P3985, DOI 10.1167/iovs.08-3364
   Birch DG, 2013, AM J OPHTHALMOL, V156, P283, DOI 10.1016/j.ajo.2013.03.021
   Bok D, 2002, EXP EYE RES, V74, P719, DOI 10.1006/exer.2002.1176
   BRESSLER NM, 1995, ARCH OPHTHALMOL-CHIC, V113, P301, DOI 10.1001/archopht.1995.01100030055022
   Bressler SB, 2008, ARCH OPHTHALMOL-CHIC, V126, P241, DOI 10.1001/archophthalmol.2007.53
   Bush RA, 2004, INVEST OPHTH VIS SCI, V45, P2420, DOI 10.1167/iovs.03-1342
   Chang MA, 2008, INVEST OPHTH VIS SCI, V49, P2395, DOI 10.1167/iovs.07-1584
   Cideciyan AV, 2007, J OPT SOC AM A, V24, P1457, DOI 10.1364/JOSAA.24.001457
   Cideciyan AV, 2011, HUM MOL GENET, V20, P1411, DOI 10.1093/hmg/ddr022
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   Curcio CA, 2011, INVEST OPHTH VIS SCI, V52, P3943, DOI 10.1167/iovs.10-6377
   Delori FC, 2000, INVEST OPHTH VIS SCI, V41, P496
   Erke MG, 2012, OPHTHALMOLOGY, V119, P1737, DOI 10.1016/j.ophtha.2012.03.016
   Farsiu S, 2014, OPHTHALMOLOGY, V121, P162, DOI 10.1016/j.ophtha.2013.07.013
   Forte R, 2012, ACTA OPHTHALMOL, V90, pE281, DOI 10.1111/j.1755-3768.2011.02331.x
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Friedman DS, 1999, OPHTHALMOLOGY, V106, P1049, DOI 10.1016/S0161-6420(99)90267-1
   Fujimura S, 2013, GRAEF ARCH CLIN EXP, V251, P1, DOI 10.1007/s00417-013-2363-y
   GASS JDM, 1973, ARCH OPHTHALMOL-CHIC, V90, P206
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Green W R, 1977, Trans Am Ophthalmol Soc, V75, P180
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Hanley JA, 2003, AM J EPIDEMIOL, V157, P364, DOI 10.1093/aje/kwf215
   Hartmann KI, 2012, RETINA-J RET VIT DIS, V32, P1492, DOI 10.1097/IAE.0b013e318242b949
   Holliday EG, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0082305, 10.1371/journal.pone.0053830]
   Hu DN, 2008, PHOTOCHEM PHOTOBIOL, V84, P639, DOI 10.1111/j.1751-1097.2008.00316.x
   Jacobson SG, 2013, HUM MOL GENET, V22, P168, DOI 10.1093/hmg/dds421
   Jacobson SG, 2011, INVEST OPHTH VIS SCI, V52, P7924, DOI 10.1167/iovs.11-8313
   Jacobson SG, 2010, NEW ENGL J MED, V363, P1669, DOI 10.1056/NEJMcibr1007685
   Johnson PT, 2003, INVEST OPHTH VIS SCI, V44, P4481, DOI 10.1167/iovs.03-0436
   Keane PA, 2012, SURV OPHTHALMOL, V57, P389, DOI 10.1016/j.survophthal.2012.01.006
   Klein R, 2013, INVEST OPHTH VIS SCI, V54, DOI 10.1167/iovs.13-12789
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Kliffen M, 1997, MICROSC RES TECHNIQ, V36, P106, DOI 10.1002/(SICI)1097-0029(19970115)36:2<106::AID-JEMT4>3.0.CO;2-N
   Lujan BJ, 2011, INVEST OPHTH VIS SCI, V52, P1486, DOI 10.1167/iovs.10-5946
   PIERAMICI DJ, 1994, ARCH OPHTHALMOL-CHIC, V112, P1043, DOI 10.1001/archopht.1994.01090200049020
   Radeke MJ, 2007, EXP EYE RES, V85, P366, DOI 10.1016/j.exer.2007.05.006
   Rickman CB, 2006, INVEST OPHTH VIS SCI, V47, P2305, DOI 10.1167/iovs.05-1437
   Sadigh S, 2013, INVEST OPHTH VIS SCI, V54, P1603, DOI 10.1167/iovs.12-11286
   SARKS JP, 1994, EYE, V8, P269, DOI 10.1038/eye.1994.57
   Sarks SH, 1999, BRIT J OPHTHALMOL, V83, P358, DOI 10.1136/bjo.83.3.358
   SCHACHAT AP, 1995, ARCH OPHTHALMOL-CHIC, V113, P728, DOI 10.1001/archopht.1995.01100060054032
   Schuman SG, 2009, OPHTHALMOLOGY, V116, P488, DOI 10.1016/j.ophtha.2008.10.006
   Sharon D, 2002, P NATL ACAD SCI USA, V99, P315, DOI 10.1073/pnas.012582799
   Spaide RF, 2012, OPHTHALMOLOGY, V119, P2203, DOI 10.1016/j.ophtha.2012.09.009
   Spaide RF, 2011, RETINA-J RET VIT DIS, V31, P1609, DOI 10.1097/IAE.0b013e3182247535
   Tackenberg MA, 2009, MOL VIS, V15, P1886
   Talcott KE, 2011, INVEST OPHTH VIS SCI, V52, P2219, DOI 10.1167/iovs.10-6479
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P2434, DOI 10.1016/j.ophtha.2011.05.008
   Zeiss CJ, 2006, EXP EYE RES, V82, P395, DOI 10.1016/j.exer.2005.07.014
   Zhang Samuel Shao-Min, 2010, J Ocul Biol Dis Infor, V3, P129, DOI 10.1007/s12177-011-9064-8
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
NR 56
TC 10
Z9 10
U1 0
U2 3
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0271-3683
EI 1460-2202
J9 CURR EYE RES
JI Curr. Eye Res.
PD APR
PY 2015
VL 40
IS 4
BP 398
EP 406
DI 10.3109/02713683.2014.925934
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CD9XU
UT WOS:000351454800005
PM 24912073
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Skaat, A
   Solomon, A
   Moroz, I
   Hai, OV
   Rechtman, E
   Dai, VV
   Rotenstreich, Y
AF Skaat, Alon
   Solomon, Arie
   Moroz, Iris
   Hai, Orit Vidne
   Rechtman, Ehud
   Dai, Vicktoria Vishnevskia
   Rotenstreich, Ygal
TI Increased electroretinogram a-wave amplitude after intravitreal
   bevacizumab injection for neovascular age-related macular degeneration
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE bevacizumab (Avastin (R)); full-field electroretinography; neovascular
   age-related macular degeneration
ID ENDOTHELIAL GROWTH-FACTOR; AVASTIN TREATMENT; B-WAVE; MEMBRANES; CANCER;
   SAFETY; CELLS; MODEL; VEGF
AB Purpose:
   To assess the effect of bevacizumab (Avastin (R)), a vascular endothelial growth factor inhibitor, on retinal function by full-field electroretinography (ERG) in patients with neovascular age-related macular degeneration (AMD).
   Design:
   A prospective, nonrandomized, controlled interventional clinical trial.
   Methods:
   Twelve patients (aged 50-85) with neovascular AMD each received one unilateral intravitreal injection of bevacizumab 1.25 mg/0.05 ml as part of the standard management for choroidal neovascular AMD. Before and 1 month after injection, all patients underwent bilateral full-field ERG scanning by a masked technician according to the ISCEV protocol, and their wave amplitudes were recorded. Untreated eyes served as controls. Scotopic responses were recorded at four incremental light intensities and photopic responses at two incremental light intensities. Changes in ERG-amplitude responses were calculated. Repeated-measures anova was used for data analysis.
   Results:
   Mean pre- and postinjection differences in a-wave amplitudes between the incremental light intensities in injected eyes were significantly higher than in controls (15.92 versus 1.33 mu V for scotopic responses and 4.97 versus -1.06 mu V for photopic responses; p = 0.057 and p = 0.01, respectively). Mean b-wave amplitudes in injected eyes were significantly higher than in controls for photopic responses (p = 0.048), but for scotopic responses, the difference between treated and untreated eyes was not significant (p = 0.23).
   Conclusions:
   Intravitreally injected bevacizumab improves both rod and cone functioning in patients with neovascular AMD, as demonstrated by the increase in the ERG a-wave responses of these patients. Other measured ERG parameters yielded no significant photoreceptor toxicity.
C1 [Rotenstreich, Ygal] Chaim Sheba Med Ctr, Goldschleger Eye Res Inst, IL-52621 Tel Hashomer, Israel.
   Tel Aviv Univ, Sackler Fac Med, Ramat Aviv, Israel.
C3 Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of
   Medicine
RP Rotenstreich, Y (通讯作者)，Chaim Sheba Med Ctr, Goldschleger Eye Res Inst, IL-52621 Tel Hashomer, Israel.
EM Ygal.rotenstreich@sheba.health.gov.il
OI Rotenstreich, Ygal/0000-0003-2366-1779
CR Brown M, 2006, DOC OPHTHALMOL, V113, P205, DOI 10.1007/s10633-006-9030-0
   Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381
   Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Hood DC, 1996, J OPT SOC AM A, V13, P623, DOI 10.1364/JOSAA.13.000623
   Ip MS, 2008, OPHTHALMOLOGY, V115, P1837, DOI 10.1016/j.ophtha.2008.08.012
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Ladewig M, 2003, ARCH OPHTHALMOL-CHIC, V121, P1557, DOI 10.1001/archopht.121.11.1557
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Maturi RK, 2006, RETINA-J RET VIT DIS, V26, P270, DOI 10.1097/00006982-200603000-00003
   Meyerhardt JA, 2005, NEW ENGL J MED, V352, P476, DOI 10.1056/NEJMra040958
   Pai SA, 2007, AM J OPHTHALMOL, V143, P601, DOI 10.1016/j.ajo.2006.12.037
   REGILLO CD, 2010, AM ACAD OPHTHALMOLOG, P31
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Robinson CJ, 2001, J CELL SCI, V114, P853
   Robson JG, 1996, J OPT SOC AM A, V13, P613, DOI 10.1364/JOSAA.13.000613
   Ronan Shawn, 2006, Trans Am Ophthalmol Soc, V104, P232
   SIEVING PA, 1994, VISUAL NEUROSCI, V11, P519, DOI 10.1017/S0952523800002431
   Walter P, 1999, GRAEF ARCH CLIN EXP, V237, P962, DOI 10.1007/s004170050331
   Ziemssen Focke, 2008, International Ophthalmology, V28, P101, DOI 10.1007/s10792-007-9122-1
NR 21
TC 7
Z9 7
U1 0
U2 6
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1755-375X
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD MAY
PY 2011
VL 89
IS 3
BP e269
EP e273
DI 10.1111/j.1755-3768.2010.02005.x
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 751TR
UT WOS:000289641000021
PM 20946333
DA 2022-11-30
ER

PT J
AU Ma, KN
   Cashman, SM
   Sweigard, JH
   Kumar-Singh, R
AF Ma, Kelly N.
   Cashman, Siobhan M.
   Sweigard, J. Harry
   Kumar-Singh, Rajendra
TI Decay Accelerating Factor (CD55)-Mediated Attenuation of Complement:
   Therapeutic Implications for Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID MEMBRANE COFACTOR PROTEIN; FACTOR-H POLYMORPHISM; COMPONENT 2 C2;
   FACTOR-B BF; ADENOVIRAL VECTOR; FUNCTIONAL-CHARACTERIZATION; CHROMOSOMAL
   LOCALIZATION; REGULATORY PROTEINS; MOLECULAR-CLONING; DRUSEN FORMATION
AB PURPOSE. Sequence variations in complement proteins are associated with age-related macular degeneration (AMD). The terminal pathway of complement results in the formation of the membrane attack complex (MAC) on the cell surface, resulting in their lysis. MAC has been documented on the retinal pigment epithelium (RPE), choroidal blood vessels, and drusen of AMD eyes. Here the investigators test the hypothesis that increasing the expression of decay accelerating factor (CD55) on RPE cells may result in reduced MAC-mediated damage.
   METHODS. The investigators constructed a recombinant adenovirus expressing human CD55 (AdCAGCD55). Mouse hepatocytes were infected with AdCAGCD55 or negative controls and subsequently incubated with normal human serum (NHS). Cell lysis and MAC formation were measured by FACS and immunocytochemistry, respectively. Adult mice were injected in the subretinal space with either AdCAGCD55 or controls; after 1 week of CD55 transgene expression, the eyecups were excised, challenged with NHS, and quantified for human MAC formation.
   RESULTS. Control-infected or uninfected mouse hepatocytes lyse at a rate of 93% and 94%, respectively. AdCAGCD55-infected mouse hepatocytes lyse at a rate of 29%. Lysis was confirmed to occur in the presence of MAC, which was reduced by 67% when cells were infected by AdCAGCD55. Mice injected in the subretinal space with AdCAGCD55 exhibited a 55.7% reduction in MAC formation on the RPE relative to controls.
   CONCLUSIONS. Adenovirus-mediated delivery of hCD55 to murine RPE confers protection against human complement. The investigators propose that the expression of hCD55 on RPE cells warrants investigation as a potential therapy for AMD. (Invest Ophthalmol Vis Sci. 2010;51:6776-6783) DOI:10.1167/iovs.10-5887
C1 [Ma, Kelly N.; Cashman, Siobhan M.; Sweigard, J. Harry; Kumar-Singh, Rajendra] Tufts Univ, Sch Med, Dept Ophthalmol, Boston, MA 02111 USA.
C3 Tufts University
RP Kumar-Singh, R (通讯作者)，Tufts Univ, Sch Med, Dept Ophthalmol, 136 Harrison Ave, Boston, MA 02111 USA.
EM rajendra.kumar-singh@tufts.edu
OI Kumar-Singh, Rajendra/0000-0002-7754-0713
FU Ellison Foundation; Virginia B. Smith Trust; National Institutes of
   Health/National Eye Institute [EY014991, EY013887]; Lions Eye
   Foundation; Research to Prevent Blindness to the Department of
   Ophthalmology at Tufts University; NATIONAL EYE INSTITUTE [R01EY014991]
   Funding Source: NIH RePORTER
FX Supported by grants from The Ellison Foundation (R.K.-S.), the Virginia
   B. Smith Trust (R.K.-S.), the National Institutes of Health/National Eye
   Institute (EY014991 and EY013887; R.K.-S.), and the Lions Eye Foundation
   and Research to Prevent Blindness to the Department of Ophthalmology at
   Tufts University.
CR An FQ, 2009, INVEST OPHTH VIS SCI, V50, P3778, DOI 10.1167/iovs.08-3264
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   BENZAQUEN LR, 1994, J EXP MED, V179, P985, DOI 10.1084/jem.179.3.985
   Campochiaro PA, 2006, HUM GENE THER, V17, P167, DOI 10.1089/hum.2006.17.167
   Chevez-Barrios P, 2005, J CLIN ONCOL, V23, P7927, DOI 10.1200/JCO.2004.00.1883
   Cocuzzi ET, 2001, CURR EYE RES, V23, P86, DOI 10.1076/ceyr.23.2.86.5478
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fallaux FJ, 1996, HUM GENE THER, V7, P215, DOI 10.1089/hum.1996.7.2-215
   Fang CJ, 2008, BLOOD, V111, P624, DOI 10.1182/blood-2007-04-084533
   Francis PJ, 2009, J MED GENET, V46, P300, DOI 10.1136/jmg.2008.062737
   Fraunfelder FW, 2005, DRUG TODAY, V41, P703, DOI 10.1358/dot.2005.41.11.917340
   Gehrs K. M., ARCH OPHTHALMOL, V128, P349
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   HALPERIN JA, 1993, J CLIN INVEST, V91, P1974, DOI 10.1172/JCI116418
   He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Kim DD, 2006, CLIN IMMUNOL, V118, P127, DOI 10.1016/j.clim.2005.10.014
   Kim IH, 2001, P NATL ACAD SCI USA, V98, P13282, DOI 10.1073/pnas.241506298
   Kimberley FC, 2007, MOL IMMUNOL, V44, P73, DOI 10.1016/j.molimm.2006.06.019
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Kreppel F, 2002, INVEST OPHTH VIS SCI, V43, P1965
   Kroshus TJ, 2000, TRANSPLANTATION, V69, P2282, DOI 10.1097/00007890-200006150-00011
   Lamartina S, 2007, J GENE MED, V9, P862, DOI 10.1002/jgm.1083
   Licht C, 2009, THROMB HAEMOSTASIS, V101, P271, DOI 10.1160/TH08-09-0575
   LUBLIN DM, 1989, ANNU REV IMMUNOL, V7, P35, DOI 10.1146/annurev.immunol.7.1.35
   Lynch SS, 2007, ANN PHARMACOTHER, V41, P614, DOI 10.1345/aph.1H316
   MULLEREBERHARD HJ, 1986, ANNU REV IMMUNOL, V4, P503, DOI 10.1146/annurev.iy.04.040186.002443
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Niculescu F, 2004, IMMUNOL RES, V30, P73, DOI 10.1385/IR:30:1:073
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   POST TW, 1990, J IMMUNOL, V144, P740
   Powell MB, 1997, J IMMUNOL, V158, P1692
   Qian YM, 2000, J IMMUNOL, V165, P2528, DOI 10.4049/jimmunol.165.5.2528
   Ramo K, 2008, INVEST OPHTH VIS SCI, V49, P4126, DOI 10.1167/iovs.08-2025
   Richardson AJ, 2009, INVEST OPHTH VIS SCI, V50, P540, DOI 10.1167/iovs.08-2423
   Ricklin D, 2007, NAT BIOTECHNOL, V25, P1265, DOI 10.1038/nbt1342
   ROLLINS SA, 1990, J IMMUNOL, V144, P3478
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   SEYA T, 1989, BIOCHEM J, V264, P581, DOI 10.1042/bj2640581
   Skerka C, 2007, MOL IMMUNOL, V44, P3398, DOI 10.1016/j.molimm.2007.02.012
   Spencer KL, 2007, HUM MOL GENET, V16, P1986, DOI 10.1093/hmg/ddm146
   Spendlove I, 2006, CANCER IMMUNOL IMMUN, V55, P987, DOI 10.1007/s00262-006-0136-8
   SPICER AP, 1995, J IMMUNOL, V155, P3079
   Tenner AJ, 2001, NEUROBIOL AGING, V22, P849, DOI 10.1016/S0197-4580(01)00301-3
   van Leeuwen R, 2003, EUR J EPIDEMIOL, V18, P845, DOI 10.1023/A:1025643303914
   Vogt SD, 2006, EXP EYE RES, V83, P834, DOI 10.1016/j.exer.2006.04.002
   Williams P, 2003, J BIOL CHEM, V278, P10691, DOI 10.1074/jbc.M212561200
   Yang P, 2009, INVEST OPHTH VIS SCI, V50, P3473, DOI 10.1167/iovs.08-3202
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
NR 56
TC 15
Z9 15
U1 0
U2 2
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD DEC
PY 2010
VL 51
IS 12
BP 6776
EP 6783
DI 10.1167/iovs.10-5887
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 688GJ
UT WOS:000284837500089
PM 20688727
OA Green Published
DA 2022-11-30
ER

PT J
AU Luu, KT
   Seal, J
   Green, M
   Winskill, C
   Attar, M
AF Luu, Kenneth T.
   Seal, Jennifer
   Green, Michelle
   Winskill, Carolyn
   Attar, Mayssa
TI Effect of Anti-VEGF Therapy on the Disease Progression of Neovascular
   Age-Related Macular Degeneration: A Systematic Review and Model-Based
   Meta-Analysis
SO JOURNAL OF CLINICAL PHARMACOLOGY
LA English
DT Review
DE disease progression; model-based meta-analysis; modeling; neovascular
   age-related macular degeneration; pharmacodynamics; pharmacokinetics
ID ENDOTHELIAL GROWTH-FACTOR; ANKYRIN REPEAT PROTEIN; INTRAVITREAL
   AFLIBERCEPT; ABICIPAR PEGOL; RANIBIZUMAB; INJECTION; TREAT; TRAP
AB Anti-vascular endothelial growth factor (VEGF) therapy is used to slow the disease progression of neovascular age-related macular degeneration. Due to the treatment burden of frequent intravitreal injections, anti-VEGFs are often used on treat and extend protocols rather than the labeled frequency. The current goal of anti-VEGF drug development is to minimize treatment burden by reducing the number of intravitreal injections. The purpose of this systemic review and model-based meta-analysis (MBMA) was to (1) perform modeling to describe the disease progression of neovascular age-related macular degeneration in the absence of treatment, as well as in the presence of abicipar, aflibercept, brolucizumab, or ranibizumab intervention; (2) and to simulate virtual head-to-head comparisons among the drugs with an extended dose schedule of once every 12 weeks (Q12). Data sources were PubMed, internal Allergan data, , and . Eligibility assessment was performed by 2 independent review authors. Randomized, controlled trials that had at least 1 arm with an anti-VEGF (aflibercept, abicipar, bevacizumab, brolucizumab, pegaptanib, or ranibizumab), a control arm of placebo or anti-VEGF, a treatment duration of at least 4 months, reported best-corrected visual acuity data, and at least 20 patients were included. A total of 22 trials, consisting of 55 arms, from across 9500+ subjects and 500+ best-corrected visual acuity observations were used to develop the model. Consistent with reported data, results from the model showed that abicipar Q12 underperformed ranibizumab (every 4 weeks), aflibercept (every 4 weeks), and brolucizumab (every 8 weeks/Q12) labeled dosing schedules. However, when all drugs were virtually tested using the extended schedule, abicipar outperformed ranibizumab and aflibercept and produced a similar week 52 change from baseline as brolucizumab. Predicted week 52 changes from baseline were 5.92 +/- 1.02, 3.04 +/- 1.61, 6.61 +/- 0.284, and 3.02 +/- 2.35 best-corrected visual acuity letters for abicipar, aflibercept, brolucizumab, and ranibizumab, respectively, using the Q12 schedule. Results demonstrate the feasibility of Q12 dosing with clinically meaningful letter gains for abicipar and brolucizumab. The model developed under this MBMA has utility for exploring different regimens for existing or novel anti-VEGF agents.
C1 [Luu, Kenneth T.; Seal, Jennifer; Attar, Mayssa] AbbVie, Irvine, CA USA.
   [Winskill, Carolyn] Certara USA, Menlo Pk, CA USA.
   [Green, Michelle] qPharmetra LLC, San Francisco, CA USA.
C3 AbbVie
RP Seal, J (通讯作者)，AbbVie, Dept Clin Pharmacol, 2525 Dupont Dr, Irvine, CA 92612 USA.
EM Jennifer.Seal@abbvie.com
FU Allergan plc, Irvine, California
FX K.L. was an employee of AbbVie Inc. at the time of the study and during
   the early drafts of the manuscript. J.S. and M.A. are employees of and
   hold stock options for AbbVie Inc. M.G. was an employee of Certara at
   the time the analysis was conducted, is a current employee of
   qPharmetra, and is a stockholder of AbbVie. C.W. is an employee of
   Certara, USA. The study was supported by Allergan plc, Irvine,
   California (prior to its acquisition by AbbVie). Neither honoraria nor
   other form of compensation were provided for authorship. Writing and
   editorial assistance was provided to the authors by Stephanie Kuwahara,
   PhD, of AbbVie and Evidence Scientific Solutions Inc, Philadelphia,
   Pennsylvania.
CR Abraham P, 2010, AM J OPHTHALMOL, V150, P315, DOI 10.1016/j.ajo.2010.04.011
   Ahn JE, 2010, J PHARMACOKINET PHAR, V37, P179, DOI 10.1007/s10928-010-9152-6
   Alovisi C, 2017, J OPHTHALMOL, V2017, DOI 10.1155/2017/3172138
   [Anonymous], EYELEA PRESCRIBING I
   [Anonymous], BEOVU PRESCRIBING IN
   [Anonymous], LUCENTIS PRESCRIBING
   [Anonymous], 2020, REV OPHTHALMOL, V27, P3
   Arnold JJ, 2015, OPHTHALMOLOGY, V122, P1212, DOI 10.1016/j.ophtha.2015.02.009
   Avery RL, 2017, RETINA-J RET VIT DIS, V37, P1847, DOI 10.1097/IAE.0000000000001493
   Avery RL, 2014, BRIT J OPHTHALMOL, V98, P1636, DOI 10.1136/bjophthalmol-2014-305252
   Bourla DH, 2006, J AM GERIATR SOC, V54, P1130, DOI 10.1111/j.1532-5415.2006.00771.x
   Boyle Jessica, 2018, Psychol Health Med, V23, P127, DOI 10.1080/13548506.2016.1274040
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Callanan D, 2018, J OCUL PHARMACOL TH, V34, P700, DOI 10.1089/jop.2018.0062
   Campochiaro PA, 2016, OPHTHALMOLOGY, V123, pS78, DOI 10.1016/j.ophtha.2016.04.056
   Campochiaro PA, 2013, AM J OPHTHALMOL, V155, P697, DOI 10.1016/j.ajo.2012.09.032
   ClinicalTrials.gov, SAF PHARM RTH258 SUB
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   D'Argenio DZ, 2012, POP APPR GROUP EUR P
   DAYNEKA NL, 1993, J PHARMACOKINET BIOP, V21, P457, DOI 10.1007/BF01061691
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Dugel PU, 2016, CLIN OPHTHALMOL, V10, DOI 10.2147/OPTH.S100764
   Eng KT, 2006, CLIN INTERV AGING, V1, P451, DOI 10.2147/ciia.2006.1.4.451
   Freund KB, 2015, RETINA-J RET VIT DIS, V35, P1489, DOI 10.1097/IAE.0000000000000627
   Haga A, 2018, ACTA OPHTHALMOL, V96, pE393, DOI 10.1111/aos.13607
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Holz FG, 2016, OPHTHALMOLOGY, V123, P1080, DOI 10.1016/j.ophtha.2015.12.030
   Hussain RM, 2020, EXPERT OPIN BIOL TH, V20, P999, DOI 10.1080/14712598.2020.1782379
   Kertes PJ, 2019, OPHTHALMOLOGY, V126, P841, DOI 10.1016/j.ophtha.2019.01.013
   Khanna S, 2019, BMJ OPEN OPHTHALMOL, V4, DOI 10.1136/bmjophth-2019-000398
   Khurana RN, 2021, OPHTHALMOLOGY, V128, P1027, DOI 10.1016/j.ophtha.2020.11.017
   Khurana RN, 2019, AM J OPHTHALMOL, V200, P161, DOI 10.1016/j.ajo.2019.01.005
   Kourlas H, 2007, CLIN THER, V29, P1850, DOI 10.1016/j.clinthera.2007.09.008
   Krohne TU, 2012, AM J OPHTHALMOL, V154, P682, DOI 10.1016/j.ajo.2012.03.047
   Kunimoto D, 2020, OPHTHALMOLOGY, V127, P1331, DOI 10.1016/j.ophtha.2020.03.035
   Kunimoto D, 2019, OSLI RETINA, V50, pE10, DOI 10.3928/23258160-20190129-13
   Lyman Gary H, 2005, BMC Med Res Methodol, V5, P14, DOI 10.1186/1471-2288-5-14
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mori R, 2017, OPHTHALMOLOGICA, V238, P17, DOI 10.1159/000468950
   Mulyukov Z, 2018, CPT-PHARMACOMET SYST, V7, P660, DOI 10.1002/psp4.12322
   Obeid A, 2018, JAMA OPHTHALMOL, V136, P1251, DOI 10.1001/jamaophthalmol.2018.3578
   Olsen TW, 2020, OPHTHALMOLOGY, V127, pP1, DOI 10.1016/j.ophtha.2019.09.024
   Pauleikhoff D, 2005, RETINA-J RET VIT DIS, V25, P1065, DOI 10.1097/00006982-200512000-00016
   Prenner JL, 2015, AM J OPHTHALMOL, V160, P725, DOI 10.1016/j.ajo.2015.06.023
   Regeneron Pharmaceuticals, EYLEA AFL INJ INTR U
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sadda SR, 2010, RETINA-J RET VIT DIS, V30, P1390, DOI 10.1097/IAE.0b013e3181e44599
   Schauwvlieghe AME, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153052
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Shibuya Masabumi, 2011, Genes Cancer, V2, P1097, DOI 10.1177/1947601911423031
   Soares RR, 2020, OPHTHALMOL RETINA, V4, P134, DOI 10.1016/j.oret.2019.07.010
   Souied EH, 2014, AM J OPHTHALMOL, V158, P724, DOI 10.1016/j.ajo.2014.05.037
   The FDA does not approve Allergan's wet AMD drug candidate abicipar pegol, 2020, EYEWIRE NEWS
   US Food and Drug Administration Center for Drug Evaluation and Research, 2011, BIOL LIC APPL APPR E
   US Food and Drug Administration Center for Drug Evaluation and Research, 2004, NDA, P21
   Weiss M, 2018, RETINA-J RET VIT DIS, V38, P2293, DOI 10.1097/IAE.0000000000001892
NR 60
TC 2
Z9 2
U1 2
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0091-2700
EI 1552-4604
J9 J CLIN PHARMACOL
JI J. Clin. Pharmacol.
PD MAY
PY 2022
VL 62
IS 5
BP 594
EP 608
DI 10.1002/jcph.2002
EA JAN 2022
PG 15
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 0I4IU
UT WOS:000739182100001
PM 34783362
OA Green Published
DA 2022-11-30
ER

PT J
AU Iacono, P
   Parodi, MB
   Bandello, F
AF Iacono, Pierluigi
   Parodi, Maurizio Battaglia
   Bandello, Francesco
TI Non-Responders to Intravitreal Ranibizumab in Subfoveal Choroidal
   Neovascularization Secondary to Age-Related Macular Degeneration
SO OPHTHALMIC RESEARCH
LA English
DT Article
DE Subfoveal choroidal neovascularization; Age-related macular
   degeneration; Non-responders; Ranibizumab
ID GROWTH-FACTOR INHIBITORS; ANTI-VEGF THERAPY; ONE-YEAR OUTCOMES;
   AFLIBERCEPT; BEVACIZUMAB; AMD; SWITCH; EYES; RECURRENT; RESPONDERS
AB Aim: Evaluation of the proportion of patients affected by subfoveal choroidal neovascularization secondary to age related macular degeneration who are non-respondent to intravitreal ranibizumab injections (IVRI). Methods: Patients received 3 monthly IVRI, with monthly retreatments, in accordance with a pro re nata scheme (fluid on optical coherence tomography, leakage on fluorescein angiography, new haemorrhages). Non-responders were classified as follows: functional non-responder (best-corrected visual acuity worsening by a minimum of 2 ETDRS lines); anatomical non responder (central foveal thickness not decreasing by at least 10% compared with baseline value); complete non-responder (both anatomical and functional non-responder criteria apply). Primary outcome measure: identification of the proportion of non-responders. Results: Four patients (7%) were functional non-responders at the 1-month examination, and 5, 5 and 7% at the 2-, 3- and 6-month examinations, respectively. Two of 4 initial non-responders were reclassified as responders during the 6-month follow-up. Twenty-three eyes (43%) were anatomical non-responders at the 1-month visit, and 32, 28 and 21% at 2, 3 and 6 months, respectively. Sixteen of 23 (70%) initially non-respondent eyes became respondent over the follow-up. Two eyes (4%) were classified as complete non-responders after 1 month. Non responders amounted to 4, 0 and 2% at the 2-, 3-and 6-month examinations, respectively. No initially complete non-responding eye remained so over the follow-up. Conclusion: Data indicate a low proportion of functional and anatomical non-responders to IVRI. Further studies are warranted providing a better definition of non-responder and a clearer picture of the magnitude of response, when present. (C) 2016 S. Karger AG, Basel
C1 [Iacono, Pierluigi] GB Bietti Fdn, IRCCS, Rome, Italy.
   [Parodi, Maurizio Battaglia; Bandello, Francesco] Osped San Raffaele, Dept Ophthalmol, Milan, Italy.
C3 IRCCS - Fondazione "G.B. Bietti" per lo Studio e la Ricerca in
   Oftalmologia; Vita-Salute San Raffaele University; IRCCS Ospedale San
   Raffaele
RP Iacono, P (通讯作者)，Fdn GB Bietti Oftalmol, IRCCS, Via Livenza 3, IT-00198 Rome, Italy.
EM pierluigi.iacono@libero.it
RI Parodi, Maurizio Battaglia/K-7876-2016; Iacono, Pierluigi/AAD-3158-2020;
   bandello, francesco/AAH-2405-2019
OI bandello, francesco/0000-0003-3238-9682; Battaglia Parodi,
   Maurizio/0000-0002-0385-7961
FU Ministry of Health; Fondazione Roma
FX The research for this paper was partially supported by the Ministry of
   Health and Fondazione Roma.
CR Arcinue CA, 2015, AM J OPHTHALMOL, V159, P426, DOI 10.1016/j.ajo.2014.11.022
   Aslankurt M, 2013, EUR J OPHTHALMOL, V23, P553, DOI 10.5301/ejo.5000268
   Bakall B, 2013, AM J OPHTHALMOL, V156, P15, DOI 10.1016/j.ajo.2013.02.017
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Ehlers JP, 2010, OPHTHAL SURG LAS IM, V41, P182, DOI 10.3928/15428877-20100303-05
   Ehlken C, 2014, EYE, V28, P538, DOI 10.1038/eye.2014.64
   Fassnacht-Riederle H, 2014, GRAEF ARCH CLIN EXP, V252, P1705, DOI 10.1007/s00417-014-2589-3
   Grewal DS, 2014, EYE, V28, P895, DOI 10.1038/eye.2014.101
   Ho VY, 2013, AM J OPHTHALMOL, V156, P23, DOI 10.1016/j.ajo.2013.02.009
   Iacono P, 2015, AM J OPHTHALMOL, V159, P996, DOI 10.1016/j.ajo.2015.02.011
   Kucukerdonmez C, 2015, EUR J OPHTHALMOL, V25, P51, DOI 10.5301/ejo.5000480
   Michalewski J, 2014, CAN J OPHTHALMOL, V49, P431, DOI 10.1016/j.jcjo.2014.07.012
   Patel PJ, 2008, INVEST OPHTH VIS SCI, V49, P4347, DOI 10.1167/iovs.08-1935
   Pinheiro-Costa J, 2014, OPHTHALMOLOGICA, V232, P149, DOI 10.1159/000363422
   Puliafito CA, 2013, OPHTHAL SURG LAS IM, V44, P109, DOI 10.3928/23258160-20130313-01
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schachat AP, 2013, AM J OPHTHALMOL, V156, P1, DOI 10.1016/j.ajo.2013.04.009
   Thorell MR, 2014, OSLI RETINA, V45, P526, DOI 10.3928/23258160-20141118-07
   Wolf A, 2008, BRIT J OPHTHALMOL, V92, P1298, DOI 10.1136/bjo.2008.138396
   Wykoff CC, 2014, BRIT J OPHTHALMOL, V98, P951, DOI 10.1136/bjophthalmol-2013-304736
   Yonekawa Y, 2013, AM J OPHTHALMOL, V156, P29, DOI 10.1016/j.ajo.2013.03.030
NR 21
TC 3
Z9 4
U1 0
U2 2
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3747
EI 1423-0259
J9 OPHTHALMIC RES
JI Ophthalmic Res.
PY 2017
VL 57
IS 1
BP 42
EP 47
DI 10.1159/000448955
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EF1KK
UT WOS:000390083500004
PM 27694751
DA 2022-11-30
ER

PT J
AU Li, D
   Peng, XY
   Sun, HY
AF Li, Dan
   Peng, XiaoYan
   Sun, HuiYu
TI Association of CX3CR1 (V249I and T280M) polymorphisms with age-related
   macular degeneration: a meta-analysis
SO CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE
LA English
DT Article
ID GENETIC ASSOCIATION; RECEPTOR CX3CR1; SEVERITY SCALE; HAN CHINESE; RISK;
   POPULATION; EXPRESSION; MICROGLIA; VARIANTS; CX(3)CR1
AB Objective: Studies investigating the associations between CX3CR1 genetic polymorphisms and age-related macular degeneration (AMD) have reported controversial results. Therefore, this meta-analysis aims to clarify the effects of CX3CR1 T280M and V249I polymorphisms on AMD risk.
   Design: Meta-analysis.
   Participants: Results from six studies were pooled in the meta-analysis.
   Methods: Relevant studies were selected through an extensive search of PubMed, EMBASE, and the Web of Science databases. Pooled odds ratio (OR) and 95% confidence interval (CI) were calculated using random-effects model.
   Results: Six studies with were included in this systematic review and meta-analysis. There was no significant association between CX3CR1 T280M polymorphism and risk of AMD under all genetic models (TT vs CC/CT: OR = 1.57, 95% Cl = 0.87-2.84; CC vs TT/CT: OR = 0.75, 95% Cl = 0.54-1.06; TT vs CC: OR = 0.58, 95% Cl = 0.30-1.144; CT vs CC: OR = 1.25, 95% Cl = 0.91-1.70). The CX3CR1 V249I polymorphism also did not significantly affect the AMD risk (AA vs GG/AG: OR = 1.23, 95% Cl = 0.98-1.55; AG/AA vs GG: OR = 0.56, 95% Cl = 0.29-1.07; AA vs GG: OR = 1.43, 95% Cl = 0.97-2.09; AG vs GG: OR = 1.07, 95% Cl = 0.85-1.36).
   Conclusions: This meta-analysis suggested that CX3CR1 T280M and V249I polymorphisms may not be associated with an increased risk of AMD based on current published data. Given the limited sample size, the finding on CX3CR1 polymorphisms needs further investigation.
C1 [Li, Dan; Sun, HuiYu] Capital Med Univ, Dept Ophthalmol, Beijing Di Tan Hosp, Beijing 100730, Peoples R China.
   [Peng, XiaoYan] Beijing Tongren Hosp, Beijng Tongren Eye Ctr, Beijing Ophthalmol & Visual Sci Key Lab, Beijing, Peoples R China.
C3 Capital Medical University; Capital Medical University
RP Sun, HY (通讯作者)，Capital Med Univ, Dept Ophthalmol, Beijing Di Tan Hosp, 8 Jing Shun Dong Jie, Beijing 100730, Peoples R China.
EM sunhuiyu123@126.com
CR Anastasopoulos E, 2012, CURR EYE RES, V37, P1148, DOI 10.3109/02713683.2012.705413
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Brion M, 2011, ACTA OPHTHALMOL, V89, pE12, DOI 10.1111/j.1755-3768.2010.02040.x
   Chakravarthy U, 2007, OPHTHALMOLOGY, V114, P1157, DOI 10.1016/j.ophtha.2006.09.022
   Chan CC, 2005, HISTOL HISTOPATHOL, V20, P857, DOI 10.14670/HH-20.857
   Chew EY, 2014, OPHTHALMOLOGY, V121, P2173, DOI 10.1016/j.ophtha.2014.05.008
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Ersoy L, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/413150
   Falk MK, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-22
   Faure S, 2000, SCIENCE, V287, P2274, DOI 10.1126/science.287.5461.2274
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Foxman EF, 2002, J IMMUNOL, V168, P2483, DOI 10.4049/jimmunol.168.5.2483
   Gupta D, 2014, ARCH MED RES, V45, P489, DOI 10.1016/j.arcmed.2014.07.005
   Hu JY, 2011, OPHTHAL EPIDEMIOL, V18, P137, DOI 10.3109/09286586.2011.574335
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kondo N, 2011, OPHTHALMOLOGY, V118, P339, DOI 10.1016/j.ophtha.2010.06.040
   Liu MM, 2011, INVEST OPHTH VIS SCI, V52, P3129, DOI 10.1167/iovs.10-6735
   McDermott DH, 2001, CIRC RES, V89, P401, DOI 10.1161/hh1701.095642
   Moatti D, 2001, BLOOD, V97, P1925, DOI 10.1182/blood.V97.7.1925
   Ng T, 2014, CANCER TREAT REV, V40, P1199, DOI 10.1016/j.ctrv.2014.10.001
   Nita M, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/930671
   Schaumberg DA, 2014, JAMA OPHTHALMOL, V132, P84, DOI 10.1001/jamaophthalmol.2013.5506
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Su Y, 2015, OPHTHALMIC GENET, V36, P218, DOI 10.3109/13816810.2013.858753
   Sunnemark D, 2003, BRAIN PATHOL, V13, P617
   Tou JS, 2004, FASEB J, V18, P1297, DOI 10.1096/fj.04-1862fje
   von Elm E, 2009, LANCET, V374, P98, DOI 10.1016/S0140-6736(09)61265-4
   Wang H, 2013, CAN J OPHTHALMOL, V48, P186, DOI 10.1016/j.jcjo.2013.01.001
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Yang X, 2010, BRIT J OPHTHALMOL, V94, P1211, DOI 10.1136/bjo.2009.165811
   Zerbib J, 2011, EXP EYE RES, V93, P382, DOI 10.1016/j.exer.2011.05.005
   Zurdel J, 2002, BRIT J OPHTHALMOL, V86, P214, DOI 10.1136/bjo.86.2.214
NR 34
TC 0
Z9 0
U1 0
U2 4
PU CANADIAN OPHTHAL SOC
PI OTTAWA
PA 1525 CARLING AVE SUITE 610, OTTAWA, ONTARIO K1Z 8R9, CANADA
SN 0008-4182
EI 1715-3360
J9 CAN J OPHTHALMOL
JI Can. J. Opthalmol.-J. Can. Opthalmol.
PD DEC
PY 2015
VL 50
IS 6
BP 451
EP 460
DI 10.1016/j.jcjo.2015.08.010
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DB2RA
UT WOS:000368355500021
PM 26651305
DA 2022-11-30
ER

PT J
AU Sabeti, F
   Lane, J
   Rohan, EMF
   Rai, BB
   Essex, RW
   McKone, E
   Maddess, T
AF Sabeti, Faran
   Lane, Jo
   Rohan, Emilie M. F.
   Rai, Bhim B.
   Essex, Rohan W.
   McKone, Elinor
   Maddess, Ted
TI Correlation of Central Versus Peripheral Macular Structure-Function With
   Acuity in Age-Related Macular Degeneration
SO TRANSLATIONAL VISION SCIENCE & TECHNOLOGY
LA English
DT Article
DE age-related macular degeneration (AMD); visual function; retinal
   structure
AB Purpose: Patients with advanced age-related macular degeneration (AMD) may have preserved visual function despite significant retinal structural changes. We aimed to evaluate the relationships among retinal thickness, macular sensitivity, and visual acuity (VA) in advanced AMD. Methods: We examined 43 eyes of 22 patients with advanced AMD (ages 66?93 years), prospectively recruited from the Canberra Hospital Ophthalmology Department. Visual function was measured on participants with low and high contrast visual acuity (LCVA and HCVA) and 10-2 Matrix visual fields. Retinal structure was determined with spectral domain optical coherence tomography (OCT), and customized software mapped the 64 OCT macular thickness regions onto the 44 regions of the 10-2 test. Results: Median retinal thickness at each 10-2 region was near normal. Just 7 of 88 regions from the OCT analysis that were thicker than the median had sensitivity that declined significantly with increasing thickness (r = ?0.698 ? 0.082, mean ? SD), whereas 17 of 88 thinner regions showed significantly decreasing sensitivity with decreasing thickness (r = 0.723 ? 0.078). The absolute value of deviations from median optical coherence tomography thickness (aOCT) outside the central eight degrees was significantly correlated with HCVA (r = ?0.34, P = 0.047). Thickness in the central eight degrees was not. Similarly, matrix sensitivities inside the central eight degrees were significantly correlated with outer aOCT (r = ?0.49, P = 0.002). Conclusions: Retinal thickness outside eight degrees were significantly associated with HCVA and macular sensitivity. These results suggest that outer macular thickness may be a useful prognostic indicator in AMD. Translational Relevance: Retinal structure at the borders of the macula may be a surrogate marker of vision and retinal thickness near fixation.
C1 [Sabeti, Faran] Univ Canberra, Fac Hlth, Discipline Optometry, Univ Dr, Canberra, ACT 2617, Australia.
   [Sabeti, Faran; Rohan, Emilie M. F.; Rai, Bhim B.; Maddess, Ted] Australian Natl Univ, John Curtin Sch Med Res JCSMR, Canberra, ACT, Australia.
   [Lane, Jo; McKone, Elinor] Australian Natl Univ, Res Sch Psychol, Canberra, ACT, Australia.
   [Lane, Jo] Australian Natl Univ, ARC Ctr Excellence Cognit & its Disorders, Canberra, ACT, Australia.
   [Essex, Rohan W.] Canberra Hosp, Canberra, ACT, Australia.
   [Essex, Rohan W.] ANU Med Sch, Acad Unit Ophthalmol, Canberra, ACT, Australia.
   [Lane, Jo; McKone, Elinor] Australian Natl Univ, ARC Ctr Excellence Cognit & its Disorders, Canberra, ACT, Australia.
C3 University of Canberra; Australian National University; John Curtin
   School of Medical Research; Australian National University; Australian
   National University; Australian National University; Canberra Hospital;
   Australian National University; Australian National University
RP Sabeti, F (通讯作者)，Univ Canberra, Fac Hlth, Discipline Optometry, Univ Dr, Canberra, ACT 2617, Australia.
EM faran.sabeti@canberra.edu.au
RI Sabeti, Faran/AAR-1767-2021; Maddess, Teddy L/A-3200-2008
OI Maddess, Teddy L/0000-0003-4591-3658; SABETI, Faran/0000-0001-9187-7569;
   Lane, Jo/0000-0002-2518-1050
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Anderson AJ, 2011, OPTOMETRY VISION SCI, V88, P806, DOI 10.1097/OPX.0b013e31821861bd
   Barbazetto I, 2003, ARCH OPHTHALMOL-CHIC, V121, P1253
   Carkeet A, 2001, OPTOMETRY VISION SCI, V78, P529, DOI 10.1097/00006324-200107000-00017
   Cimarolli VR, 2012, CLIN REHABIL, V26, P748, DOI 10.1177/0269215511429162
   Crossland MD, 2004, VISION RES, V44, P1537, DOI 10.1016/j.visres.2004.01.006
   Crossland MD, 2011, INVEST OPHTH VIS SCI, V52, P411, DOI 10.1167/iovs.10-5473
   Csaky K, 2017, INVEST OPHTH VIS SCI, V58, P3456, DOI 10.1167/iovs.17-22339
   Dimitrov PN, 2011, INVEST OPHTH VIS SCI, V52, P9457, DOI 10.1167/iovs.10-7043
   FERRIS FL, 1993, AM J OPHTHALMOL, V116, P735
   Macedo A, 2007, OPTOMETRY VISION SCI, V84, P852, DOI 10.1097/OPX.0b013e3181559beb
   Grover S, 2009, AM J OPHTHALMOL, V148, P266, DOI 10.1016/j.ajo.2009.03.006
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P829, DOI 10.1016/j.ophtha.2018.09.015
   Hatef E, 2011, AM J OPHTHALMOL, V152, P400, DOI 10.1016/j.ajo.2011.02.024
   Hazel CA, 2000, INVEST OPHTH VIS SCI, V41, P1309
   Ivers RQ, 2001, OPHTHALMOLOGY, V108, P968, DOI 10.1016/S0161-6420(00)00649-7
   Iwama D, 2010, CLIN EXP OPHTHALMOL, V38, P483, DOI 10.1111/j.1442-9071.2010.02294.x
   Lane J, 2019, J VISION, V19, DOI 10.1167/19.6.18
   Lane J, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0209218
   Lane J, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-33543-3
   Maddess T, 2014, GRAEF ARCH CLIN EXP, V252, P1611, DOI 10.1007/s00417-014-2751-y
   Maddess T, 2011, INVEST OPHTH VIS SCI, V52, P1014, DOI 10.1167/iovs.10-6014
   Midena E, 1997, INVEST OPHTH VIS SCI, V38, P469
   Midena E, 2007, BRIT J OPHTHALMOL, V91, P1499, DOI 10.1136/bjo.2007.119685
   Neelam K, 2009, SURV OPHTHALMOL, V54, P167, DOI 10.1016/j.survophthal.2008.12.003
   Numata T, 2017, TRANSL VIS SCI TECHN, V6, DOI 10.1167/tvst.6.5.8
   Owsley C, 2001, OPHTHALMOLOGY, V108, P1196, DOI 10.1016/S0161-6420(01)00580-2
   Parravano M, 2010, RETINA-J RET VIT DIS, V30, P1017, DOI 10.1097/IAE.0b013e3181cfd3c6
   Puell MC, 2012, INVEST OPHTH VIS SCI, V53, P7310, DOI 10.1167/iovs.11-8649
   Raza AS, 2011, ARCH OPHTHALMOL-CHIC, V129, P1529, DOI 10.1001/archophthalmol.2011.352
   Rohrschneider K, 2008, PROG RETIN EYE RES, V27, P536, DOI 10.1016/j.preteyeres.2008.07.003
   Ruseckaite R, 2006, DOC OPHTHALMOL, V113, P29, DOI 10.1007/s10633-006-9011-3
   Sabeti F, 2012, INVEST OPHTH VIS SCI, V53, P253, DOI 10.1167/iovs.11-8004
   Sepulveda JA, 2016, INVEST OPHTH VIS SCI, V57, P4772, DOI 10.1167/iovs.16-19288
   Shah N, 2016, BRIT J OPHTHALMOL, V100, P1346, DOI 10.1136/bjophthalmol-2015-307375
   Steinberg JS, 2015, JAMA OPHTHALMOL, V133, P690, DOI 10.1001/jamaophthalmol.2015.0477
   Tejeria L, 2002, BRIT J OPHTHALMOL, V86, P1019, DOI 10.1136/bjo.86.9.1019
   Weksler ME, 1998, GERIATRICS, V53, P70
   Woods RL, 1998, OPHTHALMOLOGY, V105, P2318, DOI 10.1016/S0161-6420(98)91235-0
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P1612, DOI 10.1016/j.ophtha.2014.02.005
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P1445, DOI 10.1016/j.ophtha.2014.01.025
NR 41
TC 3
Z9 3
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 2164-2591
J9 TRANSL VIS SCI TECHN
JI Transl. Vis. Sci. Technol.
PD FEB
PY 2021
VL 10
IS 2
DI 10.1167/tvst.10.2.10
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA RG2VZ
UT WOS:000635403100010
PM 34003894
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Du, ZJ
   Wu, XM
   Song, MX
   Li, P
   Wang, L
AF Du, Zhaojiang
   Wu, Xuemei
   Song, Meixia
   Li, Peng
   Wang, Li
TI Oxidative damage induces MCP-1 secretion and macrophage aggregation in
   age-related macular degeneration (AMD)
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Oxidized phospholipids; MCP-1;
   Macrophage
ID MONOCYTE CHEMOATTRACTANT PROTEIN-1; CHOROIDAL NEOVASCULARIZATION;
   CIGARETTE-SMOKING; INFLAMMATION; STRESS; DRUSEN; RISK; ATHEROSCLEROSIS;
   PATHOGENESIS; ACTIVATION
AB Age-related macular degeneration (AMD) is a major cause of progressive and degenerative visual impairment. Although the exact pathogenic mechanism of AMD is still unknown, clinical observations such as the high accumulation of oxidative products and macrophages in retina suggest the importance of oxidative stress and inflammation in AMD.
   Mouse photoreceptor-derived 661 W cells and human ARPE-19 cells were treated with oxidized phospholipids (Ox-PC) or H2O2 to mimic oxidative damage. The effect of monocyte chemoattractant protein 1 (MCP-1) secreted by retina cells on the migration of monocyte macrophage RAW 264.7 cells was determined using transwell chambers and antibody neutralization assay. MCP-1, tumor necrosis factor-alpha (TNF-alpha), interleukin-1 beta (IL-1 beta), and vascular endothelial growth factor (VEGF) that secreted into supernatant were measured by ELISA and their intracellular expression was detected by qRT-PCR and western blot. Intracellular Ox-PC level was detected by competitive ELISA. The amount of migrated RAW 264.7 cells was counted by flow cytometry.
   Oxidative damage by both H2O2 and Ox-PC induced the secretion of MCP-1 in human ARPE-19 and mouse 661 W cells. MCP-1 induced by oxidative damage enhanced the migration ability of macrophage RAW 264.7 cells and the secretion of TNF-alpha, IL-1 beta and VEGF, which could be reduced by anti-MCP-1 neutralizing antibodies.
   The results indicated that oxidative damage increases intracellular Ox-PC and the secretion of MCP-1 in retina cells. The increased MCP-1 induced by oxidative damage attracts macrophages to retinas, and macrophages release pro-inflammatory factor and promote the process of AMD.
C1 [Du, Zhaojiang; Song, Meixia] Fourth Mil Med Univ, Tangdu Hosp, Dept Ophthalmol, Xian 710038, Peoples R China.
   [Wu, Xuemei] Chinese Med Res Inst, Dept Ophthalmol, Xian 710003, Peoples R China.
   [Song, Meixia] PLA, Cent Hosp 153, Dept Ophthalmol, Zhengzhou 450007, Henan, Peoples R China.
   [Li, Peng] 451 Hosp PLA, Dept Ophthalmol, Xian 710054, Peoples R China.
   [Wang, Li] Xian Med Coll, Dept Optometry, Xian 710021, Peoples R China.
C3 Air Force Military Medical University; Xi'an Medical University
RP Du, ZJ (通讯作者)，Fourth Mil Med Univ, Tangdu Hosp, Dept Ophthalmol, Xian 710038, Peoples R China.
EM duzhaojiang@126.com
FU National Natural Science Foundation of China [81100670]; Scientific
   Research Foundation for the Returned Overseas Chinese Scholars, Ministry
   of Education of China
FX The Youth Fund Project of National Natural Science Foundation of China
   (No. 81100670) and the Scientific Research Foundation for the Returned
   Overseas Chinese Scholars, Ministry of Education of China provided
   financial support in the form of research funding. The sponsor had no
   role in the design or conduct of this research.
CR Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Armaiz-Pena GN, 2015, ONCOTARGET, V6, P4266, DOI 10.18632/oncotarget.2887
   Austin BA, 2009, INVEST OPHTH VIS SCI, V50, P2896, DOI 10.1167/iovs.08-2495
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Campagne MV, 2014, J PATHOL, V232, P151, DOI 10.1002/path.4266
   Chen M, 2015, J LEUKOCYTE BIOL, V98, P713, DOI 10.1189/jlb.3RI0615-239R
   Cousins SW, 2004, ARCH OPHTHALMOL-CHIC, V122, P1013, DOI 10.1001/archopht.122.7.1013
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Crane IJ, 2000, IMMUNOLOGY, V101, P426, DOI 10.1046/j.0019-2805.2000.01105.x
   Delori FC, 2000, INVEST OPHTH VIS SCI, V41, P496
   Deshmane SL, 2009, J INTERF CYTOK RES, V29, P313, DOI 10.1089/jir.2008.0027
   DUVALL J, 1985, ARCH OPHTHALMOL-CHIC, V103, P694, DOI 10.1001/archopht.1985.01050050086024
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hammond BR, 1996, VISION RES, V36, P3003, DOI 10.1016/0042-6989(96)00008-9
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   ITABE H, 1994, J BIOL CHEM, V269, P15274
   Jonas JB, 2010, ARCH OPHTHALMOL-CHIC, V128, P1281, DOI 10.1001/archophthalmol.2010.227
   Jovanovic DV, 1998, J IMMUNOL, V160, P3513
   Kanda A, 2008, BRIT J OPHTHALMOL, V92, P448, DOI 10.1136/bjo.2007.131581
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Lee S, 2012, CIRC RES, V111, P778, DOI 10.1161/CIRCRESAHA.111.256859
   Lesnefsky EJ, 2006, AGEING RES REV, V5, P402, DOI 10.1016/j.arr.2006.04.001
   Liu SX, 2006, ARTERIOSCL THROM VAS, V26, P1156, DOI 10.1161/01.ATV.0000214960.85469.68
   Melgarejo E, 2009, INT J BIOCHEM CELL B, V41, P998, DOI 10.1016/j.biocel.2008.07.018
   Niu J, 2008, J BIOL CHEM, V283, P14542, DOI 10.1074/jbc.M802139200
   O'Hayre M, 2008, BIOCHEM J, V409, P635, DOI 10.1042/BJ20071493
   Pascolini D, 2012, BRIT J OPHTHALMOL, V96, P614, DOI 10.1136/bjophthalmol-2011-300539
   Patel M, 2008, SEMIN IMMUNOPATHOL, V30, P97, DOI 10.1007/s00281-008-0112-9
   Rakoczy EP, 2015, GENE AND CELL BASED
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   Sola-Villa D, 2006, KIDNEY INT, V70, P1935, DOI 10.1038/sj.ki.5001948
   Suzuki M, 2012, J CELL SCI, V125, P2407, DOI 10.1242/jcs.097683
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   Tanaka T, 2010, BIOCHEM BIOPH RES CO, V399, P677, DOI 10.1016/j.bbrc.2010.07.141
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   Wakamatsu TH, 2008, ARQ BRAS OFTALMOL, V71, P72, DOI 10.1590/S0004-27492008000700015
NR 37
TC 16
Z9 17
U1 0
U2 19
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD DEC
PY 2016
VL 254
IS 12
BP 2469
EP 2476
DI 10.1007/s00417-016-3508-6
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EC6OT
UT WOS:000388256500021
PM 27812755
DA 2022-11-30
ER

PT J
AU Zhuang, WJ
   Li, HP
   Liu, YN
   Zhao, JJ
   Ha, SP
   Xiang, W
   Bai, XW
   Li, ZL
   Han, Y
   Sheng, XL
AF Zhuang, Wenjuan
   Li, HuiPing
   Liu, Yani
   Zhao, Jingjing
   Ha, Shaoping
   Xiang, Wei
   Bai, Xuewei
   Li, Zili
   Han, Ying
   Sheng, Xunlun
TI Association of Specific Genetic Polymorphisms with Age-related Macular
   Degeneration in a Northern Chinese Population
SO OPHTHALMIC GENETICS
LA English
DT Article
DE Age-related macular degeneration; genetic polymorphisms; specific gene
ID COMPLEMENT-FACTOR-H; COMPONENT 2 C2; FACTOR-B BF; VARIANT; RISK; CFH;
   LOC387715; Y402H; C3
AB Purpose: The associations between genetic variants located in CFH, CFB, ARMS2 and HTRA1 and the risk of age-related macular degeneration (AMD) in a northern Chinese population were investigated.
   Methods: A case-control association study of 150 AMD patients and 145 ethnicity- and gender-matched controls were recruited. Genomic DNA was prepared from peripheral blood after the participants underwent comprehensive eye examinations. All individuals were genotyped for eight single nucleotide polymorphisms (SNPs) in four specific genes. Genotypic distribution was tested for Hardy-Weinberg equilibrium. Statistical analysis was performed for genotype, allele and haplotype frequencies along with their p values and corresponding odds ratios (OR), 95% confidence intervals (95% CI) and measures of linkage disequilibrium (LD). Bonferroni corrections for multiple comparisons were performed.
   Results: Among the SNPs genotyped, p values of seven SNPs were less than 0.05 in the genotypic distributions and allele frequencies between AMD and control subjects. However, after Bonferroni correction, the genotype and allele distributions of two SNPs in CFH (rs10737680, rs1410996), one SNP (rs10490924) in ARMS2 and one SNP (rs11200638) in HTRA1 differed significantly between the controls and AMD patients. Two SNPs were significantly associated with AMD in the allele distributions. They were rs800292 (p(allele) = 0.006, OR [CI] = 1.643[1.155-2.336]) in CFH and rs641153 (p(allele) = 0.002, OR [CI] = 0.273[0.120-0.620]) in CFB. Five haplotypes in CFH significantly predisposed patients to AMD after 50,000 permutations (p = 0.0099, p = 0.0099, p = 0.0013, p = 0.0414 and p = 0.0327).
   Conclusions: Gene variants in CFH, ARMS2 and HTRA1 are related to an increased risk of AMD in a northern Chinese population.
C1 [Zhuang, Wenjuan; Li, HuiPing; Liu, Yani; Ha, Shaoping; Bai, Xuewei; Li, Zili; Han, Ying; Sheng, Xunlun] Peoples Hosp Ningxia Hui Autonomous Reg, Ningxia Eye Hosp, Yinchuan 750011, Ningxia Hui Aut, Peoples R China.
   [Zhao, Jingjing] Weifang Eye Hosp, Weifang, Peoples R China.
   [Xiang, Wei] Ningxia Med Univ, Yinchuan, Peoples R China.
C3 Ningxia Medical University
RP Sheng, XL (通讯作者)，Peoples Hosp Ningxia Hui Autonomous Reg, Ningxia Eye Hosp, 936 Huang He East Rd, Yinchuan 750011, Ningxia Hui Aut, Peoples R China.
EM shengxunlun@163.com
FU National Basic Research Program of China [973 Program] [2011CB510200];
   Department of Science and Technology of Ningxia Hui Autonomous Region
   [NZ11163, 2011ZYS175]; Department of Health Bureau of Ningxia Hui
   Autonomous Region [2011011]
FX This work was supported by grants from the National Basic Research
   Program of China [973 Program; #2011CB510200], the Department of Science
   and Technology of Ningxia Hui Autonomous Region [NZ11163 and
   2011ZYS175], and the Department of Health Bureau of Ningxia Hui
   Autonomous Region (2011011).
CR Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   Chen SJ, 2008, INVEST OPHTH VIS SCI, V49, P3126, DOI 10.1167/iovs.08-1803
   Dong L, 2011, NEUROSCI LETT, V488, P283, DOI 10.1016/j.neulet.2010.11.048
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hayashi H, 2010, INVEST OPHTH VIS SCI, V51, P5914, DOI 10.1167/iovs.10-5554
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kaur I, 2010, INVEST OPHTH VIS SCI, V51, P59, DOI 10.1167/iovs.09-4135
   Khandhadia S, 2012, IMMUNOBIOLOGY, V217, P127, DOI 10.1016/j.imbio.2011.07.019
   Kim SJ, 2012, EXP EYE RES, V96, P42, DOI 10.1016/j.exer.2012.01.005
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Liu XQ, 2010, RETINA-J RET VIT DIS, V30, P1177, DOI 10.1097/IAE.0b013e3181cea676
   Lu F, 2013, INVEST OPHTH VIS SCI, V54, P2911, DOI 10.1167/iovs.12-11381
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Montes T, 2009, P NATL ACAD SCI USA, V106, P4366, DOI 10.1073/pnas.0812584106
   Munoz B, 2000, ARCH OPHTHALMOL-CHIC, V118, P819, DOI 10.1001/archopht.118.6.819
   Patel N, 2008, EYE, V22, P768, DOI 10.1038/sj.eye.6702844
   Richardson AJ, 2009, INVEST OPHTH VIS SCI, V50, P540, DOI 10.1167/iovs.08-2423
   Seitsonen SP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003833
   Sobrin L, 2011, AM J OPHTHALMOL, V151, P345, DOI 10.1016/j.ajo.2010.08.015
   Spencer KL, 2007, HUM MOL GENET, V16, P1986, DOI 10.1093/hmg/ddm146
   Tian J, 2012, INVEST OPHTH VIS SCI, V53, P4262, DOI 10.1167/iovs.11-8542
   Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406
   Xu YL, 2008, MOL VIS, V14, P1373
   Yang K, 2011, OPHTHALMOLOGY, V118, P1395, DOI 10.1016/j.ophtha.2010.12.030
   Yang ZL, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000836
   Yuan DQ, 2013, MOL VIS, V19, P374
NR 28
TC 8
Z9 8
U1 0
U2 10
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1381-6810
EI 1744-5094
J9 OPHTHALMIC GENET
JI Ophthalmic Genet.
PD SEP
PY 2014
VL 35
IS 3
BP 156
EP 161
DI 10.3109/13816810.2014.921314
PG 6
WC Genetics & Heredity; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity; Ophthalmology
GA AN3GJ
UT WOS:000340473500006
PM 24865190
DA 2022-11-30
ER

PT J
AU Mitchell, P
   Holz, FG
   Hykin, P
   Midena, E
   Souied, E
   Allmeier, H
   Lambrou, G
   Schmelter, T
   Wolf, S
AF Mitchell, Paul
   Holz, Frank G.
   Hykin, Philip
   Midena, Edoardo
   Souied, Eric
   Allmeier, Helmut
   Lambrou, George
   Schmelter, Thomas
   Wolf, Sebastian
CA ARIES Study Investigators
TI EFFICACY AND SAFETY OF INTRAVITREAL AFLIBERCEPT USING A TREAT-AND-EXTEND
   REGIMEN FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION The ARIES
   Study: A Randomized Clinical Trial
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE neovascular age-related macular degeneration; AMD; antivascular
   endothelial growth factor; aflibercept; treat-and-extend
ID ENDOTHELIAL GROWTH-FACTOR; RANIBIZUMAB; SUPPRESSION; OUTCOMES; THERAPY
AB Background/Purpose: Treating neovascular age-related macular degeneration with intravitreal aflibercept treat-and-extend (T&E) can reduce treatment burden. ARIES assessed whether intravitreal aflibercept early-start T&E was noninferior to late-start T&E.
   Methods: A randomized, open-label, Phase 3b/4 study that included treatment-naive patients aged >= 50 years with the best-corrected visual acuity 73-25 Early Treatment Diabetic Retinopathy Study letters and active choroidal neovascularization secondary to AMD. Patients received 2 mg intravitreal aflibercept at Week (W) 0, W4, W8, and W16. At W16, patients were randomized 1:1 to early-start (2W interval adjustments) or late-start T&E (8W intervals until W48 then 2W interval adjustments). Primary endpoint: the best-corrected visual acuity change from randomization to W104.
   Results: Two-hundred seventy-one patients were randomized. The mean (SD) best-corrected visual acuity at baseline was 60.2 (12.1; early-T&E) and 61.3 (10.8; late-T&E) letters. The mean (SD) best-corrected visual acuity change (W16-104) was -2.1 (11.4) versus -0.4 (8.4) letters (early-T&E vs. late-T & E; least-squares mean difference: -2.0; 95% confidence interval: -4.75 to 0.71; P = 0.0162 for noninferior); +4.3 (13.4) versus +7.9 (11.9) letters (W0-104). The mean (SD) number of injections was 12.0 (2.3) versus 13.0 (1.8). From baseline to W104, 93.4% and 96.2% maintained best-corrected visual acuity; the mean (SD) central retinal thickness change was -161.6 (135.6) mu m and -158.6 (125.1) mu m. The last injection interval (W104) was >= 12W for 47.2% and 51.9% of patients.
   Conclusion: Outcomes were similar between patients with neovascular age-related macular degeneration treated with an intravitreal aflibercept early-T&E or late-T&E regimen after initial dosing, with one injection difference over 2 years.
C1 [Mitchell, Paul] Univ Sydney, Ctr Vis Res, Westmead Inst Med Res, Dept Ophthalmol, Sydney, NSW, Australia.
   [Holz, Frank G.] Univ Bonn, Dept Ophthalmol, Bonn, Germany.
   [Hykin, Philip] Moorfields Eye Hosp, London, England.
   [Midena, Edoardo] Univ Padua, Dept Ophthalmol, Padua, Italy.
   [Souied, Eric] Hop Intercommunal Creteil, Dept Ophtalmol, Creteil, France.
   [Allmeier, Helmut; Lambrou, George] Bayer Consumer Care AG, Pharmaceut, Basel, Switzerland.
   [Schmelter, Thomas] Bayer AG, Berlin, Germany.
   [Wolf, Sebastian] Univ Bern, Univ Hosp, Dept Ophthalmol, Inselspital, Bern, Switzerland.
C3 University of Sydney; Westmead Institute for Medical Research;
   University of Bonn; University of London; University College London;
   Moorfields Eye Hospital NHS Foundation Trust; University of Padua;
   Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil; Bayer AG;
   Bayer AG; University of Bern; University Hospital of Bern
RP Mitchell, P (通讯作者)，Univ Sydney, Ophthalmol, Sydney, NSW, Australia.; Mitchell, P (通讯作者)，Westmead Inst Med Res, Ctr Vis Res, Sydney, NSW, Australia.
EM paul.mitchell@sydney.edu.au
OI Schmelter, Thomas/0000-0003-1358-3172
FU Bayer Consumer Care AG, Switzerland; Bayer HealthCare AG, Germany
FX Medical writing and editorial support for the preparation of this
   article was funded by Bayer Consumer Care AG, Switzerland. This study
   was sponsored by Bayer HealthCare AG, Germany.
CR Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Bayer, 2018, EYLEA AFLIBERCEPT SU
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Decroos FC, 2017, AM J OPHTHALMOL, V180, P142, DOI 10.1016/j.ajo.2017.06.002
   Do DV, 2017, INVEST OPHTH VIS SCI, V58
   Eleftheriadou M, 2018, OPHTHALMOL THER, V7, P361, DOI 10.1007/s40123-018-0139-5
   Fauser S, 2016, BRIT J OPHTHALMOL, V100, P1494, DOI 10.1136/bjophthalmol-2015-308264
   Fauser S, 2014, AM J OPHTHALMOL, V158, P532, DOI 10.1016/j.ajo.2014.05.025
   Freund KB, 2015, RETINA-J RET VIT DIS, V35, P1489, DOI 10.1097/IAE.0000000000000627
   Giannakaki-Zimmermann H, 2016, OPHTHALMOLOGICA, V236, P201, DOI 10.1159/000452929
   Gillies MC, 2019, JAMA OPHTHALMOL, V137, P372, DOI 10.1001/jamaophthalmol.2018.6776
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Khurana RN, 2019, AM J OPHTHALMOL, V200, P161, DOI 10.1016/j.ajo.2019.01.005
   Kim LN, 2016, RETINA-J RET VIT DIS, V36, P1418, DOI 10.1097/IAE.0000000000001142
   Lanzetta P, 2017, GRAEF ARCH CLIN EXP, V255, P1259, DOI 10.1007/s00417-017-3647-4
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Ohji M, 2020, ADV THER, V37, P1173, DOI 10.1007/s12325-020-01236-x
   Patel PJ, 2017, CLIN OPHTHALMOL, V11, P1957, DOI 10.2147/OPTH.S145732
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
NR 20
TC 17
Z9 17
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD SEP
PY 2021
VL 41
IS 9
BP 1911
EP 1920
DI 10.1097/IAE.0000000000003128
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA WN5QE
UT WOS:000711821200037
PM 33782365
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Panchmatia, HR
   Clements, KM
   Hulbert, E
   Eriksson, M
   Wittrup-Jensen, K
   Nilsson, J
   Weinstein, MC
AF Panchmatia, Hemangi R.
   Clements, Karen M.
   Hulbert, Erin
   Eriksson, Marianne
   Wittrup-Jensen, Kim
   Nilsson, Jonas
   Weinstein, Milton C.
TI Aflibercept vs. Ranibizumab: cost-effectiveness of treatment for wet
   age-related macular degeneration in Sweden
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE aflibercept; cost-effectiveness; Markov model; wAMD
AB PurposeMonthly dosing with ranibizumab (RBZ) is needed to achieve maximal visual gains in patients with neovascular (wet') age-related macular degeneration (wAMD). In Sweden, dosing is performed as needed (RBZ PRN), resulting in suboptimal efficacy. Intravitreal aflibercept (IVT-AFL) every 2months after three initial monthly doses was clinically equivalent to RBZ monthly dosing (RBZ q4) in wAMD clinical trials. We assessed the cost-effectiveness of IVT-AFL versus RBZ q4 and RBZ PRN in Sweden.
   MethodsA Markov model compared IVT-AFL to RBZ q4 or RBZ PRN over 2years. Health states were based on visual acuity in better-seeing eye; a proportion discontinued treatment monthly or upon visual acuity <20/400. Parameters were estimated from trial data, published literature or expert opinion. Analyses were performed from a societal perspective with a lifetime horizon. The model calculated costs, quality-adjusted life years (QALYs) and incremental cost-effectiveness ratios (ICERs), discounted 3% annually. Deterministic and probabilistic sensitivity analyses were performed.
   ResultsLifetime cost of IVT-AFL was 578400 SEK, compared with 565700 SEK for RBZ PRN and 686600 SEK for RBZ q4. Compared with RBZ PRN, the ICER of IVT-AFL was 27000 SEK/QALY gained. RBZ q4 cost 20.4 million SEK/QALY gained versus IVT-AFL. Results were sensitive to IVT-AFL efficacy, but IVT-AFL had a 100% probability of being cost-effective versus both RBZ PRN and RBZ q4 at a willingness-to-pay threshold of 500000 SEK.
   ConclusionResults suggest, in Sweden, at parity price level, IVT-AFL is less costly than RBZ q4, while demonstrating similar efficacy; IVT-AFL is cost-effective versus RBZ PRN.
C1 [Panchmatia, Hemangi R.; Clements, Karen M.] Optum, Waltham, MA USA.
   [Hulbert, Erin] Optum, Eden Prairie, MN USA.
   [Eriksson, Marianne] Bayer AB, Solna, Sweden.
   [Wittrup-Jensen, Kim] Bayer Pharma AG, Berlin, Germany.
   [Nilsson, Jonas] Optum, Stockholm, Sweden.
   [Weinstein, Milton C.] Harvard Sch Publ Hlth, Boston, MA USA.
   [Weinstein, Milton C.] Harvard TH Chan Sch Publ Hlth, Boston, MA USA.
   [Clements, Karen M.] Ctr Hlth Policy & Res, Boston, MA USA.
   [Nilsson, Jonas] Mapi, Stockholm, Sweden.
C3 Optum; Optum; Bayer AG; Bayer AG; Bayer Healthcare Pharmaceuticals;
   Harvard University; Harvard T.H. Chan School of Public Health; Harvard
   University; Harvard T.H. Chan School of Public Health
RP Panchmatia, HR (通讯作者)，21 Mauriello Dr, Stoneham, MA 02180 USA.
EM hemangi.panchmatia@optum.com
FU Bayer Pharma AG; Bayer
FX This study was funded by Bayer Pharma AG. Mrs. Eriksson and Dr.
   Wittrup-Jensen are employees of Bayer. Ms. Panchmatia, Ms. Hulbert, Dr.
   Nilsson, Dr. Clements and Dr. Weinstein are paid consultants to Bayer.
CR Akademiska sjukhuset, 2013, PRISL UT 2013
   Akademiska sjukhuset, 2013, PRISL VARD UT SAMT U
   Bayer, 2011, SUMMARY REPORT STUDI
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Brown A, 2008, MANAGEMENT NEOVASCUL
   Brown GC, 2007, OPHTHALMOLOGY, V114, P1170, DOI 10.1016/j.ophtha.2006.09.019
   Cruess AF, 2008, PHARMACOECONOMICS, V26, P57, DOI 10.2165/00019053-200826010-00006
   Czoski-Murray C, 2009, VALUE HEALTH, V12, P793, DOI 10.1111/j.1524-4733.2009.00527.x
   Ekman M., 2002, THESIS
   Eurostat, 2007, MORT EUR
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Halpern MT, 2006, HEALTH CARE FINANC R, V27, P37
   Hazin R, 2009, J NATL MED ASSOC, V101, P134, DOI 10.1016/S0027-9684(15)30825-7
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hjelmqvist L, 2011, J OPHTHALMOL, V2011, DOI 10.1155/2011/405724
   Hurley SF, 2008, COST EFFECT RESOUR A, V6, P1
   Joussen AM, 2009, DTSCH ARZTEBL INT, V106, P312, DOI 10.3238/arztebl.2009.0312
   Karolinska Univeristetssjukhuset, 2011, PRISL UT 2011
   Kulkarni AD, 2005, ADV DRUG DELIVER REV, V57, P1994, DOI 10.1016/j.addr.2005.09.003
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mitchell P, 2011, CURR MED RES OPIN, V27, P1465, DOI 10.1185/03007995.2011.585394
   Norrlands Universitetssjukvard Regionsjukvard/Utomlanssjukvard, 2013, PRISL AR 2013
   PATZ A, 1985, ARCH OPHTHALMOL-CHIC, V103, P1796, DOI 10.1001/archopht.1985.01050120030015
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   S:t Eriks ogonsjukhus AB, 2012, UT 2012
   Samverkansnamnden Uppsala-orebro Sjukvardsregion Region orebro Lan, 2015, PRIS VID FAKT UT 201
   SCB Statistics Sweden, 2010, STAT DAT
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Shah AR, 2007, AM J OPHTHALMOL, V143, P83, DOI 10.1016/j.ajo.2006.09.043
   Socialstyrelsen, 2009, SOC STAT
   Sodra regionvardsnamnden, 2011, REG PRIS ERS SYD SJU
   Stockholms Lans Landsting, 2012, UTOMREGIONSPRISLISTA
   Stockholms Lans Landsting, 2011, UT STOCKH GOTL REG
   Sydostrasjukvardsregionen, 2012, PRIS ERS SYD SJUKV 2
   Vastra sjukvardsregionen, 2011, UT 2015
   Westborg I, 2010, MAKULAREGISTRET RSRA
   World Health Organization, 2007, GLOB IN EL AV BLINDN
NR 38
TC 13
Z9 14
U1 0
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD AUG
PY 2016
VL 94
IS 5
BP 441
EP 448
DI 10.1111/aos.12964
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DR8IZ
UT WOS:000380142900032
PM 27061020
DA 2022-11-30
ER

PT J
AU Cheung, CMG
   Cheung, CYL
   Yang, EL
   Mitchell, P
   Wang, JJ
   Wong, TY
AF Cheung, Chui Ming Gemmy
   Cheung, Carol Yim-Lui
   Yang, Erica Liu
   Mitchell, Paul
   Wang, Jie Jin
   Wong, Tien Yin
TI Retinal Arteriolar Wall Signs and Early Age-Related Macular
   Degeneration: The Singapore Malay Eye Study
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID BLUE MOUNTAINS EYE; BEAVER DAM EYE; CHOLESTEROL-LOWERING MEDICATIONS;
   CORONARY-ARTERY-DISEASE; RISK-FACTORS; CARDIOVASCULAR-DISEASE;
   ATHEROSCLEROSIS RISK; JAPANESE POPULATION; 5-YEAR INCIDENCE; BASAL
   DEPOSITS
AB PURPOSE: To determine whether retinal arteriolar wall signs are associated with early age-related macular degeneration (AMD).
   DESIGN: Population-based cross-sectional study.
   METHODS: The Singapore Malay Eye Study (SiMES) is a population-based eye survey including 3280 (78.7% response) persons aged 40 to 80 years. Retinal arteriolar wall signs and AMD were assessed from photographs by trained technicians, according to standardized protocols. Data on major cardiovascular risk factors and blood pressure were collected.
   RESULTS: Of the 3280 participants, 2541 had photographs that were gradable for both AMD and retinal arteriolar wall signs. Early AMD was present in 76 subjects. There were no significant associations of any retinal arteriolar wall signs with early AMD. For specific AMD signs, retinal arteriolar wall opacification was associated with presence of soft distinct drusen (odds ratio [OR] 1.58, 95% confidence interval [CI]: 1.06, 2.35). This association was most significant among non-statin users (OR 1.90, 95% CI: 1.23, 2.93). Focal arteriolar narrowing was associated with retinal hypopigmentation (OR 1.67, 95% CI: 1.02, 2.73). Arteriovenous nicking was not associated with soft drusen (OR 0.89, 95% CI: 0.51, 1.57), hyperpigmentation (OR 0.49, 95% CI: 0.22, 1.08), or hypopigmentation (OR 0.86, 95% CI: 0.46, 1.61).
   CONCLUSIONS: Retinal arteriolar wall signs are not consistently associated with early AMD. We report a new association of retinal arteriolar wall opacification and the presence of soft drusen. This finding could support the hypothesis of a link between lipids and drusen formation. (Am J Ophthalmol 2011;152: 108-113. (C) 2011 by Elsevier Inc. All rights reserved.)
C1 [Cheung, Chui Ming Gemmy; Wong, Tien Yin] Singapore Natl Eye Ctr, Singapore Eye Res Inst, Singapore 168751, Singapore.
   [Mitchell, Paul] Univ Sydney, Ctr Vis Res, Sydney, NSW 2006, Australia.
   [Wang, Jie Jin; Wong, Tien Yin] Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Melbourne, Vic 3010, Australia.
   [Wong, Tien Yin] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Ophthalmol, Singapore 117595, Singapore.
C3 National University of Singapore; Singapore National Eye Center;
   University of Sydney; Centre for Eye Research Australia; Royal Victorian
   Eye & Ear Hospital; University of Melbourne; National University of
   Singapore
RP Cheung, CMG (通讯作者)，Singapore Natl Eye Ctr, Singapore Eye Res Inst, 11 3rd Hosp Ave, Singapore 168751, Singapore.
EM gemmy.cheung.c.m@snec.com.sg
RI Wang, Jie Jin/P-1499-2014; Wong, Tien Yin/AAC-9724-2020; Cheung, Carol
   Y./G-7895-2016; Mitchell, Paul/P-1498-2014; Cheung, Carol/AAF-1101-2020;
   wang, jie/GRS-0942-2022
OI Wang, Jie Jin/0000-0001-9491-4898; Wong, Tien Yin/0000-0002-8448-1264;
   Cheung, Carol/0000-0002-9672-1819; Cheung, Carol/0000-0003-0869-859X;
   Cheung, Chui Ming Gemmy/0000-0003-3358-3516
FU SINGAPORE NATIONAL MEDICAL RESEARCH COUNCIL [0796/2003, 0863/2004,
   CSI/0002/2005]; Singapore Biomedical Research Council [501/1/25-5];
   Singapore Tissue Network; Ministry of Health, Singapore; Pfizer Inc, New
   York, New York
FX PUBLICATION OF THIS ARTICLE WAS SUPPORTED BY THE SINGAPORE NATIONAL
   MEDICAL RESEARCH COUNCIL (GRANT NOS. 0796/2003, 0863/2004, and
   CSI/0002/2005), and Singapore Biomedical Research Council Grant No.
   501/1/25-5, with additional support from the Singapore Tissue Network
   and the Ministry of Health, Singapore, and Pfizer Inc, New York, New
   York. The authors indicate no financial conflicts of interest. Involved
   in design and conduct of the study (C.C., P.M., J.J.W., T.Y.W.);
   collection (G.C., E.L.), management (C.C., C.S.P.), analysis (G.C.,
   C.Y.L.C., E.L., P.M., J.J.W., T.Y.W.), and interpretation of the data
   (G.C., C.Y.L.C., E.L., P.M., J.J.W., T.Y.W.); and preparation, review,
   and approval of the manuscript (G.C., C.Y.L.C., EL., P.M., J.J.W.,
   T.Y.W.). The Ethics Committee of the Singapore Eye Research Institute
   approved the study, and its conduct followed the tenets of the
   Declaration of Helsinki. Written informed consent was obtained from all
   patients after explaining the nature of the study. The authors thank the
   staff in the Singapore Malay Eye Study for their important contributions
   in examining and interviewing patients and data entry and the
   participants for their time.
CR Cackett P, 2008, AM J OPHTHALMOL, V146, P960, DOI 10.1016/j.ajo.2008.06.026
   Curcio CA, 2005, EXP EYE RES, V81, P731, DOI 10.1016/j.exer.2005.04.012
   Dashti N, 2006, BRIT J OPHTHALMOL, V90, P1028, DOI 10.1136/bjo.2006.093856
   FARKAS TG, 1971, AM J OPHTHALMOL, V71, P1206, DOI 10.1016/0002-9394(71)90964-0
   Guymer RH, 2005, SURV OPHTHALMOL, V50, P194, DOI 10.1016/j.survophthal.2004.12.002
   Haimovici R, 2001, INVEST OPHTH VIS SCI, V42, P1592
   Hall NF, 2001, BRIT MED J, V323, P375, DOI 10.1136/bmj.323.7309.375
   Hughes A, 2009, MICROCIRCULATION, V16, P159, DOI 10.1080/10739680802353868
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Jeganathan VSE, 2008, AM J OPHTHALMOL, V146, P954, DOI 10.1016/j.ajo.2008.07.006
   Kaushik S, 2007, OPHTHALMOLOGY, V114, P113, DOI 10.1016/j.ophtha.2006.06.046
   Kawasaki R, 2008, BRIT J OPHTHALMOL, V92, P161, DOI 10.1136/bjo.2007.127449
   Klein R, 2004, AM J OPHTHALMOL, V137, P435, DOI 10.1016/j.ajo.2003.10.020
   Klein R, 2003, OPHTHALMOLOGY, V110, P636, DOI 10.1016/S0161-6420(02)01448-3
   Klein R, 1997, OPHTHALMOLOGY, V104, P1804, DOI 10.1016/S0161-6420(97)30023-2
   Klein R, 1999, ARCH OPHTHALMOL-CHIC, V117, P1203
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 2000, ARTERIOSCL THROM VAS, V20, P1644, DOI 10.1161/01.ATV.20.6.1644
   Klein R, 2007, AM J OPHTHALMOL, V144, P1, DOI 10.1016/j.ajo.2007.02.047
   Kramer H, 2004, AM J HYPERTENS, V17, P963, DOI 10.1016/j.amjhyper.2004.06.001
   Libby P, 2002, NATURE, V420, P868, DOI 10.1161/ATVBAHA.108.179705
   Liew G, 2006, OPHTHALMOLOGY, V113, P1481, DOI 10.1016/j.ophtha.2006.03.051
   Malek G, 2003, AM J PATHOL, V162, P413, DOI 10.1016/S0002-9440(10)63836-9
   McCarty CA, 2001, MED J AUSTRALIA, V175, P340, DOI 10.5694/j.1326-5377.2001.tb143604.x
   McGwin G, 2005, OPHTHALMOLOGY, V112, P488, DOI 10.1016/j.ophtha.2004.10.027
   MICHELSON EL, 1979, ARCH INTERN MED, V139, P1139, DOI 10.1001/archinte.139.10.1139
   Miyazaki M, 2003, BRIT J OPHTHALMOL, V87, P469, DOI 10.1136/bjo.87.4.469
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Patton N, 2007, INVEST OPHTH VIS SCI, V48, P1995, DOI 10.1167/iovs.06-1123
   Reynolds R, 2010, OPHTHALMOLOGY, V117, P1989, DOI 10.1016/j.ophtha.2010.07.009
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Tan JSL, 2007, AM J OPHTHALMOL, V143, P685, DOI 10.1016/j.ajo.2006.11.021
   Tedeschi-Reiner E, 2005, AM J CARDIOL, V96, P1107, DOI 10.1016/j.amjcard.2005.05.070
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   van Leeuwen R, 2004, AM J OPHTHALMOL, V137, P750, DOI 10.1016/S0002-9394(03)01089-4
   Wang JJ, 2003, HYPERTENSION, V42, P534, DOI 10.1161/01.HYP.0000090122.38230.41
   Wilson HL, 2004, AM J OPHTHALMOL, V137, P615, DOI 10.1016/j.ajo.2003.10.025
   Wong TY, 2007, AM J OPHTHALMOL, V144, P117, DOI 10.1016/j.ajo.2007.04.018
   Wong TY, 2007, OPHTHALMOLOGY, V114, P86, DOI 10.1016/j.ophtha.2006.06.039
NR 39
TC 3
Z9 3
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JUL
PY 2011
VL 152
IS 1
BP 108
EP 113
DI 10.1016/j.ajo.2011.01.012
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 789CI
UT WOS:000292490500018
PM 21570050
DA 2022-11-30
ER

PT J
AU Tao, Y
   Libondi, T
   Jonas, JB
AF Tao, Yong
   Libondi, Teodosio
   Jonas, Jost B.
TI Long-Term Follow-Up After Multiple Intravitreal Bevacizumab Injections
   for Exudative Age-Related Macular Degeneration
SO JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
LA English
DT Article
ID CHOROIDAL NEOVASCULARIZATION; AVASTIN; RANIBIZUMAB; VERTEPORFIN;
   THERAPY; EYES
AB Purpose: To analyze the long-term effect of multiple intravitreal injections of bevacizumab as therapy of exudative age-related macular degeneration (AMD).
   Methods: The retrospective clinical interventional case series study included 45 patients (48 eyes) who received intravitreal injections of bevacizumab (1.5 mg) for treatment of exudative AMD and for whom the follow-up was >2 years. All patients received an initial series of 3 injections applied in intervals of 6-8 weeks. Subsequent injections were given in intervals ranging between 2 and 6 months. The mean number of all injections performed per eye was 8.6 +/- 2.5. The mean follow-up was 27.8 +/- 3.6 months. The main outcome parameters were best-corrected visual acuity (BCVA) and foveal thickness measurements by optical coherence tomography (OCT).
   Results: Mean BCVA improved from 0.62 +/- 0.30 LogMAR at baseline to 0.55 +/- 0.28 LogMAR (P = 0.03) at 1 month after the 3 initial injections. At the end of follow-up, BCVA decreased significantly (P = 0.02) to 0.76 +/- 0.41 LogMAR. Bivariate correlation tests showed that the change in BCVA from baseline to the final examination at the end of follow-up was significantly associated only with the baseline BCVA (correlation coefficient r = 0.39, P = 0.006). The height of the subretinal fluid reduced significantly (P = 0.004) at 1 month after the 3 initial injections and remained so till the final follow-up (P = 0.01).
   Conclusions: Multiple intravitreal bevacizumab injections initially led to an improvement in visual acuity, finally, however, failed to stabilize visual acuity after a follow-up of >2 years.
C1 [Tao, Yong; Libondi, Teodosio; Jonas, Jost B.] Heidelberg Univ, Med Fac Mannheim, Dept Ophthalmol, Heidelberg, Germany.
   [Tao, Yong] Peking Univ, Peoples Hosp, Dept Ophthalmol, Beijing 100871, Peoples R China.
   [Libondi, Teodosio] Univ Naples Federico II, Dept Ophthalmol 2, I-80138 Naples, Italy.
C3 Ruprecht Karls University Heidelberg; Peking University; University of
   Naples Federico II
RP Jonas, JB (通讯作者)，Univ Mannheim, Augenklin, Theodor Kutzer Ufer 1-3, D-68167 Mannheim, Germany.
EM Jost.Jonas@augen.ma.uni-heidelberg.de
OI Tao, Yong/0000-0003-1443-2667
FU Zeiss-Meditec Co.; Heidelberg Engineering Co.; German Academic Exchange
   Service (DAAD)
FX Proprietary interest: J.B.J. is a member of the advisory board for
   Posurdex<SUP>R</SUP> (Allergan Co.), and of advisory boards of MSD Co.
   and Pfizer Co.; he received lecture fees and grants from Zeiss-Meditec
   Co., and Heidelberg Engineering Co.; Funding: The work of Y.T. was
   supported by the K. C. Wong Fellowship from the German Academic Exchange
   Service (DAAD).
CR Algvere PV, 2008, ACTA OPHTHALMOL, V86, P482, DOI 10.1111/j.1600-0420.2007.01113.x
   Arias L, 2008, BRIT J OPHTHALMOL, V92, P1636, DOI 10.1136/bjo.2008.141721
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Azad RV, 2008, JPN J OPHTHALMOL, V52, P52, DOI 10.1007/s10384-007-0496-4
   Bashshur ZF, 2008, AM J OPHTHALMOL, V145, P249, DOI 10.1016/j.ajo.2007.09.031
   Bashshur ZF, 2006, AM J OPHTHALMOL, V142, P1, DOI 10.1016/j.ajo.2006.02.037
   Bashshur ZF, 2009, AM J OPHTHALMOL, V148, P59, DOI 10.1016/j.ajo.2009.02.006
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chen CY, 2007, AM J OPHTHALMOL, V143, P510, DOI 10.1016/j.ajo.2006.10.004
   Cleary CA, 2008, EYE, V22, P82, DOI 10.1038/sj.eye.6702936
   Emerson MV, 2007, RETINA-J RET VIT DIS, V27, P439, DOI 10.1097/IAE.0b013e31804b3e15
   Fong KCS, 2008, CLIN EXP OPHTHALMOL, V36, P748, DOI 10.1111/j.1442-9071.2008.01873.x
   Forooghian F, 2009, RETINA-J RET VIT DIS, V29, P723, DOI 10.1097/IAE.0b013e3181a2c1c3
   Goff MJ, 2007, RETINA-J RET VIT DIS, V27, P432, DOI 10.1097/IAE.0b013e318042b53f
   Goverdhan SV, 2008, BRIT J OPHTHALMOL, V92, P210, DOI 10.1136/bjo.2007.127902
   Holladay JT, 2004, J CATARACT REFR SURG, V30, P287, DOI 10.1016/j.jcrs.2004.01.014
   Ip MS, 2008, OPHTHALMOLOGY, V115, P1837, DOI 10.1016/j.ophtha.2008.08.012
   Jonas JB, 2009, OPHTHALMIC RES, V41, P21, DOI 10.1159/000162113
   Jonas JB, 2007, ACTA OPHTHALMOL SCAN, V85, P563, DOI 10.1111/j.1600-0420.2007.00891.x
   Melamud A, 2008, AM J OPHTHALMOL, V146, P91, DOI 10.1016/j.ajo.2008.03.014
   PandaJonas S, 1996, AM J OPHTHALMOL, V121, P181, DOI 10.1016/S0002-9394(14)70583-5
   PandaJonas S, 1995, OPHTHALMOLOGY, V102, P1853, DOI 10.1016/S0161-6420(95)30784-1
   Pedersen R, 2007, ACTA OPHTHALMOL SCAN, V85, P526, DOI 10.1111/j.1600-0420.2007.00895.x
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Shah AR, 2009, BRIT J OPHTHALMOL, V93, P1027, DOI 10.1136/bjo.2008.149674
   Stifter E, 2007, AM J OPHTHALMOL, V144, P886, DOI 10.1016/j.ajo.2007.07.034
   Theodossiadis PG, 2007, EUR J OPHTHALMOL, V17, P853, DOI 10.1177/112067210701700528
NR 29
TC 13
Z9 13
U1 0
U2 1
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1080-7683
EI 1557-7732
J9 J OCUL PHARMACOL TH
JI J. Ocular Pharmacol. Ther.
PD FEB
PY 2010
VL 26
IS 1
BP 79
EP 83
DI 10.1089/jop.2009.0095
PG 5
WC Ophthalmology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Pharmacology & Pharmacy
GA 562JT
UT WOS:000275047000010
PM 20148662
DA 2022-11-30
ER

PT J
AU Bashshur, ZF
   Haddad, ZA
   Schakal, A
   Jaafar, RF
   Saab, M
   Noureddin, BN
AF Bashshur, Ziad F.
   Haddad, Zeina A.
   Schakal, Alexandre
   Jaafar, Rola F.
   Saab, Marc
   Noureddin, Baha' N.
TI Intravitreal bevacizumab for treatment of neovascular age-related
   macular degeneration: A one-year prospective study
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID ANTI-VEGF ANTIBODY; SUBFOVEAL CHOROIDAL NEOVASCULARIZATION;
   MONOCLONAL-ANTIBODY; RANIBIZUMAB; INJECTION; THERAPY; AVASTIN; SAFETY;
   VERTEPORFIN; PENETRATION
AB PURPOSE: To investigate the efficacy of intravitreal bevacizumab for treatment of neovascular age-related macular degeneration (AMD).
   DESIGN: Prospective, open,label, nonrandomized clinical study.
   METHODS: Sixty patients (60 eyes) with subfoveal choroidal neovascular membrane (CNV) attributable to AMD participated in this study at the American University of Beirut and Hotel Dieu de France Retina Clinics. All lesion types were included except for retinal angiomatous proliferation. In the initial treatment phase, intravitreal bevacizurnab (2.5 mg/0.1 ml) was given at baseline, and then two additional monthly injections were given if the macula was not dry on optical coherence tomography. The criteria for re,injection after the induction phase were presence of new fluid in the macula, increased central retinal thickness (CRT) at least 100 mu m, loss of at least five letters of vision with increased fluid in the macula, new classic CNV or new macular hemorrhages. Main outcome measure was the proportion of eyes losing < 15 letters of vision after 12 months.
   RESULTS: Fifty,one patients (51 eyes) completed the 12 months. Mean visual acuity improved from 45.7 letters at baseline to 53.1 letters at 12 months (P = .004), and 47 eyes (92.2%) lost < 15 letters. Mean CRT decreased from 327.4 mu m at baseline to 227.8 mu m at 12 months W <.001). A mean of 3.4 injections were given over the course of the study, and no ocular or systemic side effects were noted.
   CONCLUSION: Eyes with neovascular AMD treated with intravitreal bevacizumab over 12 months had significant anatomical and functional improvement. Further studies need to confirm the long-term efficacy of this treatment.
C1 [Bashshur, Ziad F.; Haddad, Zeina A.; Jaafar, Rola F.; Noureddin, Baha' N.] Amer Univ Beirut, Med Ctr, Dept Ophthalmol, Beirut, Lebanon.
   [Schakal, Alexandre; Saab, Marc] St Josephs Univ, Dept Ophthalmol, Hotel Dieu, Beirut, Lebanon.
C3 American University of Beirut; American University of Beirut; Saint
   Joseph University Beirut
RP Bashshur, ZF (通讯作者)，Amer Univ Beirut, Med Ctr, Dept Ophthalmol, POB 11-0236-B11, Beirut, Lebanon.
EM zb00@aub.edu.lb
RI Jaafar, Rola F/X-9979-2018; Jaafar, Rola/AFB-0063-2022
OI Jaafar, Rola F/0000-0001-9477-7678; 
CR Barolsky P, 2004, SOURCE-NOTE HIST ART, V23, P32, DOI 10.1086/sou.23.3.23206849
   Bashshur ZF, 2006, AM J OPHTHALMOL, V142, P1, DOI 10.1016/j.ajo.2006.02.037
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1307
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chen Y, 1999, J MOL BIOL, V293, P865, DOI 10.1006/jmbi.1999.3192
   Costa RA, 2006, INVEST OPHTH VIS SCI, V47, P4569, DOI 10.1167/iovs.06-0433
   Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Fish G, 2003, OPHTHALMOLOGY, V110, P979, DOI 10.1016/S0161-6420(03)00085-X
   Fung AE, 2006, BRIT J OPHTHALMOL, V90, P1344, DOI 10.1136/bjo.2006.099598
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Grunewald M, 2006, CELL, V124, P175, DOI 10.1016/j.cell.2005.10.036
   Heiduschka P, 2007, INVEST OPHTH VIS SCI, V48, P2814, DOI 10.1167/iovs.06-1171
   Heier JS, 2006, OPHTHALMOLOGY, V113, P633, DOI 10.1016/j.ophtha.2005.10.052
   Iriyama A, 2007, BRIT J OPHTHALMOL, V91, P1230, DOI 10.1136/bjo.2007.117309
   Mordenti J, 1999, TOXICOL SCI, V52, P101, DOI 10.1093/toxsci/52.1.101
   MOSHFEGHI AA, 2006, OPHTHALMOLOGY, P113
   Ng EWM, 2005, CAN J OPHTHALMOL, V40, P352, DOI 10.1016/S0008-4182(05)80078-X
   Presta LG, 1997, CANCER RES, V57, P4593
   Ravetch JV, 2001, ANNU REV IMMUNOL, V19, P275, DOI 10.1146/annurev.immunol.19.1.275
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Rosenfeld Philip J, 2006, Ophthalmol Clin North Am, V19, P361
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2006, AM J OPHTHALMOL, V142, P141, DOI 10.1016/j.ajo.2006.03.036
   Rosenfeld PJ, 2005, OPHTHALMOLOGY, V112, P1048, DOI 10.1016/j.ophtha.2005.01.043
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Shahar J, 2006, RETINA-J RET VIT DIS, V26, P262, DOI 10.1097/00006982-200603000-00002
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   van Wijngaarden P, 2005, JAMA-J AM MED ASSOC, V293, P1509, DOI 10.1001/jama.293.12.1509
   Wang Yaning, 2004, Angiogenesis, V7, P335, DOI 10.1007/s10456-004-8272-2
NR 32
TC 148
Z9 160
U1 0
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD FEB
PY 2008
VL 145
IS 2
BP 249
EP 256
DI 10.1016/j.ajo.2007.09.031
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 263GG
UT WOS:000253205000012
PM 18067876
DA 2022-11-30
ER

PT J
AU Parameswaran, S
   Balasubramanian, S
   Babai, N
   Qiu, F
   Eudy, JD
   Thoreson, WB
   Ahmad, I
AF Parameswaran, Sowmya
   Balasubramanian, Sudha
   Babai, Norbert
   Qiu, Fang
   Eudy, James D.
   Thoreson, Wallace B.
   Ahmad, Iqbal
TI Induced Pluripotent Stem Cells Generate Both Retinal Ganglion Cells and
   Photoreceptors: Therapeutic Implications in Degenerative Changes in
   Glaucoma and Age-Related Macular Degeneration
SO STEM CELLS
LA English
DT Article
DE Induced pluripotent stem cells; Retinal ganglion cell; Rod
   photoreceptors; Cone photoreceptors; Retina; Stem cells
ID IN-VITRO; PROGENITOR CELLS; DIFFERENTIATION; TRANSPLANTATION; NEURONS;
   ROD; PROMOTES; MOUSE; PROLIFERATION; FIBROBLASTS
AB The direct reprogramming of somatic cells to a pluripotent state holds significant implications for treating intractable degenerative diseases by ex vivo cell therapy. In addition, the reprogrammed cells can serve as a model for diseases and the discovery of drugs and genes. Here, we demonstrate that mouse fibroblast induced pluripotent stem cells (iPSCs) represent a renewable and robust source of retinal progenitors, capable of generating a wide range of retinal cell types that includes retinal ganglion cells (RGCs), cone, and rod photoreceptors. They respond to simulated microenvironment of early and late retinal histogenesis by differentiating into stage-specific retinal cell types through the recruitment of normal mechanisms. The depth of the retinal potential of iPSCs suggests that they may be used to formulate stem cell approaches to understand and treat a wide range of retinal degenerative diseases from glaucoma to age-related macular degeneration (AMD). STEM CELLS 2010;28:695-703
C1 [Parameswaran, Sowmya; Balasubramanian, Sudha; Babai, Norbert; Thoreson, Wallace B.; Ahmad, Iqbal] Univ Nebraska Med Ctr, Dept Ophthalmol & Visual Sci, Omaha, NE 68198 USA.
   [Qiu, Fang] Univ Nebraska Med Ctr, Dept Biostat, Coll Publ Hlth, Omaha, NE 68198 USA.
   [Eudy, James D.] Univ Nebraska Med Ctr, Dept Genet Cell Biol & Anat, Omaha, NE 68198 USA.
C3 University of Nebraska System; University of Nebraska Medical Center;
   University of Nebraska System; University of Nebraska Medical Center;
   University of Nebraska System; University of Nebraska Medical Center
RP Ahmad, I (通讯作者)，Univ Nebraska Med Ctr, Dept Ophthalmol & Visual Sci, Omaha, NE 68198 USA.
EM iahmad@unmc.edu
RI Sowmya, Parameswaran/GZK-8635-2022; Babai, Norbert/T-2952-2019;
   Thoreson, Wallace B./F-6172-2010
OI Thoreson, Wallace B./0000-0001-7104-042X
FU Lincy Foundation; Pearson Foundation; Nebraska Department of Health and
   Human Services; Research to Prevent Blindness
FX We thank Dr. Shinya Yamanaka for providing mouse fibroblast iPSCs, Dr.
   Anand Swaroop for Nrl antibody, Dr. Rakesh Singh for cleaved caspase-3
   antibody, and Fariha Ahmed for technical help. This research was
   supported by the Lincy Foundation, the Pearson Foundation, the Nebraska
   Department of Health and Human Services, and Research to Prevent
   Blindness.
CR Abmad I, 2001, INVEST OPHTH VIS SCI, V42, P2743
   Ahmad I, 2004, SEMIN CELL DEV BIOL, V15, P53, DOI 10.1016/j.semcdb.2003.09.003
   ALTSHULER D, 1993, DEVELOPMENT, V119, P1317
   ANCHAN RM, 1991, NEURON, V6, P923, DOI 10.1016/0896-6273(91)90233-P
   Balasubramanian S, 2009, STEM CELLS, V27, P3053, DOI 10.1002/stem.242
   Bolstad BM, 2005, STAT BIOL HEALTH, P13
   Brustle O, 1999, SCIENCE, V285, P754, DOI 10.1126/science.285.5428.754
   Cepko CL, 1996, P NATL ACAD SCI USA, V93, P589, DOI 10.1073/pnas.93.2.589
   Chacko DM, 2003, VISION RES, V43, P937, DOI 10.1016/S0042-6989(02)00688-0
   Chacko DM, 2000, BIOCHEM BIOPH RES CO, V268, P842, DOI 10.1006/bbrc.2000.2153
   Chen SM, 1997, NEURON, V19, P1017, DOI 10.1016/S0896-6273(00)80394-3
   Chow RL, 2001, ANNU REV CELL DEV BI, V17, P255, DOI 10.1146/annurev.cellbio.17.1.255
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Das Ani M, 2005, Semin Ophthalmol, V20, P3, DOI 10.1080/08820530590921882
   Das AV, 2005, NEURAL DEV STEM CELL, P235
   Gissel Cornelia, 2006, V330, P191
   Hegde GV, 2007, EXP EYE RES, V84, P577, DOI 10.1016/j.exer.2006.11.012
   Hirami Y, 2009, NEUROSCI LETT, V458, P126, DOI 10.1016/j.neulet.2009.04.035
   Ikeda H, 2005, P NATL ACAD SCI USA, V102, P11331, DOI 10.1073/pnas.0500010102
   James J, 2003, J NEUROSCI, V23, P8193
   Karumbayaram S, 2009, STEM CELLS, V27, P806, DOI 10.1002/stem.31
   KELLEY MW, 1995, INVEST OPHTH VIS SCI, V36, P1280
   KELLEY MW, 1994, DEVELOPMENT, V120, P2091
   Kelley MW, 1999, NEUROREPORT, V10, P2389, DOI 10.1097/00001756-199908020-00031
   Kerrigan LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P1031, DOI 10.1001/archopht.1997.01100160201010
   Klassen HJ, 2004, INVEST OPHTH VIS SCI, V45, P4167, DOI 10.1167/iovs.04-0511
   Lamba DA, 2006, P NATL ACAD SCI USA, V103, P12769, DOI 10.1073/pnas.0601990103
   Lamba DA, 2009, CELL STEM CELL, V4, P73, DOI 10.1016/j.stem.2008.10.015
   LI ZY, 1995, OPHTHALMOLOGY, V102, P805, DOI 10.1016/S0161-6420(95)30953-0
   LUND RD, 1995, J COMP NEUROL, V356, P481, DOI 10.1002/cne.903560313
   MacLaren RE, 2006, NATURE, V444, P203, DOI 10.1038/nature05161
   MCLOON LK, 1981, BRAIN RES, V226, P15
   MCLOON SC, 1980, BRAIN RES, V197, P491, DOI 10.1016/0006-8993(80)91134-8
   Mears AJ, 2001, NAT GENET, V29, P447, DOI 10.1038/ng774
   Meyer JS, 2009, P NATL ACAD SCI USA, V106, P16698, DOI 10.1073/pnas.0905245106
   Mu XQ, 2004, SEMIN CELL DEV BIOL, V15, P115, DOI 10.1016/j.semcdb.2003.09.009
   Nishikawa S, 2008, NAT REV MOL CELL BIO, V9, P725, DOI 10.1038/nrm2466
   Okabe S, 1996, MECH DEVELOP, V59, P89, DOI 10.1016/0925-4773(96)00572-2
   Okita K, 2007, NATURE, V448, P313, DOI 10.1038/nature05934
   Osakada F, 2008, NAT BIOTECHNOL, V26, P215, DOI 10.1038/nbt1384
   Osakada F, 2009, J CELL SCI, V122, P3169, DOI 10.1242/jcs.050393
   Qiu GT, 2005, EXP EYE RES, V80, P515, DOI 10.1016/j.exer.2004.11.001
   QUIGLEY HA, 1995, INVEST OPHTH VIS SCI, V36, P774
   Rapaport DH, 2004, J COMP NEUROL, V474, P304, DOI 10.1002/cne.20134
   Sidman RL, 1961, STRUCTURE EYE, P487
   STONE JL, 1992, ARCH OPHTHALMOL-CHIC, V110, P1634, DOI 10.1001/archopht.1992.01080230134038
   WATANABE T, 1990, NEURON, V4, P461, DOI 10.1016/0896-6273(90)90058-N
   Wernig M, 2008, P NATL ACAD SCI USA, V105, P5856, DOI 10.1073/pnas.0801677105
   Yamanaka S, 2008, CELL PROLIFERAT, V41, P51, DOI 10.1111/j.1365-2184.2008.00493.x
   YOUNG RW, 1985, ANAT REC, V212, P199, DOI 10.1002/ar.1092120215
   Zhao X, 2002, BIOCHEM BIOPH RES CO, V297, P177, DOI 10.1016/S0006-291X(02)02126-5
   Zhao Xing, 2006, V330, P401
NR 52
TC 88
Z9 98
U1 0
U2 16
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1066-5099
EI 1549-4918
J9 STEM CELLS
JI Stem Cells
PD APR
PY 2010
VL 28
IS 4
BP 695
EP 703
DI 10.1002/stem.320
PG 9
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology;
   Oncology; Cell Biology; Hematology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology
GA 588SY
UT WOS:000277095400008
PM 20166150
OA Bronze
DA 2022-11-30
ER

PT J
AU Jackson, GR
   Owsley, C
   Curcio, CA
AF Jackson, GR
   Owsley, C
   Curcio, CA
TI Photoreceptor degeneration and dysfunction in aging and age-related
   maculopathy
SO AGEING RESEARCH REVIEWS
LA English
DT Review
DE rods; cones; age-related maculopathy; dark adaptation; photopic
   sensitivity; retinoid deficiency
ID VITAMIN-A; BRUCHS-MEMBRANE; MACULAR DEGENERATION; DARK-ADAPTATION;
   RETINOID COMPONENT; RHODOPSIN LEVELS; GRADING SYSTEM; VISUAL PIGMENT;
   MOUSE MODEL; RPE CELLS
AB The relative rate of rod and cone degeneration is a fundamental characteristic of any disorder affecting photoreceptors, including aging and age-related maculopathy (ARM). The human macula consists of a small cone-dominated fovea surrounded by a rod-dominated parafovea. In aging and early ARM, rods degenerate before cones, a decline in scotopic (rod-mediated) sensitivity is more prominent than a decline in photopic (cone-mediated) sensitivity, and the time course of dark adaptation of rods slows dramatically. The topography of rod dysfunction and loss in early ARM matches the location of pathology in the retinal pigment epithelium (RPE)/Bruch's membrane complex visible in the ocular fundus. Rod dysfunction and loss in aging and ARM may be due to retinoid deficiency at the level of the photoreceptors cause by impaired retinoid translocation across the RPE/Bruch's membrane complex, a hypothesis deserving of further investigation. (C) 2002 Elsevier Science Ireland Ltd. All rights reserved.
C1 Univ Alabama Birmingham, Sch Med, Dept Ophthalmol, Birmingham, AL 35294 USA.
C3 University of Alabama System; University of Alabama Birmingham
RP Curcio, CA (通讯作者)，Univ Alabama Birmingham, Sch Med, Dept Ophthalmol, Birmingham, AL 35294 USA.
EM curcio@uab.edu
FU NEI NIH HHS [EY06109] Funding Source: Medline; NIA NIH HHS [R01-AG04212]
   Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG004212]
   Funding Source: NIH RePORTER
CR *AG REL EYE DIS ST, 2002, ARCH OPHTHALMOL-CHIC, V119, P1417
   Anderson DH, 2001, AM J OPHTHALMOL, V131, P767, DOI 10.1016/S0002-9394(00)00961-2
   Ball K, 1998, ACCIDENT ANAL PREV, V30, P313, DOI 10.1016/S0001-4575(97)00102-4
   Barlow H. B., 1972, HDB SENSORY PHYSL, P1
   Beatty S, 1999, BRIT J OPHTHALMOL, V83, P867, DOI 10.1136/bjo.83.7.867
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BRESSLER NM, 1994, RETINA-J RET VIT DIS, V14, P130, DOI 10.1097/00006982-199414020-00006
   Bressler NM, 2000, INVEST OPHTH VIS SCI, V41, P624
   BRIDGES CDB, 1982, INVEST OPHTH VIS SCI, V22, P706
   BROWN B, 1986, OPHTHAL PHYSL OPT, V6, P81, DOI 10.1111/j.1475-1313.1986.tb00704.x
   CARTERDAWSON L, 1979, INVEST OPHTH VIS SCI, V18, P437
   Ciulla TA, 1998, SURV OPHTHALMOL, V43, P134, DOI 10.1016/S0039-6257(98)00014-9
   COUNCIL NAE, 1998, VISION RES NATL PLAN
   Crabtree DV, 1997, EXP EYE RES, V64, P455, DOI 10.1006/exer.1996.0237
   CURCIO CA, 1993, INVEST OPHTH VIS SCI, V34, P3278
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   Curcio CA, 1998, INVEST OPHTH VIS SCI, V39, P1085
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   CURCIO CA, 1990, J COMP NEUROL, V292, P497, DOI 10.1002/cne.902920402
   Curcio CA, 2000, OPHTHALMOLOGY, V107, P334, DOI 10.1016/S0161-6420(99)00037-8
   CURCIO CA, 2001, INVEST OPHTHALMOL VI, V42
   Delori FC, 2000, INVEST OPHTH VIS SCI, V41, P496
   Delori FC, 2001, INVEST OPHTH VIS SCI, V42, P1855
   DOWLING JE, 1958, P NATL ACAD SCI USA, V44, P648, DOI 10.1073/pnas.44.7.648
   ELDRED GE, 1998, RETINAL PIGMENT EPIT, P651
   FEENEYBURNS L, 1985, AM J OPHTHALMOL, V100, P686, DOI 10.1016/0002-9394(85)90625-7
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Haig C, 1938, SCIENCE, V87, P534, DOI 10.1126/science.87.2267.534-a
   Haimovici R, 2001, INVEST OPHTH VIS SCI, V42, P1592
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   Holz FG, 1999, INVEST OPHTH VIS SCI, V40, P737
   Hussain AA, 2002, J OPT SOC AM A, V19, P166, DOI 10.1364/JOSAA.19.000166
   Jackson GR, 1999, VISION RES, V39, P3975, DOI 10.1016/S0042-6989(99)00092-9
   Jackson GR, 1998, VISION RES, V38, P3655, DOI 10.1016/S0042-6989(98)00044-3
   Jackson GR, 2000, VISION RES, V40, P2467, DOI 10.1016/S0042-6989(00)00108-5
   JACOBSON SG, 1986, OPHTHALMOLOGY, V93, P1604
   JACOBSON SG, 1995, NAT GENET, V11, P27, DOI 10.1038/ng0995-27
   KARWATOWSKI WSS, 1995, BRIT J OPHTHALMOL, V79, P944, DOI 10.1136/bjo.79.10.944
   KATZ ML, 1991, INVEST OPHTH VIS SCI, V32, P1968
   KATZ ML, 1987, EXP EYE RES, V44, P939, DOI 10.1016/S0014-4835(87)80055-6
   KATZ ML, 1993, EXP EYE RES, V57, P393, DOI 10.1006/exer.1993.1140
   KEMP CM, 1988, EXP EYE RES, V46, P185, DOI 10.1016/S0014-4835(88)80076-9
   KEMP CM, 1989, EXP EYE RES, V49, P49
   Kim RY, 1997, AM J OPHTHALMOL, V123, P619, DOI 10.1016/S0002-9394(14)71074-8
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   KOSNIK W, 1988, J GERONTOL, V43, pP63, DOI 10.1093/geronj/43.3.P63
   Kuntz CA, 1996, INVEST OPHTH VIS SCI, V37, P1772
   LAMB TD, 1981, VISION RES, V21, P1773, DOI 10.1016/0042-6989(81)90211-X
   LAMB TD, 1980, NATURE, V287, P349, DOI 10.1038/287349a0
   LAMB TD, 1998, J PHYSL, V506, P88
   LAVAIL MM, 1981, INVEST OPHTH VIS SCI, V21, P638
   Leibrock CS, 1998, EYE, V12, P511, DOI 10.1038/eye.1998.139
   Li TS, 1998, P NATL ACAD SCI USA, V95, P11933, DOI 10.1073/pnas.95.20.11933
   Marshall J., 1998, RETINAL PIGMENT EPIT, P669
   Mata NL, 2001, INVEST OPHTH VIS SCI, V42, P1685
   McBee JK, 2001, PROG RETIN EYE RES, V20, P469, DOI 10.1016/S1350-9462(01)00002-7
   Medeiros NE, 2001, INVEST OPHTH VIS SCI, V42, P795
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Mohand-Said S, 1998, P NATL ACAD SCI USA, V95, P8357, DOI 10.1073/pnas.95.14.8357
   MOORE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1290
   Moore DJ, 2001, INVEST OPHTH VIS SCI, V42, P2970
   Owsley C, 2000, INVEST OPHTH VIS SCI, V41, P267
   Owsley C, 2001, OPHTHALMOLOGY, V108, P1196, DOI 10.1016/S0161-6420(01)00580-2
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   Redmond TM, 1998, NAT GENET, V20, P344, DOI 10.1038/3813
   Saari JC, 2000, INVEST OPHTH VIS SCI, V41, P337
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Schutt F, 2000, INVEST OPHTH VIS SCI, V41, P2303
   SCILLEY K, 2002, IN PRESS OPHTHALMOLO
   Seeliger MW, 1999, INVEST OPHTH VIS SCI, V40, P3
   Seeliger MW, 2001, NAT GENET, V29, P70, DOI 10.1038/ng712
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   SNODDERLY DM, 1995, AM J CLIN NUTR, V62, P1448
   Spraul CW, 1997, ARCH OPHTHALMOL-CHIC, V115, P267, DOI 10.1001/archopht.1997.01100150269022
   Starita C, 1997, INVEST OPHTH VIS SCI, V38, P762
   STEINMETZ RL, 1993, BRIT J OPHTHALMOL, V77, P549, DOI 10.1136/bjo.77.9.549
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   Stone EM, 2001, HUM MOL GENET, V10, P2285, DOI 10.1093/hmg/10.20.2285
   Suter M, 2000, J BIOL CHEM, V275, P39625, DOI 10.1074/jbc.M007049200
   Van Hooser JP, 2000, P NATL ACAD SCI USA, V97, P8623, DOI 10.1073/pnas.150236297
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Wang Q, 1996, INVEST OPHTH VIS SCI, V37, P2234
   Weeks DE, 2001, AM J OPHTHALMOL, V132, P682, DOI 10.1016/S0002-9394(01)01214-4
   WERNER JS, 1987, VISION RES, V27, P257, DOI 10.1016/0042-6989(87)90188-X
NR 89
TC 232
Z9 238
U1 2
U2 25
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 1568-1637
EI 1872-9649
J9 AGEING RES REV
JI Ageing Res. Rev.
PD JUN
PY 2002
VL 1
IS 3
BP 381
EP 396
AR PII S1568-1637(02)00007-7
DI 10.1016/S1568-1637(02)00007-7
PG 16
WC Cell Biology; Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Geriatrics & Gerontology
GA 603AP
UT WOS:000178536900006
PM 12067593
DA 2022-11-30
ER

PT J
AU Xin, G
   Zhang, M
   Zhong, ZH
   Tang, L
   Feng, YL
   Wei, ZL
   Li, SY
   Li, YP
   Zhang, JH
   Zhang, BL
   Zhang, M
   Rowell, N
   Chen, Z
   Niu, H
   Yu, K
   Huang, W
AF Xin, Guang
   Zhang, Ming
   Zhong, Zhihui
   Tang, Li
   Feng, Yuliang
   Wei, Zeliang
   Li, Shiyi
   Li, Youping
   Zhang, Junhua
   Zhang, Boli
   Zhang, Meng
   Rowell, Nelson
   Chen, Zhen
   Niu, Hai
   Yu, Kui
   Huang, Wen
TI Ophthalmic Drops with Nanoparticles Derived from a Natural Product for
   Treating Age-Related Macular Degeneration
SO ACS APPLIED MATERIALS & INTERFACES
LA English
DT Article
DE ophthalmic (eye) drops; age-related macular degeneration (AMD); natural
   product derivative; self-assembled nanoparticles; calcium alginate
   hydrogel
ID DRUG-DELIVERY SYSTEM; AMINOCAPROIC ACID; AMYLOID-BETA; AUTOPHAGY; MODEL;
   EYE; PERMEABILITY; ERP57/GRP58; INHIBITOR; DIOSGENIN
AB There is a continuing, urgent need for an ophthalmic (eye) drop for the clinical therapy of age-related macular degeneration (AMD), a leading cause of blindness. Here, we report the first formulation of an eye drop that is effective via autophagy for AMD treatment. This eye drop is based on a single natural product derivative (ACD), which is an amphiphilic molecule containing a 6-aminohexanoate group (H2N(CH2)(5)COO-). We demonstrate that this eye drop reverses the abnormal angiogenesis induced in a primate model of AMD that has the pathological characteristics close to that of human AMD. The ACD molecule was self-assembled in an aqueous environment leading to nanoparticles (NPs) about 9.0 nm in diameter. These NPs were encapsulated in calcium alginate hydrogel. The resulting eye drop effectively slowed the release of ACD and displayed extended release periods in both simulated blood (pH 7.4) and inflammatory (pH 5.2) environments. We show that the eye drop penetrated both the corneal and blood-eye barriers and reached the fundus. With low cellular toxicity, the drop targeted S1,25D(3)-membrane-associated rapid response steroid-binding protein (1,25D(3)-MARRS) promoting autophagy in a dose-dependent manner. In addition, the drop inhibited cell migration and tubular formation. On the other hand, when protein 1,25D(3)-MARRS was knocked down, the eye drop did not exhibit such inhibition functionalities. Our study indicates that the 6-aminohexanoate group on self-assembled NPs encapsulated in hydrogel leads to the positive in vivo outcomes. The present formulation offers a promising approach for clinical treatment of human AMD.
C1 [Xin, Guang; Zhong, Zhihui; Wei, Zeliang; Li, Shiyi; Li, Youping; Chen, Zhen; Huang, Wen] Sichuan Univ, West China Hosp, West China Sch Med, Lab Ethnopharmacol, Chengdu 610041, Sichuan, Peoples R China.
   [Zhang, Ming; Tang, Li; Feng, Yuliang] Sichuan Univ, West China Hosp, West China Sch Med, Dept Ophthalmol, Chengdu 610041, Sichuan, Peoples R China.
   [Zhang, Junhua; Zhang, Boli] Tianjin Univ Tradit Chinese Med, Tianjin 300193, Peoples R China.
   [Zhang, Meng] Sichuan Univ, Inst Atom & Mol Phys, Chengdu 610065, Sichuan, Peoples R China.
   [Rowell, Nelson] Natl Res Council Canada, Metrol Res Ctr, Ottawa, ON K1A 0R6, Canada.
   [Niu, Hai] Sichuan Univ, Coll Math, Chengdu 610065, Sichuan, Peoples R China.
   [Yu, Kui] Sichuan Univ, Engn Res Ctr Biomat, Chengdu 610065, Sichuan, Peoples R China.
C3 Sichuan University; Sichuan University; Tianjin University of
   Traditional Chinese Medicine; Sichuan University; National Research
   Council Canada; Sichuan University; Sichuan University
RP Huang, W (通讯作者)，Sichuan Univ, West China Hosp, West China Sch Med, Lab Ethnopharmacol, Chengdu 610041, Sichuan, Peoples R China.; Niu, H (通讯作者)，Sichuan Univ, Coll Math, Chengdu 610065, Sichuan, Peoples R China.; Yu, K (通讯作者)，Sichuan Univ, Engn Res Ctr Biomat, Chengdu 610065, Sichuan, Peoples R China.
EM niuhai@scu.edu.cn; kuiyu@scu.edu.cn; huangwen@scu.edu.cn
FU National Major Scientific and Technological Special Project for
   "Significant New Drugs Development" [2019ZX09201005-005-001,
   2019ZX09201005005-002, 2019ZX09201005-005-004]; National Natural Science
   Foundation of China [81673710, 81973580]; Sichuan University [HXYS19001,
   HXYS19002, 2018HXBH061, 2019HXBH024]; Sichuan Science and Technology
   Department Emergency Project for COVID-19 [2020YFS0554]; National
   Science Foundation for Young Scientists of China [81803866]; China
   Postdoctoral Science Foundation [2018M640932, 2019T120854]; Applied
   Basic Research Programs of Department of Science and Technology of
   Sichuan Province [2019YJ0095]; Post-Doctor Research Project, West China
   Hospital [2018HXBH061, 2019HXBH024]; Postdoctoral Interdisciplinary
   Research Project of Sichuan University [2019JCXK3245]
FX We thank the National Major Scientific and Technological Special Project
   for "Significant New Drugs Development" (grant nos.
   2019ZX09201005-005-001, 2019ZX09201005005-002, and
   2019ZX09201005-005-004). Also, W.H. is grateful to the National Natural
   Science Foundation of China (grant nos. 81673710 and 81973580), the
   Innovative Chinese Medicine and Health Products Research Academician
   Workstation of Academician Boli Zhang and Academician Beiwei Zhu, West
   China Hospital, and Sichuan University (grant nos. HXYS19001 and
   HXYS19002), as well as the Sichuan Science and Technology Department
   Emergency Project for COVID-19 (grant no. 2020YFS0554). G.X. pays
   gratitude to the National Science Foundation for Young Scientists of
   China (grant no. 81803866), the China Postdoctoral Science Foundation
   (grant nos. 2018M640932 and 2019T120854), the Applied Basic Research
   Programs of Department of Science and Technology of Sichuan Province
   (grant no. 2019YJ0095), the Post-Doctor Research Project, West China
   Hospital, and Sichuan University (grant nos. 2018HXBH061 and
   2019HXBH024), and the Postdoctoral Interdisciplinary Research Project of
   Sichuan University (2019JCXK3245). For TGA, we thank Dr. Shaolan Wang,
   the Analytical and Testing Center of Sichuan University. For particle
   size distribution analysis, we thank Ms. Zhihua Xing, West China
   Hospital, Sichuan University.
CR Adams CM, 2018, J MED CHEM, V61, P1622, DOI 10.1021/acs.jmedchem.7b01731
   Adeniran JMF, 2017, OCUL IMMUNOL INFLAMM, V25, P834, DOI 10.1080/09273948.2016.1184284
   ALLINGHAM RR, 1987, ARCH OPHTHALMOL-CHIC, V105, P1421
   Chang D, 2019, DRUG DISCOV TODAY, V24, P1470, DOI 10.1016/j.drudis.2019.05.037
   Chen S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020164
   Chen XR, 2018, ACS APPL MATER INTER, V10, P2328, DOI 10.1021/acsami.7b16522
   Chojnacki JE, 2015, BIOORGAN MED CHEM, V23, P7324, DOI 10.1016/j.bmc.2015.10.032
   Djebli N, 2017, EUR J DRUG METAB PH, V42, P59, DOI 10.1007/s13318-016-0319-4
   Falavarjani KG, 2013, EYE, V27, P787, DOI 10.1038/eye.2013.107
   Farnoodian M, 2018, J OPHTHAL VIS RES, V13, P470, DOI 10.4103/jovr.jovr_67_18
   Feng L, 2019, DISCOV MED, V27, P153
   Ganugula R, 2017, ACS APPL MATER INTER, V9, P25668, DOI 10.1021/acsami.7b07896
   Gharaibeh A, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005431.pub4
   Goody RJ, 2011, EXP EYE RES, V92, P464, DOI 10.1016/j.exer.2011.03.006
   Grotemeier A, 2010, CELL SIGNAL, V22, P914, DOI 10.1016/j.cellsig.2010.01.015
   Ipema HJ, 2012, ANN PHARMACOTHER, V46, P97, DOI 10.1345/aph.1Q383
   Jager K, 2009, INVEST OPHTH VIS SCI, V50, P1112, DOI 10.1167/iovs.08-2368
   Jiang SS, 2016, PHYTOMEDICINE, V23, P243, DOI 10.1016/j.phymed.2016.01.010
   Kivinen N, 2018, ACTA OPHTHALMOL, V96, P1, DOI 10.1111/aos.13753
   Kubo Y, 2015, INVEST OPHTH VIS SCI, V56, P5925, DOI 10.1167/iovs.15-17398
   Lee B, 2018, INVEST OPHTH VIS SCI, V59, P5246, DOI 10.1167/iovs.17-23600
   Lee S, 2018, ACS APPL MATER INTER, V10, P40378, DOI 10.1021/acsami.8b08254
   Li YP, 2012, ENVIRON ENG SCI, V29, P713, DOI 10.1089/ees.2011.0317
   Ling K, 2019, J CONTROL RELEASE, V295, P174, DOI 10.1016/j.jconrel.2018.12.017
   Liu JH, 2020, ACS APPL MATER INTER, V12, P4815, DOI 10.1021/acsami.9b18934
   Luo L, 2013, ACS NANO, V7, P3264, DOI 10.1021/nn305958y
   Marcos-Contreras OA, 2016, BLOOD, V128, P2423, DOI 10.1182/blood-2016-03-705384
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Mitra RN, 2017, ACS NANO, V11, P4669, DOI 10.1021/acsnano.7b00429
   Moiseev RV, 2019, PHARMACEUTICS, V11, DOI 10.3390/pharmaceutics11070321
   Nguyen CTH, 2017, ACS APPL MATER INTER, V9, P9470, DOI 10.1021/acsami.7b00411
   Parikh R, 2019, JAMA OPHTHALMOL, V137, P914, DOI 10.1001/jamaophthalmol.2019.1947
   RAMSELL TG, 1967, BRIT J OPHTHALMOL, V51, P398, DOI 10.1136/bjo.51.6.398
   Rathore MS, 2007, ASIAN J PHARM, V1, P40
   Reichle Michelle L, 2005, Optometry, V76, P450, DOI 10.1016/j.optm.2005.06.013
   Ren N, 2019, ACS APPL MATER INTER, V11, P26704, DOI 10.1021/acsami.9b08652
   Rosenfeld PJ, 2018, OPHTHALMOL RETINA, V2, P1028, DOI 10.1016/j.oret.2018.03.001
   Sidman RL, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aac4882
   Sterner O, 2017, ACS APPL MATER INTER, V9, P20150, DOI 10.1021/acsami.6b16425
   Sun JG, 2017, ACS APPL MATER INTER, V9, P7990, DOI 10.1021/acsami.6b16509
   Tohda C, 2012, SCI REP-UK, V2, DOI 10.1038/srep00535
   Turano C, 2011, CELL MOL BIOL LETT, V16, P539, DOI 10.2478/s11658-011-0022-z
   Tyagi A, 2017, J RAJASTHAN ACAD PHY, V16, P1
   Vooturi SK, 2012, MOL PHARMACEUT, V9, P3136, DOI 10.1021/mp300245r
   Wen H, 2019, ACS APPL MATER INTER, V11, P5821, DOI 10.1021/acsami.8b19438
   Wolf A, 2019, EMBO MOL MED, V11, DOI 10.15252/emmm.201910362
   Wu L, 2014, ACS NANO, V8, P2087, DOI 10.1021/nn500376w
   Yamamoto E, 2014, BIOCHEM BIOPH RES CO, V453, P19, DOI 10.1016/j.bbrc.2014.09.040
   Yi Z, 2020, ACS APPL MATER INTER, V12, P33550, DOI 10.1021/acsami.0c10282
   Yuan G, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118894
   Yuan XY, 2015, ACS NANO, V9, P1749, DOI 10.1021/nn506599f
   Zhang CY, 2019, ACS APPL MATER INTER, V11, P16380, DOI 10.1021/acsami.9b04051
   Zhang M, 2008, MOL VIS, V14, P37
   Zhou XF, 2019, ACS APPL MATER INTER, V11, P6829, DOI 10.1021/acsami.8b21886
NR 54
TC 7
Z9 7
U1 13
U2 60
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1944-8244
EI 1944-8252
J9 ACS APPL MATER INTER
JI ACS Appl. Mater. Interfaces
PD DEC 30
PY 2020
VL 12
IS 52
BP 57710
EP 57720
DI 10.1021/acsami.0c17296
PG 11
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics; Materials Science
GA PO5CN
UT WOS:000605187100005
PM 33320520
DA 2022-11-30
ER

PT J
AU Maggio, E
   Polito, A
   Guerriero, M
   Prigione, G
   Parolini, B
   Pertile, G
AF Maggio, Emilia
   Polito, Antonio
   Guerriero, Massimo
   Prigione, Guido
   Parolini, Barbara
   Pertile, Grazia
TI Vitreomacular Adhesion and the Risk of Neovascular Age-Related Macular
   Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID SEVERITY SCALE; INTERFACE; EPIDEMIOLOGY; TRACTION; THERAPY; EYE
AB Purpose: To assess the prevalence of vitreomacular adhesion (VMA) in consecutive naive eyes diagnosed with exudative age-related macular degeneration (AMD) in comparison with eyes with nonexudative AMD and age-matched controls, and to evaluate prospectively the incidence of vitreomacular interface changes over time and their influence on choroidal neovascularization (CNV) development.
   Design: Retrospective cross-sectional analysis and longitudinal cohort study conducted at Sacrocuore Hospital, Negrar, Verona, Italy.
   Participants: A total of 1067 eyes examined at Sacrocuore Hospital between August 2008 and June 2015 met the inclusion criteria and were evaluated in this study.
   Methods: Eyes were classified into 3 groups: 403 eyes of 364 patients (mean [standard deviation; SD] age 77.8 [8.0] years) affected by exudative AMD; 350 eyes of 298 subjects (mean [SD] age 78.1 [8.2] years) with nonexudative AMD; and 314 eyes of 214 subjects (mean [SD] age 74.2 [8.2] years) with no signs of AMD enrolled as the control group. The vitreomacular interface status was evaluated by spectral-domain optical coherence tomography (OCT) and was graded according to the OCT-based International Classification System developed by the International Vitreomacular Traction Study Group by 2 independent masked observers.
   Results: VMA was present in 101 (25.1%) eyes with exudative AMD, 84 (24.0%) eyes with nonexudative AMD, and 84 (26.8%) eyes with no signs of AMD (no statistical difference was found; P = 0.3384). Spontaneous release of VMA (RVMA) was found in 15 (15.3%) eyes with exudative AMD, 21 (28.0%) eyes with nonexudative AMD, and 10 (24.4%) eyes with no signs of AMD over a mean follow-up of 25.5, 25.9, and 24.1 months, respectively. The incidence of RVMA in exudative AMD eyes was significantly lower compared with nonexudative (P = 0.0207) and lower, but not statistically significant, with respect to eyes with no signs of AMD (P = 0.1013). In eyes with nonexudative AMD, de novo development of CNV occurred in 91 eyes (30.6%). There was no significant difference regarding the rate of CNV development in the presence or absence of VMA (P = 0.0966).
   Conclusions: The present study found no significant difference in the prevalence of VMA in eyes affected by AMD compared with age-matched controls and no difference in the rate of de novo CNV development in eyes with or without VMA. Conversely, a lower incidence of RVMA over time was found in eyes affected by exudative AMD. The results of this study suggest that VMA might be a consequence rather than a causative factor in the development of CNV. (C) 2017 by the American Academy of Ophthalmology
C1 [Maggio, Emilia; Polito, Antonio; Prigione, Guido; Pertile, Grazia] Sacrocuore Hosp, Verona, Italy.
   [Guerriero, Massimo] Univ Verona, Dept Comp Sci, Verona, Italy.
   [Parolini, Barbara] St Anna Inst, Dept Ophthalmol, Brescia, Italy.
C3 IRCCS Sacro Cuore Don Calabria; University of Verona
RP Maggio, E (通讯作者)，Via Don Sempreboni 5, I-37024 Verona, Italy.
EM emi_maggio@yahoo.it
RI Guerriero, Massimo/AAA-9409-2020; Pertile, Grazia/AAC-4956-2022;
   Parolini, Barbara/AAH-9913-2019; Prigione, Guido/AAA-2682-2019
OI Guerriero, Massimo/0000-0003-1310-539X; Parolini,
   Barbara/0000-0002-7838-6834
CR Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Cuilla TA, 2015, OPHTHALMOLOGY, V122, P1203, DOI 10.1016/j.ophtha.2015.02.031
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Duker JS, 2013, OPHTHALMOLOGY, V120, P2611, DOI 10.1016/j.ophtha.2013.07.042
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Geck U, 2013, GRAEF ARCH CLIN EXP, V251, P1691, DOI 10.1007/s00417-013-2266-y
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Houston SK, 2015, RETINA-J RET VIT DIS, V35, P1757, DOI 10.1097/IAE.0000000000000663
   KLEIN R, 1993, AM J EPIDEMIOL, V137, P190, DOI 10.1093/oxfordjournals.aje.a116659
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Krebs I, 2007, AM J OPHTHALMOL, V144, P741, DOI 10.1016/j.ajo.2007.07.024
   la Cour M, 2002, DRUG AGING, V19, P101, DOI 10.2165/00002512-200219020-00003
   Lee SJ, 2009, AM J OPHTHALMOL, V147, P621, DOI 10.1016/j.ajo.2008.10.003
   Maier M, 2012, KLIN MONATSBL AUGENH, V229, P1030, DOI 10.1055/s-0032-1315305
   Mayr-Sponer U, 2013, OPHTHALMOLOGY, V120, P2620, DOI 10.1016/j.ophtha.2013.05.032
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Mojana F, 2008, AM J OPHTHALMOL, V146, P218, DOI 10.1016/j.ajo.2008.04.027
   Nomura Y, 2014, JPN J OPHTHALMOL, V58, P443, DOI 10.1007/s10384-014-0333-5
   Nomura Y, 2011, OPHTHALMOLOGY, V118, P853, DOI 10.1016/j.ophtha.2010.09.001
   Ondes F, 2000, JPN J OPHTHALMOL, V44, P91, DOI 10.1016/S0021-5155(99)00174-4
   Robison CD, 2009, AM J OPHTHALMOL, V148, P79, DOI 10.1016/j.ajo.2009.01.014
   Stalmans P, 2012, NEW ENGL J MED, V367, P606, DOI 10.1056/NEJMoa1110823
   Veloso CE, 2015, OPHTHALMOLOGY, V122, P1569, DOI 10.1016/j.ophtha.2015.04.028
   Waldstein SM, 2014, AM J OPHTHALMOL, V158, P328, DOI 10.1016/j.ajo.2014.04.028
   Waldstein SM, 2012, RETINA-J RET VIT DIS, V32, P424, DOI 10.1097/IAE.0b013e3182278b80
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 26
TC 9
Z9 11
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD MAY
PY 2017
VL 124
IS 5
BP 657
EP 666
DI 10.1016/j.ophtha.2017.01.018
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EW3MT
UT WOS:000402402400018
PM 28214102
DA 2022-11-30
ER

PT J
AU Cezario, SM
   Calastri, MCJ
   Oliveira, CIF
   Carmo, TS
   Pinhel, MAD
   de Godoy, MF
   Jorge, R
   Cotrim, CC
   Souza, DRS
   Siqueira, RC
AF Cezario, Sabrina Mayara
   Jessica Calastri, Maria Clara
   Ferreira Oliveira, Camila Ive
   Carmo, Tayanne Silva
   de Souza Pinhel, Marcela Augusta
   de Godoy, Moacir Fernandes
   Jorge, Rodrigo
   Cotrim, Carina Costa
   Silva Souza, Doroteia Rossi
   Siqueira, Rubens Camargo
TI Association of high-density lipoprotein and apolipoprotein E genetic
   variants with age-related macular degeneration
SO ARQUIVOS BRASILEIROS DE OFTALMOLOGIA
LA English
DT Article
DE Polymorphism; genetic; Apolipoprotein E; Triglycerides; Lipids;
   Cholesterol; Macular degeneration; Cholesterol, HDL; LDL-receptor
   related proteins
ID EYE DISEASE; CAROTENOIDS; LUTEIN; SUSCEPTIBILITY; POLYMORPHISMS;
   ZEAXANTHIN
AB Purpose: This study aimed to evaluate the association of age-related macular degeneration (AMD) with apolipoprotein E (APOE) variants and serum lipid profiles, including levels and fractions of total serum cholesterol (TC), low-density lipoprotein cholesterol (LDLc), and high-density lipoprotein cholesterol (HDLc), and triglycerides (TG).
   Methods: Genotyping of APOE-HhaI was performed in 134 patients (study group, SG) and 164 individuals without AMD (control group, CG), aged 50-89 years. Lipid profiles were analyzed in a subgroup of 30 subjects of both groups, matched according to age and sex. The significance level was set at P<0.05.
   Results: APOE E3/E3 was more prevalent (SG=74.6%; CG=77.4%), with no difference between both groups (P=0.667). The same result was observed for risk genotypes (APOE E -/2: SG=7.4%; CG=10.3%, P=0.624). Serum levels of TC, LDLc, and TG revealed similar median values between SG (193.5, 116, and 155 mg/dL, respectively) and CG (207.5, 120, and 123.5 mg/dL, respectively; P>0.05). For HDLc, a higher median value was observed in SG (53.3 mg/dL) versus CG (42.5 mg/dL; P=0.016). Logistic regression analysis showed the same value, and the HDLc/TC ratio was -11.423 (P=0.014), as also confirmed by an increase in HDLc in SG. The association between lipid profiles and apolipoprotein E genotypes was similar in both groups (P>0.05).
   Conclusions: APOE-HhaI is not associated with AMD. However, an increase in serum HDLc level appears to exert a protective effect against the disease, irrespective of the genetic variants of apoE.
C1 [Cezario, Sabrina Mayara; Jessica Calastri, Maria Clara; Ferreira Oliveira, Camila Ive; Carmo, Tayanne Silva; de Godoy, Moacir Fernandes; Silva Souza, Doroteia Rossi; Siqueira, Rubens Camargo] Med Sch Sao Jose Rio Preto FAMERP, Sao Jose Do Rio Preto, SP, Brazil.
   [de Souza Pinhel, Marcela Augusta] Univ Sao Paulo, Med Sch Ribeirao Preto, FMRP, Ribeirao Preto, SP, Brazil.
   [Jorge, Rodrigo; Cotrim, Carina Costa; Siqueira, Rubens Camargo] Univ Sao Paulo, Med Sch Ribeirao Preto, FMRP, Dept Ophthalmol, Ribeirao Preto, SP, Brazil.
C3 Universidade de Sao Paulo; Universidade de Sao Paulo
RP Cezario, SM (通讯作者)，Fac Med Sao Jose Rio Preto FAMERP, Posgrad Ciencias Saude, Ave Brigadeiro Faria Lima 5-416, BR-15090000 Sao Jose Do Rio Preto, SP, Brazil.
EM sabrina-mayara@hotmail.com
RI Calastri, Maria Clara J/K-5529-2015; Pinhel, Marcela/F-7866-2013; Souza,
   Dorotéia/AAR-7748-2021; Silva do Carmo, Tayanne/K-2976-2015
OI Calastri, Maria Clara J/0000-0003-4413-8207; Silva do Carmo,
   Tayanne/0000-0003-4149-3318; Siqueira, Rubens/0000-0003-4563-1570
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo/FAPESP; Faculdade
   de Medicina de Sao Jose do Rio Preto/FAMERP
FX This study was supported by Fundacao de Amparo a Pesquisa do Estado de
   Sao Paulo/FAPESP and Faculdade de Medicina de Sao Jose do Rio
   Preto/FAMERP.
CR Butt AL, 2011, OPHTHALMOLOGY, V118, P1380, DOI 10.1016/j.ophtha.2010.11.007
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Cougnard-Gregoire A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090973
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   Donix M, 2012, AM J GERIAT PSYCHIAT, V20, P565, DOI 10.1097/JGP.0b013e3182107e6a
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   HIXSON JE, 1990, J LIPID RES, V31, P545
   Horie-Inoue K, 2014, BIOCHEM BIOPH RES CO, V452, P263, DOI 10.1016/j.bbrc.2014.08.013
   Huang HZ, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0059482, 10.1371/journal.pone.0071808, 10.1371/journal.pone.0076982]
   Khan Muhammad, 2014, ISRN Ophthalmol, V2014, P608390, DOI 10.1155/2014/608390
   Kijlstra A, 2012, PROG RETIN EYE RES, V31, P303, DOI 10.1016/j.preteyeres.2012.03.002
   Lorga AM, 2013, ARQ BRAS CARDIOL, V101, P1, DOI [10.5935/abc.2013S012, 10.5935/abc.2013S006, 10.5935/abc.2013S009]
   Losonczy G, 2011, ACTA OPHTHALMOL, V89, P255, DOI 10.1111/j.1755-3768.2009.01687.x
   Meyers KJ, 2014, INVEST OPHTH VIS SCI, V55, P587, DOI 10.1167/iovs.13-13216
   Moeller SM, 2006, ARCH OPHTHALMOL-CHIC, V124, P1151, DOI 10.1001/archopht.124.8.1151
   Reynolds R, 2010, OPHTHALMOLOGY, V117, P1989, DOI 10.1016/j.ophtha.2010.07.009
   Rohn TT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080180
   Rougeron V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076924
   Salazar LA, 1998, CLIN CHEM, V44, P1748
   Santos RV, 2009, CURR ANTHROPOL, V50, P787, DOI 10.1086/644532
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   Spencer KL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017784
   Sun E, 2011, MOL VIS, V17, P997
   Swaroop A, 2007, HUM MOL GENET, V16, pR174, DOI 10.1093/hmg/ddm212
   Thakkinstian A, 2006, AM J EPIDEMIOL, V164, P813, DOI 10.1093/aje/kwj279
   Trieschmann M, 2007, EXP EYE RES, V84, P718, DOI 10.1016/j.exer.2006.12.010
   Ulas F, 2013, INT OPHTHALMOL, V33, P485, DOI 10.1007/s10792-013-9728-4
   Wickremasinghe SS, 2011, INVEST OPHTH VIS SCI, V52, P4072, DOI 10.1167/iovs.10-6550
   Yeum KJ, 2002, ANNU REV NUTR, V22, P483, DOI 10.1146/annurev.nutr.22.010402.102834
NR 29
TC 6
Z9 6
U1 0
U2 6
PU CONSEL BRASIL OFTALMOLOGIA
PI SAO PAULO
PA ALAMEDA SANTOS 1343, 11 ANDAR CJ 1110, CERQUEIRA CESAR, SAO PAULO, SP
   00000, BRAZIL
SN 0004-2749
EI 1678-2925
J9 ARQ BRAS OFTALMOL
JI Arq. Bras. Oftalmol.
PD MAR-APR
PY 2015
VL 78
IS 2
BP 85
EP 88
DI 10.5935/0004-2749.20150023
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CH5CB
UT WOS:000354050800006
PM 25945528
OA Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Holekamp, NM
   Liu, Y
   Yeh, WS
   Chia, YF
   Kiss, S
   Almony, A
   Kowalski, JW
AF Holekamp, Nancy M.
   Liu, Ying
   Yeh, Wei-Shi
   Chia, Yifeng
   Kiss, Szilard
   Almony, Arghavan
   Kowalski, Jonathan W.
TI Clinical Utilization of Anti-VEGF Agents and Disease Monitoring in
   Neovascular Age-Related Macular Degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID INTRAVITREAL RANIBIZUMAB; VISUAL IMPAIRMENT; BEVACIZUMAB; TRIAL;
   MULTICENTER; SECONDARY; EFFICACY; THERAPY; SAFETY
AB PURPOSE: To examine bevacizumab and ranibizumab utilization and disease monitoring patterns in patients with neovascular age-related macular degeneration (neovascular AMD) in clinical practice.
   DESIGN: Retrospective medical claims analysis.
   METHODS: Patients receiving ranibizumab or bevacizumab injection during the 12 months after initial neovascular AMD diagnosis were included. Annual bevacizumab and/or ranibizumab injection utilization was assessed by year of first injection cohorts: 2006 and 2007 (received either agent because of billing code overlap), 2008, 2009, and January-June 2010 (received each agent). Outcome measures were time to first injection relative to neovascular AMD diagnosis and mean numbers of intravitreal injections, ophthalmologist visits, and optical coherence tomography (OCT) and fluorescein angiography (FA) examinations in 12 months.
   RESULTS: In the 2006 and 2007 cohorts (n = 8767), mean annual numbers of bevacizumab or ranibizumab injections were 4.7 and 5.0, respectively. Over 92% of patients in all cohorts received first treatment within 3 months of neovascular AMD diagnosis. In the 2008-2010 cohorts (n = 10 259), mean annual number of injections remained low (bevacizumab: 4.6, 5.1, and 5.5; ranibizumab: 6.1, 6.6, and 6.9), as did mean numbers of ophthalmologist visits (bevacizumab only) and OCT examinations (both agents), but there was no such trend in FA examinations.
   CONCLUSIONS: Compared with treatment paradigms validated by clinical trials published at the time, in clinical practice, patients with neovascular AMD received fewer bevacizumab or ranibizumab injections and less-frequent monitoring from 2006 to mid-2011. Factors contributing to this lower injection frequency and visual outcomes associated with reduced utilization need to be researched. (C) 2014 by Elsevier Inc. All rights reserved.
C1 [Holekamp, Nancy M.] Pepose Vis Inst, St Louis, MO USA.
   [Holekamp, Nancy M.] Washington Univ, Sch Med, St Louis, MO USA.
   [Liu, Ying; Yeh, Wei-Shi; Chia, Yifeng; Kowalski, Jonathan W.] Allergan Pharmaceut Inc, Irvine, CA 92715 USA.
   [Kiss, Szilard] Weill Cornell Med Coll, New York, NY USA.
   [Almony, Arghavan] Carolina Eye Associates, Southern Pines, NC USA.
C3 Washington University (WUSTL); AbbVie; Allergan; Cornell University
RP Holekamp, NM (通讯作者)，Pepose Vis Inst, 1815 Clarkson Rd, Chesterfield, MO 63017 USA.
EM nholekamp@gmail.com
OI Kiss, Szilard/0000-0003-3433-8432
FU Genentech; Allergan; Regeneron; Sequenom; Alimera; Notal Vision;
   Allergan, Inc.; Irvine, California
FX ALL AUTHORS HAVE COMPLETED AND SUBMITTED THE ICMJE FORM FOR DISCLOSURE
   OF POTENTIAL CONFLICTS OF INTEREST. Dr Holekamp reports the following:
   consulting fees or honoraria: Genentech, Allergan, Regeneron, Sequenom,
   Alimera, and Notal Vision; board membership: Katalyst Surgical; speakers
   bureau: Sequenom, Genentech, and Regeneron; clinical research projects:
   Notal Vision; and stock/stock options: Katalyst Surgical. At the time of
   data analysis, Dr Yeh was an employee of Allergan, Inc., and does not
   hold equity and/or options in Allergan, Inc. Drs Chia and Liu are
   employees of and hold equity in Allergan, Inc. Dr Kiss reports the
   following: consulting fees or, honoraria: Alimera, Allergan, Alcon,
   EyeTech, Genentech, Merge/OIS, Optos, Regeneron, and Thrombogenics;
   speakers bureau: Alimera, Allergan, Genentech, Optos, Regeneron, and
   Thrombogenics; clinical research projects: Allergan, Genentech, Optos,
   and Regeneron; and stock/stock options: Merge/OIS. Dr Almony reports a
   consulting fee with Allergan. Dr Kowalski reports being an employee of
   and holds equity and/or options in Allergan, Inc. This analysis was
   sponsored by Allergan, Inc., Irvine, California. Contributions of
   authors: design of the study (N.M.H., W.-S.Y., Y.C., S.K., A.A., Y.L.,
   J.W.K.); conduct of the study, and collection, management, analysis, and
   interpretation of the data (N.M.H., W.-S.Y., Y.C., S.K., A.A., Y.L.,
   J.W.K.); and preparation, review, and approval of the manuscript
   (N.M.H., W.-S.Y., Y.C., S.K., A.A., Y.L., J.W.K.).
CR American Society of Retina Specialists (ASRS), 2012, ANN PREF TRENDS SURV
   American Society of Retina Specialists (ASRS), 2011, ANN PREF TRENDS SURV
   Bandukwala T, 2010, CAN J OPHTHALMOL, V45, P590, DOI 10.3129/i10-082
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Cleary C A, 2011, Ir Med J, V104, P146
   Colquitt JL, 2008, HEALTH TECHNOL ASSES, V12, P1
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Costagliola C, 2012, EXPERT OPIN BIOL TH, V12, P1299, DOI 10.1517/14712598.2012.707176
   Day S, 2011, AM J OPHTHALMOL, V152, P266, DOI 10.1016/j.ajo.2011.01.053
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Fong DS, 2010, OPHTHALMOLOGY, V117, P298, DOI 10.1016/j.ophtha.2009.07.023
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Hansen LG, HLTH RES DATA REAL W
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Lally DR, 2012, CURR OPIN OPHTHALMOL, V23, P182, DOI 10.1097/ICU.0b013e328352411c
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mitchell P, 2011, CURR MED RES OPIN, V27, P1465, DOI 10.1185/03007995.2011.585394
   Munoz B, 2000, ARCH OPHTHALMOL-CHIC, V118, P819, DOI 10.1001/archopht.118.6.819
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rotsos T, 2010, CLIN OPHTHALMOL, V4, P1271, DOI 10.2147/OPTH.S14684
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Shah AR, 2009, BRIT J OPHTHALMOL, V93, P1027, DOI 10.1136/bjo.2008.149674
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Takeda AL, 2007, BRIT J OPHTHALMOL, V91, P1177, DOI 10.1136/bjo.2007.118562
   Tufail A, 2010, BMJ-BRIT MED J, V340, pc2459
   Vedula SS, 2008, COCHRANE DB SYST REV, V2
   You JY, 2012, CURR EYE RES, V37, P438, DOI 10.3109/02713683.2011.647227
NR 33
TC 63
Z9 63
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD APR
PY 2014
VL 157
IS 4
BP 825
EP 833
DI 10.1016/j.ajo.2013.12.018
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AE0LC
UT WOS:000333656800013
PM 24388973
DA 2022-11-30
ER

PT J
AU Karunakaran, DKP
   Banday, AR
   Wu, Q
   Kanadia, R
AF Karunakaran, Devi Krishna Priya
   Banday, Abdul Rouf
   Wu, Qian
   Kanadia, Rahul
TI Expression Analysis of an Evolutionarily Conserved Alternative Splicing
   Factor, Sfrs10, in Age-Related Macular Degeneration
SO PLOS ONE
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; RNA-RECOGNITION MOTIF; CPG ISLANDS; FACTOR
   TRA2-BETA-1; GENE-EXPRESSION; HUMAN GENOME; SR PROTEINS; CELLS;
   REGULATORS; PATTERNS
AB Age-related macular degeneration (AMD) is the most common cause of blindness in the elderly population. Hypoxic stress created in the micro-environment of the photoreceptors is thought to be the underlying cause that results in the pathophysiology of AMD. However, association of AMD with alternative splicing mediated gene regulation is not well explored. Alternative Splicing is one of the primary mechanisms in humans by which fewer protein coding genes are able to generate a vast proteome. Here, we investigated the expression of a known stress response gene and an alternative splicing factor called Serine-Arginine rich splicing factor 10 (Sfrs10). Sfrs10 is a member of the serine-arginine (SR) rich protein family and is 100% identical at the amino acid level in most mammals. Immunoblot analysis on retinal extracts from mouse, rat, and chicken showed a single immunoreactive band. Further, immunohistochemistry on adult mouse, rat and chicken retinae showed pan-retinal expression. However, SFRS10 was not detected in normal human retina but was observed as distinct nuclear speckles in AMD retinae. This is in agreement with previous reports that show Sfrs10 to be a stress response gene, which is upregulated under hypoxia. The difference in the expression of Sfrs10 between humans and lower mammals and the upregulation of SFRS10 in AMD is further reflected in the divergence of the promoter sequence between these species. Finally, SFRS10+ speckles were independent of the SC35+ SR protein speckles or the HSF1+ stress granules. In all, our data suggests that SFRS10 is upregulated and forms distinct stress-induced speckles and might be involved in AS of stress response genes in AMD.
C1 [Karunakaran, Devi Krishna Priya; Banday, Abdul Rouf; Kanadia, Rahul] Univ Connecticut, Storrs, CT 06260 USA.
   [Wu, Qian] Univ Connecticut, Ctr Hlth, Dept Pathol & Lab Med, Farmington, CT 06030 USA.
C3 University of Connecticut; University of Connecticut
RP Kanadia, R (通讯作者)，Univ Connecticut, Storrs, CT 06260 USA.
EM rahul.kanadia@uconn.edu
RI BANDAY, ABDUL R/A-9555-2014; Banday, A. Rouf/AAB-9082-2022
OI BANDAY, ABDUL ROUF/0000-0002-1521-340X
FU National Institute of Neurological Disorders and Stroke [5P30NS069266];
   National Eye Institute [4R00EY019547]; NATIONAL EYE INSTITUTE
   [K99EY019547] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF
   NEUROLOGICAL DISORDERS AND STROKE [P30NS069266] Funding Source: NIH
   RePORTER
FX Resources for this project were provided by P30 from National Institute
   of Neurological Disorders and Stroke-5P30NS069266
   (http://www.ninds.nih.gov/) and K99-R00 from National Eye
   Institute-4R00EY019547 (http://www.nei.nih.gov/). The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR Algvere PV, 2006, ACTA OPHTHALMOL SCAN, V84, P4, DOI 10.1111/j.1600-0420.2005.00627.x
   Amin EM, 2011, CANCER CELL, V20, P768, DOI 10.1016/j.ccr.2011.10.016
   Arden GB, 2005, BRIT J OPHTHALMOL, V89, P764, DOI 10.1136/bjo.2004.062547
   BANDZIULIS RJ, 1989, GENE DEV, V3, P431, DOI 10.1101/gad.3.4.431
   BERMAN ER, 1994, BRIT J OPHTHALMOL, V78, P82, DOI 10.1136/bjo.78.2.82
   Bird A, 1996, BRIT J OPHTHALMOL, V80, P2, DOI 10.1136/bjo.80.1.2
   BIRNEY E, 1993, NUCLEIC ACIDS RES, V21, P5803, DOI 10.1093/nar/21.25.5803
   BOULTON M, 1986, BRIT J OPHTHALMOL, V70, P808, DOI 10.1136/bjo.70.11.808
   Bressler SB, 2009, OPHTHALMOLOGY, V116, pS1, DOI 10.1016/j.ophtha.2009.06.045
   Campochiaro PA, 2004, EXPERT OPIN BIOL TH, V4, P1395, DOI 10.1517/14712598.4.9.1395
   Cotto JJ, 1997, J CELL SCI, V110, P2925
   Curcio CA, 2009, PROG RETIN EYE RES, V28, P393, DOI 10.1016/j.preteyeres.2009.08.001
   Daoud R, 1999, EUR J NEUROSCI, V11, P788, DOI 10.1046/j.1460-9568.1999.00486.x
   Daoud R, 2002, J NEUROSCI, V22, P5889
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   DOREY CK, 1989, INVEST OPHTH VIS SCI, V30, P1691
   Fang AM, 2009, MOL VIS, V15, P2710
   Feigl B, 2009, PROG RETIN EYE RES, V28, P63, DOI 10.1016/j.preteyeres.2008.11.004
   FU XD, 1992, P NATL ACAD SCI USA, V89, P11224, DOI 10.1073/pnas.89.23.11224
   FU XD, 1990, NATURE, V343, P437, DOI 10.1038/343437a0
   Grellscheid S, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002390
   Guymer R, 1999, PROG RETIN EYE RES, V18, P59, DOI 10.1016/S1350-9462(98)00012-3
   Hall LL, 2006, ANAT REC PART A, V288A, P664, DOI 10.1002/ar.a.20336
   HOGAN M J, 1972, Transactions of the American Academy of Ophthalmology and Oto-Laryngology, V76, P64
   Holz FG, 1999, GRAEF ARCH CLIN EXP, V237, P145, DOI 10.1007/s004170050209
   Huang YQ, 2005, MOL CELL, V17, P613, DOI 10.1016/j.molcel.2005.02.020
   Kajita K, 2013, J GASTROENTEROL
   Kaur I, 2013, MOL VIS, V19, P822
   Kiryu-Seo S, 1998, MOL BRAIN RES, V62, P220, DOI 10.1016/S0169-328X(98)00255-1
   KRAINER AR, 1990, GENE DEV, V4, P1158, DOI 10.1101/gad.4.7.1158
   KRAINER AR, 1985, CELL, V42, P725, DOI 10.1016/0092-8674(85)90269-7
   LANDSMAN D, 1992, NUCLEIC ACIDS RES, V20, P2861, DOI 10.1093/nar/20.11.2861
   LARSEN F, 1992, GENET ANAL-BIOMOL E, V9, P80, DOI 10.1016/1050-3862(92)90002-M
   LARSEN F, 1992, GENOMICS, V13, P1095, DOI 10.1016/0888-7543(92)90024-M
   Lazzeri S, 2012, SCI WORLD J, DOI 10.1100/2012/420190
   Li SJ, 2013, J BIOL CHEM, V288, P8898, DOI 10.1074/jbc.M113.456715
   Lin XY, 2006, HUM MOL GENET, V15, P2087, DOI 10.1093/hmg/ddl132
   Long JC, 2009, BIOCHEM J, V417, P15, DOI 10.1042/BJ20081501
   Lu F, 2013, INVEST OPHTHALMOL VI
   MATSUO N, 1995, J BIOL CHEM, V270, P28216, DOI 10.1074/jbc.270.47.28216
   Nakata I, 2012, INVEST OPHTH VIS SCI, V53, P6576, DOI 10.1167/iovs.12-10219
   Ni JZ, 2007, GENE DEV, V21, P708, DOI 10.1101/gad.1525507
   Novoyatleva T, 2008, HUM MOL GENET, V17, P52, DOI 10.1093/hmg/ddm284
   Nowak DG, 2010, J BIOL CHEM, V285, P5532, DOI 10.1074/jbc.M109.074930
   Ricci F, 2009, ARCH OPHTHALMOL-CHIC, V127, P1368, DOI 10.1001/archophthalmol.2009.237
   Segade F, 1996, FEBS LETT, V387, P152, DOI 10.1016/0014-5793(96)00496-6
   Shelley EJ, 2009, ARCH OPHTHALMOL-CHIC, V127, P483, DOI 10.1001/archophthalmol.2008.622
   Snodderly DM, 2002, INVEST OPHTH VIS SCI, V43, P2815
   Suter M, 2000, J BIOL CHEM, V275, P39625, DOI 10.1074/jbc.M007049200
   TAZI J, 1990, CELL, V60, P909, DOI 10.1016/0092-8674(90)90339-G
   Tsukamoto Y, 2001, AM J PATHOL, V158, P1685, DOI 10.1016/S0002-9440(10)64124-7
   Verhoeff F H, 1937, Trans Am Ophthalmol Soc, V35, P262
   Watermann DO, 2006, CANCER RES, V66, P4774, DOI 10.1158/0008-5472.CAN-04-3294
   YOUNG RW, 1971, J CELL BIOL, V49, P303, DOI 10.1083/jcb.49.2.303
   ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837
   Zareparsi S, 2005, HUM MOL GENET, V14, P1449, DOI 10.1093/hmg/ddi154
   ZHANG GH, 1994, NATURE, V372, P809
   Zhong XY, 2009, MOL CELL, V35, P1, DOI 10.1016/j.molcel.2009.06.016
   Zhou B, 2001, NAT GENET, V28, P345, DOI 10.1038/ng572
NR 59
TC 7
Z9 9
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 30
PY 2013
VL 8
IS 9
AR e75964
DI 10.1371/journal.pone.0075964
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 231NL
UT WOS:000325423500121
PM 24098751
OA Green Submitted, gold, Green Published
DA 2022-11-30
ER

PT J
AU Rudnicka, AR
   MacCallum, PK
   Whitelocke, R
   Meade, TW
AF Rudnicka, A. R.
   MacCallum, P. K.
   Whitelocke, R.
   Meade, T. W.
TI Circulating markers of arterial thrombosis and late-stage age-related
   macular degeneration: a case-control study
SO EYE
LA English
DT Article
DE age-related macular degeneration; atherothrombosis; factor VII; aspirin
ID CORONARY-HEART-DISEASE; C-REACTIVE PROTEIN; LONG-TERM INCIDENCE;
   RISK-FACTORS; INFLAMMATORY MARKERS; ATHEROSCLEROSIS RISK; FACTOR-VII;
   CARDIOVASCULAR-DISEASE; HEMOSTATIC FACTORS; VISUAL IMPAIRMENT
AB Purpose The aim of this study was to examine the relation of late-stage age-related macular degeneration (AMD) with markers of systemic atherothrombosis.
   Methods A hospital-based case-control study of AMD was undertaken in London, UK. Cases of AMD (n = 81) and controls (n = 77) were group matched for age and sex. Standard protocols were used for colour fundus photography and to classify AMD; physical examination included height, weight, history of or treatment for vascular-related diseases and smoking status. Blood samples were taken for measurement of fibrinogen, factor VIIc (FVIIc), factor VIIIc, prothrombin fragment F1.2 (F1.2), tissue plasminogen activator, and von Willebrand factor. Odds ratios from logistic regression analyses of each atherothrombotic marker with AMD were adjusted for age, sex, and established cardiovascular disease risk factors, including smoking, blood pressure, body mass index, and total cholesterol.
   Results After adjustment FVIIc and possibly F1.2 were inversely associated with the risk of AMD; per 1 standard deviation increase in these markers the odds ratio were, respectively, 0.62 (95% confidence interval 0.40, 0.95) and 0.71 (0.46, 1.09). None of the other atherothrombotic risk factors appeared to be related to AMD status. There was weak evidence that aspirin is associated with a lower risk of AMD.
   Conclusions This study does not provide strong evidence of associations between AMD and systematic markers of arterial thrombosis, but the potential effects of FVIIc, and F1.2 are worthy of further investigation. Eye (2010) 24, 1199-1206; doi:10.1038/eye.2010.8; published online 12 February 2010
C1 [Rudnicka, A. R.] Univ London, Div Community Hlth Sci, London SW17 0RE, England.
   [MacCallum, P. K.] Barts & London Queen Marys Sch Med & Dent, Wolfson Inst Prevent Med, London, England.
   [Whitelocke, R.] St Bartholomews Hosp, Dept Ophthalmol, Barts & London NHS Trust, London, England.
   [Meade, T. W.] London Sch Hyg & Trop Med, London WC1, England.
C3 University of London; University of London; Queen Mary University
   London; Barts Health NHS Trust; University of London; Queen Mary
   University London; University of London; London School of Hygiene &
   Tropical Medicine
RP Rudnicka, AR (通讯作者)，Univ London, Div Community Hlth Sci, London SW17 0RE, England.
EM arudnicka@sgul.ac.uk
OI Rudnicka, Alicja R/0000-0003-0369-8574
FU Medical Research Council; Medical Research Council [G0701113] Funding
   Source: researchfish; MRC [G0701113] Funding Source: UKRI
FX We thank Liz McCabe for recruitment of the participants in the study,
   Jackie Cooper for monitoring matching during recruitment, and Homeira
   Sheikh for performing all the laboratory analyses. We also thank Mr Ivor
   Levy (deceased) for his contribution in interpretation of the retinal
   photographs and Bob Tapper for performing the photographs. This research
   was funded by the Medical Research Council.
CR ANDERSSEN T, 1993, THROMB HAEMOSTASIS, V70, P414
   ARMSTRONG BG, 1990, AM J EPIDEMIOL, V132, P1176, DOI 10.1093/oxfordjournals.aje.a115761
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bunce C, 1998, BRIT J OPHTHALMOL, V82, P72, DOI 10.1136/bjo.82.1.72
   Chaine G, 1998, BRIT J OPHTHALMOL, V82, P996, DOI 10.1136/bjo.82.9.996
   Cheung N, 2007, BRIT J OPHTHALMOL, V91, P430, DOI 10.1136/bjo.2006.106054
   Christen WG, 2001, ARCH OPHTHALMOL-CHIC, V119, P1143, DOI 10.1001/archopht.119.8.1143
   CLAUSS A., 1957, ACTA HAEMATOL, V17, P237
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Cooper JA, 2000, CIRCULATION, V102, P2816
   Danesh J, 2005, JAMA-J AM MED ASSOC, V294, P1799, DOI 10.1001/jama.294.14.1799
   Dasch B, 2005, ARCH OPHTHALMOL-CHIC, V123, P1501, DOI 10.1001/archopht.123.11.1501
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   De Stavola BL, 2007, J THROMB HAEMOST, V5, P461, DOI 10.1111/j.1538-7836.2007.02330.x
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   Duan YK, 2007, OPHTHALMOLOGY, V114, P732, DOI 10.1016/j.ophtha.2006.07.045
   Evans JR, 2004, OPHTHALMOLOGY, V111, P513, DOI 10.1016/j.ophtha.2003.07.012
   Evans JR, 2005, BRIT J OPHTHALMOL, V89, P550, DOI 10.1136/bjo.2004.049726
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Hirvela H, 1996, OPHTHALMOLOGY, V103, P871, DOI 10.1016/S0161-6420(96)30593-9
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Klein R, 2005, AM J OPHTHALMOL, V140, P35, DOI 10.1016/j.ajo.2005.01.051
   Klein R, 2003, ARCH OPHTHALMOL-CHIC, V121, P674, DOI 10.1001/archopht.121.5.674
   Klein R, 2003, OPHTHALMOLOGY, V110, P25, DOI 10.1016/S0161-6420(02)01565-8
   Klein R, 2002, AM J EPIDEMIOL, V156, P589, DOI 10.1093/aje/kwf092
   Klein R, 1999, ARCH OPHTHALMOL-CHIC, V117, P1203
   Klein R, 1999, OPHTHALMOLOGY, V106, P1056, DOI 10.1016/S0161-6420(99)90255-5
   Klein R, 2001, ARCH OPHTHALMOL-CHIC, V119, P1354
   Klein R, 2007, AM J OPHTHALMOL, V143, P473, DOI 10.1016/j.ajo.2006.11.058
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   Lip PL, 2001, OPHTHALMOLOGY, V108, P705, DOI 10.1016/S0161-6420(00)00663-1
   Lowe GDO, 2004, EUR HEART J, V25, P252, DOI 10.1016/j.ehj.2003.11.004
   MacCallum PK, 2000, THROMB HAEMOSTASIS, V83, P421
   Malukiewicz-Wisniewska Grazyna, 2005, Klin Oczna, V107, P70
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P743, DOI 10.1001/archopht.1995.01100060069034
   MEADE TW, 1980, LANCET, V1, P1050
   MILLER GJ, 1994, THROMB HAEMOSTASIS, V71, P38
   Owen CG, 2003, BRIT J OPHTHALMOL, V87, P312, DOI 10.1136/bjo.87.3.312
   Rudnicka AR, 2006, J THROMB HAEMOST, V4, P2405, DOI 10.1111/j.1538-7836.2006.02221.x
   Sato E, 2006, GRAEF ARCH CLIN EXP, V244, P963, DOI 10.1007/s00417-005-0201-6
   Schaumberg DA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1259
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P300, DOI 10.1001/archopht.125.3.300
   Seddon JM, 2006, NUTRITION, V22, P441, DOI 10.1016/j.nut.2005.12.004
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Shankar A, 2007, AM J EPIDEMIOL, V165, P375, DOI 10.1093/aje/kwk022
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   SPERDUTO RD, 1986, ARCH OPHTHALMOL-CHIC, V104, P216
   Tao Y, 2010, EYE, V24, P648, DOI 10.1038/eye.2009.160
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   Wang JJ, 2008, OPHTHALMOLOGY, V115, P693, DOI 10.1016/j.ophtha.2007.05.038
   Whincup RH, 2002, EUR HEART J, V23, P1764, DOI 10.1053/euhj.2001.3237
   Wong TY, 2007, OPHTHALMOLOGY, V114, P86, DOI 10.1016/j.ophtha.2006.06.039
   Wu KHC, 2007, INVEST OPHTH VIS SCI, V48, P1983, DOI 10.1167/iovs.06-0223
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
NR 56
TC 15
Z9 15
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD JUL
PY 2010
VL 24
IS 7
BP 1199
EP 1206
DI 10.1038/eye.2010.8
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 626OT
UT WOS:000279976000012
PM 20150922
OA Bronze
DA 2022-11-30
ER

PT J
AU Klingel, R
   Fassbender, C
   Heibges, A
   Koch, F
   Nasemann, J
   Engelmann, K
   Carl, T
   Meinke, M
   Erdtracht, B
AF Klingel, Reinhard
   Fassbender, Cordula
   Heibges, Andreas
   Koch, Frank
   Nasemann, Joachim
   Engelmann, Katrin
   Carl, Thomas
   Meinke, Michael
   Erdtracht, Bernard
TI RheoNet Registry Analysis of Rheopheresis for Microcirculatory Disorders
   With a Focus on Age-Related Macular Degeneration
SO THERAPEUTIC APHERESIS AND DIALYSIS
LA English
DT Article
DE Apheresis; Dry age-related macular degeneration; Microcirculatory
   disorder; registry; Quality management; Rheopheresis
ID APHERESIS REGISTRY; ADVERSE EVENTS; TRIAL
AB The purpose of establishing the RheoNet registry was to evaluate the safety and efficacy of rheopheresis, a specific method of therapeutic apheresis used to treat microcirculatory disorders. Apheresis centers providing rheopheresis therapy and physicians caring for the underlying disease were asked to participate in the registry, and the registry data were analyzed for safety and tolerability. Age-related macular degeneration (AMD) was selected as a model disease to evaluate efficacy. The RheoNet registry was successfully established recording 7722 rheopheresis treatments of 1110 patients, including 833 AMD patients. The mean age of patients was 72 years. Adverse events (AE) were reported in 5.67% of treatments, but termination of the treatment session was only required in 0.48%. Transient hypotension was the most frequently reported AE. No age-related increase in AE was observed. Ophthalmological data of 428 eyes (of 279 treated patients) with dry AMD could be analyzed; 85 eyes of 55 untreated AMD patients served as the control. At 6.75 +/- 5.25 months post-baseline, 42% of the treated eyes had improved visual acuity. The proportion of eyes with a decline in visual acuity was 17%, compared to 40% in the untreated controls (P < 0.01). The RheoNet registry has been successfully established and data analysis revealed that rheopheresis is a safe outpatient treatment for microcirculatory disorders. Moreover, RheoNet currently provides the largest evaluation of the efficacy of rheopheresis for dry AMD. Registry analysis contributes to a safe and appropriate use of rheopheresis in clinical practice.
C1 [Klingel, Reinhard; Fassbender, Cordula; Meinke, Michael] Apherese Forschungsinst, D-50935 Cologne, Germany.
   [Erdtracht, Bernard] Rheopheresis Ctr Cologne, Cologne, Germany.
   [Klingel, Reinhard] Johannes Gutenberg Univ Mainz, Dept Internal Med 1, D-6500 Mainz, Germany.
   [Koch, Frank] Goethe Univ Frankfurt, Dept Ophthalmol, Frankfurt, Germany.
   [Nasemann, Joachim; Carl, Thomas] Ctr Ophthalmol & Vitroretinal Surg, Munich, Germany.
   [Engelmann, Katrin] Chemnitz Gen Hosp, Dept Ophthalmol, Chemnitz, Germany.
C3 Johannes Gutenberg University of Mainz; Goethe University Frankfurt;
   Chemnitz Clinic
RP Klingel, R (通讯作者)，Apherese Forschungsinst, Stadtwaldgurtel 77, D-50935 Cologne, Germany.
EM afi@apheresis-research.org
OI Fassbender, Dr. Cordula/0000-0001-6498-0210
FU Asahi Kasei Kuraray Medical, Tokyo, Japan; Diamed Medizintechnik,
   Cologne, Germany
FX We would like to thank all physicians, nurses, and patients in Germany
   and Canada for their efforts to provide data for the registry.
   Establishment of the RheoNet registry was granted by Asahi Kasei Kuraray
   Medical, Tokyo, Japan, and Diamed Medizintechnik, Cologne, Germany.
CR Berrouschot J, 1999, STROKE, V30, P787, DOI 10.1161/01.STR.30.4.787
   Bosch T, 2006, THER APHER DIAL, V10, P210, DOI 10.1111/j.1744-9987.2006.00336.x
   Brunner R, 2000, RETINA-J RET VIT DIS, V20, P483, DOI 10.1097/00006982-200009000-00009
   Gass JDM, 2003, RETINA-J RET VIT DIS, V23, P741, DOI 10.1097/00006982-200312000-00001
   Kirschkamp T, 2008, THER APHER DIAL, V12, P360, DOI 10.1111/j.1744-9987.2008.00610.x
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   Klein R., 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Klingel R, 2005, THER APHER DIAL, V9, P473, DOI 10.1111/j.1744-9987.2005.00276.x
   Klingel R, 2003, TRANSFUS APHER SCI, V29, P71, DOI 10.1016/S1473-0502(03)00101-0
   Klingel R, 2000, Ther Apher, V4, P348, DOI 10.1046/j.1526-0968.2000.004005348.x
   Klingel T, 2003, THER APHER DIAL, V7, P444, DOI 10.1046/j.1526-0968.2003.00082.x
   KORACH JM, 2000, THER APHER, V4, P200
   Koss MJ, 2009, GRAEF ARCH CLIN EXP, V247, P1297, DOI 10.1007/s00417-009-1113-7
   Malchesky PS, 2007, THER APHER DIAL, V11, P341, DOI 10.1111/j.1744-9987.2007.00507.x
   Mosges R, 2008, OTOL NEUROTOL, V29, P769, DOI 10.1097/MAO.0b013e31817e5d03
   Mosges R, 2009, EUR ARCH OTO-RHINO-L, V266, P943, DOI 10.1007/s00405-008-0823-5
   Moshfeghi DM, 2007, RETINA-J RET VIT DIS, V27, P269, DOI 10.1097/IAE.0b013e31802e3e9b
   Norda R, 2003, TRANSFUS APHER SCI, V29, P159, DOI 10.1016/S1473-0502(03)00121-6
   Norda R, 2001, TRANSFUS APHER SCI, V25, P33, DOI 10.1016/S1473-0502(01)00079-9
   Pulido Jose S, 2006, Trans Am Ophthalmol Soc, V104, P221
   Pulido JS, 2005, CAN J OPHTHALMOL, V40, P332, DOI 10.1016/S0008-4182(05)80076-6
   Rock G, 2003, TRANSFUS APHER SCI, V29, P167, DOI 10.1016/S1473-0502(03)00111-3
   Stegmayr B, 2008, TRANSFUS APHER SCI, V39, P247, DOI 10.1016/j.transci.2008.09.003
   Swartz M, 1999, INVEST OPHTH VIS SCI, V40, pS319
   US Renal Data System, 2008, USRDS 2008 ANN DAT R
   WIDDER RA, 2002, INVEST OPHTHALMOL VI, V43
   Wild C, 2009, OPHTHALMOLOGE, V106, P127, DOI 10.1007/s00347-008-1768-1
NR 27
TC 20
Z9 20
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1744-9979
EI 1744-9987
J9 THER APHER DIAL
JI Ther. Apher. Dial.
PD JUN
PY 2010
VL 14
IS 3
BP 276
EP 286
DI 10.1111/j.1744-9987.2010.00807.x
PG 11
WC Hematology; Urology & Nephrology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Hematology; Urology & Nephrology
GA 601RD
UT WOS:000278080100003
PM 20609179
DA 2022-11-30
ER

PT J
AU Clark, SJ
   Bishop, PN
   Day, AJ
AF Clark, Simon J.
   Bishop, Paul N.
   Day, Anthony J.
TI Complement factor H and age-related macular degeneration: the role of
   glycosaminoglycan recognition in disease pathology
SO BIOCHEMICAL SOCIETY TRANSACTIONS
LA English
DT Article
DE age-related macular degeneration (MAD); complement factor H (CFH);
   glycosaminoglycan (GAG); immune regulation; inflammation
ID C-REACTIVE PROTEIN; FACTOR HY402H POLYMORPHISM; HEPARIN-BINDING DOMAIN;
   MYOCARDIAL-INFARCTION; COMMON POLYMORPHISM; ALTERNATIVE PATHWAY;
   VARIANT; RISK; GENE; SEQUENCE
AB AMD (age-related macular degeneration) is the major cause of blindness in the western world, associated with the formation of extracellular deposits called drusen in the macula, i.e. the central region of the retina. These drusen contain cellular debris and proteins, including components of the complement system such as the regulator CFH (complement factor H); dysregulation of complement is thought to play a major role in the development of AMD. CFH acts through its capacity to recognize polyanionic structures [e.g. sulfated GAGs (glycosaminoglycans)] found on host tissues, and thereby inactivates any C3b that becomes deposited. Importantly, a common polymorphism in CFH (Y402H) has been strongly associated with an increased risk of AMD. This polymorphism, which causes a tyrosine to histidine coding change, has been shown to alter the binding of CFH to sulfated GAGs, as well as to other ligands including C-reactive protein, necrotic cells and bacterial coat proteins. Of these, the change in the GAG-recognition properties of CFH is likely to be of most significance to AMD. Recent research has revealed that the disease-associated 402H allotype interacts less well (compared with 402Y) with binding sites within the macula (e.g. Bruch's membrane), where the GAGs heparan sulfate and dermatan sulfate play a major role in mediating the interaction with CFH. Reduced binding of the 402H allotype could result in impaired regulation of complement leading to chronic local inflammation that may contribute to the accumulation of drusen and thus the initiation, development and progression of AMD.
C1 [Day, Anthony J.] Univ Manchester, Fac Life Sci, Wellcome Trust Ctr Cell Matrix Res, Manchester M13 9PT, Lancs, England.
   [Bishop, Paul N.] Univ Manchester, Sch Biomed, Manchester M13 9PT, Lancs, England.
   [Clark, Simon J.] Cent Manchester Fdn Trust, Manchester Acad Hlth Sci Ctr, Manchester M13 9WL, Lancs, England.
C3 University of Manchester; University of Manchester; University of
   Manchester
RP Day, AJ (通讯作者)，Univ Manchester, Fac Life Sci, Wellcome Trust Ctr Cell Matrix Res, Oxford Rd, Manchester M13 9PT, Lancs, England.
RI Day, Anthony/O-1658-2015
OI Day, Anthony/0000-0002-1415-3134; Clark, Simon/0000-0001-8394-8355;
   Bishop, Paul/0000-0001-7937-7932
FU Macular Disease Society, Medical Research Council [G0900592]; Manchester
   National Institute for Health Research Biomedical Research Centre; MRC
   [G0900538] Funding Source: UKRI; Medical Research Council [G0900538]
   Funding Source: researchfish
FX We gratefully acknowledge financial support from the Macular Disease
   Society, Medical Research Council [grant number G0900592] and Manchester
   National Institute for Health Research Biomedical Research Centre
CR Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Barlow PN, 2008, ADV EXP MED BIOL, V632, P117, DOI 10.1007/978-0-387-78952-1_10
   Blackmore TK, 1996, J IMMUNOL, V157, P5422
   Blackmore TK, 1998, J IMMUNOL, V160, P3342
   Booij JC, 2010, PROG RETIN EYE RES, V29, P1, DOI 10.1016/j.preteyeres.2009.08.003
   CARK SJ, 2010, J BIOL CHEM, DOI DOI 10.1074/;BCM110103986
   Clark SJ, 2006, J BIOL CHEM, V281, P24713, DOI 10.1074/jbc.M605083200
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   DAY AJ, 1988, IMMUNOGENETICS, V27, P211, DOI 10.1007/BF00346588
   DE CORDOBA, 2008, CLIN EXP IMMUNOL, V151, P1
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Esko JD, 2002, ANNU REV BIOCHEM, V71, P435, DOI 10.1146/annurev.biochem.71.110601.135458
   Feyzi E, 1998, J BIOL CHEM, V273, P13395, DOI 10.1074/jbc.273.22.13395
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gershov D, 2000, J EXP MED, V192, P1353, DOI 10.1084/jem.192.9.1353
   Giannakis E, 2003, EUR J IMMUNOL, V33, P962, DOI 10.1002/eji.200323541
   Haapasalo K, 2008, MOL MICROBIOL, V70, P583, DOI 10.1111/j.1365-2958.2008.06347.x
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hakobyan S, 2008, J BIOL CHEM, V283, P30451, DOI 10.1074/jbc.M803648200
   Hamilton G, 2007, NEUROMOL MED, V9, P331, DOI 10.1007/s12017-007-8013-y
   Hecker LA, 2010, HUM MOL GENET, V19, P209, DOI 10.1093/hmg/ddp472
   Herbert AP, 2007, J BIOL CHEM, V282, P18960, DOI 10.1074/jbc.M609636200
   Herbert AP, 2006, J BIOL CHEM, V281, P16512, DOI 10.1074/jbc.M513611200
   HORSTMANN RD, 1988, P NATL ACAD SCI USA, V85, P1657, DOI 10.1073/pnas.85.5.1657
   JIANG HX, 1991, J IMMUNOL, V146, P2324
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Johnson PT, 2006, P NATL ACAD SCI USA, V103, P17456, DOI 10.1073/pnas.0606234103
   Kardys I, 2006, J AM COLL CARDIOL, V47, P1568, DOI 10.1016/j.jacc.2005.11.076
   KAZATCHKINE MD, 1979, J IMMUNOL, V122, P75
   Kim DD, 2006, CLIN IMMUNOL, V118, P127, DOI 10.1016/j.clim.2005.10.014
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Laine M, 2007, J IMMUNOL, V178, P3831, DOI 10.4049/jimmunol.178.6.3831
   MERI S, 1990, P NATL ACAD SCI USA, V87, P3982, DOI 10.1073/pnas.87.10.3982
   Montes T, 2009, P NATL ACAD SCI USA, V106, P4366, DOI 10.1073/pnas.0812584106
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Mulloy B, 2000, GLYCOBIOLOGY, V10, P1147, DOI 10.1093/glycob/10.11.1147
   Ormsby RJ, 2008, INVEST OPHTH VIS SCI, V49, P1763, DOI 10.1167/iovs.07-1297
   Orth D, 2009, J IMMUNOL, V182, P6394, DOI 10.4049/jimmunol.0900151
   Prosser BE, 2007, J EXP MED, V204, P2277, DOI 10.1084/jem.20071069
   RIPOCHE J, 1988, BIOCHEM J, V249, P593, DOI 10.1042/bj2490593
   Schneider MC, 2009, NATURE, V458, P890, DOI 10.1038/nature07769
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Sjoberg AP, 2007, J BIOL CHEM, V282, P10894, DOI 10.1074/jbc.M610256200
   Sjoberg AP, 2009, MOL IMMUNOL, V46, P830, DOI 10.1016/j.molimm.2008.09.018
   Skerka C, 2007, MOL IMMUNOL, V44, P3398, DOI 10.1016/j.molimm.2007.02.012
   Stark K, 2007, CLIN SCI, V113, P213, DOI 10.1042/CS20070028
   Tammi MI, 2002, J BIOL CHEM, V277, P4581, DOI 10.1074/jbc.R100037200
   Taylor KR, 2006, FASEB J, V20, P9, DOI 10.1096/fj.05-4682rev
   Turnbull J, 2001, TRENDS CELL BIOL, V11, P75, DOI 10.1016/S0962-8924(00)01897-3
   Yu JM, 2007, BIOCHEMISTRY-US, V46, P8451, DOI 10.1021/bi700459a
   Zetterberg M, 2008, AM J MED GENET B, V147B, P720, DOI 10.1002/ajmg.b.30668
NR 55
TC 62
Z9 65
U1 0
U2 12
PU PORTLAND PRESS LTD
PI LONDON
PA CHARLES DARWIN HOUSE, 12 ROGER STREET, LONDON WC1N 2JU, ENGLAND
SN 0300-5127
EI 1470-8752
J9 BIOCHEM SOC T
JI Biochem. Soc. Trans.
PD OCT
PY 2010
VL 38
BP 1342
EP 1348
DI 10.1042/BST0381342
PN 5
PG 7
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 665MG
UT WOS:000283039000032
PM 20863311
DA 2022-11-30
ER

PT J
AU Guo, MY
   Cheng, J
   Etminan, M
   Zafari, Z
   Maberley, D
AF Guo, Michael Y.
   Cheng, Jasmine
   Etminan, Mahyar
   Zafari, Zafar
   Maberley, David
TI One year effectiveness study of intravitreal aflibercept in neovascular
   age-related macular degeneration: a meta-analysis
SO ACTA OPHTHALMOLOGICA
LA English
DT Review
DE aflibercept; age-related macular degeneration; anti-VEGF therapy;
   meta-analysis; visual acuity
ID RANIBIZUMAB VS. AFLIBERCEPT; 12-MONTH OUTCOMES
AB The current body of evidence on the efficacy and safety of aflibercept for age-related macular degeneration (AMD) is steadily growing as large clinical trials and observational studies are continually completed. Our aim was to analyse 1-year visual acuity (VA) outcomes in response to aflibercept therapy and identify factors affecting treatment response using evidence generated from a pooled analysis of current studies. A literature review of multiple electronic databases (EMBASE, MEDLINE, MedMEME) revealed 12 studies meeting inclusion and exclusion criteria for statistical analysis. Treatment posology, baseline patient characteristics, study type, sample size and 12-month change in VA were pooled in a meta-analysis with VA change as the main outcome. Data were then stratified by study design and posology in subgroup analyses. A meta-regression was conducted to regress 12-month VA change against posology, baseline VA and age. Users of aflibercept experienced an overall increase of 7.37 letters (95% confidence interval: 6.27-8.48, p heterogeneity: <0.001) in VA at 12 months of follow-up. In subgroup analyses, mean VA change was higher for randomized control trials and cohorts following regular posology (>7 injections/year) compared to observational studies and irregular posology. The meta-regression showed larger VA gains with regular posology compared to an irregular posology, and decreased effect size as age increased. This meta-analysis strongly suggests improved VA outcomes at 12 months in patients with wet AMD for 2.0 mg aflibercept, comparable to but slightly lower than landmark trials. Increased injection frequency and younger age demonstrates a trend with improved outcomes.
C1 [Guo, Michael Y.; Cheng, Jasmine] Univ British Columbia, Fac Med, Vancouver, BC, Canada.
   [Etminan, Mahyar; Maberley, David] Univ British Columbia, Dept Ophthalmol & Visual Sci, Vancouver, BC, Canada.
   [Zafari, Zafar] Univ Maryland, Sch Pharm, Baltimore, MD 21201 USA.
C3 University of British Columbia; University of British Columbia;
   University System of Maryland; University of Maryland Baltimore
RP Etminan, M (通讯作者)，Univ British Columbia, Eye Care Ctr, Dept Ophthalmol & Visual Sci, Fac Med,Dept Anesthesia Pharmacol & Therapeut, Room 323-2550 Willow St, Vancouver, BC V5Z 3N9, Canada.
EM etminanm@mail.ubc.ca
FU Bayer HealthCare
FX The study was funded by an unrestricted grant from Bayer HealthCare.
CR Ba J, 2015, DRUG DES DEV THER, V9, DOI 10.2147/DDDT.S86269
   Downs SH, 1998, J EPIDEMIOL COMMUN H, V52, P377, DOI 10.1136/jech.52.6.377
   Dugel PU, 2016, CLIN OPHTHALMOL, V10, DOI 10.2147/OPTH.S100764
   Eleftheriadou M, 2017, AM J OPHTHALMOL, V174, P160, DOI 10.1016/j.ajo.2016.09.038
   Elliott DB, 2016, OPHTHAL PHYSL OPT, V36, P355, DOI 10.1111/opo.12310
   Gillies MC, 2016, OPHTHALMOLOGY, V123, P2545, DOI 10.1016/j.ophtha.2016.08.016
   Heier JS, 2016, JAMA OPHTHALMOL, V134, P95, DOI 10.1001/jamaophthalmol.2015.4110
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Kim JH, 2016, GRAEF ARCH CLIN EXP, V254, P2101, DOI 10.1007/s00417-016-3353-7
   Korobelnik JF, 2015, BMC OPHTHALMOL, V15, DOI 10.1186/s12886-015-0035-x
   Munk MR, 2013, AM J OPHTHALMOL, V156, P633, DOI 10.1016/j.ajo.2013.05.037
   Ohnaka M, 2017, GRAEF ARCH CLIN EXP, V255, P657, DOI 10.1007/s00417-016-3507-7
   Oishi A, 2015, AM J OPHTHALMOL, V159, P853, DOI 10.1016/j.ajo.2015.01.018
   Oubraham-Mebroukine H, 2016, REAL LIFE USE INTRAV
   Park DH, 2017, INT OPHTHALMOL, V37, P1205, DOI 10.1007/s10792-016-0391-4
   Rasmussen A, 2017, ACTA OPHTHALMOL, V95, P128, DOI 10.1111/aos.13233
   Razi F, 2016, CLIN OPHTHALMOL, V10, P313, DOI 10.2147/OPTH.S97775
   Ruiz Ramos J, 2015, Arch Soc Esp Oftalmol, V90, P566, DOI 10.1016/j.oftal.2015.07.018
   Santarelli M, 2015, EXPERT OPIN PHARMACO, V16, P1769, DOI 10.1517/14656566.2015.1067679
   Seguin-Greenstein S, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/4095852
   Szabo SM, 2015, CURR MED RES OPIN, V31, P2031, DOI 10.1185/03007995.2015.1084909
   Takayama K, 2017, OPHTHALMOLOGICA, V237, P105, DOI 10.1159/000461785
   Talks JS, 2016, OPHTHALMOLOGY, V123, P337, DOI 10.1016/j.ophtha.2015.09.039
   Thomas M, 2013, CLIN OPHTHALMOL, V7, P495, DOI 10.2147/OPTH.S29974
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Zhang Y, 2017, INVEST OPHTH VIS SCI, V58, P5616, DOI 10.1167/iovs.17-22471
NR 26
TC 10
Z9 10
U1 0
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD FEB
PY 2019
VL 97
IS 1
BP E1
EP E7
DI 10.1111/aos.13825
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HJ0SF
UT WOS:000456872000001
PM 30030923
OA Bronze
DA 2022-11-30
ER

PT J
AU Zhao, L
   Grob, S
   Avery, R
   Kimura, A
   Pieramici, D
   Lee, J
   Rabena, M
   Ortiz, S
   Quach, J
   Cao, G
   Luo, H
   Zhang, M
   Pei, M
   Song, Y
   Tornambe, P
   Goldbaum, M
   Ferreyra, H
   Kozak, I
   Zhang, K
AF Zhao, L.
   Grob, S.
   Avery, R.
   Kimura, A.
   Pieramici, D.
   Lee, J.
   Rabena, M.
   Ortiz, S.
   Quach, J.
   Cao, G.
   Luo, H.
   Zhang, M.
   Pei, M.
   Song, Y.
   Tornambe, P.
   Goldbaum, M.
   Ferreyra, H.
   Kozak, I.
   Zhang, K.
TI Common Variant in VEGFA and Response to Anti-VEGF Therapy for
   Neovascular Age-Related Macular Degeneration
SO CURRENT MOLECULAR MEDICINE
LA English
DT Article
DE Anti-VEGF therapy; choroidal neovascularization; genetics; macular
   degeneration; VEGFA
ID GROWTH-FACTOR GENE; INTRAVITREAL RANIBIZUMAB; CIGARETTE-SMOKING; DOSING
   REGIMEN; RISK-FACTORS; BEVACIZUMAB; DISEASE; POLYMORPHISMS; ASSOCIATION;
   MACULOPATHY
AB Age-related macular degeneration (AMD) is a leading cause of visual impairment in aging populations in industrialized countries. Here we investigated whether the genotype of vascular endothelial growth factor A (VEGFA) gene is associated with response to anti-VEGF therapy. 223 eyes with neovascular AMD were treated with intravitreal anti-VEGF therapy. Responders were defined as patients who had an improvement in best corrected visual acuity (BCVA) of at least 5 letters or one line on the EDTRS visual acuity chart along with resolution of intraretinal or subretinal fluid over 12 months. Patients who did not meet the definition of responders were classified as poor-responders. The vision of responders (n = 148) improved while the vision of poor-responders (n = 75) worsened (P <0.001). Responders on average had a decrease in central foveal thickness (CFT), while poor-responders had an increase in CFT (P <0.001). Compared with the responder group, the poor-responder group had a higher frequency of the risk (T) allele (Allelic P = 0.019) and TT genotype (P = 0.002 under a recessive model) for the VEGFA-rs943080 polymorphism. VEGFA expression was 1.8-fold higher in cells with the VEGFA rs943080 TT genotype than in cells with the VEGFA rs943080 CC genotype (P = 0.012). Age, gender, smoking, diabetes mellitus, and hypertension did not play a significant role in treatment response, but BMI was found to be significantly different between responders and poor-responders (P = 0.033). In conclusion, we demonstrated a potential pharmacogenetic relationship between the VEGFA gene and treatment response to anti-VEGF therapy.
C1 [Zhao, L.; Zhang, K.] Peking Univ, Inst Mol Med, Beijing 100871, Peoples R China.
   [Zhao, L.; Grob, S.; Lee, J.; Ortiz, S.; Quach, J.; Luo, H.; Pei, M.; Song, Y.; Goldbaum, M.; Ferreyra, H.; Kozak, I.; Zhang, K.] Univ Calif San Diego, Dept Ophthalmol, La Jolla, CA 92037 USA.
   [Zhao, L.; Grob, S.; Lee, J.; Ortiz, S.; Quach, J.; Luo, H.; Pei, M.; Song, Y.; Goldbaum, M.; Ferreyra, H.; Kozak, I.; Zhang, K.] Univ Calif San Diego, Inst Genom Med, La Jolla, CA 92037 USA.
   [Zhao, L.; Cao, G.; Luo, H.; Zhang, M.; Zhang, K.] Sichuan Univ, West China Hosp, Dept Ophthalmol, Chengdu 610064, Peoples R China.
   [Zhao, L.; Cao, G.; Luo, H.; Zhang, M.; Zhang, K.] Sichuan Univ, West China Hosp, Mol Med Res Ctr, Chengdu 610064, Peoples R China.
   [Avery, R.; Pieramici, D.; Rabena, M.] Calif Retina Consultants & Res Fdn, Santa Barbara, CA 93103 USA.
   [Kimura, A.] Univ Colorado Denver, Rocky Mt Lions Eye Inst, Dept Ophthalmol, Aurora, CO 80045 USA.
   [Tornambe, P.] San Diego Retina Res Fdn, Poway, CA 92064 USA.
C3 Peking University; University of California System; University of
   California San Diego; University of California System; University of
   California San Diego; Sichuan University; Sichuan University; Children's
   Hospital Colorado; University of Colorado System; University of Colorado
   Anschutz Medical Campus
RP Zhang, K (通讯作者)，Univ Calif San Diego, Shiley Eye Ctr, Dept Ophthalmol, 9415 Campus Point Dr 0946, La Jolla, CA 92093 USA.
EM kang.zhang@gmail.com
RI Zhao, Ling/D-9005-2015; Kozak, Igor/AAC-4645-2019; Quach,
   John/AAS-9482-2021; Goldbaum, Michael/AAG-4258-2020; Zhang,
   Kang/Y-2740-2019
OI Goldbaum, Michael/0000-0002-7721-2736; Zhang, Kang/0000-0002-4549-1697;
   Zhao, Ling/0000-0002-6644-2886
FU 973 Program [2011CB510200, 2013CB967504]; Genentech; NEI/NIH (Bethesda);
   KACST -UCSD Center of Excellence in Nanomedicine; Research to Prevent
   Blindness Research to Prevent Blindness (New York); VA Merit Award, San
   Diego Clinical and Translational Research Institute [1TL1RR031979-01];
   NATIONAL CENTER FOR RESEARCH RESOURCES [TL1RR031979] Funding Source: NIH
   RePORTER; NATIONAL EYE INSTITUTE [R01EY021374] Funding Source: NIH
   RePORTER
FX We thank Guy Hughes and members of the K.Z. laboratory for assistance
   and helpful discussions. This study is supported in part by funding from
   973 Program (2011CB510200, 2013CB967504); Genentech, NEI/NIH (Bethesda),
   KACST -UCSD Center of Excellence in Nanomedicine, Research to Prevent
   Blindness Research to Prevent Blindness (New York), and VA Merit Award,
   San Diego Clinical and Translational Research Institute 1TL1RR031979-01.
   K.Z. is a Chang Jiang Visiting Professor at Peking University.
CR Algvere PV, 2008, ACTA OPHTHALMOL, V86, P482, DOI 10.1111/j.1600-0420.2007.01113.x
   Boekhoorn SS, 2008, OPHTHALMOLOGY, V115, P1899, DOI 10.1016/j.ophtha.2008.06.026
   Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Cano M, 2010, VISION RES, V50, P652, DOI 10.1016/j.visres.2009.08.018
   Chen YH, 2010, MOL INTERV, V10, P271, DOI 10.1124/mi.10.5.4
   Corbo JC, 2010, GENOME RES, V20, P1512, DOI 10.1101/gr.109405.110
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Dhubhghaill SSN, 2010, ADV EXP MED BIOL, V664, P437, DOI 10.1007/978-1-4419-1399-9_50
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Hirvela H, 1996, OPHTHALMOLOGY, V103, P871, DOI 10.1016/S0161-6420(96)30593-9
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Jonasson F, 2011, OPHTHALMOLOGY, V118, P825, DOI 10.1016/j.ophtha.2010.08.044
   Klein R, 1998, AM J EPIDEMIOL, V147, P103
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Kloeckener-Gruissem B, 2011, INVEST OPHTH VIS SCI, V52, P4694, DOI 10.1167/iovs.10-6080
   Lin JM, 2008, AM J OPHTHALMOL, V145, P1045, DOI 10.1016/j.ajo.2008.01.027
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   McKibbin M, 2012, BRIT J OPHTHALMOL, V96, P208, DOI 10.1136/bjo.2010.193680
   Montezuma Sandra R, 2007, Semin Ophthalmol, V22, P229, DOI 10.1080/08820530701745140
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
NR 26
TC 24
Z9 27
U1 0
U2 13
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1566-5240
J9 CURR MOL MED
JI Curr. Mol. Med.
PD JUL
PY 2013
VL 13
IS 6
BP 929
EP 934
DI 10.2174/15665240113139990048
PG 6
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA 165TP
UT WOS:000320507400005
PM 23745581
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Ota, H
   Takeuchi, J
   Nakano, Y
   Horiguchi, E
   Taki, Y
   Ito, Y
   Terasaki, H
   Nishiguchi, KM
   Kataoka, K
AF Ota, Hikaru
   Takeuchi, Jun
   Nakano, Yuyako
   Horiguchi, Etsuyo
   Taki, Yosuke
   Ito, Yasuki
   Terasaki, Hiroko
   Nishiguchi, Koji M.
   Kataoka, Keiko
TI Switching from aflibercept to brolucizumab for the treatment of
   refractory neovascular age-related macular degeneration
SO JAPANESE JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Neovascular age-related macular degeneration; Brolucizumab;
   Anti-vascular endothelial growth factor agent; Real-world outcomes
ID INTRAVITREAL AFLIBERCEPT; CHOROIDAL THICKNESS; THERAPY
AB Purpose To examine the 16-week outcomes of switching to brolucizumab in eyes with neovascular age-related macular degeneration (nAMD) refractory to aflibercept. Study design Retrospective observational study. Methods Data of eyes with nAMD who switched to brolucizumab because of resistance to aflibercept were collected. The best-corrected visual acuity (BCVA; in logarithm of the minimum angle of resolution), central retinal thickness (CRT), central choroidal thickness (CCT), and exudative status on optical coherence tomography were analyzed. Results A total of 48 eyes of 48 patients were reviewed. At 4 to 7 weeks after switching, BCVA changed from 0.26 +/- 0.19 to 0.25 +/- 0.21 (not significant; P = 0.95), but CRT significantly decreased from 298.9 +/- 108.4 mu m to 241.9 +/- 92.5 mu m (P < 0.001) and CCT from 182.6 +/- 89.3 mu m to 169.7 +/- 82.6 mu m (P < 0.001). Of the 23 eyes refractory to monthly aflibercept injections, 12 (52.2%) achieved a dry macula, and 8 (34.8%) reduced exudative changes at 1 month. At 16 weeks, 31 eyes (64.6%) achieved the treatment interval >= 8 weeks. Two patients (4.2%) dropped out, 7 eyes (14.6%) developed intraocular inflammation (IOI), and 8 eyes (16.7%) switched back to aflibercept because of the failure to extend the treatment interval >= 8 weeks. Conclusion Switching to brolucizumab in eyes refractory to aflibercept conferred favorable outcomes in controlling exudative changes. However, IOI and the regulation of the treatment interval to at least 8 weeks during the maintenance phase disrupted the continuation of brolucizumab treatment.
C1 [Ota, Hikaru; Takeuchi, Jun; Nakano, Yuyako; Horiguchi, Etsuyo; Taki, Yosuke; Ito, Yasuki; Terasaki, Hiroko; Nishiguchi, Koji M.; Kataoka, Keiko] Nagoya Univ, Dept Ophthalmol, Grad Sch Med, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.
   [Kataoka, Keiko] Kyorin Univ, Dept Ophthalmol, Sch Med, Tokyo, Japan.
   [Ito, Yasuki] Fujita Hlth Univ, Dept Ophthalmol, Toyoake, Aichi, Japan.
C3 Nagoya University; Kyorin University; Fujita Health University
RP Kataoka, K (通讯作者)，Nagoya Univ, Dept Ophthalmol, Grad Sch Med, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.; Kataoka, K (通讯作者)，Kyorin Univ, Dept Ophthalmol, Sch Med, Tokyo, Japan.
EM keiko-kataoka@ks.kyorin-u.ac.jp
CR Augsburger M, 2019, GRAEF ARCH CLIN EXP, V257, P1889, DOI 10.1007/s00417-019-04404-0
   Baumal CR, 2020, OPHTHALMOLOGY, V127, P1345, DOI 10.1016/j.ophtha.2020.04.017
   Bulirsch LM, 2022, BRIT J OPHTHALMOL, V106, P1288, DOI 10.1136/bjophthalmol-2020-318672
   Decroos FC, 2017, AM J OPHTHALMOL, V180, P142, DOI 10.1016/j.ajo.2017.06.002
   Dugel PU, 2021, OPHTHALMOLOGY, V128, P89, DOI [10.1016/j.opatha.2020.06.028, 10.1016/j.ophtha.2020.06.028]
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Enriquez AB, 2021, JAMA OPHTHALMOL, V139, P441, DOI 10.1001/jamaophthalmol.2020.7085
   Gharbiya M, 2015, J OCUL PHARMACOL TH, V31, P357, DOI 10.1089/jop.2014.0160
   Haug Sara J, 2020, Am J Ophthalmol Case Rep, V18, P100680, DOI 10.1016/j.ajoc.2020.100680
   Kataoka K, 2021, JPN J OPHTHALMOL, V65, P199, DOI 10.1007/s10384-021-00818-8
   Kim JH, 2016, BRIT J OPHTHALMOL, V100, P1634, DOI 10.1136/bjophthalmol-2015-308074
   Koizumi H, 2016, OPHTHALMOLOGY, V123, P617, DOI 10.1016/j.ophtha.2015.10.039
   Kondapalli SSA, 2020, JAMA OPHTHALMOL, V138, P1103, DOI 10.1001/jamaophthalmol.2020.2810
   Lee WK, 2018, JAMA OPHTHALMOL, V136, P786, DOI 10.1001/jamaophthalmol.2018.1804
   Maruko I, 2021, GRAEF ARCH CLIN EXP, V259, P2857, DOI 10.1007/s00417-021-05136-w
   Matsumoto H, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-86014-7
   Mazaraki K, 2015, BRIT J OPHTHALMOL, V99, P1341, DOI 10.1136/bjophthalmol-2015-306636
   Ohji M, 2020, ADV THER, V37, P1173, DOI 10.1007/s12325-020-01236-x
   Traine PG, 2019, OPHTHALMOL RETINA, V3, P393, DOI 10.1016/j.oret.2019.01.018
   Tsunekawa Y, 2021, JPN J OPHTHALMOL, V65, P69, DOI 10.1007/s10384-020-00783-8
   Witkin AJ., 2020, J VITREORETIN DIS, V4, P69, DOI [10.1177/2474126419880383, DOI 10.1177/2474126419880383]
   Yamamoto A, 2015, OPHTHALMOLOGY, V122, P1866, DOI 10.1016/j.ophtha.2015.05.024
   Yonekawa Y, 2013, AM J OPHTHALMOL, V156, P29, DOI 10.1016/j.ajo.2013.03.030
NR 23
TC 1
Z9 1
U1 2
U2 2
PU SPRINGER JAPAN KK
PI TOKYO
PA SHIROYAMA TRUST TOWER 5F, 4-3-1 TORANOMON, MINATO-KU, TOKYO, 105-6005,
   JAPAN
SN 0021-5155
EI 1613-2246
J9 JPN J OPHTHALMOL
JI Jpn. J. Ophthalmol.
PD MAY
PY 2022
VL 66
IS 3
BP 278
EP 284
DI 10.1007/s10384-022-00908-1
EA MAR 2022
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 0V8UO
UT WOS:000762905700001
PM 35233693
DA 2022-11-30
ER

PT J
AU Nomura, Y
   Takahashi, H
   Tan, X
   Fujimura, S
   Obata, R
   Yanagi, Y
AF Nomura, Yoko
   Takahashi, Hidenori
   Tan, Xue
   Fujimura, Shigeto
   Obata, Ryo
   Yanagi, Yasuo
TI Effects of vitreomacular adhesion on ranibizumab treatment in Japanese
   patients with age-related macular degeneration
SO JAPANESE JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Vitreomacular adhesion; Ranibizumab
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; GROWTH-FACTOR TREATMENT; THERAPY
AB Purpose To investigate the effects of vitreomacular adhesion (VMA) on intravitreal ranibizumab treatment in Japanese patients with exudative age-related macular degeneration (AMD).
   Methods This was a retrospective comparative study that included 123 eyes from 123 patients with exudative AMD. The presence or absence of VMA was examined by spectral domain optical coherence tomography. The association of VMA with best-corrected visual acuity (BCVA) and central retinal thickness (CRT) at 3, 6, and 12 months after ranibizumab treatment was evaluated.
   Results In the group of eyes without VMA [VMA(-)], the mean BCVA was 0.41 logMAR at baseline and significantly improved to 0.28, 0.30, and 0.29 logMAR at 3, 6, and 12 months following the initiation of treatment (P<0.0001,<0.0001,<0.0001), respectively. In the group of eyes with VMA [VMA(+)], the mean BCVA was 0.42 logMAR at baseline, and there was no improvement at any of the measurement time-points during the follow-up period [0.39, 0.40, and 0.39 logMAR at 3, 6, and 12 months (P = 0.53, 0.75, 0.67), respectively]. The mean baseline CRT in the VMA(-) and VMA(+) groups was 326 and 370 mu m, respectively, decreasing to 195 and 293 mu m (P<0.0001 and P = 0.0070), respectively, at 12 months. A better baseline BCVA was associated with poor visual response to intravitreal ranibizumab.
   Conclusions Our study of Japanese patients with AMD managed in real-world clinical practice revealed that both VMA and BCVA at baseline were associated with a poor visual response to intravitreal ranibizumab. These results are in agreement with previously reported findings for other ethnic groups.
C1 [Nomura, Yoko; Takahashi, Hidenori; Tan, Xue; Fujimura, Shigeto; Obata, Ryo; Yanagi, Yasuo] Univ Tokyo, Sch Med, Dept Ophthalmol, Bunkyo Ku, Tokyo 1138655, Japan.
C3 University of Tokyo
RP Nomura, Y (通讯作者)，Univ Tokyo, Sch Med, Dept Ophthalmol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.
EM nomurayoko-tky@umin.ac.jp
RI Yanagi, Yasuo/AAF-2670-2020; Takahashi, Hidenori/H-2945-2019; Yanagi,
   Yasuo/AAA-5441-2022
OI Takahashi, Hidenori/0000-0001-5331-4730; Yanagi,
   Yasuo/0000-0002-0362-7285; Obata, Ryo/0000-0002-1762-0797
CR Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Cho HJ, 2013, RETINA-J RET VIT DIS, V33, P2126, DOI 10.1097/IAE.0b013e3182899296
   Duker JS, 2013, OPHTHALMOLOGY, V120, P2611, DOI 10.1016/j.ophtha.2013.07.042
   Iranmanesh R, 2007, EUR J OPHTHALMOL, V17, P75, DOI 10.1177/112067210701700111
   Krebs I, 2007, AM J OPHTHALMOL, V144, P741, DOI 10.1016/j.ajo.2007.07.024
   Lee SJ, 2011, OPHTHALMOLOGY, V118, P101, DOI 10.1016/j.ophtha.2010.04.015
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Mayr-Sponer U, 2013, OPHTHALMOLOGY, V120, P2620, DOI 10.1016/j.ophtha.2013.05.032
   Mojana F, 2008, AM J OPHTHALMOL, V146, P218, DOI 10.1016/j.ajo.2008.04.027
   Nomura Y, 2011, OPHTHALMOLOGY, V118, P853, DOI 10.1016/j.ophtha.2010.09.001
   Obata R, 2006, JPN J OPHTHALMOL, V50, P354, DOI 10.1007/s10384-005-0337-2
   Ondes F, 2000, JPN J OPHTHALMOL, V44, P91, DOI 10.1016/S0021-5155(99)00174-4
   Quaranta-El Maftouhi M, 2006, EUR J OPHTHALMOL, V16, P134
   Robison CD, 2009, AM J OPHTHALMOL, V148, P79, DOI 10.1016/j.ajo.2009.01.014
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Terao R, 2014, JPN J OPHTHALMOL, V58, P139, DOI 10.1007/s10384-013-0302-4
   Uney GO, 2014, RETINA-J RET VIT DIS, V34, P32, DOI 10.1097/IAE.0b013e318295f72e
   Weber-Krause Brigitte, 1996, Ophthalmologe, V93, P660, DOI 10.1007/s003470050054
   Williams TA, 2011, EYE, V25, P1617, DOI 10.1038/eye.2011.224
NR 20
TC 22
Z9 24
U1 0
U2 3
PU SPRINGER JAPAN KK
PI TOKYO
PA SHIROYAMA TRUST TOWER 5F, 4-3-1 TORANOMON, MINATO-KU, TOKYO, 105-6005,
   JAPAN
SN 0021-5155
EI 1613-2246
J9 JPN J OPHTHALMOL
JI Jpn. J. Ophthalmol.
PD SEP
PY 2014
VL 58
IS 5
BP 443
EP 447
DI 10.1007/s10384-014-0333-5
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AP5ZE
UT WOS:000342156400009
PM 25096269
DA 2022-11-30
ER

PT J
AU Ehrlich, R
   Weinberger, D
   Priel, E
   Axer-Siegel, R
AF Ehrlich, Rita
   Weinberger, Dov
   Priel, Ethan
   Axer-Siegel, Ruth
TI OUTCOME OF BEVACIZUMAB (AVASTIN) INJECTION IN PATIENTS WITH AGE-RELATED
   MACULAR DEGENERATION AND LOW VISUAL ACUITY
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; choroidal neovascularization;
   intravitreal bevacizumab (Avastin)
ID INTRAVITREAL BEVACIZUMAB; CHOROIDAL NEOVASCULARIZATION; RANIBIZUMAB;
   PEGAPTANIB; SECONDARY; THERAPY
AB Objective: To study the effect of intravitreal bevacizumab for the treatment of long-standing exudative age-related macular degeneration (AMD) and low visual acuity.
   Methods: Forty-seven patients (48 eyes) aged 57 to 90 years with AMD for 5 months or more and visual acuity of 20/150 or less were treated with one or more injections of bevacizumab 1.25 mg/0.05 mL between December 2005 and March 2007. The files were reviewed for background data, visual acuity, fluorescein angiography, retinal thickness, and complications.
   Results: Thirty-two eyes were treated previously with photodynamic therapy. Mean duration of symptoms was 17.9 +/- 17.5 months; mean number of bevacizumab injections was 3.41 +/- 2; and mean follow-up was 27 +/- 15 weeks. Snellen visual acuity improved from 20/150 to hand movements (mean logMAR 1.34 +/- 0.29) to 20/50 to counting fingers (mean logMar 1.2 +/- 0.42) (P = 0.003, paired t-test). Visual acuity improved by >= 3 lines in 12 eyes (25%); showed no change in 9 eyes (19%); and deteriorated by >= 3 lines in 4 eyes (8.3%). Visual acuity was at least 20/150 in 16 eyes (33.3%) at the end of follow-up compared with 4 eyes (8.3%) before treatment (P = 0.02, McNemar test). Mean central retinal thickness (measured in 22 eyes) decreased from 324 +/- 121 mu m to 264 +/- 65 mu m (P = 0.02, paired t-test).
   Conclusions: Patients with chronic exudative AMD and low visual acuity may benefit from intravitreal bevacizumab injections. RETINA 28:1302-1307, 2008
C1 [Ehrlich, Rita; Weinberger, Dov; Axer-Siegel, Ruth] Rabin Med Ctr, Dept Ophthalmol, IL-49100 Petah Tiqwa, Israel.
   [Weinberger, Dov; Axer-Siegel, Ruth] Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel.
   [Priel, Ethan] Mor Inst Med Data, Bnei Braq, Israel.
C3 Rabin Medical Center; Tel Aviv University; Sackler Faculty of Medicine
RP Ehrlich, R (通讯作者)，Rabin Med Ctr, Dept Ophthalmol, Beilinson Campus, IL-49100 Petah Tiqwa, Israel.
EM ehrlichy@netvision.net.il
OI Ehrlich, Rita/0000-0002-4167-8809
CR Abraham-Marin ML, 2007, GRAEF ARCH CLIN EXP, V245, P651, DOI 10.1007/s00417-006-0411-6
   Aggio FB, 2007, GRAEF ARCH CLIN EXP, V245, P215, DOI 10.1007/s00417-006-0412-5
   Aisenbrey S, 2007, GRAEF ARCH CLIN EXP, V245, P941, DOI 10.1007/s00417-006-0471-7
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P855, DOI 10.1016/j.ophtha.2007.01.017
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chakravarthy U, 2006, OPHTHALMOLOGY, V113, P1508, DOI 10.1016/j.ophtha.2006.02.064
   Falkenstein IA, 2008, OPHTHALMOLOGY, V115, P319, DOI 10.1016/j.ophtha.2007.05.028
   Falkenstein IA, 2007, RETINA-J RET VIT DIS, V27, P701, DOI 10.1097/IAE.0b013e3180654240
   Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381
   Goff MJ, 2007, RETINA-J RET VIT DIS, V27, P432, DOI 10.1097/IAE.0b013e318042b53f
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Jonas JB, 2007, ACTA OPHTHALMOL SCAN, V85, P563, DOI 10.1111/j.1600-0420.2007.00891.x
   Mordenti J, 1999, TOXICOL PATHOL, V27, P536, DOI 10.1177/019262339902700507
   Moshfeghi AA, 2006, OPHTHALMOLOGY, V113, P2002, DOI 10.1016/j.ophtha.2006.05.070
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
NR 18
TC 19
Z9 20
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD OCT
PY 2008
VL 28
IS 9
BP 1302
EP 1307
DI 10.1097/IAE.0b013e3181803c2a
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 366IM
UT WOS:000260474200020
PM 18664935
DA 2022-11-30
ER

PT J
AU Mohaimin, SM
   Saha, SK
   Khan, AM
   Arif, AM
   Kanagasingam, Y
AF Mohaimin, Sultan Mohammad
   Saha, Sajib Kumar
   Khan, Alve Mahamud
   Arif, Abu Shamim Mohammad
   Kanagasingam, Yogesan
TI Automated method for the detection and segmentation of drusen in colour
   fundus image for the diagnosis of age-related macular degeneration
SO IET IMAGE PROCESSING
LA English
DT Article
DE eye; medical image processing; image segmentation; image colour
   analysis; object detection; automated method; drusen segmentation;
   drusen detection; colour fundus image; age-related macular degeneration
   diagnosis; AMD; quantitative mapping; retinal abnormalities detection;
   disease; retina; nonuniform illumination correction; inter-subject
   variability minimization; colour normalisation method; ARIA datasets;
   STARE dataset
ID FEATURES; SYSTEM
AB Age-related macular degeneration (AMD) is one of the main reasons for visual impairment worldwide. The assessment of risk for the development of AMD requires reliable detection and quantitative mapping of retinal abnormalities that are considered as precursors of the disease. Typical signs of the latter are the so-called drusen that appear as yellowish spots in the retina. Automated detection and segmentation of drusen provide vital information about the severity of the disease. The authors propose a novel method for the detection and segmentation of drusen in colour fundus images. The method combines colour information of the object with its boundary information for the accurate detection and segmentation of drusen. To perform non-uniform illumination correction and to minimise inter-subject variability a novel colour normalisation method has been proposed. Experiments are conducted on publicly available STARE and ARIA datasets. The method achieves an overall accuracy of 96.62% which is about 4% higher than the state-of-the-art method. The sensitivity and specificity of the proposed method are 95.96 and 97.64%, respectively.
C1 [Mohaimin, Sultan Mohammad; Khan, Alve Mahamud; Arif, Abu Shamim Mohammad] Khulna Univ, Comp Sci & Engn Discipline, Khulna, Bangladesh.
   [Saha, Sajib Kumar; Kanagasingam, Yogesan] CSIRO, Hlth Res Ctr E, Perth, WA, Australia.
C3 Khulna University; Commonwealth Scientific & Industrial Research
   Organisation (CSIRO)
RP Saha, SK (通讯作者)，CSIRO, Hlth Res Ctr E, Perth, WA, Australia.
EM Sajib.Saha@csiro.au
CR Akram MU, 2013, 2013 INTERNATIONAL CONFERENCE ON ELECTRONICS, COMPUTER AND COMPUTATION (ICECCO), P17, DOI 10.1109/ICECCO.2013.6718217
   [Anonymous], 2016, INTRO WAVELETS
   Baldevbhai PJ., 2012, J ELECT COMMUNICATIO, V1, P24, DOI [10.9790/2834-0122445, DOI 10.9790/2834-0122445]
   Bhuiyan A., 2013, J CLIN EXP OPHTHALMO, V4, P2
   CORTES C, 1995, MACH LEARN, V20, P273, DOI 10.1007/BF00994018
   Fairchild M.D., 2005, COLOR APPEARANCE MOD
   FORGY EW, 1965, BIOMETRICS, V21, P768
   Gonzalez R. C., 2008, DIGITAL IMAGE PROCES
   Grinsven V., 2013, INVEST OPHTH VIS SCI, V54, P3019
   HARALICK RM, 1973, IEEE T SYST MAN CYB, VSMC3, P610, DOI 10.1109/TSMC.1973.4309314
   Kumari K, 2015, J BIOMED ENG MED IMA, V2, P18
   Mittal D, 2015, COMPUT ELECTR ENG, V47, P82, DOI 10.1016/j.compeleceng.2015.08.014
   Mookiah MRK, 2014, COMPUT BIOL MED, V53, P55, DOI 10.1016/j.compbiomed.2014.07.015
   Mookiah MRK, 2014, MED BIOL ENG COMPUT, V52, P781, DOI 10.1007/s11517-014-1180-8
   Mookiah MRK, 2013, COMPUT BIOL MED, V43, P2136, DOI 10.1016/j.compbiomed.2013.10.007
   Mora AD, 2011, BIOMED ENG ONLINE, V10, DOI 10.1186/1475-925X-10-59
   Moreno A, 2011, LECT NOTES COMPUT SC, V6626, P165, DOI 10.1007/978-3-642-20404-3_13
   Nguyen UTV, 2013, PATTERN RECOGN, V46, P703, DOI 10.1016/j.patcog.2012.08.009
   Park M., 2006, P INT C COMP GRAPH I, P141, DOI DOI 10.1109/CGIV.2006.63
   Prasath AR, 2015, RES J INF TECHNOL, V7, P70
   Raza G, 2013, P 2013 IEEE JORD C A, P1
   Remeseiro B, 2009, LECT NOTES COMPUT SC, V5717, P187, DOI 10.1007/978-3-642-04772-5_25
   Russ JC, 1999, IMAGE PROCESSING HDB
   Saha S, 2017, J DIGIT IMAGING, P1
   Saha SK, 2017, INVEST OPHTH VIS SCI, V58
   Saha SK, 2016, J MED SYST, V40, DOI 10.1007/s10916-016-0640-0
   Soille P., 2013, MORPHOLOGICAL IMAGE
   Sundaresan V., 2015, P OPHTH MED IM AN 2, P81
   Sung JM, 2006, PATTERN RECOGN LETT, V27, P66, DOI 10.1016/j.patrec.2005.07.003
   Phan TV, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/5893601
   van de Sande KEA, 2010, IEEE T PATTERN ANAL, V32, P1582, DOI 10.1109/TPAMI.2009.154
   Wong DWK, 2013, I S BIOMED IMAGING, P884
   Zheng YJ, 2013, I S BIOMED IMAGING, P1448
NR 33
TC 3
Z9 3
U1 0
U2 4
PU INST ENGINEERING TECHNOLOGY-IET
PI HERTFORD
PA MICHAEL FARADAY HOUSE SIX HILLS WAY STEVENAGE, HERTFORD SG1 2AY, ENGLAND
SN 1751-9659
EI 1751-9667
J9 IET IMAGE PROCESS
JI IET Image Process.
PD JUN
PY 2018
VL 12
IS 6
BP 919
EP 927
DI 10.1049/iet-ipr.2017.0685
PG 9
WC Computer Science, Artificial Intelligence; Engineering, Electrical &
   Electronic; Imaging Science & Photographic Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Computer Science; Engineering; Imaging Science & Photographic Technology
GA GL6PO
UT WOS:000437310900010
DA 2022-11-30
ER

PT J
AU Keizman, D
   Yang, YX
   Gottfried, M
   Dresler, H
   Leibovitch, I
   Haynes, K
   Mamtani, R
   Boursi, B
AF Keizman, Daniel
   Yang, Yu-Xiao
   Gottfried, Maya
   Dresler, Hadas
   Leibovitch, Ilan
   Haynes, Kevin
   Mamtani, Ronac
   Boursi, Ben
TI The Association between Age-Related Macular Degeneration and Renal Cell
   Carcinoma: A Nested Case-Control Study
SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
LA English
DT Article
ID CANCER; RISK; VALIDATION
AB Background: Overexpression of VEGF is implicated in the pathogenesis of both renal cell carcinoma (RCC) and age-related macular degeneration (AMD). We evaluated the association between AMD and RCC risk.
   Methods: We conducted a matched case-control study within a population-representative database from the United Kingdom. Study cases were defined as individuals with any diagnostic code of RCC. For every case, four eligible controls were matched on age, sex, practice site, calendar time, and duration of follow-up. Exposure of interest was diagnosis of AMD prior to cancer diagnosis. Adjusted ORs and 95% confidence intervals (CI) for RCC were estimated using conditional logistic regression. In a secondary analysis, we evaluated the association between other retinopathies and RCC and AMD and the hypovascular pancreatic cancer.
   Results: The study population included 1,547 patients with RCC and 6,066 matched controls. Median follow-up time was 6 years (IQR, 3-9). AMD diagnosis was associated with a significantly increased RCC risk (OR, 1.89; 95% CI, 1.09-3.29). In contrast, there was no association between other retinopathies and RCC risk (OR, 0.8; 95% CI, 0.56-1.15). AMD was associated with a lower risk for pancreatic cancer (OR, 0.47; 95% CI, 0.35-0.64).
   Conclusions: Patients with AMD may be at higher risk for RCC. Providers should be aware of this potential link and consider screening for RCC within this population.
   Impact: Providers should be aware of the potential link between AMD and RCC. (C) 2017 AACR.
C1 [Keizman, Daniel; Gottfried, Maya; Dresler, Hadas] Meir Med Ctr, Dept Oncol, Kefar Sava, Israel.
   [Keizman, Daniel; Gottfried, Maya; Dresler, Hadas; Leibovitch, Ilan] Tel Aviv Univ, Sackler Sch Med, Tel Aviv, Israel.
   [Yang, Yu-Xiao; Haynes, Kevin; Mamtani, Ronac; Boursi, Ben] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Leibovitch, Ilan] Meir Med Ctr, Dept Urol, Kefar Sava, Israel.
C3 Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University;
   Sackler Faculty of Medicine; University of Pennsylvania; Pennsylvania
   Medicine; Tel Aviv University; Sackler Faculty of Medicine
RP Keizman, D (通讯作者)，Meir Med Ctr, Tshernichovsky 59, IL-44281 Kefar Sava, Israel.
EM danielkeizman@gmail.com
RI yang, yx/GZM-0464-2022
FU National Center for Research Resources; National Center for Advancing
   Translational Sciences, NIH [UL1TR000003]; NIH K23 grant [CA187185];
   NATIONAL CANCER INSTITUTE [K23CA187185] Funding Source: NIH RePORTER
FX The work was supported by the National Center for Research Resources and
   the National Center for Advancing Translational Sciences, NIH, through
   grant UL1TR000003. R. Mamtani was supported by NIH K23 grant CA187185.
CR Benson Tim, 2011, Inform Prim Care, V19, P173
   Blak Betina T, 2011, Inform Prim Care, V19, P251
   Boursi B, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/djv084
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chen GH, 2015, RETINA-J RET VIT DIS, V35, P187, DOI 10.1097/IAE.0000000000000301
   Cheung N, 2007, ARCH OPHTHALMOL-CHIC, V125, P1241, DOI 10.1001/archopht.125.9.1241
   CHISHOLM J, 1990, BRIT MED J, V300, P1092, DOI 10.1136/bmj.300.6732.1092
   Chow WH, 2000, NEW ENGL J MED, V343, P1305, DOI 10.1056/NEJM200011023431804
   Craven KE, 2016, ONCOTARGET, V7, P323, DOI 10.18632/oncotarget.6345
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   GREENLAND S, 1982, AM J EPIDEMIOL, V116, P547, DOI 10.1093/oxfordjournals.aje.a113439
   Haynes K, 2009, PHARMACOEPIDEM DR S, V18, P730, DOI 10.1002/pds.1774
   Hunt JD, 2005, INT J CANCER, V114, P101, DOI 10.1002/ijc.20618
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Lewis JD, 2007, PHARMACOEPIDEM DR S, V16, P393, DOI 10.1002/pds.1335
   Li LJ, 2011, HEMATOL ONCOL CLIN N, V25, P667, DOI 10.1016/j.hoc.2011.04.004
   Lindblad P, 1999, DIABETOLOGIA, V42, P107, DOI 10.1007/s001250051122
   Mamtani R, 2015, CANCER EPIDEM BIOMAR, V24, P303, DOI 10.1158/1055-9965.EPI-14-0677
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Motzer RJ, 2007, NEW ENGL J MED, V356, P115, DOI 10.1056/NEJMoa065044
   Na X, 2003, J UROLOGY, V170, P588, DOI 10.1097/01.ju.0000074870.54671.98
   PEARCE N, 1993, INT J EPIDEMIOL, V22, P1189, DOI 10.1093/ije/22.6.1189
   Rickman CB, 2013, INVEST OPHTH VIS SCI, V54, pORSF68, DOI 10.1167/iovs.13-12757
NR 23
TC 3
Z9 3
U1 0
U2 2
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1055-9965
EI 1538-7755
J9 CANCER EPIDEM BIOMAR
JI Cancer Epidemiol. Biomarkers Prev.
PD MAY
PY 2017
VL 26
IS 5
BP 743
EP 747
DI 10.1158/1055-9965.EPI-16-0759
PG 5
WC Oncology; Public, Environmental & Occupational Health
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Public, Environmental & Occupational Health
GA ET8CB
UT WOS:000400524700011
PM 28062400
DA 2022-11-30
ER

PT J
AU Toy, BC
   Krishnadev, N
   Indaram, M
   Cunningham, D
   Cukras, CA
   Chew, EY
   Wong, WT
AF Toy, Brian C.
   Krishnadev, Nupura
   Indaram, Maanasa
   Cunningham, Denise
   Cukras, Catherine A.
   Chew, Emily Y.
   Wong, Wai T.
TI Drusen Regression is Associated With Local Changes in Fundus
   Autofluorescence in Intermediate Age-Related Macular Degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID GEOGRAPHIC ATROPHY; SOFT DRUSEN; LASER PHOTOCOAGULATION; BRUCHS
   MEMBRANE; PATHOGENESIS; MACULOPATHY; MACROPHAGES; PROGRESSION;
   EVOLUTION; DISEASE
AB PURPOSE: To investigate the association of spontaneous drusen regression in intermediate age-related macular degeneration (AMD) with Changes on fundus photography and fundus autofluorescence (FAF) imaging.
   DESIGN: Prospective observational case series.
   METHODS: Fundus images from 58 eyes (in 58 patients) with intermediate AMD and large drusen were assessed over 2 years for areas of drusen regression that exceeded the area of circle Cl (diameter 125 mu m; Age-Related Eye Disease Study grading protocol). Manual segmentation and computer-based image analysis were used to detect and delineate areas of drusen regression. Delineated regions were graded as to their appearance on fundus photographs and FAF images, and changes in FAF signal were graded manually and quantitated using automated image analysis.
   RESULTS: Drusen regression was detected in approximately half of study eyes using manual (48%) and computer-assisted (50%) techniques. At year-2, the clinical appearance of areas of drusen regression on fundus photography was mostly unremarkable, with a majority of eyes (71%) demonstrating no detectable clinical abnormalities, and the remainder (29%) showing minor pigmentary changes. However, drusen regression areas were associated with local changes in FAF that were significantly more prominent than changes on fundus photography. A majority of eyes (64%-66%) demonstrated a predominant decrease in overall FAF signal, while 14%-21% of eyes demonstrated a predominant increase in overall FAF signal.
   CONCLUSIONS: FAF imaging demonstrated that drusen regression in intermediate AMD was often accompanied by changes in local autofluorescence signal. Drusen regression may be associated with concurrent structural and physiologic changes in the outer retina. (Published by Elsevier Inc.)
C1 [Toy, Brian C.; Indaram, Maanasa; Wong, Wai T.] NEI, Unit Neuron Glia Interact Retinal Dis, NIH, Bethesda, MD 20892 USA.
   [Krishnadev, Nupura; Cukras, Catherine A.; Chew, Emily Y.] NEI, Div Epidemiol & Clin Applicat, NIH, Bethesda, MD 20892 USA.
   [Cunningham, Denise] NEI, Off Clin Director, NIH, Bethesda, MD 20892 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); National Institutes of Health (NIH) - USA; NIH National Eye
   Institute (NEI); National Institutes of Health (NIH) - USA; NIH National
   Eye Institute (NEI)
RP Wong, WT (通讯作者)，NEI, Unit Neuron Glia Interact Retinal Dis, NIH, Bldg 6,Room 215, Bethesda, MD 20892 USA.
EM wongw@nei.nih.gov
RI Wong, Wai/B-6118-2017
OI Wong, Wai/0000-0003-0681-4016; Toy, Brian/0000-0002-9612-5697
FU Clinical Research Training Program; National Institutes of Health
   (Bethesda, Maryland, USA); Pfizer Inc (New York, New York, USA);
   National Eye Institute Intramural Research Program (Bethesda, Maryland,
   USA); NATIONAL EYE INSTITUTE [ZIAEY000463] Funding Source: NIH RePORTER
FX ALL AUTHORS HAVE COMPLETED AND SUBMITTED THE ICMJE FORM FOR DISCLOSURE
   OF POTENTIAL CONFLICTS OF INTEREST. Financial disclosures: B.T. was
   supported by the Clinical Research Training Program, a public-private
   partnership supported jointly by the National Institutes of Health
   (Bethesda, Maryland, USA) and Pfizer Inc (New York, New York, USA; via a
   grant to the Foundation for the National Institutes of Health [Bethesda,
   Maryland, USA] from Pfizer). The sponsor or funding organization had no
   role in the design or conduct of this research. This research was funded
   by the National Eye Institute Intramural Research Program (Bethesda,
   Maryland, USA). Contributions of authors: design of study (B.T., N.K.,
   E.C., W.W.); conduct of study (N.K., D.C., C.C., E.Y., W.W.); analysis
   and interpretation of data (B.T., N.K., M.I., W.W.); writing of
   manuscript (B.T., N.K., M.I., D.C., C.C., E.Y., W.W.); and final
   approval of version to be published (B.T., N.K., M.I., D.C., C.C., E.Y.,
   W.W.).
CR Abdelsalam A, 1999, SURV OPHTHALMOL, V44, P1, DOI 10.1016/S0039-6257(99)00072-7
   BRESSLER NM, 1995, ARCH OPHTHALMOL-CHIC, V113, P301, DOI 10.1001/archopht.1995.01100030055022
   Cherepanoff S, 2010, BRIT J OPHTHALMOL, V94, P918, DOI 10.1136/bjo.2009.165563
   Cukras C, 2010, OPHTHALMOLOGY, V117, P489, DOI 10.1016/j.ophtha.2009.12.002
   Cukras CA, 2012, ARCH OPHTHALMOL-CHIC, V130, P171, DOI 10.1001/archophthalmol.2011.332
   Degli Esposti S, 2012, INVEST OPHTH VIS SCI, V53, P6568, DOI 10.1167/iovs.12-9756
   Delori FC, 2000, INVEST OPHTH VIS SCI, V41, P496
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   Delori F, 2011, INVEST OPHTH VIS SCI, V52, P9379, DOI 10.1167/iovs.11-8319
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Figueroa MS, 1997, RETINA-J RET VIT DIS, V17, P378
   Fleckenstein M, 2008, ARCH OPHTHALMOL-CHIC, V126, P1461, DOI 10.1001/archopht.126.10.1461
   Fleckenstein M, 2008, INVEST OPHTH VIS SCI, V49, P4137, DOI 10.1167/iovs.08-1967
   FRENNESSON IC, 1995, BRIT J OPHTHALMOL, V79, P905, DOI 10.1136/bjo.79.10.905
   Friberg TR, 2009, OPHTHAL SURG LAS IM, V40, P530, DOI 10.3928/15428877-20091030-01
   GASS JDM, 1973, ARCH OPHTHALMOL-CHIC, V90, P206
   *GROUP A REDSR, 2001, AM J OPHTHALMOL, V132, P668
   *GROUP COARMDPTS, 2004, CLIN TRIALS, V1, P91
   Hammond BR, 1997, J OPT SOC AM A, V14, P1187, DOI 10.1364/JOSAA.14.001187
   Hartmann KI, 2012, RETINA-J RET VIT DIS, V32, P1492, DOI 10.1097/IAE.0b013e318242b949
   Ho AC, 1999, OPHTHALMOLOGY, V106, P1367, DOI 10.1016/S0161-6420(99)00735-6
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   Hsu J, 2005, CAN J OPHTHALMOL, V40, P320, DOI 10.1016/S0008-4182(05)80075-4
   KILBRIDE PE, 1989, VISION RES, V29, P663, DOI 10.1016/0042-6989(89)90028-X
   KILLINGSWORTH MC, 1990, EYE, V4, P613, DOI 10.1038/eye.1990.86
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1026, DOI 10.1016/j.ophtha.2007.08.030
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Little HL, 1997, OPHTHALMOLOGY, V104, P623, DOI 10.1016/S0161-6420(97)30261-9
   Ma WX, 2013, NEUROBIOL AGING, V34, P943, DOI 10.1016/j.neurobiolaging.2012.06.010
   Ma WX, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007945
   Maguire MG, 2012, OPHTHALMOLOGY, V119, P1501, DOI 10.1016/j.ophtha.2012.03.012
   Mettu PS, 2012, MOL ASPECTS MED, V33, P376, DOI 10.1016/j.mam.2012.04.006
   Park DW, 2006, OPHTHALMOLOGY, V113, P1974, DOI 10.1016/j.ophtha.2006.08.015
   RIDLER TW, 1978, IEEE T SYST MAN CYB, V8, P630, DOI 10.1109/tsmc.1978.4310039
   Robson AG, 2003, VISION RES, V43, P1765, DOI 10.1016/S0042-6989(03)00280-3
   Sallo FB, 2009, BRIT J OPHTHALMOL, V93, P1345, DOI 10.1136/bjo.2008.150334
   SARKS JP, 1994, EYE, V8, P269, DOI 10.1038/eye.1994.57
   Sarks SH, 1996, AUST NZ J OPHTHALMOL, V24, P15, DOI 10.1111/j.1442-9071.1996.tb01546.x
   Schmitz-Valckenberg S, 2004, INVEST OPHTH VIS SCI, V45, P4470, DOI 10.1167/iovs.03-1311
   Schmitz-Valckenberg S, 2002, GRAEF ARCH CLIN EXP, V240, P73, DOI 10.1007/s00417-001-0413-3
   Schmitz-Valckenberg S, 2008, RETINA-J RET VIT DIS, V28, P385, DOI 10.1097/IAE.0b013e318164a907
   Schmitz-Valckenberg S, 2009, SURV OPHTHALMOL, V54, P96, DOI 10.1016/j.survophthal.2008.10.004
   Smith RT, 2006, INVEST OPHTH VIS SCI, V47, P5495, DOI 10.1167/iovs.05-1318
   Smith RT, 2011, ARCH OPHTHALMOL-CHIC, V129, P40, DOI 10.1001/archophthalmol.2010.328
   Smith RT, 2010, BRIT J OPHTHALMOL, V94, P1618, DOI 10.1136/bjo.2009.166843
   Smith RT, 2003, BIOMED ENG ONLINE, V2, DOI 10.1186/1475-925X-2-10
   Smith RT, 2005, BRIT J OPHTHALMOL, V89, P87, DOI 10.1136/bjo.2004.042937
   Smith RT, 2005, ARCH OPHTHALMOL-CHIC, V123, P200, DOI 10.1001/archopht.123.2.200
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P392, DOI 10.1016/S0161-6420(02)01756-6
   Sparrow JR, 2010, INVEST OPHTH VIS SCI, V51, P4351, DOI 10.1167/iovs.10-5852
   Sparrow JM, 1997, EYE, V11, P315, DOI 10.1038/eye.1997.67
   STERNBERG SR, 1983, COMPUTER, V16, P22
   Sunness JS, 2006, RETINA-J RET VIT DIS, V26, P666, DOI 10.1097/00006982-200607000-00013
   van de Ven JPH, 2012, AM J OPHTHALMOL, V154, P560, DOI 10.1016/j.ajo.2012.03.012
   VONRUCKMANN A, 1995, BRIT J OPHTHALMOL, V79, P407, DOI 10.1136/bjo.79.5.407
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P2434, DOI 10.1016/j.ophtha.2011.05.008
NR 56
TC 22
Z9 22
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD SEP
PY 2013
VL 156
IS 3
BP 532
EP 542
DI 10.1016/j.ajo.2013.04.031
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 214RM
UT WOS:000324153500015
PM 23830564
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Feng, XF
   Constable, IJ
   McAllister, IL
   Isaacs, T
AF Feng, Xue-Feng
   Constable, Ian J.
   McAllister, Ian L.
   Isaacs, Timothy
TI Comparison of visual acuity outcomes between ranibizumab and bevacizumab
   treatment in neovascular age-related macular degeneration
SO INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; anti-VEGF; bevacizumab; ranibizumab;
   choroidal neovascularization
ID INTRAVITREAL BEVACIZUMAB; AVASTIN
AB AIM: To compare visual acuity (VA) outcomes between intravitreal injection of bevacizumab and ranibizumab in the treatment of neovascular age-related macular degeneration (AMD).
   METHODS: We conducted a consecutive, retrospective case series study in patients with newly diagnosed all type choroidal neovascularization (CNV) secondary to AMD who received an intravitreal injection of bevacizumab (1.25mg) or ranibizumab (0.3mg) at Lions Eye Institute, Western Australia from Mar. 2006 to May 2008. All patients received injection at baseline with additional monthly injections given at the discretion of the treating physician. Main outcome measures were changes in VA.
   RESULTS: There were 371 consecutive patients received injection at least in one eye with at least 6 months of follow up (median of 12.0 months). Bevacizumab treatment prevented 221 out of 278 (79.5%) patient from losing < 15 letters in VA compared with 79 out of 93 (84.9%) of ranibizumab treated patients (P=0.25). While 68 (24.5%) of bevacizumab treated patients gained 15 letters of VA compared with 24 (25.8%) of ranibizumab treated patients (P=0.79). 75.3% and 66.2% patients benefited from ranibizumab and bevacizumab respectively with final VA better than 6/60 (P=0.10). Multivariate analysis showed that pre-treatment VA was negatively associated with benefit outcome. Assignment of injection was not associated with VA outcome of benefit after adjusting the covariate (P=0.857).
   CONCLUSION: There are no difference in treatment efficacy in terms of VA between bevacizumab and ranibizumab in routine clinical condition.
C1 [Feng, Xue-Feng] Peking Univ, Peking Univ Hosp 3, Dept Ophthalmol, Beijing 100191, Peoples R China.
   [Constable, Ian J.; McAllister, Ian L.; Isaacs, Timothy] Univ Western Australia, Ctr Ophthalmol & Visual Sci, Lions Eye Inst, Perth, WA 6009, Australia.
C3 Peking University; Lions Eye Institute; University of Western Australia
RP Feng, XF (通讯作者)，Peking Univ, Peking Univ Hosp 3, Dept Ophthalmol, Beijing 100191, Peoples R China.
EM xue168feng@sina.com
OI constable, ian/0000-0002-2140-6478
CR Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bashshur ZF, 2008, AM J OPHTHALMOL, V145, P249, DOI 10.1016/j.ajo.2007.09.031
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Cleary CA, 2008, EYE, V22, P82, DOI 10.1038/sj.eye.6702936
   Colquitt JL, 2008, HEALTH TECHNOL ASSES, V12, P1
   Emerson MV, 2007, RETINA-J RET VIT DIS, V27, P439, DOI 10.1097/IAE.0b013e31804b3e15
   Falkenstein IA, 2008, OPHTHALMOLOGY, V115, P319, DOI 10.1016/j.ophtha.2007.05.028
   Feng XF, 2009, OPHTHALMOLOGY, V116, P1908, DOI 10.1016/j.ophtha.2009.03.011
   Fong DS, 2010, OPHTHALMOLOGY, V117, P298, DOI 10.1016/j.ophtha.2009.07.023
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Lazic R, 2007, GRAEF ARCH CLIN EXP, V245, P68, DOI 10.1007/s00417-006-0466-4
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
NR 14
TC 8
Z9 9
U1 0
U2 7
PU IJO PRESS
PI XI AN
PA NO 269 YOUYI EAST RD, XI AN, 710054, PEOPLES R CHINA
SN 2222-3959
EI 2227-4898
J9 INT J OPHTHALMOL-CHI
JI Int. J. Ophthalmol.
PD FEB 18
PY 2011
VL 4
IS 1
BP 85
EP 88
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 724IA
UT WOS:000287568100020
PM 22553617
DA 2022-11-30
ER

PT J
AU Soheilian, R
   Bonyadi, MHJ
   Moein, H
   Babanejad, M
   Ramezani, A
   Yaseri, M
   Soheilian, M
AF Soheilian, Roham
   Bonyadi, Mohammad Hossein Jabbarpour
   Moein, Hamidreza
   Babanejad, Mojgan
   Ramezani, Alireza
   Yaseri, Mehdi
   Soheilian, Masoud
TI C-reactive protein and complement factor H polymorphism interaction in
   advanced exudative age-related macular degeneration
SO INTERNATIONAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; CFH gene variants; C-reactive protein
ID CARDIOVASCULAR-DISEASE; Y402H POLYMORPHISM; COMPONENT 2; FACTOR-B;
   ASSOCIATION; POPULATION; RISK; INFLAMMATION; MACULOPATHY; PATHOGENESIS
AB To determine the association of C-reactive protein (CRP) and complement factor H (CFH) gene with exudative age-related macular degeneration (AMD) and any possible interaction among these factors.
   In this case-control study, 139 unrelated patients with exudative AMD and 123 non-AMD controls were recruited. Blood sample was taken for analysis of the CRP levels and DNA testing. DNA fragments of CFH gene variants containing 4 single nucleotide polymorphisms including rs800292, rs1061170, rs2274700, and rs3753395 were assessed. A CRP level of ae<yen>3 mg/L was considered as elevated. The association of elevated CRP and CFH gene variants polymorphism with exudative AMD was compared between the groups.
   Mean age was 72.6 +/- 6.4 for controls and 74.9 +/- 7.4 for case group (P = 0.006). The difference between CRP levels in cases and controls was not statistically significant (P = 0.055). However, Y402H variant of CFH in both homozygous and heterozygous carriers C allele was significantly more frequent among exudative AMD patients than controls, 32.1 versus 6.5 % (P < 0.001). Evaluating various CRP levels in patients with CC and non-CC genotypes disclosed that in CC genotype group, higher CRP level (> 3 mg/L) was associated with higher risk of developing exudative AMD (OR = 12.0, CI: 1.5-98.8) compared with the control group.
   This study disclosed no difference in CRP levels per se between exudative AMD patients with control group. However, higher levels of CRP in the presence of C allele of Y402H might confer more risk for the development of exudative AMD.
C1 [Soheilian, Roham; Bonyadi, Mohammad Hossein Jabbarpour; Moein, Hamidreza; Ramezani, Alireza; Yaseri, Mehdi; Soheilian, Masoud] Shahid Beheshti Univ Med Sci, Sch Med, Labbafinejad Med Ctr, Ophthalmol Dept, Pasdaran Ave Boostan 9 St, Tehran 16666, Iran.
   [Soheilian, Roham; Bonyadi, Mohammad Hossein Jabbarpour; Moein, Hamidreza; Ramezani, Alireza; Yaseri, Mehdi; Soheilian, Masoud] Shahid Beheshti Univ Med Sci, Sch Med, Labbafinejad Med Ctr, Ophthalm Res Ctr, Pasdaran Ave Boostan 9 St, Tehran 16666, Iran.
   [Babanejad, Mojgan] Univ Social Welf & Rehabil Sci, Genet Res Ctr, Tehran, Iran.
   [Ramezani, Alireza; Soheilian, Masoud] Negah Eye Hosp, Tehran, Iran.
C3 Shahid Beheshti University Medical Sciences; Shahid Beheshti University
   Medical Sciences
RP Soheilian, M (通讯作者)，Shahid Beheshti Univ Med Sci, Sch Med, Labbafinejad Med Ctr, Ophthalmol Dept, Pasdaran Ave Boostan 9 St, Tehran 16666, Iran.; Soheilian, M (通讯作者)，Shahid Beheshti Univ Med Sci, Sch Med, Labbafinejad Med Ctr, Ophthalm Res Ctr, Pasdaran Ave Boostan 9 St, Tehran 16666, Iran.
EM masoud_soheilian@yahoo.com
RI Babanejad, Mojgan/AAY-1405-2020; Yaseri, Mehdi/I-1645-2018; Babanejad,
   Mojgan/X-9925-2018; Hossein, Jabbarpoor Bonyadi Mohammad/A-1886-2014;
   Soheilian, Masoud/AAW-4743-2020; Ramezani, Alireza/AAZ-2606-2020;
   Ramezani, Alireza/AAF-4834-2020
OI Yaseri, Mehdi/0000-0002-4066-873X; Ramezani,
   Alireza/0000-0002-1925-1251; Soheilian, Masoud/0000-0001-7508-426X;
   Babanejad, Mojgan/0000-0003-2532-4303
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Augustin AJ, 2009, EXPERT OPIN THER TAR, V13, P641, DOI 10.1517/14728220902942322
   Babanejad M, 2016, OPHTHALMIC GENET, V37, P144, DOI 10.3109/13816810.2014.955585
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Boekhoorn SS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1396, DOI 10.1001/archopht.125.10.1396
   Boey PY, 2010, INVEST OPHTH VIS SCI, V51, P1880, DOI 10.1167/iovs.09-4063
   Bok D, 2005, P NATL ACAD SCI USA, V102, P7053, DOI 10.1073/pnas.0502819102
   Buentello-Volante B, 2012, MOL VIS, V18, P2518
   Dasch B, 2005, ARCH OPHTHALMOL-CHIC, V123, P1501, DOI 10.1001/archopht.123.11.1501
   de Cordoba SR, 2004, MOL IMMUNOL, V41, P355, DOI 10.1016/j.molimm.2004.02.005
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hong T, 2011, SURV OPHTHALMOL, V56, P184, DOI 10.1016/j.survophthal.2010.08.007
   Johnson PT, 2006, P NATL ACAD SCI USA, V103, P17456, DOI 10.1073/pnas.0606234103
   Kikuchi M, 2007, OPHTHALMOLOGY, V114, P1722, DOI 10.1016/j.ophtha.2006.12.021
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Klein R, 2005, AM J OPHTHALMOL, V140, P35, DOI 10.1016/j.ajo.2005.01.051
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Laine M, 2007, J IMMUNOL, V178, P3831, DOI 10.4049/jimmunol.178.6.3831
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   McGwin G, 2005, BRIT J OPHTHALMOL, V89, P1166, DOI 10.1136/bjo.2005.067397
   MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215
   Mitta VP, 2013, JAMA OPHTHALMOL, V131, P507, DOI 10.1001/jamaophthalmol.2013.2303
   Pearson TA, 2003, CIRCULATION, V107, P499, DOI 10.1161/01.CIR.0000052939.59093.45
   Robman L, 2010, OPHTHALMOLOGY, V117, P1982, DOI 10.1016/j.ophtha.2010.02.003
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Seitsonen S, 2006, MOL VIS, V12, P796
   Sepp T, 2006, INVEST OPHTH VIS SCI, V47, P536, DOI 10.1167/iovs.05-1143
   Shankar A, 2007, AM J EPIDEMIOL, V165, P375, DOI 10.1093/aje/kwk022
   Sharma NK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070193
   Simonelli F, 2006, BRIT J OPHTHALMOL, V90, P1142, DOI 10.1136/bjo.2006.096487
   Sivaprasad S, 2006, EYE, V20, P867, DOI 10.1038/sj.eye.6702176
   Souied EH, 2005, MOL VIS, V11, P1135
   STEEL DM, 1994, IMMUNOL TODAY, V15, P81, DOI 10.1016/0167-5699(94)90138-4
   Tian J, 2012, PHARMACOGENOMICS, V13, P779, DOI [10.2217/PGS.12.53, 10.2217/pgs.12.53]
   Vine AK, 2005, OPHTHALMOLOGY, V112, P2076, DOI 10.1016/j.ophtha.2005.07.004
   Wang ZF, 2004, CELL, V119, P831, DOI 10.1016/j.cell.2004.11.010
   Yucel D, 2012, OPHTHALMIC GENET, V33, P144, DOI 10.3109/13816810.2012.660225
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
   Zipfel PF, 2002, BIOCHEM SOC T, V30, P971, DOI 10.1042/bst0300971
NR 45
TC 4
Z9 4
U1 0
U2 2
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0165-5701
EI 1573-2630
J9 INT OPHTHALMOL
JI Int. Ophthalmol.
PD OCT
PY 2017
VL 37
IS 5
BP 1161
EP 1168
DI 10.1007/s10792-016-0373-6
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FJ3WG
UT WOS:000412662600011
PM 27778189
DA 2022-11-30
ER

PT J
AU Rowan, S
   Jiang, SH
   Korem, T
   Szymanski, J
   Chang, ML
   Szelog, J
   Cassalman, C
   Dasuri, K
   McGuire, C
   Nagai, R
   Du, XL
   Brownlee, M
   Rabbani, N
   Thornalley, PJ
   Baleja, JD
   Deik, AA
   Pierce, KA
   Scott, JM
   Clish, CB
   Smith, DE
   Weinberger, A
   Avnit-Sagi, T
   Lotan-Pompan, M
   Segal, E
   Taylor, A
AF Rowan, Sheldon
   Jiang, Shuhong
   Korem, Tal
   Szymanski, Jedrzej
   Chang, Min-Lee
   Szelog, Jason
   Cassalman, Christa
   Dasuri, Kalavathi
   McGuire, Christina
   Nagai, Ryoji
   Du, Xue-Liang
   Brownlee, Michael
   Rabbani, Naila
   Thornalley, Paul J.
   Baleja, James D.
   Deik, Amy A.
   Pierce, Kerry A.
   Scott, Justin M.
   Clish, Clary B.
   Smith, Donald E.
   Weinberger, Adina
   Avnit-Sagi, Tali
   Lotan-Pompan, Maya
   Segal, Eran
   Taylor, Allen
TI Involvement of a gut-retina axis in protection against dietary
   glycemia-induced age-related macular degeneration
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE age-related macular degeneration; glycemic index; advanced glycation
   end-product; gut microbiome; metabolomics
ID ADVANCED GLYCATION ENDPRODUCTS; OXIDATIVE STRESS; MICROBIAL-METABOLISM;
   PIGMENT-EPITHELIUM; DIABETES RESEARCH; ANIMAL-MODELS; END-PRODUCTS;
   MOUSE MODEL; INDEX; PROTEIN
AB Age-related macular degeneration (AMD) is the major cause of blindness in developed nations. AMD is characterized by retinal pigmented epithelial (RPE) cell dysfunction and loss of photoreceptor cells. Epidemiologic studies indicate important contributions of dietary patterns to the risk for AMD, but the mechanisms relating diet to disease remain unclear. Here we investigate the effect on AMD of isocaloric diets that differ only in the type of dietary carbohydrate in a wild-type aged-mouse model. The consumption of a high-glycemia (HG) diet resulted in many AMD features (AMDf), including RPE hypopigmentation and atrophy, lipofuscin accumulation, and photoreceptor degeneration, whereas consumption of the lower-glycemia (LG) diet did not. Critically, switching from the HG to the LG diet late in life arrested or reversed AMDf. LG diets limited the accumulation of advanced glycation end products, long-chain polyunsaturated lipids, and their peroxidation end-products and increased C3-carnitine in retina, plasma, or urine. Untargeted metabolomics revealed microbial cometabolites, particularly serotonin, as protective against AMDf. Gut microbiota were responsive to diet, and we identified microbiota in the Clostridiales order as being associated with AMDf and the HG diet, whereas protection from AMDf was associated with the Bacteroidales order and the LG diet. Network analysis revealed a nexus of metabolites and microbiota that appear to act within a gut-retina axis to protect against diet-and age-induced AMDf. The findings indicate a functional interaction between dietary carbohydrates, the metabolome, including microbial cometabolites, and AMDf. Our studies suggest a simple dietary intervention that may be useful in patients to arrest AMD.
C1 [Rowan, Sheldon; Jiang, Shuhong; Chang, Min-Lee; Szelog, Jason; Dasuri, Kalavathi; Smith, Donald E.; Taylor, Allen] Tufts Univ, Jean Mayer US Dept Agr, Human Nutr Res Ctr Aging, Boston, MA 02111 USA.
   [Korem, Tal; Weinberger, Adina; Avnit-Sagi, Tali; Lotan-Pompan, Maya; Segal, Eran] Weizmann Inst Sci, Dept Comp Sci & Appl Math, IL-7610001 Rehovot, Israel.
   [Korem, Tal; Weinberger, Adina; Avnit-Sagi, Tali; Lotan-Pompan, Maya; Segal, Eran] Weizmann Inst Sci, Dept Mol Cell Biol, IL-7610001 Rehovot, Israel.
   [Szymanski, Jedrzej] Weizmann Inst Technol, Dept Plant Sci, IL-7610001 Rehovot, Israel.
   [Cassalman, Christa] Tufts Univ, Dept Pathol & Lab Med, Sch Med, Boston, MA 02111 USA.
   [McGuire, Christina; Baleja, James D.] Tufts Univ, Dept Dev Mol & Chem Biol, Sch Med, Boston, MA 02111 USA.
   [Nagai, Ryoji] Tokai Univ, Grad Sch Agr, Lab Food & Regulat Biol, Minamiaso, Kumamoto 8691404, Japan.
   [Du, Xue-Liang; Brownlee, Michael] Albert Einstein Coll Med, Dept Med, Diabet Res Ctr, Bronx, NY 10461 USA.
   [Du, Xue-Liang; Brownlee, Michael] Albert Einstein Coll Med, Dept Pathol, Diabet Res Ctr, Bronx, NY 10461 USA.
   [Rabbani, Naila; Thornalley, Paul J.] Univ Warwick, Univ Hosp, Warwick Med Sch, Clin Sci Res Labs, Coventry CV2 2DX, W Midlands, England.
   [Deik, Amy A.; Pierce, Kerry A.; Scott, Justin M.; Clish, Clary B.] Eli & Edythe L Broad Inst MIT & Harvard, Cambridge, MA 02142 USA.
C3 Tufts University; United States Department of Agriculture (USDA);
   Weizmann Institute of Science; Weizmann Institute of Science; Tufts
   University; Tufts University; Tokai University; Yeshiva University;
   Albert Einstein College of Medicine; Yeshiva University; Albert Einstein
   College of Medicine; University of Warwick; Harvard University;
   Massachusetts Institute of Technology (MIT); Broad Institute
RP Taylor, A (通讯作者)，Tufts Univ, Jean Mayer US Dept Agr, Human Nutr Res Ctr Aging, Boston, MA 02111 USA.
EM allen.taylor@tufts.edu
RI Jiang, Shuhong/AAQ-7147-2021; Segal, Eran/AAF-4855-2019; Clish, Clary
   B/ABB-9374-2021; Rowan, Sheldon/AAA-3271-2019; Jiang,
   Shuhong/C-1596-2019; Korem, Tal/D-4155-2018; Clish, Clary/AAB-7124-2019
OI Clish, Clary B/0000-0001-8259-9245; Rowan, Sheldon/0000-0002-1123-6743;
   Korem, Tal/0000-0002-0609-0858; Jiang, Shuhong/0000-0003-3659-5950;
   Segal, Eran/0000-0002-6859-1164; Szymanski, Jedrzej/0000-0003-1086-0920;
   Rabbani, Naila/0000-0002-5819-2506; Thornalley,
   Paul/0000-0001-7659-443X; CHANG, MIN-LEE/0000-0001-9868-4030
FU NIH [RO1EY021212, RO1EY13250, RO1EY026979]; Morris Belkin Professorship
   at Weizmann Institute of Science; US Department of
   Agriculture-Agricultural Research Service [58-1950-0-014,
   58-1950-4-003]; NATIONAL EYE INSTITUTE [R01EY013250, R01EY021212,
   R01EY026979] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF
   DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK026687] Funding Source:
   NIH RePORTER
FX We thank Jennifer Cho and Jonathan Morrison for assistance with animal
   feeding, Barbara Nagel for histological and electron microscopy, Steven
   Fliesler for assistance with interpretation of electron micrographs, Joe
   Hollyfield for the CEP antibody, Christine Pelkman of Ingredion
   Incorporated. for dietary starches, and Angelo Azzi for comments on the
   manuscript. This work was supported by NIH Grants RO1EY021212,
   RO1EY13250, and RO1EY026979 (to A.T.) and the Morris Belkin
   Professorship at Weizmann Institute of Science (A.T.). This material is
   based on work supported by the US Department of Agriculture-Agricultural
   Research Service under Agreements 58-1950-0-014 and 58-1950-4-003 (to
   A.T.).
CR Aizu Y, 2002, NEUROPATHOLOGY, V22, P161, DOI 10.1046/j.1440-1789.2002.00439.x
   ALWAIZ M, 1992, METABOLISM, V41, P135, DOI 10.1016/0026-0495(92)90140-6
   AMD Alliance International, 2010, GLOB EC COST VIS IMP
   Andriessen EMMA, 2016, EMBO MOL MED, V8, P1366, DOI 10.15252/emmm.201606531
   Badr GA, 2000, DIABETES, V49, P1016, DOI 10.2337/diabetes.49.6.1016
   Barber AJ, 1998, J CLIN INVEST, V102, P783, DOI 10.1172/JCI2425
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Berner AK, 2012, DIABETOLOGIA, V55, P845, DOI 10.1007/s00125-011-2393-0
   BESHARSE JC, 1988, J COMP NEUROL, V274, P295, DOI 10.1002/cne.902740212
   Biswal MR, 2015, EXP EYE RES, V140, P94, DOI 10.1016/j.exer.2015.07.022
   Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170
   Bouatra S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073076
   Boynton GE, 2015, OPHTHALMOLOGY, V122, P957, DOI 10.1016/j.ophtha.2014.12.001
   Bylesjo M, 2007, PLANT J, V52, P1181, DOI 10.1111/j.1365-313X.2007.03293.x
   Bylesjo M, 2006, J CHEMOMETR, V20, P341, DOI 10.1002/cem.1006
   Caporaso JG, 2010, NAT METHODS, V7, P335, DOI 10.1038/nmeth.f.303
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chiu CJ, 2007, AM J CLIN NUTR, V86, P180, DOI 10.1093/ajcn/86.1.180
   Chiu CJ, 2011, PROG RETIN EYE RES, V30, P18, DOI 10.1016/j.preteyeres.2010.09.001
   Clarke G, 2013, MOL PSYCHIATR, V18, P666, DOI 10.1038/mp.2012.77
   Clemente JC, 2012, CELL, V148, P1258, DOI 10.1016/j.cell.2012.01.035
   Collier RJ, 2011, INVEST OPHTH VIS SCI, V52, P2118, DOI 10.1167/iovs.10-6304
   DELAPAZ M, 1992, INVEST OPHTH VIS SCI, V33, P3497
   DeSantis TZ, 2006, APPL ENVIRON MICROB, V72, P5069, DOI 10.1128/AEM.03006-05
   Edgar RC, 2013, NAT METHODS, V10, P996, DOI [10.1038/nmeth.2604, 10.1038/NMETH.2604]
   Emanuele E, 2014, CURR DRUG TARGETS, V15, P551, DOI 10.2174/1389450115666140225104705
   Espinosa-Heidmann DG, 2006, INVEST OPHTH VIS SCI, V47, P729, DOI 10.1167/iovs.05-0719
   Ferrington DA, 2016, PROG RETIN EYE RES, V51, P69, DOI 10.1016/j.preteyeres.2015.09.002
   FLIESLER SJ, 1983, PROG LIPID RES, V22, P79
   Frolkis A, 2010, NUCLEIC ACIDS RES, V38, pD480, DOI 10.1093/nar/gkp1002
   Genuth S, 2015, DIABETES, V64, P266, DOI 10.2337/db14-0215
   Glenn JV, 2009, BBA-GEN SUBJECTS, V1790, P1109, DOI 10.1016/j.bbagen.2009.04.016
   Gu XR, 2003, J BIOL CHEM, V278, P42027, DOI 10.1074/jbc.M305460200
   Handa JT, 2012, MOL ASPECTS MED, V33, P418, DOI 10.1016/j.mam.2012.03.006
   Heijtza RD, 2011, P NATL ACAD SCI USA, V108, P3047, DOI 10.1073/pnas.1010529108
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Jung JY, 2012, BMB REP, V45, P419, DOI 10.5483/BMBRep.2012.45.7.248
   Kaushik S, 2008, AM J CLIN NUTR, V88, P1104, DOI 10.1093/ajcn/88.4.1104
   King AJF, 2012, BRIT J PHARMACOL, V166, P877, DOI 10.1111/j.1476-5381.2012.01911.x
   Koeth RA, 2013, NAT MED, V19, P576, DOI 10.1038/nm.3145
   Kurihara T, 2016, ELIFE, V5, DOI 10.7554/eLife.14319
   Lambert NG, 2016, PROG RETIN EYE RES, V54, P64, DOI 10.1016/j.preteyeres.2016.04.003
   Langille MGI, 2013, NAT BIOTECHNOL, V31, P814, DOI 10.1038/nbt.2676
   Langille MG, 2014, MICROBIOME, V2, DOI 10.1186/s40168-014-0050-9
   LaVail M M, 1987, Prog Clin Biol Res, V247, P439
   Leiter EH, 2009, METHODS MOL BIOL, V560, P1, DOI 10.1007/978-1-59745-448-3_1
   Loske C, 1998, J NEURAL TRANSM, V105, P1005, DOI 10.1007/s007020050108
   Mackenzie AE, 2015, NEUROPHARMACOLOGY, V113, P661
   Marmorstein LHY, 2002, P NATL ACAD SCI USA, V99, P13067, DOI 10.1073/pnas.202491599
   Martin PM, 2004, INVEST OPHTH VIS SCI, V45, P3330, DOI 10.1167/iovs.04-0247
   Matsumoto K, 2009, INT J UROL, V16, P402, DOI 10.1111/j.1442-2042.2009.02259.x
   Mevik BH, 2007, J STAT SOFTW, V18, P1, DOI 10.18637/jss.v018.i02
   Nagai R, 2008, J IMMUNOL METHODS, V332, P112, DOI 10.1016/j.jim.2007.12.020
   Nankervis Scott A, 2013, Longev Healthspan, V2, P4, DOI 10.1186/2046-2395-2-4
   Ni JQ, 2009, MOL CELL PROTEOMICS, V8, P1921, DOI 10.1074/mcp.M900127-MCP200
   Nishikawa T, 2000, NATURE, V404, P787, DOI 10.1038/35008121
   Pennesi ME, 2012, MOL ASPECTS MED, V33, P487, DOI 10.1016/j.mam.2012.06.003
   Pikuleva IA, 2014, PROG RETIN EYE RES, V41, P64, DOI 10.1016/j.preteyeres.2014.03.002
   Rabbani N, 2015, BIOCHEM BIOPH RES CO, V458, P221, DOI 10.1016/j.bbrc.2015.01.140
   Rabbani N, 2014, BIOCHEM SOC T, V42, P511, DOI 10.1042/BST20140019
   Renganathan K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076325
   Rowan S, 2014, INVEST OPHTH VIS SCI, V55, P492, DOI 10.1167/iovs.13-12413
   Russell WR, 2013, MOL NUTR FOOD RES, V57, P523, DOI 10.1002/mnfr.201200594
   Samuel MA, 2014, NAT NEUROSCI, V17, P1190, DOI 10.1038/nn.3772
   Sarkar S, 2014, NEUROTOXICOLOGY, V44, P250, DOI 10.1016/j.neuro.2014.07.006
   Sarks S, 2007, INVEST OPHTH VIS SCI, V48, P968, DOI 10.1167/iovs.06-0443
   Sayin SI, 2013, CELL METAB, V17, P225, DOI 10.1016/j.cmet.2013.01.003
   Scribner KB, 2008, AM J PHYSIOL-ENDOC M, V295, pE1126, DOI 10.1152/ajpendo.90487.2008
   Seddon JM, 2013, INVEST OPHTH VIS SCI, V54, DOI 10.1167/iovs.13-13234
   Shang F, 2012, MOL ASPECTS MED, V33, P446, DOI 10.1016/j.mam.2012.04.001
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Sohn EJ, 2009, J ETHNOPHARMACOL, V121, P171, DOI 10.1016/j.jep.2008.09.036
   Suez J, 2014, NATURE, V514, P181, DOI 10.1038/nature13793
   Tang WHW, 2013, NEW ENGL J MED, V368, P1575, DOI 10.1056/NEJMoa1109400
   Toomey CB, 2015, P NATL ACAD SCI USA, V112, pE3040, DOI 10.1073/pnas.1424391112
   Townsend MK, 2013, CLIN CHEM, V59, P1657, DOI 10.1373/clinchem.2012.199133
   Troyanskaya O, 2001, BIOINFORMATICS, V17, P520, DOI 10.1093/bioinformatics/17.6.520
   Tullis BE, 2015, INVEST OPHTH VIS SCI, V56, P4560, DOI 10.1167/iovs.15-16378
   Uchiki T, 2012, AGING CELL, V11, P1, DOI 10.1111/j.1474-9726.2011.00752.x
   Vlassara H, 2013, ENDOCRIN METAB CLIN, V42, P697, DOI 10.1016/j.ecl.2013.07.005
   Wang H, 2014, CHEM RES TOXICOL, V27, P2015, DOI 10.1021/tx500216a
   Weikel KA, 2012, MOL ASPECTS MED, V33, P318, DOI 10.1016/j.mam.2012.03.005
   Weikel KA, 2012, INVEST OPHTH VIS SCI, V53, P622, DOI 10.1167/iovs.11-8545
   Weljie AM, 2006, ANAL CHEM, V78, P4430, DOI 10.1021/ac060209g
   Wikoff WR, 2009, P NATL ACAD SCI USA, V106, P3698, DOI 10.1073/pnas.0812874106
   Wishart DS, 2009, NUCLEIC ACIDS RES, V37, pD603, DOI 10.1093/nar/gkn810
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Woodell A, 2016, INVEST OPHTH VIS SCI, V57, P1728, DOI 10.1167/iovs.15-18471
   Yano JM, 2015, CELL, V161, P264, DOI 10.1016/j.cell.2015.02.047
   Yap IKS, 2008, J PROTEOME RES, V7, P3718, DOI 10.1021/pr700864x
   Yatsunenko T, 2012, NATURE, V486, P222, DOI 10.1038/nature11053
   Yuan JP, 2007, MOL NUTR FOOD RES, V51, P765, DOI 10.1002/mnfr.200600262
   Zanzottera EC, 2015, INVEST OPHTH VIS SCI, V56, P3253, DOI 10.1167/iovs.15-16431
   Zeevi D, 2015, CELL, V163, P1079, DOI 10.1016/j.cell.2015.11.001
   Zhang JJ, 2014, BIOINFORMATICS, V30, P614, DOI 10.1093/bioinformatics/btt593
   Zhang LS, 2016, GENOME MED, V8, DOI 10.1186/s13073-016-0296-x
   Zinkernagel MS, 2017, SCI REP-UK, V7, DOI 10.1038/srep40826
NR 97
TC 121
Z9 124
U1 2
U2 42
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD MAY 30
PY 2017
VL 114
IS 22
BP E4472
EP E4481
DI 10.1073/pnas.1702302114
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA EW1ZV
UT WOS:000402296700021
PM 28507131
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Haddad, WM
   Coscas, G
   Soubrane, G
AF Haddad, WM
   Coscas, G
   Soubrane, G
TI Eligibility for treatment and angiographic features at the early stage
   of exudative age related macular degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID INDOCYANINE-GREEN VIDEOANGIOGRAPHY; OCCULT CHOROIDAL NEOVASCULARIZATION;
   GUIDED LASER PHOTOCOAGULATION; PIGMENT EPITHELIAL DETACHMENTS;
   CLASSIFICATION; ANASTOMOSES; THERAPY; IMPACT
AB Aims: To determine the eligibility for loser photocoagulation treatment or for photodynamic therapy (PDT) with verteporfin in eyes at the earliest stage (first month of symptoms) of exudative age related macular degeneration (AMD) based on fluorescein anglographic (FA) features; to evaluate the potential contribution of indocyanine green angiography (ICG-A) for occult choroidal neovascularisation (CNV) at this stage.
   Methods: Retrospective review of 252 consecutive patients (269 eyes) examined within the first month of symptoms of exudative AMD.
   Results: On FA, 97 eyes (36%) had classic CNV alone. Occult CNV associated with fibrovascular retinal pigment epithelium detachments (PEDs) was observed in 71 eyes (26%) and without fibrovascular PED in 101 eyes (38%). 91 eyes (34%) met the Macular Photocoagulation Study criteria for laser photocoagulation. 53 eyes (20%) met the Verteporfin In PDT (VIP) or Treatment of AMD with PDT (TAP) studies criteria. By ICG-A, occult CNV was visualised as focal spots in 49% of eyes examined within, 15 days v 32% of eyes examined between 16 and 30 days after the onset of symptoms (p=0.07). 8.5% of late staining plaques disclosed in eyes examined within 15 days were combined with focal spots v 36% in eyes examined between 16 and 30 days (p<0.0 1),
   Conclusions: Early examination of eyes with exudative AMD would allow the treatment of 471. of eyes. 60% of eyes with subfoveal CNV would be eligible for PDT with verteporfin. Up to half of eyeswith occult CNV would be converted by ICG-A into well delineated focal spots.
C1 Univ Paris 12, Dept Ophthalmol, Creteil, France.
C3 Universite Paris-Est-Creteil-Val-de-Marne (UPEC)
RP Soubrane, G (通讯作者)，Univ Paris 12, Clin Ophthalmol, 40 Ave Verdun, F-94010 Creteil, France.
EM gisele.soubrane@chicreteil.fr
CR [Anonymous], 1982, Br J Ophthalmol, V66, P745
   [Anonymous], 1991, Arch Ophthalmol, V109, P1220
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BOTTONI FG, 1994, GRAEF ARCH CLIN EXP, V232, P458, DOI 10.1007/BF00195354
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   BRESSLER NM, 1987, ARCH OPHTHALMOL-CHIC, V105, P209
   CAPT RP, 2001, INVEST OPHTH VIS SCI, V42, pS440
   CHANG TS, 1994, RETINA-J RET VIT DIS, V14, P114, DOI 10.1097/00006982-199414020-00004
   COSCAS G, 1991, ARCH OPHTHALMOL-CHIC, V109, P1258, DOI 10.1001/archopht.1991.01080090082028
   COSCAS G, 1990, ARCH OPHTHALMOL-CHIC, V108, P1687, DOI 10.1001/archopht.1990.01070140041025
   Coscas G, 1982, Bull Mem Soc Fr Ophtalmol, V94, P149
   DESTRO M, 1989, OPHTHALMOLOGY, V96, P846
   Donati G, 1999, GRAEF ARCH CLIN EXP, V237, P881, DOI 10.1007/s004170050380
   FINE SL, 1982, ARCH OPHTHALMOL-CHIC, V100, P912
   FREUND KB, 1993, AM J OPHTHALMOL, V115, P786, DOI 10.1016/S0002-9394(14)73649-9
   Gelfand YA, 1997, OPHTHALMIC SURG LAS, V28, P823
   Gelisken F, 2001, AM J OPHTHALMOL, V131, P518, DOI 10.1016/S0002-9394(00)00813-8
   GREY RHB, 1979, BRIT J OPHTHALMOL, V63, P85, DOI 10.1136/bjo.63.2.85
   Guyer DR, 1996, ARCH OPHTHALMOL-CHIC, V114, P693, DOI 10.1001/archopht.1996.01100130685008
   Guyer DR, 1996, OPHTHALMOLOGY, V103, P2054, DOI 10.1016/S0161-6420(96)30388-6
   GUYER DR, 1994, OPHTHALMOLOGY, V101, P1727
   HAWKINS BS, 1990, ARCH OPHTHALMOL-CHIC, V108, P816
   KUHN D, 1995, ARCH OPHTHALMOL-CHIC, V113, P1392, DOI 10.1001/archopht.1995.01100110052025
   Lee BL, 1996, RETINA-J RET VIT DIS, V16, P64, DOI 10.1097/00006982-199616010-00011
   LIM JI, 1995, AM J OPHTHALMOL, V120, P75, DOI 10.1016/S0002-9394(14)73761-4
   Lommatzsch A, 2001, INVEST OPHTH VIS SCI, V42, pS439
   MAGUIRE MG, 1994, ARCH OPHTHALMOL-CHIC, V112, P480
   Margherio RR, 2000, RETINA-J RET VIT DIS, V20, P325, DOI 10.1097/00006982-200007000-00001
   MOISSEIEV J, 1995, ARCH OPHTHALMOL-CHIC, V113, P185, DOI 10.1001/archopht.1995.01100020069031
   NAKAJIMA M, 1997, J JPN OPHTHALMOL SOC, V101, P584
   REGILLO CD, 1994, OPHTHALMOLOGY, V101, P280
   Reichel E, 1995, OPHTHALMOLOGY, V102, P1871, DOI 10.1016/S0161-6420(95)30781-6
   SLAKTER JS, 1994, ARCH OPHTHALMOL-CHIC, V112, P465, DOI 10.1001/archopht.1994.01090160041020
   Slakter JS, 2000, OPHTHALMOLOGY, V107, P742, DOI 10.1016/S0161-6420(00)00009-9
   SORENSON JA, 1994, ARCH OPHTHALMOL-CHIC, V112, P473, DOI 10.1001/archopht.1994.01090160049021
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   Stevens TS, 1997, ARCH OPHTHALMOL-CHIC, V115, P345, DOI 10.1001/archopht.1997.01100150347006
   Weinberger AWA, 1999, BRIT J OPHTHALMOL, V83, P168, DOI 10.1136/bjo.83.2.168
   YANNUZZI LA, 1994, RETINA-J RET VIT DIS, V14, P99, DOI 10.1097/00006982-199414020-00003
   YANNUZZI LA, 1992, RETINA-J RET VIT DIS, V12, P191, DOI 10.1097/00006982-199212030-00003
NR 41
TC 26
Z9 28
U1 0
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD JUN
PY 2002
VL 86
IS 6
BP 663
EP 669
DI 10.1136/bjo.86.6.663
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 561WH
UT WOS:000176165700017
PM 12034690
OA Green Published, Green Submitted, Bronze
DA 2022-11-30
ER

PT J
AU Vitale, S
   Agron, E
   Clemons, TE
   Keenan, TDL
   Domalpally, A
   Danis, RP
   Chew, EY
AF Vitale, Susan
   Agron, Elvira
   Clemons, Traci E.
   Keenan, Tiarnan D. L.
   Domalpally, Amitha
   Danis, Ronald P., Jr.
   Chew, Emily Y.
TI Association of 2-Year Progression Along the AREDS AMD Scale and
   Development of Late Age-Related Macular Degeneration or Loss of Visual
   Acuity AREDS Report 41
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID EYE DISEASE; SEVERITY SCALE; DIABETIC-RETINOPATHY; COMPLICATIONS;
   PREVALENCE
AB Importance The Age-Related Eye Disease Study age-related macular degeneration (AREDS AMD) scale is designed to classify AMD severity. The present cohort study explored whether 2-year progression along this scale was useful for estimating the risk of future progression to late AMD or best-corrected visual acuity (BCVA) loss. Objective To assess whether 2-year progression along the AREDS AMD scale can be used to estimate the probability of long-term clinically meaningful outcome measures for clinical trials or epidemiologic studies. Design, Setting, and Participants Age-Related Eye Disease Study participants enrolled in a clinical trial of oral micronutrient supplements had annual color fundus photographs graded centrally using the AREDS AMD scale. Two-year progression (>= 2-step and >= 3-step increases in AMD score between baseline and the 2-year study visit) was evaluated as a method of estimating the risk of long-term progression to late AMD or BCVA loss. The AREDS (1992-2001) was a randomized, placebo-controlled clinical trial based at 11 retinal specialty clinics in the United States. The dates of analysis in the present cohort study were November 1992 through November 2005. Main Outcomes and Measures Development of neovascular (NV) AMD, central geographic atrophy (CGA), any geographic atrophy (GA), or BCVA loss of at least 2 lines or at least 3 lines. Results Among 3868 participants in the AREDS free of late AMD at baseline, the mean (SD) age was 68.3 (5.0) years, and 2180 of 3868 (56.4%) were women. In the first 2 years after randomization to the AREDS, 669 of 7458 (9.0%) of eyes had at least 2-step 2-year progression, and 275 of 7458 (3.7%) of eyes had at least 3-step 2-year progression. In the 5-year follow-up period (years 2-7), 486 of 7223 (6.7%) of eyes developed NV AMD, 339 of 7253 (4.7%) developed CGA, 726 of 7246 (10.0%) developed any GA, 2622 of 7095 (37.0%) had at least 2-line BCVA loss, and 1494 of 7155 (20.9%) had at least 3-line BCVA loss. After adjusting for demographic and clinical confounders and stratifying by baseline AMD score, statistically significant associations were observed between at least 2-step and at least 3-step 2-year progression of AMD score and subsequent 5-year development of NV AMD: hazard ratios (HRs) ranged from 3.6 (99% CI, 2.4-5.2) to 19.4 (99% CI, 7.7-48.9). For CGA, HRs ranged from 2.6 (99% CI, 1.7-4.0) to 4.7 (99% CI, 2.5-8.9); the results were similar for any GA. For at least 2-line and at least 3-line BCVA loss, HRs ranged from 1.3 (99% CI, 1.0-1.7) to 2.8 (99% CI, 1.8-4.3). For all outcomes, at least 3-step 2-year progression had stronger associations than at least 2-step 2-year progression. These findings were also validated in the AREDS2 cohort. Conclusions and Relevance Two-year progression of AMD score was associated with progression to clinically meaningful anatomic (late AMD) and vision (>= 2-line or >= 3-line loss) outcomes, suggesting that this scale may be useful for future clinical trials designed to slow the progression of AMD.
   This cohort study assesses whether 2-year progression along the Age-Related Eye Disease Study age-related macular degeneration (AREDS AMD) scale is associated with long-term clinically meaningful outcomes.
   Question Could 2-year progression along the Age-Related Eye Disease Study age-related macular degeneration (AREDS AMD) scale be used to estimate the risk of late age-related macular degeneration or loss of visual acuity? Findings Among 3868 participants in the AREDS, this cohort study found statistically significant associations between at least 2-step and at least 3-step 2-year progression of AMD score (occurring between baseline and the 2-year study visit) and subsequent 5-year development of neovascular AMD, central geographic atrophy, any geographic atrophy, or best-corrected visual acuity loss. Meaning Two-year progression of AMD score may be a useful measure in estimating the risk of late AMD outcomes and loss of visual acuity; this finding demonstrates the viability of the AREDS AMD scale in describing AMD progression.
C1 [Vitale, Susan; Agron, Elvira; Keenan, Tiarnan D. L.; Chew, Emily Y.] NEI, Div Epidemiol & Clin Applicat, NIH, 10 Ctr Dr,Room 10D45, Bethesda, MD 20892 USA.
   [Clemons, Traci E.] Emmes Co LLC, Rockville, MD USA.
   [Domalpally, Amitha; Danis, Ronald P., Jr.] Univ Wisconsin Madison, Fundus Photograph Reading Ctr, Madison, WI USA.
   [Domalpally, Amitha; Danis, Ronald P., Jr.] Univ Wisconsin Madison, Dept Ophthalmol & Visual Sci, Madison, WI USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); University of Wisconsin System; University of Wisconsin Madison;
   University of Wisconsin System; University of Wisconsin Madison
RP Vitale, S (通讯作者)，NEI, Div Epidemiol & Clin Applicat, NIH, 10 Ctr Dr,Room 10D45, Bethesda, MD 20892 USA.
EM sev@nei.nih.gov
FU NEI [NOI-EY-0-2127]; Research to Prevent Blindness
FX This study was supported by intramural program funds and contract
   NOI-EY-0-2127 from the NEI. It was supported in part by an unrestricted
   grant from Research to Prevent Blindness to the Department of
   Ophthalmology and Visual Sciences, University of Wisconsin-Madison (Drs
   Domalpally and Danis).
CR [Anonymous], 1991, Ophthalmology, V98, P823
   Chew EY, 2012, OPHTHALMOLOGY, V119, P2282, DOI 10.1016/j.ophtha.2012.05.027
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Danis RP, 2013, INVEST OPHTH VIS SCI, V54, P4548, DOI 10.1167/iovs.13-11804
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P829, DOI 10.1016/j.ophtha.2018.09.015
   Holz FG, 2014, J CLIN INVEST, V124, P1430, DOI 10.1172/JCI71029
   Hyman Leslie, 2002, Curr Opin Ophthalmol, V13, P171
   Indaram M, 2015, OPHTHALMOLOGY, V122, P888, DOI 10.1016/j.ophtha.2014.12.037
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   KLEIN R, 1989, ARCH OPHTHALMOL-CHIC, V107, P237, DOI 10.1001/archopht.1989.01070010243030
   Klein R, 2001, ARCH OPHTHALMOL-CHIC, V119, P547
   LIN DY, 1994, STAT MED, V13, P2233, DOI 10.1002/sim.4780132105
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Park DW, 2006, OPHTHALMOLOGY, V113, P1974, DOI 10.1016/j.ophtha.2006.08.015
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401
   Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6
   Vitale S, 2016, JAMA OPHTHALMOL, V134, P1041, DOI 10.1001/jamaophthalmol.2016.2383
   World Medical Association, 2013, JAMA-J AM MED ASSOC, V310, P2191, DOI [DOI 10.1001/JAMA.2013.281053, 10.1001/jama.2013.281053]
   Ying GS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1147, DOI 10.1001/archophthalmol.2009.189
NR 24
TC 5
Z9 5
U1 0
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD JUN
PY 2020
VL 138
IS 6
BP 610
EP 617
DI 10.1001/jamaophthalmol.2020.0824
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA MA8CU
UT WOS:000542139200004
PM 32271358
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Hellinen, L
   Koskela, A
   Vattulainen, E
   Liukkonen, M
   Wegler, C
   Treyer, A
   Handin, N
   Svensson, R
   Myohanen, T
   Poso, A
   Kaarniranta, K
   Artursson, P
   Urtti, A
AF Hellinen, Laura
   Koskela, Ali
   Vattulainen, Elina
   Liukkonen, Mikko
   Wegler, Christine
   Treyer, Andrea
   Handin, Niklas
   Svensson, Richard
   Myohanen, Timo
   Poso, Antti
   Kaarniranta, Kai
   Artursson, Per
   Urtti, Arto
TI Inhibition of prolyl oligopeptidase: A promising pathway to prevent the
   progression of age-related macular degeneration
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Article
DE Prolyl oligopeptidase inhibitor; Age-related macular degeneration;
   Autophagy; Retinal pigment epithelium; Proteomics; Target engagement
ID RETINAL-PIGMENT EPITHELIUM; TOTAL PROTEIN; AUTOPHAGY; DIGESTION;
   KYP-2047; ASSAYS; CELLS
AB Dry age-related macular degeneration (AMD) is a currently untreatable vision threatening disease. Impaired proteasomal clearance and autophagy in the retinal pigment epithelium (RPE) and subsequent photoreceptor damage are connected with dry AMD, but detailed pathophysiology is still unclear. In this paper, we discover inhibition of cytosolic protease, prolyl oligopeptidase (PREP), as a potential pathway to treat dry AMD. We showed that PREP inhibitor exposure induced autophagy in the RPE cells, shown by increased LC3-II levels and decreased p62 levels. PREP inhibitor treatment increased total levels of autophagic vacuoles in the RPE cells. Global proteomics was used to examine the phenotype of a commonly used cell model displaying AMD characteristics, oxidative stress and altered protein metabolism, in vitro. These RPE cells displayed induced protein aggregation and clear alterations in macromolecule metabolism, confirming the relevance of the cell model. Differences in intracellular target engagement of PREP inhibitors were observed with cellular thermal shift assay (CETSA). These differences were explained by intracellular drug exposure (the unbound cellular partition coefficient, Kpuu). Importantly, our data is in line with previous observations regarding the discrepancy between PREP's cleaving activity and outcomes in autophagy. This highlights the need to further explore PREP's role in autophagy so that more effective compounds can be designed to battle diseases in which autophagy induction is needed. The present work is the first report investigating the PREP pathway in the RPE and we predict that the PREP inhibitors can be further optimized for treatment of dry AMD.
C1 [Hellinen, Laura; Myohanen, Timo; Poso, Antti; Urtti, Arto] Univ Eastern Finland, Fac Hlth Sci, Sch Pharm, Kuopio 70210, Finland.
   [Hellinen, Laura; Wegler, Christine; Treyer, Andrea; Handin, Niklas; Artursson, Per] Uppsala Univ, Dept Pharm, S-75123 Uppsala, Sweden.
   [Koskela, Ali; Vattulainen, Elina; Liukkonen, Mikko] Univ Eastern Finland, Inst Clin Med, Dept Ophthalmol, POB 1627, FIN-70211 Kuopio, Finland.
   [Wegler, Christine; Svensson, Richard; Artursson, Per] Uppsala Univ, Drug Optimizat & Pharmaceut Profiling Platform, S-75123 Uppsala, Sweden.
   [Myohanen, Timo; Kaarniranta, Kai] Univ Helsinki, Fac Pharm, Div Pharmacol & Pharmacotherapy, Helsinki, Finland.
   [Kaarniranta, Kai] Kuopio Univ Hosp, Dept Ophthalmol, POB 1777, FIN-70211 Kuopio, Finland.
   [Artursson, Per] Uppsala Univ, Sci Life Lab, Drug Discovery & Dev Platform, S-75123 Uppsala, Sweden.
   [Urtti, Arto] Univ Helsinki, Fac Pharm, Div Pharmaceut Biosci, Drug Res Programme, POB 56, FI-00014 Helsinki, Finland.
   [Urtti, Arto] St Petersburg State Univ, Lab Biohybrid Technol, Inst Chem, St Petersburg 198504, Russia.
C3 University of Eastern Finland; Uppsala University; University of Eastern
   Finland; Uppsala University; University of Helsinki; Kuopio University
   Hospital; Uppsala University; University of Helsinki; Saint Petersburg
   State University
RP Urtti, A (通讯作者)，Univ Eastern Finland, Sch Pharm, POB 1627,Yliopistonranta 1 C, Kuopio 70211, Finland.
EM arto.urtti@uef.fi
OI Liukkonen, Mikko/0000-0002-4259-4041; Wegler,
   Christine/0000-0002-2810-7518; Myohanen, Timo/0000-0002-9277-6687
FU Academy of Finland [311122, 333903, 333302, 318327]; Finnish Cultural
   Foundation; Markku Juslin grant; NordForsk (Nordic POP project) [85352];
   Swedish Research Council [2822, 01951]; Sigrid Juselius Foundation
FX Academy of Finland (grant numbers 311122, 333903, 333302, 318327),
   Finnish Cultural Foundation (personal grant for LH), Markku Juslin grant
   (personal grant for LH), NordForsk (Nordic POP project 85352), and
   Sigrid Juselius Foundation for TM and AU. Swedish Research Council
   (grants no 2822 and 01951 to PA). Dr. Jukka Lepp anen is acknowledged
   for providing NMR data.
CR Barelli H, 1999, BIOCHEM BIOPH RES CO, V257, P657, DOI 10.1006/bbrc.1999.0366
   Blasiak J, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20010210
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Franken H, 2015, NAT PROTOC, V10, P1567, DOI 10.1038/nprot.2015.101
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Gillen CM, 1999, AM J PHYSIOL-CELL PH, V276, pC328, DOI 10.1152/ajpcell.1999.276.2.C328
   Hashimoto M, 2018, ACS CHEM BIOL, V13, P1480, DOI 10.1021/acschembio.8b00270
   Hipp MS, 2019, NAT REV MOL CELL BIO, V20, P421, DOI 10.1038/s41580-019-0101-y
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Jafari R, 2014, NAT PROTOC, V9, P2100, DOI 10.1038/nprot.2014.138
   Jalkanen AJ, 2012, NEUROCHEM INT, V60, P301, DOI 10.1016/j.neuint.2011.12.010
   Jarho EM, 2007, BIOORGAN MED CHEM, V15, P2024, DOI 10.1016/j.bmc.2006.12.036
   Kaarniranta K, 2020, PROG RETIN EYE RES, V79, DOI 10.1016/j.preteyeres.2020.100858
   Kaarniranta K, 2017, CELL BIOL TOXICOL, V33, P113, DOI 10.1007/s10565-016-9371-8
   Kaarniranta K, 2013, AUTOPHAGY, V9, P973, DOI 10.4161/auto.24546
   Kilpelainen TP, 2020, BIOMED PHARMACOTHER, V128, DOI 10.1016/j.biopha.2020.110253
   Klaips CL, 2018, J CELL BIOL, V217, P51, DOI 10.1083/jcb.201709072
   Klionsky DJ, 2021, AUTOPHAGY, V17, P1, DOI 10.1080/15548627.2020.1797280
   Kocaturk NM, 2018, FRONT CELL DEV BIOL, V6, DOI 10.3389/fcell.2018.00128
   Kvanta A, 2014, ACTA OPHTHALMOL, V92, P21, DOI 10.1111/aos.12185
   la Cour M, 2002, DRUG AGING, V19, P101, DOI 10.2165/00002512-200219020-00003
   Lajunen, 2016, PROG RETIN EYE RES
   Lambert NG, 2016, PROG RETIN EYE RES, V54, P64, DOI 10.1016/j.preteyeres.2016.04.003
   Lawandi J, 2010, J MED CHEM, V53, P3423, DOI 10.1021/jm901104g
   Levy E, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20163896
   Lopez A, 2011, EXPERT OPIN THER PAT, V21, P1023, DOI 10.1517/13543776.2011.577416
   Lu KF, 2017, AUTOPHAGY, V13, P1799, DOI 10.1080/15548627.2017.1358851
   Mateus A, 2017, PROTEOME SCI, V15, DOI 10.1186/s12953-017-0122-4
   Mateus A, 2014, J MED CHEM, V57, P3005, DOI 10.1021/jm401963n
   Mateus A, 2013, MOL PHARMACEUT, V10, P2467, DOI 10.1021/mp4000822
   Mi HY, 2019, NAT PROTOC, V14, P703, DOI 10.1038/s41596-019-0128-8
   Molina DM, 2013, SCIENCE, V341, P84, DOI 10.1126/science.1233606
   Myohanen TT, 2012, BRIT J PHARMACOL, V166, P1097, DOI 10.1111/j.1476-5381.2012.01846.x
   Nordgaard CL, 2008, INVEST OPHTH VIS SCI, V49, P2848, DOI 10.1167/iovs.07-1352
   Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200
   Parzych KR, 2014, ANTIOXID REDOX SIGN, V20, P460, DOI 10.1089/ars.2013.5371
   Poso A., 2004, COMPOUNDS HAVING PRO
   Rickman CB, 2013, INVEST OPHTH VIS SCI, V54, pORSF68, DOI 10.1167/iovs.13-12757
   Ryhanen T, 2009, J CELL MOL MED, V13, P3616, DOI 10.1111/j.1582-4934.2008.00577.x
   Savitski MM, 2014, SCIENCE, V346, P55, DOI 10.1126/science.1255784
   Savolainen MH, 2014, NEUROBIOL DIS, V68, P1, DOI 10.1016/j.nbd.2014.04.003
   Svarcbahs R, 2020, PHARMACOL RES, V151, DOI 10.1016/j.phrs.2019.104558
   Svarcbahs R, 2019, BIOCHEM PHARMACOL, V161, P113, DOI 10.1016/j.bcp.2019.01.013
   TAYLOR WL, 1980, BIOCHEM BIOPH RES CO, V94, P9, DOI 10.1016/S0006-291X(80)80179-3
   Tyanova S, 2016, NAT METHODS, V13, P731, DOI [10.1038/NMETH.3901, 10.1038/nmeth.3901]
   Viiri J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069563
   Viiri J, 2010, MOL VIS, V16, P1399
   Vizcaino JA, 2016, NUCLEIC ACIDS RES, V44, pD447, DOI 10.1093/nar/gkv1145
   WILK S, 1983, J NEUROCHEM, V41, P69, DOI 10.1111/j.1471-4159.1983.tb11815.x
   Winkler BS, 1999, MOL VIS, V5
   Wisniewski JR, 2015, ANAL CHEM, V87, P4110, DOI 10.1021/ac504689z
   Wisniewski JR, 2014, J PROTEOMICS, V109, P322, DOI 10.1016/j.jprot.2014.07.012
   Wisniewski JR, 2012, ANAL CHEM, V84, P2631, DOI 10.1021/ac300006b
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Zajac-Pytrus HM, 2015, ADV CLIN EXP MED, V24, P1099, DOI 10.17219/acem/27093
NR 56
TC 0
Z9 0
U1 1
U2 6
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY-LES-MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE
SN 0753-3322
EI 1950-6007
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD FEB
PY 2022
VL 146
AR 112501
DI 10.1016/j.biopha.2021.112501
EA DEC 2021
PG 15
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA XS7MC
UT WOS:000733087100009
PM 34891119
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Kambhampati, SP
   Bhutto, IA
   Wu, T
   Ho, K
   McLeod, DS
   Lutty, GA
   Kannan, RM
AF Kambhampati, Siva P.
   Bhutto, Imran A.
   Wu, Tony
   Ho, Katie
   McLeod, D. Scott
   Lutty, Gerard A.
   Kannan, Rangaramanujam M.
TI Systemic dendrimer nanotherapies for targeted suppression of choroidal
   inflammation and neovascularization in age-related macular degeneration
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Article
DE Age-related macular degeneration (AMD); Systemic therapies; PAMAM
   dendrimers; Microglia/macrophages; Triamcinolone acetonide; Choroidal
   neovascularization; Retinal inflammation
ID INTRAVITREAL TRIAMCINOLONE ACETONIDE; ENDOTHELIAL GROWTH-FACTOR;
   PHOTODYNAMIC THERAPY; INTRACEPTOR NANOPARTICLE; MICROGLIAL ACTIVATION;
   RETINAL MICROGLIA; BEVACIZUMAB; EDEMA; MODEL; RANIBIZUMAB
AB Inflammation and neovascularization are key pathological events in human age-related macular degeneration (AMD). Activated microglia/macrophages (mi/ma) and retinal pigmented epithelium (RPE) play an active role in every stage of disease progression. Systemic therapies that can target these cells and address both inflammation and neovascularization will broaden the impact of existing therapies and potentially open new avenues for early AMD where there are no viable therapies. Utilizing a clinically relevant rat model of AMD that mirrors many aspects that of human AMD pathological events, we show that systemic hydroxyl-terminated polyamidoamine dendrimer-triamcinolone acetonide conjugate (D-TA) is selectively taken up by the injured mi/ma and RPE (without the need for targeting ligands). D-TA suppresses choroidal neovascularization significantly (by >80%, >50-fold better than free drug), attenuates inflammation in the choroid and retina, by limiting macrophage infiltration in the pathological area, significantly suppressing pro-inflammatory cytokines and pro-angiogenic factors, with minimal side effects to healthy ocular tissue and other organs. In ex vivo studies on human postmortem diabetic eyes, the dendrimer is also taken up into choroidal macrophages. These results suggest that the systemic hydroxyl dendrimer-drugs can offer new avenues for therapies in treating early/dry AMD and late/neovascular AMD alone, or in combination with current anti-VEGF therapies. This hydroxyl dendrimer platform but conjugated to a different drug is undergoing clinical trials for severe COVID-19, potentially paving the way for faster clinical translation of similar compounds for ocular and retinal disorders.
C1 [Kambhampati, Siva P.; Wu, Tony; Lutty, Gerard A.; Kannan, Rangaramanujam M.] Johns Hopkins Univ, Sch Med, Ctr Nanomed, Wilmer Eye Inst, Baltimore, MD USA.
   [Kambhampati, Siva P.; Bhutto, Imran A.; Ho, Katie; McLeod, D. Scott; Lutty, Gerard A.; Kannan, Rangaramanujam M.] Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Baltimore, MD 21205 USA.
   [Wu, Tony] Johns Hopkins Univ, Sch Med, Dept Biomed Engn, Baltimore, MD 21205 USA.
   [Kannan, Rangaramanujam M.] Johns Hopkins Univ, Dept Chem & Biomol Engn, Baltimore, MD USA.
C3 Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins
   University; Johns Hopkins University; Johns Hopkins University
RP Kannan, RM (通讯作者)，Johns Hopkins Sch Med, Wilmer Eye Inst, Ctr Nanomed, 400 North Broadway, Baltimore, MD 21231 USA.; Lutty, GA (通讯作者)，Johns Hopkins Univ Hosp, Wilmer Ophthalmol Inst, M041 Smith Bldg,400 North Broadway, Baltimore, MD 21287 USA.
EM glutty@jhmi.edu; krangar1@jhmi.edu
RI Kambhampati, Siva Pramodh/AAK-6269-2020
FU National Eye Institute [NEI-R01EY025304, NEI-RO1EY016151, EY01765];
   Research to Prevent Blindness; Altsheler Durell foundation
FX This work was supported by National Eye Institute [NEI-R01EY025304
   (RMK); NEI-RO1EY016151 (GL), EY01765 (Wilmer)], unrestricted funds from
   Research to Prevent Blindness, and a grant from the Altsheler Durell
   foundation (GL and RMK). The authors would like to acknowledge the
   Wilmer Eye Institute NEI-sponsored CORE imaging facility for the access
   to LSM 710 confocal microscopy and Woods animal facility for animal
   housing and procedures.
CR Alnasser Y., 2018, MOL BASEL SWITZERLAN, V23
   Baba T, 2010, AM J PATHOL, V176, P3085, DOI 10.2353/ajpath.2010.090989
   Becerra EM, 2011, CURR DRUG TARGETS, V12, P149
   Bhisitkul RB, 2008, INVEST OPHTH VIS SCI, V49, P4071, DOI 10.1167/iovs.08-1892
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Bosetti F, 2016, J AM HEART ASSOC, V5, DOI 10.1161/JAHA.116.004389
   Bucolo C, 2015, J OCUL PHARMACOL TH, V31, P228, DOI 10.1089/jop.2014.0094
   Campochiaro PA, 2018, OPHTHALMOL RETINA, V2, P320, DOI 10.1016/j.oret.2017.07.013
   Campos M, 2006, INVEST OPHTH VIS SCI, V47, P5163, DOI 10.1167/iovs.06-0156
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Cruz-Inigo Y, 2014, INVEST OPHTH VIS SCI, V55
   Das A, 2015, OPHTHALMOLOGY, V122, P1375, DOI 10.1016/j.ophtha.2015.03.024
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Franiak-Pietryga I., 2018, DENDRIMERS DRUG NANO
   Ganugula R, 2017, ACS APPL MATER INTER, V9, P25668, DOI 10.1021/acsami.7b07896
   Gokce G, 2016, ARQ BRAS OFTALMOL, V79, P384, DOI 10.5935/0004-2749.20160109
   Guo Y, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154437
   Ho DCW, 2018, OCUL IMMUNOL INFLAMM, V26, P461, DOI 10.1080/09273948.2016.1245758
   Hua J, 2010, INVEST OPHTH VIS SCI, V51, P4282, DOI 10.1167/iovs.09-4360
   Hussain RM, 2016, EXPERT OPIN BIOL TH, V16, P365, DOI 10.1517/14712598.2016.1131265
   Iezzi R, 2012, BIOMATERIALS, V33, P979, DOI 10.1016/j.biomaterials.2011.10.010
   Ip MS, 2002, ARCH OPHTHALMOL-CHIC, V120, P1217
   Jawad S, 2013, INVEST OPHTH VIS SCI, V54, P5959, DOI 10.1167/iovs.12-11380
   Johnen S, 2019, KLIN MONATSBL AUGENH, V236, P1096, DOI 10.1055/a-0898-4030
   Jonas JB, 2005, PROG RETIN EYE RES, V24, P587, DOI 10.1016/j.preteyeres.2005.01.004
   Jonas JB, 2010, ARCH OPHTHALMOL-CHIC, V128, P1281, DOI 10.1001/archophthalmol.2010.227
   Julien S, 2014, BRIT J OPHTHALMOL, V98, P813, DOI 10.1136/bjophthalmol-2013-304019
   Kambhampati SP, 2015, INVEST OPHTH VIS SCI, V56, P4413, DOI 10.1167/iovs.14-16250
   Kambhampati SP, 2015, EUR J PHARM BIOPHARM, V95, P239, DOI 10.1016/j.ejpb.2015.02.013
   Karlstetter M, 2015, PROG RETIN EYE RES, V45, P30, DOI 10.1016/j.preteyeres.2014.11.004
   Kato A, 2005, RETINA-J RET VIT DIS, V25, P503, DOI 10.1097/00006982-200506000-00017
   Kiernan DF, 2009, EXPERT OPIN PHARMACO, V10, P2511, DOI 10.1517/14656560903160671
   Kim SY, 2021, EXP EYE RES, V203, DOI 10.1016/j.exer.2020.108391
   Kim SJ, 2010, ARCH OPHTHALMOL-CHIC, V128, P596, DOI 10.1001/archophthalmol.2010.69
   Kleinman ME, 2010, OPHTHALMOLOGY, V117, P1654, DOI 10.1016/j.ophtha.2010.01.052
   Kunikata H, 2013, AM J OPHTHALMOL, V155, P1028, DOI 10.1016/j.ajo.2013.01.013
   Lesniak WG, 2013, MOL PHARMACEUT, V10, P4560, DOI 10.1021/mp400371r
   Liaw K, 2020, BIOENG TRANSL MED, V5, DOI 10.1002/btm2.10160
   Luo L, 2013, ACS NANO, V7, P3264, DOI 10.1021/nn305958y
   LUTTY GA, 1993, INVEST OPHTH VIS SCI, V34, P477
   Ma WX, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007945
   Mansoor S, 2009, PHARM RES-DORDR, V26, P770, DOI 10.1007/s11095-008-9812-z
   Maruko I, 2015, RETINA-J RET VIT DIS, V35, P648, DOI 10.1097/IAE.0000000000000486
   McCarthy CA, 2013, CLIN EXP PHARMACOL P, V40, P571, DOI 10.1111/1440-1681.12099
   McLeod D.S, 2016, INVEST OPHTHALMOL VI, V57, P5855
   Mishra MK, 2014, ACS NANO, V8, P2134, DOI 10.1021/nn404872e
   Miyamoto N, 2017, CLIN OPHTHALMOL, V11, DOI 10.2147/OPTH.S133332
   Moisseiev E, 2014, GRAEF ARCH CLIN EXP, V252, P331, DOI 10.1007/s00417-013-2495-0
   Moreira-Neto CA, 2018, J OPHTHALMOL, V2018, DOI 10.1155/2018/8125267
   Nance E, 2016, BIOMATERIALS, V101, P96, DOI 10.1016/j.biomaterials.2016.05.044
   Nance E, 2015, J CONTROL RELEASE, V214, P112, DOI 10.1016/j.jconrel.2015.07.009
   Nemeth CL, 2017, NANOMED-NANOTECHNOL, V13, P2359, DOI 10.1016/j.nano.2017.06.014
   Newman AM, 2012, GENOME MED, V4, DOI [10.1186/PREACCEPT-1418491035586234, 10.1186/gm315]
   Nino DF, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aan0237
   Park SJ, 2016, INVEST OPHTH VIS SCI, V57, P2612, DOI 10.1167/iovs.16-19204
   Penfold PL, 2002, INVEST OPHTH VIS SCI, V43, P3125
   Penfold PL, 2001, CLIN EXP OPHTHALMOL, V29, P188, DOI 10.1046/j.1442-9071.2001.00407.x
   Pennesi ME, 2012, MOL ASPECTS MED, V33, P487, DOI 10.1016/j.mam.2012.06.003
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   Seddon JM, 2016, JAMA OPHTHALMOL, V134, P1272, DOI 10.1001/jamaophthalmol.2016.3519
   Shi X, 2006, EXP EYE RES, V83, P1325, DOI 10.1016/j.exer.2006.07.007
   Shimura M, 2008, AM J OPHTHALMOL, V145, P854, DOI 10.1016/j.ajo.2007.12.031
   Skeie JM, 2009, EYE, V23, P747, DOI 10.1038/eye.2008.206
   Smith BT, 2008, RETINA-J RET VIT DIS, V28, P675, DOI 10.1097/IAE.0b013e31816b316e
   Sonmez K, 2012, INT J OPHTHALMOL-CHI, V5, P719, DOI 10.3980/j.issn.2222-3959.2012.06.13
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P1517, DOI 10.1016/S0161-6420(03)00544-X
   Takata S, 2015, SCI REP-UK, V5, DOI 10.1038/srep09898
   Thetford C, 2013, BRIT J VISUAL IMPA, V31, P89, DOI 10.1177/0264619613481778
   Tsutsumi C, 2003, J LEUKOCYTE BIOL, V74, P25, DOI 10.1189/jlb.0902436
   Veritti D, 2013, J OCUL PHARMACOL TH, V29, P437, DOI 10.1089/jop.2012.0173
   Veritti D, 2012, OPHTHALMOLOGICA, V227, P11, DOI 10.1159/000337154
   Wang MH, 2014, J NEUROSCI, V34, P3793, DOI 10.1523/JNEUROSCI.3153-13.2014
   Wang YS, 2002, GRAEF ARCH CLIN EXP, V240, P42, DOI 10.1007/s00417-001-0398-y
   Weiner G., 2012, RETINA-J RET VIT DIS, P37
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xu LN, 2015, RETINA-J RET VIT DIS, V35, P176, DOI 10.1097/IAE.0000000000000374
   Young M, 2014, RETINA-J RET VIT DIS, V34, P1308, DOI 10.1097/IAE.0000000000000081
   Yu SY, 2006, RETINA-J RET VIT DIS, V26, P531, DOI 10.1097/00006982-200605000-00006
   Zhang K, 2012, NAT REV DRUG DISCOV, V11, P541, DOI 10.1038/nrd3745
   Zhang XH, 2017, MOL THER, V25, P1606, DOI 10.1016/j.ymthe.2017.01.014
   Zheng M, 2018, TRENDS BIOTECHNOL, V36, P562, DOI 10.1016/j.tibtech.2018.01.006
NR 81
TC 4
Z9 4
U1 13
U2 45
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0168-3659
EI 1873-4995
J9 J CONTROL RELEASE
JI J. Control. Release
PD JUL 10
PY 2021
VL 335
BP 527
EP 540
DI 10.1016/j.jconrel.2021.05.035
EA JUN 2021
PG 14
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Pharmacology & Pharmacy
GA TM1SF
UT WOS:000675332500003
PM 34058271
DA 2022-11-30
ER

PT J
AU Antoszyk, AN
   Tuomi, L
   Chung, CY
   Singh, A
AF Antoszyk, Andrew N.
   Tuomi, Lisa
   Chung, Carol Y.
   Singh, Angele
CA FOCUS STUDY GRP
TI Ranibizumab combined with verteporfin photodynamic therapy in
   neovascular age-related macular degeneration (FOCUS): Year 2 results
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
AB PURPOSE: To assess the efficacy and adverse,events profile of combined treatment with ranibizumab and verteporfin photodynamic therapy (PDT) in patients with predominantly classic choroidal neovascularization (CNV) secondary to neovascular age-related macular degeneration.
   DESIGN: Two-year, multicenter, randomized, single-masked, controlled study.
   METHODS: Patients received monthly intravitreal injections of ranibizumab 0.5 mg (n = 106) or sham injections (n = 56). All patients received PDT on day zero, then quarterly as needed. Efficacy assessment included changes in visual acuity (VA) and lesion characteristics and PDT frequency. Adverse events were summarized by incidence and severity.
   RESULTS: At month 24, 88% of ranibizumab + PDT patients had lost < 15 letters from baseline VA (vs 75% for PDT alone), 25% had gained 15 letters (vs 7% for PDT alone), and the two treatment arms differed by 12.4 letters in mean VA change (P <.05 for all between, group differences). The VA benefit of adding ranibizumab to PDT in year one persisted through year two. On average, ranibizumab + PDT patients exhibited less lesion growth and greater reduction of CNV leakage and subretinal fluid accumulation, and required fewer PDT retreatments, than PDT,alone patients (mean = 0.4 vs 3.0 PDT retreatments). Endophthalmitis and serious intraocular inflammation occurred, respectively, in 2.9% and 12.4% of ranibizurnab + PDT patients and 0% of PDT-alone patients. Incidences of serious nonocular adverse events were similar in the two treatment groups.
   CONCLUSIONS: Through two years, ranibizumab + PDT was more effective than PDT alone and had a low rate of associated adverse events.
C1 [Antoszyk, Andrew N.] Nose & Throat Associates, Charlotte Eye, Charlotte, NC 28210 USA.
   [Tuomi, Lisa; Chung, Carol Y.; Singh, Angele] Genetech Inc, San Francisco, CA USA.
RP Antoszyk, AN (通讯作者)，Nose & Throat Associates, Charlotte Eye, 6035 Fairview Rd, Charlotte, NC 28210 USA.
EM ana@ceenta.com
CR ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Azab M, 2004, RETINA-J RET VIT DIS, V24, P1
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Heier JS, 2006, ARCH OPHTHALMOL-CHIC, V124, P1532, DOI 10.1001/archopht.124.11.1532
   Heier JS, 2006, OPHTHALMOLOGY, V113, P633, DOI 10.1016/j.ophtha.2005.10.052
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHALMOLOGY, V112, P1048, DOI 10.1016/j.ophtha.2005.01.043
   Rosenfeld PJ, 2006, OPHTHALMOLOGY, V113, P623, DOI 10.1016/j.ophtha.2006.01.027
   Schlotzer-Schrehardt U, 2002, GRAEF ARCH CLIN EXP, V240, P748, DOI 10.1007/s00417-002-0517-4
NR 13
TC 148
Z9 162
U1 0
U2 10
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD MAY
PY 2008
VL 145
IS 5
BP 862
EP 874
DI 10.1016/j.ajo.2007.12.029
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 292YU
UT WOS:000255302800016
PM 18321465
DA 2022-11-30
ER

PT J
AU Camino, A
   Guo, YK
   You, QS
   Wang, J
   Huang, D
   Bailey, ST
   Jia, YL
AF Camino, Acner
   Guo, Yukun
   You, Qisheng
   Wang, Jie
   Huang, David
   Bailey, Steven T.
   Jia, Yali
TI Detecting and measuring areas of choriocapillaris low perfusion in
   intermediate, non-neovascular age-related macular degeneration
SO NEUROPHOTONICS
LA English
DT Article
DE optical coherence tomography angiography; choriocapillaris; age-related
   macular degeneration; drusen
ID COHERENCE TOMOGRAPHY ANGIOGRAPHY; MORPHOMETRIC-ANALYSIS; MOTION
   CORRECTION; OCT ANGIOGRAPHY; ULTRAHIGH-SPEED; FEATURES
AB Age-related macular degeneration (AMD) is a vision-threatening disease that affects the outer retina and choroid of elderly adults. Because photoreceptors are found in the outer retina and rely primarily on the trophic support of the underlying choriocapillaris, imaging of flow or lack thereof in choriocapillaris by optical coherence tomography angiography (OCTA) has great clinical potential in AMD assessment. We introduce a metric using OCTA, named "focal perfusion loss" (FPL) to describe the effects of age and non-neovascular AMD on choriocapillaris flow. Because OCTA imaging of choriocapillaris is vulnerable to artifacts-namely motion, projections, segmentation errors, and shadows-they are removed by postprocessing software. The shadow detection software is a machine learning algorithm recently developed for the evaluation of the retinal circulation and here adapted for choriocapillaris analysis. It aims to exclude areas with unreliable flow signal due to blocking of the OCT beam by objects anterior to the choriocapillaris (e.g., drusen, retinal vessels, vitreous floaters, and iris). We found that both the FPL and the capillary density were able to detect changes in the choriocapillaris of AMD and healthy age-matched subjects with respect to young controls. The dominant cause of shadowing in AMD is drusen, and the shadow exclusion algorithm helps determine which areas under drusen retain sufficient signal for perfusion evaluation and which areas must be excluded. Such analysis allowed us to determine unambiguously that choriocapillaris density under drusen is indeed reduced. (C) The Authors. Published by SPIE under a Creative Commons Attribution 4.0 Unported License.
C1 [Camino, Acner; Guo, Yukun; You, Qisheng; Wang, Jie; Huang, David; Bailey, Steven T.; Jia, Yali] Oregon Hlth & Sci Univ, Casey Eye Inst, Portland, OR 97201 USA.
C3 Oregon Health & Science University
RP Jia, YL (通讯作者)，Oregon Hlth & Sci Univ, Casey Eye Inst, Portland, OR 97201 USA.
EM jiaya@ohsu.edu
RI Guo, Yukun/AAB-6902-2020; You, Qisheng/AAG-7153-2020
OI Guo, Yukun/0000-0002-6784-2355; You, Qisheng/0000-0003-0743-7320;
   Bailey, Steven/0000-0003-4949-1464; Jia, Yali/0000-0002-2784-1905
FU U.S. National Institutes of Health (Bethesda, Maryland) [R01 EY024544,
   R01EY027833, P30 EY010572, T32 EY023211-05]; William and Mary Greve
   Special Scholar Award from Research to Prevent Blindness (New York);
   Antonio Champalimaud Vision Award; NATIONAL EYE INSTITUTE [P30EY010572,
   R01EY027833, R01EY024544, T32EY023211] Funding Source: NIH RePORTER
FX This work was supported by Grant Nos. R01 EY024544, R01EY027833, P30
   EY010572, and T32 EY023211-05 from the U.S. National Institutes of
   Health (Bethesda, Maryland), an unrestricted departmental funding grant,
   the William and Mary Greve Special Scholar Award from Research to
   Prevent Blindness (New York), and the Antonio Champalimaud Vision Award.
CR Al-Sheikh M, 2017, INVEST OPHTH VIS SCI, V58, P2063, DOI 10.1167/iovs.16-21289
   Alten F, 2016, GRAEF ARCH CLIN EXP, V254, P2165, DOI 10.1007/s00417-016-3375-1
   Borrelli E, 2017, INVEST OPHTH VIS SCI, V58, P4792, DOI 10.1167/iovs.17-22360
   Camino A, 2019, BIOMED OPT EXPRESS, V10, P1514, DOI 10.1364/BOE.10.001514
   Camino A, 2018, TRANSL VIS SCI TECHN, V7, DOI 10.1167/tvst.7.6.20
   Camino A, 2017, BIOMED OPT EXPRESS, V8, P3053, DOI 10.1364/BOE.8.003053
   Camino A, 2016, BIOMED OPT EXPRESS, V7, P3905, DOI 10.1364/BOE.7.003905
   Choi W, 2015, OPHTHALMOLOGY, V122, P2532, DOI 10.1016/j.ophtha.2015.08.029
   GREEN WR, 1986, OPHTHALMOLOGY, V93, P1169
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1435, DOI 10.1016/j.ophtha.2014.01.034
   Jia YL, 2012, OPT EXPRESS, V20, P4710, DOI 10.1364/OE.20.004710
   Kraus MF, 2012, BIOMED OPT EXPRESS, V3, P1182, DOI 10.1364/BOE.3.001182
   Kurokawa K, 2017, BIOMED OPT EXPRESS, V8, P1803, DOI 10.1364/BOE.8.001803
   Lauermann JL, 2018, OPHTHALMOLOGICA, V239, P74, DOI 10.1159/000485261
   Ma J, 2017, OPHTHALMOL EYE DIS, V9, DOI 10.1177/1179172116686075
   Matet A., RETINA
   McClintic SM, 2015, INVEST OPHTH VIS SCI, V56
   Moreira-Neto CA, 2018, J OPHTHALMOL, V12, P1
   Moult E, 2014, OSLI RETINA, V45, P496, DOI 10.3928/23258160-20141118-03
   Nassisi M, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0212563
   Nassisi M, 2019, BRIT J OPHTHALMOL, V103, P911, DOI 10.1136/bjophthalmol-2018-312643
   Nassisi M, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18112468
   Nesper PL, 2017, AM J OPHTHALMOL, V174, P42, DOI 10.1016/j.ajo.2016.10.005
   Nicolo M, 2017, INVEST OPHTH VIS SCI, V58, P2002, DOI 10.1167/iovs.17-21417
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Spaide RF, 2016, AM J OPHTHALMOL, V170, P58, DOI 10.1016/j.ajo.2016.07.023
   Wang J, 2017, BIOMED OPT EXPRESS, V8, P1536, DOI 10.1364/BOE.8.001536
   Zhang M, 2015, BIOMED OPT EXPRESS, V6, P4661, DOI 10.1364/BOE.6.004661
   Zhang QQ, 2018, INVEST OPHTH VIS SCI, V59, P203, DOI 10.1167/iovs.17-22953
   Zhao R, 2017, BIOMED OPT EXPRESS, V8, P5049, DOI 10.1364/BOE.8.005049
   Zheng F, 2019, AM J OPHTHALMOL, V200, P110, DOI 10.1016/j.ajo.2018.12.025
NR 32
TC 14
Z9 14
U1 1
U2 7
PU SPIE-SOC PHOTO-OPTICAL INSTRUMENTATION ENGINEERS
PI BELLINGHAM
PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98225 USA
SN 2329-423X
EI 2329-4248
J9 NEUROPHOTONICS
JI Neurophotonics
PD OCT-DEC
PY 2019
VL 6
IS 4
AR 041108
DI 10.1117/1.NPh.6.4.041108
PG 9
WC Neurosciences; Optics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology; Optics
GA KE5RP
UT WOS:000508613100009
PM 31528658
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Shaw, PX
   Zhang, L
   Zhang, M
   Du, HJ
   Zhao, L
   Lee, C
   Grob, S
   Lim, SL
   Hughes, G
   Lee, J
   Bedell, M
   Nelson, MH
   Lu, F
   Krupa, M
   Luo, J
   Ouyang, H
   Tu, ZD
   Su, ZG
   Zhu, J
   Wei, XR
   Feng, ZS
   Duan, Y
   Yang, ZL
   Ferreyra, H
   Bartsch, DU
   Kozak, I
   Zhang, LF
   Lin, F
   Sun, H
   Feng, H
   Zhang, K
AF Shaw, Peter X.
   Zhang, Li
   Zhang, Ming
   Du, Hongjun
   Zhao, Ling
   Lee, Clara
   Grob, Seanna
   Lim, Siok Lam
   Hughes, Guy
   Lee, Janet
   Bedell, Matthew
   Nelson, Mark H.
   Lu, Fang
   Krupa, Martin
   Luo, Jing
   Ouyang, Hong
   Tu, Zhidan
   Su, Zhiguang
   Zhu, Jin
   Wei, Xinran
   Feng, Zishan
   Duan, Yaou
   Yang, Zhenglin
   Ferreyra, Henry
   Bartsch, Dirk-Uwe
   Kozak, Igor
   Zhang, Liangfang
   Lin, Feng
   Sun, Hui
   Feng, Hong
   Zhang, Kang
TI Complement factor H genotypes impact risk of age-related macular
   degeneration by interaction with oxidized phospholipids
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
ID OXIDATION-SPECIFIC EPITOPES; NATURAL ANTIBODIES; Y402H POLYMORPHISM;
   INNATE; COMMON; ATHEROSCLEROSIS; CFH; VARIANT; DRUSEN; GENE
AB The rs1061170T/C variant encoding the Y402H change in complement factor H (CFH) has been identified by genome-wide association studies as being significantly associated with age-related macular degeneration (AMD). However, the precise mechanism by which this CFH variant impacts the risk of AMD remains largely unknown. Oxidative stress plays an important role in many aging diseases, including cardiovascular disease and AMD. A large amount of oxidized phospholipids (oxPLs) are generated in the eye because of sunlight exposure and high oxygen content. OxPLs bind to the retinal pigment epithelium and macrophages and strongly activate downstream inflammatory cascades. We hypothesize that CFH may impact the risk of AMD by modulating oxidative stress. Here we demonstrate that CFH binds to oxPLs. The CFH 402Y variant of the protective rs1061170 genotype binds oxPLs with a higher affinity and exhibits a stronger inhibitory effect on the binding of oxPLs to retinal pigment epithelium and macrophages. In addition, plasma from non-AMD subjects with the protective genotype has a lower level of systemic oxidative stress measured by oxPLs per apolipoprotein B (oxPLs/apoB). We also show that oxPL stimulation increases expression of genes involved in macrophage infiltration, inflammation, and neovascularization in the eye. OxPLs colocalize with CFH in drusen in the human AMD eye. Subretinal injection of oxPLs induces choroidal neovascularization in mice. In addition, we show that the CFH risk allele confers higher complement activation and cell lysis activity. Together, these findings suggest that CFH influences AMD risk by modulating oxidative stress, inflammation, and abnormal angiogenesis.
C1 [Yang, Zhenglin] Sichuan Acad Med Sci, Inst Lab Med, Chengdu 610072, Sichuan, Peoples R China.
   [Yang, Zhenglin] Sichuan Prov Peoples Hosp, Chengdu 610072, Sichuan, Peoples R China.
   [Shaw, Peter X.; Zhang, Ming; Du, Hongjun; Zhao, Ling; Lu, Fang; Su, Zhiguang; Zhu, Jin; Wei, Xinran; Duan, Yaou; Zhang, Kang] Sichuan Univ, W China Hosp, Mol Med Res Ctr, Chengdu 610064, Sichuan, Peoples R China.
   [Shaw, Peter X.; Zhang, Ming; Du, Hongjun; Zhao, Ling; Lu, Fang; Su, Zhiguang; Zhu, Jin; Wei, Xinran; Duan, Yaou; Zhang, Kang] Sichuan Univ, W China Hosp, Dept Ophthalmol, State Key Lab Biotherapy, Chengdu 610064, Sichuan, Peoples R China.
   [Shaw, Peter X.; Zhang, Li; Du, Hongjun; Zhao, Ling; Lee, Clara; Grob, Seanna; Lim, Siok Lam; Hughes, Guy; Lee, Janet; Bedell, Matthew; Krupa, Martin; Luo, Jing; Ouyang, Hong; Zhu, Jin; Wei, Xinran; Duan, Yaou; Zhang, Kang] Univ Calif, Inst Genom Med, La Jolla, CA 92093 USA.
   [Shaw, Peter X.; Zhang, Li; Du, Hongjun; Zhao, Ling; Lee, Clara; Grob, Seanna; Lim, Siok Lam; Hughes, Guy; Lee, Janet; Bedell, Matthew; Krupa, Martin; Luo, Jing; Ouyang, Hong; Zhu, Jin; Wei, Xinran; Duan, Yaou; Ferreyra, Henry; Bartsch, Dirk-Uwe; Kozak, Igor; Zhang, Kang] Univ Calif, Shiley Eye Ctr, La Jolla, CA 92093 USA.
   [Nelson, Mark H.] N Carolina Macular Consultants, Winston Salem, NC 27103 USA.
   [Tu, Zhidan; Lin, Feng] Case Western Reserve Univ, Dept Pathol, Cleveland, OH 44106 USA.
   [Feng, Zishan] China Med Univ, ShengJing Affiliated Hosp, Shenyang 110004, Liaoning, Peoples R China.
   [Zhang, Liangfang] Univ Calif San Diego, Dept Nanoengn, La Jolla, CA 92093 USA.
   [Sun, Hui] Univ Calif Los Angeles, Dept Physiol, Los Angeles, CA 90095 USA.
   [Feng, Hong] Shengyang Med Coll, Fengtian Hosp, Shenyang 110024, Liaoning, Peoples R China.
C3 Sichuan Provincial People's Hospital; Sichuan Provincial People's
   Hospital; Sichuan University; Sichuan University; University of
   California System; University of California San Diego; University of
   California System; University of California San Diego; Case Western
   Reserve University; China Medical University; University of California
   System; University of California San Diego; University of California
   System; University of California Los Angeles; Shenyang Medical College
RP Yang, ZL (通讯作者)，Sichuan Acad Med Sci, Inst Lab Med, Chengdu 610072, Sichuan, Peoples R China.
EM zliny@yahoo.com; fenghongcn@hotmail.com; kang.zhang@gmail.com
RI Zhao, Ling/D-9005-2015; Su, Zhiguang/AFS-0022-2022; Zhang,
   Kang/Y-2740-2019; Kozak, Igor/AAC-4645-2019
OI Zhang, Kang/0000-0002-4549-1697; Luo, Jing/0000-0002-8905-9388; Su,
   Zhiguang/0000-0001-8635-9310; Zhao, Ling/0000-0002-6644-2886; Ouyang,
   Hong/0000-0002-7622-7733
FU Natural Science Foundation of China [81130017, 81025006]; National Basic
   Research Program of China (973 Program) [2011CB510200]; National Eye
   Institute/National Institutes of Health; King Abdulaziz City for Science
   and Technology through the UC San Diego Center of Excellence in
   Nanomedicine center grant; Veterans Affairs Merit Award; Research to
   Prevent Blindness; Burroughs Wellcome Fund Clinical Scientist Award in
   Translational Research; NATIONAL EYE INSTITUTE [R01EY016323,
   R01EY021374] Funding Source: NIH RePORTER
FX We thank members of the K.Z. laboratory for assistance and helpful
   discussions. This work is supported by grants from the Natural Science
   Foundation of China (Grant 81130017 to K.Z. and Grant 81025006 to Z.Y.),
   the National Basic Research Program of China (973 Program, 2011CB510200
   to K.Z.). K.Z. is also supported by the National Eye Institute/National
   Institutes of Health, the King Abdulaziz City for Science and Technology
   through the UC San Diego Center of Excellence in Nanomedicine center
   grant, a Veterans Affairs Merit Award, Research to Prevent Blindness,
   and a Burroughs Wellcome Fund Clinical Scientist Award in Translational
   Research.
CR Ahmadi N, 2010, AM J CARDIOL, V105, P459, DOI 10.1016/j.amjcard.2009.09.052
   [Anonymous], 1999, CONTROL CLIN TRIALS, DOI 10.1016/S0197-2456(99)00031-8
   Appelboom G, 2011, J CLIN NEUROSCI, V18, P1439, DOI 10.1016/j.jocn.2011.04.001
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   BERLINER JA, 1995, CIRCULATION, V91, P2488, DOI 10.1161/01.CIR.91.9.2488
   Binder CJ, 2002, NAT MED, V8, P1218, DOI 10.1038/nm1102-1218
   Boon CJF, 2009, MOL IMMUNOL, V46, P1573, DOI 10.1016/j.molimm.2009.02.013
   Boullier A, 2001, ANN NY ACAD SCI, V947, P214
   Brewer GJ, 2007, EXP BIOL MED, V232, P323
   Chou MY, 2008, J INTERN MED, V263, P479, DOI 10.1111/j.1365-2796.2008.01968.x
   Chou MY, 2009, J CLIN INVEST, V119, P1335, DOI 10.1172/JCI36800
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Cui TT, 2011, INT J ONCOL, V39, P161, DOI 10.3892/ijo.2011.1010
   Curcio CA, 2010, J LIPID RES, V51, P451, DOI 10.1194/jlr.R002238
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   FEARON DT, 1973, J EXP MED, V138, P1305, DOI 10.1084/jem.138.6.1305
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182
   Hazen SL, 2008, J BIOL CHEM, V283, P15527, DOI 10.1074/jbc.R700054200
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Kavanagh D, 2006, BRIT MED BULL, V77-78, P5, DOI 10.1093/bmb/ldl004
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kondo N, 2009, OPHTHALMOLOGY, V116, P304, DOI 10.1016/j.ophtha.2008.11.011
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Manolio TA, 2008, J CLIN INVEST, V118, P1590, DOI 10.1172/JCI34772
   Miller YI, 2003, CURR OPIN LIPIDOL, V14, P437, DOI 10.1097/00041433-200310000-00004
   Miller YI, 2011, CIRC RES, V108, P235, DOI 10.1161/CIRCRESAHA.110.223875
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Nishio N, 2012, GENE, V499, P226, DOI 10.1016/j.gene.2012.02.027
   PALINSKI W, 1990, ARTERIOSCLEROSIS, V10, P325, DOI 10.1161/01.ATV.10.3.325
   Pegorier S, 2006, ATHEROSCLEROSIS, V188, P433, DOI 10.1016/j.atherosclerosis.2005.11.015
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   Schejbel L, 2011, GENES IMMUN, V12, P90, DOI 10.1038/gene.2010.63
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Shaw PX, 2000, J CLIN INVEST, V105, P1731, DOI 10.1172/JCI8472
   Sun MJ, 2006, J BIOL CHEM, V281, P4222, DOI 10.1074/jbc.M509769200
   Tsimikas S, 2005, NEW ENGL J MED, V353, P46, DOI 10.1056/NEJMoa043175
   Vlahopoulos S, 1999, BLOOD, V94, P1878, DOI 10.1182/blood.V94.6.1878
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   Xing C, 2008, GENES IMMUN, V9, P231, DOI 10.1038/gene.2008.10
   Yang ZL, 2008, NEW ENGL J MED, V359, P1456, DOI 10.1056/NEJMoa0802437
   YOUNG RW, 1971, J CELL BIOL, V49, P303, DOI 10.1083/jcb.49.2.303
   YOUNG RW, 1967, J CELL BIOL, V33, P61, DOI 10.1083/jcb.33.1.61
   Yu JM, 2007, BIOCHEMISTRY-US, V46, P8451, DOI 10.1021/bi700459a
   Zipfel PF, 2007, PLOS GENET, V3, P387, DOI 10.1371/journal.pgen.0030041
NR 48
TC 106
Z9 110
U1 2
U2 36
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD AUG 21
PY 2012
VL 109
IS 34
BP 13757
EP 13762
DI 10.1073/pnas.1121309109
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 996KJ
UT WOS:000308085200063
PM 22875704
OA Green Published
DA 2022-11-30
ER

PT J
AU Atmani, K
   Coscas, F
   Coscas, G
   Soubrane, G
AF Atmani, K.
   Coscas, F.
   Coscas, G.
   Soubrane, G.
TI Pegaptanib sodium for occult choroidal neovascularization in neovascular
   age-related macular degeneration: a prospective case series
SO EYE
LA English
DT Article
DE age-related macular degeneration; choroidal neovascularisation;
   pegaptanib
ID VERTEPORFIN; THERAPY
AB Purpose To assess the effects of pegaptanib in the treatment of subfoveal occult choroidal neovascularisation (CNV) associated with neovascular age-related macular degeneration (NV-AMD) in a compassionate use program in France.
   Methods Pegaptanib was authorized for patients with CNV-associated visual impairment and in whom usual care (thermal laser photocoagulation or photodynamic therapy with verteporfin) was not appropriate. Patients with occult CNV lesions received intravitreous pegaptanib (0.3 mg every 6 weeks) and were followed with repeated fluorescein angiography, scanning laser ophthalmoscopy-infracyanine green angiography, and ocular coherence tomography through 52 weeks.
   Results Of 56 patients (predominantly occult, N = 22; purely occult, N = 8; occult with chorioretinal anastomosis, N = 12; occult with pigment epithelial detachment, N = 14), 30% had earlier treatment. All received eight pegaptanib injections. At week 52, 79% were responders (lost < 15 letters of visual acuity), 43% gained >= 0 letters, and 9% gained >= 15 letters. The best functional results were obtained in the predominantly and pure occult subgroups (responders, 86 and 75%; gained >= 0 letters, 50 and 50%). Maximum visual outcomes that correlated with morphologic improvements on each diagnostic imaging tool were seen after at least three injections. No significant ocular or systemic adverse events occurred.
   Conclusion Treatment with pegaptanib was associated with objective functional improvements that can be correlated with objective clinical improvements on routine diagnostic imaging tools in patients with occult NV-AMD. Optimum treatment results appear after at least 4 months of therapy in the majority of cases. Eye (2009) 23, 1150-1154; doi:10.1038/eye.2008.194; published online 18 July 2008
C1 [Atmani, K.; Coscas, F.; Coscas, G.; Soubrane, G.] Univ Paris 12, Dept Ophthalmol Creteil, F-94010 Creteil, France.
C3 Universite Paris-Est-Creteil-Val-de-Marne (UPEC)
RP Soubrane, G (通讯作者)，Univ Paris 12, Ctr Hosp Intercommunal Cteteil, Dept Ophthalmol, 40 Ave Verdun, F-94010 Creteil, France.
EM gisele.soubrane@chicreteil.fr
FU Pfizer Inc
FX Editorial support, including contributing to the first draft of the
   manuscript, revising the paper on the basis of author feedback, and
   styling the paper for journal submission was provided by Gardiner
   Caldwell US with assistance from Zola Associates and funded by Pfizer
   Inc.
CR Bermig J, 2002, GRAEF ARCH CLIN EXP, V240, P169, DOI 10.1007/s00417-001-0378-2
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Gonzales CR, 2005, RETINA-J RET VIT DIS, V25, P815
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   KIRSCH LS, 2006, EUR 2006 MAY 18 21 L
   LUPOVITCH J, 2006, INVEST OPHTHALMOL VI, V47
   Margherio RR, 2000, RETINA-J RET VIT DIS, V20, P325, DOI 10.1097/00006982-200007000-00001
   Olsen TW, 2004, OPHTHALMOLOGY, V111, P250, DOI 10.1016/j.ophtha.2003.05.030
   *QLT INC, 2005, QLT ANN 2 YEAR RES V
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
NR 11
TC 7
Z9 8
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD MAY
PY 2009
VL 23
IS 5
BP 1150
EP 1154
DI 10.1038/eye.2008.194
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 445AY
UT WOS:000266023200024
PM 18636083
OA Bronze
DA 2022-11-30
ER

PT J
AU Nomura, Y
   Takahashi, H
   Tan, X
   Fujino, Y
   Kawashima, H
   Yanagi, Y
AF Nomura, Yoko
   Takahashi, Hidenori
   Tan, Xue
   Fujino, Yujiro
   Kawashima, Hidetoshi
   Yanagi, Yasuo
TI Effect of posterior vitreous detachment on aqueous humor level of
   vascular endothelial growth factor in exudative age-related macular
   degeneration patients
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Posterior vitreous detachment;
   Vascular endothelial growth factor; Aqueous humor
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; VITREOMACULAR ADHESION
AB Background To investigate the association of posterior vitreous detachment (PVD) with aqueous levels of vascular endothelial growth factor (VEGF) in eyes with exudative age-related macular degeneration (AMD).
   Methods This is a prospective comparative study. Subjects are 33 eyes with exudative AMD. PVD was examined by B-mode ultrasonography and the subjects were divided into a complete PVD group (PVD group) or a group with partial or no PVD (without PVD group). At the beginning of intravitreal injection of ranibizumab, aqueous humor was collected and the concentration of VEGF was measured using ELISA. The concentration was compared between the two groups.
   Results Complete PVD was observed in 13 (39 %) eyes. The mean concentration of VEGF was 58 pg/ml in the PVD group and 91 pg/ml in the without PVD group. Multiple regression analysis revealed that the concentration of VEGF was significantly lower in the eyes with PVD than in those without PVD independent of age and sex (P=0.02).
   Conclusions Complete PVD is related to the lower concentration of aqueous VEDF in AMD eyes.
C1 [Nomura, Yoko; Takahashi, Hidenori; Tan, Xue; Yanagi, Yasuo] Univ Tokyo, Dept Ophthalmol, Grad Sch Med, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.
   [Takahashi, Hidenori; Kawashima, Hidetoshi] Jichi Med Univ, Dept Ophthalmol, Shimotsuke, Tochigi, Japan.
   [Fujino, Yujiro] Japan Community Hlth Care Org Tokyo Shinjuku Med, Dept Ophthalmol, Tokyo, Japan.
C3 University of Tokyo; Jichi Medical University
RP Nomura, Y; Yanagi, Y (通讯作者)，Univ Tokyo, Dept Ophthalmol, Grad Sch Med, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.
EM nomurayoko-tky@umin.ac.jp; yanagi-tky@umin.ac.jp
RI Yanagi, Yasuo/AAA-5441-2022; Yanagi, Yasuo/AAF-2670-2020; Takahashi,
   Hidenori/H-2945-2019
OI Takahashi, Hidenori/0000-0001-5331-4730; Yanagi,
   Yasuo/0000-0002-0362-7285
CR Bressler NM, 2005, RETINA-J RET VIT DIS, V25, P119
   Cho HJ, 2013, RETINA-J RET VIT DIS, V33, P2126, DOI 10.1097/IAE.0b013e3182899296
   Holekamp NM, 2005, AM J OPHTHALMOL, V139, P302, DOI 10.1016/j.ajo.2004.09.046
   Itakura H, 2013, INVEST OPHTH VIS SCI, V54, P3102, DOI 10.1167/iovs.13-11769
   Krebs I, 2007, AM J OPHTHALMOL, V144, P741, DOI 10.1016/j.ajo.2007.07.024
   Lee SJ, 2011, OPHTHALMOLOGY, V118, P101, DOI 10.1016/j.ophtha.2010.04.015
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Mayr-Sponer U, 2013, OPHTHALMOLOGY
   Mojana F, 2008, AM J OPHTHALMOL, V146, P218, DOI 10.1016/j.ajo.2008.04.027
   Noma H, 2010, EUR J OPHTHALMOL, V20, P402, DOI 10.1177/112067211002000222
   Nomura Y, 2014, JPN J OPHTHALMOL, V58, P443, DOI 10.1007/s10384-014-0333-5
   Nomura Y, 2011, OPHTHALMOLOGY, V118, P853, DOI 10.1016/j.ophtha.2010.09.001
   Obata R, 2006, JPN J OPHTHALMOL, V50, P354, DOI 10.1007/s10384-005-0337-2
   Ondes F, 2000, JPN J OPHTHALMOL, V44, P91, DOI 10.1016/S0021-5155(99)00174-4
   Quaranta-El Maftouhi M, 2006, EUR J OPHTHALMOL, V16, P134
   Quiram PA, 2007, RETINA-J RET VIT DIS, V27, P1090, DOI 10.1097/IAE.0b013e3180654229
   Robison CD, 2009, AM J OPHTHALMOL, V148, P79, DOI 10.1016/j.ajo.2009.01.014
   Sebag J, 2007, GRAEF ARCH CLIN EXP, V245, P576, DOI 10.1007/s00417-006-0394-3
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0
   Simpson ARH, 2012, SURV OPHTHALMOL, V57, P498, DOI 10.1016/j.survophthal.2012.01.011
   Stefansson E, 2006, ACTA OPHTHALMOL SCAN, V84, P718, DOI 10.1111/j.1600-0420.2006.00778.x
   Uney GO, 2014, RETINA-J RET VIT DIS, V34, P32, DOI 10.1097/IAE.0b013e318295f72e
   Weber-Krause Brigitte, 1996, Ophthalmologe, V93, P660, DOI 10.1007/s003470050054
NR 24
TC 11
Z9 11
U1 0
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD JAN
PY 2016
VL 254
IS 1
BP 53
EP 57
DI 10.1007/s00417-015-3006-2
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DD5ZT
UT WOS:000370004200008
PM 25863675
DA 2022-11-30
ER

PT J
AU Pilotto, E
   Midena, E
   Longhin, E
   Parrozzani, R
   Frisina, R
   Frizziero, L
AF Pilotto, Elisabetta
   Midena, Edoardo
   Longhin, Evelyn
   Parrozzani, Raffaele
   Frisina, Rino
   Frizziero, Luisa
TI Muller cells and choriocapillaris in the pathogenesis of geographic
   atrophy secondary to age-related macular degeneration
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Geographic atrophy; Muller cell; Low-luminance visual acuity; Glial
   fibrillar acidic protein; Choroid; Optical coherence tomography;
   Multifocal ERG
ID FIBRILLARY ACIDIC PROTEIN; FUNDUS AUTOFLUORESCENCE; VISUAL-ACUITY;
   MICROPERIMETRY; EYES; PREVALENCE; THICKNESS
AB PurposeTo better understand the pathophysiology of geographic atrophy (GA), secondary to age-related macular degeneration, eyes affected by unilateral GA (and CNV in the fellow eye; U-GA group) or by bilateral GA (B-GA group) were evaluated using an integrated morpho-functional approach and quantifying biomarker of retinal macroglial activity.MethodsPatients with U-GA and B-GA and foveal-sparing were consecutively enrolled in a prospective study. All included eyes underwent fundus photography, fundus autofluorescence (FAF), foveal retinal and choroidal thicknesses (RT, CT), contrast sensitivity, best-corrected visual acuity (BCVA), low-luminance VA (LLVA) and low-luminance deficit (LLD), and mesopic and scotopic microperimetry and multifocal electroretinography (mfERG). Glial fibrillary acidic protein (GFAP), biomarker of Muller cell activation, was quantified in the aqueous humor (AH).ResultsForty eyes of 40 patients (18 in the U-GA group and 22 in the B-GA group) were studied. RT, GA area, BCVA, contrast sensitivity, mfERG, and microperimetry (at both background luminances) were not different between groups. CT was significantly thinner in U-GA compared to B-GA group (p=0.020). Both LLVA and LLD were significantly worse in the B-GA vs U-GA group (p=0.033 and p=0.048, respectively). GFAP intraocular concentration was significantly higher in the B-GA group (p=0.01).ConclusionsDifferent pathophysiologic mechanisms may be responsible for GA in unilateral (with CNV in the fellow eye) compared to bilateral GA cases. In unilateral cases, a thinner choroid seems to play a key role. Whereas, in bilateral cases, Muller cells and their supported photoreceptors may be primarily involved.
C1 [Pilotto, Elisabetta; Midena, Edoardo; Longhin, Evelyn; Parrozzani, Raffaele; Frisina, Rino] Univ Padua, Dept Ophthalmol, Via Giustiniani 2, I-35128 Padua, Italy.
   [Midena, Edoardo; Frizziero, Luisa] IRCCS Fdn Bietti, Rome, Italy.
C3 University of Padua; IRCCS - Fondazione "G.B. Bietti" per lo Studio e la
   Ricerca in Oftalmologia
RP Midena, E (通讯作者)，Univ Padua, Dept Ophthalmol, Via Giustiniani 2, I-35128 Padua, Italy.
EM edoardo.midena@unipd.it
RI Parrozzani, Raffaele/W-3341-2017; parrozzani, raffaele/K-2034-2016;
   Frizziero, Luisa/AAB-3249-2020; Midena, Edoardo/AAB-6010-2020; Frisina,
   Rino/C-4477-2019
OI Parrozzani, Raffaele/0000-0003-0216-727X; parrozzani,
   raffaele/0000-0003-0216-727X; Frisina, Rino/0000-0002-0247-2680
FU Fondazione Roma; Ministry of Health
FX The research contribution by the G.B. Bietti Foundation was supported by
   Fondazione Roma and Ministry of Health. The authors thank Fabiano
   Cavarzeran, Department of Ophthalmology, University of Padova, for the
   statistical elaboration of the data. Edoardo Midena and Elisabetta
   Pilotto had full access to all the data in the study and take
   responsibility for the integrity of the data and the accuracy of the
   data analysis.
CR Agte S, 2011, BIOPHYS J, V101, P2611, DOI 10.1016/j.bpj.2011.09.062
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Boyer DS, 2017, RETINA-J RET VIT DIS, V37, P819, DOI 10.1097/IAE.0000000000001392
   Crossland MD, 2011, BMC OPHTHALMOL, V11, DOI 10.1186/1471-2415-11-5
   Curcio CA, 2011, INVEST OPHTH VIS SCI, V52, P3943, DOI 10.1167/iovs.10-6377
   del Amo EM, 2017, PROG RETIN EYE RES, V57, P134, DOI 10.1016/j.preteyeres.2016.12.001
   DILORETO DA, 1995, BRAIN RES, V698, P1, DOI 10.1016/0006-8993(95)00647-9
   Ebneter A, 2016, INVEST OPHTH VIS SCI, V57, pOCT299, DOI 10.1167/iovs.15-18865
   Edwards MM, 2017, INVEST OPHTH VIS SCI, V58, P1352, DOI 10.1167/iovs.16-21229
   Forte R, 2013, RETINA-J RET VIT DIS, V33, P482, DOI 10.1097/IAE.0b013e318276e11e
   Guidry C, 2002, INVEST OPHTH VIS SCI, V43, P267
   Hippert C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120415
   Hood DC, 2012, DOC OPHTHALMOL, V124, P1, DOI 10.1007/s10633-011-9296-8
   Junemann AGM, 2015, GRAEF ARCH CLIN EXP, V253, P2181, DOI 10.1007/s00417-015-3127-7
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Li ML, 2018, RETINA-J RET VIT DIS, V38, P1937, DOI 10.1097/IAE.0000000000002182
   Longhin E, 2016, EUR J OPHTHALMOL, V26, P418, DOI 10.5301/ejo.5000800
   Marc RE, 2008, MOL VIS, V14, P782
   MAURICE DM, 1987, AM J PHYSIOL, V252, pF104, DOI 10.1152/ajprenal.1987.252.1.F104
   Midena E, 2017, EYE, V31, P985, DOI 10.1038/eye.2017.34
   Midena E, 2018, RETINA
   Midena E, 2007, BRIT J OPHTHALMOL, V91, P1499, DOI 10.1136/bjo.2007.119685
   Noma H, 2008, EYE, V22, P42, DOI 10.1038/sj.eye.6702498
   Panthier C, 2014, RETINA-J RET VIT DIS, V34, P576, DOI 10.1097/01.iae.0000433986.32991.1e
   PELLI DG, 1988, CLIN VISION SCI, V2, P187
   Pilotto E, 2016, JAMA OPHTHALMOL, V134, P873, DOI 10.1001/jamaophthalmol.2016.1535
   Pilotto E, 2015, INVEST OPHTH VIS SCI, V56, P8120, DOI 10.1167/iovs.15-17366
   Pilotto E, 2015, BRIT J OPHTHALMOL, V99, P1082, DOI 10.1136/bjophthalmol-2014-306338
   Pilotto E, 2013, CAN J OPHTHALMOL, V48, P386, DOI 10.1016/j.jcjo.2013.03.022
   Pilotto E, 2013, BRIT J OPHTHALMOL, V97, P622, DOI 10.1136/bjophthalmol-2012-302633
   Pilotto E, 2011, BRIT J OPHTHALMOL, V95, P1140, DOI 10.1136/bjo.2010.187344
   Sarthy V, 2007, EXP EYE RES, V84, P381, DOI 10.1016/j.exer.2005.12.014
   Stockman A, 2006, OPHTHAL PHYSL OPT, V26, P225, DOI 10.1111/j.1475-1313.2006.00325.x
   Sunness JS, 2008, J VISUAL IMPAIR BLIN, V102, P600
   Sunness JS, 2008, OPHTHALMOLOGY, V115, P1480, DOI 10.1016/j.ophtha.2008.03.009
   Sunness JS, 2007, OPHTHALMOLOGY, V114, P271, DOI 10.1016/j.ophtha.2006.09.016
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P910, DOI 10.1016/S0161-6420(99)00509-6
   SUNNESS JS, 1995, AM J OPHTHALMOL, V119, P143, DOI 10.1016/S0002-9394(14)73866-8
   Sunness JS, 1997, OPHTHALMOLOGY, V104, P1677, DOI 10.1016/S0161-6420(97)30079-7
   Viele K, 2014, PHARM STAT, V13, P41, DOI 10.1002/pst.1589
   Vujosevic S, 2015, INVEST OPHTH VIS SCI, V56, P3913, DOI 10.1167/iovs.15-16554
   Vujosevic S, 2013, J DIABETES RES, V2013, DOI 10.1155/2013/905058
   Wu ZC, 2015, JAMA OPHTHALMOL, V133, P442, DOI 10.1001/jamaophthalmol.2014.5963
   Yehoshua Z, 2014, OPHTHALMOLOGY, V121, P693, DOI 10.1016/j.ophtha.2013.09.044
NR 44
TC 8
Z9 8
U1 0
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD JUN
PY 2019
VL 257
IS 6
BP 1159
EP 1167
DI 10.1007/s00417-019-04289-z
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HY1XQ
UT WOS:000467911200010
PM 30903311
DA 2022-11-30
ER

PT J
AU Curcio, CA
   Zanzottera, EC
   Ach, T
   Balaratnasingam, C
   Freund, KB
AF Curcio, Christine A.
   Zanzottera, Emma C.
   Ach, Thomas
   Balaratnasingam, Chandrakumar
   Freund, K. Bailey
TI Activated Retinal Pigment Epithelium, an Optical Coherence Tomography
   Biomarker for Progression in Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE retinal pigment epithelium; age-related macular degeneration; optical
   coherence tomography; drusen; hyperreflective foci;
   transdifferentiation; apoptosis; migration; Mie scattering; electron
   microscopy; stereology
AB PURPOSE. To summarize and contextualize recent histology and clinical imaging publications on retinal pigment epithelium (RPE) fate in advanced age-related macular degeneration (AMD); to support RPE activation and migration as important precursors to atrophy, manifest as intraretinal hyperreflective foci in spectral-domain optical coherence tomography (SDOCT).
   METHODS. The Project MACULA online resource for AMD histopathology was surveyed systematically to form a catalog of 15 phenotypes of RPE and RPE-derived cells and layer thicknesses in advanced disease. Phenotypes were also sought in correlations with clinical longitudinal eye-tracked SDOCT and with ex vivo imaging-histopathology correlations in geographic atrophy (GA) and pigment epithelium detachments (PED).
   RESULTS. The morphology catalog suggested two main pathways of RPE fate: basolateral shedding of intracellular organelles (apparent apoptosis in situ) and activation with anterior migration. Acquired vitelliform lesions may represent a third pathway. Migrated cells are packed with RPE organelles and confirmed as hyperreflective on SDOCT. RPE layer thickening due to cellular dysmorphia and thick basal laminar deposit is observed near the border of GA. Drusenoid PED show a life cycle of slow growth and rapid collapse preceded by RPE layer disruption and anterior migration.
   CONCLUSIONS. RPE activation and migration comprise an important precursor to atrophy that can be observed at the cellular level in vivo via validated SDOCT. Collapse of large drusen and drusenoid PED appears to occur when RPE death and migration prevent continued production of druse components. Data implicate excessive diffusion distance from choriocapillaris in RPE death as well as support a potential benefit in targeting drusen in GA.
C1 [Curcio, Christine A.] Univ Alabama Birmingham, Sch Med, Dept Ophthalmol, Birmingham, AL USA.
   [Zanzottera, Emma C.] Univ Milan, Sacco Hosp, Dept Clin Sci Luigi Sacco, Eye Clin, Milan, Italy.
   [Ach, Thomas] Univ Hosp Wurzburg, Dept Ophthalmol, Wurzburg, Germany.
   [Balaratnasingam, Chandrakumar] Univ Western Australia, Lions Eye Inst, Ctr Ophthalmol & Visual Sci, Perth, WA, Australia.
   [Balaratnasingam, Chandrakumar] Sir Charles Gairdner Hosp, Perth, WA, Australia.
   [Freund, K. Bailey] Vitreous Retina Macula Consultants New York, New York, NY USA.
   [Freund, K. Bailey] Manhattan Eye Ear & Throat Inst, LuEsther T Mertz Retinal Res Ctr, New York, NY USA.
   [Freund, K. Bailey] NYU, Dept Ophthalmol, Langone Sch Med, 550 1St Ave, New York, NY 10016 USA.
C3 University of Alabama System; University of Alabama Birmingham;
   University of Milan; Luigi Sacco Hospital; University of Wurzburg; Lions
   Eye Institute; University of Western Australia; University of Western
   Australia; Vitreous Retina Macula Consultants of New York; New York
   University; NYU Langone Medical Center
RP Curcio, CA (通讯作者)，Univ Alabama Birmingham, Dept Ophthalmol, EyeSight Fdn Alabama, Vis Res Labs,Sch Med, 1670 Univ Blvd,Room 360, Birmingham, AL 35294 USA.
EM curcio@uab.edu
RI Ach, Thomas/AAE-7870-2021; Freund, K. Bailey/V-7488-2018
OI Ach, Thomas/0000-0001-6583-8283; Freund, K. Bailey/0000-0002-7888-9773
FU National Eye Institute [EY06109, P30 EY003039]; International Retinal
   Research Foundation; Arnold and Mabel Beckman Initiative for Macular
   Research; Edward N. and Della L. Thome Memorial Foundation; Macula
   Foundation; EyeSight Foundation of Alabama; Research to Prevent
   Blindness, Inc.; NATIONAL EYE INSTITUTE [P30EY003039] Funding Source:
   NIH RePORTER
FX Supported by National Eye Institute (EY06109, P30 EY003039) for the
   acquisition of donor eyes, International Retinal Research Foundation,
   and the Arnold and Mabel Beckman Initiative for Macular Research. The
   Project MACULA Web site was supported by these and additionally by the
   Edward N. and Della L. Thome Memorial Foundation. The Eye Donor Project
   is supported by the Macula Foundation. C. A. Curcio is supported by the
   International Retinal Research Foundation, unrestricted funds to the
   Department of Ophthalmology from Research to Prevent Blindness, Inc.,
   and EyeSight Foundation of Alabama.
CR Abbott CJ, 2009, INVEST OPHTH VIS SCI, V50, P414, DOI 10.1167/iovs.07-1197
   Ach T, 2015, INVEST OPHTH VIS SCI, V56, P3242, DOI 10.1167/iovs.14-16274
   Alliot F, 1999, DEV BRAIN RES, V117, P145, DOI 10.1016/S0165-3806(99)00113-3
   Arnold JJ, 1997, AM J OPHTHALMOL, V124, P344, DOI 10.1016/S0002-9394(14)70826-8
   Balaratnasingam C, 2017, OPHTHALMOLOGY, V124, P644, DOI 10.1016/j.ophtha.2016.12.034
   Balaratnasingam C, 2016, AM J OPHTHALMOL, V172, P28, DOI 10.1016/j.ajo.2016.09.008
   Balaratnasingam C, 2016, INVEST OPHTH VIS SCI, V57, P5479, DOI 10.1167/iovs.16-19816
   Brown NH, 2009, GRAEF ARCH CLIN EXP, V247, P1069, DOI 10.1007/s00417-009-1044-3
   CASSWELL AG, 1985, BRIT J OPHTHALMOL, V69, P397, DOI 10.1136/bjo.69.6.397
   Chauhan DS, 1999, INVEST OPHTH VIS SCI, V40, P2332
   Chen KC, 2016, AM J OPHTHALMOL, V164, P89, DOI 10.1016/j.ajo.2016.02.002
   Chen TC, 2006, AM J OPHTHALMOL, V141, P1165, DOI 10.1016/j.ajo.2006.01.086
   Christenbury JG, 2013, OPHTHALMOLOGY, V120, P1038, DOI 10.1016/j.ophtha.2012.10.018
   Cilingiroglu M, 2006, CATHETER CARDIO INTE, V67, P915, DOI 10.1002/ccd.20717
   Collin GB, 2015, HUM MOL GENET, V24, P6958, DOI 10.1093/hmg/ddv399
   Coscas G, 2013, OPHTHALMOLOGICA, V229, P32, DOI 10.1159/000342159
   Cukras C, 2010, OPHTHALMOLOGY, V117, P489, DOI 10.1016/j.ophtha.2009.12.002
   Curcio CA, 2005, EXP EYE RES, V80, P761, DOI 10.1016/j.exer.2004.09.017
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   CURCIO CA, 1990, J COMP NEUROL, V292, P497, DOI 10.1002/cne.902920402
   CURCIO CA, 1990, J COMP NEUROL, V300, P5, DOI 10.1002/cne.903000103
   Curcio CA, 2015, AM J OPHTHALMOL, V160, P1024, DOI 10.1016/j.ajo.2015.08.001
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   Curcio CA, 2010, J LIPID RES, V51, P451, DOI 10.1194/jlr.R002238
   Curcio CA, 2009, PROG RETIN EYE RES, V28, P393, DOI 10.1016/j.preteyeres.2009.08.001
   Dolz-Marco R, 2017, OPHTHALMOLOGY, V124, P1353, DOI 10.1016/j.ophtha.2017.03.043
   Drexler W, 2008, PROG RETIN EYE RES, V27, P45, DOI 10.1016/j.preteyeres.2007.07.005
   Evans JB, 2013, NAT REV DRUG DISCOV, V12, P501, DOI 10.1038/nrd4038
   Fischer MD, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007507
   Fleckenstein M, 2008, INVEST OPHTH VIS SCI, V49, P4137, DOI 10.1167/iovs.08-1967
   Folgar FA, 2012, INVEST OPHTH VIS SCI, V53, P4626, DOI 10.1167/iovs.12-9813
   Gambichler T, 2007, PHYS MED BIOL, V52, pN75, DOI 10.1088/0031-9155/52/5/N01
   Ghazi NG, 2006, AM J OPHTHALMOL, V141, P719, DOI 10.1016/j.ajo.2005.10.019
   Gloesmann M, 2003, INVEST OPHTH VIS SCI, V44, P1696, DOI 10.1167/iovs.02-0654
   Gocho K, 2013, INVEST OPHTH VIS SCI, V54, P3673, DOI 10.1167/iovs.12-10672
   Gobel AP, 2011, OPHTHALMOLOGICA, V226, P182, DOI 10.1159/000330420
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Guidry C, 2002, INVEST OPHTH VIS SCI, V43, P267
   GUYTON JR, 1988, J HISTOCHEM CYTOCHEM, V36, P1319, DOI 10.1177/36.10.2458408
   Hahn P, 2004, P NATL ACAD SCI USA, V101, P13850, DOI 10.1073/pnas.0405146101
   HARTNETT ME, 1992, GRAEF ARCH CLIN EXP, V230, P11, DOI 10.1007/BF00166756
   Ho J, 2011, OPHTHALMOLOGY, V118, P687, DOI 10.1016/j.ophtha.2010.08.010
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Holz FG, 2017, OPHTHALMOLOGY, V124, P464, DOI 10.1016/j.ophtha.2016.12.002
   Hu P, 2013, P NATL ACAD SCI USA, V110, pE4069, DOI 10.1073/pnas.1307574110
   Huang YJ, 1998, INVEST OPHTH VIS SCI, V39, P2405
   Indaram M, 2015, SCI REP-UK, V5, DOI 10.1038/srep09144
   Jiang M, 2015, J CELL BIOL, V210, P595, DOI 10.1083/jcb.201410112
   Joachim NDL, 2015, JAMA OPHTHALMOL, V133, P698, DOI 10.1001/jamaophthalmol.2015.0498
   Jobling AI, 2015, FASEB J, V29, P696, DOI 10.1096/fj.14-262444
   Johnson LV, 2011, P NATL ACAD SCI USA, V108, P18277, DOI 10.1073/pnas.1109703108
   Karlstetter M, 2015, PROG RETIN EYE RES, V45, P30, DOI 10.1016/j.preteyeres.2014.11.004
   Karlstetter M, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-3
   Keane PA, 2012, SURV OPHTHALMOL, V57, P389, DOI 10.1016/j.survophthal.2012.01.006
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1026, DOI 10.1016/j.ophtha.2007.08.030
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Kleinman ME, 2012, MOL THER, V20, P101, DOI 10.1038/mt.2011.212
   Lad EM, 2016, GRAEF ARCH CLIN EXP, V254, P1239, DOI 10.1007/s00417-015-3249-y
   Lad EM, 2015, GRAEF ARCH CLIN EXP, V253, P1941, DOI 10.1007/s00417-015-3094-z
   Lammer J, 2014, INVEST OPHTH VIS SCI, V55, P1564, DOI 10.1167/iovs.13-13539
   Lei JQ, 2017, GRAEF ARCH CLIN EXP, V255, P1551, DOI 10.1007/s00417-017-3693-y
   Litts KM, 2017, RETINA-J RET VIT DIS, V37, P978, DOI 10.1097/IAE.0000000000001265
   Litts KM, 2015, INVEST OPHTH VIS SCI, V56, P2243, DOI 10.1167/iovs.14-15838
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Mao HY, 2014, INVEST OPHTH VIS SCI, V55, P4613, DOI 10.1167/iovs.14-14633
   Marsiglia M, 2015, RETINA-J RET VIT DIS, V35, P966, DOI 10.1097/IAE.0000000000000460
   Moussa K, 2013, RETINA-J RET VIT DIS, V33, P1590, DOI 10.1097/IAE.0b013e31828d6052
   Mrejen S, 2013, RETINA-J RET VIT DIS, V33, P1735, DOI 10.1097/IAE.0b013e3182993f66
   Ooto S, 2014, JAMA OPHTHALMOL, V132, P806, DOI 10.1001/jamaophthalmol.2014.1871
   Ouyang YL, 2013, OPHTHALMOLOGY, V120, P2656, DOI 10.1016/j.ophtha.2013.05.029
   Pang CE, 2015, OPHTHALMOLOGY, V122, P2316, DOI 10.1016/j.ophtha.2015.07.008
   Patil H, 2014, J BIOL CHEM, V289, P29767, DOI 10.1074/jbc.M114.586834
   Pieroni CG, 2006, BRIT J OPHTHALMOL, V90, P191, DOI 10.1136/bjo.2005.076612
   Pikuleva IA, 2014, PROG RETIN EYE RES, V41, P64, DOI 10.1016/j.preteyeres.2014.03.002
   Pilgrim MG, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-21060
   Roquet W, 2004, BRIT J OPHTHALMOL, V88, P638, DOI 10.1136/bjo.2003.017632
   Rossi EA, 2017, P NATL ACAD SCI USA, V114, P586, DOI 10.1073/pnas.1613445114
   Rowan S, 2013, INVEST OPHTH VIS SCI, V55, P492
   Rudolf M, 2013, OPHTHALMOLOGY, V120, P821, DOI 10.1016/j.ophtha.2012.10.007
   Saksens NTM, 2016, NAT GENET, V48, P144, DOI 10.1038/ng.3474
   Sarks J, 2006, BRIT J OPHTHALMOL, V90, P442, DOI 10.1136/bjo.2005.083022
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SARKS JP, 1994, EYE, V8, P269, DOI 10.1038/eye.1994.57
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Sarks SH, 1996, AUST NZ J OPHTHALMOL, V24, P15, DOI 10.1111/j.1442-9071.1996.tb01546.x
   Sayegh RG, 2011, OPHTHALMOLOGY, V118, P1844, DOI 10.1016/j.ophtha.2011.01.043
   Schaal KB, 2015, RETINA-J RET VIT DIS, V35, P1339, DOI 10.1097/IAE.0000000000000471
   Schlanitz FG, 2017, BRIT J OPHTHALMOL, V101, P198, DOI 10.1136/bjophthalmol-2016-308422
   Schlanitz FG, 2015, AM J OPHTHALMOL, V160, P335, DOI 10.1016/j.ajo.2015.05.008
   Schmitz-Valckenberg S, 2016, OPHTHALMOLOGY, V123, P361, DOI 10.1016/j.ophtha.2015.09.036
   Schuman SG, 2009, OPHTHALMOLOGY, V116, P488, DOI 10.1016/j.ophtha.2008.10.006
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Scoles D, 2014, INVEST OPHTH VIS SCI, V55, P4244, DOI 10.1167/iovs.14-14542
   Sennlaub F, 2013, EMBO MOL MED, V5, P1775, DOI 10.1002/emmm.201302692
   Shang P, 2017, AGING CELL, V16, P349, DOI 10.1111/acel.12561
   Simader C, 2014, AM J OPHTHALMOL, V158, P557, DOI 10.1016/j.ajo.2014.05.026
   Spaide RF, 2003, RETINA-J RET VIT DIS, V23, P595, DOI 10.1097/00006982-200310000-00001
   Spaide RF, 2011, RETINA-J RET VIT DIS, V31, P1609, DOI 10.1097/IAE.0b013e3182247535
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1441, DOI 10.1097/IAE.0b013e3181ee5ce8
   Srinivasan VJ, 2006, INVEST OPHTH VIS SCI, V47, P5522, DOI 10.1167/iovs.06-0195
   Staurenghi G, 2014, OPHTHALMOLOGY, V121, P1572, DOI 10.1016/j.ophtha.2014.02.023
   STEINBERG RH, 1985, DOC OPHTHALMOL, V60, P327, DOI 10.1007/BF00158922
   Sundermeier TR, 2017, J BIOL CHEM, V292, P3366, DOI 10.1074/jbc.M116.770024
   Tan AC, 2016, RETINA, V37, P234
   Tan ACS, 2017, INVEST OPHTH VIS SCI, V58, P2349, DOI 10.1167/iovs.16-21237
   Toth CA, 1997, ARCH OPHTHALMOL-CHIC, V115, P1425, DOI 10.1001/archopht.1997.01100160595012
   Vavvas DG, 2016, EBIOMEDICINE, V5, P198, DOI 10.1016/j.ebiom.2016.01.033
   Vogt SD, 2011, EXP EYE RES, V93, P413, DOI 10.1016/j.exer.2011.06.002
   Vujosevic S, 2017, RETINA-J RET VIT DIS, V37, P1092, DOI 10.1097/IAE.0000000000001304
   Wilson JD, 2007, J BIOMED OPT, V12, DOI 10.1117/1.2743971
   Wilson JD, 2007, OPT LETT, V32, P2517, DOI 10.1364/OL.32.002517
   Wilson JD, 2007, J BIOMED OPT, V12, DOI 10.1117/1.2437765
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P2415, DOI 10.1016/j.ophtha.2014.06.034
   Xu HP, 2008, AGING CELL, V7, P58, DOI 10.1111/j.1474-9726.2007.00351.x
   Yabushita H, 2002, CIRCULATION, V106, P1640, DOI 10.1161/01.CIR.0000029927.92825.F6
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P2434, DOI 10.1016/j.ophtha.2011.05.008
   Zacks DN, 2004, ARCH OPHTHALMOL-CHIC, V122, P406, DOI 10.1001/archopht.122.3.406
   Zanzottera EC, 2016, RETINA-J RET VIT DIS, V36, pS12, DOI 10.1097/IAE.0000000000001276
   Zanzottera EC, 2016, RETINA-J RET VIT DIS, V36, pS26, DOI 10.1097/IAE.0000000000001330
   Zanzottera EC, 2015, INVEST OPHTH VIS SCI, V56, P3253, DOI 10.1167/iovs.15-16431
   Zanzottera EC, 2015, INVEST OPHTH VIS SCI, V56, P3269, DOI 10.1167/iovs.15-16432
   Zhang TJ, 2015, AM J OPHTHALMOL, V160, P290, DOI 10.1016/j.ajo.2015.04.034
   Zhao C, 2011, J CLIN INVEST, V121, P369, DOI 10.1172/JCI44303
   Zhao ZY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019456
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
NR 129
TC 79
Z9 80
U1 0
U2 1
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAY
PY 2017
VL 58
IS 6
SI SI
BP 211
EP 226
DI 10.1167/iovs.17-21872
PG 16
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA VI3AO
UT WOS:000468834100008
DA 2022-11-30
ER

PT J
AU Gin, TJ
   Wu, ZC
   Chew, SKH
   Guymer, RH
   Luu, CD
AF Gin, Thomas J.
   Wu, Zhichao
   Chew, Sky K. H.
   Guymer, Robyn H.
   Luu, Chi D.
TI Quantitative Analysis of the Ellipsoid Zone Intensity in Phenotypic
   Variations of Intermediate Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE age-related macular degeneration; spectral-domain optical coherence
   tomography; ellipsoid zone; inner-segment ellipsoids; reticular
   pseudodrusen
ID OPTICAL COHERENCE TOMOGRAPHY; OUTER RETINAL TUBULATION; SCANNING LASER
   OPHTHALMOSCOPY; 2ND REFLECTIVE BAND; RETICULAR PSEUDODRUSEN; ADAPTIVE
   OPTICS; HYPERREFLECTIVE FOCI; PHOTORECEPTOR STATUS; RISK-FACTOR;
   AUTOFLUORESCENCE
AB PURPOSE. Reduction of the ellipsoid zone (EZ) intensity has been reported in eyes with age-related macular degeneration (AMD). This study determined whether overall EZ intensity, in retinal locations undisturbed by pathologic features, is associated with the presence of clinical features, which are known important phenotypic risk factors for disease progression, large drusen, reticular pseudodrusen (RPD), and pigmentary abnormalities.
   METHODS. A horizontal B-scan through the foveola on spectral-domain optical coherence tomography (SD-OCT) was performed in both eyes of 75 participants with bilateral intermediate AMD and 10 age-similar control participants. Eyes with AMD were classified as per the presence of large drusen, RPD, and hyperpigmentary changes. The relative EZ intensity profile, up to an eccentricity of 3400 mu m, was averaged over seven 1000-mu m retinal segments. The association between relative EZ intensity profile over seven retinal segments and AMD pathologic features was analyzed.
   RESULTS. The average relative EZ intensities were significantly reduced in eyes with intermediate AMD compared to normal eyes (P <= 0.025) and with increasing age (P <= 0.020). On multivariate analyses, only the presence of hyperpigmentary changes and increasing age were significantly associated with reduced overall relative intensities (P <= 0.024), but not the presence of large drusen or RPD (P >= 0.115).
   CONCLUSIONS. The presence of hyperpigmentary change in the macula in association with large drusen, not large drusen alone, nor large drusen with RPD, was significantly associated with a generalised reduction in EZ intensity. Quantitative assessment of the relative EZ intensity may serve as an effective biomarker of disease severity and progression.
C1 [Gin, Thomas J.; Wu, Zhichao; Chew, Sky K. H.; Guymer, Robyn H.; Luu, Chi D.] Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Melbourne, Vic, Australia.
   [Guymer, Robyn H.; Luu, Chi D.] Univ Melbourne, Dept Surg Ophthalmol, Melbourne, Vic, Australia.
C3 Centre for Eye Research Australia; Royal Victorian Eye & Ear Hospital;
   University of Melbourne
RP Luu, CD (通讯作者)，Ctr Eye Res Australia, Level 8,32 Gisborne St, East Melbourne, Vic 3002, Australia.
EM cluu@unimelb.edu.au
OI Guymer, Robyn/0000-0002-9441-4356
FU National Health and Medical Research Council (NHMRC) Project [1084081,
   1027624]
FX Supported by the National Health and Medical Research Council (NH&MRC)
   Project Grants (1084081, 1027624). Centre for Eye Research Australia
   (CERA) receives operational infrastructure support from the Victorian
   Government.
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   ARNOLD JJ, 1995, RETINA-J RET VIT DIS, V15, P183, DOI 10.1097/00006982-199515030-00001
   Birch DG, 2011, INVEST OPHTH VIS SCI, V52, P7141, DOI 10.1167/iovs.11-7509
   Cai CX, 2014, INVEST OPHTH VIS SCI, V55, P7417, DOI 10.1167/iovs.14-15013
   Chai Y, 2011, CLIN OPHTHALMOL, V5, P1235, DOI 10.2147/OPTH.S23194
   Chhablani J, 2013, INT J OPHTHALMOL-CHI, V6, P62, DOI 10.3980/j.issn.2222-3959.2013.01.13
   Christenbury JG, 2013, OPHTHALMOLOGY, V120, P1038, DOI 10.1016/j.ophtha.2012.10.018
   Cnaan A, 1997, STAT MED, V16, P2349, DOI 10.1002/(SICI)1097-0258(19971030)16:20<2349::AID-SIM667>3.0.CO;2-E
   Fernandez EJ, 2008, OPT EXPRESS, V16, P11083, DOI 10.1364/OE.16.011083
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Finger RP, 2014, OPHTHALMOLOGY, V121, P1252, DOI 10.1016/j.ophtha.2013.12.034
   Fleckenstein M, 2008, INVEST OPHTH VIS SCI, V49, P4137, DOI 10.1167/iovs.08-1967
   Folgar FA, 2012, INVEST OPHTH VIS SCI, V53, P4626, DOI 10.1167/iovs.12-9813
   Hartmann KI, 2012, RETINA-J RET VIT DIS, V32, P1492, DOI 10.1097/IAE.0b013e318242b949
   Hartmann KI, 2011, RETINA-J RET VIT DIS, V31, P1323, DOI 10.1097/IAE.0b013e31820a6850
   Hashimoto H, 2015, AM J OPHTHALMOL, V159, P698, DOI 10.1016/j.ajo.2015.01.015
   Ho J, 2011, OPHTHALMOLOGY, V118, P687, DOI 10.1016/j.ophtha.2010.08.010
   Hoang QV, 2002, VISUAL NEUROSCI, V19, P395, DOI 10.1017/S0952523802194028
   Hood DC, 2011, INVEST OPHTH VIS SCI, V52, P9703, DOI 10.1167/iovs.11-8650
   Hu ZH, 2013, OSLI RETINA, V44, pS5, DOI 10.3928/23258160-20131101-02
   Jones MM, 2007, ARCH OPHTHALMOL-CHIC, V125, P1235, DOI 10.1001/archopht.125.9.1235
   Jonnal RS, 2014, INVEST OPHTH VIS SCI, V55, P7904, DOI 10.1167/iovs.14-14907
   Kenney MC, 2013, BMC MED GENET, V14, DOI 10.1186/1471-2350-14-4
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Landa G, 2011, RETINA-J RET VIT DIS, V31, P364, DOI 10.1097/IAE.0b013e3181e91132
   Lee GE, 2011, OCUL IMMUNOL INFLAMM, V19, P42, DOI 10.3109/09273948.2010.521610
   Lee SY, 2012, INVEST OPHTH VIS SCI, V53, P164, DOI 10.1167/iovs.11-8188
   Litts KM, 2015, INVEST OPHTH VIS SCI, V56, P2243, DOI 10.1167/iovs.14-15838
   Litts KM, 2015, JAMA OPHTHALMOL, V133, P609, DOI 10.1001/jamaophthalmol.2015.126
   Lujan BJ, 2011, INVEST OPHTH VIS SCI, V52, P1486, DOI 10.1167/iovs.10-5946
   Matsumoto H, 2009, AM J OPHTHALMOL, V148, P105, DOI 10.1016/j.ajo.2009.01.018
   Meadway A, 2013, OPT EXPRESS, V21, P29792, DOI 10.1364/OE.21.029792
   Murakami T, 2007, AM J OPHTHALMOL, V143, P171, DOI 10.1016/j.ajo.2006.08.030
   Oishi A, 2013, GRAEF ARCH CLIN EXP, V251, P435, DOI 10.1007/s00417-012-2034-4
   Putnam NM, 2010, OPT EXPRESS, V18, P24902, DOI 10.1364/OE.18.024902
   Querques G, 2011, RETINA-J RET VIT DIS, V31, P518, DOI 10.1097/IAE.0b013e3181f04974
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P1264, DOI 10.1167/iovs.11-9063
   Querques L, 2012, AM J OPHTHALMOL, V153, P1110, DOI 10.1016/j.ajo.2011.11.002
   Ross DH, 2015, INVEST OPHTH VIS SCI, V56, P4166, DOI 10.1167/iovs.14-15256
   Sayanagi K, 2009, BRIT J OPHTHALMOL, V93, P622, DOI 10.1136/bjo.2008.151977
   Schaal KB, 2015, RETINA-J RET VIT DIS, V35, P1339, DOI 10.1097/IAE.0000000000000471
   Schmitz-Valckenberg S, 2010, OPHTHALMOLOGY, V117, P1169, DOI 10.1016/j.ophtha.2009.10.044
   Shin HJ, 2011, RETINA-J RET VIT DIS, V31, P1627, DOI 10.1097/IAE.0b013e31820d3d01
   Spaide RF, 2011, RETINA-J RET VIT DIS, V31, P1609, DOI 10.1097/IAE.0b013e3182247535
   Staurenghi G, 2014, OPHTHALMOLOGY, V121, P1572, DOI 10.1016/j.ophtha.2014.02.023
   Subhi Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091227
   Sundaram V, 2014, OPHTHALMOLOGY, V121, P234, DOI 10.1016/j.ophtha.2013.08.017
   Tao LW, 2016, CLIN EXP OPHTHALMOL, V44, P422, DOI 10.1111/ceo.12685
   Ueda-Arakawa N, 2013, RETINA-J RET VIT DIS, V33, P490, DOI 10.1097/IAE.0b013e318276e0ae
   van der Schoot J, 2012, INVEST OPHTH VIS SCI, V53, P2424, DOI 10.1167/iovs.11-8436
   Vongkulsiri S, 2015, RETINA-J RET VIT DIS, V35, P1211, DOI 10.1097/IAE.0000000000000514
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P2415, DOI 10.1016/j.ophtha.2014.06.034
   Wu ZC, 2013, OPHTHALMOLOGY, V120, P1307, DOI 10.1016/j.ophtha.2012.12.047
   Wu ZC, 2013, INVEST OPHTH VIS SCI, V54, P2800, DOI 10.1167/iovs.13-11613
   Yi K, 2009, BR J OPHTHALMOL, V176
   Zayit-Soudry S, 2013, INVEST OPHTH VIS SCI, V54, P7498, DOI 10.1167/iovs.13-12433
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 58
TC 27
Z9 27
U1 0
U2 3
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD APR
PY 2017
VL 58
IS 4
BP 2079
EP 2086
DI 10.1167/iovs.16-20105
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA ET9SY
UT WOS:000400649600017
PM 28388704
OA Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Hernandez-Martinez, P
   Dolz-Marco, R
   Hervas-Marin, D
   Andreu-Fenoll, M
   Gallego-Pinazo, R
   Arevalo, JF
AF Hernandez-Martinez, Pablo
   Dolz-Marco, Rosa
   Hervas-Marin, David
   Andreu-Fenoll, Maria
   Gallego-Pinazo, Roberto
   Arevalo, Jose Fernando
TI Choroidal thickness and visual prognosis in type 1 lesion due to
   neovascular age-related macular degeneration
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Anti-vascular endothelial growth
   factor; Choroidal thickness; Optical coherence tomography; Visual
   function
ID OPTICAL COHERENCE TOMOGRAPHY; DOSING REGIMEN; RANIBIZUMAB; THERAPY;
   AFLIBERCEPT; MEMBRANES; OUTCOMES; TREAT
AB Purpose: To evaluate the association between subfoveal choroidal thickness and the visual outcome in eyes with type 1 choroidal neovascularization (CNV) due to neovascular age-related macular degeneration (nAMD).
   Methods: This was a retrospective, longitudinal, cross-sectional study including patients diagnosed with nAMD type 1 lesions managed with intravitreal injections of ranibizumab in a PRN strategy during 24 months. Retrospective chart review of patients with type 1 CNV recording the visual acuity, number of intravitreal injections, multimodal imaging data, and follow-up period was performed. Subfoveal choroidal thickness was measured using enhanced depth imaging scans obtained with spectral-domain optical coherence tomography.
   Results: Twenty-five eyes of 21 patients were included. The mean baseline IogMAR best-corrected visual acuity was 0.52 (+0.35) (median 0.5; range 0.1-1; interquartile range (IQR) 0.3-0.8) and improved to 0.39 (+0.39) (median 0.4; range 0.1-1; IQR 0.2-0.5) by the end of the follow-up (p = 0.038). Subfoveal choroidal thickness was 202.8 (+60.3) mu m (median 218; range 81-285; IQR 146-258). Statistical mixed effects model demonstrated an association between rate of improvement of visual acuity with subfoveal choroidal thickness after 24 months (p<0.001) (95% confidence interval 0.0002-0.0001 IogMAR month mu m); higher thickness values were correlated with better visual acuity.
   Conclusions: Thicker subfoveal choroid was associated with better visual outcomes in patients with type 1 CNV due to nAMD following a strict PRN regimen with intravitreal ranibizumab at 24 months of follow-up.
C1 [Hernandez-Martinez, Pablo; Dolz-Marco, Rosa; Andreu-Fenoll, Maria; Gallego-Pinazo, Roberto] Univ & Polytech Hosp La Fe, Dept Ophthalmol, Unit Macula, Av Fernando Abril Martorell 106, Valencia 46026, Spain.
   [Dolz-Marco, Rosa; Andreu-Fenoll, Maria; Gallego-Pinazo, Roberto] Inst Salud Carlos III, RETICS Oftared, Madrid, Spain.
   [Hervas-Marin, David] Hlth Res Inst La Fe, Biostat Unit, Valencia, Spain.
   [Arevalo, Jose Fernando] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Retina Div, Baltimore, MD 21205 USA.
C3 Instituto de Salud Carlos III; Hospital Universitari i Politecnic La Fe;
   Instituto de Investigacion Sanitaria La Fe (IIS La Fe); Johns Hopkins
   University; Johns Hopkins Medicine
RP Hernandez-Martinez, P (通讯作者)，Univ & Polytech Hosp La Fe, Dept Ophthalmol, Unit Macula, Av Fernando Abril Martorell 106, Valencia 46026, Spain.
EM pablooftalmologia@yahoo.es
RI Hervas, David/L-1322-2016
OI Hervas, David/0000-0003-0635-4961; Arevalo Suarez, Fernando
   Antonio/0000-0002-4114-5949; Dolz-Marco, Rosa/0000-0002-2963-2541
FU Alcon; Allergan; Angelini; Bayer; Novartis; Thea
FX Financial support and conflict of interest: Rosa Dolz-Marco: speaker
   (Bloss, Heidelberg Engineering, Novartis); grant support (Alcon,
   Allergan, Angelini, Bayer, Novartis, Thea). Maria Andreu-Fenoll: grant
   support (Alcon, Allergan, Angelini, Bayer, Novartis, Thea). Roberto
   Gallego-Pinazo: consultant (Alcon, Bayer, Novartis); speaker (Alcon,
   Bloss, Heidelberg Engineering, Novartis); grant support (Alcon,
   Allergan, Angelini, Bayer, Novartis, Thea). J. Fernando Arevalo:
   personal fees from Second Sight LLC, personal fees from Springer SBM
   LLC, personal fees from Alcon Laboratories, personal fees from DORC
   International By, personal fees from Bayer AG, outside the submitted
   work. Pablo Hernandez-Martinez and David Hervas-Marin have no conflict
   of interest.
CR Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Cnaan A, 1997, STAT MED, V16, P2349, DOI 10.1002/(SICI)1097-0258(19971030)16:20<2349::AID-SIM667>3.0.CO;2-E
   Coleman DJ, 2013, BRIT J OPHTHALMOL, V97, P1020, DOI 10.1136/bjophthalmol-2013-303143
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Ehrlich R, 2009, GRAEF ARCH CLIN EXP, V247, P583, DOI 10.1007/s00417-008-1018-x
   Engelbert M, 2010, RETINA-J RET VIT DIS, V30, P1368, DOI 10.1097/IAE.0b013e3181d50cbf
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   GASS JDM, 1994, AM J OPHTHALMOL, V118, P285, DOI 10.1016/S0002-9394(14)72951-4
   Grossniklaus HE, 1998, AM J OPHTHALMOL, V126, P59, DOI 10.1016/S0002-9394(98)00145-7
   Grunwald JE, 1998, ARCH OPHTHALMOL-CHIC, V116, P150
   Grunwald JE, 1998, INVEST OPHTH VIS SCI, V39, P385
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Kang HM, 2014, AM J OPHTHALMOL, V157, P1013, DOI 10.1016/j.ajo.2014.01.019
   Koizumi H, 2016, OPHTHALMOLOGY, V123, P617, DOI 10.1016/j.ophtha.2015.10.039
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Linsenmeier RA, 2000, INVEST OPHTH VIS SCI, V41, P3117
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   Mazaraki K, 2015, BRIT J OPHTHALMOL, V99, P1341, DOI 10.1136/bjophthalmol-2015-306636
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Mori K, 2005, RETINA-J RET VIT DIS, V25, P430, DOI 10.1097/00006982-200506000-00006
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Nowak JZ, 2013, PHARMACOL REP, V65, P288, DOI 10.1016/S1734-1140(13)71005-3
   Papadopoulou DN, 2009, OPHTHALMOLOGY, V116, P1755, DOI 10.1016/j.ophtha.2009.03.017
   Rayess N, 2015, AM J OPHTHALMOL, V159, P3, DOI 10.1016/j.ajo.2014.09.011
   Razavi S, 2015, AM J OPHTHALMOL, V160, P1006, DOI 10.1016/j.ajo.2015.08.009
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Shin JY, 2015, ACTA OPHTHALMOL, V93, P524, DOI 10.1111/aos.12653
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Wood A, 2011, AM J OPHTHALMOL, V152, P1030, DOI 10.1016/j.ajo.2011.05.021
   Xu W, 2010, AM J OPHTHALMOL, V150, P40, DOI 10.1016/j.ajo.2010.01.041
NR 36
TC 3
Z9 3
U1 0
U2 0
PU WICHTIG PUBLISHING
PI MILAN
PA 72/74 VIA FRIULI, 20135 MILAN, ITALY
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD MAR-APR
PY 2017
VL 27
IS 2
BP 196
EP 200
DI 10.5301/ejo.5000860
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EV4QX
UT WOS:000401747200183
PM 27646337
DA 2022-11-30
ER

PT J
AU Yildiz, BK
   Ozdek, S
   Ergun, MA
   Ergun, S
   Tuncay, FY
   Elbeg, S
AF Yildiz, Burcin Kepez
   Ozdek, Sengul
   Ergun, Mehmet Ali
   Ergun, Sezen
   Tuncay, Fulya Yaylacioglu
   Elbeg, Sehri
TI CFH Y402H and VEGF Polymorphisms and Anti-VEGF Treatment Response in
   Exudative Age-Related Macular Degeneration
SO OPHTHALMIC RESEARCH
LA English
DT Article
DE Complement factor H; VEGF-A; Polymorphism; Age-related macular
   degeneration; Anti-VEGF treatment response
ID ENDOTHELIAL GROWTH-FACTOR; COMPLEMENT FACTOR-H; INTRAVITREAL
   RANIBIZUMAB; NEOVASCULAR LESIONS; GENETIC ASSOCIATION; RISK-FACTORS;
   INTERLEUKIN-6; PHARMACOGENETICS; NONRESPONDERS; MACULOPATHY
AB Purpose: The aim of this study was to evaluate the prevalence of single nucleotide polymorphisms (SNPs) in complement factor H (CFH) Y402H and VEGF rs2146323 and rs699947 in exudative age-related macular degeneration (AMD) and their relationship with intravitreal anti-VEGF treatment response. Methods: A total of 109 exudative AMD patients and 70 controls were included. Patients were classified as 'good responders' and 'nonresponders' based on the changes in best corrected visual acuity, central fovea! thickness, lesion size, and the persistence of retinal hemorrhage after three dosages of anti-VEGF. We examined CFH, VEGF rs2146323 and rs699947 SNPs, and plasma interleukin-6 (IL-6) levels in both groups. Results: In total, 42 patients (38.5%) and 11 controls (15.7%) had homozygote wild genotype TT (p = 0.002). The variant C allele frequency was 45% in controls and 31.7% in patients (p = 0.011). A and C allele frequencies for VEGF rs699947 and rs2416323 were similar between the control and patient groups (p = 0.947,p = 0.378). Both SNPs were similar in responders and nonresponders. No significant difference was detected between plasma IL-6 levels of the control and AMD groups (p = 0.594), but the levels were higher in good responders than non responders (p < 0.001). Conclusion: CFH Y402H SNP might be protective for AMD in the Turkish population. VEGF rs2146323 and rs699947 SNPs have no relationship to exudative AMD formation, and none of these seem to have any effect on anti-VEGF response. (C) 2016 S. Karger AG, Basel
C1 [Yildiz, Burcin Kepez; Ozdek, Sengul; Tuncay, Fulya Yaylacioglu] Gazi Univ, Sch Med, Dept Ophthalmol, Ankara, Turkey.
   [Ergun, Mehmet Ali; Ergun, Sezen] Gazi Univ, Sch Med, Dept Med Genet, Ankara, Turkey.
   [Elbeg, Sehri] Gazi Univ, Sch Med, Dept Biochem, Ankara, Turkey.
C3 Gazi University; Gazi University; Gazi University
RP Yildiz, BK (通讯作者)，Beyoglu Eye Training & Res Hosp, TR-34421 Istanbul, Turkey.
EM burcinkepez@hotmail.com
RI ergun, mehmet ali/AAW-4367-2021; TUNCAY, FULYA
   YAYLACIOGLU/AAH-3357-2019; ergün, sezen güntekin/AAD-4872-2021; Özdek,
   Şengül/CAF-5314-2022
OI Özdek, Şengül/0000-0002-7494-4106; ergun, mehmet ali/0000-0001-9696-0433
FU Scientific Research Fund of Gazi University (BAP) [01-2012/64]
FX This study was supported by the Scientific Research Fund of Gazi
   University (BAP Project No. 01-2012/64).
CR Augustin Albert J, 2006, Expert Opin Emerg Drugs, V11, P725, DOI 10.1517/14728214.11.4.725
   Boekhoorn SS, 2008, OPHTHALMOLOGY, V115, P1899, DOI 10.1016/j.ophtha.2008.06.026
   Boltz A, 2012, OPHTHALMOLOGY, V119, P1615, DOI 10.1016/j.ophtha.2012.02.001
   Chen LJ, 2006, MOL VIS, V12, P1536
   Churchill AJ, 2006, HUM MOL GENET, V15, P2955, DOI 10.1093/hmg/ddl238
   CUBITT CL, 1995, INVEST OPHTH VIS SCI, V36, P330
   Del Bo R, 2005, ANN NEUROL, V57, P373, DOI 10.1002/ana.20390
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Feng XF, 2009, OPHTHALMOLOGY, V116, P1908, DOI 10.1016/j.ophtha.2009.03.011
   Finger RP, 2014, SURV OPHTHALMOL, V59, P1, DOI 10.1016/j.survophthal.2013.03.009
   Francis Peter James, 2011, Trans Am Ophthalmol Soc, V109, P115
   Gotoh N, 2006, HUM GENET, V120, P139, DOI 10.1007/s00439-006-0187-0
   Grossniklaus HE, 2005, ARCH OPHTHALMOL-CHIC, V123, P914
   Hagstrom SA, 2013, OPHTHALMOLOGY, V120, P593, DOI 10.1016/j.ophtha.2012.11.037
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Immonen I, 2010, OPHTHALMOLOGY, V117, P103, DOI 10.1016/j.ophtha.2009.06.037
   Jonas JB, 2012, ACTA OPHTHALMOL, V90, pe381, DOI 10.1111/j.1755-3768.2012.02414.x
   Kaur I, 2006, INVEST OPHTH VIS SCI, V47, P3729, DOI 10.1167/iovs.05-1430
   Kenealy SJ, 2004, MOL VIS, V10, P57
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kloeckener-Gruissem B, 2011, INVEST OPHTH VIS SCI, V52, P4694, DOI 10.1167/iovs.10-6080
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P1443, DOI 10.1136/bjophthalmol-2013-303513
   Krippl P, 2003, INT J CANCER, V106, P468, DOI 10.1002/ijc.11238
   Lee AY, 2009, BRIT J OPHTHALMOL, V93, P610, DOI 10.1136/bjo.2008.150995
   Lux A, 2007, BRIT J OPHTHALMOL, V91, P1318, DOI 10.1136/bjo.2006.113902
   McKibbin M, 2012, BRIT J OPHTHALMOL, V96, P208, DOI 10.1136/bjo.2010.193680
   Montezuma Sandra R, 2007, Semin Ophthalmol, V22, P229, DOI 10.1080/08820530701745140
   Mullins RF, 2001, EYE, V15, P390, DOI 10.1038/eye.2001.142
   Nischler C, 2011, ACTA OPHTHALMOL, V89, pE344, DOI 10.1111/j.1755-3768.2010.02080.x
   Orlin A, 2012, RETINA-J RET VIT DIS, V32, P4, DOI 10.1097/IAE.0b013e31822a2c7c
   Ozdek S, 2009, OPHTHALMOLOGY TI MAY
   Parmeggiani F, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/546786
   Perrin RM, 2005, DIABETOLOGIA, V48, P2422, DOI 10.1007/s00125-005-1951-8
   Renner W, 2000, J VASC RES, V37, P443, DOI 10.1159/000054076
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   Schlingemann RO, 2004, GRAEF ARCH CLIN EXP, V242, P91, DOI 10.1007/s00417-003-0828-0
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P2304, DOI 10.1016/j.ophtha.2012.05.040
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Soysal Y, 2012, DNA CELL BIOL, V31, P322, DOI 10.1089/dna.2011.1214
   Stone EM, 2004, NEW ENGL J MED, V351, P346, DOI 10.1056/NEJMoa040833
   Tang NP, 2009, ANN EPIDEMIOL, V19, P740, DOI 10.1016/j.annepidem.2009.03.002
   Teper SJ, 2010, MOL VIS, V16, P2598
   Volante B, 2012, MOL VIS, V18, P2518
   Weeks DE, 2004, AM J HUM GENET, V75, P174, DOI 10.1086/422476
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   Yildirim Z, 2012, INT J GERONTOL, V6, P101, DOI 10.1016/j.ijge.2012.01.018
   Yu JM, 2007, BIOCHEMISTRY-US, V46, P8451, DOI 10.1021/bi700459a
   Yucel D, 2012, OPHTHALMIC GENET, V33, P144, DOI 10.3109/13816810.2012.660225
   Zipfel PF, 2001, SEMIN THROMB HEMOST, V27, P191, DOI 10.1055/s-2001-15248
NR 53
TC 12
Z9 13
U1 0
U2 4
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3747
EI 1423-0259
J9 OPHTHALMIC RES
JI Ophthalmic Res.
PY 2016
VL 56
IS 3
BP 132
EP 138
DI 10.1159/000446186
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DW0DI
UT WOS:000383310700003
PM 27404493
DA 2022-11-30
ER

PT J
AU Java, A
   Pozzi, N
   Schroeder, MC
   Hu, Z
   Huan, TX
   Seddon, JM
   Atkinson, J
AF Java, Anuja
   Pozzi, Nicola
   Schroeder, Molly C.
   Hu, Zheng
   Huan, Tianxiao
   Seddon, Johanna M.
   Atkinson, John
TI Functional analysis of rare genetic variants in complement factor I in
   advanced age-related macular degeneration
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID HIGH-RISK; CFI GENE; FACTOR-H; SYSTEM; C9
AB Factor I (FI) is a serine protease inhibitor of the complement system. Heterozygous rare genetic variants in complement factor I (CFI) are associated with advanced age-related macular degeneration (AMD). The clinical impact of these variants is unknown since a majority have not been functionally characterized and are classified as 'variants of uncertain significance' (VUS). This study assessed the functional significance of VUS in CFI. Our previous cross-sectional study using a serum-based assay demonstrated that CFI variants in advanced AMD can be categorized into three types. Type 1 variants cause a quantitative deficiency of FI. Type 2 variants demonstrate a qualitative deficiency. However, Type 3 variants consist of VUS that are less dysfunctional than Types 1 and 2 but are not as biologically active as wild type (WT). In this study, we employed site-directed mutagenesis followed by expression of the recombinant variant and a comprehensive set of functional assays to characterize nine Type 3 variants that were identified in 37 individuals. Our studies establish that the expression of the recombinant protein compared with WT is reduced for R202I, Q217H, S221Y and G263V. Further, G362A and N536K, albeit expressed normally, have significantly less cofactor activity. These results led to re-categorization of CFI variants R202I, Q217H, S221Y and G263V as Type 1 variants and to reclassification of N536K and G362A as Type 2. The variants K441R, Q462H and I492L showed no functional defect and remained as Type 3. This study highlights the utility of an in-depth biochemical analysis in defining the pathologic and clinical implications of complement variants underlying AMD.
C1 [Java, Anuja] Washington Univ, Sch Med, Dept Med, Div Nephrol, St Louis, MO 63110 USA.
   [Pozzi, Nicola] St Louis Univ, Sch Med, Dept Biochem & Mol Biol, Edward A Doisy Res Ctr, St Louis, MO 63104 USA.
   [Schroeder, Molly C.] Washington Univ, Sch Med, Dept Pathol & Immunol, Div Lab & Genom Med, St Louis, MO 63110 USA.
   [Hu, Zheng; Atkinson, John] Washington Univ, Sch Med, Dept Med, Div Rheumatol, St Louis, MO 63110 USA.
   [Huan, Tianxiao; Seddon, Johanna M.] Univ Massachusetts, Dept Ophthalmol & Visual Sci, Chan Med Sch, Worcester, MA 01655 USA.
C3 Washington University (WUSTL); Saint Louis University; Washington
   University (WUSTL); Washington University (WUSTL); University of
   Massachusetts System; University of Massachusetts Worcester
RP Atkinson, J (通讯作者)，Washington Univ, Sch Med, Dept Med, Div Rheumatol, St Louis, MO 63110 USA.
EM ajava@wustl.edu; nicola.pozzi@health.slu.edu; molly.schroeder@wustl.edu;
   zhenghu@wustl.edu; Tianxiao.Huan@umassmed.edu; johanna_seddon@yahoo.com;
   j.p.atkinson@wustl.edu
RI Pozzi, Nicola/AAC-1771-2021
OI Pozzi, Nicola/0000-0003-2309-7100; Java, Anuja/0000-0003-0433-238X
FU NIH [R01-EY011309, R01-EY028602, 2R01GM099111, 35GM136352, R01HL150146];
   American Macular Degeneration Foundation, North ampton, MA; Macular
   Degeneration Research Fund; Department of Ophthalmology and Visual
   Sciences, University of Mass achusetts Chan Medical School, Worcester,
   MA; Barnes Jewish Hospital Foundation Fund, Division of Nephrology,
   Washington University School of Medicinein St. Louis
FX NIH R01-EY011309 and R01-EY028602 (to JMS-PI); American Macular
   Degeneration Foundation, North ampton, MA, and the Macular Degeneration
   Research Fund, Department of Ophthalmology and Visual Sciences,
   University of Mass achusetts Chan Medical School, Worcester, MA(toJMS);
   NIH R01-EY028602( toJ .S. and J.A.); NIH 2R01GM099111(to J.A. and A.J.);
   NIHR 35GM136352(to J.A.); R01HL150146(to N.P.); Barnes Jewish Hospital
   Foundation Fund, Division of Nephrology, Washington University School of
   Medicinein St. Louis(A.J.).
CR de Jong S, 2020, HUM MOL GENET, V29, P2313, DOI 10.1093/hmg/ddaa114
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Ferrara D, 2015, JAMA OPHTHALMOL, V133, P785, DOI 10.1001/jamaophthalmol.2015.0814
   Geerlings MJ, 2017, MOL IMMUNOL, V84, P65, DOI 10.1016/j.molimm.2016.11.016
   Hallam TM, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.6.18
   Java A, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.9.37
   Java A, 2019, KIDNEY INT REP, V4, P1007, DOI 10.1016/j.ekir.2019.04.003
   Kavanagh D, 2008, MOL IMMUNOL, V45, P95, DOI 10.1016/j.molimm.2007.05.004
   Kavanagh D, 2015, HUM MOL GENET, V24, P3861, DOI 10.1093/hmg/ddv091
   Liszewski MK, 2017, ANNU REV PATHOL-MECH, V12, P25, DOI 10.1146/annurev-pathol-012615-044145
   McMahon O, 2021, HUM MOL GENET, V30, P1188, DOI 10.1093/hmg/ddab086
   Pozzi N, 2016, BIOCHEMISTRY-US, V55, P3984, DOI 10.1021/acs.biochem.6b00385
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   Richards S, 2015, GENET MED, V17, P405, DOI 10.1038/gim.2015.30
   Roversi P, 2011, P NATL ACAD SCI USA, V108, P12839, DOI 10.1073/pnas.1102167108
   Schramm EC, 2014, MOL IMMUNOL, V61, P118, DOI 10.1016/j.molimm.2014.06.032
   Seddon JM, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.14.32
   Seddon JM, 2019, AM J OPHTHALMOL, V198, P223, DOI 10.1016/j.ajo.2018.10.022
   Seddon JM, 2017, INVEST OPHTH VIS SCI, V58, P6513, DOI 10.1167/iovs.17-23544
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Siner JI, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.89371
   Singh RR, 2003, BBA-PROTEINS PROTEOM, V1651, P85, DOI 10.1016/S1570-9639(03)00238-3
   Triebwasser MP, 2015, INVEST OPHTH VIS SCI, V56, P6873, DOI 10.1167/iovs.15-17432
   Tsiftsoglou SA, 2006, BBA-PROTEINS PROTEOM, V1764, P1757, DOI 10.1016/j.bbapap.2006.09.007
   Wagner EK, 2016, SCI REP-UK, V6, DOI 10.1038/srep31531
   Weiner DE, 2011, NEPHROL DIAL TRANSPL, V26, P3159, DOI 10.1093/ndt/gfr022
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xue XG, 2017, NAT STRUCT MOL BIOL, V24, P643, DOI 10.1038/nsmb.3427
   Yu Y, 2014, HUM MOL GENET, V23, P5283, DOI 10.1093/hmg/ddu226
NR 29
TC 2
Z9 2
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 1460-2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD OCT 28
PY 2022
VL 31
IS 21
BP 3683
EP 3693
DI 10.1093/hmg/ddac103
EA MAY 2022
PG 11
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 6C3XD
UT WOS:000826570600001
PM 35531992
DA 2022-11-30
ER

PT J
AU Mottet, B
   Aptel, F
   Geiser, MH
   Hera, R
   Zhou, T
   Almanjoumi, A
   Vinh, V
   Chiquet, C
AF Mottet, Benjamin
   Aptel, Florent
   Geiser, Martial Henri
   Hera, Ruxandra
   Zhou, Thierry
   Almanjoumi, Ahmed
   Vinh, Viviane
   Chiquet, Christophe
TI Choroidal blood flow after the first intravitreal ranibizumab injection
   in neovascular age-related macular degeneration patients
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration; antivascular endothelial growth
   factor; choroidal blood flow; laser Doppler flowmetry
ID BEVACIZUMAB AVASTIN(R); PHOTODYNAMIC THERAPY; CIRCULATION; PROGRESSION;
   DIAMETER; EYES
AB Purpose To analyse choroidal blood flow (ChBF) changes after the first intravitreal ranibizumab injection in naive, age-related macular degeneration (ARMD) patients. Methods Results Subfoveal ChBF was assessed by laser Doppler flowmetry (LDF) in newly diagnosed ARMD patients. Both treated and untreated eyes were assessed in each subject at each visit before the first intravitreal ranibizumab injection as well as 24 hr (day 1) and 7 days after (day 7). Central macular thickness (CMT), best-corrected visual acuity (BVCA), systemic haemodynamic parameters and LDF parameters were evaluated at each visit. Nonparametric tests were used to compare data between visits and between treated and untreated eyes. Seventeen ARMD patients were included (12 women and five men, 78 +/- 8 years old). At day 7 postintravitreal ranibizumab injection, the normalized choroidal blood velocity (ChBVel) change in the treated eye group was significant (-10.2%; p = 0.006). The choroidal blood volume (ChBVol) did not change significantly after intravitreal injection of ranibizumab. There was a trend for a reduction in ChBF at day 7 (-9.1%, p = 0.08). The sensitivity of the experiment was 12% for ChBVel, 16% for ChBVol and 9% for ChBF. Conclusion In conclusion, the laser Doppler technique provides feasible and noninvasive measurements of blood flow parameters before and after intravitreal injection of antivascular endothelial growth factor (anti-VEGF) in patients with exudative ARMD. Choroidal blood velocity decreased as early as 7 days after intravitreal ranibizumab injection, suggesting a vasoconstriction effect of anti-VEGF in large choroidal vessels in front of choriocapillaris (the site of LDF measurement).
C1 [Mottet, Benjamin; Aptel, Florent; Zhou, Thierry; Chiquet, Christophe] Grenoble Alpes Univ, Grenoble, France.
   [Mottet, Benjamin; Aptel, Florent; Hera, Ruxandra; Zhou, Thierry; Almanjoumi, Ahmed; Vinh, Viviane; Chiquet, Christophe] CHU Grenoble Alpes, Univ Hosp, Dept Ophthalmol, Grenoble, France.
   [Aptel, Florent; Chiquet, Christophe] Grenoble Alpes Univ, INSERM, U1042, Lab Hypoxia & Physiopathol, Grenoble, France.
   [Geiser, Martial Henri] Univ Appl Sci Western Switzerland, Sion, Switzerland.
C3 Communaute Universite Grenoble Alpes; UDICE-French Research
   Universities; Universite Grenoble Alpes (UGA); CHU Grenoble Alpes;
   Communaute Universite Grenoble Alpes; UDICE-French Research
   Universities; Universite Grenoble Alpes (UGA); Institut National de la
   Sante et de la Recherche Medicale (Inserm); University of Applied
   Sciences & Arts Western Switzerland
RP Chiquet, C (通讯作者)，Univ Hosp Grenoble, Dept Ophthalmol, F-38043 Grenoble 09, France.
EM cchiquet@chu-grenoble.fr
OI Aptel, Florent/0000-0003-1537-9992
FU Association de Recherche et de Formation en Ophtalmologie (ARFO);
   Association Francaise des Amblyopes Unilateraux (AFAU); Innovation
   Hospitaliere (Grenoble University Hospital)
FX The study was funded by the Association de Recherche et de Formation en
   Ophtalmologie (ARFO), Innovation Hospitaliere (Grenoble University
   Hospital) and the Association Francaise des Amblyopes Unilateraux
   (AFAU). The Grenoble University Hospital (CHU de Grenoble) was the
   promotor of the study. The authors wish to thank Nathalie Arnol for her
   statistical advice.
CR Barak A, 2012, EUR J OPHTHALMOL, V22, P423, DOI 10.5301/ejo.5000074
   Berenberg TL, 2012, RETINA-J RET VIT DIS, V32, P25, DOI 10.1097/IAE.0b013e3182150483
   Boltz A, 2010, INVEST OPHTH VIS SCI, V51, P4220, DOI 10.1167/iovs.09-4968
   Bonnin P, 2010, ACTA OPHTHALMOL, V88, P641, DOI 10.1111/j.1755-3768.2009.01526.x
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Buch H, 2005, OPHTHALMOLOGY, V112, P787, DOI 10.1016/j.ophtha.2004.11.040
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Fontaine O, 2011, INVEST OPHTH VIS SCI, V52, P7400, DOI 10.1167/iovs.10-6646
   Geiser MH, 1999, J BIOMED OPT, V4, P459, DOI 10.1117/1.429960
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   Gugleta K, 2002, INVEST OPHTH VIS SCI, V43, P723
   Hosseini H, 2012, RETINA-J RET VIT DIS, V32, P967, DOI 10.1097/IAE.0b013e31822c28d6
   Longo A, 2004, INVEST OPHTH VIS SCI, V45, P546, DOI 10.1167/iovs.03-0757
   Maar N, 2009, ACTA OPHTHALMOL, V87, P631, DOI 10.1111/j.1755-3768.2008.01311.x
   Mendrinos E, 2013, ACTA OPHTHALMOL, V91, pE184, DOI 10.1111/aos.12008
   Mendrinos E, 2009, ACTA OPHTHALMOL, V87, P290, DOI 10.1111/j.1755-3768.2008.01247.x
   Mete A, 2012, OPHTHALMIC RES, V47, P141, DOI 10.1159/000330509
   Mete A, 2010, J CLIN ULTRASOUND, V38, P66, DOI 10.1002/jcu.20650
   Metelitsina TI, 2008, INVEST OPHTH VIS SCI, V49, P358, DOI 10.1167/iovs.07-0526
   Metelitsina TI, 2004, BRIT J OPHTHALMOL, V88, P1568, DOI 10.1136/bjo.2004.046607
   Micieli JA, 2012, ACTA OPHTHALMOL, V90, pE13, DOI 10.1111/j.1755-3768.2011.02209.x
   Moreau-Gaudry VV, 2010, EYE, V24, P706, DOI 10.1038/eye.2009.130
   Papadopoulou DN, 2009, OPHTHALMOLOGY, V116, P1755, DOI 10.1016/j.ophtha.2009.03.017
   Pournaras CJ, 2006, INVEST OPHTH VIS SCI, V47, P1581, DOI 10.1167/iovs.05-0434
   Rechtman E, 2011, CLIN OPHTHALMOL, V5, P37, DOI 10.2147/OPTH.S15810
   RIVA CE, 1994, INVEST OPHTH VIS SCI, V35, P4273
   Riva CE, 2010, ACTA OPHTHALMOL, V88, P622, DOI 10.1111/j.1755-3768.2009.01621.x
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sakalar YB, 2013, J CLIN ULTRASOUND, V41, P32, DOI 10.1002/jcu.21989
   Schmetterer L, 2007, SURV OPHTHALMOL, V52, pS134, DOI 10.1016/j.survophthal.2007.08.008
   Soliman W, 2008, ACTA OPHTHALMOL, V86, P365, DOI 10.1111/j.1600-0420.2007.01057.x
   Toklu Y, 2011, ACTA OPHTHALMOL, V89, pE41, DOI 10.1111/j.1755-3768.2010.02075.x
   Wickremasinghe SS, 2012, CLIN EXP OPHTHALMOL, V40, P59, DOI 10.1111/j.1442-9071.2011.02613.x
   Xu W, 2010, AM J OPHTHALMOL, V150, P40, DOI 10.1016/j.ajo.2010.01.041
NR 34
TC 9
Z9 9
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD NOV
PY 2018
VL 96
IS 7
BP E783
EP E788
DI 10.1111/aos.13763
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HB4PF
UT WOS:000451035500019
PM 30203609
OA Bronze
DA 2022-11-30
ER

PT J
AU Kaiser, PK
   Brown, DM
   Zhang, K
   Hudson, HL
   Holz, FG
   Shapiro, H
   Schneider, S
   Acharya, NR
AF Kaiser, Peter K.
   Brown, David M.
   Zhang, Kang
   Hudson, Henry L.
   Holz, Frank G.
   Shapiro, Howard
   Schneider, Susan
   Acharya, Nisha R.
TI Ranibizumab for predominantly classic neovascular age-related macular
   degeneration: Subgroup analysis of first-year ANCHOR results
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; MEMBRANES; VERTEPORFIN
AB PURPOSE: Subgroup data from a pivotal phase 3 study comparing ranibizumab (LUCENTIS) with verteporfin (VISUDYNE) photodynamic therapy (PDT) in patients with predominantly classic choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) were retrospectively analyzed to identify patient and disease characteristics that may predict visual acuity (VA) treatment outcomes.
   DESIGN: Retrospective subgroup analysis of 12-month data from the ANCHOR study.
   METHODS: Univariate analyses were performed to assess VA outcomes across subgroups based on patients' gender and baseline age, VA score, CNV lesion size, CNV lesion type, and duration of neovascular AMD, followed by multivariate analyses to identify predictors of the VA score change from baseline at 12 months.
   MAIN OUTCOME MEASURES: Proportion of patients losing <15 letters and proportion gaining >= 15 letters from baseline VA; mean change from baseline VA.
   RESULTS: On average, all subgroups of ranibizumab, treated patients did better than PDT patients for all three VA outcome measures. In the multivariate analysis, lower baseline VA score, smaller baseline CNV lesion size, and younger baseline age were associated with greater gain of letters with ranibizumab treatment and less loss of letters with PDT.
   CONCLUSIONS: Subgroup analysis of 12,month data from the ANCHOR study showed ranibizumab to be superior to PDT in all subgroups evaluated, and was consistent with the subgroup analysis of 24,month data from the other pivotal phase 3 study of ranibizumab (MARINA) in showing that the most important predictors of VA outcomes were, in decreasing order of impact, the patient's baseline VA score, CNV lesion size, and age.
C1 Cleveland Clin Fdn, Cole Eye Inst, Cleveland, OH 44195 USA.
   Vitreoretinal Consult, Houston, TX USA.
   Univ Utah, John Moran Eye Ctr, Salt Lake City, UT USA.
   Retina Ctr, Tucson, AZ USA.
   Univ Bonn, Dept Ophthalmol, Bonn, Germany.
   Genentech Inc, San Francisco, CA USA.
   Univ Calif San Francisco, Proctor Fdn, San Francisco, CA USA.
C3 Cleveland Clinic Foundation; Utah System of Higher Education; University
   of Utah; University of Bonn; Roche Holding; Genentech; University of
   California System; University of California San Francisco
RP Kaiser, PK (通讯作者)，Cleveland Clin Fdn, Cole Eye Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA.
EM pkkaiser@aot.com
RI Zhang, Kang/Y-2740-2019
OI Zhang, Kang/0000-0002-4549-1697; Kaiser, Peter/0000-0001-5126-045X
CR Adamis AP, 2005, RETINA-J RET VIT DIS, V25, P111, DOI 10.1097/00006982-200502000-00001
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Ferrara N, 1997, EXS, V79, P209
   FERRARA N, 1995, LAB INVEST, V72, P615
   Frank RN, 1996, AM J OPHTHALMOL, V122, P393, DOI 10.1016/S0002-9394(14)72066-5
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   *NOV PHARM CORP, 2005, VISUDYNE
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
NR 11
TC 297
Z9 314
U1 0
U2 14
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD DEC
PY 2007
VL 144
IS 6
BP 850
EP 857
DI 10.1016/j.ajo.2007.08.012
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 238TI
UT WOS:000251470100007
PM 17949673
DA 2022-11-30
ER

PT J
AU Wang, WJ
   Chen, J
   Zhang, XL
   Yao, M
   Liu, XY
   Zhou, Q
   Qu, YX
AF Wang, Wen-Jie
   Chen, Jian
   Zhang, Xiao-Ling
   Yao, Min
   Liu, Xiao-Yong
   Zhou, Qing
   Qu, Yi-Xin
TI Bevacizumab versus ranibizumab for neovascular age-related macular
   degeneration: a Meta-analysis
SO INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE bevacizumab; ranibizumab; neovascular age-related macular degeneration;
   Meta-analysis
ID ENDOTHELIAL GROWTH-FACTOR; PIGMENT EPITHELIAL DETACHMENT; LOW
   VISUAL-ACUITY; CHOROIDAL NEOVASCULARIZATION; INTRAVITREAL BEVACIZUMAB;
   CLINICAL MEASURES; TRIAL; ANGIOGENESIS; REGIMENS; OUTCOMES
AB AIM: To systematically compare the efficacy and safety of off -label bevacizumab versus licensed ranibizumab intravitreal injections as well as monthly regimen versus pro re nata [PRN (as needed)] regimen in the treatment of neovascular age-related macular degeneration (nAMD).
   METHODS: Relevant publications were identified through automatically retrieve of database and manually retrieving. The methodological quality of studies included was assessed using the Jadad score and the risk-of-bias assessment. The efficacy estimates were measured by the weight mean difference (WMD) for the improvement of best-corrected visual acuity (BCVA) and central retinal thickness (CRT) reduction. The safety estimates were measured by odds ratios (OR) for adverse events rates. Statistical analysis was conducted by Revman 5.2.7.
   RESULTS: Seven studies were included in the Meta analysis. There were no statistically significant differences between bevacizumab and ranibizumab in BCVA at 1 and 2y (P=0.37, P=0.18, respectively), However, both drugs has better BCVA given monthly than given as needed at 1 and 2y (P<0.05). The results demonstrated the mean decrease in CRT was less in bevacizumab group than ranibizumab group at 1y (P<0.05), while the difference was not significant at 2y (P=0.24). Treatment monthly gained much more decrease in CRT at 1 and 2y (P<0.005).There were no differences between drugs in the rates of death, arterial thrombotic events and venous thrombotic events (P=0.41, P=0.55, P=0.10, respectively), while the rates of medical dictionary for regulatory activities (MedDAR) system organ class events and 1 systemic serious adverse events were higher in bevacizumab group than ranibizumab group (P<0.05). But the incidences of death, arterial thrombotic events, venous thrombotic events, MedDAR system organ class events as well as 1 systemic serious adverse events were not statistically different between both treatment regimens of monthly and as needed (P=0.14, P=0.76, P =0.73, P=0.12, P=0.11, respectively).
   CONCLUSION: Bevacizumab was equivalent to ranibizumab for BCVA, however bevacizumab tended gain less decrease in CRT and had higher rates serious adverse events. Compared with treatment needed, treatment monthly showed superior efficacy BCVA improvement and CRT reduction, while the rates of adverse events were similar in the two dosing regimens.
C1 [Wang, Wen-Jie; Chen, Jian; Zhang, Xiao-Ling; Yao, Min; Liu, Xiao-Yong; Zhou, Qing; Qu, Yi-Xin] Jinan Univ, Affiliated Hosp 1, Dept Ophthalmol, Guangzhou 510632, Guangdong, Peoples R China.
C3 Jinan University
RP Chen, J (通讯作者)，Jinan Univ, Affiliated Hosp 1, Dept Ophthalmol, Guangzhou 510632, Guangdong, Peoples R China.
EM drchenj@163.com
FU National Natural Science Foundation of China [81100637]
FX Supported by National Natural Science Foundation of China (No.81100637)
CR Biswas P, 2011, INDIAN J OPHTHALMOL, V59, P191, DOI 10.4103/0301-4738.81023
   Bolz M, 2007, BRIT J OPHTHALMOL, V91, P785, DOI 10.1136/bjo.2006.102467
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Brown EG, 2003, DRUG SAFETY, V26, P145, DOI 10.2165/00002018-200326030-00002
   Carneiro AM, 2012, CLIN OPHTHALMOL, V6, P1149, DOI 10.2147/OPTH.S33017
   Carneiro AM, 2012, ACTA OPHTHALMOL, V90, pE25, DOI 10.1111/j.1755-3768.2011.02240.x
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chang TS, 2009, RETINA-J RET VIT DIS, V29, P1235, DOI 10.1097/IAE.0b013e3181b20eed
   Csaky K, 2009, AM J OPHTHALMOL, V148, P647, DOI 10.1016/j.ajo.2009.06.014
   De Bats F, 2012, J FR OPHTALMOL, V35, P661, DOI 10.1016/j.jfo.2012.01.015
   Ehrlich R, 2008, RETINA-J RET VIT DIS, V28, P1302, DOI 10.1097/IAE.0b013e3181803c2a
   Ferrara N, 2005, NATURE, V438, P967, DOI 10.1038/nature04483
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Freeman WR, 2011, RETINA-J RET VIT DIS, V31, P1812, DOI 10.1097/IAE.0b013e31821987a4
   Furino C, 2009, ACTA OPHTHALMOL, V87, P404, DOI 10.1111/j.1755-3768.2008.01262.x
   Gamulescu Maria-Andreea, 2010, International Ophthalmology, V30, P261, DOI 10.1007/s10792-009-9318-7
   Gupta B, 2011, BRIT J OPHTHALMOL, V95, P386, DOI 10.1136/bjo.2010.179499
   Haller JA, 2013, OPHTHALMOLOGY, V120, pS3, DOI 10.1016/j.ophtha.2013.01.057
   Ho QT, 2007, INT J BIOCHEM CELL B, V39, P1349, DOI 10.1016/j.biocel.2007.04.010
   Hopewell S, 2013, BMJ OPEN, V3
   Inoue M, 2013, RETINA-J RET VIT DIS, V33, P990, DOI 10.1097/IAE.0b013e3182755793
   Introini U, 2012, GRAEF ARCH CLIN EXP, V250, P1283, DOI 10.1007/s00417-012-1955-2
   Kodjikian L, 2013, OPHTHALMOLOGY, V120, P2300, DOI 10.1016/j.ophtha.2013.06.020
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P266, DOI 10.1136/bjophthalmol-2012-302391
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Ladewig MS, 2006, OPHTHALMOLOGE, V103, P463, DOI 10.1007/s00347-006-1352-5
   Landa G, 2009, OPHTHALMOLOGICA, V223, P370, DOI 10.1159/000227783
   Lanzetta P, 2013, BRIT J OPHTHALMOL, V97, P1497, DOI 10.1136/bjophthalmol-2013-303394
   Lommatzsch A, 2009, EYE, V23, P2163, DOI 10.1038/eye.2008.425
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Mathenge W, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001393
   Moher D, 1998, LANCET, V352, P609, DOI 10.1016/S0140-6736(98)01085-X
   Moutray T, 2008, BRIT J OPHTHALMOL, V92, P361, DOI 10.1136/bjo.2007.123976
   Ozkaya A, 2013, J OCUL PHARMACOL TH, V29, P865, DOI 10.1089/jop.2013.0106
   Panos GD, 2013, DRUG DES DEV THER, V7, P565, DOI 10.2147/DDDT.S46610
   Patel JJ, 2012, J EVAL CLIN PRACT, V18, P247, DOI 10.1111/j.1365-2753.2010.01546.x
   Rosenfeld Philip J, 2006, Ophthalmol Clin North Am, V19, P361
   Schmucker C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042701
   Subramanian ML, 2010, EYE, V24, P1708, DOI 10.1038/eye.2010.147
   Takahashi Kanji, 2008, Nippon Ganka Gakkai Zasshi, V112, P1076
   Unver YB, 2009, EYE, V23, P453, DOI 10.1038/eye.2008.349
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
   Zou LH, 2011, THERANOSTICS, V1, P395, DOI 10.7150/thno/v01p0395
NR 46
TC 9
Z9 10
U1 0
U2 12
PU IJO PRESS
PI XI AN
PA NO 269 YOUYI EAST RD, XI AN, 710054, PEOPLES R CHINA
SN 2222-3959
EI 2227-4898
J9 INT J OPHTHALMOL-CHI
JI Int. J. Ophthalmol.
PD FEB 18
PY 2015
VL 8
IS 1
BP 138
EP 147
DI 10.3980/j.issn.2222-3959.2015.01.26
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CB3GW
UT WOS:000349517200026
PM 25709924
DA 2022-11-30
ER

PT J
AU Coscas, G
   De Benedetto, U
   Coscas, F
   Calzi, CIL
   Vismara, S
   Roudot-Thoraval, F
   Bandello, F
   Souied, E
AF Coscas, Gabriel
   De Benedetto, Umberto
   Coscas, Florence
   Calzi, Concetta I. Li
   Vismara, Sabrina
   Roudot-Thoraval, Francoise
   Bandello, Francesco
   Souied, Eric
TI Hyperreflective Dots: A New Spectral-Domain Optical Coherence Tomography
   Entity for Follow-Up and Prognosis in Exudative Age-Related Macular
   Degeneration
SO OPHTHALMOLOGICA
LA English
DT Article
DE Hyperreflective dots; Spectral-domain optical coherence tomography;
   Exudative age-related macular degeneration; Anti-vascular endothelial
   growth factor treatment
ID RETINAL VEIN OCCLUSION; PATHOGENESIS; RANIBIZUMAB; INFLAMMATION;
   MICROGLIA; EDEMA; FOCI; OCT
AB Purpose: Spectral-domain optical coherence tomography (SD-OCT) enables high-resolution analysis of retinal layers and previously unseen hyperreflective dots (HRD). HRD morphological characteristics, evolution, possible origin and prognostic value are discussed. Methods: We conducted a prospective study of 100 patients with exudative age-related macular degeneration (AMD), who were treated and followed up with monthly imaging examinations. Statistical correlations between visual acuity (VA) and pre-/post-treatment HRD characteristics were evaluated. Results: HRD were present in all cases, mainly in the outer retinal layers but also elsewhere. After treatment, HRD regressed in a few days, 1 month (p < 0.04) and 3 months (p < 0.01). Regression was evident in all VA and morphological subsets. Resolution was associated with better final VA (p < 0.001). Conclusions: Presence of initial/recurrent HRD, rapid treatment response and the growing role that early biological inflammatory reaction plays in AMD suggests HRD are activated microglia cells. The correlation between VA and HRD could make HRD a clinical marker for early decisions about treatment and retreatment. Copyright (C) 2012 S. Karger AG, Basel
C1 [Bandello, Francesco] Univ Vita Salute, San Raffaele Sci Inst, Dept Ophthalmol, Milan, Italy.
   [Coscas, Gabriel; De Benedetto, Umberto; Coscas, Florence; Vismara, Sabrina] Univ Paris 12, Ctr Ophtalmol, FR-94000 Creteil, France.
   [Coscas, Gabriel; Coscas, Florence; Calzi, Concetta I. Li; Roudot-Thoraval, Francoise; Souied, Eric] Univ Paris 12, Dept Ophthalmol, Ctr Hosp Intercommunal Creteil, FR-94000 Creteil, France.
C3 Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele;
   Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Universite
   Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil
RP Coscas, G (通讯作者)，Univ Paris 12, Dept Ophthalmol, Ctr Hosp Intercommunal Creteil, 40 Ave Verdun, FR-94000 Creteil, France.
EM gabriel.coscas@gmail.com
RI bandello, francesco/AAH-2405-2019
OI bandello, francesco/0000-0003-3238-9682
CR Akagi-Kurashige Y, 2012, GRAEFES ARCH CLIN EX
   Augustin AJ, 2009, EXPERT OPIN THER TAR, V13, P641, DOI 10.1517/14728220902942322
   Bolz M, 2009, OPHTHALMOLOGY, V116, P914, DOI 10.1016/j.ophtha.2008.12.039
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Coscas G, 2008, J FR OPHTALMOL, V31, P353, DOI 10.1016/S0181-5512(08)71429-3
   Coscas G, 2010, OPTICAL COHERENCE TOMOGRAPHY IN AGE-RELATED MACULAR DEGENERATION: OCT IN AMD, SECOND EDITION, P171
   Coscas G, 2011, OPHTHALMOLOGICA, V226, P4, DOI 10.1159/000327391
   Fong AHC, 2011, RETINA-J RET VIT DIS, V31, P502, DOI 10.1097/IAE.0b013e3182083beb
   Framme C, 2010, INVEST OPHTH VIS SCI, V51, P1671, DOI 10.1167/iovs.09-4496
   Horu T, 2012, OPHTHALMOLOGY, V119, P1047, DOI 10.1016/j.ophtha.2011.10.030
   Ma WX, 2012, ADV EXP MED BIOL, V723, P37, DOI 10.1007/978-1-4614-0631-0_6
   Marmor MF, 1999, DOC OPHTHALMOL, V97, P239, DOI 10.1023/A:1002192829817
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Ogino K, 2012, RETINA-J RET VIT DIS, V32, P77, DOI 10.1097/IAE.0b013e318217ffc7
   Omri S, 2011, AM J PATHOL, V179, P942, DOI 10.1016/j.ajpath.2011.04.018
   Ota M, 2010, OPHTHALMOLOGY, V117, P1996, DOI 10.1016/j.ophtha.2010.06.019
   Provis JM, 1996, PERSPECT DEV NEUROBI, V3, P213
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Witkin AJ, 2009, OPHTHALMOLOGY, V116, P956, DOI 10.1016/j.ophtha.2008.12.018
   Wolf-Schnurrbusch UEK, 2008, INVEST OPHTH VIS SCI, V49, P3095, DOI 10.1167/iovs.07-1460
   Xu HP, 2009, PROG RETIN EYE RES, V28, P348, DOI 10.1016/j.preteyeres.2009.06.001
   YANNUZZI LA, 1988, B NEW YORK ACAD MED, V64, P955
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 23
TC 130
Z9 135
U1 0
U2 15
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2013
VL 229
IS 1
BP 32
EP 37
DI 10.1159/000342159
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 057TH
UT WOS:000312586400005
PM 23006969
DA 2022-11-30
ER

PT J
AU Ferraz, D
   Bressanim, G
   Takahashi, B
   Pelayes, D
   Takahashi, W
AF Ferraz, Daniel
   Bressanim, Glaucio
   Takahashi, Beatriz
   Pelayes, David
   Takahashi, Walter
TI Three-monthly intravitreal bevacizumab injections for neovascular
   age-related macular degeneration: short-term visual acuity results
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Bevacizumab; Visual acuity
ID ENDOTHELIAL GROWTH-FACTOR; AVASTIN; RANIBIZUMAB
AB PURPOSE. To evaluate the change in vision after 3 monthly consecutive intravitreal injections of 1.25 mg of bevacizumab for neovascular age-related macular degeneration (AMD).
   METHODS. A retrospective analysis of 35 eyes was performed. Visual acuity (VA) at initial visit and at each follow-up visit was compared. The injection of bevacizumab was performed at 30-day intervals and patients were observed for 5 months after the last injection.
   RESULTS. Of the 35 eyes, 9 had received previous treatment with photodynamic therapy with or without 4 mg of intravitreal triamcinolone. VA was measured in Snellen table and transformed into logMAR for statistical purposes. Mean age was 76.66 years (range, 49-90 years). There were 24(69%) women and 11(31%) men. Mean VA at the initial visit was 0.92 +/- 0.50. At month 1, mean VA was 0.84 +/- 0.51 and at month 2 was 0.74 +/- 0.51. At month 3, mean VA remained 0.74 +/- 0.49. Six and 8 months after the initial visit, VA was 0.79 +/- 0.49 and 0.77 +/- 0.50, respectively. The improvement in VA was statistically significant at month 2 and at the end of the follow-up (8 months) compared with the baseline VA.
   CONCLUSIONS. Three consecutive monthly injections of intravitreal bevacizumab to treat neovascular AMD is effective in improving VA in the short term. Longer prospective studies should be performed to confirm VA stability after the third injection. (Eur J Ophthalmol 2010; 20: 740-4)
C1 [Ferraz, Daniel; Bressanim, Glaucio; Takahashi, Beatriz; Takahashi, Walter] Univ Sao Paulo, Sch Med, Dept Ophthalmol, BR-05403000 Sao Paulo, Brazil.
   [Pelayes, David] Univ Buenos Aires, Dept Ophthalmol, Buenos Aires, DF, Argentina.
   [Pelayes, David] Univ Buenos Aires, Dept Pathol, Lab Ophthalmol Invest & Visual Sci LIOCiV, Buenos Aires, DF, Argentina.
   [Pelayes, David] Univ Buenos Aires, Unit Ophthalmol, Carlos G Durand Hosp, Buenos Aires, DF, Argentina.
C3 Universidade de Sao Paulo; University of Buenos Aires; University of
   Buenos Aires; University of Buenos Aires
RP Ferraz, D (通讯作者)，Univ Sao Paulo, Sch Med, Dept Ophthalmol, Av Dr Eneas de Carvalho Aguiar,255 Cerqueira Cesa, BR-05403000 Sao Paulo, Brazil.
EM danielferraz1@hotmail.com
CR Adamis AP, 2005, RETINA-J RET VIT DIS, V25, P111, DOI 10.1097/00006982-200502000-00001
   Aiello LP, 2004, RETINA-J RET VIT DIS, V24, pS3, DOI 10.1097/00006982-200410001-00002
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   BRESSLER NM, 2004, JAMA-J AM MED ASSOC, V29, P1900
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Costa RA, 2006, INVEST OPHTH VIS SCI, V47, P4569, DOI 10.1167/iovs.06-0433
   Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Kaiser PK, 2006, AM J OPHTHALMOL, V142, P660, DOI 10.1016/j.ajo.2006.05.061
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Niemeyer M, 2007, OPHTHALMOLOGE, V104, P158, DOI 10.1007/s00347-006-1425-5
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Soliman W, 2006, ACTA OPHTHALMOL SCAN, V84, P707, DOI 10.1111/j.1600-0420.2006.00736.x
   Spandau UHM, 2006, AM J OPHTHALMOL, V142, P1068, DOI 10.1016/j.ajo.2006.06.048
   Yoganathan P, 2006, RETINA-J RET VIT DIS, V26, P994, DOI 10.1097/01.iae.0000244380.34082.67
NR 20
TC 4
Z9 4
U1 0
U2 1
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD JUL-AUG
PY 2010
VL 20
IS 4
BP 740
EP 744
DI 10.1177/112067211002000415
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 629JF
UT WOS:000280191600015
PM 20155704
DA 2022-11-30
ER

PT J
AU Ormsby, RJ
   Ranganathan, S
   Tong, JC
   Griggs, KM
   Dimasi, DP
   Hewitt, AW
   Burdon, KP
   Craig, JE
   Hoh, J
   Gordon, DL
AF Ormsby, Rebecca J.
   Ranganathan, Shoba
   Tong, Joo Chuan
   Griggs, Kim M.
   Dimasi, David P.
   Hewitt, Alex W.
   Burdon, Kathryn P.
   Craig, Jamie E.
   Hoh, Josephine
   Gordon, David L.
TI Functional and structural implications of the complement factor HY402H
   polymorphism associated with age-related macular degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID C-REACTIVE PROTEIN; H-LIKE PROTEIN-1; SHORT CONSENSUS REPEAT;
   STREPTOCOCCAL M PROTEINS; DISEASE-ASSOCIATED FORM; HEPARIN-BINDING
   DOMAIN; IMMORTALIZED HUMAN RPE; REGULATORS FACTOR-H;
   BORRELIA-BURGDORFERI; Y402H POLYMORPHISM
AB PURPOSE. A Tyr-to-His (Y402H) sequence variant in the factor H (FH) and factor H-like protein (FHL-1) gene is strongly associated with an increased susceptibility for age-related macular degeneration (AMD). The purpose of this study was to understand how the Y402H variant in FH/FHL-1 contributes to the pathogenesis of AMD and, in particular, whether interactions mediated by FH/FHL-1, including binding to C-reactive protein (CRP), group A streptococcal M protein (GAS M6), heparin, and retinal pigment epithelial cells (RPE), are affected.
   METHODS. FH was purified from sera of patients homozygous for FH(Y402) or (H402), and recombinant FH fragments representing FHL-1 were generated. Proteins were analyzed for binding to CRP, GAS M6, heparin, and RPE cells.
   RESULTS. Binding of the FH and FH1 to seven polymorphic variants to CRP and M protein was reduced. The variant did not influence the interaction of FH with heparin but did reduce binding of FHL-1. Binding of the FH and FHL-1 polymorphic variant to RPE cells was not affected.
   CONCLUSIONS. The FH Y402H polymorphism associated with AMD causes a reduction in binding of FH and FHL-1 to CRP and M protein. Both variants show comparable binding to RPE cells, indicating that AMD is unlikely to manifest as a result of impaired host cell-surface recognition. The decreased interaction between FH and CRP, which is essential for the anti-inflammatory function of CRP, provides a possible pathophysiological explanation for the association of the Y402H variant with AMD.
C1 [Ormsby, Rebecca J.; Griggs, Kim M.; Gordon, David L.] Flinders Med Ctr, Dept Microbiol & Infect Dis, Bedford Pk, SA 5042, Australia.
   [Dimasi, David P.; Hewitt, Alex W.; Burdon, Kathryn P.; Craig, Jamie E.] Flinders Med Ctr, Dept Ophthalmol, Bedford Pk, SA, Australia.
   Flinders Univ S Australia, Adelaide, SA 5001, Australia.
   [Ranganathan, Shoba] Macquarie Univ, Dept Chem & Biomol Sci, N Ryde, NSW, Australia.
   [Ranganathan, Shoba] Macquarie Univ, Biotechnol Res Inst, N Ryde, NSW, Australia.
   [Ranganathan, Shoba; Tong, Joo Chuan] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Biochem, Singapore 117548, Singapore.
   [Tong, Joo Chuan] Inst Infocomm Res, Data Mining Dept, Singapore, Singapore.
   [Hoh, Josephine] Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT USA.
C3 Flinders Medical Centre; Flinders Medical Centre; Flinders University
   South Australia; Macquarie University; Macquarie University; National
   University of Singapore; Agency for Science Technology & Research
   (A*STAR); A*STAR - Institute for Infocomm Research (I2R); Yale
   University
RP Ormsby, RJ (通讯作者)，Flinders Med Ctr, Dept Microbiol & Infect Dis, Bedford Pk, SA 5042, Australia.
EM rebecca.ormsby@flinders.edu.au
RI Burdon, Kathryn/A-5026-2009; Burdon, Kathryn/AAD-2334-2022; Hewitt, Alex
   W/D-1936-2013
OI Burdon, Kathryn/0000-0001-8217-1249; Burdon,
   Kathryn/0000-0001-8217-1249; Hewitt, Alex W/0000-0002-5123-5999; Craig,
   Jamie/0000-0001-9955-9696; Gordon, David/0000-0003-3276-9685;
   Ranganathan, Shoba/0000-0002-8290-813X; Ormsby,
   Rebecca/0000-0002-4256-7481
CR ABAGYAN R, 1994, J COMPUT CHEM, V15, P488, DOI 10.1002/jcc.540150503
   Abagyan RA, 1999, J COMPUT PHYS, V151, P402, DOI 10.1006/jcph.1999.6233
   Alge CS, 2006, J PROTEOME RES, V5, P862, DOI 10.1021/pr050420t
   Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Aronen Merja, 1993, Immunology and Infectious Diseases (Oxford), V3, P83
   Blackmore TK, 1996, J IMMUNOL, V157, P5422
   Blackmore TK, 1998, J IMMUNOL, V160, P3342
   Blackmore TK, 1998, INFECT IMMUN, V66, P1427, DOI 10.1128/IAI.66.4.1427-1431.1998
   Cai H, 2006, MOL VIS, V12, P1
   Clark SJ, 2006, J BIOL CHEM, V281, P24713, DOI 10.1074/jbc.M605083200
   Dean M, 2002, ANNU REV GENOM HUM G, V3, P263, DOI 10.1146/annurev.genom.3.022502.103149
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Duthy TG, 2002, INFECT IMMUN, V70, P5604, DOI 10.1128/IAI.70.10.5604-5611.2002
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   ESTALLER C, 1991, EUR J IMMUNOL, V21, P799, DOI 10.1002/eji.1830210337
   FEARON DT, 1977, J EXP MED, V146, P22, DOI 10.1084/jem.146.1.22
   FEARON DT, 1978, P NATL ACAD SCI USA, V75, P1971, DOI 10.1073/pnas.75.4.1971
   GABRIEL SE, 1994, SCIENCE, V266, P107, DOI 10.1126/science.7524148
   Ganesh VK, 2004, P NATL ACAD SCI USA, V101, P8924, DOI 10.1073/pnas.0400744101
   Giannakis E, 2003, EUR J IMMUNOL, V33, P962, DOI 10.1002/eji.200323541
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Halgren TA, 1996, J COMPUT CHEM, V17, P520, DOI 10.1002/(SICI)1096-987X(199604)17:6<520::AID-JCC2>3.3.CO;2-W
   Hartmann K, 2006, MOL MICROBIOL, V61, P1220, DOI 10.1111/j.1365-2958.2006.05318.x
   Hellwage J, 2001, J BIOL CHEM, V276, P8427, DOI 10.1074/jbc.M007994200
   Herbert AP, 2007, J BIOL CHEM, V282, P18960, DOI 10.1074/jbc.M609636200
   Hovis KM, 2006, INFECT IMMUN, V74, P2007, DOI 10.1128/IAI.74.4.2007-2014.2006
   INGRAM VM, 1956, NATURE, V178, P792, DOI 10.1038/178792a0
   Jarva H, 1999, J IMMUNOL, V163, P3957
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Johnsson E, 1998, J IMMUNOL, V161, P4894
   Kardys I, 2006, J AM COLL CARDIOL, V47, P1568, DOI 10.1016/j.jacc.2005.11.076
   Kaur I, 2006, INVEST OPHTH VIS SCI, V47, P3729, DOI 10.1167/iovs.05-1430
   KAZATCHKINE MD, 1979, J EXP MED, V150, P1202, DOI 10.1084/jem.150.5.1202
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4
   Kotarsky H, 1998, J IMMUNOL, V160, P3349
   Kraiczy P, 2002, INT J MED MICROBIOL, V291, P141, DOI 10.1016/S1438-4221(02)80027-3
   Kuhn S, 1996, EUR J IMMUNOL, V26, P2383, DOI 10.1002/eji.1830261017
   KUHN S, 1995, J IMMUNOL, V155, P5663
   Laine M, 2007, J IMMUNOL, V178, P3831, DOI 10.4049/jimmunol.178.6.3831
   Lau LI, 2006, INVEST OPHTH VIS SCI, V47, P3242, DOI 10.1167/iovs.05-1532
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   McDowell JV, 2005, INFECT IMMUN, V73, P7126, DOI 10.1128/IAI.73.11.7126-7132.2005
   Meri T, 2002, INFECT IMMUN, V70, P5185, DOI 10.1128/IAI.70.9.5185-5192.2002
   MOLD C, 1981, Journal of Immunology, V127, P2089
   Mold C, 1999, IMMUNOPHARMACOLOGY, V42, P23, DOI 10.1016/S0162-3109(99)00007-7
   MOLD C, 1984, J IMMUNOL, V133, P882
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   NEMETHY G, 1992, J PHYS CHEM-US, V96, P6472, DOI 10.1021/j100194a068
   Ormsby RJ, 2006, MOL IMMUNOL, V43, P1624, DOI 10.1016/j.molimm.2005.09.012
   Pandiripally V, 2003, INFECT IMMUN, V71, P7119, DOI 10.1128/IAI.71.12.7119-7128.2003
   Perez-Caballero D, 2000, EUR J IMMUNOL, V30, P1243, DOI 10.1002/(SICI)1521-4141(200004)30:4<1243::AID-IMMU1243>3.0.CO;2-D
   Ranganathan S, 2000, Pac Symp Biocomput, P155
   SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626
   SCHULZ TF, 1986, EUR J IMMUNOL, V16, P1351, DOI 10.1002/eji.1830161107
   SCHWAEBLE W, 1987, EUR J IMMUNOL, V17, P1485, DOI 10.1002/eji.1830171015
   Seitsonen S, 2006, MOL VIS, V12, P796
   Sharma AK, 1997, INFECT IMMUN, V65, P484, DOI 10.1128/IAI.65.2.484-487.1997
   Simonelli F, 2006, BRIT J OPHTHALMOL, V90, P1142, DOI 10.1136/bjo.2006.096487
   Sjoberg AP, 2007, J BIOL CHEM, V282, P10894, DOI 10.1074/jbc.M610256200
   Skerka C, 2007, MOL IMMUNOL, V44, P3398, DOI 10.1016/j.molimm.2007.02.012
   Slatkin M, 2004, AM J HUM GENET, V75, P282, DOI 10.1086/423146
   Souied EH, 2005, MOL VIS, V11, P1135
   Thakkinstian A, 2006, HUM MOL GENET, V15, P2784, DOI 10.1093/hmg/ddl220
   Totrov M, 1997, PROTEINS, P215
   WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yu JM, 2007, BIOCHEMISTRY-US, V46, P8451, DOI 10.1021/bi700459a
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
NR 72
TC 70
Z9 74
U1 0
U2 9
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAY
PY 2008
VL 49
IS 5
BP 1763
EP 1770
DI 10.1167/iovs.07-1297
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 292UH
UT WOS:000255291100005
PM 18263814
DA 2022-11-30
ER

PT J
AU Cackett, P
   Tay, WT
   Aung, T
   Wang, JJ
   Shankar, A
   Saw, SM
   Mitchell, P
   Wong, TY
AF Cackett, P.
   Tay, W. T.
   Aung, T.
   Wang, J. J.
   Shankar, A.
   Saw, S. M.
   Mitchell, P.
   Wong, T. Y.
TI Education, socio-economic status and age-related macular degeneration in
   asians: the Singapore Malay Eye Study
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID FACTOR-H GENE; VISUAL IMPAIRMENT; ADULT-POPULATION; RISK-FACTORS;
   DIETARY-FAT; BEIJING EYE; MACULOPATHY; ASSOCIATION; POLYMORPHISM;
   NUTRITION
AB Background/aims: Low socio-economic status is increasingly being identified as a risk marker for chronic diseases, but few studies have investigated the link between socio-economic factors and age-related macular degeneration (AMD). The present study aimed to assess the association between socio-economic status and the prevalence of AMD.
   Methods: A population-based cross-sectional study of 3280 (78.7% response rate) Malay adults aged 40-80 years residing in 15 south-western districts of Singapore. AMD was graded from retinal photographs at a central reading centre using the modified Wisconsin AMD scale. Early and late AMD signs were graded from retinal photographs following the Wisconsin grading system. Socio-economic status including education, housing type and income were determined from a detailed interview.
   Results: Of the participants, 3265 had photographs of sufficient quality for grading of AMD. Early AMD was present in 168 (5.1%) and late AMD in 21 (0.6%). After adjusting for age, gender, smoking, hypertension, diabetes and body mass index, participants with lower educational levels were significantly more likely to have early AMD (multivariate OR 2.2, 95% CI 1.2 to 4.0). This association was stronger in persons who had never smoked (multivariate OR 3.6, 95% confidence CI 1.4 to 9.4). However, no association with housing type or income was seen.
   Conclusions: Low educational level is associated with a higher prevalence of early AMD signs in our Asian population, independent of age, cardiovascular risk factors and cigarette smoking.
C1 [Cackett, P.; Tay, W. T.; Aung, T.; Wong, T. Y.] Singapore Eye Res Inst, Singapore, Singapore.
   [Cackett, P.; Aung, T.; Wong, T. Y.] Singapore Natl Eye Ctr, Singapore, Singapore.
   [Aung, T.; Wong, T. Y.] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Ophthalmol, Singapore 117595, Singapore.
   [Wang, J. J.; Mitchell, P.] Univ Sydney, Ctr Vis Res, Sydney, NSW 2006, Australia.
   [Wang, J. J.; Wong, T. Y.] Univ Melbourne, Ctr Eye Res Australia, Melbourne, Vic 3010, Australia.
   [Shankar, A.; Saw, S. M.] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Community Occupat & Family Med, Singapore 117595, Singapore.
C3 National University of Singapore; Singapore National Eye Center;
   Singapore National Eye Center; National University of Singapore;
   University of Sydney; Centre for Eye Research Australia; University of
   Melbourne; National University of Singapore
RP Wong, TY (通讯作者)，Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, 32 Gisborne St, Melbourne, Vic 3002, Australia.
EM twong@unimelb.edu.au
RI wang, jie/GRS-0942-2022; Wong, Tien Yin/AAC-9724-2020; Mitchell,
   Paul/P-1498-2014; Wang, Jie Jin/P-1499-2014
OI Wong, Tien Yin/0000-0002-8448-1264; Wang, Jie Jin/0000-0001-9491-4898
FU National Medical Research Council (NMRC) [0796/2003]; Biomedical
   Research Council (BMRC) [501/1/25- 5]; Singapore Tissue Network [A*STAR]
FX This study was funded by Funded by the National Medical Research Council
   (NMRC), 0796/2003 & the Biomedical Research Council (BMRC), 501/1/25- 5,
   with support from the Singapore Prospective Study Program and the
   Singapore Tissue Network, A*STAR.
CR Alboni Paolo, 2003, Ital Heart J, V4, P551
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Chen CS, 2006, BIOL BLOOD MARROW TR, V12, P42, DOI 10.1016/j.bbmt.2005.11.132
   CRUICKSHANKS KJ, 1993, ARCH OPHTHALMOL-CHIC, V111, P514, DOI 10.1001/archopht.1993.01090040106042
   Dragano N, 2007, EUR J CARDIOV PREV R, V14, P568, DOI 10.1097/HJR.0b013e32804955c4
   Foong AWP, 2007, OPHTHAL EPIDEMIOL, V14, P25, DOI 10.1080/09286580600878844
   Gotoh N, 2006, HUM GENET, V120, P139, DOI 10.1007/s00439-006-0187-0
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   James WPT, 1997, BMJ-BRIT MED J, V314, P1545, DOI 10.1136/bmj.314.7093.1545
   KAHN HA, 1977, AM J EPIDEMIOL, V106, P33, DOI 10.1093/oxfordjournals.aje.a112429
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P29, DOI 10.1136/bjo.2005.073825
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 1999, OPHTHALMOLOGY, V106, P1056, DOI 10.1016/S0161-6420(99)90255-5
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Lamoreux EL, 2008, INVEST OPHTH VIS SCI, V49, P528, DOI 10.1167/iovs.07-1036
   Lau LI, 2006, INVEST OPHTH VIS SCI, V47, P3242, DOI 10.1167/iovs.05-1532
   Li YB, 2006, AM J OPHTHALMOL, V142, P788, DOI 10.1016/j.ajo.2006.06.001
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P743, DOI 10.1001/archopht.1995.01100060069034
   McCarty CA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1455
   *MIN MAN, 2006, 22006 MIN MAN
   Morris B, 2007, POSTGRAD MED J, V83, P301, DOI 10.1136/pgmj.2006.052944
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   VANLOON AJM, 1995, SCAND J SOC MED, V23, P110, DOI 10.1177/140349489502300206
   Wong TY, 2006, BRIT J OPHTHALMOL, V90, P506, DOI 10.1136/bjo.2005.083733
   Wong TY, 2002, BRIT J OPHTHALMOL, V86, P963, DOI 10.1136/bjo.86.9.963
   Xu L, 2006, BRIT J OPHTHALMOL, V90, P1087, DOI 10.1136/bjo.2006.096123
NR 28
TC 28
Z9 30
U1 0
U2 2
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD OCT
PY 2008
VL 92
IS 10
BP 1312
EP 1315
DI 10.1136/bjo.2007.136077
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 352NJ
UT WOS:000259503600004
PM 18664503
DA 2022-11-30
ER

PT J
AU Liefers, B
   Taylor, P
   Alsaedi, A
   Bailey, C
   Balaskas, K
   Dhingra, N
   Egan, CA
   Rodrigues, FG
   Gonzalo, CG
   Heeren, TFC
   Lotery, A
   Muller, PL
   Olvera-Barrios, A
   Paul, B
   Schwartz, R
   Thomas, DS
   Warwick, AN
   Tufail, A
   Sanchez, CI
AF Liefers, Bart
   Taylor, Paul
   Alsaedi, Abdulrahman
   Bailey, Clare
   Balaskas, Konstantinos
   Dhingra, Narendra
   Egan, Catherine A.
   Rodrigues, Filipa Gomes
   Gonzalo, Cristina Gonzalez
   Heeren, Tjebo F. C.
   Lotery, Andrew
   Muller, Philipp L.
   Olvera-Barrios, Abraham
   Paul, Bobby
   Schwartz, Roy
   Thomas, Darren S.
   Warwick, Alasdair N.
   Tufail, Adnan
   Sanchez, Clara, I
TI Quantification of Key Retinal Features in Early and Late Age-Related
   Macular Degeneration Using Deep Learning
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; IMAGING BIOMARKERS; FLUID; SEGMENTATION;
   RANIBIZUMAB; PREVALENCE
AB PURPOSE: We sought to develop and validate a deep learning model for segmentation of 13 features associated with neovascular and atrophic age-related macular degeneration (AMD).
   DESIGN: Development and validation of a deep-learning model for feature segmentation.
   METHODS: Data for model development were obtained from 307 optical coherence tomography volumes. Eight experienced graders manually delineated all abnormalities in 2712 B-scans. A deep neural network was trained with these data to perform voxel-level segmentation of the 13 most common abnormalities (features). For evaluation, 112 B-scans from 112 patients with a diagnosis of neovascular AMD were annotated by 4 independent observers. The main outcome measures were Dice score, intraclass correlation coefficient, and free-response receiver operating characteristic curve.
   RESULTS: On 11 of 13 features, the model obtained a mean Dice score of 0.63 +/- 0.15, compared with 0.61 +/- 0.17 for the observers. The mean intraclass correlation coefficient for the model was 0.66 +/- 0.22, compared with 0.62 +/- 0.21 for the observers. Two features were not evaluated quantitatively because of a lack of data. Free-response receiver operating characteristic analysis demonstrated that the model scored similar or higher sensitivity per false positives compared with the observers.
   CONCLUSIONS: The quality of the automatic segmentation matches that of experienced graders for most features, exceeding human performance for some features. The quantified parameters provided by the model can be used in the current clinical routine and open possibilities for further research into treatment response outside clinical trials. ((C) 2021 The Authors. Published by Elsevier Inc.)
C1 [Liefers, Bart; Gonzalo, Cristina Gonzalez; Sanchez, Clara, I] Radboud Univ Nijmegen, Dept Radiol & Nucl Med, Diagnost Image Anal Grp, A Eye Res Grp,Med Ctr, Nijmegen, Netherlands.
   [Liefers, Bart; Gonzalo, Cristina Gonzalez; Sanchez, Clara, I] Radboud Univ Nijmegen, Cognit & Behav, Med Ctr, Donders Inst Brain, Nijmegen, Netherlands.
   [Taylor, Paul; Thomas, Darren S.] Univ Coll London UCL, Inst Hlth Informat, London, England.
   [Alsaedi, Abdulrahman] Imam Mohammad Ibn Saud Islamic Univ, Coll Med, Riyadh, Saudi Arabia.
   [Alsaedi, Abdulrahman; Egan, Catherine A.; Rodrigues, Filipa Gomes; Heeren, Tjebo F. C.; Muller, Philipp L.; Olvera-Barrios, Abraham; Schwartz, Roy; Warwick, Alasdair N.; Tufail, Adnan] Moorfields Eye Hosp NHS Fdn Trust, London, England.
   [Bailey, Clare] Univ Hosp Bristol NHS Fdn Trust, Bristol, Avon, England.
   [Liefers, Bart; Balaskas, Konstantinos] Moorfields Eye Hosp NHS Fdn Trust, Moorfields Ophthalm Reading Ctr, 162 City Rd, London EC1V 2PD, England.
   [Balaskas, Konstantinos; Egan, Catherine A.; Rodrigues, Filipa Gomes] Moorfields Eye Hosp Natl Hlth Serv NHS Fdn Trust, Natl Inst Hlth Res, Biomed Res Ctr, UCL Inst Ophthalmol, London, England.
   [Dhingra, Narendra] Mid Yorkshire Hosp NHS Trust, Southampton, Hants, England.
   [Heeren, Tjebo F. C.; Muller, Philipp L.; Olvera-Barrios, Abraham; Tufail, Adnan] UCL, Inst Ophthalmol, London, England.
   [Lotery, Andrew] Univ Southampton, Fac Med, Southampton, Hants, England.
   [Muller, Philipp L.] Univ Bonn, Dept Ophthalmol, Bonn, Germany.
   [Paul, Bobby] Barking Havering & Redbridge Univ Hosp NHS Trust, Romford, Essex, England.
   [Warwick, Alasdair N.] UCL, Inst Cardiovasc Sci, London, England.
   [Sanchez, Clara, I] Radboud Univ Nijmegen, Med Ctr, Dept Ophthalmol, Nijmegen, Netherlands.
   [Liefers, Bart] Erasmus MC, Dept Ophthalmol, Rotterdam, Netherlands.
   [Sanchez, Clara, I] Univ Amsterdam, Fac Sci, Informat Inst, Amsterdam, Netherlands.
   [Sanchez, Clara, I] Univ Amsterdam, Dept Biomed Engn & Phys, Med Ctr, Amsterdam, Netherlands.
C3 Radboud University Nijmegen; Radboud University Nijmegen; University of
   London; University College London; Imam Mohammad Ibn Saud Islamic
   University (IMSIU); University of London; University College London;
   Moorfields Eye Hospital NHS Foundation Trust; University of Bristol;
   University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust; University of London; University College London;
   Moorfields Eye Hospital NHS Foundation Trust; University of London;
   University College London; University of Southampton; University of
   Bonn; University of London; University College London; Radboud
   University Nijmegen; Erasmus University Rotterdam; Erasmus MC;
   University of Amsterdam; University of Amsterdam
RP Liefers, B (通讯作者)，Moorfields Eye Hosp NHS Fdn Trust, Moorfields Ophthalm Reading Ctr, 162 City Rd, London EC1V 2PD, England.
EM b.liefers@nhs.net
RI Olvera-Barrios, Abraham/GQH-4711-2022; Balaskas,
   Konstantinos/ABD-5979-2020; Heeren, Tjebo/R-5055-2019; Olvera-Barrios,
   Abraham/AAG-1197-2020
OI Olvera-Barrios, Abraham/0000-0002-3305-4465; Balaskas,
   Konstantinos/0000-0002-7690-6277; Heeren, Tjebo/0000-0001-5297-2301;
   Olvera-Barrios, Abraham/0000-0002-3305-4465; Gonzalez-Gonzalo,
   Cristina/0000-0001-8413-3297; Gomes Rodrigues,
   Filipa/0000-0002-8087-1177; Dhingra, Narendra/0000-0002-2785-057X;
   Tufail, Adnan/0000-0001-6131-7640; Mueller, Philipp
   L./0000-0003-1680-0224; Liefers, Bart/0000-0002-2763-6426
FU Novartis Pharmaceuticals; Automation in Medical Imaging project;
   Fraunhofer Gesellschaft; Radboud University; University Medical Center;
   German Research Foundation [MU4279/2-1]
FX Supported by a grant from Novartis Pharmaceuticals. Funding was obtained
   from the Automation in Medical Imaging project, a collaborative project
   of the Fraunhofer Gesellschaft and the Radboud University and University
   Medical Center. This research was funded by German Research Foundation
   grant no. MU4279/2-1 (to P.L.M.) . The sponsor or funding organization
   had no role in the design or conduct of this research.
CR Amoaku WM, 2015, EYE, V29, P721, DOI 10.1038/eye.2015.48
   Arnold JJ, 2016, BMC OPHTHALMOL, V16, DOI 10.1186/s12886-016-0207-3
   Bogunovic H, 2019, IEEE T MED IMAGING, V38, P1858, DOI 10.1109/TMI.2019.2901398
   Burlina PM, 2017, JAMA OPHTHALMOL, V135, P1170, DOI 10.1001/jamaophthalmol.2017.3782
   Chen XJ, 2012, IEEE T MED IMAGING, V31, P1521, DOI 10.1109/TMI.2012.2191302
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   De Fauw J, 2018, NAT MED, V24, P1342, DOI 10.1038/s41591-018-0107-6
   Gulshan V, 2016, JAMA-J AM MED ASSOC, V316, P2402, DOI 10.1001/jama.2016.17216
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Keane PA, 2012, SURV OPHTHALMOL, V57, P389, DOI 10.1016/j.survophthal.2012.01.006
   Lee H, 2018, AM J OPHTHALMOL, V191, P64, DOI 10.1016/j.ajo.2018.04.007
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Roy AG, 2017, BIOMED OPT EXPRESS, V8, P3627, DOI 10.1364/BOE.8.003627
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Schmidt-Erfurth U, 2017, EYE, V31, P26, DOI 10.1038/eye.2016.227
   Schmidt-Erfurth U, 2020, OPHTHALMOLOGY, V127, P1211, DOI 10.1016/j.ophtha.2020.03.010
   Schmidt-Erfurth U, 2018, OPHTHALMOL RETINA, V2, P24, DOI 10.1016/j.oret.2017.03.015
   Schmidt-Erfurth U, 2016, PROG RETIN EYE RES, V50, P1, DOI 10.1016/j.preteyeres.2015.07.007
   Toth CA, 2015, RETINA-J RET VIT DIS, V35, P1303, DOI 10.1097/IAE.0000000000000483
   Venhuizen FG, 2018, BIOMED OPT EXPRESS, V9, P1545, DOI 10.1364/BOE.9.001545
   Waldstein SM, 2016, JAMA OPHTHALMOL, V134, P182, DOI 10.1001/jamaophthalmol.2015.4948
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yim J, 2020, NAT MED, V26, P892, DOI 10.1038/s41591-020-0867-7
NR 26
TC 7
Z9 7
U1 0
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JUN
PY 2021
VL 226
BP 1
EP 12
DI 10.1016/j.ajo.2020.12.034
EA MAR 2021
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA TL1CP
UT WOS:000674592100001
PM 33422464
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Studnicka, J
   Rencova, E
   Blaha, M
   Rozsival, P
   Lanska, M
   Blaha, V
   Nemcansky, J
   Langrova, H
AF Studnicka, Jan
   Rencova, Eva
   Blaha, Milan
   Rozsival, Pavel
   Lanska, Miriam
   Blaha, Vladimir
   Nemcansky, Jan
   Langrova, Hana
TI Long-Term Outcomes of Rheohaemapheresis in the Treatment of Dry Form of
   Age-Related Macular Degeneration
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID ELECTRORETINOGRAPHY; GUIDELINES; DRUSEN
AB Purpose. Determining long-term effects of rheohaemapheresis on the dry form of age-related macular degeneration. Methods. This study evaluates 19 patients, average age of 67.6 years, treated with rheohaemapheresis and 18 patients, average age of 72.8 years, comprising the control group. Minimum follow up period was 3.5 years. Each treated patient received a series of 8 sessions of rheohaemapheresis of 1.5 plasma volumes within 10 weeks. We measured the drusenoid pigment epithelium detachment (DPED), best-corrected visual acuity (BCVA), electroretinography (ERG), and rheological parameters. Results. In the treatment group, the baseline BCVA was 0.74 (0.36-1.0) 95% CI and BCVA after 3.5 years was 0.79 (0.41-1.0) 95% CI (P = 0.726). In the control group, the baseline BCVA was 0.71 (0.15-1.0) 95% CI and BCVA after 3.5 years decreased to 0.7 (0.32-0.87) 95% CI (P = 0.031). Baseline DPED was 6.78 +/- 3.79mm(2); after 3.5 years, it decreased to 4.13 +/- 3.84mm(2) (P < 0.001). In the control group, the baseline DPED was 4.09 +/- 3.48mm(2); after 3.5 years, it increased to 6.69 +/- 4.2mm(2) (P = 0.001). We noted increasing levels of positive wave peaking at 50 milliseconds (P50) after treatment (P = 0.022) and a stable amplitude of photopic responses of treated patients. Conclusion. Over the long term, rheohaemapheresis reduced the DPED, improved the function of photoreceptors, and prevented the decline of BCVA.
C1 [Studnicka, Jan; Rencova, Eva; Rozsival, Pavel; Langrova, Hana] Charles Univ Prague, Med Fac & Fac Hosp, Dept Ophthalmol, Hradec Kralove, Czech Republic.
   [Blaha, Milan; Lanska, Miriam] Charles Univ Prague, Med Fac & Fac Hosp, Dept Internal Med Haematol 2, Hradec Kralove, Czech Republic.
   [Blaha, Vladimir] Charles Univ Prague, Med Fac & Fac Hosp, Dept Gerontol & Metab Care, Hradec Kralove, Czech Republic.
   [Nemcansky, Jan] Univ Hosp, Dept Ophthalmol, Ostrava, Czech Republic.
C3 Charles University Prague; Charles University Prague; Charles University
   Prague; University Hospital Ostrava
RP Studnicka, J (通讯作者)，Charles Univ Prague, Med Fac & Fac Hosp, Dept Ophthalmol, Hradec Kralove, Czech Republic.
EM jan.studnicka@fnhk.cz
RI Studnička, Jan/AAC-4127-2022; Nemcansky, Jan/AAC-6619-2019; Rozsival,
   Pavel/N-9978-2017; Studnicka, Jan/K-2875-2017; Blaha,
   Vladimir/C-1151-2016; Blaha, Milan/H-8955-2016
OI Nemcansky, Jan/0000-0003-1979-6419; Rozsival, Pavel/0000-0001-6628-7954;
   Studnicka, Jan/0000-0002-9911-4379; Blaha, Vladimir/0000-0001-8088-9919;
   Blaha, Milan/0000-0003-2330-5838; Langrova, Hana/0000-0001-8488-7208
FU Ministry of Health, CZ [NT14037-3/2013]
FX This work was supported by the Grant of the Ministry of Health, CZ, no.
   NT14037-3/2013.
CR Ben Zion I, 2007, BRIT J OPHTHALMOL, V91, P882, DOI 10.1136/bjo.2006.108340
   Blaha M, 2004, PHYSIOL RES, V53, P273
   Blaha M, 2013, ATHEROSCLEROSIS SUPP, V14, P179, DOI 10.1016/j.atherosclerosissup.2012.10.023
   Blaha M, 2002, CLIN HEMORHEOL MICRO, V26, P273
   Borberg H, 2006, TRANSFUS APHER SCI, V34, P41, DOI 10.1016/j.transci.2005.09.001
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Fiala JC, 2005, J MICROSC-OXFORD, V218, P52, DOI 10.1111/j.1365-2818.2005.01466.x
   Hood DC, 2008, DOC OPHTHALMOL, V116, P1, DOI 10.1007/s10633-007-9089-2
   Khanifar AA, 2008, OPHTHALMOLOGY, V115, P1883, DOI 10.1016/j.ophtha.2008.04.041
   Klein R, 2008, AM J OPHTHALMOL, V145, P317, DOI 10.1016/j.ajo.2007.09.008
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Klingel R, 2003, TRANSFUS APHER SCI, V29, P71, DOI 10.1016/S1473-0502(03)00101-0
   Klingel R, 2000, Ther Apher, V4, P348, DOI 10.1046/j.1526-0968.2000.004005348.x
   Marmor MF, 1995, DOC OPHTHALMOL, V91, P291, DOI 10.1007/BF01214647
   Marmor MF, 2004, DOC OPHTHALMOL, V108, P107, DOI 10.1023/B:DOOP.0000036793.44912.45
   Michelson AD, 1996, P NATL ACAD SCI USA, V93, P11877, DOI 10.1073/pnas.93.21.11877
   Pulido Jose S, 2006, Trans Am Ophthalmol Soc, V104, P221
   Pulido Jose S, 2002, Trans Am Ophthalmol Soc, V100, P85
   Rencova E, 2011, ACTA OPHTHALMOL, V89, P463, DOI 10.1111/j.1755-3768.2009.01710.x
   Seddon Johanna M., 2004, International Ophthalmology Clinics, V44, P17, DOI 10.1097/00004397-200404440-00004
   Sikorski BL, 2011, OPHTHALMOLOGY, V118, P82, DOI 10.1016/j.ophtha.2010.04.017
NR 21
TC 6
Z9 6
U1 1
U2 8
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PY 2013
VL 2013
AR 135798
DI 10.1155/2013/135798
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 279OW
UT WOS:000328970300001
PM 24455194
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Othman, H
   Gholampour, AR
   Saadat, I
   Farvardin-Jahromoi, M
   Saadat, M
AF Othman, Hasan
   Gholampour, Ahmad Reza
   Saadat, Iraj
   Farvardin-Jahromoi, Majid
   Saadat, Mostafa
TI Age-related macular degeneration and genetic polymorphisms of
   glutathione S-transferases M1 (GSTM1) and T1 (GSTT1)
SO MOLECULAR BIOLOGY REPORTS
LA English
DT Article
DE Age at onset; ARMD; GSTM1; GSTT1; Polymorphism
ID NULL GENOTYPE; SUSCEPTIBILITY; ASSOCIATION; RISK; PATHOGENESIS;
   GLAUCOMA; DELETION; SUNLIGHT; DISEASE; CANCER
AB The aim of this study is to understand the multifactorial causes of age-related macular degeneration (ARMD), and, therefore, it is reasonable to investigate whether genetic polymorphisms of antioxidant enzymes (GSTM1 and GSTT1) contribute to the development of ARMD. This study consisted of 112 subjects (44 females, 68 males) with exudative ARMD, who were recruited from Khalili Hospital ophthalmic clinic in Shiraz (southern Iran), referred by vitreoretinal surgeon. Also 112 sex-matched controls (44 females, 68 males) were randomly selected from unrelated volunteers in the same clinic. We excluded patients and controls with cataract or past history of cataract surgery, asthma, past history of malignancy, cardiovascular disease that on medication and known cases of glaucoma, because these traits were associated with GSTM1 and/or GSTT1 polymorphisms. There was no association between polymorphisms of neither GSTM1 nor GSTT1 and risk of ARMD. The combination genotypes of GSTM1 and GSTT1 were not associated with the risk of ARMD. We considered the time of deterioration of vision as the time of onset of exudative ARMD. The Kaplan-Meier analysis revealed that there was significant difference between genotypes of GSTM1 (log rank statistic = 7.03, df = 1, P = 0.008). The age at onset among GSTM1 null genotype was lower than the active genotype of GSTM1. Our results support the hypothesis that the protein encoded by the GSTM1 gene might have a protective function against oxidative stress in retina. Since the age at onset is influenced by the GSTM1 polymorphism, this implies that GSTM1 is a modifier gene.
C1 [Othman, Hasan; Saadat, Iraj; Saadat, Mostafa] Shiraz Univ, Coll Sci, Dept Biol, Shiraz 71454, Iran.
   [Gholampour, Ahmad Reza; Farvardin-Jahromoi, Majid] Shiraz Univ Med Sci, Dept Ophthalmol, Shiraz, Iran.
   [Saadat, Iraj; Saadat, Mostafa] Shiraz Univ, Inst Biotechnol, Shiraz 71454, Iran.
C3 Shiraz University; Shiraz University of Medical Science; Shiraz
   University
RP Saadat, M (通讯作者)，Shiraz Univ, Coll Sci, Dept Biol, Shiraz 71454, Iran.
EM saadat@susc.ac.ir
RI farvardin, majid/K-6950-2016
OI farvardin, majid/0000-0001-9047-0329; Saadat, Iraj/0000-0002-8169-4707;
   Saadat, Mostafa/0000-0002-0021-4055
FU Shiraz University; Shiraz University of Medical Sciences
FX The authors are indebted to the participants for their close
   cooperation. The authors are indebted to Dr. Maryam Ansari-Lari for
   critical reading of the manuscript and for her contribution in
   discussion. This study was supported by Shiraz University and Shiraz
   University of Medical Sciences.
CR Abu-Amero KK, 2008, MOL VIS, V14, P425
   Ahmadi A, 2000, BIOCHEM BIOPH RES CO, V269, P676, DOI 10.1006/bbrc.2000.2338
   Altinisik J, 2010, MOL BIOL REP, V37, P263, DOI 10.1007/s11033-009-9673-5
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   CRUICKSHANKS KJ, 1993, ARCH OPHTHALMOL-CHIC, V111, P514, DOI 10.1001/archopht.1993.01090040106042
   DEJONG JL, 1988, NUCLEIC ACIDS RES, V16, P8541, DOI 10.1093/nar/16.17.8541
   Delcourt C, 1998, ARCH OPHTHALMOL-CHIC, V116, P1031, DOI 10.1001/archopht.116.8.1031
   HARADA S, 1992, HUM GENET, V90, P62
   Katta S, 2009, J GENET, V88, P425, DOI 10.1007/s12041-009-0064-4
   KETTERER B, 1988, MUTAT RES, V202, P343, DOI 10.1016/0027-5107(88)90197-2
   Kimura K, 2000, AM J OPHTHALMOL, V130, P769, DOI 10.1016/S0002-9394(00)00552-3
   Li RL, 2001, ATHEROSCLEROSIS, V154, P729, DOI 10.1016/S0021-9150(00)00582-7
   Masoudi M, 2010, BREAST CANCER RES TR, V120, P263, DOI 10.1007/s10549-009-0521-z
   Masoudi M, 2009, MOL BIOL REP, V36, P781, DOI 10.1007/s11033-008-9245-0
   Mohamadynejad P, 2008, MOL BIOL REP, V35, P669, DOI 10.1007/s11033-007-9138-7
   Moisio AL, 1998, GASTROENTEROLOGY, V115, P1387, DOI 10.1016/S0016-5085(98)70017-4
   Newton CR., 1995, PCR2 PRACTICAL APPRO
   Oz O, 2006, EUR J OPHTHALMOL, V16, P105
   PEMBLE S, 1994, BIOCHEM J, V300, P271, DOI 10.1042/bj3000271
   Rafiee L, 2010, MOL BIOL REP, V37, P155, DOI 10.1007/s11033-009-9565-8
   Saadat M, 2006, OCCUP ENVIRON MED, V63, P503, DOI 10.1136/oem.2005.022343
   Saadat M, 2006, CANCER SCI, V97, P505, DOI 10.1111/j.1349-7006.2006.00207.x
   Saadat M, 2004, BIOCHEM BIOPH RES CO, V319, P1287, DOI 10.1016/j.bbrc.2004.05.121
   Saadat M, 2004, J ALLERGY CLIN IMMUN, V113, P996, DOI 10.1016/j.jaci.2004.02.007
   Saadat M, 2004, BIOCHEM BIOPH RES CO, V316, P749, DOI 10.1016/j.bbrc.2004.02.116
   Saadat M, 2007, PSYCHIAT RES, V153, P87, DOI 10.1016/j.psychres.2006.03.024
   SEKINE Y, 1995, EXP EYE RES, V60, P159, DOI 10.1016/S0014-4835(95)80006-9
   STRYKER WS, 1988, AM J EPIDEMIOL, V127, P283, DOI 10.1093/oxfordjournals.aje.a114804
   Tang JJ, 2010, MOL BIOL REP, V37, P405, DOI 10.1007/s11033-009-9877-8
   Unal M, 2007, BRIT J OPHTHALMOL, V91, P527, DOI 10.1136/bjo.2006.102418
   Wang LS, 2008, CLIN CHEM LAB MED, V46, P1720, DOI 10.1515/CCLM.2008.353
   Webb G, 1996, GENOMICS, V33, P121, DOI 10.1006/geno.1996.0167
   Wilson MH, 2000, FASEB J, V14, P791, DOI 10.1096/fasebj.14.5.791
   Yates JRW, 2000, J MED GENET, V37, P83, DOI 10.1136/jmg.37.2.83
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 35
TC 12
Z9 12
U1 0
U2 5
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0301-4851
EI 1573-4978
J9 MOL BIOL REP
JI Mol. Biol. Rep.
PD MAR
PY 2012
VL 39
IS 3
BP 3299
EP 3303
DI 10.1007/s11033-011-1098-2
PG 5
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 903HS
UT WOS:000301107800144
PM 21701824
DA 2022-11-30
ER

PT J
AU McKay, GJ
   Patterson, CC
   Chakravarthy, U
   Dasari, S
   Klaver, CC
   Vingerling, JR
   Ho, L
   de Jong, PTVM
   Fletcher, AE
   Young, IS
   Seland, JH
   Rahu, M
   Soubrane, G
   Tomazzoli, L
   Topouzis, F
   Vioque, J
   Hingorani, AD
   Sofat, R
   Dean, M
   Sawitzke, J
   Seddon, JM
   Peter, I
   Webster, AR
   Moore, AT
   Yates, JRW
   Cipriani, V
   Fritsche, LG
   Weber, BHF
   Keilhauer, CN
   Lotery, AJ
   Ennis, S
   Klein, ML
   Francis, PJ
   Stambolian, D
   Orlin, A
   Gorin, MB
   Weeks, DE
   Kuo, CL
   Swaroop, A
   Othman, M
   Kanda, A
   Chen, W
   Abecasis, GR
   Wright, AF
   Hayward, C
   Baird, PN
   Guymer, RH
   Attia, J
   Thakkinstian, A
   Silvestri, G
AF McKay, Gareth J.
   Patterson, Chris C.
   Chakravarthy, Usha
   Dasari, Shilpa
   Klaver, Caroline C.
   Vingerling, Johannes R.
   Ho, Lintje
   de Jong, Paulus T. V. M.
   Fletcher, Astrid E.
   Young, Ian S.
   Seland, Johan H.
   Rahu, Mati
   Soubrane, Gisele
   Tomazzoli, Laura
   Topouzis, Fotis
   Vioque, Jesus
   Hingorani, Aroon D.
   Sofat, Reecha
   Dean, Michael
   Sawitzke, Julie
   Seddon, Johanna M.
   Peter, Inga
   Webster, Andrew R.
   Moore, Anthony T.
   Yates, John R. W.
   Cipriani, Valentina
   Fritsche, Lars G.
   Weber, Bernhard H. F.
   Keilhauer, Claudia N.
   Lotery, Andrew J.
   Ennis, Sarah
   Klein, Michael L.
   Francis, Peter J.
   Stambolian, Dwight
   Orlin, Anton
   Gorin, Michael B.
   Weeks, Daniel E.
   Kuo, Chia-Ling
   Swaroop, Anand
   Othman, Mohammad
   Kanda, Atsuhiro
   Chen, Wei
   Abecasis, Goncalo R.
   Wright, Alan F.
   Hayward, Caroline
   Baird, Paul N.
   Guymer, Robyn H.
   Attia, John
   Thakkinstian, Ammarin
   Silvestri, Giuliana
TI Evidence of association of APOE with age-related macular degeneration -
   a pooled analysis of 15 studies
SO HUMAN MUTATION
LA English
DT Article
DE age-related macular degeneration; AMD; apolipoprotein E; APOE;
   case-control association study
ID COMPLEMENT FACTOR-H; APOLIPOPROTEIN-E GENE; RISK-FACTORS;
   CIGARETTE-SMOKING; COMPONENT 3; MACULOPATHY; SUSCEPTIBILITY; VARIANT;
   POLYMORPHISM; PROMOTER
AB Age-related macular degeneration (AMD) is the most common cause of incurable visual impairment in high-income countries. Previous studies report inconsistent associations between AMD and apolipoprotein E (APOE), a lipid transport protein involved in low-density cholesterol modulation. Potential interaction between APOE and sex, and smoking status has been reported. We present a pooled analysis (n = 21,160) demonstrating associations between late AMD and APOe4 (odds ratio [OR] = 0.72 per haplotype; confidence interval [CI]: 0.650.74; P = 4.41 x 10-11) and APOe2 (OR = 1.83 for homozygote carriers; CI: 1.043.23; P = 0.04), following adjustment for age group and sex within each study and smoking status. No evidence of interaction between APOE and sex or smoking was found. Ever smokers had significant increased risk relative to never smokers for both neovascular (OR = 1.54; CI: 1.381.72; P = 2.8 x 10(-15)) and atrophic (OR = 1.38; CI: 1.181.61; P = 3.37 x 10(-5)) AMD but not early AMD (OR = 0.94; CI: 0.861.03; P = 0.16), implicating smoking as a major contributing factor to disease progression from early signs to the visually disabling late forms. Extended haplotype analysis incorporating rs405509 did not identify additional risks beyond e2 and e4 haplotypes. Our expanded analysis substantially improves our understanding of the association between the APOE locus and AMD. It further provides evidence supporting the role of cholesterol modulation, and low-density cholesterol specifically, in AMD disease etiology. 32:14071416, 2011. (C) 2011 Wiley Periodicals, Inc.
C1 [McKay, Gareth J.; Patterson, Chris C.; Young, Ian S.] Queens Univ Belfast, Royal Victoria Hosp, Ctr Publ Hlth, Belfast BT12 6BA, Antrim, North Ireland.
   [Chakravarthy, Usha; Dasari, Shilpa; Silvestri, Giuliana] Queens Univ Belfast, Royal Victoria Hosp, Ctr Vis & Vasc Sci, Belfast BT12 6BA, Antrim, North Ireland.
   [Klaver, Caroline C.] Erasmus MC, Dept Ophthalmol, Rotterdam, Netherlands.
   [Vingerling, Johannes R.; Ho, Lintje] Erasmus MC, Dept Epidemiol, Rotterdam, Netherlands.
   [de Jong, Paulus T. V. M.] Dept Ophthalmol AMC, Amsterdam, Netherlands.
   [Seland, Johan H.] Univ Bergen, Stavanger Univ Hosp, Eye Dept, Stavanger, Norway.
   [Rahu, Mati] Natl Inst Hlth Dev, Dept Epidemiol & Biostat, Tallinn, Estonia.
   [Soubrane, Gisele] Univ Paris 12, Clin Ophthalmol, Paris, France.
   [Tomazzoli, Laura] Univ Verona, Clin Oculist, I-37100 Verona, Italy.
   [Topouzis, Fotis] Aristotle Univ Thessaloniki, Dept Ophthalmol, GR-54006 Thessaloniki, Greece.
   [Vioque, Jesus] Univ Miguel Hernandez, Dept Salud Publ, Alicante, Spain.
   [Vioque, Jesus] CIBERESP, Alicante, Spain.
   [Dean, Michael; Sawitzke, Julie] NCI, Canc & Inflammat Program, Frederick, MD 21701 USA.
   [Seddon, Johanna M.] Tufts Univ, Sch Med, Dept Ophthalmol, Boston, MA 02111 USA.
   [Seddon, Johanna M.] Tufts Med Ctr, Boston, MA USA.
   [Peter, Inga] Mt Sinai Sch Med, Dept Genet & Genom Sci, New York, NY USA.
   [Fritsche, Lars G.; Weber, Bernhard H. F.] Univ Regensburg, Inst Human Genet, Regensburg, Germany.
   [Keilhauer, Claudia N.] Univ Hosp Wurzburg, Dept Ophthalmol, Wurzburg, Germany.
   [Stambolian, Dwight; Orlin, Anton] Univ Penn, Dept Ophthalmol, Philadelphia, PA 19104 USA.
   [Gorin, Michael B.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Ophthalmol, Los Angeles, CA 90095 USA.
   [Weeks, Daniel E.; Kuo, Chia-Ling] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Human Genet, Pittsburgh, PA 15261 USA.
   [Swaroop, Anand; Othman, Mohammad] Univ Michigan, Kellogg Eye Ctr, Dept Ophthalmol & Visual Sci, Ann Arbor, MI 48109 USA.
   [Swaroop, Anand; Kanda, Atsuhiro] NEI, Neurobiol Neurodegenerat & Repair Lab, NIH, Bethesda, MD 20892 USA.
   [Chen, Wei; Abecasis, Goncalo R.] Univ Michigan, Dept Biostat, Ctr Stat Genet, Ann Arbor, MI 48109 USA.
   [Wright, Alan F.; Hayward, Caroline] Western Gen Hosp, MRC Human Genet Unit, Edinburgh EH4 2XU, Midlothian, Scotland.
   [Baird, Paul N.; Guymer, Robyn H.] Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Melbourne, Vic, Australia.
   [Attia, John] Univ Newcastle, Ctr Clin Epidemiol & Biostat, Newcastle, NSW 2300, Australia.
   [Attia, John] John Hunter Hosp, Hunter Med Res Inst, Newcastle, NSW, Australia.
   [Attia, John] John Hunter Hosp, Dept Gen Med, Newcastle, NSW, Australia.
   [Thakkinstian, Ammarin] Mahidol Univ, Ramathibodi Hosp, Fac Med, Sect Clin Epidemiol & Biostat, Bangkok 10400, Thailand.
   [de Jong, Paulus T. V. M.] KNAW, Netherlands Inst Neurosci, Amsterdam, Netherlands.
   [Fletcher, Astrid E.] London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, London WC1, England.
   [Hingorani, Aroon D.; Sofat, Reecha] UCL, Univ Ctr Clin Pharmacol, London, England.
   [Hingorani, Aroon D.; Sofat, Reecha] UCL, Dept Med, London, England.
   [Webster, Andrew R.; Moore, Anthony T.; Yates, John R. W.; Cipriani, Valentina] UCL, Inst Ophthalmol, London, England.
   [Webster, Andrew R.; Moore, Anthony T.; Yates, John R. W.; Cipriani, Valentina] Moorfields Eye Hosp, London, England.
   [Yates, John R. W.] Univ Cambridge, Dept Med Genet, Cambridge, England.
   [Lotery, Andrew J.] Univ Southampton, Sch Med, Clin Neurosci Div, Southampton, Hants, England.
   [Lotery, Andrew J.] Southampton Gen Hosp, Southampton Eye Unit, Southampton SO9 4XY, Hants, England.
   [Ennis, Sarah] Univ Southampton, Genet Epidemiol & Bioinformat Grp Human Genet Div, Southampton SO9 5NH, Hants, England.
   [Klein, Michael L.; Francis, Peter J.] Oregon Hlth & Sci Univ, Casey Eye Inst, Macular Degenerat Ctr, Portland, OR 97201 USA.
   [Gorin, Michael B.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Human Genet, Los Angeles, CA 90095 USA.
C3 Queens University Belfast; Queens University Belfast; Erasmus University
   Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC;
   Stavanger University Hospital; University of Bergen; National Institute
   for Health Development - Estonia; Universite
   Paris-Est-Creteil-Val-de-Marne (UPEC); University of Verona; Aristotle
   University of Thessaloniki; Universidad Miguel Hernandez de Elche; CIBER
   - Centro de Investigacion Biomedica en Red; CIBERESP; National
   Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI);
   Tufts University; Tufts Medical Center; Icahn School of Medicine at
   Mount Sinai; University of Regensburg; University of Wurzburg;
   University of Pennsylvania; University of California System; University
   of California Los Angeles; University of California Los Angeles Medical
   Center; David Geffen School of Medicine at UCLA; Pennsylvania
   Commonwealth System of Higher Education (PCSHE); University of
   Pittsburgh; University of Michigan System; University of Michigan;
   National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); University of Michigan System; University of Michigan; University
   of Edinburgh; Centre for Eye Research Australia; Royal Victorian Eye &
   Ear Hospital; University of Melbourne; University of Newcastle; Hunter
   Medical Research Institute; John Hunter Hospital; University of
   Newcastle; John Hunter Hospital; Mahidol University; Royal Netherlands
   Academy of Arts & Sciences; Netherlands Institute for Neuroscience
   (NIN-KNAW); University of London; London School of Hygiene & Tropical
   Medicine; University of London; University College London; University of
   London; University College London; University of London; University
   College London; University of London; University College London;
   Moorfields Eye Hospital NHS Foundation Trust; University of Cambridge;
   University of Southampton; University of Southampton; University of
   Southampton; Oregon Health & Science University; University of
   California System; University of California Los Angeles; University of
   California Los Angeles Medical Center; David Geffen School of Medicine
   at UCLA
RP McKay, GJ (通讯作者)，Queens Univ Belfast, Royal Victoria Hosp, Ctr Publ Hlth, Belfast BT12 6BA, Antrim, North Ireland.
EM g.j.mckay@qub.ac.uk
RI Dean, Michael C/G-8172-2012; Abecasis, Goncalo R/B-7840-2010; Klaver,
   Caroline C.W./A-2013-2016; Vioque, Jesus/A-1066-2008; Cipriani,
   Valentina/A-8549-2012; Attia, John R/F-5376-2013; Hayward,
   Caroline/M-8818-2016; McKay, Gareth/AAZ-2601-2020; Dean,
   Michael/R-7501-2019; Thakkinstian, Ammarin/J-4788-2019; Rahu,
   Mati/A-9981-2008; Weeks, Daniel E/B-2995-2012; Fritsche, Lars
   G/AAF-9387-2019
OI Dean, Michael C/0000-0003-2234-0631; Vioque, Jesus/0000-0002-2284-148X;
   Cipriani, Valentina/0000-0002-0839-9955; Attia, John
   R/0000-0001-9800-1308; Hayward, Caroline/0000-0002-9405-9550; McKay,
   Gareth/0000-0001-8197-6280; Weeks, Daniel E/0000-0001-9410-7228;
   Fritsche, Lars G/0000-0002-2110-1690; Swaroop,
   Anand/0000-0002-1975-1141; Sofat, Reecha/0000-0002-0242-6115; Hingorani,
   Aroon/0000-0001-8365-0081; Lotery, Andrew/0000-0001-5541-4305; Guymer,
   Robyn/0000-0002-9441-4356; Baird, Paul/0000-0002-1305-3502; Topouzis,
   Fotis/0000-0002-8966-537X; Silvestri, Giuliana/0000-0001-5662-5374;
   Chakravarthy, Usha/0000-0002-2606-3734; Weber, Bernhard
   H.F./0000-0002-8808-7723; Abecasis, Goncalo/0000-0003-1509-1825; Young,
   Ian/0000-0003-3890-3152; Klaver, Caroline/0000-0002-2355-5258; Sawitzke,
   Julie/0000-0002-1715-4626; Chen, Wei/0000-0001-7196-8703
FU Guide Dogs for the Blind Association UK [2008-5a, OR2006-02d]; Medical
   Research Council [G0000067]; Research and Development Office, Northern
   Ireland Health Personal Social Services [RRG 4.5 - GS]; EVI-GENORET; The
   Deutsche Forschungsgemeinschaft [WE1259/18-1, WE1259/19-1]; Alcon
   Research Institute and the Ruth and Milton Steinbach Foundation New
   York; Tufts University School of Medicine; Tufts Medical Center;
   Massachusetts Lions Eye Research Fund; Research to Prevent Blindness
   USA; Foundation Fighting Blindness; Department of Health via National
   Institute for Health Research; National Health & Medical Research
   Council of Australia Centre for Clinical Research Excellence [529923];
   Victorian Government; Macular Disease Society; T.F.C. Frost Charity;
   British Council for the Prevention of Blindness; MRC [G0601354];
   Estonian Ministry of Education and Science; NATIONAL CANCER INSTITUTE
   [ZIABC011301] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE
   [R01EY016862, ZIAEY000475] Funding Source: NIH RePORTER; British Heart
   Foundation [RG/10/12/28456] Funding Source: researchfish; Economic and
   Social Research Council [ES/G007438/1] Funding Source: researchfish;
   Medical Research Council [MC_PC_U127584475, G0601354, MC_U127584475,
   G0700704B] Funding Source: researchfish; National Institute for Health
   Research [NF-SI-0507-10094] Funding Source: researchfish; ESRC
   [ES/G007438/1] Funding Source: UKRI; MRC [G0000067, MC_U127584475]
   Funding Source: UKRI
FX Contract grant sponsors: The Guide Dogs for the Blind Association UK
   (2008-5a (to G. S.) and OR2006-02d (to A. T. M. and J.R.W.Y.)); Medical
   Research Council (G0000067 (to J.R.W.Y. and A. T. M.)); Research and
   Development Office, Northern Ireland Health Personal Social Services
   (RRG 4.5 - GS); EVI-GENORET (FP6 - UC); The Deutsche
   Forschungsgemeinschaft (WE1259/18-1 and WE1259/19-1 (to B. H. F. W.));
   The Alcon Research Institute and the Ruth and Milton Steinbach
   Foundation New York (to B. H. F. W.); Russo Grant (Tufts University
   School of Medicine; to J.M.S.); Macular Degeneration Research Fund
   (Tufts Medical Center; to J.M.S.); Massachusetts Lions Eye Research Fund
   (to J.M.S.); Research to Prevent Blindness USA (to M. L. K. and P.J.F.);
   Foundation Fighting Blindness (to P.J.F.); Department of Health (via
   National Institute for Health Research; (to J.R.W.Y. and A. T. M.); The
   National Health & Medical Research Council of Australia Centre for
   Clinical Research Excellence (#529923 (to R. H. G.)); Victorian
   Government (to P.N.B. and R. H. G.); Macular Disease Society (to G. M.
   K. and A.J.L.); T.F.C. Frost Charity (to A.J.L.); British Council for
   the Prevention of Blindness (to A.J.L.); MRC Biomarker Award (G0601354
   (to A. H. and A. F.)); Estonian Ministry of Education and Science (to M.
   R.).
CR Anderson DH, 2001, AM J OPHTHALMOL, V131, P767, DOI 10.1016/S0002-9394(00)00961-2
   Ang LS, 2008, EXP GERONTOL, V43, P615, DOI 10.1016/j.exger.2008.03.010
   Artiga MJ, 1998, HUM MOL GENET, V7, P1887, DOI 10.1093/hmg/7.12.1887
   Augood C, 2004, OPHTHAL EPIDEMIOL, V11, P117, DOI 10.1076/opep.11.2.117.28160
   Baird PN, 2006, HUM MUTAT, V27, P337, DOI 10.1002/humu.20288
   Baird PN, 2004, INVEST OPHTH VIS SCI, V45, P1311, DOI 10.1167/iovs.03-1121
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bennet AM, 2007, JAMA-J AM MED ASSOC, V298, P1300, DOI 10.1001/jama.298.11.1300
   Bergeron-Sawitzke J, 2009, EUR J HUM GENET, V17, P1190, DOI 10.1038/ejhg.2009.23
   Bojanowski CM, 2006, ENVIRON MOL MUTAGEN, V47, P594, DOI 10.1002/em.20233
   Campillos M, 2003, NUCLEIC ACIDS RES, V31, P3063, DOI 10.1093/nar/gkg435
   Canter JA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002091
   *CDC, 2004, MMWR-MORBID MORTAL W, V53, P1069
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Conley YP, 2005, HUM MOL GENET, V14, P1991, DOI 10.1093/hmg/ddi204
   Connor WE, 2007, INVEST OPHTH VIS SCI, V48, P4226, DOI 10.1167/iovs.06-1275
   Corbo RM, 1999, ANN HUM GENET, V63, P301, DOI 10.1046/j.1469-1809.1999.6340301.x
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Curcio CA, 2009, PROG RETIN EYE RES, V28, P393, DOI 10.1016/j.preteyeres.2009.08.001
   Dandekar SS, 2006, BRIT J OPHTHALMOL, V90, P724, DOI 10.1136/bjo.2005.086355
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Dudbridge F, 2008, HUM HERED, V66, P87, DOI 10.1159/000119108
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ennis S, 2008, LANCET, V372, P1828, DOI 10.1016/S0140-6736(08)61348-3
   Evans J, 1996, BRIT J OPHTHALMOL, V80, P9, DOI 10.1136/bjo.80.1.9
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Francis PJ, 2009, J MED GENET, V46, P300, DOI 10.1136/jmg.2008.062737
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Fritsche LG, 2009, HUM MUTAT, V30, P1048, DOI 10.1002/humu.20957
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Haan MN, 2006, ARCH OPHTHALMOL-CHIC, V124, P988, DOI 10.1001/archopht.124.7.988
   Hadley D, 2010, INVEST OPHTH VIS SCI, V51, P2191, DOI 10.1167/iovs.09-3798
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hammond BR, 1996, VISION RES, V36, P3003, DOI 10.1016/0042-6989(96)00008-9
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2008, ARCH OPHTHALMOL-CHIC, V126, P115, DOI 10.1001/archopht.126.1.115
   Loane E, 2010, INVEST OPHTH VIS SCI, V51, P2636, DOI 10.1167/iovs.09-4397
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   McKay GJ, 2011, AM J EPIDEMIOL, V173, P1357, DOI 10.1093/aje/kwr015
   Mckay GJ, 2010, MOL VIS, V16, P194
   McKay GJ, 2009, INVEST OPHTH VIS SCI, V50, P533, DOI 10.1167/iovs.08-2275
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Minelli C, 2005, INT J EPIDEMIOL, V34, P1319, DOI 10.1093/ije/dyi169
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Park KH, 2009, INVEST OPHTH VIS SCI, V50, P3386, DOI 10.1167/iovs.08-3231
   Ramos MC, 2005, NEUROREPORT, V16, P1027, DOI 10.1097/00001756-200506210-00029
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   SanGiovanni JP, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005508
   Schmidt S, 2005, MOL VIS, V11, P941
   Schmidt Silke, 2002, Ophthalmic Genet, V23, P209, DOI 10.1076/opge.23.4.209.13883
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   SIEST G, 1995, CLIN CHEM, V41, P1068
   Smith W, 1996, ARCH OPHTHALMOL-CHIC, V114, P1518, DOI 10.1001/archopht.1996.01100140716016
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   STRYKER WS, 1988, AM J EPIDEMIOL, V127, P283, DOI 10.1093/oxfordjournals.aje.a114804
   Suner IJ, 2004, INVEST OPHTH VIS SCI, V45, P311, DOI 10.1167/iovs.03-0733
   Swaroop A, 2007, HUM MOL GENET, V16, pR174, DOI 10.1093/hmg/ddm212
   Thakkinstian A, 2006, AM J EPIDEMIOL, V164, P813, DOI 10.1093/aje/kwj279
   van Leeuwen R, 2004, AM J OPHTHALMOL, V137, P750, DOI 10.1016/S0002-9394(03)01089-4
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Vingerling JR, 1996, ARCH OPHTHALMOL-CHIC, V114, P1193, DOI 10.1001/archopht.1996.01100140393005
   Xu L, 2006, BRIT J OPHTHALMOL, V90, P1087, DOI 10.1136/bjo.2006.096123
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zareparsi S, 2004, INVEST OPHTH VIS SCI, V45, P1306, DOI 10.1167/iovs.03-1253
NR 73
TC 94
Z9 97
U1 0
U2 17
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1059-7794
J9 HUM MUTAT
JI Hum. Mutat.
PD DEC
PY 2011
VL 32
IS 12
BP 1407
EP 1416
DI 10.1002/humu.21577
PG 10
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 851CV
UT WOS:000297246800013
PM 21882290
OA Green Accepted, Green Submitted
DA 2022-11-30
ER

PT J
AU Krebs, I
   Lie, S
   Stolba, U
   Zeiler, F
   Felke, S
   Binder, S
AF Krebs, Ilse
   Lie, Shilla
   Stolba, Ulrike
   Zeiler, Florian
   Felke, Stefan
   Binder, Susanne
TI Efficacy of intravitreal bevacizumab (Avastin((R))) therapy for early
   and advanced neovascular age-related macular degeneration
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration; Avastin((R)); bevacizumab; choroidal
   neovascularization; optical coherence tomography
ID OCCULT CHOROIDAL NEOVASCULARIZATION; ENDOTHELIAL GROWTH-FACTOR; OPTICAL
   COHERENCE TOMOGRAPHY; INJECTION; PENETRATION; SECONDARY; TOXICITY
AB Purpose:
   To evaluate the safety and efficacy of intravitreal bevacizumab therapy for early and advanced neovascular age-related macular degeneration (ARMD).
   Methods:
   A consecutive series of eyes with neovascular ARMD treated with monthly intravitreal injections of bevacizumab (1.25 mg/0.05 ml) as long as there was evidence of activity on fluorescein angiography (FA) and optical coherence tomography (OCT) was included and observed for 6 months. For further analysis they were assigned to either an early (untreated/newly diagnosed) or an advanced (predominantly fibrotic/pre-treated) ARMD group. We examined distance visual acuity (VA) with Early Treatment Diabetic Retinopathy Study (ETDRS) charts and central retinal thickness with OCT, as well as lesion size and safety aspects.
   Results:
   Forty-four patients (44 eyes) were enrolled (21 early lesions, 23 advanced lesions). Mean VA changed from 0.74 logMAR at baseline to 0.68 logMAR at month 6 (P = 0.01). Improvement in VA was statistically significant only in eyes with early lesions (n = 21) from month 1 (P = 0.015) up to month 6 (P = 0.03). The changes in central retinal thickness (CRT) (P < 0.001) and total lesion size (P < 0.001) were significant in both groups (early and advanced) at all time-points during follow-up. No significant ocular or systemic adverse effects were observed.
   Conclusion:
   Intravitreal bevacizumab was tolerated well by our patients and we did not identify any apparent short-term safety concerns. We observed stabilization in VA overall, with significant improvement in the early lesion group.
C1 [Krebs, Ilse] Rudolf Fdn Clin, Ludwig Boltzmann Inst Retinol & Biomicroscop Lase, Dept Ophthalmol, A-1030 Vienna, Austria.
   [Krebs, Ilse; Stolba, Ulrike; Felke, Stefan; Binder, Susanne] Rudolf Fdn Clin, Dept Ophthalmol & Laser Surg, A-1030 Vienna, Austria.
C3 Ludwig Boltzmann Institute
RP Krebs, I (通讯作者)，Rudolf Fdn Clin, Ludwig Boltzmann Inst Retinol & Biomicroscop Lase, Dept Ophthalmol, Juchgasse 25, A-1030 Vienna, Austria.
EM ilse.krebs@wienkav.at
FU L. Boltzmann Institute
FX Supported by an unrestricted research grant from the L. Boltzmann
   Institute (to S.B.).
CR Abraham-Marin ML, 2007, GRAEF ARCH CLIN EXP, V245, P651, DOI 10.1007/s00417-006-0411-6
   Aggio FB, 2006, ACTA OPHTHALMOL SCAN, V84, P713, DOI 10.1111/j.1600-0420.2006.00759.x
   Aisenbrey S, 2007, GRAEF ARCH CLIN EXP, V245, P941, DOI 10.1007/s00417-006-0471-7
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Axer-Siegel R, 2004, AM J OPHTHALMOL, V138, P602, DOI 10.1016/j.ajo.2004.05.074
   Bakri SJ, 2006, AM J OPHTHALMOL, V142, P162, DOI 10.1016/j.ajo.2006.03.058
   Bashshur ZF, 2006, AM J OPHTHALMOL, V142, P1, DOI 10.1016/j.ajo.2006.02.037
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Chan CK, 2007, RETINA-J RET VIT DIS, V27, P541, DOI 10.1097/IAE.0b013e3180cc2612
   Costa RA, 2006, INVEST OPHTH VIS SCI, V47, P4569, DOI 10.1167/iovs.06-0433
   Emerson MV, 2007, RETINA-J RET VIT DIS, V27, P439, DOI 10.1097/IAE.0b013e31804b3e15
   Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381
   Ferrara N, 1999, KIDNEY INT, V56, P794, DOI 10.1046/j.1523-1755.1999.00610.x
   Goff MJ, 2007, RETINA-J RET VIT DIS, V27, P432, DOI 10.1097/IAE.0b013e318042b53f
   Heiduschka P, 2007, INVEST OPHTH VIS SCI, V48, P2814, DOI 10.1167/iovs.06-1171
   Hurwitz H, 2005, ONCOLOGY-BASEL, V69, P17, DOI 10.1159/000088480
   Hurwitz H., 2004, CLIN COLORECTAL C S2, V4, P62
   Hurwitz Herbert I, 2003, Clin Adv Hematol Oncol, V1, P404
   Jonas JB, 2007, ACTA OPHTHALMOL SCAN, V85, P563, DOI 10.1111/j.1600-0420.2007.00891.x
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Krebs I, 2008, GRAEF ARCH CLIN EXP, V246, P811, DOI 10.1007/s00417-007-0755-6
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Ladewig MS, 2006, OPHTHALMOLOGE, V103, P463, DOI 10.1007/s00347-006-1352-5
   Lazic R, 2007, GRAEF ARCH CLIN EXP, V245, P68, DOI 10.1007/s00417-006-0466-4
   Manzano RPA, 2006, RETINA-J RET VIT DIS, V26, P257, DOI 10.1097/00006982-200603000-00001
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   MILLER JW, 1994, AM J PATHOL, V145, P574
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Shahar J, 2006, RETINA-J RET VIT DIS, V26, P262, DOI 10.1097/00006982-200603000-00002
   Shima C, 2008, ACTA OPHTHALMOL, V86, P372, DOI 10.1111/j.1600-0420.2007.01067.x
   Soliman W, 2006, ACTA OPHTHALMOL SCAN, V84, P707, DOI 10.1111/j.1600-0420.2006.00736.x
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Stifter E, 2007, AM J OPHTHALMOL, V144, P886, DOI 10.1016/j.ajo.2007.07.034
   Wells JA, 1996, BRIT J OPHTHALMOL, V80, P363, DOI 10.1136/bjo.80.4.363
   Yoganathan P, 2006, RETINA-J RET VIT DIS, V26, P994, DOI 10.1097/01.iae.0000244380.34082.67
NR 37
TC 20
Z9 21
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD SEP
PY 2009
VL 87
IS 6
BP 611
EP 617
DI 10.1111/j.1755-3768.2008.01312.x
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 488LF
UT WOS:000269350500004
PM 18937801
DA 2022-11-30
ER

PT J
AU Spencer, KL
   Hauser, MA
   Olson, LM
   Schmidt, S
   Scott, WK
   Gallins, P
   Agarwal, A
   Postel, EA
   Pericak-Vance, MA
   Haines, JL
AF Spencer, Kylee L.
   Hauser, Michael A.
   Olson, Lana M.
   Schmidt, Silke
   Scott, William K.
   Gallins, Paul
   Agarwal, Anita
   Postel, Eric A.
   Pericak-Vance, Margaret A.
   Haines, Jonathan L.
TI Protective effect of complement factor B and complement component 2
   variants in age-related macular degeneration
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID HTRA1 PROMOTER POLYMORPHISM; FACTOR-H POLYMORPHISM; CIGARETTE-SMOKING;
   SUSCEPTIBILITY; RISK; GENES; ASSOCIATION; LOC387715; HAPLOTYPE;
   INCREASES
AB Age-related macular degeneration (AMD) is a devastating disorder of the central retina, causing significant visual impairment for 7.5 million elderly Americans. Abnormal regulation of the complement system likely caused by the Y402H polymorphism in the complement factor H gene is a recognized risk factor for AMD, as is the A69S variant in the poorly characterized LOC387715 gene. Recently, polymorphisms in the factor B (CFB) and complement component 2 (CC2) genes were associated with decreased susceptibility to AMD. To validate this association in independent family-based and case-control Caucasian data sets, we genotyped two single-nucleotide polymorphisms (SNPs) in CC2 and four SNPs in CFB. The R32Q variant of CFB was significantly associated with protection from AMD in the family-based data set (P = 0.025). Three SNPs in CC2 and CFB were strongly associated with decreased risk of AMD in the case-control data set (CC2 E3118D: P = 0.02; CC2 rs547154: P = 9 x 10(-6); and CFB R32Q P = 2 x 10(-5)). The minor alleles at CC2 rs547154 and CFB R32Q are present in 4% of cases versus 10% of controls, and as these SNPs are in strong linkage disequilibrium (r(2) = 0.92), these results likely represent the same protective signal. After controlling for age, Y402H, A69S and smoking, the effect of CFB R32Q remained quite strong (OR 0.21, 95% confidence interval 0.11-0.39; P < 10(-4)). Likelihood ratio testing and conditional analyses in the case-control data set suggest that a weaker, independent protective effect exists for CC2 E318D.
C1 Vanderbilt Univ, Ctr Human Genet Res, Nashville, TN 37240 USA.
   Vanderbilt Univ, Med Ctr, Vanderbilt Eye Inst, Nashville, TN USA.
   Duke Univ, Duke Univ Eye Ctr, Dept Ophthalmol, Durham, NC USA.
   Univ Miami, Inst Human Gen, Miami, FL 33152 USA.
C3 Vanderbilt University; Vanderbilt University; Duke University;
   University of Miami
RP Haines, JL (通讯作者)，Vanderbilt Univ, Ctr Human Genet Res, 221 Kirkland Hall, Nashville, TN 37240 USA.
EM Jonathan@chgr.mc.vanderbilt.edu
RI Haines, Jonathan/C-3374-2012; Scott, William/A-7593-2009
OI Haines, Jonathan/0000-0002-4351-4728; Scott, William/0000-0001-9336-6404
FU NCRR NIH HHS [M01 RR00095] Funding Source: Medline; NEI NIH HHS
   [EY015216, EY12118] Funding Source: Medline; NATIONAL CENTER FOR
   RESEARCH RESOURCES [M01RR000095] Funding Source: NIH RePORTER; NATIONAL
   EYE INSTITUTE [U10EY012118, R03EY015216, R01EY012118] Funding Source:
   NIH RePORTER
CR Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   Chung RH, 2006, HUM HERED, V61, P189, DOI 10.1159/000094774
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Martin ER, 2003, AM J HUM GENET, V73, P1016, DOI 10.1086/378779
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P55, DOI 10.1001/archopht.125.1.55
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Schmidt S, 2000, MOL VIS, V6, P287
   Scott WK, 2007, OPHTHALMOLOGY, V114, P1151, DOI 10.1016/j.ophtha.2006.08.054
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yoshida T, 2007, MOL VIS, V13, P545
NR 20
TC 153
Z9 157
U1 0
U2 9
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 1460-2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD AUG 15
PY 2007
VL 16
IS 16
BP 1986
EP 1992
DI 10.1093/hmg/ddm146
PG 7
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 219LI
UT WOS:000250086300008
PM 17576744
OA Bronze
DA 2022-11-30
ER

PT J
AU Biswas, P
   Sengupta, S
   Choudhary, R
   Home, S
   Paul, A
   Sinha, S
AF Biswas, Partha
   Sengupta, Subhrangshu
   Choudhary, Ruby
   Home, Subhankar
   Paul, Ajoy
   Sinha, Sourav
TI Comparative role of intravitreal ranibizumab versus bevacizumab in
   choroidal neovascular membrane in age-related macular degeneration
SO INDIAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Ranibizumab; bevacizumab; choroidal neovascular membrane; age-related
   macular degeneration; intravitreal injection; central macular thickness;
   best corrected visual acuity
ID ENDOTHELIAL GROWTH-FACTOR; LUCENTIS; AVASTIN; INJECTIONS; THERAPY;
   ANCHOR; TRIAL
AB Context: Ranibizumab and bevacizumab are used widely for treating patients with choroidal neovascular membrane (CNVM) secondary to age-related macular degeneration (AMD). Aims: To determine and compare the efficacy and safety of intravitreal ranibizumab and bevacizumab in treatment of CNVM due to AMD. Settings and Design: Prospective comparative case series carried out in an eye institute and eye department of a hospital in Kolkata, India. Materials and Methods: One hundred and four eyes with CNVM due to AMD were randomized into two groups. Group A (n=54; 24 occult) received monthly intravitreal ranibizumab injections (0.5 mg in 0.05 ml) and Group B (n=50; 22 occult) received monthly bevacizumab injections (1.25 mg in 0.05 ml) for 3 consecutive months and then as per study criteria. Data analysis done using SPSS software. P-value of <0.05 was considered statistically significant. Results: The mean best corrected visual acuity (BCVA) in the ranibizumab group increased from 58.19 Early Treatment Diabetic Retinopathy Study (ETDRS) letters at baseline to 64 ETDRS letters at month 3 (P<0.001). In bevacizumab group mean BCVA increased from 56.80 to 61.72 ETDRS letters at month 3 (P<0.001). At the end of 18 months, there was no statistically significant difference between groups A and B with respect to change in BCVA (P=0.563) or central macular thickness (CMT; P=0.281), as measured by optical coherence tomography (Stratus OCT 3000). No significant sight-threatening complications developed. Conclusions: Ranibizumab and bevacizumab are equally safe and efficacious in treating CNVM due to AMD.
C1 [Biswas, Partha; Sengupta, Subhrangshu; Paul, Ajoy; Sinha, Sourav] BB Eye Fdn, Kolkata 700020, India.
   [Choudhary, Ruby; Home, Subhankar] BR Singh Hosp, Kolkata 700020, India.
   [Choudhary, Ruby; Home, Subhankar] Ctr Med Educ & Res, Kolkata 700020, India.
RP Biswas, P (通讯作者)，Cluster 7,House 4, Kolkata 700097, India.
EM drpartha_biswas07@yahoo.co.in
CR Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bressler NM, 2010, OPHTHALMOLOGY, V117, P747, DOI 10.1016/j.ophtha.2009.09.002
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Center for Preventive Ophthalmology and Biostatistics, COMP AG REL MAC DEG
   Chang TS, 2009, RETINA-J RET VIT DIS, V29, P1235, DOI 10.1097/IAE.0b013e3181b20eed
   Fong DS, 2010, OPHTHALMOLOGY, V117, P298, DOI 10.1016/j.ophtha.2009.07.023
   Fung AE, 2006, BRIT J OPHTHALMOL, V90, P1344, DOI 10.1136/bjo.2006.099598
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Landa G, 2009, OPHTHALMOLOGICA, V223, P370, DOI 10.1159/000227783
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Mojica G, 2008, BRIT J OPHTHALMOL, V92, P584, DOI 10.1136/bjo.2007.126193
   *NAT CANC I, 1 LIN TREATM MET COL
   Otani A, 2002, MICROVASC RES, V64, P162, DOI 10.1006/mvre.2002.2407
   Raftery J, 2007, BRIT J OPHTHALMOL, V91, P1244, DOI 10.1136/bjo.2007.116616
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Steinbrook R, 2006, NEW ENGL J MED, V355, P1409, DOI 10.1056/NEJMp068185
   Stepien KE, 2009, RETINA-J RET VIT DIS, V29, P1067, DOI 10.1097/IAE.0b013e3181b1bb06
   Subramanian ML, 2009, AM J OPHTHALMOL, V148, P875, DOI 10.1016/j.ajo.2009.07.009
   *U BRIST, INH VEGF AG REL CHOR
   Zarbin M, 2007, OPTOMETRY VISION SCI, V84, pE559, DOI 10.1097/OPX.0b013e3180de4dd7
NR 21
TC 43
Z9 45
U1 0
U2 7
PU MEDKNOW PUBLICATIONS & MEDIA PVT LTD
PI MUMBAI
PA B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075,
   INDIA
SN 0301-4738
EI 1998-3689
J9 INDIAN J OPHTHALMOL
JI Indian J. Ophthalmol.
PD MAY-JUN
PY 2011
VL 59
IS 3
BP 191
EP 196
DI 10.4103/0301-4738.81023
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 767OW
UT WOS:000290866900003
PM 21586838
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Birk, T
   Hickl, S
   Wahl, HW
   Miller, D
   Kammerer, A
   Holz, F
   Becker, S
   Volcker, HE
AF Birk, T
   Hickl, S
   Wahl, HW
   Miller, D
   Kammerer, A
   Holz, F
   Becker, S
   Volcker, HE
TI Development and pilot evaluation of a psychosocial intervention program
   for patients with age-related macular degeneration
SO GERONTOLOGIST
LA English
DT Article
DE age-related low vision; age-related macular degeneration; psychosocial
   group intervention; quality of life
ID SELF-MANAGEMENT; OLDER-ADULTS; VISION LOSS; ADAPTATION; DEPRESSION; LIFE
AB Purpose: The psychosocial needs of patients suffering from severe visual loss associated with advanced age-related macular degeneration (ARMD) are generally ignored in the clinical routine. The aim of this study was to develop and evaluate a psychosocial intervention program for ARMD patients. This intervention program was based on six modules carried out in five weekly group sessions. These modules included (a) progressive muscle relaxation; (b) exchange of disease-related experiences; (c) understanding the connections among thought, emotion, and behavior; (d) description of and emphasis on the use of available resources; (e) improvement of general problem-solving skills, and (f) information exchange on ARMD-related treatment and rehabilitation options. Design and Methods: A preliminary evaluation of this intervention program was performed with the aid of a preintervention-postintervention comparison-group research design, which included 14 individuals (mean age of 73.1 years) in the interventional group and 8 participants (mean age of 72.6 years) in the comparison group. The preintervention-postintervention assessment addressed a set of emotional (e.g., positive and negative affect) as well as behavioral (e.g., limitations to activities and instrumental activities of daily living) outcome measures. Results: Although the sample size of the pilot evaluation test was small, our results demonstrate the usefulness of this pilot program. A statistical analysis comparing the interventional group with the comparison group revealed that the intervention group benefited from the program in five out of six outcome measures. Implications: Psychosocial group intervention is a promising approach to improve the quality of life in patients suffering from ARMD.
C1 Heidelberg Univ, German Ctr Res Aging, D-69115 Heidelberg, Germany.
   Heidelberg Univ, Dept Psychol, D-69115 Heidelberg, Germany.
   Heidelberg Univ, Dept Ophthalmol, D-69115 Heidelberg, Germany.
C3 Ruprecht Karls University Heidelberg; Ruprecht Karls University
   Heidelberg; Ruprecht Karls University Heidelberg
RP Wahl, HW (通讯作者)，Heidelberg Univ, German Ctr Res Aging, Bergheimer Str 20, D-69115 Heidelberg, Germany.
EM wahl@dzfa.uni-heidelberg.de
CR Bellmann C, 2001, ASSIST TECHN RES SER, V8, P49
   Brody BL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1477, DOI 10.1001/archopht.120.11.1477
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   Brody BL, 1999, ANN BEHAV MED, V21, P322, DOI 10.1007/BF02895965
   Burmedi D, 2002, VIS IMPAIR RES, V4, P15, DOI [10.1076/vimr.4.1.15.15633, DOI 10.1076/VIMR.4.1.15.15633]
   Burmedi D., 2002, VISUAL IMPAIRMENT RE, V4, P47
   Cohen J., 1988, STAT POWER ANAL SOCI, V2nd
   DAHLINIVANOFF S, 2000, THEIS U GOTHENBURG S
   EVANS JR, 1995, CAUSES BLINDNESS PAR, V57
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   HECKHAUSEN J, 1995, PSYCHOL REV, V102, P284, DOI 10.1037/0033-295X.102.2.284
   Heyl V, 2001, J VISUAL IMPAIR BLIN, V95, P739, DOI 10.1177/0145482X0109501204
   HOLZ FG, 2003, AGE RELATED MACULAR
   Horowitz A, 2000, LIGHTHOUSE HDB VISIO, V2, P1089
   Jacobson E., 1938, J ABNORM PSYCHOL, V75, P18
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klauer K., 1993, DENKTRAINING JUGENDL
   KLEINSCHMIDT JJ, 1995, J HLTH ED, V26, P26, DOI DOI 10.1080/10556699.1995.10603073
   LAWTON MP, 1969, GERONTOLOGIST, V9, P179, DOI 10.1093/geront/9.3_Part_1.179
   LAWTON MP, 1982, J GERONTOL, V37, P91, DOI 10.1093/geronj/37.1.91
   Muthny FA, 1989, FREIBURGER FRAGEBOGE
   OSWALD WD, 2003, SOZIAL VERHALTENSWIS, P261
   Rovner BW, 2002, ARCH OPHTHALMOL-CHIC, V120, P1041
   Rybarczyk B, 2001, BEHAV MED, V27, P15, DOI 10.1080/08964280109595768
   SHEIKH J I, 1986, Clinical Gerontologist, V5, P165
   Wahl HW, 1999, J GERONTOL B-PSYCHOL, V54, pP304, DOI 10.1093/geronb/54B.5.P304
   Wahl HW, 2004, PSYCHOL AGING, V19, P235, DOI 10.1037/0882-7974.19.1.235
   WATSON D, 1988, J PERS SOC PSYCHOL, V54, P1063, DOI 10.1037/0022-3514.54.6.1063
NR 28
TC 41
Z9 42
U1 0
U2 11
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0016-9013
EI 1758-5341
J9 GERONTOLOGIST
JI Gerontologist
PD DEC
PY 2004
VL 44
IS 6
BP 836
EP 843
DI 10.1093/geront/44.6.836
PG 8
WC Gerontology
WE Social Science Citation Index (SSCI)
SC Geriatrics & Gerontology
GA 880PA
UT WOS:000225800500012
PM 15611220
OA Bronze, Green Submitted
DA 2022-11-30
ER

PT J
AU Prieto-del-Cura, M
   Villafruela-Guemes, I
   Recio-Gamo, E
   Sastre-Ibanez, M
   Fuentes-Ferrer, ME
AF Prieto-del-Cura, M.
   Villafruela-Guemes, I
   Recio-Gamo, E.
   Sastre-Ibanez, M.
   Fuentes-Ferrer, M-E
TI Predictors of good visual outcomes in patients with neovascular
   age-related macular degeneration in daily practice
SO JOURNAL FRANCAIS D OPHTALMOLOGIE
LA English
DT Article
DE Age-related macular degeneration; PRN regimen; Bevacizumab; Prediction
   of response
ID OPTICAL COHERENCE TOMOGRAPHY; PROGRESSION; THERAPY; EYES
AB Purpose. - To report predictive factors for therapeutic response to anti-VEGF in patients with neovascular age-related macular degeneration (nAMD) in daily clinical practice in our patient population.
   Methods. - Retrospective cohort study including 56 patients (69 eyes) with nAMD treated with anti-VEGF, followed for at least two years between February 2012 and April 2018. Patients received three intravitreal anti-VEGF (bevacizumab) injections (loading dose) and were monitored and treated according to a PRN regimen. We analysed whether a gain in visual acuity of 15 or more ETDRS letters at the final visit was associated with demographic characteristics, presence of systemic comorbidities, fundus lesions or measurable improvement on Cirrus optical coherence tomography (OCT) between the first and last visit.
   Results. - After a mean follow-up of 15.5 months (4.7-27.8 interquartile range), central retinal thickness (CRT) (RR: 1.004; IC 95%: 1.001-1.007; P=0.011) and macular hemorrhage (RR: 0.30; IC 95%: 0.10-0.90, P= 0.032) at baseline were found to be useful predictive factors for visual acuity improvement (<= 15 letters) in patients treated for nAMD by anti-VEGF in a real world clinical setting.
   Conclusion. - In the present series of patients with nAMD receiving a loading dose of bevacizumab and followed according to a PRN regimen for 24 months, the only predictable factors for a >= 15 letter gain in visual acuity were anatomical response as measured by OCT and macular hemorrhage at baseline. (C) 2020 Elsevier Masson SAS. All rights reserved.
C1 [Prieto-del-Cura, M.; Villafruela-Guemes, I; Recio-Gamo, E.] Hosp Univ Tajo, Dept Ophthalmol, Aranjuez, Spain.
   [Prieto-del-Cura, M.; Villafruela-Guemes, I; Recio-Gamo, E.; Fuentes-Ferrer, M-E] Univ Alfonso X El Sabio, Madrid, Spain.
   [Prieto-del-Cura, M.; Sastre-Ibanez, M.] Hosp Univ Infanta Leonor, Madrid, Spain.
   [Fuentes-Ferrer, M-E] Hosp Clin San Carlos, Inst Invest Sanitaria Hosp San Carlos, Serv Med Prevent, Madrid, Spain.
C3 Universidad Alfonso X el Sabio (UAX); Hospital Universitario Infanta
   Leonor; Hospital Clinico San Carlos
RP Prieto-del-Cura, M (通讯作者)，Hosp Univ Infanta Leonor, Serv Oftalmol, Gran Via Este 80, Madrid 28031, Spain.
EM marprieto20@yahoo.com
RI Ferrer, Manuel Enrique Fuentes Ferrer ME Fuentes/L-1086-2017
OI Ferrer, Manuel Enrique Fuentes Ferrer ME Fuentes/0000-0002-5177-1441;
   Prieto del Cura, maria del mar/0000-0003-4076-9204
FU Universidad Alfonso-X-El-Sabio (Madrid)
FX This research was funded by a grant from the Universidad
   Alfonso-X-El-Sabio (Madrid).
CR Ashraf M, 2018, ACTA OPHTHALMOL, V96, P120, DOI 10.1111/aos.13565
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bashshur ZF, 2009, AM J OPHTHALMOL, V148, P59, DOI 10.1016/j.ajo.2009.02.006
   Chakravarthy U, 2006, OPHTHALMOLOGY, V113, P1508, DOI 10.1016/j.ophtha.2006.02.064
   Chen X, 2016, RETINA, V36, P550
   Christen WG, 1996, JAMA-J AM MED ASSOC, V276, P1147, DOI 10.1001/jama.276.14.1147
   Dervenis N, 2016, CLIN OPHTHALMOL, V10, DOI 10.2147/OPTH.S106734
   Dixon JA, 2009, EXPERT OPIN INV DRUG, V18, P1573, DOI 10.1517/13543780903201684
   Fasler K, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-027441
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Fulcher C, 2019, EUR J OPHTHALMOL, V2
   Gamulescu MA, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/851648
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Jung JJ, 2014, AM J OPHTHALMOL, V158, P769, DOI 10.1016/j.ajo.2014.07.006
   Klein R, 2008, OPHTHALMOLOGY, V115, P1460, DOI 10.1016/j.ophtha.2008.01.026
   Kodjikian L, 2015, J FR OPHTALMOL, V38, P639, DOI 10.1016/j.jfo.2015.06.001
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Marsiglia M, 2015, RETINA-J RET VIT DIS, V35, P966, DOI 10.1097/IAE.0000000000000460
   Mathew R, 2013, AM J OPHTHALMOL, V155, P720, DOI 10.1016/j.ajo.2012.11.003
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Nemcasnky J, 2019, J OPTHOLMOL, V10
   Peeters A, 2008, ARCH OPHTHALMOL-CHIC, V126, P1554, DOI 10.1001/archopht.126.11.1554
   Ristau T, 2012, J CLIN EXP OPHTHALMO, V4, P264
   Sachs HG, 2016, KLIN MONATSBL AUGENH, V233, P958, DOI 10.1055/s-0041-107672
   Schmidt-Erfurth U, 2017, EYE, V31, P26, DOI 10.1038/eye.2016.227
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Veerappan M, 2016, OPHTHALMOLOGY, V123, P2554, DOI 10.1016/j.ophtha.2016.08.047
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Zou GY, 2004, AM J EPIDEMIOL, V159, P702, DOI 10.1093/aje/kwh090
NR 29
TC 0
Z9 0
U1 0
U2 1
PU MASSON EDITEUR
PI MOULINEAUX CEDEX 9
PA 21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE
SN 0181-5512
EI 1773-0597
J9 J FR OPHTALMOL
JI J. Fr. Ophthamol.
PD DEC
PY 2020
VL 43
IS 10
BP 989
EP 995
DI 10.1016/j.jfo.2020.02.032
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA OW5CC
UT WOS:000592903500019
PM 33081995
DA 2022-11-30
ER

PT J
AU Chakravarthy, U
   Pillai, N
   Syntosi, A
   Barclay, L
   Best, C
   Sagkriotis, A
AF Chakravarthy, Usha
   Pillai, Natasha
   Syntosi, Annie
   Barclay, Lorna
   Best, Catherine
   Sagkriotis, Alexandros
TI Association between visual acuity, lesion activity markers and
   retreatment decisions in neovascular age-related macular degeneration
SO EYE
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; SUBRETINAL FLUID; RANIBIZUMAB;
   AFLIBERCEPT; GUIDELINES; MANAGEMENT; THERAPY; EXTEND; TREAT; NAMD
AB Background/objectives To investigate the association between optical coherence tomography (OCT) markers of lesion activity and changes in visual acuity (VA) during anti-vascular endothelial growth factor (anti-VEGF) therapy of eyes diagnosed with neovascular age-related macular degeneration (nAMD); and how VA and OCT markers are considered in physicians' decision to retreat with anti-VEGFs. Subjects/methods Retrospective, non-comparative, non-randomised cohort study involving electronic medical record data collected from 1190 patient eyes with nAMD diagnosis at two sites in the United Kingdom. Two sub-cohorts consisting of 321 and 301 eyes, respectively, were selected for analyses. Results In 321 eyes, absence of IRF or SRF at >= 2 clinic visits resulted in a gain of five ETDRS letters from baseline, compared with two letters gained in eyes with <2 clinic visits with absence of IRF (p = 0.006) or SRF (p = 0.042). Anti-VEGF treatment was administered at 421 clinic visits, and 308 visits were without treatment. Comparing treatment visits with non-treatment visits, the maximum difference in frequency of OCT markers of lesion activity were for intraretinal fluid (IRF; 24% versus 5%) and subretinal fluid (SRF; 32% versus 5%). Pigment epithelial detachment (PED) was reported in 58% of treatment visits compared with 36% in non-treatment visits. VA loss was not a consistent trigger for retreatment as it was present in 63% of injection visits and in 49% of non-injection visits. Conclusions Retreatment decision making is most strongly influenced by the presence of IRF and SRF and less by the presence of PED or VA loss.
C1 [Chakravarthy, Usha] Queens Univ Belfast, Ctr Med Expt, Inst Clin Sci, Belfast, Antrim, North Ireland.
   [Pillai, Natasha; Barclay, Lorna] IQVIA, Basel, Switzerland.
   [Syntosi, Annie; Best, Catherine; Sagkriotis, Alexandros] Novartis Pharma AG, Basel, Switzerland.
C3 Queens University Belfast; IQVIA; Novartis
RP Chakravarthy, U (通讯作者)，Queens Univ Belfast, Ctr Med Expt, Inst Clin Sci, Belfast, Antrim, North Ireland.
EM u.chakravarthy@qub.ac.uk
CR American Academy of Ophthalmology Retina/Vitreous Panel, 2015, PREF PRACT PATT GUID
   Amoaku WM, 2015, EYE, V29, P721, DOI 10.1038/eye.2015.48
   Andrews EB, 2016, PHARMACOEPIDEM DR S, V25, P2, DOI 10.1002/pds.3891
   [Anonymous], 2001, B WORLD HEALTH ORGAN, V79, P373
   Berg K, 2016, OPHTHALMOLOGY, V123, P51, DOI 10.1016/j.ophtha.2015.09.018
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Dansingani KK, 2015, OSLI RETINA, V46, P907, DOI 10.3928/23258160-20151008-02
   Gale RP, 2019, EYE, V33, DOI 10.1038/s41433-018-0300-3
   Galloway N.R., 2006, AGING EYECOMMON EYE, P201
   Gianniou C, 2015, RETINA-J RET VIT DIS, V35, P1195, DOI 10.1097/IAE.0000000000000465
   Gillies MC, 2015, OPHTHALMOLOGY, V122, P589, DOI 10.1016/j.ophtha.2014.10.001
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Jaffe GJ, 2013, OPHTHALMOLOGY, V120, P1860, DOI 10.1016/j.ophtha.2013.01.073
   Johnston RL, 2017, ADV THER, V34, P703, DOI 10.1007/s12325-017-0483-1
   Johnston RL, 2016, OPHTHALMOLOGY, V123, P2386, DOI 10.1016/j.ophtha.2016.07.037
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Lai TT, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-36704-6
   Leung King Fai Calvin, 2018, Vision (Basel), V2, DOI 10.3390/vision2010005
   Mehta H, 2018, PROG RETIN EYE RES, V65, P127, DOI 10.1016/j.preteyeres.2017.12.002
   MOORE VDR, 2015, CAN J OPTOM, V77, P1
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2016, INVEST OPHTH VIS SCI, V57, pOCT14, DOI 10.1167/iovs.16-19969
   Rosenfeld PJ, 2006, OPHTHALMOLOGY, V113, P623, DOI 10.1016/j.ophtha.2006.01.027
   Royal College of Ophthalmologists (UK), 2013, AG REL MAC DEG GUID
   Sagkriotis A, 2018, VALUE HEALTH, V21, pS423, DOI 10.1016/j.jval.2018.09.2508
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Skelly A, 2017, ADV THER, V34, P2585, DOI 10.1007/s12325-017-0624-6
   Vandenbroucke JP, 2007, ANN INTERN MED, V147, pW163, DOI 10.7326/0003-4819-147-8-200710160-00010-w1
   Waldstein SM, 2016, JAMA OPHTHALMOL, V134, P182, DOI 10.1001/jamaophthalmol.2015.4948
   Wickremasinghe SS, 2016, RETINA-J RET VIT DIS, V36, P1331, DOI 10.1097/IAE.0000000000000902
   World Health Organization, 2007, VIS 2020 RIGHT SIGHT
   Wykoff CC, 2015, OPHTHALMOLOGY, V122, P2514, DOI 10.1016/j.ophtha.2015.08.009
   Zhang XY, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/9640131
NR 34
TC 16
Z9 16
U1 0
U2 0
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD DEC
PY 2020
VL 34
IS 12
BP 2249
EP 2256
DI 10.1038/s41433-020-0799-y
EA FEB 2020
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA QG6KF
UT WOS:000514051200001
PM 32066898
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Gaffney, AJ
   Binns, AM
   Margrain, TH
AF Gaffney, Allannah J.
   Binns, Alison M.
   Margrain, Tom H.
TI The effect of pre-adapting light intensity on dark adaptation in early
   age-related macular degeneration
SO DOCUMENTA OPHTHALMOLOGICA
LA English
DT Article
DE Early age-related macular degeneration; Dark adaptation; Diagnostic
   potential; Pre-adapting light intensity; Psychophysics
ID FOVEAL FLICKER SENSITIVITY; PIGMENT REGENERATION; A-WAVE; VISUAL
   IMPAIRMENT; MACULOPATHY; ROD; RECOVERY; EYES; ELECTRORETINOGRAM;
   MICROPERIMETRY
AB This study aimed to identify the pre-adapting light intensity that generated the maximum separation in the parameters of dark adaptation between participants with early age-related macular degeneration (AMD) and healthy control participants in the minimum recording time.
   Cone dark adaptation was monitored in 10 participants with early AMD and 10 age-matched controls after exposure to three pre-adapting light intensities, using an achromatic annulus (12A degrees radius) centred on the fovea. Threshold recovery data were modelled, and the time constant of cone recovery (tau), final cone threshold, and time to rod-cone-break (RCB) were determined. The diagnostic potential of these parameters at all pre-adapting intensities was evaluated by constructing receiver operating characteristic (ROC) curves.
   There were significant differences between those with early AMD and healthy controls in cone tau and time to RCB (p < 0.05) at all pre-adapting 'bleaching' intensities. ROC curves showed that the diagnostic potential of dark adaptometry was high following exposure to all three pre-adapting intensities, generating an area under the curve in excess of 0.87 +/- A 0.08 for cone tau and time to RCB for all conditions.
   Dark adaptation was shown to be highly diagnostic for early AMD across a range of pre-adapting light intensities, and therefore, the lower pre-adapting intensities evaluated in this study may be used to expedite dark adaptation measurement in the clinic without compromising the integrity of the data obtained. This study reinforces the suggestion that cone and rod dark adaptation are good candidate biomarkers for early AMD.
C1 [Gaffney, Allannah J.; Binns, Alison M.; Margrain, Tom H.] Cardiff Univ, Sch Optometry & Vis Sci, Cardiff CF24 4LU, S Glam, Wales.
C3 Cardiff University
RP Gaffney, AJ (通讯作者)，Cardiff Univ, Sch Optometry & Vis Sci, Maindy Rd, Cardiff CF24 4LU, S Glam, Wales.
EM gaffneyaj1@cf.ac.uk
OI Margrain, Tom/0000-0003-1280-0809; Binns, Alison/0000-0001-8621-498X
FU College of Optometrists, UK
FX This study was funded by a research grant from the College of
   Optometrists, UK.
CR BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Brainard DH, 2001, ENCY IMAGING SCI TEC, V18, P172
   Brown DM, 2009, OPHTHALMOLOGY, V116, pe55
   CHYLACK LT, 1993, ARCH OPHTHALMOL-CHIC, V111, P831, DOI 10.1001/archopht.1993.01090060119035
   Dimitrov PN, 2008, INVEST OPHTH VIS SCI, V49, P55, DOI 10.1167/iovs.06-1048
   Dimitrov PN, 2011, INVEST OPHTH VIS SCI, V52, P9457, DOI 10.1167/iovs.10-7043
   EISNER A, 1991, INVEST OPHTH VIS SCI, V32, P8
   Gaffney AJ, 2012, OPTOMETRY VISION SCI, V89, P1219, DOI 10.1097/OPX.0b013e318263c6b1
   Gaffney AJ, 2011, OPTOMETRY VISION SCI, V88, P1080, DOI 10.1097/OPX.0b013e3182223697
   Hahn GA, 2009, GRAEF ARCH CLIN EXP, V247, P43, DOI 10.1007/s00417-008-0919-z
   Haig C, 1941, J GEN PHYSIOL, V24, P735, DOI 10.1085/jgp.24.6.735
   HANLEY JA, 1983, RADIOLOGY, V148, P839, DOI 10.1148/radiology.148.3.6878708
   HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747
   Hecht S, 1937, J GEN PHYSIOL, V20, P831, DOI 10.1085/jgp.20.6.831
   HOLLINS M, 1973, J GEN PHYSIOL, V62, P430, DOI 10.1085/jgp.62.4.430
   Jackson GR, 1999, VISION RES, V39, P3975, DOI 10.1016/S0042-6989(99)00092-9
   Mahroo OAR, 2004, J PHYSIOL-LONDON, V554, P417, DOI 10.1113/jphysiol.2003.051250
   Mahroo OAR, 2012, DOC OPHTHALMOL, V125, P137, DOI 10.1007/s10633-012-9344-z
   MAYER MJ, 1992, INVEST OPHTH VIS SCI, V33, P3150
   MAYER MJ, 1992, INVEST OPHTH VIS SCI, V33, P3136
   MAYER MJ, 1992, INVEST OPHTH VIS SCI, V33, P3143
   McGwin G, 1999, BEHAV RES METH INS C, V31, P712, DOI 10.3758/BF03200752
   MCMURDO MET, 1991, GERONTOLOGY, V37, P221
   Mei M, 2007, INVEST OPHTH VIS SCI, V48, P3419, DOI 10.1167/iovs.06-0731
   Meleth AD, 2011, INVEST OPHTH VIS SCI, V52, P1119, DOI 10.1167/iovs.10-6075
   METHA AB, 1993, BEHAV RES METH INSTR, V25, P371, DOI 10.3758/BF03204528
   Midena E, 1997, INVEST OPHTH VIS SCI, V38, P469
   Minassian DC, 2011, BRIT J OPHTHALMOL, V95, P1433, DOI 10.1136/bjo.2010.195370
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   MOTE FA, 1951, J GEN PHYSIOL, V34, P657, DOI 10.1085/jgp.34.5.657
   Newsome DA, 2009, CURR EYE RES, V34, P162, DOI 10.1080/02713680802647654
   Owen CG, 2012, BRIT J OPHTHALMOL, V96, P752, DOI 10.1136/bjophthalmol-2011-301109
   Owsley C, 2001, OPHTHALMOLOGY, V108, P1196, DOI 10.1016/S0161-6420(01)00580-2
   Owsley C, 2007, OPHTHALMOLOGY, V114, P1728, DOI 10.1016/j.ophtha.2006.12.023
   Pascolini D, 2012, BRIT J OPHTHALMOL, V96, P614, DOI 10.1136/bjophthalmol-2011-300539
   Paupoo AAV, 2000, J PHYSIOL-LONDON, V529, P469, DOI 10.1111/j.1469-7793.2000.00469.x
   Phipps JA, 2003, INVEST OPHTH VIS SCI, V44, P2277, DOI 10.1167/iovs.02-0769
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rohrschneider K, 2008, PROG RETIN EYE RES, V27, P536, DOI 10.1016/j.preteyeres.2008.07.003
   Sabour-Pickett S, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/268438
   SANDBERG MA, 1995, RETINA-J RET VIT DIS, V15, P407, DOI 10.1097/00006982-199515050-00006
   Thomas MM, 1999, J PHYSIOL-LONDON, V518, P479, DOI 10.1111/j.1469-7793.1999.0479p.x
   UN, 2009, POP PROSP 2008 REV
   Wald G, 1937, J GEN PHYSIOL, V21, P93, DOI 10.1085/jgp.21.1.93
   Winsor CP, 1936, P NATL ACAD SCI USA, V22, P400, DOI 10.1073/pnas.22.6.400
   WOLF E, 1954, J OPT SOC AM, V44, P875, DOI 10.1364/JOSA.44.000875
NR 46
TC 10
Z9 11
U1 0
U2 20
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0012-4486
EI 1573-2622
J9 DOC OPHTHALMOL
JI Doc. Ophthalmol.
PD DEC
PY 2013
VL 127
IS 3
BP 191
EP 199
DI 10.1007/s10633-013-9400-3
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 244KW
UT WOS:000326388200002
PM 23860602
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Nguyen, QD
   Shah, SM
   Hafiz, G
   Do, DV
   Haller, JA
   Pili, R
   Zimmer-Galler, IE
   Janjua, K
   Symons, RCA
   Campochiaro, PA
AF Nguyen, Quan Dong
   Shah, Syed Mahmood
   Hafiz, Gulnar
   Do, Diana V.
   Haller, Julia A.
   Pili, Roberto
   Zimmer-Galler, Ingrid E.
   Janjua, Kashif
   Symons, R. C. Andrew
   Campochiaro, Peter A.
TI Intravenous bevacizumab causes regression of choroidal
   neovascularization secondary to diseases other than age-related macular
   degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID INTRAVITREAL BEVACIZUMAB; GROWTH-FACTOR; RANIBIZUMAB; MEMBRANES; AVASTIN
AB PURPOSE: To investigate the safety, tolerability, and bioactivity of intravenous infusions of bevacizumab in patients with choroidal neovascularization (CNV) attributable to causes other than age-related macular degeneration.
   DESIGN: Nonrandomized clinical trial.
   METHODS: Ten patients with CNV received infusions of 5 mg/kg of bevacizumab. The primary efficacy outcome measure was change in visual acuity (VA; Early Treatment Diabetic Retinopathy Study letters read at 4 meters) at 24 weeks and secondary measures were changes from baseline in excess foveal thickness (center subfield thickness), area of fluorescein leakage, and area of CNV.
   RESULTS: Infusions were well tolerated and there were no ocular or systemic adverse events. At baseline, median VA was 25.5 letters read at 4 meters (20/80) and median foveal thickness was 346 mu m. At the primary endpoint (24 weeks), median VA was 48.5 letters (20/32), representing four lines of improvement. from baseline (P = .005), median foveal thickness was 248 mu m representing a 72% reduction in excess foveal thickness (P = .007). Four of nine patients had complete elimination of fluorescein leakage, three had near complete elimination (reductions of 91%, 88%, and 87%), two had modest reductions, and one had no reduction. All patients except one showed a reduction in area of CNV with a median reduction of 43%.
   CONCLUSIONS: Despite the small number of patients studied, the marked improvement in VA accompanied by prominent reductions in foveal thickness, fluorescein leakage, and area of CNV suggest a beneficial effect. It may be worthwhile to consider further evaluation of systemic bevacizumab in young, patients with CNV.
C1 [Nguyen, Quan Dong; Shah, Syed Mahmood; Hafiz, Gulnar; Do, Diana V.; Haller, Julia A.; Zimmer-Galler, Ingrid E.; Janjua, Kashif; Symons, R. C. Andrew; Campochiaro, Peter A.] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Dept Ophthalmol, Baltimore, MD 21287 USA.
   [Pili, Roberto] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Dept Oncol, Baltimore, MD 21287 USA.
   [Campochiaro, Peter A.] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Dept Neurosci, Baltimore, MD 21287 USA.
C3 Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins
   University; Johns Hopkins Medicine; Johns Hopkins University; Johns
   Hopkins Medicine
RP Campochiaro, PA (通讯作者)，Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Dept Ophthalmol, Maumenee 719,600 N Wolfe St, Baltimore, MD 21287 USA.
EM pcampo@jhmi.edu
RI Shah, Syed/K-2672-2018; Symons, Robert Charles Andrew/C-2040-2017
OI Symons, Robert Charles Andrew/0000-0002-8104-881X
FU NATIONAL CANCER INSTITUTE [P30CA006973] Funding Source: NIH RePORTER;
   NATIONAL EYE INSTITUTE [K23EY013552] Funding Source: NIH RePORTER; NCI
   NIH HHS [P30 CA006973] Funding Source: Medline; NEI NIH HHS [K23 EY
   13552, K23 EY013552-01, K23 EY013552] Funding Source: Medline
CR AMIN R, 1994, INVEST OPHTH VIS SCI, V35, P3178
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chan A, 2006, ARCH OPHTHALMOL-CHIC, V124, P193, DOI 10.1001/archopht.124.2.193
   Ferrara N, 2005, NATURE, V438, P967, DOI 10.1038/nature04483
   GREEN WR, 1986, OPHTHALMOLOGY, V93, P1169
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Laud K, 2006, RETINA-J RET VIT DIS, V26, P960, DOI 10.1097/01.iae.0000240121.28034.c3
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Moshfeghi AA, 2006, OPHTHALMOLOGY, V113, P2002, DOI 10.1016/j.ophtha.2006.05.070
   Mousa SA, 1999, J CELL BIOCHEM, V74, P135, DOI 10.1002/(SICI)1097-4644(19990701)74:1<135::AID-JCB15>3.0.CO;2-#
   Nguyen QD, 2005, BRIT J OPHTHALMOL, V89, P1368, DOI 10.1136/bjo.2005.066431
   Nguyen QD, 2006, OPHTHALMOLOGY, V113, P1522, DOI 10.1016/j.ophtha.2006.05.055
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sakaguchi H, 2007, BRIT J OPHTHALMOL, V91, P161, DOI 10.1136/bjo.2006.099887
   Shah SM, 2006, INVEST OPHTH VIS SCI, V47, P5460, DOI 10.1167/iovs.06-0012
   Teixeira A, 2006, ACTA OPHTHALMOL SCAN, V84, P835, DOI 10.1111/j.1600-0420.2006.00762.x
   Tewari A, 2006, RETINA-J RET VIT DIS, V26, P1093, DOI 10.1097/01.iae.0000254896.78766.74
   Yamamoto I, 2007, BRIT J OPHTHALMOL, V91, P157, DOI 10.1136/bjo.2006.096776
NR 18
TC 24
Z9 26
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD FEB
PY 2008
VL 145
IS 2
BP 257
EP 266
DI 10.1016/j.ajo.2007.09.025
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 263GG
UT WOS:000253205000013
PM 18054887
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Kubicka-Trzaska, A
   Wilanska, J
   Romanowska-Dixon, B
   Sanak, M
AF Kubicka-Trzaska, Agnieszka
   Wilanska, Joanna
   Romanowska-Dixon, Bozena
   Sanak, Marek
TI Circulating anti-retinal antibodies in response to anti-angiogenic
   therapy in exudative age-related macular degeneration
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration; anti-retinal autoantibodies;
   anti-vascular endothelial growth factor therapy; bevacizumab
ID NATURAL AUTOANTIBODIES; ANTIRETINAL ANTIBODIES; PATHOGENESIS;
   AUTOIMMUNITY; MECHANISMS; DISEASE; DRUSEN; EYE
AB PurposeTo determine changes in anti-retinal antibodies (ARAs) during anti-VEGF therapy in patients with exudative age-related macular degeneration (AMD) and to assess the correlations between ARAs and disease activity.
   MethodsThe study comprised 98 patients treated with intravitreal bevacizumab. The ophthalmic examination included best corrected visual acuity (BCVA), slit lamp biomicroscopy, fundoscopy, fluorescein angiography (FA), and optical coherence tomography (OCT). Serum ARAs levels were assessed by indirect immunofluorescence (IIF) on normal monkey retina substrate. These studies were repeated at 4week intervals within 8months of a follow-up. The sera of 50 sex- and age-matched healthy subjects were used as controls.
   ResultsAt baseline examination, 94 (95.5%) of the 98 patients were positive for ARAs. The ARAs titres were significantly higher (p=0.0000) than in controls. A positive correlation was found between titres of ARAs and the diameter of choroidal neovascularization (CNV) as measured by FA (p=0.0000), and central retinal thickness (CRT) assessed by OCT (p=0.0000). A positive correlation was also found between the diameter of CNV, CRT and the complexity of circulating ARAs. Following treatment all patients demonstrated significant decrease in ARAs levels as well as improvement of BCVA, reduction of subretinal fluid on OCT and decreased leakage on FA.
   ConclusionChanges in serum ARAs levels occurred in parallel with clinical outcomes of anti-VEGF therapy. Treatment reduced serum levels of ARAs(,) with the greatest reduction occurring during the loading' phase. This study demonstrated that ARAs may act as a serum biomarker of the efficacy of anti-VEGF therapy.
C1 [Kubicka-Trzaska, Agnieszka; Romanowska-Dixon, Bozena] Jagiellonian Univ, Coll Med, Dept Ophthalmol & Ocular Oncol, Krakow, Poland.
   [Wilanska, Joanna; Sanak, Marek] Jagiellonian Univ, Coll Med, Div Mol Biol & Clin Genet, Krakow, Poland.
C3 Jagiellonian University; Collegium Medicum Jagiellonian University;
   Jagiellonian University; Collegium Medicum Jagiellonian University
RP Kubicka-Trzaska, A (通讯作者)，Lea Str 244-7, PL-30133 Krakow, Poland.
EM akubicka@onet.pl
RI Sanak, Marek/AAV-1628-2021
OI Sanak, Marek/0000-0001-7635-8103
FU Polish Ministry of Science and Tertiary Education [K/PBH/000052]
FX The work was supported by a grant (K/PBH/000052) from the Polish
   Ministry of Science and Tertiary Education. All authors contributed to
   the concepts expressed and the writing of this manuscript.
CR BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   CHANT SM, 1985, BRIT J OPHTHALMOL, V69, P19, DOI 10.1136/bjo.69.1.19
   Cherepanoff S, 2006, CLIN EXP OPHTHALMOL, V34, P590, DOI 10.1111/j.1442-9071.2006.01281.x
   Coutinho A, 1995, CURR OPIN IMMUNOL, V7, P812, DOI 10.1016/0952-7915(95)80053-0
   DUMONDE DC, 1985, T OPHTHAL SOC UK, V104, P232
   ELTABBAKH GH, 1995, GYNECOL ONCOL, V58, P120, DOI 10.1006/gyno.1995.1194
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   GURNE DH, 1991, OPHTHALMOLOGY, V98, P602
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Joachim SC, 2007, GRAEF ARCH CLIN EXP, V245, P619, DOI 10.1007/s00417-006-0429-9
   Karlstetter M, 2012, KLIN MONATSBL AUGENH, V229, P221, DOI 10.1055/s-0031-1282050
   KASP E, 1989, BRIT J OPHTHALMOL, V73, P722, DOI 10.1136/bjo.73.9.722
   Kubicka-Trzaska A, 2012, ACTA OPHTHALMOL, V90, pE21, DOI 10.1111/j.1755-3768.2011.02237.x
   Kubicka-Trzaska Agnieszka, 2009, Przegl Lek, V66, P944
   Kubicka-Trzaska Agnieszka, 2004, Klin Oczna, V106, P45
   Lacroix-Desmazes S, 1998, J IMMUNOL METHODS, V216, P117, DOI 10.1016/S0022-1759(98)00074-X
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Nussenblatt RB, 2007, AM J OPHTHALMOL, V144, P618, DOI 10.1016/j.ajo.2007.06.025
   Patel N, 2005, IMMUNOLOGY, V115, P422, DOI 10.1111/j.1365-2567.2005.02173.x
   PENFOLD PL, 1990, GRAEF ARCH CLIN EXP, V228, P270, DOI 10.1007/BF00920033
   Sugita S, 2009, ARCH IMMUNOL THER EX, V57, P263, DOI 10.1007/s00005-009-0030-0
   Whitcup SM, 2013, INT J INFLAM, V2013
   Yu M, 2012, INVEST OPHTH VIS SCI, V19, P7684
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zhang JS, 2010, CIRC RES, V107, P408, DOI 10.1161/CIRCRESAHA.109.210963
NR 26
TC 11
Z9 12
U1 0
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD DEC
PY 2014
VL 92
IS 8
BP e610
EP e614
DI 10.1111/aos.12435
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AU0WJ
UT WOS:000345342600003
PM 24802549
OA Bronze
DA 2022-11-30
ER

PT J
AU Li, SS
   Wang, HH
   Zhang, DW
AF Li, Shan-Shan
   Wang, Hui-Hui
   Zhang, Dawei
TI Efficacy of different nutrients in age-related macular degeneration: A
   systematic review and network meta-analysis
SO SEMINARS IN OPHTHALMOLOGY
LA English
DT Review
DE carotenoids; zinc; Age-related macular degeneration; Network
   meta-analysis
ID LUTEIN SUPPLEMENTATION; CLINICAL-TRIAL; BETA-CAROTENE; VITAMIN-E;
   OXIDATIVE STRESS; RANDOMIZED-TRIAL; VISUAL FUNCTION; ZEAXANTHIN;
   DISEASE; PLACEBO
AB Aim Age-related macular degeneration (AMD) has become a predominant global health concern. The visual function of individuals with AMD seems to improve with dietary antioxidants. We assessed the efficacy of different antioxidants (carotenoids, zinc, vitamin E, and multivitamin) on visual function and the incidence of developing late AMD. Methods We searched PubMed, EMBASE, and Cochrane Central Register of Controlled Trials for related published studies. We considered randomized controlled trials (RCTs) comparing different nutrients. The main outcomes measurements included changes in visual acuity (VA), and the rate of developing late AMD. The network meta-analysis was registered on PROSPERO (CRD42020171288). Results We identified 13 studies, including 85321 individuals randomly assigned to different nutrients or placebo groups. In the network meta-analysis, we found that there was more risk of progression to late AMD in the multivitamin group than carotenoids and vitamin E groups (RR 0.45, 95% CI 0.32 to 0.65; RR 0.56, 95% CI 0.40 to 0.79; RR 0.42, 95% CI 0.26 to 0.67). The nutrients of zinc and carotenoids (Lutein/Zeaxanthin) ranked first and second and showed better improvement in VA. The efficacy of carotenoids (beta-carotene) ranked first for delaying the progress of AMD among all of the four treatments. Conclusion Taking multivitamin supplementation may not prevent the development of late AMD. The nutrient of zinc and carotenoids (lutein/zeaxanthin) supplementation were associated with better improvement in VA. Carotenoids (beta-carotene) were the most likely to prevent the progression of late AMD.
C1 [Li, Shan-Shan; Zhang, Dawei] Capital Med Univ, Beijing Luhe Hosp, Dept Ophthalmol, Beijing 101100, Peoples R China.
   [Wang, Hui-Hui] Capital Med Univ, Beijing Chaoyang Hosp, Dept Radiol, Beijing, Peoples R China.
C3 Capital Medical University; Capital Medical University
RP Li, SS; Zhang, DW (通讯作者)，Capital Med Univ, Beijing Luhe Hosp, Dept Ophthalmol, Beijing 101100, Peoples R China.
EM shanshanli@ccmu.edu.com
FU National Natural Science Foundation of China [81870686]
FX This work was supported by the National Natural Science Foundation of
   China [81870686].
CR Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group, 1994, N Engl J Med, V330, P1029, DOI 10.1056/NEJM199404143301501
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Bartlett HE, 2007, EUR J CLIN NUTR, V61, P1121, DOI 10.1038/sj.ejcn.1602626
   Beatty S, 2013, OPHTHALMOLOGY, V120, P600, DOI 10.1016/j.ophtha.2012.08.040
   Bernstein PS, 2016, PROG RETIN EYE RES, V50, P34, DOI 10.1016/j.preteyeres.2015.10.003
   Black HS, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9030264
   Brynskov T, 2020, ACTA OPHTHALMOL, V98, P132, DOI 10.1111/aos.14183
   Buscemi S, 2018, NUTRIENTS, V10, DOI 10.3390/nu10091321
   Chaimani A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076654
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P142, DOI 10.1001/jamaophthalmol.2013.7376
   Christen WG, 1996, ANN EPIDEMIOL, V6, P60, DOI 10.1016/1047-2797(95)00094-1
   Christen WG, 2007, ARCH OPHTHALMOL-CHIC, V125, P333, DOI 10.1001/archopht.125.3.333
   Christen WG, 2012, OPHTHALMOLOGY, V119, P1642, DOI 10.1016/j.ophtha.2012.01.053
   Christen WG, 2010, OPHTHALMOLOGY, V117, P1163, DOI 10.1016/j.ophtha.2009.10.043
   CROSS CE, 1987, ANN INTERN MED, V107, P526, DOI 10.7326/0003-4819-107-4-526
   Evans J, 2008, EYE, V22, P751, DOI 10.1038/eye.2008.100
   Evans JR, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000254.pub3
   Feng LW, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0227048
   Finkel T, 2011, J CELL BIOL, V194, P7, DOI 10.1083/jcb.201102095
   Ge Y, 2020, EXPERT OPIN DRUG DEL, V17, P603, DOI 10.1080/17425247.2020.1735348
   Gopinath B, 2020, CLIN NUTR, V39, P580, DOI 10.1016/j.clnu.2019.03.009
   Higgins JPT, 2012, RES SYNTH METHODS, V3, P98, DOI 10.1002/jrsm.1044
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Hutton B, 2015, ANN INTERN MED, V162, P777, DOI 10.7326/M14-2385
   Ichiishi E, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/3458276
   Jorgensen L, 2016, SYST REV, V5, DOI 10.1186/s13643-016-0259-8
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Li SY, 2009, INVEST OPHTH VIS SCI, V50, P836, DOI 10.1167/iovs.08-2310
   Ma L, 2012, OPHTHALMOLOGY, V119, P2290, DOI 10.1016/j.ophtha.2012.06.014
   Ma L, 2012, BRIT J NUTR, V107, P350, DOI 10.1017/S0007114511004260
   Murray IJ, 2013, INVEST OPHTH VIS SCI, V54, P1781, DOI 10.1167/iovs.12-10715
   NEWSOME DA, 1988, ARCH OPHTHALMOL-CHIC, V106, P192
   Newsome DA, 2008, CURR EYE RES, V33, P591, DOI 10.1080/02713680802178437
   Piermarocchi S, 2012, EUR J OPHTHALMOL, V22, P216, DOI 10.5301/ejo.5000069
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   Rozing MP, 2020, PROG RETIN EYE RES, V76, DOI 10.1016/j.preteyeres.2019.100825
   Salanti G, 2008, STAT METHODS MED RES, V17, P279, DOI 10.1177/0962280207080643
   Salanti G, 2012, RES SYNTH METHODS, V3, P80, DOI 10.1002/jrsm.1037
   Salanti G, 2011, J CLIN EPIDEMIOL, V64, P163, DOI 10.1016/j.jclinepi.2010.03.016
   Shaw PX, 2016, AIMS MOL SCI, V3, P196, DOI 10.3934/molsci.2016.2.196
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Taylor HR, 2002, BMJ-BRIT MED J, V325, P11, DOI 10.1136/bmj.325.7354.11
   Teikari JM, 1998, ACTA OPHTHALMOL SCAN, V76, P68, DOI 10.1034/j.1600-0420.1998.760112.x
   Weigert G, 2011, INVEST OPHTH VIS SCI, V52, P8174, DOI 10.1167/iovs.11-7522
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu MF, 2019, INT J NANOMED, V14, P2667, DOI 10.2147/IJN.S194068
   Zhang PC, 2017, ASIA PAC J CLIN NUTR, V26, P406, DOI 10.6133/apjcn.032016.13
NR 47
TC 0
Z9 0
U1 2
U2 2
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0882-0538
EI 1744-5205
J9 SEMIN OPHTHALMOL
JI Semin. Ophthalmol.
PD MAY 19
PY 2022
VL 37
IS 4
BP 515
EP 523
DI 10.1080/08820538.2021.2022165
EA JAN 2022
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 2B5JZ
UT WOS:000740081200001
PM 34995151
DA 2022-11-30
ER

PT J
AU Kaneko, H
   Takashi, N
   Matsunaga, M
   Ito, Y
   Takeuchi, J
   Terasaki, H
   Yatsuya, H
   Nishiguchi, KM
AF Kaneko, Hiroki
   Takashi, Noriko
   Matsunaga, Masaaki
   Ito, Yasuki
   Takeuchi, Jun
   Terasaki, Hiroko
   Yatsuya, Hiroshi
   Nishiguchi, Koji M.
TI Seasonal variation in submacular hemorrhages in retinal macroaneurysms
   and its disappearance in age-related macular degeneration
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Submacular hemorrhages (SMHs); Age-related macular degeneration (AMD);
   Retinal arterial macroaneurysm (RMA); Seasonal variation
ID RISK-FACTORS; SUNLIGHT; MACULOPATHY; MANAGEMENT
AB Purpose To investigate whether previously reported seasonal variation and winter-dominant prevalence of acute massive submacular hemorrhages (SMHs) caused by age-related macular degeneration (AMD) disappeared, and those caused by retinal microaneurysms (RMAs) emerged. Method The medical charts of 95 patients (95 eyes) with SMH caused by AMD and 76 patients (76 eyes) with SMH caused by RMAs in 2012-2019 were retrospectively reviewed. For each subject, the month of onset, the mean ambient temperature of that month were recorded. Results The monthly numbers of cases of SMHs caused by AMD from January to December were 6, 8, 4, 9, 7, 10, 9, 11, 7, 11, 3, and 10. No significant seasonal variation in the monthly incidence was identified (Roger's R = 1.89, p = 0.39). The monthly numbers of SMHs caused by RMAs from January to December were 3, 11, 11, 8, 7, 8, 5, 5, 2, 4, 7, and 5. There was significant seasonal variation in the monthly incidence (Roger's R = 7.67, p = 0.02). There was no significant correlation between the monthly incidence of SMHs caused by RMAs and mean ambient temperature. Conclusion Our previous study conducted for cases obtained in 1998-2005 showed seasonal cyclic trend in the number of SMHs caused by AMD, with the peak in winter. However, that significant seasonal variation disappeared in 2012-2019 in the present study. Common usage of OCT devices and anti-VEGF drugs might be the reason for the lack of seasonal variation in the cases of SMH caused by AMD.
C1 [Kaneko, Hiroki; Takashi, Noriko; Ito, Yasuki; Takeuchi, Jun; Terasaki, Hiroko; Nishiguchi, Koji M.] Nagoya Univ, Grad Sch Med, Dept Ophthalmol, Nagoya, Aichi, Japan.
   [Matsunaga, Masaaki; Yatsuya, Hiroshi] Fujita Hlth Univ, Sch Med, Dept Publ Hlth, Toyoake, Aichi, Japan.
   [Ito, Yasuki] Fujita Hlth Univ, Sch Med, Dept Ophthalmol, Toyoake, Aichi, Japan.
   [Terasaki, Hiroko] Nagoya Univ, Inst Innovat Future Soc, Nagoya, Aichi, Japan.
   [Yatsuya, Hiroshi] Nagoya Univ, Grad Sch Med, Dept Publ Hlth & Hlth Syst, Nagoya, Aichi, Japan.
C3 Nagoya University; Fujita Health University; Fujita Health University;
   Nagoya University; Nagoya University
RP Kaneko, H (通讯作者)，Nagoya Univ, Grad Sch Med, Dept Ophthalmol, Nagoya, Aichi, Japan.
EM h-kaneko@med.nagoya-u.ac.jp
RI Kaneko, Hiroki/AHA-2461-2022
OI Kaneko, Hiroki/0000-0003-0731-6465
FU JSPS KAKENHI [19K09988]; Eye Research Foundation for the Aged (ERFA);
   Charitable Trust Fund for Ophthalmic Research in Commemoration of Santen
   Pharmaceutical; Bayer Retina Award Foundation; Ichihara International
   Scholarship Foundation; Aichi Health Promotion Foundation
FX This work was partially supported by Grants-in-Aid for Scientific
   Research (C) (H.K., 19K09988) from JSPS KAKENHI
   (http://www.jsps.go.jp/), the Eye Research Foundation for the Aged
   (ERFA, H.K.), Charitable Trust Fund for Ophthalmic Research in
   Commemoration of Santen Pharmaceutical's Founder (H.K.), Bayer Retina
   Award Foundation (H.K.), Ichihara International Scholarship Foundation
   (H.K.), and Aichi Health Promotion Foundation (H.K.).
CR Berrocal MH, 1996, AM J OPHTHALMOL, V122, P486, DOI 10.1016/S0002-9394(14)72107-5
   BRENNAN PJ, 1982, BMJ-BRIT MED J, V285, P919, DOI 10.1136/bmj.285.6346.919
   Brockmann C, 2013, EYE, V27, P1169, DOI 10.1038/eye.2013.159
   Castillo MM, 2015, OPHTHALMOLOGY, V122, P399, DOI 10.1016/j.ophtha.2014.07.055
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Cruickshanks KJ, 2001, ARCH OPHTHALMOL-CHIC, V119, P246
   Fukuda H, 2020, J NEUROSURG, V133, P374, DOI 10.3171/2019.4.JNS19175
   HABERMAN S, 1981, J NEUROL SCI, V52, P25, DOI 10.1016/0022-510X(81)90131-3
   Hozawa A, 2011, CLIN EXP HYPERTENS, V33, P153, DOI 10.3109/10641963.2010.531841
   Humayun M, 1998, AM J OPHTHALMOL, V126, P358, DOI 10.1016/S0002-9394(98)00090-7
   IBANEZ HE, 1995, ARCH OPHTHALMOL-CHIC, V113, P62, DOI 10.1001/archopht.1995.01100010064022
   Iguchi Y, 2006, BRIT J OPHTHALMOL, V90, P1256, DOI 10.1136/bjo.2006.099259
   Kim Kun Hae, 2015, Korean J Ophthalmol, V29, P315, DOI 10.3341/kjo.2015.29.5.315
   Nam JM, 1996, BIOMETRICAL J, V38, P661, DOI 10.1002/bimj.4710380604
   PANTON RW, 1990, BRIT J OPHTHALMOL, V74, P595, DOI 10.1136/bjo.74.10.595
   RABB MF, 1988, SURV OPHTHALMOL, V33, P73, DOI 10.1016/0039-6257(88)90160-9
   Robertson, 1973, T AM ACAD OPHTHALMOL, V77, P55
   SHINKAWA A, 1990, STROKE, V21, P1262, DOI 10.1161/01.STR.21.9.1262
   Smith RA, 2008, ANN ROY COLL SURG, V90, P389, DOI 10.1308/003588408X285892
   Stanescu-Segall D, 2016, SURV OPHTHALMOL, V61, P18, DOI 10.1016/j.survophthal.2015.04.004
   Tomany SC, 2004, ARCH OPHTHALMOL-CHIC, V122, P750, DOI 10.1001/archopht.122.5.750
NR 21
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD DEC
PY 2021
VL 259
IS 12
BP 3589
EP 3596
DI 10.1007/s00417-021-05280-3
EA JUN 2021
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA WW6CP
UT WOS:000664831900002
PM 34164725
DA 2022-11-30
ER

PT J
AU Tsai, DC
   Chen, HC
   Leu, HB
   Chen, SJ
   Hsu, NW
   Huang, CC
   Chen, JW
   Lin, SJ
   Chou, P
AF Tsai, Der-Chong
   Chen, Hsi-Chung
   Leu, Hsin-Bang
   Chen, Shih-Jen
   Hsu, Nai-Wei
   Huang, Chin-Chou
   Chen, Jaw-Wen
   Lin, Shing-Jong
   Chou, Pesus
TI The association between clinically diagnosed insomnia and age-related
   macular degeneration: a population-based cohort study
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration; cohort study; insomnia; risk factor
ID C-REACTIVE PROTEIN; CATARACT-SURGERY; SERUM MELATONIN; SLEEP DURATION;
   RISK; METAANALYSIS; TAIWAN; LEVEL; CELLS
AB Purpose The decreased level of melatonin, the substance involved in the control of the sleep-wake cycle, has been reported among the patients with age-related macular degeneration (AMD). However, knowledge about the relationship between sleep disturbance and AMD is still limited. This longitudinal case-control study aims to investigate the risk of incident AMD among the patients with clinically diagnosed insomnia using the Taiwan National Health Insurance Research Database. Methods The insomnia cohort (n = 15 465) consisted of newly diagnosed insomnia cases aged >= 55 years between 2000 and 2009. Subjects without insomnia, matched for age, gender and enrolment time, were randomly sampled as the control cohort (n = 92 790). Cox proportional hazard regressions were performed to calculate the hazard ratios (HR) of incident AMD for the two cohorts after adjusting for potential confounders. Results Of the 108 255 sampled subjects, 2094 (1.9%) were diagnosed with AMD, including 214 (0.2%) with neovascular AMD, during a mean follow-up period of 5.1 +/- 2.8 years. Insomnia patients were more likely to have subsequent AMD than those without insomnia (2.5% versus 1.8%, p < 0.001). Further, the incidence of exudative AMD was also higher in the insomnia cohort than the control cohort (0.3% versus 0.2%, p = 0.002). The adjusted HR was 1.33 (95% confidence interval [CI], 1.18-1.48, p < 0.001) for AMD and 1.67 (95% CI, 1.20-2.33, p = 0.002) for exudative AMD. Conclusions Clinically diagnosed insomnia is an independent indicator for the increased risk of subsequent AMD development.
C1 [Tsai, Der-Chong] Natl Yang Ming Univ Hosp, Dept Ophthalmol, 169 Xiaoshe Rd, Yilan 26058, Taiwan.
   [Tsai, Der-Chong; Leu, Hsin-Bang; Chen, Shih-Jen; Hsu, Nai-Wei; Huang, Chin-Chou; Chen, Jaw-Wen; Lin, Shing-Jong; Chou, Pesus] Natl Yang Ming Univ, Sch Med, Taipei, Taiwan.
   [Tsai, Der-Chong; Chen, Hsi-Chung; Hsu, Nai-Wei; Chou, Pesus] Natl Yang Ming Univ, Community Med Res Ctr, Taipei, Taiwan.
   [Tsai, Der-Chong; Chen, Hsi-Chung; Hsu, Nai-Wei; Chou, Pesus] Natl Yang Ming Univ, Inst Publ Hlth, Taipei, Taiwan.
   [Chen, Hsi-Chung] Natl Taiwan Univ Hosp, Dept Psychiat, Taipei, Taiwan.
   [Chen, Hsi-Chung] Natl Taiwan Univ Hosp, Ctr Sleep Disorders, Taipei, Taiwan.
   [Leu, Hsin-Bang; Huang, Chin-Chou; Chen, Jaw-Wen; Lin, Shing-Jong] Natl Yang Ming Univ, Cardiovasc Res Ctr, Taipei, Taiwan.
   [Leu, Hsin-Bang; Huang, Chin-Chou; Chen, Jaw-Wen; Lin, Shing-Jong] Taipei Vet Gen Hosp, Dept Med, Div Cardiol, Taipei, Taiwan.
   [Leu, Hsin-Bang; Lin, Shing-Jong] Taipei Vet Gen Hosp, Healthcare & Management Ctr, Taipei, Taiwan.
   [Chen, Shih-Jen] Taipei Vet Gen Hosp, Dept Ophthalmol, Taipei, Taiwan.
   [Hsu, Nai-Wei] Natl Yang Ming Univ Hosp, Dept Internal Med, Yilan, Taiwan.
   [Hsu, Nai-Wei] Publ Hlth Bur Yilan Cty, Yilan, Taiwan.
   [Huang, Chin-Chou; Chen, Jaw-Wen; Lin, Shing-Jong] Natl Yang Ming Univ, Inst Pharmacol, Taipei, Taiwan.
   [Huang, Chin-Chou] Taipei Vet Gen Hosp, Dept Med Educ, Taipei, Taiwan.
   [Chen, Jaw-Wen] Taipei Vet Gen Hosp, Dept Med Res, Taipei, Taiwan.
C3 National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung
   University; National Yang Ming Chiao Tung University; National Taiwan
   University; National Taiwan University Hospital; National Taiwan
   University; National Taiwan University Hospital; National Yang Ming
   Chiao Tung University; Taipei Veterans General Hospital; Taipei Veterans
   General Hospital; Taipei Veterans General Hospital; National Yang Ming
   Chiao Tung University; Taipei Veterans General Hospital; Taipei Veterans
   General Hospital
RP Tsai, DC (通讯作者)，Natl Yang Ming Univ Hosp, Dept Ophthalmol, 169 Xiaoshe Rd, Yilan 26058, Taiwan.
EM 11803@ymuh.ym.edu.tw
RI Chen, Hsi-Chung/E-9949-2017
OI Chen, Hsi-Chung/0000-0003-3191-0093
FU National Yang-Ming University Hospital, Yilan
FX A research grant for the current study was provided by National
   Yang-Ming University Hospital, Yilan. The funding organization had no
   role in the design or conduct of this research. No conflict of interest
   exists for any author. The material of this manuscript has been
   presented as poster at the American Society of Retinal Specialists
   Annual Meeting, 2018 in Vancouver, BC, Canada.
CR Acuna-Castroviejo D, 2014, CELL MOL LIFE SCI, V71, P2997, DOI 10.1007/s00018-014-1579-2
   Brondsted AE, 2015, OPHTHALMOLOGY, V122, P2115, DOI 10.1016/j.ophtha.2015.06.033
   Rodriguez JC, 2015, MED CLIN N AM, V99, P431, DOI 10.1016/j.mcna.2014.11.013
   Chellappa SL, 2019, JAMA OPHTHALMOL, V137, P878, DOI 10.1001/jamaophthalmol.2019.1406
   Chen SJ, 2008, INVEST OPHTH VIS SCI, V49, P3126, DOI 10.1167/iovs.08-1803
   Crooke A, 2017, J PINEAL RES, V63, DOI 10.1111/jpi.12430
   Czuczejko J, 2019, FREE RADICAL RES, V16, P1
   Donoso LA, 2010, SURV OPHTHALMOL, V55, P227, DOI 10.1016/j.survophthal.2009.11.001
   Galano A, 2018, J PINEAL RES, V65, DOI 10.1111/jpi.12514
   Haas P, 2015, ACTA OPHTHALMOL, V93, P533, DOI 10.1111/aos.12670
   Hardeland R, 2013, J PINEAL RES, V55, P325, DOI 10.1111/jpi.12090
   Honda S, 2001, INVEST OPHTH VIS SCI, V42, P2139
   Hong T, 2011, SURV OPHTHALMOL, V56, P184, DOI 10.1016/j.survophthal.2010.08.007
   IGUCHI H, 1982, J CLIN ENDOCR METAB, V55, P27, DOI 10.1210/jcem-55-1-27
   Irwin MR, 2015, ANNU REV PSYCHOL, V66, P143, DOI 10.1146/annurev-psych-010213-115205
   Javaheri S, 2017, CHEST, V152, P435, DOI 10.1016/j.chest.2017.01.026
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Kessel L, 2015, ACTA OPHTHALMOL, V93, P593, DOI 10.1111/aos.12665
   Khurana RN, 2016, RETINA-J RET VIT DIS, V36, P255, DOI 10.1097/IAE.0000000000000706
   Li M, 2014, INT J CARDIOL, V176, P1044, DOI 10.1016/j.ijcard.2014.07.284
   Liang FQ, 2004, EXP EYE RES, V78, P1069, DOI 10.1016/j.exer.2004.02.003
   Lin L, 2013, INT J MOL SCI, V14, P14575, DOI 10.3390/ijms140714575
   Liu L, 2003, J BIOL CHEM, V278, P31998, DOI 10.1074/jbc.M303553200
   Liukkonen T, 2007, PSYCHOSOM MED, V69, P756, DOI 10.1097/PSY.0b013e318157cb96
   Lv XD, 2016, EUR REV MED PHARMACO, V20, P4196
   Marchiafava PL, 1999, J PINEAL RES, V26, P184, DOI 10.1111/j.1600-079X.1999.tb00582.x
   Maynard ML, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-20659
   Meier-Ewert HK, 2004, J AM COLL CARDIOL, V43, P678, DOI 10.1016/j.jacc.2003.07.050
   Mitta VP, 2013, JAMA OPHTHALMOL, V131, P507, DOI 10.1001/jamaophthalmol.2013.2303
   Nowakowski S, 2018, SLEEP, V41, DOI 10.1093/sleep/zsy049
   Ohayon MM, 2002, SLEEP MED REV, V6, P97, DOI 10.1053/smrv.2002.0186
   Pandi-Perumal SR, 2017, J CARDIOVASC PHARM T, V22, P122, DOI 10.1177/1074248416660622
   Parthasarathy S, 2015, AM J MED, V128, P268, DOI 10.1016/j.amjmed.2014.10.015
   Perez-Canales JL, 2016, OPHTHAL EPIDEMIOL, V23, P20, DOI 10.3109/09286586.2015.1119288
   Permpoonputtana K, 2018, EXCLI J, V17, P634, DOI 10.17179/excli2017-654
   Rosen R, 2009, MOL VIS, V15, P1673
   Seagle BLL, 2005, P NATL ACAD SCI USA, V102, P8978, DOI 10.1073/pnas.0501971102
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Subhi Y, 2019, ACTA OPHTHALMOL, V97, P99, DOI 10.1111/aos.13886
   Tsai DC, 2015, OPHTHALMOLOGY, V122, P2327, DOI 10.1016/j.ophtha.2015.07.033
NR 40
TC 3
Z9 4
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD MAR
PY 2020
VL 98
IS 2
BP E238
EP E244
DI 10.1111/aos.14238
EA SEP 2019
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA KS3BI
UT WOS:000485558700001
PM 31496121
DA 2022-11-30
ER

PT J
AU Ebneter, A
   Jaggi, D
   Abegg, M
   Wolf, S
   Zinkernagel, MS
AF Ebneter, Andreas
   Jaggi, Damian
   Abegg, Mathias
   Wolf, Sebastian
   Zinkernagel, Martin S.
TI Relationship Between Presumptive Inner Nuclear Layer Thickness and
   Geographic Atrophy Progression in Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE geographic atrophy; retinal segmentation; optical coherence tomography;
   autofluorescence; disease progression
ID OPTICAL COHERENCE TOMOGRAPHY; FUNDUS AUTOFLUORESCENCE; FLICKER
   PERIMETRY; MULLER CELLS; SEGMENTATION; MACULOPATHY; PREVALENCE;
   PREDICTORS; SECONDARY; RETINA
AB PURPOSE. To analyze inner retinal changes in patients with geographic atrophy (GA) secondary to age-related macular degeneration and identify morphological cues for progression.
   METHODS. A total of 100 eyes with GA were assessed in this longitudinal, observational case series. Patients with GA and absent confounding pathology were compared with age-matched controls. The retinal layers on spectral-domain optical coherence tomography, acquired in tracking mode, were segmented manually on central scans through the fixation point. Zones of GA were defined based on choroidal signal enhancement from retinal pigment epithelium loss. An area of unaffected temporal retina was used for comparison. Progression of GA was quantified with fundus autofluorescence.
   RESULTS. We analyzed 41 eyes of 41 patients (mean age 79.2 +/- 6.7 years). In areas of GA, the layer representing the inner nuclear layer (INL) in healthy retina was increased in thickness. Thickness of this presumptive INL was inversely correlated with best-corrected visual acuity (r = -0.48, P < 0.01). The presumptive INL thickness increase in atrophic areas was less marked in eyes with foveal sparing. Increased INL thickness in areas adjacent to GA was associated with a higher progression rate.
   CONCLUSIONS. Optical coherence tomography findings demonstrate that atrophy of the retinal pigment epithelium-photoreceptor complex in GA is associated with an increase of thickness of the presumptive INL, presumably caused by remodeling of the degenerating retina. Similar alterations in the retina adjacent to areas clinically affected by GA were associated with higher atrophy progression rates.
C1 [Ebneter, Andreas; Jaggi, Damian; Abegg, Mathias; Wolf, Sebastian; Zinkernagel, Martin S.] Univ Bern, Univ Hosp Bern, Inselspital, Dept Ophthalmol, Bern, Switzerland.
   [Ebneter, Andreas; Zinkernagel, Martin S.] Univ Bern, Univ Hosp Bern, Inselspital, Dept Clin Res, Bern, Switzerland.
   [Wolf, Sebastian] Univ Bern, Bern Photog Reading Ctr, Bern, Switzerland.
C3 University of Bern; University Hospital of Bern; University of Bern;
   University Hospital of Bern; University of Bern
RP Ebneter, A (通讯作者)，Univ Klin Augenheilkunde, Inselspital, CH-3010 Bern, Switzerland.
EM ebneter.andreas@gmail.com
RI Zinkernagel, Martin/C-3799-2017; Ebneter, Andreas/C-5226-2017; Mitchell,
   Paul/P-1498-2014; Wolf, Sebastian/B-8782-2008
OI Zinkernagel, Martin/0000-0002-5622-114X; Ebneter,
   Andreas/0000-0001-6666-2558; Wolf, Sebastian/0000-0002-7467-7028;
   Zinkernagel, Martin S./0000-0003-3447-2359
FU Swiss National Science Foundation [320030_156019]; Stiftung zugunsten
   von Wahrnehmungsbehinderten, St. Gallen, Switzerland; Foundation OPOS
FX Supported by the Swiss National Science Foundation (MSZ; grant
   320030_156019) and by Foundation OPOS, Stiftung zugunsten von
   Wahrnehmungsbehinderten, St. Gallen, Switzerland (AE, MSZ).
CR Abdelfattah NS, DRY AMD PROGR WET AM
   Bearelly S, 2009, OPHTHALMOLOGY, V116, P1762, DOI 10.1016/j.ophtha.2009.04.015
   Biarnes M, 2015, AM J OPHTHALMOL, V160, P345, DOI 10.1016/j.ajo.2015.05.009
   Bird AC, 2014, JAMA OPHTHALMOL, V132, P338, DOI 10.1001/jamaophthalmol.2013.5799
   Bringmann A, 2000, GLIA, V29, P35, DOI 10.1002/(SICI)1098-1136(20000101)29:1<35::AID-GLIA4>3.0.CO;2-A
   Bringmann A, 2006, PROG RETIN EYE RES, V25, P397, DOI 10.1016/j.preteyeres.2006.05.003
   Domalpally A, 2013, OPHTHALMOLOGY, V120, P2666, DOI 10.1016/j.ophtha.2013.07.047
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0
   Fleckenstein M, 2008, INVEST OPHTH VIS SCI, V49, P4137, DOI 10.1167/iovs.08-1967
   Fleckenstein M, 2011, INVEST OPHTH VIS SCI, V52, P3761, DOI 10.1167/iovs.10-7021
   Fleckenstein M, 2010, INVEST OPHTH VIS SCI, V51, P3846, DOI 10.1167/iovs.09-4533
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Grassmann F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126636
   Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010
   Ho AC, 2014, OPHTHALMOLOGY, V121, P2181, DOI 10.1016/j.ophtha.2014.05.009
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   Jackson GR, 2002, AGEING RES REV, V1, P381, DOI 10.1016/S1568-1637(02)00007-7
   Jaffe GJ, 2015, AM J OPHTHALMOL, V160, P1226, DOI 10.1016/j.ajo.2015.08.024
   Jeong YJ, 2014, EYE, V28, P209, DOI 10.1038/eye.2013.275
   Jones BW, EXP EYE RES IN PRESS
   Lindner M, 2015, OPHTHALMOLOGY, V122, P1356, DOI 10.1016/j.ophtha.2015.03.027
   Luu CD, 2012, ARCH OPHTHALMOL-CHIC, V130, P690, DOI 10.1001/archophthalmol.2012.277
   Marc RE, 2003, PROG RETIN EYE RES, V22, P607, DOI 10.1016/S1350-9462(03)00039-9
   Marc RE, 2008, MOL VIS, V14, P782
   Meleth AD, 2011, CURR OPIN OPHTHALMOL, V22, P190, DOI 10.1097/ICU.0b013e32834594b0
   Midena E, 2007, BRIT J OPHTHALMOL, V91, P1499, DOI 10.1136/bjo.2007.119685
   Moussa K, 2013, RETINA-J RET VIT DIS, V33, P1590, DOI 10.1097/IAE.0b013e31828d6052
   Nita M, 2014, MED SCI MONITOR, V20, P1003, DOI 10.12659/MSM.889887
   Nittala MG, 2012, INVEST OPHTH VIS SCI, V53, P8319, DOI 10.1167/iovs.12-10582
   Nunes RP, 2013, OSLI RETINA, V44, P344, DOI 10.3928/23258160-20130715-06
   Owsley C, 2007, OPHTHALMOLOGY, V114, P1728, DOI 10.1016/j.ophtha.2006.12.023
   PATZ A, 1985, ARCH OPHTHALMOL-CHIC, V103, P1796, DOI 10.1001/archopht.1985.01050120030015
   Phipps JA, 2004, INVEST OPHTH VIS SCI, V45, P3355, DOI 10.1167/iovs.04-0253
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Sayegh RG, 2011, OPHTHALMOLOGY, V118, P1844, DOI 10.1016/j.ophtha.2011.01.043
   Schmitz-Valckenberg S, 2006, INVEST OPHTH VIS SCI, V47, P2648, DOI 10.1167/iovs.05-0892
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P1, DOI 10.1167/iovs.10-5619
   Schmitz-Valckenberg S, 2009, SURV OPHTHALMOL, V54, P96, DOI 10.1016/j.survophthal.2008.10.004
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   Waldstein SM, 2015, BRIT J OPHTHALMOL, V99, P794, DOI 10.1136/bjophthalmol-2014-305573
   Wolf-Schnurrbusch UEK, 2008, INVEST OPHTH VIS SCI, V49, P3095, DOI 10.1167/iovs.07-1460
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu KHC, 2003, BRIT J OPHTHALMOL, V87, P1159, DOI 10.1136/bjo.87.9.1159
   Wykoff CC, 2015, OPHTHALMOLOGY, V122, P2514, DOI 10.1016/j.ophtha.2015.08.009
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P679, DOI 10.1016/j.ophtha.2010.08.018
NR 46
TC 13
Z9 13
U1 0
U2 6
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JUL
PY 2016
VL 57
IS 9
BP OCT299
EP OCT306
DI 10.1167/iovs.15-18865
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DW9MY
UT WOS:000383985400028
PM 27409486
OA gold, Green Submitted, Green Published
DA 2022-11-30
ER

PT J
AU Synowiec, E
   Wysokinski, D
   Zaras, M
   Kolodziejska, U
   Stoczynska-Fidelus, E
   Janik, K
   Szaflik, J
   Blasiak, J
   Szaflik, JP
AF Synowiec, Ewelina
   Wysokinski, Daniel
   Zaras, Malgorzata
   Kolodziejska, Urszula
   Stoczynska-Fidelus, Ewelina
   Janik, Katarzyna
   Szaflik, Jerzy
   Blasiak, Janusz
   Szaflik, Jacek P.
TI ASSOCIATION BETWEEN POLYMORPHISM OF THE DNA REPAIR SMUG1 AND UNG GENES
   AND AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; gene polymorphism; SMUG1; UNG; uracil;
   uracil-DNA glycosylases
ID BASE EXCISION-REPAIR; COMPLEMENT FACTOR-H; SINGLE NUCLEOTIDE
   POLYMORPHISMS; URACIL-PROCESSING GENES; ONE-CARBON NUTRIENTS;
   CIGARETTE-SMOKING; RISK; XRCC1; XPD; DAMAGE
AB Purpose: To investigate the association between the g.4235T > C (rs2337395) polymorphism of the UNG gene and the c.-31A > G (rs3087404) polymorphism of the SMUG1 gene and the risk of age-related macular degeneration (AMD), as well as modulation of this association by some environmental and lifestyle factors.
   Methods: Overall, 272 AMD patients and 105 control subjects were enrolled in this study. Both polymorphisms were genotyped by restriction fragment length polymorphism-polymerase chain reaction (PCR-RFLP).
   Results: The C/C genotype of the g. 4235T > C polymorphism of the UNG gene was associated with an increased risk of dry AMD (odds ratio, 2.54), whereas the T/T genotype of this polymorphism decreased such risk (odds ratio, 0.41). The presence of the T allele of the g.4235T > C polymorphism and the A allele of the c.-31A > G polymorphism of the SMUG1 gene (odds ratio, 2.17 and 2.18, respectively) was associated with an increased risk of AMD severity, expressed by the comparison of the frequencies of genotypes in the group of patients with wet AMD versus those with dry AMD. Conversely, the C/C genotype of the g. 4235T > C polymorphism, the G/G genotype of the c.-31A > G polymorphism, and the C/C-G/G combined genotype of both polymorphisms had a protective effect (odds ratio, 0.48, 0.46, and 0.18; respectively).
   Conclusion: The results obtained suggest the potential role of the g.4235T > C and the c.-31A > G polymorphisms in AMD pathogenesis.
C1 [Synowiec, Ewelina; Wysokinski, Daniel; Stoczynska-Fidelus, Ewelina; Janik, Katarzyna; Blasiak, Janusz] Univ Lodz, Dept Mol Genet, PL-90131 Lodz, Poland.
   [Zaras, Malgorzata; Kolodziejska, Urszula; Szaflik, Jerzy; Szaflik, Jacek P.] Med Univ Warsaw, Dept Ophthalmol, PL-03710 Warsaw, Poland.
   [Zaras, Malgorzata; Kolodziejska, Urszula; Szaflik, Jerzy; Szaflik, Jacek P.] Samodzielny Publ Klin Szpital Okulistyczny, Warsaw, Poland.
C3 University of Lodz; Medical University of Warsaw
RP Szaflik, JP (通讯作者)，Med Univ Warsaw, Dept Ophthalmol, Sierakowskiego 13, PL-03710 Warsaw, Poland.
EM szaflik@ophthalmology.pl
RI Javadzadeh, Alireza/L-6424-2017; Janik-Superson,
   Katarzyna/ABA-2571-2021; Stoczynska-Fidelus, Ewelina/S-9948-2016;
   Stoczynska-Fidelus, Ewelina/M-4871-2015
OI Javadzadeh, Alireza/0000-0002-5151-6125; Janik-Superson,
   Katarzyna/0000-0001-9692-7238; Szaflik, Jerzy/0000-0002-7601-1326;
   Blasiak, Janusz/0000-0001-9539-9584; Stoczynska-Fidelus,
   Ewelina/0000-0002-7779-3075; Synowiec, Ewelina/0000-0002-0730-4491
FU Polish Ministry of Science and Higher Education [N N402 248336]
FX Supported in part by grant from the Polish Ministry of Science and
   Higher Education (N N402 248336).
CR Akbari M, 2007, NEUROSCIENCE, V145, P1201, DOI 10.1016/j.neuroscience.2006.10.010
   Ames BN, 2001, MUTAT RES-FUND MOL M, V475, P7, DOI 10.1016/S0027-5107(01)00070-7
   An Q, 2005, EMBO J, V24, P2205, DOI 10.1038/sj.emboj.7600689
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Augustin AJ, 2009, EXPERT OPIN THER TAR, V13, P641, DOI 10.1517/14728220902942322
   Baas DC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013786
   Baynes JW, 2002, ANN NY ACAD SCI, V959, P360, DOI 10.1111/j.1749-6632.2002.tb02107.x
   Broderick P, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-243
   Centers for Disease Control and Prevention (CDC), WHY IS VIS LOSS PUBL
   Chanson A, 2009, AM J CLIN NUTR, V89, P1927, DOI 10.3945/ajcn.2009.27429
   Christen WG, 2009, ARCH INTERN MED, V169, P335, DOI 10.1001/archinternmed.2008.574
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Duthie SJ, 2002, J NUTR, V132, p2444S, DOI 10.1093/jn/132.8.2444S
   Endres M, 2004, J CLIN INVEST, V113, P1711, DOI 10.1172/JCI200420926
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Gabriel HE, 2006, AM J CLIN NUTR, V83, P835, DOI 10.1093/ajcn/83.4.835
   Geirsdottir A, 2007, AM J OPHTHALMOL, V143, P889, DOI 10.1016/j.ajo.2006.11.057
   Gorgun E, 2010, INVEST OPHTH VIS SCI, V51, P4732, DOI 10.1167/iovs.09-4842
   Gorin MB, 2012, MOL ASPECTS MED, V33, P467, DOI 10.1016/j.mam.2012.04.004
   Haines JL, 2006, INVEST OPHTH VIS SCI, V47, P329, DOI 10.1167/iovs.05-0116
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Ho L, 2011, ARCH OPHTHALMOL-CHIC, V129, P758, DOI 10.1001/archophthalmol.2011.141
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Katta S, 2009, J GENET, V88, P425, DOI 10.1007/s12041-009-0064-4
   Kavli B, 2005, J EXP MED, V201, P2011, DOI 10.1084/jem.20050042
   Kavli B, 2002, J BIOL CHEM, V277, P39926, DOI 10.1074/jbc.M207107200
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1376, DOI 10.1016/j.ophtha.2007.11.015
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Khandhadia S, 2010, EXPERT REV MOL MED, V12, DOI 10.1017/S146239941000164X
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Klein BEK, 2001, AM J EPIDEMIOL, V154, P207, DOI 10.1093/aje/154.3.207
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Langaee T, 2010, CONCEPTS PHARMACOGEN, P29
   Luo YF, 2011, CURR EYE RES, V36, P632, DOI 10.3109/02713683.2011.571358
   Marian C, 2011, EUR J CLIN NUTR, V65, P683, DOI 10.1038/ejcn.2011.29
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Montezuma Sandra R, 2007, Semin Ophthalmol, V22, P229, DOI 10.1080/08820530701745140
   Nadeau JH, 2002, NATURE, V420, P517, DOI 10.1038/420517a
   National Eye Institute, 2013, FACTS AG REL MAC DEG
   Padma G, 2011, MOL VIS, V17, P127
   Patel N, 2008, EYE, V22, P768, DOI 10.1038/sj.eye.6702844
   Pettersen HS, 2007, NUCLEIC ACIDS RES, V35, P3879, DOI 10.1093/nar/gkm372
   Sacca SC, 2009, MUTAT RES-FUND MOL M, V667, P98, DOI 10.1016/j.mrfmmm.2008.11.002
   Sousa MML, 2007, MOL ASPECTS MED, V28, P276, DOI 10.1016/j.mam.2007.04.006
   Synowiec E, 2012, EXP EYE RES, V98, P58, DOI 10.1016/j.exer.2012.02.008
   Szaflik JP, 2009, MUTAT RES-FUND MOL M, V669, P169, DOI 10.1016/j.mrfmmm.2009.06.008
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Ting AYC, 2009, CURR OPIN OPHTHALMOL, V20, P369, DOI 10.1097/ICU.0b013e32832f8016
   Totan Y, 2009, CURR EYE RES, V34, P1089, DOI 10.3109/02713680903353772
   Tuo JS, 2006, P NATL ACAD SCI USA, V103, P9256, DOI 10.1073/pnas.0603485103
   Unal M, 2007, EXP EYE RES, V85, P328, DOI 10.1016/j.exer.2007.06.003
   Visnes T, 2009, PHILOS T R SOC B, V364, P563, DOI 10.1098/rstb.2008.0186
   WEITER JJ, 1986, INVEST OPHTH VIS SCI, V27, P145
   *WHO, PRIOR EYE DIS
   Yousaf S, 2011, MOL VIS, V17, P1153
   Zhang Y, 2012, OPHTHALMOLOGY, V119, P900, DOI 10.1016/j.ophtha.2011.11.004
NR 57
TC 6
Z9 6
U1 2
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JAN
PY 2014
VL 34
IS 1
BP 38
EP 47
DI 10.1097/IAE.0b013e31829477d8
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AI6CZ
UT WOS:000336958700008
PM 23714858
DA 2022-11-30
ER

PT J
AU Seddon, JM
   Santangelo, SL
   Book, K
   Chong, S
   Cote, J
AF Seddon, JM
   Santangelo, SL
   Book, K
   Chong, S
   Cote, J
TI A genomewide scan for age-related macular degeneration provides evidence
   for linkage to several chromosomal regions
SO AMERICAN JOURNAL OF HUMAN GENETICS
LA English
DT Article
ID DIETARY-FAT; FAMILIAL AGGREGATION; GENETIC ASSOCIATION; PEDIGREE
   ANALYSIS; APOLIPOPROTEIN-E; 5-YEAR INCIDENCE; DISEASE GENE; LOD SCORES;
   MACULOPATHY; RISK
AB We report the results of a genomewide scan for age-related macular degeneration (AMD) in 158 multiplex families. AMD classification was based on fundus photography and was assigned a grade ranging from 1 ( no disease) to 5 (exudative disease). Genotyping was performed by the National Heart, Lung, and Blood Institute Mammalian Genotyping Service at Marshfield (404 short tandem repeat markers). The sample included 158 families with two or more siblings with AMD, 490 affected individuals, 101 unaffected individuals, and 38 whose affection status was unknown. Relative pairs included 511 affected sibling, 28 avuncular, 53 cousin, 7 grandparent-grandchild, and 9 grand-avuncular pairs. Two-point parametric and multipoint parametric and nonparametric analyses were performed. Maximum two-point LOD scores of 1.0-2.0 were found for markers on chromosomes 1, 2, 8, 10, 14, 15, and 22. Multipoint analyses were consistent with the two-point results for chromosomes 1, 2, 8, 10, and 22 and provided evidence for additional linkage regions on chromosomes 3, 6, 8, 12, 16, and X. Our signals on chromosomes 1q, 6p, and 10q are consistent with some other previously published results. Significant linkage to AMD was found for one marker on chromosome 2, two adjacent markers on chromosome 3, two adjacent markers on chromosome 6, and seven contiguous markers on chromosome 8, with empirical P values of .00001. The consistency of many of the other signals across both two-point and multipoint, as well as parametric and nonparametric, analyses indicate several other regions worthy of follow-up.
C1 Massachusetts Eye & Ear Infirm, Ophthalmol Epidemiol Unit, Boston, MA 02114 USA.
   Harvard Univ, Sch Med, Boston, MA USA.
   Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
   Massachusetts Gen Hosp, Dept Psychiat, Psychiat & Neurodev Genet Unit, Charlestown, MA USA.
C3 Harvard University; Massachusetts Eye & Ear Infirmary; Harvard
   University; Harvard Medical School; Harvard University; Harvard T.H.
   Chan School of Public Health; Harvard University; Massachusetts General
   Hospital
RP Seddon, JM (通讯作者)，Massachusetts Eye & Ear Infirm, Epidemiol Unit, 243 Charles St, Boston, MA 02114 USA.
EM Johanna_Seddon@meei.harvard.edu
FU NEI NIH HHS [R01 EY011309, EY11309, U10 EY011309] Funding Source:
   Medline
CR Abecasis GR, 2002, NAT GENET, V30, P97, DOI 10.1038/ng786
   Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Allikmets R, 2000, AM J HUM GENET, V67, P487, DOI 10.1086/303018
   Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   Ayyagari R, 2001, Ophthalmic Genet, V22, P233, DOI 10.1076/opge.22.4.233.2219
   Boehnke M, 1997, AM J HUM GENET, V61, P423, DOI 10.1086/514862
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   CHYLACK LT, 1993, ARCH OPHTHALMOL-CHIC, V111, P831, DOI 10.1001/archopht.1993.01090060119035
   COTTINGHAM RW, 1993, AM J HUM GENET, V53, P252
   Danciger M, 2001, INVEST OPHTH VIS SCI, V42, P2458
   DeJong PTVM, 1997, AM J OPHTHALMOL, V124, P862, DOI 10.1016/S0002-9394(14)71715-5
   DelaPaz MA, 1997, INVEST OPHTH VIS SCI, V38, P1060
   Delcourt C, 1998, ARCH OPHTHALMOL-CHIC, V116, P1031, DOI 10.1001/archopht.116.8.1031
   Duren WL, 1997, AM J HUM GENET, V61, pA273
   Durner M, 1999, AM J HUM GENET, V64, P281, DOI 10.1086/302181
   Epstein MP, 2000, AM J HUM GENET, V67, P1219, DOI 10.1016/S0002-9297(07)62952-8
   Friedman E, 1997, AM J OPHTHALMOL, V124, P677, DOI 10.1016/S0002-9394(14)70906-7
   Gal A, 2000, NAT GENET, V26, P270, DOI 10.1038/81555
   Hamdi HK, 2002, BIOCHEM BIOPH RES CO, V295, P668, DOI 10.1016/S0006-291X(02)00728-3
   Hammond CJ, 2002, OPHTHALMOLOGY, V109, P730, DOI 10.1016/S0161-6420(01)01049-1
   HEIBA IM, 1994, GENET EPIDEMIOL, V11, P51, DOI 10.1002/gepi.1370110106
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Ikeda T, 2001, AM J OPHTHALMOL, V132, P191, DOI 10.1016/S0002-9394(01)00975-8
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kimura K, 2000, AM J OPHTHALMOL, V130, P769, DOI 10.1016/S0002-9394(00)00552-3
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Klein BEK, 2001, AM J EPIDEMIOL, V154, P207, DOI 10.1093/aje/154.3.207
   Klein ML, 1998, ARCH OPHTHALMOL-CHIC, V116, P1082, DOI 10.1001/archopht.116.8.1082
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Kong A, 1997, AM J HUM GENET, V61, P1179, DOI 10.1086/301592
   Kruglyak L, 1996, AM J HUM GENET, V58, P1347
   Lagali PS, 2002, BIOCHEM BIOPH RES CO, V293, P356, DOI 10.1016/S0006-291X(02)00228-0
   LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241
   LANGE K, 1988, GENET EPIDEMIOL, V5, P471, DOI 10.1002/gepi.1370050611
   Liu Q, 2002, INVEST OPHTH VIS SCI, V43, P22
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P743, DOI 10.1001/archopht.1995.01100060069034
   *NAT ADV EY COUNC, 2001, NIH PUBL
   SCHAFFER AA, 1994, HUM HERED, V44, P225, DOI 10.1159/000154222
   Schick JH, 2003, AM J HUM GENET, V72, P1412, DOI 10.1086/375500
   Seddon J, 2001, RETINA-J RET VIT DIS, P1039
   SEDDON JM, 1990, INVEST OPHTH VIS SCI, V31, P1592
   Seddon JM, 2001, OPHTHALMOLOGY, V108, P2060, DOI 10.1016/S0161-6420(01)00777-1
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Shastry BS, 1999, OPHTHALMOLOGICA, V213, P165, DOI 10.1159/000027413
   SMITH CAB, 1963, ANN HUM GENET, V27, P175, DOI 10.1111/j.1469-1809.1963.tb00210.x
   Smith W, 1996, ARCH OPHTHALMOL-CHIC, V114, P1518, DOI 10.1001/archopht.1996.01100140716016
   Sobel E, 1996, AM J HUM GENET, V58, P1323
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   SPERDUTO RD, 1986, ARCH OPHTHALMOL-CHIC, V104, P216
   Stone EM, 1999, NAT GENET, V22, P199, DOI 10.1038/9722
   VandenLangenberg GM, 1998, AM J EPIDEMIOL, V148, P204, DOI 10.1093/oxfordjournals.aje.a009625
   VIELAND VJ, 1992, GENET EPIDEMIOL, V9, P45, DOI 10.1002/gepi.1370090106
   Vingerling JR, 1996, ARCH OPHTHALMOL-CHIC, V114, P1193, DOI 10.1001/archopht.1996.01100140393005
   Weeks DE, 2000, HUM MOL GENET, V9, P1329, DOI 10.1093/hmg/9.9.1329
   WEEKS DE, 1995, AM J HUM GENET, V56, P1506
   Weeks DE, 2001, AM J OPHTHALMOL, V132, P682, DOI 10.1016/S0002-9394(01)01214-4
   White K, 2000, HUM MUTAT, V15, P301, DOI 10.1002/(SICI)1098-1004(200004)15:4<301::AID-HUMU1>3.0.CO;2-N
   WHITTEMORE AS, 1994, BIOMETRICS, V50, P118, DOI 10.2307/2533202
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   Yokota T, 1996, NEW ENGL J MED, V335, P1770, DOI 10.1056/NEJM199612053352315
   Zurdel J, 2002, BRIT J OPHTHALMOL, V86, P214, DOI 10.1136/bjo.86.2.214
NR 66
TC 163
Z9 171
U1 0
U2 4
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 0002-9297
EI 1537-6605
J9 AM J HUM GENET
JI Am. J. Hum. Genet.
PD OCT
PY 2003
VL 73
IS 4
BP 780
EP 790
DI 10.1086/378505
PG 11
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 727TL
UT WOS:000185676100006
PM 12945014
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Gelisken, F
   Ziemssen, F
   Voelker, M
   Bartz-Schmidt, KU
   Inhoffen, W
AF Gelisken, F.
   Ziemssen, F.
   Voelker, M.
   Bartz-Schmidt, K. U.
   Inhoffen, W.
TI Retinal pigment epithelial tears after single administration of
   intravitreal bevacizumab for neovascular age-related macular
   degeneration
SO EYE
LA English
DT Article
DE age-related macular degeneration; bevacizumab; choroidal
   neovascularization; complication; retinal pigment epithelial tear;
   vascular endothelial growth factor
ID OPTICAL COHERENCE TOMOGRAPHY; CHOROIDAL NEOVASCULARIZATION; PHOTODYNAMIC
   THERAPY; INJECTION; AVASTIN; SECONDARY; RANIBIZUMAB; PEGAPTANIB; RIP
AB Purpose To analyse retinal pigment epithelial (RPE) tears following single administration of intravitreal bevacizumab for neovascular age-related macular degeneration (AMD) during early follow-up.
   Methods Interventional, retrospective, non-comparative case series included 397 patients (409 eyes) of the 746 consecutive patients that met the eligibility criteria. Standardized visual acuity testing, fluorescein angiography, and optical coherence tomography were performed. Data collected included status of the fellow eye, previous treatment, subtypes of choroidal neovascularization (CNV), size and composition of the lesion. Multiple linear regression modelling was used to explore the effect of baseline parameters on the RPE tears. Primary end point was occurrence of RPE tears within 6 weeks after therapy.
   Results Fifteen of the 409 eyes (3.6%) developed RPE tear (95% confidence interval: 2.2-6.0, odds ratio: 26.3). The statistical modelling showed significant association between RPE tear and occult without classic CNV/predominantly haemorrhage vs predominantly/minimal classic CNV (P = 0.019), as well as medium or large (44 disc area) vs small size of the total lesion (P = 0.038). Previous treatment and status of the fellow eye did not statistically influence the risk of RPE tears.
   Conclusions An RPE tear can develop in up to 3.6% of eyes with neovascular AMD following single administration of intravitreal bevacizumab in a short-term follow-up. Medium and large lesion size and occult without classic and predominantly haemorrhagic subtype of CNV were important predictive factors. Preoperative assessment of the lesion characteristics may help in identifying the risk of individual patients with neovascular AMD before intravitreal bevacizumab treatment.
C1 [Gelisken, F.; Ziemssen, F.; Voelker, M.; Bartz-Schmidt, K. U.; Inhoffen, W.] Univ Tubingen, Ctr Ophthalmol, D-72076 Tubingen, BW, Germany.
C3 Eberhard Karls University of Tubingen; Eberhard Karls University
   Hospital
RP Gelisken, F (通讯作者)，Univ Tubingen, Ctr Ophthalmol, Schleichstr 12, D-72076 Tubingen, BW, Germany.
EM faik.gelisken@med.uni-tuebingen.de
RI , Ziemssen/B-9564-2009; Ziemssen, Focke/AAY-1686-2021
OI , Ziemssen/0000-0002-3873-0581; 
CR Amselem L, 2007, EYE, V21, P846, DOI 10.1038/sj.eye.6702702
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bakri SJ, 2007, EYE, V21, P424, DOI 10.1038/sj.eye.6702700
   Bashshur ZF, 2006, AM J OPHTHALMOL, V142, P1, DOI 10.1016/j.ajo.2006.02.037
   Bressler NM, 2005, RETINA-J RET VIT DIS, V25, P119
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   CASSWELL AG, 1985, BRIT J OPHTHALMOL, V69, P397, DOI 10.1136/bjo.69.6.397
   Chan CK, 2007, RETINA-J RET VIT DIS, V27, P541, DOI 10.1097/IAE.0b013e3180cc2612
   Chang LK, 2007, RETINA-J RET VIT DIS, V27, P523, DOI 10.1097/IAE.0b013e3180a032db
   CHUANG EL, 1988, BRIT J OPHTHALMOL, V72, P918, DOI 10.1136/bjo.72.12.918
   Dhalla MS, 2006, AM J OPHTHALMOL, V141, P752, DOI 10.1016/j.ajo.2005.10.053
   Gamulescu MA, 2007, GRAEF ARCH CLIN EXP, V245, P1037, DOI 10.1007/s00417-007-0551-3
   GASS JDM, 1984, AM J OPHTHALMOL, V98, P700
   Gelisken F, 2001, AM J OPHTHALMOL, V131, P518, DOI 10.1016/S0002-9394(00)00813-8
   Gelisken F, 2006, ACTA OPHTHALMOL SCAN, V84, P833, DOI 10.1111/j.1600-0420.2006.00765.x
   Goldstein M, 2005, EYE, V19, P1315, DOI 10.1038/sj.eye.6701765
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   HOSKIN A, 1981, BRIT J OPHTHALMOL, V65, P859, DOI 10.1136/bjo.65.12.859
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Luke M, 2006, BRIT J OPHTHALMOL, V90, P1178, DOI 10.1136/bjo.2006.094995
   Mathews JP, 2007, EYE, V21, P1004, DOI 10.1038/sj.eye.6702805
   Maturi RK, 2006, RETINA-J RET VIT DIS, V26, P270, DOI 10.1097/00006982-200603000-00003
   Meyer CH, 2006, BRIT J OPHTHALMOL, V90, P1207, DOI 10.1136/bjo.2006.093732
   Nicolo M, 2006, EUR J OPHTHALMOL, V16, P770, DOI 10.1177/112067210601600521
   Pauleikhoff D, 2002, GRAEF ARCH CLIN EXP, V240, P533, DOI 10.1007/s00417-002-0505-8
   Reynders S, 2002, GRAEF ARCH CLIN EXP, V240, P279, DOI 10.1007/s00417-002-0448-0
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Ronan SM, 2007, RETINA-J RET VIT DIS, V27, P535, DOI 10.1097/IAE.0b013e3180cc2645
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Scupola A, 1999, OPHTHALMOLOGICA, V213, P97, DOI 10.1159/000027400
   SHABEEBA R, 2007, BR J OPHTHALMOL, V91, P977
   Shah CP, 2006, AM J OPHTHALMOL, V142, P1070, DOI 10.1016/j.ajo.2006.07.037
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Spandau UHM, 2006, AM J OPHTHALMOL, V142, P1068, DOI 10.1016/j.ajo.2006.06.048
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
NR 39
TC 29
Z9 29
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD MAR
PY 2009
VL 23
IS 3
BP 694
EP 702
DI 10.1038/sj.eye.6703098
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 418AL
UT WOS:000264119500034
PM 18239678
OA Bronze
DA 2022-11-30
ER

PT J
AU Feigl, B
   Brown, B
   Lovie-Kitchin, J
   Swann, P
AF Feigl, B.
   Brown, B.
   Lovie-Kitchin, J.
   Swann, P.
TI Postreceptoral adaptation abnormalities in early age-related maculopathy
SO VISUAL NEUROSCIENCE
LA English
DT Article
DE macula; multifocal electroretinogram; retinal bipolar cell; adaptation;
   ischemia-hypoxia
ID MEDIATED MULTIFOCAL ELECTRORETINOGRAM; CHOROIDAL BLOOD-FLOW; RETINAL
   FUNCTION; ERG RESPONSES; EVOLUTION; COMPONENT; EYES
AB Age-related maculopathy (ARM) has become the major cause of blindness in the Western World. Currently its pathogenesis and primary site of functional damage is not fully understood but ischemia is believed to play a major role. Early detection and precise monitoring of progression of ARM are main goals of current research due to lack of sufficient treatment options, especially in the dry, atrophic form of this disease. We applied the multifocal electroretinogram (mfERG) that can detect any local functional deficit objectively in the central retina. We recorded two paradigms in early ARM patients, the fast flicker and the slow flash paradigm which both represent fast adaptation processes of the proximal retina but under differing photopic conditions and stimulation rates. By subtracting the waveform responses we extracted a late component in the difference waveform that was significantly reduced in the early ARM group compared to a healthy control group (p <= 0.05). We propose that this multifocal nonlinear analysis permits the detection of adaptative deficits and provides topographic mapping of retinal dysfunction in early ARM. The difference waveform component we extracted with this novel approach might indicate early functional loss in ARM caused by ischemia in postreceptoral layers such as bipolar cells and inner plexiform regions.
C1 Queensland Univ Technol, Inst Hlth & Biomed Innovat, Sch Optometry, Kelvin Grove, Qld 4059, Australia.
C3 Queensland University of Technology (QUT)
RP Feigl, B (通讯作者)，Queensland Univ Technol, Inst Hlth & Biomed Innovat, Sch Optometry, Victoria Pk Rd, Kelvin Grove, Qld 4059, Australia.
EM b.feigl@qut.edu.au
OI Feigl, Beatrix/0000-0001-7198-7373
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Arden GB, 2005, BRIT J OPHTHALMOL, V89, P764, DOI 10.1136/bjo.2004.062547
   BAILEY IL, 1976, AM J OPTOM PHYS OPT, V53, P740
   Bearse MA, 2004, INVEST OPHTH VIS SCI, V45, P296, DOI 10.1167/iovs.03-0424
   Bearse Marcus A. Jr., 2000, Documenta Ophthalmologica, V100, P185, DOI 10.1023/A:1002783719958
   Bird AC, 2003, CLIN EXP OPHTHALMOL, V31, P461, DOI 10.1046/j.1442-9071.2003.00721.x
   BROWN B, 1986, AM J OPTOM PHYS OPT, V63, P450
   CHEN JC, 1992, INVEST OPHTH VIS SCI, V33, P334
   Cimbalas Andrius, 2004, Medicina (Kaunas), V40, P671
   Ciulla TA, 1999, AM J OPHTHALMOL, V128, P75, DOI 10.1016/S0002-9394(99)00061-6
   Cringle SJ, 2002, INVEST OPHTH VIS SCI, V43, P1922
   Feigl B, 2005, INVEST OPHTH VIS SCI, V46, P4722, DOI 10.1167/iovs.05-0795
   Feigl B, 2004, CURR EYE RES, V29, P327, DOI 10.1080/02713680490516198
   FEIGL B, 2006, IN PRESS EYE
   Fortune B, 2002, INVEST OPHTH VIS SCI, V43, P2638
   Gerth C, 2006, ARCH OPHTHALMOL-CHIC, V124, P345, DOI 10.1001/archopht.124.3.345
   Gerth C, 2003, ARCH OPHTHALMOL-CHIC, V121, P1404, DOI 10.1001/archopht.121.10.1404
   Greenstein VC, 2004, VISION RES, V44, P2867, DOI 10.1016/j.visres.2004.06.020
   Grunwald JE, 1998, INVEST OPHTH VIS SCI, V39, P385
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Han Y, 2004, INVEST OPHTH VIS SCI, V45, P948, DOI 10.1167/iovs.03-1101
   HAYREH SS, 1990, EYE, V4, P273, DOI 10.1038/eye.1990.39
   Hood DC, 2002, INVEST OPHTH VIS SCI, V43, P1673
   Hood DC, 2000, PROG RETIN EYE RES, V19, P607, DOI 10.1016/S1350-9462(00)00013-6
   Hood DC, 1998, VISION RES, V38, P163, DOI 10.1016/S0042-6989(97)00143-0
   Kassoff A, 2001, AM J OPHTHALMOL, V131, P167
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   MASSAY S, 1990, PROGR RETINAL RES, P339
   PALMOWSKI A, 2001, OSA TECHNICAL DIGEST, P32
   Palmowski AM, 1997, INVEST OPHTH VIS SCI, V38, P2586
   PAULEIKHOFF D, 1990, AM J OPHTHALMOL, V109, P211, DOI 10.1016/S0002-9394(14)75989-6
   Pavlidis M, 2005, OPHTHALMOLOGICA, V219, P404, DOI 10.1159/000088387
   Phipps JA, 2003, INVEST OPHTH VIS SCI, V44, P2277, DOI 10.1167/iovs.02-0769
   Provis Jan M, 2005, Clin Exp Optom, V88, P269
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Strettoi E, 2002, J NEUROSCI, V22, P5492
   SUNNESS JS, 1988, ARCH OPHTHALMOL-CHIC, V106, P1081, DOI 10.1001/archopht.1988.01060140237032
   SUTTER EE, 1992, VISION RES, V32, P433, DOI 10.1016/0042-6989(92)90235-B
   Sutter EE, 1999, VISION RES, V39, P419, DOI 10.1016/S0042-6989(98)00161-8
   Sutter Erich, 2000, Documenta Ophthalmologica, V100, P49, DOI 10.1023/A:1002702917233
   Swann GMP, 2001, J EVOL ECON, V11, P59, DOI 10.1007/PL00003856
NR 42
TC 8
Z9 8
U1 0
U2 7
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 0952-5238
EI 1469-8714
J9 VISUAL NEUROSCI
JI Visual Neurosci.
PD NOV-DEC
PY 2006
VL 23
IS 6
BP 863
EP 870
DI 10.1017/S0952523806230190
PG 8
WC Neurosciences; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology; Ophthalmology
GA 137EK
UT WOS:000244275600003
PM 17266778
OA Green Published
DA 2022-11-30
ER

PT J
AU Jiang, PF
   Chaparro, FJ
   Cuddington, CT
   Palmer, AF
   Ohr, MP
   Lannutti, JJ
   Swindle-Reilly, KE
AF Jiang, Pengfei
   Chaparro, Francisco J.
   Cuddington, Clayton T.
   Palmer, Andre F.
   Ohr, Matthew P.
   Lannutti, John J.
   Swindle-Reilly, Katelyn E.
TI Injectable biodegradable bi-layered capsule for sustained delivery of
   bevacizumab in treating wet age-related macular degeneration
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Article
DE Microcapsule; Drug delivery; Intravitreal injection; Angiogenesis;
   Anti-VEGF; Electrospinning; Polymer; Macular degeneration
ID ENDOTHELIAL GROWTH-FACTOR; IN-VITRO; INTRAVITREAL INJECTION; CHITOSAN
   NANOPARTICLES; PLGA NANOPARTICLES; OCULAR DELIVERY; DRUG-DELIVERY;
   STABILITY; PROTEIN; POLYCAPROLACTONE
AB Vascular endothelial growth factor (VEGF) is a key regulator of abnormal blood vessel growth. As such, bevacizumab-based inhibition of VEGF has been the clinically adopted strategy to treat colorectal and breast cancers as well as age-related macular degeneration (AMD). However, as the treatment of vascular diseases often requires a high drug concentration for a long period, the burst release of bevacizumab remains a critical limitation in anti-VEGF-based therapies. Maintaining bevacizumab at high concentrations over extended periods remains challenging due to insufficient drug loading capacity and drug-device interactions. We report the development of a polymeric based bi-layered capsule that could address these challenges by extending the release over one year, thereby providing an effective platform enabling treatment of chronic vascular diseases. Remarkably, the developed capsules have a bi-layered structure which ensures the structural integrity of the injectable capsules and appropriate diffusion of bevacizumab by providing optimal physical trapping and electrostatic interaction. Meanwhile, the central hollow design enables a higher drug loading to meet the need for long-term release of bevacizumab for several months to one year. Using an in vitro drug release assay, we demonstrated that the bi-layered capsule could produce longer-term local drug administration by intravitreal injection compared to previously reported devices. The capsules also present minimal toxicity and maintain anti-VEGF potency, suggesting that our approach may have the potential to treat vascular-related diseases using bevacizumab.
C1 [Jiang, Pengfei; Cuddington, Clayton T.; Palmer, Andre F.; Swindle-Reilly, Katelyn E.] Ohio State Univ, William G Lowrie Dept Chem & Biomol Engn, 151 W Woodruff Ave, Columbus, OH 43210 USA.
   [Chaparro, Francisco J.; Lannutti, John J.] Ohio State Univ, Dept Mat Sci & Engn, 2041 N Coll Rd, Columbus, OH 43210 USA.
   [Ohr, Matthew P.; Swindle-Reilly, Katelyn E.] Ohio State Univ, Dept Ophthalmol & Visual Sci, 915 Olentangy River Rd, Columbus, OH 43212 USA.
   [Swindle-Reilly, Katelyn E.] Ohio State Univ, Dept Biomed Engn, 1080 Carmack Rd, Columbus, OH 43210 USA.
C3 University System of Ohio; Ohio State University; University System of
   Ohio; Ohio State University; University System of Ohio; Ohio State
   University; University System of Ohio; Ohio State University
RP Swindle-Reilly, KE (通讯作者)，Ohio State Univ, Dept Biomed Engn, 1080 Carmack Rd, Columbus, OH 43210 USA.
EM reilly.198@osu.edu
OI Chaparro, Francisco/0000-0002-7472-9211; Swindle-Reilly,
   Katelyn/0000-0003-1739-0263
FU Ohio Lions Eye Research Foundation; Ohio State University Institute for
   Materials Research
FX Financial support for this research was provided by the Lois
   Hagelberger-Huebner Young Investigator Grant from the Ohio Lions Eye
   Research Foundation and in part by the Materials Research Facility Grant
   from The Ohio State University Institute for Materials Research. The
   authors would like to acknowledge Dr. Yi Zhao for providing the
   fluorescent microscope, Dr. Mark Ruegsegger for helping with the capsule
   characterization by FTIR, Dr. Matthew Reilly and Bharat Kumar for
   providing the porcine eyes, and Kane Jacobs and Marissa Ruzga for
   experimental support.
CR Andres-Guerrero V, 2015, J CONTROL RELEASE, V211, P105, DOI 10.1016/j.jconrel.2015.05.279
   Arcinue CA, 2013, J OCUL PHARMACOL TH, V29, P501, DOI 10.1089/jop.2012.0180
   Armani DK, 2000, J MICROMECH MICROENG, V10, P80, DOI 10.1088/0960-1317/10/1/311
   Arnaoutova I, 2010, NAT PROTOC, V5, P628, DOI 10.1038/nprot.2010.6
   Badiee P, 2018, J BIOMED MATER RES A, V106, P2261, DOI 10.1002/jbm.a.36424
   Baker SR, 2016, MAT SCI ENG C-MATER, V59, P203, DOI 10.1016/j.msec.2015.09.102
   Bakri SJ, 2006, RETINA-J RET VIT DIS, V26, P519, DOI 10.1097/01.iae.0000225354.92444.7a
   Bernards DA, 2013, J OCUL PHARMACOL TH, V29, P249, DOI 10.1089/jop.2012.0152
   Bernards DA, 2012, NANO LETT, V12, P5355, DOI 10.1021/nl302747y
   Chan A, 2011, CLIN OPHTHALMOL, V5, P1043, DOI 10.2147/OPTH.S13775
   Chaparro FJ, 2019, J APPL POLYM SCI, V136, DOI 10.1002/app.47731
   Chaparro FJ, 2019, MAT SCI ENG C-MATER, V99, P112, DOI 10.1016/j.msec.2019.01.095
   Chen ZG, 2009, MAT SCI ENG C-MATER, V29, P2428, DOI 10.1016/j.msec.2009.07.006
   Chopra P, 2010, INT J PHARMACEUT, V388, P107, DOI 10.1016/j.ijpharm.2009.12.046
   Cipitria A, 2011, J MATER CHEM, V21, P9419, DOI 10.1039/c0jm04502k
   Courtois F, 2016, MABS-AUSTIN, V8, P99, DOI 10.1080/19420862.2015.1112477
   da Silva GR, 2010, BRAZ J PHARM SCI, V46, P585, DOI 10.1590/S1984-82502010000300024
   Darwis D, 1998, POLYM DEGRAD STABIL, V62, P259, DOI 10.1016/S0141-3910(98)00005-6
   DeCicco-Skinner KL, 2014, JOVE-J VIS EXP, DOI 10.3791/51312
   Delplace V, 2015, J CONTROL RELEASE, V219, P652, DOI 10.1016/j.jconrel.2015.09.065
   Elsaid N, 2016, MOL PHARMACEUT, V13, P2923, DOI 10.1021/acs.molpharmaceut.6b00335
   Elzein T, 2004, J COLLOID INTERF SCI, V273, P381, DOI 10.1016/j.jcis.2004.02.001
   Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381
   Ferrara N, 1999, KIDNEY INT, V56, P794, DOI 10.1046/j.1523-1755.1999.00610.x
   Garcia-Quintanilla L, 2019, PHARMACEUTICS, V11, DOI 10.3390/pharmaceutics11080365
   George M, 2006, J CONTROL RELEASE, V114, P1, DOI 10.1016/j.jconrel.2006.04.017
   Gu BK, 2013, CARBOHYD POLYM, V97, P65, DOI 10.1016/j.carbpol.2013.04.060
   Hard AL, 2011, ACTA PAEDIATR, V100, P1523, DOI 10.1111/j.1651-2227.2011.02445.x
   Heimes B, 2016, OPHTHALMOLOGE, V113, P925, DOI 10.1007/s00347-016-0275-z
   Holmes DIR, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-2-209
   Hoshi S, 2015, INVEST OPHTH VIS SCI, V56, P4705, DOI 10.1167/iovs.14-15349
   Huhtala A, 2008, J MATER SCI-MATER M, V19, P645, DOI 10.1007/s10856-007-3192-5
   Imperiale JC, 2018, J CONTROL RELEASE, V285, P106, DOI 10.1016/j.jconrel.2018.06.031
   Jayakumar R, 2010, CARBOHYD POLYM, V82, P227, DOI 10.1016/j.carbpol.2010.04.074
   Kean T, 2010, ADV DRUG DELIVER REV, V62, P3, DOI 10.1016/j.addr.2009.09.004
   Kim J, 2018, J CONTROL RELEASE, V269, P45, DOI 10.1016/j.jconrel.2017.11.008
   Kim YC, 2014, J CONTROL RELEASE, V190, P172, DOI 10.1016/j.jconrel.2014.06.043
   Koppolu BP, 2014, BIOMATERIALS, V35, P4382, DOI 10.1016/j.biomaterials.2014.01.078
   Lance KD, 2015, INVEST OPHTH VIS SCI, V56, P7331, DOI 10.1167/iovs.15-17757
   Latypov RF, 2012, J BIOL CHEM, V287, P1381, DOI 10.1074/jbc.M111.297697
   Lee SS, 2010, PHARM RES-DORDR, V27, P2043, DOI 10.1007/s11095-010-0159-x
   Li FF, 2012, OPEN OPHTHALMOL J, V6, P54, DOI 10.2174/1874364101206010054
   Li SK, 2011, J PHARMACEUT BIOMED, V55, P603, DOI 10.1016/j.jpba.2010.12.027
   Lu LC, 2001, BIOMATERIALS, V22, P3345, DOI 10.1016/S0142-9612(01)00172-7
   Lu Y, 2014, INT J OPHTHALMOL-CHI, V7, P1, DOI 10.3980/j.issn.2222-3959.2014.01.01
   Meyer CH, 2014, J OCUL PHARMACOL TH, V30, P387, DOI 10.1089/jop.2013.0231
   Mi FL, 2002, BIOMATERIALS, V23, P181, DOI 10.1016/S0142-9612(01)00094-1
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Nair LS, 2007, PROG POLYM SCI, V32, P762, DOI 10.1016/j.progpolymsci.2007.05.017
   Nam J, 2011, ACTA BIOMATER, V7, P1516, DOI 10.1016/j.actbio.2010.11.022
   Niu G, 2010, CURR DRUG TARGETS, V11, P1000, DOI 10.2174/138945010791591395
   Nomoto H, 2009, INVEST OPHTH VIS SCI, V50, P4807, DOI 10.1167/iovs.08-3148
   Ohr M, 2012, EXPERT OPIN PHARMACO, V13, P585, DOI 10.1517/14656566.2012.658368
   Oliva A, 2014, J CHROMATOGR A, V1353, P89, DOI 10.1016/j.chroma.2014.04.027
   Onishi H, 1999, BIOMATERIALS, V20, P175, DOI 10.1016/S0142-9612(98)00159-8
   Osman Z, 2003, ELECTROCHIM ACTA, V48, P993, DOI 10.1016/S0013-4686(02)00812-5
   Presta LG, 1997, CANCER RES, V57, P4593
   Querques L, 2013, OPHTHALMOLOGICA, V229, P21, DOI 10.1159/000342160
   Radhakrishnan K, 2017, DRUG DISCOV TODAY, V22, P416, DOI 10.1016/j.drudis.2016.10.015
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Salis A, 2011, LANGMUIR, V27, P11597, DOI 10.1021/la2024605
   Sampat KM, 2010, CURR OPIN OPHTHALMOL, V21, P178, DOI 10.1097/ICU.0b013e328338679a
   Sangsanoh P, 2006, BIOMACROMOLECULES, V7, P2710, DOI 10.1021/bm060286l
   Shibuya Masabumi, 2011, Genes Cancer, V2, P1097, DOI 10.1177/1947601911423031
   Sousa F, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03959-4
   Stewart MW, 2012, RETINA-J RET VIT DIS, V32, P434, DOI 10.1097/IAE.0B013E31822C290F
   Sun HF, 2006, BIOMATERIALS, V27, P1735, DOI 10.1016/j.biomaterials.2005.09.019
   Sur A, 2014, P NATL ACAD SCI USA, V111, P16754, DOI 10.1073/pnas.1419576111
   Tyagi P, 2013, MOL PHARMACEUT, V10, P2858, DOI 10.1021/mp300716t
   Varshochian R, 2015, J BIOMED MATER RES A, V103, P3148, DOI 10.1002/jbm.a.35446
   Varshochian R, 2013, EUR J PHARM SCI, V50, P341, DOI 10.1016/j.ejps.2013.07.014
   Wassmer S, 2013, ACTA BIOMATER, V9, P7855, DOI 10.1016/j.actbio.2013.04.025
   Yandrapu SK, 2013, MOL PHARMACEUT, V10, P4676, DOI 10.1021/mp400487f
   Zhu YF, 2005, ANGEW CHEM INT EDIT, V44, P5083, DOI 10.1002/anie.200501500
NR 74
TC 23
Z9 24
U1 3
U2 44
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29a, 1043 NX AMSTERDAM, NETHERLANDS
SN 0168-3659
EI 1873-4995
J9 J CONTROL RELEASE
JI J. Control. Release
PD APR 10
PY 2020
VL 320
BP 442
EP 456
DI 10.1016/j.jconrel.2020.01.036
PG 15
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Pharmacology & Pharmacy
GA KY8AU
UT WOS:000522794800037
PM 31981659
DA 2022-11-30
ER

PT J
AU Yoshizawa, C
   Saito, W
   Hirose, S
   Kitamei, H
   Noda, K
   Ishida, S
AF Yoshizawa, Chikako
   Saito, Wataru
   Hirose, Shigeki
   Kitamei, Hirokuni
   Noda, Kousuke
   Ishida, Susumu
TI Photodynamic therapy combined with intravitreal bevacizumab and
   sub-tenon triamcinolone acetonide injections for age-related macular
   degeneration
SO JAPANESE JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Photodynamic therapy; Bevacizumab;
   Sub-tenon injection; Triamcinolone acetonide
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; SUBGROUP ANALYSIS; RANIBIZUMAB;
   VERTEPORFIN; MARINA
AB To report the results of triple therapy with photodynamic therapy (PDT) (PDT combined with intravitreal injection of bevacizumab (IVB) and sub-tenon injection of triamcinolone acetonide (STTA)) for the treatment of age-related macular degeneration (AMD) in Japanese patients.
   This retrospective case series included 38 eyes of 38 patients with exudative AMD treated with PDT combined with IVB (1.25 mg) and STTA (40 mg). Retreatment was performed in the same manner with intervals of at least 3 months. All patients had been treatment na < ve, with a follow-up period of 12 months. Best-corrected visual acuity (BCVA), macular retinal thickness (MRT) on optical coherence tomography, and the number of treatments were analyzed.
   The mean logarithm of the minimum angle of resolution BCVA in patients treated with PDT triple therapy was 0.86 +/- A 0.55 at baseline and 0.62 +/- A 0.55 at 12 months (p < 0.001). The mean MRT was 554.0 +/- A 202.6 mu m at baseline and 205.1 +/- A 78.6 mu m at 12 months (p < 0.001). During the 1-year follow-up, the average number of PDT triple therapy (treatments per patient) was 1.1. No complications, for example increase in intraocular pressure, cataract, or endophthalmitis, were observed.
   In AMD patients, PDT triple therapy significantly improved visual acuity with a minimum number of treatments and a low risk of complications during the 1-year follow-up.
C1 [Yoshizawa, Chikako; Saito, Wataru; Hirose, Shigeki; Kitamei, Hirokuni; Noda, Kousuke; Ishida, Susumu] Hokkaido Univ, Grad Sch Med, Dept Ophthalmol, Kita Ku, Sapporo, Hokkaido 0608638, Japan.
C3 Hokkaido University
RP Saito, W (通讯作者)，Hokkaido Univ, Grad Sch Med, Dept Ophthalmol, Kita Ku, N-15,W-7, Sapporo, Hokkaido 0608638, Japan.
EM wsaito@med.hokudai.ac.jp
OI Saito, Wataru/0000-0001-8181-6252
CR Ahmadieh Hamid, 2007, BMC Ophthalmol, V7, P10, DOI 10.1186/1471-2415-7-10
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Carroll LA, 2002, DERMATOL SURG, V28, P704, DOI 10.1046/j.1524-4725.2002.02012.x
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Gomi F, 2008, CURR OPIN OPHTHALMOL, V19, P208, DOI 10.1097/ICU.0b013e3282fb7c33
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Gomi F, 2010, AM J OPHTHALMOL, V150, P48, DOI 10.1016/j.ajo.2010.02.008
   Honda S, 2009, JPN J OPHTHALMOL, V53, P593, DOI 10.1007/s10384-009-0741-0
   Jonas JB, 2005, ACTA OPHTHALMOL SCAN, V83, P645, DOI 10.1111/j.1600-0420.2005.00592.x
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Kaiser PK, 2007, OPHTHALMOLOGY, V114, P1868, DOI 10.1016/j.ophtha.2007.04.030
   Kovacs KD, 2010, RETINA, V31, P446
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Ruiz-Moreno JM, 2006, RETINA-J RET VIT DIS, V26, P602, DOI 10.1097/00006982-200607000-00003
   Saito K, 2009, JPN J OPHTHALMOL, V53, P512, DOI 10.1007/s10384-009-0703-6
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P2743, DOI 10.1167/iovs.02-1246
   Sato T, 2010, AM J OPHTHALMOL, V149, P947, DOI 10.1016/j.ajo.2009.12.038
   Schmidt-Erfurth U, 2002, ARCH OPHTHALMOL-CHIC, V120, P835
   Schmidt-Erfurth UM, 2003, OPHTHALMOLOGY, V110, P1306, DOI 10.1016/S0161-6420(03)00452-4
   Shah GK, 2009, RETINA-J RET VIT DIS, V29, P133, DOI 10.1097/IAE.0b013e3181960a28
   Shirakata Y, JPN J OPHTH IN PRESS
   Tamura H, 2005, INVEST OPHTH VIS SCI, V46, P1440, DOI 10.1167/iovs.04-0905
   Tano Y, 2008, OPHTHALMOLOGY, V115, P585, DOI 10.1016/j.ophtha.2007.10.018
   Ueta T, 2009, OPHTHALMOLOGY, V116, P362, DOI 10.1016/j.ophtha.2008.09.046
NR 24
TC 10
Z9 11
U1 0
U2 2
PU SPRINGER JAPAN KK
PI TOKYO
PA SHIROYAMA TRUST TOWER 5F, 4-3-1 TORANOMON, MINATO-KU, TOKYO, 105-6005,
   JAPAN
SN 0021-5155
EI 1613-2246
J9 JPN J OPHTHALMOL
JI Jpn. J. Ophthalmol.
PD JAN
PY 2013
VL 57
IS 1
BP 68
EP 73
DI 10.1007/s10384-012-0206-8
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 070FS
UT WOS:000313492200008
PM 23093314
DA 2022-11-30
ER

PT J
AU Dubchak, E
   Obasanmi, G
   Zeglinski, MR
   Granville, DJ
   Yeung, SN
   Matsubara, JA
AF Dubchak, Eden
   Obasanmi, Gideon
   Zeglinski, Matthew R.
   Granville, David J.
   Yeung, Sonia N.
   Matsubara, Joanne A.
TI Potential role of extracellular granzyme B in wet age-related macular
   degeneration and fuchs endothelial corneal dystrophy
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Review
DE extracellular matrix; corneal endothelium; retinal pigment epithelium;
   serine protease; Descemet's membrane; Bruch's membrane
ID CD8(+) T-CELLS; GROWTH-FACTOR; TGF-BETA; IN-VITRO; MAST-CELLS;
   DRUG-DELIVERY; RHEUMATOID-ARTHRITIS; HUMAN KERATINOCYTES;
   DESCEMETS-MEMBRANE; BRUCHS MEMBRANE
AB Age-related ocular diseases are the leading cause of blindness in developed countries and constitute a sizable socioeconomic burden worldwide. Age-related macular degeneration (AMD) and Fuchs endothelial corneal dystrophy (FECD) are some of the most common age-related diseases of the retina and cornea, respectively. AMD is characterized by a breakdown of the retinal pigment epithelial monolayer, which maintains retinal homeostasis, leading to retinal degeneration, while FECD is characterized by degeneration of the corneal endothelial monolayer, which maintains corneal hydration status, leading to corneal edema. Both AMD and FECD pathogenesis are characterized by disorganized local extracellular matrix (ECM) and toxic protein deposits, with both processes linked to aberrant protease activity. Granzyme B (GrB) is a serine protease traditionally known for immune-mediated initiation of apoptosis; however, it is now recognized that GrB is expressed by a variety of immune and non-immune cells and aberrant extracellular localization of GrB substantially contributes to various age-related pathologies through dysregulated cleavage of ECM, tight junction, and adherens junction proteins. Despite growing recognition of GrB involvement in multiple age-related pathologies, its role in AMD and FECD remains poorly understood. This review summarizes the pathophysiology of, and similarities between AMD and FECD, outlines the current knowledge of the role of GrB in AMD and FECD, as well as hypothesizes putative contributions of GrB to AMD and FECD pathogenesis and highlights the therapeutic potential of pharmacologically inhibiting GrB as an adjunctive treatment for AMD and FECD.
C1 [Dubchak, Eden; Obasanmi, Gideon; Yeung, Sonia N.; Matsubara, Joanne A.] Univ British Columbia UBC, Dept Ophthalmol & Visual Sci, Vancouver, BC, Canada.
   [Zeglinski, Matthew R.; Granville, David J.] Univ British Columbia, ICORD Ctr, Vancouver, BC, Canada.
   [Zeglinski, Matthew R.; Granville, David J.] Univ British Columbia, Dept Pathol & Lab Med, Vancouver Coastal Hlth Res Inst, Vancouver, BC, Canada.
C3 University of British Columbia; University of British Columbia;
   University of British Columbia; Vancouver Coastal Health Research
   Institute
RP Matsubara, JA (通讯作者)，Univ British Columbia UBC, Dept Ophthalmol & Visual Sci, Vancouver, BC, Canada.
EM joanne.matsubara@ubc.ca
FU CIHR; NSERC; FoM UBC
FX CIHR, NSERC, FoM UBC funded research stipends for GO and ED, and
   publication fees.
CR Alghisi GC, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004449
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   AMIN R, 1994, INVEST OPHTH VIS SCI, V35, P3178
   Ang LS, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.88
   Aslam MS, 2022, BIOMED RES INT, V2022, DOI 10.1155/2022/1557010
   Aslam MS, 2020, J DRUG TARGET, V28, P368, DOI 10.1080/1061186X.2019.1693576
   Austin BA, 2009, INVEST OPHTH VIS SCI, V50, P2896, DOI 10.1167/iovs.08-2495
   Awwad S, 2017, BRIT J PHARMACOL, V174, P4205, DOI 10.1111/bph.14024
   Bao CX, 2018, BIOMED PHARMACOTHER, V103, P346, DOI 10.1016/j.biopha.2018.04.023
   Barar J, 2008, EXPERT OPIN DRUG DEL, V5, P567, DOI [10.1517/17425247.5.5.567, 10.1517/17425247.5.5.567 ]
   BARFORT P, 1974, EXP EYE RES, V19, P11, DOI 10.1016/0014-4835(74)90067-0
   Berglin L, 2003, INVEST OPHTH VIS SCI, V44, P403, DOI 10.1167/iovs.02-0180
   Bergmanson JPG, 1999, OPHTHAL PHYSL OPT, V19, P210, DOI 10.1046/j.1475-1313.1999.00408.x
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Bhutto IA, 2008, ARCH OPHTHALMOL-CHIC, V126, P670, DOI 10.1001/archopht.126.5.670
   Boivin WA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033163
   Boivin WA, 2009, LAB INVEST, V89, P1195, DOI 10.1038/labinvest.2009.91
   Bonanno JA, 2003, PROG RETIN EYE RES, V22, P69, DOI 10.1016/S1350-9462(02)00059-9
   Booij JC, 2010, PROG RETIN EYE RES, V29, P1, DOI 10.1016/j.preteyeres.2009.08.003
   Bousquet E, 2015, AM J PATHOL, V185, P2083, DOI 10.1016/j.ajpath.2015.04.002
   Browning AC, 2008, BRIT J OPHTHALMOL, V92, P1003, DOI 10.1136/bjo.2007.127670
   BURNS RR, 1981, INVEST OPHTH VIS SCI, V20, P77
   Buzza MS, 2008, J BIOL CHEM, V283, P22498, DOI 10.1074/jbc.M709080200
   Buzza MS, 2005, J BIOL CHEM, V280, P23549, DOI 10.1074/jbc.M412001200
   Campagne MV, 2014, J PATHOL, V232, P151, DOI 10.1002/path.4266
   Canaday DH, 2001, J IMMUNOL, V167, P2734, DOI 10.4049/jimmunol.167.5.2734
   Chalimeswamy A, 2022, J OCUL PHARMACOL TH, V38, P74, DOI 10.1089/jop.2021.0037
   Chamberlain CM, 2010, AM J PATHOL, V176, P1038, DOI 10.2353/ajpath.2010.090700
   Chen M, 2015, J LEUKOCYTE BIOL, V98, P713, DOI 10.1189/jlb.3RI0615-239R
   Chong NHV, 2005, AM J PATHOL, V166, P241, DOI 10.1016/S0002-9440(10)62248-1
   Choy JC, 2004, ARTERIOSCL THROM VAS, V24, P2245, DOI 10.1161/01.ATV.0000147162.51930.b7
   Choy JC, 2003, MODERN PATHOL, V16, P460, DOI 10.1097/01.MP.0000067424.12280.BC
   Colijn JM, 2021, OPHTHALMOLOGY, V128, P1039, DOI 10.1016/j.ophtha.2020.11.024
   Connolly E, 2018, BRIT J OPHTHALMOL, V102, P1691, DOI 10.1136/bjophthalmol-2017-311673
   Cruz R.P., 2006, VASC PHARMACOL, V45, pe91, DOI [10.1016/j.vph.2006.08.257, DOI 10.1016/J.VPH.2006.08.257]
   da Silva PS, 2011, MOL VIS, V17, P1310
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   Davis GE, 2005, CIRC RES, V97, P1093, DOI 10.1161/01.RES.0000191547.64391.e3
   del Amo EM, 2008, DRUG DISCOV TODAY, V13, P135, DOI 10.1016/j.drudis.2007.11.002
   Digiuni Maurizio, 2012, Expert Opin Pharmacother, V13, P723, DOI 10.1517/14656566.2012.662219
   Dupont N, 2011, EMBO J, V30, P4701, DOI 10.1038/emboj.2011.398
   Ehlken C, 2014, EYE, V28, P538, DOI 10.1038/eye.2014.64
   Elavazhagan S, 2015, J IMMUNOL, V194, P2786, DOI 10.4049/jimmunol.1402316
   Elhalis H, 2010, OCUL SURF, V8, P173, DOI 10.1016/S1542-0124(12)70232-X
   Estebanez-Perpina E, 2000, BIOL CHEM, V381, P1203, DOI 10.1515/BC.2000.148
   Freishtat RJ, 2009, AM J RESP CRIT CARE, V179, P467, DOI 10.1164/rccm.200807-1085OC
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   FROELICH CJ, 1993, J IMMUNOL, V151, P7161
   Fu ZR, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154886
   Fuhrmann S, 2014, EXP EYE RES, V123, P141, DOI 10.1016/j.exer.2013.09.003
   Gain P, 2016, JAMA OPHTHALMOL, V134, P167, DOI 10.1001/jamaophthalmol.2015.4776
   Gao C, 2021, J OPHTHALMOL, V2021, DOI 10.1155/2021/8846708
   Geerlings MJ, 2017, MOL IMMUNOL, V84, P65, DOI 10.1016/j.molimm.2016.11.016
   Gettins PGW, 2002, CHEM REV, V102, P4751, DOI 10.1021/cr010170+
   Ghiringhelli F, 2009, NAT MED, V15, P1170, DOI 10.1038/nm.2028
   Gilmore AP, 2005, CELL DEATH DIFFER, V12, P1473, DOI 10.1038/sj.cdd.4401723
   Gleizes PE, 1997, STEM CELLS, V15, P190, DOI 10.1002/stem.150190
   Gordois A, 2012, GLOB PUBLIC HEALTH, V7, P465, DOI 10.1080/17441692.2011.634815
   Grossman WJ, 2003, CURR OPIN IMMUNOL, V15, P544, DOI 10.1016/S0952-7915(03)00099-2
   Grunwald JE, 2017, OPHTHALMOLOGY, V124, P97, DOI 10.1016/j.ophtha.2016.09.012
   Hagn M, 2009, J IMMUNOL, V183, P1838, DOI 10.4049/jimmunol.0901066
   Haile Y, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0376-7
   Harthan JS, 2016, CLIN OPTOM, V8, P23, DOI 10.2147/OPTO.S72079
   Hendel A, 2010, CELL DEATH DIFFER, V17, P596, DOI 10.1038/cdd.2010.5
   Hendel A, 2014, LAB INVEST, V94, P716, DOI 10.1038/labinvest.2014.62
   Hendel A, 2013, MATRIX BIOL, V32, P14, DOI 10.1016/j.matbio.2012.11.013
   Hernandez-Pigeon H, 2006, J BIOL CHEM, V281, P13525, DOI 10.1074/jbc.M512694200
   Hernandez-Pigeon H, 2007, J BIOL CHEM, V282, P8157, DOI 10.1074/jbc.M607436200
   Hiebert PR, 2013, CELL DEATH DIFFER, V20, P1404, DOI 10.1038/cdd.2013.96
   Hiebert PR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078939
   Hiebert PR, 2011, EXP GERONTOL, V46, P489, DOI 10.1016/j.exger.2011.02.004
   Hiroyasu S, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20604-3
   Hirst CE, 2001, MOL HUM REPROD, V7, P1133, DOI 10.1093/molehr/7.12.1133
   Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345
   Hoek KL, 2021, MUCOSAL IMMUNOL, V14, P1088, DOI 10.1038/s41385-021-00427-1
   Horiuchi K, 2003, J RHEUMATOL, V30, P1799
   Horvath AJ, 2005, J BIOL CHEM, V280, P43168, DOI 10.1074/jbc.M505598200
   Hribek A, 2021, AM J OPHTHALMOL, V222, P292, DOI 10.1016/j.ajo.2020.09.030
   Hsu I, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.423
   Hu MD, 2022, GASTROENTEROLOGY, V162, P877, DOI 10.1053/j.gastro.2021.11.028
   Ikemoto T, 2009, J CARDIOL, V54, P409, DOI 10.1016/j.jjcc.2009.06.009
   Imai K, 1997, BIOCHEM J, V322, P809, DOI 10.1042/bj3220809
   IRUELAARISPE ML, 1993, J CELL BIOCHEM, V52, P414, DOI 10.1002/jcb.240520406
   ISAAZ S, 1995, EUR J IMMUNOL, V25, P1071, DOI 10.1002/eji.1830250432
   Izumi-Nagai K, 2007, AM J PATHOL, V170, P2149, DOI 10.2353/ajpath.2007.061018
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jain M, 2013, J BIOL CHEM, V288, P770, DOI 10.1074/jbc.M112.431973
   Jensen C, 2020, CANCERS, V12, DOI 10.3390/cancers12102786
   Jimenez J, 2019, DRUG DISCOV TODAY, V24, P1564, DOI 10.1016/j.drudis.2019.03.005
   Jo N, 2006, AM J PATHOL, V168, P2036, DOI 10.2353/ajpath.2006.050588
   Jobling ME, 2006, RADIAT RES, V166, P839, DOI 10.1667/RR0695.1
   Joyce NC, 2002, INVEST OPHTH VIS SCI, V43, P2152
   Jung K, 2022, AM J PHYSIOL-CELL PH, V323, pC170, DOI 10.1152/ajpcell.00052.2022
   Jurkunas UV, 2018, CORNEA, V37, pS50, DOI 10.1097/ICO.0000000000001775
   Jurkunas UV, 2009, INVEST OPHTH VIS SCI, V50, P1129, DOI 10.1167/iovs.08-2525
   KAGI D, 1994, NATURE, V369, P31, DOI 10.1038/369031a0
   Katikireddy KR, 2016, AM J PATHOL, V186, P2736, DOI 10.1016/j.ajpath.2016.06.011
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Kawamura K, 2006, BLOOD, V107, P1031, DOI 10.1182/blood-2005-04-1737
   Keefe D, 2005, IMMUNITY, V23, P249, DOI 10.1016/j.immuni.2005.08.001
   Kelso A, 2002, INT IMMUNOL, V14, P605, DOI 10.1093/intimm/dxf028
   Kim EC, 2014, EXP EYE RES, V127, P20, DOI 10.1016/j.exer.2014.06.002
   KLEIN JL, 1989, GENOMICS, V5, P110, DOI 10.1016/0888-7543(89)90093-1
   Kondo H, 2009, CIRC J, V73, P503, DOI 10.1253/circj.CJ-08-0668
   Korthals M, 2007, J TRANSL MED, V5, DOI 10.1186/1479-5876-5-46
   Kubiczkova L, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-183
   Kuijpers TW, 2003, PEDIATRICS, V112, P986, DOI 10.1542/peds.112.4.986
   Kwak N, 2000, INVEST OPHTH VIS SCI, V41, P3158
   LeBleu VS, 2007, EXP BIOL MED, V232, P1121, DOI 10.3181/0703-MR-72
   Leclerc VB, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-22821-9
   Leung EW, 2000, MOL VIS, V6, P15
   Li C, 2013, AM J PATHOL, V183, P786, DOI 10.1016/j.ajpath.2013.05.025
   Li J, 2020, EXP CELL RES, V388, DOI 10.1016/j.yexcr.2019.111811
   Lin L, 2014, BMC IMMUNOL, V15, DOI 10.1186/s12865-014-0036-1
   Lin T, 2013, CYTOKINE, V62, P369, DOI 10.1016/j.cyto.2013.03.027
   Liu CL, 2020, P NATL ACAD SCI USA, V117, P573, DOI 10.1073/pnas.1912546116
   Liu XR, 2021, EYE VISION, V8, DOI 10.1186/s40662-021-00246-2
   Lu PF, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a005058
   Luibl V, 2006, J CLIN INVEST, V116, P378, DOI 10.1172/JCI25843
   Mandell KJ, 2006, INVEST OPHTH VIS SCI, V47, P2408, DOI 10.1167/iovs.05-0745
   Mansoor Naima, 2019, Curr Mol Med, V19, P705, DOI 10.2174/1566524019666190828150625
   Marom B, 2007, J LEUKOCYTE BIOL, V81, P1466, DOI 10.1189/jlb.0506328
   Marques AP, 2022, ECLINICALMEDICINE, V46, DOI 10.1016/j.eclinm.2022.101354
   Matsubara JA, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00574
   Matthaei M, 2018, EYE, V32, P840, DOI 10.1038/eye.2017.301
   MURPHY C, 1984, INVEST OPHTH VIS SCI, V25, P1402
   Myles ME, 2005, ADV DRUG DELIVER REV, V57, P2063, DOI 10.1016/j.addr.2005.08.006
   Nagineni CN, 2003, J CELL PHYSIOL, V197, P453, DOI 10.1002/jcp.10378
   Namekawa T, 1998, ARTHRITIS RHEUM, V41, P2108
   Naylor A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21010211
   Ngan David A, 2009, Ther Adv Respir Dis, V3, P113, DOI 10.1177/1753465809341965
   Nita M, 2014, MED SCI MONITOR, V20, P1003, DOI 10.12659/MSM.889887
   Nourinia Ramin, 2013, J Ophthalmic Vis Res, V8, P4
   O'Neill K, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01839
   Obasanmi G, 2021, INVEST OPHTH VIS SCI, V62
   Okumura N, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-06924-3
   Okumura N, 2015, LAB INVEST, V95, P1291, DOI 10.1038/labinvest.2015.111
   Osinska I, 2014, CENT EUR J IMMUNOL, V39, P109, DOI 10.5114/ceji.2014.42135
   Otani T, 2019, J CELL BIOL, V218, P3372, DOI 10.1083/jcb.201812157
   Pan XD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060335
   Pardo J, 2007, CELL DEATH DIFFER, V14, P1768, DOI 10.1038/sj.cdd.4402183
   Parkinson LG, 2015, AGING CELL, V14, P67, DOI 10.1111/acel.12298
   Patel Ashaben, 2013, World J Pharmacol, V2, P47
   Petrovski G, 2011, ACTA OPHTHALMOL, V89, pE30, DOI 10.1111/j.1755-3768.2010.02047.x
   Pipkin ME, 2007, CURR OPIN IMMUNOL, V19, P301, DOI 10.1016/j.coi.2007.04.011
   Plasman K, 2013, MOL CELL PROTEOMICS, V12, P2921, DOI 10.1074/mcp.M113.028670
   Pousen ET, 2014, J PROTEOME RES, V13, P4659, DOI 10.1021/pr500252r
   Prakash MD, 2009, IMMUNOL CELL BIOL, V87, P249, DOI 10.1038/icb.2008.98
   Pulai JI, 2005, J IMMUNOL, V174, P5781, DOI 10.4049/jimmunol.174.9.5781
   Qian Q, 2020, J CLIN INVEST, V130, P4133, DOI 10.1172/JCI130324
   Qiao JJ, 2020, J INT MED RES, V48, DOI 10.1177/0300060520962954
   Rakic JM, 2003, INVEST OPHTH VIS SCI, V44, P3186, DOI 10.1167/iovs.02-1092
   Rao G. Prasad, 1998, Indian Journal of Ophthalmology, V46, P145
   Reim M., 1984, GERIATRICS 3 GYNECOL, P310, DOI [10.1007/978-3-642-68976-5_12, DOI 10.1007/978-3-642-68976-5_12]
   Rissoan MC, 2002, BLOOD, V100, P3295, DOI 10.1182/blood-2002-02-0638
   ROBERTS AB, 1992, KIDNEY INT, V41, P557, DOI 10.1038/ki.1992.81
   Roh DS, 2013, AGING CELL, V12, P1122, DOI 10.1111/acel.12143
   Russo V, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28070-0
   Ryan PL, 2016, P NATL ACAD SCI USA, V113, P14378, DOI 10.1073/pnas.1611098113
   Santacruz M.S, 2018, GRANZYME B DISRUPTS, DOI [10.14288/1.0365942, DOI 10.14288/1.0365942]
   Sasson R, 2003, FASEB J, V17, P1256, DOI 10.1096/fj.02-0740com
   Schlotzer-Schrehardt U, 2011, OPHTHALMOLOGY, V118, P1950, DOI 10.1016/j.ophtha.2011.03.025
   Schull M, 2013, J IMMUNOL, V190
   Schuster AK, 2020, DTSCH ARZTEBL INT, V117, P225, DOI 10.3238/arztebl.2020.0225
   Shen Y, 2018, EXP MOL MED, V50, DOI 10.1038/s12276-018-0095-0
   Shen Y, 2016, AM J PATHOL, V186, P87, DOI 10.1016/j.ajpath.2015.09.010
   Shi L, 2005, J IMMUNOL, V174, P5456, DOI 10.4049/jimmunol.174.9.5456
   Shi M, 2022, INVEST OPHTH VIS SCI, V63
   Shiota M, 2012, CANCER RES, V72, P5261, DOI 10.1158/0008-5472.CAN-12-0254
   Simo R, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/190724
   Sipione S, 2006, J IMMUNOL, V177, P5051, DOI 10.4049/jimmunol.177.8.5051
   Skjelland M, 2007, ATHEROSCLEROSIS, V195, pE142, DOI 10.1016/j.atherosclerosis.2007.05.001
   Smyth MJ, 2000, J EXP MED, V192, P755, DOI 10.1084/jem.192.5.755
   Strik MCM, 2007, MOL IMMUNOL, V44, P3462, DOI 10.1016/j.molimm.2007.03.024
   Szatmari-Toth M, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20040926
   Tak PP, 1999, CLIN EXP IMMUNOL, V116, P366
   Tanaka E, 2015, OPHTHALMOLOGY, V122, P153, DOI 10.1016/j.ophtha.2014.07.046
   Taylor AW, 2009, J LEUKOCYTE BIOL, V85, P29, DOI 10.1189/jlb.0708415
   Thapa N, 2007, INT J BIOCHEM CELL B, V39, P2183, DOI 10.1016/j.biocel.2007.06.004
   Tone SO, 2021, PROG RETIN EYE RES, V80, DOI 10.1016/j.preteyeres.2020.100863
   Trapani JA, 2012, CELL DEATH DIFFER, V19, P21, DOI 10.1038/cdd.2011.156
   Trapani JA, 2003, CURR OPIN IMMUNOL, V15, P533, DOI 10.1016/S0952-7915(03)00107-9
   Tschopp CM, 2006, BLOOD, V108, P2290, DOI 10.1182/blood-2006-03-010348
   Tsuru R, 2008, HEART, V94, P305, DOI 10.1136/hrt.2006.110023
   Turner CT, 2021, NPJ AGING MECH DIS, V7, DOI 10.1038/s41514-021-00059-6
   Turner CT, 2021, J INVEST DERMATOL, V141, P36, DOI 10.1016/j.jid.2020.05.095
   Turner CT, 2019, MATRIX BIOL, V75-76, P126, DOI 10.1016/j.matbio.2017.12.005
   Uno K, 2006, BRIT J OPHTHALMOL, V90, P48, DOI 10.1136/bjo.2005.074005
   Varma R, 2016, JAMA OPHTHALMOL, V134, P802, DOI 10.1001/jamaophthalmol.2016.1284
   Vernooy JHJ, 2007, AM J RESP CRIT CARE, V175, P464, DOI 10.1164/rccm.200602-169OC
   Verrecchia F, 2002, J INVEST DERMATOL, V118, P211, DOI 10.1046/j.1523-1747.2002.01641.x
   Wagner C, 2004, BLOOD, V103, P1099, DOI 10.1182/blood-2003-04-1069
   Wang SJ, 2012, ARCH OPHTHALMOL-CHIC, V130, P615, DOI 10.1001/archopthalmol.2011.1892
   Weller JM, 2014, INVEST OPHTH VIS SCI, V55, P3700, DOI 10.1167/iovs.14-14154
   Wroblewski M, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00327-8
   Xia D, 2016, SCI REP-UK, V6, DOI 10.1038/srep23096
   Xu I, 2021, EXP EYE RES, V205, DOI 10.1016/j.exer.2021.108500
   Yang SQ, 2016, DRUG DES DEV THER, V10, P1857, DOI 10.2147/DDDT.S97653
   Zeglinski MR, 2020, CELL SIGNAL, V76, DOI 10.1016/j.cellsig.2020.109804
   Zhang XL, 2013, INVEST OPHTH VIS SCI, V54, P5829, DOI 10.1167/iovs.13-11918
NR 201
TC 0
Z9 0
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 1663-9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD SEP 20
PY 2022
VL 13
AR 980742
DI 10.3389/fphar.2022.980742
PG 17
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 5S8EV
UT WOS:000875416900001
PM 36204224
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Veritti, D
   Sarao, V
   Missiroli, F
   Ricci, F
   Lanzetta, P
AF Veritti, Daniele
   Sarao, Valentina
   Missiroli, Filippo
   Ricci, Federico
   Lanzetta, Paolo
TI TWELVE-MONTH OUTCOMES OF INTRAVITREAL AFLIBERCEPT FOR NEOVASCULAR
   AGE-RELATED MACULAR DEGENERATION Fixed Versus As-needed Dosing
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE aflibercept; age-related macular degeneration; AMD; choroidal
   neovascularization; CNV; fixed; intravitreal; pro-re-nata; PRN; regimen
ID CHOROIDAL NEOVASCULARIZATION; RE NATA; RANIBIZUMAB; INJECTION; THERAPY;
   REGIMEN; HORIZON; ATROPHY; AMD
AB Purpose: To compare the clinical outcomes of aflibercept used with a fixed schedule with a pro-re-nata (PRN) retreatment regimen in patients affected by neovascular age-related macular degeneration.
   Methods: This is a prospective multicenter, noninferiority, propensity score-matched study evaluating the 12-month outcomes of aflibercept given either according to labeling or following a PRN regimen. Patients included in the latter group received one initial injection, followed by monthly visits and as-needed retreatment.
   Results: One-to-one matching resulted in fixed and PRN arms containing 92 eyes each. Visual acuity improved from baseline to 12 months in both the study groups. At Month 4, the fixed regimen was equivalent to the PRN regimen (mean difference: 1.75 Early Treatment Diabetic Retinopathy Study letters, 95% confidence interval: -1.42 to +4.92). The pro-re-nata regimen failed to show noninferiority compared with the fixed regimen at both Month 8 (mean difference: 3.43 Early Treatment Diabetic Retinopathy Study letters, 95% confidence interval: +0.25 to +6.22) and Month 12 (mean difference: 4.83 Early Treatment Diabetic Retinopathy Study letters, 95% confidence interval: +1.37 to +8.29). All patients in the fixed group received seven injections. Patients included in the PRN arm received a mean of 5.5 +/- 1.6 treatments.
   Conclusions: Aflibercept given with a fixed treatment regimen produces better visual acuity outcomes than an individualized regimen.
C1 [Veritti, Daniele; Sarao, Valentina; Lanzetta, Paolo] Univ Udine, Dept Med Ophthalmol, Piazzale Santa Maria Misericordia, I-33100 Udine, Italy.
   [Veritti, Daniele; Sarao, Valentina; Lanzetta, Paolo] European Inst Ocular Microsurg IEMO, Udine, Italy.
   [Missiroli, Filippo; Ricci, Federico] Univ Roma Tor Vergata, Dept Ophthalmol, Rome, Italy.
C3 University of Udine; University of Rome Tor Vergata
RP Lanzetta, P (通讯作者)，Univ Udine, Dept Med Ophthalmol, Piazzale Santa Maria Misericordia, I-33100 Udine, Italy.
EM paolo.lanzetta@uniud.it
CR Bhisitkul RB, 2015, AM J OPHTHALMOL, V159, P915, DOI 10.1016/j.ajo.2015.01.032
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Ferreira A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133968
   Gabai A, 2014, EUR J OPHTHALMOL, V24, P396, DOI 10.5301/ejo.5000385
   Giannakaki-Zimmermann H, 2016, OPHTHALMOLOGICA, V236, P201, DOI 10.1159/000452929
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Lanzetta P, 2013, BRIT J OPHTHALMOL, V97, P1497, DOI 10.1136/bjophthalmol-2013-303394
   Lim RHF, 2017, INT J OPHTHALMOL-CHI, V10, P423, DOI 10.18240/ijo.2017.03.15
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mori R, 2017, OPHTHALMOLOGICA, V238, P17, DOI 10.1159/000468950
   Muftuoglu IK, 2016, AM J OPHTHALMOL, V167, P1, DOI 10.1016/j.ajo.2016.03.038
   Ricci F, 2016, EYE, V30, P1077, DOI 10.1038/eye.2016.95
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sarao V, 2016, RETINA-J RET VIT DIS, V36, P770, DOI 10.1097/IAE.0000000000000751
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Takayama K, 2017, OPHTHALMOLOGICA, V237, P105, DOI 10.1159/000461785
   Toth CA, 2015, RETINA-J RET VIT DIS, V35, P1303, DOI 10.1097/IAE.0000000000000483
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   Veritti D, 2017, EUR J OPHTHALMOL, V27, P74, DOI 10.5301/ejo.5000880
   Veritti D, 2012, OPHTHALMOLOGICA, V227, P11, DOI 10.1159/000337154
NR 25
TC 10
Z9 10
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD NOV
PY 2019
VL 39
IS 11
BP 2077
EP 2083
DI 10.1097/IAE.0000000000002299
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA KC9FQ
UT WOS:000507477300007
PM 30161093
DA 2022-11-30
ER

PT J
AU Querques, G
   Forte, R
   Berboucha, E
   Martinelli, D
   Coscas, G
   Soubrane, G
   Souied, EH
AF Querques, Giuseppe
   Forte, Raimondo
   Berboucha, Elya
   Martinelli, Domenico
   Coscas, Gabriel
   Soubrane, Gisele
   Souied, Eric H.
TI Spectral-Domain versus Time Domain Optical Coherence Tomography before
   and after Ranibizumab for Age-Related Macular Degeneration
SO OPHTHALMIC RESEARCH
LA English
DT Article
DE Age-related macular degeneration; Optical coherence tomography;
   Ranibizumab; Spectral domain; Time domain; Vascular endothelial growth
   factor
ID RETINAL THICKNESS MEASUREMENTS; SPEED; SCANS
AB Purpose: To study the ability to appreciate qualitative features that indicate disease activity in patients with neovascular age-related macular degeneration (AMD) and to analyze the differences in automated retinal thickness measurement, using 1 time domain optical coherence tomography (TD-OCT) and 2 different spectral-domain OCT (SD-OCT) machines. Methods: Thirty-three consecutive naive patients with neovascular AMD underwent Stratus TD-OCT, Cirrus SD-OCT and Spectralis SD-OCT, at baseline, 1 h, 1 day, 1 week and 1 month after intravitreal ranibizumab injection. Results: As regards the ability to detect retinal cysts, subretinal fluid and pigment epithelium detachment, at each follow-up visit, there was a significant correlation among all 3 OCT devices (p < 0.05), even though Cirrus SD-OCT and Spectralis SD-OCT showed the highest level of intermachine agreement. At each follow-up visit, automated retinal thickness measurements showed a greater mean central macular thickness (CMT) for both Spectralis SD-OCT and Cirrus SD-OCT, compared with Stratus TD-OCT. However, the mean paired differences in CMT among the 3 OCT devices were not statistically significant (p > 0.05). Overall, Cirrus SD-CT showed fewer segmentation errors, compared with both Spectralis SD-OCT and Stratus TD-OCT. Conclusion: SD-OCT showed a greater ability to evaluate qualitative features indicating disease activity and fewer errors in automated segmentation. However, differences in CMT changes were similar between TD-OCT and SD-OCT systems during follow-up. Copyright (C) 2011 S. Karger AG, Basel
C1 [Querques, Giuseppe; Forte, Raimondo; Berboucha, Elya; Martinelli, Domenico; Coscas, Gabriel; Soubrane, Gisele; Souied, Eric H.] Univ Paris 12, Dept Ophthalmol, Ctr Hosp Intercommunal Creteil, FR-94000 Creteil, France.
C3 Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil
RP Querques, G (通讯作者)，Univ Paris 12, Dept Ophthalmol, Ctr Hosp Intercommunal Creteil, 40 Ave Verdun, FR-94000 Creteil, France.
EM giuseppe.querques@hotmail.it
OI Querques, Giuseppe/0000-0002-3292-9581; Martinelli,
   Domenico/0000-0001-8028-3167
CR Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Browning DJ, 2008, OPHTHALMOLOGY, V115, P1366, DOI 10.1016/j.ophtha.2007.12.004
   Chen TC, 2005, ARCH OPHTHALMOL-CHIC, V123, P1715, DOI 10.1001/archopht.123.12.1715
   Costa RA, 2004, INVEST OPHTH VIS SCI, V45, P2399, DOI 10.1167/iovs.04-0155
   Drexler W, 2003, ARCH OPHTHALMOL-CHIC, V121, P695, DOI 10.1001/archopht.121.5.695
   Forte R, 2009, EYE, V23, P2071, DOI 10.1038/eye.2008.363
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Han IC, 2009, AM J OPHTHALMOL, V147, P847, DOI 10.1016/j.ajo.2008.11.019
   Jaffe GJ, 2004, AM J OPHTHALMOL, V137, P156, DOI 10.1016/S0002-9394(03)00792-X
   Keane PA, 2009, AM J OPHTHALMOL, V148, P242, DOI 10.1016/j.ajo.2009.03.004
   Krebs I, 2010, OPHTHALMOLOGY, V117, P1577, DOI 10.1016/j.ophtha.2010.04.032
   Krebs I, 2009, INVEST OPHTH VIS SCI, V50, P995, DOI 10.1167/iovs.08-2617
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Mylonas G, 2009, BRIT J OPHTHALMOL, V93, P1453, DOI 10.1136/bjo.2008.153643
   Nassif N, 2004, OPT LETT, V29, P480, DOI 10.1364/OL.29.000480
   Pons ME, 2005, OPHTHALMOLOGY, V112, P1079, DOI 10.1016/j.ophtha.2004.11.061
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sayanagi K, 2009, OPHTHALMOLOGY, V116, P947, DOI 10.1016/j.ophtha.2008.11.002
   Schmidt-Erfurth U, 2005, INVEST OPHTH VIS SCI, V46, P3393, DOI 10.1167/iovs.05-0370
   Taban M, 2009, OPHTHALMOLOGY, V116, P964, DOI 10.1016/j.ophtha.2008.12.033
   Wolf-Schnurrbusch UEK, 2009, INVEST OPHTH VIS SCI, V50, P3432, DOI 10.1167/iovs.08-2970
NR 21
TC 13
Z9 15
U1 0
U2 2
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3747
J9 OPHTHALMIC RES
JI Ophthalmic Res.
PY 2011
VL 46
IS 3
BP 152
EP 159
DI 10.1159/000325027
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 824PW
UT WOS:000295215400007
PM 21389740
DA 2022-11-30
ER

PT J
AU Hochstetler, BS
   Scott, IU
   Kunselman, AR
   Thompson, K
   Zerfoss, E
AF Hochstetler, Bradley S.
   Scott, Ingrid U.
   Kunselman, Allen R.
   Thompson, Kyle
   Zerfoss, Erica
TI ADHERENCE TO RECOMMENDATIONS OF THE AGE-RELATED EYE DISEASE STUDY IN
   PATIENTS WITH AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; age-related eye disease study;
   compliance; nutritional supplement; vitamins
ID VISUAL IMPAIRMENT; PREVALENCE; AREDS
AB Purpose: The purposes of this study were to determine the rate of adherence to the recommendations of the Age-Related Eye Disease Study (AREDS) regarding vitamin supplement use among patients with age-related macular degeneration (AMD) at a tertiary retina center and to identify factors associated with adherence.
   Methods: Consecutive patients with a history of AMD were administered an in-person survey designed to assess use of vitamin supplementation as well as to investigate factors that may influence supplementation use patterns. A retina specialist performed dilated funduscopic examinations and categorized patients' AMD severity according to the AREDS classification system. The main outcome measure was rate of adherence to AREDS recommendations.
   Results: Sixty-four patients with AMD completed the survey. Sixty-three percent of patients met AREDS criteria for vitamin supplementation. Of those patients who met the criteria, only 43% reported taking AREDS vitamins in the recommended dosages. Among patients using AREDS vitamins as recommended, 100% were return patients to the tertiary retina center and reported a retina specialist as the primary recommendation source for supplement use. Of patients who met AREDS criteria for vitamin supplementation but were not taking vitamins as per AREDS recommendations, 87% were new patients to the retina service and 75% reported that vitamin supplementation had never been recommended to them.
   Conclusion: Patients with intermediate or advanced AMD in at least one eye show a low adherence rate to the AREDS recommendations for vitamin supplementation. RETINA 30: 1166-1170, 2010
C1 [Scott, Ingrid U.] Penn State Coll Med, Dept Ophthalmol & Publ Hlth Sci, Penn State Hershey Eye Ctr, Hershey, PA 17033 USA.
   [Scott, Ingrid U.; Kunselman, Allen R.] Penn State Coll Med, Dept Publ Hlth Sci, Hershey, PA 17033 USA.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE);
   Pennsylvania State University; Penn State Health; Pennsylvania
   Commonwealth System of Higher Education (PCSHE); Pennsylvania State
   University; Penn State Health
RP Scott, IU (通讯作者)，Penn State Coll Med, Dept Ophthalmol & Publ Hlth Sci, Penn State Hershey Eye Ctr, 500 Univ Dr,HU19, Hershey, PA 17033 USA.
EM iscott@psu.edu
OI Scott, Ingrid/0000-0002-3908-7153
CR *AM AC OPHTH, 2006, AG REL MAC DEG PREF
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Chang CW, 2003, CAN J OPHTHALMOL, V38, P27, DOI 10.1016/S0008-4182(03)80005-4
   Charkoudian LD, 2008, OPHTHALMOLOGY, V115, P1032, DOI 10.1016/j.ophtha.2007.08.003
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Cox DR, 2018, ANAL BINARY DATA
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Jampol LM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1634, DOI 10.1001/archopht.121.11.1634
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kocur I, 2002, BRIT J OPHTHALMOL, V86, P716, DOI 10.1136/bjo.86.7.716
   Ng WT, 2006, CLIN EXP OPHTHALMOL, V34, P9, DOI 10.1111/j.1442-9071.2006.01141.x
NR 11
TC 12
Z9 13
U1 0
U2 13
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD SEP
PY 2010
VL 30
IS 8
BP 1166
EP 1170
DI 10.1097/IAE.0b013e3181cea5c6
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 647JF
UT WOS:000281614100003
PM 20827137
DA 2022-11-30
ER

PT J
AU Hanlon, J
   Lee, C
   Chell, E
   Gertner, M
   Hansen, S
   Howell, RW
   Bolch, WE
AF Hanlon, Justin
   Lee, Choonsik
   Chell, Erik
   Gertner, Michael
   Hansen, Steven
   Howell, Roger W.
   Bolch, Wesley E.
TI Kilovoltage stereotactic radiosurgery for age-related macular
   degeneration: Assessment of optic nerve dose and patient effective dose
SO MEDICAL PHYSICS
LA English
DT Article
DE computerised tomography; dosimetry; eye; geriatrics; image resolution;
   neurophysiology; ophthalmic lenses; phantoms; radiation therapy; vision
   defects
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; COMPUTATIONAL PHANTOMS;
   RADIATION-THERAPY; RADIOTHERAPY; TRIAL; SECONDARY; SAFETY
AB Age-related macular degeneration (AMD) is a leading cause for vision loss for people over the age of 65 in the United States and a major health problem worldwide. Research for new treatments of the wet form of the disease using kilovoltage stereotactic radiosurgery is currently underway at Oraya Therapeutics, Inc. In the present study, the authors extend their previous computational stylized model of a single treated eye [Med. Phys. 35, 5151-5160 (2008)] to include full NURBS-based reference head phantoms of the adult male and female using anatomical data from ICRP Publication 89. The treatment was subsequently modeled in MCNPX 2.5 using a 1x1x1 mm(3) voxelized version of the NURBS models. These models incorporated several organs of interest including the brain, thyroid, salivary glands, cranium, mandible, and cervical vertebrae. A higher resolution eye section at 0.5x0.5x0.5 mm(3) voxel resolution was extracted from the head phantoms to model smaller eye structures including the macula target, cornea, lens, vitreous humor, sclera/retina layer, and optic nerve. Due to lack of literature data on optic nerve pathways, a CT imaging study was undertaken to quantify the anatomical position of the optic nerve. The average absorbed doses to the organs of interest were below generally accepted thresholds for radiation safety. The estimated effective dose was 0.28 mSv which is comparable to diagnostic procedures such as a head radiograph and a factor of 10 lower than a head CT scan.
C1 [Hanlon, Justin; Lee, Choonsik; Bolch, Wesley E.] Univ Florida, Dept Nucl & Radiol Engn, Gainesville, FL 32611 USA.
   [Bolch, Wesley E.] Univ Florida, Dept Biomed Engn, Gainesville, FL 32611 USA.
   [Chell, Erik; Gertner, Michael; Hansen, Steven] Oraya Therapeut Inc, Newark, CA 94560 USA.
   [Howell, Roger W.] Univ Med & Dent New Jersey, Dept Radiol, Newark, NJ 07103 USA.
C3 State University System of Florida; University of Florida; State
   University System of Florida; University of Florida; Rutgers State
   University New Brunswick; Rutgers State University Medical Center
RP Bolch, WE (通讯作者)，Univ Florida, Dept Nucl & Radiol Engn, Gainesville, FL 32611 USA.
EM wbolch@ufl.edu
RI Lee, Choonsik/C-9023-2015; Howell, Roger/GXZ-5412-2022; Howell, Roger
   W/AAO-2086-2020
OI Lee, Choonsik/0000-0003-4289-9870; Howell, Roger W/0000-0002-7057-8110
FU Oraya Therapeutics, Inc
FX This work was supported by Oraya Therapeutics, Inc.
CR [Anonymous], 2007, Ann ICRP, V37, P1, DOI 10.1016/j.icrp.2008.08.001
   Anthoney T. R, 1994, NEUROANATOMY NEUROLO
   Arnold J, 2001, OPHTHALMOLOGY, V108, P841
   ARNOLDUSSEN ME, 2009, INVEST OPHTHALMOL VI
   Avila MP, 2009, BRIT J OPHTHALMOL, V93, P305, DOI 10.1136/bjo.2008.145912
   Avila MP, 2009, RETINA-J RET VIT DIS, V29, P157, DOI 10.1097/IAE.0b013e3181985915
   Bolch WE, 2007, RADIAT PROT DOSIM, V127, P169, DOI 10.1093/rpd/ncm268
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   CAPONE A, 2005, INVEST OPHTH VIS SCI, V46, P2362
   Churei Hisahiko, 2004, Radiat Med, V22, P398
   Cranley K., 1997, 78 I PHYS
   Cristy M, 1987, REPORT ORNLTM 8381, V1-7
   Flaxel Christina J, 2002, Ophthalmol Clin North Am, V15, P437, DOI 10.1016/S0896-1549(02)00038-X
   Girkin CA, 1997, OPHTHALMOLOGY, V104, P1634, DOI 10.1016/S0161-6420(97)30084-0
   Goverdhan SV, 2005, EYE, V19, P1137, DOI 10.1038/sj.eye.6701744
   Haas A, 2000, J NEUROSURG, V93, P172, DOI 10.3171/jns.2000.93.supplement_3.0172
   Hayashi M, 2005, J NEUROSURG, V102, P200, DOI 10.3171/jns.2005.102.s_supplement.0200
   Henderson MA, 2007, STEREOT FUNCT NEUROS, V85, P11, DOI 10.1159/000096634
   Holz FG, 1999, OPHTHALMOLOGY, V106, P2239
   International Commission on Radiological Protection (ICRP), 2002, ANN ICRP, V32, P217
   Lee C, 2008, MED PHYS, V35, P5151, DOI 10.1118/1.2990780
   Lee C, 2007, RADIAT PROT DOSIM, V127, P227, DOI 10.1093/rpd/ncm277
   Lee C, 2007, PHYS MED BIOL, V52, P3309, DOI 10.1088/0031-9155/52/12/001
   Levin LA, 2000, OPHTHALMOLOGY, V107, P370, DOI 10.1016/S0161-6420(99)00054-8
   Marcus D, 2004, AM J OPHTHALMOL, V138, P818, DOI 10.1016/j.ajo.2004.06.081
   Mettler FA, 2008, RADIOLOGY, V248, P254, DOI 10.1148/radiol.2481071451
   MURPHY RP, 1986, OPHTHALMOLOGY, V93, P969
   *NAT COUNC RAD PRO, 1999, 130 NAT COUNC RAD PR
   *NAT EYE I, AG REL MAC DEG
   National Council on Radiation Protection, 2009, ION RAD EXP POP US
   Pelowitz DB, 2005, LACP050369
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Stafford SL, 2003, INT J RADIAT ONCOL, V55, P1177, DOI 10.1016/S0360-3016(02)04380-8
   UNSOLD R, 1980, AM J ROENTGENOL, V135, P767, DOI 10.2214/ajr.135.4.767
   White DR, 1992, J INT COMM RAD UNITS, V1, pNP
   Zambarakji HJ, 2006, OPHTHALMOLOGY, V113, P2012, DOI 10.1016/j.ophtha.2006.05.036
NR 36
TC 35
Z9 35
U1 0
U2 2
PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS
PI MELVILLE
PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA
SN 0094-2405
J9 MED PHYS
JI Med. Phys.
PD AUG
PY 2009
VL 36
IS 8
BP 3671
EP 3681
DI 10.1118/1.3168554
PG 11
WC Radiology, Nuclear Medicine & Medical Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Radiology, Nuclear Medicine & Medical Imaging
GA 476KY
UT WOS:000268440600031
PM 19746800
DA 2022-11-30
ER

PT J
AU Yi, K
   Mujat, M
   Park, BH
   Sun, W
   Miller, JW
   Seddon, JM
   Young, LH
   de Boer, JF
   Chen, TC
AF Yi, K.
   Mujat, M.
   Park, B. H.
   Sun, W.
   Miller, J. W.
   Seddon, J. M.
   Young, L. H.
   de Boer, J. F.
   Chen, T. C.
TI Spectral domain optical coherence tomography for quantitative evaluation
   of drusen and associated structural changes in non-neovascular
   age-related macular degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID ULTRAHIGH-RESOLUTION; HIGH-SPEED
AB Background/aims: To demonstrate how spectral domain optical coherence tomography (SDOCT) can better evaluate drusen and associated anatomical changes in eyes with non-neovascular age-related macular degeneration (AMD) compared with time domain optical coherence tomography (TDOCT).
   Methods: Images were obtained from three eyes of three patients with AMD using an experimental SDOCT system. Both a titanium-sapphire (Ti:sapphire) laser and a superluminescent diode (SLD) were used as a broadband light source to achieve cross-sectional images of the retina. A qualitative and quantitative analysis was performed for structural changes associated with non-neovascular AMD. An automated algorithm was developed to analyse drusen area and volume from SDOCT images. TDOCT was performed using the fast macular scan (StratusOCT, Carl Zeiss Meditec, Dublin, California).
   Results: SDOCT images can demonstrate structural changes associated with non-neovascular AMD. A new SDOCT algorithm can determine drusen area, drusen volume and proportion of drusen.
   Conclusions: With new algorithms to determine drusen area and volume and its unprecedented simultaneous ultra-high speed ultra-high resolution imaging, SDOCT can improve the evaluation of structural abnormalities in non-neovascular AMD.
C1 [Yi, K.; Chen, T. C.] Massachusetts Eye & Ear Infirm, Glaucoma Serv, Boston, MA 02114 USA.
   [Yi, K.; Mujat, M.; Park, B. H.; Miller, J. W.; Young, L. H.; de Boer, J. F.; Chen, T. C.] Harvard Univ, Sch Med, Boston, MA USA.
   [Yi, K.] Hallym Univ, Kangnam Sacred Heart Hosp, Seoul, South Korea.
   [Mujat, M.; Park, B. H.; Sun, W.; de Boer, J. F.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.
   [Mujat, M.] Phys Sci Inc, Andover, MA 01810 USA.
   [Sun, W.] Boston Univ, Dept Phys, Boston, MA 02215 USA.
   [Miller, J. W.; Young, L. H.] Massachusetts Eye & Ear Infirm, Retina Serv, Boston, MA 02114 USA.
   [Seddon, J. M.] Tufts Univ, Sch Med, New England Med Ctr, Boston, MA 02111 USA.
   [de Boer, J. F.] Vrije Univ Amsterdam, Dept Phys & Astron, Amsterdam, Netherlands.
C3 Harvard University; Massachusetts Eye & Ear Infirmary; Harvard
   University; Harvard Medical School; Hallym University; Harvard
   University; Massachusetts General Hospital; Physical Sciences Inc.;
   Boston University; Harvard University; Massachusetts Eye & Ear
   Infirmary; Tufts Medical Center; Tufts University; Vrije Universiteit
   Amsterdam
RP Chen, TC (通讯作者)，Massachusetts Eye & Ear Infirm, Glaucoma Serv, 243 Charles St, Boston, MA 02114 USA.
EM teresa_chen@meei.harvard.edu
RI Mujat, Mircea/AAY-7608-2020; de Boer, Johannes F/B-7590-2012
OI de Boer, Johannes F/0000-0003-1253-4950; Young,
   Lucy/0000-0001-8634-7512; Chen, Teresa/0000-0001-5327-2016; Miller,
   Joan/0000-0003-2046-3996
FU National Institutes of Health [R01EY014975, R01-RR19768]; JFB's
   research; NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR019768] Funding
   Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY014975] Funding
   Source: NIH RePORTER
FX This paper was partially supported by the National Institutes of Health,
   Bethesda, Maryland (R01EY014975, R01-RR19768). Nidek sponsors JFB's
   research. Patents in spectral domain optical coherence tomography: JFB,
   MM, BHP.
CR Alam S, 2006, OPHTHALMOLOGY, V113, P1425, DOI 10.1016/j.ophtha.2006.03.020
   *AM NAT STAND I, 2000, Z129 ANSI, P1
   [Anonymous], 2005, ARCH OPHTHALMOL-CHIC, V123, P1570, DOI DOI 10.1001/ARCHOPHT.123.11.1570
   Cense B, 2004, OPT EXPRESS, V12, P2435, DOI 10.1364/OPEX.12.002435
   Chen TC, 2006, AM J OPHTHALMOL, V141, P1165, DOI 10.1016/j.ajo.2006.01.086
   Chen TC, 2005, ARCH OPHTHALMOL-CHIC, V123, P1715, DOI 10.1001/archopht.123.12.1715
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   de Boer JF, 2003, OPT LETT, V28, P2067, DOI 10.1364/OL.28.002067
   Drexler W, 1999, OPT LETT, V24, P1221, DOI 10.1364/OL.24.001221
   Fujimoto JG, 2003, NAT BIOTECHNOL, V21, P1361, DOI 10.1038/nbt892
   Hammer DX, 2005, J BIOMED OPT, V10, DOI 10.1117/1.1896967
   Hammer DX, 2003, APPL OPTICS, V42, P4621, DOI 10.1364/AO.42.004621
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Leitgeb RA, 2003, OPT LETT, V28, P2201, DOI 10.1364/OL.28.002201
   Mujat M, 2005, OPT EXPRESS, V13, P9480, DOI 10.1364/OPEX.13.009480
   Nassif NA, 2004, OPT EXPRESS, V12, P367, DOI 10.1364/OPEX.12.000367
   Pieroni CG, 2006, BRIT J OPHTHALMOL, V90, P191, DOI 10.1136/bjo.2005.076612
   Wojtkowski M, 2005, OPHTHALMOLOGY, V112, P1734, DOI 10.1016/j.ophtha.2005.05.023
   Wojtkowski M, 2004, OPT EXPRESS, V12, P2404, DOI 10.1364/OPEX.12.002404
   Wollstein G, 2005, OPHTHALMOLOGY, V112, P229, DOI 10.1016/j.ophtha.2004.08.021
NR 23
TC 67
Z9 72
U1 0
U2 3
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD FEB
PY 2009
VL 93
IS 2
BP 176
EP 181
DI 10.1136/bjo.2008.137356
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 399XZ
UT WOS:000262833900010
PM 18697811
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Chan, CC
   Tuo, J
   Bojanowski, CM
   Csaky, KG
   Green, WR
AF Chan, CC
   Tuo, J
   Bojanowski, CM
   Csaky, KG
   Green, WR
TI Detection of CX3CR1 single nucleotide polymorphism and expression on
   archived eyes with age-related macular degeneration
SO HISTOLOGY AND HISTOPATHOLOGY
LA English
DT Article
DE age-related macular degeneration; single nuclear polymorphism; CX3CR1;
   chemokine; macrophage
ID APOLIPOPROTEIN-E GENE; CHOROIDAL NEOVASCULARIZATION; BRUCHS MEMBRANE;
   CHEMOKINE RECEPTORS; RISK-FACTORS; FRACTALKINE; ASSOCIATION; DISEASE;
   CX(3)CR1; SUSCEPTIBILITY
AB There is a significant genetic component in age-related macular degeneration (AMD). CX3CR1, which encodes the fractalkine (chemokine, CX3CL1) receptor, has two single nucleotide polymorphisms (SNPs): V2491 and T280M. These SNPs are correlated with other aged-related diseases such as atherosclerosis. We have reported an association of CX3CR1 SNP and AMD. In this study we examined CX3CR1 SNP frequencies and protein expression on archived sections of AMD and normal eyes. We microdissected non-retinal, peripheral retinal and macular cells from archived slides of eyes of AMD patients and normal subjects. CX3CR1 SNP typing was conducted by PCR and restriction fragment length polymorphism analysis. CX3CR1 transcripts from retinal cells were also measured using RT-PCR. CX3CR1 protein expression was evaluated using avidin-biotin complex immunohistochemistry. We successfully extracted DNA from 32/40 AMD cases and 2/2 normal eyes. Among the 32 AMD cases, IS had neovascular AMD and 14 had non-neovascular AMD. The M280 allele was detected in 19/64 (32 cases x2) with a frequency of 29.7%, which was significantly higher as compared to the frequency in the normal population (11.2%). We detected CX3CR1 expression in the various retinal cells. CX3CR1 transcript and protein levels were diminished in the macular lesions. This study successfully analyzed CX3CR1 SNP and transcript expression in microdissected cells from archived paraffin fixed slides. Our data suggest that the M280 allele, a SNP resulting in aberrant CX3CR1 and CX3CL1 interaction, as well as lowered expression of macular CX3CR1, may contribute to the development of AMD.
C1 NEI, NIH, Bethesda, MD 20895 USA.
   Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Baltimore, MD 21205 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); Johns Hopkins University; Johns Hopkins Medicine
RP Chan, CC (通讯作者)，NEI, NIH, Bldg 10,Rm 10N103,10 Ctr Dr, Bethesda, MD 20895 USA.
EM chanc@nei.nih.gov
FU Intramural NIH HHS [Z01 EY000418-04, Z01 EY000222-22] Funding Source:
   Medline; NATIONAL EYE INSTITUTE [Z01EY000418, Z01EY000222] Funding
   Source: NIH RePORTER
CR Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Amouyel P, 2002, CR BIOL, V325, P741, DOI 10.1016/S1631-0691(02)01481-6
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Balkwill F, 2003, SEMIN IMMUNOL, V15, P49, DOI 10.1016/S1044-5323(02)00127-6
   Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657
   Brennan P, 2002, CARCINOGENESIS, V23, P381, DOI 10.1093/carcin/23.3.381
   Cotter R, 2002, J NEUROVIROL, V8, P585, DOI 10.1080/13550280290100950
   DASTGHEIB K, 1994, ARCH OPHTHALMOL-CHIC, V112, P813, DOI 10.1001/archopht.1994.01090180111045
   de Jong PTVM, 2001, EYE, V15, P396, DOI 10.1038/eye.2001.143
   DeVries ME, 2003, J BIOL CHEM, V278, P11985, DOI 10.1074/jbc.M211422200
   Echigo T, 2004, J ALLERGY CLIN IMMUN, V113, P940, DOI 10.1016/j.jaci.2004.02.030
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P3586, DOI 10.1167/iovs.03-0038
   Faure S, 2000, SCIENCE, V287, P2274, DOI 10.1126/science.287.5461.2274
   Feng LL, 1999, KIDNEY INT, V56, P612, DOI 10.1046/j.1523-1755.1999.00604.x
   Forrester JV, 2003, NAT MED, V9, P1350, DOI 10.1038/nm1103-1350
   Foxman EF, 2002, J IMMUNOL, V168, P2483, DOI 10.4049/jimmunol.168.5.2483
   Green W R, 1999, Mol Vis, V5, P27
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Grossniklaus HE, 2000, ARCH OPHTHALMOL-CHIC, V118, P625
   Gulcher J, 2001, CANCER J, V7, P61
   Halushka MK, 1999, NAT GENET, V22, P239, DOI 10.1038/10297
   Homey B, 2002, NAT REV IMMUNOL, V2, P175, DOI 10.1038/nri748
   Howard OMZ, 1996, TRENDS BIOTECHNOL, V14, P46, DOI 10.1016/0167-7799(96)80920-6
   Husain Deeba, 2002, Ophthalmol Clin North Am, V15, P87, DOI 10.1016/S0896-1549(01)00009-8
   Hyman Leslie, 2002, Curr Opin Ophthalmol, V13, P171
   Ikeda T, 2001, AM J OPHTHALMOL, V132, P191, DOI 10.1016/S0002-9394(01)00975-8
   KILLINGSWORTH MC, 1990, EYE, V4, P613, DOI 10.1038/eye.1990.86
   Kimura H, 1999, INVEST OPHTH VIS SCI, V40, P524
   Kimura K, 2000, AM J OPHTHALMOL, V130, P769, DOI 10.1016/S0002-9394(00)00552-3
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   la Cour M, 2002, DRUG AGING, V19, P101, DOI 10.2165/00002512-200219020-00003
   Liu Ming-xu, 2003, Zhonghua Liu Xing Bing Xue Za Zhi, V24, P595
   McDermott D H, 2000, Science, V290, P2031
   McDermott DH, 2003, J CLIN INVEST, V111, P1241, DOI 10.1172/JCI200316790
   McDermott DH, 2001, CIRC RES, V89, P401, DOI 10.1161/hh1701.095642
   Mizuno T, 2003, BRAIN RES, V979, P65, DOI 10.1016/S0006-8993(03)02867-1
   Moatti D, 2001, BLOOD, V97, P1925, DOI 10.1182/blood.V97.7.1925
   O'Brien SJ, 1999, SCIENCE, V286, P458, DOI 10.1126/science.286.5439.458
   Risch N, 1996, SCIENCE, V273, P1516, DOI 10.1126/science.273.5281.1516
   Risch NJ, 2000, NATURE, V405, P847, DOI 10.1038/35015718
   Schmidt S, 2000, MOL VIS, V6, P287
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Shen DF, 1998, OPHTHALMOLOGY, V105, P1664, DOI 10.1016/S0161-6420(98)99036-4
   Simonelli F, 2001, OPHTHALMIC RES, V33, P325, DOI 10.1159/000055688
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   Spraul CW, 1999, SURV OPHTHALMOL, V44, pS10, DOI 10.1016/S0039-6257(99)00086-7
   Stone EM, 2004, NEW ENGL J MED, V351, P346, DOI 10.1056/NEJMoa040833
   Tarozzo G, 2002, EUR J NEUROSCI, V15, P1663, DOI 10.1046/j.1460-9568.2002.02007.x
   Taub D D, 1994, Ther Immunol, V1, P229
   Tou JS, 2004, FASEB J, V18, P1297, DOI 10.1096/fj.04-1862fje
   Tsutsumi C, 2003, J LEUKOCYTE BIOL, V74, P25, DOI 10.1189/jlb.0902436
   Tuo JS, 2004, PROG RETIN EYE RES, V23, P229, DOI 10.1016/j.preteyeres.2004.02.001
   VANDERSCHAFT TL, 1992, OPHTHALMOLOGY, V99, P278
   Wang DG, 1998, SCIENCE, V280, P1077, DOI 10.1126/science.280.5366.1077
   Wright AF, 2001, EYE, V15, P401, DOI 10.1038/eye.2001.144
   Zareparsi S, 2004, INVEST OPHTH VIS SCI, V45, P1306, DOI 10.1167/iovs.03-1253
   Zingg JM, 2000, IUBMB LIFE, V49, P397
   Zlotnik A, 2000, IMMUNITY, V12, P121, DOI 10.1016/S1074-7613(00)80165-X
   Zlotnik A, 1999, CRIT REV IMMUNOL, V19, P1
NR 61
TC 57
Z9 60
U1 0
U2 3
PU F HERNANDEZ
PI MURCIA
PA PLAZA FUENSANTA 2-7 C, 30008 MURCIA, SPAIN
SN 0213-3911
EI 1699-5848
J9 HISTOL HISTOPATHOL
JI Histol. Histopath.
PD JUL
PY 2005
VL 20
IS 3
BP 857
EP 863
PG 7
WC Cell Biology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Pathology
GA 942MS
UT WOS:000230287100023
PM 15944936
DA 2022-11-30
ER

PT J
AU Theodossiadis, GP
   Panagiotidis, D
   Georgalas, IG
   Moschos, M
   Theodossiadis, PG
AF Theodossiadis, GP
   Panagiotidis, D
   Georgalas, IG
   Moschos, M
   Theodossiadis, PG
TI Retinal hemorrhage after photodynamic therapy in patients with subfoveal
   choroidal neovascularization caused by age-related macular degeneration
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
ID MACULOPATHY; PREVALENCE
AB Purpose: To report the frequency and the evolution of the extensive retinal hemorrhages that can appear within 48 h after the application of photodynamic therapy. Methods: Two hundred and fifteen individual eyes of 194 consecutive patients with subfoveal choroidal neovascularization (CNV) due to age-related macular degeneration who underwent photodynamic treatment were included in the study. The visual acuity was measured before and after treatment. Color and red-free photographs were taken. Fluorescein angiography and optical coherence tomography (OCT) were also performed in order to describe the macular hemorrhages. Results: Four out of 215 eyes developed macular hemorrhage within 48 h after the photodynamic therapy. Before treatment one of the four patients had classic CNV, one predominantly classic and two patients occult CNV without any classic component. In all four cases, the hemorrhage after photodynamic therapy (PDT) was extensive, it extended beyond the arcades and it was not absorbed during the follow-up period, which ranged from 11 to 21 months. The greatest linear dimension of the hemorrhage was extremely high (>12,000 mum). Conclusion: Extensive macular hemorrhage was observed in 1.86% of the studied cases. The hemorrhage was not related to the type of the CNV lesion before treatment. The size and the appearance of hemorrhage within 48 h after treatment support the view that the hemorrhage is a direct consequence of the photodynamic therapy and not related to the natural course of the disease.
C1 Univ Athens, Dept Ophthalmol, GR-10679 Athens, Greece.
C3 National & Kapodistrian University of Athens
RP Theodossiadis, GP (通讯作者)，13 Lykiou St, Athens 10674, Greece.
RI Georgalas, Ilias/AAD-5946-2019
OI Georgalas, Ilias/0000-0002-6171-5865
CR Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   GREEN WR, 1991, RETINA-J RET VIT DIS, V11, P328, DOI 10.1097/00006982-199111030-00010
   HAWKINS BS, 1993, ARCH OPHTHALMOL-CHIC, V111, P1200
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   MAGUIRE MG, 1994, ARCH OPHTHALMOL-CHIC, V112, P480
   Miller JW, 1999, ARCH OPHTHALMOL-CHIC, V117, P1161
   Schmidt-Erfurth U, 1999, ARCH OPHTHALMOL-CHIC, V117, P1177
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1232
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
NR 12
TC 12
Z9 13
U1 0
U2 2
PU SPRINGER-VERLAG
PI NEW YORK
PA 175 FIFTH AVE, NEW YORK, NY 10010 USA
SN 0721-832X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD JAN
PY 2003
VL 241
IS 1
BP 13
EP 18
DI 10.1007/s00417-002-0579-3
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 647ZE
UT WOS:000181123300003
PM 12545287
DA 2022-11-30
ER

PT J
AU Landa, G
   Butovsky, O
   Shoshani, J
   Schwartz, M
   Pollack, A
AF Landa, Gennady
   Butovsky, Oleg
   Shoshani, Johai
   Schwartz, Michal
   Pollack, Ayala
TI Weekly Vaccination with Copaxone (Glatiramer Acetate) as a Potential
   Therapy for Dry Age-Related Macular Degeneration
SO CURRENT EYE RESEARCH
LA English
DT Article
DE age-related macular degeneration; Copaxone; drusen; microglia
ID ALZHEIMERS-DISEASE
AB Purpose: Drusen formation in age-related macular degeneration (AMD) shares some similarities with Alzheimer's disease (AD), which is associated with amyloid deposits. Aggregated beta-amyloid induces microglia to become cytotoxic and block neurogenesis. Recent evidence showed that T cell-based vaccination with Copaxone in AD mice model resulted in modulation of microglia into neuroprotective phenotype and as a result in reduction of cognitive decline, elimination of plaque formation, and induction of neuronal survival and neurogenesis. The aim was to investigate whether the effect of Copaxone on drusen in dry AMD is similar to that on deposits of other age-related chronic neurodegenerative diseases such as Alzheimer disease (AD). Materials and Methods: Patients over 50 years of age with intermediate dry AMD in both eyes were randomized to receive Copaxone or sham injections and were weekly treated by subcutaneous injections of Copaxone (dose of 20 mg) or sham injections for 12 weeks. At baseline, 6-week, and 12-week visits, visual acuity, contrast sensitivity, fundus examination and photography, fluorescein angiography, and ocular coherent tomography were performed. Main outcome measure was a change in total drusen area (TDA) measured by Image-Pro software and presented in arbitrary units (AU). Results: Eight studied eyes of four treated patients showed a decrease in TDA from 48130 to 16205 AU at 12 weeks as compared to baseline. In contrast, four control eyes (two patients) demonstrated almost no change in TDA (from 32294 to 32781 AU). Conclusion: These preliminary results show that Copaxone reduces drusen area.
C1 [Landa, Gennady; Shoshani, Johai; Pollack, Ayala] Kaplan Med Ctr, Dept Ophthalmol, IL-76100 Rehovot, Israel.
   [Landa, Gennady] New York Eye & Ear Infirm, Dept Ophthalmol, Retina Ctr, New York, NY 10003 USA.
   [Butovsky, Oleg; Schwartz, Michal] Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel.
   [Butovsky, Oleg] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Neurol,Ctr Neurol Dis, Boston, MA 02115 USA.
C3 Hebrew University of Jerusalem; Kaplan Medical Center; New York Eye &
   Ear Infirmary of Mount Sinai; Weizmann Institute of Science; Harvard
   University; Brigham & Women's Hospital; Harvard Medical School
RP Landa, G (通讯作者)，Kaplan Med Ctr, Dept Ophthalmol, POB 1, IL-76100 Rehovot, Israel.
EM doctor.landa@gmail.com
RI Butovsky, Oleg/ABG-9086-2020
OI Butovsky, Oleg/0000-0003-0186-8867
CR [Anonymous], 2005, ARCH OPHTHALMOL-CHIC, V123, P1570, DOI DOI 10.1001/ARCHOPHT.123.11.1570
   Butovsky O, 2007, EUR J NEUROSCI, V26, P413, DOI 10.1111/j.1460-9568.2007.05652.x
   Butovsky O, 2006, P NATL ACAD SCI USA, V103, P11784, DOI 10.1073/pnas.0604681103
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
NR 5
TC 38
Z9 47
U1 0
U2 2
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0271-3683
EI 1460-2202
J9 CURR EYE RES
JI Curr. Eye Res.
PY 2008
VL 33
IS 11-12
BP 1011
EP 1013
AR PII 906653266
DI 10.1080/02713680802484637
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 383DC
UT WOS:000261653300013
PM 19085384
DA 2022-11-30
ER

PT J
AU Puell, MC
   Hurtado-Cena, FJ
   Perez-Carrasco, MJ
   Contreras, I
AF Puell, Maria Cinta
   Hurtado-Cena, Francisco Javier
   Perez-Carrasco, Maria Jesus
   Contreras, Ines
TI Association between central retinal thickness and low luminance visual
   acuity in early age-related macular degeneration
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; central retinal thickness; visual
   acuity; mesopic vision; low luminance deficit; retina
ID OPTICAL COHERENCE TOMOGRAPHY; MULLER CELLS; OLDER EYES; LAYER;
   REPEATABILITY; DYSFUNCTION; MORPHOLOGY
AB Purpose/Aim: To examine whether central retinal thickness (CRT) is related to mesopic visual acuity (VA) and low luminance deficit (LLD, difference between photopic and mesopic VA) in eyes with early and intermediate age-related macular degeneration (AMD). Materials and Methods: In a cross-sectional study, 50 pseudophakic subjects older than 63 years were divided into three groups (no AMD, early AMD and intermediate AMD). Spectral domain optical coherence tomography (SD-OCT) was used to measure CRT in the 1 mm-central-area. Best-corrected distance VA was measured under photopic or mesopic luminance conditions and LLD calculated. Subjects were stratified by VA impairment to compare CRTs across these groups. Relationships were examined by stepwise multiple linear regression. Results: No significant differences in mean CRT, photopic and mesopic VA or LLD were detected between the groups no AMD, early AMD and intermediate AMD. However, mean CRTs were 20 microns and 18 microns thicker in the eyes with impaired mesopic VA (> 0.3 logMAR) and impaired LLD (> 0.3 logMAR) compared to the eyes with non-impaired VA or LLD respectively (both p < 0.01). CRT and mesopic pupil size were independent predictors of mesopic VA (p = 0.001). CRT emerged as the only independent predictor of LLD (p = 0.004). Conclusions: Increased CRT was linked to worse retinal function when measured under mesopic conditions in eyes without AMD and eyes with early to intermediate AMD. SD-OCT imaging combined with VA measurements under low luminance conditions could be a useful tool to detect early AMD.
C1 [Puell, Maria Cinta; Perez-Carrasco, Maria Jesus] Univ Complutense Madrid, Fac Opt & Optometry, Appl Vis Res Grp, Ave Arcos de Jalon 118, Madrid 28037, Spain.
   [Hurtado-Cena, Francisco Javier; Contreras, Ines] Clin Rementeria, Madrid, Spain.
   [Contreras, Ines] Hosp Ramon & Cajal, Opthalmol, Inst Ramon y Cajal Invest Sanitarias IRYCIS, Madrid, Spain.
C3 Complutense University of Madrid; Hospital Universitario Ramon y Cajal
RP Puell, MC (通讯作者)，Univ Complutense Madrid, Fac Opt & Optometry, Appl Vis Res Grp, Ave Arcos de Jalon 118, Madrid 28037, Spain.
EM puellma@ucm.es
RI Puell, MarÃa/ABE-2972-2021
OI Puell, Maria Cinta/0000-0002-9227-4927
CR Acton JH, 2012, INVEST OPHTH VIS SCI, V53, P7618, DOI 10.1167/iovs.12-10361
   Brandl C, 2019, INVEST OPHTH VIS SCI, V60, P1581, DOI 10.1167/iovs.18-25332
   Bringmann A, 2006, PROG RETIN EYE RES, V25, P397, DOI 10.1016/j.preteyeres.2006.05.003
   Buschini E, 2011, PROG NEUROBIOL, V95, P14, DOI 10.1016/j.pneurobio.2011.05.011
   Chandramohan A, 2016, RETINA-J RET VIT DIS, V36, P1021, DOI 10.1097/IAE.0000000000001002
   Chua BE, 2004, EYE, V18, P765, DOI 10.1038/sj.eye.6701366
   Puell MC, 2019, CURR EYE RES, V44, P82, DOI 10.1080/02713683.2018.1522648
   Puell MC, 2017, OPTOMETRY VISION SCI, V94, P505, DOI 10.1097/OPX.0000000000001061
   Clark ME, 2011, BRIT J OPHTHALMOL, V95, P1427, DOI 10.1136/bjo.2010.190355
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Giani A, 2010, AM J OPHTHALMOL, V150, P815, DOI 10.1016/j.ajo.2010.06.025
   Gonzalez EG, 2007, INVEST OPHTH VIS SCI, V48, P4838, DOI 10.1167/iovs.06-1240
   Hogg RE, 2006, PROG RETIN EYE RES, V25, P249, DOI 10.1016/j.preteyeres.2005.11.002
   Lains I, 2017, OPHTHALMOLOGY, V124, P1340, DOI 10.1016/j.ophtha.2017.03.061
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Madeira MH, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/673090
   Nusinowitz S, 2018, CURR EYE RES, V43, P376, DOI 10.1080/02713683.2017.1401646
   Ou WC, 2017, AM J OPHTHALMOL, V180, P8, DOI 10.1016/j.ajo.2017.05.014
   Owsley C, 2016, INVEST OPHTH VIS SCI, V57, P1782, DOI 10.1167/iovs.15-18962
   Owsley C, 2016, CURR EYE RES, V41, P266, DOI 10.3109/02713683.2015.1011282
   Pappuru RR, 2011, INVEST OPHTH VIS SCI, V52, P6743, DOI 10.1167/iovs.10-6723
   Puell MC, 2012, INVEST OPHTH VIS SCI, V53, P7310, DOI 10.1167/iovs.11-8649
   Raasch TW, 1998, OPTOMETRY VISION SCI, V75, P342, DOI 10.1097/00006324-199805000-00024
   Reichenbach A, 2007, GRAEF ARCH CLIN EXP, V245, P627, DOI 10.1007/s00417-006-0516-y
   Ristau T, 2014, OPHTHALMOLOGICA, V231, P37, DOI 10.1159/000354551
   Sadigh S, 2013, INVEST OPHTH VIS SCI, V54, P1603, DOI 10.1167/iovs.12-11286
   Sassmannshausen M, 2018, INVEST OPHTH VIS SCI, V59, P1599, DOI 10.1167/iovs.17-22712
   Schmidt-Erfurth U, 2017, EYE, V31, P26, DOI 10.1038/eye.2016.227
   Sevilla MB, 2016, AM J OPHTHALMOL, V165, P65, DOI 10.1016/j.ajo.2016.02.021
   Sharma S, 2016, OPHTHALMOLOGY, V123, P865, DOI 10.1016/j.ophtha.2015.12.002
   Shim SH, 2016, OPHTHAL EPIDEMIOL, V23, P80, DOI 10.3109/09286586.2015.1129425
   Shin IH, 2018, RETINA-J RET VIT DIS, V38, P253, DOI 10.1097/IAE.0000000000001535
   Steinberg JS, 2016, AM J OPHTHALMOL, V168, P52, DOI 10.1016/j.ajo.2016.04.025
   Sunness JS, 2008, OPHTHALMOLOGY, V115, P1480, DOI 10.1016/j.ophtha.2008.03.009
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P1612, DOI 10.1016/j.ophtha.2014.02.005
   Xu HP, 2009, PROG RETIN EYE RES, V28, P348, DOI 10.1016/j.preteyeres.2009.06.001
NR 36
TC 0
Z9 0
U1 1
U2 2
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD SEP
PY 2021
VL 31
IS 5
BP 2467
EP 2473
AR 1120672120968740
DI 10.1177/1120672120968740
EA NOV 2020
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA XG9FP
UT WOS:000679149000001
PM 33153337
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Pujol-Lereis, LM
   Liebisch, G
   Schick, T
   Lin, YC
   Grassmann, F
   Uchida, K
   Zipfel, PF
   Fauser, S
   Skerka, C
   Weber, BHF
AF Pujol-Lereis, Luciana M.
   Liebisch, Gerhard
   Schick, Tina
   Lin, Yuchen
   Grassmann, Felix
   Uchida, Koji
   Zipfel, Peter F.
   Fauser, Sascha
   Skerka, Christine
   Weber, Bernhard H. F.
TI Evaluation of serum sphingolipids and the influence of genetic risk
   factors in age-related macular degeneration
SO PLOS ONE
LA English
DT Article
ID COMPLEMENT FACTOR-H; STRESS-INDUCED APOPTOSIS; GENOME-WIDE ASSOCIATION;
   OXIDATIVE STRESS; DENSITY-LIPOPROTEIN; PLASMA CERAMIDES;
   CHOLESTEROL-METABOLISM; CARDIOVASCULAR-DISEASE; FATTY-ACIDS;
   MALONDIALDEHYDE
AB Sphingolipids are bioactive molecules associated with oxidative stress, inflammation, and neurodegenerative diseases, but poorly studied in the context of age-related macular degeneration (AMD), a prevalent sight-threatening disease of the ageing retina. Here, we found higher serum levels of hexosylceramide (HexCer) d18:1/16:0 in patients with choroidal neovascularization (CNV) and geographic atrophy (GA), two manifestations of late stage AMD, and higher ceramide (Cer) d18:1/16:0 levels in GA patients. A sensitivity analysis of genetic variants known to be associated with late stage AMD showed that rs1061170 (p.Y402H) in the complement factor H (CFH) gene influences the association of Cer d18:1/ 16:0 with GA. To understand the possible influence of this genetic variant on ceramide levels, we established a cell-based assay to test the modulation of genes in the ceramide metabolism by factor H-like protein 1 (FHL-1), an alternative splicing variant of CFH that also harbors the 402 residue. We first showed that malondialdehyde-acetaldehyde adducts, an oxidation product commonly found in AMD retinas, induces an increase in ceramide levels in WERI-Rb1 cells in accordance with an increased expression of ceramide synthesis genes. Then, we observed that cells exposed to the non-risk FHL-1 :Y402, but not the risk associated variant FHL-1 :H402 or full-length CFH, downregulated ceramide synthase 2 and ceramide glucosyltransferase gene expression. Together, our findings show that serum ceramide and hexosylceramide species are altered in AMD patients and that ceramide levels may be influenced by AMD associated risk variants.
C1 [Pujol-Lereis, Luciana M.; Grassmann, Felix; Weber, Bernhard H. F.] Univ Regensburg, Inst Human Genet, Regensburg, Germany.
   [Liebisch, Gerhard] Univ Regensburg, Inst Clin Chem & Lab Med, Regensburg, Germany.
   [Schick, Tina; Fauser, Sascha] Univ Hosp Cologne, Dept Ophthalmol, Cologne, Germany.
   [Lin, Yuchen; Zipfel, Peter F.; Skerka, Christine] Leibniz Inst Nat Prod Res & Infect Biol, Dept Infect Biol, Jena, Germany.
   [Uchida, Koji] Univ Tokyo, Grad Sch Agr & Life Sci, Tokyo, Japan.
   [Fauser, Sascha] F Hoffmann La Roche, Basel, Switzerland.
   [Pujol-Lereis, Luciana M.] CIDIE CONICET, Ctr Invest & Desarrollo Inmunol & Enfermedades In, Cordoba, Argentina.
C3 University of Regensburg; University of Regensburg; University of
   Cologne; Hans Knoll Institute (HKI); University of Tokyo; Roche Holding
RP Pujol-Lereis, LM; Weber, BHF (通讯作者)，Univ Regensburg, Inst Human Genet, Regensburg, Germany.; Pujol-Lereis, LM (通讯作者)，CIDIE CONICET, Ctr Invest & Desarrollo Inmunol & Enfermedades In, Cordoba, Argentina.
EM lpujollereis@cidie.ucc.edu.ar; bweb@klinik.uni-regensburg.de
RI Liebisch, Gerhard/G-6130-2010
OI Liebisch, Gerhard/0000-0003-4886-0811; Uchida, Koji/0000-0003-3894-5299;
   Pujol Lereis, Luciana Mercedes/0000-0002-7009-2743; Grassmann,
   Felix/0000-0003-1390-7528
FU Alexander von Humboldt Foundation; institutional funds of Titel Group 77
   (Institute of Human Genetics); Bavarian State Ministry of Education and
   Cultural Affairs, Science and the Arts; National Scientific and
   Technical Research Council (CONICET) from Argentina; F. Hoffmann - La
   Roche
FX The work was supported by the Alexander von Humboldt Foundation and
   institutional funds of Titel Group 77 (Institute of Human Genetics).
   LMPL was supported by the Alexander von Humboldt Foundation as a Georg
   Forster Postdoctoral Fellow, and by a Grant for female scientists from
   the Bavarian State Ministry of Education and Cultural Affairs, Science
   and the Arts, and is now supported by The National Scientific and
   Technical Research Council (CONICET) from Argentina. F. Hoffmann - La
   Roche provided support in the form of salary for Dr. Sascha Fauser, but
   did not have any additional role in the study. The funders had no role
   in study design, data collection and analysis, decision to publish, or
   preparation of the manuscript. The specific roles of the authors are
   articulated in the 'author contributions' section.
CR Abrahan CE, 2010, INVEST OPHTH VIS SCI, V51, P1171, DOI 10.1167/iovs.09-3909
   Acar N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035102
   Ambreen F, 2014, J PAK MED ASSOC, V64, P664
   Bartke N, 2009, J LIPID RES, V50, pS91, DOI 10.1194/jlr.R800080-JLR200
   BASU SK, 1976, P NATL ACAD SCI USA, V73, P3178, DOI 10.1073/pnas.73.9.3178
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Blachnio-Zabielska A, 2016, ADV MED SCI-POLAND, V61, P72, DOI 10.1016/j.advms.2015.09.006
   BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911
   Bode GH, 2014, J IMMUNOL, V192, P1154, DOI 10.4049/jimmunol.1301673
   Butt AL, 2011, OPHTHALMOLOGY, V118, P1380, DOI 10.1016/j.ophtha.2010.11.007
   Cackett P, 2008, AM J OPHTHALMOL, V146, P960, DOI 10.1016/j.ajo.2008.06.026
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Clark SJ, 2014, J IMMUNOL, V193, P4962, DOI 10.4049/jimmunol.1401613
   Cougnard-Gregoire A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090973
   Cutler RG, 2004, P NATL ACAD SCI USA, V101, P2070, DOI 10.1073/pnas.0305799101
   Davari MH, 2013, J RES HEALTH SCI, V13, P98
   Demirkan A, 2013, J PSYCHIATR RES, V47, P357, DOI 10.1016/j.jpsychires.2012.11.001
   Dossarps D, 2016, OPHTHALMIC RES, V56, P41, DOI 10.1159/000444059
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Erdreich-Epstein A, 2000, CANCER RES, V60, P707
   Erke MG, 2014, ACTA OPHTHALMOL, V92, P662, DOI 10.1111/aos.12346
   Fauser S, 2011, INVEST OPHTH VIS SCI, V52, P5525, DOI 10.1167/iovs.10-6827
   Fonteh AN, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125597
   Fox TE, 2006, DIABETES, V55, P3573, DOI 10.2337/db06-0539
   FRAENKELCONRAT H, 1949, J BIOL CHEM, V177, P385
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Futerman AH, 2004, EMBO REP, V5, P777, DOI 10.1038/sj.embor.7400208
   German OL, 2006, INVEST OPHTH VIS SCI, V47, P1658, DOI 10.1167/iovs.05-1310
   Gorusupudi A, 2016, J LIPID RES, V57, P499, DOI 10.1194/jlr.P065540
   Grassmann F, 2017, GENOME MED, V9, DOI 10.1186/s13073-017-0418-0
   Grassmann F, 2017, GENETICS, V205, P919, DOI 10.1534/genetics.116.195966
   Hannun YA, 2008, NAT REV MOL CELL BIO, V9, P139, DOI 10.1038/nrm2329
   Hellwage J, 1997, BIOCHEM J, V326, P321, DOI 10.1042/bj3260321
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Kang S, 2007, HISTOPATHOLOGY AGE R, P1
   Kannan R, 2004, FREE RADICAL BIO MED, V37, P166, DOI 10.1016/j.freeradbiomed.2004.04.011
   Kim M, 2017, J ALZHEIMERS DIS, V60, P809, DOI 10.3233/JAD-160645
   KLEIN R, 1993, OPHTHALMOLOGY, V100, P406
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2014, AM J OPHTHALMOL, V158, P513, DOI 10.1016/j.ajo.2014.05.027
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   Kuhn S, 1996, EUR J IMMUNOL, V26, P2383, DOI 10.1002/eji.1830261017
   KUHN S, 1995, J IMMUNOL, V155, P5663
   Larsen PJ, 2014, MOL METAB, V3, P252, DOI 10.1016/j.molmet.2014.01.011
   Liebisch G, 1999, J LIPID RES, V40, P1539
   Liebisch G, 2004, BBA-MOL CELL BIOL L, V1686, P108, DOI 10.1016/j.bbalip.2004.09.003
   Liebisch G, 2013, J LIPID RES, V54, P1523, DOI 10.1194/jlr.M033506
   Merle BMJ, 2014, INVEST OPHTH VIS SCI, V55, P2010, DOI 10.1167/iovs.14-13916
   Merle BMJ, 2013, J NUTR, V143, P505, DOI 10.3945/jn.112.171033
   Mielke MM, 2017, J ALZHEIMERS DIS, V60, P819, DOI 10.3233/JAD-160925
   Mielke MM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073094
   Mielke MM, 2012, NEUROLOGY, V79, P633, DOI 10.1212/WNL.0b013e318264e380
   Mielke MM, 2010, NEUROBIOL AGING, V31, P17, DOI 10.1016/j.neurobiolaging.2008.03.011
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Nita M, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/3164734
   Nixon GF, 2009, BRIT J PHARMACOL, V158, P982, DOI 10.1111/j.1476-5381.2009.00281.x
   Nowak M, 2005, CLIN EXP MED, V4, P183, DOI 10.1007/s10238-004-0054-z
   Pandey MK, 2017, NATURE, V543, P108, DOI 10.1038/nature21368
   Paun CC, 2015, INVEST OPHTH VIS SCI, V56, P7766, DOI 10.1167/iovs.15-17035
   Poli V, 1998, J BIOL CHEM, V273, P29279, DOI 10.1074/jbc.273.45.29279
   Ristau T, 2014, INVEST OPHTH VIS SCI, V55, P210, DOI 10.1167/iovs.13-13248
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Sanvicens N, 2006, J NEUROCHEM, V98, P1432, DOI 10.1111/j.1471-4159.2006.03977.x
   Savica Rodolfo, 2016, Alzheimers Dement (Amst), V3, P43
   SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O
   Seidova SF, 2009, DOC OPHTHALMOL, V118, P151, DOI 10.1007/s10633-008-9142-9
   Shaaban SA, 1998, INVEST OPHTH VIS SCI, V39, P885
   Sun L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019477
   Swinkels M, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-18395-7
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   Totan Y, 2001, BRIT J OPHTHALMOL, V85, P1426, DOI 10.1136/bjo.85.12.1426
   Van Brocklyn JR, 2012, COMP BIOCHEM PHYS B, V163, P26, DOI 10.1016/j.cbpb.2012.05.006
   van Leeuwen R, 2004, AM J OPHTHALMOL, V137, P750, DOI 10.1016/S0002-9394(03)01089-4
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   Wiesner P, 2009, J LIPID RES, V50, P574, DOI 10.1194/jlr.D800028-JLR200
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xing Y, 2016, J ALZHEIMERS DIS, V52, P1029, DOI 10.3233/JAD-151158
   Yamada S, 2001, J LIPID RES, V42, P1187
   Ye FX, 2016, FREE RADICAL BIO MED, V94, P121, DOI 10.1016/j.freeradbiomed.2016.02.027
NR 83
TC 12
Z9 12
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 2
PY 2018
VL 13
IS 8
DI 10.1371/journal.pone.0200739
PG 20
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA GP3UD
UT WOS:000440778600017
PM 30071029
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Bloch, SB
   la Cour, M
   Sander, B
   Hansen, LKH
   Fuchs, J
   Lund-Andersen, H
   Larsen, M
AF Bloch, Sara B.
   la Cour, Morten
   Sander, Birgit
   Hansen, Louise K. H.
   Fuchs, Josefine
   Lund-Andersen, Henrik
   Larsen, Michael
TI Predictors of 1-year visual outcome in neovascular age-related macular
   degeneration following intravitreal ranibizumab treatment
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration; choroidal neovascular membrane;
   ranibizumab; variable dosing regimen
ID PHOTODYNAMIC THERAPY; SUBGROUP ANALYSIS; DOSING REGIMEN; VERTEPORFIN
AB . Purpose: To describe predictors of visual outcome in patients treated with intravitreal ranibizumab for choroidal neovascularisation (CNV) in age-related macular degeneration (AMD). Methods: Retrospective review of 279 patients with CNV in AMD who fulfilled MARINA/ANCHOR study eligibility criteria and were treated with repeated intravitreal injections of ranibizumab 0.5 mg in routine clinical practice, beginning with three initial injections at 4-week intervals followed by individualized retreatment for the subsequent 9 months. Study parameters included best-corrected visual acuity (BCVA) and morphological characteristics. Results: Mean BCVA relative to baseline was +4.7 (p < 0.0001), +4.2 (p < 0.0001)and -0.4 (p > 0.667) Early Treatment Diabetic Retinopathy Study letters after 3, 6 and 12 months, respectively, after a mean of 5.1 injections when the proportion of patients with BCVA =70 letters had doubled compared with baseline. Predictive factors for BCVA =35 letters after 12 months were BCVA =35 letters at baseline and month 3 (p < 0.0001) while BCVA =70 letters at month 12 was associated with BCVA =70 letters at baseline and month 3 (p < 0.001) and with total lesion size <4 DA (p = 0.0147). Conclusion: Under a ranibizumab regimen with substantially fewer injections than with fixed four-weekly injection regimens, BCVA was improved compared with the natural history of neovascular AMD, but did not achieve the visual gain observed in randomized clinical trials using fixed 4-week retreatment. Visual acuity at month 3, after the initial fixed-interval injections, was the strongest predictor of BCVA at month 12.
C1 [Bloch, Sara B.; la Cour, Morten; Sander, Birgit; Hansen, Louise K. H.; Fuchs, Josefine; Lund-Andersen, Henrik; Larsen, Michael] Glostrup Cty Hosp, Dept Ophthalmol, DK-2600 Glostrup, Denmark.
   [Bloch, Sara B.; la Cour, Morten; Sander, Birgit; Fuchs, Josefine; Lund-Andersen, Henrik; Larsen, Michael] Univ Copenhagen, Copenhagen, Denmark.
C3 University of Copenhagen; University of Copenhagen
RP Bloch, SB (通讯作者)，Glostrup Cty Hosp, Dept Ophthalmol, Nordre Ringvej 57, DK-2600 Glostrup, Denmark.
EM sabrbl01@glo.regionh.dk
RI Larsen, Michael/E-9620-2010; la Cour, Morten/L-1600-2013
OI Larsen, Michael/0000-0002-5172-5891; Dornonville de la Cour,
   Morten/0000-0002-7712-9772
FU Velux Foundation; John and Birthe Meyer Foundation; Bagenkop Nielsen
   Myopia Foundation; Center for Biomedical Optics and New laser Systems
   (BIOP); Novartis
FX Supported by The Velux Foundation, The John and Birthe Meyer Foundation,
   The Bagenkop Nielsen Myopia Foundation and The Center for Biomedical
   Optics and New laser Systems (BIOP). The funding organizations had no
   role in the design or the conduct of this research.; The Glostrup
   Hospital has received financial compensation from Novartis and competing
   commercial entities for consultancies and contract research.
CR Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Bandukwala T, 2010, CAN J OPHTHALMOL, V45, P590, DOI 10.3129/i10-082
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1443
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Cohen SY, 2009, AM J OPHTHALMOL, V148, P409, DOI 10.1016/j.ajo.2009.04.001
   Dadgostar H, 2009, OPHTHALMOLOGY, V116, P1740, DOI 10.1016/j.ophtha.2009.05.033
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gupta B, 2011, BRIT J OPHTHALMOL, V95, P386, DOI 10.1136/bjo.2010.179499
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   HAWKINS BS, 1991, ARCH OPHTHALMOL-CHIC, V109, P1109
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   MEYER CH, 2008, INVEST OPHTHALMOL VI, V49
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   Rothenbuehler SP, 2009, AM J OPHTHALMOL, V147, P831, DOI 10.1016/j.ajo.2008.12.005
   Spielberg L, 2010, GRAEF ARCH CLIN EXP, V248, P943, DOI 10.1007/s00417-009-1256-6
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
NR 22
TC 48
Z9 48
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD FEB
PY 2013
VL 91
IS 1
BP 42
EP 47
DI 10.1111/j.1755-3768.2011.02268.x
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 078WG
UT WOS:000314130400017
PM 22008284
DA 2022-11-30
ER

PT J
AU Cugati, S
   Cumming, RG
   Smith, W
   Burlutsky, G
   Mitchell, P
   Wang, JJ
AF Cugati, Sudha
   Cumming, Robert G.
   Smith, Wayne
   Burlutsky, George
   Mitchell, Paul
   Wang, Jie Jin
TI Visual impairment, age-related macular degeneration, cataract, and
   long-term mortality - The Blue Mountains Eye Study
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID NATIONAL DEATH INDEX; ALL-CAUSE MORTALITY; BEAVER DAM EYE; OLDER-ADULTS;
   LENS OPACITIES; CARDIOVASCULAR EVENTS; 5-YEAR MORTALITY; GRADING SYSTEM;
   DISEASE; POPULATION
AB Objective: To assess the association of visual impairment, age-related macular degeneration (ARMD), and cataract with long-term mortality.
   Methods: At baseline, 3654 persons 49 years and older were examined in the Blue Mountains Eye Study ( 19921994). Standardized photographic grading was used to assess ARMD and cataract. Mortality and causes of death occurring between baseline and December 31, 2003, were obtained via data linkage with the Australian National Death Index. Age-standardized mortality rates were calculated. Hazard ratios (HRs) and 95% confidence intervals (CIs) were assessed using Cox models.
   Result: Age-standardized mortality was higher in persons with vs without visual impairment (54.0% vs 34.0%), ARMD (45.8% vs 33.7%), and cataract (39.2% vs 29.5%). After adjusting for factors that predict mortality, neither visual impairment ( HR, 1.3; 95% CI, 0.98-1.7) nor ARMD ( HR, 1.0; 95% CI, 0.8-1.3) was significantly associated with all-cause mortality in all ages. Among persons younger than 75 years, however, ARMD predicted higher all-cause mortality ( HR, 1.6; 95% CI, 1.0-2.4). Any cataract ( HR, 1.3; 95% CI, 1.0-1.5) and cortical ( HR, 1.2; 95% CI, 0.97-1.4), nuclear ( HR, 1.2; 95% CI, 0.98-1.5), and posterior subcapsular ( HR, 1.3; 95% CI, 1.0-1.7) cataract were also associated with higher all-cause mortality.
   Conclusion: Cataract predicted increased mortality in persons 49 years and older, and ARMD predicted mortality in persons aged 49 to 74 years.
C1 Univ Sydney, Ctr Vis Res, Dept Ophthalmol, Westmead Millennium Inst, Westmead, NSW 2145, Australia.
   Univ Sydney, Dept Publ Hlth & Community Med, Westmead, NSW 2145, Australia.
   Univ Newcastle, Ctr Clin Epidemiol & Biostat, Newcastle, NSW 2308, Australia.
C3 University of Sydney; Westmead Institute for Medical Research;
   University of Sydney; University of Newcastle
RP Wang, JJ (通讯作者)，Univ Sydney, Ctr Vis Res, Dept Ophthalmol, Westmead Millennium Inst,Westmead Hosp, Hawkesbury Rd, Westmead, NSW 2145, Australia.
EM jiejin_wang@wmi.usyd.edu.au
RI Cugati, Sudha/ABB-1331-2021; Cumming, Robert G/R-1548-2016; wang,
   jie/GRS-0942-2022; Wang, Jie Jin/P-1499-2014; Mitchell, Paul/P-1498-2014
OI Cumming, Robert G/0000-0002-0261-6103; Wang, Jie
   Jin/0000-0001-9491-4898; 
CR Afridi I, 2003, J HYPERTENS, V21, P1983, DOI 10.1097/01.hjh.0000084751-37215.d2
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   BENGTSSON B, 1984, ACTA OPHTHALMOL, V62, P725
   BENSON WH, 1988, OPHTHALMOLOGY, V95, P1288
   Berman K, 2006, INT PSYCHOGERIATR, V18, P415, DOI 10.1017/S1041610205002905
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Borger PH, 2003, OPHTHALMOLOGY, V110, P1292, DOI 10.1016/S0161-6420(03)00450-0
   Buch H, 2005, OPHTHALMOLOGY, V112, P305, DOI 10.1016/j.ophtha.2004.08.025
   Clemons TE, 2004, ARCH OPHTHALMOL-CHIC, V122, P716
   De Martinis M, 2006, EXP MOL PATHOL, V80, P219, DOI 10.1016/j.yexmp.2005.11.004
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Empana JP, 2006, ARCH INTERN MED, V166, P195, DOI 10.1001/archinte.166.2.195
   Ganguli M, 2002, ARCH GEN PSYCHIAT, V59, P1046, DOI 10.1001/archpsyc.59.11.1046
   Hennis A, 2001, OPHTHALMOLOGY, V108, P498, DOI 10.1016/S0161-6420(00)00542-X
   Horowitz A, 2005, AGING MENT HEALTH, V9, P563, DOI 10.1080/13607860500193500
   Hu FB, 2001, AM J EPIDEMIOL, V153, P875, DOI 10.1093/aje/153.9.875
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   Ivers RQ, 2000, AM J EPIDEMIOL, V152, P633, DOI 10.1093/aje/152.7.633
   Ivers RQ, 1999, AM J PUBLIC HEALTH, V89, P85, DOI 10.2105/AJPH.89.1.85
   Ivers RQ, 1998, J AM GERIATR SOC, V46, P58
   KAHN HA, 1977, AM J EPIDEMIOL, V106, P33, DOI 10.1093/oxfordjournals.aje.a112429
   KLEIN R, 1995, ARCH OPHTHALMOL-CHIC, V113, P333, DOI 10.1001/archopht.1995.01100030089026
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Knudtson MD, 2006, ARCH OPHTHALMOL-CHIC, V124, P243, DOI 10.1001/archopht.124.2.243
   Krumpaszky HG, 1999, OPHTHALMOLOGICA, V213, P48, DOI 10.1159/000027393
   Lee DJ, 2002, ARCH OPHTHALMOL-CHIC, V120, P1544, DOI 10.1001/archopht.120.11.1544
   Lee P, 1999, AM J OPHTHALMOL, V127, P447, DOI 10.1016/S0002-9394(98)00418-8
   Magliano D, 2003, AUST NZ J PUBL HEAL, V27, P649, DOI 10.1111/j.1467-842X.2003.tb00615.x
   Margolis KL, 2005, ARCH INTERN MED, V165, P500, DOI 10.1001/archinte.165.5.500
   McCarty CA, 2001, BRIT J OPHTHALMOL, V85, P322, DOI 10.1136/bjo.85.3.322
   Mitchell P, 1997, OPHTHALMOLOGY, V104, P581, DOI 10.1016/S0161-6420(97)30266-8
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Nucci C, 2004, GRAEF ARCH CLIN EXP, V242, P289, DOI 10.1007/s00417-003-0837-z
   PODGOR MJ, 1989, AM HEART J, V117, P642, DOI 10.1016/0002-8703(89)90740-0
   Powers J, 2000, AUST NZ J PUBL HEAL, V24, P526, DOI 10.1111/j.1467-842X.2000.tb00504.x
   Reidy A, 2002, BRIT J OPHTHALMOL, V86, P424, DOI 10.1136/bjo.86.4.424
   Rumsfeld JS, 2005, AM HEART J, V150, P961, DOI 10.1016/j.ahj.2005.02.036
   Shankar A, 2007, ATHEROSCLEROSIS, V192, P177, DOI 10.1016/j.atherosclerosis.2006.04.029
   Sheps DS, 2002, CIRCULATION, V105, P1780, DOI 10.1161/01.CIR.0000014491.90666.06
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   STREET DA, 1992, AM J OPHTHALMOL, V113, P263, DOI 10.1016/S0002-9394(14)71577-6
   Thiagarajan M, 2005, ARCH OPHTHALMOL-CHIC, V123, P1397, DOI 10.1001/archopht.123.10.1397
   THOMPSON JR, 1993, ARCH OPHTHALMOL-CHIC, V111, P675, DOI 10.1001/archopht.1993.01090050109039
   Tolman J, 2005, GERONTOLOGIST, V45, P747, DOI 10.1093/geront/45.6.747
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
   VARMA SD, 1991, AM J CLIN NUTR, V53, pS335, DOI 10.1093/ajcn/53.1.335S
   Wang JJ, 2001, ARCH OPHTHALMOL-CHIC, V119, P1186, DOI 10.1001/archopht.119.8.1186
   Wang LH, 2001, COGNITIVE BRAIN RES, V12, P19, DOI 10.1016/S0926-6410(01)00022-2
   West SK, 1997, INVEST OPHTH VIS SCI, V38, P72
   West SK, 2000, ARCH OPHTHALMOL-CHIC, V118, P393, DOI 10.1001/archopht.118.3.393
   Williams SL, 2002, AM J EPIDEMIOL, V156, P127, DOI 10.1093/aje/kwf012
   WITZTUM JL, 1994, LANCET, V344, P793, DOI 10.1016/S0140-6736(94)92346-9
   World Health Organization, 1992, INT STAT CLASS DIS
   World Health Organization, 1977, INT CLASS DIS
NR 56
TC 90
Z9 90
U1 0
U2 5
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA
SN 0003-9950
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD JUL
PY 2007
VL 125
IS 7
BP 917
EP 924
DI 10.1001/archopht.125.7.917
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 188BE
UT WOS:000247892600007
PM 17620571
DA 2022-11-30
ER

PT J
AU Mukai, R
   Sato, T
   Kishi, S
AF Mukai, Ryo
   Sato, Taku
   Kishi, Shoji
TI A hyporeflective space between hyperreflective materials in pigment
   epithelial detachment and Bruch's membrane in neovascular age-related
   macular degeneration
SO BMC OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Optical coherence tomography; Pigment
   epithelial detachment; Bruch's membrane
ID OPTICAL COHERENCE TOMOGRAPHY; TEARS
AB Background: The purpose of this study was to investigate the clinical characteristics of a hyporeflective space between hyperreflective materials in pigment epithelial detachment (PED) and Bruch's membrane in neovascular age-related macular degeneration (AMD) using spectral-domain optical coherence tomography (SD-OCT) or swept source optical coherence tomography (SS-OCT).
   Methods: Among 223 patients with neovascular AMD, 227 eyes were studied retrospectively. Using SD-OCT or SS-OCT, we reviewed clinical characteristics of the space.
   Results: Twenty-two (10%) of the 227 eyes showed a space between hyperreflective materials in PED and Bruch's membrane. In all spaces, fibrovascular changes of the choroidal neovascularization (CNV) membrane were seen on funduscopy, with OCT images showing the retinal pigment epithelium (RPE) above the space adhering tightly and continuously to the CNV membranes. Nineteen (86%) of the 22 eyes with this cleft also had serous retinal detachment or cystoid macular edema. Five eyes (23%) had an RPE tear during follow-up.
   Conclusions: A hyporeflective space between hyperreflective materials in PED and Bruch's membrane sometimes appears in neovascular AMD. The appearance of such a space may indicate residual activities of the hyperreflective materials.
C1 [Mukai, Ryo; Sato, Taku; Kishi, Shoji] Gunma Univ, Dept Ophthalmol, Sch Med, Maebashi, Gunma 3718511, Japan.
C3 Gunma University
RP Mukai, R (通讯作者)，Gunma Univ, Dept Ophthalmol, Sch Med, 3-39-15 Showa Machi, Maebashi, Gunma 3718511, Japan.
EM ryohmukai@gmail.com
CR Bloch SB, 2013, AM J OPHTHALMOL, V156, P116, DOI 10.1016/j.ajo.2013.02.012
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   BRESSLER SB, 1992, ARCH OPHTHALMOL-CHIC, V110, P827, DOI 10.1001/archopht.1992.01080180099035
   Chan CK, 2010, RETINA-J RET VIT DIS, V30, P203, DOI 10.1097/IAE.0b013e3181babda5
   Chang LK, 2007, RETINA-J RET VIT DIS, V27, P523, DOI 10.1097/IAE.0b013e3180a032db
   Coscas G, 2010, OPTICAL COHERENCE TOMOGRAPHY IN AGE-RELATED MACULAR DEGENERATION: OCT IN AMD, SECOND EDITION, P1
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Giovannini A, 2000, RETINA-J RET VIT DIS, V20, P37, DOI 10.1097/00006982-200001000-00007
   Khan S, 2012, RETINA-J RET VIT DIS, V32, P1057, DOI 10.1097/IAE.0b013e31823beb14
   Leitritz M, 2008, EYE, V22, P1504, DOI 10.1038/eye.2008.145
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Mukai R, 2014, ACTA OPHTHALMOLOGICA
   Nagiel A, 2013, AM J OPHTHALMOL, V156, P981, DOI 10.1016/j.ajo.2013.06.024
   Sato T, 2007, RETINA-J RET VIT DIS, V27, P589, DOI 10.1097/01.iae.0000249386.63482.05
   Singerman Lawrence J, 2005, Retina, V25, pS1
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P644, DOI 10.1016/j.ajo.2008.10.005
   Tsujikawa A, 2007, AM J OPHTHALMOL, V143, P102, DOI 10.1016/j.ajo.2006.08.025
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   Yasuda M, 2009, OPHTHALMOLOGY, V116, P2135, DOI 10.1016/j.ophtha.2009.04.017
NR 20
TC 15
Z9 16
U1 0
U2 4
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD DEC 16
PY 2014
VL 14
AR 159
DI 10.1186/1471-2415-14-159
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AZ4BL
UT WOS:000348167200001
PM 25515712
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Melamud, A
   Stinnett, S
   Fekrat, S
AF Melamud, Alex
   Stinnett, Sandra
   Fekrat, Sharon
TI Treatment of neovascular age-related macular degeneration with
   intravitreal bevacizumab: Efficacy of three consecutive monthly
   injections
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; CHOROIDAL NEOVASCULARIZATION; AVASTIN;
   RANIBIZUMAB
AB PURPOSE: To report the efficacy of treatment of neovascular age,related macular degeneration (AMD) with intravitreal bevacizumab (Avastin; Genentech, Inc, South San Francisco, California, USA) when administered in a series of three monthly injections followed by period of observation.
   DESIGN: Retrospective case series.
   METHODS: Retrospective review of consecutive eyes with all choroidal neovascular lesion subtypes resulting from neovascular AMD treated with intravitreal bevacizumab. Treatment consisted of a pars plana injection of 1.25 mg Avastin (0.05 ml bevacizumab at a concentration of 25 mg/ml). Evaluation consisted of a complete ophthalmologic examination, including best,corrected visual acuity (VA) measurement, ophthalmoscopy, and optical coherence tomography. Eyes received a series of three monthly injections followed by a three-month period of observation.
   RESULTS: A total of 36 patients (37 eyes) received a series of three consecutive monthly intravitreal injections of bevacizumab. Twenty (54%) of 37 eyes had no previous treatments for neovascular AMD in the eye that received bevacizumab. Seventeen (46%) of 37 eyes had received some previous treatment before initiation of bevacizumab therapy. Intravitreal Avastin therapy produced an improvement in foveal thickness over time in eyes with neovascular AMD. This improvement was sustained during the series of three monthly injections. All eyes experienced worsening after three months with, out treatment. No statistically significant effect on VA was demonstrated in this series.
   CONCLUSION: Intravitreal bevacizumab therapy prodduced an improvement in foveal thickness over time in eyes with neovascular AMD when one injection was given each month for three consecutive months. All eyes experienced increased foveal thickening during the sub, sequent three months without treatment.
C1 [Melamud, Alex; Stinnett, Sandra; Fekrat, Sharon] Duke Univ, Ctr Eye, Durham, NC 27710 USA.
C3 Duke University
RP Fekrat, S (通讯作者)，Duke Univ, Ctr Eye, Erwin Rd,POB 3802, Durham, NC 27710 USA.
EM fekra001@mc.duke.edu
OI Stinnett, Sandra/0000-0001-7192-0195
CR Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Kaiser PK, 2006, AM J OPHTHALMOL, V142, P660, DOI 10.1016/j.ajo.2006.05.061
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Rosenfeld Philip J, 2006, Ophthalmol Clin North Am, V19, P361
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
NR 12
TC 37
Z9 37
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JUL
PY 2008
VL 146
IS 1
BP 91
EP 95
DI 10.1016/j.ajo.2008.03.014
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 321IW
UT WOS:000257299100015
PM 18455144
DA 2022-11-30
ER

PT J
AU Wang, SV
   Kulldorff, M
   Poor, S
   Rice, DS
   Banks, A
   Li, N
   Lii, J
   Gagne, JJ
AF Wang, Shirley, V
   Kulldorff, Martin
   Poor, Stephen
   Rice, Dennis S.
   Banks, Angela
   Li, Ning
   Lii, Joyce
   Gagne, Joshua J.
TI Screening Medications for Association with Progression to Wet
   Age-Related Macular Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
DE Drug repurposing; neovascular age-related macular degeneration;
   Screening; Tree based scan statistics; nested case-control; Neovascular
   age related macular degeneration
ID PIGMENT EPITHELIAL-CELLS; BLOOD-FLOW; ERYTHROPOIETIN; RETINOPATHY;
   INFLAMMATION; INHIBITION; PROTECTION; DATABASE; THERAPY; RISK
AB Purpose: There is an urgent need for treatments that prevent or delay development to advanced age-related macular degeneration (AMD). Drugs already on the market for other conditions could affect progression to neovascular AMD (nAMD). If identified, these drugs could provide insights for drug development targets. The objective of this study was to use a novel data mining method that can simultaneously evaluate thousands of correlated hypotheses, while adjusting for multiple testing, to screen for associations between drugs and delayed progression to nAMD.
   Design: We applied a nested case-control study to administrative insurance claims data to identify cases with nAMD and risk-set sampled controls that were 1:4 variable ratio matched on age, gender, and recent healthcare use.
   Participants: The study population included cases with nAMD and risk set matched controls.
   Methods: We used a tree-based scanning method to evaluate associations between hierarchical classifications of drugs that patients were exposed to within 6 months, 7 to 24 months, or ever before their index date. The index date was the date of first nAMD diagnosis in cases. Risk-set sampled controls were assigned the same index date as the case to which they were matched. The study was implemented using Medicare data from New Jersey and Pennsylvania, and national data from IBM MarketScan Research Database. We set an a priori threshold for statistical alerting at P <= 0.01 and focused on associations with large magnitude (relative risks >= 2.0).
   Main Outcome Measures: Progression to nAMD.
   Results: Of approximately 4000 generic drugs and drug classes evaluated, the method detected 19 distinct drug exposures with statistically significant, large relative risks indicating that cases were less frequently exposed than controls. These included (1) drugs with prior evidence for a causal relationship (e.g., megestrol); (2) drugs without prior evidence for a causal relationship, but potentially worth further exploration (e.g., donepezil, epoetin alfa); (3) drugs with alternative biologic explanations for the association (e.g., sevelamer); and (4) drugs that may have resulted in statistical alerts due to their correlation with drugs that alerted for other reasons.
   Conclusions: This exploratory drug-screening study identified several potential targets for follow-up studies to further evaluate and determine if they may prevent or delay progression to advanced AMD. (C) 2020 by the American Academy of Ophthalmology
C1 [Wang, Shirley, V; Kulldorff, Martin; Lii, Joyce; Gagne, Joshua J.] Brigham & Womens Hosp, Div Pharmacoepidemiol & Pharmacoecon, Dept Med, 1620 Tremont St,Suite 3030, Boston, MA 02120 USA.
   [Wang, Shirley, V; Kulldorff, Martin; Lii, Joyce; Gagne, Joshua J.] Harvard Med Sch, 1620 Tremont St,Suite 3030, Boston, MA 02120 USA.
   [Poor, Stephen; Rice, Dennis S.; Banks, Angela; Li, Ning] Novartis Inst Biomed Res, Ophthalmol, Cambridge, MA USA.
C3 Harvard University; Brigham & Women's Hospital; Harvard University;
   Harvard Medical School; Novartis
RP Wang, SV (通讯作者)，Brigham & Womens Hosp, Div Pharmacoepidemiol & Pharmacoecon, Dept Med, 1620 Tremont St,Suite 3030, Boston, MA 02120 USA.; Wang, SV (通讯作者)，Harvard Med Sch, 1620 Tremont St,Suite 3030, Boston, MA 02120 USA.
EM swang1@bwh.harvard.edu
OI Banks, Angela/0000-0002-1414-7607; Gagne, Joshua/0000-0001-5428-9733
FU Novartis Institutes for Biomedical Research
FX S.V.W. and J.J.G.: Funded by Novartis Institutes for Biomedical Research
   for this project. All authors participated in the design of the study,
   interpretation of the data, and preparation of the manuscript, but the
   sponsor otherwise had no role in these activities.
CR Almasieh M, 2013, INVEST OPHTH VIS SCI, V54, P3171, DOI 10.1167/iovs.12-11481
   [Anonymous], 2018, FRAMEWORK FDAS REAL
   Bakri SJ, 2019, OPHTHALMOLOGY, V126, P55, DOI 10.1016/j.ophtha.2018.07.028
   Barouch Fina C., 2007, International Ophthalmology Clinics, V47, P185, DOI 10.1097/IIO.0b013e3180377936
   Bartollino S, 2018, DRUG DES DEV THER, V12, P3485, DOI 10.2147/DDDT.S169621
   Boltz A, 2010, INVEST OPHTH VIS SCI, V51, P4220, DOI 10.1167/iovs.09-4968
   Brown Jeffrey S, 2013, Pharmaceutics, V5, P179, DOI 10.3390/pharmaceutics5010179
   Davidovic S, 2019, BMC OPHTHALMOL, V19, DOI 10.1186/s12886-019-1240-9
   Ding SLS, 2016, EYE, V30, P1293, DOI 10.1038/eye.2016.94
   Diskin CJ, 2007, AM J MED SCI, V334, P260, DOI 10.1097/MAJ.0b013e3180a5e8ed
   Doonan F, 2012, EXPERT OPIN INV DRUG, V21, P579, DOI 10.1517/13543784.2012.667400
   Doonan F, 2011, J NEUROCHEM, V118, P915, DOI 10.1111/j.1471-4159.2011.07354.x
   Ehrlich R, 2008, CLIN INTERV AGING, V3, P473
   Hernandez-Zimbron LF, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/8374647
   Feskanich D, 2008, ARCH OPHTHALMOL-CHIC, V126, P519, DOI 10.1001/archopht.126.4.519
   Fisher CR, 2018, INVEST OPHTH VIS SCI, V59, pAMD41, DOI 10.1167/iovs.18-24289
   Gawad AE, 2009, EYE, V23, P2245, DOI 10.1038/eye.2008.398
   Haan MN, 2006, ARCH OPHTHALMOL-CHIC, V124, P988, DOI 10.1001/archopht.124.7.988
   Hernandez C, 2006, DIABETES CARE, V29, P2028, DOI 10.2337/dc06-0556
   Hewing NJ, 2013, INVEST OPHTH VIS SCI, V54, P864, DOI 10.1167/iovs.12-10954
   Kulldorff M, 2003, BIOMETRICS, V59, P323, DOI 10.1111/1541-0420.00039
   Kulldorff M., TREESCAN USER GUIDE
   Kulldorff M, 2013, PHARMACOEPIDEM DR S, V22, P517, DOI 10.1002/pds.3423
   Kurz X, 2018, PHARMACOEPIDEM DR S, V27, P245, DOI 10.1002/pds.4381
   Levy O, 2015, J NEUROSCI, V35, P13568, DOI 10.1523/JNEUROSCI.2468-15.2015
   Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X
   Liu CC, 2013, NAT REV NEUROL, V9, P106, DOI 10.1038/nrneurol.2012.263
   Maro JC, 2017, SENTINEL METHODS REP
   Metelitsina TI, 2008, INVEST OPHTH VIS SCI, V49, P358, DOI 10.1167/iovs.07-0526
   Mohan N, 2012, J DIABETES COMPLICAT, V26, P435, DOI 10.1016/j.jdiacomp.2012.05.005
   Pappalardo LW, 2016, GLIA, V64, P1628, DOI 10.1002/glia.22967
   Pfizer, 2016, DILANTIN 125 HIGHLIG
   Pharmacology IBGt, ERL EMD MILL KINASEP
   Raftopoulos R, 2016, LANCET NEUROL, V15, P259, DOI 10.1016/S1474-4422(16)00004-1
   Reiner A, 2018, PROG RETIN EYE RES, V64, P96, DOI 10.1016/j.preteyeres.2017.12.001
   Rodriguez-Poncelas A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149448
   Schneeweiss S, 2005, J CLIN EPIDEMIOL, V58, P323, DOI 10.1016/j.jclinepi.2004.10.012
   Schneeweiss S, 2007, MED CARE, V45, pS131, DOI 10.1097/MLR.0b013e318070c08e
   Setoguchi S, 2011, CLIN PHARMACOL THER, V89, P674, DOI 10.1038/clpt.2011.17
   Simo R, 2018, DIABETOLOGIA, V61, P1902, DOI 10.1007/s00125-018-4692-1
   Singh M, 2013, HORM BEHAV, V63, P284, DOI 10.1016/j.yhbeh.2012.06.003
   Snow KK, 2002, AM J OPHTHALMOL, V134, P842, DOI 10.1016/S0002-9394(02)01755-5
   Stahl A, 2010, RETINA-J RET VIT DIS, V30, P1524, DOI 10.1097/IAE.0b013e3181d37539
   Suk KK, 2008, J AAPOS, V12, P233, DOI 10.1016/j.jaapos.2007.08.009
   Tabernero J, 2007, MOL CANCER RES, V5, P203, DOI 10.1158/1541-7786.MCR-06-0404
   Wang SV, 2019, CLIN PHARMACOL THER, V106, P874, DOI 10.1002/cpt.1490
   Wang SV, 2018, EPIDEMIOLOGY, V29, P895, DOI [10.1097/ede.0000000000000907, 10.1097/EDE.0000000000000907]
   Wang ZY, 2009, FREE RADICAL BIO MED, V46, P1032, DOI 10.1016/j.freeradbiomed.2008.11.027
   Watanabe D, 2005, NEW ENGL J MED, V353, P782, DOI 10.1056/NEJMoa041773
   Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073
   Yih WK, 2019, AM J EPIDEMIOL, V188, P1383, DOI 10.1093/aje/kwz104
   Zhang H, 2013, AFRICAN J BIOTECHNOL, V10, P3695
   Zheng W, 2018, OPHTHALMOLOGY, V125, P984, DOI 10.1016/j.ophtha.2018.01.007
NR 53
TC 2
Z9 3
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD FEB
PY 2021
VL 128
IS 2
BP 248
EP 255
DI 10.1016/j.ophtha.2020.08.004
EA JAN 2021
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA PV3GY
UT WOS:000609880500014
PM 32777229
DA 2022-11-30
ER

PT J
AU Tosi, GM
   Neri, G
   Caldi, E
   Fusco, F
   Bacci, T
   Tarantello, A
   Nuti, E
   Marigliani, D
   Baiocchi, S
   Traversi, C
   Barbarino, M
   Eandi, CM
   Parolini, B
   Mundo, L
   Santucci, A
   Orlandini, M
   Galvagni, F
AF Tosi, Gian Marco
   Neri, Giovanni
   Caldi, Elena
   Fusco, Fiorella
   Bacci, Tommaso
   Tarantello, Antonio
   Nuti, Elisabetta
   Marigliani, Davide
   Baiocchi, Stefano
   Traversi, Claudio
   Barbarino, Marcella
   Eandi, Chiara M.
   Parolini, Barbara
   Mundo, Lucia
   Santucci, Annalisa
   Orlandini, Maurizio
   Galvagni, Federico
TI TGF-beta concentrations and activity are down-regulated in the aqueous
   humor of patients with neovascular age-related macular degeneration
SO SCIENTIFIC REPORTS
LA English
DT Article
ID GROWTH-FACTOR-BETA; PIGMENT EPITHELIAL-CELLS; ENDOTHELIAL-CELLS;
   SIGNALING RECEPTORS; ANGIOGENESIS; PROLIFERATION; MECHANISMS;
   TGF-BETA-2; EXPRESSION; INCREASES
AB Controversy still exists regarding the role of the TGF-beta in neovascular age-related macular degeneration (nAMD), a major cause of severe visual loss in the elderly in developed countries. Here, we measured the concentrations of active TGF-beta 1, TGF-beta 2, and TGF-beta 3 by ELISA in the aqueous humor of 20 patients affected by nAMD, who received 3 consecutive monthly intravitreal injections of anti-VEGF-A antibody. Samples were collected at baseline (before the first injection), month 1 (before the second injection), and month 2 (before the third injection). The same samples were used in a luciferase-based reporter assay to test the TGF-beta pathway activation. Active TGF-beta 1 concentrations in the aqueous humor were below the minimum detectable dose. Active TGF-beta 2 concentrations were significantly lower at baseline and at month 1, compared to controls. No significant differences in active TGF-beta 3 concentration were found among the sample groups. Moreover, TGF-beta pathway activation was significantly lower at baseline compared to controls. Our data corroborate an anti-angiogenic role for TGF-beta 2 in nAMD. This should be considered from the perspective of a therapy using TGF-beta inhibitors.
C1 [Tosi, Gian Marco; Neri, Giovanni; Fusco, Fiorella; Bacci, Tommaso; Tarantello, Antonio; Nuti, Elisabetta; Marigliani, Davide; Baiocchi, Stefano; Traversi, Claudio] Univ Siena, Dept Med Surg & Neurosci, Ophthalmol Unit, I-53100 Siena, Italy.
   [Caldi, Elena; Santucci, Annalisa; Orlandini, Maurizio; Galvagni, Federico] Univ Siena, Dept Biotechnol Chem & Pharm, I-53100 Siena, Italy.
   [Barbarino, Marcella] Univ Siena, Dept Med Surg & Neurosci, I-53100 Siena, Italy.
   [Eandi, Chiara M.] Univ Turin, Dept Surg Sci, I-10124 Turin, Italy.
   [Parolini, Barbara] St Anna Hosp, Vitreoretinal Unit, Brescia, Italy.
   [Mundo, Lucia] Univ Siena, Dept Med Biotechnol, Siena, Italy.
C3 University of Siena; University of Siena; University of Siena;
   University of Turin; University of Ferrara; Arcispedale Sant'Anna;
   University of Siena
RP Orlandini, M; Galvagni, F (通讯作者)，Univ Siena, Dept Biotechnol Chem & Pharm, I-53100 Siena, Italy.
EM maurizio.orlandini@unisi.it; federico.galvagni@unisi.it
RI Orlandini, Maurizio/AAF-8247-2020; Barbarino, Marcella/R-2814-2016;
   Mundo, Lucia/ABE-8599-2021; Galvagni, Federico/F-9186-2013; Bacci,
   Tommaso/AAQ-5603-2020; Bacci, Tommaso/GQA-8840-2022; Fusco,
   Fiorella/ABH-7370-2020; Parolini, Barbara/AAH-9913-2019; Santucci,
   Annalisa/K-1932-2018
OI Orlandini, Maurizio/0000-0002-6112-4889; Barbarino,
   Marcella/0000-0001-9869-9814; Bacci, Tommaso/0000-0001-7477-2263; Fusco,
   Fiorella/0000-0002-0574-2471; Santucci, Annalisa/0000-0001-6976-9086;
   Parolini, Barbara/0000-0002-7838-6834; baiocchi,
   stefano/0000-0002-3846-1895
FU MIUR (Ministero dell'Istruzione, dell'Universita e della Ricerca) Grant
   "Dipartimento di eccellenza"
FX We thank all the volunteers for their participation in this study, Dr.
   Dagmar Beier for her careful editing of the manuscript and Prof. Gianni
   Virgili for helpful suggestions. The study was partially supported by
   MIUR (Ministero dell'Istruzione, dell'Universita e della Ricerca) Grant
   "Dipartimento di eccellenza" 2018-2022.
CR AMIN R, 1994, INVEST OPHTH VIS SCI, V35, P3178
   Bai YJ, 2014, MOL VIS, V20, P1258
   Carmeliet P, 2011, NATURE, V473, P298, DOI 10.1038/nature10144
   Choudhary P, 2016, STEM CELL TRANSL MED, V5, P925, DOI 10.5966/sctm.2015-0247
   Dagher Z, 2017, AM J PATHOL, V187, P627, DOI 10.1016/j.ajpath.2016.11.007
   Feng ZL, 2015, GRAEF ARCH CLIN EXP, V253, P875, DOI 10.1007/s00417-014-2922-x
   Fujio K, 2016, AUTOIMMUN REV, V15, P917, DOI 10.1016/j.autrev.2016.07.007
   Galvagni F, 2016, ONCOTARGET, V7, P10090, DOI 10.18632/oncotarget.7136
   Jonker L, 2014, MICROCIRCULATION, V21, P93, DOI 10.1111/micc.12099
   Kim KS, 2016, CELL TRANSPLANT, V25, P1145, DOI 10.3727/096368915X688263
   LOPEZCASILLAS F, 1994, J CELL BIOL, V124, P557, DOI 10.1083/jcb.124.4.557
   Nagineni CN, 2003, J CELL PHYSIOL, V197, P453, DOI 10.1002/jcp.10378
   Pardali E, 2010, TRENDS CELL BIOL, V20, P556, DOI 10.1016/j.tcb.2010.06.006
   Radeke MJ, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0183-x
   Recalde S, 2011, INVEST OPHTH VIS SCI, V52, P7090, DOI 10.1167/iovs.11-7300
   Saed GM, 2002, AM J REPROD IMMUNOL, V48, P387, DOI 10.1034/j.1600-0897.2002.01090.x
   Saika S, 2006, LAB INVEST, V86, P106, DOI 10.1038/labinvest.3700375
   SANKAR S, 1995, J BIOL CHEM, V270, P13567, DOI 10.1074/jbc.270.22.13567
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X
   Shih SC, 2003, P NATL ACAD SCI USA, V100, P15859, DOI 10.1073/pnas.2136855100
   Sugino IK, 2016, TRANSL VIS SCI TECHN, V5, DOI 10.1167/tvst.5.1.8
   ten Dijke P, 2007, NAT REV MOL CELL BIO, V8, P857, DOI 10.1038/nrm2262
   Tosi GM, 2017, J CELL PHYSIOL, V232, P1767, DOI 10.1002/jcp.25689
   Tosi GM, 2017, INVEST OPHTH VIS SCI, V58, P162, DOI 10.1167/iovs.16-20922
   Walshe TE, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005149
   Wang XM, 2013, NATURE, V499, P306, DOI 10.1038/nature12345
   Yafai Y, 2014, GLIA, V62, P1476, DOI 10.1002/glia.22694
   YAMASHITA H, 1994, J BIOL CHEM, V269, P1995
   Yamauchi K, 2004, J BIOL CHEM, V279, P55104, DOI 10.1074/jbc.M407423200
   Yu AL, 2009, INVEST OPHTH VIS SCI, V50, P926, DOI 10.1167/iovs.07-1003
   Zarranz-Ventura J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065434
   Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1
   Zhang H, 2012, INT J OPHTHALMOL-CHI, V5, P307, DOI 10.3980/j.issn.2222-3959.2012.03.11
   Zhang RS, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146808
NR 35
TC 17
Z9 17
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD MAY 23
PY 2018
VL 8
AR 8053
DI 10.1038/s41598-018-26442-0
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA GG6EO
UT WOS:000432789300031
PM 29795291
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Hodge, W
   Brown, A
   Kymes, S
   Cruess, A
   Blackhouse, G
   Hopkins, R
   McGahan, L
   Sharma, S
   Pan, I
   Blair, J
   Vollman, D
   Morrison, A
AF Hodge, William
   Brown, Allan
   Kymes, Steve
   Cruess, Alan
   Blackhouse, Gord
   Hopkins, Robert
   McGahan, Lynda
   Sharma, Sanjay
   Pan, Irene
   Blair, Jason
   Vollman, David
   Morrison, Andra
TI Pharmacologic management of neovascular age-related macular
   degeneration: systematic review of economic evidence and primary
   economic evaluation
SO CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE
LA English
DT Review
DE age-related macular degeneration; systematic review; pharmacologic
   treatment; cost effectiveness; quality-adjusted life year
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; BEVACIZUMAB AVASTIN THERAPY;
   COST-EFFECTIVENESS; PHOTODYNAMIC THERAPY; VISUAL-ACUITY; VERTEPORFIN;
   RANIBIZUMAB; PEGAPTANIB; UTILITY; EYES
AB Objective: To examine the economic implications for the Canadian health system of pharmacologic treatment of neovascular age-related macular degeneration (AMD).
   Design: Systematic review of economic literature and a primary economic evaluation.
   Participants: Economic literature search identified 392 potentially relevant articles, 12 of which were included for final review.
   Methods: Studies were included if they met the following criteria: (i) provision of a summary measure of the trade-off between costs and consequences; (ii) participants of 40 years and older with neovascular AMD; (iii) interventions and comparators: comparison of photodynamic therapy using verteporfin (V-PDT), pegaptanib, bevacizumab, ranibizumab, anecortave acetate, intravitreal triamcinolone, placebo, or clinically relevant combinations; and (iv) outcome reported as an incremental measure of the implication of moving from the comparator to the intervention. The following databases were searched through the OVID interface: MEDLINE, EMBASE, BIOSIS Previews, CINAHL, PubMed, Health Economic Evaluations Database (HEED), and the Cochrane Library. For the economic evaluation, we took a decision analytic approach and modeled a cost-utility analysis, conducting it as a microsimulation of a Markov model.
   Results: In general, V-PDT is more cost effective than conventional macular laser, and pegaptanib is likely more cost effective than V-PDT. The primary economic analysis revealed ranibizumab to be effective but at an unacceptably high cost per quality-adjusted life year (QALY) (>$50 000 per QALY).
   Conclusion: Although ranibizumab is effective for wet AMD, its cost is unacceptably high based on cost-utility theory.
C1 [Hodge, William; Pan, Irene] Univ Western Ontario, Dept Ophthalmol, London, ON, Canada.
   [Brown, Allan; McGahan, Lynda; Morrison, Andra] Canadian Agcy Drugs & Technol Hlth, Ottawa, ON, Canada.
   [Kymes, Steve; Vollman, David] Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, St Louis, MO 63110 USA.
   [Cruess, Alan] Dalhousie Univ, Dept Ophthalmol & Visual Sci, Halifax, NS, Canada.
   [Blackhouse, Gord; Hopkins, Robert] McMaster Univ, PATH, Res Inst, Hamilton, ON, Canada.
   [Sharma, Sanjay] Queens Univ, Dept Ophthalmol, Kingston, ON, Canada.
   [Sharma, Sanjay] Queens Univ, Dept Epidemiol, Kingston, ON, Canada.
   [Blair, Jason] Univ Ottawa, Dept Ophthalmol, Ottawa, ON, Canada.
C3 Western University (University of Western Ontario); Washington
   University (WUSTL); Dalhousie University; McMaster University; Queens
   University - Canada; Queens University - Canada; University of Ottawa
RP Hodge, W (通讯作者)，St Josephs Hosp, Ivey Eye Inst, 268 Grosvenor St, London, ON N6A 4V2, Canada.
EM William.Hodge@sjhc.london.on.ca
FU Canadian Agency for Drugs and Technologies in Health
FX This study was supported by the Canadian Agency for Drugs and
   Technologies in Health. The authors thank Francie Si, MD, MSc, Ivey Eye
   Institute, University of Western Ontario, for proofreading and editing
   citations, references, and tables, and for assistance with collection of
   copyright/authorship forms and submission. The authors have no
   proprietary or commercial interest in any materials discussed in this
   article.
CR [Anonymous], 2017, GUID EC EV HLTH TECH
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2007, AM J OPHTHALMOL, V144, P627, DOI 10.1016/j.ajo.2007.06.039
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown GC, 2005, AM J OPHTHALMOL, V140, P679, DOI 10.1016/j.ajo.2005.04.061
   Buhrmann RHW, 2006, FORECASTING VISION L
   Costa RA, 2006, INVEST OPHTH VIS SCI, V47, P4569, DOI 10.1167/iovs.06-0433
   Drummond MF, 1996, BRIT MED J, V313, P275, DOI 10.1136/bmj.313.7052.275
   Drummond MF., 2015, METHODS EC EVALUATIO, V4
   Earnshaw SR, 2007, CLIN THER, V29, P2096, DOI 10.1016/j.clinthera.2007.09.001
   Fenwick E, 2001, HEALTH ECON, V10, P779, DOI 10.1002/hec.635
   Greiner R A, 2001, Semin Ophthalmol, V16, P218, DOI 10.1076/soph.16.4.218.10302
   *HLTH CAN, 2000, DRUGS HLTH PROD NOT
   *HLTH CAN THER PRO, 2005, NOT DEC MAC
   Hopley C, 2004, BRIT J OPHTHALMOL, V88, P982, DOI 10.1136/bjo.2003.039131
   Javitt JC, 2008, VALUE HEALTH, V11, P563, DOI 10.1111/j.1524-4733.2007.00283.x
   LAROUCHE K, 2004, PHYTODYNAMIC THERAPY
   Markovitz JH, 1996, CORONARY ARTERY DIS, V7, P657, DOI 10.1097/00019501-199609000-00007
   Meads C, 2003, Health Technol Assess, V7, pv
   Meads C, 2003, HEALTH TECHNOL ASSES, V7, p[v, 1], DOI [10.3310/hta7090, DOI 10.3310/hta7090]
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Moshfeghi AA, 2006, OPHTHALMOLOGY, V113, P2002, DOI 10.1016/j.ophtha.2006.05.070
   Raftery J, 2007, BRIT J OPHTHALMOL, V91, P1244, DOI 10.1136/bjo.2007.116616
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sharma S, 2005, CAN J OPHTHALMOL, V40, P369, DOI 10.1016/S0008-4182(05)80079-1
   Sharma S, 2001, OPHTHALMOLOGY, V108, P2051, DOI 10.1016/S0161-6420(01)00764-3
   Sharma S, 2000, CAN J OPHTHALMOL, V35, P267, DOI 10.1016/S0008-4182(00)80077-0
   Smith DH, 2004, BRIT J OPHTHALMOL, V88, P1107, DOI 10.1136/bjo.2003.023986
   Weinstein MC, 2006, PHARMACOECONOMICS, V24, P1043, DOI 10.2165/00019053-200624110-00002
   Wolowacz SE, 2007, PHARMACOECONOMICS, V25, P863, DOI 10.2165/00019053-200725100-00005
NR 30
TC 17
Z9 18
U1 0
U2 4
PU CANADIAN OPHTHAL SOC
PI OTTAWA
PA 1525 CARLING AVE SUITE 610, OTTAWA, ONTARIO K1Z 8R9, CANADA
SN 0008-4182
J9 CAN J OPHTHALMOL
JI Can. J. Opthalmol.-J. Can. Opthalmol.
PD JUN
PY 2010
VL 45
IS 3
BP 223
EP 230
DI 10.3129/i10-047
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 616KZ
UT WOS:000279209600003
PM 20628420
DA 2022-11-30
ER

PT J
AU Francis, PJ
   Schultz, DW
   Hamon, S
   Ott, J
   Weleber, RG
   Klein, ML
AF Francis, Peter J.
   Schultz, Dennis W.
   Hamon, Sara
   Ott, Jurg
   Weleber, Richard G.
   Klein, Michael L.
TI Haplotypes in the Complement Factor H (CFH) Gene: Associations with
   Drusen and Advanced Age-Related Macular Degeneration
SO PLOS ONE
LA English
DT Article
AB Background. Age-related macular degeneration (AMD), the leading cause of blindness in the Western world, is a complex disease that affects people over 50 years old. The complement factor H (CFH) gene has been repeatedly shown to be a major factor in determining susceptibility to the advanced form of the condition. We aimed to better understand the functional role of this gene in the AMD disease process and assess whether it is associated with earlier forms of the disease. Methodology/Principal Findings. We genotyped SNPs at the CFH gene locus in three independent populations with AMD: (a) extended families where at least 3 family members had AMD; (b) sporadic cases of advanced AMD and (c) cases from the Age-Related Eye Disease Study (AREDS). We investigated polymorphisms and haplotypes in and around the CFH gene to assess their role in AMD. CFH is associated with early/intermediate and advanced AMD in both familial and sporadic cases. In our populations, the CFH SNP, rs2274700, is most strongly associated with AMD and when incorporated into a haplotype with the Y402H SNP and rs1061147, the strongest association is observed (p < 10(-9)). Conclusions/Significance. Our results, reproduced in three populations that represent the spectrum of AMD cases, provide evidence that the CFH gene is associated with drusen as well as with advanced AMD. We also identified novel susceptibility and protective haplotypes in the AMD populations.
C1 [Francis, Peter J.; Schultz, Dennis W.; Weleber, Richard G.; Klein, Michael L.] Oregon Hlth & Sci Univ, Casey Eye Inst, Macular Degenerat Ctr, Portland, OR 97201 USA.
   [Hamon, Sara; Ott, Jurg] Rockefeller Univ, New York, NY 10021 USA.
C3 Oregon Health & Science University; Rockefeller University
RP Francis, PJ (通讯作者)，Oregon Hlth & Sci Univ, Casey Eye Inst, Macular Degenerat Ctr, Portland, OR 97201 USA.
EM francisp@ohsu.edu
FU National Institutes of Health (NIH) National Eye Institute
   [R01-EY12203]; Foundation Fighting Blindness, Owing Mills, Md; Macular
   Vision Research Foundation; Macular Degeneration Center Research Fund,
   Casey Eye Institute, Portland, Oregon Health & Science University;
   Research to Prevent Blindness, New York, NY; PHS [5 M01 RR000334];
   NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000334] Funding Source: NIH
   RePORTER; NATIONAL EYE INSTITUTE [R01EY012203] Funding Source: NIH
   RePORTER
FX This work is supported by grants from the National Institutes of Health
   (NIH) National Eye Institute R01-EY12203 (MK); the Foundation Fighting
   Blindness, Owing Mills, Md (PF, RGW, DWS); the Macular Vision Research
   Foundation (DWS); the Macular Degeneration Center Research Fund, Casey
   Eye Institute, Portland, Oregon Health & Science University (MK), and
   Research to Prevent Blindness, New York, NY (unrestricted grant to Casey
   Eye Institute, Career Development Award to PF). Support was also
   provided by PHS Grant 5 M01 RR000334 (JO). The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Barral S, 2006, INVEST OPHTH VIS SCI, V47, P5453, DOI 10.1167/iovs.06-0655
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Giannakis E, 2003, EUR J IMMUNOL, V33, P962, DOI 10.1002/eji.200323541
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Horvath S, 2004, GENET EPIDEMIOL, V26, P61, DOI 10.1002/gepi.10295
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   Majewski J, 2003, AM J HUM GENET, V73, P540, DOI 10.1086/377701
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Schaid DJ, 2002, AM J HUM GENET, V70, P425, DOI 10.1086/338688
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Schultz Dennis W, 2005, Ophthalmic Genet, V26, P101, DOI 10.1080/13816810590968023
   Schultz DW, 2003, HUM MOL GENET, V12, P3315, DOI 10.1093/hmg/ddg348
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
   Zareparsi S, 2005, HUM MOL GENET, V14, P1449, DOI 10.1093/hmg/ddi154
NR 27
TC 71
Z9 74
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 28
PY 2007
VL 2
IS 11
AR e1197
DI 10.1371/journal.pone.0001197
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA V10JC
UT WOS:000207459300002
PM 18043728
OA gold, Green Submitted, Green Published
DA 2022-11-30
ER

PT J
AU Wu, Y
   Wei, QQ
   Yu, J
AF Wu, Yan
   Wei, Qingquan
   Yu, Jing
TI The cGAS/STING pathway: a sensor of senescence-associated DNA damage and
   trigger of inflammation in early age-related macular degeneration
SO CLINICAL INTERVENTIONS IN AGING
LA English
DT Article
DE age-related macular degeneration; cGAS/STING pathway; DNA damage;
   inflammation
ID PIGMENT EPITHELIAL-CELLS; OXIDATIVE STRESS; THERAPIES; ACID; CGAS; VEGF;
   PATHOGENESIS; INHIBITION; EXPRESSION; ANTIBODY
AB Age-related macular degeneration (AMD) is the leading cause of irreversible blindness among the elderly. Considering the relatively limited effect of therapy on early AMD, it is important to focus on the pathogenesis of AMD, especially early AMD. Ageing is one of the strongest risk factors for AMD, and analysis of the impact of ageing on AMD development is valuable. Among all the ageing hallmarks, increased DNA damage accumulation is regarded as the beginning of cellular senescence and is related to abnormal expression of inflammatory cytokines, which is called the senescence-associated secretory phenotype (SASP). The exact pathway for DNA damage that triggers senescence-associated hallmarks is poorly understood. Recently, mounting evidence has shown that the cGAS/STING pathway is an important DNA sensor related to proinflammatory factor secretion and is associated with another hallmark of ageing, SASP. Thus, we hypothesized that the cGAS/STING pathway is a vital signalling pathway for early AMD development and that inhibition of STING might be a potential therapeutic strategy for AMD cases.
C1 [Wu, Yan; Wei, Qingquan; Yu, Jing] Tongji Univ, Shanghai Peoples Hosp 10, Dept Ophthalmol, Shanghai, Peoples R China.
   [Wu, Yan] Soochow Univ, Affiliated Hosp 1, Dept Ophthalmol, Suzhou, Jiangsu, Peoples R China.
   [Yu, Jing] Ninghai First Hosp, Dept Ophthalmol, Ninghai, Zhejiang, Peoples R China.
C3 Tongji University; Soochow University - China
RP Yu, J (通讯作者)，Tongji Univ, Shanghai Peoples Hosp 10, Dept Ophthalmol, Shanghai, Peoples R China.
EM dryujing@aliyun.com
FU National Science Foundation for Young Scientists of China [81700804];
   Foundation for Young Medical Talents of Jiangsu Province [QNRC2016211]
FX This work was supported in whole or in part by the Project supported by
   the National Science Foundation for Young Scientists of China (Grant No.
   81700804) and the Foundation for Young Medical Talents of Jiangsu
   Province, 2016 (Grant No. QNRC2016211).
CR Agarwal A, 2015, CLIN OPHTHALMOL, V9, P1001, DOI [10.2147/OPTH.S59725, 10.2147/OPTH.S74959]
   Ahlers LRH, 2016, CURR CLIN MICROBIOL, V3, P132, DOI 10.1007/s40588-016-0043-5
   Amoaku WM, 2015, EYE, V29, P721, DOI 10.1038/eye.2015.48
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Blasiak J, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/5293258
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Buitendijk GHS, 2018, AM J OPHTHALMOL, V187, P130, DOI 10.1016/j.ajo.2018.01.003
   Cascella Raffaella, 2018, Oncotarget, V9, P7812, DOI 10.18632/oncotarget.23241
   Cascella R, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/582842
   Chen Q, 2016, NAT IMMUNOL, V17, P1142, DOI 10.1038/ni.3558
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chroma K, 2017, ONCOGENE, V36, P2405, DOI 10.1038/onc.2016.392
   Corominas J, 2018, OPHTHALMOLOGY, V125, P1433, DOI 10.1016/j.ophtha.2018.03.040
   Corso-Diaz X, 2018, PROG RETIN EYE RES, V65, P1, DOI 10.1016/j.preteyeres.2018.03.002
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   DeAngelis MM, 2017, HUM MOL GENET, V26, pR45, DOI 10.1093/hmg/ddx228
   Delplace V, 2015, J CONTROL RELEASE, V219, P652, DOI 10.1016/j.jconrel.2015.09.065
   El-Sayyad HIH, 2014, CLIN EXP OPHTHALMOL, V42, P169, DOI 10.1111/ceo.12123
   Espinosa-Heidmann DG, 2006, INVEST OPHTH VIS SCI, V47, P729, DOI 10.1167/iovs.05-0719
   Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381
   Fisher CR, 2018, INVEST OPHTH VIS SCI, V59, pAMD41, DOI 10.1167/iovs.18-24289
   Ghosh K, 2016, J INVEST DERMATOL, V136, P2133, DOI 10.1016/j.jid.2016.06.621
   Gluck S, 2019, CURR OPIN IMMUNOL, V56, P31, DOI 10.1016/j.coi.2018.09.013
   Haag SM, 2018, NATURE, V559, P269, DOI 10.1038/s41586-018-0287-8
   Hamczyk MR, 2018, ANNU REV PHYSIOL, V80, P27, DOI 10.1146/annurev-physiol-021317-121454
   Hurley Susan F, 2008, Cost Eff Resour Alloc, V6, P18, DOI 10.1186/1478-7547-6-18
   Kaur G, 2018, P NATL ACAD SCI USA, V115, P9014, DOI 10.1073/pnas.1805039115
   Kerur N, 2018, NAT MED, V24, P50, DOI 10.1038/nm.4450
   Khandhadia S, 2012, IMMUNOBIOLOGY, V217, P127, DOI 10.1016/j.imbio.2011.07.019
   Kujoth GC, 2005, SCIENCE, V309, P481, DOI 10.1126/science.1112125
   Liegl R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088203
   Loeser RF, 2016, NAT REV RHEUMATOL, V12, P412, DOI 10.1038/nrrheum.2016.65
   Lopez-Otin C, 2013, CELL, V153, P1194, DOI 10.1016/j.cell.2013.05.039
   Marazita MC, 2016, REDOX BIOL, V7, P78, DOI 10.1016/j.redox.2015.11.011
   Martinez-Zamudio Ricardo Ivan, 2017, Cell, V170, P816, DOI 10.1016/j.cell.2017.07.049
   Mathur V, 2017, NEURON, V96, P1290, DOI 10.1016/j.neuron.2017.11.032
   Mehta H, 2018, PROG RETIN EYE RES, V65, P127, DOI 10.1016/j.preteyeres.2017.12.002
   Mertens J, 2018, ANNU REV GENET, V52, P271, DOI 10.1146/annurev-genet-120417-031534
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Nadal-Nicolas FM, 2018, NEUROBIOL AGING, V61, P146, DOI 10.1016/j.neurobiolaging.2017.09.021
   Nagineni CN, 2003, J CELL PHYSIOL, V197, P453, DOI 10.1002/jcp.10378
   Narayanan R, 2017, CURR PHARM DESIGN, V23, P542, DOI 10.2174/1381612822666161221154424
   Owen CG, 2003, BRIT J OPHTHALMOL, V87, P312, DOI 10.1136/bjo.87.3.312
   Qin TY, 2018, J OPHTHALMOL, V2018, DOI 10.1155/2018/5392432
   Saunier V, 2018, JAMA OPHTHALMOL, V136, P473, DOI 10.1001/jamaophthalmol.2018.0504
   Tamiya S, 2016, EXP EYE RES, V142, P26, DOI 10.1016/j.exer.2015.02.008
   Thomas TC, 1996, MOL IMMUNOL, V33, P1389, DOI 10.1016/S0161-5890(96)00078-8
   Toomey CB, 2018, PROG RETIN EYE RES, V62, P38, DOI 10.1016/j.preteyeres.2017.09.001
   Ungvari Z, 2018, CIRC RES, V123, P849, DOI 10.1161/CIRCRESAHA.118.311378
   Vu KT, 2017, EXP EYE RES, V164, P31, DOI 10.1016/j.exer.2017.08.001
   Wang AS, 2018, FRONT GENET, V9, DOI 10.3389/fgene.2018.00247
   Wang C, 2018, J CONTROL RELEASE, V283, P105, DOI 10.1016/j.jconrel.2018.05.030
   Wang L, 2017, CURR MOL MED, V17, P421, DOI 10.2174/1566524018666171205140806
   Woodell A, 2016, INVEST OPHTH VIS SCI, V57, P1728, DOI 10.1167/iovs.15-18471
   Wu J, 2017, AM J CLIN NUTR, V105, P1483, DOI 10.3945/ajcn.116.143453
   Wu J, 2017, OPHTHALMOLOGY, V124, P634, DOI 10.1016/j.ophtha.2016.12.033
   Wyss-Coray T, 2016, NATURE, V539, P180, DOI 10.1038/nature20411
   Xia T, 2017, VISION RES, V139, P72, DOI 10.1016/j.visres.2017.02.006
   Yan Q, 2018, HUM MOL GENET, V27, P929, DOI 10.1093/hmg/ddy002
   Yang H, 2017, P NATL ACAD SCI USA, V114, pE4612, DOI 10.1073/pnas.1705499114
   Yehoshua Z, 2014, OPHTHALMOLOGY, V121, P693, DOI 10.1016/j.ophtha.2013.09.044
   Zarbin MA, 2010, RETINA-J RET VIT DIS, V30, P1350, DOI 10.1097/IAE.0b013e3181f57e30
   Zhang L, 2018, ANNU REV GENET, V52, P397, DOI 10.1146/annurev-genet-120417-031501
   Zhang SJ, 2016, INVEST OPHTH VIS SCI, V57, P312, DOI 10.1167/iovs.15-17578
   Zhu W, 2017, INT J NANOMED, V12, P7589, DOI 10.2147/IJN.S140275
NR 65
TC 17
Z9 19
U1 1
U2 12
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
EI 1178-1998
J9 CLIN INTERV AGING
JI Clin. Interv. Aging
PY 2019
VL 14
BP 1277
EP 1283
DI 10.2147/CIA.S200637
PG 7
WC Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology
GA IK8AZ
UT WOS:000476816600001
PM 31371933
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Jaffe, GJ
   Ciulla, TA
   Ciardella, AP
   Devin, F
   Dugel, PU
   Eandi, CM
   Masonson, H
   Mones, J
   Pearlman, JA
   Quaranta-El Maftouhi, M
   Ricci, F
   Westby, K
   Patel, SC
AF Jaffe, Glenn J.
   Ciulla, Thomas A.
   Ciardella, Antonio P.
   Devin, Francois
   Dugel, Pravin U.
   Eandi, Chiara M.
   Masonson, Harvey
   Mones, Jordi
   Pearlman, Joel A.
   Quaranta-El Maftouhi, Maddalena
   Ricci, Federico
   Westby, Keith
   Patel, Samir C.
TI Dual Antagonism of PDGF and VEGF in Neovascular Age-Related Macular
   Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID DAILY CLINICAL-PRACTICE; GROWTH-FACTOR THERAPY; CHOROIDAL
   NEOVASCULARIZATION; VISUAL-ACUITY; INTRAVITREAL RANIBIZUMAB; PERICYTE
   COVERAGE; TREATMENTS TRIALS; MECHANISMS; CELLS; ANGIOGENESIS
AB Purpose: To assess the safety and efficacy of E10030 (Fovista; Ophthotech, New York, NY), a plateletderived growth factor (PDGF) antagonist, administered in combination with the antievascular endothelial growth factor (VEGF) agent ranibizumab (Lucentis; Roche, Basel, Switzerland) compared with ranibizumab monotherapy in patients with neovascular age-related macular degeneration (nAMD).
   Design: Phase IIb global, multicenter, randomized, prospective, double-masked, controlled superiority trial.
   Participants: Four hundred forty-nine patients with treatment-naive nAMD.
   Methods: Participants were randomized in a 1: 1: 1 ratio to 1 of the following 3 intravitreal treatment groups: E10030 0.3 mg in combination with ranibizumab 0.5 mg, E10030 1.5 mg in combination with ranibizumab 0.5 mg, and sham in combination with ranibizumab 0.5 mg (anti-VEGF monotherapy). Drugs were administered monthly in each of the groups for a total duration of 24 weeks.
   Main Outcome Measures: The prespecified primary end point was the mean change in visual acuity (VA; Early Treatment Diabetic Retinopathy [ETDRS] letters) from baseline to 24 weeks.
   Results: No significant safety issues were observed in any treatment group. The E10030 (1.5 mg) combination therapy regimen met the prespecified primary end point of superiority in mean VA gain compared with anti-VEGF monotherapy (10.6 compared with 6.5 ETDRS letters at week 24; P = 0.019). A dose-response relationship was evident at each measured time point commencing at 4 weeks. Visual acuity outcomes favored the E10030 1.5 mg combination therapy group regardless of baseline VA, lesion size, or central subfield thickness on optical coherence tomography. All clinically relevant treatment end points of visual benefit (>= 15 ETDRS letter gain, final VA >= 20/40 or >= 20/25) and visual loss (>= 1 ETDRS line loss, >= 2 ETDRS line loss, final VA >= 20/125 or >= 20/200) favored the E10030 1.5 mg combination group.
   Conclusions: In this phase IIb clinical trial, a 62% relative benefit from baseline was noted in the E10030 1.5 mg combination therapy group compared with the anti-VEGF monotherapy group. A favorable safety and efficacy profile of E10030 combination therapy for nAMD was evident across multiple clinically relevant end points. This highly powered study provides strong rationale for a confirmatory phase III clinical trial. Ophthalmology 2017; 124: 224-234 (C) 2016 by the American Academy of Ophthalmology
C1 [Jaffe, Glenn J.] Duke Univ, Duke Reading Ctr, Dept Ophthalmol, Box 3802, Durham, NC 27710 USA.
   [Ciulla, Thomas A.; Masonson, Harvey; Westby, Keith; Patel, Samir C.] Ophthotech Corp, New York, NY USA.
   [Ciardella, Antonio P.] Azienda Ospedaliero Univ Bolognad Policlin S Orso, Uni Operat Oftalmol Ciardella, Bologna, Italy.
   [Devin, Francois] Ctr Paradis Monticelli, Marseilles, France.
   [Dugel, Pravin U.] Retinal Consultants Arizona, Phoenix, AZ USA.
   [Dugel, Pravin U.] Univ Southern Calif, Keck Sch Med, USC Roski Eye Inst, Los Angeles, CA USA.
   [Eandi, Chiara M.] Univ Torino, Dept Surg Sci, Eye Clin, Turin, Italy.
   [Mones, Jordi] QuironSalud & Barcelona Macula Fdn, Ctr Medico Teknon, Inst Macula, Barcelona, Spain.
   [Pearlman, Joel A.] Retinal Consultants, Sacramento, CA USA.
   [Quaranta-El Maftouhi, Maddalena] Ctr Rabelais, Lyon, France.
   [Ricci, Federico] Univ Tor Vergatad Fdn PTV Policlin Tor Vergata, Unit Operat Sempl Dipartimentale Patol Retiniche, Dipartimento Chirurg, Rome, Italy.
C3 Duke University; University of Bologna; University of Southern
   California; University of Turin; quironsalud Group
RP Jaffe, GJ (通讯作者)，Duke Univ, Duke Reading Ctr, Dept Ophthalmol, Box 3802, Durham, NC 27710 USA.
EM jaffe001@mc.duke.edu
RI Ciulla, Thomas/AAA-1299-2020; ricci, federico/AAC-3836-2020; mones,
   jordi/CAJ-2963-2022
OI Ciulla, Thomas/0000-0001-5557-6777; ricci, federico/0000-0002-4224-9280;
   mones, jordi/0000-0003-3685-2160
FU Novartis (Basel, Switzerland); Genentech/Roche (Basel, Switzerland);
   Equity owner - Ophthotech Corp. (New York, NY); Notalvision (Tel Aviv,
   Israel)
FX J.M.: Consultant e Ophthotech Corp. ( New York, NY); Ophthotech (New
   York, NY); Notal Vision, Inc. (Tel Aviv, Israel); Alcon Laboratories,
   Inc. (Fort Worth, TX); Allergan (Dublin, Ireland); Bayer Health
   Pharmaceuticals ( Leverkusen, Germany); Genentech/ Roche (Basel,
   Switzerland); Novartis (Basel, Switzerland); Financial support -
   Novartis (Basel, Switzerland); Genentech/Roche (Basel, Switzerland);
   Equity owner - Ophthotech Corp. (New York, NY); Notalvision (Tel Aviv,
   Israel) J.A.P.: Financial support - Ophthotech Corp. (New York, NY)
CR Akiyama H, 2006, J CELL PHYSIOL, V207, P407, DOI 10.1002/jcp.20583
   Andrae J, 2008, GENE DEV, V22, P1276, DOI 10.1101/gad.1653708
   Arevalo JF, 2016, RETINA-J RET VIT DIS, V36, P859, DOI 10.1097/IAE.0000000000000827
   Armulik A, 2005, CIRC RES, V97, P512, DOI 10.1161/01.RES.0000182903.16652.d7
   Benjamin LE, 1998, DEVELOPMENT, V125, P1591
   Bergers G, 2008, NAT REV CANCER, V8, P592, DOI 10.1038/nrc2442
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   CAMPOCHIARO PA, 1985, ARCH OPHTHALMOL-CHIC, V103, P576
   Carmeliet P, 2011, NAT REV DRUG DISCOV, V10, P417, DOI 10.1038/nrd3455
   Carmeliet P, 2011, NATURE, V473, P298, DOI 10.1038/nature10144
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Cohen SY, 2013, RETINA-J RET VIT DIS, V33, P474, DOI 10.1097/IAE.0b013e31827b6324
   Daniel E, 2014, OPHTHALMOLOGY, V121, P656, DOI 10.1016/j.ophtha.2013.10.019
   Erber R, 2003, FASEB J, V17, P338, DOI 10.1096/fj.03-0271fje
   Fredriksson L, 2004, CYTOKINE GROWTH F R, V15, P197, DOI 10.1016/j.cytogfr.2004.03.007
   Greenhalgh Stephen N, 2013, F1000Prime Rep, V5, P37, DOI 10.12703/P5-37
   Grossniklaus HE, 2005, ARCH OPHTHALMOL-CHIC, V123, P914
   Hall AP, 2006, TOXICOL PATHOL, V34, P763, DOI 10.1080/01926230600936290
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Helfrich I, 2011, MOL ONCOL, V5, P137, DOI 10.1016/j.molonc.2011.01.003
   Helfrich I, 2010, J EXP MED, V207, P491, DOI 10.1084/jem.20091846
   Hellstrom M, 1999, DEVELOPMENT, V126, P3047
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Jaffe GJ, 2016, OPHTHALMOLOGY, V123, P78, DOI 10.1016/j.ophtha.2015.09.004
   Jo N, 2006, AM J PATHOL, V168, P2036, DOI 10.2353/ajpath.2006.050588
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Mitchell TS, 2008, ANGIOGENESIS, V11, P141, DOI 10.1007/s10456-007-9085-x
   Rakic JM, 2013, CLIN OPHTHALMOL, V7, P1849, DOI 10.2147/OPTH.S49385
   Rasmussen A, 2013, OPHTHALMOLOGY, V120, P2630, DOI 10.1016/j.ophtha.2013.05.018
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Ross AH, 2013, EYE, V27, P56, DOI 10.1038/eye.2012.225
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Souied EH, 2015, RETINA-J RET VIT DIS, V35, P1743, DOI 10.1097/IAE.0000000000000548
   Spaide RF, 2006, AM J OPHTHALMOL, V141, P149, DOI 10.1016/j.ajo.2005.07.025
   Stark K, 2013, NAT IMMUNOL, V14, P41, DOI 10.1038/ni.2477
   Strittmatter K, 2016, AM J PATHOL, V186, P1890, DOI 10.1016/j.ajpath.2016.02.018
   Talks JS, 2016, OPHTHALMOLOGY, V123, P337, DOI 10.1016/j.ophtha.2015.09.039
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   UCHIHORI Y, 1991, INVEST OPHTH VIS SCI, V32, P2689
   van Asten F, 2015, ACTA OPHTHALMOL, V93, P126, DOI 10.1111/aos.12610
   Willoughby AS, 2015, OPHTHALMOLOGY, V122, P1846, DOI 10.1016/j.ophtha.2015.05.042
NR 42
TC 81
Z9 88
U1 2
U2 24
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD FEB
PY 2017
VL 124
IS 2
BP 224
EP 234
DI 10.1016/j.ophtha.2016.10.010
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EP2PT
UT WOS:000397226300024
PM 28029445
OA Bronze, Green Submitted
DA 2022-11-30
ER

PT J
AU Hautamaki, A
   Oikkonen, J
   Onkamo, P
   Immonen, I
AF Hautamaki, Asta
   Oikkonen, Jaana
   Onkamo, Paivi
   Immonen, Ilkka
TI Correlation between components of newly diagnosed exudative age-related
   macular degeneration lesion and focal retinal sensitivity
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration; exudative age-related macular
   degeneration; fluorescein angiography; microperimetry; optical coherence
   tomography
ID OPTICAL COHERENCE TOMOGRAPHY; SCANNING LASER OPHTHALMOSCOPE; SUBFOVEAL
   CHOROIDAL NEOVASCULARIZATION; INDOCYANINE GREEN ANGIOGRAPHY; FLUORESCEIN
   ANGIOGRAPHY; PHOTODYNAMIC THERAPY; VISUAL FUNCTION; FUNDUS PERIMETRY;
   MICROPERIMETRY; EYES
AB Purpose: To analyse lesion components determining retinal sensitivity in microperimetry in eyes with newly diagnosed exudative age-related macular degeneration (AMD). Methods: Visual acuity, contrast sensitivity, microperimetry, optical coherence tomography (OCT), and fluorescein (FA) and indocyanine green (ICGA) angiographies of 23 eyes of 23 patients were analysed. Central microperimetry grids with 28 test stimulus sites were automatically aligned with three-dimensional OCTs and manually aligned with angiographies. Thicknesses of the neuroretina, neuroepithelial detachment (NED), retinal pigment epithelial (RPE) elevation and subretinal tissue were measured under the 644 microperimetry stimulus sites. Areas of classic and occult choroidal neovascularizations (CNVs), subretinal and intraretinal haemorrhage, and late hyperfluorescence in ICGA were identified. The impact of the lesion components on retinal sensitivity was evaluated with correlation analysis and multivariate modelling. Results: Decreased retinal sensitivity correlated significantly with the presence of CNV, haemorrhage, subretinal tissue and RPE elevation. Out of the OCT parameters, the most important determinant of sensitivity was the thickness of RPE elevation (Spearman's rho, r=-0.202, p<0.0001). The thicknesses of subretinal tissue (r=-0.168, p<0.0001) and NED had weaker effects (r=-0.147, p<0.0001), and the neuroretinal thickness remained nonsignificant. In multivariate modelling, RPE elevation and subretinal tissue in OCT, CNV membranes in angiographies and haemorrhage had the strongest impacts on retinal sensitivity. Conclusion: The most important lesion components affecting retinal function were RPE elevation and subretinal tissue in OCT as well as neovascular membranes and haemorrhage in angiographies. NED and neuroretinal thickening remained less significant.
C1 [Hautamaki, Asta; Immonen, Ilkka] Univ Helsinki, Cent Hosp, Dept Ophthalmol, Helsinki 00029, Finland.
   [Oikkonen, Jaana; Onkamo, Paivi] Univ Helsinki, Dept Biol & Environm Sci, Helsinki 00029, Finland.
C3 University of Helsinki; Helsinki University Central Hospital; University
   of Helsinki
RP Hautamaki, A (通讯作者)，Univ Helsinki, Cent Hosp, Dept Ophthalmol, POB 220, Helsinki 00029, Finland.
EM asta.hautamaki@hus.fi
RI ; Hautamaki, Asta/G-3098-2014
OI Oikkonen, Jaana/0000-0002-1063-2736; Hautamaki, Asta/0000-0002-9454-8434
FU Eye Foundation, Helsinki, Finland; Eye and Tissue Bank Foundation,
   Helsinki, Finland; Evald and Hilda Nissi Foundation, Helsinki, Finland
FX This work was supported by grants from The Eye Foundation, Helsinki,
   Finland; The Eye and Tissue Bank Foundation, Helsinki, Finland; and The
   Evald and Hilda Nissi Foundation, Helsinki, Finland. Preliminary results
   were presented as a poster in Nordic Congress of Ophthalmology,
   Reykjavik, Island, August 2010. The authors have no proprietary or
   commercial interests related to this article.
CR Anastasakis A, 2011, EYE, V25, P245, DOI 10.1038/eye.2010.158
   [Anonymous], 1999, Arch Ophthalmol, V117, P1329
   Bolz M, 2010, BRIT J OPHTHALMOL, V94, P185, DOI 10.1136/bjo.2008.143974
   Bowers D, 2008, MED STAT SCRATCH INT, P151
   BRESSLER SB, 1982, AM J OPHTHALMOL, V93, P157, DOI 10.1016/0002-9394(82)90410-X
   Fujii GY, 2003, AM J OPHTHALMOL, V136, P1067, DOI 10.1016/S0002-9394(03)00663-9
   Hartmann KI, 2011, RETINA-J RET VIT DIS, V31, P1323, DOI 10.1097/IAE.0b013e31820a6850
   Jaakkola A, 1998, BRIT J OPHTHALMOL, V82, P763, DOI 10.1136/bjo.82.7.763
   Joeres S, 2007, INVEST OPHTH VIS SCI, V48, P4300, DOI 10.1167/iovs.07-0179
   Kashani AH, 2009, INVEST OPHTH VIS SCI, V50, P3366, DOI 10.1167/iovs.08-2691
   Keane PA, 2010, INVEST OPHTH VIS SCI, V51, P5431, DOI 10.1167/iovs.09-4846
   Keane PA, 2008, OPHTHALMOLOGY, V115, P2206, DOI 10.1016/j.ophtha.2008.08.016
   Khurana RN, 2010, OPHTHALMOLOGY, V117, P1376, DOI 10.1016/j.ophtha.2009.11.039
   Kiss CG, 2009, INVEST OPHTH VIS SCI, V50, P2376, DOI 10.1167/iovs.08-2017
   Landa G, 2011, RETINA-J RET VIT DIS, V31, P364, DOI 10.1097/IAE.0b013e3181e91132
   Landa G, 2010, OPHTHALMIC RES, V43, P92, DOI 10.1159/000247593
   Midena E, 2007, BRIT J OPHTHALMOL, V91, P1499, DOI 10.1136/bjo.2007.119685
   Moutray T, 2008, BRIT J OPHTHALMOL, V92, P361, DOI 10.1136/bjo.2007.123976
   Parisi V, 2007, RETINA-J RET VIT DIS, V27, P879, DOI 10.1097/IAE.0b013e318042d6aa
   Sabates FN, 2011, RETINA-J RET VIT DIS, V31, P1294, DOI 10.1097/IAE.0b013e3182019be2
   Salinas-Alaman A, 2005, AM J OPHTHALMOL, V140, P23, DOI 10.1016/j.ajo.2005.01.044
   Schmidt-Erfurth UM, 2004, OPHTHALMOLOGY, V111, P931, DOI 10.1016/j.ophtha.2003.12.025
   Schneider U, 1996, GRAEF ARCH CLIN EXP, V234, P612, DOI 10.1007/BF00185293
   SUNNESS JS, 1995, INVEST OPHTH VIS SCI, V36, P1863
   SUNNESS JS, 1988, ARCH OPHTHALMOL-CHIC, V106, P1081, DOI 10.1001/archopht.1988.01060140237032
   Talks J, 2007, BRIT J OPHTHALMOL, V91, P600, DOI 10.1136/bjo.2006.108043
   Tezel TH, 1996, OPHTHALMOLOGY, V103, P1829, DOI 10.1016/S0161-6420(96)30419-3
   TIMBERLAKE GT, 1987, INVEST OPHTH VIS SCI, V28, P1268
   Ting TD, 2002, ARCH OPHTHALMOL-CHIC, V120, P731
   Van de Moere A, 2006, BRIT J OPHTHALMOL, V90, P304, DOI 10.1136/bjo.2005.079947
   van Velthoven MEJ, 2006, GRAEF ARCH CLIN EXP, V244, P1119, DOI 10.1007/s00417-005-0209-y
   Wolf-Schnurrbusch UEK, 2009, INVEST OPHTH VIS SCI, V50, P3432, DOI 10.1167/iovs.08-2970
NR 32
TC 6
Z9 6
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD FEB
PY 2014
VL 92
IS 1
BP 51
EP 58
DI 10.1111/j.1755-3768.2012.02556.x
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 292TJ
UT WOS:000329925000015
PM 22998103
OA Bronze
DA 2022-11-30
ER

PT J
AU Bao, X
   Zhang, ZX
   Guo, YJ
   Buser, C
   Kochounian, H
   Wu, N
   Li, XH
   He, SK
   Sun, B
   Ross-Cisneros, FN
   Sadun, AA
   Huang, LZ
   Zhao, MW
   Fong, HKW
AF Bao, Xuan
   Zhang, Zhaoxia
   Guo, Yanjiang
   Buser, Christopher
   Kochounian, Harold
   Wu, Nancy
   Li, Xiaohua
   He, Shikun
   Sun, Bin
   Ross-Cisneros, Fred N.
   Sadun, Alfredo A.
   Huang, Lvzhen
   Zhao, Mingwei
   Fong, Henry K. W.
TI Human RGR Gene and Associated Features of Age-Related Macular
   Degeneration in Models of Retina-Choriocapillaris Atrophy
SO AMERICAN JOURNAL OF PATHOLOGY
LA English
DT Article
ID PROTEIN-COUPLED-RECEPTOR; PIGMENT-EPITHELIUM; BRUCHS MEMBRANE; OPSIN
   HOMOLOG; DRUSEN; CHROMOPHORE; DEPOSITION; MUTATION; DISEASES; COMPLEX
AB Age-related macular degeneration (AMD) is a progressive eye disease and the most common cause of blindness among the elderly. AMD is characterized by early atrophy of the choriocapillaris and retinal pigment epithelium (RPE). Although AMD is a multifactorial disease with many environmental and genetic risk factors, a hallmark of the disease is the origination of extracellular deposits, or drusen, between the RPE and Bruch membrane. Human retinal G-protein-coupled receptor (RGR) gene generates an exon-skipping splice variant of RGR-opsin (RGR-d; NP_001012740) that is a persistent component of small and large drusen. Herein, the findings show that abnormal RGR proteins, including RGR-d, are pathogenic in an animal retina with degeneration of the choriocapillaris, RPE, and photoreceptors. A frameshift truncating mutation resulted in severe retinal degeneration with a continuous band of basal deposits along the Bruch membrane. RGR-d produced less severe disease with choriocapillaris and RPE atrophy, including focal accumulation of abnormal RGR-d protein at the basal boundary of the RPE. Degeneration of the choriocapillaris was marked by a decrease in endothelial CD31 protein and choriocapillaris breakdown at the ultrastructural level. Fundus lesions with patchy depigmentation were characteristic of old RGR-d mice. RGR-d was mislocalized in cultured cells and caused a strong cell growth defect. These results uphold the notion of a potential hidden link between AMD and a high-frequency RGR allele.
C1 [Bao, Xuan; Guo, Yanjiang; Huang, Lvzhen; Zhao, Mingwei] Peking Univ Peoples Hosp, Beijing Key Lab Diag & Treatment Retinal & Choroi, Dept Ophthalmol, 11 Xizhimen S St, Beijing 100044, Peoples R China.
   [Bao, Xuan; Zhang, Zhaoxia; Fong, Henry K. W.] Univ Southern Calif, Keck Sch Med, Dept Ophthalmol, Mudd Mem Res Bldg,MMR 322,1333 San Pablo St, Los Angeles, CA 90089 USA.
   [He, Shikun] Univ Southern Calif, Keck Sch Med, Dept Pathol, Los Angeles, CA 90007 USA.
   [Wu, Nancy] Univ Southern Calif, Keck Sch Med, Norris Canc Ctr, Los Angeles, CA 90007 USA.
   [Zhang, Zhaoxia; Sun, Bin] Shanxi Eye Hosp, Taiyuan, Shanxi, Peoples R China.
   [Buser, Christopher] Oak Crest Inst Sci, Monrovia, CA USA.
   [Kochounian, Harold; Ross-Cisneros, Fred N.; Sadun, Alfredo A.] Doheny Eye Inst, 1355 San Pablo St, Los Angeles, CA 90033 USA.
   [Li, Xiaohua] Henan Prov Peoples Hosp, Henan Eye Inst, Zhengzhou, Henan, Peoples R China.
   [He, Shikun] Univ Calif Los Angeles, David Geffen Sch Med, Dept Ophthalmol, Los Angeles, CA 90095 USA.
   [Fong, Henry K. W.] Univ Southern Calif, Roski Eye Inst, Los Angeles, CA 90007 USA.
   [Fong, Henry K. W.] Univ Southern Calif, Dept Mol Microbiol & Immunol, Los Angeles, CA 90007 USA.
C3 University of Southern California; University of Southern California;
   University of Southern California; Shanxi Medical University; Doheny Eye
   Institute; Zhengzhou University; University of California System;
   University of California Los Angeles; University of California Los
   Angeles Medical Center; David Geffen School of Medicine at UCLA;
   University of Southern California; University of Southern California
RP Zhao, MW (通讯作者)，Peking Univ Peoples Hosp, Beijing Key Lab Diag & Treatment Retinal & Choroi, Dept Ophthalmol, 11 Xizhimen S St, Beijing 100044, Peoples R China.; Fong, HKW (通讯作者)，Univ Southern Calif, Keck Sch Med, Dept Ophthalmol, Mudd Mem Res Bldg,MMR 322,1333 San Pablo St, Los Angeles, CA 90089 USA.
EM 0062011320@bjmu.edu.cn
OI Buser, Christopher/0000-0002-4379-3878
CR Arno G, 2016, INVEST OPHTH VIS SCI, V57, P4806, DOI 10.1167/iovs.16-19687
   Ba-Abbad R, 2018, INVEST OPHTH VIS SCI, V59, P4812, DOI 10.1167/iovs.18-25061
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Biesemeier A, 2014, NEUROBIOL AGING, V35, P2562, DOI 10.1016/j.neurobiolaging.2014.05.003
   Blasiak J, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20010210
   Campos MM, 2017, ULTRASTRUCT PATHOL, V41, P312, DOI 10.1080/01913123.2017.1348418
   Chen L, 2020, RETINA-J RET VIT DIS, V40, P618, DOI 10.1097/IAE.0000000000002657
   Chen P, 2001, NAT GENET, V28, P256, DOI 10.1038/90089
   Chirco KR, 2017, EYE, V31, P10, DOI 10.1038/eye.2016.216
   Chirco KR, 2016, EXP EYE RES, V146, P393, DOI 10.1016/j.exer.2015.09.003
   Choi EH, 2021, J LIPID RES, V62, DOI 10.1194/jlr.TR120000850
   Crabb JW, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a017194
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Curcio Christine A, 2018, Invest Ophthalmol Vis Sci, V59, pAMD160, DOI 10.1167/iovs.18-24882
   Curcio Christine A, 2018, Invest Ophthalmol Vis Sci, V59, pAMD182, DOI 10.1167/iovs.18-24883
   Dryja TP, 2016, JAMA OPHTHALMOL, V134, P1281, DOI 10.1001/jamaophthalmol.2016.3031
   FEENEY L, 1978, INVEST OPHTH VIS SCI, V17, P583
   Feigl B, 2009, PROG RETIN EYE RES, V28, P63, DOI 10.1016/j.preteyeres.2008.11.004
   Ferrington DA, 2016, PROG RETIN EYE RES, V51, P69, DOI 10.1016/j.preteyeres.2015.09.002
   Fong HKW, 2006, EXP EYE RES, V83, P133, DOI 10.1016/j.exer.2005.11.013
   Forest DL, 2015, DIS MODEL MECH, V8, P421, DOI 10.1242/dmm.017236
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Galloway CA, 2017, P NATL ACAD SCI USA, V114, pE8214, DOI 10.1073/pnas.1710430114
   Geiler-Samerotte KA, 2011, P NATL ACAD SCI USA, V108, P680, DOI 10.1073/pnas.1017570108
   Golestaneh N, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.453
   Handala L, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11020165
   Hao WS, 1996, BIOCHEMISTRY-US, V35, P6251, DOI 10.1021/bi952420k
   Hao WS, 1999, J BIOL CHEM, V274, P6085, DOI 10.1074/jbc.274.10.6085
   Irvine GB, 2008, MOL MED, V14, P451, DOI 10.2119/2007-00100.Irvine
   JIANG M, 1993, INVEST OPHTH VIS SCI, V34, P3669
   JIANG MS, 1995, EXP EYE RES, V60, P401, DOI 10.1016/S0014-4835(05)80096-X
   Johnson LV, 2011, P NATL ACAD SCI USA, V108, P18277, DOI 10.1073/pnas.1109703108
   Kintaka R, 2016, SCI REP-UK, V6, DOI 10.1038/srep31774
   Kochounian H, 2016, MOL VIS, V22, P213
   Kochounian H, 2009, EXP EYE RES, V88, P1129, DOI 10.1016/j.exer.2009.01.019
   Lengyel I, 2004, INVEST OPHTH VIS SCI, V45, P2886, DOI 10.1167/iovs.03-1083
   Li JL, 2016, MOL MED REP, V14, P4811, DOI 10.3892/mmr.2016.5847
   Lin MY, 2007, MOL VIS, V13, P1203
   Maeda T, 2003, J NEUROCHEM, V85, P944, DOI 10.1046/j.1471-4159.2003.01741.x
   Malek G, 2018, EXPERT OPIN DRUG DIS, V13, P359, DOI 10.1080/17460441.2018.1430136
   Marmorstein LY, 2007, HUM MOL GENET, V16, P2423, DOI 10.1093/hmg/ddm199
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Morimura H, 1999, NAT GENET, V23, P393, DOI 10.1038/70496
   Morshedian A, 2019, NEURON, V102, P1172, DOI 10.1016/j.neuron.2019.04.004
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Mullins RF, 2014, AM J PATHOL, V184, P3142, DOI 10.1016/j.ajpath.2014.07.017
   Notomi S, 2019, P NATL ACAD SCI USA, V116, P23724, DOI 10.1073/pnas.1906643116
   Pennesi ME, 2012, MOL ASPECTS MED, V33, P487, DOI 10.1016/j.mam.2012.06.003
   Radu RA, 2008, J BIOL CHEM, V283, P19730, DOI 10.1074/jbc.M801288200
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Ratnapriya R, 2019, NAT GENET, V51, P606, DOI 10.1038/s41588-019-0351-9
   Rudolf M, 2008, INVEST OPHTH VIS SCI, V49, P1200, DOI 10.1167/iovs.07-1466
   Sarks S, 2001, RETINA-J RET VIT DIS
   Seddon JM, 2016, JAMA OPHTHALMOL, V134, P1272, DOI 10.1001/jamaophthalmol.2016.3519
   SHEN DW, 1994, BIOCHEMISTRY-US, V33, P13117, DOI 10.1021/bi00248a022
   Sohn EH, 2019, AM J PATHOL, V189, P1473, DOI 10.1016/j.ajpath.2019.04.005
   Song DL, 2018, INVEST OPHTH VIS SCI, V59, P3405, DOI 10.1167/iovs.18-24133
   Sweeney P, 2017, TRANSL NEURODEGENER, V6, DOI 10.1186/s40035-017-0077-5
   Tao L, 1998, Mol Vis, V4, P25
   Usui H, 2019, J CELL SCI, V132, DOI 10.1242/jcs.215798
   Vasquez RJ, 1997, MOL BIOL CELL, V8, P973, DOI 10.1091/mbc.8.6.973
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   Wenzel A, 2005, J BIOL CHEM, V280, P29874, DOI 10.1074/jbc.M503603200
   Wightman AJ, 2019, CLIN EXP OPTOM, V102, P455, DOI 10.1111/cxo.12842
   Zhang ZX, 2018, MOL VIS, V24, P434
NR 65
TC 1
Z9 1
U1 2
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9440
EI 1525-2191
J9 AM J PATHOL
JI Am. J. Pathol.
PD AUG
PY 2021
VL 191
IS 8
BP 1454
EP 1473
DI 10.1016/j.ajpath.2021.05.003
EA JUL 2021
PG 20
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA TP4DA
UT WOS:000677544000013
PM 34022179
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Acharya, UR
   Mookiah, MRK
   Koh, JEW
   Tan, JH
   Noronha, K
   Bhandary, SV
   Rao, AK
   Hagiwara, Y
   Chua, CK
   Laude, A
AF Acharya, U. Rajendra
   Mookiah, Muthu Rama Krishnan
   Koh, Joel E. W.
   Tan, Jen Hong
   Noronha, Kevin
   Bhandary, Sulatha V.
   Rao, A. Krishna
   Hagiwara, Yuki
   Chua, Chua Kuang
   Laude, Augustinus
TI Novel risk index for the identification of age-related macular
   degeneration using radon transform and DWT features
SO COMPUTERS IN BIOLOGY AND MEDICINE
LA English
DT Article
DE Fundus imaging; Age-related macular degeneration; Radon transform;
   Discrete wavelet transform; Locality sensitive discriminant analysis;
   Computed aided diagnosis
ID DISCRETE WAVELET TRANSFORM; DIABETIC-RETINOPATHY; INTEGRATED INDEX;
   AUTOMATED DETECTION; RETINAL IMAGES; DIAGNOSIS; DISEASE; DRUSEN;
   SEGMENTATION; EXTRACTION
AB Age-related Macular Degeneration (AMD) affects the central vision of aged people. It can be diagnosed due to the presence of drusen, Geographic Atrophy (GA) and Choroidal Neovascularization (CNV) in the fundus images. It is labor intensive and time-consuming for the ophthalmologists to screen these images. An automated digital fundus photography based screening system can overcome these drawbacks. Such a safe, non-contact and cost-effective platform can be used as a screening system for dry AMD. In this paper, we are proposing a novel algorithm using Radon Transform (RT), Discrete Wavelet Transform (DINT) coupled with Locality Sensitive Discriminant Analysis (LSDA) for automated diagnosis of AMD. First the image is subjected to RT followed by DWT. The extracted features are subjected to dimension reduction using LSDA and ranked using t-test. The performance of various supervised classifiers namely Decision Tree (DT), Support Vector Machine (SVM), Probabilistic Neural Network (PNN) and k-Nearest Neighbor (k-NN) are compared to automatically discriminate to normal and AMD classes using ranked LSDA components. The proposed approach is evaluated using private and public datasets such as ARIA and STARE. The highest classification accuracy of 99.49%, 96.89% and 100% are reported for private, ARIA and STARE datasets. Also, AMD index is devised using two LSDA components to distinguish two classes accurately. Hence, this proposed system can be extended for mass AMD screening. (C) 2016 Elsevier Ltd. All rights reserved.
C1 [Acharya, U. Rajendra; Mookiah, Muthu Rama Krishnan; Koh, Joel E. W.; Tan, Jen Hong; Hagiwara, Yuki; Chua, Chua Kuang] Ngee Ann Polytech, Dept Elect & Comp Engn, Singapore 599489, Singapore.
   [Acharya, U. Rajendra] SIM Univ, Sch Sci & Technol, Dept Biomed Engn, Singapore 599491, Singapore.
   [Acharya, U. Rajendra] Univ Malaya, Dept Biomed Engn, Fac Engn, Kuala Lumpur 50603, Malaysia.
   [Noronha, Kevin] St Francis Inst Technol, Dept Elect & Telecommun, Mumbai 400103, Maharashtra, India.
   [Bhandary, Sulatha V.; Rao, A. Krishna] Kasturba Med Coll & Hosp, Dept Ophthalmol, Manipal 576104, India.
   [Laude, Augustinus] Tan Tock Seng Hosp, Natl Healthcare Grp Eye Inst, Singapore 308433, Singapore.
C3 Singapore University of Social Sciences (SUSS); Universiti Malaya;
   Manipal Academy of Higher Education (MAHE); Kasturba Medical College,
   Manipal; Tan Tock Seng Hospital
RP Mookiah, MRK (通讯作者)，Ngee Ann Polytech, Dept Elect & Comp Engn, Singapore 599489, Singapore.
EM mkm2@np.edu.sg
RI Tan, Jenhong/AAD-3664-2020; NORONHA, KEVIN/AAV-1433-2020; Tan, Jen
   Hong/ABE-6525-2020; Acharya, Rajendra U/E-3791-2010; Mookiah, Muthu Rama
   Krishnan/G-4033-2011
OI NORONHA, KEVIN/0000-0002-8753-5918; Acharya, Rajendra
   U/0000-0003-2689-8552; Mookiah, Muthu Rama Krishnan/0000-0001-6437-1482;
   Bhandary, Sulatha/0000-0002-3150-707X; Hagiwara,
   Yuki/0000-0002-5418-738X
FU Social Innovation Research Fund (SIRF/Project), Singapore [T1202]
FX Authors thank Social Innovation Research Fund (SIRF/Project Code:
   T1202), Singapore for providing grant for this research.
CR Acharya RU, 2012, J MED SYST, V36, P1861, DOI 10.1007/s10916-010-9645-2
   Acharya UR, 2011, TECHNOL CANCER RES T, V10, P371, DOI 10.7785/tcrt.2012.500214
   Acharya UR, 2016, INFORM FUSION, V31, P43, DOI 10.1016/j.inffus.2015.12.007
   Acharya UR, 2015, EUR NEUROL, V74, P79, DOI 10.1159/000438457
   Acharya UR, 2015, KNOWL-BASED SYST, V83, P149, DOI 10.1016/j.knosys.2015.03.015
   Acharya UR, 2013, COMPUT METHOD BIOMEC, V16, P222, DOI 10.1080/10255842.2011.616945
   Acharya UR, 2012, J MED SYST, V36, P2011, DOI 10.1007/s10916-011-9663-8
   Afshari F., 2012, WET AGE RELATED MACU
   Agurto C, 2011, INVEST OPHTH VIS SCI, V52, P5862, DOI 10.1167/iovs.10-7075
   Bhuiyan A., 2014, J COMPUT SCI SYST BI
   Brandon L, 2003, LECT NOTES COMPUT SC, V2878, P618
   Breiman L., 1984, CLASSICATION REGRESS
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Burlina P, 2011, IEEE ENG MED BIO, P3962, DOI 10.1109/IEMBS.2011.6090984
   Cheng J, 2012, IEEE IMAGE PROC, P2805, DOI 10.1109/ICIP.2012.6467482
   Chopdar A, 2003, BRIT MED J, V326, P485, DOI 10.1136/bmj.326.7387.485
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   COVER TM, 1967, IEEE T INFORM THEORY, V13, P21, DOI 10.1109/TIT.1967.1053964
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Delany P, 2007, MULTIPLE CLASSIFIER, P1, DOI [10.1016/S0031-3203(00)00099-6, DOI 10.1145/3459665]
   Duda R.O., 2000, PATTERN CLASSIFICATI, DOI https://doi.org/10.1007/978-3-319-57027-3_4
   Fawcett T, 2006, PATTERN RECOGN LETT, V27, P861, DOI 10.1016/j.patrec.2005.10.010
   Freund DE, 2009, I S BIOMED IMAGING, P61, DOI 10.1109/ISBI.2009.5192983
   Gao QX, 2014, NEURAL NETWORKS, V54, P49, DOI 10.1016/j.neunet.2014.02.009
   Ghista DN, 2009, J MECH MED BIOL, V9, P643, DOI 10.1142/S0219519409003188
   Gonzalez R. C., 2018, DIGITAL IMAGE PROCES, V4th
   Gun A., 2008, FUNDAMENTALS STAT, VII
   Gun A., 2008, FUNDAMENTALS STAT, VI
   Haleem MS, 2013, COMPUT MED IMAG GRAP, V37, P581, DOI 10.1016/j.compmedimag.2013.09.005
   Hijazi M. H. A., 2015, INT J SIMUL SYST SCI, P57
   Hijazi MHA, 2010, P INT JOINT C NEUR N, P3501
   Hijazi MHA, 2012, KNOWL-BASED SYST, V29, P83, DOI 10.1016/j.knosys.2011.07.002
   Jadhav DV, 2009, NEUROCOMPUTING, V72, P1951, DOI 10.1016/j.neucom.2008.05.001
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kose C, 2008, COMPUT BIOL MED, V38, P611, DOI 10.1016/j.compbiomed.2008.02.008
   Kose C, 2010, J MED SYST, V34, P1, DOI 10.1007/s10916-008-9210-4
   Krishnan MMR, 2012, MICRON, V43, P352, DOI 10.1016/j.micron.2011.09.016
   Kulkarni AD, 2005, ADV DRUG DELIVER REV, V57, P1994, DOI 10.1016/j.addr.2005.09.003
   la Cour M, 2002, DRUG AGING, V19, P101, DOI 10.2165/00002512-200219020-00003
   Liang ZY, 2010, IEEE ENG MED BIO, P4100, DOI 10.1109/IEMBS.2010.5627289
   Lim TH, 2007, ANN ACAD MED SINGAP, V36, pS15
   Lu Y, 2015, NEUROCOMPUTING, V155, P219, DOI 10.1016/j.neucom.2014.12.026
   MALLAT SG, 1989, IEEE T PATTERN ANAL, V11, P674, DOI 10.1109/34.192463
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Mookiah MRK, 2015, KNOWL-BASED SYST, V89, P654, DOI 10.1016/j.knosys.2015.09.012
   Mookiah MRK, 2015, COMPUT BIOL MED, V63, P208, DOI 10.1016/j.compbiomed.2015.05.019
   Mookiah MRK, 2014, COMPUT BIOL MED, V53, P55, DOI 10.1016/j.compbiomed.2014.07.015
   Mookiah MRK, 2014, MED BIOL ENG COMPUT, V52, P781, DOI 10.1007/s11517-014-1180-8
   Mookiah MRK, 2013, COMPUT BIOL MED, V43, P2136, DOI 10.1016/j.compbiomed.2013.10.007
   Mookiah MRK, 2012, KNOWL-BASED SYST, V33, P73, DOI 10.1016/j.knosys.2012.02.010
   Mora AD, 2011, BIOMED ENG ONLINE, V10, DOI 10.1186/1475-925X-10-59
   Niemeijer M, 2007, INVEST OPHTH VIS SCI, V48, P2260, DOI 10.1167/iovs.06-0996
   Patidar S, 2015, KNOWL-BASED SYST, V82, P1, DOI 10.1016/j.knosys.2015.02.011
   RADON J, 1986, IEEE T MED IMAGING, V5, P170, DOI 10.1109/TMI.1986.4307775
   Rapantzikos K, 2003, MED IMAGE ANAL, V7, P95, DOI 10.1016/S1361-8415(02)00093-2
   Sharma R, 2015, ENTROPY-SWITZ, V17, P5218, DOI 10.3390/e17085218
   SPECHT DF, 1990, NEURAL NETWORKS, V3, P109, DOI 10.1016/0893-6080(90)90049-Q
   Vapnik V., 1998, STAT LEARNING THEORY
   Zeng NY, 2014, IEEE T MED IMAGING, V33, P1129, DOI 10.1109/TMI.2014.2305394
   Zheng YL, 2012, INVEST OPHTH VIS SCI, V53, P8310, DOI 10.1167/iovs.12-9576
NR 60
TC 42
Z9 45
U1 0
U2 13
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0010-4825
EI 1879-0534
J9 COMPUT BIOL MED
JI Comput. Biol. Med.
PD JUN 1
PY 2016
VL 73
BP 131
EP 140
DI 10.1016/j.compbiomed.2016.04.009
PG 10
WC Biology; Computer Science, Interdisciplinary Applications; Engineering,
   Biomedical; Mathematical & Computational Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Life Sciences & Biomedicine - Other Topics; Computer Science;
   Engineering; Mathematical & Computational Biology
GA DP4GZ
UT WOS:000378455700012
PM 27107676
DA 2022-11-30
ER

PT J
AU Bhandari, S
   Vitale, S
   Agron, E
   Clemons, TE
   Chew, EY
AF Bhandari, Sanjeeb
   Vitale, Susan
   Agron, Elvira
   Clemons, Traci E.
   Chew, Emily Y.
CA Age-Related Eye Dis Study 2 Res Gr
TI Cataract Surgery and the Risk of Developing Late Age-Related Macular
   Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
DE Cataract surgery; Geographic atrophy; Intermediate age-related macular
   degeneration; Late age-related macular degeneration; Neovascular
   age-related macular degeneration
ID EYE DISEASE; BEAVER DAM; SEVERITY SCALE; MACULOPATHY; ASSOCIATION;
   PROGRESSION
AB Purpose: To evaluate the risk of developing late age-related macular degeneration (AMD) after incident cataract surgery.
   Design: A prospective cohort study within a randomized controlled clinical trial of oral supplementation for the treatment of AMD, the Age-Related Eye Disease Study 2 (AREDS2).
   Participants: AREDS2 participants aged 50 to 85 years with bilateral large drusen or unilateral late AMD.
   Methods: In eyes free of cataract surgery and late AMD at baseline, 2 groups were compared for incident late AMD: (1) eyes that received cataract surgery after the baseline visit and before any evidence of late AMD and (2) eyes that remained phakic until study completion. Eyes with at least 2 years of follow-up after cataract surgery were included in the analysis. We used Cox regression models, matched-pairs analysis, and logistic regression models that were adjusted for age, sex, smoking, education, study treatment group, and AMD severity.
   Main Outcome Measures: Late AMD was defined as the presence of geographic atrophy or neovascular AMD detected on annual stereoscopic fundus photographs or as documented by medical records, including intravitreous injections of anti-vascular endothelial growth factor medication.
   Results: A total of 1767 eligible eyes (1195 participants) received cataract surgery; 1981 eyes (1524 participants) developed late AMD during a mean (range) follow-up of 9 (1-12) years. The Cox regression model showed no increased risk of developing late AMD after cataract surgery: hazard ratio, 0.96; 95% confidence interval (CI), 0.81-1.13 (P = 0.60) for right eyes and hazard ratio, 1.05; 95% CI, 0.89-1.25 (P = 0.56) for left eyes. Of the matched pairs, late AMD was identified in 408 eyes that received cataract surgery and in 429 phakic controls: odds ratio (OR) 0.92 (95% CI, 0.77-1.10; P = 0.34). The risk of late AMD after cataract surgery from the logistic regression model was not statistically significant (risk ratio, 0.92; 95% CI, 0.56-1.49; P = 0.73).
   Conclusions: Cataract surgery did not increase the risk of developing late AMD among AREDS2 participants with up to 10 years of follow-up. This study provides data for counseling AMD patients who might benefit from cataract surgery. (C) 2021 by the American Academy of Ophthalmology
C1 [Bhandari, Sanjeeb; Vitale, Susan; Agron, Elvira; Chew, Emily Y.] NEI, Clin Trials Branch, Div Epidemiol & Clin Applicat, NIH, BG 10 CRC RM 3-2531,10 Ctr Dr,MSC1204, Bethesda, MD 20892 USA.
   [Clemons, Traci E.] EMMES Corp LLC, Rockville, MD USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI)
RP Chew, EY (通讯作者)，NEI, Clin Trials Branch, Div Epidemiol & Clin Applicat, NIH, BG 10 CRC RM 3-2531,10 Ctr Dr,MSC1204, Bethesda, MD 20892 USA.
EM echew@nei.nih.gov
OI BHANDARI, SANJEEB/0000-0002-4110-4274
FU National Eye Institute/National Institutes of Health, Department of
   Health and Human Services, Bethesda Maryland [HHS-N-260-2005-00007-C,
   NO1-EY-5-0007]; Office of Dietary Supplements, National Center for
   Complementary and Alternative Medicine; National Institute on Aging;
   National Heart, Lung, and Blood Institute; National Institute of
   Neurological Disorders and Stroke
FX Supported by the intramural program funds and contracts from the
   National Eye Institute/National Institutes of Health, Department of
   Health and Human Services, Bethesda Maryland (Contract
   HHS-N-260-2005-00007-C; ADB Contract NO1-EY-5-0007). Funds were
   generously contributed to these contracts by the following National
   Institutes of Health: Office of Dietary Supplements, National Center for
   Complementary and Alternative Medicine; National Institute on Aging;
   National Heart, Lung, and Blood Institute; and National Institute of
   Neurological Disorders and Stroke. The sponsor and funding organization
   participated in the design and conduct of the study; data collection,
   management, analysis and interpretation; and the preparation, review,
   and approval of the manuscript.
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Armbrecht AM, 2003, J CATARACT REFR SURG, V29, P686, DOI 10.1016/S0886-3350(02)01650-4
   Baatz H, 2008, INVEST OPHTH VIS SCI, V49, P1079, DOI 10.1167/iovs.07-0557
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chew EY, 2012, OPHTHALMOLOGY, V119, P2282, DOI 10.1016/j.ophtha.2012.05.027
   Chew EY, 2009, OPHTHALMOLOGY, V116, P297, DOI 10.1016/j.ophtha.2008.09.019
   Cugati S, 2006, OPHTHALMOLOGY, V113, P2020, DOI 10.1016/j.ophtha.2006.05.047
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Dong LM, 2009, ARCH OPHTHALMOL-CHIC, V127, P1412, DOI 10.1001/archophthalmol.2009.152
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Fraser-Bell S, 2010, AM J OPHTHALMOL, V149, P735, DOI 10.1016/j.ajo.2009.11.013
   Freeman EE, 2003, AM J OPHTHALMOL, V135, P849, DOI 10.1016/S0002-9394(02)02253-5
   Ho L, 2008, INVEST OPHTH VIS SCI, V49, P4795, DOI 10.1167/iovs.08-2066
   Klein BEK, 2012, OPHTHALMOLOGY, V119, P1628, DOI 10.1016/j.ophtha.2012.01.050
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   Klein R, 1998, ARCH OPHTHALMOL-CHIC, V116, P506, DOI 10.1001/archopht.116.4.506
   Klein R, 2002, ARCH OPHTHALMOL-CHIC, V120, P1551, DOI 10.1001/archopht.120.11.1551
   KLEIN R, 1994, ARCH OPHTHALMOL-CHIC, V112, P191, DOI 10.1001/archopht.1994.01090140067025
   LIU IY, 1989, AM J PUBLIC HEALTH, V79, P765, DOI 10.2105/AJPH.79.6.765
   National Eye Institute, 2019, AGE RELATED MACULAR
   National Eye Institute, 2019, CAT DAT STAT
   Ortman J.M., 2014, AGING NATION OLDER P
   Park SJ, 2016, JAMA OPHTHALMOL, V134, P621, DOI 10.1001/jamaophthalmol.2016.0453
   Sutter FKP, 2007, INVEST OPHTH VIS SCI, V48, P1472, DOI 10.1167/iovs.06-0766
   Wang J J, 1999, Ophthalmic Epidemiol, V6, P317, DOI 10.1076/opep.6.4.317.4182
   Wang JJ, 2016, OPHTHALMOLOGY, V123, P1829, DOI 10.1016/j.ophtha.2016.02.003
   Wang JJ, 2012, OPHTHALMOLOGY, V119, P2298, DOI 10.1016/j.ophtha.2012.07.003
   Wang JJ, 2003, OPHTHALMOLOGY, V110, P1960, DOI 10.1016/S0161-6420(03)00816-9
   Xu L, 2011, GRAEF ARCH CLIN EXP, V249, P981, DOI 10.1007/s00417-010-1571-y
NR 29
TC 1
Z9 1
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD APR
PY 2022
VL 129
IS 4
BP 414
EP 420
DI 10.1016/j.ophtha.2021.11.014
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 0Z8GD
UT WOS:000791309100016
PM 34793832
DA 2022-11-30
ER

PT J
AU Ciucci, F
   Ioele, G
   Bardocci, A
   Lofoco, G
   Antonelli, B
   De Gaetano, C
   Polimanti, G
   De Luca, M
   Ragno, G
   Gattegna, R
AF Ciucci, Francesco
   Ioele, Giuseppina
   Bardocci, Antonio
   Lofoco, Giorgio
   Antonelli, Barbara
   De Gaetano, Cristiano
   Polimanti, Gabriele
   De Luca, Michele
   Ragno, Gaetano
   Gattegna, Roberto
TI Central retinal thickness fluctuations in patients treated with
   anti-VEGF for neovascular age related macular degeneration
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Central retinal thickness; foveal center point thicknesses; principal
   component analysis; fluctuations; nAMD; anti-VEGF
ID INTRAVITREAL RANIBIZUMAB; VISUAL-ACUITY; OUTCOMES; METAANALYSIS;
   RESOLUTION
AB Purpose: This is a retrospective, single-center, non randomized interventional real life study, investigating the correlation between variability of central retinal thickness (CRT) and functional outcomes during 2 years of anti-VEGF therapy in patients treated for neovascular age related macular degeneration (nAMD). Background: CRT fluctuations can depend on various factors such as the correct timing of injections, the therapeutic algorithm, and the number of injections (NI) performed; it is important to understand if CRT fluctuations are responsible for worse visual outcomes and consequently to identify the correct ways to avoid or reduce them. Methods: Forty-one patients were treated for nAMD with aflibercept: 0.5 mg intravitreal aflibercept was administered every 4 weeks during the first 3 months, then bimonthly over the first year, and after the first year adopting a PRN regimen. Standard deviation of CRT (CRT/SD), BCVA, and NI were recorded. Correlation studies were performed by Pearson's test, Ancova, and Principal Component Analysis. Results: A negative correlation was found between CRT/SD and final BCVA. In patients who lost more than 15 letters, CRT/SD mean was significantly higher in comparison with patients who lost less than 15 letters. Patients with final BCVA >65 letters showed lower CRT/SD values compared to patients with final BCVA <= 65 letters. Multivariate analysis confirmed that in patients with higher baseline BCVA, improvement of BCVA was correlated to NI, and lower values of CRT fluctuations were observed. Conclusions: CRT fluctuations, even after an appropriate NI given per year, significantly influence BCVA; a proactive treatment algorithm appears crucial when treating patients with nAMD.
C1 [Ciucci, Francesco; Bardocci, Antonio; Lofoco, Giorgio; Antonelli, Barbara; De Gaetano, Cristiano; Polimanti, Gabriele] Osped San Pietro Fatebenefratelli, Dept Ophthalmol, Via Cassia 600, I-00189 Rome, Lazio, Italy.
   [Ioele, Giuseppina; De Luca, Michele; Ragno, Gaetano] Univ Calabria, Dept Pharm Hlth & Nutr Sci, Arcavacata Di Rende, Italy.
   [Gattegna, Roberto] Osped Israelit, Dept Ophthalmol, Rome, Lazio, Italy.
C3 University of Calabria
RP Ciucci, F (通讯作者)，Osped San Pietro Fatebenefratelli, Dept Ophthalmol, Via Cassia 600, I-00189 Rome, Lazio, Italy.
EM ciuccieye@gmail.com
RI De Luca, Michele/ABA-3554-2020
OI De Luca, Michele/0000-0001-9036-1595; Ioele,
   Giuseppina/0000-0003-3910-1899; Ciucci, Francesco/0000-0003-0803-6510
CR [Anonymous], 2018, UNSCR X VERS 10 5 SO
   Carrasco J, 2020, ADV THER, V37, P300, DOI 10.1007/s12325-019-01147-6
   Cohen J., 1988, STAT POWER ANAL SOCI, V2nd
   De Luca M, 2014, ANAL CHIM ACTA, V837, P31, DOI 10.1016/j.aca.2014.05.056
   De Luca M, 2011, FOOD CHEM, V124, P1113, DOI 10.1016/j.foodchem.2010.07.010
   Eleftheriadou M, 2018, OPHTHALMOL THER, V7, P361, DOI 10.1007/s40123-018-0139-5
   Evans RN, 2020, JAMA OPHTHALMOL, V138, P1043, DOI 10.1001/jamaophthalmol.2020.3001
   Gregori NZ, 2010, RETINA-J RET VIT DIS, V30, P1046, DOI 10.1097/IAE.0b013e3181d87e04
   Ioele G, 2020, WATER-SUI, V12, DOI 10.3390/w12082214
   Ioele G, 2011, CHEM PHARM BULL, V59, P35, DOI 10.1248/cpb.59.35
   JASP, 2019, JASP VERS 0 11 1
   Kim LN, 2016, RETINA-J RET VIT DIS, V36, P1418, DOI 10.1097/IAE.0000000000001142
   Maren ES., 2019, J TORAC DIS, V11, pS574
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Verma P., 2020, DETERMINATION SAMPLE
NR 15
TC 0
Z9 0
U1 1
U2 1
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD JUL
PY 2022
VL 32
IS 4
BP 2388
EP 2394
AR 11206721211037820
DI 10.1177/11206721211037820
EA AUG 2021
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 3B9CF
UT WOS:000684885800001
PM 34392710
DA 2022-11-30
ER

PT J
AU Dans, KC
   Freeman, SR
   Lin, TZ
   Meshi, A
   Olivas, S
   Cheng, LY
   Amador-Patarroyo, MJ
   Freeman, WR
AF Dans, Kunny C.
   Freeman, Sarah R.
   Lin, Tiezhu
   Meshi, Amit
   Olivas, Sergio
   Cheng, Lingyun
   Amador-Patarroyo, Manuel J.
   Freeman, William R.
TI Durability of every-8-week aflibercept maintenance therapy in
   treatment-experienced neovascular age-related macular degeneration
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Aflibercept; Anti-VEGF; Fixed; Maintenance; Neovascular AMD; Optical
   coherence tomography
ID VISUAL-ACUITY; RANIBIZUMAB
AB PurposeTo determine the proportion of treatment-experienced eyes with exudative age-related macular degeneration successfully treated with every-4-week aflibercept that can be kept dry on fixed every-8-week aflibercept injections (maintenance).MethodsIn this retrospective chart review, we evaluated our cohort of patients treated with a treatment paradigm for CNV in AMD. Initially, patients were treated with bevacizumab or ranibizumab and switched to every-4-week aflibercept when therapeutic responses were not durable or were suboptimal. Maintenance every-8-week therapy was initiated when the retina was completely dry on every-4-week aflibercept therapy. The primary outcome measure was recurrence of exudation on optical coherence tomography (OCT) during maintenance.ResultsThirty-six eyes of 31 consecutive patients with median age of 79years (range, 65-89) were included. Maintenance was started after a median of 34 (range, 8-88) injections. Recurrence was observed in 20 eyes (55%). Of these, 11 eyes (31%) reactivated at 8weeks. Median time to failure of maintenance schedule was 40weeks by Kaplan-Meier analysis. Baseline demographic and anatomic characteristics were not associated with failure of maintenance schedule.ConclusionIn treatment-experienced eyes that respond completely to every-4-week aflibercept, maintenance therapy with every-8-week injections can only temporarily maintain anatomic success with the majority of eyes developing recurring activity. This regimen fails early in one third of eyes and has a median effective duration of 40weeks. Aflibercept appears to be inadequate to maintain control of exudation in most eyes in at least half of eyes undergoing long-term therapy.
C1 [Dans, Kunny C.; Freeman, Sarah R.; Lin, Tiezhu; Meshi, Amit; Olivas, Sergio; Cheng, Lingyun; Amador-Patarroyo, Manuel J.; Freeman, William R.] Univ Calif San Diego, Dept Ophthalmol, Jacobs Retina Ctr, Shiley Eye Inst, 9415 Campus Point Dr, La Jolla, CA 92037 USA.
   [Lin, Tiezhu] He Univ, He Eye Hosp, Dept Ophthalmol, Shenyang, Liaoning, Peoples R China.
   [Meshi, Amit] Rabin Med Ctr, Dept Ophthalmol, Petah Tiqwa, Israel.
   [Meshi, Amit] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel.
   [Amador-Patarroyo, Manuel J.] Inst Barraquer Amer, Escuela Super Oftalmol, Dept Ophthalmol, Bogota, Colombia.
C3 University of California System; University of California San Diego;
   Rabin Medical Center; Tel Aviv University; Sackler Faculty of Medicine
RP Freeman, WR (通讯作者)，Univ Calif San Diego, Dept Ophthalmol, Jacobs Retina Ctr, Shiley Eye Inst, 9415 Campus Point Dr, La Jolla, CA 92037 USA.
EM wrfreeman@ucsd.edu
RI lin, Tiezhu/AAY-1971-2020
FU UCSD Vision Research Center Core Grant [P30EY022589]; Research to
   Prevent Blindness, NY (WRF); NATIONAL EYE INSTITUTE [P30EY022589]
   Funding Source: NIH RePORTER
FX This study was supported by the UCSD Vision Research Center Core Grant
   P30EY022589, an unrestricted fund from Research to Prevent Blindness, NY
   (WRF). The funding organization had no role in the design or conduct of
   this research.
CR Arcinue CA, 2015, AM J OPHTHALMOL, V159, P426, DOI 10.1016/j.ajo.2014.11.022
   Bhavsar KV, 2014, SAUDI J OPHTHALMOL, V28, P129, DOI 10.1016/j.sjopt.2014.03.001
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chatziralli I, 2016, OPHTHALMOLOGY, V123, P1762, DOI 10.1016/j.ophtha.2016.05.002
   Dugel PU, 2017, OPHTHALMOLOGY, V124, P1296, DOI 10.1016/j.ophtha.2017.03.057
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Ho AC, 2014, OPHTHALMOLOGY, V121, P2181, DOI 10.1016/j.ophtha.2014.05.009
   Jaffe GJ, 2016, OPHTHALMOLOGY, V123, P1856, DOI 10.1016/j.ophtha.2016.05.016
   Khanani AM, 2015, CLIN OPHTHALMOL, V9, P1315, DOI 10.2147/OPTH.S88624
   Kodjikian L, 2018, RETINA-J RET VIT DIS, V38, P1492, DOI 10.1097/IAE.0000000000001736
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Muftuoglu IK, 2018, RETINA-J RET VIT DIS, V38, P516, DOI 10.1097/IAE.0000000000001572
   Muftuoglu IK, 2016, AM J OPHTHALMOL, V167, P1, DOI 10.1016/j.ajo.2016.03.038
   Regeneron Pharmaceuticals, 2011, HIGHL PRESCR INF
   Regillo C, 2018, PORT DELIVERY PHAS 2
   Richard G, 2015, OPHTHALMOLOGY, V122, P2497, DOI 10.1016/j.ophtha.2015.08.014
   Sharma S, 2016, OPHTHALMOLOGY, V123, P865, DOI 10.1016/j.ophtha.2015.12.002
   Stewart MA, 2011, ADV GLOB CHANGE RES, V45, P1, DOI [10.1007/978-94-007-0934-8_1, 10.4081/eye.2011.e5]
   Stewart MW, 2018, PHARMACEUTICS, V10, DOI 10.3390/pharmaceutics10010021
   You QS, 2018, RETINA-J RET VIT DIS, V38, P1156, DOI 10.1097/IAE.0000000000001726
NR 20
TC 5
Z9 5
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD APR
PY 2019
VL 257
IS 4
BP 741
EP 748
DI 10.1007/s00417-018-04232-8
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HR2CH
UT WOS:000462942600010
PM 30806775
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Peyrin, C
   Ramanoel, S
   Roux-Sibilon, A
   Chokron, S
   Hera, R
AF Peyrin, Carole
   Ramanoel, Stephen
   Roux-Sibilon, Alexia
   Chokron, Sylvie
   Hera, Ruxandra
TI Scene perception in age-related macular degeneration: Effect of spatial
   frequencies and contrast in residual vision
SO VISION RESEARCH
LA English
DT Article
DE Scene categorization; Contrast normalization; Root-mean square; Aging;
   Central visual loss
ID VISUAL-ACUITY; SENSITIVITY DECLINE; CONTOUR ENHANCEMENT;
   PERIPHERAL-VISION; IMAGE-ENHANCEMENT; FACE RECOGNITION; NATURAL IMAGES;
   CATEGORIZATION; IMPAIRMENT; PERFORMANCE
AB Age-related macular degeneration (AMD) is characterized by a central vision loss. Here, we investigated the ability of AMD patients to process the spatial frequency content of scenes in their residual vision, depending of the luminance contrast level. AMD patients and normally-sighted elderly participants (controls) performed a categorization task involving large scenes (outdoors vs. indoors) filtered in low spatial frequencies (LSF), high spatial frequencies (HSF), and non-filtered scenes (NF). Luminance contrast of scenes was equalized between stimuli using a root-mean square (RMS) contrast normalization. In Experiment 1, we applied an RMS contrast of 0.1 (for luminance values between 0 and 1), a value situated between the mean contrast of LSF and HSF scenes in natural conditions. In Experiment 2, we applied an RMS contrast of 0.3, corresponding to the mean contrast of HSF scenes in natural conditions. In Experiment 3, we manipulated four levels of linearly-increasing RMS contrasts (0.05, 0.10, 0.15, and 0.20) for HSF scenes only. Compared to controls, AMD patients gave more non-responses in the categorization of HSF than NF or LSF scenes, irrespective of the contrast level of scenes. Performances improved as contrast increased in HSF scenes. Controls were not differentially affected by the spatial frequency content of scenes. Overall, results suggest that LSF processing is well preserved in AMD patients and allows efficient scene categorization in their parafoveal residual vision. The HSF processing deficit could be partially restored by enhancing luminance contrast. (C) 2016 Elsevier Ltd. All rights reserved.
C1 [Peyrin, Carole; Ramanoel, Stephen; Roux-Sibilon, Alexia] Univ Grenoble Alpes, LPNC, F-38000 Grenoble, France.
   [Peyrin, Carole; Ramanoel, Stephen; Roux-Sibilon, Alexia] CNRS, LPNC, F-38000 Grenoble, France.
   [Chokron, Sylvie] Univ Paris 05, Lab Psychol Percept, Paris, France.
   [Chokron, Sylvie] CNRS, Paris, France.
   [Chokron, Sylvie] Fdn Ophtalmol Rothschild, Unite Vis & Cognit, Paris, France.
   [Hera, Ruxandra] Alpes Retine, F-38330 Montbonnot St Martin, France.
C3 Communaute Universite Grenoble Alpes; UDICE-French Research
   Universities; Universite Grenoble Alpes (UGA); Centre National de la
   Recherche Scientifique (CNRS); UDICE-French Research Universities;
   Universite Paris Cite; Centre National de la Recherche Scientifique
   (CNRS); UDICE-French Research Universities; Universite Paris Cite
RP Peyrin, C (通讯作者)，Univ Grenoble Alpes, LPNC, F-38000 Grenoble, France.
EM carole.peyrin@univ-grenoble-alpes.fr
RI Roux-Sibilon, Alexia/AAL-5540-2020; Ramanoel, Stephen/AAB-5080-2022
OI Ramanoel, Stephen/0000-0003-4735-1097; Peyrin,
   Carole/0000-0001-7792-092X
FU SFR "Sante et Societe" (Universite Pierre Mendes-France, Grenoble,
   France); RECOR "Agence Nationale pour la Recherche" [ANR-12-JHS2-0002-01
   RECOR]
FX This work was supported by the SFR "Sante et Societe" (Universite Pierre
   Mendes-France, Grenoble, France) and the RECOR "Agence Nationale pour la
   Recherche" Grant (ANR-12-JHS2-0002-01 RECOR). We thank Catherine Dal
   Molin for the English revision of the manuscript.
CR Bex PJ, 2002, J OPT SOC AM A, V19, P1096, DOI 10.1364/JOSAA.19.001096
   Bordier C, 2011, OPHTHAL PHYSL OPT, V31, P203, DOI 10.1111/j.1475-1313.2011.00820.x
   Boucart M, 2008, VISUAL NEUROSCI, V25, P603, DOI 10.1017/S0952523808080656
   Boucart M, 2010, NEUROCASE, V16, P157, DOI 10.1080/13554790903339637
   Boucart M, 2008, VISUAL NEUROSCI, V25, P685, DOI 10.1017/S0952523808080826
   BROWN B, 1993, OPTOMETRY VISION SCI, V70, P45, DOI 10.1097/00006324-199301000-00009
   Brown B, 1987, CLIN EXP OPTOM, V70, P145
   BULLIMORE MA, 1991, INVEST OPHTH VIS SCI, V32, P2020
   Campagne A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0144393
   Cheung SH, 2005, VISUAL NEUROSCI, V22, P187, DOI 10.1017/S0952523805222071
   CURCIO CA, 1990, J COMP NEUROL, V292, P497, DOI 10.1002/cne.902920402
   ELLIOTT D, 1990, VISION RES, V30, P541, DOI 10.1016/0042-6989(90)90066-T
   ELLIOTT DB, 1987, OPHTHAL PHYSL OPT, V7, P415, DOI 10.1111/j.1475-1313.1987.tb00771.x
   ELLIOTT DB, 1995, OPTOMETRY VISION SCI, V72, P186, DOI 10.1097/00006324-199503000-00006
   Elliott SL, 2010, J VISION, V10, DOI 10.1167/10.4.4
   FIELD DJ, 1987, J OPT SOC AM A, V4, P2379, DOI 10.1364/JOSAA.4.002379
   FINE EM, 1995, J OPT SOC AM A, V12, P2286, DOI 10.1364/JOSAA.12.002286
   Fletcher DC, 1999, J REHABIL RES DEV, V36, P356
   Fradcourt B, 2013, BRAIN COGNITION, V83, P104, DOI 10.1016/j.bandc.2013.07.009
   Fullerton M, 2008, J SOC INF DISPLAY, V16, P493, DOI 10.1889/1.2896328
   GITTINGS NS, 1986, EXP GERONTOL, V21, P423, DOI 10.1016/0531-5565(86)90047-1
   Gold J, 1999, VISION RES, V39, P3537, DOI 10.1016/S0042-6989(99)00080-2
   Harel A, 2009, J EXP PSYCHOL HUMAN, V35, P1264, DOI 10.1037/a0013621
   Hassan SE, 2002, OPTOMETRY VISION SCI, V79, P697, DOI 10.1097/00006324-200211000-00007
   HIGGINS KE, 1988, J OPT SOC AM A, V5, P2173, DOI 10.1364/JOSAA.5.002173
   Kauffmann L, 2015, NEUROIMAGE, V112, P86, DOI 10.1016/j.neuroimage.2015.02.058
   KLEINER RC, 1988, ARCH OPHTHALMOL-CHIC, V106, P55
   Kwon M, 2012, OPTOMETRY VISION SCI, V89, P1374, DOI 10.1097/OPX.0b013e3182678e52
   Kwon M, 2011, VISION RES, V51, P1995, DOI 10.1016/j.visres.2011.06.020
   Langagergaard U, 2003, ACTA OPHTHALMOL SCAN, V81, P455, DOI 10.1034/j.1600-0420.2003.00142.x
   LEGGE GE, 1985, VISION RES, V25, P253, DOI 10.1016/0042-6989(85)90118-X
   Lenoble Q, 2014, AGING NEUROPSYCHOL C, V21, P325, DOI 10.1080/13825585.2013.823143
   Luo G, 2012, OPHTHAL PHYSL OPT, V32, P421, DOI 10.1111/j.1475-1313.2012.00908.x
   Midena E, 1997, INVEST OPHTH VIS SCI, V38, P469
   Morrison DJ, 2001, PSYCHON B REV, V8, P454, DOI 10.3758/BF03196180
   Moshtael H, 2015, TRANSL VIS SCI TECHN, V4, DOI 10.1167/tvst.4.4.6
   Musel B, 2013, J COGNITIVE NEUROSCI, V25, P1315, DOI 10.1162/jocn_a_00397
   Musel B, 2011, VISUAL NEUROSCI, V28, P529, DOI 10.1017/S0952523811000435
   Nasanen R, 1999, VISION RES, V39, P3824, DOI 10.1016/S0042-6989(99)00096-6
   OWSLEY C, 1983, VISION RES, V23, P689, DOI 10.1016/0042-6989(83)90210-9
   Owsley C, 2011, VISION RES, V51, P1610, DOI 10.1016/j.visres.2010.10.020
   PARISH DH, 1991, VISION RES, V31, P1399, DOI 10.1016/0042-6989(91)90060-I
   Peli E, 2009, INT J ARTIF INTELL T, V18, P415, DOI 10.1142/S0218213009000214
   Ramanoel S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134554
   Rotshtein P, 2010, J VISION, V10, DOI 10.1167/10.10.25
   Rovner BW, 2002, AM J GERIAT PSYCHIAT, V10, P305
   Rubin GS, 1997, INVEST OPHTH VIS SCI, V38, P557
   SALIVE ME, 1994, J AM GERIATR SOC, V42, P287, DOI 10.1111/j.1532-5415.1994.tb01753.x
   Satgunam P, 2012, OPTOMETRY VISION SCI, V89, pE1364, DOI 10.1097/OPX.0b013e318266f92f
   Schyns PG, 1998, COGNITION, V67, P147, DOI 10.1016/S0010-0277(98)00016-X
   Schyns PG, 1999, COGNITION, V69, P243, DOI 10.1016/S0010-0277(98)00069-9
   SEKULER R, 1980, SCIENCE, V209, P1255, DOI 10.1126/science.7403884
   Tejeria L, 2002, BRIT J OPHTHALMOL, V86, P1019, DOI 10.1136/bjo.86.9.1019
   Thi HCT, 2012, OPTOMETRY VISION SCI, V89, P419, DOI 10.1097/OPX.0b013e31824c3a21
   Thi HCT, 2011, INVEST OPHTH VIS SCI, V52, P1655, DOI 10.1167/iovs.10-6003
   Thi HCT, 2010, INVEST OPHTH VIS SCI, V51, P6868, DOI 10.1167/iovs.10-5517
   Thibaut M, 2014, VISION RES, V98, P46, DOI 10.1016/j.visres.2014.03.004
   Torralba A, 2003, NETWORK-COMP NEURAL, V14, P391, DOI 10.1088/0954-898X/14/3/302
NR 58
TC 9
Z9 9
U1 0
U2 6
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0042-6989
EI 1878-5646
J9 VISION RES
JI Vision Res.
PD JAN
PY 2017
VL 130
BP 36
EP 47
DI 10.1016/j.visres.2016.11.004
PG 12
WC Neurosciences; Ophthalmology; Psychology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Neurosciences & Neurology; Ophthalmology; Psychology
GA EI5UN
UT WOS:000392560400005
PM 27876510
OA Bronze
DA 2022-11-30
ER

PT J
AU Liutkeviciene, R
   Vilkeviciute, A
   Borisovaite, D
   Miniauskiene, G
AF Liutkeviciene, Rasa
   Vilkeviciute, Alvita
   Borisovaite, Dominyka
   Miniauskiene, Goda
TI Association of exudative age-related macular degeneration with matrix
   metalloproteinases-2 (-1306 C/T) rs243865 gene polymorphism
SO INDIAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Exudative age-related macular degeneration; gene polymorphism; matrix
   metalloproteinases
ID BRUCHS MEMBRANE; GELATINASE-A; GENDER; GENOTYPE; MMP-2; PHENOTYPE;
   VARIANTS; INCREASE; DEPOSITS; SP1
AB Purpose: Age-related macular degeneration (AMD) is a disease of the macula that significantly affects eyesight and leads to irreversible central vision loss. Recent studies have demonstrated that angiogenesis is the most important mechanism of AMD development. It is associated with extracellular remodeling involving different proteolytic systems, among them matrix metalloproteinases (MMPs), which play an essential role in the etiopathogenesis of AMD. The main objective of the present study was to determine the relationship between exudative AMD and MMP-2 (-1306 C/T) rs243865 polymorphism. Methods: The study enrolled 267 patients with exudative AMD and 318 controls. DNA was extracted from peripheral venous blood leukocytes by commercial kits. Genotyping of MMP-2 (-1306 C/T) rs243865 was carried out using real-time polymerase chain reaction method. Results: The analysis of MMP-2 (-1306 C/T) polymorphism did not reveal any differences in the distribution of CC, CT, and TT genotypes between the exudative AMD and control groups: 58.8%, 31.5% and 9.7% vs. 59.75%, 33.96% and 6.29%, respectively, P = 0.287). When the study population was subdivided into age groups, MMP-2 (-1306 C/T) rs243865 CT genotype showed 5.7-fold increased the risk of exudative AMD development compared to CC and TT genotypes together in younger (< 65 years) males group (P = 0.05). Conclusion: MMP-2 (-1306 C/T) polymorphism is associated with exudative AMD development in younger males.
C1 [Liutkeviciene, Rasa; Miniauskiene, Goda] Lithuanian Univ Hlth Sci, Med Acad, Dept Ophthalmol, Eiveniu 2, Kaunas, Lithuania.
   [Liutkeviciene, Rasa; Vilkeviciute, Alvita] Lithuanian Univ Hlth Sci, Med Acad, Neurosci Inst, Kaunas, Lithuania.
   [Borisovaite, Dominyka] Lithuanian Univ Hlth Sci, Med Acad, Kaunas, Lithuania.
C3 Lithuanian University of Health Sciences; Lithuanian University of
   Health Sciences; Lithuanian University of Health Sciences
RP Liutkeviciene, R (通讯作者)，Lithuanian Univ Hlth Sci, Med Acad, Dept Ophthalmol, Eiveniu 2, Kaunas, Lithuania.
EM rliutkeviciene@gmail.com
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Bian JH, 1997, MOL CELL BIOL, V17, P6330, DOI 10.1128/MCB.17.11.6330
   Chau KY, 2007, EYE, V21, P1511, DOI [10.1038/sj.eye.6702722, 10.1038/sj.eye.6702722x]
   Cousins SW, 2003, INVEST OPHTH VIS SCI, V44, P1221, DOI 10.1167/iovs.02-0285
   Edelman EA, 2007, CLIN GENET, V71, P540, DOI 10.1111/j.1399-0004.2007.00815.x
   Grabauskas Vilius, 2003, Medicina (Kaunas), V39, P1215
   Guo L, 1999, INVEST OPHTH VIS SCI, V40, P2676
   Handa JT, 1999, INVEST OPHTH VIS SCI, V40, P775
   HEGELE RA, 1994, ARTERIOSCLER THROMB, V14, P671, DOI 10.1161/01.ATV.14.5.671
   HOLZ FG, 1994, ARCH OPHTHALMOL-CHIC, V112, P402, DOI 10.1001/archopht.1994.01090150132035
   Hussain AA, 2011, INVEST OPHTH VIS SCI, V52, P4459, DOI 10.1167/iovs.10-6678
   Hyman Leslie, 2002, Curr Opin Ophthalmol, V13, P171
   KARWATOWSKI WSS, 1995, BRIT J OPHTHALMOL, V79, P944, DOI 10.1136/bjo.79.10.944
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Lesauskaite V, 2006, GERONTOLOGY, V52, P40, DOI 10.1159/000089824
   Liutkeviciene R, 2016, OPHTHALMIC GENET, V37, P170, DOI 10.3109/13816810.2015.1020556
   Liutkeviciene R, 2015, OPHTHALMIC GENET, V36, P149, DOI 10.3109/13816810.2013.838274
   Okubo A, 1999, INVEST OPHTH VIS SCI, V40, P443
   Ortak H, 2013, OPHTHALMIC GENET, V34, P217, DOI 10.3109/13816810.2013.781192
   PAULEIKHOFF D, 1992, OPHTHALMOLOGY, V99, P1548
   Peacock RE, 1997, GENET EPIDEMIOL, V14, P265, DOI 10.1002/(SICI)1098-2272(1997)14:3<265::AID-GEPI5>3.0.CO;2-4
   Peasey A, 2006, BMC PUBLIC HEALTH, V6, DOI 10.1186/1471-2458-6-255
   Plantner JJ, 1998, EXP EYE RES, V67, P637, DOI 10.1006/exer.1998.0552
   Price SJ, 2001, J BIOL CHEM, V276, P7549, DOI 10.1074/jbc.M010242200
   Qin HW, 1999, J BIOL CHEM, V274, P29130, DOI 10.1074/jbc.274.41.29130
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Russo GT, 2003, J NUTR, V133, P3416, DOI 10.1093/jn/133.11.3416
   Russo GT, 2001, ATHEROSCLEROSIS, V158, P173, DOI 10.1016/S0021-9150(01)00409-9
   SCHAEFER EJ, 1994, ARTERIOSCLER THROMB, V14, P1105, DOI 10.1161/01.ATV.14.7.1105
   Seitzman RL, 2008, AM J EPIDEMIOL, V167, P1217, DOI 10.1093/aje/kwn024
   Steen B, 1998, INVEST OPHTH VIS SCI, V39, P2194
   Tatar O, 2007, BRIT J OPHTHALMOL, V91, P1183, DOI 10.1136/bjo.2007.114769
NR 32
TC 4
Z9 4
U1 0
U2 1
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
SN 0301-4738
EI 1998-3689
J9 INDIAN J OPHTHALMOL
JI Indian J. Ophthalmol.
PD APR
PY 2018
VL 66
IS 4
BP 551
EP 557
DI 10.4103/ijo.IJO_1050_17
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GB2CI
UT WOS:000428858100014
PM 29582818
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Leandro, JE
   Beato, J
   Pedrosa, AC
   Pinheiro-Costa, J
   Falco, M
   Falcao-Reis, F
   Carneiro, AM
AF Leandro, Joao Esteves
   Beato, Joao
   Pedrosa, Ana Catarina
   Pinheiro-Costa, Joao
   Falco, Manuel
   Falcao-Reis, Fernando
   Carneiro, Angela M.
TI The Charles Bonnet Syndrome in Patients With Neovascular Age-Related
   Macular Degeneration: Association With Proton Pump Inhibitors
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE Charles Bonnet syndrome; visual hallucinations; neovascular age-related
   macular degeneration; low vision; oral proton pump inhibitors
ID COMPLEX VISUAL HALLUCINATIONS; BONNET,CHARLES SYNDROME; PREVALENCE;
   OPHTHALMOLOGY
AB PURPOSE. We investigate the prevalence of the Charles Bonnet syndrome (CBS) in patients with neovascular age-related macular degeneration (AMD) and analyze the role of oral proton pump inhibitors (PPI.$) and other potential risk factors.
   METIRMS. A total of 510 consecutive patients with neovascular-AMD followed at a single tertiary center in Portugal were screened for CBS. Using a structured questionnaire, psychiatrically healthy individuals were interviewed systematically and divided into a CBS group and a non-CBS group. Demographic data, current medication, and ocular risk factors were collected and compared between the two groups.
   RESULTS. A total of 500 patients met the inclusion criteria and 471 with complete data were included in the final analysis. The prevalence of CBS was 9.0% (45/500). Using a binary logistic regression model, correlations were found between older age (P = 0.002), FPI intake (P 0.022), poor visual acuity (p = 0.004), and development of CBS. PPIs doubled the risk of CBS front 7% (20/304) to 15% (25/167), with an odds ratio of 2.154. The increased risk for visual hallucinations caused by PPis was independent of age (P = 0.598) and visual acuity (P = 0.739)
   CONCLUSIONS. The prevalence of CBS in neovascularAMD patients is high and mainly affects older individuals with poor visual acuity. PPIs seem to increase the risk of development of hallucinations independently of the degree of visual loss.
C1 [Leandro, Joao Esteves; Beato, Joao; Pedrosa, Ana Catarina; Pinheiro-Costa, Joao; Falco, Manuel; Falcao-Reis, Fernando; Carneiro, Angela M.] Sao Joao Hosp, Dept Ophthalmol, Ave Prof Hernani Monteiro 4202-451, Oporto, Portugal.
   [Beato, Joao; Falco, Manuel; Falcao-Reis, Fernando; Carneiro, Angela M.] Univ Porto, Dept Surg & Physiol, Fac Med, Oporto, Portugal.
   [Pinheiro-Costa, Joao] Univ Porto, Dept Anat, Fac Med, Oporto, Portugal.
C3 Sao Joao Hospital; Universidade do Porto; Universidade do Porto
RP Leandro, JE (通讯作者)，Sao Joao Hosp, Dept Ophthalmol, Ave Prof Hernani Monteiro 4202-451, Oporto, Portugal.
EM joaoedpl@gmail.com
RI Falcao/AAQ-8509-2020; Carneiro, Angela/N-9680-2013
OI Falcao/0000-0003-4718-0910; Carneiro, Angela/0000-0002-3370-7243;
   Falcao-Reis, Fernando/0000-0002-5995-9430
CR Abbou EJ, 2007, INVEST OPHTH VIS SCI, V48, P1416, DOI 10.1167/iovs.06-0942
   [Anonymous], 2006, PRILOSEC PRESCRIBING
   Batuwitage BT, 2007, POSTGRAD MED J, V83, P66, DOI 10.1136/pgmj.2006.051151
   BERRIOS GE, 1984, BRIT J PSYCHIAT, V144, P662, DOI 10.1192/bjp.144.6.662
   BROWN GC, 1992, ARCH OPHTHALMOL-CHIC, V110, P1251, DOI 10.1001/archopht.1992.01080210069027
   Burke W, 2002, J NEUROL NEUROSUR PS, V73, P535, DOI 10.1136/jnnp.73.5.535
   Chow KM, 2004, J NATL MED ASSOC, V96, P1305
   Chubineh S, 2012, SOUTH MED J, V105, P613, DOI 10.1097/SMJ.0b013e31826efbea
   COGAN DG, 1973, A GRAEF ARCH KLIN EX, V188, P139, DOI 10.1007/BF00407835
   Cox TM, 2014, BRIT J OPHTHALMOL, V98, P1236, DOI 10.1136/bjophthalmol-2014-304920
   DAMASMORA J, 1982, PSYCHOL MED, V12, P251, DOI 10.1017/S0033291700046584
   Ffytche DH, 2009, CURR OPIN NEUROL, V22, P28, DOI 10.1097/WCO.0b013e32831f1b3f
   Fraunfelder FT, 2008, CLIN OCULAR TOXICOLO, P315
   GOLD K, 1989, COMPR PSYCHIAT, V30, P90, DOI 10.1016/0010-440X(89)90122-3
   Goldner Jonathan A, 2012, J Med Case Rep, V6, P65, DOI 10.1186/1752-1947-6-65
   Hanneken AM, 2013, INVEST OPHTH VIS SCI, V54, P1485, DOI 10.1167/iovs.12-11091
   Hedges TR, 2007, SURV OPHTHALMOL, V52, P111, DOI 10.1016/j.survophthal.2006.10.007
   HOLROYD S, 1994, J NERV MENT DIS, V182, P273, DOI 10.1097/00005053-199405000-00004
   HOLROYD S, 1992, AM J PSYCHIAT, V149, P1701
   Huffman Jeff C, 2007, Dialogues Clin Neurosci, V9, P29
   Kazui H, 2009, PSYCHOGERIATRICS, V9, P77, DOI 10.1111/j.1479-8301.2009.00288.x
   Khan JC, 2008, OPHTHAL EPIDEMIOL, V15, P202, DOI 10.1080/09286580801939320
   Lannon SP, 2006, VIS IMPAIR RES, V8, P9, DOI DOI 10.1080/13882350600805761
   McCarthy DM, 2010, CURR OPIN GASTROEN, V26, P624, DOI 10.1097/MOG.0b013e32833ea9d9
   Menon GJ, 2005, ARCH OPHTHALMOL-CHIC, V123, P349, DOI 10.1001/archopht.123.3.349
   Menon GJ, 2003, SURV OPHTHALMOL, V48, P58, DOI 10.1016/S0039-6257(02)00414-9
   Meyer CH, 2007, AM J OPHTHALMOL, V143, P169, DOI 10.1016/j.ajo.2006.08.003
   NORTONWILLSON L, 1987, FAM PRACT, V4, P27, DOI 10.1093/fampra/4.1.27
   Ohayon MM, 2000, PSYCHIAT RES, V97, P153, DOI 10.1016/S0165-1781(00)00227-4
   Olbe L, 2003, NAT REV DRUG DISCOV, V2, P132, DOI 10.1038/nrd1010
   Pliskin NH, 1996, J AM GERIATR SOC, V44, P1055, DOI 10.1111/j.1532-5415.1996.tb02937.x
   PODOLL K, 1989, FORTSCHR NEUROL PSYC, V57, P43, DOI 10.1055/s-2007-1000744
   Robinson M, 2003, DRUGS, V63, P2739, DOI 10.2165/00003495-200363240-00004
   Santos-Bueso E, 2014, EUR J OPHTHALMOL, V24, P960, DOI 10.5301/ejo.5000483
   Scott IU, 2001, AM J OPHTHALMOL, V131, P590, DOI 10.1016/S0002-9394(01)00833-9
   Tan CSH, 2004, BRIT J OPHTHALMOL, V88, P1325, DOI 10.1136/bjo.2004.041947
   TEUNISSE RJ, 1995, BRIT J PSYCHIAT, V166, P254, DOI 10.1192/bjp.166.2.254
   Teunisse RJ, 1996, LANCET, V347, P794, DOI 10.1016/S0140-6736(96)90869-7
   Tokinaga N, 1996, PSYCHIAT CLIN NEUROS, V50, P337, DOI 10.1111/j.1440-1819.1996.tb00577.x
   Vandenbroucke JP, 2007, EPIDEMIOLOGY, V18, P805, DOI 10.1097/EDE.0b013e3181577511
   Vukicevic M, 2008, CLIN EXP OPHTHALMOL, V36, P659, DOI [10.1111/j.1442-9071.2008.01814.x, 10.1111/j.1442-9071.2008.01864.x]
NR 41
TC 7
Z9 7
U1 0
U2 4
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD AUG
PY 2017
VL 58
IS 10
BP 4138
EP 4142
DI 10.1167/iovs.16-21270
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA FH2AG
UT WOS:000410940400037
PM 28829845
OA gold
DA 2022-11-30
ER

PT J
AU Kanadani, TCM
   Veloso, CED
   Dorairaj, S
   Nehemy, MB
AF Moreira Kanadani, Tereza Cristina
   dos Reis Veloso, Carlos Eduardo
   Dorairaj, Syril
   Nehemy, Marcio Bittar
TI Influence of Vitreomacular Adhesion on Anti-Vascular Endothelial Growth
   Factor Treatment for Neovascular Age-Related Macular Degeneration
SO OPHTHALMIC RESEARCH
LA English
DT Article
DE Vitreomacular adhesion; Antiangiogenic treatment; Neovascular
   age-related macular degeneration
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; POSTERIOR VITREOUS DETACHMENT;
   TREATMENT OUTCOMES; JAPANESE PATIENTS; THERAPY; RANIBIZUMAB; INTERFACE;
   TRACTION; RISK; CLASSIFICATION
AB Purpose: To investigate the effect of vitreomacular adhesion (VMA) on the outcome of antiangiogenic treatment for neovascular age-related macular degeneration (AMD). Methods: Ninety-nine eyes of 83 patients were used in our cohort study. We prospectively evaluated best corrected visual acuity (BCVA) and central retinal thickness (CRT) in patients with neovascular AMD at baseline and 1, 2, 3, 6, and 12 months after treatment with anti-vascular endothelial growth factor (anti-VEGF) agents. All patients were stratified by spectral domain optical coherence tomography into 2 groups (i.e., VMA[+] and VMA[-]) according to the presence or absence of VMA, and the response to treatment was evaluated. Results: Fifty-four eyes (54.5%) were included in the VMA(-) group and 45 eyes (45.5%) comprised the VMA(+) group. In paired comparisons of mean BCVA between baseline and each follow-up visit (1, 2, 3, 6, and 12 months), the VMA(-) group showed statistically significant improvement at 1, 2, and 3 months compared to baseline, and BCVA significantly improved only at 3 months in the VMA(+) group. For both groups, paired comparisons of CRT showed a statistically significant decrease when data obtained at 1, 2, 3, 6, and 12 months were compared to baseline values (p < 0.05). Conclusions: Posterior VMA is associated with a worse short-term outcome in patients with neovascular AMD treated with anti-VEGF agents. (C) 2017 S. Karger AG, Basel
C1 [Moreira Kanadani, Tereza Cristina; dos Reis Veloso, Carlos Eduardo; Nehemy, Marcio Bittar] Univ Fed Minas Gerais, Dept Ophthalmol, Belo Horizonte, MG, Brazil.
   [Dorairaj, Syril] Mayo Clin, Dept Ophthalmol, 4500 San Pablo Rd, Jacksonville, FL 32224 USA.
C3 Universidade Federal de Minas Gerais; Mayo Clinic
RP Dorairaj, S (通讯作者)，Mayo Clin, Dept Ophthalmol, 4500 San Pablo Rd, Jacksonville, FL 32224 USA.
EM dorairaj.syril@mayo.edu
RI Nehemy, Marcio/ABD-5089-2021
OI Nehemy, Marcio/0000-0002-4104-0346
CR BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Cho HJ, 2013, RETINA-J RET VIT DIS, V33, P2126, DOI 10.1097/IAE.0b013e3182899296
   Chuo JY, 2006, AM J OPHTHALMOL, V142, P931, DOI 10.1016/j.ajo.2006.08.002
   Cuilla TA, 2015, OPHTHALMOLOGY, V122, P1203, DOI 10.1016/j.ophtha.2015.02.031
   Veloso CED, 2014, OPHTHALMIC RES, V51, P1, DOI 10.1159/000354328
   Duker JS, 2013, OPHTHALMOLOGY, V120, P2611, DOI 10.1016/j.ophtha.2013.07.042
   FOOS R Y, 1972, Transactions of the American Academy of Ophthalmology and Oto-Laryngology, V76, P480
   Goldenberg DT, 2011, RETINA-J RET VIT DIS, V31, P393, DOI 10.1097/IAE.0b013e3181e586b2
   Hilford D, 2009, EYE, V23, P1388, DOI 10.1038/eye.2008.273
   Houston SK, 2015, RETINA-J RET VIT DIS, V35, P1757, DOI 10.1097/IAE.0000000000000663
   Joachim N, 2015, OPHTHALMOLOGY, V122, P2482, DOI 10.1016/j.ophtha.2015.08.002
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Krebs I, 2007, AM J OPHTHALMOL, V144, P741, DOI 10.1016/j.ajo.2007.07.024
   Krishnan R, 2015, RETINA-J RET VIT DIS, V35, P1750, DOI 10.1097/IAE.0000000000000714
   Lee SJ, 2011, OPHTHALMOLOGY, V118, P101, DOI 10.1016/j.ophtha.2010.04.015
   Lee SJ, 2009, AM J OPHTHALMOL, V147, P621, DOI 10.1016/j.ajo.2008.10.003
   Lux A, 2007, BRIT J OPHTHALMOL, V91, P1318, DOI 10.1136/bjo.2006.113902
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Mayr-Sponer U, 2013, OPHTHALMOLOGY, V120, P2620, DOI 10.1016/j.ophtha.2013.05.032
   McKibbin MA, 2015, RETINA-J RET VIT DIS, V35, P1951, DOI 10.1097/IAE.0000000000000587
   Nehemy MB, 2011, AM AC OPHTH ANN M OR
   Nomura Y, 2014, JPN J OPHTHALMOL, V58, P443, DOI 10.1007/s10384-014-0333-5
   Nomura Y, 2011, OPHTHALMOLOGY, V118, P853, DOI 10.1016/j.ophtha.2010.09.001
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Pereira FB, 2015, OPHTHALMOLOGICA, V234, P233, DOI 10.1159/000439359
   Robison CD, 2009, AM J OPHTHALMOL, V148, P79, DOI 10.1016/j.ajo.2009.01.014
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Schulze S, 2008, ACTA OPHTHALMOL, V86, P470, DOI 10.1111/j.1755-3768.2008.01210.x
   Uney GO, 2014, RETINA-J RET VIT DIS, V34, P32, DOI 10.1097/IAE.0b013e318295f72e
   Veloso CE, 2015, OPHTHALMOLOGY, V122, P1569, DOI 10.1016/j.ophtha.2015.04.028
   Veloso Carlos Eduardo, 2014, Rev. Col. Bras. Cir., V41, P386, DOI 10.1590/0100-69912014006002
   Waldstein SM, 2014, AM J OPHTHALMOL, V158, P328, DOI 10.1016/j.ajo.2014.04.028
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 39
TC 3
Z9 3
U1 0
U2 1
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3747
EI 1423-0259
J9 OPHTHALMIC RES
JI Ophthalmic Res.
PY 2017
VL 58
IS 1
BP 18
EP 26
DI 10.1159/000459626
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EX6OX
UT WOS:000403362700004
PM 28301850
DA 2022-11-30
ER

PT J
AU Narayan, DS
   Muecke, J
AF Narayan, Daniel Sanju
   Muecke, James
TI Intravitreal aflibercept treatment in eyes with exudative age-related
   macular degeneration following prior treatment with intravitreal
   ranibizumab
SO INDIAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Aflibercept; age-related macular degeneration; choroidal
   neovascularization; intraretinal fluid; ranibizumab; subretinal fluid
ID ENDOTHELIAL GROWTH-FACTOR; VEGF-TRAP; AMD; BEVACIZUMAB; QUANTIFICATION;
   MORPHOLOGY; TRIAL
AB Background: To investigate visual and anatomical outcomes in eyes with exudative age-related macular degeneration treated with intravitreal aflibercept following prior treatment with intravitreal ranibizumab. Materials and Methods: Retrospective, single-center study of 192 eyes treated with 0.5 mg intravitreal ranibizumab every 4 weeks for three consecutive doses followed by a variable dose schedule. After more than 12 months of ranibizumab treatment, eyes that required ranibizumab injections at 4-week or 6-week intervals were switched to aflibercept therapy. Results: After 12-69 months (42 months +/- 18 months, mean +/- standard deviation [SD]) of treatment with intravitreal ranibizumab, 80 eyes were changed to 2 mg intravitreal aflibercept treatment with follow-up after 12-18 months (16 months +/- 1 month, mean +/- SD). Thirty-nine eyes had persistent macular fluid after treatment with ranibizumab. Mean logMAR visual acuity (VA) in eyes treated with ranibizumab changed by -0.089 +/- 0.310 (mean +/- SD; P = 0.0003), which correlates to an approximate gain of 4.5 letters. The number of eyes with macular fluid decreased from 39 to 23 after aflibercept treatment. Mean logMAR VA in eyes with intraretinal macular fluid treated with aflibercept changed by -0.079 +/- 0.134 (mean +/- SD; P = 0.006), which correlates to an approximate gain of 4 letters. Mean logMAR VA in eyes with submacular fluid was not significantly different after aflibercept treatment. Conclusion: Eyes with persistent intraretinal macular fluid had visual and anatomic response after changing from ranibizumab to aflibercept treatment.
C1 [Narayan, Daniel Sanju; Muecke, James] Univ Adelaide, South Australian Inst Ophthalmol, Discipline Ophthalmol & Visual Sci, Adelaide, SA 5000, Australia.
C3 University of Adelaide
RP Narayan, DS (通讯作者)，Royal Adelaide Hosp, South Australian Inst Ophthalmol, Level 8,East Wing,North Terrace, Adelaide, SA 5000, Australia.
EM daniel.s.narayan@gmail.com
CR Abraham P, 2010, AM J OPHTHALMOL, V150, P315, DOI 10.1016/j.ajo.2010.04.011
   Bakall B, 2013, AM J OPHTHALMOL, V156, P15, DOI 10.1016/j.ajo.2013.02.017
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2013, OPHTHALMOLOGY, V120, P349, DOI 10.1016/j.ophtha.2012.08.008
   Browning DJ, 2012, AM J OPHTHALMOL, V154, P222, DOI 10.1016/j.ajo.2012.04.020
   Cho H, 2013, BRIT J OPHTHALMOL, V97, P1032, DOI 10.1136/bjophthalmol-2013-303344
   Forooghian F, 2009, RETINA-J RET VIT DIS, V29, P723, DOI 10.1097/IAE.0b013e3181a2c1c3
   Frank RN, 1996, AM J OPHTHALMOL, V122, P393, DOI 10.1016/S0002-9394(14)72066-5
   Gaudreault J, 2007, RETINA-J RET VIT DIS, V27, P1260, DOI 10.1097/IAE.0b013e318134eecd
   Gerding H, 2015, KLIN MONATSBL AUGENH, V232, P560, DOI 10.1055/s-0035-1545775
   Golbaz I, 2011, INVEST OPHTH VIS SCI, V52, P1599, DOI 10.1167/iovs.09-5018
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Ip MS, 2008, OPHTHALMOLOGY, V115, P1837, DOI 10.1016/j.ophtha.2008.08.012
   Jaffe GJ, 2013, OPHTHALMOLOGY, V120, P1860, DOI 10.1016/j.ophtha.2013.01.073
   Kanesa-Thasan A, 2015, OSLI RETINA, V46, P638, DOI 10.3928/23258160-20150610-07
   Keane PA, 2008, INVEST OPHTH VIS SCI, V49, P3115, DOI 10.1167/iovs.08-1689
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Moon Da Ru Chi, 2015, Korean J Ophthalmol, V29, P226, DOI 10.3341/kjo.2015.29.4.226
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Pinheiro-Costa J, 2015, OPHTHALMOLOGICA, V233, P155, DOI 10.1159/000381221
   Rakic JM, 2003, INVEST OPHTH VIS SCI, V44, P3186, DOI 10.1167/iovs.02-1092
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Stewart MW, 2008, BRIT J OPHTHALMOL, V92, P667, DOI 10.1136/bjo.2007.134874
   Stewart MW, 2012, RETINA-J RET VIT DIS, V32, P434, DOI 10.1097/IAE.0B013E31822C290F
NR 31
TC 7
Z9 7
U1 0
U2 3
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
SN 0301-4738
EI 1998-3689
J9 INDIAN J OPHTHALMOL
JI Indian J. Ophthalmol.
PD NOV
PY 2015
VL 63
IS 11
BP 832
EP 836
DI 10.4103/0301-4738.171964
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CZ7SM
UT WOS:000367300300005
PM 26669334
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Moschos, MM
   Panayotidis, D
   Theodossiadis, G
   Moschos, M
AF Moschos, MM
   Panayotidis, D
   Theodossiadis, G
   Moschos, M
TI Assessment of macular function by multifocal electroretinogram in
   age-related macular degeneration before and after photodynamic therapy
SO JOURNAL FRANCAIS D OPHTALMOLOGIE
LA English
DT Article
DE choroidal neovascularization (CNV); age-related macular degeneration
   (ARMD); photodynamic therapy (PDT); multifocal electroretinogram
   (MF-ERG)
ID CHOROIDAL NEOVASCULARIZATION; VERTEPORFIN
AB Purpose: To evaluate macular function, before and after photodynamic therapy (PDT) using multifocal electroretinogram (MF-ERG), in eyes suffering from classic subfoveal choroidal neovascularization (CNV) resulting from age-related macular degeneration (ARMD).
   Methods: Twenty eyes of 20 patients (10 male, 10 female) with classic subfoveal CNV resulting from ARMD were studied. All received PDT with verteporfin. Fluorescein angiography and mF-ERG were performed in each patient 1 day before and 1 week, 3 months and 6 months after photodynamic therapy.
   Results: Before treatment, visual acuity (VA) and electrical retinal response densities (RRD) in the foveal and parafoveal areas were low in all patients. The mean VA (ETDRS chart) before PDT was 24.35 (SD, 15). The mean RRD before PDT in area 1 was 4.39 nV/deg(2) (SD, 2.59) and in area 2 it was 2.11 (SD, 1.86). Six months after treatment, the mean VA was stable in 70% of the patients. However, the mean RRD after PDT was 2.24 nV/deg(2) in area 1 (SD, 2.59) and 1.07 nV/deg(2) in area 2 (SD, 1.59).
   Conclusion: Multifocal ERG objectively evaluates the macular function in eyes with CNV attributable to ARMD. In this study, the stability of VA coincided with a clear impairment of electrical activity of the foveal and parafoveal areas. This finding suggests that MF-ERG should be adopted to assess the efficacy of PDT objectively in the treatment of ARMD.
C1 Hop Ophtalm Jules Gonin, CH-1004 Lausanne, Switzerland.
   Univ Lausanne, Jules Gonin Eye Hosp, CH-1015 Lausanne, Switzerland.
   Univ Athens, Dept Ophthalmol, GR-10679 Athens, Greece.
C3 University of Lausanne; National & Kapodistrian University of Athens
RP Moschos, MM (通讯作者)，Hop Ophtalm Jules Gonin, Ave France 15, CH-1004 Lausanne, Switzerland.
EM moschosmarilita@yahoo.fr
CR [Anonymous], 1991, Arch Ophthalmol, V109, P1109
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Campochiaro P A, 1999, Mol Vis, V5, P34
   CHANG TS, 1994, RETINA-J RET VIT DIS, V14, P114, DOI 10.1097/00006982-199414020-00004
   GREEN WR, 1986, OPHTHALMOLOGY, V93, P1169
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Husain D, 1999, INVEST OPHTH VIS SCI, V40, P2322
   KONDO M, 1995, INVEST OPHTH VIS SCI, V36, P2146
   Kramer M, 1996, OPHTHALMOLOGY, V103, P427
   Lutty G, 1999, MOL VIS, V5
   Ross RD, 1998, AM J OPHTHALMOL, V126, P154
   Spaide RF, 2002, AM J OPHTHALMOL, V134, P62, DOI 10.1016/S0002-9394(02)01452-6
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   SUTTER EE, 1992, VISION RES, V32, P433, DOI 10.1016/0042-6989(92)90235-B
NR 16
TC 17
Z9 20
U1 0
U2 1
PU MASSON EDITEUR
PI MOULINEAUX CEDEX 9
PA 21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE
SN 0181-5512
EI 1773-0597
J9 J FR OPHTALMOL
JI J. Fr. Ophthamol.
PD NOV
PY 2004
VL 27
IS 9
BP 1001
EP 1006
DI 10.1016/S0181-5512(04)96255-9
PN 1
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 907BE
UT WOS:000227689000005
PM 15557861
DA 2022-11-30
ER

PT J
AU Ng, ALK
   Leung, HH
   Kawasaki, R
   Ho, WL
   Chow, LLW
   Chow, SSW
   Lee, JCY
   Wong, IYH
AF Ng, Alex L-K
   Leung, Ho Hang
   Kawasaki, Ryo
   Ho, Wing-Lau
   Chow, Loraine L-W
   Chow, Sharon S-W
   Lee, Jetty Chung-Yung
   Wong, Ian Y-H
TI Dietary Habits, Fatty Acids and Carotenoid Levels Are Associated with
   Neovascular Age-Related Macular Degeneration in Chinese
SO NUTRIENTS
LA English
DT Article
DE macular degeneration; polyunsaturated fatty acid; saturated fatty acid;
   carotenoids
ID DOCOSAHEXAENOIC ACID; OXIDATIVE STRESS; SUPPLEMENTATION; PIGMENT;
   OMEGA-3; PLASMA; LUTEIN; OMEGA-3-FATTY-ACIDS; POPULATION; PREVALENCE
AB The role of diet and circulatory carotenoids and docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) are implicated in age-related macular degeneration (AMD) but not well studied in Chinese. However, other fatty acids were not comprehensively evaluated if it had additional consequence on AMD. This study investigated the relationship among dietary habits, fatty acids levels, carotenoids and AMD in Hong Kong Chinese adults. In this cross-sectional case-controlled study, plasma fatty acids including, saturated fatty acids (SFA), monounsaturated fatty acids (MUFA) and polyunsaturated fatty acids (PUFA), and carotenoids levels were quantified between patients with neovascular AMD (n = 99) and age-gender-matched controls (n = 198). A food frequency questionnaire was also conducted. Low blood carotenoid levels and omega-3 PUFAs namely DHA, EPA and alpha-linolenic acid increased the odds ratio of developing neovascular AMD. High blood omega-6 PUFAs specifically arachidonic acid and eicosadienoic acid, oleic acid (a MUFA) and SFA levels increased the odds ratio of having neovascular AMD. Neovascular AMD group had significantly less omega-3 PUFA rich food (vegetables, nuts, seafood) intake and higher SFA (meat) intake than controls. In short, neovascular AMD was associated with lower circulatory levels of carotenoids and omega-3 PUFAs, and higher level of omega-6 PUFAs, oleic acid and SFAs in the Hong Kong Chinese population. These findings enhance the understandings of dietary impacts on neovascular AMD and provide a context for future nutritional intervention studies.
C1 [Ng, Alex L-K; Wong, Ian Y-H] Univ Hong Kong, LKS Fac Med, Dept Ophthalmol, Sassoon Rd, Hong Kong, Peoples R China.
   [Ng, Alex L-K] Hong Kong Ophthalm Associate, Queens Rd, Hong Kong, Peoples R China.
   [Leung, Ho Hang; Lee, Jetty Chung-Yung] Univ Hong Kong, Sch Biol Sci, Pokfulam Rd, Hong Kong, Peoples R China.
   [Kawasaki, Ryo] Osaka Univ, Dept Vis Informat, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.
   [Ho, Wing-Lau; Chow, Loraine L-W; Chow, Sharon S-W] Grantham Hosp, Hosp Author, Wong Chuk Hang, Hong Kong, Peoples R China.
   [Wong, Ian Y-H] Hong Kong Sanat & Hosp, Dept Ophthalmol, Happy Valley, Hong Kong, Peoples R China.
C3 University of Hong Kong; University of Hong Kong; Osaka University
RP Wong, IYH (通讯作者)，Univ Hong Kong, LKS Fac Med, Dept Ophthalmol, Sassoon Rd, Hong Kong, Peoples R China.; Lee, JCY (通讯作者)，Univ Hong Kong, Sch Biol Sci, Pokfulam Rd, Hong Kong, Peoples R China.; Wong, IYH (通讯作者)，Hong Kong Sanat & Hosp, Dept Ophthalmol, Happy Valley, Hong Kong, Peoples R China.
EM jettylee@hku.hk; ianyhwong@gmail.com
RI Lee, Jetty Chung-Yung/E-1475-2011; Lee, Jetty Chung-Yung/S-1443-2019;
   Kawasaki, Ryo/B-7266-2009
OI Lee, Jetty Chung-Yung/0000-0002-8175-7069; Lee, Jetty
   Chung-Yung/0000-0002-8175-7069; Kawasaki, Ryo/0000-0002-7492-6303; Chow,
   Sharon/0000-0001-8005-1518
FU Health and Medical Research Fund [13142301]; Food and Health Bureau,
   Hong Kong
FX This work was supported by Health and Medical Research Fund (Ref:
   13142301); Food and Health Bureau, Hong Kong
CR Arnold C, 2013, JAMA OPHTHALMOL, V131, P564, DOI 10.1001/jamaophthalmol.2013.2851
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chong EWT, 2008, ARCH OPHTHALMOL-CHIC, V126, P826, DOI 10.1001/archopht.126.6.826
   Connor KM, 2007, NAT MED, V13, P868, DOI 10.1038/nm1591
   Dawczynski J, 2013, GRAEF ARCH CLIN EXP, V251, P2711, DOI 10.1007/s00417-013-2376-6
   Delyfer MN, 2012, INVEST OPHTH VIS SCI, V53, P1204, DOI 10.1167/iovs.11-8721
   Galano JM, 2015, BBA-MOL CELL BIOL L, V1851, P446, DOI 10.1016/j.bbalip.2014.11.004
   Gangwani R, 2014, GRAEF ARCH CLIN EXP, V252, P723, DOI 10.1007/s00417-013-2530-1
   Georgiou Tassos, 2015, J Stem Cells, V10, P205
   Gorusupudi A, 2016, J LIPID RES, V57, P499, DOI 10.1194/jlr.P065540
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Huang YS, 2011, MOL CELL BIOCHEM, V358, P85, DOI 10.1007/s11010-011-0924-0
   Karppi J, 2008, J CHROMATOGR B, V867, P226, DOI 10.1016/j.jchromb.2008.04.007
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Korobelnik JF, 2017, JAMA OPHTHALMOL, V135, P1259, DOI 10.1001/jamaophthalmol.2017.3398
   Leung S, 1998, AUST J NUTR DIET, V55, pS11
   Lund EK, 2013, FOOD CHEM, V140, P413, DOI 10.1016/j.foodchem.2013.01.034
   Merle BMJ, 2017, ACTA OPHTHALMOL, V95, pe763, DOI 10.1111/aos.13408
   Merle BMJ, 2014, INVEST OPHTH VIS SCI, V55, P2010, DOI 10.1167/iovs.14-13916
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   Nirmalan PK, 2004, ARCH OPHTHALMOL-CHIC, V122, P581, DOI 10.1001/archopht.122.4.581
   Quehenberger O, 2011, BBA-MOL CELL BIOL L, V1811, P648, DOI 10.1016/j.bbalip.2011.07.006
   Rotstein NP, 2003, INVEST OPHTH VIS SCI, V44, P2252, DOI 10.1167/iovs.02-0901
   Skrzypski J, 2009, BIOCHIMIE, V91, P1443, DOI 10.1016/j.biochi.2009.08.001
   Smith U, 2016, J INTERN MED, V280, P465, DOI 10.1111/joim.12540
   Souied EH, 2013, OPHTHALMOLOGY, V120, P1619, DOI 10.1016/j.ophtha.2013.01.005
   Wang X, 2014, OPHTHALMIC RES, V52, P198, DOI 10.1159/000363327
   Woo J, 1997, NUTR RES, V17, P1633, DOI 10.1016/S0271-5317(97)00170-X
   Wood KE, 2015, PROSTAG LEUKOTR ESS, V95, P47, DOI 10.1016/j.plefa.2015.01.001
   Wu J, 2017, OPHTHALMOLOGY, V124, P634, DOI 10.1016/j.ophtha.2016.12.033
   Yasuda M, 2009, OPHTHALMOLOGY, V116, P2135, DOI 10.1016/j.ophtha.2009.04.017
NR 34
TC 10
Z9 11
U1 0
U2 4
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2072-6643
J9 NUTRIENTS
JI Nutrients
PD AUG
PY 2019
VL 11
IS 8
AR 1720
DI 10.3390/nu11081720
PG 11
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA IV8HH
UT WOS:000484506000089
PM 31349710
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Zhuang, J
   Madden, DJ
   Duong-Fernandez, X
   Chen, NK
   Cousins, SW
   Potter, GG
   Diaz, MT
   Whitson, HE
AF Zhuang, Jie
   Madden, David J.
   Duong-Fernandez, Xuan
   Chen, Nan-kuei
   Cousins, Scott W.
   Potter, Guy G.
   Diaz, Michele T.
   Whitson, Heather E.
TI Language processing in age-related macular degeneration associated with
   unique functional connectivity signatures in the right hemisphere
SO NEUROBIOLOGY OF AGING
LA English
DT Article
DE Age-related macular degeneration; Functional connectivity; Cognitive
   preservation; Language processing
ID COGNITIVE IMPAIRMENT; VISUAL-CORTEX; WORD RETRIEVAL; OLDER-ADULTS; AGING
   BRAIN; FMRI DATA; BLIND; RECOGNITION; DEMENTIA; TASK
AB Age-related macular degeneration (AMD) is a retinal disease associated with significant vision loss among older adults. Previous large-scale behavioral studies indicate that people with AMD are at increased risk of cognitive deficits in language processing, particularly in verbal fluency tasks. The neural underpinnings of any relationship between AMD and higher cognitive functions, such as language processing, remain unclear. This study aims to address this issue using independent component analysis of spontaneous brain activity at rest. In 2 components associated with visual processing, we observed weaker functional connectivity in the primary visual cortex and lateral occipital cortex in AMD patients compared with healthy controls, indicating that AMD might lead to differences in the neural representation of vision. In a component related to language processing, we found that increasing connectivity within the right inferior frontal gyrus was associated with better verbal fluency performance across all older adults, and the verbal fluency effect was greater in AMD patients than controls in both right inferior frontal gyrus and right posterior temporal regions. As the behavioral performance of our patients is as good as that of controls, these findings suggest that preservation of verbal fluency performance in AMD patients might be achieved through higher contribution from right hemisphere regions in bilateral language networks. If that is the case, there may be an opportunity to promote cognitive resilience among seniors with AMD or other forms of late-life vision loss. (C) 2017 Elsevier Inc. All rights reserved.
C1 [Zhuang, Jie; Madden, David J.; Duong-Fernandez, Xuan; Chen, Nan-kuei; Potter, Guy G.; Whitson, Heather E.] Duke Univ, Med Ctr, Brain Imaging & Anal Ctr, Durham, NC 27710 USA.
   [Madden, David J.; Potter, Guy G.] Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC USA.
   [Chen, Nan-kuei; Whitson, Heather E.] Univ Arizona, Dept Biomed Engn, Tucson, AZ USA.
   [Cousins, Scott W.] Duke Univ, Med Ctr, Dept Ophthalmol, Durham, NC 27710 USA.
   [Cousins, Scott W.] Duke Univ, Med Ctr, Duke Eye Ctr, Durham, NC USA.
   [Diaz, Michele T.] Penn State Univ, Dept Psychol, State Coll, PA USA.
   [Whitson, Heather E.] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA.
   [Whitson, Heather E.] Geriatr Res Educ & Clin Ctr, Durham VA Med Ctr, Durham, NC USA.
C3 Duke University; Duke University; University of Arizona; Duke
   University; Duke University; Pennsylvania Commonwealth System of Higher
   Education (PCSHE); Pennsylvania State University; Duke University;
   Geriatric Research Education & Clinical Center; US Department of
   Veterans Affairs; Veterans Health Administration (VHA); Durham VA
   Medical Center
RP Zhuang, J (通讯作者)，Duke Univ, Med Ctr, Brain Imaging & Anal Ctr, Durham, NC 27710 USA.; Whitson, HE (通讯作者)，Duke Univ, Dept Med, DUMC 3003, Durham, NC 27710 USA.
EM jie.zhuang@duke.edu; heather.whitson@duke.edu
RI Whitson, Heather/K-8941-2019; Zhuang, Jie/AAB-5512-2020; Chen,
   Nan-kuei/E-7791-2016
OI Madden, David/0000-0003-2815-6552; Whitson, Heather/0000-0002-8417-4846;
   Zhuang, Jie/0000-0002-3316-5536; Chen, Nan-kuei/0000-0001-6564-4219;
   Diaz, Michele/0000-0001-7263-1694
FU NIH [AG 043438, AG 034138]; NATIONAL INSTITUTE ON AGING [R01AG043438,
   R01AG039684, R01AG034138] Funding Source: NIH RePORTER
FX This research was funded by NIH grant AG 043438 to HEW and NIH grant AG
   034138 to MTD and DJM. This manuscript has not been published elsewhere,
   nor is it currently under consideration for publication elsewhere. This
   research has been approved by the Duke University Medical Center
   Institutional Review Board. All authors have reviewed the contents of
   the manuscript, approved its contents, and validated the accuracy of the
   data.
CR Ardila A, 2015, BEHAV NEUROL, V37, DOI DOI 10.1155/2015/565871
   Baker CI, 2005, J NEUROSCI, V25, P614, DOI 10.1523/JNEUROSCI.3476-04.2005
   Baker ML, 2009, ARCH OPHTHALMOL-CHIC, V127, P667, DOI 10.1001/archophthalmol.2009.30
   Barrick TR, 2010, NEUROIMAGE, V51, P565, DOI 10.1016/j.neuroimage.2010.02.033
   Baseler HA, 2011, NAT NEUROSCI, V14, P649, DOI 10.1038/nn.2793
   Bedny M, 2011, P NATL ACAD SCI USA, V108, P4429, DOI 10.1073/pnas.1014818108
   BELL AJ, 1995, NEURAL COMPUT, V7, P1129, DOI 10.1162/neco.1995.7.6.1129
   Benton A. L., 1977, NEUROSENSORY CTR COM
   Bozic M, 2010, P NATL ACAD SCI USA, V107, P17439, DOI 10.1073/pnas.1000531107
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Burton H, 2002, J NEUROPHYSIOL, V87, P589, DOI 10.1152/jn.00285.2001
   Cabeza R, 2002, PSYCHOL AGING, V17, P85, DOI 10.1037//0882-7974.17.1.85
   Calhoun VD, 2004, MAGN RESON IMAGING, V22, P1181, DOI 10.1016/j.mri.2004.09.004
   Calhoun VD, 2001, HUM BRAIN MAPP, V14, P140, DOI 10.1002/hbm.1048
   Calhoun VD, 2009, NEUROIMAGE, V45, pS163, DOI 10.1016/j.neuroimage.2008.10.057
   Clemons TE, 2006, ARCH OPHTHALMOL-CHIC, V124, P537
   Davis SW, 2014, NEUROPSYCHOLOGIA, V63, P107, DOI 10.1016/j.neuropsychologia.2014.08.017
   Diaz MT, 2014, J COGNITIVE NEUROSCI, V26, P2798, DOI 10.1162/jocn_a_00665
   Fair DA, 2007, NEUROIMAGE, V35, P396, DOI 10.1016/j.neuroimage.2006.11.051
   Fjell AM, 2010, REV NEUROSCIENCE, V21, P187, DOI 10.1515/revneuro.2010.21.3.187
   FULD PA, 1990, J CLIN EXP NEUROPSYC, V12, P520, DOI 10.1080/01688639008400998
   Geva S, 2012, J COGNITIVE NEUROSCI, V24, P2135, DOI 10.1162/jocn_a_00278
   Greicius MD, 2003, P NATL ACAD SCI USA, V100, P253, DOI 10.1073/pnas.0135058100
   Hagoort P, 2005, TRENDS COGN SCI, V9, P416, DOI 10.1016/j.tics.2005.07.004
   Iverson GL, 2001, ARCH CLIN NEUROPSYCH, V16, P183, DOI 10.1016/S0887-6177(00)00060-3
   Jung-Beeman M, 2005, TRENDS COGN SCI, V9, P512, DOI 10.1016/j.tics.2005.09.009
   Kaiser Peter K, 2009, Trans Am Ophthalmol Soc, V107, P311
   Klaver CCW, 1999, AM J EPIDEMIOL, V150, P963
   Laird AR, 2011, J COGNITIVE NEUROSCI, V23, P4022, DOI 10.1162/jocn_a_00077
   Li SC, 2001, TRENDS COGN SCI, V5, P479, DOI 10.1016/S1364-6613(00)01769-1
   Liu Y, 2007, BRAIN, V130, P2085, DOI 10.1093/brain/awm121
   Logan JM, 2002, NEURON, V33, P827, DOI 10.1016/S0896-6273(02)00612-8
   Longworth CE, 2005, J COGNITIVE NEUROSCI, V17, P1087, DOI 10.1162/0898929054475109
   Masuda Y, 2008, CEREB CORTEX, V18, P2483, DOI 10.1093/cercor/bhm256
   Meinzer M, 2009, J COGNITIVE NEUROSCI, V21, P2007, DOI 10.1162/jocn.2009.21219
   MONSCH AU, 1992, ARCH NEUROL-CHICAGO, V49, P1253, DOI 10.1001/archneur.1992.00530360051017
   National Eye Institute, 2011, FACTS AG REL MAC DE
   OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4
   Park DC, 2004, P NATL ACAD SCI USA, V101, P13091, DOI 10.1073/pnas.0405148101
   Park DC, 2009, ANNU REV PSYCHOL, V60, P173, DOI 10.1146/annurev.psych.59.103006.093656
   Pascual-Leone A, 2005, ANNU REV NEUROSCI, V28, P377, DOI 10.1146/annurev.neuro.27.070203.144216
   Peelle JE, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00046
   Peelle JE, 2010, CEREB CORTEX, V20, P773, DOI 10.1093/cercor/bhp142
   Pham TQ, 2006, GERONTOLOGY, V52, P353, DOI 10.1159/000094984
   Raichle ME, 2006, ANNU REV NEUROSCI, V29, P449, DOI 10.1146/annurev.neuro.29.051605.112819
   Raichle ME, 2005, J COMP NEUROL, V493, P167, DOI 10.1002/cne.20752
   Raz N, 2005, COGNITIVE NEUROSCIEN, P19
   Sadato N, 1996, NATURE, V380, P526, DOI 10.1038/380526a0
   Sager Mark A, 2006, WMJ, V105, P25
   Shafto MA, 2014, SCIENCE, V346, P583, DOI 10.1126/science.1254404
   Shafto MA, 2010, J COGNITIVE NEUROSCI, V22, P1530, DOI 10.1162/jocn.2009.21321
   Sowell ER, 2003, NAT NEUROSCI, V6, P309, DOI 10.1038/nn1008
   Stelmack JA, 2004, INVEST OPHTH VIS SCI, V45, P3919, DOI 10.1167/iovs.04-0208
   Stewart L, 2001, NEUROPSYCHOLOGIA, V39, P1, DOI 10.1016/S0028-3932(00)00084-1
   Sunness JS, 2004, OPHTHALMOLOGY, V111, P1595, DOI 10.1016/j.ophtha.2003.12.050
   Szlyk JP, 2009, INVEST OPHTH VIS SCI, V50, P4487, DOI 10.1167/iovs.08-2258
   Szlyk JP, 2004, J VISUAL IMPAIR BLIN, V98, P261
   Thompson-Schill SL, 1997, P NATL ACAD SCI USA, V94, P14792, DOI 10.1073/pnas.94.26.14792
   Tun PA, 2006, AGE AGEING, V35, P629, DOI 10.1093/ageing/afl095
   Tyler LK, 2011, BRAIN, V134, P415, DOI 10.1093/brain/awq369
   Tyler LK, 2010, CEREB CORTEX, V20, P352, DOI 10.1093/cercor/bhp105
   Tzourio-Mazoyer N, 2002, NEUROIMAGE, V15, P273, DOI 10.1006/nimg.2001.0978
   Van Dijk KRA, 2010, J NEUROPHYSIOL, V103, P297, DOI 10.1152/jn.00783.2009
   Whitson HE, 2010, ARCH GERONTOL GERIAT, V50, P209, DOI 10.1016/j.archger.2009.03.010
   Wierenga CE, 2008, NEUROBIOL AGING, V29, P436, DOI 10.1016/j.neurobiolaging.2006.10.024
   Wingfield A, 2006, J NEUROPHYSIOL, V96, P2830, DOI 10.1152/jn.00628.2006
   Wong TY, 2002, AM J OPHTHALMOL, V134, P828
   Woo SJ, 2012, OPHTHALMOLOGY, V119, P2094, DOI 10.1016/j.ophtha.2012.04.026
   Wright P, 2011, J COGNITIVE NEUROSCI, V23, P404, DOI 10.1162/jocn.2010.21450
   Zhuang J, 2014, CEREB CORTEX, V24, P908, DOI 10.1093/cercor/bhs366
   Zhuang J, 2011, J COGNITIVE NEUROSCI, V23, P3778, DOI 10.1162/jocn_a_00046
NR 71
TC 7
Z9 8
U1 1
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0197-4580
EI 1558-1497
J9 NEUROBIOL AGING
JI Neurobiol. Aging
PD MAR
PY 2018
VL 63
BP 65
EP 74
DI 10.1016/j.neurobiolaging.2017.11.003
PG 10
WC Geriatrics & Gerontology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Geriatrics & Gerontology; Neurosciences & Neurology
GA FX0PW
UT WOS:000425749100007
PM 29223681
OA Green Accepted, Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Jin, M
   Dai, H
   Zhang, X
   Wang, Y
   Han, M
   Zhang, H
   Liu, Y
   Wang, Z
   Gao, X
   Li, L
   Wen, X
   Liu, Y
   Wei, L
   Chen, Y
AF Jin, M.
   Dai, H.
   Zhang, X.
   Wang, Y.
   Han, M.
   Zhang, H.
   Liu, Y.
   Wang, Z.
   Gao, X.
   Li, L.
   Wen, X.
   Liu, Y.
   Wei, L.
   Chen, Y.
TI A Traditional Chinese Patent Medicine ZQMT for Neovascular Age-Related
   Macular Degeneration: A Multicenter Randomized Clinical Trial
SO CURRENT MOLECULAR MEDICINE
LA English
DT Review
DE Age-related macular degeneration; traditional Chinese medicine; clinical
   trial
ID RANIBIZUMAB
AB Background: Anti-VEGF agent ranibizumab has been extensively used as a standard treatment for wet AMD. We investigated whether traditional Chinese medicine could serve as a complementary therapy for this disease.
   Methods: 144 patients with neovascular age-related macular degeneration received either intravitreal ranibizumab treatment as needed plus placebo or intravitreal ranibizumab treatment as needed plus an FDA approved traditional Chinese patent medicine named ZQMT. Both groups received treatment for 24 weeks. The primary outcome was the mean change of visual acuity at week 24 as compared to the baseline.
   Results: We found that intravitreal ranibizumab treatment plus ZQMT was non-inferior to the treatment with intravitreal ranibizumab alone in improving visual acuity scores at week 24 with patients in both groups who gained substantial numbers of letters. In addition, we found that ZQMT treatment resulted in significant improvements in reducing retinal hemorrhage, fluid, and lesion size. Importantly, administration of ZQMT reduced the number of needed ranibizumab injections (P<0.0001, analysis of variance) in wet AMD patients leading to a significant reduction of drug cost.
   Conclusion: The combinatory therapy of ranibizumab and traditional Chinese patent medicine ZQMT had equivalent effects on visual acuity improvement and safety profiles as the ranibizumab treatment alone. Ranibizumab injections coupled with ZQMT offer therapeutic advantages in terms of reduction of retinal lesions and ease the financial burden of patients undergoing treatment by reducing the frequency of necessary ranibizumab injections.
C1 [Jin, M.; Wang, Z.] China Japan Friendship Hosp, Dept Ophthalmol, Beijing 100029, Peoples R China.
   [Dai, H.] Beijing Hosp, Dept Ophthalmol, Beijing 100000, Peoples R China.
   [Zhang, X.] Capital Med Univ, Beijing Tongren Hosp, Dept Ophthalmol, Beijing 100730, Peoples R China.
   [Wang, Y.] Capital Med Univ, Beijing Friendship Hosp, Dept Ophthalmol, Beijing 100730, Peoples R China.
   [Han, M.] Tianjin Eye Hosp, Tianjin 300020, Peoples R China.
   [Zhang, H.] Chinese Acad Chinese Med Sci, Eye Hosp, Dept Ophthalmol, Beijing 100040, Peoples R China.
   [Liu, Y.] Peking Univ, Peking Univ Eye Ctr, Beijing 100191, Peoples R China.
   [Gao, X.; Li, L.] Chinese Assoc Tradit Chinese Med, Beijing 100061, Peoples R China.
   [Wen, X.; Liu, Y.; Wei, L.] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou 510060, Guangdong, Peoples R China.
   [Chen, Y.] Peking Union Med Coll, Dept Ophthalmol, Beijing 100730, Peoples R China.
C3 China-Japan Friendship Hospital; Beijing Hospital; Capital Medical
   University; Capital Medical University; Tianjin Medical University; Eye
   Hospital, CACMS; Peking University; Sun Yat Sen University; Chinese
   Academy of Medical Sciences - Peking Union Medical College; Peking Union
   Medical College
RP Jin, M (通讯作者)，China Japan Friendship Hosp, Dept Ophthalmol, Beijing 100029, Peoples R China.; Wei, L (通讯作者)，Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou 510060, Guangdong, Peoples R China.; Chen, Y (通讯作者)，Peking Union Med Coll, Dept Ophthalmol, Beijing 100730, Peoples R China.
EM jinming57@163.com; weil9@mail.sysu.edu.cn; chenyouxinpumch@163.com
RI Liu, Yue/U-8022-2017
OI Liu, Yue/0000-0002-0084-863X; Zhang, Xinyuan/0000-0002-3372-0798
FU National Natural Science Foundation of China [81373693]
FX This work was supported by the National Natural Science Foundation of
   China 81373693 to M.J.
CR Age-Related Eye Disease Study 2 Research Group, 2013, JAMA, V309, P2005, DOI 10.1001/jama.2013.4997
   Fraunfelder FW, 2005, DRUG TODAY, V41, P703, DOI 10.1358/dot.2005.41.11.917340
   Gupta OP, 2007, CURR OPIN OPHTHALMOL, V18, P201, DOI 10.1097/ICU.0b013e32810c8df4
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Jin M, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-118
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Liu D, 2016, CHIN J INTEGR MED, V5, P5
   Mangione CM, 1999, AM J OPHTHALMOL, V128, P45, DOI 10.1016/S0002-9394(99)00169-5
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Myles H, 1999, NONPARAMETRIC STAT M
   Nussenblatt RB, 2014, AM J OPHTHALMOL, V158, P5, DOI 10.1016/j.ajo.2014.03.014
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Solomon SD, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub3
   Whitmore SS, 2015, PROG RETIN EYE RES, V45, P1, DOI 10.1016/j.preteyeres.2014.11.005
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 15
TC 5
Z9 6
U1 4
U2 12
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1566-5240
EI 1875-5666
J9 CURR MOL MED
JI Curr. Mol. Med.
PY 2018
VL 18
IS 9
BP 622
EP 629
DI 10.2174/1566524019666190107155311
PG 8
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA HL7BM
UT WOS:000458892000006
PM 30621562
DA 2022-11-30
ER

PT J
AU Scharf, JM
   Corradetti, G
   Alagorie, AR
   Grondin, C
   Hilely, A
   Wang, D
   Sadda, S
   Sarraf, D
AF Scharf, Jackson M.
   Corradetti, Giulia
   Alagorie, Ahmed Roshdy
   Grondin, Christelle
   Hilely, Assaf
   Wang, Derrick
   Sadda, SriniVas
   Sarraf, David
TI Choriocapillaris Flow Deficits and Treatment-Naive Macular
   Neovascularization Secondary to Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE macular neovascularization; choriocapillaris; flow deficits; optical
   coherence; tomography angiography; age-related macular degeneration
ID COHERENCE TOMOGRAPHY ANGIOGRAPHY; CHOROIDAL NEOVASCULARIZATION;
   GEOGRAPHIC ATROPHY; MOTION CORRECTION; IMAGE; EYES
AB PURPOSE. To evaluate choriocapillaris (CC) flow deficits (FD) in eyes with treatment-naive macular neovascularization (MNV) and to compare CC FD around exudative versus nonexudative MNV.
   METHODS. Treatment-naive eyes with a diagnosis of either exudative or nonexudative AMD and type 1 MNV were included. Normal control eyes were age-matched to each AMD eye one to one. En face optical coherence tomography angiograms were analyzed for percentage of CC FD (FD%) in two concentric 500 mu m rings, ring 1 and ring 2, surrounding the dark halo around MNV. The mean CC FD% in ring 1 and ring 2 was evaluated for each eye. A secondary analysis was similarly carried out to investigate the differences in CC FD% in exudative versus nonexudative treatment-naive MNV.
   RESULTS. Twenty-three eyes with treatment-naive MNV were age matched with 23 normal controls. The mean CC FD% was significantly greater in both rings in the MNV versus the normal control group (P < 0.05) and was significantly greater in the inner ring, closer to the lesion, than the outer ring. The mean FD% was also greater in both rings in the exudative versus the nonexudative MNV group, but this difference did not reach statistical significance.
   CONCLUSIONS. The CC FD% was greater in the area surrounding MNV versus age-matched normal controls and in the ring closer to the MNV lesion. Further, CC FD was greater in eyes with exudative versus nonexudative MNV in both rings surrounding the associated dark halo, although this difference was not statistically significant.
C1 [Scharf, Jackson M.; Corradetti, Giulia; Grondin, Christelle; Hilely, Assaf; Wang, Derrick; Sarraf, David] Univ Calif Los Angeles, Stein Eye Inst, Retina Disorders & Ophthalm Genet, Los Angeles, CA 90095 USA.
   [Scharf, Jackson M.] Columbia Univ, Vagelos Coll Phys & Surg, New York, NY USA.
   [Corradetti, Giulia; Alagorie, Ahmed Roshdy; Sadda, SriniVas] Univ Calif Los Angeles, Doheny Image Reading Ctr, Doheny Eye Inst, Los Angeles, CA USA.
   [Alagorie, Ahmed Roshdy] Tanta Univ, Fac Med, Dept Ophthalmol, Tanta, Egypt.
   [Hilely, Assaf] Tel Aviv Univ, Sackler Fac Med, Tel Aviv Med Ctr, Div Ophthalmol, Tel Aviv, Israel.
   [Sadda, SriniVas; Sarraf, David] Univ Calif Los Angeles, David Geffen Sch Med, Dept Ophthalmol, Los Angeles, CA 90095 USA.
   [Sarraf, David] Greater Los Angeles VA Healthcare Ctr, Los Angeles, CA USA.
C3 University of California System; University of California Los Angeles;
   Columbia University; Doheny Eye Institute; University of California
   System; University of California Los Angeles; Egyptian Knowledge Bank
   (EKB); Tanta University; Tel Aviv University; Sackler Faculty of
   Medicine; University of California System; University of California Los
   Angeles; University of California Los Angeles Medical Center; David
   Geffen School of Medicine at UCLA; US Department of Veterans Affairs;
   Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare
   System
RP Sarraf, D (通讯作者)，Univ Calif Los Angeles, Stein Eye Inst, 100 Stein Plaza, Los Angeles, CA 90095 USA.
EM dsarraf@jsei.ucla.edu
RI Alagorie, Ahmed/AAW-5304-2020; Corradetti, Giulia/Q-5400-2019
OI Alagorie, Ahmed/0000-0001-5489-0617; Corradetti,
   Giulia/0000-0001-9213-5575; CHRISTELLE, GRONDIN/0000-0002-0778-3787
FU Prevent Blindness Inc (DS), New York, New York; Macula Foundation Inc
   (DS, KBF), New York, New York
FX Supported by Research to Prevent Blindness Inc (DS), New York, New York,
   and the Macula Foundation Inc (DS, KBF), New York, New York.
CR Al-Sheikh M, 2018, RETINA-J RET VIT DIS, V38, P220, DOI 10.1097/IAE.0000000000001628
   Alagorie AR, 2019, AM J OPHTHALMOL, V205, P132, DOI 10.1016/j.ajo.2019.04.037
   Alagorie ARR, 2019, INVEST OPHTH VIS SCI, V60
   Bailey ST, 2019, OPHTHALMOL RETINA, V3, P629, DOI 10.1016/j.oret.2019.03.008
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Biesemeier A, 2014, NEUROBIOL AGING, V35, P2562, DOI 10.1016/j.neurobiolaging.2014.05.003
   Borrelli E, 2018, AM J OPHTHALMOL, V196, P34, DOI 10.1016/j.ajo.2018.08.014
   Borrelli E, 2018, PROG RETIN EYE RES, V67, P30, DOI 10.1016/j.preteyeres.2018.07.002
   Borrelli E, 2017, INVEST OPHTH VIS SCI, V58, P4792, DOI 10.1167/iovs.17-22360
   Byon I, 2019, AM J OPHTHALMOL, V208, P397, DOI 10.1016/j.ajo.2019.08.026
   Capuano V, 2017, AM J OPHTHALMOL, V182, P45, DOI 10.1016/j.ajo.2017.07.009
   Carnevali A, 2018, OPHTHALMOL RETINA, V2, P922, DOI 10.1016/j.oret.2018.02.002
   Carnevali A, 2016, AM J OPHTHALMOL, V169, P189, DOI 10.1016/j.ajo.2016.06.042
   Chu ZD, 2019, AM J OPHTHALMOL, V208, P111, DOI 10.1016/j.ajo.2019.07.003
   Coscas F, 2019, BRIT J OPHTHALMOL, V103, P1342, DOI 10.1136/bjophthalmol-2018-313065
   Coscas GJ, 2015, RETINA-J RET VIT DIS, V35, P2219, DOI 10.1097/IAE.0000000000000766
   Forster JC, 2017, HYPOXIA, V5, P21, DOI 10.2147/HP.S133231
   Forte R, 2020, BRIT J OPHTHALMOL, V104, P1057, DOI 10.1136/bjophthalmol-2019-315189
   Garrity ST, 2017, INVEST OPHTH VIS SCI, V58, P5548, DOI 10.1167/iovs.17-22036
   Green W R, 1977, Trans Am Ophthalmol Soc, V75, P180
   HAYASHI K, 1985, OPHTHALMOLOGICA, V190, P30, DOI 10.1159/000309489
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1435, DOI 10.1016/j.ophtha.2014.01.034
   Kashani AH, 2017, PROG RETIN EYE RES, V60, P66, DOI 10.1016/j.preteyeres.2017.07.002
   Kraus MF, 2014, BIOMED OPT EXPRESS, V5, P2591, DOI 10.1364/BOE.5.002591
   Kraus MF, 2012, BIOMED OPT EXPRESS, V3, P1182, DOI 10.1364/BOE.3.001182
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Mehta N, 2019, AM J OPHTHALMOL, V205, P54, DOI 10.1016/j.ajo.2019.03.008
   Moreira-Neto CA, 2018, J OPHTHALMOL, V2018, DOI 10.1155/2018/8125267
   Moult E, 2014, OSLI RETINA, V45, P496, DOI 10.3928/23258160-20141118-03
   Moult EM, 2020, RETINA-J RET VIT DIS, V40, P428, DOI 10.1097/IAE.0000000000002556
   Moult EM, 2016, RETINA-J RET VIT DIS, V36, pS2, DOI 10.1097/IAE.0000000000001287
   Nassisi M, 2021, AM J OPHTHALMOL, V222, P302, DOI 10.1016/j.ajo.2020.04.018
   Nassisi M, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0207638
   Nassisi M, 2019, BRIT J OPHTHALMOL, V103, P911, DOI 10.1136/bjophthalmol-2018-312643
   Phansalkar Neerad, 2011, 2011 International Conference on Communications and Signal Processing (ICCSP), P218, DOI 10.1109/ICCSP.2011.5739305
   Querques G, 2013, INVEST OPHTH VIS SCI, V54, P6886, DOI 10.1167/iovs.13-11665
   Rispoli M, 2018, OSLI RETINA, V49, P918, DOI 10.3928/23258160-20181203-02
   SARKS SH, 1973, BRIT J OPHTHALMOL, V57, P951, DOI 10.1136/bjo.57.12.951
   Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089
   Serra R, 2020, RETINA-J RET VIT DIS, V40, P1224, DOI 10.1097/IAE.0000000000002604
   Spaide RF, 2018, PROG RETIN EYE RES, V64, P1, DOI 10.1016/j.preteyeres.2017.11.003
   Terheyden JH, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0230260
   Treister AD, 2018, TRANSL VIS SCI TECHN, V7, DOI 10.1167/tvst.7.5.19
   Uji A, 2017, OPHTHALMOLOGY, V124, P944, DOI 10.1016/j.ophtha.2017.02.006
   Wirth MA, 2017, ACTA OPHTHALMOL, V95, P428, DOI 10.1111/aos.13226
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Zhang QQ, 2018, INVEST OPHTH VIS SCI, V59, P203, DOI 10.1167/iovs.17-22953
   Zheng F, 2019, AM J OPHTHALMOL, V200, P110, DOI 10.1016/j.ajo.2018.12.025
NR 48
TC 9
Z9 9
U1 0
U2 1
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD SEP
PY 2020
VL 61
IS 11
AR 11
DI 10.1167/iovs.61.11.11
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA NV9SF
UT WOS:000574650900003
PM 32902576
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Pierre, M
   Mainguy, A
   Chatziralli, I
   Pakzad-Vaezi, K
   Ruiz-Medrano, J
   Bodaghi, B
   Loewenstein, A
   Ambati, J
   de Smet, MD
   Tadayoni, R
   Touhami, S
AF Pierre, Mitta
   Mainguy, Adam
   Chatziralli, Irini
   Pakzad-Vaezi, Kaivon
   Ruiz-Medrano, Jorge
   Bodaghi, Bahram
   Loewenstein, Anat
   Ambati, Jayakrishna
   de Smet, Marc D.
   Tadayoni, Ramin
   Touhami, Sara
TI Macular Hemorrhage Due to Age-Related Macular Degeneration or Retinal
   Arterial Macroaneurysm: Predictive Factors of Surgical Outcome
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Article
DE age-related macular degeneration; macular hemorrhage; macular hematoma;
   treat and extend; prognosis; retinal arterial macroaneurysm; vitrectomy
ID TISSUE-PLASMINOGEN ACTIVATOR; PIGMENT EPITHELIAL DETACHMENT; THICK
   SUBMACULAR HEMORRHAGE; PARS-PLANA VITRECTOMY; PNEUMATIC DISPLACEMENT;
   SUBRETINAL HEMORRHAGE; SUBFOVEAL HEMORRHAGE; INTRAVITREAL; MANAGEMENT;
   INJECTION
AB Objective: The study aimed to determine the outcomes and prognostic factors of vitrectomy, subretinal injection of tissue-plasminogen activator and gas tamponade in macular hemorrhage (MaH) due to age-related macular degeneration (AMD) or retinal arterial macroaneurysm (RAM). Methods: The study design utilized a multicentric retrospective case series design of consecutive patients undergoing surgery between 2014 and 2019. Results: A total of 65 eyes from 65 patients were included in the study. Surgery was performed after a mean period of 7.1 days. Displacement of MaH was achieved in 82% of the eyes. Mean best-corrected visual acuity (BCVA) improved from 20/500 to 20/125 at month(M)1 and M6 (p < 0.05). At M6, BCVA worsening was associated with an older age at diagnosis (p = 0.0002) and higher subretinal OCT elevation of MaH (p = 0.03). The use of treat and extend (TE) (OR = 16.7, p = 0.001) and small MaH fundus size (OR = 0.64 and 0.74 for horizontal and vertical fundus size, p < 0.05) were predictive of a higher likelihood of obtaining a countable BCVA at M1. Baseline BCVA was predictive of postoperative BCVA (p < 0.05). Retinal detachment and MaH recurrence occurred in 3% and 9.3% of cases at M6. Conclusion: MaH surgery stabilizes or improves BCVA in 85% of cases. Younger age at diagnosis, better baseline BCVA figures, smaller subretinal MaH height and use of TE regime were predictive of the best postoperative outcomes.
C1 [Pierre, Mitta; Tadayoni, Ramin; Touhami, Sara] Univ Paris, Hop Lariboisiere, AP HP, Dept Ophthalmol, F-75010 Paris, France.
   [Pierre, Mitta; Mainguy, Adam; Bodaghi, Bahram; Touhami, Sara] Sorbonne Univ, Pitie Salpetriere Univ Hosp, Dept Ophthalmol, F-75013 Paris, France.
   [Chatziralli, Irini] Natl & Kapodistrian Univ Athens, Dept Ophthalmol 2, Athens 10679, Greece.
   [Pakzad-Vaezi, Kaivon] Univ British Columbia, Dept Ophthalmol & Visual Sci, Vancouver, BC V6T 1Z4, Canada.
   [Ruiz-Medrano, Jorge] Puerta Hierro Majadahonda Univ Hosp, Dept Ophthalmol, Madrid 28222, Spain.
   [Loewenstein, Anat] Tel Aviv Univ, Israel Sackler Fac Med, Dept Ophthalmol, Tel Aviv Sourasky Med Ctr Tel Aviv, IL-6997801 Tel Aviv, Israel.
   [Ambati, Jayakrishna] Univ Virginia, Sch Med, Dept Microbiol Immunol & Canc Biol, Ctr Adv Vis Sci,Dept Ophthalmol,Dept Pathol, Charlottesville, VA 22908 USA.
   [de Smet, Marc D.] Leiden Univ, Dept Ophthalmol, NL-2333 ZA Leiden, Netherlands.
   [de Smet, Marc D.] MIOS Retina & Ocular Inflammat Ctr, CH-1005 Lausanne, Switzerland.
C3 Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire
   Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities;
   Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP);
   Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research
   Universities; Sorbonne Universite; National & Kapodistrian University of
   Athens; University of British Columbia; Hospital Puerta de
   Hierro-Majadahonda; Tel Aviv University; University of Virginia; Leiden
   University; Leiden University - Excl LUMC
RP Touhami, S (通讯作者)，Univ Paris, Hop Lariboisiere, AP HP, Dept Ophthalmol, F-75010 Paris, France.; Touhami, S (通讯作者)，Sorbonne Univ, Pitie Salpetriere Univ Hosp, Dept Ophthalmol, F-75013 Paris, France.
EM mitta.pierre@live.fr; adam_mainguy@hotmail.fr; eirchat@yahoo.gr;
   kaivon9@gmail.com; jorge.ruizmedrano@gmail.com; bahram.bodaghi@aphp.fr;
   anatl@tlvmc.gov.il; jambati@yahoo.com; mddesmet1@mac.com;
   ramin.tadayoni@aphp.fr; sara.touhami@aphp.fr
RI PIERRE, Mitta/HDM-7441-2022; Ruiz-Medrano, Jorge/N-6256-2016
OI Ruiz-Medrano, Jorge/0000-0002-1105-9265; Chatziralli,
   Irini/0000-0001-8523-1024; Loewenstein, Anat/0000-0002-7706-1165
CR Bhisitkul RB, 2008, INVEST OPHTH VIS SCI, V49, P4071, DOI 10.1167/iovs.08-1892
   Boiche M, 2019, J FR OPHTALMOL, V42, pE391, DOI 10.1016/j.jfo.2019.07.002
   Chan CK, 2010, RETINA-J RET VIT DIS, V30, P203, DOI 10.1097/IAE.0b013e3181babda5
   Chang W, 2014, AM J OPHTHALMOL, V157, P1250, DOI 10.1016/j.ajo.2014.02.007
   De Jong JH, 2016, RETINA-J RET VIT DIS, V36, P914, DOI 10.1097/IAE.0000000000000954
   Doguizi S, 2014, RETINA-J RET VIT DIS, V34, P1156, DOI 10.1097/IAE.0000000000000056
   Fassbender JM, 2016, RETINA-J RET VIT DIS, V36, P1860, DOI 10.1097/IAE.0000000000001030
   Gonzalez-Lopez JJ, 2016, EYE, V30, P929, DOI 10.1038/eye.2016.65
   HANSCOM TA, 1987, ARCH OPHTHALMOL-CHIC, V105, P1722
   Haupert CL, 2001, AM J OPHTHALMOL, V131, P208, DOI 10.1016/S0002-9394(00)00734-0
   Hesse L, 1999, GRAEF ARCH CLIN EXP, V237, P273, DOI 10.1007/s004170050232
   Hirashima T, 2015, RETINA-J RET VIT DIS, V35, P1969, DOI 10.1097/IAE.0000000000000574
   Quiroz-Mendoza JL, 2020, MEDWAVE, V20, DOI 10.5867/medwave.2020.02.7831
   Olivier S, 2004, OPHTHALMOLOGY, V111, P1201, DOI 10.1016/j.ophtha.2003.10.020
   Plemel DJA, 2019, RETINA-J RET VIT DIS, V39, P172, DOI 10.1097/IAE.0000000000001931
   Sandhu SS, 2010, CLIN OPHTHALMOL, V4, P637
   Sarraf D, 2013, RETINA-J RET VIT DIS, V33, P1551, DOI 10.1097/IAE.0b013e31828992f5
   Scupola A, 1999, OPHTHALMOLOGICA, V213, P97, DOI 10.1159/000027400
   Shultz RW, 2011, SEMIN OPHTHALMOL, V26, P361, DOI 10.3109/08820538.2011.585368
   Stanescu-Segall D, 2016, SURV OPHTHALMOL, V61, P18, DOI 10.1016/j.survophthal.2015.04.004
   TOTH CA, 1991, ARCH OPHTHALMOL-CHIC, V109, P723, DOI 10.1001/archopht.1991.01080050139046
   Treumer F, 2017, GRAEF ARCH CLIN EXP, V255, P1115, DOI 10.1007/s00417-017-3620-2
   Treumer F, 2010, BRIT J OPHTHALMOL, V94, P48, DOI 10.1136/bjo.2009.164707
   Treumer F, 2012, BRIT J OPHTHALMOL, V96, P708, DOI 10.1136/bjophthalmol-2011-300655
   Ueda-Arakawa N, 2012, JPN J OPHTHALMOL, V56, P589, DOI 10.1007/s10384-012-0191-y
   WADE EC, 1990, ARCH OPHTHALMOL-CHIC, V108, P973, DOI 10.1001/archopht.1990.01070090075043
NR 26
TC 2
Z9 2
U1 0
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD DEC
PY 2021
VL 10
IS 24
AR 5787
DI 10.3390/jcm10245787
PG 11
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA XZ4HK
UT WOS:000737614100001
PM 34945083
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Ahn, SJ
   Kim, TW
   Huh, JW
   Yu, HG
   Chung, H
AF Ahn, Seong Joon
   Kim, Tae Wan
   Huh, Jang Won
   Yu, Hyeong Gon
   Chung, Hum
TI Comparison of Features on SD-OCT Between Acute Central Serous
   Chorioretinopathy and Exudative Age-Related Macular Degeneration
SO OPHTHALMIC SURGERY LASERS & IMAGING
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; ULTRAHIGH-RESOLUTION; IDENTIFICATION;
   OLDER
AB BACKGROUND AND OBJECTIVE: To compare the spectral-domain optical coherence tomography (SD-OCT) features of acute central serous chorioretinopathy (CSC) versus exudative age-related macular degeneration (AMD) and explore disease-specific features of each disease.
   PATIENTS AND METHODS: SD-OCT images obtained at the time of diagnosis in 39 eyes with acute CSC (symptom onset < 2 months) and 52 eyes with exudative AMD were compared. Multiple regression analysis was performed to identify disease-specific features. The relationship between anatomical findings and visual function was also assessed.
   RESULTS: There were significant morphologic differences on SD-OCT between the two diseases, including the presence and height of retinal fluid and morphologic changes of retinal pigment epithelium (RPE). Multiple regression analysis revealed that a re-flective band with posterior shadowing was a disease-specific finding indicating exudative AMD; however, other SD-OCT findings were attributed to differences in age of onset between the two diseases. Visual acuity was correlated with subretinal fluid in CSC, whereas pigment epithelial detachment, intraretinal fluid, and diverse RPE morphologic abnormalities were associated with visual decline in exudative AMD.
   CONCLUSION: A reflective band with posterior shadowing is a disease-specific feature of exudative AMD that may be useful for the differential diagnosis. High-resolution SD-OCT images of the retinal layers identified distinguishing pathologic features of the outer retina between the two diseases. The OCT features associated with visual function were different between the two diseases. [Ophthalmic Surg Lasers Imaging 2012;43:374382.]
C1 [Kim, Tae Wan] Seoul Metropolitan Govt Seoul Natl Univ, Boramae Med Ctr, Dept Ophthalmol, Seoul 156707, South Korea.
   [Ahn, Seong Joon] Seoul Natl Univ, Bundang Hosp, Dept Ophthalmol, Songnam, South Korea.
   [Ahn, Seong Joon; Huh, Jang Won; Yu, Hyeong Gon; Chung, Hum] Seoul Natl Univ, Coll Med, Dept Ophthalmol, Seoul, South Korea.
C3 Seoul National University (SNU); Seoul National University Hospital;
   Seoul National University (SNU); Seoul National University (SNU)
RP Kim, TW (通讯作者)，Seoul Metropolitan Govt Seoul Natl Univ, Boramae Med Ctr, Dept Ophthalmol, 395 Shindaebang 2 Dong, Seoul 156707, South Korea.
EM twkim93@medimail.co.kr
RI Yu, Hyeong Gon/J-2772-2012; Chung, Hum/J-5657-2012
OI Yu, Hyeong Gon/0000-0002-1795-202X
CR Ahlers C, 2009, INVEST OPHTH VIS SCI, V50, P3417, DOI 10.1167/iovs.08-2759
   Cho M, 2010, BRIT J OPHTHALMOL, V94, P597, DOI 10.1136/bjo.2008.149724
   Coscas F, 2007, AM J OPHTHALMOL, V144, P592, DOI 10.1016/j.ajo.2007.06.014
   Cukras C, 2010, EYE, V24, P775, DOI 10.1038/eye.2009.211
   DAS A, 1992, OPHTHALMOLOGY, V99, P1368
   ELBABA F, 1986, OPHTHALMOLOGY, V93, P1581
   Fujimoto H, 2008, OPHTHALMOLOGY, V115, P1494, DOI 10.1016/j.ophtha.2008.01.021
   HEE MR, 1995, AM J OPHTHALMOL, V120, P65, DOI 10.1016/S0002-9394(14)73760-2
   Hirami Y, 2007, CLIN EXP OPHTHALMOL, V35, P225, DOI 10.1111/j.1442-9071.2006.01447.x
   Ko TH, 2005, OPHTHALMOLOGY, V112, P1922, DOI 10.1016/j.ophtha.2005.05.027
   Mitarai K, 2006, GRAEF ARCH CLIN EXP, V244, P1415, DOI 10.1007/s00417-006-0277-7
   Montero JA, 2005, BRIT J OPHTHALMOL, V89, P562, DOI 10.1136/bjo.2004.049403
   Pieroni CG, 2006, BRIT J OPHTHALMOL, V90, P191, DOI 10.1136/bjo.2005.076612
   Sato T, 2004, RETINA-J RET VIT DIS, V24, P910, DOI 10.1097/00006982-200412000-00011
   SCHATZ H, 1992, OPHTHALMOLOGY, V99, P63
   Spaide RF, 1996, OPHTHALMOLOGY, V103, P2070, DOI 10.1016/S0161-6420(96)30386-2
NR 16
TC 6
Z9 8
U1 0
U2 7
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 1542-8877
J9 OPHTHAL SURG LAS IM
JI Ophthalmic Surg. Lasers Imaging
PD SEP-OCT
PY 2012
VL 43
IS 5
BP 374
EP 382
DI 10.3928/15428877-20120628-01
PG 9
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA 054TP
UT WOS:000312367000003
PM 22767337
DA 2022-11-30
ER

PT J
AU Hyttinen, JMT
   Blasiak, J
   Niittykoski, M
   Kinnunen, K
   Kauppinen, A
   Salminen, A
   Kaarniranta, K
AF Hyttinen, Juha M. T.
   Blasiak, Janusz
   Niittykoski, Minna
   Kinnunen, Kati
   Kauppinen, Anu
   Salminen, Antero
   Kaarniranta, Kai
TI DNA damage response and autophagy in the degeneration of retinal pigment
   epithelial cells-Implications for age-related macular degeneration (AMD)
SO AGEING RESEARCH REVIEWS
LA English
DT Review
DE Age related macular degeneration; Autophagy; DNA damage response;
   Reactive oxygen species; Retinal pigment epithelium
ID CHAPERONE-MEDIATED AUTOPHAGY; PROTEIN 90-ALPHA HSP90-ALPHA;
   BREAST-CANCER CELLS; OXIDATIVE STRESS; STRAND BREAKS; MITOCHONDRIAL;
   LIPOFUSCIN; REPAIR; ATM; DEGRADATION
AB In this review we will discuss the links between autophagy, a mechanism involved in the maintenance of cellular homeostasis and controlling cellular waste management, and the DNA damage response (DDR), comprising various mechanisms preserving the integrity and stability of the genome. A reduced autophagy capacity in retinal pigment epithelium has been shown to be connected in the pathogenesis of age-related macular degeneration (AMD), an eye disease. This degenerative disease is a major and increasing cause of vision loss in the elderly in developed countries, primarily due to the profound accumulation of intra- and extracellular waste: lipofuscin and drusen. An abundance of reactive oxygen species is produced in the retina since this tissue has a high oxygen demand and contains mitochondria rich cells. The retina is exposed to light and it also houses many photoactive molecules. These factors are clearly reflected in both the autophagy and DNA damage rates, and in both nuclear and mitochondrial genomes. It remains to be revealed whether DNA damage and DDR capacity have a more direct role in the development of AMD. (C) 2017 Elsevier B.V. All rights reserved.
C1 [Hyttinen, Juha M. T.; Kaarniranta, Kai] Univ Eastern Finland, Inst Clin Med, Dept Ophthalmol, POB 1627, FI-70211 Kuopio, Finland.
   [Blasiak, Janusz] Univ Lodz, Dept Mol Genet, Pomorska 141-143, PL-90236 Lodz, Poland.
   [Niittykoski, Minna] Univ Helsinki, Inst Biotechnol, Dev Biol Program, POB 56, FI-00014 Helsinki, Finland.
   [Kinnunen, Kati; Kaarniranta, Kai] Kuopio Univ Hosp, Dept Ophthalmol, POB 100, FI-70029 Kuopio, Finland.
   [Kauppinen, Anu] Univ Eastern Finland, Sch Pharm, Fac Hlth Sci, POB 1627, FI-70211 Kuopio, Finland.
   [Salminen, Antero] Univ Eastern Finland, Inst Clin Med, Dept Neurol, POB 1627, FI-70211 Kuopio, Finland.
C3 University of Eastern Finland; University of Lodz; University of
   Helsinki; Kuopio University Hospital; University of Eastern Finland;
   University of Eastern Finland; University of Eastern Finland
RP Hyttinen, JMT (通讯作者)，Univ Eastern Finland, Inst Clin Med, Dept Ophthalmol, POB 1627, FI-70211 Kuopio, Finland.
EM Juha.Hyttinen@uef.fi
OI Hyttinen, Juha/0000-0002-3414-4032; Niittykoski,
   Minna/0000-0002-2816-9874; Blasiak, Janusz/0000-0001-9539-9584
FU Academy of Finland [AK 297267, 307341, KK 296840]; Finnish Eye
   Foundation; University of Eastern Finland; VTR from Kuopio University
   Hospital [KK 5503743]; Finnish Cultural Foundation; Alfred Kordelin
   Foundation; Blinds' Friends Foundation in Finland
FX This study was financially supported by the grants from the Academy of
   Finland (AK 297267 and 307341, KK 296840), The Finnish Eye Foundation,
   the University of Eastern Finland, VTR funding from Kuopio University
   Hospital (KK 5503743), the Finnish Cultural Foundation, the Alfred
   Kordelin Foundation, and the Blinds' Friends Foundation in Finland. The
   authors thank Dr. Ewen MacDonald for checking the language of the
   manuscript.
CR Abedin MJ, 2007, CELL DEATH DIFFER, V14, P500, DOI 10.1038/sj.cdd.4402039
   Adamec E, 1999, BRAIN RES, V849, P67, DOI 10.1016/S0006-8993(99)02004-1
   Alexander A, 2010, P NATL ACAD SCI USA, V107, P4153, DOI 10.1073/pnas.0913860107
   Alexeyev M., 2013, COLD SPRING HARB PER, V5
   Apel A, 2008, CANCER RES, V68, P1485, DOI 10.1158/0008-5472.CAN-07-0562
   Aze A, 2013, CHROMOSOMA, V122, P401, DOI 10.1007/s00412-013-0411-3
   Ba X, 2014, INT J MOL SCI, V15, P16975, DOI 10.3390/ijms150916975
   Babu JR, 2008, J NEUROCHEM, V106, P107, DOI 10.1111/j.1471-4159.2008.05340.x
   Bae H, 2011, MOL CANCER RES, V9, P1232, DOI 10.1158/1541-7786.MCR-11-0098
   Bai XC, 2010, CELL MOL LIFE SCI, V67, P239, DOI 10.1007/s00018-009-0163-7
   Bailey TA, 2004, INVEST OPHTH VIS SCI, V45, P675, DOI 10.1167/iovs.03-0351
   Bales KL, 2016, EXP EYE RES, V150, P71, DOI 10.1016/j.exer.2015.11.007
   Bautista-Nino PK, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17050748
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Ben-Shabat S, 2002, ANGEW CHEM INT EDIT, V41, P814, DOI 10.1002/1521-3773(20020301)41:5<814::AID-ANIE814>3.0.CO;2-2
   Bergmann M, 2004, FASEB J, V18, P562, DOI 10.1096/fj.03-0289fje
   Bhattacharya S, 2012, INVEST OPHTH VIS SCI, V53, P8350, DOI 10.1167/iovs.12-10495
   Bjorkoy G, 2005, J CELL BIOL, V171, P603, DOI 10.1083/jcb.200507002
   Black JRM, 2016, GENET MED, V18, P283, DOI 10.1038/gim.2015.70
   Blasiak J, 2013, INT J MOL SCI, V14, P2996, DOI 10.3390/ijms14022996
   Boesch P, 2011, BBA-MOL CELL RES, V1813, P186, DOI 10.1016/j.bbamcr.2010.10.002
   Boyer NP, 2012, J BIOL CHEM, V287, P22276, DOI 10.1074/jbc.M111.329235
   Brinkmann K, 2015, FRONT GENET, V6, DOI 10.3389/fgene.2015.00098
   Bur H, 2014, HISTOPATHOLOGY, V65, P319, DOI 10.1111/his.12389
   Buschini E, 2015, CLIN OPHTHALMOL, V9, P563, DOI 10.2147/OPTH.S59724
   Cadet J, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a012559
   Chan CM, 2015, INT J MOL SCI, V16, P5789, DOI 10.3390/ijms16035789
   Chen Y, 2009, CELL DEATH DIFFER, V16, P1040, DOI 10.1038/cdd.2009.49
   Ciccia A, 2010, MOL CELL, V40, P179, DOI 10.1016/j.molcel.2010.09.019
   Ciechanover A, 2000, BIOESSAYS, V22, P442, DOI 10.1002/(SICI)1521-1878(200005)22:5<442::AID-BIES6>3.0.CO;2-Q
   Ciechanover A, 2014, BBA-MOL CELL RES, V1843, P86, DOI 10.1016/j.bbamcr.2013.07.007
   Cimprich KA, 2008, NAT REV MOL CELL BIO, V9, P616, DOI 10.1038/nrm2450
   Clayton D A, 1975, Basic Life Sci, V5B, P589
   Cohn CA, 2008, PART FIBRE TOXICOL, V5, DOI 10.1186/1743-8977-5-2
   Cuervo AM, 2014, CELL RES, V24, P92, DOI 10.1038/cr.2013.153
   Czarny P, 2015, INT J MOL SCI, V16, P2641, DOI 10.3390/ijms16022641
   Dai Y, 2010, CLIN CANCER RES, V16, P376, DOI 10.1158/1078-0432.CCR-09-1029
   Davis PL, 1999, ONCOGENE, V18, P6000, DOI 10.1038/sj.onc.1202990
   Dickinson BC, 2010, CURR OPIN CHEM BIOL, V14, P50, DOI 10.1016/j.cbpa.2009.10.014
   Dobson CM, 2003, NATURE, V426, P884, DOI 10.1038/nature02261
   Drose S, 2012, ADV EXP MED BIOL, V748, P145, DOI 10.1007/978-1-4614-3573-0_6
   Echtenkamp F.J., 2011, MOL CELL, V45, P517
   Elliott A, 2008, TOXICOL APPL PHARM, V232, P169, DOI 10.1016/j.taap.2008.06.017
   Eskelinen EL, 2009, BBA-MOL CELL RES, V1793, P664, DOI 10.1016/j.bbamcr.2008.07.014
   Fengsrud M, 2004, AUTOPHAGY, P11
   Ferrante RJ, 1997, J NEUROCHEM, V69, P2064
   Ferrington DA, 2016, PROG RETIN EYE RES, V51, P69, DOI 10.1016/j.preteyeres.2015.09.002
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Ganley IG, 2009, J BIOL CHEM, V284, P12297, DOI 10.1074/jbc.M900573200
   Golia B, 2015, FRONT BIOSCI-LANDMRK, V20, P440, DOI 10.2741/4318
   GRIFFITHS DJF, 1995, EMBO J, V14, P5812, DOI 10.1002/j.1460-2075.1995.tb00269.x
   Haines DD, 2013, J CELL MOL MED, V17, P936, DOI 10.1111/jcmm.12074
   Handa JT, 2012, MOL ASPECTS MED, V33, P418, DOI 10.1016/j.mam.2012.03.006
   Hands SL, 2009, AGING-US, V1, P586, DOI 10.18632/aging.100070
   Hariharan N, 2010, CIRC RES, V107, P1470, DOI 10.1161/CIRCRESAHA.110.227371
   Hohn A, 2011, FREE RADICAL BIO MED, V50, P585, DOI 10.1016/j.freeradbiomed.2010.12.011
   Hohn A, 2010, FREE RADICAL BIO MED, V48, P1100, DOI 10.1016/j.freeradbiomed.2010.01.030
   Holz FG, 1999, INVEST OPHTH VIS SCI, V40, P737
   Hoyer-Hansen M, 2007, AUTOPHAGY, V3, P381, DOI 10.4161/auto.4240
   Huang J, 2011, ANTIOXID REDOX SIGN, V14, P2215, DOI 10.1089/ars.2010.3554
   Huang X, 2003, CELL CYCLE, V2, P614, DOI 10.4161/cc.2.6.565
   Huen MSY, 2010, NAT REV MOL CELL BIO, V11, P138, DOI 10.1038/nrm2831
   Huen MS, 2008, CELL RES, V18, P8, DOI 10.1038/cr.2007.109
   Hunter JJ, 2012, PROG RETIN EYE RES, V31, P28, DOI 10.1016/j.preteyeres.2011.11.001
   Hytti M, 2017, J NUTR BIOCHEM, V42, P37, DOI 10.1016/j.jnutbio.2016.12.014
   Hyttinen JMT, 2014, AGEING RES REV, V18, P16, DOI 10.1016/j.arr.2014.07.002
   Hyttinen JMT, 2013, BBA-MOL CELL RES, V1833, P503, DOI 10.1016/j.bbamcr.2012.11.018
   Hyttinen JMT, 2011, REJUV RES, V14, P651, DOI 10.1089/rej.2011.1220
   Iyama T, 2013, DNA REPAIR, V12, P620, DOI 10.1016/j.dnarep.2013.04.015
   Jackson SP, 2009, NATURE, V461, P1071, DOI 10.1038/nature08467
   Jang KH, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.437
   Jansen JG, 2015, DNA REPAIR, V29, P56, DOI 10.1016/j.dnarep.2015.01.001
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Johansson I, 2015, AUTOPHAGY, V11, P1636, DOI 10.1080/15548627.2015.1061170
   Kaarniranta K., 2016, CELL BIOL TOXICOL
   Kaarniranta K, 2013, AUTOPHAGY, V9, P973, DOI 10.4161/auto.24546
   Kaarniranta Kai, 2010, Front Biosci (Elite Ed), V2, P1374
   Kaarniranta K, 2009, AGEING RES REV, V8, P128, DOI 10.1016/j.arr.2009.01.001
   Kaemmerer E, 2007, INVEST OPHTH VIS SCI, V48, P1342, DOI 10.1167/iovs.06-0549
   Kang C, 2015, SCIENCE, V349, DOI 10.1126/science.aaa5612
   Karantza-Wadsworth V, 2007, GENE DEV, V21, P1621, DOI 10.1101/gad.1565707
   Karlsson M, 2013, EXP EYE RES, V116, P359, DOI 10.1016/j.exer.2013.10.014
   Katayama M, 2007, CELL DEATH DIFFER, V14, P548, DOI 10.1038/sj.cdd.4402030
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Kaushik S, 2015, NAT MED, V21, P1406, DOI 10.1038/nm.4001
   Khoronenkova SV, 2015, P NATL ACAD SCI USA, V112, P3997, DOI 10.1073/pnas.1416031112
   Kiffin R, 2006, ANTIOXID REDOX SIGN, V8, P152, DOI 10.1089/ars.2006.8.152
   Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152
   Kim YeonJeong, 2015, Plant Breeding and Biotechnology, V3, P11, DOI 10.9787/PBB.2015.3.1.011
   Kitada M, 2013, CLIN SCI, V124, P153, DOI 10.1042/CS20120190
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klerkx EPF, 2009, HISTOL HISTOPATHOL, V24, P749, DOI 10.14670/HH-24.749
   Konig J, 2017, REDOX BIOL, V11, P673, DOI 10.1016/j.redox.2017.01.017
   Korolchuk VI, 2009, MOL CELL, V33, P517, DOI 10.1016/j.molcel.2009.01.021
   Koskela A, 2016, NUTRIENTS, V8, DOI 10.3390/nu8050284
   Koskela A, 2014, MOL VIS, V20, P760
   Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023
   Kurz T, 2009, AUTOPHAGY, V5, P93, DOI 10.4161/auto.5.1.7248
   LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0
   Lavin MF, 2015, BIOMOLECULES, V5, P2877, DOI 10.3390/biom5042877
   Lindsey-Boltz LA, 2001, P NATL ACAD SCI USA, V98, P11236, DOI 10.1073/pnas.201373498
   Liu C, 2013, NUCLEIC ACIDS RES, V41, P1698, DOI 10.1093/nar/gks1278
   Liu EY, 2015, P NATL ACAD SCI USA, V112, P773, DOI 10.1073/pnas.1409563112
   Loeb LA, 2008, NAT REV GENET, V9, P594, DOI 10.1038/nrg2345
   Lu M, 2015, J BIOL CHEM, V290, P27986, DOI 10.1074/jbc.M115.676437
   Luzio JP, 2007, NAT REV MOL CELL BIO, V8, P622, DOI 10.1038/nrm2217
   Ma B, 2016, SCI REP-UK, V6, DOI 10.1038/srep22375
   Maiuri MC, 2010, CURR OPIN CELL BIOL, V22, P181, DOI 10.1016/j.ceb.2009.12.001
   Manjithaya R, 2010, FEBS LETT, V584, P1367, DOI 10.1016/j.febslet.2010.01.019
   Marques FC, 2015, ANNU REV PATHOL-MECH, V10, P1, DOI 10.1146/annurev-pathol-012414-040508
   Mathew R, 2007, GENE DEV, V21, P1367, DOI 10.1101/gad.1545107
   Matsuoka S, 2007, SCIENCE, V316, P1160, DOI 10.1126/science.1140321
   McKay BC, 2014, ANTIOXID REDOX SIGN, V20, P640, DOI 10.1089/ars.2013.5523
   McVey M, 2008, TRENDS GENET, V24, P529, DOI 10.1016/j.tig.2008.08.007
   Meek K, 2008, ADV IMMUNOL, V99, P33, DOI 10.1016/S0065-2776(08)00602-0
   Melser S, 2015, BBA-MOL CELL RES, V1853, P2812, DOI 10.1016/j.bbamcr.2015.05.010
   MICELI MV, 1994, EXP CELL RES, V214, P242, DOI 10.1006/excr.1994.1254
   Mijaljica D, 2011, AUTOPHAGY, V7, P673, DOI 10.4161/auto.7.7.14733
   Miller SBM, 2015, EMBO J, V34, P778, DOI 10.15252/embj.201489524
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   Mizushima N, 2007, GENE DEV, V21, P2861, DOI 10.1101/gad.1599207
   Mizushima N, 2011, CELL, V147, P728, DOI 10.1016/j.cell.2011.10.026
   Morimoto RI, 1998, GENE DEV, V12, P3788, DOI 10.1101/gad.12.24.3788
   Morimoto RI, 2011, COLD SH Q B, V76, P91, DOI 10.1101/sqb.2012.76.010637
   Munoz-Gomez JA, 2009, AUTOPHAGY, V5, P61, DOI 10.4161/auto.5.1.7272
   Ney PA, 2015, BBA-MOL CELL RES, V1853, P2775, DOI 10.1016/j.bbamcr.2015.02.022
   Nezis IP, 2012, ANTIOXID REDOX SIGN, V17, P786, DOI 10.1089/ars.2011.4394
   Nowotny K, 2014, EXP GERONTOL, V59, P3, DOI 10.1016/j.exger.2014.10.001
   Pandey UB, 2007, NATURE, V447, P859, DOI 10.1038/nature05853
   Pankiv S, 2010, J BIOL CHEM, V285, P5941, DOI 10.1074/jbc.M109.039925
   Park C, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7823
   Parzych KR, 2014, ANTIOXID REDOX SIGN, V20, P460, DOI 10.1089/ars.2013.5371
   Paull TT, 2015, ANNU REV BIOCHEM, V84, P711, DOI 10.1146/annurev-biochem-060614-034335
   Pavelic SK, 2015, BBA-MOL BASIS DIS, V1852, P1833, DOI 10.1016/j.bbadis.2015.06.006
   Pennisi R, 2015, BIOMOLECULES, V5, P2589, DOI 10.3390/biom5042589
   Perrotta I, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/130315
   Polo SE, 2011, GENE DEV, V25, P409, DOI 10.1101/gad.2021311
   Qadir MA, 2008, BREAST CANCER RES TR, V112, P389, DOI 10.1007/s10549-007-9873-4
   Quanz M, 2012, J BIOL CHEM, V287, P8803, DOI 10.1074/jbc.M111.320887
   Querques G, 2014, OPHTHALMIC RES, V52, P107, DOI 10.1159/000363187
   Rajendran R, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/368276
   Ravikumar B, 2004, NEUROREPORT, V15, P2443, DOI 10.1097/00001756-200411150-00001
   Reggiori Fulvio, 2012, Int J Cell Biol, V2012, P156272, DOI 10.1155/2012/156272
   Reinhardt HC, 2012, TRENDS GENET, V28, P128, DOI 10.1016/j.tig.2011.12.002
   Ribezzo F, 2016, SEMIN CANCER BIOL, V37-38, P26, DOI 10.1016/j.semcancer.2015.12.005
   Rieber M, 2008, CANCER BIOL THER, V7, P1561, DOI 10.4161/cbt.7.10.6540
   Rodriguez-Rocha H, 2011, MUTAT RES-FUND MOL M, V711, P158, DOI 10.1016/j.mrfmmm.2011.03.007
   Rogov V, 2014, MOL CELL, V53, P167, DOI 10.1016/j.molcel.2013.12.014
   Roos WP, 2016, NAT REV CANCER, V16, P20, DOI 10.1038/nrc.2015.2
   Rozanowska M., 2009, PHOTOBIOLOGICAL SCI
   Rozanowska M, 2012, PHOTOCHEM PHOTOBIOL, V88, P1362, DOI 10.1111/j.1751-1097.2012.01161.x
   Ryhanen T, 2009, J CELL MOL MED, V13, P3616, DOI 10.1111/j.1582-4934.2008.00577.x
   Saarikangas J, 2016, CURR GENET, V62, P711, DOI 10.1007/s00294-016-0596-0
   Sale JE, 2012, J CELL SCI, V125, P1633, DOI 10.1242/jcs.094748
   Salminen A, 2009, TRENDS MOL MED, V15, P217, DOI 10.1016/j.molmed.2009.03.004
   Savage KI, 2015, FEBS J, V282, P630, DOI 10.1111/febs.13150
   Scherz-Shouval R, 2007, EMBO J, V26, P1749, DOI 10.1038/sj.emboj.7601623
   Scherz-Shouval R, 2011, TRENDS BIOCHEM SCI, V36, P30, DOI 10.1016/j.tibs.2010.07.007
   Schrader M, 2006, BBA-MOL CELL RES, V1763, P1755, DOI 10.1016/j.bbamcr.2006.09.006
   Schreiber V, 2006, NAT REV MOL CELL BIO, V7, P517, DOI 10.1038/nrm1963
   Scott AW, 2013, CURR OPIN OPHTHALMOL, V24, P190, DOI 10.1097/ICU.0b013e32835fefee
   Scully R, 2013, MUTAT RES-FUND MOL M, V750, P5, DOI 10.1016/j.mrfmmm.2013.07.007
   Shiloh Y, 2014, EXP CELL RES, V329, P154, DOI 10.1016/j.yexcr.2014.09.002
   Sitte N, 2000, FASEB J, V14, P1490, DOI 10.1096/fj.14.11.1490
   Solier S, 2012, P NATL ACAD SCI USA, V109, P12866, DOI 10.1073/pnas.1203617109
   Sommers JA, 2015, BIOMOLECULES, V5, P590, DOI 10.3390/biom5020590
   Song D, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00024
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1441, DOI 10.1097/IAE.0b013e3181ee5ce8
   Sparrow JR, 2000, INVEST OPHTH VIS SCI, V41, P1981
   Spassky A, 1997, BIOCHEMISTRY-US, V36, P6571, DOI 10.1021/bi962761d
   Stone HR, 2014, ONCOGENE, V33, P805, DOI 10.1038/onc.2013.60
   Stracker TH, 2011, NAT REV MOL CELL BIO, V12, P90, DOI 10.1038/nrm3047
   Stratton MR, 2009, NATURE, V458, P719, DOI 10.1038/nature07943
   Subrizi A, 2015, PHARM RES-DORDR, V32, P211, DOI 10.1007/s11095-014-1456-6
   Terluk MR, 2015, J NEUROSCI, V35, P7304, DOI 10.1523/JNEUROSCI.0190-15.2015
   Terman A, 2004, INT J BIOCHEM CELL B, V36, P1400, DOI 10.1016/j.biocel.2003.08.009
   Thampi P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034468
   Thepot S, 2011, CELL CYCLE, V10, P2323, DOI 10.4161/cc.10.14.16399
   Thurn KT, 2013, MOL CANCER THER, V12, P2078, DOI 10.1158/1535-7163.MCT-12-1242
   Tokarz P, 2016, REJUV RES, V19, P131, DOI 10.1089/rej.2015.1717
   Tokarz P, 2013, BIOGERONTOLOGY, V14, P461, DOI 10.1007/s10522-013-9463-2
   Toth ML, 2008, AUTOPHAGY, V4, P330, DOI 10.4161/auto.5618
   Truman AW, 2015, J PROTEOMICS, V112, P285, DOI 10.1016/j.jprot.2014.09.028
   Valbuena A., 2010, PLOS ONE, V6
   Van Houten B, 2016, FRONT BIOSCI-LANDMRK, V21, P42, DOI 10.2741/4375
   Viiri J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069563
   Volkmer E, 1999, J BIOL CHEM, V274, P567, DOI 10.1074/jbc.274.2.567
   Wang A, 2000, J BIOL CHEM, V275, P4532, DOI 10.1074/jbc.275.6.4532
   Wang XY, 2016, NEUROBIOL AGING, V47, P168, DOI 10.1016/j.neurobiolaging.2016.07.025
   Wolf DH, 2004, BBA-MOL CELL RES, V1695, P19, DOI 10.1016/j.bbamcr.2004.10.007
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu SB, 2014, BBA-GEN SUBJECTS, V1840, P1331, DOI 10.1016/j.bbagen.2013.10.034
   Wu YL, 2014, BIOCHEM J, V460, P343, DOI 10.1042/BJ20140089
   Xiao A, 2009, NATURE, V457, P57, DOI 10.1038/nature07668
   Yang ZF, 2010, NAT CELL BIOL, V12, P814, DOI 10.1038/ncb0910-814
   Yi JJ, 2010, BBA-PROTEINS PROTEOM, V1804, P1684, DOI 10.1016/j.bbapap.2010.05.002
   Zareba M, 2006, FREE RADICAL BIO MED, V40, P87, DOI 10.1016/j.freeradbiomed.2005.08.015
   Zhang D, 2015, CANCER BIOL THER, V16, P1005, DOI 10.1080/15384047.2015.1046022
   Zhang J, 1999, AM J PATHOL, V154, P1423, DOI 10.1016/S0002-9440(10)65396-5
   Zhao J, 2007, CELL METAB, V6, P472, DOI 10.1016/j.cmet.2007.11.004
NR 200
TC 45
Z9 45
U1 0
U2 16
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 1568-1637
EI 1872-9649
J9 AGEING RES REV
JI Ageing Res. Rev.
PD JUL
PY 2017
VL 36
BP 64
EP 77
DI 10.1016/j.arr.2017.03.006
PG 14
WC Cell Biology; Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Geriatrics & Gerontology
GA EX0YT
UT WOS:000402947400007
PM 28351686
DA 2022-11-30
ER

PT J
AU Kikushima, W
   Sakurada, Y
   Sugiyama, A
   Tanabe, N
   Kume, A
   Iijima, H
AF Kikushima, Wataru
   Sakurada, Yoichi
   Sugiyama, Atsushi
   Tanabe, Naohiko
   Kume, Atsuki
   Iijima, Hiroyuki
TI Factors Predictive of Visual Outcome 1 Year After Intravitreal
   Aflibercept Injection for Typical Neovascular Age-Related Macular
   Degeneration
SO JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
LA English
DT Article
ID SUBFOVEAL CHOROIDAL THICKNESS; OPTICAL COHERENCE TOMOGRAPHY; RETICULAR
   PSEUDODRUSEN; VEGF-TRAP; RANIBIZUMAB; EYES; MACULOPATHY; THERAPY
AB Purpose: Several factors have been reported to be associated with visual outcomes after intravitreal ranibizumab treatment for neovascular age-related macular degeneration (AMD). In the present study, we investigated the factors associated with visual outcomes after intravitreal aflibercept injection (IAI) for typical neovascular AMD.
   Methods: We retrospectively studied the visual changes in 47 eyes of 51 patients with typical neovascular AMD, who had been initially treated with 3 monthly IAI followed by as-needed IAI.
   Results: Mean best-corrected visual acuity (BCVA) improved during the 12-month follow-up period in 40 eyes of 37 patients without reticular pseudodrusen (RPD) in both eyes, whereas it deteriorated in 11 eyes of 10 patients with RPD in either eye. Multiple regression analysis revealed that visual gain at 12 months after the first IAI positively correlated with worse baseline BCVA and thicker baseline subfoveal choroidal thickness (P = 0.018, P = 0.004, respectively), but not with absence of RPD (P = 0.13). Subfoveal choroidal thickness was significantly thinner in eyes with RPD compared with that in eyes without RPD (P = 0.003).
   Conclusions: Visual gain after IAI in eyes with typical neovascular AMD appears to be limited in patients with RPD, which may reflect the poor visual outcome after IAI in eyes with a thinner subfoveal choroid that is seen predominately in patients with RPD.
C1 [Kikushima, Wataru; Sakurada, Yoichi; Sugiyama, Atsushi; Tanabe, Naohiko; Kume, Atsuki; Iijima, Hiroyuki] Univ Yamanashi, Dept Ophthalmol, Fac Med, Kofu, Yamanashi, Japan.
C3 University of Yamanashi
RP Sakurada, Y (通讯作者)，Univ Yamanashi, Dept Ophthalmol, Fac Med, Chuo Ku, Shimokato 1110, Kofu, Yamanashi 4093898, Japan.
EM sakurada@yamanashi.ac.jp
CR ARNOLD JJ, 1995, RETINA-J RET VIT DIS, V15, P183, DOI 10.1097/00006982-199515030-00001
   Axer-Siegel R, 2004, AM J OPHTHALMOL, V137, P258, DOI 10.1016/j.ajo.2003.08.009
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chen Y, 1999, J MOL BIOL, V293, P865, DOI 10.1006/jmbi.1999.3192
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Haas P, 2014, INVEST OPHTH VIS SCI, V55, P2674, DOI 10.1167/iovs.13-13338
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hogg RE, 2014, OPHTHALMOLOGY, V121, P1748, DOI 10.1016/j.ophtha.2014.03.015
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Kang HM, 2014, AM J OPHTHALMOL, V157, P1013, DOI 10.1016/j.ajo.2014.01.019
   Kim SW, 2011, RETINA-J RET VIT DIS, V31, P1904, DOI 10.1097/IAE.0b013e31821801c5
   Metelitsina TI, 2008, INVEST OPHTH VIS SCI, V49, P358, DOI 10.1167/iovs.07-0526
   MIMOUN G, 1990, J FR OPHTALMOL, V13, P511
   Nickla DL, 2010, PROG RETIN EYE RES, V29, P144, DOI 10.1016/j.preteyeres.2009.12.002
   Nishida Y, 2012, RETINA-J RET VIT DIS, V32, P1229, DOI 10.1097/IAE.0b013e318242b990
   Papadopoulou DN, 2009, OPHTHALMOLOGY, V116, P1755, DOI 10.1016/j.ophtha.2009.03.017
   Pumariega NM, 2011, OPHTHALMOLOGY, V118, P1619, DOI 10.1016/j.ophtha.2011.01.029
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Ueda-Arakawa N, 2014, AM J OPHTHALMOL, V157, P994, DOI 10.1016/j.ajo.2014.01.018
   Yamazaki T, 2012, OPHTHALMOLOGY, V119, P1621, DOI 10.1016/j.ophtha.2012.02.022
   Yoneyama S, 2014, GRAEF ARCH CLIN EXP, V252, P1435, DOI 10.1007/s00417-014-2601-y
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 24
TC 11
Z9 11
U1 0
U2 2
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1080-7683
EI 1557-7732
J9 J OCUL PHARMACOL TH
JI J. Ocular Pharmacol. Ther.
PD JUL-AUG
PY 2016
VL 32
IS 6
BP 376
EP 382
DI 10.1089/jop.2015.0125
PG 7
WC Ophthalmology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Pharmacology & Pharmacy
GA DS1ZW
UT WOS:000380508900008
PM 27213222
DA 2022-11-30
ER

PT J
AU Xu, XQ
   Ritz, B
   Coleman, AL
   Liew, Z
   Deapen, D
   Lee, E
   Bernstein, L
   Pinder, R
   Marshall, SF
   Heck, JE
AF Xu, Xiaoqing
   Ritz, Beate
   Coleman, Anne L.
   Liew, Zeyan
   Deapen, Dennis
   Lee, Eunjung
   Bernstein, Leslie
   Pinder, Rich
   Marshall, Sarah F.
   Heck, Julia E.
TI Non-steroidal Anti-inflammatory Drug Use and Risk of Age-Related Macular
   Degeneration in the California Teachers Study
SO DRUGS & AGING
LA English
DT Article
ID LOW-DOSE ASPIRIN; MACULOPATHY; CYCLOOXYGENASE-2; ASSOCIATIONS;
   EXPRESSION; MORTALITY; DISEASE; TRIAL
AB Purpose The aim of this study was to examine whether use of regular aspirin and/or other non-steroidal anti-inflammatory drugs (NSAIDs) is associated with the development of age-related macular degeneration (AMD). Methods In the California Teachers Study cohort (N = 88,481) we identified diagnoses of AMD up to December 31, 2012 by linkage to statewide hospital discharge records. Aspirin, ibuprofen, other NSAIDs, and acetaminophen use and comprehensive risk factor information were collected via self-administered questionnaires at baseline in 1995-1996 and a follow-up questionnaire in 2005-2006. We employed Cox proportional hazard regression to model AMD risk. Results We did not find any associations between AMD and frequency and duration of aspirin or ibuprofen use reported at baseline. In the subsample with more specific information on medication use, we observed a 20% decrease in risk of AMD among low-dose aspirin users (HR 0.81, 95% CI 0.70-0.95) and a 55% decrease among cyclooxygenase-2 (COX-2) inhibitor users (HR 0.45, 95% CI 0.26-0.78) during 6.3 years of average follow-up. Conclusion The decrease in risk of intermediate- or late-stage AMD among women who reported regular use of low-dose aspirin or specific COX-2 inhibitors suggests a possible protective role for medications with COX-2 inhibitory properties or aspirin at doses used for cardiovascular disease prevention.
C1 [Xu, Xiaoqing; Ritz, Beate; Coleman, Anne L.; Liew, Zeyan; Heck, Julia E.] UCLA, Dept Epidemiol, Fielding Sch Publ Hlth, Los Angeles, CA 90024 USA.
   [Coleman, Anne L.] UCLA, Jules Stein Eye Inst, David Geffen Sch Med, Los Angeles, CA USA.
   [Deapen, Dennis; Lee, Eunjung; Pinder, Rich; Marshall, Sarah F.] Univ Southern Calif, Dept Preventat Med, Keck Sch Med, Los Angeles, CA USA.
   [Bernstein, Leslie] City Hope Natl Med Ctr, Dept Populat Sci, Div Biomarkers Early Detect & Prevent, Los Angeles, CA USA.
   [Bernstein, Leslie] Comprehens Canc Ctr, Los Angeles, CA USA.
   [Heck, Julia E.] Univ North Texas, Coll Hlth & Publ Serv, 1155 Union Circle 311340, Denton, TX 76203 USA.
C3 University of California System; University of California Los Angeles;
   University of California System; University of California Los Angeles;
   University of California Los Angeles Medical Center; David Geffen School
   of Medicine at UCLA; University of Southern California; City of Hope;
   University of North Texas System; University of North Texas Denton
RP Heck, JE (通讯作者)，UCLA, Dept Epidemiol, Fielding Sch Publ Hlth, Los Angeles, CA 90024 USA.; Heck, JE (通讯作者)，Univ North Texas, Coll Hlth & Publ Serv, 1155 Union Circle 311340, Denton, TX 76203 USA.
EM julia.heck@unt.edu
RI ; Heck, Julia/B-5230-2009
OI Lee, Eunjung/0000-0002-8287-6131; Heck, Julia/0000-0001-8713-8413
FU National Cancer Institute of the National Institutes of Health
   [U01-CA199277, P30-CA033572, P30-CA023100, UM1-CA164917, R01-CA077398]
FX The California Teachers Study and the research reported in this
   publication were supported by the National Cancer Institute of the
   National Institutes of Health under award number U01-CA199277;
   P30-CA033572; P30-CA023100; UM1-CA164917; and R01-CA077398. The content
   is solely the responsibility of the authors and does not necessarily
   represent the official views of the National Cancer Institute or the
   National Institutes of Health.
CR Ajani UA, 2006, AM J PREV MED, V30, P74, DOI 10.1016/j.amepre.2005.08.042
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Ayalasomayajula SP, 2003, EUR J PHARMACOL, V458, P283, DOI 10.1016/S0014-2999(02)02793-0
   Bernstein L, 2002, CANCER CAUSE CONTROL, V13, P625, DOI 10.1023/A:1019552126105
   Brown Gary C, 2005, Trans Am Ophthalmol Soc, V103, P173
   Carney RM, 1998, BEHAV MED, V24, P35, DOI 10.1080/08964289809596379
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Christen WG, 2001, ARCH OPHTHALMOL-CHIC, V119, P1143, DOI 10.1001/archopht.119.8.1143
   Christen WG, 2009, OPHTHALMOLOGY, V116, P2386, DOI 10.1016/j.ophtha.2009.05.031
   Cole SR, 2008, AM J EPIDEMIOL, V168, P656, DOI 10.1093/aje/kwn164
   Curhan GC, 2002, PHARMACOEPIDEM DR S, V11, P687, DOI 10.1002/pds.732
   de Jong PTVM, 2012, OPHTHALMOLOGY, V119, P112, DOI 10.1016/j.ophtha.2011.06.025
   Duan L, 2012, FERTIL STERIL, V97, P111, DOI 10.1016/j.fertnstert.2011.10.004
   Halpern MT, 2006, HEALTH CARE FINANC R, V27, P37
   IEZZONI LI, 1992, JAMA-J AM MED ASSOC, V267, P2197, DOI 10.1001/jama.267.16.2197
   Kahawita SK, 2014, CAN J OPHTHALMOL, V49, P35, DOI 10.1016/j.jcjo.2013.07.016
   Keenan TDL, 2015, RETINA-J RET VIT DIS, V35, P2613, DOI 10.1097/IAE.0000000000000651
   Keller DL, 2013, JAMA INTERN MED, V173, P1476, DOI 10.1001/jamainternmed.2013.8147
   Klein BEK, 2012, JAMA-J AM MED ASSOC, V308, P2469, DOI 10.1001/jama.2012.65406
   Klein R, 2001, ARCH OPHTHALMOL-CHIC, V119, P1354
   Liew G, 2013, JAMA INTERN MED, V173, P258, DOI 10.1001/jamainternmed.2013.1583
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Machado FS, 2006, NAT MED, V12, P330, DOI 10.1038/nm1355
   Maloney SC, 2009, RETINA-J RET VIT DIS, V29, P176, DOI 10.1097/IAE.0b013e3181884fa6
   Marshall SF, 2005, JNCI-J NATL CANCER I, V97, P805, DOI 10.1093/jnci/dji140
   Matteson EL., 2015, HOSPITALIZATION RATE
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Nowak JZ, 2014, EXPERT OPIN DRUG SAF, V13, P687, DOI 10.1517/14740338.2014.915939
   O'Connor P J, 1998, Eff Clin Pract, V1, P26
   Pearson TA, 2002, CIRCULATION, V106, P388, DOI 10.1161/01.CIR.0000020190.45892.75
   RIDKER PM, 1991, AM HEART J, V122, P1588, DOI 10.1016/0002-8703(91)90275-M
   Robman L, 2017, CONT CLIN TRIAL COMM, V6, P105, DOI 10.1016/j.conctc.2017.03.005
   Swanson MW, 2008, OPTOMETRY VISION SCI, V85, P947, DOI 10.1097/OPX.0b013e31818883e0
   Velez-Montoya R, 2014, RETINA-J RET VIT DIS, V34, P423, DOI 10.1097/IAE.0000000000000036
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   Wang JJ, 2003, OPHTHALMIC EPIDEMIOL, V10, P37, DOI 10.1076/opep.10.1.37.13776
   Xu XQ, 2020, J HUM HYPERTENS, V34, P568, DOI 10.1038/s41371-019-0269-9
   Ying GS, 2016, OPHTHALMOLOGY, V123, P352, DOI 10.1016/j.ophtha.2015.09.046
   Zell JA, 2009, CANCER-AM CANCER SOC, V115, P5662, DOI 10.1002/cncr.24705
   Zhu W, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058821
NR 41
TC 1
Z9 1
U1 0
U2 2
PU ADIS INT LTD
PI NORTHCOTE
PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
SN 1170-229X
EI 1179-1969
J9 DRUG AGING
JI Drugs Aging
PD SEP
PY 2021
VL 38
IS 9
BP 817
EP 828
DI 10.1007/s40266-021-00885-z
EA JUL 2021
PG 12
WC Geriatrics & Gerontology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology; Pharmacology & Pharmacy
GA UM3HO
UT WOS:000679031500001
PM 34309807
OA Green Accepted, Green Published, Green Submitted, hybrid
DA 2022-11-30
ER

PT J
AU Li, TH
   Hou, XB
   Deng, H
   Zhao, JQ
   Huang, NY
   Zeng, J
   Chen, HX
   Gu, Y
AF Li, Tinghui
   Hou, Xiaobin
   Deng, Hong
   Zhao, Jingquan
   Huang, Naiyan
   Zeng, Jing
   Chen, Hongxia
   Gu, Ying
TI Liposomal hypocrellin B as a potential photosensitizer for age-related
   macular degeneration: pharmacokinetics, photodynamic efficacy, and skin
   phototoxicity in vivo
SO PHOTOCHEMICAL & PHOTOBIOLOGICAL SCIENCES
LA English
DT Article
ID MONOACID RING-A; CHOROIDAL NEOVASCULARIZATION; THERAPY; VERTEPORFIN;
   DERIVATIVES; RANIBIZUMAB; SUBFOVEAL; AFFINITY; TYROSINE; PROGRESS
AB Photodynamic therapy (PDT) has been successfully implemented as a treatment for wet age-related macular degeneration (AMD), but very few photosensitizers have been developed for clinical use. Herein, we describe a novel formulation of liposomal hypocrellin B (LHB) that was prepared by high-pressure homogenization. The encapsulation efficiency and PDT efficacy in vitro of this new preparation were found to remain nearly constant over 1 year. Moreover, LHB is rapidly cleared from the blood, with a half-life of 2.319 +/- 0.462 h and a very low serum concentration at 24 h after injection. Testing in a rat model of choroidal neovascularization (CNV) showed that leakage of blood vessels in CNV lesions was significantly reduced when LHB PDT was given at a dose of 1 mg kg(-1) along with yellow laser irradiation; the damage to the collateral retina and the retinal pigment epithelium was minimal. Skin phototoxicity assays showed that only two of the 200 mice given a 4 mg per kg dose of LHB experienced an inflammatory reaction in the auricle irradiated at 24 h after dosing. These data collectively indicate that LHB may be a safe and effective photosensitizer for vascular-targeted PDT of AMD.
C1 [Li, Tinghui] 309 Hosp PLA, Dept Dermatol, Beijing 100091, Peoples R China.
   [Hou, Xiaobin] Chinese Peoples Liberat Army Gen Hosp, Dept Thorac Surg, Beijing 100853, Peoples R China.
   [Deng, Hong; Zhao, Jingquan] Chinese Acad Sci, Inst Chem, Key Lab Photochem, Beijing Natl Lab Mol Sci, Beijing 100190, Peoples R China.
   [Huang, Naiyan; Zeng, Jing; Chen, Hongxia; Gu, Ying] Chinese Peoples Liberat Army Gen Hosp, Dept Laser Med, Beijing 100853, Peoples R China.
C3 Chinese People's Liberation Army General Hospital; Chinese Academy of
   Sciences; Institute of Chemistry, CAS; Chinese People's Liberation Army
   General Hospital
RP Deng, H (通讯作者)，Chinese Acad Sci, Inst Chem, Key Lab Photochem, Beijing Natl Lab Mol Sci, 1st North St, Beijing 100190, Peoples R China.
EM drlitinghui@163.com; denghong010@iccas.ac.cn; guyinglaser@sina.com
RI zhao, jing/B-3868-2019
FU National Natural Science Foundation of China [21303223]
FX This project was supported by a grant from the National Natural Science
   Foundation of China (no. 21303223).
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Arnold JJ, 2004, AM J OPHTHALMOL, V137, P683, DOI 10.1016/j.ajo.2003.11.059
   AVELINE B, 1994, PHOTOCHEM PHOTOBIOL, V59, P328, DOI 10.1111/j.1751-1097.1994.tb05042.x
   BARSKY SH, 1980, J INVEST DERMATOL, V74, P154, DOI 10.1111/1523-1747.ep12535052
   Bellnier DA, 2006, CANCER CHEMOTH PHARM, V57, P40, DOI 10.1007/s00280-005-0015-6
   Berdugo M, 2008, INVEST OPHTH VIS SCI, V49, P1633, DOI 10.1167/iovs.07-0767
   Bilgin MD, 2005, J PHOTOCH PHOTOBIO B, V80, P107, DOI 10.1016/j.jphotobiol.2005.03.009
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   BRANDL M, 1990, DRUG DEV IND PHARM, V16, P2167, DOI 10.3109/03639049009023648
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Browning DJ, 2012, AM J OPHTHALMOL, V154, P222, DOI 10.1016/j.ajo.2012.04.020
   Chen HX, 2013, LASER PHYS, V23, DOI 10.1088/1054-660X/23/2/025605
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Curtis LH, 2010, ARCH OPHTHALMOL-CHIC, V128, P1273, DOI 10.1001/archophthalmol.2010.223
   Deng H, 2013, DYES PIGMENTS, V99, P930, DOI 10.1016/j.dyepig.2013.06.037
   Deng H, 2012, J MED CHEM, V55, P1910, DOI 10.1021/jm2017368
   Estey EP, 1996, CANCER CHEMOTH PHARM, V37, P343, DOI 10.1007/s002800050395
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   HUANG XD, 1995, ECOTOX ENVIRON SAFE, V32, P194, DOI 10.1006/eesa.1995.1102
   Jiang LJ, 2001, CHINESE SCI BULL, V46, P6, DOI 10.1007/BF03183199
   Jo N, 2006, AM J PATHOL, V168, P2036, DOI 10.2353/ajpath.2006.050588
   Kaihong Z., 1989, CHINESE J ORG CHEM, V9, P252
   Katz B, 2007, DERMATOL THER, V20, P448, DOI 10.1111/j.1529-8019.2007.00160.x
   Khoobehi B, 2002, OPHTHALMIC SURG LAS, V33, P207
   Leung CKS, 2007, OPHTHALMOLOGY, V114, P263, DOI 10.1016/j.ophtha.2006.06.059
   Liu F. G., 2005, CHIN J CLIN REHABILI, V9, P254
   Liu YY, 2008, J PHYS CHEM B, V112, P9959, DOI 10.1021/jp7121467
   Lock JHJ, 2011, CLIN EXP OPTOM, V94, P43, DOI 10.1111/j.1444-0938.2010.00529.x
   MAINSTER MA, 1986, OPHTHALMOLOGY, V93, P952
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Miller GG, 1997, PHOTOCHEM PHOTOBIOL, V65, P714, DOI 10.1111/j.1751-1097.1997.tb01915.x
   Ozdemir H, 2006, AM J OPHTHALMOL, V141, P574, DOI 10.1016/j.ajo.2005.09.031
   Paul BT, 2009, J PHOTOCH PHOTOBIO B, V94, P38, DOI 10.1016/j.jphotobiol.2008.09.007
   Piermarocchi S, 2006, EUR J OPHTHALMOL, V16, P686, DOI 10.1177/112067210601600505
   Stolik S, 2000, J PHOTOCH PHOTOBIO B, V57, P90, DOI 10.1016/S1011-1344(00)00082-8
   SUNDERKOTTER C, 1994, J LEUKOCYTE BIOL, V55, P410, DOI 10.1002/jlb.55.3.410
   Thomas N, 2008, PHOTOCH PHOTOBIO SCI, V7, P433, DOI 10.1039/b718259g
   Tunon J, 2009, SURV OPHTHALMOL, V54, P339, DOI 10.1016/j.survophthal.2009.02.003
   Tzekov R, 2006, INVEST OPHTH VIS SCI, V47, P377, DOI 10.1167/iovs.05-0838
   Varano M, 2014, OPHTHALMOLOGICA, V231, P204, DOI 10.1159/000357504
   WOLFORD ST, 1995, FUND APPL TOXICOL, V24, P52, DOI 10.1006/faat.1995.1007
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Wong TY, 2007, OPHTHALMOLOGY, V114, P86, DOI 10.1016/j.ophtha.2006.06.039
   Xia SQ, 2003, CHEM COMMUN, P2900, DOI 10.1039/b309024h
   Xu SJ, 2003, CHINESE SCI BULL, V48, P1775, DOI 10.1360/03wb0002
   Yano S, 2011, J PHOTOCH PHOTOBIO C, V12, P46, DOI 10.1016/j.jphotochemrev.2011.06.001
   Yu CL, 2001, PHOTOCHEM PHOTOBIOL, V73, P482, DOI 10.1562/0031-8655(2001)073<0482:SSAPAO>2.0.CO;2
   Zacks DN, 2002, INVEST OPHTH VIS SCI, V43, P2384
   Zeng ZH, 2007, J PHYS CHEM B, V111, P3742, DOI 10.1021/jp066301y
   Zhao JQ, 2010, MINI-REV MED CHEM, V10, P332, DOI 10.2174/138955710791330963
   Zhou ZX, 2011, INT J TOXICOL, V30, P174, DOI 10.1177/1091581810394548
   Zhu TC, 2008, MED PHYS, V35, P3127, DOI 10.1118/1.2937440
NR 53
TC 23
Z9 23
U1 4
U2 43
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 1474-905X
EI 1474-9092
J9 PHOTOCH PHOTOBIO SCI
JI Photochem. Photobiol. Sci.
PY 2015
VL 14
IS 5
BP 972
EP 981
DI 10.1039/c4pp00412d
PG 10
WC Biochemistry & Molecular Biology; Biophysics; Chemistry, Physical
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics; Chemistry
GA CH7IF
UT WOS:000354208500013
PM 25793654
DA 2022-11-30
ER

PT J
AU Lad, EM
   Cousins, SW
   Van Arnam, JS
   Proia, AD
AF Lad, Eleonora M.
   Cousins, Scott W.
   Van Arnam, John S.
   Proia, Alan D.
TI Abundance of infiltrating CD163+cells in the retina of postmortem eyes
   with dry and neovascular age-related macular degeneration
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Age related-macular degeneration; Macrophages; Inflammation;
   Histopathology; Postmortem eyes
ID EXPERIMENTAL CHOROIDAL NEOVASCULARIZATION; BRUCHS MEMBRANE; MACROPHAGES;
   MICROGLIA; CELLS
AB Prior research in animal models has suggested that retinal macrophages play an important role in age-related macular degeneration (AMD), but studies have insufficiently characterized the distribution of retinal macrophages in various stages of human AMD.
   In this case series, we analyzed H&E, periodic acid-Schiff, and CD163 and CD68 immunostained slides from 56 formaldehyde-fixed, paraffin-embedded autopsy eyes of patients over age 75: 11 age-matched, normal eyes, and 45 AMD eyes.
   Qualitative analysis of the macula and retinal periphery revealed that all eyes contained a significant number of CD163+ cells but a negligible number of CD68+ cells. In normal eyes and eyes with thin or infrequent basal laminar deposits, CD163+ cells were restricted to the inner retina. In contrast, in AMD eyes with thick basal deposits, choroidal neovascular membranes, and geographic atrophy, qualitatively there was a marked increase in the number and size of the CD163+ cells in the outer retina, sub-retinal, and sub-retinal pigment epithelium space in the macula.
   The changes in number and localization of retinal CD163+ cells in eyes with intermediate-severe AMD support a key role for macrophages in the pathogenesis and progression of the disease. A larger, quantitative study evaluating the distribution of macrophage subpopulations in postmortem AMD eyes is warranted.
C1 [Lad, Eleonora M.; Cousins, Scott W.; Proia, Alan D.] Duke Univ, Med Ctr, Dept Ophthalmol, Durham, NC 27710 USA.
   [Van Arnam, John S.; Proia, Alan D.] Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA.
C3 Duke University; Duke University
RP Lad, EM (通讯作者)，Duke Univ, Med Ctr, Dept Ophthalmol, DUMC 3802, Durham, NC 27710 USA.
EM nora.lad@duke.edu
FU NEI NIH HHS [K12 EY016333] Funding Source: Medline; NATIONAL EYE
   INSTITUTE [K12EY016333] Funding Source: NIH RePORTER
CR Badylak SF, 2008, TISSUE ENG PT A, V14, P1835, DOI 10.1089/ten.tea.2007.0264
   Bronkhorst IHG, 2011, INVEST OPHTH VIS SCI, V52, P643, DOI 10.1167/iovs.10-5979
   Caicedo A, 2005, J COMP NEUROL, V483, P263, DOI 10.1002/cne.20413
   Caicedo A, 2005, EXP EYE RES, V81, P38, DOI 10.1016/j.exer.2005.01.013
   Cao XG, 2011, PATHOL INT, V61, P528, DOI 10.1111/j.1440-1827.2011.02695.x
   Cherepanoff S, 2010, BRIT J OPHTHALMOL, V94, P918, DOI 10.1136/bjo.2009.165563
   Cherepanoff S, 2013, INVEST OPHTH VIS SCI, V54
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   Gupta N, 2003, EXP EYE RES, V76, P463, DOI 10.1016/S0014-4835(02)00332-9
   KILLINGSWORTH MC, 1990, EYE, V4, P613, DOI 10.1038/eye.1990.86
   Kristiansen M, 2001, NATURE, V409, P198, DOI 10.1038/35051594
   Oh H, 1999, INVEST OPHTH VIS SCI, V40, P1891
   Penfold PL, 1995, AUST NZ J OPHTHALMOL, V23, P293, DOI 10.1111/j.1442-9071.1995.tb00179.x
   PENFOLD PL, 1991, VISUAL NEUROSCI, V7, P383, DOI 10.1017/S0952523800004879
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Skeie JM, 2009, EYE, V23, P747, DOI 10.1038/eye.2008.206
   Yang PZ, 2000, OCUL IMMUNOL INFLAMM, V8, P149
NR 17
TC 63
Z9 64
U1 0
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD NOV
PY 2015
VL 253
IS 11
BP 1941
EP 1945
DI 10.1007/s00417-015-3094-z
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CT8IE
UT WOS:000363057900014
PM 26148801
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Bailey-Steinitz, LJ
   Shih, YH
   Radeke, MJ
   Coffey, PJ
AF Bailey-Steinitz, Lindsay J.
   Shih, Ying-Hsuan
   Radeke, Monte J.
   Coffey, Pete J.
TI An in vitro model of chronic wounding and its implication for
   age-related macular degeneration
SO PLOS ONE
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; ENDOTHELIAL GROWTH-FACTOR; GEOGRAPHIC
   ATROPHY; OXIDATIVE STRESS; CELLS; EXPRESSION; SECRETION; CULTURE;
   DRUSEN; INFLAMMATION
AB Degeneration of the retinal pigment epithelium (RPE) plays a central role in age-related macular degeneration (AMD). Throughout life, RPE cells are challenged by a variety of cytotoxic stressors, some of which are cumulative with age and may ultimately contribute to drusen and lipofuscin accumulation. Stressors such as these continually damage RPE cells resulting in a state of chronic wounding. Current cell-based platforms that model a state of chronic RPE cell wounding are limited, and the RPE cellular response is not entirely understood. Here, we used the electric cell-substrate impedance sensing (ECIS) system to induce a state of acute or chronic wounding on differentiated human fetal RPE cells to analyze changes in the wound repair response. RPE cells surrounding the lesioned area employ both cell migration and proliferation to repair wounds but fail to reestablish their original cell morphology or density after repetitive wounding. Chronically wounded RPE cells develop phenotypic AMD characteristics such as loss of cuboidal morphology, enlarged size, and multinucleation. Transcriptomic analysis suggests a systemic misregulation of RPE cell functions in bystander cells, which are not directly adjacent to the wound. Genes associated with the major RPE cell functions (LRAT, MITF, RDH11) significantly downregulate after wounding, in addition to differential expression of genes associated with the cell cycle (CDK1, CDC6, CDC20), inflammation (IL-18, CCL2), and apoptosis (FAS). Interestingly, repetitive wounding resulted in prolonged misregulation of genes, including FAS, LRAT, and PEDF. The use of ECIS to induce wounding resulted in an over-representation of AMD-associated genes among those dysregulated genes, particularly genes associated with advanced AMD. This simple system provides a new model for further investigation of RPE cell wound response in AMD pathogenesis.
C1 [Bailey-Steinitz, Lindsay J.; Shih, Ying-Hsuan; Radeke, Monte J.; Coffey, Pete J.] Univ Calif Santa Barbara, Neurosci Res Inst, Santa Barbara, CA 93106 USA.
   [Bailey-Steinitz, Lindsay J.; Shih, Ying-Hsuan] Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA.
   [Coffey, Pete J.] Univ Calif Santa Barbara, Neurosci Res Inst, Ctr Stem Cell Biol & Engn, Santa Barbara, CA 93106 USA.
   [Coffey, Pete J.] Univ Coll London UCL, Inst Ophthalmol, London Project Cure Blindness, ORBIT, London, England.
   [Coffey, Pete J.] Moorfields Eye Hosp NHS Fdn Trust, NIHR Biomed Res Ctr, UCL Inst Ophthalmol, London, England.
C3 University of California System; University of California Santa Barbara;
   University of California System; University of California Santa Barbara;
   University of California System; University of California Santa Barbara;
   University of London; University College London; University of London;
   University College London; Moorfields Eye Hospital NHS Foundation Trust
RP Bailey-Steinitz, LJ (通讯作者)，Univ Calif Santa Barbara, Neurosci Res Inst, Santa Barbara, CA 93106 USA.; Bailey-Steinitz, LJ (通讯作者)，Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA.
EM ljbailey@ucsb.edu
OI Coffey, Peter/0000-0002-5427-2939; Bailey-Steinitz,
   Lindsay/0000-0003-3696-3047
FU William K. Bowes Jr. Foundation; Garland Initiative for Vision;
   California Institute for Regenerative Medicine [LA1-02086]
FX This work was funded by the William K. Bowes Jr. Foundation, Garland
   Initiative for Vision (www.wkbowesjrfoundation.org), and the California
   Institute for Regenerative Medicine (LA1-02086, PC, www.cirm.ca.gov).The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Al-Hussaini H, 2009, EXP EYE RES, V88, P610, DOI 10.1016/j.exer.2008.09.021
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   ASHBURN FS, 1980, INVEST OPHTH VIS SCI, V19, P1427
   Bhatia SK, 2016, MOL VIS, V22, P898
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bird AC, 2014, JAMA OPHTHALMOL, V132, P338, DOI 10.1001/jamaophthalmol.2013.5799
   Bird AC, 2010, J CLIN INVEST, V120, P3033, DOI 10.1172/JCI42437
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   Bonilha VL, 2008, CLIN OPHTHALMOL, V2, P413
   Casaroli-Marano RP, 1999, INVEST OPHTH VIS SCI, V40, P2062
   Cassidy L, 1998, BRIT J OPHTHALMOL, V82, P181, DOI 10.1136/bjo.82.2.181
   Chen Y, 2007, J BIOL CHEM, V282, P34420, DOI 10.1074/jbc.M611289200
   Chua HL, 2004, HUM IMMUNOL, V65, P317, DOI 10.1016/j.humimm.2004.01.004
   Cramerotti A, 2013, PHOTOCINEMA: THE CREATIVE EDGES OF PHOTOGRAPHY AND FILM, P70
   Daniel E, 2014, OPHTHALMOLOGY, V121, P656, DOI 10.1016/j.ophtha.2013.10.019
   Ding JD, 2011, P NATL ACAD SCI USA, V108, pE279, DOI 10.1073/pnas.1100901108
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337
   Farazdaghi MK, 2019, J OPHTHAL VIS RES, V14, P78, DOI 10.4103/jovr.jovr_125_18
   Fisher Cody R., 2018, INVEST OPHTH VIS SCI, V59, P41, DOI DOI 10.1167/I0VS.18-24289
   Fleckenstein M, 2018, OPHTHALMOLOGY, V125, P369, DOI 10.1016/j.ophtha.2017.08.038
   Frank RN, 1996, AM J OPHTHALMOL, V122, P393, DOI 10.1016/S0002-9394(14)72066-5
   FRIEDMAN AH, 1977, SURV OPHTHALMOL, V21, P375, DOI 10.1016/0039-6257(77)90041-8
   Garcia-Layana A, 2017, CLIN INTERV AGING, V12, P1579, DOI 10.2147/CIA.S142685
   GIAEVER I, 1993, NATURE, V366, P591, DOI 10.1038/366591a0
   Greene WA, 2016, INVEST OPHTH VIS SCI, V57, P4428, DOI 10.1167/iovs.16-19192
   Grunwald JE, 2017, OPHTHALMOLOGY, V124, P97, DOI 10.1016/j.ophtha.2016.09.012
   Hahne M, 1996, EUR J IMMUNOL, V26, P721, DOI 10.1002/eji.1830260332
   Hanus J, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.478
   Hanus J, 2015, AGEING RES REV, V24, P286, DOI 10.1016/j.arr.2015.09.002
   Hirano Y, 2014, NAT MED, V20, P1372, DOI 10.1038/nm.3671
   Hu J, 2001, MOL VIS, V7, P14
   Hu J, 2010, METHODS MOL BIOL, V652, P55, DOI 10.1007/978-1-60327-325-1_2
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Jin ML, 2000, INVEST OPHTH VIS SCI, V41, P4324
   Johnson LV, 2011, P NATL ACAD SCI USA, V108, P18277, DOI 10.1073/pnas.1109703108
   Jonas JB, 2010, ARCH OPHTHALMOL-CHIC, V128, P1281, DOI 10.1001/archophthalmol.2010.227
   Kamei M, 1996, CURR EYE RES, V15, P714
   Kaplan HJ, 1999, NAT MED, V5, P292, DOI 10.1038/6509
   Kaszubski P, 2016, OPHTHALMIC RES, V55, P185, DOI 10.1159/000443209
   Kay P, 2013, J CELL MOL MED, V17, P833, DOI 10.1111/jcmm.12070
   Keese CR, 2004, P NATL ACAD SCI USA, V101, P1554, DOI 10.1073/pnas.0307588100
   Keese CR, 2003, ELECT WOUND HEALING
   Khandhadia S, 2010, EXPERT REV MOL MED, V12, DOI 10.1017/S146239941000164X
   Kim D, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-4-r36
   Kim Y, 2014, P NATL ACAD SCI USA, V111, P16082, DOI 10.1073/pnas.1403814111
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Kutty RK, 2016, MOL VIS, V22, P1156
   Lambert NG, 2016, PROG RETIN EYE RES, V54, P64, DOI 10.1016/j.preteyeres.2016.04.003
   LESCHEY KH, 1990, INVEST OPHTH VIS SCI, V31, P839
   Levy O, 2015, EMBO MOL MED, V7, P211, DOI 10.15252/emmm.201404524
   Longbottom R, 2009, P NATL ACAD SCI USA, V106, P18728, DOI 10.1073/pnas.0902593106
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Luhmann UFO, 2009, INVEST OPHTH VIS SCI, V50, P5934, DOI 10.1167/iovs.09-3462
   Maminishkis A, 2006, INVEST OPHTH VIS SCI, V47, P3612, DOI 10.1167/iovs.05-1622
   Matsumoto H, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.334
   McCarthy DJ, 2012, NUCLEIC ACIDS RES, V40, P4288, DOI 10.1093/nar/gks042
   Newman AM, 2012, GENOME MED, V4, DOI [10.1186/PREACCEPT-1418491035586234, 10.1186/gm315]
   Nita M, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/3164734
   Nivison-Smith L, 2014, OPTOMETRY VISION SCI, V91, P832, DOI 10.1097/OPX.0000000000000281
   Peitzman ER, 2015, AM J PHYSIOL-CELL PH, V309, pC847, DOI 10.1152/ajpcell.00159.2015
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Plafker SM, 2012, INT REV CEL MOL BIO, V298, P135, DOI 10.1016/B978-0-12-394309-5.00004-3
   Qiu FF, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-01119-2
   Radeke MJ, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0183-x
   Ramasamy S, 2014, INT J NANOMED, V9, P5789, DOI 10.2147/IJN.S71128
   Robinson MD, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-3-r25
   Rudnicka AR, 2015, AM J OPHTHALMOL, V160, P85, DOI 10.1016/j.ajo.2015.04.003
   Seddon JM, 2016, JAMA OPHTHALMOL, V134, P1272, DOI 10.1001/jamaophthalmol.2016.3519
   Sennlaub F, 2013, EMBO MOL MED, V5, P1775, DOI 10.1002/emmm.201302692
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   Sparrrow JR, 2010, CURR MOL MED, V10, P802
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Travis GH, 2007, ANNU REV PHARMACOL, V47, P469, DOI 10.1146/annurev.pharmtox.47.120505.105225
   Tsutsumi C, 2003, J LEUKOCYTE BIOL, V74, P25, DOI 10.1189/jlb.0902436
   Volland S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125631
   Wang CH, 2012, BIOCHEM BIOPH RES CO, V425, P33, DOI 10.1016/j.bbrc.2012.07.044
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   Yang DL, 2011, INVEST OPHTH VIS SCI, V52, P6026, DOI 10.1167/iovs.10-7023
   Yang Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep30933
NR 81
TC 1
Z9 1
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 23
PY 2020
VL 15
IS 7
AR e0236298
DI 10.1371/journal.pone.0236298
PG 22
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA NX7VK
UT WOS:000575913700072
PM 32701996
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Heinemann, M
   Welker, SG
   Li, JQ
   Wintergerst, MWM
   Turski, GN
   Turski, CA
   Terheyden, JH
   Mauschitz, MM
   Holz, FG
   Finger, RP
AF Heinemann, Manuel
   Welker, Susanne G.
   Li, Jeany Q.
   Wintergerst, Maximilian W. M.
   Turski, Gabrielle N.
   Turski, Christopher A.
   Terheyden, Jan H.
   Mauschitz, Matthias M.
   Holz, Frank G.
   Finger, Robert P.
TI Impact of visual impairment on physical activity in early and late
   age-related macular degeneration
SO PLOS ONE
LA English
DT Article
ID VISION; ACUITY; LIFE; ASSOCIATIONS; MORTALITY
AB Background
   Modifiable risk factors for age-related macular degeneration (AMD) include smoking, nutrition and likely physical activity (PA). Levels of PA, however, are impacted by any visual impairment which makes the assessment of any association with AMD difficult.
   Purpose
   To assess the impact of visual impairment under both high and low luminance conditions on levels of PA in early and late AMD.
   Methods
   Ninety participants with early to late AMD underwent a clinical assessment including conventional best-corrected visual acuity, low luminance visual acuity, contrast sensitivity and the Moorfields acuity test. PA was recorded using a wrist-worn accelerometer (GENEActiv, Activeinsights) on seven consecutive days. Patient characteristics were compared with the Wilcoxon rank-sum test and determinants of moderate-to-vigorous-PA (MVPA) were assessed using linear regression models.
   Results
   Mean age was 73.9 +/- 8.5 years (range 50-89) and 47 subjects (52.2%) were women. Average MVPA time was longer in the early (355.1 +/- 252.0 minutes/week) compared to the late AMD group (162.2 +/- 134.6 minutes/week; p< 0.001). Using linear regression, age [beta = -0.25; 95% confidence interval (CI): -12.9; -0.8, p = 0.028] and AMD stage (beta = -0.28; 95% CI: -230.9, -25.0; p = 0.015) but not visual impairment on any of the employed tests were associated with MVPA (minutes/week).
   Conclusions
   We found late AMD to be associated with reduced PA. As performance on any of the visual tests was not associated with PA, this association cannot entirely be explained by functional impairment. More research is needed to further explore the association of PA and AMD as PA may be a potentially modifiable risk factor.
C1 [Heinemann, Manuel; Welker, Susanne G.; Li, Jeany Q.; Wintergerst, Maximilian W. M.; Turski, Gabrielle N.; Turski, Christopher A.; Terheyden, Jan H.; Mauschitz, Matthias M.; Holz, Frank G.; Finger, Robert P.] Univ Bonn, Dept Ophthalmol, Ernst Abbe Str, Bonn, Germany.
C3 University of Bonn
RP Finger, RP (通讯作者)，Univ Bonn, Dept Ophthalmol, Ernst Abbe Str, Bonn, Germany.
EM Robert.Finger@ukbonn.de
RI Wintergerst, Maximilian/AAW-2972-2021; Wintergerst,
   Maximilian/E-5523-2019
OI Wintergerst, Maximilian/0000-0002-2766-7038
FU German Scholars Organization/Else Krohner Fresenius Stiftung [GSO/EKFS
   16]; Heidelberg Engineering; Carl Zeiss MediTec; CentreVue; Optos
FX This research was supported by the German Scholars Organization/Else
   Krohner Fresenius Stiftung (GSO/EKFS 16 to RPF). The department received
   financial research support and/or imaging devices from UHeidelberg
   Engineering, Carl Zeiss MediTec, CentreVue, Optos. F.G. Holz has
   received honoraria as a consultant for Heidelberg Engineering, Carl
   Zeiss MedicTec, Allergan, Alcon/Novartis, Genentech/Roche, Bayer,
   Acucela, Boehringer Ingelheim; R.P. Finger has received honoraria as a
   consultant for Bayer, Novartis, Genentech/Roche, Santen, Opthea,
   Novelion, Oxford Innovation, Santhera, Alimera. The specific roles of
   these authors are articulated in the `author contributions' section.The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Adjei NK, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-017-4979-z
   Aune D, 2015, EUR J EPIDEMIOL, V30, P529, DOI 10.1007/s10654-015-0056-z
   Bourne RRA, 2018, BRIT J OPHTHALMOL, V102, P575, DOI 10.1136/bjophthalmol-2017-311258
   Chandramohan A, 2016, RETINA-J RET VIT DIS, V36, P1021, DOI 10.1097/IAE.0000000000001002
   Colijn JM, 2019, OPHTHALMOLOGY, V126, P393, DOI 10.1016/j.ophtha.2018.09.045
   Dillon CB, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0109913
   Dimitrov PN, 2011, INVEST OPHTH VIS SCI, V52, P9457, DOI 10.1167/iovs.10-7043
   ELLIOTT DB, 1990, OPHTHAL PHYSL OPT, V10, P21, DOI 10.1111/j.1475-1313.1990.tb01100.x
   Esliger DW, 2011, MED SCI SPORT EXER, V43, P1085, DOI 10.1249/MSS.0b013e31820513be
   Fenwick EK, 2018, BRIT J OPHTHALMOL, V102, P377, DOI 10.1136/bjophthalmol-2017-310532
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Finger RP, 2011, INVEST OPHTH VIS SCI, V52, P3613, DOI 10.1167/iovs.10-7127
   Gopinath B, 2014, INVEST OPHTH VIS SCI, V55, P7799, DOI 10.1167/iovs.14-15575
   Hamer M, 2014, BRIT J SPORT MED, V48, P239, DOI 10.1136/bjsports-2013-092993
   Hartman SJ, 2018, JMIR MHEALTH UHEALTH, V6, DOI 10.2196/mhealth.8503
   Heinemann M, 2019, OPHTHALMOLOGE, V116, P351, DOI 10.1007/s00347-018-0688-y
   Johnson R, 2017, PUBLIC HEALTH, V146, P118, DOI 10.1016/j.puhe.2017.01.012
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kerr J, 2017, LANCET ONCOL, V18, pE457, DOI 10.1016/S1470-2045(17)30411-4
   Klein R, 2014, OPHTHALMOLOGY, V121, P1220, DOI 10.1016/j.ophtha.2014.01.003
   Knudtson MD, 2006, BRIT J OPHTHALMOL, V90, P1461, DOI 10.1136/bjo.2006.103796
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Loprinzi PD, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125394
   Loprinzi PD, 2014, J PHYS ACT HEALTH, V11, P1156, DOI 10.1123/jpah.2012-0354
   McGuinness MB, 2017, EYE, V31, P1345, DOI 10.1038/eye.2017.139
   Mcguinness MB, 2017, AM J OPHTHALMOL, V180, P29, DOI 10.1016/j.ajo.2017.05.016
   McGuinness MB, 2016, BRIT J OPHTHALMOL, V100, P1353, DOI 10.1136/bjophthalmol-2015-307663
   McMahon EM, 2017, EUR CHILD ADOLES PSY, V26, P111, DOI 10.1007/s00787-016-0875-9
   Munch IC, 2013, INVEST OPHTH VIS SCI, V54, P3932, DOI 10.1167/iovs.12-10785
   Nguyen AM, 2015, BMC GERIATR, V15, DOI 10.1186/s12877-015-0062-8
   PAFFENBARGER RS, 1986, NEW ENGL J MED, V314, P605, DOI 10.1056/NEJM198603063141003
   Raimundo M, 2018, ACTA OPHTHALMOL, V96, pE926, DOI 10.1111/aos.13775
   Rim TH, 2018, JAMA OPHTHALMOL, V136, P132, DOI 10.1001/jamaophthalmol.2017.5682
   Sengupta S, 2015, BMC OPHTHALMOL, V15, DOI 10.1186/1471-2415-15-9
   Shah N, 2016, BRIT J OPHTHALMOL, V100, P1346, DOI 10.1136/bjophthalmol-2015-307375
   Smith W, 1998, AUST NZ J OPHTHALMOL, V26, P203, DOI 10.1111/j.1442-9071.1998.tb01311.x
   Subhi Yousif, 2016, Dan Med J, V63
   Williams PT, 2009, INVEST OPHTH VIS SCI, V50, P101, DOI 10.1167/iovs.08-2165
   Willis JR, 2012, ARCH OPHTHALMOL-CHIC, V130, P329, DOI 10.1001/archopthalmol.2011.1773
   Wu ZC, 2016, BRIT J OPHTHALMOL, V100, P395, DOI 10.1136/bjophthalmol-2015-306621
   Wu ZC, 2015, JAMA OPHTHALMOL, V133, P442, DOI 10.1001/jamaophthalmol.2014.5963
NR 42
TC 4
Z9 4
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 21
PY 2019
VL 14
IS 10
AR e0222045
DI 10.1371/journal.pone.0222045
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA LM9KZ
UT WOS:000532568300002
PM 31634374
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Adams, M
   Ho, CYD
   Baglin, E
   Sharangan, P
   Wu, ZC
   Lawson, DJ
   Luu, CD
   Turpin, A
   McKendrick, AM
   Guymer, RH
AF Adams, Matthew
   Ho, Chi Yun Doreen
   Baglin, Elizabeth
   Sharangan, Pyrawy
   Wu, Zhichao
   Lawson, David J.
   Luu, Chi D.
   Turpin, Andrew
   McKendrick, Allison M.
   Guymer, Robyn H.
TI Home Monitoring of Retinal Sensitivity on a Tablet Device in
   Intermediate Age-Related Macular Degeneration
SO TRANSLATIONAL VISION SCIENCE & TECHNOLOGY
LA English
DT Article
DE iPad; tablet; visual function; microperimetry; age-related macular
   degeneration; home monitoring
ID CONTRAST SENSITIVITY; VISUAL-ACUITY; AMSLER CHART; VIDEO GAMES; SYSTEM;
   IPAD; EYE; SMS
AB Purpose: We determine the feasibility of using a home-based tablet device to monitor retinal sensitivity (RS) in intermediate age-related macular degeneration (iAMD), the benefits of weekly reminders, and the comparison with clinic-based results.
   Methods: A customized test for tablets was designed to measure RS (within central 2 degrees) in individuals with iAMD at weekly intervals in their home, with remote data collection. Half of the participants were randomized to receive weekly test reminders. Clinic-based microperimetric macular sensitivity results were compared to tablet results. Participation rates were analyzed at 2 months.
   Results: Of 38 participants (mean age, 70.3 years) with iAMD enrolled in the study, 21 (55%) were using the tablet-based test at 2 months. Common reasons for inactivity were noncompatible devices (41.1%) or other technology access issues (35.3%). Participants with weekly reminders completed tests more regularly (6.6 +/- 3.9 vs. 8.7 +/- 4.1 days, P = 0.01), but weekly reminders showed no effect on participation rates (P = 0.69). Mean RS from the tablet device (25.03 +/- 2.41 dB) was not significantly different from the clinic-based microperimetry performance (25.21 +/- 2.20 dB; P = 0.58).
   Conclusions: Regular monitoring of retinal function on a tablet device in a home setting in individuals with iAMD is feasible with results comparable to those of clinic-based microperimetry. Weekly reminders resulted in more frequent testing. Seamless ability to access technology will be important for higher participation rates.
   Translational Relevance: The use of home-monitoring on a tablet-device is promising, but adequate support for an older cohort to take up technology is required if such a tool is to be useful for long-term home monitoring.
C1 [Adams, Matthew; Ho, Chi Yun Doreen; Baglin, Elizabeth; Sharangan, Pyrawy; Wu, Zhichao; Luu, Chi D.; Guymer, Robyn H.] Univ Melbourne, Royal Victorian Eye & Ear Hosp, Dept Surg Ophthalmol, Ctr Eye Res Australia, Melbourne, Vic, Australia.
   [Lawson, David J.; Turpin, Andrew] Univ Melbourne, Sch Comp & Informat Syst, Melbourne, Vic, Australia.
   [McKendrick, Allison M.] Univ Melbourne, Dept Optometry & Vis Sci, Melbourne, Vic, Australia.
C3 Centre for Eye Research Australia; Royal Victorian Eye & Ear Hospital;
   University of Melbourne; University of Melbourne; University of
   Melbourne
RP Guymer, RH (通讯作者)，Macular Res Ctr Eye Res Australia, Level 8,32 Gisborne St, East Melbourne, Vic 3002, Australia.
EM rh.guymer@unimelb.edu.au
RI McKendrick, Allison M/A-2114-2008
OI McKendrick, Allison/0000-0003-1972-1222
FU National Health and Medical Research Council [GNT1103013, 1104985];
   Victorian Government
FX Supported by The National Health and Medical Research Council),
   Principal Research Fellowship (GNT1103013) and Early Career Fellowship
   (#1104985, ZW). The Centre for Eye Research Australia (CERA) receives
   Operational Infrastructure Support from the Victorian Government.
CR Aslam TM, 2013, J R SOC INTERFACE, V10, DOI 10.1098/rsif.2013.0239
   Baranowski T, 2008, AM J PREV MED, V34, P74, DOI 10.1016/j.amepre.2007.09.027
   Barnett A, 2011, J PHYS ACT HEALTH, V8, P724, DOI 10.1123/jpah.8.5.724
   Bittner Ava K, 2014, J Clin Exp Ophthalmol, V5, P320
   Bland JM, 2007, J BIOPHARM STAT, V17, P571, DOI 10.1080/10543400701329422
   Bloch SB, 2012, AM J OPHTHALMOL, V153, P209, DOI 10.1016/j.ajo.2011.10.016
   Cervantes-Castaneda RA, 2008, EYE, V22, P777, DOI 10.1038/sj.eye.6702691
   Chew EY, 2014, OPHTHALMOLOGY, V121, P535, DOI 10.1016/j.ophtha.2013.10.027
   Crossland M, 2007, BRIT J OPHTHALMOL, V91, P391, DOI 10.1136/bjo.2006.095315
   Dorr M, 2013, INVEST OPHTH VIS SCI, V54, P7266, DOI 10.1167/iovs.13-11743
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Gamberini L., 2008, J CYBERTHERAPY REHAB, V1, P37
   Hanauer DA, 2009, DIABETES TECHNOL THE, V11, P99, DOI 10.1089/dia.2008.0022
   Ho AC, 2017, JAMA OPHTHALMOL, V135, P268, DOI 10.1001/jamaophthalmol.2016.5314
   Ho CYD, 2018, TRANSL VIS SCI TECHN, V7, DOI 10.1167/tvst.7.2.2
   Kaiser PK, 2013, RETINA-J RET VIT DIS, V33, P1863, DOI 10.1097/IAE.0b013e3182899258
   Khokhar A, 2009, ASIAN PAC J CANCER P, V10, P319
   Kollbaum PS, 2014, OPTOMETRY VISION SCI, V91, P291, DOI 10.1097/OPX.0000000000000158
   Kong YXG, 2016, TRANSL VIS SCI TECHN, V5, DOI 10.1167/tvst.5.6.2
   Lim JH, 2012, AM J OPHTHALMOL, V153, P678, DOI 10.1016/j.ajo.2011.09.013
   Micheletti J Morgan, 2016, J Diabetes Sci Technol, V10, P295, DOI 10.1177/1932296816629158
   Mitchell P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101072
   Ostojic V, 2005, TELEMED J E-HEALTH, V11, P28, DOI 10.1089/tmj.2005.11.28
   Razavi H, 2018, CLIN EXP OPHTHALMOL, V46, P480, DOI 10.1111/ceo.13097
   Sunness JS, 2008, OPHTHALMOLOGY, V115, P1480, DOI 10.1016/j.ophtha.2008.03.009
   Tahir HJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095074
   Team RDC, 2015, LANG ENV STAT COMP
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   Turpin A, 2014, J VISION, V14, DOI 10.1167/14.3.16
   Waldstein SM, 2016, OPHTHALMOLOGY, V123, P1521, DOI 10.1016/j.ophtha.2016.03.037
   Wu ZC, 2015, TRANSL VIS SCI TECHN, V4, DOI 10.1167/tvst.4.3.13
   Zaidi FH, 2004, EYE, V18, P503, DOI 10.1038/sj.eye.6700708
NR 32
TC 9
Z9 9
U1 0
U2 1
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 2164-2591
J9 TRANSL VIS SCI TECHN
JI Transl. Vis. Sci. Technol.
PD SEP
PY 2018
VL 7
IS 5
AR 32
DI 10.1167/tvst.7.5.32
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GZ4WQ
UT WOS:000449410100004
PM 30386684
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Hera, R
   Keramidas, M
   Peoc'h, M
   Mouillon, M
   Romanet, JP
   Feige, JJ
AF Hera, R
   Keramidas, M
   Peoc'h, M
   Mouillon, M
   Romanet, JP
   Feige, JJ
TI Expression of VEGF and angiopoietins in subfoveal membranes from
   patients with age-related macular degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; CHOROIDAL NEOVASCULAR MEMBRANES; DYNAMIC
   BALANCE; AQUEOUS-HUMOR; ANGIOGENESIS; CELLS; EPIDEMIOLOGY; NEUROPILIN-1;
   RETINOPATHY; RECEPTORS
AB PURPOSE: Vascular endothelial growth factor (VEGF) and angiopoietins are key regulators of angiogenesis. The purpose of this study was to measure mRNA levels of these factors and of their receptors in surgically excised subfoveal membranes from patients with age-related macular degeneration (AMD) and to evaluate their relevance as prognostic markers of postsurgical recurrence of choroidal neovascularization (CNV).
   DESIGN: Prospective observational case series.
   METHODS: SETTING: Institutional.
   STUDY POPULATION: In a prospective series of 24 patients (aged 51 to 91 years) with classic CNV of AMD diagnosed less than 6 months previously, 24 subfoveal membranes (one eye per patient) were surgically removed and collected. Thirteen patients underwent treatment for recurrence of CNV within 6 months of surgery.
   MAIN OUTCOME MEASURES: Four 8-IL sections were prepared from each membrane for immunohistochemical determination of vascular density (CD31 immunostaining). The remaining tissue was used for preparation of total RNA. The levels of VEGF-A, VEGF-R1, VEGF-R2, neuropilin-1, angiopoietin-1, angiopoietin-2, Tie-2, and hypoxanthine phos, phoribosyltransferase mRNAs were determined by real-time reverse-transcriptase polymerase chain reaction.
   RESULTS: Vascular endothelial growth factor, angiopoietin-1, and angiopoietin-2 appeared to be expressed to variable levels in most samples, whereas Tie-2, VEGF-R1, and VEGF-R2 were undetectable. Low levels of VEGF expression correlated with postsurgical recurrence of CNV (P = .07). Angiopoietin-1 and angiopoietin-2 levels did not predict recurrence (P > .1).
   CONCLUSION: The results indicate that at the time of surgical excision, subfoveal membranes express angiopoietin-1, VEGF, and, to a lesser degree, angiopoietin-2. Because CNV appears to recur less often in membranes expressing high levels of VEGF, we hypothesize that VEGF acts as a stabilizer of neovessels at this stage of the disease. (Am J Ophthalmol 2005;139:589-596. (c) 2005 by Elsevier Inc. All rights reserved).
C1 CEA G, ANGIO, DRDC, INSERM,EMI 01 05, F-38054 Grenoble, France.
   Univ Hosp Grenoble, Dept Opthalmol, La Tronche, France.
   Univ Hosp Grenoble, Dept Pathol, La Tronche, France.
C3 CEA; Institut National de la Sante et de la Recherche Medicale (Inserm);
   CHU Grenoble Alpes; CHU Grenoble Alpes
RP Feige, JJ (通讯作者)，CEA G, ANGIO, DRDC, INSERM,EMI 01 05, 17 Rue Martyrs, F-38054 Grenoble, France.
EM jifeige@cea.fr
RI Feige, Jean-Jacques/M-8905-2017
OI Feige, Jean-Jacques/0000-0002-1354-7692; Peoc'h,
   michel/0000-0001-5453-0021
CR ADAMIS AP, 1994, AM J OPHTHALMOL, V118, P445, DOI 10.1016/S0002-9394(14)75794-0
   ALON T, 1995, NAT MED, V1, P1024, DOI 10.1038/nm1095-1024
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Benjamin LE, 1998, DEVELOPMENT, V125, P1591
   Davis S, 1999, CURR TOP MICROBIOL, V237, P173
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Frank RN, 1996, AM J OPHTHALMOL, V122, P393, DOI 10.1016/S0002-9394(14)72066-5
   Garrett KL, 2001, J GENE MED, V3, P373, DOI 10.1002/jgm.197
   Gupta K, 1999, EXP CELL RES, V247, P495, DOI 10.1006/excr.1998.4359
   Holash J, 1999, ONCOGENE, V18, P5356, DOI 10.1038/sj.onc.1203035
   Holekamp NM, 2002, AM J OPHTHALMOL, V134, P220, DOI 10.1016/S0002-9394(02)01549-0
   IruelaArispe ML, 1997, THROMB HAEMOSTASIS, V78, P672
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Koyama R, 2003, J CHROMATOGR B, V792, P5, DOI 10.1016/S1570-0232(03)00133-8
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   la Cour M, 2002, DRUG AGING, V19, P101, DOI 10.2165/00002512-200219020-00003
   Lip PL, 2001, OPHTHALMOLOGY, V108, P705, DOI 10.1016/S0161-6420(00)00663-1
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   McLeod DS, 2002, INVEST OPHTH VIS SCI, V43, P1986
   Otani A, 1999, INVEST OPHTH VIS SCI, V40, P1912
   SEDDON J, 2004, CONTROVERSIES ADV TR, P17
   Sheibani N, 2000, BIOCHEM BIOPH RES CO, V267, P257, DOI 10.1006/bbrc.1999.1903
   SHWEIKI D, 1993, J CLIN INVEST, V91, P2235, DOI 10.1172/JCI116450
   Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6
   Soker S, 2002, J CELL BIOCHEM, V85, P357, DOI 10.1002/jcb.10140
   Tripathi RC, 1998, OPHTHALMOLOGY, V105, P232, DOI 10.1016/S0161-6420(98)92782-8
   Upalakalin JN, 2002, COLD SPRING HARB SYM, V67, P181, DOI 10.1101/sqb.2002.67.181
   YOUNG RW, 1988, SURV OPHTHALMOL, V32, P252, DOI 10.1016/0039-6257(88)90174-9
   YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1016/0039-6257(87)90115-9
NR 30
TC 61
Z9 64
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD APR
PY 2005
VL 139
IS 4
BP 589
EP 596
DI 10.1016/j.ajo.2004.11.064
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 914IY
UT WOS:000228222300001
PM 15808152
DA 2022-11-30
ER

PT J
AU Huang, EJC
   Sung, FC
   Hung, PH
   Muo, CH
   Wu, MM
   Yeh, CC
AF Huang, Evelyn-Jou-Chen
   Sung, Fung-Chang
   Hung, Peir-Haur
   Muo, Chih-Hsin
   Wu, Meei-Maan
   Yeh, Chih-Ching
TI The Association of Erythropoietin and Age-Related Macular Degeneration
   in Hemodialysis Patients: A Nationwide Population-Based Cohort Study
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE erythropoietin; age-related macular degeneration; hemodialysis
ID CHRONIC KIDNEY-DISEASE; STAGE RENAL-DISEASE; RISK-FACTORS; EYE DISEASE;
   PROTECTS; RETINA; ANEMIA; CELLS; SERUM
AB This population-based retrospective cohort study investigated the effectiveness of erythropoietin (EPO) treatment in reducing the risk of age-related macular degeneration (AMD) in hemodialysis patients, using the National Health Insurance Research Data of Taiwan. From the database, we identified 147,318 end-stage renal disease (ESRD) patients on hemodialysis who had been diagnosed in 2000-2014 to establish the propensity-score-matched EPO user cohort and non-EPO user cohort with equal sample size of 15,992. By the end of 2016, the cumulative incidence of AMD in EPO users was about 3.29% lower than that in non-EPO users (Kaplan-Meier survival p < 0.0001). The risk of AMD was 43% lower in EPO users than in non-EPO users, with an adjusted hazard ratio (aHR) of 0.57 (95% confidence interval (CI) = 0.51-0.64) estimated in the multivariate Cox model. A significant negative dose-response relationship was identified between the EPO dosage and the risk of AMD (p < 0.0001). Another beneficial effect of EPO treatment was a reduced risk of both exudative AMD (aHR = 0.48, 95% CI = 0.40-0.61) and non-exudative AMD (aHR = 0.61, 95% CI = 0.53-0.69), also in similar dose-response relationships (p < 0.0001). Our findings suggest that EPO treatment for hemodialysis patients could reduce AMD risk in a dose-response relationship.
C1 [Huang, Evelyn-Jou-Chen] Taipei Med Univ Hosp, Dept Ophthalmol, Taipei 110, Taiwan.
   [Huang, Evelyn-Jou-Chen] Taipei Med Univ, Coll Med, Sch Med, Dept Ophthalmol, Taipei 100, Taiwan.
   [Sung, Fung-Chang] China Med Univ, Dept Hlth Serv Adm, Taichung 406, Taiwan.
   [Sung, Fung-Chang; Muo, Chih-Hsin] China Med Univ Hosp, Management Off Hlth Data, Taichung 406, Taiwan.
   [Sung, Fung-Chang] Asia Univ, Dept Food Nutr & Hlth Biotechnol, Taichung 413, Taiwan.
   [Hung, Peir-Haur] Ditmanson Med Fdn Chia Yi Christian Hosp, Dept Internal Med, Chiayi 600, Taiwan.
   [Hung, Peir-Haur] Chia Nan Univ Pharm & Sci, Dept Appl Life Sci & Hlth, Tainan 717, Taiwan.
   [Muo, Chih-Hsin] China Med Univ, Coll Med, Grad Inst Clin Med Sci, Taichung 406, Taiwan.
   [Wu, Meei-Maan] Taipei Med Univ, Coll Med, Sch Med, Dept Publ Hlth, Taipei 110, Taiwan.
   [Wu, Meei-Maan; Yeh, Chih-Ching] Taipei Med Univ, Coll Publ Hlth, Sch Publ Hlth, Taipei 110, Taiwan.
   [Wu, Meei-Maan; Yeh, Chih-Ching] Taipei Med Univ, Coll Publ Hlth, Master Program Appl Epidemiol, Taipei 110, Taiwan.
   [Yeh, Chih-Ching] China Med Univ, Coll Publ Hlth, Dept Publ Hlth, Taichung 406, Taiwan.
   [Yeh, Chih-Ching] Taipei Med Univ, Wan Fang Hosp, Canc Ctr, Taipei 116, Taiwan.
C3 Taipei Medical University; Taipei Medical University Hospital; Taipei
   Medical University; China Medical University Taiwan; China Medical
   University Taiwan; China Medical University Hospital - Taiwan; Asia
   University Taiwan; Chia Nan University of Pharmacy & Science; China
   Medical University Taiwan; Taipei Medical University; Taipei Medical
   University; Taipei Medical University; China Medical University Taiwan;
   Taipei Medical University; Taipei Municipal WanFang Hospital
RP Yeh, CC (通讯作者)，Taipei Med Univ, Coll Publ Hlth, Sch Publ Hlth, Taipei 110, Taiwan.; Yeh, CC (通讯作者)，Taipei Med Univ, Coll Publ Hlth, Master Program Appl Epidemiol, Taipei 110, Taiwan.; Yeh, CC (通讯作者)，China Med Univ, Coll Publ Hlth, Dept Publ Hlth, Taichung 406, Taiwan.; Yeh, CC (通讯作者)，Taipei Med Univ, Wan Fang Hosp, Canc Ctr, Taipei 116, Taiwan.
EM ccyeh@tmu.edu.tw
OI Hung, Peir-Haur/0000-0002-5963-6981; Yeh, Chih-Ching/0000-0001-6483-1100
FU Taiwan Ministry of Health and Welfare Clinical Trial and Research Center
   of Excellence [MOHW109-TDU-B-212-114004]; China Medical University
   Hospital, Academia Sinica Taiwan Biobank Stroke Biosignature Project
   [BM10701010021]; NRPB Stroke Clinical Trial Consortium
   [MOST109-2321-B-039-002]
FX This research was funded by Taiwan Ministry of Health and Welfare
   Clinical Trial and Research Center of Excellence
   (MOHW109-TDU-B-212-114004), China Medical University Hospital, Academia
   Sinica Taiwan Biobank Stroke Biosignature Project (BM10701010021), and
   NRPB Stroke Clinical Trial Consortium (MOST109-2321-B-039-002).
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Artunc F, 2007, NEPHROL DIAL TRANSPL, V22, P2900, DOI 10.1093/ndt/gfm316
   Bretz CA, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.10.23
   Chen L, 2021, FRONT MED-LAUSANNE, V8, DOI 10.3389/fmed.2021.710079
   Choi J, 2011, OPHTHAL EPIDEMIOL, V18, P259, DOI 10.3109/09286586.2011.602509
   Ding SLS, 2016, EYE, V30, P1293, DOI 10.1038/eye.2016.94
   Entezari M, 2014, GRAEF ARCH CLIN EXP, V252, P1309, DOI 10.1007/s00417-014-2691-6
   ESCHBACH JW, 1987, NEW ENGL J MED, V316, P73, DOI 10.1056/NEJM198701083160203
   Fang Y, 2021, EVID-BASED COMPL ALT, V2021, DOI 10.1155/2021/6657521
   Grimm C, 2002, NAT MED, V8, P718, DOI 10.1038/nm723
   Hernandez C, 2006, DIABETES CARE, V29, P2028, DOI 10.2337/dc06-0556
   Hyman Leslie, 2002, Curr Opin Ophthalmol, V13, P171
   Jaquet K, 2002, MICROVASC RES, V64, P326, DOI 10.1006/mvre.2002.2426
   Krishnaiah S, 2005, INVEST OPHTH VIS SCI, V46, P4442, DOI 10.1167/iovs.05-0853
   Lagreze WA, 2009, BRIT J OPHTHALMOL, V93, P1667, DOI 10.1136/bjo.2008.156794
   Li WY, 2010, OPHTHAL SURG LAS IM, V41, P18, DOI 10.3928/15428877-20091230-03
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lipsic E, 2006, CARDIOVASC DRUG THER, V20, P135, DOI 10.1007/s10557-006-7680-5
   Liu CY., 2006, J HLTH MANAGEMENT, V4, P1, DOI DOI 10.29805/JHM.200606.0001
   Maes C, 2012, NAT REV RHEUMATOL, V8, P358, DOI 10.1038/nrrheum.2012.36
   Mercadal L, 2012, CLIN J AM SOC NEPHRO, V7, P35, DOI 10.2215/CJN.04690511
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Modarres M, 2011, BRIT J OPHTHALMOL, V95, P992, DOI 10.1136/bjo.2010.191627
   Nekoui A, 2017, AM J MED SCI, V353, P76, DOI 10.1016/j.amjms.2016.10.009
   Phrommintikul A, 2007, LANCET, V369, P381, DOI 10.1016/S0140-6736(07)60194-9
   Reid G, 2017, VISION RES, V139, P237, DOI 10.1016/j.visres.2017.05.010
   Samson FP, 2020, ACS OMEGA, V5, P21113, DOI 10.1021/acsomega.0c02763
   Semeraro F, 2014, DIABETES METAB, V40, P445, DOI 10.1016/j.diabet.2014.04.005
   Shah Shaival S, 2009, BMC Res Notes, V2, P234, DOI 10.1186/1756-0500-2-234
   Shin HJ, 2014, INT J OPHTHALMOL-CHI, V7, P501, DOI 10.3980/j.issn.2222-3959.2014.03.21
   Sinclair SH, 2014, INVEST OPHTH VIS SCI, V55
   Suk KK, 2008, J AAPOS, V12, P233, DOI 10.1016/j.jaapos.2007.08.009
   Sun CC, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2020-037028
   Tsai DC, 2015, OPHTHALMOLOGY, V122, P2327, DOI 10.1016/j.ophtha.2015.07.033
   Wang IK, 2016, RETINA-J RET VIT DIS, V36, P1866, DOI 10.1097/IAE.0000000000001011
   Wen LY, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0250440
   Wu CM, 2019, ACTA OPHTHALMOL, V97, pE713, DOI 10.1111/aos.14032
   Xie H, 2021, DIABETOLOGIA, V64, P211, DOI 10.1007/s00125-020-05299-x
   Xu GX, 2015, INVEST OPHTH VIS SCI, V56, P8166, DOI 10.1167/iovs.15-18093
   Yeh CC, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13050790
   Zhang CY, 2019, CLIN EXP OPHTHALMOL, V47, P1182, DOI 10.1111/ceo.13619
   Zhang JF, 2008, INVEST OPHTH VIS SCI, V49, P732, DOI 10.1167/iovs.07-0721
NR 42
TC 0
Z9 0
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD SEP
PY 2022
VL 23
IS 17
AR 9634
DI 10.3390/ijms23179634
PG 10
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA 4L3HR
UT WOS:000852522700001
PM 36077032
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Zhang, J
   Liu, ZH
   Hu, SQ
   Qi, J
AF Zhang, Jun
   Liu, Zhaohui
   Hu, Shuqiong
   Qi, Jian
TI Meta-Analysis of the Pharmacogenetics of ARMS2 A69S Polymorphism and the
   Response to Advanced Age-Related Macular Degeneration
SO OPHTHALMIC RESEARCH
LA English
DT Article
DE Age-related macular degeneration; ARMS2; Polymorphism; Anti-vascular
   endothelial growth factor; Meta-analysis
AB Age-related macular degeneration (AMD) causes irreversible vision loss, and targeted anti-vascular endothelial growth factor (VEGF) therapy is now the most common and effective treatment. The aim of this meta-analysis is to discuss whether genetic polymorphism of ARMS2 A69S could confer susceptibility to advanced AMD with the response to anti-VEGF treatment. We performed a meta-analysis of relevant published studies selected through electronic databases. A total of 21 preferred studies regarding the association between ARMS2 gene and anti-VEGF treatment response in advanced AMD were generally included in the meta-analysis. The pooled results demonstrated that the carriage of G allele for ARMS2 A69S presented a better clinical prognosis for advanced AMD treated with anti-VEGF drugs (OR = 1.38, 95% CI = 1.13-1.69, p = 0.002). In addition, in the subgroup analysis based on ethnicity, ARMS2 polymorphisms were more likely to be a positive responder for East Asian patients (OR = 1.67, 95% CI = 1.29-2.16, p < 0.001). This meta-analysis through a series of rigorous methodology data demonstrated a significant association between ARMS2 A69S polymorphism and the anti-VEGF treatment response in advanced AMD, especially among East Asian population. Numerous well-designed, randomized, multicenter clinical trials with large sample size are required to validate the association.
C1 [Zhang, Jun; Liu, Zhaohui; Qi, Jian] Chongqing Med Univ, Affiliated Hosp 1, Chongqing Eye Inst, Chongqing Key Lab Ophthalmol, Chongqing, Peoples R China.
   [Hu, Shuqiong] Jingzhou Aier Eye Hosp, Dept Ophthalmol, Jingzhou, Peoples R China.
   [Qi, Jian] Army Med Univ, Daping Hosp, Dept Ophthalmol, Chongqing, Peoples R China.
C3 Chongqing Medical University; Army Medical University
RP Qi, J (通讯作者)，Chongqing Med Univ, Affiliated Hosp 1, Chongqing Key Lab Ophthalmol, Youyi Rd 1, Chongqing 400016, Peoples R China.; Qi, J (通讯作者)，Chongqing Eye Inst, Youyi Rd 1, Chongqing 400016, Peoples R China.
EM yankeqijian@qq.com
CR Abedi F, 2013, OPHTHALMOLOGY, V120, P1641, DOI 10.1016/j.ophtha.2013.01.014
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Andreoli MT, 2009, AM J OPHTHALMOL, V148, P869, DOI 10.1016/j.ajo.2009.07.002
   Bardak H, 2016, Genet Mol Res, V15, DOI 10.4238/gmr15049164
   Bloch SB, 2012, AM J OPHTHALMOL, V153, P209, DOI 10.1016/j.ajo.2011.10.016
   Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chaudhary V, 2016, OPHTHALMOLOGICA, V236, P88, DOI 10.1159/000446819
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Fang K, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/676049
   Fauser S, 2015, SURV OPHTHALMOL, V60, P138, DOI 10.1016/j.survophthal.2014.11.002
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Hagstrom SA, 2013, OPHTHALMOLOGY, V120, P593, DOI 10.1016/j.ophtha.2012.11.037
   Hata M, 2015, GRAEF ARCH CLIN EXP, V253, P221, DOI 10.1007/s00417-014-2688-1
   Hautamaki A, 2013, RETINA-J RET VIT DIS, V33, P1815, DOI 10.1097/IAE.0b013e318285cf92
   Hu ZZ, 2015, BRIT J OPHTHALMOL, V99, P593, DOI 10.1136/bjophthalmol-2014-305488
   Javitt JC, 2003, OPHTHALMOLOGY, V110, P1534, DOI 10.1016/S0161-6420(03)00495-0
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kanoff J, 2013, SEMIN OPHTHALMOL, V28, P355, DOI 10.3109/08820538.2013.825292
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Kikushima W, 2017, SCI REP-UK, V7, DOI 10.1038/srep44020
   Kitchens JW, 2013, CLIN OPHTHALMOL, V7, P1987, DOI 10.2147/OPTH.S39635
   Kortvely E, 2010, INVEST OPHTH VIS SCI, V51, P79, DOI 10.1167/iovs.09-3850
   Kuroda Y, 2015, OPHTHALMOLOGY, V122, P2303, DOI 10.1016/j.ophtha.2015.06.053
   Liew G, 2007, NEW ENGL J MED, V356, P747
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Lotery AJ, 2013, OPHTHALMOLOGY, V120, P2637, DOI 10.1016/j.ophtha.2013.07.046
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Matsumiya W, 2014, PHARMACOGENOMICS, V15, P833, DOI [10.2217/PGS.14.51, 10.2217/pgs.14.51]
   Mohamad NA, 2019, HUM GENOMICS, V13, DOI 10.1186/s40246-019-0197-3
   Orlin A, 2012, RETINA-J RET VIT DIS, V32, P4, DOI 10.1097/IAE.0b013e31822a2c7c
   Park DH, 2012, RETINA-J RET VIT DIS, V32, P299, DOI 10.1097/IAE.0b013e318225290f
   Park UC, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0631-z
   Park UC, 2014, RETINA-J RET VIT DIS, V34, P288, DOI 10.1097/IAE.0b013e3182979e1e
   Sobrin L, 2011, AM J OPHTHALMOL, V151, P345, DOI 10.1016/j.ajo.2010.08.015
   Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z
   Teper SJ, 2010, MOL VIS, V16, P2598
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   van Asten F, 2014, OPHTHAL EPIDEMIOL, V21, P347, DOI 10.3109/09286586.2014.949010
   Wang GF, 2012, EXP EYE RES, V94, P187, DOI 10.1016/j.exer.2011.11.005
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Yamashiro K, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09632-0
   Yamashiro K, 2012, AM J OPHTHALMOL, V154, P125, DOI 10.1016/j.ajo.2012.01.010
   Zhou YL, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0487-2
NR 46
TC 4
Z9 4
U1 0
U2 4
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3747
EI 1423-0259
J9 OPHTHALMIC RES
JI Ophthalmic Res.
PD MAR
PY 2021
VL 64
IS 2
BP 192
EP 204
DI 10.1159/000508738
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA QU7CX
UT WOS:000627438300004
PM 32428913
OA Bronze
DA 2022-11-30
ER

PT J
AU Sabeti, F
   Maddess, T
   Essex, RW
   James, AC
AF Sabeti, Faran
   Maddess, Ted
   Essex, Rohan W.
   James, Andrew C.
TI Multifocal Pupillography Identifies Ranibizumab-Induced Changes in
   Retinal Function for Exudative Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID VERTEPORFIN PHOTODYNAMIC THERAPY; ENDOTHELIAL GROWTH-FACTOR;
   VISUAL-EVOKED POTENTIALS; RETINITIS-PIGMENTOSA; FIELD DEFECTS;
   PERIMETRY; MEMBRANES; GLAUCOMA; CELLS
AB PURPOSE. To investigate the efficacy of multifocal pupillographic objective perimetry (mfPOP) to quantify the effects of intravitreal ranibizumab injection for choroidal neovascularization (CNV) secondary to exudative age-related macular degeneration (AMD).
   METHODS. mfPOP visual fields from 20 patients with unilateral exudative AMD treated with intravitreal ranibizumab were measured before and after 3 months of treatment and were compared with that in 30 normal subjects. Two stimulus types consisting of ensembles of 24 or 44 independent stimuli per eye had a mean presentation interval at each region of 1 second. Pupil responses were recorded with video cameras under infrared illumination. Multiple linear models were fitted to contraction amplitudes and delay to peak responses, to determine the independent effects of exudative AMD before and after ranibizumab therapy.
   RESULTS. After 3 months of treatment, mean additional response delays compared to normal subjects for the 24-region stimulus improved significantly (P < 5 x 10(-9)) from a mean of 18.82 +/- 3.0 ms at baseline to 7.45 +/- 3.15 ms. The mean effect of exudative AMD at baseline decreased constriction amplitude by -1.11 +/- 0.24 dB (P < 0.00001) with little improvement after ranibizumab therapy. Small pretreatment elevations of extrafoveal sensitivity correlated with improvements in central retinal thickness (CRT) after treatment (P < 0.0005).
   CONCLUSIONS. Improvements in mfPOP contraction amplitudes and time to peak responses were measured in eyes treated with intravitreal ranibizumab; however, response delays appeared to be the most indicative of functional improvement. Confirmation of hypersensitivity in the extrafoveal field in a larger group may support this finding as a prognostic marker for good treatment outcomes. (Invest Ophthalmol Vis Sci. 2012;53:253-260) DOI:10.1167/iovs.11-8004
C1 [Sabeti, Faran; Maddess, Ted; Essex, Rohan W.; James, Andrew C.] Australian Natl Univ, John Curtin Sch Med Res, ARC Ctr Excellence Vis Sci, Canberra, ACT 0200, Australia.
   [Essex, Rohan W.] Australian Natl Univ, Canberra Hosp, Dept Ophthalmol, Canberra, ACT 0200, Australia.
C3 Australian National University; John Curtin School of Medical Research;
   Australian National University; Canberra Hospital
RP Sabeti, F (通讯作者)，Australian Natl Univ, John Curtin Sch Med Res, ARC Ctr Excellence Vis Sci, GPO Box 4, Canberra, ACT 0200, Australia.
EM faran.sabeti@anu.edu.au
RI Sabeti, Faran/AAR-1767-2021; James, Andrew C/C-9307-2009; Maddess, Teddy
   L/A-3200-2008
OI James, Andrew C/0000-0002-2447-8549; Maddess, Teddy
   L/0000-0003-4591-3658; SABETI, Faran/0000-0001-9187-7569; Essex,
   Rohan/0000-0001-5323-0334
FU Australian Research Council (ARC) through the ARC Centre of Excellence
   in Vision Science [CE0561903]; AusIndustry; Seeing Machines, Ltd.,
   Canberra
FX Supported by the Australian Research Council (ARC) through the ARC
   Centre of Excellence in Vision Science (CE0561903), AusIndustry, and
   Seeing Machines, Ltd., Canberra. The sponsor or funding organization had
   no role in the design or conduct of this research.
CR Bell A, 2010, INVEST OPHTH VIS SCI, V51, P602, DOI 10.1167/iovs.09-3659
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Carle CF, 2011, INVEST OPHTH VIS SCI, V52, P604, DOI 10.1167/iovs.10-5737
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Fariss RN, 2000, AM J OPHTHALMOL, V129, P215, DOI 10.1016/S0002-9394(99)00401-8
   Fletcher EL, 1996, J COMP NEUROL, V376, P343
   Frennesson C, ACTA OPHTHALMOL, V88, P420
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Hood DC, 2000, INVEST OPHTH VIS SCI, V41, P1580
   Hood DC, 1998, VISION RES, V38, P163, DOI 10.1016/S0042-6989(97)00143-0
   James AC, 2003, INVEST OPHTH VIS SCI, V44, P879, DOI 10.1167/iovs.02-0608
   James AC, 2005, VISUAL NEUROSCI, V22, P45, DOI 10.1017/S0952523805221053
   James AC, 2011, J GLAUCOMA
   Kiss CG, 2008, BRIT J OPHTHALMOL, V92, P1620, DOI 10.1136/bjo.2007.135335
   Kiss CG, 2009, INVEST OPHTH VIS SCI, V50, P2376, DOI 10.1167/iovs.08-2017
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   LI ZY, 1995, J NEUROSCI, V15, P5429
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Maddess T, 2005, VISUAL NEUROSCI, V22, P153, DOI 10.1017/S0952523805222046
   Maddess T, 2011, INVEST OPHTH VIS SCI, V52, P1014, DOI 10.1167/iovs.10-6014
   Maddess T, 2011, J GLAUCOMA, V20, P336, DOI 10.1097/IJG.0b013e3181efb097
   Maddess T, 2009, CLIN EXP OPHTHALMOL, V37, P678, DOI 10.1111/j.1442-9071.2009.02107.x
   Midena E, 2007, BRIT J OPHTHALMOL, V91, P1499, DOI 10.1136/bjo.2007.119685
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sabeti F, 2011, OPTOMETRY VISION SCI, V88, P1477, DOI 10.1097/OPX.0b013e318235af61
   Sabeti F, 2011, VISION RES, V51, P303, DOI 10.1016/j.visres.2010.10.015
   Tan L, 2001, VISION RES, V41, P1073, DOI 10.1016/S0042-6989(01)00030-X
   Wilhelm H, 2000, INVEST OPHTH VIS SCI, V41, P1229
NR 29
TC 19
Z9 19
U1 0
U2 6
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JAN
PY 2012
VL 53
IS 1
BP 253
EP 260
DI 10.1167/iovs.11-8004
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 924LY
UT WOS:000302694500040
PM 22159011
OA Green Published
DA 2022-11-30
ER

PT J
AU Verdina, T
   Piaggi, S
   Peschiera, R
   Russolillo, V
   Ferraro, V
   Chester, J
   Mastropasqua, R
   Cavallini, GM
AF Verdina, Tommaso
   Piaggi, Stefania
   Peschiera, Riccardo
   Russolillo, Valeria
   Ferraro, Vanessa
   Chester, Johanna
   Mastropasqua, Rodolfo
   Cavallini, Gian Maria
TI Biofeedback Low Vision Rehabilitation with Retimax Vision Trainer in
   Patients with Advanced Age-related Macular Degeneration: A Pilot Study
SO SEMINARS IN OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration (AMD); low vision; biofeedback
   rehabilitation; plasticity of fixation; microperimetry
ID FIXATION; PLASTICITY; SCOTOMA; AMD
AB Purpose To evaluate the effectiveness of Visual Evoked Potential (VEP) biofeedback rehabilitation in selected low vision patients with advanced age-related macular degeneration (AMD). Design Retrospective observational cohort study. Methods Patients affected by advanced AMD, central macular atrophy with unstable fixation and best corrected visual acuity (BCVA) between 20/100 and 20/320 were considered. Selected patients underwent fundus photography and microperimetry with fixation analysis for the selected eye (highest BCVA). Ten consecutive training sessions of 10 min each were performed twice a week in the selected eye with Retimax Vision Trainer (CSO, Florence). BCVA, reading acuity and reading speed, contrast sensitivity, fixation, retinal sensitivity and quality of life questionnaire (VFQ-25) were evaluated at baseline and 7 days following the final session. Results Significant improvements in terms of BCVA [p= .011], reading speed [p= .007], VFQ-25 score [p= .007], retinal sensitivity [p= .021] and fixation stability in the central 2 degrees and 4 degrees [p= .048;p= .037] post-treatment were observed for the 9 patients enrolled, with insignificant improvements observed in reading acuity and contrast sensitivity [p= .335;p= .291]. Conclusions Preliminary results support VEP biofeedback rehabilitation improvements for visual function and quality of life in advanced AMD patients with low vision.
C1 [Verdina, Tommaso; Piaggi, Stefania; Peschiera, Riccardo; Russolillo, Valeria; Ferraro, Vanessa; Mastropasqua, Rodolfo; Cavallini, Gian Maria] Univ Modena & Reggio Emilia, Inst Ophthalmol, Modena, Italy.
   [Chester, Johanna] Univ Modena & Reggio Emilia, Dept Dermatol, Modena, Italy.
C3 Universita di Modena e Reggio Emilia; Universita di Modena e Reggio
   Emilia
RP Verdina, T (通讯作者)，Azienda Osped Univ Modena Policlin, Struttura Complessa Oftalmol, Via Pozzo 71, I-41100 Modena, Italy.
EM tommaso.verdina@gmail.com
RI Mastropasqua, Rodolfo/AAC-6453-2022; Verdina, Tommaso/AAL-5724-2020
OI Verdina, Tommaso/0000-0001-7877-4485; Ferraro,
   Vanessa/0000-0002-5018-1853
CR Amore FM, 2013, CAN J OPHTHALMOL, V48, P431, DOI 10.1016/j.jcjo.2013.07.013
   Andrade MA, 2001, BIOL CYBERN, V84, P445, DOI 10.1007/PL00007988
   [Anonymous], 2001, J AM DENT ASSOC S, V132, p36S, DOI DOI 10.1016/S0002-9394(01)01218-1
   Chiari M, 2014, NEUROPSYCHOL TRENDS, DOI [10.7358/neur-2014-015-chia, DOI 10.7358/NEUR-2014-015-CHIA]
   Daibert-Nido M, 2019, CAN J OPHTHALMOL, V54, P328, DOI 10.1016/j.jcjo.2018.10.016
   Greenstein VC, 2008, RETINA-J RET VIT DIS, V28, P1234, DOI 10.1097/IAE.0b013e31817c1b47
   Hamade N, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159254
   Jaffe GJ, 2019, OPHTHALMOLOGY, V126, P252, DOI 10.1016/j.ophtha.2018.08.035
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   MEZAWA M, 1990, BRIT J OPHTHALMOL, V74, P472, DOI 10.1136/bjo.74.8.472
   Morales MU, 2020, INT OPHTHALMOL, V40, P305, DOI 10.1007/s10792-019-01180-y
   Nilsson UL, 2003, VISION RES, V43, P1777, DOI 10.1016/S0042-6989(03)00219-0
   Rossi GCM, 2003, J GLAUCOMA, V12, P213, DOI 10.1097/00061198-200306000-00006
   Safran A B, 1996, Curr Opin Ophthalmol, V7, P53, DOI 10.1097/00055735-199612000-00009
   Safran AB, 1998, SURV OPHTHALMOL, V42, P449, DOI 10.1016/S0039-6257(97)00134-3
   Schuchard RA, 2005, CAN J OPHTHALMOL, V40, P303, DOI 10.1016/S0008-4182(05)80073-0
   Sunness JS, 1996, OPHTHALMOLOGY, V103, P1458, DOI 10.1016/S0161-6420(96)30483-1
   Tarita-Nistor L, 2009, VISUAL NEUROSCI, V26, P487, DOI 10.1017/S0952523809990265
   Veneruso PE, 2014, DOC OPHTHALMOL, V129, P177, DOI 10.1007/s10633-014-9462-x
   Verdina T, 2017, GRAEF ARCH CLIN EXP, V255, P1307, DOI 10.1007/s00417-017-3637-6
   Verdina T, 2013, EUR J OPHTHALMOL, V23, P723, DOI 10.5301/ejo.5000291
   Vingolo EM, 2007, APPL PSYCHOPHYS BIOF, V32, P185, DOI [10.1007/s10484-007-9038-6, 10.1007/sl0484-007-9038-6]
   Vingolo EM, 2013, APPL PSYCHOPHYS BIOF, V38, P11, DOI 10.1007/s10484-012-9203-4
   Vingolo EM, 2009, APPL PSYCHOPHYS BIOF, V34, P127, DOI 10.1007/s10484-009-9083-4
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 25
TC 1
Z9 1
U1 1
U2 6
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0882-0538
EI 1744-5205
J9 SEMIN OPHTHALMOL
JI Semin. Ophthalmol.
PD APR 2
PY 2020
VL 35
IS 3
BP 164
EP 169
DI 10.1080/08820538.2020.1774624
EA JUN 2020
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA MF5IT
UT WOS:000541999500001
PM 32476579
DA 2022-11-30
ER

PT J
AU Evans, JR
   Lawrenson, JG
AF Evans, Jennifer R.
   Lawrenson, John G.
TI A review of the evidence for dietary interventions in preventing or
   slowing the progression of age-related macular degeneration
SO OPHTHALMIC AND PHYSIOLOGICAL OPTICS
LA English
DT Review
DE Age-Related Eye Disease Study; macular degeneration; omega 3 fatty
   acids; vitamins
ID FATTY-ACIDS; EFFICACY; MULTIVITAMIN; PREVALENCE; SUPPLEMENT; SMOKING;
   DISEASE; HEALTH; TRIAL; RISK
AB Purpose: To summarise the results of recent Cochrane systematic reviews that have investigated whether nutritional supplements prevent or slow the progression of age-related macular degeneration (AMD).
   Recent findings: There is no good evidence from randomised controlled trials that the general population should be taking antioxidant vitamin supplements to reduce their risk of developing AMD later on in life. By contrast, there is moderate quality evidence that people with AMD may experience a delay in progression by taking specific antioxidant vitamin and mineral supplements. This finding is drawn from one large randomised controlled trial conducted in the USA in a relatively well-nourished population. Although observational studies have shown that the consumption of dietary omega 3 long chain polyunsaturated fatty acids may reduce the risk of progression to advanced AMD, two recently published randomised controlled trials failed to show any benefit of omega 3 supplements on AMD progression.
   Summary: There is no high quality experimental evidence that nutritional supplementation is beneficial for the primary prevention of AMD. However, people with AMD may benefit from supplementation with antioxidant vitamins. There is currently no evidence to support increasing levels of omega 3 long chain polyunsaturated fatty acids in the diet for the explicit purpose of preventing or slowing the progression of AMD.
C1 [Evans, Jennifer R.] London Sch Hyg & Trop Med, Int Ctr Eye Hlth, London WC1, England.
   [Lawrenson, John G.] City Univ London, Div Optometry & Visual Sci, London EC1V 0HB, England.
C3 University of London; London School of Hygiene & Tropical Medicine; City
   University London
RP Lawrenson, JG (通讯作者)，City Univ London, Div Optometry & Visual Sci, London EC1V 0HB, England.
EM J.G.Lawrenson@city.ac.uk
RI Evans, Jennifer/F-4672-2012
OI Evans, Jennifer/0000-0002-6137-2030; Lawrenson, John/0000-0002-2031-6390
CR Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group, 1994, N Engl J Med, V330, P1029, DOI 10.1056/NEJM199404143301501
   Bjelakovic G, 2012, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD007176.pub2, 10.1590/1516-3180.20151332T1]
   Bunce C, 2010, EYE LOND, V24, P1692, DOI DOI 10.1038/EYE.2010.122
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P142, DOI 10.1001/jamaophthalmol.2013.7376
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chong EWT, 2009, ARCH OPHTHALMOL-CHIC, V127, P674, DOI 10.1001/archophthalmol.2009.60
   Christen WG, 2014, OPHTHALMOLOGY, V121, P525, DOI 10.1016/j.ophtha.2013.09.038
   Christen WG, 2011, ARCH OPHTHALMOL-CHIC, V129, P921, DOI 10.1001/archophthalmol.2011.34
   Cong RH, 2008, ANN EPIDEMIOL, V18, P647, DOI 10.1016/j.annepidem.2008.04.002
   Cruess AF, 2008, PHARMACOECONOMICS, V26, P57, DOI 10.2165/00019053-200826010-00006
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Evans JR, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000254.pub3
   Evans JR, 2012, COCHRANE DB SYST REV, V6, DOI DOI 10.1002/14651858.CD000253.PUB3
   Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687
   GERSTER H, 1991, AGE AGEING, V20, P60, DOI 10.1093/ageing/20.1.60
   Hodge WG, 2006, OPHTHALMOLOGY, V113, P1165, DOI 10.1016/j.ophtha.2006.02.043
   Huang HY, 2006, ANN INTERN MED, V145, P372, DOI 10.7326/0003-4819-145-5-200609050-00135
   Johnson AR, 2007, J UROLOGY, V177, P639, DOI 10.1016/j.juro.2006.09.047
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kirkham JJ, 2013, TRIALS, V14, DOI 10.1186/1745-6215-14-21
   Kishan AU, 2011, SURV OPHTHALMOL, V56, P195, DOI 10.1016/j.survophthal.2010.08.008
   Lawrenson JG, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-564
   Mares JA, 2011, ARCH OPHTHALMOL-CHIC, V129, P470, DOI 10.1001/archophthalmol.2010.314
   Minassian DR., 2010, EPIDEMIOLOGICAL EC M
   Omenn GS, 2007, EUR J CANCER PREV, V16, P184, DOI 10.1097/01.cej.0000215612.98132.18
   Owen CG, 2012, BRIT J OPHTHALMOL, V96, P752, DOI 10.1136/bjophthalmol-2011-301109
   SanGiovanni JP, 2005, PROG RETIN EYE RES, V24, P87, DOI 10.1016/j.preteyeres.2004.06.002
   Souied EH, 2013, OPHTHALMOLOGY, V120, P1619, DOI 10.1016/j.ophtha.2013.01.005
   Tan JSL, 2009, ARCH OPHTHALMOL-CHIC, V127, P656, DOI 10.1001/archophthalmol.2009.76
   Weikel KA, 2012, MOL ASPECTS MED, V33, P318, DOI 10.1016/j.mam.2012.03.005
NR 30
TC 27
Z9 28
U1 0
U2 22
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0275-5408
EI 1475-1313
J9 OPHTHAL PHYSL OPT
JI Ophthalmic Physiol. Opt.
PD JUL
PY 2014
VL 34
IS 4
SI SI
BP 390
EP 396
DI 10.1111/opo.12142
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AL9UA
UT WOS:000339486100002
PM 24903538
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Kaarniranta, K
   Paananen, J
   Nevalainen, T
   Sorri, I
   Seitsonen, S
   Immonen, I
   Salminen, A
   Pulkkinen, L
   Uusitupa, M
AF Kaarniranta, Kai
   Paananen, Jussi
   Nevalainen, Tanja
   Sorri, Iris
   Seitsonen, Sanna
   Immonen, Ilkka
   Salminen, Antero
   Pulkkinen, Leena
   Uusitupa, Matti
TI Adiponectin receptor 1 gene (ADIPOR1) variant is associated with
   advanced age-related macular degeneration in Finnish population
SO NEUROSCIENCE LETTERS
LA English
DT Article
DE Adiponectin; Aging; Macular degeneration; Polymorphism
ID BODY-MASS INDEX; RISK-FACTORS; ENCODING ADIPONECTIN-RECEPTOR-1;
   CARDIOVASCULAR-DISEASE; INSULIN SENSITIVITY; MACULOPATHY; PROTEIN;
   ATHEROSCLEROSIS; AUTOPHAGY; POLYMORPHISMS
AB Adiponectin is an adipocyte-expressed protein that regulates the glucose, lipid, and energy metabolism via adiponectin receptors 1 and 2. Obesity is a known risk factor for age-related macular degeneration (AMD). We, therefore, examined associations of single nucleotide polymorphisms in Adiponectin (ADIPOQ) and Adiponectin receptors 1 and 2 (ADIPOR1 and ADIPOR2) genes with the prevalence of advanced AMD in Finnish population. Thirty-seven markers for ADIPOQ ADIPOR1 and ADIPOR2 were genotyped in a sample collection of 91 men and 177 women having exudative AMD and 18 men and 26 women having severe atrophic AMD. Patients were diagnosed by fundus photographs and fluorescein angiography. The control group (no signs of AMD in fundus photographs) consisted of 55 men and 111 women. Inclusion criteria age was over 65 years old without diabetes diagnosis. Out of the tested SNPs, rs10753929 located in intron of ADIPOR1 gene was significantly associated (p=0.0471) with AMD status when using a permutation procedure that controlled for the number of tested genotypes and genetic models. Odds ratio (OR) for the association was 1.699 (95% CI 1.192-2.423). The SNP consists of C/T alleles and the risk allele T had a minor allele frequency (MAF) of 20.4%. Distribution of proportion of cases/controls between alleles revealed an additive genetic model. Our findings reveal that rs10753929 ADIPOR1 variant is a novel candidate for AMD genetic risk factor in Finnish population. (c) 2012 Elsevier Ireland Ltd. All rights reserved.
C1 [Kaarniranta, Kai] Univ Eastern Finland, Dept Ophthalmol, Inst Clin Med, Kuopio 70211, Finland.
   [Paananen, Jussi; Pulkkinen, Leena; Uusitupa, Matti] Univ Eastern Finland, Dept Clin Nutr, Sch Publ Hlth & Clin Nutr, Kuopio 70211, Finland.
   [Paananen, Jussi; Pulkkinen, Leena; Uusitupa, Matti] Univ Eastern Finland, Food & Hlth Res Ctr, Sch Publ Hlth & Clin Nutr, Kuopio 70211, Finland.
   [Nevalainen, Tanja] N Karelia Cent Hosp, Dept Ophthalmol, Joensuu, Finland.
   [Kaarniranta, Kai; Sorri, Iris] Kuopio Univ Hosp, Dept Ophthalmol, Kuopio 70211, Finland.
   [Seitsonen, Sanna; Immonen, Ilkka] Helsinki Univ Hosp, Dept Ophthalmol, Helsinki, Finland.
   [Salminen, Antero] Univ Eastern Finland, Dept Neurol, Inst Clin Med, Kuopio 70211, Finland.
   [Salminen, Antero] Kuopio Univ Hosp, Dept Neurol, Kuopio 70211, Finland.
   [Uusitupa, Matti] Kuopio Univ Hosp, Res Unit, Kuopio 70211, Finland.
C3 University of Eastern Finland; University of Eastern Finland; University
   of Eastern Finland; Kuopio University Hospital; University of Eastern
   Finland; University of Helsinki; Helsinki University Central Hospital;
   University of Eastern Finland; Kuopio University Hospital; University of
   Eastern Finland; Kuopio University Hospital; University of Eastern
   Finland
RP Kaarniranta, K (通讯作者)，Univ Eastern Finland, Dept Ophthalmol, Inst Clin Med, POB 1777, Kuopio 70211, Finland.
EM kai.kaarniranta@uef.fi
RI Uusitupa, Matti Ilmari Julius/AAX-4929-2020
OI Kaarniranta, Kai/0000-0003-2600-8679; Paananen,
   Jussi/0000-0001-5100-4907
FU EVO of Kuopio University Hospital [5503726]; Finnish Cultural
   Foundation; North Savo Fund; Finnish Eye Foundation; Finnish Funding
   Agency for Technology and Innovation, Health Research Council of the
   Academy of Finland; Paivikki and Sakari Sohlberg Foundation
FX This work was supported by the EVO grants 5503726 of Kuopio University
   Hospital, the Finnish Cultural Foundation and its North Savo Fund, the
   Finnish Eye Foundation, the Finnish Funding Agency for Technology and
   Innovation, Health Research Council of the Academy of Finland and the
   Paivikki and Sakari Sohlberg Foundation.
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Arita Y, 1999, BIOCHEM BIOPH RES CO, V257, P79, DOI 10.1006/bbrc.1999.0255
   Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   Blasiak J, 2011, FRONT BIOSCI-LANDMRK, V16, P1551, DOI 10.2741/3804
   Chen H, 2003, J BIOL CHEM, V278, P45021, DOI 10.1074/jbc.M307878200
   Choi JK, 2011, ARCH OPHTHALMOL-CHIC, V129, P196, DOI 10.1001/archophthalmol.2010.355
   Cnop M, 2003, DIABETOLOGIA, V46, P459, DOI 10.1007/s00125-003-1074-z
   Damcott CM, 2005, DIABETES, V54, P2245, DOI 10.2337/diabetes.54.7.2245
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   Hirvela H, 1996, OPHTHALMOLOGY, V103, P871, DOI 10.1016/S0161-6420(96)30593-9
   Hotta K, 2000, ARTERIOSCL THROM VAS, V20, P1595, DOI 10.1161/01.ATV.20.6.1595
   Jung CH, 2010, FEBS LETT, V584, P1287, DOI 10.1016/j.febslet.2010.01.017
   Kaarniranta K, 2009, J MOL MED, V87, P117, DOI 10.1007/s00109-008-0418-z
   Kaarniranta K, 2011, J ALZHEIMERS DIS, V24, P615, DOI 10.3233/JAD-2011-101908
   Kaarniranta Kai, 2010, Front Biosci (Elite Ed), V2, P1374
   Kaarniranta K, 2009, AGEING RES REV, V8, P128, DOI 10.1016/j.arr.2009.01.001
   Kantartzis K, 2006, DIABETES CARE, V29, P464, DOI 10.2337/diacare.29.02.06.dc05-2020
   Klein R, 1997, OPHTHALMOLOGY, V104, P1804, DOI 10.1016/S0161-6420(97)30023-2
   Klein R, 2008, AM J OPHTHALMOL, V145, P317, DOI 10.1016/j.ajo.2007.09.008
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   Lau WB, 2011, ANTIOXID REDOX SIGN, V15, P1863, DOI 10.1089/ars.2010.3743
   Menzaghi C, 2007, DIABETES, V56, P1198, DOI 10.2337/db06-0506
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Ouchi N, 1999, CIRCULATION, V100, P2473, DOI 10.1161/01.CIR.100.25.2473
   Paunksnis A, 2005, EUR J OPHTHALMOL, V15, P255, DOI 10.1177/112067210501500213
   Peeters A, 2008, ARCH OPHTHALMOL-CHIC, V126, P1554, DOI 10.1001/archopht.126.11.1554
   Pruim RJ, 2010, BIOINFORMATICS, V26, P2336, DOI 10.1093/bioinformatics/btq419
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Ryhanen T, 2009, J CELL MOL MED, V13, P3616, DOI 10.1111/j.1582-4934.2008.00577.x
   Salminen A, 2009, TRENDS MOL MED, V15, P217, DOI 10.1016/j.molmed.2009.03.004
   Schaumberg DA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1259
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Shibata R, 2004, J BIOL CHEM, V279, P28670, DOI 10.1074/jbc.M402558200
   Siitonen N, 2006, DIABETOLOGIA, V49, P1795, DOI 10.1007/s00125-006-0291-7
   Siitonen N, 2011, BMC MED GENET, V12, DOI 10.1186/1471-2350-12-5
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   Stefan N, 2005, DIABETOLOGIA, V48, P2282, DOI 10.1007/s00125-005-1948-3
   Swarbrick Michael M., 2008, Metabolic Syndrome and Related Disorders, V6, P87, DOI 10.1089/met.2007.0029
   Tolppanen AM, 2009, MOL VIS, V15, P762
   Topouzis F, 2009, BRIT J OPHTHALMOL, V93, P1037, DOI 10.1136/bjo.2008.146316
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
   Viiri J, 2010, MOL VIS, V16, P1399
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   Wang AL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004160
   Yamauchi T, 2002, NAT MED, V8, P1288, DOI 10.1038/nm788
   Yu ZB, 2012, OBESITY, V20, P396, DOI 10.1038/oby.2011.148
   Ziemke F, 2010, AM J CLIN NUTR, V91, p258S, DOI 10.3945/ajcn.2009.28449C
NR 47
TC 27
Z9 29
U1 0
U2 5
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304-3940
EI 1872-7972
J9 NEUROSCI LETT
JI Neurosci. Lett.
PD APR 4
PY 2012
VL 513
IS 2
BP 233
EP 237
DI 10.1016/j.neulet.2012.02.050
PG 5
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 929UD
UT WOS:000303090300027
PM 22387454
DA 2022-11-30
ER

PT J
AU Dong, L
   Qu, Y
   Jiang, H
   Dai, H
   Zhou, F
   Xu, XY
   Bi, HS
   Pan, XM
   Dang, GF
AF Dong, Lun
   Qu, Yi
   Jiang, Hua
   Dai, Hong
   Zhou, Fang
   Xu, Xiaoyi
   Bi, Hongsheng
   Pan, Xuemei
   Dang, Guangfu
TI Correlation of complement factor H gene polymorphisms with exudative
   age-related macular degeneration in a Chinese cohort
SO NEUROSCIENCE LETTERS
LA English
DT Article
DE Age-related macular degeneration; Case-control study; Chinese;
   Complement factor H; Single-nucleotide polymorphism
ID RACIAL-DIFFERENCES; NO ASSOCIATION; PREVALENCE; RISK; VARIANT;
   SUSCEPTIBILITY; INDIVIDUALS; POPULATION; HAPLOTYPE; PROGRESS
AB To evaluate the association between complement factor H (CFH) gene polymorphism and the risk of exudative age-related macular degeneration (AMD) in a case-control study in a Chinese cohort. One hundred and thirty-six exudative AMD patients and 140 age- and sex-matched control subjects were recruited. We genotyped 3 common single nucleotide polymorphisms (SNPs), namely, 257C>T (rs3753394), Y402H (rs1061170) and IVS15 (rs1329428), genetic analyses were performed on all available genotype data. All the possible haplotypes of these 3 SNPs were detected. Polymerase chain reaction (PCR) and allele-specific restriction endonuclease digestion were performed, some PCR products of these 3 SNPs were sequenced. The risk alleles (T, C or G) of the 3 SNPs conferred 1.72-fold, 3.14-fold, and 1.79-fold of increased likelihood of the disease, respectively (P<0.05). The heterozygous genotype in rs1061170 (TC) revealed significant association, meanwhile rs3753394 and rs1329428 had a slight association with the disease, respectively. Significant differences were shown in the risk alleles in the 3 SNPs among different Chinese cohort. Low linkage disequilibrium was found among the 3 SNPs. The haplotypes TCG and CTG revealed as risk factors, whereas the protective haplotype CTA was over-represented in controls. We found significant association between risk alleles (T, C or G) of the 3 SNPs and the disease. The genetic divergence across multiple populations within Chinese existed. Risk haplotypes and protective haplotype were found in this study. (C) 2010 Elsevier Ireland Ltd. All rights reserved.
C1 [Qu, Yi; Jiang, Hua; Zhou, Fang; Xu, Xiaoyi] Shandong Univ, Qilu Hosp, Dept Ophthalmol, Jinan 250012, Shandong, Peoples R China.
   [Dong, Lun] Shandong Univ, Sch Med, Dept Clin Med, Jinan 250012, Shandong, Peoples R China.
   [Dai, Hong] Beijing Hosp, Dept Ophthalmol, Beijing, Peoples R China.
   [Bi, Hongsheng; Pan, Xuemei] Shierming Eye Hosp, Dept Ophthalmol, Jinan, Peoples R China.
   [Dang, Guangfu] Qianfoshan Hosp, Dept Ophthalmol, Jinan, Peoples R China.
C3 Shandong University; Shandong University; Beijing Hospital; Shandong
   First Medical University & Shandong Academy of Medical Sciences
RP Qu, Y (通讯作者)，Shandong Univ, Qilu Hosp, Dept Ophthalmol, 107 Wenhuaxi Rd, Jinan 250012, Shandong, Peoples R China.
EM drquyi@gmail.com
FU Department of Science and Technology of Shandong Province, China
   [Y2008C89, 2009GG10002016, BS2009SW056]
FX The authors thank the patients and the control subjects who participated
   in the study. This research was supported in part by Grants Y2008C89,
   2009GG10002016 and BS2009SW056 from Department of Science and Technology
   of Shandong Province, China.
CR Bressler SB, 2008, ARCH OPHTHALMOL-CHIC, V126, P241, DOI 10.1001/archophthalmol.2007.53
   Chang TS, 1999, CAN J OPHTHALMOL, V34, P266
   Chen LJ, 2006, MOL VIS, V12, P1536
   Chu J, 2008, CHINESE MED J-PEKING, V121, P2525, DOI 10.1097/00029330-200812020-00011
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Friedman DS, 1999, OPHTHALMOLOGY, V106, P1049, DOI 10.1016/S0161-6420(99)90267-1
   Gotoh N, 2006, HUM GENET, V120, P139, DOI 10.1007/s00439-006-0187-0
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jiang H, 2009, RETINA-J RET VIT DIS, V29, P974, DOI 10.1097/IAE.0b013e3181a3b90e
   Johnson PT, 2006, P NATL ACAD SCI USA, V103, P17456, DOI 10.1073/pnas.0606234103
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1376, DOI 10.1016/j.ophtha.2007.11.015
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Lau LI, 2006, INVEST OPHTH VIS SCI, V47, P3242, DOI 10.1167/iovs.05-1532
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   Ng TK, 2008, INVEST OPHTH VIS SCI, V49, P3312, DOI 10.1167/iovs.07-1517
   Okamoto H, 2006, MOL VIS, V12, P156
   Pascolini D, 2004, OPHTHAL EPIDEMIOL, V11, P67, DOI 10.1076/opep.11.2.67.28158
   Uka J, 2006, RETINA-J RET VIT DIS, V26, P985, DOI 10.1097/01.iae.0000244068.18520.3e
   Xu YL, 2008, MOL VIS, V14, P1373
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
NR 28
TC 18
Z9 22
U1 0
U2 4
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304-3940
EI 1872-7972
J9 NEUROSCI LETT
JI Neurosci. Lett.
PD JAN 25
PY 2011
VL 488
IS 3
BP 283
EP 287
DI 10.1016/j.neulet.2010.11.048
PG 5
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 714FN
UT WOS:000286793000014
PM 21111031
DA 2022-11-30
ER

PT J
AU Kaiser, PK
AF Kaiser, P. K.
TI Verteporfin photodynamic therapy and anti-angiogenic drugs: potential
   for combination therapy in exudative age-related macular degeneration
SO CURRENT MEDICAL RESEARCH AND OPINION
LA English
DT Review
DE anecortave acetate; angiogenesis; anti-angiogenic; combination therapy;
   pegaptanib; ranibizumab; verteporfin; Visudyne
ID ENDOTHELIAL GROWTH-FACTOR; EXPERIMENTAL CHOROIDAL NEOVASCULARIZATION;
   FACTOR VEGF; INTRAVITREAL INJECTION; RETINAL NEOVASCULARIZATION; OCULAR
   NEOVASCULARIZATION; VASCULAR-PERMEABILITY; BEVACIZUMAB AVASTIN;
   ANECORTAVE ACETATE; CLINICAL-TRIALS
AB Objective: To discuss the rationale for combining anti-angiogenic treatment with verteporfin (Visudyne*) photodynamic therapy in the management of choroidal neovascularization (CNV) due to age-related macular degeneration (AMD) and evaluate available evidence for the therapeutic benefits of such approaches.
   Scope: The Medline and EMBASE databases were searched in October 2006 to retrieve relevant articles. Additional articles were obtained from the reference lists of retrieved articles, as well as from recent scientific meetings and company websites.
   Findings: Treatments for CNV due to AMD can be directed at either the vascular component of CNV (the new vessels that proliferate and leak blood and fluid) or the angiogenic component that leads to the development of the condition. Verteporfin targets the vascular component, whereas anti-angiogenic agents (such as pegaptanib and ranibizumab) target key mediators of the angiogenic cascade. The different mechanisms of action of these approaches offer the potential for additive or synergistic effects with combination therapy. In addition, anti-angiogenic agents might counteract upregulation of angiogenic factors (including VEGF) that occur after verteporfin photodynamic therapy. Results from preclinical and clinical studies of the combination of ranibizumab or pegaptanib with verteporfin warrant continued investigation.
   Conclusions: The use of anti-angiogenic agents in combination with verteporfin may have the potential to improve visual outcomes and reduce the number of treatments in eyes with CNV due to AMD, and requires further evaluation in randomized, controlled clinical trials.
C1 Cleveland Clin Fdn, Cole Eye Inst, Cleveland, OH 44195 USA.
C3 Cleveland Clinic Foundation
RP Kaiser, PK (通讯作者)，Cleveland Clin Fdn, Cole Eye Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA.
EM pkkaiser@aol.com
OI Kaiser, Peter/0000-0001-5126-045X
CR Adamis AP, 2005, RETINA-J RET VIT DIS, V25, P111, DOI 10.1097/00006982-200502000-00001
   AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Arnold JJ, 2004, AM J OPHTHALMOL, V137, P683, DOI 10.1016/j.ajo.2003.11.059
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   BenEzra D, 1997, INVEST OPHTH VIS SCI, V38, P1954
   Blinder K, 2003, RETINA-J RET VIT DIS, V23, P14
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 2005, RETINA-J RET VIT DIS, V25, P119
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Campochiaro PA, 2006, HUM GENE THER, V17, P167, DOI 10.1089/hum.2006.17.167
   Campochiaro PA, 2004, EXPERT OPIN BIOL TH, V4, P1395, DOI 10.1517/14712598.4.9.1395
   Chakravarthy U, 2006, OPHTHALMOLOGY, V113, P1508, DOI 10.1016/j.ophtha.2006.02.064
   Ciulla TA, 2003, RETINA-J RET VIT DIS, V23, P808, DOI 10.1097/00006982-200312000-00011
   Clark A F, 1997, Expert Opin Investig Drugs, V6, P1867, DOI 10.1517/13543784.6.12.1867
   Clark AF, 1999, INVEST OPHTH VIS SCI, V40, P2158
   CRUM R, 1985, SCIENCE, V230, P1375, DOI 10.1126/science.2416056
   Cursiefen C, 2004, J CLIN INVEST, V113, P1040, DOI 10.1172/JCI200420465
   *EYET PHARM, 2004, AN OPHTH DRUG PROD A
   Fischer S, 2001, EUR J PHARMACOL, V411, P231, DOI 10.1016/S0014-2999(00)00915-8
   Fish G, 2003, OPHTHALMOLOGY, V110, P979, DOI 10.1016/S0161-6420(03)00085-X
   Folkman J, 1997, EXS, V79, P1
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Gremigni E, 2004, EUR J OPHTHALMOL, V14, P555, DOI 10.1177/112067210401400617
   Greve MDJ, 2005, ARCH OPHTHALMOL-CHIC, V123, P448
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   He S, 2003, ARCH OPHTHALMOL-CHIC, V121, P1283, DOI 10.1001/archopht.121.9.1283
   HEIER JS, 2006, OPHTHALMOLOGY, V113
   HEIER JS, IN PRESS ARCH OPHTHA
   Hiromatsu Y, 2003, MICROSC RES TECHNIQ, V60, P64, DOI 10.1002/jemt.10244
   Holekamp NM, 2002, AM J OPHTHALMOL, V134, P220, DOI 10.1016/S0002-9394(02)01549-0
   Husain D, 2005, ARCH OPHTHALMOL-CHIC, V123, P509, DOI 10.1001/archopht.123.4.509
   Ishida S, 2003, J EXP MED, V198, P483, DOI 10.1084/jem.20022027
   Kaiser PK, 2006, GRAEF ARCH CLIN EXP, V244, P1132, DOI 10.1007/s00417-005-0199-9
   Kaiser PK, 2005, CURR MED RES OPIN, V21, P705, DOI 10.1185/030079905X43659
   Keyt BA, 1996, J BIOL CHEM, V271, P7788, DOI 10.1074/jbc.271.13.7788
   Kim IK, 2006, INVEST OPHTH VIS SCI, V47, P357, DOI 10.1167/iovs.04-0087
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   KOROTKIN A, 2006, INVEST OPHTHALMOL VI, V47
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Kwak N, 2000, INVEST OPHTH VIS SCI, V41, P3158
   MALECAZE F, 1994, ARCH OPHTHALMOL-CHIC, V112, P1476, DOI 10.1001/archopht.1994.01090230090028
   Manzano RPA, 2006, RETINA-J RET VIT DIS, V26, P257, DOI 10.1097/00006982-200603000-00001
   McColm J, 2004, MOL VIS, V10, P512
   McNatt LG, 1999, J OCUL PHARMACOL TH, V15, P413, DOI 10.1089/jop.1999.15.413
   Michels S, 2003, INVEST OPHTH VIS SCI, V44, P2147, DOI 10.1167/iovs.02-0604
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Michels S, 2006, INVEST OPHTH VIS SCI, V47, P371, DOI 10.1167/iovs.05-0354
   MIELER WF, 2006, INVEST OPHTHALMOL VI, V47
   Miyamoto K, 2000, AM J PATHOL, V156, P1733, DOI 10.1016/S0002-9440(10)65044-4
   Ng EWM, 2005, CAN J OPHTHALMOL, V40, P352, DOI 10.1016/S0008-4182(05)80078-X
   PARK JE, 1993, MOL BIOL CELL, V4, P1317, DOI 10.1091/mbc.4.12.1317
   PEER J, 1995, LAB INVEST, V72, P638
   Penfold PL, 2000, CLIN EXP IMMUNOL, V121, P458, DOI 10.1046/j.1365-2249.2000.01316.x
   Penfold PL, 2002, INVEST OPHTH VIS SCI, V43, P3125
   Penn JS, 2001, INVEST OPHTH VIS SCI, V42, P283
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P336, DOI 10.3928/1542-8877-20050701-15
   Ruckman J, 1998, J BIOL CHEM, V273, P20556, DOI 10.1074/jbc.273.32.20556
   Russell S, 2003, OPHTHALMOLOGY, V110, P2372, DOI 10.1016/j.ophtha.2003.08.020
   Schmidt-Erfurth U, 2000, SURV OPHTHALMOL, V45, P195, DOI 10.1016/S0039-6257(00)00158-2
   Schmidt-Erfurth U, 2002, ARCH OPHTHALMOL-CHIC, V120, P835
   Schmidt-Erfurth U, 2005, EUR J OPHTHALMOL, V15, P482, DOI 10.1177/112067210501500411
   Schmidt-Erfurth U, 2002, INVEST OPHTH VIS SCI, V43, P830
   Schmidt-Erfurth U, 2003, INVEST OPHTH VIS SCI, V44, P4473, DOI 10.1167/iovs.02-1115
   SCHMIDTERFURTH UM, 2006, INVEST OPHTHALMOL VI, V47
   Schwesinger C, 2001, AM J PATHOL, V158, P1161, DOI 10.1016/S0002-9440(10)64063-1
   Semenza GL, 2000, BIOCHEM PHARMACOL, V59, P47, DOI 10.1016/S0006-2952(99)00292-0
   Shen J, 2006, GENE THER, V13, P225, DOI 10.1038/sj.gt.3302641
   SHIMA DT, 1995, MOL MED, V1, P182, DOI 10.1007/BF03401566
   Shima DT, 1996, J BIOL CHEM, V271, P3877, DOI 10.1074/jbc.271.7.3877
   SINGH RP, 2006, HIGHLIGHTS RETINAL P
   Slakter JS, 2006, OPHTHALMOLOGY, V113, P3, DOI 10.1016/j.ophtha.2005.10.019
   Spaide RF, 2006, AM J OPHTHALMOL, V141, P149, DOI 10.1016/j.ajo.2005.07.025
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Tolentino MJ, 1996, ARCH OPHTHALMOL-CHIC, V114, P964, DOI 10.1001/archopht.1996.01100140172010
   Tolentino MJ, 2002, AM J OPHTHALMOL, V133, P373, DOI 10.1016/S0002-9394(01)01381-2
   *TREATM AG REL MAC, 2004, RETINA, V24, P1
   VANDENBERGH H, 2006, INVEST OPHTHALMOL VI, V47
   Yeh DC, 2004, INVEST OPHTH VIS SCI, V45, P2368, DOI 10.1167/iovs.03-0981
   Yoshida S, 2004, GRAEF ARCH CLIN EXP, V242, P409, DOI 10.1007/s00417-004-0874-2
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zhang SX, 2005, INVEST OPHTH VIS SCI, V46
NR 85
TC 40
Z9 42
U1 1
U2 5
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0300-7995
EI 1473-4877
J9 CURR MED RES OPIN
JI Curr. Med. Res. Opin.
PD MAR
PY 2007
VL 23
IS 3
BP 477
EP 487
DI 10.1185/030079907X167624
PG 11
WC Medicine, General & Internal; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine; Research & Experimental Medicine
GA 147OD
UT WOS:000245011400002
PM 17355729
DA 2022-11-30
ER

PT J
AU Gan, ATL
   Man, REK
   Cheung, CMG
   Kumari, N
   Fenwick, EK
   Sabanayagam, C
   Tham, YC
   Tan, NYQ
   Mitchell, P
   Wong, TY
   Cheng, CY
   Lamoureux, EL
AF Gan, Alfred T. L.
   Man, Ryan E. K.
   Cheung, Chui Ming Gemmy
   Kumari, Neelam
   Fenwick, Eva K.
   Sabanayagam, Charumathi
   Tham, Yih-Chung
   Tan, Nicholas Y. Q.
   Mitchell, Paul
   Wong, Tien Yin
   Cheng, Ching-Yu
   Lamoureux, Ecosse L.
TI Cataract Surgery and the 6-year Incidence of Age-Related Macular
   Degeneration in a Multiethnic Asian Cohort
SO ASIA-PACIFIC JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; Asian and elderly population; cataract
   surgery
ID BEAVER DAM; EYE DISEASES; RISK; MACULOPATHY; EXTRACTION; CLASSIFICATION;
   ASSOCIATION; METHODOLOGY; PREVALENCE; BENEFITS
AB Purpose: The aim of this study was to determine whether cataract surgery was associated with age-related macular degeneration (AMD) development in Asian patients.
   Design: Longitudinal cohort study.
   Methods: Participants from the Singapore Malay and Indian Eye Studies were recruited between 2004 and 2015. A total of 6790 late-AMD-free eyes from 3475 individuals were followed for 6 years on average. Multivariable regression analysis using generalized estimating equations determined associations between cataract surgery and the incidence of any, early, and late AMD.
   Results: The mean age (SD) of participants was 55.5 (9.1) years; 48.1% weremale; 11.3% of eyes had cataract surgery recorded; incident any, early, and late AMD developed in 238 (3.6%), 222 (3.4%), and 29 (0.4%) eyes, respectively. Operated eyes had higher incidence of late AMD [1.4% vs 0.3%; adjusted risk ratio (RR): 3.47, 95% confidence interval (CI) 1.40-8.57], but not earlyAMD(6.0% vs 3.0%, adjusted RR: 1.12, 95% CI 0.76-1.64) or any AMD (6.9 vs 3.2%, adjusted RR: 1.23, 95% CI 0.85-1.78).
   Conclusions: Our data are consistent with findings in population-based Caucasian studies that cataract surgery may be associated with incidence of late AMD. However, the absolute risk of late AMD development remains low and physicians should continue to balance the benefits and risks of cataract surgery in elderly patients.
C1 [Gan, Alfred T. L.; Man, Ryan E. K.; Cheung, Chui Ming Gemmy; Kumari, Neelam; Fenwick, Eva K.; Sabanayagam, Charumathi; Tham, Yih-Chung; Tan, Nicholas Y. Q.; Wong, Tien Yin; Cheng, Ching-Yu; Lamoureux, Ecosse L.] Singapore Natl Eye Ctr, Singapore Eye Res Inst, Singapore, Singapore.
   [Man, Ryan E. K.; Cheung, Chui Ming Gemmy; Fenwick, Eva K.; Sabanayagam, Charumathi; Wong, Tien Yin; Cheng, Ching-Yu; Lamoureux, Ecosse L.] Duke NUS Med Sch, Singapore, Singapore.
   [Cheung, Chui Ming Gemmy; Wong, Tien Yin; Cheng, Ching-Yu; Lamoureux, Ecosse L.] Natl Univ Singapore, Dept Ophthalmol, Singapore, Singapore.
   [Mitchell, Paul] Univ Sydney, Sydney, NSW, Australia.
C3 National University of Singapore; Singapore National Eye Center;
   National University of Singapore; National University of Singapore;
   University of Sydney
RP Lamoureux, EL (通讯作者)，SERI, 20 Coll Rd,Level 6, Singapore 169856, Singapore.
EM ecosse.lamoureux@seri.com.sg
RI Cheng, Ching-Yu/Y-2229-2019; Chung, Yih/AIF-2414-2022; Sabanayagam,
   Charumathi/C-1294-2011; Wong, Tien Yin/AAC-9724-2020
OI Cheng, Ching-Yu/0000-0003-0655-885X; Chung, Yih/0000-0002-6752-797X;
   Sabanayagam, Charumathi/0000-0002-4042-4719; Wong, Tien
   Yin/0000-0002-8448-1264; Man, Ryan/0000-0001-5028-605X; Cheung, Chui
   Ming Gemmy/0000-0003-3358-3516
FU National Medical Research Council [NMRC/0796/2003, NMRC/1249/2010,
   NMRC/CIRG/1371/2013]; Biomedical Research Council [BMRC/08/1/35/19/550]
FX This study was supported by grants from the National Medical Research
   Council (NMRC/0796/2003, NMRC/1249/2010, and NMRC/CIRG/1371/2013) and
   the Biomedical Research Council (BMRC/08/1/35/19/550).
CR [Anonymous], 1991, Ophthalmology, V98, P786
   Banta James T, 2012, Int Ophthalmol Clin, V52, P73, DOI 10.1097/IIO.0b013e31824b3ed3
   Bourne RRA, 2013, LANCET GLOB HEALTH, V1, pE339, DOI 10.1016/S2214-109X(13)70113-X
   Casparis H, 2017, COCHRANE DB SYST REV, V2017
   Chew EY, 2009, OPHTHALMOLOGY, V116, P297, DOI 10.1016/j.ophtha.2008.09.019
   CHEW EY, 2015, INVEST OPHTH VIS SCI, V56
   CHYLACK LT, 1993, ARCH OPHTHALMOL-CHIC, V111, P831, DOI 10.1001/archopht.1993.01090060119035
   Cugati S, 2006, OPHTHALMOLOGY, V113, P2020, DOI 10.1016/j.ophtha.2006.05.047
   Cuthbertson FM, 2009, J CATARACT REFR SURG, V35, P1281, DOI 10.1016/j.jcrs.2009.04.017
   Ehmann DS, 2017, CURR OPIN OPHTHALMOL, V28, P58, DOI 10.1097/ICU.0000000000000331
   Foong AWP, 2007, OPHTHAL EPIDEMIOL, V14, P25, DOI 10.1080/09286580600878844
   Foster PJ, 2002, BRIT J OPHTHALMOL, V86, P238, DOI 10.1136/bjo.86.2.238
   Glazer-Hockstein C, 2006, RETINA-J RET VIT DIS, V26, P1, DOI 10.1097/00006982-200601000-00001
   Ho L, 2008, INVEST OPHTH VIS SCI, V49, P4795, DOI 10.1167/iovs.08-2066
   Kessel L, 2015, ACTA OPHTHALMOL, V93, P593, DOI 10.1111/aos.12665
   Klein BEK, 2012, OPHTHALMOLOGY, V119, P1628, DOI 10.1016/j.ophtha.2012.01.050
   Klein R, 2002, ARCH OPHTHALMOL-CHIC, V120, P1551, DOI 10.1001/archopht.120.11.1551
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Lavanya R, 2009, OPHTHAL EPIDEMIOL, V16, P325, DOI 10.3109/09286580903144738
   Ma YY, 2015, J CATARACT REFR SURG, V41, P1248, DOI 10.1016/j.jcrs.2014.09.046
   Margrain TH, 2004, PROG RETIN EYE RES, V23, P523, DOI 10.1016/j.preteyeres.2004.05.001
   Park SJ, 2016, JAMA OPHTHALMOL, V134, P621, DOI 10.1001/jamaophthalmol.2016.0453
   Patel JI, 2007, CURR OPIN OPHTHALMOL, V18, P9, DOI 10.1097/ICU.0b013e3280112a0f
   Pollack A, 1996, OPHTHALMOLOGY, V103, P1546, DOI 10.1016/S0161-6420(96)30464-8
   Qian CX, 2014, SEMIN OPHTHALMOL, V29, P301, DOI 10.3109/08820538.2014.962166
   Rim TH, 2017, SEMIN OPHTHALMOL, V32, P466, DOI 10.3109/08820538.2015.1119861
   Starr MR, 2018, AM J OPHTHALMOL, V192, P91, DOI 10.1016/j.ajo.2018.05.014
   Stock MV, 2015, INVEST OPHTH VIS SCI, V56, P2536, DOI 10.1167/iovs.14-16069
   Teh BL, 2017, SURV OPHTHALMOL, V62, P346, DOI 10.1016/j.survophthal.2016.12.003
   VANDERSCHAFT TL, 1994, BRIT J OPHTHALMOL, V78, P441, DOI 10.1136/bjo.78.6.441
   Wang JJ, 2016, OPHTHALMOLOGY, V123, P1829, DOI 10.1016/j.ophtha.2016.02.003
   Wang JJ, 2003, OPHTHALMOLOGY, V110, P1960, DOI 10.1016/S0161-6420(03)00816-9
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Wong TY, 2000, BRIT J OPHTHALMOL, V84, P1337, DOI 10.1136/bjo.84.12.1337
   Xu L, 2011, GRAEF ARCH CLIN EXP, V249, P981, DOI 10.1007/s00417-010-1571-y
NR 35
TC 2
Z9 2
U1 0
U2 0
PU ASIA-PACIFIC ACAD OPHTHALMOLOGY-APAO
PI KOWLOON
PA 4-F, HONG KONG EYE HOSP, 147K ARGYLE ST, KOWLOON, KOWLOON, HONG KONG
   00000, PEOPLES R CHINA
EI 2162-0989
J9 ASIA-PAC J OPHTHALMO
JI Asia-Pac. J. Ophthalmol.
PD MAR-APR
PY 2020
VL 9
IS 2
BP 130
EP 136
DI 10.1097/APO.0000000000000275
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA LJ4VB
UT WOS:000530163700012
PM 31996565
OA gold
DA 2022-11-30
ER

PT J
AU Montes, T
   de Jorge, EG
   Ramos, R
   Goma-i-Freixanet, M
   Pujol, O
   Sanchez-Corral, P
   de Cordoba, SR
AF Montes, Tamara
   Goicoechea de Jorge, Elena
   Ramos, Rosa
   Goma-i-Freixanet, Montserrat
   Pujol, Octavi
   Sanchez-Corral, Pilar
   Rodriguez de Cordoba, Santiago
TI Genetic deficiency of complement factor H in a patient with age-related
   macular degeneration and membranoproliferative glomerulonephritis
SO MOLECULAR IMMUNOLOGY
LA English
DT Article
DE complement; alternative pathway; age-related macular degeneration;
   membranoproliferative glomerulonephritis; factor H; human mutation
ID HEMOLYTIC-UREMIC SYNDROME; DENSE DEPOSIT DISEASE; BODY-MASS INDEX;
   ENVIRONMENTAL ASSOCIATIONS; ALTERNATIVE PATHWAY; SUSCEPTIBILITY GENE;
   FACTOR-B; RISK; VARIANT; CFH
AB Age-related macular degeneration (AMD) and membranoproliferative glomerulonephritis type II (MPGN2) are dense deposit diseases that share a genetic association with complement genes and have complement proteins as important components of the dense deposits. Here, we present the case of a 64-year-old smoker male who developed both AMD and MPGN2 in his late 50s. The patient presented persistent low plasma levels of C3, factor H levels in the lower part of the normal range and C3NeF traces. Genetic analyses of the CFH, CFB, C3, CFHR1-CFHR3 and LOC387715/HTRA1 genes revealed that the patient was heterozygote for a novel missense mutation in exon 9 of CFH (c. 1292 G > A) that results in a Cys431Tyr substitution in SCR7 of the factor H protein. In addition, he was homozygote for the His402 CFH allele, heterozygote for the Ser69 LOC387715 allele, homozygote for the Arg32 (BFS) CFB allele, heterozygote for the Gly102 (C3F) C3 allele and carried no deletion of the CFHR1/CFHR3 genes. Proteomic and functional analyses indicate absence in plasma of the factor H allele carrying the Cys431Tyr mutation. As a whole, these data recapitulate a prototypical complement genetic profile, including a partial factor H deficiency and the presence of major risk factors for AMD and MPGN2, which support the hypothesis that these dense deposit diseases have a common pathogenic mechanism involving dysregulation of the alternative pathway of complement activation. (c) 2008 Elsevier Ltd. All rights reserved.
C1 [Montes, Tamara; Goicoechea de Jorge, Elena; Rodriguez de Cordoba, Santiago] Ctr Invest Biol, Madrid 28040, Spain.
   [Montes, Tamara; Goicoechea de Jorge, Elena; Rodriguez de Cordoba, Santiago] Ctr Invest Biomed Enfermedades Raras, Madrid 28040, Spain.
   [Ramos, Rosa; Goma-i-Freixanet, Montserrat; Pujol, Octavi] Bellvitge Hosp, Dept Nefrol, Barcelona 08907, Spain.
   [Ramos, Rosa; Goma-i-Freixanet, Montserrat; Pujol, Octavi] Bellvitge Hosp, Dept Patol, Barcelona 08907, Spain.
   [Ramos, Rosa; Goma-i-Freixanet, Montserrat; Pujol, Octavi] Bellvitge Hosp, Dept Oftalmol, Barcelona 08907, Spain.
   [Sanchez-Corral, Pilar] Hosp Univ La Paz, Unidad Invest, Madrid 28046, Spain.
C3 Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de
   Investigaciones Biologicas (CIB); CIBER - Centro de Investigacion
   Biomedica en Red; CIBERER; Institut d'Investigacio Biomedica de
   Bellvitge (IDIBELL); Bellvitge University Hospital; University of
   Barcelona; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL);
   Bellvitge University Hospital; University of Barcelona; Institut
   d'Investigacio Biomedica de Bellvitge (IDIBELL); Bellvitge University
   Hospital; University of Barcelona; Hospital Universitario La Paz
RP de Cordoba, SR (通讯作者)，Ctr Invest Biol, Ramiro Maeztu 9, Madrid 28040, Spain.
EM SRdeCordoba@cib.csic.es
RI Sánchez-Corral, Pilar/GLR-0387-2022; de Cordoba, Santiago
   Rodriguez/K-6727-2014; de Jorge, Elena Goicoechea/L-4580-2016
OI de Cordoba, Santiago Rodriguez/0000-0001-6401-1874; de Jorge, Elena
   Goicoechea/0000-0002-4978-2483
CR Abrera-Abeleda MA, 2006, J MED GENET, V43, P582, DOI 10.1136/jmg.2005.038315
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Appel GB, 2005, J AM SOC NEPHROL, V16, P1392, DOI 10.1681/ASN.2005010078
   DAHA MR, 1981, IMMUNOLOGY, V43, P33
   de Cordoba SR, 2004, MOL IMMUNOL, V41, P355, DOI 10.1016/j.molimm.2004.02.005
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   de Jorge EG, 2007, P NATL ACAD SCI USA, V104, P240, DOI 10.1073/pnas.0603420103
   DEB C, 2003, AM J KIDNEY DIS, V42, pE2
   DeLano WL., 2002, CCP4 NEWSL PROTEIN C
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Dragon-Durey MA, 2004, J AM SOC NEPHROL, V15, P787, DOI 10.1097/01.ASN.0000115702.28859.A7
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Esparza-Gordillo J, 2004, IMMUNOGENETICS, V56, P77, DOI 10.1007/s00251-004-0660-7
   Framme C, 1998, KLIN MONATSBL AUGENH, V213, P252, DOI 10.1055/s-2008-1034983
   Francis PJ, 2007, HUM HERED, V63, P212, DOI 10.1159/000100046
   Fremeaux-Bacchi V, 2004, J MED GENET, V41, DOI 10.1136/jmg.2004.019083
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   HABIB R, 1975, KIDNEY INT, V7, P204, DOI 10.1038/ki.1975.32
   Hageman GS, 2006, ANN MED, V38, P592, DOI 10.1080/07853890601097030
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hakobyan S, 2007, MOL IMMUNOL, V44, P3951, DOI 10.1016/j.molimm.2007.06.101
   Hegasy GA, 2002, AM J PATHOL, V161, P2027, DOI 10.1016/S0002-9440(10)64481-1
   Hughes AE, 2007, PLOS MED, V4, P1993, DOI 10.1371/journal.pmed.0040355
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   JOH K, 1993, ACTA PATHOL JAPON, V43, P552
   Jokiranta TS, 1999, J IMMUNOL, V163, P4590
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   LEYS A, 1991, PEDIATR NEPHROL, V5, P189, DOI 10.1007/BF01095950
   Licht C, 2006, KIDNEY INT, V70, P42, DOI 10.1038/sj.ki.5000269
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   McAvoy CE, 2005, EYE, V19, P985, DOI 10.1038/sj.eye.6701697
   MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215
   Mullins RF, 2001, EYE, V15, P390, DOI 10.1038/eye.2001.142
   Perez-Caballero D, 2001, AM J HUM GENET, V68, P478, DOI 10.1086/318201
   Pickering MC, 2007, J EXP MED, V204, P1249, DOI 10.1084/jem.20070301
   Rattner A, 2006, NAT REV NEUROSCI, V7, P860, DOI 10.1038/nrn2007
   Richards A, 2003, P NATL ACAD SCI USA, V100, P12966, DOI 10.1073/pnas.2135497100
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Sanchez-Corral P, 2002, AM J HUM GENET, V71, P1285, DOI 10.1086/344515
   Scholl HPN, 2007, MOL VIS, V13, P196
   SCHREIBER RD, 1978, P NATL ACAD SCI USA, V75, P3948, DOI 10.1073/pnas.75.8.3948
   Schwertz R, 2001, PEDIAT ALLERG IMM-UK, V12, P166, DOI 10.1034/j.1399-3038.2001.012003166.x
   Seddon JM, 2006, HUM HERED, V61, P157, DOI 10.1159/000094141
   Smith RJH, 2007, J AM SOC NEPHROL, V18, P2447, DOI 10.1681/ASN.2007030356
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Zipfel PF, 2007, PLOS GENET, V3, P387, DOI 10.1371/journal.pgen.0030041
   Zipfel PF, 2006, MOL IMMUNOL, V43, P97, DOI 10.1016/j.molimm.2005.06.015
NR 51
TC 42
Z9 45
U1 0
U2 4
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0161-5890
J9 MOL IMMUNOL
JI Mol. Immunol.
PD MAY
PY 2008
VL 45
IS 10
BP 2897
EP 2904
DI 10.1016/j.molimm.2008.01.027
PG 8
WC Biochemistry & Molecular Biology; Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Immunology
GA 307KW
UT WOS:000256318800020
PM 18336910
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Wang, X
   Geng, PL
   Zhang, Y
   Zhang, MN
AF Wang, Xin
   Geng, Peiliang
   Zhang, Ying
   Zhang, Maonian
TI Association between complement factor H Val62Ile polymorphism and
   age-related macular degeneration susceptibility: A meta-analysis
SO GENE
LA English
DT Article
DE Age-related macular degeneration; Complement factor H polymorphism;
   Meta-analysis
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; GENOME-WIDE ASSOCIATION; GENE
   POLYMORPHISMS; CFH; RISK; VARIANT; C3; C2; HETEROGENEITY; SUBTYPES
AB Background: An increasing body of studies has assessed the contribution of Val62Ile polymorphism to age-related macular degeneration (AMD) risk, but the exact association still remains uncertain. This meta-analysis was undertaken in order to further characterize the potential association between Val62Ile polymorphism and AMD risk in four different ethnic populations.
   Methods: A meta-analysis was performed using data available from 16 case-control studies evaluating correlation between the Val62Ile polymorphism and AMD in Caucasian, Chinese, Japanese and South Korean populations. Data extraction and study quality assessment were performed in duplicate. Summary odds ratios (ORs) and 95% confidence intervals (Cis) of allele contrast and genotype contrast were estimated using the random-effects model. The Q-statistic test was used to identify heterogeneity, and the funnel plot was adopted to evaluate publication bias.
   Results: Sixteen studies involving a total of 11,400 subjects based on the search criteria were included in the meta-analysis. In overall populations, the Val62Ile polymorphism seemed to be associated with AMD (ORAA vs. GG = 0.40, 95% CI = 0.28-0.59; ORAA (+ GA vs. GG) = 0.72, 95% CI = 0.64-0.80; ORAA vs. GC (+) (GG) = 0.50, 95% CI = 0.36-0.70; ORA vs. (G) = 0.68, 95% CI = 0.58-0.78; ORGA vs. GG = 0.71, 95% CI = 0.65-0.77). Similarly, subgroup analysis also revealed that this polymorphism was related to AMD in all ethnicities.
   Conclusions: This meta-analysis suggested that Val62Ile polymorphism was associated with susceptibility to AMD. (C) 2014 Elsevier B.V. All rights reserved.
C1 [Wang, Xin; Zhang, Ying; Zhang, Maonian] Chinese Peoples Liberat Army Gen Hosp, Dept Ophthalmol, Beijing 100853, Peoples R China.
   [Wang, Xin; Geng, Peiliang; Zhang, Ying; Zhang, Maonian] Chinese PLA Med Sch, Beijing 100853, Peoples R China.
   [Wang, Xin] 306th Hosp Chinese PLA, Dept Ophthalmol, Beijing 100101, Peoples R China.
   [Geng, Peiliang] Chinese Peoples Liberat Army Gen Hosp, Div Internal Med, Ctr Canc, Inst Oncol,Key Lab Oncol, Beijing 100853, Peoples R China.
C3 Chinese People's Liberation Army General Hospital; Chinese People's
   Liberation Army General Hospital
RP Zhang, MN (通讯作者)，Chinese Peoples Liberat Army Gen Hosp, Dept Ophthalmol, 28 Fuxing Rd, Beijing 100853, Peoples R China.
EM zmn301@sina.com
CR Arakawa S, 2011, NAT GENET, V43, P1001, DOI 10.1038/ng.938
   Bergeron-Sawitzke J, 2009, EUR J HUM GENET, V17, P1190, DOI 10.1038/ejhg.2009.23
   Bhopal R, 2004, J EPIDEMIOL COMMUN H, V58, P441, DOI 10.1136/jech.2003.013466
   Burchard EG, 2003, NEW ENGL J MED, V348, P1170, DOI 10.1056/NEJMsb025007
   Chen LJ, 2006, MOL VIS, V12, P1536
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Egger M, 1997, BMJ-BRIT MED J, V315, P1533, DOI 10.1136/bmj.315.7121.1533
   Fuse N, 2006, AM J OPHTHALMOL, V142, P1074, DOI 10.1016/j.ajo.2006.07.030
   Goto Asako, 2009, J Ocul Biol Dis Infor, V2, P164
   Gotoh N, 2006, HUM GENET, V120, P139, DOI 10.1007/s00439-006-0187-0
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hayashi H, 2010, INVEST OPHTH VIS SCI, V51, P5914, DOI 10.1167/iovs.10-5554
   Hecker LA, 2010, HUM MOL GENET, V19, P209, DOI 10.1093/hmg/ddp472
   Heurich M, 2011, P NATL ACAD SCI USA, V108, P8761, DOI 10.1073/pnas.1019338108
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Ioannidis JPA, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000841
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kim NR, 2008, INVEST OPHTH VIS SCI, V49, P2071, DOI 10.1167/iovs.07-1195
   Kim SJ, 2012, EXP EYE RES, V96, P42, DOI 10.1016/j.exer.2012.01.005
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Lee KY, 2008, INVEST OPHTH VIS SCI, V49, P2613, DOI 10.1167/iovs.07-0860
   Lima LH, 2010, OPHTHALMOLOGY, V117, P1567, DOI 10.1016/j.ophtha.2009.12.018
   Liu XQ, 2010, RETINA-J RET VIT DIS, V30, P1177, DOI 10.1097/IAE.0b013e3181cea676
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   Mori K, 2007, INVEST OPHTH VIS SCI, V48, P5315, DOI 10.1167/iovs.07-0426
   Nakata I, 2012, INVEST OPHTH VIS SCI, V53, P794, DOI 10.1167/iovs.11-8468
   Sivakumaran TA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025598
   Stuck AE, 1998, BRIT MED J, V316, P469, DOI 10.1136/bmj.316.7129.469
   Tanaka K, 2011, MOL VIS, V17, P2751
   Tanaka K, 2011, INVEST OPHTH VIS SCI, V52, P7441, DOI 10.1167/iovs.11-7546
   Tortajada A, 2009, HUM MOL GENET, V18, P3452, DOI 10.1093/hmg/ddp289
   Tsuchihashi T, 2011, OPHTHALMOLOGY, V118, P93, DOI 10.1016/j.ophtha.2010.04.007
   Xing C, 2008, GENES IMMUN, V9, P231, DOI 10.1038/gene.2008.10
   Yachimski P, 2009, GASTROINTEST ENDOSC, V69, P205, DOI 10.1016/j.gie.2008.05.032
   Yang X, 2010, BRIT J OPHTHALMOL, V94, P1211, DOI 10.1136/bjo.2009.165811
   Yuan DQ, 2013, MOL VIS, V19, P374
NR 39
TC 4
Z9 4
U1 0
U2 5
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-1119
EI 1879-0038
J9 GENE
JI Gene
PD APR 1
PY 2014
VL 538
IS 2
BP 306
EP 312
DI 10.1016/j.gene.2014.01.032
PG 7
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA AE2FP
UT WOS:000333789000013
PM 24440287
DA 2022-11-30
ER

PT J
AU Cagini, C
   Giordanelli, A
   Fiore, T
   Giardinieri, R
   Malici, B
   De Medio, GE
   Pelli, MA
   De Bellis, F
   Capodicasa, E
AF Cagini, C.
   Giordanelli, A.
   Fiore, T.
   Giardinieri, R.
   Malici, B.
   De Medio, G. E.
   Pelli, M. A.
   De Bellis, F.
   Capodicasa, E.
TI Study of Ethane Level in Exhaled Breath in Patients with Age-Related
   Macular Degeneration: Preliminary Study
SO OPHTHALMIC RESEARCH
LA English
DT Article
DE Age-related macular degeneration; Oxidative stress; Breath ethane
ID LIPID-PEROXIDATION
AB Purpose: A variety of factors have been implicated in the pathogenesis of age-related macular degeneration (ARMD), and oxidative stress plays an important role in the onset and progression of the disease. Breath ethane is now considered a specific and non-invasive test for determining and monitoring the trend of lipid peroxidation and free radical-induced damage in vivo. This test provides an index of the patients' overall oxidative stress level. We evaluated the breath ethane concentration in exhaled air in patients with advanced ARMD. Methods: In this study, we enrolled 13 patients with advanced ARMD and a control group, and a breath analysis was carried out by gas chromatography. Results: The mean ethane level in the ARMD patients was 0.82 +/- 0.93 nmol/l (range: 0.01-2.7 nmol/l) and the mean ethane value in the control group was 0.12 +/- 0.02 nmol/l (range: 0.08-0.16 nmol/l). The difference between the values of the 2 groups was statistically significant (p < 0.005). Receiver operating characteristic analysis showed an elevated area under the curve (0.831; 95% CI: 0.634-0.948), with a significance level of p < 0.0014 (area = 0.5). Conclusions: These preliminary results seem to indicate that breath ethane levels are higher in most patients with ARMD. The breath ethane test could thus be a useful method for evaluating the level of oxidative stress in patients with ARMD. To our knowledge, there are no data on this type of analysis applied to ARMD. Copyright (C) 2011 S. Karger AG, Basel
C1 [Cagini, C.; Giordanelli, A.; Fiore, T.; Giardinieri, R.; Malici, B.] Univ Perugia, Dept Ophthalmol, I-06100 Perugia, Italy.
   [De Medio, G. E.] Univ Perugia, Dept Internal Med, I-06100 Perugia, Italy.
   [Pelli, M. A.] Univ Perugia, Dept Medicosurg Specialisat & Publ Hlth, I-06100 Perugia, Italy.
   [Capodicasa, E.] Univ Perugia, Dept Clin & Expt Med, I-06100 Perugia, Italy.
   [De Bellis, F.] Univ Perugia, Dept Emergency & Acceptance, I-06100 Perugia, Italy.
C3 University of Perugia; University of Perugia; University of Perugia;
   University of Perugia; University of Perugia
RP Cagini, C (通讯作者)，Osped S Maria Misericordia, Dept Ophthalmol, IT-06156 Perugia, Italy.
EM carlocagini@hotmail.com
RI Cagini, Carlo/L-2914-2016; Cagini, Carlo/H-3431-2019
OI Cagini, Carlo/0000-0002-3812-9219; Cagini, Carlo/0000-0002-3812-9219
CR Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Capodicasa E, 1999, NEPHRON, V82, P331, DOI 10.1159/000045448
   JEEJEEBHOY KN, 1991, FREE RADICAL BIO MED, V10, P191, DOI 10.1016/0891-5849(91)90075-E
   KNEEPKENS CMF, 1994, FREE RADICAL BIO MED, V17, P127
   Miekisch W, 2004, CLIN CHIM ACTA, V347, P25, DOI 10.1016/j.cccn.2004.04.023
   Scholpp J, 2002, CLIN CHEM LAB MED, V40, P587, DOI 10.1515/CCLM.2002.101
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   Wickremasinghe SS, 2009, EXPERT REV OPHTHALMO, V4, P79, DOI 10.1586/17469899.4.1.79
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 9
TC 1
Z9 1
U1 0
U2 12
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3747
J9 OPHTHALMIC RES
JI Ophthalmic Res.
PY 2011
VL 46
IS 3
BP 141
EP 144
DI 10.1159/000324198
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 824PW
UT WOS:000295215400005
PM 21336004
DA 2022-11-30
ER

PT J
AU Patel, PJ
   Browning, AC
   Chen, FK
   Da Cruz, L
   Tufail, A
AF Patel, Praveen J.
   Browning, Andrew C.
   Chen, Fred K.
   Da Cruz, Lyndon
   Tufail, Adnan
TI Interobserver Agreement for the Detection of Optical Coherence
   Tomography Features of Neovascular Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID RANIBIZUMAB
AB PURPOSE. To investigate the interobserver agreement for the detection of optical coherence tomography (OCT) features of disease activity in patients with neovascular age-related macular degeneration (nAMD).
   METHODS. This was a cross-sectional agreement study in which grading of OCT line scans from patients with nAMD was conducted by two retinal specialists before the patients received treatment. Scans were graded for the presence of features of nAMD disease activity (intraretinal cysts [IRC], subretinal fluid [SRF], diffuse retinal edema [DRE], retinal pigment epithelial detachment [PED], and subretinal tissue [SRT]).
   RESULTS. Although scans from 78 patients were available for analysis, five patients were excluded because of a mean signal strength of <7. Two hundred seventy-eight line scans were analyzed from 73 patients (40 with cross-hair scan sets and 33 with radial line scan sets). Agreement for per line scan analysis was 77% for IRC (kappa = 0.41), 81% for SRF (kappa = 0.62), 91% for macular fluid (kappa = 0.28), 79% for DRE (kappa = 0.10), 90% for PED (kappa = 0.78), and 79% for SRT (kappa = 0.53). Both observers disagreed regarding the presence of macular fluid in one patient (with a cross-hair scan).
   CONCLUSIONS. Interpretation of OCT line scans from patients with nAMD is subject to interobserver variability. However, when all line scans acquired are examined for the presence of fluid (IRC or SRF), there is a high level of agreement for the detection of macular fluid on a per patient basis. (Invest Ophthalmol Vis Sci. 2009; 50: 5405-5410) DOI: 10.1167/iovs.09-3505
C1 [Patel, Praveen J.; Browning, Andrew C.; Chen, Fred K.; Da Cruz, Lyndon; Tufail, Adnan] Moorfields Eye Hosp, London EC1V 2PD, England.
C3 University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust
RP Patel, PJ (通讯作者)，Moorfields Eye Hosp, 162 City Rd, London EC1V 2PD, England.
EM praveen.patel@moorfields.nhs.uk
RI , Fred/B-8158-2013
OI , Fred/0000-0003-2809-9930; Tufail, Adnan/0000-0001-6131-7640
CR AWH CC, 2008, 26 ANN M AM SOC RET
   Brown DM, 2007, AM J OPHTHALMOL, V144, P627, DOI 10.1016/j.ajo.2007.06.039
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   LANDIS JR, 1977, BIOMETRICS, V33, P174
   Lantz CA, 1996, J CLIN EPIDEMIOL, V49, P431, DOI 10.1016/0895-4356(95)00571-4
   Patel PJ, 2008, INVEST OPHTH VIS SCI, V49, P1084, DOI 10.1167/iovs.07-1203
   Patel PJ, 2008, TRIALS, V9, DOI 10.1186/1745-6215-9-56
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Viera AJ, 2005, FAM MED, V37, P360
   Wojtkowski M, 2004, AM J OPHTHALMOL, V138, P412, DOI 10.1016/j.ajo.2004.04.049
   Zhang N, 2007, AM J OPHTHALMOL, V144, P37, DOI 10.1016/j.ajo.2007.03.056
NR 12
TC 11
Z9 11
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD NOV
PY 2009
VL 50
IS 11
BP 5405
EP 5410
DI 10.1167/iovs.09-3505
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 514XH
UT WOS:000271429200051
PM 19553610
DA 2022-11-30
ER

PT J
AU Gotoh, N
   Yamada, R
   Hiratani, H
   Renault, V
   Kuroiwa, S
   Monet, M
   Toyoda, S
   Chida, S
   Mandai, M
   Otani, A
   Yoshimura, N
   Matsuda, F
AF Gotoh, Norimoto
   Yamada, Ryo
   Hiratani, Hitomi
   Renault, Victor
   Kuroiwa, Sachiko
   Monet, Marion
   Toyoda, Sachiko
   Chida, Shohei
   Mandai, Michiko
   Otani, Atsushi
   Yoshimura, Nagahisa
   Matsuda, Fumihiko
TI No association between complement factor H gene polymorphism and
   exudative age-related macular degeneration in Japanese
SO HUMAN GENETICS
LA English
DT Article
ID SUSCEPTIBILITY LOCI; DISEASE; MACULOPATHY; POPULATION; VARIANT;
   CALPAIN-10; HAPLOTYPE; SYSTEM; ROLES; SCAN
AB Age-related macular degeneration (ARMD) is the leading cause of blindness in the elderly population not only Western but also Asian industrial countries. In Caucasian, a polymorphism of the complement factor H gene (CFH), the C allele of rs1061170 (Y402H), was established as the first strong genetic factor for excursively exudative type of ARMD. In this study, we performed an extensive sequencing of the 22 exons in the CFH gene by recruiting 146 exudative ARMD patients and 105 normal controls of Japanese origin and identified 61 polymorphisms. We found that the frequency of the C allele of rs1061170 (Y402H) is much lower (0.04) in Japanese controls than in Caucasians (0.45). No case disease susceptibility to exudative ARMD was noted for rs1061170 (Y402H) (chi(2) = 3.19, P (corr) = 0.423), or other 12 single nucleotide polymorphisms (SNPs) whose frequency is greater than 0.05. When haplotypes were inferred for 13 SNPs (these 12 SNPs with a frequency greater than 0.05 and rs1061170), three haplotypes whose pattern was similar to those in Caucasians were identified but with substantial difference in frequency. Again we failed to identify genetic association between Japanese exudative ARMD and any of the haplotypes including the J1 haplotype which was shown to be susceptible to ARMD in Caucasians (chi(2) =3.92, P (corr) = 0.157). CFH does not appear to be a primary hereditary contributor to ARMD in Japanese. The absence of CFH contribution to ARMD in Japanese may correlate with the findings in ethnic differences of ARMD phenotypes.
C1 Kyoto Univ, Grad Sch Med, Sakyo Ku, Ctr Genom Med, Kyoto 6068501, Japan.
   Kyoto Univ, Grad Sch Med, Dept Ophthalmol, Kyoto 6068501, Japan.
   Shinshu Univ, Sch Med, Dept Ophthalmol, Matsumoto, Nagano 390, Japan.
C3 Kyoto University; Kyoto University; Shinshu University
RP Yamada, R (通讯作者)，Kyoto Univ, Grad Sch Med, Sakyo Ku, Ctr Genom Med, Yoshida Konoe Cho, Kyoto 6068501, Japan.
EM ryamada@src.riken.go.jp
RI Mandai, Michiko/E-7986-2011; Matsuda, Fumihiko/B-9893-2009
OI Yamada, Ryo/0000-0002-1587-630X
CR Allikmets R, 2000, AM J HUM GENET, V67, P487, DOI 10.1086/303018
   Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   Bird AC, 2003, EYE, V17, P457, DOI 10.1038/sj.eye.6700562
   Bottini N, 2004, NAT GENET, V36, P337, DOI 10.1038/ng1323
   Conley YP, 2005, HUM MOL GENET, V14, P1991, DOI 10.1093/hmg/ddi204
   de Cordoba SR, 2004, MOL IMMUNOL, V41, P355, DOI 10.1016/j.molimm.2004.02.005
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Horikawa Y, 2000, NAT GENET, V26, P163, DOI 10.1038/79876
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Lesage S, 2002, AM J HUM GENET, V70, P845, DOI 10.1086/339432
   MEYERS SM, 1995, AM J OPHTHALMOL, V120, P757, DOI 10.1016/S0002-9394(14)72729-1
   Mori M, 2005, J HUM GENET, V50, P264, DOI 10.1007/s10038-005-0246-8
   Okamoto H, 2006, MOL VIS, V12, P156
   Oshima Y, 2001, BRIT J OPHTHALMOL, V85, P1153, DOI 10.1136/bjo.85.10.1153
   Perez-Caballero D, 2001, AM J HUM GENET, V68, P478, DOI 10.1086/318201
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Souied EH, 2005, MOL VIS, V11, P1135
   Tano Y, 2003, AM J OPHTHALMOL, V136, P1049, DOI 10.1016/S0002-9394(03)00576-2
   Tsai HJ, 2001, AM J HUM GENET, V69, P1236, DOI 10.1086/324646
   Turnberg D, 2003, MOL IMMUNOL, V40, P145, DOI 10.1016/S0161-5890(03)00110-X
   *UMEDA, 2005, FASEB J          AUG, V12
   Weeks DE, 2004, AM J HUM GENET, V75, P174, DOI 10.1086/422476
   Weeks DE, 2001, AM J OPHTHALMOL, V132, P682, DOI 10.1016/S0002-9394(01)01214-4
   Yamazaki K, 2002, J HUM GENET, V47, P469, DOI 10.1007/s100380200067
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
NR 31
TC 136
Z9 148
U1 0
U2 6
PU SPRINGER
PI NEW YORK
PA 233 SPRING STREET, NEW YORK, NY 10013 USA
SN 0340-6717
J9 HUM GENET
JI Hum. Genet.
PD AUG
PY 2006
VL 120
IS 1
BP 139
EP 143
DI 10.1007/s00439-006-0187-0
PG 5
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 061HD
UT WOS:000238861300015
PM 16710702
DA 2022-11-30
ER

PT J
AU Yang, N
   Fan, CM
   Ho, CK
AF Yang, N
   Fan, CM
   Ho, CK
TI Review of first year result of photodynamic therapy on age-related
   macular degeneration in Chinese population
SO EYE
LA English
DT Article
DE retrospective case series from a single centre
ID CHOROIDAL NEOVASCULARIZATION; VERTEPORFIN
AB Purpose To evaluate the effect of verteporfin therapy (Visudyne) on age-related macular degeneration (AMD) in Chinese patients. The baseline characteristic and the visual outcome will be compared with the treatment of AMD with photodynamic therapy study (TAP) and verteporfin in photodynamic therapy study (VIP).
   Design Retrospective comparative case series.
   Method We recruited patients > 50 years old, with best-corrected visual acuity > 20/200 and fluorescein angiography documenting subfoveal either predominantly classic with greatest linear dimension < 5400 mu m or pure occult choroidal neovascularization (CNV) secondary to AMD. We applied non-thermal laser to the lesion 15 min after visudyne infusion as described in TAP study. Patients were followed up with fluorescein angiography every 3 months. Additional treatment would be offered if there was evidence of recurrence of CNV. Outcome measure Baseline characteristic and visual outcome.
   Result In all, 46 eyes of 42 patients were enrolled at our centre from July 2002 to June 2003. They comprised 11 eyes with predominantly classic lesions and 35 eyes with pure occult lesion. The mean number of treatment sessions given was 2.9 in the first year. At the 12-month examination, there were 63 and 29% of patients showing visual improvement in predominantly classic and occult groups, respectively, while there were only 16% of patients in the TAP study and 12% of patients in the VIP study showing visual improvement in the same period.
   Conclusion Verteporfin therapy for subfoveal CNV is beneficial to Chinese patients with AMD at first year. The visual result seems to be better than that observed in Caucasian patients.
C1 HKSAR, Dept Ophthalmol, Tuen Mun Hosp, Tuen Mun 852, Hong Kong, Peoples R China.
C3 Tuen Mun Hospital
RP Yang, N (通讯作者)，HKSAR, Dept Ophthalmol, Tuen Mun Hosp, Tuen Mun 852, Hong Kong, Peoples R China.
EM nyang8@hotmail.com
CR [Anonymous], 1993, Arch Ophthalmol, V111, P1200
   Arnold J, 2001, OPHTHALMOLOGY, V108, P841
   Arnold J, 2002, RETINA-J RET VIT DIS, V22, P6
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown GC, 2000, OPHTHALMOLOGY, V107, P1374, DOI 10.1016/S0161-6420(00)00169-X
   Fine SL, 1999, ARCH OPHTHALMOL-CHIC, V117, P1400, DOI 10.1001/archopht.117.10.1400
   Fong DS, 2000, OPHTHALMOLOGY, V107, P2314
   Husain D, 1999, INVEST OPHTH VIS SCI, V40, P2322
   Lim JI, 1998, RETINA-J RET VIT DIS, V18, P435
   Miller JW, 1999, ARCH OPHTHALMOL-CHIC, V117, P1161
   PIERAMICI DJ, 1994, ARCH OPHTHALMOL-CHIC, V112, P1043, DOI 10.1001/archopht.1994.01090200049020
   Schmidt-Erfurth U, 1999, ARCH OPHTHALMOL-CHIC, V117, P1177
   Sickenberg M, 2000, ARCH OPHTHALMOL-CHIC, V118, P327, DOI 10.1001/archopht.118.3.327
   Soubrane G, 2001, BRIT J OPHTHALMOL, V85, P483, DOI 10.1136/bjo.85.4.483
   *TAP, 2003, ARCH OPHTHALMOL-CHIC, V120, P1307
   Wu L, 1999, Curr Opin Ophthalmol, V10, P217, DOI 10.1097/00055735-199906000-00011
NR 18
TC 15
Z9 17
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD MAY
PY 2006
VL 20
IS 5
BP 523
EP 526
DI 10.1038/sj.eye.6701991
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 040DU
UT WOS:000237360000003
PM 16082401
OA Bronze
DA 2022-11-30
ER

PT J
AU Paulus, YM
   Jefferys, JL
   Hawkins, BS
   Scott, AW
AF Paulus, Yannis M.
   Jefferys, Joan L.
   Hawkins, Barbara S.
   Scott, Adrienne W.
TI Visual function quality of life measure changes upon conversion to
   neovascular age-related macular degeneration in second eyes
SO QUALITY OF LIFE RESEARCH
LA English
DT Article
DE Age-related macular degeneration; Choroidal neovascularization; National
   Eye Institute Visual Function Questionnaire; Quality of Life; Second
   eyes; Submacular Surgery Trials
ID FUNCTION QUESTIONNAIRE; GENERAL HEALTH; RANIBIZUMAB; PREVALENCE;
   BEVACIZUMAB; PROGRESSION; VISION; SCORES; IMPACT; TIME
AB To determine changes in quality of life measures when choroidal neovascularization (CNV) developed in the second eye of patients with initially unilateral neovascular age-related macular degeneration (AMD).
   We analyzed responses to the 39-item National Eye Institute Visual Function Questionnaire (NEI-VFQ), 36-item Short Form Health Survey (SF-36), and Hospital Anxiety and Depression Scale (HADS) at baseline, and prior to and following second eye CNV diagnosis in 92 participants enrolled in two Submacular Surgery Trials. Paired t-tests for sample sizes over 30 and Wilcoxon signed-rank tests for sample sizes < 30 were performed to compare scores.
   CNV development resulted in statistically and clinically significant changes in responses to 20 of 39 NEI-VFQ items, indicating visual function decline during a mean interval of 25 months. Little difference was noted between baseline scores and prior to CNV diagnosis, which averaged 8.9 months duration. Subscales demonstrated a statistically significant decline in general vision, near activities, distance activities, social functioning, role difficulties, dependency, and driving. There were minimal changes in the HADS and SF-36 scales.
   CNV development in the second eye had a dramatic effect on visual functioning based on patient responses to the NEI-VFQ questionnaire. Our investigation is believed to be the first study using data collected prospectively to demonstrate vision-related quality of life changes that resulted from development of CNV in AMD patients.
C1 [Paulus, Yannis M.; Jefferys, Joan L.; Hawkins, Barbara S.; Scott, Adrienne W.] Johns Hopkins Univ, Wilmer Eye Inst, Baltimore, MD 21218 USA.
   [Paulus, Yannis M.] Univ Michigan, Kellogg Eye Ctr, Ann Arbor, MI 48109 USA.
   [Scott, Adrienne W.] 600 North Wolfe St,Maumenee 719, Baltimore, MD 21287 USA.
C3 Johns Hopkins University; Johns Hopkins Medicine; University of Michigan
   System; University of Michigan
RP Scott, AW (通讯作者)，Johns Hopkins Univ, Wilmer Eye Inst, Baltimore, MD 21218 USA.; Scott, AW (通讯作者)，600 North Wolfe St,Maumenee 719, Baltimore, MD 21287 USA.
EM ascott28@jhmi.edu
OI Paulus, Yannis/0000-0002-0615-628X
FU Heed Ophthalmic Foundation; National Eye Institute Michigan Vision
   Clinician-Scientist Development Program [4K12EY022299-4]; Research to
   Prevent Blindness, New York, New York; NATIONAL EYE INSTITUTE
   [K12EY022299] Funding Source: NIH RePORTER
FX Funding was provided in part by the Heed Ophthalmic Foundation Fellows
   Grant (YMP) and the National Eye Institute Michigan Vision
   Clinician-Scientist Development Program 4K12EY022299-4 (YMP). The
   authors also received support from an unrestricted grant to the Wilmer
   Eye Institute from Research to Prevent Blindness, New York, New York.
   The authors would like to thank Judith E. Goldstein, O.D., for careful
   review of the manuscript.
CR Algvere PV, 2008, ACTA OPHTHALMOL, V86, P482, DOI 10.1111/j.1600-0420.2007.01113.x
   Bjelland I, 2002, J PSYCHOSOM RES, V52, P69, DOI 10.1016/S0022-3999(01)00296-3
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Buckle M, 2015, EYE, V29, P403, DOI 10.1038/eye.2014.296
   BURGESS DB, 1993, ARCH OPHTHALMOL-CHIC, V111, P1189
   Childs AL, 2004, OPHTHALMOLOGY, V111, P2007, DOI 10.1016/j.ophtha.2004.07.024
   Finger RP, 2014, OPHTHALMOLOGY, V121, P1246, DOI 10.1016/j.ophtha.2013.12.032
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Hawkins BS, 2004, OPHTHALMOLOGY, V111, P1967, DOI 10.1016/j.ophtha.2004.07.021
   Klein R, 2013, INVEST OPHTH VIS SCI, V54, DOI 10.1167/iovs.13-12789
   Likert R., 1932, ARCHIV PSYCHOL, V140, P1, DOI DOI 10.1111/J.1540-5834.2010.00585.X
   Lindblad AS, 2005, ARCH OPHTHALMOL-CHIC, V123, P1207
   Liu TYA, 2013, JAMA OPHTHALMOL, V131, P335, DOI 10.1001/jamaophthalmol.2013.818
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   Mangione C., 2000, NATL EYE I 25 ITEM V
   Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P227
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   Massof RW, 2007, OPHTHAL EPIDEMIOL, V14, P198, DOI 10.1080/09286580701487883
   Mejico LJ, 2004, AM J OPHTHALMOL, V137, P908, DOI 10.1016/j.ajo.2003.12.038
   Miskala PH, 2007, OPHTHAL EPIDEMIOL, V14, P205, DOI 10.1080/09286580701502970
   Miskala PH, 2004, OPHTHALMOLOGY, V111, P1981, DOI 10.1016/j.ophtha.2004.07.022
   Miskala PH, 2004, ARCH OPHTHALMOL-CHIC, V122, P758, DOI 10.1001/archopht.122.5.758
   Miskala PH, 2004, AM J OPHTHALMOL, V137, P961, DOI 10.1016/j.ajo.2003.11.018
   Miskala PH, 2003, ARCH OPHTHALMOL-CHIC, V121, P531
   Muether PS, 2011, GRAEF ARCH CLIN EXP, V249, P633, DOI 10.1007/s00417-010-1520-9
   Oliver-Fernandez M, 2005, CAN J OPHTHALMOL, V40, P313, DOI 10.1016/S0008-4182(05)80074-2
   Park DW, 2006, OPHTHALMOLOGY, V113, P1974, DOI 10.1016/j.ophtha.2006.08.015
   Rauch R, 2012, RETINA-J RET VIT DIS, V32, P1260, DOI 10.1097/IAE.0b013e3182018df6
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rudnicka AR, 2015, AM J OPHTHALMOL, V160, P85, DOI 10.1016/j.ajo.2015.04.003
   Schalnus R, 2010, OPHTHALMOLOGICA, V224, P176, DOI 10.1159/000239236
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Submacular Surgery Trials, 1998, MAN OF PROC
   Submacular Surgery Trials Research Group, 2007, Arch Ophthalmol, V125, P1323
   VANDER JF, 1989, OPHTHALMOLOGY, V96, P1422
   WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002
   Weingessel B, 2012, WIEN KLIN WOCHENSCHR, V124, P750, DOI 10.1007/s00508-012-0249-3
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
   ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x
NR 42
TC 9
Z9 9
U1 0
U2 4
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0962-9343
EI 1573-2649
J9 QUAL LIFE RES
JI Qual. Life Res.
PD AUG
PY 2017
VL 26
IS 8
BP 2139
EP 2151
DI 10.1007/s11136-017-1547-z
PG 13
WC Health Care Sciences & Services; Health Policy & Services; Public,
   Environmental & Occupational Health
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Health Care Sciences & Services; Public, Environmental & Occupational
   Health
GA FA8XC
UT WOS:000405728800015
PM 28357680
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Droege, KM
   Caramoy, A
   Kersten, A
   Luberichs-Fauser, J
   Zilkens, K
   Muller, D
   Kirchhof, B
   Fauser, S
AF Droege, Katharina M.
   Caramoy, Albert
   Kersten, Andreas
   Luberichs-Fauser, Janina
   Zilkens, Katharina
   Mueller, Dirk
   Kirchhof, Bernd
   Fauser, Sascha
TI Patient preference of ranibizumab treatment regimen for neovascular
   age-related macular degeneration - monthly injections versus pro re nata
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Ranibizumab; Healthcare research
AB To identify preference of treatment regimen in patients with anti-VEGF therapy for neovascular age-related macular degeneration (AMD) in real life.
   A cross-sectional study was conducted in 200 patients receiving ranibizumab therapy on a pro re nata regimen with monthly controls. One hundred and twenty-four patients were recruited in a tertiary health care clinic, and 76 patients were recruited in a private practice. Patients were asked to respond to a 14-item questionnaire covering items such as treatment burden and preference for treatment: either monthly injections or pro re nata.
   Mean time under anti-VEGF treatment was 33.7 months, and the mean number of intravitreal injections was 17.7. Despite a high treatment burden in 60.3 % of patients, there was an acceptance rate for monthly examinations or injections of 93 %. The proportion of patients who favoured a PRN regimen was 53.0 %, whereas 37.9 % of patients favoured continuous injections. Major concern was recurrent disease activity in 54.5 %.
   We identified two groups of patients of considerable size who would prefer either monthly injections or as-required. Overall, there was a high acceptance rate despite a high treatment burden. Nevertheless, efforts should be undertaken to improve examination and injection procedures and to consider the patient's preference for a treatment regimen.
C1 [Droege, Katharina M.; Caramoy, Albert; Kirchhof, Bernd; Fauser, Sascha] Univ Cologne, Ctr Ophthalmol, Dept Vitreo Retinal Surg, D-50924 Cologne, Germany.
   [Kersten, Andreas; Luberichs-Fauser, Janina; Zilkens, Katharina] Ambulantes Operat Zentrum Neuss, Neuss, Germany.
   [Mueller, Dirk] Univ Hosp, Inst Hlth Econ & Clin Epidemiol, Cologne, Germany.
C3 University of Cologne; University of Cologne
RP Fauser, S (通讯作者)，Univ Cologne, Ctr Ophthalmol, Dept Vitreo Retinal Surg, D-50924 Cologne, Germany.
EM sfauser@gmx.net
CR Abraham P, 2010, AM J OPHTHALMOL, V150, P315, DOI 10.1016/j.ajo.2010.04.011
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Droege KM, 2013, GRAEF ARCH CLIN EXP, V251, P1281, DOI 10.1007/s00417-012-2177-3
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Muether PS, 2013, GRAEF ARCH CLIN EXP, V251, P453, DOI 10.1007/s00417-012-2038-0
NR 5
TC 25
Z9 25
U1 0
U2 5
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD JAN
PY 2014
VL 252
IS 1
BP 31
EP 34
DI 10.1007/s00417-013-2412-6
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 283JY
UT WOS:000329243500006
PM 23860798
DA 2022-11-30
ER

PT J
AU Ahn, J
   Hwang, DDJ
   Sohn, J
   Son, G
AF Ahn, Jayoung
   Hwang, Daniel Duck-Jin
   Sohn, Joonhong
   Son, Gisung
TI Retinal Pigment Epithelium Tears after Anti-Vascular Endothelial Growth
   Factor Therapy for Neovascular Age-Related Macular Degeneration
SO OPHTHALMOLOGICA
LA English
DT Article
DE Anti-vascular growth factor injection; Neovascular age-related macular
   degeneration; Retinal pigment epithelial tear
ID VEGF TRAP-EYE; INTRAVITREAL BEVACIZUMAB; RANIBIZUMAB INJECTION;
   AFLIBERCEPT; DETACHMENT; PREDICTORS; RISK
AB Purpose: The aim of this study was to assess the visual prognostic factors of retinal pigment epithelium (RPE) tears and describe their clinical features. Methods: The medical records of treatment-naive neovascular age-related macular degeneration patients who received intravitreal anti-vascular endothelial growth factor (VEGF) injections were retrospectively reviewed. Results: The incidence of RPE tears was 1.36% (10 out of 733 eyes). The type of anti-VEGF agent administered did not affect the incidence (p = 0.985). The median best-corrected visual acuity (BCVA) of 10 patients decreased after an RPE tear (0.4-0.6 logarithm of the minimum angle of resolution [logMAR]); however, subsequent injections restored the BCVA to a level similar to that before the RPE tear (0.4 logMAR, p = 0.436). Central macular thickness improved significantly during the study (794.4-491.9 mu m, p = 0.013). The final BCVA was positively correlated with the BCVA before and immediately after the RPE tear (p = 0.025 and 0.002, respectively) and was weakly correlated with foveal involvement of the RPE tear (p = 0.061). Conclusion: The incidence of RPE tears did not differ according to the type of anti-VEGF agent. The final BCVA was proportional to the BCVA before and after RPE tears. Continuous treatment with anti-VEGF after the occurrence of RPE tears can benefit the final visual acuity and macular anatomy. (C) 2021 S. Karger AG, Basel
C1 [Ahn, Jayoung; Hwang, Daniel Duck-Jin; Sohn, Joonhong; Son, Gisung] HanGil Eye Hosp, Dept Ophthalmol, Incheon, South Korea.
   [Hwang, Daniel Duck-Jin; Son, Gisung] Catholic Kwandong Univ, Dept Ophthalmol, Coll Med, Incheon, South Korea.
C3 Catholic Kwandong University
RP Son, G (通讯作者)，HanGil Eye Hosp, Dept Ophthalmol, Incheon, South Korea.; Son, G (通讯作者)，Catholic Kwandong Univ, Dept Ophthalmol, Coll Med, Incheon, South Korea.
EM yatase@hanmail.net
OI Hwang, Daniel Duck-Jin/0000-0003-1808-3169
CR Asao K, 2014, RETINA-J RET VIT DIS, V34, P512, DOI 10.1097/IAE.0b013e31829f73eb
   Chan CK, 2015, EYE, V29, P80, DOI 10.1038/eye.2014.233
   Chan CK, 2007, RETINA-J RET VIT DIS, V27, P541, DOI 10.1097/IAE.0b013e3180cc2612
   Chan CK, 2010, RETINA-J RET VIT DIS, V30, P203, DOI 10.1097/IAE.0b013e3181babda5
   Chang LK, 2007, RETINA-J RET VIT DIS, V27, P523, DOI 10.1097/IAE.0b013e3180a032db
   Chiang A, 2008, RETINA-J RET VIT DIS, V28, P1265, DOI 10.1097/IAE.0b013e31817d5d03
   Cho HJ, 2016, RETINA-J RET VIT DIS, V36, P1851, DOI 10.1097/IAE.0000000000001009
   COSCAS G, 1990, ARCH OPHTHALMOL-CHIC, V108, P1687, DOI 10.1001/archopht.1990.01070140041025
   Coscas G, 2014, AM J OPHTHALMOL, V158, P309, DOI 10.1016/j.ajo.2014.05.004
   Cunningham ET, 2011, OPHTHALMOLOGY, V118, P2447, DOI 10.1016/j.ophtha.2011.05.026
   Guber J, 2013, BRIT J OPHTHALMOL, V97, P1486, DOI 10.1136/bjophthalmol-2013-303978
   Gutfleisch M, 2011, EYE, V25, P1181, DOI 10.1038/eye.2011.146
   Hata M, 2017, RETINA-J RET VIT DIS, V37, P1320, DOI 10.1097/IAE.0000000000001370
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Invernizzi A, 2018, OPHTHALMOLOGY, V125, P237, DOI 10.1016/j.ophtha.2017.08.039
   Klettner A, 2014, GRAEF ARCH CLIN EXP, V252, P1593, DOI 10.1007/s00417-014-2719-y
   Kook D, 2008, OPHTHALMOLOGE, V105, P158, DOI 10.1007/s00347-007-1561-6
   Larsen PP, 2019, RETINA-J RET VIT DIS, V39, P2369, DOI 10.1097/IAE.0000000000002311
   Leitritz M, 2008, EYE, V22, P1504, DOI 10.1038/eye.2008.145
   Lommatzsch A, 2009, EYE, V23, P2163, DOI 10.1038/eye.2008.425
   Moroz I, 2009, OPHTHAL SURG LAS IM, V40, P570, DOI 10.3928/15428877-20091030-06
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sarraf David, 2014, Trans Am Ophthalmol Soc, V112, P142
   Sarraf D, 2013, RETINA-J RET VIT DIS, V33, P1551, DOI 10.1097/IAE.0b013e31828992f5
   Sarraf D, 2010, RETINA-J RET VIT DIS, V30, P1039, DOI 10.1097/IAE.0b013e3181cdf366
   Shin JY, 2015, GRAEF ARCH CLIN EXP, V253, P2151, DOI 10.1007/s00417-015-2977-3
   Spandau UHM, 2006, AM J OPHTHALMOL, V142, P1068, DOI 10.1016/j.ajo.2006.06.048
   Stewart MW, 2012, BRIT J OPHTHALMOL, V96, P1157, DOI 10.1136/bjophthalmol-2011-300654
   Thomas M, 2013, CLIN OPHTHALMOL, V7, P495, DOI 10.2147/OPTH.S29974
   Vazquez-Alfageme C, 2019, RETINA-J RET VIT DIS, V39, P664, DOI 10.1097/IAE.0000000000002029
   Weinberger AWA, 2007, AM J OPHTHALMOL, V144, P294, DOI 10.1016/j.ajo.2007.03.024
NR 31
TC 0
Z9 0
U1 0
U2 0
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2022
VL 245
IS 1
BP 1
EP 9
DI 10.1159/000514991
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 2P4NS
UT WOS:000819720600002
PM 33540419
DA 2022-11-30
ER

PT J
AU Sadda, SR
   Tuomi, LL
   Ding, BY
   Fung, AE
   Hopkins, JJ
AF Sadda, SriniVas R.
   Tuomi, Lisa L.
   Ding, Beiying
   Fung, Anne E.
   Hopkins, J. Jill
TI Macular Atrophy in the HARBOR Study for Neovascular Age-Related Macular
   Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID RETINAL ANGIOMATOUS PROLIFERATION; 2.0 MG RANIBIZUMAB;
   GEOGRAPHIC-ATROPHY; RETICULAR PSEUDODRUSEN; CHOROIDAL
   NEOVASCULARIZATION; TREATMENTS TRIALS; EYE DISEASE; FOLLOW-UP; OUTCOMES;
   HORIZON
AB Purpose: To evaluate macular atrophy (MA) presence in the 24-month HARBOR study (NCT00891735) for neovascular age-related macular degeneration (AMD).
   Design: Post hoc analysis of a phase 3 multicenter, prospective, randomized, double-masked, active treatment-controlled clinical trial.
   Participants: Evaluable subjects (N = 1095) with subfoveal choroidal neovascularization (CNV) secondary to neovascular AMD treated with ranibizumab 0.5 mg or 2.0 mg monthly or pro re nata (PRN).
   Methods: Fluorescein angiograms (FAs) and color fundus photographs at baseline and months 3, 12, and 24 were retrospectively graded by masked graders for MA: well-defined areas of depigmentation with increased choroidal vessel visibility, diameter >= 250 mm, corresponding to flat areas of well-demarcated staining on FA, excluding atrophy associated with retinal pigment epithelium tears. Atrophy immediately within, adjacent, and nonadjacent to CNV lesions was included. Main Outcome Measures: Macular atrophy incidence, best-corrected visual acuity (BCVA).
   Results: At baseline, MA was detected in 11.2% (123/1095) of study eyes. At month 24, 29.4% (229/778) of eyes without baseline atrophy had detectable MA. Eyes with and without baseline MA had significant mean BCVA gains from baseline at month 24 (letters [95% confidence interval]: +6.7 [4.1-9.3]; +9.1 [8.0-10.2], respectively). Among eyes with and without MA at month 24, mean month 24 BCVA was 62.0 [60.3-63.7] and 64.7 [63.2-66.3] letters, respectively. Baseline risk factors for month 24 MA presence included intraretinal cysts (hazard ratio [HR], 2.45 [1.76-3.42]) and fellow eye atrophy (HR, 2.02 [1.42-2.87]); subretinal fluid was associated with a lower MA risk (HR, 0.50 [0.33-0.74]). Ranibizumab dose was not associated with MA development. Monthly versus PRN treatment trended toward an association with MA (HR, 1.29 [0.99-1.68]), but was not statistically significant.
   Conclusions: New MA was detected in 29% of study eyes after 24 months of treatment. Clinically significant BCVA gains were achieved with MA present over 24 months. Baseline subretinal fluid absence, intraretinal cyst presence, and fellow eye atrophy presence were associated with month 24 MA presence. With existing data, the benefits of ranibizumab for neovascular AMD outweighed the risk of MA development over 24 months in HARBOR, although outcomes > 2 years were not evaluated. (C) 2018 by the American Academy of Ophthalmology.
C1 [Sadda, SriniVas R.] Doheny Eye Inst, 1355 San Pablo St,DVRC 100, Los Angeles, CA 90033 USA.
   [Sadda, SriniVas R.] Univ Calif Los Angeles, Geffen Sch Med, Dept Ophthalmol, Los Angeles, CA USA.
   [Tuomi, Lisa L.; Ding, Beiying; Fung, Anne E.; Hopkins, J. Jill] Genentech Inc, San Francisco, CA 94080 USA.
C3 Doheny Eye Institute; University of California System; University of
   California Los Angeles; University of California Los Angeles Medical
   Center; David Geffen School of Medicine at UCLA; Roche Holding;
   Genentech
RP Sadda, SR (通讯作者)，Doheny Eye Inst, 1355 San Pablo St,DVRC 100, Los Angeles, CA 90033 USA.
EM ssadda@doheny.org
FU Genentech, Inc.; Allergan; Carl Zeiss Meditec, Inc.; Optos plc;
   Genentech, Inc., South San Francisco, California
FX The author(s) have made the following disclosure(s): S.R.S.: Consultant
   - Genentech, Inc., Allergan, Alcon, Regeneron Pharmaceuticals, Inc., F.
   Hoffmann-La Roche Ltd., Carl Zeiss Meditec, Inc., Optos plc; Research
   support - Genentech, Inc., Allergan, Carl Zeiss Meditec, Inc., Optos
   plc. L.L.T., B.D., and A.E.F.: Employees - Genentech, Inc.; Genentech,
   Inc., South San Francisco, California, provided support for the study
   and participated in the study design; conducting the study; data
   collection, management, and interpretation; and preparation, review and
   approval of the manuscript.
CR Bhisitkul RB, 2015, AM J OPHTHALMOL, V159, P915, DOI 10.1016/j.ajo.2015.01.032
   Bloch SB, 2012, AM J OPHTHALMOL, V153, P209, DOI 10.1016/j.ajo.2011.10.016
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Cackett P, 2013, INVEST OPHTH VIS SCI, V54
   Capuano V, 2017, AM J OPHTHALMOL, V182, P45, DOI 10.1016/j.ajo.2017.07.009
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P272, DOI 10.1001/jamaophthalmol.2013.6636
   Cho HJ, 2015, AM J OPHTHALMOL, V159, P285, DOI 10.1016/j.ajo.2014.10.035
   Daniel E, 2016, OPHTHALMOLOGY, V123, P609, DOI 10.1016/j.ophtha.2015.10.034
   Finger RP, 2014, OPHTHALMOLOGY, V121, P1252, DOI 10.1016/j.ophtha.2013.12.034
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Ho AC, 2014, OPHTHALMOLOGY, V121, P2181, DOI 10.1016/j.ophtha.2014.05.009
   Hogg RE, 2014, OPHTHALMOLOGY, V121, P1748, DOI 10.1016/j.ophtha.2014.03.015
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   Kiss S, 2015, INVEST OPHTH VIS SCI, V56
   Klein R, 2008, AM J OPHTHALMOL, V146, P692, DOI 10.1016/j.ajo.2008.05.050
   Kodjikian L, 2013, OPHTHALMOLOGY, V120, P2300, DOI 10.1016/j.ophtha.2013.06.020
   Lindblad AS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1168, DOI 10.1001/archophthalmol.2009.198
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Peden MC, 2015, OPHTHALMOLOGY, V122, P803, DOI 10.1016/j.ophtha.2014.11.018
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Sloan FA, 2014, JAMA OPHTHALMOL, V132, P456, DOI 10.1001/jamaophthalmol.2013.7647
   Tanaka E, 2015, OPHTHALMOLOGY, V122, P153, DOI 10.1016/j.ophtha.2014.07.046
   Ueda-Arakawa N, 2013, AM J OPHTHALMOL, V155, P260, DOI 10.1016/j.ajo.2012.08.011
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 31
TC 74
Z9 77
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JUN
PY 2018
VL 125
IS 6
BP 878
EP 886
DI 10.1016/j.ophtha.2017.12.026
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GG0MB
UT WOS:000432371600023
PM 29477692
OA hybrid
DA 2022-11-30
ER

PT J
AU Spaide, RF
   Laud, K
   Fine, HF
   Klancnik, JM
   Meyerle, CB
   Yannuzzi, LA
   Sorenson, J
   Slakter, J
   Fisher, YL
   Cooney, MJ
AF Spaide, Richard F.
   Laud, Ketan
   Fine, Howard F.
   Klancnik, James M., Jr.
   Meyerle, Catherine B.
   Yannuzzi, Lawrence A.
   Sorenson, John
   Slakter, Jason
   Fisher, Yale L.
   Cooney, Michael J.
TI Intravitreal bevacizumab treatment of choroidal neovascularization
   secondary to age-related macular degeneration
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; bevacizumab; choroidal
   neovascularization; vascular endothelial growth factor
ID THERAPY
AB Purpose: To describe the short-term anatomical and visual acuity responses after intravitreal injection of bevacizumab (Avastin, Genentech) in patients with choroidal neo-vascularization (CNV) secondary to age-related macular degeneration (AMD).
   Methods: We conducted a retrospective study of patients with CNV secondary to AMD who were treated with intravitreal injection of bevacizumab (1.25 mg) during a 3-month period. Patients underwent best-corrected Snellen visual acuity testing, optical coherence tomography, and ophthalmoscopic examination at baseline and follow-up visits.
   Results: There were 266 consecutive eyes of 266 patients who received injections, and follow-up information was available for 251 (94.4%). The mean age of the patients was 80.3 years, the mean baseline visual acuity was 20/184, and 175 (69.7%) had inadequate response to alternate methods of treatment. At the 1 -month follow-up (data available for 244 patients), the mean visual acuity was 20/137 (P < 0.001 as compared with baseline), and 74 (30.3%) of patients had improvement in visual acuity as defined by a halving of the visual angle. At the 2-month follow-up (data available for 222 patients), the mean visual acuity was 20/122 (P < 0.001), and 78 (31.1 %) of patients had visual improvement. At the 3-month follow-up (data available for 141 patients), the mean visual acuity was 20/109 (P < 0.001), and 54 (38.3%) of patients had visual acuity improvement. The mean central macular thickness at baseline was 340 mu m and decreased to a mean of 247 gm at month 1 (P < 0.001) and 213 gm at month 3 (P < 0.001). At 1 month, two patients had mild vitritis, as did one patient at 2 months, who had a history of recurrent uveitis. No endophthalmitis, increased intraocular pressure, retinal tear, or retinal detachment occurred. The risk for thromboembolic disorders did not seem to be different than reported previously in studies concerning macular degeneration.
   Conclusion: There were no apparent short-term safety concerns for intravitreal bevacizumab injection for CNV. Treated eyes had a significant decrease in macular thickness and improvement in visual acuity. The follow-up was too short to make any specific treatment recommendations, but the favorable short-term results suggest further study is needed.
C1 Manhattan Eye Ear & Throat Hosp, Vitreous Retina Macula Consulants New York, New York, NY 10021 USA.
   Manhattan Eye Ear & Throat Hosp, LuEsther T Mertz Retinal Res Ctr, New York, NY 10021 USA.
C3 Manhattan Eye Ear & Throat Hospital; Vitreous Retina Macula Consultants
   of New York; Manhattan Eye Ear & Throat Hospital
RP Spaide, RF (通讯作者)，460 Pk Ave,5th Floor, New York, NY 10022 USA.
EM vrmny@aol.com
RI Spaide, Richard/ABD-7368-2020
CR *AC PHOT STUD GROU, 1990, ARCH OPHTHALMOL-CHIC, V108, P825
   Aiello LP, 2004, RETINA, V24, P13
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   *EYET PHARM PFIZ I, PEG SOD INJ MAC
   Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381
   FINE SL, 1982, ARCH OPHTHALMOL-CHIC, V100, P912
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Jackson TL, 2003, INVEST OPHTH VIS SCI, V44, P2141, DOI 10.1167/iovs.02-1027
   Ma L, 2005, CANCER RES, V65, P5365, DOI 10.1158/0008-5472.CAN-04-3156
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Mordenti J, 1999, TOXICOL PATHOL, V27, P536, DOI 10.1177/019262339902700507
   Ravetch JV, 2001, ANNU REV IMMUNOL, V19, P275, DOI 10.1146/annurev.immunol.19.1.275
   ROSENFELD PJ, 2005, OPHTHAL SURG LAS IM, V36, P270
   Russell S, 2003, OPHTHALMOLOGY, V110, P2372, DOI 10.1016/j.ophtha.2003.08.020
   Slakter JS, 2006, OPHTHALMOLOGY, V113, P3, DOI 10.1016/j.ophtha.2005.10.019
   Spaide R, 2006, OPHTHALMOLOGY, V113, P160, DOI 10.1016/j.ophtha.2005.10.023
   Spaide RF, 2006, AM J OPHTHALMOL, V141, P149, DOI 10.1016/j.ajo.2005.07.025
NR 18
TC 518
Z9 564
U1 0
U2 30
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD APR
PY 2006
VL 26
IS 4
BP 383
EP 390
DI 10.1097/00006982-200604000-00001
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 100QX
UT WOS:000241684800001
PM 16603955
DA 2022-11-30
ER

PT J
AU Tseng, JJ
   Vance, SK
   Della Torre, KE
   Mendonca, LS
   Cooney, MJ
   Klancnik, JM
   Sorenson, JA
   Freund, KB
AF Tseng, Joseph J.
   Vance, Sushma K.
   Della Torre, Kara E.
   Mendonca, Luis S.
   Cooney, Michael J.
   Klancnik, James M., Jr.
   Sorenson, John A.
   Freund, K. Bailey
TI Sustained Increased Intraocular Pressure Related to Intravitreal
   Antivascular Endothelial Growth Factor Therapy for Neovascular
   Age-related Macular Degeneration
SO JOURNAL OF GLAUCOMA
LA English
DT Article
DE anti-VEGF; ranibizumab; bevacizumab; ocular hypertension; neovascular
   age-related macular degeneration
ID RANIBIZUMAB LUCENTIS; BEVACIZUMAB; INJECTION; CELLS
AB Purpose: To describe a series of previously normotensive eyes experiencing sustained elevated intraocular pressure (IOP) associated with long-term intravitreal antivascular endothelial growth factor (VEGF) therapy for neovascular age-related macular degeneration (AMD).
   Patients and Methods: Clinical data were reviewed for 25 eyes of 23 patients with neovascular AMD who had increased IOP while receiving interval doses of intravitreal ranibizumab and/or bevacizumab. All eyes had tolerated multiple anti-VEGF injections in the past without IOP elevations.
   Results: After a mean of 20.0 anti-VEGF injections (range, 8-40 injections), the mean IOP was 29.8 mm Hg (range, 22-58 mm Hg), compared with a baseline of 16.9 mm Hg (range, 14-21 mm Hg). The mean highest IOP while receiving intravitreal anti-VEGF therapy was 35.8 mm Hg (range, 23-58 mm Hg). Overall, 23 of 25 cases required IOP management. In the remaining 2 cases, anti-VEGF dosing was switched from regular interval dosing to an optical coherence tomography-guided variable regimen, with subsequent improvement in IOP without antiglaucoma treatment.
   Conclusions: Serial injections of anti-VEGF agents may lead to persistent IOP elevations that require glaucoma therapy. The clinician should recognize this phenomenon, as it can occur even if the patient has tolerated multiple prior injections without IOP elevation. Further exploration of the relationship between anti-VEGF therapy and IOP is needed.
C1 [Tseng, Joseph J.; Vance, Sushma K.; Della Torre, Kara E.; Mendonca, Luis S.; Cooney, Michael J.; Klancnik, James M., Jr.; Sorenson, John A.; Freund, K. Bailey] Vitreous Retina Macula Consultants New York, New York, NY USA.
   [Tseng, Joseph J.; Vance, Sushma K.; Della Torre, Kara E.; Mendonca, Luis S.; Cooney, Michael J.; Klancnik, James M., Jr.; Sorenson, John A.; Freund, K. Bailey] Manhattan Eye Ear & Throat Hosp, LuEsther T Mertz Retinal Res Ctr, New York, NY 10021 USA.
   [Vance, Sushma K.; Della Torre, Kara E.; Cooney, Michael J.; Klancnik, James M., Jr.; Sorenson, John A.; Freund, K. Bailey] NYU, Dept Ophthalmol, New York, NY 10016 USA.
   [Tseng, Joseph J.; Freund, K. Bailey] Columbia Univ Coll Phys & Surg, Edward S Harkness Eye Inst, New York, NY 10032 USA.
C3 Vitreous Retina Macula Consultants of New York; Manhattan Eye Ear &
   Throat Hospital; New York University; Columbia University
RP Freund, KB (通讯作者)，460 Pk Ave,5th Floor, New York, NY 10022 USA.
EM kbfnyf@aol.com
RI Freund, K. Bailey/V-7488-2018
OI Freund, K. Bailey/0000-0002-7888-9773
FU The Macula Foundation, Inc.
FX This work is supported by The Macula Foundation, Inc.
CR Adelman RA, 2010, J OCUL PHARMACOL TH, V26, P105, DOI 10.1089/jop.2009.0076
   Bakri SJ, 2008, RETINA-J RET VIT DIS, V28, P996, DOI 10.1097/IAE.0b013e31816c6868
   Bakri SJ, 2008, GRAEF ARCH CLIN EXP, V246, P955, DOI 10.1007/s00417-008-0819-2
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Engelbert M, 2009, RETINA-J RET VIT DIS, V29, P1424, DOI 10.1097/IAE.0b013e3181bfbd46
   Falkenstein IA, 2007, RETINA-J RET VIT DIS, V27, P1044, DOI 10.1097/IAE.0b013e3180592ba6
   Freund KB, 2006, RETINA-J RET VIT DIS, V26, P701, DOI 10.1097/00006982-200607000-00021
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gismondi M, 2009, J GLAUCOMA, V18, P658, DOI 10.1097/IJG.0b013e31819c4893
   Good TJ, 2010, BR J OPHTHALMOL
   Hollands H, 2007, CAN J OPHTHALMOL, V42, P807, DOI 10.3129/i07-172
   Kahook MY, 2010, J GLAUCOMA, V19, P437, DOI 10.1097/IJG.0b013e3181ca74de
   Kahook MY, 2010, RETINA-J RET VIT DIS, V30, P887, DOI 10.1097/IAE.0b013e3181d50cea
   Kahook MY, 2009, OPHTHAL SURG LAS IM, V40, P293, DOI 10.3928/15428877-20090430-12
   Kernt M, 2007, OPHTHALMOLOGE, V104, P965, DOI 10.1007/s00347-007-1569-y
   Kim JE, 2008, AM J OPHTHALMOL, V146, P930, DOI 10.1016/j.ajo.2008.07.007
   Kocabora MS, 2010, ACTA OPHTHALMOL, V88, pe44, DOI 10.1111/j.1755-3768.2008.01336.x
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lee K, 2009, RETINA-J RET VIT DIS, V29, P1409, DOI 10.1097/IAE.0b013e3181b21056
   Li ZQ, 2009, INVEST OPHTH VIS SCI, V50, P5217, DOI 10.1167/iovs.08-2662
   Rosenfeld Philip J, 2006, Ophthalmol Clin North Am, V19, P361
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Scott IU, 2009, AM J OPHTHALMOL, V148, P725, DOI 10.1016/j.ajo.2009.06.004
   Shah AR, 2009, BRIT J OPHTHALMOL, V93, P1027, DOI 10.1136/bjo.2008.149674
   Sharei V, 2010, EUR J OPHTHALMOL, V20, P174, DOI 10.1177/112067211002000124
   Sniegowski M, 2010, OPEN OPHTHALMOL J, V4, P28, DOI 10.2174/1874364101004010028
   Yazdani S, 2009, J GLAUCOMA, V18, P632, DOI 10.1097/IJG.0b013e3181997211
NR 27
TC 98
Z9 106
U1 1
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1057-0829
J9 J GLAUCOMA
JI J. Glaucoma
PD APR-MAY
PY 2012
VL 21
IS 4
BP 241
EP 247
DI 10.1097/IJG.0b013e31820d7d19
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 920DK
UT WOS:000302382100006
PM 21423038
DA 2022-11-30
ER

PT J
AU Yan, Q
   Jiang, YL
   Huang, H
   Swaroop, A
   Chew, EY
   Weeks, DE
   Chen, W
   Ding, Y
AF Yan, Qi
   Jiang, Yale
   Huang, Heng
   Swaroop, Anand
   Chew, Emily Y.
   Weeks, Daniel E.
   Chen, Wei
   Ding, Ying
TI Genome-Wide Association Studies-Based Machine Learning for Prediction of
   Age-Related Macular Degeneration Risk
SO TRANSLATIONAL VISION SCIENCE & TECHNOLOGY
LA English
DT Article
DE age-related macular degeneration; GWAS; machine learning; risk
   prediction
AB Purpose: Because age-related macular degeneration (AMD) is a progressive disorder and advanced AMD is currently hard to cure, an accurate and informative prediction of a person's AMD risk using genetic information is desirable for early diagnosis and potential individualized clinical management. The objective of this study was to develop and validate novel prediction models for AMD risk using large genome-wide association studies datasets with different machine learning approaches.
   Methods: Genotype data from 32,215 Caucasian individuals with age of >= 50 years from the International AMD Genomics Consortium in dbGaP were used to establish and test prediction models for AMD risk. Four different machine learning approaches-neural network, lasso regression, support vector machine, and random forest-were implemented. A standard logistic regression model using a genetic risk score was also considered.
   Results: All machine learning-based methods achieved satisfactory performance for predicting advanced AMD cases (vs. normal controls) (area under the curve = 0.81-0.82, Brier score = 0.17-0.18 in a separate test dataset) and any stage AMD (vs. normal controls) (area under the curve = 0.78-0.79, Brier score = 0.18-0.20 in a separate test dataset). The prediction performance was further validated in an independent dataset of 783 subjects from UK Biobank (area under the curve = 0.67).
   Conclusions: By applying multiple state-of-art machine learning approaches on large AMD genome-wide association studies datasets, the predictive models we established can provide an accurate estimation of an individual's AMD risk profile based on genetic information along with age. The online prediction interface is available at: https://yanq.shinyapps.io/no_vs_amd_NN/.
   Translational Relevance: The accurate and individualized risk prediction model interface will greatly improve early diagnosis and enhance tailored clinical management of AMD.
C1 [Yan, Qi] Columbia Univ, Dept Obstet & Gynecol, Irving Med Ctr, New York, NY USA.
   [Yan, Qi; Jiang, Yale; Chen, Wei] Univ Pittsburgh, Childrens Hosp Pittsburgh UPMC, Dept Pediat, Div Pulm Med Allergy & Immunol, Pittsburgh, PA USA.
   [Jiang, Yale] Tsinghua Univ, Sch Med, Beijing, Peoples R China.
   [Huang, Heng] Univ Pittsburgh, Swanson Sch Engn, Dept Elect & Comp Engn, Pittsburgh, PA USA.
   [Huang, Heng] Univ Pittsburgh, Sch Med, Dept Biomed Informat, Pittsburgh, PA USA.
   [Swaroop, Anand] NEI, Neurobiol Neurodegenerat & Repair Lab, NIH, Bethesda, MD USA.
   [Chew, Emily Y.] NEI, Div Epidemiol & Clin Applicat, NIH, Bethesda, MD USA.
   [Weeks, Daniel E.; Chen, Wei] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Human Genet, Pittsburgh, PA 15261 USA.
   [Weeks, Daniel E.; Chen, Wei; Ding, Ying] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15261 USA.
C3 Columbia University; NewYork-Presbyterian Hospital; Pennsylvania
   Commonwealth System of Higher Education (PCSHE); University of
   Pittsburgh; Tsinghua University; Pennsylvania Commonwealth System of
   Higher Education (PCSHE); University of Pittsburgh; Pennsylvania
   Commonwealth System of Higher Education (PCSHE); University of
   Pittsburgh; National Institutes of Health (NIH) - USA; NIH National Eye
   Institute (NEI); National Institutes of Health (NIH) - USA; NIH National
   Eye Institute (NEI); Pennsylvania Commonwealth System of Higher
   Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth
   System of Higher Education (PCSHE); University of Pittsburgh
RP Ding, Y (通讯作者)，Publ Hlth, 130 DeSoto St, Pittsburgh, PA 15261 USA.
EM yingding@pitt.edu
OI Weeks, Daniel/0000-0001-9410-7228
FU National Institutes of Health [R21EY030488]
FX The authors thank the International AMD Genomics Consortium for
   generating the genetic data, performing quality checks, and making the
   data available on dbGAP. This research was supported by the National
   Institutes of Health (R21EY030488 to Y.D., W.C.).
CR Chollet F., 2015, KERAS
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   DELONG ER, 1988, BIOMETRICS, V44, P837, DOI 10.2307/2531595
   Ding Y, 2017, GENETICS, V206, P119, DOI 10.1534/genetics.116.196998
   Fisher SA, 2005, HUM MOL GENET, V14, P2257, DOI 10.1093/hmg/ddi230
   Friedman J, 2010, J STAT SOFTW, V33, P1, DOI 10.18637/jss.v033.i01
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Graf E, 1999, STAT MED, V18, P2529
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Kondo N, 2011, OPHTHALMOLOGY, V118, P339, DOI 10.1016/j.ophtha.2010.06.040
   Kuhn M, 2008, J STAT SOFTW, V28, P1, DOI 10.18637/jss.v028.i05
   Restrepo NA, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.14-14246
   Spencer KL, 2012, ARCH OPHTHALMOL-CHIC, V130, P116, DOI 10.1001/archopthalmol.2011.1370
   Sudlow C, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001779
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
NR 15
TC 4
Z9 4
U1 0
U2 4
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 2164-2591
J9 TRANSL VIS SCI TECHN
JI Transl. Vis. Sci. Technol.
PD FEB
PY 2021
VL 10
IS 2
AR 29
DI 10.1167/tvst.10.2.29
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA RC6MY
UT WOS:000632914000008
PM 34003914
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Sivaprasad, S
   Hykin, P
   Saeed, A
   Beatty, S
   Grisanti, S
   Staurenghi, G
   Olea, JL
   Campos, A
   Barbosa, A
   Rito, L
   Silva, R
   Faria, R
   Eldem, B
   Kadayifcilar, S
   Kolar, P
   Feucht, N
   Maestroni, L
AF Sivaprasad, S.
   Hykin, P.
   Saeed, A.
   Beatty, S.
   Grisanti, S.
   Staurenghi, G.
   Olea, J. L.
   Campos, A.
   Barbosa, A.
   Rito, L.
   Silva, R.
   Faria, R.
   Eldem, B.
   Kadayifcilar, S.
   Kolar, P.
   Feucht, N.
   Maestroni, L.
TI Intravitreal pegaptanib sodium for choroidal neovascularisation
   secondary to age-related macular degeneration: Pan-European experience
SO EYE
LA English
DT Article
DE choroidal neovascularisation; macular degeneration; pegaptanib
ID RANIBIZUMAB
AB Purpose To evaluate visual outcomes in patients with neovascular age-related macular degeneration (NV-AMD) who were treated with pegaptanib sodium in European clinical ophthalmology practices.
   Methods Thirteen centres in eight European countries participated in this retrospective study. Medical records for patients with any angiographic subtype of subfoveal choroidal neovascularisation secondary to NV-AMD with visual acuities (study eye) of 20/40-20/320 treated with 0.3mg pegaptanib as first-line treatment and with at least 24 weeks of follow-up were identified. Anonymised data reflecting at least 24 and up to 54 weeks of follow-up were recorded. Primary end points were visual acuity outcomes at weeks 24 and 54 compared with those reported at week 54 in the vascular endothelial growth factor (VEGF) Inhibition Study in Ocular Neovascularisation (VISION) trial.
   Results In all, 253 patients were followed for at least 24 weeks; 62 patients completed 54 weeks of follow-up. A mean of 4.4 (SD, 1.8) pegaptanib injections were administered through 24 weeks. Compared with the VISION trial, the European experience showed that >90% of patients in the current cohort lost <15 letters from baseline at both time points compared with 70% in the VISION trial at 54 weeks. Pegaptanib was well tolerated with no reported cases of endophthalmitis, traumatic cataract, or iatrogenic retinal detachment.
   Conclusions Pegaptanib was found to stabilise vision in a greater percentage of patients and produced greater overall visual improvement in this group of treatment-naive patients with NV-AMD compared with outcomes reported in the VISION trial; however, interpretation of these results should be tempered given the differences in design between this retrospective study and the prospective controlled trial. Eye (2010) 24, 793-798; doi:10.1038/eye.2009.232; published online 25 September 2009
C1 [Sivaprasad, S.; Hykin, P.] Moorfields Eye Hosp, Med Retina Dept, London, England.
   [Saeed, A.; Beatty, S.] Waterford Reg Hosp, Dept Ophthalmol, Waterford, Ireland.
   [Grisanti, S.] Univ Tubingen, Dept Vitreoretinal Surg, Ctr Ophthalmol, Tubingen, Germany.
   [Staurenghi, G.] Univ Milan, Sacco Hosp, Eye Clin, Dept Clin Sci Luigi Sacco, Milan, Italy.
   [Olea, J. L.] Hosp Son Dureta, Palma de Mallorca, Spain.
   [Campos, A.] Hosp Leiria, Dept Ophthalmol, Leiria, Portugal.
   [Barbosa, A.; Rito, L.] Ctr Hosp Coimbra, Dept Ophthalmol, Coimbra, Portugal.
   [Silva, R.] Hosp Univ Coimbra, Dept Ophthalmol, Coimbra, Portugal.
   [Faria, R.] Hosp Viseu, Viseu, Portugal.
   [Eldem, B.; Kadayifcilar, S.] Hacettepe Univ Sihhiye, Dept Ophthalmol, Ankara, Turkey.
   [Kolar, P.] Masaryk Univ, Univ Hosp Brno, Eye Clin, Brno, Czech Republic.
   [Feucht, N.] Tech Univ Munich, Augenklin Rechts Isar, Munich, Germany.
   [Maestroni, L.] Policlin Monza, Clin Oculist, Milan, Italy.
C3 University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust; Eberhard Karls University of Tubingen; Eberhard
   Karls University Hospital; University of Milan; Luigi Sacco Hospital;
   Hospital Universitari Son Espases; Hospital Universitari Son Dureta;
   Universidade de Coimbra; Centro Hospitalar e Universitario de Coimbra
   (CHUC); Universidade de Coimbra; Centro Hospitalar e Universitario de
   Coimbra (CHUC); Hacettepe University; Masaryk University Brno;
   University Hospital Brno; Technical University of Munich
RP Sivaprasad, S (通讯作者)，Kings Coll Hosp London, Laser & Retinal Res Unit, Denmark Hill, London SE5 9RS, England.
EM Senswathi@aol.com
RI Silva, Rufino M/J-2817-2012; Sivaprasad, S./D-6876-2015; Feucht,
   Nikolaus/ABB-2222-2021; Campos, António/ABE-8148-2021; Staurenghi,
   Giovanni/K-4388-2017
OI Silva, Rufino M/0000-0001-8676-0833; Sivaprasad, S./0000-0001-8952-0659;
   Campos, António/0000-0003-0490-5889; Kolar, Petr/0000-0003-3709-4648;
   Staurenghi, Giovanni/0000-0002-2299-5251; OLEA, JOSE
   LUIS/0000-0002-3645-8262
CR Ahmadi MA, 2008, EXPERT OPIN PHARMACO, V9, P3045, DOI [10.1517/14656560802473480, 10.1517/14656560802473480 ]
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Chakravarthy U, 2006, OPHTHALMOLOGY, V113, P1508, DOI 10.1016/j.ophtha.2006.02.064
   D'Amico DJ, 2006, OPHTHALMOLOGY, V113, P992, DOI 10.1016/j.ophtha.2006.02.027
   Ehlers JP, 2007, OPHTHAL SURG LAS IM, V38, P371, DOI 10.3928/15428877-20070901-03
   European Medicines Agency, EPARS AUTH MED PROD
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gonzales CR, 2005, RETINA-J RET VIT DIS, V25, P815
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Marcus DM, 2008, INVEST OPHTHALMOL VI, V49
   Murjaneh S, 2009, BRIT J OPHTHALMOL, V93, P468, DOI 10.1136/bjo.2008.141366
   PEDERSEN KB, 2008, ACTA OPHTHALMOL
   Quiram PA, 2007, RETINA-J RET VIT DIS, V27, P851, DOI 10.1097/IAE.0b013e31806458f0
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Singerman LJ, 2008, BRIT J OPHTHALMOL, V92, P1606, DOI 10.1136/bjo.2007.132597
NR 18
TC 6
Z9 7
U1 0
U2 5
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD MAY
PY 2010
VL 24
IS 5
BP 793
EP 798
DI 10.1038/eye.2009.232
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 595EG
UT WOS:000277592900007
PM 19786957
OA Bronze
DA 2022-11-30
ER

PT J
AU Raimundo, M
   Mira, F
   Cachulo, MD
   Barreto, P
   Ribeiro, L
   Farinha, C
   Lains, I
   Nunes, S
   Alves, D
   Figueira, J
   Merle, BMJ
   Delcourt, C
   Santos, L
   Silva, R
AF Raimundo, Miguel
   Mira, Filipe
   Cachulo, Maria da Luz
   Barreto, Patricia
   Ribeiro, Luisa
   Farinha, Claudia
   Lains, Ines
   Nunes, Sandrina
   Alves, Dalila
   Figueira, Joao
   Merle, Benedicte M. J.
   Delcourt, Cecile
   Santos, Lelita
   Silva, Rufino
TI Adherence to a Mediterranean diet, lifestyle and age-related macular
   degeneration: the Coimbra Eye Study - report 3
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration; epidemiology; Mediterranean diet;
   micronutrients; nutrition
ID CIGARETTE-SMOKING; PHYSICAL-ACTIVITY; 5-YEAR INCIDENCE; RISK;
   MACULOPATHY; OMEGA-3-FATTY-ACIDS; PREVALENCE; ANTIOXIDANTS; PORTUGAL;
   SURVIVAL
AB Purpose To characterize the lifestyle and nutritional risk profile associated with the Mediterranean diet in a Portuguese population with and without age-related macular degeneration (AMD). Methods Nested case-control study (n = 883) within the Coimbra Eye Study, including 434 subjects with AMD and 449 age- and sex-matched subjects without AMD. All enrolled subjects underwent a full risk assessment, including lifestyle-related risk factors and a thorough food frequency questionnaire. This allowed us to build an adherence score to the Mediterranean diet (mediSCORE, range 0-9) constructed from individual food intakes. Food intake was also further analysed by conversion to micronutrient consumption. Results Our results suggest that physical activity has a protective role in AMD [p = 0.018 after multivariate adjustment, OR: 0.69 (0.51-0.93)]. High (mediSCORE >= 6) was also found to be protective [p = 0.041, OR: 0.62 (95% CI: 0.38-0.97)]. Food group analysis unveiled a specific protective role for increased fruits consumption (p = 0.029). Finally, micronutrient analysis revealed a protective role associated with increased consumption of caffeine, fibres, beta-carotene, vitamin C and vitamin E (p < 0.05). Conclusion High mediSCORE appears to confer protection against the development of AMD in a Mediterranean population. This effect is driven by increased consumption of fruits and some antioxidant micronutrients, which emerged as statistically significant protective factors. Further studies are required to establish dietary recommendations with clinical application.
C1 [Raimundo, Miguel; Cachulo, Maria da Luz; Farinha, Claudia; Lains, Ines; Figueira, Joao; Silva, Rufino] Coimbra Univ Hosp Ctr CHUC, Ophthalmol Dept, Coimbra, Portugal.
   [Mira, Filipe; Cachulo, Maria da Luz; Figueira, Joao; Santos, Lelita; Silva, Rufino] Univ Coimbra, Fac Med, FMUC, Inst Biomed Imaging & Life Sci IBILI, Coimbra, Portugal.
   [Cachulo, Maria da Luz; Barreto, Patricia; Ribeiro, Luisa; Farinha, Claudia; Nunes, Sandrina; Alves, Dalila; Figueira, Joao; Silva, Rufino] Assoc Innovat & Biomed Res Light & Image AIBILI, Coimbra, Portugal.
   [Lains, Ines] Harvard Univ, Med Sch, Massachusetts Eye & Ear Infirm, Boston, MA 02138 USA.
   [Merle, Benedicte M. J.; Delcourt, Cecile] Univ Bordeaux, INSERM, Team LEHA, Bordeaux Populat Hlth Res Ctr,UMR 1219, Bordeaux, France.
   [Santos, Lelita] Coimbra Univ Hosp Ctr, Internal Med, Coimbra, Portugal.
C3 Universidade de Coimbra; Centro Hospitalar e Universitario de Coimbra
   (CHUC); Universidade de Coimbra; Universidade de Coimbra; Harvard
   University; Harvard Medical School; Massachusetts Eye & Ear Infirmary;
   Institut National de la Sante et de la Recherche Medicale (Inserm);
   UDICE-French Research Universities; Universite de Bordeaux; Universidade
   de Coimbra; Centro Hospitalar e Universitario de Coimbra (CHUC)
RP Raimundo, M (通讯作者)，CHU Coimbra, EPE Praceta Mota Pinto, P-3000075 Coimbra, Portugal.
EM mglraimundo@gmail.com
RI Merle, Benedicte MJ/AAQ-5021-2021; Delcourt, Cecile/I-2627-2013; Silva,
   Rufino M/J-2817-2012; Merle, Benedicte MJ/F-1247-2015; Farinha,
   Claudia/R-1392-2017
OI Merle, Benedicte MJ/0000-0003-1332-0954; Delcourt,
   Cecile/0000-0002-2099-0481; Silva, Rufino M/0000-0001-8676-0833; Merle,
   Benedicte MJ/0000-0003-1332-0954; Figueira, Joao P/0000-0002-3511-1515;
   Mira, Filipe/0000-0002-5682-3116; Santos, Lelita/0000-0002-0761-5097;
   Alves, Dalila/0000-0003-3296-179X; Farinha, Claudia/0000-0003-4596-0913;
   Cachulo, Maria Luz/0000-0002-0900-4548; Nunes,
   Sandrina/0000-0001-5401-9637
FU Novartis
FX This study was supported by Novartis.
CR Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Cachulo MD, 2016, ACTA OPHTHALMOL, V94, pE442, DOI 10.1111/aos.12950
   Cachulo MD, 2015, OPHTHALMOLOGICA, V233, P119, DOI 10.1159/000371584
   Chakravarthy U, 2007, OPHTHALMOLOGY, V114, P1157, DOI 10.1016/j.ophtha.2006.09.022
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chiu CJ, 2009, OPHTHALMOLOGY, V116, P939, DOI 10.1016/j.ophtha.2008.12.025
   Delcourt C, 1998, ARCH OPHTHALMOL-CHIC, V116, P1031, DOI 10.1001/archopht.116.8.1031
   Feart C, 2009, JAMA-J AM MED ASSOC, V302, P638, DOI 10.1001/jama.2009.1146
   Gopinath B, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122548
   Ho L, 2011, ARCH OPHTHALMOL-CHIC, V129, P758, DOI 10.1001/archophthalmol.2011.141
   Hogg RE, 2017, OPHTHALMOLOGY, V124, P82, DOI 10.1016/j.ophtha.2016.09.019
   Hu CC, 2017, ACTA OPHTHALMOL, V95, pE587, DOI 10.1111/aos.13204
   Islam FMA, 2014, OPHTHALMOLOGY, V121, P1428, DOI 10.1016/j.ophtha.2014.01.002
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Knudtson MD, 2006, BRIT J OPHTHALMOL, V90, P1461, DOI 10.1136/bjo.2006.103796
   Lopes C, 2000, VALIDACAO QUESTIONAR
   Mares JA, 2011, ARCH OPHTHALMOL-CHIC, V129, P470, DOI 10.1001/archophthalmol.2010.314
   Merle B, 2011, INVEST OPHTH VIS SCI, V52, P6004, DOI 10.1167/iovs.11-7254
   Merle BMJ, 2017, ACTA OPHTHALMOL, V95, pe763, DOI 10.1111/aos.13408
   Merle BMJ, 2015, AM J CLIN NUTR, V102, P1196, DOI 10.3945/ajcn.115.111047
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   Mozaffarieh M, 2003, NUTR J, V2, DOI 10.1186/1475-2891-2-20
   Mrowicka M, 2017, ACTA OPHTHALMOL, V95, P530, DOI 10.1111/aos.13289
   Piermarocchi S, 2012, EUR J OPHTHALMOL, V22, P216, DOI 10.5301/ejo.5000069
   Pinna A, 2016, ACTA OPHTHALMOL
   Shah SU, 2013, CAN J OPHTHALMOL, V48, P204, DOI 10.1016/j.jcjo.2013.01.013
   Sin HPY, 2013, ACTA OPHTHALMOL, V91, P6, DOI 10.1111/j.1755-3768.2011.02357.x
   Tan JSL, 2008, OPHTHALMOLOGY, V115, P334, DOI 10.1016/j.ophtha.2007.03.083
   Tomany SC, 2001, AM J OPHTHALMOL, V132, P271, DOI 10.1016/S0002-9394(01)00895-9
   TRICHOPOULOU A, 1995, BMJ-BRIT MED J, V311, P1457, DOI 10.1136/bmj.311.7018.1457
   Trichopoulou A, 2003, NEW ENGL J MED, V348, P2599, DOI 10.1056/NEJMoa025039
   vansLeeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101
   VINDING T, 1992, ACTA OPHTHALMOL, V70, P66
   WILLETT WC, 1995, AM J CLIN NUTR, V61, p1402S, DOI 10.1093/ajcn/61.6.1402S
   Williams PT, 2009, INVEST OPHTH VIS SCI, V50, P101, DOI 10.1167/iovs.08-2165
NR 38
TC 18
Z9 18
U1 0
U2 14
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD DEC
PY 2018
VL 96
IS 8
BP E926
EP E932
DI 10.1111/aos.13775
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HC3IB
UT WOS:000451694500018
PM 30218481
OA Bronze, Green Submitted
DA 2022-11-30
ER

PT J
AU Matsuba, S
   Tabuchi, H
   Ohsugi, H
   Enno, H
   Ishitobi, N
   Masumoto, H
   Kiuchi, Y
AF Matsuba, Shinji
   Tabuchi, Hitoshi
   Ohsugi, Hideharu
   Enno, Hiroki
   Ishitobi, Naofumi
   Masumoto, Hiroki
   Kiuchi, Yoshiaki
TI Accuracy of ultra-wide-field fundus ophthalmoscopy-assisted deep
   learning, a machine-learning technology, for detecting age-related
   macular degeneration
SO INTERNATIONAL OPHTHALMOLOGY
LA English
DT Article
DE Ultra-wide-field scanning laser ophthalmoscope; Neural networks;
   Age-related macular degeneration; Pattern recognition; Telemedicine
ID RANIBIZUMAB; TERM; AMD
AB PurposeTo predict exudative age-related macular degeneration (AMD), we combined a deep convolutional neural network (DCNN), a machine-learning algorithm, with Optos, an ultra-wide-field fundus imaging system.MethodsFirst, to evaluate the diagnostic accuracy of DCNN, 364 photographic images (AMD: 137) were amplified and the area under the curve (AUC), sensitivity and specificity were examined. Furthermore, in order to compare the diagnostic abilities between DCNN and six ophthalmologists, we prepared yield 84 sheets comprising 50% of normal and wet-AMD data each, and calculated the correct answer rate, specificity, sensitivity, and response times.ResultsDCNN exhibited 100% sensitivity and 97.31% specificity for wet-AMD images, with an average AUC of 99.76%. Moreover, comparing the diagnostic abilities of DCNN versus six ophthalmologists, the average accuracy of the DCNN was 100%. On the other hand, the accuracy of ophthalmologists, determined only by Optos images without a fundus examination, was 81.9%.ConclusionA combination of DCNN with Optos images is not better than a medical examination; however, it can identify exudative AMD with a high level of accuracy. Our system is considered useful for screening and telemedicine.
C1 [Matsuba, Shinji; Tabuchi, Hitoshi; Ohsugi, Hideharu; Ishitobi, Naofumi; Masumoto, Hiroki] Saneikai Tsukazaki Hosp, Dept Ophthalmol, 68-1 Aboshi Waku, Himeji, Hyogo 6711227, Japan.
   [Matsuba, Shinji; Kiuchi, Yoshiaki] Hiroshima Univ, Grad Sch Biomed Sci, Dept Ophthalmol & Visual Sci, 1-2-3 Minami, Kasumi, Hioroshima 7348553, Japan.
   [Enno, Hiroki] Rist Inc, Meguro Ku, 2-11-3 Meguro, Tokyo 1530063, Japan.
C3 Hiroshima University
RP Matsuba, S (通讯作者)，Saneikai Tsukazaki Hosp, Dept Ophthalmol, 68-1 Aboshi Waku, Himeji, Hyogo 6711227, Japan.
EM s.matsuba@tsukazaki-eye.net
CR Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Burlina P, 2017, COMPUT BIOL MED, V82, P80, DOI 10.1016/j.compbiomed.2017.01.018
   Deng J, 2009, PROC CVPR IEEE, P248, DOI 10.1109/CVPRW.2009.5206848
   Gerding H, 2016, KLIN MONATSBL AUGENH, V233, P471, DOI 10.1055/s-0041-111835
   Ghasemi Falavarjani K, 2017, VISION RES, VS0042-6989, P30118
   Glorot X., 2011, P 14 INT C ART INT S, P315, DOI DOI 10.1002/ECS2.1832
   Gordois A, 2012, GLOB PUBLIC HEALTH, V7, P465, DOI 10.1080/17441692.2011.634815
   Gulshan V, 2016, JAMA-J AM MED ASSOC, V316, P2402, DOI 10.1001/jama.2016.17216
   Ioffe S., 2015, PR MACH LEARN RES, P448, DOI DOI 10.1007/S13398-014-0173-7.2
   LeCun Y, 2015, NATURE, V521, P436, DOI 10.1038/nature14539
   Lee C.-Y., 2014, ARXIV14095185
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Litjens G, 2016, SCI REP-UK, V6, DOI 10.1038/srep26286
   Liu SQ, 2015, IEEE T BIO-MED ENG, V62, P1132, DOI 10.1109/TBME.2014.2372011
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Mrsnik M, 2013, GLOBAL AGING 2013 RI
   Nagiel A, 2016, RETINA-J RET VIT DIS, V36, P660, DOI 10.1097/IAE.0000000000000937
   Nesterov Yu. E., 1983, Doklady Akademii Nauk SSSR, V269, P543
   Ohsugi H, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09891-x
   Pinaya WHL, 2016, SCI REP-UK, V6, DOI 10.1038/srep38897
   Qian N, 1999, NEURAL NETWORKS, V12, P145, DOI 10.1016/S0893-6080(98)00116-6
   Rasmussen A, 2013, OPHTHALMOLOGY, V120, P2630, DOI 10.1016/j.ophtha.2013.05.018
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Russakovsky O, 2015, INT J COMPUT VISION, V115, P211, DOI 10.1007/s11263-015-0816-y
   Schisterman EF, 2008, STAT MED, V27, P297, DOI 10.1002/sim.2993
   Selvaraju RR, 2020, INT J COMPUT VISION, V128, P336, DOI 10.1007/s11263-019-01228-7
   Soliman AZ, 2012, SEMIN OPHTHALMOL, V27, P221, DOI 10.3109/08820538.2012.708812
   Srivastava N, 2014, J MACH LEARN RES, V15, P1929
   Witmer MT, 2012, EYE, V26, P1209, DOI 10.1038/eye.2012.122
   Witmer MT, 2013, CLIN OPHTHALMOL, V7, P389, DOI 10.2147/OPTH.S41731
   Yasuda M, 2009, OPHTHALMOLOGY, V116, P2135, DOI 10.1016/j.ophtha.2009.04.017
NR 32
TC 42
Z9 43
U1 1
U2 8
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0165-5701
EI 1573-2630
J9 INT OPHTHALMOL
JI Int. Ophthalmol.
PD JUN
PY 2019
VL 39
IS 6
BP 1269
EP 1275
DI 10.1007/s10792-018-0940-0
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA IA9PI
UT WOS:000469888700010
PM 29744763
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Lains, I
   Miller, JB
   Park, DH
   Tsikata, E
   Davoudi, S
   Rahmani, S
   Pierce, J
   Silva, R
   Chen, TC
   Kim, IK
   Vavvas, D
   Miller, JW
   Husain, D
AF Lains, Ines
   Miller, John B.
   Park, Dong H.
   Tsikata, Edem
   Davoudi, Samaneh
   Rahmani, Safa
   Pierce, Jonathan
   Silva, Rufino
   Chen, Teresa C.
   Kim, Ivana K.
   Vavvas, Demetrios
   Miller, Joan W.
   Husain, Deeba
TI Structural Changes Associated with Delayed Dark Adaptation in
   Age-Related Macular Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; SUBRETINAL DRUSENOID DEPOSITS; RETICULAR
   PSEUDODRUSEN; VISUAL FUNCTION; IMAGING BIOMARKERS; SENSITIVITY;
   PREVALENCE; DISEASE; SPECIFICITY; PROGRESSION
AB Purpose: To examine the relationship between dark adaptation (DA) and optical coherence tomography (OCT)-based macular morphology in age-related macular degeneration (AMD).
   Design: Prospective, cross-sectional study.
   Participants: Patients with AMD and a comparison group (>50 years) without any vitreoretinal disease.
   Methods: All participants were imaged with spectral-domain OCT and color fundus photographs, and then staged for AMD (Age-related Eye Disease Study system). Both eyes were tested with the AdaptDx (MacuLogix, Middletown, PA) DA extended protocol (20 minutes). A software program was developed to map the DA testing spot (2 degrees circle, 5 degrees superior to the fovea) to the OCT B-scans. Two independent graders evaluated the B-scans within this testing spot, as well as the entire macula, recording the presence of several AMD-associated abnormalities. Multilevel mixed-effects models (accounting for correlated outcomes between 2 eyes) were used for analyses.
   Main Outcome Measures: The primary outcome was rod-intercept time (RIT), defined in minutes, as a continuous variable. For subjects unable to reach RIT within the 20 minutes of testing, the value of 20 was assigned.
   Results: We included 137 eyes (n = 77 subjects), 72.3% (n = 99 eyes) with AMD and the remainder belonging to the comparison group. Multivariable analysis revealed that even after adjusting for age and AMD stage, the presence of any abnormalities within the DA testing spot (beta = 4.8, P < 0.001), as well as any abnormalities in the macula (beta = 2.4, P = 0.047), were significantly associated with delayed RITs and therefore impaired DA. In eyes with no structural changes within the DA testing spot (n = 76, 55.5%), the presence of any abnormalities in the remaining macula was still associated with delayed RITs (beta = 2.00, P = 0.046). Presence of subretinal drusenoid deposits and ellipsoid zone disruption were a consistent predictor of RIT, whether located within the DA testing spot (P = 0.001 for both) or anywhere in the macula (P < 0.001 for both). Within the testing spot, the presence of classic drusen or serous pigment epithelium detachment was also significantly associated with impairments in DA (P <= 0.018).
   Conclusions: Our results suggest a significant association between macular morphology evaluated by OCT and time to dark-adapt. Subretinal drusenoid deposits and ellipsoid zone changes seem to be strongly associated with impaired dark adaptation. (C) 2017 by the American Academy of Ophthalmology
C1 [Lains, Ines; Miller, John B.; Park, Dong H.; Davoudi, Samaneh; Rahmani, Safa; Pierce, Jonathan; Kim, Ivana K.; Vavvas, Demetrios; Miller, Joan W.; Husain, Deeba] Harvard Med Sch, Dept Ophthalmol, Harvard Ophthalmol AMD Ctr Excellence, Retina Serv,Massachusetts Eye & Ear, Boston, MA 02114 USA.
   [Lains, Ines; Silva, Rufino] Univ Coimbra, Fac Med, Coimbra, Portugal.
   [Lains, Ines; Silva, Rufino] AIBILI, Assoc Innovat & Biomed Res Light, Coimbra, Portugal.
   [Lains, Ines; Silva, Rufino] Ctr Hosp Coimbra, Coimbra, Portugal.
   [Lains, Ines; Silva, Rufino] Univ Coimbra, Coimbra, Portugal.
   [Park, Dong H.] Kyungpook Natl Univ, Sch Med, Dept Ophthalmol, Daegu, South Korea.
   [Tsikata, Edem; Chen, Teresa C.] Harvard Med Sch, Dept Ophthalmol, Glaucoma Serv, Massachusetts Eye & Ear, Boston, MA 02114 USA.
C3 Harvard University; Harvard Medical School; Massachusetts Eye & Ear
   Infirmary; Universidade de Coimbra; Universidade de Coimbra;
   Universidade de Coimbra; Centro Hospitalar e Universitario de Coimbra
   (CHUC); Universidade de Coimbra; Kyungpook National University; Harvard
   University; Harvard Medical School; Massachusetts Eye & Ear Infirmary
RP Husain, D (通讯作者)，Harvard Med Sch, Massachusetts Eye & Ear, Retina Serv, 243 Charles St, Boston, MA 02114 USA.
EM Deeba_Husain@meei.harvard.edu
RI Miller, John J/GZG-5663-2022; Silva, Rufino M/J-2817-2012
OI Silva, Rufino M/0000-0001-8676-0833; Husain, Deeba/0000-0002-8494-0950;
   Vavvas, Demetrios/0000-0002-8622-6478; Kim, Ivana/0000-0003-0310-6129;
   Lains, Ines/0000-0002-8136-4724; Chen, Teresa/0000-0001-5327-2016
FU Miller Retina Research Fund (Massachusetts Eye and Ear Infirmary);
   Champalimaud Vision Award; Research to Prevent Blindness, Inc, New York;
   Portuguese Foundation for Science and Technology/Harvard Medical School
   Portugal Program [HMSP-ICJ/006/2013]; Basic Science Research Program of
   the National Research Foundation of Korea (NRF); Ministry of Education
   [NRF-2014R1A1A2055007]; Korea Health Technology R&D Project of the Korea
   Health Industry Development Institute (KHIDI); Ministry of Health &
   Welfare, Republic of Korea [HI16C1501]; NATIONAL EYE INSTITUTE
   [T32EY007145] Funding Source: NIH RePORTER
FX The authors made the following disclosures: J.W.M.: Scientific Advisory
   Board - MacuLogix, but receives no compensation; Financial support -
   Miller Retina Research Fund (Massachusetts Eye and Ear Infirmary);
   Champalimaud Vision Award; Unrestricted departmental grant - Research to
   Prevent Blindness, Inc, New York; Portuguese Foundation for Science and
   Technology/Harvard Medical School Portugal Program (HMSP-ICJ/006/2013).
   D.H.P.: Financial support - Basic Science Research Program of the
   National Research Foundation of Korea (NRF); Funding - Ministry of
   Education (NRF-2014R1A1A2055007); Korea Health Technology R&D Project of
   the Korea Health Industry Development Institute (KHIDI); Ministry of
   Health & Welfare, Republic of Korea (HI16C1501). All of the
   above-mentioned funding organizations had no role in the design or
   conduct of this research. Massachusetts Eye and Ear Infirmary received
   donation of an AdaptDx dark adaptometer.
CR Abdelfattah NS, 2016, INVEST OPHTH VIS SCI, V57, P1839, DOI 10.1167/iovs.15-18572
   Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Bonate PL, 2011, PHARMACOKINETIC-PHARMACODYNAMIC MODELING AND SIMULATION, SECOND EDITION, P189, DOI 10.1007/978-1-4419-9485-1_6
   Burton P, 1998, STAT MED, V17, P1261, DOI 10.1002/(SICI)1097-0258(19980615)17:11<1261::AID-SIM846>3.0.CO;2-Z
   Casalino G, 2016, INVEST OPHTH VIS SCI, V57, pOCT288, DOI 10.1167/iovs.15-18753
   Chan H, 2016, INVEST OPHTH VIS SCI, V57, P3058, DOI 10.1167/iovs.16-19487
   Chew EY, 2015, AM J OPHTHALMOL, V159, P659, DOI 10.1016/j.ajo.2014.12.013
   Clark ME, 2011, BRIT J OPHTHALMOL, V95, P1427, DOI 10.1136/bjo.2010.190355
   Coscas F, 2015, INVEST OPHTH VIS SCI, V56, P4129, DOI 10.1167/iovs.15-16735
   Curcio CA, 2000, INVEST OPHTH VIS SCI, V41, P2015
   Curcio CA, 2001, EYE, V15, P376, DOI 10.1038/eye.2001.140
   CURCIO CA, 1990, J COMP NEUROL, V292, P497, DOI 10.1002/cne.902920402
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   Curcio CA, 2011, INVEST OPHTH VIS SCI, V52, P3943, DOI 10.1167/iovs.10-6377
   Danis RP, 2013, INVEST OPHTH VIS SCI, V54, P4548, DOI 10.1167/iovs.13-11804
   de Sisternes L, 2014, INVEST OPHTH VIS SCI, V55, P7093, DOI 10.1167/iovs.14-14918
   Delori F, 2011, INVEST OPHTH VIS SCI, V52, P9379, DOI 10.1167/iovs.11-8319
   Dimitrov PN, 2012, INVEST OPHTH VIS SCI, V53, P5213, DOI 10.1167/iovs.11-8958
   Dimitrov PN, 2011, INVEST OPHTH VIS SCI, V52, P9457, DOI 10.1167/iovs.10-7043
   Flamendorf J, 2015, OPHTHALMOLOGY, V122, P2053, DOI 10.1016/j.ophtha.2015.06.023
   Garlipp MA, 2013, EXP EYE RES, V113, P192, DOI 10.1016/j.exer.2013.02.003
   Haymes SA, 2006, INVEST OPHTH VIS SCI, V47, P2739, DOI 10.1167/iovs.05-1419
   Hogg RE, 2006, PROG RETIN EYE RES, V25, P249, DOI 10.1016/j.preteyeres.2005.11.002
   Jackson GR, 1999, VISION RES, V39, P3975, DOI 10.1016/S0042-6989(99)00092-9
   Jackson GR, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.13-13745
   Jacobson SG, 2016, INVEST OPHTH VIS SCI, V57, DOI 10.1167/iovs.15-17654
   JACOBSON SG, 1995, NAT GENET, V11, P27, DOI 10.1038/ng0995-27
   Lamb TD, 2004, PROG RETIN EYE RES, V23, P307, DOI 10.1016/j.preteyeres.2004.03.001
   Leuschen JN, 2013, OPHTHALMOLOGY, V120, P140, DOI 10.1016/j.ophtha.2012.07.004
   McBain VA, 2007, EYE, V21, P367, DOI 10.1038/sj.eye.6702212
   Miller JW, 2013, AM J OPHTHALMOL, V155, P1, DOI 10.1016/j.ajo.2012.10.018
   Mrejen S, 2014, OPHTHALMOLOGY, V121, P545, DOI 10.1016/j.ophtha.2013.09.026
   Munch IC, 2016, BMC OPHTHALMOL, V16, DOI 10.1186/s12886-016-0273-6
   Owsley C, 2015, CURR EYE RES, V41, P1
   Owsley C, 2007, OPHTHALMOLOGY, V114, P1728, DOI 10.1016/j.ophtha.2006.12.023
   Owsley C, 2016, INVEST OPHTH VIS SCI, V57, P1782, DOI 10.1167/iovs.15-18962
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   Pilotto E, 2015, INVEST OPHTH VIS SCI, V56, P8120, DOI 10.1167/iovs.15-17366
   Rudolf M, 2008, EXP EYE RES, V87, P402, DOI 10.1016/j.exer.2008.07.010
   Salvatore S, 2014, RETINA-J RET VIT DIS, V34, P989, DOI 10.1097/IAE.0000000000000022
   Schmidt-Erfurth U, 2016, PROG RETIN EYE RES, V50, P1, DOI 10.1016/j.preteyeres.2015.07.007
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P5009, DOI 10.1167/iovs.11-7235
   Scoles D., 2015, RETINA, V36, P1
   Sevilla MB, 2016, AM J OPHTHALMOL, V165, P65, DOI 10.1016/j.ajo.2016.02.021
   Sivaprasad S, 2016, SURV OPHTHALMOL, V61, P521, DOI 10.1016/j.survophthal.2016.02.005
   Smith RT, 2009, AM J OPHTHALMOL, V148, P733, DOI 10.1016/j.ajo.2009.06.028
   Sobrin L, 2014, PROG RETIN EYE RES, V40, P1, DOI 10.1016/j.preteyeres.2013.12.004
   Sohrab MA, 2011, INVEST OPHTH VIS SCI, V52, P5743, DOI 10.1167/iovs.10-6942
   Spaide RF, 2011, RETINA-J RET VIT DIS, V31, P1609, DOI 10.1097/IAE.0b013e3182247535
   Staurenghi G, 2014, OPHTHALMOLOGY, V121, P1572, DOI 10.1016/j.ophtha.2014.02.023
   Steinberg JS, 2016, AM J OPHTHALMOL, V168, P52, DOI 10.1016/j.ajo.2016.04.025
   Steinberg JS, 2015, JAMA OPHTHALMOL, V133, P690, DOI 10.1001/jamaophthalmol.2015.0477
   Tahir HJ, 2017, EXP EYE RES, V155, P47, DOI 10.1016/j.exer.2016.11.016
   Takahashi A, 2016, AM J OPHTHALMOL, V168, P260, DOI 10.1016/j.ajo.2016.06.006
   Ueda-Arakawa N, 2013, RETINA-J RET VIT DIS, V33, P490, DOI 10.1097/IAE.0b013e318276e0ae
   Vujosevic S, 2011, OPHTHALMOLOGICA, V225, P155, DOI 10.1159/000320340
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu ZC, 2013, INVEST OPHTH VIS SCI, V54, P2800, DOI 10.1167/iovs.13-11613
   Yehoshua Z, 2013, INVEST OPHTH VIS SCI, V54, P2429, DOI 10.1167/iovs.12-11569
   Ying GS, 2008, OPHTHALMOLOGY, V115, P1876, DOI 10.1016/j.ophtha.2008.05.023
   Yonekawa Y, 2015, J CLIN MED, V4, P343, DOI 10.3390/jcm4020343
   Zarubina AV, 2016, OPHTHALMOLOGY, V123, P1090, DOI 10.1016/j.ophtha.2015.12.034
   Zhang YH, 2014, AM J OPHTHALMOL, V158, P584, DOI 10.1016/j.ajo.2014.05.038
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 65
TC 40
Z9 40
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD SEP
PY 2017
VL 124
IS 9
BP 1340
EP 1352
DI 10.1016/j.ophtha.2017.03.061
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FD8RT
UT WOS:000407792500018
PM 28501377
DA 2022-11-30
ER

PT J
AU Macnamara, A
   Coussens, S
   Chen, C
   Schinazi, VR
   Loetscher, T
AF Macnamara, Anne
   Coussens, Scott
   Chen, Celia
   Schinazi, Victor R.
   Loetscher, Tobias
TI The psychological impact of instrumental activities of daily living on
   people with simulated age-related macular degeneration
SO BJPSYCH OPEN
LA English
DT Article
DE Age-related macular degeneration; visual impairment; activities of daily
   living; stress; anxiety
ID VISUAL IMPAIRMENT; OLDER-ADULTS; VISION; STRESS
AB Background People with age-related macular degeneration (AMD) can report reduced mental health. There is also evidence that they struggle with daily tasks because of vision loss. Aims The purpose of this study was to assess the psychological impact of instrumental activities of daily living on people with simulated AMD. Method Twenty-four normally sighted participants completed 12 household tasks, in a simulated home environment, under a moderate-to-severe AMD simulation. Participants' psychological state was measured through self-report questionnaires and physiological measurements related to anxiety and stress. Tasks were completed twice, under counterbalanced vision conditions (normal and simulated AMD). Results Linear mixed models on vision condition (normal versus simulated AMD) and trial order (trial 1 versus trial 2) revealed a significant large negative effect of the AMD simulation on time to complete tasks, and the anxiety, task engagement and distress self-reports (all P < 0.024, all omega(2) > 0.177). There were also significant medium-large effects of trial order on time, task incompletion, task errors, and the anxiety and task engagement self-reports (all P < 0.047, all omega(2) > 0.130), whereby the results improved during the second attempt at the tasks. No physiological measures were significant (all P > 0.05). Conclusions Completing instrumental activities of daily living under an AMD simulation had a negative impact on participants' self-reported mental state. The observed trial order effects also illuminated how practice with tasks could ease anxiety and stress over time.
C1 [Macnamara, Anne; Coussens, Scott; Loetscher, Tobias] Univ South Australia, Cognit Ageing & Impairment Neurosci Lab, UniSA Justice & Soc, Adelaide, SA, Australia.
   [Chen, Celia] Flinders Univ S Australia, Flinders Med Ctr, Dept Ophthalmol, Adelaide, SA, Australia.
   [Schinazi, Victor R.] Bond Univ, Fac Soc & Design, Dept Psychol, Robina, Australia.
   [Schinazi, Victor R.] Campus Res Excellence & Technol Enterprise CREATE, Future Hlth Technol, Singapore ETH Ctr, Singapore, Singapore.
C3 University of South Australia; Flinders Medical Centre; Flinders
   University South Australia; Bond University
RP Macnamara, A (通讯作者)，Univ South Australia, Cognit Ageing & Impairment Neurosci Lab, UniSA Justice & Soc, Adelaide, SA, Australia.
EM anne.macnamara@mymail.unisa.edu.au
OI Loetscher, Tobias/0000-0003-1967-2926
FU Australian Government Research Training Program Scholarship - National
   Health and Medical Research Council Dementia Research Leadership
   Fellowship [GNT1136269]
FX A.M. is supported by the Australian Government Research Training Program
   Scholarship and T.L. is funded by a National Health and Medical Research
   Council Dementia Research Leadership Fellowship (grant number
   GNT1136269). Declaration of
CR Al Sayed C., 2017, HLTH TELECOMM SYST N, V6, P12
   Bakker K, 2019, BRIT J OCCUP THER, V82, P485, DOI 10.1177/0308022619841491
   Ben-Shachar M., 2020, J OPEN SOURCE SOFTW, V5, P2815, DOI 10.21105/joss.02815
   Berman K, 2006, INT PSYCHOGERIATR, V18, P415, DOI 10.1017/S1041610205002905
   Bernard JB, 2007, VISION RES, V47, P3447, DOI 10.1016/j.visres.2007.10.005
   Black Alex, 2005, Clin Exp Optom, V88, P212
   Butt T, 2015, BRIT J OPHTHALMOL, V99, P540, DOI 10.1136/bjophthalmol-2014-305802
   Carre Technologies, 2021, HEX SMART GARM SPEC
   Carre Technologies, 2022, HEX API DOC
   Cherry K, 2019, WHAT ARE PRACTICE EF
   Copolillo A, 2017, OCCUP THER HEALTH CA, V31, P115, DOI 10.1080/07380577.2016.1278295
   Court H, 2014, BMC MED, V12, DOI 10.1186/s12916-014-0181-7
   Field A., 2013, DISCOVERING STAT USI
   Fork in the Road Vision Rehabilitation Services, 2019, LOW VIS SIM
   Gopinath B, 2014, MATURITAS, V77, P263, DOI 10.1016/j.maturitas.2013.12.001
   Grantcharov PD, 2019, BJS OPEN, V3, P119, DOI 10.1002/bjs5.104
   Heesterbeek TJ, 2017, OPHTHAL PHYSL OPT, V37, P385, DOI 10.1111/opo.12388
   Helton WS, 2015, EUR J PSYCHOL ASSESS, V31, P20, DOI 10.1027/1015-5759/a000200
   Helton WS., 2004, P HUMAN FACTORS ERGO, V48, P1238, DOI 10.1177/154193120404801107
   Ho E, 2019, J VISION, V19, DOI 10.1167/19.13.22
   Hochberg C, 2012, INVEST OPHTH VIS SCI, V53, P3201, DOI 10.1167/iovs.12-9469
   Jonas JB, 2017, ASIA-PAC J OPHTHALMO, V6, P493, DOI 10.22608/APO.2017251
   Kim HG, 2018, PSYCHIAT INVEST, V15, P235, DOI 10.30773/pi.2017.08.17
   Le P., 2020, J VITREORETINAL DIS, DOI [10.1177/2474126420936455, DOI 10.1177/2474126420936455]
   Legters K, 2002, PHYS THER, V82, P264, DOI 10.1093/ptj/82.3.264
   Macnamara A, 2022, SCI REP-UK, V12, DOI 10.1038/s41598-022-07924-8
   Macnamara A, 2021, FRONT NEUROSCI-SWITZ, V15, DOI 10.3389/fnins.2021.663062
   Martens MAG, 2019, J PSYCHOPHARMACOL, V33, P1264, DOI 10.1177/0269881119860156
   Martinez CAG, 2017, USE R, P1, DOI 10.1007/978-3-319-65355-6
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Owsley C, 2016, ANNU REV VIS SCI, V2, P255, DOI 10.1146/annurev-vision-111815-114550
   Pardhan S, 2015, INVEST OPHTH VIS SCI, V56, P7169, DOI 10.1167/iovs.15-16556
   Pinquart M, 2011, BRIT J VISUAL IMPA, V29, P27, DOI 10.1177/0264619610389572
   Rousek JB, 2011, INT J IND ERGONOM, V41, P447, DOI 10.1016/j.ergon.2011.05.002
   Silva CS, 2015, CHRON RESP DIS, V12, P189, DOI 10.1177/1479972315576143
   Spielberger CD, 1983, STATE TRAIT ANXIETY
   Taylor DJ, 2020, BRIT J OPHTHALMOL, V104, P529, DOI 10.1136/bjophthalmol-2019-313864
   Taylor DJ, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-011504
   Tipton MJ, 2017, J PHYSIOL-LONDON, V595, P5729, DOI 10.1113/JP274596
   van der Aa HPA, 2015, INVEST OPHTH VIS SCI, V56, P849, DOI 10.1167/iovs.14-15848
   van Landingham SW, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-10
   van Schaik L, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0213256
   Varadaraj V, 2018, AM J OPHTHALMOL, V186, P138, DOI 10.1016/j.ajo.2017.11.026
   Walsh DV, 2014, VISION RES, V96, P75, DOI 10.1016/j.visres.2014.01.005
   Wood JM, 2011, INVEST OPHTH VIS SCI, V52, P5088, DOI 10.1167/iovs.10-6644
NR 45
TC 0
Z9 0
U1 1
U2 1
PU CAMBRIDGE UNIV PRESS
PI CAMBRIDGE
PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND
SN 2056-4724
J9 BJPSYCH OPEN
JI BJPsych Open
PD AUG 8
PY 2022
VL 8
IS 5
AR e152
DI 10.1192/bjo.2022.558
PG 10
WC Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Psychiatry
GA 3P0SO
UT WOS:000837249000001
PM 35938537
OA gold, Green Published, Green Accepted
DA 2022-11-30
ER

PT J
AU Rouvas, A
   Chatziralli, I
   Androu, A
   Mpougatsou, P
   Alonistiotis, D
   Douvali, M
   Kabanarou, SA
   Theodossiadis, P
AF Rouvas, Alexandros
   Chatziralli, Irini
   Androu, Angeliki
   Mpougatsou, Panagiota
   Alonistiotis, Dimitrios
   Douvali, Maria
   Kabanarou, Stamatina A.
   Theodossiadis, Panagiotis
TI Ranibizumab versus aflibercept for the treatment of vascularized pigment
   epithelium detachment due to age-related macular degeneration
SO INTERNATIONAL OPHTHALMOLOGY
LA English
DT Article
DE Aflibercept; Age-related macular degeneration; Pigment epithelium
   detachment; Ranibizumab; Treatment
ID OCCULT CHOROIDAL NEOVASCULARIZATION; INTRAVITREAL RANIBIZUMAB;
   BEVACIZUMAB; TEARS; PATHOGENESIS; THERAPY
AB PurposeTo compare the efficacy and safety of two intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents, ranibizumab and aflibercept, for the treatment of vascularized pigment epithelium detachment (vPED) due to age-related macular degeneration (AMD) in a follow-up time of 12months.MethodsParticipants in this study were 71 patients (71 eyes) with vPED due to AMD, who were treated with intravitreal 0.5mg ranibizumab (n=38) or 2.0mg aflibercept (n=33) and had at least 12-month follow-up. All patients underwent best-corrected visual acuity (BCVA) measurement and optical coherence tomography at baseline and at every visit. The PED height, the presence of subretinal fluid (SRF), intraretinal fluid and diffuse macular edema (DME) were recorded at each visit.ResultsThere was a statistically significant difference in BCVA between the two groups at month 12 in favor of aflibercept. However, both agents were found to improve or stabilize BCVA in the majority of patients at the end of the follow-up. The change in PED height did not differ significantly between the two groups at the end of the follow-up with similar number of injections. At month 12, there was a significant improvement in SRF presence in both groups compared to baseline.ConclusionsAlthough aflibercept was found to be superior to ranibizumab regarding BCVA improvement, both agents showed anatomical effectiveness with significant reduction in PED height and SRF absorption in patients with vPED due to AMD.
C1 [Rouvas, Alexandros; Chatziralli, Irini; Androu, Angeliki; Mpougatsou, Panagiota; Alonistiotis, Dimitrios; Douvali, Maria; Theodossiadis, Panagiotis] Univ Athens, Attikon Hosp, Dept Ophthalmol 2, 28 Papanastasiou St, Athens 17342, Greece.
   [Kabanarou, Stamatina A.] Red Cross Hosp, Korgialeneio Benakeio, Med Retina Dept, Athens, Greece.
C3 National & Kapodistrian University of Athens; University Hospital
   Attikon
RP Chatziralli, I (通讯作者)，Univ Athens, Attikon Hosp, Dept Ophthalmol 2, 28 Papanastasiou St, Athens 17342, Greece.
EM eirchat@yahoo.gr
RI Chatziralli, Irini/AAG-4779-2020
OI Chatziralli, Irini/0000-0001-8523-1024
CR Ach T, 2010, RETINA-J RET VIT DIS, V30, P1420, DOI 10.1097/IAE.0b013e3181d87e97
   Broadhead GK, 2015, RETINA-J RET VIT DIS, V35, P975, DOI 10.1097/IAE.0000000000000409
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chan CK, 2010, RETINA-J RET VIT DIS, V30, P203, DOI 10.1097/IAE.0b013e3181babda5
   Chen E, 2007, RETINA-J RET VIT DIS, V27, P445, DOI 10.1097/01.iae.0000249574.89437.40
   CHUANG EL, 1988, AM J OPHTHALMOL, V105, P285, DOI 10.1016/0002-9394(88)90011-6
   Clemens CR, 2017, ACTA OPHTHALMOL
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Doguizi S, 2014, RETINA-J RET VIT DIS, V34, P1156, DOI 10.1097/IAE.0000000000000056
   Holz FG, 2004, AM J OPHTHALMOL, V137, P504, DOI 10.1016/j.ajo.2003.11.026
   Inoue M, 2013, RETINA-J RET VIT DIS, V33, P990, DOI 10.1097/IAE.0b013e3182755793
   Iordanous Y, 2014, CAN J OPHTHALMOL, V49, P367, DOI 10.1016/j.jcjo.2014.05.010
   Joachim N, 2015, OPHTHALMOLOGY, V122, P2482, DOI 10.1016/j.ophtha.2015.08.002
   Mehta S, 2015, PRIMARY CARE, V42, P377, DOI 10.1016/j.pop.2015.05.009
   Mrejen S, 2013, RETINA-J RET VIT DIS, V33, P1735, DOI 10.1097/IAE.0b013e3182993f66
   Parodi MB, 2013, AM J OPHTHALMOL, V155, P103, DOI 10.1016/j.ajo.2012.07.001
   Pauleikhoff D, 2002, GRAEF ARCH CLIN EXP, V240, P533, DOI 10.1007/s00417-002-0505-8
   Ritter M, 2010, EYE, V24, P962, DOI 10.1038/eye.2009.265
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Stewart MW, 2012, CLIN OPHTHALMOL, V6, P1175, DOI 10.2147/OPTH.S33372
   Veritti D, 2017, EUR J OPHTHALMOL, V27, P74, DOI 10.5301/ejo.5000880
   Wasmuth S, 2010, OPHTHALMOLOGE, V107, P1109, DOI 10.1007/s00347-010-2142-7
   Wolf A, 2013, RETINA-J RET VIT DIS, V33, P1843, DOI 10.1097/IAE.0b013e318287d9be
   YANNUZZI LA, 1994, RETINA-J RET VIT DIS, V14, P99, DOI 10.1097/00006982-199414020-00003
   Yuksel H, 2013, ARQ BRAS OFTALMOL, V76, P209, DOI 10.1590/S0004-27492013000400002
   Zajac-Pytrus HM, 2015, ADV CLIN EXP MED, V24, P1099, DOI 10.17219/acem/27093
NR 27
TC 2
Z9 3
U1 0
U2 2
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0165-5701
EI 1573-2630
J9 INT OPHTHALMOL
JI Int. Ophthalmol.
PD FEB
PY 2019
VL 39
IS 2
BP 431
EP 440
DI 10.1007/s10792-018-0833-2
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HO7YB
UT WOS:000461164800019
PM 29404860
DA 2022-11-30
ER

PT J
AU Lu, Y
   Shi, YH
   Xue, CY
   Yin, J
   Huang, ZP
AF Lu, Yan
   Shi, Yuhua
   Xue, Chunyan
   Yin, Jie
   Huang, Zhenping
TI Pooled-analysis of the associations between three polymorphisms in the
   VEGF gene and age-related macular degeneration
SO MOLECULAR BIOLOGY REPORTS
LA English
DT Article
DE The vascular endothelial growth factor gene; Polymorphism; Age-related
   macular degeneration; Meta-analysis
ID ENDOTHELIAL GROWTH-FACTOR; VISUAL-LOSS; METAANALYSIS; POPULATION; RISK;
   BIAS
AB The vascular endothelial growth factor (VEGF) gene has been suggested to play an important role in the pathogenesis of age-related macular degeneration (AMD). However, the results have been inconsistent. In this study, we performed a meta-analysis to clarify the associations between VEGF polymorphisms and AMD risk across different populations. Published literature from PubMed and EMBASE were retrieved. Pooled odds ratio (OR) with 95% confidence interval (CI) was calculated using fixed- or random-effects model. Five studies (1,280 cases and 715 controls) for rs833061 polymorphism, five studies (1,033 cases and 807 controls) for rs1413711 polymorphism, and four studies (1,217 cases and 4,079 controls) for rs2010963 polymorphism were identified. No statistically significant association was found for rs833061, rs1413711 and rs2010963 polymorphisms, although there were significant associations for rs833061 polymorphism under a homogeneous co-dominant model (CC vs. TT: OR = 1.59, 95%CI 1.14-2.23) and for rs1413711 polymorphism under a recessive model (TT vs. CT + CC: OR = 1.50, 95%CI 1.08-2.08), the results were not robust by sensitivity analysis. However, there was a significant association for rs833061 among European and East Asian populations, and for rs1413711 among Europeans. The present meta-analyses indicated that there were no significantly associations between VEGF polymorphisms (rs833061, rs1413711, rs2010963) and the risk of AMD, although the association was different for each polymorphism among different populations.
C1 [Lu, Yan; Shi, Yuhua; Xue, Chunyan; Yin, Jie; Huang, Zhenping] Nanjing Univ, Dept Ophthalmol, Jinling Hosp, Sch Med, Nanjing 210002, Jiangsu, Peoples R China.
C3 Nanjing University
RP Huang, ZP (通讯作者)，Nanjing Univ, Dept Ophthalmol, Jinling Hosp, Sch Med, 305 E Zhongshan Rd, Nanjing 210002, Jiangsu, Peoples R China.
EM huangzhenping1963@163.com
CR Almeida LN, 2012, GRAEF ARCH CLIN EXP, V250, P185, DOI 10.1007/s00417-011-1807-5
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Boekhoorn SS, 2008, OPHTHALMOLOGY, V115, P1899, DOI 10.1016/j.ophtha.2008.06.026
   Brion M, 2011, ACTA OPHTHALMOL, V89, pE12, DOI 10.1111/j.1755-3768.2010.02040.x
   Churchill AJ, 2006, HUM MOL GENET, V15, P2955, DOI 10.1093/hmg/ddl238
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Fang AM, 2009, MOL VIS, V15, P2710
   Ferrara N, 1999, J MOL MED, V77, P527, DOI 10.1007/s001099900019
   Francis PJ, 2009, J MED GENET, V46, P300, DOI 10.1136/jmg.2008.062737
   Galan A, 2010, OPHTHALMOLOGY, V117, P1769, DOI 10.1016/j.ophtha.2010.01.030
   Haines JL, 2006, INVEST OPHTH VIS SCI, V47, P329, DOI 10.1167/iovs.05-0116
   Janik-Papis K, 2009, EXP MOL PATHOL, V87, P234, DOI 10.1016/j.yexmp.2009.09.005
   Kaiser PK, 2006, AM J OPHTHALMOL, V142, P660, DOI 10.1016/j.ajo.2006.05.061
   Lin JM, 2008, AM J OPHTHALMOL, V145, P1045, DOI 10.1016/j.ajo.2008.01.027
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   Marx J, 2006, SCIENCE, V311, P1704, DOI 10.1126/science.311.5768.1704
   Owen CG, 2003, BRIT J OPHTHALMOL, V87, P312, DOI 10.1136/bjo.87.3.312
   Qu Y, 2011, OPHTHALMIC RES, V45, P142, DOI 10.1159/000319543
   Richardson AJ, 2007, MOL VIS, V13, P2148
   Szaflik Jacek P, 2009, Klin Oczna, V111, P125
   Tong Y, 2010, MOL VIS, V16, P1958
NR 22
TC 9
Z9 10
U1 0
U2 8
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0301-4851
J9 MOL BIOL REP
JI Mol. Biol. Rep.
PD JUN
PY 2012
VL 39
IS 6
BP 6547
EP 6553
DI 10.1007/s11033-012-1483-5
PG 7
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 933HQ
UT WOS:000303351900017
PM 22307787
DA 2022-11-30
ER

PT J
AU Lauermann, JL
   Treder, M
   Heiduschka, P
   Clemens, CR
   Eter, N
   Alten, F
AF Lauermann, J. L.
   Treder, M.
   Heiduschka, P.
   Clemens, C. R.
   Eter, N.
   Alten, F.
TI Impact of eye-tracking technology on OCT-angiography imaging quality in
   age-related macular degeneration
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; OCT-angiography; Optical coherence
   tomography angiography; Spectral-domain optical coherence tomography;
   Eye tracking; Imaging artifacts; Motion artifacts
ID COHERENCE TOMOGRAPHY ANGIOGRAPHY; MOTION CORRECTION; ARTIFACTS
AB Objective To evaluate the impact of eye-tracking (ET) technology on optical coherence tomography angiography (OCT-A) image quality and manifestation of motion artifacts in patients with age-related macular degeneration (AMD).
   Methods In a prospective trial, multimodal retinal imaging including OCT-A was performed in 30 patients (78.97 +/- 9.7 years) affected by different stages of AMD. Central 3 x 3 mm(2) OCT-A imaging was performed four times consecutively in each patient, twice with active, and twice with inactive ET. Parameters for image evaluation were signal strength index (SSI), variability of foveal vessel density (VD), acquisition time, presence of motion artifacts caused by eye movement (blink lines, displacement) and by software correction of eye movement (quilting, stretch artifacts, vessel doubling). Images were evaluated by two independent readers with subsequent senior reader arbitration for presence of artifacts, and an OCT-A motion artifact score (MAS) was calculated.
   Results Eight patients had early and eight patients had intermediate stages of AMD. Four patients had an atrophic late stage and ten patients an exudative stage of the disease. SSI was 53.55 with inactive and 57.18 with active ET (p = 0.0005). Coefficients of variability of VD between the first and second measurement were 8.9% with inactive and 5.7% with active ET. Mean image acquisition time was 15.97 s (active ET: 22.88 s, p < 0.001). Presence of motion artifacts was significantly higher with inactive ET (mean MAS 3.27 vs. 1.93; p < 0.0001). MAS correlated with AMD disease stage [p = 0.0031 (inactive ET) and p < 0.0001 (active ET)] and with SSI (p = 0.0072 and p = 0.0006).
   Conclusions In patients with AMD, active ET technology offers an improved image quality in OCT-A imaging regarding presence of motion artifacts at the expense of higher acquisition time.
C1 [Lauermann, J. L.; Treder, M.; Heiduschka, P.; Clemens, C. R.; Eter, N.; Alten, F.] Univ Munster, Dept Ophthalmol, Med Ctr, Domagkstr 15, D-48149 Munster, Germany.
C3 University of Munster
RP Alten, F (通讯作者)，Univ Munster, Dept Ophthalmol, Med Ctr, Domagkstr 15, D-48149 Munster, Germany.
EM jost.lauermann@ukmuenster.de; maximilian.treder@ukmuenster.de;
   peter.heiduschka@ukmuenster.de; christoph.clemens@ukmuenster.de;
   nicole.eter@ukmuenster.de; florian.alten@ukmuenster.de
RI Heiduschka, Peter/AAX-3882-2021
CR Asrani S, 2014, JAMA OPHTHALMOL, V132, P396, DOI 10.1001/jamaophthalmol.2013.7974
   Camino A, 2016, BIOMED OPT EXPRESS, V7, P3905, DOI 10.1364/BOE.7.003905
   Camino A, 2016, QUANT IMAG MED SURG, V6, P391, DOI 10.21037/qims.2016.07.02
   Cole ED, 2016, RETINA-J RET VIT DIS, V36, pS83, DOI 10.1097/IAE.0000000000001338
   Coscas GJ, 2015, RETINA-J RET VIT DIS, V35, P2219, DOI 10.1097/IAE.0000000000000766
   Falavarjani KG, 2017, BRIT J OPHTHALMOL, V101, P564, DOI 10.1136/bjophthalmol-2016-309104
   Ho J, 2009, OPHTHALMOLOGY, V116, P1960, DOI 10.1016/j.ophtha.2009.03.034
   Jia YL, 2015, P NATL ACAD SCI USA, V112, pE2395, DOI 10.1073/pnas.1500185112
   Jia YL, 2012, OPT EXPRESS, V20, P4710, DOI 10.1364/OE.20.004710
   Kanagasingam Y, 2014, PROG RETIN EYE RES, V38, P20, DOI 10.1016/j.preteyeres.2013.10.002
   Kraus MF, 2012, BIOMED OPT EXPRESS, V3, P1182, DOI 10.1364/BOE.3.001182
   Sadda SR, 2006, OPHTHALMOLOGY, V113, P285, DOI 10.1016/j.ophtha.2005.10.005
   Say EAT, 2017, RETINA-J RET VIT DIS, V37, P1660, DOI 10.1097/IAE.0000000000001414
   Song Y, 2014, RETINA, V32, P569
   Spaide RF, 2015, RETINA-J RET VIT DIS, V35, P2163, DOI 10.1097/IAE.0000000000000765
   You QS, 2017, RETINA-J RET VIT DIS, V37, P1475, DOI 10.1097/IAE.0000000000001407
NR 16
TC 39
Z9 40
U1 1
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD AUG
PY 2017
VL 255
IS 8
BP 1535
EP 1542
DI 10.1007/s00417-017-3684-z
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FC8GR
UT WOS:000407080300009
PM 28474129
DA 2022-11-30
ER

PT J
AU Klein, ML
   Ferris, FL
   Armstrong, J
   Hwang, TS
   Chew, EY
   Bressler, SB
   Chandra, SR
AF Klein, Michael L.
   Ferris, Frederick L., III
   Armstrong, Jane
   Hwang, Thomas S.
   Chew, Emily Y.
   Bressler, Susan B.
   Chandra, Suresh R.
CA AREDS Res Grp
TI Retinal precursors and the development of geographic atrophy in
   age-related macular degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID FUNDUS AUTOFLUORESCENCE PATTERNS; PIGMENT EPITHELIUM; CHOROIDAL
   NEOVASCULARIZATION; PROGRESSION; DISEASE; DRUSEN; FORM
AB Purpose: To determine specific retinal precursor lesions and sequence of events preceding the onset of geographic atrophy (GA) in eyes with age-related macular degeneration (AMD).
   Design: Retrospective review.
   Participants: All participants in the Age-Related Eye Disease Study (AREDS) at 2 clinical centers (Devers Eye Institute, Portland, Oregon, and University of Wisconsin, Madison, Wisconsin) in whom GA initially appeared in at least one eye a minimum of 4 years after the baseline study visit.
   Methods: All stereoscopic fundus photographs taken before the appearance of GA in the involved (study) eye were reviewed. Fundus features at the site of future GA were graded and recorded. Three graders reviewed photographs, with independent grading and adjudication by mutual agreement. Features graded included drusen (classified by size and confluence), focal hyperpigmentation, hypopigmentation, and refractile deposits. The time between first appearance of these features and initial appearance of GA was recorded.
   Main Outcome Measure: Appearance of GA.
   Results: Of all AREDS participants at the 2 sites, 95 eyes of 77 developed GA at least 4 years after entrance into the study. Average time from baseline to initial appearance of GA was 6.6 years (range, 4-11). Drusen were found in 100% of eyes at the site of later developing GA, drusen >1 25 mu m in diameter in 96% of eyes, confluent drusen in 94%, hyperpigmentation in 96%, drusen > 250 mu m in 83%, hypopigmentation in 82%, and refractile deposits in 23%. Time from lesion appearance to onset of GA varied by lesion type, ranging from 5.9 years for drusen confluence to 2.5 years for hypopigmentation or refractile deposits. Lesions generally followed a uniform sequence of appearance.
   Conclusions: By focusing on the location of initial GA appearance and then retrospectively analyzing prior photographs, we were able to identify specific precursor lesions and the most common sequence of events leading to GA formation in eyes with AMD. The progression was usually characterized by large drusen formation and development of hyperpigmentation, followed by regression of drusen, appearance of hypopigmentation, and ultimately development of GA, sometimes preceded by the appearance of refractile deposits.
C1 [Klein, Michael L.; Hwang, Thomas S.] Oregon Hlth & Sci Univ, Macular Degenerat Ctr, Casey Eye Inst, Portland, OR 97239 USA.
   [Klein, Michael L.; Hwang, Thomas S.] Legacy Good Samaritan Hosp, Devers Eye Inst, Portland, OR USA.
   [Klein, Michael L.; Armstrong, Jane] Med Ctr, Portland, OR USA.
   [Ferris, Frederick L., III; Chew, Emily Y.] NEI, NIH, Dept Hlth & Human Serv, Bethesda, MD 20892 USA.
   [Armstrong, Jane] Univ Wisconsin, Sch Med, Dept Ophthalmol & Visual Sci, Fundus Photograph Reading Ctr, Madison, WI USA.
   [Bressler, Susan B.] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Baltimore, MD 21205 USA.
   [Chandra, Suresh R.] Univ Wisconsin, Sch Med, Dept Ophthalmol & Visual Sci, Madison, WI USA.
C3 Oregon Health & Science University; Devers Eye Institute; National
   Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI);
   University of Wisconsin System; University of Wisconsin Madison; Johns
   Hopkins University; Johns Hopkins Medicine; University of Wisconsin
   System; University of Wisconsin Madison
RP Klein, ML (通讯作者)，Oregon Hlth & Sci Univ, Macular Degenerat Ctr, Casey Eye Inst, 3375 SW Terwilliger Blvd, Portland, OR 97239 USA.
RI Hwang, Thomas/AAV-5146-2020; Hwang, Thomas S./AAW-6618-2020
OI Hwang, Thomas S./0000-0002-0535-4823; Ferris,
   Frederick/0000-0002-4933-0639
CR Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bindewald A, 2005, INVEST OPHTH VIS SCI, V46, P3309, DOI 10.1167/iovs.04-0430
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   GASS JDM, 1973, ARCH OPHTHALMOL-CHIC, V90, P206
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Hopkins J, 2006, INVEST OPHTH VIS SCI, V47, P2269, DOI 10.1167/iovs.05-1482
   Hwang JC, 2006, INVEST OPHTH VIS SCI, V47, P2655, DOI 10.1167/iovs.05-1027
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   MAGUIRE P, 1986, AM J OPHTHALMOL, V102, P621, DOI 10.1016/0002-9394(86)90535-0
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sarks J, 2006, BRIT J OPHTHALMOL, V90, P442, DOI 10.1136/bjo.2005.083022
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SARKS SH, 1982, AUST J OPHTHALMOL, V10, P91, DOI 10.1111/j.1442-9071.1982.tb00366.x
   SCHATZ H, 1989, OPHTHALMOLOGY, V96, P1541
   Schmitz-Valckenberg S, 2006, INVEST OPHTH VIS SCI, V47, P2648, DOI 10.1167/iovs.05-0892
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P910, DOI 10.1016/S0161-6420(99)00509-6
   Sunness JS, 2006, BRIT J OPHTHALMOL, V90, P398, DOI 10.1136/bjo.2005.084830
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
NR 22
TC 163
Z9 168
U1 0
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JUN
PY 2008
VL 115
IS 6
BP 1026
EP 1031
DI 10.1016/j.ophtha.2007.08.030
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 306XX
UT WOS:000256282800016
PM 17981333
DA 2022-11-30
ER

PT J
AU Jeong, S
   Park, DG
   Sagong, M
AF Jeong, Seongyong
   Park, Dong-Geun
   Sagong, Min
TI Management of a Submacular Hemorrhage Secondary to Age-Related Macular
   Degeneration: A Comparison of Three Treatment Modalities
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Article
DE age-related macular degeneration; anti-VEGF; pneumatic displacement;
   submacular hemorrhage; tissue plasminogen activator
ID TISSUE-PLASMINOGEN-ACTIVATOR; ENDOTHELIAL GROWTH-FACTOR; SUBRETINAL
   HEMORRHAGE; INTRAVITREAL BEVACIZUMAB; PNEUMATIC DISPLACEMENT; SUBFOVEAL
   HEMORRHAGE; RANIBIZUMAB; INJECTION; RTPA; GAS
AB This paper aims to compare the effects of three treatment modalities for a submacular hemorrhage (SMH) secondary to exudative age-related macular degeneration (AMD). Seventy-seven patients with an SMH were divided into three groups: small-sized (optic disc diameter (ODD) >= 1 to < 4), medium-sized (ODD >= 4 within the temporal arcade) and large-sized (ODD >= 4, exceeding the temporal arcade). Patients received anti-vascular endothelial growth factor (anti-VEGF) monotherapy, pneumatic displacement (PD) with anti-VEGF or a vitrectomy with a subretinal tissue plasminogen activator (tPA) and gas tamponade based on the surgeon's discretion. The functional and anatomical outcomes were evaluated. Among the 77 eyes, 45 eyes had a small-sized, 21 eyes had a medium-sized and 11 eyes had a large-sized SMH. In the small-sized group, all treatment modalities showed a gradual best-corrected visual acuity (BCVA) improvement with high hemorrhagic regression or displacement rates (over 75%). In the medium-sized group, PD and surgery were associated with better BCVA with more displacement than anti-VEGF monotherapy (67% and 83%, respectively, vs. 33%). In the large-sized group, surgery showed a better visual improvement with a higher displacement rate than PD (86% vs. 25%). Our findings demonstrated that visual improvement can be expected through appropriate treatment strategy regardless of the SMH size. In cases with a larger SMH, invasive techniques including PD or surgery were more advantageous than anti-VEGF monotherapy.
C1 [Jeong, Seongyong; Park, Dong-Geun; Sagong, Min] Yeungnam Univ, Dept Ophthalmol, Coll Med, Daegu 42415, South Korea.
   [Jeong, Seongyong; Park, Dong-Geun; Sagong, Min] Yeungnam Univ Hosp, Yeungnam Eye Ctr, Daegu 42415, South Korea.
C3 Yeungnam University; Yeungnam University; Yeungnam University Hospital
RP Sagong, M (通讯作者)，Yeungnam Univ, Dept Ophthalmol, Coll Med, Daegu 42415, South Korea.; Sagong, M (通讯作者)，Yeungnam Univ Hosp, Yeungnam Eye Ctr, Daegu 42415, South Korea.
EM jjsssyyyy@naver.com; bluepdg@naver.com; msagong@ynu.ac.kr
OI Park, Dong-Geun/0000-0001-8820-382X; Jeong,
   SeongYong/0000-0001-9175-9642; Sagong, Min/0000-0003-4140-5015
FU Yeungnam University [218A480006]
FX This work was supported by the 2018 Yeungnam University research grant
   (218A480006).
CR Al-Hity A, 2019, EYE, V33, P486, DOI 10.1038/s41433-018-0239-4
   Avery RL, 1996, RETINA-J RET VIT DIS, V16, P183, DOI 10.1097/00006982-199616030-00001
   Chang MA, 2010, RETINA-J RET VIT DIS, V30, P1171, DOI 10.1097/IAE.0b013e3181dd6d8a
   Chang Young Suk, 2018, Korean J Ophthalmol, V32, P361, DOI 10.3341/kjo.2017.0095
   Cho HJ, 2015, RETINA-J RET VIT DIS, V35, P205, DOI 10.1097/IAE.0000000000000295
   Cho HJ, 2013, AM J OPHTHALMOL, V156, P524, DOI 10.1016/j.ajo.2013.04.029
   Fassbender JM, 2016, RETINA-J RET VIT DIS, V36, P1860, DOI 10.1097/IAE.0000000000001030
   Gerding H, 2011, GRAEF ARCH CLIN EXP, V249, P653, DOI 10.1007/s00417-011-1636-6
   GLATT H, 1982, AM J OPHTHALMOL, V94, P762, DOI 10.1016/0002-9394(82)90301-4
   Hassan AS, 1999, OPHTHALMOLOGY, V106, P1900, DOI 10.1016/S0161-6420(99)90399-8
   Hattenbach LO, 2001, OPHTHALMOLOGY, V108, P1485, DOI 10.1016/S0161-6420(01)00648-0
   Hillenkamp J, 2010, GRAEF ARCH CLIN EXP, V248, P5, DOI 10.1007/s00417-009-1158-7
   IRVINE WD, 1991, ARCH OPHTHALMOL-CHIC, V109, P718, DOI 10.1001/archopht.1991.01080050134044
   JOHNSON MW, 1991, RETINA-J RET VIT DIS, V11, P250, DOI 10.1097/00006982-199111020-00011
   Kim JH, 2014, OPHTHALMOLOGY, V121, P926, DOI 10.1016/j.ophtha.2013.11.004
   Klettner A, 2015, BRIT J OPHTHALMOL, V99, P864, DOI 10.1136/bjophthalmol-2014-306454
   Ohji M, 1998, ARCH OPHTHALMOL-CHIC, V116, P1326, DOI 10.1001/archopht.116.10.1326
   RIJKEN DC, 1995, BAILLIERE CLIN HAEM, V8, P291, DOI 10.1016/S0950-3536(05)80269-0
   Sacu S, 2009, EYE, V23, P1404, DOI 10.1038/eye.2008.267
   Schulze SD, 2002, GRAEF ARCH CLIN EXP, V240, P717, DOI 10.1007/s00417-002-0516-5
   Sharma S, 2018, OPHTHALMOL RETINA, V2, P180, DOI 10.1016/j.oret.2017.07.012
   Shienbaum G, 2013, AM J OPHTHALMOL, V155, P1009, DOI 10.1016/j.ajo.2013.01.012
   Shin JY, 2015, AM J OPHTHALMOL, V159, P904, DOI 10.1016/j.ajo.2015.01.024
   Soliman W, 2006, ACTA OPHTHALMOL SCAN, V84, P707, DOI 10.1111/j.1600-0420.2006.00736.x
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P275, DOI 10.1097/00006982-200603000-00004
   Stanescu-Segall D, 2016, SURV OPHTHALMOL, V61, P18, DOI 10.1016/j.survophthal.2015.04.004
   Stifter E, 2007, AM J OPHTHALMOL, V144, P886, DOI 10.1016/j.ajo.2007.07.034
   Treumer F, 2017, GRAEF ARCH CLIN EXP, V255, P1115, DOI 10.1007/s00417-017-3620-2
   Treumer F, 2012, BRIT J OPHTHALMOL, V96, P708, DOI 10.1136/bjophthalmol-2011-300655
NR 29
TC 5
Z9 5
U1 0
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD OCT
PY 2020
VL 9
IS 10
AR 3088
DI 10.3390/jcm9103088
PG 10
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA ON7EQ
UT WOS:000586859700001
PM 32987903
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Bonyadi, M
   Norouzi, N
   Babaei, E
   Bonyadi, MHJ
   Javadzadeh, A
   Yaseri, M
   Soheilian, M
AF Bonyadi, Mortaza
   Norouzi, Neda
   Babaei, Esmaeil
   Bonyadi, Mohammad Hossein Jabbarpoor
   Javadzadeh, Alireza
   Yaseri, Mehdi
   Soheilian, Masoud
TI Association of polymorphisms of complement factor I rs141853578 (G119R)
   with age-related macular degeneration in Iranian population
SO INTERNATIONAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration (AMD); Complement factor I (CFI)
   rs141853578 (G119R); Single nucleotide polymorphism
ID COMMON VARIANT; HIGH-RISK; CFI GENE; C3
AB Background Age-related macular degeneration (AMD) is a complex disease, and recent studies have shown role of complement system genes in its development. Complement factor I regulates the complement pathways, and relationship between CFI polymorphisms and AMD is controversial. We evaluated the possible association of complement factor I rs141853578 (G119R) variation with advanced AMD in Iranian patients.Materials and methodsWe included 371 case-control samples consisting of 220 advanced AMD patients and 151 genetically unrelated healthy controls. Extracted DNA samples amplified to obtain fragment including the polymorphic complement factor I rs141853578 (G119R) region.ResultsThe distribution of the genotypes was significantly different in the AMD patients compared to that of controls (p=0.035). The TT genotype frequencies for CFI were significantly higher in AMD group (7.7 vs. 2%, OR 4.67, CI 1.33-16.45, p=0.016). This significant difference was maintained after adjustment for the effects of age and gender (OR 5.09, CI 1.42-18.20, p=0.012). The minor allele frequency (T allele) was also significantly higher in AMD patients compared to that of controls (29.3 vs. 21.5% OR 1.51, CI 1.07-2.13, p=0.018).ConclusionCurrent study showed that CFI rs141853578 (G119R) is a risk factor for developing advanced type AMD. This study also suggests that the frequency of G119R polymorphism in our population is not as rare as reported from other populations.
C1 [Bonyadi, Mortaza; Norouzi, Neda; Babaei, Esmaeil] Univ Tabriz, Ctr Excellence Biodivers, Fac Nat Sci, Tabriz, Iran.
   [Bonyadi, Mohammad Hossein Jabbarpoor; Yaseri, Mehdi; Soheilian, Masoud] Shahid Beheshti Univ Med Sci, Ocular Tissue Engn Res Ctr, Ophthalm Res Ctr, Tehran, Iran.
   [Javadzadeh, Alireza] Tabriz Univ Med Sci, Dept Ophthalmol, Tabriz, Iran.
C3 University of Tabriz; Shahid Beheshti University Medical Sciences;
   Tabriz University of Medical Science
RP Bonyadi, MHJ (通讯作者)，Shahid Beheshti Univ Med Sci, Ocular Tissue Engn Res Ctr, Ophthalm Res Ctr, Tehran, Iran.
EM mhbonyadi@yahoo.com
RI Soheilian, Masoud/AAW-4743-2020; Hossein, Jabbarpoor Bonyadi
   Mohammad/A-1886-2014; Javadzadeh, Alireza/L-6424-2017; Yaseri,
   Mehdi/I-1645-2018
OI Javadzadeh, Alireza/0000-0002-5151-6125; Yaseri,
   Mehdi/0000-0002-4066-873X; babaei, Esmaeil/0000-0002-1603-5166;
   Soheilian, Masoud/0000-0001-7508-426X
FU center of excellence for biodiversity, Faculty of Natural Sciences,
   University of Tabriz
FX This study was funded by the center of excellence for biodiversity,
   Faculty of Natural Sciences, University of Tabriz.
CR Alexander P, 2014, MOL VIS, V20, P1253
   Bonyadi M, 2016, OPHTHALMIC GENET, V30, P1
   Bonyadi M, 2016, ACTA OPHTHALMOL, V94, pE779, DOI 10.1111/aos.13143
   Cheng CY, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7063
   Cipriani V, 2012, EUR J HUM GENET, V20, P1, DOI 10.1038/ejhg.2011.118
   Ennis S, 2010, EUR J HUM GENET, V18, P15, DOI 10.1038/ejhg.2009.113
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Kavanagh D, 2015, HUM MOL GENET, V24, P3861, DOI 10.1093/hmg/ddv091
   Khandhadia S, 2012, IMMUNOBIOLOGY, V217, P127, DOI 10.1016/j.imbio.2011.07.019
   Kondo N, 2010, EUR J HUM GENET, V18, P634, DOI 10.1038/ejhg.2009.243
   Mullins Robert F., 2007, International Ophthalmology Clinics, V47, P1, DOI 10.1097/IIO.0b013e31802bd3e6
   Ormsby RJ, 2008, INVEST OPHTH VIS SCI, V49, P1763, DOI 10.1167/iovs.07-1297
   Qian DG, 2014, EUR J HUM GENET, V22, P1417, DOI 10.1038/ejhg.2014.37
   Regillo CD, 2013, AM AC OPHTH AAO ANN
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Spencer KL, 2007, HUM MOL GENET, V16, P1986, DOI 10.1093/hmg/ddm146
   van de Ven JPH, 2013, NAT GENET, V45, P813, DOI 10.1038/ng.2640
   Wang JY, 2008, J IMMUNOL, V181, P712, DOI 10.4049/jimmunol.181.1.712
   Wang Q, 2016, INT J OPHTHALMOL-CHI, V9, P298, DOI 10.18240/ijo.2016.02.23
   Yang F, 2014, OPHTHALMOLOGICA, V232, P37, DOI 10.1159/000358241
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
NR 22
TC 3
Z9 3
U1 1
U2 1
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0165-5701
EI 1573-2630
J9 INT OPHTHALMOL
JI Int. Ophthalmol.
PD MAR
PY 2019
VL 39
IS 3
BP 551
EP 556
DI 10.1007/s10792-018-0835-0
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HP3HS
UT WOS:000461568100005
PM 29392637
DA 2022-11-30
ER

PT J
AU Sui, GY
   Liu, GC
   Liu, GY
   Gao, YY
   Deng, Y
   Wang, WY
   Tong, SH
   Wang, L
AF Sui, Guo-Yuan
   Liu, Guang-Cong
   Liu, Guang-Ying
   Gao, Yan-Yan
   Deng, Yan
   Wang, Wen-Ying
   Tong, Shu-Hui
   Wang, Lie
TI Is sunlight exposure a risk factor for age-related macular degeneration?
   A systematic review and meta-analysis
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
ID ULTRAVIOLET-RADIATION; MACULOPATHY; PREVALENCE
AB Background Epidemiologists have recently investigated sunlight exposure as a risk factor for age-related macular degeneration (AMD), but there remains an ongoing dispute over this association due to insufficient evidence and unreliable data.
   Objectives To analyse comprehensively the epidemiological literature concerning the association between AMD and sunlight exposure.
   Methods We systematically reviewed the epidemiological literature concerning the association between AMD and sunlight exposure. An electronic search was performed of PubMed, Web of Science and CNKI, which was supplemented by hand searching. The selection of studies, data abstraction and quality assessment were performed independently by three reviewers. After these steps, we performed a random-effects meta-analysis, followed by subgroup analysis and sensitivity analysis, including a random-effects meta-regression for study-specific covariates.
   Results Fourteen studies were identified. Twelve studies identified an increasing risk of AMD with greater sunlight exposure, six of which reported significant risks. The pooled OR was 1.379 (95% CI 1.091 to 1.745). The subgroup of non-population-based studies revealed a significant risk (OR 2.018, 1.248 to 3.265, p=0.004). We identified the gross domestic product (GDP) per capita (p=0.048), but not the latitude (p=0.21), as a factor that led to heterogeneity according to the meta-regression.
   Conclusions The epidemiological literature published to date indicates that individuals with more sunlight exposure are at a significantly increased risk of AMD. The OR significantly decreased with increasing GDP per capita.
C1 [Sui, Guo-Yuan; Liu, Guang-Cong; Gao, Yan-Yan; Deng, Yan; Wang, Wen-Ying; Tong, Shu-Hui; Wang, Lie] China Med Univ, Sch Publ Hlth, Shenyang 110001, Liaoning, Peoples R China.
   [Liu, Guang-Ying] Liaoning Univ Tradit Chinese Med, Affiliated Hosp 1, Shenyang, Liaoning, Peoples R China.
C3 China Medical University; Liaoning University of Traditional Chinese
   Medicine
RP Wang, L (通讯作者)，China Med Univ, Sch Publ Hlth, 92 Beier Rd, Shenyang 110001, Liaoning, Peoples R China.
EM liewang@mail.cmu.edu.cn
CR Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Bai ZL, 2005, INT J OPHTHALMOL, V5, P1114
   Chu J, 2007, THESIS CHINA UNION M
   CRUICKSHANKS KJ, 1993, ARCH OPHTHALMOL-CHIC, V111, P514, DOI 10.1001/archopht.1993.01090040106042
   Delcourt C, 2001, ARCH OPHTHALMOL-CHIC, V119, P1463
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Fletcher AE, 2008, ARCH OPHTHALMOL-CHIC, V126, P1396, DOI 10.1001/archopht.126.10.1396
   Gallagher RP, 2006, PROG BIOPHYS MOL BIO, V92, P119, DOI 10.1016/j.pbiomolbio.2006.02.011
   Hirakawa M, 2008, BRIT J OPHTHALMOL, V92, P630, DOI 10.1136/bjo.2007.130575
   Hui S, 2009, PHOTOCHEM PHOTOBIOL, V85, P966, DOI 10.1111/j.1751-1097.2008.00506.x
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P29, DOI 10.1136/bjo.2005.073825
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Plestina-Borjan I, 2007, COLLEGIUM ANTROPOL, V31, P33
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Roberts JE, 2001, J PHOTOCH PHOTOBIO B, V64, P136, DOI 10.1016/S1011-1344(01)00196-8
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Taylor H R, 1990, Trans Am Ophthalmol Soc, V88, P163
   The Joanna Briggs Institute, 2008, JOANN BRIGGS I REV M, P151
   Tomany SC, 2004, ARCH OPHTHALMOL-CHIC, V122, P750, DOI 10.1001/archopht.122.5.750
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Vojnikovic B, 2007, COLLEGIUM ANTROPOL, V31, P43
   Xu W, 2009, THESIS HUAZHONG U SC
   Xu ZH, 2009, THESIS JI LIN U CHAN
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   Youn HY, 2007, J PHOTOCH PHOTOBIO B, V88, P21, DOI 10.1016/j.jphotobiol.2007.04.012
   Youn HY, 2011, MOL VIS, V17
NR 27
TC 129
Z9 133
U1 1
U2 43
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD APR
PY 2013
VL 97
IS 4
BP 389
EP 394
DI 10.1136/bjophthalmol-2012-302281
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 107ZM
UT WOS:000316259900004
PM 23143904
DA 2022-11-30
ER

PT J
AU Bellerive, C
   Cinq-Mars, B
   Lalonde, G
   Malenfant, M
   Tourville, E
   Tardif, Y
   Giasson, M
   Hebert, M
AF Bellerive, Claudine
   Cinq-Mars, Benoit
   Lalonde, Gilles
   Malenfant, Mario
   Tourville, Eric
   Tardif, Yvon
   Giasson, Marcelle
   Hebert, Marc
TI Bevacizumab and ranibizumab for neovascular age-related macular
   degeneration: a treatment approach based on individual patient needs
SO CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE
LA English
DT Article
ID INTRAVITREAL BEVACIZUMAB; CHOROIDAL NEOVASCULARIZATION; AVASTIN
   TREATMENT; PREVALENCE; TOXICITY
AB Objective: To compare the efficacy of intravitreal bevacizumab and ranibizumab for the treatment of neovascular age-related macular degeneration using an as-needed treatment regimen.
   Design: Retrospective chart review.
   Participants: One hundred and ninety two eyes of 184 patients.
   Methods: Patients received an initial treatment of 3 monthly intravitreal injections of ranibizumab or bevacizumab and retreatment is individually considered for each patient on the basis of optical coherence tomography, angiography, and clinical examination.
   Results: Fifty eyes treated with ranibizumab and 142 eyes treated with bevacizumab were included. The average age of the patients at baseline was 76.9 +/- 8 years and 78.4 +/- 8 years in the ranibizumab and bevacizumab group respectively. Mean visual acuity improved from 0.69 to 0.55 logMAR at 12 months in the ranibizumab group and from 0.70 to 0.67 logMAR in the bevacizumab group. At 12 months, 92% of eyes treated with ranibizumab had lost fewer than 0.3 logMAR, as compared with 83% in the bevacizumab group. The ranibizumab group received a mean of 4.92 injections, compared to 4.75 injections in the bevacizumab group over 12 months. After the first 3 injections, 20% of patients in the ranibizumab group and 26% in the bevacizumab group never needed another injection.
   Conclusions: An approach based on clinical onset and choroidal neovascularization progression at angiography may provide benefit by reducing the number of intravitreal injections required.
C1 [Cinq-Mars, Benoit] Univ Laval, Ctr Univ Ophtalmol, St Sacrement Hosp, Quebec City, PQ G1S 4L8, Canada.
   [Hebert, Marc] Res Ctr Univ Laval Robert Giffard, Laval, PQ, Canada.
C3 Laval University; Laval University
RP Cinq-Mars, B (通讯作者)，Univ Laval, Ctr Univ Ophtalmol, St Sacrement Hosp, Local D2-44c,1050 Chemin Ste Foy, Quebec City, PQ G1S 4L8, Canada.
EM bcinqmars@hotmail.com
CR Anne FE, 2007, AM J OPHTHALMOL, V143, P566
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bakri SJ, 2006, AM J OPHTHALMOL, V142, P162, DOI 10.1016/j.ajo.2006.03.058
   Bashshur ZF, 2008, AM J OPHTHALMOL, V145, P249, DOI 10.1016/j.ajo.2007.09.031
   Bashshur ZF, 2006, AM J OPHTHALMOL, V142, P1, DOI 10.1016/j.ajo.2006.02.037
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Emerson MV, 2007, RETINA-J RET VIT DIS, V27, P439, DOI 10.1097/IAE.0b013e31804b3e15
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gupta OP, ARVO 2009 ANN M FORT
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Luthra S, 2006, RETINA-J RET VIT DIS, V26, P512, DOI 10.1097/01.iae.0000222547.35820.52
   Manzano RPA, 2006, RETINA-J RET VIT DIS, V26, P257, DOI 10.1097/00006982-200603000-00001
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Maturi RK, 2006, RETINA-J RET VIT DIS, V26, P270, DOI 10.1097/00006982-200603000-00003
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Shahar J, 2006, RETINA-J RET VIT DIS, V26, P262, DOI 10.1097/00006982-200603000-00002
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
NR 24
TC 7
Z9 8
U1 0
U2 3
PU CANADIAN OPHTHAL SOC
PI OTTAWA
PA 1525 CARLING AVE SUITE 610, OTTAWA, ONTARIO K1Z 8R9, CANADA
SN 0008-4182
J9 CAN J OPHTHALMOL
JI Can. J. Opthalmol.-J. Can. Opthalmol.
PD APR
PY 2012
VL 47
IS 2
BP 165
EP 169
DI 10.1016/j.jcjo.2012.01.011
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 953RI
UT WOS:000304890100015
PM 22560423
DA 2022-11-30
ER

PT J
AU Balaskas, K
   Ali, ZC
   Saddik, T
   Gemenetzi, M
   Patel, P
   Aslam, TM
AF Balaskas, Konstantinos
   Ali, Zaria C.
   Saddik, Tarik
   Gemenetzi, Maria
   Patel, Praveen
   Aslam, Tariq M.
TI Swept-source optical coherence tomography angiography features of
   sub-retinal fibrosis in neovascular age-related macular degeneration
SO CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; optical coherence tomography
   angiography; subretinal fibrosis; swept source
ID GROWTH-FACTOR THERAPY; CHOROIDAL NEOVASCULARIZATION; HYPERREFLECTIVE
   MATERIAL; RANIBIZUMAB; LIFE; VEGF
AB ImportanceThe study highlights the role of optical coherence angiography in the management of patients with neovascular age-related macular degeneration (nAMD) who have developed sub-retinal fibrosis.
   BackgroundDevelopment of sub-retinal fibrosis in the context of nAMD is known to adversely affect visual function. The aim of this study is to assess structure and flow features obtained through swept-source optical coherence tomography angiography (OCTA) in patients with sub-retinal fibrosis and associate these with visual acuity (VA).
   DesignInstitutional retrospective cohort study.
   ParticipantsA total 39 eyes of 39 patients with nAMD with sub-retinal fibrosis imaged with OCTA were included in this study.
   MethodsPatients underwent swept-source OCTA. Thickness of sub-retinal hyper-reflective material (SHRM) and presence and configuration of a choroidal neovascular membrane were recorded in each case.
   Main Outcome MeasuresA univariate multiple regression was performed seeking associations between VA and structural and flow OCTA features.
   ResultsAverage VA on the date of OCTA was 5322 ETDRS letters. Average thickness of centre-involving SHRM was 157 +/- 73m. A choroidal neovascular membrane was detectable in 26 cases and not detectable in 13. VA was independently influenced by thickness of SHRM (P=0.034) and presence of a detectable choroidal neovascular membrane (P=0.02) on OCTA.
   Conclusions and RelevancePoorer VA in patients with nAMD and sub-retinal fibrosis is associated with presence of a detectable neovascular membrane on OCTA. The role of OCTA to guide nuanced management decisions in this patient population may be significant.
C1 [Balaskas, Konstantinos; Gemenetzi, Maria; Patel, Praveen] Moorfields Eye Hosp NHS Fdn Trust, NIHR Biomed Res Ctr, London, England.
   [Balaskas, Konstantinos; Gemenetzi, Maria; Patel, Praveen] UCL Inst Ophthalmol, London, England.
   [Balaskas, Konstantinos; Aslam, Tariq M.] Univ Manchester, Manchester, Lancs, England.
   [Ali, Zaria C.; Saddik, Tarik; Aslam, Tariq M.] Manchester Univ Hosp NHS Fdn Trust, Manchester Royal Eye Hosp, Manchester, Lancs, England.
C3 University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust; University of London; University College London;
   University of Manchester; Manchester Royal Eye Hospital; Wythenshawe
   Hospital NHS Foundation Trust
RP Balaskas, K (通讯作者)，Moorfields Eye Hosp, Reading Ctr, 162 City Rd, London EC1V 2PD, England.
EM konstantinos.balaskas@gmail.com
RI Balaskas, Konstantinos/ABD-5979-2020; Aslam, Tariq/A-8532-2016
OI Balaskas, Konstantinos/0000-0002-7690-6277; Ali,
   Zaria/0000-0002-8382-1415; Aslam, Tariq/0000-0002-9739-7280
CR Casalino G, 2016, INVEST OPHTH VIS SCI, V57, pOCT288, DOI 10.1167/iovs.15-18753
   Charafeddin W, 2015, OSLI RETINA, V46, P523, DOI 10.3928/23258160-20150521-03
   Daniel E, 2014, OPHTHALMOLOGY, V121, P656, DOI 10.1016/j.ophtha.2013.10.019
   Dansingani KK, 2016, AM J OPHTHALMOL, V169, P235, DOI 10.1016/j.ajo.2016.06.031
   Dansingani KK, 2015, OSLI RETINA, V46, P907, DOI 10.3928/23258160-20151008-02
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Huang D, 2015, RETINA-J RET VIT DIS, V35, P2260, DOI 10.1097/IAE.0000000000000846
   Jaffe GJ, 2017, OPHTHALMOLOGY, V124, P224, DOI 10.1016/j.ophtha.2016.10.010
   Jo N, 2006, AM J PATHOL, V168, P2036, DOI 10.2353/ajpath.2006.050588
   Keane PA, 2008, OPHTHALMOLOGY, V115, P2206, DOI 10.1016/j.ophtha.2008.08.016
   Kuehlewein L, 2015, EYE, V29, P932, DOI 10.1038/eye.2015.80
   Kuehlewein L, 2015, AM J OPHTHALMOL, V160, P739, DOI 10.1016/j.ajo.2015.06.030
   Liakopoulos S, 2008, INVEST OPHTH VIS SCI, V49, P5048, DOI 10.1167/iovs.08-1877
   Lumbroso B, 2015, RETINA-J RET VIT DIS, V35, P2242, DOI 10.1097/IAE.0000000000000879
   Miere A, 2015, RETINA-J RET VIT DIS, V35, P2275, DOI 10.1097/IAE.0000000000000819
   Rakic JM, 2013, CLIN OPHTHALMOL, V7, P1849, DOI 10.2147/OPTH.S49385
   Rasmussen A, 2013, OPHTHALMOLOGY, V120, P2630, DOI 10.1016/j.ophtha.2013.05.018
   Spaide RF, 2015, RETINA-J RET VIT DIS, V35, P2163, DOI 10.1097/IAE.0000000000000765
   Spaide RF, 2015, AM J OPHTHALMOL, V160, P6, DOI 10.1016/j.ajo.2015.04.012
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   Willoughby AS, 2015, OPHTHALMOLOGY, V122, P1846, DOI 10.1016/j.ophtha.2015.05.042
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
NR 23
TC 3
Z9 3
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1442-6404
EI 1442-9071
J9 CLIN EXP OPHTHALMOL
JI Clin. Exp. Ophthalmol.
PD MAR
PY 2019
VL 47
IS 2
BP 233
EP 239
DI 10.1111/ceo.13367
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HQ7PC
UT WOS:000462612000012
PM 30066485
DA 2022-11-30
ER

PT J
AU Bolz, M
   Simader, C
   Ritter, M
   Ahlers, C
   Benesch, T
   Prunte, C
   Schmidt-Erfurth, U
AF Bolz, M.
   Simader, C.
   Ritter, M.
   Ahlers, C.
   Benesch, T.
   Pruente, C.
   Schmidt-Erfurth, U.
TI Morphological and functional analysis of the loading regimen with
   intravitreal ranibizumab in neovascular age-related macular degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; FACTOR ANTIBODY FRAGMENT; CHOROIDAL
   NEOVASCULARIZATION; MEMBRANES; EXPRESSION; THERAPY
AB Aim To quantify and correlate the morphological and functional effects of the recommended loading regimen with intravitreal ranibizumab in neovascular age-related macular degeneration (AMD).
   Methods In a prospective, interventional clinical trial, 29 consecutive patients ( 29 eyes) with choroidal neovascularisation secondary to AMD received three initial monthly intravitreal injections of ranibizumab. During this loading regimen, best corrected visual acuity (BCVA) and microperimetry ( MP) testing, as well as optical coherence tomography and fluorescein angiography ( FA), were performed using a standardised protocol and the results correlated.
   Results Significant morphological and functional therapeutic effects were observed as early as 1 week following the first treatment. Throughout the loading-dose period, central retinal thickness, including intraretinal cysts and subretinal fluid, decreased fast and significantly (p<0.01); pigment epithelial detachment resolved less rapidly. The mean leakage area by FA decreased (p<0.01) and retinal function ( BCVA and MP) increased significantly (both p<0.01). However, the change in morphology and function was only significant between baseline and week 1. There was no significant additional morphological or functional benefit following the second and third injection.
   Conclusion The initial administration of intravitreal ranibizumab in neovascular AMD induced a significant effect on intra- and subretinal fluid and visual function; subsequent injections had a less pronounced effect. It remains to be determined whether this loading regimen should be mandatory in all patients or if a single dose regimen would lead to a comparable functional and morphological retinal improvement.
C1 [Bolz, M.; Simader, C.; Ritter, M.; Ahlers, C.; Pruente, C.; Schmidt-Erfurth, U.] Med Univ Vienna, Dept Ophthalmol, A-1090 Vienna, Austria.
   [Benesch, T.] Med Univ Vienna, Sect Med Stat, Core Unit Med Stat & Informat, A-1090 Vienna, Austria.
C3 Medical University of Vienna; Medical University of Vienna
RP Schmidt-Erfurth, U (通讯作者)，Med Univ Vienna, Dept Ophthalmol, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.
EM schmidt-erfurth@meduniwien.ac.at
RI Bolz, Matthias/HCI-0622-2022
OI Ritter, Markus/0000-0003-1406-8340; Schmidt-Erfurth,
   Ursula/0000-0002-7788-7311
FU Novartis Pharma, Basel, Switzerland.
FX Novartis Pharma, Basel, Switzerland.
CR Bolz M, 2007, BRIT J OPHTHALMOL, V91, P785, DOI 10.1136/bjo.2006.102467
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027
   Gohdes Dorothy M, 2005, Prev Chronic Dis, V2, pA17
   HEIER JS, 2006, OPHTHALMOLOGY, V113, P642
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Otani A, 2002, MICROVASC RES, V64, P162, DOI 10.1006/mvre.2002.2407
   Rosenfeld Philip J, 2006, Ophthalmol Clin North Am, V19, P361
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHALMOLOGY, V112, P1048, DOI 10.1016/j.ophtha.2005.01.043
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
NR 17
TC 37
Z9 39
U1 0
U2 3
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD FEB
PY 2010
VL 94
IS 2
BP 185
EP 189
DI 10.1136/bjo.2008.143974
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 552WR
UT WOS:000274325500011
PM 19692384
DA 2022-11-30
ER

PT J
AU Yu, XY
   Luo, YZ
   Chen, GY
   Liu, H
   Tian, N
   Zen, XT
   Huang, YT
AF Yu, Xiaoyi
   Luo, Yingzi
   Chen, Gangyi
   Liu, Hong
   Tian, Ni
   Zen, Xiaoting
   Huang, Yuting
TI Long non-coding RNA PWRN2 regulates cytotoxicity in an in vitro model of
   age-related macular degeneration
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE AMD; Retina; Cell death; Apoptosis; lncRNA; PWRN2
ID OXIDATIVE STRESS; CELLS; RANIBIZUMAB; MECHANISMS
AB Background: Age-related macular degeneration (AMD) may lead to irreversibly vision loss among aging populations. In this work, in an in vitro AMD cell model, we examined the expression and function of long non-coding RNA, Prader-Willi Region Non-Protein Coding RNA 2 (PWRN2) in injured human retinal pigment epithelial cells.
   Method: ARPE-19 cell line was maintained in vitro and treated with multi-module stressful conditions, including hydrogen peroxide (H2O2) tert-butylhydroperoxide (t-BuOOH) and ultraviolet B (UVB). Multimodule-stressor-induced cell death was monitored by a viability assay, and PWRN2 expression by qRTPCR. PWRN2 was either downregulated or upregulated in ARPE-19 cells. The effects of PWRN2 downregulation or upregulation on t-BuOOH-induced cell death, cellular apoptosis and mitochondrial injuries were then quantitatively evaluated.
   Results: Multi-module stressful conditions induced cell death and PWRN2 upregulation in ARPE-19 cells in vitro. We created ARPE-19 subpopulations with either downregulated or upregulated PWRN2 expressions. Quantitative assays demonstrated that, PWRN2 downregulation effectively alleviated t-BuOOH-induced cell death, apoptosis and various-type of mitochondrial injuries. On the other hand, PWRN2 upregulation worsened t-BuOOH-induced cellular damages in ARPE-19 cells.
   Conclusion: We demonstrated that downregulating PWRN2 protected multi-module-stressor-induced cell death, apoptosis and mitochondrial injuries in human retinal pigment epithelial cells, suggesting PWRN2 may be an active factor in human AMD. (C) 2020 Published by Elsevier Inc.
C1 [Yu, Xiaoyi; Luo, Yingzi; Chen, Gangyi; Liu, Hong; Tian, Ni; Zen, Xiaoting; Huang, Yuting] Guangzhou Univ Chinese Med, Dept Ophthalmol, Affiliated Hosp 1, Guangzhou 510405, Guangdong, Peoples R China.
C3 Guangzhou University of Chinese Medicine
RP Yu, XY (通讯作者)，Guangzhou Univ Chinese Med, Dept Ophthalmol, Affiliated Hosp 1, Guangzhou 510405, Guangdong, Peoples R China.
EM doctor_yuxy@aol.com
FU "Innovation strengthen Hospital" project in the Scientific Research
   series Foundation of the First Affiliated Hospital of Guangzhou
   University of Chinese Medicine [2017TD07, 2017TD04]; Scientific Research
   Foundation of Traditional Chinese Medicine Bureau of Guangdong Province
   [20172048]
FX This work was generously supported by grants from the "Innovation
   strengthen Hospital" project in the Scientific Research series
   Foundation of the First Affiliated Hospital of Guangzhou University of
   Chinese Medicine in 2017. (Grant No.2017TD07 and Grant No.2017TD04), and
   the Scientific Research Foundation of Traditional Chinese Medicine
   Bureau of Guangdong Province (Grant No.20172048).
CR Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   [Anonymous], 2011, GUIDE CARE USE LAB A
   Bailey TA, 2004, INVEST OPHTH VIS SCI, V45, P675, DOI 10.1167/iovs.03-0351
   Blasiak J, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/768026
   Buiting K, 2007, GENOMICS, V89, P588, DOI 10.1016/j.ygeno.2006.12.008
   Cai H, 2019, EXP EYE RES, V185, DOI 10.1016/j.exer.2019.04.009
   Chen X, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.382
   Glotin AL, 2008, FREE RADICAL BIO MED, V44, P1348, DOI 10.1016/j.freeradbiomed.2007.12.023
   Huang X, 2018, REPROD BIOL ENDOCRIN, V16, DOI 10.1186/s12958-018-0392-4
   Kauppinen A, 2012, IMMUNOL LETT, V147, P29, DOI 10.1016/j.imlet.2012.05.005
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Maass PG, 2014, J MOL MED, V92, P337, DOI 10.1007/s00109-014-1131-8
   Mousa SA, 1999, J CELL BIOCHEM, V74, P135, DOI 10.1002/(SICI)1097-4644(19990701)74:1<135::AID-JCB15>3.0.CO;2-#
   Rosenfeld Philip J, 2006, Ophthalmol Clin North Am, V19, P361
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmitz SU, 2016, CELL MOL LIFE SCI, V73, P2491, DOI 10.1007/s00018-016-2174-5
   Schmucker C, 2011, BRIT J OPHTHALMOL, V95, P308, DOI 10.1136/bjo.2009.178574
   Sreekumar PG, 2016, INVEST OPHTH VIS SCI, V57, P1238, DOI 10.1167/iovs.15-17053
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Weigel AL, 2002, FREE RADICAL BIO MED, V33, P1419, DOI 10.1016/S0891-5849(02)01082-1
   Wong TY, 2007, OPHTHALMOLOGY, V114, P86, DOI 10.1016/j.ophtha.2006.06.039
   Youn HY, 2007, J PHOTOCH PHOTOBIO B, V88, P21, DOI 10.1016/j.jphotobiol.2007.04.012
   Yu XY, 2019, IUBMB LIFE, V71, P1611, DOI 10.1002/iub.2102
   Yu XY, 2018, BIOCHEM BIOPH RES CO, V495, P922, DOI 10.1016/j.bbrc.2017.11.007
   Zhu W, 2017, INT J NANOMED, V12, P7589, DOI 10.2147/IJN.S140275
NR 27
TC 3
Z9 3
U1 4
U2 7
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD JAN 8
PY 2021
VL 535
BP 39
EP 46
DI 10.1016/j.bbrc.2020.10.104
PG 8
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA PR5ZY
UT WOS:000607315600007
PM 33340764
DA 2022-11-30
ER

PT J
AU Chhablani, J
   Kim, JS
   Freeman, WR
   Kozak, I
   Wang, HY
   Cheng, LY
AF Chhablani, Jay
   Kim, Jae Suk
   Freeman, William R.
   Kozak, Igor
   Wang, Hai-Yan
   Cheng, Lingyun
TI Predictors of visual outcome in eyes with choroidal neovascularization
   secondary to age related macular degeneration treated with intravitreal
   bevacizumab monotherapy
SO INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE external limiting membrane; age-related macular degeneration; choroidal
   neovascularization; avastin
ID OPTICAL COHERENCE TOMOGRAPHY; EXTERNAL LIMITING MEMBRANE; FOVEAL
   MICROSTRUCTURE; PHOTORECEPTOR LAYER; CLINICAL MEASURES; ACUITY;
   IMPAIRMENT
AB AIM: To evaluate the predictors of visual improvement in eyes with naive choroidal neovascularization secondary to age-related macular degeneration (CNV -AMD) treated with intravitreal bevacizumab (IVB) monotherapy.
   METHODS: Fifty eyes with naive CNV - AMD with pretreatment best-corrected visual acuity (BCVA) better than 20/200 and treated with IVB monotherapy were evaluated. Several variables including age, sex, pretreatment BCVA, CNV type and lesion size on fluorescein angiogram as well as SD-OCT parameters including pretreatment central macular thickness (CMT), inner - segment/outer -segment (IS/OS) junction integrity, and external limiting membrane (ELM) integrity were analyzed to predict visual outcome.
   RESULTS: On univariate regression, pretreatment ELM damage was associated with less visual improvement after treatment (P=0.0145). However, ELM damage predicted only 10% of the visual outcome. On multivariate regression, pretreatment BCVA, IS/OS junction, and ELM integrity on SD-OCT were the significant predictors for the treatment effect and together predicted 37% of visual improvement.
   CONCLUSION: Pretreatment BCVA, ELM and IS/OS junction integrity on SD-OCT are of significant value in predicting the visual improvement in naive wet AMD patients treated with IVB monotherapy.
C1 [Chhablani, Jay; Kim, Jae Suk; Freeman, William R.; Kozak, Igor; Wang, Hai-Yan; Cheng, Lingyun] Univ Calif San Diego, Shiley Eye Ctr, Jacobs Retina Ctr, San Diego, CA 92103 USA.
   [Chhablani, Jay] LV Prasad Eye Inst, Hyderabad, Andhra Pradesh, India.
   [Kim, Jae Suk] Inje Univ, Sanggye Paik Hosp, Dept Ophthalmol, Seoul, South Korea.
C3 University of California System; University of California San Diego; L.
   V. Prasad Eye Institute; Inje University
RP Cheng, LY (通讯作者)，Univ Calif San Diego, Dept Ophthalmol, Jacobs Retina Ctr, Shiley Eye Ctr, San Diego, CA 92103 USA.
EM cheng@eyecenter.ucsd.edu
RI Kozak, Igor/AAC-4645-2019
OI Chhablani, Jay/0000-0003-1772-3558
FU NIH [EY 020617, EYO 7366]; NATIONAL EYE INSTITUTE [P30EY022589] Funding
   Source: NIH RePORTER
FX Foundation items: Supported by an Unrestricted Research Fund to Jacobs
   Retina Center at Shiley Eye Center, University of California, San Diego
   (LC); NIH EY 020617 (LC); and NIH EYO 7366 (WRF)
CR [Anonymous], 1999, ARCH OPHTHALMOL, V117, P1329
   BUNTMILAM AH, 1985, INVEST OPHTH VIS SCI, V26, P1377
   Dimitrov PN, 2011, INVEST OPHTH VIS SCI, V52, P9457, DOI 10.1167/iovs.10-7043
   Doris N, 2001, BRIT J OPHTHALMOL, V85, P184, DOI 10.1136/bjo.85.2.184
   Hayashi H, 2009, AM J OPHTHALMOL, V148, P83, DOI 10.1016/j.ajo.2009.01.017
   Kang S, 2009, JPN J OPHTHALMOL, V53, P389, DOI 10.1007/s10384-009-0670-y
   Keane PA, 2008, OPHTHALMOLOGY, V115, P2206, DOI 10.1016/j.ophtha.2008.08.016
   Levy Jaime, 2009, International Ophthalmology, V29, P349, DOI 10.1007/s10792-008-9243-1
   Li D, 2007, ARCH OPHTHALMOL-CHIC, V125, P1194, DOI 10.1001/archopht.125.9.1194
   Maheshwary AS, 2010, AM J OPHTHALMOL, V150, P63, DOI 10.1016/j.ajo.2010.01.039
   Mousa SA, 2010, BIODRUGS, V24, P183, DOI 10.2165/11318550-000000000-00000
   Moutray T, 2008, BRIT J OPHTHALMOL, V92, P361, DOI 10.1136/bjo.2007.123976
   Murakami T, 2011, AM J OPHTHALMOL, V151, P310, DOI 10.1016/j.ajo.2010.08.022
   Oishi A, 2010, AM J OPHTHALMOL, V150, P27, DOI 10.1016/j.ajo.2010.02.012
   Ozkiris A, 2010, EXPERT OPIN THER PAT, V20, P103, DOI 10.1517/13543770902762885
   Pascolini D, 2004, OPHTHAL EPIDEMIOL, V11, P67, DOI 10.1076/opep.11.2.67.28158
   Piccolino FC, 2005, AM J OPHTHALMOL, V139, P87, DOI 10.1016/j.ajo.2004.08.037
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Shin HJ, 2011, RETINA-J RET VIT DIS, V31, P1627, DOI 10.1097/IAE.0b013e31820d3d01
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Theodossiadis PG, 2011, OPHTHALMOLOGICA, V225, P176, DOI 10.1159/000323322
   Unver YB, 2009, EYE, V23, P453, DOI 10.1038/eye.2008.349
   Wakabayashi T, 2010, OPHTHALMOLOGY, V117, P1815, DOI 10.1016/j.ophtha.2010.01.017
   Wakabayashi T, 2009, OPHTHALMOLOGY, V116, P519, DOI 10.1016/j.ophtha.2008.10.001
NR 24
TC 23
Z9 23
U1 0
U2 3
PU IJO PRESS
PI XI AN
PA NO 269 YOUYI EAST RD, XI AN, 710054, PEOPLES R CHINA
SN 2222-3959
J9 INT J OPHTHALMOL-CHI
JI Int. J. Ophthalmol.
PD FEB 18
PY 2013
VL 6
IS 1
BP 62
EP 66
DI 10.3980/j.issn.2222-3959.2013.01.13
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 093GV
UT WOS:000315180600013
PM 23549041
DA 2022-11-30
ER

PT J
AU Chang, MA
   Do, DV
   Bressler, SB
   Cassard, SD
   Gower, EW
   Bressler, NM
AF Chang, Margaret A.
   Do, Diana V.
   Bressler, Susan B.
   Cassard, Sandra D.
   Gower, Emily W.
   Bressler, Neil M.
TI PROSPECTIVE ONE-YEAR STUDY OF RANIBIZUMAB FOR PREDOMINANTLY HEMORRHAGIC
   CHOROIDAL NEOVASCULAR LESIONS IN AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; choroidal neovascularization;
   hemorrhagic; ranibizumab
ID TISSUE-PLASMINOGEN ACTIVATOR; SUBMACULAR HEMORRHAGE; VISUAL-ACUITY;
   VERTEPORFIN; BEVACIZUMAB; MANAGEMENT; SECONDARY; INJECTION; THERAPY
AB Purpose: To determine the safety and effect of ranibizumab on predominantly hemorrhagic choroidal neovascular lesions due to age-related macular degeneration.
   Methods: Seven subjects with predominantly hemorrhagic choroidal neovascular lesions were treated with intravitreal injections of ranibizumab at baseline, Month 1, and Month 2. Additional monthly injections were given through Month 11 at the discretion of the examiner for a potential maximum of 12 injections.
   Results: At 12 months, the median visual acuity letter score was 30 (Snellen equivalent: 20/250), with amedian change from baseline to last follow-up of + 7 letters. Three of 7 subjects (43%) gained 2 or more lines of vision, while no subject lost 2 or more lines. The median change in OCT central subfield thickness from baseline to Month 12 was -109 mu m, with a mean of 2120 6 158 mm. Two eyes had retinal pigment epithelial tears. No ocular adverse events or systemic adverse events were reported related to the usage of ranibizumab.
   Conclusion: With no subject losing 2 or more lines of visual acuity over 12 months and no new safety concerns identified, these predominantly hemorrhagic lesions treated with ranibizumab appeared to have a better visual acuity outcome than the natural history controls of the submacular surgery trials. While the study is limited by few cases enrolled, the results suggest that ranibizumab is able to penetrate through the subretinal hemorrhage to affect the underlying hemorrhagic choroidal neovascular lesion and the natural history. RETINA 30:1171-1176, 2010
C1 Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Retina Div, Baltimore, MD 21205 USA.
   Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Dana Ctr Prevent Ophthalmol, Baltimore, MD 21205 USA.
C3 Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins
   University; Johns Hopkins Medicine
RP Bressler, NM (通讯作者)，Maumenee 7,600 N Wolfe St, Baltimore, MD 21287 USA.
EM nmboffice@jhmi.edu
FU Genentech; Lincy Foundation; Jack Valenti Macular Degeneration Fund;
   Wilmer Retina Research Fund; Hutcheson Fellowship
FX Supported by an unrestricted grant from Genentech (who had no input into
   the design or analysis or writing of the manuscript), the Lincy
   Foundation, the Jack Valenti Macular Degeneration Fund, a Wilmer Retina
   Research Fund (N.M.B.), the Hutcheson Fellowship (M.A.C.), the Julia G.
   Levy, PhD Professorship (S.B.B.), and the James P. Gills Professorship
   (N.M.B.).
CR Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Bressler NM, 2008, AM J OPHTHALMOL, V145, P894, DOI 10.1016/j.ajo.2007.12.025
   Bressler NM, 2004, OPHTHALMOLOGY, V111, P1993, DOI 10.1016/j.ophtha.2004.07.023
   Bressler SB, 2005, RETINA-J RET VIT DIS, V25, P253
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Handwerger BA, 2001, ARCH OPHTHALMOL-CHIC, V119, P28
   Hassan AS, 1999, OPHTHALMOLOGY, V106, P1900, DOI 10.1016/S0161-6420(99)90399-8
   Johnson M W, 2000, Curr Opin Ophthalmol, V11, P201, DOI 10.1097/00055735-200006000-00009
   Meyer CH, 2008, ACTA OPHTHALMOL, V86, P490, DOI 10.1111/j.1600-0420.2007.01125.x
   Pauleikhoff D, 2005, RETINA-J RET VIT DIS, V25, P1065, DOI 10.1097/00006982-200512000-00016
   Ron Y, 2007, OPHTHALMOLOGICA, V221, P57, DOI 10.1159/000096524
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sacu S, 2009, EYE, V23, P1404, DOI 10.1038/eye.2008.267
   Stifter E, 2007, AM J OPHTHALMOL, V144, P886, DOI 10.1016/j.ajo.2007.07.034
   Yang Po-Min, 2005, Chang Gung Med J, V28, P852
NR 18
TC 42
Z9 43
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD SEP
PY 2010
VL 30
IS 8
BP 1171
EP 1176
DI 10.1097/IAE.0b013e3181dd6d8a
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 647JF
UT WOS:000281614100004
PM 20827138
DA 2022-11-30
ER

PT J
AU Ross, C
   Engler, CB
   Sander, B
   Bendtzen, K
AF Ross, C
   Engler, CB
   Sander, B
   Bendtzen, K
TI IFN-alpha antibodies in patients with age-related macular degeneration
   treated with recombinant human IFN-alpha 2a
SO JOURNAL OF INTERFERON AND CYTOKINE RESEARCH
LA English
DT Article
ID CHOROIDAL NEOVASCULAR MEMBRANES; CHRONIC HEPATITIS-C; INTERFERON-ALPHA;
   NEUTRALIZING ANTIBODIES; SYSTEMIC INTERFERON-ALPHA-2A; THERAPY; ALFA-2A;
   SUBFOVEAL; AUTOANTIBODIES
AB We tested for development of binding and neutralizing antibodies to interferon-alpha (IFN-alpha) during IFN-alpha2a therapy of patients with age-related macular degeneration (AMD) of the eyes. Antibodies were investigated retrospectively in sera of 34 patients treated with 3 x 10(6) IU IFN-alpha2a (Roceron-A(R), Hoffmann La-Roche, Basel, Switzerland) three times weekly for periods of 8-16 weeks with or without a drug-free 4-12-week intermission. Additionally, 10 patients were investigated prospectively; 7 received 1.5-6 x 10(6) IU IFN-alpha2a three times weekly for 12 months, and 3 received placebo. Binding antibodies were tested by molecular size and protein G affinity chromatography using I-125-IFN-alpha2a. Neutralizing activities were tested by antiviral neutralization bioassay. IgG antibodies were detected in 24 of 34 IFN-alpha2a-treated patients (71%). Significantly higher anti-IFN-alpha levels were observed in patients who after discontinuation were readministered IFN-alpha2a (p < 0.02). Three of the IFN-&alpha;2a-treated patients in the prospective study had high and 1 had low antibody titers. Neutralizing antibody titers were high against IFN-&alpha;2a and IFN-&alpha;2c and low against lymphoblastoid and leukocyte IFN-&alpha;. Impaired clinical responses were observed in antibody-positive patients (p < 0.01). The development of neutralizing anti-IFN-alpha antibodies in patients with AMD during recombinant human IFN-alpha therapy may explain the often poor clinical effect of IFN-alpha treatment.
C1 Univ Copenhagen, Rigshosp, Inst Inflammat Res 7521, DK-2100 Copenhagen, Denmark.
   Kommune Hosp Copenhagen, Dept Ophthalmol, Herlev, Denmark.
C3 Rigshospitalet; University of Copenhagen
RP Bendtzen, K (通讯作者)，Univ Copenhagen, Rigshosp, Inst Inflammat Res 7521, Blegdamsveg 9, DK-2100 Copenhagen, Denmark.
CR Antonelli G, 1997, J INTERF CYTOK RES, V17, pS39
   ANTONELLI G, 1991, J INFECT DIS, V163, P882, DOI 10.1093/infdis/163.4.882
   Antonelli G, 1999, EUR CYTOKINE NETW, V10, P413
   Bendtzen K, 1998, IMMUNOL TODAY, V19, P209, DOI 10.1016/S0167-5699(98)01252-3
   Bendtzen K, 2000, CYTOKINE INHIBITORS, P53
   Bordens R, 1997, Semin Oncol, V24, pS9
   CHAN CK, 1994, OPHTHALMOLOGY, V101, P289
   CONSTABLE I, 1992, AUST NZ J OPHTHALMOL, V20, P155, DOI 10.1111/j.1442-9071.1992.tb00933.x
   ENGLER C, 1994, BRIT J OPHTHALMOL, V78, P749, DOI 10.1136/bjo.78.10.749
   ENGLER CB, 1993, ACTA OPHTHALMOL, V71, P27
   FREUND M, 1988, BLUT, V57, P311, DOI 10.1007/BF00320360
   FUNG WE, 1991, AM J OPHTHALMOL, V112, P349, DOI 10.1016/S0002-9394(14)76743-1
   GILLIES MC, 1993, BRIT J OPHTHALMOL, V77, P759, DOI 10.1136/bjo.77.12.759
   Guyer DR, 1997, ARCH OPHTHALMOL-CHIC, V115, P865
   HANSEN MB, 1990, J IMMUNOL METHODS, V127, P241, DOI 10.1016/0022-1759(90)90074-6
   HANSEN MB, 1992, CLIN EXP IMMUNOL, V88, P559
   JAAKKOLA A, 1994, ACTA OPHTHALMOL, V72, P545
   KIRKPATRICK JNP, 1993, BRIT J OPHTHALMOL, V77, P766, DOI 10.1136/bjo.77.12.766
   Leroy V, 1998, J HEPATOL, V28, P375, DOI 10.1016/S0168-8278(98)80309-7
   LEWIS ML, 1993, GRAEF ARCH CLIN EXP, V231, P615, DOI 10.1007/BF00921954
   Liptakova H, 1998, ACTA VIROL, V42, P279
   LOUGHNAN MS, 1992, AUST NZ J OPHTHALMOL, V20, P173, DOI 10.1111/j.1442-9071.1992.tb00936.x
   MILELLA M, 1993, LIVER, V13, P146
   Nolte KU, 1996, EUR J IMMUNOL, V26, P2155, DOI 10.1002/eji.1830260929
   Palleroni AV, 1997, J INTERF CYTOK RES, V17, pS23
   ROSS C, 1995, J CLIN INVEST, V95, P1974, DOI 10.1172/JCI117881
   Tefferi A, 1996, AM J HEMATOL, V52, P231
   Thoelen A, 1995, Ger J Ophthalmol, V4, P137
   VONWUSSOW P, 1991, BRIT J HAEMATOL, V78, P210, DOI 10.1111/j.1365-2141.1991.tb04418.x
   1997, BIOTHERAPY, V10
NR 30
TC 8
Z9 11
U1 0
U2 0
PU MARY ANN LIEBERT INC PUBL
PI LARCHMONT
PA 2 MADISON AVENUE, LARCHMONT, NY 10538 USA
SN 1079-9907
J9 J INTERF CYTOK RES
JI J. Interferon Cytokine Res.
PD APR
PY 2002
VL 22
IS 4
BP 421
EP 426
DI 10.1089/10799900252952208
PG 6
WC Biochemistry & Molecular Biology; Cell Biology; Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Immunology
GA 551DL
UT WOS:000175544200004
PM 12034024
DA 2022-11-30
ER

PT J
AU Kay, P
   Yang, YC
   Paraoan, L
AF Kay, Paul
   Yang, Yit C.
   Paraoan, Luminita
TI Directional protein secretion by the retinal pigment epithelium: roles
   in retinal health and the development of age-related macular
   degeneration
SO JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
LA English
DT Review
DE retina; retinal pigment epithelium; protein secretion; polarity;
   age-related macular degeneration
ID ENDOTHELIAL GROWTH-FACTOR; PRECURSOR CYSTATIN-C; INTERPHOTORECEPTOR
   MATRIX; MDCK CELLS; BASOLATERAL SECRETION; VECTORIAL SECRETION;
   PLASMA-MEMBRANE; BRUCHS MEMBRANE; CHOROIDAL NEOVASCULARIZATION;
   METALLOPROTEINASE ACTIVITY
AB The structural and functional integrity of the retinal pigment epithelium (RPE) is fundamental for maintaining the function of the neuroretina. These specialized cells form a polarized monolayer that acts as the retinal-blood barrier, separating two distinct environments with highly specialized functions: photoreceptors of the neuroretina at the apical side and Bruch's membrane/highly vascularized choriocapillaris at the basal side. The polarized nature of the RPE is essential for the health of these two regions, not only in nutrient and waste transport but also in the synthesis and directional secretion of proteins required in maintaining retinal homoeostasis and function. Although multiple malfunctions within the RPE cells have been associated with development of age-related macular degeneration (AMD), the leading cause of legal blindness, clear causative processes have not yet been conclusively characterized at the molecular and cellular level. This article focuses on the involvement of directionally secreted RPE proteins in normal functioning of the retina and on the potential association of incorrect RPE protein secretion with development of AMD. Understanding the importance of RPE polarity and the correct secretion of essential structural and regulatory components emerge as critical factors for the development of novel therapeutic strategies targeting AMD.
C1 [Kay, Paul; Paraoan, Luminita] Univ Liverpool, Dept Eye & Vis Sci, Inst Ageing & Chron Dis, Liverpool L69 3GA, Merseyside, England.
   [Yang, Yit C.] Royal Wolverhampton NHS Trust, Dept Ophthalmol, Wolverhampton, W Midlands, England.
C3 University of Liverpool
RP Paraoan, L (通讯作者)，Univ Liverpool, Dept Eye & Vis Sci, Inst Ageing & Chron Dis, UCD Bldg,Daulby St, Liverpool L69 3GA, Merseyside, England.
EM lparaoan@liv.ac.uk
RI Paraoan, Luminita/K-1066-2016
OI Paraoan, Luminita/0000-0001-7568-7116
FU The Royal Wolverhampton NHS Trust
FX The authors gratefully acknowledge the support from R&D Fund of The
   Royal Wolverhampton NHS Trust.
CR Ablonczy Z, 2011, INVEST OPHTH VIS SCI, V52, P8614, DOI 10.1167/iovs.11-8021
   ABRAHAMSON M, 1987, FEBS LETT, V216, P229, DOI 10.1016/0014-5793(87)80695-6
   ALEXANDER JP, 1990, INVEST OPHTH VIS SCI, V31, P2520
   An E, 2006, J PROTEOME RES, V5, P2599, DOI 10.1021/pr060121j
   Aroeti B, 1998, BBA-REV BIOMEMBRANES, V1376, P57, DOI 10.1016/S0304-4157(98)00005-7
   Ballabh P, 2004, NEUROBIOL DIS, V16, P1, DOI 10.1016/j.nbd.2003.12.016
   BARRETT AJ, 1986, BIOMED BIOCHIM ACTA, V45, P1363
   Becerra SP, 2004, EXP EYE RES, V78, P223, DOI 10.1016/j.exer.2003.10.013
   Benussi L, 2003, NEUROBIOL DIS, V13, P15, DOI 10.1016/S0969-9961(03)00012-3
   Bode V, 1991, FEBS LETT, V285, P213
   BOK D, 1993, J CELL SCI, P189
   BOLL W, 1991, P NATL ACAD SCI USA, V88, P8592, DOI 10.1073/pnas.88.19.8592
   Bonilha VL, 1997, J CELL SCI, V110, P1717
   Burgi S, 2009, MOL VIS, V15, P1631
   Cao GF, 2011, BIOCHEM BIOPH RES CO, V414, P499, DOI 10.1016/j.bbrc.2011.09.094
   Cayouette M, 1999, NEUROBIOL DIS, V6, P523, DOI 10.1006/nbdi.1999.0263
   Chlenski A, 2002, CANCER RES, V62, P7357
   CLEMENTS DA, 1993, ONCOGENE, V8, P1311
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245
   De S, 2007, ARCH OPHTHALMOL-CHIC, V125, P641, DOI 10.1001/archopht.125.5.641
   Dempsey PJ, 2003, EXP CELL RES, V285, P159, DOI 10.1016/S0014-4827(03)00035-1
   des Senanayake P, 2001, J CELL SCI, V114, P199
   DESTROOPER B, 1995, J BIOL CHEM, V270, P4058, DOI 10.1074/jbc.270.8.4058
   Dornonville de la Cour M, 1993, Acta Ophthalmol Suppl, P1
   Dunn KC, 1998, INVEST OPHTH VIS SCI, V39, P2744
   Ellis MA, 2006, AM J PHYSIOL-RENAL, V291, pF707, DOI 10.1152/ajprenal.00161.2006
   Fariss RN, 1997, AM J PATHOL, V150, P323
   FERRIS FL, 1983, AM J EPIDEMIOL, V118, P132, DOI 10.1093/oxfordjournals.aje.a113624
   Finnemann SC, 2003, EMBO J, V22, P4143, DOI 10.1093/emboj/cdg416
   Folkman J, 1997, EXS, V79, P1
   Folsch H, 2009, TRAFFIC, V10, P972, DOI 10.1111/j.1600-0854.2009.00927.x
   Fritz BA, 1996, AM J PHYSIOL-GASTR L, V270, pG176, DOI 10.1152/ajpgi.1996.270.1.G176
   Gangalum RK, 2011, J BIOL CHEM, V286, P3261, DOI 10.1074/jbc.M110.160135
   Giordano FJ, 1996, NAT MED, V2, P534, DOI 10.1038/nm0596-534
   Gravotta D, 2007, P NATL ACAD SCI USA, V104, P1564, DOI 10.1073/pnas.0610700104
   Guerriero CJ, 2008, J BIOL CHEM, V283, P18040, DOI 10.1074/jbc.M802048200
   Guo L, 1999, INVEST OPHTH VIS SCI, V40, P2676
   Hamann S, 2002, INT REV CYTOL, V215, P395
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   Hauck SM, 2005, PROTEOMICS, V5, P3623, DOI 10.1002/pmic.200401223
   Hoffmann S, 2006, RETINA-J RET VIT DIS, V26, P454, DOI 10.1097/00006982-200604000-00012
   Hollborn M, 2006, CURR EYE RES, V31, P863, DOI 10.1080/02713680600888807
   Hollyfield JG, 1999, INVEST OPHTH VIS SCI, V40, P2767
   HOPPENREIJS VPT, 1994, INVEST OPHTH VIS SCI, V35, P931
   HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449
   HUNT RC, 1993, INVEST OPHTH VIS SCI, V34, P3179
   HUNZIKER W, 1994, CELL BIOL INT, V18, P321, DOI 10.1006/cbir.1994.1081
   Hussain AA, 2011, INVEST OPHTH VIS SCI, V52, P4459, DOI 10.1167/iovs.10-6678
   Jackson C, 2002, CURR OPIN NEPHROL HY, V11, P295, DOI 10.1097/00041552-200205000-00005
   Jacob R, 2003, CURR BIOL, V13, P607, DOI 10.1016/S0960-9822(03)00188-X
   Jin ML, 2005, INVEST OPHTH VIS SCI, V46, P4311, DOI 10.1167/iovs.05-0353
   Jones RPO, 2010, INVEST OPHTH VIS SCI, V51, P2356, DOI 10.1167/iovs.09-4620
   Kedzierski RM, 2001, ANNU REV PHARMACOL, V41, P851, DOI 10.1146/annurev.pharmtox.41.1.851
   Keller P, 1997, J CELL SCI, V110, P3001
   Kim YH, 2009, GRAEF ARCH CLIN EXP, V247, P651, DOI 10.1007/s00417-009-1049-y
   Kitaoka T, 1997, CURR EYE RES, V16, P396, DOI 10.1076/ceyr.16.4.396.10685
   Kolomeyer AM, 2011, INVEST OPHTH VIS SCI, V52, P5973, DOI 10.1167/iovs.10-6965
   KYTE J, 1976, J CELL BIOL, V68, P287, DOI 10.1083/jcb.68.2.287
   Lambert V, 2003, FASEB J, V17, P2290, DOI 10.1096/fj.03-0113fje
   LAVAIL MM, 1981, INVEST OPHTH VIS SCI, V21, P658
   Li RW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024417
   Maminishkis A, 2006, INVEST OPHTH VIS SCI, V47, P3612, DOI 10.1167/iovs.05-1622
   Marmorstein AD, 2000, P NATL ACAD SCI USA, V97, P12758, DOI 10.1073/pnas.220402097
   Marmorstein LHY, 2002, P NATL ACAD SCI USA, V99, P13067, DOI 10.1073/pnas.202491599
   Mellman I, 2000, CELL, V100, P99, DOI 10.1016/S0092-8674(00)81687-6
   MILLER SS, 1990, J PHYSIOL-LONDON, V424, P283, DOI 10.1113/jphysiol.1990.sp018067
   Mochimaru H, 2009, INVEST OPHTH VIS SCI, V50, P4410, DOI 10.1167/iovs.08-3044
   MORIARTY P, 1994, BRIT J OPHTHALMOL, V78, P638, DOI 10.1136/bjo.78.8.638
   Mostov KE, 2000, CURR OPIN CELL BIOL, V12, P483, DOI 10.1016/S0955-0674(00)00120-4
   MOSTOV KE, 1995, HISTOL HISTOPATHOL, V10, P423
   Mousa SA, 1999, J CELL BIOCHEM, V74, P135, DOI 10.1002/(SICI)1097-4644(19990701)74:1<135::AID-JCB15>3.0.CO;2-#
   Narayan S, 2004, EXP EYE RES, V79, P11, DOI 10.1016/j.exer.2004.03.002
   Nickel W, 2003, EUR J BIOCHEM, V270, P2109, DOI 10.1046/j.1432-1033.2003.03577.x
   Nozaki M, 2006, J CLIN INVEST, V116, P422, DOI 10.1172/JCI26316
   Ogawa T, 2005, MOL VIS, V11, P380
   OKAMI T, 1990, J HISTOCHEM CYTOCHEM, V38, P1267, DOI 10.1177/38.9.2167328
   Ozawa CR, 2004, J CLIN INVEST, V113, P516, DOI 10.1172/JCI200418420
   Padgett LC, 1997, EXP EYE RES, V64, P927, DOI 10.1006/exer.1997.0287
   PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303
   Paraoan L, 2004, TRAFFIC, V5, P884, DOI 10.1111/j.1600-0854.2004.00230.x
   Paraoan L, 2003, EXP EYE RES, V76, P753, DOI 10.1016/S0014-4835(03)00061-7
   Paraoan L, 2001, MOL MEMBR BIOL, V18, P229
   Paraoan L, 2000, INT J BIOCHEM CELL B, V32, P417, DOI 10.1016/S1357-2725(99)00143-0
   Paskowitz DM, 2004, INVEST OPHTH VIS SCI, V45, P4190, DOI 10.1167/iovs.04-0676
   Prabakaran D, 1999, J CELL SCI, V112, P1247
   Rakoczy PE, 2002, AM J PATHOL, V161, P1515, DOI 10.1016/S0002-9440(10)64427-6
   Ratnayaka A, 2007, EXP EYE RES, V84, P1135, DOI 10.1016/j.exer.2006.01.030
   REMALEY AT, 1995, J LIPID RES, V36, P407
   ROBERTS WG, 1995, J CELL SCI, V108, P2369
   Rodriguez-Boulan B, 2008, ONCOGENE, V27, P6939
   Rodriguez-Boulan E, 2005, BBA-MOL CELL RES, V1744, P455, DOI 10.1016/j.bbamcr.2005.04.007
   Rodriguez-Boulan E, 1999, TRENDS CELL BIOL, V9, P291, DOI 10.1016/S0962-8924(99)01595-0
   RODRIGUEZBOULAN E, 1993, J CELL SCI, P9
   ROHLICH P, 1970, EXP EYE RES, V10, P80, DOI 10.1016/S0014-4835(70)80013-6
   Rosenthal R, 2005, BIOCHEM BIOPH RES CO, V337, P241, DOI 10.1016/j.bbrc.2005.09.028
   Rosenthal R, 2004, BIOCHEM BIOPH RES CO, V323, P1203, DOI 10.1016/j.bbrc.2004.08.219
   Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   Sakaguchi H, 2002, EXP EYE RES, V74, P547, DOI 10.1006/exer.2002.1186
   SCHEIFFELE P, 1995, NATURE, V378, P96, DOI 10.1038/378096a0
   Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526
   SENSENBRENNER M, 1993, PROG NEUROBIOL, V41, P683, DOI 10.1016/0301-0082(93)90031-M
   Sonnier DI, 2010, J GASTROINTEST SURG, V14, P1592, DOI 10.1007/s11605-010-1321-9
   Sonoda S, 2010, AGING-US, V2, P28, DOI 10.18632/aging.100111
   Sonoda S, 2009, NAT PROTOC, V4, P662, DOI 10.1038/nprot.2009.33
   Sreekumar PG, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012578
   Stein MP, 2002, TRENDS CELL BIOL, V12, P374, DOI 10.1016/S0962-8924(02)02331-0
   Steiner-Champliaud MF, 2006, MOL VIS, V12, P892
   Stitt AW, 1996, CURR EYE RES, V15, P111, DOI 10.3109/02713689609017618
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Tan J, 2010, CURR EYE RES, V35, P37, DOI 10.3109/02713680903374190
   Traub LM, 2005, BBA-MOL CELL RES, V1744, P415, DOI 10.1016/j.bbamcr.2005.04.005
   Vranka JA, 1997, CURR EYE RES, V16, P102, DOI 10.1076/ceyr.16.2.102.5086
   Wachi H, 2007, BIOCHEM J, V402, P63, DOI 10.1042/BJ20061145
   WALTER P, 1984, CELL, V38, P5, DOI 10.1016/0092-8674(84)90520-8
   Weisz OA, 2009, J CELL SCI, V122, P4253, DOI 10.1242/jcs.032615
   Yeaman C, 1999, PHYSIOL REV, V79, P73, DOI 10.1152/physrev.1999.79.1.73
   Yokomori H, 2003, LIVER INT, V23, P467, DOI 10.1111/j.1478-3231.2003.00880.x
   Yu AL, 2009, INVEST OPHTH VIS SCI, V50, P926, DOI 10.1167/iovs.07-1003
   Zhang D, 2005, INVEST OPHTH VIS SCI, V46, P3031, DOI 10.1167/iovs.04-1510
   Zhu DH, 2011, INVEST OPHTH VIS SCI, V52, P1573, DOI 10.1167/iovs.10-6413
   Zuehlke J, 2012, CELL COMMUN SIGNAL, V10, DOI 10.1186/1478-811X-10-25
   Zurdel J, 2002, BRIT J OPHTHALMOL, V86, P214, DOI 10.1136/bjo.86.2.214
NR 124
TC 53
Z9 53
U1 0
U2 13
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
EI 1582-4934
J9 J CELL MOL MED
JI J. Cell. Mol. Med.
PD JUL
PY 2013
VL 17
IS 7
BP 833
EP 843
DI 10.1111/jcmm.12070
PG 11
WC Cell Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA 188OM
UT WOS:000322202300004
PM 23663427
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Biarnes, M
   Mones, J
   Trindade, F
   Alonso, J
   Arias, L
AF Biarnes, Marc
   Mones, Jordi
   Trindade, Fabio
   Alonso, Jordi
   Arias, Luis
TI Intra and interobserver agreement in the classification of fundus
   autofluorescence patterns in geographic atrophy secondary to age-related
   macular degeneration
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Geographic atrophy; Fundus
   autofluorescence; Reproducibility; Kappa
ID MACULOPATHY; OPHTHALMOLOGISTS; RISK
AB To describe the intra and interobserver agreement in the evaluation of fundus autofluorescence patterns in geographic atrophy secondary to age-related macular degeneration.
   A consecutive series of patients with geographic atrophy and fundus autofluorescence images of a minimum acceptable quality for grading were included. Four observers with experience in the evaluation of autofluorescence images independently classified the randomly presented series of images on two occasions, at least 1 month apart from each other (intraobserver analysis). The second determination of each observer was used for evaluation of interobserver agreement. The kappa statistic and 95% confidence intervals, together with percentages of agreement, were used to analyze the results.
   The final sample included 69 eyes of 49 patients. Intraobserver agreement ranged from substantial to almost perfect (kappa between 0.51 and 0.83), while interobserver results ranged from poor to substantial (corresponding to kappa between 0.30 and 0.62). The use of more simple classifications improved reproducibility.
   Although intraobserver reproducibility was high, interobserver agreement was variable. Clear descriptions and a uniform set of criteria to classify these patients are needed if fundus autofluorescence imaging is used to evaluate patients with geographic atrophy.
C1 [Biarnes, Marc; Mones, Jordi; Trindade, Fabio] Inst Macula & Retina, Barcelona, Spain.
   [Biarnes, Marc; Alonso, Jordi] Univ Pompeu Fabra, Dept Ciencies Expt & Salut, Barcelona, Spain.
   [Arias, Luis] Hosp Univ Bellvitge, Barcelona, Spain.
C3 Pompeu Fabra University; Institut d'Investigacio Biomedica de Bellvitge
   (IDIBELL); Bellvitge University Hospital; University of Barcelona
RP Biarnes, M (通讯作者)，Inst Macula & Retina, Barcelona, Spain.
EM biarnes@oo.upc.edu
RI mones, jordi/CAJ-2963-2022; Alonso, Jordi/A-5514-2010
OI mones, jordi/0000-0003-3685-2160; Alonso, Jordi/0000-0001-8627-9636;
   ARIAS, LUIS/0000-0001-7041-5576; Trindade, Fabio/0000-0001-9993-5188;
   Biarnes, Marc/0000-0003-2584-4894
FU Novartis; Allergan; Ophthotech; Notalvision; Bayer
FX Jordi Mones: consulting fees from Novartis, Allergan, Ophthotech,
   Notalvision and Bayer.
CR Bindewald A, 2005, BRIT J OPHTHALMOL, V89, P874, DOI 10.1136/bjo.2004.057794
   Chiang MF, 2010, ARCH OPHTHALMOL-CHIC, V128, P1153, DOI 10.1001/archophthalmol.2010.199
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Fleckenstein M, 2011, INVEST OPHTH VIS SCI, V52, P6552, DOI 10.1167/iovs.11-7298
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   Holz FG, 2003, OPHTHALMOLOGY, V110, P400, DOI 10.1016/S0161-6420(02)01770-0
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   KLEIN R, 1993, OPHTHALMOLOGY, V100, P406
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310
   Lin AP, 2011, BRIT J OPHTHALMOL, V95, P828, DOI 10.1136/bjo.2010.186569
   Nichols KJ, 2010, INT J CARDIOVASC IMA
   Schmitz-Valckenberg S, 2008, AM J OPHTHALMOL, V146, P183, DOI 10.1016/j.ajo.2008.04.006
   Singh S, 2011, RADIOLOGY, V259, P263, DOI 10.1148/radiol.10101254
   Sunness JS, 2007, OPHTHALMOLOGY, V114, P271, DOI 10.1016/j.ophtha.2006.09.016
   THOMPSON WD, 1988, J CLIN EPIDEMIOL, V41, P949, DOI 10.1016/0895-4356(88)90031-5
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Zarbin MA, 2010, RETINA-J RET VIT DIS, V30, P1350, DOI 10.1097/IAE.0b013e3181f57e30
NR 19
TC 12
Z9 12
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD APR
PY 2012
VL 250
IS 4
BP 485
EP 490
DI 10.1007/s00417-011-1846-y
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 916AR
UT WOS:000302069400003
PM 22033626
DA 2022-11-30
ER

PT J
AU Clark, SJ
   McHarg, S
   Tilakaratna, V
   Brace, N
   Bishop, PN
AF Clark, Simon J.
   McHarg, Selina
   Tilakaratna, Viranga
   Brace, Nicole
   Bishop, Paul N.
TI Bruch's Membrane Compartmentalizes Complement Regulation in the Eye with
   Implications for Therapeutic Design in Age-Related Macular Degeneration
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE complement system proteins; age-related macular degeneration; Bruch's
   membrane; diffusion; extracellular matrix; eye diseases
ID FACTOR-H; ATTACK COMPLEX; DISEASE; SYSTEM; ACTIVATION; DRUSEN; CELLS;
   RISK; RPE
AB Age-related macular degeneration (AMD) is the leading cause of blindness in the western world and affects nearly 200 million people globally. Local inflammation driven by complement system dysregulation is currently a therapeutic target. Bruch's membrane (BrM) is a sheet of extracellular matrix that separates the retina from the underlying choroid, a highly vascularized layer that supplies oxygen and nutrition to the outer retina. Here, we show that most complement proteins are unable to diffuse through BrM, although FHL-1, factor D and C5a can. AMD-associated lipid deposition in BrM decreases FHL-1 diffusion. We show that this impermeability of BrM creates two separate semi-independent compartments with respect to complement activation and regulation. Complement proteins synthesized locally on either side of BrM, or on the choroidal side if derived from the circulation, predominantly remain on their side of origin. As previous studies suggest that complement activation in AMD is confined to the choroidal side of BrM, we propose a model whereby complement activation in the choriocapillaris layer of the choroid generates C5a, which crosses BrM to interact with its specific receptor on RPE cells to initiate an inflammatory response in the retina. Understanding mechanisms underpinning AMD is essential for developing therapeutics that target the right molecule in the right anatomical compartment.
C1 [Clark, Simon J.; McHarg, Selina; Tilakaratna, Viranga; Brace, Nicole; Bishop, Paul N.] Univ Manchester, Sch Biol Sci, Fac Biol Med & Hlth, Div Evolut & Genom Med, Manchester, Lancs, England.
   [Bishop, Paul N.] Manchester Acad Hlth Sci Ctr, Manchester Univ NHS Fdn Trust, Manchester Royal Eye Hosp, Manchester, Lancs, England.
C3 University of Manchester; Manchester Royal Eye Hospital; University of
   Manchester
RP Clark, SJ (通讯作者)，Univ Manchester, Sch Biol Sci, Fac Biol Med & Hlth, Div Evolut & Genom Med, Manchester, Lancs, England.
EM simon.clark-3@manchester.ac.uk
OI Brace, Nicole/0000-0002-6047-5193; Clark, Simon/0000-0001-8394-8355
FU MRC [MR/K024418/1]; Fight for Sight UK [1517/1518]; Macular Society UK
   [12928]; Medical Research Council [MR/K024418/1] Funding Source:
   researchfish; Fight for Sight [1517/18] Funding Source: researchfish
FX MRC (MR/K024418/1); Fight for Sight UK (1517/1518); Macular Society UK
   (12928).
CR Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Brandstetter C, 2015, J BIOL CHEM, V290, P31189, DOI 10.1074/jbc.M115.671180
   Cantsilieris Stuart, 2009, Recent Pat DNA Gene Seq, V3, P102
   Clark SJ, 2018, SEMIN IMMUNOPATHOL, V40, P65, DOI 10.1007/s00281-017-0649-6
   Clark SJ, 2014, J IMMUNOL, V193, P4962, DOI 10.4049/jimmunol.1401613
   Clark SJ, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00412
   Clark SJ, 2010, BIOCHEM SOC T, V38, P1342, DOI 10.1042/BST0381342
   Clark SJ, 2010, J BIOL CHEM, V285, P30192, DOI 10.1074/jbc.M110.103986
   Curcio CA, 2009, PROG RETIN EYE RES, V28, P393, DOI 10.1016/j.preteyeres.2009.08.001
   Fenaille F, 2007, GLYCOBIOLOGY, V17, P932, DOI 10.1093/glycob/cwm060
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Keenan TDL, 2015, INVEST OPHTH VIS SCI, V56, P4870, DOI 10.1167/iovs.15-17009
   Langford-Smith A, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00025
   Liszewski MK, 2015, J INTERN MED, V277, P294, DOI 10.1111/joim.12338
   Long Q, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/6958752
   McHarg S, 2015, JOVE-J VIS EXP, DOI 10.3791/53382
   McHarg S, 2015, MOL IMMUNOL, V67, P43, DOI 10.1016/j.molimm.2015.02.032
   McLeod DS, 2016, INVEST OPHTH VIS SCI, V57, P5843, DOI 10.1167/iovs.16-20049
   Mehlem A, 2013, NAT PROTOC, V8, P1149, DOI 10.1038/nprot.2013.055
   MOORE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1290
   Moore DJ, 2001, INVEST OPHTH VIS SCI, V42, P2970
   Mullins RF, 2014, AM J PATHOL, V184, P3142, DOI 10.1016/j.ajpath.2014.07.017
   Mullins RF, 2011, EXP EYE RES, V93, P565, DOI 10.1016/j.exer.2011.06.015
   Nakanishi M, 2016, INVEST OPHTH VIS SCI, V57, P2213, DOI 10.1167/iovs.15-17934
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Ritchie GE, 2002, CHEM REV, V102, P305, DOI 10.1021/cr990294a
   Sahebjada Srujana, 2011, Recent Pat DNA Gene Seq, V5, P185
   Schramm EC, 2014, MOL IMMUNOL, V61, P118, DOI 10.1016/j.molimm.2014.06.032
   Skeie JM, 2010, INVEST OPHTH VIS SCI, V51, P5336, DOI 10.1167/iovs.10-5322
   Whitmore SS, 2015, PROG RETIN EYE RES, V45, P1, DOI 10.1016/j.preteyeres.2014.11.005
   Yaspan BL, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aaf1443
NR 32
TC 31
Z9 31
U1 0
U2 5
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015,
   SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD DEC 19
PY 2017
VL 8
AR 1778
DI 10.3389/fimmu.2017.01778
PG 10
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA FQ3VS
UT WOS:000418286600001
PM 29312308
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Sweigard, JH
   Cashman, SM
   Kumar-Singh, R
AF Sweigard, J. H.
   Cashman, S. M.
   Kumar-Singh, R.
TI Adenovirus-mediated delivery of CD46 attenuates the alternative
   complement pathway on RPE: implications for age-related macular
   degeneration
SO GENE THERAPY
LA English
DT Article
DE adenovirus; age-related macular degeneration; CD46
ID MEMBRANE COFACTOR PROTEIN; HELPER-DEPENDENT ADENOVIRUS;
   DECAY-ACCELERATING FACTOR; CELLS; MUTATIONS; VECTOR; DRUSEN; SYSTEM;
   COOPERATION; ACTIVATION
AB Activation of the alternative pathway of the complement system has been implicated in the pathogenesis of age-related macular degeneration. Membrane attack complex (MAC) has been identified mainly on the Bruch's membrane and drusen underlying the retinal pigment epithelium (RPE). Membrane cofactor protein (CD46) preferentially regulates the alternative pathway of complement. The aim of this study was to evaluate the potential of increasing CD46 expression on RPE cells using an adenovirus as a gene therapy approach to reduce alternative pathway-mediated damage to RPE cells. We generated a recombinant adenovirus vector expressing human CD46 (hCD46) and delivered the vector to murine hepatocytes and RPE cells in vitro. After incubation in human serum in conditions in which the classical pathway of complement was blocked, we measured alternative pathway-mediated damage of these cells by quantifying lysis and MAC formation. Adenovirus expressing hCD46 was delivered to the subretinal space of adult mice, and 1 week later, ocular flat mounts were challenged with human serum and the levels of complement-mediated damage was quantified. Adenovirus-mediated delivery of hCD46 localizes to the basal and lateral surfaces of RPE cells where it offers protection from alternative pathway-mediated damage, but not classical, allowing the classical pathway to function unhindered. Gene Therapy (2011) 18, 613-621; doi: 10.1038/gt.2011.6; published online 10 February 2011
C1 [Sweigard, J. H.; Cashman, S. M.; Kumar-Singh, R.] Tufts Univ, Sch Med, Sackler Sch Grad Biomed Sci, Dept Ophthalmol & Neurosci, Boston, MA 02111 USA.
   [Sweigard, J. H.; Kumar-Singh, R.] Tufts Univ, Sch Med, Sackler Sch Grad Biomed Sci, Program Cell Mol & Dev Biol, Boston, MA 02111 USA.
C3 Tufts University; Tufts University
RP Kumar-Singh, R (通讯作者)，Tufts Univ, Sch Med, Sackler Sch Grad Biomed Sci, Dept Ophthalmol & Neurosci, 136 Harrison Ave, Boston, MA 02111 USA.
EM rajendra.kumar-singh@tufts.edu
OI Kumar-Singh, Rajendra/0000-0002-7754-0713
FU Ellison Foundation; Virginia B Smith Trust; Lions Eye Foundation;
   Research to Prevent Blindness; NATIONAL EYE INSTITUTE [R01EY021805,
   R01EY013837] Funding Source: NIH RePORTER
FX This study was supported by grants to RK-S from The Ellison Foundation,
   The Virginia B Smith Trust and grants to the Department of Ophthalmology
   at Tufts University from the Lions Eye Foundation and Research to
   Prevent Blindness.
CR Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Barilla-LaBarca ML, 2002, J IMMUNOL, V168, P6298, DOI 10.4049/jimmunol.168.12.6298
   Brodbeck WG, 2000, J IMMUNOL, V165, P3999, DOI 10.4049/jimmunol.165.7.3999
   Campochiaro PA, 2006, HUM GENE THER, V17, P167, DOI 10.1089/hum.2006.17.167
   Caprioli J, 2006, BLOOD, V108, P1267, DOI 10.1182/blood-2005-10-007252
   Cashman SM, 2004, VIROLOGY, V324, P129, DOI 10.1016/j.virol.2004.04.001
   Chevez-Barrios P, 2005, J CLIN ONCOL, V23, P7927, DOI 10.1200/JCO.2004.00.1883
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fallaux FJ, 1996, HUM GENE THER, V7, P215, DOI 10.1089/hum.1996.7.2-215
   Gao LJ, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-384
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Kavanagh D, 2006, SEMIN THROMB HEMOST, V32, P155, DOI 10.1055/s-2006-939771
   Kavanagh D, 2008, ANNU REV MED, V59, P293, DOI 10.1146/annurev.med.59.060106.185110
   Kim IH, 2001, P NATL ACAD SCI USA, V98, P13282, DOI 10.1073/pnas.241506298
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Kumar-Singh R, 2000, METHOD ENZYMOL, V316, P724
   Lamartina S, 2007, J GENE MED, V9, P862, DOI 10.1002/jgm.1083
   MCNEARNEY T, 1989, J CLIN INVEST, V84, P538, DOI 10.1172/JCI114196
   Ozkiris A, 2010, EXPERT OPIN THER PAT, V20, P103, DOI 10.1517/13543770902762885
   Parks RJ, 1996, P NATL ACAD SCI USA, V93, P13565, DOI 10.1073/pnas.93.24.13565
   POST TW, 1991, J EXP MED, V174, P93, DOI 10.1084/jem.174.1.93
   Ramo K, 2008, INVEST OPHTH VIS SCI, V49, P4126, DOI 10.1167/iovs.08-2025
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Richards A, 2003, P NATL ACAD SCI USA, V100, P12966, DOI 10.1073/pnas.2135497100
   Sweigard JH, 2010, INVEST OPHTH VIS SCI, V51, P2219, DOI 10.1167/iovs.09-4367
   van Leeuwen R, 2003, EUR J EPIDEMIOL, V18, P845, DOI 10.1023/A:1025643303914
   VOGT SD, 2009, INVEST OPHTHALMOL VI, V50
   Vogt SD, 2006, EXP EYE RES, V83, P834, DOI 10.1016/j.exer.2006.04.002
NR 30
TC 9
Z9 13
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0969-7128
J9 GENE THER
JI Gene Ther.
PD JUN
PY 2011
VL 18
IS 6
BP 613
EP 621
DI 10.1038/gt.2011.6
PG 9
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity; Research & Experimental Medicine
GA 775DP
UT WOS:000291438900011
PM 21307887
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Zhou, TQ
   Guan, HJ
   Hu, JY
AF Zhou, T. Q.
   Guan, H. J.
   Hu, J. Y.
TI Genome-wide analysis of single nucleotide polymorphisms in patients with
   atrophic age-related macular degeneration in oldest old Han Chinese
SO GENETICS AND MOLECULAR RESEARCH
LA English
DT Article
DE Age-related macular degeneration; SNP; Oldest old; Atrophic macular
   degeneration; Genome-wide association study
ID GENE POLYMORPHISMS; FACTOR-B; RISK
AB The aim of this study was to identify disease-associated loci in oldest old Han Chinese with atrophic age-related macular degeneration (AMD). This genome-wide association study (GWAS) only included oldest old (>= 95 years old) subjects in Rugao County, China. Thirty atrophic AMD patients and 47 age-matched non-AMD controls were enrolled. The study subjects underwent a complete ophthalmic examination. Genomic DNA was extracted from peripheral blood samples. Single nucleotide polymorphisms (SNPs) were scanned by Genome-Wide Human Mapping SNP 6.0 Arrays and GeneChip Scanner 3000 7G. The results were read and analyzed by the Affymetrix Genotyping Console software. We filtered out the SNPs with a no-call rate >= 10%, MAF P < 0.05, and HWE P < 0.001. The remaining 561,277 SNPs were included in the association analysis. We found that the following 2 SNPs had the highest association with atrophic AMD: rs7624556 (located on 3q24) and rs13119914 (located on 4q34.3). In conclusion, we identified two atrophic AMD-associated SNPs (rs7624556 and rs13119914) in an oldest old Han Chinese population. This finding may lead to new strategies for screening of atrophic AMD for Han Chinese.
C1 [Zhou, T. Q.; Guan, H. J.; Hu, J. Y.] Nantong Univ, Dept Ophthalmol, Affiliated Hosp, Nantong, Jiangsu, Peoples R China.
C3 Nantong University
RP Guan, HJ (通讯作者)，Nantong Univ, Dept Ophthalmol, Affiliated Hosp, Nantong, Jiangsu, Peoples R China.
EM tqdoccn@163.com
CR Bjornsson OM, 2006, ACTA OPHTHALMOL SCAN, V84, P636, DOI 10.1111/j.1600-0420.2006.00696.x
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Ersoy L, 2014, INVEST OPHTH VIS SCI, V55, P1842, DOI 10.1167/iovs.13-13420
   Fritsche LG, 2012, INVEST OPHTH VIS SCI, V53, P2112, DOI 10.1167/iovs.11-8785
   Fu L, 2007, HUM MOL GENET, V16, P2411, DOI 10.1093/hmg/ddm198
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hirata FE, 2013, OPHTHALMIC GENET, V30, P1
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kannan R, 2006, MOL VIS, V12, P1649
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Leveziel N, 2007, MOL VIS, V13, P2153
   Lin JM, 2008, AM J OPHTHALMOL, V145, P1045, DOI 10.1016/j.ajo.2008.01.027
   Nazari Khanamiri Hossein, 2014, J Ophthalmic Vis Res, V9, P181
   Priya RR, 2012, OPHTHALMOLOGY, V119, P2526, DOI 10.1016/j.ophtha.2012.06.042
   Souied E, 2001, J FR OPHTALMOL, V24, P875
   Spencer KL, 2007, HUM MOL GENET, V16, P1986, DOI 10.1093/hmg/ddm146
   Stanton CM, 2012, ADV EXP MED BIOL, V723, P365, DOI 10.1007/978-1-4614-0631-0_47
   Sun C, 2012, CURR EYE RES, V37, P259, DOI 10.3109/02713683.2011.635401
   [赵文博 Zhao Wenbo], 2008, [眼科研究, Ophthalmic Research], V26, P705
NR 20
TC 3
Z9 3
U1 0
U2 3
PU FUNPEC-EDITORA
PI RIBEIRAO PRETO
PA RUA FLORIANO PEIXOTO 2444, ALTO DA BOA VISTA, RIBEIRAO PRETO, SP 00000,
   BRAZIL
SN 1676-5680
J9 GENET MOL RES
JI Genet. Mol. Res.
PY 2015
VL 14
IS 4
BP 17432
EP 17438
DI 10.4238/2015.December.21.13
PG 7
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA DF8DN
UT WOS:000371587400013
PM 26782385
OA Bronze
DA 2022-11-30
ER

PT J
AU Romero-Vazquez, S
   Adan, A
   Figueras-Roca, M
   Llorenc, V
   Slevin, M
   Vilahur, G
   Badimon, L
   Dick, AD
   Molins, B
AF Romero-Vazquez, Sara
   Adan, Alfredo
   Figueras-Roca, Marc
   Llorenc, Victor
   Slevin, Mark
   Vilahur, Gemma
   Badimon, Lina
   Dick, Andrew D.
   Molins, Blanca
TI Activation of C-reactive protein proinflammatory phenotype in the blood
   retinal barrier in vitro: implications for age-related macular
   degeneration
SO AGING-US
LA English
DT Article
DE age-related macular degeneration; retinal pigment epithelium;
   inflammation; C-reactive protein
ID COMPLEMENT FACTOR-H; INFLAMMATION; RISK; DRUSEN; CRP; EXPRESSION;
   DISEASE; CELLS; RPE; DISSOCIATION
AB The retinal pigment epithelium (RPE) is considered one of the main targets of age-related macular degeneration (AMD), the leading cause of irreversible vision loss among the ageing population worldwide. Persistent low grade inflammation and oxidative stress eventually lead to RPE dysfunction and disruption of the outer blood-retinal barrier (oBRB). Increased levels of circulating pentameric C-reactive protein (pCRP) are associated with higher risk of AMD. The monomeric form (mCRP) has been detected in drusen, the hallmark deposits associated with AMD, and we have found that mCRP induces oBRB disruption. However, it is unknown how mCRP is generated in the subretinal space. Using a Transwell model we found that both pCRP and mCRP can cross choroidal endothelial cells and reach the RPE in vitro and that mCRP, but not pCRP, is able to cross the RPE monolayer in ARPE-19 cells. Alternatively, mCRP can originate from the dissociation of pCRP in the surface of lipopolysaccharide-damaged RPE in both ARPE-19 and primary porcine RPE lines. In addition, we found that the proinflammatory phenotype of mCRP in the RPE depends on its topological localization. Together, our findings further support mCRP contribution to AMD progression enhancing oBRB disruption.
C1 [Romero-Vazquez, Sara; Adan, Alfredo; Figueras-Roca, Marc; Llorenc, Victor; Molins, Blanca] Hosp Clin Barcelona, Inst Invest Biomed Agusti Pi i Sunyer IDIBAPS, Grp Ocular Inflammat Clin & Expt Studies, Barcelona, Spain.
   [Slevin, Mark] Manchester Metropolitan Univ, Dept Life Sci, Manchester, Lancs, England.
   [Vilahur, Gemma; Badimon, Lina] Inst Carlos III, Cardiovasc Res Ctr ICCC, Hosp Santa Creu & St Pau, IIB St Pau,CiberCV, Barcelona, Spain.
   [Dick, Andrew D.] Univ Bristol, Acad Unit Ophthalmol, Sch Clin Sci, Bristol, Avon, England.
   [Dick, Andrew D.] Univ Bristol, Sch Cellular & Mol Med, Bristol, Avon, England.
   [Dick, Andrew D.] Moorfields Eye Hosp, Natl Inst Hlth Res NIHR Biomed Res Ctr, London, England.
   [Dick, Andrew D.] UCL, Inst Ophthalmol, London, England.
C3 University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS;
   Manchester Metropolitan University; CIBER - Centro de Investigacion
   Biomedica en Red; CIBERCV; Consejo Superior de Investigaciones
   Cientificas (CSIC); CSIC - Institut Catala de Ciencies Cardiovasculars
   (ICCC); Hospital of Santa Creu i Sant Pau; University of Bristol;
   University of Bristol; University of London; University College London;
   Moorfields Eye Hospital NHS Foundation Trust; University of London;
   University College London
RP Molins, B (通讯作者)，Hosp Clin Barcelona, Inst Invest Biomed Agusti Pi i Sunyer IDIBAPS, Grp Ocular Inflammat Clin & Expt Studies, Barcelona, Spain.
EM bmolins@clinic.cat
RI Slevin, Mark/AFT-1420-2022; Llorens Bellés, Víctor/V-3892-2019; slevin,
   mark a/A-1593-2008; Figueras-Roca, Marc/G-9095-2017; Badimon,
   Lina/O-4711-2014
OI Llorens Bellés, Víctor/0000-0002-7375-1564; Figueras-Roca,
   Marc/0000-0002-0548-0539; Badimon, Lina/0000-0002-9162-2459; Dick,
   Andrew/0000-0002-0742-3159
FU Ministry of Science and Innovation of Spain, 'Instituto de Salud Carlos
   III', 'Fondo de Investigacion Sanitaria' [PI19/00265]; Plan Nacional de
   Salud (PNS) from the Spanish Ministry of Science and Innovation
   [PGC2018-094025-B-I00, SAF2016-76819-R]; funds FEDER "Una Manera de
   Hacer Europa"; CIBERCV; Generalitat of Catalunya (Secretaria
   d'Universitats i Recerca del Departament d'Economia i Coneixement de la
   Generalitat) [2017 SGR 0701, 2017 SGR 1480]
FX This work was supported by the Ministry of Science and Innovation of
   Spain, 'Instituto de Salud Carlos III', 'Fondo de Investigacion
   Sanitaria' (PI19/00265) to B.M. This work was supported by Plan Nacional
   de Salud (PNS) [PGC2018-094025-B-I00 to G.V and SAF2016-76819-R to L.B.]
   from the Spanish Ministry of Science and Innovation and funds FEDER "Una
   Manera de Hacer Europa"; and CIBERCV (to L.B). We thank the support of
   the Generalitat of Catalunya (Secretaria d'Universitats i Recerca del
   Departament d'Economia i Coneixement de la Generalitat, 2017 SGR 0701
   and 2017 SGR 1480 and the Fundacion Investigacion
   Cardiovascular-Fundacion Jesus Serra for their continuous support.
CR Ablonczy Z, 2011, INVEST OPHTH VIS SCI, V52, P8614, DOI 10.1167/iovs.11-8021
   Alizadeh E, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19123846
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Bello G, 2008, ATHEROSCLEROSIS, V200, P286, DOI 10.1016/j.atherosclerosis.2007.12.046
   Bhutto IA, 2011, BRIT J OPHTHALMOL, V95, P1323, DOI 10.1136/bjo.2010.199216
   Black S, 2004, J BIOL CHEM, V279, P48487, DOI 10.1074/jbc.R400025200
   Boguslawski G, 2007, J HEART LUNG TRANSPL, V26, P705, DOI 10.1016/j.healun.2007.04.006
   Browning AC, 2005, BRIT J OPHTHALMOL, V89, P1343, DOI 10.1136/bjo.2004.063602
   Chen JY, 2016, STEM CELL RES THER, V7, DOI 10.1186/s13287-016-0377-1
   Chen M, 2019, PROG RETIN EYE RES, V69, P159, DOI 10.1016/j.preteyeres.2018.10.003
   Chirco KR, 2018, EYE, V32, P1740, DOI 10.1038/s41433-018-0170-8
   Chirco KR, 2016, J PATHOL, V240, P173, DOI 10.1002/path.4766
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Dick AD, 2017, EYE, V31, P87, DOI 10.1038/eye.2016.177
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Eisenhardt SU, 2009, CIRC RES, V105, P128, DOI 10.1161/CIRCRESAHA.108.190611
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Ji SR, 2007, FASEB J, V21, P284, DOI 10.1096/fj.06-6722com
   Ji SR, 2009, FASEB J, V23, P1806, DOI 10.1096/fj.08-116962
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Johnson PT, 2006, P NATL ACAD SCI USA, V103, P17456, DOI 10.1073/pnas.0606234103
   Khreiss T, 2004, CIRCULATION, V109, P2016, DOI 10.1161/01.CIR.0000125527.41598.68
   Khreiss T, 2002, J BIOL CHEM, V277, P40775, DOI 10.1074/jbc.M205378200
   Krupinski J, 2006, STROKE, V37, P1200, DOI 10.1161/01.STR.0000217386.37107.be
   Lauer N, 2011, J IMMUNOL, V187, P4374, DOI 10.4049/jimmunol.1002488
   Li HY, 2014, J BIOL CHEM, V289, P14283, DOI 10.1074/jbc.M114.555318
   McLeod DS, 2002, INVEST OPHTH VIS SCI, V43, P1986
   Molins B, 2008, ARTERIOSCL THROM VAS, V28, P2239, DOI 10.1161/ATVBAHA.108.174359
   Molins B, 2019, EXP EYE RES, V187, DOI 10.1016/j.exer.2019.107751
   Molins B, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00808
   Molins B, 2017, AM J PHYSIOL-CELL PH, V312, pC244, DOI 10.1152/ajpcell.00057.2016
   Molins B, 2016, SCI REP-UK, V6, DOI 10.1038/srep22889
   Mora RC, 2006, AM J PHYSIOL-CELL PH, V290, pC832, DOI 10.1152/ajpcell.00405.2005
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Schneeweis C, 2010, J ATHEROSCLER THROMB, V17, P203, DOI 10.5551/jat.3004
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Shaw AC, 2013, NAT REV IMMUNOL, V13, P875, DOI 10.1038/nri3547
   Singh U, 2006, ARTERIOSCL THROM VAS, V26, P2469, DOI 10.1161/01.ATV.0000241572.05292.fb
   Slevin M, 2015, SCI REP-UK, V5, DOI 10.1038/srep13281
   Slevin M, 2010, BRAIN PATHOL, V20, P151, DOI 10.1111/j.1750-3639.2008.00256.x
   Taylor KE, 2007, IMMUNOLOGY, V120, P404, DOI 10.1111/j.1365-2567.2006.02516.x
   Thiele JR, 2014, CIRCULATION, V130, P35, DOI 10.1161/CIRCULATIONAHA.113.007124
   Tong NT, 2019, FRONT AGING NEUROSCI, V11, DOI 10.3389/fnagi.2019.00137
   Toops KA, 2014, EXP EYE RES, V124, P74, DOI 10.1016/j.exer.2014.05.003
   Verma S, 2002, CIRCULATION, V106, P913, DOI 10.1161/01.CIR.0000029802.88087.5E
   Vine AK, 2005, OPHTHALMOLOGY, V112, P2076, DOI 10.1016/j.ophtha.2005.07.004
   Volanakis JE, 2001, MOL IMMUNOL, V38, P189, DOI 10.1016/S0161-5890(01)00042-6
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zhang L, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00511
NR 52
TC 5
Z9 6
U1 0
U2 4
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
SN 1945-4589
J9 AGING-US
JI Aging-US
PD JUL 31
PY 2020
VL 12
IS 14
BP 13905
EP 13923
PG 19
WC Cell Biology; Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Geriatrics & Gerontology
GA MY8LU
UT WOS:000558669300008
PM 32673285
OA Green Submitted, Green Accepted, gold, Green Published
DA 2022-11-30
ER

PT J
AU Vallee, A
   Lecarpentier, Y
   Vallee, R
   Guillevin, R
   Vallee, JN
AF Vallee, Alexandre
   Lecarpentier, Yves
   Vallee, Rodolphe
   Guillevin, Remy
   Vallee, Jean-Noel
TI Circadian Rhythms in Exudative Age-Related Macular Degeneration: The Key
   Role of the Canonical WNT/beta-Catenin Pathway
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Review
DE exudative AMD; circadian rhythms; WNT/beta-catenin pathway; aerobic
   glycolysis; Warburg effect
ID ENDOTHELIAL GROWTH-FACTOR; WNT SIGNALING PATHWAY; ROD OUTER SEGMENT;
   DENSITY-LIPOPROTEIN RECEPTOR; RETINAL-PIGMENT EPITHELIUM; HEMATOPOIETIC
   STEM-CELLS; INDUCIBLE FACTOR-I; BETA-CATENIN; AEROBIC GLYCOLYSIS;
   ENERGY-METABOLISM
AB Age-related macular degeneration (AMD) is considered as the main worldwide cause of blindness in elderly adults. Exudative AMD type represents 10 to 15% of macular degeneration cases, but is the main cause of vision loss and blindness. Circadian rhythm changes are associated with aging and could further accelerate it. However, the link between circadian rhythms and exudative AMD is not fully understood. Some evidence suggests that dysregulation of circadian functions could be manifestations of diseases or could be risk factors for the development of disease in elderly adults. Biological rhythms are complex systems interacting with the environment and control several physiological pathways. Recent findings have shown that the dysregulation of circadian rhythms is correlated with exudative AMD. One of the main pathways involved in exudative AMD is the canonical WNT/beta-catenin pathway. Circadian clocks have a main role in some tissues by driving the circadian expression of genes involved in physiological and metabolic functions. In exudative AMD, the increase of the canonical WNT/beta-catenin pathway is enhanced by the dysregulation of circadian rhythms. Exudative AMD progression is associated with major metabolic reprogramming, initiated by aberrant WNT/beta-catenin pathway, of aerobic glycolysis. This review focuses on the interest of circadian rhythm dysregulation in exudative AMD through the aberrant upregulation of the canonical WNT/beta-catenin pathway.
C1 [Vallee, Alexandre; Guillevin, Remy] Univ Poitiers, CNRS, LMA, DACTIM,MIS,UMR 7348,CHU Poitiers, F-86021 Poitiers, France.
   [Lecarpentier, Yves] GHEF, Ctr Rech Clin, F-77100 Meaux, France.
   [Vallee, Rodolphe] Univ Paris 13, Sorbonne Paris Cite, Univ Hosp Grp Paris Seine St Denis, APHP, F-93000 Paris, France.
   [Vallee, Jean-Noel] UPJV, CHU Amiens Picardie, F-80000 Amiens, France.
   [Vallee, Jean-Noel] Univ Poitiers, CNRS, LMA, UMR 7348, F-86021 Poitiers, France.
C3 Centre National de la Recherche Scientifique (CNRS); CNRS - National
   Institute for Mathematical Sciences (INSMI); CHU Poitiers; Universite de
   Poitiers; Assistance Publique Hopitaux Paris (APHP); Universite Paris
   13; Picardie Universites; Universite de Picardie Jules Verne (UPJV); CHU
   Amiens; Centre National de la Recherche Scientifique (CNRS); CNRS -
   National Institute for Mathematical Sciences (INSMI); Universite de
   Poitiers
RP Vallee, A (通讯作者)，Univ Poitiers, CNRS, LMA, DACTIM,MIS,UMR 7348,CHU Poitiers, F-86021 Poitiers, France.
EM alexandre.g.vallee@gmail.com; yves.c.lecarpentier@gmail.com;
   rod.vallee@gmail.com; remy.guillevin@chu-poitiers.fr; valleejn@gmail.com
OI Vallee, Rodolphe/0000-0001-9569-687X; Vallee,
   Alexandre/0000-0001-9158-4467
CR Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797
   Al-Harthi L, 2012, J NEUROIMMUNE PHARM, V7, P725, DOI 10.1007/s11481-012-9412-x
   Ambacher KK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046885
   Ambati J, 2011, INVEST OPHTH VIS SCI, V52, P2166, DOI 10.1167/iovs.11-7328
   AMES A, 1992, J NEUROSCI, V12, P840, DOI 10.1523/jneurosci.12-03-00840.1992
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Angers S., 2009, NAT REV MOL CELL BIO
   Arjamaa O, 2009, AGEING RES REV, V8, P349, DOI 10.1016/j.arr.2009.06.002
   Atger F, 2017, FRONT ENDOCRINOL, V8, DOI 10.3389/fendo.2017.00042
   BACH RR, 1988, CRC CR REV BIOCH MOL, V23, P339, DOI 10.3109/10409238809082548
   Barchitta M, 2016, DIS MARKERS, V2016, DOI 10.1155/2016/8486406
   Bell-Pedersen D, 2005, NAT REV GENET, V6, P544, DOI 10.1038/nrg1633
   Bender T, 2016, BBA-MOL CELL RES, V1863, P2436, DOI 10.1016/j.bbamcr.2016.01.017
   Bird AC, 2010, J CLIN INVEST, V120, P3033, DOI 10.1172/JCI42437
   Birdsey GM, 2015, DEV CELL, V32, P82, DOI 10.1016/j.devcel.2014.11.016
   Blask DE, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102776
   Bloch G, 2013, P ROY SOC B-BIOL SCI, V280, DOI 10.1098/rspb.2013.0035
   Brugarolas JB, 2003, CANCER CELL, V4, P147, DOI 10.1016/S1535-6108(03)00187-9
   Cao YW, 2017, AGING DIS, V8, P314, DOI 10.14336/AD.2016.1101
   Carneiro BTS, 2012, FRONT BEHAV NEUROSCI, V6, DOI 10.3389/fnbeh.2012.00083
   Carpenter AC, 2015, DEVELOPMENT, V142, P972, DOI 10.1242/dev.120022
   CASSONE VM, 1990, TRENDS NEUROSCI, V13, P457, DOI 10.1016/0166-2236(90)90099-V
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chalam KV, 2011, EYE CONTACT LENS, V37, P225, DOI 10.1097/ICL.0b013e31821fbd3e
   Chan CC, 2008, OPHTHALMIC RES, V40, P124, DOI 10.1159/000119862
   Chellappa SL, 2019, TRENDS ENDOCRIN MET, V30, P767, DOI 10.1016/j.tem.2019.07.008
   Chen JL, 2014, INT J DEV NEUROSCI, V35, P35, DOI 10.1016/j.ijdevneu.2014.03.006
   Chen TL, 2004, BONE, V35, P83, DOI 10.1016/j.bone.2004.03.019
   Chen Y, 2007, J BIOL CHEM, V282, P34420, DOI 10.1074/jbc.M611289200
   Chen Z, 2018, J CELL PHYSIOL, V233, P2839, DOI 10.1002/jcp.25998
   Chiu CJ, 2011, PROG RETIN EYE RES, V30, P18, DOI 10.1016/j.preteyeres.2010.09.001
   Chu XK, 2013, BIOENGINEERED, V4, P130, DOI 10.4161/bioe.22949
   Coffe V, 2006, NEUROCHEM RES, V31, P103, DOI 10.1007/s11064-005-9236-7
   COHEN LH, 1960, J NEUROCHEM, V5, P253, DOI 10.1111/j.1471-4159.1960.tb13363.x
   Cousins SW, 2004, ARCH OPHTHALMOL-CHIC, V122, P1013, DOI 10.1001/archopht.122.7.1013
   Cruciat CM, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a015081
   Dai ZY, 2013, J CELL BIOCHEM, V114, P1020, DOI 10.1002/jcb.24441
   Dauchy RT, 2015, COMPARATIVE MED, V65, P473
   Dhup S, 2012, CURR PHARM DESIGN, V18, P1319, DOI 10.2174/138161212799504902
   Dibner C, 2010, ANNU REV PHYSIOL, V72, P517, DOI 10.1146/annurev-physiol-021909-135821
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Duvel K, 2010, MOL CELL, V39, P171, DOI 10.1016/j.molcel.2010.06.022
   Duffield GE, 2002, CURR BIOL, V12, P551, DOI 10.1016/S0960-9822(02)00765-0
   DUGUID IGM, 1992, CURR EYE RES, V11, P153, DOI 10.3109/02713689208999526
   Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8
   Easwaran V, 2003, CANCER RES, V63, P3145
   ELNER SG, 1992, LAB INVEST, V66, P200
   Esen E, 2013, CELL METAB, V17, P745, DOI 10.1016/j.cmet.2013.03.017
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Fuhrmann Sabine, 2008, Organogenesis, V4, P60
   Fujimura N, 2016, FRONT CELL DEV BIOL, V4, DOI 10.3389/fcell.2016.00138
   Gekakis N, 1998, SCIENCE, V280, P1564, DOI 10.1126/science.280.5369.1564
   Giatromanolaki A, 2006, GYNECOL ONCOL, V103, P912, DOI 10.1016/j.ygyno.2006.05.043
   GOLDMAN AI, 1980, INVEST OPHTH VIS SCI, V19, P1257
   Grisanti S, 2015, RETINA-J RET VIT DIS, V35, P764, DOI 10.1097/IAE.0000000000000385
   Guo BY, 2012, FASEB J, V26, P3453, DOI 10.1096/fj.12-205781
   Hagglund AC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081158
   Hastings M.H., 2019, BIOLOGY, P8
   Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809
   Hogenesch JB, 1998, P NATL ACAD SCI USA, V95, P5474, DOI 10.1073/pnas.95.10.5474
   Hu Y, 2013, INVEST OPHTH VIS SCI, V54, P141, DOI 10.1167/iovs.12-10281
   Huang J, 2012, NAT MED, V18, P1778, DOI 10.1038/nm.2984
   Huang W, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152833
   Hur EM, 2010, NAT REV NEUROSCI, V11, P539, DOI 10.1038/nrn2870
   Ip MS, 2008, OPHTHALMOLOGY, V115, P1837, DOI 10.1016/j.ophtha.2008.08.012
   Janich P, 2011, NATURE, V480, P209, DOI 10.1038/nature10649
   Jensen LD, 2013, CELL CYCLE, V12, P405, DOI 10.4161/cc.23596
   Jensen LD, 2012, CELL REP, V2, P231, DOI 10.1016/j.celrep.2012.07.005
   Jin J, 2013, MOL CELL BIOCHEM, V381, P267, DOI 10.1007/s11010-013-1710-y
   Johnson CH, 2003, CHRONOBIOL INT, V20, P741, DOI 10.1081/CBI-120024211
   Jung JE, 2005, FASEB J, V19, P1296, DOI 10.1096/fj.04-3099fje
   Kaur C, 2008, CLIN OPHTHALMOL, V2, P879, DOI 10.2147/opth.s3361
   Kim JW, 2007, MOL CELL BIOL, V27, P7381, DOI 10.1128/MCB.00440-07
   Klaus A, 2008, NAT REV CANCER, V8, P387, DOI 10.1038/nrc2389
   Ko CH, 2006, HUM MOL GENET, V15, pR271, DOI 10.1093/hmg/ddl207
   Kofuji P, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0168651
   Kolev Y, 2008, ANN SURG ONCOL, V15, P2336, DOI 10.1245/s10434-008-9955-5
   Koukourakis MI, 2003, BRIT J CANCER, V89, P877, DOI 10.1038/sj.bjc.6601205
   Koukourakis MI, 2011, CLIN CANCER RES, V17, P4892, DOI 10.1158/1078-0432.CCR-10-2918
   Krebs H A, 1972, Essays Biochem, V8, P1
   Land SC, 2007, J BIOL CHEM, V282, P20534, DOI 10.1074/jbc.M611782200
   LAVAIL MM, 1976, SCIENCE, V194, P1071, DOI 10.1126/science.982063
   Leng Y, 2019, LANCET NEUROL, V18, P307, DOI 10.1016/S1474-4422(18)30461-7
   Leveillard T., 2016, CELL MOL LIFE SCI CM
   Lin FW, 2013, CELL BIOCHEM FUNCT, V31, P166, DOI 10.1002/cbf.2871
   Lindsay KJ, 2014, P NATL ACAD SCI USA, V111, P15579, DOI 10.1073/pnas.1412441111
   Liu XX, 2014, SPRINGERPLUS, V3, DOI 10.1186/2193-1801-3-356
   Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126
   Lu SL, 2013, ANTIMICROB AGENTS CH, V57, P5366, DOI 10.1128/AAC.00322-13
   Lum JJ, 2007, GENE DEV, V21, P1037, DOI 10.1101/gad.1529107
   Machon O, 2010, GENESIS, V48, P86, DOI 10.1002/dvg.20583
   Mackey SR, 2011, ADV GENET, V74, P13, DOI 10.1016/B978-0-12-387690-4.00002-7
   Mao LL, 2016, J PINEAL RES, V60, P167, DOI 10.1111/jpi.12298
   Matsu-ura T, 2018, J BIOL RHYTHM, V33, P5, DOI 10.1177/0748730417745913
   McBride JD, 2014, J INVEST DERMATOL, V134, P1725, DOI 10.1038/jid.2014.40
   Mendez I, 2016, BIOCHIMIE, V124, P178, DOI 10.1016/j.biochi.2015.04.014
   Menon G, 2009, EYE, V23, pS1, DOI 10.1038/eye.2009.13
   MICELI MV, 1990, INVEST OPHTH VIS SCI, V31, P277
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Minet E, 2001, FREE RADICAL BIO MED, V31, P847, DOI 10.1016/S0891-5849(01)00657-8
   Mohawk JA, 2012, ANNU REV NEUROSCI, V35, P445, DOI 10.1146/annurev-neuro-060909-153128
   Morohoshi K, 2012, EXP MOL PATHOL, V93, P193, DOI 10.1016/j.yexmp.2012.03.007
   Nusse R, 2017, CELL, V169, P985, DOI 10.1016/j.cell.2017.05.016
   Oguma K, 2010, FUTURE ONCOL, V6, P515, DOI [10.2217/fon.10.13, 10.2217/FON.10.13]
   Oh H, 1999, INVEST OPHTH VIS SCI, V40, P1891
   Park KS, 2004, EXP CELL RES, V297, P424, DOI 10.1016/j.yexcr.2004.03.034
   Park K, 2011, MOL CELL BIOL, V31, P3038, DOI 10.1128/MCB.01211-10
   Pate KT, 2014, EMBO J, V33, P1454, DOI 10.15252/embj.201488598
   Paul KN, 2009, REV ENDOCR METAB DIS, V10, P271, DOI 10.1007/s11154-009-9120-x
   POITRYYAMATE CL, 1995, J NEUROSCI, V15, P5179
   Polet F, 2013, J INTERN MED, V273, P156, DOI 10.1111/joim.12016
   Qiu FF, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-01119-2
   Reppert SM, 2002, NATURE, V418, P935, DOI 10.1038/nature00965
   Richards J, 2012, FASEB J, V26, P3602, DOI 10.1096/fj.12-203554
   Rosen R, 2009, MOL VIS, V15, P1673
   Sahar S, 2007, CELL CYCLE, V6, P1329, DOI 10.4161/cc.6.11.4295
   Sahar S, 2009, NAT REV CANCER, V9, P886, DOI 10.1038/nrc2747
   Sami A, 2013, TUMOR BIOL, V34, P1991, DOI 10.1007/s13277-013-0800-5
   San-Millan I., 2016, CARCINOGENESIS, V127
   Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723
   Schibler U, 2002, CELL, V111, P919, DOI 10.1016/S0092-8674(02)01225-4
   Schmid-Kubista KE, 2009, ACTA OPHTHALMOL, V87, P89, DOI 10.1111/j.1755-3768.2008.01173.x
   Schon S, 2014, INT J CANCER, V135, P1800, DOI 10.1002/ijc.28839
   Semenza GL, 2002, BIOCHEM PHARMACOL, V64, P993, DOI 10.1016/S0006-2952(02)01168-1
   Semenza GL, 2010, CURR OPIN GENET DEV, V20, P51, DOI 10.1016/j.gde.2009.10.009
   Serin Y, 2019, ANN NUTR METAB, V74, P322, DOI 10.1159/000500071
   Shao J, 2016, DEV OPHTHALMOL, V55, P125, DOI 10.1159/000438969
   Shibuya K, 2015, ONCOTARGET, V6, P651, DOI 10.18632/oncotarget.2892
   Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522
   Sotak M, 2014, ANN MED, V46, P221, DOI 10.3109/07853890.2014.892296
   Suda T, 2011, CELL STEM CELL, V9, P298, DOI 10.1016/j.stem.2011.09.010
   Sun QA, 2011, P NATL ACAD SCI USA, V108, P4129, DOI 10.1073/pnas.1014769108
   Thompson CB, 2014, EMBO J, V33, P1420, DOI 10.15252/embj.201488785
   Toschi A, 2008, J BIOL CHEM, V283, P34495, DOI 10.1074/jbc.C800170200
   Tosini G, 1996, SCIENCE, V272, P419, DOI 10.1126/science.272.5260.419
   Tuo J, 2012, NEUROBIOL AGING, V433, pe1
   Tuo JS, 2007, INVEST OPHTH VIS SCI, V48, P3827, DOI 10.1167/iovs.07-0051
   Tuo JS, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0683-x
   Tuo JS, 2009, AM J PATHOL, V175, P799, DOI 10.2353/ajpath.2009.090089
   Vallee A, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8070726
   Vallee A, 2019, CURR ISSUES MOL BIOL, V31, P21, DOI 10.21775/cimb.031.021
   Vallee A, 2018, NEUROMOL MED, V20, P174, DOI 10.1007/s12017-018-8486-x
   Vallee A, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18122537
   Vallee A, 2018, MOL BRAIN, V11, DOI 10.1186/s13041-017-0343-6
   Vallee A, 2018, LIFE SCI, V193, P141, DOI 10.1016/j.lfs.2017.10.033
   Vallee A, 2017, LIFE SCI, V188, P123, DOI 10.1016/j.lfs.2017.09.008
   Vallee A, 2017, J MOL NEUROSCI, V62, P368, DOI 10.1007/s12031-017-0947-4
   Vallee A, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00352
   Voorzanger-Rousselot N, 2009, BRIT J HAEMATOL, V145, P264, DOI 10.1111/j.1365-2141.2009.07587.x
   Wang L, 1997, INVEST OPHTH VIS SCI, V38, P48
   Wang Y, 2016, MOL VIS, V22
   WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309
   WEAVER DR, 1993, J CLIN ENDOCR METAB, V76, P295, DOI 10.1210/jc.76.2.295
   WINKLER BS, 1981, J GEN PHYSIOL, V77, P667, DOI 10.1085/jgp.77.6.667
   Winkler BS, 2000, INVEST OPHTH VIS SCI, V41, P3183
   Wolf S, 2008, JPN J OPHTHALMOL, V52, P433, DOI 10.1007/s10384-008-0580-4
   Wu DQ, 2010, TRENDS BIOCHEM SCI, V35, P161, DOI 10.1016/j.tibs.2009.10.002
   Xu Q, 2005, ONCOGENE, V24, P5552, DOI 10.1038/sj.onc.1208719
   Yang XM, 2009, J BIOCHEM, V145, P289, DOI 10.1093/jb/mvn167
   Yang XW, 2015, CELL MOL NEUROBIOL, V35, P1175, DOI 10.1007/s10571-015-0211-9
   Yasuniwa Y, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015330
   Ye X, 2009, CELL, V139, P285, DOI 10.1016/j.cell.2009.07.047
   Yeung SJ, 2008, CELL MOL LIFE SCI, V65, P3981, DOI 10.1007/s00018-008-8224-x
   Yi CX, 2005, ANN NY ACAD SCI, V1057, P384, DOI 10.1196/annals.1356.029
   Yin F, 2014, ANTIOXID REDOX SIGN, V20, P353, DOI 10.1089/ars.2012.4774
   Yokosako K, 2014, OPEN OPHTHALMOL J, V8, P39, DOI 10.2174/1874364101408010039
   YOUNG RW, 1967, J CELL BIOL, V33, P61, DOI 10.1083/jcb.33.1.61
   YOUNG RW, 1969, J CELL BIOL, V42, P392, DOI 10.1083/jcb.42.2.392
   Yue XA, 2010, BRAIN RES, V1366, P27, DOI 10.1016/j.brainres.2010.10.032
   Zhang JM, 2013, MOL CELL BIOCHEM, V379, P295, DOI 10.1007/s11010-013-1654-2
   Zhang J, 2013, SYNAPSE, V67, P515, DOI 10.1002/syn.21674
   Zhang P, 2007, OPHTHALMOLOGICA, V221, P411, DOI 10.1159/000107502
   Zhang P, 2009, GRAEF ARCH CLIN EXP, V247, P633, DOI 10.1007/s00417-008-1031-0
   Zhang XB, 2001, CANCER RES, V61, P6050
   Zhou T, 2010, INVEST OPHTH VIS SCI, V51, P4371, DOI 10.1167/iovs.09-4278
   Zhou YL, 2014, J CLIN INVEST, V124, P3825, DOI 10.1172/JCI76431
NR 178
TC 12
Z9 12
U1 0
U2 2
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD FEB
PY 2020
VL 21
IS 3
AR 820
DI 10.3390/ijms21030820
PG 19
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA KY4PQ
UT WOS:000522551602033
PM 32012797
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Xie, P
   Zheng, XH
   Yu, YQ
   Ye, XJ
   Hu, ZZ
   Yuan, DQ
   Liu, QH
AF Xie, Ping
   Zheng, Xinhua
   Yu, Yingqing
   Ye, Xiaojian
   Hu, Zizhong
   Yuan, Dongqing
   Liu, Qinghuai
TI Vitreomacular adhesion or vitreomacular traction may affect antivascular
   endothelium growth factor treatment for neovascular age-related macular
   degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
ID RETINAL VEIN OCCLUSION; CHOROIDAL NEOVASCULARIZATION; RANIBIZUMAB
   TREATMENT; SUBGROUP ANALYSIS; THERAPY; RISK; EYE; METAANALYSIS;
   VITRECTOMY; INTERFACE
AB Objective The aim of this review is to determine whether vitreomacular adhesion (VMA) or vitreomacular traction (VMT) has an influence on the outcomes of antivascular endothelium growth factor (anti-VEGF) treatment neovascular age-related macular degeneration (nAMD).
   Methods A systematic literature search was performed in Pubmed.gov, Cochrane Library, Web of Science, China National Knowledge Infrastructure, Wanfang, SinoMed and ClinicalTrials.gov up to 30 June 2016 to identify eligible studies.
   Results Nine studies and 2212 participants were finally identified. At month 6, the mean improvement in best-corrected visual acuity (BCVA) and mean decline in central retinal thickness (CRT) of the VMA/VMT(+) group was less than that of the VMA/VMT(-) group (95% CI -3.05 to -0.96 letters, p=0.0002; 15.53 to 32.98 mu m, p<0.00001; respectively); at month 12, there was a small or only marginally significant difference (-0.01 to 2.00 letters, p=0.05; 0.17 to 23.7 mu m, p=0.05; respectively) between the groups. During the 12 months, however, the VMA/VMT(+) group required more injections ((0.25 to 0.95), p=0.0008).
   Conclusions In using anti-VEGF drugs to treat nAMD, clinicians should take into account the fact that concurrent VMA or VMT might antagonise the efficacy of anti-VEGF drugs during the early stage of treatment.
C1 [Xie, Ping; Zheng, Xinhua; Ye, Xiaojian; Hu, Zizhong; Yuan, Dongqing; Liu, Qinghuai] Nanjing Med Univ, Dept Ophthalmol, Affiliated Hosp 1, Nanjing, Jiangsu, Peoples R China.
   [Zheng, Xinhua; Yu, Yingqing] Wuxi Childrens Hosp, Dept Ophthalmol, Wuxi, Jiangsu, Peoples R China.
C3 Nanjing Medical University
RP Liu, QH (通讯作者)，Nanjing Med 29 Univ, Dept Ophthalmol, Affiliated Hosp 1, Guangzhou Rd 300, Nanjing 210029, Jiangsu, Peoples R China.
EM liuqh@njmu.edu.cn
OI hu, zizhong/0000-0001-6289-1804; Xie, Ping/0000-0003-4257-8970
CR Adamis AP, 2005, RETINA-J RET VIT DIS, V25, P111, DOI 10.1097/00006982-200502000-00001
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Brockwell SE, 2001, STAT MED, V20, P825, DOI 10.1002/sim.650
   Cho HJ, 2013, RETINA-J RET VIT DIS, V33, P2126, DOI 10.1097/IAE.0b013e3182899296
   Choudhury F, 2011, AM J OPHTHALMOL, V152, P385, DOI 10.1016/j.ajo.2011.02.025
   Cuilla TA, 2015, OPHTHALMOLOGY, V122, P1203, DOI 10.1016/j.ophtha.2015.02.031
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Duker JS, 2013, OPHTHALMOLOGY, V120, P2611, DOI 10.1016/j.ophtha.2013.07.042
   Emoto Hirofumi, 2010, Retin Cases Brief Rep, V4, P312, DOI 10.1097/ICB.0b013e3181d426e8
   Filloy A, 2013, Arch Soc Esp Oftalmol, V88, P380, DOI 10.1016/j.oftal.2013.01.016
   Finger RP, 2014, SURV OPHTHALMOL, V59, P1, DOI 10.1016/j.survophthal.2013.03.009
   Goverdhan SV, 2008, EYE, V22, P849, DOI 10.1038/sj.eye.6702830
   Gupta B, 2010, BRIT J OPHTHALMOL, V94, P672, DOI 10.1136/bjo.2009.166975
   Hedges LV, 1998, PSYCHOL METHODS, V3, P486, DOI 10.1037/1082-989X.3.4.486
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hermann MM, 2014, OPHTHALMOLOGY, V121, P905, DOI 10.1016/j.ophtha.2013.10.047
   Holekamp NM, 2005, AM J OPHTHALMOL, V139, P302, DOI 10.1016/j.ajo.2004.09.046
   Houston SK, 2015, RETINA-J RET VIT DIS, V35, P1757, DOI 10.1097/IAE.0000000000000663
   Ikeda T, 2000, ACTA OPHTHALMOL SCAN, V78, P460, DOI 10.1034/j.1600-0420.2000.078004460.x
   Jackson TL, 2013, RETINA-J RET VIT DIS, V33, P1099, DOI 10.1097/IAE.0b013e31828991d6
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Krebs I, 2007, AM J OPHTHALMOL, V144, P741, DOI 10.1016/j.ajo.2007.07.024
   Krishnan R, 2015, RETINA-J RET VIT DIS, V35, P1750, DOI 10.1097/IAE.0000000000000714
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lee Kang Hoon, 2015, Korean J Ophthalmol, V29, P396, DOI 10.3341/kjo.2015.29.6.396
   Lee SJ, 2011, OPHTHALMOLOGY, V118, P101, DOI 10.1016/j.ophtha.2010.04.015
   Lee SJ, 2009, AM J OPHTHALMOL, V147, P621, DOI 10.1016/j.ajo.2008.10.003
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mayr-Sponer U, 2013, OPHTHALMOLOGY, V120, P2620, DOI 10.1016/j.ophtha.2013.05.032
   Mojana F, 2008, AM J OPHTHALMOL, V146, P218, DOI 10.1016/j.ajo.2008.04.027
   Nomura Y, 2014, JPN J OPHTHALMOL, V58, P443, DOI 10.1007/s10384-014-0333-5
   Nussenblatt RB, 2007, AM J OPHTHALMOL, V144, P618, DOI 10.1016/j.ajo.2007.06.025
   OConnell D, 2016, NEWCASTLE OTTAWA SCA
   Ondes F, 2000, JPN J OPHTHALMOL, V44, P91, DOI 10.1016/S0021-5155(99)00174-4
   Ozsutcu M, 2013, CASE REP OPHTHALM, V4, P7, DOI 10.1159/000342873
   Quaranta-El Maftouhi M, 2006, EUR J OPHTHALMOL, V16, P134
   Quiram PA, 2007, RETINA-J RET VIT DIS, V27, P1090, DOI 10.1097/IAE.0b013e3180654229
   REESE AB, 1967, AM J OPHTHALMOL, V64, P544
   Robison CD, 2009, AM J OPHTHALMOL, V148, P79, DOI 10.1016/j.ajo.2009.01.014
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   Rotsos T, 2010, BRIT J OPHTHALMOL, V94, P1205, DOI 10.1136/bjo.2009.173765
   Schulze S, 2008, ACTA OPHTHALMOL, V86, P470, DOI 10.1111/j.1755-3768.2008.01210.x
   Seko Y, 1999, INVEST OPHTH VIS SCI, V40, P3287
   Simpson ARH, 2012, SURV OPHTHALMOL, V57, P498, DOI 10.1016/j.survophthal.2012.01.011
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P2304, DOI 10.1016/j.ophtha.2012.05.040
   Spaide RF, 2003, RETINA-J RET VIT DIS, V23, P595, DOI 10.1097/00006982-200310000-00001
   Stalmans P, 2013, RETINA-J RET VIT DIS, V33, P2003, DOI 10.1097/IAE.0b013e3182993ef8
   Stalmans P, 2012, NEW ENGL J MED, V367, P606, DOI 10.1056/NEJMoa1110823
   STEFANSSON E, 1990, INVEST OPHTH VIS SCI, V31, P284
   Stefansson E, 2009, GRAEF ARCH CLIN EXP, V247, P147, DOI 10.1007/s00417-008-0980-7
   Sutton AJ, 2000, METHODS METAANALYSIS
   Syed YY, 2013, DRUGS, V73, P1617, DOI 10.1007/s40265-013-0124-1
   Waldstein SM, 2014, AM J OPHTHALMOL, V158, P328, DOI 10.1016/j.ajo.2014.04.028
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Wang R, 2007, NEW ENGL J MED, V357, P2189, DOI 10.1056/NEJMsr077003
   Weber-Krause Brigitte, 1996, Ophthalmologe, V93, P660, DOI 10.1007/s003470050054
   Yasuda M, 2009, OPHTHALMOLOGY, V116, P2135, DOI 10.1016/j.ophtha.2009.04.017
NR 62
TC 6
Z9 6
U1 2
U2 8
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD AUG
PY 2017
VL 101
IS 8
BP 1003
EP 1010
DI 10.1136/bjophthalmol-2017-310155
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FA8BV
UT WOS:000405672100002
PM 28596285
DA 2022-11-30
ER

PT J
AU Axer-Siegel, R
   Ehrlich, R
   Avisar, I
   Kramer, M
   Rosenblatt, I
   Priel, E
   Weinberger, D
AF Axer-Siegel, Ruth
   Ehrlich, Rita
   Avisar, Inbal
   Kramer, Michal
   Rosenblatt, Irit
   Priel, Ethan
   Weinberger, Dov
TI Combined photodynamic therapy and intravitreal triamcinolone acetonide
   injection for neovascular age-related macular degeneration with pigment
   epithelium detachment
SO OPHTHALMIC SURGERY LASERS & IMAGING
LA English
DT Article
ID OCCULT CHOROIDAL NEOVASCULARIZATION; INDOCYANINE GREEN ANGIOGRAPHY;
   GUIDED LASER PHOTOCOAGULATION; NATURAL-HISTORY; VERTEPORFIN; TEAR;
   EXPRESSION
AB BACKGROUND AND OBJECTIVE: To report the outcome of combined verteporfin photodynamic therapy (PDT) and intravitreal triamcinolone acetonide (IVTA) for the treatment of choroidal neovascularization (CNV) with serous pigment epithelium detachment (PED) due to age-related macular degeneration (AMD).
   PATIENTS AND METHODS: The files of all consecutive patients with CNV and serous PED who received PDT and IVTA either primarily (primary treatment group) or following previous unsuccessful PDT (secondary treatment group) were reviewed for visual and angiographic results.
   RESULTS: Ten patients (11 eyes) were included. Mean number of PDT sessions was 3.18; 8 eyes received one IVTA injection and 3 eyes received two IVTA injections. Thirty-six percent of patients retained their initial visual acuity after a mean follow-up of 15.3 months. Loss of 3 or more Snellen lines was noted in 2 of 3 eyes in the primary treatment group and 5 of 8 eyes in the secondary treatment group. Increased intraocular pressure developed in 3 patients and was controlled by topical medications.
   CONCLUSIONS: Although combined PDT and IVTA may be considered for CNV with serous PED in patients with poor prognosis with PDT alone, the regimen as administered in this small series was not beneficial. Further studies are required to determine whether alternate sequences, timing, or doses would yield a better outcome.
C1 Rabin Med Ctr, Dept Ophthalmol, IL-49100 Petah Tiqwa, Israel.
   Mor Inst Med Data, Bnei Berak, Israel.
   Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel.
C3 Rabin Medical Center; Tel Aviv University; Sackler Faculty of Medicine
RP Axer-Siegel, R (通讯作者)，Rabin Med Ctr, Dept Ophthalmol, Beilinson Campus, IL-49100 Petah Tiqwa, Israel.
CR Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Axer-Siegel R, 2004, ARCH OPHTHALMOL-CHIC, V122, P453, DOI 10.1001/archopht.122.4.453
   Axer-Siegel R, 2004, AM J OPHTHALMOL, V137, P258, DOI 10.1016/j.ajo.2003.08.009
   Axer-Siegel R, 1999, AM J OPHTHALMOL, V128, P331, DOI 10.1016/S0002-9394(99)00176-2
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Brancato R, 2000, RETINA-J RET VIT DIS, V20, P134, DOI 10.1097/00006982-200003000-00004
   Bressler NM, 2000, ARCH OPHTHALMOL-CHIC, V118, P488
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Costa RA, 2003, RETINA-J RET VIT DIS, V23, P159, DOI 10.1097/00006982-200304000-00004
   ELMAN MJ, 1986, OPHTHALMOLOGY, V93, P224
   Gelisken F, 2001, AM J OPHTHALMOL, V131, P518, DOI 10.1016/S0002-9394(00)00813-8
   Ghazi NG, 2001, RETINA-J RET VIT DIS, V21, P478, DOI 10.1097/00006982-200110000-00010
   Gillies MC, 2003, ARCH OPHTHALMOL-CHIC, V121, P667, DOI 10.1001/archopht.121.5.667
   Haddad WM, 2004, INVEST OPHTH VIS SCI, V45, pU77
   Haddad WM, 2002, BRIT J OPHTHALMOL, V86, P663, DOI 10.1136/bjo.86.6.663
   Halaby IA, 2002, MOL THER, V5, P300, DOI 10.1006/mthe.2002.0539
   Hori Y, 1996, BRIT J PHARMACOL, V118, P1584, DOI 10.1111/j.1476-5381.1996.tb15578.x
   Jonas JB, 2004, ARCH OPHTHALMOL-CHIC, V122, P218, DOI 10.1001/archopht.122.2.218
   Jonas JB, 2003, BRIT J OPHTHALMOL, V87, P462, DOI 10.1136/bjo.87.4.462
   Kramer M, 1996, OPHTHALMOLOGY, V103, P427
   Lim JI, 1997, AM J OPHTHALMOL, V123, P524, DOI 10.1016/S0002-9394(14)70178-3
   MEREDITH TA, 1979, AM J OPHTHALMOL, V88, P643, DOI 10.1016/0002-9394(79)90659-7
   Moshfeghi DM, 2003, AM J OPHTHALMOL, V135, P343, DOI 10.1016/S0002-9394(02)01936-0
   Nauck M, 1997, AM J RESP CELL MOL, V16, P398, DOI 10.1165/ajrcmb.16.4.9115750
   Pece A, 2001, RETINA-J RET VIT DIS, V21, P661, DOI 10.1097/00006982-200112000-00017
   Penfold PL, 2001, CLIN EXP OPHTHALMOL, V29, P188, DOI 10.1046/j.1442-9071.2001.00407.x
   Perretti M, 2000, MICROCIRCULATION, V7, P147, DOI 10.1038/sj.mn.7300108
   POLINER LS, 1986, OPHTHALMOLOGY, V93, P543
   Rechtman E, 2004, BRIT J OPHTHALMOL, V88, P344, DOI 10.1136/bjo.2003.027177
   Schmidt-Erfurth U, 2002, ARCH OPHTHALMOL-CHIC, V120, P835
   Schmidt-Erfurth U, 2002, INVEST OPHTH VIS SCI, V43, P830
   SLAKTER JS, 1994, ARCH OPHTHALMOL-CHIC, V112, P465, DOI 10.1001/archopht.1994.01090160041020
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P1517, DOI 10.1016/S0161-6420(03)00544-X
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   YANNUZZI LA, 1994, RETINA-J RET VIT DIS, V14, P99, DOI 10.1097/00006982-199414020-00003
NR 35
TC 14
Z9 15
U1 0
U2 1
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 1542-8877
EI 1938-2375
J9 OPHTHAL SURG LAS IM
JI Ophthalmic Surg. Lasers Imaging
PD NOV-DEC
PY 2006
VL 37
IS 6
BP 455
EP 461
DI 10.3928/15428877-20061101-02
PG 7
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA 107VD
UT WOS:000242198200002
PM 17152538
DA 2022-11-30
ER

PT J
AU De Bats, F
   Grange, JD
   Cornut, PL
   Feldman, A
   Burillon, C
   Denis, P
   Kodjikian, L
AF De Bats, F.
   Grange, J. -D.
   Cornut, P. -L.
   Feldman, A.
   Burillon, C.
   Denis, P.
   Kodjikian, L.
TI Bevacizumab versus ranibizumab in the treatment of exudative age-related
   macular degeneration: A retrospective study of 58 patients
SO JOURNAL FRANCAIS D OPHTALMOLOGIE
LA English
DT Article
DE Bevacizumab (avastin); Ranibizumab (lucentis); Neovascular age-related
   macular degeneration; Choroidal neovascularization
ID INTRAVITREAL BEVACIZUMAB; CHOROIDAL NEOVASCULARIZATION; LUCENTIS;
   AVASTIN; SAFETY; INJECTIONS
AB Aim. - To compare the efficacy and safety of bevacizumab versus ranibizumab in the treatment of patients with neovascular age-related macular degeneration (AMD).
   Patients and methods. - Retrospective case-controlled series of 30 patients treated with intravitreal bevacizumab and 28 patients treated with intravitreal ranibizumab for exudative AMD. Main outcomes measured included best-corrected visual acuity (BCVA), central macular thickness (CMT) and foveal thickness, quantity of subretinal fluid, neovessel size and total number of injections over the first year treatment period. A secondary outcome was the report of any adverse events in both groups.
   Results. - BCVA stabilized and increased from LogMAR 0.70 to 0.47 in the bevacizumab group and from 0.55 to 0.54 in the ranibizumab group (P > 0.05). CMT decreased in the bevacizumab group from 369 to 284 mu m and in the ranibizumab group from 340 to 271 mu m (P > 0.05). The number of injection was significantly lower (4.8) in the bevacizumab group than in the ranibizumab group (5.8) (P < 0.05). No serious ocular adverse events were noted in both groups.
   Conclusion. - This retrospective study failed to show a difference in visual and anatomic outcomes between bevacizumab and ranibizumab. The number of re-treatment was lower in the bevacizumab group (P = 0.03). (C) 2012 Elsevier Masson SAS. All rights reserved.
C1 [De Bats, F.; Grange, J. -D.; Denis, P.; Kodjikian, L.] Hop Croix Rousse, Serv Ophtalmol, F-69004 Lyon, France.
   [Cornut, P. -L.; Feldman, A.; Burillon, C.] Hop Edouard Herriot, Serv Ophtalmol, F-69003 Lyon, France.
C3 CHU Lyon; CHU Lyon
RP De Bats, F (通讯作者)，Hop Croix Rousse, Serv Ophtalmol, 103 Grande Rue de la Croix Rousse, F-69004 Lyon, France.
EM gonzalez_flore@yahoo.fr
CR Abraham-Marin ML, 2007, GRAEF ARCH CLIN EXP, V245, P651, DOI 10.1007/s00417-006-0411-6
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Bashshur ZF, 2006, AM J OPHTHALMOL, V142, P1, DOI 10.1016/j.ajo.2006.02.037
   Brechner RJ, 2011, AM J OPHTHALMOL, V151, P887, DOI 10.1016/j.ajo.2010.11.017
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chen CY, 2007, AM J OPHTHALMOL, V143, P510, DOI 10.1016/j.ajo.2006.10.004
   Curtis LH, 2010, ARCH OPHTHALMOL-CHIC, V128, P1273, DOI 10.1001/archophthalmol.2010.223
   Arevalo JF, 2010, OPHTHALMOLOGY, V117, P1974, DOI 10.1016/j.ophtha.2010.01.056
   Fung AE, 2006, BRIT J OPHTHALMOL, V90, P1344, DOI 10.1136/bjo.2006.099598
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   Gower E, 2011, ASS RES VIS OPHTH AN
   Ladas ID, 2009, RETINA-J RET VIT DIS, V29, P313, DOI 10.1097/IAE.0b013e31819a5f98
   Landa G, 2009, OPHTHALMOLOGICA, V223, P370, DOI 10.1159/000227783
   Machkour-Bentaleb Z, COMP MACULAR THICKNE
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mason JO, 2008, RETINA-J RET VIT DIS, V28, P564, DOI 10.1097/IAE.0b013e3181633fee
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Mojica G, 2008, BRIT J OPHTHALMOL, V92, P584, DOI 10.1136/bjo.2007.126193
   Mylonas G, 2009, BRIT J OPHTHALMOL, V93, P1453, DOI 10.1136/bjo.2008.153643
   Pilu S, 2008, AM J OPHTHALMOL, V145, P879, DOI 10.1016/j.ajo.2007.12.036
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmucker C, 2011, BRIT J OPHTHALMOL, V95, P308, DOI 10.1136/bjo.2009.178574
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Wu L, 2008, GRAEF ARCH CLIN EXP, V246, P81, DOI 10.1007/s00417-007-0660-z
NR 26
TC 7
Z9 7
U1 0
U2 17
PU MASSON EDITEUR
PI MOULINEAUX CEDEX 9
PA 21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE
SN 0181-5512
EI 1773-0597
J9 J FR OPHTALMOL
JI J. Fr. Ophthamol.
PD NOV
PY 2012
VL 35
IS 9
BP 661
EP 666
DI 10.1016/j.jfo.2012.01.015
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 043TG
UT WOS:000311571000002
PM 23040443
DA 2022-11-30
ER

PT J
AU Calvo, P
   Abadia, B
   Ferreras, A
   Ruiz-Moreno, O
   Lecinena, J
   Torron, C
AF Calvo, Pilar
   Abadia, Beatriz
   Ferreras, Antonio
   Ruiz-Moreno, Oscar
   Lecinena, Jesus
   Torron, Clemencia
TI Long-Term Visual Outcome in Wet Age-Related Macular Degeneration
   Patients Depending on the Number of Ranibizumab Injections
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID DOSING REGIMEN; THERAPY; TREAT
AB Purpose. To analyse the visual outcome in wet age-related macular degeneration (AMD) patients depending on the number of ranibizumab injections. Methods. 51 naive wet AMD patients were retrospectively recorded. Visual acuity (VA), central retinal thickness (CRT) measured with spectral domain (SD) optical coherence tomography (OCT), and number of intravitreal injections were compared at 6, 12, 18, 24, 30, and 36 months of follow-up. Kaplan-Meier survival rates (SRs) based on VA outcomes were calculated depending on the number of ranibizumab injections performed. Results. VA improved compared with baseline at 6 and 12 months (P < 0.005). No differences were found at 18, 24, 30, and 36 months (P > 0.05). CRT measured with Cirrus OCT decreased (P < 0.001) at all time points analysed. The mean number of injections received was 6.98 +/- 3.69. At 36 months, Kaplan-Meier SR was 76.5% (the proportion of patients without a decrease in vision of more than 0.3 logMAR units). VA remained stable (<0.01 logMAR units) or improved in 62.7%. Within this group, SR was 92.9% in those who received 7 or more injections versus 51.4% receiving <7 treatments (P = 0.008; log-rank test). Conclusion. Better VA outcomes were found in stable wet AMD patients after 3 years of follow-up if they received = 7 ranibizumab injections.
C1 [Calvo, Pilar; Abadia, Beatriz; Ferreras, Antonio; Ruiz-Moreno, Oscar; Lecinena, Jesus; Torron, Clemencia] Miguel Servet Univ Hosp, Ophthalmol Dept, Zaragoza 50009, Spain.
   [Calvo, Pilar; Ferreras, Antonio; Ruiz-Moreno, Oscar; Torron, Clemencia] Univ Zaragoza, Zaragoza, Spain.
C3 Miguel Servet University Hospital; University of Zaragoza
RP Calvo, P (通讯作者)，Miguel Servet Univ Hosp, Ophthalmol Dept, Isabel Catolica 1-3, Zaragoza 50009, Spain.
EM xenatrance@yahoo.es
RI Ferreras, Antonio/AAF-4220-2020
OI Ferreras, Antonio/0000-0002-2914-2593
FU Novartis Pharma, S.A
FX The authors acknowledge Novartis Pharma, S.A, for the financial support.
CR Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Brown MM, 2005, CAN J OPHTHALMOL, V40, P277, DOI 10.1016/S0008-4182(05)80070-5
   Engelbert M, 2010, RETINA-J RET VIT DIS, V30, P1368, DOI 10.1097/IAE.0b013e3181d50cbf
   Engelbert M, 2009, RETINA-J RET VIT DIS, V29, P1424, DOI 10.1097/IAE.0b013e3181bfbd46
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   HOLLADAY JT, 1989, ARCH OPHTHALMOL-CHIC, V107, P955, DOI 10.1001/archopht.1989.01070020017008
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Korb CA, 2014, GRAEF ARCH CLIN EXP, V252, P1403, DOI 10.1007/s00417-014-2591-9
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Mittra R. A., 2012, PREFERENCES TRENDS M
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Saleh M, 2013, GRAEF ARCH CLIN EXP, V251, P1901, DOI 10.1007/s00417-013-2284-9
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Spaide R, 2007, AM J OPHTHALMOL, V143, P679, DOI 10.1016/j.ajo.2007.02.024
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
NR 19
TC 9
Z9 9
U1 0
U2 1
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PY 2015
VL 2015
AR 820605
DI 10.1155/2015/820605
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CT4BV
UT WOS:000362751800001
PM 26491555
OA Green Submitted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Guber, J
   Praveen, A
   Saeed, MU
AF Guber, J.
   Praveen, A.
   Saeed, M. U.
TI Retinal Pigment Epithelium Rips After Ranibizumab in Neovascular
   Age-Related Macular Degeneration: Incidence, Risk Factors and Long-Term
   Outcome
SO KLINISCHE MONATSBLATTER FUR AUGENHEILKUNDE
LA English
DT Article
DE age-elated macular degeneration; retinal pigment epithelium rip;
   ranibizumab
ID TEARS; DETACHMENT; THERAPY
AB Background: Retinal pigment epithelium (RPE) rips after ranibizumab for wet age related macular degeneration (AMD) with a pigment epithelial detachments (PED) are a dreaded complication. Aim of this study was to analyse the incidence, the risk factors and long-term outcome after a PED tear.
   Patients and Methods: 401 patients with wet AMD were analysed. A total of 33 eyes with PED were identified. Mean follow up time was 635 days (SD +/- 311).
   Results: PED tears occurred in 8 (24%) patients. Most RPE rips (40%) occurred within the first three months. Mean visual loss was 13 letters (range -57-9). The PED tear group had a mean PED height of 521 mu m. The PED group without a tear had a mean height of 300 mu m (p <= 0.001). Patients with a PED height over 300 mu m had more than twice the risk to develop a RPE rip compared to patients with PED height smaller than 300 mu m (p <= 0.001).
   Conclusions: PED height is a relevant factor for the incidence of RPE rips after treatment with ranibizumab. Owing to the close time relationship with the therapy, this complication must be taken into account before treatment as it may lead to significant vision loss.
C1 [Guber, J.; Praveen, A.; Saeed, M. U.] Epsom & St Helier Univ Hosp, Sutton Eye Hosp, London, England.
RP Guber, J (通讯作者)，Epsom & St Helier Univ Hosp NHS Trust, Sutton Eye Hosp, Cotswold Rd, London SM2 5NF, England.
EM josef.guber@esth.nhs.uk; musmansaeed@aol.com
CR Carvounis PE, 2007, AM J OPHTHALMOL, V143, P504, DOI 10.1016/j.ajo.2006.11.028
   Chan CK, 2007, RETINA-J RET VIT DIS, V27, P541, DOI 10.1097/IAE.0b013e3180cc2612
   Chiang A, 2008, RETINA-J RET VIT DIS, V28, P1265, DOI 10.1097/IAE.0b013e31817d5d03
   GASS JDM, 1984, AM J OPHTHALMOL, V98, P700
   Gelisken F, 2001, AM J OPHTHALMOL, V131, P518, DOI 10.1016/S0002-9394(00)00813-8
   Gutfleisch M, 2011, EYE, V25, P1181, DOI 10.1038/eye.2011.146
   HOSKIN A, 1981, BRIT J OPHTHALMOL, V65, P417, DOI 10.1136/bjo.65.6.417
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lommatzsch A, 2009, EYE, V23, P2163, DOI 10.1038/eye.2008.425
   SCHOEPPNER G, 1989, AM J OPHTHALMOL, V108, P683, DOI 10.1016/0002-9394(89)90861-1
NR 10
TC 1
Z9 1
U1 0
U2 0
PU GEORG THIEME VERLAG KG
PI STUTTGART
PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY
SN 0023-2165
EI 1439-3999
J9 KLIN MONATSBL AUGENH
JI Klinische Monatsblat. Augenheilkunde
PD APR
PY 2014
VL 231
IS 4
BP 432
EP 435
DI 10.1055/s-0034-1368219
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AI4PX
UT WOS:000336848400044
PM 24771185
DA 2022-11-30
ER

PT J
AU Chen, ML
   Jin, K
   Yan, Y
   Liu, XD
   Huang, XL
   Gao, ZY
   Wang, Y
   Wang, S
   Ye, J
AF Chen, Menglu
   Jin, Kai
   Yan, Yan
   Liu, Xindi
   Huang, Xiaoling
   Gao, Zhiyuan
   Wang, Yao
   Wang, Shuai
   Ye, Juan
TI Automated diagnosis of age-related macular degeneration using
   multi-modal vertical plane feature fusion via deep learning
SO MEDICAL PHYSICS
LA English
DT Article
DE age-related macular degeneration; deep learning; feature fusion;
   multi-modality
ID OPTICAL COHERENCE TOMOGRAPHY
AB Purpose To develop a computer-aided diagnostic (CADx) system of age-related macular degeneration (AMD) through feature fusion between infrared reflectance (IR) and optical coherence tomography (OCT) modalities in order to explore the superiority of multi-modality CADx system and the optimal feature fusion patterns between multi-modality inputs. Methods This is a dual center retrospective study. We retrospectively collected 2006 pairs of IR and OCT images to develop the algorithms. Two single-modality models and three multi-modality models were constructed for the comparison of the diagnostic efficacy. The multi-modality models were designed utilizing a novel feature fusion method, namely, vertical plane feature fusion (VPFF). The results were validated using an independent external validation dataset and compared by three ophthalmologists. Results In the test set of the ZJU dataset, our best model named OCT_MAIN demonstrated diagnostic efficiency with an overall accuracy of 0.9608 and area under the curve of 0.9944 for the normal category, 0.9659 for the dry AMD category, and 0.9930 for the wet AMD category. The external validation exhibited an overall accuracy of 0.9159. Its diagnostic efficiency was comparable to that of the senior ophthalmologist. Conclusions The VPFF method was successfully employed to develop a multi-modal intelligent diagnostic system for the AMD classification. This is a valuable complement and optimization to the existing CADx system, which reveals a wide application prospect and research potential.
C1 [Chen, Menglu; Jin, Kai; Yan, Yan; Liu, Xindi; Huang, Xiaoling; Gao, Zhiyuan; Wang, Yao; Ye, Juan] Zhejiang Univ, Affiliated Hosp 2, Coll Med, Dept Ophthalmol, Hangzhou, Peoples R China.
   [Wang, Shuai] Shandong Univ, Sch Mech Elect & Informat Engn, Weihai, Peoples R China.
C3 Zhejiang University; Shandong University
RP Ye, J (通讯作者)，Zhejiang Univ, Affiliated Hosp 2, Dept Ophthalmol, Bldg 10,Jiefang Rd 88, Hangzhou 310009, Peoples R China.
EM jinkai@zju.edu.cn; yejuan@zju.edu.cn
FU National Key Research and Development Program of China [2019YFC0118401];
   Zhejiang Provincial Key Research and Development Plan [2019C03020];
   Natural Science Foundation of Zhejiang Province [LQ21H120002]; Medical
   and Health Science and Technology Program of Zhejiang Province
   [2021RC064]; Natural Science Foundation of China [81670888]; ZJU-BIOMIND
   Medical Artificial Intelligence Research
FX National Key Research and Development Program of China, Grant/Award
   Number: 2019YFC0118401; Zhejiang Provincial Key Research and Development
   Plan, Grant/Award Number: 2019C03020; Natural Science Foundation of
   Zhejiang Province, Grant/Award Number: LQ21H120002; Medical and Health
   Science and Technology Program of Zhejiang Province, Grant/Award Number:
   2021RC064; the Natural Science Foundation of China, Grant/Award Number:
   81670888; ZJU-BIOMIND Medical Artificial Intelligence Research
CR BECKMAN C, 1995, BRIT J OPHTHALMOL, V79, P900, DOI 10.1136/bjo.79.10.900
   Burlina PM, 2017, JAMA OPHTHALMOL, V135, P1170, DOI 10.1001/jamaophthalmol.2017.3782
   De Fauw J, 2018, NAT MED, V24, P1342, DOI 10.1038/s41591-018-0107-6
   Elsner AE, 1996, VISION RES, V36, P191, DOI 10.1016/0042-6989(95)00100-E
   Elsner AE, 2007, J OPT SOC AM A, V24, P1468, DOI 10.1364/JOSAA.24.001468
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Grassmann F, 2018, OPHTHALMOLOGY, V125, P1410, DOI 10.1016/j.ophtha.2018.02.037
   Guo Z, 2018, I S BIOMED IMAGING, P903, DOI 10.1109/ISBI.2018.8363717
   Hartnett ME, 1996, OPHTHALMOLOGY, V103, P58, DOI 10.1016/S0161-6420(96)30731-8
   He K., 2016, P IEEE COMPUTER SOC, P630, DOI DOI 10.1109/CVPR.2016.90
   Kermany DS, 2018, CELL, V172, P1122, DOI 10.1016/j.cell.2018.02.010
   Lee CS, 2017, OPHTHALMOL RETINA, V1, P322, DOI 10.1016/j.oret.2016.12.009
   Ly A, 2016, OPHTHAL PHYSL OPT, V36, P303, DOI 10.1111/opo.12283
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Miura M, 2002, RETINA-J RET VIT DIS, V22, P300, DOI 10.1097/00006982-200206000-00008
   Santos AM, 2018, BIOMED ENG ONLINE, V17, DOI 10.1186/s12938-018-0592-3
   Schmidt-Erfurth U, 2017, EYE, V31, P26, DOI 10.1038/eye.2016.227
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P5009, DOI 10.1167/iovs.11-7235
   Schmitz-Valckenberg S, 2010, OPHTHALMOLOGY, V117, P1169, DOI 10.1016/j.ophtha.2009.10.044
   Seebock P, 2019, IEEE T MED IMAGING, V38, P1037, DOI 10.1109/TMI.2018.2877080
   Selvaraju RR, 2020, INT J COMPUT VISION, V128, P336, DOI 10.1007/s11263-019-01228-7
   Sohrab MA, 2011, INVEST OPHTH VIS SCI, V52, P5743, DOI 10.1167/iovs.10-6942
   Stahl A, 2020, DTSCH ARZTEBL INT, V117, P513, DOI 10.3238/arztebl.2020.0513
   Steinmetz JD, 2021, LANCET GLOB HEALTH, V9, pE144, DOI 10.1016/S2214-109X(20)30489-7
   Treder M, 2018, GRAEF ARCH CLIN EXP, V256, P259, DOI 10.1007/s00417-017-3850-3
   Ueda-Arakawa N, 2013, RETINA-J RET VIT DIS, V33, P490, DOI 10.1097/IAE.0b013e318276e0ae
   Venhuizen FG, 2017, INVEST OPHTH VIS SCI, V58, P2318, DOI 10.1167/iovs.16-20541
   Xu ZY, 2021, BRIT J OPHTHALMOL, V105, P561, DOI 10.1136/bjophthalmol-2020-315817
   Yoo TK, 2019, MED BIOL ENG COMPUT, V57, P677, DOI 10.1007/s11517-018-1915-z
NR 29
TC 0
Z9 0
U1 2
U2 13
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0094-2405
EI 2473-4209
J9 MED PHYS
JI Med. Phys.
PD APR
PY 2022
VL 49
IS 4
BP 2324
EP 2333
DI 10.1002/mp.15541
EA MAR 2022
PG 10
WC Radiology, Nuclear Medicine & Medical Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Radiology, Nuclear Medicine & Medical Imaging
GA 0K9PT
UT WOS:000767168400001
PM 35172022
DA 2022-11-30
ER

PT J
AU Kiel, C
   Strunz, T
   Blanton, S
   Grassmann, F
   Weber, BHF
AF Kiel, Christina
   Strunz, Tobias
   Blanton, Susan
   Grassmann, Felix
   Weber, Bernhard H. F.
CA Int AMD Genomics Consortium IAMDGC
TI Pleiotropic Locus 15q24.1 Reveals a Gender-Specific Association with
   Neovascular but Not Atrophic Age-Related Macular Degeneration (AMD)
SO CELLS
LA English
DT Article
DE age-related macular degeneration; choroidal neovascularization;
   pleiotropy; miRNA variant; eQTL; locus analysis; gender specificity
ID GENOME-WIDE ASSOCIATION; GENE-EXPRESSION; HYPERTENSION; DISEASE; ATLAS;
   BLOOD
AB Genome-wide association studies (GWAS) have identified an abundance of genetic loci associated with complex traits and diseases. In contrast, in-depth characterization of an individual genetic signal is rarely available. Here, we focus on the genetic variant rs2168518 in 15q24.1 previously associated with age-related macular degeneration (AMD), but only with suggestive evidence. In a two-step procedure, we initially conducted a series of association analyses to further delineate the association of rs2168518 with AMD but also with other complex phenotypes by using large independent datasets from the International AMD Genomics Consortium (IAMDGC) and the UK Biobank. We then performed a functional annotation with reference to gene expression regulation based on data from the Genotype-Tissue Expression (GTEx) project and RegulomeDB. Association analysis revealed a gender-specific association with male AMD patients and an association predominantly with choroidal neovascularization. Further, the AMD association colocalizes with an association signal of several blood pressure-related phenotypes and with the gene expression regulation of CYP1A1, a member of the cytochrome P450 superfamily of monooxygenases. Functional annotation revealed altered transcription factor (TF) binding sites for gender-specific TFs, including SOX9 and SRY. In conclusion, the pleiotropic 15q24.1 association signal suggests a shared mechanism between blood pressure regulation and choroidal neovascularization with a potential involvement of CYP1A1.
C1 [Kiel, Christina; Strunz, Tobias; Grassmann, Felix; Weber, Bernhard H. F.] Univ Regensburg, Inst Human Genet, D-93053 Regensburg, Germany.
   [Blanton, Susan] Univ Miami, John P Hussman Inst Human Genom, Miami, FL 33136 USA.
   [Grassmann, Felix] Univ Aberdeen, Kings Coll, Inst Med Sci, Aberdeen AB24 3FX, Scotland.
   [Weber, Bernhard H. F.] Univ Hosp Regensburg, Inst Clin Human Genet, D-93053 Regensburg, Germany.
C3 University of Regensburg; University of Miami; University of Aberdeen;
   University of Regensburg
RP Weber, BHF (通讯作者)，Univ Regensburg, Inst Human Genet, D-93053 Regensburg, Germany.; Weber, BHF (通讯作者)，Univ Hosp Regensburg, Inst Clin Human Genet, D-93053 Regensburg, Germany.
EM Christina.Kiel@klinik.uni-regensburg.de;
   Tobias.Strunz@klinik.uni-regensburg.de; felix.grassmann@abdn.ac.uk;
   bweb@klinik.uni-regensburg.de
RI Blanton, Susan Halloran/ABF-1323-2021; Strunz, Tobias/ABD-9798-2021;
   Strunz, Tobias/ABB-6300-2020
OI Strunz, Tobias/0000-0002-3744-9595; Grassmann,
   Felix/0000-0003-1390-7528; Weber, Bernhard H.F./0000-0002-8808-7723;
   Blanton, Susan/0000-0002-5433-3439; Kiel, Christina/0000-0003-3154-4847
FU Deutsche Forschungsgemeinschaft [GR5065/1-1];  [Titel 77]
FX This research was funded by the Deutsche Forschungsgemeinschaft
   (GR5065/1-1) and institutional funds (Titel 77).
CR Agarwal V, 2015, ELIFE, V4, DOI 10.7554/eLife.05005
   Aguet F, 2020, SCIENCE, V369, P1318, DOI 10.1126/science.aaz1776
   Altshuler DM, 2012, NATURE, V491, P56, DOI 10.1038/nature11632
   [Anonymous], **NON-TRADITIONAL**
   [Anonymous], **NON-TRADITIONAL**
   [Anonymous], **NON-TRADITIONAL**
   [Anonymous], **NON-TRADITIONAL**
   [Anonymous], **NON-TRADITIONAL**
   [Anonymous], **NON-TRADITIONAL**
   [Anonymous], **NON-TRADITIONAL**
   [Anonymous], **NON-TRADITIONAL**
   Backes C, 2016, MOL DIAGN THER, V20, P509, DOI 10.1007/s40291-016-0221-4
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Bernardo BC, 2015, FUTURE MED CHEM, V7, P1771, DOI 10.4155/fmc.15.107
   Boyle AP, 2012, GENOME RES, V22, P1790, DOI 10.1101/gr.137323.112
   Bulik-Sullivan B, 2015, NAT GENET, V47, P1236, DOI 10.1038/ng.3406
   Chandradoss SD, 2015, CELL, V162, P96, DOI 10.1016/j.cell.2015.06.032
   Chen YH, 2020, NUCLEIC ACIDS RES, V48, pD127, DOI 10.1093/nar/gkz757
   Chipman LB, 2019, TRENDS GENET, V35, P215, DOI 10.1016/j.tig.2018.12.005
   Chou CH, 2018, NUCLEIC ACIDS RES, V46, pD296, DOI 10.1093/nar/gkx1067
   Cotsapas C, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002254
   de Sousa MC, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20246249
   Duan YK, 2007, OPHTHALMOLOGY, V114, P732, DOI 10.1016/j.ophtha.2006.07.045
   Esfandiary H, 2005, BRIT J OPHTHALMOL, V89, P470, DOI 10.1136/bjo.2004.047340
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Ghanbari M, 2017, HUM MUTAT, V38, P827, DOI 10.1002/humu.23226
   Ghanbari M, 2014, HUM MUTAT, V35, P1524, DOI 10.1002/humu.22706
   Giambartolomei C, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004383
   GONZALEZ FJ, 1990, PHARMACOL THERAPEUT, V45, P1, DOI 10.1016/0163-7258(90)90006-N
   Grassmann F, 2017, GENOME MED, V9, DOI 10.1186/s13073-017-0418-0
   Han XK, 2020, J HUM GENET, V65, P657, DOI 10.1038/s10038-020-0750-x
   Hoffmann TJ, 2015, CANCER DISCOV, V5, P878, DOI 10.1158/2159-8290.CD-15-0315
   Hoffmann TJ, 2011, GENOMICS, V98, P79, DOI 10.1016/j.ygeno.2011.04.005
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Ioannidis JPA, 2018, BEHAV BRAIN SCI, V41, DOI 10.1017/S0140525X18000729
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kopf PG, 2010, TOXICOL SCI, V117, P537, DOI 10.1093/toxsci/kfq218
   Kvale MN, 2015, GENETICS, V200, P1051, DOI 10.1534/genetics.115.178905
   Li MY, 2014, HUM MOL GENET, V23, P4001, DOI 10.1093/hmg/ddu114
   Li QZ, 2015, AM J TRANSL RES, V7, P393
   Liang QN, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12917-9
   MACHIELA MJ, 2015, BIOINFORMATICS, V31, P3555, DOI DOI 10.1093/BI0INF0RMATICS/BTV402
   Masland RH, 2012, NEURON, V76, P266, DOI 10.1016/j.neuron.2012.10.002
   Menon M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12780-8
   Mir R, 2019, ENDOCR METAB IMMUNE, V19, P1216, DOI 10.2174/1871530319666190417111940
   Ongen H, 2016, BIOINFORMATICS, V32, P1479, DOI 10.1093/bioinformatics/btv722
   Orozco LD, 2020, CELL REP, V30, P1246, DOI 10.1016/j.celrep.2019.12.082
   Paul S, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9071698
   Perepechaeva ML, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/530943
   Pollard KS, 2005, STAT BIOL HEALTH, P249
   Pruim RJ, 2010, BIOINFORMATICS, V26, P2336, DOI 10.1093/bioinformatics/btq419
   R Core Team, 2011, R LANG ENV STAT COMP, V1
   Ratnapriya R, 2019, NAT GENET, V51, P606, DOI 10.1038/s41588-019-0351-9
   Rheaume BA, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05134-3
   Shi ZQ, 2010, MOL PHARMACOL, V78, P46, DOI 10.1124/mol.110.063438
   Sticht C, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0206239
   Strunz T, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9102267
   Strunz T, 2020, PLOS GENET, V16, DOI 10.1371/journal.pgen.1008934
   Tower J, 2017, TRENDS ENDOCRIN MET, V28, P735, DOI 10.1016/j.tem.2017.07.002
   Turley P, 2018, NAT GENET, V50, P229, DOI 10.1038/s41588-017-0009-4
   Zhang NS, 2019, LAB INVEST, V99, P568, DOI 10.1038/s41374-018-0164-y
   Zheng XW, 2012, BIOINFORMATICS, V28, P3326, DOI 10.1093/bioinformatics/bts606
NR 63
TC 4
Z9 4
U1 0
U2 3
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2073-4409
J9 CELLS-BASEL
JI Cells
PD OCT
PY 2020
VL 9
IS 10
AR 2257
DI 10.3390/cells9102257
PG 18
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA OH4UQ
UT WOS:000582571600001
PM 33050031
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Mousavi, E
   Kafieh, R
   Rabbani, H
AF Mousavi, Elahe
   Kafieh, Rahele
   Rabbani, Hossein
TI Classification of dry age-related macular degeneration and diabetic
   macular oedema from optical coherence tomography images using dictionary
   learning
SO IET IMAGE PROCESSING
LA English
DT Article
DE feature extraction; vision defects; image classification; diseases;
   image segmentation; eye; biomedical optical imaging; medical image
   processing; optical tomography; dry age-related macular degeneration;
   diabetic macular oedema; optical coherence tomography images; AMD; DME;
   vision loss; developed countries; retinal layer structure; diseases;
   automatic classification; classification algorithm; retinal layer
   segmentation; normal region identifications; abnormal region
   identifications; local intensity gradients; dictionary learning-based
   classifiers; normal subjects; normal OCT images; edge directions;
   extracted features
ID DME
AB Age-related Macular Degeneration (AMD) and Diabetic Macular Edema (DME) are the major causes of vision loss in developed countries. Alteration of retinal layer structure and appearance of exudates are the most significant signs of these diseases. In this paper, with the aim of automatic classification of DME, AMD, and normal subjects using Optical Coherence Tomography (OCT) images, a dictionary-learning based classification is proposed. The two important issues intended in this approach are avoiding retinal layer segmentation and attempting to mimic the authors' understanding based on normal and abnormal region identifications, considering that the signs of diseases appear in a small fraction of B-Scans. The histogram of oriented gradients feature descriptor was utilized to characterize the distribution of local intensity gradients and edge directions. To capture the structure of extracted features, different dictionary learning-based classifiers are employed. The dataset consists of 45 subjects: 15 patients with AMD, 15 patients with DME, and 15 normal subjects. The proposed classifier leads to an accuracy of 95.13, 100.00, and 100.00% for DME, AMD, and normal OCT images, respectively, only by considering 4% of all B-Scans of a volume, which outperforms the state-of-the-art methods.
C1 [Mousavi, Elahe] Isfahan Univ Med Sci, Sch Adv Technol Med, Student Res Comm, Esfahan, Iran.
   [Kafieh, Rahele; Rabbani, Hossein] Isfahan Univ Med Sci, Sch Adv Technol Med, Med Image & Signal Proc Res Ctr, Esfahan, Iran.
C3 Isfahan University Medical Science; Isfahan University Medical Science
RP Kafieh, R (通讯作者)，Isfahan Univ Med Sci, Sch Adv Technol Med, Med Image & Signal Proc Res Ctr, Esfahan, Iran.
EM r_kafieh@yahoo.com
RI kafieh, rahele/E-6456-2012
OI kafieh, rahele/0000-0003-0087-9476
CR Albarrak A, 2013, P 2013 INT C MED IM, P59
   Amini Z, 2017, J BIOMED OPT, V22, DOI 10.1117/1.JBO.22.8.086011
   Amini Z, 2016, IEEE T MED IMAGING, V35, P1544, DOI 10.1109/TMI.2016.2519439
   Apostolopoulos S., 2016, ARXIV161003628
   Dalal N., 2005, CVPR
   Erginay A, 2014, ESASO COURSE SER, V4, P62, DOI 10.1159/000355918
   Farsiu S, 2014, OPHTHALMOLOGY, V121, P162, DOI 10.1016/j.ophtha.2013.07.013
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Furtado PGF, 2017, 25TH INTERNATIONAL CONFERENCE ON COMPUTERS IN EDUCATION (ICCE 2017), P11
   Kong S, 2012, LECT NOTES COMPUT SC, V7572, P186, DOI 10.1007/978-3-642-33718-5_14
   Lee CS, 2017, OPHTHALMOL RETINA, V1, P322, DOI 10.1016/j.oret.2016.12.009
   Liu YY, 2011, MED IMAGE ANAL, V15, P748, DOI 10.1016/j.media.2011.06.005
   Mahdizadehaghdam S, 2019, IEEE T IMAGE PROCESS, V28, P4790, DOI 10.1109/TIP.2019.2914376
   Rabbani H, 2008, IEEE T BIO-MED ENG, V55, P2152, DOI 10.1109/TBME.2008.923140
   Sidibe D, 2017, COMPUT METH PROG BIO, V139, P109, DOI 10.1016/j.cmpb.2016.11.001
   Srinivasan PP, 2014, BIOMED OPT EXPRESS, V5, P3568, DOI 10.1364/BOE.5.003568
   Sun YK, 2017, J BIOMED OPT, V22, DOI 10.1117/1.JBO.22.1.016012
   Tan GS, 2017, LANCET DIABETES ENDO, V5, P143, DOI 10.1016/S2213-8587(16)30052-3
   Tosic I, 2011, IEEE SIGNAL PROC MAG, V28, P27, DOI 10.1109/MSP.2010.939537
   Vu TH, 2017, IEEE T IMAGE PROCESS, V26, P5160, DOI 10.1109/TIP.2017.2729885
   Wang Y, 2016, BIOMED OPT EXPRESS, V7, P4928, DOI 10.1364/BOE.7.004928
   Yang M, 2014, INT J COMPUT VISION, V109, P209, DOI 10.1007/s11263-014-0722-8
   Zhang YG, 2014, EURASIP J ADV SIG PR, DOI 10.1186/1687-6180-2014-17
NR 23
TC 3
Z9 3
U1 0
U2 7
PU INST ENGINEERING TECHNOLOGY-IET
PI HERTFORD
PA MICHAEL FARADAY HOUSE SIX HILLS WAY STEVENAGE, HERTFORD SG1 2AY, ENGLAND
SN 1751-9659
EI 1751-9667
J9 IET IMAGE PROCESS
JI IET Image Process.
PD JUN 19
PY 2020
VL 14
IS 8
BP 1571
EP 1579
DI 10.1049/iet-ipr.2018.6186
PG 9
WC Computer Science, Artificial Intelligence; Engineering, Electrical &
   Electronic; Imaging Science & Photographic Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Computer Science; Engineering; Imaging Science & Photographic Technology
GA LU7RZ
UT WOS:000537949300015
OA Bronze
DA 2022-11-30
ER

PT J
AU Subhi, Y
   Sorensen, TL
AF Subhi, Yousif
   Sorensen, Torben Lykke
TI Neovascular Age-Related Macular Degeneration in the Very Old (>= 90
   Years): Epidemiology, Adherence to Treatment, and Comparison of Efficacy
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID VISUAL OUTCOMES; SUBGROUP ANALYSIS; RANIBIZUMAB; BEVACIZUMAB; ANCHOR;
   MARINA
AB Purpose. To investigate neovascular age-related macular degeneration (AMD) in patients aged >= 90 years from several perspectives for a comprehensive overview: prevalence, presenting characteristics, treatment adherence, reasons for discontinuation, and efficacy of antivascular endothelial growth factor (VEGF) treatment comparing Ranibizumab and Aflibercept. Methods. In this retrospective chart review, we determined the prevalence and presenting characteristics by reviewing all data for patients referred to our department with treatment-naive neovascular AMD. By looking at historical cohorts, we determined adherence to treatment, reasons for discontinuation, and treatment outcomes after loading dose, 12 months, and 24 months. Results. Patients aged >= 90 years constituted 7% of the patients. Treatment was discontinued in 51%, primarily because of death and treatment burden. Mean change in best-corrected visual acuity was 3.2, 1.5, and -2.2 ETDRS letters at 4, 12, and 24 months, respectively. Aflibercept was superior to Ranibizumab in visual and anatomic outcomes. After two years of treatment, patients losing >= 15 ETDRS letters made up 19% in the Aflibercept group and 26% in the Ranibizumab group. Conclusions. We propose that the very old patients with neovascular AMD may constitute a distinctive group warranting special attention and possibilities for individualized therapy. Possible differences between anti-VEGF agents need further investigations.
C1 [Subhi, Yousif; Sorensen, Torben Lykke] Zealand Univ Hosp, Dept Ophthalmol, Clin Eye Res Div, Roskilde, Denmark.
   [Subhi, Yousif; Sorensen, Torben Lykke] Univ Copenhagen, Fac Hlth & Med Sci, Copenhagen, Denmark.
C3 University of Copenhagen
RP Subhi, Y (通讯作者)，Zealand Univ Hosp, Dept Ophthalmol, Clin Eye Res Div, Roskilde, Denmark.; Subhi, Y (通讯作者)，Univ Copenhagen, Fac Hlth & Med Sci, Copenhagen, Denmark.
EM ysubhi@gmail.com
RI Subhi, Yousif/ABG-6330-2020
OI Subhi, Yousif/0000-0001-6620-5365
FU Novartis; Bayer
FX Author Torben Lykke Sorensen declares that there is no conflict of
   interest regarding the publication of this paper. Author Yousif Subhi
   has previously received travel grants from Novartis and Bayer.
CR Beaumont P. E., OPHTHALMOLOGY, V121
   Bhisitkul RB, 2015, AM J OPHTHALMOL, V159, P915, DOI 10.1016/j.ajo.2015.01.032
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Brinkmann M. P., 2014, INVEST OPHTHALMOL, V55
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chen M, 2016, AGING CELL, V15, P436, DOI 10.1111/acel.12447
   Csaky KG, 2008, INVEST OPHTH VIS SCI, V49, P479, DOI 10.1167/iovs.07-1132
   Danish Ophthalmological Society, 2017, TREATM REC INCL MED
   Danyliv A, 2017, ADV THER, V34, P611, DOI 10.1007/s12325-017-0484-0
   Falk MK, 2013, AM J OPHTHALMOL, V155, P89, DOI 10.1016/j.ajo.2012.06.031
   Fang K, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/676049
   Finger RP, 2014, SURV OPHTHALMOL, V59, P1, DOI 10.1016/j.survophthal.2013.03.009
   GAO H, 1992, INVEST OPHTH VIS SCI, V33, P1
   Hao Yi, 2016, J Clin Exp Ophthalmol, V7
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Kaiser Peter K, 2009, Trans Am Ophthalmol Soc, V107, P311
   Klettner A, 2014, GRAEF ARCH CLIN EXP, V252, P1593, DOI 10.1007/s00417-014-2719-y
   Levy Jaime, 2009, International Ophthalmology, V29, P349, DOI 10.1007/s10792-008-9243-1
   Lim JH, 2012, AM J OPHTHALMOL, V153, P678, DOI 10.1016/j.ajo.2011.09.013
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Newcombe RG, 1998, STAT MED, V17, P873, DOI 10.1002/(SICI)1097-0258(19980430)17:8<873::AID-SIM779>3.0.CO;2-I
   Puts MTE, 2015, CANCER TREAT REV, V41, P197, DOI 10.1016/j.ctrv.2014.12.010
   Rasmussen A, 2015, ACTA OPHTHALMOL, V93, P616, DOI 10.1111/aos.12781
   Rasul A, 2016, DAN MED J, V63
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sawilowsky SS, 2009, J MOD APPL STAT METH, V8, P597, DOI 10.22237/jmasm/1257035100
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Shin JY, 2014, RETINA-J RET VIT DIS, V34, P2359, DOI 10.1097/IAE.0000000000000225
   Sorensen Torben Lykke, 2010, Ugeskr Laeger, V172, P1685
   Statistics Denmark, 2017, POP DENM
   Subhi Y., 2016, ACTA OPHTHALMOLOGICA
   Subhi Y, 2016, DAN MED J, V63
   Subhi Y, 2016, AGEING RES REV, V29, P42, DOI 10.1016/j.arr.2016.05.013
   Subhi Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091227
   Tsilimbaris MK, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/4367631
   van Asten F, 2014, OPHTHAL EPIDEMIOL, V21, P347, DOI 10.3109/09286586.2014.949010
   Wickremasinghe SS, 2011, INVEST OPHTH VIS SCI, V52, P4072, DOI 10.1167/iovs.10-6550
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yamashiro K, 2012, AM J OPHTHALMOL, V154, P125, DOI 10.1016/j.ajo.2012.01.010
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
NR 41
TC 25
Z9 25
U1 0
U2 1
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PY 2017
VL 2017
AR 7194927
DI 10.1155/2017/7194927
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EY2EN
UT WOS:000403781400001
PM 28660080
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Matias, I
   Wang, JW
   Morlello, AS
   Nieves, A
   Woodward, DF
   Di Marzo, V
AF Matias, I.
   Wang, J. W.
   Morlello, A. Schiano
   Nieves, A.
   Woodward, D. F.
   Di Marzo, V.
TI Changes in endocannabinoid and palmitoylethanolamide levels in eye
   tissues of patients with diabetic retinopathy and age-related macular
   degeneration
SO PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS
LA English
DT Article
ID CANNABINOID CB1 RECEPTORS; ACID AMIDE HYDROLASE; INTRAOCULAR-PRESSURE;
   MESSENGER-RNA; ANANDAMIDE; RAT; SYSTEM; LOCALIZATION; EXPRESSION;
   ACTIVATION
AB Cannabinoid receptors and the endocannabinoids (anandamide (N-arachidonoylethanolamine-AEA) and 2-arachidonoylglycerol (2-AG)), as well as the AEA congener, palmitoylethanolamide (PEA), are involved in ocular physiology. We measured endocannabinoid and PEA levels by isotope-dilution liquid chromatography-mass spectrometric analysis in post-mortem eye tissues of patients with diabetic retinopathy (DR) or age-related macular degeneration (AMD). In eyes with DR, significantly enhanced levels of AEA were found in the retina (similar to 1.8-fold), ciliary body (similar to 1.5-fold) and, to a lesser extent, cornea (similar to 1.3-fold). Surprisingly, 2-AG levels were significantly higher (similar to 3-fold) only in the iris, whereas PEA levels only slightly increased (similar to 1.3-fold) in the ciliary body. In eyes with AMD, significantly enhanced levels of AEA were found in the choroid (similar to 1.3-fold), ciliary body (similar to 1.4-fold) and cornea (similar to 1.4-fold), whereas in the retina only a trend towards an increase (similar to 1.5-fold) was observed. The tissue- and disease-selective nature of the changes observed suggests that the compounds analyzed here may play different roles in the control of eye function under different pathological conditions. (c) 2006 Elsevier Ltd. All rights reserved.
C1 CNR, Inst Biomol Chem, Endocannabinoid Res Grp, I-80072 Naples, Italy.
   Allergan Pharmaceut Inc, Dept Biol Sci, Irvine, CA 92715 USA.
C3 Consiglio Nazionale delle Ricerche (CNR); AbbVie; Allergan
RP Di Marzo, V (通讯作者)，CNR, Inst Biomol Chem, Endocannabinoid Res Grp, Via Toiano 6, I-80072 Naples, Italy.
EM vdimarzo@icmib.na.cnr.it
RI Di Marzo, Vincenzo/AAD-7742-2019
OI Di Marzo, Vincenzo/0000-0002-1490-3070
CR Chen J, 2005, BIOCHEM BIOPH RES CO, V330, P1062, DOI 10.1016/j.bbrc.2005.03.095
   Chien FY, 2003, ARCH OPHTHALMOL-CHIC, V121, P87
   Conley YP, 2005, HUM MOL GENET, V14, P1991, DOI 10.1093/hmg/ddi204
   De Petrocellis L, 2005, LIFE SCI, V77, P1651, DOI 10.1016/j.lfs.2005.05.021
   De Petrocellis L, 2001, FEBS LETT, V506, P253, DOI 10.1016/S0014-5793(01)02934-9
   De Petrocellis L, 2004, BRIT J PHARMACOL, V141, P765, DOI 10.1038/sj.bjp.0705666
   DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919
   Di Marzo V, 2004, NAT REV DRUG DISCOV, V3, P771, DOI 10.1038/nrd1495
   Di Marzo V, 2006, ANNU REV MED, V57, P553, DOI 10.1146/annurev.med.57.011205.135648
   Di Marzo V, 2001, NATURE, V410, P822, DOI 10.1038/35071088
   Di Marzo V, 2002, PROSTAG LEUKOTR ESS, V66, P377, DOI 10.1054/plef.2001.0349
   Di Marzo V, 2001, BIOCHEM J, V358, P249, DOI 10.1042/0264-6021:3580249
   El-Remessy AB, 2006, AM J PATHOL, V168, P235, DOI 10.2353/ajpath.2006.050500
   Fan SF, 2003, VISUAL NEUROSCI, V20, P177, DOI 10.1017/S095252380320208X
   Funatsu H, 2002, DRUG NEWS PERSPECT, V15, P633, DOI 10.1358/dnp.2002.15.10.840018
   Gardner T W, 2000, Diabetes Technol Ther, V2, P601
   Gryziewicz L, 2005, ADV DRUG DELIVER REV, V57, P2092, DOI 10.1016/j.addr.2005.09.009
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hamdi HK, 2003, FRONT BIOSCI-LANDMRK, V8, pE305, DOI 10.2741/1019
   Howlett AC, 2002, PHARMACOL REV, V54, P161, DOI 10.1124/pr.54.2.161
   Jarvinen T, 2002, PHARMACOL THERAPEUT, V95, P203, DOI 10.1016/S0163-7258(02)00259-0
   Laine K, 2002, INVEST OPHTH VIS SCI, V43, P3216
   Laine K, 2001, PHARMACEUT RES, V18, P494, DOI 10.1023/A:1011058411804
   Lambert DM, 1999, CURR MED CHEM, V6, P757
   Lambert DM, 2002, CURR MED CHEM, V9, P663, DOI 10.2174/0929867023370707
   LoVerme J, 2005, LIFE SCI, V77, P1685, DOI 10.1016/j.lfs.2005.05.012
   Lu QJ, 2000, VISUAL NEUROSCI, V17, P91, DOI 10.1017/S0952523800171093
   Nilsson SFE, 2001, INVEST OPHTH VIS SCI, V42, P1038
   PANIKASHVILI D, 2005, NEUROBIOL DIS, V16
   Pate DW, 1998, LIFE SCI, V63, P2181, DOI 10.1016/S0024-3205(98)00499-8
   Pegorini S, 2005, BRIT J PHARMACOL, V144, P727, DOI 10.1038/sj.bjp.0706115
   Porcella A, 2001, EUR J NEUROSCI, V13, P409, DOI 10.1046/j.0953-816X.2000.01401.x
   Porcella A, 1998, MOL BRAIN RES, V58, P240, DOI 10.1016/S0169-328X(98)00105-3
   Porcella A, 2000, EUR J NEUROSCI, V12, P1123, DOI 10.1046/j.1460-9568.2000.01027.x
   Pryce G, 2003, BRAIN, V126, P2191, DOI 10.1093/brain/awg224
   Romero J, 2002, PHARMACOL THERAPEUT, V95, P137, DOI 10.1016/S0163-7258(02)00253-X
   Ross RA, 2003, BRIT J PHARMACOL, V140, P790, DOI 10.1038/sj.bjp.0705467
   Savinainen JR, 2004, CELL MOL NEUROBIOL, V24, P243, DOI 10.1023/B:CEMN.0000018619.18631.53
   Schlicker E, 1996, N-S ARCH PHARMACOL, V354, P791, DOI 10.1007/BF00166907
   Sen K, 2002, DIABETES RES CLIN PR, V56, P1, DOI 10.1016/S0168-8227(01)00341-2
   Stamer WD, 2001, EUR J PHARMACOL, V431, P277, DOI 10.1016/S0014-2999(01)01438-8
   Straiker A, 1999, P NATL ACAD SCI USA, V96, P14565, DOI 10.1073/pnas.96.25.14565
   Straiker A, 2003, J NEUROPHYSIOL, V89, P2647, DOI 10.1152/jn.00268.2002
   Straiker AJ, 1999, INVEST OPHTH VIS SCI, V40, P2442
   Sugiura T, 2000, CHEM PHYS LIPIDS, V108, P89, DOI 10.1016/S0009-3084(00)00189-4
   Veldhuis WB, 2003, J NEUROSCI, V23, P4127
   Yazulla S, 1999, J COMP NEUROL, V415, P80, DOI 10.1002/(SICI)1096-9861(19991206)415:1<80::AID-CNE6>3.0.CO;2-H
   Yazulla S, 2000, VISUAL NEUROSCI, V17, P391, DOI 10.1017/S0952523800173079
   Yazulla S, 2004, J COMP NEUROL, V474, P407, DOI 10.1002/cne.20144
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 50
TC 65
Z9 66
U1 0
U2 7
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0952-3278
EI 1532-2823
J9 PROSTAG LEUKOTR ESS
JI Prostaglandins Leukot. Essent. Fatty Acids
PD DEC
PY 2006
VL 75
IS 6
BP 413
EP 418
DI 10.1016/j.plefa.2006.08.002
PG 6
WC Biochemistry & Molecular Biology; Cell Biology; Endocrinology &
   Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Endocrinology &
   Metabolism
GA 114QL
UT WOS:000242680600008
PM 17011761
DA 2022-11-30
ER

PT J
AU Calles-Monar, PS
   Sanabria, MR
   Alonso-Tarancon, AM
   Coco-Martin, RM
   Mayo-Iscar, A
AF Calles-Monar, Paola S.
   Sanabria, Maria R.
   Alonso-Tarancon, Ana M.
   Coco-Martin, Rosa M.
   Mayo-Iscar, Agustin
TI Modifiable Determinants of Satisfaction with Intravitreal Treatment in
   Patients with Neovascular Age-Related Macular Degeneration
SO DRUGS & AGING
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; QUALITY-OF-LIFE; FOLLOW-UP; RANIBIZUMAB;
   EXPERIENCES; PREVALENCE; INJECTIONS; REGIMEN; BURDEN; VEGF
AB Background The success of intravitreal treatment for neovascular age-related macular degeneration (nAMD) depends on maximal adherence to treatment, which in turn requires patient satisfaction. Objective The aim of this study was to assess the factors associated with nAMD patient satisfaction to implement actions to improve treatment experiences and increase adherence. Design This was a prospective, observational, analytical, cross-sectional study. Subjects Our study included 100 consecutive nAMD patients under intravitreal treatment for at least 1 year. Methods Patients completed the Macular Disease Treatment Satisfaction Questionnaire (MacTSQ) and the EuroQol Visual Analog Scale (EQ VAS). A logistic regression was estimated to model the low values of the satisfaction score (MacTSQ < 50). Results The mean age of patients was 82.1 +/- 7.8 years and 62% were female. Males (p = 0.002) and patients who improved their visual acuity (p = 0.004) were more satisfied, while patients who received a higher number of injections (p = 0.036) and treatment in both eyes (p = 0.001) were less satisfied. Higher health-related quality of life was related to higher satisfaction. The sensitivity and specificity of the predictive model were 75.8% and 76.1%, respectively. Factors independently associated with low satisfaction were female sex (odds ratio [OR] 6.84), going to the clinic alone (OR 8.51), longer duration of treatment (OR 0.62), receiving treatment in both eyes (OR 3.54), and suffering a decline in visual acuity (OR 3.30). The questionnaire revealed patients' needs for more information and injection points closer to their homes. Conclusions Well-defined areas for improvement were identified, i.e. to improve the information offered to each patient, to incorporate new long-acting drugs, and to establish locations for injection services in peripheral areas.
C1 [Calles-Monar, Paola S.; Sanabria, Maria R.; Alonso-Tarancon, Ana M.] San Telmo Hosp, Ophthalmol Dept, Palencia Univ Hosp Complex, Palencia 34004, Spain.
   [Coco-Martin, Rosa M.] Univ Valladolid, Inst Appl Ophthalmobiol, Valladolid, Spain.
   [Coco-Martin, Rosa M.] Carlos III Hlth Inst, OFTARED Hlth Res Themat Network, Madrid, Spain.
   [Mayo-Iscar, Agustin] Univ Valladolid, Dept Stat & OR, Valladolid, Spain.
   [Mayo-Iscar, Agustin] Univ Valladolid, IMUVA, Valladolid, Spain.
C3 Universidad de Valladolid; Universidad de Valladolid; Universidad de
   Valladolid
RP Calles-Monar, PS (通讯作者)，San Telmo Hosp, Ophthalmol Dept, Palencia Univ Hosp Complex, Palencia 34004, Spain.
EM paolacallesm@gmail.com
RI Martin, Rosa Maria Coco/H-4511-2015
OI Martin, Rosa Maria Coco/0000-0002-1811-1417; Calles Monar, Paola
   Stefania/0000-0002-3749-3609
FU Gerencia Regional de Salud de Castilla-Leon [GRS 2111/A/19]; Spanish
   Ministerio de Economia y Competitividad [MTM2017-86061-C2-1-P];
   Consejeria de Educacion de la Junta de Castilla y Leon; FEDER [VA005P17,
   VA002G18]
FX This research was supported by a grant from Gerencia Regional de Salud
   de Castilla-Leon (GRS 2111/A/19). Agustin Mayo-Iscar has been partially
   supported by the Spanish Ministerio de Economia y Competitividad (grant
   MTM2017-86061-C2-1-P) and by Consejeria de Educacion de la Junta de
   Castilla y Leon and FEDER (grants VA005P17 and VA002G18)
CR Al-Jabi SW, 2015, HEALTH EXPECT, V18, P3336, DOI 10.1111/hex.12324
   American Academy of Ophthalmology, AGE RELATED MACULAR
   [Anonymous], 2016, PATIENT ENGAGEMENT T
   Bamm EL, 2013, DISABIL REHABIL, V35, P766, DOI 10.3109/09638288.2012.707746
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Boulanger-Scemama E, 2015, J FR OPHTALMOL, V38, P620, DOI 10.1016/j.jfo.2014.11.015
   Boyle Jessica, 2018, Psychol Health Med, V23, P127, DOI 10.1080/13548506.2016.1274040
   Boyle J, 2015, PSYCHOL HEALTH MED, V20, P296, DOI 10.1080/13548506.2014.936886
   Casaroli-Marano R, 2011, BRIT J OPHTHALMOL, V95, P931, DOI 10.1136/bjo.2010.187773
   Chakravarthy U, 2015, HEALTH TECHNOL ASSES, V19, P1, DOI 10.3310/hta19780
   Chang A, 2021, PATIENT PREFER ADHER, V15, P511, DOI 10.2147/PPA.S293941
   Chong V, 2016, EYE, V30, P270, DOI 10.1038/eye.2015.217
   de Boer AGEM, 2004, QUAL LIFE RES, V13, P311, DOI 10.1023/B:QURE.0000018499.64574.1f
   Engelbert M, 2010, RETINA-J RET VIT DIS, V30, P1368, DOI 10.1097/IAE.0b013e3181d50cbf
   Erke MG, 2012, OPHTHALMOLOGY, V119, P1737, DOI 10.1016/j.ophtha.2012.03.016
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gianniou C, 2015, EYE, V29, P342, DOI 10.1038/eye.2014.258
   Gohil R, 2016, PATIENT PREFER ADHER, V10, P949, DOI 10.2147/PPA.S105536
   Granstam E, 2016, ACTA OPHTHALMOL, V94, P646, DOI 10.1111/aos.13187
   HALL JA, 1990, SOC SCI MED, V30, P811, DOI 10.1016/0277-9536(90)90205-7
   Holladay JT, 2004, J CATARACT REFR SURG, V30, P287, DOI 10.1016/j.jcrs.2004.01.014
   Hosmer DW, 2013, WILEY SER PROBAB ST, P153
   INE, CIFR POBL CENS DEM
   Instituto Nacional de Estadistica de Espana (INE), DEM POB
   Instituto Nacional de Estadistica de Espana (INE), 2018, PROD SERV
   Kandula S, 2010, CLIN OPHTHALMOL, V4, P375
   Kaplan RS., 2021, NEJM CATAL, DOI [10.1056/CAT.20.0527, DOI 10.1056/CAT.20.0527]
   Marakis TP, 2018, INT OPHTHALMOL, V38, P565, DOI 10.1007/s10792-017-0492-8
   McClard CK, 2021, BMJ OPEN OPHTHALMOL, V6, DOI 10.1136/bmjophth-2020-000669
   Mitchell AP, 2014, J CLIN ONCOL, V32, DOI 10.1200/jco.2014.32.15_suppl.6510
   Mitchell J, 2018, J PATIENT-REP OUTCOM, V2, DOI 10.1186/s41687-018-0031-z
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Muller S, 2017, GRAEF ARCH CLIN EXP, V255, P2237, DOI 10.1007/s00417-017-3739-1
   Prenner JL, 2015, AM J OPHTHALMOL, V160, P725, DOI 10.1016/j.ajo.2015.06.023
   Sanabria MR, 2013, CURR EYE RES, V38, P278, DOI 10.3109/02713683.2012.758290
   Schriefer D, 2020, PATIENT PREFER ADHER, V14, P869, DOI 10.2147/PPA.S248272
   Shatz W, 2019, EXPERT OPIN DRUG DEL, V16, P43, DOI 10.1080/17425247.2019.1553953
   Sii S, 2018, EYE, V32, P673, DOI 10.1038/eye.2017.271
   Sixma HJ, 1998, MED CARE, V36, P212, DOI 10.1097/00005650-199802000-00010
   The Statistical Office of theEuropean Union (Eurostat), AG EUR STAT HLTH DIS
   Thiedke C Carolyn, 2007, Fam Pract Manag, V14, P33
NR 42
TC 0
Z9 0
U1 1
U2 1
PU ADIS INT LTD
PI NORTHCOTE
PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
SN 1170-229X
EI 1179-1969
J9 DRUG AGING
JI Drugs Aging
PD MAY
PY 2022
VL 39
IS 5
BP 355
EP 366
DI 10.1007/s40266-022-00937-y
EA APR 2022
PG 12
WC Geriatrics & Gerontology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology; Pharmacology & Pharmacy
GA 1U7GQ
UT WOS:000789012200001
PM 35486357
DA 2022-11-30
ER

PT J
AU Holton, H
   Christiansen, AB
   Albeck, MJ
   Johnsen, CR
AF Holton, Henrik
   Christiansen, Asger B.
   Albeck, Michael J.
   Johnsen, Claus R.
TI The impact of light source on discrimination ability in subjects with
   age-related macular degeneration
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration; contrast sensitivity; fluorescent
   light; halogen incandescent light; photopic spectral analysis
ID CONTRAST SENSITIVITY; RELIABILITY; PERFORMANCE; ADAPTATION; MOBILITY;
   PEOPLE; ACUITY; FALLS
AB Purpose: To examine the influence of light source on letter contrast sensitivity in subjects with age-related macular degeneration (AMD).
   Methods: Halogen incandescent bulbs and low-energy fluorescent tubes were tested with 70 subjects with AMD. The subjects' contrast sensitivity was determined in a randomized single-blind crossover study for each light source using photopically illuminated Pelli Robson contrast sensitivity charts. The test subjects' subjective light source preference was also determined.
   Results: The mean contrast sensitivity for the incandescent light source was 1.28 +/- 0.29 (mean +/- SD), and for the fluorescent light source 1.17 +/- 0.29, p < 0.001. The illuminance was 338 lux (+/- 9) for the incandescent light, and 339 lux (+/- 11) for the fluorescent light. Forty-nine subjects preferred the incandescent light source, while none preferred the fluorescent light source for maximum detail and clarity. Nineteen had no preference. This finding is statistically significant. Fifteen of the 19 subjects without a preference had no difference in contrast sensitivity, which supports their lack of preference. There was no significant difference with regard to sex or order of exposure to light source. Subjects with AMD had significantly reduced contrast sensitivity compared with expected normal values. We found no relationship between visual acuity and contrast sensitivity.
   Conclusion: We are only able to recommend photopic full spectral radiance incandescent light sources to visually impaired subjects for their domestic surroundings. Furthermore, we recommend the use of full spectral radiance light sources for the illumination of Pelli-Robson contrast sensitivity charts. Given equal illuminance, as in our study, the findings show that contrast sensitivity was better by illumination with incandescent light with full spectral radiance compared with fluorescent light with interrupted spectral radiance.
C1 [Holton, Henrik] Municipal Resource Ctr Blind & Visually Impaired, Vordingborg, Denmark.
   [Christiansen, Asger B.] Lab Light & Vis, Copenhagen, Denmark.
   [Albeck, Michael J.] Odense Univ Hosp, Dept Neurosurg, DK-5000 Odense, Denmark.
   [Johnsen, Claus R.] Roskilde Hosp, Dept Med, Roskilde, Region Zealand, Denmark.
C3 University of Southern Denmark; Odense University Hospital
RP Holton, H (通讯作者)，Faergegaardsvej 15 H, DK-4760 Vordingborg, Denmark.
EM schh@vordingborg.dk
CR Algvere PV, 2006, ACTA OPHTHALMOL SCAN, V84, P4, DOI 10.1111/j.1600-0420.2005.00627.x
   American Academy of Ophthalmology Refractive Errors Panel, 1994, PREF PRACT PATT REH
   American Academy of Ophthalmology Refractive Errors Panel, 2007, PREF PRACT PATT REH
   Anand V, 2003, INVEST OPHTH VIS SCI, V44, P2885, DOI 10.1167/iovs.02-1031
   Brunnstrom G, 2004, OPHTHAL PHYSL OPT, V24, P274, DOI 10.1111/j.1475-1313.2004.00192.x
   CUMMINGS SR, 1995, NEW ENGL J MED, V332, P767, DOI 10.1056/NEJM199503233321202
   de Boer MR, 2004, J BONE MINER RES, V19, P1539, DOI 10.1359/JBMR.040504
   ELLIOTT DB, 1990, OPHTHAL PHYSL OPT, V10, P21, DOI 10.1111/j.1475-1313.1990.tb01100.x
   ELLIOTT DB, 1993, INVEST OPHTH VIS SCI, V34, P108
   ELLIOTT DB, 1995, OPHTHAL PHYSL OPT, V15, P553, DOI 10.1016/0275-5408(95)00025-9
   Eperjesi F, 2007, OPHTHAL PHYSL OPT, V27, P93, DOI 10.1111/j.1475-1313.2006.00431.x
   Fosse P, 2001, OPTOMETRY VISION SCI, V78, P162, DOI 10.1097/00006324-200103000-00009
   FRENNESSON IC, 1993, DOC OPHTHALMOL, V84, P135, DOI 10.1007/BF01206248
   Ganslandt R, 1992, HDB LIGHTING DESIGN, p[35, 53]
   Haymes SA, 2006, OPHTHAL PHYSL OPT, V26, P169, DOI 10.1111/j.1475-1313.2006.00367.x
   HOFLING G, 1979, KLIN MONATSBL AUGENH, V175, P249
   KLEINER RC, 1988, ARCH OPHTHALMOL-CHIC, V106, P55
   Kuyk T, 1996, J Am Optom Assoc, V67, P403
   Kuyk T, 1999, J REHABIL RES DEV, V36, P303
   Lindner H, 2001, KLIN MONATSBL AUGENH, V218, P774, DOI 10.1055/s-2001-19688
   LORD SR, 1991, J AM GERIATR SOC, V39, P1194, DOI 10.1111/j.1532-5415.1991.tb03574.x
   Lord SR, 2006, AGE AGEING, V35, P42, DOI 10.1093/ageing/afl085
   Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P1496, DOI 10.1001/archopht.116.11.1496
   PELLI DG, 1988, CLIN VISION SCI, V2, P187
   Puell MC, 2004, J REFRACT SURG, V20, P484, DOI 10.3928/1081-597X-20040901-12
   Shady S, 2004, P NATL ACAD SCI USA, V101, P5170, DOI 10.1073/pnas.0303452101
   Swamy BN, 2009, ACTA OPHTHALMOL, V87, P335, DOI 10.1111/j.1755-3768.2008.01203.x
   Wagner HJ, 2005, PROG RETIN EYE RES, V24, P521, DOI 10.1016/j.preteyeres.2005.01.002
   Wilkins AJ., 1995, OXFORD PSYCHOL SERIE, V24
   Wood JM, 2005, OPTOMETRY VISION SCI, V82, P698, DOI 10.1097/01.opx.0000175562.27101.51
NR 30
TC 3
Z9 3
U1 0
U2 15
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD DEC
PY 2011
VL 89
IS 8
BP 779
EP 784
DI 10.1111/j.1755-3768.2009.01809.x
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 851OV
UT WOS:000297281600030
PM 20015100
OA Bronze
DA 2022-11-30
ER

PT J
AU Schmitz-Valckenberg, S
   Fleckenstein, M
   Helb, HM
   Issa, PC
   Scholl, HPN
   Holz, FG
AF Schmitz-Valckenberg, Steffen
   Fleckenstein, Monika
   Helb, Hans-Martin
   Issa, Peter Charbel
   Scholl, Hendrik P. N.
   Holz, Frank G.
TI In Vivo Imaging of Foveal Sparing in Geographic Atrophy Secondary to
   Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; SCANNING LASER OPHTHALMOSCOPE; OPTICAL
   COHERENCE TOMOGRAPHY; VISUAL-ACUITY LOSS; FUNDUS AUTOFLUORESCENCE;
   LIPOFUSCIN; MACULOPATHY; DYSFUNCTION; PROGRESSION; VULNERABILITY
AB PURPOSE. To investigate morphologic alterations in geographic atrophy caused by age-related macular degeneration (AMD) in the presence of foveal sparing using high-resolution in vivo imaging.
   METHODS. Simultaneous spectral domain optical coherence tomography (SD-OCT, 870 nm, 40,000 A-scans/s) and confocal scanning laser ophthalmoscopy (cSLO; fundus autofluorescence; excitation, 488 nm; emission, 500-700 nm) were performed in 18 eyes with geographic atrophy and foveal sparing using a combined instrument. Anatomic layers were evaluated, and retinal thickness in the fovea and the peripheral macula were measured and compared with those in controls of similar age.
   RESULTS. Fundus autofluorescence imaging showed an inhomogeneously reduced signal at the residual foveal island. SD-OCT scans disclosed mitigation of the foveal pit in the absence of extracellular fluid accumulation and an increased mean central retinal thickness of 248 +/- 28 mu m compared with 225 +/- 12 mu m in control eyes (P = 0.005). No difference in retinal thickness in the peripheral macula was observed (245 +/- 16 vs. 253 +/- 11 mu m; P = 0.6). Subanalysis revealed marked appearance of swelling and widening of visible structures at the central outer nuclear layer (153 +/- 22 mu m vs. 127 +/- 12 mu m; P = 0.003). Below the external limiting membrane, a broad band of irregular high reflectivity was detected instead of the normal three separate reflective bands.
   CONCLUSIONS. Thickening at the foveal site may reflect a pre-apoptotic stage of neuronal cellular elements indicating imminent atrophy. Limited structure-function correlation found in our study suggests that future therapeutic intervention may be beneficial in only a subset of AMD patients with foveal sparing. (Invest Ophthalmol Vis Sci. 2009; 50: 3915-3921) DOI: 10.1167/iovs.08-2484
C1 [Schmitz-Valckenberg, Steffen] Univ Bonn, Dept Ophthalmol, D-53127 Bonn, Germany.
   Univ Bonn, Grade Reading Ctr, D-53127 Bonn, Germany.
C3 University of Bonn; University of Bonn
RP Schmitz-Valckenberg, S (通讯作者)，Univ Bonn, Dept Ophthalmol, Ernst Abbe Str 2, D-53127 Bonn, Germany.
EM steffen.schmitz-valckenberg@ukb.uni-bonn.de
RI Issa, Peter Charbel/F-9603-2011; Issa, Peter Charbel/E-8935-2018; Issa,
   Peter Charbel/O-2580-2019
OI Issa, Peter Charbel/0000-0002-0351-6673; Issa, Peter
   Charbel/0000-0002-0351-6673; Fleckenstein, Monika/0000-0001-8321-8037
FU German Research Council [Ho 1926/3-1]; German Society of Ophthalmology
   Research [EU FP6]
FX Supported by German Research Council Grant Ho 1926/3-1 and by German
   Society of Ophthalmology Research Grant EU FP6.0
CR Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Bellmann C, 1997, OPHTHALMOLOGE, V94, P385, DOI 10.1007/s003470050130
   Bergmann M, 2004, FASEB J, V18, P562, DOI 10.1096/fj.03-0289fje
   Boulton M, 2001, EYE, V15, P384, DOI 10.1038/eye.2001.141
   Chen CZ, 2004, DOC OPHTHALMOL, V109, P1
   CHUANG EL, 1987, EYE, V1, P120, DOI 10.1038/eye.1987.18
   Curcio CA, 2001, EYE, V15, P376, DOI 10.1038/eye.2001.140
   CURCIO CA, 1993, INVEST OPHTH VIS SCI, V34, P3278
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   Drexler W, 2001, NAT MED, V7, P502, DOI 10.1038/86589
   FEENEYBURNS L, 1980, AM J OPHTHALMOL, V90, P783, DOI 10.1016/S0002-9394(14)75193-1
   Fleckenstein M, 2008, INVEST OPHTH VIS SCI, V49, P4137, DOI 10.1167/iovs.08-1967
   HELB HM, OPHTHALMOLO IN PRESS
   Holz F.G., 2007, ATLAS FUNDUS AUTOFLU, V1st ed.
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Jackson GR, 2002, AGEING RES REV, V1, P381, DOI 10.1016/S1568-1637(02)00007-7
   Katz ML, 2002, ARCH GERONTOL GERIAT, V34, P169, DOI 10.1016/S0167-4943(02)00005-5
   Katz ML, 2002, ARCH GERONTOL GERIAT, V34, P359, DOI 10.1016/S0167-4943(02)00012-2
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   MAGUIRE P, 1986, AM J OPHTHALMOL, V102, P621, DOI 10.1016/0002-9394(86)90535-0
   Owsley C, 2000, INVEST OPHTH VIS SCI, V41, P267
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SCHATZ H, 1989, OPHTHALMOLOGY, V96, P1541
   Schmitz-Valckenberg S, 2004, INVEST OPHTH VIS SCI, V45, P4470, DOI 10.1167/iovs.03-1311
   Schmitz-Valckenberg S, 2008, RETINA-J RET VIT DIS, V28, P385, DOI 10.1097/IAE.0b013e318164a907
   Schmitz-Valckenberg S, 2008, AM J OPHTHALMOL, V146, P183, DOI 10.1016/j.ajo.2008.04.006
   Schmitz-Valckenberg S, 2006, INVEST OPHTH VIS SCI, V47, P2648, DOI 10.1167/iovs.05-0892
   Schmitz-Valckenberg S, 2009, SURV OPHTHALMOL, V54, P96, DOI 10.1016/j.survophthal.2008.10.004
   Scholl HPN, 2004, INVEST OPHTH VIS SCI, V45, P574, DOI 10.1167/iovs.03-0495
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   Srinivasan VJ, 2008, INVEST OPHTH VIS SCI, V49, P1571, DOI 10.1167/iovs.07-0838
   Sunness JS, 2008, OPHTHALMOLOGY, V115, P1480, DOI 10.1016/j.ophtha.2008.03.009
   Sunness JS, 2007, OPHTHALMOLOGY, V114, P271, DOI 10.1016/j.ophtha.2006.09.016
   SUNNESS JS, 1995, AM J OPHTHALMOL, V119, P143, DOI 10.1016/S0002-9394(14)73866-8
   SUNNESS JS, 1995, INVEST OPHTH VIS SCI, V36, P1863
   Sunness JS, 1996, OPHTHALMOLOGY, V103, P1458, DOI 10.1016/S0161-6420(96)30483-1
   Sunness JS, 1999, MOL VIS, V5
   SUNNESS JS, 1989, OPHTHALMOLOGY, V96, P375, DOI 10.1016/S0161-6420(89)32883-1
   Sunness JS, 1997, OPHTHALMOLOGY, V104, P1677, DOI 10.1016/S0161-6420(97)30079-7
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   VONRUCKMANN A, 1995, BRIT J OPHTHALMOL, V79, P407, DOI 10.1136/bjo.79.5.407
   Wenzel A, 2005, PROG RETIN EYE RES, V24, P275, DOI 10.1016/j.preteyeres.2004.08.002
   Wojtkowski M, 2004, AM J OPHTHALMOL, V138, P412, DOI 10.1016/j.ajo.2004.04.049
NR 43
TC 63
Z9 64
U1 0
U2 1
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD AUG
PY 2009
VL 50
IS 8
BP 3915
EP 3921
DI 10.1167/iovs.08-2484
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 475XA
UT WOS:000268398000050
PM 19339734
DA 2022-11-30
ER

PT J
AU Ma, L
   Tang, FY
   Chu, WK
   Young, AL
   Brelen, ME
   Pang, CP
   Chen, LJ
AF Ma, Li
   Tang, Fang Yao
   Chu, Wai Kit
   Young, Alvin L.
   Brelen, Marten E.
   Pang, Chi Pui
   Chen, Li Jia
TI Association of toll-like receptor 3 polymorphism rs3775291 with
   age-related macular degeneration: a systematic review and meta-analysis
SO SCIENTIFIC REPORTS
LA English
DT Article
ID TOLL-LIKE RECEPTOR-3; POLYPOIDAL CHOROIDAL VASCULOPATHY; GENOME-WIDE
   ASSOCIATION; GEOGRAPHIC ATROPHY; OCULAR NEOVASCULARIZATION;
   GENETIC-VARIANTS; TLR3; SIRNA; SUPPRESSION; CHINESE
AB Association of a polymorphism rs3775291 in the toll-like receptor 3 (TLR3) gene with age-related macular degeneration (AMD) had been investigated intensively, with variable results across studies. Here we conducted a meta-analysis to verify the effect of rs3775291 on AMD. We searched for genetic association studies published in PubMed, EMBASE and Web of Science from start dates to March 10, 2015. Totally 235 reports were retrieved and 9 studies were included for meta-analysis, involving 7400 cases and 13579 controls. Summary odds ratios (ORs) with 95% confidence intervals (CIs) for alleles and genotypes were estimated. TLR3 rs3775291 was associated with both geographic atrophy (GA) and neovascular AMD (nAMD), with marginally significant pooled-P values. Stratification analysis by ethnicity indicated that rs3775291 was associated with all forms of AMD, GA and nAMD only in Caucasians (OR = 0.87, 0.78 and 0.77, respectively, for the TT genotype) but not in East Asians. However, the associations could not withstand Bonferroni correction. This meta-analysis has thus revealed suggestive evidence for TLR3 rs3775291 as an associated marker for AMD in Caucasians but not in Asians. This SNP may have only a small effect on AMD susceptibility. Further studies in larger samples are warranted to confirm its role.
C1 [Ma, Li; Tang, Fang Yao; Chu, Wai Kit; Young, Alvin L.; Brelen, Marten E.; Pang, Chi Pui; Chen, Li Jia] Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Hong Kong, Hong Kong, Peoples R China.
   [Young, Alvin L.; Brelen, Marten E.; Pang, Chi Pui; Chen, Li Jia] Prince Wales Hosp, Dept Ophthalmol & Visual Sci, Hong Kong, Hong Kong, Peoples R China.
C3 Chinese University of Hong Kong; Chinese University of Hong Kong; Prince
   of Wales Hospital
RP Chen, LJ (通讯作者)，Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Hong Kong, Hong Kong, Peoples R China.; Chen, LJ (通讯作者)，Prince Wales Hosp, Dept Ophthalmol & Visual Sci, Hong Kong, Hong Kong, Peoples R China.
EM lijia_chen@cuhk.edu.hk
RI Chen, Li Jia/I-5078-2014; TANG, Fangyao/AAF-2824-2020; Chu, Wai
   Kit/F-9405-2016; Brelen, Marten E./D-1133-2016
OI Chen, Li Jia/0000-0003-3500-5840; Chu, Wai Kit/0000-0003-2903-3247; 
CR Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560
   Allen NC, 2008, NAT GENET, V40, P827, DOI 10.1038/ng.171
   Allikmets R, 2009, NEW ENGL J MED, V360, P2252
   Bell JK, 2005, P NATL ACAD SCI USA, V102, P10976, DOI 10.1073/pnas.0505077102
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Cheng Y, 2014, GENET MOL RES, V13, P302, DOI 10.4238/2014.January.17.15
   Cho YE, 2009, INVEST OPHTH VIS SCI, V50, P5614, DOI 10.1167/iovs.09-3688
   Choe J, 2005, SCIENCE, V309, P581, DOI 10.1126/science.1115253
   Cipriani V, 2012, HUM MOL GENET, V21, P4138, DOI 10.1093/hmg/dds225
   Copas J, 2000, Biostatistics, V1, P247, DOI 10.1093/biostatistics/1.3.247
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Edwards AO, 2009, NEW ENGL J MED, V360, P2254
   Fleiss J L, 1993, Stat Methods Med Res, V2, P121, DOI 10.1177/096228029300200202
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Harbord RM, 2006, STAT MED, V25, P3443, DOI 10.1002/sim.2380
   Kleinman ME, 2008, NATURE, V452, P591, DOI 10.1038/nature06765
   Kleinman ME, 2012, MOL THER, V20, P101, DOI 10.1038/mt.2011.212
   Ma L, 2015, OPHTHALMOLOGY, V122, P1854, DOI 10.1016/j.ophtha.2015.05.012
   Maloney SC, 2010, OPHTHALMIC RES, V44, P237, DOI 10.1159/000313989
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Ranjith-Kumar CT, 2007, J BIOL CHEM, V282, P17696, DOI 10.1074/jbc.M700209200
   Reich S, 2003, MOL VIS, V9, P210
   Rock FL, 1998, P NATL ACAD SCI USA, V95, P588, DOI 10.1073/pnas.95.2.588
   Schroder M, 2005, TRENDS IMMUNOL, V26, P462, DOI 10.1016/j.it.2005.07.002
   Sharma NK, 2014, MOL CELL BIOCHEM, V393, P1, DOI 10.1007/s11010-014-2040-4
   Shen J, 2006, GENE THER, V13, P225, DOI 10.1038/sj.gt.3302641
   Sng CCA, 2011, OPHTHALMIC RES, V45, P191, DOI 10.1159/000321387
   Sun JC, 2006, J BIOL CHEM, V281, P11144, DOI 10.1074/jbc.M510442200
   Thakkinstian A, 2011, AM J EPIDEMIOL, V173, P1365, DOI 10.1093/aje/kwr025
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yang ZL, 2008, NEW ENGL J MED, V359, P1456, DOI 10.1056/NEJMoa0802437
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
   Zhou P, 2011, FASEB J, V25, P3489, DOI 10.1096/fj.11-189258
NR 34
TC 12
Z9 12
U1 0
U2 13
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD JAN 22
PY 2016
VL 6
AR 9718
DI 10.1038/srep19718
PG 7
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA DB7GF
UT WOS:000368682100002
PM 26796995
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Daftarian, N
   Zandi, S
   Piryaie, G
   Zarif, MN
   Pirmardan, ER
   Yamaguchi, M
   Nejad, QB
   Hasanpour, H
   Samiei, S
   Pfister, IB
   Soheili, ZS
   Nakao, S
   Barakat, A
   Garweg, JG
   Ahmadieh, H
   Hafezi-Moghadam, A
AF Daftarian, Narsis
   Zandi, Souska
   Piryaie, Golbarg
   Zarif, Mahin Nikougoftar
   Pirmardan, Ehsan Ranaei
   Yamaguchi, Muneo
   Nejad, Qurban Behzadian
   Hasanpour, Hossein
   Samiei, Shahram
   Pfister, Isabel B.
   Soheili, Zahra-Soheila
   Nakao, Shintaro
   Barakat, Aliaa
   Garweg, Justus G.
   Ahmadieh, Hamid
   Hafezi-Moghadam, Ali
TI Peripheral blood CD163(+) monocytes and soluble CD163 in dry and
   neovascular age-related macular degeneration
SO FASEB JOURNAL
LA English
DT Article
DE AMD pathogenesis; CD206; choroidal neovascularization (CNV); M1; M2
   differentiation; macrophage polarization
ID COMPLEMENT FACTOR-H; BRUCHS MEMBRANE; MACROPHAGES; VARIANT;
   SUSCEPTIBILITY; IDENTIFICATION; POLARIZATION; POLYMORPHISM; EXPRESSION;
   BIOMARKERS
AB Macrophages are the main infiltrating immune cells in choroidal neovascularization (CNV), a hallmark of the human wet, or neovascular age-related macular degeneration (AMD). Due to their plasticity and ability to adapt to the local microenvironment in a tissue-dependent manner, macrophages display polar functional phenotypes characterized by their cell surface markers and their cytokine profiles. We found accumulation of hemoglobin-scavenging cluster of differentiation 163 (CD163)(+) macrophages in laser-induced CNV lesions and higher expression of CD163(+) monocytes in the peripheral blood on day 7 post injury in mice. In comparison, CD80(+) macrophages did not differ with laser-injury in young or aged mice and did not significantly change in the peripheral blood of CNV mice. We examined the percentages of CD163(+), CD206(+), and CD80(+) monocytes in the peripheral blood of patients with wet AMD, patients with dry AMD, and in age-matched individuals without AMD as controls. Percentages of peripheral blood CD163(+) monocytes in both dry AMD (P < .001) and wet AMD (P < .05) were higher than in age-matched non-AMD controls, while there was no difference between the groups in the percentages of peripheral CD206(+) and CD80(+) monocytes. Further, serum level of soluble CD163 (sCD163) was elevated only in patients with wet AMD (P < .05). An examination of 40 cytokine levels across the study groups revealed that anti-VEGF treated patients with wet AMD, who showed no exudative signs on the day of blood drawing had a cytokine profile that was similar to that of non-AMD individuals. These results indicate that CD163 could be further evaluated for its potential as a useful marker of disease activity in patients with neovascular AMD. Future studies will address the origin and potential mechanistic role of CD163(+) macrophages in wet AMD pathologies of angiogenesis and leakage of blood components.
C1 [Daftarian, Narsis; Zandi, Souska; Pirmardan, Ehsan Ranaei; Barakat, Aliaa; Ahmadieh, Hamid; Hafezi-Moghadam, Ali] Brigham & Womens Hosp, Mol Biomarkers Nanoimaging Lab, 75 Francis St, Boston, MA 02115 USA.
   [Daftarian, Narsis; Pirmardan, Ehsan Ranaei; Barakat, Aliaa; Ahmadieh, Hamid; Hafezi-Moghadam, Ali] Harvard Med Sch, Dept Radiol, Boston, MA 02115 USA.
   [Daftarian, Narsis] Shahid Beheshti Univ Med Sci, Ocular Tissue Engn Res Ctr, Tehran, Iran.
   [Zandi, Souska; Pfister, Isabel B.; Garweg, Justus G.] Lindenhofspital, Rotkreuz & Berner Augenklin, Swiss Eye Inst, Bern, Switzerland.
   [Zandi, Souska; Garweg, Justus G.] Univ Bern, Bern Univ Hosp, Dept Ophthalmol, Inselspital, Bern, Switzerland.
   [Piryaie, Golbarg; Ahmadieh, Hamid] Shahid Beheshti Univ Med Sci, Ophthalm Res Ctr, Tehran, Iran.
   [Zarif, Mahin Nikougoftar; Samiei, Shahram] High Inst Res & Educ Transfus Med, Blood Transfus Res Ctr, Tehran, Iran.
   [Yamaguchi, Muneo; Nakao, Shintaro] Kyushu Univ, Grad Sch Med Sci, Dept Ophthalmol, Fukuoka, Japan.
   [Nejad, Qurban Behzadian; Hasanpour, Hossein] Shahid Beheshti Univ Med Sci, Negah Specialty Ophthalm Res Ctr, Tehran, Iran.
   [Soheili, Zahra-Soheila] Natl Inst Genet Engn & Biotechnol, Inst Med Biotechnol, Dept Mol Med, Tehran, Iran.
C3 Harvard University; Brigham & Women's Hospital; Harvard University;
   Harvard Medical School; Shahid Beheshti University Medical Sciences;
   University of Bern; University Hospital of Bern; Shahid Beheshti
   University Medical Sciences; Kyushu University; Shahid Beheshti
   University Medical Sciences
RP Hafezi-Moghadam, A (通讯作者)，Brigham & Womens Hosp, Mol Biomarkers Nanoimaging Lab MBNI, 75 Francis St,Thorn Res Bldg, Boston, MA 02115 USA.
EM ahm@bwh.harvard.edu
RI Daftarian, Narsis/AAW-5803-2020; Pirmardan, Ehsan Ranaei/AAG-3914-2021;
   Soheili, Zahra-Soheila/W-8316-2018; Ahmadieh, Hamid/M-4853-2017
OI Daftarian, Narsis/0000-0001-5846-8739; Hasanpour,
   Hossein/0000-0002-1090-1166; Zandi, Souska/0000-0001-9351-4278; Soheili,
   Zahra-Soheila/0000-0003-1292-465X; Ranaei Pirmardan,
   Ehsan/0000-0002-6848-5839; Ahmadieh, Hamid/0000-0002-8139-2661
FU Juvenile Diabetes Research Foundation (JDRF) Innovation award; Malaysian
   Palm Oil Board (MPOB)
FX This work was supported by Juvenile Diabetes Research Foundation (JDRF)
   Innovation award (AHM) and the Malaysian Palm Oil Board (MPOB).
CR Bronkhorst IHG, 2011, INVEST OPHTH VIS SCI, V52, P643, DOI 10.1167/iovs.10-5979
   Cao XG, 2011, PATHOL INT, V61, P528, DOI 10.1111/j.1440-1827.2011.02695.x
   Costantini A, 2018, AGING-US, V10, P1268, DOI 10.18632/aging.101465
   Droste A, 1999, BIOCHEM BIOPH RES CO, V256, P110, DOI 10.1006/bbrc.1999.0294
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Etzerodt A, 2010, J LEUKOCYTE BIOL, V88, P1201, DOI 10.1189/jlb.0410235
   Garweg JG, 2019, ACTA OPHTHALMOL, V97, pE580, DOI 10.1111/aos.13998
   Garweg JG, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182571
   Grunin M, 2012, INVEST OPHTH VIS SCI, V53, P5292, DOI 10.1167/iovs.11-9165
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Ikram MK, 2013, DIABETES CARE, V36, P750, DOI 10.2337/dc12-1554
   ISHIBASHI T, 1987, INVEST OPHTH VIS SCI, V28, P1116
   Jabs DA, 2019, AM J OPHTHALMOL, V199, P230, DOI 10.1016/j.ajo.2018.12.002
   Jones K, 2013, CLIN CANCER RES, V19, P731, DOI 10.1158/1078-0432.CCR-12-2693
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Kelly J, 2007, J CLIN INVEST, V117, P3421, DOI 10.1172/JCI32430
   KILLINGSWORTH MC, 1990, EYE, V4, P613, DOI 10.1038/eye.1990.86
   Kim S, 2019, MOL VIS, V25, P129
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kristiansen M, 2001, NATURE, V409, P198, DOI 10.1038/35051594
   Krohne TU, 2010, INVEST OPHTH VIS SCI, V51, P553, DOI 10.1167/iovs.09-3755
   Lad EM, 2015, GRAEF ARCH CLIN EXP, V253, P1941, DOI 10.1007/s00417-015-3094-z
   Lechner J, 2015, SCI REP-UK, V5, DOI 10.1038/srep16754
   Liu F, 2016, MOL VIS, V22, P352
   Mettu PS, 2012, MOL ASPECTS MED, V33, P376, DOI 10.1016/j.mam.2012.04.006
   Parkner T, 2012, DIABETOLOGIA, V55, P1856, DOI 10.1007/s00125-012-2533-1
   Patel M, 2008, SEMIN IMMUNOPATHOL, V30, P97, DOI 10.1007/s00281-008-0112-9
   PENFOLD PL, 1985, GRAEF ARCH CLIN EXP, V223, P69, DOI 10.1007/BF02150948
   Peng XN, 2018, EXP EYE RES, V176, P88, DOI 10.1016/j.exer.2018.06.030
   Rath M, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00532
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Singh A, 2013, OPHTHALMOLOGY, V120, P1029, DOI 10.1016/j.ophtha.2012.11.002
   Skeie JM, 2009, EYE, V23, P747, DOI 10.1038/eye.2008.206
   Spindler J, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0203337
   Stout RD, 2004, J LEUKOCYTE BIOL, V76, P509, DOI 10.1189/jlb.0504272
   Swirski FK, 2009, SCIENCE, V325, P612, DOI 10.1126/science.1175202
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Zandi S, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0214674
   Zandi S, 2016, INVEST OPHTH VIS SCI, V57, P6320, DOI 10.1167/iovs.16-20657
   Zandi S, 2015, CELL REP, V10, P1173, DOI 10.1016/j.celrep.2015.01.050
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
NR 43
TC 4
Z9 4
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0892-6638
EI 1530-6860
J9 FASEB J
JI Faseb J.
PD JUN
PY 2020
VL 34
IS 6
BP 8001
EP 8011
DI 10.1096/fj.201901902RR
EA APR 2020
PG 11
WC Biochemistry & Molecular Biology; Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA MR4QG
UT WOS:000529448100001
PM 32333612
OA Bronze
DA 2022-11-30
ER

PT J
AU Wang, ZJ
   Huang, YH
   Chu, FX
   Liao, K
   Cui, ZK
   Chen, JS
   Tang, SB
AF Wang, Zhijie
   Huang, Yinhua
   Chu, Feixue
   Liao, Kai
   Cui, Zekai
   Chen, Jiansu
   Tang, Shibo
TI Integrated Analysis of DNA methylation and transcriptome profile to
   identify key features of age-related macular degeneration
SO BIOENGINEERED
LA English
DT Article
DE Age-related macular degeneration disease; DNA methylation; transcriptome
   profile; immune cell infiltration; data integration; key genes
ID MINNESOTA GRADING SYSTEM; GENOME-WIDE ASSOCIATION; GENE-EXPRESSION;
   ALZHEIMERS-DISEASE; OXIDATIVE STRESS; IL17RC PROMOTER; PROGNOSIS;
   PACKAGE; BLOOD; HYPOMETHYLATION
AB Age-related macular degeneration (AMD) is a common vision-threatening disease. The current study sought to integrate DNA methylation with transcriptome profile to explore key features in AMD. Gene expression data were obtained from the Gene Expression Omnibus (GEO, accession ID: GSE135092) and DNA methylation data were obtained from the ArrayExpress repository (E-MTAB-7183). A total of 456 differentially expressed genes (DEGs) and 4827 intragenic differentially methylated CpGs (DMCs) were identified between AMD and controls. DEGs and DMCs were intersected and 19 epigenetically induced (EI) genes and 15 epigenetically suppressed (ES) genes were identified. Immune cell infiltration analysis was performed to estimate the abundance of different types of immune cell in each sample. Enrichment scores of inflammatory response and tumor necrosis factor-alpha (TNF alpha) signaling via nuclear factor kappa B (NF-kappa b) were positively correlated with abundance of activated memory CD4 T cells and M1 macrophages. Subsequently, two significant random forest classifiers were constructed based on DNA methylation and transcriptome data. SMAD2 and NGFR were selected as key genes through functional epigenetic modules (FEM) analysis. Expression level of SMAD2, NGFR and their integrating proteins was validated in hydrogen peroxide (H2O2) and TNF alpha co-treated retinal pigment epithelium (RPE) in vitro. The findings of the current study showed that local inflammation and systemic inflammatory host response play key roles in pathogenesis of AMD. SMAD2 and NGFR provide new insight in understanding the molecular mechanism and are potential therapeutic targets for development of AMD therapy.
C1 [Wang, Zhijie; Huang, Yinhua; Liao, Kai; Chen, Jiansu; Tang, Shibo] Cent South Univ, Aier Sch Ophthalmol, Changsha, Peoples R China.
   [Wang, Zhijie; Huang, Yinhua; Liao, Kai; Cui, Zekai; Chen, Jiansu; Tang, Shibo] Aier Eye Inst, 198,Furong Middle Rd, Changsha 410015, Peoples R China.
   [Chu, Feixue] Hangzhou Xihu Zhijiang Eye Hosp, Hangzhou, Peoples R China.
   [Chen, Jiansu] Jinan Univ, Key Lab Regenerat Med, Minist Educ, Guangzhou, Peoples R China.
   [Chen, Jiansu] Jinan Univ, Coll Med, Inst Ophthalmol, Guangzhou, Peoples R China.
   [Tang, Shibo] Chinese Acad Sci, Cas Ctr Excellence Brain Sci & Intelligence Tech, Shanghai, Peoples R China.
C3 Central South University; Jinan University; Jinan University; Chinese
   Academy of Sciences
RP Chen, JS; Tang, SB (通讯作者)，Aier Eye Inst, 198,Furong Middle Rd, Changsha 410015, Peoples R China.
EM chenjiansu2000@163.com; tangshibo@vip.163.com
RI TANG, Shi/GXH-5719-2022
FU Science and Technology Project of Changsha, Hunan [kh1901251]
FX This study was supported by grants from the Science and Technology
   Project of Changsha, Hunan (kh1901251).
CR Abu-Amero KK, 2015, J NEGAT RESULTS BIOM, V14, DOI 10.1186/s12952-015-0029-5
   Arai A, 2020, CANCER SCI, V111, P1417, DOI 10.1111/cas.14347
   Araki H, 2019, STEM CELL REP, V13, P761, DOI 10.1016/j.stemcr.2019.08.014
   Barker PA, 2004, NEURON, V42, P529, DOI 10.1016/j.neuron.2004.04.001
   BREIMAN L, 2001, MACH LEARN, V0045
   Cao XG, 2011, PATHOL INT, V61, P528, DOI 10.1111/j.1440-1827.2011.02695.x
   Chen HS, 2019, INT J BIOCHEM CELL B, V107, P6, DOI 10.1016/j.biocel.2018.11.002
   Chen M, 2020, J CELL BIOCHEM, V121, P3173, DOI 10.1002/jcb.29584
   Chen MY, 2019, J CELL PHYSIOL, V234, P13220, DOI 10.1002/jcp.27994
   Chen YN, 2020, EUR J PHARMACOL, V877, DOI 10.1016/j.ejphar.2020.173090
   Cheng Q, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.686909
   Ciechomska M, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8090953
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   Dor Y, 2018, LANCET, V392, P777, DOI 10.1016/S0140-6736(18)31268-6
   Fahnestock M, 2019, FRONT NEUROSCI-SWITZ, V13, DOI 10.3389/fnins.2019.00129
   Fernandez-Godino R, 2018, HUM MOL GENET, V27, P147, DOI 10.1093/hmg/ddx392
   Fernandez-Godino R, 2016, ADV EXP MED BIOL, V854, P53, DOI 10.1007/978-3-319-17121-0_8
   Fisher CR, 2018, INVEST OPHTH VIS SCI, V59, pAMD41, DOI 10.1167/iovs.18-24289
   Fleming NI, 2013, CANCER RES, V73, P725, DOI 10.1158/0008-5472.CAN-12-2706
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Frost S, 2016, CURR ALZHEIMER RES, V13, P1259, DOI 10.2174/1567205013666160603003800
   Gemenetzi M, 2020, CELL MOL LIFE SCI, V77, P807, DOI 10.1007/s00018-019-03421-w
   Gong GH, 2020, J OVARIAN RES, V13, DOI 10.1186/s13048-020-00632-9
   Granadillo JL, 2018, HUM MUTAT, V39, P1875, DOI 10.1002/humu.23627
   Griffiths S, 2019, AM J MED GENET A, V179, P588, DOI 10.1002/ajmg.a.61066
   Gu JN, 2019, ACTA BIOMATER, V92, P115, DOI 10.1016/j.actbio.2019.05.017
   Guo L, 2017, J HUM GENET, V62, P447, DOI 10.1038/jhg.2016.143
   Hanzelmann S, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-7
   Handa JT, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11262-1
   Hao XK, 2017, P NATL ACAD SCI USA, V114, P7414, DOI 10.1073/pnas.1703577114
   Henderson AR, 2021, FRONT GENET, V12, DOI 10.3389/fgene.2021.640266
   Huang H, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.629860
   Jiao YM, 2014, BIOINFORMATICS, V30, P2360, DOI 10.1093/bioinformatics/btu316
   Kaarniranta K, 2011, J ALZHEIMERS DIS, V24, P615, DOI 10.3233/JAD-2011-101908
   Lambert NG, 2016, PROG RETIN EYE RES, V54, P64, DOI 10.1016/j.preteyeres.2016.04.003
   Lee HG, 2020, EXP MOL MED, V52, P1255, DOI 10.1038/s12276-020-00486-7
   Leek JT, 2012, BIOINFORMATICS, V28, P882, DOI 10.1093/bioinformatics/bts034
   Li YK, 2019, J BIOL CHEM, V294, P14745, DOI 10.1074/jbc.RA119.007508
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lin X, 2000, J BIOL CHEM, V275, P36818, DOI 10.1074/jbc.C000580200
   Liu J, 2020, BIOENGINEERED, V11, P759, DOI 10.1080/21655979.2020.1787764
   Lu Y, 2013, NAT GENET, V45, P155, DOI 10.1038/ng.2506
   Ma WX, 2019, ELIFE, V8, DOI 10.7554/eLife.42049
   Mettu PS, 2012, MOL ASPECTS MED, V33, P376, DOI 10.1016/j.mam.2012.04.006
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Mohamed S, 2010, AM J MED GENET A, V152A, P2318, DOI 10.1002/ajmg.a.33560
   Mufson EJ, 2019, FRONT NEUROSCI-SWITZ, V13, DOI 10.3389/fnins.2019.00533
   Newman AM, 2015, NAT METHODS, V12, P453, DOI [10.1038/NMETH.3337, 10.1038/nmeth.3337]
   Nykjaer A, 2005, CURR OPIN NEUROBIOL, V15, P49, DOI 10.1016/j.conb.2005.01.004
   Oliver VF, 2015, EPIGENETICS-US, V10, P698, DOI 10.1080/15592294.2015.1060388
   Oliver VF, 2013, CELL REP, V5, P1527, DOI 10.1016/j.celrep.2013.11.042
   Olsen TW, 2017, INVEST OPHTH VIS SCI, V58, P5497, DOI 10.1167/iovs.17-22161
   Olsen TW, 2004, INVEST OPHTH VIS SCI, V45, P4484, DOI 10.1167/iovs.04-0342
   Ong SS, 2019, J NEUROL, V266, P1566, DOI 10.1007/s00415-018-9028-z
   Orozco LD, 2020, CELL REP, V30, P1246, DOI 10.1016/j.celrep.2019.12.082
   Oswald J, 2018, THER ADV OPHTHALMOL, V10, DOI 10.1177/2515841418774433
   Pan YB, 2018, CLIN EXP MED, V18, P1, DOI 10.1007/s10238-017-0467-0
   Porter LF, 2019, CLIN EPIGENETICS, V11, DOI 10.1186/s13148-019-0608-2
   Robin X, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-77
   Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616
   Rozing MP, 2020, PROG RETIN EYE RES, V76, DOI 10.1016/j.preteyeres.2019.100825
   Saadipour K, 2018, J NEUROCHEM, V144, P302, DOI 10.1111/jnc.14206
   Salomon MP, 2018, CLIN CANCER RES, V24, P4126, DOI 10.1158/1078-0432.CCR-17-2206
   Shaw PX, 2016, AIMS MOL SCI, V3, P196, DOI 10.3934/molsci.2016.2.196
   Shen HM, 2021, BIOENGINEERED, V12, P240, DOI 10.1080/21655979.2020.1866303
   Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X
   Smilnak GJ, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0223199
   Smith MP, 2013, JNCI-J NATL CANCER I, V105, P33, DOI 10.1093/jnci/djs471
   Sun LJ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14015-6
   Tian Y, 2017, BIOINFORMATICS, V33, P3982, DOI 10.1093/bioinformatics/btx513
   Walter W, 2015, BIOINFORMATICS, V31, P2912, DOI 10.1093/bioinformatics/btv300
   Wang CL, 2019, CLIN EPIGENETICS, V11, DOI 10.1186/s13148-019-0621-5
   Wang J, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03856-y
   Wang K, 2019, ACTA BIOCH BIOPH SIN, V51, P1, DOI 10.1093/abbs/gmy145
   Wang XL, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10124-4
   Wang YJ, 2011, J NEUROSCI, V31, P2292, DOI 10.1523/JNEUROSCI.2733-10.2011
   Wei L, 2012, CELL REP, V2, P1151, DOI 10.1016/j.celrep.2012.10.013
   Whiteside SK, 2018, TRENDS IMMUNOL, V39, P1021, DOI 10.1016/j.it.2018.10.003
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu TZ, 2021, INNOVATION-AMSTERDAM, V2, DOI 10.1016/j.xinn.2021.100141
   Xu ZX, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000015083
   Yaar M, 1997, J CLIN INVEST, V100, P2333, DOI 10.1172/JCI119772
   Yang XJ, 2014, CANCER CELL, V26, P577, DOI 10.1016/j.ccr.2014.07.028
   Ying XR, 2019, ONCOL LETT, V18, P1564, DOI 10.3892/ol.2019.10432
   Yonese I, 2019, EUR J HAEMATOL, V102, P191, DOI 10.1111/ejh.13191
   Yu HT, 2019, MED SCI MONITOR, V25, P3549, DOI 10.12659/MSM.916181
   Zeng H, 2020, INT IMMUNOPHARMACOL, V85, DOI 10.1016/j.intimp.2020.106622
   Zheng WH, 2018, MOL NEUROBIOL, V55, P1915, DOI 10.1007/s12035-017-0447-0
   Zhu DL, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287-020-01608-8
NR 89
TC 5
Z9 5
U1 5
U2 7
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 2165-5979
EI 2165-5987
J9 BIOENGINEERED
JI Bioengineered
PD JAN 1
PY 2021
VL 12
IS 1
BP 7061
EP 7078
DI 10.1080/21655979.2021.1976502
PG 18
WC Biotechnology & Applied Microbiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology
GA WA1FZ
UT WOS:000702641100001
PM 34569899
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Jamous, KF
   Jalbert, I
   Kalloniatis, M
   Boon, MY
AF Jamous, Khalid F.
   Jalbert, Isabelle
   Kalloniatis, Michael
   Boon, Mei Ying
TI Australian optometric and ophthalmologic referral pathways for people
   with age-related macular degeneration, diabetic retinopathy and glaucoma
SO CLINICAL AND EXPERIMENTAL OPTOMETRY
LA English
DT Article
DE age-related macular degeneration; diabetic retinopathy; glaucoma; low
   vision rehabilitation; ophthalmologist; optometrist; referral pathways
ID LOW-VISION REHABILITATION; HEALTH-CARE; OLDER-PEOPLE; EYE CARE;
   PARTICIPATION; IMPACT; DIAGNOSIS; SERVICES; DISEASE
AB BackgroundThis study investigated the referral pathways offered to patients with age-related macular degeneration (AMD), diabetic retinopathy (DR) or glaucoma (GL) by ophthalmologists and optometrists.
   MethodsAustralian ophthalmologists and optometrists were surveyed regarding referral decisions to other eye-care specialists (inter- or intra-professional), general medical practitioners (GPs), low vision rehabilitation (LVR) and support services. Thematic analysis and concept mapping were applied to highlight current and ideal referral pathways.
   ResultsThe survey was completed by 155 optometrists and 50 ophthalmologists and deemed representative of their respective professions in Australia. Not surprisingly, the vast majority of the participating optometrists (97 to 99 per cent) referred to ophthalmologists regardless of the underlying condition. Clear differences (Chi-square: p<0.05) were observed in the referral patterns of optometrists and ophthalmologists to GPs and support services. General medical practitioner services were almost exclusively used for patients with DR, while AMD triggered a significantly higher referral rate to low vision rehabilitation and support services than the other two disorders.
   ConclusionWhile ophthalmologists predominantly referred patients with AMD, DR or GL to low vision rehabilitation services, optometrists' referrals were highly skewed toward ophthalmology. Referrals to other supporting services by the two groups were not greatly used. The perceived referral pathways by the two eye-care professionals suggested a unidirectional route, potentially highlighting the need for a more collaborative approach that facilitates optimal use of eye health care and allied services.
C1 [Jamous, Khalid F.; Jalbert, Isabelle; Kalloniatis, Michael; Boon, Mei Ying] Univ New S Wales, Sch Optometry & Vis Sci, Kensington, NSW 2033, Australia.
   [Kalloniatis, Michael] Univ New S Wales, Ctr Eye Hlth, Kensington, NSW 2033, Australia.
   [Jamous, Khalid F.] King Saud Univ, Fac Med, Dept Ophthalmol, Riyadh, Saudi Arabia.
C3 University of New South Wales Sydney; University of New South Wales
   Sydney; King Saud University
RP Jamous, KF (通讯作者)，Univ New S Wales, Sch Optometry & Vis Sci, POB 1, Kensington, NSW 2033, Australia.
EM m.boon@unsw.edu.au
RI Jalbert, Isabelle/T-5888-2017; Boon, Mei Ying/F-2194-2016
OI Jalbert, Isabelle/0000-0002-1351-0072; Boon, Mei
   Ying/0000-0002-9759-8402; Kalloniatis, Michael/0000-0002-5264-4639
FU King Saud University at Riyadh, Saudi Arabia
FX Khalid F Jamous was supported by a scholarship from King Saud University
   at Riyadh, Saudi Arabia. This paper was presented in part at the
   American Academy of Optometry Annual meeting in Boston, USA in October
   2011. We thank Drs Andrew Whatham, Barbara Zangerl and Lisa
   Nivison-Smith for their valuable contribution in reviewing the
   manuscript.
CR Armstrong BK, 2007, MED J AUSTRALIA, V187, P485, DOI 10.5694/j.1326-5377.2007.tb01383.x
   Australian Institute of Health and Welfare, 2020, MENTAL HLTH SERVICES
   Australian Institute of Health Welfare, 2005, VIS PROBL OLD AUSTR
   Barber AJ, 2003, PROG NEURO-PSYCHOPH, V27, P283, DOI 10.1016/S0278-5846(03)00023-X
   Black AA, 2011, OPHTHAL PHYSL OPT, V31, P283, DOI 10.1111/j.1475-1313.2010.00811.x
   Chopdar A, 2003, BRIT MED J, V326, P485, DOI 10.1136/bmj.326.7387.485
   Chu J, 2008, DRUG DEVELOP RES, V69, P1, DOI 10.1002/ddr.20222
   Culham LE, 2002, BRIT J OPHTHALMOL, V86, P743, DOI 10.1136/bjo.86.7.743
   Davies M, 2011, HIGH EDUC, V62, P279, DOI 10.1007/s10734-010-9387-6
   Demers-Turco P, 1999, J Am Optom Assoc, V70, P49
   Department of Health and Aging, 2005, NAT FRAM ACT PROM EY
   Gardner TW, 2002, SURV OPHTHALMOL, V47, pS253, DOI 10.1016/S0039-6257(02)00387-9
   Green J, 2002, SOC SCI MED, V55, P257, DOI 10.1016/S0277-9536(01)00169-1
   HOFMARCHER MM, 2007, OECD HLTH WORKING PA
   Infeld DA, 1998, POSTGRAD MED J, V74, P709, DOI 10.1136/pgmj.74.878.709
   JAVITT JC, 1991, OPHTHALMOLOGY, V98, P1565
   JAVITT JC, 1994, DIABETES CARE, V17, P909, DOI 10.2337/diacare.17.8.909
   Johnson RB, 2007, J MIX METHOD RES, V1, P112, DOI 10.1177/1558689806298224
   Junghans B, DELIVERING OPTOMETRI
   Khan SA, 2002, CLIN EXP OPHTHALMOL, V30, P404, DOI 10.1046/j.1442-9071.2002.00569.x
   Kiely PM, 2009, CLIN EXP OPTOM, V92, P362, DOI 10.1111/j.1444-0938.2009.00383.x
   Kim JJ, 2011, CURR OPIN OPHTHALMOL, V22, P256, DOI 10.1097/ICU.0b013e3283479f56
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Lamoureux EL, 2007, INVEST OPHTH VIS SCI, V48, P1476, DOI 10.1167/iovs.06-0610
   Lamoureux EL, 2004, ARCH OPHTHALMOL-CHIC, V122, P84, DOI 10.1001/archopht.122.1.84
   Lord SR, 2005, J AM GERIATR SOC, V53, P1296, DOI 10.1111/j.1532-5415.2005.53425.x
   Lovie-Kitchin JE, 2010, OPTOMETRY VISION SCI, V87, P948, DOI 10.1097/OPX.0b013e3181ff99be
   Lovie-Kitchin JE., 1996, CLIN EXP OPTOM, V79, P227
   Macular Degeneration Foundation, 2009, MAC DEG AW WEEK
   MARTIN DP, 1989, AM J PUBLIC HEALTH, V79, P1628, DOI 10.2105/AJPH.79.12.1628
   Miles M.B., 1994, QUALITATIVE DATA ANA
   Noe G, 2003, CLIN EXP OPHTHALMOL, V31, P482, DOI 10.1046/j.1442-9071.2003.00712.x
   NOVAK JD, 1990, J RES SCI TEACH, V27, P937, DOI 10.1002/tea.3660271003
   O'Connor PM, 2012, MED J AUSTRALIA, V196, P646, DOI 10.5694/mja11.10856
   Optometry Board Australia, GUID US SCHED MED
   OShea JG, 1996, MED J AUSTRALIA, V165, P561, DOI 10.5694/j.1326-5377.1996.tb138643.x
   Pick ZS, 2008, CLIN EXP OPHTHALMOL, V36, P762, DOI 10.1111/j.1442-9071.2008.01874.x
   Pomeroy SEM, 2010, AUST J PRIM HEALTH, V16, P147, DOI 10.1071/PY09024
   Pooley JE, 1999, OPHTHAL PHYSL OPT, V19, pS16, DOI 10.1016/S0275-5408(99)00004-6
   Ratnarajan G, 2013, OPHTHAL PHYSL OPT, V33, P183, DOI 10.1111/opo.12029
   Rowe S, 2004, JAMA-J AM MED ASSOC, V291, P1487, DOI 10.1001/jama.291.12.1487
   Sheldrick J H, 1994, Ophthalmic Epidemiol, V1, P31, DOI 10.3109/09286589409071443
   SHUTTLEWORTH GN, 1995, BRIT J OPHTHALMOL, V79, P719, DOI 10.1136/bjo.79.8.719
   Sims J, 2000, AUST NZ J PUBL HEAL, V24, P356, DOI 10.1111/j.1467-842X.2000.tb01592.x
   Wagner EH, 2001, HEALTH AFFAIR, V20, P64, DOI 10.1377/hlthaff.20.6.64
   Wood J, 1993, CLIN EXP OPTOM, V76, P199
   Woods CA, 2006, CLIN EXP OPTOM, V89, P1, DOI 10.1111/j.1444-0938.2006.00006.x
NR 47
TC 12
Z9 12
U1 0
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0816-4622
EI 1444-0938
J9 CLIN EXP OPTOM
JI Clin. Exp. Optom.
PD MAY
PY 2014
VL 97
IS 3
BP 248
EP 255
DI 10.1111/cxo.12119
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AF8YM
UT WOS:000335001900010
PM 24400653
OA Bronze
DA 2022-11-30
ER

PT J
AU Tang, D
   Mitchell, P
   Flood, V
   Kifley, A
   Hayes, A
   Liew, G
   Gopinath, B
AF Tang, Diana
   Mitchell, Paul
   Flood, Victoria
   Kifley, Annette
   Hayes, Alison
   Liew, Gerald
   Gopinath, Bamini
TI Dietary intervention in patients with age-related macular degeneration:
   protocol for a randomised controlled trial
SO BMJ OPEN
LA English
DT Article
ID MEDITERRANEAN DIET; BETA-CAROTENE; EYE DISEASE; VISION LOSS; NUTRITION;
   ADHERENCE; RISK; SUPPLEMENTATION; ASSOCIATION; CONSUMPTION
AB Introduction Age-related macular degeneration (AMD) is a leading cause of blindness. After smoking, nutrition is the key modifiable factor in reducing AMD incidence and progression, and no other preventative treatments are currently available. At present, there is an evidence-practice gap of dietary recommendations made by eye care practitioners and those actually practised by patients with AMD. To address this gap, a telephone-delivered dietary intervention tailored to patients with AMD will be piloted. The study aims to improve dietary intake and behaviours in patients with AMD. This type of nutrition-focused healthcare is currently not considered in the long-term management of AMD and represents the first empirical evaluation of a telephone-supported application encouraging adherence to dietary recommendations for AMD.
   Methods and analysis 140 participants with AMD will be recruited for this randomised controlled trial. Those lacking English fluency; unwilling to engage in the intervention or provide informed consent were excluded. Following the completion of the baseline questionnaire, participants will be randomised into one of two arms: intervention or wait-list control (70 each in the intervention and control groups). Intervention participants will receive a detailed mail-delivered workbook containing information on healthy eating behaviours that promote optimal macular health, as well as scheduled phone calls over 4 months from an accredited practising dietitian. Descriptive statistics and multivariate stepwise linear regressions analyses will be used to summarise and determine the changes in dietary intakes, respectively. Economic analysis will be conducted to determine intervention feasibility and possibility of a large-scale rollout.
   Ethics and dissemination The study was approved by the University of Sydney Human Research Ethics Committee (HREC) (Reference: HREC 2018/219). Study findings will be disseminated via presentations at national/international conferences and peer-reviewed journal articles.
C1 [Tang, Diana; Mitchell, Paul; Kifley, Annette; Liew, Gerald; Gopinath, Bamini] Univ Sydney, Ctr Vis Res, Dept Ophthalmol, Sydney, NSW, Australia.
   [Tang, Diana; Mitchell, Paul; Kifley, Annette; Liew, Gerald; Gopinath, Bamini] Univ Sydney, Westmead Inst Med Res, Sydney, NSW, Australia.
   [Flood, Victoria] Westmead Hosp, Western Sydney Local Hlth Dist, Westmead, NSW, Australia.
   [Flood, Victoria] Univ Sydney, Fac Hlth Sci, Charles Perkins Ctr, Sydney, NSW, Australia.
   [Hayes, Alison] Univ Sydney, Fac Med & Hlth, Sydney Sch Publ Hlth, Sydney, NSW, Australia.
C3 University of Sydney; University of Sydney; Westmead Institute for
   Medical Research; University of Sydney; University of Sydney; University
   of Sydney
RP Gopinath, B (通讯作者)，Univ Sydney, Ctr Vis Res, Dept Ophthalmol, Sydney, NSW, Australia.; Gopinath, B (通讯作者)，Univ Sydney, Westmead Inst Med Res, Sydney, NSW, Australia.
EM bamini.gopinath@sydney.edu.au
RI Flood, Victoria M/A-8732-2016; Liew, Gerald/AAB-6870-2022
OI Flood, Victoria M/0000-0001-5310-7221; Tang, Diana/0000-0003-2007-9054
FU National Health and Medical Research Council (NHMRC) [APP1150101]
FX This work is supported by National Health and Medical Research Council
   (NHMRC) grant number APP1150101.
CR Broadhead GK, 2015, NUTR REV, V73, P448, DOI 10.1093/nutrit/nuv005
   CAMPBELL MK, 1994, AM J PUBLIC HEALTH, V84, P783, DOI 10.2105/AJPH.84.5.783
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P142, DOI 10.1001/jamaophthalmol.2013.7376
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Dennis SM, 2013, AUST HEALTH REV, V37, P381, DOI 10.1071/AH13005
   Downie LE, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124533
   Goldstein MG, 2004, AM J PREV MED, V27, P61, DOI 10.1016/j.amepre.2004.04.023
   Gopinath B, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122548
   Hogg RE, 2017, OPHTHALMOLOGY, V124, P82, DOI 10.1016/j.ophtha.2016.09.019
   Islam FMA, 2014, OPHTHALMOLOGY, V121, P1428, DOI 10.1016/j.ophtha.2014.01.002
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kelly JT, 2016, AM J CLIN NUTR, V104, P1693, DOI 10.3945/ajcn.116.136333
   Kim EK, 2018, EUR J CLIN NUTR, V72, P161, DOI 10.1038/ejcn.2017.152
   Lee JE, 2017, NUTR RES PRACT, V11, P247, DOI 10.4162/nrp.2017.11.3.247
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Merle BMJ, 2015, AM J CLIN NUTR, V102, P1196, DOI 10.3945/ajcn.115.111047
   National Health & Medical Research Council, 2003, DIET GUID AUSTR AD
   Ng WT, 2006, CLIN EXP OPHTHALMOL, V34, P9, DOI 10.1111/j.1442-9071.2006.01141.x
   Nunes S, 2018, NUTRITION, V51-52, P6, DOI 10.1016/j.nut.2017.12.010
   Pollard CM, 2008, PUBLIC HEALTH NUTR, V11, P314, DOI 10.1017/S1368980007000523
   Rankin A, 2017, J HEALTH PSYCHOL, V22, P1233, DOI 10.1177/1359105315624750
   Round R., 2005, PLANNING EFFECTIVE H
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671
   Sealed Envelope Ltd, 2012, POW CALC CONT OUTC S
   Shah SU, 2013, CAN J OPHTHALMOL, V48, P204, DOI 10.1016/j.jcjo.2013.01.013
   Stevens R, 2014, BRIT J VISUAL IMPA, V32, P77, DOI 10.1177/0264619613519341
   Taylor HR, 2005, MED J AUSTRALIA, V182, P565, DOI 10.5694/j.1326-5377.2005.tb06815.x
   Wang JJ, 2009, AM J EPIDEMIOL, V169, P633, DOI 10.1093/aje/kwn358
   [No title captured]
   [No title captured]
   [No title captured]
NR 34
TC 3
Z9 3
U1 2
U2 3
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2044-6055
J9 BMJ OPEN
JI BMJ Open
PD JUN
PY 2019
VL 9
IS 2
AR e024774
DI 10.1136/bmjopen-2018-024774
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA IC7AO
UT WOS:000471124600168
PM 30782917
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Wagley, S
   Marra, KV
   Salhi, RA
   Gautam, S
   Campo, R
   Veale, P
   Veale, J
   Arroyo, JG
AF Wagley, Sushant
   Marra, Kyle V.
   Salhi, Rama A.
   Gautam, Shiva
   Campo, Rafael
   Veale, Peter
   Veale, John
   Arroyo, Jorge G.
TI PERIODONTAL DISEASE AND AGE-RELATED MACULAR DEGENERATION Results From
   the National Health and Nutrition Examination Survey III
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE periodontal disease; age-related macular degeneration; oral health
ID LONG-TERM INCIDENCE; CORONARY-HEART-DISEASE; C-REACTIVE PROTEIN;
   ASSOCIATION; PREVALENCE; PROGRESSION; SMOKING; RISK
AB Purpose: To study the association between periodontal disease (PD) and age-related macular degeneration (AMD).
   Methods: For this cross-sectional analysis, 8,208 adults aged 40 years or older with retinal photographs graded for AMD were used from the National Health and Nutrition Examination Survey III. National Health and Nutrition Examination Survey III standardized dental measurements of PD status (defined as loss of >3 mm of attachment between the gum and tooth in at least 10% of sites measured). Participants were stratified into 60 years or younger and older than 60 years of age groups. Association between PD and AMD was assessed while controlling for sex, race, education, poverty income ratio, smoking, hypertension, body mass index, cardiovascular disease, and C-reactive protein.
   Results: In this population, a total of 52.30% had PD, and the prevalence of AMD was 11.45%. Logistic regression model controlled for confounders and stratified by age 60 years or younger versus older than 60 years showed PD to be independently associated with an increased risk for AMD (odds ratio = 1.96, 95% confidence interval = 1.22-3.14, P = 0.006) for those aged 60 years or younger but not for subjects older than 60 years (odds ratio = 1.32, confidence interval = 0.93-1.90, P = 0.120).
   Conclusion: In this population-based study, PD is independently associated with AMD in those aged 60 years or younger.
C1 [Wagley, Sushant; Salhi, Rama A.] Michigan State Univ, Coll Human Med, E Lansing, MI 48824 USA.
   [Marra, Kyle V.; Arroyo, Jorge G.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Ophthalmol,Dept Ophthalmol, Boston, MA 02215 USA.
   [Gautam, Shiva; Campo, Rafael] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Med, Boston, MA 02215 USA.
   [Veale, Peter; Veale, John] Veale & Veale Dent, Dartmouth, MA USA.
C3 Michigan State University; Michigan State University College of Human
   Medicine; Harvard University; Beth Israel Deaconess Medical Center;
   Harvard Medical School; Harvard University; Beth Israel Deaconess
   Medical Center; Harvard Medical School
RP Arroyo, JG (通讯作者)，Beth Israel Deaconess Med Ctr, Div Ophthalmol, 330 Brookline Ave CC-5, Boston, MA 02215 USA.
EM jarroyo@bidmc.harvard.edu
OI Arroyo, Jorge/0000-0001-9812-296X; Marra, Kyle/0000-0003-3517-7140
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   [Anonymous], 2013, PER GUM DIS
   Arroyo JG, 2006, JAMA-J AM MED ASSOC, V295, P2394, DOI 10.1001/jama.295.20.2394
   Brzozowska Aleksandra, 2012, Klin Oczna, V114, P29
   *CDC, 1996, NAT HLTH NUTR EX SUR
   Chapple ILC, 2009, J AM DENT ASSOC, V140, P178, DOI 10.14219/jada.archive.2009.0131
   Chew EY, 2013, OPHTHALMOLOGY, V120, P1604, DOI 10.1016/j.ophtha.2013.01.021
   Chiu CJ, 2014, AM J OPHTHALMOL, V158, P118, DOI 10.1016/j.ajo.2014.04.016
   Contreras M, 2010, MICROBIOL-SGM, V156, P3282, DOI 10.1099/mic.0.043174-0
   DESTEFANO F, 1993, BRIT MED J, V306, P688, DOI 10.1136/bmj.306.6879.688
   Donoso LA, 2010, SURV OPHTHALMOL, V55, P227, DOI 10.1016/j.survophthal.2009.11.001
   Eke PI, 2012, J DENT RES, V91, P914, DOI 10.1177/0022034512457373
   Elter JR, 2004, J PERIODONTOL, V75, P782, DOI 10.1902/jop.2004.75.6.782
   Ezzati T M, 1992, Vital Health Stat 2, P1
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Hujoel PP, 2001, J PERIODONTAL RES, V36, P48, DOI 10.1034/j.1600-0765.2001.00011.x
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Janket SJ, 2003, ORAL SURG ORAL MED O, V95, P559, DOI 10.1067/moe.2003.107
   Kalayoglu MV, 2005, GRAEF ARCH CLIN EXP, V243, P1080, DOI 10.1007/s00417-005-1169-y
   Karesvuo P, 2013, J PERIODONTOL, V84, P58, DOI 10.1902/jop.2012.110643
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 2008, ARCH OPHTHALMOL-CHIC, V126, P115, DOI 10.1001/archopht.126.1.115
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Kohm AP, 2003, TRENDS MICROBIOL, V11, P101, DOI 10.1016/S0966-842X(03)00006-4
   Lockhart PB, 2012, CIRCULATION, V125, P2520, DOI 10.1161/CIR.0b013e31825719f3
   Pihlstrom BL, 2005, LANCET, V366, P1809, DOI 10.1016/S0140-6736(05)67728-8
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Shankar A, 2007, AM J EPIDEMIOL, V165, P375, DOI 10.1093/aje/kwk022
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   Staufenbiel I, 2013, EUR J CLIN NUTR, V67, P836, DOI 10.1038/ejcn.2013.101
   Tan JSL, 2007, ARCH OPHTHALMOL-CHIC, V125, P1089, DOI 10.1001/archopht.125.8.1089
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
NR 36
TC 20
Z9 21
U1 0
U2 12
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAY
PY 2015
VL 35
IS 5
BP 982
EP 988
DI 10.1097/IAE.0000000000000427
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CG6KI
UT WOS:000353408900020
PM 25627087
DA 2022-11-30
ER

PT J
AU Jorgenson, E
   Melles, RB
   Hoffmann, TJ
   Jia, XM
   Sakoda, LC
   Kvale, MN
   Banda, Y
   Schaefer, C
   Risch, N
   Shen, L
AF Jorgenson, Eric
   Melles, Ronald B.
   Hoffmann, Thomas J.
   Jia, Xiaoming
   Sakoda, Lori C.
   Kvale, Mark N.
   Banda, Yambazi
   Schaefer, Catherine
   Risch, Neil
   Shen, Ling
TI Common coding variants in the HLA-DQB1 region confer susceptibility to
   age-related macular degeneration
SO EUROPEAN JOURNAL OF HUMAN GENETICS
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; GENETIC EPIDEMIOLOGY RESEARCH; AGING GERA
   COHORT; DRUSEN FORMATION; COMPLEMENT ACTIVATION; GENOTYPE IMPUTATION;
   ADULT HEALTH; PREVALENCE; COVERAGE; DISEASE
AB Age-related macular degeneration (AMD) risk variants in the complement system point to the important role of immune response and inflammation in the pathogenesis of AMD. Although the human leukocyte antigen (HLA) region has a central role in regulating immune response, previous studies of genetic variation in HLA genes and AMD have been limited by sample size or incomplete coverage of the HLA region by first-generation genotyping arrays and imputation panels. Here, we conducted a large-scale HLA fine-mapping study with 4841 AMD cases and 23 790 controls of non-Hispanic white ancestry from the Kaiser Permanente Genetic Epidemiology Research on Adult Health and Aging cohort. Genotyping was conducted using custom Affymetrix Axiom arrays, with dense coverage of the HLA region. Classic HLA polymorphisms were imputed using SNP2HLA, which utilizes a large reference panel to provide improved imputation accuracy of variants in this region. We examined a total of 6937 SNPs and 172 classical HLA alleles, conditioning on established AMD risk variants, which revealed novel associations with two non-synonymous SNPs in perfect linkage disequilibrium, rs9274390 and rs41563814 (odds ratio (OR)=1.21; P=1.4 x 10(-11)) corresponding to amino-acid changes at position 66 and 67 in HLA-DQB1, respectively, and the DQB1*02 classical HLA allele (OR=1.22; P=3.9 x 10(-10)) with the risk of AMD. We confirmed these association signals, again conditioning on established risk variants, in the MMAP data set of subjects with advanced AMD (rs9274390/rs41563814: OR=1.28; P=1.30 x 10(-3), DQB1*02: OR=1.32; P=9.00 x 10(-4)). These findings support a role of HLA class II alleles in the risk of AMD.
C1 [Jorgenson, Eric; Sakoda, Lori C.; Schaefer, Catherine; Risch, Neil; Shen, Ling] Kaiser Permanente No Calif, Div Res, 2000 Broadway, Oakland, CA 94612 USA.
   [Melles, Ronald B.] Kaiser Permanente No Calif, Redwood City Med Ctr, Dept Ophthalmol, Redwood City, CA USA.
   [Hoffmann, Thomas J.; Kvale, Mark N.; Banda, Yambazi; Risch, Neil] Univ Calif San Francisco, Inst Human Genet, San Francisco, CA 94143 USA.
   [Hoffmann, Thomas J.; Risch, Neil] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
   [Jia, Xiaoming] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA.
C3 Kaiser Permanente; Kaiser Permanente; University of California System;
   University of California San Francisco; University of California System;
   University of California San Francisco; University of California System;
   University of California San Francisco
RP Jorgenson, E (通讯作者)，Kaiser Permanente No Calif, Div Res, 2000 Broadway, Oakland, CA 94612 USA.
EM eric.jorgenson@kp.org
RI Sakoda, Lori/ABD-6828-2020
OI Sakoda, Lori/0000-0002-0900-5735; Jia, Xiaoming/0000-0002-5104-5431;
   Melles, Ronald/0000-0003-1027-4083
FU KPNC Community Benefit; National Institutes of Health [RC2 AG036607, R21
   AG046616]; NATIONAL INSTITUTE ON AGING [R21AG046616, RC2AG036607]
   Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND
   ALCOHOLISM [R21AA021223] Funding Source: NIH RePORTER
FX This work was supported by a research grant from KPNC Community Benefit,
   and grants RC2 AG036607 and R21 AG046616 from the National Institutes of
   Health.
CR Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson DH, 2001, AM J OPHTHALMOL, V131, P767, DOI 10.1016/S0002-9394(00)00961-2
   Banda Y, 2015, GENETICS, V200, P1285, DOI 10.1534/genetics.115.178616
   Brandt DYC, 2015, G3-GENES GENOM GENET, V5, P931, DOI 10.1534/g3.114.015784
   Finger RP, 2011, BRIT J OPHTHALMOL, V95, P1061, DOI 10.1136/bjo.2010.194712
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Goverdhan SV, 2008, INVEST OPHTH VIS SCI, V49, P5077, DOI 10.1167/iovs.08-1837
   Goverdhan SV, 2005, INVEST OPHTH VIS SCI, V46, P1726, DOI 10.1167/iovs.04-0928
   Hageman GS, 1999, FASEB J, V13, P477, DOI 10.1096/fasebj.13.3.477
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hoffmann TJ, 2011, GENOMICS, V98, P422, DOI 10.1016/j.ygeno.2011.08.007
   Hoffmann TJ, 2011, GENOMICS, V98, P79, DOI 10.1016/j.ygeno.2011.04.005
   Howie B, 2012, NAT GENET, V44, P955, DOI 10.1038/ng.2354
   Howie B, 2011, G3-GENES GENOM GENET, V1, P457, DOI 10.1534/g3.111.001198
   Jia XM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064683
   Johnson LV, 2011, P NATL ACAD SCI USA, V108, P18277, DOI 10.1073/pnas.1109703108
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   KRIEGER N, 1992, AM J PUBLIC HEALTH, V82, P703, DOI 10.2105/AJPH.82.5.703
   Kvale MN, 2015, GENETICS, V200, P1051, DOI 10.1534/genetics.115.178905
   Lindquist KJ, 2013, GENET EPIDEMIOL, V37, P383, DOI 10.1002/gepi.21724
   Luibl V, 2006, J CLIN INVEST, V116, P378, DOI 10.1172/JCI25843
   Manichaikul A, 2010, BIOINFORMATICS, V26, P2867, DOI 10.1093/bioinformatics/btq559
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Murray JA, 2007, CLIN GASTROENTEROL H, V5, P1406, DOI 10.1016/j.cgh.2007.08.013
   Penfold PL, 1997, INVEST OPHTH VIS SCI, V38, P2125
   Price AL, 2006, NAT GENET, V38, P904, DOI 10.1038/ng1847
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Raychaudhuri S, 2012, NAT GENET, V44, P291, DOI 10.1038/ng.1076
   Shen L, 2015, INVEST OPHTH VIS SCI, V56, P4290, DOI 10.1167/iovs.15-16533
   Team RDC, 2008, R LANG ENV STAT COMP
   Wang Y, 2011, EYE, V25, P127, DOI 10.1038/eye.2010.196
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 35
TC 9
Z9 9
U1 0
U2 4
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1018-4813
EI 1476-5438
J9 EUR J HUM GENET
JI Eur. J. Hum. Genet.
PD JUL
PY 2016
VL 24
IS 7
BP 1049
EP 1055
DI 10.1038/ejhg.2015.247
PG 7
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA DO9IA
UT WOS:000378098000017
PM 26733291
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Romdhoniyyah, DF
   Harding, SP
   Cheyne, CP
   Beare, NAV
AF Romdhoniyyah, Dewi Fathin
   Harding, Simon P.
   Cheyne, Christopher P.
   Beare, Nicholas A. V.
TI Metformin, A Potential Role in Age-Related Macular Degeneration: A
   Systematic Review and Meta-Analysis
SO OPHTHALMOLOGY AND THERAPY
LA English
DT Review
DE Metformin; Age-related macular degeneration; Age-related maculopathy;
   Systematic review; Meta-analysis
ID DIABETIC-RETINOPATHY; RISK-FACTORS; EYE DISEASE; CELLS; CLASSIFICATION;
   AUTOPHAGY; VEGF
AB Background Currently, no generally approved medical treatment can delay the onset of age-related macular degeneration (AMD) or slow the progression of degenerative changes. Repurposing drugs with beneficial effects on AMD pathophysiology offers a route to new treatments which is faster, cost-effective, and safer for patients. Recent studies indicate a potential role for metformin in delaying AMD development and progression. In this context, we conducted a systematic review and meta-analysis to look for beneficial associations between metformin and AMD. Methods We systematically searched Medline and Embase (via Ovid), Web of Science, and ClinicalTrials.gov databases for clinical studies in humans that examined the associations between metformin treatment and AMD published from inception to February 2021. We calculated pooled odds ratio (OR) with 95% confidence interval (CI) considering a random effect model in the meta-analysis. Results Five retrospective studies met the inclusion criteria. There are no prospective studies that have reported the effect of metformin in AMD. The meta-analysis showed that people taking metformin were less likely to have AMD although statistical significance was not met (pooled adjusted OR = 0.80, 95% CI 0.54-1.05, I-2 = 98.8%). Subgroup analysis of the association between metformin and early and late AMD could not be performed since the data was not available from the included studies. Conclusions Analysis of retrospective data suggests a signal that metformin may be associated with decreased risk of any AMD. It should be interpreted with caution because of the failure to meet statistical significance, the small number of studies, and the limitation of routine record data. However prospective studies are warranted in generalizable populations without diabetes, of varied ethnicities, and AMD stages. Clinical trials are needed to determine if metformin has efficacy in treating early and late-stage AMD.
C1 [Romdhoniyyah, Dewi Fathin; Harding, Simon P.; Beare, Nicholas A. V.] Univ Liverpool, Inst Life Course & Med Sci, Dept Eye & Vis Sci, Liverpool L7 8TX, Merseyside, England.
   [Harding, Simon P.; Beare, Nicholas A. V.] Liverpool Univ Hosp NHS Fdn Trust, St Pauls Eye Unit, Liverpool, Merseyside, England.
   [Harding, Simon P.; Beare, Nicholas A. V.] Liverpool Hlth Partners, Liverpool, Merseyside, England.
   [Cheyne, Christopher P.] Univ Liverpool, Inst Populat Hlth, Dept Hlth Data Sci, Liverpool, Merseyside, England.
C3 University of Liverpool; University of Liverpool
RP Romdhoniyyah, DF (通讯作者)，Univ Liverpool, Inst Life Course & Med Sci, Dept Eye & Vis Sci, Liverpool L7 8TX, Merseyside, England.
EM d.f.romdhoniyyah@liverpool.ac.uk
RI Beare, Nicholas/AAG-4946-2019
OI Beare, Nicholas/0000-0001-8086-990X; Romdhoniyyah, Dewi
   Fathin/0000-0003-3330-4847
FU Ministry of Finance of Republic of Indonesia through Indonesia Endowment
   Fund for Education [201711220412052]
FX The study and the journal's Rapid Service Fee were funded by The
   Ministry of Finance of Republic of Indonesia through Indonesia Endowment
   Fund for Education (Lembaga Pengelola Dana Pendidikan or LPDP)
   scholarship for doctoral study (grant number 201711220412052).
CR Ambati J, 2002, ARCH OPHTHALMOL-CHIC, V120, P997
   Bakhashab S, 2016, CARDIOVASC DIABETOL, V15, DOI 10.1186/s12933-016-0344-2
   Barzilai N, 2016, CELL METAB, V23, P1060, DOI 10.1016/j.cmet.2016.05.011
   Blagosklonny MV, 2007, DRUG DISCOV TODAY, V12, P218, DOI 10.1016/j.drudis.2007.01.004
   Blitzer AL, 2021, JAMA OPHTHALMOL, V139, P302, DOI 10.1001/jamaophthalmol.2020.6331
   Brown EE, 2019, INVEST OPHTH VIS SCI, V60, P1470, DOI 10.1167/iovs.18-26422
   Cameron AR, 2016, CIRC RES, V119, P652, DOI 10.1161/CIRCRESAHA.116.308445
   Campbell JM, 2018, J ALZHEIMERS DIS, V65, P1225, DOI 10.3233/JAD-180263
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chen X, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108196
   Chen YY, 2019, J OPHTHALMOL, V2019, DOI 10.1155/2019/1649156
   Cheung CMG, 2014, J INTERN MED, V276, P140, DOI 10.1111/joim.12227
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chew EY, 2012, OPHTHALMOLOGY, V119, P2282, DOI 10.1016/j.ophtha.2012.05.027
   Chiou GCY., 2011, TAIWAN J OPHTHALMOL, V1, P2, DOI [10.1016/j.tjo.2011.08.001, DOI 10.1016/J.TJO.2011.08.001]
   Chun Y, 2018, CELLS-BASEL, V7, DOI 10.3390/cells7120278
   Dallaglio K, 2014, CARCINOGENESIS, V35, P1055, DOI 10.1093/carcin/bgu001
   Das UN, 2016, ARCH MED SCI, V12, P1142, DOI 10.5114/aoms.2016.61918
   Dee TS, 2011, J POLICY ANAL MANAG, V30, P418, DOI 10.1002/pam.20586
   Downs SH, 1998, J EPIDEMIOL COMMUN H, V52, P377, DOI 10.1136/jech.52.6.377
   Eells JT, 2019, BIOLOGY-BASEL, V8, DOI 10.3390/biology8020031
   Ersoy C, 2008, DIABETES RES CLIN PR, V81, P56, DOI 10.1016/j.diabres.2008.02.006
   Esteghamati A, 2013, CLIN NUTR, V32, P179, DOI 10.1016/j.clnu.2012.08.006
   Evans JR, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000254.pub4
   Evans JR, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000253.pub4
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   Fang JQ, 2018, AGING CELL, V17, DOI 10.1111/acel.12765
   Fernandez-Robredo P, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/510285
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Golestaneh N, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.453
   Guan MP, 2018, J DIABETES RES, V2018, DOI 10.1155/2018/1031367
   Hahn P, 2013, RETINA-J RET VIT DIS, V33, P911, DOI 10.1097/IAE.0b013e3182831248
   Han J, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193031
   Hanus J, 2016, BRIT J OPHTHALMOL, V100, P122, DOI 10.1136/bjophthalmol-2015-306972
   He MS, 2018, DIABETES CARE, V41, P2202, DOI 10.2337/dc18-0707
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Hou XG, 2010, BIOCHEM BIOPH RES CO, V396, P199, DOI 10.1016/j.bbrc.2010.04.017
   Hua R, 2017, ONCOTARGET, V8, P2034, DOI 10.18632/oncotarget.14020
   Hyttinen JMT, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20225800
   Joe SG, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119708
   Kaarniranta K, 2017, CELL BIOL TOXICOL, V33, P113, DOI 10.1007/s10565-016-9371-8
   Kaarniranta K, 2011, J ALZHEIMERS DIS, V24, P615, DOI 10.3233/JAD-2011-101908
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kivinen N, 2018, ACTA OPHTHALMOL, V96, P1, DOI 10.1111/aos.13753
   Kulkarni AS, 2018, AGING CELL, V17, DOI 10.1111/acel.12723
   Lee H, 2019, YONSEI MED J, V60, P679, DOI 10.3349/ymj.2019.60.7.679
   Lei R, 2019, INT J MED SCI, V16, P960, DOI 10.7150/ijms.32157
   Li YY, 2012, GENOME MED, V4, DOI 10.1186/gm326
   Marshall SM, 2017, DIABETOLOGIA, V60, P1561, DOI 10.1007/s00125-017-4343-y
   Mitter SK, 2012, ADV EXP MED BIOL, V723, P83, DOI 10.1007/978-1-4614-0631-0_12
   Moher D, 2010, INT J SURG, V8, P336, DOI 10.1016/j.ijsu.2010.02.007
   O'Connor Sean R, 2015, BMC Res Notes, V8, P224, DOI 10.1186/s13104-015-1181-1
   Obi BC, 2016, J DIABETES RES, V2016, DOI 10.1155/2016/1635361
   Penn JS, 2008, PROG RETIN EYE RES, V27, P331, DOI 10.1016/j.preteyeres.2008.05.001
   Rabinovitch RC, 2017, CELL REP, V21, P1, DOI 10.1016/j.celrep.2017.09.026
   Rees A, 2014, EYE, V28, P832, DOI 10.1038/eye.2014.103
   Rivera JC, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/3940241
   Seigel D, 2002, ARCH OPHTHALMOL-CHIC, V120, P100
   Shu CW, 2020, GRAEF ARCH CLIN EXP, V258, P557, DOI 10.1007/s00417-019-04548-z
   Shu DY, 2017, PROG RETIN EYE RES, V60, P44, DOI 10.1016/j.preteyeres.2017.08.001
   Solomon SD, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub4
   Stewart JM, 2020, OPHTHALMOL RETINA, V4, P1118, DOI 10.1016/j.oret.2020.06.003
   Vassilev ZP, 2015, INVEST OPHTH VIS SCI, V56, P1585, DOI 10.1167/iovs.14-16271
   von Elm E, 2008, J CLIN EPIDEMIOL, V61, P344, DOI 10.1016/j.jclinepi.2007.11.008
   Wang JC, 2017, ONCOTARGET, V8, P73892, DOI 10.18632/oncotarget.18029
   Wang J, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/8212063
   Waugh N, 2018, HEALTH TECHNOL ASSES, V22, P1, DOI 10.3310/hta22270
   West SL., 2010, COMP EFFECTIVENESS R
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wong-Riley M, 2010, EYE BRAIN, V2, P99
   Wu J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089600
   Xu L, 2018, P NATL ACAD SCI USA, V115, P10475, DOI 10.1073/pnas.1802724115
   Yi QY, 2016, AM J TRANSL RES, V8, P3947
NR 74
TC 10
Z9 10
U1 1
U2 3
PU SPRINGER INT PUBL AG
PI CHAM
PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND
SN 2193-8245
EI 2193-6528
J9 OPHTHALMOL THER
JI OPHTHALMOL. THER.
PD JUN
PY 2021
VL 10
IS 2
BP 245
EP 260
DI 10.1007/s40123-021-00344-3
EA APR 2021
PG 16
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA RU0LP
UT WOS:000639728200001
PM 33846958
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Ju, MJ
   Kim, J
   Park, SK
   Kim, DH
   Choi, YH
AF Ju, Min Jae
   Kim, Junghoon
   Park, Sung Kyun
   Kim, Dong Hyun
   Choi, Yoon-Hyeong
TI Long-term exposure to ambient air pollutants and age-related macular
   degeneration in middle-aged and older adults
SO ENVIRONMENTAL RESEARCH
LA English
DT Article
DE AMD; Air pollution; Long-term exposure; PM10; NO2; CO
ID NUTRITION EXAMINATION SURVEY; OXIDATIVE STRESS; NATIONAL-HEALTH;
   POLLUTION; MACULOPATHY; DYSFUNCTION; PREVALENCE; BIOMARKERS; LIPIDS
AB In developed countries, age-related macular degeneration (AMD) is a leading cause of irreversible blindness in adults. The key pathways of AMD are suggested to be excessive oxidative stress and inflammation in the central retina. Because air pollution has been found capable of inducing oxidative stress and inflammation, it may play a role in development of AMD. This study investigated the association between ambient air pollution and AMD in 15,115 middle-aged and older adults (>= 40 years) from Korean National Health and Nutrition Examination Survey 2008-2012. After controlling for important confounders, ambient NO2 and CO in current-to-5 prior years and PM10 in 2-to-5 prior years were significantly associated with higher prevalence of early AMD, while O3 in current-to-5 prior years was significantly associated with lower prevalence of early AMD. When modeled air pollution within administrative division units, its ORs with an IQR increase in NO2, CO, and O3 at current year were 1.24 (95% CI: 1.05-1.46), 1.22 (95% CI: 1.09-1.38), and 0.80 (95% CI: 0.70-0.92), respectively. Overall, results from air pollution at local/town units were consistent with those at administrative division units. Longterm exposures to ambient air pollution may play a role in the risk of AMD in middle-aged and older adults.
C1 [Ju, Min Jae; Choi, Yoon-Hyeong] Gachon Univ, Dept Hlth Sci & Technol, GAIHST, Incheon, South Korea.
   [Ju, Min Jae; Choi, Yoon-Hyeong] Gachon Univ, Dept Prevent Med, Coll Med, 155 Gaetbeol Ro, Incheon 21999, South Korea.
   [Kim, Junghoon] Korea Maritime & Ocean Univ, Grad Sch Sports Convergence, Dept Sports Med, Busan, South Korea.
   [Park, Sung Kyun] Univ Michigan, Sch Publ Hlth, Dept Epidemiol, Ann Arbor, MI 48109 USA.
   [Park, Sung Kyun] Univ Michigan, Sch Publ Hlth, Dept Environm Hlth Sci, Ann Arbor, MI 48109 USA.
   [Kim, Dong Hyun] Gachon Univ, Gil Med Ctr, Dept Ophthalmol, Coll Med, Incheon, South Korea.
   [Kim, Dong Hyun] Gachon Univ, Gachon Particulate Matter Associated Dis Inst, Incheon, South Korea.
C3 Gachon University; Gachon University; Korea Maritime & Ocean University;
   University of Michigan System; University of Michigan; University of
   Michigan System; University of Michigan; Gachon University; Gachon
   University
RP Choi, YH (通讯作者)，Gachon Univ, Dept Prevent Med, Coll Med, 155 Gaetbeol Ro, Incheon 21999, South Korea.; Kim, DH (通讯作者)，Gachon Univ, Gil Med Ctr, Dept Ophthalmol, Coll Med, Incheon, South Korea.
EM amidfree@gmail.com; yooncho@gachon.ac.kr
RI Kim, Junghoon/H-4973-2019
OI Kim, Junghoon/0000-0003-4802-010X; Park, Sung Kyun/0000-0001-9981-6250;
   Ju, Min Jae/0000-0001-6890-1911; Choi, Yoon-Hyeong/0000-0003-3228-8179
FU Basic Science Research Program through the National Research Foundation
   of Korea (NRF) - Korea Ministry of Education [2013R1A6A3A04059556];
   Korea Ministry of Science and Information and Communication Technology
   (ITC) [2020R1A2C110170311]; Gachon University Gil Medical Center
   [GCU-2016-5202]
FX This study was supported by the Basic Science Research Program through
   the National Research Foundation of Korea (NRF) funded by the Korea
   Ministry of Education [grant numbers 2013R1A6A3A04059556] and by the
   Korea Ministry of Science and Information and Communication Technology
   (ITC) [grant numbers 2020R1A2C110170311], and was supported by the
   Gachon University Gil Medical Center (Grant number GCU-2016-5202). The
   funding sources played no role in the study design, data collection,
   data analysis, and interpretation of results, or the decisions made in
   preparation and submission of the article.
CR [Anonymous], 2012, KOR HLTH STAT 2012 K
   [Anonymous], 2018, PREV BLINDN VIS IMP
   Bateson TF, 2007, J EXPO SCI ENV EPID, V17, pS90, DOI 10.1038/sj.jes.7500631
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bobb JF, 2015, BIOSTATISTICS, V16, P493, DOI 10.1093/biostatistics/kxu058
   Chang KH, 2019, J INVEST MED, V67, P1076, DOI 10.1136/jim-2019-001007
   Choi YH, 2018, ENVIRON SCI POLLUT R, V25, P10636, DOI 10.1007/s11356-018-1266-1
   Chuang KJ, 2007, AM J RESP CRIT CARE, V176, P370, DOI 10.1164/rccm.200611-1627OC
   Chuang KJ, 2010, J OCCUP ENVIRON MED, V52, P258, DOI 10.1097/JOM.0b013e3181ceff7a
   Delfino RJ, 2011, AIR QUAL ATMOS HLTH, V4, P37, DOI 10.1007/s11869-010-0095-2
   Handa JT, 2017, BBA-MOL CELL BIOL L, V1862, P430, DOI 10.1016/j.bbalip.2016.07.013
   Handa JT, 2012, MOL ASPECTS MED, V33, P418, DOI 10.1016/j.mam.2012.03.006
   Hoek Gerard, 2017, Curr Environ Health Rep, V4, P450, DOI 10.1007/s40572-017-0169-5
   Hwang HS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134338
   Hwang SH, 2016, JAMA OPHTHALMOL, V134, P503, DOI 10.1001/jamaophthalmol.2016.0139
   Imamura Y, 2006, P NATL ACAD SCI USA, V103, P11282, DOI 10.1073/pnas.0602131103
   Keil AP, 2020, ENVIRON HEALTH PERSP, V128, DOI 10.1289/EHP5838
   Kim HJ, 2018, ANN OCCUP ENVIRON ME, V30, DOI 10.1186/s40557-018-0226-z
   Kim JH, 2012, TOXICOL LETT, V214, P263, DOI 10.1016/j.toxlet.2012.09.006
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Korea Census Bureau, 2015, POPULATION HOUSING C
   Korea Centers for Disease Control and Prevention, 2012, SAS MAN KOR NAT HLTH
   Lamichhane DK, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15020363
   Lee KW, 2017, J KOREAN MED SCI, V32, P143, DOI 10.3346/jkms.2017.32.1.143
   Li ZW, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/3628762
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Mitchell P, 2002, ARCH OPHTHALMOL-CHIC, V120, P1357, DOI 10.1001/archopht.120.10.1357
   National Health Insurance Service, 2017, AGE RELATED MACULAR
   National Institute of Environmental Research, 2012, ANN REP AIR QUAL KOR
   Park SJ, 2014, OPHTHALMOLOGY, V121, P1756, DOI 10.1016/j.ophtha.2014.03.022
   Park SK, 2017, ENVIRON HEALTH-GLOB, V16, DOI 10.1186/s12940-017-0310-9
   Rozanova E, 2009, ARH HIG RADA TOKSIKO, V60, P205, DOI 10.2478/10004-1254-60-2009-1869
   Sanidas E, 2017, J AM SOC HYPERTENS, V11, P709, DOI 10.1016/j.jash.2017.09.008
   Shahid H, 2012, BRIT J OPHTHALMOL, V96, P427, DOI 10.1136/bjophthalmol-2011-300193
   Shaw PX, 2016, AIMS MOL SCI, V3, P196, DOI 10.3934/molsci.2016.2.196
   Shin J, 2019, NUTR METAB CARDIOVAS, V29, P144, DOI 10.1016/j.numecd.2018.09.008
   Sun ZC, 2013, ENVIRON HEALTH-GLOB, V12, DOI 10.1186/1476-069X-12-85
   Thiering E, 2015, TRENDS ENDOCRIN MET, V26, P384, DOI 10.1016/j.tem.2015.05.002
   Velilla S, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/895147
   WHO, 2016, AMBIENT AIR POLLUTIO, DOI DOI 10.17159/2410-972X/2016/V26N2A4
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu EW, 2014, ENVIRON RES, V133, P178, DOI 10.1016/j.envres.2014.05.023
   Zafrilla P, 2013, J NUTR HEALTH AGING, V17, P219, DOI 10.1007/s12603-012-0095-z
NR 43
TC 3
Z9 3
U1 5
U2 23
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0013-9351
EI 1096-0953
J9 ENVIRON RES
JI Environ. Res.
PD MAR
PY 2022
VL 204
AR 111953
DI 10.1016/j.envres.2021.111953
EA SEP 2021
PN A
PG 8
WC Environmental Sciences; Public, Environmental & Occupational Health
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
   Health
GA WD1LC
UT WOS:000704710100004
PM 34454934
DA 2022-11-30
ER

PT J
AU Kubicka-Trzaska, A
   Wilanska, J
   Romanowska-Dixon, B
   Sanak, M
AF Kubicka-Trzaska, Agnieszka
   Wilanska, Joanna
   Romanowska-Dixon, Bozena
   Sanak, Marek
TI Circulating antiretinal antibodies predict the outcome of anti-VEGF
   therapy in patients with exudative age-related macular degeneration
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration; antiretinal autoantibody; antivascular
   endothelial growth factor therapy; bevacizumab
AB Purpose: To determine serum antiretinal antibody (ARA) levels in response to treatment with intravitreal bevacizumab of exudative age-related macular degeneration (AMD).
   Methods:The study comprised 22 patients treated with intravitreal bevacizumab (Avastin) 1.25 mg. In all patients, serum ARA levels were assessed by indirect immunofluorescence on normal monkey retina substrate. The ophthalmic examination including best corrected visual acuity (BCVA), fundoscopy, fluorescein angiography, optical coherence tomography (OCT) and immunohistochemical investigations. These were repeated at 4-week intervals during a loading phase of antiangiogenic therapy. Sera of 22 sex-and age-matched healthy subjects were used as controls for immunohistochemical studies.
   Results:Before bevacizumab therapy, ARAs were detected in the sera of all patients at titres ranging from 1:40 to 1:1280. The titres were significantly higher (p < 0.01) than in controls (1:10-1:40). There was no significant correlation between serum ARA titres and neither the type nor the dimensions of choroidal neovascularization, as well as central retinal thickness. Following treatment, all patients demonstrated significant decrease in ARA levels. This correlated with improvement of BCVA, decreased leakage of fluorescein and reduction of subretinal fluid on OCT.
   Conclusion:Serum ARA levels demonstrate a dynamic change which occurs in parallel with clinical outcomes of antiangiogenic therapy. They also may act as markers of the therapeutic benefits of vascular endothelial growth factor inhibition.
C1 [Kubicka-Trzaska, Agnieszka; Romanowska-Dixon, Bozena] Jagiellonian Univ, Coll Med, Dept Ophthalmol & Ocular Oncol, Krakow, Poland.
   [Wilanska, Joanna; Sanak, Marek] Jagiellonian Univ, Coll Med, Div Mol Biol & Clin Genet, Krakow, Poland.
C3 Jagiellonian University; Collegium Medicum Jagiellonian University;
   Jagiellonian University; Collegium Medicum Jagiellonian University
RP Kubicka-Trzaska, A (通讯作者)，Lea Str 244-7, PL-30133 Krakow, Poland.
EM akubicka@onet.pl
RI Sanak, Marek/AAV-1628-2021
OI Sanak, Marek/0000-0001-7635-8103
FU Polish Ministry of Science and Tertiary Education [K/PBH/000052]
FX The work was supported by a grant (K/PBH/000052) from the Polish
   Ministry of Science and Tertiary Education. None of the authors has any
   financial disclosure to make relevant to this manuscript. All authors
   contributed to the concepts expressed and the writing of this
   manuscript.
CR BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   CHANT SM, 1985, BRIT J OPHTHALMOL, V69, P19, DOI 10.1136/bjo.69.1.19
   Cherepanoff S, 2006, CLIN EXP OPHTHALMOL, V34, P590, DOI 10.1111/j.1442-9071.2006.01281.x
   Coutinho A, 1995, CURR OPIN IMMUNOL, V7, P812, DOI 10.1016/0952-7915(95)80053-0
   DUMONDE DC, 1985, T OPHTHAL SOC UK, V104, P232
   ELTABBAKH GH, 1995, GYNECOL ONCOL, V58, P120, DOI 10.1006/gyno.1995.1194
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   GURNE DH, 1991, OPHTHALMOLOGY, V98, P602
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Joachim SC, 2007, GRAEF ARCH CLIN EXP, V245, P619, DOI 10.1007/s00417-006-0429-9
   KASP E, 1989, BRIT J OPHTHALMOL, V73, P722, DOI 10.1136/bjo.73.9.722
   Kubicka-Trzaska Agnieszka, 2009, Przegl Lek, V66, P944
   Kubicka-Trzaska Agnieszka, 2004, Klin Oczna, V106, P45
   Lacroix-Desmazes S, 1998, J IMMUNOL METHODS, V216, P117, DOI 10.1016/S0022-1759(98)00074-X
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Nussenblatt RB, 2007, AM J OPHTHALMOL, V144, P618, DOI 10.1016/j.ajo.2007.06.025
   Patel N, 2005, IMMUNOLOGY, V115, P422, DOI 10.1111/j.1365-2567.2005.02173.x
   PENFOLD PL, 1990, GRAEF ARCH CLIN EXP, V228, P270, DOI 10.1007/BF00920033
   Sugita S, 2009, ARCH IMMUNOL THER EX, V57, P263, DOI 10.1007/s00005-009-0030-0
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zhang J, 2010, CIRC RES, V6, P408
NR 23
TC 12
Z9 13
U1 0
U2 2
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1755-375X
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD FEB
PY 2012
VL 90
IS 1
BP E21
EP E24
DI 10.1111/j.1755-3768.2011.02237.x
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 883HK
UT WOS:000299624600004
PM 21883989
OA Bronze
DA 2022-11-30
ER

PT J
AU Falk, MK
   Singh, A
   Faber, C
   Nissen, MH
   Hviid, T
   Sorensen, TL
AF Falk, Mads Kruger
   Singh, Amardeep
   Faber, Carsten
   Nissen, Mogens Holst
   Hviid, Thomas
   Sorensen, Torben Lykke
TI Blood expression levels of chemokine receptor CCR3 and chemokine CCL11
   in age-related macular degeneration: a case-control study
SO BMC OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; chemokine; CCR3; CCL11
ID EOTAXIN; CELLS; RANIBIZUMAB; BIOMARKERS; DISEASE; TARGET
AB Background: Dysregulation of the CCR3/ CCL11 pathway has been implicated in the pathogenesis of choroidal neovascularisation, a common feature of late age-related macular degeneration (AMD). The aim of this study was to investigate the expression of CCR3 and its ligand CCL11 in peripheral blood in patients with neovascular AMD.
   Methods: Patients with neovascular AMD and healthy controls were included. Blood samples were obtained and prepared for flow cytometry to investigate the expression of CCR3. Levels of CCL11 were measured in plasma using Cytometric Bead Array. Differences between the groups were tested using Kruskal-Wallis test and Mann-Whitney U test.
   Results: Patients (n = 83) with neovascular AMD and healthy control persons (n = 114) were included in the study. No significant difference in the expression of CCR3 was found on CD9+ granulocytes when comparing patients suffering from neovascular AMD with any of the control groups. We did not find any alteration in CCL11 levels in patients among the age matched groups. There was no correlation between expression of CCR3/ CCL11 and clinical response to treatment with anti-vascular endothelial growth factor (VEGF).
   Conclusion: Our results do not suggest a systemic alteration of the CCR3/ CCL11 receptor/ligand complex in patients with neovascular AMD.
C1 [Falk, Mads Kruger; Singh, Amardeep; Sorensen, Torben Lykke] Univ Copenhagen, Dept Ophthalmol, Clin Eye Res Unit, DK-4000 Roskilde, Denmark.
   [Falk, Mads Kruger; Singh, Amardeep; Sorensen, Torben Lykke] Univ Copenhagen, Fac Hlth Sci, DK-4000 Roskilde, Denmark.
   [Faber, Carsten; Nissen, Mogens Holst] Univ Copenhagen, Fac Hlth Sci, Dept Microbiol Immunol & Int Hlth, Copenhagen, Denmark.
   [Hviid, Thomas] Univ Copenhagen, Ctr Immune Regulat & Reprod Immunol, Dept Clin Biochem, DK-4000 Roskilde, Denmark.
   [Hviid, Thomas] Univ Copenhagen, Copenhagen, Denmark.
C3 University of Copenhagen; University of Copenhagen; University of
   Copenhagen; University of Copenhagen
RP Falk, MK (通讯作者)，Univ Copenhagen, Dept Ophthalmol, Clin Eye Res Unit, Kogevej 7-13, DK-4000 Roskilde, Denmark.
EM mailtilmads@gmail.com
RI Singh, Amardeep/ABI-4544-2020; Sørensen, Torben Lykke L/N-1417-2014;
   Faber, Carsten/N-3210-2019; Faber, Carsten/I-4150-2013
OI Sørensen, Torben Lykke L/0000-0002-6790-0199; Faber,
   Carsten/0000-0002-2517-7270; Faber, Carsten/0000-0002-2517-7270
FU Danish Eye Health Society (Vaern om Synet); Danish Eye Research
   foundation; Region Zealand's Research Fund; Synoptik Foundation
FX This study was supported by the Danish Eye Health Society (Vaern om
   Synet), the Danish Eye Research foundation, Region Zealand's Research
   Fund, and the Synoptik Foundation. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Ahmad I, 2011, INVEST OPHTH VIS SCI, V52, P2868, DOI 10.1167/iovs.10-6608
   Bloch SB, 2013, ACTA OPHTHALMOL, V91, P42, DOI 10.1111/j.1755-3768.2011.02268.x
   Burgisser P, 2007, CYTOM PART A, V71A, P632, DOI 10.1002/cyto.a.20414
   Eghoj MS, 2012, BRIT J OPHTHALMOL, V96, P21, DOI 10.1136/bjo.2011.203893
   Falk MK, 2013, AM J OPHTHALMOL, V155, P89, DOI 10.1016/j.ajo.2012.06.031
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Jeon H, 2012, CYTOKINE, V60, P487, DOI 10.1016/j.cyto.2012.07.014
   Li YW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017106
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Miller JW, 2013, AM J OPHTHALMOL, V155, P1, DOI 10.1016/j.ajo.2012.10.018
   Mizutani T, 2013, INVEST OPHTH VIS SCI, V54, P1564, DOI 10.1167/iovs.11-9095
   Mo FM, 2010, INVEST OPHTH VIS SCI, V51, P4226, DOI 10.1167/iovs.09-3910
   Pease JE, 2006, J ALLERGY CLIN IMMUN, V118, P305, DOI 10.1016/j.jaci.2006.06.010
   Rankin SM, 2000, MOL MED TODAY, V6, P20, DOI 10.1016/S1357-4310(99)01635-4
   Romagnani P, 1999, AM J PATHOL, V155, P1195, DOI 10.1016/S0002-9440(10)65222-4
   Salcedo R, 2001, J IMMUNOL, V166, P7571, DOI 10.4049/jimmunol.166.12.7571
   Sharma NK, 2013, GENE, V523, P106, DOI 10.1016/j.gene.2013.03.052
   Sharma NK, 2012, DNA CELL BIOL, V31, P1618, DOI 10.1089/dna.2012.1786
   Shurin GV, 2007, CYTOKINE, V39, P123, DOI 10.1016/j.cyto.2007.06.006
   Singh A, 2013, OPHTHALMOLOGY, V120, P1029, DOI 10.1016/j.ophtha.2012.11.002
   Takeda A, 2009, NATURE, V460, P225, DOI 10.1038/nature08151
   Villeda SA, 2011, NATURE, V477, P90, DOI 10.1038/nature10357
   Wang HB, 2011, INVEST OPHTH VIS SCI, V52, P8271, DOI 10.1167/iovs.11-8230
   Xie P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028933
NR 24
TC 12
Z9 12
U1 0
U2 2
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD FEB 27
PY 2014
VL 14
AR 22
DI 10.1186/1471-2415-14-22
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AF1FC
UT WOS:000334458800001
PM 24575855
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Abdelfattah, NS
   Sadda, J
   Wang, ZY
   Hu, ZH
   Sadda, S
AF Abdelfattah, Nizar Saleh
   Sadda, Jaya
   Wang, Ziyuan
   Hu, Zhihong
   Sadda, Srinivas
TI Near-Infrared Reflectance Imaging for Quantification of Atrophy
   Associated with Age-Related Macular Degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID GEOGRAPHIC ATROPHY; FUNDUS AUTOFLUORESCENCE
AB PURPOSE: To compare measurements of area of geographic atrophy (GA) in dry age-related macular degeneration (AMD) obtained by fundus autofluorescence (FAF) to those obtained by near-infrared reflectance (NIR).
   DESIGN: Interrater reliability analysis.
   METHODS: Ninety-seven confocal NIR images (Heidelberg HRA + Spectralis) and FAF images from 97 patients/eyes with GA with dry AMD were collected retrospectively from existing anonymized Doheny Image Reading Center datasets. Two masked reading center graders (N.S., J.S.) independently and blindly performed manual segmentation of the GA lesions on each NIR and FAF image using GNU Image Manipulation Program software (version 2.8.22). GA on NIR/FAF images was defined in accordance to recently published Classification of Atrophy Meeting criteria as sharply demarcated hyperreflective regions 2250 pm in diameter. The difference and point-to-point correspondence between gradings in GA area measurements between NIR and FAF were assessed by mean difference, overlap ratio, and Dice similarity coefficient.
   RESULTS: Among the 97 eyes with dry AMD, the mean GA area was 7.62 +/- 7.77 mm 2 from FAF images and 7.65 +/- 7.83 mm(2) from NIR, with a mean nonsignificant difference of 0.31 +/- 0.55 mm(2) (2-tailed t test, P = .65). The overlap ratio in the segmented GA lesion between modalities was 0.84 +/- 0.28 with a Dice similarity coefficient of 0.87 +/- 0.27. Intermodal reliability was high (intraclass correlation coefficient = 0.998, P < .01). Of note, in 5 cases (5.2%), the GA lesion could be identified on the FAF image but not on the NIR image, translating into a sensitivity of 94.8%.
   CONCLUSIONS: GA lesions in dry AMD can be identified and quantified reliably using NIR images in many cases, though eyes with a thin choroid resulting in isoreflective GA lesions may be challenging. NIR imaging is comfortable for patients and is commonly obtained along with OCT, and therefore NIR-based GA assessment may be a useful surrogate in clinical settings. (C) 2020 Elsevier Inc. All rights reserved.
C1 [Abdelfattah, Nizar Saleh; Sadda, Srinivas] Univ Calif Los Angeles, David Geffen Sch Med, Dept Ophthalmol, Los Angeles, CA 90032 USA.
   [Abdelfattah, Nizar Saleh] Montefiore Med Ctr, Albert Einstein Coll Med, Bronx, NY 10467 USA.
   [Sadda, Jaya; Wang, Ziyuan; Hu, Zhihong; Sadda, Srinivas] Doheny Eye Inst, Doheny Image Anal Lab, 1355 San Pablo St, Los Angeles, CA 90033 USA.
C3 University of California System; University of California Los Angeles;
   University of California Los Angeles Medical Center; David Geffen School
   of Medicine at UCLA; Montefiore Medical Center; Yeshiva University;
   Albert Einstein College of Medicine; Doheny Eye Institute
RP Abdelfattah, NS (通讯作者)，Univ Calif Los Angeles, David Geffen Sch Med, Doheny Eye Inst, Dept Ophthalmol, 1355 San Pablo St,Ste 100, Los Angeles, CA 90032 USA.
EM myretina@outlook.com
RI Abdelfattah, Nizar Saleh/H-6908-2019
OI Abdelfattah, Nizar Saleh/0000-0002-9396-3054
FU BrightFocus Foundation; Macula Vision Research Foundation
FX Publication of this article was supported in part by grant support from
   the BrightFocus Foundation and the Macula Vision Research Foundation.
CR Abdelfattah NS, 2017, OPHTHALMOLOGY, V124, P215, DOI 10.1016/j.ophtha.2016.10.002
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Dolz-Marco R, 2016, INVEST OPHTH VIS SCI, V57, P6440, DOI 10.1167/iovs.16-20265
   Forte R, 2012, ACTA OPHTHALMOL, V90, pE281, DOI 10.1111/j.1755-3768.2011.02331.x
   Holz FG, 2017, OPHTHALMOLOGY, V124, P464, DOI 10.1016/j.ophtha.2016.12.002
   Hwang JC, 2006, INVEST OPHTH VIS SCI, V47, P2655, DOI 10.1167/iovs.05-1027
   Lindblad AS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1168, DOI 10.1001/archophthalmol.2009.198
   Lindner M, 2015, OPHTHALMOLOGY, V122, P1356, DOI 10.1016/j.ophtha.2015.03.027
   Ly A, 2016, OPHTHAL PHYSL OPT, V36, P303, DOI 10.1111/opo.12283
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P878, DOI 10.1016/j.ophtha.2017.12.026
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Schmitz-Valckenberg S, 2008, AM J OPHTHALMOL, V146, P183, DOI 10.1016/j.ajo.2008.04.006
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P7640, DOI 10.1167/iovs.11-7457
   Sparrow JR, 2012, PROG RETIN EYE RES, V31, P121, DOI 10.1016/j.preteyeres.2011.12.001
   VONRUCKMANN A, 1995, BRIT J OPHTHALMOL, V79, P407, DOI 10.1136/bjo.79.5.407
NR 17
TC 6
Z9 6
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD APR
PY 2020
VL 212
BP 169
EP 174
DI 10.1016/j.ajo.2020.01.005
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA LG1DC
UT WOS:000527849400019
PM 31945331
DA 2022-11-30
ER

PT J
AU Zhao, S
   Lan, XW
   Wu, JY
   Yue, S
   Zhang, H
   Wu, Q
   Zhang, GS
   Liu, L
AF Zhao, Shan
   Lan, Xiaowen
   Wu, Jingyang
   Yue, Song
   Zhang, Han
   Wu, Qiang
   Zhang, Guisen
   Liu, Lei
TI Protocol of global incidence and progression of age-related macular
   degeneration: A systematic review
SO MEDICINE
LA English
DT Review
DE age-related macular degeneration; burden; incidence; meta-analysis;
   progression
ID PREVALENCE; DISEASE; BIAS
AB Background:There have been many reports on the prevalence and incidence of age-related macular degeneration (AMD), and there are some systematic reviews reporting on the pooled prevalence of AMD. However, there is no systematic review of incidence or progression of AMD worldwide. Given the few evidences regarding the pooled incidence or progression of AMD, we performed this meta-analysis protocol to investigate the global incidence or progression of AMD. In addition, we will investigate the risk factors for AMD incidence or progression using meta-analysis.Methods:Four English databases (PubMed, EMBASE, Cochrane Library, and Web of Science) and four Chinese databases (CMB, CNKI, VIP, and Wanfang database) will be searched to identify relevant studies. The primary outcome of this meta-analysis is the incidence or progression of AMD. The second outcome of this meta-analysis is risk factors for the incidence or progression of AMD. Meta-analysis was performed to calculate the pooled incidence or progression rate and 95% confidence interval of AMD. Pooled risk ratios of risk factors (age, gender, smoking, and hypertension) for AMD incidence or progression were computed as the Mantel-Haenszel-weighted average of the risk ratios for all included studies. Sensitivity analysis, subgroup analysis, quality assessment, and publication bias analysis will be performed to ensure the reliability of our findings.Results:This study will provide a current evidence of global pooled incidence or progression of AMD. Further, current study will provide evidence-based risk factors for AMD incidence or progression. Moreover, our study will project the incident number of people with AMD from 2030 to 2050.Conclusion:This systematic review and meta-analysis will provide evidence to develop major public health strategies for preventing AMD. Ethics and dissemination: ethical approval is not required because our systematic review and meta-analysis will be based on published data without interventions on patients. The findings of this study will be published in a peer-reviewed journal.
C1 [Zhao, Shan] China Med Univ, Affiliated Hosp 1, Dept Rheumatol & Immunol, Shenyang, Liaoning, Peoples R China.
   [Lan, Xiaowen; Wu, Qiang] Datong Chaoju Eye Hosp, Datong, Peoples R China.
   [Wu, Jingyang; Yue, Song; Zhang, Han; Liu, Lei] China Med Univ, Affiliated Hosp 1, Dept Ophthalmol, Shenyang, Liaoning, Peoples R China.
   [Zhang, Guisen] Hohhot Chaoju Eye Hosp, Hohhot, Peoples R China.
C3 China Medical University; China Medical University
RP Zhang, GS; Liu, L (通讯作者)，China Med Univ, Hosp 1, Shenyang 110001, Liaoning, Peoples R China.
EM zhangguisen76@sohu.com; liuleijiao@163.com
OI Zhang, Han/0000-0002-9338-0051
FU National Natural Science Foundation of China [81300783]; Department of
   Education of Liaoning Province [LQNK201703]
FX This article is supported by the National Natural Science Foundation of
   China (No. 81300783) and Department of Education of Liaoning Province
   (No. LQNK201703). The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Hoy D, 2012, J CLIN EPIDEMIOL, V65, P934, DOI 10.1016/j.jclinepi.2011.11.014
   Knobloch K, 2011, J CRANIO MAXILL SURG, V39, P91, DOI 10.1016/j.jcms.2010.11.001
   Koye DN, 2017, DIABETIC MED, V34, P887, DOI 10.1111/dme.13324
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Moher D., 2009, CULT MED PSYCHIAT, V6, DOI [10.1371/journal.pmed.1000097, DOI 10.1023/B:MEDI.0000005484.26741.79, 10.1371/journal.pmed1000097]
   Rudnicka AR, 2015, AM J OPHTHALMOL, V160, P85, DOI 10.1016/j.ajo.2015.04.003
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 8
TC 7
Z9 8
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD MAR
PY 2019
VL 98
IS 10
AR e14645
DI 10.1097/MD.0000000000014645
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA HQ6ZY
UT WOS:000462570100021
PM 30855452
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Gopinath, B
   Liew, G
   Kifley, A
   Flood, VM
   Joachim, N
   Lewis, JR
   Hodgson, JM
   Mitchell, P
AF Gopinath, Bamini
   Liew, Gerald
   Kifley, Annette
   Flood, Victoria M.
   Joachim, Nichole
   Lewis, Joshua R.
   Hodgson, Jonathan M.
   Mitchell, Paul
TI Dietary flavonoids and the prevalence and 15-y incidence of age-related
   macular degeneration
SO AMERICAN JOURNAL OF CLINICAL NUTRITION
LA English
DT Article
DE age-related macular degeneration; flavonoids; Blue Mountains Eye Study;
   prevalence; incidence
ID EYE DISEASE; 10-YEAR INCIDENCE; NITRIC-OXIDE; PRODUCTS; ANTIOXIDANT;
   MACULOPATHY; DYSFUNCTION; PROGRESSION; QUERCETIN; AUSTRALIA
AB Background: The majority of research performed to date has examined the effects of commonly known antioxidants such as vitamins C, E, and A and carotenoids on age-related macular degeneration (AMD) risk and progression. To date, there is limited research on promising phytochemicals with antioxidant and antiinflammatory properties, including flavonoids.
   Objective: In this exploratory study, we aimed to assess the independent associations between dietary intake of total flavonoids and common flavonoid classes with the prevalence and 15-y incidence of AMD.
   Design: In this population-based cohort study, 2856 adults aged >= 49 y at baseline and 2037 followed up 15 y later were included in prevalence and incidence analyses, respectively. Dietary intake was assessed by using a semiquantitative food-frequency questionnaire (FFQ). Estimates of the flavonoid content of foods in the FFQ were assessed by using the USDA Flavonoid, Isoflavone, and Proanthocyanidin databases. AMD was assessed from retinal photographs.
   Results: In cross-sectional analysis, each 1-SD increase in total overall flavonoid intake was associated with a reduced likelihood of any AMD (multivariable-adjusted OR: 0.76; 95% CI: 0.58, 0.99). Each 1-SD increase in dietary intake of total flavonols and total flavanones was associated with reduced odds of the prevalence of any AMD [multivariable-adjusted OR (95% CI): 0.75 (0.58, 0.97) and 0.77 (0.60, 0.99), respectively]. A marginally significant trend (P = 0.05) was observed between increasing the intake of total flavanone and hesperidin (from the first to the fourth quartile) and reduced likelihood of incident late AMD, after multivariable adjustment. Participants who reported >= 1 serving of oranges/d compared with those who never consumed oranges at baseline had a reduced risk of late AMD 15 y later (multivariable-adjusted OR: 0.39; 95% CI: 0.18, 0.85).
   Conclusions: Our findings suggest an independent and protective association between dietary intake of flavonoids and the likelihood of having AMD.
C1 [Gopinath, Bamini; Liew, Gerald; Kifley, Annette; Joachim, Nichole; Mitchell, Paul] Univ Sydney, Sch Publ Hlth, Dept Ophthalmol, Ctr Vis Res, Sydney, NSW, Australia.
   [Gopinath, Bamini; Liew, Gerald; Kifley, Annette; Joachim, Nichole; Mitchell, Paul] Univ Sydney, Sch Publ Hlth, Westmead Inst Med Res, Sydney, NSW, Australia.
   [Flood, Victoria M.] Univ Sydney, Sch Publ Hlth, Fac Hlth Sci, Sydney, NSW, Australia.
   [Lewis, Joshua R.] Univ Sydney, Sch Publ Hlth, Ctr Kidney Res, Sydney, NSW, Australia.
   [Flood, Victoria M.] Western Sydney Local Hlth Dist, Westmead Hosp, Westmead, NSW, Australia.
   [Lewis, Joshua R.; Hodgson, Jonathan M.] Edith Cowan Univ, Sch Med & Hlth Sci, Perth, WA, Australia.
   [Lewis, Joshua R.; Hodgson, Jonathan M.] Univ Western Australia, Sch Med, Perth, WA, Australia.
C3 University of Sydney; University of Sydney; Westmead Institute for
   Medical Research; University of Sydney; University of Sydney; University
   of Sydney; Edith Cowan University; University of Western Australia
RP Gopinath, B (通讯作者)，Univ Sydney, Sch Publ Hlth, Dept Ophthalmol, Ctr Vis Res, Sydney, NSW, Australia.; Gopinath, B (通讯作者)，Univ Sydney, Sch Publ Hlth, Westmead Inst Med Res, Sydney, NSW, Australia.
EM bamini.gopinath@sydney.edu.au
RI Liew, Gerald/AAB-6870-2022; Flood, Victoria M/A-8732-2016; Gopinath,
   Bamini/K-4286-2019; lewis, josh/GZG-7164-2022; Hodgson, Jonathan
   M/C-3900-2008
OI Flood, Victoria M/0000-0001-5310-7221; Gopinath,
   Bamini/0000-0003-3573-359X; Hodgson, Jonathan M/0000-0001-6184-7764
FU Australian National Health and Medical Research Council [974159, 991407,
   211069, 262120]; Westmead Institute for Medical Research; National
   Health and Medical Research Council (NHMRC) Senior Research Fellowship;
   Royal Perth Hospital Medical Research Foundation Fellowship; NHMRC
   Career Development Fellowship [1107474]
FX The Blue Mountains Eye Study was funded by the Australian National
   Health and Medical Research Council (grants 974159, 991407, 211069, and
   262120) and the Westmead Institute for Medical Research. The salary of
   JMH was supported by a National Health and Medical Research Council
   (NHMRC) Senior Research Fellowship and a Royal Perth Hospital Medical
   Research Foundation Fellowship. The salary of JRL is supported by an
   NHMRC Career Development Fellowship (ID: 1107474).
CR [Anonymous], 2005, ARCH OPHTHALMOL-CHIC, V123, P1570, DOI DOI 10.1001/ARCHOPHT.123.11.1570
   Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   Bhagwat S, 2008, USDA DATABASE ISOFLA
   Bhagwat S., 2015, USDA DATABASE PROANT
   Bhagwat S, 2014, USDA DATABASE FLAVIN
   Bondonno CP, 2015, NUTR REV, V73, P216, DOI 10.1093/nutrit/nuu014
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Broadhead GK, 2015, NUTR REV, V73, P448, DOI 10.1093/nutrit/nuv005
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P142, DOI 10.1001/jamaophthalmol.2013.7376
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chew EY, 2012, OPHTHALMOLOGY, V119, P2282, DOI 10.1016/j.ophtha.2012.05.027
   CHUGAHUJA JK, 1993, J AM DIET ASSOC, V93, P318, DOI 10.1016/0002-8223(93)91559-9
   COX DR, 1972, J R STAT SOC B, V34, P187
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Fine JP, 1999, J AM STAT ASSOC, V94, P496, DOI 10.2307/2670170
   Foran S, 2003, OPHTHALMIC EPIDEMIOL, V10, P215, DOI 10.1076/opep.10.4.215.15906
   Gopinath B, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-04697-3
   Gopinath B, 2016, INVEST OPHTH VIS SCI, V57, P5273, DOI 10.1167/iovs.16-19735
   Gopinath B, 2014, BRIT J NUTR, V111, P1673, DOI 10.1017/S000711451300408X
   Gopinath B, 2013, AM J CLIN NUTR, V98, P129, DOI 10.3945/ajcn.112.057091
   Holliday EG, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0082305, 10.1371/journal.pone.0053830]
   Ivey KL, 2015, AM J CLIN NUTR, V101, P1012, DOI 10.3945/ajcn.113.073106
   Ivey KL, 2013, BRIT J NUTR, V110, P1648, DOI 10.1017/S0007114513000780
   Johannot L, 2006, PUBLIC HEALTH NUTR, V9, P1045, DOI 10.1017/PHN2006971
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kaushik S, 2008, AM J CLIN NUTR, V88, P1104, DOI 10.1093/ajcn/88.4.1104
   KLEIN BEK, 1989, INVEST OPHTH VIS SCI, V30, P304
   Klein R, 2014, JAMA OPHTHALMOL, V132, P446, DOI 10.1001/jamaophthalmol.2013.7671
   Loke WM, 2008, AM J CLIN NUTR, V88, P1018, DOI 10.1093/ajcn/88.4.1018
   Loke WM, 2008, BIOCHEM PHARMACOL, V75, P1045, DOI 10.1016/j.bcp.2007.11.002
   Majumdar S, 2010, J PHARM PHARMACOL, V62, P951, DOI 10.1211/jpp.62.08.0001
   McLennan W, 1995, 48070 AUSTR BUR STAT
   Middleton E, 1998, ADV EXP MED BIOL, V439, P175
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Mink PJ, 2007, AM J CLIN NUTR, V85, P895, DOI 10.1093/ajcn/85.3.895
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Nijveldt RJ, 2001, AM J CLIN NUTR, V74, P418
   Paper DH, 1998, PLANTA MED, V64, P686, DOI 10.1055/s-2006-957559
   Rhone M, 2008, NUTR REV, V66, P465, DOI 10.1111/j.1753-4887.2008.00078.x
   RiceEvans CA, 1996, BIOCHEM SOC T, V24, P790, DOI 10.1042/bst0240790
   Schroeter H, 2006, P NATL ACAD SCI USA, V103, P1024, DOI 10.1073/pnas.0510168103
   Tan JSL, 2009, ARCH OPHTHALMOL-CHIC, V127, P656, DOI 10.1001/archophthalmol.2009.76
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   WILLETT WC, 1988, AM J EPIDEMIOL, V127, P188, DOI 10.1093/oxfordjournals.aje.a114780
NR 44
TC 17
Z9 17
U1 1
U2 10
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0002-9165
EI 1938-3207
J9 AM J CLIN NUTR
JI Am. J. Clin. Nutr.
PD AUG
PY 2018
VL 108
IS 2
BP 381
EP 387
DI 10.1093/ajcn/nqy114
PG 7
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA GT3ML
UT WOS:000444407100018
PM 29982448
OA Bronze, Green Submitted
DA 2022-11-30
ER

PT J
AU Costagliola, C
   Agnifili, L
   Arcidiacono, B
   Duse, S
   Fasanella, V
   Mastropasqua, R
   Verolino, M
   Semeraro, F
AF Costagliola, Ciro
   Agnifili, Luca
   Arcidiacono, Barbara
   Duse, Sarah
   Fasanella, Vincenzo
   Mastropasqua, Rodolfo
   Verolino, Marco
   Semeraro, Francesco
TI Systemic thromboembolic adverse events in patients treated with
   intravitreal anti-VEGF drugs for neovascular age-related macular
   degeneration
SO EXPERT OPINION ON BIOLOGICAL THERAPY
LA English
DT Review
DE aflibercept; age-related macular degeneration; anti-VEGF; bevacizumab;
   intravitreal administration; pegaptanib; ranibizumab; systemic adverse
   events; systemic side effects
ID ENDOTHELIAL GROWTH-FACTOR; VERTEPORFIN PHOTODYNAMIC THERAPY;
   VASCULAR-PERMEABILITY FACTOR; RETINAL-PIGMENT EPITHELIUM; FACTOR
   TRAP-EYE; BEVACIZUMAB AVASTIN(R); CHOROIDAL NEOVASCULARIZATION; VISUAL
   IMPAIRMENT; SUBGROUP ANALYSIS; IN-VITRO
AB Introduction: The consistent association between choroid neovascularization (CNV) and increased VEGF-A expression provides a strong reason for exploring the therapeutic potential of anti-VEGF agents in the treatment of neovascular age-related macular degeneration (AMD). The authors report the systemic side effects secondary to intravitreal administration of these compounds, that is, the main cardiovascular effects, as well as the less frequent cerebrovascular accidents, myocardial infarction, transient ischemic attacks, deep vein thrombosis, pulmonary embolism and thromboflebitis.
   Areas covered: The authors reviewed major Clinical Trials and publications concerning systemic adverse events of anti-VEGF drugs in order to identify the main thromboembolic events related to the use of these agents and their occurrence. Anti-VEGF efficacy, safety and tolerability are also discussed.
   Expert opinion: Three compounds (pegaptanib, ranibizumab and aflibercept) have been approved for the treatment of AMD; a fourth agent, bevacizumab, is used off-label. Anti-VEGF therapy has not shown the ability to fully eradicate the CNV, so that recurrences are common when the intravitreal injections are suspended. Although no evident rise in anti-VEGF-induced thromboembolic side effects was reported, more data are required to evaluate hemodynamic and pharmacokinetics of these compounds. Since only few studies have focused on these aspects, further researches are mandatory to determine distribution, effects and duration of these substances.
C1 [Arcidiacono, Barbara; Duse, Sarah; Semeraro, Francesco] Univ Brescia, Dipartimento Specialita Chirurg Sci Radiol & Med, Brescia, Italy.
   [Costagliola, Ciro; Verolino, Marco] Univ Molise, Dipartimento Sci Salute, Campobasso, Italy.
   [Agnifili, Luca; Fasanella, Vincenzo] Univ G dAnnunzio, Dipartimento Med & Sci Invecchiamento, Chieti, Italy.
   [Mastropasqua, Rodolfo] Univ Verona, Dipartimento Sci Neurol Neuropsicol Morfol & Moto, I-37100 Verona, Italy.
C3 University of Brescia; University of Molise; G d'Annunzio University of
   Chieti-Pescara; University of Verona
RP Semeraro, F (通讯作者)，Univ Brescia, Dipartimento Specialita Chirurg Sci Radiol & Med, Brescia, Italy.
EM semeraro@med.unibs.it
RI Semeraro, Francesco fs/K-8667-2016; Mastropasqua, Rodolfo/AAC-6453-2022;
   Costagliola, Ciro/G-5707-2012; Agnifili, Luca/AAC-6345-2022
OI Semeraro, Francesco fs/0000-0002-2275-4917; Costagliola,
   Ciro/0000-0001-8477-6188; 
CR Abraham P, 2010, AM J OPHTHALMOL, V150, P315, DOI 10.1016/j.ajo.2010.04.011
   [Anonymous], 2006, LUC PACK INS
   Antoszyk AN, 2008, AM J OPHTHALMOL, V145, P862, DOI 10.1016/j.ajo.2007.12.029
   Apte RS, 2007, OPHTHALMOLOGY, V114, P1702, DOI 10.1016/j.ophtha.2007.02.021
   ASAHARA T, 1995, CIRCULATION, V91, P2793, DOI 10.1161/01.CIR.91.11.2793
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P2179, DOI 10.1016/j.ophtha.2007.09.012
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P855, DOI 10.1016/j.ophtha.2007.01.017
   Barleon B, 1996, BLOOD, V87, P3336, DOI 10.1182/blood.V87.8.3336.bloodjournal8783336
   Bashshur ZF, 2007, ARCH OPHTHALMOL-CHIC, V125, P1357, DOI 10.1001/archopht.125.10.1357
   Bhisitkul RB, 2006, BRIT J OPHTHALMOL, V90, P1542, DOI 10.1136/bjo.2006.098426
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Boyer DS, 2008, ANN M AM AC OPHTH 8
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2011, OPHTHALMOLOGY, V118, P1089, DOI 10.1016/j.ophtha.2011.02.039
   Campa C, 2011, CURR DRUG TARGETS, V12, P173, DOI 10.2174/138945011794182674
   Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0
   Chakravarthy U, 2006, OPHTHALMOLOGY, V113, P1508, DOI 10.1016/j.ophtha.2006.02.064
   Chong NV, 2009, EYE, V23, P1250, DOI 10.1038/eye.2009.84
   Ciulla TA, 2009, CURR OPIN OPHTHALMOL, V20, P158, DOI 10.1097/ICU.0b013e32832d25b3
   CONNOLLY DT, 1989, J CLIN INVEST, V84, P1470, DOI 10.1172/JCI114322
   Costagliola C, 2010, BRIT J OPHTHALMOL, V94, P180, DOI 10.1136/bjo.2009.159343
   Csaky K, 2009, AM J OPHTHALMOL, V148, P647, DOI 10.1016/j.ajo.2009.06.014
   CUNHAVAZ J, 1975, BRIT J OPHTHALMOL, V59, P649, DOI 10.1136/bjo.59.11.649
   Curtis LH, 2010, ARCH OPHTHALMOL-CHIC, V128, P1273, DOI 10.1001/archophthalmol.2010.223
   Dincer M, 2006, ANN PHARMACOTHER, V40, P2278, DOI 10.1345/aph.1H244
   Do DV, 2007, IOVS, V48
   Drolet DW, 2000, PHARMACEUT RES, V17, P1503, DOI 10.1023/A:1007657109012
   Eremina V, 2008, NEW ENGL J MED, V358, P1129, DOI 10.1056/NEJMoa0707330
   Espinosa-Heidmann DG, 2005, EXP EYE RES, V80, P413, DOI 10.1016/j.exer.2004.10.008
   Fauser S, 2004, GRAEF ARCH CLIN EXP, V242, P582, DOI 10.1007/s00417-004-0895-x
   Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381
   Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027
   FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V22, P64
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   Gennaro G, 2003, CIRCULATION, V107, P230, DOI 10.1161/01.CIR.0000050652.47145.4C
   Gerber HP, 1998, J BIOL CHEM, V273, P13313, DOI 10.1074/jbc.273.21.13313
   Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336
   Gerhardt H, 2003, J CELL BIOL, V161, P1163, DOI 10.1083/jcb.200302047
   Gogat K, 2004, INVEST OPHTH VIS SCI, V45, P7, DOI 10.1167/iovs.02-1096
   Gordon MS, 2005, ONCOLOGY-BASEL, V69, P25, DOI 10.1159/000088481
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Grisanti Salvatore, 2007, Indian Journal of Ophthalmology, V55, P417
   Heier JS, 2011, OPHTHALMOLOGY, V118, P1098, DOI 10.1016/j.ophtha.2011.03.020
   Heier JS, 2011, ANG EX DEG 2011 12 F
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Hood JD, 1998, AM J PHYSIOL-HEART C, V274, pH1054
   Hutter R, 2004, CIRCULATION, V110, P2430, DOI 10.1161/01.CIR.0000145120.37891.8A
   Ishida S, 2003, J EXP MED, V198, P483, DOI 10.1084/jem.20022027
   Ishida S, 2003, INVEST OPHTH VIS SCI, V44, P2155, DOI 10.1167/iovs.02-0807
   Iyer MN, 2006, INVEST OPHTH VIS SCI, V47, P317, DOI 10.1167/iovs.05-1124
   Jin KL, 2002, P NATL ACAD SCI USA, V99, P11946, DOI 10.1073/pnas.182296499
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Kaiser PK, 2007, OPHTHALMOLOGY, V114, P1868, DOI 10.1016/j.ophtha.2007.04.030
   Kilickap S, 2003, J CLIN ONCOL, V21, P3542, DOI 10.1200/JCO.2003.99.046
   Kim I, 1999, INVEST OPHTH VIS SCI, V40, P2115
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Krohne TU, 2008, AM J OPHTHALMOL, V146, P508, DOI 10.1016/j.ajo.2008.05.036
   Lee JH, 2005, P NATL ACAD SCI USA, V102, P18902, DOI 10.1073/pnas.0509069102
   Lee S, 2005, J CELL BIOL, V169, P681, DOI 10.1083/jcb.200409115
   LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986
   Marneros AG, 2005, AM J PATHOL, V167, P1451, DOI 10.1016/S0002-9440(10)61231-X
   Martin AC, 2004, INVEST OPHTH VIS SCI, V45, P3387, DOI 10.1167/iovs.04-0349
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Matsuyama K, 2010, BRIT J OPHTHALMOL, V94, P1215, DOI 10.1136/bjo.2008.156810
   Mete A, 2010, J CLIN ULTRASOUND, V38, P66, DOI 10.1002/jcu.20650
   Meyer T, 2009, J THROMB HAEMOST, V7, P171, DOI 10.1111/j.1538-7836.2008.03212.x
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Miyake T, 2010, INVEST OPHTH VIS SCI, V51, P1606, DOI 10.1167/iovs.09-4140
   Mourad JJ, 2008, ANN ONCOL, V19, P927, DOI 10.1093/annonc/mdm550
   Ng E, 2006, INVEST OPHTH VIS SCI, V47, P4829
   Ng EWM, 2006, NAT REV DRUG DISCOV, V5, P123, DOI 10.1038/nrd1955
   Nguyen QD, 2006, OPHTHALMOLOGY, V113, P1522, DOI 10.1016/j.ophtha.2006.05.055
   Nguyen QD, 2009, OPHTHALMOLOGY, V116, P2141, DOI 10.1016/j.ophtha.2009.04.030
   Ohr M, 2012, EXPERT OPIN PHARMACO, V13, P585, DOI 10.1517/14656566.2012.658368
   Olofsson B, 1998, P NATL ACAD SCI USA, V95, P11709, DOI 10.1073/pnas.95.20.11709
   PARK JE, 1993, MOL BIOL CELL, V4, P1317, DOI 10.1091/mbc.4.12.1317
   PARK JE, 1994, J BIOL CHEM, V269, P25646
   Pepper MS, 2001, THROMB HAEMOSTASIS, V86, P346
   Presta LG, 1997, CANCER RES, V57, P4593
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Roh MI, 2009, RETINA-J RET VIT DIS, V29, P523, DOI 10.1097/IAE.0b013e318195cb15
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHALMOLOGY, V112, P1048, DOI 10.1016/j.ophtha.2005.01.043
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Rosenstein JM, 2004, EXP NEUROL, V187, P246, DOI 10.1016/j.expneurol.2004.01.022
   Safran M, 2003, J CLIN INVEST, V111, P779, DOI 10.1172/JCI200318181
   Saishin Y, 2003, J CELL PHYSIOL, V195, P241, DOI 10.1002/jcp.10246
   Sane David C., 2004, Angiogenesis, V7, P193, DOI 10.1007/s10456-004-2699-3
   Scappaticci FA, 2007, JNCI-J NATL CANCER I, V99, P1232, DOI 10.1093/jnci/djm086
   Schmidt-Erfurth U, 2011, ANG EX DEG 2011 12 F
   SCHOLES GN, 1985, ARCH OPHTHALMOL-CHIC, V103, P1567
   SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562
   SHIBUYA M, 1990, ONCOGENE, V5, P519
   Stewart MW, 2012, MAYO CLIN PROC, V87, P77, DOI 10.1016/j.mayocp.2011.10.001
   Stewart Michael W., 2011, Inflammation & Allergy Drug Targets, V10, P497
   STONE J, 1995, J NEUROSCI, V15, P4738, DOI 10.1523/jneurosci.15-07-04738.1995
   Takahashi H, 2005, CLIN SCI, V109, P227, DOI 10.1042/CS20040370
   Tam BYY, 2006, NAT MED, V12, P793, DOI 10.1038/nm1428
   Tunon J, 2009, SURV OPHTHALMOL, V54, P339, DOI 10.1016/j.survophthal.2009.02.003
   Ueta T, 2009, OPHTHALMOLOGY, V116, P362, DOI 10.1016/j.ophtha.2008.09.046
   van Wijngaarden P, 2005, JAMA-J AM MED ASSOC, V293, P1509, DOI 10.1001/jama.293.12.1509
   Vedula S S, 2008, COCHRANE DATABASE SY
   Vinores SA, 1999, DOC OPHTHALMOL, V97, P217, DOI 10.1023/A:1002136712070
   von Hanno T, 2010, ACTA OPHTHALMOL, V88, P263, DOI 10.1111/j.1755-3768.2008.01406.x
   Waheed Nadia K., 2004, International Ophthalmology Clinics, V44, P11, DOI 10.1097/00004397-200404430-00004
   Weltermann A, 1999, ARTERIOSCL THROM VAS, V19, P1757, DOI 10.1161/01.ATV.19.7.1757
   Winn RK, 2005, J THROMB HAEMOST, V3, P1815, DOI 10.1111/j.1538-7836.2005.01378.x
   Wormald R, 2007, COCHRANE DATABASE SY, P3
   Wu KK, 1996, ANNU REV MED, V47, P315
   Wu L, 2008, GRAEF ARCH CLIN EXP, V246, P81, DOI 10.1007/s00417-007-0660-z
   Zachary I, 2001, AM J PHYSIOL-CELL PH, V280, pC1375, DOI 10.1152/ajpcell.2001.280.6.C1375
   ZIMMER E, 2006, INVEST OPHTHALMOL VI, V47
NR 120
TC 42
Z9 44
U1 1
U2 10
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1471-2598
EI 1744-7682
J9 EXPERT OPIN BIOL TH
JI Expert Opin. Biol. Ther.
PD OCT
PY 2012
VL 12
IS 10
BP 1299
EP 1313
DI 10.1517/14712598.2012.707176
PG 15
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA 004EQ
UT WOS:000308663600002
PM 22866908
DA 2022-11-30
ER

PT J
AU Tatar, O
   Adam, A
   Shinoda, K
   Yoeruek, E
   Szurman, P
   Bopp, S
   Eckardt, C
   Bartz-Schmidt, KU
   Grisanti, S
AF Tatar, Olcay
   Adam, Annemarie
   Shinoda, Kei
   Yoeruek, Efdal
   Szurman, Peter
   Bopp, Silvia
   Eckardt, Claus
   Bartz-Schmidt, Karl Ulrich
   Grisanti, Salvatore
TI Influence of vertepon photodynamic therapy on inflammation in human
   choroidal neovascular membranes secondary to age-related macular
   degeneration
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; choroidal neovascular membranes;
   verteportin photodynamic therapy; CD68; Thy-1; CD45; Ki-67
ID ENDOTHELIAL GROWTH-FACTOR; PIGMENT EPITHELIAL-CELLS; INTRAVITREAL
   TRIAMCINOLONE; MONOCYTE ACTIVATION; VISUAL-ACUITY; LESION SIZE;
   EXPRESSION; ANGIOGENESIS; MACROPHAGES; COMBINATION
AB Purpose: To examine the short- and long-term consequences of verteporfin photodynamic therapy (PDT) on inflammation with regard to infiltration of macrophages and leukocytes and expression of thy-1 in human choroidal neovascularization membranes (CNV) secondary to age-related macular degeneration (AMD).
   Methods: Retrospective review of an interventional case series of 43 patients who underwent removal of CNV. Twenty patients were treated with PDT 3 to 246 days preoperatively. Twenty-three CNV without previous treatment were used as control. CNV were stained for CD34, CD105, cytokeratin 18, Ki-67, thy-1, an endothelial cell glycoprotein known to be upregulated only by inflammatory cytokines, CD68 (macrophages), and CD45 (common leukocyte antigen).
   Results: Specimens treated by PDT 3 days previously showed significantly reduced endothelial thy-1 expression (P = 0.008), leukocyte (P = 0.04) and macrophage (P = 0.0063) infiltration, and proliferative activity (P = 0.02) compared to control CNV. Specimens at longer intervals after PDT, in contrast, disclosed a significantly increased expression of thy-1 (P = 0.004), infiltration with leukocytes (P = 0.044) and macrophages (P = 0.01), and proliferative activity (P = 0.03) compared to CNV excised 3 days after PDT.
   Conclusions: The rebound effect after PDT seems to be based on an inflammatory response that contributes to enhanced proliferation. These data support the need for an anti-inflammatory therapy as adjuvant to PDT.
C1 Univ Tubingen, Univ Eye Hosp, Ctr Ophthalmol, D-72076 Tubingen, Germany.
   Univ Tubingen, Dept Pathol, Tubingen, Germany.
   Natl Inst Sensory Organs, Lab Visual Physiol, Tokyo, Japan.
   Univ Sallee, Eye Clin, Bremen, Germany.
   Augenklin Staedtischen Kliniken, Frankfurt, Germany.
C3 Eberhard Karls University of Tubingen; Eberhard Karls University
   Hospital; Eberhard Karls University of Tubingen; Eberhard Karls
   University Hospital
RP Grisanti, S (通讯作者)，Univ Tubingen, Univ Eye Hosp, Ctr Ophthalmol, Schleichstr 12-15, D-72076 Tubingen, Germany.
EM Salvatore.Grisanti@med.uni-tuebingen.de
RI Bopp, Silvia/AAF-2638-2020; Shinoda, Kei/ABC-7993-2020
OI Shinoda, Kei/0000-0002-1543-9345
CR Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Arras M, 1998, J CLIN INVEST, V101, P40, DOI 10.1172/JCI119877
   Augustin AJ, 2006, AM J OPHTHALMOL, V141, P638, DOI 10.1016/j.ajo.2005.11.058
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   BENEZRA D, 1990, ARCH OPHTHALMOL-CHIC, V108, P573, DOI 10.1001/archopht.1990.01070060121061
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1443
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown GC, 2005, AM J OPHTHALMOL, V140, P679, DOI 10.1016/j.ajo.2005.04.061
   Campochiaro PA, 2006, INVEST OPHTH VIS SCI, V47, P462, DOI 10.1167/iovs.05-1494
   CLAUSS M, 1990, J EXP MED, V172, P1535, DOI 10.1084/jem.172.6.1535
   Cousins SW, 2004, ARCH OPHTHALMOL-CHIC, V122, P1013, DOI 10.1001/archopht.122.7.1013
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P3586, DOI 10.1167/iovs.03-0038
   Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027
   Fish G, 2003, OPHTHALMOLOGY, V110, P979, DOI 10.1016/S0161-6420(03)00085-X
   Ghazi NG, 2001, RETINA-J RET VIT DIS, V21, P478, DOI 10.1097/00006982-200110000-00010
   Gollnick SO, 2003, BRIT J CANCER, V88, P1772, DOI 10.1038/sj.bjc.6600864
   Gollnick SO, 1997, CANCER RES, V57, P3904
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   GRANT WE, 1994, BRIT J CANCER, V70, P72, DOI 10.1038/bjc.1994.252
   Grossniklaus HE, 2005, ARCH OPHTHALMOL-CHIC, V123, P914
   GROSSNIKLAUS HE, 1992, AM J OPHTHALMOL, V114, P464, DOI 10.1016/S0002-9394(14)71859-8
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   GUYER DR, 1986, ARCH OPHTHALMOL-CHIC, V104, P702, DOI 10.1001/archopht.1986.01050170092029
   Hawkins BS, 2004, OPHTHALMOLOGY, V111, P1967, DOI 10.1016/j.ophtha.2004.07.021
   HEIER JS, 2006, OPHTHALMOLOGY, V113, P642
   Hinton DR, 1998, ARCH OPHTHALMOL-CHIC, V116, P203
   Hunt D. W., 1999, DRUGS, V2, P231
   Hunt DWC, 1999, IMMUNOPHARMACOLOGY, V41, P31, DOI 10.1016/S0162-3109(98)00051-4
   Husain D, 2005, ARCH OPHTHALMOL-CHIC, V123, P509, DOI 10.1001/archopht.123.4.509
   HYMAN L, 1987, EYE, V1, P330, DOI 10.1038/eye.1987.53
   Ishibashi T, 1997, GRAEF ARCH CLIN EXP, V235, P159, DOI 10.1007/BF00941723
   JAFFE GJ, 1995, EXP EYE RES, V60, P533, DOI 10.1016/S0014-4835(05)80068-5
   Jalili A, 2004, CLIN CANCER RES, V10, P4498, DOI 10.1158/1078-0432.CCR-04-0367
   Kaiser PK, 2006, GRAEF ARCH CLIN EXP, V244, P1132, DOI 10.1007/s00417-005-0199-9
   Karak AK, 1997, INDIAN J MED RES, V105, P235
   Lee WS, 1998, CIRC RES, V82, P845
   LEIBOVICH SJ, 1987, NATURE, V329, P630, DOI 10.1038/329630a0
   LOPEZ PF, 1993, OPHTHALMOLOGY, V100, P415
   LOPEZ PF, 1991, AM J OPHTHALMOL, V112, P647, DOI 10.1016/S0002-9394(14)77270-8
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Mirshahi A, 2005, KLIN MONATSBL AUGENH, V222, P586, DOI 10.1055/s-2005-858434
   NISHIMURA T, 1990, OPHTHALMOLOGICA, V200, P39, DOI 10.1159/000310075
   Oh H, 1999, INVEST OPHTH VIS SCI, V40, P1891
   Otani A, 2002, MICROVASC RES, V64, P162, DOI 10.1006/mvre.2002.2407
   Park CH, 2003, AM J OPHTHALMOL, V136, P830, DOI 10.1016/S0002-9394(03)00723-2
   Petermeier K, 2006, BRIT J OPHTHALMOL, V90, P1034, DOI 10.1136/bjo.2006.090852
   Rosenfeld PJ, 2006, OPHTHALMOLOGY, V113, P623, DOI 10.1016/j.ophtha.2006.01.027
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   Schmidt-Erfurth U, 2000, SURV OPHTHALMOL, V45, P195, DOI 10.1016/S0039-6257(00)00158-2
   Schmidt-Erfurth U, 2002, ARCH OPHTHALMOL-CHIC, V120, P835
   SEREGARD S, 1994, GRAEF ARCH CLIN EXP, V232, P325, DOI 10.1007/BF00175983
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Spaide RF, 2005, RETINA-J RET VIT DIS, V25, P685, DOI 10.1097/00006982-200509000-00001
   SUNDERKOTTER C, 1994, J LEUKOCYTE BIOL, V55, P410, DOI 10.1002/jlb.55.3.410
   Tatar O, 2006, EXP EYE RES, V83, P329, DOI 10.1016/j.exer.2005.12.017
   Tatar O, 2006, ARCH OPHTHALMOL-CHIC, V124, P815, DOI 10.1001/archopht.124.6.815
   Tezel TH, 2004, TRENDS MOL MED, V10, P417, DOI 10.1016/j.molmed.2004.07.004
   Tsutsumi C, 2003, J LEUKOCYTE BIOL, V74, P25, DOI 10.1189/jlb.0902436
   Tsutsumi-Miyahara C, 2004, BRIT J OPHTHALMOL, V88, P1217, DOI 10.1136/bjo.2003.036392
   Volanti C, 2004, ONCOGENE, V23, P8649, DOI 10.1038/sj.onc.1207871
   Yasukawa T, 2000, CURR EYE RES, V21, P952, DOI 10.1076/ceyr.21.6.952.6992
   Yeh DC, 2004, INVEST OPHTH VIS SCI, V45, P2368, DOI 10.1167/iovs.03-0981
NR 64
TC 27
Z9 28
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUL-AUG
PY 2007
VL 27
IS 6
BP 713
EP 723
DI 10.1097/IAE.0b013e318042d3b0
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 189NT
UT WOS:000247996400008
PM 17621180
DA 2022-11-30
ER

PT J
AU Xu, ZY
   Gao, JF
   Zhang, L
AF Xu, Zhi-Yu
   Gao, Jing-Fan
   Zhang, Lu
TI Association of CFI, IL-8, TF and TFR2 Genetic Polymorphisms with
   Age-Related Macular Degeneration in a Northeastern Chinese Population
SO CURRENT EYE RESEARCH
LA English
DT Article
DE Age-related macular degeneration; CFI; IL-8; single-nucleotide
   polymorphism; TF; TFR2
ID COMPLEMENT FACTOR-I; TRANSFERRIN GENE; RISK; VARIANT
AB Purpose: To explore the relationship between single-nucleotide polymorphisms (SNPs) in complement factor I (CFI), interleukin-8 (IL-8), transferrin (TF), and transferrin receptor 2 (TFR2) and age-related macular degeneration (AMD) in a northeastern Chinese population. Methods: A total of 400 AMD patients (200 wet AMD and 200 dry AMD) and 200 controls were enrolled in this study, and genetic polymorphisms in the above genes were detected by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). The chi(2) test was used to compare differences in allele frequencies in each group, and the associations of genotype frequencies with AMD were determined by multivariate logistic regression analysis. Results: Our research shows that CFI rs141853578, IL-8 rs2227543, TF rs8177178 and TFR2 rs2075674 are associated with the incidence of AMD. In wet AMD, allele T of CFI rs141853578, IL-8 rs2227543 and TFR2 rs2075674 may be a risk factor. Allele A of TF rs8177178 may increase the risk of dry AMD. Conclusions: CFI rs141853578, IL-8 rs2227543, TF rs8177178 and TFR2 rs2075674 genetic polymorphisms are associated with the occurrence of AMD in a northeastern Chinese population, especially wet AMD.
C1 [Xu, Zhi-Yu; Gao, Jing-Fan; Zhang, Lu] Harbin Med Univ, Hosp Eye, Affiliated Hosp 1, Harbin, Peoples R China.
C3 Harbin Medical University
RP Zhang, L (通讯作者)，Harbin Med Univ, Hosp Eye, Affiliated Hosp 1, Harbin, Peoples R China.
EM 13796089809@163.com
FU Natural Science Foundation of Heilongjiang Province [LC2017036]
FX This work was supported by grants from the Natural Science Foundation of
   Heilongjiang Province [LC2017036].
CR Alexander P, 2014, MOL VIS, V20, P1253
   Ambreen F, 2015, MOL VIS, V21, P985
   Aygun FB, 2020, OPHTHALMOLOGICA, V243, P187, DOI 10.1159/000503327
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Hautamaki A, 2015, ACTA OPHTHALMOL, V93, P726, DOI 10.1111/aos.12799
   Hautamaki A, 2013, RETINA-J RET VIT DIS, V33, P1815, DOI 10.1097/IAE.0b013e318285cf92
   Jonas JB, 2012, ACTA OPHTHALMOL, V90, pe381, DOI 10.1111/j.1755-3768.2012.02414.x
   Khandhadia S, 2012, IMMUNOBIOLOGY, V217, P127, DOI 10.1016/j.imbio.2011.07.019
   Kondo N, 2010, EUR J HUM GENET, V18, P634, DOI 10.1038/ejhg.2009.243
   Mitchell P, 2005, ARCH OPHTHALMOL-CHIC, V123, P1598, DOI 10.1001/archopht.123.11.1598
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Tsai YY, 2008, INVEST OPHTH VIS SCI, V49, P693, DOI 10.1167/iovs.07-0125
   Wysokinski D, 2015, ACTA BIOCHIM POL, V62, P177, DOI 10.18388/abp.2014_843
   Wysokinski D, 2014, DIS MARKERS, V2014, DOI 10.1155/2014/507356
   Wysokinski D, 2013, EXP EYE RES, V106, P14, DOI 10.1016/j.exer.2012.10.003
   Wysokinski D, 2011, TOHOKU J EXP MED, V223, P253, DOI 10.1620/tjem.223.253
NR 16
TC 0
Z9 0
U1 1
U2 4
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0271-3683
EI 1460-2202
J9 CURR EYE RES
JI Curr. Eye Res.
PD MAY 4
PY 2022
VL 47
IS 5
BP 786
EP 790
DI 10.1080/02713683.2022.2026976
EA APR 2022
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 1S4UG
UT WOS:000781898700001
PM 35180024
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Xu, KY
   Gupta, V
   Bae, S
   Sharma, S
AF Xu, Kunyong
   Gupta, Vasudha
   Bae, Steven
   Sharma, Sanjay
TI Metamorphopsia and vision-related quality of life among patients with
   age-related macular degeneration
SO CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE
LA English
DT Article
ID VISUAL IMPAIRMENT; M-CHARTS; DEPRESSION; DISABILITY; QUANTIFICATION;
   IMPACT
AB Objective: To assess subjective and quantified metamorphopsia, as well as vision-related quality of life (QOL), in patients with age related macular degeneration (AMD) to determine whether there is a correlation between quantified metamorphopsia and vision related QOL in patients with AMD.
   Methods: A cross-sectional study of patients with AMD. Patients who had a best-corrected visual acuity less than 20/200, vitreomacular adhesion, vitreomacular traction, epiretinal membrane, macular hole, macular edema by causes other than AMD, diabetic retinopathy, retinal detachment, previous retinal surgery, glaucoma, amblyopia, or strabismus were excluded. Subjective perceptions of metamorphopsia were captured by a validated 10-item questionnaire. M-CHARTS (Inami, Japan) was used to detect quantified metamorphopsia. Quantified metamorphopsia was scored horizontally and vertically. The mean values of 3 repeated examinations were used for data analysis. The 25-item National Eye Institute Visual Functioning Questionnaire (VFQ-25) was used to assess vision-related QOL.
   Results: Among 102 eyes with AMD, the most commonly reported subjective perception of metamorphopsia included lines of words on books, newspapers, or computer displays (45.1%), followed by frames of windows or bookshelves (22.6%), lines of tiles on bathroom wall (21.6%), and people's faces (18.6%). Eyes with wet AMD had significantly higher horizontal and vertical metamorphopsia scores compared with eyes with dry AMD (p < 0.0001). The higher horizontal metamorphopsia score and the higher vertical metamorphopsia score between the 2 eyes were both negatively correlated with the NEI VFQ-25 composite score (Spearman rank correlation r = -0.3207, p = 0.0010; Spearman rank correlation r = -0.3190, p = 0.0011).
   Conclusions: In our study, the most common subjective metamorphopsia was distortion of lines of words on books, newspapers, or computer displays. Compared to eyes with dry AMD, those with wet AMD had higher quantified horizontal and vertical metamorphopsia. Between the 2 eyes, both the higher horizontal and vertical metamorphopsia scores were correlated with the NEI VFQ-25 composite score.
C1 [Xu, Kunyong] Weill Cornell Med, Dept Ophthalmol, New York, NY USA.
   [Gupta, Vasudha; Bae, Steven; Sharma, Sanjay] Queens Univ, Hotel Dieu Hosp, Dept Ophthalmol, Kingston, ON, Canada.
C3 Cornell University; Queens University - Canada
RP Sharma, S (通讯作者)，Hop Hotel Dieu, 166 Brock St, Kingston, ON K7L 5G2, Canada.
EM drsharma@insiderme-dicine.com
OI Bae, Steven/0000-0001-5759-3036
CR Arimura E, 2011, INVEST OPHTH VIS SCI, V52, P128, DOI 10.1167/iovs.09-3535
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   BROWN GC, 1992, ARCH OPHTHALMOL-CHIC, V110, P1251, DOI 10.1001/archopht.1992.01080210069027
   Brown GC, 1998, INT OPHTHALMOL, V22, P307, DOI 10.1023/A:1006311910304
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Fletcher DC, 1999, J REHABIL RES DEV, V36, P356
   Hassell JB, 2006, BRIT J OPHTHALMOL, V90, P593, DOI 10.1136/bjo.2005.086595
   Matsumoto C, 2003, INVEST OPHTH VIS SCI, V44, P4012, DOI 10.1167/iovs.03-0117
   Nomoto H, 2013, EYE, V27, P924, DOI 10.1038/eye.2013.108
   Nowomiejska K, 2013, BMC OPHTHALMOL, V13, DOI 10.1186/1471-2415-13-13
   Okamoto F, 2012, INVEST OPHTH VIS SCI, V53, P6770, DOI 10.1167/iovs.12-9683
   Pascolini D, 2004, OPHTHAL EPIDEMIOL, V11, P67, DOI 10.1076/opep.11.2.67.28158
   Revicki DA, 2010, INVEST OPHTH VIS SCI, V51, P712, DOI 10.1167/iovs.09-3766
   Rovner BW, 2002, ARCH OPHTHALMOL-CHIC, V120, P1041
   Rovner BW, 2002, AM J GERIAT PSYCHIAT, V10, P305
   Rovner BW, 2001, J AM GERIATR SOC, V49, P1097, DOI 10.1046/j.1532-5415.2001.49215.x
   RUBIN GS, 1994, OPTOMETRY VISION SCI, V71, P750, DOI 10.1097/00006324-199412000-00005
   Slakter JS, 2005, SURV OPHTHALMOL, V50, P263, DOI 10.1016/j.survophthal.2005.02.007
   Watanabe A, 2009, OPHTHALMOLOGY, V116, P1788, DOI 10.1016/j.ophtha.2009.04.046
   Wiecek E, 2015, INVEST OPHTH VIS SCI, V56, P494, DOI 10.1167/iovs.14-15394
NR 20
TC 20
Z9 20
U1 0
U2 6
PU CANADIAN OPHTHAL SOC
PI OTTAWA
PA 1525 CARLING AVE SUITE 610, OTTAWA, ONTARIO K1Z 8R9, CANADA
SN 0008-4182
EI 1715-3360
J9 CAN J OPHTHALMOL
JI Can. J. Opthalmol.-J. Can. Opthalmol.
PD APR
PY 2018
VL 53
IS 2
BP 168
EP 172
DI 10.1016/j.jcjo.2017.08.006
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GC2NH
UT WOS:000429619200032
PM 29631830
DA 2022-11-30
ER

PT J
AU Hughes, AE
   Orr, N
   Esfandiary, H
   Diaz-Torres, M
   Goodship, T
   Chakravarthy, U
AF Hughes, Anne E.
   Orr, Nick
   Esfandiary, Hossein
   Diaz-Torres, Martha
   Goodship, Timothy
   Chakravarthy, Usha
TI A common CFH haplotype, with deletion of CFHR1 and CFHR3, is associated
   with lower risk of age-related macular degeneration
SO NATURE GENETICS
LA English
DT Article
ID COMPLEMENT FACTOR-H; SUSCEPTIBILITY; POLYMORPHISM; MACULOPATHY; VARIANT;
   GENE
AB Age-related macular degeneration (AMD; OMIM #603075) is the most frequent cause of visual impairment in the elderly population, with severe disease affecting nearly 10% of individuals of European descent over the age of 75 years. It is a complex disease in which genetic and environmental factors contribute to susceptibility. Complement factor H (CFH) has recently been identified as a major AMD susceptibility gene, and the Y402H polymorphism has been proposed as the likely causative factor. We genotyped polymorphisms spanning the cluster of CFH and five CFH-related genes on chromosome 1q23 in 173 individuals with severe neovascular AMD and 170 elderly controls with no signs of AMD. Detailed analysis showed a common haplotype associated with decreased risk of AMD that was present on 20% of chromosomes of controls and 8% of chromosomes of individuals with AMD. We found that this haplotype carried a deletion of CFHR1 and CFHR3, and the proteins encoded by these genes were absent in serum of homozygotes. The protective effect of the deletion haplotype cannot be attributed to linkage disequilibrium with Y402H and was replicated in an independent sample.
C1 Queens Univ Belfast, Dept Med Genet, Belfast BT12 6BL, Antrim, North Ireland.
   Newcastle Univ, Inst Human Genet, Newcastle Upon Tyne NE1 3BZ, Tyne & Wear, England.
   Queens Univ Belfast, Ctr Vis Sci & Vasc Biol, Belfast BT12 6BL, Antrim, North Ireland.
C3 Queens University Belfast; Newcastle University - UK; Queens University
   Belfast
RP Hughes, AE (通讯作者)，Queens Univ Belfast, Dept Med Genet, Belfast BT12 6BL, Antrim, North Ireland.
EM A.Hughes@qub.ac.uk
RI Hughes, Anne/A-1307-2012
OI Chakravarthy, Usha/0000-0002-2606-3734
CR Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   DISCIPIO RG, 1992, J IMMUNOL, V149, P2592
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Heinen Stefan, 2006, Hum Mutat, V27, P292, DOI 10.1002/humu.9408
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Jozsi M, 2005, EUR J HUM GENET, V13, P321, DOI 10.1038/sj.ejhg.5201324
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Mullins RF, 2001, EYE, V15, P390, DOI 10.1038/eye.2001.142
   REID KBM, 1986, IMMUNOL TODAY, V7, P230, DOI 10.1016/0167-5699(86)90110-6
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Schouten JP, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf056
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
NR 16
TC 359
Z9 383
U1 0
U2 11
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1061-4036
EI 1546-1718
J9 NAT GENET
JI Nature Genet.
PD OCT
PY 2006
VL 38
IS 10
BP 1173
EP 1177
DI 10.1038/ng1890
PG 5
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 094PJ
UT WOS:000241251100017
PM 16998489
DA 2022-11-30
ER

PT J
AU Armbrecht, AM
   Aspinall, PA
   Dhillon, B
AF Armbrecht, AM
   Aspinall, PA
   Dhillon, B
TI A prospective study of visual function and quality of life following PDT
   in patients with wet age related macular degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID CHOROIDAL NEOVASCULARIZATION; PHOTODYNAMIC THERAPY; VERTEPORFIN
AB Aims: ( 1) A prospective study to assess visual function measures and quality of life (QoL) in patients with wet age related macular degeneration (AMD) treated with photodynamic therapy (PDT). ( 2) To assess if PDT prevents severe visual loss ( loss of six or more lines of distance visual acuity) in the treated eye.
   Methods: 48 of 51 recruited patients with predominantly classic subfoveal choroidal neovascularisation (CNV) secondary AMD who were treated with PDT were followed up for 1 year. Assessment included distance and near visual acuity, contrast sensitivity, vision related quality of life and fluorescein angiography. Photodynamic therapy using Visudyne was carried out according to standard protocol. Patients were followed up every 3 months and treatment repeated if there was significant leakage from CNV.
   Results: At the 12 month follow up, 71% ( n = 34) of the patients lost less than three lines of best corrected distance visual acuity. Although there were significant decreases in some of the QoL items tested, patients were significantly less anxious and more independent outdoors at the 12 month follow up.
   Conclusion: This study is in keeping with published literature with PDT preventing severe visual loss in two thirds of treated patients with predominantly classic CNV.
C1 Princess Alexandra Eye Pavil, Edinburgh EH3 9HA, Midlothian, Scotland.
   Heriot Watt Univ, Edinburgh EH14 4AS, Midlothian, Scotland.
C3 Heriot Watt University
RP Armbrecht, AM (通讯作者)，Princess Alexandra Eye Pavil, Chalmers St, Edinburgh EH3 9HA, Midlothian, Scotland.
EM amarmbrecht@yahoo.com
CR [Anonymous], 1993, Arch Ophthalmol, V111, P1200
   Armbrecht AM, 2003, J CATARACT REFR SURG, V29, P686, DOI 10.1016/S0886-3350(02)01650-4
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1307
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Ciulla TA, 1998, SURV OPHTHALMOL, V43, P134, DOI 10.1016/S0039-6257(98)00014-9
   Hooper CY, 2003, CLIN EXP OPHTHALMOL, V31, P376, DOI 10.1046/j.1442-9071.2003.00683.x
   Husain D, 1999, INVEST OPHTH VIS SCI, V40, P2322
   Husain D, 1996, ARCH OPHTHALMOL-CHIC, V114, P978, DOI 10.1001/archopht.1996.01100140186012
   KLEIN R, 1999, AGE RELATED MACULAR, P1
   Kramer M, 1996, OPHTHALMOLOGY, V103, P427
   MAGUIRE M, 1999, AGE RELATED MACULAR, P26
   MAGUIRE MG, 1994, ARCH OPHTHALMOL-CHIC, V112, P480
   Miller JW, 1999, ARCH OPHTHALMOL-CHIC, V117, P1161
   Parodi MB, 2003, BRIT J OPHTHALMOL, V87, P177, DOI 10.1136/bjo.87.2.177
   SCHACHAT AP, 1994, ARCH OPHTHALMOL-CHIC, V112, P500
   Schmidt-Erfurth U, 2000, SURV OPHTHALMOL, V45, P195, DOI 10.1016/S0039-6257(00)00158-2
   Schmidt-Erfurth U, 1999, ARCH OPHTHALMOL-CHIC, V117, P1177
   Schmidt-Erfurth U, 2002, INVEST OPHTH VIS SCI, V43, P830
   SCHMIDTERFURTH U, 1994, OPHTHALMOLOGY, V101, P1953
   Sickenberg M, 2000, ARCH OPHTHALMOL-CHIC, V118, P327, DOI 10.1001/archopht.118.3.327
   STEINBERG EP, 1994, ARCH OPHTHALMOL-CHIC, V112, P630, DOI 10.1001/archopht.1994.01090170074026
NR 22
TC 25
Z9 30
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD OCT
PY 2004
VL 88
IS 10
BP 1270
EP 1273
DI 10.1136/bjo.2003.038604
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 855CR
UT WOS:000223951100012
PM 15377549
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Brandl, C
   Zimmermann, ME
   Guenther, F
   Barth, T
   Olden, M
   Schelter, SC
   Kronenberg, F
   Loss, J
   Kuechenhoff, H
   Helbig, H
   Weber, BHF
   Stark, KJ
   Heid, IM
AF Brandl, Caroline
   Zimmermann, Martina E.
   Guenther, Felix
   Barth, Teresa
   Olden, Matthias
   Schelter, Sabine C.
   Kronenberg, Florian
   Loss, Julika
   Kuechenhoff, Helmut
   Helbig, Horst
   Weber, Bernhard H. F.
   Stark, Klaus J.
   Heid, Iris M.
TI On the impact of different approaches to classify age-related macular
   degeneration: Results from the German AugUR study
SO SCIENTIFIC REPORTS
LA English
DT Article
ID SIMPLIFIED SEVERITY SCALE; PREVALENCE; MACULOPATHY; EYE; CLASSIFICATION;
   RANIBIZUMAB; ROTTERDAM; DISEASE; COHORT; AMD
AB While age-related macular degeneration (AMD) poses an important personal and public health burden, comparing epidemiological studies on AMD is hampered by differing approaches to classify AMD. In our AugUR study survey, recruiting residents from in/around Regensburg, Germany, aged 70+, we analyzed the AMD status derived from color fundus images applying two different classification systems. Based on 1,040 participants with gradable fundus images for at least one eye, we show that including individuals with only one gradable eye (n = 155) underestimates AMD prevalence and we provide a correction procedure. Bias-corrected and standardized to the Bavarian population, late AMD prevalence is 7.3% (95% confidence interval = [5.4; 9.4]). We find substantially different prevalence estimates for "early/intermediate AMD" depending on the classification system: 45.3% (95%-CI = [41.8; 48.7]) applying the Clinical Classification (early/intermediate AMD) or 17.1% (95%-CI = [14.6; 19.7]) applying the Three Continent AMD Consortium Severity Scale (mild/moderate/severe early AMD). We thus provide a first effort to grade AMD in a complete study with different classification systems, a first approach for bias-correction from individuals with only one gradable eye, and the first AMD prevalence estimates from a German elderly population. Our results underscore substantial differences for early/intermediate AMD prevalence estimates between classification systems and an urgent need for harmonization.
C1 [Brandl, Caroline; Zimmermann, Martina E.; Olden, Matthias; Schelter, Sabine C.; Stark, Klaus J.; Heid, Iris M.] Univ Regensburg, Dept Genet Epidemiol, Regensburg, Germany.
   [Brandl, Caroline; Barth, Teresa; Helbig, Horst] Univ Hosp Regensburg, Dept Ophthalmol, Regensburg, Germany.
   [Brandl, Caroline; Weber, Bernhard H. F.] Univ Regensburg, Inst Human Genet, Regensburg, Germany.
   [Guenther, Felix; Kuechenhoff, Helmut] Ludwig Maximilians Univ Munchen, Dept Stat, Stat Consulting Unit StaBLab, Munich, Germany.
   [Schelter, Sabine C.] Univ Hosp Regensburg, Ctr Clin Studies, Regensburg, Germany.
   [Kronenberg, Florian] Med Univ Innsbruck, Div Genet Epidemiol, Innsbruck, Austria.
   [Loss, Julika] Univ Regensburg, Inst Epidemiol & Prevent Med, Med Sociol, Regensburg, Germany.
C3 University of Regensburg; University of Regensburg; University of
   Regensburg; University of Munich; University of Regensburg; Medical
   University of Innsbruck; University of Regensburg
RP Heid, IM (通讯作者)，Univ Regensburg, Dept Genet Epidemiol, Regensburg, Germany.
EM iris.heid@klinik.uni-regensburg.de
RI Kronenberg, Florian/B-1736-2008; Stark, Klaus/L-7367-2013; Zimmermann,
   Martina/AAL-2990-2021
OI Kronenberg, Florian/0000-0003-2229-1120; Stark,
   Klaus/0000-0002-7832-1942; Zimmermann, Martina/0000-0002-6916-4404;
   Brandl, Caroline/0000-0001-8223-6137; Kuchenhoff,
   Helmut/0000-0002-6372-2487
FU German Federal Ministry of Education and Research [BMBF 01ER1206, BMBF
   01ER1507, BMBF 01GP1308]; Institute of Human Genetics, Department of
   Genetic Epidemiology, University of Regensburg
FX We gratefully acknowledge the excellent supporting assistance of Sylvia
   Pfreintner, Sven Schmalfuss, and Josef Simon. Moreover, we thank all
   study participants for contributing to the AugUR study. This study and
   investigation is supported by grants from the German Federal Ministry of
   Education and Research (BMBF 01ER1206, BMBF 01ER1507 to I.M.H., and BMBF
   01GP1308 to J.L), and institutional budget (Institute of Human Genetics,
   Department of Genetic Epidemiology, University of Regensburg).
CR Akuffo KO, 2015, BRIT J OPHTHALMOL, V99, P1037, DOI 10.1136/bjophthalmol-2014-305768
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Brandl C, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167181
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   FLEISS JL, 1973, EDUC PSYCHOL MEAS, V33, P613, DOI 10.1177/001316447303300309
   Jonasson F, 2011, OPHTHALMOLOGY, V118, P825, DOI 10.1016/j.ophtha.2010.08.044
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 2014, OPHTHAL EPIDEMIOL, V21, P14, DOI 10.3109/09286586.2013.867512
   Korb CA, 2014, GRAEF ARCH CLIN EXP, V252, P1403, DOI 10.1007/s00417-014-2591-9
   Leitritz MA, 2013, KLIN MONATSBL AUGENH, V230, P1238, DOI 10.1055/s-0033-1350685
   Liew G, 2016, OPHTHALMOLOGY, V123, P1874, DOI 10.1016/j.ophtha.2016.05.043
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2011, NEW ENGL J MED, V364, P1966, DOI 10.1056/NEJMe1103334
   Stark K, 2015, BMC GERIATR, V15, DOI 10.1186/s12877-015-0122-0
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Wilde C, 2017, EYE, V31, P1042, DOI 10.1038/eye.2017.30
   Wolfram C, 2012, WEISSBUCH SITUATION
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 24
TC 19
Z9 19
U1 0
U2 3
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD JUN 6
PY 2018
VL 8
AR 8675
DI 10.1038/s41598-018-26629-5
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA GI3DQ
UT WOS:000434252000011
PM 29875478
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Qu, Y
   Dai, H
   Zhou, F
   Zhang, XY
   Xu, XY
   Zhang, X
   Bi, HS
   Pan, XM
   Wang, HG
   Jiang, H
   Yin, NN
   Dang, GF
AF Qu, Yi
   Dai, Hong
   Zhou, Fang
   Zhang, Xiaoyan
   Xu, Xiaoyi
   Zhang, Xiao
   Bi, Hongsheng
   Pan, Xuemei
   Wang, Hongge
   Jiang, Hua
   Yin, Ningning
   Dang, Guangfu
TI Vascular Endothelial Growth Factor Gene Polymorphisms and Risk of
   Neovascular Age-Related Macular Degeneration in a Chinese Cohort
SO OPHTHALMIC RESEARCH
LA English
DT Article
DE Age-related macular degeneration; Vascular endothelial growth factor;
   Single-nucleotide polymorphism; Case-control study, Chinese
ID SINGLE NUCLEOTIDE POLYMORPHISMS; EYE DISEASE; VEGF; ANGIOGENESIS;
   ASSOCIATION; POPULATION
AB Aims: To evaluate the association between vascular endothelial growth factor (VEGF) gene polymorphism and the risk of neovascular age-related macular degeneration (AMD) in a case-control study in a Chinese cohort. Methods: We genotyped 4 common single-nucleotide polymorphisms (SNPs), namely -460T/C (rs833061), +405C/G (rs2010963), +674C/T (rs1413711) and +936C/T (rs3025039), simultaneously detected 7 tag SNPs (tSNPs) in the VEGF gene, in 159 neovascular AMD patients and 140 age-and sex-matched control subjects. Genetic analyses for an additive, dominant and recessive model were performed on all available genotype data. All the possible haplotypes of these 11 SNPs were detected. Results: No evident association was found in the allele frequencies of any individual SNP between patients and controls; the combined p values in each genotype group were greater than 0.05. Haplotype analyses of these SNPs did not provide any evidence for an association with the risk of neovascular AMD in this Chinese cohort (p > 0.05). Conclusions: Detection of 4 common SNPs and 7 tSNPs in the VEGF gene did not find any statistically significant association with neovascular AMD in the Chinese cohort. Further studies of comprehensive VEGF gene variations are required to characterize the susceptibility of the VEGF gene in the pathogenesis of AMD. Copyright (C) 2010 S. Karger AG, Basel
C1 [Qu, Yi; Zhou, Fang; Zhang, Xiaoyan; Xu, Xiaoyi; Zhang, Xiao; Jiang, Hua] Shandong Univ, Qilu Hosp, Dept Ophthalmol, Jinan 250012, Peoples R China.
   [Bi, Hongsheng; Pan, Xuemei] Shierming Eye Hosp, Jinan, Peoples R China.
   [Wang, Hongge] Shandong Eye Hosp, Jinan, Peoples R China.
   [Dang, Guangfu] Qianfoshan Hosp, Jinan, Peoples R China.
   [Yin, Ningning] Beijing Hosp, Beijing, Peoples R China.
C3 Shandong University; Shandong First Medical University & Shandong
   Academy of Medical Sciences; Beijing Hospital
RP Qu, Y (通讯作者)，Shandong Univ, Qilu Hosp, Dept Ophthalmol, 107 Wenhuaxi Rd, Jinan 250012, Peoples R China.
EM drquyi@gmail.com
FU Department of Science and Technology of Shandong Province
   [2009GG10002016, BS2009SW056]
FX The authors thank the patients and the control subjects who participated
   in the study. This research was supported in part by grants
   2009GG10002016 and BS2009SW056 from the Department of Science and
   Technology of Shandong Province.
CR Campochiaro PA, 2000, J CELL PHYSIOL, V184, P301, DOI 10.1002/1097-4652(200009)184:3<301::AID-JCP3>3.0.CO;2-H
   Carmeliet P, 2005, ONCOLOGY-BASEL, V69, P4, DOI 10.1159/000088478
   Chu JY, 1998, P NATL ACAD SCI USA, V95, P11763, DOI 10.1073/pnas.95.20.11763
   Churchill AJ, 2006, HUM MOL GENET, V15, P2955, DOI 10.1093/hmg/ddl238
   DEJONG PT, 2007, INVEST OPHTHALMOL VI
   Fang AM, 2009, MOL VIS, V15, P2710
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Ferrara N, 1999, J MOL MED, V77, P527, DOI 10.1007/s001099900019
   Haines JL, 2006, INVEST OPHTH VIS SCI, V47, P329, DOI 10.1167/iovs.05-0116
   Janik-Papis K, 2009, EXP MOL PATHOL, V87, P234, DOI 10.1016/j.yexmp.2009.09.005
   Jiang H, 2009, RETINA-J RET VIT DIS, V29, P974, DOI 10.1097/IAE.0b013e3181a3b90e
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Lin JM, 2008, AM J OPHTHALMOL, V145, P1045, DOI 10.1016/j.ajo.2008.01.027
   Pascolini D, 2004, OPHTHAL EPIDEMIOL, V11, P67, DOI 10.1076/opep.11.2.67.28158
   Penn JS, 2008, PROG RETIN EYE RES, V27, P331, DOI 10.1016/j.preteyeres.2008.05.001
   Perrin RM, 2005, DIABETOLOGIA, V48, P2422, DOI 10.1007/s00125-005-1951-8
   Renner W, 2000, J VASC RES, V37, P443, DOI 10.1159/000054076
   Richardson AJ, 2007, MOL VIS, V13, P2148
   SMITH SR, 2007, INVEST OPHTHALMOL VI
   Stevens A, 2003, CANCER RES, V63, P812
   Vincenti V, 1996, CIRCULATION, V93, P1493, DOI 10.1161/01.CIR.93.8.1493
   Watson CJ, 2000, CYTOKINE, V12, P1232, DOI 10.1006/cyto.2000.0692
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
NR 24
TC 22
Z9 26
U1 0
U2 4
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3747
J9 OPHTHALMIC RES
JI Ophthalmic Res.
PY 2011
VL 45
IS 3
BP 142
EP 148
DI 10.1159/000319543
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 758IE
UT WOS:000290157000005
PM 20847577
DA 2022-11-30
ER

PT J
AU Naj, AC
   Scott, WK
   Courtenay, MD
   Cade, WH
   Schwartz, SG
   Kovach, JL
   Agarwal, A
   Wang, GF
   Haines, JL
   Pericak-Vance, MA
AF Naj, Adam C.
   Scott, William K.
   Courtenay, Monique D.
   Cade, William H.
   Schwartz, Stephen G.
   Kovach, Jaclyn L.
   Agarwal, Anita
   Wang, Gaofeng
   Haines, Jonathan L.
   Pericak-Vance, Margaret A.
TI Genetic Factors in Nonsmokers with Age-Related Macular Degeneration
   Revealed Through Genome-Wide Gene-Environment Interaction Analysis
SO ANNALS OF HUMAN GENETICS
LA English
DT Article
DE Age-related macular degeneration; age-related maculopathy; genome-wide
   association studies (GWAS); gene-environment interaction; genome-wide
   gene-environment interaction studies; smoking; smoking-gene interactions
ID COMPLEMENT FACTOR-H; APOLIPOPROTEIN-E GENE; RISK-FACTORS; COMPONENT 2;
   FACTOR-B; STRONG ASSOCIATION; VISUAL IMPAIRMENT; CIGARETTE-SMOKING;
   POOLED FINDINGS; SUSCEPTIBILITY
AB Relatively little is known about the interaction between genes and environment in the complex etiology of age-related macular degeneration (AMD). This study aimed to identify novel factors associated with AMD by analyzing gene-smoking interactions in a genome-wide association study of 1207 AMD cases and 686 controls of Caucasian background with genotype data on 668,238 single nucleotide polymorphisms (SNPs) after quality control. Participants' history of smoking at least 100 cigarettes lifetime was determined by a self-administered questionnaire. SNP associations modeled the effect of the minor allele additively on AMD using logistic regression, with adjustment for age, sex, and ever/never smoking. Joint effects of SNPs and smoking were examined comparing a null model containing only age, sex, and smoking against an extended model including genotypic and interaction terms. Genome-wide significant main effects were detected at three known AMD loci: CFH (P= 7.51x1030), ARMS2 (P= 1.94x1023), and RDBP/CFB/C2 (P= 4.37x1010), while joint effects analysis revealed three genomic regions with P< 105. Analyses stratified by smoking found genetic associations largely restricted to nonsmokers, with one notable exception: the chromosome 18q22.1 intergenic SNP rs17073641 (between SERPINB8 and CDH7), more strongly associated in nonsmokers (OR= 0.57, P= 2.73 x 105), with an inverse association among smokers (OR= 1.42, P= 0.00228), suggesting that smoking modifies the effect of some genetic polymorphisms on AMD risk.
C1 [Naj, Adam C.] Univ Penn, Dept Biostat & Epidemiol, Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Scott, William K.; Courtenay, Monique D.; Cade, William H.; Wang, Gaofeng; Pericak-Vance, Margaret A.] Univ Miami, Miller Sch Med, John P Hussman Inst Human Genom, Miami, FL 33136 USA.
   [Scott, William K.; Courtenay, Monique D.; Wang, Gaofeng; Pericak-Vance, Margaret A.] Univ Miami, Miller Sch Med, Dept Human Genet, Miami, FL 33136 USA.
   [Schwartz, Stephen G.; Kovach, Jaclyn L.] Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, Miami, FL 33136 USA.
   [Agarwal, Anita] Vanderbilt Univ, Vanderbilt Eye Inst, Nashville, TN USA.
   [Haines, Jonathan L.] Vanderbilt Univ, Ctr Human Genet Res, Nashville, TN USA.
C3 University of Pennsylvania; Pennsylvania Medicine; University of Miami;
   University of Miami; Bascom Palmer Eye Institute; University of Miami;
   Vanderbilt University; Vanderbilt University
RP Pericak-Vance, MA (通讯作者)，Univ Miami, Miller Sch Med, John P Hussman Inst Human Genom, 1501 NW 10th Ave Biomed Res Bldg,Room 318, Miami, FL 33136 USA.
EM mpericak@med.miami.edu
RI Haines, Jonathan/C-3374-2012
OI Haines, Jonathan/0000-0002-4351-4728; Scott, William/0000-0001-9336-6404
FU NIH [7R01EY012118]; NATIONAL EYE INSTITUTE [R01EY012118] Funding Source:
   NIH RePORTER
FX This work is partially supported by NIH Grant 7R01EY012118.
CR Abecasis GR, 2001, BIOINFORMATICS, V17, P742, DOI 10.1093/bioinformatics/17.8.742
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Andersen JS, 1999, INVEST OPHTH VIS SCI, V40, pS596
   Ayala-Haedo JA, 2010, ANN HUM GENET, V74, P195, DOI 10.1111/j.1469-1809.2010.00570.x
   Baird PN, 2008, HUM MOL GENET, V17, P1299, DOI 10.1093/hmg/ddn018
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Conley YP, 2006, HUM MOL GENET, V15, P3206, DOI 10.1093/hmg/ddl396
   DeAngelis MM, 2007, ARCH OPHTHALMOL-CHIC, V125, P49, DOI 10.1001/archopht.125.1.49
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Etzrodt J, 2009, BMC NEUROSCI, V10, DOI 10.1186/1471-2202-10-153
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   GOLDBERG J, 1988, AM J EPIDEMIOL, V128, P700, DOI 10.1093/oxfordjournals.aje.a115023
   Goldberg JL, 2004, J NEUROSCI, V24, P4989, DOI 10.1523/JNEUROSCI.4390-03.2004
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hammond CJ, 2002, OPHTHALMOLOGY, V109, P730, DOI 10.1016/S0161-6420(01)01049-1
   HOLZ FG, 1995, ARCH OPHTHALMOL-CHIC, V113, P178, DOI 10.1001/archopht.1995.01100020062029
   Hughes AE, 2007, PLOS MED, V4, P1993, DOI 10.1371/journal.pmed.0040355
   Inamori Y, 2007, HUM GENET, V122, P151, DOI 10.1007/s00439-007-0388-1
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Kniazeva M, 2000, AM J OPHTHALMOL, V130, P197, DOI 10.1016/S0002-9394(00)00585-7
   Kniazeva M F, 1999, Ophthalmic Genet, V20, P71, DOI 10.1076/opge.20.2.71.2287
   Kopplin LJ, 2010, GENES IMMUN, V11, P609, DOI 10.1038/gene.2010.39
   Korn JM, 2008, NAT GENET, V40, P1253, DOI 10.1038/ng.237
   Kraft P, 2007, HUM HERED, V63, P111, DOI 10.1159/000099183
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Li Y, 2006, AM J HUM GENET S, VS79, P2290
   Liu B, 2007, GENE EXPR PATTERNS, V7, P15, DOI 10.1016/j.modgep.2006.05.002
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   McCarty CA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1455
   McKay GJ, 2009, INVEST OPHTH VIS SCI, V50, P533, DOI 10.1167/iovs.08-2275
   Michaelides M, 2003, INVEST OPHTH VIS SCI, V44, P2178, DOI 10.1167/iovs.02-1094
   Mikelsaar R, 2007, OPHTHALMIC GENET, V28, P216, DOI 10.1080/13816810701635269
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Paluru P, 2003, INVEST OPHTH VIS SCI, V44, P1830, DOI 10.1167/iovs.02-0697
   Price AL, 2006, NAT GENET, V38, P904, DOI 10.1038/ng1847
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Schmidt S, 2005, MOL VIS, V11, P941
   Schmidt S, 2000, MOL VIS, V6, P287
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   SMALL KW, 1992, GENOMICS, V13, P681, DOI 10.1016/0888-7543(92)90141-E
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   Spencer KL, 2007, HUM MOL GENET, V16, P1986, DOI 10.1093/hmg/ddm146
   STONE EM, 1994, ARCH OPHTHALMOL-CHIC, V112, P765, DOI 10.1001/archopht.1994.01090180063036
   Tam POS, 2008, INVEST OPHTH VIS SCI, V49, P2357, DOI 10.1167/iovs.07-1520
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Vingerling JR, 1996, ARCH OPHTHALMOL-CHIC, V114, P1193, DOI 10.1001/archopht.1996.01100140393005
   Wang JJ, 1998, INVEST OPHTH VIS SCI, V39, P2167
   Wohrn JCP, 1998, J COMP NEUROL, V396, P20
   Wong TY, 2002, INVEST OPHTH VIS SCI, V43, P2869
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
NR 62
TC 36
Z9 36
U1 0
U2 11
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0003-4800
EI 1469-1809
J9 ANN HUM GENET
JI Ann. Hum. Genet.
PD MAY
PY 2013
VL 77
BP 215
EP 231
DI 10.1111/ahg.12011
PN 3
PG 17
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 127AI
UT WOS:000317665500004
PM 23577725
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Kanda, A
   Chen, W
   Othman, M
   Branham, KEH
   Brooks, M
   Khanna, R
   He, S
   Lyons, R
   Abecasis, GR
   Swaroop, A
AF Kanda, Atsuhiro
   Chen, Wei
   Othman, Mohammad
   Branham, Kari E. H.
   Brooks, Matthew
   Khanna, Ritu
   He, Shirley
   Lyons, Robert
   Abecasis, Goncalo R.
   Swaroop, Anand
TI A variant of mitochondrial protein LOC387715/ARMS2, not HTRA1, is
   strongly associated with age-related macular degeneration
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE aging; genetic association; mitochondria; neurodegeneration; retinal
   disease
ID COMPLEMENT FACTOR-H; SUSCEPTIBILITY LOCI; OXIDATIVE STRESS; GENE;
   POLYMORPHISM; MACULOPATHY; DISEASE; LINKAGE; GENOME; RISK
AB Genetic variants at chromosomes 1q31-32 and 10q26 are strongly associated with susceptibility to age-related macular degeneration (AMD), a common blinding disease of the elderly. We demonstrate, by evaluating 45 tag SNPs spanning HTRA1, PLEKHA1, and predicted gene LOC387715/ARMS2, that rs10490924 SNP alone, or a variant in strong linkage disequilibrium, can explain the bulk of association between the 10q26 chromosomal region and AMD. A previously suggested causal SNP, rs11200638, and other examined SNPs in the region are only indirectly associated with the disease. Contrary to previous reports, we show that rs11200638 SNP has no significant impact on HTRA1 promoter activity in three different cell lines, and HTRA1 mRNA expression exhibits no significant change between control and AMD retinas. However, SNP rs10490924 shows the strongest association with AMD (P = 5.3 x 10(-30)), revealing an estimated relative risk of 2.66 for GT heterozygotes and 7.05 for TT homozygotes. The rs10490924 SNP results in nonsynonymous A69S alteration in the predicted protein LOC387715/ARMS2, which has a highly conserved ortholog in chimpanzee, but not in other vertebrate sequences. We demonstrate that LOC387715/ARMS2 mRNA is detected in the human retina and various cell lines and encodes a 12-kDa protein, which localizes to the mitochondrial outer membrane when expressed in mammalian cells. We propose that rs10490924 represents a major susceptibility variant for AMD at 10q26. A likely biological mechanism is that the A69S change in the LOC387715/ARMS2 protein affects its presumptive function in mitochondria.
C1 Univ Michigan, Dept Ophthalmol & Visual Sci, Ann Arbor, MI 48105 USA.
   Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48105 USA.
   Univ Michigan, Dept Biostat, Ann Arbor, MI 48105 USA.
   Univ Michigan, Dept Human Genet, Ann Arbor, MI 48105 USA.
C3 University of Michigan System; University of Michigan; University of
   Michigan System; University of Michigan; University of Michigan System;
   University of Michigan; University of Michigan System; University of
   Michigan
RP Abecasis, GR (通讯作者)，Univ Michigan, Dept Ophthalmol & Visual Sci, Ann Arbor, MI 48105 USA.
EM goncalo@umich.edu; swaroop@umich.edu
RI Branham, Kari/AAA-8336-2022; Abecasis, Goncalo R/B-7840-2010; Chen,
   Wei/AAX-5994-2020
OI Chen, Wei/0000-0001-7196-8703; Swaroop, Anand/0000-0002-1975-1141;
   Branham, Kari/0000-0002-2492-254X; Abecasis, Goncalo/0000-0003-1509-1825
FU NATIONAL EYE INSTITUTE [Z01EY000449] Funding Source: NIH RePORTER
CR Abecasis GR, 2004, AM J HUM GENET, V74, P482, DOI 10.1086/382786
   Abecasis GR, 2000, BIOINFORMATICS, V16, P182, DOI 10.1093/bioinformatics/16.2.182
   Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   Altshuler D, 2005, NATURE, V437, P1299, DOI 10.1038/nature04226
   AMES BN, 1995, BBA-MOL BASIS DIS, V1271, P165, DOI 10.1016/0925-4439(95)00024-X
   Ausubel FM., 1995, CURRENT PROTOCOLS MO
   Barron MJ, 2001, INVEST OPHTH VIS SCI, V42, P3016
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   BONIFACINO JS, 2007, CURRENT PROTOCOLS CE
   Carelli V, 2004, PROG RETIN EYE RES, V23, P53, DOI 10.1016/j.preteyeres.2003.10.003
   Churchill AJ, 2006, HUM MOL GENET, V15, P2955, DOI 10.1093/hmg/ddl238
   Conley YP, 2005, HUM MOL GENET, V14, P1991, DOI 10.1093/hmg/ddi204
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Feher J, 2006, NEUROBIOL AGING, V27, P983, DOI 10.1016/j.neurobiolaging.2005.05.012
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Fisher SA, 2005, HUM MOL GENET, V14, P2257, DOI 10.1093/hmg/ddi230
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Kanda A, 2007, HUM MUTAT, V28, P589, DOI 10.1002/humu.20488
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Li MY, 2005, AM J HUM GENET, V76, P934, DOI 10.1086/430277
   Lin MT, 2006, NATURE, V443, P787, DOI 10.1038/nature05292
   Loots GG, 2002, GENOME RES, V12, P832, DOI 10.1101/gr.225502
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   McBride HM, 2006, CURR BIOL, V16, pR551, DOI 10.1016/j.cub.2006.06.054
   RISCH N, 1990, AM J HUM GENET, V46, P222
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Sambrook J, 2001, MOL CLONING LAB MANU, V3rd
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Scheet P, 2006, AM J HUM GENET, V78, P629, DOI 10.1086/502802
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Stone EM, 2004, NEW ENGL J MED, V351, P346, DOI 10.1056/NEJMoa040833
   Swain PK, 2001, J BIOL CHEM, V276, P36824, DOI 10.1074/jbc.M105855200
   Tuo JS, 2006, P NATL ACAD SCI USA, V103, P9256, DOI 10.1073/pnas.0603485103
   Wallace DC, 2005, ANNU REV GENET, V39, P359, DOI 10.1146/annurev.genet.39.110304.095751
   Weeks DE, 2004, AM J HUM GENET, V75, P174, DOI 10.1086/422476
   Wigginton JE, 2005, AM J HUM GENET, V76, P887, DOI 10.1086/429864
   Wright AF, 2004, NAT GENET, V36, P1153, DOI 10.1038/ng1448
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1016/0039-6257(87)90115-9
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
   Zareparsi S, 2005, HUM MOL GENET, V14, P1449, DOI 10.1093/hmg/ddi154
NR 48
TC 341
Z9 354
U1 0
U2 13
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD OCT 9
PY 2007
VL 104
IS 41
BP 16227
EP 16232
DI 10.1073/pnas.0703933104
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 220AH
UT WOS:000250128800047
PM 17884985
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Teo, KYC
   Nguyen, V
   Cheung, CMG
   Arnold, JJ
   Chen, FK
   Barthelmes, D
   Gillies, MC
AF Teo, Kelvin Yi Chong
   Vuong Nguyen
   Cheung, Chui Ming Gemmy
   Arnold, Jennifer J.
   Chen, Fred K.
   Barthelmes, Daniel
   Gillies, Mark C.
TI THE IMPACT OF DISEASE ACTIVITY ON 5-YEAR OUTCOMES IN PATIENTS UNDERGOING
   TREATMENT FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
ID GEOGRAPHIC ATROPHY; RANIBIZUMAB; RISK; EYES; PREVALENCE; FIBROSIS;
   GROWTH; EXTEND
AB Purpose: To assess the impact of disease activity on clinical outcomes in a "real-world" cohort with neovascular age-related macular degeneration over 5 years.
   Methods: Data were obtained from the prospectively defined Fight Retinal Blindness! registry. Eyes were divided into tertiles based on the proportion of visits where choroidal neovascular lesion was active (low, moderate, and high) up until 5 years.
   Results: Data from 2,109 eyes were included. The adjusted mean (95% confidence interval) visual acuity change was 20.5 letters (21.8 to 1.1), 1.8 letters (0.2 to 3.4), and 22.5 letters (24.2 to 21.3) in the low, moderate, and high activity groups respectively, P < 0.001. Eyes in the low activity group were more likely to develop macular atrophy (56, 47 and 26% in the low, moderate, and high activity groups respectively, P < 0.001) but less likely to develop subretinal fibrosis (27, 35 and 42% in the low, moderate, and high activity groups respectively, P < 0.001).
   Conclusion: Eyes with higher and lower levels of disease activity had poorer outcomes than eyes with moderate activity over 5 years, apparently because of the development of subretinal fibrosis or macular atrophy.
C1 [Teo, Kelvin Yi Chong; Cheung, Chui Ming Gemmy] Singapore Natl Eye Ctr, Singapore Eye Res Inst, Med Retina Dept, Singapore, Singapore.
   [Teo, Kelvin Yi Chong; Cheung, Chui Ming Gemmy] Natl Univ Singapore, Duke NUS Med Sch, Singapore, Singapore.
   [Teo, Kelvin Yi Chong; Vuong Nguyen; Barthelmes, Daniel; Gillies, Mark C.] Univ Sydney, Sydney Med Sch, Save Sight Inst Discipline Ophthalmol, Sydney, NSW, Australia.
   [Arnold, Jennifer J.] Marsden Eye Specialists, Sydney, NSW, Australia.
   [Chen, Fred K.] Univ Western Australia, Incorporating Lions Eye Inst, Ctr Ophthalmol & Visual Sci, Perth, WA, Australia.
   [Barthelmes, Daniel] Univ Hosp Zurich, Zurich, Switzerland.
   [Barthelmes, Daniel] Univ Zurich, Zurich, Switzerland.
C3 National University of Singapore; Singapore National Eye Center;
   National University of Singapore; University of Sydney; Lions Eye
   Institute; University of Western Australia; University of Zurich;
   University Zurich Hospital; University of Zurich
RP Teo, KYC (通讯作者)，Singapore Eye Res Inst, 11 Third Hosp Ave, Singapore 168751, Singapore.
EM kelvin.teo.y.c@singhealth.com.sg
OI Teo, Kelvin/0000-0002-7458-7081; Chen, Fred/0000-0003-2809-9930
FU Royal Australian NZ College of Ophthalmologists Eye Foundation; National
   Health and Medical Research Council, Australia (NHMRC); Macula Disease
   Foundation, Australia; NHMRC practitioner fellowship; Walter and Gertrud
   Siegenthaler Foundation Zurich, Switzerland; Swiss National Foundation;
   National Medical Research Council [NMRC/LCG/0042018]; NHMRC/Medical
   Research Future Fund career development fellowship [MRF1142962];
   Novartis; Bayer
FX Supported by a grant from the Royal Australian NZ College of
   Ophthalmologists Eye Foundation (2007-2009), a grant from the National
   Health and Medical Research Council, Australia (NHMRC 2010-2012) and a
   grant from the Macula Disease Foundation, Australia. M. C. Gillies is a
   Sydney Medical Foundation Fellow and is supported by an NHMRC
   practitioner fellowship. D. Barthelmes was supported by the Walter and
   Gertrud Siegenthaler Foundation Zurich, Switzerland and the Swiss
   National Foundation. C. M. Gemmy Cheung is supported grant by a grant
   from the National Medical Research Council, (Open Fund Large
   Collaborative grant no: NMRC/LCG/0042018). F. K. Chen is supported by an
   NHMRC/Medical Research Future Fund career development fellowship
   (MRF1142962). Funding was also provided by Novartis and Bayer. Novartis
   made non-binding comments on the design of the study.
CR Arnold JJ, 2016, BMC OPHTHALMOL, V16, DOI 10.1186/s12886-016-0207-3
   Barthelmes D, 2015, BRIT J OPHTHALMOL, V99, P359, DOI 10.1136/bjophthalmol-2014-305514
   Bloch SB, 2013, AM J OPHTHALMOL, V156, P116, DOI 10.1016/j.ajo.2013.02.012
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Cheung CMG, 2019, OPHTHALMOL RETINA, V3, P1045, DOI 10.1016/j.oret.2019.06.002
   Daien V, 2020, BRIT J OPHTHALMOL, V104, P1064, DOI 10.1136/bjophthalmol-2019-315055
   Daniel E, 2018, OPHTHALMOLOGY, V125, P1037, DOI 10.1016/j.ophtha.2018.01.004
   Daniel E, 2014, OPHTHALMOLOGY, V121, P656, DOI 10.1016/j.ophtha.2013.10.019
   Gale RP, 2019, EYE, V33, DOI 10.1038/s41433-018-0300-3
   Gillies MC, 2015, OPHTHALMOLOGY, V122, P1837, DOI 10.1016/j.ophtha.2015.05.010
   Gillies MC, 2014, RETINA-J RET VIT DIS, V34, P188, DOI 10.1097/IAE.0b013e318296b271
   Gonzalez-Buendia L, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0544-x
   Grunwald JE, 2017, OPHTHALMOLOGY, V124, P97, DOI 10.1016/j.ophtha.2016.09.012
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Jaffe GJ, 2019, OPHTHALMOLOGY, V126, P252, DOI 10.1016/j.ophtha.2018.08.035
   Jaffe GJ, 2013, OPHTHALMOLOGY, V120, P1860, DOI 10.1016/j.ophtha.2013.01.073
   Kodjikian L, 2013, OPHTHALMOLOGY, V120, P2300, DOI 10.1016/j.ophtha.2013.06.020
   Lai TYY, 2011, RETINA-J RET VIT DIS, V31, P1581, DOI 10.1097/IAE.0b013e31820d3f3f
   Lois N, 2013, RETINA-J RET VIT DIS, V33, P13, DOI 10.1097/IAE.0b013e3182657fff
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Payne JF, 2019, AM J OPHTHALMOL, V202, P91, DOI 10.1016/j.ajo.2019.02.005
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Silva R, 2018, OPHTHALMOLOGY, V125, P57, DOI 10.1016/j.ophtha.2017.07.014
   Teo KYC, 2020, RETINA-J RET VIT DIS, V40, P2285, DOI 10.1097/IAE.0000000000002779
   Teo KYC, 2020, OPHTHALMOL RETINA, V4, P871, DOI 10.1016/j.oret.2020.03.017
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   Wykoff CC, 2015, OPHTHALMOLOGY, V122, P2514, DOI 10.1016/j.ophtha.2015.08.009
NR 29
TC 2
Z9 2
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JAN
PY 2022
VL 42
IS 1
BP 95
EP 106
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA XS3RA
UT WOS:000732829100022
PM 34292225
DA 2022-11-30
ER

PT J
AU Ritter, M
   Simader, C
   Bolz, M
   Deak, GG
   Mayr-Sponer, U
   Sayegh, R
   Kundi, M
   Schmidt-Erfurth, UM
AF Ritter, Markus
   Simader, Christian
   Bolz, Matthias
   Deak, Gabor G.
   Mayr-Sponer, Ulrike
   Sayegh, Ramzi
   Kundi, Michael
   Schmidt-Erfurth, Ursula M.
TI Intraretinal cysts are the most relevant prognostic biomarker in
   neovascular age-related macular degeneration independent of the
   therapeutic strategy
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; SUBFOVEAL CHOROIDAL NEOVASCULARIZATION;
   VERTEPORFIN PLUS RANIBIZUMAB; PHOTODYNAMIC THERAPY; VISUAL FUNCTION;
   BEVACIZUMAB; COMBINATION; PREDICTORS; PARAMETERS; MORPHOLOGY
AB Background/aims To investigate the impact of antiangiogenic monotherapy and photodynamic therapy (PDT) as add-on strategy on retinal morphology, and to analyse prognostic biomarkers for visual outcome and retreatment frequency in neovascular age-related macular degeneration (nAMD).
   Methods 255 patients participating in the MONT BLANC study were evaluated. Patients were randomised to receive as-needed ranibizumab monotherapy or combination therapy (verteporfin PDT and ranibizumab). Outcome measures included visual acuity (VA), retinal morphology assessed by optical coherence tomography and retreatment frequency.
   Results The proportion of scans showing intraretinal cysts (IRC) or subretinal fluid (SRF) decreased more intensively in the combination than in the monotherapy group. Pigment epithelial detachments (PED) decreased significantly only in the combination group. Patients with IRC presented the lowest initial VA, and IRC had the strongest negative predictive value for functional improvement in both groups. SRF showed a predictive value for a higher number of ranibizumab injections (combination, +0.9; monotherapy, +0.8) and a higher number of PDT treatments in the combination group (+0.3). PED was associated with a higher number of ranibizumab injections only in the monotherapy group (+1.2).
   Conclusions Combination and monotherapy showed a distinct response pattern for morphological parameters in nAMD. IRC was the only relevant prognostic parameter for functional outcome.
C1 [Ritter, Markus; Simader, Christian; Bolz, Matthias; Deak, Gabor G.; Mayr-Sponer, Ulrike; Sayegh, Ramzi; Schmidt-Erfurth, Ursula M.] Med Univ Vienna, Dept Ophthalmol, A-1090 Vienna, Austria.
   [Kundi, Michael] Med Univ Vienna, Inst Environm Hlth, Ctr Publ Hlth, A-1090 Vienna, Austria.
C3 Medical University of Vienna; Medical University of Vienna
RP Simader, C (通讯作者)，Med Univ Vienna, Dept Ophthalmol, Waehringer Guertel 18-20, A-1090 Vienna, Austria.
EM christian.simader@meduniwien.ac.at
RI Bolz, Matthias/HCI-0622-2022
OI Ritter, Markus/0000-0003-1406-8340; Schmidt-Erfurth,
   Ursula/0000-0002-7788-7311; Bolz, Matthias/0000-0001-8691-5276
CR Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Chhablani J, 2013, INT J OPHTHALMOL-CHI, V6, P62, DOI 10.3980/j.issn.2222-3959.2013.01.13
   Eter N, 2005, RETINA-J RET VIT DIS, V25, P691, DOI 10.1097/00006982-200509000-00002
   Ferrara N, 2007, ANNU REV MED, V58, P491, DOI 10.1146/annurev.med.58.061705.145635
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Golbaz I, 2011, INVEST OPHTH VIS SCI, V52, P1599, DOI 10.1167/iovs.09-5018
   Jaffe GJ, 2013, OPHTHALMOLOGY, V120, P1860, DOI 10.1016/j.ophtha.2013.01.073
   Kaiser PK, 2012, OPHTHALMOLOGY, V119, P1001, DOI 10.1016/j.ophtha.2012.02.003
   Keane PA, 2012, INVEST OPHTH VIS SCI, V53, P1152, DOI 10.1167/iovs.11-8130
   Keane PA, 2008, OPHTHALMOLOGY, V115, P2206, DOI 10.1016/j.ophtha.2008.08.016
   Kiss CG, 2008, BRIT J OPHTHALMOL, V92, P1620, DOI 10.1136/bjo.2007.135335
   Kiss CG, 2009, INVEST OPHTH VIS SCI, V50, P2376, DOI 10.1167/iovs.08-2017
   Krebs I, 2005, BRIT J OPHTHALMOL, V89, P1184, DOI 10.1136/bjo.2005.067389
   Larsen M, 2012, OPHTHALMOLOGY, V119, P992, DOI 10.1016/j.ophtha.2012.02.002
   Moutray T, 2008, BRIT J OPHTHALMOL, V92, P361, DOI 10.1136/bjo.2007.123976
   Ritter M, 2011, BRIT J OPHTHALMOL, V95, P381, DOI 10.1136/bjo.2009.175976
   Rogers AH, 2002, AM J OPHTHALMOL, V134, P566, DOI 10.1016/S0002-9394(02)01566-0
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2002, INVEST OPHTH VIS SCI, V43, P830
   Simader C, 2014, OPHTHALMOLOGY, V121, P1237, DOI 10.1016/j.ophtha.2013.12.029
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Tozer K, 2013, OPHTHALMOLOGY, V120, P2029, DOI 10.1016/j.ophtha.2013.03.016
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
NR 24
TC 54
Z9 54
U1 0
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD DEC
PY 2014
VL 98
IS 12
BP 1629
EP 1635
DI 10.1136/bjophthalmol-2014-305186
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AU0AB
UT WOS:000345284300006
PM 25079064
DA 2022-11-30
ER

PT J
AU Nordestgaard, LT
   Tybjaerg-Hansen, A
   Frikke-Schmidt, R
   Nordestgaard, BG
AF Nordestgaard, Liv Tybjaerg
   Tybjaerg-Hansen, Anne
   Frikke-Schmidt, Ruth
   Nordestgaard, Borge Gronne
TI Elevated Apolipoprotein A1 and HDL Cholesterol Associated with
   Age-related Macular Degeneration: 2 Population Cohorts
SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
LA English
DT Article
DE Lipoproteins; cholesterol; blindness; drusen; eye disease; epidemiology
ID DISEASE; RISK; IMPAIRMENT
AB Context: To enable prevention and treatment of age-related macular degeneration (AMD), understanding risk factors for AMD is important.
   Objective: We tested the hypotheses that elevated plasma apolipoprotein A1 and high-density lipoprotein (HDL) cholesterol and low levels of low-density lipoprotein (LDL) cholesterol are associated with increased risk of AMD.
   Methods: From the Danish general population, we studied 106 703 and 16 032 individuals in the Copenhagen General Population Study (CGPS) and the Copenhagen City Heart Study (CCHS) with median follow-up of 9 and 32 years, respectively.
   The main outcome measures were 1787 AMD in CGPS and 206 in CCHS.
   Results: Higher concentrations of plasma apolipoprotein A1 and HDL cholesterol, and lower concentrations of LDL cholesterol, were associated with higher risk of AMD in CGPS. After multifactorial adjustment, individuals in the highest versus lowest quartile of plasma apolipoprotein A1 and HDL cholesterol had hazard ratios for AMD of 1.40 (95% CI: 1.20-1.63) and 1.22 (1.03-1.45). Corresponding hazard ratios for individuals in the lowest versus highest quartile of LDL cholesterol were 1.18 (1.02-1.37). Per 100 mg/dL higher plasma apolipoprotein A1, 1 mmol/L (39 mg/dL) higher HDL, and 1 mmol/L (39 mmol/L) lower LDL cholesterol, the hazard ratios for AMD were 1.53(1.31-1.80), 1.19 (1.07-1.32), and 1.05 (1.00-1.11), respectively, with similar results across strata of different risk factors. Higher concentrations of HDL cholesterol were also associated with higher risk of AMD in the CCHS.
   Conclusion: Elevated plasma apolipoprotein A1 and HDL cholesterol and lower LDL cholesterol are associated with increased risk of AMD.
C1 [Nordestgaard, Liv Tybjaerg; Tybjaerg-Hansen, Anne; Frikke-Schmidt, Ruth] Copenhagen Univ Hosp, Rigshosp, Dept Clin Biochem, Copenhagen, Denmark.
   [Nordestgaard, Liv Tybjaerg; Tybjaerg-Hansen, Anne; Frikke-Schmidt, Ruth; Nordestgaard, Borge Gronne] Copenhagen Univ Hosp, Herlev & Gentofte Hosp, Copenhagen Gen Populat Study, Herlev, Denmark.
   [Tybjaerg-Hansen, Anne; Nordestgaard, Borge Gronne] Copenhagen Univ Hosp, Frederiksberg Hosp, Copenhagen City Heart Study, Frederiksberg, Denmark.
   [Nordestgaard, Liv Tybjaerg; Tybjaerg-Hansen, Anne; Frikke-Schmidt, Ruth; Nordestgaard, Borge Gronne] Univ Copenhagen, Fac Hlth & Med Sci, Dept Clin Med, Copenhagen, Denmark.
   [Nordestgaard, Borge Gronne] Copenhagen Univ Hosp, Herlev & Gentofte Hosp, Dept Clin Biochem, Herlev, Denmark.
C3 Rigshospitalet; University of Copenhagen; University of Copenhagen;
   University of Copenhagen; University of Copenhagen; University of
   Copenhagen
RP Nordestgaard, BG (通讯作者)，Herlev & Gentofte Hosp, Dept Clin Biochem, Borgmester Ib Juuls Vej 73, DK-2730 Herlev, Denmark.
EM Borge.Nordestgaard@regionh.dk
OI Frikke-Schmidt, Ruth/0000-0003-4084-5027; Tybjaerg Nordestgaard,
   Liv/0000-0002-5490-0034; Nordestgaard, Borge/0000-0002-1954-7220
FU Research Council at Rigshospitalet [E-22016-07]; European
   Atherosclerosis Society; Kirsten og Freddy Johansens Fond; European
   Union, TransCard [FP7603091]; Copenhagen County Foundation; Odd fellow
   order; Anitschkow Award
FX Supported by the Research Council at Rigshospitalet (E-22016-07), the
   Odd fellow order, the Anitschkow Award, European Atherosclerosis
   Society, Kirsten og Freddy Johansens Fond, the European Union, TransCard
   (FP7603091), and the Copenhagen County Foundation. The sponsor or
   funding organization had no role in the design or conduct of this
   research.
CR Burgess S, 2017, OPHTHALMOLOGY, V124, P1165, DOI 10.1016/j.ophtha.2017.03.042
   Cheung CMG, 2014, J INTERN MED, V276, P140, DOI 10.1111/joim.12227
   Colijn JM, 2019, OPHTHALMOLOGY, V126, P393, DOI 10.1016/j.ophtha.2018.09.045
   Congdon NG, 2003, JAMA-J AM MED ASSOC, V290, P2057, DOI 10.1001/jama.290.15.2057
   Fan Q, 2017, INT J EPIDEMIOL, V46, P1891, DOI 10.1093/ije/dyx189
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Grundy SM, 2019, CIRCULATION, V139, pE1082, DOI 10.1161/CIR.0000000000000625
   Han XK, 2021, INT J EPIDEMIOL, V50, P325, DOI 10.1093/ije/dyaa178
   Kersten E, 2018, SURV OPHTHALMOL, V63, P9, DOI 10.1016/j.survophthal.2017.05.003
   Langsted A, 2020, J CLIN ENDOCR METAB, V105, DOI 10.1210/clinem/dgz265
   Mach F, 2020, EUR HEART J, V41, P111, DOI [10.15829/1560-4071-2020-3826, 10.1093/eurheartj/ehz455]
   Madsen CM, 2021, ARTERIOSCL THROM VAS, V41, P128, DOI 10.1161/ATVBAHA.120.314050
   Madsen CM, 2018, EUR HEART J, V39, P1181, DOI 10.1093/eurheartj/ehx665
   Madsen CM, 2017, EUR HEART J, V38, P2478, DOI 10.1093/eurheartj/ehx163
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Nordestgaard BG, 2017, J AM COLL CARDIOL, V70, P1637, DOI 10.1016/j.jacc.2017.08.006
   Nordestgaard LT, 2015, ALZHEIMERS DEMENT, V11, P1430, DOI 10.1016/j.jalz.2015.04.006
   Ottosen SJ, 2017, ALDERSRELATERET MACU
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   Yan Q, 2018, HUM MOL GENET, V27, P929, DOI 10.1093/hmg/ddy002
   Zacho J, 2008, NEW ENGL J MED, V359, P1897, DOI 10.1056/NEJMoa0707402
NR 26
TC 6
Z9 6
U1 1
U2 3
PU ENDOCRINE SOC
PI WASHINGTON
PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA
SN 0021-972X
EI 1945-7197
J9 J CLIN ENDOCR METAB
JI J. Clin. Endocrinol. Metab.
PD JUL
PY 2021
VL 106
IS 7
BP E2749
EP E2758
DI 10.1210/clinem/dgab095
EA FEB 2021
PG 10
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism
GA UN4CC
UT WOS:000693963100051
PM 33596319
OA Bronze
DA 2022-11-30
ER

PT J
AU Lois, N
   Owens, SL
   Coco, R
   Hopkins, J
   Fitzke, FW
   Bird, AC
AF Lois, N
   Owens, SL
   Coco, R
   Hopkins, J
   Fitzke, FW
   Bird, AC
TI Fundus autofluorescence in patients with age-related macular
   degeneration and high risk of visual loss
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; IN-VIVO; BRUCHS MEMBRANE; DRUSEN; PROGNOSIS;
   ABNORMALITIES; FLUORESCENCE; DETACHMENT; LIPOFUSCIN; DISEASE
AB Purpose: To describe fundus autofluorescence (AF) patterns and their change over time in patients with age-related macular degeneration (AMD) and high risk of visual loss participating in the drusen laser study (DLS).
   Design: Randomized clinical trial.
   Methods: The study population consisted of 29 patients (35 eyes) participating in the DLS, which is a prospective, randomized, controlled clinical trial of prophylactic laser therapy in patients with AMD and high risk of neovascular complications. The intervention consisted of 16 eyes having prophylactic laser and 19 receiving no treatment. The main outcome measures were changes in the distribution of drusen and AF. Patients were reviewed for a median follow-up or 24 months (range 12-36 months).
   Results: At baseline, four patterns of fundus AF were recognized: focal increased AF (n=18), reticular AF (n=3), combined focal and reticular AF (n=2), and homogeneous AF (n=12). At last follow-up, fundus AF remained unchanged in 15 untreated (78%) and in seven treated (43%) eyes. In only one untreated eye, focal areas of increased AF returned to background levels and were no longer detectable at last follow,up, compared with six treated eyes. This difference was statistically significant (P=.03). Only large foveal soft drusen (drusenoid pigment epithelium detachments) consistently corresponded with focal changes in AF, whereas no obvious correspondence was found between small soft drusen located elsewhere and changes in AF.
   Conclusion: The lack of obvious correspondence between the distribution of drusen and of AF found in this study appears to indicate that drusen and AF represent independent measures of aging in the posterior pole. (Am J Ophthalmol 2002;133:341-349. (C) 2002 by Elsevier Science Inc. All rights reserved.).
C1 Moorfields Eye Hosp, Med Retinal Serv, London, England.
   Inst Ophthalmol, Dept Visual Sci, London WC1H 9QS, England.
C3 University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust; University of London; University College London
RP Lois, N (通讯作者)，Aberdeen Royal Infirm, Dept Ophthalmol, Retina Serv, Aberdeen AB25 2ZN, Scotland.
EM noemilois@aol.com
RI Fitzke, Fred/C-3535-2008; Martin, Rosa Maria Coco/H-4511-2015
OI Martin, Rosa Maria Coco/0000-0002-1811-1417
CR BIRD AC, 1991, EYE, V5, P1
   BRESSLER SB, 1990, ARCH OPHTHALMOL-CHIC, V108, P1442, DOI 10.1001/archopht.1990.01070120090035
   CHEN JC, 1992, INVEST OPHTH VIS SCI, V33, P334
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P2327
   DELORI FC, 1994, APPL OPTICS, V33, P7439, DOI 10.1364/AO.33.007439
   Delori FC, 2000, INVEST OPHTH VIS SCI, V41, P496
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   Dorey K, 1993, RETINAL DEGENERATION, P3
   Dubovy SR, 2000, RETINA-J RET VIT DIS, V20, P638, DOI 10.1097/00006982-200011000-00009
   DUVALL J, 1985, ARCH OPHTHALMOL-CHIC, V103, P694, DOI 10.1001/archopht.1985.01050050086024
   FEENEYBURNS L, 1985, AM J OPHTHALMOL, V100, P686, DOI 10.1016/0002-9394(85)90625-7
   FEENEYBURNS L, 1987, INVEST OPHTH VIS SCI, V28, P1138
   GASS JDM, 1973, ARCH OPHTHALMOL-CHIC, V90, P206
   GRAGOUDAS ES, 1976, ARCH OPHTHALMOL-CHIC, V94, P755, DOI 10.1001/archopht.1976.03910030365003
   Green W R, 1977, Trans Am Ophthalmol Soc, V75, P180
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   GREGOR Z, 1977, BRIT J OPHTHALMOL, V61, P141, DOI 10.1136/bjo.61.2.141
   HOLZ FG, 1994, OPHTHALMOLOGY, V101, P1522
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   KITAGAWA K, 1989, OPHTHALMOLOGICA, V199, P116, DOI 10.1159/000310027
   Lois N, 1999, BRIT J OPHTHALMOL, V83, P276, DOI 10.1136/bjo.83.3.276
   Lois N, 2000, BRIT J OPHTHALMOL, V84, P741, DOI 10.1136/bjo.84.7.741
   MOORE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1290
   Okubo A, 1999, INVEST OPHTH VIS SCI, V40, P443
   Owens SL, 1999, AM J OPHTHALMOL, V127, P681, DOI 10.1016/S0002-9394(99)00043-4
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   PAULEIKHOFF D, 1990, AM J OPHTHALMOL, V109, P211, DOI 10.1016/S0002-9394(14)75989-6
   PAULEIKHOFF D, 1990, AM J OPHTHALMOL, V109, P38, DOI 10.1016/S0002-9394(14)75576-X
   PIGUET B, 1992, AM J OPHTHALMOL, V113, P657, DOI 10.1016/S0002-9394(14)74790-7
   SARKS JP, 1988, EVOLUTION GEOGRPHIC, P552
   SARKS SH, 1973, BRIT J OPHTHALMOL, V57, P951, DOI 10.1136/bjo.57.12.951
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   SMIDDY WE, 1984, OPHTHALMOLOGY, V91, P271
   STRAHLMAN ER, 1983, ARCH OPHTHALMOL-CHIC, V101, P1191
   VONRUCKMANN A, 1995, BRIT J OPHTHALMOL, V79, P407, DOI 10.1136/bjo.79.5.407
   vonRuckmann A, 1997, INVEST OPHTH VIS SCI, V38, P478
   vonRuckmann A, 1997, ARCH OPHTHALMOL-CHIC, V115, P609, DOI 10.1001/archopht.1997.01100150611006
   Wade AR, 1998, OPT EXPRESS, V3, P190, DOI 10.1364/OE.3.000190
   YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1016/0039-6257(87)90115-9
NR 39
TC 149
Z9 158
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD MAR
PY 2002
VL 133
IS 3
BP 341
EP 349
AR PII S0002-9394(01)01404-0
DI 10.1016/S0002-9394(01)01404-0
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 528WX
UT WOS:000174268600007
PM 11860971
DA 2022-11-30
ER

PT J
AU Subramanian, A
   Han, D
   Braithwaite, T
   Thayakaran, R
   Zemedikun, DT
   Gokhale, KM
   Lee, WH
   Coker, J
   Keane, PA
   Denniston, AK
   Nirantharakumar, K
   Azoulay, L
   Adderley, NJ
AF Subramanian, Anuradhaa
   Han, Diana
   Braithwaite, Tasanee
   Thayakaran, Rasiah
   Zemedikun, Dawit T.
   Gokhale, Krishna M.
   Lee, Wen Hwa
   Coker, Jesse
   Keane, Pearse A.
   Denniston, Alastair K.
   Nirantharakumar, Krishnarajah
   Azoulay, Laurent
   Adderley, Nicola J.
TI Angiotensin-converting enzyme inhibitors and risk of age-related macular
   degeneration in individuals with hypertension
SO BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
LA English
DT Article
DE age-related macular degeneration; angiotensin-converting enzyme
   inhibitors; hypertension
ID CHOROIDAL NEOVASCULARIZATION; RECEPTOR BLOCKERS; BLOOD-PRESSURE;
   MEDICATION USE; MACULOPATHY; PREVALENCE; STATINS
AB Aims Several observational studies have examined the potential protective effect of angiotensin-converting enzyme inhibitor (ACE-I) use on the risk of age-related macular degeneration (AMD) and have reported contradictory results owing to confounding and time-related biases. We aimed to assess the risk of AMD in a base cohort of patients aged 40 years and above with hypertension among new users of ACE-I compared to an active comparator cohort of new users of calcium channel blockers (CCB) using data obtained from IQVIA Medical Research Data, a primary care database in the UK. Methods In this study, 53 832 and 43 106 new users of ACE-I and CCB were included between 1995 and 2019, respectively. In an on-treatment analysis, patients were followed up from the time of index drug initiation to the date of AMD diagnosis, loss to follow-up, discontinuation or switch to the comparator drug. A comprehensive range of covariates were used to estimate propensity scores to weight and match new users of ACE-I and CCB. Standardized mortality ratio weighted Cox proportional hazards model was used to estimate hazard ratios of developing AMD. Results During a median follow-up of 2 years (interquartile range 1-5 years), the incidence rate of AMD was 2.4 (95% confidence interval 2.2-2.6) and 2.2 (2.0-2.4) per 1000 person-years among the weighted new users of ACE-I and CCB, respectively. There was no association of ACE-I use on the risk of AMD compared to CCB use in either the propensity score weighted or matched, on-treatment analysis (adjusted hazard ratio: 1.07 [95% confidence interval 0.90-1.27] and 0.87 [0.71-1.07], respectively). Conclusion We found no evidence that the use of ACE-I is associated with risk of AMD in patients with hypertension.
C1 [Subramanian, Anuradhaa; Han, Diana; Braithwaite, Tasanee; Thayakaran, Rasiah; Zemedikun, Dawit T.; Gokhale, Krishna M.; Nirantharakumar, Krishnarajah; Adderley, Nicola J.] Univ Birmingham, Inst Appl Hlth Res, Birmingham B15 2TT, W Midlands, England.
   [Braithwaite, Tasanee] Kings Coll London, Sch Immunol & Microbial Sci, London, England.
   [Braithwaite, Tasanee] Kings Coll London, Sch Life Course Sci, London, England.
   [Braithwaite, Tasanee] Guys & St Thomas NHS Fdn Trust, Med Eye Unit, London, England.
   [Lee, Wen Hwa; Coker, Jesse] Act Age Related Macular Degenerat, London, England.
   [Keane, Pearse A.; Denniston, Alastair K.] UCL, Moorfields Eye Hosp NHS Fdn Trust, NIHR Biomed Res Ctr, London, England.
   [Keane, Pearse A.; Denniston, Alastair K.] UCL, Inst Ophthalmol, London, England.
   [Denniston, Alastair K.] Univ Hosp Birmingham NHS Fdn Trust, Birmingham, W Midlands, England.
   [Denniston, Alastair K.; Nirantharakumar, Krishnarajah] Hlth Data Res UK HDRUK, London, England.
   [Denniston, Alastair K.] Univ Birmingham, Inst Inflammat & Ageing, Birmingham, W Midlands, England.
   [Azoulay, Laurent] McGill Univ, Dept Epidemiol Biostat & Occupat Hlth, Montreal, PQ, Canada.
   [Azoulay, Laurent] Lady Davis Inst, Ctr Clin Epidemiol, Montreal, PQ, Canada.
   [Azoulay, Laurent] McGill Univ, Gerald Bronfman Dept Oncol, Montreal, PQ, Canada.
C3 University of Birmingham; University of London; King's College London;
   University of London; King's College London; Guy's & St Thomas' NHS
   Foundation Trust; University of London; University College London;
   Moorfields Eye Hospital NHS Foundation Trust; University of London;
   University College London; University of Birmingham; University of
   Birmingham; McGill University; Lady Davis Institute; McGill University;
   McGill University
RP Nirantharakumar, K (通讯作者)，Univ Birmingham, Inst Appl Hlth Res, Birmingham B15 2TT, W Midlands, England.
EM k.nirantharan@bham.ac.uk
RI Zemedikun, Dawit T/AAR-2439-2021; Lee, Wen Hwa/GZA-8183-2022
OI Zemedikun, Dawit T/0000-0003-3642-0456; Lee, Wen
   Hwa/0000-0002-4098-5225; Han, Ji Eun Diana/0000-0002-7435-0658;
   Denniston, Alastair/0000-0001-7849-0087; Adderley,
   Nicola/0000-0003-0543-3254; Keane, Pearse/0000-0002-9239-745X
FU Action Against Age-related Macular Degeneration [1 170 224, SC048549]
FX This research was funded by Action Against Age-related Macular
   Degeneration, Charity numbers 1 170 224 and SC048549.
CR [Anonymous], 2006, DRUG AGING, V23, p217
   Barro-Soria R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049624
   Bourne RRA, 2013, LANCET GLOB HEALTH, V1, pE339, DOI 10.1016/S2214-109X(13)70113-X
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   Christoforidis JB, 2011, CURR DRUG TARGETS, V12, P221
   Dandona L, 1998, ARCH OPHTHALMOL-CHIC, V116, P545, DOI 10.1001/archopht.116.4.514
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   Dusetzina SB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063973
   Etminan M, 2008, CURR DRUG SAF, V3, P24, DOI 10.2174/157488608783333952
   Fletcher EL, 2010, PROG RETIN EYE RES, V29, P284, DOI 10.1016/j.preteyeres.2010.03.003
   Granger E, 2019, STAT MED, V38, P5120, DOI 10.1002/sim.8355
   Hikichi T, 2001, AM J OPHTHALMOL, V132, P587, DOI 10.1016/S0002-9394(01)01139-4
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jonas JB, 2017, ASIA-PAC J OPHTHALMO, V6, P493, DOI 10.22608/APO.2017251
   Katsi VK, 2015, J HYPERTENS, V33, P2382, DOI 10.1097/HJH.0000000000000766
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2001, ARCH OPHTHALMOL-CHIC, V119, P1354
   Klein R, 2014, OPHTHALMOLOGY, V121, P1604, DOI 10.1016/j.ophtha.2014.03.005
   Lee H, 2019, YONSEI MED J, V60, P679, DOI 10.3349/ymj.2019.60.7.679
   Lund Jennifer L, 2015, Curr Epidemiol Rep, V2, P221
   Mack CD, 2013, PHARMACOEPIDEM DR S, V22, P810, DOI 10.1002/pds.3386
   Maguire A, 2009, PHARMACOEPIDEM DR S, V18, P76, DOI 10.1002/pds.1688
   Marback RF, 2007, CLINICS, V62, P573, DOI 10.1590/S1807-59322007000500007
   McCarty CA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1455
   Myland M., 2021, SPRINGER SERIES EPID, DOI [10.1007/978-3-030-51455-6_4, DOI 10.1007/978]
   Nagai N, 2006, ARTERIOSCL THROM VAS, V26, P2252, DOI 10.1161/01.ATV.0000240050.15321.fe
   Park SJ, 2014, OPHTHALMOLOGY, V121, P1756, DOI 10.1016/j.ophtha.2014.03.022
   Petty DR, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/1472-6963-14-76
   Praddaude F, 2009, EXP EYE RES, V89, P109, DOI 10.1016/j.exer.2009.02.020
   Ray WA, 2003, AM J EPIDEMIOL, V158, P915, DOI 10.1093/aje/kwg231
   Ren C, 2020, J OPHTHALMOL, V2020, DOI 10.1155/2020/4252031
   Sato T, 2003, EPIDEMIOLOGY, V14, P680, DOI 10.1097/01.EDE.0000081989.82616.7d
   Satofuka S, 2008, AM J PATHOL, V173, P1911, DOI 10.2353/ajpath.2008.080457
   Smith T, 2019, BRIT J GEN PRACT, V69, pE689, DOI 10.3399/bjgp19X705521
   SPERDUTO RD, 1986, ARCH OPHTHALMOL-CHIC, V104, P216
   Striker GE, 2008, AM J PHYSIOL-CELL PH, V295, pC1633, DOI 10.1152/ajpcell.00092.2008
   Thomas AS, 2015, RETINA-J RET VIT DIS, V35, P1964, DOI 10.1097/IAE.0000000000000603
   Van Leeuwen R, 2004, OPHTHALMOLOGY, V111, P1169, DOI 10.1016/j.ophtha.2003.10.024
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
   Williams B, 2004, BMJ-BRIT MED J, V328, P634, DOI 10.1136/bmj.328.7440.634
   Wu KHC, 2004, ACTA OPHTHALMOL SCAN, V82, P298, DOI 10.1111/j.1600-0420.2004.00265.x
NR 42
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0306-5251
EI 1365-2125
J9 BRIT J CLIN PHARMACO
JI Br. J. Clin. Pharmacol.
PD SEP
PY 2022
VL 88
IS 9
BP 4199
EP 4210
DI 10.1111/bcp.15366
EA MAY 2022
PG 12
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 3W5TJ
UT WOS:000793204600001
PM 35474585
OA Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Pinna, A
   Boscia, F
   Paliogiannis, P
   Carru, C
   Zinellu, A
AF Pinna, Antonio
   Boscia, Francesco
   Paliogiannis, Panagiotis
   Carru, Ciriaco
   Zinellu, Angelo
TI MALONDIALDEHYDE LEVELS IN PATIENTS WITH AGE-RELATED MACULAR DEGENERATION
   A Systematic Review and Meta-analysis
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Review
DE plasma malondialdehyde; age-related macular degeneration; systematic
   review; meta-analysis; random-effects model
ID LIPID-PEROXIDATION; PLASMA MALONDIALDEHYDE; CIGARETTE-SMOKING; OXIDATIVE
   STRESS; NITRIC-OXIDE; RISK; PATHOGENESIS; POLYMORPHISM; ASSOCIATION
AB Background/Purpose: The role of blood malondialdehyde (MDA) in age-related macular degeneration (AMD), the leading cause of new blindness in industrialized countries, is still matter of debate. We performed a systematic review and meta-analysis of the published data on the MDA levels in AMD patients. Methods: PubMed, ISI Web of Sciences, and Scopus searches were performed according to MOOSE guidelines. Case-control studies were eligible for inclusion. Participants and controls were AMD patients and subjects without AMD, respectively. The main outcome measures were wet AMD and dry AMD. MDA level was the main exposure variable. Data were pooled using a random-effects model. Results: Twelve case-control studies were identified. A total of 634 AMD patients (mean age 66.7 years) and 656 controls without AMD (mean age 67.8 years) were evaluated. Extreme between-study heterogeneity was observed (I-2 = 96.8%, P < 0.001). Pooled standardized mean difference showed that MDA values were significantly higher in patients with AMD (standardized mean difference = 1.91 mu mol/L, 95% confidence interval = 1.08-2.74; P < 0.001). In a model including five studies, homogenous for age, sample matrix, and laboratory testing for MDA, heterogeneity decreased from extreme to moderate (I-2 = 46.4%, P = 0.113), and pooled standardized mean difference, though attenuated, remained significantly higher in AMD patients (standardized mean difference = 1.07 mu mol/L, 95% confidence interval = 0.82-1.31; P < 0.001). Conclusion: There is some evidence of higher levels of MDA in AMD patients compared with healthy controls; however, this result should be interpreted with caution because of extreme between-study heterogeneity and the possible effect of publication bias. Future studies, preferably well age-matched and of cohort design, are necessary before any firm conclusions on the putative role of elevated MDA on AMD can be drawn.
C1 [Pinna, Antonio; Boscia, Francesco; Paliogiannis, Panagiotis] Univ Sassari, Dept Med Surg & Expt Sci, Sassari, Italy.
   [Pinna, Antonio; Boscia, Francesco; Carru, Ciriaco] Azienda Osped Univ Sassari, Sassari, Italy.
   [Carru, Ciriaco; Zinellu, Angelo] Univ Sassari, Dept Biomed Sci, Sassari, Italy.
C3 University of Sassari; University of Sassari; University of Sassari
RP Pinna, A (通讯作者)，Univ Sassari, Sect Ophthalmol, Dept Surg Microsurg & Med Sci, Viale San Pietro 43 A, I-07100 Sassari, Italy.
EM apinna@uniss.it
RI Pinna, Antonio/H-5067-2018; Paliogiannis, Panagiotis/M-6870-2016; Carru,
   Ciriaco/AAI-9996-2021; Boscia, Francesco/AAC-7729-2022
OI Pinna, Antonio/0000-0003-3052-2662; Paliogiannis,
   Panagiotis/0000-0001-5485-6056; Carru, Ciriaco/0000-0002-6985-4907
CR Aktas S, 2017, ARQ BRAS OFTALMOL, V80, P234, DOI 10.5935/0004-2749.20170057
   Ates O, 2009, TOHOKU J EXP MED, V217, P17, DOI 10.1620/tjem.217.17
   Baskol G, 2006, OPHTHALMOLOGICA, V220, P12, DOI 10.1159/000089269
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bowden J, 2011, BMC MED RES METHODOL, V11, DOI 10.1186/1471-2288-11-41
   Campagne MV, 2014, J PATHOL, V232, P151, DOI 10.1002/path.4266
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Evereklioglu C, 2003, DOC OPHTHALMOL, V106, P129, DOI 10.1023/A:1022512402811
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Hong N, 2016, ACTA OPHTHALMOL, V94, P334, DOI 10.1111/aos.13049
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kato R, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3205-9
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Niki E, 2009, FREE RADICAL BIO MED, V47, P469, DOI 10.1016/j.freeradbiomed.2009.05.032
   Park DH, 2014, RETINA-J RET VIT DIS, V34, P1167, DOI 10.1097/IAE.0000000000000047
   Pinna A, 2018, ACTA OPHTHALMOL, V96, pE269, DOI 10.1111/aos.13343
   Shen XL, 2012, J NUTR HEALTH AGING, V16, P201, DOI 10.1007/s12603-011-0350-8
   Sterne JAC, 2001, J CLIN EPIDEMIOL, V54, P1046, DOI 10.1016/S0895-4356(01)00377-8
   Tobias A., 1999, STATA TECH B, V47, P15
   Totan Y, 2001, BRIT J OPHTHALMOL, V85, P1426, DOI 10.1136/bjo.85.12.1426
   Totan Y, 2009, CURR EYE RES, V34, P1089, DOI 10.3109/02713680903353772
   Uchida K, 2015, FREE RADICAL RES, V49, P896, DOI 10.3109/10715762.2015.1036052
   Venza I, 2012, AGING CLIN EXP RES, V24, P530, DOI 10.3275/8477
   Wells G, 2018, NEWCASTLE OTTAWA SCA
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yildirim O, 2004, OPHTHALMOLOGICA, V218, P202, DOI 10.1159/000076845
   Yildirim Z, 2011, CLINICS, V66, P743, DOI 10.1590/S1807-59322011000500006
NR 29
TC 5
Z9 5
U1 2
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD FEB
PY 2020
VL 40
IS 2
BP 195
EP 203
DI 10.1097/IAE.0000000000002574
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA LA1QP
UT WOS:000523729800007
PM 31972788
DA 2022-11-30
ER

PT J
AU Qi, HJ
   Li, XX
   Zhang, JY
   Zhao, MW
AF Qi, Hui-Jun
   Li, Xiao-Xin
   Zhang, Jun-Yan
   Zhao, Ming-Wei
TI Efficacy and safety of ranibizumab for wet age-related macular
   degeneration in Chinese patients
SO INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE antiangiogenic drug; ranibizumab; wet age-related macular degeneration;
   fluorescence fundus angiography; indocyanine green angiography; optical
   coherence tomography; visual acuity; central foveal thickness
ID ENDOTHELIAL GROWTH-FACTOR; CHOROIDAL NEOVASCULARIZATION; ANGIOGENESIS;
   THERAPY; REGIMEN
AB AIM: To evaluate the clinical efficacy and safety of ranibizumab for wet age-related macular degeneration (wAMD) in Chinese patients, and to determine the mean number of injections administered over one year of follow-up.
   METHODS: This single centre, retrospective observational case series study included data from 121 patients with wAMD (121 eyes) who were diagnosed by indirect ophthalmoscopy, fluorescence fundus angiography (FFA), indocyanine green angiography, and optical coherence tomography. Ranibizumab was injected into the vitreous cavities once per month for 3mo and as needed afterwards. Changes in visual acuity and central foveal thickness (CFT) during the follow-up period were compared, and the mean number of injections over the year was calculated. Patients with one or more adverse events related to the drugs and injections were recorded for further adverse events analysis.
   RESULTS: The study population included 70 males and 51 females aged between 50 and 87y (mean: 71.32 +/- 9.41y). The mean number of injections over the first year was 5 +/- 1 (range: 3-9). The mean best-corrected visual acuity by Early Treatment Diabetic Retinopathy Study increased from 43.2 +/- 19.3 (95%CI: 39.8-46.7) at baseline to 51.7 +/- 20.1 (95%CI: 48.1-55.3), and CFT decreased from 526.5 +/- 277.0 mu m (95%CI: 476.6-576.4) to 258.2 +/- 161.6 pm (95%CI: 229.2-287.3) at 12mo. The differences were statistically significant (P<0.001). Visual acuity significantly improved in 34.1% of the patients (38 eyes), stabilized in 66.1% of the patients (80 eyes), and significantly decreased in 2.5% of the patients (3 eyes). CFT at baseline was an independent risk factor of decreased CFT and increased visual acuity. None of the patients had severe adverse events during the follow-up period.
   CONCLUSION: Ranibizumab can effectively control disease progression and improve visual acuity in patients with wAMD. The disease conditions of most patients stabilized after a one-year treatment with an average of 5 injections.
C1 [Qi, Hui-Jun; Li, Xiao-Xin; Zhao, Ming-Wei] Peking Univ, Peoples Hosp, Dept Ophthalmol, 11 Xizhimen South Ave, Beijing 100044, Peoples R China.
   [Zhang, Jun-Yan] Bothwin Pte Ltd, Shanghai 200232, Peoples R China.
   [Zhang, Jun-Yan] Shanghai Med Assoc, Branch Clin Epidemiol & Evidence Based Med, Shanghai 200240, Peoples R China.
C3 Peking University
RP Zhao, MW (通讯作者)，Peking Univ, Peoples Hosp, Dept Ophthalmol, 11 Xizhimen South Ave, Beijing 100044, Peoples R China.
EM drzhaomingwei@163.com
OI ZHANG, JUNYAN/0000-0002-7890-3707
CR ADAMIS AP, 1993, BIOCHEM BIOPH RES CO, V193, P631, DOI 10.1006/bbrc.1993.1671
   Arias L, 2011, RETINA-J RET VIT DIS, V31, P1261, DOI 10.1097/IAE.0b013e318207d152
   Bandukwala T, 2010, CAN J OPHTHALMOL, V45, P590, DOI 10.3129/i10-082
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Campochiaro PA, 2000, J CELL PHYSIOL, V184, P301, DOI 10.1002/1097-4652(200009)184:3<301::AID-JCP3>3.0.CO;2-H
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Cursiefen C, 2004, J CLIN INVEST, V113, P1040, DOI 10.1172/JCI200420465
   Das A, 2003, PROG RETIN EYE RES, V22, P721, DOI 10.1016/j.preteyeres.2003.08.001
   Ferrara N, 2001, ACTA HAEMATOL-BASEL, V106, P148, DOI 10.1159/000046610
   Hjelmqvist L, 2011, J OPHTHALMOL, V2011, DOI 10.1155/2011/405724
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Kumar A, 2011, BRIT J OPHTHALMOL, V95, P530, DOI 10.1136/bjo.2009.171868
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Li J, 2013, INT J OPHTHALMOL-CHI, V6, P169, DOI 10.3980/j.issn.2222-3959.2013.02.12
   Li Xiao-Xin, 2013, CHIN J OPHTHALMOL, V29, P343
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Muniraju R, 2013, OPHTHALMOLOGICA, V230, P27, DOI 10.1159/000350238
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Williams TA, 2011, EYE, V25, P1617, DOI 10.1038/eye.2011.224
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Zou Hai-dong, 2005, Zhonghua Yan Ke Za Zhi, V41, P15
NR 23
TC 7
Z9 8
U1 0
U2 3
PU IJO PRESS
PI XI AN
PA NO 269 YOUYI EAST RD, XI AN, 710054, PEOPLES R CHINA
SN 2222-3959
EI 2227-4898
J9 INT J OPHTHALMOL-CHI
JI Int. J. Ophthalmol.
PD JAN 18
PY 2017
VL 10
IS 1
BP 91
EP 97
DI 10.18240/ijo.2017.01.15
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EH4XU
UT WOS:000391778000015
PM 28149783
OA Green Submitted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Grassmann, F
   Schoenberger, PGA
   Brandl, C
   Schick, T
   Hasler, D
   Meister, G
   Fleckenstein, M
   Lindner, M
   Helbig, H
   Fauser, S
   Weber, BHF
AF Grassmann, Felix
   Schoenberger, Peter G. A.
   Brandl, Caroline
   Schick, Tina
   Hasler, Daniele
   Meister, Gunter
   Fleckenstein, Monika
   Lindner, Moritz
   Helbig, Horst
   Fauser, Sascha
   Weber, Bernhard H. F.
TI A Circulating MicroRNA Profile Is Associated with Late-Stage Neovascular
   Age-Related Macular Degeneration
SO PLOS ONE
LA English
DT Article
ID PREVALENCE; SEVERITY; RNA
AB Age-related macular degeneration (AMD) is the leading cause of severe vision impairment in Western populations over 55 years. A growing number of gene variants have been identified which are strongly associated with an altered risk to develop AMD. Nevertheless, gene-based biomarkers which could be dysregulated at defined stages of AMD may point toward key processes in disease mechanism and thus may support efforts to design novel treatment regimens for this blinding disorder. Circulating microRNAs (cmiRNAs) which are carried by nanosized exosomes or microvesicles in blood plasma or serum, have been recognized as valuable indicators for various age-related diseases. We therefore aimed to elucidate the role of cmiRNAs in AMD by genome-wide miRNA expression profiling and replication analyses in 147 controls and 129 neovascular AMD patients. We identified three microRNAs differentially secreted in neovascular (NV) AMD (hsa-mir-301-3p, p(corrected) = 5.6*10(-5), hsa-mir-361-5p, p(corrected) = 8.0*10(-4) and hsa-mir-424-5p, p(corrected) = 9.6*10(-3)). A combined profile of the three miRNAs revealed an area under the curve (AUC) value of 0.727 and was highly associated with NV AMD (p = 1.2*10(-8)). To evaluate subtype-specificity, an additional 59 AMD cases with pure unilateral or bilateral geographic atrophy (GA) were analyzed for microRNAs hsa-mir-301-3p, hsa-mir-361-5p, and hsa-mir-424-5p. While we found no significant differences between GA AMD and controls neither individually nor for a combined microRNAs profile, hsa-mir-424-5p levels remained significantly higher in GA AMD when compared to NV (p(corrected)<0.005). Pathway enrichment analysis on genes predicted to be regulated by microRNAs hsa-mir-301-3p, hsa-mir-361-5p, and hsa-mir-424-5p, suggests canonical TGF beta, mTOR and related pathways to be involved in NV AMD. In addition, knockdown of hsa-mir-361-5p resulted in increased neovascularization in an in vitro angiogenesis assay.
C1 [Grassmann, Felix; Schoenberger, Peter G. A.; Brandl, Caroline; Weber, Bernhard H. F.] Univ Regensburg, Inst Human Genet, D-93053 Regensburg, Germany.
   [Brandl, Caroline; Helbig, Horst] Univ Hosp Regensburg, Dept Ophthalmol, Regensburg, Germany.
   [Schick, Tina; Fauser, Sascha] Univ Hosp Cologne, Dept Ophthalmol, Cologne, Germany.
   [Hasler, Daniele; Meister, Gunter] Univ Regensburg, Lab RNA Biol, Biochem Ctr Regensburg BZR, D-93053 Regensburg, Germany.
   [Fleckenstein, Monika; Lindner, Moritz] Univ Bonn, Dept Ophthalmol, Bonn, Germany.
C3 University of Regensburg; University of Regensburg; University of
   Cologne; University of Regensburg; University of Bonn
RP Weber, BHF (通讯作者)，Univ Regensburg, Inst Human Genet, D-93053 Regensburg, Germany.
EM bweb@klinik.uni-regensburg.de
RI Lindner, Moritz/AAC-8639-2021; Hasler, Daniele/AAA-5411-2021
OI Lindner, Moritz/0000-0002-4416-3421; Hasler,
   Daniele/0000-0002-1786-0563; Fleckenstein, Monika/0000-0001-8321-8037;
   Brandl, Caroline/0000-0001-8223-6137; Grassmann,
   Felix/0000-0003-1390-7528; Weber, Bernhard H.F./0000-0002-8808-7723
FU Deutsche Forschungsgemeinschaft [WE 1259/19-1, FL 658/4-1]; Novartis
   Pharma [3625340]; Alcon Research Institute
FX This study was supported in part by grants from the Deutsche
   Forschungsgemeinschaft (WE 1259/19-1 to BHFW, FL 658/4-1 to MF),
   Novartis Pharma (grant #3625340) and the Alcon Research Institute (to
   BHFW). The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Bonauer A, 2009, SCIENCE, V324, P1710, DOI 10.1126/science.1174381
   Carpentier GMM, 2012, 4 IMAGEJ USER DEV C, P198
   Chongsuvivatwong Virasakdi, 2012, EP EP CALC R PACK VE
   Cohen J., 1988, STAT POWER ANAL SOCI, V2nd
   Dreyhaupt J, 2005, OPHTHAL EPIDEMIOL, V12, P353, DOI 10.1080/09286580591005723
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Friedlander MR, 2008, NAT BIOTECHNOL, V26, P407, DOI 10.1038/nbt1394
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Gallo A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030679
   Grassmann F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037979
   Hagan Emily L, 2009, Cold Spring Harb Protoc, V2009, DOI 10.1101/pdb.prot5172
   Hu ZB, 2010, J CLIN ONCOL, V28, P1721, DOI 10.1200/JCO.2009.24.9342
   Hurteau GJ, 2006, CELL CYCLE, V5, P1951, DOI 10.4161/cc.5.17.3133
   Johnson WE, 2007, BIOSTATISTICS, V8, P118, DOI 10.1093/biostatistics/kxj037
   Jonasson F, 2011, OPHTHALMOLOGY, V118, P825, DOI 10.1016/j.ophtha.2010.08.044
   Kanitz A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049568
   Klein ML, 2010, OPHTHALMOLOGY, V117, P1554, DOI 10.1016/j.ophtha.2009.12.012
   Koh JT, 2007, ACS CHEM BIOL, V2, P599, DOI 10.1021/cb700183s
   Kosaka Nobuyoshi, 2010, Silence, V1, P7, DOI 10.1186/1758-907X-1-7
   Lasser C, 2012, EXPERT OPIN BIOL TH, V12, pS189, DOI 10.1517/14712598.2012.680018
   Leveziel N, 2010, INVEST OPHTH VIS SCI, V51, P2620, DOI 10.1167/iovs.09-4423
   Lu TP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042390
   Ristau T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093459
   Scott AW, 2013, CURR OPIN OPHTHALMOL, V24, P190, DOI 10.1097/ICU.0b013e32835fefee
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Swaroop A, 2007, HUM MOL GENET, V16, pR174, DOI 10.1093/hmg/ddm212
   Team RC, 2013, R LANG ENV STAT COMP
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Turchinovich A, 2012, TRENDS BIOCHEM SCI, V37, P460, DOI 10.1016/j.tibs.2012.08.003
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   Vlachos IS, 2012, NUCLEIC ACIDS RES, V40, pW498, DOI 10.1093/nar/gks494
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
   Zhang YJ, 2010, MOL CELL, V39, P133, DOI 10.1016/j.molcel.2010.06.010
   Zhao HP, 2013, STROKE, V44, P1706, DOI 10.1161/STROKEAHA.111.000504
NR 36
TC 52
Z9 53
U1 0
U2 19
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 9
PY 2014
VL 9
IS 9
AR e107461
DI 10.1371/journal.pone.0107461
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA AQ3IF
UT WOS:000342684500101
PM 25203061
OA gold, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Gewaily, DY
   Grunwald, JE
   Pistilli, M
   Ying, GS
   Maguire, MG
   Daniel, E
   Ostroff, CP
   Fine, SL
AF Gewaily, Dina Y.
   Grunwald, Juan E.
   Pistilli, Maxwell
   Ying, Gui-Shuang
   Maguire, Maureen G.
   Daniel, Ebenezer
   Ostroff, Candace P.
   Fine, Stuart L.
CA CATT RES GRP
TI Delayed Patchy Choroidal Filling in the Comparison of Age-Related
   Macular Degeneration Treatments Trials (CATT)
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID OCULAR BLOOD-FLOW; INDOCYANINE GREEN ANGIOGRAPHY; DIABETIC-RETINOPATHY;
   CIRCULATION; NEOVASCULARIZATION; RANIBIZUMAB; BEVACIZUMAB; PERFUSION;
   DISEASE
AB PURPOSE: To determine the relationship between delayed patchy choroidal filling and morphologic and functional outcomes among eyes treated with ranibizumab or bevacizumab.
   DESIGN: Cohort study.
   METHODS: Comparison of Age-related Macular Degeneration Treatment Trials participants were assigned randomly to ranibizumab or bevacizumab on a monthly or as-needed schedule. Presence of delayed patchy choroidal filling and morphologic and functional outcomes were evaluated among eyes with gradable fluorescein angiography at baseline (n = 973) and at 1 year (n = 860) eyes.
   RESULTS: Delayed filling was present in 75 (7.7%) of 973 eyes at baseline. Eyes with incident delayed filling at 1 year (23 [2.9%] of 798) showed a mean decrease of 1.7 letters in visual acuity, whereas eyes without incident delayed filling had a mean improvement of 8.1 letters (difference [Delta], -9.8; 95% confidence interval [CI], -15.8 to -3.9; P < .01). Eyes with incident delayed filling had a larger increase in mean total lesion area of choroidal neovascularization (3.00 mm(2)) than eyes without incident delayed filling (0.56 mm(2); Delta, 2.4; 95% CI, 0.4 to 4.4; P = .02). The proportion with incident delayed filling at 1 year was similar among eyes treated with ranibizumab (10 [2.4%] of 413) or bevacizumab (13 [3.3%] of 385; P = .53) and among eyes treated monthly (12 [3.1%] of 388) or as needed (11 [2.7%] of 410; P = .83).
   CONCLUSIONS: Delayed patchy choroidal filling was uncommon at baseline. Although only a small percentage of eyes demonstrated delayed filling during the first year of anti-vascular endothelial growth factor treatment, these eyes had worse visual acuity and a larger increase in total lesion area of choroidal neovascularization. (C) 2014 by Elsevier Inc. All rights reserved.
C1 [Gewaily, Dina Y.; Grunwald, Juan E.; Pistilli, Maxwell; Ying, Gui-Shuang; Maguire, Maureen G.; Daniel, Ebenezer; Ostroff, Candace P.] Univ Penn, Dept Ophthalmol, Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Fine, Stuart L.] Univ Colorado, Dept Ophthalmol, Aurora, CO USA.
C3 University of Pennsylvania; University of Colorado System; University of
   Colorado Anschutz Medical Campus
RP Gewaily, DY (通讯作者)，Univ Penn, Dept Ophthalmol, Scheie Eye Inst, 51 North 39th St, Philadelphia, PA 19104 USA.
EM dina.gewaily@gmail.com
OI Pistilli, Maxwell/0000-0002-4266-4150
FU National Eye Institute, National Institutes of Health, Bethesda,
   Maryland [U10 EY017823, U10 EY017825, U10 EY017826, U10 EY017828];
   NATIONAL EYE INSTITUTE [U10EY017825, U10EY017826, U10EY017828,
   U10EY017823] Funding Source: NIH RePORTER
FX ALL AUTHORS HAVE COMPLETED AND SUBMITTED THE ICMJE FORM FOR DISCLOSURE
   OF POTENTIAL CONFLICTS OF INTEREST and none were reported. The
   Comparison of Age-Related Treatment Trials is supported by Grants U10
   EY017823, U10 EY017825, U10 EY017826, and U10 EY017828 from the National
   Eye Institute, National Institutes of Health, Bethesda, Maryland.
   Involved in Conception and design of study (D.Y.G., J.E.G., M.P.,
   G.-S.Y., M.G.M., E.B.); Analysis and interpretation of data (D.Y.G.,
   J.E.G., M.P., G.-S.Y., M.G.M., E.B., S.L.F.); Data collection (D.Y.G.,
   C.P.O.); Provision of materials, patients, or resources (J.E.G., M.G.M.,
   S.L.F.); Statistical expertise (M.P., G.-S.Y., M.G.M.); Obtaining
   funding (J.E.G., M.G.M., S.L.F.); Literature search (D.Y.G., J.E.G.);
   Administrative, technical, or logistical support (J.E.G., M.G.M.,
   S.L.F.); Writing article (D.Y.G., J.E.G., M.P., G.-S.Y., M.G.M., E.B.);
   Critical revision of article (J.E.G., M.P., G.-S.Y., M.G.M., E.B.,
   S.L.F.); Final approval of article (J.E.G., M.P., G.-S.Y., M.G.M., E.B.,
   S.L.F.).
CR Beck RW, 2003, AM J OPHTHALMOL, V135, P194, DOI 10.1016/S0002-9394(02)01825-1
   Berenberg TL, 2012, RETINA-J RET VIT DIS, V32, P25, DOI 10.1097/IAE.0b013e3182150483
   Boltz A, 2010, INVEST OPHTH VIS SCI, V51, P4220, DOI 10.1167/iovs.09-4968
   Chen SJ, 2001, BRIT J OPHTHALMOL, V85, P1411, DOI 10.1136/bjo.85.12.1411
   Ciulla TA, 1999, AM J OPHTHALMOL, V128, P75, DOI 10.1016/S0002-9394(99)00061-6
   Fontaine O, 2011, INVEST OPHTH VIS SCI, V52, P7400, DOI 10.1167/iovs.10-6646
   FRIEDMAN E, 1995, OPHTHALMOLOGY, V102, P640, DOI 10.1016/S0161-6420(95)30974-8
   Friedman E, 2008, AM J OPHTHALMOL, V146, P348, DOI 10.1016/j.ajo.2008.05.017
   GAUDRIC A, 1982, AM J OPHTHALMOL, V94, P489, DOI 10.1016/0002-9394(82)90242-2
   Goldberg MF, 1998, OPHTHALMIC SURG LAS, V29, P385
   Grunwald JE, 1998, ARCH OPHTHALMOL-CHIC, V116, P150
   Grunwald JE, 1998, INVEST OPHTH VIS SCI, V39, P385
   HAYASHI K, 1985, OPHTHALMOLOGICA, V190, P30, DOI 10.1159/000309489
   Hosal BM, 1998, EUR J OPHTHALMOL, V8, P234, DOI 10.1177/112067219800800406
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Mendrinos E, 2009, ACTA OPHTHALMOL, V87, P290, DOI 10.1111/j.1755-3768.2008.01247.x
   Metelitsina TI, 2008, INVEST OPHTH VIS SCI, V49, P358, DOI 10.1167/iovs.07-0526
   Mori F, 2001, BRIT J OPHTHALMOL, V85, P531, DOI 10.1136/bjo.85.5.531
   Mori Fumihiko, 2003, Nippon Ganka Gakkai Zasshi, V107, P674
   Papadopoulou DN, 2009, OPHTHALMOLOGY, V116, P1755, DOI 10.1016/j.ophtha.2009.03.017
   Pauleikhoff D, 1999, ARCH OPHTHALMOL-CHIC, V117, P1353, DOI 10.1001/archopht.117.10.1353
   PIGUET B, 1992, AM J OPHTHALMOL, V113, P657, DOI 10.1016/S0002-9394(14)74790-7
   Pournaras CJ, 2006, INVEST OPHTH VIS SCI, V47, P1581, DOI 10.1167/iovs.05-0434
   Ross RD, 1998, AM J OPHTHALMOL, V125, P71, DOI 10.1016/S0002-9394(99)80237-2
   Schmetterer L, 1998, GRAEF ARCH CLIN EXP, V236, P160, DOI 10.1007/s004170050058
   Stefansson E, 2011, PROG RETIN EYE RES, V30, P72, DOI 10.1016/j.preteyeres.2010.09.003
   Uretmen O, 2003, OPHTHALMOLOGICA, V217, P137, DOI 10.1159/000068559
   Xu W, 2010, AM J OPHTHALMOL, V150, P40, DOI 10.1016/j.ajo.2010.01.041
   Yamazaki T, 2012, OPHTHALMOLOGY, V119, P1621, DOI 10.1016/j.ophtha.2012.02.022
   ZAHARIA M, 1987, CAN J OPHTHALMOL, V22, P257
NR 31
TC 6
Z9 6
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD SEP
PY 2014
VL 158
IS 3
BP 525
EP 531
DI 10.1016/j.ajo.2014.06.004
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AO2CZ
UT WOS:000341124400015
PM 24949820
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Guenther, F
   Brandl, C
   Winkler, TW
   Wanner, V
   Stark, K
   Kuechenhoff, H
   Heid, IM
AF Guenther, Felix
   Brandl, Caroline
   Winkler, Thomas W.
   Wanner, Veronika
   Stark, Klaus
   Kuechenhoff, Helmut
   Heid, Iris M.
TI Chances and challenges of machine learning-based disease classification
   in genetic association studies illustrated on age-related macular
   degeneration
SO GENETIC EPIDEMIOLOGY
LA English
DT Article
DE age-related macular degeneration (AMD); genome-wide association study;
   machine learning-based disease classification; response
   misclassification; UK Biobank
ID MISCLASSIFICATION; VALIDATION; IMAGES; RARE
AB Imaging technology and machine learning algorithms for disease classification set the stage for high-throughput phenotyping and promising new avenues for genome-wide association studies (GWAS). Despite emerging algorithms, there has been no successful application in GWAS so far. We establish machine learning-based phenotyping in genetic association analysis as misclassification problem. To evaluate chances and challenges, we performed a GWAS based on automatically classified age-related macular degeneration (AMD) in UK Biobank (images from 135,500 eyes; 68,400 persons). We quantified misclassification of automatically derived AMD in internal validation data (4,001 eyes; 2,013 persons) and developed a maximum likelihood approach (MLA) to account for it when estimating genetic association. We demonstrate that our MLA guards against bias and artifacts in simulation studies. By combining a GWAS on automatically derived AMD and our MLA in UK Biobank data, we were able to dissect true association (ARMS2/HTRA1,CFH) from artifacts (nearHERC2) and identified eye color as associated with the misclassification. On this example, we provide a proof-of-concept that a GWAS using machine learning-derived disease classification yields relevant results and that misclassification needs to be considered in analysis. These findings generalize to other phenotypes and emphasize the utility of genetic data for understanding misclassification structure of machine learning algorithms.
C1 [Guenther, Felix; Brandl, Caroline; Winkler, Thomas W.; Wanner, Veronika; Stark, Klaus; Heid, Iris M.] Univ Regensburg, Dept Genet Epidemiol, D-93053 Regensburg, Germany.
   [Guenther, Felix; Kuechenhoff, Helmut] Ludwig Maximilian Univ Munich, Dept Stat, Stat Consulting Unit, StaBLab, D-80539 Munich, Germany.
   [Brandl, Caroline] Univ Hosp Regensburg, Dept Ophthalmol, Regensburg, Germany.
C3 University of Regensburg; University of Munich; University of Regensburg
RP Heid, IM (通讯作者)，Univ Regensburg, Dept Genet Epidemiol, D-93053 Regensburg, Germany.; Kuechenhoff, H (通讯作者)，Ludwig Maximilian Univ Munich, Dept Stat, Stat Consulting Unit, StaBLab, D-80539 Munich, Germany.
EM kuechenhoff@stat.uni-muenchen.de; iris.heid@klinik.uni-regensburg.de
OI Guenther, Felix/0000-0001-6582-1174; Winkler, Thomas/0000-0003-0292-5421
FU DFG [HE 3690/5-1]; NIH [R01 EY RES 511967]; University of Regensburg;
   Ludwig Maximilians University Munich; Welsh Assembly Government; British
   Heart Foundation; Diabetes UK; Projekt DEAL
FX This study was supported by the DFG HE 3690/5-1 (to I. M. H.) and NIH
   R01 EY RES 511967 (to I. M. H.), the University of Regensburg and the
   Ludwig Maximilians University Munich. The UK Biobank (accessed via
   application number 33999) was established by the Wellcome Trust medical
   charity, Medical Research Council, Department of Health, Scottish
   Government, and the Northwest Regional Development Agency. This study
   was also supported by the Welsh Assembly Government, British Heart
   Foundation and Diabetes UK. The authors would also like to thank the two
   anonymous reviewers whose comments helped improve and clarify this
   manuscript. Open access funding enabled and organized by Projekt DEAL.
CR Brandl C, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-26629-5
   Buniello A, 2019, NUCLEIC ACIDS RES, V47, pD1005, DOI 10.1093/nar/gky1120
   Burlina PM, 2017, JAMA OPHTHALMOL, V135, P1170, DOI 10.1001/jamaophthalmol.2017.3782
   Bycroft C, 2018, NATURE, V562, P203, DOI 10.1038/s41586-018-0579-z
   Carroll R. J., 2006, MEASUREMENT ERROR NO, DOI DOI 10.1201/9781420010138
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Csurka G, 2017, ADV COMPUT VIS PATT, P1, DOI 10.1007/978-3-319-58347-1_1
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Devlin A. B., 2013, BIOMETRICS, V55, P997
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Grassmann F, 2018, OPHTHALMOLOGY, V125, P1410, DOI 10.1016/j.ophtha.2018.02.037
   Gunther F, 2019, BIOMETRICAL J, V61, P1033, DOI 10.1002/bimj.201900039
   Hausman JA, 1998, J ECONOMETRICS, V87, P239, DOI 10.1016/S0304-4076(98)00015-3
   Heinze-Deml C., 2017, ARXIV171011469STATML
   Keane PA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0164095
   Klein R, 2014, OPHTHAL EPIDEMIOL, V21, P14, DOI 10.3109/09286586.2013.867512
   Kutalik Z, 2011, BIOSTATISTICS, V12, P1, DOI 10.1093/biostatistics/kxq039
   Litjens G, 2017, MED IMAGE ANAL, V42, P60, DOI 10.1016/j.media.2017.07.005
   Loh PR, 2018, NAT GENET, V50, P906, DOI 10.1038/s41588-018-0144-6
   Lyles RH, 2011, EPIDEMIOLOGY, V22, P589, DOI 10.1097/EDE.0b013e3182117c85
   Ma C, 2013, GENET EPIDEMIOL, V37, P539, DOI 10.1002/gepi.21742
   Machiela MJ, 2015, BIOINFORMATICS, V31, P3555, DOI 10.1093/bioinformatics/btv402
   McCarthy S, 2016, NAT GENET, V48, P1279, DOI 10.1038/ng.3643
   Mihailidis P, 2013, J INTERACT MEDIA EDU
   Moreno-Torres JG, 2012, PATTERN RECOGN, V45, P521, DOI 10.1016/j.patcog.2011.06.019
   Nelson MR, 2015, NAT GENET, V47, P856, DOI 10.1038/ng.3314
   Neuhaus JM, 1999, BIOMETRIKA, V86, P843, DOI 10.1093/biomet/86.4.843
   Peng YF, 2019, OPHTHALMOLOGY, V126, P565, DOI 10.1016/j.ophtha.2018.11.015
   R Core Team, 2019, R LANG ENV STAT COMP
   Stark K, 2015, BMC GERIATR, V15, DOI 10.1186/s12877-015-0122-0
   Sturm RA, 2008, AM J HUM GENET, V82, P424, DOI 10.1016/j.ajhg.2007.11.005
   Ting DSW, 2017, JAMA-J AM MED ASSOC, V318, P2211, DOI 10.1001/jama.2017.18152
   Walter K, 2015, NATURE, V526, P82, DOI 10.1038/nature14962
NR 33
TC 4
Z9 4
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0741-0395
EI 1098-2272
J9 GENET EPIDEMIOL
JI Genet. Epidemiol.
PD OCT
PY 2020
VL 44
IS 7
BP 759
EP 777
DI 10.1002/gepi.22336
EA AUG 2020
PG 19
WC Genetics & Heredity; Mathematical & Computational Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity; Mathematical & Computational Biology
GA NM2DZ
UT WOS:000563939400001
PM 32741009
OA Green Published, Green Submitted, hybrid
DA 2022-11-30
ER

PT J
AU Chowers, I
   Cohen, Y
   Goldenberg-Cohen, N
   Vicuna-Kojchen, J
   Lichtinger, A
   Weinstein, O
   Pollack, A
   Axer-Siegel, R
   Hemo, I
   Averbukh, E
   Banin, E
   Meir, T
   Lederman, M
AF Chowers, Itay
   Cohen, Yoram
   Goldenberg-Cohen, Nitza
   Vicuna-Kojchen, Joaquin
   Lichtinger, Alejandro
   Weinstein, Orly
   Pollack, Ayala
   Axer-Siegel, Ruth
   Hemo, Itzhak
   Averbukh, Edward
   Banin, Eyal
   Meir, Tal
   Lederman, Michal
TI Association of complement factor H Y402H polymorphism with phenotype of
   neovascular age related macular degeneration in Israel
SO MOLECULAR VISION
LA English
DT Article
ID FACTOR HY402H POLYMORPHISM; GENE POLYMORPHISM; CHOROIDAL
   NEOVASCULARIZATION; HEMICENTIN-1 GENES; NO ASSOCIATION; VARIANT; CFH;
   SUSCEPTIBILITY; RISK; LOC387715
AB Purpose: The Tyr402His variant of complement factor H (CFH) is associated with age-related macular degeneration (AMD) in several populations. Our aim was to evaluate if this single nucleotide polymorphism (SNP) is associated with AMD in the Israeli population and see if it underlies heterogeneity in clinical manifestation and responses to photodynamic therapy (PDT), which characterize neovascular AMD (NVAMD).
   Methods: Genotyping for the Tyr402His variant was performed in 240 NVAMD patients (78.1 +/- 7 age range) and 118 controls (70.8 +/- 8.2 age range). Genotyping was correlated with clinical characteristics and treatment parameters in sequential 131 NVAMD patients who underwent PDT.
   Results: The Tyr402His coding allele was associated with NVAMD in the Israeli population: odds ratio(OR) = 1.9; 95% confidence interval (CI)= 1.3-2.6; p = 0.0002. Homozygosity for this variant was associated with an OR of 3.4 (95% CI: 1.7-6.8) for having AMD. There was no association among this SNP and age of onset of NVAMD, gender, neovascular lesion size, initial or final visual acuity, and number of PDT sessions required.
   Conclusions: In accordance with findings from the majority of previous study populations, the Tyr402His variant of CFH is associated with NVAMD in Israel. However, heterogeneity in clinical manifestations of NVAMD and in its response to PDT is not underlined by this CFH variant and may be accounted for by other genetic and environmental factors.
C1 [Chowers, Itay; Vicuna-Kojchen, Joaquin; Lichtinger, Alejandro; Hemo, Itzhak; Averbukh, Edward; Banin, Eyal; Meir, Tal; Lederman, Michal] Hadassah Hebrew Univ, Med Ctr, Dept Ophthalmol, IL-91120 Jerusalem, Israel.
   [Chowers, Itay; Vicuna-Kojchen, Joaquin; Lichtinger, Alejandro; Hemo, Itzhak; Averbukh, Edward; Banin, Eyal; Meir, Tal; Lederman, Michal] Hebrew Univ Jerusalem, Sch Med, IL-91010 Jerusalem, Israel.
   [Cohen, Yoram] Tel Aviv Univ, Chaim Sheba Med Ctr, Canc Res Ctr, IL-69978 Tel Aviv, Israel.
   [Goldenberg-Cohen, Nitza; Axer-Siegel, Ruth] Rabin Med Ctr, Dept Ophthalmol, Petah Tiqwa, Israel.
   [Weinstein, Orly] Soroka Univ, Med Ctr, Dept Ophthalmol, Beer Sheva, Israel.
   [Pollack, Ayala] Kaplan Med Ctr, Dept Ophthalmol, Rehovot, Israel.
C3 Hebrew University of Jerusalem; Hadassah University Medical Center;
   Hebrew University of Jerusalem; Chaim Sheba Medical Center; Tel Aviv
   University; Rabin Medical Center; Ben Gurion University; Soroka Medical
   Center; Hebrew University of Jerusalem; Kaplan Medical Center
RP Chowers, I (通讯作者)，Hadassah Hebrew Univ, Med Ctr, Dept Ophthalmol, POB 12000, IL-91120 Jerusalem, Israel.
EM chowers@hadassah.org.il
RI Goldenberg-Cohen, Nitza/O-1638-2019; Goldenberg-Cohen, Nitza/F-2936-2018
OI Goldenberg-Cohen, Nitza/0000-0002-5648-1873; Goldenberg-Cohen,
   Nitza/0000-0002-5648-1873
FU Israel Science Fund [624/05]
FX We thank the individuals who provided blood samples for the purpose of
   the study. This study was supported in part by a grant from the Israel
   Science Fund (624/05).
CR Abu Asleh S, 2007, ISRAEL MED ASSOC J, V9, P656
   Baird PN, 2006, INVEST OPHTH VIS SCI, V47, P4194, DOI 10.1167/iovs.05-1285
   Bora NS, 2006, J IMMUNOL, V177, P1872, DOI 10.4049/jimmunol.177.3.1872
   BRANTLEY MA, 2008, EYE
   Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   Brantley MA, 2007, AM J OPHTHALMOL, V144, P404, DOI 10.1016/j.ajo.2007.05.018
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Campochiaro PA, 2000, J CELL PHYSIOL, V184, P301, DOI 10.1002/1097-4652(200009)184:3<301::AID-JCP3>3.0.CO;2-H
   Conley YP, 2006, HUM MOL GENET, V15, P3206, DOI 10.1093/hmg/ddl396
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fisher SA, 2007, BRIT J OPHTHALMOL, V91, P576, DOI 10.1136/bjo.2006.105577
   Fuse N, 2006, AM J OPHTHALMOL, V142, P1074, DOI 10.1016/j.ajo.2006.07.030
   Gotoh N, 2006, HUM GENET, V120, P139, DOI 10.1007/s00439-006-0187-0
   Goverdhan SV, 2008, EYE, V22, P849, DOI 10.1038/sj.eye.6702830
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Jackson JR, 1997, FASEB J, V11, P457, DOI 10.1096/fasebj.11.6.9194526
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kaur I, 2006, INVEST OPHTH VIS SCI, V47, P3729, DOI 10.1167/iovs.05-1430
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Lau LI, 2006, INVEST OPHTH VIS SCI, V47, P3242, DOI 10.1167/iovs.05-1532
   LEVEZIE IN, INVEST OPHTHALMOL VI
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Seitsonen SP, 2007, EUR J OPHTHALMOL, V17, P943, DOI 10.1177/112067210701700612
   Seitsonen S, 2008, ACTA OPHTHALMOL, V86, P390, DOI 10.1111/j.1600-0420.2007.01050.x
   Seitsonen S, 2006, MOL VIS, V12, P796
   Sepp T, 2006, INVEST OPHTH VIS SCI, V47, P536, DOI 10.1167/iovs.05-1143
   Simonelli F, 2006, BRIT J OPHTHALMOL, V90, P1142, DOI 10.1136/bjo.2006.096487
   Sivaprasad S, 2006, EYE, V20, P867, DOI 10.1038/sj.eye.6702176
   Souied EH, 2005, MOL VIS, V11, P1135
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   SWAROOP A, 2007, HUM MOL GENET
   Uka J, 2006, RETINA-J RET VIT DIS, V26, P985, DOI 10.1097/01.iae.0000244068.18520.3e
   Wegscheider BJ, 2007, OPHTHALMOLOGY, V114, P738, DOI 10.1016/j.ophtha.2006.07.048
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
NR 40
TC 36
Z9 37
U1 0
U2 1
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD OCT 8
PY 2008
VL 14
IS 216
BP 1829
EP 1834
PG 6
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA 376BX
UT WOS:000261159100001
PM 18852870
DA 2022-11-30
ER

PT J
AU Iordanous, Y
   Powell, AM
   Mao, A
   Hooper, PL
   Eng, KT
   Schwartz, C
   Kertes, PJ
   Sheidow, TG
AF Iordanous, Yiannis
   Powell, Anne-Marie
   Mao, Alex
   Hooper, Philip L.
   Eng, Kenneth T.
   Schwartz, Carol
   Kertes, Peter J.
   Sheidow, Thomas G.
TI Intravitreal ranibizumab for the treatment of fibrovascular pigment
   epithelial detachment in age-related macular degeneration
SO CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE
LA English
DT Article
ID OCCULT CHOROIDAL NEOVASCULARIZATION; PHOTODYNAMIC THERAPY; BEVACIZUMAB;
   VERTEPORFIN; PHOTOCOAGULATION; CLASSIFICATION; LESIONS; TEARS
AB Objective: To determine the response of predominantly fibrovascular pigment epithelial detachments (PED)-type lesions (secondary to age-related macular degeneration [AMD]) to intravitreal ranibizumab.
   Design: This was an open-label prospective study.
   Participants: Thirty-two patients with predominantly fibrovascular FED-type lesions secondary to AMD were included in this study. Three patients were excluded from the final analysis.
   Methods: Patients received monthly intravitreal ranibizumab injections for 6 months (induction). At 6 months, patients not experiencing a visual improvement from baseline Early Treatment of Diabetic Retinopathy Study (ETDRS) visual acuity or not showing a reduction in FED height (based on optical coherence tomography [OCT]) were deemed ranibizumab nonresponders and received no further injections but underwent re-evaluation at 12 months. Patients deemed responders continued with OCT-guided active treatment on an as-needed basis for an additional 6 months.
   Results: Twenty-four patients (82.8%) were ranibizumab responders and 5 were (17.2%) nonresponders. For ranibizumab responders, mean ETDRS visual acuity improved by 7.2 +/- 9.8 letters at 6 months (p = 0.002) and 6.3 +/- 8.6 letters at 12 months (p = 0.002). Ranibizumab nonresponders experienced a decline in mean visual acuity of 8.2 +/- 4.6 letters at 6 months (p = 0.02) and 18.2 +/- 10.11 letters at 12 months (p = 0.02). At baseline, responders had a mean FED height of 345.8 +/- 96.0 mu m, which decreased to 111.6 +/- 133.2 mu m at 6 months (p < 0.001) and had a slight increase at 12 months to 144.8 +/- 146.3 mu m (p < 0.001). Two responders (8.3%) and 2 nonresponders (40%) developed retinal pigment epithelium tears while on treatment.
   Conclusions: Intravitreal ranibizumab appears to be a well-tolerated treatment option for patients with fibrovascular FED. Further large-scale, prospective studies may assist in delineating the best treatment protocol.
C1 [Iordanous, Yiannis; Powell, Anne-Marie; Mao, Alex; Hooper, Philip L.; Sheidow, Thomas G.] Univ Western Ontario, Dept Ophthalmol, Ivey Eye Inst, London, ON, Canada.
   [Eng, Kenneth T.; Schwartz, Carol; Kertes, Peter J.] Sunnybrook Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada.
C3 Western University (University of Western Ontario); University of
   Toronto; Sunnybrook Research Institute; University Toronto Affiliates;
   Sunnybrook Health Science Center
RP Sheidow, TG (通讯作者)，Ivey Eye Inst, 268 Grosvenor St, London, ON N6A 4V2, Canada.
EM sheidowt@rogers.com
FU Novartis
FX This study was funded by an unrestricted research grant from Novartis.
CR Ach T, 2010, RETINA-J RET VIT DIS, V30, P1420, DOI 10.1097/IAE.0b013e3181d87e97
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bolz M, 2007, BRIT J OPHTHALMOL, V91, P785, DOI 10.1136/bjo.2006.102467
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Chan CK, 2010, RETINA-J RET VIT DIS, V30, P203, DOI 10.1097/IAE.0b013e3181babda5
   Chen E, 2007, RETINA-J RET VIT DIS, V27, P445, DOI 10.1097/01.iae.0000249574.89437.40
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Coscas F, 2007, AM J OPHTHALMOL, V144, P592, DOI 10.1016/j.ajo.2007.06.014
   FINE SL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1583
   GASS JDM, 1984, BRIT J OPHTHALMOL, V68, P513, DOI 10.1136/bjo.68.8.513
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   HARTNETT ME, 1992, GRAEF ARCH CLIN EXP, V230, P11, DOI 10.1007/BF00166756
   Inoue M, 2013, RETINA-J RET VIT DIS, V33, P990, DOI 10.1097/IAE.0b013e3182755793
   Parodi MB, 2013, AM J OPHTHALMOL, V155, P103, DOI 10.1016/j.ajo.2012.07.001
   Pauleikhoff D, 2002, GRAEF ARCH CLIN EXP, V240, P533, DOI 10.1007/s00417-002-0505-8
   Pepple K, 2011, SEMIN OPHTHALMOL, V26, P198, DOI 10.3109/08820538.2011.570850
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P644, DOI 10.1016/j.ajo.2008.10.005
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   Zayit-Soudry S, 2007, SURV OPHTHALMOL, V52, P227, DOI 10.1016/j.survophthal.2007.02.008
NR 21
TC 11
Z9 11
U1 0
U2 6
PU CANADIAN OPHTHAL SOC
PI OTTAWA
PA 1525 CARLING AVE SUITE 610, OTTAWA, ONTARIO K1Z 8R9, CANADA
SN 0008-4182
EI 1715-3360
J9 CAN J OPHTHALMOL
JI Can. J. Opthalmol.-J. Can. Opthalmol.
PD AUG
PY 2014
VL 49
IS 4
BP 367
EP 376
DI 10.1016/j.jcjo.2014.05.010
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AR2GI
UT WOS:000343401400020
PM 25103655
DA 2022-11-30
ER

PT J
AU Owen, CG
   Jarrar, Z
   Wormald, R
   Cook, DG
   Fletcher, AE
   Rudnicka, AR
AF Owen, Christopher G.
   Jarrar, Zakariya
   Wormald, Richard
   Cook, Derek G.
   Fletcher, Astrid E.
   Rudnicka, Alicja R.
TI The estimated prevalence and incidence of late stage age related macular
   degeneration in the UK
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID VISUAL IMPAIRMENT; 10-YEAR INCIDENCE; 5-YEAR INCIDENCE; EYE DISEASE;
   MACULOPATHY; PROGRESSION; MORTALITY; RISK
AB Background UK estimates of age related macular degeneration (AMD) occurrence vary.
   Aims To estimate prevalence, number and incidence of AMD by type in the UK population aged >= 50 years.
   Methods Age-specific prevalence rates of AMD obtained from a Bayesian meta-analysis of AMD prevalence were applied to UK 2007-2009 population data. Incidence was estimated from modelled age-specific prevalence.
   Results Overall prevalence of late AMD was 2.4% (95% credible interval (CrI) 1.7% to 3.3%), equivalent to 513 000 cases (95% CrI 363 000 to 699 000); estimated to increase to 679 000 cases by 2020. Prevalences were 4.8% aged >= 65 years, 12.2% aged >= 80 years. Geographical atrophy (GA) prevalence rates were 1.3% (95% CrI 0.9% to 1.9%), 2.6% (95% CrI 1.8% to 3.7%) and 6.7% (95% CrI 4.6% to 9.6%); neovascular AMD (NVAMD) 1.2% (95% CrI 0.9% to 1.7%), 2.5% (95% CrI 1.8% to 3.4%) and 6.3% (95% CrI 4.5% to 8.6%), respectively. The estimated number of prevalent cases of late AMD were 60% higher in women versus men (314 000 cases in women, 192 000 men). Annual incidence of late AMD, GA and NVAMD per 1000 women was 4.1 (95% CrI 2.4% to 6.8%), 2.4 (95% CrI 1.5% to 3.9%) and 2.3 (95% CrI 1.4% to 4.0%); in men 2.6 (95% CrI 1.5% to 4.4%), 1.7 (95% CrI 1.0% to 2.8%) and 1.4 (95% CrI 0.8% to 2.4%), respectively. 71 000 new cases of late AMD were estimated per year.
   Conclusions These estimates will guide health and social service provision for those with late AMD and enable estimation of the cost of introducing new treatments.
C1 [Owen, Christopher G.; Jarrar, Zakariya; Cook, Derek G.; Rudnicka, Alicja R.] St Georges Univ London, Div Populat Hlth Sci & Educ, London SW17 0RE, England.
   [Wormald, Richard; Fletcher, Astrid E.] London Sch Hyg & Trop Med, London WC1, England.
   [Wormald, Richard] Moorfields Eye Hosp, London, England.
C3 St Georges University London; University of London; London School of
   Hygiene & Tropical Medicine; University of London; University College
   London; Moorfields Eye Hospital NHS Foundation Trust
RP Owen, CG (通讯作者)，St Georges Univ London, Div Populat Hlth Sci & Educ, London SW17 0RE, England.
EM cowen@sgul.ac.uk
RI Cook, Derek G/C-3271-2008
OI Cook, Derek/0000-0002-9723-5759; Rudnicka, Alicja R/0000-0003-0369-8574;
   Owen, Christopher/0000-0003-1135-5977
FU Macular Diseases Society
FX The work was supported by a grant from the Macular Diseases Society and
   commissioned on behalf of the Macular Interest Group of Vision 2020, UK.
CR Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Buch H, 2005, OPHTHALMOLOGY, V112, P787, DOI 10.1016/j.ophtha.2004.11.040
   Bunce C, 2010, EYE, V24, P1692, DOI 10.1038/eye.2010.122
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Colquitt JL, 2008, HEALTH TECHNOL ASSES, V12, P1
   Cugati S, 2007, ARCH OPHTHALMOL-CHIC, V125, P917, DOI 10.1001/archopht.125.7.917
   DAS BN, 1994, J ROY SOC MED, V87, P219
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   GIBSON JM, 1985, T OPHTHAL SOC UK, V104, P196
   Harding S, 2001, EYE, V15, P407, DOI 10.1038/eye.2001.145
   Hicks J., 1999, CENTURY CHANGE TREND
   Karnon J, 2008, Health Technol Assess, V12, piii
   Karnon J, 2008, HEALTH TECHNOL ASSES, V12, p[iii, ix, 124]
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 1996, INVEST OPHTH VIS SCI, V37, P1916
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   LESKE MC, 1981, AM J EPIDEMIOL, V113, P606, DOI 10.1093/oxfordjournals.aje.a113138
   Meads C, 2003, HEALTH TECHNOL ASSES, V7, pv
   Minassian DC, 2011, BRIT J OPHTHALMOL, V95, P1433, DOI 10.1136/bjo.2010.195370
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   National Institute for Health and Clinical Excellence, 2006, RAN PEG TREATM AG RE
   Office for National Statistics, 2011, CURR EST POP EST ETH
   Office for National Statistics, 2010, UK POP EST PROJ 1971
   Office for National Statistics, 2009, POP EST UK ENGL WAL
   Office for National Statistics, 2010, UK INT LIF TABL 1980
   Office for National Statistics, POP EST UK ENGL WAL
   Owen CG, 2003, BRIT J OPHTHALMOL, V87, P312, DOI 10.1136/bjo.87.3.312
   Pauleikhoff D, 1992, Ger J Ophthalmol, V1, P12
   Rudnicka AR, 2011, OPHTHALMOLOGY, DOI [10.1016/j.ophtha.2011.08.038, DOI 10.1016/J.OPHTHA.2011.08.038]
   The Royal College of Ophthalmologists, 2007, COMM CONT AMD SERV G
   Thiagarajan M, 2005, ARCH OPHTHALMOL-CHIC, V123, P1397, DOI 10.1001/archopht.123.10.1397
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   van Leeuwen R, 2003, EUR J EPIDEMIOL, V18, P845, DOI 10.1023/A:1025643303914
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   vanLeeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P955
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Wong TY, 2007, LANCET, V370, P204, DOI 10.1016/S0140-6736(07)61104-0
   Xu L, 2009, OPHTHALMOLOGY, V116, P732, DOI 10.1016/j.ophtha.2008.11.003
NR 42
TC 215
Z9 219
U1 0
U2 62
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD MAY
PY 2012
VL 96
IS 5
BP 752
EP 756
DI 10.1136/bjophthalmol-2011-301109
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 927UX
UT WOS:000302936900029
PM 22329913
OA hybrid, Green Published, Green Submitted, Green Accepted
DA 2022-11-30
ER

PT J
AU Chowers, I
   Wong, R
   Dentchev, T
   Farkas, RH
   Iacovelli, J
   Gunatilaka, TL
   Medeiros, NE
   Presley, JB
   Campochiaro, PA
   Curcio, CA
   Dunaief, JL
   Zack, DJ
AF Chowers, Itay
   Wong, Robert
   Dentchev, Tzvete
   Farkas, Ronald H.
   Iacovelli, Jared
   Gunatilaka, Tushara L.
   Medeiros, Nancy E.
   Presley, J. Brett
   Campochiaro, Peter A.
   Curcio, Christine A.
   Dunaief, Joshua L.
   Zack, Donald J.
TI The iron carrier transferrin is upregulated in retinas from patients
   with age-related macular degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID PIGMENT EPITHELIUM; INCREASED EXPRESSION; CERULOPLASMIN; DISEASE;
   COLLAGEN; PROTEIN; DRUSEN; BRAIN; RATS; EYES
AB PURPOSE. Iron can cause oxidative stress, and elevated iron levels have been associated with several neurodegenerative diseases including age-related macular degeneration (AMD). Transferrin, an iron transport protein, is expressed at high levels in the retina. The purpose of this study was to assess transferrin involvement in AMD by determining the expression profile of transferrin in retinas with AMD compared with retinas without evidence of disease.
   METHODS. Postmortem retinas were obtained from AMD and non-AMD eyes. Expression of transferrin was assessed in a microarray dataset from 33 retinas of unaffected donors and 12 retinas of patients with AMD (six with neovascular AMD and six with non-neovascular AMD). Quantitative real-time RT-PCR (QPCR) was used to confirm the microarray results. Transferrin protein expression was assessed by semiquantitative Western blot analysis and immunohistochemistry.
   RESULTS. In comparison to unaffected retinas, mean transferrin mRNA levels, as measured by microarray analysis were elevated 3.5- and 2.1-fold in non-neovascular and neovascular AMD retinas, respectively. Semiquantitative Western blot analysis demonstrated a 2.1-fold increase in transferrin protein in AMD eyes. Immunohistochemistry showed more intense and widespread transferrin label in AMD maculas, particularly in large drusen, Muller cells, and photoreceptors.
   CONCLUSIONS. These data demonstrate that transferrin expression is increased in the retinas of patients with AMD relative to those of healthy control patients of comparable age. Along with previous studies that have demonstrated elevated iron levels in AMD retinas, early onset drusen formation in a patient with retinal iron overload resulting from aceruloplasminemia, and retinal degeneration with some features of macular degeneration in the iron-overloaded retinas of ceruloplasmin/hephestin knockout mice, the present study suggests that altered iron homeostasis is associated with AMD.
C1 Johns Hopkins Univ, Sch Med, Guerrieri Ctr Genet Engn & Mol Ophthalmol, Wilmer Ophthalmol Inst,Dept Ophthalmol, Baltimore, MD 21287 USA.
   Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21287 USA.
   Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21287 USA.
   Johns Hopkins Univ, Sch Med, McKusick Nathans Inst Genet Med, Baltimore, MD 21287 USA.
   Hebrew Univ Jerusalem, Dept Ophthalmol, Hadassah Med Ctr, Jerusalem, Israel.
   FM Kirby Ctr Mol Ophthalmol, Scheie Eye Inst, Philadelphia, PA USA.
   Retina Specialists N Alabama, Huntsville, AL USA.
   Univ Alabama Birmingham, Dept Ophthalmol, Birmingham, AL 35294 USA.
C3 Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins
   University; Johns Hopkins University; Johns Hopkins University; Hebrew
   University of Jerusalem; Hadassah University Medical Center; University
   of Pennsylvania; Pennsylvania Medicine; University of Alabama System;
   University of Alabama Birmingham
RP Zack, DJ (通讯作者)，Johns Hopkins Univ, Sch Med, Guerrieri Ctr Genet Engn & Mol Ophthalmol, Wilmer Ophthalmol Inst,Dept Ophthalmol, 809 Maumenee Bldg,600 N Wolfe St, Baltimore, MD 21287 USA.
EM dzack@bs.jhmi.edu
RI Iacovelli, Jared/G-3668-2011
OI Zack, Don/0000-0002-7966-1973
FU NATIONAL EYE INSTITUTE [R01EY015240, R01EY005951, R01EY006109,
   R01EY009769, P30EY001765] Funding Source: NIH RePORTER; NEI NIH HHS
   [P30EY001765, R01EY009769, R01EY015240, R01EY05951, R01EY06109] Funding
   Source: Medline
CR Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bruinink A, 1996, INT J DEV NEUROSCI, V14, P785, DOI 10.1016/S0736-5748(96)00035-4
   Cabrera OEE, 1997, J NEUROSCI RES, V47, P603
   Chen L, 2003, MOL VIS, V9, P151
   Chowers I, 2003, HUM MOL GENET, V12, P2881, DOI 10.1093/hmg/ddg326
   Chowers I, 2003, INVEST OPHTH VIS SCI, V44, P3732, DOI 10.1167/iovs.02-1080
   Curcio CA, 2005, EXP EYE RES, V80, P761, DOI 10.1016/j.exer.2004.09.017
   Curcio CA, 1998, INVEST OPHTH VIS SCI, V39, P1085
   DAVIS AA, 1993, J CELL PHYSIOL, V156, P280, DOI 10.1002/jcp.1041560209
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   Farkas RH, 2004, INVEST OPHTH VIS SCI, V45, P1410, DOI 10.1167/iovs.03-0872
   Guidry C, 2002, INVEST OPHTH VIS SCI, V43, P267
   Hahn P, 2004, P NATL ACAD SCI USA, V101, P13850, DOI 10.1073/pnas.0405146101
   Hahn P, 2003, ARCH OPHTHALMOL-CHIC, V121, P1099, DOI 10.1001/archopht.121.8.1099
   HYNDMAN AG, 1991, BRAIN RES, V561, P318, DOI 10.1016/0006-8993(91)91610-D
   Kaur D, 2003, NEURON, V37, P899, DOI 10.1016/S0896-6273(03)00126-0
   Knupp C, 2000, J STRUCT BIOL, V129, P38, DOI 10.1006/jsbi.1999.4202
   MADIGAN MC, 1994, RETINA-J RET VIT DIS, V14, P65, DOI 10.1097/00006982-199401000-00014
   MAYNE R, 1980, BIOCHEMISTRY-US, V19, P4065, DOI 10.1021/bi00558a025
   Moos T, 2004, ANN NY ACAD SCI, V1012, P14, DOI 10.1196/annals.1306.002
   Morse LJ, 2004, J MOL NEUROSCI, V24, P129, DOI 10.1385/JMN:24:1:129
   PAULEIKHOFF D, 1990, AM J OPHTHALMOL, V109, P38, DOI 10.1016/S0002-9394(14)75576-X
   Sharon D, 2002, P NATL ACAD SCI USA, V99, P315, DOI 10.1073/pnas.012582799
   TAWARA A, 1986, INVEST OPHTH VIS SCI, V27, P226
   Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498
   Wu KHC, 2003, BRIT J OPHTHALMOL, V87, P1159, DOI 10.1136/bjo.87.9.1159
   Yamaguchi K, 1998, OPHTHALMOLOGICA, V212, P11, DOI 10.1159/000027251
   Yefimova MG, 2002, INVEST OPHTH VIS SCI, V43, P537
   Yefimova MG, 2000, INVEST OPHTH VIS SCI, V41, P2343
   Youdim MBH, 2005, MECH AGEING DEV, V126, P317, DOI 10.1016/j.mad.2004.08.023
   ZEEVALK GD, 1988, NEUROSCI LETT, V92, P149, DOI 10.1016/0304-3940(88)90051-1
NR 31
TC 79
Z9 83
U1 0
U2 4
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAY
PY 2006
VL 47
IS 5
BP 2135
EP 2140
DI 10.1167/iovs.05-1135
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 041JL
UT WOS:000237451100054
PM 16639025
DA 2022-11-30
ER

PT J
AU Semeraro, F
   Morescalchi, F
   Parmeggiani, F
   Arcidiacono, B
   Costagliola, C
AF Semeraro, Francesco
   Morescalchi, Francesco
   Parmeggiani, Francesco
   Arcidiacono, Barbara
   Costagliola, Ciro
TI Systemic Adverse Drug Reactions Secondary to Anti-VEGF Intravitreal
   Injection in Patients with Neovascular Age-Related Macular Degeneration
SO CURRENT VASCULAR PHARMACOLOGY
LA English
DT Article
DE Anti-VEGF; age related macular degeneration; bevacizumab; ranibizumab;
   pegaptanib; side effects; hypertension; stroke; proteinuria; bleeding
ID ENDOTHELIAL-GROWTH-FACTOR; VASCULAR-PERMEABILITY FACTOR; OCCULT
   CHOROIDAL NEOVASCULARIZATION; VERTEPORFIN PHOTODYNAMIC THERAPY;
   METASTATIC COLORECTAL-CANCER; RETINAL-PIGMENT EPITHELIUM; BEVACIZUMAB
   AVASTIN; PHASE-II; OCULAR NEOVASCULARIZATION; RANIBIZUMAB LUCENTIS
AB The wet form of age related macular degeneration (AMD), known also as exudative or neovascular, is characterized by the formation of a pathological choroidal neovascular membrane (CNV) responsible for most cases of severe blindness. Vascular endothelial growth factor (VEGF) is a homodimeric glycoprotein acting as a growth factor selective for endothelial cells; it regulates angiogenesis and enhances vascular permeability and plays a leading role in this disorder. The consistent association between CNV and increased VEGF-A expression provides a strong reason for exploring the therapeutic potential of anti-VEGF agents in the treatment of neovascular AMD. The importance of VEGF for the development of AMD-related CNV has led to the development of a strategy able to block its pathologic effects. The rationale is that a blockade of VEGF actions could be effective in arresting choroidal angiogenesis and also reducing the vascular permeability, which is frequently the main cause of visual acuity deterioration. However, VEGF has also important functions in vascular physiology. The effects of anti-VEGF therapy may inhibit these functions. Herein we report the systemic adverse events secondary to intravitreal administration of these compounds, i.e. the main cardiovascular effects (thrombosis, hemorrhage, hypertension, proteinuria), as well as the less frequent cerebrovascular accidents, myocardial infarction, transient ischemic attacks, deep vein thrombosis, pulmonary embolism and thrombophlebitis.
C1 [Costagliola, Ciro] Univ Molise, Dipartimento Sci Salute, Cattedra Oculist, I-86100 Campobasso, Italy.
   [Semeraro, Francesco; Morescalchi, Francesco; Arcidiacono, Barbara] Univ Brescia, Clin Oculist, Dipartimento Specialita Chirurg Sci Radiol & Med, Brescia, Italy.
   [Parmeggiani, Francesco] Univ Ferrara, Sez Oculist, Dipartimento Discipline Med Chirurg Comunicaz & C, I-44100 Ferrara, Italy.
C3 University of Molise; University of Brescia; University of Ferrara
RP Costagliola, C (通讯作者)，Univ Molise, Dipartimento Sci Salute, Cattedra Oculist, Via F De Sanctis, I-86100 Campobasso, Italy.
EM ciro.costagliola@unimol.it
RI Costagliola, Ciro/G-5707-2012; Semeraro, Francesco fs/K-8667-2016
OI Costagliola, Ciro/0000-0001-8477-6188; Semeraro, Francesco
   fs/0000-0002-2275-4917
CR Adamis AP, 1996, ARCH OPHTHALMOL-CHIC, V114, P66, DOI 10.1001/archopht.1996.01100130062010
   Aggio FB, 2007, GRAEF ARCH CLIN EXP, V245, P215, DOI 10.1007/s00417-006-0412-5
   Aiello LP, 1997, OPHTHALMIC RES, V29, P354, DOI 10.1159/000268033
   AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Aisenbrey S, 2007, GRAEF ARCH CLIN EXP, V245, P941, DOI 10.1007/s00417-006-0471-7
   Algvere PV, 2008, ACTA OPHTHALMOL, V86, P482, DOI 10.1111/j.1600-0420.2007.01113.x
   Allen JA, 2006, ARCH NEUROL-CHICAGO, V63, P1475, DOI 10.1001/archneur.63.10.1475
   ALON T, 1995, NAT MED, V1, P1024, DOI 10.1038/nm1095-1024
   [Anonymous], 1978, Ophthalmology, V85, P82
   [Anonymous], 2006, LUC PACK INS
   Antoszyk AN, 2008, AM J OPHTHALMOL, V145, P862, DOI 10.1016/j.ajo.2007.12.029
   Apte RS, 2007, OPHTHALMOLOGY, V114, P1702, DOI 10.1016/j.ophtha.2007.02.021
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Avery RL, 2006, OPHTHALMOLOGY, V113, P1695, DOI 10.1016/j.ophtha.2006.05.064
   Avery RL, 2007, LANCET, V370, P1479, DOI 10.1016/S0140-6736(07)61625-0
   Azad RV, 2008, JPN J OPHTHALMOL, V52, P52, DOI 10.1007/s10384-007-0496-4
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P2179, DOI 10.1016/j.ophtha.2007.09.012
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P855, DOI 10.1016/j.ophtha.2007.01.017
   Bates David O, 2003, Int J Low Extrem Wounds, V2, P107, DOI 10.1016/j.jss.2008.04.023
   Barleon B, 1996, BLOOD, V87, P3336, DOI 10.1182/blood.V87.8.3336.bloodjournal8783336
   Bashshur ZF, 2007, ARCH OPHTHALMOL-CHIC, V125, P1357, DOI 10.1001/archopht.125.10.1357
   Bauer SM, 2005, J VASC SURG, V41, P699, DOI 10.1016/j.jvs.2005.01.015
   Becerra EM, 2011, CURR DRUG TARGETS, V12, P149
   Benjamin LE, 1999, J CLIN INVEST, V103, P159, DOI 10.1172/JCI5028
   Bhisitkul RB, 2006, BRIT J OPHTHALMOL, V90, P1542, DOI 10.1136/bjo.2006.098426
   BINGAMAN D, 2007, INVEST OPHTHALMOL VI, V48
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   BOYER DS, 2008, ANN M AM AC OPHTH NO
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown MM, 2008, OPHTHALMOLOGY, V115, P1039, DOI 10.1016/j.ophtha.2007.08.033
   CAMPOS S, 2007, J CLIN ONCOL, V25, pS278
   Carden CP, 2008, NEURO-ONCOLOGY, V10, P624, DOI 10.1215/15228517-2008-010
   Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0
   Chakravarthy U, 2006, OPHTHALMOLOGY, V113, P1508, DOI 10.1016/j.ophtha.2006.02.064
   Chappelow AV, 2008, DRUGS, V68, P1029, DOI 10.2165/00003495-200868080-00002
   Chen CY, 2007, AM J OPHTHALMOL, V143, P510, DOI 10.1016/j.ajo.2006.10.004
   Chen E, 2007, RETINA-J RET VIT DIS, V27, P445, DOI 10.1097/01.iae.0000249574.89437.40
   CHEN ZZ, 2007, INVEST OPHTHALMOL VI, V48
   Chong NV, 2009, EYE, V23, P1250, DOI 10.1038/eye.2009.84
   Ciulla TA, 2009, CURR OPIN OPHTHALMOL, V20, P158, DOI 10.1097/ICU.0b013e32832d25b3
   *CLIN, SAF EFF OR PTK787 PA
   *CLIN, STUD EV PHARM SAF PH
   *CLIN, OP LAB PIL STUD TG10
   *CLIN, SAF EFF STUD EV COMB
   Cohen MH, 2007, ONCOLOGIST, V12, P356, DOI 10.1634/theoncologist.12-3-356
   CONNOLLY DT, 1989, J CLIN INVEST, V84, P1470, DOI 10.1172/JCI114322
   Conrad PW, 2008, CLIN OPHTHALMOL, V2, P727
   Costagliola C, 2009, RETINA-J RET VIT DIS, V29, P1227, DOI 10.1097/IAE.0b013e3181b773e1
   Costagliola C, 2009, GRAEF ARCH CLIN EXP, V247, P1031, DOI 10.1007/s00417-009-1081-y
   Dincer M, 2006, ANN PHARMACOTHER, V40, P2278, DOI 10.1345/aph.1H244
   Doukas J, 2008, J CELL PHYSIOL, V216, P29, DOI 10.1002/jcp.21426
   Drolet DW, 2000, PHARMACEUT RES, V17, P1503, DOI 10.1023/A:1007657109012
   Duan YK, 2007, OPHTHALMOLOGY, V114, P732, DOI 10.1016/j.ophtha.2006.07.045
   Dvorak HF, 2002, J CLIN ONCOL, V20, P4368, DOI 10.1200/JCO.2002.10.088
   ELDEM MB, 2009, INVEST OPHTHALMOL VI, V50
   Eremina V, 2003, J CLIN INVEST, V111, P707, DOI 10.1172/JCI200317423
   Eremina V, 2008, NEW ENGL J MED, V358, P1129, DOI 10.1056/NEJMoa0707330
   Escudier B, 2007, LANCET, V370, P2103, DOI 10.1016/S0140-6736(07)61904-7
   Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381
   Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027
   FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8
   Ferrara N, 2002, SEMIN ONCOL, V29, P10, DOI 10.1053/sonc.2002.37264
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Frank RN, 1996, AM J OPHTHALMOL, V122, P393, DOI 10.1016/S0002-9394(14)72066-5
   FRANK RN, 2006, RETINA, P1240
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fung AE, 2006, BRIT J OPHTHALMOL, V90, P1344, DOI 10.1136/bjo.2006.099598
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   Genentech Actemra, HIGHL PRESCR INF
   Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336
   Gerhardt H, 2003, J CELL BIOL, V161, P1163, DOI 10.1083/jcb.200302047
   Giantonio BJ, 2007, J CLIN ONCOL, V25, P1539, DOI 10.1200/JCO.2006.09.6305
   Gogat K, 2004, INVEST OPHTH VIS SCI, V45, P7, DOI 10.1167/iovs.02-1096
   Gordon JD, 1996, J CLIN ENDOCR METAB, V81, P353, DOI 10.1210/jc.81.1.353
   Gordon MS, 2001, J CLIN ONCOL, V19, P843, DOI 10.1200/JCO.2001.19.3.843
   Gordon MS, 2005, ONCOLOGY-BASEL, V69, P25, DOI 10.1159/000088481
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Grisanti Salvatore, 2007, Indian Journal of Ophthalmology, V55, P417
   GROTHEY A, 2006, ONCOLOGY S10, V20, P1
   Heiduschka P, 2007, INVEST OPHTH VIS SCI, V48, P2814, DOI 10.1167/iovs.06-1171
   Heier, 2007, ARCH OPHTHALMOL-CHIC, V125, P138
   Heier JS, 2006, ARCH OPHTHALMOL-CHIC, V124, P1532, DOI 10.1001/archopht.124.11.1532
   Holz FG, 2010, INVEST OPHTH VIS SCI, V51, P405, DOI 10.1167/iovs.09-3813
   Hood JD, 1998, AM J PHYSIOL-HEART C, V274, pH1054
   HOUCK KA, 1992, J BIOL CHEM, V267, P26031
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   Inai T, 2004, AM J PATHOL, V165, P35, DOI 10.1016/S0002-9440(10)63273-7
   Infanger M, 2007, CARDIOVASC PATHOL, V16, P291, DOI 10.1016/j.carpath.2007.04.001
   Ishida S, 2003, J EXP MED, V198, P483, DOI 10.1084/jem.20022027
   Ishida S, 2003, INVEST OPHTH VIS SCI, V44, P2155, DOI 10.1167/iovs.02-0807
   Jain RK, 2005, SCIENCE, V307, P58, DOI 10.1126/science.1104819
   Jin KL, 2002, P NATL ACAD SCI USA, V99, P11946, DOI 10.1073/pnas.182296499
   Johnson DH, 2004, J CLIN ONCOL, V22, P2184, DOI 10.1200/JCO.2004.11.022
   Jonas JB, 2007, ACTA OPHTHALMOL SCAN, V85, P563, DOI 10.1111/j.1600-0420.2007.00891.x
   Kabbinavar F, 2003, J CLIN ONCOL, V21, P60, DOI 10.1200/JCO.2003.10.066
   Kabbinavar FF, 2005, J CLIN ONCOL, V23, P3697, DOI 10.1200/JCO.2005.05.112
   Kamba T, 2007, BRIT J CANCER, V96, P1788, DOI 10.1038/sj.bjc.6603813
   Kamba T, 2006, AM J PHYSIOL-HEART C, V290, pH560, DOI 10.1152/ajpheart.00133.2005
   KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987
   Kilickap S, 2003, J CLIN ONCOL, V21, P3542, DOI 10.1200/JCO.2003.99.046
   Kim I, 1999, INVEST OPHTH VIS SCI, V40, P2115
   KIRCHHOFF B, 2009, INVEST OPHTHALMOL VI, V50
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Ko J, 2005, J SURG RES, V129, P251, DOI 10.1016/j.jss.2005.05.006
   KUPPERMANN BD, 2009, RETINA, V29, P24
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   LACOUR M, 2007, ACTA OPHTHALMOL SCAN, V114, P855
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lamoreaux WJ, 1998, MICROVASC RES, V55, P29, DOI 10.1006/mvre.1997.2056
   Larsson A., 2002, Angiogenesis, V5, P107, DOI 10.1023/A:1021588227705
   Lee JH, 2005, P NATL ACAD SCI USA, V102, P18902, DOI 10.1073/pnas.0509069102
   Lee S, 2005, J CELL BIOL, V169, P681, DOI 10.1083/jcb.200409115
   LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Maier P, 2005, GRAEF ARCH CLIN EXP, V243, P593, DOI 10.1007/s00417-004-1021-9
   MALECAZE F, 1994, ARCH OPHTHALMOL-CHIC, V112, P1476, DOI 10.1001/archopht.1994.01090230090028
   Marneros AG, 2005, AM J PATHOL, V167, P1451, DOI 10.1016/S0002-9440(10)61231-X
   Martin AC, 2004, INVEST OPHTH VIS SCI, V45, P3387, DOI 10.1167/iovs.04-0349
   Matsuyama K, 2010, BRIT J OPHTHALMOL, V94, P1215, DOI 10.1136/bjo.2008.156810
   Mennel S, 2007, ACTA OPHTHALMOL SCAN, V85, P689, DOI 10.1111/j.1600-0420.2007.00926.x
   Mete A, 2010, J CLIN ULTRASOUND, V38, P66, DOI 10.1002/jcu.20650
   Michaelson I.C., 1948, T OPHTHALMOL SOC, V68, P137
   MILLER JW, 1994, AM J PATHOL, V145, P574
   Miller K, 2007, NEW ENGL J MED, V357, P2666, DOI 10.1056/NEJMoa072113
   Miller KD, 2005, J CLIN ONCOL, V23, P792, DOI 10.1200/JCO.2005.05.098
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Monsky WL, 1999, CANCER RES, V59, P4129
   MORDENTI J, 1999, TOXICOL SCI, V29, P579
   Mourad JJ, 2008, ANN ONCOL, V19, P927, DOI 10.1093/annonc/mdm550
   *NAT EYE, CATT STUD COMP AMD T
   Neubauer AS, 2010, CLIN THER, V32, P1343, DOI 10.1016/j.clinthera.2010.07.010
   NG E, 2006, INVEST OPHTH VIS SCI, V4, P4829
   Ng EWM, 2006, NAT REV DRUG DISCOV, V5, P123, DOI 10.1038/nrd1955
   Okamoto N, 1997, AM J PATHOL, V151, P281
   Okines A, 2009, EUR J CANCER, V45, P2452, DOI 10.1016/j.ejca.2009.06.028
   Olofsson B, 1998, P NATL ACAD SCI USA, V95, P11709, DOI 10.1073/pnas.95.20.11709
   Ozaki H, 2000, AM J PATHOL, V156, P697, DOI 10.1016/S0002-9440(10)64773-6
   Ozkiris A, 2010, EXPERT OPIN THER PAT, V20, P103, DOI 10.1517/13543770902762885
   PAJUSOLA K, 1992, CANCER RES, V52, P5738
   PARK JE, 1993, MOL BIOL CELL, V4, P1317, DOI 10.1091/mbc.4.12.1317
   PARK JE, 1994, J BIOL CHEM, V269, P25646
   PATEL JJ, 2010, J EVAL CLIN PRA 0916
   Pedersen R, 2007, ACTA OPHTHALMOL SCAN, V85, P526, DOI 10.1111/j.1600-0420.2007.00895.x
   Pepper MS, 2001, THROMB HAEMOSTASIS, V86, P346
   Pierce EA, 1996, ARCH OPHTHALMOL-CHIC, V114, P1219, DOI 10.1001/archopht.1996.01100140419009
   Presta LG, 1997, CANCER RES, V57, P4593
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   ROBERTS WG, 1999, CANCER RES, V59, P4129
   Robinson GS, 1996, P NATL ACAD SCI USA, V93, P4851, DOI 10.1073/pnas.93.10.4851
   ROSENBERG N, 1986, ARCH OPHTHALMOL-CHIC, V104, P34
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Rosengart TK, 1999, CIRCULATION, V100, P468, DOI 10.1161/01.CIR.100.5.468
   Rosenstein JM, 2004, EXP NEUROL, V187, P246, DOI 10.1016/j.expneurol.2004.01.022
   Rosiak Jean, 2005, Clin J Oncol Nurs, V9, P407
   Safran M, 2003, J CLIN INVEST, V111, P779, DOI 10.1172/JCI200318181
   Sandler A, 2006, NEW ENGL J MED, V355, P2542, DOI 10.1056/NEJMoa061884
   Sane David C., 2004, Angiogenesis, V7, P193, DOI 10.1007/s10456-004-2699-3
   Scappaticci FA, 2005, J SURG ONCOL, V91, P173, DOI 10.1002/jso.20301
   Scappaticci FA, 2008, JNCI-J NATL CANCER I, V100, P156
   Scappaticci FA, 2007, JNCI-J NATL CANCER I, V99, P1232
   Scappaticci FA, 2007, JNCI-J NATL CANCER I, V99, P1232, DOI 10.1093/jnci/djm086
   Schmidt-Erfurth U, 2008, BRIT J OPHTHALMOL, V92, P1628, DOI 10.1136/bjo.2007.135277
   SCHMUCKER C, 2010, BR J OPHTHALMOL 1022
   Schmucker C, 2010, CURR OPIN OPHTHALMOL, V21, P218, DOI 10.1097/ICU.0b013e3283386783
   Schrijvers BF, 2004, KIDNEY INT, V65, P2003, DOI 10.1111/j.1523-1755.2004.00621.x
   SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562
   Shahar J, 2006, RETINA-J RET VIT DIS, V26, P262, DOI 10.1097/00006982-200603000-00002
   SHELL JW, 1982, SURV OPHTHALMOL, V26, P207, DOI 10.1016/0039-6257(82)90081-9
   SHIBUYA M, 1990, ONCOGENE, V5, P519
   Shih T, 2006, CLIN THER, V28, P1779, DOI 10.1016/j.clinthera.2006.11.015
   Shima C, 2008, ACTA OPHTHALMOL, V86, P372, DOI 10.1111/j.1600-0420.2007.01067.x
   SHIMA DT, 1995, MOL MED, V1, P182, DOI 10.1007/BF03401566
   SINGER M, 2009, INVEST OPHTHALMOL VI, V50
   Singerman LJ, 2008, BRIT J OPHTHALMOL, V92, P1606, DOI 10.1136/bjo.2007.132597
   Smiddy WE, 2009, OPHTHALMOLOGY, V116, P481, DOI 10.1016/j.ophtha.2008.10.029
   Spilsbury K, 2000, AM J PATHOL, V157, P135, DOI 10.1016/S0002-9440(10)64525-7
   Stacker SA, 2001, NAT MED, V7, P186, DOI 10.1038/84635
   Steinbrook R, 2006, NEW ENGL J MED, V355, P1409, DOI 10.1056/NEJMp068185
   STONE J, 1995, J NEUROSCI, V15, P4738, DOI 10.1523/jneurosci.15-07-04738.1995
   Sugimoto H, 2003, J BIOL CHEM, V278, P12605, DOI 10.1074/jbc.C300012200
   Takahashi H, 2005, CLIN SCI, V109, P227, DOI 10.1042/CS20040370
   Takahashi K, 2009, ARCH OPHTHALMOL-CHIC, V127, P494, DOI 10.1001/archophthalmol.2009.27
   Tam BYY, 2006, NAT MED, V12, P793, DOI 10.1038/nm1428
   Tufail A, 2010, BMJ-BRIT MED J, V340, pc2459
   Tunon J, 2009, SURV OPHTHALMOL, V54, P339, DOI 10.1016/j.survophthal.2009.02.003
   *U BRIST, 2009, IVAN RAND CONTR TRIA
   Ueta T, 2009, OPHTHALMOLOGY, V116, P362, DOI 10.1016/j.ophtha.2008.09.046
   *US FDA, 2005, MEDWATCH
   van Wijngaarden P, 2005, JAMA-J AM MED ASSOC, V293, P1509, DOI 10.1001/jama.293.12.1509
   Vinores SA, 1999, DOC OPHTHALMOL, V97, P217, DOI 10.1023/A:1002136712070
   von Hanno T, 2010, ACTA OPHTHALMOL, V88, P263, DOI 10.1111/j.1755-3768.2008.01406.x
   Waheed Nadia K., 2004, International Ophthalmology Clinics, V44, P11, DOI 10.1097/00004397-200404430-00004
   Weigert G, 2008, BRIT J OPHTHALMOL, V92, P356, DOI 10.1136/bjo.2007.125823
   Wells JA, 1996, BRIT J OPHTHALMOL, V80, P363, DOI 10.1136/bjo.80.4.363
   Wong TY, 2006, ANN INTERN MED, V145, P98, DOI 10.7326/0003-4819-145-2-200607180-00007
   WONG TY, 2007, PHARMACOECONOMICS, V25, P863
   Wu L, 2008, GRAEF ARCH CLIN EXP, V246, P81, DOI 10.1007/s00417-007-0660-z
   Yoganathan P, 2006, RETINA-J RET VIT DIS, V26, P994, DOI 10.1097/01.iae.0000244380.34082.67
   Yonekura H, 1999, J BIOL CHEM, V274, P35172, DOI 10.1074/jbc.274.49.35172
   Yuan F, 1996, P NATL ACAD SCI USA, V93, P14765, DOI 10.1073/pnas.93.25.14765
   Zachary I, 2001, AM J PHYSIOL-CELL PH, V280, pC1375, DOI 10.1152/ajpcell.2001.280.6.C1375
   Ziemssen Focke, 2009, International Ophthalmology, V29, P213, DOI 10.1007/s10792-008-9221-7
   Zlokovic BV, 2006, NAT MED, V12, P390, DOI 10.1038/nm0406-390
   VIBERA TRIAL PREVENT
   LUCENTIS ONE YEAR
NR 213
TC 29
Z9 30
U1 0
U2 5
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1570-1611
EI 1875-6212
J9 CURR VASC PHARMACOL
JI Current Vascular Pharmacology
PD SEP
PY 2011
VL 9
IS 5
BP 629
EP 646
DI 10.2174/157016111796642670
PG 18
WC Pharmacology & Pharmacy; Peripheral Vascular Disease
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy; Cardiovascular System & Cardiology
GA 827FN
UT WOS:000295413500008
PM 21470108
DA 2022-11-30
ER

PT J
AU Sharma, S
   Bakal, J
   Oliver-Fernandez, A
   Blair, J
AF Sharma, S
   Bakal, J
   Oliver-Fernandez, A
   Blair, J
TI Photodynamic therapy with verteporfin for subfoveal choroidal
   neovascularization in age-related macular degeneration - Results of an
   effectiveness study
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID RANDOMIZED CLINICAL-TRIALS; QUALITY-OF-LIFE; LASER PHOTOCOAGULATION;
   OUTCOMES RESEARCH; VISUAL-ACUITY; FELLOW EYES; SECONDARY; EFFICACY;
   LESIONS
AB Objective: To determine the postapproval effectiveness of photodynamic therapy (PDT) with verteporfin for the treatment of predominantly classic subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration.
   Methods: Forty-five consecutive patients treated with PDT for subfoveal CNV were compared with an untreated historical control group. Control patients had subfoveal CNV and were first seen by us within 1 year before Health Canada's approval of verteporfin. Both groups were followed up for the development of significant visual loss, stability, or improvement. Multivariate models were constructed to evaluate the effectiveness of PDT, controlling for multiple covariates (age, sex, baseline visual acuity, follow-up time, lesion size, and number of treatments).
   Results: Significant differences were noted in the change in visual acuity between those who did and did not receive PDT (chi(2) = 5.9, P = .048). Patients who received PDT were 2.9 times (95% confidence interval, 0.9-9.1) less likely to develop a moderate (> 2 lines) visual loss (chi(2) = 3.2, P = .07). Controlling for covariates, patients who received PDT were 13.7 times (95% confidence interval, 1.4-132.6) more likely to develop a visual improvement of at least 1 line.
   Conclusion: Compared with historical controls, PDT was demonstrated to be effective for the treatment of predominantly classic subfoveal CNV.
C1 Hop Hotel Dieu, Cost Effect Ocular Hlth Policy Unit, Kingston, ON K7L 5G2, Canada.
   Queens Univ, Dept Epidemiol, Kingston, ON K7L 3N6, Canada.
   Queens Univ, Dept Ophthalmol, Kingston, ON, Canada.
   Queens Univ, Dept Math & Stat, Kingston, ON, Canada.
C3 Queens University - Canada; Queens University - Canada; Queens
   University - Canada; Queens University - Canada
RP Sharma, S (通讯作者)，Hop Hotel Dieu, Cost Effect Ocular Hlth Policy Unit, Brock 2-224B,166 Brock St, Kingston, ON K7L 5G2, Canada.
EM sanjay_sharma60@hotmail.com
RI Bakal, Jeff/ABE-4051-2021
OI Bakal, Jeffrey/0000-0002-3658-2554
CR BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown MM, 2002, ARCH OPHTHALMOL-CHIC, V120, P481
   BURGESS DB, 1993, ARCH OPHTHALMOL-CHIC, V111, P1189
   Cohen SJ, 2000, MED CARE, V38, P449, DOI 10.1097/00005650-200005000-00001
   DAGOSTINO RB, 1995, MED CARE, V33, pAS95
   Freund D, 1999, ANNU REV PUBL HEALTH, V20, P337, DOI 10.1146/annurev.publhealth.20.1.337
   Gelfand YA, 1997, OPHTHALMIC SURG LAS, V28, P823
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Kupfer C, 1998, OPTOMETRY VISION SCI, V75, P235, DOI 10.1097/00006324-199804000-00001
   Kupfer C, 1996, AM J OPHTHALMOL, V122, P883, DOI 10.1016/S0002-9394(14)70386-1
   Mackenzie PJ, 2002, OPHTHALMOLOGY, V109, P720, DOI 10.1016/S0161-6420(01)01021-1
   MAGUIRE MG, 1994, ARCH OPHTHALMOL-CHIC, V112, P480
   MOISSEIEV J, 1995, ARCH OPHTHALMOL-CHIC, V113, P185, DOI 10.1001/archopht.1995.01100020069031
   SCHACHAT AP, 1994, ARCH OPHTHALMOL-CHIC, V112, P500
   Sharma S, 2001, CAN J OPHTHALMOL, V36, P332, DOI 10.1016/S0008-4182(01)80120-4
   Sharma S, 2001, OPHTHALMOLOGY, V108, P2051, DOI 10.1016/S0161-6420(01)00764-3
   Sharma S, 1997, CAN J OPHTHALMOL, V32, P359
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1232
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1220
   2000, MED CARE S, V38, pI17
NR 21
TC 9
Z9 9
U1 0
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610 USA
SN 0003-9950
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD JUN
PY 2004
VL 122
IS 6
BP 853
EP 856
DI 10.1001/archopht.122.6.853
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 828IS
UT WOS:000221967600006
PM 15197060
OA Bronze
DA 2022-11-30
ER

PT J
AU Gui, W
   Au, A
   Rabina, G
   Kapelushnik, N
   Cohen, S
   Masarwa, D
   Hosseini, H
   Heilweil, G
   Schwartz, S
   Loewenstein, A
   Schwartz, SD
AF Gui, Wei
   Au, Adrian
   Rabina, Gilad
   Kapelushnik, Noa
   Cohen, Shai
   Masarwa, Dua
   Hosseini, Hamid
   Heilweil, Gad
   Schwartz, Shulamit
   Loewenstein, Anat
   Schwartz, Steven D.
TI PIGMENT EPITHELIAL DETACHMENT IN AGE-RELATED MACULAR DEGENERATION
   Long-Term Visual Acuity May Improve With Higher Injection Index
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE retinal pigment epithelial detachment; age-related macular degeneration;
   injection index
ID ANTI-VEGF AGENTS; TREAT-AND-EXTEND; 7-YEAR OUTCOMES; RANIBIZUMAB;
   AFLIBERCEPT; PREDICTORS; ATROPHY; VISION; ANCHOR; MARINA
AB Purpose: To define injection index (II) and assess its impact on visual acuity (VA) in pigment epithelial detachment from age-related macular degeneration over 5 years.
   Methods: Injection index is defined as the mean anti-vascular endothelial growth factor injections per year from presentation. A retrospective study of 256 eyes in 213 patients was performed. Patients were stratified by II (high: >= 9, low: <9).
   Results: Baseline characteristics showed no differences across II groups. Mean (range) follow-up, in years, was 5.02 (1.04-12.74) for all patients. Mean logMAR VA (Snellen VA) were 0.60 (20/80) and 0.56 (20/73) at baseline, 0.52 (20/66) and 0.59 (20/78) at Year 1, 0.45 (20/56) and 0.67 (20/94) at Year 2, 0.38 (20/48) and 0.66 (20/91) at Year 3, 0.41 (20/51) and 0.89 (20/155) at Year 4, and 0.35 (20/45) and 0.79 (20/123) at Year 5 for the high and low II groups, respectively. Linear regression analysis showed a gain of 0.5 approxETDRS letters with each additional injection per year.
   Conclusion: Increased II was associated with better mean VA, suggesting that long-term continuous vascular endothelial growth factor suppression may improve VA in eyes thought to carry poor prognoses.
C1 [Gui, Wei; Au, Adrian; Hosseini, Hamid; Heilweil, Gad; Schwartz, Steven D.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Ophthalmol, Los Angeles, CA 90095 USA.
   [Rabina, Gilad; Kapelushnik, Noa; Cohen, Shai; Masarwa, Dua; Schwartz, Shulamit; Loewenstein, Anat] Tel Aviv Med Ctr & Sch Med, Sackler Fac Med, Dept Ophthalmol, Tel Aviv, Israel.
C3 University of California System; University of California Los Angeles;
   University of California Los Angeles Medical Center; David Geffen School
   of Medicine at UCLA; Tel Aviv University; Sackler Faculty of Medicine
RP Schwartz, SD (通讯作者)，Univ Calif Los Angeles, Stein Eye Inst, Dept Ophthalmol, 100 Stein Plaza, Los Angeles, CA 90095 USA.
EM sdschwartz@mednet.ucla.edu
OI Masarwa, Dua/0000-0001-5207-3525
CR Bhisitkul RB, 2016, OPHTHALMOLOGY, V123, P1269, DOI 10.1016/j.ophtha.2016.01.033
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chae B, 2015, INVEST OPHTH VIS SCI, V56, P5040, DOI 10.1167/iovs.15-16494
   Chiang A, 2008, RETINA-J RET VIT DIS, V28, P1265, DOI 10.1097/IAE.0b013e31817d5d03
   Chin-Yee D, 2016, BRIT J OPHTHALMOL, V100, P914, DOI 10.1136/bjophthalmol-2015-306987
   Clemens CR, 2014, ACTA OPHTHALMOL, V92, pE50, DOI 10.1111/aos.12234
   Clemens CR, 2012, BRIT J OPHTHALMOL, V96, P1088, DOI 10.1136/bjophthalmol-2011-301415
   Dugel PU, 2017, OPHTHALMOLOGY, V124, P1296, DOI 10.1016/j.ophtha.2017.03.057
   Freund KB, 2015, RETINA-J RET VIT DIS, V35, P1489, DOI 10.1097/IAE.0000000000000627
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gregori NZ, 2010, RETINA-J RET VIT DIS, V30, P1046, DOI 10.1097/IAE.0b013e3181d87e04
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Holekamp NM, 2014, AM J OPHTHALMOL, V157, P825, DOI 10.1016/j.ajo.2013.12.018
   Holladay JT, 1997, J REFRACT SURG, V13, P388
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Kim LN, 2016, RETINA-J RET VIT DIS, V36, P1418, DOI 10.1097/IAE.0000000000001142
   Patel KH, 2013, EYE, V27, P664, DOI 10.1038/eye.2013.31
   Peden MC, 2015, OPHTHALMOLOGY, V122, P803, DOI 10.1016/j.ophtha.2014.11.018
   Rao P, 2018, OPHTHALMOLOGY, V125, P522, DOI 10.1016/j.ophtha.2017.10.010
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2015, OPHTHALMOLOGY, V122, P822, DOI 10.1016/j.ophtha.2014.11.017
   Solomon SD, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub4
   Spooner KL, 2020, OPHTHALMOLOGY, V127, P1663, DOI 10.1016/j.ophtha.2020.06.019
   Tan ACS, 2016, AM J OPHTHALMOL, V172, P13, DOI 10.1016/j.ajo.2016.09.004
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   Vaze A, 2018, RETINA-J RET VIT DIS, V38, P1954, DOI 10.1097/IAE.0000000000001815
   Zarranz-Ventura J, 2014, OPHTHALMOLOGY, V121, P1966, DOI 10.1016/j.ophtha.2014.04.026
   Zayit-Soudry S, 2007, SURV OPHTHALMOL, V52, P227, DOI 10.1016/j.survophthal.2007.02.008
   Zinkernagel MS, 2016, OPHTHALMOLOGICA, V235, P42, DOI 10.1159/000441428
NR 30
TC 1
Z9 1
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD NOV
PY 2021
VL 41
IS 11
BP 2229
EP 2235
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA ZB6BH
UT WOS:000756924700006
PM 34673665
DA 2022-11-30
ER

PT J
AU Sato, T
   Iida, T
   Hagimura, N
   Kishi, S
AF Sato, T
   Iida, T
   Hagimura, N
   Kishi, S
TI Correlation of optical coherence tomography with angiography in retinal
   pigment epithelial detachment associated with age-related macular
   degeneration
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; choroidal neovascularization; notch
   sign; optical coherence tomography; retinal pigment epithelial
   detachment
ID INDOCYANINE-GREEN VIDEOANGIOGRAPHY; OCCULT CHOROIDAL NEOVASCULARIZATION
AB Purpose: To correlate optical coherence tomography (OCT) with angiographic signs of choroidal neovascularization (CNV) in retinal pigment epithelial detachment (PED) associated with age-related macular degeneration (ARMD).
   Methods: Prospectively, the authors performed OCT in 35 eyes of 35 patients (30 men and 5 women with a mean age of 71.6 years [range, 56-76 years]) with ARMD. All 35 eyes had CNV in the area of PED or adjacent to it, which was shown by fluorescein or indocyanine green angiography. Cross-sectional images were obtained by the OCT scanning line through the CNV and PED.
   Results: In 10 (56%) of 18 eyes in which the CNV was at the margin of the PED, a small PIED was adjacent to the central, dome-shaped PED. There was a notch between the central and small mounds of PED. In 13 (76%) of 17 eyes in which the CNV was within the PED, a notch was seen in the dome-shaped PED, resulting in a contour with 2 mounds. One of the 2 mounds contained a highly reflective mass immediately beneath the detached retinal pigment epithelium in 8 (62%) of the 13 eyes.
   Conclusion: A tomographic notch in the PED may be diagnostically important as an indication of CNV beneath the detached retinal pigment epithelium in eyes with ARMD.
C1 Gunma Univ, Sch Med, Dept Ophthalmol, Maebashi, Gumma 3718511, Japan.
   Fukushima Med Univ, Sch Med, Fukushima, Japan.
C3 Gunma University; Fukushima Medical University
RP Sato, T (通讯作者)，Gunma Univ, Sch Med, Dept Ophthalmol, 3 Showamachi, Maebashi, Gumma 3718511, Japan.
EM takusato@showa.gunma-u.ac.jp
CR CHANG TS, 1994, RETINA-J RET VIT DIS, V14, P114, DOI 10.1097/00006982-199414020-00004
   FREUND KB, 1993, AM J OPHTHALMOL, V115, P786, DOI 10.1016/S0002-9394(14)73649-9
   GASS JDM, 1994, AM J OPHTHALMOL, V118, P285, DOI 10.1016/S0002-9394(14)72951-4
   GASS JDM, 1984, RETINA-J RET VIT DIS, V4, P205, DOI 10.1097/00006982-198400440-00001
   GREEN WR, 1992, OPHTHALMOLOGY, V100, P1519
   GUYER DR, 1994, OPHTHALMOLOGY, V101, P1727
   Hee MR, 1996, OPHTHALMOLOGY, V103, P1260, DOI 10.1016/S0161-6420(96)30512-5
   IP M, 1999, AGE RELATED MACULAR, P179
   PULIAFITO CA, 1997, OPTICAL COHERENCE TO, P187
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   YANNUZZI LA, 1994, RETINA-J RET VIT DIS, V14, P99, DOI 10.1097/00006982-199414020-00003
   YANNUZZI LA, 1992, RETINA-J RET VIT DIS, V12, P191, DOI 10.1097/00006982-199212030-00003
NR 12
TC 34
Z9 36
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD DEC
PY 2004
VL 24
IS 6
BP 910
EP 914
DI 10.1097/00006982-200412000-00011
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 881EL
UT WOS:000225846100011
PM 15579989
DA 2022-11-30
ER

PT J
AU Liang, FQ
   Godley, BF
AF Liang, FQ
   Godley, BF
TI Oxidative stress-induced mitochondrial DNA damage in human retinal
   pigment epithelial cells: a possible mechanism for RPE aging and
   age-related macular degeneration
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Review
DE RPE; oxidative stress; DNA damage; mitochondria; aging; AMD
ID HYDROGEN-PEROXIDE; BLUE-LIGHT; LIPID-PEROXIDATION; NUCLEAR-DNA;
   IN-VITRO; FAMILIAL AGGREGATION; ACID HYDROPEROXIDE; RADICAL CHEMISTRY;
   RCS RAT; MACULOPATHY
AB Oxidative stress is believed to contribute to the pathogenesis of many diseases, including age-related macular degeneration (AMD). Although the vision loss of AMD results from photoreceptor damage in the central retina, the initial pathogenesis involves degeneration of RPE cells. Evidence from a variety of studies suggests that RPE cells are susceptible to oxidative damage. Mitochondrial DNA (mtDNA) is particularly prone to oxidative damage compared to nuclear DNA (nDNA). Using the quantitative PCR assay, a powerful tool to measure oxidative DNA damage and repair, we have shown that human RPE cells treated with H2O, or rod outer segments resulted in preferential damage to mtDNA, but not nDNA; and damaged mtDNA is not efficiently repaired, leading to compromised mitochondrial redox function as indicated by the MTT assay. Thus, the susceptibility of mtDNA to oxidative damage in human RPE cells, together with the age-related decrease of cellular anti-oxidant system, provides the rationale for a mitochondria-based model of AMD. (C) 2003 Elsevier Science Ltd. All rights reserved.
C1 Retina Fdn SW, Anderson Vis Res Ctr, Dallas, TX 75231 USA.
   Univ Texas, SW Med Ctr, Dept Ophthalmol, Dallas, TX 75230 USA.
C3 Retina Foundation of the Southwest; University of Texas System;
   University of Texas Dallas; University of Texas Southwestern Medical
   Center Dallas
RP Godley, BF (通讯作者)，Retina Fdn SW, Anderson Vis Res Ctr, 9900 N Cent Expressway,Suite 400, Dallas, TX 75231 USA.
EM bgodley@retinafoundation.org
CR Akeo K, 1996, CURR EYE RES, V15, P467, DOI 10.3109/02713689609000758
   Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   *AR GROUP, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417
   BABBS CF, 1990, FREE RADICAL BIO MED, V8, P471, DOI 10.1016/0891-5849(90)90060-V
   Ballinger SW, 1999, EXP EYE RES, V68, P765, DOI 10.1006/exer.1998.0661
   Ballinger SW, 2000, CIRC RES, V86, P960, DOI 10.1161/01.RES.86.9.960
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Beatty S, 2001, INVEST OPHTH VIS SCI, V42, P439
   Beckman K B, 1996, Methods Enzymol, V264, P442, DOI 10.1016/S0076-6879(96)64040-3
   Briggs CE, 2001, INVEST OPHTH VIS SCI, V42, P2229
   Cai JY, 1999, INVEST OPHTH VIS SCI, V40, P959
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527
   Chen KH, 1998, NUCLEIC ACIDS RES, V26, P2001, DOI 10.1093/nar/26.8.2001
   CHOW CK, 1986, J AM COLL NUTR, V5, P305
   CHURCH DF, 1985, ENVIRON HEALTH PERSP, V64, P111, DOI 10.2307/3430003
   CLAYTON DA, 1974, P NATL ACAD SCI USA, V71, P2777, DOI 10.1073/pnas.71.7.2777
   Cortopassi GA, 1999, BBA-BIOENERGETICS, V1410, P183, DOI 10.1016/S0005-2728(98)00166-2
   Croteau DL, 1997, J BIOL CHEM, V272, P25409, DOI 10.1074/jbc.272.41.25409
   CRUICKSHANKS KJ, 1993, ARCH OPHTHALMOL-CHIC, V111, P514, DOI 10.1001/archopht.1993.01090040106042
   Cruickshanks KJ, 2001, ARCH OPHTHALMOL-CHIC, V119, P246
   D'Cruz PM, 2000, HUM MOL GENET, V9, P645, DOI 10.1093/hmg/9.4.645
   Darzins P, 1997, OPHTHALMOLOGY, V104, P770, DOI 10.1016/S0161-6420(97)30235-8
   DEMPLE B, 1994, ANNU REV BIOCHEM, V63, P915, DOI 10.1146/annurev.bi.63.070194.004411
   DOREY CK, 1990, CURR EYE RES, V9, P549, DOI 10.3109/02713689008999595
   DOREY CK, 1989, INVEST OPHTH VIS SCI, V30, P1691
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6
   GAILLARD ER, 1995, PHOTOCHEM PHOTOBIOL, V61, P448, DOI 10.1111/j.1751-1097.1995.tb02343.x
   Gal A, 2000, NAT GENET, V26, P270, DOI 10.1038/81555
   GARDNER HW, 1989, FREE RADICAL BIO MED, V7, P65, DOI 10.1016/0891-5849(89)90102-0
   Godley BF, 2002, EXP EYE RES, V74, P663, DOI 10.1006/exer.2001.1146
   Godley BF, 2001, INVEST OPHTH VIS SCI, V42, pS943
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   GREEN WR, 1985, OPHTHALMOLOGY, V92, P615
   Hammond BR, 1996, VISION RES, V36, P3003, DOI 10.1016/0042-6989(96)00008-9
   HARMAN D, 1981, P NATL ACAD SCI-BIOL, V78, P7124, DOI 10.1073/pnas.78.11.7124
   Hinton DR, 1998, ARCH OPHTHALMOL-CHIC, V116, P203
   Honda S, 2001, MOL VIS, V7, P63
   ISHIBASHI T, 1986, INVEST OPHTH VIS SCI, V27, P184
   Jin GF, 2001, CURR EYE RES, V23, P11, DOI 10.1076/ceyr.23.1.11.5423
   Jin GF, 2001, CURR EYE RES, V22, P165, DOI 10.1076/ceyr.22.3.165.5517
   Kayatz P, 1999, INVEST OPHTH VIS SCI, V40, P2314
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   KLEIN ML, 1994, ARCH OPHTHALMOL-CHIC, V112, P932, DOI 10.1001/archopht.1994.01090190080025
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Laval F, 1997, Rev Physiol Biochem Pharmacol, V131, P175
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   LILES MR, 1991, ARCH OPHTHALMOL-CHIC, V109, P1285, DOI 10.1001/archopht.1991.01080090111033
   Mandavilli BS, 2002, MUTAT RES-FUND MOL M, V509, P127, DOI 10.1016/S0027-5107(02)00220-8
   Mandavilli BS, 2000, BRAIN RES, V885, P45, DOI 10.1016/S0006-8993(00)02926-7
   NEWSOME DA, 1990, INVEST OPHTH VIS SCI, V31, P2508
   RICHTER C, 1988, P NATL ACAD SCI USA, V85, P6465, DOI 10.1073/pnas.85.17.6465
   ROZANOWSKA M, 1995, J BIOL CHEM, V270, P18825, DOI 10.1074/jbc.270.32.18825
   Salazar JJ, 1997, MUTAT RES-DNA REPAIR, V385, P139, DOI 10.1016/S0921-8777(97)00047-5
   Sawyer DE, 2001, REDOX REP, V6, P182, DOI 10.1179/135100001101536157
   SEDDON JM, 1994, ARCH OPHTHALMOL-CHIC, V112, P176, DOI 10.1001/archopht.1994.01090140052021
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   SIPPY BD, 1995, CURR EYE RES, V14, P495, DOI 10.3109/02713689509003761
   Smith W, 1996, ARCH OPHTHALMOL-CHIC, V114, P1518, DOI 10.1001/archopht.1996.01100140716016
   SNODDERLY DM, 1995, AM J CLIN NUTR, V62, P1448
   Sparrow JR, 2001, INVEST OPHTH VIS SCI, V42, P1356
   Sparrow JR, 2000, INVEST OPHTH VIS SCI, V41, P1981
   Spraul CW, 1996, INVEST OPHTH VIS SCI, V37, P2724
   Srivastava S, 1995, BIOCHEM BIOPH RES CO, V217, P741, DOI 10.1006/bbrc.1995.2835
   STADTMAN ER, 1992, SCIENCE, V257, P1220, DOI 10.1126/science.1355616
   TATE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1271
   TATE DJ, 1993, INVEST OPHTH VIS SCI, V34, P2348
   Tyni T, 2002, PEDIATR RES, V52, P595, DOI 10.1203/01.PDR.0000030874.20888.2D
   Ueda T, 1996, OPHTHALMIC RES, V28, P184, DOI 10.1159/000267901
   Winkler BS, 1999, MOL VIS, V5
   Wu GS, 1999, INVEST OPHTH VIS SCI, V40, P831
   Yakes FM, 1997, P NATL ACAD SCI USA, V94, P514, DOI 10.1073/pnas.94.2.514
NR 73
TC 416
Z9 456
U1 1
U2 60
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD APR
PY 2003
VL 76
IS 4
BP 397
EP 403
DI 10.1016/S0014-4835(03)00023-X
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 661RE
UT WOS:000181902900001
PM 12634104
DA 2022-11-30
ER

PT J
AU Fonteh, CN
   Mathias, MT
   Mandava, N
   Manoharan, N
   Lynch, AM
   Navo, R
   Patnaik, JL
AF Fonteh, Cheryl N.
   Mathias, Marc T.
   Mandava, Naresh
   Manoharan, Niranjan
   Lynch, Anne M.
   Navo, Roxanne
   Patnaik, Jennifer L.
CA Univ Colorado Retina Res Grp
TI Mental health and visual acuity in patients with age-related macular
   degeneration
SO BMC OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Mental health; Retina; Vison function
   questionnaires
ID FUNCTION-QUESTIONNAIRE; DEPRESSION; PREVALENCE; EYE; UPDATE
AB Background Visual acuity (VA) loss has been associated with depression in patients with age-related macular degeneration (AMD). However, previous studies did not incorporate subgroups of AMD when correlating VA and mental health. The goal of this study was to describe the relationship between VA and mental health questions in patients with different classifications of AMD, and to identify associations of mental health subscale scores. Methods AMD patients classified by multi-modal imaging were recruited into an AMD registry. Habitual VA was obtained by ophthalmic technicians using the Snellen VA at distance. At enrollment, patients completed the NEI-VFQ-25, which includes 25 questions regarding the patient's visual functionality. Median with interquartile-range (IQR) scores on the mental health subscale of the VFQ were calculated by AMD classification and VA groups. Univariate and multivariable general linear models were used to estimate associations between mental health scores and variables of interest. Results Eight hundred seventy-five patients were included in the study. Patients with bilateral geographic atrophy (GA) or bilateral GA and neovascular (NV) AMD scored lowest on the mental health subscales with a median (IQR) of 58.2 (38-88) and 59.3 (38-88). When stratified by VA, patients with a habitual VA of 20/200 or worse scored the lowest on mental health subscales scores: median of 43.8 (IQR: 31-62). Patients with a VA of 20/20 scored the highest: 87.5 (IQR: 81-94). Habitual VA of the better- and worse-seeing eye and AMD classification were significantly associated with mental health subscale scores (all p < 0.0001 in both the univariate and multivariable analysis, except the VA of the worse-seeing eye in multivariable model p = 0.027). Patients enrolled during the COVID pandemic had mental health scores that were 2.7 points lower than prior to the pandemic, but this difference was not significant in univariate (p = 0.300) or multivariable analysis (p = 0.202). Conclusion There is a significant association between mental health questionnaire scores and AMD classification, as well as VA in both the better and worse-seeing eyes in patients with AMD. It is important for clinicians to recognize feelings of worry/ frustration in these patients, so they can be appropriately referred, screened, and treated for mental health problems.
C1 [Fonteh, Cheryl N.; Mathias, Marc T.; Mandava, Naresh; Manoharan, Niranjan; Lynch, Anne M.; Navo, Roxanne; Patnaik, Jennifer L.] Univ Colorado, Sch Med, Dept Ophthalmol, Aurora, CO USA.
   [Fonteh, Cheryl N.] Univ Colorado, Sch Med, Dept Ophthalmol, Div Ophthalm Epidemiol, Mail Stop F731,1675 Aurora Court, Aurora, CO 80045 USA.
C3 University of Colorado System; University of Colorado Anschutz Medical
   Campus; University of Colorado System; University of Colorado Anschutz
   Medical Campus
RP Fonteh, CN (通讯作者)，Univ Colorado, Sch Med, Dept Ophthalmol, Div Ophthalm Epidemiol, Mail Stop F731,1675 Aurora Court, Aurora, CO 80045 USA.
EM cheryl.fonteh@cuanschutz.edu
FU National Eye Institute of the National Institutes of Health
   [R01EY032456]; Research to Prevent Blindness; NIH/NCATS Colorado CTSA
   Grant [UL1 TR002535]; Sue Anschutz-Rogers Eye Center Research Fund;
   Frederic C. Hamilton Macular Degeneration Center
FX Research supported in this publication is in part supported by the
   National Eye Institute of the National Institutes of Health under award
   number R01EY032456 (AML), a Research to Prevent Blindness grant to the
   Department of Ophthalmology, University of Colorado, the Frederic C.
   Hamilton Macular Degeneration Center, Sue Anschutz-Rogers Eye Center
   Research Fund, and by NIH/NCATS Colorado CTSA Grant Number UL1 TR002535.
CR Alexapoulos GS, 2005, LANCET, V365, P1961, DOI 10.1016/S0140-6736(05)66665-2
   Banerjee A, 2008, INDIAN J OPHTHALMOL, V56, P469
   Blazer DG, 2002, J GERONTOL A-BIOL, V57, pM150, DOI 10.1093/gerona/57.3.M150
   Casten RJ, 2013, CURR OPIN OPHTHALMOL, V24, P239, DOI 10.1097/ICU.0b013e32835f8e55
   Cimarolli VR, 2016, CLIN OPHTHALMOL, V10, P55, DOI 10.2147/OPTH.S80489
   Dawson SR, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-78
   Dillon L, 2021, OPHTHAL PHYSL OPT, V41, P255, DOI 10.1111/opo.12779
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Garcia-Layana A, 2017, CLIN INTERV AGING, V12, P1579, DOI 10.2147/CIA.S142685
   Horowitz A, 2004, TOP GERIATR REHABIL, V20, P185
   Lynch AM, 2020, BMJ OPEN OPHTHALMOL, V5, DOI 10.1136/bmjophth-2019-000361
   Lynch AM, 2019, RETINA-J RET VIT DIS, V39, P656, DOI 10.1097/IAE.0000000000002023
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   Miskala PH, 2007, OPHTHAL EPIDEMIOL, V14, P205, DOI 10.1080/09286580701502970
   Osaba Matias, 2019, Med Hypothesis Discov Innov Ophthalmol, V8, P306
   Ou WC, 2021, AM J OPHTHALMOL, V226, P148, DOI 10.1016/j.ajo.2021.01.017
   Owsley C, 2004, OPHTHALMOLOGY, V111, P2259, DOI 10.1016/j.ophtha.2004.06.026
   Patnaik JL, 2021, ACTA OPHTHALMOL, V99, P750, DOI 10.1111/aos.14731
   Patnaik JL, 2019, OPHTHALMOL RETINA, V3, P336, DOI 10.1016/j.oret.2018.11.004
   Podbielski DW, 2013, CAN J OPHTHALMOL, V48, P381, DOI 10.1016/j.jcjo.2013.04.004
   Rezapour J, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-61706-8
   Rovner BW, 2006, OPHTHALMOLOGY, V113, P1743, DOI 10.1016/j.ophtha.2006.05.033
   Rovner BW, 2002, ARCH OPHTHALMOL-CHIC, V120, P1041
   Sabel BA, 2018, RESTOR NEUROL NEUROS, V36, P767, DOI 10.3233/RNN-180880
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Sepulveda-Loyola W, 2020, J NUTR HEALTH AGING, DOI [10.1007/s12603-020-1469-2, 10.1007/s12603-020-1500-7]
   Stelmack JA, 2012, ARCH OPHTHALMOL-CHIC, V130, P1162, DOI 10.1001/archophthalmol.2012.1820
   Taylor DJ, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-011504
   Wu TC, 2021, J AFFECT DISORDERS, V281, P91, DOI 10.1016/j.jad.2020.11.117
   Yan XY, 2011, J INT MED RES, V39, P1142, DOI 10.1177/147323001103900402
NR 30
TC 0
Z9 0
U1 1
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD OCT 2
PY 2022
VL 22
IS 1
AR 391
DI 10.1186/s12886-022-02602-9
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 5A0BU
UT WOS:000862563000001
PM 36183081
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU John, S
   Natarajan, S
   Parikumar, P
   Shanmugam, MP
   Senthilkumar, R
   Green, DW
   Abraham, SJK
AF John, Sudhakar
   Natarajan, Sundaram
   Parikumar, Periyasamy
   Shanmugam, Mahesh P.
   Senthilkumar, Rajappa
   Green, David William
   Abraham, Samuel J. K.
TI Choice of Cell Source in Cell-Based Therapies for Retinal Damage due to
   Age-Related Macular Degeneration: A Review
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
ID AUTOLOGOUS BONE-MARROW; MESENCHYMAL STEM-CELLS; PIGMENT EPITHELIUM RPE;
   STROMAL CELLS; TRANSPLANTATION; DIFFERENTIATE; NEURONS; TRANSLOCATION;
   RAT; TRANSDIFFERENTIATION
AB Background. Age-related macular degeneration (AMD) is a complex disorder that affects primarily the macula involving the retinal pigment epithelium (RPE) but also to a certain extent the photoreceptor layer and the retinal neurons. Cell transplantation is a promising option for AMD and clinical trials are underway using different cell types. Methods. We hypothesize that instead of focusing on a particular cell source for concurrent regeneration of all the retinal layers and also to prevent exhaustive research on an array of cell sources for regeneration of each layer, the choice should depend on, precisely, which layer is damaged. Results. Thus, for a damage limited to the retinal pigment epithelial (RPE) layer, the choice we suggest would be RPE cells. When the damage extends to rods and cones, the choice would be bone marrow stem cells and when retinal neurons are involved, relatively immature stem cell populations with an inherent capacity to yield neuronal lineage such as hematopoietic stem cells, embryonic stem cells, or induced pluripotent stem cells can be tried. Conclusion. This short review will prove to be a valuable guideline for those working on cell therapy for AMD to plan their future directions of research and therapy for this condition.
C1 [John, Sudhakar; Senthilkumar, Rajappa; Abraham, Samuel J. K.] NCRM, MYTH, Chennai 600034, Tamil Nadu, India.
   [Natarajan, Sundaram] Aditya Jyot Eye Hosp, Mumbai 400031, Maharashtra, India.
   [Parikumar, Periyasamy] Light Eye Hosp, Dharmapuri 636701, Tamil Nadu, India.
   [Shanmugam, Mahesh P.] Sankara Eye Hosp, Bangalore 560037, Karnataka, India.
   [Senthilkumar, Rajappa] Acharya Nagarjuna Univ, Dept Biotechnol, Guntur 522510, Andhra Pradesh, India.
   [Green, David William] Univ Hong Kong, Fac Dent, Pokfulam, Hong Kong, Peoples R China.
   [Abraham, Samuel J. K.] Yamanashi Univ, Fac Med, Dept Clin Res, Chuo 4093898, Japan.
C3 Aditya Jyot Eye Hospital; Acharya Nagarjuna University; University of
   Hong Kong; University of Yamanashi
RP Abraham, SJK (通讯作者)，NCRM, MYTH, POB 1262, Chennai 600034, Tamil Nadu, India.
EM drabrahamsj@ybb.ne.jp
RI Abraham, Samuel JK/GPK-1414-2022; Green, David W/ABE-6354-2021
OI Abraham, Samuel JK/0000-0003-2646-2687; Green, David
   W/0000-0003-0678-7134; Green, David William/0000-0003-2325-6781
FU Loyola ICAM College of Engineering Technology (LICET); Loyola Institute
   of Frontier Energy (LIFE)
FX The authors acknowledge Professor Masaru Iwasaki, Deptartment of
   Clinical Research, Yamanashi University, Japan, Chennai Cell Cluster
   (CCC) for the technical advice, and Loyola ICAM College of Engineering
   Technology (LICET) and Loyola Institute of Frontier Energy (LIFE) for
   their support to our research work.
CR Algvere PV, 1997, GRAEF ARCH CLIN EXP, V235, P149, DOI 10.1007/BF00941722
   Araujo A, 2008, ARQ BRAS OFTALMOL, V71, P246, DOI 10.1590/S0004-27492008000200021
   Barber AC, 2013, P NATL ACAD SCI USA, V110, P354, DOI 10.1073/pnas.1212677110
   Binder S, 2004, INVEST OPHTH VIS SCI, V45, P4151, DOI 10.1167/iovs.04-0118
   Binder S, 2002, AM J OPHTHALMOL, V133, P215, DOI 10.1016/S0002-9394(01)01373-3
   Binder S, 2007, PROG RETIN EYE RES, V26, P516, DOI 10.1016/j.preteyeres.2007.02.002
   Binder S, 2011, BRIT J OPHTHALMOL, V95, P441, DOI 10.1136/bjo.2009.171926
   Bonilla S, 2005, NEUROSCIENCE, V133, P85, DOI 10.1016/j.neuroscience.2005.02.019
   Buchholz DE, 2009, STEM CELLS, V27, P2427, DOI 10.1002/stem.189
   Cereda MG, 2010, GRAEF ARCH CLIN EXP, V248, P37, DOI 10.1007/s00417-009-1201-8
   Chan-Ling T, 2006, AM J PATHOL, V168, P1031, DOI 10.2353/ajpath.2006.050697
   Chanda D, 2010, J CELL BIOCHEM, V111, P249, DOI 10.1002/jcb.22701
   Chen MF, 2010, INVEST OPHTH VIS SCI, V51, P5970, DOI 10.1167/iovs.09-4504
   Chopdar A, 2003, BRIT MED J, V326, P485, DOI 10.1136/bmj.326.7387.485
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Falkner-Radler CI, 2011, BRIT J OPHTHALMOL, V95, P370, DOI 10.1136/bjo.2009.176305
   Fischer AJ, 2001, DEV NEUROSCI-BASEL, V23, P268, DOI 10.1159/000048710
   Franzco FKC, 2009, CLIN EXP OPHTHALMOL, V37, P275, DOI 10.1111/j.1442-9071.2009.01915.x
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Geffner LF, 2008, CELL TRANSPLANT, V17, P1277, DOI 10.3727/096368908787648074
   Gouras P, 1996, VISION RES, V36, P4121, DOI 10.1016/S0042-6989(96)00180-0
   Heussen FMA, 2008, EYE, V22, P799, DOI 10.1038/sj.eye.6702823
   HITCHCOCK PF, 1992, TRENDS NEUROSCI, V15, P103, DOI 10.1016/0166-2236(92)90020-9
   Hong Y, 2011, INT J OPHTHALMOL-CHI, V4, P466, DOI 10.3980/j.issn.2222-3959.2011.05.02
   Howden SE, 2011, P NATL ACAD SCI USA, V108, P6537, DOI 10.1073/pnas.1103388108
   Huang YM, 2011, STEM CELL REV REP, V7, P434, DOI 10.1007/s12015-010-9192-8
   Hubschman JP, 2009, CLIN OPHTHALMOL, V3, P155
   Jonas JB, 2008, ACTA OPHTHALMOL, V86, P225, DOI 10.1111/j.1600-0420.2007.00987.x
   Jonas JB, 2010, ACTA OPHTHALMOL, V88, pe131, DOI 10.1111/j.1755-3768.2009.01564.x
   Joussen AM, 2006, AM J OPHTHALMOL, V142, P17, DOI 10.1016/j.ajo.2006.01.090
   Kasemkijwattana Channarong, 2011, Journal of the Medical Association of Thailand, V94, P395
   Katta S, 2009, J GENET, V88, P425, DOI 10.1007/s12041-009-0064-4
   Kicic A, 2003, J NEUROSCI, V23, P7742
   Kokkinaki M, 2011, STEM CELLS, V29, P825, DOI 10.1002/stem.635
   Lee CJ, 2002, ARCH OPHTHALMOL-CHIC, V120, P1714
   LI LX, 1988, EXP EYE RES, V47, P911, DOI 10.1016/0014-4835(88)90073-5
   Locatelli F, 2003, J HEMATOTH STEM CELL, V12, P727, DOI 10.1089/15258160360732740
   LOPEZ R, 1987, INVEST OPHTH VIS SCI, V28, P1131
   Ma WX, 2009, STEM CELLS, V27, P1376, DOI 10.1002/stem.48
   Mao WM, 2008, MOL VIS, V14, P2309
   Medeiros NE, 2001, INVEST OPHTH VIS SCI, V42, P795
   Mitchell J, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-97
   Moviglia GA, 2012, OPHTHALMIC RES, V48, P1, DOI 10.1159/000339839
   Mozaffarieh M, 2006, CURR OPIN INVEST DR, V7, P18
   Otani A, 2004, J CLIN INVEST, V114, P765, DOI 10.1172/JCI200421686
   Pearson RA, 2012, NATURE, V485, P99, DOI 10.1038/nature10997
   PEYMAN GA, 1991, OPHTHALMIC SURG LAS, V22, P102
   ROYO PARIS E., 1959, GROWTH, V23, P313
   Salero E, 2012, CELL STEM CELL, V10, P88, DOI 10.1016/j.stem.2011.11.018
   Sanchez-Ramos J, 2000, EXP NEUROL, V164, P247, DOI 10.1006/exnr.2000.7389
   SEATON AD, 1992, INVEST OPHTH VIS SCI, V33, P83
   Senthilkumar R., 2012, CURR TRENDS BIOTECHN, V6, P44
   SHENG Y, 1995, INVEST OPHTH VIS SCI, V36, P381
   Sigurjonsson OE, 2005, P NATL ACAD SCI USA, V102, P5227, DOI 10.1073/pnas.0501029102
   Siqueira R. C., 2007, 9 INT OC INFL SOC IO, P117
   Siqueira RC, 2010, ARQ BRAS OFTALMOL, V73, P474, DOI 10.1590/S0004-27492010000500019
   Siqueira RC, 2009, ARQ BRAS OFTALMOL, V72, P123, DOI 10.1590/S0004-27492009000100027
   Stanga PE, 2002, OPHTHALMOLOGY, V109, P1492, DOI 10.1016/S0161-6420(02)01099-0
   Stopa M, 2012, VIDEOSURGERY MINIINV, V7, P220, DOI 10.5114/wiitm.2011.28910
   Suen WLL, 2013, J CONTROL RELEASE, V167, P21, DOI 10.1016/j.jconrel.2013.01.004
   Tao YX, 2010, INDIAN J EXP BIOL, V48, P444
   Tendera M, 2005, FOLIA HISTOCHEM CYTO, V43, P233
   Terai S, 2006, STEM CELLS, V24, P2292, DOI 10.1634/stemcells.2005-0542
   Tomita M, 2002, STEM CELLS, V20, P279, DOI 10.1634/stemcells.20-4-279
   Tucker BA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018992
   van Meurs JC, 2004, BRIT J OPHTHALMOL, V88, P110, DOI 10.1136/bjo.88.1.110
   Wang SZ, 2010, EXPERT OPIN BIOL TH, V10, P1227, DOI 10.1517/14712598.2010.495218
   Weimann JM, 2003, P NATL ACAD SCI USA, V100, P2088, DOI 10.1073/pnas.0337659100
   Wong IYH, 2011, GRAEF ARCH CLIN EXP, V249, P1439, DOI 10.1007/s00417-011-1764-z
   Yan RT, 2010, J COMP NEUROL, V518, P526, DOI 10.1002/cne.22236
   Yoshii C, 2007, DEV BIOL, V303, P45, DOI 10.1016/j.ydbio.2006.11.024
   Zhao TB, 2011, NATURE, V474, P212, DOI 10.1038/nature10135
NR 72
TC 12
Z9 14
U1 0
U2 21
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PY 2013
VL 2013
AR 465169
DI 10.1155/2013/465169
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 141EM
UT WOS:000318708400001
PM 23710332
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Rovner, BW
   Casten, RJ
   Hegel, MT
   Massof, RW
   Leiby, BE
   Ho, AC
   Tasman, WS
AF Rovner, Barry W.
   Casten, Robin J.
   Hegel, Mark T.
   Massof, Robert W.
   Leiby, Benjamin E.
   Ho, Allen C.
   Tasman, William S.
TI Low Vision Depression Prevention Trial in Age-Related Macular
   Degeneration A Randomized Clinical Trial
SO OPHTHALMOLOGY
LA English
DT Article
ID VISUAL FUNCTION QUESTIONNAIRE; BEHAVIORAL ACTIVATION; OLDER-ADULTS; NEI
   VFQ-25; OUTCOMES; HEALTH; POPULATION; IMPAIRMENT; DEMENTIA; VALIDITY
AB Purpose: To compare the efficacy of behavior activation (BA) + low vision rehabilitation (LVR) with supportive therapy (ST) + LVR to prevent depressive disorders in patients with age-related macular degeneration (AMD).
   Design: Single-masked, attention-controlled, randomized, clinical trial with outcome assessment at 4 months.
   Participants: Patients with AMD and subsyndromal depressive symptoms attending retina practices (n = 188).
   Interventions: Before randomization, all subjects had 2 outpatient LVR visits, and were then randomized to in-home BA+LVR or ST+LVR. Behavior activation is a structured behavioral treatment that aims to increase adaptive behaviors and achieve valued goals. Supportive therapy is a nondirective, psychological treatment that provides emotional support and controls for attention.
   Main Outcome Measures: The Diagnostic and Statistical Manual IV defined depressive disorder based on the Patient Health Questionnaire-9 (primary outcome), Activities Inventory, National Eye Institute Vision Function Questionnairee25 plus Supplement (NEI-VFQ), and NEI-VFQ quality of life (secondary outcomes).
   Results: At 4 months, 11 BA+LVR subjects (12.6%) and 18 ST+LVR subjects (23.4%) developed a depressive disorder (relative risk [RR], 0.54; 95% CI, 0.27-1.06; P = 0.067). In planned adjusted analyses the RR was 0.51 (95% CI, 0.27-0.98; P = 0.04). A mediational analysis suggested that BA+LVR prevented depression to the extent that it enabled subjects to remain socially engaged. In addition, BA+LVR was associated with greater improvements in functional vision than ST+LVR, although there was no significant between-group difference. There was no significant change or between-group difference in quality of life.
   Conclusions: An integrated mental health and low vision intervention halved the incidence of depressive disorders relative to standard outpatient LVR in patients with AMD. As the population ages, the number of persons with AMD and the adverse effects of comorbid depression will increase. Promoting interactions between ophthalmology, optometry, rehabilitation, psychiatry, and behavioral psychology may prevent depression in this population. (C) 2014 by the American Academy of Ophthalmology.
C1 [Rovner, Barry W.] Thomas Jefferson Univ, Jefferson Med Coll, Jefferson Hosp Neurosci, Dept Psychiat & Neurol, Philadelphia, PA 19107 USA.
   [Casten, Robin J.] Thomas Jefferson Univ, Jefferson Med Coll, Jefferson Hosp Neurosci, Dept Psychiat & Human Behav, Philadelphia, PA 19107 USA.
   [Hegel, Mark T.] Dartmouth Hitchcock Med Ctr, Dartmouth Med Sch, Dept Psychiat, Lebanon, NH 03766 USA.
   [Massof, Robert W.] Dartmouth Hitchcock Med Ctr, Dartmouth Med Sch, Dept Community & Family Med, Lebanon, NH 03766 USA.
   [Massof, Robert W.] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Lions Vis Res & Rehabil Ctr, Baltimore, MD 21205 USA.
   [Leiby, Benjamin E.] Thomas Jefferson Univ, Jefferson Med Coll, Dept Pharmacol & Expt Therapeut, Div Biostat, Philadelphia, PA 19107 USA.
   [Ho, Allen C.; Tasman, William S.] Thomas Jefferson Univ, Jefferson Med Coll, Wills Eye Inst, Dept Ophthalmol, Philadelphia, PA 19107 USA.
C3 Jefferson University; Jefferson University; Dartmouth College; Dartmouth
   College; Johns Hopkins University; Johns Hopkins Medicine; Jefferson
   University; Jefferson University
RP Rovner, BW (通讯作者)，Jefferson Hosp Neurosci, 900 Walnut St,2nd Floor, Philadelphia, PA 19107 USA.
EM barry.rovner@jefferson.edu
OI Ho, Allen/0000-0003-3921-608X
FU NEI [U01 EY018819]; NATIONAL EYE INSTITUTE [U01EY018819] Funding Source:
   NIH RePORTER
FX This work was supported by NEI grant U01 EY018819.
CR APA, 1994, DIAGNOSTIC STAT MANU
   Brody BL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1477, DOI 10.1001/archopht.120.11.1477
   Casten R, 2010, ARCH OPHTHALMOL-CHIC, V128, P506, DOI 10.1001/archophthalmol.2010.24
   Casten RJ, 2013, CURR OPIN OPHTHALMOL, V24, P239, DOI 10.1097/ICU.0b013e32835f8e55
   Centers for Medicare & Medicaid Services, 2009, CMS MAN SYST PUB
   Cuijpers P, 2012, JAMA-J AM MED ASSOC, V307, P1033, DOI 10.1001/jama.2012.271
   GALECKI AT, 1994, COMMUN STAT THEORY, V23, P3105, DOI 10.1080/03610929408831436
   Hamer M, 2011, AM J GERIAT PSYCHIAT, V19, P72, DOI 10.1097/JGP.0b013e3181df465e
   Horowitz A, 2005, AM J GERIAT PSYCHIAT, V13, P180, DOI 10.1176/appi.ajgp.13.3.180
   Horowitz A, 2006, J GERONTOL B-PSYCHOL, V61, pS274, DOI 10.1093/geronb/61.5.S274
   Iacobucci D, 2007, J CONSUM PSYCHOL, V17, P139, DOI 10.1016/S1057-7408(07)70020-7
   Kanter JW, 2007, J PSYCHOPATHOL BEHAV, V29, P191, DOI 10.1007/s10862-006-9038-5
   Kanter JW, 2010, CLIN PSYCHOL REV, V30, P608, DOI 10.1016/j.cpr.2010.04.001
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x
   Lam BL, 2008, ARCH OPHTHALMOL-CHIC, V126, P975, DOI 10.1001/archopht.126.7.975
   Lamoureux EL, 2009, OPTOMETRY VISION SCI, V86, P139, DOI 10.1097/OPX.0b013e318194eb47
   Laureano JAS, 1999, AUST NZ J OPHTHALMOL, V27, P137, DOI 10.1046/j.1440-1606.1999.00177.x
   Lebowitz BD, 1997, JAMA-J AM MED ASSOC, V278, P1186, DOI 10.1001/jama.278.14.1186
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   Marella M, 2010, INVEST OPHTH VIS SCI, V51, P2878, DOI 10.1167/iovs.09-4494
   Massof RW, 2007, OPTOMETRY VISION SCI, V84, P763, DOI 10.1097/OPX.0b013e3181339efd
   Massof RW, 2013, OPTOMETRY VISION SCI, V90, P788, DOI 10.1097/OPX.0000000000000011
   McCrae RR, 1990, PERSONALITY ADULTHOO, P41
   Montlahuc C, 2011, NEUROLOGY, V77, P1457, DOI 10.1212/WNL.0b013e31823303e1
   Novalis PN, 1993, CLIN MANUAL SUPPORTI, P3
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Reischies FM, 1997, BRIT J PSYCHIAT, V171, P449, DOI 10.1192/bjp.171.5.449
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rovner BW, 2007, ARCH GEN PSYCHIAT, V64, P886, DOI 10.1001/archpsyc.64.8.886
   Rovner BW, 2013, OPHTHALMOLOGY, V120, P1649, DOI 10.1016/j.ophtha.2013.01.022
   Sloan FA, 2014, JAMA OPHTHALMOL, V132, P456, DOI 10.1001/jamaophthalmol.2013.7647
   Soubrane G, 2007, ARCH OPHTHALMOL-CHIC, V125, P1249, DOI 10.1001/archopht.125.9.1249
   Stelmack JA, 2002, INVEST OPHTH VIS SCI, V43, P2859
   Stelmack JA, 2008, ARCH OPHTHALMOL-CHIC, V126, P608, DOI 10.1001/archopht.126.5.608
   Thiebaut R, 2002, COMPUT METH PROG BIO, V69, P249, DOI 10.1016/S0169-2607(02)00017-2
   Unutzer J, 2009, J AM GERIATR SOC, V57, P506, DOI 10.1111/j.1532-5415.2008.02134.x
   VONKORFF M, 1992, J CLIN EPIDEMIOL, V45, P197, DOI 10.1016/0895-4356(92)90016-G
   Waern M, 2002, BMJ-BRIT MED J, V324, P1355, DOI 10.1136/bmj.324.7350.1355
   WARE JE, 1992, MEASURING FUNCTIONIN, P291
   Wysong A, 2009, ARCH OPHTHALMOL-CHIC, V127, P320, DOI 10.1001/archophthalmol.2008.613
   Zou GY, 2004, AM J EPIDEMIOL, V159, P702, DOI 10.1093/aje/kwh090
NR 42
TC 81
Z9 87
U1 0
U2 39
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD NOV
PY 2014
VL 121
IS 11
BP 2204
EP 2211
DI 10.1016/j.ophtha.2014.05.002
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA AS8DM
UT WOS:000344480400026
PM 25016366
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Reynolds, R
   Rosner, B
   Seddon, JM
AF Reynolds, Robyn
   Rosner, Bernard
   Seddon, Johanna M.
TI Serum Lipid Biomarkers and Hepatic Lipase Gene Associations with
   Age-Related Macular Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID FACTOR-H POLYMORPHISM; C-REACTIVE PROTEIN; RISK-FACTORS;
   CARDIOVASCULAR-DISEASE; VARIANT; SUSCEPTIBILITY; LIPOPROTEIN;
   CHOLESTEROL; MACULOPATHY; PROGRESSION
AB Objective: A genetic variant in the high-density lipoprotein (HDL) cholesterol pathway, hepatic lipase (LIPC), was discovered to be associated with advanced age-related macular degeneration (AMD) in a genome-wide association study. In this study, we evaluated whether LIPC is associated with serum lipids, and whether this gene and serum lipids are independently associated with AMD.
   Design: Case-control study.
   Participants: A total of 458 participants from the Progression Study of Macular Degeneration and the Age-Related Eye Disease Ancillary Biomarker Study, including 318 advanced AMD cases with either geographic atrophy (n = 123) or neovascular disease (n = 195) and 140 controls.
   Methods: Participants were genotyped for 8 variants associated with AMD: 2 CFH variants, C2, CFB, C3, CFI, the ARMS2/HTRA1 gene region, and LIPC. Fasting blood specimens were obtained at study onset, and serum levels of total cholesterol, low-density lipoprotein (LDL), HDL, and triglycerides were determined. Logistic and linear regression were used to evaluate associations between serum lipids, LIPC genotype, and AMD.
   Main Outcome Measures: LIPC and serum lipid associations with AMD.
   Results: The minor T allele of the LIPC gene was associated with a reduced risk of AMD (odds ratio, 0.4; 95% confidence interval, 0.2-0.9; P = 0.01, trend for number of T alleles, controlling for age and gender). Mean level of HDL was lower (P = 0.05) and mean level of LDL (P = 0.03) was higher in cases of advanced AMD compared with controls. Higher total cholesterol and LDL levels were associated with increased risk of AMD, with P for trend = 0.01 for both, in models controlling for environmental and genetic covariates. The T allele of LIPC was associated with higher levels of HDL, although LIPC was associated with advanced AMD independent of HDL level.
   Conclusions: The HDL-raising allele of the LIPC gene (T) was associated with a reduced risk of AMD. Higher total cholesterol and LDL levels were associated with increased risk, whereas higher HDL levels tended to reduce the risk of AMD. The specific mechanisms underlying the association between AMD and LIPC require further investigation.
C1 [Reynolds, Robyn; Seddon, Johanna M.] Tufts Med Ctr, Ophthalm Epidemiol & Genet Serv, New England Eye Ctr, Dept Ophthalmol, Boston, MA 02111 USA.
   [Rosner, Bernard] Channing Labs, Boston, MA USA.
   [Seddon, Johanna M.] Tufts Univ, Sch Med, Dept Ophthalmol, Boston, MA 02111 USA.
C3 Tufts Medical Center; Tufts University
RP Seddon, JM (通讯作者)，Tufts Med Ctr, Ophthalm Epidemiol & Genet Serv, New England Eye Ctr, Dept Ophthalmol, 800 Washington St 450, Boston, MA 02111 USA.
FU National Eye Institute, National Institutes of Health, Bethesda,
   Maryland; Massachusetts Lions Eye Research Fund, Inc., New Bedford,
   Massachusetts; Research to Prevent Blindness, Inc., New York, New York;
   Macular Degeneration Research Fund-Ophthalmic Epidemiology and Genetics
   Service, Tufts Medical Center, Tufts University School of Medicine,
   Boston, Massachusetts; American Macular Degeneration Foundation
   Northampton, Massachusetts; S. Elizabeth O'Brien Trust, Boston,
   Massachusetts; NATIONAL EYE INSTITUTE [R01EY011309] Funding Source: NIH
   RePORTER
FX Supported by an anonymous donor (to the research of JMS); the National
   Eye Institute, National Institutes of Health, Bethesda, Maryland
   (R01-EY11309); Massachusetts Lions Eye Research Fund, Inc., New Bedford,
   Massachusetts; Research to Prevent Blindness, Inc., New York, New York;
   Macular Degeneration Research Fund-Ophthalmic Epidemiology and Genetics
   Service, Tufts Medical Center, Tufts University School of Medicine,
   Boston, Massachusetts; The American Macular Degeneration Foundation
   Northampton, Massachusetts; and the S. Elizabeth O'Brien Trust, Boston,
   Massachusetts.
CR Abalain JH, 2002, CLIN CHIM ACTA, V326, P97, DOI 10.1016/S0009-8981(02)00288-7
   Chasman DI, 2008, CIRC-CARDIOVASC GENE, V1, P21, DOI 10.1161/CIRCGENETICS.108.773168
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Curcio CA, 2009, PROG RETIN EYE RES, V28, P393, DOI 10.1016/j.preteyeres.2009.08.001
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hogg RE, 2008, OPHTHALMOLOGY, V115, P1046, DOI 10.1016/j.ophtha.2007.07.031
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kathiresan S, 2009, NAT GENET, V41, P56, DOI 10.1038/ng.291
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Mora S, 2009, CLIN CHEM, V55, P888, DOI 10.1373/clinchem.2008.117929
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Nowak M, 2005, CLIN EXP MED, V4, P183, DOI 10.1007/s10238-004-0054-z
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Tserentsoodol N, 2006, MOL VIS, V12, P1319
   van Leeuwen R, 2004, AM J OPHTHALMOL, V137, P750, DOI 10.1016/S0002-9394(03)01089-4
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
NR 37
TC 108
Z9 113
U1 1
U2 15
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
J9 OPHTHALMOLOGY
JI Ophthalmology
PD OCT
PY 2010
VL 117
IS 10
BP 1989
EP 1995
DI 10.1016/j.ophtha.2010.07.009
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 656VV
UT WOS:000282370100019
PM 20888482
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Cruz-Gonzalez, F
   Cabrillo-Estevez, L
   Rivero-Gutierrez, V
   Sanchez-Jara, A
   De Juan-Marcos, L
   Gonzalez-Sarmiento, R
AF Cruz-Gonzalez, Fernando
   Cabrillo-Estevez, Lucia
   Rivero-Gutierrez, Vanesa
   Sanchez-Jara, Ana
   De Juan-Marcos, Lourdes
   Gonzalez-Sarmiento, Rogelio
TI Influence of CFH, HTRA1 and ARMS2 polymorphisms in the response to
   intravitreal ranibizumab treatment for wet age-related macular
   degeneration in a Spanish population
SO INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; polymorphisms; ARMS2; HTRA1;
   complement factor H; ranibizumab
ID COMPLEMENT FACTOR-H; PHOTODYNAMIC THERAPY; GENE POLYMORPHISMS; LOC387715
   GENOTYPES; Y402H VARIANT; ASSOCIATION; RISK; AMD; SUSCEPTIBILITY;
   DISEASE
AB AIM: To determine whether gene polymorphisms of the major genetic risk loci for age-related macular degeneration (AMD): ARMS2 (rs10490923), the complement factor H (CFH) (rs1410996) and HTRA1 (rs11200638) influence the response to a treatment regimen with ranibizumab for exudative AMD.
   METHODS: This study included 100 patients (100 eyes) with exudative AMD. Patients underwent a treatment with ranibizumab injections monthly during three months. Reinjections were made when the best corrected visual acuity (BCVA) decrease five letters (ETDRS) or central subfield retinal thickness gained 100 pm in optical coherence tomography image. Genotypes (rs10490923, rs1410996 and rs11200638) were analyzed using TaqMan probes or polymerase chain reaction-restricted fragment length polymorphisms analysis.
   RESULTS: There were no statistically significant differences in allelic distribution of CFH (rs1410996), ARMS2 (rs10490923) and HTRA1 (rs11200638) polymorphisms regarding to response to ranibizumab treatment.
   CONCLUSION: Ranibizumab treatment response is not related to CFH (rs1410996), ARMS2 (rs10490923) and HTRA1 (rs11200638) poymorphisms.
C1 [Cruz-Gonzalez, Fernando; Cabrillo-Estevez, Lucia; Rivero-Gutierrez, Vanesa; Sanchez-Jara, Ana; De Juan-Marcos, Lourdes; Gonzalez-Sarmiento, Rogelio] Hosp Univ Salamanca, Dept Ophthalmol, Paseo San Vicente 158, Salamanca 37007, Spain.
RP Cruz-Gonzalez, F (通讯作者)，Hosp Univ Salamanca, Dept Ophthalmol, Paseo San Vicente 158, Salamanca 37007, Spain.
EM cruzgonzalez.fernando@gmail.com
RI Gonzalez-Sarmiento, Rogelio/V-5526-2019
OI Gonzalez-Sarmiento, Rogelio/0000-0002-2726-6795
FU Gerencia Regional de Salud de Castillay Leon [GRS 957/A/14]
FX Supported by a Grant from Gerencia Regional de Salud de Castillay Leon
   GRS 957/A/14.
CR Assink JJM, 2005, OPHTHALMOLOGY, V112, P482, DOI 10.1016/j.ophtha.2004.10.035
   Brantley MA, 2009, EYE, V23, P626, DOI 10.1038/eye.2008.28
   Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   Brantley MA, 2007, AM J OPHTHALMOL, V144, P404, DOI 10.1016/j.ajo.2007.05.018
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chen H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042464
   Chen HY, 2008, VISION RES, V48, P690, DOI 10.1016/j.visres.2007.10.014
   Chowers I, 2008, MOL VIS, V14, P2263
   Cruz-Gonzalez F, 2014, OPHTHALMIC GENET, V35, P68, DOI 10.3109/13816810.2013.781193
   Daly AK, 2001, BRIT J CLIN PHARMACO, V52, P489, DOI 10.1046/j.0306-5251.2001.01510.x
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Dikmetas O, 2013, MOL VIS, V19, P2571
   Fauser S, 2015, SURV OPHTHALMOL, V60, P138, DOI 10.1016/j.survophthal.2014.11.002
   Goverdhan SV, 2008, EYE, V22, P849, DOI 10.1038/sj.eye.6702830
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hao XF, 2015, INT J CLIN EXP PATHO, V8, P3186
   HEIBA IM, 1994, GENET EPIDEMIOL, V11, P51, DOI 10.1002/gepi.1370110106
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   McKibbin M, 2015, EYE, V29, pS1, DOI 10.1038/eye.2015.77
   McKibbin M, 2012, BRIT J OPHTHALMOL, V96, P208, DOI 10.1136/bjo.2010.193680
   Orlin A, 2012, RETINA-J RET VIT DIS, V32, P4, DOI 10.1097/IAE.0b013e31822a2c7c
   Pascolini D, 2004, OPHTHAL EPIDEMIOL, V11, P67, DOI 10.1076/opep.11.2.67.28158
   Restrepo NA, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.14-14246
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Seddon JM, 2015, INVEST OPHTH VIS SCI, V56, P2192, DOI 10.1167/iovs.14-15841
   Tong Y, 2010, MOL VIS, V16, P1958
   Tsuchihashi T, 2011, OPHTHALMOLOGY, V118, P93, DOI 10.1016/j.ophtha.2010.04.007
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
NR 30
TC 7
Z9 8
U1 0
U2 2
PU IJO PRESS
PI XI AN
PA NO 269 YOUYI EAST RD, XI AN, 710054, PEOPLES R CHINA
SN 2222-3959
EI 2227-4898
J9 INT J OPHTHALMOL-CHI
JI Int. J. Ophthalmol.
PD SEP 18
PY 2016
VL 9
IS 9
BP 1304
EP 1309
DI 10.18240/ijo.2016.09.12
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DW1OE
UT WOS:000383411700012
PM 27672596
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Joachim, N
   Mitchell, P
   Younan, C
   Burlutsky, G
   Cheng, CY
   Cheung, CMG
   Zheng, YF
   Moffitt, M
   Wong, TY
   Wang, JJ
AF Joachim, Nichole
   Mitchell, Paul
   Younan, Christine
   Burlutsky, George
   Cheng, Ching-Yu
   Cheung, Chui Ming Gemmy
   Zheng, Yingfeng
   Moffitt, Mireille
   Wong, Tien Yin
   Wang, Jie Jin
TI Ethnic Variation in Early Age-Related Macular Degeneration Lesions
   Between White Australians and Singaporean Asians
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE age-related macular degeneration; AMD; Asian; Australian; early AMD;
   late AMD; drusen; pigment
ID BLUE-MOUNTAINS-EYE; COMPLEMENT FACTOR-H; BEAVER DAM EYE; RISK-FACTORS;
   MALAY EYE; RACIAL-DIFFERENCES; 5-YEAR INCIDENCE; CHINESE COHORT; GRADING
   SYSTEM; PREVALENCE
AB PURPOSE. We compared early age-related macular degeneration (AMD) lesion characteristics between white Australians and Singaporean Asians.
   METHODS. Participants of the Blue Mountains Eye Study (BMES; whites, n = 3508) and the Singapore Epidemiology of Eye Disease Study (SEED; Malay, n = 3280, Indian, n = 3400, and Chinese, n = 3353) underwent examinations, including retinal photography. The AMD lesions were assessed following the Wisconsin AMD grading protocol by the same photographic grader. Prevalence and characteristics of early AMD lesions were compared between the BMES and the SEED. The associations between ethnicity and early AMD lesion types were analyzed using logistic regression models adjusting for age, sex, smoking status, lipids, and genetic polymorphisms associated with AMD.
   RESULTS. After age-standardization to the BMES population, the prevalence of distinct soft drusen was significantly higher in Singaporeans compared to Australians (23.9%, 95% confidence interval [CI] 22.9-25.0 vs. 6.2%, 95% CI 5.3-7.0), with an adjusted odds ratio (OR) of 4.6 (95% CI 3.4-6.0). In contrast, the prevalence of indistinct soft or reticular drusen was significantly lower in Singaporeans compared to Australians (6.5%, 95% CI 5.9-7.1 vs. 8.3%, 95% CI 7.4-9.3, with nonsignificant adjusted OR of 1.2, 95% CI 0.8-1.7). Soft drusen of any type were present frequently at the inner and outer macula (within a zone >= 500 to <3000 mu m radius from the foveal center) among Singaporeans, while among Australians soft drusen were present more frequently at the central macula (<500 mu m radius).
   CONCLUSIONS. Singaporean Asians had a milder spectrum of early AMD lesions and lesion characteristics (predominantly distinct soft drusen and noncentral location) compared to white Australians.
C1 [Joachim, Nichole; Mitchell, Paul; Younan, Christine; Burlutsky, George; Moffitt, Mireille; Wang, Jie Jin] Univ Sydney, Dept Ophthalmol, Ctr Vis Res, Sydney, NSW 2006, Australia.
   [Joachim, Nichole; Mitchell, Paul; Younan, Christine; Burlutsky, George; Moffitt, Mireille; Wang, Jie Jin] Univ Sydney, Westmead Millennium Inst, Sydney, NSW 2006, Australia.
   [Cheng, Ching-Yu; Cheung, Chui Ming Gemmy; Wong, Tien Yin] Singapore Natl Eye Ctr, Singapore Eye Res Inst, Singapore, Singapore.
   [Cheng, Ching-Yu; Cheung, Chui Ming Gemmy; Wong, Tien Yin] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Ophthalmol, Singapore 117595, Singapore.
   [Cheng, Ching-Yu; Cheung, Chui Ming Gemmy; Zheng, Yingfeng; Wong, Tien Yin] Natl Univ Hlth Syst, Singapore, Singapore.
   [Cheng, Ching-Yu; Cheung, Chui Ming Gemmy] Natl Univ Singapore, Duke NUS, Ophthalmol Acad Clin Program, Singapore 117548, Singapore.
   [Cheng, Ching-Yu; Zheng, Yingfeng] Natl Univ Singapore, Saw Swee Hock Sch Publ Hlth, Singapore 117548, Singapore.
C3 University of Sydney; University of Sydney; Westmead Institute for
   Medical Research; National University of Singapore; Singapore National
   Eye Center; National University of Singapore; National University of
   Singapore; National University of Singapore; National University of
   Singapore
RP Wang, JJ (通讯作者)，Univ Sydney, Dept Ophthalmol, Ctr Vis Res, C24,Hawkesbury Rd, Westmead, NSW 2145, Australia.
EM jiejin.wang@sydney.edu.au
RI Mitchell, Paul/P-1498-2014; Cheng, Ching-Yu/Y-2229-2019; Wang, Jie
   Jin/P-1499-2014; Wong, Tien Yin/AAC-9724-2020; Zheng,
   Yingfeng/AAE-2983-2022; wang, jie/GRS-0942-2022; Zheng,
   Yingfeng/CAE-9225-2022
OI Cheng, Ching-Yu/0000-0003-0655-885X; Wang, Jie Jin/0000-0001-9491-4898;
   Wong, Tien Yin/0000-0002-8448-1264; Zheng, Yingfeng/0000-0002-0914-7864;
   Cheung, Chui Ming Gemmy/0000-0003-3358-3516
FU National Health and Medical Research Council (NHMRC), Australia [974159,
   211069, 457349]; National Medical Research Council [0796/2003,
   IRG07nov013, IRG09nov014, STaR/0003/2008, CG/SERI/2010]; Biomedical
   Research Council [08/1/35/19/550, 09/1/35/19/616]
FX Supported by the National Health and Medical Research Council (NHMRC),
   Australia (Grants 974159, 211069, 457349). The NHMRC Australia had no
   role in the design or conduct of this research. The SEED is supported by
   National Medical Research Council (Grants 0796/2003, IRG07nov013,
   IRG09nov014, STaR/0003/2008, CG/SERI/2010) and Biomedical Research
   Council (Grants 08/1/35/19/550, 09/1/35/19/616).
CR Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bressler SB, 2008, ARCH OPHTHALMOL-CHIC, V126, P241, DOI 10.1001/archophthalmol.2007.53
   Cackett P, 2008, AM J OPHTHALMOL, V146, P960, DOI 10.1016/j.ajo.2008.06.026
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Cheung CMG, 2013, AM J OPHTHALMOL, V155, P764, DOI 10.1016/j.ajo.2012.10.013
   Cheung CMG, 2012, ARCH OPHTHALMOL-CHIC, V130, P480, DOI 10.1001/archophthalmol.2011.376
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Foong AWP, 2007, OPHTHAL EPIDEMIOL, V14, P25, DOI 10.1080/09286580600878844
   Francis PJ, 2008, MOL VIS, V14, P1395
   Friedman DS, 1999, OPHTHALMOLOGY, V106, P1049, DOI 10.1016/S0161-6420(99)90267-1
   Holliday EG, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0082305, 10.1371/journal.pone.0053830]
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jiang H, 2009, RETINA-J RET VIT DIS, V29, P974, DOI 10.1097/IAE.0b013e3181a3b90e
   Kaur I, 2008, INVEST OPHTH VIS SCI, V49, P1771, DOI 10.1167/iovs.07-0560
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1735, DOI 10.1016/j.ophtha.2008.02.012
   Kawasaki R, 2011, OPHTHAL EPIDEMIOL, V18, P253, DOI 10.3109/09286586.2011.602505
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Krishnaiah S, 2005, INVEST OPHTH VIS SCI, V46, P4442, DOI 10.1167/iovs.05-0853
   Lau LI, 2006, INVEST OPHTH VIS SCI, V47, P3242, DOI 10.1167/iovs.05-1532
   Lavanya R, 2009, OPHTHAL EPIDEMIOL, V16, P325, DOI 10.3109/09286580903144738
   Li X, 2013, INVEST OPHTH VIS SCI, V54, P3650, DOI 10.1167/iovs.12-11126
   Lim LS, 2013, ASIA-PAC J OPHTHALMO, V2, P32, DOI 10.1097/APO.0b013e31827ff5bc
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Pai ASI, 2009, ARCH OPHTHALMOL-CHIC, V127, P1339, DOI 10.1001/archophthalmol.2009.239
   Saw SM, 2008, OPHTHALMOLOGY, V115, P1713, DOI 10.1016/j.ophtha.2008.03.016
   Seddon JM, 2010, MOL VIS, V16, P2412
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Tan JSL, 2007, ARCH OPHTHALMOL-CHIC, V125, P1089, DOI 10.1001/archopht.125.8.1089
   Tedeschi-Blok N, 2007, OPHTHALMOLOGY, V114, P99, DOI 10.1016/j.ophtha.2006.07.043
   Uka J, 2006, RETINA-J RET VIT DIS, V26, P985, DOI 10.1097/01.iae.0000244068.18520.3e
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Wang JJ, 2003, ARCH OPHTHALMOL-CHIC, V121, P658, DOI 10.1001/archopht.121.5.658
   Wong TY, 2006, BRIT J OPHTHALMOL, V90, P506, DOI 10.1136/bjo.2005.083733
   Yang K, 2011, OPHTHALMOLOGY, V118, P1395, DOI 10.1016/j.ophtha.2010.12.030
   Zheng YF, 2011, OPHTHALMOLOGY, V118, P1798, DOI 10.1016/j.ophtha.2011.02.014
NR 42
TC 15
Z9 15
U1 0
U2 6
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JUL
PY 2014
VL 55
IS 7
BP 4421
EP 4429
DI 10.1167/iovs.14-14476
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AL9UI
UT WOS:000339487000051
PM 24970259
DA 2022-11-30
ER

PT J
AU Forte, R
   Querques, G
   Querques, L
   Leveziel, N
   Benhamou, N
   Souied, EH
AF Forte, Raimondo
   Querques, Giuseppe
   Querques, Lea
   Leveziel, Nicolas
   Benhamou, Nathanael
   Souied, Eric H.
TI MULTIMODAL EVALUATION OF FOVEAL SPARING IN PATIENTS WITH
   GEOGRAPHICATROPHY DUE TO AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE autofluorescence; dry age-related macular degeneration; microperimetry;
   near-infrared; spectral-domain optical coherence tomography
ID SCANNING LASER OPHTHALMOSCOPE; OPTICAL COHERENCE TOMOGRAPHY; FUNDUS
   AUTOFLUORESCENCE; HIGH-RESOLUTION; VISUAL-LOSS; ATROPHY; MICROPERIMETRY;
   FLUORESCENCE
AB Purpose: To compare the ability of spectral domain optical coherence tomography (SD-OCT), blue light fundus autofluorescence (FAF), and near-infrared fundus autofluorescence (NIR-FAF) to evaluate foveal involvement in geographic atrophy as a result of age-related macular degeneration.
   Methods: All consecutive patients with geographic atrophy underwent FAF (excitation lambda = 488 nm; emission lambda > 500 nm), NIR-FAF (excitation lambda = 787 nm; emission lambda > 800 nm), and simultaneous SD-OCT scanning (Spectralis HRA + OCT; Heidelberg Engineering). Two readers independently graded foveal involvement on FAF, NIR-FAF, and SD-OCT and measured the width of foveal sparing. In eyes with an intergrader agreement of foveal sparing by at least one among FAF, NIR-FAF, and SD-OCT, microperimetry (Spectral OCT/SLO; OPKO-OTI) was analyzed.
   Results: A total of 158 eyes (83 patients; 53 women, 30 men, mean age 69.2 +/- 4.8 years) with geographic atrophy were included. Spectral domain OCT showed the highest intergrader agreement of foveal involvement (k = k' = 0.8, P = 0.001 vs. k = k' = 0.7, P = 0.01 for NIR-FAF and k = k' = 0.5, P = 0.01 for FAF). In 74 eyes (46.8%) foveal sparing was present according to interobserver agreement. Width of the foveal sparing was larger on SD-OCT than on NIR-FAF and FAF (1,334 +/- 943 mu m vs. 1,228 +/- 912 mu m, P < 0.001 and 1,201 +/- 922 mu m, P < 0.001, respectively). Retinal fixation was predominantly central and stable in 97.3% of eyes with foveal sparing.
   Conclusion: Spectral domain OCT is an appropriate imaging modality for evaluating the presence and extent of foveal sparing, followed by NIR-FAF and FAF. RETINA 33:482-489, 2013
C1 [Forte, Raimondo; Querques, Giuseppe; Querques, Lea; Leveziel, Nicolas; Benhamou, Nathanael; Souied, Eric H.] Univ Paris Est Creteil, Ctr Hosp Intercommunal Creteil, Dept Ophthalmol, F-94000 Creteil, France.
   [Querques, Giuseppe; Querques, Lea] Univ Sci Inst San Raffaele, Dept Ophthalmol, Milan, Italy.
C3 Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil
RP Querques, G (通讯作者)，Univ Paris Est Creteil, Ctr Hosp Intercommunal Creteil, Dept Ophthalmol, 40 Ave Verdun, F-94000 Creteil, France.
EM giuseppe.querques@hotmail.it
OI Querques, Giuseppe/0000-0002-3292-9581
CR Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   Fleckenstein M, 2008, INVEST OPHTH VIS SCI, V49, P4137, DOI 10.1167/iovs.08-1967
   Fujii GY, 2003, AM J OPHTHALMOL, V136, P1067, DOI 10.1016/S0002-9394(03)00663-9
   Helb HM, 2010, ACTA OPHTHALMOL, V88, P842, DOI 10.1111/j.1755-3768.2009.01602.x
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Landa G, 2010, OPHTHALMIC RES, V43, P92, DOI 10.1159/000247593
   Midena E, 2007, BRIT J OPHTHALMOL, V91, P1499, DOI 10.1136/bjo.2007.119685
   Piccolino FC, 1996, OPHTHALMOLOGY, V103, P1837
   Pilotto E, 2011, BRIT J OPHTHALMOL, V95, P1140, DOI 10.1136/bjo.2010.187344
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Sayegh RG, 2011, OPHTHALMOLOGY, V118, P1844, DOI 10.1016/j.ophtha.2011.01.043
   Schmitz-Valckenberg S, 2004, INVEST OPHTH VIS SCI, V45, P4470, DOI 10.1167/iovs.03-1311
   Schmitz-Valckenberg S, 2008, AM J OPHTHALMOL, V146, P183, DOI 10.1016/j.ajo.2008.04.006
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P7640, DOI 10.1167/iovs.11-7457
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P1, DOI 10.1167/iovs.10-5619
   Sunness JS, 2006, RETINA-J RET VIT DIS, V26, P666, DOI 10.1097/00006982-200607000-00013
   SUNNESS JS, 1995, AM J OPHTHALMOL, V119, P143, DOI 10.1016/S0002-9394(14)73866-8
NR 20
TC 29
Z9 29
U1 0
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAR
PY 2013
VL 33
IS 3
BP 482
EP 489
DI 10.1097/IAE.0b013e318276e11e
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 097DW
UT WOS:000315455200004
PM 23400084
DA 2022-11-30
ER

PT J
AU Sukkarieh, G
   Vasseur, V
   Lejoyeux, R
   Wolff, B
   Mauget-Faysse, M
AF Sukkarieh, Georges
   Vasseur, Vivien
   Lejoyeux, Raphael
   Wolff, Benjamin
   Mauget-Faysse, Martine
TI One-year outcome of neovascular age-related macular degeneration
   patients followed-up using different optical coherence tomography
   modalities
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE neovascular age-related macular degeneration; optical coherence
   tomography b-scan; optical coherence tomography angiography;
   anti-vascular endothelial growth factor
ID OCT-ANGIOGRAPHY; CHOROIDAL NEOVASCULARIZATION; QUANTITATIVE-ANALYSIS;
   RANIBIZUMAB; PREVALENCE; AMD; CNV
AB Purpose The aim of this study is to compare the one year outcome of neovascular age-related macular degeneration (nAMD) patients treated by a PRN regimen of Anti-vascular endothelial growth factor (VEGF) intravitreal injections (IVTs), using optical coherence tomography B-scan (OCT-B) or OCT Angiography (OCT-A) imaging modalities during follow-up. Methods Patients older than 50 years with nAMD currently treated by PRN regimen of Anti-VEGF IVTs were recruited from Rothschild Foundation Hospital - Paris and Centre Ophtalmologique Maison Rouge - Strasbourg and followed-up for a year. Patients were randomized in two groups: one group was followed by OCT-B while the other was followed by OCT-A. Results Thirty-three patients were followed by OCT-A and 31 patients were followed by OCT-B. Twenty-nine patients in the OCT-A group and 27 patients in the OCT-B group attended the last visit. No statistically significant difference was found between the two groups at 1 year concerning: improvement or stabilization of the best corrected distance visual acuity (BCVA) (p > 0.9), exudative signs (p > 0.9), number of injections (p = 0.8) and the delay until the first reinjection was performed (p = 0.5). Conclusion The use of OCT-A or OCT-B as imaging modalities in nAMD treated by a PRN regimen of Anti-VEGF IVTs seem to be comparable at one year.
C1 [Sukkarieh, Georges; Vasseur, Vivien; Lejoyeux, Raphael; Mauget-Faysse, Martine] Rothschild Fdn Hosp, Dept Surg Retina, Paris, France.
   [Wolff, Benjamin] Ophthalmol Ctr Maison Rouge, Strasbourg, France.
C3 Fondation Adolphe de Rothschild
RP Sukkarieh, G (通讯作者)，Rothschild Fdn Hosp, Dept Surg Retina, Paris, France.; Sukkarieh, G (通讯作者)，Rothschild Fdn Hosp, 29 Manin St, F-75019 Paris, France.
EM georgessuccarieh18@gmail.com
OI Sukkarieh, Georges/0000-0002-5496-0432
CR Arrigo A, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.9.48
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Bruy?re E., 2019, EMC OPHTALMOLOGIE, V16
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Coscas F, 2019, BRIT J OPHTHALMOL, V103, P1342, DOI 10.1136/bjophthalmol-2018-313065
   Coscas G, 2015, OPHTHALMIC RES, V54, P57, DOI 10.1159/000433547
   Coscas GJ, 2015, RETINA-J RET VIT DIS, V35, P2219, DOI 10.1097/IAE.0000000000000766
   Costanzo E, 2016, INVEST OPHTH VIS SCI, V57, pOCT307, DOI 10.1167/iovs.15-18830
   Faatz H, 2019, EYE, V33, P1466, DOI 10.1038/s41433-019-0429-8
   Faatz H, 2017, KLIN MONATSBL AUGENH, V234, P1125, DOI 10.1055/s-0043-118346
   Farecki ML, 2017, GRAEF ARCH CLIN EXP, V255, P913, DOI 10.1007/s00417-017-3588-y
   Faridi A, 2017, OPHTHALMOL RETINA, V1, P294, DOI 10.1016/j.oret.2017.02.007
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Inoue M, 2016, INVEST OPHTH VIS SCI, V57, pOCT314, DOI 10.1167/iovs.15-18900
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1435, DOI 10.1016/j.ophtha.2014.01.034
   Khurana RN, 2010, OPHTHALMOLOGY, V117, P1376, DOI 10.1016/j.ophtha.2009.11.039
   Kuehlewein L, 2015, EYE, V29, P932, DOI 10.1038/eye.2015.80
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lindner M, 2016, INVEST OPHTH VIS SCI, V57, P6342, DOI 10.1167/iovs.16-19741
   Malamos P, 2017, CURR EYE RES, V42, P1689, DOI 10.1080/02713683.2017.1356336
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Mokwa NF, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/385915
   Palejwala NV, 2015, RETINA-J RET VIT DIS, V35, P2204, DOI 10.1097/IAE.0000000000000867
   Roisman Luiz, 2017, Curr Ophthalmol Rep, V5, P136, DOI 10.1007/s40135-017-0131-6
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Schneider EW, 2018, CURR OPIN OPHTHALMOL, V29, P217, DOI 10.1097/ICU.0000000000000469
   Solecki L, 2021, EYE, V35, P644, DOI 10.1038/s41433-020-0936-7
   Sulzbacher F, 2017, ACTA OPHTHALMOL, V95, P414, DOI 10.1111/aos.13364
   Wilde C, 2015, EYE, V29, P602, DOI 10.1038/eye.2015.44
NR 29
TC 0
Z9 0
U1 1
U2 1
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD NOV
PY 2022
VL 32
IS 6
BP 3503
EP 3509
AR 11206721221088260
DI 10.1177/11206721221088260
EA MAR 2022
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 4Z0VS
UT WOS:000771925700001
PM 35285308
DA 2022-11-30
ER

PT J
AU Lee, H
   Jeon, HL
   Park, SJ
   Shin, JY
AF Lee, Hyesung
   Jeon, Ha-Lim
   Park, Sang Jun
   Shin, Ju-Young
TI Effect of Statins, Metformin, Angiotensin-Converting Enzyme Inhibitors,
   and Angiotensin II Receptor Blockers on Age-Related Macular Degeneration
SO YONSEI MEDICAL JOURNAL
LA English
DT Article
DE Age-related macular degeneration; preventive effect; cardiovascular
   medications
ID CHOLESTEROL-LOWERING MEDICATIONS; RISK; MACULOPATHY; PREVALENCE
AB Purpose: Statins, metformin, angiotensin-converting enzyme (ACE) inhibitors, and angiotensin receptor blockers (ARBs) have been suggested for treating age-related macular degeneration (AMD) due to their pleiotropic effects. Therefore, we investigated whether these drugs prevent AMD.
   Materials and Methods: We conducted a nested case-control study using the Korean National Health Insurance Service database. Using risk-set sampling of age, sex, cohort entry date, and follow-up duration, we identified incident patients with AMD and 10 matching controls in cohorts with diabetes mellitus or cardiovascular diseases. Exposure was assessed within one year before the index date using patient prescription records. We conducted conditional logistic regression to estimate the odds ratios (ORs) and 95% confidence intervals (CIs) to evaluate the association between cardiovascular medications and AMD.
   Results: Our study included 2330 cases and 23278 controls from a cohort of 231274 patients. The ORs (95% CI) for AMD occurrence in users prescribed with statins, metformin, ACE inhibitors, and ARBs were 1.12 (0.94-1.32), 1.15 (0.91-1.45), 0.90 (0.61-1.34), and 1.21 (1.05-1.39), respectively. A duration-response was not observed.
   Conclusion: Statins, metformin, ACE inhibitors, and ARBs did not inhibit AMD in elderly patients. The absence of a duration-response supports the lack of a causal relationship.
C1 [Lee, Hyesung; Jeon, Ha-Lim; Shin, Ju-Young] Sungkyunkwan Univ, Sch Pharm, 2066 Seobu Ro, Suwon 16419, South Korea.
   [Park, Sang Jun] Seoul Natl Univ, Coll Med, Dept Ophthalmol, Bundang Hosp, Seongnam, South Korea.
C3 Sungkyunkwan University (SKKU); Seoul National University (SNU)
RP Shin, JY (通讯作者)，Sungkyunkwan Univ, Sch Pharm, 2066 Seobu Ro, Suwon 16419, South Korea.
EM shin.jy@skku.edu
RI Lee, Hyesung/GPC-5111-2022; Park, Sang Jun/C-3234-2015
OI Park, Sang Jun/0000-0003-0542-2758; Jeon, Ha-Lim/0000-0002-9429-8711;
   Lee, Hyesung/0000-0001-6556-9984
FU Basic Science Research Program of the National Research Foundation of
   Korea (NRF) [NRF-2017R1C1B5017907]
FX This study was supported by a grant from the Basic Science Research
   Program of the National Research Foundation of Korea (NRF), which was
   founded by the Ministry of Education (Grant number:
   NRF-2017R1C1B5017907).
CR Chrysant Steven G, 2006, J Clin Hypertens (Greenwich), V8, P261, DOI 10.1111/j.1524-6175.2005.05264.x
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Congdon NG, 2003, JAMA-J AM MED ASSOC, V290, P2057, DOI 10.1001/jama.290.15.2057
   Etminan M, 2008, CURR DRUG SAF, V3, P24, DOI 10.2174/157488608783333952
   Forouzandeh F, 2014, J AM HEART ASSOC, V3, DOI 10.1161/JAHA.114.001202
   Geum-joon Cho，, 2017, Anesthesia and Pain Medicine, V12, P9
   Hall NF, 2001, BRIT MED J, V323, P375, DOI 10.1136/bmj.323.7309.375
   Klein R, 2003, ARCH OPHTHALMOL-CHIC, V121, P1151, DOI 10.1001/archopht.121.8.1151
   Kortekaas KE, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111952
   Ma L, 2015, SCI REP-UK, V5, DOI 10.1038/srep18280
   McCarty CA, 2001, MED J AUSTRALIA, V175, P340, DOI 10.5694/j.1326-5377.2001.tb143604.x
   McGwin G, 2005, OPHTHALMOLOGY, V112, P488, DOI 10.1016/j.ophtha.2004.10.027
   McGwin G, 2003, BRIT J OPHTHALMOL, V87, P1121, DOI 10.1136/bjo.87.9.1121
   National Health Insurance Service (NHIS), 2017, MAN NAT HLTH INS SER
   Oesterle A, 2017, CIRC RES, V120, P229, DOI 10.1161/CIRCRESAHA.116.308537
   Park BJ, 2003, REPORT EVALUATION VA
   Park SJ, 2015, OPHTHALMOLOGY, V122, P2063, DOI 10.1016/j.ophtha.2015.06.018
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P300, DOI 10.1001/archopht.125.3.300
   SEDGWICK P, 2014, BMJ-BRIT MED J, V348, DOI DOI 10.1136/BMJ.G1532
   Shin JY, 2011, J KOREAN MED SCI, V26, P1461, DOI 10.3346/jkms.2011.26.11.1461
   Smeeth L, 2005, BRIT J OPHTHALMOL, V89, P1171, DOI 10.1136/bjo.2004.064477
   Smith BT, 2007, CURR OPIN OPHTHALMOL, V18, P240, DOI 10.1097/ICU.0b013e32810c8e05
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   Suissa S, 2015, EPIDEMIOLOGY, V26, P242, DOI 10.1097/EDE.0000000000000221
   Thomas AS, 2015, RETINA-J RET VIT DIS, V35, P1964, DOI 10.1097/IAE.0000000000000603
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   Van Leeuwen R, 2004, OPHTHALMOLOGY, V111, P1169, DOI 10.1016/j.ophtha.2003.10.024
NR 27
TC 16
Z9 16
U1 0
U2 6
PU YONSEI UNIV COLL MEDICINE
PI SEOUL
PA 50-1 YONSEI-RO, SEODAEMUN-GU, SEOUL 120-752, SOUTH KOREA
SN 0513-5796
EI 1976-2437
J9 YONSEI MED J
JI Yonsei Med. J.
PD JUL
PY 2019
VL 60
IS 7
BP 679
EP 686
DI 10.3349/ymj.2019.60.7.679
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA IF4LH
UT WOS:000473052300011
PM 31250582
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU van Zeeburg, EJT
   van Meurs, JC
AF van Zeeburg, Elsbeth J. T.
   van Meurs, Jan C.
TI Literature Review of Recombinant Tissue Plasminogen Activator Used for
   Recent-Onset Submacular Hemorrhage Displacement in Age-Related Macular
   Degeneration
SO OPHTHALMOLOGICA
LA English
DT Review
DE Age-related macular degeneration; Recombinant tissue plasminogen
   activator; Hemorrhage
ID EXPERIMENTAL SUBRETINAL HEMORRHAGE; PNEUMATIC DISPLACEMENT; INTRAVITREAL
   INJECTION; BEVACIZUMAB AVASTIN; RETINAL TOXICITY; GAS INJECTION;
   EXPANSILE GAS; NATURAL-HISTORY; MANAGEMENT; SECONDARY
AB Aims: To review and discuss the literature on recombinant tissue plasminogen activator (rtPA) for the treatment of a recent-onset submacular hemorrhage in patients with age-related macular degeneration. Methods: The administration technique of rtPA, the use of additional gas and vascular endothelial growth factor inhibitors (anti-VEGF), and the displacement rate of submacular hemorrhage and complications were noted from published reports, and a case series from the Rotterdam Eye Hospital (REH). Results: 38 studies with a total of 1,185 patients (1,176 eyes), and 28 patients from the REH were analyzed. Several methods for rtPA administration are available, which can be divided into two groups: submacular rtPA administration with vitrectomy; or intravitreal rtPA administration without vitrectomy. In both groups, the administration of gas and/or anti-VEGF agents could be additional. There appears to be no clear difference in complete displacement or complication rate between the more or the less invasive treatment groups. Conclusion: Although intravitreal injection of rtPA and gas only was reported to be as effective as subretinal rtPA with vitrectomy and gas, recent studies tend to use vitrectomy. These data underscore the need for a randomized controlled trial to choose the most effective and safe method of rtPA administration. Copyright (C) 2012 S. Karger AG, Basel
C1 [van Zeeburg, Elsbeth J. T.] Rotterdam Ophthalm Inst, NL-3011 BH Rotterdam, Netherlands.
   [van Zeeburg, Elsbeth J. T.; van Meurs, Jan C.] Rotterdam Eye Hosp, Rotterdam, Netherlands.
   [van Meurs, Jan C.] Erasmus MC, Univ Med Ctr, Rotterdam, Netherlands.
C3 Rotterdam Eye Hospital; Erasmus University Rotterdam; Erasmus MC
RP van Zeeburg, EJT (通讯作者)，Rotterdam Ophthalm Inst, Schiedamse Vest 160-D, NL-3011 BH Rotterdam, Netherlands.
EM e.vanzeeburg@oogziekenhuis.nl
FU Rotterdam Eye Hospital Flieringa Research Foundation, Rotterdam, The
   Netherlands; Royal Visio, Rotterdam, The Netherlands
FX Funding/Support; (1) The Rotterdam Eye Hospital Flieringa Research
   Foundation, Rotterdam, The Netherlands.; (2) Royal Visio, Rotterdam, The
   Netherlands.
CR Ameri H, 2007, INVEST OPHTH VIS SCI, V48, P5708, DOI 10.1167/iovs.07-0731
   Arias L, 2010, CLIN OPHTHALMOL, V4, P67
   Avery RL, 1996, RETINA-J RET VIT DIS, V16, P183, DOI 10.1097/00006982-199616030-00001
   BENNER JD, 1994, OPHTHALMOLOGY, V101, P672
   BENNETT SR, 1990, AM J OPHTHALMOL, V109, P33, DOI 10.1016/S0002-9394(14)75575-8
   Bhisitkul RB, 2008, INVEST OPHTH VIS SCI, V49, P4071, DOI 10.1167/iovs.08-1892
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Buhl M, 1999, OPHTHALMOLOGE, V96, P792, DOI 10.1007/s003470050498
   BUNTMILAM AH, 1985, INVEST OPHTH VIS SCI, V26, P1377
   Cakir M, 2010, EUR J OPHTHALMOL, V20, P565, DOI 10.1177/112067211002000305
   Chen CY, 2007, RETINA-J RET VIT DIS, V27, P321, DOI 10.1097/01.iae.0000237586.48231.75
   Chen SN, 2003, OPHTHALMOLOGY, V110, P704, DOI 10.1016/S0161-6420(02)01979-6
   ELBABA F, 1986, OPHTHALMOLOGY, V93, P1581
   Fang IM, 2009, EYE, V23, P397, DOI 10.1038/sj.eye.6703017
   Feiner L, 2006, RETINA-J RET VIT DIS, V26, P882, DOI 10.1097/01.iae.0000230717.85319.f5
   Fine HF, 2010, RETINA-J RET VIT DIS, V30, P1588, DOI 10.1097/IAE.0b013e3181e2263c
   Framme C, 2000, KLIN MONATSBL AUGENH, V216, P33, DOI 10.1055/s-2000-10513
   GILLIES A, 1983, ANN OPHTHALMOL, V15, P1068
   GLATT H, 1982, AM J OPHTHALMOL, V94, P762, DOI 10.1016/0002-9394(82)90301-4
   Gopalakrishan M, 2007, RETINA-J RET VIT DIS, V27, P329, DOI 10.1097/01.iae.0000231544.43093.40
   Guthoff R, 2011, RETINA-J RET VIT DIS, V31, P36, DOI 10.1097/IAE.0b013e3181e37884
   Handwerger BA, 2001, ARCH OPHTHALMOL-CHIC, V119, P28
   Hassan AS, 1999, OPHTHALMOLOGY, V106, P1900, DOI 10.1016/S0161-6420(99)90399-8
   Hattenbach LO, 2001, OPHTHALMOLOGY, V108, P1485, DOI 10.1016/S0161-6420(01)00648-0
   Hattenbach LO, 2002, KLIN MONATSBL AUGENH, V219, P512, DOI 10.1055/s-2002-33584
   Haupert CL, 2001, AM J OPHTHALMOL, V131, P208, DOI 10.1016/S0002-9394(00)00734-0
   Heiduschka P, 2008, RETINA-J RET VIT DIS, V28, P46, DOI 10.1097/IAE.0b013e31815e9368
   Heriot WJ, 1996, INTRAVITREAL GAS TPA
   Hesse L, 1999, GRAEF ARCH CLIN EXP, V237, P273, DOI 10.1007/s004170050232
   Hillenkamp J, 2010, GRAEF ARCH CLIN EXP, V248, P5, DOI 10.1007/s00417-009-1158-7
   Holladay JT, 2004, J CATARACT REFR SURG, V30, P287, DOI 10.1016/j.jcrs.2004.01.014
   Hrach CJ, 2000, ARCH OPHTHALMOL-CHIC, V118, P659
   JOHNSON MW, 1990, ARCH OPHTHALMOL-CHIC, V108, P259, DOI 10.1001/archopht.1990.01070040111042
   Kamei M, 1999, AM J OPHTHALMOL, V128, P739, DOI 10.1016/S0002-9394(99)00239-1
   Kamei M, 2000, Semin Ophthalmol, V15, P44
   Kiernan DF, 2010, RETINA-J RET VIT DIS, V30, P1573, DOI 10.1097/IAE.0b013e3181e2266d
   Klettner A, 2012, ARCH OPHTHALMOL-CHIC, V130, P875, DOI 10.1001/archophthalmol.2012.120
   Krepler K, 2000, RETINA-J RET VIT DIS, V20, P251, DOI 10.1097/00006982-200003000-00005
   Kung YH, 2010, J OCUL PHARMACOL TH, V26, P469, DOI 10.1089/jop.2010.0066
   LEWIS H, 1994, AM J OPHTHALMOL, V118, P559, DOI 10.1016/S0002-9394(14)76571-7
   Lincoff H, 2008, RETINA-J RET VIT DIS, V28, P56, DOI 10.1097/IAE.0b013e31806e60db
   Luke M, 2007, BRIT J OPHTHALMOL, V91, P1077, DOI 10.1136/bjo.2006.111260
   Lux A, 2007, BRIT J OPHTHALMOL, V91, P1318, DOI 10.1136/bjo.2006.113902
   Manzano RPA, 2006, RETINA-J RET VIT DIS, V26, P257, DOI 10.1097/00006982-200603000-00001
   Matt G, 2010, KLIN MONATSBL AUGENH, V227, P221, DOI 10.1055/s-0028-1109750
   Mayer WJ, 2013, ACTA OPHTHALMOL, V91, P274, DOI 10.1111/j.1755-3768.2011.02264.x
   Meier P, 1999, OPHTHALMOLOGE, V96, P643, DOI 10.1007/s003470050467
   Meyer CH, 2008, ACTA OPHTHALMOL, V86, P490, DOI 10.1111/j.1600-0420.2007.01125.x
   Mizutani T, 2011, GRAEF ARCH CLIN EXP, V249, P1153, DOI 10.1007/s00417-011-1649-1
   Morse LS, 1996, BRIT J OPHTHALMOL, V80, P658, DOI 10.1136/bjo.80.7.658
   Ohji M, 1998, ARCH OPHTHALMOL-CHIC, V116, P1326, DOI 10.1001/archopht.116.10.1326
   Olivier S, 2004, OPHTHALMOLOGY, V111, P1201, DOI 10.1016/j.ophtha.2003.10.020
   RANBY M, 1982, THROMB RES, V27, P175, DOI 10.1016/0049-3848(82)90197-9
   Ratanasukon M, 2005, EYE, V19, P1328, DOI 10.1038/sj.eye.6701769
   Ron Y, 2007, OPHTHALMOLOGICA, V221, P57, DOI 10.1159/000096524
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sacu S, 2009, EYE, V23, P1404, DOI 10.1038/eye.2008.267
   Sandhu SS, 2010, CLIN OPHTHALMOL, V4, P637
   Sari A, 2009, RETINA-J RET VIT DIS, V29, P1346, DOI 10.1097/IAE.0b013e3181b26343
   Schulze SD, 2002, GRAEF ARCH CLIN EXP, V240, P717, DOI 10.1007/s00417-002-0516-5
   Scupola A, 1999, OPHTHALMOLOGICA, V213, P97, DOI 10.1159/000027400
   Singh RP, 2006, BRIT J OPHTHALMOL, V90, P429, DOI 10.1136/bjo.2005.085001
   Stopa M, 2007, RETINA-J RET VIT DIS, V27, P370, DOI 10.1097/IAE.0b013e3180439bc9
   Thompson John T, 2005, Trans Am Ophthalmol Soc, V103, P98
   TOTH CA, 1991, ARCH OPHTHALMOL-CHIC, V109, P723, DOI 10.1001/archopht.1991.01080050139046
   Treumer F, 2010, BRIT J OPHTHALMOL, V94, P48, DOI 10.1136/bjo.2009.164707
   Treumer F, 2012, BRIT J OPHTHALMOL, V96, P708, DOI 10.1136/bjophthalmol-2011-300655
   Tsai San-Chang, 2003, Kaohsiung Journal of Medical Sciences, V19, P608
   Tsymanava A, 2012, ACTA OPHTHALMOL, V90, P633, DOI 10.1111/j.1755-3768.2011.02115.x
   van Bilsen K, 2011, BRIT J OPHTHALMOL, V95, P864, DOI 10.1136/bjo.2010.187930
   Wu TT, 2011, RETINA-J RET VIT DIS, V31, P2071, DOI 10.1097/IAE.0b013e31822528c8
   Yang Po-Min, 2005, Chang Gung Med J, V28, P852
NR 72
TC 50
Z9 51
U1 0
U2 5
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2013
VL 229
IS 1
BP 1
EP 14
DI 10.1159/000343066
PG 14
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 057TH
UT WOS:000312586400001
PM 23075629
OA Bronze
DA 2022-11-30
ER

PT J
AU Jackson, TL
   Kirkpatrick, L
   Tang, G
   Prasad, S
AF Jackson, T. L.
   Kirkpatrick, L.
   Tang, G.
   Prasad, S.
TI Cost analysis comparing adjuvant epimacular brachytherapy with anti-VEGF
   monotherapy for the management of neovascular age-related macular
   degeneration
SO EYE
LA English
DT Article
DE epimacular brachytherapy; neovascular age-related macular degeneration;
   ranibizumab; bevacizumab; cost; health economics
ID RANIBIZUMAB; BEVACIZUMAB; SECONDARY; SAFETY
AB Aims To consider the cost implication of adopting epimacular brachytherapy (EMB) for the treatment of neovascular (wet) age-related macular degeneration (wAMD), compared with ranibizumab or bevacizumab monotherapy.
   Methods This analysis compared the cumulative 3-year costs of anti-VEGF (vascular endothelial growth factor) monotherapy to EMB combined with anti-VEGF therapy. Two patient groups were considered: newly diagnosed (treatment-naive) patients; and patients already receiving chronic anti-VEGF therapy.
   Results In the treatment-naive patients, the highest cumulative treatment costs were associated with ranibizumab monotherapy (25 pound 658), followed by bevacizumab monotherapy (16 pound 177), EMB with ranibizumab (14 pound 002), then EMB with bevacizumab (10 pound 289). In previously treated patients, the highest treatment costs were ranibizumab monotherapy (18 pound 355), followed by EMB with ranibizumab (17 pound 428), bevacizumab monotherapy (16 pound 177), then EMB with bevacizumab (12 pound 129).
   Conclusion EMB combined with anti-VEGF treatment has the potential to yield considerable cost savings, compared with anti-VEGF monotherapy. If the ongoing large studies of EMB confirm the published feasibility data, then adjuvant EMB may represent a cost-effective alternative to anti-VEGF monotherapy. Eye (2012) 26, 557-563; doi:10.1038/eye.2011.351; published online 20 January 2012
C1 [Jackson, T. L.; Kirkpatrick, L.] Kings Coll Hosp London, Dept Ophthalmol, London, England.
   [Jackson, T. L.] Kings Coll London, Sch Med, London WC2R 2LS, England.
   [Tang, G.] Quorum Consulting, San Francisco, CA USA.
   [Prasad, S.] Arrowe Pk Hosp, Dept Ophthalmol, Wirral, Merseyside, England.
C3 King's College Hospital NHS Foundation Trust; King's College Hospital;
   University of London; King's College London
RP Jackson, TL (通讯作者)，Kings Coll Hosp London, Dept Ophthalmol, London, England.
EM t.jackson1@nhs.net
RI Prasad, Som/AEZ-0065-2022
OI Jackson, Timothy/0000-0001-7618-1555
FU NeoVista; Novartis; Oraya and Thrombogenics; DORC; Alcon; Allergan
FX T Jackson has received research funding from NeoVista, Novartis, Oraya
   and Thrombogenics. He is on the advisory board of Bausch and Lomb, DORC
   and Oraya, and has been a consultant to Merck and NicOx. He has received
   conference support from DORC and NeoVista. S Prasad is a consultant for
   Bausch and Lomb, and Nidek. He has also received a conference support
   from Alcon, Allergan, and Novartis. L Kirkpatrick and Quorum Consulting
   received funding from NeoVista.
CR Avila MP, 2009, BRIT J OPHTHALMOL, V93, P305, DOI 10.1136/bjo.2008.145912
   Avila MP, 2012, RETINA-J RET VIT DIS, V32, P10, DOI 10.1097/IAE.0b013e31822528fc
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Bunce C, 2006, BMC PUBLIC HEALTH, V6, DOI 10.1186/1471-2458-6-58
   Dugel P, OPHTHALMOLO IN PRESS
   Excellence N.I.f.H.a.C., 2008, NICE TECHN APPR GUID
   Jackson TL, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5058
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   MHP, 2011, PATH GP COMM
   Minassian DC, 2011, BRIT J OPHTHALMOL, V95, P1433, DOI 10.1136/bjo.2010.195370
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   The Royal College of Ophthalmologists, 2007, COMM CONT AMD SERV G
NR 12
TC 6
Z9 7
U1 0
U2 4
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD APR
PY 2012
VL 26
IS 4
BP 557
EP 563
DI 10.1038/eye.2011.351
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 927VN
UT WOS:000302938500011
PM 22261737
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Nassisi, M
   Tepelus, T
   Corradetti, G
   Sadda, SR
AF Nassisi, Marco
   Tepelus, Tudor
   Corradetti, Giulia
   Sadda, Srinivas R.
TI Relationship Between Choriocapillaris Flow and Scotopic Microperimetry
   in Early and Intermediate Age-related Macular Degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
AB PURPOSE: To evaluate the correlation between choriocapillaris (CC) flow alterations and scotopic macular sensitivity (sMS) in patients with early and intermediate age-related macular degeneration (AMD).
   DESIGN: Prospective cross-sectional study.
   METHODS: We acquired 2 3 X 3 mm and 2 6 X 6 mm swept-source optical coherence tomography angiography (OCTA) images of 1 eye of consecutive early or intermediate AMD patients at the Doheny UCLA Eye Centers. After 30 minutes of dark adaptation, the same eye underwent scotopic microperimetry with an 18-degree-wide grid (52 stimuli) centered on the fovea. The 2 en face CC angiograms obtained from each scan pattern were compensated for signal loss and averaged. The main outcome measures were correlation between percentages of flow deficits (FD(3mm )and FD6mm) and sMS in the central 10 degrees (MS10) and the overall pattern (MS18).
   RESULTS: Thirty eyes of 30 patients were enrolled, with 14 (46.7%) having subretinal drusenoid deposits (SDD). In the averaged OCTA scans, the FD3mm was 12.56% +/- 2.41% while the FD6mm was 9.33% +/- 1.84%. The mean MS10 and MS18 were 13.84 +/- 5.89 dB and 14.64 +/- 5.21 dB, respectively. For the MS10, the multivariate regression analysis showed a significant association only with FD3mm (beta: - 0.628, P < .001) while the MS18 was significantly correlated with both SDD (beta: -0.32, P = .047) and FD6mm (beta: - 0.473, P = .005).
   CONCLUSIONS: Our study reports a significant correlation between the CC flow impairment and the sMS in eyes with early or intermediate AMD. If replicated in future longitudinal studies, the choriocapillaris FD may prove to be a useful parameter for evaluating the functional status and prognosis of these eyes. (C) 2020 Elsevier Inc. All rights reserved.
C1 Doheny Eye Inst, Doheny Image Reading Ctr, 1355 San Pablo St, Los Angeles, CA 90033 USA.
   Univ Calif Los Angeles, David Geffen Sch Med, Dept Ophthalmol, Los Angeles, CA 90095 USA.
C3 Doheny Eye Institute; University of California System; University of
   California Los Angeles; University of California Los Angeles Medical
   Center; David Geffen School of Medicine at UCLA
RP Sadda, SR (通讯作者)，1355 San Pablo St,Suite 211, Los Angeles, CA 90033 USA.
EM SSadda@doheny.org
RI Corradetti, Giulia/Q-5400-2019; Nassisi, Marco/P-9939-2019
OI Corradetti, Giulia/0000-0001-9213-5575; Nassisi,
   Marco/0000-0002-9354-9005
CR Alagorie AR, 2019, AM J OPHTHALMOL, V205, P132, DOI 10.1016/j.ajo.2019.04.037
   An D, 2018, EXP EYE RES, V170, P13, DOI 10.1016/j.exer.2018.02.006
   Balaratnasingam C, 2018, AM J OPHTHALMOL, V189, P55, DOI 10.1016/j.ajo.2018.02.007
   Biesemeier A, 2014, NEUROBIOL AGING, V35, P2562, DOI 10.1016/j.neurobiolaging.2014.05.003
   Borrelli E, 2018, AM J OPHTHALMOL, V196, P34, DOI 10.1016/j.ajo.2018.08.014
   Borrelli E, 2018, INVEST OPHTH VIS SCI, V59, DOI 10.1167/iovs.18-23943
   Byon I, 2019, AM J OPHTHALMOL, V208, P397, DOI 10.1016/j.ajo.2019.08.026
   Camino A, 2019, NEUROPHOTONICS, V6, DOI 10.1117/1.NPh.6.4.041108
   Cavallotti C, 2004, CAN J OPHTHALMOL, V39, P61, DOI 10.1016/S0008-4182(04)80054-1
   Chen KG, 2019, OPHTHALMOLOGY, V126, P856, DOI 10.1016/j.ophtha.2018.09.039
   Choi W, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081499
   Curcio CA, 2000, INVEST OPHTH VIS SCI, V41, P2015
   Curcio CA, 2001, EYE, V15, P376, DOI 10.1038/eye.2001.140
   CURCIO CA, 1993, INVEST OPHTH VIS SCI, V34, P3278
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   Feigl B, 2006, CURR EYE RES, V31, P635, DOI 10.1080/02713680600762739
   Ferrari S, 2011, CURR GENOMICS, V12, P238, DOI 10.2174/138920211795860107
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Jackson GR, 2000, VISION RES, V40, P2467, DOI 10.1016/S0042-6989(00)00108-5
   Jackson Gregory R, 2008, J Ocul Biol Dis Infor, V1, P7, DOI 10.1007/s12177-008-9002-6
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   KORTE GE, 1984, INVEST OPHTH VIS SCI, V25, P1135
   Lee B, 2018, INVEST OPHTH VIS SCI, V59, P5246, DOI 10.1167/iovs.17-23600
   Luu CD, 2018, OPHTHALMOL RETINA, V2, P1206, DOI 10.1016/j.oret.2018.06.016
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Morales MU, 2016, TRANSL VIS SCI TECHN, V5, DOI 10.1167/tvst.5.6.6
   Moult EM, 2016, RETINA-J RET VIT DIS, V36, pS2, DOI 10.1097/IAE.0000000000001287
   Nassisi M, 2019, OPHTHALMOLOGY, V126, P1667, DOI 10.1016/j.ophtha.2019.05.016
   Nassisi M, 2019, GRAEF ARCH CLIN EXP, V257, P2079, DOI 10.1007/s00417-019-04403-1
   Nassisi M, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0212563
   Nassisi M, 2019, BRIT J OPHTHALMOL, V103, P911, DOI 10.1136/bjophthalmol-2018-312643
   Nebbioso M, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/671529
   Nesper PL, 2017, AM J OPHTHALMOL, V174, P42, DOI 10.1016/j.ajo.2016.10.005
   Owsley C, 2000, INVEST OPHTH VIS SCI, V41, P267
   Owsley C, 2007, OPHTHALMOLOGY, V114, P1728, DOI 10.1016/j.ophtha.2006.12.023
   Schmitz-Valckenberg S, 2009, RETINA-J RET VIT DIS, V29, P1314, DOI 10.1097/IAE.0b013e3181a4d2f1
   Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089
   Spaide RF, 2018, SURV OPHTHALMOL, V63, P782, DOI 10.1016/j.survophthal.2018.05.005
   Spaide RF, 2018, PROG RETIN EYE RES, V64, P1, DOI 10.1016/j.preteyeres.2017.11.003
   Spaide RF, 2015, RETINA-J RET VIT DIS, V35, P2163, DOI 10.1097/IAE.0000000000000765
   Spaide RF, 2015, JAMA OPHTHALMOL, V133, P45, DOI 10.1001/jamaophthalmol.2014.3616
   Steinberg JS, 2015, JAMA OPHTHALMOL, V133, P690, DOI 10.1001/jamaophthalmol.2015.0477
   Thulliez M, 2019, OPHTHALMOL RETINA, V3, P478, DOI 10.1016/j.oret.2019.01.024
   Uji A, 2019, GRAEF ARCH CLIN EXP, V257, P1679, DOI 10.1007/s00417-019-04368-1
   Uji A, 2017, OPHTHALMOLOGY, V124, P944, DOI 10.1016/j.ophtha.2017.02.006
   Vujosevic S, 2019, ACTA OPHTHALMOL, V97, pE919, DOI 10.1111/aos.14088
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P1612, DOI 10.1016/j.ophtha.2014.02.005
   Zeitz C, 2015, PROG RETIN EYE RES, V45, P58, DOI 10.1016/j.preteyeres.2014.09.001
   Zhang QQ, 2018, QUANT IMAG MED SURG, V8, P658, DOI 10.21037/qims.2018.08.10
   Zhang QQ, 2018, INVEST OPHTH VIS SCI, V59, P203, DOI 10.1167/iovs.17-22953
   Zhang QQ, 2017, OPHTHALMOL RETINA, V1, P124, DOI 10.1016/j.oret.2016.08.005
NR 51
TC 11
Z9 11
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD FEB
PY 2021
VL 222
BP 302
EP 309
DI 10.1016/j.ajo.2020.04.018
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA QR9UO
UT WOS:000625556500002
PM 32360341
DA 2022-11-30
ER

PT J
AU Schulze, S
   Neugebauer, A
   Kroll, P
AF Schulze, Stephan
   Neugebauer, Arne
   Kroll, Peter
TI Appearance of age-related macular degeneration in vitrectomized and
   nonvitrectomized eyes: an intraindividual case study
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE abnormal vitreous attachment; age-related macular degeneration; pars
   plana vitrectomy; posterior vitreous detachment; vitreomacular traction
ID POSTERIOR VITREOUS DETACHMENT; CHOROIDAL NEOVASCULARIZATION;
   VITREOMACULAR TRACTION; PHOTODYNAMIC THERAPY; RISK; ADHESION; HOLE
AB . Purpose: This study analyses the consequences of vitreoretinal traction on the macula and in particular the impact of a vitrectomy on the development of the age-related macular degeneration (ARMD). Methods: In this retrospective case study, 42 eyes of 21 subjects were examined. The vitreous of one eye must have been removed by vitrectomy at least 8 years ago. At that point in time, the patients had to be at least 50 years old, with a healthy vitreous body of the other eye and a healthy macula in both eyes. Both eyes were examined using an optical coherence tomography (OCT) scan, B-scan ultrasound, a binocular slit-lamp funduscopy and a fluorescence angiography (FAG) to evaluate the potential development stage of an ARMD and the vitreous status. Results: In the follow-up examination, the patients had an average age of 73.6 years. In 0 of 21 vitrectomized eyes (0%), there were signs for an early ARMD. In 5 of 21 nonvitrectomized eyes (23.8%), we found ARMD-like changes in the angiography and slit-lamp examinations. Of these 21 eyes, five eyes presented persistent attachment of the posterior vitreous cortex to the macula, while 16 eyes showed complete posterior vitreous detachment. All five eyes (100%) with premonitory signs of an ARMD showed persistent attachment of the posterior vitreous to the macula. Conclusion: We demonstrated a positive relationship between a persistent attachment of the posterior vitreous cortex to the macula and early signs of ARMD. Although the precise mechanism of this relationship remains unclear, the role of chronic low-grade inflammation, chronic oxidative and mechanical stress and an increase in VEGF is discussed. Persistent vitreous attachment is likely to be another risk factor for ARMD.
C1 [Schulze, Stephan; Kroll, Peter] Univ Marburg, Dept Ophthalmol, D-35032 Marburg, Germany.
   [Neugebauer, Arne] Univ Marburg, Dept Med, D-35032 Marburg, Germany.
C3 Philipps University Marburg; Philipps University Marburg
RP Schulze, S (通讯作者)，Univ Hosp Marburg, Dept Ophthalmol, Robert Koch Str 4, D-35033 Marburg, Germany.
EM schulzes@med.uni-marburg.de
RI Meyer, Carsten/A-3981-2017
OI Meyer, Carsten/0000-0002-0530-5298
CR GASS JDM, 1988, ARCH OPHTHALMOL-CHIC, V106, P629, DOI 10.1001/archopht.1988.01060130683026
   Gulkilik G, 2006, CAN J OPHTHALMOL, V41, P699, DOI 10.1139/I06-062
   Hayreh SS, 2004, OPHTHALMOLOGICA, V218, P333, DOI 10.1159/000079476
   Hoerle S, 2002, GRAEF ARCH CLIN EXP, V240, P197, DOI 10.1007/s00417-002-0432-8
   Kishi S, 1996, AM J OPHTHALMOL, V122, P622, DOI 10.1016/S0002-9394(14)70480-5
   Krebs I, 2009, SPEKTRUM AUGENHEILKD, V23, P2, DOI 10.1007/s00717-009-0309-x
   Krebs I, 2007, AM J OPHTHALMOL, V144, P741, DOI 10.1016/j.ajo.2007.07.024
   LAMBERT HM, 1992, AM J OPHTHALMOL, V113, P257, DOI 10.1016/S0002-9394(14)71576-4
   Lee SJ, 2009, AM J OPHTHALMOL, V147, P621, DOI 10.1016/j.ajo.2008.10.003
   Ondes F, 2000, JPN J OPHTHALMOL, V44, P91, DOI 10.1016/S0021-5155(99)00174-4
   PERICHON JY, 1993, J FR OPHTALMOL, V16, P538
   Quaranta-El Maftouhi M, 2006, EUR J OPHTHALMOL, V16, P134
   Quiram PA, 2007, RETINA-J RET VIT DIS, V27, P1090, DOI 10.1097/IAE.0b013e3180654229
   Robison CD, 2009, AM J OPHTHALMOL, V148, P79, DOI 10.1016/j.ajo.2009.01.014
   Sahni J, 2005, BRIT J OPHTHALMOL, V89, P316, DOI 10.1136/bjo.2004.043364
   Schmidt JC, 2006, BRIT J OPHTHALMOL, V90, P1361, DOI 10.1136/bjo.2006.094201
   Schulze S, 2008, ACTA OPHTHALMOL, V86, P470, DOI 10.1111/j.1755-3768.2008.01210.x
   Sebag J, 2004, GRAEF ARCH CLIN EXP, V242, P690, DOI 10.1007/s00417-004-0980-1
   Stefansson E, 2009, GRAEF ARCH CLIN EXP, V247, P147, DOI 10.1007/s00417-008-0980-7
   Weber-Krause Brigitte, 1996, Ophthalmologe, V93, P660, DOI 10.1007/s003470050054
NR 20
TC 9
Z9 9
U1 0
U2 3
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1755-375X
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD MAY
PY 2012
VL 90
IS 3
BP 244
EP 247
DI 10.1111/j.1755-3768.2010.01929.x
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 932SS
UT WOS:000303311400030
PM 20491689
OA Bronze
DA 2022-11-30
ER

PT J
AU Nitsch, D
   Douglas, I
   Smeeth, L
   Fletcher, A
AF Nitsch, Dorothea
   Douglas, Ian
   Smeeth, Liam
   Fletcher, Astrid
TI Age-related Macular Degeneration and Complement Activation-related
   Diseases A Population-Based Case-Control Study
SO OPHTHALMOLOGY
LA English
DT Article
ID IDIOPATHIC MEMBRANOUS NEPHROPATHY; PRACTICE RESEARCH DATABASE; DENSE
   DEPOSIT DISEASE; FACTOR-H POLYMORPHISM; MEMBRANOPROLIFERATIVE
   GLOMERULONEPHRITIS; DRUSEN FORMATION; ACUTE INFECTION; RENAL-DISEASE;
   RISK-FACTORS; INCREASES
AB Objective: Recent evidence suggests an important role for the complement system in the etiology of age-related macular degeneration (AMD). We aimed to investigate whether other diseases known to be associated with complement activation are associated with AMD.
   Design: Case-control study.
   Participants: We reviewed medical records from the United Kingdom General Practice Research Database (GPRD). Cases (n = 18 007) were defined as people aged >= 50 years with a first diagnosis of AMD while registered with a practice included in the GPRD between 1987 and 2002. For each case, 5 controls with no record of AMD (n = 86 169) were matched by gender, practice, and age (within 5 years).
   Methods: Records were searched for diagnoses of systemic lupus erythematosus (SLE), glomerulonephritis, and diabetic nephropathy occurring before the AMD diagnosis date (or equivalent date for controls).
   Main Outcome Measures: Diagnosis of AMD.
   Results: A diagnosis of SLE was found in 0.07% of controls and 0.13% of AMD cases (confounder-adjusted odds ratio [OR], 1.69; 95% confidence interval [CI], 1.05-2.72). Glomerulonephritis was diagnosed in 0.13% of controls and 0.2% of cases (adjusted OR 1.46; 95% Cl, 0.99-2.13). Diabetic nephropathy was strongly associated with AMD with an adjusted OR of 3.00 and a 95% Cl of 1.55-5.97, which was independent of the association of diabetes with AMD.
   Conclusions: Specific diseases that are associated with complement activation are also associated with AMD. The impact of diabetic nephropathy on AMD may be larger than previously recognized.
   Financial Disclosure(s): The authors have no proprietary or commercial interest in any materials discussed in this article. Ophthalmology 2008;115:1904-1910 (C) 2008 by the American Academy of Ophthalmology.
C1 [Nitsch, Dorothea; Douglas, Ian; Smeeth, Liam; Fletcher, Astrid] Univ London London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, London WC1E 7HT, England.
C3 University of London; London School of Hygiene & Tropical Medicine
RP Nitsch, D (通讯作者)，Univ London London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, Keppel St, London WC1E 7HT, England.
EM Dorothea.Nitsch@lshtm.ac.uk
RI ; Smeeth, Liam/X-5862-2018
OI Nitsch, Dorothea/0000-0001-5767-248X; Smeeth, Liam/0000-0002-9168-6022
FU Medical Research Council Funding Source: Medline; Wellcome Trust
   [082178] Funding Source: Medline
CR Acosta J, 2000, P NATL ACAD SCI USA, V97, P5450, DOI 10.1073/pnas.97.10.5450
   Acosta J, 2004, CURR PHARM DESIGN, V10, P203, DOI 10.2174/1381612043453441
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Appel GB, 2005, J AM SOC NEPHROL, V16, P1392, DOI 10.1681/ASN.2005010078
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   BRAI M, 1988, J CLIN IMMUNOL, V8, P50, DOI 10.1007/BF00915156
   Cho EY, 2000, ARCH OPHTHALMOL-CHIC, V118, P681, DOI 10.1001/archopht.118.5.681
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Endo M, 2004, NEPHRON CLIN PRACT, V97, pC147, DOI 10.1159/000079174
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hageman GS, 2006, ANN MED, V38, P592, DOI 10.1080/07853890601097030
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hallan S, 2006, AM J KIDNEY DIS, V47, P396, DOI 10.1053/j.ajkd.2005.11.027
   Hallan SI, 2006, BMJ-BRIT MED J, V333, P1047, DOI 10.1136/bmj.39001.657755.BE
   JICK HJ, 2001, BRIT MED J, V302, P766
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   KON SP, 1995, KIDNEY INT, V48, P1953, DOI 10.1038/ki.1995.496
   Lawson DH, 1998, QJM-MON J ASSOC PHYS, V91, P445, DOI 10.1093/qjmed/91.6.445
   Liew G, 2008, J AM SOC NEPHROL, V19, P806, DOI 10.1681/ASN.2007080844
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Mathieson PW, 1998, KIDNEY INT, V54, P1429, DOI 10.1046/j.1523-1755.1998.00129.x
   Mollnes TE, 2007, MOL IMMUNOL, V44, P3838, DOI 10.1016/j.molimm.2007.06.150
   Morita Y, 2000, J AM SOC NEPHROL, V11, P700, DOI 10.1681/ASN.V114700
   Mullins RF, 2001, EYE, V15, P390, DOI 10.1038/eye.2001.142
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   *OFF NAT STAT, 2000, STAND OCC CLASS 2000, V2, P4
   Papagianni AA, 2002, NEPHROL DIAL TRANSPL, V17, P57, DOI 10.1093/ndt/17.1.57
   Pickering MC, 2008, CLIN EXP IMMUNOL, V151, P210, DOI 10.1111/j.1365-2249.2007.03574.x
   Rao PV, 2007, DIABETES CARE, V30, P629, DOI 10.2337/dc06-2056
   Rodriguez LAG, 1998, BRIT J CLIN PHARMACO, V45, P419
   Ruiz-Irastorza G, 2001, LANCET, V357, P1027, DOI 10.1016/S0140-6736(00)04239-2
   Seelen MA, 2006, AUTOIMMUNITY, V39, P411, DOI 10.1080/08916930600739688
   Skattum L, 1997, J INTERN MED, V242, P455, DOI 10.1111/j.1365-2796.1997.tb00018.x
   Smeeth L, 2004, NEW ENGL J MED, V351, P2611, DOI 10.1056/NEJMoa041747
   Smeeth L, 2006, LANCET, V367, P1075, DOI 10.1016/S0140-6736(06)68474-2
   Smeeth L, 2005, BRIT J OPHTHALMOL, V89, P1171, DOI 10.1136/bjo.2004.064477
   Smith KD, 2005, CURR OPIN NEPHROL HY, V14, P396, DOI 10.1097/01.mnh.0000172729.60122.f9
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Smith W, 1996, AM J OPHTHALMOL, V122, P743, DOI 10.1016/S0002-9394(14)70503-3
   Thompson CL, 2007, HUM MOL GENET, V16, P2135, DOI 10.1093/hmg/ddm164
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
NR 45
TC 24
Z9 24
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
J9 OPHTHALMOLOGY
JI Ophthalmology
PD NOV
PY 2008
VL 115
IS 11
BP 1904
EP 1910
DI 10.1016/j.ophtha.2008.06.035
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 365ZO
UT WOS:000260448900008
PM 18801575
DA 2022-11-30
ER

PT J
AU Gong, Y
   Zhan, Y
   Yuan, T
   Liao, YH
   Zhang, LY
   Liu, XT
   Zheng, YH
   Bao, YB
AF Gong, Yan
   Zhan, Yu
   Yuan, Tao
   Liao, Yanhong
   Zhang, Lingyi
   Liu, Xiaotian
   Zheng, Yuanhao
   Bao, Yongbo
TI Association of HTRA1 and CFH gene polymorphisms with age-related macular
   degeneration in Ningbo, China
SO INTERNATIONAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; CFH; HTRA1; SNP; Correlation
ID FACTOR-H GENE; VARIANT; RISK; LOC387715; AMD
AB Background Age-related macular degeneration (AMD) is one of the major causes of blindness, and the incidence of this disease has been increasing in recent years.
   Objective To investigate the association between the single nucleotide polymorphisms (SNPs) of the high temperature requirement factor A-1 (HTRA1) and complement factor H (CFH) genes and susceptibility to AMD in Ningbo, China.
   Methods Ninety-eight patients with AMD and seventy-three controls were recruited at the Sixth Hospital of Ningbo from August 2017 to April 2019 in China. Genomic DNA was extracted from the venous blood provided by the hospital, and the genotypes of the AMD susceptibility genes CFH and HTAR1 were detected by polymerase chain reaction and sequenced directly. The SNPs rs11200638 on the HTRA1 gene and rs3753394 on the CFH gene were selected for genotype and association analysis. The correlations between the different genotypes of HTRA1 and CFH and AMD were analysed by the Chi-squared test.
   Results All the genotypes adhered to the Hardy-Weinberg equilibrium. There were three genotypes (AA, AG and GG) in HTRA1 (rs11200638). The differences in genotypes and allele frequency between the AMD group and the control group were statistically significant (P < 0.05). The A allele was a risk allele (OR: 4.19, 95% Cl: 2.28 similar to 7.70, P < 0.05), with a frequency of 61.7% in patients versus 43.8% in controls. However, the rs3753394 SNP in CFH was not associated with AMD in our study (P > 0.05).
   Conclusions The rs11200638 SNP of the HTRA1 gene is associated with AMD, and the AA genotype is a risk factor for AMD in the Ningbo population. There is no significant correlation between the rs3753394 SNP of the CFH gene and AMD.
C1 [Gong, Yan; Yuan, Tao; Liao, Yanhong; Zhang, Lingyi; Liu, Xiaotian; Zheng, Yuanhao] Ningbo Eye Hosp, Dept Eyes, Ningbo 315000, Peoples R China.
   [Zhan, Yu; Bao, Yongbo] Zhejiang Wanli Univ, Coll Biol & Environm Sci, Ningbo 315100, Peoples R China.
   [Zhan, Yu] Shanghai Ocean Univ, Coll Fisheries & Life Sci, Shanghai 201306, Peoples R China.
C3 Zhejiang Wanli University; Shanghai Ocean University
RP Bao, YB (通讯作者)，Zhejiang Wanli Univ, Coll Biol & Environm Sci, Ningbo 315100, Peoples R China.
EM bobbao2001@gmail.com
OI Liu, Xiaotian/0000-0003-1331-9718; Bao, Yongbo/0000-0002-8268-1887
FU Natural science foundation of Zhejiang Province [LY19H120001]; Zhejiang
   Province Traditional Chinese Medicine Science and Technology Plan
   Project [2018ZA111]; Ningbo Leading and Outstanding Talents Cultivation
   Project Selects and Supports Scientific Research Projects; Ningbo
   Yinzhou District Science and Technology Bureau Agricultural and Social
   Science and Technology Plan Project [110]; Ningbo Natural Science
   Foundation [2019A610353]; Ningbo Yinzhou District Agriculture and Social
   Development Science and Technology Plan Project [74]; Ningbo Public
   Welfare Science and Technology Plan Project [2019C50059]
FX This study was funded by Natural science foundation of Zhejiang Province
   (LY19H120001), Zhejiang Province Traditional Chinese Medicine Science
   and Technology Plan Project (2018ZA111), Ningbo Leading and Outstanding
   Talents Cultivation Project Selects and Supports Scientific Research
   Projects, Ningbo Public Welfare Science and Technology Plan Project
   2019C50059, Ningbo Yinzhou District Science and Technology Bureau
   Agricultural and Social Science and Technology Plan Project (Yinke
   [2017] No. 110) and Ningbo Natural Science Foundation (2019A610353),
   Ningbo Yinzhou District Agriculture and Social Development Science and
   Technology Plan Project (Yinke [2018] No. 74).
CR Abbas RO, 2013, OPHTHALMIC GENET, V34, P209, DOI 10.3109/13816810.2012.762934
   Ayub H, 2019, ANN HUM GENET, V83, P285, DOI 10.1111/ahg.12311
   Bonyadi MHJ, 2019, INT OPHTHALMOL, V39, P949, DOI 10.1007/s10792-018-0853-y
   Bonyadi MHJ, 2017, INT OPHTHALMOL, V37, P1397, DOI 10.1007/s10792-016-0413-2
   Chen L., 2007, SCI FISH FARM, V2, P1, DOI DOI 10.1016/j.ajo.2006.12.019
   Churchill AJ, 2006, HUM MOL GENET, V15, P2955, DOI 10.1093/hmg/ddl238
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Dong L, 2011, NEUROSCI LETT, V488, P283, DOI 10.1016/j.neulet.2010.11.048
   Fang K, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/821918
   Gourgouli K, 2020, INT OPHTHALMOL, V40, P985, DOI 10.1007/s10792-019-01274-7
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Jiang H, 2003, CANCER CELL INT, V3, DOI 10.1186/1475-2867-3-2
   Kassem H, 2017, MIDDLE E J MED GENET, V6, P22, DOI [10.1097/01.MXE.0000512347.39933.9c, DOI 10.1097/01.MXE.0000512347.39933.9C]
   Kaur I, 2008, INVEST OPHTH VIS SCI, V49, P1771, DOI 10.1167/iovs.07-0560
   Lana TP, 2018, OPHTHALMIC GENET, V39, P46, DOI 10.1080/13816810.2017.1354382
   Lau LI, 2006, INVEST OPHTH VIS SCI, V47, P3242, DOI 10.1167/iovs.05-1532
   [李娜 Li Na], 2016, [中国全科医学, Chinese General Practice], V19, P724
   Liao X, 2016, ARCH GERONTOL GERIAT, V64, P123, DOI 10.1016/j.archger.2016.01.011
   Liu SC, 2019, BMC MED GENET, V20, DOI 10.1186/s12881-019-0756-4
   Lu F, 2007, VISION RES, V47, P3120, DOI 10.1016/j.visres.2007.08.010
   Mori K, 2007, J HUM GENET, V52, P636, DOI 10.1007/s10038-007-0162-1
   Rattner A, 2006, NAT REV NEUROSCI, V7, P860, DOI 10.1038/nrn2007
   Shijo T, 2020, INT OPHTHALMOL, V40, P2735, DOI 10.1007/s10792-020-01460-y
   Soheilian R, 2017, INT OPHTHALMOL, V37, P1161, DOI 10.1007/s10792-016-0373-6
   [王林妮 Wang Linni], 2010, [眼科研究, Ophthalmic Research], V28, P566
   [王云瑞 Wang Yunrui], 2003, [眼科研究, Ophthalmic Research], V21, P557
   Xu J, 2018, WORLD LATEST MED INF, V18, P15, DOI [10.19613/j.cnki.1671-3141.2018.53.008, DOI 10.19613/J.CNKI.1671-3141.2018.53.008]
   Xu YL, 2008, MOL VIS, V14, P1373
   Yan LY, 2018, RECENT ADV OPHTHALMO, V38, P851, DOI [10.13389/j.cnki.rao.2018.0201, DOI 10.13389/J.CNKI.RAO.2018.0201]
   Yang N, 2018, GUOJI YANKE ZAZHI, V18, P815, DOI DOI 10.3980/j.issn.1672-5123.2018.5.10
   Yang Y, 2012, MED RECAPITULATE, V18, P2954, DOI [10.3969/j.issn.1006-2084.2012.18.006, DOI 10.3969/J.ISSN.1006-2084.2012.18.006]
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Zhang Kaiyan, 2015, Zhonghua Yan Ke Za Zhi, V51, P236
   Zhang Y, 2017, RECENT ADV OPHTHALMO, V37, P379, DOI [10.13389/j.cnki.rao.2017.0097, DOI 10.13389/J.CNKI.RAO.2017.0097]
NR 34
TC 1
Z9 1
U1 7
U2 10
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0165-5701
EI 1573-2630
J9 INT OPHTHALMOL
JI Int. Ophthalmol.
PD MAR
PY 2021
VL 41
IS 3
BP 995
EP 1002
DI 10.1007/s10792-020-01655-3
EA JAN 2021
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA QT8ZB
UT WOS:000604222700006
PM 33387109
DA 2022-11-30
ER

PT J
AU Scheepers, R
   Pettet, GJ
   van Heijster, P
   Araujo, RP
AF Scheepers, Ronel
   Pettet, Graeme J.
   van Heijster, Peter
   Araujo, Robyn P.
TI Cholesterol Regulation in Age-Related Macular Degeneration: A Framework
   for Mathematical Modelling of Drusen Biogenesis
SO BULLETIN OF MATHEMATICAL BIOLOGY
LA English
DT Article
DE Macula; AMD; Drusen; Cholesterol; Homeostasis; Mathematical modelling
ID RETINAL-PIGMENT EPITHELIUM; DENSITY-LIPOPROTEIN RECEPTOR; CHOROIDAL
   NEOVASCULARIZATION; OXIDATIVE STRESS; LIPID-METABOLISM; BRUCHS MEMBRANE;
   BASAL DEPOSITS; RISK-FACTORS; EYES; RPE
AB In age-related macular degeneration (AMD), there is, in common with many other age-related diseases, the need to distinguish between changes in the ageing eye that lead to disease and those changes that are considered part of a healthy, ageing eye. Various studies investigating the multitude of mechanisms involved in the aetiology of AMD exist within the field of ophthalmology and related medical fields, yet many aspects of it remain poorly understood and only a limited number of therapies are available. A recent study relates drusen's topographically cellular characteristics to the neural retina's metabolic needs and associated cholesterol involvement within the retina. In particular, there is a need to fully understand the maintenance of cholesterol homeostasis in the retina to prevent normal ageing processes from being perturbed towards maculopathy. Here, we present an extensive review of the clinical and physiological features of the ageing retina, as well as mechanisms implicated in pathology, synthesised from a vast body of the published literature. We use this novel synthesis to construct a comprehensive process schematic, encompassing all key species and physiological processes such as nutrients, waste and lipoprotein management. We are therefore able to express these processes in a mathematical language via a comprehensive modelling framework, comprising a set of twenty-three equations spanning three distinct biological compartments. This very general modelling framework may now be adapted to more focused studies on individual mechanisms, processes or components underlying of the many facets of AMD. As an example of such a focused application, we conclude this article with a one-compartment, four-species model of the retinal pigment epithelium, which considers the parametric conditions under which either cholesterol homeostasis or unregulated accumulation of cholesterol may obtain in the ageing eye.
C1 [Scheepers, Ronel; Pettet, Graeme J.; van Heijster, Peter; Araujo, Robyn P.] Queensland Univ Technol, Sch Math Sci, Brisbane, Qld 4000, Australia.
   [Scheepers, Ronel; Pettet, Graeme J.; Araujo, Robyn P.] Inst Hlth & Biomed Innovat IHBI, 60 Musk Ave, Kelvin Grove, Qld 4059, Australia.
C3 Queensland University of Technology (QUT)
RP Araujo, RP (通讯作者)，Queensland Univ Technol, Sch Math Sci, Brisbane, Qld 4000, Australia.; Araujo, RP (通讯作者)，Inst Hlth & Biomed Innovat IHBI, 60 Musk Ave, Kelvin Grove, Qld 4059, Australia.
EM ronel.scheepers@hdr.qut.edu.au; r.araujo@qut.edu.au
RI Araujo, Robyn/AGF-8051-2022
OI van Heijster, Petrus/0000-0001-6072-3102; Araujo,
   Robyn/0000-0002-3360-2214
FU Australian Research Council (ARC) Future Fellowship - Australian
   Government [FT190100645]
FX Robyn P. Araujo is the recipient of an Australian Research Council (ARC)
   Future Fellowship (project number FT190100645) funded by the Australian
   Government.
CR Araujo RP, 2004, B MATH BIOL, V66, P1039, DOI 10.1016/j.bulm.2003.11.002
   Ardeljan D, 2013, PROG RETIN EYE RES, V37, P68, DOI 10.1016/j.preteyeres.2013.07.003
   Ayala A, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/360438
   Beattie JR, 2010, FASEB J, V24, P4816, DOI 10.1096/fj.10-166090
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Booij JC, 2010, PROG RETIN EYE RES, V29, P1, DOI 10.1016/j.preteyeres.2009.08.003
   BOULTON M, 1991, PROG RETIN RES, V11, P125, DOI 10.1016/0278-4327(91)90027-Y
   BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311
   BROWN MS, 1975, CELL, V6, P307, DOI 10.1016/0092-8674(75)90182-8
   Buch H, 2005, ACTA OPHTHALMOL SCAN, V83, P400, DOI [10.1111/j.1600-0420.2005.00474.x, 10.1111/j.1600-0420.2005.thesis.x]
   Buschini E, 2011, PROG NEUROBIOL, V95, P14, DOI 10.1016/j.pneurobio.2011.05.011
   Campagne MV, 2014, J PATHOL, V232, P151, DOI 10.1002/path.4266
   Chiras D, 2015, CRIT REV CL LAB SCI, V52, P12, DOI 10.3109/10408363.2014.968703
   Covic A, 2014, DYSLIPIDEMIAS KIDNEY
   Curcio C.A., 2013, RETINA-J RET VIT DIS, V5th, P465
   Curcio CA, 2005, EXP EYE RES, V81, P731, DOI 10.1016/j.exer.2005.04.012
   Curcio CA, 2005, EXP EYE RES, V80, P761, DOI 10.1016/j.exer.2004.09.017
   CURCIO CA, 1993, INVEST OPHTH VIS SCI, V34, P3278
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Curcio Christine A, 2018, Invest Ophthalmol Vis Sci, V59, pAMD160, DOI 10.1167/iovs.18-24882
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   DOREY CK, 1989, INVEST OPHTH VIS SCI, V30, P1691
   Feinberg M., 2019, FDN CHEM REACTION NE, DOI 10.1007/978-3-030-03858-8
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   FLIESLER SJ, 1983, PROG LIPID RES, V22, P79
   Fliesler SJ, 2010, J LIPID RES, V51, P3399, DOI 10.1194/jlr.R010538
   Fliesler SJ, 2010, J LIPID RES, V51, P1, DOI 10.1194/jlr.E003533-JLR200
   GAO H, 1992, INVEST OPHTH VIS SCI, V33, P1
   Gatenby RA, 2003, NATURE, V421, P321, DOI 10.1038/421321a
   Giachelli CM, 2009, KIDNEY INT, V75, P890, DOI 10.1038/ki.2008.644
   Gordiyenko N, 2004, INVEST OPHTH VIS SCI, V45, P2822, DOI 10.1167/iovs.04-0074
   Grassmann F, 2018, OPHTHALMOLOGY, V125, P1410, DOI 10.1016/j.ophtha.2018.02.037
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Handa JT, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11262-1
   HARTNETT ME, 1992, GRAEF ARCH CLIN EXP, V230, P11, DOI 10.1007/BF00166756
   Hussain MA, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0198281
   Ioseliani O, 2006, NEW DEV EYE RES NOVA
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Kent D, 2003, MOL VIS, V9, P747
   Kijlstra A, 2015, OPHTHALMIC RES, V54, P64, DOI 10.1159/000432401
   Kim JY, 2013, CELL, V154, P365, DOI 10.1016/j.cell.2013.06.012
   KRINSKY NI, 1958, ARCH BIOCHEM BIOPHYS, V73, P233, DOI 10.1016/0003-9861(58)90259-5
   Lambert NG, 2016, PROG RETIN EYE RES, V54, P64, DOI 10.1016/j.preteyeres.2016.04.003
   Liscum L, 2002, BIOCH LIPIDS LIPOPRO, P409, DOI DOI 10.1016/S0167-7306(02)36017-4
   Luthert P, 2010, MIN OC PATH
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   Marmor M. F., 1998, RETINAL PIGMENT EPIT, DOI [10.1098/rsif.2015.0563, DOI 10.1098/RSIF.2015.0563]
   Mast N, 2011, INVEST OPHTH VIS SCI, V52, P594, DOI 10.1167/iovs.10-6021
   McHarg S, 2015, MOL IMMUNOL, V67, P43, DOI 10.1016/j.molimm.2015.02.032
   Noske UM, 1998, OPHTHALMOLOGE, V95, P814, DOI 10.1007/s003470050358
   Obana A, 2017, INVEST OPHTH VIS SCI, V58, P5157, DOI 10.1167/iovs.17-22347
   Oyster C. W., 1999, HUMAN EYE
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   PAULEIKHOFF D, 1992, OPHTHALMOLOGY, V99, P1548
   Pikuleva IA, 2014, PROG RETIN EYE RES, V41, P64, DOI 10.1016/j.preteyeres.2014.03.002
   Reichenbach A, 2013, GLIA, V61, P651, DOI 10.1002/glia.22477
   Roberts PA, 2016, PROG RETIN EYE RES, V53, P48, DOI 10.1016/j.preteyeres.2016.04.001
   Rodriguez IR, 2010, J LIPID RES, V51, P2847, DOI 10.1194/jlr.R004820
   Rudolf M, 2008, INVEST OPHTH VIS SCI, V49, P1200, DOI 10.1167/iovs.07-1466
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Savic RM, 2007, J PHARMACOKINET PHAR, V34, P711, DOI 10.1007/s10928-007-9066-0
   Schaal KB, 2015, RETINA-J RET VIT DIS, V35, P1339, DOI 10.1097/IAE.0000000000000471
   Scholl HPN, 2007, MOL VIS, V13, P196
   Schultz R, 2018, INVEST OPHTH VIS SCI, V59
   Shirinifard A, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002440
   Spaide RF, 2003, RETINA-J RET VIT DIS, V23, P595, DOI 10.1097/00006982-200310000-00001
   Spraul CW, 1999, SURV OPHTHALMOL, V44, pS10, DOI 10.1016/S0039-6257(99)00086-7
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Subczynski WK, 2010, ARCH BIOCHEM BIOPHYS, V504, P61, DOI 10.1016/j.abb.2010.05.015
   Tabas I, 2007, CIRCULATION, V116, P1832, DOI 10.1161/CIRCULATIONAHA.106.676890
   Thomas SE, 2016, J LIPID RES, V57, P1865, DOI 10.1194/jlr.M070193
   Tserentsoodol N, 2006, MOL VIS, V12, P1319
   Tserentsoodol N, 2006, MOL VIS, V12, P1306
   Wang L, 2009, INVEST OPHTH VIS SCI, V50, P870, DOI 10.1167/iovs.08-2376
   Wang ZL, 2014, CENT EUR J BIOL, V9, P469, DOI 10.2478/s11535-014-0290-5
   Wattis JAD, 2008, B MATH BIOL, V70, P2303, DOI 10.1007/s11538-008-9347-9
   Wecker T, 2017, BRIT J OPHTHALMOL, V101, P353, DOI 10.1136/bjophthalmol-2016-308668
   Wikimedia Commons, 2019, FIL SCHEM DIAGR HUM
   Wikimedia Commons, 2018, FIL RET LAY SVG
   WILLIAMS KJ, 1995, ARTERIOSCL THROM VAS, V15, P551, DOI 10.1161/01.ATV.15.5.551
   WOLTER JR, 1962, ARCH OPHTHALMOL-CHIC, V68, P219
   Xue YL, 2015, J CLIN INVEST, V125, P727, DOI 10.1172/JCI79651
   ZAMBON S, 1995, EUR J CLIN INVEST, V25, P143, DOI 10.1111/j.1365-2362.1995.tb01540.x
   Zarbin MA, 2010, RETINA-J RET VIT DIS, V30, P1350, DOI 10.1097/IAE.0b013e3181f57e30
   Zekavat SM, 2017, J LIPID RES, V58, P1325, DOI 10.1194/jlr.M074088
   Zheng WC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037926
   Zouache MA, 2015, J FLUID MECH, V774, P37, DOI 10.1017/jfm.2015.243
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 90
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0092-8240
EI 1522-9602
J9 B MATH BIOL
JI Bull. Math. Biol.
PD OCT 12
PY 2020
VL 82
IS 10
AR 135
DI 10.1007/s11538-020-00812-0
PG 48
WC Biology; Mathematical & Computational Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Life Sciences & Biomedicine - Other Topics; Mathematical & Computational
   Biology
GA OC3ZX
UT WOS:000579098400001
PM 33044644
DA 2022-11-30
ER

PT J
AU Zhang, CX
   Zhang, GM
   Ma, N
   Xia, S
   Yang, JY
   Chen, YX
AF Zhang, Chen-Xi
   Zhang, Gu-Muyang
   Ma, Nan
   Xia, Song
   Yang, Jing-Yuan
   Chen, You-Xin
TI Awareness of Age-related Macular Degeneration and Its Risk Factors among
   Beijing Residents in China
SO CHINESE MEDICAL JOURNAL
LA English
DT Article
DE Age-related Macular Degeneration; Awareness; Chinese; Risk Factor;
   Smoking
ID SINGAPORE RESIDENTS; EYE DISEASES; KNOWLEDGE; ATTITUDES; SMOKING; HEALTH
AB Background: Age-related macular degeneration (AMD) is a major cause of irreversible blindness, and awareness of this disease is important in the prevention of blindness. However, lack of public awareness of AMD was shown in previous studies, and there was no report of AMD awareness in the Mainland of China. Therefore, the aim of our study was to assess the awareness of AMD and its risk factors among Beijing residents in China.
   Methods: A cross-sectional, computer-assisted, telephone investigation was conducted to measure the awareness of AMD among Beijing residents. All the contacts of potential respondents were randomly generated by computer. Only those above 18 years of age and willing to participate in the study were included. The questionnaire for the study was modified from the AMD Alliance International Global Report. Pearsons Chi-square test and binary logistic regression analysis were used to identify the factors that affected the knowledge of AMD.
   Results: Among 385 Beijing residents who agreed to participate, the awareness of AMD was 6.8%, far below than that of cataract and glaucoma. Participants who were above 30 years of age (odds ratio [OR] 6.17, confidence interval [CI] 1.44-26.57), with experience of health-related work (OR 8.11, CI 3.25-20.27), and whose relatives/friends or themselves suffering from AMD (OR 32.18, CI 11.29-91.68) had better AMD awareness. Among those familiar with AMD, only 35% of them identified smoking as a risk factor, and only 23.1% of the residents believed that smoking could lead to blindness.
   Conclusions: The sample of Chinese population had limited knowledge of AMD. Educational programs need to be carried out to raise public awareness of AMD.
C1 [Zhang, Chen-Xi; Zhang, Gu-Muyang; Ma, Nan; Xia, Song; Yang, Jing-Yuan; Chen, You-Xin] Beijing Union Med Coll Hosp, Peking Union Med Coll, Dept Ophthalmol, Beijing 100730, Peoples R China.
   [Zhang, Chen-Xi; Zhang, Gu-Muyang; Ma, Nan; Xia, Song; Yang, Jing-Yuan; Chen, You-Xin] Chinese Acad Med Sci, Beijing 100730, Peoples R China.
   [Zhang, Gu-Muyang] Beijing Union Med Coll Hosp, Peking Union Med Coll, Dept Radiol, Beijing 100730, Peoples R China.
   [Ma, Nan] Capital Med Univ, Beijing Ophthalmol & Visual Sci Key Lab, Beijing Tongren Hosp, Beijing Tongren Eye Ctr, Beijing 100730, Peoples R China.
C3 Chinese Academy of Medical Sciences - Peking Union Medical College;
   Peking Union Medical College; Peking Union Medical College Hospital;
   Chinese Academy of Medical Sciences - Peking Union Medical College;
   Chinese Academy of Medical Sciences - Peking Union Medical College;
   Peking Union Medical College; Peking Union Medical College Hospital;
   Capital Medical University
RP Chen, YX (通讯作者)，Beijing Union Med Coll Hosp, Peking Union Med Coll, Dept Ophthalmol, Beijing 100730, Peoples R China.; Chen, YX (通讯作者)，Chinese Acad Med Sci, Beijing 100730, Peoples R China.
EM chenyouxinpumch@163.com
FU Beijing Ophthalmologist Association of Beijing Medical Doctor
   Association
FX This project was supported by a grant from Beijing Ophthalmologist
   Association of Beijing Medical Doctor Association.
CR Attebo K, 1997, AUST NZ J OPHTHALMOL, V25, P283, DOI 10.1111/j.1442-9071.1997.tb01516.x
   Bidwell G, 2005, EYE, V19, P945, DOI 10.1038/sj.eye.6701955
   Guymer RH, 2006, MED J AUSTRALIA, V184, P455, DOI 10.5694/j.1326-5377.2006.tb00318.x
   Huang OS, 2013, OPHTHAL EPIDEMIOL, V20, P52, DOI 10.3109/09286586.2012.751429
   Islam FMA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133043
   Lau JTF, 2002, BRIT J OPHTHALMOL, V86, P1080, DOI 10.1136/bjo.86.10.1080
   Livingston PM, 1998, BRIT J OPHTHALMOL, V82, P780, DOI 10.1136/bjo.82.7.780
   Noertjojo K, 2006, CAN J OPHTHALMOL, V41, P617, DOI 10.1016/S0008-4182(06)80035-9
   Rosenthal Bruce, 2003, Optometry, V74, P16
   Sanjay S, 2014, OPHTHAL EPIDEMIOL, V21, P230, DOI 10.3109/09286586.2014.929708
   Sanjay S, 2009, CLIN EXP OPHTHALMOL, V37, P795, DOI 10.1111/j.1442-9071.2009.02153.x
   Scott AW, 2016, JAMA OPHTHALMOL, V134, P1111, DOI 10.1001/jamaophthalmol.2016.2627
   Solberg Y, 1998, SURV OPHTHALMOL, V42, P535, DOI 10.1016/S0039-6257(98)00002-2
   Thapa R, 2015, BMC OPHTHALMOL, V15, DOI 10.1186/s12886-015-0175-z
   The Royal College of Ophthalmologists, 2017, NAT EL AG REL MAC DA
   WHO, 2004, PREV BLINDN VIS IMP
   Winyard S, 2005, INT C SERIES, V1282, P418
   Woo JH, 2008, SINGAP MED J, V49, P850
   Zou Hai-dong, 2005, Zhonghua Yan Ke Za Zhi, V41, P15
NR 19
TC 3
Z9 3
U1 0
U2 6
PU MEDKNOW PUBLICATIONS & MEDIA PVT LTD
PI MUMBAI
PA B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075,
   INDIA
SN 0366-6999
J9 CHINESE MED J-PEKING
JI Chin. Med. J.
PD JAN 20
PY 2017
VL 130
IS 2
BP 155
EP 159
DI 10.4103/0366-6999.197994
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA EK5MV
UT WOS:000393971400006
PM 28091406
DA 2022-11-30
ER

PT J
AU Thibaut, M
   Tran, THC
   Delerue, C
   Boucart, M
AF Thibaut, Miguel
   Thi Ha Chau Tran
   Delerue, Celine
   Boucart, Muriel
TI Misidentifying a tennis racket as keys: object identification in people
   with age-related macular degeneration
SO OPHTHALMIC AND PHYSIOLOGICAL OPTICS
LA English
DT Article
DE low vision; macular degeneration; object recognition; scene and eye
   movement
ID PERIPHERAL-VISION; READING SPEED; RECOGNITION; DISCRIMINATION;
   CATEGORIZATION; PSYCHOPHYSICS; PERFORMANCE; IMPLICIT; CONTEXT; IMAGES
AB PurposePrevious studies showed that people with age-related macular degeneration (AMD) can categorise a pre-defined target object or scene with high accuracy (above 80%). In these studies participants were asked to detect the target (e.g. an animal) in serial visual presentation. People with AMD must rely on peripheral vision which is more adapted to the low resolution required for detection than for the higher resolution required to identify a specific exemplar. We investigated the ability of people with central vision loss to identify photographs of objects and scenes.
   MethodsPhotographs of isolated objects, natural scenes and objects in scenes were centrally displayed for 2s each. Participants were asked to name the stimuli. We measured accuracy and naming times in 20 patients with AMD, 15 age-matched and 12 young controls.
   ResultsAccuracy was lower (by about 30%) and naming times were longer (by about 300ms) in people with AMD than in age-matched controls in the three categories of images. Correct identification occurred in 62-66% of the stimuli for patients. More than 20% of the misidentifications resulted from a structural and/or semantic similarity between the object and the name (e.g. spectacles for dog plates or dolphin for shark). Accuracy and naming times did not differ significantly between young and older normally sighted participants indicating that the deficits resulted from pathology rather than to normal ageing.
   ConclusionsThese results show that, in contrast to performance for categorisation of a single pre-defined target, people with central vision loss are impaired at identifying various objects and scenes. The decrease in accuracy and the increase in response times in patients with AMD indicate that peripheral vision might be sufficient for object and scene categorisation but not for precise scene or object identification.
C1 [Thibaut, Miguel; Delerue, Celine; Boucart, Muriel] Univ Lille Nord France, Ctr Natl Rech Sci, Lab Neurosci Fonctionnelles & Pathol, Lille, France.
   [Thi Ha Chau Tran] Hop St Vincent de Paul, Lille, France.
C3 Centre National de la Recherche Scientifique (CNRS); Universite de Lille
   - ISITE; Universite de Lille
RP Thibaut, M (通讯作者)，Univ Lille Nord France, Ctr Natl Rech Sci, Lab Neurosci Fonctionnelles & Pathol, Lille, France.
EM muriel.boucart@chru-lille.fr
RI TRAN, Thi Ha Chau/AAF-2162-2020
OI TRAN, Thi Ha Chau/0000-0001-9066-7092
FU grant 'LowVision' from the French National Research Agency; French
   Ministry of Research
FX The authors are grateful to Sebastien Szaffarczyk for technical help, to
   Christine Moroni for help in statistics and to all patients and controls
   for agreeing to participate. The study was funded by a grant 'LowVision'
   from the French National Research Agency to the last author and a PhD
   grant from the French Ministry of Research to the first author.
CR Allen PA, 2011, EXP AGING RES, V37, P261, DOI 10.1080/0361073X.2011.568805
   Bedell HE, 2009, OPTOMETRY VISION SCI, V86, P485, DOI 10.1097/OPX.0b013e31819fa6e2
   Blackmore-Wright S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080325
   Boucart M, 2013, VISION RES, V86, P35, DOI 10.1016/j.visres.2013.04.006
   Boucart M, 2013, INVEST OPHTH VIS SCI, V54, P1950, DOI 10.1167/iovs.12-9680
   Boucart M, 2010, VIS COGN, V18, P839, DOI 10.1080/13506280903287845
   Boucart M, 2010, NEUROCASE, V16, P157, DOI 10.1080/13554790903339637
   Boucart M, 2008, VISUAL NEUROSCI, V25, P685, DOI 10.1017/S0952523808080826
   Calabrese A, 2010, INVEST OPHTH VIS SCI, V51, P1247, DOI 10.1167/iovs.09-3682
   Cheong AMY, 2008, VISION RES, V48, P577, DOI 10.1016/j.visres.2007.11.022
   Cheung SH, 2005, VISUAL NEUROSCI, V22, P187, DOI 10.1017/S0952523805222071
   Chung STL, 2008, OPTOMETRY VISION SCI, V85, P827, DOI 10.1097/OPX.0b013e31818527ea
   Crossland MD, 2011, INVEST OPHTH VIS SCI, V52, P411, DOI 10.1167/iovs.10-5473
   Fletcher Donald C, 2012, Optom Vis Sci, V89, P1395, DOI 10.1097/OPX.0b013e318264cc77
   Geringswald F, 2013, J VIS, V13, P1, DOI DOI 10.1167/13
   Greenstein VC, 2008, RETINA-J RET VIT DIS, V28, P1234, DOI 10.1097/IAE.0b013e31817c1b47
   Henderson JM, 1997, PERCEPT PSYCHOPHYS, V59, P323, DOI 10.3758/BF03211901
   Kabanarou SA, 2006, OPHTHALMOLOGY, V113, P2251, DOI 10.1016/j.ophtha.2006.06.028
   Kwon M, 2012, OPTOMETRY VISION SCI, V89, P1374, DOI 10.1097/OPX.0b013e3182678e52
   Larson AM, 2009, J VISION, V9, DOI 10.1167/9.10.6
   LEGGE GE, 1985, VISION RES, V25, P253, DOI 10.1016/0042-6989(85)90118-X
   LEGGE GE, 1989, OPTOMETRY VISION SCI, V66, P843, DOI 10.1097/00006324-198912000-00008
   Lei H, 1997, INVEST OPHTH VIS SCI, V38, P1812
   Mace MJM, 2005, EUR J NEUROSCI, V21, P2007, DOI 10.1111/j.1460-9568.2005.04029.x
   Makela P, 2001, VISION RES, V41, P599, DOI 10.1016/S0042-6989(00)00259-5
   McIlreavy L, 2012, OPTOMETRY VISION SCI, V89, P1385, DOI 10.1097/OPX.0b013e318267a914
   Musel B, 2011, VISUAL NEUROSCI, V28, P529, DOI 10.1017/S0952523811000435
   Neelam K, 2009, SURV OPHTHALMOL, V54, P167, DOI 10.1016/j.survophthal.2008.12.003
   Oliva A, 2000, COGNITIVE PSYCHOL, V41, P176, DOI 10.1006/cogp.1999.0728
   Oliva Aude, 2005, P251, DOI 10.1016/B978-012375731-9/50045-8
   Pelli DG, 2004, J VISION, V4, P1136, DOI 10.1167/4.12.12
   Qiu F, 2009, CLIN EXP OPTOM, V92, P90, DOI 10.1111/j.1444-0938.2008.00343.x
   Querques G, 2012, GRAEF ARCH CLIN EXP, V250, P479, DOI 10.1007/s00417-011-1831-5
   Strasburger H, 1996, EUR J NEUROSCI, V8, P1787, DOI 10.1111/j.1460-9568.1996.tb01322.x
   STRASBURGER H, 1991, PERCEPT PSYCHOPHYS, V49, P495, DOI 10.3758/BF03212183
   Strasburger H, 2011, J VISION, V11, DOI 10.1167/11.5.13
   Tarita-Nistor L, 2011, INVEST OPHTH VIS SCI, V52, P1887, DOI 10.1167/iovs.10-6059
   Tejeria L, 2002, BRIT J OPHTHALMOL, V86, P1019, DOI 10.1136/bjo.86.9.1019
   Thi HCT, 2011, OPHTHAL SURG LAS IM, V42, P498, DOI 10.3928/15428877-20110804-04
   Thi HCT, 2012, OPTOMETRY VISION SCI, V89, P419, DOI 10.1097/OPX.0b013e31824c3a21
   Thi HCT, 2011, INVEST OPHTH VIS SCI, V52, P1655, DOI 10.1167/iovs.10-6003
   Thi HCT, 2010, INVEST OPHTH VIS SCI, V51, P6868, DOI 10.1167/iovs.10-5517
   Thorpe SJ, 2001, EUR J NEUROSCI, V14, P869, DOI 10.1046/j.0953-816x.2001.01717.x
   Wang YZ, 2002, INVEST OPHTH VIS SCI, V43, P2055
NR 44
TC 5
Z9 5
U1 0
U2 13
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0275-5408
EI 1475-1313
J9 OPHTHAL PHYSL OPT
JI Ophthalmic Physiol. Opt.
PD MAY
PY 2015
VL 35
IS 3
BP 336
EP 344
DI 10.1111/opo.12201
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CH3WL
UT WOS:000353961400011
PM 25847590
DA 2022-11-30
ER

PT J
AU Querques, G
   Berboucha, E
   Leveziel, N
   Pece, A
   Souied, EH
AF Querques, Giuseppe
   Berboucha, Elya
   Leveziel, Nicolas
   Pece, Alfredo
   Souied, Eric H.
TI Preferential hyperacuity perimeter in assessing responsiveness to
   ranibizumab therapy for exudative age-related macular degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID VISUAL FUNCTION; CHOROIDAL NEOVASCULARIZATION
AB Aim To investigate the ability of the preferential hyperacuity perimeter test to assess responsiveness to ranibizumab therapy for exudative age-related macular degeneration (AMD).
   Methods Fourteen consecutive patients with newly diagnosed choroidal neovascularisation underwent a preferential hyperacuity perimeter metamorphopsia test (main outcome measures) 1 h before (baseline) and 1 h, 1 day, 1 week and 1 month after one intravitreal injection of ranibizumab (0.05 ml/0.5 mg). Best corrected visual acuity (BCVA) and several spectral domain optical coherence tomography (OCT) parameters (secondary outcome measures) were compared with the metamorphopsia test.
   Results Fourteen eyes (14 patients, 78% women, mean age 83 +/- 6.2 years) were included in the analysis. The mean preferential hyperacuity perimeter metamorphopsia test score improved significantly from 20.4 +/- 35 at baseline to 9.2 +/- 23 after the single ranibizumab injection (p < 0.05). The mean reduction in central macular thickness, maximal retinal thickness at the fovea, maximal height of subretinal fluid, maximal diameter of the largest retinal cyst and maximal height of pigment epithelial detachment, as evaluated by spectral domain OCT, closely reflected the functional improvements as evaluated by preferential hyperacuity perimeter, showing a significant correlation with metamorphopsia changes (Spearman correlation 0.9, p < 0.05). Mean BCVA improved significantly from 20/80 to 20/60 (p < 0.05). A significant correlation was also found between the mean BCVA changes and the mean metamorphopsia changes (Spearman correlation 0.97, p < 0.05). The correlation coefficient between OCT measurements and preferential hyperacuity perimeter score within subjects was 0.51 (p < 0.05).
   Conclusion The improvement in metamorphopsia test score after intravitreal ranibizumab injection, which correlated closely with improvement in several OCT parameters, suggests that the preferential hyperacuity perimeter test may be used to monitor the response to anti-vascular endothelial growth factor (VEGF) treatment in patients with exudative AMD.
C1 [Querques, Giuseppe; Berboucha, Elya; Leveziel, Nicolas; Souied, Eric H.] Univ Paris 12, Ctr Hosp Intercommunal Creteil, Dept Ophthalmol, F-94000 Creteil, France.
   [Querques, Giuseppe; Pece, Alfredo] Retina 3000 Fdn ONLUS, Milan, Italy.
C3 Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil
RP Querques, G (通讯作者)，Univ Paris 12, Ctr Hosp Intercommunal Creteil, Dept Ophthalmol, 40 Ave Verdun, F-94000 Creteil, France.
EM giuseppe.querques@hotmail.it
OI Nicolas, Leveziel/0000-0001-8533-9457; Querques,
   Giuseppe/0000-0002-3292-9581
FU Retina 3000 Foundation
FX This study was supported thorough a research fellowship by the Retina
   3000 Foundation.
CR Alster Y, 2005, OPHTHALMOLOGY, V112, P1758, DOI 10.1016/j.ophtha.2005.06.008
   BLAND JM, 1995, BRIT MED J, V310, P446, DOI 10.1136/bmj.310.6977.446
   Browning DJ, 2007, OPHTHALMOLOGY, V114, P525, DOI 10.1016/j.ophtha.2006.06.052
   Das R, 2009, RETINA-J RET VIT DIS, V29, P1013, DOI 10.1097/IAE.0b013e3181a91dbf
   Doris N, 2001, BRIT J OPHTHALMOL, V85, P184, DOI 10.1136/bjo.85.2.184
   Goldstein M, 2005, RETINA-J RET VIT DIS, V25, P296
   Hogg R, 2003, BRIT J OPHTHALMOL, V87, P609, DOI 10.1136/bjo.87.5.609
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Loewenstein A, 2010, RETINA-J RET VIT DIS, V30, P1058, DOI 10.1097/IAE.0b013e3181d1a75e
   McClure ME, 2000, BRIT J OPHTHALMOL, V84, P244, DOI 10.1136/bjo.84.3.244
   Mitchell J, 2008, AM J OPHTHALMOL, V146, P447, DOI 10.1016/j.ajo.2008.04.031
   Moutray T, 2008, BRIT J OPHTHALMOL, V92, P361, DOI 10.1136/bjo.2007.123976
   Querques G, 2008, AM J OPHTHALMOL, V146, P135, DOI 10.1016/j.ajo.2008.02.017
   Querques G, 2010, BRIT J OPHTHALMOL, V94, P292, DOI 10.1136/bjo.2009.170670
   Trevino R, 2008, OPHTHAL PHYSL OPT, V28, P183, DOI 10.1111/j.1475-1313.2008.00561.x
NR 15
TC 10
Z9 10
U1 0
U2 3
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD JUL
PY 2011
VL 95
IS 7
BP 986
EP 991
DI 10.1136/bjo.2010.190942
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 778PX
UT WOS:000291717700019
PM 21183512
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Kaarniranta, K
   Salminen, A
   Eskelinen, EL
   Kopitz, J
AF Kaarniranta, Kai
   Salminen, Antero
   Eskelinen, Eeva-Liisa
   Kopitz, Juergen
TI Heat shock proteins as gatekeepers of proteolytic pathways-Implications
   for age-related macular degeneration (AMD)
SO AGEING RESEARCH REVIEWS
LA English
DT Review
DE Autophagy; Heat shock proteins; Lysosome; Proteasome
ID RETINAL-PIGMENT EPITHELIUM; CHAPERONE-MEDIATED AUTOPHAGY;
   UBIQUITIN-PROTEASOME SYSTEM; FACTOR-H POLYMORPHISM; RAT-LIVER LYSOSOMES;
   MOLECULAR CHAPERONES; HISTONE DEACETYLASE-6; TRANSCRIPTION FACTOR;
   AGGRESOME FORMATION; OXIDATIVE STRESS
AB Age-related macular degeneration (AMD) is the major diagnosis for severe and irreversible central loss of vision in elderly people in the developed countries. The loss of vision involves primarily a progressive degeneration and cell death of postmitotic retinal pigment epithelial cells (RPE), which secondarily evokes adverse effects on photoreceptor cells. The RPE cells are exposed to chronic oxidative stress from three sources: their high levels of oxygen consumption, their exposure to the high levels of lipid peroxidation derived from the photoreceptor outer segments and their exposure to constant light stimuli. Cells increase the expression of heat shock proteins (HSPs) in order to normalize their growth conditions in response to various environmental stress factors, e.g. oxidative stress. The HSPs function as molecular chaperones by preventing the accumulation of cellular cytotoxic protein aggregates and assisting in correct folding of both nascent and misfolded proteins. Increased HSPs levels are observed in the retina of AMD patients, evidence of stressed tissue. A hallmark of RPE cell aging is lysosomal lipofuscin accumulation reflecting a weakened capacity to degrade proteins in lysosomes. The presence of lipofuscin increases the misfolding of intracellular proteins, which evokes additional stress in the RPE cells. If the capacity of HSPs to repair protein damages is overwhelmed, then the proteins are mainly cleared in proteasomes or in lysosomes. In this review, we discuss the role of heat shock proteins, proteasomes, and lysosomes and autophagic processes in RPE cell proteolysis and how these might be involved in development of AMD. In addition to classical lysosomal proteolysis, we focus on the increasing evidence that, HSPs, proteasomes and autophagy regulate protein turnover in the RPE cells and thus have important roles in AMD disease. (C) 2009 Elsevier Ireland Ltd. All rights reserved.
C1 [Kaarniranta, Kai] Univ Kuopio, Dept Ophthalmol, FIN-70211 Kuopio, Finland.
   [Kaarniranta, Kai] Kuopio Univ Hosp, Dept Ophthalmol, SF-70210 Kuopio, Finland.
   [Salminen, Antero] Univ Kuopio, Dept Neurol & Neurosci, Kuopio, Finland.
   [Eskelinen, Eeva-Liisa] Univ Helsinki, Dept Biol & Environm Sci, Div Biochem, Helsinki, Finland.
   [Kopitz, Juergen] Heidelberg Univ, Inst Mol Pathol, Fac Med, D-6900 Heidelberg, Germany.
C3 University of Eastern Finland; Kuopio University Hospital; University of
   Eastern Finland; University of Eastern Finland; University of Helsinki;
   Ruprecht Karls University Heidelberg
RP Kaarniranta, K (通讯作者)，Univ Kuopio, Dept Ophthalmol, POB 1627, FIN-70211 Kuopio, Finland.
EM kaarnira@messi.uku.fi
RI Eskelinen, Eeva-Liisa/AAF-3496-2019
OI Eskelinen, Eeva-Liisa/0000-0003-0006-7785; Kaarniranta,
   Kai/0000-0003-2600-8679
CR ABRAVAYA K, 1991, GENE DEV, V5, P2117, DOI 10.1101/gad.5.11.2117
   ABRAVAYA K, 1991, MOL CELL BIOL, V11, P586, DOI 10.1128/MCB.11.1.586
   ABRAVAYA K, 1992, GENE DEV, V6, P1153, DOI 10.1101/gad.6.7.1153
   ADLER AJ, 1992, OPHTHALMIC RES, V24, P243, DOI 10.1159/000267174
   ADLER AJ, 1989, EXP EYE RES, V49, P1067, DOI 10.1016/S0014-4835(89)80027-2
   Agarraberes FA, 2001, J CELL SCI, V114, P2491
   Agarraberes FA, 1997, J CELL BIOL, V137, P825, DOI 10.1083/jcb.137.4.825
   Agarraberes FA, 2001, BBA-BIOMEMBRANES, V1513, P1, DOI 10.1016/S0304-4157(01)00005-3
   AHLBERG J, 1982, LAB INVEST, V47, P523
   Algvere PV, 2002, ACTA OPHTHALMOL SCAN, V80, P136, DOI 10.1034/j.1600-0420.2002.800204.x
   ALLEN SP, 1992, J BACTERIOL, V174, P6938, DOI 10.1128/JB.174.21.6938-6947.1992
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Anckar J, 2006, MOL CELL BIOL, V26, P955, DOI 10.1128/MCB.26.3.955-964.2006
   Anckar J, 2007, ADV EXP MED BIOL, V594, P78
   Aoyagi S, 2005, TRENDS CELL BIOL, V15, P565, DOI 10.1016/j.tcb.2005.09.003
   Bali P, 2005, J BIOL CHEM, V280, P26729, DOI 10.1074/jbc.C500186200
   Ban Y, 2000, AM J PHYSIOL-CELL PH, V279, pC744, DOI 10.1152/ajpcell.2000.279.3.C744
   Basha E, 2004, J BIOL CHEM, V279, P7566, DOI 10.1074/jbc.M310684200
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Benjamin IJ, 1998, CIRC RES, V83, P117, DOI 10.1161/01.RES.83.2.117
   Bergmann M, 2004, FASEB J, V18, P562, DOI 10.1096/fj.03-0289fje
   Bertos NR, 2004, J BIOL CHEM, V279, P48246, DOI 10.1074/jbc.M408583200
   Bjorkoy G, 2006, AUTOPHAGY, V2, P138, DOI 10.4161/auto.2.2.2405
   BOK D, 1993, J CELL SCI, P189
   BOULTON M, 1993, J PHOTOCH PHOTOBIO B, V19, P201, DOI 10.1016/1011-1344(93)87085-2
   BOULTON M, 1985, EXP EYE RES, V41, P209, DOI 10.1016/0014-4835(85)90026-0
   Boulton M, 2001, EYE, V15, P384, DOI 10.1038/eye.2001.141
   Boyault C, 2007, GENE DEV, V21, P2172, DOI 10.1101/gad.436407
   BRESSLER NM, 1987, ARCH OPHTHALMOL-CHIC, V105, P209
   Brunk UT, 1995, GERONTOLOGY, V41, P201
   Buch H, 2005, ACTA OPHTHALMOL SCAN, V83, P400, DOI [10.1111/j.1600-0420.2005.00474.x, 10.1111/j.1600-0420.2005.thesis.x]
   Buchner J, 1996, FASEB J, V10, P10, DOI 10.1096/fasebj.10.1.8566529
   Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9
   Bukau B, 2006, CELL, V125, P443, DOI 10.1016/j.cell.2006.04.014
   Chadli A, 2000, P NATL ACAD SCI USA, V97, P12524, DOI 10.1073/pnas.220430297
   CHIANG HL, 1989, SCIENCE, V246, P382, DOI 10.1126/science.2799391
   Ciechanover A, 2005, ANGEW CHEM INT EDIT, V44, P5944, DOI 10.1002/anie.200501428
   Codogno P, 2005, CELL DEATH DIFFER, V12, P1509, DOI 10.1038/sj.cdd.4401751
   Csermely P, 1998, PHARMACOL THERAPEUT, V79, P129, DOI 10.1016/S0163-7258(98)00013-8
   Cuervo AM, 2000, J BIOL CHEM, V275, P31505, DOI 10.1074/jbc.M002102200
   Cuervo AM, 1997, J BIOL CHEM, V272, P5606, DOI 10.1074/jbc.272.9.5606
   Cuervo AM, 2003, EMBO J, V22, P47, DOI 10.1093/emboj/cdg002
   Cuervo AM, 1996, SCIENCE, V273, P501, DOI 10.1126/science.273.5274.501
   Daugaard M, 2007, FEBS LETT, V581, P3702, DOI [10.1016/j.febslet.2007.05.039, 10.1016/j.febsiet.2007.05.039]
   Daugaard M, 2007, CANCER RES, V67, P2559, DOI 10.1158/0008-5472.CAN-06-4121
   De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321
   Decanini A, 2007, AM J OPHTHALMOL, V143, P607, DOI 10.1016/j.ajo.2006.12.006
   Demand J, 1998, MOL CELL BIOL, V18, P2023, DOI 10.1128/MCB.18.4.2023
   Dice JF, 2007, AUTOPHAGY, V3, P295, DOI 10.4161/auto.4144
   DWORNICZAK B, 1987, NUCLEIC ACIDS RES, V15, P5181, DOI 10.1093/nar/15.13.5181
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   ELDRED GE, 1988, EXP EYE RES, V47, P71, DOI 10.1016/0014-4835(88)90025-5
   ELDRED GE, 1993, NATURE, V361, P724, DOI 10.1038/361724a0
   Erbse A, 2004, BIOCHEM SOC T, V32, P617, DOI 10.1042/BST0320617
   Eskelinen EL, 2008, INT REV CEL MOL BIO, V266, P207, DOI 10.1016/S1937-6448(07)66005-5
   Eskelinen EL, 2008, AUTOPHAGY, V4, P3, DOI 10.4161/auto.5180
   Eskelinen EL, 2005, AUTOPHAGY, V1, P1, DOI 10.4161/auto.1.1.1270
   Eskelinen EL, 2005, TRAFFIC, V6, P1058, DOI 10.1111/j.1600-0854.2005.00337.x
   Eskelinen EL, 2003, TRENDS CELL BIOL, V13, P137, DOI 10.1016/S0962-8924(03)00005-9
   Eskelinen EL, 2002, MOL BIOL CELL, V13, P3355, DOI 10.1091/mbc.E02-02-0114
   ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6
   Fass E, 2006, J BIOL CHEM, V281, P36303, DOI 10.1074/jbc.M607031200
   Franzmann TM, 2005, J MOL BIOL, V350, P1083, DOI 10.1016/j.jmb.2005.05.034
   Garcia-Mata R, 1999, J CELL BIOL, V146, P1239, DOI 10.1083/jcb.146.6.1239
   Garron L K, 1963, Trans Am Ophthalmol Soc, V61, P545
   Goldberg AL, 2003, NATURE, V426, P895, DOI 10.1038/nature02263
   GOLDBERG AL, 1974, ANNU REV BIOCHEM, V43, P835, DOI 10.1146/annurev.bi.43.070174.004155
   Grammatikakis N, 2002, J BIOL CHEM, V277, P8312, DOI 10.1074/jbc.M109200200
   Guymer R, 1999, PROG RETIN EYE RES, V18, P59, DOI 10.1016/S1350-9462(98)00012-3
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hara T, 2006, NATURE, V441, P885, DOI 10.1038/nature04724
   HARTL FU, 1995, CURR OPIN STRUC BIOL, V5, P92
   Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0
   Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408
   HARTUNG GH, 1992, MED EXERC NUTR HLTH, V1, P293
   Haslbeck M, 2002, CELL MOL LIFE SCI, V59, P1649, DOI 10.1007/PL00012492
   Haslbeck M, 2005, NAT STRUCT MOL BIOL, V12, P842, DOI 10.1038/nsmb993
   Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425
   HICKEY E, 1989, MOL CELL BIOL, V9, P2615, DOI 10.1128/MCB.9.6.2615
   Hietakangas V, 2003, MOL CELL BIOL, V23, P2953, DOI 10.1128/MCB.23.8.2953-2968.2003
   Hjelmeland LM, 1999, MOL VIS, V5
   HOHFELD J, 1995, CELL, V83, P589
   Hollyfield JG, 1999, EXP EYE RES, V69, P311, DOI 10.1006/exer.1999.0707
   Holmberg CI, 2001, EMBO J, V20, P3800, DOI 10.1093/emboj/20.14.3800
   Holz FG, 2004, AM J OPHTHALMOL, V137, P504, DOI 10.1016/j.ajo.2003.11.026
   Holz FG, 1999, INVEST OPHTH VIS SCI, V40, P737
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Hook SS, 2002, P NATL ACAD SCI USA, V99, P13425, DOI 10.1073/pnas.172511699
   Hubbert C, 2002, NATURE, V417, P455, DOI 10.1038/417455a
   Huynh KK, 2007, EMBO J, V26, P313, DOI 10.1038/sj.emboj.7601511
   Iwata A, 2005, J BIOL CHEM, V280, P40282, DOI 10.1074/jbc.M508786200
   Jaattela M, 1999, EXP CELL RES, V248, P30, DOI 10.1006/excr.1999.4455
   Jager S, 2004, J CELL SCI, V117, P4837, DOI 10.1242/jcs.01370
   Johnston JA, 2002, CELL MOTIL CYTOSKEL, V53, P26, DOI 10.1002/cm.10057
   Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883
   Jung T, 2007, ANN NY ACAD SCI, V1119, P97, DOI 10.1196/annals.1404.008
   Kaarniranta K, 2005, NEUROSCI LETT, V382, P185, DOI 10.1016/j.neulet.2005.03.009
   Kaarniranta K, 1998, P NATL ACAD SCI USA, V95, P2319, DOI 10.1073/pnas.95.5.2319
   Kadowaki Motoni, 2006, Molecular Aspects of Medicine, V27, P426, DOI 10.1016/j.mam.2006.08.010
   Kaemmerer E, 2007, INVEST OPHTH VIS SCI, V48, P1342, DOI 10.1167/iovs.06-0549
   KATZ ML, 1989, ADV EXP MED BIOL, V266, P109
   Kaushik S, 2006, EMBO J, V25, P3921, DOI 10.1038/sj.emboj.7601283
   Kawaguchi Y, 2003, CELL, V115, P727, DOI 10.1016/S0092-8674(03)00939-5
   Kiffin R, 2004, MOL BIOL CELL, V15, P4829, DOI 10.1091/mbc.E04-06-0477
   Kiffin R, 2007, J CELL SCI, V120, P782, DOI 10.1242/jcs.001073
   Kim J, 2002, J BIOL CHEM, V277, P763, DOI 10.1074/jbc.M109134200
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klionsky DJ, 2006, NATURE, V441, P819, DOI 10.1038/441819a
   Komatsu M, 2005, J CELL BIOL, V169, P425, DOI 10.1083/jcb.200412022
   Komatsu M, 2006, NATURE, V441, P880, DOI 10.1038/nature04723
   Kopito RR, 2000, TRENDS CELL BIOL, V10, P524, DOI 10.1016/S0962-8924(00)01852-3
   Kopitz J, 2004, BIOCHIMIE, V86, P825, DOI 10.1016/j.biochi.2004.09.029
   Kovacs JJ, 2005, MOL CELL, V18, P601, DOI 10.1016/j.molcel.2005.04.021
   Kwon S, 2007, GENE DEV, V21, P3381, DOI 10.1101/gad.461107
   Kyrylenko S, 2003, CELL MOL LIFE SCI, V60, P1990, DOI 10.1007/s00018-003-3090-z
   Lamb LE, 2004, PHOTOCHEM PHOTOBIOL, V79, P127, DOI 10.1562/0031-8655(2004)079<0127:AACOOL>2.0.CO;2
   Laskowska E, 1996, BIOCHIMIE, V78, P117, DOI 10.1016/0300-9084(96)82643-5
   Lee GJ, 2000, PLANT PHYSIOL, V122, P189, DOI 10.1104/pp.122.1.189
   Leppa S, 1997, ANN MED, V29, P73, DOI 10.3109/07853899708998745
   MARMOR MF, 1990, EYE, V4, P340, DOI 10.1038/eye.1990.46
   Marmorstein AD, 2001, TRAFFIC, V2, P867, DOI 10.1034/j.1600-0854.2001.21202.x
   Marmorstein AD, 1998, ANN NY ACAD SCI, V857, P1, DOI 10.1111/j.1749-6632.1998.tb10102.x
   MARSHALL J, 1987, EYE-T OPHTH SOC UK, V1, P282, DOI 10.1038/eye.1987.47
   Martinez-Vicente M, 2005, EXP GERONTOL, V40, P622, DOI 10.1016/j.exger.2005.07.005
   Massey AC, 2006, P NATL ACAD SCI USA, V103, P5805, DOI 10.1073/pnas.0507436103
   Matsuyama A, 2002, EMBO J, V21, P6820, DOI 10.1093/emboj/cdf682
   Mayer MP, 1999, CURR BIOL, V9, pR322, DOI 10.1016/S0960-9822(99)80203-6
   MEHLEN P, 1994, EUR J BIOCHEM, V221, P327, DOI 10.1111/j.1432-1033.1994.tb18744.x
   Meijer Alfred J., 2006, Molecular Aspects of Medicine, V27, P411, DOI 10.1016/j.mam.2006.08.002
   MILNER CM, 1990, IMMUNOGENETICS, V32, P242
   Minnnaugh EG, 2004, MOL CANCER THER, V3, P551
   Mitch WE, 1996, NEW ENGL J MED, V335, P1897, DOI 10.1056/NEJM199612193352507
   MORIMOTO RI, 1993, SCIENCE, V259, P1409, DOI 10.1126/science.8451637
   Morimoto RI, 1998, GENE DEV, V12, P3788, DOI 10.1101/gad.12.24.3788
   Morimoto RI, 2008, GENE DEV, V22, P1427, DOI 10.1101/gad.1657108
   Nilsson SEG, 2003, DOC OPHTHALMOL, V106, P13, DOI 10.1023/A:1022419606629
   Nordgaard CL, 2008, INVEST OPHTH VIS SCI, V49, P2848, DOI 10.1167/iovs.07-1352
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Oksala NKJ, 2002, EUR SURG RES, V34, P397, DOI 10.1159/000065708
   Pandey UB, 2007, AUTOPHAGY, V3, P643, DOI 10.4161/auto.5050
   Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200
   Parish CA, 1998, P NATL ACAD SCI USA, V95, P14609, DOI 10.1073/pnas.95.25.14609
   Pearl LH, 2008, BIOCHEM J, V410, P439, DOI 10.1042/BJ20071640
   Pearl LH, 2002, ADV PROTEIN CHEM, V59, P157
   Pirkkala L, 2000, MOL CELL BIOL, V20, P2670, DOI 10.1128/MCB.20.8.2670-2675.2000
   Polier S, 2008, CELL, V133, P1068, DOI 10.1016/j.cell.2008.05.022
   Prodromou C, 2000, EMBO J, V19, P4383, DOI 10.1093/emboj/19.16.4383
   Ravikumar B, 2004, NAT GENET, V36, P585, DOI 10.1038/ng1362
   Richter K, 2001, J CELL PHYSIOL, V188, P281, DOI 10.1002/jcp.1131
   Richter K, 2001, J BIOL CHEM, V276, P33689, DOI 10.1074/jbc.M103832200
   Richter K, 2006, CELL, V127, P251, DOI 10.1016/j.cell.2006.10.004
   RYHANEN T, 2008, J CELL MOL MED
   Ryhanen T, 2008, EUR J PHARMACOL, V584, P229, DOI 10.1016/j.ejphar.2008.02.010
   Salminen A, 2008, CELL MOL LIFE SCI, V65, P1049, DOI 10.1007/s00018-008-7461-3
   Salvador N, 2000, J BIOL CHEM, V275, P27447
   SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392
   Schubert U, 2000, NATURE, V404, P770, DOI 10.1038/35008096
   Schutt F, 2003, INVEST OPHTH VIS SCI, V44, P3663, DOI 10.1167/iovs.03-0172
   Schutt F, 2002, FEBS LETT, V528, P217, DOI 10.1016/S0014-5793(02)03312-4
   Schutt F, 2001, OPHTHALMOLOGE, V98, P721, DOI 10.1007/s003470170078
   Seigneurin-Berny D, 2001, MOL CELL BIOL, V21, P8035, DOI 10.1128/MCB.21.23.8035-8044.2001
   Seitsonen SP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003833
   Shamsi FA, 2001, INVEST OPHTH VIS SCI, V42, P3041
   Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993
   Simonsen A, 2004, J CELL SCI, V117, P4239, DOI 10.1242/jcs.01287
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   Sparrow JR, 2003, ADV EXP MED BIOL, V533, P205
   SUGASAWA K, 1994, CELL STRUCT FUNCT, V19, P21, DOI 10.1247/csf.19.21
   Suh WC, 1999, J BIOL CHEM, V274, P30534, DOI 10.1074/jbc.274.43.30534
   Suter M, 2000, J BIOL CHEM, V275, P39625, DOI 10.1074/jbc.M007049200
   Suzuki K, 2001, EMBO J, V20, P5971, DOI 10.1093/emboj/20.21.5971
   Tanaka Y, 2000, NATURE, V406, P902, DOI 10.1038/35022595
   Taylor JP, 2003, HUM MOL GENET, V12, P749, DOI 10.1093/hmg/ddg074
   TERLECKY SR, 1992, J BIOL CHEM, V267, P9202
   Terman A, 2007, J PATHOL, V211, P134, DOI 10.1002/path.2094
   Terman A, 2004, INT J BIOCHEM CELL B, V36, P1400, DOI 10.1016/j.biocel.2003.08.009
   Verdel A, 2000, CURR BIOL, V10, P747, DOI 10.1016/S0960-9822(00)00542-X
   Verdel A, 1999, J BIOL CHEM, V274, P2440, DOI 10.1074/jbc.274.4.2440
   Wassell J, 1997, BRIT J OPHTHALMOL, V81, P911, DOI 10.1136/bjo.81.10.911
   Winkler BS, 1999, MOL VIS, V5
   Wojcik C, 2002, J CELL MOL MED, V6, P25, DOI 10.1111/j.1582-4934.2002.tb00309.x
   XIAO H, 1988, SCIENCE, V239, P1139, DOI 10.1126/science.3125608
   Xie ZP, 2007, NAT CELL BIOL, V9, P1102, DOI 10.1038/ncb1007-1102
   Yang SH, 2005, EMBO J, V24, P2161, DOI 10.1038/sj.emboj.7600690
   Zhang C, 2008, NAT MED, V14, P959, DOI 10.1038/nm.1851
   Zhang Y, 2003, EMBO J, V22, P1168, DOI 10.1093/emboj/cdg115
   Zhang Y, 2006, J BIOL CHEM, V281, P2401, DOI 10.1074/jbc.C500241200
   Zou JY, 1998, CELL, V94, P471, DOI 10.1016/S0092-8674(00)81588-3
NR 189
TC 87
Z9 89
U1 1
U2 12
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 1568-1637
EI 1872-9649
J9 AGEING RES REV
JI Ageing Res. Rev.
PD APR
PY 2009
VL 8
IS 2
BP 128
EP 139
DI 10.1016/j.arr.2009.01.001
PG 12
WC Cell Biology; Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Geriatrics & Gerontology
GA 425US
UT WOS:000264663500007
PM 19274853
DA 2022-11-30
ER

PT J
AU Fletcher, EC
   Lade, RJ
   Adewoyin, T
   Chong, NV
AF Fletcher, E. C.
   Lade, R. J.
   Adewoyin, T.
   Chong, N. V.
TI Computerized Model of Cost-Utility Analysis for Treatment of Age-Related
   Macular Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID QUALITY-OF-LIFE; SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; CONTRAST
   SENSITIVITY; CLINICAL-TRIALS; VISUAL-ACUITY; RANIBIZUMAB; VERTEPORFIN;
   BLINDNESS; THERAPY
AB Purpose: To present a computerized model assessing individualized cost utility for current treatments for neovascular age-related macular degeneration (AMD) to enhance discussion regarding treatment options.
   Design: Case- and eye-specific cost-utility analysis using individual case scenarios.
   Participants: Visual acuity data from published randomized controlled trials are incorporated into this analysis.
   Methods: Computerized model (Microsoft Visual Basic 6.0 programming) to establish preference-based cost-utility analysis in association with individual cost of treatment and blindness for neovascular AMD for both the better and worst seeing eye, with extrapolation of results over a 5-year term.
   Main Outcome Measures: Cost per quality-adjusted life-year (QALY) and cost per QALY gained for comparison of treatments for specific visual acuities.
   Results: All treatments show an increase in utility in comparison with best supportive care (BSC) if the better-seeing eye is treated. Ranibizumab, using the Phase IIIb, Multicenter, Randomized, Double-Masked, Sham Injection-Controlled Study of the Efficacy and Safety of Ranibizumab in Subjects with Subfoveal Choroidal Neovascularisation (CNV) with or without Classic CNV Secondary to AMD (PIER) regimen, is the most cost effective at $626 938 per QALY gained for treatment of the better seeing eye. To increase utility value when treating the worst seeing eye, the vision must improve to such a degree that it becomes the better seeing eye. This level of improvement is only possible if there is <9 letters difference between the 2 eyes and treated with ranibizumab. Over 5 years, increasing influence from the cost of blindness results in increasing costs for those treatments unable to stabilize vision. Within 5 years, the cost per QALY for the BSC is greater than all treatments except monthly ranibizumab injections.
   Conclusions: Assessment of cost of treatment incorporates both effectiveness of treatment, cost of treatment, and cost of blindness. Cost analysis enables incorporation of these aspects of treatment with the quality of life data to provide a better comparison of treatments over time. This analysis has provided a method for individual analysis and therefore can provide the structure for resource allocation.
   Financial Disclosure(s): The authors have no proprietary or commercial interest in any materials discussed in this article. Ophthalmology 2008;115:2192-2198 (C) 2008 by the American Academy of Ophthalmology.
C1 [Fletcher, E. C.; Adewoyin, T.; Chong, N. V.] Kings Coll Hosp London, London, England.
   [Lade, R. J.] Kings Coll Hosp London, London, England.
C3 King's College Hospital NHS Foundation Trust; King's College Hospital;
   King's College Hospital NHS Foundation Trust; King's College Hospital
RP Fletcher, EC (通讯作者)，Stoke Mandeville Hosp, Mandeville Rd, Aylesbury HP21 8AL, Bucks, England.
EM emily_efletcher@yahoo.co.uk
RI Chong, Ngaihang V/A-5141-2009; Chong, Victor/Q-6565-2018
OI Chong, Victor/0000-0002-7693-522X
FU Novartis; Pfizer; Allergan; Eyetech; Eli Lilly
FX N. V. Chong served on Advisory Board and has received Honorarium and
   Speaker Fees from Novartis, Bayer, Regeneron. Pfizer, and Astex. The
   authors' department has received research funding from Novartis, Pfizer,
   Allergan, Eyetech, and Eli Lilly. However, this project was not funded
   by any of the above companies.
CR Bansback N, 2007, EYE, V21, P1455, DOI 10.1038/sj.eye.6702636
   Bansback N, 2007, QUAL LIFE RES, V16, P533, DOI 10.1007/s11136-006-9126-8
   Brown G C, 2001, Trans Am Ophthalmol Soc, V99, P199
   Brown MM, 2008, OPHTHALMOLOGY, V115, P1039, DOI 10.1016/j.ophtha.2007.08.033
   Brown MM, 2001, BRIT J OPHTHALMOL, V85, P327, DOI 10.1136/bjo.85.3.327
   Chakravarthy U, 2006, OPHTHALMOLOGY, V113, P1508, DOI 10.1016/j.ophtha.2006.02.064
   Dempster M, 2000, HEART, V83, P641, DOI 10.1136/heart.83.6.641
   Kaiser PK, 2006, GRAEF ARCH CLIN EXP, V244, P1132, DOI 10.1007/s00417-005-0199-9
   LAUPACIS A, 1992, CAN MED ASSOC J, V146, P473
   Meads C, 2003, BRIT J OPHTHALMOL, V87, P1201, DOI 10.1136/bjo.87.10.1201
   MEADS C, 2002, CLIN EFFECTIVENESS C, P16
   Nguyen NX, 2007, ACTA OPHTHALMOL SCAN, V85, P877, DOI 10.1111/j.1600-0420.2007.00963.x
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sharma S, 2001, OPHTHALMOLOGY, V108, P2051, DOI 10.1016/S0161-6420(01)00764-3
   Sharma S, 2000, CAN J OPHTHALMOL, V35, P267, DOI 10.1016/S0008-4182(00)80077-0
   Simon Pickard A, 2005, QUAL LIFE RES, V14, P207, DOI 10.1007/s11136-004-3928-3
   Soubrane G, 2007, ARCH OPHTHALMOL-CHIC, V125, P1249, DOI 10.1001/archopht.125.9.1249
NR 18
TC 25
Z9 26
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD DEC
PY 2008
VL 115
IS 12
BP 2192
EP 2198
DI 10.1016/j.ophtha.2008.07.018
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 381PK
UT WOS:000261548200011
PM 18930556
DA 2022-11-30
ER

PT J
AU Marcus, D
   Sheils, WC
   Benson, J
   Leibach, D
   Stanley, M
   Akins, W
   Rogers, CL
   Thomas, T
   Honea, N
   Radcliff, L
   DeBeus, A
   Gordon, A
   Reinke, M
   Sell, C
   Lam, S
   Wickman, B
   Duncan, C
   George, C
   Flaxel, CJ
   Walonker, F
   Morales, RB
   Nichols, T
   Thomas, M
   Petrovich, Z
   Astrahan, M
   Weissgold, DJ
   Corrada, F
   Bourassa, L
   Church, L
   Millay, RM
   Roland, T
   Goodwin, J
   Bianchi, A
   Hatch, D
   Brucker, A
   Dupont, J
   Wilson-Miller, P
   Elkins, D
   Nyberg, B
   Weeney, L
   Fine, S
   Glatstein, E
   Das, I
   Aaberg, T
   Burian, G
   Batcha, M
   Gilman, J
   Myles, B
   Hubbard, GB
   Davis, L
   Butker, E
   Schmitz, N
   Arend, L
   Plater, N
   Holm, J
   Irwin, R
   Prusak, R
   Redfield, T
   Noguchi, B
   Hawkins, R
   Goodin, F
   Ferran, J
   Minturn, J
   Agugliaro, D
   Lamb, C
   Garrett, P
   Frye, D
   Cohen, S
   Grecula, J
   Kanellitsas, C
   Sansami, N
   Gupta, N
   Chaudhuri, C
   Milliron, J
   Olsen, KR
   Green, D
   Campbell, AF
   Deutsch, M
   Blodgett, K
   Wilcox, L
   Fine, SL
   Maguire, M
   Peskin, E
   Brightwell-Arnold, M
   Holmes, C
   Jewell, M
   Jarnes, A
   O'Brien, L
   Stanford, NN
   Whearry, C
   Ying, GS
   Maguire, A
   Alexander, J
   Begley, S
   Elsner, K
   Javornik, N
   Marcus, DM
   McWilliams, K
   Whittock, ER
   Fotlowill, D
   Cotch, F
   Kurinij, N
   Redford, M
   Dienerwest, M
   Martin, D
   McCcormick, B
   Murray, T
   Marcus, D
   Peskin, E
   Maguire, M
   Weissgold, D
   Alexander, J
   Fine, S
   Followill, D
AF Marcus, D
   Sheils, WC
   Benson, J
   Leibach, D
   Stanley, M
   Akins, W
   Rogers, CL
   Thomas, T
   Honea, N
   Radcliff, L
   DeBeus, A
   Gordon, A
   Reinke, M
   Sell, C
   Lam, S
   Wickman, B
   Duncan, C
   George, C
   Flaxel, CJ
   Walonker, F
   Morales, RB
   Nichols, T
   Thomas, M
   Petrovich, Z
   Astrahan, M
   Weissgold, DJ
   Corrada, F
   Bourassa, L
   Church, L
   Millay, RM
   Roland, T
   Goodwin, J
   Bianchi, A
   Hatch, D
   Brucker, A
   Dupont, J
   Wilson-Miller, P
   Elkins, D
   Nyberg, B
   Weeney, L
   Fine, S
   Glatstein, E
   Das, I
   Aaberg, T
   Burian, G
   Batcha, M
   Gilman, J
   Myles, B
   Hubbard, GB
   Davis, L
   Butker, E
   Schmitz, N
   Arend, L
   Plater, N
   Holm, J
   Irwin, R
   Prusak, R
   Redfield, T
   Noguchi, B
   Hawkins, R
   Goodin, F
   Ferran, J
   Minturn, J
   Agugliaro, D
   Lamb, C
   Garrett, P
   Frye, D
   Cohen, S
   Grecula, J
   Kanellitsas, C
   Sansami, N
   Gupta, N
   Chaudhuri, C
   Milliron, J
   Olsen, KR
   Green, D
   Campbell, AF
   Deutsch, M
   Blodgett, K
   Wilcox, L
   Fine, SL
   Maguire, M
   Peskin, E
   Brightwell-Arnold, M
   Holmes, C
   Jewell, M
   Jarnes, A
   O'Brien, L
   Stanford, NN
   Whearry, C
   Ying, GS
   Maguire, A
   Alexander, J
   Begley, S
   Elsner, K
   Javornik, N
   Marcus, DM
   McWilliams, K
   Whittock, ER
   Fotlowill, D
   Cotch, F
   Kurinij, N
   Redford, M
   Dienerwest, M
   Martin, D
   McCcormick, B
   Murray, T
   Marcus, D
   Peskin, E
   Maguire, M
   Weissgold, D
   Alexander, J
   Fine, S
   Followill, D
CA AMDRT Res Grp
TI The age-related macular degeneration radiotherapy trial (AMDRT): One
   year results from a pilot study
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; PROTON-BEAM IRRADIATION;
   RADIATION-THERAPY; ENDOTHELIAL-CELLS; TELETHERAPY; RADIOSENSITIVITY;
   MEMBRANES
AB PURPOSE: To assess the short-term safety and efficacy of treating subfoveal choroidal neovascularization (CNV) with external beam radiation delivered in 5 x 4 Gy fractions among patients having age-related macular degeneration (AMD).
   DESIGN: A multicenter prospective randomized controlled pilot study.
   METHODS: Eighty-eight patients were enrolled through 10 sites and were randomized to radiotherapy (20 Gy delivered in 5 daily fractions of 4 Gy each; 6 MV [N = 411) or no radiotherapy (sham radiotherapy EN = 22] or observation [N = 25]). Eligibility criteria included visual acuity of at least 20/320 and subfoveal CNV not ame- nable to treatment. Randomization was stratified by lesion type (new or recurrent CNV) and blood (<50% or greater than or equal to50% of the lesion [N = 13]). The primary outcome measure was loss of greater than or equal to3 lines of visual acuity. Secondary outcome measures were angiographic response and side effects.
   RESULTS: At baseline, patient and ocular characteristics were similar between treatment groups. At six months, 9 radiated eyes (26%) and 17 eyes not radiated (49%) lost greater than or equal to3 lines of visual acuity (P =.04; stratified X 2 test). At 12 months, 13 radiated eyes (42%) and 9 observed eyes (49%) lost greater than or equal to3 visual acuity lines (P =.60). The radiated group demonstrated smaller lesions and less fibrosis than the nonradiated group (P =.05 and .004, respectively) at 12 months. Radiation,induced complications were not observed except for one radiated eye with numerous cotton wool spots and possible radiation retinopathy.
   CONCLUSIONS: External beam radiation at 5 x 4 Gy may have a modest and short,lived (six month) benefit in preserving visual acuity. (C) 2004 by Elsevier Inc. All rights reserved.
C1 Univ Penn, Dept Ophthalmol, Philadelphia, PA 19104 USA.
C3 University of Pennsylvania
RP Peskin, E (通讯作者)，Univ Penn, Dept Ophthalmol, 3535 Market St, Philadelphia, PA 19104 USA.
EM peskin@mail.med.upenn.edu
RI Grecula, John/E-3149-2011
FU NATIONAL EYE INSTITUTE [R21EY012341] Funding Source: NIH RePORTER; NEI
   NIH HHS [R21 EY12341] Funding Source: Medline
CR ARLETT CF, 1980, CANCER RES, V40, P926
   Bergink GJ, 1998, GRAEF ARCH CLIN EXP, V236, P321, DOI 10.1007/s004170050085
   BERGINK GJ, 1995, DOC OPHTHALMOL, V90, P67, DOI 10.1007/BF01203296
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   CHAKRAVARTHY U, 1993, BRIT J OPHTHALMOL, V77, P265, DOI 10.1136/bjo.77.5.265
   Char DH, 1999, AM J OPHTHALMOL, V127, P574, DOI 10.1016/S0002-9394(99)00038-0
   Ciulla TA, 2002, AM J OPHTHALMOL, V134, P905, DOI 10.1016/S0002-9394(02)01821-4
   FAJARDO LF, 1988, PATHOL ANNU, V23, P297
   Finger PT, 1996, OPHTHALMOLOGY, V103, P878, DOI 10.1016/S0161-6420(96)30592-7
   Finger PT, 1999, AM J OPHTHALMOL, V127, P170, DOI 10.1016/S0002-9394(98)00389-4
   Flaxel CJ, 2000, EYE, V14, P155, DOI 10.1038/eye.2000.46
   Freire J, 1996, INT J RADIAT ONCOL, V36, P857, DOI 10.1016/S0360-3016(96)00428-2
   HART PM, 1995, BRIT J OPHTHALMOL, V79, P562, DOI 10.1136/bjo.79.6.562
   Hart PM, 1996, BRIT J OPHTHALMOL, V80, P1046, DOI 10.1136/bjo.80.12.1046
   Hart PM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1029
   Holz FG, 1999, OPHTHALMOLOGY, V106, P2239
   JOHNSON LK, 1982, ANAL QUANT CYTOL, V4, P188
   Kobayashi H, 2000, AM J OPHTHALMOL, V130, P617, DOI 10.1016/S0002-9394(00)00534-1
   Marcus DM, 2001, ARCH OPHTHALMOL-CHIC, V119, P171
   Newcombe RG., 2000, STAT CONFIDENCE, V2nd
   Postgens H, 1997, GRAEF ARCH CLIN EXP, V235, P656, DOI 10.1007/BF00946943
   REINHOLD HS, 1973, BRIT J RADIOL, V46, P54, DOI 10.1259/0007-1285-46-541-54
   ROSANDER K, 1995, ACTA ONCOL, V34, P111, DOI 10.3109/02841869509093648
   Rubin DB, 1996, RADIAT RES, V145, P210, DOI 10.2307/3579176
   Saornil MA, 1997, ARCH OPHTHALMOL-CHIC, V115, P1395, DOI 10.1001/archopht.1997.01100160565006
   SAORNIL MA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1112, DOI 10.1001/archopht.1992.01080200092031
   Spaide RF, 1998, OPHTHALMOLOGY, V105, P24, DOI 10.1016/S0161-6420(98)90980-0
   Stalmans P, 1997, RETINA-J RET VIT DIS, V17, P481
   Valmaggia C, 2002, AM J OPHTHALMOL, V133, P521, DOI 10.1016/S0002-9394(02)01336-3
   Yonemoto LT, 1996, INT J RADIAT ONCOL, V36, P867, DOI 10.1016/S0360-3016(96)00339-2
   YONEMOTO LT, 2000, J RADIOSURG, V3, P47
   1998, PB98166648 NTIS
NR 32
TC 34
Z9 50
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD NOV
PY 2004
VL 138
IS 5
BP 818
EP 828
DI 10.1016/j.ajo.2004.06.081
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 870UF
UT WOS:000225083100016
PM 15531318
DA 2022-11-30
ER

PT J
AU Ponnusamy, C
   Sugumaran, A
   Krishnaswami, V
   Kandasamy, R
   Natesan, S
AF Ponnusamy, Chandrasekar
   Sugumaran, Abimanyu
   Krishnaswami, Venkateshwaran
   Kandasamy, Ruckmani
   Natesan, Subramanian
TI Design and development of artemisinin and dexamethasone loaded topical
   nanodispersion for the effective treatment of age-related macular
   degeneration
SO IET NANOBIOTECHNOLOGY
LA English
DT Article
DE drug delivery systems; drugs; eye; blood vessels; DNA; biochemistry;
   nanofabrication; molecular biophysics; nanomedicine; diseases;
   biomedical materials; polymers; membranes; topical administration;
   enhanced ocular residence time; controlled prolonged drug delivery;
   disease site; eye; topical ocular administration; polymeric surfactant;
   dexamethasone release; dexamethasone nanodispersion; AMD treatment;
   blood vessel formation; drug concentration; in-vitro drug release;
   antiangiogenic effect; artemisinin; dexamethasone loaded topical
   nanodispersion; age-related macular degeneration effective treatment;
   antivascular endothelial growth factor agents; antiangiogenic
   endothelial growth factor agents; antiVEGF agent; polyvinyl pyrrolidone
   K90; polymer concentration; Poloxamer 407; size 12; 0 nm to 26; 0 nm;
   chorioallantoic membrane assay; DNA damage; haemolysis
ID IN-VITRO; DELIVERY SYSTEM; DRUG-DELIVERY; PERMEABILITY; ENHANCEMENT;
   TRANSFERRIN; SOLUBILITY; WATER
AB Age-related macular degeneration (AMD) is a disease affecting the macula by the new blood vessels formation. AMD is widely treated with a combination of anti-angiogenic and anti-vascular endothelial growth factor (VEGF) agents. The topical administration of nanodispersions showed enhanced ocular residence time with controlled and prolonged drug delivery to the disease site at the back of the eye. In the present study we developed and characterized nanodispersion containing anti-angiogenic (artemisinin) and anti-VEGF agent (dexamethasone) for the topical ocular administration in order to obtain a required drug concentration in the posterior part of the eye. The nanodispersions were prepared with varying concentration of polymer, polyvinyl pyrrolidone K90 and polymeric surfactant, Poloxamer 407. The nanodispersions were found to be smooth and spherical in shape with a size range of 12-26 nm. In-vitro drug release studies showed the 90-101% of artemisinin and 55-103% of dexamethasone release from the nanodispersions. The blank formulation with a high concentration of polymer and polymeric surfactant showed an acceptable level of haemolysis and DNA damage. The chorioallantoic membrane assay suggested that the nanodispersion possess good anti-angiogenic effect. Hence the formulated artemisinin and dexamethasone nanodispersion may have the great potential for the AMD treatment.
C1 [Ponnusamy, Chandrasekar; Krishnaswami, Venkateshwaran; Kandasamy, Ruckmani; Natesan, Subramanian] Anna Univ, Bharathidasan Inst Technol, Dept Pharmaceut Technol, Tiruchirappalli, Tamil Nadu, India.
   [Sugumaran, Abimanyu] SRM Inst Sci & Technol, Dept Pharmaceut, Kattankulathur, Tamil Nadu, India.
C3 Anna University; Anna University of Technology Tiruchirappalli; SRM
   Institute of Science & Technology Chennai
RP Natesan, S (通讯作者)，Anna Univ, Bharathidasan Inst Technol, Dept Pharmaceut Technol, Tiruchirappalli, Tamil Nadu, India.
EM natesansubbu@gmail.com
RI Sugumaran, Dr Abimanyu/M-5806-2019
OI Sugumaran, Dr Abimanyu/0000-0003-2321-9876; Kandasamy,
   Ruckmani/0000-0003-4125-0244
FU University Grants Commission
FX The authors thank the BASF, Mumbai for providing PVP K90 and Poloxamer
   407 to carry out this research work successfully. One of the authors Dr
   P. Chandrasekar is very thankful to the University Grants Commission for
   providing the research fellowship (RGNF).
CR Amin K, 2006, J PHARM SCI-US, V95, P1173, DOI 10.1002/jps.20627
   Augustin A. J., 2008, RETINA TODAY, P49
   Brown DM, 2007, AM J OPHTHALMOL, V144, P627, DOI 10.1016/j.ajo.2007.06.039
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown MM, 2005, CAN J OPHTHALMOL, V40, P277, DOI 10.1016/S0008-4182(05)80070-5
   Browning AC, 2004, J ROY SOC MED, V97, P166, DOI 10.1258/jrsm.97.4.166
   Cao YX, 2007, J CONTROL RELEASE, V120, P186, DOI 10.1016/j.jconrel.2007.05.009
   Chakravarthy U, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c981
   Chowers I, 2006, INVEST OPHTH VIS SCI, V47, P2135, DOI 10.1167/iovs.05-1135
   Urban MCC, 2009, BRAZ J PHARM SCI, V45, P87, DOI 10.1590/S1984-82502009000100010
   Crespo-Ortiz MP, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/247597
   Diebold Y, 2010, PROG RETIN EYE RES, V29, P596, DOI 10.1016/j.preteyeres.2010.08.002
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Dixit M, 2011, INDIAN J PHARM EDUC, V45, P346
   Efferth T, 2004, FREE RADICAL BIO MED, V37, P998, DOI 10.1016/j.freeradbiomed.2004.06.023
   El-Kamel AH, 2002, INT J PHARMACEUT, V241, P47, DOI 10.1016/S0378-5173(02)00234-X
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Galeska I, 2005, AAPS J, V7, pE231, DOI 10.1208/aapsj070122
   Gallego JML, 2002, J PHARMACEUT BIOMED, V30, P1255, DOI 10.1016/S0731-7085(02)00468-5
   Garg AK, 2013, INT J PHARM BIO SCI, V4, P934
   Gaudana R, 2010, AAPS J, V12, P348, DOI 10.1208/s12248-010-9183-3
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Ghate D, 2007, INVEST OPHTH VIS SCI, V48, P2230, DOI 10.1167/iovs.06-0954
   Ghate Deepta, 2006, Expert Opin Drug Deliv, V3, P275, DOI 10.1517/17425247.3.2.275
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Kumavat S. D., 2013, INT J PHARM RES SCI, V2, P693
   Kwak H W, 1995, Korean J Ophthalmol, V9, P79
   Li C, 2010, J CHROMATOGR A, V1217, P411, DOI 10.1016/j.chroma.2009.12.015
   Li X, 2009, DRUG DELIV, V16, P224, DOI 10.1080/10717540902850567
   Majumdar S, 2009, PHARM RES-DORDR, V26, P1217, DOI 10.1007/s11095-008-9729-6
   Malhotra Manjusha, 2001, Indian Journal of Experimental Biology, V39, P11
   Medhi B, 2009, PHARMACOLOGY, V84, P323, DOI 10.1159/000252658
   Nagarwal RC, 2009, J CONTROL RELEASE, V136, P2, DOI 10.1016/j.jconrel.2008.12.018
   Nakase I, 2008, INT J PHARM, V354, P28, DOI 10.1016/j.ijpharm.2007.09.003
   O'Neill PM, 2010, MOLECULES, V15, P1705, DOI 10.3390/molecules15031705
   Pascolini D, 2004, OPHTHAL EPIDEMIOL, V11, P67, DOI 10.1076/opep.11.2.67.28158
   Patel J, 2011, J ADV PHARM TECHNOL, V2, P9, DOI 10.4103/2231-4040.79799
   Ponnusamy C, 2014, CURR PHARM ANAL, V10, P44, DOI 10.2174/157341291001140102111031
   Raghava Swita, 2004, Expert Opin Drug Deliv, V1, P99, DOI 10.1517/17425247.1.1.99
   Rajaguru R, 2002, MUTAT RES-GEN TOX EN, V517, P29, DOI 10.1016/S1383-5718(02)00025-6
   Seow LJ, 2011, J ETHNOPHARMACOL, V134, P221, DOI 10.1016/j.jep.2010.12.007
   Song M, 2010, J NANOSCI NANOTECHNO, V10, P6934, DOI 10.1166/jnn.2010.2984
   Tao Weng, 2006, Expert Opin Biol Ther, V6, P717, DOI 10.1517/14712598.6.7.717
   UEDA A, 1987, CELL TISSUE RES, V249, P473
   Vyas V, 2009, ACTA PHARMACEUT, V59, P453, DOI 10.2478/v10007-009-0037-4
   Wen H, 2010, PHARM RES-DORDR, V27, P2446, DOI 10.1007/s11095-010-0237-0
   Zhang Y, 2006, J NANOSCI NANOTECHNO, V6, P3877, DOI 10.1166/jnn.2006.673
NR 48
TC 4
Z9 4
U1 1
U2 16
PU INST ENGINEERING TECHNOLOGY-IET
PI HERTFORD
PA MICHAEL FARADAY HOUSE SIX HILLS WAY STEVENAGE, HERTFORD SG1 2AY, ENGLAND
SN 1751-8741
EI 1751-875X
J9 IET NANOBIOTECHNOL
JI IET Nanobiotechnol.
PD OCT
PY 2019
VL 13
IS 8
BP 868
EP 874
DI 10.1049/iet-nbt.2019.0130
PG 7
WC Biochemical Research Methods; Nanoscience & Nanotechnology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Science & Technology - Other Topics
GA JE1PE
UT WOS:000490467100014
PM 31625529
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Ohnaka, M
   Nagai, Y
   Sho, K
   Miki, K
   Kimura, M
   Chihara, T
   Takahashi, K
AF Ohnaka, Masayuki
   Nagai, Yoshimi
   Sho, Kenichiro
   Miki, Katsuaki
   Kimura, Motoki
   Chihara, Tomoyuki
   Takahashi, Kanji
TI A modified treat-and-extend regimen of aflibercept for treatment-na < ve
   patients with neovascular age-related macular degeneration
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Neovascular age-related macular degeneration; Anti-vascular endothelial
   growth factor; Aflibercept; Treat-and-extend regimen; Pro re nata dosing
   regimen; Treatment-naive patients
ID INTRAVITREAL AFLIBERCEPT; VISUAL IMPAIRMENT; RANIBIZUMAB; PEGAPTANIB;
   EFFICACY; OUTCOMES; SAFETY; AMD
AB To evaluate a modified treat-and-extend (TAE) regimen of intravitreal aflibercept injection (IAI) for treatment-naive patients with neovascular age-related macular degeneration (AMD).
   Thirty-six eyes (36 patients) treated with the modified TAE regimen were evaluated at 12 months retrospectively. The modified TAE regimen consisted of three steps: 1) an induction phase, during which patients were treated with ae 3-monthly IAIs until exudative activity disappeared, 2) an observation phase, during which patients were monitored until exudative activity appeared, and 3) a TAE phase, for which the initial treatment interval was determined based on the disease recurrence interval, followed by treatment intervals changing by 2 weeks.
   Mean logMAR BCVA improved significantly from 0.48 +/- 0.51 at baseline to 0.40 +/- 0.53 at 12 months (P < 0.01), and was maintained (losing < 0.3 logMAR units) in 35 eyes (97.2 %). Mean central retinal thickness and central choroidal thickness decreased significantly after 12 months. In the TAE phase, the distribution of treatment intervals was ae8 weeks in 64.7 % (11 eyes) at 12 months. The mean number of injections was 4.53.
   A modified TAE regimen of IAI for neovascular AMD produced good functional outcomes over 12 months with the small number of injections.
C1 [Ohnaka, Masayuki; Nagai, Yoshimi; Sho, Kenichiro; Miki, Katsuaki; Kimura, Motoki; Chihara, Tomoyuki; Takahashi, Kanji] Kansai Med Univ, Dept Ophthalmol, 2-5-1 Shinmachi, Hirakata, Osaka 5731010, Japan.
C3 Kansai Medical University
RP Ohnaka, M (通讯作者)，Kansai Med Univ, Dept Ophthalmol, 2-5-1 Shinmachi, Hirakata, Osaka 5731010, Japan.
EM ohnakam@hirakata.kmu.ac.jp
CR Abedi F, 2014, RETINA-J RET VIT DIS, V34, P1531, DOI 10.1097/IAE.0000000000000134
   Augustin AJ, 2009, EXPERT OPIN THER TAR, V13, P641, DOI 10.1517/14728220902942322
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chakravarthy U, 2006, OPHTHALMOLOGY, V113, P1508, DOI 10.1016/j.ophtha.2006.02.064
   Cho H, 2013, BRIT J OPHTHALMOL, V97, P1032, DOI 10.1136/bjophthalmol-2013-303344
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Grewal DS, 2014, EYE, V28, P895, DOI 10.1038/eye.2014.101
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Kawashima Y, 2015, GRAEF ARCH CLIN EXP, V253, P1471, DOI 10.1007/s00417-014-2838-5
   Kuroda Y, 2015, OPHTHALMOLOGY, V122, P2303, DOI 10.1016/j.ophtha.2015.06.053
   Mantel I, 2014, BRIT J OPHTHALMOL, V98, P1192, DOI 10.1136/bjophthalmol-2013-304556
   McKibbin M, 2015, EYE, V29, pS1, DOI 10.1038/eye.2015.77
   Rayess N, 2015, AM J OPHTHALMOL, V159, P3, DOI 10.1016/j.ajo.2014.09.011
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Singerman LJ, 2008, BRIT J OPHTHALMOL, V92, P1606, DOI 10.1136/bjo.2007.132597
   Wecker T, 2017, BRIT J OPHTHALMOL, V101, P353, DOI 10.1136/bjophthalmol-2016-308668
   Wolf A, 2014, GRAEF ARCH CLIN EXP, V252, P647, DOI 10.1007/s00417-013-2562-6
   Yonekawa Y, 2013, AM J OPHTHALMOL, V156, P29, DOI 10.1016/j.ajo.2013.03.030
NR 22
TC 20
Z9 20
U1 0
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD APR
PY 2017
VL 255
IS 4
BP 657
EP 664
DI 10.1007/s00417-016-3507-7
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA ER5DE
UT WOS:000398820800003
PM 27743159
DA 2022-11-30
ER

PT J
AU Mokwa, NF
   Ristau, T
   Keane, PA
   Kirchhof, B
   Sadda, SR
   Liakopoulos, S
AF Mokwa, Nils F.
   Ristau, Tina
   Keane, Pearse A.
   Kirchhof, Bernd
   Sadda, Srinivas R.
   Liakopoulos, Sandra
TI Grading of Age-Related Macular Degeneration: Comparison between Color
   Fundus Photography, Fluorescein Angiography, and Spectral Domain Optical
   Coherence Tomography
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID CHOROIDAL NEOVASCULARIZATION; RANIBIZUMAB; VERTEPORFIN; MACULOPATHY;
   LEAKAGE
AB Purpose. To compare color fundus photography (FP), fluorescein angiography (FA), and spectral domain optical coherence tomography (SDOCT) for the detection of age-related macular degeneration (AMD), choroidal neovascularisation (CNV), and CNV activity. Methods. FPs, FAs, and SDOCT volume scans from 120 eyes of 66 AMD and control patients were randomly collected. Control eyes were required to show noAMD, but other retinal pathology was allowed. The presence of drusen, pigmentary changes, CNV, and signs for CNV activity was independently analyzed for all imaging modalities. Results. AMD was diagnosed based on FP in 75 eyes. SDOCT and FA showed sensitivity (specificity) of 89% (76%) and 92% (82%), respectively. CNV was present on FA in 68 eyes. Sensitivity (specificity) was 78% (100%) for FP and 94% (98%) for SDOCT. CNV activity was detected by SDOCT or FA in 60 eyes with an agreement in 46 eyes. Sensitivity was 88% for SDOCT and 88% for FA. FP showed sensitivity of 38% and specificity of 98%. Conclusions. CNV lesions and activity may be missed by FP alone, but FP may help identifying drusen and pigmentary changes. SDOCT is highly sensitive for the detection of AMD, CNV, and CNV activity; however, it cannot fully replace FA.
C1 [Mokwa, Nils F.; Ristau, Tina; Kirchhof, Bernd; Liakopoulos, Sandra] Univ Cologne, Dept Ophthalmol, Cologne Image Reading Ctr & Lab, D-50924 Cologne, Germany.
   [Keane, Pearse A.] Moorfields Eye Hosp NHS Fdn Trust, Biomed Res Ctr Ophthalmol, London EC1V 2PD, England.
   [Keane, Pearse A.] UCL Inst Ophthalmol, London EC1V 2PD, England.
   [Sadda, Srinivas R.] Univ So Calif, Keck Sch Med, Doheny Eye Inst, Doheny Image Reading Ctr, Los Angeles, CA 90033 USA.
C3 University of Cologne; University of London; University College London;
   Moorfields Eye Hospital NHS Foundation Trust; University of London;
   University College London; Doheny Eye Institute; University of Southern
   California
RP Liakopoulos, S (通讯作者)，Univ Cologne, Dept Ophthalmol, Cologne Image Reading Ctr & Lab, D-50924 Cologne, Germany.
EM sandra.liakopoulos@uk-koeln.de
RI Kariti, Yotvat/W-7091-2019; Keane, Pearse/AAE-5709-2019
OI Kariti, Yotvat/0000-0002-8620-4877; Keane, Pearse/0000-0002-9239-745X
FU Carl Zeiss Meditec; Optos; Optovue, Inc.; Retinovit Foundation, Cologne,
   Germany; Academy of Medical Sciences (AMS) [AMS-SGCL6-Keane] Funding
   Source: researchfish; National Institute for Health Research
   [CL-2010-18-004] Funding Source: researchfish
FX Srinivas R. Sadda is a coinventor of Doheny intellectual property
   related to optical coherence tomography that has been licensed by Topcon
   Medical Systems and a member of the scientific advisory board for
   Heidelberg Engineering. Srinivas R. Sadda also receives research support
   from Carl Zeiss Meditec, Optos, and Optovue, Inc. However, it is not
   related to the subject matter of this paper.; This research has been
   supported in part by the Retinovit Foundation, Cologne, Germany.
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Barbazetto I, 2003, ARCH OPHTHALMOL-CHIC, V121, P1253
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Do DV, 2012, OPHTHALMOLOGY, V119, P771, DOI 10.1016/j.ophtha.2011.10.019
   Eter N, 2005, RETINA-J RET VIT DIS, V25, P691, DOI 10.1097/00006982-200509000-00002
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Giani A, 2011, INVEST OPHTH VIS SCI, V52, P5579, DOI 10.1167/iovs.10-6617
   Grossniklaus HE, 1998, AM J OPHTHALMOL, V126, P59, DOI 10.1016/S0002-9394(98)00145-7
   HAWKINS BS, 1993, ARCH OPHTHALMOL-CHIC, V111, P1200
   Jain N, 2010, INVEST OPHTH VIS SCI, V51, P4875, DOI 10.1167/iovs.09-4962
   Kaiser PK, 2007, OPHTHALMOLOGY, V114, P1868, DOI 10.1016/j.ophtha.2007.04.030
   Keane PA, 2012, SURV OPHTHALMOL, V57, P389, DOI 10.1016/j.survophthal.2012.01.006
   Keane PA, 2009, AM J OPHTHALMOL, V148, P242, DOI 10.1016/j.ajo.2009.03.004
   Khurana RN, 2010, OPHTHALMOLOGY, V117, P1376, DOI 10.1016/j.ophtha.2009.11.039
   Kozak I, 2008, RETINA-J RET VIT DIS, V28, P538, DOI 10.1097/IAE.0b013e318167270b
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Zweifel SA, 2009, ARCH OPHTHALMOL-CHIC, V127, P1596, DOI 10.1001/archophthalmol.2009.326
NR 21
TC 47
Z9 48
U1 1
U2 10
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PY 2013
VL 2013
AR 385915
DI 10.1155/2013/385915
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 147EB
UT WOS:000319147300001
PM 23762528
OA Green Submitted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Reeves, BC
   Scott, LJ
   Taylor, J
   Harding, SP
   Peto, T
   Muldrew, A
   Hogg, RE
   Wordsworth, S
   Mills, N
   O'Reilly, D
   Rogers, CA
   Chakravarthy, U
AF Reeves, Barnaby C.
   Scott, Lauren J.
   Taylor, Jodi
   Harding, Simon P.
   Peto, Tunde
   Muldrew, Alyson
   Hogg, Ruth E.
   Wordsworth, Sarah
   Mills, Nicola
   O'Reilly, Dermot
   Rogers, Chris A.
   Chakravarthy, Usha
TI Effectiveness of Community versus Hospital Eye Service follow-up for
   patients with neovascular age-related macular degeneration with
   quiescent disease (ECHoES): a virtual non-inferiority trial
SO BMJ OPEN
LA English
DT Article
ID OPTOMETRISTS
AB Objectives: To compare the ability of ophthalmologists versus optometrists to correctly classify retinal lesions due to neovascular age-related macular degeneration (nAMD). Design: Randomised balanced incomplete block trial. Optometrists in the community and ophthalmologists in the Hospital Eye Service classified lesions from vignettes comprising clinical information, colour fundus photographs and optical coherence tomographic images. Participants' classifications were validated against experts' classifications (reference standard).
   Setting: Internet-based application.
   Participants: Ophthalmologists with experience in the age-related macular degeneration service; fully qualified optometrists not participating in nAMD shared care.
   Interventions: The trial emulated a conventional trial comparing optometrists' and ophthalmologists' decision-making, but vignettes, not patients, were assessed. Therefore, there were no interventions and the trial was virtual. Participants received training before assessing vignettes.
   Main outcome measures: Primary outcome-correct classification of the activity status of a lesion based on a vignette, compared with a reference standard. Secondary outcomes-potentially sight-threatening errors, judgements about specific lesion components and participants' confidence in their decisions.
   Results: In total, 155 participants registered for the trial; 96 (48 in each group) completed all assessments and formed the analysis population. Optometrists and ophthalmologists achieved 1702/2016 (84.4%) and 1722/2016 (85.4%) correct classifications, respectively (OR 0.91, 95% CI 0.66 to 1.25; p=0.543). Optometrists' decision-making was non-inferior to ophthalmologists' with respect to the prespecified limit of 10% absolute difference (0.298 on the odds scale). Optometrists and ophthalmologists made similar numbers of sight-threatening errors (57/994 (5.7%) vs 62/994 (6.2%), OR 0.93, 95% CI 0.55 to 1.57; p=0.789). Ophthalmologists assessed lesion components as present less often than optometrists and were more confident about their classifications than optometrists.
   Conclusions: Optometrists' ability to make nAMD retreatment decisions from vignettes is not inferior to ophthalmologists' ability. Shared care with optometrists monitoring quiescent nAMD lesions has the potential to reduce workload in hospitals.
C1 [Reeves, Barnaby C.; Scott, Lauren J.; Taylor, Jodi; Rogers, Chris A.] Univ Bristol, Sch Clin Sci, Clin Trials & Evaluat Unit, Bristol, Avon, England.
   [Harding, Simon P.] Univ Liverpool, Inst Ageing & Chron Dis, Dept Eye & Vis Sci, Liverpool, Merseyside, England.
   [Peto, Tunde] Moorfields Eye Hosp NHS Fdn Trust, NIHR BMRC, London, England.
   [Peto, Tunde] UCL Inst Ophthalmol, London, England.
   [Muldrew, Alyson; Hogg, Ruth E.; Chakravarthy, Usha] Queens Univ Belfast, Ctr Expt Med, Belfast, Antrim, North Ireland.
   [Wordsworth, Sarah] Univ Oxford, Nuffield Dept Populat Hlth, Hlth Econ Res Ctr, Oxford, England.
   [Mills, Nicola] Univ Bristol, Sch Social & Community Med, Bristol, Avon, England.
   [O'Reilly, Dermot] Queens Univ Belfast, Ctr Publ Hlth, Belfast, Antrim, North Ireland.
C3 University of Bristol; University of Liverpool; University of London;
   University College London; Moorfields Eye Hospital NHS Foundation Trust;
   University of London; University College London; Queens University
   Belfast; University of Oxford; University of Bristol; Queens University
   Belfast
RP Chakravarthy, U (通讯作者)，Queens Univ Belfast, Ctr Expt Med, Belfast, Antrim, North Ireland.
EM u.chakravarthy@qub.ac.uk
RI Peto, Tunde/G-8812-2018; Hogg, Ruth E./ABC-9602-2020
OI Peto, Tunde/0000-0001-6265-0381; Hogg, Ruth E./0000-0001-9413-2669;
   Reeves, Barnaby/0000-0002-5101-9487; Wordsworth,
   Sarah/0000-0002-2361-3040; Mills, Nicola/0000-0002-2960-2940;
   Chakravarthy, Usha/0000-0002-2606-3734
FU National Institute for Health Research Health Technology Assessment
   Programme [11/129/195]; Medical Research Council [MR/K025643/1] Funding
   Source: researchfish; National Institute for Health Research
   [NF-SI-0514-10114, 11/129/195] Funding Source: researchfish; MRC
   [MR/K025643/1] Funding Source: UKRI
FX The trial is funded by the National Institute for Health Research Health
   Technology Assessment Programme (project number 11/129/195).
CR Amoaku W, 2012, EYE, V26, pS2, DOI 10.1038/eye.2011.343
   Banes MJ, 2006, BRIT J OPHTHALMOL, V90, P579, DOI 10.1136/bjo.2005.082388
   Cameron JR, 2009, EYE, V23, P1134, DOI 10.1038/eye.2008.196
   Chakravarthy U, 2015, HEALTH TECHNOL ASSES, V19, P1, DOI 10.3310/hta19780
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Cochran W. G., 1992, EXPT DESIGNS, P611
   Coomber N, DELIVERING CANC WAIT
   FLEISS JL, 1981, APPL PSYCH MEAS, V5, P105, DOI 10.1177/014662168100500115
   Hau S, 2007, BRIT J OPHTHALMOL, V91, P437, DOI 10.1136/bjo.2006.105593
   Kelly SP, 2011, CLIN OPHTHALMOL, V5, P1673, DOI 10.2147/OPTH.S26753
   LU Y, 1995, STAT MED, V14, P1831, DOI 10.1002/sim.4780141611
   National Institute for Health and Clinical Excellence, 2008, RAN PEG TREATM AG RE
   Taylor J, 2016, EYE, V30, P68, DOI 10.1038/eye.2015.170
   Townsend D, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2014-007400
NR 14
TC 7
Z9 7
U1 0
U2 3
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2044-6055
J9 BMJ OPEN
JI BMJ Open
PY 2016
VL 6
IS 7
AR e010685
DI 10.1136/bmjopen-2015-010685
PG 10
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA DU5LB
UT WOS:000382252100104
PM 27401357
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Gohil, R
   Crosby-Nwaobi, R
   Forbes, A
   Burton, BJ
   Hykin, P
   Sivaprasad, S
AF Gohil, Rishma
   Crosby-Nwaobi, Roxanne
   Forbes, Angus
   Burton, Ben J.
   Hykin, Philip
   Sivaprasad, Sobha
TI Treatment satisfaction of patients undergoing ranibizumab therapy for
   neovascular age-related macular degeneration in a real-life setting
SO PATIENT PREFERENCE AND ADHERENCE
LA English
DT Article
DE macular treatment satisfaction questionnaire; patient related outcome
   measure; treatment history; quality of life
AB Context: Treatment satisfaction with a loading phase of monthly injections for 3 months followed by a pro-re-nata regimen of ranibizumab in neovascular age-related macular degeneration (nAMD) remains unclear.
   Aims: The aim was to evaluate the treatment satisfaction of persons with nAMD treated with ranibizumab in a real-life setting.
   Settings and design: A cross-sectional study was conducted across three eye clinics within the National Health Service in the UK, where treatment is provided free at point of contact.
   Materials and methods: A total of 250 patients were selected randomly for the study. Treatment satisfaction was assessed using the Macular Treatment Satisfaction Questionnaire. Data were collected on satisfaction of the service provided (Client Service Questionnaire-8) and the patients' demographic and quality of life and treatment history. Factors governing treatment questionnaire were determined.
   Results: The most important factors that determined the satisfaction were the service provided at the clinic (Client Service Questionnaire-8), health-related quality of life (EQ-5D-3L), and duration of AMD. Visual acuity changes were rated as less important than one would have expected.
   Conclusion: The study result suggested that treatment satisfaction for nAMD was governed by the perception of being reviewed and injected regularly over a long period of time than the actual change in visual acuity from the treatment.
C1 [Gohil, Rishma; Crosby-Nwaobi, Roxanne; Hykin, Philip; Sivaprasad, Sobha] Moorfields Biomed Res Ctr, Natl Inst Hlth Res, 162 City Rd, London EC1V 2PD, England.
   [Gohil, Rishma; Crosby-Nwaobi, Roxanne; Forbes, Angus] Kings Coll London, Diabet Nursing, London WC2R 2LS, England.
   [Burton, Ben J.] James Paget Univ Hosp, Dept Ophthalmol, Great Yarmouth, England.
   [Sivaprasad, Sobha] Kings Coll Hosp London, Laser & Retinal Res Unit, London, England.
C3 University of London; King's College London; King's College Hospital NHS
   Foundation Trust; King's College Hospital
RP Sivaprasad, S (通讯作者)，Moorfields Biomed Res Ctr, Natl Inst Hlth Res, 162 City Rd, London EC1V 2PD, England.
EM senswathi@aol.com
RI Sivaprasad, S./D-6876-2015
OI Sivaprasad, S./0000-0001-8952-0659; Forbes, Angus/0000-0003-3331-755X;
   Burton, Ben/0000-0001-9579-9078
FU Macula Society; Bayer Plc Limited; Macula Society, London; Bayer Plc;
   National Institute for Health Research (NIHR) Biomedical Research Centre
   based at Moorfields Eye Hospital NHS Foundation Trust; UCL Institute of
   Ophthalmology; Department of Health's NIHR Biomedical Research Centre
   for Ophthalmology at Moorfields Eye Hospital; University College London,
   Institute of Ophthalmology; Novartis; Allergan; Bayer
FX This study was funded by Macula Society and Bayer Plc Limited. The
   research was funded by unrestricted research grant from Macula Society,
   London and Bayer Plc and the National Institute for Health Research
   (NIHR) Biomedical Research Centre based at Moorfields Eye Hospital NHS
   Foundation Trust and UCL Institute of Ophthalmology. The views expressed
   are those of the author(s) and not necessarily those of the NHS, the
   NIHR or the Department of Health. SS, RC-N, PH have received a
   proportion of their funding from the Department of Health's NIHR
   Biomedical Research Centre for Ophthalmology at Moorfields Eye Hospital
   and University College London, Institute of Ophthalmology. SS,
   consultancy, payment for lectures/speaker bureaus, and travel support
   (Novartis, Allergan, Bayer); PH, consultancy and grant support
   (Novartis, Allergan, Bayer); and BB, consultancy and grant support
   (Novartis, Allergan, Bayer).
CR Amoaku WM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128403
   [Anonymous], MAC DEG AG REL RAN P
   Au CPY, 2015, BMC OPHTHALMOL, V15, DOI 10.1186/s12886-015-0071-6
   Brooks R, 1996, HEALTH POLICY, V37, P53, DOI 10.1016/0168-8510(96)00822-6
   Brose LS, 2009, PSYCHOL HEALTH MED, V14, P740, DOI 10.1080/13548500903431485
   Buys L, 2008, AUST J RURAL HEALTH, V16, P33, DOI 10.1111/j.1440-1584.2007.00948.x
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Darzi A, 2008, HIGH QUALITY CARE AL
   Evans JR, 2008, ARCH OPHTHALMOL-CHIC, V126, P1428, DOI 10.1001/archopht.126.10.1428
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Finger R, 2012, BRIT J OPHTHALMOL, V96, P997, DOI 10.1136/bjophthalmol-2011-301201
   Freeman EE, 2005, INVEST OPHTH VIS SCI, V46, P4040, DOI 10.1167/iovs.05-0687
   Gohil R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129361
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Larsen D L, 1979, Eval Program Plann, V2, P197, DOI 10.1016/0149-7189(79)90094-6
   Malde S, 2015, BJU INT, V116, P443, DOI 10.1111/bju.13025
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mitchell J, 2007, QUAL LIFE RES, V120, P2
   Mitchell Jan, 2005, Health Qual Life Outcomes, V3, P25, DOI 10.1186/1477-7525-3-25
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   van Asten F, 2015, ACTA OPHTHALMOL, V93, P126, DOI 10.1111/aos.12610
   Wang JJ, 1999, AUST NZ J PUBL HEAL, V23, P147, DOI 10.1111/j.1467-842X.1999.tb01225.x
   Woodcock A., 2006, P VIS 2005 INT C SER, V1282, P342
NR 25
TC 15
Z9 15
U1 0
U2 1
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1177-889X
J9 PATIENT PREFER ADHER
JI Patient Prefer. Adherence
PY 2016
VL 10
BP 949
EP 955
DI 10.2147/PPA.S105536
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC General & Internal Medicine
GA DM8WP
UT WOS:000376645500001
PM 27307715
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Rapantzikos, K
   Zervakis, M
   Balas, K
AF Rapantzikos, K
   Zervakis, M
   Balas, K
TI Detection and segmentation of drusen deposits on human retina: Potential
   in the diagnosis of age-related macular degeneration
SO MEDICAL IMAGE ANALYSIS
LA English
DT Article
DE age-related macular degeneration; drusen; segmentation algorithm
ID FUNDUS PHOTOGRAPHS; PROGNOSIS; MACULOPATHY
AB Assessment of the risk for the development of age-related macular degeneration requires reliable detection and quantitative mapping of retinal abnormalities that are considered as precursors of the disease. Typical signs for the latter are the so-called drusen that appear as abnormal white-yellow deposits on the retina. Segmentation of these features using conventional image analysis methods is quite complicated mainly due to the non-uniform illumination and the variability of the pigmentation of the background tissue. This paper presents a novel segmentation algorithm for the automatic detection and mapping of drusen in retina images acquired with the aid of a digital Fundus camera. We employ a modified adaptive histogram equalization, namely the multilevel histogram equalization (MLE) scheme, for enhancing local intensity structures. For the detection of drusen in retina images, we develop a novel segmentation technique, the histogram-based adaptive local thresholding (HALT), which extracts the useful information from an image without being affected by the presence of other structures. We provide experimental results from the application of our technique to real images, where certain abnormalities (drusen) have slightly different characteristics from the background. The performance of the, algorithm is established through statistical analysis of the results. This analysis indicates that the proposed drusen detector gives reliable detection accuracy in both position and mass size. (C) 2002 Elsevier Science B.V. All rights reserved.
C1 Tech Univ Crete, Dept Elect Comp Engn, Digital Image & Signal Proc Lab, GR-73100 Iraklion, Greece.
C3 Technical University of Crete
RP Zervakis, M (通讯作者)，Tech Univ Crete, Dept Elect Comp Engn, Digital Image & Signal Proc Lab, GR-73100 Iraklion, Greece.
EM michalis@dilos.systems.tuc.gr
RI Rapantzikos, Konstantinos/B-3755-2009; Rapantzikos,
   Konstantinos/C-3069-2009
OI Rapantzikos, Konstantinos/0000-0003-3313-6732
CR [Anonymous], 1998, Ophthalmology, V105, P11
   [Anonymous], 1990, NONLINEAR DIGITAL FI
   BOUKHAROUBA S, 1985, COMPUT VISION GRAPH, V29, P47, DOI 10.1016/S0734-189X(85)90150-1
   BRESSLER SB, 1990, ARCH OPHTHALMOL-CHIC, V108, P1442, DOI 10.1001/archopht.1990.01070120090035
   Friberg TR, 2000, OPHTHALMOLOGY, V107, P2239, DOI 10.1016/S0161-6420(00)00418-8
   FRIBERT TR, 1992, OCULAR MICROCIRCULAT, P173
   Hampel FR., 1986, ROBUST STAT APPROACH
   HOLZ FG, 1994, OPHTHALMOLOGY, V101, P1522
   HUBER PS, 1983, ROBUST STAT
   *INT ARM EP STUD G, 1995, SURV OPHTHALMOL, V39, P368
   KIRKPATRICK JNP, 1995, EYE, V9, P48, DOI 10.1038/eye.1995.7
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   MORGAN WH, 1994, AUST NZ J OPHTHALMOL, V22, P7, DOI 10.1111/j.1442-9071.1994.tb01688.x
   Olk RJ, 1999, OPHTHALMOLOGY, V106, P2082, DOI 10.1016/S0161-6420(99)90487-6
   OTSU N, 1979, IEEE T SYST MAN CYB, V9, P62, DOI 10.1109/TSMC.1979.4310076
   Papoulis A, 1984, PROBABILITY RANDOM V
   PAPPAS TN, 1992, IEEE T SIGNAL PROCES, V40, P901, DOI 10.1109/78.127962
   PELI E, 1986, OPHTHALMOLOGY, V93, P1575
   Russ JC, 1999, IMAGE PROCESSING HDB
   SAHOO PK, 1988, SURVEY THRESHOLDING
   SHIN DS, 1999, OPHTHALMOLOGY, V106, P6
   SMIDDY WE, 1984, OPHTHALMOLOGY, V91, P271
NR 23
TC 101
Z9 102
U1 0
U2 8
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1361-8415
EI 1361-8423
J9 MED IMAGE ANAL
JI Med. Image Anal.
PD MAR
PY 2003
VL 7
IS 1
BP 95
EP 108
AR PII S1361-8415(02)00093-2
DI 10.1016/S1361-8415(02)00093-2
PG 14
WC Computer Science, Artificial Intelligence; Computer Science,
   Interdisciplinary Applications; Engineering, Biomedical; Radiology,
   Nuclear Medicine & Medical Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Computer Science; Engineering; Radiology, Nuclear Medicine & Medical
   Imaging
GA 636AK
UT WOS:000180432200006
PM 12467724
DA 2022-11-30
ER

PT J
AU Rothenbuehler, SP
   Waeber, D
   Brinkmann, CK
   Wolf, S
   Wolf-Schnurrbusch, UEK
AF Rothenbuehler, Simon P.
   Waeber, David
   Brinkmann, Christian K.
   Wolf, Sebastian
   Wolf-Schnurrbusch, Ute E. K.
TI Effects of Ranibizumab in Patients with Subfoveal Choroidal
   Neovascularization Attributable to Age-related Macular Degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; FAMILY
AB PURPOSE: To demonstrate not only prevention of vision loss but also improvement in best-corrected visual acuity (BCVA) after treatment with ranibizumab on a variable-dosing regimen over 24 months in patients with age-related macular degeneration (AMD).
   DESIGN: Interventional case series.
   METHODS: SETTING: Institutional. STUDY POPULATION: One hundred and thirty-eight eyes of 138 patients treated intravitreally with 0.5 mg ranibizumab (Lucentis; Novartis, Basel, Switzerland). Age above 50 years, BCVA 0.2 to 1.2 logarithm of the minimal angle of resolution (logMAR), primary or recurrent subfoveal choroidal neovascularization (CNV) secondary to AMD. OBSERVATION PROCEDURES: After single initial treatment, Monthly follow-up examination. Retreatment in case of one of the following: sign of subretinal fluid or intraretinal edema, increase in central retinal thickness (CRT) on optical coherence tomography (OCT), active CNV on fluorescein angiography, increase of metamorphopsia, and loss of BCVA >5 letters on Early Treatment Diabetic Retinopathy Study (ETDRS) chart. MAIN OUT-COME MEASURES: Compared with baseline: proportion of eyes gaining 15 letters, proportion of eyes losing or gaining < 15 letters, change in CRT.
   RESULTS. After 24 months, 30% of eyes gained >= 15 letters. After 24 months, 55% of eyes lost or gained < 15 letters. Mean CRT of 386 +/- 145 mu m at baseline was significantly reduced to 211 +/- 39 mu m after 24 months (P = .036). Mean injection number per patient was 5.6 +/- 2.9 and 4.3 +/- 3.8 from baseline to month 12 and month 12 to 24, respectively.
   CONCLUSION: Intravitreal ranibizumab on a variable-dosing regimen was effective in significantly increasing mean BVCA and reducing CRT. This beneficial outcome was achieved with a low-rate of mild ocular adverse effects among our patients. (Am J Ophthalmol 2009;147: 831-837. (c) 2009 by Elsevier Inc. All rights reserved.)
C1 [Rothenbuehler, Simon P.; Waeber, David; Wolf, Sebastian; Wolf-Schnurrbusch, Ute E. K.] Univ Bern, Inselspital, Univ Klin Augenheilkunde, Bern Photog Reading Ctr, CH-3010 Bern, Switzerland.
C3 University of Bern; University Hospital of Bern
RP Rothenbuehler, SP (通讯作者)，Univ Bern, Inselspital, Univ Klin Augenheilkunde, Bern Photog Reading Ctr, CH-3010 Bern, Switzerland.
EM simon.rothenbuehler@insel.ch
RI Wolf, Sebastian/B-8782-2008
OI Wolf, Sebastian/0000-0002-7467-7028; Rothenbuehler,
   Simon/0000-0002-5223-6483
CR Arnold J, 2002, RETINA-J RET VIT DIS, V22, P6
   Azab M, 2004, RETINA-J RET VIT DIS, V24, P1
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Frank RN, 1996, AM J OPHTHALMOL, V122, P393, DOI 10.1016/S0002-9394(14)72066-5
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Otani A, 2002, MICROVASC RES, V64, P162, DOI 10.1006/mvre.2002.2407
   Rakic JM, 2003, INVEST OPHTH VIS SCI, V44, P3186, DOI 10.1167/iovs.02-1092
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
NR 15
TC 79
Z9 83
U1 1
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD MAY
PY 2009
VL 147
IS 5
BP 831
EP 837
DI 10.1016/j.ajo.2008.12.005
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 441IQ
UT WOS:000265762900013
PM 19217019
DA 2022-11-30
ER

PT J
AU Jonas, JB
   Strueven, V
   Kamppeter, BA
   Harder, B
   Spandau, UH
   Schlichtenbrede, F
AF Jonas, Jost B.
   Strueven, Vanessa
   Kamppeter, Bernd A.
   Harder, Bjoern
   Spandau, Ulrich H.
   Schlichtenbrede, Frank
TI Visual acuity change after intravitreal triamcinolone in various types
   of exudative age-related macular degeneration
SO JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
LA English
DT Article
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; COMBINED PHOTODYNAMIC THERAPY;
   COHERENCE TOMOGRAPHY FINDINGS; SUBRETINAL NEOVASCULARIZATION;
   BEVACIZUMAB AVASTIN(R); VERTEPORFIN THERAPY; ACETONIDE; INJECTION;
   COMBINATION; PROLIFERATION
AB Objective: The aim of this study was to compare the visual acuity change after an intravitreal high-dose injection of triamcinolone acetonide (TA) in various types of exudative age-related macular degeneration (AMD).
   Participants: The interventional comparative case series study included 142 patients (146 eyes) with progressive exudative AMD differentiated into the occult type (n = 78; 53.4%), minimal classic type (n = 45; 30.8%), predominantly classic type (n = 17; 11.6%), and the purely classic type (n = 6; 4.1%). Mean follow-up was 9.7.-t 7.0 months (3-35.7 months).
   Methods: Single intravitreal injection of approximately 20 mg of TA.
   Outcome measures: Visual acuity, intraocular pressure (IOP).
   Results: Gain in visual acuity measured at 1 month (P = 0.20), 2 months (P = 0.43), and at 3 months W = 0.38) after the intravitreal injection of triamcinolone and maximal gain in visual acuity during the whole follow-up W = 0.81) did not vary significantly between the 4 study groups. Correspondingly, the size of a retinal pigment epithelium detachment was not significantly associated with the change in visual acuity at 1 month (P = 0.62), 2 months (P = 0.24), 3 months (P = 0.96), or the maximal gain in visual acuity during follow-up (P = 0.93). The amount of rise in IOP, compared with the baseline value (6.5 +/- 7.4 mmHg), was statistically not associated with the type of subfoveal membrane W = 0.20; 95% confidence interval: -0.52, 2.45).
   Conclusions: The change in visual acuity and the rise in IOP in patients with exudative AMD receiving an intravitreal triamcinolone monotherapy is statistically independent of the type of subfoveal membrane, including the size of a retinal epithelium detachment.
C1 Heidelberg Univ, Dept Ophthalmol, Fac Clin Med Mannheim, Heidelberg, Germany.
C3 Ruprecht Karls University Heidelberg
RP Jonas, JB (通讯作者)，Univ Mannheim, Augenklin, Theodor Kutzer Ufer 1-3, D-68167 Mannheim, Germany.
EM Jost.Jonas@augen.ma.uni-heidelberg.de
CR ANTOSZYK AN, 1993, GRAEF ARCH CLIN EXP, V231, P34, DOI 10.1007/BF01681698
   Arevalo JF, 2005, GRAEF ARCH CLIN EXP, V243, P1180, DOI 10.1007/s00417-005-1177-y
   Augustin AJ, 2006, AM J OPHTHALMOL, V141, P638, DOI 10.1016/j.ajo.2005.11.058
   Augustin AJ, 2006, OPHTHALMOLOGY, V113, P14, DOI 10.1016/j.ophtha.2005.09.002
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1443
   Challa JK, 1998, AUST NZ J OPHTHALMOL, V26, P277, DOI 10.1111/j.1442-9071.1998.tb01330.x
   Ciulla TA, 2001, ARCH OPHTHALMOL-CHIC, V119, P399, DOI 10.1001/archopht.119.3.399
   Danis RP, 1996, OPHTHALMOLOGY, V103, P2099, DOI 10.1016/S0161-6420(96)30383-7
   Danis RP, 2000, RETINA-J RET VIT DIS, V20, P244, DOI 10.1097/00006982-200003000-00004
   Degenring RF, 2005, ACTA OPHTHALMOL SCAN, V83, P621, DOI 10.1111/j.1600-0420.2005.00506.x
   Fish G, 2003, OPHTHALMOLOGY, V110, P979, DOI 10.1016/S0161-6420(03)00085-X
   Gillies MC, 2003, ARCH OPHTHALMOL-CHIC, V121, P667, DOI 10.1001/archopht.121.5.667
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Heier JS, 2006, OPHTHALMOLOGY, V113, pe1, DOI DOI 10.1016/J.0PHTHA.2005.10.052)
   ISHIBASHI T, 1985, ARCH OPHTHALMOL-CHIC, V103, P708
   Jonas JB, 2006, EUR J OPHTHALMOL, V16, P566, DOI 10.1177/112067210601600411
   Jonas JB, 2005, ACTA OPHTHALMOL SCAN, V83, P645, DOI 10.1111/j.1600-0420.2005.00592.x
   Jonas JB, 2005, AM J OPHTHALMOL, V139, P1073, DOI 10.1016/j.ajo.2005.01.032
   Jonas JB, 2005, EYE, V19, P163, DOI 10.1038/sj.eye.6701438
   Jonas JB, 2004, BRIT J OPHTHALMOL, V88, P1557, DOI 10.1136/bjo.2003.039552
   Jonas JB, 2004, ARCH OPHTHALMOL-CHIC, V122, P218, DOI 10.1001/archopht.122.2.218
   Jonas JB, 2003, BRIT J OPHTHALMOL, V87, P462, DOI 10.1136/bjo.87.4.462
   Jonas JB, 2002, GRAEF ARCH CLIN EXP, V240, P872, DOI 10.1007/s00417-002-0547-y
   JONAS JB, 2006, IN PRESS OPHTHALMIC
   JONAS JB, 2006, IN PRESS IND J OPHTH
   Jonas JB, 2006, J OCUL PHARMACOL TH, V22, P194, DOI 10.1089/jop.2006.22.194
   Larsson J, 2005, CLIN EXP OPHTHALMOL, V33, P544, DOI 10.1111/j.1442-9071.2005.01082.x
   Manzano RPA, 2006, RETINA-J RET VIT DIS, V26, P257, DOI 10.1097/00006982-200603000-00001
   Martin DF, 2002, RETINA-J RET VIT DIS, V22, P143
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Nicolo M, 2005, EUR J OPHTHALMOL, V15, P415, DOI 10.1177/112067210501500318
   PENFOLD L, 2002, BR J OPHTHALMOL, V86, P527
   Penfold PL, 1995, AUST NZ J OPHTHALMOL, V23, P293, DOI 10.1111/j.1442-9071.1995.tb00179.x
   Penfold PL, 2002, INVEST OPHTH VIS SCI, V43, P3125
   Penfold PL, 2002, BRIT J OPHTHALMOL, V86, P600, DOI 10.1136/bjo.86.6.600
   Penfold PL, 2001, CLIN EXP OPHTHALMOL, V29, P188, DOI 10.1046/j.1442-9071.2001.00407.x
   Potter MJ, 2006, GRAEF ARCH CLIN EXP, V244, P639, DOI 10.1007/s00417-005-0115-3
   Ranson NT, 2002, BRIT J OPHTHALMOL, V86, P527, DOI 10.1136/bjo.86.5.527
   Rechtman E, 2004, BRIT J OPHTHALMOL, V88, P344, DOI 10.1136/bjo.2003.027177
   Rosenfeld PJ, 2005, OPHTHALMOLOGY, V112, P1048, DOI 10.1016/j.ophtha.2005.01.043
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P336, DOI 10.3928/1542-8877-20050701-15
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Shahar J, 2006, RETINA-J RET VIT DIS, V26, P262, DOI 10.1097/00006982-200603000-00002
   SINGERMAN LJ, 2004, RETIN PHYS, V1, P34
   Smithen LM, 2004, AM J OPHTHALMOL, V138, P884, DOI 10.1016/j.ajo.2004.05.073
   Spaide RF, 2005, OPHTHALMOLOGY, V112, P301, DOI 10.1016/j.ophtha.2004.08.012
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P1517, DOI 10.1016/S0161-6420(03)00544-X
   Spaide RF, 2005, RETINA-J RET VIT DIS, V25, P685, DOI 10.1097/00006982-200509000-00001
   Spandau UHM, 2005, BRIT J OPHTHALMOL, V89, P745, DOI 10.1136/bjo.2004.052563
   Spandau UHM, 2005, AM J OPHTHALMOL, V139, P712, DOI 10.1016/j.ajo.2004.09.059
   TANO Y, 1980, AM J OPHTHALMOL, V89, P131, DOI 10.1016/0002-9394(80)90239-1
   TANO Y, 1980, AM J OPHTHALMOL, V90, P810, DOI 10.1016/S0002-9394(14)75196-7
   Wingate RJB, 1999, AUST NZ J OPHTHALMOL, V27, P431
NR 54
TC 8
Z9 8
U1 0
U2 2
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1080-7683
EI 1557-7732
J9 J OCUL PHARMACOL TH
JI J. Ocular Pharmacol. Ther.
PD OCT
PY 2006
VL 22
IS 5
BP 370
EP 376
DI 10.1089/jop.2006.22.370
PG 7
WC Ophthalmology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Pharmacology & Pharmacy
GA 101XR
UT WOS:000241775100010
PM 17076632
DA 2022-11-30
ER

PT J
AU Olson, JM
   Scott, IU
   Kerchner, DL
   Kunselman, AR
AF Olson, Joanna M.
   Scott, Ingrid U.
   Kerchner, Denise L.
   Kunselman, Allen R.
TI Association Between Systemic Anticoagulation and Rate of Intraocular
   Hemorrhage Following Intravitreal Anti-VEGF Therapy for Age-Related
   Macular Degeneration
SO OPHTHALMIC SURGERY LASERS & IMAGING
LA English
DT Article
ID BEVACIZUMAB AVASTIN; GINKGO-BILOBA; RANIBIZUMAB; COMPLICATIONS;
   INJECTIONS; SAFETY; TRENDS
AB BACKGROUND AND OBJECTIVE: To investigate the association between systemic anticoagulant medication usage at the time of intravitreal anti-vascular endothelial growth factor (anti-VEGF) injection with post-injection intraocular hemorrhage among patients with age-related macular degeneration (AMD).
   PATIENTS AND METHODS: Retrospective, consecutive case series of all patients treated with anti-VEGF injection for neovascular AMD at the Penn State Hershey Eye Center between 2004 and 2010: 1,710 anti-VEGF injections performed in 228 eyes of 191 patients. Each injection was analyzed according to whether the patient was taking systemic anticoagulant medication at the time of injection.
   RESULTS: Intraocular hemorrhage occurred after intravitreal anti-VEGF injection in four eyes (0.25%). Vitreous hemorrhage occurred in three patients taking systemic anticoagulation. Subretinal hemorrhage occurred in one patient not on anticoagulant therapy. In a bivariate analysis, the odds of intraocular hemorrhage are 1.9 times higher for injections performed in patients on systemic anticoagulation versus those not on systemic anticoagulation; this difference is not statistically significant.
   CONCLUSION: The rate of intraocular hemorrhage after intravitreal injection of anti-VEGF therapy among patients with AMD is low, and there is no significant difference between patients taking systemic anticoagulant medications at the time of injection and patients not on anticoagulation.
C1 [Olson, Joanna M.; Scott, Ingrid U.; Kerchner, Denise L.; Kunselman, Allen R.] Penn State Coll Med, Penn State Hershey Eye Ctr, Dept Publ Hlth Sci, Hershey, PA 17033 USA.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE);
   Pennsylvania State University; Penn State Health
RP Scott, IU (通讯作者)，Penn State Coll Med, Penn State Hershey Eye Ctr, 500 Univ Dr,HU19, Hershey, PA 17033 USA.
EM iscott@hmc.psu.edu
OI Scott, Ingrid/0000-0002-3908-7153
CR Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Cho HJ, 2007, BIOL PHARM BULL, V30, P2340, DOI 10.1248/bpb.30.2340
   Day S, 2011, AM J OPHTHALMOL, V152, P266, DOI 10.1016/j.ajo.2011.01.053
   Dayani PN, 2007, AM J OPHTHALMOL, V144, P451, DOI 10.1016/j.ajo.2007.05.006
   FIHN SD, 1993, ANN INTERN MED, V118, P511, DOI 10.7326/0003-4819-118-7-199304010-00005
   Fung AE, 2006, BRIT J OPHTHALMOL, V90, P1344, DOI 10.1136/bjo.2006.099598
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kaufman DW, 2002, JAMA-J AM MED ASSOC, V287, P337, DOI 10.1001/jama.287.3.337
   Kaye AD, 2000, J CLIN ANESTH, V12, P468, DOI 10.1016/S0952-8180(00)00195-1
   Kelly JP, 2005, ARCH INTERN MED, V165, P281, DOI 10.1001/archinte.165.3.281
   Kiernan DF, 2010, RETINA-J RET VIT DIS, V30, P1573, DOI 10.1097/IAE.0b013e3181e2266d
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13
   Loukopoulos V, 2010, KLIN MONATSBL AUGENH, V227, P289, DOI 10.1055/s-0029-1245225
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mason JO, 2010, RETINA-J RET VIT DIS, V30, P1386, DOI 10.1097/IAE.0b013e3181e09739
   Matthews MK, 1998, NEUROLOGY, V50, P1933, DOI 10.1212/WNL.50.6.1933
   Rosenblatt M, 1997, NEW ENGL J MED, V336, P1108, DOI 10.1056/NEJM199704103361518
   Rosenfeld Philip J, 2006, Ophthalmol Clin North Am, V19, P361
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Spaide R, 2007, AM J OPHTHALMOL, V143, P679, DOI 10.1016/j.ajo.2007.02.024
   Stone EM, 2006, NEW ENGL J MED, V355, P1493, DOI 10.1056/NEJMe068191
   Tolentino M, 2011, SURV OPHTHALMOL, V56, P95, DOI 10.1016/j.survophthal.2010.08.006
NR 25
TC 7
Z9 7
U1 0
U2 7
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 1542-8877
EI 1938-2375
J9 OPHTHAL SURG LAS IM
JI Ophthalmic Surg. Lasers Imaging
PD SEP-OCT
PY 2013
VL 44
IS 5
BP 455
EP 459
DI 10.3928/23258160-20130909-06
PG 5
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA 296NS
UT WOS:000330192400005
PM 24044707
DA 2022-11-30
ER

PT J
AU Coscas, F
   Querques, G
   Forte, R
   Terrada, C
   Coscas, G
   Souied, EH
AF Coscas, Florence
   Querques, Giuseppe
   Forte, Raimondo
   Terrada, Celine
   Coscas, Gabriel
   Souied, Eric H.
TI COMBINED FLUORESCEIN ANGIOGRAPHY AND SPECTRAL-DOMAIN OPTICAL COHERENCE
   TOMOGRAPHY IMAGING OF CLASSIC CHOROIDAL NEOVASCULARIZATION SECONDARY TO
   AGE-RELATED MACULAR DEGENERATION BEFORE AND AFTER INTRAVITREAL
   RANIBIZUMAB INJECTIONS
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; choroidal neovascularization;
   fluorescein angiography; optical coherence tomography; ranibizumab
ID MEMBRANES; VERTEPORFIN
AB Purpose: To evaluate the combined fluorescein angiography and spectral-domain optical coherence tomography features in a consecutive series of exudative age-related macular degeneration eyes with classic choroidal neovascularization before and after anti-vascular endothelial growth factor treatment.
   Methods: Retrospective interventional study. All consecutive patients with exudative age-related macular degeneration because of newly diagnosed classic choroidal neovascularization visited during 3 months and treated by intravitreal ranibizumab injection on "as-needed" basis were analyzed. Combined fluorescein angiography and spectral-domain optical coherence tomography examination (Spectralis Heidelberg Retina Angiograph OCT) was performed at baseline and at the 12-month follow-up visit.
   Results: Twenty-nine treatment-naive eyes (29 patients, 10 men and 19 women, mean age 76.28 +/- 10.86 years) were included. A mean of 5.3 +/- 3.5 injections was administered during 12 months. At Month 12 visit, patients showed an improved best-corrected visual acuity (P = 0.01), a reduction of linear dimension of the entire lesion on fluorescein angiography (P = 0.02), and a reduction of the entire lesion width on spectral-domain optical coherence tomography (P < 0.001). At baseline, in all cases we distinguished on spectral-domain optical coherence tomography scan a highly reflective subretinal lesion, above and separate from the retinal pigment epithelium. The highly reflective subretinal lesion showed a significant reduction of width along the length of a single B-scan, at Month 12 follow-up visit (P < 0.001). It is notable that a small "discreet" pigment epithelial detachment associated with the highly reflective subretinal lesions was present in 28 of 29 eyes at baseline and after treatment (at Month 12 follow-up visit).
   Conclusion: A discreet pigment epithelial detachment represents a common associated finding of classic choroidal neovascularization. Our study demonstrated that anti-vascular endothelial growth factor treatment may not only stop the growth of the highly reflective subretinal lesion that colocalize with the classic choroidal neovascularization but also determine its regression. RETINA 32: 1069-1076, 2012
C1 [Coscas, Florence; Querques, Giuseppe; Forte, Raimondo; Terrada, Celine; Coscas, Gabriel; Souied, Eric H.] Univ Paris Est Creteil, Ctr Hosp Intercommunal Creteil, Creteil Eye Clin, Dept Ophthalmol, F-94000 Creteil, France.
C3 Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil
RP Souied, EH (通讯作者)，Univ Paris Est Creteil, Ctr Hosp Intercommunal Creteil, Creteil Eye Clin, Dept Ophthalmol, 40 Ave Verdun, F-94000 Creteil, France.
EM esouied@hotmail.com
OI Querques, Giuseppe/0000-0002-3292-9581
CR Barbazetto I, 2003, ARCH OPHTHALMOL-CHIC, V121, P1253
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chen Y, 1999, J MOL BIOL, V293, P865, DOI 10.1006/jmbi.1999.3192
   Coscas F, 2007, AM J OPHTHALMOL, V144, P592, DOI 10.1016/j.ajo.2007.06.014
   Coscas G, 2010, OPTICAL COHERENCE TOMOGRAPHY IN AGE-RELATED MACULAR DEGENERATION: OCT IN AMD, SECOND EDITION, P1
   Framme C, 2010, INVEST OPHTH VIS SCI, V51, P1671, DOI 10.1167/iovs.09-4496
   Fukuchi T, 2001, JPN J OPHTHALMOL, V45, P252, DOI 10.1016/S0021-5155(00)00381-6
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   GASS JDM, 1994, AM J OPHTHALMOL, V118, P285, DOI 10.1016/S0002-9394(14)72951-4
   Golbaz I, 2009, OPHTHALMOLOGE, V106, P1103, DOI 10.1007/s00347-008-1880-2
   Hermans P, 2003, OPHTHALMOLOGE, V100, P378, DOI 10.1007/s00347-002-0742-6
   Hughes EH, 2005, AM J OPHTHALMOL, V139, P344, DOI 10.1016/j.ajo.2004.07.058
   Keane PA, 2008, INVEST OPHTH VIS SCI, V49, P3115, DOI 10.1167/iovs.08-1689
   Lafaut BA, 2000, BRIT J OPHTHALMOL, V84, P239, DOI 10.1136/bjo.84.3.239
   Liakopoulos S, 2008, INVEST OPHTH VIS SCI, V49, P5048, DOI 10.1167/iovs.08-1877
   Park SS, 2010, INVEST OPHTH VIS SCI, V51, P4200, DOI 10.1167/iovs.09-4256
   Querques G, 2010, BRIT J OPHTHALMOL, V94, P292, DOI 10.1136/bjo.2009.170670
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rothenbuehler SP, 2009, AM J OPHTHALMOL, V147, P831, DOI 10.1016/j.ajo.2008.12.005
   Sadda SR, 2010, GRAEF ARCH CLIN EXP, V248, P175, DOI 10.1007/s00417-009-1193-4
   Sandhu SS, 2005, BRIT J OPHTHALMOL, V89, P967, DOI 10.1136/bjo.2004.060863
   Sato T, 2004, RETINA-J RET VIT DIS, V24, P910, DOI 10.1097/00006982-200412000-00011
   Submacular Surgery Trials Research Group, 2006, OPHTHALMOLOGY, V113, p279e1
NR 24
TC 11
Z9 12
U1 0
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUN
PY 2012
VL 32
IS 6
BP 1069
EP 1076
DI 10.1097/IAE.0b013e318240a529
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 948VY
UT WOS:000304532100004
PM 22466476
DA 2022-11-30
ER

PT J
AU Marques, IR
   Fonseca, P
   Cachulo, ML
   Pires, I
   Figueira, J
   de Abreu, JRF
   Silva, R
AF Marques, Ines R.
   Fonseca, Pedro
   Cachulo, M. Luz
   Pires, Isabel
   Figueira, Joao
   de Abreu, J. R. Faria
   Silva, Rufino
TI Treatment of Exudative Age-Related Macular Degeneration with
   Intravitreal Ranibizumab in Clinical Practice: A 3-Year Follow-Up
SO OPHTHALMOLOGICA
LA English
DT Article
DE Age-related macular degeneration; Antiangiogenesis agents; Choroidal
   neovascularization; Ranibizunnab; Vascular endothelial growth factor
ID VERTEPORFIN; TRIAL
AB Purpose: To evaluate the 36-month efficacy of intravitreal ranibizumab injections for choroidal neovascularization secondary to age-related macular degeneration (AMD) in real world clinical practice. Methods: Retrospective study involving 84 eyes of 77 patients; 52 eyes completed 3 years of follow-up. Subjects were observed initially on a monthly basis and with extended follow-up intervals if signs of quiescence were detected, according to an established protocol. A comprehensive ophthalmologic examination was performed, including best-corrected visual acuity (BCVA) determined with Early Treatment Diabetic Retinopathy Study charts, stereoscopic macular biomicroscopy and optical coherence tomography (OCT) with fluorescein angiography and indocyanine green angiography if considered necessary. Treatment was given if signs of active lesions were present. Results: The mean baseline BCVA was 49.33 and 49.52 letters at the 36-month visit. The average of treatments was 8.6 at 3 years. At this time point, 77% of treated eyes stabilized or improved their vision (VA loss <= 5 letters). A predictive value for better VA was found for younger age, better baseline VA, good response on OCT and more frequent treatments. Conclusion: At 3 years, intravitreal ranibizumab is able to maintain baseline VA in exudative AMD patients, with a reduced number of injections, but not to show VA improvement, in clinical practice. Copyright (C) 2013 S. Karger AG, Basel
C1 [Marques, Ines R.; Fonseca, Pedro; Cachulo, M. Luz; Pires, Isabel; Figueira, Joao; Silva, Rufino] Coimbra Univ Hosp, Dept Ophthalmol, P-3049 Coimbra, Portugal.
   [Marques, Ines R.; Cachulo, M. Luz; Pires, Isabel; de Abreu, J. R. Faria] Univ Coimbra, AIBILI, Coimbra, Portugal.
   [Fonseca, Pedro; Figueira, Joao; Silva, Rufino] Univ Coimbra, Fac Med, Coimbra, Portugal.
C3 Universidade de Coimbra; Centro Hospitalar e Universitario de Coimbra
   (CHUC); Universidade de Coimbra; Universidade de Coimbra
RP Marques, IR (通讯作者)，Coimbra Univ Hosp, Dept Ophthalmol, P-3049 Coimbra, Portugal.
EM inespdmarques@yahoo.com
RI Silva, Rufino M/J-2817-2012
OI Silva, Rufino M/0000-0001-8676-0833; Figueira, Joao
   P/0000-0002-3511-1515; Marques, Ines/0000-0001-9170-6997; Pires,
   Isabel/0000-0002-5764-0178
CR Abedi G, 2011, GRAEF ARCH CLIN EXP, V249, P1353, DOI 10.1007/s00417-011-1725-6
   Bolz M, 2008, 8 EURETINA C VIENN M
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Brown DM, 2007, AM J OPHTHALMOL, V144, P627, DOI 10.1016/j.ajo.2007.06.039
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Cohen SY, 2009, AM J OPHTHALMOL, V148, P409, DOI 10.1016/j.ajo.2009.04.001
   Dadgostar H, 2009, OPHTHALMOLOGY, V116, P1740, DOI 10.1016/j.ophtha.2009.05.033
   Eyeworld.org, LUC ON YEAR
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   MEYER CH, 2008, INVEST OPHTHALMOL VI, V49
   Querques G, 2010, BRIT J OPHTHALMOL, V94, P292, DOI 10.1136/bjo.2009.170670
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rothenbuehler SP, 2009, AM J OPHTHALMOL, V147, P831, DOI 10.1016/j.ajo.2008.12.005
NR 18
TC 10
Z9 10
U1 0
U2 1
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2013
VL 229
IS 3
BP 158
EP 167
DI 10.1159/000343709
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 126RT
UT WOS:000317639600006
PM 23485818
OA Green Published
DA 2022-11-30
ER

PT J
AU Krebs, I
   Hagen, S
   Smretschnig, E
   Womastek, I
   Brannath, W
   Binder, S
AF Krebs, Ilse
   Hagen, Stefan
   Smretschnig, Eva
   Womastek, Irene
   Brannath, Werner
   Binder, Susanne
TI Conversion of Stratus optical coherence tomography (OCT) retinal
   thickness to Cirrus OCT values in age-related macular degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID SPECTRAL-DOMAIN; TIME-DOMAIN; FLUORESCEIN ANGIOGRAPHY
AB Aim Spectral domain optical coherence tomography (SD OCT) is of increasing importance and is gradually replacing time domain OCT (TD OCT). Our aim was to determine a formula to convert Stratus OCT (TD OCT) to Cirrus OCT (SD OCT) retinal thickness.
   Methods Central retinal thickness (CRT) and retinal volume (RV) were obtained by the macular thickness program of Stratus OCT and the cube 512x128 program of Cirrus OCT in patients with exudative age-related macular degeneration (AMD). Algorithm line failures were corrected. A linear model with Stratus OCT CRT as fixed factor and Cirrus OCT CRT as dependent variable was applied to calculate the conversion formula.
   Results OCT examinations of 104 eyes of 104 patients were reviewed and corrected when necessary. Stratus and Cirrus OCT CRT were significantly correlated (p<0.0001). For CRT the formula Cirrus CRT=58.63 +0.943 Stratus CRT was calculated. The correlation was significantly influenced by the height of the CRT values (p<0.0001), but not by whether correction was necessary. For RV the formula Cirrus OCT RV=3.098 +0.983 Stratus OCT RV was calculated.
   Conclusion Stratus OCT and Cirrus OCT use a different posterior reference line within the hyper-reflective band of the outer retina. Therefore a conversion formula is necessary to compare Stratus and Cirrus OCT CRT values, and this has been determined in our study.
C1 [Krebs, Ilse; Hagen, Stefan; Binder, Susanne] Rudolf Fdn Clin, Dept Ophthalmol, A-1030 Vienna, Austria.
   [Krebs, Ilse; Hagen, Stefan; Smretschnig, Eva; Binder, Susanne] Ludwig Boltzmann Inst Retinol & Biomicroscop Lase, Vienna, Austria.
   [Womastek, Irene; Brannath, Werner] Med Univ, Core Unit Med Stat & Informat, Vienna, Austria.
C3 Ludwig Boltzmann Institute
RP Krebs, I (通讯作者)，Rudolf Fdn Clin, Dept Ophthalmol, Juchgasse 25, A-1030 Vienna, Austria.
EM ilse.krebs@wienkav.at
CR Carpineto P, 2010, EYE, V24, P251, DOI 10.1038/eye.2009.76
   Forooghian F, 2008, INVEST OPHTH VIS SCI, V49, P4290, DOI 10.1167/iovs.08-2113
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Kiernan DF, 2009, AM J OPHTHALMOL, V147, P267, DOI 10.1016/j.ajo.2008.08.018
   Krebs I, 2008, GRAEF ARCH CLIN EXP, V246, P811, DOI 10.1007/s00417-007-0755-6
   Krebs I, 2010, OPHTHALMOLOGY, V117, P1577, DOI 10.1016/j.ophtha.2010.04.032
   Krebs I, 2009, INVEST OPHTH VIS SCI, V50, P995, DOI 10.1167/iovs.08-2617
   Leung CKS, 2008, INVEST OPHTH VIS SCI, V49, P4893, DOI 10.1167/iovs.07-1326
   Malamos P, 2009, INVEST OPHTH VIS SCI, V50, P4926, DOI 10.1167/iovs.09-3610
   Patel PJ, 2008, INVEST OPHTH VIS SCI, V49, P1084, DOI 10.1167/iovs.07-1203
   Sayanagi K, 2009, AM J OPHTHALMOL, V148, P431, DOI 10.1016/j.ajo.2009.04.008
   Wolf-Schnurrbusch UEK, 2009, INVEST OPHTH VIS SCI, V50, P3432, DOI 10.1167/iovs.08-2970
NR 12
TC 17
Z9 17
U1 0
U2 4
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD NOV
PY 2011
VL 95
IS 11
BP 1552
EP 1554
DI 10.1136/bjo.2010.194670
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 837VK
UT WOS:000296233900016
PM 21349936
DA 2022-11-30
ER

PT J
AU Rong, SS
   Lee, BY
   Kuk, AK
   Yu, XT
   Li, SS
   Li, J
   Guo, YJ
   Yin, YL
   Osterbur, DL
   Yam, JCS
   Cheung, CY
   Chen, LJ
   Wong, TY
   Ng, DSC
AF Rong, Shi Song
   Lee, Bo Yee
   Kuk, Andrew K.
   Yu, Xin Ting
   Li, Suki S.
   Li, Jian
   Guo, Yanjun
   Yin, Yilin
   Osterbur, David L.
   Yam, Jason C. S.
   Cheung, Carol Y.
   Chen, Li Jia
   Wong, Tien Y.
   Ng, Danny Siu-Chun
TI Comorbidity of dementia and age-related macular degeneration calls for
   clinical awareness: a meta-analysis
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE macula; degeneration; retina; epidemiology
ID PIGMENT OPTICAL-DENSITY; COGNITIVE FUNCTION; ALZHEIMERS-DISEASE; VISUAL
   IMPAIRMENT; EYE DISEASES; RISK; PREVALENCE; DRUSEN; ASSOCIATIONS;
   PATHOLOGIES
AB Aim To determine the association between dementia and age-related macular degeneration (AMD) using meta-analysis. Methods We searched in the MEDLINE, EMBASE, Web of Knowledge, PsycInfo and Cochrane database of systematic reviews for studies published from March 1959 to March 2018. We included cross-sectional, case-control and cohort studies that evaluated the association of dementia/Alzheimer's disease (AD) with AMD (as outcome) and the association of AMD with dementia/AD (as outcome). Studies that compared cognitive functions between AMD and controls were also included. The summary outcomes, namely odds ratio (OR), relative risk, mean differences and corresponding 95% CIs, were estimated using random effects models. We performed sensitivity analysis based on study quality and individual study effect to control for potential biases. Results Among 2159 citation records, we identified 21 studies consisting of 7 876 499 study subjects for meta-analysis. Patients with dementia (p(adjusted)<= 0.017, OR >= 1.24, I-2 <= 9%) or AD (p=0.001, ORunadjusted=2.22, I-2=50%) were at risk for AMD, particularly for late AMD (p(adjusted)<0.001, OR=1.37, I-2=0). AMD was also significantly associated with increased risk of AD/cognitive impairment (p(adjusted)=0.037, OR=2.42, I-2=38%). Moreover, patients with AMD had poorer cognitive functions when compared with controls, including Mini-Mental State Examination (p<0.001, I-2 <= 79%) and Trail Making Test A (p<0.001, I-2=0). Sensitivity analysis and Egger's test indicated our results were less likely biased. Conclusions A significant association between dementia/AD and AMD calls for greater clinical awareness. The cost-effectiveness of routine screening for the other condition in patients with primary diagnosis of dementia/AD or AMD requires further study.
C1 [Rong, Shi Song; Lee, Bo Yee; Li, Suki S.; Li, Jian; Yam, Jason C. S.; Cheung, Carol Y.; Chen, Li Jia; Ng, Danny Siu-Chun] Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Hong Kong, Peoples R China.
   [Rong, Shi Song; Yin, Yilin] Harvard Med Sch, Dept Ophthalmol, Boston, MA 02115 USA.
   [Kuk, Andrew K.] Tung Wah Eastern Hosp, Dept Ophthalmol, Hong Kong, Peoples R China.
   [Yu, Xin Ting] Harvard Univ, Dept Nutr, TH Chan Sch Publ Hlth, Boston, MA USA.
   [Li, Jian] Zhejiang Univ, Affiliated Hangzhou Peoples Hosp 1, Sch Med, Dept Ophthalmol, Hangzhou, Zhejiang, Peoples R China.
   [Guo, Yanjun] Capital Med Univ, Beijing Friendship Hosp, Dept Neurol, Beijing, Peoples R China.
   [Osterbur, David L.] Harvard Med Sch, Countway Lib Med, Boston, MA 02115 USA.
   [Wong, Tien Y.] Singapore Natl Eye Ctr, Ophthalmol & Visual Sci Program, Singapore, Singapore.
   [Wong, Tien Y.] Natl Univ Singapore, Duke NUS Med Sch, Singapore, Singapore.
C3 Chinese University of Hong Kong; Harvard University; Harvard Medical
   School; Harvard University; Harvard T.H. Chan School of Public Health;
   Zhejiang University; Capital Medical University; Harvard University;
   Harvard Medical School; Singapore National Eye Center; National
   University of Singapore
RP Rong, SS (通讯作者)，Harvard Med Sch, Massachusetts Eye & Ear, Dept Ophthalmol, Boston, MA 02115 USA.; Rong, SS; Ng, DSC (通讯作者)，Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Hong Kong, Peoples R China.
EM dannyng@cuhk.edu.hk; dannyng@cuhk.edu.hk
RI Ng, Danny Siu Chun/AAG-3081-2020; Cheung, Carol Y./G-7895-2016; Rong,
   Shi Song/L-9735-2019; Yam, Jason C./AAI-2522-2020; Cheung,
   Carol/AAF-1101-2020; Chen, Li Jia/I-5078-2014; Wong, Tien
   Yin/AAC-9724-2020; Osterbur, David/A-3576-2010
OI Ng, Danny Siu Chun/0000-0001-6566-1019; Rong, Shi
   Song/0000-0001-8352-6363; Yam, Jason C./0000-0002-2156-1486; Cheung,
   Carol/0000-0002-9672-1819; Chen, Li Jia/0000-0003-3500-5840; Wong, Tien
   Yin/0000-0002-8448-1264; Osterbur, David/0000-0002-5953-538X
CR Al-Salem KM, 2014, JAMA OPHTHALMOL, V132, P906, DOI 10.1001/jamaophthalmol.2014.1785
   Al-Salem Khalil M, 2014, Retina, V34, P868, DOI 10.1097/IAE.0000000000000006
   Baker ML, 2009, ARCH OPHTHALMOL-CHIC, V127, P667, DOI 10.1001/archophthalmol.2009.30
   Blagodatny ML, 2007, J AM GERIATR SOC, V55, pS166
   Chen S.-C., 2016, NEURO OPHTHALMOL JAP, V33, P311, DOI [10.11476/shinkeiganka.33.311, DOI 10.11476/SHINKEIGANKA.33.311]
   Chiu K, 2012, AGE, V34, P633, DOI 10.1007/s11357-011-9260-2
   Chung SD, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120003
   Chung SD, 2014, AM J OPHTHALMOL, V157, P464, DOI 10.1016/j.ajo.2013.09.026
   Clapcote SJ, 2005, COMPARATIVE MED, V55, P310
   Clark HS, 1918, J AMER MED ASSOC, V71, P1799, DOI 10.1001/jama.1918.02600480015005
   Clemons TE, 2006, ARCH OPHTHALMOL-CHIC, V124, P537
   Cruickshanks KJ, 2013, AM J EPIDEMIOL, V177, pS177
   Demirci S, 2015, TURK J MED SCI, V45, P1115, DOI 10.3906/sag-1406-135
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Ding JD, 2011, P NATL ACAD SCI USA, V108, pE279, DOI 10.1073/pnas.1100901108
   Feeney J, 2013, NEUROBIOL AGING, V34, P2449, DOI 10.1016/j.neurobiolaging.2013.05.007
   Frost S, 2016, CURR ALZHEIMER RES, V13, P1259, DOI 10.2174/1567205013666160603003800
   Gupta V, 2016, CELL MOL LIFE SCI, V73, P4279, DOI 10.1007/s00018-016-2295-x
   Harrabi H, 2015, INVEST OPHTH VIS SCI, V56, P1217, DOI 10.1167/iovs.14-15370
   HIGGINS JPT, 2011, COCHRANE HDB SYSTEMA, V0001
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Isas JM, 2010, INVEST OPHTH VIS SCI, V51, P1304, DOI 10.1167/iovs.09-4207
   Jonna G, 2013, OPHTHALMOLOGY, V120, P1106, DOI 10.1016/j.ophtha.2013.01.041
   Kaczmarczyk Kamila, 2007, Klin Oczna, V109, P482
   Keenan TDL, 2014, JAMA OPHTHALMOL, V132, P63, DOI 10.1001/jamaophthalmol.2013.5696
   Killen A, 2013, AGE AGEING, V42, P98, DOI 10.1093/ageing/afs157
   Kirkwood B, 2003, BLACKWELL SCI
   Klaver CCW, 1999, AM J EPIDEMIOL, V150, P963
   Koronyo-Hamaoui M, 2011, NEUROIMAGE, V54, pS204, DOI 10.1016/j.neuroimage.2010.06.020
   Lindekleiv H, 2013, EYE, V27, P1281, DOI 10.1038/eye.2013.181
   Lindekleiv H, 2012, EUR J NEUROL, V19, P431
   Mandas A, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00309
   McKee AC, 2006, J NEUROPATH EXP NEUR, V65, P621, DOI 10.1097/00005072-200606000-00010
   McPheeters Melissa L, 2012, Evid Rep Technol Assess (Full Rep), P1
   Millan-Calenti J. C., 2005, Geriatrika (Madrid), V21, P10
   Montoliu-Gaya L, 2016, EXPERT REV MOL MED, V18, DOI 10.1017/erm.2016.11
   Nesterova A A, 2015, Adv Gerontol, V28, P42
   Nolan JM, 2014, J ALZHEIMERS DIS, V42, P1191, DOI 10.3233/JAD-140507
   Nowacka B, 2014, MED SCI MONITOR, V20, P2243, DOI 10.12659/MSM.890861
   Ong SY, 2012, ARCH OPHTHALMOL-CHIC, V130, P895, DOI 10.1001/archophthalmol.2012.152
   Peiretti E, 2014, EXP EYE RES, V124, P11, DOI 10.1016/j.exer.2014.04.017
   Peters JL, 2008, J CLIN EPIDEMIOL, V61, P991, DOI 10.1016/j.jclinepi.2007.11.010
   Pham TQ, 2006, GERONTOLOGY, V52, P353, DOI 10.1159/000094984
   Renzi LM, 2014, NEUROBIOL AGING, V35, P1695, DOI 10.1016/j.neurobiolaging.2013.12.024
   Roca-Santiago H.M., 2006, Arch Soc Esp Oftalmol, V81, P73
   Rong SS, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-04393-2
   Rong SS, 2016, OPHTHALMOLOGY, V123, P1211, DOI 10.1016/j.ophtha.2015.12.027
   Rong SS, 2014, INVEST OPHTH VIS SCI, V55, P6235, DOI 10.1167/iovs.14-15046
   Rovner BW, 2011, ARCH OPHTHALMOL-CHIC, V129, P885, DOI 10.1001/archophthalmol.2011.146
   Rozzini L, 2014, AM J ALZHEIMERS DIS, V29, P256, DOI 10.1177/1533317513517032
   Sterne JAC, 2000, J CLIN EPIDEMIOL, V53, P1119, DOI 10.1016/S0895-4356(00)00242-0
   Tsai DC, 2015, OPHTHALMOLOGY, V122, P2327, DOI 10.1016/j.ophtha.2015.07.033
   Whitson H, 2010, J AM GERIATR SOC, V58, P128
   Williams MA, 2015, AM J GERIAT PSYCHIAT, V23, P1290, DOI 10.1016/j.jagp.2015.06.005
   Williams MA, 2014, J ALZHEIMERS DIS, V42, P909, DOI 10.3233/JAD-140243
   Wong MYZ, 2015, J AM GERIATR SOC, V63, P192, DOI 10.1111/jgs.13228
   Wong TY, 2002, AM J OPHTHALMOL, V134, P828
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Woo SJ, 2012, OPHTHALMOLOGY, V119, P2094, DOI 10.1016/j.ophtha.2012.04.026
   Wood JM, 2011, INVEST OPHTH VIS SCI, V52, P5088, DOI 10.1167/iovs.10-6644
   World Health Organization, 2015, DEM SEC DEM
   Wyss-Coray T, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006346
   Zhou LX, 2016, CLIN INTERV AGING, V11, P215, DOI 10.2147/CIA.S102213
NR 64
TC 24
Z9 24
U1 1
U2 7
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD DEC
PY 2019
VL 103
IS 12
BP 1777
EP 1783
DI 10.1136/bjophthalmol-2018-313277
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA JT7FH
UT WOS:000501150600016
PM 31000510
DA 2022-11-30
ER

PT J
AU Reiter, GS
   Told, R
   Schlanitz, FG
   Baumann, L
   Schmidt-Erfurth, U
   Sacu, S
AF Reiter, Gregor Sebastian
   Told, Reinhard
   Schlanitz, Ferdinand Georg
   Baumann, Lukas
   Schmidt-Erfurth, Ursula
   Sacu, Stefan
TI Longitudinal Association Between Drusen Volume and Retinal Capillary
   Perfusion in Intermediate Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE age-related macular degeneration; AMD; drusen; flow area; optical
   coherence tomography; optical coherence tomography angiography; OCT-A;
   vessel density
ID COHERENCE TOMOGRAPHY ANGIOGRAPHY; QUANTITATIVE-ANALYSIS; PIGMENT
   EPITHELIUM; VASCULAR DENSITY; CHORIOCAPILLARIS; SEGMENTATION;
   REPRODUCIBILITY; EYES; PREVALENCE; PLEXUSES
AB PURPOSE. To evaluate vascular changes in the superficial and deep retinal capillary plexus (SCP, DCP) and their association with drusen volume changes in intermediate age-related macular degeneration (iAMD).
   METHODS. Patients with iAMD were examined at baseline and 12 months thereafter. Drusen volume was extracted from 20 degrees x 20 degrees OCT scans using a 3-mm ETDRS grid using a customized algorithm with manual correction. Vessel density (VD) and flow area (FA) were extracted from 3 3 3 mm SD-OCT-A scans after manual correction of the segmentation. Associations were investigated using multiple regression models.
   RESULTS. We used 31 eyes of 31 patients for evaluation. The mean age at baseline was 74.9 +/- 5.4 years; 26 patients were female. Baseline visual acuity (VA) was 0.05 +/- 0.08 logMAR (Snellen equivalent approximately 20/22). The initial mean 3-mm central drusen volume was 0.144 +/- 0.136 mm(3). A significant association with the signal strength index was consistently found, therefore all capillary measurements were corrected. VD in the same area was 49.88% +/- 7.38% and 55.43% +/- 9.31% for the SCP and DCP, respectively. The baseline FA resulted in 3.292 +/- 0.218 mm(2) and 3.433 +/- 0.224 mm(2) for the SCP and DCP, respectively. No association was found between changes in drusen volume and FA or VD after 12 months (all P > 0.05). VA worsened (P = 0.013) and the foveal FA of the SCP increased significantly (P = 0.014).
   CONCLUSIONS. No significant association was found between the increase in drusen volume in iAMD and capillary retinal perfusion over a 12-month follow-up. Although VA decreased statistically over this time period, the foveal FA of the SCP increased.
C1 [Reiter, Gregor Sebastian; Told, Reinhard; Schlanitz, Ferdinand Georg; Schmidt-Erfurth, Ursula; Sacu, Stefan] Med Univ Vienna, Dept Ophthalmol & Optometry, Vienna Clin Trial Ctr VTC, Vienna, Austria.
   [Baumann, Lukas] Med Univ Vienna, Ctr Med Stat Informat & Intelligent Syst, Vienna, Austria.
C3 Medical University of Vienna; Medical University of Vienna
RP Schmidt-Erfurth, U (通讯作者)，Med Univ Vienna, Dept Ophthalmol & Optometry, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.
EM ursula.schmidt-erfurth@meduniwien.ac.at
OI Baumann, Lukas/0000-0001-7931-7470; Reiter, Gregor/0000-0001-7661-4015;
   Told, Reinhard/0000-0003-2046-7081
CR Al-Sheikh Mayss, 2017, Int J Retina Vitreous, V3, P13, DOI 10.1186/s40942-017-0068-9
   Alten F, 2017, GRAEFES ARCH CLIN EX, V255, P1
   Alten F, 2016, GRAEF ARCH CLIN EXP, V254, P2165, DOI 10.1007/s00417-016-3375-1
   Balaratnasingam C, 2016, INVEST OPHTH VIS SCI, V57, P5479, DOI 10.1167/iovs.16-19816
   Bogunovic H, 2017, INVEST OPHTH VIS SCI, V58, pBIO141, DOI 10.1167/iovs.17-21789
   Borrelli E, 2017, INVEST OPHTH VIS SCI, V58, P4792, DOI 10.1167/iovs.17-22360
   Cicinelli MV, 2017, BRIT J OPHTHALMOL, V101, P1193, DOI 10.1136/bjophthalmol-2016-309481
   Coscas F, 2016, INVEST OPHTH VIS SCI, V57, pOCT211, DOI 10.1167/iovs.15-18793
   Fenner BJ, 2017, BR J OPHTHALMOL, P1
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Folgar FA, 2016, OPHTHALMOLOGY, V123, P39, DOI 10.1016/j.ophtha.2015.09.016
   Freeman SR, 2010, RETINA-J RET VIT DIS, V30, P431, DOI 10.1097/IAE.0b013e3181bd2f94
   Garrity ST, 2017, INVEST OPHTH VIS SCI, V58, P5548, DOI 10.1167/iovs.17-22036
   Iafe NA, 2016, INVEST OPHTH VIS SCI, V57, P5780, DOI 10.1167/iovs.16-20045
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Lane M, 2016, INVEST OPHTH VIS SCI, V57, pOCT585, DOI 10.1167/iovs.15-18915
   Lauermann JL, 2018, GRAEF ARCH CLIN EXP, V256, P1807, DOI 10.1007/s00417-018-4053-2
   Lei JQ, 2017, JAMA OPHTHALMOL, V135, P1092, DOI 10.1001/jamaophthalmol.2017.3431
   Mastropasqua L, 2017, RETINA-J RET VIT DIS, V37, P247, DOI 10.1097/IAE.0000000000001145
   Nittala MG, 2012, INVEST OPHTH VIS SCI, V53, P8319, DOI 10.1167/iovs.12-10582
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Schlanitz FG, 2017, BRIT J OPHTHALMOL, V101, P198, DOI 10.1136/bjophthalmol-2016-308422
   Spaide RF, 2017, JAMA OPHTHALMOL, V135, P259, DOI 10.1001/jamaophthalmol.2016.5327
   Toto L, 2017, BRIT J OPHTHALMOL, V101, P774, DOI 10.1136/bjophthalmol-2016-309160
   Toto L, 2016, RETINA-J RET VIT DIS, V36, P1566, DOI 10.1097/IAE.0000000000000962
   Wang Q, 2016, AM J OPHTHALMOL, V168, P95, DOI 10.1016/j.ajo.2016.05.005
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu ZC, 2016, INVEST OPHTH VIS SCI, V57, P3714, DOI 10.1167/iovs.15-18294
   You QS, 2017, RETINA-J RET VIT DIS, V37, P1475, DOI 10.1097/IAE.0000000000001407
   Zucchiatti I, 2015, AM J OPHTHALMOL, V160, P602, DOI 10.1016/j.ajo.2015.05.030
NR 30
TC 5
Z9 5
U1 1
U2 4
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JUN
PY 2019
VL 60
IS 7
BP 2503
EP 2508
DI 10.1167/iovs.18-26237
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA IE9UB
UT WOS:000472721000012
PM 31185089
OA gold
DA 2022-11-30
ER

PT J
AU Wu, ZC
   Ayton, LN
   Luu, CD
   Guymer, RH
AF Wu, Zhichao
   Ayton, Lauren N.
   Luu, Chi D.
   Guymer, Robyn H.
TI Relationship between Retinal Microstructures on Optical Coherence
   Tomography and Microperimetry in Age-Related Macular Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID TEST-RETEST VARIABILITY; 2ND REFLECTIVE BAND; FUNDUS AUTOFLUORESCENCE;
   GEOGRAPHIC ATROPHY; VISUAL-ACUITY; DRUSEN; LASER; SENSITIVITY;
   RETINOPATHY; THICKNESS
AB Purpose: To determine the relationship between structural parameters of the outer retina on spectral-domain optical coherence tomography (SD-OCT) and microperimetric retinal sensitivity in early stages of age-related macular degeneration (AMD).
   Design: Prospective, observational study.
   Participants: Seventy-five eyes of 75 participants with early stages of AMD (drusen >= 125 mu m, with/without pigmentary abnormalities) and 25 control participants of a similar age.
   Methods: Participants underwent microperimetry testing and high-resolution SD-OCT scans. Structural parameters at 5 central points (0 degrees, 1 degrees, and 2.33 degrees nasal and temporal to the fovea along the horizontal axis) corresponding to areas tested by microperimetry were compared. Structural parameters included outer segment (OS) length, thickness and elevation of the retinal pigment epithelium (RPE) band, grading of the inner-segment ellipsoid (ISe) band integrity, and presence of hyperreflective foci (HF).
   Main Outcome Measures: Relationship between structural parameters and retinal sensitivity.
   Results: Retinal sensitivity was significantly correlated with RPE elevation (P < 0.001), ISe grading (P < 0.001), and presence of HF (P <= 0.018) at all test points, but not with OS length (P >= 0.093) or RPE thickness (P >= 0.125). However, multiple linear regression analyses revealed that only ISe grading (P <= 0.011) and RPE elevation (P <= 0.030) remained significantly associated with retinal sensitivity at all points. By using a simple linear model incorporating ISe grading and RPE elevation to predict values of retinal sensitivity, the 95% limits of agreement between the predicted and the actual value was +/- 3.83 dB.
   Conclusions: The integrity of the ISe band and drusen-associated RPE elevation are significant independent predictors of microperimetric retinal sensitivity. Our findings imply that these 2 structural parameters may be surrogate markers of retinal function in the early stages of AMD. (C) 2014 by the American Academy of Ophthalmology.
C1 [Wu, Zhichao; Ayton, Lauren N.; Luu, Chi D.; Guymer, Robyn H.] Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Melbourne, Vic 3010, Australia.
C3 Centre for Eye Research Australia; Royal Victorian Eye & Ear Hospital;
   University of Melbourne
RP Guymer, RH (通讯作者)，Ctr Eye Res Australia, Macular Res Unit, Level 1,32 Gisborne St, East Melbourne, Vic 3002, Australia.
EM rh.guymer@unimelb.edu.au
RI Ayton, Lauren/AAV-2977-2021
OI Ayton, Lauren/0000-0001-9907-084X; Luu, Chi/0000-0002-7604-7097; Guymer,
   Robyn/0000-0002-9441-4356
FU National Health and Medical Research Council (NHMRC) [1027624]; NH&MRC
   practitioner fellowship (RHG) [529905]; Macular Disease Foundation
   Australia Research Grant; Bupa Health Foundation (Australia); William
   Angliss (Victoria) Charitable Fund Research Grant; BrightFocus
   Foundation; Perpetual Trust Foundation; MR & RA Brownless Perpetual
   Charitable Trust; NH&MRC Centre for Clinical Research Excellence -
   Translational Clinical Research in Major Eye Diseases [529923]
FX Supported by the National Health and Medical Research Council (NH&MRC)
   Project Grant (1027624), NH&MRC practitioner fellowship (RHG, #529905),
   Macular Disease Foundation Australia Research Grant, Bupa Health
   Foundation (Australia), William Angliss (Victoria) Charitable Fund
   Research Grant, BrightFocus Foundation, The Perpetual Trust Foundation
   and MR & RA Brownless Perpetual Charitable Trust funding administered by
   the Trust Company. The Centre for Eye Research Australia receives
   Operational Infrastructure Support from the Victorian Government. This
   study was supported by the NH&MRC Centre for Clinical Research
   Excellence #529923 - Translational Clinical Research in Major Eye
   Diseases.
CR Acton JH, 2012, INVEST OPHTH VIS SCI, V53, P7618, DOI 10.1167/iovs.12-10361
   BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8
   Chen FK, 2009, INVEST OPHTH VIS SCI, V50, P3464, DOI 10.1167/iovs.08-2926
   Cho HJ, 2013, AM J OPHTHALMOL, V155, P118, DOI 10.1016/j.ajo.2012.07.009
   Christenbury JG, 2013, OPHTHALMOLOGY, V120, P1038, DOI 10.1016/j.ophtha.2012.10.018
   Cideciyan AV, 2012, INVEST OPHTH VIS SCI, V53, P841, DOI 10.1167/iovs.11-8415
   Csaky KG, 2008, INVEST OPHTH VIS SCI, V49, P479, DOI 10.1167/iovs.07-1132
   Ehrlich R, 2012, CLIN EXP OPHTHALMOL, V40, pE32, DOI 10.1111/j.1442-9071.2011.02654.x
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Folgar FA, 2012, INVEST OPHTH VIS SCI, V53, P4626, DOI 10.1167/iovs.12-9813
   Hartmann KI, 2012, RETINA-J RET VIT DIS, V32, P1492, DOI 10.1097/IAE.0b013e318242b949
   Hartmann KI, 2011, RETINA-J RET VIT DIS, V31, P1323, DOI 10.1097/IAE.0b013e31820a6850
   Ho J, 2011, OPHTHALMOLOGY, V118, P687, DOI 10.1016/j.ophtha.2010.08.010
   Jain N, 2010, INVEST OPHTH VIS SCI, V51, P4875, DOI 10.1167/iovs.09-4962
   Jivrajka RV, 2013, EYE, V27, P1044, DOI 10.1038/eye.2013.112
   Johnson PT, 2005, INVEST OPHTH VIS SCI, V46, P4788, DOI 10.1167/iovs.05-0767
   Johnson PT, 2003, INVEST OPHTH VIS SCI, V44, P4481, DOI 10.1167/iovs.03-0436
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1026, DOI 10.1016/j.ophtha.2007.08.030
   Landa G, 2012, OPHTHALMIC RES, V47, P81, DOI 10.1159/000324988
   Landa G, 2011, RETINA-J RET VIT DIS, V31, P364, DOI 10.1097/IAE.0b013e3181e91132
   Leuschen JN, 2013, OPHTHALMOLOGY, V120, P140, DOI 10.1016/j.ophtha.2012.07.004
   Luu CD, 2012, ARCH OPHTHALMOL-CHIC, V130, P690, DOI 10.1001/archophthalmol.2012.277
   Midena E, 2007, BRIT J OPHTHALMOL, V91, P1499, DOI 10.1136/bjo.2007.119685
   Pappuru RR, 2011, INVEST OPHTH VIS SCI, V52, P6743, DOI 10.1167/iovs.10-6723
   Parisi V, 2007, RETINA-J RET VIT DIS, V27, P879, DOI 10.1097/IAE.0b013e318042d6aa
   Park DW, 2006, OPHTHALMOLOGY, V113, P1974, DOI 10.1016/j.ophtha.2006.08.015
   Parravano M, 2009, RETINA-J RET VIT DIS, V29, P329, DOI 10.1097/IAE.0b013e31819093e6
   Pilotto E, 2013, BRIT J OPHTHALMOL, V97, P622, DOI 10.1136/bjophthalmol-2012-302633
   Querques L, 2012, AM J OPHTHALMOL, V153, P1110, DOI 10.1016/j.ajo.2011.11.002
   Remky A, 2005, BRIT J OPHTHALMOL, V89, P464, DOI 10.1136/bjo.2004.050260
   Sadigh S, 2013, INVEST OPHTH VIS SCI, V54, P1603, DOI 10.1167/iovs.12-11286
   Schuman SG, 2009, OPHTHALMOLOGY, V116, P488, DOI 10.1016/j.ophtha.2008.10.006
   Spaide RF, 2011, RETINA-J RET VIT DIS, V31, P1609, DOI 10.1097/IAE.0b013e3182247535
   Squirrell DM, 2010, RETINA-J RET VIT DIS, V30, P436, DOI 10.1097/IAE.0b013e3181bd2f29
   SUNNESS JS, 1988, ARCH OPHTHALMOL-CHIC, V106, P1081, DOI 10.1001/archopht.1988.01060140237032
   Takamine Y, 1998, GRAEF ARCH CLIN EXP, V236, P285, DOI 10.1007/s004170050079
   Vujosevic S, 2011, OPHTHALMOLOGICA, V225, P155, DOI 10.1159/000320340
   Vujosevic S, 2010, RETINA-J RET VIT DIS, V30, P908, DOI 10.1097/IAE.0b013e3181c96986
   Winterhalter S, 2012, GRAEF ARCH CLIN EXP, V250, P175, DOI 10.1007/s00417-011-1784-8
   Wong IY, 2012, CURR OPIN OPHTHALMOL, V23, P210, DOI 10.1097/ICU.0b013e3283524162
   Wong WT, 2010, INVEST OPHTH VIS SCI, V51, P6131, DOI 10.1167/iovs.10-5637
   Wu ZC, 2013, INVEST OPHTH VIS SCI, V54, P7378, DOI 10.1167/iovs.13-12617
   Wu ZC, 2013, OPHTHALMOLOGY, V120, P1307, DOI 10.1016/j.ophtha.2012.12.047
   Wu ZC, 2013, INVEST OPHTH VIS SCI, V54, P2800, DOI 10.1167/iovs.13-11613
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P2434, DOI 10.1016/j.ophtha.2011.05.008
   Yi K, 2009, BRIT J OPHTHALMOL, V93, P176, DOI 10.1136/bjo.2008.137356
NR 47
TC 51
Z9 53
U1 0
U2 10
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JUL
PY 2014
VL 121
IS 7
BP 1445
EP 1452
DI 10.1016/j.ophtha.2014.01.025
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AO2II
UT WOS:000341142800026
PM 24629618
DA 2022-11-30
ER

PT J
AU Zouache, MA
   Bennion, A
   Hageman, JL
   Pappas, C
   Richards, BT
   Hageman, GS
AF Zouache, Moussa A.
   Bennion, Alex
   Hageman, Jill L.
   Pappas, Christian
   Richards, Burt T.
   Hageman, Gregory S.
TI Macular retinal thickness differs markedly in age-related macular
   degeneration driven by risk polymorphisms on chromosomes 1 and 10
SO SCIENTIFIC REPORTS
LA English
DT Article
ID COMPLEMENT FACTOR-H; PIGMENT EPITHELIUM; BRUCHS MEMBRANE; ALLOTYPIC
   VARIANT; LAYER THICKNESS; BLOOD-FLOW; SUSCEPTIBILITY; ASSOCIATION;
   PREVALENCE; BINDING
AB The two most common genetic contributors to age-related macular degeneration (AMD), a leading cause of irreversible vision loss worldwide, are variants associated with CFH-CFHR5 on chromosome 1 (Chr1) and ARMS2/HTRA1 on chromosome 10 (Chr10). We sought to determine if risk and protective variants associated with these two loci drive differences in macular retinal thickness prior and subsequent to the onset of clinically observable signs of AMD. We considered 299 individuals (547 eyes) homozygous for risk variants or haplotypes on Chr1 or Chr10 exclusively (Chr1-risk and Chr10-risk, respectively) or homozygous for a neutral haplotype (Chr1-neu), for the protective I62 tagged haplotype (Chr1-prot-I62) or for the protection conferring CFHR1/3 deletion haplotype (Chr1-prot-del) on Chr1 without any risk alleles on Chr10. Among eyes with no clinically observable signs of AMD, the deletion of CFHR1/3, which is strongly protective against this disease, is associated with significantly thicker retinas in the perifovea. When controlling for age, Chr10-risk eyes with early or intermediate AMD have thinner retinas as compared to eyes from the Chr1-risk group with similar disease severity. Our analysis indicates that this difference likely results from distinct biological and disease initiation and progression events associated with Chr1- and Chr10-directed AMD.
C1 [Zouache, Moussa A.; Bennion, Alex; Hageman, Jill L.; Pappas, Christian; Richards, Burt T.; Hageman, Gregory S.] Univ Utah, Dept Ophthalmol & Visual Sci, Steele Ctr Translat Med, John A Moran Eye Ctr, Salt Lake City, UT 84132 USA.
C3 Utah System of Higher Education; University of Utah
RP Zouache, MA; Hageman, GS (通讯作者)，Univ Utah, Dept Ophthalmol & Visual Sci, Steele Ctr Translat Med, John A Moran Eye Ctr, Salt Lake City, UT 84132 USA.
EM moussa.zouache@hsc.utah.edu; gregory.hageman@hsc.utah.edu
FU National Eye Institute of the National Institutes of Health
   [R24EY017404]; Research to Prevent Blindness, New York, NY
FX This work was supported in part by the National Eye Institute of the
   National Institutes of Health under award numbers R24EY017404 (GSH).
   Additional support from an Unrestricted Grant from Research to Prevent
   Blindness, New York, NY, to the Department of Ophthalmology & Visual
   Sciences, University of Utah.
CR Abedi F, 2013, OPHTHALMOLOGY, V120, P1641, DOI 10.1016/j.ophtha.2013.01.014
   Acton JH, 2012, INVEST OPHTH VIS SCI, V53, P7618, DOI 10.1167/iovs.12-10361
   Adhi M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037638
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   [Anonymous], 2018, OPHTHALMOLOGY, V125, P1913
   Bates D, 2015, J STAT SOFTW, V67, P1, DOI 10.18637/jss.v067.i01
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Brandl C, 2019, INVEST OPHTH VIS SCI, V60, P1581, DOI 10.1167/iovs.18-25332
   Bressler SB, 2008, ARCH OPHTHALMOL-CHIC, V126, P241, DOI 10.1001/archophthalmol.2007.53
   Chauhan BC, 2020, OPHTHALMOLOGY, V127, P177, DOI 10.1016/j.ophtha.2019.09.013
   Cheung CMG, 2014, OPHTHALMOLOGY, V121, P1598, DOI 10.1016/j.ophtha.2014.02.004
   Chong NHV, 2005, AM J PATHOL, V166, P241, DOI 10.1016/S0002-9440(10)62248-1
   Cipriani V, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-14499-3
   Clark SJ, 2006, J BIOL CHEM, V281, P24713, DOI 10.1074/jbc.M605083200
   Clark SJ, 2010, J BIOL CHEM, V285, P30192, DOI 10.1074/jbc.M110.103986
   Curcio CA, 2001, EYE, V15, P376, DOI 10.1038/eye.2001.140
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   CURCIO CA, 1990, J COMP NEUROL, V292, P497, DOI 10.1002/cne.902920402
   CURCIO CA, 1990, J COMP NEUROL, V300, P5, DOI 10.1002/cne.903000103
   Duman R, 2017, CUTAN OCUL TOXICOL, V36, P366, DOI 10.1080/15569527.2017.1300162
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Eriksson U, 2009, BRIT J OPHTHALMOL, V93, P1448, DOI 10.1136/bjo.2007.131094
   Farsiu S, 2014, OPHTHALMOLOGY, V121, P162, DOI 10.1016/j.ophtha.2013.07.013
   Francis PJ, 2007, HUM HERED, V63, P212, DOI 10.1159/000100046
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Gao XR, 2019, HUM MOL GENET, V28, P1162, DOI 10.1093/hmg/ddy422
   de Jorge EG, 2018, MOL IMMUNOL, V102, P42, DOI 10.1016/j.molimm.2018.06.011
   Grassmann F, 2017, GENETICS, V205, P919, DOI 10.1534/genetics.116.195966
   Grassmann F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126636
   Grover S, 2009, AM J OPHTHALMOL, V148, P266, DOI 10.1016/j.ajo.2009.03.006
   Hageman GS, 2006, ANN MED, V38, P592, DOI 10.1080/07853890601097030
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hecker LA, 2010, ADV EXP MED BIOL, V703, P49, DOI 10.1007/978-1-4419-5635-4_4
   Heesterbeek TJ, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-43144-3
   Hogan J., 1971, HISTOLOGY HUMAN EYE, P320
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Invernizzi A, 2018, OPHTHALMOL RETINA, V2, P808, DOI 10.1016/j.oret.2017.12.012
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Karampelas M, 2013, BRIT J OPHTHALMOL, V97, P1256, DOI 10.1136/bjophthalmol-2013-303219
   Keenan T. D, PROGR GEOGRAPHIC ATR
   Keenan TDL, 2015, INVEST OPHTH VIS SCI, V56, P4870, DOI 10.1167/iovs.15-17009
   Kenmochi J, 2017, RETINA-J RET VIT DIS, V37, P47, DOI 10.1097/IAE.0000000000001131
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2013, INVEST OPHTH VIS SCI, V54, DOI 10.1167/iovs.13-12789
   Ko F, 2017, OPHTHALMOLOGY, V124, P105, DOI 10.1016/j.ophtha.2016.07.033
   Lamin A, 2019, EYE, V33, P428, DOI 10.1038/s41433-018-0234-9
   Lenth R, 2018, **DATA OBJECT**
   Martinez-Barricarte R, 2012, INVEST OPHTH VIS SCI, V53, P1087, DOI 10.1167/iovs.11-8709
   Myers CE, 2015, AM J OPHTHALMOL, V159, P445, DOI 10.1016/j.ajo.2014.11.025
   NEGI A, 1986, INVEST OPHTH VIS SCI, V27, P1564
   Nivison-Smith L, 2018, OPTOMETRY VISION SCI, V95, P648, DOI 10.1097/OPX.0000000000001256
   Nusinowitz S, 2018, CURR EYE RES, V43, P376, DOI 10.1080/02713683.2017.1401646
   Oeverhaus M, 2017, OPHTHALMOLOGICA, V238, P6, DOI 10.1159/000468949
   Perlee LT, 2013, OPHTHALMOLOGY, V120, P1880, DOI 10.1016/j.ophtha.2013.02.007
   Prosser BE, 2007, J EXP MED, V204, P2277, DOI 10.1084/jem.20071069
   Ramon C, 2019, CLIN EXP OPTOM, V102, P601, DOI 10.1111/cxo.12894
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Rogala J, 2015, INVEST OPHTH VIS SCI, V56, P1689, DOI 10.1167/iovs.14-16221
   ROHRENBECK J, 1989, EUR J NEUROSCI, V1, P407, DOI 10.1111/j.1460-9568.1989.tb00349.x
   Ryoo NK, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0209276
   Sadigh S, 2013, INVEST OPHTH VIS SCI, V54, P1603, DOI 10.1167/iovs.12-11286
   Sassmannshausen M, 2018, INVEST OPHTH VIS SCI, V59, P1599, DOI 10.1167/iovs.17-22712
   Schaid DJ, 2002, AM J HUM GENET, V70, P425, DOI 10.1086/338688
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P55, DOI 10.1001/archopht.125.1.55
   Skerka C, 2007, MOL IMMUNOL, V44, P3398, DOI 10.1016/j.molimm.2007.02.012
   Sobrin L, 2011, AM J OPHTHALMOL, V151, P345, DOI 10.1016/j.ajo.2010.08.015
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Team R. C, R LANGUAGE ENV STAT
   Tong J, 2019, AM J OPHTHALMOL, V208, P166, DOI 10.1016/j.ajo.2019.04.020
   Tortajada A, 2009, HUM MOL GENET, V18, P3452, DOI 10.1093/hmg/ddp289
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   von Hanno T, 2017, ACTA OPHTHALMOL, V95, P262, DOI 10.1111/aos.13337
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wood A, 2011, AM J OPHTHALMOL, V152, P1030, DOI 10.1016/j.ajo.2011.05.021
   Yang TK, 2019, J OPHTHALMOL, V2019, DOI 10.1155/2019/8079127
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
   Zouache MA, 2019, J FLUID MECH, V858, P184, DOI 10.1017/jfm.2018.771
   Zouache MA, 2016, SCI REP-UK, V6, DOI 10.1038/srep35754
   Zouache MA, 2015, J FLUID MECH, V774, P37, DOI 10.1017/jfm.2015.243
NR 82
TC 13
Z9 13
U1 0
U2 2
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD DEC 3
PY 2020
VL 10
IS 1
AR 21093
DI 10.1038/s41598-020-78059-x
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA QD2ZZ
UT WOS:000615394300093
PM 33273512
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Hsu, MY
   Chen, SJ
   Chen, KH
   Hung, YC
   Tsai, HY
   Cheng, CM
AF Hsu, Min-Yen
   Chen, Shih-Jen
   Chen, Kuan-Hung
   Hung, Yu-Chien
   Tsai, Hin-Yeung
   Cheng, Chao-Min
TI Monitoring VEGF levels with low-volume sampling in major
   vision-threatening diseases: age-related macular degeneration and
   diabetic retinopathy
SO LAB ON A CHIP
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; AQUEOUS-HUMOR; INTRAVITREAL INJECTION;
   RANIBIZUMAB; BEVACIZUMAB; EYE; EDEMA; ELISA
AB The purpose of this article is to demonstrate the capacity of paper-based ELISA (P-ELISA) to monitor VEGF in patients requiring treatment for vision-threatening diseases. The most commonly encountered vision-threatening diseases are age-related macular degeneration (AMD) and diabetic retinopathy (DR), both of which may require short-term or life-long anti-VEGF injection treatment therapy. Accurate measurement of VEGF concentration in aqueous humor can provide significant and timely information to diagnose the disease state. Adequate and precise therapy may consequently be provided. At odds with conventional diagnostic approaches is the fact that a maximum of only 200 microliters of aqueous humor can be safely removed from the eye for testing. Fortunately, new diagnostic platforms, such as P-ELISA, require only minute volumes, i.e., approximately 2 microliters per test "well" and approximately 40 microliters total to quantify VEGF levels, and the testing process takes less than an hour. Thus, point-of-care (POC) diagnostics, such as P-ELISA, should be examined and improved upon as needed in order to develop an efficient tool for outpatient clinics and others to obtain semi-quantitative results that might facilitate accurate dosing of anti-VEGF treatment and delay or prevent the progression of AMD and DR.
C1 [Hsu, Min-Yen; Chen, Kuan-Hung; Cheng, Chao-Min] Natl Tsing Hua Univ, Inst Nanoengn & Microsyst, Hsinchu 300, Taiwan.
   [Hsu, Min-Yen; Hung, Yu-Chien] Taichung Vet Gen Hosp, Dept Ophthalmol, Taichung 407, Taiwan.
   [Chen, Shih-Jen] Taipei Vet Gen Hosp, Dept Ophthalmol, Taipei 112, Taiwan.
   [Tsai, Hin-Yeung] Taichung Tzu Chi Hosp, Dept Ophthalmol, Taichung 427, Taiwan.
C3 National Tsing Hua University; Taichung Veterans General Hospital;
   Taipei Veterans General Hospital; Buddhist Tzu Chi General Hospital;
   Taichung Tzu Chi Hospital
RP Cheng, CM (通讯作者)，Natl Tsing Hua Univ, Inst Nanoengn & Microsyst, Hsinchu 300, Taiwan.
EM chaomin@mx.nthu.edu.tw
RI Hsu, MinYen/AAT-2200-2021
CR Brown DM, 2013, OPHTHALMOLOGY, V120, P2013, DOI 10.1016/j.ophtha.2013.02.034
   Campochiaro PA, 2008, MOL THER, V16, P791, DOI 10.1038/mt.2008.10
   Campochiaro PA, 2009, OPHTHALMOLOGY, V116, P2158, DOI 10.1016/j.ophtha.2009.04.038
   Cheng CM, 2010, ANGEW CHEM INT EDIT, V49, P4771, DOI 10.1002/anie.201001005
   Cheung N, 2010, LANCET, V376, P124, DOI 10.1016/S0140-6736(09)62124-3
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Dell'Omo R, 2012, AM J OPHTHALMOL, V153, P155, DOI 10.1016/j.ajo.2011.06.001
   Engelgau MM, 2004, ANN INTERN MED, V140, P945, DOI 10.7326/0003-4819-140-11-200406010-00035
   Falavarjani KG, 2013, EYE, V27, P787, DOI 10.1038/eye.2013.107
   Funatsu H, 2005, GRAEF ARCH CLIN EXP, V243, P3, DOI 10.1007/s00417-004-0950-7
   Hsu CK, 2014, ANAL CHEM, V86, P4605, DOI 10.1021/ac500835k
   Hsu MY, 2014, BIOMATERIALS, V35, P3729, DOI 10.1016/j.biomaterials.2014.01.030
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jani IV, 2013, NEW ENGL J MED, V368, P2319, DOI 10.1056/NEJMsb1214197
   Krohne TU, 2008, AM J OPHTHALMOL, V146, P508, DOI 10.1016/j.ajo.2008.05.036
   Kumar S, 2003, VET RES, V34, P71, DOI 10.1051/vetres:2002055
   Kuzmin A, 2013, OPHTHALMOL THER, V2, P41, DOI 10.1007/s40123-013-0014-3
   Kwan ASL, 2006, CLIN EXP OPHTHALMOL, V34, P33, DOI 10.1111/j.1442-9071.2006.01136.x
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Martinez S. T. P. A. W., 2008, ANAL CHEM, V80, P9
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Moja L, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011230.pub2
   Muether PS, 2012, OPHTHALMOLOGY, V119, P2082, DOI 10.1016/j.ophtha.2012.07.041
   Pai NP, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001306
   Penn JS, 2008, PROG RETIN EYE RES, V27, P331, DOI 10.1016/j.preteyeres.2008.05.001
   Nguyen QD, 2012, OPHTHALMOLOGY, V119, P789, DOI 10.1016/j.ophtha.2011.12.039
   Sawada O, 2007, ARCH OPHTHALMOL-CHIC, V125, P1363, DOI 10.1001/archopht.125.10.1363
   Schein OD, 1997, OPHTHALMOLOGY, V104, P1395, DOI 10.1016/S0161-6420(97)30125-0
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Selim KM, 2010, INDIAN J OPHTHALMOL, V58, P375, DOI 10.4103/0301-4738.67042
   Shams Naveed, 2006, Ophthalmol Clin North Am, V19, P335
   Silverman Ed, 2011, Biotechnol Healthc, V8, P14
   Stewart MW, 2012, RETINA-J RET VIT DIS, V32, P434, DOI 10.1097/IAE.0B013E31822C290F
   Vu HTV, 2005, BRIT J OPHTHALMOL, V89, P360, DOI 10.1136/bjo.2004.047498
   Yang Chang-Sue, 2007, J Chin Med Assoc, V70, P348, DOI 10.1016/S1726-4901(08)70017-0
   Yetisen AK, 2013, LAB CHIP, V13, P2210, DOI 10.1039/c3lc50169h
NR 36
TC 23
Z9 23
U1 2
U2 13
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1473-0197
EI 1473-0189
J9 LAB CHIP
JI Lab Chip
PY 2015
VL 15
IS 11
BP 2357
EP 2363
DI 10.1039/c4lc01052c
PG 7
WC Biochemical Research Methods; Chemistry, Multidisciplinary; Chemistry,
   Analytical; Nanoscience & Nanotechnology; Instruments & Instrumentation
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry; Science & Technology -
   Other Topics; Instruments & Instrumentation
GA CI7RZ
UT WOS:000354963400002
PM 25923964
DA 2022-11-30
ER

PT J
AU Schlanitz, FG
   Sacu, S
   Baumann, B
   Bolz, M
   Platzer, M
   Pircher, M
   Hitzenberger, CK
   Schmidt-Erfurth, U
AF Schlanitz, Ferdinand G.
   Sacu, Stefan
   Baumann, Bernhard
   Bolz, Matthias
   Platzer, Maria
   Pircher, Michael
   Hitzenberger, Christoph K.
   Schmidt-Erfurth, Ursula
TI Identification of Drusen Characteristics in Age-Related Macular
   Degeneration by Polarization-Sensitive Optical Coherence Tomography
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; NATURAL-HISTORY; SEVERITY SCALE;
   SEGMENTATION; PREVALENCE; MORPHOLOGY; DISEASE; MELANIN; EYES
AB PURPOSE: To describe qualitative characteristics of drusen in eyes with nonadvanced age-related macular degeneration (AMD) using polarization-sensitive optical coherence tomography (OCT).
   DESIGN: Cross-sectional study.
   METHODS: Twenty-five eyes of 25 patients with early to intermediate (nonadvanced) AMD were imaged with polarization-sensitive OCT using macular volume scans. All individual drusen in each B-scan were manually delineated by experts certified by a reading center and graded for 6 different morphologic characteristics based on a defined classification scheme, including the presence of internal depolarizing structures and associated depolarizing foci. With the use of a custom-made software, the central B-scan of each individual druse was selected and used to analyze its location, diameter, and characteristics and assess the prevalence of the different features and relations between them.
   RESULTS: Using the macular volume scans, 6224 individual drusen could be identified, including their position within the retina, their characteristics, and their association with any pigmentary alterations. The most common drusen type was a convex-shaped druse with homogeneous medium internal reflectivity and no depolarizing contents (55.3% of drusen). A total of 30.5% of the drusen exhibited internal depolarizing material; 0.3% presented overlying hyperreflective foci, and in 54.5% the foci were also depolarizing. Significant correlations were found between the diameter of the drusen and their distribution throughout the retina, shape, homogeneity of internal reflectivity, presence of internal depolarizing characteristics, and presence of overlying foci (P < .001 each). Significant relations were found between reflectivity, homogeneity, and polarization-sensitive internal characteristics (P < .001).
   CONCLUSIONS: Polarization-sensitive OCT reveals characteristic morphologic features of different druse types highlighting the pathophysiological spectrum of early to intermediate AMD. ((C) 2015 The Authors. Published by Elsevier Inc.)
C1 [Schlanitz, Ferdinand G.; Sacu, Stefan; Bolz, Matthias; Platzer, Maria; Schmidt-Erfurth, Ursula] Med Univ Vienna, Dept Ophthalmol & Optometry, A-1090 Vienna, Austria.
   [Baumann, Bernhard; Pircher, Michael; Hitzenberger, Christoph K.] Med Univ Vienna, Ctr Med Phys & Biomed Engn, A-1090 Vienna, Austria.
C3 Medical University of Vienna; Medical University of Vienna
RP Schmidt-Erfurth, U (通讯作者)，Med Univ Vienna, Dept Ophthalmol & Optometry, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.
EM ursula.schmidt-erfurth@meduniwien.ac.at
RI Bolz, Matthias/HCI-0622-2022
OI Michael, Pircher/0000-0001-9285-7527; Baumann,
   Bernhard/0000-0001-6419-1932; Bolz, Matthias/0000-0001-8691-5276;
   Hitzenberger, Christoph/0000-0002-6608-8821; Schmidt-Erfurth,
   Ursula/0000-0002-7788-7311
FU FWF, Austrian Science Fund, Vienna, Austria [P19624-B02]; European Union
   (FP7 HEALTH program, FUN-OCT, Brussels, Belgium) [201880]; Canon (Tokyo,
   Japan); Herzfeldersche Familienstiftung [AP0044120FF]
FX C.K. Hitzenberger has received support from an independent scientific
   grant (FWF grant P19624-B02, Austrian Science Fund, Vienna, Austria),
   the European Union (FP7 HEALTH program grant 201880, FUN-OCT, Brussels,
   Belgium), and Canon (Tokyo, Japan). U. Schmidt-Erfurth has received
   support from an independent scientific grant (Herzfeldersche
   Familienstiftung, grant AP0044120FF). None of the grantors had any
   influence on reporting the study data and interpretation of the data.
   All authors attest that they meet the current ICMJE requirements to
   qualify as authors.
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Ahlers C, 2010, INVEST OPHTH VIS SCI, V51, P2149, DOI 10.1167/iovs.09-3817
   American National Standards Institute, 2000, AM DENT ASS SPEC, P1
   Baumann B, 2012, BIOMED OPT EXPRESS, V3, P1670, DOI 10.1364/BOE.3.001670
   Baumann B, 2010, J BIOMED OPT, V15, DOI 10.1117/1.3499420
   Baumann B, 2009, J BIOPHOTONICS, V2, P426, DOI 10.1002/jbio.200910031
   Christenbury JG, 2013, OPHTHALMOLOGY, V120, P1038, DOI 10.1016/j.ophtha.2012.10.018
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fleckenstein M, 2008, INVEST OPHTH VIS SCI, V49, P4137, DOI 10.1167/iovs.08-1967
   Gotzinger E, 2009, OPT EXPRESS, V17, P4151, DOI 10.1364/OE.17.004151
   Gotzinger E, 2008, OPT EXPRESS, V16, P16410, DOI 10.1364/OE.16.016410
   Gotzinger E, 2005, OPT EXPRESS, V13, P10217, DOI 10.1364/OPEX.13.010217
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Ho J, 2011, OPHTHALMOLOGY, V118, P687, DOI 10.1016/j.ophtha.2010.08.010
   Hu DN, 2008, PHOTOCHEM PHOTOBIOL, V84, P639, DOI 10.1111/j.1751-1097.2008.00316.x
   International Electrotechnical Commission, 2001, 608251 IEC, P6
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Khanifar AA, 2008, OPHTHALMOLOGY, V115, P1883, DOI 10.1016/j.ophtha.2008.04.041
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Lammer J, 2014, INVEST OPHTH VIS SCI, V55, P1564, DOI 10.1167/iovs.13-13539
   Leuschen JN, 2013, OPHTHALMOLOGY, V120, P140, DOI 10.1016/j.ophtha.2012.07.004
   Michels S, 2008, BRIT J OPHTHALMOL, V92, P204, DOI 10.1136/bjo.2007.130047
   Ouyang YL, 2013, OPHTHALMOLOGY, V120, P2656, DOI 10.1016/j.ophtha.2013.05.029
   Pircher M, 2004, OPT EXPRESS, V12, P5940, DOI 10.1364/OPEX.12.005940
   Pircher M, 2006, INVEST OPHTH VIS SCI, V47, P5487, DOI 10.1167/iovs.05-1589
   Pircher M, 2011, PROG RETIN EYE RES, V30, P431, DOI 10.1016/j.preteyeres.2011.06.003
   Querques G, 2011, GRAEF ARCH CLIN EXP, V249, P1617, DOI 10.1007/s00417-011-1702-0
   Rudolf M, 2008, INVEST OPHTH VIS SCI, V49, P1200, DOI 10.1167/iovs.07-1466
   Sarks SH, 1999, BRIT J OPHTHALMOL, V83, P358, DOI 10.1136/bjo.83.3.358
   Schlanitz FG, 2011, INVEST OPHTH VIS SCI, V52, P4571, DOI 10.1167/iovs.10-6846
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1441, DOI 10.1097/IAE.0b013e3181ee5ce8
   Wojtkowski M, 2009, OPT EXPRESS, V17, P4189, DOI 10.1364/OE.17.004189
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P2434, DOI 10.1016/j.ophtha.2011.05.008
NR 37
TC 32
Z9 32
U1 1
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD AUG
PY 2015
VL 160
IS 2
BP 335
EP 344
DI 10.1016/j.ajo.2015.05.008
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CN6NY
UT WOS:000358552700016
PM 25982973
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Acton, JH
   Smith, RT
   Hood, DC
   Greenstein, VC
AF Acton, Jennifer H.
   Smith, R. Theodore
   Hood, Donald C.
   Greenstein, Vivienne C.
TI Relationship between Retinal Layer Thickness and the Visual Field in
   Early Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; ROD-CONE INTERACTION; FOLLOW-UP; DRUSEN;
   MICROPERIMETRY; MACULOPATHY; SYSTEM; AUTOFLUORESCENCE; CLASSIFICATION;
   SENSITIVITY
AB PURPOSE. To quantify and compare the structural and functional changes in subjects with early age-related macular degeneration (AMD), using spectral-domain optical coherence tomography (SD-OCT) and microperimetry.
   METHODS. Twenty-one eyes of 21 subjects with early AMD were examined. MP-1 10-2 visual fields (VFs) and SD-OCT line and detail volume scans were acquired. The thicknesses of the outer segment (OS; distance between inner segment ellipsoid band and upper retinal pigment epithelium [RPE] border) and RPE layers and elevation of the RPE from Bruch's membrane were measured using a computer-aided manual segmentation technique. Thickness values were compared with those for 15 controls, and values at locations with VF total deviation defects were compared with values at nondefect locations at equivalent eccentricities.
   RESULTS. Sixteen of 21 eyes with AMD had VF defects. Compared with controls, line scans showed significant thinning of the OS layer (P = 0.006) and thickening and elevation of the RPE (P = 0.037, P = 0.002). The OS layer was significantly thinner in locations with VF defects compared with locations without defects (P = 0.003). There was a negligible difference between the retinal layer thickness values of the 5 eyes without VF defects and the values of normal controls.
   CONCLUSIONS. In early AMD, when VF defects were present, there was significant thinning of the OS layer and thickening and elevation of the RPE. OS layer thinning was significantly associated with decreased visual sensitivity, consistent with known photoreceptor loss in early AMD. For AMD subjects without VF defects, thickness values were normal. The results highlight the clinical utility of both SD-OCT retinal layer quantification and VF testing in early AMD. (Invest Ophthalmol Vis Sci. 2012; 53: 7618-7624) DOI:10.1167/iovs.12-10361
C1 [Acton, Jennifer H.] Cardiff Univ, Sch Optometry & Vis Sci, Cardiff CF24 4LU, S Glam, Wales.
   [Acton, Jennifer H.; Smith, R. Theodore; Hood, Donald C.; Greenstein, Vivienne C.] Columbia Univ, Dept Ophthalmol, New York, NY 10027 USA.
   [Hood, Donald C.] Columbia Univ, Dept Psychol, New York, NY 10027 USA.
   [Acton, Jennifer H.; Smith, R. Theodore; Greenstein, Vivienne C.] NYU, Dept Ophthalmol, New York, NY 10016 USA.
C3 Cardiff University; Columbia University; Columbia University; New York
   University
RP Acton, JH (通讯作者)，Cardiff Univ, Sch Optometry & Vis Sci, Maindy Rd, Cardiff CF24 4LU, S Glam, Wales.
EM jenniferhacton@gmail.com
RI Acton, Jennifer/AAU-3307-2021
OI Acton, Jennifer/0000-0002-0347-7651; smith, theodore/0000-0002-1693-943X
FU National Eye Institute/National Institutes of Health [R01 EY02115, R01
   EY09076, R01 EY015520]; New York Community Trust; Research to Prevent
   Blindness (New York, New York); Topcon, Inc., Tokyo, Japan; NATIONAL EYE
   INSTITUTE [R01EY015520, R01EY002115, R01EY009076] Funding Source: NIH
   RePORTER
FX Supported by National Eye Institute/National Institutes of Health Grants
   R01 EY02115, R01 EY09076, and R01 EY015520; The New York Community
   Trust; Research to Prevent Blindness (New York, New York); and Topcon,
   Inc., Tokyo, Japan (DCH).
CR Acton JH, 2011, OPTOMETRY VISION SCI, V88, P1288, DOI 10.1097/OPX.0b013e31822b3746
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Chen CZ, 2004, DOC OPHTHALMOL, V109, P1
   CHYLACK LT, 1993, ARCH OPHTHALMOL-CHIC, V111, P831, DOI 10.1001/archopht.1993.01090060119035
   Clark ME, 2011, BRIT J OPHTHALMOL, V95, P1427, DOI 10.1136/bjo.2010.190355
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   Durad AC, 1910, J AMER MED ASSOC, V55, P369, DOI 10.1001/jama.1910.04330050007004
   Ehrlich R, 2012, CLIN EXP OPHTHALMOL, V40, pE32, DOI 10.1111/j.1442-9071.2011.02654.x
   Finger RP, 2011, AM J OPHTHALMOL, V152, P695, DOI 10.1016/j.ajo.2011.03.022
   Freeman SR, 2010, RETINA-J RET VIT DIS, V30, P431, DOI 10.1097/IAE.0b013e3181bd2f94
   FRUMKES TE, 1973, VISION RES, V13, P1269, DOI 10.1016/0042-6989(73)90202-2
   Genead MA, 2012, RETINA-J RET VIT DIS, V32, P826, DOI 10.1097/IAE.0b013e3182215ae9
   Gerth C, 2006, ARCH OPHTHALMOL-CHIC, V124, P345, DOI 10.1001/archopht.124.3.345
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hartmann KI, 2011, RETINA-J RET VIT DIS, V31, P1323, DOI 10.1097/IAE.0b013e31820a6850
   Heijl Anders, 1987, DOC OPHTHALMOL P SER, P153, DOI DOI 10.1007/978-94-009-3325-5_23
   Hood DC, 2011, OPTOMETRY VISION SCI, V88, P113, DOI 10.1097/OPX.0b013e3181fc3625
   Hood DC, 2009, INVEST OPHTH VIS SCI, V50, P2328, DOI 10.1167/iovs.08-2936
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Johnson PT, 2005, INVEST OPHTH VIS SCI, V46, P4788, DOI 10.1167/iovs.05-0767
   Johnson PT, 2003, INVEST OPHTH VIS SCI, V44, P4481, DOI 10.1167/iovs.03-0436
   Khanifar AA, 2008, OPHTHALMOLOGY, V115, P1883, DOI 10.1016/j.ophtha.2008.04.041
   Landa G, 2011, RETINA-J RET VIT DIS, V31, P364, DOI 10.1097/IAE.0b013e3181e91132
   LATCH M, 1977, J PHYSIOL-LONDON, V269, P517, DOI 10.1113/jphysiol.1977.sp011912
   Midena E, 2007, BRIT J OPHTHALMOL, V91, P1499, DOI 10.1136/bjo.2007.119685
   Owsley C, 2000, INVEST OPHTH VIS SCI, V41, P267
   Pappuru RR, 2011, INVEST OPHTH VIS SCI, V52, P6743, DOI 10.1167/iovs.10-6723
   Phipps JA, 2003, INVEST OPHTH VIS SCI, V44, P2277, DOI 10.1167/iovs.02-0769
   Querques L, 2012, AM J OPHTHALMOL, V153, P1110, DOI 10.1016/j.ajo.2011.11.002
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Remky A, 2005, BRIT J OPHTHALMOL, V89, P464, DOI 10.1136/bjo.2004.050260
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Sallo FB, 2009, BRIT J OPHTHALMOL, V93, P1345, DOI 10.1136/bjo.2008.150334
   Sarks S, 2007, INVEST OPHTH VIS SCI, V48, P968, DOI 10.1167/iovs.06-0443
   Schuman SG, 2009, OPHTHALMOLOGY, V116, P488, DOI 10.1016/j.ophtha.2008.10.006
   Spaide RF, 2011, RETINA-J RET VIT DIS, V31, P1609, DOI 10.1097/IAE.0b013e3182247535
   Stockman A, 2006, OPHTHAL PHYSL OPT, V26, P225, DOI 10.1111/j.1475-1313.2006.00325.x
   SUNNESS JS, 1988, ARCH OPHTHALMOL-CHIC, V106, P1081, DOI 10.1001/archopht.1988.01060140237032
   Takamine Y, 1998, GRAEF ARCH CLIN EXP, V236, P285, DOI 10.1007/s004170050079
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   van Zeeburg EJT, 2012, AM J OPHTHALMOL, V153, P120, DOI 10.1016/j.ajo.2011.06.007
   Vogt SD, 2011, EXP EYE RES, V93, P413, DOI 10.1016/j.exer.2011.06.002
   Wang FH, 2012, RETINA-J RET VIT DIS, V32, P679, DOI 10.1097/IAE.0b013e318227ab24
   Wyszecki G., 2000, COLOR SCI
NR 45
TC 61
Z9 64
U1 0
U2 15
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD NOV
PY 2012
VL 53
IS 12
BP 7618
EP 7624
DI 10.1167/iovs.12-10361
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 064EE
UT WOS:000313053500025
PM 23074210
OA Green Published, Green Accepted
DA 2022-11-30
ER

PT J
AU Zhang, Y
   Sun, F
   Liu, H
AF Zhang, Ya
   Sun, Fei
   Liu, Hua
TI Two Zn(II)-based meta-organic frameworks: Selective detection of
   antibiotics and treatment activity on age-related macular degeneration
   by reducing inflammasome activation
SO JOURNAL OF THE CHINESE CHEMICAL SOCIETY
LA English
DT Article
DE age-related macular degeneration; interpenetration; MOF; nitrofurazone
   detection; water stability
ID DIELECTRIC-PROPERTIES; LUMINESCENT PROBE; FE3+; SERIES; CO2
AB Via utilizing the mixed-ligand method, two novel Zn(II)-containing meta-organic frameworks with the chemical formula of {[Zn(L)(5-HIP)]center dot H2O}(n)(1) and [Zn(L)(2,6-NDC)](n)(2) were prepared under the solvothermal conditions by applying aromatic dicarboxylic acids ligands (5-H2HIP = 5-hydroxyisophthalic acid; 2,6-H2NDC = 2,6-naphthalenedicarboxylic acid) and 1,4-bis(benzimidazol-1-yl)-2-butylene (L). Due to its good water stability as well as the strong luminescent emission around room temperature, complex2has the high selectivity and sensibility of fluorescence detection to the ceftriaxone sodium (a kind of antibiotic) with the detection limit up to ppm lever. The treatment activity of the compounds on age-related macular degeneration was assessed and the specific mechanism was investigated. First of all, the inflammasome activation in the endothelial cells of retina was evaluated with western blot. In addition to this, the down-stream production of the inflammasome activation was also measured with ELISA detection kit.
C1 [Zhang, Ya; Liu, Hua] Jinan Univ, Dept Ophthalmol, Affiliated Hosp 1, Guangzhou, Guangdong, Peoples R China.
   [Zhang, Ya] Shijiazhuang Aier Eye Hosp, Dept Ophthalmol, Shijiazhuang, Hebei, Peoples R China.
   [Sun, Fei] Hebei Med Univ, Dept Emergency, Affiliated Hosp 1, Shijiazhuang, Hebei, Peoples R China.
   [Liu, Hua] Jinzhou Med Univ, Dept Ophthalmol, Affiliated Hosp 3, Jinzhou, Liaoning, Peoples R China.
C3 Jinan University; Hebei Medical University; Jinzhou Medical University
RP Liu, H (通讯作者)，Jinan Univ, Dept Ophthalmol, Affiliated Hosp 1, Guangzhou, Guangdong, Peoples R China.
EM hua_liu11@163.com
CR Arshad M, 2020, CERAM INT, V46, P2238, DOI 10.1016/j.ceramint.2019.09.208
   Chen DM, 2019, J SOLID STATE CHEM, V278, DOI 10.1016/j.jssc.2019.120906
   Chen DM, 2019, CRYSTENGCOMM, V21, P4696, DOI 10.1039/c9ce00760a
   Cui YJ, 2015, ADV FUNCT MATER, V25, P4796, DOI 10.1002/adfm.201501756
   Du HL, 2018, PROCESS APPL CERAM, V12, P303, DOI 10.2298/PAC1804303D
   Feng X, 2017, INORG CHEM, V56, P1713, DOI 10.1021/acs.inorgchem.6b02851
   Feng X, 2013, DALTON T, V42, P7741, DOI 10.1039/c3dt33002h
   Hao JN, 2015, J MATER CHEM A, V3, P4788, DOI 10.1039/c4ta06462c
   He H, 2015, J MATER CHEM A, V4, P1166
   Hou BL, 2016, INORG CHEM, V55, P10580, DOI 10.1021/acs.inorgchem.6b01809
   Hwang IC, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0232593
   Jiang SY, 2018, INORG CHEM, V57, P6118, DOI 10.1021/acs.inorgchem.8b00704
   Kuang Y, 2020, ENVIRON SCI POLLUT R, V27, P18145, DOI 10.1007/s11356-020-08207-3
   Liu JQ, 2016, CHEMPLUSCHEM, V81, P1299, DOI 10.1002/cplu.201600289
   Nagarkar SS, 2014, CHEM COMMUN, V50, P8915, DOI 10.1039/c4cc03053b
   Owsley C, 2020, OPHTHALMOLOGY, V127, P667, DOI 10.1016/j.ophtha.2020.01.051
   Razavi SAA, 2017, INORG CHEM, V56, P9646, DOI 10.1021/acs.inorgchem.7b01155
   Shen X, 2016, RSC ADV, V6, P28165, DOI 10.1039/c6ra02043g
   Sun MY, 2018, POLYHEDRON, V147, P80, DOI 10.1016/j.poly.2018.03.020
   Wang J, 2016, CHEM-EUR J, V22, P13023, DOI 10.1002/chem.201602974
   Xu YS, 2020, MEDICINE, V99, DOI 10.1097/MD.0000000000019081
   Zhang D, 2020, INT J ELECTROCHEM SC, V15, P4117, DOI 10.20964/2020.05.25
NR 22
TC 0
Z9 0
U1 3
U2 24
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 0009-4536
EI 2192-6549
J9 J CHIN CHEM SOC-TAIP
JI J. Chin. Chem. Soc.
PD JAN
PY 2021
VL 68
IS 1
BP 177
EP 185
DI 10.1002/jccs.202000193
EA OCT 2020
PG 9
WC Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry
GA QD0RO
UT WOS:000574164400001
DA 2022-11-30
ER

PT J
AU Tolppanen, AM
   Nevalainen, T
   Kolehmainen, M
   Seitsonen, S
   Immonen, I
   Uusitupa, M
   Kaarniranta, K
   Pulkkinen, L
AF Tolppanen, Anna-Maija
   Nevalainen, Tanja
   Kolehmainen, Marjukka
   Seitsonen, Sanna
   Immonen, Ilkka
   Uusitupa, Matti
   Kaarniranta, Kai
   Pulkkinen, Leena
TI Single nucleotide polymorphisms of the tenomodulin gene (TNMD) in
   age-related macular degeneration
SO MOLECULAR VISION
LA English
DT Article
ID COMPLEMENT-FACTOR-H; ENDOTHELIAL GROWTH-FACTOR; FINNISH DIABETES
   PREVENTION; HTRA1 PROMOTER POLYMORPHISM; CHONDROMODULIN-I; MET72THR
   POLYMORPHISM; JAPANESE POPULATION; MOLECULAR-CLONING; VARIANT INCREASES;
   X-CHROMOSOME
AB Purpose: Tenomodulin (TNMD) is located in the X-chromosome encoding a putative angiogenesis inhibitor which is expressed in retina. Associations of single nucleotide polymorphisms of TNMD with the prevalence of age-related macular degeneration (AMD) were examined.
   Methods: Six markers covering 75% of the common sequence variation in the coding region of TNMD and 10 kb up-and downstream were genotyped in a sample consisting of 89 men and 175 women with exudative AMD, 18 men and 25 women with atrophic AMD, and 55 men and 113 women without AMD. All participants were over 65 years old and did not have diabetes mellitus. Due to the chromosomal locus, the association of genotypes with AMD was assessed genderwise.
   Results: Three markers, rs1155974, rs2073163, and rs7890586, were associated with a risk of AMD in women. In comparison to women with other genotypes, the women who were homozygous for the minor allele (genotypes rs1155974-TT or rs2073163-CC) had 2.6 fold (p=0.021) or 1.9 fold (p=0.067) risk for having AMD, respectively. These differences were due to the unequal prevalence of exudative AMD. In comparison to women who were homozygous for the major alleles, the women with rs1155974-TT genotype had a 2.8 fold risk (p=0.021 in additive model; p=0.022 in recessive model) for exudative AMD, and the women with rs2073163-CC genotype had a 1.8 fold risk (p=0.09 in additive model; p=0.038 in recessive model). Furthermore, women carrying the rare rs7890586-AA genotype had a significantly smaller risk for having AMD than women with the other genotypes (odds ratio 0.083; p=0.001 in recessive model), but due to the low frequency of this genotype, this finding must be interpreted cautiously. The false discovery rate was <10% for all of the aforementioned results.
   Conclusions: On the basis of the putative antiangiogenic role of TNMD and the present genetic associations of TNMD with AMD in women, we suggest that TNMD could be a novel candidate gene for AMD. These results should be confirmed in further studies.
C1 [Tolppanen, Anna-Maija; Kolehmainen, Marjukka; Uusitupa, Matti; Pulkkinen, Leena] Univ Kuopio, Dept Clin Nutr, Sch Publ Hlth & Clin Nutr, FI-70211 Kuopio, Finland.
   [Tolppanen, Anna-Maija; Kolehmainen, Marjukka; Uusitupa, Matti; Pulkkinen, Leena] Univ Kuopio, Food & Hlth Res Ctr, Sch Publ Hlth & Clin Nutr, FI-70211 Kuopio, Finland.
   [Seitsonen, Sanna; Immonen, Ilkka] Helsinki Univ Hosp, Dept Ophthalmol, Helsinki, Finland.
   [Nevalainen, Tanja; Kaarniranta, Kai] Kuopio Univ Hosp, Dept Ophthalmol, SF-70210 Kuopio, Finland.
C3 University of Eastern Finland; University of Eastern Finland; University
   of Helsinki; Helsinki University Central Hospital; Kuopio University
   Hospital; University of Eastern Finland
RP Tolppanen, AM (通讯作者)，Univ Kuopio, Dept Clin Nutr, Sch Publ Hlth & Clin Nutr, POB 1627, FI-70211 Kuopio, Finland.
EM anna-maija.tolppanen@uku.fi
RI Uusitupa, Matti Ilmari Julius/AAX-4929-2020
OI Kaarniranta, Kai/0000-0003-2600-8679
FU Finnish Graduate School on Applied Bioscience: Bioengineering, Food and
   Nutrition, Environment; Sigrid Juselius Foundation; Academy of Finland
   [117844, 211497, 209445]; EVO fund of the Kuopio University Hospital
   [5179, 5198, 5503709]; Ministry of Health and Social Affairs; Emil
   Aaltonen Foundation; Finnish Cultural Foundation; Finnish Eye
   Foundation; Finnish Eye and Tissue Bank Foundation; Finnish Funding
   Agency for Technology and Innovation
FX We gratefully acknowledge Ms. P ivi Turunen for excellent technical
   assistance. This study was funded by the Finnish Graduate School on
   Applied Bioscience: Bioengineering, Food and Nutrition, Environment (A.
   M. T.), Sigrid Juselius Foundation, Academy of Finland (grants 117844,
   211497, M. U.; 209445, M. K.), the EVO fund of the Kuopio University
   Hospital (5179 and 5198, M. U.; 5503709, T. N.), from the Ministry of
   Health and Social Affairs, Emil Aaltonen Foundation (K. K.), the Finnish
   Cultural Foundation and its North Savo Fund (K. K.), the Finnish Eye
   Foundation (K. K., T. N.), the Finnish Eye and Tissue Bank Foundation
   (K. K.), and the Finnish Funding Agency for Technology and Innovation
   (K. K.).
CR Allikmets R, 2000, AM J HUM GENET, V67, P793, DOI 10.1086/303100
   Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Boekhoorn SS, 2008, OPHTHALMOLOGY, V115, P1899, DOI 10.1016/j.ophtha.2008.06.026
   Brandau O, 2001, DEV DYNAM, V221, P72, DOI 10.1002/dvdy.1126
   BRESSLER SB, 2001, BASIC CLIN SCI COURS
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Buch H, 2005, ACTA OPHTHALMOL SCAN, V83, P409, DOI 10.1111/J.1600-0420.2005.00492.x
   Carrel L, 2005, NATURE, V434, P400, DOI 10.1038/nature03479
   Churchill AJ, 2006, HUM MOL GENET, V15, P2955, DOI 10.1093/hmg/ddl238
   de Bakker PIW, 2005, NAT GENET, V37, P1217, DOI 10.1038/ng1669
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Docheva D, 2005, MOL CELL BIOL, V25, P699, DOI 10.1128/MCB.25.2.699-705.2005
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Grisanti S, 2008, PROG RETIN EYE RES, V27, P372, DOI 10.1016/j.preteyeres.2008.05.002
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2006, INVEST OPHTH VIS SCI, V47, P329, DOI 10.1167/iovs.05-0116
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Holz F.G., 2004, AGE RELATED MACULAR, P24
   Hyman Leslie, 2002, Curr Opin Ophthalmol, V13, P171
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   Kolehmainen M, 2008, INT J OBESITY, V32, P292, DOI 10.1038/sj.ijo.0803718
   Lau LI, 2006, INVEST OPHTH VIS SCI, V47, P3242, DOI 10.1167/iovs.05-1532
   Lin JM, 2008, AM J OPHTHALMOL, V145, P1045, DOI 10.1016/j.ajo.2008.01.027
   Lin JM, 2008, AM J OPHTHALMOL, V145, P716, DOI 10.1016/j.ajo.2007.11.006
   Lu F, 2007, VISION RES, V47, P3120, DOI 10.1016/j.visres.2007.08.010
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Mori K, 2007, J HUM GENET, V52, P636, DOI 10.1007/s10038-007-0162-1
   Oshima Y, 2004, J CELL SCI, V117, P2731, DOI 10.1242/jcs.01112
   Oshima Y, 2003, INVEST OPHTH VIS SCI, V44, P1814, DOI 10.1167/iovs.02-0664
   Rinn JL, 2005, TRENDS GENET, V21, P298, DOI 10.1016/j.tig.2005.03.005
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Rivera A, 2000, AM J HUM GENET, V67, P800, DOI 10.1086/303090
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Ross RJ, 2007, INVEST OPHTH VIS SCI, V48, P1128, DOI 10.1167/iovs.06-0999
   Schmidt Silke, 2002, Ophthalmic Genet, V23, P209, DOI 10.1076/opge.23.4.209.13883
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seitsonen S, 2006, MOL VIS, V12, P796
   Seitsonen SP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003833
   Shukunami C, 2001, BIOCHEM BIOPH RES CO, V280, P1323, DOI 10.1006/bbrc.2001.4271
   Smith W, 1998, AUST NZ J OPHTHALMOL, V26, P203, DOI 10.1111/j.1442-9071.1998.tb01311.x
   Souied EH, 2005, MOL VIS, V11, P1135
   Storey JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI 10.1073/pnas.1530509100
   Tanimoto S, 2007, NEUROSCI LETT, V414, P71, DOI 10.1016/j.neulet.2006.12.011
   Tolppanen AM, 2008, INT J OBESITY, V32, P1868, DOI 10.1038/ijo.2008.217
   Tolppanen AM, 2008, GENET MED, V10, P536, DOI [10.1097/GIM.0b013e3181772129, 10.1097GIM.0b013e3181772129]
   Tolppanen AM, 2007, OBESITY, V15, P1082, DOI 10.1038/oby.2007.613
   Tregouet DA, 2004, ANN HUM GENET, V68, P165, DOI 10.1046/j.1529-8817.2003.00085.x
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
   van Leeuwen R, 2003, EUR J EPIDEMIOL, V18, P845, DOI 10.1023/A:1025643303914
   Van PL, 2006, JAMA-J AM MED ASSOC, V295, P1373, DOI 10.1001/jama.295.12.1373
   Weger M, 2007, MOL VIS, V13, P1274
   Yamagishi S, 2005, MED HYPOTHESES, V64, P1202, DOI 10.1016/j.mehy.2005.01.017
   Yamana K, 2001, BIOCHEM BIOPH RES CO, V280, P1101, DOI 10.1006/bbrc.2000.4245
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yoshida T, 2007, MOL VIS, V13, P545
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zareparsi S, 2004, INVEST OPHTH VIS SCI, V45, P1306, DOI 10.1167/iovs.03-1253
   Zheng G, 2007, GENET EPIDEMIOL, V31, P834, DOI 10.1002/gepi.20244
NR 64
TC 11
Z9 11
U1 0
U2 2
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD APR 15
PY 2009
VL 15
IS 77-78
BP 762
EP 770
PG 9
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA 450OI
UT WOS:000266410300002
PM 19381347
DA 2022-11-30
ER

PT J
AU Moraes, G
   Fu, DJ
   Wilson, M
   Khalid, H
   Wagner, SK
   Korot, E
   Ferraz, D
   Faes, L
   Kelly, CJ
   Spitz, T
   Patel, PJ
   Balaskas, K
   Keenan, TDL
   Keane, PA
   Chopra, R
AF Moraes, Gabriella
   Fu, Dun Jack
   Wilson, Marc
   Khalid, Hagar
   Wagner, Siegfried K.
   Korot, Edward
   Ferraz, Daniel
   Faes, Livia
   Kelly, Christopher J.
   Spitz, Terry
   Patel, Praveen J.
   Balaskas, Konstantinos
   Keenan, Tiarnan D. L.
   Keane, Pearse A.
   Chopra, Reena
TI Quantitative Analysis of OCT for Neovascular Age-Related Macular
   Degeneration Using Deep Learning
SO OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; neovascular; deep learning; OCT;
   automated
ID OPTICAL COHERENCE TOMOGRAPHY; PIGMENT EPITHELIAL DETACHMENT;
   VISUAL-ACUITY; THICKNESS MEASUREMENTS; HYPERREFLECTIVE FOCI; RETINAL
   THICKNESS; SUBRETINAL FLUID; DOSING REGIMEN; RANIBIZUMAB; SEGMENTATION
AB Purpose: To apply a deep learning algorithm for automated, objective, and comprehensive quantification of OCT scans to a large real-world dataset of eyes with neovascular age-related macular degeneration (AMD) and make the raw segmentation output data openly available for further research.
   Design: Retrospective analysis of OCT images from the Moorfields Eye Hospital AMD Database.
   Participants: A total of 2473 first-treated eyes and 493 second-treated eyes that commenced therapy for neovascular AMD between June 2012 and June 2017.
   Methods: A deep learning algorithm was used to segment all baseline OCT scans. Volumes were calculated for segmented features such as neurosensory retina (NSR), drusen, intraretinal fluid (IRF), subretinal fluid (SRF), subretinal hyperreflective material (SHRM), retinal pigment epithelium (RPE), hyperreflective foci (HRF), fibro-vascular pigment epithelium detachment (fvPED), and serous PED (sPED). Analyses included comparisons between first- and second-treated eyes by visual acuity (VA) and race/ethnicity and correlations between volumes.
   Main Outcome Measures: Volumes of segmented features (mm(3)) and central subfield thickness (CST) (mm).
   Results: In first-treated eyes, the majority had both IRF and SRF (54.7%). First-treated eyes had greater volumes for all segmented tissues, with the exception of drusen, which was greater in second-treated eyes. In first-treated eyes, older age was associated with lower volumes for RPE, SRF, NSR, and sPED; in second-treated eyes, older age was associated with lower volumes of NSR, RPE, sPED, fvPED, and SRF. Eyes from Black individuals had higher SRF, RPE, and serous PED volumes compared with other ethnic groups. Greater volumes of the majority of features were associated with worse VA.
   Conclusions: We report the results of large-scale automated quantification of a novel range of baseline features in neovascular AMD. Major differences between first- and second-treated eyes, with increasing age, and between ethnicities are highlighted. In the coming years, enhanced, automated OCT segmentation may assist personalization of real-world care and the detection of novel structure-function correlations. These data will be made publicly available for replication and future investigation by the AMD research community. (C) 2020 by the American Academy of Ophthalmology.
C1 [Moraes, Gabriella; Fu, Dun Jack; Khalid, Hagar; Wagner, Siegfried K.; Korot, Edward; Ferraz, Daniel; Faes, Livia; Patel, Praveen J.; Balaskas, Konstantinos; Keane, Pearse A.; Chopra, Reena] Moorfields Eye Hosp NHS Fdn Trust, NIHR Biomed Res Ctr Ophthalmol, London, England.
   [Moraes, Gabriella; Fu, Dun Jack; Khalid, Hagar; Wagner, Siegfried K.; Korot, Edward; Ferraz, Daniel; Faes, Livia; Patel, Praveen J.; Balaskas, Konstantinos; Keane, Pearse A.; Chopra, Reena] UCL Inst Ophthalmol, London, England.
   [Wilson, Marc; Kelly, Christopher J.; Spitz, Terry; Chopra, Reena] Google Hlth, London, England.
   [Ferraz, Daniel] Univ Fed Sao Paulo, Dept Ophthalmol, Sao Paulo, Brazil.
   [Keenan, Tiarnan D. L.] NEI, Div Epidemiol & Clin Applicat, NIH, Bethesda, MD 20892 USA.
C3 University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust; University of London; University College London;
   Universidade Federal de Sao Paulo (UNIFESP); National Institutes of
   Health (NIH) - USA; NIH National Eye Institute (NEI)
RP Keane, PA (通讯作者)，UCL Inst Ophthalmol, London, England.; Keane, PA (通讯作者)，Moorfields Eye Hosp NHS Fdn Trust, NIHR Biomed Res Ctr, London, England.
EM p.keane@ucl.ac.uk
RI Balaskas, Konstantinos/ABD-5979-2020
OI Balaskas, Konstantinos/0000-0002-7690-6277; Fu, Dun
   Jack/0000-0003-2852-6912; Spitz, Terry/0000-0002-9791-3767; Keane,
   Pearse/0000-0002-9239-745X; Korot, Edward/0000-0002-5687-1564; Faes,
   Livia/0000-0002-4159-3960; Kelly, Christopher/0000-0002-1246-844X;
   Ferraz, Daniel/0000-0002-0259-432X
FU Macular Society [179050]; Moorfields Eye Charity Career Development
   Award [R190028A]; UK Research & Innovation Future Leaders Fellowship
   [MR/T019050/1]; MRC [MR/T000953/1, MC_PC_19005] Funding Source: UKRI;
   UKRI [MR/T019050/1] Funding Source: UKRI
FX Supported by Macular Society Grant Award Number 179050, Moorfields Eye
   Charity Career Development Award (R190028A), and UK Research &
   Innovation Future Leaders Fellowship (MR/T019050/1).
CR Akagi-Kurashige Y, 2012, GRAEF ARCH CLIN EXP, V250, P1129, DOI 10.1007/s00417-012-1928-5
   Avery RL, 2017, RETINA-J RET VIT DIS, V37, P1847, DOI 10.1097/IAE.0000000000001493
   Bogunovic H, 2019, IEEE T MED IMAGING, V38, P1858, DOI 10.1109/TMI.2019.2901398
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Cheong KX, 2020, SURV OPHTHALMOL, V30087-4, DOI [10.1016/j.sur-vophthal.2020.05.003, DOI 10.1016/J.SUR-VOPHTHAL.2020.05.003]
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Chevreaud O, 2016, EUR J OPHTHALMOL, V26, P44, DOI 10.5301/ejo.5000649
   Cho HJ, 2016, AM J OPHTHALMOL, V166, P112, DOI 10.1016/j.ajo.2016.03.039
   De Fauw J, 2018, NAT MED, V24, P1342, DOI 10.1038/s41591-018-0107-6
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Fasler K, 2020, BRIT J OPHTHALMOL, V104, P684, DOI 10.1136/bjophthalmol-2019-314446
   Fasler K, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-027441
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gao K, 2019, COMPUT METH PROG BIO, V176, P69, DOI 10.1016/j.cmpb.2019.04.027
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P723, DOI 10.1016/j.ophtha.2018.11.025
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holz FG, 2016, BRIT J OPHTHALMOL, V100, P1623, DOI 10.1136/bjophthalmol-2015-308166
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Hu XF, 2020, RETINA-J RET VIT DIS, V40, P1070, DOI 10.1097/IAE.0000000000002531
   Huang JJ, 2009, RETINA-J RET VIT DIS, V29, P980, DOI 10.1097/IAE.0b013e3181a2c1a7
   Jaffe GJ, 2013, OPHTHALMOLOGY, V120, P1860, DOI 10.1016/j.ophtha.2013.01.073
   Joeres S, 2007, INVEST OPHTH VIS SCI, V48, P4300, DOI 10.1167/iovs.07-0179
   Keane PA, 2009, RETINA-J RET VIT DIS, V29, P592, DOI 10.1097/IAE.0b013e31819b17a5
   Keane PA, 2008, OPHTHALMOLOGY, V115, P2206, DOI 10.1016/j.ophtha.2008.08.016
   Lai TT, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-36704-6
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lee CS, 2017, BIOMED OPT EXPRESS, V8, P3440, DOI 10.1364/BOE.8.003440
   Lee H, 2018, AM J OPHTHALMOL, V191, P64, DOI 10.1016/j.ajo.2018.04.007
   Lee H, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-20637
   Lee H, 2016, RETINA-J RET VIT DIS, V36, P465, DOI 10.1097/IAE.0000000000000645
   Li MX, 2019, INT J OPHTHALMOL-CHI, V12, P1012, DOI 10.18240/ijo.2019.06.22
   Lu DH, 2019, MED IMAGE ANAL, V54, P100, DOI 10.1016/j.media.2019.02.011
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mohamed R, 2018, OPHTHALMOLOGICA, V240, P157, DOI 10.1159/000486403
   Ou WC, 2017, AM J OPHTHALMOL, V180, P8, DOI 10.1016/j.ajo.2017.05.014
   Owen CG, 2012, BRIT J OPHTHALMOL, V96, P752, DOI 10.1136/bjophthalmol-2011-301109
   Patel SN, 2020, OPHTHALMOLOGY, V127, P280, DOI 10.1016/j.ophtha.2019.09.038
   Penha FM, 2013, RETINA-J RET VIT DIS, V33, P459, DOI 10.1097/IAE.0b013e31827d2657
   Peyman M, 2019, J CURR OPHTHALMOL, V31, P55, DOI 10.1016/j.joco.2018.09.007
   Pontikos N, 2020, AM J OPHTHALMOL, V211, P229, DOI 10.1016/j.ajo.2019.09.021
   Ristau T, 2014, OPHTHALMOLOGICA, V231, P37, DOI 10.1159/000354551
   Ritter M, 2014, BRIT J OPHTHALMOL, V98, P1629, DOI 10.1136/bjophthalmol-2014-305186
   Sadda SR, 2006, OPHTHALMOLOGY, V113, P285, DOI 10.1016/j.ophtha.2005.10.005
   Schlegl T, 2018, OPHTHALMOLOGY, V125, P549, DOI 10.1016/j.ophtha.2017.10.031
   Schmidt-Erfurth U, 2020, OPHTHALMOLOGY, V127, P1211, DOI 10.1016/j.ophtha.2020.03.010
   Schmidt-Erfurth U, 2018, PROG RETIN EYE RES, V67, P1, DOI 10.1016/j.preteyeres.2018.07.004
   Schmidt-Erfurth U, 2016, PROG RETIN EYE RES, V50, P1, DOI 10.1016/j.preteyeres.2015.07.007
   Schmidt-Erfurth U, 2015, OPHTHALMOLOGY, V122, P822, DOI 10.1016/j.ophtha.2014.11.017
   Segal O, 2016, RETINA-J RET VIT DIS, V36, P2175, DOI 10.1097/IAE.0000000000001033
   Shah VP, 2014, RETINA-J RET VIT DIS, V34, P1281, DOI 10.1097/IAE.0000000000000166
   Sharma HE, 2014, BRIT J OPHTHALMOL, V98, P1625, DOI 10.1136/bjophthalmol-2014-304959
   Sharma S, 2016, OPHTHALMOLOGY, V123, P865, DOI 10.1016/j.ophtha.2015.12.002
   Simader C, 2014, OPHTHALMOLOGY, V121, P1237, DOI 10.1016/j.ophtha.2013.12.029
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
   Torkamani A, 2017, CELL, V170, P828, DOI 10.1016/j.cell.2017.08.007
   Toth CA, 2015, RETINA-J RET VIT DIS, V35, P1303, DOI 10.1097/IAE.0000000000000483
   Waldstein SM, 2016, OPHTHALMOLOGY, V123, P1521, DOI 10.1016/j.ophtha.2016.03.037
   Waldstein SM, 2016, JAMA OPHTHALMOL, V134, P182, DOI 10.1001/jamaophthalmol.2015.4948
   Waldstein SM, 2016, OPHTHALMOLOGY, V123, P60, DOI 10.1016/j.ophtha.2015.09.013
   Waldstein SM, 2015, BRIT J OPHTHALMOL, V99, P794, DOI 10.1136/bjophthalmol-2014-305573
   Willoughby AS, 2015, OPHTHALMOLOGY, V122, P1846, DOI 10.1016/j.ophtha.2015.05.042
   Wu ZC, 2016, INVEST OPHTH VIS SCI, V57, P3714, DOI 10.1167/iovs.15-18294
   Yim J, 2020, NAT MED, V26, P892, DOI 10.1038/s41591-020-0867-7
   ZHANG X, 2018, BIOMED RES INT, V2018, DOI DOI 10.1155/2018/9640131
   Zheng YL, 2013, AM J OPHTHALMOL, V155, P277, DOI 10.1016/j.ajo.2012.07.030
NR 68
TC 25
Z9 25
U1 4
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD MAY
PY 2021
VL 128
IS 5
BP 693
EP 705
DI 10.1016/j.ophtha.2020.09.025
EA APR 2021
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA RQ1AM
UT WOS:000642151600008
PM 32980396
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Toma, C
   De Cilla, S
   Palumbo, A
   Garhwal, DP
   Grossini, E
AF Toma, Caterina
   De Cilla, Stefano
   Palumbo, Aurelio
   Garhwal, Divya Praveen
   Grossini, Elena
TI Oxidative and Nitrosative Stress in Age-Related Macular Degeneration: A
   Review of Their Role in Different Stages of Disease
SO ANTIOXIDANTS
LA English
DT Review
DE age-related macular degeneration; oxidative stress; nitrosative stress;
   mitochondrial function; autophagy; anti-vascular endothelial growth
   factor agents
ID RETINAL-PIGMENT EPITHELIUM; ENDOTHELIAL GROWTH-FACTOR; NITRIC-OXIDE
   SYNTHASES; ARYL-HYDROCARBON RECEPTOR; LIPID-PEROXIDATION PRODUCTS;
   MITOCHONDRIAL-DNA DAMAGE; REACTIVE OXYGEN; ANTIOXIDANT RESPONSE;
   GENE-EXPRESSION; NADPH OXIDASE
AB Although the exact pathogenetic mechanisms leading to age-related macular degeneration (AMD) have not been clearly identified, oxidative damage in the retina and choroid due to an imbalance between local oxidants/anti-oxidant systems leading to chronic inflammation could represent the trigger event. Different in vitro and in vivo models have demonstrated the involvement of reactive oxygen species generated in a highly oxidative environment in the development of drusen and retinal pigment epithelium (RPE) changes in the initial pathologic processes of AMD; moreover, recent evidence has highlighted the possible association of oxidative stress and neovascular AMD. Nitric oxide (NO), which is known to play a key role in retinal physiological processes and in the regulation of choroidal blood flow, under pathologic conditions could lead to RPE/photoreceptor degeneration due to the generation of peroxynitrite, a potentially cytotoxic tyrosine-nitrating molecule. Furthermore, the altered expression of the different isoforms of NO synthases could be involved in choroidal microvascular changes leading to neovascularization. The purpose of this review was to investigate the different pathways activated by oxidative/nitrosative stress in the pathogenesis of AMD, focusing on the mechanisms leading to neovascularization and on the possible protective role of anti-vascular endothelial growth factor agents in this context.
C1 [Toma, Caterina; De Cilla, Stefano; Palumbo, Aurelio] Univ Hosp Maggiore Carita, Eye Clin, I-28100 Novara, Italy.
   [De Cilla, Stefano] Univ East Piedmont A Avogadro, Dept Hlth Sci, I-28100 Novara, Italy.
   [Garhwal, Divya Praveen; Grossini, Elena] Univ East Piedmont A Avogadro, Dept Translat Med, Lab Physiol & Expt Surg, I-28100 Novara, Italy.
C3 Azienda Ospedaliera Maggiore della Carita di Novara; University of
   Eastern Piedmont Amedeo Avogadro; University of Eastern Piedmont Amedeo
   Avogadro
RP Grossini, E (通讯作者)，Univ East Piedmont A Avogadro, Dept Translat Med, Lab Physiol & Expt Surg, I-28100 Novara, Italy.
EM caterina.toma@maggioreosp.novara.it; stefano.decilla@med.uniupo.it;
   aurepa95@gmail.com; divya.praveen@uniupo.it;
   elena.grossini@med.uniupo.it
OI Grossini, Elena/0000-0002-3012-259X; Toma, Caterina/0000-0002-1505-6029
CR Adams MKM, 2012, AM J EPIDEMIOL, V176, P289, DOI 10.1093/aje/kws004
   Alderton WK, 2001, BIOCHEM J, V357, P593, DOI 10.1042/0264-6021:3570593
   Allio R, 2017, MOL BIOL EVOL, V34, P2762, DOI 10.1093/molbev/msx197
   Ando A, 2002, MOL PHARMACOL, V62, P539, DOI 10.1124/mol.62.3.539
   ANDREA LW, 2003, FREE RADICAL BIO MED, V35, P465, DOI DOI 10.1016/S0891-5849(03)00320-4
   Armstrong JS, 2006, BIOESSAYS, V28, P253, DOI 10.1002/bies.20370
   ARSTILA AU, 1972, SCIENCE, V175, P530, DOI 10.1126/science.175.4021.530
   Badia A, 2021, EXP EYE RES, V203, DOI 10.1016/j.exer.2020.108424
   Barot M, 2011, CURR EYE RES, V36, P1069, DOI 10.3109/02713683.2011.607536
   Baskol G, 2006, OPHTHALMOLOGICA, V220, P12, DOI 10.1159/000089269
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bellezza I, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01280
   Bergmann M, 2011, GRAEF ARCH CLIN EXP, V249, P1477, DOI 10.1007/s00417-011-1682-0
   Bernatchez PN, 2005, P NATL ACAD SCI USA, V102, P761, DOI 10.1073/pnas.0407224102
   Bhisitkul RB, 2015, AM J OPHTHALMOL, V159, P915, DOI 10.1016/j.ajo.2015.01.032
   Bhutto IA, 2006, EXP EYE RES, V82, P99, DOI 10.1016/j.exer.2005.05.007
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Bhutto IA, 2010, EXP EYE RES, V90, P155, DOI 10.1016/j.exer.2009.10.004
   Bienert GP, 2007, J BIOL CHEM, V282, P1183, DOI 10.1074/jbc.M603761200
   Blasiak J, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21228840
   Blasiak J, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/768026
   Blasiak J, 2013, INT J MOL SCI, V14, P2996, DOI 10.3390/ijms14022996
   Blom J, 2012, J COMP NEUROL, V520, P4204, DOI 10.1002/cne.23148
   Borras C, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-50420-9
   Borrelli E, 2017, AM J OPHTHALMOL, V181, P1, DOI 10.1016/j.ajo.2017.06.005
   Brown EE, 2019, REDOX BIOL, V24, DOI 10.1016/j.redox.2019.101201
   Brown EE, 2018, ADV EXP MED BIOL, V1074, P11, DOI 10.1007/978-3-319-75402-4_2
   Cano M, 2010, VISION RES, V50, P652, DOI 10.1016/j.visres.2009.08.018
   Canto A, 2019, ANTIOXIDANTS-BASEL, V8, DOI 10.3390/antiox8110543
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chan TCW, 2020, EXP EYE RES, V201, DOI 10.1016/j.exer.2020.108255
   Chaum E, 2011, NEUROCHEM RES, V36, P574, DOI 10.1007/s11064-010-0370-5
   Chen CC, 2004, MOL PHARMACOL, V66, P683
   Chen M, 2019, PROG RETIN EYE RES, V69, P159, DOI 10.1016/j.preteyeres.2018.10.003
   Colijn JM, 2021, OPHTHALMOLOGY, V128, P1039, DOI 10.1016/j.ophtha.2020.11.024
   Crabtree MJ, 2013, J BIOL CHEM, V288, P561, DOI 10.1074/jbc.M112.415992
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   De Cilla Stefano, 2020, Cell Physiol Biochem, V54, P161, DOI 10.33594/000000212
   De Cilla S, 2017, CELL PHYSIOL BIOCHEM, V42, P1725, DOI 10.1159/000479441
   Decanini A, 2007, AM J OPHTHALMOL, V143, P607, DOI 10.1016/j.ajo.2006.12.006
   Demontis GC, 2002, INVEST OPHTH VIS SCI, V43, P2421
   Dinkova-Kostova AT, 2005, CHEM RES TOXICOL, V18, P1779, DOI 10.1021/tx050217c
   Dong A, 2009, J CELL PHYSIOL, V219, P544, DOI 10.1002/jcp.21698
   Duda DG, 2004, TRENDS MOL MED, V10, P143, DOI 10.1016/j.molmed.2004.02.001
   Eells JT, 2019, BIOLOGY-BASEL, V8, DOI 10.3390/biology8020031
   Ellis EA, 2000, FREE RADICAL BIO MED, V28, P91, DOI 10.1016/S0891-5849(99)00216-6
   Ethen CM, 2007, INVEST OPHTH VIS SCI, V48, P3469, DOI 10.1167/iovs.06-1058
   Evans MD, 2004, MUTAT RES-REV MUTAT, V567, P1, DOI 10.1016/j.mrrev.2003.11.001
   Feher J, 2006, NEUROBIOL AGING, V27, P983, DOI 10.1016/j.neurobiolaging.2005.05.012
   Felszeghy S, 2019, REDOX BIOL, V20, P1, DOI 10.1016/j.redox.2018.09.011
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Finkel T, 2011, J CELL BIOL, V194, P7, DOI 10.1083/jcb.201102095
   Forstermann U, 2012, EUR HEART J, V33, P829, DOI 10.1093/eurheartj/ehr304
   Friedman E, 1997, AM J OPHTHALMOL, V124, P677, DOI 10.1016/S0002-9394(14)70906-7
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Fuortes, 1972, PHYSL PHOTORECEPTOR, VVolume 7/2, P667
   Gao JY, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/690243
   Gemenetzi M, 2017, EYE, V31, P1, DOI 10.1038/eye.2016.208
   Giove TJ, 2009, J NEUROSCI RES, V87, P3134, DOI 10.1002/jnr.22133
   Glotin AL, 2008, FREE RADICAL BIO MED, V44, P1348, DOI 10.1016/j.freeradbiomed.2007.12.023
   Goldstein IM, 1996, VISION RES, V36, P2979, DOI 10.1016/0042-6989(96)00017-X
   Golestaneh N, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.453
   Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320
   Grunwald JE, 1998, ARCH OPHTHALMOL-CHIC, V116, P150
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   Grunwald JE, 2017, OPHTHALMOLOGY, V124, P97, DOI 10.1016/j.ophtha.2016.09.012
   Handa JT, 2012, MOL ASPECTS MED, V33, P418, DOI 10.1016/j.mam.2012.03.006
   Hanus J, 2016, CELL DEATH DISCOV, V2, DOI 10.1038/cddiscovery.2016.54
   Hanus J, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.478
   Hattenbach LO, 2002, OPHTHALMOLOGICA, V216, P209, DOI 10.1159/000059634
   Haverkamp S, 1998, NEUROREPORT, V9, P2231, DOI 10.1097/00001756-199807130-00015
   Heesterbeek TJ, 2020, OPHTHAL PHYSL OPT, V40, P140, DOI 10.1111/opo.12675
   Holley AK, 2011, INT J MOL SCI, V12, P7114, DOI 10.3390/ijms12107114
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Hu P, 2013, P NATL ACAD SCI USA, V110, pE4069, DOI 10.1073/pnas.1307574110
   Hurst J, 2017, ATLA-ALTERN LAB ANIM, V45, P11, DOI 10.1177/026119291704500105
   Hyttinen JMT, 2017, AGEING RES REV, V36, P64, DOI 10.1016/j.arr.2017.03.006
   Imamura Y, 2006, P NATL ACAD SCI USA, V103, P11282, DOI 10.1073/pnas.0602131103
   Jain A, 2010, J BIOL CHEM, V285, P22576, DOI 10.1074/jbc.M110.118976
   Jarrett SG, 2008, PROG RETIN EYE RES, V27, P596, DOI 10.1016/j.preteyeres.2008.09.001
   Jiang HY, 2017, J NEUROCHEM, V143, P375, DOI 10.1111/jnc.14214
   Johansen T, 2020, J MOL BIOL, V432, P80, DOI 10.1016/j.jmb.2019.07.016
   Jones DP, 2015, REDOX BIOL, V5, P71, DOI 10.1016/j.redox.2015.03.004
   Juel HB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064619
   Jun SJ, 2019, EXP EYE RES, V181, P346, DOI 10.1016/j.exer.2018.09.023
   Justilien V, 2007, INVEST OPHTH VIS SCI, V48, P4407, DOI 10.1167/iovs.07-0432
   Kaarniranta K, 2009, J MOL MED, V87, P117, DOI 10.1007/s00109-008-0418-z
   Kaarniranta K, 2020, PROG RETIN EYE RES, V79, DOI 10.1016/j.preteyeres.2020.100858
   Kaarniranta K, 2017, CELL BIOL TOXICOL, V33, P113, DOI 10.1007/s10565-016-9371-8
   Kaidzu S, 2008, EXP EYE RES, V86, P856, DOI 10.1016/j.exer.2008.01.016
   Kang R, 2011, CELL DEATH DIFFER, V18, P571, DOI 10.1038/cdd.2010.191
   Kannan R, 2006, MOL VIS, V12, P1649
   Kansanen E, 2013, REDOX BIOL, V1, P45, DOI 10.1016/j.redox.2012.10.001
   Karlsson M, 2013, EXP EYE RES, V116, P359, DOI 10.1016/j.exer.2013.10.014
   Kim SY, 2021, EXP EYE RES, V203, DOI 10.1016/j.exer.2020.108391
   Kim SY, 2014, INVEST OPHTH VIS SCI, V55, P6031, DOI 10.1167/iovs.14-15091
   Klettner A, 2009, GRAEF ARCH CLIN EXP, V247, P1487, DOI 10.1007/s00417-009-1139-x
   Knott AB, 2009, ANTIOXID REDOX SIGN, V11, P541, DOI [10.1089/ars.2008.2234, 10.1089/ARS.2008.2234]
   KNOWLES RG, 1994, BIOCHEM J, V298, P249, DOI 10.1042/bj2980249
   Kobayashi M, 2005, ANTIOXID REDOX SIGN, V7, P385, DOI 10.1089/ars.2005.7.385
   Kopitz J, 2004, BIOCHIMIE, V86, P825, DOI 10.1016/j.biochi.2004.09.029
   KORTE GE, 1984, INVEST OPHTH VIS SCI, V25, P1135
   Kortuem K, 2000, INVEST OPHTH VIS SCI, V41, P3176
   Kunchithapautham K, 2014, J BIOL CHEM, V289, P14534, DOI 10.1074/jbc.M114.564674
   Lambert NG, 2016, PROG RETIN EYE RES, V54, P64, DOI 10.1016/j.preteyeres.2016.04.003
   Lau A, 2010, MOL CELL BIOL, V30, P3275, DOI 10.1128/MCB.00248-10
   Li GY, 2010, BIOMED ENVIRON SCI, V23, P371, DOI 10.1016/S0895-3988(10)60078-5
   Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X
   Lois N, 2013, RETINA-J RET VIT DIS, V33, P13, DOI 10.1097/IAE.0b013e3182657fff
   LSHABRAWEY M, 2008, INVEST OPHTH VIS SCI, V49, P3239, DOI DOI 10.1167/IOVS.08-1755
   Lu L, 2006, J CELL PHYSIOL, V206, P119, DOI 10.1002/jcp.20439
   Lum F, 2016, OPHTHALMOLOGY, V123, P928, DOI [10.1016/j.ophtha.2016.01.024, 10.1016/j.ophtha.2015.10.047]
   Lutty GA, 2020, EXP EYE RES, V192, DOI 10.1016/j.exer.2020.107939
   Ma Q, 2013, ANNU REV PHARMACOL, V53, P401, DOI 10.1146/annurev-pharmtox-011112-140320
   Madeira MH, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20733-2
   Malek G, 2012, ADV EXP MED BIOL, V723, P51, DOI 10.1007/978-1-4614-0631-0_8
   Malik D, 2014, BRIT J OPHTHALMOL, V98, P11, DOI 10.1136/bjophthalmol-2014-305302
   Marquioni-Ramella MD, 2015, PHOTOCH PHOTOBIO SCI, V14, P1560, DOI 10.1039/c5pp00188a
   MARSHALL J, 1987, EYE-T OPHTH SOC UK, V1, P282, DOI 10.1038/eye.1987.47
   Martinez-Ruiz A, 2011, FREE RADICAL BIO MED, V51, P17, DOI 10.1016/j.freeradbiomed.2011.04.010
   Matsuura T, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/9548767
   McLaren AT, 2007, AM J PHYSIOL-REG I, V292, pR403, DOI 10.1152/ajpregu.00403.2006
   McLeod DS, 2012, GRAEF ARCH CLIN EXP, V250, P839, DOI 10.1007/s00417-012-1969-9
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   McLeod DS, 2002, INVEST OPHTH VIS SCI, V43, P1986
   MICELI MV, 1994, EXP CELL RES, V214, P242, DOI 10.1006/excr.1994.1254
   Mitchell P, 2002, ARCH OPHTHALMOL-CHIC, V120, P1357, DOI 10.1001/archopht.120.10.1357
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   Monaghan-Benson E, 2010, AM J PATHOL, V177, P2091, DOI 10.2353/ajpath.2010.090878
   Murakami Y, 2014, CELL DEATH DIFFER, V21, P270, DOI 10.1038/cdd.2013.109
   Murakami Y, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21197170
   Myeku N, 2011, J BIOL CHEM, V286, P22426, DOI 10.1074/jbc.M110.149252
   Nagata Makoto, 2005, Current Drug Targets - Inflammation and Allergy, V4, P503, DOI 10.2174/1568010054526322
   Nguyen T, 2003, ANNU REV PHARMACOL, V43, P233, DOI 10.1146/annurev.pharmtox.43.100901.140229
   Nordgaard CL, 2008, INVEST OPHTH VIS SCI, V49, P2848, DOI 10.1167/iovs.07-1352
   Othman A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057254
   Pang JJ, 2010, J COMP NEUROL, V518, P2456, DOI 10.1002/cne.22347
   Papapetropoulos A, 1997, J CLIN INVEST, V100, P3131, DOI 10.1172/JCI119868
   Park GB, 2018, MOL MED REP, V17, P3563, DOI 10.3892/mmr.2017.8355
   Piippo N, 2018, CELL PHYSIOL BIOCHEM, V49, P359, DOI 10.1159/000492886
   Querques G, 2014, OPHTHALMIC RES, V52, P107, DOI 10.1159/000363187
   Rabin DM, 2013, AGING-US, V5, P51
   Rangasamy T, 2004, J CLIN INVEST, V114, P1248, DOI 10.1172/JCI200421146
   Roth F, 2004, GRAEF ARCH CLIN EXP, V242, P710, DOI 10.1007/s00417-004-0976-x
   ROZANOWSKA M, 1995, J BIOL CHEM, V270, P18825, DOI 10.1074/jbc.270.32.18825
   Ruan Y, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22031296
   Santiago AR, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/465694
   Schaaf MBE, 2016, FASEB J, V30, P3961, DOI 10.1096/fj.201600698R
   Schick T, 2016, RETINA-J RET VIT DIS, V36, P787, DOI 10.1097/IAE.0000000000000756
   Schmetterer L, 2001, PROG RETIN EYE RES, V20, P823, DOI 10.1016/S1350-9462(01)00014-3
   Schutt F, 2003, INVEST OPHTH VIS SCI, V44, P3663, DOI 10.1167/iovs.03-0172
   Seddon JM, 2016, JAMA OPHTHALMOL, V134, P1272, DOI 10.1001/jamaophthalmol.2016.3519
   Sennlaub F, 2001, J CLIN INVEST, V107, P717, DOI 10.1172/JCI10874
   Shamsi FA, 2001, INVEST OPHTH VIS SCI, V42, P3041
   Sharma A, 2008, ARCH BIOCHEM BIOPHYS, V480, P85, DOI 10.1016/j.abb.2008.09.016
   Shaw PX, 2012, P NATL ACAD SCI USA, V109, P13757, DOI 10.1073/pnas.1121309109
   Shen XL, 2012, J NUTR HEALTH AGING, V16, P201, DOI 10.1007/s12603-011-0350-8
   Sheu SJ, 2015, ACTA OPHTHALMOL, V93, pE631, DOI 10.1111/aos.12745
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   Sparrow JR, 2000, INVEST OPHTH VIS SCI, V41, P1981
   Sripathi Srinivas R, 2012, Adv Biosci Biotechnol, V3, P1167, DOI 10.4236/abb.2012.38143
   Stefansson E, 2019, PROG RETIN EYE RES, V70, P1, DOI 10.1016/j.preteyeres.2019.04.001
   Stefansson E, 2011, PROG RETIN EYE RES, V30, P72, DOI 10.1016/j.preteyeres.2010.09.003
   Steinmetz JD, 2021, LANCET GLOB HEALTH, V9, pE144, DOI 10.1016/S2214-109X(20)30489-7
   STONE WL, 1979, EXP EYE RES, V28, P387, DOI 10.1016/0014-4835(79)90114-3
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Stringham JM, 2015, FOODS, V4, P678, DOI 10.3390/foods4040678
   Strunnikova N, 2004, INVEST OPHTH VIS SCI, V45, P3767, DOI 10.1167/iovs.04-0311
   Sui GY, 2013, BRIT J OPHTHALMOL, V97, P389, DOI 10.1136/bjophthalmol-2012-302281
   Sukseree S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161640
   Suzuki M, 2012, J CELL SCI, V125, P2407, DOI 10.1242/jcs.097683
   Tanito M, 2005, INVEST OPHTH VIS SCI, V46, P3859, DOI 10.1167/iovs.05-0672
   TATE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1271
   Tekmen-Clark M, 2013, VISUAL NEUROSCI, V30, P91, DOI 10.1017/S0952523813000126
   Terluk MR, 2015, J NEUROSCI, V35, P7304, DOI 10.1523/JNEUROSCI.0190-15.2015
   Thimmulappa RK, 2002, CANCER RES, V62, P5196
   Tisi A, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-63449-y
   Tisi A, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10010064
   Totan Yϋksel, 2015, J Ophthalmic Vis Res, V10, P151, DOI 10.4103/2008-322X.163765
   Totan Y, 2009, CURR EYE RES, V34, P1089, DOI 10.3109/02713680903353772
   Totsuka K, 2019, EXP EYE RES, V181, P316, DOI 10.1016/j.exer.2018.08.019
   Ushio-Fukai M, 2007, ANTIOXID REDOX SIGN, V9, P731, DOI 10.1089/ars.2007.1556
   Ushio-Fukai M, 2006, CARDIOVASC RES, V71, P226, DOI 10.1016/j.cardiores.2006.04.015
   Vielma AH, 2012, BRAIN RES, V1430, P112, DOI 10.1016/j.brainres.2011.10.045
   Vujosevic S, 2019, ACTA OPHTHALMOL, V97, pE919, DOI 10.1111/aos.14088
   Wakabayashi N, 2003, NAT GENET, V35, P238, DOI 10.1038/ng1248
   WALDMAN SA, 1987, PHARMACOL REV, V39, P163
   Wang HB, 2014, MOL VIS, V20, P231
   Wang H, 2011, INVEST OPHTH VIS SCI, V52, P570, DOI 10.1167/iovs.10-5595
   Wang K, 2017, J BIOCHEM MOL TOXIC, V31, DOI 10.1002/jbt.21887
   Wang L, 2014, FREE RADICAL BIO MED, V70, P155, DOI 10.1016/j.freeradbiomed.2014.01.015
   Wangsa-Wirawan ND, 2003, ARCH OPHTHALMOL-CHIC, V121, P547, DOI 10.1001/archopht.121.4.547
   Weigel AL, 2002, FREE RADICAL BIO MED, V33, P1419, DOI 10.1016/S0891-5849(02)01082-1
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wons J, 2017, J OPHTHALMOL, V2017, DOI 10.1155/2017/7432739
   Wu WC, 2010, MOL VIS, V16, P1864
   Yadav UCS, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/690545
   Yang LP, 2007, MOL VIS, V13, P1073
   Yang M, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21197279
   Yaniv Y, 2013, TRENDS ENDOCRIN MET, V24, P495, DOI 10.1016/j.tem.2013.06.001
   Yao JY, 2015, AUTOPHAGY, V11, P939, DOI 10.1080/15548627.2015.1041699
   Ye FX, 2016, FREE RADICAL BIO MED, V94, P121, DOI 10.1016/j.freeradbiomed.2016.02.027
   Zarbin MA, 2010, RETINA-J RET VIT DIS, V30, P1350, DOI 10.1097/IAE.0b013e3181f57e30
   Zhang K, 2012, NAT REV DRUG DISCOV, V11, P541, DOI 10.1038/nrd3745
   Zhang M, 2018, DIS MODEL MECH, V11, DOI 10.1242/dmm.032698
   Zhang M, 2007, INVEST OPHTH VIS SCI, V48, P285, DOI 10.1167/iovs.06-0792
   Zhang Y, 2017, MOL VIS, V23, P228
   Zhang ZY, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/2896036
   Zhao ZY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019456
   Zor RK, 2020, THER ADV OPHTHALMOL, V12, DOI 10.1177/2515841420951682
   Zorov DB, 2005, BIOCHEMISTRY-MOSCOW+, V70, P215, DOI 10.1007/s10541-005-0103-6
NR 214
TC 14
Z9 14
U1 2
U2 6
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2076-3921
J9 ANTIOXIDANTS-BASEL
JI Antioxidants
PD MAY
PY 2021
VL 10
IS 5
AR 653
DI 10.3390/antiox10050653
PG 21
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Food Science &
   Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Food Science
   & Technology
GA SG3PZ
UT WOS:000653355100001
PM 33922463
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Sivapathasuntharam, C
   Hayes, MJ
   Shinhmar, H
   Kam, JH
   Sivaprasad, S
   Jeffery, G
AF Sivapathasuntharam, Chrishne
   Hayes, Matthew John
   Shinhmar, Harpreet
   Kam, Jaimie Hoh
   Sivaprasad, Sobha
   Jeffery, Glen
TI Complement factor H regulates retinal development and its absence may
   establish a footprint for age related macular degeneration
SO SCIENTIFIC REPORTS
LA English
DT Article
ID PIGMENT EPITHELIUM; CELL-DEATH; EXPRESSION; PHOTORECEPTORS;
   MITOCHONDRIA; POLYMORPHISM; MAINTENANCE; MEMBRANE; PATTERNS; SYSTEM
AB Age related macular degeneration (AMD) is the most common blinding disease in those over 60 years. In 50% of cases it is associated with polymorphisms of complement factor H (FH), implicating immune vulnerability. But such individuals may exhibit abnormal outer retinal blood flow decades before disease initiation, suggesting an early disease footprint. FH is expressed in the retinal pigmented epithelium (RPE). During development the RPE is adjacent to the site of retinal mitosis and complex regulatory interactions occur between the relatively mature RPE and retinal neuronal precursors that control the cell cycle. Here we ask if the absence of FH from the RPE influences retinal development using a mouse CFH knockout (Cfh(-/-)) with an aged retinal degenerative phenotype. We reveal that from birth, these mice have significantly disrupted and delayed retinal development. However, once development is complete, their retinae appear relatively normal, although many photoreceptor and RPE mitochondria are abnormally large, suggesting dysfunction consistent with premature ATP decline in Cfh(-/-). Total retinal mtDNA is also reduced and these deficits are associated shortly after with reduced retinal function. Cfh(-/+) mice also show significant abnormal patterns of cell production but not as great as in Cfh(-/-). These results reveal that not only is FH an important player in sculpting retinal development but also that the developmental abnormality in Cfh(-/-) likely establishes critical vulnerability for later aged retinal degeneration.
C1 [Sivapathasuntharam, Chrishne; Hayes, Matthew John; Shinhmar, Harpreet; Kam, Jaimie Hoh; Sivaprasad, Sobha; Jeffery, Glen] UCL, Inst Ophthalmol, London EC1V9EL, England.
C3 University of London; University College London
RP Jeffery, G (通讯作者)，UCL, Inst Ophthalmol, London EC1V9EL, England.
EM g.jeffery@ucl.ac.uk
RI Sivaprasad, S./D-6876-2015
OI Sivaprasad, S./0000-0001-8952-0659; Jeffery, Glen/0000-0002-8777-4521
FU BBSRC [BB/N000250/1]
FX This research was supported by the BBSRC (Ref. BB/N000250/1). We thank
   Matthew Pickering for kindly supplying Cfh<SUP>-/+</SUP>.
CR Calaza KC, 2015, NEUROBIOL AGING, V36, P2869, DOI 10.1016/j.neurobiolaging.2015.06.010
   CARTERDAWSON LD, 1979, J COMP NEUROL, V188, P245, DOI 10.1002/cne.901880204
   Chirco KR, 2016, EXP EYE RES, V146, P393, DOI 10.1016/j.exer.2015.09.003
   Clark SJ, 2015, J CLIN MED, V4, P18, DOI 10.3390/jcm4010018
   Cunea A, 2007, VISUAL NEUROSCI, V24, P151, DOI 10.1017/S0952523807070204
   Curcio C. A., 2012, RETINA, V1, P465
   CURCIO CA, 1993, ANN NEUROL, V33, P248, DOI 10.1002/ana.410330305
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Finkel T, 2015, NAT MED, V21, P1416, DOI 10.1038/nm.3998
   Guymer R, 1999, PROG RETIN EYE RES, V18, P59, DOI 10.1016/S1350-9462(98)00012-3
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hoang QV, 2002, VISUAL NEUROSCI, V19, P395, DOI 10.1017/S0952523802194028
   Ilia M, 1999, J COMP NEUROL, V405, P394, DOI 10.1002/(SICI)1096-9861(19990315)405:3<394::AID-CNE9>3.0.CO;2-Y
   JEFFERY G, 1984, DEV BRAIN RES, V13, P81, DOI 10.1016/0165-3806(84)90079-8
   Kam JH, 2016, EXP EYE RES, V149, P116, DOI 10.1016/j.exer.2016.07.002
   Kam JH, 2013, AM J PATHOL, V183, P480, DOI 10.1016/j.ajpath.2013.04.008
   Keir LS, 2017, J CLIN INVEST, V127, P199, DOI 10.1172/JCI86418
   KINNEAR PE, 1985, SURV OPHTHALMOL, V30, P75, DOI 10.1016/0039-6257(85)90077-3
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Linsenmeier RA, 2000, INVEST OPHTH VIS SCI, V41, P3117
   Livesey FJ, 2001, NAT REV NEUROSCI, V2, P109, DOI 10.1038/35053522
   Lopez-Otin C, 2013, CELL, V153, P1194, DOI 10.1016/j.cell.2013.05.039
   Mandal NA, 2006, INVEST OPHTH VIS SCI, V47, P4091, DOI 10.1167/iovs.05-1655
   Marneros AG, 2005, AM J PATHOL, V167, P1451, DOI 10.1016/S0002-9440(10)61231-X
   Mullins RF, 2011, EXP EYE RES, V93, P565, DOI 10.1016/j.exer.2011.06.015
   Presumey J, 2017, ADV IMMUNOL, V135, P53, DOI 10.1016/bs.ai.2017.06.004
   RAYMOND SM, 1995, CURR BIOL, V5, P1286, DOI 10.1016/S0960-9822(95)00255-7
   ROBINSON SR, 1988, J COMP NEUROL, V267, P507, DOI 10.1002/cne.902670405
   Stephan AH, 2012, ANNU REV NEUROSCI, V35, P369, DOI 10.1146/annurev-neuro-061010-113810
   Stevens B, 2007, CELL, V131, P1164, DOI 10.1016/j.cell.2007.10.036
   Stone J, 2008, BRAIN RES, V1189, P58, DOI 10.1016/j.brainres.2007.10.083
   Thompson H, 2010, DEV BIOL, V347, P40, DOI 10.1016/j.ydbio.2010.08.006
   Tibber MS, 2007, J COMP NEUROL, V503, P128, DOI 10.1002/cne.21388
   Tibber MS, 2006, J COMP NEUROL, V496, P369, DOI 10.1002/cne.20920
   Told R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060424
   Toomey CB, 2018, PROG RETIN EYE RES, V62, P38, DOI 10.1016/j.preteyeres.2017.09.001
   von Leithner PL, 2009, AM J PATHOL, V175, P412, DOI 10.2353/ajpath.2009.080927
   Wang AL, 2010, NEUROBIOL AGING, V31, P2002, DOI 10.1016/j.neurobiolaging.2008.10.019
   West AP, 2011, NAT REV IMMUNOL, V11, P389, DOI 10.1038/nri2975
   Young R W, 1983, Trans Am Ophthalmol Soc, V81, P193
   Zhang JZ, 2014, INT J MOL MED, V33, P817, DOI 10.3892/ijmm.2014.1650
   Zhang Q, 2010, NATURE, V464, P104, DOI 10.1038/nature08780
   Zhao SL, 2001, MOL VIS, V7, P277
NR 43
TC 18
Z9 18
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD JAN 31
PY 2019
VL 9
AR 1082
DI 10.1038/s41598-018-37673-6
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA HJ6HN
UT WOS:000457287000070
PM 30705315
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Seitsonen, SP
   Jarvela, IE
   Meri, S
   Tommila, PV
   Ranta, PH
   Immonen, IJ
AF Seitsonen, S. P.
   Jarvela, I. E.
   Meri, S.
   Tommila, P. V.
   Ranta, P. H.
   Immonen, I. J.
TI The effect of complement factor HY402H polymorphism on the outcome of
   photodynamic therapy in age-related macular degeneration
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; complement factor H; photodynamic
   therapy
ID FACTOR-H POLYMORPHISM; SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; Y402H
   VARIANT; 2 PARTS; VERTEPORFIN; RISK; GENE; SUSCEPTIBILITY; POPULATION;
   INCREASES
AB PURPOSE. Photodynamic therapy (PDT) has been widely used in the treatment of age-related macular degeneration (AMD). The complement cascade has an important role in the tissue reactions occurring after PDT. The Y402H polymorphism of the complement factor H (CFH) gene has been identified as a risk factor for AMD. Since CFH is central in the regulation of the complement system the authors wanted to analyze whether the CFH Y402H polymorphism modifies the PDT outcome in AMD.
   METHODS. A total of 88 patients having been treated with PDT and without further scheduled PDT sessions were analyzed. Depending on the situation at their final PDT session the patients were classified retrospectively as PDT-responders or PDT-nonresponders. All patients were genotyped for the CFH Y402H polymorphism.
   RESULTS. The proportion of PDT-responders was 18/26 (69.2%) in patients homozygous for the CFH Y402H risk allele, 34/50 (68.0%) in heterozygous, and 7/12 (58.3%) in patients with the normal genotype (p=0.520). The median number of PDT treatments of the PDT-responders was three for all the genotypes.
   CONCLUSIONS. The dysfunction of the CFH related to the risk of AMD and caused by the Y402H polymorphism does not modify the outcome of PDT. Genotyping for CFH Y402H cannot be used to select patients for this treatment.
C1 [Seitsonen, S. P.; Tommila, P. V.; Ranta, P. H.; Immonen, I. J.] Univ Helsinki, Cent Hosp, Dept Ophthalmol, FIN-00029 Helsinki, Finland.
   [Jarvela, I. E.] Univ Helsinki, Haartman Inst, Dept Med Genet, Helsinki, Finland.
   [Meri, S.] Univ Helsinki, Haartman Inst, Dept Bacterial Immunol, Helsinki, Finland.
C3 University of Helsinki; Helsinki University Central Hospital; University
   of Helsinki; University of Helsinki
RP Seitsonen, SP (通讯作者)，Univ Helsinki, Cent Hosp, Dept Ophthalmol, PO Box 220, FIN-00029 Helsinki, Finland.
EM sanna.seitsonen@hus.fi
RI Jarvela, Irma E/L-5836-2013
OI Jarvela, Irma E/0000-0002-1770-6187; Meri, Seppo/0000-0001-9142-501X
CR Arias L, 2006, OPHTHALMOLOGY, V113, P2243, DOI 10.1016/j.ophtha.2006.04.039
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Baird PN, 2006, INVEST OPHTH VIS SCI, V47, P4194, DOI 10.1167/iovs.05-1285
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bora PS, 2005, J IMMUNOL, V174, P491, DOI 10.4049/jimmunol.174.1.491
   Conley YP, 2005, HUM MOL GENET, V14, P1991, DOI 10.1093/hmg/ddi204
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Frennesson CI, 2004, ACTA OPHTHALMOL SCAN, V82, P645, DOI 10.1111/j.1600-0420.2004.00368.x
   GOVERDHAN SV, 2007, EYE             0427
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Husain D, 1999, INVEST OPHTH VIS SCI, V40, P2322
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Korbelik M, 2007, BRIT J CANCER, V96, P67, DOI 10.1038/sj.bjc.6603508
   Korbelik M, 2006, LASER SURG MED, V38, P500, DOI 10.1002/lsm.20337
   Kramer M, 1996, OPHTHALMOLOGY, V103, P427
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   Postel EA, 2006, OPHTHALMOLOGY, V113, P1504, DOI 10.1016/j.ophtha.2006.02.049
   Schmidt-Erfurth U, 2000, SURV OPHTHALMOL, V45, P195, DOI 10.1016/S0039-6257(00)00158-2
   Schmidt-Erfurth U, 2002, INVEST OPHTH VIS SCI, V43, P830
   SCHMIDTERFURTH U, 1994, OPHTHALMOLOGY, V101, P1953
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Seitsonen S, 2006, MOL VIS, V12, P796
   Simonelli F, 2006, BRIT J OPHTHALMOL, V90, P1142, DOI 10.1136/bjo.2006.096487
   Souied EH, 2005, MOL VIS, V11, P1135
   Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406
   Walport MJ, 2001, NEW ENGL J MED, V344, P1140, DOI 10.1056/NEJM200104123441506
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
   Zipfel PF, 1999, MOL IMMUNOL, V36, P241, DOI 10.1016/S0161-5890(99)00038-3
   2002, RETINA, V22, P6
NR 33
TC 39
Z9 43
U1 0
U2 1
PU WICHTIG EDITORE
PI MILAN
PA 72/74 VIA FRIULI, 20135 MILAN, ITALY
SN 1120-6721
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD NOV-DEC
PY 2007
VL 17
IS 6
BP 943
EP 949
DI 10.1177/112067210701700612
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 265UO
UT WOS:000253386800012
PM 18050121
DA 2022-11-30
ER

PT J
AU Shienbaum, G
   Garcia, CAA
   Flynn, HW
   Nunes, RP
   Smiddy, WE
   Rosenfeld, PJ
AF Shienbaum, Gary
   Garcia Filho, Carlos Alexandre A.
   Flynn, Harry W., Jr.
   Nunes, Renata Portella
   Smiddy, William E.
   Rosenfeld, Philip J.
TI Management of Submacular Hemorrhage Secondary to Neovascular Age-Related
   Macular Degeneration With Anti-Vascular Endothelial Growth Factor
   Monotherapy
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID TISSUE-PLASMINOGEN ACTIVATOR; PARS-PLANA VITRECTOMY; SUBRETINAL
   HEMORRHAGE; PNEUMATIC DISPLACEMENT; INJECTION; RANIBIZUMAB; DRAINAGE;
   REMOVAL; LESIONS
AB PURPOSE: To report the visual and anatomic outcomes of anti-vascular endothelial growth factor (VEGF) monotherapy in the management of marked submacular hemorrhage secondary to neovascular age-related macular degeneration (AMD).
   DESIGN: Retrospective, interventional, consecutive case series.
   METHODS: Nineteen eyes of 18 patients with neovascular AMD and fovea involving submacular hemorrhage comprising greater than 50% of the lesion area were treated with anti-VEGF monotherapy. Main outcome measures included mean visual acuity change from baseline, mean central lesion thickness change from baseline, mean number of injections at 6 months, and adverse events. Snellen visual acuity was converted to approximate ETDRS letter score for the purpose of statistical analysis.
   RESULTS: The mean change in approximate ETDRS letter score from baseline was + 12 letters at 3 months (P = .003), + 18 letters at 6 months (P = .001), and +17 letters at 12 months follow-up (P = .02). Seven eyes received ranibizumab, 6 eyes received bevacizumab, and 6 eyes received both at various time points. The mean number of injections at 6 months was 4.7. The mean OCT central lesion thickness decreased from 755 mu m to 349 gm at 6 months follow-up (P = .0008).
   CONCLUSIONS: Management with anti-VEGF monotherapy may yield visual and anatomic improvements in eyes with marked submacular hemorrhage secondary to neovascular AMD. ((c) 2013 by Elsevier Inc. All rights reserved.)
C1 [Shienbaum, Gary; Garcia Filho, Carlos Alexandre A.; Flynn, Harry W., Jr.; Nunes, Renata Portella; Smiddy, William E.; Rosenfeld, Philip J.] Univ Miami, Miller Sch Med, Dept Ophthalmol, Bascom Palmer Eye Inst, Miami, FL 33136 USA.
C3 Bascom Palmer Eye Institute; University of Miami
RP Flynn, HW (通讯作者)，900 NW 17 St, Miami, FL 33136 USA.
EM hflynn@med.miami.edu
FU Carl Zeiss Meditec; Alexion Pharmaceutical; Potentia; GlaxoSmithKline;
   Research to Prevent Blindness, New York, New York
FX Harry W. Flynn Jr: consultant, Alimera, Pfizer, Santen; Philip J.
   Rosenfeld: consultant, Oraya, Novartis, Chengdu Kanghong Biotech,
   Acucela, ThromboGenics, Canon, Inc; research grants, Carl Zeiss Meditec,
   Alexion Pharmaceutical, Potentia, GlaxoSmithKline; lecturer, Carl Zeiss
   Meditec, Allergan, Topcon. Publication of this article was supported in
   part by Research to Prevent Blindness, New York, New York. Contributions
   of authors: design and conduct of the study (G.S., C.A.A.G.F., H.W.F.,
   R.P.N., W.E.S., P.J.R.); collection (G.S., C.A.A.G.F., R.P.N.),
   management (G.S., C.A.A.G.F., R.P.N,), analysis (G.S., C.A.A.G.F:,
   H.W.F., R.P.N., P.J.R.), and interpretation of the data (G.S.,
   C.A.A.G.F., H.W.F., R.P.N., P.J.R.); and preparation (G.S., H.W.F.,
   W.E.S., P.J.R.), review (G.S., H.W.F., W.E.S., P.J.R.), and approval of
   the manuscript (G.S., H.W.F., W.E.S., P.J.R.).
CR Avery RL, 1996, RETINA-J RET VIT DIS, V16, P183, DOI 10.1097/00006982-199616030-00001
   Berrocal MH, 1996, AM J OPHTHALMOL, V122, P486, DOI 10.1016/S0002-9394(14)72107-5
   Bressler NM, 2004, OPHTHALMOLOGY, V111, P1993, DOI 10.1016/j.ophtha.2004.07.023
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chang MA, 2010, RETINA-J RET VIT DIS, V30, P1171, DOI 10.1097/IAE.0b013e3181dd6d8a
   Fine HF, 2010, RETINA-J RET VIT DIS, V30, P1588, DOI 10.1097/IAE.0b013e3181e2263c
   GLATT H, 1982, AM J OPHTHALMOL, V94, P762, DOI 10.1016/0002-9394(82)90301-4
   Gopalakrishan M, 2007, RETINA-J RET VIT DIS, V27, P329, DOI 10.1097/01.iae.0000231544.43093.40
   Gregori NZ, 2010, RETINA-J RET VIT DIS, V30, P1046, DOI 10.1097/IAE.0b013e3181d87e04
   Hassan AS, 1999, OPHTHALMOLOGY, V106, P1900, DOI 10.1016/S0161-6420(99)90399-8
   Haupert CL, 2001, AM J OPHTHALMOL, V131, P208, DOI 10.1016/S0002-9394(00)00734-0
   LEWIS H, 1994, AM J OPHTHALMOL, V118, P559, DOI 10.1016/S0002-9394(14)76571-7
   LIM JI, 1995, OPHTHALMOLOGY, V102, P1393, DOI 10.1016/S0161-6420(95)30858-5
   MANDELCORN MS, 1993, CAN J OPHTHALMOL, V28, P19
   Olivier S, 2004, OPHTHALMOLOGY, V111, P1201, DOI 10.1016/j.ophtha.2003.10.020
   Ron Y, 2007, OPHTHALMOLOGICA, V221, P57, DOI 10.1159/000096524
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schulze SD, 2002, GRAEF ARCH CLIN EXP, V240, P717, DOI 10.1007/s00417-002-0516-5
   Stifter E, 2007, AM J OPHTHALMOL, V144, P886, DOI 10.1016/j.ajo.2007.07.034
   Todorich B, 2011, RETINA-J RET VIT DIS, V31, P1749, DOI 10.1097/IAE.0b013e31821504df
   TOTH CA, 1991, ARCH OPHTHALMOL-CHIC, V109, P723, DOI 10.1001/archopht.1991.01080050139046
   WADE EC, 1990, ARCH OPHTHALMOL-CHIC, V108, P973, DOI 10.1001/archopht.1990.01070090075043
NR 22
TC 52
Z9 54
U1 0
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JUN
PY 2013
VL 155
IS 6
BP 1009
EP 1013
DI 10.1016/j.ajo.2013.01.012
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 157JU
UT WOS:000319893200006
PM 23465269
DA 2022-11-30
ER

PT J
AU Hariprasad, SM
   Morse, LS
   Shapiro, H
   Wong, P
   Tuomi, L
AF Hariprasad, Seenu M.
   Morse, Lawrence S.
   Shapiro, Howard
   Wong, Pamela
   Tuomi, Lisa
TI Fixed Monthly versus Less Frequent Ranibizumab Dosing and Predictors of
   Visual Response in Exudative Age-Related Macular Degeneration
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID SUBGROUP ANALYSIS; BEVACIZUMAB
AB Purpose. To examine temporal patterns of visual acuity (VA) response to pooled 0.3 mg/0.5 mg ranibizumab treatment in patients with age-related macular degeneration and identify potential baseline predictors of response. Design. Retrospective analysis. Methods. Results from 1824 ranibizumab-treated patients receiving fixed monthly, quarterly, or as-needed dosing after three monthly loading doses in four phase III/IIIb trials (ANCHOR, MARINA, PIER, and SAILOR) were analyzed. Results. At month 3, 14.9% to 29.4% of patients had gained >= 15 letters. Not all patients achieved peak gains at month 3; many continued to have VA increases throughout treatment. After three monthly loading doses, continued monthly dosing resulted in further gains, as there were more delayed 15-letter responders at month 12 (14.7-16.1%) than with less frequent dosing (5.0-6.0%). Monthly dosing also resulted in more patients maintaining VA gains at later time points. Early 15-letter responders had lower baseline mean VA than delayed 15-letter responders in ANCHOR and MARINA; no other differences in baseline characteristics were noted. Conclusions. Although some patients have rapid improvements in VA, others do not experience peak VA until later during treatment. Continued monthly dosing resulted in a greater percentage of patients gaining >= 15 letters than with switching to less frequent dosing regimens.
C1 [Hariprasad, Seenu M.] Univ Chicago, Dept Surg, Sect Ophthalmol & Visual Sci, Chicago, IL 60637 USA.
   [Morse, Lawrence S.] Univ Calif Davis, Hlth Syst Eye Ctr, Dept Ophthalmol & Vis Sci, Sacramento, CA 95817 USA.
   [Shapiro, Howard; Wong, Pamela; Tuomi, Lisa] Genentech Inc, San Francisco, CA 94080 USA.
C3 University of Chicago; University of California System; University of
   California Davis; Roche Holding; Genentech
RP Hariprasad, SM (通讯作者)，Univ Chicago, Dept Surg, Sect Ophthalmol & Visual Sci, 5841 S Maryland Ave, Chicago, IL 60637 USA.
EM retina@uchicago.edu
OI Morse, Lawrence/0000-0002-1758-2348
FU Genentech, Inc.
FX The design and conduct of the analysis as well as the data collection,
   management, and analysis and interpretation of the data were supported
   by Genentech, Inc. S. M. Hariprasad and L. S. Morse have received no
   financial support for this analysis. Medical writing and editorial
   support were provided by Christina McManus, PhD, of Envision Scientific
   Solutions and were funded by Genentech, Inc.
CR Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Carneiro AM, 2012, CLIN OPHTHALMOL, V6, P1149, DOI 10.2147/OPTH.S33017
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Ikemori S, 2012, J CLIN EXPT OPHTHALM, V3, P221
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Spaide R, 2007, AM J OPHTHALMOL, V143, P679, DOI 10.1016/j.ajo.2007.02.024
NR 13
TC 14
Z9 15
U1 0
U2 3
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PY 2012
VL 2012
AR 690641
DI 10.1155/2012/690641
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 049XM
UT WOS:000312016700001
PM 23251787
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Kim, JM
   Kim, SY
   Chin, HS
   Kim, HJ
   Kim, NR
AF Kim, Joon Mo
   Kim, Se Young
   Chin, Hee Seung
   Kim, Hyun Ji
   Kim, Na Rae
CA Korean Ophthalmological Soc
TI Relationships between Hearing Loss and the Prevalences of Cataract,
   Glaucoma, Diabetic Retinopathy, and Age-Related Macular Degeneration in
   Korea
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Article
DE age-related macular degeneration; cataract; diabetic retinopathy;
   glaucoma; hearing loss
ID DUAL SENSORY LOSS; INNER-EAR; IMPAIRMENT; PSEUDOEXFOLIATION; MELANIN;
   RISK; DEPRESSION; MELLITUS
AB This study was conducted using the database of the Korea National Health and Nutrition Examination Survey to determine whether age-related eye diseases such as cataract, glaucoma, diabetic retinopathy (DR), and age-related macular degeneration (AMD), are related to hearing loss. 12,899 participants >= 40 years of age were included. The weighted prevalence of diabetic retinopathy was not significantly different between the normal hearing group and hearing-impaired group, but the weighted prevalences of cataract, glaucoma, early AMD, and late AMD were significantly different in the two groups. The odds ratio for cataract in the hearing-impaired group was 1.373 (1.118-1.687). The odds ratios of glaucoma, DR, early AMD, and late AMD were not significantly different in the hearing-impaired group. Age was significantly associated with the presence of concurrent cataract and hearing impairment by 6.574-fold per decade. Significant factors that increased the risk of concurrent glaucoma and hearing impairment were age, male gender, and triglyceride. Age, ex-smoker, systolic BP elevation, BMI decline, and fasting blood sugar significantly predicted the presence of concurrent DR and hearing loss. In early AMD, age and triglyceride, and in late AMD, age and systolic BP elevations increased the risk of concurrent AMD and hearing impairment.
C1 [Kim, Joon Mo] Sungkyunkwan Univ, Sch Med, Dept Ophthalmol, Kangbuk Samsung Hosp, Seoul 03181, South Korea.
   [Kim, Se Young; Chin, Hee Seung; Kim, Na Rae] Inha Univ, Sch Med, Dept Ophthalmol, Incheon 22332, South Korea.
   [Kim, Se Young; Chin, Hee Seung; Kim, Na Rae] Inha Univ, Sch Med, Inha Vis Sci Lab, Incheon 22332, South Korea.
   [Kim, Hyun Ji] Inha Univ, Sch Med, Dept Otorhinolaryngol, Incheon 22332, South Korea.
C3 Sungkyunkwan University (SKKU); Inha University; Inha University; Inha
   University
RP Kim, NR (通讯作者)，Inha Univ, Sch Med, Dept Ophthalmol, Incheon 22332, South Korea.; Kim, NR (通讯作者)，Inha Univ, Sch Med, Inha Vis Sci Lab, Incheon 22332, South Korea.
EM nrkim@inha.ac.kr
OI Kim, Na Rae/0000-0003-4224-5447
FU Inha University Research Grant
FX This work was supported by an Inha University Research Grant.
CR Ashkezari SJ, 2018, J DIABETES METAB DIS, V17, P173, DOI 10.1007/s40200-018-0357-3
   Bener A, 2017, DIABETES METAB SYND, V11, pS45, DOI 10.1016/j.dsx.2016.09.004
   Cahill M, 2002, EYE, V16, P261, DOI 10.1038/sj.eye.6700011
   Caljkusic-Mance T, 2010, COLLEGIUM ANTROPOL, V34, P65
   Capella-McDonnall NE, 2005, INT J GERIATR PSYCH, V20, P855, DOI 10.1002/gps.1368
   Cosh S, 2018, INT J GERIATR PSYCH, V33, P598, DOI 10.1002/gps.4827
   Detorakis ET, 2008, EUR J OPHTHALMOL, V18, P71, DOI 10.1177/112067210801800112
   Foster PJ, 2002, BRIT J OPHTHALMOL, V86, P238, DOI 10.1136/bjo.86.2.238
   Ghasemi Hassan, 2016, J Ophthalmic Vis Res, V11, P54, DOI 10.4103/2008-322X.180699
   Green KA, 2013, J AM GERIATR SOC, V61, P252, DOI 10.1111/jgs.12091
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hayashi H, 2007, ARCH OTOLARYNGOL, V133, P151, DOI 10.1001/archotol.133.2.151
   Jun HJ, 2015, LARYNGOSCOPE, V125, P690, DOI 10.1002/lary.24913
   Klein BEK, 2001, AM J OPHTHALMOL, V132, P537, DOI 10.1016/S0002-9394(01)01126-6
   Klein R, 1998, OPHTHALMOLOGY, V105, P1801, DOI 10.1016/S0161-6420(98)91020-X
   Klein R, 1998, ARCH OPHTHALMOL-CHIC, V116, P360, DOI 10.1001/archopht.116.3.360
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   Konrad-Martin D, 2015, EAR HEARING, V36, P381, DOI 10.1097/AUD.0000000000000137
   KOVAR M, 1973, ORL J OTO-RHINO-LARY, V35, P42, DOI 10.1159/000275086
   Kremmer S, 2004, BRIT J OPHTHALMOL, V88, P1259, DOI 10.1136/bjo.2003.040832
   Loprinzi PD, 2013, MAYO CLIN PROC, V88, P690, DOI 10.1016/j.mayocp.2013.04.008
   Medeiros FA, 2004, AM J OPHTHALMOL, V137, P863, DOI 10.1016/j.ajo.2003.12.009
   MILLER JJ, 1983, AM J OTOLARYNG, V4, P342, DOI 10.1016/S0196-0709(83)80021-0
   Mitoku K, 2016, BMC GERIATR, V16, DOI 10.1186/s12877-016-0286-2
   Murillo-Cuesta S, 2010, PIGM CELL MELANOMA R, V23, P72, DOI 10.1111/j.1755-148X.2009.00646.x
   NADOL JB, 1982, LARYNGOSCOPE, V92, P1028
   Paliobei VP, 2011, OTOLARYNG HEAD NECK, V145, P125, DOI 10.1177/0194599811401206
   Papadopoulos TA, 2010, CLIN EXP OPHTHALMOL, V38, P456, DOI 10.1111/j.1442-9071.2010.02289.x
   SCHMIDT SY, 1986, INVEST OPHTH VIS SCI, V27, P1063
   Schneider JM, 2011, J AGING HEALTH, V23, P1309, DOI 10.1177/0898264311408418
   SCHUKNECHT HF, 1993, ANN OTO RHINOL LARYN, V102, P1
   Tryggvason G, 2016, ACTA OPHTHALMOL, V94, P140, DOI 10.1111/aos.12914
   Turacli ME, 2007, CAN J OPHTHALMOL, V42, P56, DOI 10.3129/canjophthalmol.06-087
   Viljanen A, 2014, EUR J AGEING, V11, P155, DOI 10.1007/s10433-013-0291-7
   WACKYM PA, 1986, AM J OTOL, V7, P176
   Yazdani S, 2008, OPHTHALMOLOGY, V115, P425, DOI 10.1016/j.ophtha.2007.10.038
   Yoon Kyung-Chul, 2011, Korean J Ophthalmol, V25, P421, DOI 10.3341/kjo.2011.25.6.421
NR 37
TC 6
Z9 6
U1 0
U2 2
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD JUL
PY 2019
VL 8
IS 7
AR 1078
DI 10.3390/jcm8071078
PG 11
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC General & Internal Medicine
GA IN9MO
UT WOS:000479003300160
PM 31336642
OA gold, Green Submitted, Green Published
DA 2022-11-30
ER

PT J
AU Catchpole, T
   Nguyen, TD
   Gilfoyle, A
   Csaky, KG
AF Catchpole, Timothy
   Nguyen, Timothy D.
   Gilfoyle, Alexa
   Csaky, Karl G.
TI A profile of circulating vascular progenitor cells in human neovascular
   age-related macular degeneration
SO PLOS ONE
LA English
DT Article
ID PERIPHERAL-BLOOD; STEM-CELLS; RESISTANCE; THERAPY; VEGFA; GENE
AB Background/objective
   A subset of neovascular age-related macular degeneration (nvAMD) subjects appears to be refractory to the effects of anti-VEGF treatment and require frequent intravitreal injections. The vascular phenotype of the choroidal neovascular (CNV) lesions may contribute to the resistance. Animal studies of CNV lesions have shown that cells originating from bone marrow are capable of forming varying cell types in the lesions. This raised the possibility of a similar cell population in human nvAMD subjects.
   Materials and methods
   Blood draws were obtained from subjects with active nvAMD while patients were receiving standard of care anti-VEGF injections. Subjects were classified as refractory or non-refractory to anti-VEGF treatment based on previous number of injections in the preceding 12 months. Peripheral blood mononuclear cells (PBMCs) were isolated and CD34-positive cells purified using magnetic bead sorting. The isolated cells were expanded in StemSpan SFEM media to increase cell numbers. After expansion, the cells were split and plated in either endothelial or mesenchymal promoting conditions. Phenotype analysis was performed via qPCR.
   Results
   There was no significant difference in the number of PBMCs and CD34-positive cells between refractory and non-refractory nvAMD subjects. The growth pattern distribution between endothelial and mesenchymal media conditions were very similar between refractory and non-refractory subjects. qPCR and immunostaining demonstrated positive expression of endothelial markers in endothelial media, and markers such as NG2 and aSMA in mesenchymal media. However, analysis of subsequent samples from AMD subjects demonstrated high variability in both the numbers and differentiation properties of this cell population.
   Conclusions
   CD34+ cells can be isolated from nvAMD subjects and show both endothelial and pericyte-like characteristics after differentiation in certain media conditions. However, nvAMD subjects show high variability in both numbers of cells and differentiation characteristics in repeat sampling. This variability highlights the importance of taking multiple samples from nvAMD subjects for any clinical trials focused on biomarkers for the disease.
C1 [Catchpole, Timothy; Nguyen, Timothy D.; Gilfoyle, Alexa; Csaky, Karl G.] Retina Fdn Southwest, Dallas, TX 75231 USA.
   [Csaky, Karl G.] Univ Texas Southwestern Med Ctr Dallas, Dept Ophthalmol, Dallas, TX USA.
C3 Retina Foundation of the Southwest; University of Texas System;
   University of Texas Southwestern Medical Center Dallas
RP Catchpole, T (通讯作者)，Retina Fdn Southwest, Dallas, TX 75231 USA.
EM tcatch@retinafoundation.org
FU NEI [R21EY024422]; Harrington Foundation; T. Boone Pickens Foundation
FX Financial support was provided by NEI grant R21EY024422, the Harrington
   Foundation and the T. Boone Pickens Foundation for support of Dr. Karl
   Csaky. The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript. There
   was no additional external funding received for this study.
CR Abedi F, 2013, OPHTHALMOLOGY, V120, P115, DOI 10.1016/j.ophtha.2012.10.006
   Azam F, 2010, EUR J CANCER, V46, P1323, DOI 10.1016/j.ejca.2010.02.020
   BENDER JG, 1991, BLOOD, V77, P2591
   Bergers G, 2008, NAT REV CANCER, V8, P592, DOI 10.1038/nrc2442
   BEYTH S, 2015, BONE MARROW RES, P84364, DOI DOI 10.1155/2015/914935
   Catchpole T, 2016, EXP EYE RES, V148, P45, DOI 10.1016/j.exer.2016.05.025
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P4914, DOI 10.1167/iovs.03-0371
   Ferreira LS, 2007, CIRC RES, V101, P286, DOI 10.1161/CIRCRESAHA.107.150201
   Francis Peter James, 2011, Trans Am Ophthalmol Soc, V109, P115
   Hagstrom SA, 2014, JAMA OPHTHALMOL, V132, P521, DOI 10.1001/jamaophthalmol.2014.109
   Helfrich I, 2010, J EXP MED, V207, P491, DOI 10.1084/jem.20091846
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Korbling M, 2001, BLOOD, V98, P2900, DOI 10.1182/blood.V98.10.2900
   Llufrio EM, 2018, REDOX BIOL, V16, P381, DOI 10.1016/j.redox.2018.03.004
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Sidney LE, 2014, STEM CELLS, V32, P1380, DOI 10.1002/stem.1661
   Wei L, 2012, CELL REP, V2, P1151, DOI 10.1016/j.celrep.2012.10.013
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
NR 19
TC 1
Z9 1
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 27
PY 2020
VL 15
IS 2
AR e0229504
DI 10.1371/journal.pone.0229504
PG 14
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA LQ8GQ
UT WOS:000535237000036
PM 32106279
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Mori, K
   Ishikawa, K
   Fukuda, Y
   Ji, R
   Wada, I
   Kubo, Y
   Akiyama, M
   Notomi, S
   Murakami, Y
   Nakao, S
   Arakawa, S
   Shiose, S
   Hisatomi, T
   Yoshida, S
   Kannan, R
   Sonoda, KH
AF Mori, Kenichiro
   Ishikawa, Keijiro
   Fukuda, Yosuke
   Ji, Rui
   Wada, Iori
   Kubo, Yuki
   Akiyama, Masato
   Notomi, Shoji
   Murakami, Yusuke
   Nakao, Shintaro
   Arakawa, Satoshi
   Shiose, Satomi
   Hisatomi, Toshio
   Yoshida, Shigeo
   Kannan, Ram
   Sonoda, Koh-Hei
TI TNFRSF10A downregulation induces retinal pigment epithelium degeneration
   during the pathogenesis of age-related macular degeneration and central
   serous chorioretinopathy
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID PROTEIN-KINASE-C; GENOME-WIDE ASSOCIATION; OXIDATIVE STRESS; APOPTOSIS;
   CELLS; DEATH; ACTIVATION; INDUCTION; UPDATE; GROWTH
AB Age-related macular degeneration (AMD) and central serous chorioretinopathy (CSC) are common diseases that can cause vision loss in older and younger populations. These diseases share pathophysiological conditions derived from retinal pigment epithelium (RPE) dysfunction. Tumor necrosis factor receptor superfamily 10A (TNFRSF10A)-LOC389641 with the same lead single-nucleotide polymorphism (SNP) (rs13278062) is the only overlapped susceptibility locus found in both AMD and CSC through genome-wide association studies. This lead SNP has been reported to alter the transcriptional activity of TNFRSF10A. This study aimed to elucidate the function of TNFRSF10A in RPE degeneration using human primary RPE cells and Tnfrsf10 knockout (Tnfrsf10(-/-)) mice. TNFRSF10A was found to be localized in human RPE. In vitro assays revealed that a T allele of rs13278062, the risk allele for AMD and CSC, downregulated TNFRSF10A transcription in RPE, leading to decreased cell viability and increased apoptosis through protein kinase C-alpha (PKCA) downregulation. Treatment with phorbol 12-myristate 13-acetate, a PKC activator, rescued the cell viability. Morphological RPE abnormality was found in the retina of Tnfrsf10(-/-) mice. Our data suggest that downregulation of TNFRSF10A expression inactivates PKCA signaling and causes cellular vulnerability of the RPE, which may contribute to the pathogenesis of AMD and CSC.
C1 [Mori, Kenichiro; Ishikawa, Keijiro; Fukuda, Yosuke; Ji, Rui; Wada, Iori; Kubo, Yuki; Notomi, Shoji; Murakami, Yusuke; Nakao, Shintaro; Arakawa, Satoshi; Shiose, Satomi; Sonoda, Koh-Hei] Kyushu Univ, Dept Ophthalmol, Grad Sch Med Sci, Fukuoka 8128582, Japan.
   [Akiyama, Masato] Kyushu Univ, Dept Ocular Pathol & Imaging Sci, Grad Sch Med Sci, Fukuoka 8128582, Japan.
   [Hisatomi, Toshio] Fukuoka Univ, Chikushi Hosp, Dept Ophthalmol, Chikushino, Fukuoka 8180067, Japan.
   [Yoshida, Shigeo] Kurume Univ, Grad Sch Med Sci, Dept Ophthalmol, Kurume, Fukuoka 8300011, Japan.
   [Kannan, Ram] Doheny Eye Inst, Stephen J Ryan Initiat Macular Res RIMR, Los Angeles, CA 90086 USA.
   [Kannan, Ram] Univ Calif Los Angeles, Geffen Sch Med, Stein Eye Inst, Los Angeles, CA 90095 USA.
C3 Kyushu University; Kyushu University; Fukuoka University; Kurume
   University; Doheny Eye Institute; University of California System;
   University of California Los Angeles; University of California Los
   Angeles Medical Center; David Geffen School of Medicine at UCLA
RP Ishikawa, K (通讯作者)，3-1-1 Maidashi,Higashi Ku, Fukuoka 8128582, Japan.
EM ishikawa.keijiro.609@m.kyushu-u.ac.jp
RI Akiyama, Masato/AHC-2589-2022
OI Notomi, Shoji/0000-0002-7935-4244; Mori, Kenichiro/0000-0002-6615-7153
FU KAKENHI [JP20K09828]; Fund for Ophthalmic Research in Commemoration of
   Santen Pharmaceutical; Bayer Retina Award Foundation; ROHTO Award; Nidek
   Co. Ltd; Hoya Co. Ltd; Santen Pharmaceutical Co. Ltd
FX Grants-in-Aid for Scientific Research from KAKENHI[#JP20K09828toK.I.];
   the Fund for Ophthalmic Research in Commemoration of Santen
   Pharmaceutical's Founder(to K.I.); Bayer Retina Award Foundation
   (toK.I.); ROHTO Award(to K.I.); Nidek Co. Ltd (toM.A.) and Hoya Co. Ltd,
   Santen Pharmaceutical Co. Ltd (K.H.S.).
CR Al-Zamil WM, 2017, CLIN INTERV AGING, V12, P1313, DOI 10.2147/CIA.S143508
   Arakawa S, 2011, NAT GENET, V43, P1001, DOI 10.1038/ng.938
   Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bujarborua D, 2001, ACTA OPHTHALMOL SCAN, V79, P417, DOI 10.1034/j.1600-0420.2001.079004417.x
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Chappelow AV, 2000, ARCH OPHTHALMOL-CHIC, V118, P1211
   Daruich A, 2015, PROG RETIN EYE RES, V48, P82, DOI 10.1016/j.preteyeres.2015.05.003
   Falschlehner C, 2007, INT J BIOCHEM CELL B, V39, P1462, DOI 10.1016/j.biocel.2007.02.007
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Gao QY, 2009, MOL VIS, V15, P2683
   Gemenetzi M, 2010, EYE, V24, P1743, DOI 10.1038/eye.2010.130
   Gerth C, 2009, DOC OPHTHALMOL, V118, P63, DOI 10.1007/s10633-008-9133-x
   Haller JA, 2013, OPHTHALMOLOGY, V120, pS3, DOI 10.1016/j.ophtha.2013.01.057
   Hamada M, 2006, APOPTOSIS, V11, P47, DOI 10.1007/s10495-005-3348-z
   Handa JT, 2012, MOL ASPECTS MED, V33, P418, DOI 10.1016/j.mam.2012.03.006
   Hanus J, 2015, AGEING RES REV, V24, P286, DOI 10.1016/j.arr.2015.09.002
   Harris MS, 1996, CURR EYE RES, V15, P255, DOI 10.3109/02713689609007619
   Hosoda Y, 2019, COMMUN BIOL, V2, DOI 10.1038/s42003-019-0712-z
   Kaarniranta K, 2013, AUTOPHAGY, V9, P973, DOI 10.4161/auto.24546
   Kitzmann AS, 2008, OPHTHALMOLOGY, V115, P169, DOI [10.1016/j.ophtha.2007.02.032, 10.1016/j.ophtha.2008.01.009]
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lu L, 2006, J CELL PHYSIOL, V206, P119, DOI 10.1002/jcp.20439
   MARMOR MF, 1994, ARCH OPHTHALMOL-CHIC, V112, P830, DOI 10.1001/archopht.1994.01090180130047
   Nicholson B, 2013, SURV OPHTHALMOL, V58, P103, DOI 10.1016/j.survophthal.2012.07.004
   Notomi S, 2019, P NATL ACAD SCI USA, V116, P23724, DOI 10.1073/pnas.1906643116
   Nowak JZ, 2013, PHARMACOL REP, V65, P288, DOI 10.1016/S1734-1140(13)71005-3
   Orozco LD, 2020, CELL REP, V30, P1246, DOI 10.1016/j.celrep.2019.12.082
   Rickman CB, 2013, INVEST OPHTH VIS SCI, V54, pORSF68, DOI 10.1167/iovs.13-12757
   Semeraro F, 2013, DRUG DES DEV THER, V7, P711, DOI 10.2147/DDDT.S40215
   Tokarz P, 2013, BIOGERONTOLOGY, V14, P461, DOI 10.1007/s10522-013-9463-2
   Totsuka K, 2019, EXP EYE RES, V181, P316, DOI 10.1016/j.exer.2018.08.019
   Trauzold A, 2001, ONCOGENE, V20, P4258, DOI 10.1038/sj.onc.1204559
   van Rijssen TJ, 2019, PROG RETIN EYE RES, V73, DOI 10.1016/j.preteyeres.2019.07.003
   van Roosmalen IAM, 2014, BIOCHEM PHARMACOL, V91, P447, DOI 10.1016/j.bcp.2014.08.010
   Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517
   Wood JPM, 1997, NEUROCHEM INT, V31, P261, DOI 10.1016/S0197-0186(96)00157-X
   Wu GS, 1999, CANCER RES, V59, P2770
   Yamashiro K, 2020, JPN J OPHTHALMOL, V64, P555, DOI 10.1007/s10384-020-00773-w
   Yanagi Y, 2020, JPN J OPHTHALMOL, V64, P323, DOI 10.1007/s10384-020-00740-5
   Yang P, 2014, INVEST OPHTH VIS SCI, V55, P3012, DOI 10.1167/iovs.13-13554
NR 42
TC 2
Z9 2
U1 1
U2 1
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 1460-2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD JUL 7
PY 2022
VL 31
IS 13
BP 2194
EP 2206
DI 10.1093/hmg/ddac020
EA FEB 2022
PG 13
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 2X9HJ
UT WOS:000759041300001
PM 35103281
DA 2022-11-30
ER

PT J
AU Goh, KL
   Chen, FK
   Balaratnasingam, C
   Abbott, CJ
   Hodgson, LAB
   Guymer, RH
   Wu, ZC
AF Goh, Kai Lyn
   Chen, Fred K.
   Balaratnasingam, Chandrakumar
   Abbott, Carla J.
   Hodgson, Lauren A. B.
   Guymer, Robyn H.
   Wu, Zhichao
TI Cuticular Drusen in Age-Related Macular Degeneration Association with
   Progression and Impact on Visual Sensitivity
SO OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Basal laminar drusen; Cuticular
   drusen; Geographic atrophy; Microperimetry; OCT; Prognosis; Progression;
   Risk factors; Visual sensitivity
ID OPTICAL COHERENCE TOMOGRAPHY; RETICULAR PSEUDODRUSEN;
   GEOGRAPHIC-ATROPHY; RISK-FACTOR
AB Purpose: To determine the prognostic significance and impact on visual function of the cuticular drusen phenotype in a cohort with intermediate age-related macular degeneration (AMD).
   Design: Longitudinal, observational study.
   Participants: Participants aged 50 years or older, with bilateral large conventional drusen, without late AMD.
   Methods: Multimodal imaging (MMI) and microperimetry were performed at baseline and then every 6 months for up to 3 years. Eyes were graded for the MMI-based presence of cuticular drusen at baseline. Color fundus photographs were used to grade for the presence of pigmentary abnormalities. OCT scans were used to calculate drusen volume. The associations between cuticular drusen and progression to MMI-defined late AMD (including OCT signs of atrophy) and the impact on visual sensitivity were examined with and without adjustment for the confounders of baseline age, pigmentary abnormalities, and drusen volume.
   Main Outcome Measures: Time to develop MMI-defined late AMD and change in mean visual sensitivity.
   Results: A total of 280 eyes from 140 participants were included, with 70 eyes from 35 individuals (25%) having cuticular drusen at baseline. Cuticular drusen were not significantly associated with an increased rate of progression to late AMD with and without adjustment for confounders (P >= 0.784 for both). In an adjusted model, cuticular drusen were not associated with lower baseline visual sensitivity (P = 0.758) or a faster rate of visual sensitivity decline (P = 0.196).
   Conclusions: In a cohort with bilateral large conventional drusen, individuals with the cuticular drusen phenotype had neither a higher nor lower risk of developing late AMD over 3 years and were not associated with a difference in rate of visual sensitivity decline compared with those without this phenotype. As such, individuals with this phenotype currently warrant similar monitoring strategies as those with conventional drusen. (C) 2022 by the American Academy of Ophthalmology
C1 [Goh, Kai Lyn; Abbott, Carla J.; Hodgson, Lauren A. B.; Guymer, Robyn H.; Wu, Zhichao] Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, East Melbourne, Australia.
   [Goh, Kai Lyn; Abbott, Carla J.; Guymer, Robyn H.; Wu, Zhichao] Univ Melbourne, Dept Surg Ophthalmol, Melbourne, Vic, Australia.
   [Chen, Fred K.; Balaratnasingam, Chandrakumar] Univ Western Australia, Incorporating Lions Eye Inst, Ctr Ophthalmol & Visual Sci, Perth, WA, Australia.
   [Chen, Fred K.] Royal Perth Hosp, Dept Ophthalmol, Perth, WA, Australia.
   [Balaratnasingam, Chandrakumar] Sir Charles Gairdner Hosp, Dept Ophthalmol, Nedlands, WA, Australia.
C3 Centre for Eye Research Australia; Royal Victorian Eye & Ear Hospital;
   University of Melbourne; Lions Eye Institute; University of Western
   Australia; Royal Perth Hospital; University of Western Australia;
   University of Western Australia
RP Wu, ZC (通讯作者)，Ctr Eye Res Australia, Level 7,32 Gisbome St, East Melbourne, Vic 3002, Australia.
EM wu.z@unimelb.edu.au
OI Goh, Kai Lyn/0000-0003-2828-8723; Chen, Fred/0000-0003-2809-9930
FU National Health & Medical Research Council of Australia [APP1027624,
   MRF1142962, GNT1103013, 2008382]; Macular Disease Foundation Australia;
   BrightFocus Foundation [M2019073]
FX This study was supported by National Health & Medical Research Council
   of Australia (project grant no.: APP1027624 [to R.H.G.], and fellowship
   grant no.: MRF1142962 [to F.K.C.], GNT1103013 [to R.H.G.], #2008382 [to
   Z.W.]), and grants from the Macular Disease Foundation Australia (to
   Z.W. and R.H.G.) and the BrightFocus Foundation (grant no.: M2019073 [to
   Z.W.]). CERA receives operational infrastructure support from the
   Victorian Government. The sponsor or funding organization had no role in
   the design or conduct of this research.
CR ARNOLD JJ, 1995, RETINA-J RET VIT DIS, V15, P183, DOI 10.1097/00006982-199515030-00001
   Balaratnasingam C, 2018, OPHTHALMOLOGY, V125, P100, DOI 10.1016/j.ophtha.2017.08.033
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Boon CJE, 2008, AM J HUM GENET, V82, P516, DOI 10.1016/j.ajhg.2007.11.007
   Boon CJF, 2013, PROG RETIN EYE RES, V37, P90, DOI 10.1016/j.preteyeres.2013.08.003
   COHEN Y, 1994, BRIT J OPHTHALMOL, V78, P437
   Drexler W, 2001, NAT MED, V7, P502, DOI 10.1038/86589
   Duvvari MR, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152047
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Finger RP, 2014, OPHTHALMOLOGY, V121, P1252, DOI 10.1016/j.ophtha.2013.12.034
   Finger RP, 2010, RETINA-J RET VIT DIS, V30, P1455, DOI 10.1097/IAE.0b013e3181e09829
   GASS JDM, 1985, AM J OPHTHALMOL, V99, P445
   Gass JDM., 1977, STEREOSCOPIC ATLAS M, V5th
   Gregori G, 2011, OPHTHALMOLOGY, V118, P1373, DOI 10.1016/j.ophtha.2010.11.013
   Guigui B, 2011, BRIT J OPHTHALMOL, V95, P238, DOI 10.1136/bjo.2009.178400
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P829, DOI 10.1016/j.ophtha.2018.09.015
   Guymer RH, 2018, OPHTHALMOLOGY, V125, P6, DOI 10.1016/j.ophtha.2017.09.007
   Hoeg TB, 2016, BRIT J OPHTHALMOL, V100, P378, DOI 10.1136/bjophthalmol-2015-307197
   Jaffe GJ, 2021, OPHTHALMOL RETINA, V5, P855, DOI 10.1016/j.oret.2020.12.009
   Khanifar AA, 2008, OPHTHALMOLOGY, V115, P1883, DOI 10.1016/j.ophtha.2008.04.041
   Lek JJ, 2017, OPHTHALMOL RETINA, V1, P227, DOI 10.1016/j.oret.2016.12.001
   Meyerle CB, 2007, RETINA-J RET VIT DIS, V27, P1101, DOI 10.1097/IAE.0b013e3181451617
   Muller H, 2013, A VONGRAEFES ARCH OP, V2, P1
   Nathoo NA, 2014, AM J OPHTHALMOL, V158, P757, DOI 10.1016/j.ajo.2014.06.021
   Pfau M, 2018, EYE, V32, P1819, DOI 10.1038/s41433-018-0183-3
   Russell SR, 2004, AM J OPHTHALMOL, V137, P924, DOI 10.1016/j.ajo.2003.12.043
   Russell SR, 2000, AM J OPHTHALMOL, V129, P205, DOI 10.1016/S0002-9394(99)00345-1
   Sakurada Y, 2020, RETINA-J RET VIT DIS, V40, P257, DOI 10.1097/IAE.0000000000002399
   SARKS JP, 1994, EYE, V8, P269, DOI 10.1038/eye.1994.57
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P2203, DOI 10.1016/j.ophtha.2011.04.029
   Spaide RF, 2018, RETINA-J RET VIT DIS, V38, P708, DOI 10.1097/IAE.0000000000001689
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1441, DOI 10.1097/IAE.0b013e3181ee5ce8
   Wu ZC, 2022, PROG RETIN EYE RES, V88, DOI 10.1016/j.preteyeres.2021.101017
   Wu ZC, 2021, OPHTHALMOL RETINA, V5, P118, DOI 10.1016/j.oret.2020.06.026
   Wu ZC, 2021, BRIT J OPHTHALMOL, V105, P711, DOI 10.1136/bjophthalmol-2020-315935
   Wu ZC, 2020, OPHTHALMOL RETINA, V4, P568, DOI 10.1016/j.oret.2019.12.011
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P2415, DOI 10.1016/j.ophtha.2014.06.034
   Wu ZC, 2013, INVEST OPHTH VIS SCI, V54, P7378, DOI 10.1167/iovs.13-12617
   YANNUZZI LA, 1986, OPHTHALMOLOGY, V93, P611
   Zadeh SG, 2017, LECT NOTES COMPUT SC, V10553, P65, DOI 10.1007/978-3-319-67558-9_8
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 41
TC 3
Z9 3
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JUN
PY 2022
VL 129
IS 6
BP 653
EP 660
DI 10.1016/j.ophtha.2022.01.028
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 3E1OX
UT WOS:000829760600013
PM 35120992
OA Bronze
DA 2022-11-30
ER

PT J
AU Souied, EH
   Addou-Regnard, M
   Ohayon, A
   Semoun, O
   Querques, G
   Blanco-Garavito, R
   Bunod, R
   Jung, C
   Sikorav, A
   Miere, A
AF Souied, Eric H.
   Addou-Regnard, Manar
   Ohayon, Avi
   Semoun, Oudy
   Querques, Giuseppe
   Blanco-Garavito, Rocio
   Bunod, Roxane
   Jung, Camille
   Sikorav, Anne
   Miere, Alexandra
TI Spectral-Domain Optical Coherence Tomography Analysis of Fibrotic
   Lesions in Neovascular Age-Related Macular Degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID PIGMENT EPITHELIAL DETACHMENT; OCCULT CHOROIDAL NEOVASCULARIZATION;
   SUBRETINAL HYPERREFLECTIVE MATERIAL; VERTEPORFIN PHOTODYNAMIC THERAPY;
   GROWTH-FACTOR THERAPY; FLUORESCEIN ANGIOGRAPHY; NATURAL-HISTORY; BRUCHS
   MEMBRANE; RANIBIZUMAB; FIBROSIS
AB PURPOSE: To describe the spectral-domain optical coherence tomography (OCT) features of fibrotic lesions associated with neovascular age-related macular degeneration (nAMD) and to outline the progression pathways from initial macular choroidal neovascular lesions (CNVs) to fibrosis.
   METHODS: Patients with nAMD were retrospectively included when macular subretinal fibrosis was present. Fibrosis was categorized using spectral-domain OCT with respect to retinal pigment epithelium (RPE) in 836 spectral-domain OCT slices from 44 eyes of 39 patients. In addition, in 47 distinct eyes, 4181 spectral domain OCT slices were retrospectively reviewed to longitudinally assess progression from the initial lesion to the final fibrosis.
   RESULTS: Cross-sectional analysis classified fibrosis on spectral-domain OCT slices, as type A if located underneath the RPE, as type B if located above the RPE, and as type C if the remaining RPE was undistinguishable. The longitudinal analysis series revealed 3 progression pathways from the original CNV: 1) progression to type A, followed by RPE erosion and subretinal hyperreflective material, then type B and type C fibroglial lesion (FGL; 17/47 eyes); 2) progression to type B then type C FGL (17/47 eyes); and 3) persistence of type A with development of a flat, fibroatrophic lesion (13/47 eyes). Subretinal hyperreflective material, macular hemorrhage, or RPE tear occurred in 14 of 47, 13 of 47, and 10 of 47 eyes, respectively.
   CONCLUSION: This spectral-domain OCT analysis identified various patterns of macular fibrosis in eyes with nAMD. Three pathways of progression to fibrosis were described including the well-established pathway of type 2 CNV progression to FGL and the progression of type 1 fibrovascular CNV to FGL or fibroatrophic lesion. ((C) 2020 Elsevier Inc. All rights reserved.)
C1 [Souied, Eric H.; Addou-Regnard, Manar; Ohayon, Avi; Semoun, Oudy; Querques, Giuseppe; Blanco-Garavito, Rocio; Bunod, Roxane; Sikorav, Anne; Miere, Alexandra] Univ Paris Est Creteil, Ctr Hosp Intercommunal Creteil, Dept Ophthalmol, 40 Ave Verdun, F-94000 Creteil, France.
   [Souied, Eric H.; Jung, Camille; Miere, Alexandra] Ctr Hosp Intercommunal Creteil, GRC Macula, Clin Res Ctr, Creteil, France.
   [Souied, Eric H.; Jung, Camille; Miere, Alexandra] Ctr Hosp Intercommunal Creteil, Biol Ressources Ctr, Creteil, France.
C3 Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil;
   Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil;
   Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil
RP Souied, EH (通讯作者)，Univ Paris Est Creteil, Ctr Hosp Intercommunal Creteil, Dept Ophthalmol, 40 Ave Verdun, F-94000 Creteil, France.
EM eric.souied@chicreteil.fr
RI Miere, Alexandra/AIC-4074-2022; Ohayon, Avi/R-2676-2018
OI Miere, Alexandra/0000-0003-4123-8210; Ohayon, Avi/0000-0002-4435-8659;
   Querques, Giuseppe/0000-0002-3292-9581
CR Avery RL, 1996, RETINA-J RET VIT DIS, V16, P183, DOI 10.1097/00006982-199616030-00001
   Bastiaans J, 2014, INVEST OPHTH VIS SCI, V55, P4659, DOI 10.1167/iovs.14-14818
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bloch SB, 2013, AM J OPHTHALMOL, V156, P116, DOI 10.1016/j.ajo.2013.02.012
   Bloom SM, 2011, RETINA-J RET VIT DIS, V31, P316, DOI 10.1097/IAE.0b013e3181ed8c9a
   Boulanger-Scemama E, 2015, J FR OPHTALMOL, V38, P620, DOI 10.1016/j.jfo.2014.11.015
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Casalino G, 2016, INVEST OPHTH VIS SCI, V57, pOCT288, DOI 10.1167/iovs.15-18753
   Cheung CMG, 2013, AM J OPHTHALMOL, V155, P764, DOI 10.1016/j.ajo.2012.10.013
   Chong NHV, 2005, AM J PATHOL, V166, P241, DOI 10.1016/S0002-9440(10)62248-1
   CLEARY PE, 1979, AM J OPHTHALMOL, V88, P221, DOI 10.1016/0002-9394(79)90469-0
   Cohen SY, 2012, RETINA-J RET VIT DIS, V32, P1480, DOI 10.1097/IAE.0b013e318240a516
   Coscas F, 2007, AM J OPHTHALMOL, V144, P592, DOI 10.1016/j.ajo.2007.06.014
   Coscas F, 2012, RETINA-J RET VIT DIS, V32, P1069, DOI 10.1097/IAE.0b013e318240a529
   Daniel E, 2018, OPHTHALMOLOGY, V125, P1037, DOI 10.1016/j.ophtha.2018.01.004
   Daniel E, 2014, OPHTHALMOLOGY, V121, P656, DOI 10.1016/j.ophtha.2013.10.019
   Dansingani KK, 2018, CLIN EXP OPHTHALMOL, V46, P189, DOI 10.1111/ceo.13114
   Dansingani KK, 2016, AM J OPHTHALMOL, V169, P235, DOI 10.1016/j.ajo.2016.06.031
   de Boer JF, 2003, OPT LETT, V28, P2067, DOI 10.1364/OL.28.002067
   Dolz-Marco R, 2017, RETINA-J RET VIT DIS, V37, P222, DOI 10.1097/IAE.0000000000001279
   Giani A, 2011, INVEST OPHTH VIS SCI, V52, P5579, DOI 10.1167/iovs.10-6617
   Harrell CR, 2018, J BIOMED SCI, V25, DOI 10.1186/s12929-018-0423-7
   He YG, 2009, CURR EYE RES, V34, P957, DOI 10.3109/02713680903231135
   Heier JS, 2011, OPHTHALMOLOGY, V118, P1098, DOI 10.1016/j.ophtha.2011.03.020
   Hwang JC, 2011, OPHTHAL SURG LAS IM, V42, DOI 10.3928/15428877-20100924-01
   Jaffe GJ, 2017, OPHTHALMOLOGY, V124, P224, DOI 10.1016/j.ophtha.2016.10.010
   Jo YJ, 2011, INVEST OPHTH VIS SCI, V52, P6089, DOI 10.1167/iovs.10-5189
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Kaiser PK, 2007, OPHTHALMOLOGY, V114, P1868, DOI 10.1016/j.ophtha.2007.04.030
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Kawashima Y, 2017, AM J OPHTHALMOL, V181, P61, DOI 10.1016/j.ajo.2017.06.015
   Keane PA, 2008, INVEST OPHTH VIS SCI, V49, P3115, DOI 10.1167/iovs.08-1689
   Keane PA, 2012, SURV OPHTHALMOL, V57, P389, DOI 10.1016/j.survophthal.2012.01.006
   Kimura K, 2015, J MOL MED, V93, P749, DOI 10.1007/s00109-015-1289-8
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Kuiper EJ, 2006, ARCH OPHTHALMOL-CHIC, V124, P1457, DOI 10.1001/archopht.124.10.1457
   Kuiper EJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002675
   Mehta H, 2018, PROG RETIN EYE RES, V65, P127, DOI 10.1016/j.preteyeres.2017.12.002
   Miere A, 2015, RETINA-J RET VIT DIS, V35, P2275, DOI 10.1097/IAE.0000000000000819
   Mrejen S, 2013, RETINA-J RET VIT DIS, V33, P1735, DOI 10.1097/IAE.0b013e3182993f66
   Mukai R, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-159
   Ores R, 2014, AM J OPHTHALMOL, V158, P354, DOI 10.1016/j.ajo.2014.04.025
   Pedrosa AC, 2017, J OPHTHALMOL, V2017, DOI 10.1155/2017/4263017
   Pokroy R, 2018, RETINA-J RET VIT DIS, V38, P1485, DOI 10.1097/IAE.0000000000001748
   Querques G, 2016, INVEST OPHTH VIS SCI, V57, P2578, DOI 10.1167/iovs.16-19083
   Rahimy E, 2014, RETINA-J RET VIT DIS, V34, P1289, DOI 10.1097/IAE.0000000000000130
   Roberts P, 2016, INVEST OPHTH VIS SCI, V57, P1699, DOI 10.1167/iovs.15-18694
   Rogers AH, 2002, AM J OPHTHALMOL, V134, P566, DOI 10.1016/S0002-9394(02)01566-0
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   Sarraf David, 2014, Trans Am Ophthalmol Soc, V112, P142
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Scupola A, 1999, OPHTHALMOLOGICA, V213, P97, DOI 10.1159/000027400
   Shah VP, 2014, RETINA-J RET VIT DIS, V34, P1281, DOI 10.1097/IAE.0000000000000166
   Stevens TS, 1997, ARCH OPHTHALMOL-CHIC, V115, P345, DOI 10.1001/archopht.1997.01100150347006
   Su D, 2016, RETINA-J RET VIT DIS, V36, pS40, DOI 10.1097/IAE.0000000000001268
   Tan ACS, 2016, OPHTHALMOLOGICA, V236, P8, DOI 10.1159/000446857
   Toth LA, 2015, RETINA-J RET VIT DIS, V35, P1957, DOI 10.1097/IAE.0000000000000583
   Unver Y, 2008, EYE LOND, V23, P453
   Willoughby AS, 2015, OPHTHALMOLOGY, V122, P1846, DOI 10.1016/j.ophtha.2015.05.042
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yang SQ, 2016, DRUG DES DEV THER, V10, P1857, DOI 10.2147/DDDT.S97653
   Zayit-Soudry S, 2007, SURV OPHTHALMOL, V52, P227, DOI 10.1016/j.survophthal.2007.02.008
NR 65
TC 8
Z9 8
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JUN
PY 2020
VL 214
BP 151
EP 171
DI 10.1016/j.ajo.2020.02.016
PG 21
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA LW7UK
UT WOS:000539348900018
PM 32112774
DA 2022-11-30
ER

PT J
AU Choi, S
   Jahng, WJ
   Park, SM
   Jee, D
AF Choi, Seulggie
   Jahng, Wan Jin
   Park, Sang Min
   Jee, Donghyun
TI Association of Age-Related Macular Degeneration on Alzheimer or
   Parkinson Disease: A Retrospective Cohort Study
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID GLOBAL BURDEN; RISK; PREVALENCE; DEMENTIA; LAYER
AB PURPOSE: To determine the association of age-related macular degeneration (AMD) with Alzheimer disease (AD) and Parkinson disease (PD).
   DESIGN: Retrospective cohort study.
   METHODS: The study population consisted of 308,340 participants aged 50 years or older from the Korean National Health Insurance Service Health Screening Cohort. After exclusion of participants with AMD during 2002, participants were detected for AMD during 2003-2005. Starting from January 1, 2006, all participants were followed up for AD and PD until December 31, 2013. Multivariate Cox proportional hazards regression was used to calculate the adjusted hazard ratios (aHRs) and 95% confidence intervals (CIs) for AD and PD risk.
   RESULTS: Compared to non-AMD participants, AMD patients had higher risk for AD (aHR 1.48, 95% CI 1.25-1.74) and PD (aHR 1.46, 95% CI 1.14-1.88). The risk-increasing association of AMD with AD (aHR 2.25, 95% CI 1.39-3.66) and PD (aHR 2.02, 95% CI 1.00-4.08) were preserved among participants who were never-smokers, did not consume alcohol, and exercised regularly. Finally, AMD was associated with higher risk of AD (aHR 1.96, 95% CI 1.46-2.65 for age < 70 years and aHR 1.53, 95% CI 1.26-1.86 for age >= 70 years) and PD (aHR 1.90, 95% CI 1.29-2.80 for age < 70 years and aHR 1.47, 95% CI 1.06-2.04 for age >= 70 years) according to subgroups divided by age.
   CONCLUSIONS: Compared to non-AMD participants, AMD patients had higher risk for AD and PD even among those with healthy lifestyle behaviors. Patients with AMD must be closely monitored for possible subsequent development of AD or PD. ((C) 2019 Elsevier Inc. All rights reserved.)
C1 [Choi, Seulggie; Park, Sang Min] Seoul Natl Univ, Dept Biomed Sci, Grad Sch, Seoul, South Korea.
   [Jahng, Wan Jin] Amer Univ Nigeria, Dept Petr Chem, Yola, Nigeria.
   [Park, Sang Min] Seoul Natl Univ Hosp, Dept Family Med, Seoul, South Korea.
   [Jee, Donghyun] Catholic Univ Korea, St Vincents Hosp, Dept Ophthalmol, 93 Jungbu Daero, Suwon, South Korea.
C3 Seoul National University (SNU); American University of Nigeria; Seoul
   National University (SNU); Seoul National University Hospital; Catholic
   University of Korea
RP Jee, D (通讯作者)，Catholic Univ Korea, St Vincents Hosp, Dept Ophthalmol, 93 Jungbu Daero, Suwon, South Korea.; Park, SM (通讯作者)，Seoul Natl Univ Hosp, Dept Biomed Sci & Family Med, 101 Daehak Ro, Seoul, South Korea.
EM smpark.snuh@gmail.com; doj087@mail.harvard.edu
RI Jahng, Wan Jin/C-1236-2018
OI Jahng, Wan Jin/0000-0001-8241-7739; Park, Sang Min/0000-0002-7498-4829
FU DATA SCIENCE RESEARCH PROJECT 2018 BY SEOUL NATIONAL UNIversity Big Data
   Institute [2018-0000]; Basic Science Research Program through the
   National Research Foundation of Korea - Ministry of Education
   [2016R1A6A1A03010528]; Brain Korea 21 -Plus Education Program by the
   National Research Foundation of Korea
FX THIS STUDY WAS SUPPORTED BY THE DATA SCIENCE RESEARCH PROJECT 2018 BY
   SEOUL NATIONAL UNIversity Big Data Institute (grant number: 2018-0000)
   and Basic Science Research Program through the National Research
   Foundation of Korea, funded by the Ministry of Education (grant number:
   2016R1A6A1A03010528). S. Choi received support from the Brain Korea 21
   -Plus Education Program by the National Research Foundation of Korea.
CR Adams MKM, 2012, AM J EPIDEMIOL, V176, P289, DOI 10.1093/aje/kws004
   Al-Salem Khalil M, 2014, Retina, V34, P868, DOI 10.1097/IAE.0000000000000006
   Bae JB, 2015, DEMENT GERIATR COGN, V39, P105, DOI 10.1159/000366555
   Bettiol SS, 2015, J PARKINSON DIS, V5, P425, DOI 10.3233/JPD-150533
   Brookmeyer R, 2007, ALZHEIMERS DEMENT, V3, P186, DOI 10.1016/j.jalz.2007.04.381
   Bruban J, 2009, AGING CELL, V8, P162, DOI 10.1111/j.1474-9726.2009.00456.x
   Butterfield DA, 2004, BRAIN PATHOL, V14, P426
   Choi D, 2018, ANN CLIN TRANSL NEUR, V5, P1192, DOI 10.1002/acn3.633
   Chung SD, 2014, AM J OPHTHALMOL, V157, P464, DOI 10.1016/j.ajo.2013.09.026
   Elbaz A, 2002, J CLIN EPIDEMIOL, V55, P25, DOI 10.1016/S0895-4356(01)00425-5
   Etminan M, 2018, J CURR OPHTHALMOL, V30, P365, DOI 10.1016/j.joco.2018.08.004
   Garcia-Martin E, 2014, AM J OPHTHALMOL, V157, P470, DOI 10.1016/j.ajo.2013.09.028
   Hirtz D, 2007, NEUROLOGY, V68, P326, DOI 10.1212/01.wnl.0000252807.38124.a3
   Jeong SM, 2017, ALZHEIMERS RES THER, V9, DOI 10.1186/s13195-017-0322-2
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Kim K, 2018, EUR HEART J, V39, P1523, DOI 10.1093/eurheartj/ehx761
   Lee CS, 2019, ALZHEIMERS DEMENT, V15, P34, DOI 10.1016/j.jalz.2018.06.2856
   Lee EK, 2015, INVEST OPHTH VIS SCI, V56, P3976, DOI 10.1167/iovs.15-17013
   Lee SH, 2018, J CLIN NEUROL, V14, P478, DOI 10.3988/jcn.2018.14.4.478
   Moon JY, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-29557-6
   Ngandu T, 2015, LANCET, V385, P2255, DOI 10.1016/S0140-6736(15)60461-5
   Romano GL, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00168
   Romano GL, 2015, PROG BRAIN RES, V220, P217, DOI 10.1016/bs.pbr.2015.04.013
   Rozzini L, 2014, AM J ALZHEIMERS DIS, V29, P256, DOI 10.1177/1533317513517032
   Rudnicka AR, 2015, AM J OPHTHALMOL, V160, P85, DOI 10.1016/j.ajo.2015.04.003
   Seong SC, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-016640
   Seong SC, 2017, INT J EPIDEMIOL, V46, P799, DOI 10.1093/ije/dyw253
   Song F, 2009, BRAIN RES REV, V61, P69, DOI 10.1016/j.brainresrev.2009.05.003
   Tsai DC, 2015, OPHTHALMOLOGY, V122, P2327, DOI 10.1016/j.ophtha.2015.07.033
   Tysnes OB, 2017, J NEURAL TRANSM, V124, P901, DOI 10.1007/s00702-017-1686-y
   Velilla S, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/895147
   Vos T, 2015, LANCET, V386, P743, DOI 10.1016/S0140-6736(15)60692-4
   Zetterberg M, 2008, AM J MED GENET B, V147B, P720, DOI 10.1002/ajmg.b.30668
NR 33
TC 21
Z9 21
U1 0
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD FEB
PY 2020
VL 210
BP 41
EP 47
DI 10.1016/j.ajo.2019.11.001
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA KJ7CQ
UT WOS:000512216200007
PM 31712068
DA 2022-11-30
ER

PT J
AU Lee, EK
   Lee, SY
   Yu, HG
AF Lee, Eun Kyoung
   Lee, Sang-Yoon
   Yu, Hyeong Gon
TI EPIRETINAL MEMBRANE IN NONEXUDATIVE AGE-RELATED MACULAR DEGENERATION
   Anatomical Features, Visual Outcomes and Prognostic Factors
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; epiretinal membrane; spectral-domain
   optical coherence tomography; visual outcomes; vitrectomy
ID OPTICAL COHERENCE TOMOGRAPHY; ASSOCIATIONS; PREVALENCE; VITRECTOMY
AB Purpose: To evaluate clinical characteristics, assess surgical outcomes, and determine prognostic factors after vitrectomy for epiretinal membrane (ERM) associated with nonexudative age-related macular degeneration (AMD).
   Methods: This study comprised 171 consecutive patients with idiopathic ERM (n = 132) or nonexudative AMD-associated ERM (AMD-ERM, n = 39) undergoing vitrectomy. Preoperative morphologic characteristics on spectral-domain optical coherence tomography images and postoperative outcomes of the two groups were compared. Factors influencing postoperative best-corrected visual acuity in the AMD-ERM group were also analyzed.
   Results: The AMD-ERM group was more likely to have an ERM with a smooth appearance (P = 0.009), a less severe vessel traction score (P = 0.002), a thinner central foveal thickness (P = 0.016), and more photoreceptor disruption than idiopathic ERM group. Mean central foveal thickness improved from 404.92 +/- 82.08 and 369.87 +/- 68.17 mm at baseline to 339.77 +/- 39.27 and 331.72 +/- 45.76 mm 1 year after surgery in eyes with idiopathic ERM and AMD-ERM, respectively (all P < 0.001). Mean logarithm of the minimum angle of resolution best-corrected visual acuity improved from 0.30 (20/40) +/- 0.21 and 0.32 (20/42) +/- 0.18 at baseline to 0.02 (20/21) +/- 0.09 and 0.13 (20/27) +/- 0.17 1 year after surgery in the idiopathic ERM and AMD-ERM groups, respectively (all P < 0.001). Baseline integrity of the ellipsoid zone line (P = 0.009) and preoperative best-corrected visual acuity (P = 0.024) were significantly correlated with visual outcome in the AMD-ERM group.
   Conclusion: Morphologic differences between AMD-ERM and idiopathic ERM were identified. Vitrectomy resulted in significant anatomical and visual improvements in eyes with AMD-ERM, but final visual outcome was worse in these eyes than in those with idiopathic ERM.
C1 [Lee, Eun Kyoung; Lee, Sang-Yoon; Yu, Hyeong Gon] Seoul Natl Univ, Coll Med, Seoul Natl Univ Hosp, Dept Ophthalmol, Seoul, South Korea.
C3 Seoul National University (SNU); Seoul National University Hospital
RP Yu, HG (通讯作者)，Seoul Natl Univ Hosp, Dept Ophthalmol, 101 Daehak Ro, Seoul 110744, South Korea.
EM hgonyu@snu.ac.kr
FU SNUH Research Fund [03-2012-0250]
FX This research was supported by the SNUH Research Fund (03-2012-0250).
CR Fraser-Bell S, 2004, INVEST OPHTH VIS SCI, V45, P1732, DOI 10.1167/iovs.03-1295
   Gregori G, 2011, OPHTHALMOLOGY, V118, P1373, DOI 10.1016/j.ophtha.2010.11.013
   Inoue M, 2011, RETINA-J RET VIT DIS, V31, P1366, DOI 10.1097/IAE.0b013e318203c156
   Itoh Y, 2013, INVEST OPHTH VIS SCI, V54, P7302, DOI 10.1167/iovs.13-12702
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kim JS, 2012, AM J OPHTHALMOL, V153, P692, DOI 10.1016/j.ajo.2011.08.042
   Lee EK, 2014, OPHTHALMOLOGY, V121, P1579, DOI 10.1016/j.ophtha.2014.02.010
   Leuschen JN, 2013, OPHTHALMOLOGY, V120, P140, DOI 10.1016/j.ophtha.2012.07.004
   McCarty DJ, 2005, AM J OPHTHALMOL, V140, P288, DOI 10.1016/j.ajo.2005.03.032
   MEYERS SM, 1982, AM J OPHTHALMOL, V94, P26, DOI 10.1016/0002-9394(82)90186-6
   Mitchell P, 1997, OPHTHALMOLOGY, V104, P1033, DOI 10.1016/S0161-6420(97)30190-0
   Nathoo NA, 2014, AM J OPHTHALMOL, V158, P757, DOI 10.1016/j.ajo.2014.06.021
   PODGOR MJ, 1983, AM J EPIDEMIOL, V118, P206, DOI 10.1093/oxfordjournals.aje.a113628
   RICE TA, 1986, OPHTHALMOLOGY, V93, P602
   Rothman AL, 2014, RETINA-J RET VIT DIS, V34, P1323, DOI 10.1097/IAE.0000000000000113
   Shimozono M, 2012, AM J OPHTHALMOL, V153, P698, DOI 10.1016/j.ajo.2011.09.011
   Shiono A, 2013, OPHTHALMOLOGY, V120, P788, DOI 10.1016/j.ophtha.2012.09.044
   Suh MH, 2009, AM J OPHTHALMOL, V147, P473, DOI 10.1016/j.ajo.2008.09.020
   Watanabe K, 2013, JAMA OPHTHALMOL, V131, P172, DOI 10.1001/jamaophthalmol.2013.686
   WISE GN, 1975, AM J OPHTHALMOL, V79, P349, DOI 10.1016/0002-9394(75)90605-4
NR 20
TC 4
Z9 4
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD AUG
PY 2016
VL 36
IS 8
BP 1557
EP 1565
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DS7MI
UT WOS:000380967200035
PM 27456023
DA 2022-11-30
ER

PT J
AU Fritsche, LG
   Freita-Wolf, S
   Bettecken, T
   Meitinger, T
   Keilhauer, CN
   Krawczak, M
   Weber, BHF
AF Fritsche, Lars G.
   Freita-Wolf, Sandra
   Bettecken, Thomas
   Meitinger, Thomas
   Keilhauer, Claudia N.
   Krawczak, Michael
   Weber, Bernhard H. F.
TI Age-Related Macular Degeneration and Functional Promoter and Coding
   Variants of the Apolipoprotein E Gene
SO HUMAN MUTATION
LA English
DT Article
DE age-related macular degeneration; AMD; apolipoprotein E; APOE; epsilon
   isoforms; promoter variants; case-control association study
ID COMPLEMENT FACTOR-H; DEVELOPING ALZHEIMERS-DISEASE; APOE GENE;
   REGULATORY REGION; LINKAGE DISEQUILIBRIUM; EPSILON-4 ALLELE; E
   POLYMORPHISMS; FACTOR-B; RISK; ASSOCIATION
AB Age-related macular degeneration (AMD) is a frequent, multifactorial disease of the central retina and a major cause of irreversible vision loss in industrialized countries. Apolipoprotein E (APOE) has been consistently associated with AMD, particularly its two functional isoforms E2 (predisposing) and E4 (protective). The biological correlate of this association, however, is still unclear. In this study, we have defined an extended haplotype block encompassing the entire APOE gene locus, including known coding as well as cis-regulatory promoter variants. Of the five extended APOE haplotypes common in the general population, two were found to be significantly associated with AMD, namely G-G-G-G-epsilon 2 (odds ratio [OR], 1.59; 95% confidence interval [CI], 1.19-2.12) and T-G-A-G-epsilon 4 (OR, 0.76; 95% CI, 0.58-0.99). When analyzing common extended haplotype combinations, T-C-G-G-epsilon 3/T-G-A-G-epsilon 4 exhibited the most prominent effect (OR, 0.32; 95% CI, 0.20-0.51). Intriguingly, we also found one extended epsilon 3-haplotype, G-G-G-A-epsilon 3 to be protective in the homozygous state (OR, 0.65; 95% CI, 0.49-0.87). Since single nucleotide polymorphism (SNT) rs405509:G > T is a constituent of the extended epsilon-haplotype block and is known to significantly influence APOE promoter activity, we hypothesize that both the relative rate of APOE isoform. expression in conjunction with established functional differences of the respective isoforms may be crucial in mediating AMD pathology. This would also imply that genotyping of the core epsilon-haplotypes alone is not sufficient to estimate AMD risk, but that determination of extended haplotype combinations, including the functional promoter SNP rs405509, is required instead. Hum Mutat 30:1048-1053, 2009. (C) 2008 Wiley-Liss, Inc.
C1 [Fritsche, Lars G.; Weber, Bernhard H. F.] Univ Regensburg, Inst Human Genet, D-93053 Regensburg, Germany.
   [Freita-Wolf, Sandra; Krawczak, Michael] Univ Kiel, Univ Hosp Schleswig Holstein, Inst Med Informat & Stat, Kiel, Germany.
   [Bettecken, Thomas] Max Planck Inst Psychiat, D-80804 Munich, Germany.
   [Meitinger, Thomas] German Res Ctr Environm Hlth, Helmholtz Zentrum Munchen, Inst Human Genet, Neuherberg, Germany.
   [Meitinger, Thomas] Tech Univ Munich, Klinikum Rechts Isar, Inst Human Genet, D-80804 Munich, Germany.
   [Keilhauer, Claudia N.] Univ Wurzburg, Dept Ophthalmol, Wurzburg, Germany.
C3 University of Regensburg; University of Kiel; Schleswig Holstein
   University Hospital; Max Planck Society; Helmholtz Association;
   Helmholtz-Center Munich - German Research Center for Environmental
   Health; Technical University of Munich; University of Wurzburg
RP Weber, BHF (通讯作者)，Univ Regensburg, Inst Human Genet, Franz Josef Str Allee 11, D-93053 Regensburg, Germany.
EM bweb@klinik.uni-regensburg.de
RI Krawczak, Michael/A-8964-2010; Meitinger, Thomas/O-1318-2015; Fritsche,
   Lars G/AAF-9387-2019
OI Krawczak, Michael/0000-0003-2603-1502; Fritsche, Lars
   G/0000-0002-2110-1690; Meitinger, Thomas/0000-0002-8838-8403; Weber,
   Bernhard H.F./0000-0002-8808-7723
FU Deutsche Forschungsgemeinschaft [We 1259/14-3, We 1259/18-1]; Alcon
   Research Institute; Ruth and Milton Steinbach Foundation New York
FX We are grateful to the patients and control subjects for their
   participation in this study. We thank Andrea Rivera (Institute of Human
   Genetics, Regensburg, Germany) for excellent technical support and
   Jurgen Kaschkoto (Institute of Human Genetics, Regensburg, Germany) for
   help with database management. This work was supported in parts by
   grants of the Deutsche Forschungsgemeinschaft (We 1259/14-3 and We
   1259/18-1), the Alcon Research Institute, and the Ruth and Milton
   Steinbach Foundation New York.
CR Artiga MJ, 1998, HUM MOL GENET, V7, P1887, DOI 10.1093/hmg/7.12.1887
   Artiga MJ, 1998, FEBS LETT, V421, P105, DOI 10.1016/S0014-5793(97)01543-3
   Baird PN, 2006, HUM MUTAT, V27, P337, DOI 10.1002/humu.20288
   Baird PN, 2004, INVEST OPHTH VIS SCI, V45, P1311, DOI 10.1167/iovs.03-1121
   Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   Becker T, 2004, GENET EPIDEMIOL, V27, P21, DOI 10.1002/gepi.10323
   Belbin O, 2007, HUM MOL GENET, V16, P2199, DOI 10.1093/hmg/ddm171
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Bojanowski CM, 2006, ENVIRON MOL MUTAGEN, V47, P594, DOI 10.1002/em.20233
   Bullido MJ, 1998, NAT GENET, V18, P69, DOI 10.1038/ng0198-69
   Campillos M, 2003, NUCLEIC ACIDS RES, V31, P3063, DOI 10.1093/nar/gkg435
   Canter JA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002091
   Chang SJ, 2005, P NATL ACAD SCI USA, V102, P18694, DOI 10.1073/pnas.0508254102
   DeAngelis MM, 2007, ARCH OPHTHALMOL-CHIC, V125, P49, DOI 10.1001/archopht.125.1.49
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Dudbridge F, 2003, GENET EPIDEMIOL, V25, P115, DOI 10.1002/gepi.10252
   DUDBRIDGE F, 2006, UNPHASED USER GUIDE, P1
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gotoh N, 2004, AM J OPHTHALMOL, V138, P567, DOI 10.1016/j.ajo.2004.05.025
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hui DY, 2004, REV ENDOCR METAB DIS, V5, P335, DOI 10.1023/B:REMD.0000045105.26290.2d
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Jakobsdottir J, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002199
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Lambert JC, 2000, HUM MOL GENET, V9, P57, DOI 10.1093/hmg/9.1.57
   Lambert JC, 1998, HUM MOL GENET, V7, P533, DOI 10.1093/hmg/7.3.533
   Lambert JC, 1998, HUM MOL GENET, V7, P1511, DOI 10.1093/hmg/7.9.1511
   Mahley RW, 2000, ANNU REV GENOM HUM G, V1, P507, DOI 10.1146/annurev.genom.1.1.507
   MAHLEY RW, 1984, J LIPID RES, V25, P1277
   MAHLEY RW, 1989, ARTERIOSCLER, V9, P114
   Malek G, 2005, P NATL ACAD SCI USA, V102, P11900, DOI 10.1073/pnas.0503015102
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Moreno JA, 2004, AM J CLIN NUTR, V80, P1404, DOI 10.1093/ajcn/80.5.1404
   Pang CP, 2000, OPHTHALMOLOGICA, V214, P289, DOI 10.1159/000027506
   Ramos MC, 2005, NEUROREPORT, V16, P1027, DOI 10.1097/00001756-200506210-00029
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Schmidt S, 2005, MOL VIS, V11, P941
   Schmidt S, 2000, MOL VIS, V6, P287
   Schmidt Silke, 2002, Ophthalmic Genet, V23, P209, DOI 10.1076/opge.23.4.209.13883
   Schultz DW, 2003, ARCH OPHTHALMOL-CHIC, V121, P679, DOI 10.1001/archopht.121.5.679
   SHIMANO H, 1992, J CLIN INVEST, V90, P2084, DOI 10.1172/JCI116091
   Simonelli F, 2001, OPHTHALMIC RES, V33, P325, DOI 10.1159/000055688
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   Spencer KL, 2007, HUM MOL GENET, V16, P1986, DOI 10.1093/hmg/ddm146
   Town T, 1998, NEUROSCI LETT, V252, P95, DOI 10.1016/S0304-3940(98)00567-9
   Winkelmann J, 2007, NAT GENET, V39, P1000, DOI 10.1038/ng2099
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yu CE, 2007, GENOMICS, V89, P655, DOI 10.1016/j.ygeno.2007.02.002
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zareparsi S, 2004, INVEST OPHTH VIS SCI, V45, P1306, DOI 10.1167/iovs.03-1253
NR 58
TC 29
Z9 29
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1059-7794
EI 1098-1004
J9 HUM MUTAT
JI Hum. Mutat.
PD JUL
PY 2009
VL 30
IS 7
BP 1048
EP 1053
DI 10.1002/humu.20957
PG 6
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 468CQ
UT WOS:000267791700004
PM 19384966
DA 2022-11-30
ER

PT J
AU Haines, JL
   Schnetz-Boutaud, N
   Schmidt, S
   Scott, WK
   Agarwal, A
   Postel, EA
   Olson, L
   Kenealy, SJ
   Hauser, M
   Gilbert, JR
   Pericak-Vance, MA
AF Haines, JL
   Schnetz-Boutaud, N
   Schmidt, S
   Scott, WK
   Agarwal, A
   Postel, EA
   Olson, L
   Kenealy, SJ
   Hauser, M
   Gilbert, JR
   Pericak-Vance, MA
TI Functional candidate genes in age-related macular degeneration:
   Significant association with VEGF, VLDLR, and LRP6
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID STARGARDT-DISEASE GENE; BEAVER DAM EYE; NONFAMILIAL JAPANESE PATIENTS;
   RECEPTOR-RELATED PROTEIN; FACTOR-H POLYMORPHISM; SUSCEPTIBILITY LOCI;
   APOLIPOPROTEIN-E; LINKAGE ANALYSIS; GENOMEWIDE-SCAN; FAMILIAL
   AGGREGATION
AB PURPOSE. Age-related macular degeneration (AMD) is a retinal degenerative disease that is the leading cause of blindness worldwide for individuals over the age of 60. Although the etiology of AMD remains largely unknown, numerous studies have suggested that both genes and environmental risk factors significantly influence the risk of developing AMD. Identification of the underlying genes has been difficult, with both genomic screen (locational) and candidate gene (functional) approaches being used. The present study tested candidate genes for association with AMD.
   METHODS. Eight genes (alpha-2-macroglobulin [A2M], creatine kinase [CKB], angiotensin-converting enzyme [DCP1], interleukin-1 alpha [IL1A], low-density lipoprotein receptor-related protein 6 [LRP6], microsomal glutathione-S-transferase 1 [MGST1], vascular entothelial growth factor [VEGF], and very low density lipoprotein receptor [VLDLR]) were tested for genetic linkage and allelic association, using two independent datasets: a family-based association dataset including 162 families and an independent case-control dataset with 399 cases and 159 fully evaluated controls.
   RESULTS. Test results suggested that genetic variation in five of these genes (IL1A, CKB, A2M, MGST1, and DCP1) is unlikely to explain a significant fraction of the risk of developing AMD in this population. LRP6 showed evidence both for linkage (heterogeneity lod [HLOD] = 1.14) in the family-based dataset and for association (P = 0.004) in the case-control dataset. VEGF showed evidence of linkage (HLOD = 1.32) and demonstrated significant independent allelic association in both the family-based (P = 0.001) and case-control (P = 0.02) datasets. VLDLR showed evidence of association in both the family based (P = 0.03) and case-control (P = 0.01) datasets.
   CONCLUSIONS. These data suggest that LRP6, VEGF, and VLDLR may play a role in the risk of developing AMD.
C1 Vanderbilt Univ, Med Ctr, Ctr Human Genet Res, Nashville, TN 37232 USA.
   Vanderbilt Univ, Med Ctr, Dept Ophthalmol & Visual Sci, Nashville, TN 37232 USA.
   Duke Univ, Med Ctr, Ctr Eye, Durham, NC 27710 USA.
   Duke Univ, Med Ctr, Ctr Human Genet, Durham, NC 27710 USA.
   Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA.
   Duke Univ, Med Ctr, Dept Ophthalmol, Durham, NC 27710 USA.
C3 Vanderbilt University; Vanderbilt University; Duke University; Duke
   University; Duke University; Duke University
RP Haines, JL (通讯作者)，Vanderbilt Univ, Med Ctr, Ctr Human Genet Res, 519 Light Hall, Nashville, TN 37232 USA.
EM jonathan@chgr.mc.vanderbilt.edu
RI Scott, William/A-7593-2009; Haines, Jonathan/C-3374-2012
OI Haines, Jonathan/0000-0002-4351-4728; Scott, William/0000-0001-9336-6404
FU NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000095] Funding Source: NIH
   RePORTER; NATIONAL EYE INSTITUTE [R01EY012118, R03EY015216, U10EY012118]
   Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P60AG011268]
   Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR 00095] Funding
   Source: Medline; NEI NIH HHS [EY015216, EY12118] Funding Source:
   Medline; NIA NIH HHS [AG11268] Funding Source: Medline
CR Abecasis GR, 2004, AM J HUM GENET, V74, P482, DOI 10.1086/382786
   Abecasis GR, 2000, BIOINFORMATICS, V16, P182, DOI 10.1093/bioinformatics/16.2.182
   Akimoto A, 2001, GRAEF ARCH CLIN EXP, V239, P66, DOI 10.1007/PL00007900
   Allikmets R, 1999, HUM GENET, V104, P449, DOI 10.1007/s004390050986
   Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   Ayyagari R, 2001, Ophthalmic Genet, V22, P233, DOI 10.1076/opge.22.4.233.2219
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   *CDCO, 2004, MMWR-MORBID MORTAL W, V53, P1069
   D'Arcangelo G, 1999, NEURON, V24, P471, DOI 10.1016/S0896-6273(00)80860-0
   De La Paz MA, 1999, OPHTHALMOLOGY, V106, P1531, DOI 10.1016/S0161-6420(99)90449-9
   DelaPaz MA, 1997, INVEST OPHTH VIS SCI, V38, P1060
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Esfandiary H, 2005, BRIT J OPHTHALMOL, V89, P470, DOI 10.1136/bjo.2004.047340
   FERRIS FL, 1983, AM J EPIDEMIOL, V118, P132, DOI 10.1093/oxfordjournals.aje.a113624
   Fish G, 2003, OPHTHALMOLOGY, V110, P979, DOI 10.1016/S0161-6420(03)00085-X
   Gudbjartsson DF, 2000, NAT GENET, V25, P12, DOI 10.1038/75514
   Guymer RH, 2001, ARCH OPHTHALMOL-CHIC, V119, P745, DOI 10.1001/archopht.119.5.745
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hamdi HK, 2002, BIOCHEM BIOPH RES CO, V295, P668, DOI 10.1016/S0006-291X(02)00728-3
   Hammond CJ, 2002, OPHTHALMOLOGY, V109, P730, DOI 10.1016/S0161-6420(01)01049-1
   HEIBA IM, 1994, GENET EPIDEMIOL, V11, P51, DOI 10.1002/gepi.1370110106
   Hyman BT, 2000, ARCH NEUROL-CHICAGO, V57, P646, DOI 10.1001/archneur.57.5.646
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   Iyengar SK, 2004, AM J HUM GENET, V74, P20, DOI 10.1086/380912
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   KLEIN ML, 1994, ARCH OPHTHALMOL-CHIC, V112, P932, DOI 10.1001/archopht.1994.01090190080025
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kuroiwa S, 1999, BRIT J OPHTHALMOL, V83, P613, DOI 10.1136/bjo.83.5.613
   LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241
   Lange C, 2004, AM J HUM GENET, V74, P367, DOI 10.1086/381563
   Maeda A, 2005, BIOCHEMISTRY-US, V44, P480, DOI 10.1021/bi048016f
   Majewski J, 2003, AM J HUM GENET, V73, P540, DOI 10.1086/377701
   Martin ER, 2000, AM J HUM GENET, V67, P146, DOI 10.1086/302957
   MEYERS SM, 1995, AM J OPHTHALMOL, V120, P757, DOI 10.1016/S0002-9394(14)72729-1
   O'Connell JR, 1998, AM J HUM GENET, V63, P259, DOI 10.1086/301904
   Rivera A, 2000, AM J HUM GENET, V67, P800, DOI 10.1086/303090
   *SAS I, 2002, SAS VERS 8
   Schick JH, 2003, AM J HUM GENET, V72, P1412, DOI 10.1086/375500
   Schmidt S, 2004, BMC GENET, V5, DOI 10.1186/1471-2156-5-18
   Schmidt S, 2003, INVEST OPHTH VIS SCI, V44, P2868, DOI 10.1167/iovs.02-0957
   Schmidt S, 2000, MOL VIS, V6, P287
   Schmidt Silke, 2002, Ophthalmic Genet, V23, P209, DOI 10.1076/opge.23.4.209.13883
   Seddon JM, 2003, AM J HUM GENET, V73, P780, DOI 10.1086/378505
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   Shastry BS, 1999, OPHTHALMOLOGICA, V213, P165, DOI 10.1159/000027413
   SILVESTRI G, 1994, EYE, V8, P564, DOI 10.1038/eye.1994.138
   Simonelli F, 2001, OPHTHALMIC RES, V33, P325, DOI 10.1159/000055688
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   Tou JS, 2004, FASEB J, V18, P1297, DOI 10.1096/fj.04-1862fje
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Wang XH, 2004, AM J PHYSIOL-HEART C, V287, pH2376, DOI 10.1152/ajpheart.01173.2003
   Webster AR, 2001, INVEST OPHTH VIS SCI, V42, P1179
   Weeks DE, 2004, AM J HUM GENET, V75, P174, DOI 10.1086/422476
   Weeks DE, 2001, AM J OPHTHALMOL, V132, P682, DOI 10.1016/S0002-9394(01)01214-4
   WELLS J, 1993, NAT GENET, V3, P213, DOI 10.1038/ng0393-213
   WROBLEWSKI JJ, 1994, OPHTHALMOLOGY, V101, P12
   Yoshida S, 2002, INVEST OPHTH VIS SCI, V43, P2554
   Zareparsi S, 2005, HUM MOL GENET, V14, P1449, DOI 10.1093/hmg/ddi154
NR 60
TC 146
Z9 156
U1 0
U2 9
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JAN
PY 2006
VL 47
IS 1
BP 329
EP 335
DI 10.1167/iovs.05-0116
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 998AH
UT WOS:000234289700046
PM 16384981
DA 2022-11-30
ER

PT J
AU Shalev, V
   Sror, M
   Goldshtein, I
   Kokia, E
   Chodick, G
AF Shalev, Varda
   Sror, Miri
   Goldshtein, Inbal
   Kokia, Ehud
   Chodick, Gabriel
TI Statin Use and the Risk of Age Related Macular Degeneration in a Large
   Health Organization in Israel
SO OPHTHALMIC EPIDEMIOLOGY
LA English
DT Article
DE Statins; AMD; Persistence; Israel; Visual impairment
ID BEAVER DAM EYE; BLUE MOUNTAINS EYE; C-REACTIVE PROTEIN;
   CARDIOVASCULAR-DISEASE; VISUAL IMPAIRMENT; CIGARETTE-SMOKING;
   RETROSPECTIVE COHORT; 10-YEAR INCIDENCE; POOLED FINDINGS; MEDICATION USE
AB Objective: To investigate the association between persistent use of statins and the risk of age-related macular degeneration (AMD).
   Design: A population-based retrospective cohort among adults who began statin therapy between 1998 and 2006 in a large health organization in Israel. The organization''s central computerized databases were used to collect data on incident AMD cases diagnosed by ophthalmologists.
   Results: A total of 108,973 individuals aged 55 or older were identified. During the study follow-up period 409,113 person-years, there were 2,732 incident AMD cases (6.68 per 1,000 person-years). The crude incidence density rate of AMD among patients at the lowest quintile of persistence with statins (7.18 per 1,000) was comparable to that of highest persistence quintile (7.13 per 1,000). After adjustment for potential confounders, patients in the highest quintile of persistence with statins had a hazard ratio of 0.99 (95% Confidence Interval: 0.78--1.26) for AMD compared with patients in the lowest proportion of days covered (PDC) quintile. In addition to age, AMD was found to associate with past smoking, asthma, diabetes and frequent visits to ophthalmologists or primary physicians prior to index date
   Conclusions: Our study agrees with previous studies that showed no association between persistent use of statins and reduced risk of AMD. These results suggest that the early reports on a strong protective effect of statins against AMD development were probably a result of a small study effect.
C1 [Shalev, Varda; Sror, Miri; Goldshtein, Inbal; Kokia, Ehud; Chodick, Gabriel] Maccabi Healthcare Serv, IL-68125 Tel Aviv, Israel.
   [Shalev, Varda; Chodick, Gabriel] Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel.
   [Sror, Miri] Hasharon Hosp, Rabin Med, Petah Tiqwa, Israel.
C3 Tel Aviv University; Sackler Faculty of Medicine; Rabin Medical Center
RP Chodick, G (通讯作者)，Maccabi Healthcare Serv, 27 HaMered St, IL-68125 Tel Aviv, Israel.
EM hodik_g@mac.org.il
RI goldshtein, inbal/D-2113-2011
OI goldshtein, inbal/0000-0002-5317-2848; /0000-0002-5189-8995
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Boekhoorn SS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1396, DOI 10.1001/archopht.125.10.1396
   Chodick G, 2003, EUR J EPIDEMIOL, V18, P1143, DOI 10.1023/B:EJEP.0000006635.36802.c8
   Chodick G, 2010, ANN EPIDEMIOL, V20, P136, DOI 10.1016/j.annepidem.2009.10.007
   Chodick G, 2008, CLIN THER, V30, P2167, DOI 10.1016/j.clinthera.2008.11.012
   Christen WG, 1996, JAMA-J AM MED ASSOC, V276, P1147, DOI 10.1001/jama.276.14.1147
   Ciulla TA, 2001, BRIT J OPHTHALMOL, V85, P510, DOI 10.1136/bjo.85.5.510
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Davignon J, 2005, VASC HEALTH RISK MAN, V1, P29, DOI 10.2147/vhrm.1.1.29.58937
   Delcourt C, 1998, ARCH OPHTHALMOL-CHIC, V116, P1031, DOI 10.1001/archopht.116.8.1031
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   Dujovne CA, 2000, MAYO CLIN PROC, V75, P1124, DOI 10.4065/75.11.1124
   Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027
   FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8
   Folkman J, 1996, Harvey Lect, V92, P65
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Hall NF, 2001, BRIT MED J, V323, P375, DOI 10.1136/bmj.323.7309.375
   Hansson GK, 2005, NEW ENGL J MED, V352, P1685, DOI 10.1056/NEJMra043430
   HYMAN L, 2002, CURR OPIN OPHTHALMOL, V13, P174
   *ISR CENTR BUR STA, 1998, 1995 CENS POP HOUS J
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Johnson LV, 2004, NEW ENGL J MED, V351, P320, DOI 10.1056/NEJMp048131
   Jones P, 1998, AM J CARDIOL, V81, P582, DOI 10.1016/S0002-9149(97)00965-X
   Kalayoglu MV, 2005, GRAEF ARCH CLIN EXP, V243, P1080, DOI 10.1007/s00417-005-1169-y
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Klein R, 1998, AM J EPIDEMIOL, V147, P103
   Klein R, 2003, OPHTHALMOLOGY, V110, P636, DOI 10.1016/S0161-6420(02)01448-3
   Klein R, 2003, OPHTHALMOLOGY, V110, P25, DOI 10.1016/S0161-6420(02)01565-8
   Klein R, 1999, ARCH OPHTHALMOL-CHIC, V117, P1203
   Klein R, 2001, ARCH OPHTHALMOL-CHIC, V119, P1354
   KLEIN R, 1993, OPHTHALMOLOGY, V100, P406
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   Lord SR, 2001, J AM GERIATR SOC, V49, P508, DOI 10.1046/j.1532-5415.2001.49107.x
   Maguire MG, 2009, OPHTHALMOLOGY, V116, P2381, DOI 10.1016/j.ophtha.2009.06.055
   McCarty CA, 2001, MED J AUSTRALIA, V175, P340, DOI 10.5694/j.1326-5377.2001.tb143604.x
   Meyer JW, 2005, VALUE HEALTH, V8, P601, DOI 10.1111/j.1524-4733.2005.00052.x
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Nissen SE, 2006, JAMA-J AM MED ASSOC, V295, P1556, DOI 10.1001/jama.295.13.jpc60002
   Pascolini D, 2004, OPHTHAL EPIDEMIOL, V11, P67, DOI 10.1076/opep.11.2.67.28158
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P300, DOI 10.1001/archopht.125.3.300
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Shafiq N, 2005, J NEGAT RESULTS BIOM, V4, DOI 10.1186/1477-5751-4-3
   Shalev V, 2009, ARCH INTERN MED, V169, P260, DOI 10.1001/archinternmed.2008.552
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   Tan JSL, 2007, AM J OPHTHALMOL, V143, P685, DOI 10.1016/j.ajo.2006.11.021
   Tomany SC, 2004, ARCH OPHTHALMOL-CHIC, V122, P750, DOI 10.1001/archopht.122.5.750
   Topouzis F, 2009, BRIT J OPHTHALMOL, V93, P1037, DOI 10.1136/bjo.2008.146316
   Valuck RJ, 2003, CLIN THER, V25, P2936, DOI 10.1016/S0149-2918(03)80346-6
   Van Leeuwen R, 2004, OPHTHALMOLOGY, V111, P1169, DOI 10.1016/j.ophtha.2003.10.024
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
   van Leeuwen R, 2003, BRIT MED J, V326, P255, DOI 10.1136/bmj.326.7383.255
   Vine AK, 2005, OPHTHALMOLOGY, V112, P2076, DOI 10.1016/j.ophtha.2005.07.004
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Watson KE, 2009, REV CARDIOVASC MED, V10, P91
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 61
TC 24
Z9 25
U1 0
U2 2
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 0928-6586
EI 1744-5086
J9 OPHTHAL EPIDEMIOL
JI Ophthalmic Epidemiol.
PD APR
PY 2011
VL 18
IS 2
BP 83
EP 90
DI 10.3109/09286586.2011.560746
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 734IA
UT WOS:000288326600006
PM 21401416
DA 2022-11-30
ER

PT J
AU Kozhevnikova, OS
   Telegina, DV
   Tyumentsev, MA
   Kolosova, NG
AF Kozhevnikova, Oyuna S.
   Telegina, Darya V.
   Tyumentsev, Mikhail A.
   Kolosova, Nataliya G.
TI Disruptions of Autophagy in the Rat Retina with Age During the
   Development of Age-Related-Macular-Degeneration-like Retinopathy
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE autophagy; age-related macular degeneration; retina; retinal pigment
   epithelium; transcriptome; chloroquine; fasting
ID AMD-LIKE RETINOPATHY; DELETION; PATHWAY; DEATH; RPE
AB Age-related macular degeneration (AMD) is one of the main causes of vision impairment in the elderly. Autophagy is the process of delivery of cytoplasmic components into lysosomes for cleavage; its age-related malfunction may contribute to AMD. Here we showed that the development of AMD-like retinopathy in OXYS rats is accompanied by retinal transcriptome changes affecting genes involved in autophagy. These genes are associated with kinase activity, immune processes, and FoxO, mTOR, PI3K-AKT, MAPK, AMPK, and neurotrophin pathways at preclinical and manifestation stages, as well as vesicle transport and processes in lysosomes at the progression stage. We demonstrated a reduced response to autophagy modulation (inhibition or induction) in the OXYS retina at age 16 months: expression of genes Atg5, Atg7, Becn1, Nbr1, Map1lc3b, p62, and Gabarapl1 differed between OXYS and Wistar (control) rats. The impaired reactivity of autophagy was confirmed by a decreased number of autophagosomes under the conditions of blocked autophagosome-lysosomal fusion according to immunohistochemical analysis and transmission electron microscopy. Thus, the development of AMD signs occurs against the background of changes in the expression of autophagy-related genes and a decrease in autophagy reactivity: the ability to enhance autophagic flux in response to stress.
C1 [Kozhevnikova, Oyuna S.; Telegina, Darya V.; Tyumentsev, Mikhail A.; Kolosova, Nataliya G.] RAS, SB, Inst Cytol & Genet, Pr Lavrentyeva 10, Novosibirsk 630090, Russia.
C3 Russian Academy of Sciences; Institute of Cytology & Genetics ICG SB RAS
RP Kozhevnikova, OS (通讯作者)，RAS, SB, Inst Cytol & Genet, Pr Lavrentyeva 10, Novosibirsk 630090, Russia.
EM oidopova@bionet.nsc.ru
RI Tyumentsev, Mikhail/AAZ-9826-2020; Kolosova, Nataliya G/AAR-7409-2020;
   Kozhevnikova, Oyuna S./H-3588-2016; Telegina, Darya/AAQ-6062-2020
OI Kolosova, Nataliya G/0000-0003-2398-8544; Kozhevnikova, Oyuna
   S./0000-0001-6475-4061; Telegina, Darya/0000-0001-8096-0519
FU Russian Scientific Foundation [18-75-00031]; Russian Science Foundation
   [18-75-00031] Funding Source: Russian Science Foundation
FX This work was supported by a Russian Scientific Foundation Grant
   (18-75-00031).
CR Abada A, 2017, P NATL ACAD SCI USA, V114, P12749, DOI 10.1073/pnas.1705572114
   Blasiak J, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20010210
   Blasiak J, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/5293258
   Barbosa MC, 2019, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00790
   Esteban-Martinez L, 2015, METHODS, V75, P79, DOI 10.1016/j.ymeth.2015.01.008
   Fedoseeva LA, 2019, BMC GENOMICS, V20, DOI 10.1186/s12864-019-5540-5
   Felszeghy S, 2019, REDOX BIOL, V20, P1, DOI 10.1016/j.redox.2018.09.011
   Feng YJ, 2018, BIOCHEM BIOPH RES CO, V496, P1148, DOI 10.1016/j.bbrc.2018.01.159
   Jankauskas SS, 2017, SCI REP-UK, V7, DOI 10.1038/srep44430
   Kaarniranta K, 2017, CELL BIOL TOXICOL, V33, P113, DOI 10.1007/s10565-016-9371-8
   Keeling E, 2018, CELLS-BASEL, V7, DOI 10.3390/cells7020016
   Kim JY, 2013, CELL, V154, P365, DOI 10.1016/j.cell.2013.06.012
   Klettner A, 2013, INT J BIOCHEM CELL B, V45, P1457, DOI 10.1016/j.biocel.2013.04.013
   Klionsky DJ, 2016, AUTOPHAGY, V12, P1, DOI 10.1080/15548627.2015.1100356
   Kolosova N. G., 2014, ADV GERONTOL, V4, P294, DOI DOI 10.1134/S2079057014040146
   Kolosova NG, 2018, AGING-US, V10, P2136, DOI 10.18632/aging.101537
   Korbolina EE, 2016, BMC GENET, V17, DOI 10.1186/s12863-016-0461-7
   Korbolina EE, 2012, AGING-US, V4, P49, DOI 10.18632/aging.100427
   Kozhevnikova OS, 2018, BIOGERONTOLOGY, V19, P223, DOI 10.1007/s10522-018-9751-y
   Kozhevnikova OS, 2013, BIOGERONTOLOGY, V14, P753, DOI 10.1007/s10522-013-9439-2
   Kozhevnikova OS, 2013, CELL CYCLE, V12, P1745, DOI 10.4161/cc.24825
   Lei L, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18040728
   Liu XD, 2012, J BIOL CHEM, V287, P19687, DOI 10.1074/jbc.M112.350934
   Mauthe M, 2018, AUTOPHAGY, V14, P1435, DOI 10.1080/15548627.2018.1474314
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   Muraleva NA, 2019, ANTIOXIDANTS-BASEL, V8, DOI 10.3390/antiox8060177
   Rubinsztein DC, 2012, NAT REV DRUG DISCOV, V11, P709, DOI 10.1038/nrd3802
   Russo R, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1044-5
   Sinha D, 2016, EXP EYE RES, V144, P46, DOI 10.1016/j.exer.2015.08.018
   Telegina DV, 2019, BMC MED GENOMICS, V12, DOI 10.1186/s12920-019-0493-8
   Telegina DV, 2017, SCI REP-UK, V7, DOI 10.1038/srep41533
   Telegina DV, 2015, CELL CYCLE, V14, P3544, DOI 10.1080/15384101.2015.1080399
   Wang SB, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/3632169
   Yao JY, 2015, AUTOPHAGY, V11, P939, DOI 10.1080/15548627.2015.1041699
   Yla-Anttila Paivi, 2018, Small GTPases, V9, P57, DOI 10.1080/21541248.2017.1317699
   Yu B, 2018, SCI SIGNAL, V11, DOI 10.1126/scisignal.aag3315
   Zhang Y, 2017, MOL VIS, V23, P228
   Zhang YY, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18102146
NR 39
TC 8
Z9 9
U1 1
U2 5
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD OCT
PY 2019
VL 20
IS 19
AR 4804
DI 10.3390/ijms20194804
PG 21
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA JK4FF
UT WOS:000494798300145
PM 31569675
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Takahashi, A
   Ooto, S
   Yamashiro, K
   Oishi, A
   Tamura, H
   Nakanishi, H
   Ueda-Arakawa, N
   Tsujikawa, A
   Yoshimura, N
AF Takahashi, Ayako
   Ooto, Sotaro
   Yamashiro, Kenji
   Oishi, Akio
   Tamura, Hiroshi
   Nakanishi, Hideo
   Ueda-Arakawa, Naoko
   Tsujikawa, Akitaka
   Yoshimura, Nagahisa
TI Photoreceptor Damage and Reduction of Retinal Sensitivity Surrounding
   Geographic Atrophy in Age-Related Macular Degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; SUBRETINAL DRUSENOID DEPOSITS; RETICULAR
   PSEUDODRUSEN; FUNDUS AUTOFLUORESCENCE; VISUAL-ACUITY; EYES;
   MICROPERIMETRY; PREVALENCE; MORPHOLOGY; ASSOCIATION
AB PURPOSE: To quantify the area of photoreceptor damage surrounding geographic atrophy (GA) and evaluate the relationship between structural abnormalities and retinal function in eyes with GA.
   DESIGN: Prospective cross-sectional study.
   METHODS: Twenty-five eyes of 25 patients with GA associated with age-related macular degeneration underwent a full ophthalmologic examination, including spectral-domain optical coherence tomography (SDOCT), fundus autofluorescence (FAF), and micro-perimetry. ImageJ software was used to quantify the disruption of the ellipsoid zone on SDOCT images. Hypo fluorescent areas of the FAF images indicated areas of retinal pigment epithelium (RPE) loss. Areas of interest graded by SDOCT (photoreceptor damage) and FAF (RPE loss) were registered with microperimetry within a 6-mm circle centered on the fovea.
   RESULTS: The mean area of photoreceptor damage was 7.69 +/- 5.36 mm(2), which was significantly greater than the mean area of RPE loss (4.57 +/- 4.07 mm(2), P < .001). The average retinal sensitivity of the area with photoreceptor damage outside the area of RPE loss was lower than that of the area without photoreceptor damage (6.57 +/- 4.13 dB vs 11.27 +/- 3.78 dB, P < .001). The area of photoreceptor damage surrounding the area of RPE loss was larger in eyes with pseudodrusen than in eyes without pseudodrusen (4.96 mm(2) vs 1.91 mm(2), P = .008). The only significant predictor of decreased retinal sensitivity was the area of the photoreceptor damage (P < .001).
   CONCLUSIONS: Widespread photoreceptor damage surrounding sites of RPE loss occurred in eyes with GA, and it correlated with visual function. Evaluation of photoreceptor damage surrounding sites of RPE loss using OCT is important in patients with GA associated with AMD. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Takahashi, Ayako; Ooto, Sotaro; Yamashiro, Kenji; Oishi, Akio; Tamura, Hiroshi; Nakanishi, Hideo; Ueda-Arakawa, Naoko; Tsujikawa, Akitaka; Yoshimura, Nagahisa] Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Kyoto, Japan.
   [Tsujikawa, Akitaka] Kagawa Univ, Fac Med, Dept Ophthalmol, Kagawa, Japan.
C3 Kyoto University; Kagawa University
RP Ooto, S (通讯作者)，Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Sakyo Ku, 54 Kawahara Cho, Kyoto 6068507, Japan.
EM ohoto@kuhp.kyoto-u.ac.jp
RI TAMURA, Hiroshi/H-1855-2011; Oishi, Akio/AAE-9996-2020
OI TAMURA, Hiroshi/0000-0002-7740-2732; Oishi, Akio/0000-0002-0977-9458;
   Tsujikawa, Akitaka/0000-0003-0779-7799; Yamashiro,
   Kenji/0000-0001-9354-8558
FU JAPAN SOCIETY FOR THE PROMOTION OF SCIENCE, TOKYO, Japan [26893131];
   Innovative Techno-Hub for Integrated Medical Bio-Imaging of the Project
   for Developing Innovation Systems-a project of the Ministry of
   Education, Culture, Sports, Science, and Technology, Japan
FX THIS STUDY WAS SUPPORTED IN PART BY THE JAPAN SOCIETY FOR THE PROMOTION
   OF SCIENCE, TOKYO, Japan (Grant-in-Aid for Scientific Research, No.
   26893131), as well as by the Innovative Techno-Hub for Integrated
   Medical Bio-Imaging of the Project for Developing Innovation Systems-a
   project of the Ministry of Education, Culture, Sports, Science, and
   Technology, Japan.
CR Barteselli G, 2013, AM J OPHTHALMOL, V156, P588, DOI 10.1016/j.ajo.2013.04.030
   Bearelly S, 2009, OPHTHALMOLOGY, V116, P1762, DOI 10.1016/j.ophtha.2009.04.015
   Bird AC, 2014, JAMA OPHTHALMOL, V132, P338, DOI 10.1001/jamaophthalmol.2013.5799
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   Finger RP, 2014, OPHTHALMOLOGY, V121, P1252, DOI 10.1016/j.ophtha.2013.12.034
   Fleckenstein M, 2008, INVEST OPHTH VIS SCI, V49, P4137, DOI 10.1167/iovs.08-1967
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   Landa G, 2011, RETINA-J RET VIT DIS, V31, P364, DOI 10.1097/IAE.0b013e3181e91132
   Marsiglia M, 2013, INVEST OPHTH VIS SCI, V54, P7362, DOI 10.1167/iovs.12-11073
   Meleth AD, 2011, INVEST OPHTH VIS SCI, V52, P1119, DOI 10.1167/iovs.10-6075
   Mrejen S, 2014, OPHTHALMOLOGY, V121, P545, DOI 10.1016/j.ophtha.2013.09.026
   Ooto S, 2015, RETINA-J RET VIT DIS, V35, P1726, DOI 10.1097/IAE.0000000000000608
   Ooto S, 2013, AM J OPHTHALMOL, V156, P1184, DOI 10.1016/j.ajo.2013.06.036
   Panorgias A, 2013, INVEST OPHTH VIS SCI, V54, P4372, DOI 10.1167/iovs.12-11525
   Pilotto E, 2013, CAN J OPHTHALMOL, V48, P386, DOI 10.1016/j.jcjo.2013.03.022
   Pilotto E, 2013, BRIT J OPHTHALMOL, V97, P622, DOI 10.1136/bjophthalmol-2012-302633
   Querques G, 2014, RETINA-J RET VIT DIS, V34, P321, DOI 10.1097/IAE.0b013e3182993df1
   Querques L, 2012, AM J OPHTHALMOL, V153, P1110, DOI 10.1016/j.ajo.2011.11.002
   Sarks J, 2011, BRIT J OPHTHALMOL, V95, P979, DOI 10.1136/bjo.2010.194977
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Sayegh RG, 2014, BRIT J OPHTHALMOL, V98, P1050, DOI 10.1136/bjophthalmol-2014-305195
   Schmitz-Valckenberg S, 2004, INVEST OPHTH VIS SCI, V45, P4470, DOI 10.1167/iovs.03-1311
   Schmitz-Valckenberg S, 2016, OPHTHALMOLOGICA, V235, P215, DOI 10.1159/000445217
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P5009, DOI 10.1167/iovs.11-7235
   Spaide RF, 2013, RETINA-J RET VIT DIS, V33, P1800, DOI 10.1097/IAE.0b013e31829c3765
   Spaide RF, 2011, RETINA-J RET VIT DIS, V31, P1609, DOI 10.1097/IAE.0b013e3182247535
   Steinberg JS, 2015, JAMA OPHTHALMOL, V133, P690, DOI 10.1001/jamaophthalmol.2015.0477
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   Ueda-Arakawa N, 2013, AM J OPHTHALMOL, V155, P260, DOI 10.1016/j.ajo.2012.08.011
   Wakazono T, 2013, RETINA-J RET VIT DIS, V33, P642, DOI 10.1097/IAE.0b013e3182671104
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu ZC, 2015, INVEST OPHTH VIS SCI, V56, P115, DOI 10.1167/iovs.14-15614
   Zanzottera EC, 2015, INVEST OPHTH VIS SCI, V56, P3253, DOI 10.1167/iovs.15-16431
   Zhang YH, 2014, AM J OPHTHALMOL, V158, P584, DOI 10.1016/j.ajo.2014.05.038
NR 34
TC 36
Z9 37
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD AUG
PY 2016
VL 168
BP 260
EP 268
DI 10.1016/j.ajo.2016.06.006
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DT0IG
UT WOS:000381166600028
PM 27296489
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Schultz, DW
   Klein, ML
   Humpert, A
   Majewski, J
   Schain, M
   Weleber, RG
   Ott, J
   Acott, TS
AF Schultz, DW
   Klein, ML
   Humpert, A
   Majewski, J
   Schain, M
   Weleber, RG
   Ott, J
   Acott, TS
TI Lack of an association of apolipoprotein E gene polymorphisms with
   familial age-related macular degeneration
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID LINKAGE; ALLELE
AB Background: Previously, the epsilon4 allele of apolipoprotein E (APOE) was reported to have a significant association with a decreased risk of age-related macular degeneration (AMD). In addition, the epsilon2 allele of APOE was reported to be possibly associated with an increased risk of AMD.
   Objective: To determine if APOE polymorphisms, previously reported to be associated with AMD, affect its expression in medium to large families, as well as in unrelated patients with AMD.
   Methods: The APOE genotype was determined by HhaI restriction digests of polymerase chain reaction-amplified products in a collection of 259 affected and 207 unaffected individuals from 56 AMD families. Genotypes were determined similarly in a set of 104 unrelated AMD patients and in 113 unaffected control subjects. Diagnosis of AMD was based on clinical examination and evaluation of fundus photographs. Evidence of an association between alleles of APOE and AMD in families was tested by the following 4 statistical methods: chi(2) analysis of simple allele counting, logistic regression analysis adjusting for age, construction of likelihood ratios of haplotype frequencies, and the pedigree disequilibrium test.
   Results: None of the statistical methods used showed a significant association between the common alleles of APOE and AMD in our collection of families or in the set of unrelated AMD patients.
   Conclusions: No evidence was found to support an association between AMD in medium to large families and the epsilon4 or epsilon2 alleles of APOE. Neither was any evidence found for an association of APOE polymorphisms with the set of unrelated patients with AMD. However, a trend for a decreased risk of AMD associated with APOE epsilon4 was observed in the set of unrelated patients with a family history of AMD.
C1 Oregon Hlth & Sci Univ, Casey Eye Inst, Portland, OR 97239 USA.
   Rockefeller Univ, Lab Stat Genet, New York, NY USA.
C3 Oregon Health & Science University; Rockefeller University
RP Schultz, DW (通讯作者)，Oregon Hlth & Sci Univ, Casey Eye Inst, 3375 SW Terwilliger Blvd, Portland, OR 97239 USA.
FU NATIONAL EYE INSTITUTE [P30EY010572, R01EY003279, R01EY012203] Funding
   Source: NIH RePORTER; NEI NIH HHS [EY 03279, EY 10572, EY 12203] Funding
   Source: Medline; NHGRI NIH HHS [HG00008] Funding Source: Medline
CR Anderson DH, 2001, AM J OPHTHALMOL, V131, P767, DOI 10.1016/S0002-9394(00)00961-2
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   DAVIGNON J, 1988, ARTERIOSCLEROSIS, V8, P1, DOI 10.1161/01.ATV.8.1.1
   Evans J, 1996, BRIT J OPHTHALMOL, V80, P9, DOI 10.1136/bjo.80.1.9
   HIXSON JE, 1990, J LIPID RES, V31, P545
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klein ML, 1998, ARCH OPHTHALMOL-CHIC, V116, P1082, DOI 10.1001/archopht.116.8.1082
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443
   MAGUIRE MG, 1994, ARCH OPHTHALMOL-CHIC, V112, P489
   MAGUIRE MG, 1994, ARCH OPHTHALMOL-CHIC, V112, P480
   Mahley RW, 2000, ANNU REV GENOM HUM G, V1, P507, DOI 10.1146/annurev.genom.1.1.507
   Martin ER, 2000, AM J HUM GENET, V67, P146, DOI 10.1086/302957
   SCHACHTER F, 1994, NAT GENET, V6, P29, DOI 10.1038/ng0194-29
   Schmidt S, 2000, MOL VIS, V6, P287
   Simonelli F, 2001, OPHTHALMIC RES, V33, P325, DOI 10.1159/000055688
   Smith JD, 2000, ANN MED, V32, P118, DOI 10.3109/07853890009011761
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
NR 20
TC 50
Z9 54
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610 USA
SN 0003-9950
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD MAY
PY 2003
VL 121
IS 5
BP 679
EP 683
DI 10.1001/archopht.121.5.679
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 676XU
UT WOS:000182778500011
PM 12742846
OA Bronze
DA 2022-11-30
ER

PT J
AU Kolomeyer, AM
   Maguire, MG
   Pan, W
   Vanderbeek, BL
AF Kolomeyer, Anton M.
   Maguire, Maureen G.
   Pan, Wei
   Vanderbeek, Brian L.
TI SYSTEMIC BETA-BLOCKERS AND RISK OF PROGRESSION TO NEOVASCULAR
   AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE beta-blocker; neovascular; age-related; macular degeneration;
   antihypertensive medications
ID 5-YEAR INCIDENCE; MEDICATION USE; MACULOPATHY
AB Purpose: To determine whether oral beta-blockers (BBs) are associated with the development of neovascular age-related macular degeneration (nAMD).
   Methods: Retrospective cohort study of patients from 2000 to 2014 using data from a large national U.S. insurer's administrative medical claims database. Patients with non-exudative AMD who initiated (index date) BB, a calcium channel blocker (CCB), an angiotensin-converting enzyme/angiotensin receptor blocker, or a diuretic. Patients were excluded for,2 years in the plan before the index date, any history of nAMD or diagnosis, or treatment for an ocular disease that could be confused with nAMD. Hazard of developing of nAMD was the main outcome measure. Primary analysis compared BB with CCB patients with BB versus the other classes as secondary analyses. In addition, a sensitivity analysis was performed between BB and CCB cohorts using 1:1 propensity score matching. Cox proportional hazard regression was performed to estimate the hazard ratio (HR) of developing nAMD at 90, 180, and 365 days for BB. Covariates of interest included demographic information, year of index date, number of antihypertensive medications, and other comorbid systemic conditions.
   Results: Eighteen thousand seven hundred and fifty-four BB patients and 12,784 CCB patients met criteria for inclusion. After controlling for covariates, patients on BB had a lower hazard for nAMD at both 90 and 180 days than patients on CCB (HRs: 0.67-0.71; P < 0.01 for both) and diuretics (HRs: 0.55-0.62; P, 0.01). Patients on BB versus angiotensin-converting enzyme/angiotensin receptor blocker at all time points and BB versus CCB and diuretics at 365 days did not have a significantly lower association with nAMD (HR: 0.73-0.85; P. 0.06 for all comparisons). A sensitivity analysis using propensity score matching yielded similar results with patients on BB significantly less likely to develop nAMD at 90 and 180 days (HR: 0.70-0.76; P < 0.049 for both) but not at 365 days (HR: 0.88; P = 0.30) compared with patients on CCB.
   Conclusion: No evidence was found that BB usage increased the hazard for nAMD relative to other antihypertensive medications.
C1 [Kolomeyer, Anton M.; Vanderbeek, Brian L.] Univ Penn, Scheie Eye Inst, Dept Ophthalmol, Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Maguire, Maureen G.; Pan, Wei] Univ Penn, Perelman Sch Med, Ctr Prevent Ophthalmol & Biostat, Philadelphia, PA 19104 USA.
   [Maguire, Maureen G.; Vanderbeek, Brian L.] Univ Penn, Perelman Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA.
   [Vanderbeek, Brian L.] Univ Penn, Leonard Davis Inst, Perelman Sch Med, Philadelphia, PA 19104 USA.
C3 University of Pennsylvania; Pennsylvania Medicine; University of
   Pennsylvania; Pennsylvania Medicine; University of Pennsylvania;
   Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine
RP Vanderbeek, BL (通讯作者)，Scheie Eye Inst, 51 North 39th St, Philadelphia, PA 19104 USA.
EM brian.vanderbeek@uphs.upenn.edu
FU National Institutes of Health [1K23EY025729 - 01]; University of
   Pennsylvania [2P30EYEY001583]; Research to Prevent Blindness; Paul and
   Evanina Mackall Foundation; Heed Ophthalmic Research Foundation;
   NATIONAL EYE INSTITUTE [K23EY025729, P30EY001583] Funding Source: NIH
   RePORTER
FX Supported by National Institutes of Health K23 Award (1K23EY025729 - 01;
   B.L.V.) and University of Pennsylvania Core Grant for Vision Research
   (2P30EYEY001583). The content is solely the responsibility of the
   authors and does not necessarily represent the official views of the
   NIH. Additional funding was provided by Research to Prevent Blindness,
   the Paul and Evanina Mackall Foundation, and the Heed Ophthalmic
   Research Foundation (A.M.K.).
CR Davis A, 2012, ACTA OPHTHALMOL, V90, pe162, DOI 10.1111/j.1755-3768.2011.02117.x
   Dezsi CA, 2017, AM J CARDIOVASC DRUG, V17, P361, DOI 10.1007/s40256-017-0221-8
   Fredriksson JM, 2000, J BIOL CHEM, V275, P13802, DOI 10.1074/jbc.275.18.13802
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   KLEIN R, 1993, AM J EPIDEMIOL, V137, P190, DOI 10.1093/oxfordjournals.aje.a116659
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Klein R, 2001, ARCH OPHTHALMOL-CHIC, V119, P1354
   Klein R, 2014, OPHTHALMOLOGY, V121, P1604, DOI 10.1016/j.ophtha.2014.03.005
   Kolomeyer AM, 2017, OPHTHALMOLOGY, V124, pE70, DOI 10.1016/j.ophtha.2017.03.063
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Montero JA, 2013, RETINA-J RET VIT DIS, V33, P508, DOI 10.1097/IAE.0b013e3182695ba0
   Osborne NN, 2006, INVEST OPHTH VIS SCI, V47, P3178, DOI 10.1167/iovs.05-1370
   Thomas AS, 2015, RETINA-J RET VIT DIS, V35, P1964, DOI 10.1097/IAE.0000000000000603
   Traband A, 2017, RETINA-J RET VIT DIS, V37, P41, DOI 10.1097/IAE.0000000000001226
   Van Leeuwen R, 2004, OPHTHALMOLOGY, V111, P1169, DOI 10.1016/j.ophtha.2003.10.024
   Yeung L, 2017, OPHTHALMOLOGY, V124, P409, DOI 10.1016/j.ophtha.2016.10.023
NR 16
TC 7
Z9 7
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAY
PY 2019
VL 39
IS 5
BP 918
EP 925
DI 10.1097/IAE.0000000000002059
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA IQ4VP
UT WOS:000480749600023
PM 29394237
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Gorin, MB
AF Gorin, Michael B.
TI A clinician's view of the molecular genetics of age-related maculopathy
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID COMPLEMENT FACTOR-H; MACULAR DEGENERATION; APOLIPOPROTEIN-E;
   DIETARY-FAT; CIGARETTE-SMOKING; NATIONAL-HEALTH; VITAMIN-E; ASSOCIATION;
   DISEASE; RISK
AB Molecular genetic studies of age-related maculopathy (ARM), including family-based linkage studies and case-control association studies, have yielded valuable insights into the risks of developing this condition and potential disease-causing mechanisms. Variants in the complement factor H gene and LOC387715 have consistently been shown to be major risk factors for ARM. Additional genes, and environmental, behavioral, and dietary factors, also play a major role in ARM pathogenesis. The present studies are a starting point toward our understanding of the causes of ARM and for future therapeutic studies. As clinicians, we can already begin to use our knowledge of ARM genetics to counsel and care for our patients at risk.
C1 Jules Stein Eye Inst, Los Angeles, CA 90095 USA.
   Univ Calif Los Angeles, David Geffen Sch Med, Dept Ophthalmol, Los Angeles, CA USA.
   Univ Pittsburgh, Sch Med, Pittsburgh, PA USA.
   Univ Pittsburgh, Med Ctr, Grad Sch Publ Hlth, Ctr Eye, Pittsburgh, PA USA.
C3 University of California System; University of California Los Angeles;
   University of California Los Angeles Medical Center; David Geffen School
   of Medicine at UCLA; Pennsylvania Commonwealth System of Higher
   Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth
   System of Higher Education (PCSHE); University of Pittsburgh
RP Gorin, MB (通讯作者)，Jules Stein Eye Inst, 200 Stein Pl,Room 3-310B, Los Angeles, CA 90095 USA.
EM gorin@jsei.ucla.edu
FU NEI NIH HHS [R01 EY0098598] Funding Source: Medline
CR Assink JJM, 2005, OPHTHALMOLOGY, V112, P482, DOI 10.1016/j.ophtha.2004.10.035
   Bartlett H, 2003, OPHTHAL PHYSL OPT, V23, P383, DOI 10.1046/j.1475-1313.2003.00130.x
   Brown MM, 2005, CAN J OPHTHALMOL, V40, P277, DOI 10.1016/S0008-4182(05)80070-5
   Cardinault N, 2005, CLIN CHIM ACTA, V357, P34, DOI 10.1016/j.cccn.2005.01.030
   Chew EY, 2005, ARCH OPHTHALMOL-CHIC, V123, P395, DOI 10.1001/archopht.123.3.395
   CHRISTEN WG, 1994, AM J MED, V97, pS14, DOI 10.1016/0002-9343(94)90293-3
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Conley YP, 2005, HUM MOL GENET, V14, P1991, DOI 10.1093/hmg/ddi204
   CONLEY YP, IN PRESS HUM MOL GEN
   Constable LJ, 2004, MED J AUSTRALIA, V181, P471, DOI 10.5694/j.1326-5377.2004.tb06401.x
   Dasch B, 2005, GRAEF ARCH CLIN EXP, V243, P1028, DOI 10.1007/s00417-005-1176-z
   Davignon J, 2004, CORONARY ARTERY DIS, V15, P251, DOI 10.1097/01.mca.0000131573.31966.34
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   FERRIS FL, 1983, AM J EPIDEMIOL, V118, P132, DOI 10.1093/oxfordjournals.aje.a113624
   Fisher SA, 2005, HUM MOL GENET, V14, P2257, DOI 10.1093/hmg/ddi230
   Flood V, 2006, BRIT J OPHTHALMOL, V90, P927, DOI 10.1136/bjo.2006.095976
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gale CR, 2003, INVEST OPHTH VIS SCI, V44, P2461, DOI 10.1167/iovs.02-0929
   GASS JDM, 1973, ARCH OPHTHALMOL-CHIC, V90, P206
   Gensler G, 2002, J NUTR, V132, P697
   Gohdes Dorothy M, 2005, Prev Chronic Dis, V2, pA17
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   GOLDBERG J, 1988, AM J EPIDEMIOL, V128, P700, DOI 10.1093/oxfordjournals.aje.a115023
   Gorin MB, 1998, OX MG MED G, P407
   Gotoh N, 2006, HUM GENET, V120, P139, DOI 10.1007/s00439-006-0187-0
   Guymer RH, 2001, ARCH OPHTHALMOL-CHIC, V119, P745, DOI 10.1001/archopht.119.5.745
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Heuberger RA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1833, DOI 10.1001/archopht.119.12.1833
   Hopley C, 2004, BRIT J OPHTHALMOL, V88, P982, DOI 10.1136/bjo.2003.039131
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klein R, 2004, AM J OPHTHALMOL, V137, P747, DOI 10.1016/j.ajo.2004.01.037
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Lotery AJ, 2000, INVEST OPHTH VIS SCI, V41, P1291
   MaresPerlman JA, 1996, ARCH OPHTHALMOL-CHIC, V114, P991, DOI 10.1001/archopht.1996.01100140199014
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P743, DOI 10.1001/archopht.1995.01100060069034
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P1518, DOI 10.1001/archopht.1995.01100120048007
   McGeer PL, 2005, NEUROBIOL AGING, V26, P1199, DOI 10.1016/j.neurobiolaging.2005.02.003
   McGwin G, 2005, OPHTHALMOLOGY, V112, P488, DOI 10.1016/j.ophtha.2004.10.027
   McGwin G, 2004, AM J OPHTHALMOL, V138, P688, DOI 10.1016/j.ajo.2004.05.015
   Moeller SM, 2000, J AM COLL NUTR, V19, p522S, DOI 10.1080/07315724.2000.10718975
   Postel EA, 2005, AM J OPHTHALMOL, V139, P820, DOI 10.1016/j.ajo.2004.12.029
   Ribaya-Mereado JD, 2004, J AM COLL NUTR, V23, p567S, DOI 10.1080/07315724.2004.10719427
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Schaumberg DA, 2006, INVEST OPHTH VIS SCI, V47, P2336, DOI 10.1167/iovs.05-1456
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Schmidt S, 2000, MOL VIS, V6, P287
   Schmidt Silke, 2002, Ophthalmic Genet, V23, P209, DOI 10.1076/opge.23.4.209.13883
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Seddon JM, 2006, HUM HERED, V61, P157, DOI 10.1159/000094141
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Seddon Johanna M., 2004, International Ophthalmology Clinics, V44, P17, DOI 10.1097/00004397-200404440-00004
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Smeeth L, 2005, BRIT J OPHTHALMOL, V89, P1171, DOI 10.1136/bjo.2004.064477
   Stoll LL, 2004, DRUG TODAY, V40, P975, DOI 10.1358/dot.2004.40.12.872573
   Stone EM, 2001, HUM MOL GENET, V10, P2285, DOI 10.1093/hmg/10.20.2285
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   VandenLangenberg GM, 1998, AM J EPIDEMIOL, V148, P204, DOI 10.1093/oxfordjournals.aje.a009625
   YANG Z, 2006, SCIENCE, DOI DOI 10.1126/SCIENCE.133811
   Zack DJ, 1999, MOL VIS, V5, pU37
   Zareparsi S, 2004, INVEST OPHTH VIS SCI, V45, P1306, DOI 10.1167/iovs.03-1253
NR 65
TC 27
Z9 27
U1 0
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD JAN
PY 2007
VL 125
IS 1
BP 21
EP 29
DI 10.1001/archopht.125.1.21
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 123ZQ
UT WOS:000243336800003
PM 17210848
OA Bronze
DA 2022-11-30
ER

PT J
AU Chakravarthy, U
   Soubrane, G
   Bandello, F
   Chong, V
   Creuzot-Garcher, C
   Dimitrakos, SA
   Korobelnik, JF
   Larsen, M
   Mones, J
   Pauleikhoff, D
   Pournaras, CJ
   Staurenghi, G
   Virgili, G
   Wolf, S
AF Chakravarthy, U.
   Soubrane, G.
   Bandello, F.
   Chong, V.
   Creuzot-Garcher, C.
   Dimitrakos, S. A., II
   Korobelnik, J-F
   Larsen, M.
   Mones, J.
   Pauleikhoff, D.
   Pournaras, C. J.
   Staurenghi, G.
   Virgili, G.
   Wolf, S.
TI Evolving European guidance on the medical management of neovascular age
   related macular degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
ID INTRAVITREAL BEVACIZUMAB AVASTIN; COHERENCE TOMOGRAPHY FINDINGS;
   CHOROIDAL NEOVASCULARIZATION; PHOTODYNAMIC THERAPY; TRIAMCINOLONE
   ACETONIDE; INJECTION; VERTEPORFIN; EDEMA
AB Background: Until recently, only two options were available for the treatment of choroidal neovascularisation (CNV) associated with age related macular degeneration (AMD)-thermal laser photocoagulation and photodynamic therapy with verteporfin (PDT-V). However, new treatments for CNV are in development, and data from phase III clinical trials of some of these pharmacological interventions are now available. In light of these new data, expert guidance is required to enable retina specialists with expertise in the management of AMD to select and use the most appropriate therapies for the treatment of neovascular AMD.
   Methods: Consensus from a round table of European retina specialists was obtained based on best available scientific data. Data rated at evidence levels 1 and 2 were evaluated for laser photocoagulation, PDT-V, pegaptanib sodium, and ranibizumab. Other treatments discussed are anecortave acetate, triamcinolone acetonide, bevacizumab, rostaporfin (SnET2), squalamine, and transpupillary thermotherapy.
   Results: PDT-V is currently recommended for subfoveal lesions with predominantly classic CNV, or with occult with no classic CNV with evidence of recent disease progression and a lesion size <= 4 Macular Photocoagulation Study (MPS) disc areas (DA). The new classes of anti-angiogenic agents-namely, pegaptanib sodium and ranibizumab (the latter when peer reviewed phase III data become available) are recommended for subfoveal lesions with any proportion of classic CNV or occult with no classic CNV. For juxtafoveal classic CNV, PDT-V or anti-angiogenic therapy should be considered if the new vessels are so close to the fovea that laser photocoagulation would almost certainly extend under the centre of the foveal avascular zone. For all other well demarcated juxtafoveal lesions and for extrafoveal classic lesions, laser photocoagulation remains the standard treatment. Therapy should be undertaken within 1 week of the fluorescein angiogram on which the clinical decision to treat is based. At each follow up, fluorescein angiography should be performed and best corrected visual acuity measured as a minimum requirement.
   Conclusions: These recommendations provide evidence based guidance for the choice and use of nonsurgical therapies for the management of neovascular AMD. Revisions of the recommendations may be required as new data become available.
C1 Univ Paris 12, Dept Ophthalmol, F-94010 Creteil, France.
   Queens Univ Belfast, Belfast BT7 1NN, Antrim, North Ireland.
   Royal Victoria Hosp, Belfast BT12 6BA, Antrim, North Ireland.
   Univ Udine, Dept Ophthalmol, I-33100 Udine, Italy.
   Kings Coll Hosp London, London, England.
   Univ Bourgogne, Serv Ophtalmol, Dijon, France.
   Aristotle Univ Thessaloniki, Dept Ophthalmol, Thessaloniki, Greece.
   Hop Pellegrin, Serv Ophthalmol, F-33076 Bordeaux, France.
   Univ Copenhagen, Herlev Hosp, DK-1168 Copenhagen, Denmark.
   Inst Microcirugia Ocular Barcelona, Barcelona, Spain.
   St Franziskus Hosp, Munster, Germany.
   Univ Hosp Geneva, Geneva, Switzerland.
   Univ Milan, Eye Clin, I-20122 Milan, Italy.
   Univ Florence, Eye Clin, I-50121 Florence, Italy.
   Univ Bern, Inselspital, Ophthalmol Clin, CH-3010 Bern, Switzerland.
C3 Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Queens University
   Belfast; University of Udine; King's College Hospital NHS Foundation
   Trust; King's College Hospital; Universite de Bourgogne; Aristotle
   University of Thessaloniki; CHU Bordeaux; University of Copenhagen;
   Herlev & Gentofte Hospital; St. Franziskus-Hospital; University of
   Geneva; University of Milan; University of Florence; University of Bern;
   University Hospital of Bern
RP Soubrane, G (通讯作者)，Univ Paris 12, Dept Ophthalmol, 40 Ave Verdun, F-94010 Creteil, France.
EM gisele.soubrane@chicreteil.fr
RI mones, jordi/CAJ-2963-2022; Larsen, Michael/E-9620-2010; Wolf,
   Sebastian/B-8782-2008; KOROBELNIK, Jean-Francois/A-5448-2016; bandello,
   francesco/AAH-2405-2019; Chong, Ngaihang V/A-5141-2009; Chong,
   Victor/Q-6565-2018; Virgili, Gianni/P-6607-2014; Staurenghi,
   Giovanni/K-4388-2017
OI mones, jordi/0000-0003-3685-2160; Larsen, Michael/0000-0002-5172-5891;
   Wolf, Sebastian/0000-0002-7467-7028; bandello,
   francesco/0000-0003-3238-9682; Chong, Victor/0000-0002-7693-522X;
   Chakravarthy, Usha/0000-0002-2606-3734; Virgili,
   Gianni/0000-0002-9960-2989; Dimitrakos, Stavros/0000-0003-1742-0725;
   Staurenghi, Giovanni/0000-0002-2299-5251
CR Aiello LP, 2004, RETINA-J RET VIT DIS, V24, pS3, DOI 10.1097/00006982-200410001-00002
   [Anonymous], 1994, Arch Ophthalmol, V112, P489
   [Anonymous], 1991, Arch Ophthalmol, V109, P1109
   Arnold J, 2002, RETINA-J RET VIT DIS, V22, P6
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Arnold JJ, 2004, AM J OPHTHALMOL, V137, P683, DOI 10.1016/j.ajo.2003.11.059
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Avery RL, 2006, RETINA-J RET VIT DIS, V26, P352, DOI 10.1097/00006982-200603000-00016
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 2005, RETINA-J RET VIT DIS, V25, P119
   Ciulla TA, 1998, SURV OPHTHALMOL, V43, P134, DOI 10.1016/S0039-6257(98)00014-9
   CIULLA TA, 2005, INVEST OPHTHALMOL VI, V46
   COSCAS G, 1991, ARCH OPHTHALMOL-CHIC, V109, P1258, DOI 10.1001/archopht.1991.01080090082028
   Coscas G, 1982, Bull Mem Soc Fr Ophtalmol, V94, P149
   DAMICO DJ, 2005, INVEST OPHTHALMOL VI, V46
   DAMICO DJ, 2002, INVEST OPHTHALMOL VI, V43
   Danis RP, 2000, RETINA-J RET VIT DIS, V20, P244, DOI 10.1097/00006982-200003000-00004
   Davidorf FH, 2006, RETINA-J RET VIT DIS, V26, P354, DOI 10.1097/00006982-200603000-00017
   GARCIA CA, 2004, INVEST OPHTHALMOL VI, V45
   *GEN INC, 2005, PREL PHAS 1 2 DAT SH
   Gillies MC, 2003, ARCH OPHTHALMOL-CHIC, V121, P667, DOI 10.1001/archopht.121.5.667
   Gragoudas E. S., 2004, INVEST OPHTHALMOL VI, V45
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Greve MDJ, 2005, ARCH OPHTHALMOL-CHIC, V123, P448
   Heier J. S., 2004, INVEST OPHTHALMOL VI, V45
   Heier JS, 2005, INVEST OPHTH VIS SCI, V46
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   Iturralde D, 2006, RETINA-J RET VIT DIS, V26, P279, DOI 10.1097/00006982-200603000-00005
   Kaiser PK, 2005, CURR MED RES OPIN, V21, P705, DOI 10.1185/030079905X43659
   KAISER PK, 2003, INVEST OPHTHALMOL VI, V44
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   KUPPERMANN BD, 2004, AM AC OPHTH EUR SOC
   Manzano RPA, 2006, RETINA-J RET VIT DIS, V26, P257, DOI 10.1097/00006982-200603000-00001
   Mason JO, 2006, RETINA-J RET VIT DIS, V26, P356, DOI 10.1097/00006982-200603000-00018
   Maturi RK, 2006, RETINA-J RET VIT DIS, V26, P270, DOI 10.1097/00006982-200603000-00003
   Nguyen QD, 2005, BRIT J OPHTHALMOL, V89, P1368, DOI 10.1136/bjo.2005.066431
   Rechtman E, 2004, BRIT J OPHTHALMOL, V88, P344, DOI 10.1136/bjo.2003.027177
   Regillo CD, 2005, INVEST OPHTH VIS SCI, V46
   REGILLO CD, 2004, INVEST OPHTHALMOL VI, V45
   REICHEL E, 2004, AAO RET SUBSP DAY 22
   Rosenfeld PJ, 2001, INVEST OPHTH VIS SCI, V42, pS512
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P336, DOI 10.3928/1542-8877-20050701-15
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   ROTH DB, 2004, INVEST OPHTHALMOL VI, V45
   Russell S, 2003, OPHTHALMOLOGY, V110, P2372, DOI 10.1016/j.ophtha.2003.08.020
   Schmidt-Erfurth U, 2003, INVEST OPHTH VIS SCI, V44, P4473, DOI 10.1167/iovs.02-1115
   SCHWARTZ SD, 2004, AAO RET SUBSP DAY 22
   Shahar J, 2006, RETINA-J RET VIT DIS, V26, P262, DOI 10.1097/00006982-200603000-00002
   Sickenberg M, 2001, OPHTHALMOLOGICA, V215, P247, DOI 10.1159/000050869
   Slakter JS, 2006, OPHTHALMOLOGY, V113, P3, DOI 10.1016/j.ophtha.2005.10.019
   SLAKTER JS, 2004, INVEST OPHTHALMOL VI, V45
   SLAKTER JS, 1927, INVEST OPHTHALMOL VI, V45
   SLAKTER JS, 2004, AM AC OPHT EUR SOC O
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P1517, DOI 10.1016/S0161-6420(03)00544-X
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P275, DOI 10.1097/00006982-200603000-00004
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   THOMAS EL, 2004, AM AC OPHTH EUR SOC
   THOMAS EL, 2004, INVEST OPHTHALMOL VI, V45
NR 60
TC 54
Z9 63
U1 0
U2 6
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD SEP
PY 2006
VL 90
IS 9
BP 1188
EP 1196
DI 10.1136/bjo.2005.082255
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 076ZP
UT WOS:000239997700032
PM 16929063
OA Green Published
DA 2022-11-30
ER

PT J
AU Zhou, HY
   Zhao, XF
   Johnson, EJ
   Lim, A
   Sun, ED
   Yu, J
   Zhang, YB
   Liu, XP
   Snellingen, T
   Shang, F
   Liu, NP
AF Zhou, Haiying
   Zhao, Xianfeng
   Johnson, Elizabeth J.
   Lim, Apiradee
   Sun, Erdan
   Yu, Jie
   Zhang, Yinbo
   Liu, Xipu
   Snellingen, Torkel
   Shang, Fu
   Liu, Ningpu
TI Serum Carotenoids and Risk of Age-Related Macular Degeneration in a
   Chinese Population Sample
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID VITAMIN-A; ADIPOSE-TISSUE; DIETARY ANTIOXIDANTS; ADULT-POPULATION;
   BETA-CAROTENE; LUNG-CANCER; LUTEIN; ZEAXANTHIN; MACULOPATHY; PIGMENT
AB PURPOSE. It has been hypothesized that the macular carotenoids protect against age-related macular degeneration (AMD). In this study, the association between serum concentrations of carotenoids and the presence of AMD was evaluated in a case-control sample of elderly Chinese subjects.
   METHODS. Two hundred sixty-three individuals aged between 50 and 88 years enrolled in the study. Subjects included 82 cases with exudative AMD, 92 cases with early AMD, and 89 control individuals. Serum carotenoids (lutein, zeaxanthin, lycopene, alpha- and beta-carotenes, and beta-cryptoxanthin) and retinol were measured with reversed-phase high-performance liquid chromatography (HPLC).
   RESULTS. Serum levels of carotenoids and retinol were significantly lower in the cases with exudative AMD than in the controls. Median levels of lutein and zeaxanthin were 0.538 and 0.101 mu M, respectively, in the control subjects, and 0.488 and 0.076 mu M, respectively, in cases with exudative AMD. After adjustment for age, sex, smoking status, and body mass index (BMI), a significant inverse association was observed for exudative AMD with serum zeaxanthin (relative risk ratio [RRR], 0.04; 95% confidence interval [CI], 0-0.35), lycopene (RRR, 0.22; 95% CI, 0.1-0.48), and alpha-carotene (RRR, 0.24; 95% CI, 0.12-0.51). Early AMD was inversely associated only with lycopene (RRR, 0.49; 95% CI, 0.28-0.86) but was positively associated with alpha-carotene (RRR, 2.22; 95% CI, 1.37-3.58). No significant associations were observed between serum lutein and cases with early or exudative AMD.
   CONCLUSIONS. The data suggest that higher levels of serum carotenoids, in particular zeaxanthin and lycopene, are associated with a lower likelihood of having exudative AMD. Serum levels of carotenoids were relatively higher in this Chinese cohort than in samples of other ethnicities in previous reports. ( Invest Ophthalmol Vis Sci. 2011;52:4338-4344) DOI:10.1167/iovs.10-6519
C1 [Zhou, Haiying; Sun, Erdan; Yu, Jie; Zhang, Yinbo; Liu, Ningpu] Capital Med Univ, Beijing Tongren Eye Ctr, Beijing Tongren Hosp, Beijing Ophthalmol & Visual Sci Key Lab, Beijing 100730, Peoples R China.
   [Zhao, Xianfeng] Chinese Ctr Dis Control & Prevent, Natl Inst Nutr & Food Safety, Beijing, Peoples R China.
   [Johnson, Elizabeth J.; Shang, Fu] Tufts Univ, Human Nutr Res Ctr Aging, Jean Mayer US Dept Agr, Boston, MA 02111 USA.
   [Lim, Apiradee] Prince Songkla Univ, Fac Sci & Technol, Dept Math & Comp Sci, Muang Pattani, Thailand.
   [Liu, Xipu; Snellingen, Torkel] Sekwa Eye Hosp, Beijing, Peoples R China.
C3 Capital Medical University; Chinese Center for Disease Control &
   Prevention; Tufts University; United States Department of Agriculture
   (USDA); Prince of Songkla University
RP Liu, NP (通讯作者)，Capital Med Univ, Beijing Tongren Eye Ctr, Beijing Tongren Hosp, Beijing Ophthalmol & Visual Sci Key Lab, 1 Dong Jiao Min Xiang, Beijing 100730, Peoples R China.
EM nliu001@gmail.com
FU National Basic Research Program of China (Program 973) [2007CB512201];
   Beijing Municipal Health Bureau [2009208]
FX Supported by the National Basic Research Program of China (Program 973)
   Grant 2007CB512201 and the Beijing Municipal Health Bureau Grant
   2009208.
CR Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Barouch Fina C., 2007, International Ophthalmology Clinics, V47, P185, DOI 10.1097/IIO.0b013e3180377936
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Berendschot TTJM, 2000, INVEST OPHTH VIS SCI, V41, P3322
   Bermudez OI, 2005, J NUTR, V135, P1496, DOI 10.1093/jn/135.6.1496
   Bird AC, 2003, EYE, V17, P457, DOI 10.1038/sj.eye.6700562
   Bok D, 2005, P NATL ACAD SCI USA, V102, P7053, DOI 10.1073/pnas.0502819102
   Bone RA, 2001, INVEST OPHTH VIS SCI, V42, P235
   BONE RA, 1992, METHOD ENZYMOL, V213, P360
   Bone RA, 2000, EXP EYE RES, V71, P239, DOI 10.1006/exer.2000.0870
   Broekmans WMR, 2002, AM J CLIN NUTR, V76, P595, DOI 10.1093/ajcn/76.3.595
   Burke JD, 2005, J NUTR, V135, P1208, DOI 10.1093/jn/135.5.1208
   Cardinault N, 2005, CLIN CHIM ACTA, V357, P34, DOI 10.1016/j.cccn.2005.01.030
   Chong EWT, 2007, BMJ-BRIT MED J, V335, P755, DOI 10.1136/bmj.39350.500428.47
   Cui L, 2010, INVEST OPHTH VIS SCI, V51, P1116, DOI 10.1167/iovs.09-4265
   Curran-Celentano J, 2001, AM J CLIN NUTR, V74, P796
   Dasch B, 2005, GRAEF ARCH CLIN EXP, V243, P1028, DOI 10.1007/s00417-005-1176-z
   Delcourt C, 2006, INVEST OPHTH VIS SCI, V47, P2329, DOI 10.1167/iovs.05-1235
   Despriet DDG, 2009, OPHTHALMOLOGY, V116, P474, DOI 10.1016/j.ophtha.2008.09.055
   El-Sohemy A, 2002, AM J CLIN NUTR, V76, P172, DOI 10.1093/ajcn/76.1.172
   Flood V, 2002, OPHTHALMOLOGY, V109, P2272, DOI 10.1016/S0161-6420(02)01263-0
   Gabriel HE, 2006, CANCER EPIDEM BIOMAR, V15, P993, DOI 10.1158/1055-9965.EPI-05-0664
   Gale CR, 2003, INVEST OPHTH VIS SCI, V44, P2461, DOI 10.1167/iovs.02-0929
   Imamura Y, 2006, P NATL ACAD SCI USA, V103, P11282, DOI 10.1073/pnas.0602131103
   Johnson EJ, 2005, INVEST OPHTH VIS SCI, V46, P692, DOI 10.1167/iovs.02-1192
   Johnson EJ, 2000, AM J CLIN NUTR, V71, P1555
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Krinsky Norman I., 2005, Molecular Aspects of Medicine, V26, P459
   Landrum JT, 1999, METHOD ENZYMOL, V299, P457
   Li YB, 2006, AM J OPHTHALMOL, V142, P788, DOI 10.1016/j.ajo.2006.06.001
   Mares-Perlman JA, 2001, AM J EPIDEMIOL, V153, P424, DOI 10.1093/aje/153.5.424
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P1518, DOI 10.1001/archopht.1995.01100120048007
   Michikawa T, 2009, ASIA PAC J CLIN NUTR, V18, P1
   Moeller SM, 2006, ARCH OPHTHALMOL-CHIC, V124, P1151, DOI 10.1001/archopht.124.8.1151
   Moshfeghi DM, 2007, RETINA-J RET VIT DIS, V27, P269, DOI 10.1097/IAE.0b013e31802e3e9b
   Nolan J, 2004, INVEST OPHTH VIS SCI, V45, P3940, DOI 10.1167/iovs.04-0273
   Obana A, 2008, OPHTHALMOLOGY, V115, P147, DOI 10.1016/j.ophtha.2007.02.028
   Omenn GS, 1996, J NATL CANCER I, V88, P1550, DOI 10.1093/jnci/88.21.1550
   Omenn GS, 1996, NEW ENGL J MED, V334, P1150, DOI 10.1056/NEJM199605023341802
   R Development Core Team, R LANG ENV STAT COMP
   Rock CL, 2002, J NUTR, V132, p525S, DOI 10.1093/jn/132.3.525S
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Snellen ELM, 2002, ACTA OPHTHALMOL SCAN, V80, P368, DOI 10.1034/j.1600-0420.2002.800404.x
   SNODDERLY DM, 1995, AM J CLIN NUTR, V62, P1448
   Tan JSL, 2008, OPHTHALMOLOGY, V115, P334, DOI 10.1016/j.ophtha.2007.03.083
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   Wang GY, 1996, BRIT J NUTR, V76, P809, DOI 10.1079/BJN19960088
   Xu L, 2006, BRIT J OPHTHALMOL, V90, P1087, DOI 10.1136/bjo.2006.096123
   Xu YL, 2008, MOL VIS, V14, P1373
NR 53
TC 24
Z9 27
U1 1
U2 13
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JUN
PY 2011
VL 52
IS 7
BP 4338
EP 4344
DI 10.1167/iovs.10-6519
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 800BP
UT WOS:000293332500054
PM 21508112
DA 2022-11-30
ER

PT J
AU Liu, K
   Fang, JW
   Jin, J
   Zhu, SP
   Xu, XY
   Xu, YP
   Ye, B
   Lin, SH
   Xu, X
AF Liu, Kun
   Fang, Junwei
   Jin, Jing
   Zhu, Shaopin
   Xu, Xiaoyin
   Xu, Yupeng
   Ye, Bin
   Lin, Shu-Hai
   Xu, Xun
TI Serum Metabolomics Reveals Personalized Metabolic Patterns for Macular
   Neovascular Disease Patient Stratification
SO JOURNAL OF PROTEOME RESEARCH
LA English
DT Article
DE metabolomics; GC-MS; choroidal neovascularization; AMD; PCV; PM;
   multivariate analysis; OLPS-DA; ROC; biomarkers
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; PENTOSE-PHOSPHATE PATHWAY; OXIDATIVE
   STRESS; DEGENERATION; INFLAMMATION; GLYCOLYSIS; MARKERS
AB The macular neovascular disease is a group disorder with complex pathogenesis of neovascularization for vision impairment and irreversible blindness, posing great challenges to precise diagnosis and management. We prospectively recruited participants with age-related macular degeneration (AMD), polypoidal choroidal vasculopathy (PCV), and pathological myopia (PM) and compared with cataract patients without fundus diseases as a control group. The serum metabolome was profiled by gas chromatography coupled with time-of-flight mass spectrometry (GC-TOFMS) analysis. Multivariate statistical methods as well as data mining were performed for interpretation of macular neovascularization. A total of 446 participants with macular neovascularization and 138 cataract subjects as the control group were enrolled in this study. By employing GC-TOFMS, 131 metabolites were identified and 33 differentiating metabolites were highlighted in patients with macular neovascularization. For differential diagnosis, three panels of specific metabolomics-based biomarkers provided areas under the curve of 0.967, 0.938, and 0.877 in the discovery phase (n = 328) and predictive values of 87.3%, 79%, and 85.7% in the test phase (n = 256). Personalized pathway dysregulation scores measurement using Lilikoi package in R language revealed the pentose phosphate pathway and mitochondrial electron transport chain as the most important pathways in AMD; purine metabolism and glycolysis were identified as the major disturbed pathways in PCV, while the altered thiamine metabolism and purine metabolism may contribute to PM phenotypes. Serum metabolomics are powerful for characterizing metabolic disturbances of the macular neovascular disease. Differences in metabolic pathways may reflect an underlying macular neovascular disease and serve as therapeutic targets for macular neovascular treatment.
C1 [Liu, Kun; Fang, Junwei; Jin, Jing; Zhu, Shaopin; Xu, Xiaoyin; Xu, Yupeng; Ye, Bin; Xu, Xun] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Dept Ophthalmol, Sch Med, Shanghai 200040, Peoples R China.
   [Fang, Junwei; Lin, Shu-Hai] Shanghai Gen Hosp, Shanghai Engn Ctr Visual Sci & Photomed, Shanghai Key Lab Ocular Fundus Dis, Shanghai 200040, Peoples R China.
   [Fang, Junwei; Lin, Shu-Hai] Shanghai Jiao Tong Univ, Coll Basic Med Sci, Sch Med, Shanghai 200025, Peoples R China.
   [Lin, Shu-Hai] Xiamen Univ, Sch Life Sci, State Key Lab Cellular Stress Biol, Xiamen 361005, Fujian, Peoples R China.
C3 Shanghai Jiao Tong University; Shanghai Jiao Tong University; Xiamen
   University
RP Xu, X (通讯作者)，Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Dept Ophthalmol, Sch Med, Shanghai 200040, Peoples R China.; Lin, SH (通讯作者)，Shanghai Gen Hosp, Shanghai Engn Ctr Visual Sci & Photomed, Shanghai Key Lab Ocular Fundus Dis, Shanghai 200040, Peoples R China.; Lin, SH (通讯作者)，Shanghai Jiao Tong Univ, Coll Basic Med Sci, Sch Med, Shanghai 200025, Peoples R China.; Lin, SH (通讯作者)，Xiamen Univ, Sch Life Sci, State Key Lab Cellular Stress Biol, Xiamen 361005, Fujian, Peoples R China.
EM shuhai@xmu.edu.cn; drxuxun@sjtu.edu.cn
OI Fang, Junwei/0000-0002-4303-1750
FU National Key Research and Development Program of China [2016YFC0904800]
FX This work was supported by the grant from the National Key Research and
   Development Program of China (no. 2016YFC0904800). The authors would
   like to thank Mingming Su at Metabo-Profile Biotechnology (Shanghai)
   Co., Ltd. for his assistance on the GC-TOFMS analysis.
CR Al-Akwaa FM, 2018, GIGASCIENCE, V7, DOI 10.1093/gigascience/giy136
   Axer-Siegez R, 2004, OPHTHAL SURG LAS IM, V35, P139, DOI 10.3928/1542-8877-20040301-09
   Chao JR, 2017, J BIOL CHEM, V292, P12895, DOI 10.1074/jbc.M117.788422
   Chen GB, 2017, ANAL CHEM, V89, P4897, DOI 10.1021/acs.analchem.6b05006
   Chen WL, 2016, CANCER CELL, V30, P779, DOI 10.1016/j.ccell.2016.09.006
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Cheung CMG, 2017, OPHTHALMOLOGY, V124, P1690, DOI 10.1016/j.ophtha.2017.04.028
   Cho ES, 2018, BIOMOL THER, V26, P29, DOI 10.4062/biomolther.2017.179
   Conley YP, 2005, HUM MOL GENET, V14, P1991, DOI 10.1093/hmg/ddi204
   Costantini A, 2016, NEURAL REGEN RES, V11, P1487, DOI 10.4103/1673-5374.191225
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   De Bock K, 2013, CELL, V154, P651, DOI 10.1016/j.cell.2013.06.037
   Domalpally A, 2018, OPHTHALMOL RETINA, V2, P1021, DOI 10.1016/j.oret.2018.04.009
   Fang JW, 2017, MOL BIOSYST, V13, P1575, DOI 10.1039/c7mb00093f
   Garcia-Layana A, 2006, BRIT J OPHTHALMOL, V90, P555, DOI 10.1136/bjo.2005.085555
   Gerasimovskaya E, 2010, EXTRACELLULAR ATP AND ADENOSINE AS REGULATORS OF ENDOTHELIAL CELL FUNCTION, P1, DOI 10.1007/978-90-481-3435-9
   Haggarty J, 2017, CURR OPIN BIOTECH, V43, P77, DOI 10.1016/j.copbio.2016.09.006
   Halouska S, 2012, ACS CHEM BIOL, V7, P166, DOI 10.1021/cb200348m
   Horai H, 2010, J MASS SPECTROM, V45, P703, DOI 10.1002/jms.1777
   Huang S, 2016, GENOME MED, V8, DOI 10.1186/s13073-016-0289-9
   Jiang HY, 2017, J NEUROCHEM, V143, P375, DOI 10.1111/jnc.14214
   Ke CF, 2016, SCI REP-UK, V6, DOI 10.1038/srep23334
   Klein R, 2014, JAMA OPHTHALMOL, V132, P446, DOI 10.1001/jamaophthalmol.2013.7671
   Lains I, 2019, J PROTEOME RES, V18, P1278, DOI 10.1021/acs.jproteome.8b00877
   Lains I, 2018, OPHTHALMOLOGY, V125, P245, DOI 10.1016/j.ophtha.2017.08.008
   Lains I, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177749
   Li ML, 2016, SCI REP-UK, V6, DOI 10.1038/srep38342
   Liu XY, 2016, ANAL BIOANAL CHEM, V408, P6497, DOI 10.1007/s00216-016-9768-5
   Min L., 2013, J 3 MIL MED U, V10, P16
   Moriyama M, 2007, OPHTHALMOLOGY, V114, P1755, DOI 10.1016/j.ophtha.2006.11.034
   Paris LP, 2016, METABOLOMICS, V12, DOI 10.1007/s11306-015-0877-5
   Patra KC, 2014, TRENDS BIOCHEM SCI, V39, P347, DOI 10.1016/j.tibs.2014.06.005
   Rath M, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00532
   Schoors S, 2014, CELL METAB, V19, P37, DOI 10.1016/j.cmet.2013.11.008
   Shaw PX, 2016, AIMS MOL SCI, V3, P196, DOI 10.3934/molsci.2016.2.196
   Shen J, 2017, J CHROMATOGR B, V1057, P40, DOI 10.1016/j.jchromb.2017.04.042
   Trotta AP, 2017, J BIOL CHEM, V292, P11727, DOI 10.1074/jbc.M117.786442
   Valls MD, 2009, BIOCHEM PHARMACOL, V77, P1117, DOI 10.1016/j.bcp.2008.11.002
   Wang Y, 2015, RSC ADV, V5, P78728, DOI 10.1039/c5ra14058g
   Weyand CM, 2018, FREE RADICAL BIO MED, V125, P36, DOI 10.1016/j.freeradbiomed.2018.03.004
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xia Jianguo, 2016, Curr Protoc Bioinformatics, V55, DOI 10.1002/cpbi.11
NR 43
TC 10
Z9 11
U1 2
U2 22
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1535-3893
EI 1535-3907
J9 J PROTEOME RES
JI J. Proteome Res.
PD FEB
PY 2020
VL 19
IS 2
BP 699
EP 707
DI 10.1021/acs.jproteome.9b00574
PG 9
WC Biochemical Research Methods
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA KK9WO
UT WOS:000513085100013
PM 31755721
DA 2022-11-30
ER

PT J
AU Wang, YW
   Bo, QY
   Jia, HX
   Sun, MS
   Yu, Y
   Huang, PR
   Wang, J
   Xu, NN
   Wang, FH
   Wang, H
   Sun, XD
AF Wang, Yuwei
   Bo, Qiyu
   Jia, Huixun
   Sun, Mengsha
   Yu, Yang
   Huang, Peirong
   Wang, Jing
   Xu, Nana
   Wang, Fenghua
   Wang, Hong
   Sun, Xiaodong
TI Small dome-shaped pigment epithelium detachment in polypoidal choroidal
   vasculopathy: an under-recognized sign of polypoidal lesions on optical
   coherence tomography?
SO EYE
LA English
DT Article
AB Purpose To evaluate the diagnostic accuracy of spectral-domain optical coherence tomography (SD-OCT) and swept-source optical coherence tomographic angiography (SS-OCTA) to identify polypoidal lesions in serous or serosanguinous maculopathy. Materials and methods A retrospective review of patients presenting pigment epithelial detachments (PEDs) with the diagnosis of polypoidal choroidal vasculopathy (PCV), neovascular age-related macular degeneration (nAMD), and central serous chorioretinopathy (CSC), all of which underwent SD-OCT, SS-OCTA, and indocyanine green angiography (ICGA). Typical features of polypoidal lesions on SD-OCT included sharply peaked PED, notched PED, and hyperreflective ring underneath PED. SS-OCTA feature was vascularized PEDs on cross-sectional images corresponding to cluster-like structures on en face images. The parameters of PEDs were measured for analysis. Results Of 72 eyes, 30 had PCV, 22 had nAMD, and 20 had CSC. A total of 128 localized PEDs were detected on SD-OCT. Typical features on SD-OCT had a high specificity (94.0%) but a limited sensitivity (73.8%). SS-OCTA features provided a higher sensitivity (96.7%). PEDs of the polypoidal lesions unrecognized by SD-OCT were dome-shaped, with smaller ratio of height to base diameter and less area, and almost had heterogeneous internal reflectivity and a connected double-layer sign. Some lesions misidentified by SS-OCTA developed into ICGA-proven polypoidal lesions at follow-up visits. Conclusion A small dome-shaped PED with heterogeneous internal reflectivity and a connected double-layer sign on SD-OCT may suggest a polypoidal lesion of PCV. SS-OCTA may be a helpful tool to investigate preclinical PCV and observe the formation of polypoidal lesions.
C1 [Wang, Yuwei; Bo, Qiyu; Jia, Huixun; Sun, Mengsha; Yu, Yang; Huang, Peirong; Wang, Jing; Xu, Nana; Wang, Fenghua; Wang, Hong; Sun, Xiaodong] Shanghai Jiao Tong Univ, Sch Med, Shanghai Gen Hosp, Dept Ophthalmol, Shanghai, Peoples R China.
   [Wang, Yuwei; Bo, Qiyu; Jia, Huixun; Sun, Mengsha; Huang, Peirong; Wang, Jing; Xu, Nana; Wang, Fenghua; Wang, Hong; Sun, Xiaodong] Natl Clin Res Ctr Eye Dis, Shanghai, Peoples R China.
   [Wang, Fenghua; Wang, Hong; Sun, Xiaodong] Shanghai Key Lab Fundus Dis, Shanghai, Peoples R China.
C3 Shanghai Jiao Tong University
RP Wang, FH; Wang, H (通讯作者)，Shanghai Jiao Tong Univ, Sch Med, Shanghai Gen Hosp, Dept Ophthalmol, Shanghai, Peoples R China.; Wang, FH; Wang, H (通讯作者)，Natl Clin Res Ctr Eye Dis, Shanghai, Peoples R China.; Wang, FH; Wang, H (通讯作者)，Shanghai Key Lab Fundus Dis, Shanghai, Peoples R China.
EM shretina@sjtu.edu.cn; wanghong700520@126.com
RI Sun, Mengsha/HCH-7851-2022
OI Jing, Wang/0000-0003-4477-9442
FU National Major Scientific and Technological Special Project for
   "Significant New Drugs Development" during the Thirtieth Five-year Plan
   Period [2019ZX09301113]; National Natural Science Foundation of China
   [81730026]; National Key RD Program [2017YFA0105301]; Science and
   Technology Commission of Shanghai Municipality [CTCCR-2016B02,
   17411953000, 19495800700]; Shanghai Collaborative Innovation Center for
   Translational Medicine [TM201722]; Leaders Training Program of Shanghai
   Municipality Commission of Health and Family Planning [2018BR10];
   Bethune-Langmu eye research fund for the young and middle-aged
   ophthalmologist [BJ-LM2018001J]
FX The study was supported by the National Major Scientific and
   Technological Special Project for "Significant New Drugs Development"
   during the Thirtieth Five-year Plan Period (2019ZX09301113); National
   Natural Science Foundation of China (81730026); National Key R&D Program
   (2017YFA0105301); Science and Technology Commission of Shanghai
   Municipality (CTCCR-2016B02, 17411953000, 19495800700); Shanghai
   Collaborative Innovation Center for Translational Medicine (TM201722);
   Leaders Training Program of Shanghai Municipality Commission of Health
   and Family Planning (2018BR10); and Bethune-Langmu eye research fund for
   the young and middle-aged ophthalmologist (BJ-LM2018001J).
CR Baek J, 2019, INVEST OPHTH VIS SCI, V60, P590, DOI 10.1167/iovs.18-24244
   Barteselli G, 2016, RETINA-J RET VIT DIS, V36, P1153, DOI 10.1097/IAE.0000000000000842
   Bo QY, 2019, JAMA OPHTHALMOL, V137, P642, DOI 10.1001/jamaophthalmol.2019.0449
   Chaikitmongkol V, 2019, JAMA OPHTHALMOL, V137, P661, DOI 10.1001/jamaophthalmol.2019.0565
   Chaikitmongkol V, 2018, AM J OPHTHALMOL, V192, P77, DOI 10.1016/j.ajo.2018.05.005
   Chan SY, 2018, RETINA-J RET VIT DIS, V38, P1187, DOI 10.1097/IAE.0000000000001702
   Chen L, 2018, GRAEF ARCH CLIN EXP, V256, P2283, DOI 10.1007/s00417-018-4138-y
   Cheong KX, 2020, EYE, V34, P2257, DOI 10.1038/s41433-020-0803-6
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Cheung CMG, 2017, RETINA-J RET VIT DIS, V37, P1464, DOI 10.1097/IAE.0000000000001391
   Cheung CMG, 2015, RETINA-J RET VIT DIS, V35, P1375, DOI 10.1097/IAE.0000000000000482
   Chi YT, 2017, JAMA OPHTHALMOL, V135, P1310, DOI 10.1001/jamaophthalmol.2017.4360
   Cho JH, 2020, RETINA-J RET VIT DIS, V40, P468, DOI 10.1097/IAE.0000000000002384
   Cicinelli MV, 2020, RETINA-J RET VIT DIS, V40, P499, DOI 10.1097/IAE.0000000000002452
   Daruich A, 2015, PROG RETIN EYE RES, V48, P82, DOI 10.1016/j.preteyeres.2015.05.003
   de Carlo TE, 2019, RETINA-J RET VIT DIS, V39, P1343, DOI 10.1097/IAE.0000000000002139
   De Salvo G, 2014, AM J OPHTHALMOL, V158, P1228, DOI 10.1016/j.ajo.2014.08.025
   Fujita A, 2020, RETINA-J RET VIT DIS, V40, P2296, DOI 10.1097/IAE.0000000000002760
   Holmen IC, 2020, JAMA OPHTHALMOL, V138, P119, DOI 10.1001/jamaophthalmol.2019.4971
   HOPEROSS M, 1994, OPHTHALMOLOGY, V101, P529
   Iijima H, 2000, AM J OPHTHALMOL, V129, P21, DOI 10.1016/S0002-9394(99)00253-6
   Inoue M, 2015, RETINA-J RET VIT DIS, V35, P2265, DOI 10.1097/IAE.0000000000000777
   Kang HM, 2014, AM J OPHTHALMOL, V157, P598, DOI 10.1016/j.ajo.2013.11.015
   Kang H, 2019, RETINA-J RET VIT DIS, V39, P1551, DOI 10.1097/IAE.0000000000002201
   Kang SW, 2017, GRAEF ARCH CLIN EXP, V255, P281, DOI 10.1007/s00417-016-3452-5
   Kim YT, 2012, BRIT J OPHTHALMOL, V96, P1217, DOI 10.1136/bjophthalmol-2012-301644
   Koizumi H, 2015, BRIT J OPHTHALMOL, V99, P1284, DOI 10.1136/bjophthalmol-2014-306432
   Lee YA, 2012, AM J OPHTHALMOL, V154, P872, DOI 10.1016/j.ajo.2012.03.051
   Liu R, 2016, RETINA-J RET VIT DIS, V36, P778, DOI 10.1097/IAE.0000000000000794
   Lorentzen TD, 2018, ACTA OPHTHALMOL, V96, P475, DOI 10.1111/aos.13646
   Miller AR, 2017, INVEST OPHTH VIS SCI, V58, P1499, DOI 10.1167/iovs.16-20969
   Novais EA, 2016, AM J OPHTHALMOL, V164, P80, DOI 10.1016/j.ajo.2016.01.011
   Sato T, 2004, RETINA-J RET VIT DIS, V24, P910, DOI 10.1097/00006982-200412000-00011
   Spaide RF, 2015, RETINA-J RET VIT DIS, V35, P2163, DOI 10.1097/IAE.0000000000000765
   Takayama K, 2017, EYE, V31, P45, DOI 10.1038/eye.2016.232
   Tan ACS, 2018, RETINA-J RET VIT DIS, V38, P1759, DOI 10.1097/IAE.0000000000002016
   Tan ACS, 2016, AM J OPHTHALMOL, V172, P13, DOI 10.1016/j.ajo.2016.09.004
   Tan CS, 2015, BRIT J OPHTHALMOL, V99, P624, DOI 10.1136/bjophthalmol-2014-305674
   Tanaka K, 2017, BRIT J OPHTHALMOL, V101, P51, DOI 10.1136/bjophthalmol-2016-309264
   Ting DSW, 2015, CLIN EXP OPHTHALMOL, V43, P815, DOI 10.1111/ceo.12580
   Tsujikawa A, 2007, AM J OPHTHALMOL, V143, P102, DOI 10.1016/j.ajo.2006.08.025
   Ueta T, 2008, AM J OPHTHALMOL, V146, P96, DOI 10.1016/j.ajo.2008.03.002
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Wang M, 2016, INVEST OPHTH VIS SCI, V57, pOCT526, DOI 10.1167/iovs.15-18955
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Yang LH, 2013, INVEST OPHTH VIS SCI, V54, P4659, DOI 10.1167/iovs.12-10991
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yeung L, 2018, RETINA-J RET VIT DIS, V38, P263, DOI 10.1097/IAE.0000000000001556
   Zayit-Soudry S, 2007, SURV OPHTHALMOL, V52, P227, DOI 10.1016/j.survophthal.2007.02.008
   Zhang QQ, 2017, INVEST OPHTH VIS SCI, V58, P1506, DOI 10.1167/iovs.16-20977
NR 50
TC 1
Z9 2
U1 1
U2 2
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD APR
PY 2022
VL 36
IS 4
BP 733
EP 741
DI 10.1038/s41433-020-01390-0
EA APR 2021
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA ZZ4YG
UT WOS:000638044900002
PM 33833415
DA 2022-11-30
ER

PT J
AU Waksmunski, AR
   Igo, RP
   Song, YE
   Bailey, JNC
   Laux, R
   Fuzzell, D
   Fuzzell, S
   Adams, LD
   Caywood, L
   Prough, M
   Stambolians, D
   Scotto, WK
   Pericak-Vance, MA
   Haines, JL
AF Waksmunski, Andrea R.
   Igo, Robert P., Jr.
   Song, Yeunjoo E.
   Bailey, Jessica N. Cooke
   Laux, Renee
   Fuzzell, Denise
   Fuzzell, Sarada
   Adams, Larry D.
   Caywood, Laura
   Prough, Michael
   Stambolians, Dwight
   Scotto, William K.
   Pericak-Vance, Margaret A.
   Haines, Jonathan L.
TI Rare variants and loci for age-related macular degeneration in the Ohio
   and Indiana Amish
SO HUMAN GENETICS
LA English
DT Article
ID COMPLEMENT FACTOR-H; GENOME-WIDE ASSOCIATION; TELOMERE LENGTH; RISK;
   HERITABILITY; ORGANIZATION; MACULOPATHY; HAPLOTYPE; LINKAGE; DISEASE
AB Age-related macular degeneration (AMD) is a leading cause of blindness in the world. While dozens of independent genomic variants are associated with AMD, about one-third of AMD heritability is still unexplained. To identify novel variants and loci for AMD, we analyzed Illumina HumanExome chip data from 87 Amish individuals with early or late AMD, 79 unaffected Amish individuals, and 15 related Amish individuals with unknown AMD affection status. We retained 37,428 polymorphic autosomal variants across 175 samples for association and linkage analyses. After correcting for multiple testing (n = 37,428), we identified four variants significantly associated with AMD: rs200437673 (LCN9, p = 1.50 x 10(-11)), rs151214675 (RTEL1, p = 3.18 x 10(-8)), rs140250387 (DLGAP1, p = 4.49 x 10(-7)), and rs115333865 (CGRRF1, p = 1.05 x 10(-6)). These variants have not been previously associated with AMD and are not in linkage disequilibrium with the 52 known AMD-associated variants reported by the International AMD Genomics Consortium based on physical distance. Genome-wide significant linkage peaks were observed on chromosomes 8q21.11-q21.13 (maximum recessive HLOD = 4.03) and 18q21.2-21.32 (maximum dominant HLOD = 3.87; maximum recessive HLOD = 4.27). These loci do not overlap with loci previously linked to AMD. Through gene ontology enrichment analysis with ClueGO in Cytoscape, we determined that several genes in the 1-HLOD support interval of the chromosome 8 locus are involved in fatty acid binding and triglyceride catabolic processes, and the 1-HLOD support interval of the linkage region on chromosome 18 is enriched in genes that participate in serine-type endopeptidase inhibitor activity and the positive regulation of epithelial to mesenchymal transition. These results nominate novel variants and loci for AMD that require further investigation.
C1 [Waksmunski, Andrea R.; Haines, Jonathan L.] Case Western Reserve Univ, Dept Genet & Genome Sci, Cleveland, OH 44106 USA.
   [Waksmunski, Andrea R.; Bailey, Jessica N. Cooke; Haines, Jonathan L.] Case Western Reserve Univ, Cleveland Inst Computat Biol, Cleveland, OH 44106 USA.
   [Waksmunski, Andrea R.; Igo, Robert P., Jr.; Song, Yeunjoo E.; Bailey, Jessica N. Cooke; Laux, Renee; Fuzzell, Denise; Fuzzell, Sarada; Haines, Jonathan L.] Case Western Reserve Univ, Dept Populat & Quantitat Hlth Sci, Cleveland, OH 44106 USA.
   [Adams, Larry D.; Caywood, Laura; Prough, Michael; Scotto, William K.; Pericak-Vance, Margaret A.] Univ Miami, Miller Sch Med, John P Hussman Inst Human Genom, Miami, FL 33136 USA.
   [Stambolians, Dwight] Univ Penn, Dept Ophthalmol, Philadelphia, PA 19104 USA.
C3 Case Western Reserve University; Case Western Reserve University; Case
   Western Reserve University; University of Miami; University of
   Pennsylvania
RP Haines, JL (通讯作者)，Case Western Reserve Univ, Dept Genet & Genome Sci, Cleveland, OH 44106 USA.; Haines, JL (通讯作者)，Case Western Reserve Univ, Cleveland Inst Computat Biol, Cleveland, OH 44106 USA.; Haines, JL (通讯作者)，Case Western Reserve Univ, Dept Populat & Quantitat Hlth Sci, Cleveland, OH 44106 USA.
EM jonathan.haines@case.edu
RI Cooke Bailey, Jessica Nicole/AFQ-5925-2022
OI Cooke Bailey, Jessica Nicole/0000-0002-4001-8702; Scott,
   William/0000-0001-9336-6404; Song, Yeunjoo/0000-0002-7452-3731;
   Waksmunski, Andrea/0000-0001-7223-7371
FU National Institutes of Health [EY023164]; PhRMA Informatics Postdoctoral
   Fellowship
FX We thank the Amish families for allowing us into their communities and
   for participating in our study. We also acknowledge the contributions of
   the Anabaptist Genealogy Database and Swiss Anabaptist Genealogy
   Association. The authors acknowledge the contributions of the Vanderbilt
   Technologies for Advanced Genomics (VANTAGE) DNA Resources Core. This
   work was supported by the National Institutes of Health [EY023164].
   J.N.C.B. was supported in part by a PhRMA Informatics Postdoctoral
   Fellowship. This work made use of the High Performance Computing
   Resource in the Core Facility for Advanced Research Computing at Case
   Western Reserve University.
CR Abecasis GR, 2002, NAT GENET, V30, P97, DOI 10.1038/ng786
   Abecasis Lab, 2013, EX CHIP DES WIK SIT
   Agarwala R, 2003, AM J MED GENET C, V121C, P32, DOI 10.1002/ajmg.c.20004
   Auer PL, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0138-2
   Ayoub T, 2009, J ROY SOC MED, V102, P56, DOI 10.1258/jrsm.2009.080298
   Baratz KH, 2010, NEW ENGL J MED, V363, P1016, DOI 10.1056/NEJMoa1007064
   Barber LJ, 2008, CELL, V135, P261, DOI 10.1016/j.cell.2008.08.016
   Bindea G, 2009, BIOINFORMATICS, V25, P1091, DOI 10.1093/bioinformatics/btp101
   Bourgain C, 2003, KININBCOEF CALCULATI
   Codd V, 2013, NAT GENET, V45, P422, DOI 10.1038/ng.2528
   Colijn JM, 2019, OPHTHALMOLOGY, V126, P393, DOI 10.1016/j.ophtha.2018.09.045
   Delcourt C, 2007, EUR J CLIN NUTR, V61, P1341, DOI 10.1038/sj.ejcn.1602685
   Ding H, 2004, CELL, V117, P873, DOI 10.1016/j.cell.2004.05.026
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Feng W, 2009, NAT REV NEUROSCI, V10, P87, DOI 10.1038/nrn2540
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Fritsche LG, 2010, HUM MOL GENET, V19, P4694, DOI 10.1093/hmg/ddq399
   Ghosh S, 2018, INVEST OPHTH VIS SCI, V59, P104, DOI 10.1167/iovs.18-24132
   Glaeser K, 2018, EMBO J, V37, DOI 10.15252/embj.201797311
   Goldstein JI, 2012, BIOINFORMATICS, V28, P2543, DOI 10.1093/bioinformatics/bts479
   Grove ML, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068095
   Guo Y, 2014, NAT PROTOC, V9, P2643, DOI 10.1038/nprot.2014.174
   Hageman GS, 2006, ANN MED, V38, P592, DOI 10.1080/07853890601097030
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hirschhorn JN, 2005, NAT REV GENET, V6, P95, DOI 10.1038/nrg1521
   Hoffman JD, 2014, INVEST OPHTH VIS SCI, V55, P4455, DOI 10.1167/iovs.13-13684
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Ishikawa K, 2016, AM J PATHOL, V186, P859, DOI 10.1016/j.ajpath.2015.11.014
   Ishikawa K, 2016, EXP EYE RES, V142, P19, DOI 10.1016/j.exer.2015.03.009
   Kallo G, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158000
   Klein R, 2003, OPHTHALMOLOGY, V110, P25, DOI 10.1016/S0161-6420(02)01565-8
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kobayashi M, 2019, INVEST OPHTH VIS SCI, V60, P528, DOI 10.1167/iovs.18-25678
   Kuot A, 2012, EUR J HUM GENET, V20, P632, DOI 10.1038/ejhg.2011.248
   Lee MK, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176566
   Li J, 2016, SCI SIGNAL, V9, DOI 10.1126/scisignal.aaf6716
   Li YJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018044
   Liu F, 2008, EUR J HUM GENET, V16, P854, DOI 10.1038/ejhg.2008.24
   Lores-Motta L, 2018, OPHTHALMOLOGY, V125, P1064, DOI 10.1016/j.ophtha.2017.12.023
   Machiela MJ, 2015, BIOINFORMATICS, V31, P3555, DOI 10.1093/bioinformatics/btv402
   Male DA, 2000, MOL IMMUNOL, V37, P41, DOI 10.1016/S0161-5890(00)00024-9
   Manolio TA, 2009, NATURE, V461, P747, DOI 10.1038/nature08494
   Martinez-Barricarte R, 2012, INVEST OPHTH VIS SCI, V53, P1087, DOI 10.1167/iovs.11-8709
   MCKUSICK VA, 1964, B JOHNS HOPKINS HOSP, V115, P203
   Merle BMJ, 2014, INVEST OPHTH VIS SCI, V55, P2010, DOI 10.1167/iovs.14-13916
   MORTON NE, 1955, AM J HUM GENET, V7, P277
   Munch IC, 2013, INVEST OPHTH VIS SCI, V54, P3932, DOI 10.1167/iovs.12-10785
   Naj AC, 2013, ANN HUM GENET, V77, P215, DOI 10.1111/ahg.12011
   Nowak M, 2005, CLIN EXP MED, V4, P183, DOI 10.1007/s10238-004-0054-z
   Parmar T, 2018, J IMMUNOL, V200, P3128, DOI 10.4049/jimmunol.1701573
   Paun CC, 2015, INVEST OPHTH VIS SCI, V56, P7766, DOI 10.1167/iovs.15-17035
   Pescosolido N, 2014, MOLECULES, V19, P20557, DOI 10.3390/molecules191220557
   Price AL, 2006, NAT GENET, V38, P904, DOI 10.1038/ng1847
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   Riazuddin SA, 2011, INVEST OPHTH VIS SCI, V52, P2825, DOI 10.1167/iovs.10-6497
   Roh MI, 2008, YONSEI MED J, V49, P931, DOI 10.3349/ymj.2008.49.6.931
   SanGiovanni JP, 2008, ARCH OPHTHALMOL-CHIC, V126, P1274, DOI 10.1001/archopht.126.9.1274
   SanGiovanni JP, 2005, PROG RETIN EYE RES, V24, P87, DOI 10.1016/j.preteyeres.2004.06.002
   Sardell RJ, 2016, OPHTHALMOLOGY, V123, P2537, DOI 10.1016/j.ophtha.2016.09.001
   Scavello GS, 2005, MOL VIS, V11, P97
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Seddon JM, 2003, AM J HUM GENET, V73, P780, DOI 10.1086/378505
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Seddon JM, 2013, INVEST OPHTH VIS SCI, V54, DOI 10.1167/iovs.13-13234
   Semba RD, 2014, JAMA OPHTHALMOL, V132, P464, DOI 10.1001/jamaophthalmol.2013.7664
   Shalev V, 2011, OPHTHAL EPIDEMIOL, V18, P83, DOI 10.3109/09286586.2011.560746
   Shaw PX, 2016, AIMS MOL SCI, V3, P196, DOI 10.3934/molsci.2016.2.196
   Shellenberger TD, 2005, CANCER RES, V65, P11501, DOI 10.1158/0008-5472.CAN-05-2262
   Skeie JM, 2014, JAMA OPHTHALMOL, V132, P1271, DOI 10.1001/jamaophthalmol.2014.2065
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Sobrin L, 2012, OPHTHALMOLOGY, V119, P1874, DOI 10.1016/j.ophtha.2012.03.014
   Sofat R, 2012, INT J EPIDEMIOL, V41, P250, DOI 10.1093/ije/dyr204
   Strauss KA, 2009, ANNU REV GENOM HUM G, V10, P513, DOI 10.1146/annurev-genom-082908-150040
   Suzuki K, 2004, GENE, V339, P49, DOI 10.1016/j.gene.2004.06.027
   Thalamuthu A, 2011, INVEST OPHTH VIS SCI, V52, P5573, DOI 10.1167/iovs.11-7568
   Thornton T, 2010, AM J HUM GENET, V86, P172, DOI 10.1016/j.ajhg.2010.01.001
   von Zglinicki T, 2005, CURR MOL MED, V5, P197
   Wang JC, 2017, BIOSENS BIOELECTRON, V89, P701, DOI 10.1016/j.bios.2016.11.014
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   Wiggs JL, 2012, PLOS GENET, V8, P413, DOI 10.1371/journal.pgen.1002654
   Winkler TW, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0194321
   Young TL, 1998, AM J HUM GENET, V63, P109, DOI 10.1086/301907
   Zhang M, 2000, NAT MED, V6, P196, DOI 10.1038/72303
   Zhou T, 2010, INVEST OPHTH VIS SCI, V51, P4371, DOI 10.1167/iovs.09-4278
NR 88
TC 3
Z9 3
U1 1
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0340-6717
EI 1432-1203
J9 HUM GENET
JI Hum. Genet.
PD OCT
PY 2019
VL 138
IS 10
BP 1171
EP 1182
DI 10.1007/s00439-019-02050-4
PG 12
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA IX8KQ
UT WOS:000485936200010
PM 31367973
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Boey, PY
   Tay, WT
   Lamoureux, E
   Tai, ES
   Mitchell, P
   Wang, JJ
   Saw, SM
   Wong, TY
AF Boey, Pui Yi
   Tay, Wan Ting
   Lamoureux, Ecosse
   Tai, E. Shyong
   Mitchell, Paul
   Wang, Jie Jin
   Saw, Seang Mei
   Wong, Tien Yin
TI C-Reactive Protein and Age-Related Macular Degeneration and Cataract:
   The Singapore Malay Eye Study
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID COMPLEMENT FACTOR-H; ENDOTHELIAL DYSFUNCTION; CIGARETTE-SMOKING;
   RISK-FACTORS; INFLAMMATION; MARKERS; DRUSEN; ATHEROSCLEROSIS;
   POLYMORPHISM; ASSOCIATION
AB PURPOSE. To describe associations between C-reactive protein (CRP) and age-related macular degeneration (AMD) and cataract in an Asian population.
   METHODS. A population-based, cross-sectional study of 3280 (78.7% response) Malay persons aged 40 to 80 years was conducted in Singapore. Wisconsin grading protocols were used to grade retinal photographs for signs of early and late AMD, and lens photographs were assessed for nuclear, cortical, and posterior subcapsular (PSC) cataract. Venous blood samples were assessed for serum CRP.
   RESULTS. Of 3100 (94.5%) subjects with gradable fundus photographs, 177 (5.7%) had any AMD, 155 (5.0%) early AMD, and 22 (0.7%) late AMD. No association was found between CRP and AMD. After subjects were stratified by diabetes status, the data showed that higher CRP was associated with any AMD in 2385 persons without diabetes (multivariate-adjusted odds ratio [OR], 1.73; 95% confidence interval [CI], 1.03-2.91, comparing the 4th versus the 1st quartiles of CRP). Cataract was present in 1431 (48.5%) subjects, and 634 (21.5%), 881 (29.9%) and 443 (15.0%) had nuclear, cortical, and PSC cataract, respectively. After multivariate analysis, no association was found between CRP and any cataract (OR, 0.99; 95% CI, 0.73-1.34), nuclear (OR, 0.98; 95% CI, 0.68-1.40), cortical (OR, 0.94; 95% CI, 0.71-1.23), or PSC (OR, 1.12; 95% CI, 0.81-1.55) cataract.
   CONCLUSIONS. In the general population, there were no associations between CRP and AMD or cataract. In persons without diabetes, higher CRP was associated with AMD. These data suggest only a weak link between systemic inflammation and AMD and cataract in Asian people. (Invest Ophthalmol Vis Sci. 2010; 51:1880-1885) DOI: 10.1167/iovs.09-4063
C1 [Boey, Pui Yi; Tay, Wan Ting; Lamoureux, Ecosse; Wong, Tien Yin] Singapore Natl Eye Ctr, Singapore Eye Res Inst, Singapore 168751, Singapore.
   [Lamoureux, Ecosse; Wang, Jie Jin; Wong, Tien Yin] Univ Melbourne, Ctr Eye Res Australia, Melbourne, Vic, Australia.
   [Tai, E. Shyong] Singapore Gen Hosp, Dept Endocrinol, Singapore 0316, Singapore.
   [Mitchell, Paul; Wang, Jie Jin] Univ Sydney, Ctr Vis Res, Sydney, NSW 2006, Australia.
   [Saw, Seang Mei] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Community Occupat & Family Med, Singapore 117595, Singapore.
C3 National University of Singapore; Singapore National Eye Center; Centre
   for Eye Research Australia; University of Melbourne; Singapore General
   Hospital; University of Sydney; National University of Singapore
RP Wong, TY (通讯作者)，Singapore Natl Eye Ctr, Singapore Eye Res Inst, 11 3rd Hosp Ave, Singapore 168751, Singapore.
EM ophwty@nus.edu.sg
RI Wong, Tien Yin/AAC-9724-2020; Mitchell, Paul/P-1498-2014; Tai, E
   Shyong/J-9831-2013; Wang, Jie Jin/P-1499-2014; wang, jie/GRS-0942-2022;
   Lamoureux, Ecosse/Z-5482-2019
OI Wong, Tien Yin/0000-0002-8448-1264; Wang, Jie Jin/0000-0001-9491-4898;
   Tai, E Shyong/0000-0003-2929-8966
FU National Medical Research Council [0796/2003, 0863/2004, CSI/0002/2005];
   Biomedical Research Council [501/1/25-5]
FX Supported by National Medical Research Council Grants 0796/2003,
   0863/2004, and CSI/0002/2005 and Biomedical Research Council Grant
   501/1/25-5. The sponsors had no role in the study design, acquisition of
   data, statistical analysis, and interpretation, and the final
   presentation and publication of the study.
CR Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   [Anonymous], 1997, Diabetes Care, V20 Suppl 1, pS1
   [Anonymous], 1991, Ophthalmology, V98, P786
   BARNEY NP, 1993, INT OPHTHALMOL CLIN, V33, P87, DOI 10.1097/00004397-199303320-00009
   Biasucci LM, 2009, CLIN CHEM, V55, P365, DOI 10.1373/clinchem.2008.119156
   Casas JP, 2006, INT J EPIDEMIOL, V35, P922, DOI 10.1093/ije/dyl041
   CHRISTEN WG, 1992, JAMA-J AM MED ASSOC, V268, P989
   Dana MR, 1997, OPHTHALMOLOGY, V104, P236, DOI 10.1016/S0161-6420(97)30329-7
   Danesh J, 2004, NEW ENGL J MED, V350, P1387, DOI 10.1056/NEJMoa032804
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Du Clos TW, 2000, ANN MED, V32, P274, DOI 10.3109/07853890009011772
   Elliott P, 2009, JAMA-J AM MED ASSOC, V302, P37, DOI 10.1001/jama.2009.954
   Foong AWP, 2007, OPHTHAL EPIDEMIOL, V14, P25, DOI 10.1080/09286580600878844
   Gallagher D, 2000, AM J CLIN NUTR, V72, P694, DOI 10.1093/ajcn/72.3.694
   GLYNN RJ, 1995, ARCH OPHTHALMOL-CHIC, V113, P1131, DOI 10.1001/archopht.1995.01100090057023
   Goodrich M E, 1999, Ophthalmic Epidemiol, V6, P279, DOI 10.1076/opep.6.4.279.4188
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Islam FMA, 2009, EYE, V23, P1719, DOI 10.1038/eye.2008.362
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Kannel W B, 1979, Diabetes Care, V2, P120, DOI 10.2337/diacare.2.2.120
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1735, DOI 10.1016/j.ophtha.2008.02.012
   Kim IK, 2008, MOL VIS, V14, P1487
   Klein BEK, 2006, AM J OPHTHALMOL, V141, P116, DOI 10.1016/j.ajo.2005.08.021
   KLEIN BEK, 1990, OPHTHALMOLOGY, V97, P1428
   Klein R, 2005, AM J OPHTHALMOL, V140, P35, DOI 10.1016/j.ajo.2005.01.051
   Klein R, 2003, OPHTHALMOLOGY, V110, P25, DOI 10.1016/S0161-6420(02)01565-8
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kramer H, 2004, AM J HYPERTENS, V17, P963, DOI 10.1016/j.amjhyper.2004.06.001
   Lee CC, 2009, DIABETOLOGIA, V52, P1040, DOI 10.1007/s00125-009-1338-3
   LESKE MC, 1991, ARCH OPHTHALMOL-CHIC, V109, P244, DOI 10.1001/archopht.1991.01080020090051
   McGwin G, 2005, BRIT J OPHTHALMOL, V89, P1166, DOI 10.1136/bjo.2005.067397
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Narayanan R, 2007, OPHTHALMOLOGY, V114, P1327, DOI 10.1016/j.ophtha.2006.10.035
   Nash David T, 2005, J Natl Med Assoc, V97, P1600
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Ridker PM, 2003, CIRCULATION, V107, P363, DOI 10.1161/01.CIR.0000053730.47739.3C
   Schaumberg DA, 1999, ANN EPIDEMIOL, V9, P166, DOI 10.1016/S1047-2797(98)00049-0
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P300, DOI 10.1001/archopht.125.3.300
   Schaumberg DA, 2006, INVEST OPHTH VIS SCI, V47, P2336, DOI 10.1167/iovs.05-1456
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   STEEL DM, 1994, IMMUNOL TODAY, V15, P81, DOI 10.1016/0167-5699(94)90138-4
   TUFT SJ, 1991, OPHTHALMOLOGY, V98, P150
   Wong TY, 2007, OPHTHALMOLOGY, V114, P86, DOI 10.1016/j.ophtha.2006.06.039
NR 50
TC 20
Z9 20
U1 0
U2 2
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD APR
PY 2010
VL 51
IS 4
BP 1880
EP 1885
DI 10.1167/iovs.09-4063
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 574ND
UT WOS:000275995800011
PM 19933187
DA 2022-11-30
ER

PT J
AU Nivison-Smith, L
   Wang, H
   Assaad, N
   Kalloniatis, M
AF Nivison-Smith, Lisa
   Wang, Henrietta
   Assaad, Nagi
   Kalloniatis, Michael
TI Retinal Thickness Changes throughout the Natural History of Drusen in
   Age-related Macular Degeneration
SO OPTOMETRY AND VISION SCIENCE
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; PIGMENT EPITHELIAL ABNORMALITIES; FUNDUS
   AUTOFLUORESCENCE; VISUAL-ACUITY; EYES; QUANTIFICATION; SEGMENTATION;
   ATROPHY; LAYER
AB SIGNIFICANCE: Drusen are associated with retinal thinning in age-related macular degeneration (AMD). These changes, however, have mostly been examined at single time points, ignoring the evolution of drusen from emergence to regression. Understanding the full breadth of retinal changes associated with drusen will improve understanding of disease pathogenesis.
   PURPOSE: The purpose of this study was to assess how the natural history of drusen affects retinal thickness, focusing on the photoreceptor and retinal pigment epithelium (RPE) layers.
   METHODS: Spectral domain optical coherence tomography of subjects with intermediate AMD (n = 50) who attended the Centre for Eye Health, Sydney, Australia, for two separate visits (476 16 days between visits) was extracted. Scans were automatically segmented with manufacturer software then assessed for drusen that had emerged, grown, or regressed between visits. For each identified lesion, the thickness of each retinal layer at the drusen peak and at adjacent drusen-free areas (150 m nasal and temporal to the druse) was compared between visits.
   RESULTS: Before drusen emergence, the RPE was significantly thicker at the drusen site (14.2 +/- 2.6%) compared with neighboring drusen-free areas. There was a 71% sensitivity of RPE thickening predicting drusen emergence. Once drusen emerged, significant thinning of all outer retinal layers was observed, consistent with previous studies. Drusen growth was significantly correlated with thinning of the outer retina (r = -0.38, P < .001). Drusen regression resulted in outer retinal layers returning to thicknesses not significantly different from baseline.
   CONCLUSIONS: The natural history of drusen is associated with RPE thickening before drusen emergence, thinning of the outer nuclear layer as well as photoreceptor and RPE layers proportional to drusen growth, and return to baseline thickness after drusen regression. These findings have useful clinical applications, providing a potential marker for predicting drusen emergence for AMD prognostic and intervention studies and highlighting that areas of normal retinal thickness in AMD may be former sites of regressed drusen.
C1 [Nivison-Smith, Lisa; Wang, Henrietta; Kalloniatis, Michael] Univ New South Wales, Sch Optometry & Vis Sci, Sydney, NSW, Australia.
   [Nivison-Smith, Lisa; Wang, Henrietta; Assaad, Nagi; Kalloniatis, Michael] Univ New South Wales, Ctr Eye Hlth, Sydney, NSW, Australia.
   [Assaad, Nagi] Prince Wales Hosp, Dept Ophthalmol, Randwick, NSW, Australia.
C3 University of New South Wales Sydney; University of New South Wales
   Sydney
RP Nivison-Smith, L (通讯作者)，Univ New South Wales, Sch Optometry & Vis Sci, Sydney, NSW, Australia.; Nivison-Smith, L (通讯作者)，Univ New South Wales, Ctr Eye Hlth, Sydney, NSW, Australia.
EM l.nivison-smith@unsw.edu.au
OI Wang, Henrietta/0000-0002-6694-7622; Kalloniatis,
   Michael/0000-0002-5264-4639
FU National Health and Medical Research Council of Australia [1033224];
   UNSW Sydney; Guide Dogs NSW/ACT
FX National Health and Medical Research Council of Australia (1033224; to
   MK); UNSW Sydney (Early Career Research Grant 2015 and 2016; to LN-S);
   and Guide Dogs NSW/ACT (to MK).
CR Acton JH, 2012, INVEST OPHTH VIS SCI, V53, P7618, DOI 10.1167/iovs.12-10361
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   BRESSLER NM, 1995, ARCH OPHTHALMOL-CHIC, V113, P301, DOI 10.1001/archopht.1995.01100030055022
   BRESSLER NM, 1994, RETINA-J RET VIT DIS, V14, P130, DOI 10.1097/00006982-199414020-00006
   BRESSLER SB, 1990, ARCH OPHTHALMOL-CHIC, V108, P1442, DOI 10.1001/archopht.1990.01070120090035
   Chen Q, 2013, MED IMAGE ANAL, V17, P1058, DOI 10.1016/j.media.2013.06.003
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Curcio CA, 2005, EXP EYE RES, V81, P731, DOI 10.1016/j.exer.2005.04.012
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   de Sisternes L, 2014, INVEST OPHTH VIS SCI, V55, P7093, DOI 10.1167/iovs.14-14918
   Ebneter A, 2016, INVEST OPHTH VIS SCI, V57
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Gobel AP, 2016, GRAEF ARCH CLIN EXP, V254, P59, DOI 10.1007/s00417-015-3012-4
   Hartmann KI, 2012, RETINA-J RET VIT DIS, V32, P1492, DOI 10.1097/IAE.0b013e318242b949
   Jamous KF, 2015, CLIN EXP OPHTHALMOL, V43, P308, DOI 10.1111/ceo.12466
   Johnson PT, 2003, INVEST OPHTH VIS SCI, V44, P4481, DOI 10.1167/iovs.03-0436
   Karampelas M, 2013, BRIT J OPHTHALMOL, V97, P1256, DOI 10.1136/bjophthalmol-2013-303219
   Khanifar AA, 2008, OPHTHALMOLOGY, V115, P1883, DOI 10.1016/j.ophtha.2008.04.041
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1026, DOI 10.1016/j.ophtha.2007.08.030
   Landa G, 2012, OPHTHALMIC RES, V47, P81, DOI 10.1159/000324988
   Ly A, 2018, CLIN EXP OPTOM, V101, P172, DOI 10.1111/cxo.12624
   Nittala MG, 2012, INVEST OPHTH VIS SCI, V53, P8319, DOI 10.1167/iovs.12-10582
   Nivison-Smith L, 2014, OPTOMETRY VISION SCI, V91, P832, DOI 10.1097/OPX.0000000000000281
   Ouyang YL, 2013, OPHTHALMOLOGY, V120, P2656, DOI 10.1016/j.ophtha.2013.05.029
   Pappuru RR, 2011, INVEST OPHTH VIS SCI, V52, P6743, DOI 10.1167/iovs.10-6723
   Pecen PE, 2015, CURR OPIN OPHTHALMOL, V26, P188, DOI 10.1097/ICU.0000000000000147
   Rogala J, 2015, INVEST OPHTH VIS SCI, V56, P1689, DOI 10.1167/iovs.14-16221
   Sadigh S, 2013, INVEST OPHTH VIS SCI, V54, P1603, DOI 10.1167/iovs.12-11286
   Sallo FB, 2009, BRIT J OPHTHALMOL, V93, P1345, DOI 10.1136/bjo.2008.150334
   Schlanitz FG, 2017, BRIT J OPHTHALMOL, V101, P198, DOI 10.1136/bjophthalmol-2016-308422
   Schuman SG, 2009, OPHTHALMOLOGY, V116, P488, DOI 10.1016/j.ophtha.2008.10.006
   Sohn EH, 2015, RETINA-J RET VIT DIS, V35, P48, DOI 10.1097/IAE.0000000000000263
   Toy BC, 2013, AM J OPHTHALMOL, V156, P532, DOI 10.1016/j.ajo.2013.04.031
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu ZC, 2015, JAMA OPHTHALMOL, V133, P442, DOI 10.1001/jamaophthalmol.2014.5963
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P2415, DOI 10.1016/j.ophtha.2014.06.034
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P2434, DOI 10.1016/j.ophtha.2011.05.008
   Zweifel SA, 2012, KLIN MONATSBL AUGENH, V229, P399, DOI 10.1055/s-0031-1299404
NR 39
TC 10
Z9 10
U1 0
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-5488
EI 1538-9235
J9 OPTOMETRY VISION SCI
JI Optom. Vis. Sci.
PD AUG
PY 2018
VL 95
IS 8
BP 648
EP 655
DI 10.1097/OPX.0000000000001256
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GR3ED
UT WOS:000442471700004
PM 30063666
DA 2022-11-30
ER

PT J
AU Stanislovaitiene, D
   Zaliuniene, D
   Steponaviciute, R
   Zemaitiene, R
   Gustiene, O
   Zaliunas, R
AF Stanislovaitiene, Daiva
   Zaliuniene, Dalia
   Steponaviciute, Rasa
   Zemaitiene, Reda
   Gustiene, Olivija
   Zaliunas, Remigijus
TI N-carboxymethyllysine as a biomarker for coronary artery disease and
   age-related macular degeneration
SO MEDICINA-LITHUANIA
LA English
DT Article
DE N-carboxymethyllysine; Coronary artery disease; Age-related macular
   degeneration
ID GLYCATION END-PRODUCT; N-EPSILON-(CARBOXYMETHYL)LYSINE; ACCUMULATION;
   LYSINE
AB Background and objective: An association between coronary artery disease (CAD) and age-related macular degeneration (ARMD) has long been postulated, but exact mechanisms remain unclear. The global prevalence of CAD and ARMD increases and early biomarkers for early diagnosis of these diseases are necessary. The aim of this study was to investigate the plasma level of oxidative stress biomarker CML in patients with and without angiographic findings of atherosclerosis in the coronary arteries (CADath+ and CADath-, respectively) and to assess if there was an association of CAD with ARMD.
   Materials and methods: The study enrolled 233 subjects. Based on cardiologic and ophthalmologic examinations, the patients were divided into four subgroups: CADath+ ARMD+, CADath+ ARMD, CADath ARMD+, and CADath ARMD. The enzyme-linked immunosorbent assay was used for the measurement of plasma CML levels. Serum lipid levels were determined by an automatic analyzer using conventional enzymatic methods.
   Results: CADath+ patients had higher CML concentration compared to CADath- subjects (1.04 +/- 0.6 vs. 0.83 +/- 0.4 ng/mL, P < 0.001). The highest mean CML level (1.12 +/- 0.7 ng/mL) was found in CADath+ ARMD+ patients. The mean plasma CML concentration was higher in subjects with any of the analyzed diseases compared to CADath ARMD subjects. A significant positive association of CADath+ (OR = 2.50, 95% CI 1.60-3.90, P = 0.0001), ARMD (OR = 2.08, 95% CI 1.40-3.11, P = 0.0001) and both analyzed diseases (OR = 4.67, 95% CI 2.29-9.53, P = 0.0001) with an increased level of plasma CML in a logistic regression model adjusting by age was identified.
   Conclusions: The level of CML, an oxidative stress biomarker, reflects the presence of atherosclerosis in coronary arteries and shows a possible link between ARMD and CADath+ via oxidative status. (C) 2016 The Lithuanian University of Health Sciences. Production and hosting by Elsevier B.V.
C1 [Stanislovaitiene, Daiva; Zaliuniene, Dalia; Zemaitiene, Reda] Lithuanian Univ Hlth Sci, Med Acad, Dept Ophthalmol, Eiveniu 2, LT-50161 Kaunas, Lithuania.
   [Steponaviciute, Rasa] Lithuanian Univ Hlth Sci, Med Acad, Dept Lab Med, LT-50161 Kaunas, Lithuania.
   [Gustiene, Olivija; Zaliunas, Remigijus] Lithuanian Univ Hlth Sci, Med Acad, Dept Cardiol, LT-50161 Kaunas, Lithuania.
C3 Lithuanian University of Health Sciences; Lithuanian University of
   Health Sciences; Lithuanian University of Health Sciences
RP Stanislovaitiene, D (通讯作者)，Lithuanian Univ Hlth Sci, Med Acad, Dept Ophthalmol, Eiveniu 2, LT-50161 Kaunas, Lithuania.
EM daivastanislovaitiene@yahoo.com; daliazal@yahoo.com;
   rasastepkons@gmail.com; reda.zemaitiene@kaunoklinikos.lt;
   olivija.gustiene@gmail.com; rektoratas@lsmuni.lt
CR Ahmed KA, 2007, J CLIN BIOCHEM NUTR, V41, P97, DOI 10.3164/jcbn.2007014
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Cimbalas Andrius, 2003, Medicina (Kaunas), V39, P1237
   Curcio CA, 2009, PROG RETIN EYE RES, V28, P393, DOI 10.1016/j.preteyeres.2009.08.001
   Curtiss LK, 2009, NEW ENGL J MED, V360, P1144, DOI 10.1056/NEJMcibr0810383
   Ebrahimi KB, 2011, J LIPIDS, V2011, DOI 10.1155/2011/802059
   Fischer T., 2012, J NEUROSCI BEHAV HLT, V4, P42
   Fu MX, 1996, J BIOL CHEM, V271, P9982, DOI 10.1074/jbc.271.17.9982
   Hammes HP, 1999, INVEST OPHTH VIS SCI, V40, P1855
   Ishibashi T, 1998, ARCH OPHTHALMOL-CHIC, V116, P1629, DOI 10.1001/archopht.116.12.1629
   Kalousova M, 2005, Cas Lek Cesk, V144, P385
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Kralev S, 2009, CLIN CHEM LAB MED, V47, P446, DOI 10.1515/CCLM.2009.100
   Ni JQ, 2009, MOL CELL PROTEOMICS, V8, P1921, DOI 10.1074/mcp.M900127-MCP200
   Schleicher E, 2005, ANN NY ACAD SCI, V1043, P343, DOI 10.1196/annals.1333.041
   Schleicher ED, 1997, J CLIN INVEST, V99, P457, DOI 10.1172/JCI119180
   Sebekova K, 2009, INT J PEDIATR OBES, V4, P112, DOI 10.1080/17477160802248039
   Semba RD, 2014, JAMA OPHTHALMOL, V132, P464, DOI 10.1001/jamaophthalmol.2013.7664
   Semba RD, 2010, J GERONTOL A-BIOL, V65, P963, DOI 10.1093/gerona/glq074
   Semba RD, 2009, J AM GERIATR SOC, V57, P1874, DOI 10.1111/j.1532-5415.2009.02438.x
   Semba RD, 2009, AM J HYPERTENS, V22, P74, DOI 10.1038/ajh.2008.320
   Sharma K, 2013, GLOB HEART, V8, P105, DOI 10.1016/j.gheart.2013.02.001
   Sun C, 2009, OPHTHALMOLOGY, V116, P1913, DOI 10.1016/j.ophtha.2009.03.046
   Tousoulis D, 2013, CURR PHARM DESIGN, V19, P1593
   van Diepen JA, 2013, ATHEROSCLEROSIS, V228, P306, DOI 10.1016/j.atherosclerosis.2013.02.028
NR 25
TC 2
Z9 2
U1 0
U2 5
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 1010-660X
EI 1648-9144
J9 MEDICINA-LITHUANIA
JI Med. Lith.
PY 2016
VL 52
IS 2
BP 99
EP 103
DI 10.1016/j.medici.2016.02.001
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA DL7WO
UT WOS:000375851300004
PM 27170482
OA gold
DA 2022-11-30
ER

PT J
AU Slakter, JS
   Stur, M
AF Slakter, JS
   Stur, M
TI Quality of life in patients with age-related macular degeneration:
   Impact of the condition and benefits of treatment
SO SURVEY OF OPHTHALMOLOGY
LA English
DT Review
DE age-related macular degeneration; choroidal neovascularization; laser
   photocoagulation; quality of life; verteporfin therapy; visual function
ID CHOROIDAL NEOVASCULARIZATION SECONDARY; VISUAL FUNCTION QUESTIONNAIRE;
   RANDOMIZED PILOT TRIAL; SUBMACULAR SURGERY; OLDER ADULTS; LASER
   PHOTOCOAGULATION; PHOTODYNAMIC THERAPY; SELF-MANAGEMENT; VISION
   FUNCTION; EYE
AB Age-related macular degeneration (AMD) is a chronic, progressive, degenerative disease of the macula and is the leading cause of central vision loss among elderly people in the western world. Traditionally, clinical studies of AMD have described the impact of AMD, and treatments for AMD, in terms of the patient's visual acuity. However, Visual acuity alone does not provide information about a patient's perception of his or her quality of life. Researchers have used a variety of instruments to measure quality of life. Several studies have shown that AMD can severely impair quality of life and that increasing vision loss is associated with increasing impairment of quality of life and frequently causes depression. Interestingly, patients with only one eye affected may become more depressed than those with both eyes affected, possibly because of uncertainty surrounding future vision loss in patients with one eye affected and a greater acceptance of the condition in those with both eyes affected. Studies also have provided some information on the possible quality of life benefits of therapy for AMD. By incorporating measurements of quality of life into the design of future prospective studies, clinical researchers may be able to obtain more comprehensive data on the impact of AMD on patients and the relative benefits of different therapies. (c) 2005 Elsevier Inc. All rights reserved.
C1 Vitreous Retina Macula Consultants New York, New York, NY 10022 USA.
   Klin Augenheilkunde & Optometrie, Allgemeines Krankenhaus, Vienna, Austria.
C3 Vitreous Retina Macula Consultants of New York
RP Slakter, JS (通讯作者)，Vitreous Retina Macula Consultants New York, 460 Pk Ave,5th Floor, New York, NY 10022 USA.
CR Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   Bass E, 2000, AM J OPHTHALMOL, V130, P408
   Bressler NM, 2000, AM J OPHTHALMOL, V130, P387
   Brody BL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1477, DOI 10.1001/archopht.120.11.1477
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1901
   Brody BL, 1999, ANN BEHAV MED, V21, P322, DOI 10.1007/BF02895965
   Brown G C, 1999, Trans Am Ophthalmol Soc, V97, P473
   BROWN GC, 1992, ARCH OPHTHALMOL-CHIC, V110, P1251, DOI 10.1001/archopht.1992.01080210069027
   Brown GC, 1998, INT OPHTHALMOL, V22, P307, DOI 10.1023/A:1006311910304
   Clemons TE, 2003, ARCH OPHTHALMOL-CHIC, V121, P211
   Dandona L, 1998, ARCH OPHTHALMOL-CHIC, V116, P545, DOI 10.1001/archopht.116.4.514
   DeCarlo DK, 2003, OPTOMETRY VISION SCI, V80, P207, DOI 10.1097/00006324-200303000-00010
   Fletcher DC, 1999, J REHABIL RES DEV, V36, P356
   Frost A, 2001, EYE, V15, P739, DOI 10.1038/eye.2001.241
   Frost N A, 1998, Ophthalmic Epidemiol, V5, P185, DOI 10.1076/opep.5.4.185.4191
   Fujikado T, 2002, AM J OPHTHALMOL, V134, P849, DOI 10.1016/S0002-9394(02)01756-7
   GHAFOUR IM, 1983, BRIT J OPHTHALMOL, V67, P209, DOI 10.1136/bjo.67.4.209
   Hart PM, 1999, BRIT J OPHTHALMOL, V83, P1115, DOI 10.1136/bjo.83.10.1115
   Hazel CA, 2000, INVEST OPHTH VIS SCI, V41, P1309
   Klein BEK, 1998, OPHTHALMOLOGY, V105, P160, DOI 10.1016/S0161-6420(98)91911-X
   Kuyk T, 1999, J REHABIL RES DEV, V36, P303
   Mangione CM, 1999, AM J OPHTHALMOL, V128, P45, DOI 10.1016/S0002-9394(99)00169-5
   MANGIONE CM, 1992, MED CARE, V30, P1111, DOI 10.1097/00005650-199212000-00004
   Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P1496, DOI 10.1001/archopht.116.11.1496
   Mejico LJ, 2004, AM J OPHTHALMOL, V137, P908, DOI 10.1016/j.ajo.2003.12.038
   Miskala PH, 2003, ARCH OPHTHALMOL-CHIC, V121, P531
   Moore LW, 2000, WESTERN J NURS RES, V22, P571, DOI 10.1177/01939450022044601
   OWSLEY C, 1987, BRIT J OPHTHALMOL, V71, P791, DOI 10.1136/bjo.71.10.791
   Owsley C, 2001, OPTOMETRY VISION SCI, V78, P350, DOI 10.1097/00006324-200105000-00019
   Riusala A, 2003, AM J OPHTHALMOL, V135, P206, DOI 10.1016/S0002-9394(02)01832-9
   Rovner BW, 2002, ARCH OPHTHALMOL-CHIC, V120, P1041
   Rovner BW, 2002, AM J GERIAT PSYCHIAT, V10, P305
   Rovner BW, 2001, J AM GERIATR SOC, V49, P1097, DOI 10.1046/j.1532-5415.2001.49215.x
   RUBIN GS, 1994, OPTOMETRY VISION SCI, V71, P750, DOI 10.1097/00006324-199412000-00005
   Scott IU, 1999, AM J OPHTHALMOL, V128, P54, DOI 10.1016/S0002-9394(99)00108-7
   Scott IU, 2002, AM J OPHTHALMOL, V133, P350, DOI 10.1016/S0002-9394(01)01406-4
   Scott IU, 2001, AM J OPHTHALMOL, V131, P584, DOI 10.1016/S0002-9394(01)00832-7
   Sharma S, 2001, CAN J OPHTHALMOL, V36, P332, DOI 10.1016/S0008-4182(01)80120-4
   Sharma S, 2001, OPHTHALMOLOGY, V108, P2051, DOI 10.1016/S0161-6420(01)00764-3
   WALSH AW, 1989, ANN OPHTHALMOL, V21, P348
   West CG, 2002, J AM GERIATR SOC, V50, P136, DOI 10.1046/j.1532-5415.2002.50019.x
   West SK, 2002, ARCH OPHTHALMOL-CHIC, V120, P774
   1991, ARCH OPHTHALMOL, V10, P1220
NR 44
TC 72
Z9 74
U1 3
U2 17
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0039-6257
EI 1879-3304
J9 SURV OPHTHALMOL
JI Surv. Ophthalmol.
PD MAY-JUN
PY 2005
VL 50
IS 3
BP 263
EP 273
DI 10.1016/j.survophthal.2005.02.007
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA 926QT
UT WOS:000229138400004
PM 15850815
DA 2022-11-30
ER

PT J
AU Gorin, MB
AF Gorin, Michael B.
TI Genetic insights into age-related macular degeneration: Controversies
   addressing risk, causality, and therapeutics
SO MOLECULAR ASPECTS OF MEDICINE
LA English
DT Review
ID COMPLEMENT FACTOR-H; POLYPOIDAL CHOROIDAL VASCULOPATHY; SINGLE
   NUCLEOTIDE POLYMORPHISMS; TOLL-LIKE RECEPTOR-3; GROWTH-FACTOR GENE;
   MITOCHONDRIAL-DNA HAPLOGROUPS; PIGMENT EPITHELIAL-CELLS; GENOME-WIDE
   ASSOCIATION; COPY NUMBER VARIATION; GEOGRAPHIC ATROPHY
AB Age-related macular degeneration (AMD) is a common condition among the elderly population that leads to the progressive central vision loss and serious compromise of quality of life for its sufferers. It is also one of the few disorders for whom the investigation of its genetics has yielded rich insights into its diversity and causality and holds the promise of enabling clinicians to provide better risk assessments for individuals as well as to develop and selectively deploy new therapeutics to either prevent or slow the development of disease and lessen the threat of vision loss. The genetics of AMD began initially with the appreciation of familial aggregation and increase risk and expanded with the initial association of APOE variants with the disease. The first major breakthroughs came with family-based linkage studies of affected (and discordant) sibs, which identified a number of genetic loci and led to the targeted search of the 1q31 and 10q26 loci for associated variants. Three of the initial four reports for the CFH variant, Y402H, were based on regional candidate searches, as were the two initial reports of the ARMS2/HTRA1 locus variants. Case-control association studies initially also played a role in discovering the major genetic variants for AMD, and the success of those early studies have been used to fuel enthusiasm for the methodology for a number of diseases. Until 2010, all of the subsequent genetic variants associated with AMD came from candidate gene testing based on the complement factor pathway. In 2010, several large-scale genome-wide association studies (GWAS) identified genes that had not been previously identified. Much of this historical information is available in a number of recent reviews (Chen et al., 2010b; Deangelis et al., 2011; Fafowora and Gorin, 2012b; Francis and Klein, 2011; Kokotas et al., 2011). Large meta analysis of AMD GWAS has added new loci and variants to this collection (Chen et al., 2010a; Kopplin et al., 2010; Yu et al., 2011). This paper will focus on the ongoing controversies that are confronting AMD genetics at this time, rather than attempting to summarize this field, which has exploded in the past 5 years. (C) 2012 Elsevier Ltd. All rights reserved.
C1 [Gorin, Michael B.] UC, David Geffen Sch Med, Dept Ophthalmol, Los Angeles, CA USA.
   [Gorin, Michael B.] UC, David Geffen Sch Med, Dept Human Genet, Los Angeles, CA USA.
   [Gorin, Michael B.] Jules Stein Eye Inst, Los Angeles, CA 90095 USA.
C3 University of California System; University of California Los Angeles;
   University of California Los Angeles Medical Center; David Geffen School
   of Medicine at UCLA; University of California System; University of
   California Los Angeles; University of California Los Angeles Medical
   Center; David Geffen School of Medicine at UCLA
RP Gorin, MB (通讯作者)，UC, David Geffen Sch Med, Dept Ophthalmol, Los Angeles, CA USA.
EM gorin@jsei.ucla.edu
FU NEI [R01-EY09859]; Harold and Pauline Price Foundation; Research to
   Prevent Blindness; NATIONAL EYE INSTITUTE [R01EY009859] Funding Source:
   NIH RePORTER
FX This work was made possible by the support from NEI R01-EY09859, Harold
   and Pauline Price Foundation, and Research to Prevent Blindness.
CR Abarrategui-Garrido C, 2009, BLOOD, V114, P4261, DOI 10.1182/blood-2009-05-223834
   Abecasis GR, 2004, AM J HUM GENET, V74, P482, DOI 10.1086/382786
   Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   Allikmets R, 2009, NEW ENGL J MED, V360, P2252
   An E, 2010, INVEST OPHTH VIS SCI, V51, P3379, DOI 10.1167/iovs.09-4853
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Andreoli MT, 2009, AM J OPHTHALMOL, V148, P869, DOI 10.1016/j.ajo.2009.07.002
   Arjamaa O, 2009, AGEING RES REV, V8, P349, DOI 10.1016/j.arr.2009.06.002
   Auer-Grumbach M, 2011, BRAIN, V134, P1839, DOI 10.1093/brain/awr076
   Ayala-Haedo JA, 2010, ANN HUM GENET, V74, P195, DOI 10.1111/j.1469-1809.2010.00570.x
   Ayyagari R, 2005, INVEST OPHTH VIS SCI, V46, P3363, DOI 10.1167/iovs.05-0159
   Baird PN, 2004, AM J OPHTHALMOL, V138, P665, DOI 10.1016/j.ajo.2004.04.053
   Barral S, 2006, INVEST OPHTH VIS SCI, V47, P5453, DOI 10.1167/iovs.06-0655
   Bessho H, 2011, MOL VIS, V17, P977
   Boekhoorn SS, 2008, OPHTHALMOLOGY, V115, P1899, DOI 10.1016/j.ophtha.2008.06.026
   Boon CJE, 2008, AM J HUM GENET, V82, P516, DOI 10.1016/j.ajhg.2007.11.007
   Boon CJF, 2009, OPHTHALMOLOGY, V116, P771, DOI 10.1016/j.ophtha.2008.12.019
   Brion M, 2011, ACTA OPHTHALMOL, V89, pE12, DOI 10.1111/j.1755-3768.2010.02040.x
   Canter JA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002091
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Chen YH, 2011, ARCH OPHTHALMOL-CHIC, V129, P344, DOI 10.1001/archophthalmol.2011.10
   Chen YH, 2010, MOL INTERV, V10, P271, DOI 10.1124/mi.10.5.4
   Chiu CJ, 2011, INVEST OPHTH VIS SCI, V52, P9099, DOI 10.1167/iovs.11-7782
   Cho YE, 2009, INVEST OPHTH VIS SCI, V50, P5614, DOI 10.1167/iovs.09-3688
   Chowers I, 2006, INVEST OPHTH VIS SCI, V47, P2135, DOI 10.1167/iovs.05-1135
   Churchill AJ, 2006, HUM MOL GENET, V15, P2955, DOI 10.1093/hmg/ddl238
   Clark SJ, 2010, J BIOL CHEM, V285, P30192, DOI 10.1074/jbc.M110.103986
   DeAngelis MM, 2007, ARCH OPHTHALMOL-CHIC, V125, P49, DOI 10.1001/archopht.125.1.49
   DeAngelis MM, 2011, SEMIN OPHTHALMOL, V26, P77, DOI 10.3109/08820538.2011.577129
   Despriet DDG, 2008, INVEST OPHTH VIS SCI, V49, P364, DOI 10.1167/iovs.07-0656
   Ding JD, 2011, P NATL ACAD SCI USA, V108, pE279, DOI 10.1073/pnas.1100901108
   Dinu V, 2007, GENET EPIDEMIOL, V31, P224, DOI 10.1002/gepi.20204
   Edwards AO, 2008, INVEST OPHTH VIS SCI, V49, P1652, DOI 10.1167/iovs.07-1378
   Edwards AO, 2009, NEW ENGL J MED, V360, P2254
   Edwards DRV, 2010, INVEST OPHTH VIS SCI, V51, P1873, DOI 10.1167/iovs.09-4000
   Ennis S, 2008, LANCET, V372, P1828, DOI 10.1016/S0140-6736(08)61348-3
   Fafowora O, 2012, GENETIC DIS EYE, P543
   Fang AM, 2009, MOL VIS, V15, P2710
   Farwick A, 2010, INVEST OPHTH VIS SCI, V51, P731, DOI 10.1167/iovs.09-3953
   Fauser S, 2011, INVEST OPHTH VIS SCI, V52, P5525, DOI 10.1167/iovs.10-6827
   Feigl B, 2011, CURR MED RES OPIN, V27, P1745, DOI 10.1185/03007995.2011.603301
   Feigl B, 2011, INVEST OPHTH VIS SCI, V52, P1145, DOI 10.1167/iovs.10-5967
   Fisher SA, 2005, HUM MOL GENET, V14, P2257, DOI 10.1093/hmg/ddi230
   Francis PJ, 2009, J MED GENET, V46, P300, DOI 10.1136/jmg.2008.062737
   Francis PJ, 2011, CLIN OPHTHALMOL, V5, P1127, DOI 10.2147/OPTH.S11627
   Fritsche LG, 2010, HUM MOL GENET, V19, P4694, DOI 10.1093/hmg/ddq399
   Fu L, 2007, HUM MOL GENET, V16, P2411, DOI 10.1093/hmg/ddm198
   Fuse N, 2011, AM J OPHTHALMOL, V151, P550, DOI 10.1016/j.ajo.2010.08.048
   Gibson J, 2010, BRIT J OPHTHALMOL, V94, P1382, DOI 10.1136/bjo.2010.182568
   Gotoh N, 2010, JPN J OPHTHALMOL, V54, P609, DOI 10.1007/s10384-010-0865-2
   Grassi MA, 2007, ARCH OPHTHALMOL-CHIC, V125, P93, DOI 10.1001/archopht.125.1.93
   Gu JY, 2010, ADV EXP MED BIOL, V664, P411, DOI 10.1007/978-1-4419-1399-9_47
   Gu XR, 2003, J BIOL CHEM, V278, P42027, DOI 10.1074/jbc.M305460200
   Haas P, 2011, CURR EYE RES, V36, P143, DOI 10.3109/02713683.2010.533808
   Hageman GS, 2006, ANN MED, V38, P592, DOI 10.1080/07853890601097030
   Haines JL, 2006, INVEST OPHTH VIS SCI, V47, P329, DOI 10.1167/iovs.05-0116
   Hayashi H, 2010, INVEST OPHTH VIS SCI, V51, P5914, DOI 10.1167/iovs.10-5554
   Ho L, 2011, ARCH OPHTHALMOL-CHIC, V129, P758, DOI 10.1001/archophthalmol.2011.141
   Hu JY, 2011, OPHTHAL EPIDEMIOL, V18, P137, DOI 10.3109/09286586.2011.574335
   Hughes AE, 2007, PLOS MED, V4, P1993, DOI 10.1371/journal.pmed.0040355
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Ikeda T, 2001, AM J OPHTHALMOL, V132, P191, DOI 10.1016/S0002-9394(01)00975-8
   Immonen I, 2010, OPHTHALMOLOGY, V117, P103, DOI 10.1016/j.ophtha.2009.06.037
   Iyengar SK, 2004, AM J HUM GENET, V74, P20, DOI 10.1086/380912
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Jakobsdottir J, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000337
   Jakobsdottir J, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002199
   Jones MM, 2007, ARCH OPHTHALMOL-CHIC, V125, P1235, DOI 10.1001/archopht.125.9.1235
   Jun G, 2005, INVEST OPHTH VIS SCI, V46, P3081, DOI 10.1167/iovs.04-1360
   Kaarniranta K., 2012, NEUROSCI LETT
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kaneko H, 2011, NATURE, V471, P325, DOI 10.1038/nature09830
   Katta S, 2009, J GENET, V88, P425, DOI 10.1007/s12041-009-0064-4
   Kenney MC, 2010, INVEST OPHTH VIS SCI, V51, P4289, DOI 10.1167/iovs.09-4778
   Kim IK, 2008, MOL VIS, V14, P1487
   Klaver CCW, 2008, LANCET, V372, P1788, DOI 10.1016/S0140-6736(08)61349-5
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Klegeris A, 2007, BIOCHEM BIOPH RES CO, V357, P1096, DOI 10.1016/j.bbrc.2007.04.055
   Klein ML, 2010, OPHTHALMOLOGY, V117, P1554, DOI 10.1016/j.ophtha.2009.12.012
   Kleinman ME, 2008, NATURE, V452, P591, DOI 10.1038/nature06765
   Kloeckener-Gruissem B, 2011, INVEST OPHTH VIS SCI, V52, P4694, DOI 10.1167/iovs.10-6080
   Kokotas H, 2011, CLIN CHEM LAB MED, V49, P601, DOI 10.1515/CCLM.2011.091
   Kondo N, 2009, MOL VIS, V15, P1819
   Kopplin LJ, 2010, GENES IMMUN, V11, P609, DOI 10.1038/gene.2010.39
   Kortvely E, 2010, INVEST OPHTH VIS SCI, V51, P79, DOI 10.1167/iovs.09-3850
   Kralovicova J, 2009, LANCET, V373, P461, DOI 10.1016/S0140-6736(09)60168-9
   Kubicka-Trzaska A, 2012, ACTA OPHTHALMOL, V90, pE21, DOI 10.1111/j.1755-3768.2011.02237.x
   Kubista KE, 2011, MOL VIS, V17, P2080
   Kurji KH, 2010, INVEST OPHTH VIS SCI, V51, P1151, DOI 10.1167/iovs.09-3622
   Kutty RK, 2010, BIOCHEM BIOPH RES CO, V402, P390, DOI 10.1016/j.bbrc.2010.10.042
   Lauer N, 2011, J IMMUNOL, V187, P4374, DOI 10.4049/jimmunol.1002488
   Lee AY, 2010, BRIT J OPHTHALMOL, V94, P915, DOI 10.1136/bjo.2009.172007
   Lepre T, 2011, AM J OPHTHALMOL, V152, P325, DOI 10.1016/j.ajo.2011.04.021
   Lewin AS, 2009, NEW ENGL J MED, V360, P2251, DOI 10.1056/NEJMc082233
   Liew G, 2009, NEW ENGL J MED, V360, P2252
   Lima LH, 2010, OPHTHALMOLOGY, V117, P1567, DOI 10.1016/j.ophtha.2009.12.018
   Lin HJ, 2011, INVEST OPHTH VIS SCI, V52, P3521, DOI 10.1167/iovs.10-6163
   Lin JM, 2008, AM J OPHTHALMOL, V145, P1045, DOI 10.1016/j.ajo.2008.01.027
   Lin RJ, 2006, AM J OPHTHALMOL, V142, P839, DOI 10.1016/j.ajo.2006.06.003
   Liu MM, 2011, INVEST OPHTH VIS SCI, V52, P3129, DOI 10.1167/iovs.10-6735
   Lu F, 2010, MOL VIS, V16, P1
   Luibl V, 2006, J CLIN INVEST, V116, P378, DOI 10.1172/JCI25843
   Majewski J, 2003, AM J HUM GENET, V73, P540, DOI 10.1086/377701
   Martinez-Barricarte R, 2012, INVEST OPHTH VIS SCI, V53, P1087, DOI 10.1167/iovs.11-8709
   Meyer KJ, 2011, HUM GENET, V129, P91, DOI 10.1007/s00439-010-0904-6
   Millen AE, 2011, ARCH OPHTHALMOL-CHIC, V129, P481, DOI 10.1001/archophthalmol.2011.48
   Morrison Margaux A., 2011, Human Genomics, V5, P538
   Mullins RF, 2011, BMC MED GENET, V12, DOI 10.1186/1471-2350-12-58
   Nakanishi H, 2010, INVEST OPHTH VIS SCI, V51, P6183, DOI 10.1167/iovs.09-4948
   Nakata I, 2011, JPN J OPHTHALMOL, V55, P435, DOI 10.1007/s10384-011-0061-z
   Narendra U, 2009, MOL VIS, V15, P731
   Narendran N, 2005, EYE, V19, P11, DOI 10.1038/sj.eye.6701435
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Okamoto H, 2010, EXP ANIM TOKYO, V59, P171, DOI 10.1538/expanim.59.171
   Ormsby RJ, 2008, INVEST OPHTH VIS SCI, V49, P1763, DOI 10.1167/iovs.07-1297
   Parekh N, 2007, ARCH OPHTHALMOL-CHIC, V125, P661, DOI 10.1001/archopht.125.5.661
   Park KH, 2009, MOL VIS, V15, P200
   Parmeggiani F, 2011, CURR DRUG TARGETS, V12, P138, DOI 10.2174/138945011794182773
   Pauer GJT, 2010, AM J OPHTHALMOL, V149, P513, DOI 10.1016/j.ajo.2009.09.024
   Peter I, 2011, AM J OPHTHALMOL, V152, P1005, DOI 10.1016/j.ajo.2011.05.016
   Qu Y, 2011, OPHTHALMIC RES, V45, P142, DOI 10.1159/000319543
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   Raychaudhuri S, 2010, NAT GENET, V42, P553, DOI 10.1038/ng0710-553
   Reynolds R, 2010, OPHTHALMOLOGY, V117, P1989, DOI 10.1016/j.ophtha.2010.07.009
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Richardson AJ, 2007, MOL VIS, V13, P2148
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Robman L, 2010, OPHTHALMOLOGY, V117, P1982, DOI 10.1016/j.ophtha.2010.02.003
   Roca-Santiago H.M., 2006, Arch Soc Esp Oftalmol, V81, P73
   Sakurada Y, 2011, AM J OPHTHALMOL, V152, P499, DOI 10.1016/j.ajo.2011.04.022
   SanGiovanni JP, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005508
   Santangelo Susan L, 2005, Ophthalmic Genet, V26, P61, DOI 10.1080/13816810490967944
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P55, DOI 10.1001/archopht.125.1.55
   Schaumberg DA, 2010, ARCH OPHTHALMOL-CHIC, V128, P1462, DOI 10.1001/archophthalmol.2010.261
   Schick JH, 2003, AM J HUM GENET, V72, P1412, DOI 10.1086/375500
   Schmid-Kubista KE, 2009, INVEST OPHTH VIS SCI, V50, P5070, DOI 10.1167/iovs.09-3975
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Schu M.C., 2012, ARVO M, V53, P2259
   Schultz DW, 2003, HUM MOL GENET, V12, P3315, DOI 10.1093/hmg/ddg348
   Seddon JM, 2003, AM J HUM GENET, V73, P780, DOI 10.1086/378505
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P2203, DOI 10.1016/j.ophtha.2011.04.029
   Seddon JM, 2010, OPHTHALMOLOGY, V117, P1560, DOI 10.1016/j.ophtha.2009.11.020
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P586, DOI 10.1167/iovs.08-2514
   Shastry B, 2010, GRAEF ARCH CLIN EXP, V248, P1057, DOI 10.1007/s00417-010-1333-x
   Shu XH, 2006, ADV EXP MED BIOL, V572, P41
   Shu XH, 2006, HUM MOL GENET, V15, P1680, DOI 10.1093/hmg/ddl091
   Silveira AC, 2010, VISION RES, V50, P698, DOI 10.1016/j.visres.2009.09.016
   Smith RT, 2011, ARCH OPHTHALMOL-CHIC, V129, P1061, DOI 10.1001/archophthalmol.2011.212
   Sng CCA, 2011, OPHTHALMIC RES, V45, P191, DOI 10.1159/000321387
   Sobrin L, 2011, AM J OPHTHALMOL, V151, P345, DOI 10.1016/j.ajo.2010.08.015
   Spencer KL, 2008, HUM MOL GENET, V17, P971, DOI 10.1093/hmg/ddm369
   Spencer KL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017784
   Spencer KL, 2011, INVEST OPHTH VIS SCI, V52, P1748, DOI 10.1167/iovs.09-5112
   Stanton CM, 2012, ADV EXP MED BIOL, V723, P365, DOI 10.1007/978-1-4614-0631-0_47
   Stone EM, 2004, NEW ENGL J MED, V351, P346, DOI 10.1056/NEJMoa040833
   Suuronen T, 2007, BIOCHEM BIOPH RES CO, V357, P397, DOI 10.1016/j.bbrc.2007.03.135
   Synowiec E, 2012, MOL BIOL REP, V39, P2081, DOI 10.1007/s11033-011-0955-3
   Tanaka K, 2011, INVEST OPHTH VIS SCI, V52, P7441, DOI 10.1167/iovs.11-7546
   Teper SJ, 2010, MOL VIS, V16, P2598
   Tong Y, 2010, MOL VIS, V16, P1958
   Tsuchihashi T, 2011, OPHTHALMOLOGY, V118, P93, DOI 10.1016/j.ophtha.2010.04.007
   Udar N, 2009, INVEST OPHTH VIS SCI, V50, P2966, DOI 10.1167/iovs.08-2646
   Vierkotten S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022959
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   Wang AL, 2008, MOL VIS, V14, P644
   Wang GF, 2012, EXP EYE RES, V94, P187, DOI 10.1016/j.exer.2011.11.005
   Wang GF, 2010, HUM GENET, V127, P595, DOI 10.1007/s00439-010-0805-8
   Wang GF, 2009, INVEST OPHTH VIS SCI, V50, P3084, DOI 10.1167/iovs.08-3240
   Wang JY, 2008, J IMMUNOL, V181, P712, DOI 10.4049/jimmunol.181.1.712
   Wang JY, 2009, J CELL PHYSIOL, V220, P119, DOI 10.1002/jcp.21742
   Weeks DE, 2000, HUM MOL GENET, V9, P1329, DOI 10.1093/hmg/9.9.1329
   Weeks DE, 2004, AM J HUM GENET, V75, P174, DOI 10.1086/422476
   Weeks DE, 2001, AM J OPHTHALMOL, V132, P682, DOI 10.1016/S0002-9394(01)01214-4
   Wegscheider BJ, 2007, OPHTHALMOLOGY, V114, P738, DOI 10.1016/j.ophtha.2006.07.048
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   Wong RW, 2007, RETINA-J RET VIT DIS, V27, P997, DOI 10.1097/IAE.0b013e318074c290
   Wysokinski D, 2011, MED SCI MONITOR, V17, pCR449, DOI 10.12659/MSM.881906
   Wysokinski D, 2011, TOHOKU J EXP MED, V223, P253, DOI 10.1620/tjem.223.253
   Yamashiro K, 2011, INVEST OPHTH VIS SCI, V52, P8780, DOI 10.1167/iovs.11-8205
   Yang ZL, 2008, NEW ENGL J MED, V359, P1456, DOI 10.1056/NEJMoa0802437
   Yu Y, 2012, INVEST OPHTH VIS SCI, V53, P1548, DOI 10.1167/iovs.11-8657
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
   Zareparsi S, 2005, HUM MOL GENET, V14, P1449, DOI 10.1093/hmg/ddi154
   Zeng JX, 2010, MOL VIS, V16, P2273
   Zerbib J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007341
   Zhang XZ, 2011, INVEST OPHTH VIS SCI, V52, P8063, DOI 10.1167/iovs.11-7820
   Zhou P, 2011, FASEB J, V25, P3489, DOI 10.1096/fj.11-189258
NR 189
TC 70
Z9 80
U1 0
U2 21
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0098-2997
EI 1872-9452
J9 MOL ASPECTS MED
JI Mol. Asp. Med.
PD AUG
PY 2012
VL 33
IS 4
SI SI
BP 467
EP 486
DI 10.1016/j.mam.2012.04.004
PG 20
WC Biochemistry & Molecular Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Research & Experimental Medicine
GA 983WR
UT WOS:000307149900009
PM 22561651
OA Green Accepted, Green Published
DA 2022-11-30
ER

PT J
AU Zhang, Q
   Chrenek, MA
   Bhatia, S
   Rashid, A
   Ferdous, S
   Donaldson, KJ
   Skelton, H
   Wu, WF
   See, TRO
   Jiang, Y
   Dalal, N
   Nickerson, JM
   Grossniklaus, HE
AF Zhang, Qing
   Chrenek, Micah A.
   Bhatia, Shagun
   Rashid, Alia
   Ferdous, Salma
   Donaldson, Kevin J.
   Skelton, Henry
   Wu, Wenfei
   See, Thonnie Rose O.
   Jiang, Yi
   Dalal, Nupur
   Nickerson, John M.
   Grossniklaus, Hans E.
TI Comparison of histologic findings in age-related macular degeneration
   with RPE flatmount images
SO MOLECULAR VISION
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; SUBRETINAL DRUSENOID DEPOSITS; PHOTORECEPTOR
   LAYER; PATHOGENESIS; LIPOFUSCIN; EYES; CELL; COMPLEMENT; ACCUMULATION;
   MACULOPATHY
AB Purpose: To visualize and analyze ex vivo flatmounted human RPE morphology from patients with age-related macular degeneration (AMD), and to compare the morphology with histologic findings. To establish whether the sub-RPE structures identified en face in RPE flatmount preparations are drusen with histopathological registration in serial sections. To detect characteristic patterns found en face in RPE with the same structures in histological cross sections from eyes from cadavers of patients with AMD.
   Methods: Twenty-eight postmortem eyes from 14 patients (16 eyes with AMD and 12 age-matched control eyes) were oriented and microdissected yielding a RPE-choroid preparation. The tissues were flatmounted, stained with Alexa Fluor 635 Phalloidin (AF635-phalloidin) for f-actin and propidium iodide for DNA, and imaged using confocal microscopy. Portions of tissue from macular regions were processed for electron microscopic examination. After confocal imaging, the samples were remounted for histologic processing, embedded in paraffin, and serially sectioned perpendicular to the plane of the RPE-choroid sheet. Scaled two-dimensional (2D) maps of drusen locations found with the histological cross sections were constructed and correlated with the en face confocal microscopic images.
   Results: Twenty-eight postmortem eyes with a mean time of death to tissue preservation of 23.7 h (range 8.0-51 h) from 14 donors (seven women and seven men) with an average age of 78 years (range 60-93 years) were evaluated. Eight donors had AMD, and six served as controls. Scattered small, hard drusen were present in the periphery of the eyes with AMD and the healthy eyes. The macular region of the eyes with AMD contained small (<63 mu m), medium (63.0-124 mu m), and large (125 mu m) drusen. The RPE was arranged in rosette-like structures overlying small drusen, attenuated overlying medium-sized drusen, and consisted of large multinucleated cells overlying large drusen. The RPE in the area of geographic atrophy was attenuated and depigmented.
   Conclusions: Confocal images of flatmounts from eyes with AMD showed RPE patterns overlying various types of drusen and geographic atrophy that correlated with histologic characteristics. We propose RPE repair mechanisms that may result in the patterns that we observed.
C1 [Zhang, Qing; Chrenek, Micah A.; Bhatia, Shagun; Rashid, Alia; Ferdous, Salma; Donaldson, Kevin J.; Skelton, Henry; Wu, Wenfei; See, Thonnie Rose O.; Dalal, Nupur; Nickerson, John M.; Grossniklaus, Hans E.] Emory Univ, Sch Med, Dept Ophthalmol, Atlanta, GA 30322 USA.
   [Jiang, Yi] Georgia State Univ, Dept Math & Stat, Atlanta, GA 30303 USA.
   [Grossniklaus, Hans E.] Emory Univ, Sch Med, Dept Pathol, Atlanta, GA 30322 USA.
C3 Emory University; University System of Georgia; Georgia State
   University; Emory University
RP Grossniklaus, HE (通讯作者)，LF Montgomery Ophthalm Pathol Lab, BT428,1365 Clifton Rd, Atlanta, GA 30322 USA.
EM ophtheg@emory.edu
OI Jiang, Yi/0000-0002-7519-6365; Donaldson, Kevin/0000-0002-9144-3776;
   Skelton, Henry/0000-0002-1393-510X; Ferdous, Salma/0000-0002-0109-5481
FU National Eye Institute [R01EY028450, R01EY021592, P30EY006360,
   T32EY007092, F31EY028855]; Research to Prevent Blindness, Inc.; Emory
   Neuroscience Initiative Interdisciplinary Seed Grant; NATIONAL EYE
   INSTITUTE [F31EY028855, P30EY006360, T32EY007092, R01EY021592,
   R01EY028450] Funding Source: NIH RePORTER; Veterans Affairs
   [I21RX001924] Funding Source: NIH RePORTER
FX This work was supported in part by the National Eye Institute
   R01EY028450, R01EY021592, P30EY006360, T32EY007092, F31EY028855, an
   unrestricted departmental grant from Research to Prevent Blindness,
   Inc., and an Emory Neuroscience Initiative Interdisciplinary Seed Grant.
CR Abdelsalam A, 1999, SURV OPHTHALMOL, V44, P1, DOI 10.1016/S0039-6257(99)00072-7
   Ach T, 2015, INVEST OPHTH VIS SCI, V56, P3242, DOI 10.1167/iovs.14-16274
   Adler R, 1999, MOL VIS, V5
   Alexander P, 2015, EYE, V29, P992, DOI 10.1038/eye.2015.89
   Algvere PV, 2016, ACTA OPHTHALMOL, V94, P427, DOI 10.1111/aos.13011
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Baddeley A, 2005, J STAT SOFTW, V12, P1, DOI 10.18637/jss.v012.i06
   Bhatia SK, 2016, MOL VIS, V22, P898
   Blasiak J, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/768026
   Boatright JH, 2015, MOL VIS, V21, P40
   Brandstetter C, 2015, J BIOL CHEM, V290, P31189, DOI 10.1074/jbc.M115.671180
   Brunk UT, 2002, FREE RADICAL BIO MED, V33, P611, DOI 10.1016/S0891-5849(02)00959-0
   Campagne MV, 2016, IMMUNOBIOLOGY, V221, P733, DOI 10.1016/j.imbio.2015.11.007
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   Ding JD, 2011, P NATL ACAD SCI USA, V108, pE279, DOI 10.1073/pnas.1100901108
   DOREY CK, 1989, INVEST OPHTH VIS SCI, V30, P1691
   Ferrington DA, 2016, PROG RETIN EYE RES, V51, P69, DOI 10.1016/j.preteyeres.2015.09.002
   Green W R, 1999, Mol Vis, V5, P27
   Hughes AE, 2016, INVEST OPHTH VIS SCI, V57, P2763, DOI 10.1167/iovs.15-18744
   Jiang Y, 2013, INVEST OPHTH VIS SCI, V54, P7274, DOI 10.1167/iovs.13-12450
   Karlsson M, 2016, ACTA OPHTHALMOL, V94, P556, DOI 10.1111/aos.13076
   Kay P, 2013, J CELL MOL MED, V17, P833, DOI 10.1111/jcmm.12070
   Kim HU, 2016, SCI REP-UK, V6, DOI 10.1038/srep34587
   Kim SY, 2016, TRANSL VIS SCI TECHN, V5, DOI 10.1167/tvst.5.1.6
   Kinnunen K, 2012, ACTA OPHTHALMOL, V90, P299, DOI 10.1111/j.1755-3768.2011.02179.x
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Kopitz J, 2004, BIOCHIMIE, V86, P825, DOI 10.1016/j.biochi.2004.09.029
   Lamprecht MR, 2007, BIOTECHNIQUES, V42, P71, DOI 10.2144/000112257
   Mettu PS, 2012, MOL ASPECTS MED, V33, P376, DOI 10.1016/j.mam.2012.04.006
   Mitrut I, 2010, OPHTHALMOLOGY, V117, P1280, DOI 10.1016/j.ophtha.2010.01.047
   Mohr LKM, 2015, INVEST OPHTH VIS SCI, V56, P6404, DOI 10.1167/iovs.15-16898
   Mrejen S, 2014, OPHTHALMOLOGY, V121, P545, DOI 10.1016/j.ophtha.2013.09.026
   Nowak JZ, 2013, PHARMACOL REP, V65, P288, DOI 10.1016/S1734-1140(13)71005-3
   Okubo A, 1999, INVEST OPHTH VIS SCI, V40, P443
   Rashid A, 2016, ADV EXP MED BIOL, V854, P757, DOI 10.1007/978-3-319-17121-0_101
   Roh M, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0196481
   Rudnicka AR, 2015, AM J OPHTHALMOL, V160, P85, DOI 10.1016/j.ajo.2015.04.003
   Rudolf M, 2013, OPHTHALMOLOGY, V120, P821, DOI 10.1016/j.ophtha.2012.10.007
   Sadigh S, 2015, CURR EYE RES, V40, P398, DOI 10.3109/02713683.2014.925934
   Sadigh S, 2013, INVEST OPHTH VIS SCI, V54, P1603, DOI 10.1167/iovs.12-11286
   Spaide RF, 2013, RETINA-J RET VIT DIS, V33, P1800, DOI 10.1097/IAE.0b013e31829c3765
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Theodossiadis PG, 2014, EUR J OPHTHALMOL, V24, P582, DOI 10.5301/ejo.5000412
   Wagner EK, 2016, SCI REP, P6
   WING GL, 1978, INVEST OPHTH VIS SCI, V17, P601
   Winkler BS, 1999, MOL VIS, V5
   YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1016/0039-6257(87)90115-9
   Zanzottera EC, 2016, RETINA-J RET VIT DIS, V36, pS26, DOI 10.1097/IAE.0000000000001330
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 49
TC 9
Z9 9
U1 0
U2 0
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD FEB 7
PY 2019
VL 25
BP 70
EP 78
PG 9
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA HL8AF
UT WOS:000458962500003
PM 30820143
DA 2022-11-30
ER

PT J
AU Hata, M
   Oishi, A
   Yamashiro, K
   Ooto, S
   Tamura, H
   Nakanishi, H
   Ueda-Arakawa, N
   Akagi-Kurashige, Y
   Kuroda, Y
   Takahashi, A
   Tsujikawa, A
   Yoshimura, N
AF Hata, Masayuki
   Oishi, Akio
   Yamashiro, Kenji
   Ooto, Sotaro
   Tamura, Hiroshi
   Nakanishi, Hideo
   Ueda-Arakawa, Naoko
   Akagi-Kurashige, Yumiko
   Kuroda, Yoshimasa
   Takahashi, Ayako
   Tsujikawa, Akitaka
   Yoshimura, Nagahisa
TI INCIDENCE AND CAUSES OF VISION LOSS DURING AFLIBERCEPT TREATMENT FOR
   NEOVASCULAR AGE-RELATED MACULAR DEGENERATION One-Year Follow-up
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE aflibercept; age-related macular degeneration; antivascular endothelial
   growth factor; pigment epithelium detachment; subretinal hemorrhage;
   vision loss
ID TREATMENTS TRIALS CATT; ANTI-VEGF THERAPY; RETINAL ANGIOMATOUS
   PROLIFERATION; ENDOTHELIAL GROWTH-FACTOR; PIGMENT EPITHELIUM TEARS;
   VISUAL-ACUITY LOSS; GEOGRAPHIC ATROPHY; RISK-FACTORS; RANIBIZUMAB;
   OUTCOMES
AB Purpose: To investigate the incidence rate, risk factors, and final outcomes of patients with age-related macular degeneration (AMD) who have experienced vision loss despite periodic aflibercept treatment.
   Methods: Subjects with treatment-naive AMD were prospectively recruited and treated with three monthly injections followed by two monthly injections of aflibercept. The incidence rate and risk factors of more than two lines of vision loss at any visit were investigated.
   Results: We included 196 eyes of 196 patients. Vision loss was observed in 16 patients (8.2%). Eleven of 16 patients developed vision loss during the initial 3 months (68.8%). Vision loss remained in 11 eyes (68.8%) at the final visit. The maximum pigment epithelium detachment (PED) height (odds ratio = 1.46 for a 100-mm increase in the PED height) and disruption of the external limiting membrane (odds ratio = 4.45) were identified as risk factors for developing vision loss on logistic regression analysis.
   Conclusion: The incidence rate of vision loss during aflibercept treatment was relatively low. Identifying high-risk patients, those with a high PED height and disruption of the external limiting membrane, would be helpful in ensuring appropriate informed consent before treatment. Further studies are needed to establish optimal treatment for these patients.
C1 [Hata, Masayuki; Oishi, Akio; Yamashiro, Kenji; Ooto, Sotaro; Tamura, Hiroshi; Nakanishi, Hideo; Ueda-Arakawa, Naoko; Akagi-Kurashige, Yumiko; Kuroda, Yoshimasa; Takahashi, Ayako; Yoshimura, Nagahisa] Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Kyoto, Japan.
   [Tsujikawa, Akitaka] Kagawa Univ, Fac Med, Dept Ophthalmol, Miki, Kagawa, Japan.
C3 Kyoto University; Kagawa University
RP Oishi, A (通讯作者)，Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Sakyo Ku, 54 Kawahara, Kyoto 6068507, Japan.
EM aquio@kuhp.kyoto-u.ac.jp
RI Oishi, Akio/AAE-9996-2020; TAMURA, Hiroshi/H-1855-2011
OI Oishi, Akio/0000-0002-0977-9458; TAMURA, Hiroshi/0000-0002-7740-2732;
   Yamashiro, Kenji/0000-0001-9354-8558; Tsujikawa,
   Akitaka/0000-0003-0779-7799
FU Japan Society for the Promotion of Science, Tokyo, Japan [24791847];
   Innovative Techno-Hub for Integrated Medical Bio-Imaging of the Project
   for Developing Innovation Systems from the Ministry of Education,
   Culture, Sports, Science, and Technology (MEXT), Tokyo, Japan; Novartis
   (Basel, Switzerland); Bayer (Leverkusen, Germany); Pfizer (New York,
   NY); Topcon Corporation (Tokyo, Japan); Nidek (Tokyo, Japan); Canon
   (Tokyo, Japan)
FX Supported in part by a grant-in-aid for scientific research (no.
   24791847) from the Japan Society for the Promotion of Science, Tokyo,
   Japan and the Innovative Techno-Hub for Integrated Medical Bio-Imaging
   of the Project for Developing Innovation Systems from the Ministry of
   Education, Culture, Sports, Science, and Technology (MEXT), Tokyo,
   Japan.; A. Oishi, K. Yamashiro, S. Ooto, A. Takahashi, A. Tsujikawa, and
   N. Yoshimura received lecture fees from several companies, including
   Novartis (Basel, Switzerland) and Bayer (Leverkusen, Germany). A. Oishi
   received financial support from Bayer (Leverkusen, Germany). A.
   Takahashi and A. Tsujikawa received financial support from Pfizer (New
   York, NY). N. Yoshimura is a consultant of Nidek (Gamagori, Japan) and
   received financial support from the Topcon Corporation (Tokyo, Japan),
   Nidek (Tokyo, Japan), and Canon (Tokyo, Japan). The remaining authors
   have no conflicting interests to disclose.
CR Altaweel MM, 2015, OPHTHALMOLOGY, V122, P391, DOI 10.1016/j.ophtha.2014.08.020
   Bhisitkul RB, 2015, AM J OPHTHALMOL, V159, P915, DOI 10.1016/j.ajo.2015.01.032
   Boulanger-Scemama E, 2015, J FR OPHTALMOL, V38, P620, DOI 10.1016/j.jfo.2014.11.015
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chiang A, 2008, RETINA-J RET VIT DIS, V28, P1265, DOI 10.1097/IAE.0b013e31817d5d03
   Cho HJ, 2015, AM J OPHTHALMOL, V159, P285, DOI 10.1016/j.ajo.2014.10.035
   Clemens CR, 2016, OPHTHALMOLOGICA, V235, P1, DOI 10.1159/000439445
   Daniel E, 2016, OPHTHALMOLOGY, V123, P609, DOI 10.1016/j.ophtha.2015.10.034
   Doguizi S, 2014, RETINA-J RET VIT DIS, V34, P1156, DOI 10.1097/IAE.0000000000000056
   Grunwald JE, 2015, OPHTHALMOLOGY, V122, P809, DOI 10.1016/j.ophtha.2014.11.007
   Guber J, 2013, BRIT J OPHTHALMOL, V97, P1486, DOI 10.1136/bjophthalmol-2013-303978
   Hayashi H, 2009, AM J OPHTHALMOL, V148, P83, DOI 10.1016/j.ajo.2009.01.017
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holz FG, 2013, BRIT J OPHTHALMOL, V97, P1161, DOI 10.1136/bjophthalmol-2013-303232
   Kim BJ, 2014, AM J OPHTHALMOL, V158, P128, DOI 10.1016/j.ajo.2014.04.004
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Nagiel A, 2013, AM J OPHTHALMOL, V156, P981, DOI 10.1016/j.ajo.2013.06.024
   Oishi A, 2015, AM J OPHTHALMOL, V159, P853, DOI 10.1016/j.ajo.2015.01.018
   Oishi A, 2013, GRAEF ARCH CLIN EXP, V251, P435, DOI 10.1007/s00417-012-2034-4
   Oishi A, 2011, EUR J OPHTHALMOL, V21, P777, DOI 10.5301/EJO.2011.7430
   Oishi A, 2010, AM J OPHTHALMOL, V150, P27, DOI 10.1016/j.ajo.2010.02.012
   Omri S, 2010, CLIN OPHTHALMOL, V4, P183
   Real JP, 2015, GRAEF ARCH CLIN EXP, V253, P1859, DOI 10.1007/s00417-014-2885-y
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   Sarraf David, 2014, Trans Am Ophthalmol Soc, V112, P142
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Schutze C, 2015, AM J OPHTHALMOL, V159, P1100, DOI 10.1016/j.ajo.2015.02.020
   Stewart MW, 2012, NAT REV DRUG DISCOV, V11, P269, DOI 10.1038/nrd3700
   Xu LN, 2015, RETINA-J RET VIT DIS, V35, P176, DOI 10.1097/IAE.0000000000000374
   Ying GS, 2016, OPHTHALMOLOGY, V123, P352, DOI 10.1016/j.ophtha.2015.09.046
   Ying GS, 2014, JAMA OPHTHALMOL, V132, P915, DOI 10.1001/jamaophthalmol.2014.1019
NR 32
TC 10
Z9 11
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUL
PY 2017
VL 37
IS 7
BP 1320
EP 1328
DI 10.1097/IAE.0000000000001370
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EY6ZG
UT WOS:000404133400017
PM 27787445
DA 2022-11-30
ER

PT J
AU Mukai, RG
   Matsumoto, HG
   Akiyama, HG
AF Mukai, Ryo G.
   Matsumoto, Hidetaka G.
   Akiyama, Hideo G.
TI Risk factors for emerging intraocular inflammation after intravitreal
   brolucizumab injection for age-related macular degeneration
SO PLOS ONE
LA English
DT Article
ID DISEASE; SAFETY; RANIBIZUMAB; MORTALITY
AB PurposeTo analyze the risk factors associated with emerging intraocular inflammation (IOI) after intravitreal brolucizumab injection (IVBr) to treat age-related macular degeneration (AMD). MethodsThis study included 93 eyes of 90 patients. The incidence of emerging IOI was analyzed. The patients were classified into IOI or non-IOI groups, and background clinical characteristics in each group were compared. ResultsIOI occurred in 14 eyes of 14 cases (16%; five women, nine men [5:9]; IOI group) after IVBr; contrastingly, no IOI occurred in 76 patients (10 women, 66 men [10:66]; non-IOI group). The mean ages in IOI and non-IOI groups were 79.4 +/- 8.1 and 73.8 +/- 8.9 years old, respectively, and the average age in the IOI group was significantly higher than that in the non-IOI group (P = 0.0425). In addition, the percentages of females in the IOI and non-IOI groups were 43% and 13%, respectively, and IOI occurred predominantly in females (odds ratio: 4.95, P = 0.0076). Moreover, the prevalence of diabetes in the IOI and non-IOI groups was 64% and 32%, respectively, with a significant difference (odds ratio: 3.90, P = 0.0196). In contrast, the prevalence of hypertension in the IOI and non-IOI groups was 36% and 57%, respectively, with no significant difference (P = 0.15). ConclusionThe comparison of clinical profiles of IOI or non-IOI cases in IVBr treatment for AMD suggests that the risk factors for IOI are old age, female sex, and history of diabetes; however, IOI with vasculitis or vascular occlusion in this cohort does not seem to cause severe visual impairment. Further studies are required to investigate potential risk factors for IOI.
C1 [Mukai, Ryo G.; Matsumoto, Hidetaka G.; Akiyama, Hideo G.] Gunma Univ, Dept Ophthalmol, Grad Sch Med, Maebashi, Gunma, Japan.
C3 Gunma University
RP Mukai, RG (通讯作者)，Gunma Univ, Dept Ophthalmol, Grad Sch Med, Maebashi, Gunma, Japan.
EM rmukai@gunma-u.ac.jp
OI Mukai, Ryo/0000-0003-1796-9232; Matsumoto, Hidetaka/0000-0003-2311-0280
CR Beovu&TRADE;(brolucizumab), POSTMARKETING DAT
   Berg K, 2017, ACTA OPHTHALMOL, V95, P796, DOI 10.1111/aos.13522
   Dugel PU, 2021, OPHTHALMOLOGY, V128, P89, DOI [10.1016/j.opatha.2020.06.028, 10.1016/j.ophtha.2020.06.028]
   Enriquez AB, 2021, JAMA OPHTHALMOL, V139, P441, DOI 10.1001/jamaophthalmol.2020.7085
   Haffner SM, 1998, NEW ENGL J MED, V339, P229, DOI 10.1056/NEJM199807233390404
   Haug Sara J, 2020, Am J Ophthalmol Case Rep, V18, P100680, DOI 10.1016/j.ajoc.2020.100680
   Iyer Prashanth G, 2020, Am J Ophthalmol Case Rep, V20, P100989, DOI 10.1016/j.ajoc.2020.100989
   Jain Atul, 2020, Am J Ophthalmol Case Rep, V18, P100687, DOI 10.1016/j.ajoc.2020.100687
   JANKA HU, 1985, HORM METAB RES, V15, P15
   Kitchens JW, 2016, OPHTHALMOLOGY, V123, P1511, DOI 10.1016/j.ophtha.2016.02.046
   Krentz AJ, 2009, J VASC RES, V46, P515, DOI 10.1159/000226220
   Kubo M, 2003, STROKE, V34, P2349, DOI 10.1161/01.STR.0000090348.52943.A2
   Li JQ, 2020, BRIT J OPHTHALMOL, V104, P1077, DOI 10.1136/bjophthalmol-2019-314422
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Maruko I, 2021, GRAEF ARCH CLIN EXP, V259, P2857, DOI 10.1007/s00417-021-05136-w
   Matsumoto H, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-86014-7
   Mones J, 2021, OPHTHALMOLOGY, V128, P1050, DOI 10.1016/j.ophtha.2020.11.011
   Noma H, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22073427
   Ogura Yuichiro, 2016, Nippon Ganka Gakkai Zasshi, V120, P87
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sauerborn M, 2010, TRENDS PHARMACOL SCI, V31, P53, DOI 10.1016/j.tips.2009.11.001
   Sharma A, 2021, EYE, V35, P1292, DOI 10.1038/s41433-020-01227-w
   Spinelli FR, 2013, CLIN EXP RHEUMATOL, V31, P954
   STOUT RW, 1979, DIABETOLOGIA, V16, P141, DOI 10.1007/BF01219790
   Tolentino M, 2011, SURV OPHTHALMOL, V56, P95, DOI 10.1016/j.survophthal.2010.08.006
   Uemura A, 2021, PROG RETIN EYE RES, V84, DOI 10.1016/j.preteyeres.2021.100954
   Ueta T, 2014, OPHTHALMOLOGY, V121, P2193, DOI 10.1016/j.ophtha.2014.05.022
   Witkin Andre J, 2020, J Vitreoretin Dis, V4, P269, DOI 10.1177/2474126420930863
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Zarbin MA, 2018, ASIA-PAC J OPHTHALMO, V7, P63, DOI 10.22608/APO.2017495
NR 32
TC 5
Z9 5
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PY 2021
VL 16
IS 12
AR e0259879
DI 10.1371/journal.pone.0259879
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA XM1MC
UT WOS:000728598900004
PM 34871313
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Spooner, K
   Hong, T
   Nair, R
   Chow, NCC
   Broadhead, GK
   Wijeyakumar, W
   Chang, AA
AF Spooner, Kimberly
   Hong, Thomas
   Nair, Rashmi
   Chow, Nicholas Chian Chiang
   Broadhead, Geoffrey K.
   Wijeyakumar, Wijeyanthy
   Chang, Andrew A.
TI Long-term outcomes of switching to aflibercept for treatment-resistant
   neovascular age-related macular degeneration
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration; anti-VEGF; long-term; treatment
   resistance
ID FUNDUS AUTOFLUORESCENCE PATTERNS; GEOGRAPHIC ATROPHY; INTRAVITREAL
   AFLIBERCEPT; FELLOW EYE; RANIBIZUMAB; PROGRESSION; BEVACIZUMAB;
   PREVALENCE; CONVERSION; FLUID
AB Purpose To report 4-year outcomes following the switch to aflibercept in treatment-resistant neovascular age-related macular degeneration (nAMD). Methods In this prospective, open-label, non-controlled, clinical trial, 49 patients with treatment-resistant nAMD received 2 mg intravitreal aflibercept as three loading doses every 4 weeks, followed by injections every 8 weeks for the first 48 weeks, then an individualized regimen for a further 36 months, following previous treatment with ranibizumab and/or bevacizumab. Outcome measures included best-corrected visual acuity (BCVA), central retinal thickness (CRT), pigment epithelial detachment (PED) height and geographic atrophy (GA) surface area. Results Of the 49 patients who were initially recruited, data from 39 eyes of 39 patients were available at 48-month follow-up. Mean age was 76.7 +/- 7.2 years. Over the 48 months, these eyes received a mean of 32.1 +/- 5.6 injections. The mean BCVA improved significantly following 12 months of treatment (4.9 +/- 9.0 ETDRS letters, p < 0.001); however, this was not maintained and was similar to baseline after 48 months (mean difference -0.4 +/- 13.3 letters between baseline and 48 months, p < 0.001). The reduction in CRT from baseline was 170.3 +/- 143.3 mu m (p < 0.001) with absence of macular fluid in 56% of the 39 eyes at the end of month 48. PED height reduced by a mean 77.5 +/- 20.0 mu m, and geographic atrophy increased by a mean of 4.1 +/- 3.4 mm(2) (p < 0.01) over the 48 months. Conclusion Aflibercept is an effective alternative therapy for treatment-resistant nAMD. Good anatomical and stable functional responses are achievable with continued therapy. The lack of continued visual improvement may be representative of GA progression, reflecting the progression of late-stage nAMD in these patients.
C1 [Spooner, Kimberly; Hong, Thomas; Nair, Rashmi; Chow, Nicholas Chian Chiang; Broadhead, Geoffrey K.; Wijeyakumar, Wijeyanthy; Chang, Andrew A.] Sydney Retina Clin & Day Surg, Level 13,Pk House 187 Macquarie St, Sydney, NSW 2000, Australia.
   [Spooner, Kimberly; Hong, Thomas; Nair, Rashmi; Chow, Nicholas Chian Chiang; Broadhead, Geoffrey K.; Wijeyakumar, Wijeyanthy; Chang, Andrew A.] Sydney Inst Vis Sci, Sydney, NSW, Australia.
   [Spooner, Kimberly; Nair, Rashmi; Chang, Andrew A.] Univ Sydney, Sydney, NSW, Australia.
C3 University of Sydney
RP Chang, AA (通讯作者)，Sydney Retina Clin & Day Surg, Level 13,Pk House 187 Macquarie St, Sydney, NSW 2000, Australia.
EM achang@sydneyretina.com.au
FU Bayer Corporation Global
FX Dr Andrew A. Chang has acted as a consultant for Alcon, Bayer and
   Novartis. Financial support was provided by Bayer Corporation Global.
   The sponsor had no role in the design, conduct or analysis of this
   research. None of the authors have any proprietary interest in any
   material or method presented. All authors certify that they have no
   affiliations with or involvement in any organization or entity with any
   financial interest (such as honoraria; educational grants; participation
   in speakers' bureaus; membership, employment, consultancies, stock
   ownership, or other equity interest; and expert testimony or
   patent-licensing arrangements), or non-financial interest (such as
   personal or professional relationships, affiliations, knowledge or
   beliefs) in the subject matter or materials discussed in this
   manuscript.
CR Abdelfattah NS, 2016, RETINA-J RET VIT DIS, V36, P1843, DOI 10.1097/IAE.0000000000001059
   Aghdam KA, 2016, EUR J OPHTHALMOL, V26, P473, DOI 10.5301/ejo.5000757
   Batioglu F, 2014, OPHTHALMIC RES, V52, P53, DOI 10.1159/000361077
   Bhisitkul RB, 2016, OPHTHALMOLOGY, V123, P1269, DOI 10.1016/j.ophtha.2016.01.033
   Binder S, 2012, BRIT J OPHTHALMOL, V96, P1, DOI 10.1136/bjophthalmol-2011-301236
   Brown DM, 2013, OPHTHALMOLOGY, V120, P349, DOI 10.1016/j.ophtha.2012.08.008
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chang AA, 2014, OPHTHALMOLOGY, V121, P188, DOI 10.1016/j.ophtha.2013.08.035
   Cho H, 2013, BRIT J OPHTHALMOL, V97, P1032, DOI 10.1136/bjophthalmol-2013-303344
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Eadie JA, 2014, OSLI RETINA, V45, P394, DOI 10.3928/23258160-20140909-03
   Ehlken C, 2014, EYE, V28, P538, DOI 10.1038/eye.2014.64
   Gemenetzi M, 2017, EYE, V31, P1, DOI 10.1038/eye.2016.208
   Giannakaki-Zimmermann H, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0452-0
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Hall LB, 2014, J OCUL PHARMACOL TH, V30, P346, DOI 10.1089/jop.2013.0188
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Jeong YJ, 2014, EYE, V28, P209, DOI 10.1038/eye.2013.275
   Joachim N, 2013, OPHTHALMOLOGY, V120, P2042, DOI 10.1016/j.ophtha.2013.03.029
   Karagiannis DA, 2009, CLIN INTERV AGING, V4, P457
   Klein R, 2008, AM J OPHTHALMOL, V146, P692, DOI 10.1016/j.ajo.2008.05.050
   Kumar N, 2013, RETINA-J RET VIT DIS, V33, P1605, DOI 10.1097/IAE.0b013e31828e8551
   Larsen M, 2012, OPHTHALMOLOGY, V119, P992, DOI 10.1016/j.ophtha.2012.02.002
   Lindblad AS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1168, DOI 10.1001/archophthalmol.2009.198
   MARCUS DM, 2014, INVEST OPHTH VIS SCI, V55
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Neely DC, 2017, JAMA OPHTHALMOL, V135, P570, DOI 10.1001/jamaophthalmol.2017.0830
   Panthier C, 2014, RETINA-J RET VIT DIS, V34, P576, DOI 10.1097/01.iae.0000433986.32991.1e
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P7640, DOI 10.1167/iovs.11-7457
   Sikorav A, 2017, BRIT J OPHTHALMOL, V101, P438, DOI 10.1136/bjophthalmol-2015-308065
   Spaide RF, 2012, OPHTHALMOLOGY, V119, P2203, DOI 10.1016/j.ophtha.2012.09.009
   Spooner K, 2017, CLIN OPHTHALMOL, V11, P161, DOI 10.2147/OPTH.S125676
   Stewart MW, 2012, RETINA-J RET VIT DIS, V32, P434, DOI 10.1097/IAE.0B013E31822C290F
   Thalgott V, 2016, OPHTHALMOLOGE, V113, P668, DOI 10.1007/s00347-016-0228-6
   Thavikulwat AT, 2017, OPHTHALMOL RETINA, V1, P34, DOI 10.1016/j.oret.2016.09.005
   Yonekawa Y, 2013, AM J OPHTHALMOL, V156, P29, DOI 10.1016/j.ajo.2013.03.030
   You QS, 2017, RETINA, V38, P1156
   Zhu MD, 2015, GRAEF ARCH CLIN EXP, V253, P1217, DOI 10.1007/s00417-014-2799-8
NR 41
TC 8
Z9 9
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD AUG
PY 2019
VL 97
IS 5
BP E706
EP E712
DI 10.1111/aos.14046
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA IH9DK
UT WOS:000474806400018
PM 30740921
DA 2022-11-30
ER

PT J
AU Schutze, C
   Wedl, M
   Baumann, B
   Pircher, M
   Hitzenberger, CK
   Schmidt-Erfurth, U
AF Schuetze, Christopher
   Wedl, Manuela
   Baumann, Bernhard
   Pircher, Michael
   Hitzenberger, Christoph K.
   Schmidt-Erfurth, Ursula
TI Progression of Retinal Pigment Epithelial Atrophy in Antiangiogenic
   Therapy of Neovascular Age-Related Macular Degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; ENDOTHELIAL GROWTH-FACTOR; GEOGRAPHIC
   ATROPHY; HYPERREFLECTIVE FOCI; TREATMENTS TRIALS; RANIBIZUMAB; EYE;
   PREVALENCE; REDUCTION; DISEASE
AB PURPOSE: To monitor retinal pigment epithelial (RPE) atrophy progression during antiangiogenic therapy of neovascular age-related macular degeneration (AMD) over 2 years using polarization-sensitive optical coherence tomography (OCT).
   DESIGN: Prospective interventional case series.
   METHODS: SETTING: Clinical practice. STUDY POPULATION: Thirty patients (31 eyes) with treatment-naive neovascular AMD. OBSERVATION PROCEDURES: Standard intravitreal therapy (0.5 mg ranibizumab) was administered monthly during the first year and pro re nata (PRN; as-needed) during the second year. Spectral-domain (SD) OCT and polarization-sensitive OCT (selectively imaging the RPE) examinations were performed at baseline and at 1, 3, 6, 12, and 24 months using a standardized protocol. RPE-related changes were evaluated using a semi-automated polarization-sensitive OCT segmentation algorithm and correlated with SD OCT and fundus autofluorescence (FAF) findings. MAIN OUTCOME MEASURES: RPE response, geographic atrophy (GA) progression.
   RESULTS: Atrophic RPE changes included RPE thinning, RPE porosity, focal RPE atrophy, and development of GA. Early RPE loss (ie, RPE porosity, focal atrophy) increased progressively during initial monthly treatment and remained stable during subsequent PRN-based therapy. GA developed in 61% of eyes at month 24. Mean GA area increased from 0.77 mm(2) at 12 months to 1.10 mm(2) (standard deviation = 1.09 mm(2)) at 24 months. Reactive accumulation of RPE-related material at the lesion borders increased until month 3 and subsequently decreased. "
   CONCLUSIONS: Progressive RPE atrophy and GA developed in the majority of eyes. RPE migration signifies certain RPE plasticity. Polarization-sensitive OCT specifically images RPE-related changes in neovascular AMD, contrary to conventional imaging methods. Polarization-sensitive OCT allows for precisely monitoring the sequence of RPE-related morphologic changes. (C) 2015 The Authors. Published by Elsevier Inc.
C1 [Schuetze, Christopher; Wedl, Manuela; Schmidt-Erfurth, Ursula] Med Univ Vienna, Dept Ophthalmol, A-1090 Vienna, Austria.
   [Baumann, Bernhard; Pircher, Michael; Hitzenberger, Christoph K.] Med Univ Vienna, Ctr Med Phys & Biomed Engn, A-1090 Vienna, Austria.
C3 Medical University of Vienna; Medical University of Vienna
RP Schmidt-Erfurth, U (通讯作者)，Med Univ Vienna, Guertel 18-20, A-1090 Vienna, Austria.
EM ursula.schmidt-erfurth@meduniwien.ac.at
OI Baumann, Bernhard/0000-0001-6419-1932; Michael,
   Pircher/0000-0001-9285-7527; Hitzenberger,
   Christoph/0000-0002-6608-8821; Schmidt-Erfurth,
   Ursula/0000-0002-7788-7311
FU FWF, Austrian Science Fund, Vienna, Austria [P19624-B02]; European Union
   (FP7 HEALTH program, FUN-OCT, Brussels, Belgium) [201880]; Canon (Tokyo,
   Japan); Alcon Laboratories, Inc (Fort Worth, Texas); Bayer, Healthcare
   (Vienna, Austria); Novartis (Basel, Switzerland); Allergan (Irvine,
   California); Boehringer (Ingelheim, Germany)
FX ALL AUTHORS HAVE COMPLETED AND SUBMITTED THE ICMJE FORM FOR DISCLOSURE
   OF POTENTIAL CONFLICTS OF INTERest. No conflicting relationship exists
   for any author. C.K. Hitzenberger has received support by an independent
   scientific grant (FWF grant P19624-B02, Austrian Science Fund, Vienna,
   Austria), the European Union (FP7 HEALTH program grant 201880, FUN-OCT,
   Brussels, Belgium), and Canon (Tokyo, Japan). U. Schmidt-Erfurth
   receives consultancy and lecture fees and travel support from Alcon
   Laboratories, Inc (Fort Worth, Texas), Bayer, Healthcare (Vienna,
   Austria), Novartis (Basel, Switzerland), Allergan (Irvine, California),
   and Boehringer (Ingelheim, Germany). M. Pircher and B. Baumann have
   received support from Canon (Tokyo, Japan). Polarization-sensitive OCT
   was constructed and provided by the Center for Biomedical Engineering
   and Physics, Medical University of Vienna, Vienna, Austria. All authors
   attest that they meet the current ICMJE requirements to qualify as
   authors.
CR Ahlers C, 2010, INVEST OPHTH VIS SCI, V51, P2149, DOI 10.1167/iovs.09-3817
   Baumann B, 2010, J BIOMED OPT, V15, DOI 10.1117/1.3499420
   Bird AC, 2014, JAMA OPHTHALMOL, V132, P338, DOI 10.1001/jamaophthalmol.2013.5799
   Bolz M, 2009, OPHTHALMOLOGY, V116, P914, DOI 10.1016/j.ophtha.2008.12.039
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Chang TS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1460, DOI 10.1001/archopht.125.11.1460
   Christenbury JG, 2013, OPHTHALMOLOGY, V120, P1038, DOI 10.1016/j.ophtha.2012.10.018
   Ferrara N, 2007, ANNU REV MED, V58, P491, DOI 10.1146/annurev.med.58.061705.145635
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gibran SK, 2007, BRIT J OPHTHALMOL, V91, P602, DOI 10.1136/bjo.2006.108795
   Gotzinger E, 2011, OPT EXPRESS, V19, P14568, DOI 10.1364/OE.19.014568
   Gotzinger E, 2008, OPT EXPRESS, V16, P16410, DOI 10.1364/OE.16.016410
   Grisanti S, 2008, PROG RETIN EYE RES, V27, P372, DOI 10.1016/j.preteyeres.2008.05.002
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Ho J, 2011, OPHTHALMOLOGY, V118, P687, DOI 10.1016/j.ophtha.2010.08.010
   Jaffe GJ, 2013, OPHTHALMOLOGY, V120, P1860, DOI 10.1016/j.ophtha.2013.01.073
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Joachim N, 2013, OPHTHALMOLOGY, V120, P2042, DOI 10.1016/j.ophtha.2013.03.029
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Kumar N, 2013, OPHTHALMOLOGY, V120, P334, DOI 10.1016/j.ophtha.2012.07.076
   Marmor MF, 2004, RETINAL PIGMENT EPIT, P775
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Penn JS, 2008, PROG RETIN EYE RES, V27, P331, DOI 10.1016/j.preteyeres.2008.05.001
   Pircher M, 2011, PROG RETIN EYE RES, V30, P431, DOI 10.1016/j.preteyeres.2011.06.003
   Rabenlehner D, 2008, GRAEF ARCH CLIN EXP, V246, P345, DOI 10.1007/s00417-007-0658-6
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schlanitz FG, 2011, INVEST OPHTH VIS SCI, V52, P4571, DOI 10.1167/iovs.10-6846
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P5009, DOI 10.1167/iovs.11-7235
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P1, DOI 10.1167/iovs.10-5619
   Schutze C, 2013, INVEST OPHTH VIS SCI, V54, P739, DOI 10.1167/iovs.11-7877
   Semoun O, 2009, BRIT J OPHTHALMOL, V93, P182, DOI 10.1136/bjo.2008.145235
   Spaide RF, 2011, RETINA-J RET VIT DIS, V31, P1609, DOI 10.1097/IAE.0b013e3182247535
   Staurenghi G, 2014, OPHTHALMOLOGY, V121, P1572, DOI 10.1016/j.ophtha.2014.02.023
   Sugita M, 2015, J BIOMED OPT, V20, DOI 10.1117/1.JBO.20.1.016011
   TSUBOI S, 1987, INVEST OPHTH VIS SCI, V28, P1788
   Xu LN, 2013, RETINA-J RET VIT DIS, V33, P1850, DOI 10.1097/IAE.0b013e31828991b2
   Yamanari M, 2008, OPT EXPRESS, V16, P5892, DOI 10.1364/OE.16.005892
   Zhang QX, 2013, SCI REP-UK, V3, DOI 10.1038/srep02644
NR 42
TC 55
Z9 61
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JUN
PY 2015
VL 159
IS 6
BP 1100
EP 1114
DI 10.1016/j.ajo.2015.02.020
PG 15
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CI9DL
UT WOS:000355070500014
PM 25769245
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Yu, AL
   Paul, T
   Schaumberger, M
   Welge-Lussen, U
AF Yu, Alice L.
   Paul, Tobias
   Schaumberger, Markus
   Welge-Lussen, Ulrich
TI Factors Influencing Self-Reported Use of Antioxidant Supplements in
   Patients with Age-Related Macular Degeneration
SO CURRENT EYE RESEARCH
LA English
DT Article
DE Age-related macular degeneration; antioxidants; AREDS; micronutrients;
   use
ID RISK-FACTORS; EYE DISEASE; PREVALENCE; MACULOPATHY; AREDS; ADHERENCE;
   IMPACT
AB Aim: The goals of the present study were to evaluate the current use and accuracy of dose-taking prescription among patients with age-related macular degeneration (AMD) and to detect potential factors influencing the use or non-use of oral antioxidant supplements.
   Materials and methods: This is a cross-sectional questionnaire-based study of 65 patients with AMD of Age-Related Eye Disease Study (AREDS) category 3 (intermediate AMD) or category 4 (unilateral advanced AMD). Self-report data were obtained from a structural clinical interview in clinic. The patients were asked questions regarding their demographic, ophthalmologic and systemic data, their source of recommendation for antioxidant supplement use and/or their reasons for non-use. Afterwards, this information was correlated with the use or non-use of antioxidant supplements. Statistical analyses were conducted using a series of Mann-Whitney U-tests and Fisher's exact tests.
   Results: There were 55.4% (36 of 65) of the patients reporting antioxidant supplement use for AMD and 44.6% (29 of 65) with no supplement use. However, only 56.7% (17 of 30) took the recommended dose on label. There were significantly more female patients taking supplements than male patients (p = 0.010). A statistically significant correlation was also found between supplement use and the number of visits to an ophthalmologist per year (p = 0.037). The main reason for antioxidant supplement non-use was the missing awareness of the availability of antioxidant supplements.
   Conclusions: Despite the recommendation of oral antioxidant supplements in the ARED Study for patients with AMD of category 3 or 4, only about half of these patients took the supplements in this study. Identifying the factors, which influenced the decision against supplement use, may help to better support patients in the prevention of severe vision loss caused by AMD.
C1 [Yu, Alice L.; Paul, Tobias; Schaumberger, Markus] Univ Munich, Dept Ophthalmol, D-80336 Munich, Germany.
   [Welge-Lussen, Ulrich] Univ Erlangen Nurnberg, Dept Ophthalmol, Erlangen, Germany.
C3 University of Munich; University of Erlangen Nuremberg
RP Yu, AL (通讯作者)，Univ Munich, Dept Ophthalmol, Mathildenstr 8, D-80336 Munich, Germany.
EM alice.yu@med.uni-muenchen.de
CR Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Chang CW, 2003, CAN J OPHTHALMOL, V38, P27, DOI 10.1016/S0008-4182(03)80005-4
   Charkoudian LD, 2008, OPHTHALMOLOGY, V115, P1032, DOI 10.1016/j.ophtha.2007.08.003
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   Fahed DC, 2011, EUR J OPHTHALMOL, V21, P67, DOI 10.5301/EJO.2010.4138
   Friedman DS, 2009, OPHTHALMOLOGY, V116, P1097, DOI 10.1016/j.ophtha.2009.01.021
   Hawkins BS, 1999, MOL VIS, V5
   Hochstetler BS, 2010, RETINA-J RET VIT DIS, V30, P1166, DOI 10.1097/IAE.0b013e3181cea5c6
   Jampol LM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1634, DOI 10.1001/archopht.121.11.1634
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Ng WT, 2006, CLIN EXP OPHTHALMOL, V34, P9, DOI 10.1111/j.1442-9071.2006.01141.x
   Rees G, 2013, J GLAUCOMA
   Rolnick SJ, 2013, CLIN MED RES, V11, P54, DOI 10.3121/cmr.2013.1113
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Stryker JE, 2010, J GLAUCOMA, V19, P66, DOI 10.1097/IJG.0b013e31819c4679
   Turner Perry, 2002, N Z Med J, V115, pU218
   Vingerling JR, 1995, EPIDEMIOL REV, V17, P347, DOI 10.1093/oxfordjournals.epirev.a036198
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
NR 22
TC 0
Z9 0
U1 0
U2 4
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0271-3683
EI 1460-2202
J9 CURR EYE RES
JI Curr. Eye Res.
PD DEC
PY 2014
VL 39
IS 12
BP 1240
EP 1246
DI 10.3109/02713683.2014.906622
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AT2MJ
UT WOS:000344768600014
PM 24749547
DA 2022-11-30
ER

PT J
AU Kawasaki, R
   Wang, JJ
   Aung, T
   Tan, DTH
   Mitchell, P
   Sandar, M
   Saw, SM
   Wong, TY
AF Kawasaki, Ryo
   Wang, Jie Jin
   Aung, Tin
   Tan, Donald T. H.
   Mitchell, Paul
   Sandar, Maya
   Saw, Seang-Mei
   Wong, Tien Y.
CA Singapore Malay Eye Study Grp
TI Prevalence of age-related macular degeneration in a Malay population -
   The Singapore Malay Eye Study
SO OPHTHALMOLOGY
LA English
DT Article
ID RISK-FACTORS; JAPANESE POPULATION; 5-YEAR INCIDENCE; MACULOPATHY;
   WISCONSIN; DISEASES; THERAPY; LATINOS; HEALTH; WOMEN
AB Objective: To describe the prevalence of age-related macular degeneration (AMD) in an Asian Malay population.
   Design: Population-based cross-sectional study.
   Participants: An age-stratified random sample of Malay persons aged 40 to 80 years living in Singapore.
   Methods: Participants were invited to a central clinic for a comprehensive examination.
   Main Outcome Measures: Early and late AMD signs were graded from retinal photographs following the Wisconsin grading system.
   Results: Of 3280 participants who participated (78.7% response rate), 3265 had photographs of sufficient quality for grading of AMD signs. Early and late AMD were present in 160 (4.9%) and 23 (0.70%) participants, respectively. After age standardization, the prevalence of early AMD in Malay persons aged 40 to 80 years was estimated to be 3.5% (95% confidence interval [CI], 2.9%-4.1 %) and that of late AMD was 0.34% (95% CI, 0.20%-0.49%). Early AMD was more prevalent in men than in women (6.1 % vs. 3.8%); this was significant despite-adjusting for age and smoking (odds ratio [OR], 1.56; 95% CI, 1.11-2.20). Late AMD also was more prevalent in men than in women (1.0% vs. 0.4%), although this was not statistically significant after adjusting for age and smoking (OR, 1.39; 95% CI, 0.52-3.68). The prevalence of early and late AMD was similar to that reported in the Blue Mountains Eye Study among white persons.
   Conclusions: The prevalence of AMD in Asian Malay people is similar to that in white persons from the Blue Mountains Eye Study. Early AMD signs were more frequent in men compared with women, an association that was not fully explained by the higher smoking rates in men.
C1 [Kawasaki, Ryo; Wang, Jie Jin; Wong, Tien Y.] Univ Melbourne, Ctr Eye Res Australia, Melbourne, Vic 3002, Australia.
   [Wang, Jie Jin; Mitchell, Paul; Wong, Tien Y.] Univ Sydney, Ctr Vis Res, Sydney, NSW 2006, Australia.
   [Aung, Tin; Tan, Donald T. H.; Sandar, Maya; Saw, Seang-Mei; Wong, Tien Y.] Singapore Eye Res Inst, Singapore, Singapore.
   [Aung, Tin; Tan, Donald T. H.; Wong, Tien Y.] Singapore Natl Eye Ctr, Singapore, Singapore.
   [Aung, Tin; Tan, Donald T. H.; Wong, Tien Y.] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Ophthalmol, Singapore 117595, Singapore.
   [Saw, Seang-Mei] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Community Occupat & Family Med, Singapore 117595, Singapore.
C3 Centre for Eye Research Australia; University of Melbourne; University
   of Sydney; National University of Singapore; Singapore National Eye
   Center; Singapore National Eye Center; National University of Singapore;
   National University of Singapore
RP Wong, TY (通讯作者)，Univ Melbourne, Ctr Eye Res Australia, 32 Gisborne St, Melbourne, Vic 3002, Australia.
EM twong@unimelb.edu.au
RI Mitchell, Paul/P-1498-2014; Wong, Tien Yin/AAC-9724-2020; Kawasaki,
   Ryo/B-7266-2009; Kawasaki, Ryo/H-9716-2019; Wang, Jie Jin/P-1499-2014;
   wang, jie/GRS-0942-2022
OI Wong, Tien Yin/0000-0002-8448-1264; Kawasaki, Ryo/0000-0002-7492-6303;
   Wang, Jie Jin/0000-0001-9491-4898; 
FU National Medical Research Council [0796/2003, 0863/2004, CSI/0002/2005];
   Biomedical Research Council [501/1/25-5]; Singapore Tissue Network;
   Ministry of Health, Singapore; Republic of Singapore; Pfizer, Inc.,
   Singapore, Singapore
FX The authors have no conflicts of interest and no proprietary interests
   related to this article.; Supported by the National Medical Research
   Council (grant nos.: 0796/2003, 0863/2004, and CSI/0002/2005); and the
   Biomedical Research Council (grant no. 501/1/25-5); with additional
   support from the Singapore Tissue Network and the Ministry of Health,
   Singapore, Republic of Singapore; and Pfizer, Inc., Singapore,
   Singapore. The sponsors had no role in the study design, acquisition of
   data, statistical analysis and interpretation, and the final
   presentation and publication of the study.
CR [Anonymous], 1991, Ophthalmology, V98, P786
   Chua B, 2006, ARCH OPHTHALMOL-CHIC, V124, P981, DOI 10.1001/archopht.124.7.981
   Cruickshanks KJ, 1997, ARCH OPHTHALMOL-CHIC, V115, P242, DOI 10.1001/archopht.1997.01100150244015
   Defay R, 2004, ANN EPIDEMIOL, V14, P202, DOI 10.1016/S1047-2797(03)00130-3
   Foong AWP, 2007, OPHTHAL EPIDEMIOL, V14, P25, DOI 10.1080/09286580600878844
   Fraser-Bell S, 2006, AM J OPHTHALMOL, V141, P79, DOI 10.1016/j.ajo.2005.08.024
   Freeman EE, 2005, OPHTHAL EPIDEMIOL, V12, P37, DOI 10.1080/09286580490907779
   Friedman DS, 1999, OPHTHALMOLOGY, V106, P1049, DOI 10.1016/S0161-6420(99)90267-1
   Grassi MA, 2006, HUM MUTAT, V27, P921, DOI 10.1002/humu.20359
   Gupta SK, 2007, INVEST OPHTH VIS SCI, V48, P1007, DOI 10.1167/iovs.06-0712
   Haan MN, 2006, ARCH OPHTHALMOL-CHIC, V124, P988, DOI 10.1001/archopht.124.7.988
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1376, DOI 10.1016/j.ophtha.2007.11.015
   Klein B E, 1994, Trans Am Ophthalmol Soc, V92, P289
   Klein BEK, 2000, AM J OPHTHALMOL, V130, P322, DOI 10.1016/S0002-9394(00)00474-8
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 1999, OPHTHALMOLOGY, V106, P1056, DOI 10.1016/S0161-6420(99)90255-5
   Krishnaiah S, 2005, INVEST OPHTH VIS SCI, V46, P4442, DOI 10.1167/iovs.05-0853
   Li YB, 2006, AM J OPHTHALMOL, V142, P788, DOI 10.1016/j.ajo.2006.06.001
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Miyazaki M, 2005, INVEST OPHTH VIS SCI, V46, P1907, DOI 10.1167/iovs.04-0923
   Oshima Y, 2001, BRIT J OPHTHALMOL, V85, P1153, DOI 10.1136/bjo.85.10.1153
   SCHACHAT AP, 1995, ARCH OPHTHALMOL-CHIC, V113, P728, DOI 10.1001/archopht.1995.01100060054032
   Seitzman RL, 2007, J AM GERIATR SOC, V55, P740, DOI 10.1111/j.1532-5415.2007.01138.x
   Smith TJ, 1997, J PALLIATIVE CARE, V13, P5, DOI 10.1177/082585979701300102
   Su DHW, 2008, OPHTHALMOLOGY, V115, P964, DOI 10.1016/j.ophtha.2007.08.021
   Varma R, 2004, OPHTHALMOLOGY, V111, P1288, DOI 10.1016/j.ophtha.2004.01.023
   Wong TY, 2006, BRIT J OPHTHALMOL, V90, P506, DOI 10.1136/bjo.2005.083733
   WORLD POPULATION DAT
NR 29
TC 85
Z9 85
U1 0
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD OCT
PY 2008
VL 115
IS 10
BP 1735
EP 1741
DI 10.1016/j.ophtha.2008.02.012
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 357NJ
UT WOS:000259852200014
PM 18439679
DA 2022-11-30
ER

PT J
AU Senra, H
   Macedo, AF
   Nunes, N
   Balaskas, K
   Aslam, T
   Costa, E
AF Senra, Hugo
   Macedo, Antonio Filipe
   Nunes, Nuno
   Balaskas, Konstantinos
   Aslam, Tariq
   Costa, Emilia
TI Psychological and Psychosocial Interventions for Depression and Anxiety
   in Patients With Age-Related Macular Degeneration: A Systematic Review
SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY
LA English
DT Review
DE Psychosocial intervention; psychological intervention; age-related
   macular degeneration; depression; anxiety; vision disorders
ID QUALITY-OF-LIFE; SELF-MANAGEMENT; LOW-VISION; INTERPERSONAL
   PSYCHOTHERAPY; OLDER-ADULTS; SUBTHRESHOLD DEPRESSION; LIVED EXPERIENCE;
   META-SYNTHESIS; RISK-FACTORS; REMAIN WELL
AB Objective: To review the current literature on psychosocial and psychological interventions to prevent and treat depression and anxiety in patients with age-related macular degeneration (AMD). Methods: The authors conducted a systematic review of literature evaluating psychosocial and psychological interventions for depression and anxiety in patients with AMD. Primary searches of PubMed, Cochrane library, EMBASE, Global Health, Web of Science, EBSCO, and Science Direct were conducted to include all articles published up to April 21, 2018. Results: Of a total of 398 citations retrieved, the authors selected 12 eligible studies published between 2002 and 2016. The authors found nine randomized controlled trials (RCT), and three non-randomized intervention (NRI) studies. RCT studies suggested that interventions using group self-management techniques and individual behavioral activation plus low vision rehabilitation can be effective to treat and prevent depression in patients with AMD, and one study suggested that a stepped-care intervention using cognitive-behavioral techniques can be effective to manage anxiety and depression over time. NRI studies highlighted a positive effect of self-help and emotion-focused interventions to reduce depression. Conclusion: Clinical practice with patients with AMD can rely on some tailored cognitive-behavioral therapeutic protocols to improve patients' mental health, but further clinical trials will generate the necessary evidence-based knowledge to improve those therapeutic techniques and offer additional tailored interventions for patients with AMD.
C1 [Senra, Hugo] Kings Coll London, Inst Psychiat Psychol & Neurosci, London, England.
   [Macedo, Antonio Filipe; Nunes, Nuno; Costa, Emilia] Linnaeus Univ, Dept Med & Optometry, Kalmar, Sweden.
   [Macedo, Antonio Filipe; Nunes, Nuno; Costa, Emilia] Univ Minho, Low Vis & Visual Rehabil Lab, Dept & Ctr Phys Optometry & Vis Sci, Braga, Portugal.
   [Nunes, Nuno; Costa, Emilia] Univ Porto, Ctr Psychol, Fac Psychol & Educ Sci, Porto, Portugal.
   [Balaskas, Konstantinos; Aslam, Tariq] Moorfields Eye Hosp NHS Fdn Trust, NIHR Biomed Res Ctr, London, England.
   [Balaskas, Konstantinos; Aslam, Tariq] UCL Inst Ophthalmol, London, England.
   [Aslam, Tariq] Univ Manchester, Div Pharm & Optometry, Fac Biol Med & Hlth, Sch Hlth Sci, Manchester, Lancs, England.
   [Aslam, Tariq] Cent Manchester Fdn Trust, Manchester Royal Eye Hosp, Manchester, Lancs, England.
C3 University of London; King's College London; Linnaeus University;
   Universidade do Minho; Universidade do Porto; University of London;
   University College London; Moorfields Eye Hospital NHS Foundation Trust;
   University of London; University College London; University of
   Manchester; Manchester Royal Eye Hospital
RP Senra, H (通讯作者)，Kings Coll London, Inst Psychiat Psychol & Neurosci, London, England.
RI Macedo, Antonio/I-8108-2013; Balaskas, Konstantinos/ABD-5979-2020;
   Nunes, Nuno/GXH-4259-2022; Costa, Maria Emilia/M-7641-2013; Aslam,
   Tariq/A-8532-2016
OI Macedo, Antonio/0000-0003-3436-2010; Balaskas,
   Konstantinos/0000-0002-7690-6277; Nunes, Nuno/0000-0002-1404-4026;
   Costa, Maria Emilia/0000-0002-9573-5784; Aslam,
   Tariq/0000-0002-9739-7280
FU Portuguese Foundation for Science and Technology [99434/2014]
FX This work was partially supported by a grant received from the
   Portuguese Foundation for Science and Technology (ref. 99434/2014). The
   authors report no conflicts of interest in respect to this work.
CR Andreescu C, 2015, CURR PSYCHIAT REP, V17, DOI 10.1007/s11920-015-0595-8
   Azar AR, 2005, AM J GERIAT PSYCHIAT, V13, P329, DOI 10.1176/appi.ajgp.13.4.329
   Ba J, 2015, DRUG DES DEV THER, V9, DOI 10.2147/DDDT.S86269
   Barth J, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001454
   Bennion AE, 2012, SOC SCI MED, V75, P976, DOI 10.1016/j.socscimed.2012.04.023
   Biderman A, 2002, J EPIDEMIOL COMMUN H, V56, P631, DOI 10.1136/jech.56.8.631
   Birk T, 2004, GERONTOLOGIST, V44, P836, DOI 10.1093/geront/44.6.836
   Bisschop MI, 2004, SOC SCI MED, V59, P721, DOI 10.1016/j.socscimed.2003.11.038
   Bosmans JE, 2007, INT J TECHNOL ASSESS, V23, P480, DOI 10.1017/S0266462307070572
   Braam AW, 2005, BRIT J PSYCHIAT, V187, P35, DOI 10.1192/bjp.187.1.35
   Brody BL, 2006, J AM GERIATR SOC, V54, P1557, DOI 10.1111/j.1532-5415.2006.00881.x
   Brody BL, 2005, ARCH OPHTHALMOL-CHIC, V123, P46, DOI 10.1001/archopht.123.1.46
   Brody BL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1477, DOI 10.1001/archopht.120.11.1477
   Burton AE, 2015, J HEALTH PSYCHOL, V20, P1285, DOI 10.1177/1359105313511134
   Casten R, 2008, J VISUAL IMPAIR BLIN, V102, P591, DOI 10.1177/0145482X0810201003
   Casten R, 2010, ARCH OPHTHALMOL-CHIC, V128, P506, DOI 10.1001/archophthalmol.2010.24
   Casten Robin J, 2004, Curr Opin Ophthalmol, V15, P181, DOI 10.1097/01.icu.0000120710.35941.3f
   Chua PYS, 2009, ARCH OPHTHALMOL-CHIC, V127, P939, DOI 10.1001/archophthalmol.2009.139
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Cuijpers P, 2008, J CONSULT CLIN PSYCH, V76, P909, DOI 10.1037/a0013075
   Das-Munshi J, 2007, PSYCHOSOM MED, V69, P543, DOI 10.1097/PSY.0b013e3180cc3062
   Dawson SR, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-78
   Deeks J J, 2003, Health Technol Assess, V7, piii
   Domenech-Abella J, 2019, J AFFECT DISORDERS, V246, P82, DOI 10.1016/j.jad.2018.12.043
   Dreer LE, 2008, BRIT J HEALTH PSYCH, V13, P449, DOI 10.1348/135910707X209835
   Eramudugolla R, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00056
   Feely M, 2007, J VISUAL IMPAIR BLIN, V101, P44, DOI 10.1177/0145482X0710100106
   Ferrari AJ, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001547
   Gibbons MBC, 2016, JAMA PSYCHIAT, V73, P904, DOI 10.1001/jamapsychiatry.2016.1720
   Girdler SJ, 2010, BRIT J OPHTHALMOL, V94, P223, DOI 10.1136/bjo.2008.147538
   Gopinath B, 2014, MATURITAS, V77, P263, DOI 10.1016/j.maturitas.2013.12.001
   Heesterbeek TJ, 2017, OPHTHAL PHYSL OPT, V37, P385, DOI 10.1111/opo.12388
   Heun R, 2005, EUR PSYCHIAT, V20, P199, DOI 10.1016/j.eurpsy.2004.09.036
   Holloway EE, 2015, AUST J PRIM HEALTH, V21, P169, DOI 10.1071/PY13085
   Horowitz A, 2005, AM J GERIAT PSYCHIAT, V13, P180, DOI 10.1176/appi.ajgp.13.3.180
   Hunot V, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001848
   Jelin E, 2018, ACTA OPHTHALMOL, V96, P804, DOI 10.1111/aos.13847
   Jorm AF, 2005, AM J PSYCHIAT, V162, P699, DOI 10.1176/appi.ajp.162.4.699
   Kamga H, 2017, CLIN EXP OPHTHALMOL, V45, P371, DOI 10.1111/ceo.12890
   Kataja M, 2018, BRIT J OPHTHALMOL, V102, P959, DOI 10.1136/bjophthalmol-2017-311055
   Lee WJ, 2013, ASIA-PAC J OPHTHALMO, V2, P23, DOI 10.1097/APO.0b013e31827be8b1
   Livingston G, 2000, J AFFECT DISORDERS, V58, P125, DOI 10.1016/S0165-0327(99)00103-2
   Macdonald Geraldine, 2012, Cochrane Database Syst Rev, pCD001930, DOI 10.1002/14651858.CD001930.pub3
   Macedo AF, 2017, ACTA OPHTHALMOL, V95, pe783, DOI 10.1111/aos.13430
   Mathew RS, 2011, OPHTHAL PHYSL OPT, V31, P375, DOI 10.1111/j.1475-1313.2011.00848.x
   McCloud C, 2015, EYE, V29, P1561, DOI 10.1038/eye.2015.167
   McCloud C, 2014, OPTOMETRY VISION SCI, V91, P966, DOI 10.1097/OPX.0000000000000320
   Mental Health Foundation, 2017, CREAT CONN IMP REP 2
   Monopoli J, 2000, CLIN GERONTOL, V21, P49
   Moss AS, 2015, J APPL GERONTOL, V34, P518, DOI 10.1177/0733464814559411
   National Institute of Clinical Excellence NICE, 2012, SUMM SEL NEW EV REL, P14
   Nyman SR, 2012, DISABIL REHABIL, V34, P971, DOI 10.3109/09638288.2011.626487
   Owsley C, 2006, REHABIL PSYCHOL, V51, P23, DOI 10.1037/0090-5550.51.1.23
   Papadopoulos K, 2014, RES DEV DISABIL, V35, P1734, DOI 10.1016/j.ridd.2014.02.019
   Paterniti S, 1999, PSYCHOSOM MED, V61, P77, DOI 10.1097/00006842-199901000-00013
   Pelletier AL, 2009, AM FAM PHYSICIAN, V79, P963
   Reddy M S, 2010, Indian J Psychol Med, V32, P1, DOI 10.4103/0253-7176.70510
   Rees G, 2015, PATIENT EDUC COUNS, V98, P174, DOI 10.1016/j.pec.2014.11.008
   Rees G, 2010, EXPERT REV OPHTHALMO, V5, P385, DOI 10.1586/EOP.10.32
   Rees G, 2010, INVEST OPHTH VIS SCI, V51, P2891, DOI 10.1167/iovs.09-5080
   Reynolds CF, 1997, AM J PSYCHIAT, V154, P958
   Rovner BW, 2007, ARCH GEN PSYCHIAT, V64, P886, DOI 10.1001/archpsyc.64.8.886
   Rovner BW, 2014, OPHTHALMOLOGY, V121, P2204, DOI 10.1016/j.ophtha.2014.05.002
   Santabarbara J, 2019, ACTA PSYCHIAT SCAND, V139, P6, DOI 10.1111/acps.12966
   Schoevers RA, 2005, AM J GERIAT PSYCHIAT, V13, P31, DOI 10.1176/appi.ajgp.13.1.31
   Senra H, 2017, AM J OPHTHALMOL, V177, P213, DOI 10.1016/j.ajo.2017.03.005
   Senra H, 2015, OPHTHALMOLOGY, V122, P851, DOI 10.1016/j.ophtha.2014.10.022
   Sivaprasad S, 2019, OPHTHALMOL THER, V8, P115, DOI 10.1007/s40123-019-0160-3
   Solomon SD, 2016, OPHTHALMOLOGY, V123, P70, DOI 10.1016/j.ophtha.2015.09.002
   Sterne JAC, 2016, BMJ-BRIT MED J, V355, DOI 10.1136/bmj.i4919
   Sturrock BA, 2016, INVEST OPHTH VIS SCI, V57, P3032, DOI 10.1167/iovs.16-19110
   Taylor DJ, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-011504
   Taylor MP, 1999, DEPRESS ANXIETY, V10, P55
   Thetford C, 2013, BRIT J VISUAL IMPA, V31, P89, DOI 10.1177/0264619613481778
   Vamos EP, 2009, PSYCHOSOM MED, V71, P501, DOI 10.1097/PSY.0b013e3181a5a7ad
   van der Aa HPA, 2016, OPHTHAL PHYSL OPT, V36, P584, DOI 10.1111/opo.12313
   van der Aa HPA, 2015, BMJ-BRIT MED J, V351, DOI 10.1136/bmj.h6127
   van der Aa HPA, 2015, QUAL LIFE RES, V24, P2885, DOI 10.1007/s11136-015-1032-5
   Vink D, 2008, J AFFECT DISORDERS, V106, P29, DOI 10.1016/j.jad.2007.06.005
   Wahl HW, 2006, J VISUAL IMPAIR BLIN, V100, P533
   Walker JG, 2006, BRIT J HEALTH PSYCH, V11, P303, DOI 10.1348/135910705X68681
   Wetherell JL, 2011, INT J GERIATR PSYCH, V26, P869, DOI 10.1002/gps.2619
   WHO, 2017, DEPRESSION OTHER COM
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 84
TC 12
Z9 12
U1 5
U2 23
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1064-7481
EI 1545-7214
J9 AM J GERIAT PSYCHIAT
JI Am. J. Geriatr. Psychiatr.
PD AUG
PY 2019
VL 27
IS 8
BP 755
EP 773
DI 10.1016/j.jagp.2019.03.001
PG 19
WC Geriatrics & Gerontology; Gerontology; Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Geriatrics & Gerontology; Psychiatry
GA IJ5EG
UT WOS:000475925000001
PM 31005495
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Skelly, A
   Taylor, N
   Fasser, C
   Malkowski, JP
   Goswamy, P
   Downey, L
AF Skelly, Adrian
   Taylor, Nicholas
   Fasser, Christina
   Malkowski, Jean-Pierre
   Goswamy, Pushpendra
   Downey, Louise
TI Patient Preferences in the Management of Wet Age-Related Macular
   Degeneration: A Conjoint Analysis
SO ADVANCES IN THERAPY
LA English
DT Article
DE Conjoint survey; Neovascular age-related macular degeneration; Patient
   activation measure (PAM); Patient preference; Preference drivers;
   Treatment adherence
ID TRAP-EYE; RANIBIZUMAB; VERTEPORFIN; OUTCOMES; THERAPY
AB Introduction To identify patient preference drivers related to the management of wet age-related macular degeneration (wet AMD). Methods In this cross-sectional study, a self-explicated 'conjoint analysis' survey was administered online to eligible patients with wet AMD (receiving anti-vascular endothelial growth factor [VEGF] treatment for at least 12 months) from the USA, Canada, UK, France, Spain, Germany, Italy, Japan, Taiwan, and Australia. The survey consisted of six domains with 21 attributes, which were selected on the basis of a literature review, social media listening, and tele-interviews/discussions with patients, clinical experts, and patient groups. Utility and relative importance scores were generated for each attribute and utility difference significance testing was performed using 'unequal variances t tests'. The Patient Activation Measure (PAM-13) questionnaire was administered to assess patients' knowledge, skill, and confidence in self-management. Results A total of 466 patients (mean age, 68 years; women, 54%; binocular wet AMD, 28%) with an average anti-VEGF treatment duration of 3.9 years completed the survey. The most important preference domains were 'treatment effects on vision' (non-significant) and 'vision-related symptom burdens' (p < 0.001), followed by 'treatment risk' (p < 0.05), 'impact on daily activities' (p < 0.05), 'burden of clinic/hospital visits' (p < 0.001), and 'impact on psychological well-being'. The five most important attributes in order of importance were clarity of vision, treatment effect on symptoms, quality of vision, time to treatment effect, and time to re-administration. The two most important attributes globally were also in the top three attributes across countries. The majority of participants in the study were level 3 or level 4 of the PAM-13 questionnaire. Conclusions This study identified the most important disease and treatment attributes to patients using patient-centred methods. The data showed the degree of harmonization of preferences across geographies and that participants actively adopt behaviours required for improved treatment outcomes. The identified preference drivers may inform future clinical development.
C1 [Skelly, Adrian; Malkowski, Jean-Pierre; Goswamy, Pushpendra] Novartis Pharma AG, Basel, Switzerland.
   [Taylor, Nicholas] Inpharmation, Stokenchurch, England.
   [Fasser, Christina] Retina Int, Zurich, Switzerland.
   [Downey, Louise] Hull Royal Infirm, Kingston Upon Hull, N Humberside, England.
C3 Novartis; University of Hull
RP Skelly, A (通讯作者)，Novartis Pharma AG, Basel, Switzerland.
EM adrian.skelly@novartis.com
FU Novartis Pharma AG, Basel, Switzerland; Novartis
FX This study was funded by Novartis Pharma AG, Basel, Switzerland.
   Novartis has also funded the journal's Rapid Service and Open Access
   Fees.
CR Agarwal A, 2016, MIDDLE EAST AFR J OP, V23, P27, DOI 10.4103/0974-9233.173133
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Baxter JM, 2016, EYE, V30, P698, DOI 10.1038/eye.2016.18
   Bouvy JC, 2020, PATIENT, V13, P145, DOI 10.1007/s40271-019-00408-4
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2011, OPHTHALMOLOGY, V118, P1089, DOI 10.1016/j.ophtha.2011.02.039
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chatziralli I, 2017, SEMIN OPHTHALMOL, V32, P772, DOI 10.1080/08820538.2016.1181192
   Cimarolli VR, 2016, CLIN OPHTHALMOL, V10, P55, DOI 10.2147/OPTH.S80489
   Costa RA, 2006, INVEST OPHTH VIS SCI, V47, P4569, DOI 10.1167/iovs.06-0433
   Dugel PU, 2021, OPHTHALMOLOGY, V128, P89, DOI [10.1016/j.opatha.2020.06.028, 10.1016/j.ophtha.2020.06.028]
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Gimbel R, 2017, JMIR RES PROTOC, V6, P71, DOI 10.2196/resprot.6993
   Gimbel RW, 2020, J MED INTERNET RES, V22, DOI 10.2196/17968
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hibbard JH, 2004, HEALTH SERV RES, V39, P1005, DOI 10.1111/j.1475-6773.2004.00269.x
   Holekamp NM, 2019, AM J MANAG CARE, V25, pS172
   Hsu J, 2020, OPHTHALMOLOGY, V127, P1189, DOI 10.1016/j.ophtha.2020.03.034
   Joachim N, 2015, OPHTHALMOLOGY, V122, P2482, DOI 10.1016/j.ophtha.2015.08.002
   Joko T, 2020, PATIENT PREFER ADHER, V14, P553, DOI 10.2147/PPA.S228890
   Jonas JB, 2017, ASIA-PAC J OPHTHALMO, V6, P493, DOI 10.22608/APO.2017251
   Kinney RL, 2015, PATIENT EDUC COUNS, V98, P545, DOI 10.1016/j.pec.2015.02.005
   Kovach JL, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/786870
   Mekjavic PJ, 2019, VALUE HEALTH REG ISS, V19, P1, DOI 10.1016/j.vhri.2018.11.002
   Morse AR, 2021, J HEALTH PSYCHOL, V26, P2603, DOI 10.1177/1359105320922303
   Mueller S, 2016, OPHTHALMOLOGY, V123, P876, DOI 10.1016/j.ophtha.2015.12.001
   Nguyen QD, 2009, OPHTHALMOLOGY, V116, P2141, DOI 10.1016/j.ophtha.2009.04.030
   Pedrosa AC, 2017, J OPHTHALMOL, V2017, DOI 10.1155/2017/4263017
   Remillard ML, 2014, J AM GERIATR SOC, V62, P696, DOI 10.1111/jgs.12747
   Rivera-Almaraz A, 2018, BMC GERIATR, V18, DOI 10.1186/s12877-018-0928-7
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Say RE, 2003, BMJ-BRIT MED J, V327, P542, DOI 10.1136/bmj.327.7414.542
   Skelly A, 2018, VALUE HEALTH, V21, pS433, DOI 10.1016/j.jval.2018.09.2562
   Soubrane G, 2007, ARCH OPHTHALMOL-CHIC, V125, P1249, DOI 10.1001/archopht.125.9.1249
   Stahl A, 2020, DTSCH ARZTEBL INT, V117, P513, DOI 10.3238/arztebl.2020.0513
   Street RL, 2012, EXPERT REV PHARM OUT, V12, P167, DOI [10.1586/erp.12.3, 10.1586/ERP.12.3]
   Taylor DJ, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-011504
   Tufail A, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2459
   Tusa N, 2020, BMC FAM PRACT, V21, DOI 10.1186/s12875-020-01301-y
   van Overbeeke E, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01395
NR 40
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0741-238X
EI 1865-8652
J9 ADV THER
JI Adv. Ther.
PD OCT
PY 2022
VL 39
IS 10
BP 4808
EP 4820
DI 10.1007/s12325-022-02248-5
EA AUG 2022
PG 13
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA 4L4CT
UT WOS:000842856500002
PM 35995894
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Schick, T
   Lores-Motta, L
   Altay, L
   Fritsche, LG
   den Hollander, AI
   Fauser, S
AF Schick, Tina
   Lores-Motta, Laura
   Altay, Lebriz
   Fritsche, Lars G.
   den Hollander, Anneke, I
   Fauser, Sascha
TI The Effect of Genetic Variants Associated With Age-Related Macular
   Degeneration Varies With Age
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE age-related macular degeneration; risk factors; genetic variants
ID RISK-FACTORS; PREVALENCE; PROGRESSION; MORTALITY
AB PURPOSE. The prevalence of age-related macular degeneration (AMD) increases dramatically with age. This large collaborative study investigates the effects of 51 late-AMD-associated genetic variants in different ages, focusing on individuals above the age of 90 years.
   METHODS. The study included 27,996 individuals of the International AMD Genomics Consortium; 14,539 showed late AMD (51.9%) and 13,457 were controls (48.1%). Four age groups were compiled: 60 to 69 years, n = 6514, AMD = 2210 (33.9%); 70 to 79 years, n = 12228, AMD = 6217 (51.7%); 80 to 89 years, n = 8285, AMD = 5326 (64.3%); and >= 90 years, n = 969, AMD = 686 (70.8%). The effect sizes of 51 AMD-associated genetic variants were calculated for all age groups and were compared among the age groups.
   RESULTS. Six variants were associated with late AMD in individuals >= 90 years of age (P <= 0.0006). For rs10922109 and rs570618 (both in CFH), the minor allele (MA) was protective, and minor allele frequency (MAF) increased with age in cases and controls. For rs116503776 in C2/CFB/SKIV2L, the MA was protective, and MAF increased in cases. For rs3750846 in ARMS2/HTRA1, the MA increased risk, and MAF was lower in cases with increasing age. For rs6565597 in NPLOC4/TSPAN10, the MA increased risk. For rs5754227 in SYN3/TIMP3, the MA was protective, and there was no consistent variation in MAF with age. Variants in CFH and ARMS2 showed lower effect sizes at greater age. Interaction analysis showed strong age-related effects for rs570618 (P = 2.24 x 10(-7)) and rs3750846 (P = 0.001). Total genetic risk was lower in individuals >= 90 years old (area under the curve [AUC], 0.795) than in those 70 to 79 years old (AUC, 0.831; P = 0.03)
   CONCLUSIONS. Effect sizes and MAF of genetic risk factors for late AMD differed among the age groups. These results could guide future work on AMD risk assessment in older individuals.
C1 [Schick, Tina] MVZ ADTC Siegburg GmbH, AugenZentrum Siegburg, Siegburg, Germany.
   [Schick, Tina; Altay, Lebriz; Fauser, Sascha] Univ Hosp Cologne, Dept Ophthalmol, Kerpener Str 62, D-50937 Cologne, Germany.
   [Lores-Motta, Laura; den Hollander, Anneke, I] Radboud Univ Nijmegen Med Ctr, Donders Inst Brain Cognit & Behav, Dept Ophthalmol, Nijmegen, Netherlands.
   [Fritsche, Lars G.] Univ Michigan, Sch Publ Hlth, Dept Biostat, Ctr Stat Genet, Ann Arbor, MI 48109 USA.
   [den Hollander, Anneke, I] Radboud Univ Nijmegen Med Ctr, Donders Inst Brain Cognit & Behav, Dept Human Genet, Nijmegen, Netherlands.
   [Fauser, Sascha] F Hoffmann La Roche, Basel, Switzerland.
C3 University of Cologne; Radboud University Nijmegen; University of
   Michigan System; University of Michigan; Radboud University Nijmegen;
   Roche Holding
RP Schick, T (通讯作者)，Univ Hosp Cologne, Dept Ophthalmol, Kerpener Str 62, D-50937 Cologne, Germany.
EM ristau.tina@gmail.com
RI Fritsche, Lars G/AAF-9387-2019
OI Fritsche, Lars G/0000-0002-2110-1690
FU National Eye Institute, National Institutes of Health [R01 EY022310]
FX The authors thank the excellent International Age-Related Macular
   Degeneration Genomics Consortium (http://amdgenetics.org/), which is
   supported by a grant from the National Eye Institute, National
   Institutes of Health (R01 EY022310). The list of consortium members
   reflects the author list of the previous publication by Fritsche et
   al.<SUP>6</SUP>
CR Adams MKM, 2012, HUM MOL GENET, V21, P5229, DOI 10.1093/hmg/dds364
   Altshuler DM, 2012, NATURE, V491, P56, DOI 10.1038/nature11632
   Beekman M, 2013, AGING CELL, V12, P184, DOI 10.1111/acel.12039
   Black JRM, 2016, GENET MED, V18, P283, DOI 10.1038/gim.2015.70
   Cohen J., 1988, STAT POWER ANAL SOCI, V2nd
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   DeAngelis MM, 2017, HUM MOL GENET, V26, pR45, DOI 10.1093/hmg/ddx228
   Dietzel M, 2014, GRAEF ARCH CLIN EXP, V252, P1273, DOI 10.1007/s00417-014-2690-7
   Ersoy L, 2014, INVEST OPHTH VIS SCI, V55, P1842, DOI 10.1167/iovs.13-13420
   Fisher DE, 2015, OPHTHALMOLOGY, V122, P382, DOI 10.1016/j.ophtha.2014.08.006
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Grassmann F, 2017, GENOME MED, V9, DOI 10.1186/s13073-017-0418-0
   Grassmann F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037979
   Hermann M, 2012, ACTA OPHTHALMOL, V90, pe500, DOI 10.1111/j.1755-3768.2011.02347.x
   Kenyon CJ, 2010, NATURE, V464, P504, DOI 10.1038/nature08980
   Lambert NG, 2016, PROG RETIN EYE RES, V54, P64, DOI 10.1016/j.preteyeres.2016.04.003
   McGuinness MB, 2017, OPHTHAL EPIDEMIOL, V24, P141, DOI 10.1080/09286586.2016.1259422
   Papudesu C, 2018, OPHTHALMOLOGY, V125, P512, DOI 10.1016/j.ophtha.2017.10.028
   Pilling LC, 2017, AGING-US, V9, P2504, DOI 10.18632/aging.101334
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P2203, DOI 10.1016/j.ophtha.2011.04.029
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Slagboom PE, 2011, PHILOS T R SOC B, V366, P35, DOI 10.1098/rstb.2010.0284
   Spencer KL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017784
   Timmers PRHJ, 2019, ELIFE, V8, DOI 10.7554/eLife.39856
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Zhu ZT, 2019, JAMA OPHTHALMOL, V137, P248, DOI 10.1001/jamaophthalmol.2018.6150
NR 27
TC 3
Z9 3
U1 1
U2 1
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD DEC
PY 2020
VL 61
IS 14
AR 17
DI 10.1167/iovs.61.14.17
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA PN0YS
UT WOS:000604213900009
PM 33320170
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Hall, LB
   Zebardast, N
   Huang, JJ
   Adelman, RA
AF Hall, Laura B.
   Zebardast, Nazlee
   Huang, John J.
   Adelman, Ron A.
TI Aflibercept in the Treatment of Neovascular Age-Related Macular
   Degeneration in Previously Treated Patients
SO JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
LA English
DT Article
ID VEGF TRAP-EYE; INTRAVITREAL AFLIBERCEPT; VISUAL IMPAIRMENT; RANIBIZUMAB;
   BEVACIZUMAB; OUTCOMES; THERAPY; FLUID
AB Purpose: To study the visual outcomes and change in central macular thickness (CMT) in patients with neovascular age-related macular degeneration (AMD) who were previously treated with ranibizumab (Lucentis) and/or bevacizumab (Avastin) and were subsequently switched to aflibercept (VEGF Trap-Eye; Eylea). Methods: Retrospective study of patients who received intravitreal aflibercept from December 2011 to December 2012 and had previous anti-vascular endothelial growth factor treatment for AMD. The main outcome measures were best-corrected visual acuity (BCVA) and CMT as measured by optical coherence tomography. Results: The study population included 30 patients aged 80.41.45 (mean +/- SEM) who received 6.27 +/- 0.37 (range 4-11) aflibercept injections. Eighteen patients had previously received only bevacizumab (12.4 +/- 2.18 injections), 2 had received only ranibizumab (19 +/- 6 injections), and 10 had received both ranibizumab and bevacizumab (mean 19.3 injections). BCVA logMAR at the initial visit (aflibercept initiation) was 0.506 +/- 0.054 (mean VA 20/64), and then, follow ups at 1-month 0.504 +/- 0.055 (20/64) P=0.903, 3-months 0.458 +/- 0.061 (20/57) P=0.112, 6-months 0.413 +/- 0.071 (20/52) P=0.036, and 12-months 0.521 +/- 0.076 (20/66) P=0.836. CMT at the initial visit was 261 +/- 10.9, and then, at 1-month 238 +/- 12.4 P=0.021, 3-months 245 +/- 10.6 P=0.102, 6-months 245 +/- 10.4 P=0.099, and 12-months 237 +/- 10.2 P=0.012. Results were similar in a subset of patients (n=15) with central macular edema or submacular fluid at aflibercept initiation. While on aflibercept, 2 patients developed intraocular pressure increases that required treatment. Conclusions: These findings demonstrate a significant decrease in CMT but no statistically significant improvement in BCVA through the 12-month follow up in patients previously treated who were switched to aflibercept for AMD. Patients may develop ocular hypertension after multiple aflibercept injections.
C1 [Hall, Laura B.; Zebardast, Nazlee; Huang, John J.; Adelman, Ron A.] Yale Univ, Sch Med, Dept Ophthalmol & Visual Sci, Yale Eye Ctr, New Haven, CT 06510 USA.
C3 Yale University
RP Adelman, RA (通讯作者)，Yale Univ, Sch Med, Dept Ophthalmol & Visual Sci, Yale Eye Ctr, 40 Temple St,Suite 3D, New Haven, CT 06510 USA.
EM ron.adelman@yale.edu
FU Richard K. Gershon M. D. Student Research Fellowship (New Haven, CT);
   Leir Foundation (New York City, NY); Newman's Own Foundation (Westport,
   CT); Research to Prevent Blindness (New York, NY)
FX This research was supported in part by the Richard K. Gershon M. D.
   Student Research Fellowship (New Haven, CT), Leir Foundation (New York
   City, NY), Newman's Own Foundation (Westport, CT), and Research to
   Prevent Blindness (New York, NY). The sponsors or funding organizations
   had no role in the design or conduct of this research. The authors would
   like to thank Victoria Donaldson for technical support.
CR Abedi G, 2013, SEMIN OPHTHALMOL, V28, P126, DOI 10.3109/08820538.2013.771195
   Adelman RA, 2010, J OCUL PHARMACOL TH, V26, P105, DOI 10.1089/jop.2009.0076
   [Anonymous], 2012, OPHTHALMOLOGY, V119, P1
   Bakall B, 2013, AM J OPHTHALMOL, V156, P15, DOI 10.1016/j.ajo.2013.02.017
   Cho H, 2013, BRIT J OPHTHALMOL, V97, P1032, DOI 10.1136/bjophthalmol-2013-303344
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Do DV, 2012, OPHTHALMOLOGY, V119, P1658, DOI 10.1016/j.ophtha.2012.02.010
   Dorrell M, 2007, SURV OPHTHALMOL, V52, pS3, DOI 10.1016/j.survophthal.2006.10.017
   Engelbert M, 2010, RETINA-J RET VIT DIS, V30, P1368, DOI 10.1097/IAE.0b013e3181d50cbf
   Engelbert M, 2009, RETINA-J RET VIT DIS, V29, P1424, DOI 10.1097/IAE.0b013e3181bfbd46
   Ford JA, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2012-002269
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Heier JS, 2011, OPHTHALMOLOGY, V118, P1098, DOI 10.1016/j.ophtha.2011.03.020
   Ho VY, 2013, AM J OPHTHALMOL, V156, P23, DOI 10.1016/j.ajo.2013.02.009
   Kumar N, 2013, RETINA-J RET VIT DIS, V33, P1605, DOI 10.1097/IAE.0b013e31828e8551
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Pascolini D, 2004, OPHTHAL EPIDEMIOL, V11, P67, DOI 10.1076/opep.11.2.67.28158
   Patel KH, 2013, EYE, V27, P664, DOI 10.1038/eye.2013.31
   Seth R. K., 2011, US OPHTHAL REV, V4, P96
   Stewart MW, 2008, BRIT J OPHTHALMOL, V92, P667, DOI 10.1136/bjo.2007.134874
   Stewart MW, 2012, CLIN OPHTHALMOL, V6, P1175, DOI 10.2147/OPTH.S33372
   Yonekawa Y, 2013, AM J OPHTHALMOL, V156, P29, DOI 10.1016/j.ajo.2013.03.030
NR 22
TC 16
Z9 17
U1 0
U2 8
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1080-7683
EI 1557-7732
J9 J OCUL PHARMACOL TH
JI J. Ocular Pharmacol. Ther.
PD MAY 1
PY 2014
VL 30
IS 4
BP 346
EP 352
DI 10.1089/jop.2013.0188
PG 7
WC Ophthalmology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Pharmacology & Pharmacy
GA AG5SG
UT WOS:000335478200009
PM 24552305
DA 2022-11-30
ER

PT J
AU Boyer, DS
   Antoszyk, AN
   Awh, CC
   Bhisitkul, RB
   Shapiro, H
   Acharya, NR
AF Boyer, David S.
   Antoszyk, Andrew N.
   Awh, Carl C.
   Bhisitkul, Robert B.
   Shapiro, Howard
   Acharya, Nisha R.
CA MARINA Study Grp
TI Subgroup analysis of the MARINA study of ranibizumab in neovascular
   age-related macular degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR
AB Objective: An examination of clinically relevant subgroups of patients in the MARINA study of ranibizumab in treatment of minimally classic or occult with no classic choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) was done. Objectives were to determine the effectiveness of ranibizumab across subgroups, compare the effectiveness of ranibizumab with that of sham injection within subgroups, and evaluate the relationship between selected baseline characteristics and visual acuity (VA) outcomes.
   Design: Retrospective subgroup analyses of 24-month data from the MARINA study.
   Participants and Controls: Seven hundred sixteen patients were randomly assigned to 0.3 mg ranibizumab (n = 238), 0.5 mg ranibizumab (n = 240), or sham treatment (n = 238).
   Methods: Efficacy outcomes were compared across subgroups based on patients' gender, age, baseline VA score, baseline CNV lesion size, CNV lesion type, and duration of neovascular AMD using univariate analyses. Multivariate analyses were performed on the change from baseline to 24 months in VA score-to assess further the correlation between baseline characteristics and VA outcome.
   Main Outcome Measures: Proportion of patients losing < 15 letters from baseline, proportion gaining >= 15 letters from baseline, and mean VA score change from baseline.
   Results: For each of the 3 VA end points, all subgroups of ranibizumab-treated patients did better on average than the sham-treated patients. Increasing age, larger CNV lesion size at baseline, and a higher baseline VA score were all associated with greater loss of letters in the sham group or less gain of letters in the ranibizumab groups. However, the net benefit of ranibizumab versus sham treatment was greater in patients who scored higher than in those who scored lower in baseline VA.
   Conclusions: This subgroup analysis of 24-month data from the MARINA study indicates that ranibizumab treatment was associated with an average increase from baseline VA in all subgroups evaluated, and that ranibizumab treatment was superior to sham treatment across all subgroups. The most important predictors of VA outcomes were, in decreasing order of importance, baseline VA score, CNV lesion size, and age.
C1 Retina Vitreous Associates, Beverly Hills, CA USA.
   Charlotte Eye Ear Nose & Throat Associates, Charlotte, NC USA.
   Retina Vitreous Associates, Nashville, TN USA.
   Univ Calif San Francisco, Sch Med, Dept Ophthalmol, San Francisco, CA 94143 USA.
   Genentech Inc, San Francisco, CA 94080 USA.
C3 Retina Vitreous Associates Medical Group; University of California
   System; University of California San Francisco; Roche Holding; Genentech
RP Boyer, DS (通讯作者)，8641 Wilshire Blvd,Suite 210, Beverly Hills, CA 90211 USA.
EM vitdoc@aol.com
CR Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Frank RN, 1996, AM J OPHTHALMOL, V122, P393, DOI 10.1016/S0002-9394(14)72066-5
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
NR 7
TC 310
Z9 329
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD FEB
PY 2007
VL 114
IS 2
BP 246
EP 252
DI 10.1016/j.ophtha.2006.10.045
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 131CC
UT WOS:000243844600009
PM 17270674
DA 2022-11-30
ER

PT J
AU Wong, TY
   Lanzetta, P
   Bandello, F
   Eldem, B
   Navarro, R
   Lovestam-Adrian, M
   Loewenstein, A
AF Wong, Tien Yin
   Lanzetta, Paolo
   Bandello, Francesco
   Eldem, Bora
   Navarro, Rafael
   Lovestam-Adrian, Monica
   Loewenstein, Anat
TI CURRENT CONCEPTS AND MODALITIES FOR MONITORING THE FELLOW EYE IN
   NEOVASCULAR AGE-RELATED MACULAR DEGENERATION An Expert Panel Consensus
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Review
DE age-related macular degeneration; bilateral; choroidal
   neovascularization; fellow eye; home-based monitoring; monitoring;
   vision loss
ID OPTICAL COHERENCE TOMOGRAPHY; CHOROIDAL NEOVASCULARIZATION; CONTRAST
   SENSITIVITY; VISUAL FUNCTION; HYPERACUITY PERIMETRY;
   SHAPE-DISCRIMINATION; GEOGRAPHIC ATROPHY; NATURAL-HISTORY; OUTCOMES;
   RANIBIZUMAB
AB Purpose: The presence of neovascular age-related macular degeneration (nAMD) in one eye is a major risk factor for the development of disease in the fellow eye. Several methods exist to help physicians monitor the fellow eye, with new technologies becoming increasingly available. Methods: We provide an overview of modalities for nAMD monitoring, including advances in home-based options, and review their utility for fellow-eye monitoring, based on a review of the literature and a consensus of retinal experts. Results: Studies demonstrate the importance of early detection of nAMD in the fellow eye so that interventions can be made before significant vision loss occurs. A series of techniques exist for the early detection of nAMD including chart-based methods and imaging devices. The increased availability of home-based methods has presented an opportunity for patients to monitor their vision at home. Conclusion: Frequent monitoring of the fellow eye in patients with unilateral nAMD is of critical importance to prevent vision loss and maintain quality of life. Patients should be examined every 3 to 4 months from the time of choroidal neovascularization diagnosis and encouraged to monitor their vision at home using home-based technologies where available, to provide the best opportunity for early detection.
C1 [Wong, Tien Yin] Natl Univ Singapore, Duke NUS Med Sch, Singapore Natl Eye Ctr, Singapore Eye Res Inst, Singapore, Singapore.
   [Lanzetta, Paolo] Univ Udine, Dept Med Ophthalmol, Udine, Italy.
   [Bandello, Francesco] Univ Vita Salute San Raffaele, San Raffaele Sci Inst, Dept Ophthalmol, Milan, Italy.
   [Eldem, Bora] Hacettepe Univ, Dept Ophthalmol, Ankara, Turkey.
   [Navarro, Rafael] Inst Ocular Microsurg, Retina & Vitreous Dept, Barcelona, Spain.
   [Lovestam-Adrian, Monica] Lund Univ Hosp, Dept Ophthalmol, Lund, Sweden.
   [Loewenstein, Anat] Tel Aviv Univ, Sackler Fac Med, Tel Aviv Med Ctr, Div Ophthalmol, Tel Aviv, Israel.
C3 National University of Singapore; Singapore National Eye Center;
   University of Udine; Vita-Salute San Raffaele University; IRCCS Ospedale
   San Raffaele; Hacettepe University; Lund University; Skane University
   Hospital; Tel Aviv University; Sackler Faculty of Medicine
RP Wong, TY (通讯作者)，Singapore Natl Eye Ctr, 11 Third Hosp Ave, Singapore 168751, Singapore.
EM wong.tien.yin@snec.com.sg
RI Wong, Tien Yin/AAC-9724-2020
OI Wong, Tien Yin/0000-0002-8448-1264; bandello,
   francesco/0000-0003-3238-9682
FU Bayer Consumer Care AG, Pharmaceuticals, Basel, Switzerland
FX They thank Helen Woodroof, PhD, and Katie L. Beski, PhD, of Complete
   HealthVizion, Ltd, for editorial assistance in the writing and revision
   of the draft manuscript on the basis of detailed discussion and feedback
   from all the authors; this assistance was funded by Bayer Consumer Care
   AG, Pharmaceuticals, Basel, Switzerland.
CR Acton JH, 2011, OPTOMETRY VISION SCI, V88, P1288, DOI 10.1097/OPX.0b013e31822b3746
   Adrian ML, 2019, ACTA OPHTHALMOL, V97, P91, DOI 10.1111/aos.13864
   Al-Zamil WM, 2017, CLIN INTERV AGING, V12, P1313, DOI 10.2147/CIA.S143508
   ARDEN GB, 1978, BRIT J OPHTHALMOL, V62, P198, DOI 10.1136/bjo.62.4.198
   Barbazetto IA, 2010, AM J OPHTHALMOL, V149, P939, DOI 10.1016/j.ajo.2010.01.007
   Bartlett Hannah, 2005, BMC Ophthalmol, V5, P18, DOI 10.1186/1471-2415-5-18
   Bellmann C, 2002, ARCH OPHTHALMOL-CHIC, V120, P579, DOI 10.1001/archopht.120.5.579
   Bloch SB, 2012, AM J OPHTHALMOL, V153, P209, DOI 10.1016/j.ajo.2011.10.016
   Bolster Nigel M, 2015, J Diabetes Sci Technol, V10, P318, DOI 10.1177/1932296815617969
   Borooah S, 2015, EYE, V29, P1156, DOI 10.1038/eye.2015.83
   Brady CJ, 2015, JAMA-J AM MED ASSOC, V314, P2682, DOI 10.1001/jama.2015.15855
   Bressler Neil M, 2002, J Am Board Fam Pract, V15, P142
   Cachulo L, 2011, OPHTHALMOLOGICA, V225, P144, DOI 10.1159/000321064
   Capuano V, 2017, AM J OPHTHALMOL, V182, P45, DOI 10.1016/j.ajo.2017.07.009
   Cascella Raffaella, 2018, Oncotarget, V9, P7812, DOI 10.18632/oncotarget.23241
   Chew EY, 2014, OPHTHALMOLOGY, V121, P535, DOI 10.1016/j.ophtha.2013.10.027
   Chew JK, 2017, OPHTHALMOLOGICA, V238, P23, DOI 10.1159/000469652
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Cruess AF, 2008, PHARMACOECONOMICS, V26, P57, DOI 10.2165/00019053-200826010-00006
   Dias JRD, 2018, OPHTHALMOLOGY, V125, P255, DOI 10.1016/j.ophtha.2017.08.030
   Dorr M, 2013, INVEST OPHTH VIS SCI, V54, P7266, DOI 10.1167/iovs.13-11743
   Elshout M, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0514-3
   ENOCH JM, 1984, ARCH OPHTHALMOL-CHIC, V102, P1164, DOI 10.1001/archopht.1984.01040030942019
   Faes L, 2014, EYE, V28, P788, DOI 10.1038/eye.2014.104
   Freeman WR, 2004, ARCH OPHTHALMOL-CHIC, V122, P1647, DOI 10.1001/archopht.122.11.1647
   Gillies MC, 2015, OPHTHALMOLOGY, V122, P1837, DOI 10.1016/j.ophtha.2015.05.010
   Ho CYD, 2018, TRANSL VIS SCI TECHN, V7, DOI 10.1167/tvst.7.2.2
   Joachim N, 2017, BRIT J OPHTHALMOL, V101, P1185, DOI 10.1136/bjophthalmol-2016-309729
   Kaiser PK, 2013, RETINA-J RET VIT DIS, V33, P1863, DOI 10.1097/IAE.0b013e3182899258
   Kara S, 2016, ARQ BRAS OFTALMOL, V79, P323, DOI 10.5935/0004-2749.20160092
   Keane PA, 2015, CLIN OPHTHALMOL, V9, P353, DOI 10.2147/OPTH.S59012
   Kim TN, 2018, TRANSL VIS SCI TECHN, V7, DOI 10.1167/tvst.7.5.21
   Laishram M, 2017, J CLIN DIAGN RES, V11, pNC08, DOI 10.7860/JCDR/2017/25799.10213
   LAKSHMINARAYANAN V, 1992, OPTOMETRY VISION SCI, V69, P423, DOI 10.1097/00006324-199206000-00002
   LAVIN MJ, 1991, BRIT J OPHTHALMOL, V75, P133, DOI 10.1136/bjo.75.3.133
   Lee AY, 2015, BRIT J OPHTHALMOL, V99, P1045, DOI 10.1136/bjophthalmol-2014-306229
   Liu TYA, 2013, JAMA OPHTHALMOL, V131, P335, DOI 10.1001/jamaophthalmol.2013.818
   Liutkeviciene R, 2014, MEDICINA-LITHUANIA, V50, P281, DOI 10.1016/j.medici.2014.10.008
   Lovie-Kitchin Jan, 2005, Clin Exp Optom, V88, P292
   Maguire MG, 2013, OPHTHALMOLOGY, V120, P2035, DOI 10.1016/j.ophtha.2013.03.017
   Mann SS, 2011, GRAEF ARCH CLIN EXP, V249, P209, DOI 10.1007/s00417-010-1483-x
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Nixon DR, 2017, CLIN OPHTHALMOL, V11, P715, DOI 10.2147/OPTH.S131343
   Okada K, 2009, CLIN OPHTHALMOL, V3, P483
   Palejwala NV, 2015, RETINA-J RET VIT DIS, V35, P2204, DOI 10.1097/IAE.0000000000000867
   Paulus YM, 2017, QUAL LIFE RES, V26, P2139, DOI 10.1007/s11136-017-1547-z
   Reinsberg M, 2017, CLIN OPHTHALMOL, V11, P621, DOI 10.2147/OPTH.S123513
   Roisman L, 2016, OPHTHALMOLOGY, V123, P1309, DOI 10.1016/j.ophtha.2016.01.044
   Saunier V, 2018, JAMA OPHTHALMOL, V136, P473, DOI 10.1001/jamaophthalmol.2018.0504
   Schmidt-Erfurth U, 2017, EYE, V31, P26, DOI 10.1038/eye.2016.227
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Schwartz Roy, 2015, Int J Retina Vitreous, V1, P20, DOI 10.1186/s40942-015-0022-7
   Silva R, 2011, OPHTHALMOLOGICA, V226, DOI 10.1159/000329473
   Skaat A, 2012, AM J OPHTHALMOL, V153, P214, DOI 10.1016/j.ajo.2011.08.035
   Soubrane G, 2007, ARCH OPHTHALMOL-CHIC, V125, P1249, DOI 10.1001/archopht.125.9.1249
   Talks JS, 2016, OPHTHALMOLOGY, V123, P337, DOI 10.1016/j.ophtha.2015.09.039
   Tofigh S, 2015, EYE, V29, P1464, DOI 10.1038/eye.2015.138
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   Ueta T, 2008, AM J OPHTHALMOL, V146, P96, DOI 10.1016/j.ajo.2008.03.002
   Varano M, 2015, CLIN OPHTHALMOL, V9, P2243, DOI 10.2147/OPTH.S92548
   Venkatesh P, 2018, NATL MED J INDIA, V31, P345, DOI 10.4103/0970-258X.262914
   Walsh Alexander C, 2011, Ophthalmic Surg Lasers Imaging, V42 Suppl, pS95, DOI 10.3928/15428877-20110627-09
   Wang YZ, 2013, INVEST OPHTH VIS SCI, V54, P5497, DOI 10.1167/iovs.13-12037
   Wang YZ, 2002, INVEST OPHTH VIS SCI, V43, P2055
   Winther C, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/285463
   Wolf S, 2016, OPHTHALMOLOGICA, V236, P95, DOI 10.1159/000447725
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Wu ZC, 2015, TRANSL VIS SCI TECHN, V4, DOI 10.1167/tvst.4.3.13
   Wylegala A, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000004907
   Yanagi Y, 2018, JAMA OPHTHALMOL, V136, P905, DOI 10.1001/jamaophthalmol.2018.2154
   Yanagi Y, 2017, INVEST OPHTH VIS SCI, V58, P3488, DOI 10.1167/iovs.16-21167
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
   Zarranz-Ventura J, 2014, OPHTHALMOLOGY, V121, P1966, DOI 10.1016/j.ophtha.2014.04.026
NR 73
TC 13
Z9 13
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD APR
PY 2020
VL 40
IS 4
BP 599
EP 611
DI 10.1097/IAE.0000000000002768
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA LB2WI
UT WOS:000524497800002
PM 32032258
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Qi, M
   Abdelatti, M
   Krilis, M
   Madigan, MC
   Weaver, J
   Guymer, RH
   McCluskey, P
   Wang, Y
   Zhou, SJ
   Krilis, SA
   Giannakopoulos, B
AF Qi, Miao
   Abdelatti, Mahmoud
   Krilis, Matthew
   Madigan, Michele C.
   Weaver, James
   Guymer, Robyn H.
   McCluskey, Peter
   Wang, Ying
   Zhou, Saijun
   Krilis, Steven A.
   Giannakopoulos, Bill
TI Do Beta 2-Glycoprotein I Disulfide Bonds Protect the Human Retina in the
   Setting of Age-Related Macular Degeneration?
SO ANTIOXIDANTS & REDOX SIGNALING
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; PIGMENT EPITHELIAL-CELLS; APOPTOSIS
AB Age-related macular degeneration (AMD) affects the region of the retina that is responsible for high-resolution vision. It is a major cause of blindness in the aging population. This is the first study that examines the association of redox-modified, cysteine-based, post-translational forms of beta 2-glycoprotein I (2GPI) in the plasma of individuals with early and late stages of patients with AMD compared with controls. Exploration is also undertaken to assess whether the free thiol form of 2GPI versus the oxidized disulfide form have distinct functional properties in the setting of hydrogen peroxide (H2O2)-mediated cell death of an immortalized human retinal pigment epithelium (RPE) cell line. We demonstrate 2GPI in the retina and choroid of patients with AMD. Free thiol 2GPI is shown to protect the immortalized human RPE cell line against H2O2-induced cell death, whereas the oxidized form of 2GPI and free thiol bovine serum albumin were not protective. Free thiol 2GPI levels were significantly decreased in patients with late AMD compared with early AMD and healthy controls. Our observations lead to the hypothesis that free thiol 2GPI may protect against oxidative stress injury to RPE cells in the early stages of AMD.
C1 [Qi, Miao; Abdelatti, Mahmoud; Weaver, James; Wang, Ying; Zhou, Saijun; Krilis, Steven A.; Giannakopoulos, Bill] Univ New S Wales, St George Hosp, Dept Infect Dis Immunol & Sexual Hlth, Sydney, NSW 2217, Australia.
   [Qi, Miao; Abdelatti, Mahmoud; Weaver, James; Wang, Ying; Zhou, Saijun; Krilis, Steven A.; Giannakopoulos, Bill] Univ New S Wales, St George Hosp, Dept Med, Sydney, NSW 2217, Australia.
   [Krilis, Matthew; Madigan, Michele C.; McCluskey, Peter] Univ Sydney, Save Sight Inst, Sydney, NSW 2006, Australia.
   [Krilis, Matthew; Madigan, Michele C.; McCluskey, Peter] Sydney Eye Hosp, Sydney, NSW, Australia.
   [Madigan, Michele C.] Univ New S Wales, Sch Optometry & Vis Sci, Sydney, NSW 2217, Australia.
   [Weaver, James] St George Hosp, Dept Cardiol, Sydney, NSW, Australia.
   [Guymer, Robyn H.] Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Melbourne, Vic, Australia.
C3 St George Hospital; University of New South Wales Sydney; St George
   Hospital; University of New South Wales Sydney; University of Sydney;
   University of New South Wales Sydney; St George Hospital; Centre for Eye
   Research Australia; Royal Victorian Eye & Ear Hospital; University of
   Melbourne
RP Giannakopoulos, B (通讯作者)，Univ New S Wales, St George Hosp, Dept Infect Dis Immunol & Sexual Hlth, 2 South St, Sydney, NSW 2217, Australia.
EM bill.giannakopoulos@unsw.edu.au
RI McCluskey, Peter J/H-7607-2013
OI McCluskey, Peter J/0000-0002-8177-1637; Guymer,
   Robyn/0000-0002-9441-4356
CR Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   Giannakopoulos B, 2013, NEW ENGL J MED, V368, P1033, DOI 10.1056/NEJMra1112830
   Jiang SN, 2005, INVEST OPHTH VIS SCI, V46, P1054, DOI 10.1167/iovs.04-0949
   Kuroki M, 1996, J CLIN INVEST, V98, P1667, DOI 10.1172/JCI118962
   Kurz T, 2009, AUTOPHAGY, V5, P494, DOI 10.4161/auto.5.4.7961
   Robman L, 2010, OPHTHALMOLOGY, V117, P1982, DOI 10.1016/j.ophtha.2010.02.003
   Sheng Y, 2001, CLIN EXP IMMUNOL, V124, P502, DOI 10.1046/j.1365-2249.2001.01555.x
   Yu P, 2008, J THROMB HAEMOST, V6, P1215, DOI 10.1111/j.1538-7836.2008.03000.x
NR 9
TC 9
Z9 9
U1 0
U2 5
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1523-0864
EI 1557-7716
J9 ANTIOXID REDOX SIGN
JI Antioxid. Redox Signal.
PD JAN 1
PY 2016
VL 24
IS 1
BP 32
EP 38
DI 10.1089/ars.2014.6052
PG 7
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA DA5ED
UT WOS:000367824500003
PM 25827171
DA 2022-11-30
ER

PT J
AU Brantley, MA
   Edelstein, SL
   King, JM
   Plotzke, MR
   Apte, RS
   Kymes, SM
   Shiels, A
AF Brantley, M. A., Jr.
   Edelstein, S. L.
   King, J. M.
   Plotzke, M. R.
   Apte, R. S.
   Kymes, S. M.
   Shiels, A.
TI Association of complement factor H and LOC387715 genotypes with response
   of exudative age-related macular degeneration to photodynamic therapy
SO EYE
LA English
DT Article
DE AMD; CFH; LOC387715; photodynamic
ID POLYMORPHISM; GENE; INCREASES; VARIANT; RISK
AB Aim To determine whether there is an association between complement factor H (CFH) or LOC387715 genotypes and response to treatment with photodynamic therapy (PDT) for exudative age-related macular degeneration (AMD).
   Methods Sixty-nine patients being treated for neovascular AMD with PDT were genotyped for the CFH Y402H and LOC387715 A69S polymorphisms by allele-specific digestion of PCR products. AMD phenotypes were characterized by clinical examination, fundus photography, and fluorescein angiography.
   Results Adjusting for age, pre-PDT visual acuity (VA), and lesion type, mean VA after PDT was significantly worse for the CFH TT genotype than for the TC or CC genotypes (P = 0.05). Post-PDT VA was significantly worse for the CFH TT genotype in the subgroup of patients with predominantly classic choroidal neovascular lesions (P = 0.04), but not for the patients with occult lesions (P = 0.22). For the LOC387715 A69S variant, there was no significant difference among the genotypes in response to PDT therapy.
   Conclusions The CFH Y402H variant was associated with a response to PDT treatment in this study. Patients with the CFH TT genotype fared significantly worse with PDT than did those with the CFH TC and CC genotypes, suggesting a potential relationship between CFH genotype and response to PDT.
C1 [Brantley, M. A., Jr.; Edelstein, S. L.; King, J. M.; Plotzke, M. R.; Apte, R. S.; Kymes, S. M.; Shiels, A.] Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, St Louis, MO 63110 USA.
   [Brantley, M. A., Jr.; Apte, R. S.] Barnes Retina Inst, St Louis, MO USA.
C3 Washington University (WUSTL); Washington University (WUSTL)
RP Brantley, MA (通讯作者)，Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, 660 S Euclid Ave,Campus Box 8096, St Louis, MO 63110 USA.
EM brantley@vision.wustl.edu
FU NEI [EY012284, 5 P30 EY02687]; Research to Prevent Blindness to the
   Department of Ophthalmology and Visual Sciences at Washington University
   School of Medicine; NATIONAL EYE INSTITUTE [P30EY002687, R01EY012284]
   Funding Source: NIH RePORTER
FX This study was supported by NEI Grant EY012284, NEI Core Grant 5 P30
   EY02687, and a grant from Research to Prevent Blindness to the
   Department of Ophthalmology and Visual Sciences at Washington University
   School of Medicine. No conflicting relationship exists for any author.
CR Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   Brantley MA, 2007, AM J OPHTHALMOL, V144, P404, DOI 10.1016/j.ajo.2007.05.018
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1443
   Bressler NM, 2005, RETINA-J RET VIT DIS, V25, P119
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   GOVERDHAN SV, 2007, EYE
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Lau LI, 2006, INVEST OPHTH VIS SCI, V47, P3242, DOI 10.1167/iovs.05-1532
   Postel EA, 2006, OPHTHALMOLOGY, V113, P1504, DOI 10.1016/j.ophtha.2006.02.049
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Souied EH, 2005, MOL VIS, V11, P1135
   Virgili G, 2007, ACTA OPHTHALMOL SCAN, V85, P6, DOI 10.1111/j.1600-0420.2006.00711.x
   Wegscheider BJ, 2007, OPHTHALMOLOGY, V114, P738, DOI 10.1016/j.ophtha.2006.07.048
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
NR 20
TC 60
Z9 64
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD MAR
PY 2009
VL 23
IS 3
BP 626
EP 631
DI 10.1038/eye.2008.28
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 418AL
UT WOS:000264119500022
PM 18292785
OA Green Accepted, Bronze
DA 2022-11-30
ER

PT J
AU Peng, ML
   Chiu, HF
   Chou, H
   Liao, HJ
   Chen, ST
   Wong, YC
   Shen, YC
   Venkatakrishnan, K
   Wang, CK
AF Peng, Mei-Ling
   Chiu, Hui-Fang
   Chou, Hsuan
   Liao, Hui-Ju
   Chen, Shyan-Tarng
   Wong, Yue-Ching
   Shen, You-Cheng
   Venkatakrishnan, Kamesh
   Wang, Chin-Kun
TI Influence/impact of lutein complex (marigold flower and wolfberry) on
   visual function with early age-related macular degeneration subjects: A
   randomized clinical trial
SO JOURNAL OF FUNCTIONAL FOODS
LA English
DT Article
DE Lutein complex; Oxidative stress; Inflammation; Macular pigment optical
   density; Age-related macular disorder
ID PIGMENT OPTICAL-DENSITY; C-REACTIVE PROTEIN; BETA-CAROTENE;
   SUPPLEMENTATION; INFLAMMATION; ANTIOXIDANTS; RISK; LUTEIN/ZEAXANTHIN;
   XANTHOPHYLL; ACTIVATION
AB Age-related macular degeneration (AMD) is the age-related disease characterized by chronic and progressive degeneration of photoreceptors. The retinoprotective effect of lutein complex (LC) derived from marigold (lutein) and wolfberry (zeaxanthin) was assessed in subjects with early stage AMD (n = 56). Each subject was instructed to take 60 mL of LC beverage for 5 months. Supplementation with LC substantially escalated the concentrations of serum lutein and zeaxanthin as well as the activities of antioxidant enzymes and the levels of total antioxidative capacity, ocular comfort index (OCI) and macular pigment optical density (MPOD) as compared to baseline. Oxidative stress index (total free radicals and TBARS), inflammatory markers, best-corrected visual acuity (BCVA), and interocular pressure (IOP) were concomitantly lowered in subjects when treated with LC for 5 months. Thus, long-term consumption of LC may suppress the oxidative stress by enhancing the antioxidant status and thereby preclude the incidence of AMD. (c) 2016 Published by Elsevier Ltd.
C1 [Peng, Mei-Ling] Chung Shan Med Univ Hosp, Dept Ophthalmol, Taichung 40201, Taiwan.
   [Chiu, Hui-Fang] Taichung Hosp, Minist Hlth & Well Being, Dept Chinese Med, Taichung, Taiwan.
   [Chou, Hsuan; Liao, Hui-Ju; Wong, Yue-Ching; Venkatakrishnan, Kamesh; Wang, Chin-Kun] Chung Shan Med Univ, Sch Nutr, 110,Sec 1,Jianguo North Rd, Taichung, Taiwan.
   [Chen, Shyan-Tarng] Chung Shan Med Univ, Sch Optometry, 110,Sec 1,Jianguo North Rd, Taichung, Taiwan.
   [Shen, You-Cheng] Chung Shan Med Univ, Sch Hlth Diet & Ind Management, 110,Sec 1,Jianguo North Rd, Taichung, Taiwan.
C3 Chung Shan Medical University; Chung Shan Medical University Hospital;
   Chung Shan Medical University; Chung Shan Medical University; Chung Shan
   Medical University
RP Wang, CK (通讯作者)，Chung Shan Med Univ, Sch Nutr, 110,Sec 1,Jianguo North Rd, Taichung, Taiwan.
EM wck@csmu.edu.tw
RI /AAS-4633-2020; Shen, You-Cheng/AAW-2665-2020; Wang,
   Chin-Kun/S-6253-2019
OI Shen, You-Cheng/0000-0002-3098-4712; Wang, Chin-Kun/0000-0003-1308-2909
FU Chung Shan Medical University, Taiwan [CS-13028]
FX The study was supported by Chung Shan Medical University (CS-13028),
   Taiwan. The authors are grateful to Standard Foods, Taiwan, for
   providing lutein complex.
CR ARNAO MB, 1990, ANAL BIOCHEM, V185, P335, DOI 10.1016/0003-2697(90)90304-R
   Arnold C, 2013, NUTRITION, V29, P1412, DOI 10.1016/j.nut.2013.05.012
   Beatty S, 2013, OPHTHALMOLOGY, V120, P600, DOI 10.1016/j.ophtha.2012.08.040
   Bian QN, 2012, FREE RADICAL BIO MED, V53, P1298, DOI 10.1016/j.freeradbiomed.2012.06.024
   Bucheli P, 2011, OPTOMETRY VISION SCI, V88, P257, DOI 10.1097/OPX.0b013e318205a18f
   Calvo MM, 2005, CRIT REV FOOD SCI, V45, P671, DOI 10.1080/10408690590957034
   Chang RCC, 2010, RECENT ADV NUTR PREV, V2010, P169
   Cho EY, 2008, AM J CLIN NUTR, V87, P1837, DOI 10.1093/ajcn/87.6.1837
   Cho EY, 2004, ARCH OPHTHALMOL-CHIC, V122, P883, DOI 10.1001/archopht.122.6.883
   Collin HB, 2008, CLIN EXP OPTOM, V91, P425, DOI 10.1111/j.1444-0938.2008.00303.x
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   DRAPER HH, 1990, METHOD ENZYMOL, V186, P421
   Garcia-Layana A, 2013, NUTRIENTS, V5, P543, DOI 10.3390/nu5020543
   HALLIWELL B, 1990, ARCH BIOCHEM BIOPHYS, V280, P1, DOI 10.1016/0003-9861(90)90510-6
   He NW, 2012, FOOD CHEM, V133, P978, DOI 10.1016/j.foodchem.2012.02.018
   Huang LL, 2008, INVEST OPHTH VIS SCI, V49, P3864, DOI 10.1167/iovs.07-1420
   Huang YM, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/564738
   Huang YM, 2013, NUTRITION, V29, P387, DOI 10.1016/j.nut.2012.06.009
   Johnson ME, 2007, INVEST OPHTH VIS SCI, V48, P4451, DOI 10.1167/iovs.06-1253
   Jung HY, 2016, J FUNCT FOODS, V21, P27, DOI 10.1016/j.jff.2015.11.036
   Khachik F, 1995, US Patent, Patent No. [5,382,714, 5382714]
   Khandhadia S., 2014, SYSTEMS BIOL FREE RA, P3625
   Kim Y, 2011, J NUTR SCI VITAMINOL, V57, P216, DOI 10.3177/jnsv.57.216
   Klein R, 2014, JAMA OPHTHALMOL, V132, P446, DOI 10.1001/jamaophthalmol.2013.7671
   Li DJ, 2015, INT J FOOD PROP, V18, P178, DOI 10.1080/10942912.2013.828748
   Li HY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068881
   Liu R, 2015, INVEST OPHTH VIS SCI, V56, P252, DOI 10.1167/iovs.14-15553
   Loughman J, 2010, VISION RES, V50, P1249, DOI 10.1016/j.visres.2010.04.009
   Lu FJ, 1996, EXPERIENTIA, V52, P141, DOI 10.1007/BF01923359
   Ma L, 2012, BRIT J NUTR, V107, P350, DOI 10.1017/S0007114511004260
   Margrain TH, 2004, PROG RETIN EYE RES, V23, P523, DOI 10.1016/j.preteyeres.2004.05.001
   MILLER NJ, 1993, CLIN SCI, V84, P407, DOI 10.1042/cs0840407
   Murray IJ, 2013, INVEST OPHTH VIS SCI, V54, P1781, DOI 10.1167/iovs.12-10715
   Plestina-Borjan I, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/804054
   Potterat O, 2010, PLANTA MED, V76, P7, DOI 10.1055/s-0029-1186218
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P300, DOI 10.1001/archopht.125.3.300
   Schertz FM, 1925, J AGRIC RES, V30, P0253
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Siriamornpun S, 2012, J FUNCT FOODS, V4, P757, DOI 10.1016/j.jff.2012.05.002
   Stringham JM, 2011, INVEST OPHTH VIS SCI, V52, P7406, DOI 10.1167/iovs.10-6699
   Sundelin SP, 2001, FREE RADICAL BIO MED, V31, P217, DOI 10.1016/S0891-5849(01)00573-1
   Talwar D, 1998, CLIN CHIM ACTA, V270, P85, DOI 10.1016/S0009-8981(97)00224-6
   Tan JSL, 2008, OPHTHALMOLOGY, V115, P334, DOI 10.1016/j.ophtha.2007.03.083
   Telander DG, 2011, SEMIN OPHTHALMOL, V26, P192, DOI 10.3109/08820538.2011.570849
   Tokarz P, 2013, BIOGERONTOLOGY, V14, P461, DOI 10.1007/s10522-013-9463-2
   Wang MX, 2013, ATHEROSCLEROSIS, V227, P380, DOI 10.1016/j.atherosclerosis.2013.01.021
   Wang MC, 2006, FOOD CHEM TOXICOL, V44, P1522, DOI 10.1016/j.fct.2006.04.005
   Weigert G, 2011, INVEST OPHTH VIS SCI, V52, P8174, DOI 10.1167/iovs.11-7522
   Wielgus AR, 2010, PHOTOCH PHOTOBIO SCI, V9, P1505, DOI 10.1039/c0pp00133c
   Yonekura L, 2007, MOL NUTR FOOD RES, V51, P107, DOI 10.1002/mnfr.200600145
   Zhou JL, 2006, P NATL ACAD SCI USA, V103, P16182, DOI 10.1073/pnas.0604255103
NR 51
TC 18
Z9 19
U1 0
U2 39
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1756-4646
J9 J FUNCT FOODS
JI J. Funct. Food.
PD JUN
PY 2016
VL 24
BP 122
EP 130
DI 10.1016/j.jff.2016.04.006
PG 9
WC Food Science & Technology; Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Food Science & Technology; Nutrition & Dietetics
GA DP3BJ
UT WOS:000378367100013
DA 2022-11-30
ER

PT J
AU Zerbib, J
   Delcourt, C
   Puche, N
   Querques, G
   Cohen, SY
   Sahel, J
   Korobelnik, JF
   Le Goff, M
   Souied, EH
AF Zerbib, Jennyfer
   Delcourt, Cecile
   Puche, Nathalie
   Querques, Giuseppe
   Cohen, Salomon Yves
   Sahel, Jose
   Korobelnik, Jean-Francois
   Le Goff, Melanie
   Souied, Eric H.
TI Risk factors for exudative age-related macular degeneration in a large
   French case-control study
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Macular degeneration; Epidemiology; Risk factor; Case-control study;
   Omega-3 fatty acid; Smoking
ID COMPLEMENT FACTOR-H; BODY-MASS INDEX; CIGARETTE-SMOKING; ENVIRONMENTAL
   ASSOCIATIONS; 10-YEAR INCIDENCE; POOLED FINDINGS; FATTY-ACIDS;
   VITAMIN-C; MACULOPATHY; VARIANT
AB Purpose The purpose of the CAP (Creteil AMD PHRC-funded) Study was to analyze risk factors of exudative age-related macular degeneration (AMD) in a large French case-control population.
   Patients and methods One thousand and twenty-four patients with exudative AMD and 275 controls were recruited. Information about lifestyle, medical history, and dietary intake were collected. Associations of risk factors were estimated using logistic regression.
   Results After multivariate adjustment, CFH Y402H and ARMS2 A69S polymorphisms were associated with very high risk for exudative AMD (OR=6.21 and OR=11.7, respectively, p < 0.0001). Risk for exudative AMD was increased in current smokers (OR = 3.79, p = 0.0003) and former smokers having quitted since less than 20 years ago (OR=2.30, p=0.002), but not in former smokers having quitted since 20 years or more ago (OR=0.81, p=0.43). Heavy smokers (at least 25 pack-years) were particularly at risk (OR=3.61, p < 0.0001). Use of cooking oils rich in omega 3 fatty acids was significantly associated with a reduced risk of exudative AMD (OR=0.55, 95 % CI: 0.36-0.84, p=0.006), as well as a high consumption of fruits (OR=0.60, 95 % CI: 0.37-0.98, p=0.04), but not the consumption of fish, vegetables or oils rich in omega 6. High waist circumference was associated with increased risk for exudative AMD (OR=2.53, p<0.0001), but not hypercholesterolemia, hypertension, or body mass index.
   Conclusions The CAP Study confirms major genetic risk factors for exudative AMD. It further documents the high risk in heavy smokers and the long persistence of risk after smoking cessation, and the associations with waist circumference and fruit consumption. Furthermore, we observed an
C1 [Zerbib, Jennyfer; Puche, Nathalie; Querques, Giuseppe; Souied, Eric H.] Univ Paris Est Creteil, Hop Intercommunal Creteil, Dept Ophthalmol, Creteil, France.
   [Delcourt, Cecile; Korobelnik, Jean-Francois; Le Goff, Melanie] Univ Bordeaux, ISPED, F-33000 Bordeaux, France.
   [Delcourt, Cecile; Korobelnik, Jean-Francois; Le Goff, Melanie] INSERM, Ctr INSERM Epidemiol Biostat U897, F-33000 Bordeaux, France.
   [Cohen, Salomon Yves] Ctr Imagerie & Laser, Paris, France.
   [Sahel, Jose] Hop Quinze Vingts, Paris, France.
   [Korobelnik, Jean-Francois] Univ Bordeaux 2, CHU Bordeaux, INSERM U897, F-33076 Bordeaux, France.
   [Souied, Eric H.] Hop Intercommunal Creteil, Unite Fonct Rech Clin, F-94000 Creteil, France.
   [Souied, Eric H.] Hop Intercommunal Creteil, Dept Ophthalmol, F-94000 Creteil, France.
C3 Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil;
   UDICE-French Research Universities; Universite de Bordeaux; Institut
   National de la Sante et de la Recherche Medicale (Inserm); CHNO des
   Quinze-Vingts; UDICE-French Research Universities; Sorbonne Universite;
   CHU Bordeaux; Institut National de la Sante et de la Recherche Medicale
   (Inserm); UDICE-French Research Universities; Universite de Bordeaux;
   Assistance Publique Hopitaux Paris (APHP); Universite
   Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire
   Henri-Mondor - APHP; CHI Creteil; Universite
   Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil
RP Souied, EH (通讯作者)，Hop Intercommunal Creteil, Dept Ophthalmol, 40 Ave Verdun, F-94000 Creteil, France.
EM eric.souied@chicreteil.fr
RI Sahel, Jose-Alain/F-3172-2017; LE GOFF, Mélanie/A-3541-2016; Delcourt,
   Cecile/I-2627-2013; KOROBELNIK, Jean-Francois/A-5448-2016
OI Sahel, Jose-Alain/0000-0002-4831-1153; Delcourt,
   Cecile/0000-0002-2099-0481; Querques, Giuseppe/0000-0002-3292-9581; LE
   GOFF, Melanie/0000-0003-2848-6287
FU Association DMLA; Fondation pour la Recherche Medicale; national PHRC
FX The CAP Study received financial support from the Association DMLA, the
   Fondation pour la Recherche Medicale, and the national PHRC funding
   program.
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Astorg P, 2004, LIPIDS, V39, P527, DOI 10.1007/s11745-004-1259-6
   Chakravarthy U, 2007, OPHTHALMOLOGY, V114, P1157, DOI 10.1016/j.ophtha.2006.09.022
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Cho EY, 2004, ARCH OPHTHALMOL-CHIC, V122, P883, DOI 10.1001/archopht.122.6.883
   Chong EWT, 2009, ARCH OPHTHALMOL-CHIC, V127, P674, DOI 10.1001/archophthalmol.2009.60
   Chong EWT, 2008, ARCH OPHTHALMOL-CHIC, V126, P826, DOI 10.1001/archopht.126.6.826
   Delcourt C, 1998, ARCH OPHTHALMOL-CHIC, V116, P1031, DOI 10.1001/archopht.116.8.1031
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   Delcourt C, 2010, J NUTR HEALTH AGING, V14, P854, DOI 10.1007/s12603-010-0131-9
   Delcourt C, 2011, INVEST OPHTH VIS SCI, V52, P5955, DOI 10.1167/iovs.10-6235
   Delcourt C, 2006, INVEST OPHTH VIS SCI, V47, P2329, DOI 10.1167/iovs.05-1235
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   FLIESLER SJ, 1983, PROG LIPID RES, V22, P79
   Francis PJ, 2007, HUM HERED, V63, P212, DOI 10.1159/000100046
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hogg RE, 2008, OPHTHALMOLOGY, V115, P1046, DOI 10.1016/j.ophtha.2007.07.031
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Klein R, 2002, AM J EPIDEMIOL, V156, P589, DOI 10.1093/aje/kwf092
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Leveziel N, 2007, MOL VIS, V13, P2153
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Linseisen J, 2002, PUBLIC HEALTH NUTR, V5, P1227, DOI 10.1079/PHN2002401
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Merle B, 2011, INVEST OPHTH VIS SCI, V52, P6004, DOI 10.1167/iovs.11-7254
   Mitchell P, 2002, ARCH OPHTHALMOL-CHIC, V120, P1357, DOI 10.1001/archopht.120.10.1357
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Ryu E, 2010, MOL VIS, V16, P2811
   SanGiovanni JP, 2008, ARCH OPHTHALMOL-CHIC, V126, P1274, DOI 10.1001/archopht.126.9.1274
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671
   SanGiovanni JP, 2009, AM J CLIN NUTR, V90, P1601, DOI 10.3945/ajcn.2009.27594
   SanGiovanni JP, 2005, PROG RETIN EYE RES, V24, P87, DOI 10.1016/j.preteyeres.2004.06.002
   Seddon J, 2007, PRINCIPLES PRACTICE, P413
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Seddon JM, 2006, HUM HERED, V61, P157, DOI 10.1159/000094141
   Seddon JM, 2010, OPHTHALMOLOGY, V117, P1560, DOI 10.1016/j.ophtha.2009.11.020
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Souied EH, 2005, MOL VIS, V11, P1135
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   Tan JSL, 2009, ARCH OPHTHALMOL-CHIC, V127, P656, DOI 10.1001/archophthalmol.2009.76
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Vingerling JR, 1996, ARCH OPHTHALMOL-CHIC, V114, P1193, DOI 10.1001/archopht.1996.01100140393005
   Wang JJ, 2009, AM J EPIDEMIOL, V169, P633, DOI 10.1093/aje/kwn358
   Zarbin MA, 2010, RETINA-J RET VIT DIS, V30, P1350, DOI 10.1097/IAE.0b013e3181f57e30
   Zerbib J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007341
NR 54
TC 18
Z9 18
U1 0
U2 14
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD JUN
PY 2014
VL 252
IS 6
BP 899
EP 907
DI 10.1007/s00417-013-2537-7
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AK5UN
UT WOS:000338492000005
PM 24362810
DA 2022-11-30
ER

PT J
AU Meagher, KA
   Thurnham, DI
   Beatty, S
   Howard, AN
   Connolly, E
   Cummins, W
   Nolan, JM
AF Meagher, Katherine A.
   Thurnham, David I.
   Beatty, Stephen
   Howard, Alan N.
   Connolly, Eithne
   Cummins, Wayne
   Nolan, John M.
TI Serum response to supplemental macular carotenoids in subjects with and
   without age-related macular degeneration
SO BRITISH JOURNAL OF NUTRITION
LA English
DT Article
DE Age-related macular degeneration; Macular carotenoids; Lutein;
   Zeaxanthin; meso-Zeaxanthin; HPLC separation
ID PIGMENT OPTICAL-DENSITY; MESO-ZEAXANTHIN; LUTEIN SUPPLEMENTATION; PLASMA
   KINETICS; HUMAN RETINA; MACULOPATHY; 3'-DEHYDRO-LUTEIN; TRANSFORMATIONS;
   IDENTIFICATION; LIPOPROTEINS
AB Macular pigment (MP) is composed of lutein (L), zeaxanthin (Z) and meso-zeaxanthin (MZ). The present study reports on serum response to three different MP supplements in normal subjects (n 27) and in subjects with age-related macular degeneration (AMD) (n 27). Subjects were randomly assigned to: Group 1 (20 mg L and 2 mg Z), Group 2 (10 mg L, 2 mg Z and 10 mg MZ) or Group 3 (3 mg L, 2 mg Z and 17 mg MZ). Serum carotenoids were quantified at baseline, and at 4 and 8 weeks using HPLC. Response data for normal and AMD subjects were comparable and therefore combined for analysis. We report response as the average of the 4- and 8-week concentrations (saturation plateau). Serum L increased significantly in Group 1 (0.036 mu mol/l per mg (269 %); P<0.001) and Group 2 (0.079 mu mol/l per mg (340 %); P<0.001), with no significant change in Group 3 (0.006 mu mol/l per mg (7%); P=0.466). Serum Z increased significantly in Group 1 (0.037 mu mol/l per mg (69 %); P=0.001) and Group 2 (0.015 mu mol/l per mg (75 %); P<0.001), with no significant change in Group 3 (-0.0002 mu mol/l per mg (-6 %); P=0.384). Serum MZ increased significantly in Group 1 (0.0094 mu mol/l (absolute value); P=0.015), Group 2 (0.005 mu mol/l per mg; P<0.001) and Group 3 (0.004 mu mol/l per mg; P<0.001). The formulation containing all three macular carotenoids (Group 2 supplement) was the most efficacious in terms of achieving the highest combined concentration of the three MP constituent carotenoids in serum, thereby potentially optimising the bioavailability of these compounds for capture by the target tissue (retina).
C1 [Meagher, Katherine A.; Beatty, Stephen; Connolly, Eithne; Nolan, John M.] Waterford Inst Technol, Dept Chem & Life Sci, Macular Pigment Res Grp, Waterford, Ireland.
   [Thurnham, David I.] Univ Ulster, Ctr Food & Hlth NICHE, Coleraine BT52 1SA, Londonderry, North Ireland.
   [Beatty, Stephen; Nolan, John M.] Whitfield Clin, Inst Vis Res, Waterford, Ireland.
   [Howard, Alan N.] Howard Fdn, Cambridge, England.
   [Howard, Alan N.] Univ Cambridge Downing Coll, Cambridge CB2 1DQ, England.
   [Cummins, Wayne] Waterford Inst Technol, Dept Chem & Life Sci, Pharmaceut & Mol Biotechnol Res Ctr, Waterford, Ireland.
C3 South East Technological University (SETU); Ulster University;
   University of Cambridge; South East Technological University (SETU)
RP Meagher, KA (通讯作者)，Waterford Inst Technol, Dept Chem & Life Sci, Macular Pigment Res Grp, Waterford, Ireland.
EM kmeagher@wit.ie
RI Nolan, John/N-4921-2014
OI Nolan, John/0000-0002-5503-7084
FU Howard Foundation, Cambridge, UK; European Research Council (ERC);
   Howard Foundation
FX The authors acknowledge the support given by the Howard Foundation,
   Cambridge, UK. J. M. N. is a Fulbright Scholar and is funded by the
   European Research Council (ERC). K. A. M. carried out the experimental
   procedures, the data interpretation and statistical analysis, and
   drafted the manuscript. D. I. T. helped with data interpretation and
   statistical analysis, and helped to draft the manuscript. S. B. helped
   to the draft the manuscript. A. N. H. helped with the design of the
   trial and to draft the manuscript. E. C. carried out the recruitment of
   subjects, managed the clinical visitations and collected the serum
   samples. W. C. supported the experimental procedures. J. M. N. designed
   and supervised the study, helped with data interpretation and
   statistical analysis and helped to draft the manuscript. All authors
   have read and approved the manuscript. J. M. N. and S. B. do consultancy
   work for nutraceutical companies, in a personal capacity, and as
   directors of Nutrasight Consultancy Limited. D. I. T. is a consultant to
   the Howard Foundation and receives consulting fees for the same. All
   other authors report no potential conflicts of interest.
CR Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Berendschot TTJM, 2000, INVEST OPHTH VIS SCI, V41, P3322
   Bone RA, 1997, EXP EYE RES, V64, P211, DOI 10.1006/exer.1996.0210
   Bone RA, 2003, J NUTR, V133, P992, DOI 10.1093/jn/133.4.992
   BONE RA, 1985, VISION RES, V25, P1531, DOI 10.1016/0042-6989(85)90123-3
   Bone RA, 2001, INVEST OPHTH VIS SCI, V42, P235
   BONE RA, 1993, INVEST OPHTH VIS SCI, V34, P2033
   Bone RA, 2007, NUTR METAB, V4, DOI 10.1186/1743-7075-4-12
   Bone RA, 2010, ARCH BIOCHEM BIOPHYS, V504, P50, DOI 10.1016/j.abb.2010.06.019
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Britton G, 1995, FASEB J, V9, P1551, DOI 10.1096/fasebj.9.15.8529834
   Connolly EE, 2011, INVEST OPHTH VIS SCI, V52, P9207, DOI 10.1167/iovs.11-8025
   Connolly EE, 2010, CURR EYE RES, V35, P335, DOI 10.3109/02713680903521951
   Harrison EH, 2012, BBA-MOL CELL BIOL L, V1821, P70, DOI 10.1016/j.bbalip.2011.06.002
   Hartmann D, 2004, AM J CLIN NUTR, V79, P410
   HIRSCH J, 1989, VISION RES, V29, P1095, DOI 10.1016/0042-6989(89)90058-8
   Huang LL, 2008, INVEST OPHTH VIS SCI, V49, P3864, DOI 10.1167/iovs.07-1420
   Hughes DA, 2000, J INFECT DIS, V182, pS11, DOI 10.1086/315910
   Johnson EJ, 2005, INVEST OPHTH VIS SCI, V46, P692, DOI 10.1167/iovs.02-1192
   Johnson EJ, 2000, AM J CLIN NUTR, V71, P1555
   Johnson EJ, 2008, AM J CLIN NUTR, V87, P1521, DOI 10.1093/ajcn/87.5.1521
   Junghans A, 2001, ARCH BIOCHEM BIOPHYS, V391, P160, DOI 10.1006/abbi.2001.2411
   Khachik F, 1997, ANAL CHEM, V69, P1873, DOI 10.1021/ac961085i
   Khachik F, 2002, INVEST OPHTH VIS SCI, V43, P3383
   Khachik F, 2006, INVEST OPHTH VIS SCI, V47, P5234, DOI 10.1167/iovs.06-0504
   Kirby ML, 2010, INVEST OPHTH VIS SCI, V51, P6722, DOI 10.1167/iovs.10-5344
   Koh HH, 2004, EXP EYE RES, V79, P21, DOI 10.1016/j.exer.2004.03.001
   Li BX, 2010, ARCH BIOCHEM BIOPHYS, V504, P56, DOI 10.1016/j.abb.2010.07.024
   Loane E, 2008, BRIT J OPHTHALMOL, V92, P1163, DOI 10.1136/bjo.2007.135566
   Loughman J., 2010, J OPTOM, V3, P74
   Loughman J, 2011, OPTOMETRY PRACTICE, V12, P135
   MAOKA T, 1986, COMP BIOCHEM PHYS B, V83, P121, DOI 10.1016/0305-0491(86)90341-X
   Neelam K, 2009, RETINA-J RET VIT DIS, V29, P192, DOI 10.1097/IAE.0b013e31818c178f
   Nolan JM, 2007, EXP EYE RES, V84, P61, DOI 10.1016/j.exer.2006.08.016
   Nolan JM, 2011, VISION RES, V51, P459, DOI 10.1016/j.visres.2010.12.016
   Perry A, 2009, J FOOD COMPOS ANAL, V22, P9, DOI 10.1016/j.jfca.2008.07.006
   Pintea A, 2011, J FOOD COMPOS ANAL, V24, P830, DOI 10.1016/j.jfca.2011.03.007
   Schalch W, 2007, ARCH BIOCHEM BIOPHYS, V458, P128, DOI 10.1016/j.abb.2006.09.032
   SCHIEDT K, 1985, PURE APPL CHEM, V57, P685, DOI 10.1351/pac198557050685
   Snodderly DM, 1999, NUTR ENV INFLUENCES
   Stringham JM, 2011, INVEST OPHTH VIS SCI, V52, P7406, DOI 10.1167/iovs.10-6699
   Thurmann PA, 2005, AM J CLIN NUTR, V82, P88
   Thurnham DI, 2008, BRIT J NUTR, V100, P1307, DOI 10.1017/S0007114508971336
   Trevithick-Sutton CC, 2006, MOL VIS, V12, P1127
   Trieschmann M, 2007, EXP EYE RES, V84, P718, DOI 10.1016/j.exer.2006.12.010
   Wang W, 2007, AM J CLIN NUTR, V85, P762, DOI 10.1093/ajcn/85.3.762
   Wooten BR, 1999, INVEST OPHTH VIS SCI, V40, P2481
   Young AJ, 1996, J PHOTOCH PHOTOBIO B, V36, P3, DOI 10.1016/S1011-1344(96)07397-6
   Zhao XF, 2006, AM J CLIN NUTR, V83, P163
NR 49
TC 26
Z9 26
U1 0
U2 22
PU CAMBRIDGE UNIV PRESS
PI CAMBRIDGE
PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND
SN 0007-1145
J9 BRIT J NUTR
JI Br. J. Nutr.
PD JUL 28
PY 2013
VL 110
IS 2
BP 289
EP 300
DI 10.1017/S0007114512004837
PG 12
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA 166HD
UT WOS:000320544400010
PM 23211762
OA Bronze
DA 2022-11-30
ER

PT J
AU Sia, DIT
   Ebneter, A
   Sinkar, S
   Gilhotra, J
AF Sia, David I. T.
   Ebneter, Andreas
   Sinkar, Swati
   Gilhotra, Jagjit
TI Polypoidal choroidal vasculopathy: naked polyp
SO INTERNATIONAL OPHTHALMOLOGY
LA English
DT Article
AB We present an unusual case of polypoidal choroidal vasculopathy (PCV) lying above the retinal pigment epithelium (RPE) in a 60-year-old Caucasian female. PCV lesions are typically located beneath the RPE layer. However, they may rarely lie above the level of the RPE due to a discontinuity in the RPE and Bruch's membrane.
RP Sia, DIT (通讯作者)，Univ Adelaide, Royal Adelaide Hosp, Discipline Ophthalmol & Visual Sci, S Australian Inst Ophthalmol, North Terrace, Adelaide, SA 5000, Australia.
EM daviditsia@gmail.com
RI Ebneter, Andreas/C-5226-2017
OI Ebneter, Andreas/0000-0001-6666-2558; Sia, David Ik
   Tuo/0000-0003-0749-7614
CR Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Ojima Y, 2009, RETINA-J RET VIT DIS, V29, P52, DOI 10.1097/IAE.0b013e3181884fbf
   Tamura H, 2007, BRIT J OPHTHALMOL, V91, P1152, DOI 10.1136/bjo.2006.112318
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 5
TC 2
Z9 2
U1 0
U2 0
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0165-5701
EI 1573-2630
J9 INT OPHTHALMOL
JI Int. Ophthalmol.
PD FEB
PY 2013
VL 33
IS 1
BP 67
EP 69
DI 10.1007/s10792-012-9681-7
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 063NK
UT WOS:000313006400012
PM 23183910
OA Green Published
DA 2022-11-30
ER

PT J
AU Rezar-Dreindl, S
   Sacu, S
   Eibenberger, K
   Pollreisz, A
   Buhl, W
   Georgopoulos, M
   Krall, C
   Weigert, G
   Schmidt-Erfurth, U
AF Rezar-Dreindl, Sandra
   Sacu, Stefan
   Eibenberger, Katharina
   Pollreisz, Andreas
   Buehl, Wolf
   Georgopoulos, Michael
   Krall, Christoph
   Weigert, Guenther
   Schmidt-Erfurth, Ursula
TI The Intraocular Cytokine Profile and Therapeutic Response in Persistent
   Neovascular Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE neovascular age-related macular degeneration; cytokines; dexamethasone
   intravitreal implant; anti-vascular endothelial growth factor
ID ENDOTHELIAL GROWTH-FACTOR; DEXAMETHASONE INTRAVITREAL IMPLANT; CHOROIDAL
   NEOVASCULARIZATION; TRIAMCINOLONE ACETONIDE; RETINAL TOXICITY;
   MESSENGER-RNA; AQUEOUS-HUMOR; FACTOR-BETA; RANIBIZUMAB; EXPRESSION
AB PURPOSE. To investigate the course of inflammatory and angiogenic cytokines in the aqueous humor of patients with persistent/recurrent neovascular age-related macular degeneration (nAMD) under ranibizumab monotherapy (IVM) or ranibizumab plus dexamethasone combination treatment.
   METHODS. In this 12-month prospective study, 40 eyes with nAMD were treated with either IVM or combined treatment with ranibizumab plus intravitreal dexamethasone implant (IVC). Patients in the IVM group were treated following an "as needed'' treatment regimen; patients in the IVC group received ranibizumab and a dexamethasone implant at baseline and were retreated with ranibizumab. At baseline and at each time of retreatment aqueous humor samples were taken.
   RESULTS. Before treatment, levels of macrophage chemoattractant protein (MCP)-1, monokine induced by c interferon (MIG), and lipocalin-2/neutrophil gelatinase-associated lipocalin (NGAL) were elevated in nAMD patients compared to healthy controls (P = 0.024; P = 0.04; P = 0.01). In contrast, tumor necrosis factor a, IL-12p70, and secreted protein acidic and rich in cysteine (SPARC) concentrations were lower (P = 0.001; P = 0.008; P = 0.03), while vascular endothelial growth factor (VEGF) was not altered (45+/-6/51+/-12 pg/mL nAMD/control group; P = 0.6). During IVC, levels of VEGF, MIG, platelet-derived growth factor (PDGF)-AA, and transforming growth factor beta 1 (P = 0.005; P = 0.011; P = 0.008; P = 0.013) were reduced. Ranibizumab monotherapy did not influence the course of any inflammatory/angiogenic cytokine. Interleukin 6 and PDGF-AA levels correlated with central retinal thickness changes (P = 0.007; P = 0.022). Over the 12-month period visual function was maintained with no significant differences during or between both treatment groups.
   CONCLUSIONS. Inflammatory proteins are involved in the pathogenesis of chronic macular edema due to AMD and are associated with disease activity. During combined treatment, levels of inflammatory and angiogenic cytokines decreased over a 12-month period with no superiority in functional outcome.
C1 [Rezar-Dreindl, Sandra; Sacu, Stefan; Eibenberger, Katharina; Pollreisz, Andreas; Buehl, Wolf; Georgopoulos, Michael; Weigert, Guenther; Schmidt-Erfurth, Ursula] Med Univ Vienna, Dept Ophthalmol, Waehringer Guertel 18-20, A-1090 Vienna, Austria.
   [Krall, Christoph] Med Univ Vienna, Dept Med Stat, Vienna, Austria.
C3 Medical University of Vienna; Medical University of Vienna
RP Sacu, S (通讯作者)，Med Univ Vienna, Dept Ophthalmol, Waehringer Guertel 18-20, A-1090 Vienna, Austria.
EM stefan.sacu@meduniwien.ac.at
RI Pollreisz, Andreas/AAJ-1538-2021
OI Schmidt-Erfurth, Ursula/0000-0002-7788-7311
CR Agawa T, 2014, RETINA-J RET VIT DIS, V34, P1811, DOI 10.1097/IAE.0000000000000157
   Bian ZM, 2007, EXP EYE RES, V84, P812, DOI 10.1016/j.exer.2006.12.016
   Broadhead GK, 2014, ACTA OPHTHALMOL, V92, P713, DOI 10.1111/aos.12463
   Campa C, 2010, MEDIAT INFLAMM, V2010, DOI 10.1155/2010/546826
   Campochiaro P A, 1999, Mol Vis, V5, P34
   Cao JH, 2014, OPHTHALMOLOGY, V121, P1871, DOI 10.1016/j.ophtha.2014.04.012
   Farber JM, 1997, J LEUKOCYTE BIOL, V61, P246, DOI 10.1002/jlb.61.3.246
   Fauser S, 2015, ACTA OPHTHALMOL, V93, P734, DOI 10.1111/aos.12770
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Funk M, 2009, OPHTHALMOLOGY, V116, P2393, DOI 10.1016/j.ophtha.2009.05.039
   Haller JA, 2011, OPHTHALMOLOGY, V118, P2453, DOI 10.1016/j.ophtha.2011.05.014
   Jonas JB, 2004, ARCH OPHTHALMOL-CHIC, V122, P218, DOI 10.1001/archopht.122.2.218
   Jonas JB, 2010, ARCH OPHTHALMOL-CHIC, V128, P1281, DOI 10.1001/archophthalmol.2010.227
   KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Kuppermann BD, 2015, OPHTHALMOLOGICA, V234, P40, DOI 10.1159/000381865
   KWAK HW, 1992, ARCH OPHTHALMOL-CHIC, V110, P259, DOI 10.1001/archopht.1992.01080140115038
   Lim JI, 2015, BRIT J OPHTHALMOL, V99, P618, DOI 10.1136/bjophthalmol-2014-306002
   Michels Stephan, 2006, Expert Opin Investig Drugs, V15, P779, DOI 10.1517/13543784.15.7.779
   Nauck M, 1998, EUR J PHARMACOL, V341, P309, DOI 10.1016/S0014-2999(97)01464-7
   Ogata N, 1997, CURR EYE RES, V16, P9, DOI 10.1076/ceyr.16.1.9.5121
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Penn JS, 2008, PROG RETIN EYE RES, V27, P331, DOI 10.1016/j.preteyeres.2008.05.001
   Potchinsky M, 1996, J CELL PHYSIOL, V166, P380, DOI 10.1002/(SICI)1097-4652(199602)166:2<380::AID-JCP16>3.0.CO;2-F
   Rayess N, 2015, AM J OPHTHALMOL, V159, P3, DOI 10.1016/j.ajo.2014.09.011
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Roh MI, 2009, RETINA-J RET VIT DIS, V29, P523, DOI 10.1097/IAE.0b013e318195cb15
   Rosenfeld Philip J, 2006, Ophthalmol Clin North Am, V19, P361
   Scaramuzzi M, 2015, RETINA-J RET VIT DIS, V35, P1216, DOI 10.1097/IAE.0000000000000443
   Shikada Y, 2005, CANCER RES, V65, P7241, DOI 10.1158/0008-5472.CAN-04-4171
   SHURE D, 1992, BIOCHEM BIOPH RES CO, V186, P1510, DOI 10.1016/S0006-291X(05)81577-3
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Yu SY, 2006, RETINA-J RET VIT DIS, V26, P531, DOI 10.1097/00006982-200605000-00006
   Zarranz-Ventura J, 2013, PLOS ONE, V31, P8
NR 35
TC 52
Z9 54
U1 1
U2 4
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD AUG
PY 2016
VL 57
IS 10
BP 4144
EP 4150
DI 10.1167/iovs.16-19772
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DW9LR
UT WOS:000383981600023
PM 27537264
OA gold
DA 2022-11-30
ER

PT J
AU McCusker, MM
   Durrani, K
   Payette, MJ
   Suchecki, J
AF McCusker, Meagen M.
   Durrani, Khayyam
   Payette, Michael J.
   Suchecki, Jeanine
TI An eye on nutrition: The role of vitamins, essential fatty acids, and
   antioxidants in age-related macular degeneration, dry eye syndrome, and
   cataract
SO CLINICS IN DERMATOLOGY
LA English
DT Article
ID PIGMENT; CAROTENOIDS; HEALTH; TRIAL; OMEGA-3-FATTY-ACIDS;
   SUPPLEMENTATION; ZEAXANTHIN; DISEASE; LUTEIN
AB Visual impairment is a global epidemic. In developing countries, nutritional deficiency and cataracts continue to be the leading cause of blindness, whereas age-related macular degeneration (AMD) and cataracts are the leading causes in developed nations. The World Health Organization has instituted VISION 2020: "The Right to Sight" as a global mission to put an end to worldwide blindness. In industrialized societies, patients, physicians, researchers, nutritionists, and biochemists have been looking toward vitamins and nutrients to prevent AMD, cataracts, and dry eye syndrome (DES). Nutrients from the AREDS2 study (lutein, zeaxanthin, vitamin C, vitamin E, zinc, copper, eicosapentanoic acid [EPA], and docosahexanoic acid [DHA]) set forth by the National Institutes of Health remain the most proven nutritional therapy for reducing the rate of advanced AMD. Omega-3 fatty acids, especially DHA, have been found to improve DES in randomized clinical trials. Conflicting results have been seen with regard to multivitamin supplementation on the prevention of cataract. (C) 2016 Published by Elsevier Inc.
C1 [McCusker, Meagen M.; Payette, Michael J.] Univ Connecticut, Ctr Hlth, Dept Dermatol, Farmington, CT USA.
   [Durrani, Khayyam; Suchecki, Jeanine] Univ Connecticut, Ctr Hlth, Dept Surg, Div Ophthalmol, Farmington, CT USA.
C3 University of Connecticut; University of Connecticut
RP McCusker, MM (通讯作者)，Univ Connecticut, Ctr Hlth, Dept Dermatol, Farmington, CT USA.
EM mccusker@uchc.edu
CR Abdel-Aal EM, 2013, NUTRIENTS, V5, P1169, DOI 10.3390/nu5041169
   American Academy of Ophthalmology Retina Panel, 2008, PREF PRACT PATT GUID
   Anastassov I, 2014, J NEUROCHEM, V129, P249, DOI 10.1111/jnc.12627
   Augood C, 2008, AM J CLIN NUTR, V88, P398, DOI 10.1093/ajcn/88.2.398
   Bhargava R, 2013, INT J OPHTHALMOL-CHI, V6, P811, DOI 10.3980/j.issn.2222-3959.2013.06.13
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P142, DOI 10.1001/jamaophthalmol.2013.7376
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chong EWT, 2007, BMJ-BRIT MED J, V335, P755, DOI 10.1136/bmj.39350.500428.47
   Christen WG, 2014, OPHTHALMOLOGY, V121, P525, DOI 10.1016/j.ophtha.2013.09.038
   Feng ZH, 2010, J NUTR BIOCHEM, V21, P1222, DOI 10.1016/j.jnutbio.2009.10.010
   George Mateljan Foundation, OM 3 FATT AC
   HEINONEN OP, 1994, NEW ENGL J MED, V330, P1029
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1439, DOI 10.1001/archopht.119.10.1439
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   LaRowe TL, 2008, OPHTHALMOLOGY, V115, P876, DOI 10.1016/j.ophtha.2007.06.015
   Loskutova E, 2013, NUTRIENTS, V5, P1962, DOI 10.3390/nu5061962
   Maraini G, 2008, OPHTHALMOLOGY, V115, P599, DOI 10.1016/j.ophtha.2008.01.005
   National Institutes of Health Office of Dietary Supplements, VIT E FACT SHEET HLT
   National Institutes of Health Office of Dietary Supplements, ZINC FACT SHEET HLTH
   National Institutes of Health Office of Dietary Supplements, VIT C FACT SHEET HLT
   Newsome DA, 1998, ARCH OPHTHALMOL-CHIC, V106, P192
   Olenik A, 2013, CLIN INTERV AGING, V8, P1133, DOI 10.2147/CIA.S48955
   Omenn GS, 1996, J NATL CANCER I, V88, P1550, DOI 10.1093/jnci/88.21.1550
   Pinazo-Duran MD, 2013, CLIN INTERV AGING, V8, P139, DOI 10.2147/CIA.S40640
   Press VG, 2013, J HEALTH COMMUN, V18, P197, DOI 10.1080/10810730.2013.830346
   SanGiovanni JP, 2005, PROG RETIN EYE RES, V24, P87, DOI 10.1016/j.preteyeres.2004.06.002
   SCHAEFFER JL, 1988, POULTRY SCI, V67, P608, DOI 10.3382/ps.0670608
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Smith JR, 2004, OCUL IMMUNOL INFLAMM, V12, P203, DOI 10.1080/092739490500200
   Sommerburg O, 1998, BRIT J OPHTHALMOL, V82, P907, DOI 10.1136/bjo.82.8.907
   SPERDUTO RD, 1993, ARCH OPHTHALMOL-CHIC, V111, P1246, DOI 10.1001/archopht.1993.01090090098027
   Sullivan BD, 2006, ARCH OPHTHALMOL-CHIC, V124, P1286, DOI 10.1001/archopht.124.9.1286
   Tan JSL, 2009, ARCH OPHTHALMOL-CHIC, V127, P656, DOI 10.1001/archophthalmol.2009.76
   The Age-Related Eye Disease Study Research Group 2, 2013, JAMA OPHTHALMOL, V119, P1439
   van Staa TP, 2013, HEART, V99, P1597, DOI 10.1136/heartjnl-2013-303698
   VanderBeek BL, 2013, RETINA-J RET VIT DIS, V33, P414, DOI 10.1097/IAE.0b013e318276e0cf
   Vishwanathan R, 2009, AM J CLIN NUTR, V90, P1272, DOI 10.3945/ajcn.2009.28013
   World Health Organization, WHAT IS VISION 2020
   World Health Organization, PREV BLINDN VIS IMP
NR 40
TC 40
Z9 40
U1 3
U2 57
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0738-081X
EI 1879-1131
J9 CLIN DERMATOL
JI Clin. Dermatol.
PD MAR-APR
PY 2016
VL 34
IS 2
BP 276
EP 285
DI 10.1016/j.clindermatol.2015.11.009
PG 10
WC Dermatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Dermatology
GA DG0JN
UT WOS:000371751200012
PM 26903189
DA 2022-11-30
ER

PT J
AU Querques, G
   Georges, A
   Ben Moussa, N
   Sterkers, M
   Souied, EH
AF Querques, Giuseppe
   Georges, Anouk
   Ben Moussa, Naima
   Sterkers, Margaret
   Souied, Eric H.
TI Appearance of Regressing Drusen on Optical Coherence Tomography in
   Age-related Macular Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; BRUCHS MEMBRANE; CHOLESTEROL; EYES;
   MACULOPATHY; DEPOSIT
AB Objective: To describe and interpret a multilaminar sub-retinal pigment epithelium (RPE) intense hyper-reflectivity observed in vivo in eyes clinically diagnosed with regressing drusen.
   Design: Observational case series.
   Participants: Twenty-three consecutive patients clinically diagnosed with regressing calcific drusen due to nonneovascular age-related macular degeneration (AMD).
   Methods: Patients were submitted to confocal scanning laser ophthalmoscopy (cSLO) fundus imaging and "eye-tracked"spectral-domain optical coherence tomography (SD-OCT).
   Main Outcome Measures: Localization and possible origin and composition of the multilaminar sub-RPE hyperreflectivity.
   Results: Thirty eyes of 23 consecutive patients (8 male and 15 female; mean age, 82.7 +/- 10.1 years) showing on SD-OCT an intense multilaminar sub-RPE hyperreflectivity, which matched with regressing calcific drusen as visualized by cSLO infrared (IR) and MultiColor (Heidelberg Engineering, Heidelberg, Germany) images, were included in this study. The multilaminar hyperreflectivity was found to localize to beneath the RPE and above the outer Bruch's membrane (oBM) layer. A mean of 1.2 multilaminar sub-RPE hyperreflectivities per SD-OCT scan were identified by 2 readers. The SD-OCT analysis allowed the 2 readers to describe 3 different types of sub-RPE hyperreflectivity. "Type 1"laminar/multilaminar hyperreflectivity (found in 24 scans of 12 eyes) was characterized by an intense signal originating from what we interpreted as the inner Bruch's membrane (iBM) layer. "Type 2"multilaminar hyperreflectivity (found in 130 scans of 27 eyes) was characterized by an intense signal originating from the oBM layer. "Type 3"multilaminar fragmented hyperreflectivity (found in 22 scans of 11 eyes) was characterized by an intense signal originating from what we interpreted as both the iBM and the oBM, showing different degrees of fragmentation.
   Conclusions: We describe a novel SD-OCT finding appearing as multilaminar sub-RPE intense hyperreflectivity observed in vivo in eyes with regressing drusen. This multilaminar sub-RPE hyperreflectivity could be interpreted as layers of lipid mineralization (membranous debris also called "lipoprotein-derived debris"developing calcification), internal and external to the basement membrane, with different degrees of fragmentation. (C) 2014 by the American Academy of Ophthalmology.
C1 [Querques, Giuseppe; Georges, Anouk; Ben Moussa, Naima; Sterkers, Margaret; Souied, Eric H.] Univ Paris Est Creteil, Ctr Hosp Intercommunal Creteil, Dept Ophthalmol, Creteil, France.
C3 Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil
RP Querques, G (通讯作者)，Ctr Hosp Intercommunal Creteil, Dept Ophthalmol, 40 Ave Verdun, F-94000 Creteil, France.
EM giuseppe.querques@hotmail.it
OI Querques, Giuseppe/0000-0002-3292-9581
CR Bloom SM, 2011, RETINA-J RET VIT DIS, V31, P316, DOI 10.1097/IAE.0b013e3181ed8c9a
   CHAO FF, 1990, AM J PATHOL, V136, P169
   CHUNG BH, 1994, ARTERIOSCLER THROMB, V14, P622, DOI 10.1161/01.ATV.14.4.622
   Curcio CA, 2005, EXP EYE RES, V81, P731, DOI 10.1016/j.exer.2005.04.012
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   Curcio CA, 1998, INVEST OPHTH VIS SCI, V39, P1085
   Curcio CA, 2009, PROG RETIN EYE RES, V28, P393, DOI 10.1016/j.preteyeres.2009.08.001
   Green W R, 1999, Mol Vis, V5, P27
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Kruth HS, 2001, J LIPID RES, V42, P1492
   MARSHALL GE, 1994, GRAEF ARCH CLIN EXP, V232, P133, DOI 10.1007/BF00176781
   Miller JW, 2013, AM J OPHTHALMOL, V155, P1, DOI 10.1016/j.ajo.2012.10.018
   Mukkamala SK, 2012, ARCH OPHTHALMOL-CHIC, V130, P1547, DOI 10.1001/archophthalmol.2012.2491
   Nair A, 2002, CIRCULATION, V106, P2200, DOI 10.1161/01.CIR.0000035654.18341.5E
   PAULEIKHOFF D, 1990, AM J OPHTHALMOL, V109, P38, DOI 10.1016/S0002-9394(14)75576-X
   ROBENEK H, 1988, ARTERIOSCLEROSIS, V8, P57, DOI 10.1161/01.ATV.8.1.57
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Sarks S, 2007, INVEST OPHTH VIS SCI, V48, P968, DOI 10.1167/iovs.06-0443
   Spaide RF, 2003, RETINA-J RET VIT DIS, V23, P595, DOI 10.1097/00006982-200310000-00001
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Spaide RF, 2012, OPHTHALMOLOGY, V119, P2203, DOI 10.1016/j.ophtha.2012.09.009
   Spaide RF, 2011, RETINA-J RET VIT DIS, V31, P1609, DOI 10.1097/IAE.0b013e3182247535
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1441, DOI 10.1097/IAE.0b013e3181ee5ce8
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P644, DOI 10.1016/j.ajo.2008.10.005
   Spraul CW, 1999, SURV OPHTHALMOL, V44, pS10, DOI 10.1016/S0039-6257(99)00086-7
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
NR 27
TC 30
Z9 30
U1 0
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JAN
PY 2014
VL 121
IS 1
BP 173
EP 179
DI 10.1016/j.ophtha.2013.06.024
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 282KG
UT WOS:000329169500031
PM 23891523
OA Bronze
DA 2022-11-30
ER

PT J
AU Mitchell, J
   Bradley, C
AF Mitchell, Jan
   Bradley, Clare
TI Quality of life in age-related macular degeneration: a review of the
   literature
SO HEALTH AND QUALITY OF LIFE OUTCOMES
LA English
DT Review
ID HEALTH-EDUCATION PROGRAM; VISUAL FUNCTION QUESTIONNAIRE; LOW-VISION
   REHABILITATION; WELL-BEING QUESTIONNAIRE; DIABETIC-RETINOPATHY;
   CATARACT-SURGERY; INDIVIDUALIZED QUESTIONNAIRE; PSYCHOMETRIC PROPERTIES;
   PHOTODYNAMIC THERAPY; HEARING IMPAIRMENT
AB Background: The Age-related Macular Degeneration Alliance International commissioned a review of the literature on quality of life (QoL) in macular degeneration ( MD) with a view to increasing awareness of MD, reducing its impact and improving services for people with MD worldwide.
   Method: A systematic review was conducted using electronic databases, conference proceedings and key journal hand search checks. The resulting 'White Paper' was posted on the AMD Alliance website and is reproduced here.
   Review: MD is a chronic, largely untreatable eye condition which leads to loss of central vision needed for tasks such as reading, watching TV, driving, recognising faces. It is the most common cause of blindness in the Western world. Shock of diagnosis, coupled with lack of information and support are a common experience. Incidence of depression is twice that found in the community-dwelling elderly, fuelled by functional decline and loss of leisure activities. Some people feel suicidal. MD threatens independence, especially when comorbidity exacerbates functional limitations. Rehabilitation, including low vision aid (LVA) provision and training, peer support and education, can improve functional and psychological outcomes but many people do not receive services likely to benefit them. Medical treatments, suitable for only a small minority of people with MD, can improve vision but most limit progress of MD, at least for a time, rather than cure. The White Paper considers difficulties associated with inappropriate use of health status measures and misinterpretation of utility values as QoL measures: evidence suggests they have poor validity in MD.
   Conclusion: There is considerable evidence for the major damage done to QoL by MD which is underestimated by health status and utility measures. Medical treatments are limited to a small proportion of people. However, much can be done to improve QoL by early diagnosis of MD with good communication of prognosis and continuing support. Support could include provision of LVAs, peer support, education and effective help in adjusting to MD. It is vital that appropriate measures of visual function and QoL be used in building a sound evidence base for the effectiveness of rehabilitation and treatment.
C1 Univ London, Royal Holloway, Dept Psychol, Egham TW20 0EX, Surrey, England.
C3 University of London; Royal Holloway University London
RP Mitchell, J (通讯作者)，Univ London, Royal Holloway, Dept Psychol, Egham TW20 0EX, Surrey, England.
EM j.mitchell@rhul.ac.uk; c.bradley@rhul.ac.uk
OI Bradley, Clare/0000-0002-4079-0364
CR Acquadro C., 2004, LINGUISTIC VALIDATIO
   Amiel S, 2002, BRIT MED J, V325, P746, DOI 10.1136/bmj.325.7367.746
   Armbrecht AM, 2004, BRIT J OPHTHALMOL, V88, P1270, DOI 10.1136/bjo.2003.038604
   Armbrecht AM, 2003, J CATARACT REFR SURG, V29, P686, DOI 10.1016/S0886-3350(02)01650-4
   Armbrecht AM, 2000, BRIT J OPHTHALMOL, V84, P1343, DOI 10.1136/bjo.84.12.1343
   Asplund R, 2000, ARCH GERONTOL GERIAT, V30, P7, DOI 10.1016/S0167-4943(99)00045-X
   BAILEY IL, 1991, INVEST OPHTH VIS SCI, V32, P422
   Bass E, 2000, AM J OPHTHALMOL, V130, P408
   BERGNER M, 1993, QUALITY LIFE ASSESSM
   Birk T, 2004, GERONTOLOGIST, V44, P836, DOI 10.1093/geront/44.6.836
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bonastre J, 2003, PHARMACOECONOMICS, V21, P181, DOI 10.2165/00019053-200321030-00003
   Bradley C, 2001, LANCET, V357, P7, DOI 10.1016/S0140-6736(00)03562-5
   Bradley C, 1999, QUAL LIFE RES, V8, P79, DOI 10.1023/A:1026485130100
   BRADLEY C, 2006, DIGEST J MACULAR DIS, P31
   BRADLEYP, 2005, INT C SERIES, V1282, P211
   Brazier J, 1999, HLTH TECHNOL ASSESS, V3
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brody BL, 2005, ARCH OPHTHALMOL-CHIC, V123, P46, DOI 10.1001/archopht.123.1.46
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1901
   Brody BL, 1999, ANN BEHAV MED, V21, P322, DOI 10.1007/BF02895965
   Brooks R, 1996, HEALTH POLICY, V37, P53, DOI 10.1016/0168-8510(96)00822-6
   Brown G C, 1999, Trans Am Ophthalmol Soc, V97, P473
   Brown GC, 2000, ARCH OPHTHALMOL-CHIC, V118, P47
   Brown GC, 2000, CAN J OPHTHALMOL, V35, P127, DOI 10.1016/S0008-4182(00)80005-8
   Brown M M, 1999, Curr Opin Ophthalmol, V10, P221, DOI 10.1097/00055735-199906000-00012
   Brown MM, 2006, CURR OPIN OPHTHALMOL, V17, P257
   Brown MM, 2002, ARCH OPHTHALMOL-CHIC, V120, P481
   Brown MM, 2001, BRIT J OPHTHALMOL, V85, P327, DOI 10.1136/bjo.85.3.327
   Brunnstrom G, 2004, OPHTHAL PHYSL OPT, V24, P274, DOI 10.1111/j.1475-1313.2004.00192.x
   BUGGAGE RR, 2006, INVEST OPHTHALMOL VI, V47
   BUSH JW, 1984, ASSESSMENT QUALITY L
   Cahill MT, 2005, OPHTHALMOLOGY, V112, P144, DOI 10.1016/j.ophtha.2004.06.035
   Capella-McDonnall NE, 2005, INT J GERIATR PSYCH, V20, P855, DOI 10.1002/gps.1368
   Carr AJ, 2001, BRIT MED J, V322, P1357, DOI 10.1136/bmj.322.7298.1357
   CHALIFOUX LM, 1991, J VIS IMP BLIND  JUN, P249
   CHANG TS, 2006, INVEST OPHTHALMOL VI, V47
   Childs AL, 2004, OPHTHALMOLOGY, V111, P2007, DOI 10.1016/j.ophtha.2004.07.024
   Childs AL, 2004, AM J OPHTHALMOL, V137, P373, DOI 10.1016/S0002-9394(03)00911-5
   Chopdar A, 2003, BRIT MED J, V326, P485, DOI 10.1136/bmj.326.7387.485
   Cohen SY, 2003, BRIT J OPHTHALMOL, V87, P977, DOI 10.1136/bjo.87.8.977
   COVERT D, 2007, IN PRESS SURV OPHTHA
   Cox A, 2005, EYE, V19, P652, DOI 10.1038/sj.eye.6701610
   Crews JE, 2004, AM J PUBLIC HEALTH, V94, P823, DOI 10.2105/AJPH.94.5.823
   CRUESS AF, 2006, INVEST OPHTHALMOL VI, V47
   Culham LE, 2004, OPHTHAL PHYSL OPT, V24, P281, DOI 10.1111/j.1475-1313.2004.00193.x
   Dahlin-Ivanoff S, 1998, PATIENT EDUC COUNS, V34, P63, DOI 10.1016/S0738-3991(98)00041-X
   Dandona L, 1998, ARCH OPHTHALMOL-CHIC, V116, P545, DOI 10.1001/archopht.116.4.514
   DargentMolina P, 1996, LANCET, V348, P145, DOI 10.1016/S0140-6736(96)01440-7
   DAVIS C, 1995, J VISUAL IMPAIR BLIN, V89, P16
   de Boer MR, 2004, OPHTHAL PHYSL OPT, V24, P257, DOI 10.1111/j.1475-1313.2004.00187.x
   De Wit GA, 2000, HEALTH ECON, V9, P109, DOI 10.1002/(SICI)1099-1050(200003)9:2<109::AID-HEC503>3.0.CO;2-L
   DIAMOND BL, 1945, AM J PSYCHIAT, V102, P367, DOI 10.1176/ajp.102.3.367
   Dodds A G, 1993, Int J Rehabil Res, V16, P177, DOI 10.1097/00004356-199309000-00001
   DODDS AG, 1991, J VISUAL IMPAIR BLIN, V85, P306
   Dolan P, 2002, SOC SCI MED, V54, P919, DOI 10.1016/S0277-9536(01)00066-1
   DONATI G, 2005, INT C SERIES, V1282, P100
   Dupuy HJ, 1984, ASSESSMENT QUALITY L
   Dutton GN, 2000, BRIT J OPHTHALMOL, V84, P945, DOI 10.1136/bjo.84.9.945
   Eklund K, 2004, DISABIL REHABIL, V26, P401, DOI 10.1080/09638280410001662950
   Espallargues M, 2005, INVEST OPHTH VIS SCI, V46, P4016, DOI 10.1167/iovs.05-0072
   Feeny D, 2002, MED CARE, V40, P113, DOI 10.1097/00005650-200202000-00006
   First MB, 1995, USERS GUIDE STRUCTUR
   FOLSTEIN MF, 1985, PSYCHOL MED, V15, P809, DOI 10.1017/S0033291700005031
   Frost N A, 1998, Ophthalmic Epidemiol, V5, P185, DOI 10.1076/opep.5.4.185.4191
   Frost N A, 2001, Ophthalmic Epidemiol, V8, P1, DOI 10.1076/opep.8.1.1.1539
   Fujikado T, 2002, AM J OPHTHALMOL, V134, P849, DOI 10.1016/S0002-9394(02)01756-7
   Goldberg D., 1978, MANUAL GEN HLTH QUES
   GRANTJORDAN P, 2006, INVEST OPHTHALMOL VI, V47
   Harper R, 1999, OPHTHAL PHYSL OPT, V19, P3, DOI 10.1046/j.1475-1313.1999.00411.x
   Hart PM, 1999, BRIT J OPHTHALMOL, V83, P1115, DOI 10.1136/bjo.83.10.1115
   Haymes SA, 2006, OPHTHAL PHYSL OPT, V26, P169, DOI 10.1111/j.1475-1313.2006.00367.x
   Hill AR, 2005, INT C SERIES, V1282, P573
   Hinds A, 2003, BRIT J OPHTHALMOL, V87, P1391, DOI 10.1136/bjo.87.11.1391
   HOLROYD S, 1992, AM J PSYCHIAT, V149, P1701
   HOROWITZ A, 1991, J GERONTOL SOC WORK, V17, P37, DOI 10.1300/J083v17n03_04
   Ivanoff SD, 1996, DISABIL REHABIL, V18, P515, DOI 10.3109/09638289609166038
   Jacob A, 2004, BMJ-BRIT MED J, V328, P1552, DOI 10.1136/bmj.328.7455.1552
   JAMES O, 1986, BRIT J PSYCHIAT, V149, P647, DOI 10.1192/bjp.149.5.647
   Jongenelis K, 2004, J AFFECT DISORDERS, V83, P135, DOI 10.1016/j.jad.2004.06.001
   JOYCE CRB, 1994, QUALITY LIFE FOLLOWI, P43
   Keller BK, 1999, J AM GERIATR SOC, V47, P1319, DOI 10.1111/j.1532-5415.1999.tb07432.x
   Knudtson MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P807, DOI 10.1001/archopht.123.6.807
   LAWTON MP, 1982, J GERONTOL, V37, P91, DOI 10.1093/geronj/37.1.91
   Lee P, 1999, AM J OPHTHALMOL, V127, P447, DOI 10.1016/S0002-9394(98)00418-8
   Lieberman D, 2004, J REHABIL RES DEV, V41, P669, DOI 10.1682/JRRD.2003.11.0168
   Lin MY, 2004, J AM GERIATR SOC, V52, P1996, DOI 10.1111/j.1532-5415.2004.52554.x
   Lindblad AS, 2005, ARCH OPHTHALMOL-CHIC, V123, P1207
   Lundstrom M, 2002, BRIT J OPHTHALMOL, V86, P1330, DOI 10.1136/bjo.86.12.1330
   Mackenzie PJ, 2002, OPHTHALMOLOGY, V109, P720, DOI 10.1016/S0161-6420(01)01021-1
   Mangione CM, 1999, AM J OPHTHALMOL, V128, P45, DOI 10.1016/S0002-9394(99)00169-5
   MANGIONE CM, 1992, MED CARE, V30, P1111, DOI 10.1097/00005650-199212000-00004
   Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P1496, DOI 10.1001/archopht.116.11.1496
   Margolis MK, 2002, PHARMACOECONOMICS, V20, P791, DOI 10.2165/00019053-200220120-00001
   MARX MS, 1994, J VIS IMP BLIND  SEP, P462
   McCarty CA, 2001, BRIT J OPHTHALMOL, V85, P322, DOI 10.1136/bjo.85.3.322
   MCGEE HM, 1991, PSYCHOL MED, V21, P749, DOI 10.1017/S0033291700022388
   MCMILLAN CV, 2006, IN PRESS HLTH QUAL L
   McNair DM, 1971, MANUAL PROFILE MOOD
   Mejico LJ, 2004, AM J OPHTHALMOL, V137, P908, DOI 10.1016/j.ajo.2003.12.038
   Menon GJ, 2003, SURV OPHTHALMOL, V48, P58, DOI 10.1016/S0039-6257(02)00414-9
   Miskala PH, 2004, ARCH OPHTHALMOL-CHIC, V122, P758, DOI 10.1001/archopht.122.5.758
   Mitchell J, 2002, BRIT J OPHTHALMOL, V86, P777, DOI 10.1136/bjo.86.7.777
   Mitchell J, 2001, QUAL LIFE RES, V10, P465, DOI 10.1023/A:1012540100613
   Mitchell J, 2005, INT C SER, V1282, P654
   Mitchell Jan, 2005, Health Qual Life Outcomes, V3, P25, DOI 10.1186/1477-7525-3-25
   Mitchell J, 2004, QUAL LIFE RES, V13, P1548, DOI 10.1023/B:QURE.0000031348.51292.4a
   Moore LW, 2003, J ADV NURS, V43, P10
   Mruthyunjaya P, 2004, OPHTHALMOLOGY, V111, P1715, DOI 10.1016/j.ophtha.2004.03.022
   MUTHNY FA, 1989, FREIBURG INVENTORY C
   *NAT STAT ONL, POP EST
   Nilsson UL, 2003, VISION RES, V43, P1777, DOI 10.1016/S0042-6989(03)00219-0
   Owen CG, 2003, BRIT J OPHTHALMOL, V87, P312, DOI 10.1136/bjo.87.3.312
   Pouwer F, 2000, PSYCHOL MED, V30, P455, DOI 10.1017/S0033291700001719
   Reeves BC, 2004, BRIT J OPHTHALMOL, V88, P1443, DOI 10.1136/bjo.2003.037457
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Riusala A, 2003, AM J OPHTHALMOL, V135, P206, DOI 10.1016/S0002-9394(02)01832-9
   Rovner BW, 2002, ARCH OPHTHALMOL-CHIC, V120, P1041
   Rovner BW, 2002, AM J GERIAT PSYCHIAT, V10, P305
   *ROYAL COLL OPHTH, 2000, AG REL MAC DEG BEST
   SARTORE M, 2006, INVEST OPHTHALMOL VI, V47
   Scanlan JM, 2004, J VISUAL IMPAIR BLIN, V98, P601, DOI 10.1177/0145482X0409801005
   Scott IU, 1999, AM J OPHTHALMOL, V128, P54, DOI 10.1016/S0002-9394(99)00108-7
   Scott IU, 2001, AM J OPHTHALMOL, V131, P590, DOI 10.1016/S0002-9394(01)00833-9
   SCOTT IU, 1994, ARCH OPHTHALMOL-CHIC, V112, P329, DOI 10.1001/archopht.1994.01090150059023
   Shah VA, 2004, OPHTHAL EPIDEMIOL, V11, P43, DOI 10.1076/opep.11.1.43.26436
   Sharma S, 2001, CAN J OPHTHALMOL, V36, P332, DOI 10.1016/S0008-4182(01)80120-4
   Slakter JS, 2005, SURV OPHTHALMOL, V50, P263, DOI 10.1016/j.survophthal.2005.02.007
   Stein JD, 2003, BRIT J OPHTHALMOL, V87, P8, DOI 10.1136/bjo.87.1.8
   STEINBERG EP, 1994, ARCH OPHTHALMOL-CHIC, V112, P630, DOI 10.1001/archopht.1994.01090170074026
   Stevenson MR, 2005, BRIT J OPHTHALMOL, V89, P1045, DOI 10.1136/bjo.2003.030445
   Stevenson MR, 2004, BRIT J OPHTHALMOL, V88, P1125, DOI 10.1136/bjo.2003.032383
   STIGGELBOUT AM, 1995, J CLIN EPIDEMIOL, V48, P1207, DOI 10.1016/0895-4356(95)00011-R
   The Royal College of Ophthalmologists, 2017, NAT EL AG REL MAC DA
   TIELSCH JM, 1995, NEW ENGL J MED, V332, P1205, DOI 10.1056/NEJM199505043321806
   Tolman J, 2005, GERONTOLOGIST, V45, P747, DOI 10.1093/geront/45.6.747
   VALE D, 2004, UNSEEN NEGLECT ISOLA
   Waern M, 2002, BMJ-BRIT MED J, V324, P1355, DOI 10.1136/bmj.324.7350.1355
   Ware JE., 1993, SCORING SF 36 SF 36
   WATSON D, 1988, J PERS SOC PSYCHOL, V54, P1063, DOI 10.1037/0022-3514.54.6.1063
   WHO, 2004, MAGN CAUS VIS IMP
   WILLIAMS GP, 2006, EYE
   Wolffsohn JS, 2000, AM J OPHTHALMOL, V130, P793, DOI 10.1016/S0002-9394(00)00610-3
   Wolffsohn JS, 2000, BRIT J OPHTHALMOL, V84, P1035, DOI 10.1136/bjo.84.9.1035
   WONG EYH, 2004, J VIS IMP BLIND  OCT, P629
   Woodcock A, 2004, PATIENT EDUC COUNS, V53, P365, DOI 10.1016/j.pec.2003.10.007
   Woodcock A., 2006, P VIS 2005 INT C SER, V1282, P342
   YESAVAGE JA, 1983, J PSYCHIATR RES, V17, P37, DOI 10.1016/0022-3956(82)90033-4
   ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x
   ZLATEVA G, 2006, INVEST OPHTHALMOL VI, V47
NR 151
TC 175
Z9 178
U1 2
U2 45
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1477-7525
J9 HEALTH QUAL LIFE OUT
JI Health Qual. Life Outcomes
PD DEC 21
PY 2006
VL 4
AR 97
DI 10.1186/1477-7525-4-97
PG 20
WC Health Care Sciences & Services; Health Policy & Services
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Health Care Sciences & Services
GA 129HB
UT WOS:000243718300001
PM 17184527
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Demirel, S
   Ozmert, E
   Batioglu, F
   Gedik-Oguz, Y
AF Demirel, Sibel
   Ozmert, Emin
   Batioglu, Figen
   Gedik-Oguz, Yesim
TI A Color Perimetric Test to Evaluate Macular Pigment Density in
   Age-Related Macular Degeneration
SO OPTOMETRY AND VISION SCIENCE
LA English
DT Article
DE age-related macular degeneration; color perimetry; macular pigment optic
   density; short-term repeatability
ID DIETARY ANTIOXIDANTS; OPTICAL-DENSITY; MACULOPATHY; LUTEIN; RISK;
   CAROTENOIDS; RETINA; WHITE; ZINC; EYES
AB Purpose To evaluate differences in measurements of macular pigment optical density (MPOD) in patients with dry age-related macular degeneration (AMD) and a group of healthy patients (control group). Short-term repeatability of MPOD measures was also assessed in the control group.
   Methods This cross-sectional study included 31 eyes from 31 patients with bilateral dry AMD, 21 eyes from 21 cases with dry AMD in the study eye and exudative AMD in the fellow eye. The control group included 17 eyes from 17 healthy patients of similar age and sex. The MPOD values were measured using a commercially available color perimetry technique (CP). Short-term repeatability of MPOD measurements by the CP technique was assessed in 20 eyes of 20 healthy subjects who were measured 3 times on 3 consecutive days.
   Results The mean values for MPOD were 5.59 2.06 dB in cases in which both eyes had dry AMD, 5.25 +/- 2.72 dB in cases in which one eye had wet AMD and the studied eye had dry AMD, and 5.97 +/- 2.14 dB in the eyes of the healthy control group. The mean value was lower in cases in which the fellow eye had wet AMD; however, no significant difference in MPOD was found between the three groups (p = 0.659) or between the group with dry AMD in both eyes and the healthy control group (p = 0.977). The intraclass correlation coefficient (ICC) value was 0.664 between day 1 and day 2, and 0.822 between day 2 and day 3.
   Conclusions Our results do not show a direct relation between MPOD and dry AMD. Color perimetry does not provide acceptable short-term repeatability for measuring MPOD. Learning effects may contribute to the measured test-retest variability. Other studies are needed to determine if CP is suitable for repeated measurements during the long term follow-up with the same patient.
C1 [Demirel, Sibel; Ozmert, Emin; Batioglu, Figen; Gedik-Oguz, Yesim] Ankara Univ, Fac Med, Dept Ophthalmol, TR-06100 Ankara, Turkey.
C3 Ankara University
RP Demirel, S (通讯作者)，Ankara Univ, Vehbi Koc Eye Hosp, Fac Med, Dept Ophthalmol, Mamak Caddesi, Dikimevi, Turkey.
EM drsibeldemireltr@yahoo.com.tr
RI Batıoğlu, Figen/AAQ-3727-2020; DEMIREL, SIBEL/GQH-3232-2022; Demirel,
   Sibel/AAQ-4282-2020
OI Batıoğlu, Figen/0000-0002-5834-7512; DEMIREL, SIBEL/0000-0002-2477-9974;
   Demirel, Sibel/0000-0002-6430-6565
CR Bartlett H, 2010, CLIN EXP OPTOM, V93, P300, DOI 10.1111/j.1444-0938.2010.00499.x
   Beatty S, 2001, INVEST OPHTH VIS SCI, V42, P439
   Berendschot TTJM, 2002, INVEST OPHTH VIS SCI, V43, P1928
   Bland JM, 1996, BRIT MED J, V313, P41, DOI 10.1136/bmj.313.7048.41
   BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8
   Bone RA, 1997, EXP EYE RES, V64, P211, DOI 10.1006/exer.1996.0210
   Bone RA, 2001, INVEST OPHTH VIS SCI, V42, P235
   BONE RA, 1993, INVEST OPHTH VIS SCI, V34, P2033
   Bone RA, 2010, ARCH BIOCHEM BIOPHYS, V504, P50, DOI 10.1016/j.abb.2010.06.019
   Cho EY, 2008, AM J CLIN NUTR, V87, P1837, DOI 10.1093/ajcn/87.6.1837
   Dasch B, 2005, GRAEF ARCH CLIN EXP, V243, P1028, DOI 10.1007/s00417-005-1176-z
   Delori FC, 2001, J OPT SOC AM A, V18, P1212, DOI 10.1364/JOSAA.18.001212
   Demirel S, 2014, GRAEF ARCH CLIN EXP, V252, P213, DOI 10.1007/s00417-013-2424-2
   FERRIS FL, 1983, AM J EPIDEMIOL, V118, P132, DOI 10.1093/oxfordjournals.aje.a113624
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   Hammond BR, 1997, INVEST OPHTH VIS SCI, V38, P1795
   Hammond CJ, 2012, INVEST OPHTH VIS SCI, V53, P4963, DOI 10.1167/iovs.12-9618
   Harwerth RS, 1999, OPTOMETRY VISION SCI, V76, P558, DOI 10.1097/00006324-199908000-00025
   Ho L, 2011, ARCH OPHTHALMOL-CHIC, V129, P758, DOI 10.1001/archophthalmol.2011.141
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kaya S, 2012, ACTA OPHTHALMOL, V90, pe399, DOI 10.1111/j.1755-3768.2012.02423.x
   Kijlstra A, 2012, PROG RETIN EYE RES, V31, P303, DOI 10.1016/j.preteyeres.2012.03.002
   Koh HH, 2004, EXP EYE RES, V79, P21, DOI 10.1016/j.exer.2004.03.001
   Murthy RK, 2014, CUTAN OCUL TOXICOL, V33, P132, DOI 10.3109/15569527.2013.812108
   Obana A, 2008, OPHTHALMOLOGY, V115, P147, DOI 10.1016/j.ophtha.2007.02.028
   Puell MC, 2013, ACTA OPHTHALMOL, V91, pE298, DOI 10.1111/aos.12067
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   Snodderly DM, 2004, INVEST OPHTH VIS SCI, V45, P531, DOI 10.1167/iovs.03-0762
   Tan JSL, 2008, OPHTHALMOLOGY, V115, P334, DOI 10.1016/j.ophtha.2007.03.083
   Trieschmann M, 2008, EYE, V22, P132, DOI 10.1038/sj.eye.6702780
   Trieschmann M, 2003, GRAEF ARCH CLIN EXP, V241, P1006, DOI 10.1007/s00417-003-0796-4
   Tsika C, 2011, ACTA OPHTHALMOL, V89, pE573, DOI 10.1111/j.1755-3768.2011.02170.x
   VandenLangenberg GM, 1998, AM J EPIDEMIOL, V148, P204, DOI 10.1093/oxfordjournals.aje.a009625
   Weir JP, 2005, J STRENGTH COND RES, V19, P231, DOI 10.1519/15184.1
   Yonekawa Y, 2015, J CLIN MED, V4, P343, DOI 10.3390/jcm4020343
   Zele AJ, 2008, OPTOMETRY VISION SCI, V85, P309, DOI 10.1097/OPX.0b013e31816be9e3
   ZHAO J, 1995, INT OPHTHALMOL, V19, P1, DOI 10.1007/BF00156412
NR 38
TC 3
Z9 3
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-5488
EI 1538-9235
J9 OPTOMETRY VISION SCI
JI Optom. Vis. Sci.
PD JUN
PY 2016
VL 93
IS 6
BP 632
EP 639
DI 10.1097/OPX.0000000000000834
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DO5WB
UT WOS:000377852500012
PM 26927521
DA 2022-11-30
ER

PT J
AU Leveziel, N
   Souied, EH
   Richard, F
   Barbu, V
   Zourdani, A
   Morineau, G
   Zerbib, J
   Coscas, G
   Soubrane, G
   Benlian, P
AF Leveziel, Nicolas
   Souied, Eric H.
   Richard, Florence
   Barbu, Veronique
   Zourdani, Alain
   Morineau, Gilles
   Zerbib, Jennyfer
   Coscas, Gabriel
   Soubrane, Gisele
   Benlian, Pascale
TI PLEKHA1-LOC387715-HTRA1 polymorphisms and exudative age-related macular
   degeneration in the French population
SO MOLECULAR VISION
LA English
DT Article
ID COMPLEMENT FACTOR-H; HTRA1 PROMOTER POLYMORPHISM; STARGARDT-DISEASE
   GENE; JAPANESE POPULATION; SUSCEPTIBILITY LOCI; CHROMOSOME 10Q26;
   LINKAGE ANALYSIS; GENOMEWIDE-SCAN; LARGE FAMILY; RISK-FACTORS
AB Purpose: Identification of genetic factors for age-related macular degeneration (AMD) is of crucial importance in this common cause of blindness. Exudative AMD is rapidly progressive and usually associated with severe prognosis. Our purpose was to investigate this association on locus 10q26 in a case-control study including French patients specifically affected with exudative AMD.
   Methods: Polymorphisms rs4146894: G > A of Pleckstrin Homology Domain-containing Protein Family A member 1 (PLEKHA1) gene, rs10490924: G > T at LOC387715, and rs11200638: G > A of HTRA1 (HTRA serine peptidase 1) gene were analysed in AMD cases (n=118, age=72.3 +/- 3.8 years old) and healthy controls (n=116, age=72.0 +/- 3.8 years old).
   Results: PLEKHA1 polymorphism was associated with AMD. The A allele frequency was 0.67 in cases versus 0.41 in controls, (p=0.0001). After age and sex adjustment, the odds ratio for risk of AMD was 9.1 (4.0-20.9, 95% CI, p=0.0001) for the AA genotype and 2.6 (1.3-5.5, 95% CI, p=0.04) for the AG genotype, conditional on HTRA1. Association was even stronger and independent with HTRA1. The A allele frequency was 0.51 in cases versus 0.22 in controls, (p=0.0001). The odds ratio was 15.5 (5.5-43.9, 95% CI, p=0.0001) for the AA genotype and 3.4 (1.9-6.1, 95% CI, p=0.0001) for the AG genotype. No further information was obtained from LOC387715 due to virtually complete linkage disequilibrium with HTRA1 polymorphism in cases (D'=1.0) and controls (D'=0.98). Although a role for PLEKHA1 could not be totally excluded, there was a four times higher AMD risk was associated with haplotype "A-T-A" involving "PLEKHA1-LOC387715- HTRA1" risk alleles.
   Conclusions: Compared to PLEKHA1, HTRA1/LOC387715 genetic variations were independently and strongly associated with exudative AMD in the French population. Chromosome-10 genetic variants appear as potentially useful risk markers for early detection of AMD.
C1 [Leveziel, Nicolas; Souied, Eric H.; Zourdani, Alain; Zerbib, Jennyfer; Coscas, Gabriel; Soubrane, Gisele] Creteil Univ, Eye Clin, Fac Med Henri Mondor, F-94000 Creteil, France.
   [Leveziel, Nicolas; Morineau, Gilles; Benlian, Pascale] Univ Paris 06, Fac Med Pierre & Marie Curie, Paris, France.
   [Leveziel, Nicolas; Morineau, Gilles; Benlian, Pascale] Hop St Antoine, Dept Mol Biol & Biochem, F-75571 Paris, France.
   [Souied, Eric H.; Soubrane, Gisele] Unite Fonct Rech Clin, Creteil, France.
   [Richard, Florence] Inst Pasteur, INSERM, UMR744, F-59019 Lille, France.
   [Richard, Florence] Univ Lille 2, Lille, France.
   [Barbu, Veronique] Univ Paris 06, Hop St Antoine, LCBGM, Paris, France.
C3 Assistance Publique Hopitaux Paris (APHP); Universite
   Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire
   Henri-Mondor - APHP; UDICE-French Research Universities; Sorbonne
   Universite; Assistance Publique Hopitaux Paris (APHP); Hopital
   Universitaire Saint-Antoine - APHP; UDICE-French Research Universities;
   Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP);
   Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire
   Henri-Mondor - APHP; Institut National de la Sante et de la Recherche
   Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP);
   Universite de Lille - ISITE; Institut Pasteur Lille; Universite de
   Lille; Universite de Lille - ISITE; Universite de Lille; Assistance
   Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine -
   APHP; UDICE-French Research Universities; Sorbonne Universite
RP Souied, EH (通讯作者)，Creteil Univ, Eye Clin, Fac Med Henri Mondor, 40 Ave Verdun, F-94000 Creteil, France.
EM eric.souied@chicreteil.fr
OI Nicolas, Leveziel/0000-0001-8533-9457
CR Abecasis GR, 2004, AM J HUM GENET, V74, P482, DOI 10.1086/382786
   Allikmets R, 2000, AM J HUM GENET, V67, P487, DOI 10.1086/303018
   Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Cameron DJ, 2007, CELL CYCLE, V6, P1122, DOI 10.4161/cc.6.9.4157
   Chien J, 2006, J CLIN INVEST, V116, P1994, DOI 10.1172/JCI27698
   Conley YP, 2005, HUM MOL GENET, V14, P1991, DOI 10.1093/hmg/ddi204
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Dowler S, 2000, BIOCHEM J, V351, P19, DOI 10.1042/0264-6021:3510019
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fisher SA, 2005, HUM MOL GENET, V14, P2257, DOI 10.1093/hmg/ddi230
   Franke TF, 2003, ONCOGENE, V22, P8983, DOI 10.1038/sj.onc.1207115
   GOLDBERG J, 1988, AM J EPIDEMIOL, V128, P700, DOI 10.1093/oxfordjournals.aje.a115023
   Golden RM, 2000, J MATH PSYCHOL, V44, P153, DOI 10.1006/jmps.1999.1281
   Grau S, 2006, J BIOL CHEM, V281, P6124, DOI 10.1074/jbc.M500361200
   Guymer RH, 2001, ARCH OPHTHALMOL-CHIC, V119, P745, DOI 10.1001/archopht.119.5.745
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Iyengar SK, 2004, AM J HUM GENET, V74, P20, DOI 10.1086/380912
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Kenealy SJ, 2004, MOL VIS, V10, P57
   KLAVER CC, 1998, AM J HUM GENET, V63, P1252
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Klein ML, 1998, ARCH OPHTHALMOL-CHIC, V116, P1082, DOI 10.1001/archopht.116.8.1082
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Marshall AJ, 2002, MOL CELL BIOL, V22, P5479, DOI 10.1128/MCB.22.15.5479-5491.2002
   Oka C, 2004, DEVELOPMENT, V131, P1041, DOI 10.1242/dev.00999
   Okamoto H, 2006, MOL VIS, V12, P156
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P55, DOI 10.1001/archopht.125.1.55
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Schmidt S, 2004, BMC GENET, V5, DOI 10.1186/1471-2156-5-18
   Schultz DW, 2003, HUM MOL GENET, V12, P3315, DOI 10.1093/hmg/ddg348
   Seddom JM, 2007, JAMA-J AM MED ASSOC, V297, P2585
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Seddon JM, 2006, HUM HERED, V61, P157, DOI 10.1159/000094141
   Shuler RK, 2007, ARCH OPHTHALMOL-CHIC, V125, P63, DOI 10.1001/archopht.125.1.63
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   Souied EH, 2005, MOL VIS, V11, P1135
   SPERDUTO RD, 1986, ARCH OPHTHALMOL-CHIC, V104, P216
   Stone EM, 2004, NEW ENGL J MED, V351, P346, DOI 10.1056/NEJMoa040833
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Tregouet DA, 2004, ANN HUM GENET, V68, P165, DOI 10.1046/j.1529-8817.2003.00085.x
   Tregouet DA, 2002, HUM MOL GENET, V11, P2015, DOI 10.1093/hmg/11.17.2015
   Uka J, 2006, RETINA-J RET VIT DIS, V26, P985, DOI 10.1097/01.iae.0000244068.18520.3e
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
   Weeks DE, 2004, AM J HUM GENET, V75, P174, DOI 10.1086/422476
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yoshida T, 2007, MOL VIS, V13, P545
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
   Zumbrunn J, 1996, FEBS LETT, V398, P187, DOI 10.1016/S0014-5793(96)01229-X
NR 58
TC 44
Z9 47
U1 0
U2 5
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD NOV 26
PY 2007
VL 13
IS 242-45
BP 2153
EP 2159
PG 7
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA 310QW
UT WOS:000256546100004
PM 18079691
DA 2022-11-30
ER

PT J
AU Coscas, F
   Cabral, D
   Pereira, T
   Geraldes, C
   Narotamo, H
   Miere, A
   Lupidi, M
   Sellam, A
   Papoila, A
   Coscas, G
   Souied, E
AF Coscas, Florence
   Cabral, Diogo
   Pereira, Telmo
   Geraldes, Carlos
   Narotamo, Hemaxi
   Miere, Alexandra
   Lupidi, Marco
   Sellam, Alexandre
   Papoila, Ana
   Coscas, Gabriel
   Souied, Eric
TI Quantitative optical coherence tomography angiography biomarkers for
   neovascular age-related macular degeneration in remission
SO PLOS ONE
LA English
DT Article
ID CHOROIDAL NEOVASCULARIZATION; SWEPT-SOURCE; RANIBIZUMAB; LACUNARITY;
   GUIDELINES; THERAPY
AB Purpose
   To characterize quantitative optical coherence tomography angiography (OCT-A) parameters in active neovascular age-related macular degeneration (nAMD) patients under treatment and remission nAMD patients.
   Design
   Retrospective, cross-sectional study.
   Participants
   One hundred and four patients of whom 72 were in Group 1 (active nAMD) and 32 in Group 2 (remission nAMD) based on SD-OCT (Spectral Domain OCT) qualitative morphology.
   Methods
   This study was conducted at the Centre Ophtalmologique de l'Odeon between June 2016 and December 2017. Eyes were analyzed using SD-OCT and high-speed (100 000 Ascans/second) 1050-nm wavelength swept-source OCT-A. Speckle noise removal and choroidal neovascularization (CNV) blood flow delineation were automatically performed. Quantitative parameters analyzed included blood flow area (Area), vessel density, fractal dimension (FD) and lacunarity. OCT-A image algorithms and graphical user interfaces were built as a unified tool in Matlab coding language. Generalized Additive Models were used to study the association between OCT-A parameters and nAMD remission on structural OCT. The models' performance was assessed by the Akaike Information Criterion (AIC), Brier Score and by the area under the receiver operating characteristic curve (AUC). A p value of <= 0.05 was considered as statistically significant.
   Results
   Area, vessel density and FD were different (p<0.001) in the two groups. Regarding the association with CNV activity, Area alone had the highest AUC (AUC = 0.85; 95% CI: 0.77-0.93) followed by FD (AUC = 0.80; 95% CI: 0.71-0.88). Again, Area obtained the best values followed by FD in the AIC and Brier Score evaluations. The multivariate model that included both these variables attained the best performance considering all assessment criteria.
   Conclusions
   Blood flow characteristics on OCT-A may be associated with exudative signs on structural OCT. In the future, analyses of OCT-A quantitative parameters could potentially help evaluate CNV activity status and to develop personalized treatment and follow-up cycles.
C1 [Coscas, Florence; Cabral, Diogo; Coscas, Gabriel] Ctr Ophtalmol Odeon, Paris, France.
   [Coscas, Florence; Miere, Alexandra; Coscas, Gabriel; Souied, Eric] Creteil Univ Paris Est Creteil XIl, Ctr Hosp Intercommunal, Dept Ophthalmol, Creteil, France.
   [Cabral, Diogo; Pereira, Telmo; Geraldes, Carlos; Papoila, Ana] Univ Nova Lisboa, Fac Ciencias Med, NOVA Med Sch, Lisbon, Portugal.
   [Cabral, Diogo; Pereira, Telmo; Narotamo, Hemaxi] Univ Nova Lisboa, Chron Dis Res Ctr, CEDOC, Lisbon, Portugal.
   [Cabral, Diogo] Inst Oftalmol Dr Gama Pinto, Lisbon, Portugal.
   [Geraldes, Carlos; Papoila, Ana] Univ Lisbon, Ctr Estat & Aplicacoes, CEAUL, Lisbon, Portugal.
   [Lupidi, Marco] Univ Perugia, S Maria Misericordia Hosp, Dept Biomed & Surg Sci, Sect Ophthalmol, Perugia, Italy.
   [Sellam, Alexandre] Sorbonne Univ, Fac Med, Quinze Vingts Natl Eye Hosp, Paris, France.
C3 Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil;
   Universidade Nova de Lisboa; Universidade Nova de Lisboa; Universidade
   de Lisboa; University of Perugia; CHNO des Quinze-Vingts; UDICE-French
   Research Universities; Sorbonne Universite; Universite de Franche-Comte
RP Cabral, D (通讯作者)，Ctr Ophtalmol Odeon, Paris, France.; Cabral, D (通讯作者)，Univ Nova Lisboa, Fac Ciencias Med, NOVA Med Sch, Lisbon, Portugal.; Cabral, D (通讯作者)，Univ Nova Lisboa, Chron Dis Res Ctr, CEDOC, Lisbon, Portugal.; Cabral, D (通讯作者)，Inst Oftalmol Dr Gama Pinto, Lisbon, Portugal.
EM diogo.cabral@nms.unl.pt
RI Geraldes, Carlos/A-4358-2019; Miere, Alexandra/AIC-4074-2022; Cabral,
   Diogo/AAG-3865-2019; Papoila, Ana/S-2164-2019
OI Geraldes, Carlos/0000-0002-1551-6531; Miere,
   Alexandra/0000-0003-4123-8210; Cabral, Diogo/0000-0003-1968-3561;
   Papoila, Ana/0000-0002-2918-8364; Pereira, Telmo/0000-0002-6903-9187;
   Lupidi, Marco/0000-0002-6817-2488; Narotamo, Hemaxi/0000-0003-1933-4273
CR al Sharaa M, 2017, NATO SCI PEACE SEC, V138, P1, DOI 10.3233/978-1-61499-802-0-1
   Al-Sheikh M, 2017, OSLI RETINA, V48, P385, DOI 10.3928/23258160-20170428-04
   Amoroso F, 2018, BRIT J OPHTHALMOL, V102, P821, DOI 10.1136/bjophthalmol-2017-310569
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Coscas GJ, 2015, RETINA-J RET VIT DIS, V35, P2219, DOI 10.1097/IAE.0000000000000766
   Costanzo E, 2016, INVEST OPHTH VIS SCI, V57, pOCT307, DOI 10.1167/iovs.15-18830
   Dutheil C, 2018, EUR J OPHTHALMOL
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Gess AJ, 2011, SEMIN OPHTHALMOL, V26, P225, DOI 10.3109/08820538.2011.582533
   Guidolin D, 2004, LEUKEMIA, V18, P1745, DOI 10.1038/sj.leu.2403526
   Hastie T, 1990, CHAPMAN HALL CRC MON, DOI [10.1093/jncimonographs/lgu023, DOI 10.1093/JNCIMONOGRAPHS/LGU023]
   Ho AC, 2014, OPHTHALMOLOGY, V121, P2181, DOI 10.1016/j.ophtha.2014.05.009
   Inoue M, 2016, INVEST OPHTH VIS SCI, V57, pOCT314, DOI 10.1167/iovs.15-18900
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1435, DOI 10.1016/j.ophtha.2014.01.034
   Jung JJ, 2014, AM J OPHTHALMOL, V158, P769, DOI 10.1016/j.ajo.2014.07.006
   Masters BR, 2004, ANNU REV BIOMED ENG, V6, P427, DOI 10.1146/annurev.bioeng.6.040803.140100
   Miere A, 2019, RETINA-J RET VIT DIS, V39, P548, DOI 10.1097/IAE.0000000000001964
   Miere A, 2018, J OPHTHALMOL, V2018, DOI 10.1155/2018/3751702
   Muakkassa NW, 2015, RETINA-J RET VIT DIS, V35, P2252, DOI 10.1097/IAE.0000000000000836
   Munk MR, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177059
   Phansalkar Neerad, 2011, 2011 International Conference on Communications and Signal Processing (ICCSP), P218, DOI 10.1109/ICCSP.2011.5739305
   Roberts PK, 2017, RETINA-J RET VIT DIS, V37, P1492, DOI 10.1097/IAE.0000000000001400
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Smith TG, 1996, J NEUROSCI METH, V69, P123, DOI 10.1016/S0165-0270(96)00080-5
   Spaide RF, 2017, RETINA-J RET VIT DIS, V37, P609, DOI 10.1097/IAE.0000000000001575
   Spaide RF, 2015, AM J OPHTHALMOL, V160, P6, DOI 10.1016/j.ajo.2015.04.012
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   Team RC, 2013, R LANG ENV STAT COMP
   Tolle CR, 2008, PHYSICA D, V237, P306, DOI 10.1016/j.physd.2007.09.017
   Xu D, 2018, AM J OPHTHALMOL, V187, P10, DOI 10.1016/j.ajo.2017.12.005
   Zhang QQ, 2017, OPHTHALMOL RETINA, V1, P124, DOI 10.1016/j.oret.2016.08.005
   Zheng F, 2017, INVEST OPHTH VIS SCI, V58, P5098, DOI 10.1167/iovs.17-22506
NR 33
TC 29
Z9 30
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 9
PY 2018
VL 13
IS 10
AR e0205513
DI 10.1371/journal.pone.0205513
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA GW4OW
UT WOS:000446897200072
PM 30300393
OA gold, Green Submitted, Green Published
DA 2022-11-30
ER

PT J
AU Schachar, IH
   Zahid, S
   Comer, GM
   Stem, M
   Schachar, AG
   Saxe, SJ
   Gardner, TW
   Elner, VM
   Jayasundera, T
AF Schachar, Ira H.
   Zahid, Sarwar
   Comer, Grant M.
   Stem, Maxwell
   Schachar, Asa G.
   Saxe, Stephen J.
   Gardner, Thomas W.
   Elner, Victor M.
   Jayasundera, Thiran
TI Quantification of Fundus Autofluorescence to Detect Disease Severity in
   Nonexudative Age-Related Macular Degeneration
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID GEOGRAPHIC ATROPHY; OCULAR FUNDUS
AB IMPORTANCE Accurate assessment of disease burden and determination of disease progression are challenging in dry age-related macular degeneration (AMD). We assessed the utility of quantified fundus autofluorescence in (FAF) the evaluation and follow-up of dry AMD.
   OBJECTIVE To develop a method for quantitative FAF image analysis that is capable of stratifying severity of nonexudative AMD.
   DESIGN, SETTING, AND PARTICIPANTS A retrospective analysis from 2008 to 2012 at a university eye center of FAF images taken of normal and nonexudative AMD eyes compared the Index of Retinal Autofluorescence (IRA) with retinal specialists' clinical rankings of FAF images and the Age-Related Eye Disease Study (AREDS) grading scheme of corresponding color fundus photographs.
   INTERVENTION Digital files of Heidelberg Spectralis FAF images taken of normal and nonexudative AMD eyes were analyzed. For each image, a unique horizontally oriented FAF signature composed of vertically averaged gray-scale values was generated through the fovea. A pairwise comparison of 2 signatures was performed using a modified difference of squares method, which generated a single quantitative value, the IRA.
   MAIN OUTCOMES AND MEASURES The effects of intersession testing, cataract extraction, pupillary dilation, focal plane, and gain settings on the IRA were assessed.
   RESULTS The FAF images taken of the same subjects at different times demonstrated low intersession variability of the IRA (intraclass coefficient = 0.75; 95% CI, 0.45-0.92). The IRA was affected by cataract severity, cataract extraction, small pupillary diameters (<5.5 mm), defocusing, and excessive high or low camera gain. The IRA values correlated with both subjective clinical rankings by retinal specialists (r(s) = 0.77). The IRA was positively correlated with AREDS score (r(s) = 0.73) and could statistically distinguish AREDS grades 3 and 4 (P < .001). Serial imaging demonstrated the utility of the method for identifying clinically meaningful disease progression.
   CONCLUSIONS AND RELEVANCE The IRA method applied to FAF digital files can quantify AMD disease severity and may be helpful in identifying AMD progression.
C1 [Schachar, Ira H.; Zahid, Sarwar; Comer, Grant M.; Stem, Maxwell; Schachar, Asa G.; Saxe, Stephen J.; Gardner, Thomas W.; Elner, Victor M.; Jayasundera, Thiran] Univ Michigan, Kellogg Eye Ctr, Dept Ophthalmol & Visual Sci, Ann Arbor, MI 48105 USA.
C3 University of Michigan System; University of Michigan
RP Elner, VM (通讯作者)，Univ Michigan, Kellogg Eye Ctr, 1000 Wall St, Ann Arbor, MI 48105 USA.
EM velner@umich.edu
OI Gardner, Thomas/0000-0002-5112-5810; Jayasundera,
   Kanishka/0000-0003-4895-4818; Elner, Victor/0000-0001-7708-1898
FU Fight for Sight; Physician Scientist Award from Research to Prevent
   Blindness
FX Financial support from Fight for Sight is gratefully acknowledged. Dr
   Gardner is supported by a Physician Scientist Award from Research to
   Prevent Blindness and a Taubman Scholar.
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Bearelly S, 2011, RETINA-J RET VIT DIS, V31, P81, DOI 10.1097/IAE.0b013e3181e0958b
   Bearelly S, 2010, ADV EXP MED BIOL, V664, P395, DOI 10.1007/978-1-4419-1399-9_45
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Delori FC, 2000, INVEST OPHTH VIS SCI, V41, P496
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   Delori F, 2011, INVEST OPHTH VIS SCI, V52, P9379, DOI 10.1167/iovs.11-8319
   DOREY CK, 1989, INVEST OPHTH VIS SCI, V30, P1691
   Gobel AP, 2011, OPHTHALMOLOGICA, V226, P182, DOI 10.1159/000330420
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   Hwang JC, 2006, INVEST OPHTH VIS SCI, V47, P2655, DOI 10.1167/iovs.05-1027
   Issa PC, 2012, INVEST OPHTH VIS SCI, V53, P1066, DOI 10.1167/iovs.11-8767
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Schmitz-Valckenberg S, 2008, RETINA-J RET VIT DIS, V28, P385, DOI 10.1097/IAE.0b013e318164a907
   Schmitz-Valckenberg S, 2006, INVEST OPHTH VIS SCI, V47, P2648, DOI 10.1167/iovs.05-0892
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P7640, DOI 10.1167/iovs.11-7457
   Sunness JS, 1999, INVEST OPHTH VIS SCI, V40, P1761
   vonRuckmann A, 1997, ARCH OPHTHALMOL-CHIC, V115, P609, DOI 10.1001/archopht.1997.01100150611006
NR 18
TC 7
Z9 7
U1 0
U2 10
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD AUG
PY 2013
VL 131
IS 8
BP 1009
EP 1015
DI 10.1001/jamaophthalmol.2013.4014
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 206WD
UT WOS:000323554700006
PM 23787960
OA Bronze
DA 2022-11-30
ER

PT J
AU Steinberg, JS
   Fitzke, FW
   Fimmers, R
   Fleckenstein, M
   Holz, FG
   Schmitz-Valckenberg, S
AF Steinberg, Julia S.
   Fitzke, Fred W.
   Fimmers, Rolf
   Fleckenstein, Monika
   Holz, Frank G.
   Schmitz-Valckenberg, Steffen
TI Scotopic and Photopic Microperimetry in Patients With Reticular Drusen
   and Age-Related Macular Degeneration
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID TEST-RETEST VARIABILITY; GEOGRAPHIC-ATROPHY; FUNDUS AUTOFLUORESCENCE;
   RETINAL SENSITIVITY; DARK-ADAPTATION; RISK-FACTOR; PSEUDODRUSEN; EYES;
   DEPOSITS; MACULOPATHY
AB IMPORTANCE Clinical observations suggest that patients with age-related macular degeneration (AMD) have vision problems, particularly in dim light conditions. Previous studies on structural-functional analysis in patients with AMD with reticular drusen (RDR) have focused on photopic sensitivity testing but have not specifically assessed scotopic function.
   OBJECTIVE To evaluate retinal function by scotopic and photopic microperimetry in patients with AMD and a well-demarcated area of RDR.
   DESIGN, SETTING, AND PARTICIPANTS Prospective case series in a referral center of 22 eyes from 18 patients (mean age, 74.7 years; range, 62-87 years). The study was conducted from June 1, 2014, to October 31, 2014.
   INTERVENTIONS With the use of combined confocal scanning laser ophthalmoscopy and spectral-domain optical coherence tomography imaging, retinal areas with RDR (category 1) and no visible pathologic alterations (category 2) were identified in each eye. Scotopic and photopic microperimetry (MP-1S; Nidek Technologies) was performed using a grid with 56 stimulus points.
   MAIN OUTCOMES AND MEASURES Comparison of mean threshold sensitivities for each category for scotopic and photopic microperimetry.
   RESULTS In all eyes, areas of category 1 showed a relative and sharply demarcated reduction of scotopic threshold values compared with areas of category 2, but only less-pronounced differences were seen for photopic testing. Statistical analysis in the 18 eyes in which the 1.0-log unit neutral density filter was applied revealed a difference of scotopic threshold values in areas of category 1 (mean, 13.5 dB [95% CI, 12.1-15.0]) vs category 2 (mean, 18.3 dB; [95% CI, 17.4-19.3] (P <= .001). For photopic testing, the mean threshold values were 16.8 dB (95% CI, 15.5-18.2) in category 1 and 18.4 dB (95% CI, 17.1-19.6) in category 2 (P = .03).
   CONCLUSIONS AND RELEVANCE The results of this study suggest that rod function is more severely affected than cone function in retinal areas with RDR. This differential structural-functional correlation underscores the functional relevance of RDR in patients with AMD.
C1 [Steinberg, Julia S.; Fleckenstein, Monika; Holz, Frank G.; Schmitz-Valckenberg, Steffen] Univ Bonn, Dept Ophthalmol, D-53127 Bonn, Germany.
   [Fitzke, Fred W.] UCL, Inst Ophthalmol, London, England.
   [Fimmers, Rolf] Univ Bonn, Inst Biostat, D-53127 Bonn, Germany.
C3 University of Bonn; University of London; University College London;
   University of Bonn
RP Schmitz-Valckenberg, S (通讯作者)，Univ Bonn, Dept Ophthalmol, Ernst Abbe Str 2, D-53127 Bonn, Germany.
EM steffen.schmitz-valckenberg@ukb.uni-bonn.de
OI Fleckenstein, Monika/0000-0001-8321-8037
FU Heidelberg Engineering; Getrud Kusen Foundation; Optos
FX All authors have completed and submitted the ICMJE Form for Disclosure
   of Potential Conflicts of Interest. The Department of Ophthalmology,
   University of Bonn has received nonfinancial support for the supply of
   technical equipment from several imaging device manufacturers, including
   Heidelberg Engineering, Optos, and Zeiss MedTec. In addition, Drs
   Fleckenstein, Holz, and Schmitz-Valckenberg have received personal fees
   and honoraria from Heidelberg Engineering and Optos for consulting and
   lectures, and Dr Steinberg has received a personal fellowship from the
   Getrud Kusen Foundation. No other disclosures were reported.
CR ALEXANDER KR, 1984, BRIT J OPHTHALMOL, V68, P561, DOI 10.1136/bjo.68.8.561
   Alten F, 2014, INVEST OPHTH VIS SCI, V55, P6073, DOI 10.1167/iovs.13-13804
   Alten F, 2012, RETINA-J RET VIT DIS, V32, P1727, DOI 10.1097/IAE.0b013e3182475b03
   Alten F, 2012, INVEST OPHTH VIS SCI, V53, P6263, DOI 10.1167/iovs.12-10094
   ARNOLD JJ, 1995, RETINA-J RET VIT DIS, V15, P183, DOI 10.1097/00006982-199515030-00001
   Auge J, 2014, OPHTHALMOLOGE, V111, P765, DOI 10.1007/s00347-013-2965-0
   BROWN B, 1983, AM J OPTOM PHYS OPT, V60, P645
   Chen FK, 2009, INVEST OPHTH VIS SCI, V50, P3464, DOI 10.1167/iovs.08-2926
   Crossland MD, 2011, BMC OPHTHALMOL, V11, DOI 10.1186/1471-2415-11-5
   Curcio CA, 2001, EYE, V15, P376, DOI 10.1038/eye.2001.140
   CURCIO CA, 1993, INVEST OPHTH VIS SCI, V34, P3278
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Finger RP, 2014, OPHTHALMOLOGY, V121, P1252, DOI 10.1016/j.ophtha.2013.12.034
   Fleckenstein M, 2008, INVEST OPHTH VIS SCI, V49, P4137, DOI 10.1167/iovs.08-1967
   Forte R, 2014, OPHTHALMIC RES, V51, P32, DOI 10.1159/000354117
   Guymer RH, 1997, ARCH OPHTHALMOL-CHIC, V115, P595, DOI 10.1001/archopht.1997.01100150597004
   Iwama D, 2010, CLIN EXP OPHTHALMOL, V38, P483, DOI 10.1111/j.1442-9071.2010.02294.x
   Jackson GR, 1998, VISION RES, V38, P3655, DOI 10.1016/S0042-6989(98)00044-3
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Lois N, 2002, AM J OPHTHALMOL, V133, P341, DOI 10.1016/S0002-9394(01)01404-0
   Marmor MF, 2004, DOC OPHTHALMOL, V108, P107, DOI 10.1023/B:DOOP.0000036793.44912.45
   Midena E, 2007, BRIT J OPHTHALMOL, V91, P1499, DOI 10.1136/bjo.2007.119685
   MIMOUN G, 1990, J FR OPHTALMOL, V13, P511
   Ooto S, 2013, AM J OPHTHALMOL, V156, P1184, DOI 10.1016/j.ajo.2013.06.036
   Parisi V, 2007, RETINA-J RET VIT DIS, V27, P879, DOI 10.1097/IAE.0b013e318042d6aa
   Pumariega NM, 2011, OPHTHALMOLOGY, V118, P1619, DOI 10.1016/j.ophtha.2011.01.029
   Querques G, 2014, RETINA-J RET VIT DIS, V34, P321, DOI 10.1097/IAE.0b013e3182993df1
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P1264, DOI 10.1167/iovs.11-9063
   Sarks J, 2011, BRIT J OPHTHALMOL, V95, P979, DOI 10.1136/bjo.2010.194977
   Schmitz-Valckenberg S, 2004, INVEST OPHTH VIS SCI, V45, P4470, DOI 10.1167/iovs.03-1311
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P5009, DOI 10.1167/iovs.11-7235
   Schmitz-Valckenberg S, 2010, OPHTHALMOLOGY, V117, P1169, DOI 10.1016/j.ophtha.2009.10.044
   Scholl HPN, 2004, INVEST OPHTH VIS SCI, V45, P574, DOI 10.1167/iovs.03-0495
   SLOAN LL, 1969, DOC OPHTHALMOL, V26, P384, DOI 10.1007/BF00943999
   Smith RT, 2009, AM J OPHTHALMOL, V148, P733, DOI 10.1016/j.ajo.2009.06.028
   Sohrab MA, 2011, INVEST OPHTH VIS SCI, V52, P5743, DOI 10.1167/iovs.10-6942
   Spaide RF, 2013, RETINA-J RET VIT DIS, V33, P1800, DOI 10.1097/IAE.0b013e31829c3765
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1441, DOI 10.1097/IAE.0b013e3181ee5ce8
   Steinberg JS, 2014, ASS RES VIS OPHTH MA
   Steinberg JS, 2013, INVEST OPHTH VIS SCI, V54, P4054, DOI 10.1167/iovs.12-11538
   Sunness J S, 1998, Geriatrics, V53, P70
   SUNNESS JS, 1985, ARCH OPHTHALMOL-CHIC, V103, P811
   SUNNESS JS, 1988, ARCH OPHTHALMOL-CHIC, V106, P1081, DOI 10.1001/archopht.1988.01060140237032
   Sunness JS, 1997, OPHTHALMOLOGY, V104, P1677, DOI 10.1016/S0161-6420(97)30079-7
   Sunness JS., 1998, GERIATRICS, V53, P77
   Wu ZC, 2013, INVEST OPHTH VIS SCI, V54, P7378, DOI 10.1167/iovs.13-12617
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 48
TC 65
Z9 66
U1 1
U2 9
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD JUN
PY 2015
VL 133
IS 6
BP 690
EP 697
DI 10.1001/jamaophthalmol.2015.0477
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CK2MI
UT WOS:000356044400020
PM 25811917
OA Bronze
DA 2022-11-30
ER

PT J
AU O'Connell, ED
   Nolan, JM
   Stack, J
   Greenberg, D
   Kyle, J
   Maddock, L
   Beatty, S
AF O'Connell, Eamonn D.
   Nolan, John M.
   Stack, Jim
   Greenberg, David
   Kyle, Janet
   Maddock, LeighAnne
   Beatty, Stephen
TI Diet and risk factors for age-related maculopathy
SO AMERICAN JOURNAL OF CLINICAL NUTRITION
LA English
DT Article
DE age-related macular degeneration; age-related maculopathy; antioxidants;
   lutein; n-3 fatty acids; zeaxanthin
ID BEAVER DAM EYE; FOOD-FREQUENCY QUESTIONNAIRE; BLUE-MOUNTAINS EYE;
   NUTRITION EXAMINATION SURVEY; SENILE MACULAR DEGENERATION; PIGMENT
   OPTICAL-DENSITY; 3RD NATIONAL-HEALTH; 5-YEAR INCIDENCE; JAPANESE
   POPULATION; SEASONAL-VARIATION
AB Background: Evidence continues to accumulate that oxidative stress is etiologically important in the pathogenesis of age-related maculopathy (ARM) and that appropriate antioxidants of dietary origin may protect against this condition.
   Objective: Risk factors for ARM may be classed as established or putative. We report a study designed to investigate whether such risk factors are associated with a dietary lack of antioxidants relevant to retinal health.
   Design: Dietary, anthropometric, and sociodemographic details relating to 828 healthy Irish subjects aged 20-60 y were recorded in a cross-sectional fashion and analyzed for associations between risk factors for ARM and dietary intake of relevant nutrients.
   Results: Of the established risk factors for ARM, increasing age was associated with a relative lack of dietary zeaxanthin (P < 0.05) and tobacco use with a relative lack of dietary vitamin C (P < 0.05). Of the putative risk factors for ARM, alcohol consumption was associated with a relative lack of dietary a-linoleic acid (P < 0.05), and female sex was associated with a relative lack of dietary zinc (P < 0.05).
   Conclusions: We showed that several variables related to risk for ARM are associated with a relative dietary lack of key nutrients. Our finding that age, the most important and universal risk factor for ARM, is associated with a relative lack of dietary zeaxanthin, is an important finding that warrants further investigation.
C1 [O'Connell, Eamonn D.; Beatty, Stephen] Waterford Reg Hosp, Dept Ophthalmol, Waterford, Ireland.
   [O'Connell, Eamonn D.; Nolan, John M.; Maddock, LeighAnne; Beatty, Stephen] Waterford Inst Technol, Dept Chem & Life Sci, Macular Pigment Res Grp, Waterford, Ireland.
   [Stack, Jim] Waterford Inst Technol, Dept Phys & Quantitat Sci, Waterford, Ireland.
   [O'Connell, Eamonn D.] Univ Coll Dublin, Dept Anat, Dublin 2, Ireland.
   [Greenberg, David] MRC Human Nutr Res, Cambridge, England.
   [Kyle, Janet] Univ Aberdeen, Dept Environm & Occupat Med, Scottish Collaborat Grp, Aberdeen, Scotland.
C3 South East Technological University (SETU); South East Technological
   University (SETU); University College Dublin; UK Research & Innovation
   (UKRI); Medical Research Council UK (MRC); MRC Human Nutrition Research;
   University of Aberdeen
RP O'Connell, ED (通讯作者)，Waterford Reg Hosp, Dept Ophthalmol, Waterford, Ireland.
EM dreamonnoconnell@iolfree.ie
RI Nolan, John/N-4921-2014
OI Nolan, John/0000-0002-5503-7084
FU MRC [MC_U105960384] Funding Source: UKRI; Medical Research Council
   [MC_U105960384] Funding Source: Medline
CR *AG REL EYE DIS ST, 2000, OPHTHALMOLOGY, V107, P2224
   Ambrose JA, 2004, J AM COLL CARDIOL, V43, P1731, DOI 10.1016/j.jacc.2003.12.047
   Beatty S, 1999, BRIT J OPHTHALMOL, V83, P867, DOI 10.1136/bjo.83.7.867
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bodner CH, 1998, J HUM NUTR DIET, V11, P373, DOI 10.1046/j.1365-277X.1998.00119.x
   BOLTONSMITH C, 1991, BRIT J NUTR, V65, P337, DOI 10.1079/BJN19910094
   CANTILENA LR, 1992, AM J CLIN NUTR, V55, P659, DOI 10.1093/ajcn/55.3.659
   Chiu CJ, 2006, AM J CLIN NUTR, V83, P880, DOI 10.1093/ajcn/83.4.880
   Dallongeville J, 1998, J NUTR, V128, P1450
   Delcourt C, 1998, ARCH OPHTHALMOL-CHIC, V116, P1031, DOI 10.1001/archopht.116.8.1031
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   Deli J, 2001, J AGR FOOD CHEM, V49, P1517, DOI 10.1021/jf000958d
   Eong KGA, 2002, AGE-RELATED MACULAR DEGENERATION, P355
   Flood V, 2002, OPHTHALMOLOGY, V109, P2272, DOI 10.1016/S0161-6420(02)01263-0
   Gale CR, 2003, INVEST OPHTH VIS SCI, V44, P2461, DOI 10.1167/iovs.02-0929
   HALLFRISCH J, 1990, J GERONTOL, V45, pM186, DOI 10.1093/geronj/45.6.M186
   HOLZ FG, 1994, AM J OPHTHALMOL, V117, P19, DOI 10.1016/S0002-9394(14)73010-7
   Hornero-Mendez D, 2000, J AGR FOOD CHEM, V48, P3857, DOI 10.1021/jf991020r
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   JARVINEN R, 1994, J EPIDEMIOL COMMUN H, V48, P549, DOI 10.1136/jech.48.6.549
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KLEIN R, 1993, AM J EPIDEMIOL, V137, P190, DOI 10.1093/oxfordjournals.aje.a116659
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1995, OPHTHALMOLOGY, V102, P371
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Ma J, 2000, AM J CLIN NUTR, V71, P774, DOI 10.1093/ajcn/71.3.774
   Mares-Perlman JA, 2001, AM J EPIDEMIOL, V153, P424, DOI 10.1093/aje/153.5.424
   Masson LF, 2003, PUBLIC HEALTH NUTR, V6, P313, DOI 10.1079/PHN2002429
   Mellerio J, 2002, CURR EYE RES, V25, P37, DOI 10.1076/ceyr.25.1.37.9961
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Miyazaki M, 2005, INVEST OPHTH VIS SCI, V46, P1907, DOI 10.1167/iovs.04-0923
   Miyazaki M, 2003, BRIT J OPHTHALMOL, V87, P469, DOI 10.1136/bjo.87.4.469
   Moros EE, 2002, J AGR FOOD CHEM, V50, P5787, DOI 10.1021/jf020109l
   NEELAM K, 2006, NUTR EYE PRACTICAL A, P73
   New SA, 1997, AM J CLIN NUTR, V65, P1831, DOI 10.1093/ajcn/65.6.1831
   NEW SA, 1993, P NUTR SOC, V52, P330
   Newsome DA, 1995, J TRACE ELEM EXP MED, V8, P193
   Nolan JM, 2006, CURR EYE RES, V31, P199, DOI 10.1080/02713680500514677
   Nolan JM, 2007, INVEST OPHTH VIS SCI, V48, P571, DOI 10.1167/iovs.06-0864
   O'Connell E, 2006, ANN ACAD MED SINGAP, V35, P821
   *PAN DIET ANT REL, 2001, DIET REF INT VIT A V
   Panel on Dietary Antioxidants and Related Compounds Subcommittee on Upper Reference Levels of Nutrients Food and Nutrition Board-USA Institute of Medicine, 2000, DIET REF INT VIT C V
   Phillips ELR, 2000, ANN EPIDEMIOL, V10, P417, DOI 10.1016/S1047-2797(00)00064-8
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Smith W, 1996, ARCH OPHTHALMOL-CHIC, V114, P1518, DOI 10.1001/archopht.1996.01100140716016
   Snellen ELM, 2002, ACTA OPHTHALMOL SCAN, V80, P368, DOI 10.1034/j.1600-0420.2002.800404.x
   Sommerburg O, 1998, BRIT J OPHTHALMOL, V82, P907, DOI 10.1136/bjo.82.8.907
   SPERDUTO RD, 1993, ARCH OPHTHALMOL-CHIC, V111, P104
   SPERDUTO RD, 1980, AM J OPHTHALMOL, V90, P86, DOI 10.1016/S0002-9394(14)75081-0
   Strategic Task Force on Alcohol, 2004, STRAT TASK FORC ALC
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   TUCKER MA, 1985, NEW ENGL J MED, V313, P789, DOI 10.1056/NEJM198509263131305
   VandenLangenberg GM, 1998, AM J EPIDEMIOL, V148, P204, DOI 10.1093/oxfordjournals.aje.a009625
   Vellas BJ, 1997, NUTRITION, V13, P515, DOI 10.1016/S0899-9007(97)00029-4
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Vingerling JR, 1996, ARCH OPHTHALMOL-CHIC, V114, P1193, DOI 10.1001/archopht.1996.01100140393005
   Wei W, 2001, AM J PUBLIC HEALTH, V91, P258, DOI 10.2105/AJPH.91.2.258
   WEITER JJ, 1985, AM J OPHTHALMOL, V99, P185, DOI 10.1016/0002-9394(85)90230-2
   WILLET WC, 2006, ISSUES ANAL PRESENTA
   Willett W., 2012, NUTR EPIDEMIOLOGY, DOI [DOI 10.1093/ACPROF:OSO/9780195122978.003.11, 10.1093/acprof:oso/9780195122978.001.0001, DOI 10.1093/ACPROF:OSO/9780195122978.001.0001]
   Willett W., 2013, NUTR EPIDEMIOLOGY, V3rd
   WILLETT WC, 1983, AM J CLIN NUTR, V38, P631, DOI 10.1093/ajcn/38.4.631
   WILLETT WC, 1994, AM J CLIN NUTR S, V59, P171
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   Yuzawa M, 1997, INT OPHTHALMOL, V21, P1, DOI 10.1023/A:1005845521424
   ZIEGLER RG, 1987, AM J CLIN NUTR, V45, P107, DOI 10.1093/ajcn/45.1.107
NR 68
TC 29
Z9 29
U1 0
U2 15
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0002-9165
EI 1938-3207
J9 AM J CLIN NUTR
JI Am. J. Clin. Nutr.
PD MAR
PY 2008
VL 87
IS 3
BP 712
EP 722
DI 10.1093/ajcn/87.3.712
PG 11
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA 273KA
UT WOS:000253927700025
PM 18326611
OA Bronze, Green Accepted
DA 2022-11-30
ER

PT J
AU Grenga, PL
   Fragiotta, S
   Meduri, A
   Lupo, S
   Marenco, M
   Vingolo, EM
AF Grenga, Pier Luigi
   Fragiotta, Serena
   Meduri, Alessandro
   Lupo, Stefano
   Marenco, Marco
   Vingolo, Enzo M.
TI Fixation stability measurements in patients with neovascular age-related
   macular degeneration treated with ranibizumab
SO CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE
LA English
DT Article
ID SCANNING LASER OPHTHALMOSCOPE; VERTEPORFIN PHOTODYNAMIC THERAPY; OPTICAL
   COHERENCE TOMOGRAPHY; PREFERRED RETINAL LOCI; NIDEK MP-1;
   MICROPERIMETRY; DISEASE; MACULOPATHY; PREVALENCE; MP1
AB Objective: To evaluate which of 2 measuring units (bivariate contour ellipse area [BCEA] vs Fujii) yields more accurate measurements of fixation stability, obtained using the MP-1 device, in patients with neovascular age-related macular degeneration (nAMD) treated with intravitreal injections of ranibizumab, during a 12-month follow-up period.
   Design: Small retrospective, noncomparative, interventional case series. Participants: A total of 25 eyes in 25 patients (13 males, 12 females; mean age 71.72 +/- 7.98 years).
   Methods: All participants were older than 50 years, diagnosed with active subfoveal choroidal neovascularization, had best corrected visual acuity (BCVA) values above 20/100, and all lesion types were included. All patients underwent a loading phase with 3 consecutive intravitreal injections of 0.05 mg ranibizumab at monthly intervals. Patients were retreated after the third injection if they exhibited a 100-mu m increase in macular thickness or evidence of intraretinal and/or subretinal fluid and new subretinal hemorrhage, observed with spectral-domain optical coherence tomography and fluorescein angiography. The data collected included BCVA and mean macular sensitivities, BCEA, and fixation patterns, performed at baseline and at months 4 and 12, using the MP-1 device.
   Results: The mean total injection number was 5.92 +/- 1.18 (minimum 3, maximum 8). Mean BCVA at baseline was 0.55 +/- 0.28 logMAR and increased significantly to 0.50 +/- 0.33 logMAR. Mean macular sensitivity at baseline was 7.06 +/- 4.59 dB and increased significantly to 8.40 +/- 4.82. Mean BCEA was 2.19 +/- 1.38 deg(2) and decreased significantly to 1.68 +/- 1.43 deg(2). Fixation stability patterns, according to the protocol set out by Fujii, did not change significantly during follow-up.
   Conclusions: Compared with Fujii fixation stability patterns, BCEA correlated better with variations in macular sensitivity and BCVA. BCEA can be added to the traditional parameters used to evaluate the efficacy of intravitreal injections in patients with nAMD.
C1 [Grenga, Pier Luigi; Fragiotta, Serena; Lupo, Stefano; Marenco, Marco; Vingolo, Enzo M.] Univ Roma La Sapienza, Polo Pontino A Fiorini Hosp, Dept Ophthalmol, Terracina, Italy.
   [Meduri, Alessandro] Univ Messina, Ophthalmol Clin, Dept Surg Specialities, Messina, Italy.
C3 Sapienza University Rome; University of Messina
RP Grenga, PL (通讯作者)，Viale Carlo Felice 101, I-00185 Rome, Italy.
EM plgrenga@hotmail.it
RI Vingolo, Enzo Maria/E-6674-2010; Fragiotta, Serena/I-5227-2016
OI Vingolo, Enzo Maria/0000-0002-8363-5866; Fragiotta,
   Serena/0000-0002-6214-6270; Meduri, Alessandro/0000-0001-7546-9178;
   Marenco, Marco/0000-0002-6978-3790
CR Abraham P, 2010, AM J OPHTHALMOL, V150, P315, DOI 10.1016/j.ajo.2010.04.011
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chen FK, 2011, OPTOMETRY VISION SCI, V88, P742, DOI 10.1097/OPX.0b013e3182167641
   Chen FK, 2009, INVEST OPHTH VIS SCI, V50, P3464, DOI 10.1167/iovs.08-2926
   Crossland MD, 2004, OPHTHAL PHYSL OPT, V24, P327, DOI 10.1111/j.1475-1313.2004.00213.x
   Crossland MD, 2005, OPHTHALMOLOGY, V112, P1579, DOI 10.1016/j.ophtha.2005.03.027
   Crossland MD, 2009, RETINA-J RET VIT DIS, V29, P651, DOI 10.1097/IAE.0b013e318196bd65
   Deruaz A, 2002, VISION RES, V42, P2947, DOI 10.1016/S0042-6989(02)00354-1
   Dunbar HMP, 2010, INVEST OPHTH VIS SCI, V51, P4346, DOI 10.1167/iovs.09-4556
   Fujii GY, 2002, OPHTHALMOLOGY, V109, P1737, DOI 10.1016/S0161-6420(02)01120-X
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Grenga P, 2008, RETINA-J RET VIT DIS, V28, P1270, DOI 10.1097/IAE.0b013e31817d5d1c
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Heier JS, 2006, ARCH OPHTHALMOL-CHIC, V124, P1532, DOI 10.1001/archopht.124.11.1532
   Holladay JT, 2004, J CATARACT REFR SURG, V30, P287, DOI 10.1016/j.jcrs.2004.01.014
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lei H, 1997, INVEST OPHTH VIS SCI, V38, P1812
   Midena E, 2007, BRIT J OPHTHALMOL, V91, P1499, DOI 10.1136/bjo.2007.119685
   Parravano M, 2010, RETINA-J RET VIT DIS, V30, P1017, DOI 10.1097/IAE.0b013e3181cfd3c6
   Pearce E, 2011, EYE, V25, P149, DOI 10.1038/eye.2010.167
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   SANSBURY RV, 1973, J OPT SOC AM, V63, P612, DOI 10.1364/JOSA.63.000612
   STEINMAN RM, 1965, J OPT SOC AM, V55, P1158, DOI 10.1364/JOSA.55.001158
   Tarita-Nistor L, 2008, RETINA-J RET VIT DIS, V28, P125, DOI 10.1097/IAE.0b013e3180ed4571
   Timberlake GT, 2005, OPTOMETRY VISION SCI, V82, P177
   WHITTAKER SG, 1988, INVEST OPHTH VIS SCI, V29, P268
   Yamaike N, 2007, AM J OPHTHALMOL, V143, P342, DOI 10.1016/j.ajo.2006.09.034
NR 32
TC 17
Z9 17
U1 0
U2 10
PU CANADIAN OPHTHAL SOC
PI OTTAWA
PA 1525 CARLING AVE SUITE 610, OTTAWA, ONTARIO K1Z 8R9, CANADA
SN 0008-4182
EI 1715-3360
J9 CAN J OPHTHALMOL
JI Can. J. Opthalmol.-J. Can. Opthalmol.
PD OCT
PY 2013
VL 48
IS 5
BP 394
EP 399
DI 10.1016/j.jcjo.2013.04.006
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AA5OM
UT WOS:000331149300024
PM 24093186
OA Green Published
DA 2022-11-30
ER

PT J
AU Ayachit, A
   Singh, SR
   Subramanyam, A
   Tiwari, S
   Heranjal, A
   Chattannavar, G
   Pandey, P
   Salti, H
   Mansour, MA
   Mansour, A
   Chhablani, J
AF Ayachit, Apoorva
   Singh, Sumit Randhir
   Subramanyam, Anand
   Tiwari, Sarvesh
   Heranjal, Abhishek
   Chattannavar, Goura
   Pandey, Priti
   Salti, Haitham
   Mansour, Mohamad A.
   Mansour, Ahmad
   Chhablani, Jay
TI Comparison of Loading Doses of Ziv-Aflibercept and Aflibercept in
   Neovascular Age-Related Macular Degeneration
SO ASIA-PACIFIC JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE aflibercept; neovascular age related macular degeneration (n-AMD);
   ziv-aflibercept
ID TERM SAFETY; EFFICACY
AB Purpose: The aim of this study was to compare outcomes of 3 loading doses of ziv-aflibercept and aflibercept in treatment-naive neovascular age-related macular degeneration (nAMD).
   Design: Retrospective, nonrandomized, comparative study.
   Methods: This was a retrospective chart review which included cases with treatment-naive nAMD. The patients were divided into 2 groups (group 1, ziv-aflibercept; group 2, aflibercept). Groups 1 and 2 received 1.25 mg/0.05mL of intravitreal ziv-aflibercept and 2 mg/0.05mL aflibercept, respectively every month for 3 months. Best-corrected visual acuity (BCVA) in Snellen and logarithm of minimum angle of resolution (logMAR), central subfoveal thickness (CSFT), subretinal hyper-reflective material height, neurosensory detachment height, and pigment epithelial detachment height were recorded at baseline and 3 monthly follow-up.
   Results: Twenty-three eyes of 23 patients were included (males 14, females 9). Twelve and 11 eyes were included in group 1 and group 2, respectively. Group 1 showed statistically significant improvement in BCVA (P < 0.001) and CSFT (P=0.007) through 3 months compared with baseline. There was significant change in BCVA from baseline at 1st month (P = 0.007), 2nd month (P = 0.002) and 3rd month (P = 0.008). In group 2, there was no significant improvement in BCVA, CSFT, subretinal hyperreflective material height, neurosensory detachment, and pigment epithelial detachment height from baseline through 3 months.
   Conclusions: After 3 loading doses, ziv-aflibercept showed efficacy in terms of improved BCVA and reduction of CSFT from baseline whereas aflibercept did not show such improvement. Considering the cost-effectiveness and the proven safety of ziv-aflibercept, it is a viable option for the crucial, initial 3 doses in the treatment of nAMD.
C1 [Ayachit, Apoorva; Subramanyam, Anand; Tiwari, Sarvesh; Heranjal, Abhishek] KB Haji Bachooali Charitable Ophthalm & ENT Hosp, Dept Vitreoretina, Mumbai, Maharashtra, India.
   [Singh, Sumit Randhir; Chattannavar, Goura; Pandey, Priti; Chhablani, Jay] LV Prasad Eye Inst, Smt Kanuri Santhamma Ctr Vitreo Retinal Dis, Hyderabad, India.
   [Singh, Sumit Randhir] LV Prasad Eye Inst, Retina & Uveitis Dept, GMR Varalakshmi Campus, Visakhapatnam, Andhra Pradesh, India.
   [Salti, Haitham; Mansour, Mohamad A.; Mansour, Ahmad] Amer Univ Beirut, Dept Ophthalmol, Beirut, Lebanon.
   [Mansour, Ahmad] Rafik Hariri Univ Hosp, Dept Ophthalmol, Beirut, Lebanon.
   [Chhablani, Jay] Univ Pittsburgh, UPMC Eye Ctr, 203 Lothrop St, Pittsburgh, PA 15213 USA.
C3 L. V. Prasad Eye Institute; L. V. Prasad Eye Institute; American
   University of Beirut; American University of Beirut; Pennsylvania
   Commonwealth System of Higher Education (PCSHE); University of
   Pittsburgh
RP Chhablani, J (通讯作者)，Univ Pittsburgh, UPMC Eye Ctr, 203 Lothrop St, Pittsburgh, PA 15213 USA.
EM jay.chhablani@gmail.com
OI Chhablani, Jay/0000-0003-1772-3558
CR Baghi A, 2017, OPHTHALMOL RETINA, V1, P103, DOI 10.1016/j.oret.2016.08.007
   Chhablani J, 2016, RETINA-J RET VIT DIS, V36, P1126, DOI 10.1097/IAE.0000000000000913
   Chhablani J, 2015, INDIAN J OPHTHALMOL, V63, P469, DOI 10.4103/0301-4738.159909
   de Oliveira AL, 2016, REV PORT INVESTIG CO, V2, P3
   Dias JRDO, 2017, RETINA-J RET VIT DIS, V37, P1499, DOI 10.1097/IAE.0000000000001385
   Hutton D, 2014, HEALTH AFFAIR, V33, P931, DOI 10.1377/hlthaff.2013.0832
   Mansour AM, 2018, BRIT J OPHTHALMOL, V102, P1387, DOI 10.1136/bjophthalmol-2017-311591
   Mansour AM, 2017, BRIT J OPHTHALMOL, V101, P1374, DOI 10.1136/bjophthalmol-2016-309724
   Mansour AM, 2016, BRIT J OPHTHALMOL, V100, P1629, DOI 10.1136/bjophthalmol-2015-308319
   Mansour AM, 2015, BRIT J OPHTHALMOL, V99, P1055, DOI 10.1136/bjophthalmol-2014-306319
   Patel S, 2018, OPHTHALMOL RETINA, V2, P785, DOI 10.1016/j.oret.2017.12.006
   Providencia J, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/9276580
   Singh SR, 2019, BRIT J OPHTHALMOL, V103, P805, DOI 10.1136/bjophthalmol-2018-312453
   Singh SR, 2017, ASIA-PAC J OPHTHALMO, V6, P561, DOI 10.22608/APO.2017263
   Trichonas G, 2013, OPHTHALMOL THER, V2, P89, DOI 10.1007/s40123-013-0015-2
   van Asten F, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197670
NR 16
TC 0
Z9 0
U1 0
U2 2
PU ASIA-PACIFIC ACAD OPHTHALMOLOGY-APAO
PI KOWLOON
PA 4-F, HONG KONG EYE HOSP, 147K ARGYLE ST, KOWLOON, KOWLOON, HONG KONG
   00000, PEOPLES R CHINA
EI 2162-0989
J9 ASIA-PAC J OPHTHALMO
JI Asia-Pac. J. Ophthalmol.
PD MAR-APR
PY 2020
VL 9
IS 2
BP 144
EP 148
DI 10.1097/APO.0000000000000277
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA LJ4VB
UT WOS:000530163700014
PM 32175924
OA gold
DA 2022-11-30
ER

PT J
AU Zerbib, J
   Seddon, JM
   Richard, F
   Reynolds, R
   Leveziel, N
   Benlian, P
   Borel, P
   Feingold, J
   Munnich, A
   Soubrane, G
   Kaplan, J
   Rozet, JM
   Souied, EH
AF Zerbib, Jennyfer
   Seddon, Johanna M.
   Richard, Florence
   Reynolds, Robyn
   Leveziel, Nicolas
   Benlian, Pascale
   Borel, Patrick
   Feingold, Josue
   Munnich, Arnold
   Soubrane, Gisele
   Kaplan, Josseline
   Rozet, Jean-Michel
   Souied, Eric H.
TI rs5888 Variant of SCARB1 Gene Is a Possible Susceptibility Factor for
   Age-Related Macular Degeneration
SO PLOS ONE
LA English
DT Article
ID B TYPE-I; COMPLEMENT FACTOR-H; SCAVENGER RECEPTOR; SR-BI;
   CIGARETTE-SMOKING; APOLIPOPROTEIN-E; RISK-FACTORS; VITAMIN-E;
   CARDIOVASCULAR-DISEASE; POOLED FINDINGS
AB Major genetic factors for age-related macular degeneration (AMD) have recently been identified as susceptibility risk factors, including variants in the CFH gene and the ARMS2 LOC387715/HTRA1locus. Our purpose was to perform a case-control study in two populations among individuals who did not carry risk variants for CFHY402H and LOC387715 A69S (ARMS2), called "study'' individuals, in order to identify new genetic risk factors. Based on a candidate gene approach, we analyzed SNP rs5888 of the SCARB1 gene, coding for SRBI, which is involved in the lipid and lutein pathways. This study was conducted in a French series of 1241 AMD patients and 297 controls, and in a North American series of 1257 patients with advanced AMD and 1732 controls. Among these individuals, we identified 61 French patients, 77 French controls, 85 North American patients and 338 North American controls who did not carry the CFH nor ARMS2 polymorphisms. An association between AMD and the SCARB1 gene was seen among the study subjects. The genotypic distribution of the rs5888 polymorphism was significantly different between cases and controls in the French population (p<0.006). Heterozygosity at the rs5888 SNP increased risk of AMD compared to the CC genotypes in the French study population (odds ratio (OR) = 3.5, CI95%: 1.4-8.9, p<0.01) and after pooling the 2 populations (OR = 2.9, 95% CI: 1.6-5.3, p<0.002). Subgroup analysis in exudative forms of AMD revealed a pooled OR of 3.6 for individuals heterozygous for rs5888 (95% CI: 1.7-7.6, p<0.0015). These results suggest the possible contribution of SCARB1, a new genetic factor in AMD, and implicate a role for cholesterol and antioxidant micronutrient (lutein and vitamin E) metabolism in AMD.
RP Zerbib, J (通讯作者)，Creteil Univ, Eye Clin, Fac Med Henri Mondor, Creteil, France.
EM eric.souied@chicreteil.fr
RI Borel, Patrick/A-4057-2015; ROZET, Jean-Michel/E-5737-2016; Benlian,
   Pascale/I-7964-2016; KAPLAN, Josseline/I-2622-2017
OI Borel, Patrick/0000-0001-9977-3238; ROZET,
   Jean-Michel/0000-0001-7951-7886; Benlian, Pascale/0000-0002-3423-8979;
   KAPLAN, Josseline/0000-0002-1849-8658; Nicolas,
   Leveziel/0000-0001-8533-9457
CR Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518
   Acton S, 1999, ARTERIOSCL THROM VAS, V19, P1734, DOI 10.1161/01.ATV.19.7.1734
   Allikmets R, 2000, AM J HUM GENET, V67, P487, DOI 10.1086/303018
   Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Borel P, 2007, J NUTR, V137, P2653, DOI 10.1093/jn/137.12.2653
   Delcourt C, 1999, ARCH OPHTHALMOL-CHIC, V117, P1384, DOI 10.1001/archopht.117.10.1384
   Duncan KG, 2002, BIOCHEM BIOPH RES CO, V292, P1017, DOI 10.1006/bbrc.2002.6756
   During A, 2008, J LIPID RES, V49, P1715, DOI 10.1194/jlr.M700580-JLR200
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Fazio S, 2005, CIRCULATION, V111, P3349, DOI 10.1161/CIRCULATIONAHA.105.545996
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hsu Chin-Chun, 2003, MULTINATIONAL BUSINE, V11, P23, DOI DOI 10.1108/1525383X200300015
   Huang ZH, 2002, J LIPID RES, V43, P375
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Ji Y, 1997, J BIOL CHEM, V272, P20982, DOI 10.1074/jbc.272.34.20982
   Jian B, 1998, J BIOL CHEM, V273, P5599, DOI 10.1074/jbc.273.10.5599
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klein ML, 1998, ARCH OPHTHALMOL-CHIC, V116, P1082, DOI 10.1001/archopht.116.8.1082
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2007, AM J OPHTHALMOL, V143, P473, DOI 10.1016/j.ajo.2006.11.058
   Leveziel N, 2007, MOL VIS, V13, P2153
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Morabia A, 2004, ATHEROSCLEROSIS, V175, P159, DOI 10.1016/j.atherosclerosis.2004.03.014
   Reboul E, 2005, BIOCHEM J, V387, P455, DOI 10.1042/BJ20040554
   Reboul E, 2006, J BIOL CHEM, V281, P4739, DOI 10.1074/jbc.M509042200
   Rigotti A, 2003, ENDOCR REV, V24, P357, DOI 10.1210/er.2001-0037
   Ritsch A, 2007, METABOLISM, V56, P1135, DOI 10.1016/j.metabol.2007.04.009
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Roberts CGP, 2007, HUM HERED, V64, P107, DOI 10.1159/000101962
   Rodriguez-Esparragon F, 2005, ARTERIOSCL THROM VAS, V25, P854, DOI 10.1161/01.ATV.0000157581.88838.03
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P55, DOI 10.1001/archopht.125.1.55
   Schick JH, 2003, AM J HUM GENET, V72, P1412, DOI 10.1086/375500
   Seddon J, 2007, PRINCIPLES PRACTICE, P413
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Seddon JM, 2003, AM J HUM GENET, V73, P780, DOI 10.1086/378505
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Shuler RK, 2007, ARCH OPHTHALMOL-CHIC, V125, P63, DOI 10.1001/archopht.125.1.63
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   Souied EH, 2005, MOL VIS, V11, P1135
   Swaroop A, 2007, HUM MOL GENET, V16, pR174, DOI 10.1093/hmg/ddm212
   Tan JSL, 2008, BRIT J OPHTHALMOL, V92, P509, DOI 10.1136/bjo.2007.131706
   Tanaka T, 2007, J NUTR, V137, P578, DOI 10.1093/jn/137.3.578
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
NR 64
TC 51
Z9 55
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 5
PY 2009
VL 4
IS 10
AR e7341
DI 10.1371/journal.pone.0007341
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 504DG
UT WOS:000270593600014
PM 19806217
OA Green Submitted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Holz, FG
   Bindewald-Wittich, A
   Fleckenstein, M
   Dreyhaupt, J
   Scholl, HPN
   Schmitz-Valckenberg, S
AF Holz, Frank G.
   Bindewald-Wittich, Almut
   Fleckenstein, Monika
   Dreyhaupt, Jens
   Scholl, Hendrik P. N.
   Schmitz-Valckenberg, Steffen
CA FAM-Study Grp
TI Progression of geographic atrophy and impact of fundus autofluorescence
   patterns in age-related macular degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID COMPLEMENT FACTOR-H; RETINAL-PIGMENT EPITHELIUM; JUNCTIONAL ZONE;
   CIGARETTE-SMOKING; RISK-FACTORS; RPE CELLS; LIPOFUSCIN; CLASSIFICATION;
   POLYMORPHISM; COMPONENT
AB center dot PURPOSE: To test if fundus autofluorescence (FAF) patterns around geographic atrophy (GA) have an impact on GA progression rates over time in atrophic age,related macular degeneration (AMD).
   center dot DESIGN: Prospective longitudinal multicenter natural history study.
   center dot METHODS: Standardized digital FAF images were obtained from 195 eyes of 129 patients with GA using confocal scanning laser ophthalmoscopy (excitation 488 nm, emission > 500 nm). Areas of GA were quantified and patterns of abnormal FAF in the junctional zone were classified. Repeated FAF images were obtained over a median follow-up period of 1.80 years (interquartile range [IQR], 1.28 to 3.34).
   center dot RESULTS: Areas of GA (median, 7.04 mm 2 at baseline; IQR, 3.12 to 10.0) showed a median enlargement of 1.52 mm(2)/year (IQR, 0.81 to 2.33). Progression rates in eyes with the banded (median 1.81 mm(2)/year) and the diffuse FAF pattern (1.77 mm(2)/year) were significantly higher compared to eyes without FAF abnormalities (0.38 mm(2)/year) and focal FAF patterns (0.81 mm(2)/year, P <.0001). Within the group of the diffuse pattern, eyes with a diffuse trickling pattern could be identified that exhibited an even higher spread rate (median 3.02 mm(2)/year) compared to the other diffuse types (1.67 mm(2)/year, P = .001).
   center dot CONCLUSIONS: The results indicate that distinct phenotypic FAF patterns have an impact on disease progression in eyes with atrophic AMD and may therefore serve as prognostic determinants. The findings underscore the relevance of FAF imaging and the pathogenetic role of excessive retinal pigment epithelium (RPE) lipofuscin (LF) accumulation in GA. Natural history data and identification of high-risk characteristics will be helpful to design interventional studies aiming at slowing the spread of atrophy.
C1 Univ Bonn, Dept Ophthalmol, D-53127 Bonn, Germany.
   Heidelberg Univ, Inst Med Biometry & Informat, Heidelberg, Germany.
C3 University of Bonn; Ruprecht Karls University Heidelberg
RP Holz, FG (通讯作者)，Univ Bonn, Dept Ophthalmol, Ernst Abbe Str,2, D-53127 Bonn, Germany.
EM Frank.Holz@ukb.uni-bonn.de
OI Bindewald-Wittich, Almut/0000-0002-8151-3953; Fleckenstein,
   Monika/0000-0001-8321-8037
CR Altman DG, 1991, PRACTICAL STAT MED R
   American National Standards Institute, 2000, Z1361 ANSI LAS I AM
   Bellmann C, 2002, ARCH OPHTHALMOL-CHIC, V120, P579, DOI 10.1001/archopht.120.5.579
   Bellmann C, 1997, OPHTHALMOLOGE, V94, P385, DOI 10.1007/s003470050130
   Bindewald A, 2005, INVEST OPHTH VIS SCI, V46, P3309, DOI 10.1167/iovs.04-0430
   Bindewald A, 2005, BRIT J OPHTHALMOL, V89, P874, DOI 10.1136/bjo.2004.057794
   Bindewald A, 2005, OPHTHALMOLOGE, V102, P259, DOI 10.1007/s00347-004-1121-2
   Bindewald A, 2004, AM J OPHTHALMOL, V137, P556, DOI 10.1016/j.ajo.2003.08.004
   Bindewald A, 2005, ESSENT OPHTHALMOL, P19
   BOULTON M, 1991, PROG RETIN RES, V11, P125, DOI 10.1016/0278-4327(91)90027-Y
   Boulton M, 2001, EYE, V15, P384, DOI 10.1038/eye.2001.141
   Chaine G, 1998, BRIT J OPHTHALMOL, V82, P996, DOI 10.1136/bjo.82.9.996
   Christen WG, 1996, JAMA-J AM MED ASSOC, V276, P1147, DOI 10.1001/jama.276.14.1147
   Deckert A, 2005, BMC Ophthalmol, V5, P8, DOI 10.1186/1471-2415-5-8
   Delori FC, 2001, INVEST OPHTH VIS SCI, V42, P1855
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   Dreyhaupt J, 2005, OPHTHAL EPIDEMIOL, V12, P353, DOI 10.1080/09286580591005723
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   Holz FG, 2004, AM J OPHTHALMOL, V137, P504, DOI 10.1016/j.ajo.2003.11.026
   Holz FG, 1998, AM J OPHTHALMOL, V125, P227, DOI 10.1016/S0002-9394(99)80095-6
   Holz FG, 1999, GRAEF ARCH CLIN EXP, V237, P145, DOI 10.1007/s004170050209
   Holz FG, 1999, INVEST OPHTH VIS SCI, V40, P737
   Hwang JC, 2006, INVEST OPHTH VIS SCI, V47, P2655, DOI 10.1167/iovs.05-1027
   Jorzik JJ, 2005, RETINA-J RET VIT DIS, V25, P405, DOI 10.1097/00006982-200506000-00003
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   MAGUIRE P, 1986, AM J OPHTHALMOL, V102, P621, DOI 10.1016/0002-9394(86)90535-0
   Maiti P, 2006, BIOCHEMISTRY-US, V45, P852, DOI 10.1021/bi0518545
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   OGORMAN S, 1988, ARCH OPHTHALMOL-CHIC, V106, P1261
   Radu RA, 2005, INVEST OPHTH VIS SCI, V46, P4393, DOI 10.1167/iovs.05-0820
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SCHATZ H, 1989, OPHTHALMOLOGY, V96, P1541
   Schmitz-Valckenberg S, 2004, INVEST OPHTH VIS SCI, V45, P4470, DOI 10.1167/iovs.03-1311
   Schmitz-Valckenberg S, 2006, INVEST OPHTH VIS SCI, V47, P2648, DOI 10.1167/iovs.05-0892
   Scholl HPN, 2005, OPHTHALMOLOGE, V102, P1152, DOI 10.1007/s00347-005-1293-4
   Scholl HPN, 2005, OPHTHALMOLOGE, V102, P1029, DOI 10.1007/s00347-005-1270-y
   Scholl HPN, 2004, INVEST OPHTH VIS SCI, V45, P574, DOI 10.1167/iovs.03-0495
   Schutt F, 2000, INVEST OPHTH VIS SCI, V41, P2303
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Sparrow JR, 2000, INVEST OPHTH VIS SCI, V41, P1981
   STEINMETZ RL, 1991, OPHTHALMOLOGY, V98, P953
   Sunness JS, 1999, MOL VIS, V5
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   van Leeuwen R, 2003, EUR J EPIDEMIOL, V18, P845, DOI 10.1023/A:1025643303914
   vonRuckmann A, 1997, INVEST OPHTH VIS SCI, V38, P478
   WEITER JJ, 1986, INVEST OPHTH VIS SCI, V27, P145
NR 57
TC 403
Z9 413
U1 0
U2 26
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD MAR
PY 2007
VL 143
IS 3
BP 463
EP 472
DI 10.1016/j.ajo.2006.11.041
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 141CZ
UT WOS:000244555700012
PM 17239336
DA 2022-11-30
ER

PT J
AU Falsini, B
   Focosi, F
   Molle, F
   Manganelli, C
   Iarossi, G
   Fadda, A
   Dorin, G
   Mainster, MA
AF Falsini, B
   Focosi, F
   Molle, F
   Manganelli, C
   Iarossi, G
   Fadda, A
   Dorin, G
   Mainster, MA
TI Monitoring retinal function during transpupillary thermotherapy for
   occult choroidal neovascularization in age-related macular degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID RETINITIS-PIGMENTOSA; PATTERN ELECTRORETINOGRAM; LASER PHOTOCOAGULATION;
   ERG COMPONENTS; OUTER-RETINA; FELLOW EYES; FOCAL ERG; FLICKER;
   SENSITIVITY; HUMANS
AB PURPOSE. To use focal electroretinography to evaluate changes in retinal function during transpupillary thermotherapy (TTT) for neovascular age-related macular degeneration (ARMD).
   METHODS. Sixteen eyes of 16 patients with ARMD with occult choroidal neovascularization (CNV) were studied. A 630-nm photocoagulator aiming beam was modified for use as a 41-Hz square-wave focal electroretinogram (fERG) stimulus. The stimulus was presented on a light-adapting background by a Goldmann-type lens (visual angle, 18degrees; mean luminance, 50 cd/m(2)). fERGs were continuously monitored before, during, and after TTT for occult CNV. The amplitude and phase of the fERG's fundamental harmonic were measured.
   RESULTS. No suprathreshold or adverse clinical events occurred during the course of the study. fERG amplitude decreased transiently during TTT (23% +/- 9% [SE]; P < 0.05). The decrease in amplitude was greatest 16 to 20 seconds and 32 to 40 seconds after the onset of TTT. it was followed by a recovery to baseline amplitude during TTT (48 to 60 seconds after TTT was begun). Within 60 seconds after TTT was completed, fERG amplitude was within the range of baseline. TTT did not alter the fERG phase. Mean fERG amplitudes and phases recorded 1 week and 1 month after TTT were comparable to mean pretreatment levels.
   CONCLUSIONS. fERG amplitude decreases transiently during TTT, despite the absence of ophthalmoscopically apparent lesions. Intraoperative amplitude depression may result from an adaptation effect to laser light energy and/or hyperthermia, resulting in desensitization of cone photoreceptors and bipolar cells. Treatment sites are electrophysiologically functional 1 month after TTT. Detailed parametric study of a larger patient group is needed to determine whether fERG testing is potentially useful for monitoring and perhaps for controlling and optimizing TTT for choroidal neovascularization.
C1 Univ Cattolica Sacro Cuore, Ist Oftalmol, I-00168 Rome, Italy.
   Iridex Corp, Mountain View, CA USA.
   Univ Kansas, Med Ctr, Dept Ophthalmol, Kansas City, KS 66103 USA.
C3 Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli;
   University of Kansas; University of Kansas Medical Center
RP Falsini, B (通讯作者)，Univ Cattolica Sacro Cuore, Ist Oftalmol, Lgo F Vito 1, I-00168 Rome, Italy.
EM md0571@mclink.it
RI Fadda, Antonello/J-1560-2012; Falsini, Benedetto/V-1070-2019; Falsini,
   Benedetto/AAC-5907-2022; Iarossi, giancarlo/AAB-4916-2020
OI Fadda, Antonello/0000-0001-7004-5245; Falsini,
   Benedetto/0000-0002-1694-1062; Falsini, Benedetto/0000-0002-3569-4968
CR Ahuja R M, 2001, Semin Ophthalmol, V16, P81, DOI 10.1076/soph.16.2.81.4215
   Algvere P V, 2001, Semin Ophthalmol, V16, P90, DOI 10.1076/soph.16.2.90.4210
   BARLOW RB, 1993, NATURE, V366, P64, DOI 10.1038/366064a0
   BERSON EL, 1985, AM J OPHTHALMOL, V99, P240, DOI 10.1016/0002-9394(85)90351-4
   BIERSDORF WR, 1989, DOC OPHTHALMOL, V73, P313, DOI 10.1007/BF00154487
   BIRCH DG, 1992, INVEST OPHTH VIS SCI, V33, P2097
   Birngruber R, 1977, Mod Probl Ophthalmol, V18, P383
   BORLAND RG, 1978, EXP EYE RES, V27, P471, DOI 10.1016/0014-4835(78)90025-8
   BRINDLEY GS, 1965, J PHYSIOL-LONDON, V179, P518, DOI 10.1113/jphysiol.1965.sp007678
   BRODIE SE, 1992, OPHTHALMOLOGY, V99, P522
   Bush RA, 1996, J OPT SOC AM A, V13, P557, DOI 10.1364/JOSAA.13.000557
   CAPOFERRI C, 1990, GRAEF ARCH CLIN EXP, V228, P232, DOI 10.1007/BF00920026
   Ciavarella P, 1997, CURR EYE RES, V16, P111, DOI 10.1076/ceyr.16.2.111.5094
   FADDA A, 1989, COMPUT METH PROG BIO, V28, P45, DOI 10.1016/0169-2607(89)90180-6
   Fadda A, 1997, MED BIOL ENG COMPUT, V35, P441, DOI 10.1007/BF02534106
   FALSINI B, 1994, INVEST OPHTH VIS SCI, V35, P4282
   Falsini B, 1996, CURR EYE RES, V15, P638, DOI 10.3109/02713689609008904
   Falsini B, 1999, GRAEF ARCH CLIN EXP, V237, P193, DOI 10.1007/s004170050218
   Falsini B, 2000, INVEST OPHTH VIS SCI, V41, P1498
   Francois J, 1977, Ophthalmologica, V176, P133
   FRANK RN, 1975, ARCH OPHTHALMOL-CHIC, V93, P591
   Greenstein VC, 2000, INVEST OPHTH VIS SCI, V41, P3655
   Hood DC, 2000, PROG RETIN EYE RES, V19, P607, DOI 10.1016/S1350-9462(00)00013-6
   JERATH MR, 1994, IEEE T BIO-MED ENG, V41, P201, DOI 10.1109/10.284934
   JOHNSON RN, 2001, RETINA, V2, P875
   Kondo M, 2001, INVEST OPHTH VIS SCI, V42, P305
   Koskelainen A, 2000, NATURE, V403, P220, DOI 10.1038/35003242
   KUNLIN J, 1948, CR HEBD ACAD SCI, V226, P357, DOI 10.1007/BF00369741
   LAMB TD, 1984, J PHYSIOL-LONDON, V346, P557, DOI 10.1113/jphysiol.1984.sp015041
   Mainster M A, 1999, Semin Ophthalmol, V14, P200
   MAINSTER MA, 1970, J OPT SOC AM, V60, P264, DOI 10.1364/JOSA.60.000264
   MAINSTER MA, 1970, J OPT SOC AM, V60, P848, DOI 10.1364/JOSA.60.000848
   Mainster MA, 2000, OPHTHALMIC SURG LAS, V31, P359
   Mordon S, 1999, LASER SURG MED, V24, P338
   Newsom RSB, 2001, BRIT J OPHTHALMOL, V85, P173, DOI 10.1136/bjo.85.2.173
   PERLMAN I, 1985, BRIT J OPHTHALMOL, V69, P240, DOI 10.1136/bjo.69.4.240
   POMERANTZEFF O, 1983, ARCH OPHTHALMOL-CHIC, V101, P949
   PORCIATTI V, 1992, VISION RES, V32, P1199, DOI 10.1016/0042-6989(92)90214-4
   PORCIATTI V, 1989, CLIN VISION SCI, V4, P323
   PRIEBE LA, 1973, AEROSPACE MED, V44, P1246
   PRIEBE LA, 1975, AM J OPHTHALMOL, V79, P405, DOI 10.1016/0002-9394(75)90613-3
   Reichel E, 1999, OPHTHALMOLOGY, V106, P1908, DOI 10.1016/S0161-6420(99)90400-1
   REMULLA JFC, 1995, BRIT J OPHTHALMOL, V79, P558, DOI 10.1136/bjo.79.6.558
   Rogers AH, 2001, CURR OPIN OPHTHALMOL, V12, P212, DOI 10.1097/00055735-200106000-00012
   Roider J, 1999, GRAEF ARCH CLIN EXP, V237, P45, DOI 10.1007/s004170050193
   Roider J, 1999, ARCH OPHTHALMOL-CHIC, V117, P1028
   ROIDER J, 1993, P NATL ACAD SCI USA, V90, P8643, DOI 10.1073/pnas.90.18.8643
   SANDBERG MA, 1993, INVEST OPHTH VIS SCI, V34, P3477
   SEDDON JM, 1990, INVEST OPHTH VIS SCI, V31, P1592
   SEIPLE W, 1992, VISION RES, V32, P2043, DOI 10.1016/0042-6989(92)90065-Q
   Seiple W, 1996, J OPT SOC AM A, V13, P658, DOI 10.1364/JOSAA.13.000658
   SEIPLE WH, 1986, INVEST OPHTH VIS SCI, V27, P1123
   SEIPLE WH, 1993, INVEST OPHTH VIS SCI, V34, P2638
   Shields CL, 1996, OPHTHALMOLOGY, V103, P1642, DOI 10.1016/S0161-6420(96)30451-X
   SLINEY DH, 1976, J OPT SOC AM, V66, P339, DOI 10.1364/JOSA.66.000339
   Stevens TS, 1997, ARCH OPHTHALMOL-CHIC, V115, P345, DOI 10.1001/archopht.1997.01100150347006
   SUTTER EE, 1992, VISION RES, V32, P433, DOI 10.1016/0042-6989(92)90235-B
   Thompson JT, 2001, AM J OPHTHALMOL, V131, P662, DOI 10.1016/S0002-9394(00)00879-5
   WEITER JJ, 1986, INVEST OPHTH VIS SCI, V27, P145
   Wyszecki G., 1967, COLOR SCI
NR 60
TC 11
Z9 12
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAY
PY 2003
VL 44
IS 5
BP 2133
EP 2140
DI 10.1167/iovs.02-0716
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 672CQ
UT WOS:000182503700048
PM 12714653
DA 2022-11-30
ER

PT J
AU Kim, YH
   Kim, HS
   Mok, JW
   Joo, CK
AF Kim, Yeong Hoon
   Kim, Hyun-Seok
   Mok, Jee Won
   Joo, Choun-Ki
TI Gene-Gene Interactions of CFH and LOC387715/ARMS2 with Korean Exudative
   Age-related Macular Degeneration Patients
SO OPHTHALMIC GENETICS
LA English
DT Article
DE age-related macular degeneration; association; complement factor H;
   LOC387715/ARMS2; haplotype; multifactor-dimensionality reduction method;
   single nucleotide polymorphisms
ID COMPLEMENT-FACTOR-H; MULTIFACTOR-DIMENSIONALITY REDUCTION; POLYPOIDAL
   CHOROIDAL VASCULOPATHY; CIGARETTE-SMOKING; ASSOCIATION; POLYMORPHISMS;
   DRUSEN; HTRA1; RISK; VARIANT
AB Purpose: To evaluate the association and interaction of single nucleotide polymorphisms in CFH and LOC387715/ARMS2 with age-related macular degeneration (AMD) in a Korean population.
   Methods: A total of 114 exudative AMD patients and 240 normal subjects participated in the study. PCR and direct sequencing were used to screen SNPs in the CFH and in the LOC387715/ARMS2. Genotype and haplotype analyses were performed. Two-locus gene-gene interactions were evaluated by the data mining approach multifactor-dimensionality reduction method.
   Results: The *C/*T genotype frequency of rs1061170 in CFH showed a significant difference (OR = 1.79). Genotype and allele frequencies of rs551397 (*C/*C, OR = 2.84; *C, OR = 1.67) and rs800292 (*G/*G, OR = 2.198; *G, OR = 1.676) in CFH, and rs10490924 (T/*T, OR = 12.45; *T, OR = 4.45) and rs2736911 (*C/*C, OR = 3.21; *C, OR = 2.71) in LOC387715/ARMS2 were significantly higher in patients. In the haplotype analysis, C-T of rs2736911-rs10490924 in LOC387715/ARMS2 (OR = 4.85) and C-G of rs551397-rs800292 in CFH (OR = 2.22) predisposed significantly to AMD. After cross-validation consistency (CVC) and permutation tests, we identified the 1 marker model (rs10490924), which has a prediction accuracy of 73.5%, and the two locus model, rs10490924_ rs800292, with 75.3% balanced accuracy in predicting AMD disease risk.
   Conclusions: Korean individuals with the LOC387715/ARMS2 rs10490924, and to a lesser extent, CFH rs800292 variants might be at a greater risk for the development of exudative AMD. Furthermore, the risk of exudative AMD may increase significantly if these variants are both present in the two genes.
C1 [Kim, Yeong Hoon; Joo, Choun-Ki] Catholic Univ Korea, Dept Ophthalmol & Visual Sci, Seoul 137040, South Korea.
   [Kim, Yeong Hoon; Kim, Hyun-Seok; Mok, Jee Won; Joo, Choun-Ki] Catholic Univ Korea, Catholic Inst Visual Sci, Seoul 137040, South Korea.
   [Joo, Choun-Ki] Seoul St Marys Hosp, Inst Eye, Seoul, South Korea.
C3 Catholic University of Korea; Catholic University of Korea; Seoul St.
   Mary's Hospital
RP Joo, CK (通讯作者)，Catholic Univ Korea, Catholic Inst Visual Sci, 505 Banpo Dong, Seoul 137040, South Korea.
EM ckjoo@catholic.ac.kr
FU Catholic Medical Center Research Foundation
FX This work was supported by the Catholic Medical Center Research
   Foundation (Program year of 2007).
CR Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X
   Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Arakawa S, 2011, NAT GENET, V43, P1001, DOI 10.1038/ng.938
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bok D, 2005, P NATL ACAD SCI USA, V102, P7053, DOI 10.1073/pnas.0502819102
   Chen LJ, 2006, MOL VIS, V12, P1536
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Daiger SP, 2005, SCIENCE, V308, P362, DOI 10.1126/science.1111655
   de Cordoba SR, 2004, MOL IMMUNOL, V41, P355, DOI 10.1016/j.molimm.2004.02.005
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Francis PJ, 2008, MOL VIS, V14, P1395
   Friese MA, 1999, MOL IMMUNOL, V36, P809, DOI 10.1016/S0161-5890(99)00101-7
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Gotoh N, 2008, CLIN EXP OPHTHALMOL, V36, P437, DOI 10.1111/j.1442-9071.2008.01791.x
   Gotoh N, 2006, HUM GENET, V120, P139, DOI 10.1007/s00439-006-0187-0
   Goverdhan SV, 2008, EYE, V22, P849, DOI 10.1038/sj.eye.6702830
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hahn LW, 2003, BIOINFORMATICS, V19, P376, DOI 10.1093/bioinformatics/btf869
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Johnson LR, 2000, IEEE ANN HIST COMPUT, V22, P70
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Kim J, 2010, JPN J OPHTHALMOL, V54, P325, DOI 10.1007/s10384-010-0825-x
   Kim NR, 2008, INVEST OPHTH VIS SCI, V49, P2071, DOI 10.1167/iovs.07-1195
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kondo N, 2007, AM J OPHTHALMOL, V144, P608, DOI 10.1016/j.ajo.2007.06.003
   Lee KY, 2008, INVEST OPHTH VIS SCI, V49, P2613, DOI 10.1167/iovs.07-0860
   Lee SE, 2010, DERMATOL SIN, V28, P1
   Loane E, 2011, EXP EYE RES, V93, P592, DOI 10.1016/j.exer.2011.07.005
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   Moore JH, 2002, ANN MED, V34, P88, DOI 10.1080/07853890252953473
   Mori K, 2007, INVEST OPHTH VIS SCI, V48, P5315, DOI 10.1167/iovs.07-0426
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Nakanishi H, 2010, EYE, V24, P1078, DOI 10.1038/eye.2009.215
   Okamoto H, 2006, MOL VIS, V12, P156
   Ritchie MD, 2001, AM J HUM GENET, V69, P138, DOI 10.1086/321276
   Ritchie MD, 2003, GENET EPIDEMIOL, V24, P150, DOI 10.1002/gepi.10218
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Seitsonen SP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003833
   Shastry BS, 2007, J HUM GENET, V52, P384, DOI 10.1007/s10038-007-0120-y
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Tanimoto S, 2007, NEUROSCI LETT, V414, P71, DOI 10.1016/j.neulet.2006.12.011
   Wiggs JL, 2006, ARCH OPHTHALMOL-CHIC, V124, P577, DOI 10.1001/archopht.124.4.577
   Xu YL, 2008, MOL VIS, V14, P1373
   Yang ZL, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000836
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
NR 51
TC 11
Z9 12
U1 0
U2 5
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1381-6810
EI 1744-5094
J9 OPHTHALMIC GENET
JI Ophthalmic Genet.
PD SEP
PY 2013
VL 34
IS 3
BP 151
EP 159
DI 10.3109/13816810.2012.749287
PG 9
WC Genetics & Heredity; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity; Ophthalmology
GA 180IC
UT WOS:000321586400005
PM 23289807
DA 2022-11-30
ER

PT J
AU Trinh, M
   Tong, J
   Yoshioka, N
   Zangerl, B
   Kalloniatis, M
   Nivison-Smith, L
AF Trinh, Matt
   Tong, Janelle
   Yoshioka, Nayuta
   Zangerl, Barbara
   Kalloniatis, Michael
   Nivison-Smith, Lisa
TI Macula Ganglion Cell Thickness Changes Display Location-Specific
   Variation Patterns in Intermediate Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE optical coherence tomography; age-related macular degeneration; inner
   retinal thickness
ID RECOGNITION ANALYSIS; LAYER THICKNESSES; RETINAL LAYERS; COMPLEX;
   CLASSIFICATION; VULNERABILITY; PREVALENCE; GLAUCOMA; NEURONS; DISEASE
AB PURPOSE. The purpose of this study was to examine changes in the ganglion cell layer (GCL) of individuals with intermediate age-related macular degeneration (AMD) using grid-wise analysis for macular optical coherence tomography (OCT) volume scans. We also aim to validate the use of age-correction functions for GCL thickness in diseased eyes.
   METHODS. OCT macular cube scans covering 30 degrees x 25 degrees were acquired using Spectralis spectral-domain OCT for 87 eyes with intermediate AMD, 77 age-matched normal eyes, and 254 non-age-matched normal eyes. The thickness of the ganglion cell layer (GCL) was defined after segmentation at 60 locations across an 8 x 8 grid centered on the fovea, where each grid location covered 0.74 mm(2) (approximately 3 degrees x 3 degrees) within the macula. Each GCL location of normal eyes (n = 77) were assigned to a specific iso-ganglion cell density cluster in the macula, based on patterns of age-related GCL thickness loss. Analyses were then performed comparing AMD GCL grid-wise data against corresponding spatial clusters, and significant AMD GCL thickness changes were denoted as values outside the 95% distribution limits.
   RESULTS. Analysis of GCL thickness changes revealed significant differences between spatial clusters, with thinning toward the fovea, and thickening toward the peripheral macula. The direction of GCL thickness changes in AMD were associated more so with thickening than thinning in all analyses. Results were corroborated by the application of GCL thickness age-correction functions.
   CONCLUSIONS. GCL thickness changed significantly and nonuniformly within the macula of intermediate AMD eyes. Further characterization of these changes is critical to improve diagnoses and monitoring of GCL-altering pathologies.
C1 [Trinh, Matt; Tong, Janelle; Yoshioka, Nayuta; Zangerl, Barbara; Kalloniatis, Michael; Nivison-Smith, Lisa] Univ New South Wales, Ctr Eye Hlth, Sydney, NSW, Australia.
   [Trinh, Matt; Tong, Janelle; Yoshioka, Nayuta; Zangerl, Barbara; Kalloniatis, Michael; Nivison-Smith, Lisa] Univ New South Wales, Sch Optometry & Vis Sci, Sydney, NSW 2052, Australia.
C3 University of New South Wales Sydney; University of New South Wales
   Sydney
RP Nivison-Smith, L (通讯作者)，Univ New South Wales, Sch Optometry & Vis Sci, Sydney, NSW 2052, Australia.
EM l.nivison-smith@unsw.edu.au
RI Trinh, Matt/AAV-1249-2021
OI Kalloniatis, Michael/0000-0002-5264-4639; Tong,
   Janelle/0000-0002-4268-5138; Trinh, Matt/0000-0002-6184-0666
FU Australian Postgraduate PhD scholarship; Guide Dogs NSW/ACT; Rebecca
   Cooper Foundation
FX Supported by the Australian Postgraduate PhD scholarship (MT). Guide
   Dogs NSW/ACT provides support for the Centre for Eye Health (the clinic
   of recruitment), top-up PhD scholarship (NY), and salary support (JT,
   BZ, MK, and LN-S). Supported, in part, by a research grant from the
   Rebecca Cooper Foundation (LN-S).
CR Bengtsson B, 1999, ACTA OPHTHALMOL SCAN, V77, P125, DOI 10.1034/j.1600-0420.1999.770201.x
   Bhagat Purvi Raj, 2014, J Curr Glaucoma Pract, V8, P101, DOI 10.5005/jp-journals-10008-1171
   Borrelli E, 2017, AM J OPHTHALMOL, V181, P1, DOI 10.1016/j.ajo.2017.06.005
   Brandl C, 2019, INVEST OPHTH VIS SCI, V60, P1581, DOI 10.1167/iovs.18-25332
   BROWN B, 1986, AM J OPTOM PHYS OPT, V63, P733
   Brynskov T, 2016, ACTA OPHTHALMOL, V94, P668, DOI 10.1111/aos.13087
   Camacho P, 2017, OPHTHALMOLOGICA, V238, P31, DOI 10.1159/000468965
   Chao TI, 1997, J NEUROCYTOL, V26, P439, DOI 10.1023/A:1018525222826
   Cheng D, 2016, INVEST OPHTH VIS SCI, V57, P5470, DOI 10.1167/iovs.16-19568
   Choi AYJ, 2019, SCI REP, V9, P1, DOI DOI 10.1038/S41598-018-37186-2
   Chua J, 2013, J COMP NEUROL, V521, P2439, DOI 10.1002/cne.23307
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   CURCIO CA, 1990, J COMP NEUROL, V300, P5, DOI 10.1002/cne.903000103
   DILORETO DA, 1995, BRAIN RES, V698, P1, DOI 10.1016/0006-8993(95)00647-9
   Eriksson U, 2012, ACTA OPHTHALMOL, V90, P620, DOI 10.1111/j.1755-3768.2011.02112.x
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Gomez ML, 2009, OPHTHALMOLOGY, V116, P2407, DOI 10.1016/j.ophtha.2009.05.012
   Griffith JF, 2015, CLIN OPHTHALMOL, V9, P1275, DOI 10.2147/OPTH.S85851
   He MS, 2018, DIABETES CARE, V41, P2202, DOI 10.2337/dc18-0707
   Jamous KF, 2015, CLIN EXP OPHTHALMOL, V43, P308, DOI 10.1111/ceo.12466
   Jones BW, 2016, FRONT CELL NEUROSCI, V10, DOI 10.3389/fncel.2016.00103
   Kim SY, 2002, RETINA-J RET VIT DIS, V22, P471, DOI 10.1097/00006982-200208000-00012
   Klein R, 2014, OPHTHAL EPIDEMIOL, V21, P14, DOI 10.3109/09286586.2013.867512
   Lamin A, 2019, EYE, V33, P428, DOI 10.1038/s41433-018-0234-9
   Lee EK, 2015, INVEST OPHTH VIS SCI, V56, P3976, DOI 10.1167/iovs.15-17013
   Lee HJ, 2016, AM J OPHTHALMOL, V161, P214, DOI 10.1016/j.ajo.2015.09.020
   Maynard ML, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-20659
   Medeiros NE, 2001, INVEST OPHTH VIS SCI, V42, P795
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Muftuoglu IK, 2018, GRAEF ARCH CLIN EXP, V256, P2035, DOI 10.1007/s00417-018-4093-7
   Muftuoglu IK, 2018, RETINA-J RET VIT DIS, V38, P1478, DOI 10.1097/IAE.0000000000001759
   Nagasaka Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep33921
   Olsson J, 1997, ACTA OPHTHALMOL SCAN, V75, P665
   Owsley C, 2000, INVEST OPHTH VIS SCI, V41, P267
   Ozaki E, 2014, ADV EXP MED BIOL, V801, P229, DOI 10.1007/978-1-4614-3209-8_30
   Phu J, 2018, TRANSL VIS SCI TECHN, V7, DOI 10.1167/tvst.7.5.3
   Phu J, 2017, INVEST OPHTH VIS SCI, V58, P4863, DOI 10.1167/iovs.17-22371
   Pilotto E, 2013, CAN J OPHTHALMOL, V48, P386, DOI 10.1016/j.jcjo.2013.03.022
   Pincelli Netto Mario, 2018, Med Hypothesis Discov Innov Ophthalmol, V7, P133
   Ramkumar HL, 2018, RETINA-J RET VIT DIS, V38, P2159, DOI 10.1097/IAE.0000000000001867
   Sadigh S, 2013, INVEST OPHTH VIS SCI, V54, P1603, DOI 10.1167/iovs.12-11286
   Savastano MC, 2014, INVEST OPHTH VIS SCI, V55, P560, DOI 10.1167/iovs.13-12172
   Schlanitz FG, 2017, BRIT J OPHTHALMOL, V101, P198, DOI 10.1136/bjophthalmol-2016-308422
   Sullivan RKP, 2007, INVEST OPHTH VIS SCI, V48, P2782, DOI 10.1167/iovs.06-1283
   Tong J, 2019, AM J OPHTHALMOL, V208, P166, DOI 10.1016/j.ajo.2019.04.020
   Toto L, 2016, RETINA-J RET VIT DIS, V36, P1566, DOI 10.1097/IAE.0000000000000962
   Trinh M, 2019, TRANSL VIS SCI TECHN, V8, DOI 10.1167/tvst.8.4.20
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yenice E, 2015, EYE, V29, P1076, DOI 10.1038/eye.2015.86
   Yoshioka N, 2018, INVEST OPHTH VIS SCI, V59, P1693, DOI 10.1167/iovs.17-23683
   Yoshioka N, 2017, INVEST OPHTH VIS SCI, V58, P3086, DOI 10.1167/iovs.17-21450
   Yu J, 2016, INVEST OPHTH VIS SCI, V57, pOCT204, DOI 10.1167/iovs.15-18630
   Zucchiatti I, 2015, AM J OPHTHALMOL, V160, P602, DOI 10.1016/j.ajo.2015.05.030
NR 53
TC 6
Z9 6
U1 0
U2 3
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAR
PY 2020
VL 61
IS 3
AR 2
DI 10.1167/iovs.61.3.2
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA LA8BU
UT WOS:000524168000002
PM 32150251
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Amoroso, F
   Miere, A
   Semoun, O
   Jung, C
   Capuano, V
   Souied, EH
AF Amoroso, Francesca
   Miere, Alexandra
   Semoun, Oudy
   Jung, Camille
   Capuano, Vittorio
   Souied, Eric H.
TI Optical coherence tomography angiography reproducibility of lesion size
   measurements in neovascular age-related macular degeneration (AMD)
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE OCT angiography; reproducibility; neovascular AMD
ID CLASSIC CHOROIDAL NEOVASCULARIZATION; INDOCYANINE GREEN ANGIOGRAPHY;
   MEMBRANES; TYPE-1
AB Purpose To evaluate the reproducibility and interuser agreement of measurements of choroidal neovascularisation in optical coherence tomography angiography (OCTA).
   Design Prospective non-interventional study.
   Methods Consecutive patients, presenting with neovascular age-related macular degeneration (AMD), underwent two sequential OCTA examinations (AngioVue, Optovue, Fremont, California, USA), performed by the same trained examiner. Neovascular lesion area was then measured on both examinations in the choriocapillaris automatic segmentation by two masked readers, using the semiautomated measuring software embedded in the instrument. Two measuring features were used: the first corresponding to the total manually contoured lesion area with the flow draw tool (select area) and the second to the total area of solely vessels with high flow within the lesion (vessel area). These measurements were then compared in order to assess both the reproducibility of OCTA examination and the interuser agreement with the embedded software.
   Results Forty-eight eyes of 46 patients (77.4 mean age,+/-8.2SD, range from 62 to 95 years old, eight men, 38 women) were included in our study. Mean choroidal neovascularisation area was of 0.72+/-0.7mm(2) for the first measurement and 0.75+/-0.76mm(2) for the second measurement; difference between the first and the second measurement was 0.03mm(2). Intrauser agreement was of 0.98 (CI 0.98 to 0.99) for both vessel area' and select area' features. Interuser agreement was of 0.98 (CI 0.97 to 0.99) for select area' and vessel area' features.
   Conclusion Our data suggest that OCTA provide reproducible imaging for evaluation of the neovascular size in the setting of AMD.
C1 [Amoroso, Francesca; Miere, Alexandra; Semoun, Oudy; Jung, Camille; Capuano, Vittorio; Souied, Eric H.] Univ Paris Est Creteil, Ctr Hosp Intercommunal Creteil, Dept Ophthalmol, F-94000 Creteil, France.
   [Amoroso, Francesca] Univ Napoli Federico II, Dept Neurosci, Eye Clin, Reprod & Odontostomatol Sci, Naples, Italy.
   [Jung, Camille; Souied, Eric H.] Univ Paris Est, GRC Macula Biol Resources Ctr, Ctr Clin Res Ctr, Creteil, France.
C3 Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil;
   University of Naples Federico II; Universite
   Paris-Est-Creteil-Val-de-Marne (UPEC)
RP Souied, EH (通讯作者)，Univ Paris Est Creteil, Ctr Hosp Intercommunal Creteil, Dept Ophthalmol, F-94000 Creteil, France.
EM eric.souied@chicreteil.fr
RI Miere, Alexandra/AIC-4074-2022
OI Miere, Alexandra/0000-0003-4123-8210; JUNG, Camille/0000-0001-8486-8939
CR Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Bruyere E, 2017, RETINA-J RET VIT DIS, V37, P2095, DOI 10.1097/IAE.0000000000001456
   Carpineto P, 2016, BRIT J OPHTHALMOL, V100, P671, DOI 10.1136/bjophthalmol-2015-307330
   Costanzo E, 2016, INVEST OPHTH VIS SCI, V57, pOCT307, DOI 10.1167/iovs.15-18830
   El Ameen A, 2015, RETINA-J RET VIT DIS, V35, P2212, DOI 10.1097/IAE.0000000000000773
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Gao SS, 2016, J BIOMED OPT, V21, DOI 10.1117/1.JBO.21.7.076010
   GASS JDM, 1994, AM J OPHTHALMOL, V118, P285, DOI 10.1016/S0002-9394(14)72951-4
   Gelisken F, 1998, JPN J OPHTHALMOL, V42, P300, DOI 10.1016/S0021-5155(98)00010-0
   Grossniklaus HE, 1998, AM J OPHTHALMOL, V126, P59, DOI 10.1016/S0002-9394(98)00145-7
   Hee MR, 1996, OPHTHALMOLOGY, V103, P1260, DOI 10.1016/S0161-6420(96)30512-5
   Jia YL, 2012, OPT EXPRESS, V20, P4710, DOI 10.1364/OE.20.004710
   Kuehlewein L, 2015, AM J OPHTHALMOL, V160, P739, DOI 10.1016/j.ajo.2015.06.030
   LOPEZ PF, 1993, OPHTHALMOLOGY, V100, P415
   Miere A, 2015, RETINA-J RET VIT DIS, V35, P2236, DOI 10.1097/IAE.0000000000000834
   Puliafito CA, 2014, OSLI RETINA, V45, P360, DOI 10.3928/23258160-20140925-01
   Semoun O, 2009, BRIT J OPHTHALMOL, V93, P182, DOI 10.1136/bjo.2008.145235
   Spaide RF, 2015, RETINA-J RET VIT DIS, V35, P2163, DOI 10.1097/IAE.0000000000000765
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
NR 20
TC 10
Z9 10
U1 0
U2 4
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD JUN
PY 2018
VL 102
IS 6
BP 821
EP 826
DI 10.1136/bjophthalmol-2017-310569
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GH2KR
UT WOS:000433231300018
PM 28855197
DA 2022-11-30
ER

PT J
AU Pushpoth, S
   Sykakis, E
   Merchant, K
   Browning, AC
   Gupta, R
   Talks, SJ
AF Pushpoth, Sreekumari
   Sykakis, Evripidis
   Merchant, Kinnar
   Browning, Andrew C.
   Gupta, Rajen
   Talks, S. James
TI Measuring the benefit of 4 years of intravitreal ranibizumab treatment
   for neovascular age-related macular degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID VERTEPORFIN; SECONDARY
AB Aim To analyse the benefit of intravitreal ranibizumab over 4 years for patients with neovascular age-related macular degeneration (AMD).
   Methods A retrospective case note review of all patients who started treatment between August 2007 and September 2009 in our unit, minimum follow-up 2 years, maximum 4 years. The main outcome measures were: numbers of patients with different levels of vision, changes in visual acuity, number of treatments and numbers remaining under follow-up.
   Results 1086 eyes of 1017 patients received treatment. Numbers of patients remaining under follow-up were 892/1017 (87.71%) at 12 months, 730/1017 (71.78%) at 24 months, 468/730 (64.11%) at 36 months and 110/217 (50.69%) at48 months. The main reasons for patients no longer being under follow-up were the consequences of old age or transfer of care. 50% of patients had 6/18 or better over 4 years. Patients received on average 5.79 +/- 2.53, 9.15 +/- 3.79, 11.22 +/- 4.92 and 13.7 +/- 7.84 injections by 12, 24, 36 and 48 months, respectively.
   Conclusions We suggest that the numbers of patients with a particular level of vision may best reflect the actual benefit of AMD treatment provided by a service. Long-term follow-up is required as only 72/730 (10%) had been discharged at 36 months, half of whom had good vision of greater than 60 letters. 83% and 65% of patients needed treatment in the third and fourth year. Follow-up may be for the rest of the patients' life or at some point they may no longer be well enough to attend.
C1 [Pushpoth, Sreekumari; Merchant, Kinnar; Browning, Andrew C.; Gupta, Rajen; Talks, S. James] Royal Victoria Infirm, Dept Ophthalmol, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England.
   [Sykakis, Evripidis] Whipps Cross Univ Hosp, Dept Ophthalmol, London, England.
C3 Newcastle University - UK; University of London; Queen Mary University
   London
RP Talks, SJ (通讯作者)，Royal Victoria Infirm, Dept Ophthalmol, Queen Victoria Rd, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England.
EM James.Talks@nuth.nhs.uk
RI Sykakis, Evripidis/AAE-2542-2022
CR AMD guidelines group, AMD GUID GROUP CLIN
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Mariani A, 2011, GRAEF ARCH CLIN EXP, V249, P1635, DOI 10.1007/s00417-011-1734-5
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   Sadda SR, 2010, RETINA-J RET VIT DIS, V30, P1390, DOI 10.1097/IAE.0b013e3181e44599
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
NR 13
TC 37
Z9 37
U1 0
U2 3
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD DEC
PY 2012
VL 96
IS 12
BP 1469
EP 1473
DI 10.1136/bjophthalmol-2012-302167
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 041SX
UT WOS:000311422600006
PM 23001255
DA 2022-11-30
ER

PT J
AU Brody, BL
   Roch-Levecq, AC
   Kaplan, RM
   Moutier, CY
   Brown, SI
AF Brody, Barbara L.
   Roch-Levecq, Anne-Catherine
   Kaplan, Robert M.
   Moutier, Christine Y.
   Brown, Stuart I.
TI Age-related macular degeneration: Self-management and reduction of
   depressive symptoms in a randomized, controlled study
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Article
DE age-related macular degeneration; cognitive-behavioral; self-management;
   self-efficacy; randomized controlled study; Geriatric Depression Scale
ID PHYSICAL-DISABILITY; VISUAL-ACUITY; LATE-LIFE; ANXIETY
AB OBJECTIVES: To assess the effectiveness of a self-management program for age-related macular degeneration (AMD) in reducing depressive symptoms.
   DESIGN: Analysis of 6-month follow-up for a subset of participants in a randomized, controlled trial who were clinically depressed at baseline.
   SETTING: University ophthalmology clinic.
   PARTICIPANTS: Thirty-two depressed older adult volunteers (mean age 81.5) with advanced AMD who had been randomized to a self-management program (n = 12) or one of two control conditions (n = 20). Subjects were included if at baseline they met criteria from the Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders, Axis, 1, Fourth Edition, Research Version, for major or minor depressive disorder with significant depressive symptoms (>= 5 points) on the 15-item Geriatric Depression Scale (GDS-15).
   INTERVENTION: AMD self-management program consisting of cognitive and behavioral elements including health education and enhancement of problem-solving skills.
   MEASUREMENTS: Primary outcome measure was GDS-15. Secondary outcome measures included National Eye Institute Visual Function Questionnaire (NEI-VFQ) and AMD Self-Efficacy Questionnaire.
   RESULTS: At 6-month follow-up, the self-management group had a significantly greater reduction in depressive symptoms on the GDS-15 than the controls (P = .03). The mean reduction of 2.92 points in the self-management group was more than the 2-point change threshold considered to be clinically meaningful. Change on the NEI-VFQ was nonsignificant. Reduction in depressive symptoms was associated with greater self-efficacy in the self-management group.
   CONCLUSION: These findings may support the effectiveness of an AMD self-management program for depressed older adults with advanced vision loss from AMD.
C1 Univ Calif San Diego, Dept Ophthalmol, Shiley Eye Ctr, La Jolla, CA 92093 USA.
   Univ Calif San Diego, Dept Family & Prevent Med, La Jolla, CA 92093 USA.
   Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA.
   Univ Calif Los Angeles, Dept Hlth Serv, Los Angeles, CA USA.
   Univ Calif Los Angeles, Dept Med, Los Angeles, CA USA.
C3 University of California System; University of California San Diego;
   University of California System; University of California San Diego;
   University of California System; University of California San Diego;
   University of California System; University of California Los Angeles;
   University of California System; University of California Los Angeles
RP Brown, SI (通讯作者)，Univ Calif San Diego, Dept Ophthalmol, Shiley Eye Ctr, 9415 Campus Point Dr, La Jolla, CA 92093 USA.
EM sbrown@eyecenter.ucsd.edu
RI KAPLAN, Robert/AAK-7342-2021
FU NATIONAL EYE INSTITUTE [R03EY013995, R01EY011924] Funding Source: NIH
   RePORTER
CR [Anonymous], 2001, HLTH BEH INT BIOL BE
   BAILEY IL, 1976, AM J OPTOM PHYS OPT, V53, P740
   Bandura Albert., 1992, SELF EFFICACY THOUGH, P3
   Blazer DG, 2003, J GERONTOL A-BIOL, V58, P249
   Brody BL, 2005, ARCH OPHTHALMOL-CHIC, V123, P46, DOI 10.1001/archopht.123.1.46
   Brody BL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1477, DOI 10.1001/archopht.120.11.1477
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   Brody BL, 1999, ANN BEHAV MED, V21, P322, DOI 10.1007/BF02895965
   Cohen J., 1988, STAT POWER ANAL BEHA, DOI DOI 10.1016/B978-0-12-179060-8.50006-2
   Dandona L, 1998, ARCH OPHTHALMOL-CHIC, V116, P545, DOI 10.1001/archopht.116.4.514
   Fawzy Fawzy I., 1994, General Hospital Psychiatry, V16, P149, DOI 10.1016/0163-8343(94)90098-1
   First MB, 1995, USERS GUIDE STRUCTUR
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gottlieb JL, 2002, JAMA-J AM MED ASSOC, V288, P2233, DOI 10.1001/jama.288.18.2233
   Hollingshead A.B., 1957, 2 FACTOR INDEX SOCIA
   KATZMAN R, 1983, AM J PSYCHIAT, V140, P734
   KOENIG HG, 1993, PSYCHOSOMATICS, V34, P61, DOI 10.1016/S0033-3182(93)71928-3
   Lee AG, 2004, J AM GERIATR SOC, V52, P453, DOI 10.1111/j.1532-5415.2004.52121.x
   Lenze EJ, 2001, AM J GERIAT PSYCHIAT, V9, P113, DOI 10.1176/appi.ajgp.9.2.113
   LORIG K, 1984, GERONTOLOGIST, V24, P455
   Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P1496, DOI 10.1001/archopht.116.11.1496
   OSSIPKLEIN D, 1997, ASSESSING HLTH STATU, P180
   Penninx BWJH, 1999, AM J PUBLIC HEALTH, V89, P1346, DOI 10.2105/AJPH.89.9.1346
   Rovner BW, 2002, ARCH OPHTHALMOL-CHIC, V120, P1041
   SCHEIER MF, 1994, J PERS SOC PSYCHOL, V67, P1063, DOI 10.1037/0022-3514.67.6.1063
   SHEIKH J I, 1986, Clinical Gerontologist, V5, P165
   Vinkers DJ, 2004, INT J GERIATR PSYCH, V19, P80, DOI 10.1002/gps.1043
NR 27
TC 53
Z9 54
U1 0
U2 12
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
EI 1532-5415
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD OCT
PY 2006
VL 54
IS 10
BP 1557
EP 1562
DI 10.1111/j.1532-5415.2006.00881.x
PG 6
WC Geriatrics & Gerontology; Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Geriatrics & Gerontology
GA 096NY
UT WOS:000241385300011
PM 17038074
DA 2022-11-30
ER

PT J
AU Zweifel, SA
   Imamura, Y
   Spaide, TC
   Fujiwara, T
   Spaide, RF
AF Zweifel, Sandrine A.
   Imamura, Yutaka
   Spaide, Theodore C.
   Fujiwara, Takamitsu
   Spaide, Richard F.
TI Prevalence and Significance of Subretinal Drusenoid Deposits (Reticular
   Pseudodrusen) in Age-Related Macular Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID 10-YEAR INCIDENCE; MACULOPATHY; RISK; PROGRESSION
AB Purpose: To determine the prevalence and significance of subretinal drusenoid deposits (reticular pseudodrusen) among patients with age-related macular degeneration (AMD).
   Design: A prospective study with a nested case-control study of consecutive patients with AMD seen in a referral retinal practice.
   Participants: There were 153 patients with AMD, 131 of whom had >= 1 eye with late AMD, which was defined as either central geographic atrophy or choroidal neovascularization. The control group consisted of 101 patients who did not have AMD as their primary diagnosis, central serous chorioretinopathy, high myopia, retinal detachment, or laser treatment in the macular area.
   Methods: The presence of subretinal drusenoid deposits was determined by 2 methods, using the blue channel of color fundus photograph and the spectral domain optical coherence tomography (SD-OCT) sections. Soft drusen were determined from color fundus photographs and confirmed by SD-OCT.
   Main Outcome Measures: Prevalence of ocular risk factors and subretinal drusenoid deposits in eyes with AMD and their association with late AMD. Results: There were 153 patients who had any form of AMD, with a mean age of 80.3 years. Subretinal drusenoid deposits were diagnosed in the case group in 13 (8.7%) of right and 18 (12.0%) of left eyes using the blue channel of the color photograph and in 58 (38.4%) of right and 54 (35.8%) of left eyes using SD-OCT. Soft drusen and subretinal drusenoid deposits detected by SD-OCT were found to be independently correlated with late AMD (soft drusen odds ratio = 16.66 [P<0.001]; subretinal drusenoid deposits as detected by OCT odds ratio = 2.64 [P = 0.034]). In the control group, subretinal drusenoid deposits were diagnosed in 6 (6.5%) of right and 6 (6.3%) of left eyes using SD-OCT.
   Conclusions: Both soft drusen and subretinal drusenoid deposits occur in patients with AMD and both are significantly associated with late AMD. These findings suggest that detection and classification of drusen and consequently assignment of risk should be based on a methodology that includes SD-OCT.
C1 [Zweifel, Sandrine A.; Imamura, Yutaka; Fujiwara, Takamitsu] Manhattan Eye Ear & Throat Hosp, LuEsther T Mertz Retinal Res Ctr, New York, NY 10021 USA.
   [Zweifel, Sandrine A.; Imamura, Yutaka; Spaide, Theodore C.; Fujiwara, Takamitsu; Spaide, Richard F.] Vitreous Retina Macula Consultants New York, New York, NY USA.
C3 Manhattan Eye Ear & Throat Hospital; Vitreous Retina Macula Consultants
   of New York
RP Spaide, RF (通讯作者)，460 Pk Ave,5th Floor, New York, NY 10022 USA.
EM rickspaide@yahoo.com
RI Spaide, Richard/ABD-7368-2020; Mitchell, Paul/P-1498-2014; Zweifel,
   Sandrine/AAX-5045-2020
FU Koureisha Ganshikkan Kenkyu Zaidan; Mishima Saiichi-kinen Gankakenkyu
   Kokusaikouryu Kikin; Takeda Kagaku Shinkou Zaidan; Iwate Medical
   University
FX Yutaka Imamura - received grants from Koureisha Ganshikkan Kenkyu
   Zaidan, Mishima Saiichi-kinen Gankakenkyu Kokusaikouryu Kikin, and
   Takeda Kagaku Shinkou Zaidan. Takamitsu Fujiwara - funded by Iwate
   Medical University.
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   [Anonymous], 2005, ARCH OPHTHALMOL-CHIC, V123, P1570, DOI DOI 10.1001/ARCHOPHT.123.11.1570
   ARNOLD JJ, 1995, RETINA-J RET VIT DIS, V15, P183, DOI 10.1097/00006982-199515030-00001
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P354, DOI 10.1136/bjo.2006.101022
   DELORI FC, 1975, INVEST OPHTH VISUAL, V14, P487
   Hamel CP, 2009, AM J OPHTHALMOL, V147, P609, DOI 10.1016/j.ajo.2008.10.022
   Hubbard LD, 2008, INVEST OPHTH VIS SCI, V49, P3269, DOI 10.1167/iovs.07-1267
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 2008, AM J OPHTHALMOL, V145, P317, DOI 10.1016/j.ajo.2007.09.008
   MIMOUN G, 1990, J FR OPHTALMOL, V13, P511
   Prenner JL, 2003, RETINA-J RET VIT DIS, V23, P307, DOI 10.1097/00006982-200306000-00004
   Rudolf M, 2008, EXP EYE RES, V87, P402, DOI 10.1016/j.exer.2008.07.010
   Smith RT, 2006, INVEST OPHTH VIS SCI, V47, P5495, DOI 10.1167/iovs.05-1318
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 18
TC 231
Z9 237
U1 0
U2 15
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD SEP
PY 2010
VL 117
IS 9
BP 1775
EP 1781
DI 10.1016/j.ophtha.2010.01.027
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 646DY
UT WOS:000281518100017
PM 20472293
DA 2022-11-30
ER

PT J
AU Saksens, NTM
   Geerlings, MJ
   Bakker, B
   Schick, T
   Daha, MR
   Fauser, S
   Boon, CJF
   de Jong, EK
   Hoyng, CB
   den Hollander, AI
AF Saksens, Nicole T. M.
   Geerlings, Maartje J.
   Bakker, Bjorn
   Schick, Tina
   Daha, Mohamed R.
   Fauser, Sascha
   Boon, Camiel J. F.
   de Jong, Eiko K.
   Hoyng, Carel B.
   den Hollander, Anneke I.
TI Rare Genetic Variants Associated With Development of Age-Related Macular
   Degeneration
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID HIGH-RISK; FAMILIAL AGGREGATION; CFH GENE; COMPLEMENT; MACULOPATHY;
   ACTIVATION; MUTATION; CONFERS; C3
AB IMPORTANCE Rare variants in the complement genes CFH, CFI, C9, and C3 have been found to be highly associated with age-related macular degeneration (AMD); however, the effect on clinical characteristics and familial segregation by these variants is lacking.
   OBJECTIVES To determine the contribution of rare CFH Arg1210Cys, CFI Gly119Arg, C9 Pro167Ser, and C3 Lys155Gln variants in the development of AMD in 22 multiplex families and to describe clinical differences in carriers vs noncarriers in these families and a large case-control cohort.
   DESIGN, SETTING, AND PARTICIPANTS This retrospective case-control study included 114 affected and 60 unaffected members of 22 multiplex families with AMD as well as 1589 unrelated patients with AMD and 1386 unrelated control individuals enrolled in the European Genetic Database (EUGENDA). Patients were recruited from March 29, 2006, to April 26, 2013, and data were collected from April 20, 2012, to May 7, 2014. All participants underwent an extensive ophthalmic examination and completed a questionnaire. Venous blood samples were obtained from all participants for genetic analysis, including whole-exome sequencing and measurements of complement activation. Data were analyzed from September 23, 2014, to November 4, 2015.
   MAIN OUTCOMES AND MEASURES Differences between carriers and noncarriers of rare variants in age at onset of symptoms, the family history of AMD, complement activation levels (C3d: C3 ratio), the presence of reticular pseudodrusen, and AMD phenotype.
   RESULTS Among the 114 affected and 60 unaffected members of 22 multiplex families with AMD and the 1598 unrelated patients with AMD and 1386 controls in the EUGENDA cohort who underwent analysis, the presence of the CFI Gly119Arg, C9 Pro167Ser, or C3 Lys155Gln variant was confirmed in 18 individuals in 5 families but did not completely segregate with the disease. In the case-control cohort, the 91 affected carriers of these variants were younger at symptom onset (mean [SD] age, 67.4 [8.5] vs 71.3 [8.9] years; P = .01) and more often reported a positive family history (35 of 79 [44.3%] vs 367 of 1201 [30.6%]; P = .008) compared with the 1498 noncarriers. Patients with advanced atrophic AMD carried these rare variants more frequently than patients with neovascular AMD (11 of 93 [11.8%] vs 40 of 835 [4.8%]; P = .04).
   CONCLUSIONS AND RELEVANCE Previously reported rare variants do not completely segregate within families with AMD. However, patients carrying these rare variants differ clinically from noncarriers by an earlier age at symptom onset, higher prevalence of a positive family history, and AMD phenotype. These results suggest that genetic tests for AMD might be designed to detect common and rare genetic variants, especially in families, because rare variants contribute to the age at onset and progression of the disease.
C1 [Saksens, Nicole T. M.; Geerlings, Maartje J.; Bakker, Bjorn; Boon, Camiel J. F.; de Jong, Eiko K.; Hoyng, Carel B.; den Hollander, Anneke I.] Radboud Univ Nijmegen, Med Ctr, Dept Ophthalmol, POB 9101, NL-6500 HB Nijmegen, Netherlands.
   [Schick, Tina; Fauser, Sascha] Univ Hosp Cologne, Dept Ophthalmol, Cologne, Germany.
   [Daha, Mohamed R.] Leiden Univ, Med Ctr, Dept Nephrol, Leiden, Netherlands.
   [Boon, Camiel J. F.] Leiden Univ, Med Ctr, Dept Ophthalmol, Leiden, Netherlands.
   [den Hollander, Anneke I.] Radboud Univ Nijmegen, Med Ctr, Dept Human Genet, NL-6500 HB Nijmegen, Netherlands.
C3 Radboud University Nijmegen; University of Cologne; Leiden University;
   Leiden University Medical Center (LUMC); Leiden University - Excl LUMC;
   Leiden University; Leiden University Medical Center (LUMC); Leiden
   University - Excl LUMC; Radboud University Nijmegen
RP den Hollander, AI (通讯作者)，Radboud Univ Nijmegen, Med Ctr, Dept Ophthalmol, POB 9101, NL-6500 HB Nijmegen, Netherlands.
EM anneke.denhollander@radboudumc.nl
RI de Jong, Eiko/P-3407-2015; Bakker, Bjorn/E-2842-2016; Hollander, Anneke
   den/N-4911-2014; Geerlings, Maartje/P-3338-2019; Boon, CJF/P-7534-2014
OI de Jong, Eiko/0000-0001-6520-0407; Geerlings,
   Maartje/0000-0003-1164-3573; Boon, CJF/0000-0002-6737-7932
FU European Research Council under the European Union [310644]; Foundation
   Fighting Blindness USA [C-GE-0811-0548-RAD04]; Nederlandse Oogonderzoek
   Stichting; Diana Hermens Stiching; MD Fonds; Oogfonds; Algemene
   Nederlandse Vereniging ter Voorkoming van Blindheid; Stichting
   Nederlands Oogheelkundig Onderzoek; Gelderse Blindenstichting
FX This study was supported by grant agreement 310644 (MACULA) from the
   European Research Council under the European Union's Seventh Framework
   Programme (FP/2007-2013), grant C-GE-0811-0548-RAD04 from the Foundation
   Fighting Blindness USA, Nederlandse Oogonderzoek Stichting, Diana
   Hermens Stiching, MD Fonds, Oogfonds, Algemene Nederlandse Vereniging
   ter Voorkoming van Blindheid, Stichting Nederlands Oogheelkundig
   Onderzoek, and Gelderse Blindenstichting.
CR Agarwal A, 2015, CLIN OPHTHALMOL, V9, P1001, DOI [10.2147/OPTH.S59725, 10.2147/OPTH.S74959]
   Alexander P, 2014, MOL VIS, V20, P1253
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Boon CJE, 2008, AM J HUM GENET, V82, P516, DOI 10.1016/j.ajhg.2007.11.007
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Duvvari MR, 2015, MOL VIS, V21, P285
   Duvvari MR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094165
   Ferrara D, 2015, JAMA OPHTHALMOL, V133, P785, DOI 10.1001/jamaophthalmol.2015.0814
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fritsche LG, 2013, NAT GENET, V45, p[433, 439e1]
   General Assembly of the World Medical Association, 2014, J Am Coll Dent, V81, P14
   Hecker LA, 2010, HUM MOL GENET, V19, P209, DOI 10.1093/hmg/ddp472
   HEIBA IM, 1994, GENET EPIDEMIOL, V11, P51, DOI 10.1002/gepi.1370110106
   Helgason H, 2013, NAT GENET, V45, P1371, DOI 10.1038/ng.2740
   Hoffman JD, 2014, INVEST OPHTH VIS SCI, V55, P4455, DOI 10.1167/iovs.13-13684
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Jun G, 2012, AM J HUM GENET, V91, P839, DOI 10.1016/j.ajhg.2012.09.004
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   KLEIN ML, 1994, ARCH OPHTHALMOL-CHIC, V112, P932, DOI 10.1001/archopht.1994.01090190080025
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324
   Luo L, 2008, VISION RES, V48, P494, DOI 10.1016/j.visres.2007.11.013
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110
   MEYERS SM, 1995, AM J OPHTHALMOL, V120, P757, DOI 10.1016/S0002-9394(14)72729-1
   Mokwa NF, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/385915
   Ratnapriya R, 2014, HUM MOL GENET, V23, P5827, DOI 10.1093/hmg/ddu276
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   ROTHER E, 1993, CLIN RHEUMATOL, V12, P31, DOI 10.1007/BF02231555
   Saksens NTM, 2014, INVEST OPHTH VIS SCI, V55, P7085, DOI 10.1167/iovs.14-14659
   Saksens NTM, 2014, PROG RETIN EYE RES, V39, P23, DOI 10.1016/j.preteyeres.2013.11.001
   Schramm EC, 2014, MOL IMMUNOL, V61, P118, DOI 10.1016/j.molimm.2014.06.032
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Shahid H, 2012, BRIT J OPHTHALMOL, V96, P427, DOI 10.1136/bjophthalmol-2011-300193
   Shen Si-kui, 2012, Zhonghua Yixue Yichuanxue Zazhi, V29, P570, DOI 10.3760/cma.j.issn.1003-9406.2012.05.015
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P339, DOI 10.1016/j.ophtha.2011.07.056
   van de Ven JPH, 2013, NAT GENET, V45, P813, DOI 10.1038/ng.2640
   Volz C, 2015, EUR J PHARM BIOPHARM, V95, P158, DOI 10.1016/j.ejpb.2015.02.020
   Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq603
   Yu Y, 2014, HUM MOL GENET, V23, P5283, DOI 10.1093/hmg/ddu226
   Zhan XW, 2013, NAT GENET, V45, P1375, DOI 10.1038/ng.2758
NR 44
TC 41
Z9 41
U1 4
U2 9
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD MAR
PY 2016
VL 134
IS 3
BP 287
EP 293
DI 10.1001/jamaophthalmol.2015.5592
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DH1JN
UT WOS:000372540300015
PM 26767664
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Sivakumaran, TA
   Igo, RP
   Kidd, JM
   Itsara, A
   Kopplin, LJ
   Chen, W
   Hagstrom, SA
   Peachey, NS
   Francis, PJ
   Klein, ML
   Chew, EY
   Ramprasad, VL
   Tay, WT
   Mitchell, P
   Seielstad, M
   Stambolian, DE
   Edwards, AO
   Lee, KE
   Leontiev, DV
   Jun, G
   Wang, Y
   Tian, LP
   Qiu, FY
   Henning, AK
   LaFramboise, T
   Sen, P
   Aarthi, M
   George, R
   Raman, R
   Das, MK
   Vijaya, L
   Kumaramanickavel, G
   Wong, TY
   Swaroop, A
   Abecasis, GR
   Klein, R
   Klein, BEK
   Nickerson, DA
   Eichler, EE
   Iyengar, SK
AF Sivakumaran, Theru A.
   Igo, Robert P., Jr.
   Kidd, Jeffrey M.
   Itsara, Andy
   Kopplin, Laura J.
   Chen, Wei
   Hagstrom, Stephanie A.
   Peachey, Neal S.
   Francis, Peter J.
   Klein, Michael L.
   Chew, Emily Y.
   Ramprasad, Vedam L.
   Tay, Wan-Ting
   Mitchell, Paul
   Seielstad, Mark
   Stambolian, Dwight E.
   Edwards, Albert O.
   Lee, Kristine E.
   Leontiev, Dmitry V.
   Jun, Gyungah
   Wang, Yang
   Tian, Liping
   Qiu, Feiyou
   Henning, Alice K.
   LaFramboise, Thomas
   Sen, Parveen
   Aarthi, Manoharan
   George, Ronnie
   Raman, Rajiv
   Das, Manmath Kumar
   Vijaya, Lingam
   Kumaramanickavel, Govindasamy
   Wong, Tien Y.
   Swaroop, Anand
   Abecasis, Goncalo R.
   Klein, Ronald
   Klein, Barbara E. K.
   Nickerson, Deborah A.
   Eichler, Evan E.
   Iyengar, Sudha K.
TI A 32 kb Critical Region Excluding Y402H in CFH Mediates Risk for
   Age-Related Macular Degeneration
SO PLOS ONE
LA English
DT Article
ID COMPLEMENT FACTOR-H; SEGMENTAL DUPLICATIONS; SUSCEPTIBILITY; HAPLOTYPE;
   VARIANT; GENOME; GENES; ASSOCIATION; MACULOPATHY; PROTEINS
AB Complement factor H shows very strong association with Age-related Macular Degeneration (AMD), and recent data suggest that multiple causal variants are associated with disease. To refine the location of the disease associated variants, we characterized in detail the structural variation at CFH and its paralogs, including two copy number polymorphisms (CNP), CNP147 and CNP148, and several rare deletions and duplications. Examination of 34 AMD-enriched extended families (N = 293) and AMD cases (White N = 4210 Indian = 134; Malay = 140) and controls (White N = 3229; Indian = 117; Malay = 2390) demonstrated that deletion CNP148 was protective against AMD, independent of SNPs at CFH. Regression analysis of seven common haplotypes showed three haplotypes, H1, H6 and H7, as conferring risk for AMD development. Being the most common haplotype H1 confers the greatest risk by increasing the odds of AMD by 2.75-fold (95% CI = [2.51, 3.01]; p = 8.31 x 10(-109)); Caucasian (H6) and Indian-specific (H7) recombinant haplotypes increase the odds of AMD by 1.85-fold (p = 3.52 x 10(-9)) and by 15.57-fold (P = 0.007), respectively. We identified a 32-kb region downstreamof Y402H (rs1061170), shared by all three risk haplotypes, suggesting that this region may be critical for AMD development. Further analysis showed that two SNPs within the 32 kb block, rs1329428 and rs203687, optimally explain disease association. rs1329428 resides in 20 kb unique sequence block, but rs203687 resides in a 12 kb block that is 89% similar to a noncoding region contained in Delta CNP148. We conclude that causal variation in this region potentially encompasses both regulatory effects at single markers and copy number.
C1 [Sivakumaran, Theru A.; Igo, Robert P., Jr.; Leontiev, Dmitry V.; Jun, Gyungah; Wang, Yang; Tian, Liping; Qiu, Feiyou] Case Western Reserve Univ, Dept Epidemiol & Biostat, Cleveland, OH 44106 USA.
   [Sivakumaran, Theru A.] Cincinnati Childrens Hosp Med Ctr, Div Human Genet, Cincinnati, OH USA.
   [Kopplin, Laura J.; LaFramboise, Thomas; Iyengar, Sudha K.] Case Western Reserve Univ, Dept Genet, Cleveland, OH 44106 USA.
   [Iyengar, Sudha K.] Case Western Reserve Univ, Dept Ophthalmol, Cleveland, OH 44106 USA.
   [Kidd, Jeffrey M.; Itsara, Andy; Nickerson, Deborah A.; Eichler, Evan E.] Univ Washington, Dept Genome Sci, Seattle, WA 98195 USA.
   [Chen, Wei; Abecasis, Goncalo R.] Univ Michigan Sch Publ Hlth, Ctr Stat Genet, Dept Biostat, Ann Arbor, MI USA.
   [Hagstrom, Stephanie A.; Peachey, Neal S.] Cleveland Clin, Cole Eye Inst, Cleveland, OH 44106 USA.
   [Hagstrom, Stephanie A.; Peachey, Neal S.] Case Western Reserve Univ, Dept Ophthalmol, Cleveland Clin Lerner Coll Med, Cleveland, OH 44106 USA.
   [Peachey, Neal S.] Vet Affairs Med Ctr, Louis Stokes Cleveland Dept, Res Serv, Cleveland, OH USA.
   [Francis, Peter J.; Klein, Michael L.] Oregon Hlth & Sci Univ, Casey Eye Inst, Portland, OR 97201 USA.
   [Chew, Emily Y.] NEI, Div Epidemiol & Clin Applicat, Bethesda, MD 20892 USA.
   [Ramprasad, Vedam L.; Aarthi, Manoharan; Kumaramanickavel, Govindasamy] Sankara Nethralaya, Vis Res Fdn, SNONGC Dept Genet & Mol Biol, Chennai, Tamil Nadu, India.
   [Tay, Wan-Ting; Wong, Tien Y.] Natl Univ Singapore, Yong Loo Lin Sch Med, Singapore Eye Res Inst, Singapore 117595, Singapore.
   [Mitchell, Paul] Univ Sydney, Ctr Vis Res, Sydney, NSW 2006, Australia.
   [Seielstad, Mark] Genome Inst Singapore, Singapore, Singapore.
   [Stambolian, Dwight E.] Univ Penn, Dept Ophthalmol, Philadelphia, PA 19104 USA.
   [Stambolian, Dwight E.] Univ Penn, Dept Genet, Philadelphia, PA 19104 USA.
   [Edwards, Albert O.] Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA.
   [Lee, Kristine E.; Klein, Ronald; Klein, Barbara E. K.] Univ Wisconsin Sch Med & Publ Hlth, Dept Ophthalmol & Visual Sci, Madison, WI USA.
   [Jun, Gyungah] Boston Univ, Dept Med, Boston, MA 02215 USA.
   [Jun, Gyungah] Boston Univ, Dept Ophthalmol, Boston, MA 02215 USA.
   [Jun, Gyungah] Boston Univ, Dept Biostat, Boston, MA 02215 USA.
   [Henning, Alice K.] EMMES Corp, Rockville, MD USA.
   [Sen, Parveen; Raman, Rajiv; Das, Manmath Kumar; Vijaya, Lingam] Sankara Nethralaya, Vis Res Fdn, Dept Med Retina, Chennai, Tamil Nadu, India.
   [George, Ronnie] Sankara Nethralaya, Vis Res Fdn, Dept Glaucoma, Chennai, Tamil Nadu, India.
   [Wong, Tien Y.] Univ Melbourne, Ctr Eye Res Australia, Melbourne, Australia.
   [Swaroop, Anand] NEI, Neurobiol Neurodegenerat & Repair Lab, Bethesda, MD 20892 USA.
   [Swaroop, Anand] Univ Michigan, Kellogg Eye Ctr, Ann Arbor, MI 48109 USA.
   [Swaroop, Anand] Univ Michigan, Dept Human Genet, Ann Arbor, MI 48109 USA.
   [Eichler, Evan E.] Univ Washington, Howard Hughes Med Inst, Seattle, WA 98195 USA.
C3 Case Western Reserve University; Cincinnati Children's Hospital Medical
   Center; Case Western Reserve University; Case Western Reserve
   University; University of Washington; University of Washington Seattle;
   University of Michigan System; University of Michigan; Cleveland Clinic
   Foundation; Case Western Reserve University; Cleveland Clinic
   Foundation; US Department of Veterans Affairs; Veterans Health
   Administration (VHA); Case Western Reserve University; Louis Stokes
   Cleveland Veterans Affairs Medical Center; Oregon Health & Science
   University; National Institutes of Health (NIH) - USA; NIH National Eye
   Institute (NEI); National University of Singapore; Singapore National
   Eye Center; University of Sydney; Agency for Science Technology &
   Research (A*STAR); A*STAR - Genome Institute of Singapore (GIS);
   University of Pennsylvania; University of Pennsylvania; University of
   Oregon; University of Wisconsin System; Boston University; Boston
   University; Boston University; Emmes Corporation; Centre for Eye
   Research Australia; University of Melbourne; National Institutes of
   Health (NIH) - USA; NIH National Eye Institute (NEI); University of
   Michigan System; University of Michigan; University of Michigan System;
   University of Michigan; Howard Hughes Medical Institute; University of
   Washington; University of Washington Seattle
RP Sivakumaran, TA (通讯作者)，Case Western Reserve Univ, Dept Epidemiol & Biostat, Cleveland, OH 44106 USA.
EM ski@case.edu
RI Mitchell, Paul/P-1498-2014; Chen, Wei/AAX-5994-2020; KUMARAMANICKAVEL,
   GOVINDASAMY/AAN-9203-2021; Raman, Rajiv/A-7234-2009; Igo,
   Rob/P-3438-2019; Seielstad, Mark/T-7841-2019; Peachey, Neal/G-5533-2010;
   Wong, Tien Yin/AAC-9724-2020; /S-1190-2019; Sen, Parveen/W-4707-2019
OI Chen, Wei/0000-0001-7196-8703; KUMARAMANICKAVEL,
   GOVINDASAMY/0000-0001-8516-8301; Raman, Rajiv/0000-0001-5842-0233; Igo,
   Rob/0000-0002-0024-1993; Peachey, Neal/0000-0002-4419-7226; Wong, Tien
   Yin/0000-0002-8448-1264; /0000-0001-7488-250X; Manoharan,
   Aarthi/0000-0003-2318-2786; Klein, Ronald/0000-0002-4428-6237; Jun,
   Gyungah/0000-0002-3230-8697; Swaroop, Anand/0000-0002-1975-1141;
   Seielstad, Mark/0000-0001-5783-1401; Abecasis,
   Goncalo/0000-0003-1509-1825; Kidd, Jeffrey/0000-0002-9631-1465; george,
   ronnie/0000-0001-7368-0252
FU National Eye Institute [EY015810, U10EY06594, EY015286, EY13438,
   EY10605, T32 EY007157]; Retina Research Foundation; Department of
   Biotechnology, Government of India, New Delhi, India
   [DBT/PR7788/MED/12/299/2006]; National Heart, Lung, and Blood Institute
   [HL07567]; National Institute of Diabetes and Digestive and Kidney
   Diseases [U01DK057292]; National Institutes of Health [T32 GM07250];
   Singapore's National Medical Research Council [0796/2003, 0863/2004,
   CSI/0002/2005]; Biomedical Research Council [501/1/25-5]; Singapore
   Tissue Network; U.S. Public Health Service Resource from National Center
   for Research Resources [RR03655]; Gene Expression and Genotyping
   Facility of the Comprehensive Cancer Center at Case Western Reserve
   University; University Hospitals of Cleveland [P30CA43703]; NATIONAL
   CANCER INSTITUTE [P30CA043703] Funding Source: NIH RePORTER; NATIONAL
   CENTER FOR RESEARCH RESOURCES [P41RR003655] Funding Source: NIH
   RePORTER; NATIONAL EYE INSTITUTE [R03EY013438, ZIAEY000475, T32EY007157,
   U10EY006594, R01EY015286, R01EY015810, R01EY010605] Funding Source: NIH
   RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007567]
   Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND
   DIGESTIVE AND KIDNEY DISEASES [U01DK057292] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007266,
   T32GM007250] Funding Source: NIH RePORTER
FX This study was supported, in part, by EY015810, U10EY06594, EY015286,
   EY13438, EY10605 and T32 EY007157 from the National Eye Institute; the
   Retina Research Foundation; the Department of Biotechnology
   (DBT/PR7788/MED/12/299/2006), Government of India, New Delhi, India
   (GK); training grant HL07567, from the National Heart, Lung, and Blood
   Institute; U01DK057292 from the National Institute of Diabetes and
   Digestive and Kidney Diseases; and the Medical Sciences Training Program
   T32 GM07250 (LJK), National Institutes of Health; grants from
   Singapore's National Medical Research Council Grant (0796/2003,
   0863/2004 and CSI/0002/2005), Biomedical Research Council (501/1/25-5)
   and Singapore Tissue Network. Some of the analyses were carried out
   using the software package S.A.G.E., which is supported by a U.S. Public
   Health Service Resource Grant (RR03655) from the National Center for
   Research Resources. This research was also supported by the Gene
   Expression and Genotyping Facility of the Comprehensive Cancer Center at
   Case Western Reserve University and University Hospitals of Cleveland
   (P30CA43703). The funders had no role in study design, data collection
   and analysis, decision to publish, or preparation of the manuscript.
CR Bailey JA, 2002, SCIENCE, V297, P1003, DOI 10.1126/science.1072047
   Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Dewan A, 2007, CURR OPIN GENET DEV, V17, P228, DOI 10.1016/j.gde.2007.04.004
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Eichler EE, 2007, NATURE, V447, P161, DOI 10.1038/447161a
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Francis PJ, 2008, HUM MOL GENET, V17, P2673, DOI 10.1093/hmg/ddn167
   Fritsche LG, 2010, HUM MOL GENET, V19, P4694, DOI 10.1093/hmg/ddq399
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hageman GS, 2006, ANN MED, V38, P592, DOI 10.1080/07853890601097030
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hakobyan S, 2008, INVEST OPHTH VIS SCI, V49, P1983, DOI 10.1167/iovs.07-1523
   Heinen S, 2009, BLOOD, V114, P2439, DOI 10.1182/blood-2009-02-205641
   Hellwage J, 1999, FEBS LETT, V462, P345, DOI 10.1016/S0014-5793(99)01554-9
   Huang L, 2009, AM J HUM GENET, V84, P235, DOI 10.1016/j.ajhg.2009.01.013
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Iyengar SK, 2004, AM J HUM GENET, V74, P20, DOI 10.1086/380912
   Jokiranta TS, 2000, J BIOL CHEM, V275, P27657
   Jozsi M, 2008, TRENDS IMMUNOL, V29, P380, DOI 10.1016/j.it.2008.04.008
   Kidd JM, 2008, NATURE, V453, P56, DOI 10.1038/nature06862
   Kidd JM, 2008, GENOME RES, V18, P2016, DOI 10.1101/gr.081786.108
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2002, AM J EPIDEMIOL, V156, P589, DOI 10.1093/aje/kwf092
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kopplin LJ, 2010, GENES IMMUN, V11, P609, DOI 10.1038/gene.2010.39
   Korn JM, 2008, NAT GENET, V40, P1253, DOI 10.1038/ng.237
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Marchini J, 2006, AM J HUM GENET, V78, P437, DOI 10.1086/500808
   Marques-Bonet T, 2009, NATURE, V457, P877, DOI 10.1038/nature07744
   McCarroll SA, 2008, NAT GENET, V40, P1166, DOI 10.1038/ng.238
   Patel N, 2008, EYE, V22, P768, DOI 10.1038/sj.eye.6702844
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Raychaudhuri S, 2010, NAT GENET, V42, P553, DOI 10.1038/ng0710-553
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Schick JH, 2003, AM J HUM GENET, V72, P1412, DOI 10.1086/375500
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Spencer KL, 2008, HUM MOL GENET, V17, P971, DOI 10.1093/hmg/ddm369
   Stephens M, 2001, AM J HUM GENET, V68, P978, DOI 10.1086/319501
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   Tamura K, 2007, MOL BIOL EVOL, V24, P1596, DOI 10.1093/molbev/msm092
   Thompson CL, 2007, HUM MOL GENET, V16, P2135, DOI 10.1093/hmg/ddm164
   Wang K, 2007, GENOME RES, V17, P1665, DOI 10.1101/gr.6861907
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
NR 46
TC 45
Z9 50
U1 0
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 12
PY 2011
VL 6
IS 10
AR e25598
DI 10.1371/journal.pone.0025598
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 834PW
UT WOS:000295976000025
PM 22022419
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Tuo, JS
   Wang, YJ
   Cheng, R
   Li, YC
   Chen, M
   Qiu, FF
   Qian, HH
   Shen, DF
   Penalva, R
   Xu, HP
   Ma, JX
   Chan, CC
AF Tuo, Jingsheng
   Wang, Yujuan
   Cheng, Rui
   Li, Yichao
   Chen, Mei
   Qiu, Fangfang
   Qian, Haohua
   Shen, Defen
   Penalva, Rosana
   Xu, Heping
   Ma, Jian-Xing
   Chan, Chi-Chao
TI Wnt signaling in age-related macular degeneration: human macular tissue
   and mouse model
SO JOURNAL OF TRANSLATIONAL MEDICINE
LA English
DT Article
DE Wnt signaling; Antibody against Wnt receptor LRP6; Mouse model; Retinal
   lesion; Ccl2(-/-)/Cx3cr1(-/-)/rd8 mouse; Ccl2(-/-)/Cx3cr1(gfp/gfp)
   mouse; Serum kallistatin
ID CCL2/CX3CR1-DEFICIENT MICE; RETINAL DEGENERATION; PATHOGENIC ROLE;
   PATHWAY; INFLAMMATION; LESIONS; NEUROPROTECTION; ACCUMULATION;
   EXPRESSION; INHIBITOR
AB Background: The wingless-type MMTV integration site (Wnt) signaling is a group of signal transduction pathways. In canonical Wnt pathway, Wnt ligands bind to low-density lipoprotein receptor-related protein 5 or 6 (LRP5 or LRP6), resulting in phosphorylation and activation of the receptor. We hypothesize that canonical Wnt pathway plays a role in the retinal lesion of age-related macular degeneration (AMD), a leading cause of irreversible central visual loss in elderly.
   Methods: We examined LRP6 phosphorylation and Wnt signaling cascade in human retinal sections and plasma kallistatin, an endogenous inhibitor of the Wnt pathway in AMD patients and non-AMD subjects. We also used the Ccl2(-/-)/Cx3cr1(-/-)/rd8 and Ccl2(-/-)/Cx3cr1(gfp/gfp) mouse models with AMD-like retinal degeneration to further explore the involvement of Wnt signaling activation in the retinal lesions in those models and to preclinically evaluate the role of Wnt signaling suppression as a potential therapeutic option for AMD.
   Results: We found higher levels of LRP6 (a key Wnt signaling receptor) protein phosphorylation and transcripts of the Wnt pathway-targeted genes, as well as higher beta-catenin protein in AMD macula compared to controls. Kallistatin was decreased in the plasma of AMD patients. Retinal non-phosphorylated-beta-catenin and phosphorylated-LRP6 were higher in Ccl2(-/-)/Cx3cr1(-/-)/rd8 mice than that in wild type. Intravitreal administration of an anti-LRP6 antibody slowed the progression of retinal lesions in Ccl2(-/-)/Cx3cr1(-/-)/rd8 and Ccl2(-/-)/Cx3cr1(gfp/gfp) mice. Electroretinography of treated eyes exhibited larger amplitudes compared to controls in both mouse models. A2E, a retinoid byproduct associated with AMD was lower in the treated eyes of Ccl2(-/-)/Cx3cr1(-/-)/rd8 mice. Anti-LRP6 also suppressed the expression of Tnf-alpha and Icam-1 in Ccl2(-/-)/Cx3cr1(-/-)/rd8 retinas.
   Conclusions: Wnt signaling may be disturbed in AMD patients, which could contribute to the retinal inflammation and increased A2E levels found in AMD. Aberrant activation of canonical Wnt signaling might also contribute to the focal retinal degenerative lesions of mouse models with Ccl2 and Cx3cr1 deficiency, and intravitreal administration of anti-LRP6 antibody could be beneficial by deactivating the canonical Wnt pathway.
C1 [Tuo, Jingsheng; Wang, Yujuan; Shen, Defen; Chan, Chi-Chao] NEI, Immunol Lab, NIH, Bethesda, MD 20892 USA.
   [Cheng, Rui; Qiu, Fangfang; Ma, Jian-Xing] Univ Oklahoma, Hlth Sci Ctr, Dept Physiol, Oklahoma City, OK USA.
   [Li, Yichao; Qian, Haohua] NEI, Visual Funct Core, NIH, Bethesda, MD 20892 USA.
   [Chen, Mei; Penalva, Rosana; Xu, Heping] Queens Univ Belfast, Ctr Med Expt, Belfast, Antrim, North Ireland.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); University of Oklahoma System; University of Oklahoma Health
   Sciences Center; National Institutes of Health (NIH) - USA; NIH National
   Eye Institute (NEI); Queens University Belfast
RP Chan, CC (通讯作者)，NEI, Immunol Lab, NIH, 10 Ctr Dr,Bldg 10,Rm 10N103, Bethesda, MD 20892 USA.
EM chanc@nei.nih.gov
RI Qiu, Fangfang/GLT-3181-2022; Xu, Heping/A-4430-2008; Qiu,
   Fangfang/GLT-3151-2022; wang, yujuan/C-8428-2016
OI Qiu, Fangfang/0000-0002-3584-0275; Xu, Heping/0000-0003-4000-931X; Qiu,
   Fangfang/0000-0002-3584-0275; 
FU Intramural Research Program of National Eye Institute, National
   Institutes of Health; NIH [EY019309, EY018659, EY012231]; Fight for
   Sight Pioneering eye research, UK; JDRF grant; NATIONAL EYE INSTITUTE
   [R01EY012231, R01EY019309, ZIAEY000530, ZICEY000503, R01EY018659]
   Funding Source: NIH RePORTER; Fight for Sight [1361/62] Funding Source:
   researchfish
FX This work was supported by the Intramural Research Program of National
   Eye Institute, National Institutes of Health; NIH research Grants
   EY019309, EY018659, and EY012231; Fight for Sight Pioneering eye
   research, UK; and a JDRF grant. We thank Mr. Nicholas Popp (NEI) for
   language editing.
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Ardeljan D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095900
   Ben-Shabat S, 2001, BIOORG MED CHEM LETT, V11, P1533, DOI 10.1016/S0960-894X(01)00314-6
   Bilic J, 2007, SCIENCE, V316, P1619, DOI 10.1126/science.1137065
   Cerpa W, 2009, DRUG NEWS PERSPECT, V22, P579, DOI [10.1358/dnp.2009.10.1436817, 10.1358/dnp.2009.22.10.1443391]
   Chan CC, 2008, OPHTHALMIC RES, V40, P124, DOI 10.1159/000119862
   Chen JJ, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/658925
   Chen M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061381
   Chen M, 2013, INVEST OPHTH VIS SCI, V54, P682, DOI 10.1167/iovs.12-10888
   Chen M, 2012, GLIA, V60, P833, DOI 10.1002/glia.22315
   Chu XK, 2014, AGE, V36, P1453, DOI 10.1007/s11357-014-9627-2
   Chu XK, 2013, BIOENGINEERED, V4, P130, DOI 10.4161/bioe.22949
   Cui L, 2013, J CLIN INVEST, V123, P1647, DOI 10.1172/JCI65048
   Dai ZY, 2013, J CELL BIOCHEM, V114, P1020, DOI 10.1002/jcb.24441
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Hackam AS, 2005, IUBMB LIFE, V57, P381, DOI 10.1080/15216540500137586
   Hombrebueno JR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097970
   Hu Y, 2013, INVEST OPHTH VIS SCI, V54, P141, DOI 10.1167/iovs.12-10281
   Jenkins Alicia J, 2010, J Angiogenes Res, V2, P19, DOI 10.1186/2040-2384-2-19
   Karan G, 2005, P NATL ACAD SCI USA, V102, P4164, DOI 10.1073/pnas.0407698102
   Klaus A, 2008, NAT REV CANCER, V8, P387, DOI 10.1038/nrc2389
   Lee K, 2014, J CELL SCI, V127, P4857, DOI 10.1242/jcs.149302
   Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126
   Lu SL, 2013, ANTIMICROB AGENTS CH, V57, P5366, DOI 10.1128/AAC.00322-13
   MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016
   MacDonald BT, 2012, COLD SPRING HARB PER, V4, P1, DOI DOI 10.1101/CSHPERSPECT.A007880)
   Marchetti B, 2013, EUR J NEUROSCI, V37, P1550, DOI 10.1111/ejn.12166
   McBride JD, 2014, J INVEST DERMATOL, V134, P1725, DOI 10.1038/jid.2014.40
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Nussenblatt RB, 2014, AM J OPHTHALMOL, V158, P5, DOI 10.1016/j.ajo.2014.03.014
   Oguma K, 2010, FUTURE ONCOL, V6, P515, DOI [10.2217/fon.10.13, 10.2217/FON.10.13]
   Paques M, 2007, INVEST OPHTH VIS SCI, V48, P2769, DOI 10.1167/iovs.06-1099
   Parish CA, 1998, P NATL ACAD SCI USA, V95, P14609, DOI 10.1073/pnas.95.25.14609
   Park K, 2011, MOL CELL BIOL, V31, P3038, DOI 10.1128/MCB.01211-10
   Park KH, 2014, INVEST OPHTH VIS SCI, V55, P5522, DOI 10.1167/iovs.14-14566
   Popp N, 2013, J CLIN EXP OPHTHALMO, V4
   Ramkumar HL, 2013, J NUTR, V143, P1129, DOI 10.3945/jn.112.169649
   Ross RJ, 2008, EXP EYE RES, V86, P675, DOI 10.1016/j.exer.2008.01.014
   Schon S, 2014, INT J CANCER, V135, P1800, DOI 10.1002/ijc.28839
   Shen DF, 2011, INVEST OPHTH VIS SCI, V52, P2897, DOI 10.1167/iovs.10-6114
   Toledo EM, 2008, PROG NEUROBIOL, V86, P281, DOI 10.1016/j.pneurobio.2008.08.001
   Tuo J, 2012, NEUROBIOL AGING, V33, pe410
   Tuo JS, 2007, INVEST OPHTH VIS SCI, V48, P3827, DOI 10.1167/iovs.07-0051
   Tuo JS, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-59
   Tuo JS, 2009, AM J PATHOL, V175, P799, DOI 10.2353/ajpath.2009.090089
   Wang YJ, 2014, LAB INVEST, V94, P674, DOI 10.1038/labinvest.2014.60
   Wang YJ, 2013, ASN NEURO, V5, DOI 10.1042/AN20130028
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
   Xu HP, 2008, EXP EYE RES, V87, P319, DOI 10.1016/j.exer.2008.06.012
   Zarbin MA, 1998, EUR J OPHTHALMOL, V8, P199, DOI 10.1177/112067219800800401
   Zhang B, 2010, P NATL ACAD SCI USA, V107, P6900, DOI 10.1073/pnas.0906764107
   Zhang JM, 2013, MOL CELL BIOCHEM, V379, P295, DOI 10.1007/s11010-013-1654-2
   Zhang J, 2013, SYNAPSE, V67, P515, DOI 10.1002/syn.21674
   Zhou T, 2010, INVEST OPHTH VIS SCI, V51, P4371, DOI 10.1167/iovs.09-4278
NR 56
TC 28
Z9 28
U1 0
U2 10
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1479-5876
J9 J TRANSL MED
JI J. Transl. Med.
PD OCT 17
PY 2015
VL 13
AR 330
DI 10.1186/s12967-015-0683-x
PG 12
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA CT5TX
UT WOS:000362874900001
PM 26476672
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Hatz, K
   Schneider, U
   Henrich, PB
   Braun, B
   Sacu, S
   Prunte, C
AF Hatz, Katja
   Schneider, Ulrike
   Henrich, P. Bernhard
   Braun, Beatrice
   Sacu, Stefan
   Pruente, Christian
TI Ranibizumab plus Verteporfin Photodynamic Therapy in Neovascular
   Age-Related Macular Degeneration: 12 Months of Retreatment and Vision
   Outcomes from a Randomized Study
SO OPHTHALMOLOGICA
LA English
DT Article
DE Age-related macular degeneration; Anti-VEGF; Photodynamic therapy
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; INTRAVITREAL TRIAMCINOLONE;
   PIGMENT EPITHELIUM; CLINICAL-TRIALS; DOSING REGIMEN; COMBINATION;
   MONOTHERAPY; VEGF; EXPRESSION; EFFICACY
AB Purpose: To investigate the injection frequency and visual acuity (VA) outcomes with combination therapy (ranibizumab plus verteporfin photodynamic therapy, PDT) versus monotherapy (ranibizumab). Methods: A total of 40 patients with exudative age-related macular degeneration were randomized 1:1 to ranibizumab 0.3 mg plus single standard verteporfin PDT or ranibizumab 0.3 mg plus sham PDT. Ranibizumab was administered 3 times monthly followed by 'as needed' to month 12 based on predetermined vision/anatomical criteria. Retreatment rates, VA outcomes and safety were assessed. Results: During months 3-12, combination therapy patients required fewer ranibizumab injections (mean 1.3) compared with monotherapy patients (2.8). Mean VA improved by 9.0 letters with combination therapy versus 7.5 letters in the monotherapy group at month 12. Both treatment regimens were well tolerated. Conclusion: The need for ranibizumab retreatment might be reduced by administering a single verteporfin PDT on the same day as the first ranibizumab injection, without compromising VA outcomes or safety. (C) 2014 S. Karger AG, Basel
C1 [Hatz, Katja; Pruente, Christian] Vista Klin, CH-4102 Binningen, Switzerland.
   [Hatz, Katja; Pruente, Christian] Kantonsspital Liestal, Dept Ophthalmol, CH-4410 Liestal, Switzerland.
   [Hatz, Katja; Schneider, Ulrike; Henrich, P. Bernhard; Braun, Beatrice; Pruente, Christian] Univ Basel, Dept Ophthalmol, Basel, Switzerland.
   [Sacu, Stefan; Pruente, Christian] Med Univ Vienna, Dept Ophthalmol & Optometry, Vienna, Austria.
C3 Kantonsspital Baselland; University of Basel; Medical University of
   Vienna
RP Prunte, C (通讯作者)，Vista Klin, Hauptstr 55, CH-4102 Binningen, Switzerland.
EM cpruente@vistaklinik.ch
FU Novartis Pharma AG
FX The authors would like to acknowledge Shona Cowper of Chameleon
   Communications International, who provided medical writing services with
   funding from Novartis Pharma AG. This encompassed the preparation of a
   first draft, editing, checking content and language, formatting,
   referencing, preparing tables and figures, and incorporating the
   authors' revisions, all under the direction of the authors. At all
   stages, the authors have had control over the content of this
   manuscript, for which they have given final approval and take full
   responsibility. Novartis Pharma AG enforces a 'no ghost-writing' policy.
   As funding sponsors, they have had the opportunity to review the
   manuscript, but do not have authority to change any aspect of a
   manuscript.
CR Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Augustin AJ, 2006, OPHTHALMOLOGY, V113, P14, DOI 10.1016/j.ophtha.2005.09.002
   Bashshur ZF, 2011, RETINA-J RET VIT DIS, V31, P636, DOI 10.1097/IAE.0b013e3181fe54ab
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Chen E, 2010, CLIN OPHTHALMOL, V4, P1073, DOI 10.2147/OPTH.S13969
   Cruess AF, 2009, ACTA OPHTHALMOL, V87, P118, DOI 10.1111/j.1755-3768.2008.01218.x
   Dewi NA, 2008, JPN J OPHTHALMOL, V52, P277, DOI 10.1007/s10384-008-0551-9
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Giustolisi Rosalia, 2011, Digit J Ophthalmol, V17, P23, DOI 10.5693/djo.01.2011.05.003
   HOLM S, 1979, SCAND J STAT, V6, P65
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Kaiser PK, 2007, CURR MED RES OPIN, V23, P477, DOI 10.1185/030079907X167624
   Kaiser PK, 2012, OPHTHALMOLOGY, V119, P1001, DOI 10.1016/j.ophtha.2012.02.003
   Krebs I, 2013, ACTA OPHTHALMOL, V91, pE178, DOI 10.1111/aos.12018
   Larsen M, 2012, OPHTHALMOLOGY, V119, P992, DOI 10.1016/j.ophtha.2012.02.002
   Lazic R, 2007, OPHTHALMOLOGY, V114, P1179, DOI 10.1016/j.ophtha.2007.03.006
   Novartis Europharm Ltd, 2013, LUC RAN SUMM PROD CH
   Ozkiris A, 2010, EXPERT OPIN THER PAT, V20, P103, DOI 10.1517/13543770902762885
   Sacu S, 2008, BRIT J OPHTHALMOL, V92, P1347, DOI 10.1136/bjo.2008.137885
   Schmidt-Erfurth U, 2000, SURV OPHTHALMOL, V45, P195, DOI 10.1016/S0039-6257(00)00158-2
   Schmidt-Erfurth U, 2003, INVEST OPHTH VIS SCI, V44, P4473, DOI 10.1167/iovs.02-1115
   Tatar O, 2006, AM J OPHTHALMOL, V142, P95, DOI 10.1016/j.ajo.2006.01.085
   Vallance JH, 2010, EYE, V24, P1561, DOI 10.1038/eye.2010.84
   Wolf-Schnurrbusch UEK, 2011, ACTA OPHTHALMOL, V89, P585, DOI 10.1111/j.1755-3768.2009.01747.x
   Zhang J, 1997, CONTROL CLIN TRIALS, V18, P204, DOI 10.1016/S0197-2456(96)00129-8
NR 25
TC 15
Z9 15
U1 0
U2 5
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2015
VL 233
IS 2
BP 66
EP 73
DI 10.1159/000367603
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CC8AX
UT WOS:000350591400002
PM 25471330
DA 2022-11-30
ER

PT J
AU Aoki, A
   Tan, X
   Yamagishi, R
   Shinkai, S
   Obata, R
   Miyaji, T
   Yamaguchi, T
   Numaga, J
   Ito, H
   Yanagi, Y
AF Aoki, Aya
   Tan, Xue
   Yamagishi, Reiko
   Shinkai, Shoji
   Obata, Ryo
   Miyaji, Tempei
   Yamaguchi, Takuhiro
   Numaga, Jiro
   Ito, Hideki
   Yanagi, Yasuo
TI Risk Factors for Age-Related Macular Degeneration in an Elderly Japanese
   Population: The Hatoyama Study
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE AMD; complement factor H; age-related maculopathy susceptibility 2
ID COMPLEMENT FACTOR-H; C-REACTIVE PROTEIN; HTRA1 PROMOTER POLYMORPHISM;
   GENE POLYMORPHISMS; PREVALENCE; ASSOCIATION; SUSCEPTIBILITY;
   MACULOPATHY; VARIANTS
AB PURPOSE. To estimate the risk factors of AMD in an elderly Japanese population from a suburban area north of metropolitan Tokyo.
   METHODS. The Hatoyama Cohort Study was launched in 2010, and 742 persons participated in the baseline study. Among these participants, 596 persons who attended the 2-year follow-up examinations in 2012 were evaluated, and the presence of early and late AMD was determined via grading of their fundus photographs. Based on the cohorts' data, logistic regression analyses were performed to identify the risk factors for AMD. The possible risk factors that we examined were age, sex, medical history of systemic disorders, smoking, inflammatory markers at baseline, and the complement factor H (CFH) I62V and age-related maculopathy susceptibility 2 (ARMS2) A69S variants.
   RESULTS. We assessed 480 participants (40.0% women) who had gradable fundus photographs. The prevalence of early AMD was 37.9% and the prevalence of late AMD was 0.6%. Mantel-Haenszel analysis revealed that the CFH I62V and ARMS2 A69S variants were significantly associated with the prevalence of AMD (P = 0.029 and 0.025, respectively).
   CONCLUSIONS. The CFH I62V and ARMS2 A69S variants were significantly associated with the prevalence of AMD.
C1 [Aoki, Aya; Tan, Xue; Yamagishi, Reiko; Obata, Ryo; Yanagi, Yasuo] Univ Tokyo, Dept Ophthalmol, Grad Sch Med, Bunkyo Ku, Tokyo 1138655, Japan.
   [Aoki, Aya; Tan, Xue; Yamagishi, Reiko; Obata, Ryo; Yanagi, Yasuo] Univ Tokyo, Fac Med, Bunkyo Ku, Tokyo 1138655, Japan.
   [Aoki, Aya; Shinkai, Shoji; Numaga, Jiro; Ito, Hideki] Tokyo Metropolitan Inst Gerontol, Itabashi Ku, Tokyo, Japan.
   [Miyaji, Tempei; Yamaguchi, Takuhiro] Univ Tokyo, Dept Clin Trial Data Management, Grad Sch Med, Bunkyo Ku, Tokyo, Japan.
   [Yamaguchi, Takuhiro] Tohoku Univ, Grad Sch Med, Div Biostat, Sendai, Miyagi 980, Japan.
C3 University of Tokyo; University of Tokyo; Tokyo Metropolitan Institute
   of Gerontology; University of Tokyo; Tohoku University
RP Yanagi, Y (通讯作者)，Univ Tokyo, Dept Ophthalmol, Grad Sch Med, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.
EM yanagi-tky@umin.ac.jp
RI Yanagi, Yasuo/AAF-2670-2020; Yanagi, Yasuo/AAA-5441-2022
OI Yanagi, Yasuo/0000-0002-0362-7285; Obata, Ryo/0000-0002-1762-0797
FU Ministry of Education, Culture, Sports, Science and Technology of Japan
   (Tokyo, Japan) [25861663]
FX Supported in part by a Grant-in-Aid from the Ministry of Education,
   Culture, Sports, Science and Technology of Japan (Grant# 25861663, AA;
   Tokyo, Japan).
CR Ahmad O.B., 2001, GENEVA WORLD HEAL OR
   Boekhoorn SS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1396, DOI 10.1001/archopht.125.10.1396
   Boey PY, 2010, INVEST OPHTH VIS SCI, V51, P1880, DOI 10.1167/iovs.09-4063
   Cougnard-Gregoire A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090973
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Gotoh N, 2006, HUM GENET, V120, P139, DOI 10.1007/s00439-006-0187-0
   Holliday EG, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0082305, 10.1371/journal.pone.0053830]
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1735, DOI 10.1016/j.ophtha.2008.02.012
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1376, DOI 10.1016/j.ophtha.2007.11.015
   Kim NR, 2008, INVEST OPHTH VIS SCI, V49, P2071, DOI 10.1167/iovs.07-1195
   Klein R, 2003, OPHTHALMOLOGY, V110, P25, DOI 10.1016/S0161-6420(02)01565-8
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2014, JAMA OPHTHALMOL, V132, P446, DOI 10.1001/jamaophthalmol.2013.7671
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   Kondo N, 2007, AM J OPHTHALMOL, V144, P608, DOI 10.1016/j.ajo.2007.06.003
   LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Mori K, 2007, INVEST OPHTH VIS SCI, V48, P5315, DOI 10.1167/iovs.07-0426
   Murayama H, 2012, J EPIDEMIOL, V22, P551, DOI 10.2188/jea.JE20120015
   Nakata I, 2013, AM J OPHTHALMOL, V156, P1002, DOI 10.1016/j.ajo.2013.06.007
   Ng TK, 2008, INVEST OPHTH VIS SCI, V49, P3312, DOI 10.1167/iovs.07-1517
   Oshima Y, 2001, BRIT J OPHTHALMOL, V85, P1153, DOI 10.1136/bjo.85.10.1153
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Seddon JM, 2010, OPHTHALMOLOGY, V117, P1560, DOI 10.1016/j.ophtha.2009.11.020
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   Yamashiro K, 2011, INVEST OPHTH VIS SCI, V52, P8780, DOI 10.1167/iovs.11-8205
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   Yoshida T, 2007, MOL VIS, V13, P545
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
NR 31
TC 14
Z9 14
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD APR
PY 2015
VL 56
IS 4
BP 2580
EP 2585
DI 10.1167/iovs.14-16339
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CJ1NP
UT WOS:000355250700057
PM 25788651
DA 2022-11-30
ER

PT J
AU Chen, RC
   Palestine, AG
   Lynch, AM
   Patnaik, JL
   Wagner, BD
   Mathias, MT
   Mandava, N
AF Chen, Rachel C.
   Palestine, Alan G.
   Lynch, Anne M.
   Patnaik, Jennifer L.
   Wagner, Brandie D.
   Mathias, Marc T.
   Mandava, Naresh
TI Increased Systemic C-Reactive Protein Is Associated With Choroidal
   Thinning in Intermediate Age-Related Macular Degeneration
SO TRANSLATIONAL VISION SCIENCE & TECHNOLOGY
LA English
DT Article
DE C-reactive protein; macular degeneration; choroid; optical coherence
   tomography
ID COMPLEMENT FACTOR-H; RETICULAR PSEUDODRUSEN; PROGRESSION; THICKNESS;
   RISK; EYES; ATROPHY; DRUSEN; BIOMARKERS; FEATURES
AB Purpose: C-reactive protein (CRP) and decreased choroidal thickness (CT) are risk factors for progression to advanced age-related macular degeneration (AMD). We examined the association between systemic levels of CRP and CT in patients with intermediate AMD (iAMD).
   Methods: Patients with iAMD in the Colorado AMD Registry were included. Baseline serum samples and multimodal imaging including spectral domain-optical coher-ence tomography (SD-OCT), fundus photography, and autofluorescence were obtained. Medical and social histories were surveyed. CT was obtained by manual segmentation of OCT images. High-sensitivity CRP levels were quantified in serum samples. Univariate and multivariable linear regression models accounting for the intrasubject correlation of two eyes were fit using log-transformed CT as the outcome.
   Results: The study included 213 eyes from 107 patients with a mean age of 76.8 years (SD, 6.8). Median CT was 200.5 mu m (range, 86.5-447.0). Median CRP was 1.43 mg/L (range, 0.13-17.10). Higher CRP was associated with decreased CT in the univariate model (P = 0.01). Older age and presence of reticular pseudodrusen (RPD) were associated with decreased CT (P < 0.01), whereas gender, body mass index, and smoking were not associated with CT. Higher CRP remained significantly associated with decreased CT after adjustment for age and RPD (P = 0.01).
   Conclusions: Increased CRP may damage the choroid, leading to choroidal thinning and increased risk of progression to advanced AMD. Alternatively, CRP may be a marker for inflammatory events that mediate ocular disease. The results of this study further strengthen the association between inflammation and AMD.
C1 [Chen, Rachel C.; Palestine, Alan G.; Lynch, Anne M.; Patnaik, Jennifer L.; Wagner, Brandie D.; Mathias, Marc T.; Mandava, Naresh] Univ Colorado, UCHlth Sue Anschutz Rodgers Eye Ctr, 1675 Aurora Court, Aurora, CO 80045 USA.
   [Wagner, Brandie D.] Univ Colorado, Colorado Sch Publ Hlth, Dept Biostat & Informat, Anschutz Med Campus, Aurora, CO USA.
C3 University of Colorado System; University of Colorado Anschutz Medical
   Campus; Colorado School of Public Health; University of Colorado System;
   University of Colorado Anschutz Medical Campus
RP Palestine, AG (通讯作者)，Univ Colorado, UCHlth Sue Anschutz Rodgers Eye Ctr, 1675 Aurora Court, Aurora, CO 80045 USA.
EM alan.palestine@cuanschutz.edu
FU National Eye Institute, National Institutes of Health [R01EY032456];
   Research to Prevent Blindness; Sue Anschutz-Rodgers Eye Center Research
   Fund; National Center for Advancing Translational Sciences, National
   Institutes of Health, Colorado Clinical and Translational Science Award
   [UL1 TR002535]
FX Supported by the National Eye Institute, National Institutes of Health,
   under award number R01EY032456 (AML) ; a Research to Prevent Blindness
   grant to the Department of Ophthalmology, University of Colorado School
   of Medicine, Frederic C. Hamilton Macular Degeneration Center; by the
   Sue Anschutz-Rodgers Eye Center Research Fund; and by a National Center
   for Advancing Translational Sciences, National Institutes of Health,
   Colorado Clinical and Translational Science Award (UL1 TR002535) .
CR Ahmad M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175691
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Bhutto IA, 2011, BRIT J OPHTHALMOL, V95, P1323, DOI 10.1136/bjo.2010.199216
   Boddu S, 2014, AM J OPHTHALMOL, V157, P985, DOI 10.1016/j.ajo.2014.01.023
   Chakravarthy U, 2020, OPHTHALMOL RETINA, V4, P662, DOI 10.1016/j.oret.2020.01.012
   Chirco KR, 2016, J PATHOL, V240, P173, DOI 10.1002/path.4766
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   de Sisternes L, 2014, INVEST OPHTH VIS SCI, V55, P7093, DOI 10.1167/iovs.14-14918
   Di Staso F, 2019, IN VIVO, V33, P1403, DOI 10.21873/invivo.11617
   Fan WY, 2018, GRAEF ARCH CLIN EXP, V256, P511, DOI 10.1007/s00417-017-3888-2
   Ferrara D, 2017, INVEST OPHTH VIS SCI, V58, P3519, DOI 10.1167/iovs.17-21696
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Gil JQ, 2017, EYE, V31, P364, DOI 10.1038/eye.2016.207
   Govetto A, 2017, BRIT J OPHTHALMOL, V101, P764, DOI 10.1136/bjophthalmol-2016-309281
   Joachim N, 2014, OPHTHALMOLOGY, V121, P917, DOI 10.1016/j.ophtha.2013.10.043
   Johnson PT, 2006, P NATL ACAD SCI USA, V103, P17456, DOI 10.1073/pnas.0606234103
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Keenan TD, 2020, RETINA-J RET VIT DIS, V40, P632, DOI 10.1097/IAE.0000000000002434
   Koh LHL, 2017, ACTA OPHTHALMOL, V95, pE597, DOI 10.1111/aos.13399
   Kong M, 2018, TRANSL VIS SCI TECHN, V7, DOI 10.1167/tvst.7.5.16
   Legocki AT, 2016, OSLI RETINA, V47, P618, DOI 10.3928/23258160-20160707-02
   Lynch AM, 2020, BMJ OPEN OPHTHALMOL, V5, DOI 10.1136/bmjophth-2019-000361
   Lynch AM, 2020, EUR J OPHTHALMOL, V30, P1061, DOI 10.1177/1120672119857896
   Lynch AM, 2019, RETINA-J RET VIT DIS, V39, P656, DOI 10.1097/IAE.0000000000002023
   McFadyen JD, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01351
   McGrath FDG, 2006, J IMMUNOL, V176, P2950, DOI 10.4049/jimmunol.176.5.2950
   Molins B, 2016, SCI REP-UK, V6, DOI 10.1038/srep22889
   Nassisi M, 2019, GRAEF ARCH CLIN EXP, V257, P2079, DOI 10.1007/s00417-019-04403-1
   Rishi P, 2013, EYE, V27, P1038, DOI 10.1038/eye.2013.106
   Rodrigo F, 2018, INDIAN J OPHTHALMOL, V66, P89, DOI 10.4103/ijo.IJO_488_17
   Ryoo NK, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0209276
   Sacconi R, 2021, BRIT J OPHTHALMOL, V105, P97, DOI 10.1136/bjophthalmol-2019-315800
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Sigler EJ, 2013, INVEST OPHTH VIS SCI, V54, P6307, DOI 10.1167/iovs.13-12653
   Skeie JM, 2010, INVEST OPHTH VIS SCI, V51, P5336, DOI 10.1167/iovs.10-5322
   Sohrab MA, 2011, INVEST OPHTH VIS SCI, V52, P5743, DOI 10.1167/iovs.10-6942
   Song IU, 2015, INT J MED SCI, V12, P613, DOI 10.7150/ijms.12742
   Spraul CW, 1999, SURV OPHTHALMOL, V44, pS10, DOI 10.1016/S0039-6257(99)00086-7
   Steiner M, 2019, SURV OPHTHALMOL, V64, P757, DOI 10.1016/j.survophthal.2019.04.007
   Ueda-Arakawa N, 2013, AM J OPHTHALMOL, V155, P260, DOI 10.1016/j.ajo.2012.08.011
   Veerappan M, 2016, OPHTHALMOLOGY, V123, P2554, DOI 10.1016/j.ophtha.2016.08.047
   Wagner BD, 2022, OPHTHAL EPIDEMIOL, V29, P139, DOI 10.1080/09286586.2021.1910314
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P2415, DOI 10.1016/j.ophtha.2014.06.034
   Yang TK, 2019, J OPHTHALMOL, V2019, DOI 10.1155/2019/8079127
NR 47
TC 3
Z9 3
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 2164-2591
J9 TRANSL VIS SCI TECHN
JI Transl. Vis. Sci. Technol.
PD OCT
PY 2021
VL 10
IS 12
AR 7
DI 10.1167/tvst.10.12.7
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA XM9KP
UT WOS:000729136600005
PM 34609476
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Coscas, F
   Lupidi, M
   Boulet, JF
   Sellam, A
   Cabral, D
   Serra, R
   Francais, C
   Souied, EH
   Coscas, G
AF Coscas, Florence
   Lupidi, Marco
   Boulet, Jean Francois
   Sellam, Alexandre
   Cabral, Diogo
   Serra, Rita
   Francais, Catherine
   Souied, Eric H.
   Coscas, Gabriel
TI Optical coherence tomography angiography in exudative age-related
   macular degeneration: a predictive model for treatment decisions
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE AMD; age-related macular degeneration; exudative-AMD; choroidal
   neovascularisation; optical coherence tomography angiography; OCT
   angiography; predictive model; structuralOCT
ID INDOCYANINE GREEN ANGIOGRAPHY; CHOROIDAL NEOVASCULARIZATION; FLUORESCEIN
   ANGIOGRAPHY; THERAPY
AB Aims To evaluate on optical coherence tomography angiography (OCT-A), the predictive role of different qualitative findings of choroidal neovascularisations (CNV) in assessing the status of exudative age-related macular degeneration (eAMD) and to develop a potential model to predict the CNV activity. Methods Retrospective review of the multimodal imaging records of patients with eAMD obtained during treatment for type 1 or type 2 CNV. The qualitative analysis of CNVs on OCT angiograms assessed the presence or absence of tiny branching vessels, loops, peripheral anastomotic arcades and choriocapillaris hypointense halo. These findings were then correlated with those of structural OCT scans. A score forecast was built and validated. Results One hundred and twenty-six eAMD eyes were enrolled in the study. Exudation was observed in 90 eyes (71%) on structural OCT. The qualitative OCT-A analysis revealed: tiny branching vessels in 82.5% of the cases, vascular loops in 81.7%, peripheral anastomotic arcades in 66.7% and choriocapillaris hypointense halo in 54.8%. In the univariate analysis, each OCT-A parameter showed a statistically significant correlation with exudation on structural OCT (p<0.001). The overall analysis demonstrated a sensitivity of 96.7% and a positive predictive value of 87.9%. In the multivariate analysis, a model with four criteria predicted an exudative lesion in 97.6% of cases and one with two criteria (tiny branching vessels and peripheral anastomotic arcades) in 71.2%. Conclusions The presence of tiny branching vessels and a peripheral anastomotic arcade appears to predict the lesion activity with a good accuracy and the model based on four criteria enables optimal decisions regarding retreatment in eAMD.
C1 [Coscas, Florence; Lupidi, Marco; Cabral, Diogo; Francais, Catherine; Coscas, Gabriel] Ctr Ophtalmol Odeon, Paris, France.
   [Coscas, Florence; Souied, Eric H.; Coscas, Gabriel] Univ Paris Est Creteil, Ctr Hosp Intercommunal Creteil, Dept Ophthalmol, Creteil, France.
   [Lupidi, Marco] Univ Perugia S Maria della Misericordia Hosp, Dept Biomed & Surg Sci, Sect Ophthalmol, Perugia, Italy.
   [Boulet, Jean Francois; Sellam, Alexandre] Paris VI Univ, UPMC, Paris, France.
   [Cabral, Diogo] Inst Oftalmol Dr Gama Pinto, Retina Dept, Lisbon, Portugal.
   [Cabral, Diogo] Univ Nova Lisboa, NOVA Med Sch, Lisbon, Portugal.
   [Serra, Rita] Univ Cagliari, Dept Surg Sci, Eye Clin, Cagliari, Italy.
C3 Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil;
   UDICE-French Research Universities; Sorbonne Universite; Universidade
   Nova de Lisboa; University of Cagliari
RP Coscas, F (通讯作者)，Univ Paris Est, Ctr Hosp Intercommunal Creteil, F-94010 Creteil, France.
EM coscas.f@gmail.com
RI Javadzadeh, Alireza/L-6424-2017; Cabral, Diogo/AAG-3865-2019
OI Javadzadeh, Alireza/0000-0002-5151-6125; Cabral,
   Diogo/0000-0003-1968-3561; SERRA, RITA/0000-0002-6341-1435; Lupidi,
   Marco/0000-0002-6817-2488
CR Adhi M, 2014, AM J OPHTHALMOL, V157, P1272, DOI 10.1016/j.ajo.2014.02.034
   Al-Sheikh M, 2018, RETINA-J RET VIT DIS, V38, P220, DOI 10.1097/IAE.0000000000001628
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Coscas GJ, 2015, RETINA-J RET VIT DIS, V35, P2219, DOI 10.1097/IAE.0000000000000766
   de Carlo TE, 2015, OPHTHALMOLOGY, V122, P1228, DOI 10.1016/j.ophtha.2015.01.029
   Eandi CM, 2017, INVEST OPHTH VIS SCI, V58, P3690, DOI 10.1167/iovs.17-21941
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Gess AJ, 2011, SEMIN OPHTHALMOL, V26, P225, DOI 10.3109/08820538.2011.582533
   Hoerster R, 2011, BRIT J OPHTHALMOL, V95, P1424, DOI 10.1136/bjo.2010.201129
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Huang D, 2015, RETINA-J RET VIT DIS, V35, P2260, DOI 10.1097/IAE.0000000000000846
   Inoue M, 2016, INVEST OPHTH VIS SCI, V57, pOCT314, DOI 10.1167/iovs.15-18900
   Jain RK, 2001, NAT MED, V7, P987, DOI 10.1038/nm0901-987
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1435, DOI 10.1016/j.ophtha.2014.01.034
   Kuehlewein L, 2015, AM J OPHTHALMOL, V160, P739, DOI 10.1016/j.ajo.2015.06.030
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Liakopoulos S, 2008, INVEST OPHTH VIS SCI, V49, P5048, DOI 10.1167/iovs.08-1877
   Lumbroso B, 2015, RETINA-J RET VIT DIS, V35, P2242, DOI 10.1097/IAE.0000000000000879
   Moult E, 2014, OSLI RETINA, V45, P496, DOI 10.3928/23258160-20141118-03
   Musa F, 2006, ACTA OPHTHALMOL SCAN, V84, P740, DOI 10.1111/j.1600-0420.2006.00728.x
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Spaide RF, 2015, AM J OPHTHALMOL, V160, P6, DOI 10.1016/j.ajo.2015.04.012
   Spaide RF, 2015, JAMA OPHTHALMOL, V133, P45, DOI 10.1001/jamaophthalmol.2014.3616
   Sulzbacher F, 2011, AM J OPHTHALMOL, V152, P799, DOI 10.1016/j.ajo.2011.04.011
   Zhang M, 2016, BIOMED OPT EXPRESS, V7, P816, DOI 10.1364/BOE.7.000816
NR 25
TC 31
Z9 33
U1 0
U2 5
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD SEP
PY 2019
VL 103
IS 9
BP 1342
EP 1346
DI 10.1136/bjophthalmol-2018-313065
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA IT4RP
UT WOS:000482848500025
PM 30467129
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Takagi, S
   Mandai, M
   Hirami, Y
   Sugita, S
   Takahashi, M
   Kurimoto, Y
AF Takagi, Seiji
   Mandai, Michiko
   Hirami, Yasuhiko
   Sugita, Sunao
   Takahashi, Masayo
   Kurimoto, Yasuo
TI Frequencies of human leukocyte antigen alleles and haplotypes among
   Japanese patients with age-related macular degeneration
SO JAPANESE JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Haplotype frequency; Human leukocyte
   antigen; Japan; Induced pluripotent stem cells
ID PIGMENT EPITHELIAL-CELLS; HLA-CLASS-I; STEM-CELLS; TRANSPLANTATION;
   ASSOCIATION; POPULATION; LOCI
AB Purpose Stem cell therapy is a potential treatment for retinal disorders. We are currently exploring treating HLA matched patients of age-related macular degeneration (AMD) by using allogenic retinal pigment epithelium cells derived from induced pluripotent stem cells (iPS-RPE) from human leukocyte antigen (HLA) homozygote donors. The purpose of this study was to investigate the frequency of HLA class I and II alleles and haplotypes in Japanese patients with AMD.
   Study design Cross-sectional observation clinical study.
   Methods A total of 138 consecutive patients diagnosed with neovascular AMD (mean age, 76.0 +/- 7.8 years, 105 men) and 300 controls were included in the study. The frequencies of HLA-A, -B, -C, -DRB1, -DQB1, and -DPB1 alleles were determined using illumina MiSeq platform. Frequencies of HLA alleles at six loci in patients with AMD were compared with those of the controls.
   Results The alleles with the highest prevalence at each locus were A*24:02 (29.7%), B*52:01 (15.5%), C*12:02 (16.1%), DRB1*09:01 (19.1%), DQB1*06:01 (23.2%), and DPB1* 05:01 (40.5%). There were no significant associations between the HLA alleles and AMD. The most common haplotype was A*24:02-B*52:01-C*12:02-DRB1*15:02-DQB1*06:01-DPB1*09:01, with a 9.8% genetic frequency among all haplotypes, detected in 18.8% of the patients.
   Conclusion The genotype of HLA in patients with AMD was not different from that in the Japanese control population. Thus, therapy with iPS-RPEof the most frequent HLA haplotype could be a feasible alternative for AMD in a wider population.
C1 [Takagi, Seiji; Mandai, Michiko; Hirami, Yasuhiko; Sugita, Sunao; Takahashi, Masayo; Kurimoto, Yasuo] Kobe City Eye Hosp, Dept Ophthalmol, Chuo Ku, 2-1-8 Minatojima Minamimachi, Kobe, Hyogo 6500047, Japan.
   [Takagi, Seiji; Mandai, Michiko; Hirami, Yasuhiko; Sugita, Sunao; Takahashi, Masayo; Kurimoto, Yasuo] Kobe City Med Ctr Gen Hosp, Dept Ophthalmol, Chuo Ku, 2-2 Minatojima Minamimachi, Kobe, Hyogo 6500047, Japan.
   [Takagi, Seiji] Toho Univ, Dept Ophthalmol, Ohashi Med Ctr, Meguro Ku, 2-6-17 Ohashi, Tokyo 1538515, Japan.
   [Mandai, Michiko; Hirami, Yasuhiko; Sugita, Sunao; Takahashi, Masayo; Kurimoto, Yasuo] RIKEN, Lab Retinal Regenerat, Ctr Dev Biol, Chuo Ku, 2-2-3 Minatojima Minamimachi, Kobe, Hyogo 6500047, Japan.
C3 Kobe City Medical Center General Hospital; Toho University; RIKEN
RP Takagi, S (通讯作者)，Kobe City Eye Hosp, Dept Ophthalmol, Chuo Ku, 2-1-8 Minatojima Minamimachi, Kobe, Hyogo 6500047, Japan.; Takagi, S (通讯作者)，Kobe City Med Ctr Gen Hosp, Dept Ophthalmol, Chuo Ku, 2-2 Minatojima Minamimachi, Kobe, Hyogo 6500047, Japan.; Takagi, S (通讯作者)，Toho Univ, Dept Ophthalmol, Ohashi Med Ctr, Meguro Ku, 2-6-17 Ohashi, Tokyo 1538515, Japan.
EM tigerseiji@gmail.com
FU HLA Foundation laboratory
FX This work was supported by the HLA Foundation laboratory. Although this
   study did not receive specific funding, we received normal data from the
   HLA Foundation laboratory. We thank them for their help in providing the
   data. We thank Dr Noriko Miyamoto and Dr Akihiro Nishida for their help
   in acquisition of informed consent. We also thank for professor. Goji
   Tomita for helpful advice. This paper received editorial support from
   Editage.
CR ALGVERE PV, 1994, GRAEF ARCH CLIN EXP, V232, P707, DOI 10.1007/BF00184273
   Brown D.M., 2009, OPHTHALMOLOGY, V116, pe5
   Cao K, 2001, HUM IMMUNOL, V62, P1009, DOI 10.1016/S0198-8859(01)00298-1
   Craig J, 2017, LANCET, V3
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Goverdhan SV, 2008, INVEST OPHTH VIS SCI, V49, P5077, DOI 10.1167/iovs.08-1837
   Goverdhan SV, 2005, INVEST OPHTH VIS SCI, V46, P1726, DOI 10.1167/iovs.04-0928
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Haruta M, 2004, INVEST OPHTH VIS SCI, V45, P1020, DOI 10.1167/iovs.03-1034
   Horan J, 2012, BLOOD, V120, P2918, DOI 10.1182/blood-2012-03-417758
   Ikeda N, 2015, TISSUE ANTIGENS, V85, P252, DOI 10.1111/tan.12536
   Maaijwee KJ, 2012, AM J OPHTHALMOL, V153, pe2
   Mandai M, 2017, NEW ENGL J MED, V376, P1038, DOI 10.1056/NEJMoa1608368
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Okita K, 2011, NAT METHODS, V8, P409, DOI [10.1038/NMETH.1591, 10.1038/nmeth.1591]
   Penfold PL, 1997, INVEST OPHTH VIS SCI, V38, P2125
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Saito S, 2000, TISSUE ANTIGENS, V56, P522, DOI 10.1034/j.1399-0039.2000.560606.x
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Sugita S, 2016, STEM CELL REP, V7, P619, DOI 10.1016/j.stemcr.2016.08.011
   Sugita S, 2016, STEM CELL REP, V7, P635, DOI 10.1016/j.stemcr.2016.08.010
   Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019
   Taylor CJ, 2011, PHILOS T R SOC B, V366, P2312, DOI 10.1098/rstb.2011.0030
   Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145
   Thorsby E, 2005, TRANSPL IMMUNOL, V14, P175, DOI 10.1016/j.trim.2005.03.021
   Tokunaga K, 1997, IMMUNOGENETICS, V46, P199, DOI 10.1007/s002510050262
   Becerri EV, 2009, CELL MOL IMMUNOL, V6, P303, DOI 10.1038/cmi.2009.40
   Zarbin MA, 2010, RETINA-J RET VIT DIS, V30, P1350, DOI 10.1097/IAE.0b013e3181f57e30
NR 28
TC 5
Z9 5
U1 0
U2 4
PU SPRINGER JAPAN KK
PI TOKYO
PA CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065,
   JAPAN
SN 0021-5155
EI 1613-2246
J9 JPN J OPHTHALMOL
JI Jpn. J. Ophthalmol.
PD SEP
PY 2018
VL 62
IS 5
BP 568
EP 575
DI 10.1007/s10384-018-0611-8
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GR6CR
UT WOS:000442733200006
PM 30003355
DA 2022-11-30
ER

PT J
AU Kashani, AH
AF Kashani, Amir H.
TI Stem cell-derived retinal pigment epithelium transplantation in
   age-related macular degeneration: recent advances and challenges
SO CURRENT OPINION IN OPHTHALMOLOGY
LA English
DT Review
DE age-related macular degeneration; immune response; retinal pigment
   epithelium; stem cell
ID AUTOLOGOUS TRANSLOCATION; SUBRETINAL IMPLANTATION; RPE; MONOLAYER;
   THERAPIES; PRIVILEGE; APOPTOSIS; SECONDARY; SURVIVAL; EYES
AB Purpose of review Age-related macular degeneration (AMD) is one of the leading causes of irreversible vision loss in the world with more than 80% of the prevalence accounted for by the nonneovascular (NNAMD) or 'dry' form of the disease. NNAMD does not have any definitive treatment once vision loss has ensued and presents a major unmet medical need. This review will highlight stem cell-based therapies that are a promising form of treatment for advanced NNAMD. Recent findings In the past decade, clinical trials utilizing both induced pluripotent stem cell-derived RPE and human embryonic stem cell-derived RPE have been aggressively pursued as potential treatments of RPE loss and prevention of overlying neurosensory atrophy. While promising preliminary results demonstrating safety and potential efficacy have been published, new challenges have also been identified. These include selecting the most appropriate cell-based therapy, identifying and managing potential immune response as well as characterizing anatomic and functional efficacy. In this review, we will discuss some of these challenges in light of the available data from several early phase clinical trials and discuss the strategies that are being considered to further advance the field. Cell-based therapies demonstrate promising potential to treat advanced stages of NNAMD. Several early phase clinical trials using both induced pluripotent stem cells (iPSC) and human embryonic stem cell derived (hESC) have demonstrated safety and preliminary signs of efficacy and highlighted remaining challenges which appear surmountable. These challenges include development of selection criteria for use of cell suspensions versus RPE sheets, especially in light of immunological properties of RPE that are intrinsic to the status of RPE differentiation in each of these cell formulations.
C1 [Kashani, Amir H.] Johns Hopkins Univ, Wilmer Eye Inst, Dept Ophthalmol & Biomed Engn, T Boone Pickens Professorship Ophthalmol, Baltimore, MD 21218 USA.
C3 Johns Hopkins University; Johns Hopkins Medicine
RP Kashani, AH (通讯作者)，Johns Hopkins Univ, Wilmer Eye Inst, Dept Ophthalmol & Biomed Engn, T Boone Pickens Professorship Ophthalmol, Baltimore, MD 21218 USA.
EM akashan1@jhmi.edu
FU Wilmer Eye Institute; Johns Hopkins University through the T Boone
   Pickens Endowed Professorship in Ophthalmology; Regenerative Patch
   Technologies
FX This work was supported by the Wilmer Eye Institute and the Johns
   Hopkins University through the T Boone Pickens Endowed Professorship in
   Ophthalmology. Dr. Kashani's former employer, the University of Southern
   California, received grant funding from Regenerative Patch Technologies
   to support Dr. Kashani's role as principal investigator in a clinical
   trial utilizing stem cell derived RPE in the treatment of NNAMD.
CR Algvere PV, 1999, EUR J OPHTHALMOL, V9, P217, DOI 10.1177/112067219900900310
   Algvere PV, 1997, GRAEF ARCH CLIN EXP, V235, P149, DOI 10.1007/BF00941722
   Benner JD, 2002, ARCH OPHTHALMOL-CHIC, V120, P586, DOI 10.1001/archopht.120.5.586
   Buchholz DE, 2009, STEM CELLS, V27, P2427, DOI 10.1002/stem.189
   Caramoy A, 2010, BRIT J OPHTHALMOL, V94, P1040, DOI 10.1136/bjo.2009.161299
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P142, DOI 10.1001/jamaophthalmol.2013.7376
   da Cruz L, 2018, NAT BIOTECHNOL, V36, P1, DOI 10.1038/nbt.4114
   Diniz B, 2013, INVEST OPHTH VIS SCI, V54, P5087, DOI 10.1167/iovs.12-11239
   Eandi CM, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006928.pub2
   Gornalusse GG, 2017, NAT BIOTECHNOL, V35, P765, DOI 10.1038/nbt.3860
   GOURAS P, 1984, AN ACAD BRAS CIENC, V56, P431
   Heier JS, 2020, OPHTHALMOL RETINA, V4, P384, DOI 10.1016/j.oret.2019.11.011
   Heussen FMA, 2008, EYE, V22, P799, DOI 10.1038/sj.eye.6702823
   Ho AC, 2017, AM J OPHTHALMOL, V179, P67, DOI 10.1016/j.ajo.2017.04.006
   Hsiung J, 2015, STEM CELL TRANSL MED, V4, P10, DOI 10.5966/sctm.2014-0205
   Idelson M, 2018, STEM CELL REP, V11, P681, DOI 10.1016/j.stemcr.2018.07.009
   Jha BS, 2021, STEM CELL TRANSL MED, V10, P198, DOI 10.1002/sctm.20-0242
   Jorgensen A, 1998, INVEST OPHTH VIS SCI, V39, P1590
   Joussen AM, 2007, OPHTHALMOLOGY, V114, P551, DOI 10.1016/j.ophtha.2006.08.016
   Kaestel CG, 2002, EXP EYE RES, V74, P627, DOI 10.1006/exer.2002.1183
   Kashani A., 2022, STEM CELL REP, V1-11
   Kashani AH, 2021, TRANSL VIS SCI TECHN, V10, DOI 10.1167/tvst.10.10.13
   Kashani AH, 2019, ADV EXP MED BIOL, V1185, P569, DOI 10.1007/978-3-030-27378-1_93
   Kashani AH, 2020, OPHTHALMOL RETINA, V4, P264, DOI 10.1016/j.oret.2019.09.017
   Kashani AH, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aao4097
   Kashani AH, 2016, INVEST OPHTH VIS SCI, V57, DOI 10.1167/iovs.15-17681
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Khateb S, 2021, ADV EXP MED BIOL, V1256, P265, DOI 10.1007/978-3-030-66014-7_11
   LI LX, 1988, EXP EYE RES, V47, P911, DOI 10.1016/0014-4835(88)90073-5
   Mehat MS, 2018, OPHTHALMOLOGY, V125, P1765, DOI 10.1016/j.ophtha.2018.04.037
   Merrill PT, 1999, OPHTHALMOLOGY, V106, P782, DOI 10.1016/S0161-6420(99)90167-7
   Miller JW, 2013, AM J OPHTHALMOL, V155, P1, DOI 10.1016/j.ajo.2012.10.018
   Miura K, 2009, NAT BIOTECHNOL, V27, P743, DOI 10.1038/nbt.1554
   Mo JS, 2007, OCUL IMMUNOL INFLAMM, V15, P249, DOI 10.1080/09273940701382176
   Nazari H, 2015, PROG RETIN EYE RES, V48, P1, DOI 10.1016/j.preteyeres.2015.06.004
   Pennington BO, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-85631-6
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rezai KA, 1999, CURR EYE RES, V18, P430, DOI 10.1076/ceyr.18.6.430.5269
   Rizzolo LJ, 2007, INT REV CYTOL, V258, P195, DOI 10.1016/S0074-7696(07)58004-6
   Schwartz SD, 2016, INVEST OPHTH VIS SCI, V57, DOI 10.1167/iovs.15-18681
   Sharma R, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aat5580
   Singh MS, 2020, PROG RETIN EYE RES, V75, DOI 10.1016/j.preteyeres.2019.100779
   Sohn EH, 2015, SCI REP-UK, V5, DOI 10.1038/srep11791
   Streilein JW, 2002, VISION RES, V42, P487, DOI 10.1016/S0042-6989(01)00185-7
   Sugita S, 2021, PROG RETIN EYE RES, V84, DOI 10.1016/j.preteyeres.2021.100950
   Sugita S, 2020, J CLIN MED, V9, DOI 10.3390/jcm9072217
   Sugita S, 2018, INVEST OPHTH VIS SCI, V59, P4198, DOI 10.1167/iovs.18-24769
   Sugita S, 2016, STEM CELL REP, V7, P619, DOI 10.1016/j.stemcr.2016.08.011
   Sugita S, 2015, INVEST OPHTH VIS SCI, V56, P1051, DOI 10.1167/iovs.14-15619
   Takagi S, 2019, OPHTHALMOL RETINA, V3, P850, DOI 10.1016/j.oret.2019.04.021
   Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019
   Thomas BB, 2016, INVEST OPHTH VIS SCI, V57, P2877, DOI 10.1167/iovs.16-19238
   Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145
   Wenkel H, 2000, INVEST OPHTH VIS SCI, V41, P3467
   Yamasaki S, 2021, STEM CELL REP, V16, P851, DOI 10.1016/j.stemcr.2021.02.021
   Zhu DH, 2011, INVEST OPHTH VIS SCI, V52, P1573, DOI 10.1167/iovs.10-6413
NR 56
TC 1
Z9 1
U1 5
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-8738
EI 1531-7021
J9 CURR OPIN OPHTHALMOL
JI Curr. Opin. Ophthalmol.
PD MAY
PY 2022
VL 33
IS 3
BP 211
EP 218
DI 10.1097/ICU.0000000000000838
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 1M9RJ
UT WOS:000800301800011
PM 35200164
DA 2022-11-30
ER

PT J
AU Mahmoudzadeh, R
   Salabati, M
   Khan, MA
   Garg, SJ
   Hsu, J
AF Mahmoudzadeh, Raziyeh
   Salabati, Mirataollah
   Khan, M. Ali
   Garg, Sunir J.
   Hsu, Jason
TI Manual Versus Semi-Automated Measurement of Geographic Atrophy Area in
   Eyes With Age-Related Macular Degeneration
SO TRANSLATIONAL VISION SCIENCE & TECHNOLOGY
LA English
DT Article
DE geographic atrophy; fundus autofluorescence; age-related macular
   degeneration
ID FUNDUS AUTOFLUORESCENCE; PROGRESSION; IMAGE
AB Purpose: To investigate the agreement between and correlation of manual and semi-automated area measurements of geographic atrophy (GA) in eyes with age-related macular degeneration (AMD) using Heidelberg Eye Explorer and ImageJ software.
   Methods: Fundus autofluorescence (FAF) images of eyes with GA secondary to AMD were analyzed. Two graders measured the atrophic area using Heidelberg Eye Explorer manual and semi-automated (RegionFinder) software, as well as ImageJ manual and semi-automated (Color Threshold) software.
   Results: Fifty-four FAF images were analyzed. The mean (SD) areas were 10.55 (11.4) mm(2) and 9.6 (9.8) mm(2) using the Heidelberg manual and semi-automated tools, respectively. The mean (SD) areas were 11.04 (12.25) mm(2) and 9.75 (10.3) mm(2) using ImageJ manual and semi-automated tools, respectively. Compared with the semi-automated Heidelberg RegionFinder (gold standard) area measurements, Bland-Altman plots showed mean differences of 0.96 mm(2), 1.4 mm(2), and 0.16 mm(2) with manual Heidelberg, manual ImageJ, and semi-automated ImageJ measurements, respectively. Homogeneous GA lesions showed less disparity in area measurements across modalities compared with non-homogeneous lesions.
   Conclusions: ImageJ appears to be a reliable tool for GA area measurements when proprietary OCT software is unavailable. Manual measurements with Heidelberg Eye Explorer and ImageJ were comparable, as were semi-automated measurements with Heidelberg RegionFinder and ImageJ Color Threshold.
   Translational Relevance: Novel GA measurement techniques using open-source software appear to be comparable to established techniques using proprietary platform-specific software, which may permit more widespread analysis of GA progression from multiple platforms and databases.
C1 [Mahmoudzadeh, Raziyeh; Salabati, Mirataollah; Khan, M. Ali; Garg, Sunir J.; Hsu, Jason] Wills Eye Hosp & Res Inst, Mid Atlantic Retina, Retina Serv, 840 Walnut St,Unit 1020, Philadelphia, PA 19107 USA.
C3 Jefferson University
RP Hsu, J (通讯作者)，Wills Eye Hosp & Res Inst, Mid Atlantic Retina, Retina Serv, 840 Walnut St,Unit 1020, Philadelphia, PA 19107 USA.
EM jhsu@midatlanticretina.com
RI Mahmoudzadeh, Raziyeh/AAD-3047-2019
OI Mahmoudzadeh, Raziyeh/0000-0002-5818-9083
CR Biarnes M, 2015, AM J OPHTHALMOL, V160, P345, DOI 10.1016/j.ajo.2015.05.009
   Chaikitmongkol V, 2016, CURR OPIN OPHTHALMOL, V27, P217, DOI 10.1097/ICU.0000000000000259
   Deckert A, 2005, BMC Ophthalmol, V5, P8, DOI 10.1186/1471-2415-5-8
   Fisher CR, 2018, INVEST OPHTH VIS SCI, V59, pAMD41, DOI 10.1167/iovs.18-24289
   Grunwald JE, 2015, OPHTHALMOLOGY, V122, P809, DOI 10.1016/j.ophtha.2014.11.007
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   Jaffe GJ, 2021, OPHTHALMOLOGY, V128, P576, DOI 10.1016/j.ophtha.2020.08.027
   Jeong YJ, 2014, EYE, V28, P209, DOI 10.1038/eye.2013.275
   Liao DS, 2020, OPHTHALMOLOGY, V127, P186, DOI 10.1016/j.ophtha.2019.07.011
   Lindner M, 2017, INVEST OPHTH VIS SCI, V58, pBIO61, DOI 10.1167/iovs.16-21210
   Panthier C, 2014, RETINA-J RET VIT DIS, V34, P576, DOI 10.1097/01.iae.0000433986.32991.1e
   Samara WA, 2015, RETINA-J RET VIT DIS, V35, P2188, DOI 10.1097/IAE.0000000000000847
   Schmitz-Valckenberg S, 2002, GRAEF ARCH CLIN EXP, V240, P73, DOI 10.1007/s00417-001-0413-3
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P7640, DOI 10.1167/iovs.11-7457
   Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089
   Shahlaee A, 2016, AM J OPHTHALMOL, V161, P50, DOI 10.1016/j.ajo.2015.09.026
NR 17
TC 0
Z9 0
U1 0
U2 1
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 2164-2591
J9 TRANSL VIS SCI TECHN
JI Transl. Vis. Sci. Technol.
PD AUG
PY 2021
VL 10
IS 9
AR 33
DI 10.1167/tvst.10.9.33
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 3L5HO
UT WOS:000834792100017
PM 34436542
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Gunawan, JR
   Thiele, SH
   Isselmann, B
   Caruso, E
   Guymer, RH
   Luu, CD
AF Gunawan, Josephine R.
   Thiele, Sarah H.
   Isselmann, Ben
   Caruso, Emily
   Guymer, Robyn H.
   Luu, Chi D.
TI Effect of subthreshold nanosecond laser on retinal structure and
   function in intermediate age-related macular degeneration
SO CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; relative ellipsoid zone reflectivity
   (rEZR); retinal thickness; rod-mediated function; subthreshold
   nanosecond laser treatment
ID OPTICAL COHERENCE TOMOGRAPHY; CONVENTIONAL PHOTOCOAGULATOR; ROD
   FUNCTION; AMD
AB Background Subthreshold nanosecond laser (SNL) treatment has been studied as a potential intervention in intermediate age-related macular degeneration (iAMD). This study investigated the effect of 100 SNL treatment spots on retinal structure and function. Methods A prospective single-arm interventional pilot study. SNL treatment was delivered as 100 spots around the retinal vascular arcades of the study eye (worst visual acuity) in a single session in subjects with iAMD. Multimodal retinal imaging and dark-adapted chromatic perimetry were performed at baseline and at 0.5, 3, 6 and 12 months post treatment. Post treatment changes in best corrected visual acuity (BCVA), retinal thickness, relative ellipsoid zone reflectivity (rEZR) and rod-mediated functional parameters were compared to baseline. Results Twenty-one subjects with iAMD were recruited. SNL treatment was associated with an increase in retinal thickness (p = 0.008) and decrease in rEZR (p < 0.001) at 2 weeks post laser. Recovery of retinal thickness and rEZR was observed at the 3-month post laser visit. A gradual improvement in BCVA was observed after laser treatment. The mean change in BCVA between baseline and 12-month visit was +1.9 +/- 3.3 letters for the SNL treated eyes, compared to -0.4 +/- 3.0 letters for the fellow eyes (p = 0.027). Rod-mediated function improved at 3 months post laser (p < 0.001) and returned to the baseline levels at 12 months post treatment. Conclusions A single treatment with 100 SNL spots causes a short-term change in retinal structure and improvement in retinal function that are apparent at 3 months post treatment.
C1 [Gunawan, Josephine R.; Caruso, Emily; Guymer, Robyn H.; Luu, Chi D.] Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Melbourne, Vic, Australia.
   [Thiele, Sarah H.; Isselmann, Ben] Univ Bonn, Dept Ophthalmol, Bonn, Germany.
   [Guymer, Robyn H.; Luu, Chi D.] Univ Melbourne, Dept Surg, Ophthalmol, Melbourne, Vic, Australia.
C3 Centre for Eye Research Australia; Royal Victorian Eye & Ear Hospital;
   University of Bonn; University of Melbourne
RP Luu, CD (通讯作者)，Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Level 8 SFW,32 Gisborne St, East Melbourne, Vic 3002, Australia.
EM cluu@unimelb.edu.au
OI Guymer, Robyn/0000-0002-9441-4356; Luu, Chi/0000-0002-7604-7097
FU National Health & Medical Research Council of Australia [GNT1027624,
   GNT1103013]; Victorian Government; Ellex R&D Pty Ltd (Adelaide,
   Australia)
FX This study was supported by National Health & Medical Research Council
   of Australia (project grant no.: GNT1027624 [RHG and CDL], and
   fellowship grant no.: GNT1103013 [RHG]). The Centre for Eye Research
   Australia (CERA) receives operational infrastructure support from the
   Victorian Government. Ellex R&D Pty Ltd (Adelaide, Australia) provided
   the inkind provision of Ellex 2RT (R) laser systems. The web-based
   Research Electronic Data Capture (REDCap) application and open-source
   platform OpenClinica allowed secure electronic data capture.
CR Chidlow G, 2013, INVEST OPHTH VIS SCI, V54, P2319, DOI 10.1167/iovs.12-11204
   Cohn AC, 2021, OSLI RETINA, V52, P380, DOI 10.3928/23258160-20210628-04
   Cohn AC, 2021, J CLIN MED, V10, DOI 10.3390/jcm10030484
   Dimitrov PN, 2008, INVEST OPHTH VIS SCI, V49, P55, DOI 10.1167/iovs.06-1048
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Flamendorf J, 2015, OPHTHALMOLOGY, V122, P2053, DOI 10.1016/j.ophtha.2015.06.023
   Fraser RG, 2016, INVEST OPHTH VIS SCI, V57, P5436, DOI 10.1167/iovs.16-19295
   Gin TJ, 2017, INVEST OPHTH VIS SCI, V58, P2079, DOI 10.1167/iovs.16-20105
   Guymer RH, OPHTHALMOL RETINA, V5, P1196
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P829, DOI 10.1016/j.ophtha.2018.09.015
   Guymer RH, 2014, CLIN EXP OPHTHALMOL, V42, P466, DOI 10.1111/ceo.12247
   Jobling AI, 2015, FASEB J, V29, P696, DOI 10.1096/fj.14-262444
   Luu CD, 2020, CLIN EXP OPHTHALMOL, V48, P938, DOI 10.1111/ceo.13823
   Owens SL, 2006, AM J OPHTHALMOL, V141, P276, DOI 10.1016/j.ajo.2005.08.019
   Spaide RF, 2011, RETINA-J RET VIT DIS, V31, P1609, DOI 10.1097/IAE.0b013e3182247535
   Staurenghi G, 2014, OPHTHALMOLOGY, V121, P1572, DOI 10.1016/j.ophtha.2014.02.023
   Tan R, 2018, INVEST OPHTH VIS SCI, V59, P4154, DOI 10.1167/iovs.18-23970
   Tan RS, 2019, INVEST OPHTH VIS SCI, V60, P1511, DOI 10.1167/iovs.18-26385
   Tan RS, 2018, TRANSL VIS SCI TECHN, V7, DOI 10.1167/tvst.7.3.3
   Thiele S, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.11.17
   Vessey KA, 2018, INVEST OPHTH VIS SCI, V59, P731, DOI 10.1167/iovs.17-23098
   Wood JPM, 2013, INVEST OPHTH VIS SCI, V54, P2305, DOI 10.1167/iovs.12-11203
   Wood JPM, 2011, LASER SURG MED, V43, P499, DOI 10.1002/lsm.21087
   Wu ZC, 2013, INVEST OPHTH VIS SCI, V54, P2800, DOI 10.1167/iovs.13-11613
   Zhang JJ, 2012, INVEST OPHTH VIS SCI, V53, P2928, DOI 10.1167/iovs.11-8585
NR 25
TC 0
Z9 0
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1442-6404
EI 1442-9071
J9 CLIN EXP OPHTHALMOL
JI Clin. Exp. Ophthalmol.
PD JAN
PY 2022
VL 50
IS 1
BP 31
EP 39
DI 10.1111/ceo.14018
EA OCT 2021
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA YY5OZ
UT WOS:000710297500001
PM 34652058
DA 2022-11-30
ER

PT J
AU Spaide, RF
AF Spaide, Richard F.
TI Enhanced Depth Imaging Optical Coherence Tomography of Retinal Pigment
   Epithelial Detachment in Age-related Macular Degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID OCCULT CHOROIDAL NEOVASCULARIZATION; ENDOTHELIAL GROWTH-FACTOR;
   CLINICOPATHOLOGICAL CORRELATION; ANGIOMATOUS PROLIFERATION; BRUCHS
   MEMBRANE; TEARS; PATHOGENESIS; ANASTOMOSES; PHOTOCOAGULATION; EXPRESSION
AB PURPOSE: To describe the internal structure of pigment epithelial detachments (PEDs) seen in eyes with age-related macular degeneration (AMD) as imaged with enhanced depth imaging (EDI) spectral-domain optical coherence tomography (OCT).
   DESIGN: Retrospective observational case series.
   METHODS: The images were obtained by positioning a spectral-domain OCT device close enough to the eye to obtain an inverted image and 7 sections, each comprised of 100 averaged scans, were obtained within a 5 degrees X 15 degrees or larger rectangle to encompass the PED and accompanying neovascularization if present. The resultant images were reinverted and compared with fluorescein and indocyanine green angiographic findings.
   RESULTS: The full extent of the choroid was visualized under the PED in each of the 22 consecutive eyes imaged with EDI OCT. The entire PED cavity filled with hyperreflective tissue in 11 eyes. In the remaining 11 regions, what appeared to be serous fluid and collections of reflective material were found within the PED. The reflective material was seen to be contiguous with subretinal pigment epithelial neovascularization, had angio, graphic suggestive of fibrovascular proliferation, and was seen to course up along the back surface of the retinal pigment epithelium (RPE). Intravitreal ranibizumab injection caused PED flattening with apparent contracture of the accumulated material within the PED.
   CONCLUSIONS: PEDs in the context of AMD show material suggestive of choroidal neovascularization, frequently on the back surface of the RPE. These findings can help explain the pathogenesis of PEDs, retinal vascular anastomosis with choroidal neovascularization, and RPE tears. (Am J Ophthalmol 2009;147:644-652. (C) 2009 by Elsevier Inc. All rights reserved.)
C1 [Spaide, Richard F.] Vitreous Retina Macula Consultants New York, New York, NY 10022 USA.
   [Spaide, Richard F.] Manhattan Eye Ear & Throat Hosp, LuEsther T Mertz Retinal Res Ctr, New York, NY 10021 USA.
C3 Vitreous Retina Macula Consultants of New York; Manhattan Eye Ear &
   Throat Hospital
RP Spaide, RF (通讯作者)，Vitreous Retina Macula Consultants New York, 460 Pk Ave,5th Floor, New York, NY 10022 USA.
EM rickspaide@yahoo.com
RI Spaide, Richard/ABD-7368-2020
CR Arevalo JF, 2008, BRIT J OPHTHALMOL, V92, P213, DOI 10.1136/bjo.2007.127142
   Axer-Siegel R, 2002, OPHTHALMOLOGY, V109, P1726, DOI 10.1016/S0161-6420(02)01149-1
   Baffi J, 2000, INVEST OPHTH VIS SCI, V41, P3582
   BIRD AC, 1991, EYE, V5, P1
   BIRD AC, 1986, T OPHTHAL SOC UK, V105, P674
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   CASSWELL AG, 1985, BRIT J OPHTHALMOL, V69, P397, DOI 10.1136/bjo.69.6.397
   Chang LK, 2007, RETINA-J RET VIT DIS, V27, P523, DOI 10.1097/IAE.0b013e3180a032db
   CHUANG EL, 1988, AM J OPHTHALMOL, V105, P285, DOI 10.1016/0002-9394(88)90011-6
   Coscas F, 2007, AM J OPHTHALMOL, V144, P592, DOI 10.1016/j.ajo.2007.06.014
   COSCAS G, 1990, ARCH OPHTHALMOL-CHIC, V108, P1687, DOI 10.1001/archopht.1990.01070140041025
   Gass J D, 1972, Trans Am Ophthalmol Soc, V70, P409
   Gass J D, 1966, Trans Am Acad Ophthalmol Otolaryngol, V70, P990
   Gass JDM, 2003, RETINA-J RET VIT DIS, V23, P741, DOI 10.1097/00006982-200312000-00001
   GASS JDM, 1984, AM J OPHTHALMOL, V98, P700
   GASS JDM, 1984, BRIT J OPHTHALMOL, V68, P513, DOI 10.1136/bjo.68.8.513
   GASS JDM, 1984, RETINA-J RET VIT DIS, V4, P205, DOI 10.1097/00006982-198400440-00001
   Gibran SK, 2007, BRIT J OPHTHALMOL, V91, P602, DOI 10.1136/bjo.2006.108795
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Grossniklaus HE, 2005, ARCH OPHTHALMOL-CHIC, V123, P914
   Grossniklaus HE, 1998, ARCH OPHTHALMOL-CHIC, V116, P745, DOI 10.1001/archopht.116.6.745
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   HOSKIN A, 1981, BRIT J OPHTHALMOL, V65, P417, DOI 10.1136/bjo.65.6.417
   Kannan R, 2006, MOL VIS, V12, P1649
   KUHN D, 1995, ARCH OPHTHALMOL-CHIC, V113, P1392, DOI 10.1001/archopht.1995.01100110052025
   Lafaut BA, 2001, BRIT J OPHTHALMOL, V85, P454, DOI 10.1136/bjo.85.4.454
   MEYER PAR, 1990, BRIT J OPHTHALMOL, V74, P275, DOI 10.1136/bjo.74.5.275
   MORRE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1290
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   Schlingemann RO, 2004, GRAEF ARCH CLIN EXP, V242, P91, DOI 10.1007/s00417-003-0828-0
   Slakter JS, 2000, OPHTHALMOLOGY, V107, P742, DOI 10.1016/S0161-6420(00)00009-9
   Spaide RF, 2006, AM J OPHTHALMOL, V141, P149, DOI 10.1016/j.ajo.2005.07.025
   Spaide RF, 1998, OPHTHALMOLOGY, V105, P680, DOI 10.1016/S0161-6420(98)94024-6
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Spilsbury K, 2000, AM J PATHOL, V157, P135, DOI 10.1016/S0002-9440(10)64525-7
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   TOTH CA, 1995, OPHTHALMOLOGY, V102, P272
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   Yannuzzi LA, 2008, RETINA-J RET VIT DIS, V28, P375, DOI 10.1097/IAE.0b013e3181619c55
NR 40
TC 222
Z9 235
U1 0
U2 15
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD APR
PY 2009
VL 147
IS 4
BP 644
EP 652
DI 10.1016/j.ajo.2008.10.005
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 424KW
UT WOS:000264566600014
PM 19152869
DA 2022-11-30
ER

PT J
AU Silva, R
   Cachulo, ML
   Fonseca, P
   Bernardes, R
   Nunes, S
   Vilhena, N
   de Abreu, JRF
AF Silva, Rufino
   Cachulo, M. L.
   Fonseca, Pedro
   Bernardes, Rui
   Nunes, S.
   Vilhena, Nelson
   Faria de Abreu, J. R.
TI Age-Related Macular Degeneration and Risk Factors for the Development of
   Choroidal Neovascularisation in the Fellow Eye: A 3-Year Follow-Up Study
SO OPHTHALMOLOGICA
LA English
DT Article
DE Age-related maculopathy; Drusen; Indocyanine green angiography hot
   spots; Risk factors; Exudative age-related macular degeneration;
   Computer-assisted grading; Retinal leakage analyzer
ID RETINAL ANGIOMATOUS PROLIFERATION; BEAVER DAM EYE; FUNDUS
   AUTOFLUORESCENCE; 5-YEAR INCIDENCE; MACULOPATHY; DRUSEN; CLASSIFICATION;
   FILM
AB Introduction: The presence of large-sized drusen (6 125 mu m), soft indistinct drusen, pigmentary changes, a large area of drusen and a choroidal neovascular membrane in one eye have been found to be predictive risk factors of late exudative age-related macular degeneration (AMD). Multimodal imaging potentially increases the possibility of indentifying further potential risk factors of developing wet AMD. Purpose: To identify morphological and/or functional baseline risk factors for the development of choroidal neovascularization (CNV) in a multimodal set of images from fellow eyes of patients with exudative AMD. Methods: Single-center, prospective, observational, longitudinal 2-year plus 1-year extension study of 62 patients with neovascular AMD in one eye (the nonstudy eye) and early age-related maculopathy (ARM) in the fellow eye (study eye). Best-corrected ETDRS visual acuity, fluorescein angiography (FA) and indocyanine green angiography (ICG), fundus photography, retinal leakage analysis, fundus autofluorescence imaging and optical coherence tomography (OCT Stratus 4.0.2, Carl Zeiss Meditech Inc.) were performed at baseline and every 6 months in order to identify both conversion to CNV as well as possible predictive features present before conversion. A semiautomated computer-assisted grading system was used for classifying fundus color images. Only eyes with 3 years of follow-up were considered for statistical analysis. Results: Fifty-two patients completed the 3-year study follow-up: 26 men and 26 women aged from 56 to 92 years (mean +/- SD: 76 +/- 6 years). CNV confirmed with FA developed in 46% of the 52 study eyes during the 3-year follow-up (24 converted eyes: 7 in the first year, 11 in the second and 6 in the third). A significantly higher risk for conversion to wet AMD was found only for leakage on a retinal leakage analyzer (odds ratio, OR = 5.0; 95% confidence interval, CI = 1.5-16.4; p = 0.006) detected at least in one visit before the onset of exudative lesions, for baseline ICG hot spots (OR = 7.2; 95% CI = 2.0-25.7; p = 0.002), baseline late ICG hot spots (OR = 4.7; 95% CI = 1.4-15.4; p = 0.009) and baseline early ICG hypofluorescent spots (OR = 3.7; 95% CI = 1.2-12.1; p = 0.025). The total area of drusen, the area of drusen in subfield 1, inner circle or outer circle, the total number of drusen and the number of drusen >= 125 mu m, fundus autofluorescence patterns, OCT findings and the severity of ARM at baseline did not show any correlation with an increased risk of conversion to wet AMD. Conclusion: At 3 years, progression from early to late exudative AMD was superior to the expected rate (44%). ICG early and late hyperfluorescent spots or areas, ICG early hypofluorescent spots or areas and early leakage detected with the retinal leakage analyzer, but not pigmentary changes, large drusen, number and area of drusen at any location or a greater severity of ARM at baseline, showed to be a predictive parameter of conversion to wet AMD. Copyright (C) 2011 S. Karger AG, Basel
C1 [Silva, Rufino; Cachulo, M. L.; Fonseca, Pedro] Univ Coimbra, Dept Ophthalmol, Coimbra, Portugal.
   [Bernardes, Rui] Univ Coimbra, Inst Biophys & Biomath, Fac Med, Coimbra, Portugal.
   [Silva, Rufino; Cachulo, M. L.; Fonseca, Pedro; Bernardes, Rui; Nunes, S.; Faria de Abreu, J. R.] Ctr New Technol Med, Assoc Innovat & Biomed Res Light & Image, Coimbra, Portugal.
   [Vilhena, Nelson] Crit Hlth, Coimbra, Portugal.
C3 Universidade de Coimbra; Universidade de Coimbra; Universidade de
   Coimbra
RP Silva, R (通讯作者)，Univ Hosp Coimbra, Dept Ophthalmol, Ave Bissaya Barreto, P-3000075 Coimbra, Portugal.
EM rufino.silva@oftalmologia.co.pt
RI Silva, Rufino M/J-2817-2012; Bernardes, Rui/M-4231-2013
OI Silva, Rufino M/0000-0001-8676-0833; Bernardes, Rui/0000-0002-6677-2754;
   Cachulo, Maria Luz/0000-0002-0900-4548; Nunes,
   Sandrina/0000-0001-5401-9637
CR Bernardes R, 2005, IEEE T BIO-MED ENG, V52, P106, DOI 10.1109/TBME.2004.839801
   Bindewald A, 2005, INVEST OPHTH VIS SCI, V46, P3309, DOI 10.1167/iovs.04-0430
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BRESSLER NM, 1995, ARCH OPHTHALMOL-CHIC, V113, P301, DOI 10.1001/archopht.1995.01100030055022
   BURGESS DB, 1993, ARCH OPHTHALMOL-CHIC, V111, P1189
   CACHULO ML, 2011, OPHTHALMOLOGICA, V225, P144
   Einbock W, 2005, GRAEF ARCH CLIN EXP, V243, P300, DOI 10.1007/s00417-004-1027-3
   Fernandes LHS, 2002, RETINA-J RET VIT DIS, V22, P557, DOI 10.1097/00006982-200210000-00005
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Gross NE, 2005, RETINA-J RET VIT DIS, V25, P713, DOI 10.1097/00006982-200509000-00005
   Hanutsaha P, 1998, OPHTHALMOLOGY, V105, P1632, DOI 10.1016/S0161-6420(98)99030-3
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   Klein R, 2004, ARCH OPHTHALMOL-CHIC, V122, P1642, DOI 10.1001/archopht.122.11.1642
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Lafaut BA, 2000, BRIT J OPHTHALMOL, V84, P1269, DOI 10.1136/bjo.84.11.1269
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   Malek G, 2003, AM J PATHOL, V162, P413, DOI 10.1016/S0002-9440(10)63836-9
   McBain VA, 2007, BRIT J OPHTHALMOL, V91, P491, DOI 10.1136/bjo.2006.095109
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   Saito Tamiya, 1996, Nippon Ganka Gakkai Zasshi, V100, P617
   Schmitz-Valckenberg S, 2008, RETINA-J RET VIT DIS, V28, P385, DOI 10.1097/IAE.0b013e318164a907
   SMITH TR, 2006, INVEST OPHTH VIS SCI, V47, P5495
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   van Leeuwen R, 2003, OPHTHALMOLOGY, V110, P1540, DOI 10.1016/S0161-6420(03)00501-3
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
NR 26
TC 30
Z9 32
U1 0
U2 10
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2011
VL 226
IS 3
DI 10.1159/000329473
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 821DP
UT WOS:000294955400003
PM 21822000
DA 2022-11-30
ER

PT J
AU Mulligan, K
   Seabury, SA
   Dugel, PU
   Blim, JF
   Goldman, DP
   Humayun, MS
AF Mulligan, Karen
   Seabury, Seth A.
   Dugel, Pravin U.
   Blim, Jill F.
   Goldman, Dana P.
   Humayun, Mark S.
TI Economic Value of Anti-Vascular Endothelial Growth Factor Treatment for
   Patients With Wet Age-Related Macular Degeneration in the United States
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID TREATMENT PATTERNS; COST-EFFECTIVENESS; VISUAL IMPAIRMENT; RANIBIZUMAB;
   EXTEND; GAINS; OUTCOMES; REGIMEN; PEOPLE; BURDEN
AB Question How much economic value do anti-vascular endothelial growth factor (anti-VEGF) treatments generate for patients with wet age-related macular degeneration and society in the United States? Findings In this economic evaluation study, visual acuity improvement associated with anti-VEGF treatments generated $5.1 billion to $8.2 billion in patient benefits and $0.9 billion to $3.0 billion in societal value (patient benefits net of treatment costs) across 3 years. Treatment innovations associated with improved adherence generated an additional $7.3 billion to $15.0 billion in patient benefits and $0.9 million to $4.3 billion in societal value compared with current treatment scenarios. Meaning This study's findings suggest that improved visual acuity associated with anti-VEGF treatment may provide economic value, and future innovations may result in added economic benefit.
   Importance Anti-vascular endothelial growth factor (anti-VEGF) is a breakthrough treatment for wet age-related macular degeneration (wAMD), the most common cause of blindness in western countries. Anti-VEGF treatment prevents vision loss and has been shown to produce vision gains lasting as long as 5 years. Although this treatment is costly, the benefits associated with vision gains are large. Objective To estimate the economic value of benefits, costs for patients with wAMD, and societal value in the United States generated from vision improvement associated with anti-VEGF treatment. Design, Setting, and Participants This economic evaluation study used data from the published literature to simulate vision outcomes for a cohort of 168 820 patients with wAMD aged 65 years or older and to translate them into economic variables. Data were collected and analyzed from March 2018 to November 2018. Main Outcomes and Measures Main outcomes included patient benefits, costs, and societal value. Each outcome was estimated for a newly diagnosed cohort and the full population across 5 years, with a focus on year 3 as the primary outcome because data beyond that point may be less representative of the general population. Drug costs were the weighted mean across anti-VEGF therapies. Two current treatment scenarios were considered: less frequent injections (mean [SD], 8.2 [1.6] injections annually) and more frequent injections (mean [range], 10.5 [6.8-13.1] injections annually). The 2 treatment innovation scenarios, improved adherence and best case, had the same vision outcomes as the current treatment scenarios had but included more patients treated from higher initiation and lower discontinuation. Results The study population included 168 820 patients aged 65 years at the time of diagnosis with wAMD. The underlying clinical trials that were used to parameterize the model did not stratify visual acuity outcomes or treatment frequency by sex; therefore, the model parameters could not be stratified by sex. The current treatment scenario of less frequent injections generated $1.1 billion for the full population in year 1 and $5.1 billion in year 3, whereas the scenario of more frequent injections generated $1.6 billion (year 1) and $8.2 billion (year 3). Three-year benefits ranged from $7.3 billion to $11.4 billion in the improved adherence scenario and from $9.7 billion to $15.0 billion if 100% of the patients initiated anti-VEGF treatment and the discontinuation rates were 6% per year or equivalent to clinical trial discontinuation (best-case scenario). Societal value (patient benefits net of treatment cost) ranged from $0.9 billion to $3.0 billion across 3 years in the current treatment scenarios and from $0.9 billion to $4.3 billion in the treatment innovation scenarios. Conclusions and Relevance This study's findings suggest that improved vision associated with anti-VEGF treatment may provide economic value to patients and society if the outcomes match published outcomes data used in these analyses; however, future innovations that increase treatment utilization may result in added economic benefit.
   This economic evaluation study estimates the value generated by anti-vascular endothelial growth factor treatment for patients with wet age-related macular degeneration and society in the United States.
C1 [Mulligan, Karen; Goldman, Dana P.] Univ Southern Calif, Sol Price Sch Publ Policy, Los Angeles, CA 90007 USA.
   [Seabury, Seth A.; Goldman, Dana P.] Univ Southern Calif, Sch Pharm, Los Angeles, CA 90007 USA.
   [Dugel, Pravin U.] Retinal Res Inst LLC, Phoenix, AZ USA.
   [Dugel, Pravin U.; Humayun, Mark S.] Univ Southern Calif, Roski Eye Inst, Los Angeles, CA 90007 USA.
   [Blim, Jill F.] Amer Soc Retina Specialists, Chicago, IL USA.
   [Mulligan, Karen; Seabury, Seth A.; Goldman, Dana P.] Univ Southern Calif, Leonard D Schaeffer Ctr Hlth Policy & Econ, Los Angeles, CA 90007 USA.
   [Humayun, Mark S.] Univ Southern Calif, Ginsburg Inst Biomed Therapeut, Los Angeles, CA 90007 USA.
C3 University of Southern California; University of Southern California;
   University of Southern California; University of Southern California;
   University of Southern California
RP Mulligan, K (通讯作者)，Univ Southern Calif, Sol Price Sch Publ Policy, Leonard D Schaeffer Ctr Hlth Policy & Econ, 635 Downey Way,Verna & Peter Dauterive Hall, Los Angeles, CA 90089 USA.
EM karenmul@usc.edu
RI Mulligan, Karen/AAD-1991-2022; Goldman, Dana P/E-7667-2013
OI Mulligan, Karen/0000-0002-6071-5564; Goldman, Dana P/0000-0001-8498-6396
FU American Society of Retina Specialists (ASRS); USC Schaeffer Center
FX Partial funding for this project was provided by an unrestricted gift
   from the American Society of Retina Specialists (ASRS) to the authors
   affiliated with the USC Schaeffer Center (Drs Mulligan, Seabury, and
   Goldman).
CR [Anonymous], AG REL MAC DEG AMD D
   Berger S, 2008, J AGING HEALTH, V20, P504, DOI 10.1177/0898264308317534
   Brown Gary C, 2005, Trans Am Ophthalmol Soc, V103, P173
   Casten RJ, 2013, CURR OPIN OPHTHALMOL, V24, P239, DOI 10.1097/ICU.0b013e32835f8e55
   Centers for Medicare and Medicaid Services, 2018, ASP DRUG PRIC FIL
   Centers for Medicare and Medicaid Services, 2018, PHYS FEE SCHEDULE
   Curtis LH, 2012, AM J OPHTHALMOL, V153, P1116, DOI 10.1016/j.ajo.2011.11.032
   Duffy M, 2017, NEW RES 2 POTENETIAL
   Elshout M, 2018, ACTA OPHTHALMOL, V96, P770, DOI 10.1111/aos.13824
   Freund KB, 2015, RETINA-J RET VIT DIS, V35, P1489, DOI 10.1097/IAE.0000000000000627
   Genentech, 2006, LUC RAN INJ PACK INS
   Ginsburg P, 2017, TREATMENT SPECIFIC P
   Hirth RA, 2000, MED DECIS MAKING, V20, P332, DOI 10.1177/0272989X0002000310
   Ho AC, 2017, JAMA OPHTHALMOL, V135, P268, DOI 10.1001/jamaophthalmol.2016.5314
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Hutton D, 2014, HEALTH AFFAIR, V33, P931, DOI 10.1377/hlthaff.2013.0832
   Institute for Clinical and Economic Review, 2016, TREATM OP REL REFR M
   Institute for Clinical and Economic Review, 2017, POL ADP RIB POL PARP
   Institute for Clinical and Economic Review, 2017, TARG IMM MOD RHEUM A
   Institute for Clinical and Economic Review. ICER, 2016, TREATM OPT ADV NONSM
   Jena AB, 2016, AM J MANAG CARE, V22, pE199
   Lad EM, 2014, AM J OPHTHALMOL, V158, P537, DOI 10.1016/j.ajo.2014.05.014
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Medicare Payment Advisory Commission, REP C MED HLTH CARE
   Mitchell P, 2011, PHARMACOECONOMICS, V29, P107, DOI 10.2165/11585520-000000000-00000
   Mrejen S, 2015, J CLIN MED, V4, P1380, DOI 10.3390/jcm4071380
   Murphy Sherry L, 2017, Natl Vital Stat Rep, V66, P1
   Neumann PJ, 2014, NEW ENGL J MED, V371, P796, DOI 10.1056/NEJMp1405158
   Okada M, 2018, AM J OPHTHALMOL, V192, P184, DOI 10.1016/j.ajo.2018.05.026
   Parikh R, 2017, OPHTHALMOLOGY, V124, P352, DOI 10.1016/j.ophtha.2016.10.036
   Patel S, 2018, OPHTHALMOL RETINA, V2, P785, DOI 10.1016/j.oret.2017.12.006
   Peden MC, 2015, OPHTHALMOLOGY, V122, P803, DOI 10.1016/j.ophtha.2014.11.018
   Prenner JL, 2015, AM J OPHTHALMOL, V160, P725, DOI 10.1016/j.ajo.2015.06.023
   Prevent blindness, LIV AMD
   Qin VL, 2018, RETINA-J RET VIT DIS, V38, P1500, DOI 10.1097/IAE.0000000000001753
   Rasmussen A, 2013, OPHTHALMOLOGY, V120, P2630, DOI 10.1016/j.ophtha.2013.05.018
   Rezaei K, 2015, AM SOC RETINA SPECIA
   Roach L, 2016, EYENET MAGAZINE
   Romley JA, 2014, HEALTH AFFAIR, V33, P370, DOI 10.1377/hlthaff.2013.0623
   Rudnicka AR, 2015, AM J OPHTHALMOL, V160, P85, DOI 10.1016/j.ajo.2015.04.003
   Schmier JK, 2006, RETINA-J RET VIT DIS, V26, P1056, DOI 10.1097/01.iae.0000254890.48272.5a
   Silva R, 2018, OPHTHALMOLOGY, V125, P57, DOI 10.1016/j.ophtha.2017.07.014
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Soubrane G, 2007, ARCH OPHTHALMOL-CHIC, V125, P1249, DOI 10.1001/archopht.125.9.1249
   Stone TW, 2017, ASRS 2017 PREFERENCE
   Thiagarajan M, 2005, ARCH OPHTHALMOL-CHIC, V123, P1397, DOI 10.1001/archopht.123.10.1397
   United States Census Bureau, 2017, NAT POP TOT
   van Asten F, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197670
   Van Nuys K, 2015, HEALTH AFFAIR, V34, P1666, DOI 10.1377/hlthaff.2014.1193
   Varano M, 2015, CLIN OPHTHALMOL, V9, P2243, DOI 10.2147/OPTH.S92548
   Wittenborn J, 2013, COST VISION PROBLEMS
   Yin W, 2012, AM J MANAG CARE, V18, pS257
NR 52
TC 14
Z9 14
U1 0
U2 4
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD JAN
PY 2020
VL 138
IS 1
BP 40
EP 47
DI 10.1001/jamaophthalmol.2019.4557
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA KB6VZ
UT WOS:000506631600008
PM 31725830
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Vessey, KA
   Jobling, AI
   Tran, MX
   Wang, AY
   Greferath, U
   Fletcher, EL
AF Vessey, Kirstan A.
   Jobling, Andrew, I
   Tran, Mai X.
   Wang, Anna Y.
   Greferath, Ursula
   Fletcher, Erica L.
TI Treatments targeting autophagy ameliorate the age-related macular
   degeneration phenotype in mice lacking APOE (apolipoprotein E)
SO AUTOPHAGY
LA English
DT Article
DE B6; bruch's membrane; metformin; retina; retinal pigment epithelium;
   trehalose
ID DARK-ADAPTATION; BRUCHS MEMBRANE; ROD; MODEL; ABNORMALITIES;
   PATHOGENESIS; SUBSTRATE; METFORMIN; DISEASE; STRESS
AB Age-related macular degeneration (AMD) is a leading cause of vision loss with recent evidence indicating an important role for macroautophagy/autophagy in disease progression. In this study we investigate the efficacy of targeting autophagy for slowing dysfunction in a mouse model with features of early AMD. Mice lacking APOE (apolipoprotein E; B6.129P2-Apoe(tm1Unc)J/Arc) and C57BL/6 J- (wild-type, WT) mice were treated with metformin or trehalose in the drinking water from 5 months of age and the ocular phenotype investigated at 13 months. Control mice received normal drinking water. APOE-control mice had reduced retinal function and thickening of Bruch's membrane consistent with an early AMD phenotype. Immunohistochemical labeling showed reductions in MAP1LC3B/LC3 (microtubule-associated protein 1 light chain 3 beta) and LAMP1 (lysosomal-associated membrane protein 1) labeling in the photoreceptors and retinal pigment epithelium (RPE). This correlated with increased LC3-II:LC3-I ratio and alterations in protein expression in multiple autophagy pathways measured by reverse phase protein array, suggesting autophagy was slowed. Treatment of APOE-mice with metformin or trehalose ameliorated the loss of retinal function and reduced Bruch's membrane thickening, enhancing LC3 and LAMP1 labeling in the ocular tissues and restoring LC3-II:LC3-I ratio to WT levels. Protein analysis indicated that both treatments boost ATM-AMPK driven autophagy. Additionally, trehalose increased p-MAPK14/p38 to enhance autophagy. Our study shows that treatments targeting pathways to enhance autophagy have the potential for treating early AMD and provide support for the use of metformin, which has been found to reduce the risk of AMD development in human patients.
C1 [Vessey, Kirstan A.; Jobling, Andrew, I; Tran, Mai X.; Wang, Anna Y.; Greferath, Ursula; Fletcher, Erica L.] Univ Melbourne, Dept Anat & Physiol, Level 5,Med Bldg,Grattan St, Parkville, Vic 3010, Australia.
C3 University of Melbourne
RP Vessey, KA (通讯作者)，Univ Melbourne, Dept Anat & Physiol, Level 5,Med Bldg,Grattan St, Parkville, Vic 3010, Australia.
EM k.vessey@unimelb.edu.au
RI Fletcher, Erica/E-6364-2012; Jobling, Andrew/C-8221-2015
OI Fletcher, Erica/0000-0001-9412-9523; Jobling,
   Andrew/0000-0002-7827-3135; Greferath, Ursula/0000-0003-1028-648X
FU National Health and Medical Research Council [APP2011200, APP1138253,
   APP1181010]; Rebecca L. Cooper Medical Research Foundation
FX This work was supported by the National Health and Medical Research
   Council [National Health and Medical Research Council; APP1138253];
   National Health and Medical Research Council [Award number: National
   Health and Medical Research Council; APP2011200]; National Health and
   Medical Research Council [National Health and Medical Research Council:
   Synergy Grant; APP1181010]; The Rebecca L. Cooper Medical Research
   Foundation.
CR Adams MKM, 2012, AM J EPIDEMIOL, V175, P511, DOI 10.1093/aje/kwr329
   Adler R, 1999, MOL VIS, V5
   Alexander A, 2010, P NATL ACAD SCI USA, V107, P4153, DOI 10.1073/pnas.0913860107
   Anderson DH, 2001, AM J OPHTHALMOL, V131, P767, DOI 10.1016/S0002-9394(00)00961-2
   Batool A, 2017, EUR J CELL BIOL, V96, P325, DOI 10.1016/j.ejcb.2017.03.013
   Beekman C, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0195850
   Boellner Stefanie, 2015, Microarrays (Basel), V4, P98, DOI 10.3390/microarrays4020098
   Brown EE, 2019, INVEST OPHTH VIS SCI, V60, P1470, DOI 10.1167/iovs.18-26422
   Cannizzo B, 2012, EXP DIABETES RES, DOI 10.1155/2012/941304
   Dhahbi JM, 2005, PHYSIOL GENOMICS, V23, P343, DOI 10.1152/physiolgenomics.00069.2005
   Dimitrov PN, 2008, INVEST OPHTH VIS SCI, V49, P55, DOI 10.1167/iovs.06-1048
   Dithmar S, 2000, INVEST OPHTH VIS SCI, V41, P2035
   Fletcher EL, 2014, OPTOMETRY VISION SCI, V91, P878, DOI 10.1097/OPX.0000000000000322
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Frost LS, 2014, EXP EYE RES, V124, P56, DOI 10.1016/j.exer.2014.04.010
   Gibson GE, 2010, BBA-MOL BASIS DIS, V1802, P122, DOI 10.1016/j.bbadis.2009.08.010
   HOGAN MJ, 1967, ARCH OPHTHALMOL-CHIC, V77, P410, DOI 10.1001/archopht.1967.00980020412022
   Honda Y, 2010, AGING CELL, V9, P558, DOI 10.1111/j.1474-9726.2010.00582.x
   Huang R, 2015, AUTOPHAGY, V11, P852, DOI 10.1080/15548627.2015.1038016
   Indira D, 2018, EUR J CELL BIOL, V97, P1, DOI 10.1016/j.ejcb.2017.10.003
   Jackson GR, 1999, VISION RES, V39, P3975, DOI 10.1016/S0042-6989(99)00092-9
   Jeon SM, 2016, EXP MOL MED, V48, DOI 10.1038/emm.2016.81
   Jobling AI, 2015, FASEB J, V29, P696, DOI 10.1096/fj.14-262444
   Kuoa SY, 2015, P NATL ACAD SCI USA, V112, pE4281, DOI 10.1073/pnas.1512289112
   LaRocca TJ, 2014, EXP GERONTOL, V58, P78, DOI 10.1016/j.exger.2014.07.008
   Levine B, 2008, NAT CELL BIOL, V10, P637, DOI 10.1038/ncb0608-637
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Malek G, 2005, P NATL ACAD SCI USA, V102, P11900, DOI 10.1073/pnas.0503015102
   Martin-Montalvo A, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3192
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   Onken B, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008758
   Owens SL, 1999, AM J OPHTHALMOL, V127, P681, DOI 10.1016/S0002-9394(99)00043-4
   Owsley C, 2016, OPHTHALMOLOGY, V123, P344, DOI 10.1016/j.ophtha.2015.09.041
   Panjwani N, 2013, ENDOCRINOLOGY, V154, P127, DOI 10.1210/en.2012-1937
   Pikuleva IA, 2014, PROG RETIN EYE RES, V41, P64, DOI 10.1016/j.preteyeres.2014.03.002
   Rabanal-Ruiz Y, 2017, ESSAYS BIOCHEM, V61, P565, DOI 10.1042/EBC20170027
   Sahani MH, 2014, AUTOPHAGY, V10, P431, DOI 10.4161/auto.27344
   Samuel MA, 2014, NAT NEUROSCI, V17, P1190, DOI 10.1038/nn.3772
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Scarpello JHB, 2003, DIABETES METAB, V29, pS36
   Schneider JG, 2006, CELL METAB, V4, P377, DOI 10.1016/j.cmet.2006.10.002
   STEINMETZ RL, 1993, BRIT J OPHTHALMOL, V77, P549, DOI 10.1136/bjo.77.9.549
   Sui XB, 2014, CANCER LETT, V344, P174, DOI 10.1016/j.canlet.2013.11.019
   Tanaka M, 2004, NAT MED, V10, P148, DOI 10.1038/nm985
   Terman A, 2007, J PATHOL, V211, P134, DOI 10.1002/path.2094
   Vessey KA, 2018, INVEST OPHTH VIS SCI, V59, P731, DOI 10.1167/iovs.17-23098
   Vessey KA, 2017, AM J PATHOL, V187, P1670, DOI 10.1016/j.ajpath.2017.04.016
   Vessey KA, 2015, INVEST OPHTH VIS SCI, V56, P1238, DOI 10.1167/iovs.14-15334
   Vessey KA, 2012, PLOS ONE, V7, P290, DOI 10.1371/journal.pone.0029990
   von Eisenhart-Rothe P, 2018, INVEST OPHTH VIS SCI, V59, P5082, DOI 10.1167/iovs.18-24757
   Weymouth AE, 2008, PROG RETIN EYE RES, V27, P1, DOI 10.1016/j.preteyeres.2007.09.003
   Xu L, 2018, P NATL ACAD SCI USA, V115, P10475, DOI 10.1073/pnas.1802724115
   Yin YB, 2018, VIRULENCE, V9, P83, DOI 10.1080/21505594.2017.1326443
NR 53
TC 3
Z9 3
U1 6
U2 13
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1554-8627
EI 1554-8635
J9 AUTOPHAGY
JI Autophagy
PD OCT 3
PY 2022
VL 18
IS 10
BP 2368
EP 2384
DI 10.1080/15548627.2022.2034131
EA FEB 2022
PG 17
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 5B2RP
UT WOS:000760124800001
PM 35196199
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Finger, RP
   Xie, J
   Fotis, K
   Parikh, S
   Cummins, R
   Mitchell, P
   Guymer, RH
AF Finger, Robert P.
   Xie, Jing
   Fotis, Kathy
   Parikh, Sumit
   Cummins, Rob
   Mitchell, Paul
   Guymer, Robyn H.
TI Disparities in access to anti-vascular endothelial growth factor
   treatment for neovascular age-related macular degeneration
SO CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE access; anti-VEGF; Australia; neovascular age-related macular
   degeneration
ID HEALTH-CARE UTILIZATION; VISUAL IMPAIRMENT; LEGAL BLINDNESS; AUSTRALIA;
   DISTANCE; OUTCOMES
AB Background: Late neovascular age-related macular degeneration (nvAMD) is very common and causes irreversible severe visual loss unless treated swiftly with vascular endothelial growth factor (VEGF) inhibitors. Although publicly subsidized access to treatment may be inequitable, which is why we assessed treatment provision across Australia.
   Design: Secondary analysis of Australian data.
   Participants: All Pharmaceutical Benefits Scheme (including Repatriation PBS) beneficiaries.
   Methods: Treatment and incidence data were obtained from Medicare Australia, the Royal Australian and New Zealand College of Ophthalmologists, Optometry Australia, the Blue Mountains Eye Study and the Australian Bureau of Statistics. Data were mapped using geographical information software, and factors associated with treatment provision were assessed using multiple linear regression models.
   Main Outcome Measure: Unmet need (%) for anti-VEGF treatment for nvAMD.
   Results: On average, we estimated 7316 incident cases of nvAMD not to be treated per year from 2010 to 2014 (50.1% of total). Number of ophthalmologists and optometrists (per 1000, beta = -0.024; 95% confidence interval [CI] -0.041, -0.007) and being located in remote regions (beta = 0.186; 95% CI 0.110, 0.262) were associated with percentage of untreated cases. A higher proportion of the population speaking a language other than English at home was associated in univariate analyses only (beta = 0.0015; 95% CI -0.0004, 0.0027; P = 0.007).
   Conclusion: A large proportion of incident nvAMD is not treated with anti-VEGF. Not receiving treatment is more likely in regional or remote areas and areas with fewer service providers. Not speaking English at home may further limit access. Service delivery models for more equitable service provision are needed.
C1 [Finger, Robert P.; Xie, Jing; Fotis, Kathy; Parikh, Sumit; Guymer, Robyn H.] Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Melbourne, Vic, Australia.
   [Finger, Robert P.; Xie, Jing; Fotis, Kathy; Parikh, Sumit; Guymer, Robyn H.] Univ Melbourne, Dept Surg, Dept Ophthalmol, Melbourne, Vic, Australia.
   [Cummins, Rob] Macular Dis Fdn Australia, Sydney, NSW, Australia.
   [Mitchell, Paul] Univ Sydney, Westmead Millennium Inst, Dept Ophthalmol, Ctr Vis Res, Sydney, NSW, Australia.
C3 Centre for Eye Research Australia; Royal Victorian Eye & Ear Hospital;
   University of Melbourne; University of Melbourne; University of Sydney;
   Westmead Institute for Medical Research
RP Finger, RP (通讯作者)，Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Dept Ophthalmol,Dept Surg, Level 1,32 Gisborne St, East Melbourne, Vic 3002, Australia.
EM robertfinger@gmx.net
RI xie, jing/GRY-1689-2022; Mitchell, Paul/P-1498-2014
OI /0000-0001-6694-3587; Finger, Robert P/0000-0003-4253-7597; Guymer,
   Robyn/0000-0002-9441-4356
FU MDFA; Charles Viertel Charitable Foundation; Lloyd and Kathleen Ansell
   Ophthalmology Foundation; Mankiewicz-Zelkin Fellowship of the University
   of Melbourne; Novartis Australia; Bayer Australia; NSW Government;
   Federal Government
FX This study was supported by the MDFA, the Charles Viertel Charitable
   Foundation, the Lloyd and Kathleen Ansell Ophthalmology Foundation and
   the Mankiewicz-Zelkin Fellowship of the University of Melbourne to Dr
   Finger. CERA receives Operational Infrastructure Support from the
   Victorian Government. The MDFA receives funding from Novartis Australia,
   Bayer Australia and the NSW and Federal Governments. The funders had no
   role in designing, implementing, analysing or reporting of this study.
CR Arnold JJ, 2015, OPHTHALMOLOGY, V122, P1212, DOI 10.1016/j.ophtha.2015.02.009
   Billi JE, 2007, HEALTH CARE MANAGE R, V32, P22, DOI 10.1097/00004010-200701000-00004
   Bloch SB, 2012, AM J OPHTHALMOL, V153, P209, DOI 10.1016/j.ajo.2011.10.016
   Bressler NM, 2011, ARCH OPHTHALMOL-CHIC, V129, P709, DOI 10.1001/archophthalmol.2011.140
   [Drug utilisation sub-committee (DUSC) Pharmaceutical Benefits Scheme], 2015, AG REL MAC DEG UT AN
   Finger RP, 2014, OPHTHALMOLOGY, V121, P1246, DOI 10.1016/j.ophtha.2013.12.032
   Finger RP, 2013, MED J AUSTRALIA, V198, P260, DOI 10.5694/mja12.11295
   Gruen RL, 2002, J EPIDEMIOL COMMUN H, V56, P517, DOI 10.1136/jech.56.7.517
   Hall SE, 2005, BJU INT, V95, P51, DOI 10.1111/j.1464-410X.2005.05248.x
   Jonas JB, 2014, AM J OPHTHALMOL, V158, P808, DOI 10.1016/j.ajo.2014.06.012
   Keenan TDL, 2012, BRIT J OPHTHALMOL, V96, P413, DOI 10.1136/bjophthalmol-2011-300338
   Korda RJ, 2007, INT J EPIDEMIOL, V36, P157, DOI [10.1093/ijc/dyl282, 10.1093/ije/dyl282]
   Lim JH, 2012, AM J OPHTHALMOL, V153, P678, DOI 10.1016/j.ajo.2011.09.013
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Mitchell P, 2011, EYES FUTURE CLEAR OU
   Mitchell P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101072
   Nemet GF, 2000, SOC SCI MED, V50, P1197, DOI 10.1016/S0277-9536(99)00365-2
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Wilson K, 2004, HEALTH POLICY, V67, P137, DOI 10.1016/S0168-8510(03)00101-5
NR 19
TC 9
Z9 9
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1442-6404
EI 1442-9071
J9 CLIN EXP OPHTHALMOL
JI Clin. Exp. Ophthalmol.
PD MAR
PY 2017
VL 45
IS 2
BP 143
EP 151
DI 10.1111/ceo.12804
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA EQ4OY
UT WOS:000398058700008
PM 27449314
OA Green Published
DA 2022-11-30
ER

PT J
AU Baird, PN
   Islam, FMA
   Richardson, AJ
   Cain, M
   Hunt, N
   Guymer, R
AF Baird, Paul N.
   Islam, F. M. Amirul
   Richardson, Andrea J.
   Cain, Melinda
   Hunt, Nicola
   Guymer, Robyn
TI Analysis of the Y402H variant of the complement factor H gene in
   age-related macular degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID SUSCEPTIBILITY LOCI; GENOMEWIDE-SCAN; VISUAL IMPAIRMENT; MACULOPATHY;
   POLYMORPHISM; ASSOCIATION; POPULATION; INFECTION; BIOLOGY; LINKAGE
AB PURPOSE. Recent studies in U. S. populations have indicated that the Y402H variant of the complement factor H (CFH) gene contains a major risk susceptibility allele for age-related macular degeneration (AMD). This study was conducted to ascertain whether this is also true in a non-U.S. population and also whether the at-risk allele is associated with the clinical phenotype of disease and the age at diagnosis.
   METHODS. Two hundred thirty-six unrelated individuals with AMD and 144 unrelated but ethnically matched control subjects were recruited and examined. All subjects completed a standard questionnaire, were given a fundus examination, and provided a blood sample for DNA extraction. Alleles of Y402H in the CFH gene were determined by use of a MALDI-TOF based approach followed by statistical analysis.
   RESULTS. Individuals with AMD who had at least one copy of the C allele of Y402H had an increased risk of disease (odds ratio [OR] 2.98; 95% confidence interval [CI] 1.81-4.93) compared with cases with the T allele. On subgroup analysis, this risk was found to be most significant in individuals with neovascular disease (OR 4.34; 95% CI 1.94, 9.71). In addition, individuals with neovascular disease who were homozygous CC presented with a significant 7.0-year earlier age at diagnosis relative to those individuals who were homozygous TT. The population-attributable risk for the C allele ranged between 47% to 69%, depending on the AMD disease subtype.
   CONCLUSIONS. The C allele of Y402H represents a significant risk factor in individuals with AMD, and this effect is most pronounced in individuals with neovascular disease.
C1 Univ Melbourne, Ctr Eye Res Australia, Melbourne, Vic 3002, Australia.
C3 Centre for Eye Research Australia; University of Melbourne
RP Baird, PN (通讯作者)，Univ Melbourne, Ctr Eye Res Australia, 32 Gisborne St, Melbourne, Vic 3002, Australia.
EM pnb@unimelb.edu.au
RI Islam, Fakir M Amirul/P-6665-2015
OI Islam, Fakir M Amirul/0000-0003-3897-3302; Guymer,
   Robyn/0000-0002-9441-4356; Baird, Paul/0000-0002-1305-3502
CR Abecasis GR, 2004, AM J HUM GENET, V74, P482, DOI 10.1086/382786
   Baird PN, 2004, INVEST OPHTH VIS SCI, V45, P1311, DOI 10.1167/iovs.03-1121
   Blackmore TK, 1998, INFECT IMMUN, V66, P1427, DOI 10.1128/IAI.66.4.1427-1431.1998
   Conley YP, 2005, HUM MOL GENET, V14, P1991, DOI 10.1093/hmg/ddi204
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fisher SA, 2005, HUM MOL GENET, V14, P2257, DOI 10.1093/hmg/ddi230
   Giannakis E, 2003, EUR J IMMUNOL, V33, P962, DOI 10.1002/eji.200323541
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hammond CJ, 2002, OPHTHALMOLOGY, V109, P730, DOI 10.1016/S0161-6420(01)01049-1
   HEIBA IM, 1994, GENET EPIDEMIOL, V11, P51, DOI 10.1002/gepi.1370110106
   Iyengar SK, 2004, AM J HUM GENET, V74, P20, DOI 10.1086/380912
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Jurinke C, 2001, Methods Mol Biol, V170, P103
   Kalayoglu MV, 2005, GRAEF ARCH CLIN EXP, V243, P1080, DOI 10.1007/s00417-005-1169-y
   KINOSHITA T, 1991, IMMUNOL TODAY, V12, P291, DOI 10.1016/0167-5699(91)90001-A
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Klein ML, 1998, ARCH OPHTHALMOL-CHIC, V116, P1082, DOI 10.1001/archopht.116.8.1082
   KLEIN ML, 1994, ARCH OPHTHALMOL-CHIC, V112, P932, DOI 10.1001/archopht.1994.01090190080025
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Majewski J, 2003, AM J HUM GENET, V73, P540, DOI 10.1086/377701
   MEYERS SM, 1995, AM J OPHTHALMOL, V120, P757, DOI 10.1016/S0002-9394(14)72729-1
   Miller DM, 2004, AM J OPHTHALMOL, V138, P323, DOI 10.1016/j.ajo.2004.03.018
   Morgan BP, 1999, CRIT REV IMMUNOL, V19, P173
   MORGAN BP, 1991, IMMUNOL TODAY, V12, P301, DOI 10.1016/0167-5699(91)90003-C
   Muller-Eberhard H J, 1980, Adv Immunol, V29, P1, DOI 10.1016/S0065-2776(08)60042-5
   Robman L, 2005, AM J EPIDEMIOL, V161, P1013, DOI 10.1093/aje/kwi130
   Schick JH, 2003, AM J HUM GENET, V72, P1412, DOI 10.1086/375500
   Schultz DW, 2003, HUM MOL GENET, V12, P3315, DOI 10.1093/hmg/ddg348
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 2003, AM J HUM GENET, V73, P780, DOI 10.1086/378505
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Stone EM, 2004, NEW ENGL J MED, V351, P346, DOI 10.1056/NEJMoa040833
   Taylor HR, 1997, AM J OPHTHALMOL, V123, P328, DOI 10.1016/S0002-9394(14)70128-X
   Weeks DE, 2000, HUM MOL GENET, V9, P1329, DOI 10.1093/hmg/9.9.1329
   Weeks DE, 2004, AM J HUM GENET, V75, P174, DOI 10.1086/422476
   Weeks DE, 2001, AM J OPHTHALMOL, V132, P682, DOI 10.1016/S0002-9394(01)01214-4
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
NR 39
TC 65
Z9 67
U1 0
U2 4
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD OCT
PY 2006
VL 47
IS 10
BP 4194
EP 4198
DI 10.1167/iovs.05-1285
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 088AU
UT WOS:000240784700003
PM 17003406
DA 2022-11-30
ER

PT J
AU Wu, L
   Tao, QS
   Chen, W
   Wang, Z
   Song, YP
   Sheng, SY
   Li, PC
   Zhou, JJ
AF Wu, Lin
   Tao, Qiushan
   Chen, Wen
   Wang, Zhi
   Song, Yanping
   Sheng, Shuangyan
   Li, Pengcheng
   Zhou, Jingjing
TI Association between Polymorphisms of Complement Pathway Genes and
   Age-Related Macular Degeneration in a Chinese Population
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID FACTOR-H POLYMORPHISM; COMPONENT 2 C2; FACTOR-B BF; TRAIT ASSOCIATIONS;
   SNP HAPLOTYPES; C3; RISK; PREVALENCE; CFB; ATTRIBUTES
AB PURPOSE. We assessed the association between complement pathway genes and age-related macular degeneration (AMD) in a Chinese population.
   METHODS. In a case-control study, 165 AMD patients and 216 unrelated controls were recruited from two hospitals in central China. We selected and genotyped six single nucleotide polymorphisms (SNPs) of four complement pathway genes, including rs800292 and rs1410996 of complement H (CFH), rs9332739 of complement 2 (C2), rs4151667 of complement factor B (CFB), and rs2241394 and rs2230199 of complement 3 (C3). The associations between SNPs and AMD, adjusted by age and sex, were assessed by using logistic regression models and haplotype association analysis.
   RESULTS. In our study, two SNPs of CFH and their haplotypes were associated significantly with AMD, and the adjusted odd ratios (ORs) were 2.45 (95% confidence interval [CI] 1.25-4.79) for rs800292 (genotype GG versus AA), 2.49 (95% CI 1.24-5.00) for rs1410996 (genotype TT versus CC), and 4.45 (95% CI 2.32-8.55) for haplotype block of rs800292-rs1410996 (haplotype G-C versus A-C), respectively. The haplotype of C2/CFB also was associated significantly with AMD, and the adjusted OR was 8.86 (95% CI 1.88-41.69) for the haplotype block of rs9332739-rs4151667 (haplotype G-A versus G-T), though no relationship was found in genotype association analysis of the two SNPs of C2/CFB. With the sample size of our study, no relationship was found for AMD and the two SNPs of C3.
   CONCLUSIONS. Gene variants in CFH and C2/CFB contribute to AMD in the Chinese population. (Invest Ophthalmol Vis Sci. 2013;54:170-174) DOI: 10.1167/iovs.12-10453
C1 [Wu, Lin; Chen, Wen; Wang, Zhi; Sheng, Shuangyan; Li, Pengcheng; Zhou, Jingjing] Huazhong Univ Sci & Technol, Tongji Med Coll, Dept Ophthalmol, Union Hosp, Wuhan 430022, Peoples R China.
   [Tao, Qiushan] Peking Univ, Hlth Sci Ctr, Sch Publ Hlth, Dept Epidemiol & Biostat, Beijing 100871, Peoples R China.
   [Song, Yanping] Wuhan Gen Hosp Guangzhou Mil Reg, Dept Ophthalmol, Wuhan, Peoples R China.
C3 Huazhong University of Science & Technology; Peking University
RP Chen, W (通讯作者)，Huazhong Univ Sci & Technol, Tongji Med Coll, Dept Ophthalmol, Union Hosp, Wuhan 430022, Peoples R China.
EM chwhust@hotmail.com
OI Chen, Wen/0000-0001-8493-0157
FU Natural Science Foundation of Hubei Province [2010CDB07801];
   International Collaborative Genetic Research Training Grant NIH/FIC [D43
   TW06176]; FOGARTY INTERNATIONAL CENTER [D43TW006176] Funding Source: NIH
   RePORTER
FX Supported by Grant 2010CDB07801 from The Natural Science Foundation of
   Hubei Province and by International Collaborative Genetic Research
   Training Grant NIH/FIC, D43 TW06176.
CR [Anonymous], 2012, R LANG ENV STAT COMP
   Burkett K, 2004, HUM HERED, V57, P200, DOI 10.1159/000081447
   Burkett K, 2006, J STAT SOFTW, V16, P1
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Conti DV, 2004, GENET EPIDEMIOL, V27, P429, DOI 10.1002/gepi.20039
   Despriet DDG, 2009, OPHTHALMOLOGY, V116, P474, DOI 10.1016/j.ophtha.2008.09.055
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Francis PJ, 2009, J MED GENET, V46, P300, DOI 10.1136/jmg.2008.062737
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Heurich M, 2011, P NATL ACAD SCI USA, V108, P8761, DOI 10.1073/pnas.1019338108
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Khandhadia S, 2012, IMMUNOBIOLOGY, V217, P127, DOI 10.1016/j.imbio.2011.07.019
   Kim SJ, 2012, EXP EYE RES, V96, P42, DOI 10.1016/j.exer.2012.01.005
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Liu XQ, 2010, RETINA-J RET VIT DIS, V30, P1177, DOI 10.1097/IAE.0b013e3181cea676
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Owen CG, 2012, BRIT J OPHTHALMOL, V96, P752, DOI 10.1136/bjophthalmol-2011-301109
   Patel N, 2008, EYE, V22, P768, DOI 10.1038/sj.eye.6702844
   Pei XT, 2009, CURR EYE RES, V34, P615, DOI 10.1080/02713680903003484
   Richardson AJ, 2009, INVEST OPHTH VIS SCI, V50, P540, DOI 10.1167/iovs.08-2423
   Ryu E, 2010, MOL VIS, V16, P2811
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Tian J, 2012, INVEST OPHTH VIS SCI, V53, P4262, DOI 10.1167/iovs.11-8542
   Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
NR 30
TC 22
Z9 24
U1 0
U2 2
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JAN
PY 2013
VL 54
IS 1
BP 170
EP 174
DI 10.1167/iovs.12-10453
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 081QX
UT WOS:000314338400021
PM 23233260
OA Green Published
DA 2022-11-30
ER

PT J
AU Sudhalkar, A
   Sethi, V
   Gogte, P
   Bondalapati, S
   Khodani, M
   Chhablani, JK
AF Sudhalkar, Aditya
   Sethi, Vaibhav
   Gogte, Priyanka
   Bondalapati, Sailaja
   Khodani, Mitali
   Chhablani, Jay Kumar
TI Retrospective hospital-based analysis of age-related macular
   degeneration patterns in India: 5-year follow-up
SO INDIAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; anti-vascular endothelial growth
   factor therapy; hospital-based analysis; India
ID BLUE MOUNTAINS EYE; RISK-FACTORS; MACULOPATHY LESIONS; POPULATION;
   PREVALENCE; RANIBIZUMAB; PROGRESSION; DISEASE; SYSTEM
AB Purpose: To provide a detailed analysis of age-related macular degeneration (AMD) with a 5-year follow-up at a Tertiary Eye Care Center in India. Methods: In this retrospective institutional study, 408 eyes of 204 subjects (100 males) with a diagnosis of AMD with minimum 5-year follow-up were included. Data collected included demographics, details of the ocular exam, special investigations performed, treatment offered, complications, and systemic diseases, if any. Results: The median age was 74.24 +/- 8.23 years. Median follow-up was 5.77 years. The visual acuity (VA) at baseline and last visit was 0.74 +/- 0.12 (Snellen's equivalent 20/100) and 0.54 +/- 0.12 logarithm of the minimum angle of resolution (Snellen's equivalent 20/50; P = 0.032) in patients with choroidal neovascular membrane (CNVM). The most common complaint was decreased vision (94.5%). AMD (any stage) was found to be bilateral in 93% of patients at baseline and 197 patients (96.56%) at 5 years. Seventeen eyes had active CNVM (12 of these were occult) at presentation. At baseline, 43 eyes had a disciform scar. Three hundred twenty-one eyes had dry AMD at baseline (geographic atrophy - 12 [3.7%] eyes). Five-year conversion rate into wet AMD and geographic atrophy was 2.87% and 3.12%. Median number of anti-vascular endothelial growth factor injections administered per patient was 2.8 +/- 1.2. CNVM bilaterality was low (7.5%). Conclusion: Patients with AMD in India presented later in the course of the disease. Bilateral advanced AMD and geographic atrophy were uncommon. Five-year conversion rate into wet AMD and geographic atrophy was 2.87% and 3.12%.
C1 [Sudhalkar, Aditya] Eye Hosp & Retina Ctr, Vadodara, Gujarat, India.
   [Sethi, Vaibhav; Gogte, Priyanka; Khodani, Mitali] LV Prasad Eye Inst, Smt Kanuri Santhamma Ctr Vitreoretinal Dis, Hyderabad, Telangana, India.
   [Chhablani, Jay Kumar] LV Prasad Eye Inst, Smt Kanuri Santhamma Retina Vitreous Ctr, Kallam Anji Reddy Campus,Banjara Hills, Hyderabad 500034, Telangana, India.
   [Bondalapati, Sailaja] Univ N Carolina, Sch Med, Smt Kannuri Santhamma Ctr Vitreoretinal Dis, Chapel Hill, NC USA.
C3 L. V. Prasad Eye Institute; L. V. Prasad Eye Institute; University of
   North Carolina; University of North Carolina Chapel Hill; University of
   North Carolina School of Medicine
RP Chhablani, JK (通讯作者)，LV Prasad Eye Inst, Smt Kanuri Santhamma Retina Vitreous Ctr, Kallam Anji Reddy Campus,Banjara Hills, Hyderabad 500034, Telangana, India.
EM jay.chhablani@gmail.com
CR Anastasopoulos E, 2006, AM J OPHTHALMOL, V142, P1081, DOI 10.1016/j.ajo.2006.06.058
   Azad Rajvardhan, 2007, Indian Journal of Ophthalmology, V55, P441
   Biarnes M, 2011, OPTOMETRY VISION SCI, V88, P881, DOI 10.1097/OPX.0b013e31821988c1
   Biswas P, 2011, INDIAN J OPHTHALMOL, V59, P191, DOI 10.4103/0301-4738.81023
   Cheung CMG, 2014, OPHTHALMOLOGY, V121, P1598, DOI 10.1016/j.ophtha.2014.02.004
   Emery J., 1983, KELMAN PHACOEMULSIFI
   Englander M, 2013, CURR OPIN OPHTHALMOL, V24, P233, DOI 10.1097/ICU.0b013e32835f8eaa
   GREGOR Z, 1978, BRIT J OPHTHALMOL, V62, P547, DOI 10.1136/bjo.62.8.547
   Ivan SI, 2012, OPHTHALMOLOGY, V119, P1399, DOI DOI 10.1016/J.0PHTHA.2012.04.015
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Krishnaiah S, 2005, INVEST OPHTH VIS SCI, V46, P4442, DOI 10.1167/iovs.05-0853
   Krishnan T, 2010, INVEST OPHTH VIS SCI, V51, P701, DOI 10.1167/iovs.09-4114
   Kulkarni SR, 2013, INDIAN J OPHTHALMOL, V61, P196, DOI 10.4103/0301-4738.99870
   Levinson D., MEDICARE PAYMENTS DR
   Mitchell P, 2005, ARCH OPHTHALMOL-CHIC, V123, P1598, DOI 10.1001/archopht.123.11.1598
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   Miyazaki M, 2003, BRIT J OPHTHALMOL, V87, P469, DOI 10.1136/bjo.87.4.469
   Nangia V, 2011, RETINA-J RET VIT DIS, V31, P1179, DOI 10.1097/IAE.0b013e3181f57ff2
   Neubauer AS, 2010, CLIN THER, V32, P1343, DOI 10.1016/j.clinthera.2010.07.010
   Olsen TW, 2004, OPHTHALMOLOGY, V111, P250, DOI 10.1016/j.ophtha.2003.05.030
   Pokharel S, 2009, J NEPAL MED ASSOC, V48, P217
   Sallo FB, 2009, CURR EYE RES, V34, P238, DOI 10.1080/02713680802714058
   Shanmugam PM, 2014, INDIAN J OPHTHALMOL, V62, P88, DOI 10.4103/0301-4738.126189
   Stein Joshua D, 2013, Trans Am Ophthalmol Soc, V111, P56
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Wang JJ, 1998, BRIT J OPHTHALMOL, V82, P743, DOI 10.1136/bjo.82.7.743
   Woo JH, 2009, ACTA OPHTHALMOL, V87, P262, DOI 10.1111/j.1755-3768.2008.01376.x
NR 28
TC 3
Z9 3
U1 0
U2 0
PU MEDKNOW PUBLICATIONS & MEDIA PVT LTD
PI MUMBAI
PA B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075,
   INDIA
SN 0301-4738
EI 1998-3689
J9 INDIAN J OPHTHALMOL
JI Indian J. Ophthalmol.
PD DEC
PY 2015
VL 63
IS 12
BP 899
EP 904
DI 10.4103/0301-4738.176025
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DG6PE
UT WOS:000372207000006
PM 26862094
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Hanhart, J
   Comaneshter, DS
   Vinker, S
AF Hanhart, Joel
   Comaneshter, Doron S.
   Vinker, Shlomo
TI Mortality after a cerebrovascular event in age-related macular
   degeneration patients treated with bevacizumab ocular injections
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE anti-VEGF; bevacizumab; mortality; neovascular AMD; stroke
ID ENDOTHELIAL GROWTH-FACTOR; UNILATERAL INTRAVITREAL BEVACIZUMAB;
   PLASMA-LEVELS; SYSTEMIC SAFETY; RISK; RANIBIZUMAB; STROKE; THERAPY;
   EDEMA; ANGIOGENESIS
AB Purpose
   To analyse the mortality associated with intravitreal injections of bevacizumab for age-related macular degeneration (AMD) in patients previously diagnosed with stroke or transient ischaemic attack (TIA).
   MethodsResultsWe reviewed bevacizumab-treated AMD patients with a diagnosis of stroke or TIA prior to their first bevacizumab injection (n=948). Those patients, naive to any anti-vascular endothelial growth factor (anti-VEGF) at the time of stroke/TIA, were then compared to age- and gender-matched patients who had a stroke/TIA at the same time and had never been exposed to anti-VEGF. Survival analysis was performed using adjusted Cox regression. The main outcome measure was survival. Adjusted variables were age, smoking, alcohol abuse, hypertension, diabetes mellitus, obesity, ischaemic heart disease, congestive heart failure and liver cancer.
   Age and gender distribution of bevacizumab-treated patients and controls were similar (mean age: 83.4 versus 83.7years, p=0.3; 51.7% males versus 52.5% males, p=0.7). The adjusted mortality in patients who received bevacizumab within 3months after stroke/TIA was significantly different than in patients non-exposed to bevacizumab (OR=6.92, 95%, CI 1.88-25.43, p<0.01). Within 6months after stroke/TIA, the difference in adjusted mortality showed a strong trend (OR=2.00, 95%, CI 0.96-4.16, p=0.064). Within 12months, it was insignificant (OR=1.30, 95%, CI 0.75-2.26, p=0.348).
   ConclusionWe found increased mortality within three months after a cerebrovascular event in patients treated with bevacizumab for AMD compared to patients for whom there was no record of a prescription to any anti-VEGF agent.
C1 [Hanhart, Joel] Shaare Zedek Med Ctr, Dept Ophthalmol, 12 Beyt St, IL-91031 Jerusalem, Israel.
   [Comaneshter, Doron S.; Vinker, Shlomo] Clalit Hlth Serv, Cent Headquarters, Tel Aviv, Israel.
   [Vinker, Shlomo] Tel Aviv Univ, Sackler Sch Med, Tel Aviv, Israel.
C3 Hebrew University of Jerusalem; Shaare Zedek Medical Center; Clalit
   Health Services; Tel Aviv University; Sackler Faculty of Medicine
RP Hanhart, J (通讯作者)，Shaare Zedek Med Ctr, Dept Ophthalmol, 12 Beyt St, IL-91031 Jerusalem, Israel.
EM hanhart@szmc.org.il
OI Hanhart, Joel/0000-0003-0952-3740
CR Amadio M., 2015, PHARM RES, V103, P253
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Avery RL, 2016, JAMA OPHTHALMOL, V134, P21, DOI 10.1001/jamaophthalmol.2015.4070
   Avery RL, 2014, BRIT J OPHTHALMOL, V98, P1636, DOI 10.1136/bjophthalmol-2014-305252
   Avery RL, 2014, BRIT J OPHTHALMOL, V98, P7, DOI 10.1136/bjophthalmol-2013-303844
   Ayata C, 2004, J CEREBR BLOOD F MET, V24, P744, DOI 10.1097/01.WCB.0000122745.72175.D5
   Bakbak B, 2013, J OCUL PHARMACOL TH, V29, P728, DOI 10.1089/jop.2013.0049
   Berg K, 2017, ACTA OPHTHALMOL, V95, P796, DOI 10.1111/aos.13522
   Boberg-Ans G, 2006, ACTA OPHTHALMOL SCAN, V84, P613, DOI 10.1111/j.1600-0420.2006.00719.x
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Bressler NM, 2012, RETINA-J RET VIT DIS, V32, P1821, DOI 10.1097/IAE.0b013e31825db6ba
   Brito IAS, 2015, CASE REP OPHTHALMOL, V2015, DOI 10.1155/2015/516921
   BURN J, 1994, STROKE, V25, P333, DOI 10.1161/01.STR.25.2.333
   Carneiro AM, 2012, ACTA OPHTHALMOL, V90, pE25, DOI 10.1111/j.1755-3768.2011.02240.x
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Croll SD, 2001, MOL NEUROBIOL, V23, P121, DOI 10.1385/MN:23:2-3:121
   Davis TME, 1999, ARCH INTERN MED, V159, P1097, DOI 10.1001/archinte.159.10.1097
   Giles MF, 2007, LANCET NEUROL, V6, P1063, DOI 10.1016/S1474-4422(07)70274-0
   Gottlieb SS, 1997, LANCET, V349, P662, DOI 10.1016/S0140-6736(97)22010-6
   Grinnon ST, 2012, CLIN TRIALS, V9, P322, DOI 10.1177/1740774512438980
   Grivas AA, 2009, J BUON, V14, P115
   Hanhart J, 2014, EYE, V28, P646, DOI 10.1038/eye.2014.94
   Hershman DL, 2013, J CLIN ONCOL, V31, P3592, DOI 10.1200/JCO.2012.48.4857
   Hicks KA, 2015, CIRCULATION, V132, P302, DOI 10.1161/CIR.0000000000000156
   Hirai FE, 2008, AM J OPHTHALMOL, V145, P700, DOI 10.1016/j.ajo.2007.11.019
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Hosseini H, 2012, RETINA-J RET VIT DIS, V32, P967, DOI 10.1097/IAE.0b013e31822c28d6
   Ikram MK, 2012, STROKE, V43, P1681, DOI 10.1161/STROKEAHA.112.654632
   Karaca C, 2013, JAMA OPHTHALMOL, V131, P1099, DOI 10.1001/jamaophthalmol.2013.400
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Lapi D, 2015, J VASC RES, V52, P22, DOI 10.1159/000381096
   Letarte N, 2013, CANCER CHEMOTH PHARM, V71, P1561, DOI 10.1007/s00280-013-2155-4
   Lim LS, 2011, AM J OPHTHALMOL, V152, P329, DOI 10.1016/j.ajo.2011.05.040
   Madhusudhana KC, 2016, BRIT J OPHTHALMOL, V100, P1617, DOI 10.1136/bjophthalmol-2015-308077
   Matsuyama K, 2010, BRIT J OPHTHALMOL, V94, P1215, DOI 10.1136/bjo.2008.156810
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Pendlebury Sarah T, 2009, Cerebrovasc Dis, V27 Suppl 3, P1, DOI 10.1159/000209260
   Ranpura V, 2010, ACTA ONCOL, V49, P287, DOI 10.3109/02841860903524396
   Rennert G, 2001, ISR MED ASSOC J, V3, P404
   Seet RCS, 2011, NEUROCRIT CARE, V15, P421, DOI 10.1007/s12028-011-9552-5
   Seidel C, 2013, J NEUROL, V260, P847, DOI 10.1007/s00415-012-6718-9
   Semeraro F, 2015, CURR DRUG METAB, V16, P572, DOI 10.2174/1389200216666151001120831
   Solomon SD, 2016, OPHTHALMOLOGY, V123, P70, DOI 10.1016/j.ophtha.2015.09.002
   Sun YJ, 2003, J CLIN INVEST, V111, P1843, DOI 10.1172/JCI200317977
   Thulliez M, 2014, JAMA OPHTHALMOL, V132, P1317, DOI 10.1001/jamaophthalmol.2014.2333
   Tunon J, 2009, SURV OPHTHALMOL, V54, P339, DOI 10.1016/j.survophthal.2009.02.003
   Tuuminen R, 2017, ACTA OPHTHALMOL, V95, DOI 10.1111/aos.13501
   Zehetner C, 2013, BRIT J OPHTHALMOL, V97, P454, DOI 10.1136/bjophthalmol-2012-302451
   Zuo PY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102484
NR 49
TC 15
Z9 18
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD SEP
PY 2018
VL 96
IS 6
BP E732
EP E739
DI 10.1111/aos.13731
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GW8US
UT WOS:000447257100025
PM 29660843
DA 2022-11-30
ER

PT J
AU Xu, D
   Zhao, C
   Luo, X
   Yu, J
   Wang, F
AF Xu, Ding
   Zhao, Chun
   Luo, Xu
   Yu, Jing
   Wang, Fang
TI Ranibizumab as needed therapy for wet age-related macular degeneration
   combined with serous pigment epithelial detachment
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE
LA English
DT Article
DE Anti-VEGF; ranibizumab; wAMD
ID INTRAVITREAL RANIBIZUMAB; BEIJING-EYE; CLASSIFICATION; BEVACIZUMAB;
   SECONDARY
AB Purpose: To evaluate the effect of ranibizumab on wet age-related macular degeneration (wAMD) combined with serous pigment epithelium detachment (PED). Design: Retrospective, noncomparative case series. Methods: Thirteen eyes of 13 patients with wAMD and associated serious PED were included in the study. All the patients were treated with intravitreal ranibizumab as needed from the first injection and followed up for 12 months. The follow-up data included the best-corrected ETDRS letter score, maximum PED height, PED area and PED volume, and central retinal thickness (CRT) on ocular coherence tomography (OCT). Results: The mean ETDRS letter score was 57.54 +/- 10.28 at the last visit compared to 46.69 +/- 11.58 at the baseline (t = -3.47, P < 0.05). The mean change of the ETDRS letter score was 10.85 +/- 10.84. The mean maximum PED height, area and volume at the baseline and month 12 were 342.38 +/- 176.39 mu m and 189.23 +/- 134.69 mu m (z = -2.83, P < 0.05), 5.12 +/- 4.69 mm(2) and 2.74 +/- 2.89 mm(2) (z = -2.67, P < 0.05), 1.07 +/- 1.73 mm(3) and 0.25 +/- 0.46 mm(3) (z = -2.90, P < 0.05), respectively. The CRT were decreased from 331.54 +/- 60.08 mu m at the baseline to 286.85 +/- 82.47 mu m at month 12 (t = 1.85, P > 0.05). The mean number of injections during the study period was 3.3 +/- 1.1. Conclusions: Intravitreal ranibizumab as needed for treatment of wAMD combined with sPED was shown to be effective.
C1 [Xu, Ding; Zhao, Chun; Luo, Xu; Yu, Jing; Wang, Fang] Tongji Univ, Shanghai Peoples Hosp 10, Sch Med, Dept Ophthalmol, Shanghai, Peoples R China.
C3 Tongji University
RP Yu, J; Wang, F (通讯作者)，Tongji Univ, Shanghai Peoples Hosp 10, Sch Med, Dept Ophthalmol, Shanghai, Peoples R China.
EM dryujing@yahoo.com.cn; wangfangzhuren@163.com
CR Ach T, 2010, RETINA-J RET VIT DIS, V30, P1420, DOI 10.1097/IAE.0b013e3181d87e97
   Arias L, 2010, CLIN OPHTHALMOL, V4, P369
   Arora S, 2011, EYE, V25, P1034, DOI 10.1038/eye.2011.115
   Barbazetto I, 2003, ARCH OPHTHALMOL-CHIC, V121, P1253
   CASSWELL AG, 1985, BRIT J OPHTHALMOL, V69, P397, DOI 10.1136/bjo.69.6.397
   Chang TS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1460, DOI 10.1001/archopht.125.11.1460
   Giansanti F, 2014, EUR J OPHTHALMOL, V24, P402, DOI 10.5301/ejo.5000388
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   HARTNETT ME, 1992, GRAEF ARCH CLIN EXP, V230, P11, DOI 10.1007/BF00166756
   Inoue M, 2013, RETINA-J RET VIT DIS, V33, P990, DOI 10.1097/IAE.0b013e3182755793
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Li YB, 2008, AM J OPHTHALMOL, V146, P329, DOI 10.1016/j.ajo.2008.04.015
   Menke MN, 2014, BRIT J OPHTHALMOL, V98, P1197, DOI 10.1136/bjophthalmol-2013-304775
   Pauleikhoff D, 2002, GRAEF ARCH CLIN EXP, V240, P533, DOI 10.1007/s00417-002-0505-8
   POLINER LS, 1986, OPHTHALMOLOGY, V93, P543
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Shima C, 2009, GRAEF ARCH CLIN EXP, V247, P899, DOI 10.1007/s00417-009-1067-9
   You QS, 2012, OPHTHALMOLOGY, V119, P2519, DOI 10.1016/j.ophtha.2012.06.043
NR 19
TC 0
Z9 0
U1 0
U2 0
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1940-5901
J9 INT J CLIN EXP MED
JI Int. J. Clin. Exp. Med.
PY 2016
VL 9
IS 7
BP 13650
EP 13656
PG 7
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA EA2MT
UT WOS:000386428400151
DA 2022-11-30
ER

PT J
AU Falk, MK
   Singh, A
   Faber, C
   Nissen, MH
   Hviid, T
   Sorensen, TL
AF Falk, Mads Kruger
   Singh, Amardeep
   Faber, Carsten
   Nissen, Mogens Holst
   Hviid, Thomas
   Sorensen, Torben Lykke
TI Dysregulation of CXCR3 Expression on Peripheral Blood Leukocytes in
   Patients With Neovascular Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE AMD; chemokines; neovascularization; VEGF
ID T-CELLS; ANGIOGENESIS; INFLAMMATION; CHEMOKINES; IP-10; INHIBITION;
   RECEPTORS; DISEASE; RETINA; CANCER
AB PURPOSE. The chemokine receptor CXCR3 has been strongly related to inhibition of angiogenesis. The purpose of this study was to investigate the association between expression of CXCR3 on peripheral blood leukocytes and age-related wet macular degeneration. Furthermore, we measured the plasma concentration of chemokines CXCL9 to -11.
   METHODS. The study group consisted of patients with age-related macular degeneration (AMD) attending our department. Patients referred for reasons other than AMD were enrolled as control subjects. The expression of CXCR3 on T cells and the plasma concentration of CXCL9 to -11 were measured using flow cytometry.
   RESULTS. We looked at all CD8(+) T cells expressing CXCR3 and found a significantly lower percentage of these cells in the neovascular AMD group compared to the age-matched control group (P = 0.05). When dividing the CD8(+) cells into functional groups according to their expression of CXCR3, we found a significantly lower percentage of CD8(+) CXCR3(high) cells in the group with neovascular AMD compared to the control group (P = 0.038). We found a lower percentage of CD4(+)CD69(+)CXCR3(+) T cells in the group of patients with neovascular AMD when compared to the age-matched control group (P = 0.052).
   CONCLUSIONS. Our results point toward a systemic dysregulation of CXCR3 in patients with neovascular AMD. Since there is evidence to suggest that CXCR3 is able to alter the response of VEGF, the primary driver of choroidal neovascularization (CNV) formation, low levels of CXCR3 could potentially drive some patients toward a more angiogenic profile leading to CNV formation and growth. CXCR3-enhancing molecules could therefore be a possible target for treatment of AMD.
C1 [Falk, Mads Kruger; Singh, Amardeep; Sorensen, Torben Lykke] Copenhagen Univ Hosp Roskilde, Dept Ophthalmol, Clin Eye Res Unit, DK-4000 Roskilde, Denmark.
   [Falk, Mads Kruger; Singh, Amardeep; Hviid, Thomas; Sorensen, Torben Lykke] Univ Copenhagen, Fac Hlth Sci, Copenhagen, Denmark.
   [Faber, Carsten; Nissen, Mogens Holst] Univ Copenhagen, Fac Hlth Sci, Dept Microbiol Immunol & Int Hlth, Copenhagen, Denmark.
   [Hviid, Thomas] Copenhagen Univ Hosp Roskilde, Ctr Immune Regulat & Reprod Immunol, Dept Clin Biochem, DK-4000 Roskilde, Denmark.
C3 University of Copenhagen; University of Copenhagen; University of
   Copenhagen; University of Copenhagen
RP Falk, MK (通讯作者)，Copenhagen Univ Hosp Roskilde, Dept Ophthalmol, Kogevej 7-13, DK-4000 Roskilde, Denmark.
EM madskrugerfalk@gmail.com
RI Faber, Carsten/N-3210-2019; Faber, Carsten/I-4150-2013; Sørensen, Torben
   Lykke L/N-1417-2014; Nissen, Mogens/B-4825-2008; Singh,
   Amardeep/ABI-4544-2020
OI Faber, Carsten/0000-0002-2517-7270; Faber, Carsten/0000-0002-2517-7270;
   Sørensen, Torben Lykke L/0000-0002-6790-0199; Nissen,
   Mogens/0000-0001-7729-8667; 
FU Danish Eye Health Society (Vaern om Synet); Danish Eye Research
   Foundation, Region Zealand's Research Fund; Synoptik Foundation
FX Supported by the Danish Eye Health Society (Vaern om Synet), the Danish
   Eye Research Foundation, Region Zealand's Research Fund, and the
   Synoptik Foundation. The authors alone are responsible for the content
   and writing of the paper.
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Balestrieri ML, 2008, CARDIOVASC RES, V78, P250, DOI 10.1093/cvr/cvn029
   Bloch SB, 2013, ACTA OPHTHALMOL, V91, P42, DOI 10.1111/j.1755-3768.2011.02268.x
   Bodnar RJ, 2006, CIRC RES, V98, P617, DOI 10.1161/01.RES.0000209968.66606.10
   Burgisser P, 2007, CYTOM PART A, V71A, P632, DOI 10.1002/cyto.a.20414
   Buschini E, 2011, PROG NEUROBIOL, V95, P14, DOI 10.1016/j.pneurobio.2011.05.011
   Chamberlain M, 2006, SURV OPHTHALMOL, V51, P576, DOI 10.1016/j.survophthal.2006.08.003
   Charo IF, 2006, NEW ENGL J MED, V354, P610, DOI 10.1056/NEJMra052723
   Curbishley SM, 2005, AM J PATHOL, V167, P887, DOI 10.1016/S0002-9440(10)62060-3
   Faber C, 2013, OPHTHALMOLOGY, V120, P2310, DOI 10.1016/j.ophtha.2013.04.014
   Falk MK, 2013, AM J OPHTHALMOL, V155, P89, DOI 10.1016/j.ajo.2012.06.031
   Freedman ND, 2008, LANCET ONCOL, V9, P649, DOI 10.1016/S1470-2045(08)70154-2
   Fujimura S, 2012, INVEST OPHTH VIS SCI, V53, P1999, DOI 10.1167/iovs.11-8232
   Groom JR, 2011, EXP CELL RES, V317, P620, DOI 10.1016/j.yexcr.2010.12.017
   Hu JK, 2011, P NATL ACAD SCI USA, V108, pE118, DOI 10.1073/pnas.1101881108
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kobayashi N, 2006, J LEUKOCYTE BIOL, V80, P320, DOI 10.1189/jlb.1205725
   KOCH AE, 1992, SCIENCE, V258, P1798, DOI 10.1126/science.1281554
   Lasagni L, 2003, J EXP MED, V197, P1537, DOI 10.1084/jem.20021897
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Mo FM, 2010, INVEST OPHTH VIS SCI, V51, P4226, DOI 10.1167/iovs.09-3910
   Romagnani P, 2001, J CLIN INVEST, V107, P53, DOI 10.1172/JCI9775
   Romagnani P, 2004, TRENDS IMMUNOL, V25, P201, DOI 10.1016/j.it.2004.02.006
   Rosas LE, 2005, EUR J IMMUNOL, V35, P515, DOI 10.1002/eji.200425422
   Rossi D, 2000, ANNU REV IMMUNOL, V18, P217, DOI 10.1146/annurev.immunol.18.1.217
   Singh A, 2013, OPHTHALMOLOGY, V120, P1029, DOI 10.1016/j.ophtha.2012.11.002
   Singh A, 2012, AM J OPHTHALMOL, V154, P193, DOI 10.1016/j.ajo.2012.01.036
   Strieter RM, 2006, EUR J CANCER, V42, P768, DOI 10.1016/j.ejca.2006.01.006
   Xu HP, 2009, PROG RETIN EYE RES, V28, P348, DOI 10.1016/j.preteyeres.2009.06.001
   Yates CC, 2012, BIRTH DEFECTS RES C, V96, P325, DOI 10.1002/bdrc.21024
   Yates-Binder CC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040812
NR 31
TC 24
Z9 25
U1 0
U2 5
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JUL
PY 2014
VL 55
IS 7
BP 4050
EP 4056
DI 10.1167/iovs.14-14107
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AL9UI
UT WOS:000339487000007
PM 24812555
DA 2022-11-30
ER

PT J
AU Rastmanesh, R
AF Rastmanesh, Reza
TI Potential of melatonin to treat or prevent age-related macular
   degeneration through stimulation of telomerase activity
SO MEDICAL HYPOTHESES
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; URINARY 6-SULFATOXYMELATONIN LEVEL; INDUCED
   OXIDATIVE STRESS; LOW-DENSITY-LIPOPROTEIN; IN-SITU HYBRIDIZATION;
   VITAMIN-E; REVERSE-TRANSCRIPTASE; ALZHEIMERS-DISEASE; RAT RETINA; CELLS
AB Melatonin may play a causal role in the occurrence of age-related macular degeneration (AMD). Replicative capacity and response to injury in the retinal pigment epithelium (RPE) is compromised during aging. Prevention of telomere shortening by antioxidants may be a useful approach for reducing the cumulative effects of oxidative stress in RPE cells. Melatonin, a well known antioxidant, which acts advantageously as an amphiphilic agent, may benefit AMD patients more than commonly used lipophilic or hydrophilic antioxidants. It also may act through mechanisms other than antioxidant mechanisms because melatonin has receptors localized in the RPE, which act locally as a neurohormone and/or neuromodulator. Results of a clinical trial showed that 3 mg melatonin given orally each night at bedtime for 3 months to AMD patients reduced pathologic macular changes. I hypothesize that melatonin exerts additional benefit through down-regulating hTERT (catalytic subunit if telomerase) expression and stimulated telomerase activity in RPE, which subsequently helps to prevent or treat AMD. I suggest that melatonin therapy as pharmacologic agents and/or melatonin-rich foods, especially in AMD patients with measured low serum melatonin levels or high risk patients would be possibly an alternative approach to prevent and/or treat AMD. I suggest that melatonin has potential to prevent telomere shortening in RPE, while not precluding other mechanisms, namely antioxidative properties and/or restoration of inner blood-retina barrier (iBRB) integrity, reduced vascular endothelial growth factor (VEGF) and nitric oxide (NO) levels as well as leakage of horseradish peroxidase (HRP), inhibiting hypoxia-inducible factor-1alpha (H1F-1alpha) stabilization under hypoxia. (C) 2010 Elsevier Ltd. All rights reserved.
C1 Shahid Beheshti Univ Med Sci SBMU, Fac Nutr & Food Sci, Dept Clin Nutr & Dietet, Tehran, Iran.
C3 Shahid Beheshti University Medical Sciences
RP Rastmanesh, R (通讯作者)，Shahid Beheshti Univ Med Sci SBMU, Fac Nutr & Food Sci, Dept Clin Nutr & Dietet, Tehran, Iran.
EM r.rastmanesh@sbmu.ac.ir
RI Rastmanesh, Reza/AAM-9681-2021; Rastmanesh, Reza/AAD-7636-2021
OI Rastmanesh, Reza/0000-0002-6221-9062; 
CR Akbulut KG, 2009, J PINEAL RES, V47, P308, DOI 10.1111/j.1600-079X.2009.00715.x
   Allegra M, 2003, J PINEAL RES, V34, P1, DOI 10.1034/j.1600-079X.2003.02112.x
   Anderson CJ, 2006, ONCOGENE, V25, P61, DOI 10.1038/sj.onc.1209011
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Baydas G, 2002, J PINEAL RES, V32, P225, DOI 10.1034/j.1600-079X.2002.01856.x
   Bonnefont-Rousselot D, 2002, J PINEAL RES, V33, P109, DOI 10.1034/j.1600-079X.2002.02911.x
   Bonnefont-Rousselot D, 2010, TOXICOLOGY
   Bratlid Trond, 2003, Int J Circumpolar Health, V62, P242
   Brennan R, 2007, EYE, V21, P901, DOI 10.1038/sj.eye.6702597
   Bressler SB, 2009, OPHTHALMOLOGY, V116, pS1, DOI 10.1016/j.ophtha.2009.06.045
   Bubenik GA, 2002, DIGEST DIS SCI, V47, P2336, DOI 10.1023/A:1020107915919
   BURKE JM, 1988, INVEST OPHTH VIS SCI, V29, P1784
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Carrillo-Vico A, 2004, FASEB J, V18, P537, DOI 10.1096/fj.03-0694fje
   Champier J, 1997, LIFE SCI, V60, P2191, DOI 10.1016/S0024-3205(97)00234-8
   Chen GF, 2003, LIFE SCI, V73, P19, DOI 10.1016/S0024-3205(03)00252-2
   Conti A, 2000, J PINEAL RES, V28, P193, DOI 10.1034/j.1600-079X.2000.280401.x
   Cui PL, 2008, J PINEAL RES, V44, P107, DOI 10.1111/j.1600-079X.2007.00496.x
   de la Puerta C, 2007, FOOD CHEM, V104, P609, DOI 10.1016/j.foodchem.2006.12.010
   DOLLINS AB, 1994, P NATL ACAD SCI USA, V91, P1824, DOI 10.1073/pnas.91.5.1824
   El-Missiry MA, 2007, ECOTOX ENVIRON SAFE, V66, P278, DOI 10.1016/j.ecoenv.2006.03.008
   Eltz S, 2008, BJU INT, V102, P532, DOI 10.1111/j.1464-410X.2008.07659.x
   Finnemann SC, 2002, P NATL ACAD SCI USA, V99, P3842, DOI 10.1073/pnas.052025899
   Gillam Tony, 2009, Nurs Older People, V21, P30
   Gitto E, 2001, J PHARM PHARMACOL, V53, P1393, DOI 10.1211/0022357011777747
   Gozzo A, 1999, FREE RADICAL BIO MED, V26, P1538, DOI 10.1016/S0891-5849(99)00020-9
   Green W R, 1977, Trans Am Ophthalmol Soc, V75, P180
   Guenther AL, 2005, J PINEAL RES, V39, P251, DOI 10.1111/j.1600-079X.2005.00242.x
   Gulcin I, 2002, J PINEAL RES, V33, P167, DOI 10.1034/j.1600-079X.2002.20920.x
   Hammond BR, 1996, VISION RES, V36, P3003, DOI 10.1016/0042-6989(96)00008-9
   Hardeland R, 2005, ENDOCRINE, V27, P119, DOI 10.1385/ENDO:27:2:119
   Hardeland Rudiger, 2005, Nutr Metab (Lond), V2, P22, DOI 10.1186/1743-7075-2-22
   HATTORI A, 1995, BIOCHEM MOL BIOL INT, V35, P627
   Hjelmeland LM, 1999, MOL VIS, V5
   Ianas O, 1999, ADV EXP MED BIOL, V460, P321
   IGUCHI H, 1982, J CLIN ENDOCR METAB, V55, P27, DOI 10.1210/jcem-55-1-27
   Jackson GR, 2002, AGEING RES REV, V1, P381, DOI 10.1016/S1568-1637(02)00007-7
   Kaur C, 2008, PROG RETIN EYE RES, V27, P622, DOI 10.1016/j.preteyeres.2008.09.003
   Kaya H, 1999, Zentralbl Gynakol, V121, P499
   Kelly MR, 1997, J PINEAL RES, V22, P203, DOI 10.1111/j.1600-079X.1997.tb00323.x
   KINSEY VE, 1947, AM J OPHTHALMOL, V30, P1262, DOI 10.1016/S0002-9394(14)77648-2
   Korkmaz A, 2008, J PINEAL RES, V44, P41, DOI 10.1111/j.1600-079X.2007.00509.x
   Laakso ML, 2007, SLEEP MED, V8, P222, DOI 10.1016/j.sleep.2006.09.006
   LAM KW, 1993, OPHTHALMIC RES, V25, P100, DOI 10.1159/000267272
   Lau BWM, 2007, J MOL NEUROSCI, V32, P160, DOI 10.1007/s12031-007-0031-6
   Lau BWM, 2008, J MOL NEUROSCI, V34, P63, DOI 10.1007/s12031-007-0072-x
   Lee JJ, 2010, CARCINOGENESIS, V31, P427, DOI 10.1093/carcin/bgp326
   Leon J, 2004, LIFE SCI, V75, P765, DOI 10.1016/j.lfs.2004.03.003
   LEONE AM, 1987, J PINEAL RES, V4, P253, DOI 10.1111/j.1600-079X.1987.tb00863.x
   Liang FQ, 2004, EXP EYE RES, V78, P1069, DOI 10.1016/j.exer.2004.02.003
   Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X
   LINNER E, 1952, ACTA PHYSIOL SCAND, V26, P57, DOI 10.1111/j.1748-1716.1952.tb00891.x
   Liu CM, 2004, CELL TISSUE RES, V315, P197, DOI 10.1007/s00441-003-0822-1
   Lundmark PO, 2007, EXP EYE RES, V84, P1021, DOI 10.1016/j.exer.2006.10.018
   Martinez-Campa CM, 2008, CANCER LETT, V268, P272, DOI 10.1016/j.canlet.2008.04.001
   Martinez-Cruz F, 2002, J NEUROSCI RES, V69, P550, DOI 10.1002/jnr.10307
   Matsunaga H, 1999, INVEST OPHTH VIS SCI, V40, P197
   Meeker AK, 2002, AM J PATHOL, V160, P1259, DOI 10.1016/S0002-9440(10)62553-9
   Mekhloufi J, 2005, J PINEAL RES, V39, P27, DOI 10.1111/j.1600-079X.2005.00208.x
   Messner M, 1998, J PINEAL RES, V25, P251, DOI 10.1111/j.1600-079X.1998.tb00395.x
   Min Xiao-jie, 2009, Zhonghua Yan Ke Za Zhi, V45, P199
   Mistraletti G, 2010, J PINEAL RES, V48, P142, DOI 10.1111/j.1600-079X.2009.00737.x
   Nagata C, 2005, CANCER EPIDEM BIOMAR, V14, P1333, DOI 10.1158/1055-9965.EPI-04-0915
   NORDLUND JJ, 1977, J CLIN ENDOCR METAB, V45, P768, DOI 10.1210/jcem-45-4-768
   Ohno-Matsui K, 2001, J CELL PHYSIOL, V189, P323, DOI 10.1002/jcp.10026
   Owen CG, 2003, BRIT J OPHTHALMOL, V87, P312, DOI 10.1136/bjo.87.3.312
   Pandi-Perumal SR, 2006, FEBS J, V273, P2813, DOI 10.1111/j.1742-4658.2006.05322.x
   Paredes SD, 2009, J EXP BOT, V60, P57, DOI 10.1093/jxb/ern284
   Park SY, 2010, J PINEAL RES, V48, P178, DOI 10.1111/j.1600-079X.2009.00742.x
   Pieri C, 1996, BIOCHEM BIOPH RES CO, V222, P256, DOI 10.1006/bbrc.1996.0731
   Pitkanen L, 2005, INVEST OPHTH VIS SCI, V46, P641, DOI 10.1167/iovs.04-1051
   Reiter RJ, 2002, ANN NY ACAD SCI, V957, P341, DOI 10.1111/j.1749-6632.2002.tb02938.x
   Reiter RJ, 2005, NUTRITION, V21, P920, DOI 10.1016/j.nut.2005.02.005
   Reiter RJ, 2004, POL J PHARMACOL, V56, P159
   Reiter RJ, 2001, NUTR REV, V59, P286, DOI 10.1111/j.1753-4887.2001.tb07018.x
   Ren Ruo-Jin, 2004, Zhonghua Yan Ke Za Zhi, V40, P234
   REPPERT SM, 1994, NEURON, V13, P1177, DOI 10.1016/0896-6273(94)90055-8
   Roberts JE, 1998, J PHOTOCH PHOTOBIO B, V42, P125, DOI 10.1016/S1011-1344(97)00132-2
   Rodriguez C, 2004, J PINEAL RES, V36, P1, DOI 10.1046/j.1600-079X.2003.00092.x
   Roider J, 1999, GRAEF ARCH CLIN EXP, V237, P45, DOI 10.1007/s004170050193
   Rosen R, 2009, MOL VIS, V15, P1673
   Rosenstein RE, 2010, J PINEAL RES
   Rowe-Rendleman C, 2004, BRAIN RES BULL, V62, P549, DOI 10.1016/S0361-9230(03)00072-8
   SACK RL, 1986, J PINEAL RES, V3, P379, DOI 10.1111/j.1600-079X.1986.tb00760.x
   Schmid-Kubista KE, 2009, ACTA OPHTHALMOL, V87, P89, DOI 10.1111/j.1755-3768.2008.01173.x
   SHIDA CS, 1994, J PINEAL RES, V16, P198, DOI 10.1111/j.1600-079X.1994.tb00102.x
   Siu AW, 2006, J PINEAL RES, V40, P101, DOI 10.1111/j.1600-079X.2005.00304.x
   Sivakumar V, 2008, BRAIN PATHOL, V18, P71, DOI 10.1111/j.1750-3639.2007.00104.x
   Skene DJ, 2003, EXP GERONTOL, V38, P199, DOI 10.1016/S0531-5565(02)00198-5
   Slominski A, 2005, ENDOCRINE, V27, P137, DOI 10.1385/ENDO:27:2:137
   Slominski A, 2005, FASEB J, V19, P176, DOI 10.1096/fj.04-2079rev
   Tan Dun-Xian, 2002, Current Topics in Medicinal Chemistry, V2, P181, DOI 10.2174/1568026023394443
   Tan DX, 2003, J PINEAL RES, V34, P249, DOI 10.1034/j.1600-079X.2003.00037.x
   TAN DX, 1993, CANCER LETT, V70, P65, DOI 10.1016/0304-3835(93)90076-L
   Taylor SR, 2009, POPUL HEALTH MANAG, V12, P317, DOI 10.1089/pop.2008.0047
   Tomany SC, 2004, ARCH OPHTHALMOL-CHIC, V122, P750, DOI 10.1001/archopht.122.5.750
   Tosini G, 2000, CHRONOBIOL INT, V17, P599, DOI 10.1081/CBI-100101067
   Trivedi D, 2010, ADV EXP MED BIOL, V664, P185, DOI 10.1007/978-1-4419-1399-9_21
   Vijayalaxmi, 1996, MUTAT RES-GENET TOX, V371, P221
   VIJAYALAXMI, 1995, MUTAT RES LETT, V346, P23, DOI 10.1016/0165-7992(95)90065-9
   Vijayalaxmi, 1998, MUTAT RES-FUND MOL M, V404, P187, DOI 10.1016/S0027-5107(98)00112-2
   Vijayalaxmi, 2004, INT J RADIAT ONCOL, V59, P639, DOI 10.1016/j.ijrobp.2004.02.006
   VONZGLINICKI T, 1995, EXP CELL RES, V220, P186, DOI 10.1006/excr.1995.1305
   WALDHAUSER F, 1988, J CLIN ENDOCR METAB, V66, P648, DOI 10.1210/jcem-66-3-648
   Wiechmann AF, 2008, EXP EYE RES, V86, P241, DOI 10.1016/j.exer.2007.10.015
   Winiarska K, 2006, J PINEAL RES, V40, P168, DOI 10.1111/j.1600-079X.2005.00295.x
   Winkler BS, 1999, MOL VIS, V5
   Woo JH, 2009, ACTA OPHTHALMOL, V87, P262, DOI 10.1111/j.1755-3768.2008.01376.x
   Wu YH, 2005, J PINEAL RES, V38, P145, DOI 10.1111/j.1600-079X.2004.00196.x
   Yi CX, 2005, ANN NY ACAD SCI, V1057, P384, DOI 10.1196/annals.1356.029
   Zmijewski MA, 2009, MOL CELL ENDOCRINOL, V307, P211, DOI 10.1016/j.mce.2009.04.010
NR 111
TC 30
Z9 31
U1 0
U2 11
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0306-9877
EI 1532-2777
J9 MED HYPOTHESES
JI Med. Hypotheses
PD JAN
PY 2011
VL 76
IS 1
BP 79
EP 85
DI 10.1016/j.mehy.2010.08.036
PG 7
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA 715VP
UT WOS:000286918400018
PM 20884126
DA 2022-11-30
ER

PT J
AU Obata, R
   Yanagi, Y
   Tamaki, Y
AF Obata, Ryo
   Yanagi, Yasuo
   Tamaki, Yasuhiro
TI Postoperative assessment of retinal function using a multifocal
   electroretinogram after the removal of subfoveal choroidal
   neovascularization secondary to age-related macular degeneration
SO JAPANESE JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; choroidal neovascularization;
   multifocal electroretinogram; surgical removal of choroidal
   neovascularization
ID SURGERY
AB Purpose: To assess retinal function in a macular lesion with multifocal electroretinography (mfERG) after successful surgical removal of choroidal neovascularization (CNV).
   Methods: We prospectively studied 15 patients (15 eyes) who underwent surgical removal of subfoveal CNV secondary to age-related macular degeneration. Three and 6 months after surgery, retinal thickness in the parafoveal lesion and the size of the serous retinal detachment (SRD) were measured. The mfERG was also recorded, and the data from each of six concentric ring annuli were averaged.
   Results: After surgery, the parafoveal retinal thickness significantly decreased compared with the preoperative value, and SRD was not recognized in any patient. The change in the amplitude of the P1-wave within 2 degrees to 15 degrees in diameter positively correlated with the decrease in the parafoveal retinal thickness. Additionally, amplitude within 8 degrees to 24 degrees in diameter positively correlated with the size of the preoperative SRD.
   Conclusion: mfERG is helpful to quantitatively and objectively assess the effect of the surgical removal of CNV on retinal function, not only in the fovea but also in the entire macular area.
C1 Univ Tokyo, Sch Med, Dept Ophthalmol, Tokyo 113, Japan.
C3 University of Tokyo
EM robata-tky@umin.ac.jp
RI Yanagi, Yasuo/AAA-5441-2022; Yanagi, Yasuo/AAF-2670-2020
OI Yanagi, Yasuo/0000-0002-0362-7285; Obata, Ryo/0000-0002-1762-0797
CR Fujii GY, 2002, OPHTHALMOLOGY, V109, P1737, DOI 10.1016/S0161-6420(02)01120-X
   Hawkins BS, 2004, OPHTHALMOLOGY, V111, P1967, DOI 10.1016/j.ophtha.2004.07.021
   KLEIN R, 1999, EPIDEMIOLOGY AGE REL, P31
   SUTTER EE, 1992, VISION RES, V32, P433, DOI 10.1016/0042-6989(92)90235-B
   Terasaki H, 2002, INVEST OPHTH VIS SCI, V43, P1540
NR 5
TC 3
Z9 3
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0021-5155
J9 JPN J OPHTHALMOL
JI Jpn. J. Ophthalmol.
PD SEP-OCT
PY 2006
VL 50
IS 5
BP 479
EP 482
DI 10.1007/s10384-006-0355-8
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 093AQ
UT WOS:000241139900014
PM 17013704
DA 2022-11-30
ER

PT J
AU Saunier, V
   Merle, BMJ
   Delyfer, MN
   Cougnard-Gregoire, A
   Rougier, MB
   Amouyel, P
   Lambert, JC
   Dartigues, JF
   Korobelnik, JF
   Delcourt, C
AF Saunier, Valentine
   Merle, Benedicte M. J.
   Delyfer, Marie-Noelle
   Cougnard-Gregoire, Audrey
   Rougier, Marie-Benedicte
   Amouyel, Philippe
   Lambert, Jean-Charles
   Dartigues, Jean-Francois
   Korobelnik, Jean-Francois
   Delcourt, Cecile
TI Incidence of and Risk Factors Associated With Age-Related Macular
   Degeneration Four-Year Follow-up From the ALIENOR Study
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID 5-YEAR INCIDENCE; MACULOPATHY; PROGRESSION; EYE; PREVALENCE;
   CLASSIFICATION; SCALE; A69S
AB IMPORTANCE While the prevalence of age-related macular degeneration (AMD) differs according to continents and races/ethnicities, its incidence in the European continent has been scarcely documented.
   OBJECTIVE To describe the incidence and associated risk factors of AMD in elderly French individuals.
   DESIGN, SETTING, AND PARTICIPANTS This population-based cohort study of 963 residents of Bordeaux, France, who were 73 years or older at baseline and participated in the Antioxydants, Lipides Essentiels. Nutrition et Maladies Oculaires (ALIENOR) Study between October 2, 2006, and December 21, 2012. Of 829 participants at risk for incident AMD, 659 (79.5%) were observed for a mean (SD) duration of 3.8 (1.1) years. Data were analyzed from August 2016 to March 2017.
   MAIN OUTCOM ES AND MEASURES Age-related macular degeneration was graded from retinal photographs and spectral-domain optical coherence tomography into 5 exclusive stages: no AMID, early AMD1, early AMD2, late atrophic AMD, and late neovascular AMD.
   RESULTS Of the 659 eligible participants, 413 (62.7%) were women, and the mean (SD; range) age was 79.7 (4.4; 73-94) years. A total of 120 incident cases of early AMD and 45 incident cases of advanced AMD were recorded. Incidence rates of early and advanced AMD were 79.9 (95% CI, 66.8-95.5) per 1000 person-years and 18.6 (95% CI, 13.9-24.9) per 1000 person-years, respectively, corresponding to 5-year risks of 32.9% and 8.9%. Incidence of advanced AMD per 1000 eye-years was 1.5 in eyes without any AMD at baseline, 42.4 in those with early AMD1, and 85.1 in those with early AMD2. In multivariate analysis without correction for multiple testing, progression from early to advanced AMD was associated with AMD grade in the fellow eye (hazard ratio [HR] according to grade, 13.0 [95% CI, 2.8-61.2] to 22.5 [95% CI, 2.6-195.9]), having smoked at least 20 pack-years (calculated as number of smoking years x mean number of cigarettes per day / 20; HR, 3.0; 95% CI, 1.4-6.5), and complement factor H (CFH) Y402H genotype (CC genotype: HR, 2.3; 95% CI, 1.0-5.3; TC genotype: HR, 1.5; 95% CI, 0.6-3.7). Incidence of early AMD was associated with early AMD in the fellow eye (early AMD1: HR, 2.6; 95% CI, 1.6-4.2; early AMD2: HR, 5.6; 95% CI, 3.3-9.4) and high plasma high-density lipoprotein cholesterol levels (HR, 1.2; 95% CI, 1.0-1.4).
   CONCLUSIONS AND RELEVANCE In this cohort, AMD incidence rates were similar to those observed in other European populations. This study suggests a high risk for incident early AMD in individuals with high plasma high-density lipoprotein cholesterol levels while confirming the high risk for progression from early to advanced AMD in heavy smokers and carriers of CFH Y402H at-risk genotypes.
C1 [Saunier, Valentine; Merle, Benedicte M. J.; Delyfer, Marie-Noelle; Cougnard-Gregoire, Audrey; Rougier, Marie-Benedicte; Dartigues, Jean-Francois; Korobelnik, Jean-Francois; Delcourt, Cecile] Univ Bordeaux, INSERM, Bordeaux Populat Hlth Res Ctr, Team Lifelong Exposures Hlth & Aging LEHA,UMR 121, 146 Rue Leo Saignat, F-33076 Bordeaux, France.
   [Saunier, Valentine; Delyfer, Marie-Noelle; Rougier, Marie-Benedicte; Korobelnik, Jean-Francois] Ctr Hosp Univ Bordeaux, Serv Ophtalmol, Bordeaux, France.
   [Amouyel, Philippe; Lambert, Jean-Charles] Univ Lille, CHU Lille, INSERM U1167, Inst Pasteur Lille,DISTALZ Lab Excellence, Lille, France.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   UDICE-French Research Universities; Universite de Bordeaux; CHU
   Bordeaux; Institut National de la Sante et de la Recherche Medicale
   (Inserm); Le Reseau International des Instituts Pasteur (RIIP);
   Universite de Lille - ISITE; Institut Pasteur Lille; CHU Lille;
   Universite de Lille
RP Delcourt, C (通讯作者)，Univ Bordeaux, INSERM, Bordeaux Populat Hlth Res Ctr, Team Lifelong Exposures Hlth & Aging LEHA,UMR 121, 146 Rue Leo Saignat, F-33076 Bordeaux, France.
EM cecile.delcourt@u-bordeaux.fr
RI Delcourt, Cecile/I-2627-2013; lambert, jean-charles/F-8787-2013;
   DARTIGUES, Jean François/T-4513-2019; Delyfer, Marie-Noelle/T-3304-2019;
   Lambert, jean-charles/A-9553-2014; Merle, Benedicte MJ/AAQ-5021-2021;
   KOROBELNIK, Jean-Francois/A-5448-2016; Merle, Benedicte MJ/F-1247-2015;
   COUGNARD-GREGOIRE, Audrey/T-4443-2019
OI Delcourt, Cecile/0000-0002-2099-0481; lambert,
   jean-charles/0000-0003-0829-7817; Lambert,
   jean-charles/0000-0003-0829-7817; Merle, Benedicte
   MJ/0000-0003-1332-0954; Merle, Benedicte MJ/0000-0003-1332-0954;
   COUGNARD-GREGOIRE, Audrey/0000-0002-1494-5764; Amouyel,
   Philippe/0000-0001-9088-234X
FU Laboratoires Thea; Fondation Voir et Entendre; Agence Nationale de la
   Recherche [2010-PRSP-011]; Caisse Nationale pour la Solidarite et
   l'Autonomie; Universite de Bordeaux
FX This study was supported by Laboratoires Thea, Universite de Bordeaux,
   Fondation Voir et Entendre, Agence Nationale de la Recherche (grant
   2010-PRSP-011), and Caisse Nationale pour la Solidarite et l'Autonomie.
CR Alperovitch A, 2003, NEUROEPIDEMIOLOGY, V22, P316, DOI 10.1159/000072920
   Bastawrous A, 2017, JAMA OPHTHALMOL, V135, P631, DOI 10.1001/jamaophthalmol.2017.1109
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bourne RRA, 2013, LANCET GLOB HEALTH, V1, pE339, DOI 10.1016/S2214-109X(13)70113-X
   Buch H, 2005, ACTA OPHTHALMOL SCAN, V83, P409, DOI 10.1111/J.1600-0420.2005.00492.x
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Cougnard-Gregoire A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090973
   Cougnard-Gregoire A, 2013, INVEST OPHTH VIS SCI, V54, P1905, DOI 10.1167/iovs.12-10192
   Cruickshanks KJ, 2017, JAMA OPHTHALMOL, V135, P1417, DOI 10.1001/jamaophthalmol.2017.5001
   Delcourt C, 2005, AM J OPHTHALMOL, V140, P924, DOI 10.1016/j.ajo.2005.05.002
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   Delcourt C, 2010, J NUTR HEALTH AGING, V14, P854, DOI 10.1007/s12603-010-0131-9
   Delcourt C, 2012, ARCH OPHTHALMOL-CHIC, V130, P1077, DOI 10.1001/archophthalmol.2012.420
   Delcourt C, 2011, INVEST OPHTH VIS SCI, V52, P5955, DOI 10.1167/iovs.10-6235
   Fan Q, 2017, INT J EPIDEMIOL, V46, P1891, DOI 10.1093/ije/dyx189
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Glynn RJ, 2012, OPHTHAL EPIDEMIOL, V19, P159, DOI 10.3109/09286586.2012.674614
   Jonasson F, 2005, OPHTHALMOLOGY, V112, P132, DOI 10.1016/j.ophtha.2004.07.020
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Lamarca R, 1998, J GERONTOL A-BIOL, V53, pM337, DOI 10.1093/gerona/53A.5.M337
   Leffondre K, 2013, INT J EPIDEMIOL, V42, P1177, DOI 10.1093/ije/dyt126
   Leske MC, 2004, OPHTHALMOLOGY, V111, P706, DOI 10.1016/j.ophtha.2003.07.003
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   McGuinness MB, 2017, OPHTHAL EPIDEMIOL, V24, P229, DOI 10.1080/09286586.2016.1276934
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   Mukesh BN, 2004, OPHTHALMOLOGY, V111, P1176, DOI 10.1016/j.ophtha.2003.08.042
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Shuler RK, 2008, AM J OPHTHALMOL, V145, P303, DOI 10.1016/j.ajo.2007.09.027
   Tabue-Teguo M, 2018, J GERONTOL A-BIOL, V73, P109, DOI 10.1093/gerona/glx068
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   Varma R, 2010, AM J OPHTHALMOL, V149, P741, DOI 10.1016/j.ajo.2010.01.009
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yasuda M, 2009, OPHTHALMOLOGY, V116, P2135, DOI 10.1016/j.ophtha.2009.04.017
   You QS, 2012, OPHTHALMOLOGY, V119, P2519, DOI 10.1016/j.ophtha.2012.06.043
NR 38
TC 37
Z9 37
U1 0
U2 18
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD MAY
PY 2018
VL 136
IS 5
BP 473
EP 481
DI 10.1001/jamaophthalmol.2018.0504
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GF3QI
UT WOS:000431870300003
PM 29596588
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Voisin, A
   Monville, C
   Plancheron, A
   Bere, E
   Gaillard, A
   Leveziel, N
AF Voisin, Audrey
   Monville, Christelle
   Plancheron, Alexandra
   Bere, Emile
   Gaillard, Afsaneh
   Leveziel, Nicolas
TI Cathepsin B pH-Dependent Activity Is Involved in Lysosomal Dysregulation
   in Atrophic Age-Related Macular Degeneration
SO OXIDATIVE MEDICINE AND CELLULAR LONGEVITY
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; OXIDATIVE STRESS; ARPE-19 CELLS; DISEASE;
   IRON; DYSFUNCTION; EXPRESSION; MODEL; DIFFERENTIATION; PHAGOCYTOSIS
AB Age-related macular degeneration (AMD) is characterized by retinal pigment epithelial (RPE) cell dysfunction beginning at early stages of the disease. The lack of an appropriate in vitro model is a major limitation in understanding the mechanisms leading to the occurrence of AMD. This study compared human-induced pluripotent stem cell- (hiPSC-) RPE cells derived from atrophic AMD patients (77 y/o +/- 7) to hiPSC-RPE cells derived from healthy elderly individuals with no drusen or pigmentary alteration (62.5 y/o +/- 17.5). Control and AMD hiPSC-RPE cell lines were characterized by immunofluorescence, flow cytometry, and electronic microscopy. The toxicity level of iron after Fe-NTA treatment was evaluated by an MTT test and by the detection of dichloro-dihydro-fluorescein diacetate. Twelve hiPSC-RPE cell lines (6 AMD and 6 controls) were used for the experiment. Under basal conditions, all hiPSC-RPE cells expressed a phenotypic profile of senescent cells with rounded mitochondria at passage 2. However, the treatment with Fe-NTA induced higher reactive oxygen species production and cell death in hiPSC-RPE AMD cells than in hiPSC-RPE Control cells. Interestingly, functional analysis showed differences in lysosomal activity between the two populations. Indeed, Cathepsin B activity was higher in hiPSC-RPE AMD cells compared to hiPSC-RPE Control cells in basal condition and link to a pH more acidic in this cell population. Moreover, oxidative stress exposure leads to an increase of Cathepsin D immature form levels in both populations, but in a higher proportion in hiPSC-RPE AMD cells. These findings could demonstrate that hiPSC-RPE AMD cells have a typical disease phenotype compared to hiPSC-RPE Control cells.
C1 [Voisin, Audrey; Bere, Emile; Gaillard, Afsaneh; Leveziel, Nicolas] Univ Poitiers, Lab Neurosci Expt & Clin, Equipe Therapie Cellulaire Pathol Cerebrales, F-86073 Poitiers, France.
   [Voisin, Audrey; Gaillard, Afsaneh; Leveziel, Nicolas] INSERM, U1084, Lab Neurosci Expt & Clin, Equipe Therapie Cellulaire Pathol Cerebrales, F-86022 Poitiers, France.
   [Voisin, Audrey; Leveziel, Nicolas] CHU Poitiers, F-86021 Poitiers, France.
   [Monville, Christelle; Plancheron, Alexandra] INSERM, UMR861, I Stem, AFM, Genopole Campus 1, F-91030 Evry, France.
   [Monville, Christelle] UEVE Paris Saclay, UMR861, I Stem, AFM,CRCT, F-91100 Corbeil Essonnes, France.
   [Plancheron, Alexandra] CECS, I Stem AFM, CRCT, F-91100 Corbeil Essonnes, France.
   [Bere, Emile] Plateforme ImageUP, 1 Rue Georges Bonnet, F-86022 Poitiers, France.
C3 Universite de Poitiers; Institut National de la Sante et de la Recherche
   Medicale (Inserm); Universite de Poitiers; CHU Poitiers; Universite de
   Poitiers; Genopole; Institut National de la Sante et de la Recherche
   Medicale (Inserm); UDICE-French Research Universities; Universite Paris
   Saclay; UDICE-French Research Universities; Universite Paris Saclay
RP Voisin, A (通讯作者)，Univ Poitiers, Lab Neurosci Expt & Clin, Equipe Therapie Cellulaire Pathol Cerebrales, F-86073 Poitiers, France.; Voisin, A (通讯作者)，INSERM, U1084, Lab Neurosci Expt & Clin, Equipe Therapie Cellulaire Pathol Cerebrales, F-86022 Poitiers, France.; Voisin, A (通讯作者)，CHU Poitiers, F-86021 Poitiers, France.
EM leguenaudrey@ymail.com
OI Voisin, Audrey/0000-0002-9766-5759
FU Novartis; CHU Poitiers; Fond Alienor; association DMLA; European Union's
   FEDER; Region of Nouvelle Aquitaine
FX This work was funded by grants from the Novartis, the CHU Poitiers, the
   Fond Alienor, the association DMLA, the financial participation of the
   European Union's FEDER, and the Region of Nouvelle Aquitaine. The
   authors would like to thank Jeffrey Arsham for having reread and
   corrected our original English language manuscript, Adriana Delwail for
   her help during cytometry experiments, Anais Balbous for rereading the
   manuscript, and Pr Jack Flacon and Pr Alicia Torriglia for their MET
   analysis.
CR Ablonczy Z, 2011, INVEST OPHTH VIS SCI, V52, P8614, DOI 10.1167/iovs.11-8021
   Ach T, 2015, INVEST OPHTH VIS SCI, V56, P3242, DOI 10.1167/iovs.14-16274
   Balaban RS, 2005, CELL, V120, P483, DOI 10.1016/j.cell.2005.02.001
   Benes P, 2008, CRIT REV ONCOL HEMAT, V68, P12, DOI 10.1016/j.critrevonc.2008.02.008
   Bingol B, 2016, FREE RADICAL BIO MED, V100, P210, DOI 10.1016/j.freeradbiomed.2016.04.015
   Bonilha VL, 2008, CLIN OPHTHALMOL, V2, P413
   Buchholz DE, 2013, STEM CELL TRANSL MED, V2, P384, DOI 10.5966/sctm.2012-0163
   Cai H, 2006, MOL VIS, V12, P1
   Chen H, 2009, INVEST OPHTH VIS SCI, V50, P1895, DOI 10.1167/iovs.08-2850
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Dentchev T, 2005, ARCH OPHTHALMOL-CHIC, V123, P1745, DOI 10.1001/archopht.123.12.1745
   DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363
   Dixon SJ, 2012, CELL, V149, P1060, DOI 10.1016/j.cell.2012.03.042
   Garcia TY, 2015, INVEST OPHTH VIS SCI, V56, P7480, DOI 10.1167/iovs.15-17251
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Golestaneh N, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.453
   Golestaneh N, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-1101-8
   He XN, 2007, PROG RETIN EYE RES, V26, P649, DOI 10.1016/j.preteyeres.2007.07.004
   Hohn A, 2013, REDOX BIOL, V1, P140, DOI 10.1016/j.redox.2013.01.006
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Karlsson M, 2016, ACTA OPHTHALMOL, V94, P556, DOI 10.1111/aos.13076
   Kawai A, 2007, AUTOPHAGY, V3, P154, DOI 10.4161/auto.3634
   Kevany BM, 2010, PHYSIOLOGY, V25, P8, DOI 10.1152/physiol.00038.2009
   Khandhadia S, 2010, EXPERT REV MOL MED, V12, DOI 10.1017/S146239941000164X
   KHOURI HE, 1991, BIOCHEM J, V275, P751, DOI 10.1042/bj2750751
   Krohne TU, 2010, EXP EYE RES, V90, P261, DOI 10.1016/j.exer.2009.10.014
   Kurz T, 2007, ARCH BIOCHEM BIOPHYS, V462, P220, DOI 10.1016/j.abb.2007.01.013
   Laurent-Matha V, 2006, J BIOCHEM, V139, P363, DOI 10.1093/jb/mvj037
   Lee BY, 2006, AGING CELL, V5, P187, DOI 10.1111/j.1474-9726.2006.00199.x
   Lefevere E, 2017, MITOCHONDRION, V36, P66, DOI 10.1016/j.mito.2017.03.006
   Liu L, 2017, SCI REP-UK, V7, DOI 10.1038/srep41862
   Maruotti J, 2013, STEM CELL TRANSL MED, V2, P341, DOI 10.5966/sctm.2012-0106
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   Ng V. Y., 2010, OPEN STEM CELL J, V2, P8, DOI 10.2174/1876893801002010008
   Parvini M, 2014, MOL NEUROBIOL, V50, P597, DOI 10.1007/s12035-014-8684-y
   Pratico Domenico, 2002, Sci Aging Knowledge Environ, V2002, pre5
   Rabin DM, 2013, AGING-US, V5, P51
   Reichman S, 2014, P NATL ACAD SCI USA, V111, P8518, DOI 10.1073/pnas.1324212111
   Rickman CB, 2013, INVEST OPHTH VIS SCI, V54, pORSF68, DOI 10.1167/iovs.13-12757
   ROSENKRANZ AR, 1992, J IMMUNOL METHODS, V156, P39, DOI 10.1016/0022-1759(92)90008-H
   Saini JS, 2017, CELL STEM CELL, V20, P635, DOI 10.1016/j.stem.2016.12.015
   Salminen A, 2010, MOL MED, V16, P535, DOI 10.2119/molmed.2010.00070
   Samuel W, 2017, MOL VIS, V23, P60
   Sharma K, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00151
   Smailhodzic D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112682
   Song DL, 2016, EXP EYE RES, V151, P122, DOI 10.1016/j.exer.2016.08.008
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Taghiloo S, 2017, EUR J HAEMATOL, V98, P622, DOI 10.1111/ejh.12880
   Tanaka Y, 2017, HUM MOL GENET, V26, P969, DOI 10.1093/hmg/ddx011
   Terluk MR, 2015, J NEUROSCI, V35, P7304, DOI 10.1523/JNEUROSCI.0190-15.2015
   Voisin A, 2018, EXP EYE RES, V177, P76, DOI 10.1016/j.exer.2018.07.017
   Xiao B, 2016, FRONT CELL NEUROSCI, V10, DOI 10.3389/fncel.2016.00076
   Yang J, 2014, HUM MOL GENET, V23, P3445, DOI 10.1093/hmg/ddu053
NR 53
TC 5
Z9 5
U1 1
U2 7
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1942-0900
EI 1942-0994
J9 OXID MED CELL LONGEV
JI Oxidative Med. Cell. Longev.
PD DEC 6
PY 2019
VL 2019
AR 5637075
DI 10.1155/2019/5637075
PG 15
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA JX5NF
UT WOS:000503780800007
PM 31885803
OA Green Published, gold, Green Accepted
DA 2022-11-30
ER

PT J
AU Roddy, GW
   Rosa, RH
   Viker, KB
   Holman, BH
   Hann, CR
   Krishnan, A
   Gores, GJ
   Bakri, SJ
   Fautsch, MP
AF Roddy, Gavin W.
   Rosa, Robert H., Jr.
   Viker, Kimberly B.
   Holman, Bradley H.
   Hann, Cheryl R.
   Krishnan, Anuradha
   Gores, Gregory J.
   Bakri, Sophie J.
   Fautsch, Michael P.
TI Diet Mimicking "Fast Food" Causes Structural Changes to the Retina
   Relevant to Age-Related Macular Degeneration
SO CURRENT EYE RESEARCH
LA English
DT Article
DE Drusen; basal laminar deposits; macular degeneration; metabolic syndrome
ID BASAL LAMINAR DEPOSIT; METABOLIC SYNDROME; PIGMENT EPITHELIUM;
   PHYSICAL-ACTIVITY; BRUCHS MEMBRANE; TRANSGENIC MICE; SERUM-LIPIDS;
   RISK-FACTORS; FAT; INFLAMMATION
AB Introduction: Metabolic syndrome is a disorder characterized by a constellation of findings including truncal obesity, elevated blood pressure, abnormal cholesterol levels, and high blood glucose. Recent evidence suggests that metabolic syndrome may be associated with increased risk of age-related macular degeneration (AMD) and other eye diseases. Recently, C57BL/6J wild-type mice fed with a "fast food" diet consisting of high fat, cholesterol, and fructose-supplemented water showed unique systemic pathology consistent with metabolic syndrome and nonalcoholic steatohepatitis. Additionally, these mice showed higher levels of fibrosis, inflammation, endoplasmic reticulum stress, and mitochondrial dysfunction compared to mice fed with only a high-fat diet alone. Since similar pathways are activated in AMD, we sought to determine whether mice fed a "fast food" diet exhibited retinal changes. Methods: 3-month-old wild-type mice were randomized to a standard chow (n = 11) or a "fast food" (n = 18) diet and fed for 9 months. At 1 year of age, tissues were collected and retinas were analyzed using transmission electron microscopy. Quantitative measures of Bruch's membrane thickness and retinal pigment epithelium (RPE) cell counts were performed. Results: "Fast food" fed mice showed ocular pathology relevant to various stages of AMD including basal laminar deposits, focal thickening of Bruch's membrane, and a significant loss of RPE cells. Discussion/conclusion: A wild-type mouse model of metabolic syndrome fed a "fast food" diet developed changes to the retina similar to some of the pathologic features seen in AMD. Further investigations into this and similar animal models as well as further epidemiological studies are needed to more clearly define the association between metabolic syndrome and AMD.
C1 [Roddy, Gavin W.; Viker, Kimberly B.; Holman, Bradley H.; Hann, Cheryl R.; Bakri, Sophie J.; Fautsch, Michael P.] Mayo Clin, Dept Ophthalmol, 200 First St SW, Rochester, MN 55905 USA.
   [Rosa, Robert H., Jr.] Baylor Scott & White Eye Inst, Dept Ophthalmol, Temple, TX USA.
   [Krishnan, Anuradha; Gores, Gregory J.] Mayo Clin, Dept Gastroenterol, Rochester, MN USA.
C3 Mayo Clinic; Baylor Health Care System; Mayo Clinic
RP Roddy, GW (通讯作者)，Mayo Clin, Dept Ophthalmol, 200 First St SW, Rochester, MN 55905 USA.
EM roddy.gavin@mayo.edu
FU National Eye Institute [EY 21727, EY26490]; Mayo Foundation, Rochester,
   MN; Liles Macular Degeneration Research Fund, Baylor Scott &
   White-Central Texas Foundation, Temple, TX; Center for Scientific Review
   [21727, 26490]; NATIONAL EYE INSTITUTE [R01EY021727] Funding Source: NIH
   RePORTER
FX National Eye Institute grants [EY 21727 and EY26490]; Mayo Foundation,
   Rochester, MN; Liles Macular Degeneration Research Fund, Baylor Scott &
   White-Central Texas Foundation, Temple, TX; and Center for Scientific
   Review [21727, 26490].
CR Adams MKM, 2011, AM J EPIDEMIOL, V173, P1246, DOI 10.1093/aje/kwr005
   Aguilar M, 2015, JAMA-J AM MED ASSOC, V313, P1973, DOI 10.1001/jama.2015.4260
   Ambreen F, 2014, J PAK MED ASSOC, V64, P664
   [Anonymous], 1997, DIAGNOSIS TREATMENT
   Ardeljan CP, 2014, J CLIN MED, V3, P1542, DOI 10.3390/jcm3041542
   Bahadoran Z, 2015, HEALTH PROMOT PERSPE, V5, P231, DOI 10.15171/hpp.2015.028
   Balaratnasingam C, 2016, INVEST OPHTH VIS SCI, V57, P5479, DOI 10.1167/iovs.16-19816
   Bonomini F, 2015, AGING DIS, V6, P109, DOI 10.14336/AD.2014.0305
   Booij JC, 2010, PROG RETIN EYE RES, V29, P1, DOI 10.1016/j.preteyeres.2009.08.003
   Burgess S, 2017, OPHTHALMOLOGY, V124, P1165, DOI 10.1016/j.ophtha.2017.03.042
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chang RCA, 2015, INVEST OPHTH VIS SCI, V56, P2367, DOI 10.1167/iovs.14-16143
   Charlton M, 2011, AM J PHYSIOL-GASTR L, V301, pG825, DOI 10.1152/ajpgi.00145.2011
   Chen L, 2020, RETINA-J RET VIT DIS, V40, P618, DOI 10.1097/IAE.0000000000002657
   Chen M, 2015, J LEUKOCYTE BIOL, V98, P713, DOI 10.1189/jlb.3RI0615-239R
   Chowdhury UR, 2013, INVEST OPHTH VIS SCI, V54, P4892, DOI 10.1167/iovs.13-11872
   Colijn JM, 2019, OPHTHALMOLOGY, V126, P393, DOI 10.1016/j.ophtha.2018.09.045
   Dasari B, 2011, BMC OPHTHALMOL, V11, DOI 10.1186/1471-2415-11-22
   Dashti N, 2006, BRIT J OPHTHALMOL, V90, P1028, DOI 10.1136/bjo.2006.093856
   Dong ZZ, 2012, BMC NEUROSCI, V13, DOI 10.1186/1471-2202-13-34
   Elliot SJ, 2010, EXP EYE RES, V90, P10, DOI 10.1016/j.exer.2009.09.001
   Espinosa-Heidmann DG, 2004, INVEST OPHTH VIS SCI, V45, P260, DOI 10.1167/iovs.03-0910
   Fragiotta S, 2019, INVEST OPHTH VIS SCI, V60, P3100, DOI 10.1167/iovs.19-26589
   Fujihara M, 2009, EXP EYE RES, V88, P1115, DOI 10.1016/j.exer.2009.01.017
   Gaston SA, 2019, ANN EPIDEMIOL, V30, P30, DOI 10.1016/j.annepidem.2018.11.009
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Haas P, 2015, ACTA OPHTHALMOL, V93, P533, DOI 10.1111/aos.12670
   Hogan MJ, 1971, HISTOLOGY HUMAN EYE
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Howard KP, 2014, INVEST OPHTH VIS SCI, V55, P2592, DOI 10.1167/iovs.13-13763
   Jaisankar D, 2018, INDIAN J OPHTHALMOL, V66, P976, DOI 10.4103/ijo.IJO_1265_17
   Joo J, 2019, INT J OBESITY, V43, P1681, DOI 10.1038/s41366-018-0299-3
   Kim D, 2018, CLIN LIVER DIS, V22, P133, DOI 10.1016/j.cld.2017.08.010
   Klein B E, 2001, Ophthalmic Epidemiol, V8, P251, DOI 10.1076/opep.8.4.251.1612
   Klein R, 2007, AM J OPHTHALMOL, V143, P473, DOI 10.1016/j.ajo.2006.11.058
   Krishnan A, 2017, AM J PHYSIOL-GASTR L, V312, pG666, DOI 10.1152/ajpgi.00213.2016
   Li ML, 2019, OPHTHALMOL RETINA, V3, P99, DOI 10.1016/j.oret.2018.08.008
   Love S, 2017, ONCOTARGET, V8, P113403, DOI 10.18632/oncotarget.15194
   Maralani HG, 2015, RETINA-J RET VIT DIS, V35, P459, DOI 10.1097/IAE.0000000000000338
   Mcguinness MB, 2017, AM J OPHTHALMOL, V180, P29, DOI 10.1016/j.ajo.2017.05.016
   Miceli MV, 2000, CURR EYE RES, V20, P8, DOI 10.1076/0271-3683(200001)20:1;1-H;FT008
   Munch IC, 2013, INVEST OPHTH VIS SCI, V54, P3932, DOI 10.1167/iovs.12-10785
   Nussenblatt RB, 2014, AM J OPHTHALMOL, V158, P5, DOI 10.1016/j.ajo.2014.03.014
   Parmeggiani F, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/435607
   Pikuleva IA, 2014, PROG RETIN EYE RES, V41, P64, DOI 10.1016/j.preteyeres.2014.03.002
   Poh S, 2016, DIABETES RES CLIN PR, V113, P86, DOI 10.1016/j.diabres.2016.01.016
   Provost AC, 2009, INVEST OPHTH VIS SCI, V50, P3931, DOI 10.1167/iovs.08-2527
   Purkayastha S, 2013, MOL METAB, V2, P356, DOI 10.1016/j.molmet.2013.09.005
   Robinson R, 2012, DIS MODEL MECH, V5, P444, DOI 10.1242/dmm.009597
   Rowan S, 2017, P NATL ACAD SCI USA, V114, pE4472, DOI 10.1073/pnas.1702302114
   Sabanayagam C, 2011, INVEST OPHTH VIS SCI, V52, P2397, DOI 10.1167/iovs.10-6373
   Sallo FB, 2009, EXP EYE RES, V89, P178, DOI 10.1016/j.exer.2009.03.006
   Samson SL, 2014, ENDOCRIN METAB CLIN, V43, P1, DOI 10.1016/j.ecl.2013.09.009
   Sarks S, 2007, INVEST OPHTH VIS SCI, V48, P968, DOI 10.1167/iovs.06-0443
   Schmidt-Erfurth U, 2008, INVEST OPHTH VIS SCI, V49, P390, DOI 10.1167/iovs.07-0227
   Schultz R, 2018, INVEST OPHTH VIS SCI, V59
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Sharma L, 2019, TOXICOL LETT, V304, P21, DOI 10.1016/j.toxlet.2019.01.001
   Spaide RF, 2018, SURV OPHTHALMOL, V63, P782, DOI 10.1016/j.survophthal.2018.05.005
   Thierry M, 2015, EXP EYE RES, V135, P37, DOI 10.1016/j.exer.2015.04.012
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Topouzis F, 2009, BRIT J OPHTHALMOL, V93, P1037, DOI 10.1136/bjo.2008.146316
   Volland S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125631
   Zanzottera EC, 2015, INVEST OPHTH VIS SCI, V56, P3253, DOI 10.1167/iovs.15-16431
   Zanzottera EC, 2015, INVEST OPHTH VIS SCI, V56, P3269, DOI 10.1167/iovs.15-16432
NR 65
TC 13
Z9 14
U1 1
U2 8
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0271-3683
EI 1460-2202
J9 CURR EYE RES
JI Curr. Eye Res.
PD JUN 2
PY 2020
VL 45
IS 6
BP 726
EP 732
DI 10.1080/02713683.2019.1694156
EA NOV 2019
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA LO5YY
UT WOS:000500101000001
PM 31735070
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Denniss, J
   Baggaley, HC
   Brown, GM
   Rubin, GS
   Astle, AT
AF Denniss, Jonathan
   Baggaley, Helen C.
   Brown, Graham M.
   Rubin, Gary S.
   Astle, Andrew T.
TI Properties of Visual Field Defects Around the Monocular Preferred
   Retinal Locus in Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE age-related macular degeneration; perimetry; fixation; microperimetry;
   scotoma
ID FUNDUS AUTOFLUORESCENCE; GEOGRAPHIC ATROPHY; FIXATION; MICROPERIMETRY;
   DISEASE; SENSITIVITY; BIOFEEDBACK; SCOTOMA; EYES; PERIMETRY
AB PURPOSE. To compare microperimetric sensitivity around the monocular preferred retinal locus (mPRL) in age-related macular degeneration (AMD) to normative data, and to describe the characteristics of visual field defects around the mPRL in AMD.
   METHODS. Participants with AMD (total n = 185) were either prospectively recruited (n = 135) or retrospectively reviewed from an existing database (n = 50). Participants underwent microperimetry using a test pattern (37 point, 58 radius) centered on their mPRL. Sensitivities were compared to normative data by spatial interpolation, and conventional perimetric indices were calculated. The location of the mPRL relative to the fovea and to visual field defects was also investigated.
   RESULTS. Location of mPRL varied approximately 15 degrees horizontally and vertically. Visual field loss within 5 degrees of the mPRL was considerable in the majority of participants (median mean deviation -14.7 dB, interquartile range [IQR] -19.6 to -9.6 dB, median pattern standard deviation 7.1 dB [IQR 4.8-9.0 dB]). Over 95% of participants had mean total deviation worse than -2 dB across all tested locations and similarly within 1 degrees of their mPRL. A common pattern of placing the mPRL just foveal to a region of normal pattern deviation was found in 78% of participants. Total deviation was outside normal limits in this region in 68%.
   CONCLUSIONS. Despite altering fixation to improve vision, people with AMD exhibit considerable visual field loss at and around their mPRL. The location of the mPRL was typically just foveal to, but not within, a region of relatively normal sensitivity for the individual, suggesting that a combination of factors drives mPRL selection.
C1 [Denniss, Jonathan; Baggaley, Helen C.; Astle, Andrew T.] Univ Nottingham, Sch Psychol, Visual Neurosci Grp, Nottingham, England.
   [Baggaley, Helen C.] Nottingham Univ Hosp NHS Trust, Dept Ophthalmol, Optometry Unit, Nottingham, England.
   [Brown, Graham M.; Rubin, Gary S.] UCL, Inst Ophthalmol, London, England.
   [Brown, Graham M.; Rubin, Gary S.] Moorfields Eye Hosp NHS Fdn Trust, London, England.
   [Brown, Graham M.; Rubin, Gary S.] NIHR Moorfields Biomed Res Ctr, London, England.
C3 University of Nottingham; Nottingham University Hospital NHS Trust;
   University of London; University College London; University of London;
   University College London; Moorfields Eye Hospital NHS Foundation Trust
RP Denniss, J (通讯作者)，Univ Bradford, Sch Optometry & Vis Sci, Bradford BD7 1DP, W Yorkshire, England.
EM j.denniss@bradford.ac.uk
OI Astle, Andrew/0000-0001-9795-8546
FU College of Optometrists Postdoctoral Award; National Institute for
   Health Research (NIHR) Postdoctoral Fellowship; Fight for Sight
   Programme Grant; NIHR; National Institute for Health Research
   [PDF-2013-06-057] Funding Source: researchfish
FX Supported by a College of Optometrists Postdoctoral Award (JD, ATA), a
   National Institute for Health Research (NIHR) Postdoctoral Fellowship
   (ATA), and a Fight for Sight Programme Grant (GSR). This report presents
   independent research funded by the NIHR. The views expressed are those
   of the authors and not necessarily those of the National Health Service
   (NHS), the NIHR, or the Department of Health.
CR Amore FM, 2013, CAN J OPHTHALMOL, V48, P431, DOI 10.1016/j.jcjo.2013.07.013
   Astle AT, 2016, DATA BRIEF, V9, P673, DOI 10.1016/j.dib.2016.07.061
   Auguie B., 2017, GRIDEXTRA MISCELLANE
   Crossland M., 2007, VISUAL IMPAIRMENT RE, V9, P59, DOI DOI 10.1080/13882350701643582
   Crossland MD, 2004, OPHTHAL PHYSL OPT, V24, P327, DOI 10.1111/j.1475-1313.2004.00213.x
   Crossland MD, 2005, OPHTHALMOLOGY, V112, P1579, DOI 10.1016/j.ophtha.2005.03.027
   Denniss J, 2016, INVEST OPHTH VIS SCI, V57, P5449, DOI 10.1167/iovs.16-20222
   Fletcher DC, 1997, OPHTHALMOLOGY, V104, P632, DOI 10.1016/S0161-6420(97)30260-7
   Greenstein VC, 2008, RETINA-J RET VIT DIS, V28, P1234, DOI 10.1097/IAE.0b013e31817c1b47
   GUEZ JE, 1993, VISION RES, V33, P1271, DOI 10.1016/0042-6989(93)90213-G
   HEIJL A, 1987, ARCH OPHTHALMOL-CHIC, V105, P1544
   Heijl A, 1987, DOC OPHTHALMOL, P154
   Iwama D, 2010, CLIN EXP OPHTHALMOL, V38, P483, DOI 10.1111/j.1442-9071.2010.02294.x
   Leonova A, 2003, VISION RES, V43, P2133, DOI 10.1016/S0042-6989(03)00333-X
   Meleth AD, 2011, INVEST OPHTH VIS SCI, V52, P1119, DOI 10.1167/iovs.10-6075
   Midena E, 2007, BRIT J OPHTHALMOL, V91, P1499, DOI 10.1136/bjo.2007.119685
   Morales MU, 2015, BMJ CASE REP
   Parisi V, 2007, RETINA-J RET VIT DIS, V27, P879, DOI 10.1097/IAE.0b013e318042d6aa
   Rees AL, 2005, INT C SER, V1282, P694, DOI DOI 10.1016/J.ICS.2005.05.172
   Rohrschneider K, 2008, PROG RETIN EYE RES, V27, P536, DOI 10.1016/j.preteyeres.2008.07.003
   Schmitz-Valckenberg S, 2004, INVEST OPHTH VIS SCI, V45, P4470, DOI 10.1167/iovs.03-1311
   Shima N, 2010, CAN J OPHTHALMOL, V45, P62, DOI 10.3129/i09-236
   Sunness JS, 1996, OPHTHALMOLOGY, V103, P1458, DOI 10.1016/S0161-6420(96)30483-1
   Tarita-Nistor L, 2009, VISUAL NEUROSCI, V26, P487, DOI 10.1017/S0952523809990265
   TIMBERLAKE GT, 1986, INVEST OPHTH VIS SCI, V27, P1137
   Vingolo EM, 2007, APPL PSYCHOPHYS BIOF, V32, P185, DOI [10.1007/s10484-007-9038-6, 10.1007/sl0484-007-9038-6]
   Vingolo EM, 2009, APPL PSYCHOPHYS BIOF, V34, P127, DOI 10.1007/s10484-009-9083-4
   WHITTAKER SG, 1988, INVEST OPHTH VIS SCI, V29, P268
NR 28
TC 8
Z9 8
U1 0
U2 6
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAY
PY 2017
VL 58
IS 5
BP 2652
EP 2658
DI 10.1167/iovs.16-21086
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EZ3DV
UT WOS:000404591500028
PM 28524928
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Alkin, Z
   Ozkaya, A
   Osmanbasoglu, OA
   Agca, A
   Karakucuk, Y
   Yazici, AT
   Demirok, A
AF Alkin, Zeynep
   Ozkaya, Abdullah
   Osmanbasoglu, Ozen Ayranci
   Agca, Alper
   Karakucuk, Yalcin
   Yazici, Ahmet Taylan
   Demirok, Ahmet
TI The Role of Epiretinal Membrane on Treatment of Neovascular Age-Related
   Macular Degeneration with Intravitreal Bevacizumab
SO SCIENTIFIC WORLD JOURNAL
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; ENDOTHELIAL GROWTH-FACTOR; CHOROIDAL
   NEOVASCULARIZATION; VITREOMACULAR ADHESION; VITRECTOMY; THERAPY;
   RANIBIZUMAB; PREVALENCE; INJECTION; FEATURES
AB Purpose. To determine the effect of epiretinal membranes (ERM) on the treatment response and the number of intravitreal bevacizumab injections (IVB) in patients with neovascular age-related macular degeneration (nAMD). Methods. A retrospective chart review was performed on 63 eyes of 63 patients. The patients were divided into AMD group (n = 35) and AMD/ERM group (n = 28). Best corrected visual acuity (BCVA) and central retinal thickness (CRT), as well as the number of injections, were evaluated. Results. There was a significant improvement in BCVA at 3 months for the AMD and AMD/ERM groups (P = 0.02, P = 0.03, resp.). At 6, 12, and 18 months, BCVA did not change significantly in either of the groups compared to baseline (P > 0.05 for all). At 3, 6, 12, and 24 months, the AMD group had an improvement in BCVA (logMAR) of 0.09, 0.06, 0.06, and 0.03 versus 0.08, 0.07, 0.05, and 0.03 for the AMD/ERM group (P = 0.29, P = 0.88, P = 0.74, P = 0.85, resp.). A significant decrease in CRT occurred in both groups for all time points (P < 0.001 for all). The change in CRT was not statistically different between the two groups at all time points (P > 0.05 for all). The mean number of injections over 24 months was 8.8 in the AMD group and 9.2 in the AMD/ERM group (P = 0.76). Conclusion. During 24 months, visual and anatomical outcomes of IVB in nAMD patients were comparable with those in nAMD patients with ERM with similar injection numbers.
C1 [Alkin, Zeynep; Ozkaya, Abdullah; Osmanbasoglu, Ozen Ayranci; Agca, Alper; Karakucuk, Yalcin; Yazici, Ahmet Taylan; Demirok, Ahmet] Beyoglu Eye Training & Res Hosp, Istanbul, Turkey.
   [Demirok, Ahmet] Medeniyet Univ, TR-34700 Istanbul, Turkey.
C3 Istanbul Prof Dr N Resat Belger Beyoglu Eye Training & Research
   Hospital; Istanbul Medeniyet University
RP Alkin, Z (通讯作者)，Beyoglu Eye Training & Res Hosp, Bereketzade Cami Sok 2 Beyoglu, Istanbul, Turkey.
EM zeynepalkin@gmail.com
RI Demirok, Ahmet/AAE-1713-2020; Alkin, Zeynep/V-7252-2017; Agca,
   Alper/E-2166-2013; Ozkaya, Abdullah/L-5745-2013
OI Demirok, Ahmet/0000-0001-8197-2458; Alkin, Zeynep/0000-0002-5363-1944;
   Agca, Alper/0000-0001-5435-075X; Ozkaya, Abdullah/0000-0002-1940-8669;
   karakucuk, Yalcin/0000-0001-6430-2233
CR Adamis A P, 1999, Angiogenesis, V3, P9, DOI 10.1023/A:1009071601454
   [Anonymous], 1987, STEREOSCOPIC ATLAS M
   Brar M, 2010, RETINA-J RET VIT DIS, V30, P383, DOI 10.1097/IAE.0b013e3181cd4803
   Brown DM, 2007, AM J OPHTHALMOL, V144, P627, DOI 10.1016/j.ajo.2007.06.039
   Chen CH, 2011, J OCUL PHARMACOL TH, V27, P287, DOI 10.1089/jop.2010.0166
   Christoforidis JB, 2013, CURR EYE RES, V38, P761, DOI 10.3109/02713683.2013.763988
   El-Mollayess GM, 2012, AM J OPHTHALMOL, V153, P481, DOI 10.1016/j.ajo.2011.08.018
   Eter N, 2005, RETINA-J RET VIT DIS, V25, P691, DOI 10.1097/00006982-200509000-00002
   Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027
   Friedman SM, 2000, AM J OPHTHALMOL, V130, P839, DOI 10.1016/S0002-9394(00)00605-X
   Golbaz I, 2011, INVEST OPHTH VIS SCI, V52, P1599, DOI 10.1167/iovs.09-5018
   Ikeda T, 2000, ACTA OPHTHALMOL SCAN, V78, P460, DOI 10.1034/j.1600-0420.2000.078004460.x
   Johnson Mark W, 2005, Trans Am Ophthalmol Soc, V103, P537
   KAHN HA, 1977, AM J EPIDEMIOL, V106, P17, DOI 10.1093/oxfordjournals.aje.a112428
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Krebs I, 2007, AM J OPHTHALMOL, V144, P741, DOI 10.1016/j.ajo.2007.07.024
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Luttrull JK, 2008, OPHTHAL SURG LAS IM, V39, P455, DOI 10.3928/15428877-20081101-08
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Massin P, 2000, AM J OPHTHALMOL, V130, P732, DOI 10.1016/S0002-9394(00)00574-2
   Mojana F, 2008, AM J OPHTHALMOL, V146, P218, DOI 10.1016/j.ajo.2008.04.027
   Ozkaya A., 2013, J OPHTHALMOLOGY, V2013
   Pierro L, 2012, CLIN OPHTHALMOL, V6, P219, DOI 10.2147/OPTH.S27656
   Quaranta-El Maftouhi M, 2006, EUR J OPHTHALMOL, V16, P134
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Sahni J, 2005, BRIT J OPHTHALMOL, V89, P316, DOI 10.1136/bjo.2004.043364
   Seko Y, 1999, INVEST OPHTH VIS SCI, V40, P3287
   Sonmez K, 2011, RETINA-J RET VIT DIS, V31, P645, DOI 10.1097/IAE.0b013e3182012d18
   Tufail A, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2459
   Witkin AJ, 2009, OPHTHALMOLOGY, V116, P956, DOI 10.1016/j.ophtha.2008.12.018
   Yanyali A, 2007, AM J OPHTHALMOL, V144, P124, DOI 10.1016/j.ajo.2007.02.048
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
NR 33
TC 4
Z9 4
U1 0
U2 3
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1537-744X
J9 SCI WORLD J
JI Sci. World J.
PY 2013
AR 958724
DI 10.1155/2013/958724
PG 7
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 289US
UT WOS:000329708400001
PM 24453930
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Wegscheider, BJ
   Weger, M
   Renner, W
   Steinbrugger, I
   Marz, W
   Mossbock, G
   Ternmel, W
   El-Shabrawi, Y
   Schmut, O
   Jahrbacher, R
   Haas, A
AF Wegscheider, Beate J.
   Weger, Martin
   Renner, Wilfried
   Steinbrugger, Iris
   Marz, Winfried
   Mossbock, Georg
   Ternmel, Werner
   El-Shabrawi, Yosuf
   Schmut, Otto
   Jahrbacher, Renate
   Haas, Anton
TI Association of complement factor HY402H gene polymorphism with different
   subtypes of exudative age-related macular degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; FACTOR-H POLYMORPHISM;
   C-REACTIVE PROTEIN; RISK-FACTORS; EYE DISEASE; MACULOPATHY; VARIANT;
   COMMON; SUSCEPTIBILITY; PREVALENCE
AB Objective: Exudative age-related macular degeneration (AMD) is a common cause for a severe central visual loss. The complement system has been implicated in the pathogenesis of drusen. Recently, a complement factor H (CFH) polymorphism, which is characterized by a tyrosine (Y)-to-histidine (H) exchange at position 402 of the CFH gene, has been suggested as a major risk factor for AMD in a North American population. The aim of the present study was to investigate a hypothesized association between the CFH Y402H polymorphism and the presence of exudative AMD in a Central European population of Caucasoid descent as well as to determine the genotype distribution among different types of exudative AMD.
   Design: Retrospective case-control study.
   Participants: The study cohort consisted of 179 patients with exudative AMD and 163 controls.
   Methods: Determination of genotypes was carried out by allele-specific digestion of polymerase chain reaction products.
   Main Outcome Measures: Genotypes of CFH Y402H polymorphism.
   Results: The prevalence of the CFH 402HH genotype was significantly higher in patients with exudative AMD than among controls (35.2% vs. 8.6%; P < 0.001). Homozygosity for the CFH Y402H polymorphism was associated with an odds ratio of 5.78 (95% confidence interval, 3.09-10.83) for exudative AMD. Subgroup analysis revealed that the CFH 402HH genotype was significantly more prevalent in eyes with predominantly classic with no occult choroidal neovascularization (CNV) than in those with either retinal angiomatous proliferation, occult with no classic CNV, or predominantly classic with occult CNV.
   Conclusion: Our data suggest that the CFH Y402H polymorphism is a major risk factor for exudative AMD in a Central European population.
C1 Med Univ Graz, Dept Ophthalmol, A-8036 Graz, Austria.
   Med Univ Graz, Clin Inst Med & Chem Lab Diagnost, A-8036 Graz, Austria.
C3 Medical University of Graz; Medical University of Graz
RP Haas, A (通讯作者)，Med Univ Graz, Dept Ophthalmol, Auenbruggerpl 4, A-8036 Graz, Austria.
EM anton.haas@meduni-graz.at
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Blackmore TK, 1998, INFECT IMMUN, V66, P1427, DOI 10.1128/IAI.66.4.1427-1431.1998
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Caprioli J, 2003, HUM MOL GENET, V12, P3385, DOI 10.1093/hmg/ddg363
   Conley YP, 2005, HUM MOL GENET, V14, P1991, DOI 10.1093/hmg/ddi204
   de Cordoba SR, 2004, MOL IMMUNOL, V41, P355, DOI 10.1016/j.molimm.2004.02.005
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   FEARON DT, 1978, P NATL ACAD SCI USA, V75, P1971, DOI 10.1073/pnas.75.4.1971
   Giannakis E, 2003, EUR J IMMUNOL, V33, P962, DOI 10.1002/eji.200323541
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   MOLD C, 1984, J IMMUNOL, V133, P882
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Niffenegger J, 1998, OPHTHALMOLOGY, V105, P1364
   REES DC, 1995, LANCET, V346, P1133, DOI 10.1016/S0140-6736(95)91803-5
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Rosendaal FR, 1998, THROMB HAEMOSTASIS, V79, P706
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Spaide RF, 2003, RETINA-J RET VIT DIS, V23, P595, DOI 10.1097/00006982-200310000-00001
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
   Zipfel PF, 2002, BIOCHEM SOC T, V30, P971, DOI 10.1042/bst0300971
   Zipfel PF, 2001, SEMIN THROMB HEMOST, V27, P191, DOI 10.1055/s-2001-15248
NR 30
TC 74
Z9 74
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
J9 OPHTHALMOLOGY
JI Ophthalmology
PD APR
PY 2007
VL 114
IS 4
BP 738
EP 742
DI 10.1016/j.ophtha.2006.07.048
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 153MU
UT WOS:000245440400020
PM 17398321
DA 2022-11-30
ER

PT J
AU Fu, HJ
   Zhang, B
   Tong, JL
   Bedell, H
   Zhang, HC
   Yang, YT
   Nie, CC
   Luo, YD
   Liu, XL
AF Fu, Haojie
   Zhang, Bin
   Tong, Jianliang
   Bedell, Harold
   Zhang, Hecheng
   Yang, Yating
   Nie, Chaochao
   Luo, Yingdong
   Liu, Xiaoling
TI Relationships of orientation discrimination threshold and visual acuity
   with macular lesions in age-related macular degeneration
SO PLOS ONE
LA English
DT Article
ID CENTRAL SEROUS CHORIORETINOPATHY; TREATMENTS TRIALS; CHOROIDAL
   NEOVASCULARIZATION; VISION LOSS; FILLING-IN; METAMORPHOPSIA;
   RANIBIZUMAB; BEVACIZUMAB; MORPHOLOGY; MEMBRANE
AB Purpose
   To measure visual acuity and metamorphopsia in patients with age-related macular degeneration (AMD) and to explore their relationship with macular lesions.
   Methods
   In this cross-sectional study, a total of 32 normal subjects (32 eyes) and 35 AMD patients (35 eyes) were recruited. They were categorized into 4 groups: normal, dry AMD, non-active wet AMD, and active wet AMD. Best-corrected visual acuity (BCVA) was measured using the Early Treatment Diabetic Retinopathy Study protocol. Metamorphopsia was quantified with the orientation discrimination threshold (ODT). Macular lesions, including drusen, subretinal fluid (SRF), intra-retinal fluid (IRF), pigmented epithelium detachment (PED), and scarring, were identified with spectral-domain optical coherence tomography (SD-OCT). A linear regression model was established to identify the relationships between the functional and structural changes.
   Results
   BCVA progressively worsened across the normal, dry AMD, non-active wet AMD, and active wet AMD groups (P < 0.001), and ODT increased across the groups (P < 0.001). The correlation between BCVA and ODT varied among the groups. The partial correlation between BCVA and ODT was -0.61 (P < 0.001). Linear regression showed that ODT significantly depended on IRF (beta = 0.61, P < 0.001), SRF (beta = 0.34, P = 0.003), and scarring (beta = 0.26, P = 0.050), while BCVA significantly depended only on scarring (beta = -0.52, P < 0.001), and IRF (beta = -0.36, P = 0.016).
   Conclusions
   From dry AMD to active wet AMD, BCVA gradually worsened while ODT increased. The correlation between BCVA and ODT varied among these groups, indicating that AMD lesions affect them differently. ODT and BCVA should be used concurrently for better monitoring of the disease.
C1 [Fu, Haojie; Zhang, Hecheng; Yang, Yating; Nie, Chaochao; Luo, Yingdong; Liu, Xiaoling] Wenzhou Med Univ, Sch Ophthalmol & Optometry, Wenzhou, Zhejiang, Peoples R China.
   [Zhang, Bin] Nova Southeastern Univ, Coll Optometry, Davie, FL USA.
   [Tong, Jianliang] Brain Trauma Fdn, New York, NY USA.
   [Bedell, Harold] Univ Houston, Coll Optometry, Houston, TX USA.
   [Tong, Jianliang] New England Coll Optometry, Boston, MA USA.
C3 Wenzhou Medical University; Nova Southeastern University; University of
   Houston System; University of Houston
RP Liu, XL (通讯作者)，Wenzhou Med Univ, Sch Ophthalmol & Optometry, Wenzhou, Zhejiang, Peoples R China.
EM drliuxiaolin@163.com
RI Zhang, Bin/GOH-1376-2022
OI Yang, yating/0000-0001-7073-0162
CR Arimura E, 2011, INVEST OPHTH VIS SCI, V52, P128, DOI 10.1167/iovs.09-3535
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bae SW, 2013, INDIAN J OPHTHALMOL, V61, P172, DOI 10.4103/0301-4738.112162
   Bedell HE, 2009, OPTOMETRY VISION SCI, V86, P485, DOI 10.1097/OPX.0b013e31819fa6e2
   Bloch SB, 2013, AM J OPHTHALMOL, V156, P116, DOI 10.1016/j.ajo.2013.02.012
   Brainard DH, 1997, SPATIAL VISION, V10, P433, DOI 10.1163/156856897X00357
   Brar VS, 2010, MOL VIS, V16, P1848
   Bringmann A, 2004, OPHTHALMIC RES, V36, P241, DOI 10.1159/000081203
   Buschini E, 2011, PROG NEUROBIOL, V95, P14, DOI 10.1016/j.pneurobio.2011.05.011
   Cherepanoff S, 2010, BRIT J OPHTHALMOL, V94, P918, DOI 10.1136/bjo.2009.165563
   De Weerd P, 2006, PROG BRAIN RES, V154, P227, DOI 10.1016/S0079-6123(06)54012-9
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Jaffe GJ, 2013, OPHTHALMOLOGY, V120, P1860, DOI 10.1016/j.ophtha.2013.01.073
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KINGSMITH PE, 1994, VISION RES, V34, P885, DOI 10.1016/0042-6989(94)90039-6
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Kleiner M, 2007, PERCEPTION, V36, P14
   Liu L, 2010, OPTOMETRY VISION SCI, V87, P532, DOI 10.1097/OPX.0b013e3181e3dc10
   Loewenstein A, 2003, OPHTHALMOLOGY, V110, P966, DOI 10.1016/S0161-6420(03)00074-5
   Lovie-Kitchin Jan, 2005, Clin Exp Optom, V88, P292
   Luckoff A, 2016, EMBO MOL MED, V8, P670, DOI 10.15252/emmm.201505994
   Manabe K, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153817
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Nagai N, 2006, ARTERIOSCL THROM VAS, V26, P2252, DOI 10.1161/01.ATV.0000240050.15321.fe
   Okamoto F, 2012, INVEST OPHTH VIS SCI, V53, P6770, DOI 10.1167/iovs.12-9683
   Olsen TW, 2004, OPHTHALMOLOGY, V111, P250, DOI 10.1016/j.ophtha.2003.05.030
   Pelli DG, 1997, SPATIAL VISION, V10, P437, DOI 10.1163/156856897X00366
   Querques G, 2010, BRIT J OPHTHALMOL, V94, P292, DOI 10.1136/bjo.2009.170670
   Ritter M, 2011, BRIT J OPHTHALMOL, V95, P381, DOI 10.1136/bjo.2009.175976
   Schmidt-Erfurth U, 2015, OPHTHALMOLOGY, V122, P822, DOI 10.1016/j.ophtha.2014.11.017
   SCHUCHARD RA, 1993, ARCH OPHTHALMOL-CHIC, V111, P776, DOI 10.1001/archopht.1993.01090060064024
   Sharma S, 2016, OPHTHALMOLOGY, V123, P865, DOI 10.1016/j.ophtha.2015.12.002
   Simader C, 2014, OPHTHALMOLOGY, V121, P1237, DOI 10.1016/j.ophtha.2013.12.029
   Simunovic MP, 2015, RETINA-J RET VIT DIS, V35, P1285, DOI 10.1097/IAE.0000000000000581
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Suzuki M, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-176
   Wang YZ, 2002, INVEST OPHTH VIS SCI, V43, P2055
   WATSON AB, 1983, PERCEPT PSYCHOPHYS, V33, P113, DOI 10.3758/BF03202828
   Weinberger D, 1996, AM J OPHTHALMOL, V122, P864, DOI 10.1016/S0002-9394(14)70383-6
   Williams MA, 2009, AGE AGEING, V38, P648, DOI 10.1093/ageing/afp136
   Willoughby AS, 2015, OPHTHALMOLOGY, V122, P1846, DOI 10.1016/j.ophtha.2015.05.042
   Zur D, 2003, VISION RES, V43, P971, DOI 10.1016/S0042-6989(03)00038-5
NR 45
TC 4
Z9 4
U1 1
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 18
PY 2017
VL 12
IS 9
AR e0185070
DI 10.1371/journal.pone.0185070
PG 16
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA FH3OQ
UT WOS:000411059300055
PM 28922378
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Yun, C
   Ahn, J
   Kim, M
   Hwang, SY
   Kim, SW
   Oh, J
AF Yun, Cheolmin
   Ahn, Jaemoon
   Kim, Minjung
   Hwang, Soon-Young
   Kim, Seong-Woo
   Oh, Jaeryung
TI Ocular Perfusion Pressure and Choroidal Thickness in Early Age-Related
   Macular Degeneration Patients With Reticular Pseudodrusen
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE age-related macular degeneration; choroidal thickness; ocular perfusion
   pressure; optical coherence tomography; pseudodrusen
ID OPTICAL COHERENCE TOMOGRAPHY; CARDIOVASCULAR-DISEASE;
   GEOGRAPHIC-ATROPHY; BLOOD-FLOW; FELLOW-EYES; RISK-FACTOR; ASSOCIATION;
   DRUSEN; HYPERTENSION; MACULOPATHY
AB PURPOSE. The purpose of this study was to investigate the relationship between the ocular perfusion pressure (OPP) and subfoveal choroidal thickness (CT) in eyes with early age-related macular degeneration (AMD) with or without reticular pseudodrusen (RPD).
   METHODS. We evaluated the clinical history, blood pressure parameters, fundus photography, and optical coherence tomography images of consecutive patients with early AMD. We calculated the mean OPP from blood pressure and intraocular pressure.
   RESULTS. We included 103 eyes from 103 patients, classifying 45 as the RPD group and 58 as the non-RPD group. The mean OPP of the RPD group (46.1 +/- 6.5 mm Hg) did not differ from that of the non-RPD group (45.1 +/- 5.1 mm Hg, P = 0.325), but the RPD group showed a thinner mean subfoveal CT (158.3 +/- 73.0 mu m) than the non-RPD group (220.9 +/- 67.0 mu m, P < 0.001). Among 64 patients who underwent follow-up examination, the rate of change in subfoveal CT in the RPD group (-4.74 +/- 0.86 mu m/y) was greater than that in the non-RPD group (-2.46 +/- 0.75 mu m/y, P = 0.028). In the RPD group, a history of systemic hypertension and lower baseline OPP were associated with a higher rate of change in subfoveal CT (P = 0.019 and P = 0.010, respectively).
   CONCLUSIONS. Subfoveal CT was thinner in early AMD patients with RPD than in those without RPD. Lower baseline mean OPP and a history of systemic hypertension could be risk factors associated with the progression of choroidal thinning in early AMD patients with RPD.
C1 [Yun, Cheolmin; Kim, Minjung; Kim, Seong-Woo; Oh, Jaeryung] Korea Univ, Coll Med, Dept Ophthalmol, 126-1 Anam Dong 5 Ga, Seoul 136705, South Korea.
   [Hwang, Soon-Young] Korea Univ, Coll Med, Dept Biostat, Seoul, South Korea.
C3 Korea University; Korea University Medicine (KU Medicine); Korea
   University; Korea University Medicine (KU Medicine)
RP Oh, J (通讯作者)，Korea Univ, Coll Med, Dept Ophthalmol, 126-1 Anam Dong 5 Ga, Seoul 136705, South Korea.
EM ojr4991@korea.ac.kr
RI Oh, Jaeryung/ABD-3090-2021
OI Oh, Jaeryung/0000-0002-1036-6562; Hwang, Soon Young/0000-0001-7474-1803
FU Korea University, Seoul, Korea [K1600851]
FX This study was supported by a grant from the Korea University, Seoul,
   Korea (K1600851).
CR A Martillo Miguel, 2012, Med Hypothesis Discov Innov Ophthalmol, V1, P37
   ALM A, 1973, EXP EYE RES, V15, P15, DOI 10.1016/0014-4835(73)90185-1
   Alten F, 2015, BRIT J OPHTHALMOL, V99, P717, DOI 10.1136/bjophthalmol-2014-305339
   Alten F, 2013, INVEST OPHTH VIS SCI, V54, P3250, DOI 10.1167/iovs.13-11923
   ARNOLD JJ, 1995, RETINA-J RET VIT DIS, V15, P183, DOI 10.1097/00006982-199515030-00001
   Bachschmid MM, 2013, ANN MED, V45, P17, DOI 10.3109/07853890.2011.645498
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Boddu S, 2014, AM J OPHTHALMOL, V157, P985, DOI 10.1016/j.ajo.2014.01.023
   Chakraborty R, 2011, INVEST OPHTH VIS SCI, V52, P5121, DOI 10.1167/iovs.11-7364
   Cheng H, 2016, CURR EYE RES, V41, P1
   Cymerman RM, 2016, CURR EYE RES, V41, P1482, DOI 10.3109/02713683.2015.1128552
   Finger RP, 2014, OPHTHALMOLOGY, V121, P1252, DOI 10.1016/j.ophtha.2013.12.034
   Garg A, 2013, INVEST OPHTH VIS SCI, V54, P7075, DOI 10.1167/iovs.13-12474
   Gherghel D, 2000, AM J OPHTHALMOL, V130, P597, DOI 10.1016/S0002-9394(00)00766-2
   Haas P, 2014, INVEST OPHTH VIS SCI, V55, P2674, DOI 10.1167/iovs.13-13338
   Harvey A, 2015, J MOL CELL CARDIOL, V83, P112, DOI 10.1016/j.yjmcc.2015.04.011
   Hogg RE, 2014, OPHTHALMOLOGY, V121, P1748, DOI 10.1016/j.ophtha.2014.03.015
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kim M, 2012, INVEST OPHTH VIS SCI, V53, P7710, DOI 10.1167/iovs.12-10464
   Lee JY, 2013, INVEST OPHTH VIS SCI, V54, P7812, DOI 10.1167/iovs.13-12284
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   Marsiglia M, 2013, INVEST OPHTH VIS SCI, V54, P7362, DOI 10.1167/iovs.12-11073
   Mrejen S, 2013, SURV OPHTHALMOL, V58, P387, DOI 10.1016/j.survophthal.2012.12.001
   Nickla DL, 2010, PROG RETIN EYE RES, V29, P144, DOI 10.1016/j.preteyeres.2009.12.002
   Pumariega NM, 2011, OPHTHALMOLOGY, V118, P1619, DOI 10.1016/j.ophtha.2011.01.029
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P1258, DOI 10.1167/iovs.11-8907
   Rastogi N, 2016, SURV OPHTHALMOL, V61, P422, DOI 10.1016/j.survophthal.2015.10.003
   Rishi P, 2013, EYE, V27, P1038, DOI 10.1038/eye.2013.106
   Sansom LT, 2016, ACTA OPHTHALMOL, V94, pE157, DOI 10.1111/aos.12794
   Schmidl D, 2011, EXP EYE RES, V93, P141, DOI 10.1016/j.exer.2010.09.002
   Skondra D, 2012, SEMIN OPHTHALMOL, V27, P209, DOI 10.3109/08820538.2012.708807
   Smith RT, 2006, INVEST OPHTH VIS SCI, V47, P5495, DOI 10.1167/iovs.05-1318
   Smith RT, 2009, AM J OPHTHALMOL, V148, P733, DOI 10.1016/j.ajo.2009.06.028
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1441, DOI 10.1097/IAE.0b013e3181ee5ce8
   Tan JSL, 2008, BRIT J OPHTHALMOL, V92, P509, DOI 10.1136/bjo.2007.131706
   Ueda-Arakawa N, 2013, RETINA-J RET VIT DIS, V33, P490, DOI 10.1097/IAE.0b013e318276e0ae
   Xu LN, 2013, RETINA-J RET VIT DIS, V33, P1850, DOI 10.1097/IAE.0b013e31828991b2
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P2434, DOI 10.1016/j.ophtha.2011.05.008
   Yun C, 2016, GRAEF ARCH CLIN EXP, V254, P427, DOI 10.1007/s00417-015-3054-7
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
NR 42
TC 20
Z9 20
U1 0
U2 1
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD DEC
PY 2016
VL 57
IS 15
BP 6604
EP 6609
DI 10.1167/iovs.16-19989
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EJ0VR
UT WOS:000392929500014
PM 27926751
OA gold
DA 2022-11-30
ER

PT J
AU Shah, AR
   Williams, S
   Baumal, CR
   Rosner, B
   Duker, JS
   Seddon, JM
AF Shah, Anjali R.
   Williams, Steven
   Baumal, Caroline R.
   Rosner, Bernard
   Duker, Jay S.
   Seddon, Johanna M.
TI Predictors of Response to Intravitreal Anti-Vascular Endothelial Growth
   Factor Treatment of Age-Related Macular Degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID COMPLEMENT FACTOR-H; VISUAL-ACUITY; RANIBIZUMAB; CFH; ASSOCIATION;
   GENOTYPES; ARMS2; AMD; POLYMORPHISMS; ANTIOXIDANTS
AB PURPOSE: To identify factors that influence visual and anatomic response to treatment with intravitreal anti-vascular endothelial growth factor (VEGF) for neovascular age-related macular degeneration (AMD).
   DESIGN: Observational cohort study.
   METHODS: Seventy-two patients were included in this study. Best-corrected Snellen visual acuity (VA) and central foveal thickness measured on optical coherence tomography (OCT) at time of treatment and post-treatment follow-up visits were recorded. Associations between demographic, behavioral, and genetic risk factors and the 2 outcomes were analyzed using mixed-effects linear regression models. Two loci in complement factor H (CFH) were included in a risk score to determine the association between CFH risk and improvement in VA and central foveal thickness.
   RESULTS: There was a small improvement in VA following anti-VEGF treatment (mean: 3.7 +/- 3.0 letters), which was not statistically significant. Significant improvement in VA was observed for the nonrisk CFH Y402H genotype (P<.001) and for a low CFH risk score (P=.019). Regarding the outcome of change in central foveal thickness, improvement was noted in all genotype groups, but reduction after treatment was significantly higher in the low CFH risk score group (P=.033). A significant improvement in mean VA was seen among smokers (P<.001), but this relationship was not observed for central foveal thickness.
   CONCLUSION: After anti-VEGF therapy, significant improvement in VA was observed for low-risk CFH genotypes and subjects with a low risk score. There was a statistically significant reduction in central fovea! thickness overall, and subjects with a low CFH risk score improved more than the high-risk group. (C) 2016 by Elsevier Inc. All rights reserved.
C1 [Shah, Anjali R.] Univ Michigan Hlth Syst, Kellogg Eye Ctr, Ann Arbor, MI USA.
   [Williams, Steven] Calif Pacific Med Ctr, Dept Ophthalmol, San Francisco, CA USA.
   [Baumal, Caroline R.; Duker, Jay S.; Seddon, Johanna M.] Tufts Univ, Sch Med, Tufts Med Ctr, New England Eye Ctr, Boston, MA 02111 USA.
   [Rosner, Bernard] Harvard Univ, Channing Div Network Med, Boston, MA 02115 USA.
C3 University of Michigan System; University of Michigan; California
   Pacific Medical Center; Tufts Medical Center; Tufts University; Harvard
   University
RP Seddon, JM (通讯作者)，Tufts Med Ctr, Ophthalm Epidemiol & Genet Serv, 800 Washington St 450, Boston, MA 02111 USA.
EM jseddon@tuftsmedicalcenter.org
OI Shah, Anjali/0000-0001-6440-423X
FU NATIONAL INSTITUTES OF HEALTH [RO1-EY11309]; MASSACHUSETTS Lions Eye
   Research Fund Inc, New Bedford, Massachusetts; Research to Prevent
   Blindness Inc, New York, New York; Genentech Inc, San Francisco,
   California; Age-Related Macular Degeneration Research Fund, Ophthalmic
   Epidemiology and Genetics Service, Tufts Medical Center, Tufts
   University School of Medicine, Boston; Massachusetts; NATIONAL EYE
   INSTITUTE [R01EY011309] Funding Source: NIH RePORTER
FX SUPPORTED BY GRANT RO1-EY11309 FROM THE NATIONAL INSTITUTES OF HEALTH;
   THE MASSACHUSETTS Lions Eye Research Fund Inc, New Bedford,
   Massachusetts; unrestricted grants from Research to Prevent Blindness
   Inc, New York, New York; research grant from Genentech Inc, San
   Francisco, California (Johanna M. Seddon); and the Age-Related Macular
   Degeneration Research Fund, Ophthalmic Epidemiology and Genetics
   Service, Tufts Medical Center, Tufts University School of Medicine,
   Boston; Massachusetts.
CR Alexander P, 2012, EYE, V26, P678, DOI 10.1038/eye.2012.7
   Awh CC, 2013, OPHTHALMOLOGY, V120, P2317, DOI 10.1016/j.ophtha.2013.07.039
   Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chew EY, 2014, OPHTHALMOLOGY, V121, P2173, DOI 10.1016/j.ophtha.2014.05.008
   Dikmetas O, 2013, MOL VIS, V19, P2571
   Francis Peter James, 2011, Trans Am Ophthalmol Soc, V109, P115
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Gregori NZ, 2010, RETINA-J RET VIT DIS, V30, P1046, DOI 10.1097/IAE.0b013e3181d87e04
   Hagstrom SA, 2013, OPHTHALMOLOGY, V120, P593, DOI 10.1016/j.ophtha.2012.11.037
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1019, DOI 10.1016/j.ophtha.2008.01.036
   Kloeckener-Gruissem B, 2011, INVEST OPHTH VIS SCI, V52, P4694, DOI 10.1167/iovs.10-6080
   Landa G, 2011, RETINA-J RET VIT DIS, V31, P364, DOI 10.1097/IAE.0b013e3181e91132
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lotery AJ, 2013, OPHTHALMOLOGY, V120, P2637, DOI 10.1016/j.ophtha.2013.07.046
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Matsumiya W, 2014, PHARMACOGENOMICS, V15, P833, DOI [10.2217/PGS.14.51, 10.2217/pgs.14.51]
   Nischler C, 2011, ACTA OPHTHALMOL, V89, pE344, DOI 10.1111/j.1755-3768.2010.02080.x
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rubin GS, 1997, INVEST OPHTH VIS SCI, V38, P557
   Seddon JM, 2015, INVEST OPHTH VIS SCI, V56, P2192, DOI 10.1167/iovs.14-15841
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P2304, DOI 10.1016/j.ophtha.2012.05.040
   Sobrin L, 2014, PROG RETIN EYE RES, V40, P1, DOI 10.1016/j.preteyeres.2013.12.004
   Sobrin L, 2011, AM J OPHTHALMOL, V151, P345, DOI 10.1016/j.ajo.2010.08.015
   Sunness JS, 1997, OPHTHALMOLOGY, V104, P1677, DOI 10.1016/S0161-6420(97)30079-7
NR 27
TC 32
Z9 35
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD MAR
PY 2016
VL 163
BP 154
EP 166
DI 10.1016/j.ajo.2015.11.033
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DF6EA
UT WOS:000371447500021
PM 26705092
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Theodossiadis, PG
   Theodoropoulou, S
   Stamatiou, P
   Datseris, I
   Theodossiadis, GP
AF Theodossiadis, Panagiotis G.
   Theodoropoulou, Sofia
   Stamatiou, Polixeni
   Datseris, Ioannis
   Theodossiadis, George P.
TI Photoreceptor layer changes overlying drusen in eyes with age-related
   macular degeneration associated with vitreomacular traction
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Drusen; Optical coherence tomography;
   Photoreceptor layer; Vitreomacular traction
ID OPTICAL COHERENCE TOMOGRAPHY; RETICULAR PSEUDODRUSEN; BRUCHS MEMBRANE;
   AGING EYE; PREVALENCE; EDEMA; RETINA; MACULOPATHY; PATHOLOGY; ADHESION
AB Purpose: To investigate by spectral-domain optical coherence tomography (SD-OCT) changes of photoreceptor layers over drusen in cases of dry type age-related macular degeneration associated with vitreomacular traction (VMT).
   Methods: Clinical examination, fluorescein angiography, fundus photography, and SD-OCT data were retrospectively studied for a consecutive series of 27 patients with drusen, pseudodrusen, and VMT. Control groups of 32 patients with VMT without drusen and 34 patients with drusen and pseudodrusen without VMT were also studied.
   Results: The examination revealed disruption of the line corresponding to the inner segment ellipsoid (ISel), previously called inner segment/ outer segment junction, of photoreceptor layer, and development of cystoid edema in significantly higher incidence in VMT associated with drusen group. 22 out of 32 eyes with VMT and drusen (68.75%) had disrupted ISel, compared to 8 out of 37 (21.6%) control eyes with drusen only and to 12 out of 37 (32.4%) control eyes with VMT only. Chi-square analysis showed significant association between drusen and pseudodrusen on fovea, VMT, and localization of ISel disruption. The changes of the ISel were mainly found in the area that corresponded to VMT. The SD-OCT revealed drusen throughout the macula and discontinuation of ISel only in the fovea in 4 of 32 (12.5%) eyes with VMT, whereas none of 37 control eyes with drusen only had similar appearance.
   Conclusions: The drusen in association with the cystoid macular edema induced by vitreous traction contribute to the photoreceptor layer defect overlying drusen in the fovea. In addition, the number of drusen and pseudodrusen was increased in the area of the vitreous traction compared to the peripheral retina.
C1 [Theodossiadis, Panagiotis G.; Theodoropoulou, Sofia; Stamatiou, Polixeni] Univ Athens, Attikon Univ Hosp, Dept Ophthalmol 2, Athens, Greece.
   [Datseris, Ioannis] Ophthalm Inst, Athens, Greece.
   [Theodossiadis, George P.] Henry Dunant Hosp, Dept Ophthalmol 2, Athens 11526, Greece.
C3 National & Kapodistrian University of Athens; University Hospital
   Attikon; Henry Dunant Hospital
RP Theodossiadis, GP (通讯作者)，Henry Dunant Hosp, Dept Ophthalmol 2, 107 Mesogion Av, Athens 11526, Greece.
EM theodossiadisg@ath.forthnet.gr
OI Theodoropoulou, Sofia/0000-0003-3038-5354
CR Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P354, DOI 10.1136/bjo.2006.101022
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Curcio CA, 1998, INVEST OPHTH VIS SCI, V39, P1085
   FISHER SK, 2001, RETINA, V3, P1961
   Funatsu H, 2003, AM J OPHTHALMOL, V135, P321, DOI 10.1016/S0002-9394(02)01971-2
   Gallemore RP, 2000, RETINA-J RET VIT DIS, V20, P115, DOI 10.1097/00006982-200003000-00001
   Green W R, 1999, Mol Vis, V5, P27
   Ito Y, 2000, RETINA-J RET VIT DIS, V20, P403, DOI 10.1097/00006982-200004000-00016
   Johnson Mark W, 2005, Trans Am Ophthalmol Soc, V103, P537
   Johnson MW, 2005, AM J OPHTHALMOL, V140, P184, DOI 10.1016/j.ajo.2005.01.033
   Johnson PT, 2005, INVEST OPHTH VIS SCI, V46, P4788, DOI 10.1167/iovs.05-0767
   Johnson PT, 2003, INVEST OPHTH VIS SCI, V44, P4481, DOI 10.1167/iovs.03-0436
   Kishi S, 1996, AM J OPHTHALMOL, V122, P622, DOI 10.1016/S0002-9394(14)70480-5
   Klein R, 2006, AM J OPHTHALMOL, V142, P539, DOI 10.1016/j.ajo.2006.06.015
   Krebs I, 2007, AM J OPHTHALMOL, V144, P741, DOI 10.1016/j.ajo.2007.07.024
   la Cour M, 2002, DRUG AGING, V19, P101, DOI 10.2165/00002512-200219020-00003
   LAMBERT HM, 1992, AM J OPHTHALMOL, V113, P257, DOI 10.1016/S0002-9394(14)71576-4
   Linsenmeier RA, 2000, INVEST OPHTH VIS SCI, V41, P3117
   Meyer CH, 2007, OPHTHALMOLOGICA, V221, P118, DOI 10.1159/000098257
   Meyer CH, 2001, GRAEF ARCH CLIN EXP, V239, P325, DOI 10.1007/s004170100259
   MIMOUN G, 1990, J FR OPHTALMOL, V13, P511
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Mojana F, 2008, AM J OPHTHALMOL, V146, P218, DOI 10.1016/j.ajo.2008.04.027
   NASRALLAH FP, 1988, OPHTHALMOLOGY, V95, P1335
   Ondes F, 2000, JPN J OPHTHALMOL, V44, P91, DOI 10.1016/S0021-5155(99)00174-4
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   Sarks SH, 1999, BRIT J OPHTHALMOL, V83, P358, DOI 10.1136/bjo.83.3.358
   Schulze S, 2008, ACTA OPHTHALMOL, V86, P470, DOI 10.1111/j.1755-3768.2008.01210.x
   Schuman SG, 2009, OPHTHALMOLOGY, V116, P488, DOI 10.1016/j.ophtha.2008.10.006
   SMIDDY WE, 1990, RETINA-J RET VIT DIS, V10, P288, DOI 10.1097/00006982-199010000-00012
   Spaide RF, 1999, RETINA-J RET VIT DIS, V19, P141, DOI 10.1097/00006982-199902000-00010
   Spaide RF, 2012, RETINA S2, V32, pS190
   Spaide Richard F, 2012, Retina, V32 Suppl 2, pS187, DOI 10.1097/IAE.0b013e31825befb6
   Spaide RF, 2011, RETINA-J RET VIT DIS, V31, P1609, DOI 10.1097/IAE.0b013e3182247535
   Stefansson E, 2009, GRAEF ARCH CLIN EXP, V247, P147, DOI 10.1007/s00417-008-0980-7
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
NR 39
TC 4
Z9 4
U1 0
U2 5
PU WICHTIG PUBLISHING
PI MILAN
PA 72/74 VIA FRIULI, 20135 MILAN, ITALY
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD JUL-AUG
PY 2014
VL 24
IS 4
BP 582
EP 592
DI 10.5301/ejo.5000412
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AY3FT
UT WOS:000347470700018
PM 24338584
DA 2022-11-30
ER

PT J
AU Henschel, A
   Spital, G
   Lommatzsch, A
   Pauleikhoff, D
AF Henschel, Andreas
   Spital, Georg
   Lommatzsch, Albrecht
   Pauleikhoff, Daniel
TI Optical coherence tomography in neovascular age-related macular
   degeneration compared to fluorescein angiography and visual acuity
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
CT 104th Annual Meeting of the Deutsche-Ophthalmologische-Gesellschaft
CY SEP 21-24, 2006
CL Berlin, GERMANY
SP Deutsch Ophthalmol Gesell
DE AMD; Fluorescein angiography; Monitoring; OCT; PDT
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; INDOCYANINE GREEN ANGIOGRAPHY;
   PHOTODYNAMIC THERAPY; VERTEPORFIN
AB PURPOSE. To assess the sensitivity and specificity of optical coherence tomography (OCT) for monitoring patients with choroidal neovascularization (CNV) after photodynamic therapy (PDT) in comparison to fluorescein angiography (FA).
   METHODS. Prospective study of 14 patients with CNV secondary to age-related macular degeneration receiving PDT. Best-corrected visual acuity (BCVA), fluorescein angiography, and OCT (Zeiss Stratus OCT3) were performed before and at 2, 6, 12, and 24 weeks after treatment. FA images were assessed for leakage and presence of subretinal or intraretinal fluid was assessed on OCT images. Retinal thickness was measured automatically. OCT sensitivity and specificity levels for detecting leaking CNV were calculated. Retinal thickness was correlated with visual acuity.
   RESULTS. Mean follow-up time was 14.1 weeks. Sixty-one OCT/FA examinations were analyzed. Thirty-one examinations presented leakage (51%). OCT showed intraretinal fluid in 46 (75%) and subretinal fluid in 30 cases (49%). In 49 cases (80%), either intraretinal or subretinal fluid was present. Sensitivity for detecting intraretinal fluid in OCT was 90% (specificity 40%) and 71% (specificity 73%) for subretinal fluid. Combined sensitivity for intraretinal or subretinal fluid was 97% (specificity 37%). Increased central foveal thickness correlated with decreased BCVA. Correlations were significant (p<0.05).
   CONCLUSIONS. OCT showed good sensitivity in detecting active CNV. Specificity was only moderate. Central foveal thickness correlated negatively with visual acuity. Owing to different aspects of active CNV shown by FA and OCT, OCT should be combined with other examinations, and may not substitute FA for indication/reindication of PDT but can be a valuable addition in difficult cases. (Eur J Ophthalmol 2009; 19: 831-5)
C1 [Henschel, Andreas; Spital, Georg; Lommatzsch, Albrecht; Pauleikhoff, Daniel] St Franziskus Hosp, Dept Ophthalmol, Munster, Germany.
C3 St. Franziskus-Hospital
RP Henschel, A (通讯作者)，Hohenzollernring 74, D-48145 Munster, Germany.
EM henscha@arcor.de
CR [Anonymous], 1999, ARCH OPHTHALMOL, V117, P1329
   Arias L, 2008, GRAEF ARCH CLIN EXP, V246, P245, DOI 10.1007/s00417-007-0642-1
   Barbazetto I, 2003, ARCH OPHTHALMOL-CHIC, V121, P1253
   Costa RA, 2003, RETINA-J RET VIT DIS, V23, P159, DOI 10.1097/00006982-200304000-00004
   Costa RA, 2004, INVEST OPHTH VIS SCI, V45, P2399, DOI 10.1167/iovs.04-0155
   Hee MR, 1996, OPHTHALMOLOGY, V103, P1260, DOI 10.1016/S0161-6420(96)30512-5
   HEE MR, 1995, ARCH OPHTHALMOL-CHIC, V113, P325, DOI 10.1001/archopht.1995.01100030081025
   Kozak I, 2008, RETINA-J RET VIT DIS, V28, P538, DOI 10.1097/IAE.0b013e318167270b
   PULIAFITO CA, 1995, OPHTHALMOLOGY, V102, P217
   Rogers AH, 2002, AM J OPHTHALMOL, V134, P566, DOI 10.1016/S0002-9394(02)01566-0
   Salinas-Alaman A, 2005, AM J OPHTHALMOL, V140, P23, DOI 10.1016/j.ajo.2005.01.044
   Sandhu SS, 2005, BRIT J OPHTHALMOL, V89, P967, DOI 10.1136/bjo.2004.060863
   Talks J, 2007, BRIT J OPHTHALMOL, V91, P600, DOI 10.1136/bjo.2006.108043
   Tran THC, 2008, BRIT J OPHTHALMOL, V92, P922, DOI 10.1136/bjo.2007.136846
NR 14
TC 7
Z9 7
U1 0
U2 3
PU WICHTIG EDITORE
PI MILAN
PA 72/74 VIA FRIULI, 20135 MILAN, ITALY
SN 1120-6721
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD SEP-OCT
PY 2009
VL 19
IS 5
BP 831
EP 835
DI 10.1177/112067210901900523
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 520LF
UT WOS:000271845100022
PM 19787605
DA 2022-11-30
ER

PT J
AU Wang, IK
   Lin, HJ
   Wan, L
   Lin, CL
   Yen, TH
   Sung, FC
AF Wang, I-Kuan
   Lin, Hui-Ju
   Wan, Lei
   Lin, Cheng-Li
   Yen, Tzung-Hai
   Sung, Fung-Chang
TI RISK OF AGE-RELATED MACULAR DEGENERATION IN END-STAGE RENAL DISEASE
   PATIENTS RECEIVING LONG-TERM DIALYSIS
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE end-stage renal disease; hemodialysis; age-related macular degeneration;
   peritoneal dialysis
ID CHRONIC KIDNEY-DISEASE; DENSE DEPOSIT DISEASE; HEMODIALYSIS-PATIENTS;
   EYE DISEASES; COMPLEMENT; GLOMERULONEPHRITIS; ASSOCIATION; MACULOPATHY;
   PROGRESSION; PREVALENCE
AB Purpose:This study investigated the risk of age-related macular degeneration (AMD) in patients with end-stage renal disease (ESRD) receiving long-term dialysis and compared the risk between various dialysis modalities using propensity score-matching methods.Methods:From the National Health Insurance Research Database of Taiwan, the authors identified 27,232 patients with ESRD newly diagnosed from 2000 to 2010, including 9,287 patients on peritoneal dialysis (PD) and 17,945 patients on hemodialysis (HD). A total of 108,928 controls without kidney disease were randomly selected and frequency matched by age, sex, and index year of ESRD patients. The authors established an additional HD cohort matched by propensity scores of PD patients (N = 9,256 each). All cohorts were followed up until the end of 2011 to measure the incidence of AMD.Results:The incidences of AMD were 1.84, 4.03, 5.37, and 3.50 per 1,000 person-years in the control, ESRD (PD and HD), PD, and HD cohorts, respectively. The hazard ratios for AMD were 1.72, 2.47, and 1.43 for the ESRD, PD, and HD cohorts, with 95% confidence intervals of 1.50 to 1.97, 2.05 to 2.98, and 1.22 to 1.68, respectively, compared with the control cohort. The patients on PD exhibited a hazard ratio of 1.74 (95% confidence interval = 1.27-2.38) for developing AMD compared with propensity score-matched patients on HD.Conclusion:Patients with ESRD may exhibit a higher risk of AMD than people without kidney disease. Patients on PD may be more likely to develop AMD than patients on HD.
C1 [Wang, I-Kuan; Lin, Cheng-Li; Sung, Fung-Chang] China Med Univ, Grad Inst Clin Med Sci, Taichung, Taiwan.
   [Wang, I-Kuan] China Med Univ, Dept Internal Med, Coll Med, Taichung, Taiwan.
   [Wang, I-Kuan] China Med Univ Hosp, Div Nephrol, Taichung, Taiwan.
   [Lin, Hui-Ju] China Med Univ Hosp, Div Ophthalmol, Taichung, Taiwan.
   [Wan, Lei] China Med Univ, Sch Chinese Med, Taichung, Taiwan.
   [Lin, Cheng-Li; Sung, Fung-Chang] China Med Univ Hosp, Management Off Hlth Data, Taichung, Taiwan.
   [Yen, Tzung-Hai] Chang Gung Mem Hosp, Div Nephrol, Taipei, Taiwan.
   [Yen, Tzung-Hai] Chang Gung Univ Coll Med, Taoyuan, Taiwan.
   [Sung, Fung-Chang] China Med Univ Coll Publ Hlth, Dept Hlth Serv Adm, Taichung, Taiwan.
C3 China Medical University Taiwan; China Medical University Taiwan; China
   Medical University Taiwan; China Medical University Hospital - Taiwan;
   China Medical University Taiwan; China Medical University Hospital -
   Taiwan; China Medical University Taiwan; China Medical University
   Taiwan; China Medical University Hospital - Taiwan; Chang Gung Memorial
   Hospital; Chang Gung University
RP Sung, FC (通讯作者)，China Med Univ, Grad Inst Clin Med Sci, Taichung, Taiwan.
EM fcsung1008@yahoo.com
RI Yen, Tzung-Hai/AAQ-4525-2020
OI Yen, Tzung-Hai/0000-0002-0907-1505
FU National Science Council, Executive Yuan, Taiwan [NSC
   100-2621-M-039-001]; research laboratory of pediatrics, Children's
   Hospital of China Medical University [DMR-103-130]; China Medical
   University Hospital [DMR-101-016, DMR-103-013, DMR-104-015]; Taiwan
   Ministry of Health and Welfare Clinical Trial, and Research Center of
   Excellence [MOHW104-TDU-B-212-113002]
FX Supported by the National Science Council, Executive Yuan, Taiwan (grant
   number NSC 100-2621-M-039-001), the research laboratory of pediatrics,
   Children's Hospital of China Medical University (grant number
   DMR-103-130), China Medical University Hospital (grant numbers
   DMR-101-016, DMR-103-013, and DMR-104-015), and Taiwan Ministry of
   Health and Welfare Clinical Trial, and Research Center of Excellence
   (grant number MOHW104-TDU-B-212-113002).
CR Abrera-Abeleda MA, 2006, J MED GENET, V43, P582, DOI 10.1136/jmg.2005.038315
   Appel GB, 2005, J AM SOC NEPHROL, V16, P1392, DOI 10.1681/ASN.2005010078
   Bourne RRA, 2013, LANCET GLOB HEALTH, V1, pE339, DOI 10.1016/S2214-109X(13)70113-X
   Cong RH, 2008, ANN EPIDEMIOL, V18, P647, DOI 10.1016/j.annepidem.2008.04.002
   Enia G, 2001, NEPHROL DIAL TRANSPL, V16, P1459, DOI 10.1093/ndt/16.7.1459
   Friedman E, 2000, AM J OPHTHALMOL, V130, P658, DOI 10.1016/S0002-9394(00)00643-7
   Hallan SI, 2006, BMJ-BRIT MED J, V333, P1047, DOI 10.1136/bmj.39001.657755.BE
   Izzedine H, 2003, J AM SOC NEPHROL, V14, P516, DOI 10.1097/01.ASN.0000051705.97966.AD
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Johnson DW, 2007, NEPHROLOGY, V12, P391, DOI 10.1111/j.1440-1797.2007.00804.x
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2009, ARCH OPHTHALMOL-CHIC, V127, P193, DOI 10.1001/archophthalmol.2008.551
   Liew G, 2008, J AM SOC NEPHROL, V19, P806, DOI 10.1681/ASN.2007080844
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Nitsch D, 2009, OPHTHAL EPIDEMIOL, V16, P181, DOI 10.1080/09286580902863064
   Oberg BP, 2004, KIDNEY INT, V65, P1009, DOI 10.1111/j.1523-1755.2004.00465.x
   RAMBAUSEK M, 1987, SEMIN NEPHROL, V7, P370
   Schmidt Silke, 2002, Ophthalmic Genet, V23, P209, DOI 10.1076/opge.23.4.209.13883
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   Stein JD, 2011, INVEST OPHTH VIS SCI, V52, P6842, DOI 10.1167/iovs.11-7179
   Stenvinkel P, 2013, AM J KIDNEY DIS, V62, P339, DOI 10.1053/j.ajkd.2012.11.051
   van Biesen W, 2013, NEPHROL DIAL TRANSPL, V28, P2620, DOI 10.1093/ndt/gft296
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
   Weiner DE, 2011, NEPHROL DIAL TRANSPL, V26, P3159, DOI 10.1093/ndt/gfr022
   Wong CW, 2014, KIDNEY INT, V85, P1290, DOI 10.1038/ki.2013.491
   Yamagata K, 2007, KIDNEY INT, V71, P159, DOI 10.1038/sj.ki.5002017
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Zipfel PF, 2006, MOL IMMUNOL, V43, P97, DOI 10.1016/j.molimm.2005.06.015
NR 31
TC 11
Z9 11
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD OCT
PY 2016
VL 36
IS 10
BP 1866
EP 1873
DI 10.1097/IAE.0000000000001011
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DZ6US
UT WOS:000385998600020
PM 26966867
DA 2022-11-30
ER

PT J
AU Schmitz-Valckenberg, S
   Brinkmann, CK
   Alten, F
   Herrmann, P
   Stratmann, NK
   Gobel, AP
   Fleckenstein, M
   Diller, M
   Jaffe, GJ
   Holz, FG
AF Schmitz-Valckenberg, Steffen
   Brinkmann, Christian K.
   Alten, Florian
   Herrmann, Philipp
   Stratmann, Nina K.
   Goebel, Arno P.
   Fleckenstein, Monika
   Diller, Martin
   Jaffe, Glenn J.
   Holz, Frank G.
TI Semiautomated Image Processing Method for Identification and
   Quantification of Geographic Atrophy in Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; OPTICAL COHERENCE TOMOGRAPHY; FUNDUS
   AUTOFLUORESCENCE; PROGRESSION; DISEASE; AREA; EYE
AB PURPOSE. To determine intraobserver and interobserver longitudinal measurement variability of novel semiautomated software for quantification of age-related macular degeneration-associated geographic atrophy (GA) based on confocal scanning laser ophthalmoscopy fundus autofluorescence (FAF) imaging.
   METHODS. Three-field FAF (excitation 488 nm, emission 500-700 nm), near-infrared reflectance (820 nm), and blue reflectance (488 nm) images of 30 GA subjects were recorded according to a standardized protocol at baseline after 6 and 12 months. At all visits, the GA area was analyzed on central FAF images by seven independent readers using semiautomated software. The software allows direct export of FAF images from the database and semiautomated detection of atrophic areas by shadow correction, vessel detection, and selection of seed points.
   RESULTS. The mean size of atrophy at baseline and the mean progression rate were 5.96 mm(2) (range, 1.80-15.87) and 1.25 mm(2)/year (0.42-2.93), respectively. Mean difference of interobserver agreement (Bland-Altman statistics) ranged from -0.25 to 0.30 mm(2) for the baseline visit and from -0.14 to 0.11 mm(2)/year for the atrophy progression rate. Corresponding reflectance images were helpful for lesion boundary discrimination, particularly for evaluation of foveal GA involvement and when image quality was poor.
   CONCLUSIONS. The new image processing software offers an accurate, reproducible, and time-efficient identification and quantification of outer retinal atrophy and its progression over time. It facilitates measurements both in natural history studies and in interventional trials to evaluate new pharmacologic agents designed to limit GA enlargement. (Invest Ophthalmol Vis Sci. 2011;52:7640-7646) DOI:10.1167/iovs.11-7457
C1 [Schmitz-Valckenberg, Steffen; Brinkmann, Christian K.; Alten, Florian; Herrmann, Philipp; Stratmann, Nina K.; Goebel, Arno P.; Fleckenstein, Monika; Holz, Frank G.] Univ Bonn, Dept Ophthalmol, D-53127 Bonn, Germany.
   [Schmitz-Valckenberg, Steffen; Brinkmann, Christian K.; Alten, Florian; Herrmann, Philipp; Stratmann, Nina K.; Goebel, Arno P.; Fleckenstein, Monika; Holz, Frank G.] Univ Bonn, GRADE Reading Ctr, D-53127 Bonn, Germany.
   [Diller, Martin] Heidelberg Engn GmbH, Heidelberg, Germany.
   [Jaffe, Glenn J.] Duke Univ, Ctr Eye, Dept Ophthalmol, Durham, NC 27710 USA.
   [Jaffe, Glenn J.] Duke Reading Ctr, Durham, NC USA.
C3 University of Bonn; University of Bonn; Duke University
RP Schmitz-Valckenberg, S (通讯作者)，Univ Bonn, Dept Ophthalmol, Ernst Abbe Str 2, D-53127 Bonn, Germany.
EM steffen.schmitz-valckenberg@ukb.uni-bonn.de
OI Fleckenstein, Monika/0000-0001-8321-8037
CR Baumann B, 2010, J BIOMED OPT, V15, DOI 10.1117/1.3499420
   BLAIR CJ, 1975, ARCH OPHTHALMOL-CHIC, V93, P19, DOI 10.1001/archopht.1975.01010020023003
   BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8
   Deckert A, 2005, BMC Ophthalmol, V5, P8, DOI 10.1186/1471-2415-5-8
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   Douglas IJ, 2007, OPHTHALMOLOGY, V114, P1164, DOI 10.1016/j.ophtha.2006.09.018
   Fleckenstein M, 2009, INVEST OPHTH VIS SCI, V51, P637
   Fleckenstein M, 2010, INVEST OPHTH VIS SCI, V51, P3846, DOI 10.1167/iovs.09-4533
   Gass J.D., 1967, AM J OPHTHALMOL, V63, P1
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Klein ML, 2010, OPHTHALMOLOGY, V117, P1554, DOI 10.1016/j.ophtha.2009.12.012
   Klein R, ARCH OPHTHALMOL, V129, P75
   Klein R, 2006, AM J OPHTHALMOL, V142, P539, DOI 10.1016/j.ajo.2006.06.015
   Lindblad AS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1168, DOI 10.1001/archophthalmol.2009.198
   MAGUIRE P, 1986, AM J OPHTHALMOL, V102, P621, DOI 10.1016/0002-9394(86)90535-0
   Pirbhai A, 2005, AM J OPHTHALMOL, V139, P455, DOI 10.1016/j.ajo.2004.09.077
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   SCHATZ H, 1989, OPHTHALMOLOGY, V96, P1541
   Schmitz-Valckenberg S, 2002, GRAEF ARCH CLIN EXP, V240, P73, DOI 10.1007/s00417-001-0413-3
   Schmitz-Valckenberg S, 2008, RETINA-J RET VIT DIS, V28, P385, DOI 10.1097/IAE.0b013e318164a907
   Schmitz-Valckenberg S, 2006, INVEST OPHTH VIS SCI, V47, P2648, DOI 10.1167/iovs.05-0892
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P1, DOI 10.1167/iovs.10-5619
   Scholl HPN, 2004, OPHTHALMOLOGY, V111, P125, DOI 10.1016/j.ophtha.2003.05.003
   Sunness JS, 2007, OPHTHALMOLOGY, V114, P271, DOI 10.1016/j.ophtha.2006.09.016
   Sunness JS, 1999, MOL VIS, V5
   Sunness JS, 1999, INVEST OPHTH VIS SCI, V40, P1761
   VONRUCKMANN A, 1995, BRIT J OPHTHALMOL, V79, P407, DOI 10.1136/bjo.79.5.407
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P679, DOI 10.1016/j.ophtha.2010.08.018
NR 30
TC 127
Z9 128
U1 2
U2 5
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD SEP
PY 2011
VL 52
IS 10
BP 7640
EP 7646
DI 10.1167/iovs.11-7457
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 827YU
UT WOS:000295467200078
PM 21873669
DA 2022-11-30
ER

PT J
AU Mettu, PS
   Wielgus, AR
   Ong, SS
   Cousins, SW
AF Mettu, Priyatham S.
   Wielgus, Albert R.
   Ong, Sally S.
   Cousins, Scott W.
TI Retinal pigment epithelium response to oxidant injury in the
   pathogenesis of early age-related macular degeneration
SO MOLECULAR ASPECTS OF MEDICINE
LA English
DT Review
DE Age-related macular degeneration; Retinal pigment epithelium; Oxidative
   injury; Drusen; Extracellular matrix; Macrophage
ID BASAL LAMINAR DEPOSIT; HEAT-SHOCK-PROTEIN; ANGIOTENSIN-II RECEPTORS;
   EXTRACELLULAR-MATRIX TURNOVER; INDUCED-OXIDATIVE STRESS; FACTOR-H
   POLYMORPHISM; CHOROIDAL BLOOD-FLOW; ALPHA-LINOLENIC ACID; SUB-RPE
   DEPOSITS; HIGH-FAT DIET
AB Age-related macular degeneration (AMD) represents the leading cause of vision loss in the elderly. Accumulation of lipid- and protein-rich deposits under the retinal pigment epithelium (RPE) heralds the onset of early AMD, but the pathogenesis of subretinal deposit formation is poorly understood. Numerous hypothetical models of deposit formation have been proposed, including hypotheses for a genetic basis, choroidal hypoperfusion, abnormal barrier formation, and lysosomal failure. This review explore the RPE injury hypothesis, characterized by three distinct stages (1) Initial RPE oxidant injury, caused by any number of endogenous or exogenous oxidants, results in extrusion of cell membrane "blebs," together with decreased activity of matrix metalloproteinases (MMPs), promoting bleb accumulation under the RPE as basal laminar deposits (BLD). (2) RPE cells are subsequently stimulated to increase synthesis of MMPs and other molecules responsible for extracellular matrix turnover (i.e., producing decreased collagen), affecting both RPE basement membrane and Bruchs membrane (BrM). This process leads to progression of BLD into basal linear deposits (BLinD) and drusen by admixture of blebs into BrM, followed by the formation of new basement membrane under the RPE to trap these deposits within BrM. We postulate that various hormones and other plasma-derived molecules related to systemic health cofactors are implicated in this second stage. (3) Finally, macrophages are recruited to sites of RPE injury and deposit formation. The recruitment of nonactivated or scavenging macrophages may remove deposits without further injury, while the recruitment of activated or reparative macrophages, through the release of inflammatory mediators, growth factors, or other substances, may promote complications and progression to the late forms of the disease. (C) 2012 Elsevier Ltd. All rights reserved.
C1 [Cousins, Scott W.] Duke Eye Ctr, Duke Ctr Macular Dis, Durham, NC 27710 USA.
   Duke Univ, Sch Med, Dept Immunol, Durham, NC 27710 USA.
C3 Duke University; Duke University
RP Cousins, SW (通讯作者)，Duke Eye Ctr, Duke Ctr Macular Dis, POB 3802,2351 Erwin Rd, Durham, NC 27710 USA.
EM scott.cousins@duke.edu
OI Ong, Sally/0000-0003-3599-9021
CR Abdelsalam A, 1999, SURV OPHTHALMOL, V44, P1, DOI 10.1016/S0039-6257(99)00072-7
   Alcazar O, 2007, INVEST OPHTH VIS SCI, V48, P5662, DOI 10.1167/iovs.07-0392
   Alcazar O, 2009, MOL CELL PROTEOMICS, V8, P2201, DOI 10.1074/mcp.M900203-MCP200
   ALEXANDER JP, 1990, INVEST OPHTH VIS SCI, V31, P2520
   ALLISON A C, 1974, P419
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   ASHWOODSMITH MJ, 1988, HUM REPROD, V3, P795, DOI 10.1093/oxfordjournals.humrep.a136785
   Atkinson SJ, 2001, FEBS LETT, V491, P222, DOI 10.1016/S0014-5793(01)02204-9
   Aumailley M, 1998, J MOL MED-JMM, V76, P253, DOI 10.1007/s001090050215
   BAZAN NG, 1992, ADV EXP MED BIOL, V318, P295
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Belkhiri A, 1997, LAB INVEST, V77, P533
   Berenberg TL, 2012, RETINA-J RET VIT DIS, V32, P25, DOI 10.1097/IAE.0b013e3182150483
   Bermann M, 2001, EXP EYE RES, V72, P191
   Bertram KM, 2009, AM J PHYSIOL-CELL PH, V297, pC1200, DOI 10.1152/ajpcell.00126.2009
   BEZARD J, 1994, REPROD NUTR DEV, V34, P539, DOI 10.1051/rnd:19940603
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Blokhina O, 2003, ANN BOT-LONDON, V91, P179, DOI 10.1093/aob/mcf118
   Bolton JL, 2000, CHEM RES TOXICOL, V13, P135, DOI 10.1021/tx9902082
   Boulton M, 2004, GRAEF ARCH CLIN EXP, V242, P76, DOI 10.1007/s00417-003-0812-8
   Boulton M, 2001, EYE, V15, P384, DOI 10.1038/eye.2001.141
   BRECHLER V, 1994, RECEPTOR CHANNEL, V2, P79
   BRUNK UT, 1995, FREE RADICAL BIO MED, V19, P813, DOI 10.1016/0891-5849(95)02001-Q
   Brunk UT, 2002, FREE RADICAL BIO MED, V33, P611, DOI 10.1016/S0891-5849(02)00959-0
   Burdge GC, 2006, PROSTAG LEUKOTR ESS, V75, P161, DOI 10.1016/j.plefa.2006.05.013
   Burdge GC, 2005, REPROD NUTR DEV, V45, P581, DOI 10.1051/rnd:2005047
   Burns R P, 1980, Trans Am Ophthalmol Soc, V78, P206
   Cano M, 2010, VISION RES, V50, P652, DOI 10.1016/j.visres.2009.08.018
   Chen W P, 1999, Zhonghua Yi Xue Za Zhi (Taipei), V62, P657
   Cherepanoff S, 2010, BRIT J OPHTHALMOL, V94, P918, DOI 10.1136/bjo.2009.165563
   Chi ZL, 2010, ADV EXP MED BIOL, V703, P127, DOI 10.1007/978-1-4419-5635-4_9
   Chisolm GM, 1999, J BIOL CHEM, V274, P25959, DOI 10.1074/jbc.274.37.25959
   Chiu SJ, 2012, INVEST OPHTH VIS SCI, V53, P53, DOI 10.1167/iovs.11-7640
   Chiu T, 2003, AM J PHYSIOL-GASTR L, V285, pG1, DOI 10.1152/ajpgi.00419.2002
   Christen WG, 2011, ARCH OPHTHALMOL-CHIC, V129, P921, DOI 10.1001/archophthalmol.2011.34
   Chung Mina, 2002, Ophthalmol Clin North Am, V15, P459, DOI 10.1016/S0896-1549(02)00045-7
   Concannon CG, 2003, APOPTOSIS, V8, P61, DOI 10.1023/A:1021601103096
   Constantin B, 1998, J CELL SCI, V111, P1695
   Cousins SW, 2004, ARCH OPHTHALMOL-CHIC, V122, P1013, DOI 10.1001/archopht.122.7.1013
   Cousins SW, 2003, INVEST OPHTH VIS SCI, V44, pU381
   Cousins SW, 2002, AGE-RELATED MACULAR DEGENERATION, P27
   Cousins SW, 2003, INVEST OPHTH VIS SCI, V44, P1221, DOI 10.1167/iovs.02-0285
   Cousins SW, 2002, EXP EYE RES, V75, P543, DOI 10.1006/exer.2002.2047
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   CRIBIER S, 1993, PROSTAG LEUKOTR ESS, V48, P27, DOI 10.1016/0952-3278(93)90006-I
   Curcio CA, 2000, INVEST OPHTH VIS SCI, V41, P2015
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   Curcio CA, 2010, J LIPID RES, V51, P451, DOI 10.1194/jlr.R002238
   Curcio CA, 2009, PROG RETIN EYE RES, V28, P393, DOI 10.1016/j.preteyeres.2009.08.001
   Dalle-Donne I, 2001, FREE RADICAL BIO MED, V31, P1624, DOI 10.1016/S0891-5849(01)00749-3
   DAY DA, 1995, J BIOENERG BIOMEMBR, V27, P379, DOI 10.1007/BF02110000
   de Lanerolle Primal, 2002, Sci STKE, V2002, ppe30
   Decanini A, 2007, AM J OPHTHALMOL, V143, P607, DOI 10.1016/j.ajo.2006.12.006
   Delogu Giovanna, 2002, Curr Opin Crit Care, V8, P411, DOI 10.1097/00075198-200210000-00007
   Deryugina EI, 1998, CANCER RES, V58, P3743
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Ding JD, 2011, P NATL ACAD SCI USA, V108, pE279, DOI 10.1073/pnas.1100901108
   Dinh DT, 2001, CLIN SCI, V100, P481, DOI 10.1042/CS20000263
   Dithmar S, 2001, ARCH OPHTHALMOL-CHIC, V119, P1643, DOI 10.1001/archopht.119.11.1643
   DOWNEY GP, 1994, CURR OPIN IMMUNOL, V6, P113, DOI 10.1016/0952-7915(94)90042-6
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Eichler W, 2002, INVEST OPHTH VIS SCI, V43, P2767
   Elliot S, 2006, INVEST OPHTH VIS SCI, V47, P1696, DOI 10.1167/iovs.05-1258
   Elliot S, 2008, EXP EYE RES, V86, P653, DOI 10.1016/j.exer.2008.01.010
   Elliot SJ, 2010, EXP EYE RES, V90, P10, DOI 10.1016/j.exer.2009.09.001
   Espinosa-Heidmann DG, 2006, INVEST OPHTH VIS SCI, V47, P729, DOI 10.1167/iovs.05-0719
   Espinosa-Heidmann DG, 2005, EXP EYE RES, V80, P413, DOI 10.1016/j.exer.2004.10.008
   Espinosa-Heidmann DG, 2004, INVEST OPHTH VIS SCI, V45, P260, DOI 10.1167/iovs.03-0910
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P3586, DOI 10.1167/iovs.03-0038
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P4914, DOI 10.1167/iovs.03-0371
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   FEENEYBURNS L, 1987, INVEST OPHTH VIS SCI, V28, P1138
   Felbor U, 1997, ARCH OPHTHALMOL-CHIC, V115, P1569, DOI 10.1001/archopht.1997.01100160739011
   Fillmore HL, 1999, CANCER LETT, V141, P9, DOI 10.1016/S0304-3835(99)00053-1
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Finnemann SC, 2002, P NATL ACAD SCI USA, V99, P3842, DOI 10.1073/pnas.052025899
   FLORENCE TM, 1995, AUST NZ J OPHTHALMOL, V23, P3, DOI 10.1111/j.1442-9071.1995.tb01638.x
   Ganea E, 2001, CURR PROTEIN PEPT SC, V2, P205, DOI 10.2174/1389203013381107
   Gao Xiang-Dong, 2003, ScientificWorldJournal, V3, P1359
   Garbe TR, 2000, ARCH MICROBIOL, V173, P78, DOI 10.1007/s002030050012
   Gass J D, 1972, Trans Am Ophthalmol Soc, V70, P409
   Gerthoffer WT, 2001, J APPL PHYSIOL, V91, P963, DOI 10.1152/jappl.2001.91.2.963
   Gorin MB, 1999, MOL VIS, V5, pU31
   Green W R, 1999, Mol Vis, V5, P27
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Gregori G, 2011, OPHTHALMOLOGY, V118, P1373, DOI 10.1016/j.ophtha.2010.11.013
   GRIENDLING KK, 1994, CIRC RES, V74, P1141, DOI 10.1161/01.RES.74.6.1141
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   Grossniklaus HE, 2000, ARCH OPHTHALMOL-CHIC, V118, P625
   Grunwald J., 1995, AGE RELATED MACULAR, P167
   Grunwald JE, 1998, ARCH OPHTHALMOL-CHIC, V116, P150
   Grunwald JE, 1998, INVEST OPHTH VIS SCI, V39, P385
   Gubin AN, 1997, BIOCHEM BIOPH RES CO, V236, P347, DOI 10.1006/bbrc.1997.6963
   Guymer R, 1999, PROG RETIN EYE RES, V18, P59, DOI 10.1016/S1350-9462(98)00012-3
   Ha HJ, 2000, KIDNEY INT, V58, pS19, DOI 10.1046/j.1523-1755.2000.07704.x
   Hageman GS, 1999, MOL VIS, V5
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   HAGEMAN GS, 1995, INVEST OPHTH VIS SCI, V36, pS432
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hagmann J, 1999, J CELL BIOCHEM, V73, P488, DOI 10.1002/(SICI)1097-4644(19990615)73:4<488::AID-JCB7>3.0.CO;2-P
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   HALLIWELL B, 1993, BRIT MED J, V307, P885, DOI 10.1136/bmj.307.6909.885
   Halliwell B, 1996, ANNU REV NUTR, V16, P33, DOI 10.1146/annurev.nu.16.070196.000341
   Hamdi HK, 2003, FRONT BIOSCI-LANDMRK, V8, pE305, DOI 10.2741/1019
   Hammond CJ, 2002, OPHTHALMOLOGY, V109, P730, DOI 10.1016/S0161-6420(01)01049-1
   HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O
   HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8
   Hannken T, 1998, KIDNEY INT, V54, P1923, DOI 10.1046/j.1523-1755.1998.00212.x
   Haslbeck M, 2002, CELL MOL LIFE SCI, V59, P1649, DOI 10.1007/PL00012492
   Heitzer T, 1999, KIDNEY INT, V55, P252, DOI 10.1046/j.1523-1755.1999.00229.x
   Henson P M, 1976, Front Biol, V45, P99
   HEWITT AT, 1989, INVEST OPHTH VIS SCI, V30, P478
   HINSHAW DB, 1986, AM J PATHOL, V123, P454
   Hinton DR, 1998, ARCH OPHTHALMOL-CHIC, V116, P203
   Hirai Y, 2001, LIFE SCI, V68, P913, DOI 10.1016/S0024-3205(00)00998-X
   Hirokawa Nobutaka, 1993, Current Opinion in Neurobiology, V3, P724, DOI 10.1016/0959-4388(93)90144-N
   Hiscott P, 1999, PROG RETIN EYE RES, V18, P167, DOI 10.1016/S1350-9462(98)00024-X
   Hollar M.W., 2011, INVEST OPHTHALMOL, V52, P945
   Hollyfield JG, 2003, ADV EXP MED BIOL, V533, P83
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Hollyfield JG, 2010, INVEST OPHTH VIS SCI, V51, P1276, DOI 10.1167/iovs.09-4478
   Hughes AD, 1998, J HUM HYPERTENS, V12, P275, DOI 10.1038/sj.jhh.1000635
   HULBERT PB, 1983, BIOCHEM BIOPH RES CO, V117, P129, DOI 10.1016/0006-291X(83)91550-4
   Huot J, 1998, J CELL BIOL, V143, P1361, DOI 10.1083/jcb.143.5.1361
   Hyman Leslie, 2002, Curr Opin Ophthalmol, V13, P171
   Imamura Y, 2006, P NATL ACAD SCI USA, V103, P11282, DOI 10.1073/pnas.0602131103
   INAGAMI T, 1994, J HYPERTENS, V12, pS83
   Inagami T, 1999, J AM SOC NEPHROL, V10, pS57
   Inatani M, 2002, PROG RETIN EYE RES, V21, P429, DOI 10.1016/S1350-9462(02)00009-5
   ISHIBASHI T, 1986, INVEST OPHTH VIS SCI, V27, P184
   ISHIBASHI T, 1986, AM J OPHTHALMOL, V101, P342, DOI 10.1016/0002-9394(86)90830-5
   Iwai K, 2003, J BIOCHEM, V134, P175, DOI 10.1093/jb/mvg127
   Jacot TA, 1996, LAB INVEST, V75, P791
   Jaimes EA, 1998, KIDNEY INT, V54, P775, DOI 10.1046/j.1523-1755.1998.00068.x
   Jia LH, 2007, INVEST OPHTH VIS SCI, V48, P339, DOI 10.1167/iovs.06-0248
   Jonas JB, 2003, GRAEF ARCH CLIN EXP, V241, P125, DOI 10.1007/s00417-002-0615-3
   Justilien V, 2007, INVEST OPHTH VIS SCI, V48, P4407, DOI 10.1167/iovs.07-0432
   Kaemmerer E, 2007, INVEST OPHTH VIS SCI, V48, P1342, DOI 10.1167/iovs.06-0549
   Kaibuchi K, 1999, ANNU REV BIOCHEM, V68, P459, DOI 10.1146/annurev.biochem.68.1.459
   Katsuda Shogo, 2003, J Atheroscler Thromb, V10, P267
   Khan Safdar Ali, 1995, Natural Toxins, V3, P119, DOI 10.1002/nt.2620030302
   Khanifar AA, 2008, OPHTHALMOLOGY, V115, P1883, DOI 10.1016/j.ophtha.2008.04.041
   KILLINGSWORTH MC, 1990, EYE, V4, P613, DOI 10.1038/eye.1990.86
   Kinnula VL, 1998, AM J RESP CELL MOL, V19, P445, DOI 10.1165/ajrcmb.19.3.2884
   Klaver CCW, 2003, DEV OPHTHALMOL, V37, P155
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1026, DOI 10.1016/j.ophtha.2007.08.030
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Kliffen M, 1997, MICROSC RES TECHNIQ, V36, P106, DOI 10.1002/(SICI)1097-0029(19970115)36:2<106::AID-JEMT4>3.0.CO;2-N
   Krohne TU, 2010, EXP EYE RES, V90, P465, DOI 10.1016/j.exer.2009.12.011
   Krohne TU, 2010, EXP EYE RES, V90, P261, DOI 10.1016/j.exer.2009.10.014
   Kuzuya Masafumi, 2003, J Atheroscler Thromb, V10, P275
   la Cour M, 2002, DRUG AGING, V19, P101, DOI 10.2165/00002512-200219020-00003
   Lakkaraju A, 2007, P NATL ACAD SCI USA, V104, P11026, DOI 10.1073/pnas.0702504104
   Lamb LE, 2004, PHOTOCHEM PHOTOBIOL, V79, P127, DOI 10.1562/0031-8655(2004)079<0127:AACOOL>2.0.CO;2
   Landry J, 1995, BIOCHEM CELL BIOL, V73, P703, DOI 10.1139/o95-078
   Lanzetti L, 2001, EXP CELL RES, V271, P45, DOI 10.1006/excr.2001.5369
   Lee HB, 2003, J AM SOC NEPHROL, V14, pS241, DOI 10.1097/01.ASN.0000077410.66390.0F
   Lei J, 1998, AM J PHYSIOL-RENAL, V274, pF252, DOI 10.1152/ajprenal.1998.274.2.F252
   Lenaz G, 1998, BBA-BIOENERGETICS, V1364, P207, DOI 10.1016/S0005-2728(98)00028-0
   Li YH, 2000, J BIOL CHEM, V275, P17187, DOI 10.1074/jbc.M005301200
   LOPEZ PF, 1991, AM J OPHTHALMOL, V112, P647, DOI 10.1016/S0002-9394(14)77270-8
   LOWE DG, 1987, CELL, V48, P137, DOI 10.1016/0092-8674(87)90364-3
   Luft FC, 1999, HYPERTENSION, V33, P212, DOI 10.1161/01.HYP.33.1.212
   Lutty G., 1999, CHANGES CHORIOCAPILL
   MACHLIN LJ, 1987, FASEB J, V1, P441, DOI 10.1096/fasebj.1.6.3315807
   Malek G, 2005, P NATL ACAD SCI USA, V102, P11900, DOI 10.1073/pnas.0503015102
   MALORNI W, 1992, ANN NY ACAD SCI, V663, P218, DOI 10.1111/j.1749-6632.1992.tb38666.x
   MALORNI W, 1994, J PHOTOCH PHOTOBIO B, V26, P265, DOI 10.1016/1011-1344(94)85002-X
   MALORNI W, 1991, CHEM-BIOL INTERACT, V80, P217, DOI 10.1016/0009-2797(91)90026-4
   Marin-Castano M.E., 2004, INVEST OPHTHALMOL, V45, P1811
   Marin-Castano ME, 2006, INVEST OPHTH VIS SCI, V47, P4098, DOI 10.1167/iovs.05-1230
   Marin-Castano ME, 2005, INVEST OPHTH VIS SCI, V46, P3331, DOI 10.1167/iovs.04-1224
   Marin-Castano ME, 2003, INVEST OPHTH VIS SCI, V44, P50, DOI 10.1167/iovs.01-1276
   Martin JL, 1999, GENE EXPRESSION, V7, P349
   Martin JL, 1997, CIRCULATION, V96, P4343
   Mattana J, 1999, FREE RADICAL BIO MED, V27, P315, DOI 10.1016/S0891-5849(99)00048-9
   McCarty CA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1455
   MEHLEN P, 1995, J CELL BIOCHEM, V58, P248, DOI 10.1002/jcb.240580213
   Merle B, 2011, INVEST OPHTH VIS SCI, V52, P6004, DOI 10.1167/iovs.11-7254
   MICELI MV, 1994, EXP CELL RES, V214, P242, DOI 10.1006/excr.1994.1254
   Milzani A, 1997, ARCH BIOCHEM BIOPHYS, V339, P267, DOI 10.1006/abbi.1996.9847
   Misawa M, 2002, INT J ONCOL, V21, P1087
   Monroy D, 2001, INVEST OPHTH VIS SCI, V42, pS758
   MOORE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1290
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Mullins RF, 2007, EXP EYE RES, V84, P378, DOI 10.1016/j.exer.2006.09.021
   Musarella Maria A., 2001, Documenta Ophthalmologica, V102, P165, DOI 10.1023/A:1017510515893
   Nelson KC, 1999, INVEST OPHTH VIS SCI, V40, P1927
   Nelson KC, 2002, INVEST OPHTH VIS SCI, V43, P3550
   NIKI E, 1993, ANN NY ACAD SCI, V686, P29, DOI 10.1111/j.1749-6632.1993.tb39150.x
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Oh H, 1999, INVEST OPHTH VIS SCI, V40, P1891
   Ohbayashi H, 2002, CURR PROTEIN PEPT SC, V3, P409, DOI 10.2174/1389203023380549
   Okamoto K, 2002, APOPTOSIS, V7, P77, DOI 10.1023/A:1013569029907
   Oliver J M, 1979, Symp Soc Exp Biol, V33, P277
   Osborn M.P., 2011, AM J OPHTHALMOLOGY
   Padgett LC, 1997, EXP EYE RES, V64, P927, DOI 10.1006/exer.1997.0287
   Parthasarathy Sampath, 1994, Current Opinion in Lipidology, V5, P371, DOI 10.1097/00041433-199410000-00009
   PENFOLD P, 1984, AUST J OPHTHALMOL, V12, P23
   PENFOLD PL, 1985, GRAEF ARCH CLIN EXP, V223, P69, DOI 10.1007/BF02150948
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   PETEN EP, 1992, AM J PHYSIOL, V263, pF951, DOI 10.1152/ajprenal.1992.263.5.F951
   Pons M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016722
   Potier M, 2001, J AM SOC NEPHROL, V12, P241, DOI 10.1681/ASN.V122241
   Praddaude F, 2009, EXP EYE RES, V89, P109, DOI 10.1016/j.exer.2009.02.020
   Preville X, 1998, J CELL BIOCHEM, V69, P436, DOI 10.1002/(SICI)1097-4644(19980615)69:4<436::AID-JCB5>3.3.CO;2-H
   Pryor WA, 1997, ENVIRON HEALTH PERSP, V105, P875, DOI 10.2307/3433297
   Pueyo ME, 1997, GEN PHARMACOL-VASC S, V29, P691, DOI 10.1016/S0306-3623(97)00021-9
   PUISTOLA U, 1995, FERTIL STERIL, V64, P81, DOI 10.1016/S0015-0282(16)57659-6
   PUTTING BJ, 1993, GRAEF ARCH CLIN EXP, V231, P600, DOI 10.1007/BF00936526
   Rao A, 2000, HIPPOCAMPUS, V10, P527, DOI 10.1002/1098-1063(2000)10:5<527::AID-HIPO3>3.0.CO;2-B
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Rhinehart K, 2003, AM J PHYSIOL-HEART C, V284, pH779, DOI 10.1152/ajpheart.00317.2002
   RIES C, 1995, BIOL CHEM H-S, V376, P345
   Rodriguez OC, 2003, NAT CELL BIOL, V5, P599, DOI 10.1038/ncb0703-599
   Rozanowska M, 1997, PHOTOCHEM PHOTOBIOL, V65, P472, DOI 10.1111/j.1751-1097.1997.tb08593.x
   ROZANOWSKA M, 1995, J BIOL CHEM, V270, P18825, DOI 10.1074/jbc.270.32.18825
   SanGiovanni JP, 2008, ARCH OPHTHALMOL-CHIC, V126, P1274, DOI 10.1001/archopht.126.9.1274
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671
   Sarks SH, 1999, BRIT J OPHTHALMOL, V83, P358, DOI 10.1136/bjo.83.3.358
   Sarks S, 2007, INVEST OPHTH VIS SCI, V48, P968, DOI 10.1167/iovs.06-0443
   SATO T, 1991, BIOCHEM J, V275, P645, DOI 10.1042/bj2750645
   Sawitzke J, 2011, OPHTHALMOLOGY, V118, P2442, DOI 10.1016/j.ophtha.2011.05.027
   Schlanitz FG, 2011, INVEST OPHTH VIS SCI, V52, P4571, DOI 10.1167/iovs.10-6846
   Schneider GB, 1998, J CELL PHYSIOL, V177, P575, DOI 10.1002/(SICI)1097-4652(199812)177:4<575::AID-JCP8>3.3.CO;2-T
   Schroen DJ, 1996, GENE EXPRESSION, V6, P197
   Sheridan C, 2004, GRAEF ARCH CLIN EXP, V242, P68, DOI 10.1007/s00417-003-0800-z
   Silbiger S, 1999, KIDNEY INT, V55, P1268, DOI 10.1046/j.1523-1755.1999.00376.x
   Simopoulos AP, 2006, BIOMED PHARMACOTHER, V60, P502, DOI 10.1016/j.biopha.2006.07.080
   Sivakumaran TA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025598
   Smith W, 1996, ARCH OPHTHALMOL-CHIC, V114, P1518, DOI 10.1001/archopht.1996.01100140716016
   Smoyer WE, 2002, FASEB J, V16, DOI 10.1096/fj.01-0681com
   St-Pierre Yves, 2003, Current Drug Targets - Inflammation and Allergy, V2, P206, DOI 10.2174/1568010033484133
   Starita C, 1997, INVEST OPHTH VIS SCI, V38, P762
   Starita C, 1996, EXP EYE RES, V62, P565, DOI 10.1006/exer.1996.0066
   Stohs S J, 1995, J Basic Clin Physiol Pharmacol, V6, P205
   STOKOE D, 1992, FEBS LETT, V313, P307, DOI 10.1016/0014-5793(92)81216-9
   Stone EM, 2004, NEW ENGL J MED, V351, P346, DOI 10.1056/NEJMoa040833
   Strauss O, 1998, ACTA ANAT, V162, P101
   Striker GE, 2008, AM J PHYSIOL-CELL PH, V295, pC1633, DOI 10.1152/ajpcell.00092.2008
   Strunnikova N, 2004, INVEST OPHTH VIS SCI, V45, P3767, DOI 10.1167/iovs.04-0311
   Strunnikova N, 2001, INVEST OPHTH VIS SCI, V42, P2130
   Suner IJ, 2004, INVEST OPHTH VIS SCI, V45, pU723
   Suner IJ, 2004, INVEST OPHTH VIS SCI, V45, P311, DOI 10.1167/iovs.03-0733
   TATE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1271
   Tate DJ, 2002, CURR EYE RES, V24, P12, DOI 10.1076/ceyr.24.1.12.5426
   Tauchi T, 2002, CLIN CANCER RES, V8, P3341
   Taunton J, 2001, CURR OPIN CELL BIOL, V13, P85, DOI 10.1016/S0955-0674(00)00178-2
   Terman A, 2004, INT J BIOCHEM CELL B, V36, P1400, DOI 10.1016/j.biocel.2003.08.009
   Tezel G, 2000, ARCH OPHTHALMOL-CHIC, V118, P511, DOI 10.1001/archopht.118.4.511
   Troutbeck R, 2012, CLIN EXP OPHTHALMOL, V40, P18, DOI 10.1111/j.1442-9071.2011.02581.x
   Tuo JS, 2004, PROG RETIN EYE RES, V23, P229, DOI 10.1016/j.preteyeres.2004.02.001
   Uchiki T, 2012, AGING CELL, V11, P1, DOI 10.1111/j.1474-9726.2011.00752.x
   Ungar A, 2000, PROSTAG OTH LIPID M, V62, P117, DOI 10.1016/S0090-6980(00)00077-0
   Ursini F, 2002, TRENDS MOL MED, V8, P370, DOI 10.1016/S1471-4914(02)02382-1
   Valentijn K, 1999, BIOCHEM BIOPH RES CO, V266, P652, DOI 10.1006/bbrc.1999.1883
   VANDERSCHAFT TL, 1992, OPHTHALMOLOGY, V99, P278
   VANDERSCHAFT TL, 1993, GRAEF ARCH CLIN EXP, V231, P470, DOI 10.1007/BF02044234
   VANDERSCHAFT TL, 1994, GRAEF ARCH CLIN EXP, V232, P40, DOI 10.1007/BF00176436
   Wang AL, 2009, AUTOPHAGY, V5, P563, DOI 10.4161/auto.5.4.8163
   Wang AL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004160
   Wang JJ, 2003, ARCH OPHTHALMOL-CHIC, V121, P658, DOI 10.1001/archopht.121.5.658
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   Weed SA, 2001, ONCOGENE, V20, P6418, DOI 10.1038/sj.onc.1204783
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   Wheeler-Schilling TH, 1999, EUR J NEUROSCI, V11, P3387, DOI 10.1046/j.1460-9568.1999.00787.x
   Wielgus AR, 2010, INVEST OPHTH VIS SCI, V51
   Wielgus A.R., 2011, INVEST OPHTHALMOL, V52, P2309
   Wilhelm J, 1990, Acta Univ Carol Med Monogr, V137, P1
   Winkler B S, 1999, Mol Vis, V5, P32
   WINSTON GW, 1993, ARCH BIOCHEM BIOPHYS, V304, P371, DOI 10.1006/abbi.1993.1364
   Wu YL, 2010, P NATL ACAD SCI USA, V107, P7275, DOI 10.1073/pnas.0913112107
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yoshida A, 2000, JPN J OPHTHALMOL, V44, P290, DOI 10.1016/S0021-5155(99)00227-0
   YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1016/0039-6257(87)90115-9
   Zack DJ, 1999, MOL VIS, V5, pU37
   Zarbin MA, 1998, EUR J OPHTHALMOL, V8, P199, DOI 10.1177/112067219800800401
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zhang CX, 2003, J CELL SCI, V116, P1915, DOI 10.1242/jcs.00390
   Zhao ZY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019456
   Zhou JL, 2006, P NATL ACAD SCI USA, V103, P16182, DOI 10.1073/pnas.0604255103
   ZHU ZR, 1988, CURR EYE RES, V7, P581, DOI 10.3109/02713688809031814
   Zhuge Y, 2001, J BIOL CHEM, V276, P16248, DOI 10.1074/jbc.M010190200
NR 287
TC 77
Z9 80
U1 0
U2 14
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0098-2997
EI 1872-9452
J9 MOL ASPECTS MED
JI Mol. Asp. Med.
PD AUG
PY 2012
VL 33
IS 4
SI SI
BP 376
EP 398
DI 10.1016/j.mam.2012.04.006
PG 23
WC Biochemistry & Molecular Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Research & Experimental Medicine
GA 983WR
UT WOS:000307149900004
PM 22575354
DA 2022-11-30
ER

PT J
AU Augustin, AJ
   Schmidt-Erfurth, U
AF Augustin, AJ
   Schmidt-Erfurth, U
TI Verteporfin and intravitreal triamcinolone acetonide combination therapy
   for occult choroidal neovascularization in age-related macular
   degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID PHOTODYNAMIC THERAPY; EDEMA; EXPRESSION; INJECTION; SAFETY; RECURRENCE
AB PURPOSE: To evaluate the efficacy and safety of photodynamic therapy (PDT) with verteporfin combined with intravitreal triamcinolone (IVTA) in occult choroidal neovascularization (CNV) secondary to age,related macular degeneration (AMD).
   DESIGN: Single center, nonrandomized interventional case series.
   METHODS: A prospective, noncomparative, interventional case series of 41 eyes of 41 patients with a two-year follow-up period. Verteporfin PDT was performed using the recommended standard procedure for approved forms of AMD. A solution containing 25 mg of crystalline triamcinolone acetonide was injected intravitreally 16 hours post PDT. The procedure was repeated after three months in case of persistent CNV leakage.
   RESULTS: The mean number of treatments needed was 1.8. Thirty-four eyes (82.9%) required one retreatment at three months. No additional retreatments were necessary. Visual acuity improved gradually in most of the patients with mean values of 20/133 and 20/115 at baseline and three months; 20/101 and 20/84 at six and twelve months; and 20/83 and 20/81 at eighteen and twenty-four months. Eleven of 41 treated study eyes (26.8%) underwent cataract surgery between six and fifteen months after the first treatment. Nine patients required local or systemic glaucoma therapy because of a transient steroid induced intraocular pressure increase.
   CONCLUSIONS: Verteporfin PDT combined with intravitreal triamcinolone may improve the outcome of standard verteporfin PDT in the treatment of occult CNV secondary to AMD. An improvement in visual acuity was observed in most of the treated patients and was maintained during a two-year follow-up period. Retreatment numbers were lower than expected from monotherapy trials.
C1 Univ Vienna, Dept Ophthalmol, Vienna, Austria.
   Klinikum Karlsruhe, Dept Ophthalmol, Karlsruhe, Germany.
C3 University of Vienna; Municipal Hospital Karlsruhe
RP Schmidt-Erfurth, U (通讯作者)，Med Univ Vienna, Dept Ophthalmol, Waehringer Guertel 18-20, A-1090 Vienna, Austria.
EM ursula.schmidt-erfurth@meduniwien.ac.at
OI Augustin, Prof. Dr. Albert J./0000-0003-1591-0536
CR Antcliff RJ, 2001, OPHTHALMOLOGY, V108, P765, DOI 10.1016/S0161-6420(00)00658-8
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Azab M, 2004, RETINA-J RET VIT DIS, V24, P1
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Challa JK, 1998, AUST NZ J OPHTHALMOL, V26, P277, DOI 10.1111/j.1442-9071.1998.tb01330.x
   Ciulla TA, 2001, ARCH OPHTHALMOL-CHIC, V119, P399, DOI 10.1001/archopht.119.3.399
   Danis RP, 2000, RETINA-J RET VIT DIS, V20, P244, DOI 10.1097/00006982-200003000-00004
   Gillies MC, 2003, ARCH OPHTHALMOL-CHIC, V121, P667, DOI 10.1001/archopht.121.5.667
   Gillies MC, 2004, ARCH OPHTHALMOL-CHIC, V122, P336, DOI 10.1001/archopht.122.3.336
   Gollnick SO, 2003, BRIT J CANCER, V88, P1772, DOI 10.1038/sj.bjc.6600864
   Greenberg PB, 2002, BRIT J OPHTHALMOL, V86, P247, DOI 10.1136/bjo.86.2.247
   HIDA T, 1986, AM J OPHTHALMOL, V101, P190, DOI 10.1016/0002-9394(86)90593-3
   Holladay JT, 1997, J REFRACT SURG, V13, P388
   Ip MS, 2002, ARCH OPHTHALMOL-CHIC, V120, P1217
   Jonas JB, 2003, BRIT J OPHTHALMOL, V87, P24, DOI 10.1136/bjo.87.1.24
   Jonas JB, 2003, BRIT J OPHTHALMOL, V87, P462, DOI 10.1136/bjo.87.4.462
   Jonas JB, 2002, GRAEF ARCH CLIN EXP, V240, P872, DOI 10.1007/s00417-002-0547-y
   Jonas JB, 2001, AM J OPHTHALMOL, V131, P468, DOI 10.1016/S0002-9394(00)00882-5
   Kent D, 2003, MOL VIS, V9, P747
   Martidis A, 2002, OPHTHALMOLOGY, V109, P920, DOI 10.1016/S0161-6420(02)00975-2
   Moshfeghi DM, 2003, AM J OPHTHALMOL, V136, P791, DOI 10.1016/S0002-9394(03)00483-5
   Penfold PL, 1995, AUST NZ J OPHTHALMOL, V23, P293, DOI 10.1111/j.1442-9071.1995.tb00179.x
   Penfold PL, 2000, CLIN EXP IMMUNOL, V121, P458, DOI 10.1046/j.1365-2249.2000.01316.x
   Penfold PL, 2002, BRIT J OPHTHALMOL, V86, P600, DOI 10.1136/bjo.86.6.600
   Penfold PL, 2001, CLIN EXP OPHTHALMOL, V29, P188, DOI 10.1046/j.1442-9071.2001.00407.x
   Peyman GA, 2004, RETINA-J RET VIT DIS, V24, P488, DOI 10.1097/00006982-200406000-00032
   Ranson NT, 2002, BRIT J OPHTHALMOL, V86, P527, DOI 10.1136/bjo.86.5.527
   Rechtman E, 2004, BRIT J OPHTHALMOL, V88, P344, DOI 10.1136/bjo.2003.027177
   Schmidt-Erfurth U, 2002, ARCH OPHTHALMOL-CHIC, V120, P835
   Schmidt-Erfurth U, 2003, INVEST OPHTH VIS SCI, V44, P4473, DOI 10.1167/iovs.02-1115
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P1517, DOI 10.1016/S0161-6420(03)00544-X
   Walter P, 1999, CELL MOL NEUROBIOL, V19, P87, DOI 10.1023/A:1006968608825
   Wingate RJB, 1999, AUST NZ J OPHTHALMOL, V27, P431
   WORMALD R, 2004, COCHRANE LIB
   Young S, 2001, CLIN EXP OPHTHALMOL, V29, P2, DOI 10.1046/j.1442-9071.2001.00360.x
NR 37
TC 77
Z9 88
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD APR
PY 2006
VL 141
IS 4
BP 638
EP 645
DI 10.1016/j.ajo.2005.11.058
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 030GG
UT WOS:000236621800005
PM 16564797
DA 2022-11-30
ER

PT J
AU Rudnicka, AR
   Kapetanakis, VV
   Jarrar, Z
   Wathern, AK
   Wormald, R
   Fletcher, AE
   Cook, DG
   Owen, CG
AF Rudnicka, Alicja R.
   Kapetanakis, Venediktos V.
   Jarrar, Zakariya
   Wathern, Andrea K.
   Wormald, Richard
   Fletcher, Astrid E.
   Cook, Derek G.
   Owen, Christopher G.
TI Incidence of Late-Stage Age-Related Macular Degeneration in American
   Whites: Systematic Review and Meta-analysis
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
ID BLUE MOUNTAINS EYE; OPEN-ANGLE GLAUCOMA; 5-YEAR INCIDENCE; VISUAL
   IMPAIRMENT; RISK-FACTORS; 10-YEAR INCIDENCE; UNITED-KINGDOM; GRADING
   SYSTEM; FOLLOW-UP; MACULOPATHY
AB PURPOSE: To estimate incidence of age-related macular degeneration (AMD) by subtype in American whites aged >= 50 years.
   DESIGN: Systematic review and meta-analysis.
   METHODS: SETTING: Prospective cohort studies of AMD incidence in populations of white European ancestry published in MEDLINE, EMBASE, and Web of Science.
   STUDY POPULATION: Fourteen publications in 10 populations that examined AMD incident cases were identified.
   OBSERVATION PROCEDURE: Data on age-sex-specific incidence of late AMD, geographic atrophy (GA) and neovascular AMD (NVAMD), year of recruitment, AMD grading method, and continent were extracted.
   MAIN OUTCOME MEASURE(S): Annual incidence of late AMD, GA, and NVAMD by age-sex in American whites aged >= 50 years from a Bayesian meta-analysis of incidence studies was compared with incidence extrapolated from published prevalence estimates.
   RESULTS: Incidence rates from the review agreed with those derived from prevalence, but the latter were based on more data, especially at older ages and by AMD subtypes. Annual incidence (estimated from prevalence) of late AMD in American whites was 3.5 per 1000 aged >= 50 years (95% credible interval 2.5, 4.7 per 1000), equivalent to 293 000 new cases in American whites per year (95% credible interval 207 000, 400 000). Incidence rates approximately quadrupled per decade in age. Annual incidence GA rates were 1.9 per 1000 aged >= 50 years, NVAMD rates were 1.8 per 1000. Late AMD incidence was 38% higher in women vs men (95% credible interval 6%, 82%).
   CONCLUSIONS: Estimating AMD incidence from prevalence allows better characterization at older ages and by AMD subtype where longitudinal data from incidence studies are limited. (C) 2015 The Authors. Published by Elsevier Inc.
C1 [Rudnicka, Alicja R.; Kapetanakis, Venediktos V.; Jarrar, Zakariya; Wathern, Andrea K.; Cook, Derek G.; Owen, Christopher G.] Univ London, Populat Hlth Res Inst, London SW17 ORE, England.
   [Wormald, Richard; Fletcher, Astrid E.] London Sch Hyg & Trop Med, London WC1, England.
   [Wormald, Richard] Moorfields Eye Hosp, NIHR Biomed Res Ctr Ophthalmol, London, England.
C3 University of London; University of London; London School of Hygiene &
   Tropical Medicine; University of London; University College London;
   Moorfields Eye Hospital NHS Foundation Trust
RP Rudnicka, AR (通讯作者)，Univ London, Populat Hlth Res Inst, Cranmer Terrace, London SW17 ORE, England.
EM arudnick@sgul.ac.uk
RI Cook, Derek G/C-3271-2008
OI Cook, Derek/0000-0002-9723-5759; Rudnicka, Alicja R/0000-0003-0369-8574;
   Owen, Christopher/0000-0003-1135-5977
FU Macular Diseases Society
FX The work was supported by a grant from the Macular Diseases Society, and
   Commissioned on behalf of the United Kingdom Macular Interest Group of
   Vision 2020.
CR Appelros P, 2009, STROKE, V40, P1082, DOI 10.1161/STROKEAHA.108.540781
   Arias E., 2006, US LIFE TABLES 2006
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BRESSLER NM, 1995, ARCH OPHTHALMOL-CHIC, V113, P301, DOI 10.1001/archopht.1995.01100030055022
   Buch H, 2005, OPHTHALMOLOGY, V112, P787, DOI 10.1016/j.ophtha.2004.11.040
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chang MA, 2008, INVEST OPHTH VIS SCI, V49, P2395, DOI 10.1167/iovs.07-1584
   Coleman AL, 2010, AM J OPHTHALMOL, V149, P160, DOI 10.1016/j.ajo.2009.07.025
   Cugati S, 2007, ARCH OPHTHALMOL-CHIC, V125, P917, DOI 10.1001/archopht.125.7.917
   Delcourt C, 2005, AM J OPHTHALMOL, V140, P924, DOI 10.1016/j.ajo.2005.05.002
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Jonasson F, 2005, OPHTHALMOLOGY, V112, P132, DOI 10.1016/j.ophtha.2004.07.020
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Meads C, 2003, HEALTH TECHNOL ASSES, V7, p[v, 1], DOI [10.3310/hta7090, DOI 10.3310/hta7090]
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   Mukesh BN, 2004, OPHTHALMOLOGY, V111, P1176, DOI 10.1016/j.ophtha.2003.08.042
   Owen CG, 2003, BRIT J OPHTHALMOL, V87, P312, DOI 10.1136/bjo.87.3.312
   PODGOR MJ, 1983, AM J EPIDEMIOL, V118, P206, DOI 10.1093/oxfordjournals.aje.a113628
   Population Projections Branch USCB, US INT PROJ AG SEX R
   Rudnicka AR, 2006, INVEST OPHTH VIS SCI, V47, P4254, DOI 10.1167/iovs.06-0299
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   Sparrow JM, 1997, EYE, V11, P315, DOI 10.1038/eye.1997.67
   Thiagarajan M, 2005, ARCH OPHTHALMOL-CHIC, V123, P1397, DOI 10.1001/archopht.123.10.1397
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   van Leeuwen R, 2003, EUR J EPIDEMIOL, V18, P845, DOI 10.1023/A:1025643303914
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Wong TY, 2007, LANCET, V370, P204, DOI 10.1016/S0140-6736(07)61104-0
   Wong TY, 2010, STROKE, V41, P575, DOI 10.1161/STROKEAHA.109.574475
   Xu L, 2009, OPHTHALMOLOGY, V116, P732, DOI 10.1016/j.ophtha.2008.11.003
NR 37
TC 93
Z9 93
U1 1
U2 14
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JUL
PY 2015
VL 160
IS 1
BP 85
EP 93
DI 10.1016/j.ajo.2015.04.003
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CL4FS
UT WOS:000356908600011
PM 25857680
OA hybrid, Green Accepted
DA 2022-11-30
ER

PT J
AU Tisi, A
   Flati, V
   Delle Monache, S
   Lozzi, L
   Passacantando, M
   Maccarone, R
AF Tisi, Annamaria
   Flati, Vincenzo
   Delle Monache, Simona
   Lozzi, Luca
   Passacantando, Maurizio
   Maccarone, Rita
TI Nanoceria Particles Are an Eligible Candidate to Prevent Age-Related
   Macular Degeneration by Inhibiting Retinal Pigment Epithelium Cell Death
   and Autophagy Alterations
SO CELLS
LA English
DT Article
DE nanomedicine; nanoceria; retinal pigment epithelium; light damage;
   autophagy; atrophic AMD
ID CERIUM OXIDE NANOPARTICLES; PHOTORECEPTOR DEGENERATION; GEOGRAPHIC
   ATROPHY; OXIDATIVE STRESS; RPE CELLS; MICE; SUSCEPTIBILITY; PROTECTION;
   DAMAGE; EMT
AB Retinal pigment epithelium (RPE) dysfunction and degeneration underlie the development of age-related macular degeneration (AMD), which is the leading cause of blindness worldwide. In this study, we investigated whether cerium oxide nanoparticles (CeO2-NPs or nanoceria), which are anti-oxidant agents with auto-regenerative properties, are able to preserve the RPE. On ARPE-19 cells, we found that CeO2-NPs promoted cell viability against H2O2-induced cellular damage. For the in vivo studies, we used a rat model of acute light damage (LD), which mimics many features of AMD. CeO2-NPs intravitreally injected three days before LD prevented RPE cell death and degeneration and nanoceria labelled with fluorescein were found localized in the cytoplasm of RPE cells. CeO2-NPs inhibited epithelial-mesenchymal transition of RPE cells and modulated autophagy by the down-regulation of LC3B-II and p62. Moreover, the treatment inhibited nuclear localization of LC3B. Taken together, our study demonstrates that CeO2-NPs represent an eligible candidate to counteract RPE degeneration and, therefore, a powerful therapy for AMD.
C1 [Tisi, Annamaria; Flati, Vincenzo; Delle Monache, Simona; Maccarone, Rita] Univ Aquila, Dept Biotechnol & Appl Clin Sci, Via Vetoio,Coppito 2, I-67100 Laquila, Italy.
   [Lozzi, Luca; Passacantando, Maurizio] Univ Aquila, Dept Phys & Chem Sci, Via Vetoio,Coppito 1, I-67100 Laquila, Italy.
C3 University of L'Aquila; University of L'Aquila
RP Maccarone, R (通讯作者)，Univ Aquila, Dept Biotechnol & Appl Clin Sci, Via Vetoio,Coppito 2, I-67100 Laquila, Italy.
EM annamaria.tisi@graduate.univaq.it; vincenzo.flati@univaq.it;
   simona.dellemonache@univaq.it; luca.lozzi@univaq.it;
   maurizio.passacantando@univaq.it; rita.maccarone@univaq.it
RI Delle Monache, Simona/M-5618-2014; PASSACANTANDO, Maurizio/A-2122-2019;
   FLATI, VINCENZO/R-6231-2018
OI Delle Monache, Simona/0000-0002-8153-915X; Lozzi,
   Luca/0000-0002-0150-5727; MACCARONE, Rita/0000-0003-0648-3771;
   PASSACANTANDO, Maurizio/0000-0002-3680-5295; FLATI,
   VINCENZO/0000-0003-1014-297X
CR Ammar MJ, 2020, CURR OPIN OPHTHALMOL, V31, P215, DOI 10.1097/ICU.0000000000000657
   Ao Y., 2020, REV ENV CONTAM TOXIC, V210, P1
   Bandello Francesco, 2017, F1000Res, V6, P245, DOI 10.12688/f1000research.10664.1
   Blasiak J, 2020, CELL MOL LIFE SCI, V77, P789, DOI 10.1007/s00018-019-03420-x
   Cai X, 2016, MOL VIS, V22, P1176
   Cai X, 2012, BIOMATERIALS, V33, P8771, DOI 10.1016/j.biomaterials.2012.08.030
   Chen JP, 2006, NAT NANOTECHNOL, V1, P142, DOI 10.1038/nnano.2006.91
   Cunha-Vaz J, 2011, EUR J OPHTHALMOL, V21, pS3, DOI 10.5301/EJO.2010.6049
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   Defoe DM, 2007, MOL VIS, V13, P273
   Dou ZX, 2015, NATURE, V527, P105, DOI 10.1038/nature15548
   Ferguson TA, 2014, AUTOPHAGY, V10, P165, DOI 10.4161/auto.26735
   Fields MA, 2020, PROG RETIN EYE RES, V76, DOI 10.1016/j.preteyeres.2019.100803
   Fiorani L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140387
   Fleckenstein M, 2018, OPHTHALMOLOGY, V125, P369, DOI 10.1016/j.ophtha.2017.08.038
   Frost LS, 2014, EXP EYE RES, V124, P56, DOI 10.1016/j.exer.2014.04.010
   Ghosh S, 2018, INVEST OPHTH VIS SCI, V59, P104, DOI 10.1167/iovs.18-24132
   Grimm C, 2000, NAT GENET, V25, P63, DOI 10.1038/75614
   Guerra F, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00295
   Gugnoni M, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.415
   Hunter JJ, 2012, PROG RETIN EYE RES, V31, P28, DOI 10.1016/j.preteyeres.2011.11.001
   Jaadane I, 2017, J CELL MOL MED, V21, P3453, DOI 10.1111/jcmm.13255
   Kaarniranta K, 2020, PROG RETIN EYE RES, V79, DOI 10.1016/j.preteyeres.2020.100858
   Kaarniranta K, 2017, CELL BIOL TOXICOL, V33, P113, DOI 10.1007/s10565-016-9371-8
   Kaczara P, 2010, FREE RADICAL BIO MED, V48, P1064, DOI 10.1016/j.freeradbiomed.2010.01.022
   Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104
   Kasprowska-Liskiewicz D, 2017, POSTEP HIG MED DOSW, V71, P825, DOI 10.5604/01.3001.0010.4672
   Kimura K, 2015, J MOL MED, V93, P749, DOI 10.1007/s00109-015-1289-8
   Lei L, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18040728
   Lin W, 2019, OPHTHALMIC RES, V61, P65, DOI 10.1159/000487486
   Maccarone R, 2020, J OCUL PHARMACOL TH, V36, P376, DOI 10.1089/jop.2019.0105
   Maslim J, 1997, INVEST OPHTH VIS SCI, V38, P1667
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   Mitter SK, 2012, ADV EXP MED BIOL, V723, P83, DOI 10.1007/978-1-4614-0631-0_12
   Moreno ML, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.01008
   Naylor A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21010211
   Noell W K, 1966, Invest Ophthalmol, V5, P450
   Parzych KR, 2014, ANTIOXID REDOX SIGN, V20, P460, DOI 10.1089/ars.2013.5371
   Passacantando M, 2013, J NANOPART RES, V15, DOI 10.1007/s11051-013-1785-0
   Portioli C, 2013, NANOSCI NANOTECH LET, V5, P1174, DOI 10.1166/nnl.2013.1715
   Radeke MJ, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0183-x
   Ravanan P, 2017, LIFE SCI, V188, P53, DOI 10.1016/j.lfs.2017.08.029
   Rosales MAB, 2019, LIFE SCI ALLIANCE, V2, DOI [10.26508/lsa.201800212, 10.26508/lsa.201900436]
   Saenz-de-Viteri M, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/637137
   Schwertheim S, 2019, J PATHOL CLIN RES, V5, P164, DOI 10.1002/cjp2.129
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Telegina DV, 2017, SCI REP-UK, V7, DOI 10.1038/srep41533
   Tisi A, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-63449-y
   Tisi A, 2019, EXP EYE RES, V188, DOI 10.1016/j.exer.2019.107797
   Tisi A, 2019, EXP EYE RES, V182, P30, DOI 10.1016/j.exer.2019.03.003
   Wang SB, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/3632169
   Wong LL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058431
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   ZAJCPYTRUS HM, 2015, ADV CLIN EXP MED, V24, P1099
   Zanzottera EC, 2016, RETINA-J RET VIT DIS, V36, pS12, DOI 10.1097/IAE.0000000000001276
   Zhang TZ, 2014, BIOCHEM BIOPH RES CO, V450, P966, DOI 10.1016/j.bbrc.2014.06.082
   Zhao C, 2011, J CLIN INVEST, V121, P369, DOI 10.1172/JCI44303
   Zhao HL, 2019, INT J MOL MED, V43, P936, DOI 10.3892/ijmm.2018.4027
NR 59
TC 13
Z9 14
U1 4
U2 9
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2073-4409
J9 CELLS-BASEL
JI Cells
PD JUL
PY 2020
VL 9
IS 7
AR 1617
DI 10.3390/cells9071617
PG 17
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA MW6YN
UT WOS:000557179600001
PM 32635502
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Cackett, P
   Htoon, H
   Wong, D
   Yeo, I
AF Cackett, P.
   Htoon, H.
   Wong, D.
   Yeo, I.
TI Haemorrhagic pigment epithelial detachment as a predictive feature of
   polypoidal choroidal vasculopathy in a Chinese population
SO EYE
LA English
DT Article
DE serosanguineous maculopathy; polypoidal choroidal vasculopathy;
   choroidal neovascularization; Chinese ethnicity; indocyanine green
   angiography; haemorrhagic pigment epithelial detachment
ID MACULAR DEGENERATION
AB Purpose To determine the frequency of haemorrhagic pigment epithelial detachment (PED) among patients presenting with either polypoidal choroidal vasculopathy (PCV) or choroidal neovascularization (CNV) and calculate the degree to which the presence of a haemorrhagic PED can be used to predict the diagnosis of PCV.
   Methods A retrospective review of 290 eyes of 253 patients presenting to the Singapore National Eye Centre with serosanguineous maculopathy. Patients underwent ophthalmologic examination including digital colour fundus photography and stereoscopic fluorescein angiography and indocyanine green angiography (ICGA). Classification into PCV or CNV was based on ICGA findings, and presence or absence of haemorrhagic PED was documented.
   Results In total, 138 eyes of 123 patients were diagnosed with PCV and 152 eyes of 130 patients with CNV. A haemorrhagic PED was a significantly more common (P<0.001) presenting feature in PCV eyes (63, 45.7%) than CNV eyes (6, 3.9%) (odds ratio (OR) 20.4, 95% confidence interval (CI) 8.5-49.4). Age-related maculopathy was found significantly more frequently (P<0.001) in the unaffected fellow eye of CNV patients (57, 52.8%) than PCV patients (28, 22.8%) (OR 3.2, 95% CI 1.8-5.7).
   Conclusions In patients of Chinese ethnicity, a haemorrhagic PED is significantly more likely to be the presenting feature of PCV than CNV. Patients presenting with this clinical feature should make the clinician suspicious of an underlying diagnosis of PCV. Eye (2010) 24, 789-792; doi:10.1038/eye.2009.214; published online 11 September 2009
C1 [Cackett, P.; Wong, D.; Yeo, I.] Singapore Natl Eye Ctr, Vitreo Retina Serv, Singapore 168751, Singapore.
   [Cackett, P.; Htoon, H.; Yeo, I.] Singapore Eye Res Inst, Singapore, Singapore.
C3 Singapore National Eye Center; National University of Singapore;
   Singapore National Eye Center
RP Yeo, I (通讯作者)，Singapore Natl Eye Ctr, Vitreo Retina Serv, 11 3rd Hosp Ave, Singapore 168751, Singapore.
EM ian.yeo.y.s@snec.com.sg
OI Wong, Damon/0000-0003-4601-9121
FU Singhealth [SHF/FG381P/2007]
FX The authors acknowledge the assistance of Drs Ranjana Mathur, Jacob
   Cheng, Chui Ming Gemmy Cheung, Adrian Koh, Lee Shu Yen, Bobby Cheng,
   Edmund Wong, Yeo Kim Teck, Ronald Yeoh and Professors Ang Chong Lye and
   Ong Sze Guan who all contributed cases to this study. This study was
   supported by Singhealth Grant SHF/FG381P/2007.
CR Ahuja RM, 2000, BRIT J OPHTHALMOL, V84, P479, DOI 10.1136/bjo.84.5.479
   Ciardella Antonio P, 2002, Ophthalmol Clin North Am, V15, P537, DOI 10.1016/S0896-1549(02)00053-6
   DESTRO M, 1989, OPHTHALMOLOGY, V96, P846
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Kondo N, 2008, INVEST OPHTH VIS SCI, V49, P1101, DOI 10.1167/iovs.07-1145
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Scassellati-Sforzolini B, 2001, RETINA-J RET VIT DIS, V21, P121, DOI 10.1097/00006982-200104000-00004
   STERN RM, 1985, AM J OPHTHALMOL, V100, P560, DOI 10.1016/0002-9394(85)90682-8
   Tsujikawa A, 2007, AM J OPHTHALMOL, V143, P102, DOI 10.1016/j.ajo.2006.08.025
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
NR 16
TC 17
Z9 20
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD MAY
PY 2010
VL 24
IS 5
BP 789
EP 792
DI 10.1038/eye.2009.214
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 595EG
UT WOS:000277592900006
PM 19745836
OA Bronze
DA 2022-11-30
ER

PT J
AU Tan, RS
   Guymer, RH
   Aung, KZ
   Caruso, E
   Luu, CD
AF Tan, Rose S.
   Guymer, Robyn H.
   Aung, Khin-Zaw
   Caruso, Emily
   Luu, Chi D.
TI Longitudinal Assessment of Rod Function in Intermediate Age-Related
   Macular Degeneration With and Without Reticular Pseudodrusen
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE rod function; age-related macular degeneration; reticular pseudodrusen
ID SUBRETINAL DRUSENOID DEPOSITS; MEDIATED DARK-ADAPTATION; VISUAL
   FUNCTION; FELLOW-EYES; CLINICAL CHARACTERISTICS; RISK-FACTOR;
   ASSOCIATION; PREVALENCE
AB PURPOSE. To evaluate rod function longitudinally in intermediate age-related macular degeneration subjects with reticular pseudodrusen (RPD) and without RPD (AMD).
   METHODS. Retinal sensitivities (505 and 625 nm) during dark adaptation, at 14 locations within the central 12 degrees macula were obtained after photobleaching at baseline and 12-month visits. Pointwise sensitivity differences between both stimuli were used to assess static rod function, while rod intercept time (RIT) and rod recovery rate (RRR) were used to evaluate dynamic function. Changes in function over time were compared between groups.
   RESULTS. A total of 23 controls, 12 AMD, and 13 RPD cases were followed-up. At baseline, the RPD group had significantly worst static and dynamic rod function compared to AMD and control groups. Static function in AMD was similar to controls. Static and dynamic function across the central 12 degrees was consistent in controls; however, it was most impaired at 4 degrees compared to 12 degrees eccentricity in disease groups. Over 12 months, no AMD cases progressed clinically and static function in AMD improved (P <= 0.04), but remained unchanged in control and RPD groups (P >= 0.17). The RRR for control and RPD groups remained stable, while the AMD group deteriorated, but only at 12 degrees (P = 0.02). The RIT was stable in AMD (P = 0.75) and RPD (P = 0.71) groups but improved in the control group (P = 0.002).
   CONCLUSIONS. A decrease in RRR was detected over 12 months at 12 degrees eccentricity in the AMD group. Evaluating changes in rod function requires testing at multiple locations including the peripheral macula.
C1 [Tan, Rose S.; Guymer, Robyn H.; Aung, Khin-Zaw; Caruso, Emily; Luu, Chi D.] Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Melbourne, Vic, Australia.
   [Tan, Rose S.; Guymer, Robyn H.; Luu, Chi D.] Univ Melbourne, Ophthalmol, Dept Surg, Melbourne, Vic, Australia.
   [Tan, Rose S.] Trisakti Univ, Dept Ophthalmol, Jakarta, Indonesia.
C3 Centre for Eye Research Australia; Royal Victorian Eye & Ear Hospital;
   University of Melbourne; Universitas Trisakti
RP Luu, CD (通讯作者)，Ctr Eye Res Australia, Level 8,32 Gisborne St, East Melbourne, Vic 3002, Australia.
EM cluu@unimelb.edu.au
OI Rose, Rose/0000-0002-7351-2774
FU Ryan Initiative for Macular Research; Macular Disease Foundation
   Australia; Australia Awards Scholarship; National Health and Medical
   Research Council (NHMRC) [1103013]
FX Supported by Ryan Initiative for Macular Research, Macular Disease
   Foundation Australia, Australia Awards Scholarship (RST), National
   Health and Medical Research Council (NHMRC) Fellowship (#1103013, RHG).
   The Centre for Eye Research Australia (CERA) receives Operational
   Infrastructure Support from the Victorian Government.
CR ARNOLD JJ, 1995, RETINA-J RET VIT DIS, V15, P183, DOI 10.1097/00006982-199515030-00001
   Binns AM, 2018, INVEST OPHTH VIS SCI, V59
   Chen KG, 2018, OPHTHALMOLOGY, VS0161- S6420, P31121
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P354, DOI 10.1136/bjo.2006.101022
   Corvi F, 2019, RETINA-J RET VIT DIS, V39, P2378, DOI 10.1097/IAE.0000000000002335
   Curcio CA, 2000, INVEST OPHTH VIS SCI, V41, P2015
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   Dimitrov PN, 2008, INVEST OPHTH VIS SCI, V49, P55, DOI 10.1167/iovs.06-1048
   Dimitrov PN, 2012, INVEST OPHTH VIS SCI, V53, P5213, DOI 10.1167/iovs.11-8958
   Dimitrov PN, 2011, INVEST OPHTH VIS SCI, V52, P9457, DOI 10.1167/iovs.10-7043
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Finger RP, 2016, OPHTHALMOLOGY, V123, P599, DOI 10.1016/j.ophtha.2015.10.029
   Finger RP, 2014, OPHTHALMOLOGY, V121, P1252, DOI 10.1016/j.ophtha.2013.12.034
   Flamendorf J, 2015, OPHTHALMOLOGY, V122, P2053, DOI 10.1016/j.ophtha.2015.06.023
   Flynn OJ, 2018, INVEST OPHTH VIS SCI, V59, P2411, DOI 10.1167/iovs.17-22874
   Fraser RG, 2016, INVEST OPHTH VIS SCI, V57, P5436, DOI 10.1167/iovs.16-19295
   Gil JQ, 2016, EYE LOND, V31, P364
   Haimovici R, 2002, GRAEF ARCH CLIN EXP, V240, P90, DOI 10.1007/s00417-001-0417-z
   Hogg RE, 2014, OPHTHALMOLOGY, V121, P1748, DOI 10.1016/j.ophtha.2014.03.015
   Jackson GR, 2014, OPTOMETRY VISION SCI, V91, P925, DOI 10.1097/OPX.0000000000000247
   Jackson Gregory R, 2008, J Ocul Biol Dis Infor, V1, P7, DOI 10.1007/s12177-008-9002-6
   Kaszubski PA, 2017, INT OPHTHALMOL, V123, P1530
   Lamb TD, 2004, PROG RETIN EYE RES, V23, P307, DOI 10.1016/j.preteyeres.2004.03.001
   Lamb TD, 2006, INVEST OPHTH VIS SCI, V47, P5138, DOI 10.1167/iovs.06-0849
   Luo XD, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125700
   Luu CD, 2018, OPHTHALMOL RETINA, V2, P1206, DOI 10.1016/j.oret.2018.06.016
   Marsiglia M, 2015, RETINA-J RET VIT DIS, V35, P966, DOI 10.1097/IAE.0000000000000460
   Mrejen S, 2014, OPHTHALMOLOGY, V121, P545, DOI 10.1016/j.ophtha.2013.09.026
   Neely D, 2017, RETINA-J RET VIT DIS, V37, P1329, DOI 10.1097/IAE.0000000000001454
   Nguyen CT, 2018, INVEST OPHTH VIS SCI, V59, DOI 10.1167/iovs.17-23084
   Owsley C, 2001, OPHTHALMOLOGY, V108, P1196, DOI 10.1016/S0161-6420(01)00580-2
   Owsley C, 2017, TRANSL VIS SCI TECHN, V6, DOI 10.1167/tvst.6.3.15
   Owsley C, 2016, CURR EYE RES, V41, P266, DOI 10.3109/02713683.2015.1011282
   Owsley C, 2016, OPHTHALMOLOGY, V123, P344, DOI 10.1016/j.ophtha.2015.09.041
   Pfau M, 2018, EYE, V32, P1819, DOI 10.1038/s41433-018-0183-3
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P5009, DOI 10.1167/iovs.11-7235
   Spaide RF, 2018, SURV OPHTHALMOL, V63, P782, DOI 10.1016/j.survophthal.2018.05.005
   Steinberg JS, 2017, TRANSL VIS SCI TECHN, V6, DOI 10.1167/tvst.6.4.7
   Steinberg JS, 2015, INVEST OPHTH VIS SCI, V56, P4267, DOI 10.1167/iovs.15-16657
   Tan R, 2018, INVEST OPHTH VIS SCI, V59, P4154, DOI 10.1167/iovs.18-23970
   Tan RS, 2018, TRANSL VIS SCI TECHN, V7, DOI 10.1167/tvst.7.3.3
   Thylefors B, 2002, OPHTHALMIC EPIDEMIOL, V9, P83, DOI 10.1076/opep.9.2.83.1523
   Wu ZC, 2016, BRIT J OPHTHALMOL, V100, P395, DOI 10.1136/bjophthalmol-2015-306621
   ZEAVIN BH, 1956, AM J OPHTHALMOL, V42, P253, DOI 10.1016/0002-9394(56)90377-4
   Zhou Q, 2016, OPHTHALMOLOGY, V123, P1530, DOI 10.1016/j.ophtha.2016.02.043
NR 45
TC 12
Z9 13
U1 0
U2 4
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD APR
PY 2019
VL 60
IS 5
BP 1511
EP 1518
DI 10.1167/iovs.18-26385
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HW5VL
UT WOS:000466757300026
PM 30994862
OA gold
DA 2022-11-30
ER

PT J
AU Hao, XL
   Cheng, J
   Zhang, ZC
AF Hao, Xiaolin
   Cheng, Jie
   Zhang, Zhongchen
TI Polymorphisms in PEDF linked with the susceptibility to age-related
   macular degeneration A case-control study
SO MEDICINE
LA English
DT Article
DE age-related macular degeneration; PEDF; polymorphism
ID EPITHELIUM-DERIVED FACTOR; RISK-FACTORS; ANGIOGENESIS; MACULOPATHY;
   DISEASE; PATHOGENESIS; RETINOPATHY; NEURONS; GROWTH; EYE
AB To study the relationship between pigment epithelium-derived factor (PEDF) rs1136287, rs1894286 polymorphisms and the risk of age-related macular degeneration (AMD) in northern Chinese populations.
   The study was carried out on case-control methods. Ninety-six patients with AMD and 98 health controls were recruited who were matched with the former by age and gender, rs1136287 and rs1894286 were genotyped by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). Hardy-Weinberg equilibrium (HWE) was also checked by chi(2) test. The distribution frequencies of genotype, allele, and haplotype were calculated by direct counting method.
   The genotype, allele, and haplotype distribution differences between the case and control groups were analyzed by chi-square test, and odds ratio (OR) and 95% confidence interval (CI) was used to express the relative risk of AMD in northern Chinese populations. The linkage disequilibrium (LD) and haplotype analyses were conducted with Haploview software. The genotype and allele distribution frequencies in rs1136287 were obviously between in cases and controls (P<.05). TT genotype might lead to 3.24 times risk of AMD occurrence compared with CC genotype (OR=3.24, 95% CI=1.26-8.32), and C allele also played an increased risk role in the attack of AMD (OR=1.58, 95% CI=1.06-2.38). The T-C haplotype frequency of rs1136287-rs1894286 in PEDF were significantly correlated to the increased susceptibility to AMD (OR=1.57, 95% CI=1.02-2.40).
   The rs1136287 polymorphism in PEDF may be related to the occurrence risk of AMD. Additionally, a haplotype is also a non-ignorable risk factor.
C1 [Hao, Xiaolin; Cheng, Jie; Zhang, Zhongchen] Aerosp Cent Hosp, Dept Ophthalmol, Beijing 100049, Peoples R China.
RP Zhang, ZC (通讯作者)，Aerosp Cent Hosp, Dept Ophthalmol, Beijing 100049, Peoples R China.
EM nfj203oid@yeah.net
CR Abramson LP, 2003, J PEDIATR SURG, V38, P336, DOI 10.1053/jpsu.2003.50104
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Bilak MM, 1999, J NEUROPATH EXP NEUR, V58, P719, DOI 10.1097/00005072-199907000-00006
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Cao W, 2001, INVEST OPHTH VIS SCI, V42, P1646
   Cao W, 1999, J NEUROSCI RES, V57, P789, DOI 10.1002/(SICI)1097-4547(19990915)57:6<789::AID-JNR4>3.0.CO;2-M
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Hirvela H, 1996, OPHTHALMOLOGY, V103, P871, DOI 10.1016/S0161-6420(96)30593-9
   Hjelmeland LM, 1999, MOL VIS, V5
   Holekamp NM, 2002, AM J OPHTHALMOL, V134, P220, DOI 10.1016/S0002-9394(02)01549-0
   Holz FG, 2004, AM J OPHTHALMOL, V137, P504, DOI 10.1016/j.ajo.2003.11.026
   Karakousis PC, 2001, MOL VIS, V7, P154
   Klein R, 1998, AM J EPIDEMIOL, V147, P103
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Libby RT, 2007, BMC NEUROSCI, V8, DOI 10.1186/1471-2202-8-108
   Ogata N, 2001, AM J OPHTHALMOL, V132, P378, DOI 10.1016/S0002-9394(01)01008-X
   Sawant S, 2004, BIOCHEM BIOPH RES CO, V325, P408, DOI 10.1016/j.bbrc.2004.10.041
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Stellmach V, 2001, P NATL ACAD SCI USA, V98, P2593, DOI 10.1073/pnas.031252398
   Swaroop A, 2007, HUM MOL GENET, V16, pR174, DOI 10.1093/hmg/ddm212
   Tombran-Tink J, 2005, FRONT BIOSCI-LANDMRK, V10, P2131, DOI 10.2741/1686
   Tombran-Tink J, 2004, BIOCHEM BIOPH RES CO, V316, P573, DOI 10.1016/j.bbrc.2004.02.076
   TOMBRANTINK J, 1991, EXP EYE RES, V53, P411, DOI 10.1016/0014-4835(91)90248-D
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
   Yamagishi S, 2005, MED HYPOTHESES, V64, P1202, DOI 10.1016/j.mehy.2005.01.017
NR 27
TC 4
Z9 4
U1 2
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD AUG
PY 2018
VL 97
IS 34
AR e11981
DI 10.1097/MD.0000000000011981
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GW0XD
UT WOS:000446592300083
PM 30142832
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Feehan, M
   Hartman, J
   Durante, R
   Morrison, MA
   Miller, JW
   Kim, IK
   DeAngelis, MM
AF Feehan, Michael
   Hartman, John
   Durante, Richard
   Morrison, Margaux A.
   Miller, Joan W.
   Kim, Ivana K.
   DeAngelis, Margaret M.
TI Identifying subtypes of patients with neovascular age-related macular
   degeneration by genotypic and cardiovascular risk characteristics
SO BMC MEDICAL GENETICS
LA English
DT Article
ID COMPLEMENT FACTOR-H; BEAVER DAM EYE; LOW-DENSITY LIPOPROTEINS;
   BLUE-MOUNTAINS-EYE; CHOROIDAL NEOVASCULARIZATION; PERSONALIZED MEDICINE;
   ALCOHOL-CONSUMPTION; CIGARETTE-SMOKING; 10-YEAR INCIDENCE;
   EPITHELIAL-CELLS
AB Background: One of the challenges in the interpretation of studies showing associations between environmental and genotypic data with disease outcomes such as neovascular age-related macular degeneration (AMD) is understanding the phenotypic heterogeneity within a patient population with regard to any risk factor associated with the condition. This is critical when considering the potential therapeutic response of patients to any drug developed to treat the condition. In the present study, we identify patient subtypes or clusters which could represent several different targets for treatment development, based on genetic pathways in AMD and cardiovascular pathology.
   Methods: We identified a sample of patients with neovascular AMD, that in previous studies had been shown to be at elevated risk for the disease through environmental factors such as cigarette smoking and genetic variants including the complement factor H gene (CFH) on chromosome 1q25 and variants in the ARMS2/HtrA serine peptidase 1 (HTRA1) gene(s) on chromosome 10q26. We conducted a multivariate segmentation analysis of 253 of these patients utilizing available epidemiologic and genetic data.
   Results: In a multivariate model, cigarette smoking failed to differentiate subtypes of patients. However, four meaningfully distinct clusters of patients were identified that were most strongly differentiated by their cardiovascular health status (histories of hypercholesterolemia and hypertension), and the alleles of ARMS2/HTRA1 rs1049331.
   Conclusions: These results have significant personalized medicine implications for drug developers attempting to determine the effective size of the treatable neovascular AMD population. Patient subtypes or clusters may represent different targets for therapeutic development based on genetic pathways in AMD and cardiovascular pathology, and treatments developed that may elevate CV risk, may be ill advised for certain of the clusters identified.
C1 [Morrison, Margaux A.; Miller, Joan W.; Kim, Ivana K.; DeAngelis, Margaret M.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Ocular Mol Genet Inst, Boston, MA 02114 USA.
   [Morrison, Margaux A.; Miller, Joan W.; Kim, Ivana K.; DeAngelis, Margaret M.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Ophthalmol,Retina Serv, Boston, MA 02114 USA.
   [Feehan, Michael; Hartman, John; Durante, Richard] Observant LLC, Waltham, MA 02451 USA.
   [Morrison, Margaux A.; DeAngelis, Margaret M.] Univ Utah, Moran Eye Ctr, Salt Lake City, UT 84132 USA.
C3 Harvard University; Harvard Medical School; Massachusetts Eye & Ear
   Infirmary; Harvard University; Harvard Medical School; Massachusetts Eye
   & Ear Infirmary; Utah System of Higher Education; University of Utah
RP DeAngelis, MM (通讯作者)，Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Ocular Mol Genet Inst, 243 Charles St, Boston, MA 02114 USA.
EM Margaret.deangelis@utah.edu
RI DeAngelis, e/J-7863-2015
OI Kim, Ivana/0000-0003-0310-6129; Miller, Joan/0000-0003-2046-3996
FU Lincy Foundation; Marion W. and Edward F. Knight Age-Related Macular
   Degeneration Fund; Genetics of Age-Related Macular Degeneration Fund;
   MEEI; Research to Prevent Blindness (University of Utah); Edward N. and
   Della L. Thome Award; NIH [EY014458]; NATIONAL EYE INSTITUTE
   [P30EY014800, R01EY014458] Funding Source: NIH RePORTER
FX Supported by grants from the Lincy Foundation, the Marion W. and Edward
   F. Knight Age-Related Macular Degeneration Fund, Genetics of Age-Related
   Macular Degeneration Fund, MEEI, Unrestricted grant from the Research to
   Prevent Blindness (University of Utah), The Edward N. and Della L. Thome
   Award, and NIH grant EY014458. We thank Liza Pliss and Michael Walsh
   from Observant LLC for support in these analyses, and we are especially
   grateful to the patients for their participation in this study.
CR Ajani UA, 1999, ANN EPIDEMIOL, V9, P172, DOI 10.1016/S1047-2797(98)00053-2
   Andreoli MT, 2009, AM J OPHTHALMOL, V148, P869, DOI 10.1016/j.ajo.2009.07.002
   [Anonymous], 1996, ACM SIGMOD
   [Anonymous], 2000, OPHTHALMOLOGY, V107, P2224
   Baird PN, 2008, HUM MOL GENET, V17, P1299, DOI 10.1093/hmg/ddn018
   Baird PN, 2009, CLIN EXP OPHTHALMOL, V37, P814, DOI 10.1111/j.1442-9071.2009.02136.x
   Baker ML, 2009, ARCH OPHTHALMOL-CHIC, V127, P667, DOI 10.1001/archophthalmol.2009.30
   Bozinov D, 2002, BIOINFORMATICS, V18, P747, DOI 10.1093/bioinformatics/18.5.747
   Chaine G, 1998, BRIT J OPHTHALMOL, V82, P996, DOI 10.1136/bjo.82.9.996
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Cheung N, 2007, SURV OPHTHALMOL, V52, P180, DOI 10.1016/j.survophthal.2006.12.003
   Cho EY, 2000, ARCH OPHTHALMOL-CHIC, V118, P681, DOI 10.1001/archopht.118.5.681
   Cong RH, 2008, ANN EPIDEMIOL, V18, P647, DOI 10.1016/j.annepidem.2008.04.002
   Conley YP, 2006, HUM MOL GENET, V15, P3206, DOI 10.1093/hmg/ddl396
   DeAngelis MM, 2008, OPHTHALMOLOGY, V115, P1209, DOI 10.1016/j.ophtha.2007.10.032
   DeAngelis MM, 2007, ARCH OPHTHALMOL-CHIC, V125, P49, DOI 10.1001/archopht.125.1.49
   DeAngelis MM, 2004, ARCH OPHTHALMOL-CHIC, V122, P575, DOI 10.1001/archopht.122.4.575
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ellis TE, 1996, J CLIN PSYCHOL, V52, P411, DOI 10.1002/(SICI)1097-4679(199607)52:4<411::AID-JCLP5>3.3.CO;2-K
   Enseleit F, 2010, CURR HYPERTENS REP, V12, P33, DOI 10.1007/s11906-009-0082-x
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Han KJ, 2008, IEEE T AUDIO SPEECH, V16, P1590, DOI 10.1109/TASL.2008.2002085
   Hogg RE, 2008, OPHTHALMOLOGY, V115, P1046, DOI 10.1016/j.ophtha.2007.07.031
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Jakobsdottir J, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000337
   Jakobsson M, 2008, NATURE, V451, P998, DOI 10.1038/nature06742
   Jardine N., 1971, MATH TAXONOMY
   Lobera IJ, 2010, J PSYCHIATR MENT HLT, V17, P775, DOI 10.1111/j.1365-2850.2010.01611.x
   Klein R, 2003, ARCH OPHTHALMOL-CHIC, V121, P1151, DOI 10.1001/archopht.121.8.1151
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 1997, OPHTHALMOLOGY, V104, P1804, DOI 10.1016/S0161-6420(97)30023-2
   Klein R, 2002, AM J EPIDEMIOL, V156, P589, DOI 10.1093/aje/kwf092
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2007, AM J OPHTHALMOL, V143, P473, DOI 10.1016/j.ajo.2006.11.058
   McCarty CA, 2008, BMC OPHTHALMOL, V8, DOI 10.1186/1471-2415-8-25
   McGwin G, 2005, OPHTHALMOLOGY, V112, P488, DOI 10.1016/j.ophtha.2004.10.027
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Ng PC, 2009, NATURE, V461, P724, DOI 10.1038/461724a
   Nguyen-Khoa BA, 2008, ARCH OPHTHALMOL-CHIC, V126, P1280, DOI 10.1001/archopht.126.9.1280
   PHIPPS A, 1994, ADV METHODS MARKETIN, P160
   PUNJ G, 1983, J MARKETING RES, V20, P134, DOI 10.2307/3151680
   Quirk SW, 1998, ASSESSMENT, V5, P157, DOI 10.1177/107319119800500206
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Sallo FB, 2009, EXP EYE RES, V89, P178, DOI 10.1016/j.exer.2009.03.006
   Schaumberg DA, 2010, ARCH OPHTHALMOL-CHIC, V128, P1462, DOI 10.1001/archophthalmol.2010.261
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Silveira AC, 2010, VISION RES, V50, P698, DOI 10.1016/j.visres.2009.09.016
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Sneath Peter HA., 1973, NUMERICAL TAXONOMY P, DOI 10.2307/2412767
   Sun C, 2009, OPHTHALMOLOGY, V116, P1913, DOI 10.1016/j.ophtha.2009.03.046
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   Tan JSL, 2009, ARCH OPHTHALMOL-CHIC, V127, P656, DOI 10.1001/archophthalmol.2009.76
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   van Leeuwen R, 2003, BRIT MED J, V326, P255, DOI 10.1136/bmj.326.7383.255
   VANROODEN SM, 2010, MOV DISORD
   Wedel M, 2002, MARKET LETT, V13, P17, DOI 10.1023/A:1015059024154
   Wedel M., 2000, MARKET SEGMENTATION
   Wilson HL, 2004, AM J OPHTHALMOL, V137, P615, DOI 10.1016/j.ajo.2003.10.025
   WINKEL P, 1970, COMPUT BIOMED RES, V3, P657, DOI 10.1016/0010-4809(70)90033-9
   Wong TY, 2007, OPHTHALMOLOGY, V114, P86, DOI 10.1016/j.ophtha.2006.06.039
   Yamada Y, 2008, J NEUROCHEM, V105, P1187, DOI 10.1111/j.1471-4159.2008.05211.x
   Yang YH, 2002, J COMPUT GRAPH STAT, V11, P108, DOI 10.1198/106186002317375640
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yu AL, 2009, EXP EYE RES, V88, P495, DOI 10.1016/j.exer.2008.10.028
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
   Zhang H, 2008, BMC MED GENET, V9, DOI 10.1186/1471-2350-9-51
NR 73
TC 12
Z9 14
U1 0
U2 9
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2350
J9 BMC MED GENET
JI BMC Med. Genet.
PD JUN 17
PY 2011
VL 12
AR 83
DI 10.1186/1471-2350-12-83
PG 8
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 793OA
UT WOS:000292831800001
PM 21682878
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Korobelnik, JF
   Souied, EH
   Oubraham, H
   Razavi, S
   Mauget-Faysse, M
   Savel, H
   Chene, G
   Wolf, S
AF Korobelnik, Jean-Francois
   Souied, Eric H.
   Oubraham, Hassiba
   Razavi, Sam
   Mauget-Faysse, Martine
   Savel, Helene
   Chene, Genevieve
   Wolf, Sebastian
TI ASSESSMENT OF EARLY CHANGES IN SPECTRAL DOMAIN-OPTICAL COHERENCE
   TOMOGRAPHY AFTER INITIATION OF TREATMENT WITH INTRAVITREAL AFLIBERCEPT
   (EYLEA) OVER A 12-WEEK PERIOD FOR PATIENTS WITH NEOVASCULAR AGE-RELATED
   MACULAR DEGENERATION A Multicenter French Study (START)
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
ID TRAP-EYE
AB Purpose: To assess early changes in spectral-domain optical coherence tomography during the loading phase with intravitreal aflibercept therapy in patients with neovascular age-related macular degeneration.
   Methods: In this prospective, open-label, single-arm, multicenter study, patients with neovascular age-related macular degeneration, who were antivascular endothelial growth factor treatment-naive, received three monthly initial doses of intravitreal aflibercept 2 mg. The primary outcome was the proportion of patients with dry spectral-domain optical coherence tomography at 12 weeks, defined as an absence of intraretinal edema, intraretinal cysts, subretinal fluid, and subretinal pigment epithelium fluid.
   Results: Fifty eyes of 50 patients were investigated. At 12 weeks, 34.0% (17/50) had dry spectral-domain optical coherence tomography. Marked reductions were observed for all other spectral-domain optical coherence tomography parameters. The mean macular central thickness fell significantly from 463.2 +/- 184.3 ,u,m at baseline to 288.9 +/- 76.8 ,u,rn at Week 12 (P < 0.0001). The mean best-corrected visual acuity also improved significantly from 61.0 +/- 16.0 letters at baseline to 66.6 +/- 19.0 letters at Week 12 (P = 0.0006).
   Conclusion: The anatomic and functional outcomes improved over the 12-week study period. All outcome variables peaked after the third aflibercept injection, confirming the benefit of three initial doses.
C1 [Korobelnik, Jean-Francois] CHU Bordeaux, Serv Ophtalmol, Hop Pellegrin, F-33000 Bordeaux, France.
   [Korobelnik, Jean-Francois] Univ Bordeaux, Bordeaux Populat Hlth Res Ctr, Leha Team, UMR 1219,INSERM, Bordeaux, France.
   [Souied, Eric H.; Oubraham, Hassiba] Univ Paris Est, Dept Ophthalmol, Hop Intercommunal Creteil, Creteil, France.
   [Razavi, Sam] Ctr Ophtalmol Transparence Tours, Tours, France.
   [Mauget-Faysse, Martine] Rothschild Fdn, Ctr Invest Clin, Paris, France.
   [Savel, Helene; Chene, Genevieve] CHU Bordeaux, Pole Sante Publ, Unite Soutien Methodol Rech Clin & Epidemiol, Bordeaux, France.
   [Savel, Helene; Chene, Genevieve] CIC 1401 EC, Bordeaux, France.
   [Wolf, Sebastian] Univ Hosp, Dept Ophthalmol, Inselspital, Bern, Switzerland.
   [Wolf, Sebastian] Univ Bern, Bern, Switzerland.
C3 CHU Bordeaux; Institut National de la Sante et de la Recherche Medicale
   (Inserm); UDICE-French Research Universities; Universite de Bordeaux;
   Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil; Institut
   National de la Sante et de la Recherche Medicale (Inserm); CHU Bordeaux;
   University of Bern; University Hospital of Bern; University of Bern
RP Korobelnik, JF (通讯作者)，CHU Bordeaux, Serv Ophtalmol, Hop Pellegrin, F-33000 Bordeaux, France.
EM jean-francois.korobelnik@chu-bordeaux.fr
RI chene, genevieve/H-8665-2014
OI chene, genevieve/0000-0002-8368-6460
FU Bayer Inc.
FX The authors thank Dr. Zhizhi Fiske of Inspired Science, London, UK, for
   writing and editorial support, Dr. Joel Uzzan, Dr. Catherine
   Creuzot-Garcher, Dr. Salomon Yves Cohen, Dr. Laurent Kodjikian, and Dr.
   Michel Weber, who were involved in treating the patients included in
   this study, and all the patients who participated in the study. The
   study was in part supported by Bayer Inc.
CR Al-Zamil WM, 2017, CLIN INTERV AGING, V12, P1313, DOI 10.2147/CIA.S143508
   Ba J, 2015, DRUG DES DEV THER, V9, DOI 10.2147/DDDT.S86269
   Bailey IL, 2013, VISION RES, V90, P2, DOI 10.1016/j.visres.2013.05.004
   Cheung CMG, 2013, LANCET, V382, P1230, DOI 10.1016/S0140-6736(13)61580-9
   Dervenis N, 2016, CLIN OPHTHALMOL, V10, DOI 10.2147/OPTH.S106734
   Ebneter A, 2015, OPHTHALMOLOGICA, V234, P61, DOI 10.1159/000430103
   Finger RP, 2014, SURV OPHTHALMOL, V59, P1, DOI 10.1016/j.survophthal.2013.03.009
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Heier JS, 2011, OPHTHALMOLOGY, V118, P1098, DOI 10.1016/j.ophtha.2011.03.020
   Jonas JB, 2017, ASIA-PAC J OPHTHALMO, V6, P493, DOI 10.22608/APO.2017251
   Phadikar Prateep, 2017, Int J Retina Vitreous, V3, P1, DOI 10.1186/s40942-016-0054-7
   Pierro L, 2012, CLIN OPHTHALMOL, V6, P219, DOI 10.2147/OPTH.S27656
   Regatieri Caio V, 2011, Ophthalmic Surg Lasers Imaging, V42 Suppl, pS56, DOI 10.3928/15428877-20110627-05
   Ritter M, 2014, BRIT J OPHTHALMOL, V98, P1629, DOI 10.1136/bjophthalmol-2014-305186
   Schmidt-Erfurth U, 2016, PROG RETIN EYE RES, V50, P1, DOI 10.1016/j.preteyeres.2015.07.007
   Solomon SD, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub4
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Zhang Y, 2017, INVEST OPHTH VIS SCI, V58, P5616, DOI 10.1167/iovs.17-22471
NR 19
TC 0
Z9 0
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAR
PY 2021
VL 41
IS 3
BP 588
EP 594
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA SL1OK
UT WOS:000656688600026
PM 33600134
DA 2022-11-30
ER

PT J
AU Park, SJ
   Kim, BH
   Park, KH
   Woo, SJ
AF Park, Sang Jun
   Kim, Bo Hyuck
   Park, Kyu Hyung
   Woo, Se Joon
TI Punctate Hyperfluorescence Spot as a Common Choroidopathy of Central
   Serous Chorioretinopathy and Polypoidal Choroidal Vasculopathy
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID INDOCYANINE GREEN ANGIOGRAPHY; OPTICAL COHERENCE TOMOGRAPHY; MACULAR
   DEGENERATION; CLINICAL CHARACTERISTICS; THICKNESS
AB PURPOSE: To characterize punctate hyperfluorescence spot as common choroidopathy in central serous chorioretinopathy (CSC) and polypoidal choroidal vasculopathy (PCV).
   DESIGN: Cross-sectional retrospective study.
   METHODS: A total of 150 patients with 50 each allocated to CSC, PCV, and typical neovascular age-related macular degeneration (AMD) groups were included. Punctate hyperfluorescence spot was determined using mid-to late-phase indocyanine green angiography and subfoveal choroidal thickness by enhanced depth imaging optical coherence tomography. Each group was subcategorized based on concurrent punctate hyperfluorescence spot.
   RESULTS: The punctate hyperfluorescence spot incidence was higher in CSC (80.0%) and PCV (86.0%) than in AMD (40.0%, P < .001), with similar contralateral findings (86.1%, 86.7%, and 60%, respectively, P = .014). Punctate hyperfluorescence spot lesions comprised clustered polyps connected to vascular networks mimicking PCV. Choroidal thickness was 370.7 +/- 81.9 mu m, 332.6 +/- 101.6 mu m, and 172.5 +/- 80.1 mu m in affected eyes (P < .001) and 323.0 +/- 70.5 mu m, 306.4 +/- 94.4 mu m, and 180.2 +/- 83.6 mu m in contralateral eyes (P < .001) in CSC, PCV, and AMD groups, respectively. In the AMD group, choroidal thickness was greater in eyes with punctate hyperfluorescence spot (204.8 +/- 92.3 mu m) than in those without punctate hyperfluorescence spot (150.2 +/- 62.9 mu m, P = .028) in affected eyes; however, the difference was not observed in contralateral eyes in the AMD group and in both eyes in the CSC and PCV groups.
   CONCLUSIONS: Based on angiography and OCT, punctate hyperfluorescence spot may be a form of PCV, and CSC and PCV may share common choroidopathy distinct from typical neovascular AMD. However, infrequent PHS lesions along with thickened choroids in AMD eyes suggest that AMD may encompass a wide choroidal pathologic spectrum shared in part with PCV. ((C) 2014 by Elsevier Inc. All rights reserved.)
C1 [Park, Sang Jun; Kim, Bo Hyuck; Park, Kyu Hyung; Woo, Se Joon] Seoul Natl Univ, Bundang Hosp, Coll Med, Dept Ophthalmol, Songnam 463707, Gyeonggi Do, South Korea.
C3 Seoul National University (SNU)
RP Woo, SJ (通讯作者)，Seoul Natl Univ, Bundang Hosp, Dept Ophthalmol, 300 Gumi Dong, Songnam 463707, Gyeonggi Do, South Korea.
EM sejoon1@snu.ac.kr
RI Park, Sang Jun/C-3234-2015
OI Park, Sang Jun/0000-0003-0542-2758
FU National Research Foundation in South Korea [2012R1A2A2A02012821]
FX This study was supported by a grant (2012R1A2A2A02012821) funded by the
   National Research Foundation in South Korea. The funding organization
   had no role in the design or conduct of this research.
CR Ahuja RM, 2001, OPHTHALMOLOGY, V108, P1009, DOI 10.1016/S0161-6420(00)00614-X
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Fleiss J.L., 1986, DESIGN ANAL CLIN EXP
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Iida T, 1999, RETINA-J RET VIT DIS, V19, P508, DOI 10.1097/00006982-199911000-00005
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Iwama D, 2008, JPN J OPHTHALMOL, V52, P116, DOI 10.1007/s10384-007-0503-9
   Jirarattanasopa P, 2012, OPHTHALMOLOGY, V119, P1666, DOI 10.1016/j.ophtha.2012.02.021
   Jirarattanasopa P, 2012, INVEST OPHTH VIS SCI, V53, P3663, DOI 10.1167/iovs.12-9619
   Kim SW, 2011, RETINA-J RET VIT DIS, V31, P1904, DOI 10.1097/IAE.0b013e31821801c5
   Koizumi H, 2013, AM J OPHTHALMOL, V155, P305, DOI 10.1016/j.ajo.2012.07.018
   Lafaut BA, 1998, GRAEF ARCH CLIN EXP, V236, P513, DOI 10.1007/s004170050114
   Lavik EB, 2013, DRUG DELIV, V1, P734
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Maruko I, 2011, AM J OPHTHALMOL, V151, P594, DOI 10.1016/j.ajo.2010.10.030
   Menchini U, 1997, INT OPHTHALMOL, V21, P57, DOI 10.1023/A:1005880129005
   Ooto S, 2011, RETINA-J RET VIT DIS, V31, P527, DOI 10.1097/IAE.0b013e3181eef2db
   Park Han Sang, 2012, Korean J Ophthalmol, V26, P15, DOI 10.3341/kjo.2012.26.1.15
   Park SS, 2010, INVEST OPHTH VIS SCI, V51, P4200, DOI 10.1167/iovs.09-4256
   Ramezani Alireza, 2013, J Ophthalmic Vis Res, V8, P66
   Sasahara M, 2006, AM J OPHTHALMOL, V142, P601, DOI 10.1016/j.ajo.2006.05.051
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Tsai DC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066858
   Tsujikawa A, 2010, RETINA-J RET VIT DIS, V30, P801, DOI 10.1097/IAE.0b013e3181c72068
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 2000, OPHTHALMOLOGY, V107, P767, DOI 10.1016/S0161-6420(99)00173-6
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
NR 27
TC 24
Z9 24
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD DEC
PY 2014
VL 158
IS 6
BP 1155
EP 1163
DI 10.1016/j.ajo.2014.08.010
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AU8AZ
UT WOS:000345820400009
PM 25127698
DA 2022-11-30
ER

PT J
AU Starr, MR
   Barkmeier, AJ
   Engman, SJ
   Kitzmann, A
   Bakri, SJ
AF Starr, Matthew R.
   Barkmeier, Andrew J.
   Engman, Steven J.
   Kitzmann, Anna
   Bakri, Sophie J.
TI Telemedicine in the Management of Exudative Age-Related Macular
   Degeneration within an Integrated health care System
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID RANIBIZUMAB; RETINOPATHY; HOME; TELEOPHTHALMOLOGY; VERTEPORFIN; EYE
AB PURPOSE: To investigate the outcomes of patients with exudative age-related macular degeneration (AMD) treated with intravitreal antivascular endothelial growth factors (VEGF) using a telemedicine system.
   DESIGN: Interventional case series.
   METHODS: This study examined all patients with exudative AMD who were receiving intravitreal anti-VEGF injections from September 1, 2015, through August 31, 2017, using electronic consultations at a single academic center and health system. Patients were managed initially by a retinal specialist and then allowed to receive further care with their local ophthalmologist. There were 200 electronic consultations placed during this time period for 83 eyes of 59 patients. Data collected included the retina specialist's recommendations: intravitreal agent, interval between injections, number of injections, and when the patient was to follow-up. All occurrences of recommendations that were not completed were reported.
   RESULTS: The mean age of the patients at the time of electronic consultations was 82.3 +/- 7.3 years with a mean follow-up time of 2.4 +/- 0.81 years. The mean distance from the home of the patient to the retina specialist was 70 44 miles. There were 14 consultations (7.1%) that did not comply with the recommendations of the retina specialist. Most of these were due to other medical comorbidities leading to missed appointments or scheduling errors.
   CONCLUSIONS: In an integrated health care setting, 59 patients with exudative AMD were identified who were able to be effectively managed using a telemedicine system. In the appropriate setting, telemedicine may be able to assist in the management of patients with wet AMD. ((C) 2019 Elsevier Inc. All rights reserved.)
C1 [Starr, Matthew R.; Barkmeier, Andrew J.; Engman, Steven J.; Kitzmann, Anna; Bakri, Sophie J.] Mayo Clin, Dept Ophthalmol, 200 First St Southwest, Rochester, MN 55905 USA.
C3 Mayo Clinic
RP Bakri, SJ (通讯作者)，Mayo Clin, Dept Ophthalmol, 200 First St Southwest, Rochester, MN 55905 USA.
EM bakri.sophie@mayo.edu
RI Barkmeier, Andrew/AAV-1021-2020
OI Starr, Matthew/0000-0002-3021-5630
CR Andonegui J, 2016, RETINA-J RET VIT DIS, V36, P279, DOI 10.1097/IAE.0000000000000729
   [Anonymous], 2018, DATAMANAGER ONL
   Atchison EA, 2017, RETINA-J RET VIT DIS, V37, P1371, DOI 10.1097/IAE.0000000000001372
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chew EY, 2016, RETINA-J RET VIT DIS, V36, P1542, DOI 10.1097/IAE.0000000000000940
   Chew EY, 2014, OPHTHALMOLOGY, V121, P535, DOI 10.1016/j.ophtha.2013.10.027
   Day S, 2011, AM J OPHTHALMOL, V152, P1014, DOI 10.1016/j.ajo.2011.05.008
   Fierson WM, 2015, PEDIATRICS, V135, pE238, DOI 10.1542/peds.2014-0978
   Fijalkowski N, 2014, OSLI RETINA, V45, P106, DOI 10.3928/23258160-20140122-01
   Heier JS, 2006, ARCH OPHTHALMOL-CHIC, V124, P1532, DOI 10.1001/archopht.124.11.1532
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Jansen ME, 2018, OSLI RETINA, V49, P186, DOI 10.3928/23258160-20180221-06
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Li B, 2015, JAMA OPHTHALMOL, V133, P276, DOI 10.1001/jamaophthalmol.2014.5014
   Liang MC, 2016, RETINA-J RET VIT DIS, V36, P2265, DOI 10.1097/IAE.0000000000001102
   Prenner JL, 2015, AM J OPHTHALMOL, V160, P725, DOI 10.1016/j.ajo.2015.06.023
   Quinn GE, 2014, JAMA OPHTHALMOL, V132, P1178, DOI 10.1001/jamaophthalmol.2014.1604
   Rathi S, 2017, OPHTHALMOLOGY, V124, P1729, DOI 10.1016/j.ophtha.2017.05.026
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Strouthidis NG, 2014, BRIT J OPHTHALMOL, V98, P1605, DOI 10.1136/bjophthalmol-2013-304133
   Tsaousis KT, 2016, ACTA OPHTHALMOL, V94, pe353, DOI 10.1111/aos.12832
   Wittenborn JS, 2017, JAMA OPHTHALMOL, V135, P452, DOI 10.1001/jamaophthalmol.2017.0255
NR 22
TC 13
Z9 14
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD DEC
PY 2019
VL 208
BP 206
EP 210
DI 10.1016/j.ajo.2019.03.021
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA JZ0OI
UT WOS:000504803400022
PM 30905726
DA 2022-11-30
ER

PT J
AU ten Berge, JC
   Fazil, Z
   van den Born, I
   Wolfs, RCW
   Schreurs, MWJ
   Dik, WA
   Rothova, A
AF ten Berge, Josianne C.
   Fazil, Zainab
   van den Born, Ingeborgh
   Wolfs, Roger C. W.
   Schreurs, Marco W. J.
   Dik, Wim A.
   Rothova, Aniki
TI Intraocular cytokine profile and autoimmune reactions in retinitis
   pigmentosa, age-related macular degeneration, glaucoma and cataract
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration; antiretinal antibodies; cytokines;
   glaucoma; indirect immunofluorescence; intraocular fluid; multiplex bead
   immunoassay; retinitis pigmentosa
ID NECROSIS-FACTOR-ALPHA; ENDOTHELIAL GROWTH-FACTOR; AQUEOUS-HUMOR;
   ANTIRETINAL ANTIBODIES; SOLUBLE IL-6; TNF-ALPHA; T-CELLS; INFLAMMATION;
   EYES; EXPRESSION
AB Purpose To analyse intraocular cytokine levels and prevalence of intraocular antiretinal antibodies (ARAs) in patients with retinitis pigmentosa (RP), age-related macular degeneration (AMD), glaucoma and cataract, and correlate the results to clinical manifestations. Methods We collected intraocular fluid samples from patients with RP (n = 25), AMD (n = 12), glaucoma (n = 28) and cataract (n = 22), and serum samples paired with the intraocular fluids from patients with RP (N = 7) and cataract (n = 10). Interleukin (IL)-1 beta, IL-1ra, IL-2, IL-6, IL-6r alpha, IL-7, IL-8, IL-10, IL-17A, IL-23, thymus- and activation-regulated chemokine (TARC), monocyte chemoattractant protein-1 (MCP-1), tumour necrosis factor-alpha (TNF-alpha), placental growth factor (PlGF) and vascular endothelial growth factor (VEGF) were measured using a multiplex assay. Antiretinal antibodies (ARA) detection was performed by indirect immunofluorescence. Results Increasing age was associated with increasing levels of IL-6, IL-8, TNF-alpha and VEGF. All patient groups exhibited distinct profiles of intraocular cytokines. Intraocular levels of IL-8 were highest in patients with AMD and glaucoma. Cataract patients exhibited high intraocular levels of IL-23. Intraocular levels of IL-2, IL-6, MCP-1 and PlGF in RP patients exceeded the levels of serum, indicating intraocular production. Intraocular ARAs were found in only one patient with AMD. Conclusion Increased levels of inflammatory cytokines in intraocular fluid of patients with originally noninflammatory ocular diseases show that intraocular inflammation is involved in their pathogenesis of these entities. Moreover, we show that increasing age is associated with increasing levels of intraocular cytokines and conclude that future studies on intraocular mediators should be corrected for age of patients.
C1 [ten Berge, Josianne C.; Fazil, Zainab; Wolfs, Roger C. W.; Rothova, Aniki] Erasmus MC, Dept Ophthalmol, S Gravendijkwal 230, NL-3015 CE Rotterdam, Netherlands.
   [van den Born, Ingeborgh] Rotterdam Eye Hosp, Rotterdam, Netherlands.
   [Schreurs, Marco W. J.; Dik, Wim A.] Erasmus MC, Lab Med Immunol, Dept Immunol, Rotterdam, Netherlands.
C3 Erasmus University Rotterdam; Erasmus MC; Rotterdam Eye Hospital;
   Erasmus University Rotterdam; Erasmus MC
RP ten Berge, JC (通讯作者)，Erasmus MC, Dept Ophthalmol, S Gravendijkwal 230, NL-3015 CE Rotterdam, Netherlands.
EM j.tenberge@erasmusmc.nl
FU Stichting Lijf en Leven
FX This research was supported by Stichting Lijf en Leven. This funding
   organization had no role in the design or conduct of this research.
CR Adamus G, 2017, AUTOIMMUN REV, V16, P231, DOI 10.1016/j.autrev.2017.01.005
   Agawa T, 2014, RETINA-J RET VIT DIS, V34, P1811, DOI 10.1097/IAE.0000000000000157
   Balaiya S, 2011, CLIN OPHTHALMOL, V5, P553, DOI 10.2147/OPTH.S19453
   Barkhausen T, 2011, CRIT CARE MED, V39, P1407, DOI 10.1097/CCM.0b013e318211ff56
   Bell K, 2013, PROG RETIN EYE RES, V36, P199, DOI 10.1016/j.preteyeres.2013.02.003
   Castelo-Branco C, 2014, GYNECOL ENDOCRINOL, V30, P16, DOI 10.3109/09513590.2013.852531
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chalam KV, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/502174
   CHANT SM, 1985, BRIT J OPHTHALMOL, V69, P19, DOI 10.1136/bjo.69.1.19
   Chiu K, 2010, CELL MOL IMMUNOL, V7, P61, DOI 10.1038/cmi.2009.110
   Curnow SJ, 2004, J IMMUNOL, V173, P5290, DOI 10.4049/jimmunol.173.8.5290
   D'Elios MM, 2010, EXPERT OPIN THER TAR, V14, P759, DOI 10.1517/14728222.2010.497143
   Du SL, 2016, BMC OPHTHALMOL, V16, DOI 10.1186/s12886-016-0182-8
   ELNER VM, 1992, EXP EYE RES, V54, P361, DOI 10.1016/0014-4835(92)90048-W
   Feng J, 2017, ACTA OPHTHALMOL, V95, P608, DOI 10.1111/aos.13151
   Forooghian F, 2016, CAN J OPHTHALMOL, V51, P87, DOI 10.1016/j.jcjo.2015.11.001
   Freedman J, 2013, INVEST OPHTH VIS SCI, V54, P4851, DOI 10.1167/iovs.13-12274
   Ghasemi H, 2011, OCUL IMMUNOL INFLAMM, V19, P401, DOI 10.3109/09273948.2011.618902
   Heckenlively JR, 1999, AM J OPHTHALMOL, V127, P565, DOI 10.1016/S0002-9394(98)00446-2
   Hettinga YM, 2016, OPHTHALMOLOGY, V123, P2043, DOI 10.1016/j.ophtha.2016.03.046
   Holtkamp GM, 1998, CLIN EXP IMMUNOL, V112, P34
   Huang WB, 2014, INVEST OPHTH VIS SCI, V55, P1088, DOI 10.1167/iovs.13-13591
   Joachim SC, 2007, CURR EYE RES, V32, P501, DOI 10.1080/02713680701375183
   Jonas JB, 2012, ACTA OPHTHALMOL, V90, pe381, DOI 10.1111/j.1755-3768.2012.02414.x
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Khalef Nervana, 2017, Electron Physician, V9, P3833, DOI 10.19082/3833
   Knickelbein Jared E, 2015, Int Ophthalmol Clin, V55, P63, DOI 10.1097/IIO.0000000000000073
   Kokubun T, 2018, OCUL IMMUNOL INFLAMM, V26, P1177, DOI 10.1080/09273948.2017.1327605
   Kubicka-Trzaska A, 2016, ACTA OPHTHALMOL, V94, pE617, DOI 10.1111/aos.13033
   Kuchtey J, 2010, INVEST OPHTH VIS SCI, V51, P6441, DOI 10.1167/iovs.10-5216
   Langowski JL, 2006, NATURE, V442, P461, DOI 10.1038/nature04808
   Leske MC, 2008, OPHTHALMOLOGY, V115, P85, DOI 10.1016/j.ophtha.2007.03.017
   Liang DC, 2013, J IMMUNOL, V191, P1118, DOI 10.4049/jimmunol.1300626
   Lubberts E, 2015, NAT REV RHEUMATOL, V11, P415, DOI 10.1038/nrrheum.2015.53
   Nelson BH, 2004, J IMMUNOL, V172, P3983, DOI 10.4049/jimmunol.172.7.3983
   Nie W, 2017, BIOCHEM BIOPH RES CO, V482, P1400, DOI 10.1016/j.bbrc.2016.12.048
   Nikita E, 2017, OPHTHALMOL THER, V6, P323, DOI 10.1007/s40123-017-0096-4
   Nishijima K, 2007, AM J PATHOL, V171, P53, DOI 10.2353/ajpath.2007.061237
   Nowell MA, 2003, J IMMUNOL, V171, P3202, DOI 10.4049/jimmunol.171.6.3202
   Nussenblatt RB, 2013, INT REV IMMUNOL, V32, P97, DOI 10.3109/08830185.2012.740536
   Rezar-Dreindl S, 2017, ACTA OPHTHALMOL, V95, pE119, DOI 10.1111/aos.13152
   Rezar-Dreindl S, 2016, INVEST OPHTH VIS SCI, V57, P4144, DOI 10.1167/iovs.16-19772
   Rose-John S, 2012, INT J BIOL SCI, V8, P1237, DOI 10.7150/ijbs.4989
   Saint-Geniez M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003554
   Salom D, 2008, INVEST OPHTH VIS SCI, V49, P3499, DOI 10.1167/iovs.07-1168
   Sawada H, 2010, INVEST OPHTH VIS SCI, V51, P903, DOI 10.1167/iovs.09-4247
   Shiraya T, 2017, ACTA OPHTHALMOL, V95, pE340, DOI 10.1111/aos.13232
   Takai Y, 2012, INVEST OPHTH VIS SCI, V53, P241, DOI 10.1167/iovs.11-8434
   Taurone S, 2015, MOL MED REP, V11, P1384, DOI 10.3892/mmr.2014.2772
   ten Berge JCEM, 2016, ACTA OPHTHALMOL, V94, P282, DOI 10.1111/aos.12939
   Teng MWL, 2010, P NATL ACAD SCI USA, V107, P8328, DOI 10.1073/pnas.1003251107
   Tezel G, 2001, INVEST OPHTH VIS SCI, V42, P1787
   Xu HP, 2009, PROG RETIN EYE RES, V28, P348, DOI 10.1016/j.preteyeres.2009.06.001
   Yoshida N, 2013, OPHTHALMOLOGY, V120, P100, DOI 10.1016/j.ophtha.2012.07.006
   Yuan L, 2000, GLIA, V32, P42, DOI 10.1002/1098-1136(200010)32:1<42::AID-GLIA40>3.0.CO;2-3
NR 55
TC 53
Z9 57
U1 1
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD MAR
PY 2019
VL 97
IS 2
BP 185
EP 192
DI 10.1111/aos.13899
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HM7DQ
UT WOS:000459637900014
PM 30298670
OA Green Submitted, Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Decroos, FC
   Reed, D
   Adam, MK
   Salz, D
   Gupta, OP
   Ho, AC
   Regillo, CD
AF Decroos, Francis Char
   Reed, David
   Adam, Murtaza K.
   Salz, David
   Gupta, Omesh P.
   Ho, Allen C.
   Regillo, Carl D.
TI Treat-and-Extend Therapy Using Aflibercept for Neovascular Age-related
   Macular Degeneration: A Prospective Clinical Trial
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID VEGF TRAP; RANIBIZUMAB; BEVACIZUMAB; OUTCOMES; REGIMEN; GROWTH; FLUID
AB PURPOSE: To determine the efficacy and durability of aflibercept used in a treat-and-extend (TAE) regimen for neovascular age-related macular degeneration (NVAMD).
   DESIGN: Multicenter, prospective, open label, noncomparative, interventional study.
   METHODS: Forty eyes of 40 patients with treatment nave NVAMD were managed with a TAE regimen of intravitreal aflibercept. The main endpoints were the change in mean and median best-corrected visual acuity from baseline at years 1 and 2. Other endpoints included mean number of annual injections and treatment intervals.
   RESULTS: Thirty-five (87.5%) and 31 patients (77.5%) completed year 1 and year 2, respectively. The mean letter gain was 7.2 (P < .001) and 2.4 (P = .269) letters at 1 and 2 years, respectively, from a mean baseline of 58.9 letters (20/63 Snellen equivalent). The median visual gain was 11.5 and 7.5 letters at 1 and 2 years, respectively, from a median baseline of 59.0 letters (20/63 Snellen equivalent). The mean number of injections was 8.0 and 6.5 during the first and second year, respectively. Twelve-week or longer treatment intervals were used in 35% and 38% of patients during the first- and second-year time points, respectively.
   CONCLUSION: Intravitreal aflibercept TAE therapy led to significant visual improvement in eyes with NVAMD at 1 year, with some loss in the visual gains at the end of year 2 that was not related to loss of exudative control. TAE therapy with aflibercept is a rational strategy to reduce treatments and clinic evaluations over 2 years with satisfactory outcomes. (C) 2017 Elsevier Inc. All rights reserved.
C1 [Decroos, Francis Char; Reed, David; Adam, Murtaza K.; Salz, David; Gupta, Omesh P.; Ho, Allen C.; Regillo, Carl D.] Wills Eye Hosp & Res Inst, Mid Atlantic Retina, Retina Serv, 840 Walnut St,Suite 1020, Philadelphia, PA 19107 USA.
   [Decroos, Francis Char] Southeastern Retina Associates, Chattanooga, TN USA.
C3 Jefferson University
RP Regillo, CD (通讯作者)，Wills Eye Hosp & Res Inst, Mid Atlantic Retina, Retina Serv, 840 Walnut St,Suite 1020, Philadelphia, PA 19107 USA.
EM cregillo@midatanticretina.com
OI Ho, Allen/0000-0003-3921-608X
FU REGENERON (TARRYTOWN, NEW YORK, USA)
FX THIS WORK WAS SUPPORTED BY REGENERON (TARRYTOWN, NEW YORK, USA).
CR Abedi F, 2014, RETINA-J RET VIT DIS, V34, P1531, DOI 10.1097/IAE.0000000000000134
   Arnold JJ, 2015, OPHTHALMOLOGY, V122, P1212, DOI 10.1016/j.ophtha.2015.02.009
   Barthelmes D, 2016, BRIT J OPHTHALMOL, V100, P1640, DOI 10.1136/bjophthalmol-2015-308090
   Berg K, 2016, OPHTHALMOLOGY, V123, P51, DOI 10.1016/j.ophtha.2015.09.018
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Freund KB, 2015, RETINA-J RET VIT DIS, V35, P1489, DOI 10.1097/IAE.0000000000000627
   Grunwald JE, 2017, OPHTHALMOLOGY, V124, P97, DOI 10.1016/j.ophtha.2016.09.012
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Homer N, 2015, EYE, V29, P1152, DOI 10.1038/eye.2015.87
   Jaffe GJ, 2016, OPHTHALMOLOGY, V123, P1856, DOI 10.1016/j.ophtha.2016.05.016
   Kodjikian L, 2013, OPHTHALMOLOGY, V120, P2300, DOI 10.1016/j.ophtha.2013.06.020
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P266, DOI 10.1136/bjophthalmol-2012-302391
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Oubraham H, 2011, RETINA-J RET VIT DIS, V31, P26, DOI 10.1097/IAE.0b013e3181de5609
   Peden MC, 2015, OPHTHALMOLOGY, V122, P803, DOI 10.1016/j.ophtha.2014.11.018
   Rahimy E, 2015, RETINA, V36, P875
   Rayess N, 2015, AM J OPHTHALMOL, V159, P3, DOI 10.1016/j.ajo.2014.09.011
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Shienbaum G, 2012, AM J OPHTHALMOL, V153, P468, DOI 10.1016/j.ajo.2011.08.011
   Spaide RF, 2009, AM J OPHTHALMOL, V148, P1, DOI 10.1016/j.ajo.2009.04.010
   Stewart MW, 2008, BRIT J OPHTHALMOL, V92, P667, DOI 10.1136/bjo.2007.134874
   Stone TW, 2016, ASRS PREFERENCES TRE
   Toalster N, 2013, RETINA-J RET VIT DIS, V33, P1351, DOI 10.1097/IAE.0b013e3182831265
   Toth CA, 2015, RETINA-J RET VIT DIS, V35, P1303, DOI 10.1097/IAE.0000000000000483
   Waldstein SM, 2016, OPHTHALMOLOGY, V123, P1521, DOI 10.1016/j.ophtha.2016.03.037
   Wykoff CC, 2015, OPHTHALMOLOGY, V122, P2514, DOI 10.1016/j.ophtha.2015.08.009
NR 33
TC 52
Z9 52
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD AUG
PY 2017
VL 180
BP 142
EP 150
DI 10.1016/j.ajo.2017.06.002
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FC6ZK
UT WOS:000406990000020
PM 28624325
DA 2022-11-30
ER

PT J
AU Shen, LBL
   Sun, MY
   Ahluwalia, A
   Park, MM
   Young, BK
   Lad, EM
   Toth, C
   Del Priore, LV
AF Shen, Liangbo L.
   Sun, Mengyuan
   Ahluwalia, Aneesha
   Park, Michael M.
   Young, Benjamin K.
   Lad, Eleonora M.
   Toth, Cynthia
   Del Priore, Lucian, V
TI Natural history of central sparing in geographic atrophy secondary to
   non-exudative age-related macular degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE retina; macula; degeneration; treatment medical
ID VISUAL-ACUITY; BETA-CAROTENE; VITAMIN-C; PROGRESSION; METAANALYSIS;
   DISEASE; EYES; SUPPLEMENTATION; PREVENTION; ZINC
AB Background The macular central 1 mm diameter zone is crucial to patients' visual acuity, but the long-term natural history of central sparing in eyes with geographic atrophy (GA) is unknown. Methods We manually segmented GA in 210 eyes with GA involving central 1 mm diameter zone (mean follow-up=3.8 years) in the Age-Related Eye Disease Study. We measured the residual area in central 1 mm diameter zone and calculated central residual effective radius (CRER) as square root of (residual area/pi). A linear mixed-effects model was used to model residual size over time. We added a horizontal translation factor to each data set to account for different durations of GA involving the central zone. Results The decline rate of central residual area was associated with baseline residual area (p=0.008), but a transformation from central residual area to CRER eliminated this relationship (p=0.51). After the introduction of horizontal translation factors to each data set, CRER declined linearly over approximately 13 years (r(2)=0.80). The growth rate of total GA effective radius was 0.14 mm/year (95% CI 0.12 to 0.15), 3.7-fold higher than the decline rate of CRER (0.038 mm/year, 95% CI 0.034 to 0.042). The decline rate of CRER was 53.3% higher in eyes with than without advanced age-related macular degeneration in the fellow eyes at any visit (p=0.007). Conclusions CRER in eyes with GA declined linearly over approximately 13 years and may serve as an anatomic endpoint in future clinical trials aiming to preserve the central zone.
C1 [Shen, Liangbo L.; Ahluwalia, Aneesha; Park, Michael M.; Young, Benjamin K.; Del Priore, Lucian, V] Yale Univ, Dept Ophthalmol & Visual Sci, Sch Med, New Haven, CT 06510 USA.
   [Sun, Mengyuan] Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06510 USA.
   [Lad, Eleonora M.; Toth, Cynthia] Duke Univ, Dept Ophthalmol, Sch Med, Durham, NC USA.
   [Toth, Cynthia] Duke Univ, Dept Biomed Engn, Durham, NC USA.
C3 Yale University; Yale University; Duke University; Duke University
RP Del Priore, LV (通讯作者)，Yale Univ, Dept Ophthalmol & Visual Sci, Sch Med, New Haven, CT 06510 USA.
EM ldelpriore@yahoo.com
OI Shen, Liangbo/0000-0002-1823-0854
FU Richard K. Gershon, M.D., Student Research Fellowship; National Eye
   Institute (NEI) [P30 EY026878]
FX We thank the AREDS group for gathering the data and making the data
   available through dbGaP.<SUP>15</SUP> This publication was made possible
   by the Richard K. Gershon, M.D., Student Research Fellowship (Recipient:
   Shen), and P30 EY026878 from the National Eye Institute (NEI)
   (Recipient: Yale Vision Science Core).
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Age-Related Eye Disease Study 2 Research Group, 2013, JAMA, V309, P2005, DOI 10.1001/jama.2013.4997
   Aslam Tariq, 2014, Clin Ophthalmol, V8, P2045, DOI 10.2147/OPTH.S63937
   Bagheri Saghar, 2019, J Vitreoretin Dis, V3, P278, DOI 10.1177/2474126419859454
   Bates D, 2015, J STAT SOFTW, V67, P1, DOI 10.18637/jss.v067.i01
   Bjelakovic G, 2007, JAMA-J AM MED ASSOC, V297, P842, DOI 10.1001/jama.297.8.842
   Chew EY, 2013, OPHTHALMOLOGY, V120, P1604, DOI 10.1016/j.ophtha.2013.01.021
   Druesne-Pecollo N, 2010, INT J CANCER, V127, P172, DOI 10.1002/ijc.25008
   Guymer RH, 2020, OPHTHALMOLOGY, V127, P394, DOI 10.1016/j.ophtha.2019.09.035
   Heier JS, 2020, OPHTHALMOL RETINA, V4, P673, DOI 10.1016/j.oret.2020.01.019
   Holz FG, 2017, OPHTHALMOLOGY, V124, P464, DOI 10.1016/j.ophtha.2016.12.002
   Jaffe GJ, 2021, OPHTHALMOLOGY, V128, P576, DOI 10.1016/j.ophtha.2020.08.027
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Keenan TD, 2018, OPHTHALMOLOGY, V125, P1913, DOI 10.1016/j.ophtha.2018.05.028
   Li ML, 2018, RETINA-J RET VIT DIS, V38, P1937, DOI 10.1097/IAE.0000000000002182
   Lindblad AS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1168, DOI 10.1001/archophthalmol.2009.198
   Lindner M, 2017, INVEST OPHTH VIS SCI, V58, pBIO61, DOI 10.1167/iovs.16-21210
   Lindner M, 2015, OPHTHALMOLOGY, V122, P1356, DOI 10.1016/j.ophtha.2015.03.027
   Mailman MD, 2007, NAT GENET, V39, P1181, DOI 10.1038/ng1007-1181
   Mauschitz MM, 2012, INVEST OPHTH VIS SCI, V53, P4932, DOI 10.1167/iovs.12-9711
   Rosenfeld PJ, 2018, OPHTHALMOLOGY, V125, P1556, DOI 10.1016/j.ophtha.2018.03.059
   Rueden CT, 2017, BMC BIOINFORMATICS, V18, DOI 10.1186/s12859-017-1934-z
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   Sayegh RG, 2017, AM J OPHTHALMOL, V179, P118, DOI 10.1016/j.ajo.2017.03.031
   Schmitz-Valckenberg S, 2016, OPHTHALMOLOGICA, V235, P215, DOI 10.1159/000445217
   Sesso HD, 2008, JAMA-J AM MED ASSOC, V300, P2123, DOI 10.1001/jama.2008.600
   Shen LB, 2018, OPHTHALMOL RETINA, V2, P914, DOI 10.1016/j.oret.2018.01.019
   Shen LBL, 2021, BRIT J OPHTHALMOL, V105, P271, DOI 10.1136/bjophthalmol-2020-316028
   Shen LL, 2021, OPHTHALMOL RETINA, V5, P868, DOI 10.1016/j.oret.2020.12.002
   Shen LL, 2021, OPHTHALMOL RETINA, V5, P761, DOI 10.1016/j.oret.2020.11.003
   Shen LL, 2020, OPHTHALMOL RETINA, V4, P899, DOI 10.1016/j.oret.2020.03.020
   Shen LL, 2020, OPHTHALMOL RETINA, V4, P840, DOI 10.1016/j.oret.2020.03.003
   Shen LBL, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.1.2
   Shen LBL, 2019, OPHTHALMOLOGY, V126, P1288, DOI 10.1016/j.ophtha.2019.05.015
   Shen LBL, 2019, OPHTHALMOL RETINA, V3, P305, DOI 10.1016/j.oret.2018.11.013
   Shen LBL, 2019, RETINA-J RET VIT DIS, V39, P1829, DOI 10.1097/IAE.0000000000002480
   Sunness JS, 1999, INVEST OPHTH VIS SCI, V40, P1761
   Veritti D, 2020, EXPERT OPIN PHARMACO, V21, P773, DOI 10.1080/14656566.2020.1736557
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P679, DOI 10.1016/j.ophtha.2010.08.018
NR 42
TC 3
Z9 3
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD MAY
PY 2022
VL 106
IS 5
BP 689
EP 695
DI 10.1136/bjophthalmol-2020-317636
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 0V8MH
UT WOS:000788593700017
PM 33361441
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Nikoi, ND
   Berwick, M
   Bryant, JA
   Riordan, L
   Slope, L
   Peacock, AFA
   de Cogan, F
AF Nikoi, Naa-Dei
   Berwick, Matthew
   Bryant, Jack A.
   Riordan, Lily
   Slope, Louise
   Peacock, Anna F. A.
   de Cogan, Felicity
TI Stability of Cell-Penetrating Peptide anti-VEGF Formulations for the
   Treatment of Age-Related Macular Degeneration
SO CURRENT EYE RESEARCH
LA English
DT Article
DE Ocular drug delivery; stability; eye drops; cell-penetrating peptide
   (CPP); vascular endothelial growth factor (VEGF)
AB Aim
   The development of a polyarginine cell-penetrating peptide (CPP) could enable the treatment of age-related macular degeneration, with drugs like bevacizumab, to be administered using eye drops instead of intravitreal injections. Topical formulations have a vast potential impact on healthcare by increasing patient compliance while reducing the financial burden. However, as the ocular preparations may contain several doses, it is essential to understand the stability of the bevacizumab+CPP conjugate produced.
   Materials and Methods
   In this work, we examine the stability of a bevacizumab solution with and without cell-penetrating peptide using dynamic light scattering and circular dichroism to assess the physical stability. We use HPLC to assess the chemical stability and ELISA to assess its biological activity. We also examine the potential of the CPP to be used as an antimicrobial agent in place of preservatives in the eye drop.
   Results
   The structural stability of bevacizumab with and without the CPP was found not to be affected by temperature: samples stored at either 20 degrees C or 4 degrees C were identical in behavior. However, physical instability was observed after five weeks, leading to aggregation and precipitation. Further investigation revealed that the addition of the polypeptide led to increased aggregation, as revealed through dynamic light scattering and concentration analysis of the peptide through HPLC. Complexing the bevacizumab with CPP had no effect on biological stability or degradation.
   Conclusions
   Our findings suggest that the shelf life of CPP+bevacizumab complexes is at least 38 days from its initial formulation. Currently, the mechanism for aggregation is not fully understood but does not appear to occur through chemical degradation.
C1 [Nikoi, Naa-Dei; Berwick, Matthew; Bryant, Jack A.; Riordan, Lily; Slope, Louise; de Cogan, Felicity] Univ Birmingham, Inst Microbiol & Infect, Birmingham, W Midlands, England.
   [Nikoi, Naa-Dei] Univ Hosp Coventry & Warwickshire Trust, Pharm Dept, Coventry, W Midlands, England.
   [Berwick, Matthew; Peacock, Anna F. A.] Univ Birmingham, Sch Chem, Birmingham, W Midlands, England.
C3 University of Birmingham; University of Birmingham
RP de Cogan, F (通讯作者)，Univ Birmingham, Inst Microbiol & Infect, Birmingham, W Midlands, England.
EM F.deCogan@bham.ac.uk
OI de Cogan, Felicity/0000-0001-5083-7130; Nikoi,
   Naa-Dei/0000-0001-9628-6100; Riordan, Lily/0000-0002-7474-1659
FU Wellcome Trust Pathfinder Award; University of Birmingham; Pharmacy
   Department, University Hospitals Coventry and Warwickshire NHS Trust
FX This work has been funded by a Wellcome Trust Pathfinder Award, the
   University of Birmingham and the Pharmacy Department, University
   Hospitals Coventry and Warwickshire NHS Trust.
CR Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   [Anonymous], 2016, BRIT PHARMACOPOEIA
   Artunay O, 2009, EYE, V23, P2187, DOI 10.1038/eye.2009.7
   Bahnsen JS, 2013, BBA-BIOMEMBRANES, V1828, P223, DOI 10.1016/j.bbamem.2012.10.010
   Bhavsar AR, 2009, ARCH OPHTHALMOL-CHIC, V127, P1581, DOI 10.1001/archophthalmol.2009.304
   Bird AC, 2010, J CLIN INVEST, V120, P3033, DOI 10.1172/JCI42437
   British Pharmacopoeia, 2016, BRIT PHARMACOPOEIA
   Chen C, 2017, BIOMATERIALS, V112, P218, DOI 10.1016/j.biomaterials.2016.09.022
   Das T, 2015, CLIN EXP OPHTHALMOL, V43, P466, DOI 10.1111/ceo.12489
   de Cogan F, 2017, INVEST OPHTH VIS SCI, V58, P2578, DOI 10.1167/iovs.16-20072
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Heier JS, 2006, OPHTHALMOLOGY, V113, P633, DOI 10.1016/j.ophtha.2005.10.052
   Henriques ST, 2006, BIOCHEM J, V399, P1, DOI 10.1042/BJ20061100
   Lyall DAM, 2012, EYE, V26, P1517, DOI 10.1038/eye.2012.199
   Manosroi J, 2013, DRUG DEV IND PHARM, V39, P520, DOI 10.3109/03639045.2012.684388
   NHS Pharmaceutical Quality Assurance Committee, 2017, STAND PROT DER ASS S
   Owen CG, 2012, BRIT J OPHTHALMOL, V96, P752, DOI 10.1136/bjophthalmol-2011-301109
   Pescina S, 2010, J PHARM PHARMACOL, V62, P1189, DOI 10.1111/j.2042-7158.2010.01153.x
   Recereum, 2017, RECEREUM
   Singh T, 2018, DRUG DELIV, V25, P1996, DOI 10.1080/10717544.2018.1543366
   Wang Y, 2014, BIOMATERIALS, V35, P3102, DOI 10.1016/j.biomaterials.2013.12.049
   Xiang B, 2017, INT J NANOMED, V12, P2385, DOI 10.2147/IJN.S129574
   ZASSLOFF M, 2002, NATURE, V415
NR 23
TC 0
Z9 0
U1 3
U2 12
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0271-3683
EI 1460-2202
J9 CURR EYE RES
JI Curr. Eye Res.
PD MAY 4
PY 2021
VL 46
IS 5
BP 751
EP 757
DI 10.1080/02713683.2020.1830117
EA APR 2021
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA RU3DD
UT WOS:000643832200001
PM 33896277
DA 2022-11-30
ER

PT J
AU Trinh, M
   Kalloniatis, M
   Nivison-Smith, L
AF Trinh, Matt
   Kalloniatis, Michael
   Nivison-Smith, Lisa
TI Radial Peripapillary Capillary Plexus Sparing and Underlying Retinal
   Vascular Impairment in Intermediate Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE optical coherence tomography angiography; vessel perfusion; age-related;
   macular degeneration
ID OPTICAL COHERENCE TOMOGRAPHY; RETROBULBAR CIRCULATION;
   CARDIOVASCULAR-DISEASE; QUANTITATIVE-ANALYSIS; VESSEL DENSITY;
   ANGIOGRAPHY; MICROVASCULATURE; MACULOPATHY; MICROCIRCULATION;
   CHORIOCAPILLARIS
AB PURPOSE. To examine location-specific retinal vascular changes in intermediate age-related macular degeneration (iAMD) using age-matched, high-density en face optical coherence tomography angiography (OCTA) cluster analysis.
   METHODS. En face OCTA images of the 6 x 6 mm macular area were retrospectively acquired from 60 iAMD eyes and 60 age-matched normal eyes and then subdivided into 126 x 126 (47.62 x 47.62 mu m) grids within the superficial and deep vascular complex. Grid-wise vessel perfusion (VP) were compared between iAMD and normal eyes from the corresponding 10-yearly age cohort, forming difference plots. Difference plots were further separated by normative topographical map spatial clusters (C1-6), derived from normal(database) eyes (n = 236, 20-81 years old).
   RESULTS. Overall difference plots showed decreased VP in the superficial (-12.19%) and deep vascular complex (-6.44%) of iAMD compared to normal eyes (P < 0.0001 both comparisons). Cluster-based difference plots highlighted nonuniform changes in the superficial vascular complex, with sparing of VP at the nasal macula (corresponding to the radial peripapillary capillary plexus) versus decreased VP toward the temporal macula and foveal avascular zone (FAZ) (C1-6 all comparisons P < 0.0001, except C-1 vs. C-2 P > 0.99 and C-4 vs. C-5 P = 0.11). The deep vascular complex displayed diffusely decreased VP, greater at the FAZ (P < 0.0001).
   CONCLUSIONS. High-density en face OCTA cluster analysis suggests relative sparing of the radial peripapillary capillary plexus and impairment of underlying retinal vasculature, supporting potential anterograde transsynaptic degeneration in iAMD. These location-specific data may better guide future diagnostic and management protocol of iAMD.
C1 [Trinh, Matt; Kalloniatis, Michael; Nivison-Smith, Lisa] Univ New South Wales, Ctr Eye Hlth, Sydney, NSW, Australia.
   [Trinh, Matt; Kalloniatis, Michael; Nivison-Smith, Lisa] Univ New South Wales, Sch Optometry & Vis Sci, Rupert Myers Bldg,Gate 14,Barker St, Sydney, NSW 2052, Australia.
C3 University of New South Wales Sydney; University of New South Wales
   Sydney
RP Nivison-Smith, L (通讯作者)，Univ New South Wales, Sch Optometry & Vis Sci, Rupert Myers Bldg,Gate 14,Barker St, Sydney, NSW 2052, Australia.
EM l.nivison-smith@unsw.edu.au
RI Trinh, Matt/AAV-1249-2021
OI Trinh, Matt/0000-0002-6184-0666
FU Rebecca Cooper Foundation; National Health and Medical Research Council
   of Australia (NHMRC) [1174385]; Australian Research Training Program
   scholarship; Guide Dogs NSW/ACT
FX Supported by research grants from the Rebecca Cooper Foundation and the
   National Health and Medical Research Council of Australia (NHMRC Grant
   no. 1174385), the Australian Research Training Program scholarship, and
   Guide Dogs NSW/ACT.
CR Ahn SM, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-0866-3
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Attwell D, 2010, NATURE, V468, P232, DOI 10.1038/nature09613
   BELL MA, 1981, ACTA NEUROPATHOL, V53, P299, DOI 10.1007/BF00690372
   Biesemeier A, 2014, NEUROBIOL AGING, V35, P2562, DOI 10.1016/j.neurobiolaging.2014.05.003
   Borrelli E, 2019, OPHTHALMOL THER, V8, P215, DOI 10.1007/s40123-019-0178-6
   Campbell JP, 2017, SCI REP-UK, V7, DOI 10.1038/srep42201
   Chan G, 2015, MICROVASC RES, V100, P32, DOI 10.1016/j.mvr.2015.04.006
   Chan G, 2012, INVEST OPHTH VIS SCI, V53, P5502, DOI 10.1167/iovs.12-10265
   Cheung CMG, 2014, J INTERN MED, V276, P140, DOI 10.1111/joim.12227
   Choi AYJ, 2019, SCI REP, V9, P1, DOI DOI 10.1038/S41598-018-37186-2
   Cicinelli MV, 2018, BRIT J OPHTHALMOL, V102, P1192, DOI 10.1136/bjophthalmol-2017-311317
   Cicinelli MV, 2018, SURV OPHTHALMOL, V63, P236, DOI 10.1016/j.survophthal.2017.06.005
   Ciloglu E, 2020, J CURR OPHTHALMOL, V32, P53, DOI 10.1016/j.joco.2019.09.002
   Ciulla TA, 1999, AM J OPHTHALMOL, V128, P75, DOI 10.1016/S0002-9394(99)00061-6
   Clemons Traci E, 2005, Ophthalmology, V112, P533
   Cole ED, 2017, OPHTHALMOL RETINA, V1, P435, DOI 10.1016/j.oret.2017.01.019
   Cuenca N, 2020, PROG RETIN EYE RES, V77, DOI 10.1016/j.preteyeres.2019.100828
   Czako C, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.5.10
   DERKSEN S, 1992, BRIT J MATH STAT PSY, V45, P265, DOI 10.1111/j.2044-8317.1992.tb00992.x
   Dimitrova G, 2002, EYE, V16, P580, DOI 10.1038/sj.eye.6700161
   Feigl B, 2007, EYE, V21, P689, DOI 10.1038/sj.eye.6702389
   Feigl B, 2007, CLIN EXP OPTOM, V90, P263, DOI 10.1111/j.1444-0938.2007.00152.x
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Freund KB, 2018, AM J OPHTHALMOL, V190, P78, DOI 10.1016/j.ajo.2018.03.029
   FRIEDMAN E, 1995, OPHTHALMOLOGY, V102, P640, DOI 10.1016/S0161-6420(95)30974-8
   Garrity ST, 2017, INVEST OPHTH VIS SCI, V58, P5548, DOI 10.1167/iovs.17-22036
   Gelbard R, 2007, DATA KNOWL ENG, V63, P155, DOI 10.1016/j.datak.2007.01.002
   Guymer RH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083759
   Hallak JA, 2019, JAMA OPHTHALMOL, V137, P738, DOI 10.1001/jamaophthalmol.2019.0868
   Hashmani N, 2019, CLIN OPHTHALMOL, V13, P295, DOI 10.2147/OPTH.S189515
   Hosal BM, 1998, EUR J OPHTHALMOL, V8, P234, DOI 10.1177/112067219800800406
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Iafe NA, 2016, INVEST OPHTH VIS SCI, V57, P5780, DOI 10.1167/iovs.16-20045
   JAESCHKE R, 1989, CONTROL CLIN TRIALS, V10, P407, DOI 10.1016/0197-2456(89)90005-6
   Keefe RS, 2013, INNOVATIONS CLIN SA, V10, p4S
   Klein R, 2007, ARCH OPHTHALMOL-CHIC, V125, P534, DOI 10.1001/archopht.125.4.534
   KORNZWEIG AL, 1966, ARCH OPHTHALMOL-CHIC, V75, P326
   KORTE GE, 1984, INVEST OPHTH VIS SCI, V25, P1135
   Kraker JA, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.11.7
   Lavia C, 2019, RETINA-J RET VIT DIS, V39, P247, DOI 10.1097/IAE.0000000000002413
   Lee B, 2018, INVEST OPHTH VIS SCI, V59, P5246, DOI 10.1167/iovs.17-23600
   Lee SC, 2020, AM J OPHTHALMOL, V212, P7, DOI 10.1016/j.ajo.2019.11.031
   Leung H, 2005, EYE, V19, P861, DOI 10.1038/sj.eye.6701668
   Lim HB, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-31321-9
   Lutty GA, 2020, EXP EYE RES, V192, DOI 10.1016/j.exer.2020.107939
   Macmillan N., 2004, DETECTION THEORY USE, Vxix
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P743, DOI 10.1001/archopht.1995.01100060069034
   Trinh M, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-020-79424-6
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Muraoka Y, 2018, INVEST OPHTH VIS SCI, V59, P5847, DOI 10.1167/iovs.18-25301
   Onishi AC, 2018, INVEST OPHTH VIS SCI, V59, P2167, DOI 10.1167/iovs.17-23304
   Ozcaliskan S, 2020, PHOTODIAGN PHOTODYN, V32, DOI 10.1016/j.pdpdt.2020.102030
   Panneman EL, 2019, NEURO-OPHTHALMOLOGY, V43, P382, DOI 10.1080/01658107.2019.1599027
   Parisi V, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.5.11
   Park JJ, 2016, RETINA-J RET VIT DIS, V36, P2039, DOI 10.1097/IAE.0000000000001077
   Rabiolo A, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0205773
   Rao HL, 2017, J GLAUCOMA, V26, P491, DOI 10.1097/IJG.0000000000000655
   Reiter GS, 2019, INVEST OPHTH VIS SCI, V60, P2503, DOI 10.1167/iovs.18-26237
   Sato E, 2006, EYE, V20, P697, DOI 10.1038/sj.eye.6701951
   Shin YI, 2020, OPHTHALMOLOGICA, V243, P145, DOI 10.1159/000503295
   Sleiman K, 2017, OPHTHALMOLOGY, V124, P1764, DOI 10.1016/j.ophtha.2017.06.032
   Spaide RF, 2018, PROG RETIN EYE RES, V64, P1, DOI 10.1016/j.preteyeres.2017.11.003
   Sullivan Gail M, 2012, J Grad Med Educ, V4, P279, DOI 10.4300/JGME-D-12-00156.1
   Tan PEZ, 2015, INVEST OPHTH VIS SCI, V56, P3989, DOI 10.1167/iovs.14-15879
   Tan PEZ, 2012, INVEST OPHTH VIS SCI, V53, P5728, DOI 10.1167/iovs.12-10017
   Terheyden JH, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0230260
   Tong J, 2019, AM J OPHTHALMOL, V208, P166, DOI 10.1016/j.ajo.2019.04.020
   Toto L, 2017, BRIT J OPHTHALMOL, V101, P774, DOI 10.1136/bjophthalmol-2016-309160
   Toto L, 2016, RETINA-J RET VIT DIS, V36, P1566, DOI 10.1097/IAE.0000000000000962
   Trinh M, 2019, TRANSL VIS SCI TECHN, V8, DOI 10.1167/tvst.8.4.20
   Vaghefi E, 2020, ASIA-PAC J OPHTHALMO, V9, P137, DOI 10.1097/APO.0000000000000278
   Vecino E, 2016, PROG RETIN EYE RES, V51, P1, DOI 10.1016/j.preteyeres.2015.06.003
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   Waldstein SM, 2020, JAMA OPHTHALMOL, V138, P740, DOI 10.1001/jamaophthalmol.2020.1376
   Wang H, 2021, CLIN EXP OPTOM, V104, P625, DOI 10.1080/08164622.2021.1878846
   Wang J, 2019, BIOMED OPT EXPRESS, V10, P1532, DOI 10.1364/BOE.10.001532
   Wang JJ, 2004, BRIT J OPHTHALMOL, V88, P104, DOI 10.1136/bjo.88.1.104
   Wei YT, 2017, INVEST OPHTH VIS SCI, V58, P3804, DOI 10.1167/iovs.17-21460
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yoshioka N, 2018, INVEST OPHTH VIS SCI, V59, P1693, DOI 10.1167/iovs.17-23683
   Yoshioka N, 2017, INVEST OPHTH VIS SCI, V58, P3086, DOI 10.1167/iovs.17-21450
   Yu JJ, 2019, OPHTHALMOL RETINA, V3, P835, DOI 10.1016/j.oret.2019.04.029
NR 83
TC 2
Z9 2
U1 0
U2 2
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD APR
PY 2021
VL 62
IS 4
AR 2
DI 10.1167/iovs.62.4.2
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA RM2XB
UT WOS:000639527200002
PM 33792619
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Warwick, AN
   Leaver, HH
   Lotery, AJ
   Goverdhan, SV
AF Warwick, Alasdair N.
   Leaver, Hannah H.
   Lotery, Andrew J.
   Goverdhan, Srini V.
TI Fixed bimonthly aflibercept in naive and switched neovascular
   age-related macular degeneration patients: one year outcomes
SO INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; ranibizumab; aflibercept;
   anti-vascular endothelial growth factor
ID INTRAVITREAL AFLIBERCEPT; ANATOMICAL OUTCOMES; CLINICAL-EXPERIENCE;
   RANIBIZUMAB; EYES; VERTEPORFIN; INJECTION; FLUID
AB AIM: To determine real life clinical outcomes in poorly responsive and treatment-naive neovascular age-related macular degeneration (nvAMD) patients using bimonthly fixed dosing aflibercept regimen.
   METHODS: This was a retrospective study of 165 eyes with nvAMD started on aflibercept at Southampton Eye Unit between June 2013 and June 2014. Patients were either switched from pro re nata (PRN) ranibizumab/bevacizumab due to poor response (107 eyes), or treatment-nave (58 eyes). Patients initially received 3-monthly intravitreal aflibercept injections followed by 2-monthly fixed doses. Clinic visits were scheduled at month 0, 4, 10 and 12. Mean change in best-corrected visual acuity (BCVA) and central retinal thickness (CRT) from baseline were assessed using the Wilcoxon signed rank test. The proportion of patients maintaining BCVA (<15 letters loss) at 12mo was also evaluated.
   RESULTS: Mean BCVA change at month 12 was +3.29 and +4.67 letters in the switched and naive aflibercept groups respectively (P<0.01). BCVA was maintained in 95.3% of switched and 96.6% of naive patients. CRT at month 12 showed a decrease of -6.16 mu m in the switched group and -35.36 mu m in the nave group (P<0.01). Patients previously treated with ranibizumab/bevacizumab had on average received 7.4 ranibizumab/bevacizumab injections over 12.6mo, attending 10 clinic visits. The fixed dosing aflibercept regimen required an average of 7.1 injections (naive group), 7.5 injections (switched group) and 4 clinic visits per year.
   CONCLUSION: Fixed bimonthly aflibercept is effective in both treatment-naive and poorly responsive nvAMD patients. Adopting a fixed dosing regimen can reduce patient burden without compromising on outcomes.
C1 [Warwick, Alasdair N.; Leaver, Hannah H.; Lotery, Andrew J.; Goverdhan, Srini V.] Univ Southampton, Fac Med, Clin Neurosci Res Grp, Clin & Expt Sci, Southampton, Hants, England.
   [Warwick, Alasdair N.; Lotery, Andrew J.; Goverdhan, Srini V.] Univ Hosp Southampton NHS Fdn Trust, Southampton Eye Unit, Southampton, Hants, England.
C3 University of Southampton; University of Southampton; University
   Hospital Southampton NHS Foundation Trust
RP Goverdhan, SV (通讯作者)，Southampton Eye Unit, Tremona Rd, Southampton SO16 6YD, Hants, England.
EM s.goverdhan@soton.ac.uk
OI Warwick, Alasdair/0000-0002-0800-2890; Lotery,
   Andrew/0000-0001-5541-4305
FU Bayer; Novartis
FX Alasdair N Warwick has been supported by a travel grant from Bayer.
   Andrew J Lotery has served on medical advisory boards for Bayer, Roche
   and Novartis pharmaceuticals. Srini V Goverdhan has been supported by
   travel grants from Novartis and Bayer. Hannah H Leaver, None.
CR Arcinue CA, 2015, AM J OPHTHALMOL, V159, P426, DOI 10.1016/j.ajo.2014.11.022
   Bakall B, 2013, AM J OPHTHALMOL, V156, P15, DOI 10.1016/j.ajo.2013.02.017
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chang AA, 2014, OPHTHALMOLOGY, V121, P188, DOI 10.1016/j.ophtha.2013.08.035
   Cho H, 2013, BRIT J OPHTHALMOL, V97, P1032, DOI 10.1136/bjophthalmol-2013-303344
   Ferrone PJ, 2014, BRIT J OPHTHALMOL, V98, P17, DOI 10.1136/bjophthalmol-2013-304474
   Gharbiya M, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/273754
   Grewal DS, 2014, EYE, V28, P895, DOI 10.1038/eye.2014.101
   He LM, 2015, OSLI RETINA, V46, P542, DOI 10.3928/23258160-20150521-05
   Ho VY, 2013, AM J OPHTHALMOL, V156, P23, DOI 10.1016/j.ajo.2013.02.009
   Kawashima Y, 2015, GRAEF ARCH CLIN EXP, V253, P1471, DOI 10.1007/s00417-014-2838-5
   Khanani AM, 2015, CLIN OPHTHALMOL, V9, P1315, DOI 10.2147/OPTH.S88624
   Klein R, 2004, AM OPHTHALMOL, V137, P486
   Kumar N, 2013, RETINA-J RET VIT DIS, V33, P1605, DOI 10.1097/IAE.0b013e31828e8551
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Larsen M, 2012, OPHTHALMOLOGY, V119, P992, DOI 10.1016/j.ophtha.2012.02.002
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Messenger WB, 2014, BRIT J OPHTHALMOL, V98, P1205, DOI 10.1136/bjophthalmol-2013-304829
   Moon Da Ru Chi, 2015, Korean J Ophthalmol, V29, P226, DOI 10.3341/kjo.2015.29.4.226
   Oishi A, 2015, AM J OPHTHALMOL, V159, P853, DOI 10.1016/j.ajo.2015.01.018
   Peden MC, 2015, OPHTHALMOLOGY, V122, P803, DOI 10.1016/j.ophtha.2014.11.018
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Singh RP, 2014, BRIT J OPHTHALMOL, V98, P1, DOI 10.1136/bjophthalmol-2014-305502
   Talks JS, 2016, OPHTHALMOLOGY, V123, P337, DOI 10.1016/j.ophtha.2015.09.039
   Wykoff CC, 2014, BR J OPHTHALMOL, V98, P951
NR 30
TC 7
Z9 7
U1 0
U2 0
PU IJO PRESS
PI XI AN
PA NO 269 YOUYI EAST RD, XI AN, 710054, PEOPLES R CHINA
SN 2222-3959
EI 2227-4898
J9 INT J OPHTHALMOL-CHI
JI Int. J. Ophthalmol.
PD AUG 18
PY 2016
VL 9
IS 8
BP 1156
EP 1162
DI 10.18240/ijo.2016.08.12
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DT8CP
UT WOS:000381716900012
PM 27588271
OA Green Published, gold, Green Submitted, Green Accepted
DA 2022-11-30
ER

PT J
AU Potapenko, I
   Thiesson, B
   Kristensen, M
   Hajari, JN
   Ilginis, T
   Fuchs, J
   Hamann, S
   la Cour, M
AF Potapenko, Ivan
   Thiesson, Bo
   Kristensen, Mads
   Hajari, Javad Nouri
   Ilginis, Tomas
   Fuchs, Josefine
   Hamann, Steffen
   la Cour, Morten
TI Automated artificial intelligence-based system for clinical follow-up of
   patients with age-related macular degeneration
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE artificial intelligence; age-related macular degeneration; anti-vegf;
   follow-up
ID VISUAL-ACUITY; QUANTIFICATION; FLUID
AB Purpose In this study, we investigate the potential of a novel artificial intelligence-based system for autonomous follow-up of patients treated for neovascular age-related macular degeneration (AMD). Methods A temporal deep learning model was trained on a data set of 84 489 optical coherence tomography scans from AMD patients to recognize disease activity, and its performance was compared with a published non-temporal model trained on the same data (Acta Ophthalmol, 2021). An autonomous follow-up system was created by augmenting the AI model with deterministic logic to suggest treatment according to the observe-and-plan regimen. To validate the AI-based system, a data set comprising clinical decisions and imaging data from 200 follow-up consultations was collected prospectively. In each case, both the autonomous AI decision and original clinical decision were compared with an expert panel consensus. Results The temporal AI model proved superior at detecting disease activity compared with the model without temporal input (area under the curve 0.900 (95% CI 0.894-0.906) and 0.857 (95% CI 0.846-0.867) respectively). The AI-based follow-up system could make an autonomous decision in 73% of the cases, 91.8% of which were in agreement with expert consensus. This was on par with the 87.7% agreement rate between decisions made in the clinic and expert consensus (p = 0.33). Conclusions The proposed autonomous follow-up system was shown to be safe and compliant with expert consensus on par with clinical practice. The system could in the future ease the pressure on public ophthalmology services from an increasing number of AMD patients.
C1 [Potapenko, Ivan; Hajari, Javad Nouri; Ilginis, Tomas; Fuchs, Josefine; Hamann, Steffen; la Cour, Morten] Rigshosp, Dept Ophthalmol, Valdemar Hansens Vej 1-23, DK-2600 Copenhagen, Denmark.
   [Potapenko, Ivan; Hamann, Steffen; la Cour, Morten] Univ Copenhagen, Fac Hlth & Med Sci, Copenhagen, Denmark.
   [Thiesson, Bo; Kristensen, Mads] Enversion AS, Aarhus, Denmark.
   [Thiesson, Bo] Aarhus Univ, Dept Engn, Aarhus, Denmark.
C3 Rigshospitalet; University of Copenhagen; University of Copenhagen;
   Aarhus University
RP Potapenko, I (通讯作者)，Rigshosp, Dept Ophthalmol, Valdemar Hansens Vej 1-23, DK-2600 Copenhagen, Denmark.
EM ivan.olegovich.potapenko@regionh.dk
OI Potapenko, Ivan/0000-0002-7201-655X
CR Abramoff MD, 2018, NPJ DIGIT MED, V1, DOI 10.1038/s41746-018-0040-6
   Baek SK, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-49749-y
   Bhavsar KV, 2014, SAUDI J OPHTHALMOL, V28, P129, DOI 10.1016/j.sjopt.2014.03.001
   Bhuiyan A., 2021, ANN EYE SCI, V6, P12
   Brown DM, 2007, AM J OPHTHALMOL, V144, P627, DOI 10.1016/j.ajo.2007.06.039
   Brynskov T, 2020, ACTA OPHTHALMOL, V98, P132, DOI 10.1111/aos.14183
   Burlina P, 2018, JAMA OPHTHALMOL, V136, P1305, DOI 10.1001/jamaophthalmol.2018.3799
   Chandra S., 2021, EYE, V2021, P1
   De Fauw J, 2018, NAT MED, V24, P1342, DOI 10.1038/s41591-018-0107-6
   Gao K, 2019, COMPUT METH PROG BIO, V176, P69, DOI 10.1016/j.cmpb.2019.04.027
   Gheisari S, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-81554-4
   He MG, 2020, ASIA-PAC J OPHTHALMO, V9, P299, DOI 10.1097/APO.0000000000000301
   Ho AC, 2017, JAMA OPHTHALMOL, V135, P268, DOI 10.1001/jamaophthalmol.2016.5314
   Hwang DK, 2019, THERANOSTICS, V9, P232, DOI 10.7150/thno.28447
   Ipp E, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.34254
   Jang LN, 2015, GRAEF ARCH CLIN EXP, V253, P1211, DOI 10.1007/s00417-014-2789-x
   Jiang JW, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0201142
   Lee CS, 2017, OPHTHALMOL RETINA, V1, P322, DOI 10.1016/j.oret.2016.12.009
   Li MX, 2019, INT J OPHTHALMOL-CHI, V12, P1012, DOI 10.18240/ijo.2019.06.22
   Motozawa N, 2019, OPHTHALMOL THER, V8, P527, DOI 10.1007/s40123-019-00207-y
   Muller PL, 2021, TRANSL VIS SCI TECHN, V10, DOI 10.1167/tvst.10.3.4
   Papadopoulos Z, 2020, CURR MED SCI, V40, P851, DOI 10.1007/s11596-020-2253-6
   Parvin P, 2017, GRAEF ARCH CLIN EXP, V255, P2127, DOI 10.1007/s00417-017-3762-2
   Patel Y, 2020, OPHTHALMOL RETINA, V4, P141, DOI 10.1016/j.oret.2019.09.006
   Potapenko I, 2022, ACTA OPHTHALMOL, V100, P103, DOI 10.1111/aos.14895
   Potapenko I, 2021, ACTA OPHTHALMOL, V99, pE1348, DOI 10.1111/aos.14802
   Prahl A, 2017, COUNS VALUES, V62, P144, DOI 10.1002/cvj.12056
   Sabottke CF, 2020, RADIOL-ARTIF INTELL, V2, DOI 10.1148/ryai.2019190015
   Schlegl T, 2018, OPHTHALMOLOGY, V125, P549, DOI 10.1016/j.ophtha.2017.10.031
   Schmidt-Erfurth U, 2022, PROG RETIN EYE RES, V86, DOI 10.1016/j.preteyeres.2021.100972
   Schmidt-Erfurth U, 2020, OPHTHALMOLOGY, V127, P1211, DOI 10.1016/j.ophtha.2020.03.010
   Ting DSW, 2019, BRIT J OPHTHALMOL, V103, P167, DOI 10.1136/bjophthalmol-2018-313173
   Tsuji T, 2020, BMC OPHTHALMOL, V20, DOI 10.1186/s12886-020-01382-4
   Vittrup M., 2019, COMMUNICATION
NR 34
TC 1
Z9 1
U1 3
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD DEC
PY 2022
VL 100
IS 8
BP 927
EP 936
DI 10.1111/aos.15133
EA MAR 2022
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 6D4SX
UT WOS:000772226600001
PM 35322564
DA 2022-11-30
ER

PT J
AU Wakuta, M
   Nomi, N
   Ogata, T
   Ota, M
   Yamashiro, C
   Hatano, M
   Yanai, R
   Tokuda, K
   Kimura, K
AF Wakuta, Makiko
   Nomi, Nanami
   Ogata, Tadahiko
   Ota, Manami
   Yamashiro, Chiemi
   Hatano, Makoto
   Yanai, Ryoji
   Tokuda, Kazuhiro
   Kimura, Kazuhiro
TI A Trinity regimen with aflibercept for treatment-naive neovascular
   age-related macular degeneration: 2-year outcomes
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Neovascular age-related macular degeneration; Pro re nata regimen; Treat
   and extend regimen; Fixed regimen; Antivascular endothelial growth
   factor; Aflibercept
ID EXTEND REGIMEN; VISUAL IMPAIRMENT; RANIBIZUMAB; THERAPY; RECURRENCE
AB Purpose To evaluate the advantages of the Trinity regimen for treatment-naive neovascular age-related macular degeneration (nAMD). Methods Thirty-one treatment-naive nAMD eyes were treated using the Trinity regimen with an intravitreal aflibercept injection (IVA) and evaluated after 24 months. Three treatment methods, pro re nata (PRN), treat and extend (TAE), and fixed regimen were changed depending on recurrence frequency. After the initial treatment, PRN or TAE (started for 4 or 8 weeks) was selected as per the recurrence interval. Subsequently, the recurrence interval became constant, transitioning from a TAE to fixed regimen. When the recurrence frequency became irregular, the treatment regimen was changed to TAE. Results After the initial treatment, 15 eyes (48.4%) were allocated to the PRN group, 12 (38.7%) to the TAE 8-week group, and 4 (12.9%) to the TAE 4-week group. Mean logMAR significantly improved in all cases, 0.53 +/- 0.40 at baseline to 0.36 +/- 0.34 at 24 months (p < 0.01), in the PRN group (0.63 +/- 0.46 to 0.42 +/- 0.43, p < 0.01), and the TAE 8-week group (0.44 +/- 0.29 to 0.27 +/- 0.19, p < 0.05). LogMAR in the TAE 4-week group was maintained. The mean number of injections for all and in the PRN, TAE 8-week, and TAE 4-week groups were 9.7, 5.3, 13.1, and 15.8, respectively, with the PRN group being significantly less (p < 0.01). Conclusion The Trinity regimen delivered the benefits of the PRN, TAE, and FIXED regimens while minimizing injections during the early treatment phase without visual loss.
C1 [Wakuta, Makiko; Ogata, Tadahiko; Ota, Manami; Yamashiro, Chiemi; Hatano, Makoto; Yanai, Ryoji; Tokuda, Kazuhiro; Kimura, Kazuhiro] Yamaguchi Univ, Grad Sch Med, Dept Ophthalmol, 1-1-1 Minami Kogushi, Ube, Yamaguchi 7550046, Japan.
   [Wakuta, Makiko] Ube Kohsan Cent Hosp, Ube, Yamaguchi, Japan.
   [Nomi, Nanami] JCHO Shimonoseki Med Ctr, Shimonoseki, Yamaguchi, Japan.
C3 Yamaguchi University
RP Kimura, K (通讯作者)，Yamaguchi Univ, Grad Sch Med, Dept Ophthalmol, 1-1-1 Minami Kogushi, Ube, Yamaguchi 7550046, Japan.
EM k.kimura@yamaguchi-u.ac.jp
CR Adrean SD, 2018, OPHTHALMOL RETINA, V2, P225, DOI 10.1016/j.oret.2017.07.009
   Augsburger M, 2019, GRAEF ARCH CLIN EXP, V257, P1889, DOI 10.1007/s00417-019-04404-0
   Barthelmes D, 2018, RETINA-J RET VIT DIS, V38, P20, DOI 10.1097/IAE.0000000000001496
   Berg K, 2016, OPHTHALMOLOGY, V123, P51, DOI 10.1016/j.ophtha.2015.09.018
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Gillies MC, 2019, JAMA OPHTHALMOL, V137, P372, DOI 10.1001/jamaophthalmol.2018.6776
   Hatz K, 2017, ACTA OPHTHALMOL, V95, pE67, DOI 10.1111/aos.13031
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Horster R, 2011, GRAEF ARCH CLIN EXP, V249, P645, DOI 10.1007/s00417-010-1588-2
   Ito A, 2017, OPHTHALMOLOGICA, V238, P236, DOI 10.1159/000479937
   Khurana RN, 2019, AM J OPHTHALMOL, V200, P161, DOI 10.1016/j.ajo.2019.01.005
   Koizumi H, 2016, OPHTHALMOLOGY, V123, P617, DOI 10.1016/j.ophtha.2015.10.039
   Kuroda Y, 2015, OPHTHALMOLOGY, V122, P2303, DOI 10.1016/j.ophtha.2015.06.053
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Morimoto M, 2017, GRAEF ARCH CLIN EXP, V255, P1891, DOI 10.1007/s00417-017-3718-6
   Ohnaka M, 2017, GRAEF ARCH CLIN EXP, V255, P657, DOI 10.1007/s00417-016-3507-7
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Traine PG, 2019, OPHTHALMOL RETINA, V3, P393, DOI 10.1016/j.oret.2019.01.018
   Veritti D, 2019, RETINA-J RET VIT DIS, V39, P2077, DOI 10.1097/IAE.0000000000002299
   Wykoff CC, 2015, OPHTHALMOLOGY, V122, P2514, DOI 10.1016/j.ophtha.2015.08.009
NR 25
TC 3
Z9 3
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD AUG
PY 2020
VL 258
IS 8
BP 1663
EP 1670
DI 10.1007/s00417-020-04745-1
EA MAY 2020
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA MN9RI
UT WOS:000534453400001
PM 32436085
DA 2022-11-30
ER

PT J
AU Garcia, M
   Alvarez, L
   Fernandez, A
   Gonzalez-Iglesias, H
   Escribano, J
   Fernandez-Vega, B
   Villota, E
   Cueto, LFV
   Fernandez-Vega, A
   Coca-Prados, M
AF Garcia, Montserrat
   Alvarez, Lydia
   Fernandez, Angela
   Gonzalez-Iglesias, Hector
   Escribano, Julio
   Fernandez-Vega, Beatriz
   Villota, Eva
   Fernandez-Vega Cueto, Luis
   Fernandez-Vega, Alvaro
   Coca-Prados, Miguel
TI Metallothionein polymorphisms in a Northern Spanish population with
   neovascular and dry forms of age-related macular degeneration
SO OPHTHALMIC GENETICS
LA English
DT Article
DE Age-related macular degeneration; genetic association; haplotypes;
   metallothionein genes; single nucleotide polymorphism
ID RETINAL-PIGMENT EPITHELIUM; 2A GENETIC POLYMORPHISMS; CIGARETTE-SMOKING;
   SINGLE-NUCLEOTIDE; SUPEROXIDE-DISMUTASE; MT2A POLYMORPHISM;
   DRUG-RESISTANCE; PROSTATE-CANCER; ZINC; ASSOCIATION
AB Background: To elucidate the potential role of single nucleotide polymorphisms (SNPs) in the metallothionein (MT) genes in Northern Spanish patients with age-related macular degeneration (AMD).Methods: A total of 130 unrelated Northern Spanish natives diagnosed with AMD (46 dry, 35 neovascular, and 49 mixed) and 96 healthy controls, matched by age and ethnicity, were enrolled in a case-control study. DNA was isolated from peripheral blood and genotyped for 14 SNPs located at 5 MT genes (MT1A: rs11076161, rs 11640851, rs8052394, and rs7196890; MT1B: rs8052334, rs964372, and rs7191779; MT1M: rs2270836 and rs9936741; MT2A: rs28366003, rs1610216, rs10636, and rs1580833; MT3: rs45570941) using TaqMan probes. The association study was performed using the HaploView 4.0 software.Results: The allelic and genotypic frequencies analysis revealed that rs28366003 at MT2A gene is significantly associated with dry AMD. The frequency of genotype AG was significantly higher in dry AMD than in control cases (p = 2.65 x 10(-4); AG vs. AA) conferring more than ninefold increased risk to dry AMD (OR = 9.39, 95% CI: 2.11-41.72), whereas the genotype AA confers disease protection (OR = 0.82, 95% CI: 0.71-0.95). No statistically significant differences were observed between AMD subjects and controls in the rest of the 14 SNPs analyzed.Conclusions: The present study is the first to investigate the potential association of SNPs at MT genes with susceptibility to AMD. We found a significant association of SNP rs28366003 at MT2A gene with susceptibility to the dry form of AMD in a Northern Spanish population.
C1 [Garcia, Montserrat; Alvarez, Lydia; Fernandez, Angela; Gonzalez-Iglesias, Hector; Fernandez-Vega, Beatriz; Villota, Eva; Fernandez-Vega Cueto, Luis; Fernandez-Vega, Alvaro; Coca-Prados, Miguel] Univ Oviedo, Fdn Ophthalmol Invest, Fernandez Vega Univ Inst, Oviedo, Spain.
   [Garcia, Montserrat; Gonzalez-Iglesias, Hector; Fernandez-Vega, Beatriz; Villota, Eva; Fernandez-Vega Cueto, Luis; Fernandez-Vega, Alvaro; Coca-Prados, Miguel] Fernandez Vega Ophthalmol Inst, Dept Neurodegenerat Eye Dis, Oviedo, Spain.
   [Escribano, Julio] Univ Castilla La Mancha, Inst Invest Neurol Disabil IDINE, Fac Med, Lab Human Mol Genet, Albacete, Spain.
   [Coca-Prados, Miguel] Yale Univ, Sch Med, Dept Ophthalmol & Visual Sci, New Haven, CT 06510 USA.
C3 University of Oviedo; Universidad de Castilla-La Mancha; Yale University
RP Garcia, M (通讯作者)，Inst Univ Fernandez Vega, Inst Oftalmol Fernandez Vega, Fdn Invest Oftalmol, Avda Doctores Fernandez Vega 34, Oviedo 33012, Spain.
EM mgarciadiaz@fio.as
RI García Diaz, Montserrat/GXV-7857-2022; Escribano, Julio/D-9742-2015;
   Garcia, Montserrat/AAA-7781-2019; Sanz, Beatriz
   Fernandez-Vega/AAB-5990-2019; Gonzalez-Iglesias, Hector/K-2447-2014;
   Gonzalez-Iglesias, Hector/AAB-5993-2019; Alvarez, Lydia/AAA-7736-2019
OI Escribano, Julio/0000-0002-8919-8134; Garcia,
   Montserrat/0000-0001-9983-546X; Sanz, Beatriz
   Fernandez-Vega/0000-0002-0600-5916; Gonzalez-Iglesias,
   Hector/0000-0001-5251-0967; Fernandez-Vega Cueto Felgueroso,
   Luis/0000-0001-9197-5847; Alvarez Fernandez, Lydia/0000-0002-0604-7411;
   Fernandez-Iglesias, Angela/0000-0003-2585-4734
FU Fundacion de Investigacion Oftalmologica; Fundacion Ma Cristina Masaveu
   Peterson; Fundacion Rafael del Pino; Torres Quevedo Fellowship from the
   Spanish Ministry of Economy and Competitiveness [PTQ-12-05444]; "Plan de
   Ciencia, Tecnologia e Innovacion de Asturias (PCTI)" [IE14-030]; "Fondo
   Europeo de Desarrollo Regional (FEDER)"
FX This study has been supported in part by Fundacion de Investigacion
   Oftalmologica (http://fio.fernandez-vega.com), Fundacion Ma Cristina
   Masaveu Peterson (http://www.fundacioncristinamasaveu.com), Fundacion
   Rafael del Pino (http://www.frdelpino.es), Torres Quevedo Fellowship
   (PTQ-12-05444) from the Spanish Ministry of Economy and Competitiveness,
   grant IE14-030 from the "Plan de Ciencia, Tecnologia e Innovacion de
   Asturias (PCTI)" and "Fondo Europeo de Desarrollo Regional (FEDER)."
   Miguel Coca-Prados is "Catedratico Rafael del Pino en Oftalmologia" in
   the "Fundacion de Investigacion Oftalmologica, Instituto Oftalmologico
   Fernandez-Vega," Oviedo, Spain. The authors would like to acknowledge
   the contribution of the COST Action TD1304, The network for the biology
   of zinc (Zinc-net; http://zinc-net.com).
CR Adams SV, 2015, TOXICOL APPL PHARM, V289, P381, DOI 10.1016/j.taap.2015.10.024
   Alvarez L, 2012, J BIOL CHEM, V287, P28456, DOI 10.1074/jbc.M112.365015
   Armitage P, 2002, STAT METHODS MED RES, V4th
   Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   Barzegar-Befroei N, 2011, ZINC EYE DIS
   Cackett P, 2011, OPHTHALMOLOGY, V118, P846, DOI 10.1016/j.ophtha.2010.09.026
   Chen YH, 2010, MOL INTERV, V10, P271, DOI 10.1124/mi.10.5.4
   CHIN JL, 1993, CANCER, V72, P3029, DOI 10.1002/1097-0142(19931115)72:10<3029::AID-CNCR2820721027>3.0.CO;2-6
   Cipriano C, 2006, BIOGERONTOLOGY, V7, P357, DOI 10.1007/s10522-006-9050-x
   Colvin RA, 2010, METALLOMICS, V2, P306, DOI 10.1039/b926662c
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Flinn JM, 2014, METALLOMICS, V6, P1223, DOI 10.1039/c4mt00058g
   Forma E, 2012, CANCER GENET-NY, V205, P432, DOI 10.1016/j.cancergen.2012.05.005
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Fuertes MA, 2003, CHEM REV, V103, P645, DOI 10.1021/cr020010d
   Gabriel SB, 2002, SCIENCE, V296, P2225, DOI 10.1126/science.1069424
   Garcia M, 2015, ACTA OPHTHALMOL, V93, pE658, DOI 10.1111/aos.12790
   Giacconi R, 2005, BIOGERONTOLOGY, V6, P407, DOI 10.1007/s10522-005-4907-y
   Giacconi R, 2007, MOL MED, V13, P388, DOI 10.2119/2007-00045.Giacconi
   Gonzalez-Iglesias H, 2014, METALLOMICS, V6, P201, DOI 10.1039/c3mt00298e
   Gorin MB, 2012, MOL ASPECTS MED, V33, P467, DOI 10.1016/j.mam.2012.04.004
   Hanada K, 1998, J INVEST DERMATOL, V111, P582, DOI 10.1046/j.1523-1747.1998.00342.x
   Hayashi Y, 2006, AMYOTROPH LATERAL SC, V7, P22, DOI 10.1080/14660820600618766
   Hyman Leslie, 2002, Curr Opin Ophthalmol, V13, P171
   Kabasawa S, 2011, OPHTHALMOLOGY, V118, P1082, DOI 10.1016/j.ophtha.2010.10.012
   KARIN M, 1984, P NATL ACAD SCI-BIOL, V81, P5494, DOI 10.1073/pnas.81.17.5494
   Katta S, 2009, J GENET, V88, P425, DOI 10.1007/s12041-009-0064-4
   Kayaalti Z, 2011, TOXICOL APPL PHARM, V256, P1, DOI 10.1016/j.taap.2011.06.023
   Kayaalti Z, 2010, TOXICOL APPL PHARM, V245, P252, DOI 10.1016/j.taap.2010.03.007
   Kayaalti Z, 2010, MOL BIOL REP, V37, P185, DOI 10.1007/s11033-009-9586-3
   KELLEY SL, 1988, SCIENCE, V241, P1813, DOI 10.1126/science.3175622
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Kimura K, 2000, AM J OPHTHALMOL, V130, P769, DOI 10.1016/S0002-9394(00)00552-3
   Kita K, 2006, HUM GENET, V120, P553, DOI 10.1007/s00439-006-0238-6
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Krzeslak A, 2014, CLIN EXP MED, V14, P107, DOI 10.1007/s10238-012-0215-4
   Krzeslak A, 2013, TOXICOL APPL PHARM, V268, P278, DOI 10.1016/j.taap.2013.02.013
   Lengyel I, 2007, EXP EYE RES, V84, P772, DOI 10.1016/j.exer.2006.12.015
   Liu MM, 2012, HUM GENOMICS, V6, DOI 10.1186/1479-7364-6-13
   Nan R, 2013, J BIOL CHEM, V288, P19197, DOI 10.1074/jbc.M113.476143
   Newsome DA, 1995, J TRACE ELEM EXP MED, V8, P193
   Pascolini D, 2004, OPHTHAL EPIDEMIOL, V11, P67, DOI 10.1076/opep.11.2.67.28158
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Raudenska M, 2014, METALLOMICS, V6, P55, DOI 10.1039/c3mt00132f
   Reeve VE, 2000, IMMUNOLOGY, V100, P399, DOI 10.1046/j.1365-2567.2000.00026.x
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Sobrin L, 2012, OPHTHALMOLOGY, V119, P1874, DOI 10.1016/j.ophtha.2012.03.014
   Sunada F, 2005, WORLD J GASTROENTERO, V11, P5696, DOI 10.3748/wjg.v11.i36.5696
   TATE DJ, 1993, INVEST OPHTH VIS SCI, V34, P2348
   Thompson RB, 2015, P NATL ACAD SCI USA, V112, P1565, DOI 10.1073/pnas.1413347112
   Ugarte M, 2001, PROG NEUROBIOL, V64, P219, DOI 10.1016/S0301-0082(00)00057-5
   Wang Y, 2012, ENVIRON HEALTH PERSP, V120, P530, DOI 10.1289/ehp.1104079
   Wong RH, 2013, ANN SURG ONCOL, V20, P2088, DOI 10.1245/s10434-012-2456-6
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yang L, 2008, AM J PHYSIOL-ENDOC M, V294, pE987, DOI 10.1152/ajpendo.90234.2008
   Zavras AI, 2011, ANN SURG ONCOL, V18, P1478, DOI 10.1245/s10434-010-1431-3
NR 58
TC 2
Z9 2
U1 0
U2 4
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1381-6810
EI 1744-5094
J9 OPHTHALMIC GENET
JI Ophthalmic Genet.
PY 2017
VL 38
IS 5
BP 451
EP 458
DI 10.1080/13816810.2017.1288825
PG 8
WC Genetics & Heredity; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity; Ophthalmology
GA FN4HL
UT WOS:000415965700009
PM 28635422
DA 2022-11-30
ER

PT J
AU Kahkonen, M
   Tuuminen, R
   Aaltonen, V
AF Kahkonen, Mikael
   Tuuminen, Raimo
   Aaltonen, Vesa
TI Long-term effects of intravitreal bevacizumab and aflibercept on
   intraocular pressure in wet age-related macular degeneration
SO BMC OPHTHALMOLOGY
LA English
DT Article
DE Wet age-related macular degeneration; Anti-vascular endothelial growth
   factor; Bevacizumab; Aflibercept; Intraocular pressure
ID ELEVATION; INJECTIONS; VEGF
AB Background To evaluate the incidence of sustained elevation of intraocular pressure (SE-IOP) associated with intravitreal injections of anti-vascular endothelial growth factors (anti-VEGF) bevacizumab and aflibercept in patients with wet age-related macular degeneration (wAMD). Methods A retrospective cohort study consisting of 120 eyes from 120 patients with anti-VEGF treatment for wAMD. Three different anti-VEGF groups were considered: i) 71 cases receiving bevacizumab only, ii) 49 cases receiving bevacizumab before switch to aflibercept, iii) 49 cases after switch to aflibercept. 120 uninjected fellow eyes served as controls. SE-IOP was defined as an increase from baseline >= 5 mmHg on 2 consecutive follow-up visits. The incidence of SE-IOP was analysed using exact Poisson tests and survival analysis. The time course of IOP was evaluated with linear mixed effect modelling. Results In total, 6 treated eyes (2.38% incidence per eye-year) and 9 fellow eyes (3.58% incidence per eye-year) developed SE-IOP, and survival analysis showed no statistically significant difference (p = 0.43). Furthermore, the incidence of SE-IOP did not differ between the three anti-VEGF groups. Comparing the injected eyes of patients under 70 years to those of patients over 70 years, there was a statistically significant difference in survival without SE-IOP (incidence of 16.7% vs 0.7%, respectively, p < 0.0001). Conclusion Intravitreal anti-VEGF injections were not associated with sustained elevation of IOP. These results do not support the claim that repeated anti-VEGF injections could elevate IOP.
C1 [Kahkonen, Mikael; Aaltonen, Vesa] Turku Univ Hosp, Dept Ophthalmol, POB 52, Turku 20521, Finland.
   [Kahkonen, Mikael; Aaltonen, Vesa] Univ Turku, Dept Ophthalmol, Turku, Finland.
   [Tuuminen, Raimo] Univ Helsinki, Fac Med, Helsinki Retina Res Grp, Helsinki, Finland.
   [Tuuminen, Raimo] Helsinki Univ Hosp, Dept Ophthalmol, Helsinki, Finland.
C3 University of Turku; University of Turku; University of Helsinki;
   University of Helsinki; Helsinki University Central Hospital
RP Aaltonen, V (通讯作者)，Turku Univ Hosp, Dept Ophthalmol, POB 52, Turku 20521, Finland.; Aaltonen, V (通讯作者)，Univ Turku, Dept Ophthalmol, Turku, Finland.
EM vesa.aaltonen@tyks.fi
FU University of Turku
FX The study was supported by grants from the University of Turku. The
   funding body had no role in the design or conduct of this research.
CR Abedi G, 2013, SEMIN OPHTHALMOL, V28, P126, DOI 10.3109/08820538.2013.771195
   Achiron Asaf, 2017, J Curr Glaucoma Pract, V11, P63, DOI 10.5005/jp-journals-10028-1225
   Atchison EA, 2018, OPHTHALMOLOGY, V125, P676, DOI 10.1016/j.ophtha.2017.11.027
   Baek S, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-53461-2
   Bakri SJ, 2019, OPHTHALMOLOGY, V126, P55, DOI 10.1016/j.ophtha.2018.07.028
   Battista SA, 2008, INVEST OPHTH VIS SCI, V49, P5346, DOI 10.1167/iovs.08-1707
   Beato J, 2016, OPHTHALMIC RES, V56, P30, DOI 10.1159/000444395
   Bilgic A, 2020, J OPHTHALMOL, V2020, DOI 10.1155/2020/7462098
   Bloch SB, 2012, AM J OPHTHALMOL, V153, P209, DOI 10.1016/j.ajo.2011.10.016
   Carneiro AM, 2012, ACTA OPHTHALMOL, V90, pE25, DOI 10.1111/j.1755-3768.2011.02240.x
   Chappelow A.V., 2010, RETINAL PHARMACOTHER, P128
   de Vries VA, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-70269-7
   Freund KB, 2015, OPHTHALMOLOGY, V122, P1802, DOI 10.1016/j.ophtha.2015.04.018
   Fujimoto T, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161332
   Grzybowski A, 2019, CURR OPIN OPHTHALMOL, V30, P56, DOI 10.1097/ICU.0000000000000545
   Hollands H, 2007, CAN J OPHTHALMOL, V42, P807, DOI 10.3129/i07-172
   Jonas JB, 2017, ASIA-PAC J OPHTHALMO, V6, P493, DOI 10.22608/APO.2017251
   Kim D, 2014, J GLAUCOMA, V23, P446, DOI 10.1097/IJG.0b013e3182946505
   Lee JW, 2016, BMC OPHTHALMOL, V16, DOI 10.1186/s12886-016-0255-8
   Moraru Andreea, 2017, Rom J Ophthalmol, V61, P207
   Nariani A, 2016, INDIAN J OPHTHALMOL, V64, P643, DOI 10.4103/0301-4738.194329
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Reis Gustavo Msm, 2017, J Curr Glaucoma Pract, V11, P3, DOI 10.5005/jp-journals-10008-1213
   Schargus M, 2018, RETINA-J RET VIT DIS, V38, P2088, DOI 10.1097/IAE.0000000000001809
   Wehrli SJ, 2012, RETINA-J RET VIT DIS, V32, P1295, DOI 10.1097/IAE.0b013e31823f0c95
   Yannuzzi NA, 2014, AM J OPHTHALMOL, V158, P319, DOI 10.1016/j.ajo.2014.04.029
   Zhou YD, 2016, SCI REP-UK, V6, DOI 10.1038/srep39301
NR 27
TC 0
Z9 0
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD AUG 28
PY 2021
VL 21
IS 1
AR 312
DI 10.1186/s12886-021-02076-1
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA UI9QV
UT WOS:000690932800003
PM 34454473
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Kent, JS
   Iordanous, Y
   Mao, A
   Powell, AM
   Kent, SS
   Sheidow, TG
AF Kent, Jerrod S.
   Iordanous, Yiannis
   Mao, Alex
   Powell, Anne-Marie
   Kent, Shefalee Shukla
   Sheidow, Tom G.
TI Comparison of outcomes after switching treatment from intravitreal
   bevacizumab to ranibizumab in neovascular age-related macular
   degeneration
SO CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE
LA English
DT Article
ID VERTEPORFIN PHOTODYNAMIC THERAPY
AB Objective: To compare visual acuity and central retinal thickness in patients initially treated with bevacizumab (Avastin) and switched to ranibizumab (Lucentis) for neovascular age-related macular degeneration (AMD).
   Design: A retrospective chart review.
   Participants: This study included 87 eyes from 80 patients over the age of 65 with neovascular AMD.
   Methods: Patients were initially treated with bevacizumab injections every 6 weeks and then switched to ranibizumab every 4 weeks when it became publicly funded by the Ontario government. Outcomes include comparison of visual acuity and central retinal thickness after bevacizumab treatment, and after switching to ranibizumab.
   Results: Visual acuity improved significantly versus initial baseline values following a treatment course of 3 or more injections of bevacizumab (0.58 logMar, SD = 0.30 vs 0.73 logMar, SD = 0.41; p = 0.0007). Patients then showed a further significant improvement in visual acuity after switching and receiving a course of ranibizumab (0.51 logMar, SD = 0.32) (p = 0.0122). Mean central retinal thickness as measured by optical coherence tomography significantly decreased after a course of bevacizumab (p = 0.0158), and a further decrease was noted after a subsequent course of ranibizumab (p < 0.0001).
   Conclusions: There was a significant improvement in visual acuity and central retinal thickness in patients with neovascular AMD initially treated with bevacizumab. When these patients were uniformly switched to ranibizumab there was a further significant improvement in visual acuity and a reduction of retinal thickness. It appears that ranibizumab can maintain, or improve the effect achieved after an initial course of bevacizumab.
C1 [Kent, Jerrod S.; Iordanous, Yiannis; Mao, Alex; Powell, Anne-Marie; Kent, Shefalee Shukla; Sheidow, Tom G.] Univ Western Ontario, Dept Ophthalmol, Ivey Eye Inst, London, ON N6A 4V2, Canada.
C3 Western University (University of Western Ontario)
RP Sheidow, TG (通讯作者)，Univ Western Ontario, Dept Ophthalmol, Ivey Eye Inst, 268 Grosvenor St, London, ON N6A 4V2, Canada.
EM sheidowt@rogers.com
OI Sheidow, Tom/0000-0001-6370-1857
FU Novartis; QLT; Pfizer
FX The authors have no proprietary or commercial interest in any materials
   discussed in this article. Dr. Sheidow is an advisory board member for
   Novartis and QLT and currently holds research grants-in-aid from
   Novartis, QLT and Pfizer unrelated to the current manuscript.
CR Adamis AP, 2005, RETINA-J RET VIT DIS, V25, P111, DOI 10.1097/00006982-200502000-00001
   Antoszyk AN, 2008, AM J OPHTHALMOL, V145, P862, DOI 10.1016/j.ajo.2007.12.029
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chang TS, 2009, RETINA-J RET VIT DIS, V29, P1235, DOI 10.1097/IAE.0b013e3181b20eed
   DURBIN M, 2007, RETINAL MEASUREMENTS
   Ehlers JP, 2010, OPHTHAL SURG LAS IM, V41, P182, DOI 10.3928/15428877-20100303-05
   Karagiannis DA, 2009, CLIN INTERV AGING, V4, P457
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Steinbrook R, 2006, NEW ENGL J MED, V355, P1409, DOI 10.1056/NEJMp068185
   Stepien KE, 2009, RETINA-J RET VIT DIS, V29, P1067, DOI 10.1097/IAE.0b013e3181b1bb06
NR 14
TC 17
Z9 17
U1 0
U2 5
PU CANADIAN OPHTHAL SOC
PI OTTAWA
PA 1525 CARLING AVE SUITE 610, OTTAWA, ONTARIO K1Z 8R9, CANADA
SN 0008-4182
J9 CAN J OPHTHALMOL
JI Can. J. Opthalmol.-J. Can. Opthalmol.
PD APR
PY 2012
VL 47
IS 2
BP 159
EP 164
DI 10.1016/j.jcjo.2012.01.003
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 953RI
UT WOS:000304890100014
PM 22560422
DA 2022-11-30
ER

PT J
AU Cho, HJ
   Kim, JM
   Kim, HS
   Lee, DW
   Kim, CG
   Kim, JW
AF Cho, Han Joo
   Kim, Jae Min
   Kim, Hyoung Seok
   Lee, Dong Won
   Kim, Chul Gu
   Kim, Jong Woo
TI Effect of Epiretinal Membranes on Antivascular Endothelial Growth Factor
   Treatment for Neovascular Age-Related Macular Degeneration
SO JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
LA English
DT Article
DE age-related macular degeneration; antivascular endothelial growth
   factor; choroidal neovascularization; epiretinal membrane
ID OPTICAL COHERENCE TOMOGRAPHY; VITREOMACULAR TRACTION SYNDROME; BLUE
   MOUNTAINS EYE; VEGF TRAP-EYE; LIMITING MEMBRANE; VITRECTOMY; INTERFACE;
   ADHESION; ASSOCIATIONS; PREVALENCE
AB Purpose: To evaluate the effect of epiretinal membranes (ERMs), detected with spectral-domain optical coherence tomography (SD-OCT), on the outcome of antivascular endothelial growth factor (VEGF) treatment for neovascular age-related macular degeneration (nAMD).
   Methods: A total of 434 eyes with treatment-naive nAMD were retrospectively included and analyzed. All patients were administered an initial series of 3 monthly loading injections of ranibizumab or aflibercept, followed by further injections as required. The visual and anatomical outcomes were compared between the eyes with ERMs and those without. Features of ERMs at baseline assessed with SD-OCT were evaluated and correlated with visual outcomes.
   Results: Sixty-eight eyes (15.7%) with nAMD presented ERMs at baseline. The mean best-corrected visual acuity (BCVA) of these eyes, expressed as the logarithm of the minimum angle of resolution, improved from 0.750.48 (Snellen equivalent: 20/112) to 0.59 +/- 0.44 (20/77) after 12 months of treatment (P = 0.021). Central foveal thickness also decreased from 381 +/- 191 mu m to 294 +/- 167 mu m (P < 0.001). Compared to the eyes without ERMs (366 eyes), the eyes with ERMs had a significantly thicker central fovea after treatment (P = 0.020). However, the intergroup differences in BCVA improvement were not significant. No significant association was found between visual outcome after treatment and ERM features on OCT at baseline.
   Conclusions: In eyes with nAMD, ERMs were infrequent. Central foveal thickness was significantly greater after anti-VEGF treatment in eyes with nAMD and ERMs. However, the presence of ERMs in eyes with nAMD did not affect visual outcome.
C1 [Cho, Han Joo; Kim, Jae Min; Kim, Hyoung Seok; Lee, Dong Won; Kim, Chul Gu; Kim, Jong Woo] Konyang Univ, Kims Eye Hosp, Myung Gok Eye Res Inst, Coll Med,Dept Ophthalmol, 156 4ga Yeoungdeungpo Dong, Seoul 07301, South Korea.
C3 Konyang University
RP Cho, HJ (通讯作者)，Konyang Univ, Kims Eye Hosp, Myung Gok Eye Res Inst, Coll Med,Dept Ophthalmol, 156 4ga Yeoungdeungpo Dong, Seoul 07301, South Korea.
EM chojoo@kimeye.com
OI Cho, Han Joo/0000-0001-7336-5762
CR [Anonymous], 1997, DIAGNOSIS TREATMENT
   Ardeljan D, 2013, PROG RETIN EYE RES, V37, P68, DOI 10.1016/j.preteyeres.2013.07.003
   Blasiak Janusz, 2013, Front Biosci (Schol Ed), V5, P412
   Bu SC, 2014, RETINA-J RET VIT DIS, V34, P2317, DOI 10.1097/IAE.0000000000000349
   Cho HJ, 2013, RETINA-J RET VIT DIS, V33, P2126, DOI 10.1097/IAE.0b013e3182899296
   Cuilla TA, 2015, OPHTHALMOLOGY, V122, P1203, DOI 10.1016/j.ophtha.2015.02.031
   Edwards MM, 2016, EXP EYE RES, V150, P44, DOI 10.1016/j.exer.2015.07.016
   Fraser-Bell S, 2003, OPHTHALMOLOGY, V110, P34, DOI 10.1016/S0161-6420(02)01443-4
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Inoue M, 2010, AM J OPHTHALMOL, V150, P834, DOI 10.1016/j.ajo.2010.06.006
   Jackson TL, 2013, RETINA-J RET VIT DIS, V33, P2012, DOI 10.1097/IAE.0b013e3182a6b3e2
   Joshi M, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/192582
   Katz MSJ, 2014, SURV OPHTHALMOL, V59, P260, DOI 10.1016/j.survophthal.2013.06.002
   Kimura S, 2016, GRAEF ARCH CLIN EXP, V254, P1731, DOI 10.1007/s00417-016-3314-1
   Klein R, 1994, Trans Am Ophthalmol Soc, V92, P403
   Klein R, 1994, T AM OPHTHAL SOC, V92, P425
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lee SJ, 2011, OPHTHALMOLOGY, V118, P101, DOI 10.1016/j.ophtha.2010.04.015
   Matsuoka Y, 2012, INVEST OPHTH VIS SCI, V53, P3054, DOI 10.1167/iovs.11-9153
   Mayr-Sponer U, 2013, OPHTHALMOLOGY, V120, P2620, DOI 10.1016/j.ophtha.2013.05.032
   Meuer SM, 2015, OPHTHALMOLOGY, V122, P787, DOI 10.1016/j.ophtha.2014.10.014
   Mitchell P, 1997, OPHTHALMOLOGY, V104, P1033, DOI 10.1016/S0161-6420(97)30190-0
   Mojana F, 2008, AM J OPHTHALMOL, V146, P218, DOI 10.1016/j.ajo.2008.04.027
   Nomura Y, 2011, OPHTHALMOLOGY, V118, P853, DOI 10.1016/j.ophtha.2010.09.001
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Steel DHW, 2015, INVEST OPHTH VIS SCI, V56, P4038, DOI 10.1167/iovs.15-16409
   Stewart MW, 2012, BRIT J OPHTHALMOL, V96, P1157, DOI 10.1136/bjophthalmol-2011-300654
   Veloso CE, 2015, OPHTHALMOLOGY, V122, P1569, DOI 10.1016/j.ophtha.2015.04.028
   Ye HH, 2015, BRIT J OPHTHALMOL, V99, P1594, DOI 10.1136/bjophthalmol-2015-307050
   Zhao F, 2013, RETINA-J RET VIT DIS, V33, P77, DOI 10.1097/IAE.0b013e3182602087
NR 30
TC 8
Z9 8
U1 0
U2 0
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1080-7683
EI 1557-7732
J9 J OCUL PHARMACOL TH
JI J. Ocular Pharmacol. Ther.
PD JUL-AUG
PY 2017
VL 33
IS 6
BP 452
EP 458
DI 10.1089/jop.2016.0178
PG 7
WC Ophthalmology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Pharmacology & Pharmacy
GA EZ8NM
UT WOS:000404983300005
PM 28445077
DA 2022-11-30
ER

PT J
AU Bringmann, A
   Hollborn, M
   Kohen, L
   Wiedemann, P
AF Bringmann, Andreas
   Hollborn, Margrit
   Kohen, Leon
   Wiedemann, Peter
TI Intake of dietary salt and drinking water: Implications for the
   development of age-related macular degeneration
SO MOLECULAR VISION
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; ENDOTHELIAL GROWTH-FACTOR; CHOROIDAL
   BLOOD-FLOW; CARDIOVASCULAR-DISEASE; SYSTEMIC HYPERTENSION;
   DIABETIC-RETINOPATHY; ALDOSE REDUCTASE; RISK-FACTORS; HYPEROSMOLARITY
   RESPONSE; INCREASED EXPRESSION
AB Purpose: Systemic hypertension is a risk factor of age-related retinal diseases such as diabetic retinopathy and age-related macular degeneration. High intake of dietary salt and low intake of water increase extracellular osmolality resulting in hypertension, in particular in salt-sensitive individuals. This review summarizes the present knowledge regarding the impact of salt and water intake on the regulation of blood pressure, retinal function, and the development of age-related retinal diseases.
   Methods: A literature search of the Medline database and a summary of recent studies that used human RPE cells.
   Results: The salt sensitivity of the blood pressure and plasma osmolality increase with age, and body water deficits are common in older individuals. High plasma osmolality has adverse effects in the retina. In RPE cells, high osmolality induces expression and secretion of angiogenic factors, such as vascular endothelial growth factor (VEGF), placental growth factor, and basic fibroblast growth factor, and expression of aquaporin-5, a water channel implicated in transepithelial water transport. The transcriptional activities of hypoxia-inducible factor-1 (HIF-1) and nuclear factor of activated T cell 5 (NFAT5) are critical for the production of VEGF in response to salt-induced osmotic stress. Salt-induced osmotic stress also induces priming of the NLRP3 inflammasome and activates inflammatory enzymes in RPE cells.
   Conclusions: Raised plasma osmolality may aggravate age-related retinal diseases by stimulation of local inflammation and angiogenic factor production in the RPE. Alterations in salt and water consumption, and of minerals that stimulate renal salt excretion, may offer nutritional approaches to prevent age-related retinal disorders, in particular in salt-sensitive individuals and individuals who show signs of body dehydration.
C1 [Bringmann, Andreas; Hollborn, Margrit; Kohen, Leon; Wiedemann, Peter] Univ Leipzig, Dept Ophthalmol, Liebigstr 10-14, D-04103 Leipzig, Germany.
   [Bringmann, Andreas; Hollborn, Margrit; Kohen, Leon; Wiedemann, Peter] Univ Leipzig, Hosp Eye, Liebigstr 10-14, D-04103 Leipzig, Germany.
   [Kohen, Leon] Helios Klinikum Aue, Aue, Germany.
C3 Leipzig University; Leipzig University; Helios Kliniken
RP Bringmann, A (通讯作者)，Univ Leipzig, Dept Ophthalmol, Liebigstr 10-14, D-04103 Leipzig, Germany.; Bringmann, A (通讯作者)，Univ Leipzig, Hosp Eye, Liebigstr 10-14, D-04103 Leipzig, Germany.
EM bria@medizin.uni-leipzig.de
FU Deutsche Forschungsgemeinschaft [KO 1547/7-1]; Geschwister Freter
   Stiftung (Hannover, Germany)
FX Some of the work presented in this review was conducted with grants from
   the Deutsche Forschungsgemeinschaft (KO 1547/7-1 to L.K.) and the
   Geschwister Freter Stiftung (Hannover, Germany, to P.W.).
CR Aburto NJ, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f1326
   Agostoni C, 2010, EFSA J, V8, DOI 10.2903/j.efsa.2010.1459
   Alderman MH, 2007, J HYPERTENS, V25, P903, DOI 10.1097/HJH.0b013e3280c14394
   Alderman MH, 2006, J AM COLL NUTR, V25, p256S, DOI 10.1080/07315724.2006.10719575
   AMIN R, 1994, INVEST OPHTH VIS SCI, V35, P3178
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Anderson DE, 2008, AM J PHYSIOL-REG I, V294, pR1248, DOI 10.1152/ajpregu.00782.2007
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Appel LJ, 2006, HYPERTENSION, V47, P296, DOI 10.1161/01.HYP.0000202568.01167.B6
   Arsenijevic T, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.189
   Asnaghi V, 2003, DIABETES, V52, P506, DOI 10.2337/diabetes.52.2.506
   Bell SJ, 1987, NUTR CLIN PRACT, V2, P241
   Bhargava M, 2012, J HUM HYPERTENS, V26, P71, DOI 10.1038/jhh.2011.37
   Bhutto IA, 2010, EXP EYE RES, V90, P155, DOI 10.1016/j.exer.2009.10.004
   Bressler NM, 2001, RETINA, V2001, P1100
   Bringmann A, 2006, PROG RETIN EYE RES, V25, P397, DOI 10.1016/j.preteyeres.2006.05.003
   Chan J, 2002, AM J EPIDEMIOL, V155, P827, DOI 10.1093/aje/155.9.827
   Chang A, 2013, NAT REV NEPHROL, V9, P376, DOI 10.1038/nrneph.2013.107
   Charra Bernard, 2007, Hemodial Int, V11, P21, DOI 10.1111/j.1542-4758.2007.00148.x
   Cheung AKH, 2007, EXP EYE RES, V85, P608, DOI 10.1016/j.exer.2007.07.013
   Cheung CMG, 2014, J INTERN MED, V276, P140, DOI 10.1111/joim.12227
   Cheung Chris Yk, 2013, J Mol Signal, V8, P5, DOI 10.1186/1750-2187-8-5
   Ciulla TA, 2002, BRIT J OPHTHALMOL, V86, P209, DOI 10.1136/bjo.86.2.209
   Coleman DJ, 2013, BRIT J OPHTHALMOL, V97, P1020, DOI 10.1136/bjophthalmol-2013-303143
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Cousins SW, 2002, EXP EYE RES, V75, P543, DOI 10.1006/exer.2002.2047
   Dallinger S, 1998, J AM GERIATR SOC, V46, P484, DOI 10.1111/j.1532-5415.1998.tb02471.x
   de Wardener HE, 2004, KIDNEY INT, V66, P2454, DOI 10.1111/j.1523-1755.2004.66018.x
   Deeg CA, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0554-2
   deKozak Y, 1997, OCUL IMMUNOL INFLAMM, V5, P85, DOI 10.3109/09273949709085056
   Deliyanti D, 2014, ARTERIOSCL THROM VAS, V34, P2033, DOI 10.1161/ATVBAHA.114.303792
   DellaCroce JT, 2008, CURR OPIN OPHTHALMOL, V19, P493, DOI 10.1097/ICU.0b013e3283129779
   Delles C, 2004, STROKE, V35, P1289, DOI 10.1161/01.STR.0000126597.11534.3b
   Ehrlich R, 2009, GRAEF ARCH CLIN EXP, V247, P583, DOI 10.1007/s00417-008-1018-x
   Ekmekcioglu C, 2013, FORSCH KOMPLEMENTMED, V20, P454, DOI 10.1159/000357413
   Etminan M, 2008, CURR DRUG SAF, V3, P24, DOI 10.2174/157488608783333952
   FEENEYBURNS L, 1980, AM J OPHTHALMOL, V90, P783, DOI 10.1016/S0002-9394(14)75193-1
   Ferraris JD, 2006, CONTRIB NEPHROL, V152, P125, DOI 10.1159/000096320
   Ferrington DA, 2016, PROG RETIN EYE RES, V51, P69, DOI 10.1016/j.preteyeres.2015.09.002
   Fitzgerald MEC, 2005, EXP EYE RES, V81, P478, DOI 10.1016/j.exer.2005.03.008
   Fraser-Bell S, 2008, AM J OPHTHALMOL, V145, P308, DOI 10.1016/j.ajo.2007.10.007
   Gallen IW, 1998, AM J KIDNEY DIS, V31, P19, DOI 10.1053/ajkd.1998.v31.pm9428447
   Gibbs CR, 2000, BRIT MED J, V320, P366, DOI 10.1136/bmj.320.7231.366
   GILCREASE MZ, 1991, DIABETES RES CLIN EX, V16, P149
   Gleadle JM, 1997, BLOOD, V89, P503, DOI 10.1182/blood.V89.2.503
   GOLDBERG J, 1988, AM J EPIDEMIOL, V128, P700, DOI 10.1093/oxfordjournals.aje.a115023
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Halterman JA, 2012, AM J PHYSIOL-CELL PH, V302, pC1, DOI 10.1152/ajpcell.00327.2011
   He FJ, 2005, HYPERTENSION, V45, P98, DOI 10.1161/01.HYP.0000149431.79450.a2
   HOFFMAN NB, 1991, GERIATRICS, V46, P35
   Hogg RE, 2008, OPHTHALMOLOGY, V115, P1046, DOI 10.1016/j.ophtha.2007.07.031
   Hollborn M, 2006, CURR EYE RES, V31, P863, DOI 10.1080/02713680600888807
   Hollborn M, 2006, GRAEF ARCH CLIN EXP, V244, P732, DOI 10.1007/s00417-005-0154-9
   Hollborn M, 2016, MOL BIOL REP, V43, P803, DOI 10.1007/s11033-016-4016-9
   Hollborn M, 2015, MOL VIS, V21, P360
   Hollborn M, 2012, INVEST OPHTH VIS SCI, V53, P5930, DOI 10.1167/iovs.11-9214
   Hollborn M, 2009, INVEST OPHTH VIS SCI, V50, P4452, DOI 10.1167/iovs.08-3194
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Iandiev I, 2007, NEUROSCI LETT, V421, P132, DOI 10.1016/j.neulet.2007.04.076
   Iandiev I, 2006, NEUROSCI LETT, V408, P108, DOI 10.1016/j.neulet.2006.08.084
   Ishibashi T, 1997, GRAEF ARCH CLIN EXP, V235, P159, DOI 10.1007/BF00941723
   Jo N, 2006, AM J PATHOL, V168, P2036, DOI 10.2353/ajpath.2006.050588
   Joussen AM, 2001, AM J PATHOL, V158, P147, DOI 10.1016/S0002-9440(10)63952-1
   Kaarniranta K, 2013, AUTOPHAGY, V9, P973, DOI 10.4161/auto.24546
   Kant AK, 2009, AM J CLIN NUTR, V90, P655, DOI 10.3945/ajcn.2009.27749
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Kaur C, 2006, INVEST OPHTH VIS SCI, V47, P1126, DOI 10.1167/iovs.05-0518
   Kawasaka K, 1977, JPN J OPHTHALMOL, V31, P23
   KAWASAKI K, 1984, DOC OPHTHALMOL, V58, P375, DOI 10.1007/BF00679800
   Kenney WL, 2001, MED SCI SPORT EXER, V33, P1524, DOI 10.1097/00005768-200109000-00016
   Kerur N, 2013, INVEST OPHTH VIS SCI, V54, P7395, DOI 10.1167/iovs.13-12500
   KHAW KT, 1988, CIRCULATION, V77, P53, DOI 10.1161/01.CIR.77.1.53
   Klein R, 2014, OPHTHALMOLOGY, V121, P1604, DOI 10.1016/j.ophtha.2014.03.005
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Kopitz J, 2004, BIOCHIMIE, V86, P825, DOI 10.1016/j.biochi.2004.09.029
   KOSTRABA JN, 1991, AM J EPIDEMIOL, V133, P381, DOI 10.1093/oxfordjournals.aje.a115892
   KUPARI M, 1994, CIRCULATION, V89, P1041, DOI 10.1161/01.CIR.89.3.1041
   Kur J, 2012, PROG RETIN EYE RES, V31, P377, DOI 10.1016/j.preteyeres.2012.04.004
   Latz E, 2013, NAT REV IMMUNOL, V13, P397, DOI 10.1038/nri3452
   Li XY, 2012, CNS NEUROSCI THER, V18, P691, DOI 10.1111/j.1755-5949.2012.00355.x
   Lifton RP, 2001, CELL, V104, P545, DOI 10.1016/S0092-8674(01)00241-0
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Maeno E, 2000, P NATL ACAD SCI USA, V97, P9487, DOI 10.1073/pnas.140216197
   Manz F, 2005, NUTR REV, V63, pS55, DOI 10.1111/j.1753-4887.2005.tb00154.x
   Marneros AG, 2013, CELL REP, V4, P945, DOI 10.1016/j.celrep.2013.08.002
   Matz R, 1996, JAMA-J AM MED ASSOC, V275, P911, DOI 10.1001/jama.1996.03530360021030
   McCarron DA, 1997, AM J CLIN NUTR, V65, P712
   McCarty CA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1455
   MCLEOD DS, 1994, INVEST OPHTH VIS SCI, V35, P3799
   Metelitsina TI, 2006, BRIT J OPHTHALMOL, V90, P342, DOI 10.1136/bjo.2005.082974
   MILLAY RH, 1986, AM J OPHTHALMOL, V102, P626, DOI 10.1016/0002-9394(86)90536-2
   MINASSIAN DC, 1989, BRIT J OPHTHALMOL, V73, P100, DOI 10.1136/bjo.73.2.100
   MORGAN TO, 1982, CLIN SCI, V63, pS407, DOI 10.1042/cs063407s
   Morris RC, 1999, HYPERTENSION, V33, P18, DOI 10.1161/01.HYP.33.1.18
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Nagaoka T, 2004, BRIT J OPHTHALMOL, V88, P1060, DOI 10.1136/bjo.2003.035345
   Nagelhus EA, 2004, NEUROSCIENCE, V129, P905, DOI 10.1016/j.neuroscience.2004.08.053
   Neuhofer W, 2010, CURR GENOMICS, V11, P584, DOI 10.2174/138920210793360961
   Ng SW, 2012, BRIT J NUTR, V108, P536, DOI 10.1017/S0007114511006465
   Nita M, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/930671
   Notomi S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053338
   ONEILL PA, 1989, GERONTOLOGY, V35, P205, DOI 10.1159/000213024
   Opinion of the Scientific Panel on Dietetic Products, 2005, EFSA J, V209, P1
   Orgul S, 1993, Ger J Ophthalmol, V2, P436
   Orlov SN, 2015, PFLUG ARCH EUR J PHY, V467, P489, DOI 10.1007/s00424-014-1650-8
   Oshima Y, 2004, J CELL PHYSIOL, V201, P393, DOI 10.1002/jcp.20110
   Parikh NI, 2007, EUR HEART J, V28, P2644, DOI 10.1093/eurheartj/ehm399
   Park J, 2014, EXP EYE RES, V122, P13, DOI 10.1016/j.exer.2014.03.001
   Piippo N, 2014, BBA-MOL CELL RES, V1843, P3038, DOI 10.1016/j.bbamcr.2014.09.015
   Prager P, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165653
   Qin YW, 2012, INVEST OPHTH VIS SCI, V53, P3047, DOI 10.1167/iovs.11-9154
   Qin YW, 2009, EXP EYE RES, V89, P741, DOI 10.1016/j.exer.2009.06.020
   Qin YW, 2009, EXP EYE RES, V89, P88, DOI 10.1016/j.exer.2009.02.017
   Raff U, 2012, ATHEROSCLEROSIS, V222, P235, DOI 10.1016/j.atherosclerosis.2012.02.006
   Rakic JM, 2003, INVEST OPHTH VIS SCI, V44, P3186, DOI 10.1167/iovs.02-1092
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Ritz E, 2006, NEPHROL DIAL TRANSPL, V21, P2052, DOI 10.1093/ndt/gfi256
   Rodrigues SL, 2014, J AM SOC HYPERTENS, V8, P232, DOI 10.1016/j.jash.2014.01.001
   Rodriguez-Iturbe B, 2004, AM J PHYSIOL-RENAL, V286, pF606, DOI 10.1152/ajprenal.00269.2003
   Roth F, 2004, GRAEF ARCH CLIN EXP, V242, P710, DOI 10.1007/s00417-004-0976-x
   Ruepp B, 1996, P NATL ACAD SCI USA, V93, P8624, DOI 10.1073/pnas.93.16.8624
   Ryan GJ, 2007, AM J HEALTH-SYST PH, V64, pS15, DOI 10.2146/ajhp070332
   Sabbatini M, 2001, J HYPERTENS, V19, P1861, DOI 10.1097/00004872-200110000-00022
   Sacks FM, 2001, NEW ENGL J MED, V344, P3, DOI 10.1056/NEJM200101043440101
   Safar ME, 2000, CARDIOVASC RES, V46, P269, DOI 10.1016/S0008-6363(99)00426-5
   Sanders PW, 2004, HYPERTENSION, V43, P142, DOI 10.1161/01.HYP.0000114022.20424.22
   Sato E, 2006, GRAEF ARCH CLIN EXP, V244, P963, DOI 10.1007/s00417-005-0201-6
   Schlingemann RO, 2004, GRAEF ARCH CLIN EXP, V242, P91, DOI 10.1007/s00417-003-0828-0
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Seko Y, 1999, INVEST OPHTH VIS SCI, V40, P3287
   SHIRAO Y, 1987, INVEST OPHTH VIS SCI, V28, P2015
   Silva KC, 2007, CURR EYE RES, V32, P533, DOI 10.1080/02713680701435391
   SPERDUTO RD, 1986, ARCH OPHTHALMOL-CHIC, V104, P216
   Stamer WD, 2003, INVEST OPHTH VIS SCI, V44, P2803, DOI 10.1167/iovs.03-0001
   Stearne MR, 1998, BMJ-BRIT MED J, V317, P703
   Steinberg RH, 1985, PROG RETIN RES, V4, P33, DOI [10.1016/0278-4327(85)90004-5, DOI 10.1016/0278-4327(85)90004-5]
   Stookey JD, 2005, PUBLIC HEALTH NUTR, V8, P1275, DOI 10.1079/PHN2005829
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Sugiyama T, 2005, AM J PHYSIOL-CELL PH, V288, pC568, DOI 10.1152/ajpcell.00380.2004
   Suzuma I, 2001, DIABETES, V50, P444, DOI 10.2337/diabetes.50.2.444
   Takeda Y, 2000, ENDOCRINOLOGY, V141, P1901, DOI 10.1210/en.141.5.1901
   THIMM F, 1992, ADV EXP MED BIOL, V317, P793
   Tranos P, 2013, DRUG DES DEV THER, V7, P485, DOI 10.2147/DDDT.S43470
   Van Leeuwen R, 2004, OPHTHALMOLOGY, V111, P1169, DOI 10.1016/j.ophtha.2003.10.024
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
   van Leeuwen R, 2003, EUR J EPIDEMIOL, V18, P845, DOI 10.1023/A:1025643303914
   Vasan RS, 2002, JAMA-J AM MED ASSOC, V287, P1003, DOI 10.1001/jama.287.8.1003
   Veltmann M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147312
   Verkman AS, 2008, PROG RETIN EYE RES, V27, P420, DOI 10.1016/j.preteyeres.2008.04.001
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   Vinores SA, 2006, J CELL PHYSIOL, V206, P749, DOI 10.1002/jcp.20525
   von Leithner PL, 2009, AM J PATHOL, V175, P412, DOI 10.2353/ajpath.2009.080927
   Walsh NP, 2012, INVEST OPHTH VIS SCI, V53, P6622, DOI 10.1167/iovs.12-10175
   Wang YF, 2004, ARCH INTERN MED, V164, P2126, DOI 10.1001/archinte.164.19.2126
   WATSON PE, 1980, AM J CLIN NUTR, V33, P27, DOI 10.1093/ajcn/33.1.27
   Weinberger MH, 2001, HYPERTENSION, V37, P429, DOI 10.1161/01.HYP.37.2.429
   Whelton PK, 2014, CURR OPIN LIPIDOL, V25, P75, DOI 10.1097/MOL.0000000000000033
   Wilson MMG, 2003, EUR J CLIN NUTR, V57, pS24, DOI 10.1038/sj.ejcn.1601898
   Winges A, 2016, GRAEFES ARC IN PRESS
   Winkler BS, 2003, EXP EYE RES, V77, P115, DOI 10.1016/S0014-4835(03)00085-X
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
   Wong T, 2007, LANCET, V369, P425, DOI 10.1016/S0140-6736(07)60198-6
   Wong TY, 2004, NEW ENGL J MED, V351, P2310, DOI 10.1056/NEJMra032865
   Xu HP, 2009, PROG RETIN EYE RES, V28, P348, DOI 10.1016/j.preteyeres.2009.06.001
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   YONEMURA D, 1984, DOC OPHTHALMOL, V57, P163, DOI 10.1007/BF00143080
   Yu WF, 1995, J NEUROSCI METH, V62, P159, DOI 10.1016/0165-0270(95)00071-2
   Zhang D, 2015, MEDIAT INFLAMM, V2015
   Ziello Jennifer E, 2007, Yale J Biol Med, V80, P51
NR 172
TC 15
Z9 16
U1 0
U2 10
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD DEC 22
PY 2016
VL 22
BP 1437
EP 1454
PG 18
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA EK4PP
UT WOS:000393909500001
PM 28031693
DA 2022-11-30
ER

PT J
AU Micieli, JA
   Tsui, E
   Lam, WC
   Brent, MH
   Devenyi, RG
   Hudson, C
AF Micieli, Jonathan A.
   Tsui, Edmund
   Lam, Wai-Ching
   Brent, Michael H.
   Devenyi, Robert G.
   Hudson, Chris
TI Retinal blood flow in response to an intravitreal injection of
   ranibizumab for neovascular age-related macular degeneration
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration; blood flow; intravitreal; ranibizumab;
   vascular endothelial growth factor
AB Purpose: To assess the hemodynamic response of retinal arterioles and venules following a single intravitreal injection of ranibizumab in neovascular age-related macular degeneration (NV-AMD) patients and to assess the influence of the number of prior injections on this response.
   Methods: Fifteen NV-AMD patients were prospectively recruited and grouped according to the dosage of ranibizumab previously received. Group 1 NV-AMD patients (n = 7) had previously received 1.50 mg or less, and group 2 patients (n = 8) had received more than 1.50 mg in the study eye. A group of 12 non-NV AMD patients were also recruited for control comparison. Vessel diameter, centreline blood velocity and blood flow were assessed with the Canon Laser Blood Flowmeter immediately prior to an injection and at a mean follow-up of 37.7 and 36.7 days for group 1 and group 2 patients, respectively.
   Results: The NV-AMD patients as a whole and the group 1 cohort had a significantly greater arteriolar diameter at baseline than the non-NV AMD patients. There was a significant reduction in arteriolar diameter, velocity and blood flow in group 1 but not in group 2 NV-AMD patients at follow-up. There was only an insignificant decrease in measured parameters of the retinal venules. At follow-up, there was no difference in the diameter, velocity or flow between AMD patients.
   Conclusion: Intravitreal ranibizumab treatment for NV-AMD induces a reduction in arteriolar diameter, velocity, and blood flow in patients who have received <1.50 mg of ranibizumab.
C1 [Micieli, Jonathan A.; Tsui, Edmund; Lam, Wai-Ching; Brent, Michael H.; Devenyi, Robert G.; Hudson, Chris] Univ Toronto, Dept Ophthalmol & Vis Sci, Retina Res Grp, Toronto, ON, Canada.
   [Hudson, Chris] Univ Waterloo, Sch Optometry, Waterloo, ON N2L 3G1, Canada.
C3 University of Toronto; University of Waterloo
RP Hudson, C (通讯作者)，Toronto Western Hosp, Dept Ophthalmol & Vis Sci, Room 6F401,399 Bathurst St, Toronto, ON M5T 2S8, Canada.
EM chudson@uwaterloo.ca
OI Lam, Wai-Ching/0000-0003-2057-9374; Tsui, Edmund/0000-0001-7532-9191
FU Canadian Institutes of Health Research; Canada Foundation for
   Innovation; Toronto Western Hospital; Institute of Medical Science,
   University of Toronto
FX The authors acknowledge the technical assistance and expertise of Tien
   Wong. This work was funded by the Canadian Institutes of Health Research
   operating grant, a Canada Foundation for Innovation New Opportunities
   Infrastructure Grant (recipient CH), by the Toronto Western Hospital
   Practice Plan (recipient JAM) and the Institute of Medical Science,
   University of Toronto Scholarship (recipient JAM). This work was
   presented as a poster at the 2010 Association for Research in Vision and
   Ophthalmology (ARVO conference and the 2010 International Society for
   Eye Research meetings.
CR Bergers G, 2003, J CLIN INVEST, V111, P1287, DOI 10.1172/JCI200317929
   Bonnin P, 2010, ACTA OPHTHALMOL, V88, P641, DOI 10.1111/j.1755-3768.2009.01526.x
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chen YM, 2006, AM J PHYSIOL-LUNG C, V291, pL378, DOI 10.1152/ajplung.00424.2005
   DELORI FC, 1988, GRAEF ARCH CLIN EXP, V226, P393, DOI 10.1007/BF02172974
   DEMEY JG, 1982, CIRC RES, V51, P439, DOI 10.1161/01.RES.51.4.439
   FEKE GT, 1987, IEEE T BIO-MED ENG, V34, P673, DOI 10.1109/TBME.1987.325992
   Fukaya Y, 1996, AM J PHYSIOL-HEART C, V270, pH99, DOI 10.1152/ajpheart.1996.270.1.H99
   Garcia JPS, 2002, OPHTHALMIC RES, V34, P295, DOI 10.1159/000065600
   Gilmore ED, 2008, INVEST OPHTH VIS SCI, V49, P699, DOI 10.1167/iovs.07-0339
   Gilmore ED, 2007, INVEST OPHTH VIS SCI, V48, P1744, DOI 10.1167/iovs.06-1016
   Ikram MK, 2005, OPHTHALMOLOGY, V112, P548, DOI 10.1016/j.ophtha.2004.10.038
   Jeganathan VSE, 2008, AM J OPHTHALMOL, V146, P954, DOI 10.1016/j.ajo.2008.07.006
   Jo N, 2006, AM J PATHOL, V168, P2036, DOI 10.2353/ajpath.2006.050588
   Kida T, 2002, GRAEF ARCH CLIN EXP, V240, P342, DOI 10.1007/s00417-002-0437-3
   Kisilevsky M, 2008, MICROVASC RES, V75, P263, DOI 10.1016/j.mvr.2007.07.007
   Kisilevsky M, 2008, INVEST OPHTH VIS SCI, V49, P5503, DOI 10.1167/iovs.08-1854
   Klein R, 2004, AM J OPHTHALMOL, V137, P435, DOI 10.1016/j.ajo.2003.10.020
   Liew G, 2006, OPHTHALMOLOGY, V113, P1481, DOI 10.1016/j.ophtha.2006.03.051
   Mendrinos E, 2009, INVEST OPHT IN PRESS
   Mete A, 2010, J CLIN ULTRASOUND, V38, P66, DOI 10.1002/jcu.20650
   Micieli JA, 2010, CAN J OPHTHALMOL, V45, P231, DOI 10.3129/i10-027
   MILBOCKER MT, 1991, IEEE T BIO-MED ENG, V38, P928, DOI 10.1109/10.83614
   Papadopoulou DN, 2009, OPHTHALMOLOGY, V116, P1755, DOI 10.1016/j.ophtha.2009.03.017
   Parodi MB, 2010, EUR J OPHTHALMOL, V20, P1076, DOI 10.1177/112067211002000609
   Pournaras CJ, 2008, PROG RETIN EYE RES, V27, P284, DOI 10.1016/j.preteyeres.2008.02.002
   Rose PA, 2007, MICROVASC RES, V73, P35, DOI 10.1016/j.mvr.2006.10.001
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Soliman W, 2008, ACTA OPHTHALMOL, V86, P365, DOI 10.1111/j.1600-0420.2007.01057.x
   Tayyari F, 2009, INVEST OPHTH VIS SCI, V50, P4814, DOI 10.1167/iovs.09-3373
   Venkataraman ST, 2008, EXP EYE RES, V87, P535, DOI 10.1016/j.exer.2008.08.020
   von Hanno T, 2010, ACTA OPHTHALMOL, V88, P263, DOI 10.1111/j.1755-3768.2008.01406.x
   Xu LA, 2006, AM J OPHTHALMOL, V142, P688, DOI 10.1016/j.ajo.2006.05.028
   Yoshida A, 2003, AM J OPHTHALMOL, V135, P356, DOI 10.1016/S0002-9394(02)01949-9
NR 34
TC 17
Z9 17
U1 0
U2 4
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1755-375X
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD FEB
PY 2012
VL 90
IS 1
BP E13
EP E20
DI 10.1111/j.1755-3768.2011.02209.x
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 883HK
UT WOS:000299624600003
PM 21801339
OA Bronze
DA 2022-11-30
ER

PT J
AU Nischler, C
   Oberkofler, H
   Ortner, C
   Paikl, D
   Riha, W
   Lang, N
   Patsch, W
   Egger, SF
AF Nischler, Christian
   Oberkofler, Hannes
   Ortner, Christoph
   Paikl, Doris
   Riha, Wolfgang
   Lang, Nora
   Patsch, Wolfgang
   Egger, Stefan F.
TI Complement factor H Y402H gene polymorphism and response to intravitreal
   bevacizumab in exudative age-related macular degeneration
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration; anti-VEGF; bevacizumab; complement
   factor H
ID C-REACTIVE PROTEIN; POOLED FINDINGS; RISK-FACTORS; ASSOCIATION; VARIANT;
   COMMON; SUSCEPTIBILITY; MACULOPATHY; PROGRESSION; LOC387715
AB Purpose: To determine whether different complement factor H (CFH) genotypes play a role in treatment of age-related macular degeneration (AMD) with intravitreal bevacizumab.
   Methods: In this prospective study, we included 197 patients with exudative AMD and treated with 1.25 mg intravitreal bevacizumab at 6-week intervals until choroidal neovascularization (CNV) was no longer active. In all patients, ophthalmological examinations, visual acuity, optical coherence tomography (OCT), fundus photography and fluorescein angiography were performed. Single nucleotide polymorphism (SNP) genotyping was performed using restriction fragment length polymorphism (RFLP) analysis of polymerase chain reaction (PCR) products.
   Results: Age, gender and baseline mean visual acuity were similar among the three CFH genotypes. There was no significant difference in underlying lesion type of CNV, lesion size, number of injections or macula thickness. When examining the effect of genotype on post-treatment visual acuities, we observed a significant worse outcome for distance and reading visual acuity in the CFH 402HH genotype group. The number of patients who lost 3 or more lines in distance and reading visual acuity testing was significantly higher in the CFH 402HH (41%, 46%) genotype group than in patients with the CFH 402YY (28%, 26%) and CFH 402YH (26%, 24%) genotype.
   Conclusions: In addition to the higher risk for exudative AMD in patients with the CFH 402HH genotype that was found in previous studies, our results show that the CFH 402HH genotype also correlates with lower visual acuity outcome after treatment with bevacizumab, suggesting that pharmacogenetics of CFH plays a role in response to treatment of wet AMD.
C1 [Nischler, Christian; Ortner, Christoph; Paikl, Doris; Riha, Wolfgang; Lang, Nora; Egger, Stefan F.] Paracelsus Private Med Univ Salzburg, Dept Ophthalmol, A-5020 Salzburg, Austria.
   [Oberkofler, Hannes; Patsch, Wolfgang] Paracelsus Private Med Univ Salzburg, Clin Inst Med & Chem Lab Diagnost, A-5020 Salzburg, Austria.
C3 Paracelsus Private Medical University; Paracelsus Private Medical
   University
RP Nischler, C (通讯作者)，Paracelsus Private Med Univ Salzburg, Dept Ophthalmol, Muellner Hauptstr 48, A-5020 Salzburg, Austria.
EM c.nischler@salk.at
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Blackmore TK, 1998, INFECT IMMUN, V66, P1427, DOI 10.1128/IAI.66.4.1427-1431.1998
   Brantley MA, 2009, EYE, V23, P626, DOI 10.1038/eye.2008.28
   Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   Brantley MA, 2007, AM J OPHTHALMOL, V144, P404, DOI 10.1016/j.ajo.2007.05.018
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Chowers I, 2008, MOL VIS, V14, P1829
   Conley YP, 2005, HUM MOL GENET, V14, P1991, DOI 10.1093/hmg/ddi204
   de Cordoba SR, 2004, MOL IMMUNOL, V41, P355, DOI 10.1016/j.molimm.2004.02.005
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Feng XF, 2009, OPHTHALMOLOGY, V116, P1908, DOI 10.1016/j.ophtha.2009.03.011
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Giannakis E, 2003, EUR J IMMUNOL, V33, P962, DOI 10.1002/eji.200323541
   Goverdhan SV, 2008, EYE, V22, P849, DOI 10.1038/sj.eye.6702830
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Lee AY, 2009, BRIT J OPHTHALMOL, V93, P610, DOI 10.1136/bjo.2008.150995
   Majewski J, 2003, AM J HUM GENET, V73, P540, DOI 10.1086/377701
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Radner T, 1998, KLIN MONATSBL AUGENH, V213, P174, DOI 10.1055/s-2008-1034969
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Schick JH, 2003, AM J HUM GENET, V72, P1412, DOI 10.1086/375500
   Scholl HPN, 2007, MOL VIS, V13, P196
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Seddon JM, 2003, AM J HUM GENET, V73, P780, DOI 10.1086/378505
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Seitsonen SP, 2007, EUR J OPHTHALMOL, V17, P943, DOI 10.1177/112067210701700612
   Seitsonen S, 2006, MOL VIS, V12, P796
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   *STATSOFT INC, 1999, STATISTICA WIND COMP
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Wegscheider BJ, 2007, OPHTHALMOLOGY, V114, P738, DOI 10.1016/j.ophtha.2006.07.048
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
   Zipfel PF, 2001, SEMIN THROMB HEMOST, V27, P191, DOI 10.1055/s-2001-15248
NR 45
TC 64
Z9 71
U1 0
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD JUN
PY 2011
VL 89
IS 4
BP E344
EP E349
DI 10.1111/j.1755-3768.2010.02080.x
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 769ZQ
UT WOS:000291057200009
PM 21232084
OA Bronze
DA 2022-11-30
ER

PT J
AU Bashshur, ZF
   Haddad, ZA
   Schakal, AR
   Jaafar, RF
   Saad, A
   Noureddin, BN
AF Bashshur, Ziad F.
   Haddad, Zeina A.
   Schakal, Alexandre R.
   Jaafar, Rola F.
   Saad, Alain
   Noureddin, Baha' N.
TI Intravitreal Bevacizumab for Treatment of Neovascular Age-related
   Macular Degeneration: The Second Year of a Prospective Study
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID CHOROIDAL NEOVASCULARIZATION; AVASTIN; RANIBIZUMAB; THERAPY;
   PHARMACOKINETICS; ANGIOGENESIS; INJECTION; LUCENTIS; SAFETY
AB PURPOSE: To demonstrate the efficacy of intravitreal bevacizumab for treatment of neovascular age-related macular degeneration (AMD).
   DESIGN: Prospective, open-label, nonrandomized clinical study.
   METHODS: Fifty,one patients (51 eyes) with subfoveal choroidal neovascularization (CNV) resulting from AMD participated in this study at the American University of Beirut and Hotel Dieu de France Retina Clinics. These patients had already completed 12 months of follow-up. The criteria for reinjection were presence of fluid in the macula, increased central retinal thickness (CRT) of at least 100 mu m, loss of at least 5 letters of vision associated with increased fluid in the macula, new classic CNV, or new macular hemorrhage. The main outcome measure was the proportion of eyes losing fewer than 15 letters of vision after 12 months.
   RESULTS: Fifty-one patients (51 eyes) completed the additional 12 months. Mean visual acuity improved from 45.7 letters at baseline to 54.3 letters at 24 months (P = .001), and 47 eyes (92.2%) lost fewer than 15 letters. Mean CRT decreased from 327.4 mu m at baseline to 246.6 mu m at 24 months (P < .001). A mean of 1.5 injections were administered over the course of the second year. No serious ocular or systemic side effects were noted.
   CONCLUSIONS. Eyes with neovascular AMD treated with intravitreal bevacizumab over 2 years had significant anatomic and functional improvement compared with baseline. Further studies are necessary to confirm the long,term efficacy and safety of this treatment. (Am J Ophthalmol 2009;148:59-65. (C) 2009 by Elsevier Inc. All rights reserved.)
C1 [Bashshur, Ziad F.] Amer Univ Beirut, Med Ctr, Dept Ophthalmol, Beirut, Lebanon.
   [Schakal, Alexandre R.; Saad, Alain] St Joseph Univ, Hotel Dieu France, Dept Ophthalmol, Beirut, Lebanon.
C3 American University of Beirut; American University of Beirut
RP Bashshur, ZF (通讯作者)，Amer Univ Beirut, Med Ctr, Dept Ophthalmol, POB 11-0236-B11, Beirut, Lebanon.
EM zb00@aub.edu.lb
RI Jaafar, Rola/AFB-0063-2022; Jaafar, Rola F/X-9979-2018
OI Jaafar, Rola F/0000-0001-9477-7678; Saad, Alain/0000-0001-9855-8333
FU DEPARTMENT OF OPHTHALMOLOGY, AMERICAN UNIVERSITY OF BEIRUT MEDICAL
   Center, Beirut, Lebanon
FX THIS STUDY WAS SUPPORTED BY THE DEPARTMENT OF OPHTHALMOLOGY, AMERICAN
   UNIVERSITY OF BEIRUT MEDICAL Center, Beirut, Lebanon. The authors
   indicate no financial conflict of interest. Involved in design Of Study
   (Z.F.B, B.N.N.); conduct Of Study (Z.F.B., Z.A.H., A.R.S., A.S.); data
   collection (Z.A.H., R.F.J., A.S.); management, analysis, and
   interpretation of data (Z.F.B., Z.A.H., R.F.J.); preparation (Z.F.B.,
   Z.A.H.), review (Z.F.B., B.N.N., A.R.S.), and approval of the manuscript
   (Z.F.B., Z.A.H., A.R.S., R.F.J., A.S., B.N.N.). This Study was approved
   by the Institutional Review Board at the American University of Beirut
   Medical Center and was in adherence to the tenets of the Declaration of
   Helsinki.; The authors thank Dr Ziad Mahfoud, American University of
   Beirut Medical Center, Beirut, Lebanon, for his assistance in
   statistical analysis.
CR Abdollahi A, 2005, DRUG RESIST UPDATE, V8, P59, DOI 10.1016/j.drup.2005.03.001
   Arevalo JF, 2008, RETINA-J RET VIT DIS, V28, P1387, DOI 10.1097/IAE.0b013e3181884ff4
   Arias L, 2008, BRIT J OPHTHALMOL, V92, P1636, DOI 10.1136/bjo.2008.141721
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P855, DOI 10.1016/j.ophtha.2007.01.017
   Bashshur ZF, 2008, AM J OPHTHALMOL, V145, P249, DOI 10.1016/j.ajo.2007.09.031
   Bashshur ZF, 2006, AM J OPHTHALMOL, V142, P1, DOI 10.1016/j.ajo.2006.02.037
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Ferrara N, 2005, NATURE, V438, P967, DOI 10.1038/nature04483
   Fung AE, 2006, BRIT J OPHTHALMOL, V90, P1344, DOI 10.1136/bjo.2006.099598
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Grunewald M, 2006, CELL, V124, P175, DOI 10.1016/j.cell.2005.10.036
   Heier JS, 2006, OPHTHALMOLOGY, V113, P633, DOI 10.1016/j.ophtha.2005.10.052
   Krohne TU, 2008, AM J OPHTHALMOL, V146, P508, DOI 10.1016/j.ajo.2008.05.036
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Mulcahy MF, 2005, EXPERT OPIN BIOL TH, V5, P997, DOI 10.1517/14712598.5.7.997
   Ng EWM, 2005, CAN J OPHTHALMOL, V40, P352, DOI 10.1016/S0008-4182(05)80078-X
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2006, AM J OPHTHALMOL, V142, P141, DOI 10.1016/j.ajo.2006.03.036
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Schaal S, 2008, OPHTHALMOLOGY, V115, P2199, DOI 10.1016/j.ophtha.2008.07.007
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Steinbrook R, 2006, NEW ENGL J MED, V355, P1409, DOI 10.1056/NEJMp068185
   Ton NC, 2004, CURR PHARM DESIGN, V10, P51
   van Kempen LCL, 2006, EUR J CELL BIOL, V85, P61, DOI 10.1016/j.ejcb.2005.10.003
   van Wijngaarden P, 2005, JAMA-J AM MED ASSOC, V293, P1509, DOI 10.1001/jama.293.12.1509
   Wang Yaning, 2004, Angiogenesis, V7, P335, DOI 10.1007/s10456-004-8272-2
NR 28
TC 65
Z9 70
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JUL
PY 2009
VL 148
IS 1
BP 59
EP 65
DI 10.1016/j.ajo.2009.02.006
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 464CE
UT WOS:000267481700010
PM 19375689
DA 2022-11-30
ER

PT J
AU Sadda, S
   Holekamp, NM
   Sarraf, D
   Ebraheem, A
   Fan, WY
   Hill, L
   Blotner, S
   Spicer, G
   Gune, S
AF Sadda, SriniVas
   Holekamp, Nancy M.
   Sarraf, David
   Ebraheem, Adel
   Fan, Wenying
   Hill, Lauren
   Blotner, Steve
   Spicer, Galin
   Gune, Shamika
TI Relationship between retinal fluid characteristics and vision in
   neovascular age-related macular degeneration: HARBOR post hoc analysis
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Intraretinal; Fluid; Neovascular age-related macular degeneration;
   Retinal fluid; Subretinal; Vision
ID OPTICAL COHERENCE TOMOGRAPHY; 2.0 MG RANIBIZUMAB; TREAT-AND-EXTEND;
   VISUAL-ACUITY; MORPHOLOGY; EFFICACY; REGIMEN; ATROPHY; SAFETY
AB Purpose To evaluate the relationship between retinal fluid location, amount/severity, and vision with ranibizumab-treated neovascular age-related macular degeneration (nAMD). Methods In the phase 3 HARBOR trial (NCT00891735), treatment-naive patients with nAMD received ranibizumab 0.5 or 2.0 mg through month 24. This post hoc analysis included eyes with subretinal fluid (SRF) and/or intraretinal fluid (IRF) at screening, baseline, or week 1, and optical coherence tomography data at months 12 and 24 (n = 917). Outcomes were best-corrected visual acuity (BCVA) change from baseline and proportion of eyes with 20/40 or better vision at months 12 and 24. Eyes were stratified by the location, amount, and/or severity of fluid. Results At baseline, 86% and 63% of eyes had SRF and IRF, respectively. Among eyes with residual SRF, mean BCVA gains at each time point were greater in eyes with central versus noncentral SRF; location did not affect the odds of having 20/40 or better vision over 24 months. Eyes with 20/40 or better BCVA at month 12 had significantly lower SRF thickness versus eyes with worse vision; however, no difference was apparent at month 24. Vision was comparatively worse in eyes with residual IRF at months 12 and 24; location and severity did not appear to affect this outcome. Conclusion Residual IRF was associated with worse vision outcomes, regardless of location/severity, whereas, despite continued treatment, residual SRF was not associated with worse vision outcome at 24 months, regardless of location/thickness. These data suggest complex relationships between residual fluid, severity, and vision.
C1 [Sadda, SriniVas; Ebraheem, Adel; Fan, Wenying] Doheny Eye Inst, 625 S Fair Oaks Ave,Suite 280, Pasadena, CA 91105 USA.
   [Holekamp, Nancy M.] Pepose Vis Inst, Chesterfield, MO USA.
   [Sarraf, David] Ronald Reagan UCLA Med Ctr, UCLA Stein Eye Inst, Los Angeles, CA USA.
   [Hill, Lauren; Blotner, Steve; Spicer, Galin; Gune, Shamika] Genentech Inc, San Francisco, CA 94080 USA.
C3 Doheny Eye Institute; University of California System; University of
   California Los Angeles; University of California Los Angeles Medical
   Center; Ronald Reagan UCLA Medical Center; Roche Holding; Genentech
RP Sadda, S (通讯作者)，Doheny Eye Inst, 625 S Fair Oaks Ave,Suite 280, Pasadena, CA 91105 USA.
EM ssadda@doheny.org
RI fan, wenying/GSI-5125-2022
FU Genentech, Inc.
FX Financial support was provided by Genentech, Inc., a member of the Roche
   Group (South San Francisco, CA). The sponsor participated in the design
   of the study; collection, management, analysis, and interpretation of
   the data; and preparation, review, and approval of the manuscript.
   Funding was provided by Genentech, Inc., a member of the Roche Group,
   for third-party writing assistance, which was provided by Luke Carey,
   PhD, CMPP, of Envision Pharma Group.
CR Amoaku WM, 2015, EYE, V29, P1397, DOI 10.1038/eye.2015.159
   Bloch SB, 2012, AM J OPHTHALMOL, V153, P209, DOI 10.1016/j.ajo.2011.10.016
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Chen L, 2020, OPHTHALMOLOGY, V127, P931, DOI 10.1016/j.ophtha.2020.01.040
   Corvi F, 2021, GRAEF ARCH CLIN EXP, V259, P2887, DOI 10.1007/s00417-021-05167-3
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Grunwald JE, 2017, OPHTHALMOLOGY, V124, P97, DOI 10.1016/j.ophtha.2016.09.012
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P723, DOI 10.1016/j.ophtha.2018.11.025
   Heussen FM, 2011, INVEST OPHTH VIS SCI, V52, P7792, DOI 10.1167/iovs.11-8023
   Ho AC, 2014, OPHTHALMOLOGY, V121, P2181, DOI 10.1016/j.ophtha.2014.05.009
   Jaffe GJ, 2019, OPHTHALMOLOGY, V126, P252, DOI 10.1016/j.ophtha.2018.08.035
   Jaffe GJ, 2016, OPHTHALMOLOGY, V123, P1856, DOI 10.1016/j.ophtha.2016.05.016
   Jaffe GJ, 2013, OPHTHALMOLOGY, V120, P1860, DOI 10.1016/j.ophtha.2013.01.073
   Kertes PJ, 2019, OPHTHALMOLOGY, V126, P841, DOI 10.1016/j.ophtha.2019.01.013
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Leung King Fai Calvin, 2018, Vision (Basel), V2, DOI 10.3390/vision2010005
   Olsen TW, 2020, OPHTHALMOLOGY, V127, pP1, DOI 10.1016/j.ophtha.2019.09.024
   Ritter M, 2014, BRIT J OPHTHALMOL, V98, P1629, DOI 10.1136/bjophthalmol-2014-305186
   Sadda S, 2019, 52 ANN SCI M RETINA
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P878, DOI 10.1016/j.ophtha.2017.12.026
   Sharma S, 2016, OPHTHALMOLOGY, V123, P865, DOI 10.1016/j.ophtha.2015.12.002
   Silva R, 2018, OPHTHALMOLOGY, V125, P57, DOI 10.1016/j.ophtha.2017.07.014
   Sloan FA, 2014, JAMA OPHTHALMOL, V132, P456, DOI 10.1001/jamaophthalmol.2013.7647
   Waldstein SM, 2016, OPHTHALMOLOGY, V123, P60, DOI 10.1016/j.ophtha.2015.09.013
   Wykoff CC, 2015, OPHTHALMOLOGY, V122, P2514, DOI 10.1016/j.ophtha.2015.08.009
NR 25
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD DEC
PY 2022
VL 260
IS 12
BP 3781
EP 3789
DI 10.1007/s00417-022-05716-4
EA JUN 2022
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 6F8MV
UT WOS:000809318900001
PM 35687173
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Gili, P
   Martin, LL
   Martin-Rodrigo, JC
   Kim-Yeon, N
   Modamio-Gardeta, L
   Fernandez-Garcia, JL
   Rebolledo-Poves, AB
   Gomez-Blazquez, E
   Pazos-Rodriguez, R
   Perez-Fernandez, E
   Velasco, M
AF Gili, Pablo
   Lloreda Martin, Leyre
   Martin-Rodrigo, Jose-Carlos
   Kim-Yeon, Naon
   Modamio-Gardeta, Laura
   Fernandez-Garcia, Javier L.
   Rebolledo-Poves, Ana Belen
   Gomez-Blazquez, Elena
   Pazos-Rodriguez, Ruth
   Perez-Fernandez, Elia
   Velasco, Maria
TI Gene polymorphisms associated with an increased risk of exudative
   age-related macular degeneration in a Spanish population
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; gene polymorphisms; genotyping; risk
   factors
ID COMPLEMENT FACTOR-H; SINGLE-NUCLEOTIDE POLYMORPHISMS; FACTOR-B; HTRA1;
   LOC387715; DISEASE; VARIANT; SUSCEPTIBILITY; MACULOPATHY; RS1410996
AB Purpose: To identify the association between single-nucleotide polymorphisms (SNPs) in CFH, ARMS2, HTRA1, CFB, C2, and C3 genes and exudative age-related macular degeneration (AMD) in a Spanish population. Methods: In 187 exudative AMD patients and 196 healthy controls (61% women, mean age 75 years), 12 SNPs as risk factors for AMD in CFH (rs1410996, rs1061170, r380390), ARMS2 (rs10490924, rs10490923), HTRA1 (rs11200638), CFB (rs641153), C2 (rs547154, rs9332739), and C3 (rs147859257, rs2230199, rs1047286) genes were analyzed. Results: The G allele was the most frequent in CFH gene (rs1410996) with a 7-fold increased risk of AMD (OR 7.69, 95% CI 3.17-18.69), whereas carriers of C allele in CFH (rs1061170) showed a 3-fold increased risk for AMD (OR 3.22, 95% CI 1.93-5.40). In CFH (rs380390), the presence of G allele increased the risk for AMD by 2-fold (OR 2.52, 95% CI 1.47-4.30). In ARMS2 (rs10490924), the T-allele was associated with an almost 5-fold increased risk (OR 5.49, 95% CI 3.23-9.31). The A allele in HTRA1 (rs11200638) was more prevalent in AMD versus controls (OR 6.44, 95% CI 3.62-11.47). In C2 gene (rs9332739) the presence of C increased risk for AMD by 3-fold (OR 3.10, 95% CI 1.06-9.06). Conclusion: SNPs in CFH, ARMS2, HTRA1, and C2 genes were associated in our study with an increased risk for exudative AMD in Spanish patients.
C1 [Gili, Pablo; Lloreda Martin, Leyre; Martin-Rodrigo, Jose-Carlos; Kim-Yeon, Naon; Modamio-Gardeta, Laura; Fernandez-Garcia, Javier L.] Hosp Univ Fdn Alcorcon, Unit Ophthalmol, C Budapest 1, E-28922 Madrid, Spain.
   [Rebolledo-Poves, Ana Belen; Gomez-Blazquez, Elena; Pazos-Rodriguez, Ruth] Hosp Univ Fdn Alcorcon, Res Support Lab, Madrid, Spain.
   [Perez-Fernandez, Elia; Velasco, Maria] Hosp Univ Fdn Alcorcon, Res Unit, Madrid, Spain.
C3 Alcorcon Foundation University Hospital; Alcorcon Foundation University
   Hospital; Alcorcon Foundation University Hospital
RP Gili, P (通讯作者)，Hosp Univ Fdn Alcorcon, Unit Ophthalmol, C Budapest 1, E-28922 Madrid, Spain.
EM pgili@fhalcorcon.es
RI Pazos, Ruth/D-6797-2019
OI Pazos, Ruth/0000-0001-7613-795X; Velasco Arribas,
   Maria/0000-0001-6554-2095; Perez-Fernandez, Elia/0000-0003-2726-8683
FU FIS Project, National 2014-2017 I+D+I. Instituto de Salud Carlos III [PI
   00965/2014]
FX The author(s) disclosed receipt of the following financial support for
   the research, authorship, and/or publication of this article: Supported
   by a FIS Project, PI 00965/2014, integrated in the National 2014-2017
   I+D+I. Instituto de Salud Carlos III.
CR Armada F, 2006, ATEN PRIM, V38, P151
   Bergeron-Sawitzke J, 2009, EUR J HUM GENET, V17, P1190, DOI 10.1038/ejhg.2009.23
   Bonyadi MHJ, 2019, INT OPHTHALMOL, V39, P949, DOI 10.1007/s10792-018-0853-y
   Bonyadi M, 2017, OPHTHALMIC GENET, V38, P61, DOI 10.3109/13816810.2015.1126612
   Cruz-Gonzalez F, 2016, Arch Soc Esp Oftalmol, V91, P177, DOI 10.1016/j.oftal.2015.12.016
   Cruz-Gonzalez F, 2014, OPHTHALMIC GENET, V35, P68, DOI 10.3109/13816810.2013.781193
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Habibi I, 2017, KLIN MONATSBL AUGENH, V234, P478, DOI 10.1055/s-0043-104419
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hammond CJ, 2002, OPHTHALMOLOGY, V109, P730, DOI 10.1016/S0161-6420(01)01049-1
   Ho L, 2011, ARCH OPHTHALMOL-CHIC, V129, P758, DOI 10.1001/archophthalmol.2011.141
   Jiang H, 2009, RETINA-J RET VIT DIS, V29, P974, DOI 10.1097/IAE.0b013e3181a3b90e
   Joachim N, 2018, OPHTHALMOL RETINA, V2, P684, DOI 10.1016/j.oret.2017.10.019
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kaur I, 2010, INVEST OPHTH VIS SCI, V51, P59, DOI 10.1167/iovs.09-4135
   Kawa MP, 2014, J IMMUNOL RES, V2014, DOI 10.1155/2014/483960
   Lambert NG, 2016, PROG RETIN EYE RES, V54, P64, DOI 10.1016/j.preteyeres.2016.04.003
   Liao X, 2016, ARCH GERONTOL GERIAT, V64, P123, DOI 10.1016/j.archger.2016.01.011
   Maguire MG, 2016, JAMA OPHTHALMOL, V134, P674, DOI 10.1001/jamaophthalmol.2016.0669
   Ng TK, 2016, SCI REP-UK, V6, DOI 10.1038/srep28639
   Piermarocchi S, 2015, ACTA OPHTHALMOL, V93, pE451, DOI 10.1111/aos.12587
   Priya RR, 2012, OPHTHALMOLOGY, V119, P2526, DOI 10.1016/j.ophtha.2012.06.042
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Sobrin L, 2012, OPHTHALMOLOGY, V119, P1874, DOI 10.1016/j.ophtha.2012.03.014
   Spencer KL, 2007, HUM MOL GENET, V16, P1986, DOI 10.1093/hmg/ddm146
   Weeks DE, 2000, HUM MOL GENET, V9, P1329, DOI 10.1093/hmg/9.9.1329
   Wu MX, 2016, OPHTHALMIC RES, V55, P135, DOI 10.1159/000442257
   Zhang J, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-0945-5
   Zhou YL, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0487-2
NR 36
TC 3
Z9 3
U1 2
U2 3
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD JAN
PY 2022
VL 32
IS 1
BP 651
EP 657
AR 11206721211002698
DI 10.1177/11206721211002698
EA MAR 2021
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA YK3MJ
UT WOS:000679140200001
PM 33765843
DA 2022-11-30
ER

PT J
AU Gangnon, RE
   Lee, KE
   Klein, BEK
   Iyengar, SK
   Sivakumaran, TA
   Klein, R
AF Gangnon, Ronald E.
   Lee, Kristine E.
   Klein, Barbara E. K.
   Iyengar, Sudha K.
   Sivakumaran, Theru A.
   Klein, Ronald
TI Misclassification Can Explain Most Apparent Regression of Age-Related
   Macular Degeneration: Results From Multistate Models With
   Misclassification
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE age-related macular degeneration; CFH; epidemiology
ID COMPLEMENT FACTOR-H; BEAVER-DAM-EYE; 5-YEAR INCIDENCE; VISUAL-ACUITY;
   FOLLOW-UP; MACULOPATHY; PROGRESSION; RISK; POPULATION; DRUSEN
AB PURPOSE. To investigate the impact of misclassification of age-related macular degeneration (AMD) on the baseline intensity and estimated effects of age, sex, and the Y402H variant in the complement factor H (CFH) gene on incidence, progression, and regression of AMD.
   METHODS. The Beaver Dam Eye Study, a longitudinal population-based study of age-related eye diseases conducted in the city and township of Beaver Dam, Wisconsin, performed examinations every 5 years during a 20-year period (1988-1990 through 2008-2010). Study participants (N = 4379) aged 43 to 86 years at the baseline examination had retinal photographs taken at baseline and up to four subsequent examinations. Multistate models with misclassification in continuous time were used to model the effects of age, sex, and CFH genotype on incidence, progression, and regression of AMD and mortality.
   RESULTS. After accounting for AMD misclassification, the occurrence of any AMD regression was rare (1%-4%), while it was relatively common (14%-21%) in models that do not account for misclassification. Failure to account for misclassification attenuated estimated age effects on incidence and progression to moderately severe early AMD and attenuated estimated CFH effects on incidence and progressions to moderately severe and severe early AMD.
   CONCLUSIONS. Apparent regression of AMD can largely, if not completely, be explained by misclassification. Estimated age effects on incidence and progression to moderately severe early AMD and estimated CFH effects on incidence and progressions to moderately severe and severe early AMD were attenuated in multistate models that did not account for misclassification.
C1 [Gangnon, Ronald E.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Biostat & Med Informat, Madison, WI 53726 USA.
   [Gangnon, Ronald E.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Populat Hlth Sci, Madison, WI 53726 USA.
   [Lee, Kristine E.; Klein, Barbara E. K.; Klein, Ronald] Univ Wisconsin, Sch Med & Publ Hlth, Dept Ophthalmol & Visual Sci, Madison, WI 53726 USA.
   [Iyengar, Sudha K.; Sivakumaran, Theru A.] Case Western Reserve Univ, Dept Epidemiol & Biostat, Cleveland, OH 44106 USA.
   [Iyengar, Sudha K.; Sivakumaran, Theru A.] Case Western Reserve Univ, Dept Genet, Cleveland, OH 44106 USA.
   [Iyengar, Sudha K.; Sivakumaran, Theru A.] Case Western Reserve Univ, Dept Ophthalmol, Cleveland, OH 44106 USA.
   [Sivakumaran, Theru A.] Cincinnati Childrens Hosp Med Ctr, Div Human Genet, Cincinnati, OH 45229 USA.
C3 University of Wisconsin System; University of Wisconsin Madison;
   University of Wisconsin System; University of Wisconsin Madison;
   University of Wisconsin System; University of Wisconsin Madison; Case
   Western Reserve University; Case Western Reserve University; Case
   Western Reserve University; Cincinnati Children's Hospital Medical
   Center
RP Klein, R (通讯作者)，Univ Wisconsin, Sch Med & Publ Hlth, Dept Ophthalmol & Visual Sci, 610 N Walnut St,417 WARF, Madison, WI 53726 USA.
EM kleinr@epi.ophth.wisc.edu
RI /S-1190-2019
OI /0000-0001-7488-250X; Gangnon, Ronald/0000-0003-2587-6714
FU National Institutes of Health [EY06594]; Research to Prevent Blindness,
   New York, New York
FX Supported by The National Institutes of Health Grant EY06594 (RK, BEKK),
   which provided funding for the entire study including collection and
   analyses of data; further support for data analyses was provided by an
   unrestricted grant from Research to Prevent Blindness, New York, New
   York. These funding organizations had no role in the design and conduct
   of the study, in the collection, analysis, or interpretation of the
   data, or in the preparation, review, or approval of the manuscript. REG
   and RK had full access to all the data in the study and take
   responsibility for the integrity of the data and the accuracy of the
   data analysis. The content is solely the responsibility of the authors
   and does not necessarily reflect the official views of the National Eye
   Institute or the National Institutes of Health.
CR AKAIKE H, 1974, IEEE T AUTOMAT CONTR, VAC19, P716, DOI 10.1109/TAC.1974.1100705
   Andersen PK, 2002, STAT METHODS MED RES, V11, P91, DOI 10.1191/0962280202SM276ra
   Andersen PK., 2012, STAT MODELS BASED CO
   [Anonymous], 1987, STAT DECIS
   BRESSLER NM, 1995, ARCH OPHTHALMOL-CHIC, V113, P301, DOI 10.1001/archopht.1995.01100030055022
   Buch H, 2005, OPHTHALMOLOGY, V112, P787, DOI 10.1016/j.ophtha.2004.11.040
   Commenges D, 2002, STAT METHODS MED RES, V11, P167, DOI 10.1191/0962280202sm279ra
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Gangnon RE, 2013, J R STAT SOC C, V51, P485
   Gangnon RE, 2012, ARCH OPHTHALMOL-CHIC, V130, P1169, DOI 10.1001/archophthalmol.2012.693
   GASS JDM, 1973, ARCH OPHTHALMOL-CHIC, V90, P206
   GENTLEMAN RC, 1994, STAT MED, V13, P805, DOI 10.1002/sim.4780130803
   GRUGER J, 1991, BIOMETRICS, V47, P595, DOI 10.2307/2532149
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   HUI SL, 1980, BIOMETRICS, V36, P167, DOI 10.2307/2530508
   Jackson CH, 2011, J STAT SOFTW, V38, P1
   Kalbfleisch J.D., 2002, STAT ANAL FAILURE TI
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   Klein ML, 2011, ARCH OPHTHALMOL-CHIC, V129, P1543, DOI 10.1001/archophthalmol.2011.216
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2001, OPHTHALMOLOGY, V108, P1757, DOI 10.1016/S0161-6420(01)00769-2
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1310
   Klein R, 1996, OPHTHALMOLOGY, V103, P1169, DOI 10.1016/S0161-6420(96)30526-5
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 1995, BEAVER DAM EYE STUDY, P61
   Klein R, 2013, JAMA OPHTHA IN PRESS, DOI [10.1001/jamaophthalmol. 2013.713, DOI 10.1001/JAMA0PHTHALM0L.2013.713]
   Klein R, 1991, BEAVER DAM EYE STUDY, P74
   Klein R, OPHTHALMOLO IN PRESS
   Klein R, 1991, WISCONSIN AGE RELATE
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Klein R, 2006, AM J OPHTHALMOL, V142, P539, DOI 10.1016/j.ajo.2006.06.015
   Lawless J. F., 2002, STAT MODELS METHODS, V2nd, DOI DOI 10.1002/9781118033005
   LINTON KLP, 1991, AM J EPIDEMIOL, V134, P1438, DOI 10.1093/oxfordjournals.aje.a116049
   MARSHALL G, 1995, STAT MED, V14, P1975, DOI 10.1002/sim.4780141804
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   R Development Core Team, 2020, R VERS 4 0 3 LANG EN
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P2203, DOI 10.1016/j.ophtha.2011.04.029
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Sparrow JM, 1997, EYE, V11, P315, DOI 10.1038/eye.1997.67
   THERNEAU TM, 2000, STAT BIOL HEALTH, pR7
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   Wang JJ, 2003, ARCH OPHTHALMOL-CHIC, V121, P658, DOI 10.1001/archopht.121.5.658
NR 47
TC 3
Z9 3
U1 0
U2 2
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAR
PY 2014
VL 55
IS 3
BP 1780
EP 1786
DI 10.1167/iovs.13-12375
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AE0HZ
UT WOS:000333645900010
PM 24550369
OA Green Published
DA 2022-11-30
ER

PT J
AU Durhuus, JA
   Rozing, MP
   Nielsen, MK
   Molbech, CR
   Keijzers, G
   Scheibye-Knudsen, M
   Rasmussen, LJ
   Westendorp, RGJ
   Sorensen, TL
AF Durhuus, Jon Ambaek
   Rozing, Maarten P.
   Nielsen, Marie Krogh
   Molbech, Christopher Rue
   Keijzers, Guido
   Scheibye-Knudsen, Morten
   Rasmussen, Lene Juel
   Westendorp, Rudi G. J.
   Sorensen, Torben Lykke
TI EX-vivo whole blood stimulation with A2E does not elicit an inflammatory
   cytokine response in patients with age-related macular degeneration
SO SCIENTIFIC REPORTS
LA English
DT Article
ID EXPRESSION; IMMUNITY; CULTURE; ISO-A2E; SYSTEM; ALPHA; CELLS; RISK; PCR
AB Age-related macular degeneration (AMD) is a highly prevalent degenerative disease and a leading cause of vision loss worldwide. Evidence for an inflammatory component in the development of AMD exists, yet the exact mechanisms remain unclear. Bisretinoid N-retinylidene-N-retinylethanolamine (A2E) in retinal pigmental epithelial (RPE) cells, and in extracellular deposits constitutes a hallmark of AMD, but its role in the pathology of AMD is elusive. Here, we tested the hypothesis that A2E is responsible for the heightened inflammatory activity in AMD. To this end, we measured ex vivo mRNA expression of the cytokines TNF-alpha, IL-6, and IL-10 in whole blood samples after stimulation with A2E in a clinical sample of 27 patients with neovascular AMD and 24 patients with geographic atrophy secondary to AMD. Patients' spouses (n=30) were included as non-affected controls. After stimulation with A2E, no statistical differences were found in the median expression level of TNF-alpha, IL-6, IL-10 between the control group, and the neovascular AMD and the geographic atrophy group. Our findings do not support evidence for the hypothesis, that A2E per se contributes to heightened inflammatory activity in AMD.
C1 [Rozing, Maarten P.] Univ Copenhagen, Dept Publ Hlth, Res Unit Gen Practice, Copenhagen, Denmark.
   [Rozing, Maarten P.] Univ Copenhagen, Dept Publ Hlth, Sect Gen Practice, Copenhagen, Denmark.
   [Durhuus, Jon Ambaek; Keijzers, Guido; Scheibye-Knudsen, Morten; Rasmussen, Lene Juel; Westendorp, Rudi G. J.] Univ Copenhagen, Fac Hlth & Med Sci, Ctr Hlth Aging, Dept Cellular & Mol Med, Copenhagen, Denmark.
   [Nielsen, Marie Krogh; Molbech, Christopher Rue; Sorensen, Torben Lykke] Zealand Univ, Hosp Roskilde, Dept Ophthalmol, Clin Eye Res Div, Roskilde, Denmark.
   [Nielsen, Marie Krogh; Molbech, Christopher Rue; Sorensen, Torben Lykke] Univ Copenhagen, Fac Hlth & Med Sci, Copenhagen, Denmark.
   [Rozing, Maarten P.; Westendorp, Rudi G. J.] Univ Copenhagen, Dept Publ Hlth, Sect Epidemiol, Copenhagen, Denmark.
   [Keijzers, Guido; Scheibye-Knudsen, Morten; Rasmussen, Lene Juel] Univ Copenhagen, Dept Cellular & Mol Med, Copenhagen, Denmark.
   [Durhuus, Jon Ambaek] Copenhagen Univ Hosp, Clin Res Dept, HNPCC Register, Hvidovre, Denmark.
C3 University of Copenhagen; University of Copenhagen; University of
   Copenhagen; University of Copenhagen; University of Copenhagen;
   University of Copenhagen; University of Copenhagen
RP Sorensen, TL (通讯作者)，Zealand Univ, Hosp Roskilde, Dept Ophthalmol, Clin Eye Res Div, Roskilde, Denmark.; Sorensen, TL (通讯作者)，Univ Copenhagen, Fac Hlth & Med Sci, Copenhagen, Denmark.
EM tlso@regionsjaelland.dk
RI Rozing, Maarten/AHC-7454-2022; Durhuus, Jon/AAZ-8283-2021; Keijzers,
   Guido/H-2423-2016
OI Keijzers, Guido/0000-0001-9353-8042; Scheibye-Knudsen,
   Morten/0000-0002-6637-1280; Rasmussen, Lene Juel/0000-0001-6864-963X
CR Abbasi A, 2013, EXERC IMMUNOL REV, V19, P8
   Allali Julien, 2012, Advances in Bioinformatics, V2012, P893048, DOI 10.1155/2012/893048
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Amsen Derk, 2009, V511, P107, DOI 10.1007/978-1-59745-447-6_5
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson OA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067263
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Chiswick EL, 2012, METHODS MOL BIOL, V844, P15, DOI 10.1007/978-1-61779-527-5_2
   Damsgaard CT, 2009, J IMMUNOL METHODS, V340, P95, DOI 10.1016/j.jim.2008.10.005
   de Craen AJM, 2005, GENES IMMUN, V6, P167, DOI 10.1038/sj.gene.6364162
   Duque GA, 2014, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00491
   Freedman ND, 2008, LANCET ONCOL, V9, P649, DOI 10.1016/S1470-2045(08)70154-2
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Huang J, 2015, AGEING RES REV, V24, P3, DOI 10.1016/j.arr.2014.10.004
   Jee EH, 2012, J CHROMATOGR A, V1251, P232, DOI 10.1016/j.chroma.2012.06.046
   Kaiser Peter K, 2009, Trans Am Ophthalmol Soc, V107, P311
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Liu JH, 2000, J BIOL CHEM, V275, P29354, DOI 10.1074/jbc.M910191199
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Louis E, 1998, CLIN EXP IMMUNOL, V113, P401
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Mujal AM, 2019, SCIENCE, V364, P28, DOI 10.1126/science.aau8694
   Niazi S, 2019, ACTA OPHTHALMOL, V97, P558, DOI 10.1111/aos.14072
   Nielsen MK, 2017, IMMUN AGEING, V14, DOI 10.1186/s12979-017-0100-9
   Nowotny K, 2015, BIOMOLECULES, V5, P194, DOI 10.3390/biom5010194
   Parish CA, 1998, P NATL ACAD SCI USA, V95, P14609, DOI 10.1073/pnas.95.25.14609
   Park SI, 2016, B KOREAN CHEM SOC, V37, P1541, DOI 10.1002/bkcs.10903
   Parmar VM, 2018, STEM CELL RES, V27, P95, DOI 10.1016/j.scr.2018.01.014
   Potuckova L, 2011, J IMMUNOL METHODS, V371, P38, DOI 10.1016/j.jim.2011.06.012
   Radu RA, 2011, J BIOL CHEM, V286, P18593, DOI 10.1074/jbc.M110.191866
   Rozing MP, 2020, PROG RETIN EYE RES, V76, DOI 10.1016/j.preteyeres.2019.100825
   Schaefer L, 2014, J BIOL CHEM, V289, P35237, DOI 10.1074/jbc.R114.619304
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Segre E, 2016, SHOCK, V45, P490, DOI 10.1097/SHK.0000000000000557
   Sharif U, 2019, J CELL MOL MED, V23, P405, DOI 10.1111/jcmm.13944
   Shi C, 2011, NAT REV IMMUNOL, V11, P762, DOI 10.1038/nri3070
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Stenken JA, 2015, ANAL CHIM ACTA, V853, P95, DOI 10.1016/j.aca.2014.10.009
   Subhi Y, 2017, ACTA OPHTHALMOL, V95, P472, DOI 10.1111/aos.13330
   Subhi Y, 2016, AGEING RES REV, V29, P42, DOI 10.1016/j.arr.2016.05.013
   Subhi Y, 2014, CLIN OPHTHALMOL, V8, P15, DOI 10.2147/OPTH.S55080
   Tecchio C, 2016, SEMIN IMMUNOL, V28, P119, DOI 10.1016/j.smim.2016.04.003
   Urban CF, 2006, CELL MICROBIOL, V8, P1687, DOI 10.1111/j.1462-5822.2006.00792.x
   van der Linden MW, 1998, J IMMUNOL METHODS, V218, P63, DOI 10.1016/S0022-1759(98)00108-2
   Wang AL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004160
   Wynn TA, 2016, IMMUNITY, V44, P450, DOI 10.1016/j.immuni.2016.02.015
   Xu HP, 2009, PROG RETIN EYE RES, V28, P348, DOI 10.1016/j.preteyeres.2009.06.001
   Zhang J, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.330
NR 49
TC 1
Z9 1
U1 0
U2 1
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD APR 15
PY 2021
VL 11
IS 1
AR 8226
DI 10.1038/s41598-021-87337-1
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA RP6LQ
UT WOS:000641838600008
PM 33859228
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Datseris, I
   Kontadakis, GA
   Diamanti, R
   Datseris, I
   Pallikaris, IG
   Theodossiadis, P
   Tsilimbaris, MK
AF Datseris, Ioannis
   Kontadakis, Georgios A.
   Diamanti, Ramza
   Datseris, Iordanis
   Pallikaris, Ioannis G.
   Theodossiadis, Panagiotis
   Tsilimbaris, Miltiadis K.
TI Prospective Comparison of Low-Fluence Photodynamic Therapy Combined with
   Intravitreal Bevacizumab versus Bevacizumab Monotherapy for Choroidal
   Neovascularization in Age-Related Macular Degeneration
SO SEMINARS IN OPHTHALMOLOGY
LA English
DT Article
DE Age; related macular degeneration; bevacizumab; choroidal
   neovascularization; photodynamic therapy; verteporfin
ID COMBINATION TREATMENT; VERTEPORFIN THERAPY; ENDOPHTHALMITIS;
   RANIBIZUMAB; INJECTION; AVASTIN; EXPERIENCE; VEGF
AB Purpose: To evaluate combination treatment with reduced-fluence photodynamic therapy (RDPDT) with Verteporfin and intravitreal bevacizumab, compared to bevacizumab alone, for choroidal neovascularization (CNV) in age-related macular degeneration. Methods: This was a prospective, randomized comparative study comprising 95 patients with CNV. 49 patients received RDPDT (25 J/cm(2)) followed by intravitreal bevacizumab 1.25mg one hour later, while 46 received intravitreal bevacizumab alone. Patients were followed for 12 months at four-week intervals with visual acuity (VA) assessment and Optical Coherence Tomography (OCT) of the macula. Bevacizumab re-injections were performed as needed. Results: On average, patients were re-injected 4.45 times in the combination group and 6.96 times in the bavacizumab group (p<0.001). At 12 months, VA improved by 8.64 letters in the bevacizumab group and by 8.37 letters in the combination group (p = 0.922). Conclusion: Adding a reduced-fluence PDT arm in combination with bevacizumab offers similar results to those of intravitreal bevacizumab alone with significantly reduced number of injection repetitions.
C1 [Datseris, Ioannis; Diamanti, Ramza; Datseris, Iordanis] OMMA Eye Inst, Athens, Greece.
   [Kontadakis, Georgios A.; Pallikaris, Ioannis G.; Tsilimbaris, Miltiadis K.] Univ Crete, Sch Med, Dept Ophthalmol, Iraklion, Greece.
   [Theodossiadis, Panagiotis] Univ Athens, Attikon Univ Hosp, Dept Ophthalmol 2, Athens, Greece.
C3 University of Crete; National & Kapodistrian University of Athens;
   University Hospital Attikon
RP Tsilimbaris, MK (通讯作者)，Univ Hosp Herakl, Dept Ophthalmol, GR-71003 Iraklion, Crete, Greece.
EM tsilimb@med.uoc.gr
RI Kontadakis, Georgios/AAF-7608-2020; Kontadakis, George/AAZ-1764-2020
OI Kontadakis, Georgios/0000-0003-4549-7682; Tsilimbaris,
   Miltiadis/0000-0002-0130-1150
CR Ahmadieh H, 2008, EUR J OPHTHALMOL, V18, P297, DOI 10.1177/112067210801800222
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P747
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Bressler SB, 2009, OPHTHALMOLOGY, V116, pS1, DOI 10.1016/j.ophtha.2009.06.045
   Carneiro AM, 2011, OPHTHALMOLOGICA, V225, P211, DOI 10.1159/000323943
   Costa RA, 2007, GRAEF ARCH CLIN EXP, V245, P1273, DOI 10.1007/s00417-007-0557-x
   Costagliola C, 2010, BRIT J OPHTHALMOL, V94, P180, DOI 10.1136/bjo.2009.159343
   Dhalla MS, 2006, RETINA-J RET VIT DIS, V26, P988, DOI 10.1097/01.iae.0000247164.70376.91
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Inoue M, 2011, OPHTHALMOLOGICA, V226, DOI 10.1159/000329863
   Kaiser PK, 2012, OPHTHALMOLOGY, V119, P1001, DOI 10.1016/j.ophtha.2012.02.003
   Klein RM, 2007, RETINA-J RET VIT DIS, V27, P1163, DOI 10.1097/IAE.0b013e31815e9322
   Ladas ID, 2009, RETINA-J RET VIT DIS, V29, P313, DOI 10.1097/IAE.0b013e31819a5f98
   Ladewig MS, 2008, GRAEF ARCH CLIN EXP, V246, P17, DOI 10.1007/s00417-007-0654-x
   Lazic R, 2007, OPHTHALMOLOGY, V114, P1179, DOI 10.1016/j.ophtha.2007.03.006
   Lyall DAM, 2012, EYE, V26, P1517, DOI 10.1038/eye.2012.199
   Moshfeghi AA, 2011, RETINA-J RET VIT DIS, V31, P662, DOI 10.1097/IAE.0b013e31821067c4
   Schmidt-Erfurth U, 2002, ARCH OPHTHALMOL-CHIC, V120, P835
   Schmidt-Erfurth U, 2003, INVEST OPHTH VIS SCI, V44, P4473, DOI 10.1167/iovs.02-1115
   Schmidt-Erfurth UM, 2007, PROG RETIN EYE RES, V26, P437, DOI 10.1016/j.preteyeres.2007.03.002
   Singh CN, 2008, RETINA-J RET VIT DIS, V28, P789, DOI 10.1097/IAE.0b013e31817082d7
   Sivaprasad S, 2011, OPHTHALMOLOGICA, V225, P200, DOI 10.1159/000322363
   Smith BT, 2008, RETINA-J RET VIT DIS, V28, P675, DOI 10.1097/IAE.0b013e31816b316e
   Stewart MW, 2011, RETINA-J RET VIT DIS, V31, P1981, DOI 10.1097/IAE.0B013E318234CB33
NR 27
TC 8
Z9 8
U1 0
U2 7
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0882-0538
EI 1744-5205
J9 SEMIN OPHTHALMOL
JI Semin. Ophthalmol.
PD MAR
PY 2015
VL 30
IS 2
BP 112
EP 117
DI 10.3109/08820538.2013.833268
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CC6CF
UT WOS:000350451500005
PM 24117412
DA 2022-11-30
ER

PT J
AU Du, MB
   Shen, S
   Liang, LN
   Xu, K
   He, AP
   Yao, Y
   Liu, SZ
AF Du, Maobo
   Shen, Shuo
   Liang, Lina
   Xu, Kai
   He, Aiping
   Yao, Yao
   Liu, Shuzhi
TI Evaluations of the Chuanqi Ophthalmic Microemulsion In Situ Gel on Dry
   Age-Related Macular Degeneration Treatment
SO EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; DELIVERY SYSTEM; CYCLOSPORINE-A;
   DRUG-DELIVERY; VITRO; IRRITATION; DESIGN
AB Age-related macular degeneration (AMD) is the third largest eye disease. However, the eye has a variety of drug delivery barriers, which prevent the drug from reaching the lesions in the posterior segment of the eye, coupled with the pathogenesis of dry-AMD; these lead to the lack of effective treatment drugs for dry-AMD. Therefore, the developments of a suitable therapeutic drug and a novel ophthalmic preparation are of great significance for the treatment of dry-AMD. The purposes of this study were to construct a novel traditional Chinese medicine (Chuanqi Fang) anti-AMD microemulsion in situ gel for treating dry-AMD and investigate its characteristic, efficiency, irritation, and tissue distribution. In this study, the characteristic of the Chuanqi microemulsion in situ gel was measured by dynamic light scattering. The electroretinogram (ERG) indicators and the number of retinal pigment epithelial cells were measured to evaluate the therapeutic effect of the novel ophthalmic nanopreparations. Irritation was evaluated according to Technical Guideline Principles (ZGPT4-1). The analysis of tissue distribution was carried out with LC-MS. The research showed that the particle size of microemulsion was 38.56 +/- 0.21 nm. The Chuanqi microemulsion in situ gel had certain roles in repairing retina damage of the dry-AMD animal model and showed no irritation. The tissue distribution study found that the microemulsion in situ gel could effectively deliver the drug to the posterior eye of the AMD model rat through the route of cornea-vitreous body-retina. In conclusion, this study provided a meaningful research strategy and research basis for the development of new dry-AMD therapeutic drugs.
C1 [Du, Maobo; Shen, Shuo; He, Aiping; Yao, Yao; Liu, Shuzhi] China Acad Chinese Med Sci, Inst Chinese Mat Med, Beijing, Peoples R China.
   [Liang, Lina; Xu, Kai] China Acad Chinese Med Sci, Eye Hosp, Beijing, Peoples R China.
C3 China Academy of Chinese Medical Sciences; Institute of Chinese Materia
   Medica, CACMS; China Academy of Chinese Medical Sciences; Eye Hospital,
   CACMS
RP Liu, SZ (通讯作者)，China Acad Chinese Med Sci, Inst Chinese Mat Med, Beijing, Peoples R China.
EM liushuzhi2004@sina.com
FU National Natural Science Foundation of China [81373977]; Fundamental
   Research Funds for the Central Public Welfare Research Institutes
   [ZZ13-YQ-052, ZZ13-YQ-108]
FX This work was supported by grants from the National Natural Science
   Foundation of China (Grant no. 81373977) and the Fundamental Research
   Funds for the Central Public Welfare Research Institutes (Grant nos.
   ZZ13-YQ-052 and ZZ13-YQ-108).
CR Basile A, 2010, J FOOT ANKLE SURG, V49, P25, DOI 10.1053/j.jfas.2009.08.001
   Bhasker S, 2015, TOXICOL IN VITRO, V29, P917, DOI 10.1016/j.tiv.2015.01.007
   Bonferoni MC, 2004, EUR J PHARM BIOPHARM, V57, P465, DOI 10.1016/j.ejpb.2003.12.002
   Chastain JE, 2016, EXP EYE RES, V145, P58, DOI 10.1016/j.exer.2015.10.009
   Chinese Pharmacopoeia Committee, 2015, PHARM PEOPL REP CHIN
   Code.org, 2019, GUID LOC IRR HEM TRA
   Cortesi R, 2006, INT J PHARMACEUT, V317, P90, DOI 10.1016/j.ijpharm.2006.02.050
   Di Tommaso C, 2012, EUR J PHARM BIOPHARM, V81, P257, DOI 10.1016/j.ejpb.2012.02.014
   Du Mao-Bo, 2017, Zhongguo Zhong Yao Za Zhi, V42, P628, DOI 10.19540/j.cnki.cjcmm.20170121.007
   [杜茂波 Du Maobo], 2019, [中国实验方剂学杂志, Chinese Journal of Experimental Traditional Medical Formulae], V25, P151
   [杜茂波 Du Maobo], 2015, [中国实验方剂学杂志, Chinese Journal of Experimental Traditional Medical Formulae], V21, P137
   El-Kamel AH, 2002, INT J PHARMACEUT, V241, P47, DOI 10.1016/S0378-5173(02)00234-X
   Bosch ME, 2008, J PHARMACEUT BIOMED, V47, P451, DOI 10.1016/j.jpba.2008.01.047
   Feng YB, 2015, EVID-BASED COMPL ALT, V2015, DOI 10.1155/2015/178128
   Hoar TP, 1943, NATURE, V152, P102, DOI 10.1038/152102a0
   Jadeja RN, 2020, DATA BRIEF, V28, DOI 10.1016/j.dib.2019.104874
   Jiang Y, 2012, INT J PHARMACEUT, V436, P806, DOI 10.1016/j.ijpharm.2012.07.053
   Kiuchi K, 2002, CURR EYE RES, V25, P373, DOI 10.1076/ceyr.25.6.373.14227
   Kumar-Singh R, 2019, EXP EYE RES, V184, P266, DOI 10.1016/j.exer.2019.05.006
   Lee YM, 2016, BMC COMPLEM ALTERN M, V16, DOI 10.1186/s12906-016-1216-8
   Li Y, 2007, INVEST OPHTH VIS SCI, V48, P4321, DOI 10.1167/iovs.06-1015
   [林艳琼 Lin Yanqiong], 2006, [中国药学杂志, Chinese Pharmaceutical Journal], V41, P358
   REIDY JJ, 1990, CORNEA, V9, P196
   ROBINSON JR, 1995, ADV DRUG DELIVER REV, V16, P45, DOI 10.1016/0169-409X(95)00013-W
   Sandalon S, 2009, DOC OPHTHALMOL, V118, P101, DOI 10.1007/s10633-008-9141-x
   Shen J, 2010, INT J PHARMACEUT, V402, P248, DOI 10.1016/j.ijpharm.2010.10.008
   Shi WL, 2019, EVID-BASED COMPL ALT, V2019, DOI 10.1155/2019/7912402
   Tajika T, 2011, J OCUL PHARMACOL TH, V27, P43, DOI 10.1089/jop.2010.0093
   Tan SQ, 2017, BMC COMPLEM ALTERN M, V17, DOI 10.1186/s12906-017-1857-2
   Tao Z, 2013, MOL NEUROBIOL, V47, P241, DOI 10.1007/s12035-012-8366-6
   Tayel SA, 2013, INT J PHARMACEUT, V443, P293, DOI 10.1016/j.ijpharm.2012.12.049
   Velez G, 1999, BRIT J OPHTHALMOL, V83, P1225, DOI 10.1136/bjo.83.11.1225
   Vincent A, 2013, RETINA-J RET VIT DIS, V33, P5, DOI 10.1097/IAE.0b013e31827e2306
   Wang Z, 2015, INT J NANOMED, V10, P633, DOI 10.2147/IJN.S74079
   World Health Organization, 2020, VIS 2020 RIGHT SLIGH
   Wu HY, 2011, INT J PHARMACEUT, V410, P31, DOI 10.1016/j.ijpharm.2011.03.007
   Xiao JH, 2017, INVEST OPHTH VIS SCI, V58, P1801, DOI 10.1167/iovs.16-21392
   Yamashita H, 2010, EXP EYE RES, V90, P591, DOI 10.1016/j.exer.2010.02.003
   [杨文蕾 Yang Wenlei], 2010, [上海交通大学学报. 医学版, Journal of Shanghai Jiaotong University. Medical Science], V30, P832
   Yasuda S, 2015, ACTA OPHTHALMOL, V93, pE465, DOI 10.1111/aos.12674
   [尹连荣 Yin Lianrong], 2016, [北京中医药大学学报, Journal of Beijing University of Traditional Chinese Medicine], V39, P828
   Zhang XY, 2016, SCI REP-UK, V6, DOI 10.1038/srep37279
   Zhao K. Q., 2006, INT J OPHTHALMOLOGY, V6, P1042
   李春武, 2002, [中国实用眼科杂志, Chinese Journal of Practical Ophthalmology], V20, P945
NR 44
TC 2
Z9 2
U1 4
U2 12
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1741-427X
EI 1741-4288
J9 EVID-BASED COMPL ALT
JI Evid.-based Complement Altern. Med.
PD AUG 19
PY 2020
VL 2020
AR 3805967
DI 10.1155/2020/3805967
PG 14
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Integrative & Complementary Medicine
GA NY0WO
UT WOS:000576120600001
OA gold
DA 2022-11-30
ER

PT J
AU Bojke, L
   Claxton, K
   Sculpher, MJ
   Palmer, S
AF Bojke, Laura
   Claxton, Karl
   Sculpher, Mark J.
   Palmer, Stephen
TI Identifying research priorities: The value of information associated
   with repeat screening for age-related macular degeneration
SO MEDICAL DECISION MAKING
LA English
DT Article
DE decision making; modeling; research prioritization
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; HEALTH TECHNOLOGY-ASSESSMENT;
   COST-EFFECTIVENESS; PHOTODYNAMIC THERAPY; VERTEPORFIN THERAPY;
   CLINICAL-TRIAL
AB The authors report an analysis that was developed as part of a pilot study examining the use of decision analysis and value-of-information methods to inform research prioritization decisions for the UK health care system. This analysis was conducted to inform decision makers whether additional research on screening for age-related macular degeneration (AMD) would be worthwhile and to demonstrate the benefits and feasibility of using such analytic methods to inform policy decision within the time-lines demanded by existing procedures. A probabilistic decision model was developed to establish the cost-effectiveness of a policy of repeat screening for AMD using the Amsler grid followed by treatment with photodynamic therapy (PDT) compared with 2 alternatives: PDT without screening (self-referral) and no screening or treatment. Screening for AMD appears to be cost-effective on the basis of existing evidence; however, the decision to implement a policy of screening is somewhat uncertain, with a probability that screening is cost-effective of 0.87 and 0.72 for the 20/40 and 20/80 models, respectively, at a threshold of (sic)30,000 per quality-adjusted life-year. The expected value of perfect information (EVPI) associated with this decision is substantial ((sic)6.9 million for the 20/40 model and (sic)14.5 million for the 20/80 model), with a sizeable EVPI associated with the effect of PDT on quality of life. The analysis demonstrates that EVPI analysis can be implemented in a timely fashion to inform the type of research prioritization decisions faced by any health care system. This case study also illustrates the need to account for any structural uncertainties appropriately.
C1 [Bojke, Laura; Claxton, Karl; Sculpher, Mark J.; Palmer, Stephen] Univ York, Ctr Hlth Econ, York YO10 5DD, N Yorkshire, England.
   [Claxton, Karl] Univ York, Dept Econ, York YO10 5DD, N Yorkshire, England.
C3 University of York - UK; University of York - UK
RP Bojke, L (通讯作者)，Univ York, Ctr Hlth Econ, York YO10 5DD, N Yorkshire, England.
EM kpc1@york.ac.uk
OI Sculpher, Mark/0000-0003-3746-9913
FU MRC [MC_U145079308] Funding Source: UKRI; Medical Research Council
   [MC_U145079308] Funding Source: Medline
CR Ades AE, 2004, MED DECIS MAKING, V24, P207, DOI 10.1177/0272989X04263162
   *AMD ALL INT, 2002, AMSL GRID CHECK YOUR
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Briggs A, 1998, PHARMACOECONOMICS, V13, P397, DOI 10.2165/00019053-199813040-00003
   Brown MM, 2001, BRIT J OPHTHALMOL, V85, P327, DOI 10.1136/bjo.85.3.327
   BUXTON M, 1997, 24 HERG RES BRUN U
   *CHART I PUBL FIN, 2001, HLTH SERV FIN DAT
   Claxton K, 2004, HEALTH TECHNOL ASSES, V8, P1, DOI 10.3310/hta8310
   Claxton K, 1999, J HEALTH ECON, V18, P341, DOI 10.1016/S0167-6296(98)00039-3
   Davies L, 2000, INT J TECHNOL ASSESS, V16, P73, DOI 10.1017/S0266462300016172
   Fenwick E, 2001, HEALTH ECON, V10, P779, DOI 10.1002/hec.635
   FINE AM, 1986, ARCH OPHTHALMOL-CHIC, V104, P513
   GREGOR Z, 1977, BRIT J OPHTHALMOL, V61, P141, DOI 10.1136/bjo.61.2.141
   *HM TREAS, 2003, GREEN BOOK APPR EV G
   JOHANNESSON M, 1993, J HEALTH ECON, V12, P459, DOI 10.1016/0167-6296(93)90005-Y
   Margherio RR, 2000, RETINA-J RET VIT DIS, V20, P325, DOI 10.1097/00006982-200007000-00001
   MEADS C, 2002, CLIN EFFECT COST UT
   Michaud CM, 2001, JAMA-J AM MED ASSOC, V285, P535, DOI 10.1001/jama.285.5.535
   *NAT I CLIN EXC, 2004, GUID MAN SPONS CONTR
   *NAT I CLIN EXC, 2003, GUID US PHOT THER AG
   *OFF NAT STAT, 2002, CENS 2001 POP ENG WA
   PHELPS CE, 1990, MED CARE, V28, P703, DOI 10.1097/00005650-199008000-00004
   PHILIPS Z, 2005, 27 ANN M SOC MED DEC
   Royal College of Ophthalmologists, 2000, AG REL MAC DEG GUID
   Schlaifer RO., 1959, PROBABILITY STAT BUS
   SCHUCHARD RA, 1993, ARCH OPHTHALMOL-CHIC, V111, P776, DOI 10.1001/archopht.1993.01090060064024
   Smith DH, 2004, BRIT J OPHTHALMOL, V88, P1107, DOI 10.1136/bjo.2003.023986
   Townsend J, 1997, HEALTH POLICY, V39, P181, DOI 10.1016/S0168-8510(96)00870-6
   VANHOUT BA, 1994, HEALTH ECON, V3, P309, DOI 10.1002/hec.4730030505
NR 30
TC 21
Z9 22
U1 0
U2 1
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0272-989X
EI 1552-681X
J9 MED DECIS MAKING
JI Med. Decis. Mak.
PD JAN-FEB
PY 2008
VL 28
IS 1
BP 33
EP 43
DI 10.1177/0272989X07309638
PG 11
WC Health Care Sciences & Services; Health Policy & Services; Medical
   Informatics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Health Care Sciences & Services; Medical Informatics
GA 258GH
UT WOS:000252855900004
PM 18263560
DA 2022-11-30
ER

PT J
AU Lambert, V
   Hansen, S
   Schoumacher, M
   Lecomte, J
   Leenders, J
   Hubert, P
   Herfs, M
   Blacher, S
   Carnet, O
   Yip, C
   Blaise, P
   Duchateau, E
   Locht, B
   Thys, M
   Cavalier, E
   Gothot, A
   Govaerts, B
   Rakic, JM
   Noel, A
   de Tullio, P
AF Lambert, Vincent
   Hansen, Sylvain
   Schoumacher, Matthieu
   Lecomte, Julie
   Leenders, Justine
   Hubert, Pascale
   Herfs, Michael
   Blacher, Silvia
   Carnet, Oriane
   Yip, Cassandre
   Blaise, Pierre
   Duchateau, Edouard
   Locht, Benedicte
   Thys, Michele
   Cavalier, Etienne
   Gothot, Andre
   Govaerts, Bernadette
   Rakic, Jean-Marie
   Noel, Agnes
   de Tullio, Pascal
TI Pyruvate dehydrogenase kinase/lactate axis: a therapeutic target for
   neovascular age-related macular degeneration identified by metabolomics
SO JOURNAL OF MOLECULAR MEDICINE-JMM
LA English
DT Article
DE Neovascular AMD; Metabolomics; Inflammation; Angiogenesis; Therapeutic
   target; Lactate
ID CHOROIDAL NEOVASCULARIZATION; LACTATE; MACROPHAGES; CELL; ANGIOGENESIS;
   POLARIZATION; INHIBITION; MANAGEMENT; PROTOCOL; PATHWAY
AB Neovascular age-related macular degeneration (nAMD) is the leading cause of blindness in aging populations. Here, we applied metabolomics to human sera of patients with nAMD during an active (exudative) phase of the pathology and found higher lactate levels and a shift in the lipoprotein profile (increased VLDL-LDL/HDL ratio). Similar metabolomics changes were detected in the sera of mice subjected to laser-induced choroidal neovascularization (CNV). In this experimental model, we provide evidence for two sites of lactate production: first, a local one in the injured eye, and second a systemic site associated with the recruitment of bone marrow-derived inflammatory cells. Mechanistically, lactate promotes the angiogenic response and M2-like macrophage accumulation in the eyes. The therapeutic potential of our findings is demonstrated by the pharmacological control of lactate levels through pyruvate dehydrogenase kinase (PDK) inhibition by dichloroacetic acid (DCA). Mice treated with DCA exhibited normalized lactate levels and lipoprotein profiles, and inhibited CNV formation. Collectively, our findings implicate the key role of the PDK/lactate axis in AMD pathogenesis and reveal that the regulation of PDK activity has potential therapeutic value in this ocular disease. The results indicate that the lipoprotein profile is a traceable pattern that is worth considering for patient follow-up. Key messages
   Lactate and lipoprotein profile are associated with the active phase of AMD and CNV development. Lactate is a relevant and functional metabolite correlated with AMD progression. Modulating lactate through pyruvate dehydrogenase kinase led to a decrease of CNV progression. Pyruvate dehydrogenase kinase is a new therapeutic target for neovascular AMD.
C1 [Lambert, Vincent; Blaise, Pierre; Duchateau, Edouard; Locht, Benedicte; Thys, Michele; Rakic, Jean-Marie] Univ Hosp Liege, Dept Ophthalmol, Liege, Belgium.
   [Lambert, Vincent; Hansen, Sylvain; Lecomte, Julie; Blacher, Silvia; Carnet, Oriane; Yip, Cassandre; Noel, Agnes] Univ Liege, GIGA, Lab Tumor & Dev Biol, Liege, Belgium.
   [Schoumacher, Matthieu; Leenders, Justine; de Tullio, Pascal] Univ Liege, Metabol Grp, Ctr Interdisciplinary Res Med, Liege, Belgium.
   [Hubert, Pascale; Herfs, Michael] Univ Liege, GIGA, Lab Expt Pathol, Ave Hippocrate, Liege, Belgium.
   [Cavalier, Etienne] Univ Hosp Liege, Dept Med Chem, Liege, Belgium.
   [Gothot, Andre] Univ Hosp Liege, Dept Hematol & Immunohematol, Liege, Belgium.
   [Govaerts, Bernadette] Catholic Univ Louvain, Inst Stat Biostat & Actuarial Sci, Louvain La Neuve, Belgium.
C3 University of Liege; University of Liege; University of Liege;
   University of Liege; University of Liege; University of Liege;
   Universite Catholique Louvain
RP de Tullio, P (通讯作者)，Univ Liege, Metabol Grp, Ctr Interdisciplinary Res Med, Liege, Belgium.
EM P.deTullio@uLiege.be
RI Cavalier, Etienne/E-8661-2011; De Tullio, Pascal/ABE-5585-2021
OI Cavalier, Etienne/0000-0003-0947-2226; 
FU Fonds de la Recherche Scientifique FNRS (F.R.S.-FNRS, Belgium); Fonds
   speciaux de la Recherche (University of Liege); Fondation Hospitalo
   Universitaire Leon Fredericq (FHULF, University of Liege); REGION
   WALLONNE (Direction Generale Operationnelle de l'Economie, de l'Emploi
   et de la Recherche, SPW, Belgium); FEDER [DMLA-AB/ULG]
FX This work was supported by grants from the Fonds de la Recherche
   Scientifique FNRS (F.R.S.-FNRS, Belgium), the Fonds speciaux de la
   Recherche (University of Liege), the Fondation Hospitalo Universitaire
   Leon Fredericq (FHULF, University of Liege), the REGION WALLONNE
   (Direction Generale Operationnelle de l'Economie, de l'Emploi et de la
   Recherche, SPW, Belgium), and the FEDER project No. DMLA-AB/ULG (Fonds
   europeen de developpement regional). P. de Tullio is a Research Director
   of the F.R.S.-FNRS.
CR Adeva M, 2013, MITOCHONDRION, V13, P615, DOI 10.1016/j.mito.2013.08.011
   Beckert S, 2006, WOUND REPAIR REGEN, V14, P321, DOI 10.1111/j.1743-6109.2006.00127.x
   Beger RD, 2016, METABOLOMICS, V12, DOI 10.1007/s11306-016-1094-6
   Bian L, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2799
   Brizel DM, 2001, INT J RADIAT ONCOL, V51, P349, DOI 10.1016/S0360-3016(01)01630-3
   Brown CN, 2019, METABOLITES, V9, DOI 10.3390/metabo9010004
   Cascella R, 2018, PROG RETIN EYE RES, V63, P132, DOI 10.1016/j.preteyeres.2017.11.004
   Cheung GCM, 2017, ASIA-PAC J OPHTHALMO, V6, P527, DOI 10.22608/APO.2017260
   Colegio OR, 2014, NATURE, V513, P559, DOI 10.1038/nature13490
   Colijn JM, 2019, OPHTHALMOLOGY, V126, P393, DOI 10.1016/j.ophtha.2018.09.045
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   De Bock K, 2013, CELL, V154, P651, DOI 10.1016/j.cell.2013.06.037
   DeAngelis MM, 2017, HUM MOL GENET, V26, pR45, DOI 10.1093/hmg/ddx228
   Dhup S, 2012, CURR PHARM DESIGN, V18, P1319, DOI 10.2174/138161212799504902
   Doyle SL, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007616
   Draoui N, 2017, OPEN BIOL, V7, DOI 10.1098/rsob.170219
   Edin S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074982
   Frederich M, 2016, J MED CHEM, V59, P8649, DOI 10.1021/acs.jmedchem.5b01335
   Hubert P, 1999, AM J PATHOL, V154, P775, DOI 10.1016/S0002-9440(10)65324-2
   Hurley JB, 2015, J NEUROSCI RES, V93, P1079, DOI 10.1002/jnr.23583
   Jetten N, 2014, ANGIOGENESIS, V17, P109, DOI 10.1007/s10456-013-9381-6
   Kersten E, 2018, SURV OPHTHALMOL, V63, P9, DOI 10.1016/j.survophthal.2017.05.003
   Lai TT, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-36704-6
   Lains I, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177749
   Lambert V, 2013, NAT PROTOC, V8, P2197, DOI 10.1038/nprot.2013.135
   Lavalette S, 2011, AM J PATHOL, V178, P2416, DOI 10.1016/j.ajpath.2011.01.013
   Li BB, 2017, MOLECULES, V22, DOI 10.3390/molecules22071173
   Liu K, 2014, OPHTHALMOLOGY, V121, P911, DOI 10.1016/j.ophtha.2013.10.042
   Luo D, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0555-7
   Matheus N, 2014, PHYTOCHEM ANALYSIS, V25, P342, DOI 10.1002/pca.2498
   Mia S, 2014, SCAND J IMMUNOL, V79, P305, DOI 10.1111/sji.12162
   Michelakis ED, 2008, BRIT J CANCER, V99, P989, DOI 10.1038/sj.bjc.6604554
   Mills E, 2014, TRENDS CELL BIOL, V24, P313, DOI 10.1016/j.tcb.2013.11.008
   Mitchell SL, 2018, INVEST OPHTH VIS SCI, V59, P4978, DOI 10.1167/iovs.18-25137
   Nagai N, 2016, SCI REP-UK, V6, DOI 10.1038/srep29619
   Nita M, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/930671
   Noel A, 2007, TRENDS MOL MED, V13, P345, DOI 10.1016/j.molmed.2007.06.005
   Osborn MP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072737
   Parmeggiani F, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/546786
   Pennesi ME, 2012, MOL ASPECTS MED, V33, P487, DOI 10.1016/j.mam.2012.06.003
   Porporato PE, 2012, ANGIOGENESIS, V15, P581, DOI 10.1007/s10456-012-9282-0
   Quennet V, 2006, RADIOTHER ONCOL, V81, P130, DOI 10.1016/j.radonc.2006.08.012
   Roche TE, 2007, CELL MOL LIFE SCI, V64, P830, DOI 10.1007/s00018-007-6380-z
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   Schmidt-Erfurth U, 2017, EYE, V31, P26, DOI 10.1038/eye.2016.227
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Skeie JM, 2009, EYE, V23, P747, DOI 10.1038/eye.2008.206
   Sounni NE, 2014, CELL METAB, V20, P280, DOI 10.1016/j.cmet.2014.05.022
   SUN X, 2016, RESISTANCE ANTIVEGF, V1857
   Xi HK, 2016, J EXP MED, V213, P189, DOI 10.1084/jem.20150894
   Zandi S, 2015, CELL REP, V10, P1173, DOI 10.1016/j.celrep.2015.01.050
NR 51
TC 8
Z9 8
U1 0
U2 4
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0946-2716
EI 1432-1440
J9 J MOL MED
JI J. Mol. Med.
PD DEC
PY 2020
VL 98
IS 12
BP 1737
EP 1751
DI 10.1007/s00109-020-01994-9
EA OCT 2020
PG 15
WC Genetics & Heredity; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity; Research & Experimental Medicine
GA OT9GX
UT WOS:000581754200001
PM 33079232
DA 2022-11-30
ER

PT J
AU Parikh, R
   Avery, RL
   Saroj, N
   Thompson, D
   Freund, KB
AF Parikh, Ravi
   Avery, Robert L.
   Saroj, Namrata
   Thompson, Desmond
   Freund, K. Bailey
TI Incidence of New Choroidal Neovascularization in Fellow Eyes of Patients
   With Age-Related Macular Degeneration Treated With Intravitreal
   Aflibercept or Ranibizumab
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID COHERENCE TOMOGRAPHY ANGIOGRAPHY; 5-YEAR INCIDENCE; FOLLOW-UP;
   INJECTION; BEVACIZUMAB; MACULOPATHY; PHARMACOKINETICS; EDEMA
AB Key PointsQuestionWhat were the incidence of and factors influencing the conversion of the untreated fellow eye in patients who had had neovascular age-related macular degeneration (AMD) and were treated with intravitreal aflibercept or ranibizumab in the Vascular Endothelial Growth Factor Trap-Eye: Investigation of Efficacy and Safety in Wet AMD studies? FindingsIn this second analyses of randomized clinical trial data, the incidence of fellow eye conversion was 26.2% to 32.2% across treatment groups through week 96. Baseline characteristics associated with higher risk of fellow eye conversion were increasing age, female sex, baseline intraretinal fluid in the study eye, and increasing choroidal neovascularization lesion size in the study eye; no difference in the rates of conversion across treatment groups was identified. MeaningPer this analysis, patients with active neovascular AMD in 1 eye are at high risk for fellow eye conversion and should be monitored closely.
   This second analysis of data from 2 randomized clinical trials investigated the association of intravitreal aflibercept vs ranibizumab and baseline characteristics with fellow eye conversion in patients treated for neovascular age-related macular degeneration in 1 eye.
   ImportanceIncidence of conversion to neovascular age-related macular degeneration (nAMD) in untreated fellow eyes of patients who are treated for nAMD in 1 eye with anti-vascular endothelial growth factor agents provides important prognostic information to clinically manage patients. ObjectiveTo investigate the association of treatment assignment (intravitreal aflibercept vs ranibizumab) and baseline characteristics with fellow eye conversion to nAMD in the VEGF (Vascular Endothelial Growth Factor) Trap-Eye: Investigation of Efficacy and Safety in Wet AMD (VIEW) studies. Design, Setting, and ParticipantsThis post hoc analysis of the VIEW 1 and VIEW 2 studies (randomized, double-masked, active-controlled, multicenter, 96-week, phase 3 trials comparing the efficacy and safety of intravitreal aflibercept in 2457 patients with treatment-naive eyes with nAMD) analyzed a subgroup of participants treated for nAMD in 1 eye who had untreated fellow eyes without neovascularization at baseline. All participants in the VIEW studies were included in 1 of 4 groups: ranibizumab, 0.5 mg, every 4 weeks; aflibercept, 2 mg, every 4 weeks; aflibercept, 0.5 mg, every 4 weeks; or aflibercept, 2 mg, every 8 weeks after 3 injections at 4-week intervals. Data collection in the VIEW studies occurred from July 2007 to August 2011; the data analysis presented in this report took place from April 2016 to November 2018. InterventionsPatients received no treatment in the fellow eyes unless after conversion to nAMD, when any treatment approved by heath authorities was given per the investigators' discretion. Main Outcomes and MeasuresIncidence of conversion to nAMD in patients with untreated fellow eyes that had not had clinical signs of neovascularization at baseline. ResultsA total of 1561 participants were included in this analysis. At 96 weeks, 375 patients (24.0%) experienced cases of conversion to neovascular disease in the fellow eye, including 107 of the 399 individuals who received ranibizumab, 0.5 mg, every 4 weeks; 93 of the 387 individuals who received aflibercept, 2 mg, every 4 weeks; 84 of the 387 individuals who received aflibercept, 0.5 mg, every 4 weeks; and 91 of the 388 individuals who received aflibercept, 2 mg, every 8 weeks after 3 doses at 4-week intervals. The rates were 18.1, 16.2, 14.7, and 16.0 per 100 patient-years at risk at week 96, respectively. On multivariate analysis, fellow eye conversion was associated with increasing patient age (per 10 years) at baseline (hazard ratio [HR], 1.20 [95% CI, 1.05-1.36]), female sex (HR, 1.32 [95% CI, 1.06-1.63]), intraretinal fluid in the study eye at baseline (HR, 1.28 [95% CI, 1.02-1.61]), and increasing choroidal neovascularization lesion size (per 10 mm(2)) in the study eye at baseline (HR, 1.29 [95% CI, 1.06-1.57]). Rates of fellow eye conversion were similar with either of the treatments. Conclusions and RelevanceIn this secondary analysis of randomized clinical trial data, patients with active nAMD in 1 eye appeared to have a high risk for fellow eye conversion. Such patients should be monitored closely.
C1 [Parikh, Ravi; Freund, K. Bailey] Vitreous Retina Macula Consultants New York, 460 Pk Ave, New York, NY 10022 USA.
   [Parikh, Ravi; Freund, K. Bailey] NYU, Dept Ophthalmol, Sch Med, 550 1St Ave, New York, NY 10016 USA.
   [Parikh, Ravi] Harvard Med Sch, Massachusetts Eye & Ear, Dept Ophthalmol, Retina Serv, Boston, MA 02115 USA.
   [Avery, Robert L.] Calif Retina Consultants, Santa Barbara, CA USA.
   [Saroj, Namrata; Thompson, Desmond] Regeneron Pharmaceut Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA.
C3 Vitreous Retina Macula Consultants of New York; New York University;
   Harvard University; Harvard Medical School; Massachusetts Eye & Ear
   Infirmary; Regeneron
RP Freund, KB (通讯作者)，Vitreous Retina Macula Consultants New York, 460 Pk Ave, New York, NY 10022 USA.
EM kbfnyf@aol.com
RI Freund, K. Bailey/V-7488-2018
OI Freund, K. Bailey/0000-0002-7888-9773; Parikh, Ravi/0000-0003-3369-4224
FU Regeneron Pharmaceuticals Inc; Bayer HealthCare
FX The VEGF (Vascular Endothelial Growth Factor) Trap-Eye: Investigation of
   Efficacy and Safety inWet AMD (Age-Related Macular Degeneration) 1 and 2
   studies were funded by Regeneron Pharmaceuticals Inc and Bayer
   HealthCare.
CR Acharya NR, 2011, RETINA-J RET VIT DIS, V31, P1871, DOI 10.1097/IAE.0b013e318213da43
   Avery RL, 2006, OPHTHALMOLOGY, V113, P1695, DOI 10.1016/j.ophtha.2006.05.064
   Avery RL, 2014, BRIT J OPHTHALMOL, V98, P1636, DOI 10.1136/bjophthalmol-2014-305252
   Bakbak B, 2013, J OCUL PHARMACOL TH, V29, P728, DOI 10.1089/jop.2013.0049
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P2179, DOI 10.1016/j.ophtha.2007.09.012
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P855, DOI 10.1016/j.ophtha.2007.01.017
   Barbazetto IA, 2010, AM J OPHTHALMOL, V149, P939, DOI 10.1016/j.ajo.2010.01.007
   Carnevali A, 2016, AM J OPHTHALMOL, V169, P189, DOI 10.1016/j.ajo.2016.06.042
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P272, DOI 10.1001/jamaophthalmol.2013.6636
   Dias JRD, 2018, OPHTHALMOLOGY, V125, P255, DOI 10.1016/j.ophtha.2017.08.030
   Hanhart J, 2014, EYE, V28, P646, DOI 10.1038/eye.2014.94
   Hanutsaha P, 1998, OPHTHALMOLOGY, V105, P1632, DOI 10.1016/S0161-6420(98)99030-3
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Maguire MG, 2013, OPHTHALMOLOGY, V120, P2035, DOI 10.1016/j.ophtha.2013.03.017
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Mukesh BN, 2004, OPHTHALMOLOGY, V111, P1176, DOI 10.1016/j.ophtha.2003.08.042
   Roisman L, 2016, OPHTHALMOLOGY, V123, P1309, DOI 10.1016/j.ophtha.2016.01.044
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rotsos T, 2014, INT OPHTHALMOL, V34, P1271, DOI 10.1007/s10792-014-9921-0
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Schneider U, 1997, INT OPHTHALMOL, V21, P79, DOI 10.1023/A:1005848806641
   US National Library of Medicine ClinicalTrials, INTRAVITREAL AFLIBER
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   Zehetner C, 2015, ACTA OPHTHALMOL, V93, pE154, DOI 10.1111/aos.12604
   2008, OPHTHALMOLOGY, V115, P1474
NR 27
TC 15
Z9 16
U1 1
U2 7
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD AUG
PY 2019
VL 137
IS 8
BP 914
EP 920
DI 10.1001/jamaophthalmol.2019.1947
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA IP8JE
UT WOS:000480291900011
PM 31294771
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Kan, MY
   Weng, XL
   Wang, T
   Liu, FT
   Ye, JY
   Zhang, H
   Xu, MQ
   Zhou, DZ
   He, L
   Liu, Y
AF Kan, Mengyuan
   Weng, Xiaoling
   Wang, Ting
   Liu, Fatao
   Ye, Junyi
   Zhang, Hong
   Xu, Mingqing
   Zhou, Daizhan
   He, Lin
   Liu, Yun
TI No evidence of association between variant rs2075650 in lipid
   metabolism-related locus APOE/TOMM40 and advanced age-related macular
   degeneration in Han Chinese population
SO EXPERIMENTAL BIOLOGY AND MEDICINE
LA English
DT Article
DE Age-related macular degeneration; APOE; TOMM40 locus; Han Chinese
   population; association study; lipid metabolism-related genes
ID GENOME-WIDE ASSOCIATION; APOLIPOPROTEIN-E; ALZHEIMERS-DISEASE; GENE;
   MEMBRANE; RISK; POLYMORPHISM; EXPRESSION; IMPORT; REGION
AB Age-related macular degeneration (AMD) is a late-onset, neurodegenerative disease. Genes related to lipid metabolism are important in AMD pathogenesis. Recently, a variant rs2075650 located in lipid metabolism-related locus APOE/TOMM40 was identified to be associated with advanced AMD and early AMD, respectively, in two genome-wide association studies with European ancestry, while no association study between rs2075650 and overall advanced AMD in Chinese population has been conducted before. We evaluated the potential effect of this variant on advanced AMD in a Han Chinese cohort with 204 advanced AMD patients and 1536 healthy controls. The results suggested that rs2075650 was neither associated with advanced AMD in allele level (P=0.348) nor in genotype level (P=0.890 under additive model with age and sex adjusted). In conclusion, our study did not confirm the impact of rs2075650 on advanced AMD risk, indicating that rs2075650 is unlikely a superior marker for APOE/TOMM40 susceptible region with advanced AMD in Han Chinese population.
C1 [Kan, Mengyuan; Wang, Ting; Liu, Fatao; He, Lin] Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Nutr Sci, Shanghai 200031, Peoples R China.
   [Weng, Xiaoling; Ye, Junyi; Zhang, Hong; He, Lin; Liu, Yun] Fudan Univ, Inst Biomed Sci, Shanghai 200032, Peoples R China.
   [Xu, Mingqing; Zhou, Daizhan; He, Lin] Shanghai Jiao Tong Univ, Bio X Inst, Minist Educ, Key Lab Genet Dev & Neuropsychiat Disorders, Shanghai 200030, Peoples R China.
C3 Chinese Academy of Sciences; Shanghai Institutes for Biological
   Sciences, CAS; Fudan University; Shanghai Jiao Tong University
RP He, L (通讯作者)，Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Nutr Sci, Shanghai 200031, Peoples R China.
EM helin@bio-x.cn; superliuyun@gmail.com
FU 973 Program [2010CB529600, 2011CB504000]; National Key Technology RD
   Program [2012BAI01B09]; National Natural Science Foundation of China
   [31200954, 81121001, 81361120389]
FX This work was supported by the 973 Program (2010CB529600 and
   2011CB504000), the National Key Technology R&D Program (2012BAI01B09),
   and the National Natural Science Foundation of China (31200954,
   81121001, and 81361120389). We gratefully thank Dr Dingguo Qian, who
   helped with sample collection and AMD diagnosis.
CR BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Chen Z, 2010, EXP BIOL MED, V235, P857, DOI 10.1258/ebm.2010.010024
   Cipriani V, 2012, HUM MOL GENET, V21, P4138, DOI 10.1093/hmg/dds225
   Curcio CA, 2009, PROG RETIN EYE RES, V28, P393, DOI 10.1016/j.preteyeres.2009.08.001
   Davies G, 2014, MOL PSYCHIATR, V19, P76, DOI 10.1038/mp.2012.159
   De Jager PL, 2012, NEUROBIOL AGING, V33, DOI 10.1016/j.neurobiolaging.2011.09.033
   Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146
   Freitas EM, 1998, DNA SEQUENCE, V9, P89, DOI 10.3109/10425179809086433
   Gabriel K, 2003, EMBO J, V22, P2380, DOI 10.1093/emboj/cdg229
   Guo J, 2013, MOL VIS, V19, P2050
   Harold D, 2009, NAT GENET, V41, P1088, DOI 10.1038/ng.440
   Holliday EG, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0082305, 10.1371/journal.pone.0053830]
   Humphries AD, 2005, J BIOL CHEM, V280, P11535, DOI 10.1074/jbc.M413816200
   Ishida BY, 2004, J LIPID RES, V45, P263, DOI 10.1194/jlr.M300306-JLR200
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kan MY, 2010, DIABETIC MED, V27, P598, DOI 10.1111/j.1464-5491.2010.02975.x
   Kan MY, 2014, DIAGN PATHOL, V9, DOI 10.1186/1746-1596-9-73
   Kishan AU, 2011, SURV OPHTHALMOL, V56, P195, DOI 10.1016/j.survophthal.2010.08.008
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   Liu Y, 2008, DIABETOLOGIA, V51, P2134, DOI 10.1007/s00125-008-1141-6
   Liu Y, 2009, DIABETOLOGIA, V52, P1315, DOI 10.1007/s00125-009-1375-y
   Manczak M, 2004, NEUROMOL MED, V5, P147, DOI 10.1385/NMM:5:2:147
   McKay GJ, 2011, AM J EPIDEMIOL, V173, P1357, DOI 10.1093/aje/kwr015
   Naj AC, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001130
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Ohno-Matsui K, 2011, PROG RETIN EYE RES, V30, P217, DOI 10.1016/j.preteyeres.2011.02.004
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   Qian D, 2014, EUR J HUM GENET
   Ramanan VK, 2014, MOL PSYCHIATR, V19, P351, DOI 10.1038/mp.2013.19
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   Wang L, 2009, INVEST OPHTH VIS SCI, V50, P870, DOI 10.1167/iovs.08-2376
   Wigginton JE, 2005, AM J HUM GENET, V76, P887, DOI 10.1086/429864
   Yu CE, 2007, GENOMICS, V89, P655, DOI 10.1016/j.ygeno.2007.02.002
   Zhao T, 2011, J HUM GENET, V56, P12, DOI 10.1038/jhg.2010.124
   Zhou DZ, 2010, J HUM GENET, V55, P810, DOI 10.1038/jhg.2010.117
   Zhou DZ, 2009, J HUM GENET, V54, P433, DOI 10.1038/jhg.2009.54
NR 38
TC 5
Z9 5
U1 0
U2 8
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1535-3702
EI 1535-3699
J9 EXP BIOL MED
JI Exp. Biol. Med.
PD FEB
PY 2015
VL 240
IS 2
BP 230
EP 234
DI 10.1177/1535370214553770
PG 5
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA CB4VT
UT WOS:000349627100011
PM 25304313
OA Green Published
DA 2022-11-30
ER

PT J
AU Gu, BJ
   Baird, PN
   Vessey, KA
   Skarratt, KK
   Fletcher, EL
   Fuller, SJ
   Richardson, AJ
   Guymer, RH
   Wiley, JS
AF Gu, Ben J.
   Baird, Paul N.
   Vessey, Kirstan A.
   Skarratt, Kristen K.
   Fletcher, Erica L.
   Fuller, Stephen J.
   Richardson, Andrea J.
   Guymer, Robyn H.
   Wiley, James S.
TI A rare functional haplotype of the P2RX4 and P2RX7 genes leads to loss
   of innate phagocytosis and confers increased risk of age-related macular
   degeneration
SO FASEB JOURNAL
LA English
DT Article
DE drusen; microglia; scavenger receptor
ID RETINAL-PIGMENT EPITHELIUM; EXTRACELLULAR ATP; APOPTOTIC CELLS; P2X(7)
   RECEPTOR; SCAVENGER RECEPTOR; BRUCHS MEMBRANE; P2X7 RECEPTOR;
   POLYMORPHISM; MICROGLIA; BRAIN
AB Age-related macular degeneration (AMD) is a leading cause of blindness in Western countries and is diagnosed by the clinical appearance of yellow subretinal deposits called drusen. Genetic changes in immune components are clearly implicated in the pathology of this disease. We have previously shown that the purinergic receptor P2X7 can act as a scavenger receptor, mediating phagocytosis of apoptotic cells and insoluble debris. We performed a genetic association study of functional polymorphisms in the P2RX7 and P2RX4 genes in a cohort of 744 patients with AMD and 557 age-matched Caucasian control subjects. The P2X4 Tyr315Cys variant was 2-fold more frequent in patients with AMD compared to control subjects, with the minor allele predicting susceptibility to disease. Pairwise linkage disequilibrium was observed between Tyr315Cys in the P2RX4 gene and Gly150Arg in the P2RX7 gene, and these two minor alleles formed a rare haplotype that was overrepresented in patients with AMD (n=17) compared with control subjects (n=3) (odds ratio 4.05, P=0.026). Expression of P2X7 (wild type or variant 150Arg) in HEK293 cells conferred robust phagocytosis toward latex beads, whereas coexpression of the P2X7 150Arg with P2X4 315Cys variants almost completely inhibited phagocytic capacity. Fresh human monocytes harboring this heterozygous 150Arg-315Cys haplotype showed 40% reduction in bead phagocytosis. In the primate eye, immunohistochemistry indicated that P2X7 and P2X4 receptors were coexpressed on microglia and macrophages, but neither receptor was seen on retinal pigment epithelial cells. These results demonstrate that a haplotype including two rare variants in P2RX7 and P2RX4 confers a functional interaction between these two variant receptors that impairs the normal scavenger function of macrophages and microglia. Failure of this P2X7-mediated phagocytic pathway may impair removal of subretinal deposits and predispose individuals toward AMD.-Gu, B. J., Baird, P. N., Vessey, K. A., Skarratt, K. K., Fletcher, E. L., Fuller, S. J., Richardson, A. J., Guymer, R. H., Wiley, J. S. A rare functional haplotype of the P2RX4 and P2RX7 genes leads to loss of innate phagocytosis and confers increased risk of age related macular degeneration. FASEB J. 27, 1479-1487 (2013). www.fasebj.org
C1 [Gu, Ben J.; Wiley, James S.] Univ Melbourne, Florey Inst Neurosci & Mental Hlth, Parkville, Vic 3010, Australia.
   [Vessey, Kirstan A.; Fletcher, Erica L.] Univ Melbourne, Dept Anat & Neurosci, Parkville, Vic 3010, Australia.
   [Baird, Paul N.; Richardson, Andrea J.; Guymer, Robyn H.] Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, East Melbourne, Vic, Australia.
   [Skarratt, Kristen K.; Fuller, Stephen J.; Wiley, James S.] Univ Sydney, Nepean Hosp, Nepean Clin Sch, Penrith, NSW, Australia.
C3 Florey Institute of Neuroscience & Mental Health; University of
   Melbourne; University of Melbourne; Centre for Eye Research Australia;
   Royal Victorian Eye & Ear Hospital; University of Melbourne; Nepean
   Hospital; University of Sydney
RP Wiley, JS (通讯作者)，Univ Melbourne, Florey Neurosci Inst, Parkville, Vic 3010, Australia.
EM james.wiley@florey.edu.au
RI Skarratt, Kristy/AAN-1479-2020; Fuller, Stephen/W-6646-2019; Fletcher,
   Erica/E-6364-2012
OI Fuller, Stephen/0000-0003-4637-7391; Fletcher,
   Erica/0000-0001-9412-9523; Skarratt, Kristy/0000-0003-4971-2773; Baird,
   Paul/0000-0002-1305-3502; Gu, Ben/0000-0001-5500-4453; Guymer,
   Robyn/0000-0002-9441-4356; Vessey, Kirstan/0000-0003-1031-1964; Wiley,
   James/0000-0001-9421-4154
FU Australian National Health and Medical Research Council (NHMRC)
   [1048082, 633275, 566814, 529905, 1028444]; Centre for Clinical Research
   Excellence [529923]; American Health Assistance Foundation; Macular
   Degeneration Research grant; Australian Research Council [FT120100581];
   Centre for Eye Research Australia
FX This study was supported by Australian National Health and Medical
   Research Council (NHMRC) project grants 1048082, 633275, and 566814;
   Centre for Clinical Research Excellence grant 529923 (Translational
   Clinical Research in Major Eye Diseases); an American Health Assistance
   Foundation, Macular Degeneration Research grant to E. L. F.; Australian
   Research Council Future Fellowship FT120100581 to B.J.G.; NHMRC
   Practitioner Fellowship 529905 to R. H. G.; and NHMRC Senior Research
   Fellowship 1028444 to P.N.B. Centre for Eye Research Australia receives
   operational infrastructure support from the Victorian government.
CR Anderson CM, 2006, TRENDS NEUROSCI, V29, P257, DOI 10.1016/j.tins.2006.03.003
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Antonio LS, 2011, BRIT J PHARMACOL, V163, P1069, DOI 10.1111/j.1476-5381.2011.01303.x
   Baird PN, 2006, INVEST OPHTH VIS SCI, V47, P4194, DOI 10.1167/iovs.05-1285
   Baird PN, 2009, CLIN EXP OPHTHALMOL, V37, P814, DOI 10.1111/j.1442-9071.2009.02136.x
   Buschini E, 2011, PROG NEUROBIOL, V95, P14, DOI 10.1016/j.pneurobio.2011.05.011
   Durocher Y, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.2.e9
   Finneman SC, 2001, J EXP MED, V194, P1289, DOI 10.1084/jem.194.9.1289
   Finnemann SC, 2002, P NATL ACAD SCI USA, V99, P3842, DOI 10.1073/pnas.052025899
   Finnemann SC, 1999, J EXP MED, V190, P861, DOI 10.1084/jem.190.6.861
   Fletcher EL, 2010, OPTOMETRY VISION SCI, V87, P269, DOI 10.1097/OPX.0b013e3181c9132b
   Gerszten RE, 2012, NEW ENGL J MED, V366, P1734, DOI 10.1056/NEJMcibr1200164
   Gu BJ, 2011, J IMMUNOL, V187, P2365, DOI 10.4049/jimmunol.1101178
   Gu BJ, 2010, BLOOD, V115, P1621, DOI 10.1182/blood-2009-11-251744
   Gu BJ, 2009, AM J PHYSIOL-CELL PH, V297, pC430, DOI 10.1152/ajpcell.00079.2009
   Gu BJ, 2001, J BIOL CHEM, V276, P11135, DOI 10.1074/jbc.M010353200
   Gupta N, 2003, EXP EYE RES, V76, P463, DOI 10.1016/S0014-4835(02)00332-9
   Guymer R, 1999, PROG RETIN EYE RES, V18, P59, DOI 10.1016/S1350-9462(98)00012-3
   Hoppe G, 2001, INVEST OPHTH VIS SCI, V42, P2714
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Karala AR, 2010, J MOL BIOL, V396, P883, DOI 10.1016/j.jmb.2009.12.014
   Kawate T, 2009, NATURE, V460, P592, DOI 10.1038/nature08198
   KILLINGSWORTH MC, 1990, EYE, V4, P613, DOI 10.1038/eye.1990.86
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Mariathasan S, 2006, NATURE, V440, P228, DOI 10.1038/nature04515
   Monif M, 2010, INT J BIOCHEM CELL B, V42, P1753, DOI 10.1016/j.biocel.2010.06.021
   Newman EA, 2001, J NEUROSCI, V21, P2215, DOI 10.1523/JNEUROSCI.21-07-02215.2001
   Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647
   Okumura M, 2011, FEBS J, V278, P1137, DOI 10.1111/j.1742-4658.2011.08039.x
   Paolicelli RC, 2011, SCIENCE, V333, P1456, DOI 10.1126/science.1202529
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Puthussery T, 2009, J COMP NEUROL, V513, P430, DOI 10.1002/cne.21964
   Qureshi OS, 2007, J CELL SCI, V120, P3838, DOI 10.1242/jcs.010348
   Richardson AJ, 2006, J LAB CLIN MED, V147, P290, DOI 10.1016/j.lab.2006.01.005
   Stokes L, 2011, HYPERTENSION, V58, P1086, DOI 10.1161/HYPERTENSIONAHA.111.176180
   Stokes L, 2010, FASEB J, V24, P2916, DOI 10.1096/fj.09-150862
   Stokes L, 2009, EUR J IMMUNOL, V39, P986, DOI 10.1002/eji.200838818
   Sugiyama T, 2010, INVEST OPHTH VIS SCI, V51, P3236, DOI 10.1167/iovs.09-4192
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   Ting AYC, 2009, CURR OPIN OPHTHALMOL, V20, P369, DOI 10.1097/ICU.0b013e32832f8016
   Wiley JS, 2011, TISSUE ANTIGENS, V78, P321, DOI 10.1111/j.1399-0039.2011.01780.x
   Wiley JS, 2012, PURINERG SIGNAL, V8, P579, DOI 10.1007/s11302-012-9308-5
   Wixey JA, 2009, J NEUROIMMUNOL, V212, P35, DOI 10.1016/j.jneuroim.2009.04.016
   Young MT, 2010, TRENDS BIOCHEM SCI, V35, P83, DOI 10.1016/j.tibs.2009.09.006
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 45
TC 48
Z9 50
U1 0
U2 12
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2013
VL 27
IS 4
BP 1479
EP 1487
DI 10.1096/fj.12-215368
PG 9
WC Biochemistry & Molecular Biology; Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA 117GF
UT WOS:000316940800020
PM 23303206
DA 2022-11-30
ER

PT J
AU Ba, J
   Peng, RS
   Xu, D
   Li, YH
   Shi, H
   Wang, QY
   Yu, J
AF Ba, Jun
   Peng, Run-Sheng
   Xu, Ding
   Li, Yan-Hong
   Shi, Hui
   Wang, Qianyi
   Yu, Jing
TI Intravitreal anti-VEGF injections for treating wet age-related macular
   degeneration: a systematic review and meta-analysis
SO DRUG DESIGN DEVELOPMENT AND THERAPY
LA English
DT Review
DE age-related macular degeneration; VEGF; ranibizumab; bevacizumab;
   aflibercept; meta-analysis
ID VERTEPORFIN PHOTODYNAMIC THERAPY; RANDOMIZED CLINICAL-TRIAL; CHOROIDAL
   NEOVASCULARIZATION; RANIBIZUMAB MONOTHERAPY; BEVACIZUMAB AVASTIN; PLUS
   RANIBIZUMAB; AFLIBERCEPT; COMBINATION; PREVALENCE; EFFICACY
AB Aims: Age-related macular degeneration (AMD) is the main cause of blindness. Anti-vascular endothelial growth factor is used to prevent further neovascularization due to wet AMD. The purpose of this systematic review was to investigate the effect and protocol of anti-vascular endothelial growth factor treatment on wet AMD.
   Methods: A comprehensive literature search was performed in PubMed, Embase, the Cochrane Library, CNKI, and reference lists. Meta-analysis was performed using Stata12.0 software, best corrected visual acuity (BCVA), retinal thickness, and lesion size were evaluated.
   Results: Twelve randomized controlled trials spanning from 2010 to 2014 and involving 5,225 patients were included. A significant difference was observed between the intravitreal ranibizumab (IVR) group and the intravitreal bevacizumab group (standard mean difference =-0.14, 95% confidence interval [CI] =-0.23 to -0.05). No significant differences were observed in best corrected VA, retinal thickness, or lesion size between IVR and the intravitreal aflibercept group. Compared to monthly injection, IVR as-needed injections (PRN) can raise VA by 1.97 letters (weighted mean difference = 1.97, 95% CI = 0.14-3.794). Combination therapy of IVR and photodynamic therapy can significantly raise VA by 2.74 letters when combined with IVR monotherapy (weighted mean difference = 2.74, 95% CI = 0.26-5.21).
   Conclusion: The superiority remains unclear between IVR and intravitreal bevacizumab in the treatment of neovascular AMD. Intravitreal aflibercept dosed every 2 months required fewer injection times, but produced similar efficacy as monthly IVR. IVR PRN could significantly increase VA. Combined with photodynamic therapy, IVR therapy could also increase VA effectively.
C1 [Ba, Jun; Xu, Ding; Li, Yan-Hong; Shi, Hui; Wang, Qianyi; Yu, Jing] Tongji Univ, Shanghai Peoples Hosp 10, Dept Ophthalmol, Shanghai 200072, Peoples R China.
   [Ba, Jun; Peng, Run-Sheng] Tongji Univ, Affiliated Zhongshan Hosp, Inst Cardiovasc Dis, Dept Cardiac Surg, Shanghai 200072, Peoples R China.
   [Shi, Hui] Nanjing Med Univ, Dept Clin Med Coll 1, Nanjing, Jiangsu, Peoples R China.
C3 Tongji University; Tongji University; Nanjing Medical University
RP Yu, J (通讯作者)，Tongji Univ, Shanghai Peoples Hosp 10, Dept Ophthalmol, 301 Middle Yanchang Rd, Shanghai 200072, Peoples R China.
EM dryujing@aliyun.com
RI li, yan/GTI-4638-2022
FU National Nature Science Foundation Project [81470648]; New Excellence
   Project of Shanghai Health Bureau [XYQ2011067]
FX This work was supported in whole or in part, by National Nature Science
   Foundation Project (81470648) and The New Excellence Project of Shanghai
   Health Bureau (XYQ2011067).
CR Bashshur ZF, 2009, ARCH OPHTHALMOL-CHIC, V125, P1357
   Bashshur ZF, 2008, AM J OPHTHALMOL, V145, P249, DOI 10.1016/j.ajo.2007.09.031
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Browning DJ, 2012, AM J OPHTHALMOL, V154, P222, DOI 10.1016/j.ajo.2012.04.020
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Cruess AF, 2012, CAN J OPHTHALMOL, V47, P227, DOI 10.1016/j.jcjo.2012.03.007
   Emerson MV, 2008, CLIN OPHTHALMOL, V2, P377
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Ghazi NG, 2008, RETINA-J RET VIT DIS, V28, P689, DOI 10.1097/IAE.0b013e318162d982
   Goff MJ, 2007, RETINA-J RET VIT DIS, V27, P432, DOI 10.1097/IAE.0b013e318042b53f
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4
   Kaiser PK, 2007, OPHTHALMOLOGY, V114, P1868, DOI 10.1016/j.ophtha.2007.04.030
   Kaiser PK, 2012, OPHTHALMOLOGY, V119, P1001, DOI 10.1016/j.ophtha.2012.02.003
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Kodjikian L, 2013, OPHTHALMOLOGY, V120, P2300, DOI 10.1016/j.ophtha.2013.06.020
   Krebs I, 2013, ACTA OPHTHALMOL, V91, pE178, DOI 10.1111/aos.12018
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P266, DOI 10.1136/bjophthalmol-2012-302391
   Larsen M, 2012, OPHTHALMOLOGY, V119, P992, DOI 10.1016/j.ophtha.2012.02.002
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Pascolini D, 2004, OPHTHAL EPIDEMIOL, V11, P67, DOI 10.1076/opep.11.2.67.28158
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sacu S, 2009, EYE, V23, P2223, DOI 10.1038/eye.2008.423
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Solomon SD, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub3
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Stewart MW, 2012, CLIN OPHTHALMOL, V6, P1175, DOI 10.2147/OPTH.S33372
   Subramanian ML, 2010, EYE, V24, P1708, DOI 10.1038/eye.2010.147
   Thomas M, 2013, CLIN OPHTHALMOL, V7, P495, DOI 10.2147/OPTH.S29974
   Tufail A, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2459
   Vallance JH, 2010, EYE, V24, P1561, DOI 10.1038/eye.2010.84
   Williams PD, 2012, CLIN OPHTHALMOL, V6, P1519, DOI 10.2147/OPTH.S31010
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Zhang XY, 2014, INT J OPHTHALMOL-CHI, V7, P355, DOI 10.3980/j.issn.2222-3959.2014.02.30
NR 38
TC 72
Z9 74
U1 1
U2 11
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1177-8881
J9 DRUG DES DEV THER
JI Drug Des. Dev. Ther.
PY 2015
VL 9
DI 10.2147/DDDT.S86269
PG 9
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA CS1AZ
UT WOS:000361795500002
PM 26451092
OA Green Submitted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Vaghefi, E
   Hill, S
   Kersten, HM
   Squirrell, D
AF Vaghefi, Ehsan
   Hill, Sophie
   Kersten, Hannah M.
   Squirrell, David
TI Quantification of Optical Coherence Tomography Angiography in Age and
   Age-Related Macular Degeneration Using Vessel Density Analysis
SO ASIA-PACIFIC JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; optical coherence tomography
   angiography; retinal blood flow; vessel density
ID FOVEAL AVASCULAR ZONE; CHOROIDAL THICKNESS; VASCULAR DENSITY; IMAGE
   ARTIFACTS
AB Purpose: The aim of this study was to determine whether vessel density (VD) as measured by optical coherence tomography (OCT) angiography provided insights into retinal and choriocapillaris vascular changes with aging and intermediate dry age-related macular degeneration (AMD).
   Design: Non-randomized observational study.
   Methods: Seventy-five participants were recruited into 3 cohorts: young healthy group, old healthy, and those at high-risk for exudative AMD. Raw OCT and OCT angiography data from TOPCON DRI OCT Triton were exported using Topcon IMAGENET 6.0 software, and 3D datasets were analysed to determine retinal thickness and VD.
   Results: Central macular thickness measurements revealed a trend of overall retinal thinning with increasing age. VD through the full thickness of the retina was highest in Early Treatment Diabetic Retinopathy Study (ETDRS) sector 4 (the inferior macula) in all the cohorts. Mean VD was significantly higher in the deep capillary plexus than the superficial capillary plexus in all ETDRS sectors in all cohorts, but there was no significant difference noted between groups. Choriocapillaris VD was significantly lower in all ETDRS sectors in the AMD group compared with the young healthy and the old healthy groups.
   Conclusions: Retinal VD maps, derived from the retinal plexi, are not reliable biomarkers for assessing the aging macular. Our nonproprietary analysis of the vascular density of the choriocapillaris revealed a significant drop off of VD with age and disease, but further work is required to corroborate this finding. If repeatable, choriocapillaris VD may provide a noninvasive biomarker of healthy aging and disease.
C1 [Vaghefi, Ehsan; Kersten, Hannah M.] Univ Auckland, Sch Optometry & Vis Sci, Auckland, New Zealand.
   [Vaghefi, Ehsan] Univ Auckland, Auckland Bioengn Inst, Auckland, New Zealand.
   [Hill, Sophie; Squirrell, David] Univ Auckland, Dept Ophthalmol, Auckland, New Zealand.
C3 University of Auckland; University of Auckland; University of Auckland
RP Vaghefi, E (通讯作者)，Univ Auckland, Sch Optometry & Vis Sci, Auckland, New Zealand.
EM e.vaghefi@auckland.ac.nz
FU Faculty Research Development fund, The University of Auckland
FX This work was funded by Faculty Research Development fund, The
   University of Auckland.
CR Agemy SA, 2015, RETINA-J RET VIT DIS, V35, P2353, DOI 10.1097/IAE.0000000000000862
   Al-Sheikh Mayss, 2017, Int J Retina Vitreous, V3, P13, DOI 10.1186/s40942-017-0068-9
   Chalam K V, 2016, J Ophthalmic Vis Res, V11, P84, DOI 10.4103/2008-322X.180709
   Chen FK, 2016, CLIN EXP OPHTHALMOL, V44, P388, DOI 10.1111/ceo.12683
   Chu ZD, 2016, J BIOMED OPT, V21, DOI 10.1117/1.JBO.21.6.066008
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Coscas F, 2016, INVEST OPHTH VIS SCI, V57, pOCT211, DOI 10.1167/iovs.15-18793
   de Carlo Talisa E, 2015, Int J Retina Vitreous, V1, P5
   Esmaeelpour M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099690
   Falavarjani KG, 2018, J OPHTHAL VIS RES, V13, P260, DOI 10.4103/jovr.jovr_173_17
   Gadde SGK, 2016, INVEST OPHTH VIS SCI, V57, P246, DOI 10.1167/iovs.15-18287
   GARIANO RF, 1994, INVEST OPHTH VIS SCI, V35, P3442
   Hirano T, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-27536-5
   Iafe NA, 2016, INVEST OPHTH VIS SCI, V57, P5780, DOI 10.1167/iovs.16-20045
   Jia YL, 2015, P NATL ACAD SCI USA, V112, pE2395, DOI 10.1073/pnas.1500185112
   Lee J, 2016, CURR DIABETES REP, V16, DOI 10.1007/s11892-016-0811-x
   Manjunath V, 2010, AM J OPHTHALMOL, V150, P325, DOI 10.1016/j.ajo.2010.04.018
   Pichi F, 2017, INT OPHTHALMOL, V37, P221, DOI 10.1007/s10792-016-0265-9
   Rabiolo A, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0205773
   Reif R, 2012, INT J BIOMED IMAGING, V2012, DOI 10.1155/2012/509783
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Shahlaee A, 2016, AM J OPHTHALMOL, V165, P39, DOI 10.1016/j.ajo.2016.02.018
   Sigler EJ, 2013, INVEST OPHTH VIS SCI, V54, P6307, DOI 10.1167/iovs.13-12653
   Spaide RF, 2018, PROG RETIN EYE RES, V64, P1, DOI 10.1016/j.preteyeres.2017.11.003
   Spaide RF, 2016, AM J OPHTHALMOL, V170, P58, DOI 10.1016/j.ajo.2016.07.023
   Spaide RF, 2015, RETINA-J RET VIT DIS, V35, P2163, DOI 10.1097/IAE.0000000000000765
   Spaide RF, 2015, JAMA OPHTHALMOL, V133, P45, DOI 10.1001/jamaophthalmol.2014.3616
   Stavrev V., 2018, OPEN J OPHTHALMOL, V8, P133, DOI [10.4236/ojoph.2018.83017, DOI 10.4236/OJOPH.2018.83017]
   Tan PEZ, 2012, INVEST OPHTH VIS SCI, V53, P5728, DOI 10.1167/iovs.12-10017
   Wood A, 2011, AM J OPHTHALMOL, V152, P1030, DOI 10.1016/j.ajo.2011.05.021
   Zhang ZX, 2015, J BIOMED OPT, V20, DOI 10.1117/1.JBO.20.5.051043
NR 32
TC 3
Z9 3
U1 0
U2 1
PU ASIA-PACIFIC ACAD OPHTHALMOLOGY-APAO
PI KOWLOON
PA 4-F, HONG KONG EYE HOSP, 147K ARGYLE ST, KOWLOON, KOWLOON, HONG KONG
   00000, PEOPLES R CHINA
EI 2162-0989
J9 ASIA-PAC J OPHTHALMO
JI Asia-Pac. J. Ophthalmol.
PD MAR-APR
PY 2020
VL 9
IS 2
BP 137
EP 143
DI 10.1097/APO.0000000000000278
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA LJ4VB
UT WOS:000530163700013
PM 32205475
OA gold, Green Published, Green Submitted
DA 2022-11-30
ER

EF